F@@	B-Chemical	D015738	8701013
am@@	I-Chemical	-1	8701013
o@@	I-Chemical	-1	8701013
tid@@	I-Chemical	-1	8701013
ine	I-Chemical	-1	8701013
-@@	O	-1	8701013
associated	O	-1	8701013
de@@	B-Disease	D003693	8701013
li@@	I-Disease	-1	8701013
ri@@	I-Disease	-1	8701013
um	I-Disease	-1	8701013
.	O	-1	8701013
A	O	-1	8701013
seri@@	O	-1	8701013
es	O	-1	8701013
of	O	-1	8701013
six	O	-1	8701013
cas@@	O	-1	8701013
es.	O	-1	8701013
F@@	B-Chemical	D015738	8701013
am@@	I-Chemical	-1	8701013
o@@	I-Chemical	-1	8701013
tid@@	I-Chemical	-1	8701013
ine	I-Chemical	-1	8701013
is	O	-1	8701013
a	O	-1	8701013
hist@@	O	-1	8701013
amine	O	-1	8701013
H@@	O	-1	8701013
2-@@	O	-1	8701013
receptor	O	-1	8701013
antagonist	O	-1	8701013
used	O	-1	8701013
in	O	-1	8701013
in@@	O	-1	8701013
patient	O	-1	8701013
se@@	O	-1	8701013
t@@	O	-1	8701013
t@@	O	-1	8701013
ings	O	-1	8701013
for	O	-1	8701013
pre@@	O	-1	8701013
ven@@	O	-1	8701013
tion	O	-1	8701013
of	O	-1	8701013
stres@@	O	-1	8701013
s	O	-1	8701013
ul@@	B-Disease	D014456	8701013
c@@	I-Disease	-1	8701013
ers	I-Disease	-1	8701013
and	O	-1	8701013
is	O	-1	8701013
show@@	O	-1	8701013
ing	O	-1	8701013
increas@@	O	-1	8701013
ing	O	-1	8701013
po@@	O	-1	8701013
pul@@	O	-1	8701013
ar@@	O	-1	8701013
ity	O	-1	8701013
because	O	-1	8701013
of	O	-1	8701013
its	O	-1	8701013
low	O	-1	8701013
co@@	O	-1	8701013
st@@	O	-1	8701013
.	O	-1	8701013
Although	O	-1	8701013
all	O	-1	8701013
of	O	-1	8701013
the	O	-1	8701013
cur@@	O	-1	8701013
ren@@	O	-1	8701013
tly	O	-1	8701013
av@@	O	-1	8701013
ail@@	O	-1	8701013
able	O	-1	8701013
H@@	O	-1	8701013
2-@@	O	-1	8701013
receptor	O	-1	8701013
antagonist@@	O	-1	8701013
s	O	-1	8701013
have	O	-1	8701013
shown	O	-1	8701013
the	O	-1	8701013
pro@@	O	-1	8701013
pen@@	O	-1	8701013
s@@	O	-1	8701013
ity	O	-1	8701013
to	O	-1	8701013
cause	O	-1	8701013
de@@	B-Disease	D003693	8701013
li@@	I-Disease	-1	8701013
ri@@	I-Disease	-1	8701013
um	I-Disease	-1	8701013
,	O	-1	8701013
only	O	-1	8701013
two	O	-1	8701013
previously	O	-1	8701013
reported	O	-1	8701013
cases	O	-1	8701013
have	O	-1	8701013
been	O	-1	8701013
associated	O	-1	8701013
with	O	-1	8701013
f@@	B-Chemical	D015738	8701013
am@@	I-Chemical	-1	8701013
o@@	I-Chemical	-1	8701013
tid@@	I-Chemical	-1	8701013
ine	I-Chemical	-1	8701013
.	O	-1	8701013
The	O	-1	8701013
au@@	O	-1	8701013
th@@	O	-1	8701013
ors	O	-1	8701013
report	O	-1	8701013
on	O	-1	8701013
six	O	-1	8701013
cases	O	-1	8701013
of	O	-1	8701013
f@@	B-Chemical	D015738	8701013
am@@	I-Chemical	-1	8701013
o@@	I-Chemical	-1	8701013
tid@@	I-Chemical	-1	8701013
ine	I-Chemical	-1	8701013
-@@	O	-1	8701013
associated	O	-1	8701013
de@@	B-Disease	D003693	8701013
li@@	I-Disease	-1	8701013
ri@@	I-Disease	-1	8701013
um	I-Disease	-1	8701013
in	O	-1	8701013
hospit@@	O	-1	8701013
al@@	O	-1	8701013
ized	O	-1	8701013
patients	O	-1	8701013
who	O	-1	8701013
c@@	O	-1	8701013
le@@	O	-1	8701013
a@@	O	-1	8701013
red	O	-1	8701013
complete@@	O	-1	8701013
ly	O	-1	8701013
up@@	O	-1	8701013
on	O	-1	8701013
re@@	O	-1	8701013
mo@@	O	-1	8701013
v@@	O	-1	8701013
al	O	-1	8701013
of	O	-1	8701013
f@@	B-Chemical	D015738	8701013
am@@	I-Chemical	-1	8701013
o@@	I-Chemical	-1	8701013
tid@@	I-Chemical	-1	8701013
ine	I-Chemical	-1	8701013
.	O	-1	8701013
The	O	-1	8701013
pharmac@@	O	-1	8701013
o@@	O	-1	8701013
kine@@	O	-1	8701013
tics	O	-1	8701013
of	O	-1	8701013
f@@	B-Chemical	D015738	8701013
am@@	I-Chemical	-1	8701013
o@@	I-Chemical	-1	8701013
tid@@	I-Chemical	-1	8701013
ine	I-Chemical	-1	8701013
are	O	-1	8701013
revie@@	O	-1	8701013
we@@	O	-1	8701013
d,	O	-1	8701013
with	O	-1	8701013
no	O	-1	8701013
change	O	-1	8701013
in	O	-1	8701013
its	O	-1	8701013
metabol@@	O	-1	8701013
ism	O	-1	8701013
in	O	-1	8701013
the	O	-1	8701013
el@@	O	-1	8701013
der@@	O	-1	8701013
ly	O	-1	8701013
po@@	O	-1	8701013
p@@	O	-1	8701013
ulation	O	-1	8701013
se@@	O	-1	8701013
en@@	O	-1	8701013
.	O	-1	8701013
The	O	-1	8701013
implic@@	O	-1	8701013
ations	O	-1	8701013
of	O	-1	8701013
using	O	-1	8701013
f@@	B-Chemical	D015738	8701013
am@@	I-Chemical	-1	8701013
o@@	I-Chemical	-1	8701013
tid@@	I-Chemical	-1	8701013
ine	I-Chemical	-1	8701013
in	O	-1	8701013
el@@	O	-1	8701013
der@@	O	-1	8701013
ly	O	-1	8701013
per@@	O	-1	8701013
son@@	O	-1	8701013
s	O	-1	8701013
are	O	-1	8701013
discus@@	O	-1	8701013
sed.	O	-1	8701013

In@@	B-Chemical	D007213	439781
do@@	I-Chemical	-1	439781
meth@@	I-Chemical	-1	439781
ac@@	I-Chemical	-1	439781
in	I-Chemical	-1	439781
induced	O	-1	439781
hypotension	B-Disease	D007022	439781
in	O	-1	439781
sodium	B-Chemical	D012964	439781
and	O	-1	439781
volume	O	-1	439781
deple@@	O	-1	439781
ted	O	-1	439781
rats.	O	-1	439781
After	O	-1	439781
a	O	-1	439781
single	O	-1	439781
oral	O	-1	439781
dose	O	-1	439781
of	O	-1	439781
4	O	-1	439781
mg/kg	O	-1	439781
in@@	B-Chemical	D007213	439781
do@@	I-Chemical	-1	439781
meth@@	I-Chemical	-1	439781
ac@@	I-Chemical	-1	439781
in	I-Chemical	-1	439781
(	O	-1	439781
I@@	B-Chemical	D007213	439781
D@@	I-Chemical	-1	439781
M	I-Chemical	-1	439781
)	O	-1	439781
to	O	-1	439781
sodium	B-Chemical	D012964	439781
and	O	-1	439781
volume	O	-1	439781
deple@@	O	-1	439781
ted	O	-1	439781
rats	O	-1	439781
plasma	O	-1	439781
ren@@	O	-1	439781
in	O	-1	439781
activity	O	-1	439781
(P@@	O	-1	439781
R@@	O	-1	439781
A@@	O	-1	439781
)	O	-1	439781
and	O	-1	439781
systolic	O	-1	439781
blood	O	-1	439781
pressure	O	-1	439781
f@@	O	-1	439781
el@@	O	-1	439781
l	O	-1	439781
significantly	O	-1	439781
within	O	-1	439781
four	O	-1	439781
hour@@	O	-1	439781
s.	O	-1	439781
In	O	-1	439781
sodium	B-Chemical	D012964	439781
re@@	O	-1	439781
ple@@	O	-1	439781
ted	O	-1	439781
animals	O	-1	439781
in@@	B-Chemical	D007213	439781
do@@	I-Chemical	-1	439781
meth@@	I-Chemical	-1	439781
ac@@	I-Chemical	-1	439781
in	I-Chemical	-1	439781
did	O	-1	439781
not	O	-1	439781
change	O	-1	439781
systolic	O	-1	439781
blood	O	-1	439781
pressure	O	-1	439781
(B@@	O	-1	439781
P)	O	-1	439781
although	O	-1	439781
plasma	O	-1	439781
ren@@	O	-1	439781
in	O	-1	439781
activity	O	-1	439781
was	O	-1	439781
decreas@@	O	-1	439781
ed.	O	-1	439781
Th@@	O	-1	439781
us,	O	-1	439781
in@@	B-Chemical	D007213	439781
do@@	I-Chemical	-1	439781
meth@@	I-Chemical	-1	439781
ac@@	I-Chemical	-1	439781
in	I-Chemical	-1	439781
by	O	-1	439781
inhibition	O	-1	439781
of	O	-1	439781
pro@@	B-Chemical	D011453	439781
st@@	I-Chemical	-1	439781
ag@@	I-Chemical	-1	439781
l@@	I-Chemical	-1	439781
and@@	I-Chemical	-1	439781
in	I-Chemical	-1	439781
syn@@	O	-1	439781
thesis	O	-1	439781
may	O	-1	439781
di@@	O	-1	439781
min@@	O	-1	439781
is@@	O	-1	439781
h	O	-1	439781
the	O	-1	439781
blood	O	-1	439781
pressure	O	-1	439781
maint@@	O	-1	439781
aining	O	-1	439781
effect	O	-1	439781
of	O	-1	439781
the	O	-1	439781
stimul@@	O	-1	439781
ated	O	-1	439781
ren@@	O	-1	439781
in@@	O	-1	439781
-	O	-1	439781
angiotens@@	B-Chemical	D000809	439781
in	I-Chemical	-1	439781
system	O	-1	439781
in	O	-1	439781
sodium	B-Chemical	D012964	439781
and	O	-1	439781
volume	O	-1	439781
deple@@	O	-1	439781
tion.	O	-1	439781

L@@	O	-1	22836123
at@@	O	-1	22836123
e-@@	O	-1	22836123
onset	O	-1	22836123
s@@	B-Disease	D007674	22836123
clero@@	I-Disease	-1	22836123
der@@	I-Disease	-1	22836123
ma	I-Disease	-1	22836123
renal	I-Disease	-1	22836123
cri@@	I-Disease	-1	22836123
sis	I-Disease	-1	22836123
induced	O	-1	22836123
by	O	-1	22836123
tacrolimus	B-Chemical	D016559	22836123
and	O	-1	22836123
pre@@	B-Chemical	D011239	22836123
d@@	I-Chemical	-1	22836123
n@@	I-Chemical	-1	22836123
isol@@	I-Chemical	-1	22836123
one	I-Chemical	-1	22836123
:	O	-1	22836123
a	O	-1	22836123
case	O	-1	22836123
repor@@	O	-1	22836123
t.	O	-1	22836123
S@@	B-Disease	D007674	22836123
clero@@	I-Disease	-1	22836123
der@@	I-Disease	-1	22836123
ma	I-Disease	-1	22836123
renal	I-Disease	-1	22836123
cri@@	I-Disease	-1	22836123
sis	I-Disease	-1	22836123
(	O	-1	22836123
SR@@	B-Disease	D007674	22836123
C	I-Disease	-1	22836123
)	O	-1	22836123
is	O	-1	22836123
a	O	-1	22836123
r@@	O	-1	22836123
are	O	-1	22836123
complication	O	-1	22836123
of	O	-1	22836123
systemic	B-Disease	D012595	22836123
s@@	I-Disease	-1	22836123
clero@@	I-Disease	-1	22836123
sis	I-Disease	-1	22836123
(	O	-1	22836123
S@@	B-Disease	D012595	22836123
S@@	I-Disease	-1	22836123
c	I-Disease	-1	22836123
)	O	-1	22836123
but	O	-1	22836123
can	O	-1	22836123
be	O	-1	22836123
severe	O	-1	22836123
en@@	O	-1	22836123
ou@@	O	-1	22836123
gh	O	-1	22836123
to	O	-1	22836123
requ@@	O	-1	22836123
ir@@	O	-1	22836123
e	O	-1	22836123
tempor@@	O	-1	22836123
ary	O	-1	22836123
or	O	-1	22836123
per@@	O	-1	22836123
man@@	O	-1	22836123
ent	O	-1	22836123
renal	O	-1	22836123
re@@	O	-1	22836123
pl@@	O	-1	22836123
ac@@	O	-1	22836123
ement	O	-1	22836123
therapy.	O	-1	22836123
M@@	O	-1	22836123
o@@	O	-1	22836123
der@@	O	-1	22836123
ate	O	-1	22836123
to	O	-1	22836123
high	O	-1	22836123
dose	O	-1	22836123
cortico@@	B-Chemical	D000305	22836123
ster@@	I-Chemical	-1	22836123
oid	I-Chemical	-1	22836123
use	O	-1	22836123
is	O	-1	22836123
reco@@	O	-1	22836123
gn@@	O	-1	22836123
ized	O	-1	22836123
as	O	-1	22836123
a	O	-1	22836123
major	O	-1	22836123
risk	O	-1	22836123
factor	O	-1	22836123
for	O	-1	22836123
SR@@	B-Disease	D007674	22836123
C	I-Disease	-1	22836123
.	O	-1	22836123
F@@	O	-1	22836123
ur@@	O	-1	22836123
ther@@	O	-1	22836123
mo@@	O	-1	22836123
re,	O	-1	22836123
there	O	-1	22836123
have	O	-1	22836123
been	O	-1	22836123
reports	O	-1	22836123
of	O	-1	22836123
thrombotic	B-Disease	D057049	22836123
microangio@@	I-Disease	-1	22836123
pathy	I-Disease	-1	22836123
pre@@	O	-1	22836123
ci@@	O	-1	22836123
pit@@	O	-1	22836123
ated	O	-1	22836123
by	O	-1	22836123
cyclospor@@	B-Chemical	D016572	22836123
ine	I-Chemical	-1	22836123
in	O	-1	22836123
patients	O	-1	22836123
with	O	-1	22836123
S@@	B-Disease	D012595	22836123
S@@	I-Disease	-1	22836123
c	I-Disease	-1	22836123
.	O	-1	22836123
In	O	-1	22836123
this	O	-1	22836123
ar@@	O	-1	22836123
tic@@	O	-1	22836123
le@@	O	-1	22836123
,	O	-1	22836123
we	O	-1	22836123
report	O	-1	22836123
a	O	-1	22836123
patient	O	-1	22836123
with	O	-1	22836123
SR@@	B-Disease	D007674	22836123
C	I-Disease	-1	22836123
induced	O	-1	22836123
by	O	-1	22836123
tacrolimus	B-Chemical	D016559	22836123
and	O	-1	22836123
cortico@@	B-Chemical	D000305	22836123
steroid@@	I-Chemical	-1	22836123
s	I-Chemical	-1	22836123
.	O	-1	22836123
The	O	-1	22836123
a@@	O	-1	22836123
im	O	-1	22836123
of	O	-1	22836123
this	O	-1	22836123
wor@@	O	-1	22836123
k	O	-1	22836123
is	O	-1	22836123
to	O	-1	22836123
c@@	O	-1	22836123
all	O	-1	22836123
atten@@	O	-1	22836123
tion	O	-1	22836123
to	O	-1	22836123
the	O	-1	22836123
risk	O	-1	22836123
of	O	-1	22836123
tacrolimus	B-Chemical	D016559	22836123
use	O	-1	22836123
in	O	-1	22836123
patients	O	-1	22836123
with	O	-1	22836123
S@@	B-Disease	D012595	22836123
S@@	I-Disease	-1	22836123
c	I-Disease	-1	22836123
.	O	-1	22836123

The	O	-1	23433219
risk	O	-1	23433219
and	O	-1	23433219
associated	O	-1	23433219
factors	O	-1	23433219
of	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
psycho@@	B-Disease	D011605	23433219
sis	I-Disease	-1	23433219
in	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
-@@	O	-1	23433219
dependent	O	-1	23433219
patients	O	-1	23433219
in	O	-1	23433219
M@@	O	-1	23433219
al@@	O	-1	23433219
ay@@	O	-1	23433219
sia.	O	-1	23433219
OBJECTIVE:	O	-1	23433219
The	O	-1	23433219
ob@@	O	-1	23433219
j@@	O	-1	23433219
ective	O	-1	23433219
of	O	-1	23433219
this	O	-1	23433219
study	O	-1	23433219
was	O	-1	23433219
to	O	-1	23433219
determine	O	-1	23433219
the	O	-1	23433219
risk	O	-1	23433219
of	O	-1	23433219
li@@	O	-1	23433219
fe@@	O	-1	23433219
time	O	-1	23433219
and	O	-1	23433219
current	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
-induced	O	-1	23433219
psycho@@	B-Disease	D011605	23433219
sis	I-Disease	-1	23433219
in	O	-1	23433219
patients	O	-1	23433219
with	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
depend@@	O	-1	23433219
ence@@	O	-1	23433219
.	O	-1	23433219
The	O	-1	23433219
association	O	-1	23433219
between	O	-1	23433219
psych@@	O	-1	23433219
i@@	O	-1	23433219
atric	O	-1	23433219
co-@@	O	-1	23433219
mor@@	O	-1	23433219
b@@	O	-1	23433219
idity	O	-1	23433219
and	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
-induced	O	-1	23433219
psycho@@	B-Disease	D011605	23433219
sis	I-Disease	-1	23433219
was	O	-1	23433219
also	O	-1	23433219
studi@@	O	-1	23433219
ed.	O	-1	23433219
METHODS:	O	-1	23433219
This	O	-1	23433219
was	O	-1	23433219
a	O	-1	23433219
cros@@	O	-1	23433219
s-@@	O	-1	23433219
sec@@	O	-1	23433219
tional	O	-1	23433219
study	O	-1	23433219
con@@	O	-1	23433219
duc@@	O	-1	23433219
ted	O	-1	23433219
con@@	O	-1	23433219
cur@@	O	-1	23433219
ren@@	O	-1	23433219
tly	O	-1	23433219
at	O	-1	23433219
a	O	-1	23433219
te@@	O	-1	23433219
ac@@	O	-1	23433219
h@@	O	-1	23433219
ing	O	-1	23433219
hospit@@	O	-1	23433219
al	O	-1	23433219
and	O	-1	23433219
a	O	-1	23433219
drug	O	-1	23433219
re@@	O	-1	23433219
h@@	O	-1	23433219
abil@@	O	-1	23433219
it@@	O	-1	23433219
ation	O	-1	23433219
c@@	O	-1	23433219
ent@@	O	-1	23433219
er	O	-1	23433219
in	O	-1	23433219
M@@	O	-1	23433219
al@@	O	-1	23433219
ay@@	O	-1	23433219
sia.	O	-1	23433219
Patients	O	-1	23433219
with	O	-1	23433219
the	O	-1	23433219
diagnosis	O	-1	23433219
of	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
bas@@	O	-1	23433219
ed	O	-1	23433219
on	O	-1	23433219
D@@	O	-1	23433219
S@@	O	-1	23433219
M@@	O	-1	23433219
-@@	O	-1	23433219
IV	O	-1	23433219
were	O	-1	23433219
inter@@	O	-1	23433219
vie@@	O	-1	23433219
w@@	O	-1	23433219
ed	O	-1	23433219
using	O	-1	23433219
the	O	-1	23433219
M@@	O	-1	23433219
in@@	O	-1	23433219
i	O	-1	23433219
In@@	O	-1	23433219
tern@@	O	-1	23433219
ation@@	O	-1	23433219
al	O	-1	23433219
Ne@@	O	-1	23433219
uro@@	O	-1	23433219
psych@@	O	-1	23433219
i@@	O	-1	23433219
atric	O	-1	23433219
In@@	O	-1	23433219
ter@@	O	-1	23433219
vie@@	O	-1	23433219
w	O	-1	23433219
(@@	O	-1	23433219
M@@	O	-1	23433219
.@@	O	-1	23433219
I@@	O	-1	23433219
.@@	O	-1	23433219
N@@	O	-1	23433219
.@@	O	-1	23433219
I@@	O	-1	23433219
.)	O	-1	23433219
for	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
-induced	O	-1	23433219
psycho@@	B-Disease	D011605	23433219
sis	I-Disease	-1	23433219
and	O	-1	23433219
other	O	-1	23433219
A@@	O	-1	23433219
x@@	O	-1	23433219
is	O	-1	23433219
I	O	-1	23433219
psych@@	B-Disease	D001523	23433219
i@@	I-Disease	-1	23433219
atric	I-Disease	-1	23433219
disorder@@	I-Disease	-1	23433219
s	I-Disease	-1	23433219
.	O	-1	23433219
The	O	-1	23433219
inf@@	O	-1	23433219
orm@@	O	-1	23433219
ation	O	-1	23433219
on	O	-1	23433219
s@@	O	-1	23433219
oc@@	O	-1	23433219
io@@	O	-1	23433219
de@@	O	-1	23433219
mo@@	O	-1	23433219
graph@@	O	-1	23433219
ic	O	-1	23433219
bac@@	O	-1	23433219
kg@@	O	-1	23433219
ro@@	O	-1	23433219
un@@	O	-1	23433219
d	O	-1	23433219
and	O	-1	23433219
drug	O	-1	23433219
use	O	-1	23433219
hist@@	O	-1	23433219
ory	O	-1	23433219
was	O	-1	23433219
obtained	O	-1	23433219
from	O	-1	23433219
inter@@	O	-1	23433219
vie@@	O	-1	23433219
w	O	-1	23433219
or	O	-1	23433219
med@@	O	-1	23433219
ical	O	-1	23433219
recor@@	O	-1	23433219
d@@	O	-1	23433219
s.	O	-1	23433219
RESULTS:	O	-1	23433219
Of	O	-1	23433219
2@@	O	-1	23433219
9@@	O	-1	23433219
2	O	-1	23433219
subj@@	O	-1	23433219
ect@@	O	-1	23433219
s,	O	-1	23433219
4@@	O	-1	23433219
7.@@	O	-1	23433219
9@@	O	-1	23433219
%	O	-1	23433219
of	O	-1	23433219
the	O	-1	23433219
subjects	O	-1	23433219
had	O	-1	23433219
a	O	-1	23433219
p@@	O	-1	23433219
ast	O	-1	23433219
hist@@	O	-1	23433219
ory	O	-1	23433219
of	O	-1	23433219
psycho@@	B-Disease	D011605	23433219
tic	I-Disease	-1	23433219
symptoms	I-Disease	-1	23433219
and	O	-1	23433219
1@@	O	-1	23433219
3.@@	O	-1	23433219
0%	O	-1	23433219
of	O	-1	23433219
the	O	-1	23433219
patients	O	-1	23433219
were	O	-1	23433219
ha@@	O	-1	23433219
ving	O	-1	23433219
current	O	-1	23433219
psycho@@	B-Disease	D011605	23433219
tic	I-Disease	-1	23433219
symptoms	I-Disease	-1	23433219
.	O	-1	23433219
C@@	O	-1	23433219
o@@	O	-1	23433219
-@@	O	-1	23433219
mor@@	O	-1	23433219
b@@	O	-1	23433219
id	O	-1	23433219
major	O	-1	23433219
de@@	B-Disease	D003866	23433219
pressive	I-Disease	-1	23433219
disor@@	I-Disease	-1	23433219
der	I-Disease	-1	23433219
(@@	O	-1	23433219
O@@	O	-1	23433219
R@@	O	-1	23433219
=@@	O	-1	23433219
7.@@	O	-1	23433219
18@@	O	-1	23433219
,	O	-1	23433219
9@@	O	-1	23433219
5	O	-1	23433219
CI@@	O	-1	23433219
=@@	O	-1	23433219
2.@@	O	-1	23433219
6@@	O	-1	23433219
1@@	O	-1	23433219
2-@@	O	-1	23433219
19@@	O	-1	23433219
.@@	O	-1	23433219
7@@	O	-1	23433219
0@@	O	-1	23433219
8@@	O	-1	23433219
),	O	-1	23433219
b@@	B-Disease	D001714	23433219
ip@@	I-Disease	-1	23433219
ol@@	I-Disease	-1	23433219
ar	I-Disease	-1	23433219
disor@@	I-Disease	-1	23433219
der	I-Disease	-1	23433219
(@@	O	-1	23433219
O@@	O	-1	23433219
R@@	O	-1	23433219
=@@	O	-1	23433219
1@@	O	-1	23433219
3.@@	O	-1	23433219
80@@	O	-1	23433219
7@@	O	-1	23433219
,	O	-1	23433219
9@@	O	-1	23433219
5	O	-1	23433219
CI@@	O	-1	23433219
=@@	O	-1	23433219
5.@@	O	-1	23433219
19@@	O	-1	23433219
4-@@	O	-1	23433219
3@@	O	-1	23433219
6.@@	O	-1	23433219
7@@	O	-1	23433219
0@@	O	-1	23433219
6@@	O	-1	23433219
),	O	-1	23433219
anti@@	B-Disease	D000987	23433219
s@@	I-Disease	-1	23433219
oci@@	I-Disease	-1	23433219
al	I-Disease	-1	23433219
per@@	I-Disease	-1	23433219
son@@	I-Disease	-1	23433219
ality	I-Disease	-1	23433219
disor@@	I-Disease	-1	23433219
der	I-Disease	-1	23433219
(@@	O	-1	23433219
O@@	O	-1	23433219
R@@	O	-1	23433219
=@@	O	-1	23433219
1@@	O	-1	23433219
2.@@	O	-1	23433219
6@@	O	-1	23433219
19@@	O	-1	23433219
,	O	-1	23433219
9@@	O	-1	23433219
5	O	-1	23433219
CI@@	O	-1	23433219
=@@	O	-1	23433219
6.@@	O	-1	23433219
7@@	O	-1	23433219
0@@	O	-1	23433219
2-@@	O	-1	23433219
2@@	O	-1	23433219
3.@@	O	-1	23433219
7@@	O	-1	23433219
5@@	O	-1	23433219
9@@	O	-1	23433219
)	O	-1	23433219
and	O	-1	23433219
he@@	O	-1	23433219
av@@	O	-1	23433219
y	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
u@@	O	-1	23433219
ses	O	-1	23433219
were	O	-1	23433219
significantly	O	-1	23433219
associated	O	-1	23433219
with	O	-1	23433219
li@@	O	-1	23433219
fe@@	O	-1	23433219
time	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
-induced	O	-1	23433219
psycho@@	B-Disease	D011605	23433219
sis	I-Disease	-1	23433219
after	O	-1	23433219
adjust@@	O	-1	23433219
ed	O	-1	23433219
for	O	-1	23433219
other	O	-1	23433219
fact@@	O	-1	23433219
or@@	O	-1	23433219
s.	O	-1	23433219
M@@	B-Disease	D003865	23433219
a@@	I-Disease	-1	23433219
j@@	I-Disease	-1	23433219
or	I-Disease	-1	23433219
de@@	I-Disease	-1	23433219
pressive	I-Disease	-1	23433219
disor@@	I-Disease	-1	23433219
der	I-Disease	-1	23433219
(@@	O	-1	23433219
O@@	O	-1	23433219
R@@	O	-1	23433219
=@@	O	-1	23433219
2.@@	O	-1	23433219
8@@	O	-1	23433219
7@@	O	-1	23433219
0@@	O	-1	23433219
,	O	-1	23433219
CI@@	O	-1	23433219
=@@	O	-1	23433219
1.@@	O	-1	23433219
1@@	O	-1	23433219
5@@	O	-1	23433219
4-@@	O	-1	23433219
7.@@	O	-1	23433219
14@@	O	-1	23433219
2)	O	-1	23433219
and	O	-1	23433219
anti@@	B-Disease	D000987	23433219
s@@	I-Disease	-1	23433219
oci@@	I-Disease	-1	23433219
al	I-Disease	-1	23433219
per@@	I-Disease	-1	23433219
son@@	I-Disease	-1	23433219
ality	I-Disease	-1	23433219
disor@@	I-Disease	-1	23433219
der	I-Disease	-1	23433219
(@@	O	-1	23433219
O@@	O	-1	23433219
R@@	O	-1	23433219
=@@	O	-1	23433219
3.@@	O	-1	23433219
2@@	O	-1	23433219
9@@	O	-1	23433219
9@@	O	-1	23433219
,	O	-1	23433219
9@@	O	-1	23433219
5	O	-1	23433219
CI@@	O	-1	23433219
=@@	O	-1	23433219
1.@@	O	-1	23433219
3@@	O	-1	23433219
7@@	O	-1	23433219
5-@@	O	-1	23433219
7.@@	O	-1	23433219
9@@	O	-1	23433219
14@@	O	-1	23433219
)	O	-1	23433219
were	O	-1	23433219
the	O	-1	23433219
only	O	-1	23433219
factors	O	-1	23433219
associated	O	-1	23433219
with	O	-1	23433219
current	O	-1	23433219
psycho@@	B-Disease	D011605	23433219
sis	I-Disease	-1	23433219
.	O	-1	23433219
CONCLUSION:	O	-1	23433219
There	O	-1	23433219
was	O	-1	23433219
a	O	-1	23433219
high	O	-1	23433219
risk	O	-1	23433219
of	O	-1	23433219
psycho@@	B-Disease	D011605	23433219
sis	I-Disease	-1	23433219
in	O	-1	23433219
patients	O	-1	23433219
with	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
depend@@	O	-1	23433219
ence@@	O	-1	23433219
.	O	-1	23433219
It	O	-1	23433219
was	O	-1	23433219
associated	O	-1	23433219
with	O	-1	23433219
co-@@	O	-1	23433219
mor@@	O	-1	23433219
b@@	O	-1	23433219
id	O	-1	23433219
aff@@	B-Disease	D019964	23433219
ective	I-Disease	-1	23433219
disor@@	I-Disease	-1	23433219
der	I-Disease	-1	23433219
,	O	-1	23433219
anti@@	B-Disease	D000987	23433219
s@@	I-Disease	-1	23433219
oci@@	I-Disease	-1	23433219
al	I-Disease	-1	23433219
per@@	I-Disease	-1	23433219
son@@	I-Disease	-1	23433219
ality	I-Disease	-1	23433219
,	O	-1	23433219
and	O	-1	23433219
he@@	O	-1	23433219
av@@	O	-1	23433219
y	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
use.	O	-1	23433219
It	O	-1	23433219
is	O	-1	23433219
recomm@@	O	-1	23433219
en@@	O	-1	23433219
ded	O	-1	23433219
that	O	-1	23433219
all	O	-1	23433219
cases	O	-1	23433219
of	O	-1	23433219
meth@@	B-Chemical	D008694	23433219
amphetamine	I-Chemical	-1	23433219
depend@@	O	-1	23433219
ence	O	-1	23433219
should	O	-1	23433219
be	O	-1	23433219
s@@	O	-1	23433219
cre@@	O	-1	23433219
en@@	O	-1	23433219
ed	O	-1	23433219
for	O	-1	23433219
psycho@@	B-Disease	D011605	23433219
tic	I-Disease	-1	23433219
symptoms	I-Disease	-1	23433219
.	O	-1	23433219

C@@	O	-1	23535177
e@@	O	-1	23535177
re@@	O	-1	23535177
bell@@	O	-1	23535177
ar	O	-1	23535177
sens@@	O	-1	23535177
ory	O	-1	23535177
pro@@	O	-1	23535177
cess@@	O	-1	23535177
ing	O	-1	23535177
al@@	O	-1	23535177
ter@@	O	-1	23535177
ations	O	-1	23535177
im@@	O	-1	23535177
pac@@	O	-1	23535177
t	O	-1	23535177
motor	O	-1	23535177
cor@@	O	-1	23535177
tical	O	-1	23535177
plas@@	O	-1	23535177
tic@@	O	-1	23535177
ity	O	-1	23535177
in	O	-1	23535177
Parkinson's	B-Disease	D010300	23535177
disease	I-Disease	-1	23535177
:	O	-1	23535177
cl@@	O	-1	23535177
u@@	O	-1	23535177
es	O	-1	23535177
from	O	-1	23535177
dyskine@@	B-Disease	D004409	23535177
tic	I-Disease	-1	23535177
patients.	O	-1	23535177
The	O	-1	23535177
plas@@	O	-1	23535177
tic@@	O	-1	23535177
ity	O	-1	23535177
of	O	-1	23535177
prim@@	O	-1	23535177
ary	O	-1	23535177
motor	O	-1	23535177
cor@@	O	-1	23535177
te@@	O	-1	23535177
x	O	-1	23535177
(@@	O	-1	23535177
M@@	O	-1	23535177
1)	O	-1	23535177
in	O	-1	23535177
patients	O	-1	23535177
with	O	-1	23535177
Parkinson's	B-Disease	D010300	23535177
disease	I-Disease	-1	23535177
(	O	-1	23535177
P@@	B-Disease	D010300	23535177
D	I-Disease	-1	23535177
)	O	-1	23535177
and	O	-1	23535177
levo@@	B-Chemical	D007980	23535177
dopa	I-Chemical	-1	23535177
-induced	O	-1	23535177
dyskine@@	B-Disease	D004409	23535177
si@@	I-Disease	-1	23535177
as	I-Disease	-1	23535177
(	O	-1	23535177
L@@	B-Disease	D004409	23535177
I@@	I-Disease	-1	23535177
D@@	I-Disease	-1	23535177
s	I-Disease	-1	23535177
)	O	-1	23535177
is	O	-1	23535177
se@@	O	-1	23535177
ve@@	O	-1	23535177
re@@	O	-1	23535177
ly	O	-1	23535177
impa@@	O	-1	23535177
i@@	O	-1	23535177
red.	O	-1	23535177
We	O	-1	23535177
rec@@	O	-1	23535177
ently	O	-1	23535177
reported	O	-1	23535177
in	O	-1	23535177
youn@@	O	-1	23535177
g	O	-1	23535177
healthy	O	-1	23535177
subjects	O	-1	23535177
that	O	-1	23535177
inhibit@@	O	-1	23535177
ory	O	-1	23535177
ce@@	O	-1	23535177
re@@	O	-1	23535177
bell@@	O	-1	23535177
ar	O	-1	23535177
stimulation	O	-1	23535177
enhanced	O	-1	23535177
the	O	-1	23535177
sens@@	O	-1	23535177
or@@	O	-1	23535177
im@@	O	-1	23535177
otor	O	-1	23535177
plas@@	O	-1	23535177
tic@@	O	-1	23535177
ity	O	-1	23535177
of	O	-1	23535177
M@@	O	-1	23535177
1	O	-1	23535177
that	O	-1	23535177
was	O	-1	23535177
induced	O	-1	23535177
by	O	-1	23535177
pa@@	O	-1	23535177
ired	O	-1	23535177
associ@@	O	-1	23535177
ative	O	-1	23535177
stimulation	O	-1	23535177
(@@	O	-1	23535177
PA@@	O	-1	23535177
S@@	O	-1	23535177
).	O	-1	23535177
This	O	-1	23535177
study	O	-1	23535177
demon@@	O	-1	23535177
strat@@	O	-1	23535177
es	O	-1	23535177
that	O	-1	23535177
the	O	-1	23535177
defici@@	O	-1	23535177
ent	O	-1	23535177
sens@@	O	-1	23535177
or@@	O	-1	23535177
im@@	O	-1	23535177
otor	O	-1	23535177
M@@	O	-1	23535177
1	O	-1	23535177
plas@@	O	-1	23535177
tic@@	O	-1	23535177
ity	O	-1	23535177
in	O	-1	23535177
16	O	-1	23535177
patients	O	-1	23535177
with	O	-1	23535177
L@@	B-Disease	D004409	23535177
I@@	I-Disease	-1	23535177
D@@	I-Disease	-1	23535177
s	I-Disease	-1	23535177
could	O	-1	23535177
be	O	-1	23535177
re@@	O	-1	23535177
in@@	O	-1	23535177
st@@	O	-1	23535177
ated	O	-1	23535177
by	O	-1	23535177
a	O	-1	23535177
single	O	-1	23535177
s@@	O	-1	23535177
es@@	O	-1	23535177
sion	O	-1	23535177
of	O	-1	23535177
re@@	O	-1	23535177
al	O	-1	23535177
inhibit@@	O	-1	23535177
ory	O	-1	23535177
ce@@	O	-1	23535177
re@@	O	-1	23535177
bell@@	O	-1	23535177
ar	O	-1	23535177
stimulation	O	-1	23535177
but	O	-1	23535177
not	O	-1	23535177
s@@	O	-1	23535177
ha@@	O	-1	23535177
m	O	-1	23535177
stimul@@	O	-1	23535177
ation.	O	-1	23535177
This	O	-1	23535177
was	O	-1	23535177
ev@@	O	-1	23535177
id@@	O	-1	23535177
ent	O	-1	23535177
only	O	-1	23535177
when	O	-1	23535177
a	O	-1	23535177
sens@@	O	-1	23535177
ory	O	-1	23535177
comp@@	O	-1	23535177
on@@	O	-1	23535177
ent	O	-1	23535177
was	O	-1	23535177
involved	O	-1	23535177
in	O	-1	23535177
the	O	-1	23535177
induction	O	-1	23535177
of	O	-1	23535177
plas@@	O	-1	23535177
tic@@	O	-1	23535177
ity,	O	-1	23535177
indicating	O	-1	23535177
that	O	-1	23535177
ce@@	O	-1	23535177
re@@	O	-1	23535177
bell@@	O	-1	23535177
ar	O	-1	23535177
sens@@	O	-1	23535177
ory	O	-1	23535177
pro@@	O	-1	23535177
cess@@	O	-1	23535177
ing	O	-1	23535177
function	O	-1	23535177
is	O	-1	23535177
involved	O	-1	23535177
in	O	-1	23535177
the	O	-1	23535177
res@@	O	-1	23535177
ur@@	O	-1	23535177
gen@@	O	-1	23535177
ce	O	-1	23535177
of	O	-1	23535177
M@@	O	-1	23535177
1	O	-1	23535177
plas@@	O	-1	23535177
tic@@	O	-1	23535177
ity.	O	-1	23535177
The	O	-1	23535177
ben@@	O	-1	23535177
e@@	O	-1	23535177
fi@@	O	-1	23535177
t	O	-1	23535177
of	O	-1	23535177
inhibit@@	O	-1	23535177
ory	O	-1	23535177
ce@@	O	-1	23535177
re@@	O	-1	23535177
bell@@	O	-1	23535177
ar	O	-1	23535177
stimulation	O	-1	23535177
on	O	-1	23535177
L@@	B-Disease	D004409	23535177
I@@	I-Disease	-1	23535177
D@@	I-Disease	-1	23535177
s	I-Disease	-1	23535177
is	O	-1	23535177
know@@	O	-1	23535177
n@@	O	-1	23535177
.	O	-1	23535177
To	O	-1	23535177
expl@@	O	-1	23535177
or@@	O	-1	23535177
e	O	-1	23535177
whether	O	-1	23535177
this	O	-1	23535177
ben@@	O	-1	23535177
e@@	O	-1	23535177
fi@@	O	-1	23535177
t	O	-1	23535177
is	O	-1	23535177
lin@@	O	-1	23535177
ked	O	-1	23535177
to	O	-1	23535177
the	O	-1	23535177
rest@@	O	-1	23535177
or@@	O	-1	23535177
ation	O	-1	23535177
of	O	-1	23535177
sens@@	O	-1	23535177
or@@	O	-1	23535177
im@@	O	-1	23535177
otor	O	-1	23535177
plas@@	O	-1	23535177
tic@@	O	-1	23535177
ity	O	-1	23535177
of	O	-1	23535177
M@@	O	-1	23535177
1,	O	-1	23535177
we	O	-1	23535177
con@@	O	-1	23535177
duc@@	O	-1	23535177
ted	O	-1	23535177
an	O	-1	23535177
addi@@	O	-1	23535177
tional	O	-1	23535177
study	O	-1	23535177
lo@@	O	-1	23535177
o@@	O	-1	23535177
king	O	-1	23535177
at	O	-1	23535177
changes	O	-1	23535177
in	O	-1	23535177
L@@	B-Disease	D004409	23535177
I@@	I-Disease	-1	23535177
D@@	I-Disease	-1	23535177
s	I-Disease	-1	23535177
and	O	-1	23535177
PA@@	O	-1	23535177
S@@	O	-1	23535177
-induced	O	-1	23535177
plas@@	O	-1	23535177
tic@@	O	-1	23535177
ity	O	-1	23535177
after	O	-1	23535177
10	O	-1	23535177
s@@	O	-1	23535177
es@@	O	-1	23535177
sions	O	-1	23535177
of	O	-1	23535177
either	O	-1	23535177
bil@@	O	-1	23535177
at@@	O	-1	23535177
er@@	O	-1	23535177
al,	O	-1	23535177
re@@	O	-1	23535177
al	O	-1	23535177
inhibit@@	O	-1	23535177
ory	O	-1	23535177
ce@@	O	-1	23535177
re@@	O	-1	23535177
bell@@	O	-1	23535177
ar	O	-1	23535177
stimulation	O	-1	23535177
or	O	-1	23535177
s@@	O	-1	23535177
ha@@	O	-1	23535177
m	O	-1	23535177
stimul@@	O	-1	23535177
ation.	O	-1	23535177
On@@	O	-1	23535177
ly	O	-1	23535177
re@@	O	-1	23535177
al	O	-1	23535177
and	O	-1	23535177
not	O	-1	23535177
s@@	O	-1	23535177
ha@@	O	-1	23535177
m	O	-1	23535177
stimulation	O	-1	23535177
had	O	-1	23535177
an	O	-1	23535177
anti@@	O	-1	23535177
dyskine@@	O	-1	23535177
tic	O	-1	23535177
effect	O	-1	23535177
and	O	-1	23535177
it	O	-1	23535177
was	O	-1	23535177
par@@	O	-1	23535177
al@@	O	-1	23535177
le@@	O	-1	23535177
l@@	O	-1	23535177
ed	O	-1	23535177
by	O	-1	23535177
a	O	-1	23535177
res@@	O	-1	23535177
ur@@	O	-1	23535177
gen@@	O	-1	23535177
ce	O	-1	23535177
in	O	-1	23535177
the	O	-1	23535177
sens@@	O	-1	23535177
or@@	O	-1	23535177
im@@	O	-1	23535177
otor	O	-1	23535177
plas@@	O	-1	23535177
tic@@	O	-1	23535177
ity	O	-1	23535177
of	O	-1	23535177
M@@	O	-1	23535177
1@@	O	-1	23535177
.	O	-1	23535177
These	O	-1	23535177
results	O	-1	23535177
suggest	O	-1	23535177
that	O	-1	23535177
al@@	O	-1	23535177
ter@@	O	-1	23535177
ations	O	-1	23535177
in	O	-1	23535177
ce@@	O	-1	23535177
re@@	O	-1	23535177
bell@@	O	-1	23535177
ar	O	-1	23535177
sens@@	O	-1	23535177
ory	O	-1	23535177
pro@@	O	-1	23535177
cess@@	O	-1	23535177
ing	O	-1	23535177
func@@	O	-1	23535177
tion,	O	-1	23535177
occur@@	O	-1	23535177
r@@	O	-1	23535177
ing	O	-1	23535177
secondary	O	-1	23535177
to	O	-1	23535177
ab@@	O	-1	23535177
normal	O	-1	23535177
bas@@	O	-1	23535177
al	O	-1	23535177
g@@	O	-1	23535177
ang@@	O	-1	23535177
li@@	O	-1	23535177
a	O	-1	23535177
sign@@	O	-1	23535177
als	O	-1	23535177
reac@@	O	-1	23535177
h@@	O	-1	23535177
ing	O	-1	23535177
it@@	O	-1	23535177
,	O	-1	23535177
may	O	-1	23535177
be	O	-1	23535177
an	O	-1	23535177
important	O	-1	23535177
e@@	O	-1	23535177
le@@	O	-1	23535177
ment	O	-1	23535177
cont@@	O	-1	23535177
ri@@	O	-1	23535177
but@@	O	-1	23535177
ing	O	-1	23535177
to	O	-1	23535177
the	O	-1	23535177
mal@@	O	-1	23535177
ad@@	O	-1	23535177
ap@@	O	-1	23535177
tive	O	-1	23535177
sens@@	O	-1	23535177
or@@	O	-1	23535177
im@@	O	-1	23535177
otor	O	-1	23535177
plas@@	O	-1	23535177
tic@@	O	-1	23535177
ity	O	-1	23535177
of	O	-1	23535177
M@@	O	-1	23535177
1	O	-1	23535177
and	O	-1	23535177
the	O	-1	23535177
em@@	O	-1	23535177
er@@	O	-1	23535177
gen@@	O	-1	23535177
ce	O	-1	23535177
of	O	-1	23535177
ab@@	B-Disease	D004409	23535177
normal	I-Disease	-1	23535177
invol@@	I-Disease	-1	23535177
un@@	I-Disease	-1	23535177
t@@	I-Disease	-1	23535177
ary	I-Disease	-1	23535177
mo@@	I-Disease	-1	23535177
ve@@	I-Disease	-1	23535177
ments	I-Disease	-1	23535177
.	O	-1	23535177

The	O	-1	23666265
function	O	-1	23666265
of	O	-1	23666265
P@@	O	-1	23666265
2@@	O	-1	23666265
X@@	O	-1	23666265
3	O	-1	23666265
receptor	O	-1	23666265
and	O	-1	23666265
N@@	O	-1	23666265
K@@	O	-1	23666265
1	O	-1	23666265
receptor	O	-1	23666265
antagonist@@	O	-1	23666265
s	O	-1	23666265
on	O	-1	23666265
cyclophosph@@	B-Chemical	D003520	23666265
amide	I-Chemical	-1	23666265
-induced	O	-1	23666265
cys@@	B-Disease	D003556	23666265
ti@@	I-Disease	-1	23666265
tis	I-Disease	-1	23666265
in	O	-1	23666265
rats.	O	-1	23666265
P@@	O	-1	23666265
U@@	O	-1	23666265
R@@	O	-1	23666265
P@@	O	-1	23666265
O@@	O	-1	23666265
S@@	O	-1	23666265
E:	O	-1	23666265
The	O	-1	23666265
pur@@	O	-1	23666265
p@@	O	-1	23666265
ose	O	-1	23666265
of	O	-1	23666265
the	O	-1	23666265
study	O	-1	23666265
is	O	-1	23666265
to	O	-1	23666265
expl@@	O	-1	23666265
or@@	O	-1	23666265
e	O	-1	23666265
the	O	-1	23666265
function	O	-1	23666265
of	O	-1	23666265
P@@	O	-1	23666265
2@@	O	-1	23666265
X@@	O	-1	23666265
3	O	-1	23666265
and	O	-1	23666265
N@@	O	-1	23666265
K@@	O	-1	23666265
1	O	-1	23666265
receptors	O	-1	23666265
antagonist@@	O	-1	23666265
s	O	-1	23666265
on	O	-1	23666265
cyclophosph@@	B-Chemical	D003520	23666265
amide	I-Chemical	-1	23666265
(	O	-1	23666265
C@@	B-Chemical	D003520	23666265
Y@@	I-Chemical	-1	23666265
P	I-Chemical	-1	23666265
)@@	O	-1	23666265
-induced	O	-1	23666265
cys@@	B-Disease	D003556	23666265
ti@@	I-Disease	-1	23666265
tis	I-Disease	-1	23666265
in	O	-1	23666265
rats.	O	-1	23666265
METHODS:	O	-1	23666265
Si@@	O	-1	23666265
x@@	O	-1	23666265
t@@	O	-1	23666265
y	O	-1	23666265
female	O	-1	23666265
S@@	O	-1	23666265
pra@@	O	-1	23666265
gu@@	O	-1	23666265
e-@@	O	-1	23666265
D@@	O	-1	23666265
aw@@	O	-1	23666265
le@@	O	-1	23666265
y	O	-1	23666265
(S@@	O	-1	23666265
D)	O	-1	23666265
rats	O	-1	23666265
were	O	-1	23666265
random@@	O	-1	23666265
ly	O	-1	23666265
divid@@	O	-1	23666265
ed	O	-1	23666265
into	O	-1	23666265
three	O	-1	23666265
groups.	O	-1	23666265
The	O	-1	23666265
rats	O	-1	23666265
in	O	-1	23666265
the	O	-1	23666265
control	O	-1	23666265
group	O	-1	23666265
were	O	-1	23666265
intra@@	O	-1	23666265
per@@	O	-1	23666265
it@@	O	-1	23666265
one@@	O	-1	23666265
ally	O	-1	23666265
(@@	O	-1	23666265
i.p.@@	O	-1	23666265
)	O	-1	23666265
injected	O	-1	23666265
with	O	-1	23666265
0.@@	O	-1	23666265
9@@	O	-1	23666265
%	O	-1	23666265
saline	O	-1	23666265
(@@	O	-1	23666265
4	O	-1	23666265
ml@@	O	-1	23666265
/@@	O	-1	23666265
kg@@	O	-1	23666265
);	O	-1	23666265
the	O	-1	23666265
rats	O	-1	23666265
in	O	-1	23666265
the	O	-1	23666265
model	O	-1	23666265
group	O	-1	23666265
were	O	-1	23666265
i.@@	O	-1	23666265
p@@	O	-1	23666265
.	O	-1	23666265
injected	O	-1	23666265
with	O	-1	23666265
C@@	B-Chemical	D003520	23666265
Y@@	I-Chemical	-1	23666265
P	I-Chemical	-1	23666265
(1@@	O	-1	23666265
50	O	-1	23666265
mg/kg@@	O	-1	23666265
);	O	-1	23666265
and	O	-1	23666265
the	O	-1	23666265
rats	O	-1	23666265
in	O	-1	23666265
the	O	-1	23666265
inter@@	O	-1	23666265
ven@@	O	-1	23666265
tion	O	-1	23666265
group	O	-1	23666265
were	O	-1	23666265
i.@@	O	-1	23666265
p@@	O	-1	23666265
.	O	-1	23666265
injected	O	-1	23666265
with	O	-1	23666265
C@@	B-Chemical	D003520	23666265
Y@@	I-Chemical	-1	23666265
P	I-Chemical	-1	23666265
with	O	-1	23666265
subsequ@@	O	-1	23666265
ently	O	-1	23666265
per@@	O	-1	23666265
f@@	O	-1	23666265
usion	O	-1	23666265
of	O	-1	23666265
bladder	O	-1	23666265
with	O	-1	23666265
P@@	O	-1	23666265
2@@	O	-1	23666265
X@@	O	-1	23666265
3	O	-1	23666265
and	O	-1	23666265
N@@	O	-1	23666265
K@@	O	-1	23666265
1	O	-1	23666265
receptor@@	O	-1	23666265
s@@	O	-1	23666265
'	O	-1	23666265
antagonist@@	O	-1	23666265
s,	O	-1	23666265
S@@	B-Chemical	D013498	23666265
ur@@	I-Chemical	-1	23666265
amin	I-Chemical	-1	23666265
and	O	-1	23666265
G@@	B-Chemical	C079014	23666265
R	I-Chemical	-1	23666265
8@@	I-Chemical	-1	23666265
2@@	I-Chemical	-1	23666265
3@@	I-Chemical	-1	23666265
3@@	I-Chemical	-1	23666265
4	I-Chemical	-1	23666265
.	O	-1	23666265
S@@	O	-1	23666265
p@@	O	-1	23666265
ont@@	O	-1	23666265
aneous	O	-1	23666265
pain	B-Disease	D010146	23666265
behavi@@	O	-1	23666265
ors	O	-1	23666265
following	O	-1	23666265
the	O	-1	23666265
administration	O	-1	23666265
of	O	-1	23666265
C@@	B-Chemical	D003520	23666265
Y@@	I-Chemical	-1	23666265
P	I-Chemical	-1	23666265
were	O	-1	23666265
obser@@	O	-1	23666265
ved.	O	-1	23666265
U@@	O	-1	23666265
ro@@	O	-1	23666265
dynam@@	O	-1	23666265
ic	O	-1	23666265
par@@	O	-1	23666265
ame@@	O	-1	23666265
ter@@	O	-1	23666265
s,	O	-1	23666265
bladder	O	-1	23666265
pressu@@	O	-1	23666265
re@@	O	-1	23666265
-@@	O	-1	23666265
volume	O	-1	23666265
cur@@	O	-1	23666265
ve,	O	-1	23666265
maxim@@	O	-1	23666265
um	O	-1	23666265
v@@	O	-1	23666265
oid@@	O	-1	23666265
ing	O	-1	23666265
pressure	O	-1	23666265
(@@	O	-1	23666265
M@@	O	-1	23666265
V@@	O	-1	23666265
P@@	O	-1	23666265
),	O	-1	23666265
and	O	-1	23666265
maxim@@	O	-1	23666265
um	O	-1	23666265
cy@@	O	-1	23666265
sto@@	O	-1	23666265
me@@	O	-1	23666265
tri@@	O	-1	23666265
c	O	-1	23666265
cap@@	O	-1	23666265
ac@@	O	-1	23666265
ity	O	-1	23666265
(@@	O	-1	23666265
M@@	O	-1	23666265
C@@	O	-1	23666265
C@@	O	-1	23666265
),	O	-1	23666265
were	O	-1	23666265
recor@@	O	-1	23666265
de@@	O	-1	23666265
d.	O	-1	23666265
P@@	O	-1	23666265
ath@@	O	-1	23666265
ological	O	-1	23666265
changes	O	-1	23666265
in	O	-1	23666265
bladder	O	-1	23666265
tissue	O	-1	23666265
were	O	-1	23666265
obser@@	O	-1	23666265
ved.	O	-1	23666265
Im@@	O	-1	23666265
mun@@	O	-1	23666265
o@@	O	-1	23666265
fluo@@	O	-1	23666265
res@@	O	-1	23666265
c@@	O	-1	23666265
ence	O	-1	23666265
was	O	-1	23666265
used	O	-1	23666265
to	O	-1	23666265
det@@	O	-1	23666265
ect	O	-1	23666265
the	O	-1	23666265
expression	O	-1	23666265
of	O	-1	23666265
P@@	O	-1	23666265
2@@	O	-1	23666265
X@@	O	-1	23666265
3	O	-1	23666265
and	O	-1	23666265
N@@	O	-1	23666265
K@@	O	-1	23666265
1	O	-1	23666265
receptors	O	-1	23666265
in	O	-1	23666265
blad@@	O	-1	23666265
der@@	O	-1	23666265
.	O	-1	23666265
RESULTS:	O	-1	23666265
C@@	B-Chemical	D003520	23666265
yc@@	I-Chemical	-1	23666265
lo@@	I-Chemical	-1	23666265
phosph@@	I-Chemical	-1	23666265
amide	I-Chemical	-1	23666265
treatment	O	-1	23666265
increased	O	-1	23666265
the	O	-1	23666265
spont@@	O	-1	23666265
aneous	O	-1	23666265
pain	B-Disease	D010146	23666265
behavi@@	O	-1	23666265
ors	O	-1	23666265
sco@@	O	-1	23666265
res@@	O	-1	23666265
.	O	-1	23666265
The	O	-1	23666265
incidence	O	-1	23666265
of	O	-1	23666265
bladder	O	-1	23666265
in@@	O	-1	23666265
st@@	O	-1	23666265
ability	O	-1	23666265
during	O	-1	23666265
urine	O	-1	23666265
st@@	O	-1	23666265
or@@	O	-1	23666265
age	O	-1	23666265
period	O	-1	23666265
of	O	-1	23666265
model	O	-1	23666265
group	O	-1	23666265
was	O	-1	23666265
significantly	O	-1	23666265
higher	O	-1	23666265
than	O	-1	23666265
inter@@	O	-1	23666265
ven@@	O	-1	23666265
tion	O	-1	23666265
group	O	-1	23666265
(@@	O	-1	23666265
X@@	O	-1	23666265
(2@@	O	-1	23666265
)	O	-1	23666265
=	O	-1	23666265
7.@@	O	-1	23666265
6@@	O	-1	23666265
19@@	O	-1	23666265
,	O	-1	23666265
P	O	-1	23666265
=	O	-1	23666265
0.00@@	O	-1	23666265
7@@	O	-1	23666265
)	O	-1	23666265
and	O	-1	23666265
control	O	-1	23666265
group	O	-1	23666265
(@@	O	-1	23666265
X@@	O	-1	23666265
(2@@	O	-1	23666265
)	O	-1	23666265
=	O	-1	23666265
1@@	O	-1	23666265
3.@@	O	-1	23666265
7@@	O	-1	23666265
55@@	O	-1	23666265
,	O	-1	23666265
P	O	-1	23666265
=	O	-1	23666265
0.00@@	O	-1	23666265
0@@	O	-1	23666265
).	O	-1	23666265
M@@	O	-1	23666265
C@@	O	-1	23666265
C	O	-1	23666265
in	O	-1	23666265
the	O	-1	23666265
model	O	-1	23666265
group	O	-1	23666265
was	O	-1	23666265
lower	O	-1	23666265
than	O	-1	23666265
the	O	-1	23666265
control	O	-1	23666265
and	O	-1	23666265
inter@@	O	-1	23666265
ven@@	O	-1	23666265
tion	O	-1	23666265
groups	O	-1	23666265
(P	O	-1	23666265
<	O	-1	23666265
0.0@@	O	-1	23666265
1).	O	-1	23666265
H@@	O	-1	23666265
ist@@	O	-1	23666265
ological	O	-1	23666265
changes	O	-1	23666265
ev@@	O	-1	23666265
id@@	O	-1	23666265
ent	O	-1	23666265
in	O	-1	23666265
model	O	-1	23666265
and	O	-1	23666265
inter@@	O	-1	23666265
ven@@	O	-1	23666265
tion	O	-1	23666265
groups	O	-1	23666265
rat@@	O	-1	23666265
s@@	O	-1	23666265
'	O	-1	23666265
bladder	O	-1	23666265
included	O	-1	23666265
e@@	B-Disease	D004487	23666265
de@@	I-Disease	-1	23666265
ma	I-Disease	-1	23666265
,	O	-1	23666265
vas@@	O	-1	23666265
odi@@	O	-1	23666265
l@@	O	-1	23666265
ation,	O	-1	23666265
and	O	-1	23666265
inf@@	O	-1	23666265
iltration	O	-1	23666265
of	O	-1	23666265
inflam@@	O	-1	23666265
mat@@	O	-1	23666265
ory	O	-1	23666265
cell@@	O	-1	23666265
s.	O	-1	23666265
In	O	-1	23666265
model	O	-1	23666265
group@@	O	-1	23666265
,	O	-1	23666265
the	O	-1	23666265
expression	O	-1	23666265
of	O	-1	23666265
P@@	O	-1	23666265
2@@	O	-1	23666265
X@@	O	-1	23666265
3	O	-1	23666265
receptor	O	-1	23666265
increased	O	-1	23666265
in	O	-1	23666265
uro@@	O	-1	23666265
the@@	O	-1	23666265
li@@	O	-1	23666265
um	O	-1	23666265
and	O	-1	23666265
su@@	O	-1	23666265
bu@@	O	-1	23666265
ro@@	O	-1	23666265
the@@	O	-1	23666265
li@@	O	-1	23666265
um,	O	-1	23666265
and	O	-1	23666265
N@@	O	-1	23666265
K@@	O	-1	23666265
1	O	-1	23666265
receptor	O	-1	23666265
increased	O	-1	23666265
in	O	-1	23666265
su@@	O	-1	23666265
bu@@	O	-1	23666265
ro@@	O	-1	23666265
the@@	O	-1	23666265
li@@	O	-1	23666265
um,	O	-1	23666265
while	O	-1	23666265
the	O	-1	23666265
expression	O	-1	23666265
of	O	-1	23666265
the@@	O	-1	23666265
m	O	-1	23666265
in	O	-1	23666265
inter@@	O	-1	23666265
ven@@	O	-1	23666265
tion	O	-1	23666265
group	O	-1	23666265
was	O	-1	23666265
low@@	O	-1	23666265
er.	O	-1	23666265
CONCLUSIONS:	O	-1	23666265
In	O	-1	23666265
C@@	B-Chemical	D003520	23666265
Y@@	I-Chemical	-1	23666265
P	I-Chemical	-1	23666265
-induced	O	-1	23666265
cys@@	B-Disease	D003556	23666265
ti@@	I-Disease	-1	23666265
tis	I-Disease	-1	23666265
,	O	-1	23666265
the	O	-1	23666265
expression	O	-1	23666265
of	O	-1	23666265
P@@	O	-1	23666265
2@@	O	-1	23666265
X@@	O	-1	23666265
3	O	-1	23666265
and	O	-1	23666265
N@@	O	-1	23666265
K@@	O	-1	23666265
1	O	-1	23666265
receptors	O	-1	23666265
increased	O	-1	23666265
in	O	-1	23666265
uro@@	O	-1	23666265
the@@	O	-1	23666265
li@@	O	-1	23666265
um	O	-1	23666265
and/or	O	-1	23666265
su@@	O	-1	23666265
bu@@	O	-1	23666265
ro@@	O	-1	23666265
the@@	O	-1	23666265
li@@	O	-1	23666265
um@@	O	-1	23666265
.	O	-1	23666265
P@@	O	-1	23666265
er@@	O	-1	23666265
f@@	O	-1	23666265
usion	O	-1	23666265
of	O	-1	23666265
bladder	O	-1	23666265
with	O	-1	23666265
P@@	O	-1	23666265
2@@	O	-1	23666265
X@@	O	-1	23666265
3	O	-1	23666265
and	O	-1	23666265
N@@	O	-1	23666265
K@@	O	-1	23666265
1	O	-1	23666265
receptors	O	-1	23666265
antagonist@@	O	-1	23666265
s	O	-1	23666265
ame@@	O	-1	23666265
li@@	O	-1	23666265
or@@	O	-1	23666265
ated	O	-1	23666265
the	O	-1	23666265
bladder	O	-1	23666265
func@@	O	-1	23666265
tion.	O	-1	23666265

Ac@@	O	-1	23846525
ute	O	-1	23846525
hepatitis	B-Disease	D056486	23846525
associated	O	-1	23846525
with	O	-1	23846525
c@@	B-Chemical	C055162	23846525
lop@@	I-Chemical	-1	23846525
id@@	I-Chemical	-1	23846525
o@@	I-Chemical	-1	23846525
gre@@	I-Chemical	-1	23846525
l	I-Chemical	-1	23846525
:	O	-1	23846525
a	O	-1	23846525
case	O	-1	23846525
report	O	-1	23846525
and	O	-1	23846525
revie@@	O	-1	23846525
w	O	-1	23846525
of	O	-1	23846525
the	O	-1	23846525
literat@@	O	-1	23846525
ure.	O	-1	23846525
D@@	O	-1	23846525
ru@@	O	-1	23846525
g@@	O	-1	23846525
-induced	O	-1	23846525
hepat@@	B-Disease	D056486	23846525
otoxicity	I-Disease	-1	23846525
is	O	-1	23846525
a	O	-1	23846525
common	O	-1	23846525
cause	O	-1	23846525
of	O	-1	23846525
acute	O	-1	23846525
hepatitis	B-Disease	D056486	23846525
,	O	-1	23846525
and	O	-1	23846525
the	O	-1	23846525
reco@@	O	-1	23846525
gn@@	O	-1	23846525
ition	O	-1	23846525
of	O	-1	23846525
the	O	-1	23846525
respon@@	O	-1	23846525
sible	O	-1	23846525
drug	O	-1	23846525
may	O	-1	23846525
be	O	-1	23846525
diff@@	O	-1	23846525
ic@@	O	-1	23846525
ult@@	O	-1	23846525
.	O	-1	23846525
We	O	-1	23846525
describe	O	-1	23846525
a	O	-1	23846525
case	O	-1	23846525
of	O	-1	23846525
c@@	B-Chemical	C055162	23846525
lop@@	I-Chemical	-1	23846525
id@@	I-Chemical	-1	23846525
o@@	I-Chemical	-1	23846525
gre@@	I-Chemical	-1	23846525
l	I-Chemical	-1	23846525
-@@	O	-1	23846525
related	O	-1	23846525
acute	O	-1	23846525
hepatitis	B-Disease	D056486	23846525
.	O	-1	23846525
The	O	-1	23846525
diagnosis	O	-1	23846525
is	O	-1	23846525
st@@	O	-1	23846525
ron@@	O	-1	23846525
g@@	O	-1	23846525
ly	O	-1	23846525
suggested	O	-1	23846525
by	O	-1	23846525
an	O	-1	23846525
ac@@	O	-1	23846525
cur@@	O	-1	23846525
ate	O	-1	23846525
med@@	O	-1	23846525
ical	O	-1	23846525
hist@@	O	-1	23846525
ory	O	-1	23846525
and	O	-1	23846525
liver	O	-1	23846525
bio@@	O	-1	23846525
psy@@	O	-1	23846525
.	O	-1	23846525
Re@@	O	-1	23846525
por@@	O	-1	23846525
ts	O	-1	23846525
about	O	-1	23846525
cases	O	-1	23846525
of	O	-1	23846525
hepat@@	B-Disease	D056486	23846525
otoxicity	I-Disease	-1	23846525
due	O	-1	23846525
to	O	-1	23846525
c@@	B-Chemical	C055162	23846525
lop@@	I-Chemical	-1	23846525
id@@	I-Chemical	-1	23846525
o@@	I-Chemical	-1	23846525
gre@@	I-Chemical	-1	23846525
l	I-Chemical	-1	23846525
are	O	-1	23846525
increas@@	O	-1	23846525
ing	O	-1	23846525
in	O	-1	23846525
the	O	-1	23846525
las@@	O	-1	23846525
t	O	-1	23846525
fe@@	O	-1	23846525
w	O	-1	23846525
year@@	O	-1	23846525
s,	O	-1	23846525
after	O	-1	23846525
the	O	-1	23846525
increased	O	-1	23846525
use	O	-1	23846525
of	O	-1	23846525
this	O	-1	23846525
drug.	O	-1	23846525
In	O	-1	23846525
concl@@	O	-1	23846525
u@@	O	-1	23846525
sion,	O	-1	23846525
we	O	-1	23846525
be@@	O	-1	23846525
li@@	O	-1	23846525
e@@	O	-1	23846525
ve	O	-1	23846525
that	O	-1	23846525
physi@@	O	-1	23846525
ci@@	O	-1	23846525
ans	O	-1	23846525
should	O	-1	23846525
ca@@	O	-1	23846525
ref@@	O	-1	23846525
ul@@	O	-1	23846525
ly	O	-1	23846525
con@@	O	-1	23846525
si@@	O	-1	23846525
der	O	-1	23846525
the	O	-1	23846525
risk	O	-1	23846525
of	O	-1	23846525
drug@@	O	-1	23846525
-induced	O	-1	23846525
hepatic	B-Disease	D056486	23846525
injury	I-Disease	-1	23846525
when	O	-1	23846525
c@@	B-Chemical	C055162	23846525
lop@@	I-Chemical	-1	23846525
id@@	I-Chemical	-1	23846525
o@@	I-Chemical	-1	23846525
gre@@	I-Chemical	-1	23846525
l	I-Chemical	-1	23846525
is	O	-1	23846525
prescri@@	O	-1	23846525
be@@	O	-1	23846525
d.	O	-1	23846525

B@@	B-Chemical	C400082	23864035
or@@	I-Chemical	-1	23864035
te@@	I-Chemical	-1	23864035
z@@	I-Chemical	-1	23864035
om@@	I-Chemical	-1	23864035
i@@	I-Chemical	-1	23864035
b	I-Chemical	-1	23864035
and	O	-1	23864035
de@@	B-Chemical	D003907	23864035
xameth@@	I-Chemical	-1	23864035
as@@	I-Chemical	-1	23864035
one	I-Chemical	-1	23864035
as	O	-1	23864035
sal@@	O	-1	23864035
v@@	O	-1	23864035
age	O	-1	23864035
therapy	O	-1	23864035
in	O	-1	23864035
patients	O	-1	23864035
with	O	-1	23864035
rel@@	O	-1	23864035
ap@@	O	-1	23864035
sed@@	O	-1	23864035
/@@	O	-1	23864035
ref@@	O	-1	23864035
rac@@	O	-1	23864035
t@@	O	-1	23864035
ory	O	-1	23864035
multiple	B-Disease	D009101	23864035
my@@	I-Disease	-1	23864035
e@@	I-Disease	-1	23864035
lo@@	I-Disease	-1	23864035
ma	I-Disease	-1	23864035
:	O	-1	23864035
analysis	O	-1	23864035
of	O	-1	23864035
long-term	O	-1	23864035
clinical	O	-1	23864035
outcom@@	O	-1	23864035
es.	O	-1	23864035
B@@	B-Chemical	C400082	23864035
or@@	I-Chemical	-1	23864035
te@@	I-Chemical	-1	23864035
z@@	I-Chemical	-1	23864035
om@@	I-Chemical	-1	23864035
i@@	I-Chemical	-1	23864035
b	I-Chemical	-1	23864035
(	O	-1	23864035
b@@	B-Chemical	C400082	23864035
ort	I-Chemical	-1	23864035
)@@	O	-1	23864035
-	O	-1	23864035
de@@	B-Chemical	D003907	23864035
xameth@@	I-Chemical	-1	23864035
as@@	I-Chemical	-1	23864035
one	I-Chemical	-1	23864035
(	O	-1	23864035
de@@	B-Chemical	D003907	23864035
x	I-Chemical	-1	23864035
)	O	-1	23864035
is	O	-1	23864035
an	O	-1	23864035
effective	O	-1	23864035
therapy	O	-1	23864035
for	O	-1	23864035
rel@@	O	-1	23864035
ap@@	O	-1	23864035
sed@@	O	-1	23864035
/@@	O	-1	23864035
ref@@	O	-1	23864035
rac@@	O	-1	23864035
t@@	O	-1	23864035
ory	O	-1	23864035
(@@	O	-1	23864035
R@@	O	-1	23864035
/@@	O	-1	23864035
R@@	O	-1	23864035
)	O	-1	23864035
multiple	B-Disease	D009101	23864035
my@@	I-Disease	-1	23864035
e@@	I-Disease	-1	23864035
lo@@	I-Disease	-1	23864035
ma	I-Disease	-1	23864035
(	O	-1	23864035
M@@	B-Disease	D009101	23864035
M	I-Disease	-1	23864035
).	O	-1	23864035
This	O	-1	23864035
ret@@	O	-1	23864035
ro@@	O	-1	23864035
sp@@	O	-1	23864035
ective	O	-1	23864035
study	O	-1	23864035
investigated	O	-1	23864035
the	O	-1	23864035
combination	O	-1	23864035
of	O	-1	23864035
b@@	B-Chemical	C400082	23864035
ort	I-Chemical	-1	23864035
(1@@	O	-1	23864035
.@@	O	-1	23864035
3	O	-1	23864035
mg/m@@	O	-1	23864035
(2@@	O	-1	23864035
)	O	-1	23864035
on	O	-1	23864035
days	O	-1	23864035
1,	O	-1	23864035
4@@	O	-1	23864035
,	O	-1	23864035
8@@	O	-1	23864035
,	O	-1	23864035
and	O	-1	23864035
11	O	-1	23864035
every	O	-1	23864035
3	O	-1	23864035
week@@	O	-1	23864035
s)	O	-1	23864035
and	O	-1	23864035
de@@	B-Chemical	D003907	23864035
x	I-Chemical	-1	23864035
(2@@	O	-1	23864035
0	O	-1	23864035
mg	O	-1	23864035
on	O	-1	23864035
the	O	-1	23864035
day	O	-1	23864035
of	O	-1	23864035
and	O	-1	23864035
the	O	-1	23864035
day	O	-1	23864035
after	O	-1	23864035
b@@	B-Chemical	C400082	23864035
ort	I-Chemical	-1	23864035
)	O	-1	23864035
as	O	-1	23864035
sal@@	O	-1	23864035
v@@	O	-1	23864035
age	O	-1	23864035
treatment	O	-1	23864035
in	O	-1	23864035
8@@	O	-1	23864035
5	O	-1	23864035
patients	O	-1	23864035
with	O	-1	23864035
R@@	O	-1	23864035
/@@	O	-1	23864035
R	O	-1	23864035
M@@	B-Disease	D009101	23864035
M	I-Disease	-1	23864035
after	O	-1	23864035
prior	O	-1	23864035
auto@@	O	-1	23864035
log@@	O	-1	23864035
ous	O	-1	23864035
st@@	O	-1	23864035
em	O	-1	23864035
cell	O	-1	23864035
transplant@@	O	-1	23864035
ation	O	-1	23864035
or	O	-1	23864035
con@@	O	-1	23864035
ven@@	O	-1	23864035
tional	O	-1	23864035
chemo@@	O	-1	23864035
therapy.	O	-1	23864035
The	O	-1	23864035
median	O	-1	23864035
number	O	-1	23864035
of	O	-1	23864035
prior	O	-1	23864035
lin@@	O	-1	23864035
es	O	-1	23864035
of	O	-1	23864035
therapy	O	-1	23864035
was	O	-1	23864035
2@@	O	-1	23864035
.	O	-1	23864035
E@@	O	-1	23864035
igh@@	O	-1	23864035
ty-@@	O	-1	23864035
seven	O	-1	23864035
perc@@	O	-1	23864035
ent	O	-1	23864035
of	O	-1	23864035
the	O	-1	23864035
patients	O	-1	23864035
had	O	-1	23864035
received	O	-1	23864035
immuno@@	O	-1	23864035
mod@@	O	-1	23864035
ul@@	O	-1	23864035
atory	O	-1	23864035
drugs	O	-1	23864035
included	O	-1	23864035
in	O	-1	23864035
some	O	-1	23864035
line	O	-1	23864035
of	O	-1	23864035
therapy	O	-1	23864035
before	O	-1	23864035
b@@	B-Chemical	C400082	23864035
ort	I-Chemical	-1	23864035
-	O	-1	23864035
de@@	B-Chemical	D003907	23864035
x	I-Chemical	-1	23864035
.	O	-1	23864035
The	O	-1	23864035
median	O	-1	23864035
number	O	-1	23864035
of	O	-1	23864035
b@@	B-Chemical	C400082	23864035
ort	I-Chemical	-1	23864035
-	O	-1	23864035
de@@	B-Chemical	D003907	23864035
x	I-Chemical	-1	23864035
cyc@@	O	-1	23864035
le@@	O	-1	23864035
s	O	-1	23864035
was	O	-1	23864035
6,	O	-1	23864035
up	O	-1	23864035
to	O	-1	23864035
a	O	-1	23864035
maxim@@	O	-1	23864035
um	O	-1	23864035
of	O	-1	23864035
12	O	-1	23864035
cy@@	O	-1	23864035
cl@@	O	-1	23864035
es.	O	-1	23864035
O@@	O	-1	23864035
n	O	-1	23864035
an	O	-1	23864035
int@@	O	-1	23864035
en@@	O	-1	23864035
tion@@	O	-1	23864035
-@@	O	-1	23864035
to@@	O	-1	23864035
-@@	O	-1	23864035
tre@@	O	-1	23864035
at	O	-1	23864035
b@@	O	-1	23864035
a@@	O	-1	23864035
sis,	O	-1	23864035
5@@	O	-1	23864035
5	O	-1	23864035
%	O	-1	23864035
of	O	-1	23864035
the	O	-1	23864035
patients	O	-1	23864035
achi@@	O	-1	23864035
ev@@	O	-1	23864035
ed	O	-1	23864035
at	O	-1	23864035
le@@	O	-1	23864035
ast	O	-1	23864035
partial	O	-1	23864035
respon@@	O	-1	23864035
se@@	O	-1	23864035
,	O	-1	23864035
including	O	-1	23864035
1@@	O	-1	23864035
9	O	-1	23864035
%	O	-1	23864035
C@@	O	-1	23864035
R	O	-1	23864035
and	O	-1	23864035
3@@	O	-1	23864035
5	O	-1	23864035
%	O	-1	23864035
achi@@	O	-1	23864035
ev@@	O	-1	23864035
ed	O	-1	23864035
at	O	-1	23864035
le@@	O	-1	23864035
ast	O	-1	23864035
very	O	-1	23864035
go@@	O	-1	23864035
od	O	-1	23864035
partial	O	-1	23864035
respon@@	O	-1	23864035
se.	O	-1	23864035
M@@	O	-1	23864035
edi@@	O	-1	23864035
an	O	-1	23864035
dur@@	O	-1	23864035
ations	O	-1	23864035
of	O	-1	23864035
respon@@	O	-1	23864035
se@@	O	-1	23864035
,	O	-1	23864035
time	O	-1	23864035
to	O	-1	23864035
ne@@	O	-1	23864035
x@@	O	-1	23864035
t	O	-1	23864035
therapy	O	-1	23864035
and	O	-1	23864035
treatment@@	O	-1	23864035
-@@	O	-1	23864035
free	O	-1	23864035
interv@@	O	-1	23864035
al	O	-1	23864035
were	O	-1	23864035
8@@	O	-1	23864035
,	O	-1	23864035
1@@	O	-1	23864035
1.@@	O	-1	23864035
2,	O	-1	23864035
and	O	-1	23864035
5.@@	O	-1	23864035
1	O	-1	23864035
month@@	O	-1	23864035
s,	O	-1	23864035
respectively.	O	-1	23864035
The	O	-1	23864035
most	O	-1	23864035
re@@	O	-1	23864035
lev@@	O	-1	23864035
ant	O	-1	23864035
adverse	O	-1	23864035
ev@@	O	-1	23864035
ent	O	-1	23864035
was	O	-1	23864035
peripheral	B-Disease	D010523	23864035
neuropathy	I-Disease	-1	23864035
,	O	-1	23864035
which	O	-1	23864035
occurred	O	-1	23864035
in	O	-1	23864035
7@@	O	-1	23864035
8	O	-1	23864035
%	O	-1	23864035
of	O	-1	23864035
the	O	-1	23864035
patients	O	-1	23864035
(@@	O	-1	23864035
gra@@	O	-1	23864035
de	O	-1	23864035
II@@	O	-1	23864035
,	O	-1	23864035
3@@	O	-1	23864035
8	O	-1	23864035
%@@	O	-1	23864035
;	O	-1	23864035
gra@@	O	-1	23864035
de	O	-1	23864035
II@@	O	-1	23864035
I@@	O	-1	23864035
,	O	-1	23864035
21	O	-1	23864035
%)	O	-1	23864035
and	O	-1	23864035
l@@	O	-1	23864035
ed	O	-1	23864035
to	O	-1	23864035
treatment	O	-1	23864035
discontinu@@	O	-1	23864035
ation	O	-1	23864035
in	O	-1	23864035
6	O	-1	23864035
%.	O	-1	23864035
W@@	O	-1	23864035
it@@	O	-1	23864035
h	O	-1	23864035
a	O	-1	23864035
median	O	-1	23864035
fol@@	O	-1	23864035
low	O	-1	23864035
up	O	-1	23864035
of	O	-1	23864035
2@@	O	-1	23864035
2	O	-1	23864035
month@@	O	-1	23864035
s,	O	-1	23864035
median	O	-1	23864035
time	O	-1	23864035
to	O	-1	23864035
progres@@	O	-1	23864035
sion,	O	-1	23864035
progres@@	O	-1	23864035
sion@@	O	-1	23864035
-@@	O	-1	23864035
free	O	-1	23864035
sur@@	O	-1	23864035
viv@@	O	-1	23864035
al	O	-1	23864035
(P@@	O	-1	23864035
F@@	O	-1	23864035
S)	O	-1	23864035
and	O	-1	23864035
over@@	O	-1	23864035
all	O	-1	23864035
sur@@	O	-1	23864035
viv@@	O	-1	23864035
al	O	-1	23864035
(@@	O	-1	23864035
O@@	O	-1	23864035
S)	O	-1	23864035
were	O	-1	23864035
8.@@	O	-1	23864035
9@@	O	-1	23864035
,	O	-1	23864035
8.@@	O	-1	23864035
7@@	O	-1	23864035
,	O	-1	23864035
and	O	-1	23864035
2@@	O	-1	23864035
2	O	-1	23864035
month@@	O	-1	23864035
s,	O	-1	23864035
respectively.	O	-1	23864035
Pro@@	O	-1	23864035
long@@	O	-1	23864035
ed	O	-1	23864035
P@@	O	-1	23864035
F@@	O	-1	23864035
S	O	-1	23864035
and	O	-1	23864035
O@@	O	-1	23864035
S	O	-1	23864035
were	O	-1	23864035
observed	O	-1	23864035
in	O	-1	23864035
patients	O	-1	23864035
achi@@	O	-1	23864035
ev@@	O	-1	23864035
ing	O	-1	23864035
C@@	O	-1	23864035
R	O	-1	23864035
and	O	-1	23864035
receiving	O	-1	23864035
b@@	B-Chemical	C400082	23864035
ort	I-Chemical	-1	23864035
-	O	-1	23864035
de@@	B-Chemical	D003907	23864035
x	I-Chemical	-1	23864035
a	O	-1	23864035
single	O	-1	23864035
line	O	-1	23864035
of	O	-1	23864035
prior	O	-1	23864035
therapy.	O	-1	23864035
B@@	B-Chemical	C400082	23864035
ort	I-Chemical	-1	23864035
-	O	-1	23864035
de@@	B-Chemical	D003907	23864035
x	I-Chemical	-1	23864035
was	O	-1	23864035
an	O	-1	23864035
effective	O	-1	23864035
sal@@	O	-1	23864035
v@@	O	-1	23864035
age	O	-1	23864035
treatment	O	-1	23864035
for	O	-1	23864035
M@@	B-Disease	D009101	23864035
M	I-Disease	-1	23864035
patients,	O	-1	23864035
partic@@	O	-1	23864035
ul@@	O	-1	23864035
arly	O	-1	23864035
for	O	-1	23864035
those	O	-1	23864035
in	O	-1	23864035
first	O	-1	23864035
rel@@	O	-1	23864035
ap@@	O	-1	23864035
se.	O	-1	23864035

P@@	O	-1	23871786
ub@@	O	-1	23871786
er@@	O	-1	23871786
t@@	O	-1	23871786
al	O	-1	23871786
exposure	O	-1	23871786
to	O	-1	23871786
B@@	B-Chemical	C006780	23871786
is@@	I-Chemical	-1	23871786
phen@@	I-Chemical	-1	23871786
ol	I-Chemical	-1	23871786
A	I-Chemical	-1	23871786
increases	O	-1	23871786
an@@	B-Disease	D001008	23871786
xi@@	I-Disease	-1	23871786
ety	I-Disease	-1	23871786
-@@	O	-1	23871786
like	O	-1	23871786
behavi@@	O	-1	23871786
or	O	-1	23871786
and	O	-1	23871786
decreas@@	O	-1	23871786
es	O	-1	23871786
acet@@	O	-1	23871786
ylchol@@	O	-1	23871786
ine@@	O	-1	23871786
ster@@	O	-1	23871786
ase	O	-1	23871786
activity	O	-1	23871786
of	O	-1	23871786
hippocamp@@	O	-1	23871786
us	O	-1	23871786
in	O	-1	23871786
ad@@	O	-1	23871786
ult	O	-1	23871786
male	O	-1	23871786
mice.	O	-1	23871786
The	O	-1	23871786
negative	O	-1	23871786
effects	O	-1	23871786
of	O	-1	23871786
B@@	B-Chemical	C006780	23871786
is@@	I-Chemical	-1	23871786
phen@@	I-Chemical	-1	23871786
ol	I-Chemical	-1	23871786
A	I-Chemical	-1	23871786
(	O	-1	23871786
B@@	B-Chemical	C006780	23871786
P@@	I-Chemical	-1	23871786
A	I-Chemical	-1	23871786
)	O	-1	23871786
on	O	-1	23871786
neuro@@	O	-1	23871786
development	O	-1	23871786
and	O	-1	23871786
behavi@@	O	-1	23871786
ors	O	-1	23871786
have	O	-1	23871786
been	O	-1	23871786
well	O	-1	23871786
est@@	O	-1	23871786
abl@@	O	-1	23871786
is@@	O	-1	23871786
he@@	O	-1	23871786
d.	O	-1	23871786
A@@	O	-1	23871786
ce@@	O	-1	23871786
t@@	O	-1	23871786
ylchol@@	O	-1	23871786
ine@@	O	-1	23871786
ster@@	O	-1	23871786
ase	O	-1	23871786
(@@	O	-1	23871786
AC@@	O	-1	23871786
h@@	O	-1	23871786
E@@	O	-1	23871786
)	O	-1	23871786
is	O	-1	23871786
a	O	-1	23871786
reg@@	O	-1	23871786
ul@@	O	-1	23871786
atory	O	-1	23871786
enzyme	O	-1	23871786
which	O	-1	23871786
is	O	-1	23871786
involved	O	-1	23871786
in	O	-1	23871786
an@@	B-Disease	D001008	23871786
xi@@	I-Disease	-1	23871786
ety	I-Disease	-1	23871786
-@@	O	-1	23871786
like	O	-1	23871786
behavi@@	O	-1	23871786
or@@	O	-1	23871786
.	O	-1	23871786
This	O	-1	23871786
study	O	-1	23871786
investigated	O	-1	23871786
behavioral	O	-1	23871786
phen@@	O	-1	23871786
ot@@	O	-1	23871786
yp@@	O	-1	23871786
es	O	-1	23871786
and	O	-1	23871786
AC@@	O	-1	23871786
h@@	O	-1	23871786
E	O	-1	23871786
activity	O	-1	23871786
in	O	-1	23871786
male	O	-1	23871786
mice	O	-1	23871786
following	O	-1	23871786
B@@	B-Chemical	C006780	23871786
P@@	I-Chemical	-1	23871786
A	I-Chemical	-1	23871786
exposure	O	-1	23871786
during	O	-1	23871786
p@@	O	-1	23871786
ub@@	O	-1	23871786
er@@	O	-1	23871786
t@@	O	-1	23871786
y.	O	-1	23871786
O@@	O	-1	23871786
n	O	-1	23871786
post@@	O	-1	23871786
n@@	O	-1	23871786
atal	O	-1	23871786
day	O	-1	23871786
(P@@	O	-1	23871786
N@@	O	-1	23871786
D)	O	-1	23871786
3@@	O	-1	23871786
5,	O	-1	23871786
male	O	-1	23871786
mice	O	-1	23871786
were	O	-1	23871786
exposed	O	-1	23871786
to	O	-1	23871786
50@@	O	-1	23871786
mg	O	-1	23871786
B@@	B-Chemical	C006780	23871786
P@@	I-Chemical	-1	23871786
A	I-Chemical	-1	23871786
/@@	O	-1	23871786
k@@	O	-1	23871786
g	O	-1	23871786
diet	O	-1	23871786
per	O	-1	23871786
day	O	-1	23871786
for	O	-1	23871786
a	O	-1	23871786
period	O	-1	23871786
of	O	-1	23871786
3@@	O	-1	23871786
5	O	-1	23871786
days.	O	-1	23871786
O@@	O	-1	23871786
n	O	-1	23871786
P@@	O	-1	23871786
N@@	O	-1	23871786
D@@	O	-1	23871786
7@@	O	-1	23871786
1,	O	-1	23871786
a	O	-1	23871786
behavioral	O	-1	23871786
ass@@	O	-1	23871786
ay	O	-1	23871786
was	O	-1	23871786
performed	O	-1	23871786
using	O	-1	23871786
the	O	-1	23871786
elevated	O	-1	23871786
plus	O	-1	23871786
ma@@	O	-1	23871786
ze	O	-1	23871786
(@@	O	-1	23871786
EP@@	O	-1	23871786
M@@	O	-1	23871786
)	O	-1	23871786
and	O	-1	23871786
the	O	-1	23871786
li@@	O	-1	23871786
gh@@	O	-1	23871786
t@@	O	-1	23871786
/@@	O	-1	23871786
d@@	O	-1	23871786
ar@@	O	-1	23871786
k	O	-1	23871786
test@@	O	-1	23871786
.	O	-1	23871786
In	O	-1	23871786
addi@@	O	-1	23871786
tion,	O	-1	23871786
AC@@	O	-1	23871786
h@@	O	-1	23871786
E	O	-1	23871786
activity	O	-1	23871786
was	O	-1	23871786
measured	O	-1	23871786
in	O	-1	23871786
the	O	-1	23871786
pre@@	O	-1	23871786
fron@@	O	-1	23871786
t@@	O	-1	23871786
al	O	-1	23871786
cor@@	O	-1	23871786
t@@	O	-1	23871786
ex@@	O	-1	23871786
,	O	-1	23871786
hypo@@	O	-1	23871786
thal@@	O	-1	23871786
am@@	O	-1	23871786
us,	O	-1	23871786
ce@@	O	-1	23871786
re@@	O	-1	23871786
bell@@	O	-1	23871786
um	O	-1	23871786
and	O	-1	23871786
hippocamp@@	O	-1	23871786
us.	O	-1	23871786
R@@	O	-1	23871786
es@@	O	-1	23871786
ult@@	O	-1	23871786
s	O	-1	23871786
from	O	-1	23871786
our	O	-1	23871786
behavioral	O	-1	23871786
phen@@	O	-1	23871786
ot@@	O	-1	23871786
yp@@	O	-1	23871786
ing	O	-1	23871786
indic@@	O	-1	23871786
ated	O	-1	23871786
that	O	-1	23871786
an@@	B-Disease	D001008	23871786
xi@@	I-Disease	-1	23871786
ety	I-Disease	-1	23871786
-@@	O	-1	23871786
like	O	-1	23871786
behavi@@	O	-1	23871786
or	O	-1	23871786
was	O	-1	23871786
increased	O	-1	23871786
in	O	-1	23871786
mice	O	-1	23871786
exposed	O	-1	23871786
to	O	-1	23871786
B@@	B-Chemical	C006780	23871786
P@@	I-Chemical	-1	23871786
A	I-Chemical	-1	23871786
.	O	-1	23871786
AC@@	O	-1	23871786
h@@	O	-1	23871786
E	O	-1	23871786
activity	O	-1	23871786
was	O	-1	23871786
significantly	O	-1	23871786
decreased	O	-1	23871786
in	O	-1	23871786
the	O	-1	23871786
hippocamp@@	O	-1	23871786
us	O	-1	23871786
of	O	-1	23871786
mice	O	-1	23871786
with	O	-1	23871786
B@@	B-Chemical	C006780	23871786
P@@	I-Chemical	-1	23871786
A	I-Chemical	-1	23871786
compared	O	-1	23871786
to	O	-1	23871786
control	O	-1	23871786
mic@@	O	-1	23871786
e,	O	-1	23871786
whereas	O	-1	23871786
no	O	-1	23871786
difference	O	-1	23871786
was	O	-1	23871786
found	O	-1	23871786
in	O	-1	23871786
the	O	-1	23871786
pre@@	O	-1	23871786
fron@@	O	-1	23871786
t@@	O	-1	23871786
al	O	-1	23871786
cor@@	O	-1	23871786
t@@	O	-1	23871786
ex@@	O	-1	23871786
,	O	-1	23871786
hypo@@	O	-1	23871786
thal@@	O	-1	23871786
am@@	O	-1	23871786
us	O	-1	23871786
and	O	-1	23871786
ce@@	O	-1	23871786
re@@	O	-1	23871786
bell@@	O	-1	23871786
um@@	O	-1	23871786
.	O	-1	23871786
Our	O	-1	23871786
findings	O	-1	23871786
showed	O	-1	23871786
that	O	-1	23871786
p@@	O	-1	23871786
ub@@	O	-1	23871786
er@@	O	-1	23871786
t@@	O	-1	23871786
al	O	-1	23871786
B@@	B-Chemical	C006780	23871786
P@@	I-Chemical	-1	23871786
A	I-Chemical	-1	23871786
exposure	O	-1	23871786
increased	O	-1	23871786
an@@	B-Disease	D001008	23871786
xi@@	I-Disease	-1	23871786
ety	I-Disease	-1	23871786
-@@	O	-1	23871786
like	O	-1	23871786
behavi@@	O	-1	23871786
or@@	O	-1	23871786
,	O	-1	23871786
which	O	-1	23871786
may	O	-1	23871786
be	O	-1	23871786
associated	O	-1	23871786
with	O	-1	23871786
decreased	O	-1	23871786
AC@@	O	-1	23871786
h@@	O	-1	23871786
E	O	-1	23871786
activity	O	-1	23871786
of	O	-1	23871786
the	O	-1	23871786
hippocamp@@	O	-1	23871786
us	O	-1	23871786
in	O	-1	23871786
ad@@	O	-1	23871786
ult	O	-1	23871786
male	O	-1	23871786
mice.	O	-1	23871786
F@@	O	-1	23871786
urther	O	-1	23871786
studies	O	-1	23871786
are	O	-1	23871786
nec@@	O	-1	23871786
ess@@	O	-1	23871786
ary	O	-1	23871786
to	O	-1	23871786
investigate	O	-1	23871786
the	O	-1	23871786
cholinergic	O	-1	23871786
sign@@	O	-1	23871786
al@@	O	-1	23871786
ing	O	-1	23871786
of	O	-1	23871786
the	O	-1	23871786
hippocamp@@	O	-1	23871786
us	O	-1	23871786
in	O	-1	23871786
P@@	O	-1	23871786
B@@	O	-1	23871786
E	O	-1	23871786
induced	O	-1	23871786
an@@	B-Disease	D001008	23871786
xi@@	I-Disease	-1	23871786
ety	I-Disease	-1	23871786
-@@	O	-1	23871786
like	O	-1	23871786
behavi@@	O	-1	23871786
or@@	O	-1	23871786
s.	O	-1	23871786

B@@	O	-1	23872883
io@@	O	-1	23872883
chemical	O	-1	23872883
effects	O	-1	23872883
of	O	-1	23872883
S@@	O	-1	23872883
ol@@	O	-1	23872883
id@@	O	-1	23872883
ag@@	O	-1	23872883
o	O	-1	23872883
vi@@	O	-1	23872883
r@@	O	-1	23872883
g@@	O	-1	23872883
a@@	O	-1	23872883
ure@@	O	-1	23872883
a	O	-1	23872883
extrac@@	O	-1	23872883
t	O	-1	23872883
on	O	-1	23872883
experimental	O	-1	23872883
cardi@@	B-Disease	D066126	23872883
otoxicity	I-Disease	-1	23872883
.	O	-1	23872883
C@@	B-Disease	D002318	23872883
ardi@@	I-Disease	-1	23872883
o@@	I-Disease	-1	23872883
vascular	I-Disease	-1	23872883
diseas@@	I-Disease	-1	23872883
es	I-Disease	-1	23872883
(	O	-1	23872883
C@@	B-Disease	D002318	23872883
V@@	I-Disease	-1	23872883
D@@	I-Disease	-1	23872883
s	I-Disease	-1	23872883
)	O	-1	23872883
are	O	-1	23872883
the	O	-1	23872883
major	O	-1	23872883
heal@@	O	-1	23872883
th	O	-1	23872883
pro@@	O	-1	23872883
ble@@	O	-1	23872883
m	O	-1	23872883
of	O	-1	23872883
adv@@	O	-1	23872883
anced	O	-1	23872883
as	O	-1	23872883
well	O	-1	23872883
as	O	-1	23872883
develop@@	O	-1	23872883
ing	O	-1	23872883
coun@@	O	-1	23872883
tri@@	O	-1	23872883
es	O	-1	23872883
of	O	-1	23872883
the	O	-1	23872883
wor@@	O	-1	23872883
l@@	O	-1	23872883
d.	O	-1	23872883
The	O	-1	23872883
a@@	O	-1	23872883
im	O	-1	23872883
of	O	-1	23872883
the	O	-1	23872883
present	O	-1	23872883
study	O	-1	23872883
was	O	-1	23872883
to	O	-1	23872883
investigate	O	-1	23872883
the	O	-1	23872883
protective	O	-1	23872883
effect	O	-1	23872883
of	O	-1	23872883
the	O	-1	23872883
S@@	O	-1	23872883
ol@@	O	-1	23872883
id@@	O	-1	23872883
ag@@	O	-1	23872883
o	O	-1	23872883
vi@@	O	-1	23872883
r@@	O	-1	23872883
g@@	O	-1	23872883
a@@	O	-1	23872883
ure@@	O	-1	23872883
a	O	-1	23872883
extrac@@	O	-1	23872883
t	O	-1	23872883
on	O	-1	23872883
isoproteren@@	B-Chemical	D007545	23872883
ol	I-Chemical	-1	23872883
-induced	O	-1	23872883
cardi@@	B-Disease	D066126	23872883
otoxicity	I-Disease	-1	23872883
in	O	-1	23872883
rats.	O	-1	23872883
The	O	-1	23872883
sub@@	O	-1	23872883
c@@	O	-1	23872883
utaneous	O	-1	23872883
injection	O	-1	23872883
of	O	-1	23872883
isoproteren@@	B-Chemical	D007545	23872883
ol	I-Chemical	-1	23872883
(@@	O	-1	23872883
30	O	-1	23872883
mg/kg)	O	-1	23872883
into	O	-1	23872883
rats	O	-1	23872883
tw@@	O	-1	23872883
ic@@	O	-1	23872883
e	O	-1	23872883
at	O	-1	23872883
an	O	-1	23872883
interv@@	O	-1	23872883
al	O	-1	23872883
of	O	-1	23872883
24	O	-1	23872883
h@@	O	-1	23872883
,	O	-1	23872883
for	O	-1	23872883
two	O	-1	23872883
con@@	O	-1	23872883
sec@@	O	-1	23872883
utive	O	-1	23872883
day@@	O	-1	23872883
s,	O	-1	23872883
l@@	O	-1	23872883
ed	O	-1	23872883
to	O	-1	23872883
a	O	-1	23872883
significant	O	-1	23872883
increase	O	-1	23872883
in	O	-1	23872883
serum	O	-1	23872883
l@@	B-Chemical	D019344	23872883
act@@	I-Chemical	-1	23872883
ate	I-Chemical	-1	23872883
de@@	O	-1	23872883
hydro@@	O	-1	23872883
gen@@	O	-1	23872883
ase,	O	-1	23872883
creat@@	B-Chemical	D003401	23872883
ine	I-Chemical	-1	23872883
phosph@@	O	-1	23872883
o@@	O	-1	23872883
kin@@	O	-1	23872883
ase,	O	-1	23872883
al@@	B-Chemical	D000409	23872883
an@@	I-Chemical	-1	23872883
ine	I-Chemical	-1	23872883
trans@@	O	-1	23872883
amin@@	O	-1	23872883
ase,	O	-1	23872883
as@@	B-Chemical	D001224	23872883
part@@	I-Chemical	-1	23872883
ate	I-Chemical	-1	23872883
trans@@	O	-1	23872883
amin@@	O	-1	23872883
ase,	O	-1	23872883
and	O	-1	23872883
angiotens@@	B-Chemical	D000809	23872883
in	I-Chemical	-1	23872883
-@@	O	-1	23872883
conver@@	O	-1	23872883
ting	O	-1	23872883
enzyme	O	-1	23872883
ac@@	O	-1	23872883
ti@@	O	-1	23872883
vi@@	O	-1	23872883
ti@@	O	-1	23872883
es,	O	-1	23872883
total	O	-1	23872883
cholester@@	B-Chemical	D002784	23872883
ol	I-Chemical	-1	23872883
,	O	-1	23872883
tri@@	B-Chemical	D014280	23872883
glycer@@	I-Chemical	-1	23872883
i@@	I-Chemical	-1	23872883
des	I-Chemical	-1	23872883
,	O	-1	23872883
free	O	-1	23872883
serum	O	-1	23872883
f@@	B-Chemical	D005227	23872883
at@@	I-Chemical	-1	23872883
t@@	I-Chemical	-1	23872883
y	I-Chemical	-1	23872883
acid	I-Chemical	-1	23872883
,	O	-1	23872883
cardiac	O	-1	23872883
tissue	O	-1	23872883
mal@@	B-Chemical	D008315	23872883
on@@	I-Chemical	-1	23872883
di@@	I-Chemical	-1	23872883
al@@	I-Chemical	-1	23872883
de@@	I-Chemical	-1	23872883
hy@@	I-Chemical	-1	23872883
de	I-Chemical	-1	23872883
(	O	-1	23872883
MD@@	B-Chemical	D008315	23872883
A	I-Chemical	-1	23872883
),	O	-1	23872883
and	O	-1	23872883
nit@@	B-Chemical	D009569	23872883
ric	I-Chemical	-1	23872883
ox@@	I-Chemical	-1	23872883
ide	I-Chemical	-1	23872883
levels	O	-1	23872883
and	O	-1	23872883
a	O	-1	23872883
significant	O	-1	23872883
decrease	O	-1	23872883
in	O	-1	23872883
levels	O	-1	23872883
of	O	-1	23872883
glut@@	B-Chemical	D005978	23872883
athi@@	I-Chemical	-1	23872883
one	I-Chemical	-1	23872883
and	O	-1	23872883
su@@	B-Chemical	D013481	23872883
per@@	I-Chemical	-1	23872883
ox@@	I-Chemical	-1	23872883
ide	I-Chemical	-1	23872883
dis@@	O	-1	23872883
mut@@	O	-1	23872883
ase	O	-1	23872883
in	O	-1	23872883
cardiac	O	-1	23872883
tissue	O	-1	23872883
as	O	-1	23872883
compared	O	-1	23872883
to	O	-1	23872883
the	O	-1	23872883
normal	O	-1	23872883
control	O	-1	23872883
group	O	-1	23872883
(P	O	-1	23872883
<	O	-1	23872883
0.05@@	O	-1	23872883
).	O	-1	23872883
Pre@@	O	-1	23872883
treatment	O	-1	23872883
with	O	-1	23872883
S@@	O	-1	23872883
.	O	-1	23872883
vi@@	O	-1	23872883
r@@	O	-1	23872883
g@@	O	-1	23872883
a@@	O	-1	23872883
ure@@	O	-1	23872883
a	O	-1	23872883
extrac@@	O	-1	23872883
t	O	-1	23872883
for	O	-1	23872883
5	O	-1	23872883
weeks	O	-1	23872883
at	O	-1	23872883
a	O	-1	23872883
dose	O	-1	23872883
of	O	-1	23872883
2@@	O	-1	23872883
50	O	-1	23872883
mg/kg	O	-1	23872883
followed	O	-1	23872883
by	O	-1	23872883
isoproteren@@	B-Chemical	D007545	23872883
ol	I-Chemical	-1	23872883
injection	O	-1	23872883
significantly	O	-1	23872883
prevent@@	O	-1	23872883
ed	O	-1	23872883
the	O	-1	23872883
observed	O	-1	23872883
al@@	O	-1	23872883
ter@@	O	-1	23872883
ations.	O	-1	23872883
C@@	B-Chemical	D002216	23872883
ap@@	I-Chemical	-1	23872883
to@@	I-Chemical	-1	23872883
pri@@	I-Chemical	-1	23872883
l	I-Chemical	-1	23872883
(@@	O	-1	23872883
50	O	-1	23872883
mg/k@@	O	-1	23872883
g/@@	O	-1	23872883
da@@	O	-1	23872883
y,	O	-1	23872883
given	O	-1	23872883
or@@	O	-1	23872883
all@@	O	-1	23872883
y@@	O	-1	23872883
),	O	-1	23872883
an	O	-1	23872883
inhibitor	O	-1	23872883
of	O	-1	23872883
angiotens@@	B-Chemical	D000809	23872883
in	I-Chemical	-1	23872883
-@@	O	-1	23872883
conver@@	O	-1	23872883
ting	O	-1	23872883
enzyme	O	-1	23872883
used	O	-1	23872883
as	O	-1	23872883
a	O	-1	23872883
standard	O	-1	23872883
cardio@@	O	-1	23872883
protective	O	-1	23872883
drug@@	O	-1	23872883
,	O	-1	23872883
was	O	-1	23872883
used	O	-1	23872883
as	O	-1	23872883
a	O	-1	23872883
positive	O	-1	23872883
control	O	-1	23872883
in	O	-1	23872883
this	O	-1	23872883
study.	O	-1	23872883
The	O	-1	23872883
data	O	-1	23872883
of	O	-1	23872883
the	O	-1	23872883
present	O	-1	23872883
study	O	-1	23872883
suggest	O	-1	23872883
that	O	-1	23872883
S@@	O	-1	23872883
.	O	-1	23872883
vi@@	O	-1	23872883
r@@	O	-1	23872883
g@@	O	-1	23872883
a@@	O	-1	23872883
ure@@	O	-1	23872883
a	O	-1	23872883
extrac@@	O	-1	23872883
t	O	-1	23872883
ex@@	O	-1	23872883
er@@	O	-1	23872883
ts	O	-1	23872883
its	O	-1	23872883
protective	O	-1	23872883
effect	O	-1	23872883
by	O	-1	23872883
decreas@@	O	-1	23872883
ing	O	-1	23872883
MD@@	B-Chemical	D008315	23872883
A	I-Chemical	-1	23872883
level	O	-1	23872883
and	O	-1	23872883
increas@@	O	-1	23872883
ing	O	-1	23872883
the	O	-1	23872883
anti@@	O	-1	23872883
oxid@@	O	-1	23872883
ant	O	-1	23872883
status	O	-1	23872883
in	O	-1	23872883
isoproteren@@	B-Chemical	D007545	23872883
ol	I-Chemical	-1	23872883
-treated	O	-1	23872883
rats.	O	-1	23872883
The	O	-1	23872883
study	O	-1	23872883
em@@	O	-1	23872883
pha@@	O	-1	23872883
si@@	O	-1	23872883
z@@	O	-1	23872883
es	O	-1	23872883
the	O	-1	23872883
ben@@	O	-1	23872883
e@@	O	-1	23872883
fic@@	O	-1	23872883
ial	O	-1	23872883
action	O	-1	23872883
of	O	-1	23872883
S@@	O	-1	23872883
.	O	-1	23872883
vi@@	O	-1	23872883
r@@	O	-1	23872883
g@@	O	-1	23872883
a@@	O	-1	23872883
ure@@	O	-1	23872883
a	O	-1	23872883
extrac@@	O	-1	23872883
t	O	-1	23872883
as	O	-1	23872883
a	O	-1	23872883
cardio@@	O	-1	23872883
protective	O	-1	23872883
agent@@	O	-1	23872883
.	O	-1	23872883

"@@	O	-1	23892921
Re@@	O	-1	23892921
al@@	O	-1	23892921
-@@	O	-1	23892921
wor@@	O	-1	23892921
l@@	O	-1	23892921
d@@	O	-1	23892921
"	O	-1	23892921
data	O	-1	23892921
on	O	-1	23892921
the	O	-1	23892921
efficacy	O	-1	23892921
and	O	-1	23892921
safety	O	-1	23892921
of	O	-1	23892921
l@@	B-Chemical	C467567	23892921
en@@	I-Chemical	-1	23892921
al@@	I-Chemical	-1	23892921
id@@	I-Chemical	-1	23892921
om@@	I-Chemical	-1	23892921
ide	I-Chemical	-1	23892921
and	O	-1	23892921
de@@	B-Chemical	D003907	23892921
xameth@@	I-Chemical	-1	23892921
as@@	I-Chemical	-1	23892921
one	I-Chemical	-1	23892921
in	O	-1	23892921
patients	O	-1	23892921
with	O	-1	23892921
rel@@	O	-1	23892921
ap@@	O	-1	23892921
sed@@	O	-1	23892921
/@@	O	-1	23892921
ref@@	O	-1	23892921
rac@@	O	-1	23892921
t@@	O	-1	23892921
ory	O	-1	23892921
multiple	B-Disease	D009101	23892921
my@@	I-Disease	-1	23892921
e@@	I-Disease	-1	23892921
lo@@	I-Disease	-1	23892921
ma	I-Disease	-1	23892921
who	O	-1	23892921
were	O	-1	23892921
treated	O	-1	23892921
ac@@	O	-1	23892921
cor@@	O	-1	23892921
ding	O	-1	23892921
to	O	-1	23892921
the	O	-1	23892921
standard	O	-1	23892921
clinical	O	-1	23892921
p@@	O	-1	23892921
rac@@	O	-1	23892921
ti@@	O	-1	23892921
ce@@	O	-1	23892921
:	O	-1	23892921
a	O	-1	23892921
study	O	-1	23892921
of	O	-1	23892921
the	O	-1	23892921
G@@	O	-1	23892921
re@@	O	-1	23892921
e@@	O	-1	23892921
k	O	-1	23892921
M@@	B-Disease	D009101	23892921
ye@@	I-Disease	-1	23892921
lo@@	I-Disease	-1	23892921
ma	I-Disease	-1	23892921
S@@	O	-1	23892921
t@@	O	-1	23892921
ud@@	O	-1	23892921
y	O	-1	23892921
Grou@@	O	-1	23892921
p@@	O	-1	23892921
.	O	-1	23892921
L@@	B-Chemical	C467567	23892921
en@@	I-Chemical	-1	23892921
al@@	I-Chemical	-1	23892921
id@@	I-Chemical	-1	23892921
om@@	I-Chemical	-1	23892921
ide	I-Chemical	-1	23892921
and	O	-1	23892921
de@@	B-Chemical	D003907	23892921
xameth@@	I-Chemical	-1	23892921
as@@	I-Chemical	-1	23892921
one	I-Chemical	-1	23892921
(	O	-1	23892921
R@@	B-Chemical	C467567	23892921
D	I-Chemical	-1	23892921
R@@	B-Chemical	D003907	23892921
D	I-Chemical	-1	23892921
)	O	-1	23892921
is	O	-1	23892921
a	O	-1	23892921
standard	O	-1	23892921
of	O	-1	23892921
car@@	O	-1	23892921
e	O	-1	23892921
for	O	-1	23892921
rel@@	O	-1	23892921
ap@@	O	-1	23892921
sed@@	O	-1	23892921
/@@	O	-1	23892921
ref@@	O	-1	23892921
rac@@	O	-1	23892921
t@@	O	-1	23892921
ory	O	-1	23892921
multiple	B-Disease	D009101	23892921
my@@	I-Disease	-1	23892921
e@@	I-Disease	-1	23892921
lo@@	I-Disease	-1	23892921
ma	I-Disease	-1	23892921
(	O	-1	23892921
R@@	B-Disease	D009101	23892921
R@@	I-Disease	-1	23892921
M@@	I-Disease	-1	23892921
M	I-Disease	-1	23892921
),	O	-1	23892921
but	O	-1	23892921
there	O	-1	23892921
is	O	-1	23892921
lim@@	O	-1	23892921
ited	O	-1	23892921
pu@@	O	-1	23892921
bl@@	O	-1	23892921
ished	O	-1	23892921
data	O	-1	23892921
on	O	-1	23892921
its	O	-1	23892921
efficacy	O	-1	23892921
and	O	-1	23892921
safety	O	-1	23892921
in	O	-1	23892921
the	O	-1	23892921
"@@	O	-1	23892921
re@@	O	-1	23892921
al	O	-1	23892921
wor@@	O	-1	23892921
l@@	O	-1	23892921
d@@	O	-1	23892921
"	O	-1	23892921
(@@	O	-1	23892921
R@@	O	-1	23892921
W@@	O	-1	23892921
),	O	-1	23892921
ac@@	O	-1	23892921
cor@@	O	-1	23892921
ding	O	-1	23892921
to	O	-1	23892921
the	O	-1	23892921
In@@	O	-1	23892921
tern@@	O	-1	23892921
ation@@	O	-1	23892921
al	O	-1	23892921
S@@	O	-1	23892921
oci@@	O	-1	23892921
ety	O	-1	23892921
of	O	-1	23892921
Ph@@	O	-1	23892921
armac@@	O	-1	23892921
o@@	O	-1	23892921
ec@@	O	-1	23892921
on@@	O	-1	23892921
om@@	O	-1	23892921
ic@@	O	-1	23892921
s	O	-1	23892921
and	O	-1	23892921
O@@	O	-1	23892921
ut@@	O	-1	23892921
com@@	O	-1	23892921
es	O	-1	23892921
R@@	O	-1	23892921
es@@	O	-1	23892921
ear@@	O	-1	23892921
ch	O	-1	23892921
def@@	O	-1	23892921
in@@	O	-1	23892921
i@@	O	-1	23892921
tion.	O	-1	23892921
We	O	-1	23892921
studied	O	-1	23892921
2@@	O	-1	23892921
12	O	-1	23892921
R@@	B-Disease	D009101	23892921
R@@	I-Disease	-1	23892921
M@@	I-Disease	-1	23892921
M	I-Disease	-1	23892921
patients	O	-1	23892921
who	O	-1	23892921
received	O	-1	23892921
R@@	B-Chemical	C467567	23892921
D	I-Chemical	-1	23892921
R@@	B-Chemical	D003907	23892921
D	I-Chemical	-1	23892921
in	O	-1	23892921
R@@	O	-1	23892921
W@@	O	-1	23892921
.	O	-1	23892921
O@@	O	-1	23892921
b@@	O	-1	23892921
j@@	O	-1	23892921
ective	O	-1	23892921
response	O	-1	23892921
(@@	O	-1	23892921
>@@	O	-1	23892921
P@@	O	-1	23892921
R	O	-1	23892921
(@@	O	-1	23892921
partial	O	-1	23892921
respon@@	O	-1	23892921
se@@	O	-1	23892921
)@@	O	-1	23892921
)	O	-1	23892921
rate	O	-1	23892921
was	O	-1	23892921
7@@	O	-1	23892921
7.@@	O	-1	23892921
4	O	-1	23892921
%	O	-1	23892921
(@@	O	-1	23892921
complete	O	-1	23892921
response	O	-1	23892921
(C@@	O	-1	23892921
R@@	O	-1	23892921
),	O	-1	23892921
2@@	O	-1	23892921
0.@@	O	-1	23892921
2	O	-1	23892921
%).	O	-1	23892921
M@@	O	-1	23892921
edi@@	O	-1	23892921
an	O	-1	23892921
time	O	-1	23892921
to	O	-1	23892921
first	O	-1	23892921
and	O	-1	23892921
b@@	O	-1	23892921
est	O	-1	23892921
response	O	-1	23892921
was	O	-1	23892921
2	O	-1	23892921
and	O	-1	23892921
5	O	-1	23892921
month@@	O	-1	23892921
s,	O	-1	23892921
respectively.	O	-1	23892921
M@@	O	-1	23892921
edi@@	O	-1	23892921
an	O	-1	23892921
time	O	-1	23892921
to	O	-1	23892921
C@@	O	-1	23892921
R	O	-1	23892921
when	O	-1	23892921
R@@	B-Chemical	C467567	23892921
D	I-Chemical	-1	23892921
R@@	B-Chemical	D003907	23892921
D	I-Chemical	-1	23892921
was	O	-1	23892921
given	O	-1	23892921
as	O	-1	23892921
2@@	O	-1	23892921
n@@	O	-1	23892921
d	O	-1	23892921
or	O	-1	23892921
>@@	O	-1	23892921
2@@	O	-1	23892921
(n@@	O	-1	23892921
d@@	O	-1	23892921
)-@@	O	-1	23892921
line	O	-1	23892921
treatment	O	-1	23892921
at	O	-1	23892921
4	O	-1	23892921
and	O	-1	23892921
11	O	-1	23892921
month@@	O	-1	23892921
s,	O	-1	23892921
respectively.	O	-1	23892921
Q@@	O	-1	23892921
u@@	O	-1	23892921
ality	O	-1	23892921
of	O	-1	23892921
response	O	-1	23892921
was	O	-1	23892921
in@@	O	-1	23892921
dependent	O	-1	23892921
of	O	-1	23892921
previ@@	O	-1	23892921
ous	O	-1	23892921
lin@@	O	-1	23892921
es	O	-1	23892921
of	O	-1	23892921
therap@@	O	-1	23892921
i@@	O	-1	23892921
es	O	-1	23892921
or	O	-1	23892921
previ@@	O	-1	23892921
ous	O	-1	23892921
exposure	O	-1	23892921
to	O	-1	23892921
thal@@	B-Chemical	D013792	23892921
id@@	I-Chemical	-1	23892921
om@@	I-Chemical	-1	23892921
ide	I-Chemical	-1	23892921
or	O	-1	23892921
b@@	B-Chemical	C400082	23892921
or@@	I-Chemical	-1	23892921
te@@	I-Chemical	-1	23892921
z@@	I-Chemical	-1	23892921
om@@	I-Chemical	-1	23892921
i@@	I-Chemical	-1	23892921
b	I-Chemical	-1	23892921
.	O	-1	23892921
M@@	O	-1	23892921
edi@@	O	-1	23892921
an	O	-1	23892921
duration	O	-1	23892921
of	O	-1	23892921
response	O	-1	23892921
was	O	-1	23892921
3@@	O	-1	23892921
4.@@	O	-1	23892921
4	O	-1	23892921
month@@	O	-1	23892921
s,	O	-1	23892921
and	O	-1	23892921
it	O	-1	23892921
was	O	-1	23892921
higher	O	-1	23892921
in	O	-1	23892921
patients	O	-1	23892921
who	O	-1	23892921
received	O	-1	23892921
R@@	B-Chemical	C467567	23892921
D	I-Chemical	-1	23892921
R@@	B-Chemical	D003907	23892921
D	I-Chemical	-1	23892921
un@@	O	-1	23892921
ti@@	O	-1	23892921
l	O	-1	23892921
progres@@	O	-1	23892921
sion	O	-1	23892921
(@@	O	-1	23892921
not	O	-1	23892921
reac@@	O	-1	23892921
h@@	O	-1	23892921
ed	O	-1	23892921
versus	O	-1	23892921
1@@	O	-1	23892921
9	O	-1	23892921
month@@	O	-1	23892921
s,	O	-1	23892921
p	O	-1	23892921
<	O	-1	23892921
0.00@@	O	-1	23892921
1).	O	-1	23892921
Im@@	O	-1	23892921
pro@@	O	-1	23892921
vement	O	-1	23892921
of	O	-1	23892921
h@@	O	-1	23892921
u@@	O	-1	23892921
mor@@	O	-1	23892921
al	O	-1	23892921
immun@@	O	-1	23892921
ity	O	-1	23892921
occurred	O	-1	23892921
in	O	-1	23892921
60	O	-1	23892921
%	O	-1	23892921
of	O	-1	23892921
respon@@	O	-1	23892921
der@@	O	-1	23892921
s	O	-1	23892921
(p	O	-1	23892921
<	O	-1	23892921
0.00@@	O	-1	23892921
1)	O	-1	23892921
and	O	-1	23892921
in	O	-1	23892921
the	O	-1	23892921
maj@@	O	-1	23892921
or@@	O	-1	23892921
ity	O	-1	23892921
of	O	-1	23892921
patients	O	-1	23892921
who	O	-1	23892921
achi@@	O	-1	23892921
ev@@	O	-1	23892921
ed	O	-1	23892921
st@@	O	-1	23892921
able	O	-1	23892921
disease.	O	-1	23892921
Ad@@	O	-1	23892921
verse	O	-1	23892921
events	O	-1	23892921
were	O	-1	23892921
reported	O	-1	23892921
in	O	-1	23892921
6@@	O	-1	23892921
8.@@	O	-1	23892921
9	O	-1	23892921
%	O	-1	23892921
of	O	-1	23892921
patients	O	-1	23892921
(	O	-1	23892921
my@@	B-Disease	D001855	23892921
e@@	I-Disease	-1	23892921
lo@@	I-Disease	-1	23892921
sup@@	I-Disease	-1	23892921
pression	I-Disease	-1	23892921
in	O	-1	23892921
4@@	O	-1	23892921
9.@@	O	-1	23892921
4	O	-1	23892921
%)	O	-1	23892921
and	O	-1	23892921
1@@	O	-1	23892921
2.@@	O	-1	23892921
7	O	-1	23892921
%	O	-1	23892921
of	O	-1	23892921
patients	O	-1	23892921
ne@@	O	-1	23892921
ed@@	O	-1	23892921
ed	O	-1	23892921
hospit@@	O	-1	23892921
al@@	O	-1	23892921
iz@@	O	-1	23892921
ation.	O	-1	23892921
P@@	B-Disease	D010523	23892921
er@@	I-Disease	-1	23892921
i@@	I-Disease	-1	23892921
pheral	I-Disease	-1	23892921
neuropathy	I-Disease	-1	23892921
was	O	-1	23892921
observed	O	-1	23892921
only	O	-1	23892921
in	O	-1	23892921
2.@@	O	-1	23892921
5	O	-1	23892921
%	O	-1	23892921
of	O	-1	23892921
patients	O	-1	23892921
and	O	-1	23892921
de@@	B-Disease	D020246	23892921
ep	I-Disease	-1	23892921
ve@@	I-Disease	-1	23892921
in	I-Disease	-1	23892921
thrombo@@	I-Disease	-1	23892921
sis	I-Disease	-1	23892921
in	O	-1	23892921
5.@@	O	-1	23892921
7	O	-1	23892921
%.	O	-1	23892921
D@@	O	-1	23892921
ose	O	-1	23892921
reduc@@	O	-1	23892921
tions	O	-1	23892921
were	O	-1	23892921
ne@@	O	-1	23892921
ed@@	O	-1	23892921
ed	O	-1	23892921
in	O	-1	23892921
3@@	O	-1	23892921
1	O	-1	23892921
%	O	-1	23892921
of	O	-1	23892921
patients	O	-1	23892921
and	O	-1	23892921
per@@	O	-1	23892921
man@@	O	-1	23892921
ent	O	-1	23892921
discontinu@@	O	-1	23892921
ation	O	-1	23892921
in	O	-1	23892921
3@@	O	-1	23892921
8.@@	O	-1	23892921
9	O	-1	23892921
%.	O	-1	23892921
M@@	O	-1	23892921
edi@@	O	-1	23892921
an	O	-1	23892921
time	O	-1	23892921
to	O	-1	23892921
treatment	O	-1	23892921
discontinu@@	O	-1	23892921
ation	O	-1	23892921
was	O	-1	23892921
1@@	O	-1	23892921
6.@@	O	-1	23892921
8	O	-1	23892921
months.	O	-1	23892921
P@@	O	-1	23892921
er@@	O	-1	23892921
form@@	O	-1	23892921
ance	O	-1	23892921
status	O	-1	23892921
(P@@	O	-1	23892921
S)	O	-1	23892921
and	O	-1	23892921
initial	O	-1	23892921
l@@	B-Chemical	C467567	23892921
en@@	I-Chemical	-1	23892921
al@@	I-Chemical	-1	23892921
id@@	I-Chemical	-1	23892921
om@@	I-Chemical	-1	23892921
ide	I-Chemical	-1	23892921
dose	O	-1	23892921
predic@@	O	-1	23892921
ted	O	-1	23892921
for	O	-1	23892921
treatment	O	-1	23892921
discontinu@@	O	-1	23892921
ation.	O	-1	23892921
E@@	O	-1	23892921
x@@	O	-1	23892921
tra@@	O	-1	23892921
-@@	O	-1	23892921
med@@	O	-1	23892921
ul@@	O	-1	23892921
l@@	O	-1	23892921
ary	O	-1	23892921
rel@@	O	-1	23892921
ap@@	O	-1	23892921
ses	O	-1	23892921
occurred	O	-1	23892921
in	O	-1	23892921
3.@@	O	-1	23892921
8	O	-1	23892921
%	O	-1	23892921
of	O	-1	23892921
patients.	O	-1	23892921
Our	O	-1	23892921
study	O	-1	23892921
con@@	O	-1	23892921
fir@@	O	-1	23892921
ms	O	-1	23892921
that	O	-1	23892921
R@@	B-Chemical	C467567	23892921
D	I-Chemical	-1	23892921
R@@	B-Chemical	D003907	23892921
D	I-Chemical	-1	23892921
is	O	-1	23892921
effective	O	-1	23892921
and	O	-1	23892921
saf@@	O	-1	23892921
e	O	-1	23892921
in	O	-1	23892921
R@@	B-Disease	D009101	23892921
R@@	I-Disease	-1	23892921
M@@	I-Disease	-1	23892921
M	I-Disease	-1	23892921
in	O	-1	23892921
the	O	-1	23892921
R@@	O	-1	23892921
W@@	O	-1	23892921
;	O	-1	23892921
it	O	-1	23892921
produc@@	O	-1	23892921
es	O	-1	23892921
dur@@	O	-1	23892921
able	O	-1	23892921
responses	O	-1	23892921
es@@	O	-1	23892921
p@@	O	-1	23892921
ec@@	O	-1	23892921
i@@	O	-1	23892921
ally	O	-1	23892921
in	O	-1	23892921
patients	O	-1	23892921
who	O	-1	23892921
continu@@	O	-1	23892921
e	O	-1	23892921
on	O	-1	23892921
treatment	O	-1	23892921
ti@@	O	-1	23892921
ll	O	-1	23892921
progres@@	O	-1	23892921
sion	O	-1	23892921
and	O	-1	23892921
impro@@	O	-1	23892921
v@@	O	-1	23892921
es	O	-1	23892921
h@@	O	-1	23892921
u@@	O	-1	23892921
mor@@	O	-1	23892921
al	O	-1	23892921
immun@@	O	-1	23892921
ity	O	-1	23892921
even	O	-1	23892921
in	O	-1	23892921
patients	O	-1	23892921
with	O	-1	23892921
st@@	O	-1	23892921
able	O	-1	23892921
disease.	O	-1	23892921

The	O	-1	23949582
cyto@@	O	-1	23949582
gene@@	O	-1	23949582
tic	O	-1	23949582
action	O	-1	23949582
of	O	-1	23949582
if@@	B-Chemical	D007069	23949582
os@@	I-Chemical	-1	23949582
f@@	I-Chemical	-1	23949582
amide	I-Chemical	-1	23949582
,	O	-1	23949582
m@@	B-Chemical	D015080	23949582
es@@	I-Chemical	-1	23949582
n@@	I-Chemical	-1	23949582
a	I-Chemical	-1	23949582
,	O	-1	23949582
and	O	-1	23949582
their	O	-1	23949582
combination	O	-1	23949582
on	O	-1	23949582
peripheral	O	-1	23949582
ra@@	O	-1	23949582
b@@	O	-1	23949582
b@@	O	-1	23949582
it	O	-1	23949582
lymph@@	O	-1	23949582
ocy@@	O	-1	23949582
t@@	O	-1	23949582
es@@	O	-1	23949582
:	O	-1	23949582
an	O	-1	23949582
in	O	-1	23949582
viv@@	O	-1	23949582
o@@	O	-1	23949582
/@@	O	-1	23949582
in	O	-1	23949582
vit@@	O	-1	23949582
r@@	O	-1	23949582
o	O	-1	23949582
cyto@@	O	-1	23949582
gene@@	O	-1	23949582
tic	O	-1	23949582
study.	O	-1	23949582
I@@	B-Chemical	D007069	23949582
f@@	I-Chemical	-1	23949582
os@@	I-Chemical	-1	23949582
f@@	I-Chemical	-1	23949582
amide	I-Chemical	-1	23949582
(	O	-1	23949582
I@@	B-Chemical	D007069	23949582
F@@	I-Chemical	-1	23949582
O	I-Chemical	-1	23949582
)	O	-1	23949582
is	O	-1	23949582
an	O	-1	23949582
al@@	O	-1	23949582
k@@	O	-1	23949582
yl@@	O	-1	23949582
ating	O	-1	23949582
nitro@@	B-Chemical	D009584	23949582
gen	I-Chemical	-1	23949582
m@@	O	-1	23949582
u@@	O	-1	23949582
star@@	O	-1	23949582
d,	O	-1	23949582
administr@@	O	-1	23949582
ated	O	-1	23949582
as	O	-1	23949582
an	O	-1	23949582
ant@@	O	-1	23949582
ine@@	O	-1	23949582
o@@	O	-1	23949582
plas@@	O	-1	23949582
mic	O	-1	23949582
agent@@	O	-1	23949582
.	O	-1	23949582
It	O	-1	23949582
is	O	-1	23949582
character@@	O	-1	23949582
ized	O	-1	23949582
by	O	-1	23949582
its	O	-1	23949582
int@@	O	-1	23949582
en@@	O	-1	23949582
se	O	-1	23949582
uro@@	O	-1	23949582
toxic	O	-1	23949582
ac@@	O	-1	23949582
tion,	O	-1	23949582
lead@@	O	-1	23949582
ing	O	-1	23949582
to	O	-1	23949582
hemorrh@@	B-Disease	D006470	23949582
ag@@	I-Disease	-1	23949582
ic	I-Disease	-1	23949582
cys@@	I-Disease	-1	23949582
ti@@	I-Disease	-1	23949582
tis	I-Disease	-1	23949582
hemorrh@@	B-Disease	D003556	23949582
ag@@	I-Disease	-1	23949582
ic	I-Disease	-1	23949582
cys@@	I-Disease	-1	23949582
ti@@	I-Disease	-1	23949582
tis	I-Disease	-1	23949582
.	O	-1	23949582
This	O	-1	23949582
side	O	-1	23949582
effect	O	-1	23949582
of	O	-1	23949582
I@@	B-Chemical	D007069	23949582
F@@	I-Chemical	-1	23949582
O	I-Chemical	-1	23949582
ra@@	O	-1	23949582
i@@	O	-1	23949582
ses	O	-1	23949582
the	O	-1	23949582
requ@@	O	-1	23949582
i@@	O	-1	23949582
re@@	O	-1	23949582
ment	O	-1	23949582
for	O	-1	23949582
the	O	-1	23949582
co-@@	O	-1	23949582
administration	O	-1	23949582
with	O	-1	23949582
sodium	B-Chemical	D015080	23949582
2-@@	I-Chemical	-1	23949582
sulf@@	I-Chemical	-1	23949582
an@@	I-Chemical	-1	23949582
y@@	I-Chemical	-1	23949582
le@@	I-Chemical	-1	23949582
th@@	I-Chemical	-1	23949582
an@@	I-Chemical	-1	23949582
es@@	I-Chemical	-1	23949582
ul@@	I-Chemical	-1	23949582
f@@	I-Chemical	-1	23949582
on@@	I-Chemical	-1	23949582
ate	I-Chemical	-1	23949582
(	O	-1	23949582
M@@	B-Chemical	D015080	23949582
es@@	I-Chemical	-1	23949582
n@@	I-Chemical	-1	23949582
a	I-Chemical	-1	23949582
)	O	-1	23949582
a@@	O	-1	23949582
im@@	O	-1	23949582
ing	O	-1	23949582
to	O	-1	23949582
av@@	O	-1	23949582
oid	O	-1	23949582
or	O	-1	23949582
minim@@	O	-1	23949582
iz@@	O	-1	23949582
e	O	-1	23949582
this	O	-1	23949582
effect@@	O	-1	23949582
.	O	-1	23949582
I@@	B-Chemical	D007069	23949582
F@@	I-Chemical	-1	23949582
O	I-Chemical	-1	23949582
and	O	-1	23949582
M@@	B-Chemical	D015080	23949582
es@@	I-Chemical	-1	23949582
n@@	I-Chemical	-1	23949582
a	I-Chemical	-1	23949582
were	O	-1	23949582
administr@@	O	-1	23949582
ated	O	-1	23949582
se@@	O	-1	23949582
par@@	O	-1	23949582
ately	O	-1	23949582
on	O	-1	23949582
ra@@	O	-1	23949582
b@@	O	-1	23949582
b@@	O	-1	23949582
it@@	O	-1	23949582
's	O	-1	23949582
lymph@@	O	-1	23949582
ocy@@	O	-1	23949582
tes	O	-1	23949582
in	O	-1	23949582
viv@@	O	-1	23949582
o@@	O	-1	23949582
,	O	-1	23949582
which	O	-1	23949582
were	O	-1	23949582
lat@@	O	-1	23949582
er	O	-1	23949582
developed	O	-1	23949582
in	O	-1	23949582
vit@@	O	-1	23949582
ro@@	O	-1	23949582
.	O	-1	23949582
C@@	O	-1	23949582
y@@	O	-1	23949582
to@@	O	-1	23949582
gene@@	O	-1	23949582
tic	O	-1	23949582
mark@@	O	-1	23949582
ers	O	-1	23949582
for	O	-1	23949582
sist@@	O	-1	23949582
er	O	-1	23949582
ch@@	O	-1	23949582
rom@@	O	-1	23949582
ati@@	O	-1	23949582
d	O	-1	23949582
ex@@	O	-1	23949582
changes	O	-1	23949582
(S@@	O	-1	23949582
C@@	O	-1	23949582
E@@	O	-1	23949582
s),	O	-1	23949582
pro@@	O	-1	23949582
li@@	O	-1	23949582
fer@@	O	-1	23949582
ation	O	-1	23949582
rate	O	-1	23949582
in@@	O	-1	23949582
de@@	O	-1	23949582
x	O	-1	23949582
(P@@	O	-1	23949582
R@@	O	-1	23949582
I@@	O	-1	23949582
)	O	-1	23949582
and	O	-1	23949582
M@@	O	-1	23949582
it@@	O	-1	23949582
o@@	O	-1	23949582
tic	O	-1	23949582
In@@	O	-1	23949582
de@@	O	-1	23949582
x	O	-1	23949582
were	O	-1	23949582
recor@@	O	-1	23949582
de@@	O	-1	23949582
d.	O	-1	23949582
M@@	B-Chemical	D015080	23949582
es@@	I-Chemical	-1	23949582
n@@	I-Chemical	-1	23949582
a	I-Chemical	-1	23949582
's	O	-1	23949582
ac@@	O	-1	23949582
tion,	O	-1	23949582
in	O	-1	23949582
con@@	O	-1	23949582
j@@	O	-1	23949582
unc@@	O	-1	23949582
tion	O	-1	23949582
with	O	-1	23949582
I@@	B-Chemical	D007069	23949582
F@@	I-Chemical	-1	23949582
O	I-Chemical	-1	23949582
reduc@@	O	-1	23949582
es	O	-1	23949582
the	O	-1	23949582
frequency	O	-1	23949582
of	O	-1	23949582
S@@	O	-1	23949582
C@@	O	-1	23949582
E@@	O	-1	23949582
s,	O	-1	23949582
in	O	-1	23949582
compar@@	O	-1	23949582
ison	O	-1	23949582
with	O	-1	23949582
the	O	-1	23949582
S@@	O	-1	23949582
C@@	O	-1	23949582
E@@	O	-1	23949582
s	O	-1	23949582
recor@@	O	-1	23949582
d@@	O	-1	23949582
ings	O	-1	23949582
obtained	O	-1	23949582
when	O	-1	23949582
I@@	B-Chemical	D007069	23949582
F@@	I-Chemical	-1	23949582
O	I-Chemical	-1	23949582
is	O	-1	23949582
administered	O	-1	23949582
al@@	O	-1	23949582
one.	O	-1	23949582
In	O	-1	23949582
addition	O	-1	23949582
to	O	-1	23949582
th@@	O	-1	23949582
is@@	O	-1	23949582
,	O	-1	23949582
when	O	-1	23949582
high	O	-1	23949582
concentrations	O	-1	23949582
of	O	-1	23949582
M@@	B-Chemical	D015080	23949582
es@@	I-Chemical	-1	23949582
n@@	I-Chemical	-1	23949582
a	I-Chemical	-1	23949582
were	O	-1	23949582
administered	O	-1	23949582
alone	O	-1	23949582
significant	O	-1	23949582
reduc@@	O	-1	23949582
tions	O	-1	23949582
of	O	-1	23949582
the	O	-1	23949582
P@@	O	-1	23949582
R@@	O	-1	23949582
I	O	-1	23949582
were	O	-1	23949582
not@@	O	-1	23949582
ed,	O	-1	23949582
than	O	-1	23949582
with	O	-1	23949582
I@@	B-Chemical	D007069	23949582
F@@	I-Chemical	-1	23949582
O	I-Chemical	-1	23949582
act@@	O	-1	23949582
ing	O	-1	23949582
at	O	-1	23949582
the	O	-1	23949582
same	O	-1	23949582
concentration	O	-1	23949582
on	O	-1	23949582
the	O	-1	23949582
lymph@@	O	-1	23949582
ocy@@	O	-1	23949582
t@@	O	-1	23949582
es.	O	-1	23949582
M@@	B-Chemical	D015080	23949582
es@@	I-Chemical	-1	23949582
n@@	I-Chemical	-1	23949582
a	I-Chemical	-1	23949582
significantly	O	-1	23949582
reduc@@	O	-1	23949582
es	O	-1	23949582
I@@	B-Chemical	D007069	23949582
F@@	I-Chemical	-1	23949582
O	I-Chemical	-1	23949582
's	O	-1	23949582
gen@@	B-Disease	D030342	23949582
otoxicity	I-Disease	-1	23949582
,	O	-1	23949582
while	O	-1	23949582
when	O	-1	23949582
administered	O	-1	23949582
in	O	-1	23949582
high	O	-1	23949582
concentrations	O	-1	23949582
it	O	-1	23949582
act@@	O	-1	23949582
s	O	-1	23949582
in	O	-1	23949582
an	O	-1	23949582
inhibit@@	O	-1	23949582
ory	O	-1	23949582
f@@	O	-1	23949582
as@@	O	-1	23949582
hi@@	O	-1	23949582
on	O	-1	23949582
on	O	-1	23949582
the	O	-1	23949582
cyto@@	O	-1	23949582
st@@	O	-1	23949582
atic	O	-1	23949582
action	O	-1	23949582
of	O	-1	23949582
the	O	-1	23949582
drug.	O	-1	23949582

R@@	O	-1	23952588
is@@	O	-1	23952588
k	O	-1	23952588
factors	O	-1	23952588
and	O	-1	23952588
predic@@	O	-1	23952588
t@@	O	-1	23952588
ors	O	-1	23952588
of	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
-induced	O	-1	23952588
dyskine@@	B-Disease	D004409	23952588
sia	I-Disease	-1	23952588
among	O	-1	23952588
multi@@	O	-1	23952588
eth@@	O	-1	23952588
n@@	O	-1	23952588
ic	O	-1	23952588
M@@	O	-1	23952588
al@@	O	-1	23952588
ay@@	O	-1	23952588
si@@	O	-1	23952588
ans	O	-1	23952588
with	O	-1	23952588
Parkinson's	B-Disease	D010300	23952588
disease	I-Disease	-1	23952588
.	O	-1	23952588
Ch@@	O	-1	23952588
ron@@	O	-1	23952588
ic	O	-1	23952588
pul@@	O	-1	23952588
s@@	O	-1	23952588
ati@@	O	-1	23952588
le	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
therapy	O	-1	23952588
for	O	-1	23952588
Parkinson's	B-Disease	D010300	23952588
disease	I-Disease	-1	23952588
(	O	-1	23952588
P@@	B-Disease	D010300	23952588
D	I-Disease	-1	23952588
)	O	-1	23952588
lead@@	O	-1	23952588
s	O	-1	23952588
to	O	-1	23952588
the	O	-1	23952588
development	O	-1	23952588
of	O	-1	23952588
motor	O	-1	23952588
f@@	O	-1	23952588
l@@	O	-1	23952588
uc@@	O	-1	23952588
tu@@	O	-1	23952588
ations	O	-1	23952588
and	O	-1	23952588
dyskine@@	B-Disease	D004409	23952588
sia	I-Disease	-1	23952588
.	O	-1	23952588
We	O	-1	23952588
studied	O	-1	23952588
the	O	-1	23952588
prev@@	O	-1	23952588
al@@	O	-1	23952588
ence	O	-1	23952588
and	O	-1	23952588
predic@@	O	-1	23952588
t@@	O	-1	23952588
ors	O	-1	23952588
of	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
-induced	O	-1	23952588
dyskine@@	B-Disease	D004409	23952588
sia	I-Disease	-1	23952588
among	O	-1	23952588
multi@@	O	-1	23952588
eth@@	O	-1	23952588
n@@	O	-1	23952588
ic	O	-1	23952588
M@@	O	-1	23952588
al@@	O	-1	23952588
ay@@	O	-1	23952588
si@@	O	-1	23952588
an	O	-1	23952588
patients	O	-1	23952588
with	O	-1	23952588
P@@	B-Disease	D010300	23952588
D	I-Disease	-1	23952588
.	O	-1	23952588
METHODS:	O	-1	23952588
This	O	-1	23952588
is	O	-1	23952588
a	O	-1	23952588
cros@@	O	-1	23952588
s-@@	O	-1	23952588
sec@@	O	-1	23952588
tional	O	-1	23952588
study	O	-1	23952588
invol@@	O	-1	23952588
ving	O	-1	23952588
9@@	O	-1	23952588
5	O	-1	23952588
patients	O	-1	23952588
with	O	-1	23952588
P@@	B-Disease	D010300	23952588
D	I-Disease	-1	23952588
on	O	-1	23952588
un@@	O	-1	23952588
inter@@	O	-1	23952588
ru@@	O	-1	23952588
pt@@	O	-1	23952588
ed	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
therapy	O	-1	23952588
for	O	-1	23952588
at	O	-1	23952588
le@@	O	-1	23952588
ast	O	-1	23952588
6	O	-1	23952588
months.	O	-1	23952588
The	O	-1	23952588
in@@	O	-1	23952588
st@@	O	-1	23952588
ru@@	O	-1	23952588
ment	O	-1	23952588
used	O	-1	23952588
was	O	-1	23952588
the	O	-1	23952588
U@@	O	-1	23952588
P@@	O	-1	23952588
D@@	O	-1	23952588
R@@	O	-1	23952588
S	O	-1	23952588
qu@@	O	-1	23952588
es@@	O	-1	23952588
tion@@	O	-1	23952588
na@@	O	-1	23952588
i@@	O	-1	23952588
res@@	O	-1	23952588
.	O	-1	23952588
The	O	-1	23952588
predic@@	O	-1	23952588
t@@	O	-1	23952588
ors	O	-1	23952588
of	O	-1	23952588
dyskine@@	B-Disease	D004409	23952588
sia	I-Disease	-1	23952588
were	O	-1	23952588
determined	O	-1	23952588
using	O	-1	23952588
mul@@	O	-1	23952588
tiv@@	O	-1	23952588
ari@@	O	-1	23952588
ate	O	-1	23952588
log@@	O	-1	23952588
istic	O	-1	23952588
reg@@	O	-1	23952588
res@@	O	-1	23952588
sion	O	-1	23952588
analy@@	O	-1	23952588
sis.	O	-1	23952588
RESULTS:	O	-1	23952588
The	O	-1	23952588
mean	O	-1	23952588
age	O	-1	23952588
was	O	-1	23952588
6@@	O	-1	23952588
5.@@	O	-1	23952588
6	O	-1	23952588
+	O	-1	23952588
8.@@	O	-1	23952588
5	O	-1	23952588
year@@	O	-1	23952588
s.	O	-1	23952588
The	O	-1	23952588
mean	O	-1	23952588
onset	O	-1	23952588
age	O	-1	23952588
was	O	-1	23952588
5@@	O	-1	23952588
8.@@	O	-1	23952588
5	O	-1	23952588
+	O	-1	23952588
9.@@	O	-1	23952588
8	O	-1	23952588
year@@	O	-1	23952588
s.	O	-1	23952588
The	O	-1	23952588
median	O	-1	23952588
disease	O	-1	23952588
duration	O	-1	23952588
was	O	-1	23952588
6	O	-1	23952588
(@@	O	-1	23952588
7@@	O	-1	23952588
)	O	-1	23952588
year@@	O	-1	23952588
s.	O	-1	23952588
D@@	B-Disease	D004409	23952588
ys@@	I-Disease	-1	23952588
kine@@	I-Disease	-1	23952588
sia	I-Disease	-1	23952588
was	O	-1	23952588
present	O	-1	23952588
in	O	-1	23952588
4@@	O	-1	23952588
4@@	O	-1	23952588
%	O	-1	23952588
(n	O	-1	23952588
=	O	-1	23952588
4@@	O	-1	23952588
2)	O	-1	23952588
with	O	-1	23952588
median	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
therapy	O	-1	23952588
of	O	-1	23952588
3	O	-1	23952588
year@@	O	-1	23952588
s.	O	-1	23952588
There	O	-1	23952588
were	O	-1	23952588
6@@	O	-1	23952588
4.@@	O	-1	23952588
3@@	O	-1	23952588
%	O	-1	23952588
Ch@@	O	-1	23952588
in@@	O	-1	23952588
es@@	O	-1	23952588
e,	O	-1	23952588
3@@	O	-1	23952588
1@@	O	-1	23952588
%	O	-1	23952588
M@@	O	-1	23952588
al@@	O	-1	23952588
ay@@	O	-1	23952588
s,	O	-1	23952588
and	O	-1	23952588
3.@@	O	-1	23952588
7@@	O	-1	23952588
%	O	-1	23952588
In@@	O	-1	23952588
di@@	O	-1	23952588
ans	O	-1	23952588
and	O	-1	23952588
other	O	-1	23952588
eth@@	O	-1	23952588
n@@	O	-1	23952588
ic	O	-1	23952588
groups.	O	-1	23952588
E@@	O	-1	23952588
igh@@	O	-1	23952588
ty-@@	O	-1	23952588
one	O	-1	23952588
perc@@	O	-1	23952588
ent	O	-1	23952588
of	O	-1	23952588
patients	O	-1	23952588
with	O	-1	23952588
dyskine@@	B-Disease	D004409	23952588
sia	I-Disease	-1	23952588
had	O	-1	23952588
clinical	O	-1	23952588
f@@	O	-1	23952588
l@@	O	-1	23952588
uc@@	O	-1	23952588
tu@@	O	-1	23952588
ations.	O	-1	23952588
Patients	O	-1	23952588
with	O	-1	23952588
dyskine@@	B-Disease	D004409	23952588
sia	I-Disease	-1	23952588
had	O	-1	23952588
lower	O	-1	23952588
onset	O	-1	23952588
age	O	-1	23952588
(	O	-1	23952588
p	O	-1	23952588
<	O	-1	23952588
0.00@@	O	-1	23952588
1),	O	-1	23952588
long@@	O	-1	23952588
er	O	-1	23952588
duration	O	-1	23952588
of	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
therapy	O	-1	23952588
(	O	-1	23952588
p	O	-1	23952588
<	O	-1	23952588
0.00@@	O	-1	23952588
1),	O	-1	23952588
long@@	O	-1	23952588
er	O	-1	23952588
disease	O	-1	23952588
duration	O	-1	23952588
(	O	-1	23952588
p	O	-1	23952588
<	O	-1	23952588
0.00@@	O	-1	23952588
1),	O	-1	23952588
higher	O	-1	23952588
total	O	-1	23952588
daily	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
dose	O	-1	23952588
(	O	-1	23952588
p	O	-1	23952588
<	O	-1	23952588
0.00@@	O	-1	23952588
1),	O	-1	23952588
and	O	-1	23952588
higher	O	-1	23952588
total	O	-1	23952588
U@@	O	-1	23952588
P@@	O	-1	23952588
D@@	O	-1	23952588
R@@	O	-1	23952588
S	O	-1	23952588
sco@@	O	-1	23952588
res	O	-1	23952588
(	O	-1	23952588
p	O	-1	23952588
=	O	-1	23952588
0.00@@	O	-1	23952588
5@@	O	-1	23952588
)	O	-1	23952588
than	O	-1	23952588
patients	O	-1	23952588
without	O	-1	23952588
dyskine@@	B-Disease	D004409	23952588
sia	I-Disease	-1	23952588
.	O	-1	23952588
The	O	-1	23952588
three	O	-1	23952588
significant	O	-1	23952588
predic@@	O	-1	23952588
t@@	O	-1	23952588
ors	O	-1	23952588
of	O	-1	23952588
dyskine@@	B-Disease	D004409	23952588
sia	I-Disease	-1	23952588
were	O	-1	23952588
duration	O	-1	23952588
of	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
therapy,	O	-1	23952588
onset	O	-1	23952588
age,	O	-1	23952588
and	O	-1	23952588
total	O	-1	23952588
daily	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
dose.	O	-1	23952588
CONCLUSIONS:	O	-1	23952588
The	O	-1	23952588
prev@@	O	-1	23952588
al@@	O	-1	23952588
ence	O	-1	23952588
of	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
-induced	O	-1	23952588
dyskine@@	B-Disease	D004409	23952588
sia	I-Disease	-1	23952588
in	O	-1	23952588
our	O	-1	23952588
patients	O	-1	23952588
was	O	-1	23952588
4@@	O	-1	23952588
4@@	O	-1	23952588
%.	O	-1	23952588
The	O	-1	23952588
most	O	-1	23952588
significant	O	-1	23952588
predic@@	O	-1	23952588
t@@	O	-1	23952588
ors	O	-1	23952588
were	O	-1	23952588
duration	O	-1	23952588
of	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
therapy,	O	-1	23952588
total	O	-1	23952588
daily	O	-1	23952588
levo@@	B-Chemical	D007980	23952588
dopa	I-Chemical	-1	23952588
dose@@	O	-1	23952588
,	O	-1	23952588
and	O	-1	23952588
onset	O	-1	23952588
age.	O	-1	23952588

An	O	-1	24040781
un@@	O	-1	24040781
ex@@	O	-1	24040781
p@@	O	-1	24040781
ected	O	-1	24040781
diagnosis	O	-1	24040781
in	O	-1	24040781
a	O	-1	24040781
ren@@	O	-1	24040781
al@@	O	-1	24040781
-@@	O	-1	24040781
transplant	O	-1	24040781
patient	O	-1	24040781
with	O	-1	24040781
proteinuria	B-Disease	D011507	24040781
treated	O	-1	24040781
with	O	-1	24040781
e@@	B-Chemical	C107135	24040781
ver@@	I-Chemical	-1	24040781
ol@@	I-Chemical	-1	24040781
im@@	I-Chemical	-1	24040781
us	I-Chemical	-1	24040781
:	O	-1	24040781
A@@	B-Disease	D000686	24040781
L	I-Disease	-1	24040781
am@@	B-Disease	D000686	24040781
y@@	I-Disease	-1	24040781
lo@@	I-Disease	-1	24040781
id@@	I-Disease	-1	24040781
o@@	I-Disease	-1	24040781
sis	I-Disease	-1	24040781
.	O	-1	24040781
Pro@@	B-Disease	D011507	24040781
te@@	I-Disease	-1	24040781
in@@	I-Disease	-1	24040781
uria	I-Disease	-1	24040781
is	O	-1	24040781
an	O	-1	24040781
ex@@	O	-1	24040781
p@@	O	-1	24040781
ected	O	-1	24040781
complication	O	-1	24040781
in	O	-1	24040781
transplant	O	-1	24040781
patients	O	-1	24040781
treated	O	-1	24040781
with	O	-1	24040781
m@@	O	-1	24040781
am@@	O	-1	24040781
mal@@	O	-1	24040781
i@@	O	-1	24040781
an	O	-1	24040781
t@@	O	-1	24040781
arg@@	O	-1	24040781
et	O	-1	24040781
of	O	-1	24040781
ra@@	B-Chemical	D020123	24040781
p@@	I-Chemical	-1	24040781
am@@	I-Chemical	-1	24040781
ycin	I-Chemical	-1	24040781
inhibitors	O	-1	24040781
(@@	O	-1	24040781
m@@	O	-1	24040781
T@@	O	-1	24040781
O@@	O	-1	24040781
R@@	O	-1	24040781
-@@	O	-1	24040781
i@@	O	-1	24040781
).	O	-1	24040781
However,	O	-1	24040781
clinical	O	-1	24040781
sus@@	O	-1	24040781
p@@	O	-1	24040781
ici@@	O	-1	24040781
on	O	-1	24040781
should	O	-1	24040781
al@@	O	-1	24040781
w@@	O	-1	24040781
ays	O	-1	24040781
be	O	-1	24040781
suppor@@	O	-1	24040781
ted	O	-1	24040781
by	O	-1	24040781
hist@@	O	-1	24040781
ological	O	-1	24040781
evidence	O	-1	24040781
in	O	-1	24040781
or@@	O	-1	24040781
der	O	-1	24040781
to	O	-1	24040781
investigate	O	-1	24040781
potential	O	-1	24040781
al@@	O	-1	24040781
tern@@	O	-1	24040781
ate	O	-1	24040781
diagno@@	O	-1	24040781
ses	O	-1	24040781
such	O	-1	24040781
as	O	-1	24040781
acute	O	-1	24040781
or	O	-1	24040781
chronic	O	-1	24040781
re@@	O	-1	24040781
j@@	O	-1	24040781
ec@@	O	-1	24040781
tion,	O	-1	24040781
interstitial	O	-1	24040781
fib@@	B-Disease	D005355	24040781
ro@@	I-Disease	-1	24040781
sis	I-Disease	-1	24040781
and	O	-1	24040781
tub@@	O	-1	24040781
ular	O	-1	24040781
atro@@	B-Disease	D001284	24040781
ph@@	I-Disease	-1	24040781
y	I-Disease	-1	24040781
,	O	-1	24040781
or	O	-1	24040781
recur@@	O	-1	24040781
rent	O	-1	24040781
or	O	-1	24040781
de	O	-1	24040781
no@@	O	-1	24040781
v@@	O	-1	24040781
o	O	-1	24040781
glomer@@	B-Disease	D007674	24040781
ulo@@	I-Disease	-1	24040781
pathy	I-Disease	-1	24040781
.	O	-1	24040781
In	O	-1	24040781
this	O	-1	24040781
case	O	-1	24040781
we	O	-1	24040781
report	O	-1	24040781
the	O	-1	24040781
un@@	O	-1	24040781
ex@@	O	-1	24040781
p@@	O	-1	24040781
ected	O	-1	24040781
diagnosis	O	-1	24040781
of	O	-1	24040781
am@@	B-Disease	D000686	24040781
y@@	I-Disease	-1	24040781
lo@@	I-Disease	-1	24040781
id@@	I-Disease	-1	24040781
o@@	I-Disease	-1	24040781
sis	I-Disease	-1	24040781
in	O	-1	24040781
a	O	-1	24040781
ren@@	O	-1	24040781
al@@	O	-1	24040781
-@@	O	-1	24040781
transplant	O	-1	24040781
patient	O	-1	24040781
with	O	-1	24040781
pre-@@	O	-1	24040781
transplant	O	-1	24040781
mon@@	O	-1	24040781
oc@@	O	-1	24040781
lon@@	O	-1	24040781
al	O	-1	24040781
gam@@	O	-1	24040781
m@@	O	-1	24040781
ap@@	O	-1	24040781
ath@@	O	-1	24040781
y	O	-1	24040781
of	O	-1	24040781
un@@	O	-1	24040781
determined	O	-1	24040781
signific@@	O	-1	24040781
ance	O	-1	24040781
who	O	-1	24040781
developed	O	-1	24040781
proteinuria	B-Disease	D011507	24040781
after	O	-1	24040781
conver@@	O	-1	24040781
sion	O	-1	24040781
from	O	-1	24040781
tacrolimus	B-Chemical	D016559	24040781
to	O	-1	24040781
e@@	B-Chemical	C107135	24040781
ver@@	I-Chemical	-1	24040781
ol@@	I-Chemical	-1	24040781
im@@	I-Chemical	-1	24040781
us	I-Chemical	-1	24040781
.	O	-1	24040781

An	O	-1	24067251
investig@@	O	-1	24067251
ation	O	-1	24067251
of	O	-1	24067251
the	O	-1	24067251
pat@@	O	-1	24067251
ter@@	O	-1	24067251
n	O	-1	24067251
of	O	-1	24067251
kidney	B-Disease	D007674	24067251
injury	I-Disease	-1	24067251
in	O	-1	24067251
H@@	O	-1	24067251
I@@	O	-1	24067251
V@@	O	-1	24067251
-@@	O	-1	24067251
positive	O	-1	24067251
per@@	O	-1	24067251
son@@	O	-1	24067251
s	O	-1	24067251
exposed	O	-1	24067251
to	O	-1	24067251
ten@@	B-Chemical	C418563	24067251
of@@	I-Chemical	-1	24067251
o@@	I-Chemical	-1	24067251
vi@@	I-Chemical	-1	24067251
r	I-Chemical	-1	24067251
dis@@	I-Chemical	-1	24067251
o@@	I-Chemical	-1	24067251
pro@@	I-Chemical	-1	24067251
x@@	I-Chemical	-1	24067251
il	I-Chemical	-1	24067251
f@@	I-Chemical	-1	24067251
um@@	I-Chemical	-1	24067251
ar@@	I-Chemical	-1	24067251
ate	I-Chemical	-1	24067251
:	O	-1	24067251
an	O	-1	24067251
examin@@	O	-1	24067251
ation	O	-1	24067251
of	O	-1	24067251
a	O	-1	24067251
larg@@	O	-1	24067251
e	O	-1	24067251
po@@	O	-1	24067251
p@@	O	-1	24067251
ulation	O	-1	24067251
dat@@	O	-1	24067251
ab@@	O	-1	24067251
ase	O	-1	24067251
(@@	O	-1	24067251
M@@	O	-1	24067251
H@@	O	-1	24067251
R@@	O	-1	24067251
A	O	-1	24067251
dat@@	O	-1	24067251
ab@@	O	-1	24067251
as@@	O	-1	24067251
e@@	O	-1	24067251
).	O	-1	24067251
The	O	-1	24067251
potential	O	-1	24067251
for	O	-1	24067251
ten@@	B-Chemical	C096918	24067251
of@@	I-Chemical	-1	24067251
o@@	I-Chemical	-1	24067251
vi@@	I-Chemical	-1	24067251
r	I-Chemical	-1	24067251
to	O	-1	24067251
cause	O	-1	24067251
a	O	-1	24067251
range	O	-1	24067251
of	O	-1	24067251
kidney	O	-1	24067251
syndrom@@	O	-1	24067251
es	O	-1	24067251
has	O	-1	24067251
been	O	-1	24067251
est@@	O	-1	24067251
abl@@	O	-1	24067251
ished	O	-1	24067251
from	O	-1	24067251
mechanis@@	O	-1	24067251
tic	O	-1	24067251
and	O	-1	24067251
random@@	O	-1	24067251
is@@	O	-1	24067251
ed	O	-1	24067251
clinical	O	-1	24067251
tri@@	O	-1	24067251
al@@	O	-1	24067251
s.	O	-1	24067251
However,	O	-1	24067251
the	O	-1	24067251
ex@@	O	-1	24067251
ac@@	O	-1	24067251
t	O	-1	24067251
pat@@	O	-1	24067251
ter@@	O	-1	24067251
n	O	-1	24067251
of	O	-1	24067251
kidney	O	-1	24067251
invol@@	O	-1	24067251
vement	O	-1	24067251
is	O	-1	24067251
sti@@	O	-1	24067251
ll	O	-1	24067251
unc@@	O	-1	24067251
er@@	O	-1	24067251
t@@	O	-1	24067251
ain@@	O	-1	24067251
.	O	-1	24067251
We	O	-1	24067251
under@@	O	-1	24067251
to@@	O	-1	24067251
o@@	O	-1	24067251
k	O	-1	24067251
a	O	-1	24067251
descri@@	O	-1	24067251
p@@	O	-1	24067251
tive	O	-1	24067251
analysis	O	-1	24067251
of	O	-1	24067251
Y@@	O	-1	24067251
el@@	O	-1	24067251
low	O	-1	24067251
C@@	O	-1	24067251
ard	O	-1	24067251
recor@@	O	-1	24067251
ds	O	-1	24067251
of	O	-1	24067251
4@@	O	-1	24067251
0@@	O	-1	24067251
7	O	-1	24067251
H@@	O	-1	24067251
I@@	O	-1	24067251
V@@	O	-1	24067251
-@@	O	-1	24067251
positive	O	-1	24067251
per@@	O	-1	24067251
son@@	O	-1	24067251
s	O	-1	24067251
taking	O	-1	24067251
ten@@	B-Chemical	C418563	24067251
of@@	I-Chemical	-1	24067251
o@@	I-Chemical	-1	24067251
vi@@	I-Chemical	-1	24067251
r	I-Chemical	-1	24067251
dis@@	I-Chemical	-1	24067251
o@@	I-Chemical	-1	24067251
pro@@	I-Chemical	-1	24067251
x@@	I-Chemical	-1	24067251
il	I-Chemical	-1	24067251
f@@	I-Chemical	-1	24067251
um@@	I-Chemical	-1	24067251
ar@@	I-Chemical	-1	24067251
ate	I-Chemical	-1	24067251
(	O	-1	24067251
T@@	B-Chemical	C418563	24067251
D@@	I-Chemical	-1	24067251
F	I-Chemical	-1	24067251
)	O	-1	24067251
as	O	-1	24067251
par@@	O	-1	24067251
t	O	-1	24067251
of	O	-1	24067251
their	O	-1	24067251
anti@@	O	-1	24067251
ret@@	O	-1	24067251
ro@@	O	-1	24067251
viral	O	-1	24067251
therapy	O	-1	24067251
regi@@	O	-1	24067251
men	O	-1	24067251
and	O	-1	24067251
sub@@	O	-1	24067251
mit@@	O	-1	24067251
ted	O	-1	24067251
to	O	-1	24067251
the	O	-1	24067251
M@@	O	-1	24067251
ed@@	O	-1	24067251
ic@@	O	-1	24067251
in@@	O	-1	24067251
es	O	-1	24067251
and	O	-1	24067251
He@@	O	-1	24067251
al@@	O	-1	24067251
th@@	O	-1	24067251
car@@	O	-1	24067251
e	O	-1	24067251
Pro@@	O	-1	24067251
duc@@	O	-1	24067251
ts	O	-1	24067251
Re@@	O	-1	24067251
g@@	O	-1	24067251
ul@@	O	-1	24067251
atory	O	-1	24067251
A@@	O	-1	24067251
gen@@	O	-1	24067251
c@@	O	-1	24067251
y	O	-1	24067251
(@@	O	-1	24067251
M@@	O	-1	24067251
H@@	O	-1	24067251
R@@	O	-1	24067251
A@@	O	-1	24067251
)	O	-1	24067251
with	O	-1	24067251
sus@@	O	-1	24067251
p@@	O	-1	24067251
ected	O	-1	24067251
kidney	O	-1	24067251
adverse	O	-1	24067251
effects.	O	-1	24067251
Re@@	O	-1	24067251
por@@	O	-1	24067251
ts	O	-1	24067251
that	O	-1	24067251
s@@	O	-1	24067251
atis@@	O	-1	24067251
f@@	O	-1	24067251
y	O	-1	24067251
def@@	O	-1	24067251
in@@	O	-1	24067251
ed	O	-1	24067251
c@@	O	-1	24067251
rit@@	O	-1	24067251
er@@	O	-1	24067251
ia	O	-1	24067251
were	O	-1	24067251
cl@@	O	-1	24067251
assi@@	O	-1	24067251
fied	O	-1	24067251
as	O	-1	24067251
acute	B-Disease	D058186	24067251
kidney	I-Disease	-1	24067251
injury	I-Disease	-1	24067251
,	O	-1	24067251
kidney	B-Disease	D007674	24067251
tub@@	I-Disease	-1	24067251
ular	I-Disease	-1	24067251
dysfunction	I-Disease	-1	24067251
and	O	-1	24067251
F@@	B-Disease	D005198	24067251
an@@	I-Disease	-1	24067251
con@@	I-Disease	-1	24067251
i	I-Disease	-1	24067251
syndrome	I-Disease	-1	24067251
.	O	-1	24067251
Of	O	-1	24067251
the	O	-1	24067251
4@@	O	-1	24067251
0@@	O	-1	24067251
7	O	-1	24067251
Y@@	O	-1	24067251
el@@	O	-1	24067251
low	O	-1	24067251
C@@	O	-1	24067251
ard	O	-1	24067251
recor@@	O	-1	24067251
ds	O	-1	24067251
analy@@	O	-1	24067251
se@@	O	-1	24067251
d,	O	-1	24067251
10@@	O	-1	24067251
6	O	-1	24067251
s@@	O	-1	24067251
atis@@	O	-1	24067251
fied	O	-1	24067251
c@@	O	-1	24067251
rit@@	O	-1	24067251
er@@	O	-1	24067251
ia	O	-1	24067251
for	O	-1	24067251
T@@	B-Chemical	C418563	24067251
D@@	I-Chemical	-1	24067251
F	I-Chemical	-1	24067251
-@@	O	-1	24067251
related	O	-1	24067251
kidney	B-Disease	D007674	24067251
disease	I-Disease	-1	24067251
,	O	-1	24067251
of	O	-1	24067251
which	O	-1	24067251
5@@	O	-1	24067251
3	O	-1	24067251
(@@	O	-1	24067251
50@@	O	-1	24067251
%)	O	-1	24067251
had	O	-1	24067251
feat@@	O	-1	24067251
ures	O	-1	24067251
of	O	-1	24067251
kidney	B-Disease	D007674	24067251
tub@@	I-Disease	-1	24067251
ular	I-Disease	-1	24067251
dysfunction	I-Disease	-1	24067251
,	O	-1	24067251
3@@	O	-1	24067251
5	O	-1	24067251
(3@@	O	-1	24067251
3@@	O	-1	24067251
%)	O	-1	24067251
were	O	-1	24067251
found	O	-1	24067251
to	O	-1	24067251
have	O	-1	24067251
feat@@	O	-1	24067251
ures	O	-1	24067251
of	O	-1	24067251
glomerular	B-Disease	D007674	24067251
dysfunction	I-Disease	-1	24067251
and	O	-1	24067251
1@@	O	-1	24067251
8	O	-1	24067251
(1@@	O	-1	24067251
7@@	O	-1	24067251
%)	O	-1	24067251
had	O	-1	24067251
F@@	B-Disease	D005198	24067251
an@@	I-Disease	-1	24067251
con@@	I-Disease	-1	24067251
i	I-Disease	-1	24067251
syndrome	I-Disease	-1	24067251
.	O	-1	24067251
The	O	-1	24067251
median	O	-1	24067251
T@@	B-Chemical	C418563	24067251
D@@	I-Chemical	-1	24067251
F	I-Chemical	-1	24067251
exposure	O	-1	24067251
was	O	-1	24067251
3@@	O	-1	24067251
16	O	-1	24067251
days	O	-1	24067251
(@@	O	-1	24067251
inter@@	O	-1	24067251
qu@@	O	-1	24067251
ar@@	O	-1	24067251
ti@@	O	-1	24067251
le	O	-1	24067251
range	O	-1	24067251
1@@	O	-1	24067251
20@@	O	-1	24067251
-@@	O	-1	24067251
7@@	O	-1	24067251
4@@	O	-1	24067251
0@@	O	-1	24067251
).	O	-1	24067251
The	O	-1	24067251
incidence	O	-1	24067251
of	O	-1	24067251
hospit@@	O	-1	24067251
al@@	O	-1	24067251
is@@	O	-1	24067251
ation	O	-1	24067251
for	O	-1	24067251
T@@	B-Chemical	C418563	24067251
D@@	I-Chemical	-1	24067251
F	I-Chemical	-1	24067251
kidney	O	-1	24067251
adverse	O	-1	24067251
effects	O	-1	24067251
was	O	-1	24067251
high@@	O	-1	24067251
,	O	-1	24067251
partic@@	O	-1	24067251
ul@@	O	-1	24067251
arly	O	-1	24067251
am@@	O	-1	24067251
on@@	O	-1	24067251
g@@	O	-1	24067251
st	O	-1	24067251
patients	O	-1	24067251
with	O	-1	24067251
feat@@	O	-1	24067251
ures	O	-1	24067251
of	O	-1	24067251
F@@	B-Disease	D005198	24067251
an@@	I-Disease	-1	24067251
con@@	I-Disease	-1	24067251
i	I-Disease	-1	24067251
syndrome	I-Disease	-1	24067251
.	O	-1	24067251
The	O	-1	24067251
pat@@	O	-1	24067251
ter@@	O	-1	24067251
n	O	-1	24067251
of	O	-1	24067251
kidney	O	-1	24067251
syndrom@@	O	-1	24067251
es	O	-1	24067251
in	O	-1	24067251
this	O	-1	24067251
po@@	O	-1	24067251
p@@	O	-1	24067251
ulation	O	-1	24067251
seri@@	O	-1	24067251
es	O	-1	24067251
m@@	O	-1	24067251
ir@@	O	-1	24067251
ro@@	O	-1	24067251
r@@	O	-1	24067251
s	O	-1	24067251
that	O	-1	24067251
reported	O	-1	24067251
in	O	-1	24067251
random@@	O	-1	24067251
is@@	O	-1	24067251
ed	O	-1	24067251
clinical	O	-1	24067251
tri@@	O	-1	24067251
al@@	O	-1	24067251
s.	O	-1	24067251
C@@	O	-1	24067251
ess@@	O	-1	24067251
ation	O	-1	24067251
of	O	-1	24067251
T@@	B-Chemical	C418563	24067251
D@@	I-Chemical	-1	24067251
F	I-Chemical	-1	24067251
was	O	-1	24067251
associated	O	-1	24067251
with	O	-1	24067251
complete	O	-1	24067251
rest@@	O	-1	24067251
or@@	O	-1	24067251
ation	O	-1	24067251
of	O	-1	24067251
kidney	O	-1	24067251
function	O	-1	24067251
in	O	-1	24067251
up	O	-1	24067251
h@@	O	-1	24067251
al@@	O	-1	24067251
f	O	-1	24067251
of	O	-1	24067251
the	O	-1	24067251
patients	O	-1	24067251
in	O	-1	24067251
this	O	-1	24067251
repor@@	O	-1	24067251
t.	O	-1	24067251

In@@	O	-1	24068571
c@@	O	-1	24068571
idence	O	-1	24068571
of	O	-1	24068571
postoperative	B-Disease	D011183	24068571
de@@	I-Disease	-1	24068571
li@@	I-Disease	-1	24068571
ri@@	I-Disease	-1	24068571
um	I-Disease	-1	24068571
is	O	-1	24068571
high	O	-1	24068571
even	O	-1	24068571
in	O	-1	24068571
a	O	-1	24068571
po@@	O	-1	24068571
p@@	O	-1	24068571
ulation	O	-1	24068571
without	O	-1	24068571
known	O	-1	24068571
risk	O	-1	24068571
fact@@	O	-1	24068571
or@@	O	-1	24068571
s.	O	-1	24068571
P@@	O	-1	24068571
U@@	O	-1	24068571
R@@	O	-1	24068571
P@@	O	-1	24068571
O@@	O	-1	24068571
S@@	O	-1	24068571
E:	O	-1	24068571
P@@	B-Disease	D011183	24068571
o@@	I-Disease	-1	24068571
sto@@	I-Disease	-1	24068571
perative	I-Disease	-1	24068571
de@@	I-Disease	-1	24068571
li@@	I-Disease	-1	24068571
ri@@	I-Disease	-1	24068571
um	I-Disease	-1	24068571
is	O	-1	24068571
a	O	-1	24068571
reco@@	O	-1	24068571
gn@@	O	-1	24068571
ized	O	-1	24068571
complication	O	-1	24068571
in	O	-1	24068571
po@@	O	-1	24068571
pul@@	O	-1	24068571
ations	O	-1	24068571
at	O	-1	24068571
ris@@	O	-1	24068571
k@@	O	-1	24068571
.	O	-1	24068571
The	O	-1	24068571
a@@	O	-1	24068571
im	O	-1	24068571
of	O	-1	24068571
this	O	-1	24068571
study	O	-1	24068571
is	O	-1	24068571
to	O	-1	24068571
ass@@	O	-1	24068571
ess	O	-1	24068571
the	O	-1	24068571
prev@@	O	-1	24068571
al@@	O	-1	24068571
ence	O	-1	24068571
of	O	-1	24068571
early	O	-1	24068571
postoperative	B-Disease	D011183	24068571
de@@	I-Disease	-1	24068571
li@@	I-Disease	-1	24068571
ri@@	I-Disease	-1	24068571
um	I-Disease	-1	24068571
in	O	-1	24068571
a	O	-1	24068571
po@@	O	-1	24068571
p@@	O	-1	24068571
ulation	O	-1	24068571
without	O	-1	24068571
known	O	-1	24068571
risk	O	-1	24068571
factors	O	-1	24068571
ad@@	O	-1	24068571
mit@@	O	-1	24068571
ted	O	-1	24068571
to	O	-1	24068571
the	O	-1	24068571
IC@@	O	-1	24068571
U	O	-1	24068571
for	O	-1	24068571
postoperative	O	-1	24068571
monit@@	O	-1	24068571
or@@	O	-1	24068571
ing	O	-1	24068571
after	O	-1	24068571
el@@	O	-1	24068571
ective	O	-1	24068571
major	O	-1	24068571
surger@@	O	-1	24068571
y.	O	-1	24068571
The	O	-1	24068571
secondary	O	-1	24068571
outcom@@	O	-1	24068571
e	O	-1	24068571
investigated	O	-1	24068571
is	O	-1	24068571
to	O	-1	24068571
identi@@	O	-1	24068571
f@@	O	-1	24068571
y	O	-1	24068571
event@@	O	-1	24068571
ual	O	-1	24068571
in@@	O	-1	24068571
dependent	O	-1	24068571
risk	O	-1	24068571
factors	O	-1	24068571
among	O	-1	24068571
de@@	O	-1	24068571
mo@@	O	-1	24068571
graph@@	O	-1	24068571
ic	O	-1	24068571
data	O	-1	24068571
and	O	-1	24068571
anesthe@@	O	-1	24068571
tic	O	-1	24068571
drugs	O	-1	24068571
use@@	O	-1	24068571
d.	O	-1	24068571
METHODS:	O	-1	24068571
An	O	-1	24068571
observ@@	O	-1	24068571
ation@@	O	-1	24068571
al,	O	-1	24068571
pro@@	O	-1	24068571
sp@@	O	-1	24068571
ective	O	-1	24068571
study	O	-1	24068571
was	O	-1	24068571
con@@	O	-1	24068571
duc@@	O	-1	24068571
ted	O	-1	24068571
on	O	-1	24068571
a	O	-1	24068571
con@@	O	-1	24068571
sec@@	O	-1	24068571
utive	O	-1	24068571
co@@	O	-1	24068571
h@@	O	-1	24068571
ort	O	-1	24068571
of	O	-1	24068571
patients	O	-1	24068571
ad@@	O	-1	24068571
mit@@	O	-1	24068571
ted	O	-1	24068571
to	O	-1	24068571
our	O	-1	24068571
IC@@	O	-1	24068571
U	O	-1	24068571
within	O	-1	24068571
and	O	-1	24068571
for	O	-1	24068571
at	O	-1	24068571
le@@	O	-1	24068571
ast	O	-1	24068571
24	O	-1	24068571
h	O	-1	24068571
after	O	-1	24068571
major	O	-1	24068571
surg@@	O	-1	24068571
ical	O	-1	24068571
proce@@	O	-1	24068571
du@@	O	-1	24068571
res@@	O	-1	24068571
.	O	-1	24068571
E@@	O	-1	24068571
x@@	O	-1	24068571
cl@@	O	-1	24068571
usion	O	-1	24068571
c@@	O	-1	24068571
rit@@	O	-1	24068571
er@@	O	-1	24068571
ia	O	-1	24068571
were	O	-1	24068571
any	O	-1	24068571
pre@@	O	-1	24068571
ex@@	O	-1	24068571
ist@@	O	-1	24068571
ing	O	-1	24068571
pre@@	O	-1	24068571
dis@@	O	-1	24068571
pos@@	O	-1	24068571
ing	O	-1	24068571
factor	O	-1	24068571
for	O	-1	24068571
de@@	B-Disease	D003693	24068571
li@@	I-Disease	-1	24068571
ri@@	I-Disease	-1	24068571
um	I-Disease	-1	24068571
or	O	-1	24068571
other	O	-1	24068571
potenti@@	O	-1	24068571
ally	O	-1	24068571
conf@@	O	-1	24068571
oun@@	O	-1	24068571
ding	O	-1	24068571
neurolog@@	B-Disease	D009422	24068571
ical	I-Disease	-1	24068571
dysfunc@@	I-Disease	-1	24068571
tions	I-Disease	-1	24068571
.	O	-1	24068571
Patients	O	-1	24068571
were	O	-1	24068571
assessed	O	-1	24068571
daily	O	-1	24068571
using	O	-1	24068571
the	O	-1	24068571
conf@@	B-Disease	D003221	24068571
usion	I-Disease	-1	24068571
assess@@	O	-1	24068571
ment	O	-1	24068571
meth@@	O	-1	24068571
od	O	-1	24068571
for	O	-1	24068571
the	O	-1	24068571
IC@@	O	-1	24068571
U	O	-1	24068571
s@@	O	-1	24068571
cal@@	O	-1	24068571
e	O	-1	24068571
for	O	-1	24068571
3	O	-1	24068571
days	O	-1	24068571
after	O	-1	24068571
the	O	-1	24068571
surg@@	O	-1	24068571
ical	O	-1	24068571
proce@@	O	-1	24068571
d@@	O	-1	24068571
ure.	O	-1	24068571
E@@	O	-1	24068571
arly	O	-1	24068571
postoperative	B-Disease	D011183	24068571
de@@	I-Disease	-1	24068571
li@@	I-Disease	-1	24068571
ri@@	I-Disease	-1	24068571
um	I-Disease	-1	24068571
incidence	O	-1	24068571
risk	O	-1	24068571
factors	O	-1	24068571
were	O	-1	24068571
then	O	-1	24068571
assessed	O	-1	24068571
through	O	-1	24068571
three	O	-1	24068571
different	O	-1	24068571
multiple	O	-1	24068571
reg@@	O	-1	24068571
res@@	O	-1	24068571
sion	O	-1	24068571
model@@	O	-1	24068571
s.	O	-1	24068571
RESULTS:	O	-1	24068571
Ac@@	O	-1	24068571
cor@@	O	-1	24068571
ding	O	-1	24068571
to	O	-1	24068571
the	O	-1	24068571
conf@@	O	-1	24068571
usion	O	-1	24068571
assess@@	O	-1	24068571
ment	O	-1	24068571
meth@@	O	-1	24068571
od	O	-1	24068571
for	O	-1	24068571
the	O	-1	24068571
IC@@	O	-1	24068571
U	O	-1	24068571
s@@	O	-1	24068571
cal@@	O	-1	24068571
e,	O	-1	24068571
2@@	O	-1	24068571
8	O	-1	24068571
%	O	-1	24068571
of	O	-1	24068571
patients	O	-1	24068571
were	O	-1	24068571
diagnos@@	O	-1	24068571
ed	O	-1	24068571
with	O	-1	24068571
early	O	-1	24068571
postoperative	B-Disease	D011183	24068571
de@@	I-Disease	-1	24068571
li@@	I-Disease	-1	24068571
ri@@	I-Disease	-1	24068571
um	I-Disease	-1	24068571
.	O	-1	24068571
The	O	-1	24068571
use	O	-1	24068571
of	O	-1	24068571
th@@	B-Chemical	D013874	24068571
io@@	I-Chemical	-1	24068571
pent@@	I-Chemical	-1	24068571
one	I-Chemical	-1	24068571
was	O	-1	24068571
significantly	O	-1	24068571
associated	O	-1	24068571
with	O	-1	24068571
an	O	-1	24068571
e@@	O	-1	24068571
igh@@	O	-1	24068571
t-@@	O	-1	24068571
fol@@	O	-1	24068571
d-@@	O	-1	24068571
higher	O	-1	24068571
risk	O	-1	24068571
for	O	-1	24068571
de@@	B-Disease	D003693	24068571
li@@	I-Disease	-1	24068571
ri@@	I-Disease	-1	24068571
um	I-Disease	-1	24068571
compared	O	-1	24068571
to	O	-1	24068571
pro@@	B-Chemical	D015742	24068571
po@@	I-Chemical	-1	24068571
f@@	I-Chemical	-1	24068571
ol	I-Chemical	-1	24068571
(5@@	O	-1	24068571
7.@@	O	-1	24068571
1@@	O	-1	24068571
%	O	-1	24068571
vs.	O	-1	24068571
7.@@	O	-1	24068571
1@@	O	-1	24068571
%,	O	-1	24068571
R@@	O	-1	24068571
R	O	-1	24068571
=	O	-1	24068571
8.@@	O	-1	24068571
0@@	O	-1	24068571
,	O	-1	24068571
X@@	O	-1	24068571
2	O	-1	24068571
=	O	-1	24068571
4.@@	O	-1	24068571
25@@	O	-1	24068571
6@@	O	-1	24068571
;	O	-1	24068571
d@@	O	-1	24068571
f	O	-1	24068571
=	O	-1	24068571
1@@	O	-1	24068571
;	O	-1	24068571
0.0@@	O	-1	24068571
5	O	-1	24068571
<	O	-1	24068571
p	O	-1	24068571
<	O	-1	24068571
0.0@@	O	-1	24068571
2@@	O	-1	24068571
).	O	-1	24068571
CONCLUSION:	O	-1	24068571
In	O	-1	24068571
this	O	-1	24068571
study	O	-1	24068571
early	O	-1	24068571
postoperative	B-Disease	D011183	24068571
de@@	I-Disease	-1	24068571
li@@	I-Disease	-1	24068571
ri@@	I-Disease	-1	24068571
um	I-Disease	-1	24068571
was	O	-1	24068571
found	O	-1	24068571
to	O	-1	24068571
be	O	-1	24068571
a	O	-1	24068571
very	O	-1	24068571
common	O	-1	24068571
complication	O	-1	24068571
after	O	-1	24068571
major	O	-1	24068571
surger@@	O	-1	24068571
y,	O	-1	24068571
even	O	-1	24068571
in	O	-1	24068571
a	O	-1	24068571
po@@	O	-1	24068571
p@@	O	-1	24068571
ulation	O	-1	24068571
without	O	-1	24068571
known	O	-1	24068571
risk	O	-1	24068571
fact@@	O	-1	24068571
or@@	O	-1	24068571
s.	O	-1	24068571
Th@@	B-Chemical	D013874	24068571
io@@	I-Chemical	-1	24068571
pent@@	I-Chemical	-1	24068571
one	I-Chemical	-1	24068571
was	O	-1	24068571
in@@	O	-1	24068571
depend@@	O	-1	24068571
ently	O	-1	24068571
associated	O	-1	24068571
with	O	-1	24068571
an	O	-1	24068571
increase	O	-1	24068571
in	O	-1	24068571
its	O	-1	24068571
rel@@	O	-1	24068571
ative	O	-1	24068571
ris@@	O	-1	24068571
k@@	O	-1	24068571
.	O	-1	24068571

A	O	-1	24072398
single	O	-1	24072398
neuro@@	B-Disease	D020258	24072398
toxic	I-Disease	-1	24072398
dose	O	-1	24072398
of	O	-1	24072398
meth@@	B-Chemical	D008694	24072398
amphetamine	I-Chemical	-1	24072398
induc@@	O	-1	24072398
es	O	-1	24072398
a	O	-1	24072398
long@@	O	-1	24072398
-@@	O	-1	24072398
l@@	O	-1	24072398
ast@@	O	-1	24072398
ing	O	-1	24072398
de@@	B-Disease	D003866	24072398
pressive	I-Disease	-1	24072398
-@@	O	-1	24072398
like	O	-1	24072398
behavi@@	O	-1	24072398
our	O	-1	24072398
in	O	-1	24072398
mice.	O	-1	24072398
M@@	B-Chemical	D008694	24072398
eth@@	I-Chemical	-1	24072398
amphetamine	I-Chemical	-1	24072398
(	O	-1	24072398
MET@@	B-Chemical	D008694	24072398
H	I-Chemical	-1	24072398
)	O	-1	24072398
tri@@	O	-1	24072398
g@@	O	-1	24072398
g@@	O	-1	24072398
ers	O	-1	24072398
a	O	-1	24072398
dis@@	O	-1	24072398
ru@@	O	-1	24072398
ption	O	-1	24072398
of	O	-1	24072398
the	O	-1	24072398
mon@@	O	-1	24072398
o@@	O	-1	24072398
aminergic	O	-1	24072398
system	O	-1	24072398
and	O	-1	24072398
MET@@	B-Chemical	D008694	24072398
H	I-Chemical	-1	24072398
ab@@	O	-1	24072398
use	O	-1	24072398
lead@@	O	-1	24072398
s	O	-1	24072398
to	O	-1	24072398
negative	O	-1	24072398
em@@	O	-1	24072398
o@@	O	-1	24072398
tional	O	-1	24072398
st@@	O	-1	24072398
ates	O	-1	24072398
including	O	-1	24072398
de@@	B-Disease	D003866	24072398
pressive	I-Disease	-1	24072398
symptoms	I-Disease	-1	24072398
during	O	-1	24072398
drug	O	-1	24072398
withdraw@@	O	-1	24072398
al.	O	-1	24072398
However,	O	-1	24072398
it	O	-1	24072398
is	O	-1	24072398
cur@@	O	-1	24072398
ren@@	O	-1	24072398
tly	O	-1	24072398
un@@	O	-1	24072398
known	O	-1	24072398
if	O	-1	24072398
the	O	-1	24072398
acute	O	-1	24072398
toxic	O	-1	24072398
dos@@	O	-1	24072398
age	O	-1	24072398
of	O	-1	24072398
MET@@	B-Chemical	D008694	24072398
H	I-Chemical	-1	24072398
also	O	-1	24072398
causes	O	-1	24072398
a	O	-1	24072398
long@@	O	-1	24072398
-@@	O	-1	24072398
l@@	O	-1	24072398
ast@@	O	-1	24072398
ing	O	-1	24072398
de@@	B-Disease	D003866	24072398
pressive	I-Disease	-1	24072398
phen@@	O	-1	24072398
ot@@	O	-1	24072398
yp@@	O	-1	24072398
e	O	-1	24072398
and	O	-1	24072398
per@@	O	-1	24072398
sist@@	O	-1	24072398
ent	O	-1	24072398
mon@@	O	-1	24072398
o@@	O	-1	24072398
aminergic	O	-1	24072398
defic@@	O	-1	24072398
it@@	O	-1	24072398
s.	O	-1	24072398
Th@@	O	-1	24072398
us,	O	-1	24072398
we	O	-1	24072398
no@@	O	-1	24072398
w	O	-1	24072398
assessed	O	-1	24072398
the	O	-1	24072398
de@@	B-Disease	D003866	24072398
pressive	I-Disease	-1	24072398
-@@	O	-1	24072398
like	O	-1	24072398
behavi@@	O	-1	24072398
our	O	-1	24072398
in	O	-1	24072398
mice	O	-1	24072398
at	O	-1	24072398
early	O	-1	24072398
and	O	-1	24072398
long-term	O	-1	24072398
perio@@	O	-1	24072398
ds	O	-1	24072398
following	O	-1	24072398
a	O	-1	24072398
single	O	-1	24072398
high	O	-1	24072398
MET@@	B-Chemical	D008694	24072398
H	I-Chemical	-1	24072398
dose	O	-1	24072398
(@@	O	-1	24072398
30	O	-1	24072398
mg/kg@@	O	-1	24072398
,	O	-1	24072398
i.p.@@	O	-1	24072398
).	O	-1	24072398
MET@@	B-Chemical	D008694	24072398
H	I-Chemical	-1	24072398
did	O	-1	24072398
not	O	-1	24072398
al@@	O	-1	24072398
ter	O	-1	24072398
the	O	-1	24072398
motor	O	-1	24072398
function	O	-1	24072398
and	O	-1	24072398
proce@@	O	-1	24072398
dur@@	O	-1	24072398
al	O	-1	24072398
memory	O	-1	24072398
of	O	-1	24072398
mice	O	-1	24072398
as	O	-1	24072398
assessed	O	-1	24072398
by	O	-1	24072398
s@@	O	-1	24072398
w@@	O	-1	24072398
im@@	O	-1	24072398
m@@	O	-1	24072398
ing	O	-1	24072398
sp@@	O	-1	24072398
e@@	O	-1	24072398
ed	O	-1	24072398
and	O	-1	24072398
es@@	O	-1	24072398
cap@@	O	-1	24072398
e	O	-1	24072398
lat@@	O	-1	24072398
ency	O	-1	24072398
to	O	-1	24072398
f@@	O	-1	24072398
ind	O	-1	24072398
the	O	-1	24072398
pl@@	O	-1	24072398
at@@	O	-1	24072398
form	O	-1	24072398
in	O	-1	24072398
a	O	-1	24072398
c@@	O	-1	24072398
u@@	O	-1	24072398
ed	O	-1	24072398
ver@@	O	-1	24072398
sion	O	-1	24072398
of	O	-1	24072398
the	O	-1	24072398
w@@	O	-1	24072398
at@@	O	-1	24072398
er	O	-1	24072398
ma@@	O	-1	24072398
ze	O	-1	24072398
t@@	O	-1	24072398
as@@	O	-1	24072398
k@@	O	-1	24072398
.	O	-1	24072398
However,	O	-1	24072398
MET@@	B-Chemical	D008694	24072398
H	I-Chemical	-1	24072398
significantly	O	-1	24072398
increased	O	-1	24072398
the	O	-1	24072398
im@@	O	-1	24072398
mo@@	O	-1	24072398
b@@	O	-1	24072398
ility	O	-1	24072398
time	O	-1	24072398
in	O	-1	24072398
the	O	-1	24072398
t@@	O	-1	24072398
a@@	O	-1	24072398
il	O	-1	24072398
sus@@	O	-1	24072398
pen@@	O	-1	24072398
sion	O	-1	24072398
test	O	-1	24072398
at	O	-1	24072398
3	O	-1	24072398
and	O	-1	24072398
4@@	O	-1	24072398
9	O	-1	24072398
days	O	-1	24072398
post@@	O	-1	24072398
-@@	O	-1	24072398
administr@@	O	-1	24072398
ation.	O	-1	24072398
This	O	-1	24072398
de@@	B-Disease	D003866	24072398
pressive	I-Disease	-1	24072398
-@@	O	-1	24072398
like	O	-1	24072398
prof@@	O	-1	24072398
ile	O	-1	24072398
induced	O	-1	24072398
by	O	-1	24072398
MET@@	B-Chemical	D008694	24072398
H	I-Chemical	-1	24072398
was	O	-1	24072398
ac@@	O	-1	24072398
comp@@	O	-1	24072398
an@@	O	-1	24072398
ied	O	-1	24072398
by	O	-1	24072398
a	O	-1	24072398
mark@@	O	-1	24072398
ed	O	-1	24072398
deple@@	O	-1	24072398
tion	O	-1	24072398
of	O	-1	24072398
fron@@	O	-1	24072398
to@@	O	-1	24072398
stri@@	O	-1	24072398
atal	O	-1	24072398
dop@@	O	-1	24072398
aminergic	O	-1	24072398
and	O	-1	24072398
seroton@@	O	-1	24072398
ergic	O	-1	24072398
neuro@@	O	-1	24072398
trans@@	O	-1	24072398
mis@@	O	-1	24072398
sion,	O	-1	24072398
indic@@	O	-1	24072398
ated	O	-1	24072398
by	O	-1	24072398
a	O	-1	24072398
reduction	O	-1	24072398
in	O	-1	24072398
the	O	-1	24072398
levels	O	-1	24072398
of	O	-1	24072398
dopamine	B-Chemical	D004298	24072398
,	O	-1	24072398
DO@@	B-Chemical	D015102	24072398
PA@@	I-Chemical	-1	24072398
C	I-Chemical	-1	24072398
and	O	-1	24072398
H@@	B-Chemical	D006719	24072398
V@@	I-Chemical	-1	24072398
A	I-Chemical	-1	24072398
,	O	-1	24072398
ty@@	B-Chemical	D014443	24072398
ros@@	I-Chemical	-1	24072398
ine	I-Chemical	-1	24072398
hydrox@@	O	-1	24072398
yl@@	O	-1	24072398
ase	O	-1	24072398
and	O	-1	24072398
seroton@@	B-Chemical	D012701	24072398
in	I-Chemical	-1	24072398
,	O	-1	24072398
observed	O	-1	24072398
at	O	-1	24072398
both	O	-1	24072398
3	O	-1	24072398
and	O	-1	24072398
4@@	O	-1	24072398
9	O	-1	24072398
days	O	-1	24072398
post@@	O	-1	24072398
-@@	O	-1	24072398
administr@@	O	-1	24072398
ation.	O	-1	24072398
In	O	-1	24072398
par@@	O	-1	24072398
al@@	O	-1	24072398
le@@	O	-1	24072398
l@@	O	-1	24072398
,	O	-1	24072398
an@@	O	-1	24072398
other	O	-1	24072398
neuro@@	O	-1	24072398
chemical	O	-1	24072398
feat@@	O	-1	24072398
ure	O	-1	24072398
of	O	-1	24072398
de@@	B-Disease	D003866	24072398
pression	I-Disease	-1	24072398
-@@	O	-1	24072398
-@@	O	-1	24072398
ast@@	O	-1	24072398
ro@@	O	-1	24072398
g@@	O	-1	24072398
lial	O	-1	24072398
dysfunc@@	O	-1	24072398
tion@@	O	-1	24072398
-@@	O	-1	24072398
-@@	O	-1	24072398
was	O	-1	24072398
un@@	O	-1	24072398
affected	O	-1	24072398
in	O	-1	24072398
the	O	-1	24072398
cor@@	O	-1	24072398
te@@	O	-1	24072398
x	O	-1	24072398
and	O	-1	24072398
the	O	-1	24072398
stri@@	O	-1	24072398
atal	O	-1	24072398
levels	O	-1	24072398
of	O	-1	24072398
the	O	-1	24072398
ast@@	O	-1	24072398
ro@@	O	-1	24072398
cy@@	O	-1	24072398
tic	O	-1	24072398
protein	O	-1	24072398
mark@@	O	-1	24072398
er,	O	-1	24072398
g@@	O	-1	24072398
lial	O	-1	24072398
fibrill@@	O	-1	24072398
ary	O	-1	24072398
ac@@	O	-1	24072398
i@@	O	-1	24072398
di@@	O	-1	24072398
c	O	-1	24072398
protein@@	O	-1	24072398
,	O	-1	24072398
were	O	-1	24072398
only	O	-1	24072398
transi@@	O	-1	24072398
ently	O	-1	24072398
increased	O	-1	24072398
at	O	-1	24072398
3	O	-1	24072398
days.	O	-1	24072398
These	O	-1	24072398
findings	O	-1	24072398
demon@@	O	-1	24072398
st@@	O	-1	24072398
rate	O	-1	24072398
for	O	-1	24072398
the	O	-1	24072398
first	O	-1	24072398
time	O	-1	24072398
that	O	-1	24072398
a	O	-1	24072398
single	O	-1	24072398
high	O	-1	24072398
dose	O	-1	24072398
of	O	-1	24072398
MET@@	B-Chemical	D008694	24072398
H	I-Chemical	-1	24072398
induc@@	O	-1	24072398
es	O	-1	24072398
long@@	O	-1	24072398
-@@	O	-1	24072398
l@@	O	-1	24072398
ast@@	O	-1	24072398
ing	O	-1	24072398
de@@	B-Disease	D003866	24072398
pressive	I-Disease	-1	24072398
-@@	O	-1	24072398
like	O	-1	24072398
behavi@@	O	-1	24072398
our	O	-1	24072398
in	O	-1	24072398
mice	O	-1	24072398
associated	O	-1	24072398
with	O	-1	24072398
a	O	-1	24072398
per@@	O	-1	24072398
sist@@	O	-1	24072398
ent	O	-1	24072398
dis@@	O	-1	24072398
ru@@	O	-1	24072398
ption	O	-1	24072398
of	O	-1	24072398
fron@@	O	-1	24072398
to@@	O	-1	24072398
stri@@	O	-1	24072398
atal	O	-1	24072398
dop@@	O	-1	24072398
aminergic	O	-1	24072398
and	O	-1	24072398
seroton@@	O	-1	24072398
ergic	O	-1	24072398
ho@@	O	-1	24072398
mo@@	O	-1	24072398
e@@	O	-1	24072398
ost@@	O	-1	24072398
a@@	O	-1	24072398
sis.	O	-1	24072398

L@@	B-Chemical	C098010	24088636
ine@@	I-Chemical	-1	24088636
z@@	I-Chemical	-1	24088636
ol@@	I-Chemical	-1	24088636
id	I-Chemical	-1	24088636
-induced	O	-1	24088636
op@@	B-Disease	D009901	24088636
tic	I-Disease	-1	24088636
neuropathy	I-Disease	-1	24088636
.	O	-1	24088636
M@@	O	-1	24088636
any	O	-1	24088636
systemic	O	-1	24088636
anti@@	O	-1	24088636
micro@@	O	-1	24088636
b@@	O	-1	24088636
i@@	O	-1	24088636
als	O	-1	24088636
have	O	-1	24088636
been	O	-1	24088636
implic@@	O	-1	24088636
ated	O	-1	24088636
to	O	-1	24088636
cause	O	-1	24088636
oc@@	O	-1	24088636
ular	O	-1	24088636
adverse	O	-1	24088636
effects.	O	-1	24088636
This	O	-1	24088636
is	O	-1	24088636
es@@	O	-1	24088636
p@@	O	-1	24088636
ec@@	O	-1	24088636
i@@	O	-1	24088636
ally	O	-1	24088636
re@@	O	-1	24088636
lev@@	O	-1	24088636
ant	O	-1	24088636
in	O	-1	24088636
multi@@	O	-1	24088636
drug	O	-1	24088636
therapy	O	-1	24088636
wh@@	O	-1	24088636
ere	O	-1	24088636
more	O	-1	24088636
than	O	-1	24088636
one	O	-1	24088636
drug	O	-1	24088636
can	O	-1	24088636
cause	O	-1	24088636
a	O	-1	24088636
similar	O	-1	24088636
oc@@	O	-1	24088636
ular	O	-1	24088636
adverse	O	-1	24088636
effect@@	O	-1	24088636
.	O	-1	24088636
We	O	-1	24088636
describe	O	-1	24088636
a	O	-1	24088636
case	O	-1	24088636
of	O	-1	24088636
progressive	O	-1	24088636
loss	B-Disease	D014786	24088636
of	I-Disease	-1	24088636
vi@@	I-Disease	-1	24088636
sion	I-Disease	-1	24088636
associated	O	-1	24088636
with	O	-1	24088636
l@@	B-Chemical	C098010	24088636
ine@@	I-Chemical	-1	24088636
z@@	I-Chemical	-1	24088636
ol@@	I-Chemical	-1	24088636
id	I-Chemical	-1	24088636
therapy.	O	-1	24088636
A	O	-1	24088636
4@@	O	-1	24088636
5-@@	O	-1	24088636
year-old	O	-1	24088636
male	O	-1	24088636
patient	O	-1	24088636
who	O	-1	24088636
was	O	-1	24088636
on	O	-1	24088636
treatment	O	-1	24088636
with	O	-1	24088636
multiple	O	-1	24088636
secon@@	O	-1	24088636
d-@@	O	-1	24088636
line	O	-1	24088636
anti@@	O	-1	24088636
-@@	O	-1	24088636
tub@@	O	-1	24088636
er@@	O	-1	24088636
c@@	O	-1	24088636
ulo@@	O	-1	24088636
us	O	-1	24088636
drugs	O	-1	24088636
including	O	-1	24088636
l@@	B-Chemical	C098010	24088636
ine@@	I-Chemical	-1	24088636
z@@	I-Chemical	-1	24088636
ol@@	I-Chemical	-1	24088636
id	I-Chemical	-1	24088636
and	O	-1	24088636
eth@@	B-Chemical	D004977	24088636
am@@	I-Chemical	-1	24088636
bu@@	I-Chemical	-1	24088636
to@@	I-Chemical	-1	24088636
l	I-Chemical	-1	24088636
for	O	-1	24088636
exten@@	B-Disease	D054908	24088636
si@@	I-Disease	-1	24088636
vely	I-Disease	-1	24088636
drug@@	I-Disease	-1	24088636
-@@	I-Disease	-1	24088636
resist@@	I-Disease	-1	24088636
ant	I-Disease	-1	24088636
tub@@	I-Disease	-1	24088636
er@@	I-Disease	-1	24088636
c@@	I-Disease	-1	24088636
ulo@@	I-Disease	-1	24088636
sis	I-Disease	-1	24088636
(	O	-1	24088636
X@@	B-Disease	D054908	24088636
D@@	I-Disease	-1	24088636
R@@	I-Disease	-1	24088636
-@@	I-Disease	-1	24088636
T@@	I-Disease	-1	24088636
B	I-Disease	-1	24088636
)	O	-1	24088636
presented	O	-1	24088636
to	O	-1	24088636
us	O	-1	24088636
with	O	-1	24088636
pa@@	O	-1	24088636
in@@	O	-1	24088636
less	O	-1	24088636
progressive	O	-1	24088636
loss	B-Disease	D014786	24088636
of	I-Disease	-1	24088636
vi@@	I-Disease	-1	24088636
sion	I-Disease	-1	24088636
in	O	-1	24088636
both	O	-1	24088636
e@@	O	-1	24088636
y@@	O	-1	24088636
es.	O	-1	24088636
C@@	O	-1	24088636
o@@	O	-1	24088636
lo@@	O	-1	24088636
r	O	-1	24088636
vi@@	O	-1	24088636
sion	O	-1	24088636
was	O	-1	24088636
def@@	O	-1	24088636
ective	O	-1	24088636
and	O	-1	24088636
f@@	O	-1	24088636
und@@	O	-1	24088636
us	O	-1	24088636
examin@@	O	-1	24088636
ation	O	-1	24088636
revealed	O	-1	24088636
op@@	B-Disease	C531767	24088636
tic	I-Disease	-1	24088636
dis@@	I-Disease	-1	24088636
c	I-Disease	-1	24088636
e@@	I-Disease	-1	24088636
de@@	I-Disease	-1	24088636
ma	I-Disease	-1	24088636
in	O	-1	24088636
both	O	-1	24088636
e@@	O	-1	24088636
y@@	O	-1	24088636
es.	O	-1	24088636
E@@	B-Chemical	D004977	24088636
th@@	I-Chemical	-1	24088636
am@@	I-Chemical	-1	24088636
bu@@	I-Chemical	-1	24088636
to@@	I-Chemical	-1	24088636
l	I-Chemical	-1	24088636
-induced	O	-1	24088636
toxic	B-Disease	D009901	24088636
op@@	I-Disease	-1	24088636
tic	I-Disease	-1	24088636
neuropathy	I-Disease	-1	24088636
was	O	-1	24088636
sus@@	O	-1	24088636
p@@	O	-1	24088636
ected	O	-1	24088636
and	O	-1	24088636
t@@	O	-1	24088636
able@@	O	-1	24088636
t	O	-1	24088636
eth@@	B-Chemical	D004977	24088636
am@@	I-Chemical	-1	24088636
bu@@	I-Chemical	-1	24088636
to@@	I-Chemical	-1	24088636
l	I-Chemical	-1	24088636
was	O	-1	24088636
withdraw@@	O	-1	24088636
n@@	O	-1	24088636
.	O	-1	24088636
De@@	B-Disease	D015354	24088636
ter@@	I-Disease	-1	24088636
i@@	I-Disease	-1	24088636
or@@	I-Disease	-1	24088636
ation	I-Disease	-1	24088636
of	I-Disease	-1	24088636
vi@@	I-Disease	-1	24088636
sion	I-Disease	-1	24088636
occurred	O	-1	24088636
des@@	O	-1	24088636
pit@@	O	-1	24088636
e	O	-1	24088636
withdrawal	O	-1	24088636
of	O	-1	24088636
eth@@	B-Chemical	D004977	24088636
am@@	I-Chemical	-1	24088636
bu@@	I-Chemical	-1	24088636
to@@	I-Chemical	-1	24088636
l	I-Chemical	-1	24088636
.	O	-1	24088636
D@@	O	-1	24088636
is@@	O	-1	24088636
continu@@	O	-1	24088636
ation	O	-1	24088636
of	O	-1	24088636
l@@	B-Chemical	C098010	24088636
ine@@	I-Chemical	-1	24088636
z@@	I-Chemical	-1	24088636
ol@@	I-Chemical	-1	24088636
id	I-Chemical	-1	24088636
resulted	O	-1	24088636
in	O	-1	24088636
mark@@	O	-1	24088636
ed	O	-1	24088636
impro@@	O	-1	24088636
vement	O	-1	24088636
of	O	-1	24088636
vi@@	O	-1	24088636
sion.	O	-1	24088636
Our	O	-1	24088636
report	O	-1	24088636
em@@	O	-1	24088636
pha@@	O	-1	24088636
si@@	O	-1	24088636
z@@	O	-1	24088636
es	O	-1	24088636
the	O	-1	24088636
need	O	-1	24088636
for	O	-1	24088636
monit@@	O	-1	24088636
or@@	O	-1	24088636
ing	O	-1	24088636
of	O	-1	24088636
visual	O	-1	24088636
function	O	-1	24088636
in	O	-1	24088636
patients	O	-1	24088636
on	O	-1	24088636
long-term	O	-1	24088636
l@@	B-Chemical	C098010	24088636
ine@@	I-Chemical	-1	24088636
z@@	I-Chemical	-1	24088636
ol@@	I-Chemical	-1	24088636
id	I-Chemical	-1	24088636
treatment.	O	-1	24088636

R@@	O	-1	24091473
es@@	O	-1	24091473
us@@	O	-1	24091473
cit@@	O	-1	24091473
ation	O	-1	24091473
with	O	-1	24091473
li@@	O	-1	24091473
pid@@	O	-1	24091473
,	O	-1	24091473
ep@@	B-Chemical	D004837	24091473
ine@@	I-Chemical	-1	24091473
phrine	I-Chemical	-1	24091473
,	O	-1	24091473
or	O	-1	24091473
both	O	-1	24091473
in	O	-1	24091473
levo@@	B-Chemical	C476513	24091473
bupivac@@	I-Chemical	-1	24091473
aine	I-Chemical	-1	24091473
-induced	O	-1	24091473
cardiac	B-Disease	D066126	24091473
toxicity	I-Disease	-1	24091473
in	O	-1	24091473
ne@@	O	-1	24091473
w@@	O	-1	24091473
b@@	O	-1	24091473
or@@	O	-1	24091473
n	O	-1	24091473
pi@@	O	-1	24091473
g@@	O	-1	24091473
le@@	O	-1	24091473
t@@	O	-1	24091473
s.	O	-1	24091473
BACKGROUND:	O	-1	24091473
The	O	-1	24091473
op@@	O	-1	24091473
tim@@	O	-1	24091473
al	O	-1	24091473
dos@@	O	-1	24091473
ing	O	-1	24091473
regimen@@	O	-1	24091473
s	O	-1	24091473
of	O	-1	24091473
li@@	O	-1	24091473
pid	O	-1	24091473
em@@	O	-1	24091473
ul@@	O	-1	24091473
sion,	O	-1	24091473
ep@@	B-Chemical	D004837	24091473
ine@@	I-Chemical	-1	24091473
phrine	I-Chemical	-1	24091473
,	O	-1	24091473
or	O	-1	24091473
both	O	-1	24091473
are	O	-1	24091473
not	O	-1	24091473
y@@	O	-1	24091473
et	O	-1	24091473
determined	O	-1	24091473
in	O	-1	24091473
ne@@	O	-1	24091473
on@@	O	-1	24091473
ates	O	-1	24091473
in	O	-1	24091473
cases	O	-1	24091473
of	O	-1	24091473
loc@@	O	-1	24091473
al	O	-1	24091473
anaesthe@@	O	-1	24091473
tic	O	-1	24091473
systemic	O	-1	24091473
toxicity	B-Disease	D064420	24091473
(@@	O	-1	24091473
L@@	O	-1	24091473
A@@	O	-1	24091473
S@@	O	-1	24091473
T@@	O	-1	24091473
).	O	-1	24091473
METHODS:	O	-1	24091473
Ne@@	O	-1	24091473
w@@	O	-1	24091473
b@@	O	-1	24091473
or@@	O	-1	24091473
n	O	-1	24091473
pi@@	O	-1	24091473
g@@	O	-1	24091473
le@@	O	-1	24091473
ts	O	-1	24091473
received	O	-1	24091473
levo@@	B-Chemical	C476513	24091473
bupivac@@	I-Chemical	-1	24091473
aine	I-Chemical	-1	24091473
un@@	O	-1	24091473
ti@@	O	-1	24091473
l	O	-1	24091473
cardiovascular	B-Disease	D002318	24091473
coll@@	I-Disease	-1	24091473
ap@@	I-Disease	-1	24091473
se	I-Disease	-1	24091473
occur@@	O	-1	24091473
red.	O	-1	24091473
S@@	O	-1	24091473
t@@	O	-1	24091473
and@@	O	-1	24091473
ard	O	-1	24091473
cardio@@	O	-1	24091473
pulmonary	O	-1	24091473
res@@	O	-1	24091473
us@@	O	-1	24091473
cit@@	O	-1	24091473
ation	O	-1	24091473
was	O	-1	24091473
star@@	O	-1	24091473
ted	O	-1	24091473
and	O	-1	24091473
electro@@	O	-1	24091473
cardio@@	O	-1	24091473
gra@@	O	-1	24091473
m	O	-1	24091473
(@@	O	-1	24091473
EC@@	O	-1	24091473
G@@	O	-1	24091473
)	O	-1	24091473
was	O	-1	24091473
monit@@	O	-1	24091473
o@@	O	-1	24091473
red	O	-1	24091473
for	O	-1	24091473
ventricular	B-Disease	D017180	24091473
tachycardia	I-Disease	-1	24091473
,	O	-1	24091473
fibrill@@	B-Disease	D001281	24091473
ation	I-Disease	-1	24091473
,	O	-1	24091473
or	O	-1	24091473
Q@@	O	-1	24091473
R@@	O	-1	24091473
S	O	-1	24091473
prolong@@	O	-1	24091473
ation.	O	-1	24091473
P@@	O	-1	24091473
ig@@	O	-1	24091473
le@@	O	-1	24091473
ts	O	-1	24091473
were	O	-1	24091473
then	O	-1	24091473
random@@	O	-1	24091473
ly	O	-1	24091473
al@@	O	-1	24091473
loc@@	O	-1	24091473
ated	O	-1	24091473
to	O	-1	24091473
four	O	-1	24091473
group@@	O	-1	24091473
s:	O	-1	24091473
control	O	-1	24091473
(@@	O	-1	24091473
sal@@	O	-1	24091473
ine@@	O	-1	24091473
),	O	-1	24091473
In@@	O	-1	24091473
tr@@	O	-1	24091473
al@@	O	-1	24091473
ip@@	O	-1	24091473
id@@	O	-1	24091473
(	O	-1	24091473
)	O	-1	24091473
al@@	O	-1	24091473
one,	O	-1	24091473
ep@@	B-Chemical	D004837	24091473
ine@@	I-Chemical	-1	24091473
phrine	I-Chemical	-1	24091473
al@@	O	-1	24091473
one,	O	-1	24091473
or	O	-1	24091473
a	O	-1	24091473
combination	O	-1	24091473
of	O	-1	24091473
In@@	O	-1	24091473
tr@@	O	-1	24091473
al@@	O	-1	24091473
ip@@	O	-1	24091473
d	O	-1	24091473
plus	O	-1	24091473
ep@@	B-Chemical	D004837	24091473
ine@@	I-Chemical	-1	24091473
phrine	I-Chemical	-1	24091473
.	O	-1	24091473
R@@	O	-1	24091473
es@@	O	-1	24091473
us@@	O	-1	24091473
cit@@	O	-1	24091473
ation	O	-1	24091473
continu@@	O	-1	24091473
ed	O	-1	24091473
for	O	-1	24091473
30	O	-1	24091473
min	O	-1	24091473
or	O	-1	24091473
un@@	O	-1	24091473
ti@@	O	-1	24091473
l	O	-1	24091473
there	O	-1	24091473
was	O	-1	24091473
a	O	-1	24091473
retur@@	O	-1	24091473
n	O	-1	24091473
of	O	-1	24091473
spont@@	O	-1	24091473
aneous	O	-1	24091473
cir@@	O	-1	24091473
c@@	O	-1	24091473
ulation	O	-1	24091473
(@@	O	-1	24091473
RO@@	O	-1	24091473
S@@	O	-1	24091473
C@@	O	-1	24091473
)	O	-1	24091473
ac@@	O	-1	24091473
comp@@	O	-1	24091473
an@@	O	-1	24091473
ied	O	-1	24091473
by	O	-1	24091473
a	O	-1	24091473
mean	O	-1	24091473
arterial	O	-1	24091473
pressure	O	-1	24091473
at	O	-1	24091473
or	O	-1	24091473
su@@	O	-1	24091473
peri@@	O	-1	24091473
or	O	-1	24091473
to	O	-1	24091473
the	O	-1	24091473
baseline	O	-1	24091473
pressure	O	-1	24091473
and	O	-1	24091473
normal	O	-1	24091473
s@@	O	-1	24091473
in@@	O	-1	24091473
us	O	-1	24091473
rhyth@@	O	-1	24091473
m	O	-1	24091473
for	O	-1	24091473
a	O	-1	24091473
period	O	-1	24091473
of	O	-1	24091473
30	O	-1	24091473
min@@	O	-1	24091473
.	O	-1	24091473
RESULTS:	O	-1	24091473
RO@@	O	-1	24091473
S@@	O	-1	24091473
C	O	-1	24091473
was	O	-1	24091473
achi@@	O	-1	24091473
ev@@	O	-1	24091473
ed	O	-1	24091473
in	O	-1	24091473
only	O	-1	24091473
one	O	-1	24091473
of	O	-1	24091473
the	O	-1	24091473
control	O	-1	24091473
pi@@	O	-1	24091473
g@@	O	-1	24091473
le@@	O	-1	24091473
ts	O	-1	24091473
compared	O	-1	24091473
with	O	-1	24091473
most	O	-1	24091473
of	O	-1	24091473
the	O	-1	24091473
treated	O	-1	24091473
pi@@	O	-1	24091473
g@@	O	-1	24091473
le@@	O	-1	24091473
t@@	O	-1	24091473
s.	O	-1	24091473
M@@	O	-1	24091473
ort@@	O	-1	24091473
ality	O	-1	24091473
was	O	-1	24091473
not	O	-1	24091473
significantly	O	-1	24091473
different	O	-1	24091473
between	O	-1	24091473
the	O	-1	24091473
three	O	-1	24091473
treatment	O	-1	24091473
group@@	O	-1	24091473
s,	O	-1	24091473
but	O	-1	24091473
was	O	-1	24091473
significantly	O	-1	24091473
lower	O	-1	24091473
in	O	-1	24091473
all	O	-1	24091473
the	O	-1	24091473
treatment	O	-1	24091473
groups	O	-1	24091473
compared	O	-1	24091473
with	O	-1	24091473
control@@	O	-1	24091473
.	O	-1	24091473
The	O	-1	24091473
number	O	-1	24091473
of	O	-1	24091473
EC@@	O	-1	24091473
G	O	-1	24091473
abnormal@@	O	-1	24091473
ities	O	-1	24091473
was	O	-1	24091473
z@@	O	-1	24091473
er@@	O	-1	24091473
o	O	-1	24091473
in	O	-1	24091473
the	O	-1	24091473
In@@	O	-1	24091473
tr@@	O	-1	24091473
al@@	O	-1	24091473
i@@	O	-1	24091473
pid	O	-1	24091473
only	O	-1	24091473
group@@	O	-1	24091473
,	O	-1	24091473
but	O	-1	24091473
14	O	-1	24091473
and	O	-1	24091473
17@@	O	-1	24091473
,	O	-1	24091473
respectivel@@	O	-1	24091473
y,	O	-1	24091473
in	O	-1	24091473
the	O	-1	24091473
ep@@	B-Chemical	D004837	24091473
ine@@	I-Chemical	-1	24091473
phrine	I-Chemical	-1	24091473
and	O	-1	24091473
ep@@	B-Chemical	D004837	24091473
ine@@	I-Chemical	-1	24091473
phrine	I-Chemical	-1	24091473
plus	O	-1	24091473
li@@	O	-1	24091473
pid	O	-1	24091473
groups	O	-1	24091473
(P@@	O	-1	24091473
<@@	O	-1	24091473
0.05@@	O	-1	24091473
).	O	-1	24091473
CONCLUSIONS:	O	-1	24091473
L@@	O	-1	24091473
i@@	O	-1	24091473
pid	O	-1	24091473
em@@	O	-1	24091473
ul@@	O	-1	24091473
sion	O	-1	24091473
with	O	-1	24091473
or	O	-1	24091473
without	O	-1	24091473
ep@@	B-Chemical	D004837	24091473
ine@@	I-Chemical	-1	24091473
phrine	I-Chemical	-1	24091473
,	O	-1	24091473
or	O	-1	24091473
ep@@	B-Chemical	D004837	24091473
ine@@	I-Chemical	-1	24091473
phrine	I-Chemical	-1	24091473
alone	O	-1	24091473
were	O	-1	24091473
equ@@	O	-1	24091473
ally	O	-1	24091473
effective	O	-1	24091473
in	O	-1	24091473
achi@@	O	-1	24091473
ev@@	O	-1	24091473
ing	O	-1	24091473
a	O	-1	24091473
retur@@	O	-1	24091473
n	O	-1	24091473
to	O	-1	24091473
spont@@	O	-1	24091473
aneous	O	-1	24091473
cir@@	O	-1	24091473
c@@	O	-1	24091473
ulation	O	-1	24091473
in	O	-1	24091473
this	O	-1	24091473
model	O	-1	24091473
of	O	-1	24091473
L@@	O	-1	24091473
A@@	O	-1	24091473
S@@	O	-1	24091473
T@@	O	-1	24091473
.	O	-1	24091473
E@@	B-Chemical	D004837	24091473
p@@	I-Chemical	-1	24091473
ine@@	I-Chemical	-1	24091473
phrine	I-Chemical	-1	24091473
alone	O	-1	24091473
or	O	-1	24091473
in	O	-1	24091473
combination	O	-1	24091473
with	O	-1	24091473
li@@	O	-1	24091473
pid	O	-1	24091473
was	O	-1	24091473
associated	O	-1	24091473
with	O	-1	24091473
an	O	-1	24091473
increased	O	-1	24091473
number	O	-1	24091473
of	O	-1	24091473
EC@@	O	-1	24091473
G	O	-1	24091473
abnormal@@	O	-1	24091473
ities	O	-1	24091473
compared	O	-1	24091473
with	O	-1	24091473
li@@	O	-1	24091473
pid	O	-1	24091473
em@@	O	-1	24091473
ul@@	O	-1	24091473
sion	O	-1	24091473
al@@	O	-1	24091473
one.	O	-1	24091473

In@@	O	-1	24100055
c@@	O	-1	24100055
idence	O	-1	24100055
of	O	-1	24100055
hepar@@	B-Chemical	D006493	24100055
in	I-Chemical	-1	24100055
-induced	O	-1	24100055
throm@@	B-Disease	D013921	24100055
b@@	I-Disease	-1	24100055
ocyto@@	I-Disease	-1	24100055
pen@@	I-Disease	-1	24100055
ia	I-Disease	-1	24100055
type	I-Disease	-1	24100055
II	I-Disease	-1	24100055
and	O	-1	24100055
postoperative	O	-1	24100055
recovery	O	-1	24100055
of	O	-1	24100055
platele@@	O	-1	24100055
t	O	-1	24100055
coun@@	O	-1	24100055
t	O	-1	24100055
in	O	-1	24100055
liver	O	-1	24100055
gra@@	O	-1	24100055
ft	O	-1	24100055
re@@	O	-1	24100055
ci@@	O	-1	24100055
pi@@	O	-1	24100055
ent@@	O	-1	24100055
s:	O	-1	24100055
a	O	-1	24100055
ret@@	O	-1	24100055
ro@@	O	-1	24100055
sp@@	O	-1	24100055
ective	O	-1	24100055
co@@	O	-1	24100055
h@@	O	-1	24100055
ort	O	-1	24100055
analy@@	O	-1	24100055
sis.	O	-1	24100055
BACKGROUND:	O	-1	24100055
Th@@	B-Disease	D013921	24100055
rom@@	I-Disease	-1	24100055
b@@	I-Disease	-1	24100055
ocyto@@	I-Disease	-1	24100055
pen@@	I-Disease	-1	24100055
ia	I-Disease	-1	24100055
in	O	-1	24100055
patients	O	-1	24100055
with	O	-1	24100055
en@@	B-Disease	D058625	24100055
d-@@	I-Disease	-1	24100055
st@@	I-Disease	-1	24100055
age	I-Disease	-1	24100055
liver	I-Disease	-1	24100055
disease	I-Disease	-1	24100055
is	O	-1	24100055
a	O	-1	24100055
common	O	-1	24100055
disor@@	O	-1	24100055
der	O	-1	24100055
caused	O	-1	24100055
main@@	O	-1	24100055
ly	O	-1	24100055
by	O	-1	24100055
port@@	B-Disease	D006975	24100055
al	I-Disease	-1	24100055
hypertension	I-Disease	-1	24100055
,	O	-1	24100055
low	O	-1	24100055
levels	O	-1	24100055
of	O	-1	24100055
thrombo@@	O	-1	24100055
po@@	O	-1	24100055
et@@	O	-1	24100055
in,	O	-1	24100055
and	O	-1	24100055
en@@	B-Disease	D019446	24100055
d@@	I-Disease	-1	24100055
ot@@	I-Disease	-1	24100055
ox@@	I-Disease	-1	24100055
emia	I-Disease	-1	24100055
.	O	-1	24100055
The	O	-1	24100055
im@@	O	-1	24100055
pac@@	O	-1	24100055
t	O	-1	24100055
of	O	-1	24100055
immun@@	O	-1	24100055
e-@@	O	-1	24100055
mediated	O	-1	24100055
hepar@@	B-Chemical	D006493	24100055
in	I-Chemical	-1	24100055
-induced	O	-1	24100055
throm@@	B-Disease	D013921	24100055
b@@	I-Disease	-1	24100055
ocyto@@	I-Disease	-1	24100055
pen@@	I-Disease	-1	24100055
ia	I-Disease	-1	24100055
type	I-Disease	-1	24100055
II	I-Disease	-1	24100055
(	O	-1	24100055
H@@	B-Disease	D013921	24100055
I@@	I-Disease	-1	24100055
T	I-Disease	-1	24100055
type	I-Disease	-1	24100055
II	I-Disease	-1	24100055
)	O	-1	24100055
as	O	-1	24100055
a	O	-1	24100055
cause	O	-1	24100055
of	O	-1	24100055
throm@@	B-Disease	D013921	24100055
b@@	I-Disease	-1	24100055
ocyto@@	I-Disease	-1	24100055
pen@@	I-Disease	-1	24100055
ia	I-Disease	-1	24100055
after	O	-1	24100055
liver	O	-1	24100055
transplant@@	O	-1	24100055
ation	O	-1	24100055
is	O	-1	24100055
not	O	-1	24100055
y@@	O	-1	24100055
et	O	-1	24100055
under@@	O	-1	24100055
sto@@	O	-1	24100055
o@@	O	-1	24100055
d,	O	-1	24100055
with	O	-1	24100055
fe@@	O	-1	24100055
w	O	-1	24100055
literat@@	O	-1	24100055
ure	O	-1	24100055
cit@@	O	-1	24100055
ations	O	-1	24100055
repor@@	O	-1	24100055
ting	O	-1	24100055
contra@@	O	-1	24100055
dic@@	O	-1	24100055
t@@	O	-1	24100055
ory	O	-1	24100055
result@@	O	-1	24100055
s.	O	-1	24100055
The	O	-1	24100055
a@@	O	-1	24100055
im	O	-1	24100055
of	O	-1	24100055
our	O	-1	24100055
study	O	-1	24100055
was	O	-1	24100055
to	O	-1	24100055
demon@@	O	-1	24100055
st@@	O	-1	24100055
rate	O	-1	24100055
the	O	-1	24100055
perio@@	O	-1	24100055
perative	O	-1	24100055
course	O	-1	24100055
of	O	-1	24100055
throm@@	B-Disease	D013921	24100055
b@@	I-Disease	-1	24100055
ocyto@@	I-Disease	-1	24100055
pen@@	I-Disease	-1	24100055
ia	I-Disease	-1	24100055
after	O	-1	24100055
liver	O	-1	24100055
transplant@@	O	-1	24100055
ation	O	-1	24100055
and	O	-1	24100055
determine	O	-1	24100055
the	O	-1	24100055
occur@@	O	-1	24100055
rence	O	-1	24100055
of	O	-1	24100055
clinical	O	-1	24100055
H@@	B-Disease	D013921	24100055
I@@	I-Disease	-1	24100055
T	I-Disease	-1	24100055
type	I-Disease	-1	24100055
II	I-Disease	-1	24100055
.	O	-1	24100055
METHOD@@	O	-1	24100055
:	O	-1	24100055
We	O	-1	24100055
ret@@	O	-1	24100055
ro@@	O	-1	24100055
sp@@	O	-1	24100055
ectively	O	-1	24100055
evaluated	O	-1	24100055
the	O	-1	24100055
med@@	O	-1	24100055
ical	O	-1	24100055
recor@@	O	-1	24100055
ds	O	-1	24100055
of	O	-1	24100055
20@@	O	-1	24100055
5	O	-1	24100055
con@@	O	-1	24100055
sec@@	O	-1	24100055
utive	O	-1	24100055
ad@@	O	-1	24100055
ult	O	-1	24100055
patients	O	-1	24100055
who	O	-1	24100055
under@@	O	-1	24100055
w@@	O	-1	24100055
ent	O	-1	24100055
ful@@	O	-1	24100055
l@@	O	-1	24100055
-@@	O	-1	24100055
size	O	-1	24100055
liver	O	-1	24100055
transplant@@	O	-1	24100055
ation	O	-1	24100055
between	O	-1	24100055
J@@	O	-1	24100055
an@@	O	-1	24100055
u@@	O	-1	24100055
ary	O	-1	24100055
20@@	O	-1	24100055
0@@	O	-1	24100055
6	O	-1	24100055
and	O	-1	24100055
D@@	O	-1	24100055
ec@@	O	-1	24100055
emb@@	O	-1	24100055
er	O	-1	24100055
20@@	O	-1	24100055
10	O	-1	24100055
due	O	-1	24100055
to	O	-1	24100055
en@@	B-Disease	D058625	24100055
d-@@	I-Disease	-1	24100055
st@@	I-Disease	-1	24100055
age	I-Disease	-1	24100055
or	I-Disease	-1	24100055
mal@@	I-Disease	-1	24100055
i@@	I-Disease	-1	24100055
gn@@	I-Disease	-1	24100055
ant	I-Disease	-1	24100055
liver	I-Disease	-1	24100055
disease	I-Disease	-1	24100055
en@@	B-Disease	D017114	24100055
d-@@	I-Disease	-1	24100055
st@@	I-Disease	-1	24100055
age	I-Disease	-1	24100055
or	I-Disease	-1	24100055
mal@@	I-Disease	-1	24100055
i@@	I-Disease	-1	24100055
gn@@	I-Disease	-1	24100055
ant	I-Disease	-1	24100055
liver	I-Disease	-1	24100055
disease	I-Disease	-1	24100055
.	O	-1	24100055
Pre@@	O	-1	24100055
o@@	O	-1	24100055
perative	O	-1	24100055
platele@@	O	-1	24100055
t	O	-1	24100055
coun@@	O	-1	24100055
t,	O	-1	24100055
postoperative	O	-1	24100055
course	O	-1	24100055
of	O	-1	24100055
platele@@	O	-1	24100055
t@@	O	-1	24100055
s,	O	-1	24100055
and	O	-1	24100055
clinical	O	-1	24100055
signs	O	-1	24100055
of	O	-1	24100055
H@@	B-Disease	D013921	24100055
I@@	I-Disease	-1	24100055
T	I-Disease	-1	24100055
type	I-Disease	-1	24100055
II	I-Disease	-1	24100055
were	O	-1	24100055
analy@@	O	-1	24100055
z@@	O	-1	24100055
ed.	O	-1	24100055
RESULTS:	O	-1	24100055
A	O	-1	24100055
total	O	-1	24100055
of	O	-1	24100055
1@@	O	-1	24100055
5@@	O	-1	24100055
5	O	-1	24100055
(@@	O	-1	24100055
7@@	O	-1	24100055
5.@@	O	-1	24100055
6@@	O	-1	24100055
%)	O	-1	24100055
of	O	-1	24100055
20@@	O	-1	24100055
5	O	-1	24100055
patients	O	-1	24100055
had	O	-1	24100055
throm@@	B-Disease	D013921	24100055
b@@	I-Disease	-1	24100055
ocyto@@	I-Disease	-1	24100055
pen@@	I-Disease	-1	24100055
ia	I-Disease	-1	24100055
before	O	-1	24100055
transplant@@	O	-1	24100055
ation,	O	-1	24100055
significantly	O	-1	24100055
influ@@	O	-1	24100055
enc@@	O	-1	24100055
ed	O	-1	24100055
by	O	-1	24100055
M@@	O	-1	24100055
o@@	O	-1	24100055
de@@	O	-1	24100055
l	O	-1	24100055
of	O	-1	24100055
E@@	B-Disease	D058625	24100055
n@@	I-Disease	-1	24100055
d-@@	I-Disease	-1	24100055
S@@	I-Disease	-1	24100055
t@@	I-Disease	-1	24100055
age	I-Disease	-1	24100055
L@@	I-Disease	-1	24100055
i@@	I-Disease	-1	24100055
ver	I-Disease	-1	24100055
Di@@	I-Disease	-1	24100055
se@@	I-Disease	-1	24100055
ase	I-Disease	-1	24100055
scor@@	O	-1	24100055
e	O	-1	24100055
and	O	-1	24100055
liver	B-Disease	D008103	24100055
cir@@	I-Disease	-1	24100055
r@@	I-Disease	-1	24100055
ho@@	I-Disease	-1	24100055
sis	I-Disease	-1	24100055
.	O	-1	24100055
The	O	-1	24100055
platele@@	O	-1	24100055
t	O	-1	24100055
coun@@	O	-1	24100055
t	O	-1	24100055
ex@@	O	-1	24100055
ce@@	O	-1	24100055
ed@@	O	-1	24100055
ed	O	-1	24100055
10@@	O	-1	24100055
0@@	O	-1	24100055
,@@	O	-1	24100055
0@@	O	-1	24100055
0@@	O	-1	24100055
0@@	O	-1	24100055
/@@	O	-1	24100055
u@@	O	-1	24100055
L	O	-1	24100055
in	O	-1	24100055
most	O	-1	24100055
of	O	-1	24100055
the	O	-1	24100055
patients	O	-1	24100055
(n	O	-1	24100055
=	O	-1	24100055
19@@	O	-1	24100055
3@@	O	-1	24100055
)	O	-1	24100055
at	O	-1	24100055
a	O	-1	24100055
medi@@	O	-1	24100055
um	O	-1	24100055
of	O	-1	24100055
7	O	-1	24100055
d.	O	-1	24100055
Re@@	O	-1	24100055
g@@	O	-1	24100055
ar@@	O	-1	24100055
ding	O	-1	24100055
H@@	B-Disease	D013921	24100055
I@@	I-Disease	-1	24100055
T	I-Disease	-1	24100055
II	I-Disease	-1	24100055
,	O	-1	24100055
there	O	-1	24100055
were	O	-1	24100055
four	O	-1	24100055
(1@@	O	-1	24100055
.@@	O	-1	24100055
9@@	O	-1	24100055
5@@	O	-1	24100055
%)	O	-1	24100055
patients	O	-1	24100055
with	O	-1	24100055
a	O	-1	24100055
bac@@	O	-1	24100055
kg@@	O	-1	24100055
ro@@	O	-1	24100055
un@@	O	-1	24100055
d	O	-1	24100055
of	O	-1	24100055
H@@	B-Disease	D013921	24100055
I@@	I-Disease	-1	24100055
T	I-Disease	-1	24100055
type	I-Disease	-1	24100055
II	I-Disease	-1	24100055
.	O	-1	24100055
CONCLUSIONS:	O	-1	24100055
The	O	-1	24100055
incidence	O	-1	24100055
of	O	-1	24100055
H@@	B-Disease	D013921	24100055
I@@	I-Disease	-1	24100055
T	I-Disease	-1	24100055
in	O	-1	24100055
patients	O	-1	24100055
with	O	-1	24100055
en@@	B-Disease	D058625	24100055
d-@@	I-Disease	-1	24100055
st@@	I-Disease	-1	24100055
age	I-Disease	-1	24100055
hepatic	I-Disease	-1	24100055
failure	I-Disease	-1	24100055
is@@	O	-1	24100055
,	O	-1	24100055
with	O	-1	24100055
about	O	-1	24100055
1.@@	O	-1	24100055
9@@	O	-1	24100055
5@@	O	-1	24100055
%,	O	-1	24100055
ra@@	O	-1	24100055
re.	O	-1	24100055
F@@	O	-1	24100055
or	O	-1	24100055
further	O	-1	24100055
reduction	O	-1	24100055
of	O	-1	24100055
H@@	B-Disease	D013921	24100055
I@@	I-Disease	-1	24100055
T	I-Disease	-1	24100055
type	I-Disease	-1	24100055
II	I-Disease	-1	24100055
,	O	-1	24100055
the	O	-1	24100055
use	O	-1	24100055
of	O	-1	24100055
intravenous	O	-1	24100055
hepar@@	B-Chemical	D006493	24100055
in	I-Chemical	-1	24100055
should	O	-1	24100055
be	O	-1	24100055
avoid@@	O	-1	24100055
ed	O	-1	24100055
and	O	-1	24100055
the	O	-1	24100055
pro@@	O	-1	24100055
phyl@@	O	-1	24100055
ac@@	O	-1	24100055
tic	O	-1	24100055
anti@@	O	-1	24100055
co@@	O	-1	24100055
ag@@	O	-1	24100055
ulation	O	-1	24100055
should	O	-1	24100055
be	O	-1	24100055
performed	O	-1	24100055
with	O	-1	24100055
low@@	O	-1	24100055
-@@	O	-1	24100055
mol@@	O	-1	24100055
ec@@	O	-1	24100055
ul@@	O	-1	24100055
ar@@	O	-1	24100055
-@@	O	-1	24100055
weight	O	-1	24100055
hepar@@	B-Chemical	D006493	24100055
in	I-Chemical	-1	24100055
after	O	-1	24100055
normal@@	O	-1	24100055
ization	O	-1	24100055
of	O	-1	24100055
platele@@	O	-1	24100055
t	O	-1	24100055
coun@@	O	-1	24100055
t.	O	-1	24100055

T@@	B-Disease	D054549	24100257
ak@@	I-Disease	-1	24100257
ot@@	I-Disease	-1	24100257
sub@@	I-Disease	-1	24100257
o	I-Disease	-1	24100257
syndrome	I-Disease	-1	24100257
(@@	O	-1	24100257
or	O	-1	24100257
ap@@	B-Disease	D054549	24100257
ical	I-Disease	-1	24100257
b@@	I-Disease	-1	24100257
al@@	I-Disease	-1	24100257
lo@@	I-Disease	-1	24100257
on@@	I-Disease	-1	24100257
ing	I-Disease	-1	24100257
syndrome	I-Disease	-1	24100257
)	O	-1	24100257
secondary	O	-1	24100257
to	O	-1	24100257
Z@@	B-Chemical	C089750	24100257
ol@@	I-Chemical	-1	24100257
mit@@	I-Chemical	-1	24100257
ript@@	I-Chemical	-1	24100257
an	I-Chemical	-1	24100257
.	O	-1	24100257
T@@	B-Disease	D054549	24100257
ak@@	I-Disease	-1	24100257
ot@@	I-Disease	-1	24100257
sub@@	I-Disease	-1	24100257
o	I-Disease	-1	24100257
syndrome	I-Disease	-1	24100257
(	O	-1	24100257
T@@	B-Disease	D054549	24100257
S	I-Disease	-1	24100257
),	O	-1	24100257
also	O	-1	24100257
known	O	-1	24100257
as	O	-1	24100257
b@@	B-Disease	D054549	24100257
ro@@	I-Disease	-1	24100257
k@@	I-Disease	-1	24100257
en	I-Disease	-1	24100257
heart	I-Disease	-1	24100257
syndrome	I-Disease	-1	24100257
,	O	-1	24100257
is	O	-1	24100257
character@@	O	-1	24100257
ized	O	-1	24100257
by	O	-1	24100257
left	O	-1	24100257
ventric@@	O	-1	24100257
le	O	-1	24100257
ap@@	O	-1	24100257
ical	O	-1	24100257
b@@	O	-1	24100257
al@@	O	-1	24100257
lo@@	O	-1	24100257
on@@	O	-1	24100257
ing	O	-1	24100257
with	O	-1	24100257
elevated	O	-1	24100257
cardiac	O	-1	24100257
b@@	O	-1	24100257
i@@	O	-1	24100257
om@@	O	-1	24100257
ark@@	O	-1	24100257
ers	O	-1	24100257
and	O	-1	24100257
electro@@	O	-1	24100257
cardio@@	O	-1	24100257
graph@@	O	-1	24100257
ic	O	-1	24100257
changes	O	-1	24100257
sugg@@	O	-1	24100257
es@@	O	-1	24100257
tive	O	-1	24100257
of	O	-1	24100257
an	O	-1	24100257
acute	B-Disease	D054058	24100257
coronary	I-Disease	-1	24100257
syndrome	I-Disease	-1	24100257
(@@	O	-1	24100257
i@@	O	-1	24100257
e,	O	-1	24100257
S@@	O	-1	24100257
T@@	O	-1	24100257
-@@	O	-1	24100257
seg@@	O	-1	24100257
ment	O	-1	24100257
elev@@	O	-1	24100257
ation,	O	-1	24100257
T	O	-1	24100257
w@@	O	-1	24100257
a@@	O	-1	24100257
ve	O	-1	24100257
in@@	O	-1	24100257
ver@@	O	-1	24100257
sion@@	O	-1	24100257
s,	O	-1	24100257
and	O	-1	24100257
path@@	O	-1	24100257
ologic	O	-1	24100257
Q	O	-1	24100257
w@@	O	-1	24100257
av@@	O	-1	24100257
es@@	O	-1	24100257
).	O	-1	24100257
We	O	-1	24100257
report	O	-1	24100257
a	O	-1	24100257
case	O	-1	24100257
of	O	-1	24100257
5@@	O	-1	24100257
4-@@	O	-1	24100257
year-old	O	-1	24100257
woman	O	-1	24100257
with	O	-1	24100257
med@@	O	-1	24100257
ical	O	-1	24100257
hist@@	O	-1	24100257
ory	O	-1	24100257
of	O	-1	24100257
mit@@	B-Disease	D008945	24100257
ral	I-Disease	-1	24100257
val@@	I-Disease	-1	24100257
ve	I-Disease	-1	24100257
prol@@	I-Disease	-1	24100257
ap@@	I-Disease	-1	24100257
se	I-Disease	-1	24100257
and	O	-1	24100257
migra@@	B-Disease	D008881	24100257
in@@	I-Disease	-1	24100257
es	I-Disease	-1	24100257
,	O	-1	24100257
who	O	-1	24100257
was	O	-1	24100257
ad@@	O	-1	24100257
mit@@	O	-1	24100257
ted	O	-1	24100257
to	O	-1	24100257
the	O	-1	24100257
hospit@@	O	-1	24100257
al	O	-1	24100257
for	O	-1	24100257
sub@@	O	-1	24100257
ster@@	O	-1	24100257
n@@	O	-1	24100257
al	O	-1	24100257
ch@@	B-Disease	D002637	24100257
est	I-Disease	-1	24100257
pain	I-Disease	-1	24100257
and	O	-1	24100257
electro@@	O	-1	24100257
cardio@@	O	-1	24100257
gra@@	O	-1	24100257
m	O	-1	24100257
demonstrated	O	-1	24100257
1@@	O	-1	24100257
/@@	O	-1	24100257
2	O	-1	24100257
mm	O	-1	24100257
S@@	O	-1	24100257
T@@	O	-1	24100257
-@@	O	-1	24100257
seg@@	O	-1	24100257
ment	O	-1	24100257
elev@@	O	-1	24100257
ation	O	-1	24100257
in	O	-1	24100257
lead@@	O	-1	24100257
s	O	-1	24100257
II@@	O	-1	24100257
,	O	-1	24100257
II@@	O	-1	24100257
I@@	O	-1	24100257
,	O	-1	24100257
a@@	O	-1	24100257
V@@	O	-1	24100257
F@@	O	-1	24100257
,	O	-1	24100257
V@@	O	-1	24100257
5,	O	-1	24100257
and	O	-1	24100257
V@@	O	-1	24100257
6	O	-1	24100257
and	O	-1	24100257
positive	O	-1	24100257
tro@@	O	-1	24100257
p@@	O	-1	24100257
on@@	O	-1	24100257
in	O	-1	24100257
I@@	O	-1	24100257
.	O	-1	24100257
E@@	O	-1	24100257
m@@	O	-1	24100257
erg@@	O	-1	24100257
ent	O	-1	24100257
coronary	O	-1	24100257
angio@@	O	-1	24100257
gra@@	O	-1	24100257
m	O	-1	24100257
revealed	O	-1	24100257
normal	O	-1	24100257
coronary	O	-1	24100257
arter@@	O	-1	24100257
i@@	O	-1	24100257
es	O	-1	24100257
with	O	-1	24100257
moder@@	O	-1	24100257
ately	O	-1	24100257
reduced	O	-1	24100257
left	O	-1	24100257
ventricular	O	-1	24100257
e@@	O	-1	24100257
j@@	O	-1	24100257
ection	O	-1	24100257
frac@@	O	-1	24100257
tion	O	-1	24100257
with	O	-1	24100257
w@@	O	-1	24100257
all	O	-1	24100257
mo@@	O	-1	24100257
tion	O	-1	24100257
abnormal@@	O	-1	24100257
ities	O	-1	24100257
consist@@	O	-1	24100257
ent	O	-1	24100257
with	O	-1	24100257
T@@	B-Disease	D054549	24100257
S	I-Disease	-1	24100257
.	O	-1	24100257
D@@	O	-1	24100257
et@@	O	-1	24100257
ail@@	O	-1	24100257
ed	O	-1	24100257
hist@@	O	-1	24100257
ory	O	-1	24100257
obtained	O	-1	24100257
ret@@	O	-1	24100257
ro@@	O	-1	24100257
sp@@	O	-1	24100257
ectively	O	-1	24100257
revealed	O	-1	24100257
that	O	-1	24100257
the	O	-1	24100257
patient	O	-1	24100257
to@@	O	-1	24100257
o@@	O	-1	24100257
k	O	-1	24100257
z@@	B-Chemical	C089750	24100257
ol@@	I-Chemical	-1	24100257
mit@@	I-Chemical	-1	24100257
ript@@	I-Chemical	-1	24100257
an	I-Chemical	-1	24100257
s@@	O	-1	24100257
par@@	O	-1	24100257
ing@@	O	-1	24100257
ly	O	-1	24100257
only	O	-1	24100257
when	O	-1	24100257
sh@@	O	-1	24100257
e	O	-1	24100257
had	O	-1	24100257
migra@@	B-Disease	D008881	24100257
in@@	I-Disease	-1	24100257
es	I-Disease	-1	24100257
.	O	-1	24100257
B@@	O	-1	24100257
u@@	O	-1	24100257
t	O	-1	24100257
before	O	-1	24100257
this	O	-1	24100257
event@@	O	-1	24100257
,	O	-1	24100257
sh@@	O	-1	24100257
e	O	-1	24100257
was	O	-1	24100257
taking	O	-1	24100257
z@@	B-Chemical	C089750	24100257
ol@@	I-Chemical	-1	24100257
mit@@	I-Chemical	-1	24100257
ript@@	I-Chemical	-1	24100257
an	I-Chemical	-1	24100257
2-@@	O	-1	24100257
3	O	-1	24100257
times	O	-1	24100257
daily	O	-1	24100257
for	O	-1	24100257
several	O	-1	24100257
days	O	-1	24100257
because	O	-1	24100257
of	O	-1	24100257
a	O	-1	24100257
per@@	O	-1	24100257
sist@@	O	-1	24100257
ent	O	-1	24100257
migra@@	B-Disease	D008881	24100257
ine	I-Disease	-1	24100257
headac@@	I-Disease	-1	24100257
he	I-Disease	-1	24100257
.	O	-1	24100257
S@@	O	-1	24100257
he	O	-1	24100257
o@@	O	-1	24100257
ther@@	O	-1	24100257
w@@	O	-1	24100257
is@@	O	-1	24100257
e	O	-1	24100257
reported	O	-1	24100257
that	O	-1	24100257
sh@@	O	-1	24100257
e	O	-1	24100257
is	O	-1	24100257
qu@@	O	-1	24100257
ite	O	-1	24100257
ac@@	O	-1	24100257
ti@@	O	-1	24100257
ve,	O	-1	24100257
ri@@	O	-1	24100257
des	O	-1	24100257
h@@	O	-1	24100257
or@@	O	-1	24100257
s@@	O	-1	24100257
es,	O	-1	24100257
and	O	-1	24100257
does	O	-1	24100257
show	O	-1	24100257
j@@	O	-1	24100257
um@@	O	-1	24100257
p@@	O	-1	24100257
ing	O	-1	24100257
without	O	-1	24100257
any	O	-1	24100257
lim@@	O	-1	24100257
it@@	O	-1	24100257
ations	O	-1	24100257
in	O	-1	24100257
h@@	O	-1	24100257
er	O	-1	24100257
physi@@	O	-1	24100257
c@@	O	-1	24100257
al	O	-1	24100257
activ@@	O	-1	24100257
ity.	O	-1	24100257
There	O	-1	24100257
was	O	-1	24100257
no	O	-1	24100257
evidence	O	-1	24100257
of	O	-1	24100257
any	O	-1	24100257
rec@@	O	-1	24100257
ent	O	-1	24100257
stres@@	O	-1	24100257
s	O	-1	24100257
or	O	-1	24100257
status	B-Disease	D008881	24100257
migra@@	I-Disease	-1	24100257
in@@	I-Disease	-1	24100257
os@@	I-Disease	-1	24100257
us	I-Disease	-1	24100257
.	O	-1	24100257
E@@	O	-1	24100257
x@@	O	-1	24100257
ten@@	O	-1	24100257
sive	O	-1	24100257
literat@@	O	-1	24100257
ure	O	-1	24100257
se@@	O	-1	24100257
arc@@	O	-1	24100257
h	O	-1	24100257
revealed	O	-1	24100257
multiple	O	-1	24100257
cases	O	-1	24100257
of	O	-1	24100257
coronary	B-Disease	D003329	24100257
artery	I-Disease	-1	24100257
vas@@	I-Disease	-1	24100257
os@@	I-Disease	-1	24100257
p@@	I-Disease	-1	24100257
as@@	I-Disease	-1	24100257
m	I-Disease	-1	24100257
secondary	O	-1	24100257
to	O	-1	24100257
z@@	B-Chemical	C089750	24100257
ol@@	I-Chemical	-1	24100257
mit@@	I-Chemical	-1	24100257
ript@@	I-Chemical	-1	24100257
an	I-Chemical	-1	24100257
,	O	-1	24100257
but	O	-1	24100257
n@@	O	-1	24100257
one	O	-1	24100257
of	O	-1	24100257
the	O	-1	24100257
cases	O	-1	24100257
were	O	-1	24100257
associated	O	-1	24100257
with	O	-1	24100257
T@@	B-Disease	D054549	24100257
S	I-Disease	-1	24100257
.	O	-1	24100257

De@@	B-Disease	D003866	24114426
pression	I-Disease	-1	24114426
,	O	-1	24114426
im@@	B-Disease	D010554	24114426
pul@@	I-Disease	-1	24114426
si@@	I-Disease	-1	24114426
ven@@	I-Disease	-1	24114426
ess	I-Disease	-1	24114426
,	O	-1	24114426
sle@@	O	-1	24114426
ep@@	O	-1	24114426
,	O	-1	24114426
and	O	-1	24114426
memory	O	-1	24114426
in	O	-1	24114426
p@@	O	-1	24114426
ast	O	-1	24114426
and	O	-1	24114426
present	O	-1	24114426
poly@@	O	-1	24114426
drug	O	-1	24114426
users	O	-1	24114426
of	O	-1	24114426
3@@	B-Chemical	D018817	24114426
,@@	I-Chemical	-1	24114426
4-@@	I-Chemical	-1	24114426
methyl@@	I-Chemical	-1	24114426
en@@	I-Chemical	-1	24114426
edi@@	I-Chemical	-1	24114426
oxy@@	I-Chemical	-1	24114426
meth@@	I-Chemical	-1	24114426
amphetamine	I-Chemical	-1	24114426
(	O	-1	24114426
MD@@	B-Chemical	D018817	24114426
M@@	I-Chemical	-1	24114426
A	I-Chemical	-1	24114426
,	O	-1	24114426
ec@@	B-Chemical	D018817	24114426
st@@	I-Chemical	-1	24114426
as@@	I-Chemical	-1	24114426
y	I-Chemical	-1	24114426
).	O	-1	24114426
R@@	O	-1	24114426
AT@@	O	-1	24114426
ION@@	O	-1	24114426
AL@@	O	-1	24114426
E:	O	-1	24114426
E@@	B-Chemical	D018817	24114426
c@@	I-Chemical	-1	24114426
st@@	I-Chemical	-1	24114426
as@@	I-Chemical	-1	24114426
y	I-Chemical	-1	24114426
(	O	-1	24114426
3@@	B-Chemical	D018817	24114426
,@@	I-Chemical	-1	24114426
4-@@	I-Chemical	-1	24114426
methyl@@	I-Chemical	-1	24114426
en@@	I-Chemical	-1	24114426
edi@@	I-Chemical	-1	24114426
oxy@@	I-Chemical	-1	24114426
meth@@	I-Chemical	-1	24114426
amphetamine	I-Chemical	-1	24114426
,	O	-1	24114426
MD@@	B-Chemical	D018817	24114426
M@@	I-Chemical	-1	24114426
A	I-Chemical	-1	24114426
)	O	-1	24114426
is	O	-1	24114426
a	O	-1	24114426
wor@@	O	-1	24114426
l@@	O	-1	24114426
d@@	O	-1	24114426
w@@	O	-1	24114426
ide	O	-1	24114426
rec@@	O	-1	24114426
re@@	O	-1	24114426
ation@@	O	-1	24114426
al	O	-1	24114426
drug	O	-1	24114426
of	O	-1	24114426
ab@@	O	-1	24114426
use.	O	-1	24114426
U@@	O	-1	24114426
n@@	O	-1	24114426
for@@	O	-1	24114426
t@@	O	-1	24114426
un@@	O	-1	24114426
at@@	O	-1	24114426
el@@	O	-1	24114426
y,	O	-1	24114426
the	O	-1	24114426
results	O	-1	24114426
from	O	-1	24114426
human	O	-1	24114426
re@@	O	-1	24114426
se@@	O	-1	24114426
arc@@	O	-1	24114426
h	O	-1	24114426
investig@@	O	-1	24114426
ating	O	-1	24114426
its	O	-1	24114426
psych@@	O	-1	24114426
ological	O	-1	24114426
effects	O	-1	24114426
have	O	-1	24114426
been	O	-1	24114426
in@@	O	-1	24114426
consist@@	O	-1	24114426
ent@@	O	-1	24114426
.	O	-1	24114426
OBJECTIV@@	O	-1	24114426
E@@	O	-1	24114426
S:	O	-1	24114426
The	O	-1	24114426
present	O	-1	24114426
study	O	-1	24114426
a@@	O	-1	24114426
im@@	O	-1	24114426
ed	O	-1	24114426
to	O	-1	24114426
be	O	-1	24114426
the	O	-1	24114426
larg@@	O	-1	24114426
est	O	-1	24114426
to	O	-1	24114426
d@@	O	-1	24114426
ate	O	-1	24114426
in	O	-1	24114426
sam@@	O	-1	24114426
ple	O	-1	24114426
size	O	-1	24114426
and	O	-1	24114426
5@@	O	-1	24114426
H@@	O	-1	24114426
T@@	O	-1	24114426
-@@	O	-1	24114426
related	O	-1	24114426
behavi@@	O	-1	24114426
or@@	O	-1	24114426
s;	O	-1	24114426
the	O	-1	24114426
first	O	-1	24114426
to	O	-1	24114426
compar@@	O	-1	24114426
e	O	-1	24114426
present	O	-1	24114426
ec@@	B-Chemical	D018817	24114426
st@@	I-Chemical	-1	24114426
as@@	I-Chemical	-1	24114426
y	I-Chemical	-1	24114426
users	O	-1	24114426
with	O	-1	24114426
p@@	O	-1	24114426
ast	O	-1	24114426
users	O	-1	24114426
after	O	-1	24114426
an	O	-1	24114426
ab@@	O	-1	24114426
st@@	O	-1	24114426
in@@	O	-1	24114426
ence	O	-1	24114426
of	O	-1	24114426
4	O	-1	24114426
or	O	-1	24114426
more	O	-1	24114426
year@@	O	-1	24114426
s,	O	-1	24114426
and	O	-1	24114426
the	O	-1	24114426
first	O	-1	24114426
to	O	-1	24114426
includ@@	O	-1	24114426
e	O	-1	24114426
ro@@	O	-1	24114426
b@@	O	-1	24114426
us@@	O	-1	24114426
t	O	-1	24114426
controls	O	-1	24114426
for	O	-1	24114426
other	O	-1	24114426
rec@@	O	-1	24114426
re@@	O	-1	24114426
ation@@	O	-1	24114426
al	O	-1	24114426
subst@@	O	-1	24114426
anc@@	O	-1	24114426
es.	O	-1	24114426
METHODS:	O	-1	24114426
A	O	-1	24114426
sam@@	O	-1	24114426
ple	O	-1	24114426
of	O	-1	24114426
9@@	O	-1	24114426
9@@	O	-1	24114426
7	O	-1	24114426
partic@@	O	-1	24114426
ip@@	O	-1	24114426
ants	O	-1	24114426
(5@@	O	-1	24114426
2	O	-1	24114426
%	O	-1	24114426
mal@@	O	-1	24114426
e@@	O	-1	24114426
)	O	-1	24114426
was	O	-1	24114426
rec@@	O	-1	24114426
ru@@	O	-1	24114426
ited	O	-1	24114426
to	O	-1	24114426
four	O	-1	24114426
control	O	-1	24114426
groups	O	-1	24114426
(@@	O	-1	24114426
non-@@	O	-1	24114426
drug	O	-1	24114426
(N@@	O	-1	24114426
D@@	O	-1	24114426
),	O	-1	24114426
alco@@	B-Chemical	D000431	24114426
hol	I-Chemical	-1	24114426
/	O	-1	24114426
nicotine	B-Chemical	D009538	24114426
(	O	-1	24114426
A@@	B-Chemical	D000431	24114426
N	I-Chemical	-1	24114426
A@@	B-Chemical	D009538	24114426
N	I-Chemical	-1	24114426
),	O	-1	24114426
can@@	B-Chemical	D002188	24114426
n@@	I-Chemical	-1	24114426
ab@@	I-Chemical	-1	24114426
is	I-Chemical	-1	24114426
/	O	-1	24114426
alco@@	B-Chemical	D000431	24114426
hol	I-Chemical	-1	24114426
/	O	-1	24114426
nicotine	B-Chemical	D009538	24114426
(	O	-1	24114426
CA@@	B-Chemical	D002188	24114426
N	I-Chemical	-1	24114426
CA@@	B-Chemical	D000431	24114426
N	I-Chemical	-1	24114426
CA@@	B-Chemical	D009538	24114426
N	I-Chemical	-1	24114426
),	O	-1	24114426
non@@	O	-1	24114426
-	O	-1	24114426
ec@@	B-Chemical	D018817	24114426
st@@	I-Chemical	-1	24114426
as@@	I-Chemical	-1	24114426
y	I-Chemical	-1	24114426
poly@@	O	-1	24114426
drug	O	-1	24114426
(P@@	O	-1	24114426
D@@	O	-1	24114426
)@@	O	-1	24114426
),	O	-1	24114426
and	O	-1	24114426
two	O	-1	24114426
ec@@	B-Chemical	D018817	24114426
st@@	I-Chemical	-1	24114426
as@@	I-Chemical	-1	24114426
y	I-Chemical	-1	24114426
poly@@	O	-1	24114426
drug	O	-1	24114426
groups	O	-1	24114426
(@@	O	-1	24114426
present	O	-1	24114426
(	O	-1	24114426
MD@@	B-Chemical	D018817	24114426
M@@	I-Chemical	-1	24114426
A	I-Chemical	-1	24114426
)	O	-1	24114426
and	O	-1	24114426
p@@	O	-1	24114426
ast	O	-1	24114426
users	O	-1	24114426
(@@	O	-1	24114426
E@@	O	-1	24114426
X@@	O	-1	24114426
-	O	-1	24114426
MD@@	B-Chemical	D018817	24114426
M@@	I-Chemical	-1	24114426
A	I-Chemical	-1	24114426
).	O	-1	24114426
P@@	O	-1	24114426
ar@@	O	-1	24114426
tic@@	O	-1	24114426
ip@@	O	-1	24114426
ants	O	-1	24114426
comple@@	O	-1	24114426
ted	O	-1	24114426
a	O	-1	24114426
drug	O	-1	24114426
hist@@	O	-1	24114426
ory	O	-1	24114426
qu@@	O	-1	24114426
es@@	O	-1	24114426
tion@@	O	-1	24114426
na@@	O	-1	24114426
i@@	O	-1	24114426
re,	O	-1	24114426
B@@	O	-1	24114426
ec@@	O	-1	24114426
k	O	-1	24114426
De@@	B-Disease	D003866	24114426
pression	I-Disease	-1	24114426
In@@	O	-1	24114426
v@@	O	-1	24114426
ent@@	O	-1	24114426
or@@	O	-1	24114426
y,	O	-1	24114426
B@@	O	-1	24114426
ar@@	O	-1	24114426
rat@@	O	-1	24114426
t	O	-1	24114426
Im@@	B-Disease	D010554	24114426
pul@@	I-Disease	-1	24114426
si@@	I-Disease	-1	24114426
ven@@	I-Disease	-1	24114426
ess	I-Disease	-1	24114426
S@@	O	-1	24114426
cal@@	O	-1	24114426
e,	O	-1	24114426
P@@	O	-1	24114426
it@@	O	-1	24114426
t@@	O	-1	24114426
s@@	O	-1	24114426
b@@	O	-1	24114426
ur@@	O	-1	24114426
gh	O	-1	24114426
S@@	O	-1	24114426
le@@	O	-1	24114426
ep	O	-1	24114426
Q@@	O	-1	24114426
u@@	O	-1	24114426
ality	O	-1	24114426
In@@	O	-1	24114426
de@@	O	-1	24114426
x@@	O	-1	24114426
,	O	-1	24114426
and	O	-1	24114426
W@@	O	-1	24114426
ech@@	O	-1	24114426
s@@	O	-1	24114426
l@@	O	-1	24114426
er	O	-1	24114426
M@@	O	-1	24114426
em@@	O	-1	24114426
ory	O	-1	24114426
S@@	O	-1	24114426
cal@@	O	-1	24114426
e-@@	O	-1	24114426
R@@	O	-1	24114426
ev@@	O	-1	24114426
is@@	O	-1	24114426
ed	O	-1	24114426
wh@@	O	-1	24114426
ic@@	O	-1	24114426
h@@	O	-1	24114426
,	O	-1	24114426
in	O	-1	24114426
tot@@	O	-1	24114426
al,	O	-1	24114426
pro@@	O	-1	24114426
vid@@	O	-1	24114426
ed	O	-1	24114426
13	O	-1	24114426
psycho@@	O	-1	24114426
me@@	O	-1	24114426
tri@@	O	-1	24114426
c	O	-1	24114426
meas@@	O	-1	24114426
ures@@	O	-1	24114426
.	O	-1	24114426
RESULTS:	O	-1	24114426
W@@	O	-1	24114426
h@@	O	-1	24114426
ile	O	-1	24114426
the	O	-1	24114426
CA@@	B-Chemical	D002188	24114426
N	I-Chemical	-1	24114426
CA@@	B-Chemical	D000431	24114426
N	I-Chemical	-1	24114426
CA@@	B-Chemical	D009538	24114426
N	I-Chemical	-1	24114426
and	O	-1	24114426
P@@	O	-1	24114426
D	O	-1	24114426
groups	O	-1	24114426
ten@@	O	-1	24114426
ded	O	-1	24114426
to	O	-1	24114426
recor@@	O	-1	24114426
d	O	-1	24114426
greater	O	-1	24114426
defic@@	O	-1	24114426
its	O	-1	24114426
than	O	-1	24114426
the	O	-1	24114426
non-@@	O	-1	24114426
drug	O	-1	24114426
control@@	O	-1	24114426
s,	O	-1	24114426
the	O	-1	24114426
MD@@	B-Chemical	D018817	24114426
M@@	I-Chemical	-1	24114426
A	I-Chemical	-1	24114426
and	O	-1	24114426
E@@	O	-1	24114426
X@@	O	-1	24114426
-	O	-1	24114426
MD@@	B-Chemical	D018817	24114426
M@@	I-Chemical	-1	24114426
A	I-Chemical	-1	24114426
groups	O	-1	24114426
recor@@	O	-1	24114426
ded	O	-1	24114426
greater	O	-1	24114426
defic@@	O	-1	24114426
its	O	-1	24114426
than	O	-1	24114426
all	O	-1	24114426
the	O	-1	24114426
control	O	-1	24114426
groups	O	-1	24114426
on	O	-1	24114426
ten	O	-1	24114426
of	O	-1	24114426
the	O	-1	24114426
13	O	-1	24114426
psycho@@	O	-1	24114426
me@@	O	-1	24114426
tri@@	O	-1	24114426
c	O	-1	24114426
meas@@	O	-1	24114426
ures@@	O	-1	24114426
.	O	-1	24114426
S@@	O	-1	24114426
tri@@	O	-1	24114426
k@@	O	-1	24114426
ing@@	O	-1	24114426
ly,	O	-1	24114426
des@@	O	-1	24114426
pit@@	O	-1	24114426
e	O	-1	24114426
prolonged	O	-1	24114426
ab@@	O	-1	24114426
st@@	O	-1	24114426
in@@	O	-1	24114426
ence	O	-1	24114426
(@@	O	-1	24114426
me@@	O	-1	24114426
an@@	O	-1	24114426
,	O	-1	24114426
4.@@	O	-1	24114426
9@@	O	-1	24114426
8@@	O	-1	24114426
;	O	-1	24114426
rang@@	O	-1	24114426
e,	O	-1	24114426
4-@@	O	-1	24114426
9	O	-1	24114426
year@@	O	-1	24114426
s),	O	-1	24114426
p@@	O	-1	24114426
ast	O	-1	24114426
ec@@	B-Chemical	D018817	24114426
st@@	I-Chemical	-1	24114426
as@@	I-Chemical	-1	24114426
y	I-Chemical	-1	24114426
users	O	-1	24114426
showed	O	-1	24114426
fe@@	O	-1	24114426
w	O	-1	24114426
signs	O	-1	24114426
of	O	-1	24114426
reco@@	O	-1	24114426
ver@@	O	-1	24114426
y.	O	-1	24114426
Com@@	O	-1	24114426
pared	O	-1	24114426
with	O	-1	24114426
present	O	-1	24114426
ec@@	B-Chemical	D018817	24114426
st@@	I-Chemical	-1	24114426
as@@	I-Chemical	-1	24114426
y	I-Chemical	-1	24114426
us@@	O	-1	24114426
er@@	O	-1	24114426
s,	O	-1	24114426
the	O	-1	24114426
p@@	O	-1	24114426
ast	O	-1	24114426
users	O	-1	24114426
showed	O	-1	24114426
no	O	-1	24114426
change	O	-1	24114426
for	O	-1	24114426
ten	O	-1	24114426
meas@@	O	-1	24114426
ures@@	O	-1	24114426
,	O	-1	24114426
increased	O	-1	24114426
impair@@	O	-1	24114426
ment	O	-1	24114426
for	O	-1	24114426
two	O	-1	24114426
meas@@	O	-1	24114426
ures@@	O	-1	24114426
,	O	-1	24114426
and	O	-1	24114426
impro@@	O	-1	24114426
vement	O	-1	24114426
on	O	-1	24114426
j@@	O	-1	24114426
us@@	O	-1	24114426
t	O	-1	24114426
one	O	-1	24114426
meas@@	O	-1	24114426
ure.	O	-1	24114426
CONCLUSIONS:	O	-1	24114426
G@@	O	-1	24114426
i@@	O	-1	24114426
ven	O	-1	24114426
this	O	-1	24114426
recor@@	O	-1	24114426
d	O	-1	24114426
of	O	-1	24114426
impaired	B-Disease	D008569	24114426
memory	I-Disease	-1	24114426
and	O	-1	24114426
clin@@	O	-1	24114426
ically	O	-1	24114426
significant	O	-1	24114426
levels	O	-1	24114426
of	O	-1	24114426
de@@	B-Disease	D003866	24114426
pression	I-Disease	-1	24114426
,	O	-1	24114426
im@@	B-Disease	D010554	24114426
pul@@	I-Disease	-1	24114426
si@@	I-Disease	-1	24114426
ven@@	I-Disease	-1	24114426
ess	I-Disease	-1	24114426
,	O	-1	24114426
and	O	-1	24114426
sleep	B-Disease	D020920	24114426
dist@@	I-Disease	-1	24114426
urb@@	I-Disease	-1	24114426
ance	I-Disease	-1	24114426
,	O	-1	24114426
the	O	-1	24114426
pro@@	O	-1	24114426
g@@	O	-1	24114426
no@@	O	-1	24114426
sis	O	-1	24114426
for	O	-1	24114426
the	O	-1	24114426
current	O	-1	24114426
generation	O	-1	24114426
of	O	-1	24114426
ec@@	B-Chemical	D018817	24114426
st@@	I-Chemical	-1	24114426
as@@	I-Chemical	-1	24114426
y	I-Chemical	-1	24114426
users	O	-1	24114426
is	O	-1	24114426
a	O	-1	24114426
major	O	-1	24114426
cause	O	-1	24114426
for	O	-1	24114426
con@@	O	-1	24114426
cer@@	O	-1	24114426
n@@	O	-1	24114426
.	O	-1	24114426

A@@	O	-1	24126708
s@@	O	-1	24126708
s@@	O	-1	24126708
oci@@	O	-1	24126708
ation	O	-1	24126708
of	O	-1	24126708
common	O	-1	24126708
gene@@	O	-1	24126708
tic	O	-1	24126708
vari@@	O	-1	24126708
ants	O	-1	24126708
of	O	-1	24126708
HO@@	O	-1	24126708
M@@	O	-1	24126708
E@@	O	-1	24126708
R@@	O	-1	24126708
1	O	-1	24126708
gen@@	O	-1	24126708
e	O	-1	24126708
with	O	-1	24126708
levo@@	B-Chemical	D007980	24126708
dopa	I-Chemical	-1	24126708
adverse	O	-1	24126708
effects	O	-1	24126708
in	O	-1	24126708
Parkinson's	B-Disease	D010300	24126708
disease	I-Disease	-1	24126708
patients.	O	-1	24126708
L@@	B-Chemical	D007980	24126708
evo@@	I-Chemical	-1	24126708
dopa	I-Chemical	-1	24126708
is	O	-1	24126708
the	O	-1	24126708
most	O	-1	24126708
effective	O	-1	24126708
symptom@@	O	-1	24126708
atic	O	-1	24126708
therapy	O	-1	24126708
for	O	-1	24126708
Parkinson's	B-Disease	D010300	24126708
disease	I-Disease	-1	24126708
,	O	-1	24126708
but	O	-1	24126708
its	O	-1	24126708
chronic	O	-1	24126708
use	O	-1	24126708
could	O	-1	24126708
le@@	O	-1	24126708
ad	O	-1	24126708
to	O	-1	24126708
chronic	O	-1	24126708
adverse	O	-1	24126708
outcom@@	O	-1	24126708
es,	O	-1	24126708
such	O	-1	24126708
as	O	-1	24126708
motor	O	-1	24126708
f@@	O	-1	24126708
l@@	O	-1	24126708
uc@@	O	-1	24126708
tu@@	O	-1	24126708
ation@@	O	-1	24126708
s,	O	-1	24126708
dyskine@@	B-Disease	D004409	24126708
sia	I-Disease	-1	24126708
and	O	-1	24126708
visual	B-Disease	D006212	24126708
h@@	I-Disease	-1	24126708
all@@	I-Disease	-1	24126708
uc@@	I-Disease	-1	24126708
in@@	I-Disease	-1	24126708
ations	I-Disease	-1	24126708
.	O	-1	24126708
HO@@	O	-1	24126708
M@@	O	-1	24126708
E@@	O	-1	24126708
R@@	O	-1	24126708
1	O	-1	24126708
is	O	-1	24126708
a	O	-1	24126708
protein	O	-1	24126708
with	O	-1	24126708
pi@@	O	-1	24126708
v@@	O	-1	24126708
ot@@	O	-1	24126708
al	O	-1	24126708
function	O	-1	24126708
in	O	-1	24126708
glutamate	B-Chemical	D018698	24126708
trans@@	O	-1	24126708
mis@@	O	-1	24126708
sion,	O	-1	24126708
which	O	-1	24126708
has	O	-1	24126708
been	O	-1	24126708
related	O	-1	24126708
to	O	-1	24126708
the	O	-1	24126708
path@@	O	-1	24126708
o@@	O	-1	24126708
genesis	O	-1	24126708
of	O	-1	24126708
these	O	-1	24126708
complic@@	O	-1	24126708
ations.	O	-1	24126708
This	O	-1	24126708
study	O	-1	24126708
investig@@	O	-1	24126708
ates	O	-1	24126708
whether	O	-1	24126708
poly@@	O	-1	24126708
morph@@	O	-1	24126708
is@@	O	-1	24126708
ms	O	-1	24126708
in	O	-1	24126708
the	O	-1	24126708
HO@@	O	-1	24126708
M@@	O	-1	24126708
E@@	O	-1	24126708
R@@	O	-1	24126708
1	O	-1	24126708
gen@@	O	-1	24126708
e	O	-1	24126708
pro@@	O	-1	24126708
m@@	O	-1	24126708
ot@@	O	-1	24126708
er	O	-1	24126708
regi@@	O	-1	24126708
on	O	-1	24126708
are	O	-1	24126708
associated	O	-1	24126708
with	O	-1	24126708
the	O	-1	24126708
occur@@	O	-1	24126708
rence	O	-1	24126708
of	O	-1	24126708
the	O	-1	24126708
chronic	O	-1	24126708
complications	O	-1	24126708
of	O	-1	24126708
levo@@	B-Chemical	D007980	24126708
dopa	I-Chemical	-1	24126708
therapy.	O	-1	24126708
A	O	-1	24126708
total	O	-1	24126708
of	O	-1	24126708
20@@	O	-1	24126708
5	O	-1	24126708
patients	O	-1	24126708
with	O	-1	24126708
i@@	B-Disease	D010300	24126708
di@@	I-Disease	-1	24126708
o@@	I-Disease	-1	24126708
path@@	I-Disease	-1	24126708
ic	I-Disease	-1	24126708
Parkinson's	I-Disease	-1	24126708
disease	I-Disease	-1	24126708
were	O	-1	24126708
investig@@	O	-1	24126708
ated.	O	-1	24126708
Patients	O	-1	24126708
were	O	-1	24126708
gen@@	O	-1	24126708
ot@@	O	-1	24126708
yp@@	O	-1	24126708
ed	O	-1	24126708
for	O	-1	24126708
r@@	O	-1	24126708
s@@	O	-1	24126708
4@@	O	-1	24126708
7@@	O	-1	24126708
0@@	O	-1	24126708
4@@	O	-1	24126708
55@@	O	-1	24126708
9@@	O	-1	24126708
,	O	-1	24126708
r@@	O	-1	24126708
s@@	O	-1	24126708
10@@	O	-1	24126708
9@@	O	-1	24126708
4@@	O	-1	24126708
2@@	O	-1	24126708
8@@	O	-1	24126708
9@@	O	-1	24126708
1	O	-1	24126708
and	O	-1	24126708
r@@	O	-1	24126708
s@@	O	-1	24126708
4@@	O	-1	24126708
7@@	O	-1	24126708
0@@	O	-1	24126708
4@@	O	-1	24126708
5@@	O	-1	24126708
60	O	-1	24126708
by	O	-1	24126708
al@@	O	-1	24126708
le@@	O	-1	24126708
l@@	O	-1	24126708
ic	O	-1	24126708
dis@@	O	-1	24126708
cri@@	O	-1	24126708
min@@	O	-1	24126708
ation	O	-1	24126708
with	O	-1	24126708
T@@	O	-1	24126708
a@@	O	-1	24126708
q@@	O	-1	24126708
man	O	-1	24126708
ass@@	O	-1	24126708
ay@@	O	-1	24126708
s.	O	-1	24126708
The	O	-1	24126708
r@@	O	-1	24126708
s@@	O	-1	24126708
4@@	O	-1	24126708
7@@	O	-1	24126708
0@@	O	-1	24126708
4@@	O	-1	24126708
55@@	O	-1	24126708
9	O	-1	24126708
G	O	-1	24126708
al@@	O	-1	24126708
le@@	O	-1	24126708
le	O	-1	24126708
was	O	-1	24126708
associated	O	-1	24126708
with	O	-1	24126708
a	O	-1	24126708
lower	O	-1	24126708
prev@@	O	-1	24126708
al@@	O	-1	24126708
ence	O	-1	24126708
of	O	-1	24126708
dyskine@@	B-Disease	D004409	24126708
sia	I-Disease	-1	24126708
(@@	O	-1	24126708
prev@@	O	-1	24126708
al@@	O	-1	24126708
ence	O	-1	24126708
rati@@	O	-1	24126708
o	O	-1	24126708
(P@@	O	-1	24126708
R@@	O	-1	24126708
)@@	O	-1	24126708
=@@	O	-1	24126708
0.@@	O	-1	24126708
6@@	O	-1	24126708
1@@	O	-1	24126708
5,	O	-1	24126708
95%	O	-1	24126708
conf@@	O	-1	24126708
idence	O	-1	24126708
interv@@	O	-1	24126708
al	O	-1	24126708
(C@@	O	-1	24126708
I@@	O	-1	24126708
)	O	-1	24126708
0.@@	O	-1	24126708
4@@	O	-1	24126708
2@@	O	-1	24126708
6-@@	O	-1	24126708
0.@@	O	-1	24126708
8@@	O	-1	24126708
8@@	O	-1	24126708
7@@	O	-1	24126708
,	O	-1	24126708
P@@	O	-1	24126708
=@@	O	-1	24126708
0.00@@	O	-1	24126708
9@@	O	-1	24126708
)	O	-1	24126708
and	O	-1	24126708
visual	B-Disease	D006212	24126708
h@@	I-Disease	-1	24126708
all@@	I-Disease	-1	24126708
uc@@	I-Disease	-1	24126708
in@@	I-Disease	-1	24126708
ations	I-Disease	-1	24126708
(P@@	O	-1	24126708
R@@	O	-1	24126708
=@@	O	-1	24126708
0.@@	O	-1	24126708
5@@	O	-1	24126708
1@@	O	-1	24126708
5,	O	-1	24126708
95%	O	-1	24126708
C@@	O	-1	24126708
I	O	-1	24126708
0.@@	O	-1	24126708
2@@	O	-1	24126708
9@@	O	-1	24126708
5-@@	O	-1	24126708
0.@@	O	-1	24126708
8@@	O	-1	24126708
9@@	O	-1	24126708
9@@	O	-1	24126708
,	O	-1	24126708
P@@	O	-1	24126708
=@@	O	-1	24126708
0.0@@	O	-1	24126708
20@@	O	-1	24126708
).	O	-1	24126708
Our	O	-1	24126708
data	O	-1	24126708
suggest	O	-1	24126708
that	O	-1	24126708
HO@@	O	-1	24126708
M@@	O	-1	24126708
E@@	O	-1	24126708
R@@	O	-1	24126708
1	O	-1	24126708
r@@	O	-1	24126708
s@@	O	-1	24126708
4@@	O	-1	24126708
7@@	O	-1	24126708
0@@	O	-1	24126708
4@@	O	-1	24126708
55@@	O	-1	24126708
9	O	-1	24126708
G	O	-1	24126708
al@@	O	-1	24126708
le@@	O	-1	24126708
le	O	-1	24126708
has	O	-1	24126708
a	O	-1	24126708
protective	O	-1	24126708
role	O	-1	24126708
for	O	-1	24126708
the	O	-1	24126708
development	O	-1	24126708
of	O	-1	24126708
levo@@	B-Chemical	D007980	24126708
dopa	I-Chemical	-1	24126708
adverse	O	-1	24126708
effects.	O	-1	24126708

C@@	B-Chemical	C029036	24132704
ro@@	I-Chemical	-1	24132704
c@@	I-Chemical	-1	24132704
in	I-Chemical	-1	24132704
impro@@	O	-1	24132704
v@@	O	-1	24132704
es	O	-1	24132704
li@@	O	-1	24132704
pid	O	-1	24132704
dys@@	O	-1	24132704
reg@@	O	-1	24132704
ulation	O	-1	24132704
in	O	-1	24132704
sub@@	O	-1	24132704
acute	O	-1	24132704
di@@	B-Chemical	D003976	24132704
az@@	I-Chemical	-1	24132704
in@@	I-Chemical	-1	24132704
on	I-Chemical	-1	24132704
exposure	O	-1	24132704
through	O	-1	24132704
E@@	O	-1	24132704
R@@	O	-1	24132704
K@@	O	-1	24132704
1@@	O	-1	24132704
/@@	O	-1	24132704
2	O	-1	24132704
path@@	O	-1	24132704
w@@	O	-1	24132704
ay	O	-1	24132704
in	O	-1	24132704
rat	O	-1	24132704
li@@	O	-1	24132704
ver@@	O	-1	24132704
.	O	-1	24132704
IN@@	O	-1	24132704
T@@	O	-1	24132704
RO@@	O	-1	24132704
D@@	O	-1	24132704
U@@	O	-1	24132704
C@@	O	-1	24132704
T@@	O	-1	24132704
ION@@	O	-1	24132704
:	O	-1	24132704
Di@@	B-Chemical	D003976	24132704
az@@	I-Chemical	-1	24132704
in@@	I-Chemical	-1	24132704
on	I-Chemical	-1	24132704
Y@@	O	-1	24132704
is	O	-1	24132704
one	O	-1	24132704
of	O	-1	24132704
the	O	-1	24132704
most	O	-1	24132704
b@@	O	-1	24132704
ro@@	O	-1	24132704
ad@@	O	-1	24132704
ly	O	-1	24132704
used	O	-1	24132704
org@@	B-Chemical	D010755	24132704
an@@	I-Chemical	-1	24132704
oph@@	I-Chemical	-1	24132704
osph@@	I-Chemical	-1	24132704
or@@	I-Chemical	-1	24132704
us	I-Chemical	-1	24132704
in@@	O	-1	24132704
sec@@	O	-1	24132704
tic@@	O	-1	24132704
i@@	O	-1	24132704
des	O	-1	24132704
in	O	-1	24132704
ag@@	O	-1	24132704
r@@	O	-1	24132704
ic@@	O	-1	24132704
ult@@	O	-1	24132704
ure.	O	-1	24132704
It	O	-1	24132704
has	O	-1	24132704
been	O	-1	24132704
shown	O	-1	24132704
that	O	-1	24132704
exposure	O	-1	24132704
to	O	-1	24132704
di@@	B-Chemical	D003976	24132704
az@@	I-Chemical	-1	24132704
in@@	I-Chemical	-1	24132704
on	I-Chemical	-1	24132704
may	O	-1	24132704
inter@@	O	-1	24132704
f@@	O	-1	24132704
ere	O	-1	24132704
with	O	-1	24132704
li@@	O	-1	24132704
pid	O	-1	24132704
metabol@@	O	-1	24132704
is@@	O	-1	24132704
m.	O	-1	24132704
M@@	O	-1	24132704
ore@@	O	-1	24132704
o@@	O	-1	24132704
ver,	O	-1	24132704
the	O	-1	24132704
hy@@	O	-1	24132704
pol@@	O	-1	24132704
i@@	O	-1	24132704
pi@@	O	-1	24132704
de@@	O	-1	24132704
mic	O	-1	24132704
effect	O	-1	24132704
of	O	-1	24132704
c@@	B-Chemical	C029036	24132704
ro@@	I-Chemical	-1	24132704
c@@	I-Chemical	-1	24132704
in	I-Chemical	-1	24132704
has	O	-1	24132704
been	O	-1	24132704
est@@	O	-1	24132704
abl@@	O	-1	24132704
is@@	O	-1	24132704
he@@	O	-1	24132704
d.	O	-1	24132704
E@@	O	-1	24132704
ar@@	O	-1	24132704
li@@	O	-1	24132704
er	O	-1	24132704
studies	O	-1	24132704
revealed	O	-1	24132704
the	O	-1	24132704
major	O	-1	24132704
role	O	-1	24132704
of	O	-1	24132704
E@@	O	-1	24132704
x@@	O	-1	24132704
trac@@	O	-1	24132704
ell@@	O	-1	24132704
ular	O	-1	24132704
sign@@	O	-1	24132704
al@@	O	-1	24132704
-@@	O	-1	24132704
reg@@	O	-1	24132704
ul@@	O	-1	24132704
ated	O	-1	24132704
kin@@	O	-1	24132704
ase	O	-1	24132704
(@@	O	-1	24132704
E@@	O	-1	24132704
R@@	O	-1	24132704
K@@	O	-1	24132704
)	O	-1	24132704
path@@	O	-1	24132704
w@@	O	-1	24132704
ays	O	-1	24132704
in	O	-1	24132704
low@@	O	-1	24132704
-@@	O	-1	24132704
d@@	O	-1	24132704
ensity	O	-1	24132704
li@@	O	-1	24132704
po@@	O	-1	24132704
protein	O	-1	24132704
receptor	O	-1	24132704
(@@	O	-1	24132704
L@@	O	-1	24132704
D@@	O	-1	24132704
L@@	O	-1	24132704
r@@	O	-1	24132704
)	O	-1	24132704
ex@@	O	-1	24132704
pres@@	O	-1	24132704
sion.	O	-1	24132704
The	O	-1	24132704
a@@	O	-1	24132704
im	O	-1	24132704
of	O	-1	24132704
this	O	-1	24132704
study	O	-1	24132704
was	O	-1	24132704
to	O	-1	24132704
evalu@@	O	-1	24132704
ate	O	-1	24132704
changes	O	-1	24132704
in	O	-1	24132704
the	O	-1	24132704
reg@@	O	-1	24132704
ulation	O	-1	24132704
of	O	-1	24132704
li@@	O	-1	24132704
pid	O	-1	24132704
metabol@@	O	-1	24132704
is@@	O	-1	24132704
m@@	O	-1	24132704
,	O	-1	24132704
E@@	O	-1	24132704
R@@	O	-1	24132704
K	O	-1	24132704
and	O	-1	24132704
L@@	O	-1	24132704
D@@	O	-1	24132704
L@@	O	-1	24132704
r	O	-1	24132704
expression	O	-1	24132704
in	O	-1	24132704
the	O	-1	24132704
liver	O	-1	24132704
of	O	-1	24132704
rats	O	-1	24132704
exposed	O	-1	24132704
to	O	-1	24132704
sub@@	O	-1	24132704
acute	O	-1	24132704
di@@	B-Chemical	D003976	24132704
az@@	I-Chemical	-1	24132704
in@@	I-Chemical	-1	24132704
on	I-Chemical	-1	24132704
.	O	-1	24132704
F@@	O	-1	24132704
ur@@	O	-1	24132704
ther@@	O	-1	24132704
more	O	-1	24132704
ame@@	O	-1	24132704
li@@	O	-1	24132704
or@@	O	-1	24132704
ating	O	-1	24132704
effect	O	-1	24132704
of	O	-1	24132704
c@@	B-Chemical	C029036	24132704
ro@@	I-Chemical	-1	24132704
c@@	I-Chemical	-1	24132704
in	I-Chemical	-1	24132704
on	O	-1	24132704
di@@	B-Chemical	D003976	24132704
az@@	I-Chemical	-1	24132704
in@@	I-Chemical	-1	24132704
on	I-Chemical	-1	24132704
induced	O	-1	24132704
dist@@	O	-1	24132704
ur@@	O	-1	24132704
bed	O	-1	24132704
cholester@@	B-Chemical	D002784	24132704
ol	I-Chemical	-1	24132704
ho@@	O	-1	24132704
me@@	O	-1	24132704
ost@@	O	-1	24132704
asis	O	-1	24132704
was	O	-1	24132704
studi@@	O	-1	24132704
ed.	O	-1	24132704
METHODS:	O	-1	24132704
24	O	-1	24132704
R@@	O	-1	24132704
at@@	O	-1	24132704
s	O	-1	24132704
were	O	-1	24132704
divid@@	O	-1	24132704
ed	O	-1	24132704
into	O	-1	24132704
4	O	-1	24132704
groups	O	-1	24132704
and	O	-1	24132704
received	O	-1	24132704
following	O	-1	24132704
treat@@	O	-1	24132704
ments	O	-1	24132704
for	O	-1	24132704
4	O	-1	24132704
week@@	O	-1	24132704
s;	O	-1	24132704
C@@	O	-1	24132704
or@@	O	-1	24132704
n	O	-1	24132704
o@@	O	-1	24132704
il	O	-1	24132704
(@@	O	-1	24132704
control@@	O	-1	24132704
),	O	-1	24132704
di@@	B-Chemical	D003976	24132704
az@@	I-Chemical	-1	24132704
in@@	I-Chemical	-1	24132704
on	I-Chemical	-1	24132704
(1@@	O	-1	24132704
5@@	O	-1	24132704
mg/kg	O	-1	24132704
per	O	-1	24132704
da@@	O	-1	24132704
y,	O	-1	24132704
or@@	O	-1	24132704
all@@	O	-1	24132704
y@@	O	-1	24132704
)	O	-1	24132704
and	O	-1	24132704
c@@	B-Chemical	C029036	24132704
ro@@	I-Chemical	-1	24132704
c@@	I-Chemical	-1	24132704
in	I-Chemical	-1	24132704
(1@@	O	-1	24132704
2.@@	O	-1	24132704
5	O	-1	24132704
and	O	-1	24132704
25@@	O	-1	24132704
mg/kg	O	-1	24132704
per	O	-1	24132704
da@@	O	-1	24132704
y,	O	-1	24132704
intra@@	O	-1	24132704
per@@	O	-1	24132704
it@@	O	-1	24132704
one@@	O	-1	24132704
all@@	O	-1	24132704
y@@	O	-1	24132704
)	O	-1	24132704
in	O	-1	24132704
combination	O	-1	24132704
with	O	-1	24132704
di@@	B-Chemical	D003976	24132704
az@@	I-Chemical	-1	24132704
in@@	I-Chemical	-1	24132704
on	I-Chemical	-1	24132704
(1@@	O	-1	24132704
5	O	-1	24132704
mg/kg@@	O	-1	24132704
).	O	-1	24132704
The	O	-1	24132704
levels	O	-1	24132704
of	O	-1	24132704
cholester@@	B-Chemical	D002784	24132704
ol	I-Chemical	-1	24132704
,	O	-1	24132704
tri@@	B-Chemical	D014280	24132704
glycer@@	I-Chemical	-1	24132704
ide	I-Chemical	-1	24132704
and	O	-1	24132704
L@@	O	-1	24132704
D@@	O	-1	24132704
L	O	-1	24132704
in	O	-1	24132704
blood	O	-1	24132704
of	O	-1	24132704
rats	O	-1	24132704
were	O	-1	24132704
analy@@	O	-1	24132704
z@@	O	-1	24132704
ed.	O	-1	24132704
M@@	O	-1	24132704
ore@@	O	-1	24132704
over	O	-1	24132704
mRNA	O	-1	24132704
levels	O	-1	24132704
of	O	-1	24132704
L@@	O	-1	24132704
D@@	O	-1	24132704
L@@	O	-1	24132704
r	O	-1	24132704
and	O	-1	24132704
E@@	O	-1	24132704
R@@	O	-1	24132704
K@@	O	-1	24132704
1@@	O	-1	24132704
/@@	O	-1	24132704
2	O	-1	24132704
as	O	-1	24132704
well	O	-1	24132704
as	O	-1	24132704
protein	O	-1	24132704
levels	O	-1	24132704
of	O	-1	24132704
total	O	-1	24132704
and	O	-1	24132704
activ@@	O	-1	24132704
ated	O	-1	24132704
form@@	O	-1	24132704
s	O	-1	24132704
of	O	-1	24132704
E@@	O	-1	24132704
R@@	O	-1	24132704
K@@	O	-1	24132704
1@@	O	-1	24132704
/@@	O	-1	24132704
2	O	-1	24132704
in	O	-1	24132704
rat	O	-1	24132704
liver	O	-1	24132704
were	O	-1	24132704
evaluated	O	-1	24132704
by	O	-1	24132704
W@@	O	-1	24132704
est@@	O	-1	24132704
er@@	O	-1	24132704
n	O	-1	24132704
blo@@	O	-1	24132704
t@@	O	-1	24132704
ting	O	-1	24132704
and	O	-1	24132704
qu@@	O	-1	24132704
anti@@	O	-1	24132704
t@@	O	-1	24132704
ative	O	-1	24132704
re@@	O	-1	24132704
al	O	-1	24132704
time	O	-1	24132704
poly@@	O	-1	24132704
mer@@	O	-1	24132704
ase	O	-1	24132704
ch@@	O	-1	24132704
ain	O	-1	24132704
reaction	O	-1	24132704
analy@@	O	-1	24132704
sis.	O	-1	24132704
RESULTS:	O	-1	24132704
Our	O	-1	24132704
data	O	-1	24132704
showed	O	-1	24132704
that	O	-1	24132704
sub@@	O	-1	24132704
acute	O	-1	24132704
exposure	O	-1	24132704
to	O	-1	24132704
di@@	B-Chemical	D003976	24132704
az@@	I-Chemical	-1	24132704
in@@	I-Chemical	-1	24132704
on	I-Chemical	-1	24132704
significantly	O	-1	24132704
increased	O	-1	24132704
concentrations	O	-1	24132704
of	O	-1	24132704
cholester@@	B-Chemical	D002784	24132704
ol	I-Chemical	-1	24132704
,	O	-1	24132704
tri@@	B-Chemical	D014280	24132704
glycer@@	I-Chemical	-1	24132704
ide	I-Chemical	-1	24132704
and	O	-1	24132704
L@@	O	-1	24132704
D@@	O	-1	24132704
L@@	O	-1	24132704
.	O	-1	24132704
M@@	O	-1	24132704
ore@@	O	-1	24132704
over	O	-1	24132704
di@@	B-Chemical	D003976	24132704
az@@	I-Chemical	-1	24132704
in@@	I-Chemical	-1	24132704
on	I-Chemical	-1	24132704
decreased	O	-1	24132704
E@@	O	-1	24132704
R@@	O	-1	24132704
K@@	O	-1	24132704
1@@	O	-1	24132704
/@@	O	-1	24132704
2	O	-1	24132704
protein	O	-1	24132704
phosph@@	O	-1	24132704
or@@	O	-1	24132704
yl@@	O	-1	24132704
ation	O	-1	24132704
and	O	-1	24132704
L@@	O	-1	24132704
D@@	O	-1	24132704
L@@	O	-1	24132704
r	O	-1	24132704
trans@@	O	-1	24132704
cri@@	O	-1	24132704
pt@@	O	-1	24132704
.	O	-1	24132704
C@@	B-Chemical	C029036	24132704
ro@@	I-Chemical	-1	24132704
c@@	I-Chemical	-1	24132704
in	I-Chemical	-1	24132704
reduced	O	-1	24132704
inhibition	O	-1	24132704
of	O	-1	24132704
E@@	O	-1	24132704
R@@	O	-1	24132704
K	O	-1	24132704
activation	O	-1	24132704
and	O	-1	24132704
di@@	B-Chemical	D003976	24132704
az@@	I-Chemical	-1	24132704
in@@	I-Chemical	-1	24132704
on	I-Chemical	-1	24132704
-induced	O	-1	24132704
hyper@@	B-Disease	D006949	24132704
li@@	I-Disease	-1	24132704
p@@	I-Disease	-1	24132704
emia	I-Disease	-1	24132704
and	O	-1	24132704
increased	O	-1	24132704
levels	O	-1	24132704
of	O	-1	24132704
L@@	O	-1	24132704
D@@	O	-1	24132704
L@@	O	-1	24132704
r	O	-1	24132704
trans@@	O	-1	24132704
cri@@	O	-1	24132704
pt@@	O	-1	24132704
.	O	-1	24132704
CONCLUSIONS:	O	-1	24132704
C@@	B-Chemical	C029036	24132704
ro@@	I-Chemical	-1	24132704
c@@	I-Chemical	-1	24132704
in	I-Chemical	-1	24132704
may	O	-1	24132704
be	O	-1	24132704
considered	O	-1	24132704
as	O	-1	24132704
a	O	-1	24132704
novel	O	-1	24132704
protective	O	-1	24132704
agent	O	-1	24132704
in	O	-1	24132704
di@@	B-Chemical	D003976	24132704
az@@	I-Chemical	-1	24132704
in@@	I-Chemical	-1	24132704
on	I-Chemical	-1	24132704
-induced	O	-1	24132704
hyper@@	B-Disease	D006949	24132704
li@@	I-Disease	-1	24132704
p@@	I-Disease	-1	24132704
emia	I-Disease	-1	24132704
through	O	-1	24132704
mod@@	O	-1	24132704
ul@@	O	-1	24132704
ating	O	-1	24132704
of	O	-1	24132704
E@@	O	-1	24132704
R@@	O	-1	24132704
K	O	-1	24132704
path@@	O	-1	24132704
w@@	O	-1	24132704
ay	O	-1	24132704
and	O	-1	24132704
increase	O	-1	24132704
of	O	-1	24132704
L@@	O	-1	24132704
D@@	O	-1	24132704
L@@	O	-1	24132704
r	O	-1	24132704
ex@@	O	-1	24132704
pres@@	O	-1	24132704
sion.	O	-1	24132704

G@@	B-Chemical	C056507	24158386
E@@	I-Chemical	-1	24158386
M	I-Chemical	-1	24158386
-@@	O	-1	24158386
P	O	-1	24158386
chemotherapy	O	-1	24158386
is	O	-1	24158386
active	O	-1	24158386
in	O	-1	24158386
the	O	-1	24158386
treatment	O	-1	24158386
of	O	-1	24158386
rel@@	O	-1	24158386
ap@@	O	-1	24158386
sed	O	-1	24158386
Ho@@	B-Disease	D006689	24158386
d@@	I-Disease	-1	24158386
g@@	I-Disease	-1	24158386
k@@	I-Disease	-1	24158386
in	I-Disease	-1	24158386
lymph@@	I-Disease	-1	24158386
oma	I-Disease	-1	24158386
.	O	-1	24158386
Ho@@	B-Disease	D006689	24158386
d@@	I-Disease	-1	24158386
g@@	I-Disease	-1	24158386
k@@	I-Disease	-1	24158386
in	I-Disease	-1	24158386
lymph@@	I-Disease	-1	24158386
oma	I-Disease	-1	24158386
(	O	-1	24158386
H@@	B-Disease	D006689	24158386
L	I-Disease	-1	24158386
)	O	-1	24158386
is	O	-1	24158386
a	O	-1	24158386
rel@@	O	-1	24158386
atively	O	-1	24158386
chem@@	O	-1	24158386
os@@	O	-1	24158386
en@@	O	-1	24158386
si@@	O	-1	24158386
tive	O	-1	24158386
mal@@	B-Disease	D009369	24158386
i@@	I-Disease	-1	24158386
gn@@	I-Disease	-1	24158386
anc@@	I-Disease	-1	24158386
y	I-Disease	-1	24158386
.	O	-1	24158386
However,	O	-1	24158386
for	O	-1	24158386
those	O	-1	24158386
who	O	-1	24158386
rel@@	O	-1	24158386
ap@@	O	-1	24158386
se@@	O	-1	24158386
,	O	-1	24158386
high-dose	O	-1	24158386
chemotherapy	O	-1	24158386
with	O	-1	24158386
auto@@	O	-1	24158386
log@@	O	-1	24158386
ous	O	-1	24158386
st@@	O	-1	24158386
em	O	-1	24158386
cell	O	-1	24158386
transplant	O	-1	24158386
is	O	-1	24158386
the	O	-1	24158386
treatment	O	-1	24158386
of	O	-1	24158386
ch@@	O	-1	24158386
o@@	O	-1	24158386
ic@@	O	-1	24158386
e	O	-1	24158386
which	O	-1	24158386
re@@	O	-1	24158386
li@@	O	-1	24158386
es	O	-1	24158386
on	O	-1	24158386
ade@@	O	-1	24158386
qu@@	O	-1	24158386
ate	O	-1	24158386
disease	O	-1	24158386
control	O	-1	24158386
with	O	-1	24158386
sal@@	O	-1	24158386
v@@	O	-1	24158386
age	O	-1	24158386
chemo@@	O	-1	24158386
therapy.	O	-1	24158386
Re@@	O	-1	24158386
g@@	O	-1	24158386
imen@@	O	-1	24158386
s	O	-1	24158386
common@@	O	-1	24158386
ly	O	-1	24158386
used	O	-1	24158386
often	O	-1	24158386
requ@@	O	-1	24158386
ir@@	O	-1	24158386
e	O	-1	24158386
in@@	O	-1	24158386
patient	O	-1	24158386
administration	O	-1	24158386
and	O	-1	24158386
can	O	-1	24158386
be	O	-1	24158386
diff@@	O	-1	24158386
ic@@	O	-1	24158386
ult	O	-1	24158386
to	O	-1	24158386
de@@	O	-1	24158386
liver	O	-1	24158386
due	O	-1	24158386
to	O	-1	24158386
toxicity	B-Disease	D064420	24158386
.	O	-1	24158386
G@@	B-Chemical	C056507	24158386
em@@	I-Chemical	-1	24158386
cit@@	I-Chemical	-1	24158386
ab@@	I-Chemical	-1	24158386
ine	I-Chemical	-1	24158386
and	O	-1	24158386
cisplatin	B-Chemical	D002945	24158386
have	O	-1	24158386
activity	O	-1	24158386
in	O	-1	24158386
H@@	B-Disease	D006689	24158386
L	I-Disease	-1	24158386
,	O	-1	24158386
non-@@	O	-1	24158386
over@@	O	-1	24158386
l@@	O	-1	24158386
app@@	O	-1	24158386
ing	O	-1	24158386
toxicity	B-Disease	D064420	24158386
with	O	-1	24158386
fir@@	O	-1	24158386
st@@	O	-1	24158386
-@@	O	-1	24158386
line	O	-1	24158386
chemo@@	O	-1	24158386
therapeu@@	O	-1	24158386
tic@@	O	-1	24158386
s,	O	-1	24158386
and	O	-1	24158386
may	O	-1	24158386
be	O	-1	24158386
de@@	O	-1	24158386
li@@	O	-1	24158386
vered	O	-1	24158386
in	O	-1	24158386
an	O	-1	24158386
out@@	O	-1	24158386
patient	O	-1	24158386
se@@	O	-1	24158386
t@@	O	-1	24158386
t@@	O	-1	24158386
ing.	O	-1	24158386
In	O	-1	24158386
this	O	-1	24158386
ret@@	O	-1	24158386
ro@@	O	-1	24158386
sp@@	O	-1	24158386
ective	O	-1	24158386
sing@@	O	-1	24158386
le@@	O	-1	24158386
-@@	O	-1	24158386
centr@@	O	-1	24158386
e	O	-1	24158386
analy@@	O	-1	24158386
sis,	O	-1	24158386
patients	O	-1	24158386
with	O	-1	24158386
rel@@	O	-1	24158386
ap@@	O	-1	24158386
sed	O	-1	24158386
or	O	-1	24158386
ref@@	O	-1	24158386
rac@@	O	-1	24158386
t@@	O	-1	24158386
ory	O	-1	24158386
H@@	B-Disease	D006689	24158386
L	I-Disease	-1	24158386
treated	O	-1	24158386
with	O	-1	24158386
g@@	B-Chemical	C056507	24158386
em@@	I-Chemical	-1	24158386
cit@@	I-Chemical	-1	24158386
ab@@	I-Chemical	-1	24158386
ine	I-Chemical	-1	24158386
1@@	O	-1	24158386
,@@	O	-1	24158386
0@@	O	-1	24158386
00	O	-1	24158386
mg/m@@	O	-1	24158386
(2@@	O	-1	24158386
)	O	-1	24158386
day	O	-1	24158386
(D@@	O	-1	24158386
)@@	O	-1	24158386
1,	O	-1	24158386
D@@	O	-1	24158386
8	O	-1	24158386
and	O	-1	24158386
D@@	O	-1	24158386
1@@	O	-1	24158386
5@@	O	-1	24158386
;	O	-1	24158386
methyl@@	B-Chemical	D008775	24158386
pre@@	I-Chemical	-1	24158386
d@@	I-Chemical	-1	24158386
n@@	I-Chemical	-1	24158386
isol@@	I-Chemical	-1	24158386
one	I-Chemical	-1	24158386
1@@	O	-1	24158386
,@@	O	-1	24158386
0@@	O	-1	24158386
00	O	-1	24158386
mg	O	-1	24158386
D@@	O	-1	24158386
1-@@	O	-1	24158386
5@@	O	-1	24158386
;	O	-1	24158386
and	O	-1	24158386
cisplatin	B-Chemical	D002945	24158386
100	O	-1	24158386
mg/m@@	O	-1	24158386
(2@@	O	-1	24158386
)	O	-1	24158386
D@@	O	-1	24158386
1@@	O	-1	24158386
5,	O	-1	24158386
every	O	-1	24158386
2@@	O	-1	24158386
8	O	-1	24158386
days	O	-1	24158386
(	O	-1	24158386
G@@	B-Chemical	C056507	24158386
E@@	I-Chemical	-1	24158386
M	I-Chemical	-1	24158386
-@@	O	-1	24158386
P)	O	-1	24158386
were	O	-1	24158386
inc@@	O	-1	24158386
lu@@	O	-1	24158386
de@@	O	-1	24158386
d.	O	-1	24158386
D@@	O	-1	24158386
em@@	O	-1	24158386
ograph@@	O	-1	24158386
ic@@	O	-1	24158386
,	O	-1	24158386
sur@@	O	-1	24158386
vi@@	O	-1	24158386
val@@	O	-1	24158386
,	O	-1	24158386
response	O	-1	24158386
and	O	-1	24158386
toxicity	B-Disease	D064420	24158386
data	O	-1	24158386
were	O	-1	24158386
recor@@	O	-1	24158386
de@@	O	-1	24158386
d.	O	-1	24158386
F@@	O	-1	24158386
or@@	O	-1	24158386
ty-@@	O	-1	24158386
one	O	-1	24158386
e@@	O	-1	24158386
li@@	O	-1	24158386
gi@@	O	-1	24158386
ble	O	-1	24158386
patients	O	-1	24158386
were	O	-1	24158386
identi@@	O	-1	24158386
fi@@	O	-1	24158386
ed@@	O	-1	24158386
:	O	-1	24158386
median	O	-1	24158386
age	O	-1	24158386
27@@	O	-1	24158386
.	O	-1	24158386
One	O	-1	24158386
h@@	O	-1	24158386
und@@	O	-1	24158386
red	O	-1	24158386
and	O	-1	24158386
tw@@	O	-1	24158386
ent@@	O	-1	24158386
y-@@	O	-1	24158386
two	O	-1	24158386
cyc@@	O	-1	24158386
le@@	O	-1	24158386
s	O	-1	24158386
of	O	-1	24158386
G@@	B-Chemical	C056507	24158386
E@@	I-Chemical	-1	24158386
M	I-Chemical	-1	24158386
-@@	O	-1	24158386
P	O	-1	24158386
were	O	-1	24158386
administered	O	-1	24158386
in	O	-1	24158386
total	O	-1	24158386
(@@	O	-1	24158386
median	O	-1	24158386
3	O	-1	24158386
cy@@	O	-1	24158386
cl@@	O	-1	24158386
es@@	O	-1	24158386
;	O	-1	24158386
range	O	-1	24158386
1-@@	O	-1	24158386
6@@	O	-1	24158386
).	O	-1	24158386
Tw@@	O	-1	24158386
ent@@	O	-1	24158386
y	O	-1	24158386
of	O	-1	24158386
4@@	O	-1	24158386
1	O	-1	24158386
(4@@	O	-1	24158386
8	O	-1	24158386
%)	O	-1	24158386
patients	O	-1	24158386
received	O	-1	24158386
G@@	B-Chemical	C056507	24158386
E@@	I-Chemical	-1	24158386
M	I-Chemical	-1	24158386
-@@	O	-1	24158386
P	O	-1	24158386
as	O	-1	24158386
secon@@	O	-1	24158386
d-@@	O	-1	24158386
line	O	-1	24158386
treatment	O	-1	24158386
and	O	-1	24158386
1@@	O	-1	24158386
1@@	O	-1	24158386
/@@	O	-1	24158386
4@@	O	-1	24158386
1	O	-1	24158386
(2@@	O	-1	24158386
7	O	-1	24158386
%)	O	-1	24158386
as	O	-1	24158386
thir@@	O	-1	24158386
d-@@	O	-1	24158386
line	O	-1	24158386
therapy.	O	-1	24158386
O@@	O	-1	24158386
ver@@	O	-1	24158386
all	O	-1	24158386
response	O	-1	24158386
rate	O	-1	24158386
(@@	O	-1	24158386
O@@	O	-1	24158386
R@@	O	-1	24158386
R@@	O	-1	24158386
)	O	-1	24158386
to	O	-1	24158386
G@@	B-Chemical	C056507	24158386
E@@	I-Chemical	-1	24158386
M	I-Chemical	-1	24158386
-@@	O	-1	24158386
P	O	-1	24158386
in	O	-1	24158386
the	O	-1	24158386
enti@@	O	-1	24158386
r@@	O	-1	24158386
e	O	-1	24158386
co@@	O	-1	24158386
h@@	O	-1	24158386
ort	O	-1	24158386
was	O	-1	24158386
8@@	O	-1	24158386
0	O	-1	24158386
%	O	-1	24158386
(@@	O	-1	24158386
complete	O	-1	24158386
response	O	-1	24158386
(C@@	O	-1	24158386
R@@	O	-1	24158386
)	O	-1	24158386
3@@	O	-1	24158386
7	O	-1	24158386
%,	O	-1	24158386
partial	O	-1	24158386
response	O	-1	24158386
4@@	O	-1	24158386
4	O	-1	24158386
%)	O	-1	24158386
with	O	-1	24158386
14@@	O	-1	24158386
/@@	O	-1	24158386
15	O	-1	24158386
C@@	O	-1	24158386
R	O	-1	24158386
con@@	O	-1	24158386
fir@@	O	-1	24158386
m@@	O	-1	24158386
ed	O	-1	24158386
as	O	-1	24158386
a	O	-1	24158386
met@@	O	-1	24158386
ab@@	O	-1	24158386
olic	O	-1	24158386
C@@	O	-1	24158386
R	O	-1	24158386
on	O	-1	24158386
P@@	O	-1	24158386
E@@	O	-1	24158386
T	O	-1	24158386
and	O	-1	24158386
O@@	O	-1	24158386
R@@	O	-1	24158386
R	O	-1	24158386
of	O	-1	24158386
8@@	O	-1	24158386
5	O	-1	24158386
%	O	-1	24158386
in	O	-1	24158386
the	O	-1	24158386
20	O	-1	24158386
secon@@	O	-1	24158386
d-@@	O	-1	24158386
line	O	-1	24158386
patients.	O	-1	24158386
The	O	-1	24158386
most	O	-1	24158386
common	O	-1	24158386
gra@@	O	-1	24158386
de	O	-1	24158386
3@@	O	-1	24158386
/@@	O	-1	24158386
4	O	-1	24158386
toxic@@	B-Disease	D064420	24158386
ities	I-Disease	-1	24158386
were	O	-1	24158386
haem@@	O	-1	24158386
at@@	O	-1	24158386
olog@@	O	-1	24158386
ic@@	O	-1	24158386
al@@	O	-1	24158386
:	O	-1	24158386
ne@@	B-Disease	D009503	24158386
ut@@	I-Disease	-1	24158386
ro@@	I-Disease	-1	24158386
pen@@	I-Disease	-1	24158386
ia	I-Disease	-1	24158386
5@@	O	-1	24158386
4	O	-1	24158386
%	O	-1	24158386
and	O	-1	24158386
throm@@	B-Disease	D013921	24158386
b@@	I-Disease	-1	24158386
ocyto@@	I-Disease	-1	24158386
pen@@	I-Disease	-1	24158386
ia	I-Disease	-1	24158386
5@@	O	-1	24158386
1	O	-1	24158386
%.	O	-1	24158386
M@@	O	-1	24158386
edi@@	O	-1	24158386
an	O	-1	24158386
follow-up	O	-1	24158386
from	O	-1	24158386
the	O	-1	24158386
star@@	O	-1	24158386
t	O	-1	24158386
of	O	-1	24158386
G@@	B-Chemical	C056507	24158386
E@@	I-Chemical	-1	24158386
M	I-Chemical	-1	24158386
-@@	O	-1	24158386
P	O	-1	24158386
was	O	-1	24158386
4.@@	O	-1	24158386
5	O	-1	24158386
year@@	O	-1	24158386
s.	O	-1	24158386
F@@	O	-1	24158386
ol@@	O	-1	24158386
low@@	O	-1	24158386
ing	O	-1	24158386
G@@	B-Chemical	C056507	24158386
E@@	I-Chemical	-1	24158386
M	I-Chemical	-1	24158386
-@@	O	-1	24158386
P@@	O	-1	24158386
,	O	-1	24158386
5-@@	O	-1	24158386
year	O	-1	24158386
progres@@	O	-1	24158386
sion@@	O	-1	24158386
-@@	O	-1	24158386
free	O	-1	24158386
sur@@	O	-1	24158386
viv@@	O	-1	24158386
al	O	-1	24158386
was	O	-1	24158386
4@@	O	-1	24158386
6	O	-1	24158386
%	O	-1	24158386
(@@	O	-1	24158386
9@@	O	-1	24158386
5	O	-1	24158386
%	O	-1	24158386
conf@@	O	-1	24158386
idence	O	-1	24158386
interv@@	O	-1	24158386
al	O	-1	24158386
(C@@	O	-1	24158386
I@@	O	-1	24158386
),	O	-1	24158386
3@@	O	-1	24158386
0-@@	O	-1	24158386
6@@	O	-1	24158386
2	O	-1	24158386
%)	O	-1	24158386
and	O	-1	24158386
5-@@	O	-1	24158386
year	O	-1	24158386
over@@	O	-1	24158386
all	O	-1	24158386
sur@@	O	-1	24158386
viv@@	O	-1	24158386
al	O	-1	24158386
was	O	-1	24158386
5@@	O	-1	24158386
9	O	-1	24158386
%	O	-1	24158386
(@@	O	-1	24158386
9@@	O	-1	24158386
5	O	-1	24158386
%	O	-1	24158386
CI@@	O	-1	24158386
,	O	-1	24158386
4@@	O	-1	24158386
3-@@	O	-1	24158386
7@@	O	-1	24158386
4	O	-1	24158386
%).	O	-1	24158386
F@@	O	-1	24158386
o@@	O	-1	24158386
ur@@	O	-1	24158386
te@@	O	-1	24158386
en	O	-1	24158386
of	O	-1	24158386
4@@	O	-1	24158386
1	O	-1	24158386
patients	O	-1	24158386
proce@@	O	-1	24158386
ed@@	O	-1	24158386
ed	O	-1	24158386
direc@@	O	-1	24158386
tly	O	-1	24158386
to	O	-1	24158386
auto@@	O	-1	24158386
log@@	O	-1	24158386
ous	O	-1	24158386
transplant@@	O	-1	24158386
.	O	-1	24158386
G@@	B-Chemical	C056507	24158386
E@@	I-Chemical	-1	24158386
M	I-Chemical	-1	24158386
-@@	O	-1	24158386
P	O	-1	24158386
is	O	-1	24158386
a	O	-1	24158386
sal@@	O	-1	24158386
v@@	O	-1	24158386
age	O	-1	24158386
chemotherapy	O	-1	24158386
with	O	-1	24158386
rel@@	O	-1	24158386
atively	O	-1	24158386
high	O	-1	24158386
response	O	-1	24158386
rat@@	O	-1	24158386
es,	O	-1	24158386
lead@@	O	-1	24158386
ing	O	-1	24158386
to	O	-1	24158386
suc@@	O	-1	24158386
cess@@	O	-1	24158386
ful	O	-1	24158386
transplant@@	O	-1	24158386
ation	O	-1	24158386
in	O	-1	24158386
appro@@	O	-1	24158386
pri@@	O	-1	24158386
ate	O	-1	24158386
patients,	O	-1	24158386
in	O	-1	24158386
the	O	-1	24158386
treatment	O	-1	24158386
of	O	-1	24158386
rel@@	O	-1	24158386
ap@@	O	-1	24158386
sed	O	-1	24158386
or	O	-1	24158386
ref@@	O	-1	24158386
rac@@	O	-1	24158386
t@@	O	-1	24158386
ory	O	-1	24158386
H@@	B-Disease	D006689	24158386
L	I-Disease	-1	24158386
.	O	-1	24158386

B@@	O	-1	24190587
as@@	O	-1	24190587
al	O	-1	24190587
func@@	O	-1	24190587
tion@@	O	-1	24190587
ing	O	-1	24190587
of	O	-1	24190587
the	O	-1	24190587
hypo@@	O	-1	24190587
thal@@	O	-1	24190587
am@@	O	-1	24190587
ic@@	O	-1	24190587
-@@	O	-1	24190587
pit@@	O	-1	24190587
u@@	O	-1	24190587
it@@	O	-1	24190587
ar@@	O	-1	24190587
y-@@	O	-1	24190587
ad@@	O	-1	24190587
renal	O	-1	24190587
(@@	O	-1	24190587
H@@	O	-1	24190587
PA@@	O	-1	24190587
)	O	-1	24190587
ax@@	O	-1	24190587
is	O	-1	24190587
and	O	-1	24190587
psych@@	O	-1	24190587
ological	O	-1	24190587
dist@@	O	-1	24190587
res@@	O	-1	24190587
s	O	-1	24190587
in	O	-1	24190587
rec@@	O	-1	24190587
re@@	O	-1	24190587
ation@@	O	-1	24190587
al	O	-1	24190587
ec@@	B-Chemical	D018817	24190587
st@@	I-Chemical	-1	24190587
as@@	I-Chemical	-1	24190587
y	I-Chemical	-1	24190587
poly@@	O	-1	24190587
drug	O	-1	24190587
us@@	O	-1	24190587
ers.	O	-1	24190587
R@@	O	-1	24190587
AT@@	O	-1	24190587
ION@@	O	-1	24190587
AL@@	O	-1	24190587
E:	O	-1	24190587
E@@	B-Chemical	D018817	24190587
c@@	I-Chemical	-1	24190587
st@@	I-Chemical	-1	24190587
as@@	I-Chemical	-1	24190587
y	I-Chemical	-1	24190587
(	O	-1	24190587
MD@@	B-Chemical	D018817	24190587
M@@	I-Chemical	-1	24190587
A	I-Chemical	-1	24190587
)	O	-1	24190587
is	O	-1	24190587
a	O	-1	24190587
psych@@	O	-1	24190587
os@@	O	-1	24190587
tim@@	O	-1	24190587
ul@@	O	-1	24190587
ant	O	-1	24190587
drug	O	-1	24190587
which	O	-1	24190587
is	O	-1	24190587
increas@@	O	-1	24190587
ing@@	O	-1	24190587
ly	O	-1	24190587
associated	O	-1	24190587
with	O	-1	24190587
psych@@	B-Disease	D008107	24190587
ob@@	I-Disease	-1	24190587
io@@	I-Disease	-1	24190587
log@@	I-Disease	-1	24190587
ical	I-Disease	-1	24190587
dysfunction	I-Disease	-1	24190587
.	O	-1	24190587
W@@	O	-1	24190587
h@@	O	-1	24190587
ile	O	-1	24190587
some	O	-1	24190587
rec@@	O	-1	24190587
ent	O	-1	24190587
studies	O	-1	24190587
suggest	O	-1	24190587
acute	O	-1	24190587
changes	O	-1	24190587
in	O	-1	24190587
neuro@@	O	-1	24190587
en@@	O	-1	24190587
doc@@	O	-1	24190587
rine	O	-1	24190587
func@@	O	-1	24190587
tion,	O	-1	24190587
less	O	-1	24190587
is	O	-1	24190587
known	O	-1	24190587
about	O	-1	24190587
long-term	O	-1	24190587
changes	O	-1	24190587
in	O	-1	24190587
H@@	O	-1	24190587
P@@	O	-1	24190587
A	O	-1	24190587
func@@	O	-1	24190587
tion@@	O	-1	24190587
ality	O	-1	24190587
in	O	-1	24190587
rec@@	O	-1	24190587
re@@	O	-1	24190587
ation@@	O	-1	24190587
al	O	-1	24190587
us@@	O	-1	24190587
ers.	O	-1	24190587
OBJECTIV@@	O	-1	24190587
E@@	O	-1	24190587
S:	O	-1	24190587
The	O	-1	24190587
current	O	-1	24190587
study	O	-1	24190587
is	O	-1	24190587
the	O	-1	24190587
first	O	-1	24190587
to	O	-1	24190587
expl@@	O	-1	24190587
or@@	O	-1	24190587
e	O	-1	24190587
the	O	-1	24190587
effects	O	-1	24190587
of	O	-1	24190587
ec@@	B-Chemical	D018817	24190587
st@@	I-Chemical	-1	24190587
as@@	I-Chemical	-1	24190587
y	I-Chemical	-1	24190587
-@@	O	-1	24190587
poly@@	O	-1	24190587
drug	O	-1	24190587
use	O	-1	24190587
on	O	-1	24190587
psych@@	O	-1	24190587
ological	O	-1	24190587
dist@@	O	-1	24190587
res@@	O	-1	24190587
s	O	-1	24190587
and	O	-1	24190587
bas@@	O	-1	24190587
al	O	-1	24190587
func@@	O	-1	24190587
tion@@	O	-1	24190587
ing	O	-1	24190587
of	O	-1	24190587
the	O	-1	24190587
H@@	O	-1	24190587
P@@	O	-1	24190587
A	O	-1	24190587
ax@@	O	-1	24190587
is	O	-1	24190587
through	O	-1	24190587
assess@@	O	-1	24190587
ing	O	-1	24190587
the	O	-1	24190587
secre@@	O	-1	24190587
tion	O	-1	24190587
of	O	-1	24190587
cor@@	B-Chemical	D006854	24190587
tis@@	I-Chemical	-1	24190587
ol	I-Chemical	-1	24190587
ac@@	O	-1	24190587
ros@@	O	-1	24190587
s	O	-1	24190587
the	O	-1	24190587
di@@	O	-1	24190587
ur@@	O	-1	24190587
n@@	O	-1	24190587
al	O	-1	24190587
perio@@	O	-1	24190587
d.	O	-1	24190587
METHOD@@	O	-1	24190587
:	O	-1	24190587
S@@	O	-1	24190587
event@@	O	-1	24190587
y-@@	O	-1	24190587
six	O	-1	24190587
partic@@	O	-1	24190587
ip@@	O	-1	24190587
ants	O	-1	24190587
(2@@	O	-1	24190587
1	O	-1	24190587
non@@	O	-1	24190587
us@@	O	-1	24190587
er@@	O	-1	24190587
s,	O	-1	24190587
2@@	O	-1	24190587
9	O	-1	24190587
li@@	O	-1	24190587
ght	O	-1	24190587
ec@@	B-Chemical	D018817	24190587
st@@	I-Chemical	-1	24190587
as@@	I-Chemical	-1	24190587
y	I-Chemical	-1	24190587
-@@	O	-1	24190587
poly@@	O	-1	24190587
drug	O	-1	24190587
us@@	O	-1	24190587
er@@	O	-1	24190587
s,	O	-1	24190587
2@@	O	-1	24190587
6	O	-1	24190587
he@@	O	-1	24190587
av@@	O	-1	24190587
y	O	-1	24190587
ec@@	B-Chemical	D018817	24190587
st@@	I-Chemical	-1	24190587
as@@	I-Chemical	-1	24190587
y	I-Chemical	-1	24190587
-@@	O	-1	24190587
poly@@	O	-1	24190587
drug	O	-1	24190587
us@@	O	-1	24190587
er@@	O	-1	24190587
s)	O	-1	24190587
comple@@	O	-1	24190587
ted	O	-1	24190587
a	O	-1	24190587
subst@@	O	-1	24190587
ance	O	-1	24190587
use	O	-1	24190587
inv@@	O	-1	24190587
ent@@	O	-1	24190587
ory	O	-1	24190587
and	O	-1	24190587
meas@@	O	-1	24190587
ures	O	-1	24190587
of	O	-1	24190587
psych@@	O	-1	24190587
ological	O	-1	24190587
dist@@	O	-1	24190587
res@@	O	-1	24190587
s	O	-1	24190587
at	O	-1	24190587
basel@@	O	-1	24190587
ine,	O	-1	24190587
then	O	-1	24190587
two	O	-1	24190587
con@@	O	-1	24190587
sec@@	O	-1	24190587
utive	O	-1	24190587
days	O	-1	24190587
of	O	-1	24190587
cor@@	B-Chemical	D006854	24190587
tis@@	I-Chemical	-1	24190587
ol	I-Chemical	-1	24190587
sam@@	O	-1	24190587
pl@@	O	-1	24190587
ing	O	-1	24190587
(@@	O	-1	24190587
on	O	-1	24190587
aw@@	O	-1	24190587
ak@@	O	-1	24190587
en@@	O	-1	24190587
ing,	O	-1	24190587
30	O	-1	24190587
min	O	-1	24190587
pos@@	O	-1	24190587
t	O	-1	24190587
aw@@	O	-1	24190587
ak@@	O	-1	24190587
en@@	O	-1	24190587
ing,	O	-1	24190587
between	O	-1	24190587
14@@	O	-1	24190587
00	O	-1	24190587
and	O	-1	24190587
1@@	O	-1	24190587
6@@	O	-1	24190587
00	O	-1	24190587
hours	O	-1	24190587
and	O	-1	24190587
pr@@	O	-1	24190587
e	O	-1	24190587
be@@	O	-1	24190587
d@@	O	-1	24190587
ti@@	O	-1	24190587
me@@	O	-1	24190587
).	O	-1	24190587
O@@	O	-1	24190587
n	O	-1	24190587
day	O	-1	24190587
2,	O	-1	24190587
partic@@	O	-1	24190587
ip@@	O	-1	24190587
ants	O	-1	24190587
also	O	-1	24190587
atten@@	O	-1	24190587
ded	O	-1	24190587
the	O	-1	24190587
labor@@	O	-1	24190587
atory	O	-1	24190587
to	O	-1	24190587
complete	O	-1	24190587
a	O	-1	24190587
20@@	O	-1	24190587
-@@	O	-1	24190587
min	O	-1	24190587
multi@@	O	-1	24190587
t@@	O	-1	24190587
as@@	O	-1	24190587
king	O	-1	24190587
stres@@	O	-1	24190587
s@@	O	-1	24190587
or@@	O	-1	24190587
.	O	-1	24190587
RESULTS:	O	-1	24190587
B@@	O	-1	24190587
oth	O	-1	24190587
us@@	O	-1	24190587
er	O	-1	24190587
groups	O	-1	24190587
ex@@	O	-1	24190587
hib@@	O	-1	24190587
ited	O	-1	24190587
significantly	O	-1	24190587
greater	O	-1	24190587
levels	O	-1	24190587
of	O	-1	24190587
an@@	B-Disease	D001008	24190587
xi@@	I-Disease	-1	24190587
ety	I-Disease	-1	24190587
and	O	-1	24190587
de@@	B-Disease	D003866	24190587
pression	I-Disease	-1	24190587
than	O	-1	24190587
non@@	O	-1	24190587
us@@	O	-1	24190587
ers.	O	-1	24190587
O@@	O	-1	24190587
n	O	-1	24190587
day	O	-1	24190587
1,	O	-1	24190587
all	O	-1	24190587
partic@@	O	-1	24190587
ip@@	O	-1	24190587
ants	O	-1	24190587
ex@@	O	-1	24190587
hib@@	O	-1	24190587
ited	O	-1	24190587
a	O	-1	24190587
typ@@	O	-1	24190587
ical	O	-1	24190587
cor@@	B-Chemical	D006854	24190587
tis@@	I-Chemical	-1	24190587
ol	I-Chemical	-1	24190587
pro@@	O	-1	24190587
fi@@	O	-1	24190587
le@@	O	-1	24190587
,	O	-1	24190587
though	O	-1	24190587
li@@	O	-1	24190587
ght	O	-1	24190587
users	O	-1	24190587
had	O	-1	24190587
significantly	O	-1	24190587
elevated	O	-1	24190587
levels	O	-1	24190587
pre-@@	O	-1	24190587
be@@	O	-1	24190587
d.	O	-1	24190587
O@@	O	-1	24190587
n	O	-1	24190587
day	O	-1	24190587
2,	O	-1	24190587
he@@	O	-1	24190587
av@@	O	-1	24190587
y	O	-1	24190587
users	O	-1	24190587
demonstrated	O	-1	24190587
elevated	O	-1	24190587
levels	O	-1	24190587
up@@	O	-1	24190587
on	O	-1	24190587
aw@@	O	-1	24190587
ak@@	O	-1	24190587
en@@	O	-1	24190587
ing	O	-1	24190587
and	O	-1	24190587
all	O	-1	24190587
ec@@	B-Chemical	D018817	24190587
st@@	I-Chemical	-1	24190587
as@@	I-Chemical	-1	24190587
y	I-Chemical	-1	24190587
-@@	O	-1	24190587
poly@@	O	-1	24190587
drug	O	-1	24190587
users	O	-1	24190587
demonstrated	O	-1	24190587
elevated	O	-1	24190587
pre-@@	O	-1	24190587
bed	O	-1	24190587
levels	O	-1	24190587
compared	O	-1	24190587
to	O	-1	24190587
non-@@	O	-1	24190587
us@@	O	-1	24190587
ers.	O	-1	24190587
Si@@	O	-1	24190587
gn@@	O	-1	24190587
ific@@	O	-1	24190587
ant	O	-1	24190587
between	O	-1	24190587
group	O	-1	24190587
differences	O	-1	24190587
were	O	-1	24190587
also	O	-1	24190587
observed	O	-1	24190587
in	O	-1	24190587
af@@	O	-1	24190587
ter@@	O	-1	24190587
no@@	O	-1	24190587
on	O	-1	24190587
cor@@	B-Chemical	D006854	24190587
tis@@	I-Chemical	-1	24190587
ol	I-Chemical	-1	24190587
levels	O	-1	24190587
and	O	-1	24190587
in	O	-1	24190587
over@@	O	-1	24190587
all	O	-1	24190587
cor@@	B-Chemical	D006854	24190587
tis@@	I-Chemical	-1	24190587
ol	I-Chemical	-1	24190587
secre@@	O	-1	24190587
tion	O	-1	24190587
ac@@	O	-1	24190587
ros@@	O	-1	24190587
s	O	-1	24190587
the	O	-1	24190587
da@@	O	-1	24190587
y.	O	-1	24190587
CONCLUSIONS:	O	-1	24190587
The	O	-1	24190587
increases	O	-1	24190587
in	O	-1	24190587
an@@	B-Disease	D001008	24190587
xi@@	I-Disease	-1	24190587
ety	I-Disease	-1	24190587
and	O	-1	24190587
de@@	B-Disease	D003866	24190587
pression	I-Disease	-1	24190587
are	O	-1	24190587
in	O	-1	24190587
line	O	-1	24190587
with	O	-1	24190587
previ@@	O	-1	24190587
ous	O	-1	24190587
observ@@	O	-1	24190587
ations	O	-1	24190587
in	O	-1	24190587
rec@@	O	-1	24190587
re@@	O	-1	24190587
ation@@	O	-1	24190587
al	O	-1	24190587
ec@@	B-Chemical	D018817	24190587
st@@	I-Chemical	-1	24190587
as@@	I-Chemical	-1	24190587
y	I-Chemical	-1	24190587
-@@	O	-1	24190587
poly@@	O	-1	24190587
drug	O	-1	24190587
us@@	O	-1	24190587
ers.	O	-1	24190587
D@@	O	-1	24190587
ys@@	O	-1	24190587
reg@@	O	-1	24190587
ul@@	O	-1	24190587
ated	O	-1	24190587
di@@	O	-1	24190587
ur@@	O	-1	24190587
n@@	O	-1	24190587
al	O	-1	24190587
cor@@	B-Chemical	D006854	24190587
tis@@	I-Chemical	-1	24190587
ol	I-Chemical	-1	24190587
may	O	-1	24190587
be	O	-1	24190587
indic@@	O	-1	24190587
ative	O	-1	24190587
of	O	-1	24190587
in@@	O	-1	24190587
appro@@	O	-1	24190587
pri@@	O	-1	24190587
ate	O	-1	24190587
anti@@	O	-1	24190587
ci@@	O	-1	24190587
p@@	O	-1	24190587
ation	O	-1	24190587
of	O	-1	24190587
for@@	O	-1	24190587
th@@	O	-1	24190587
com@@	O	-1	24190587
ing	O	-1	24190587
de@@	O	-1	24190587
m@@	O	-1	24190587
and@@	O	-1	24190587
s	O	-1	24190587
and	O	-1	24190587
hyper@@	O	-1	24190587
secre@@	O	-1	24190587
tion	O	-1	24190587
may	O	-1	24190587
le@@	O	-1	24190587
ad	O	-1	24190587
to	O	-1	24190587
the	O	-1	24190587
increased	O	-1	24190587
psych@@	O	-1	24190587
ological	O	-1	24190587
and	O	-1	24190587
physi@@	O	-1	24190587
c@@	O	-1	24190587
al	O	-1	24190587
mor@@	O	-1	24190587
b@@	O	-1	24190587
idity	O	-1	24190587
associated	O	-1	24190587
with	O	-1	24190587
he@@	O	-1	24190587
av@@	O	-1	24190587
y	O	-1	24190587
rec@@	O	-1	24190587
re@@	O	-1	24190587
ation@@	O	-1	24190587
al	O	-1	24190587
use	O	-1	24190587
of	O	-1	24190587
ec@@	B-Chemical	D018817	24190587
st@@	I-Chemical	-1	24190587
as@@	I-Chemical	-1	24190587
y	I-Chemical	-1	24190587
.	O	-1	24190587

I@@	B-Chemical	D007069	24209900
f@@	I-Chemical	-1	24209900
os@@	I-Chemical	-1	24209900
f@@	I-Chemical	-1	24209900
amide	I-Chemical	-1	24209900
related	O	-1	24209900
encephalo@@	B-Disease	D001927	24209900
pathy	I-Disease	-1	24209900
:	O	-1	24209900
the	O	-1	24209900
need	O	-1	24209900
for	O	-1	24209900
a	O	-1	24209900
ti@@	O	-1	24209900
me@@	O	-1	24209900
ly	O	-1	24209900
E@@	O	-1	24209900
E@@	O	-1	24209900
G	O	-1	24209900
evalu@@	O	-1	24209900
ation.	O	-1	24209900
BACKGROUND:	O	-1	24209900
I@@	B-Chemical	D007069	24209900
f@@	I-Chemical	-1	24209900
os@@	I-Chemical	-1	24209900
f@@	I-Chemical	-1	24209900
amide	I-Chemical	-1	24209900
is	O	-1	24209900
an	O	-1	24209900
al@@	O	-1	24209900
k@@	O	-1	24209900
yl@@	O	-1	24209900
ating	O	-1	24209900
agent	O	-1	24209900
use@@	O	-1	24209900
ful	O	-1	24209900
in	O	-1	24209900
the	O	-1	24209900
treatment	O	-1	24209900
of	O	-1	24209900
a	O	-1	24209900
w@@	O	-1	24209900
ide	O	-1	24209900
range	O	-1	24209900
of	O	-1	24209900
canc@@	B-Disease	D009369	24209900
ers	I-Disease	-1	24209900
including	O	-1	24209900
s@@	B-Disease	D012509	24209900
ar@@	I-Disease	-1	24209900
com@@	I-Disease	-1	24209900
as	I-Disease	-1	24209900
,	O	-1	24209900
lymph@@	B-Disease	D008223	24209900
oma	I-Disease	-1	24209900
,	O	-1	24209900
g@@	B-Disease	D009369	24209900
y@@	I-Disease	-1	24209900
nec@@	I-Disease	-1	24209900
ologic	I-Disease	-1	24209900
and	I-Disease	-1	24209900
t@@	I-Disease	-1	24209900
es@@	I-Disease	-1	24209900
tic@@	I-Disease	-1	24209900
ular	I-Disease	-1	24209900
canc@@	I-Disease	-1	24209900
ers	I-Disease	-1	24209900
.	O	-1	24209900
E@@	B-Disease	D001927	24209900
n@@	I-Disease	-1	24209900
ce@@	I-Disease	-1	24209900
ph@@	I-Disease	-1	24209900
alo@@	I-Disease	-1	24209900
pathy	I-Disease	-1	24209900
has	O	-1	24209900
been	O	-1	24209900
reported	O	-1	24209900
in	O	-1	24209900
10-@@	O	-1	24209900
4@@	O	-1	24209900
0%	O	-1	24209900
of	O	-1	24209900
patients	O	-1	24209900
receiving	O	-1	24209900
high-dose	O	-1	24209900
IV	O	-1	24209900
if@@	B-Chemical	D007069	24209900
os@@	I-Chemical	-1	24209900
f@@	I-Chemical	-1	24209900
amide	I-Chemical	-1	24209900
.	O	-1	24209900
OBJECTIVE:	O	-1	24209900
To	O	-1	24209900
high@@	O	-1	24209900
li@@	O	-1	24209900
ght	O	-1	24209900
the	O	-1	24209900
role	O	-1	24209900
of	O	-1	24209900
electro@@	O	-1	24209900
encephalo@@	O	-1	24209900
gra@@	O	-1	24209900
m	O	-1	24209900
(@@	O	-1	24209900
E@@	O	-1	24209900
E@@	O	-1	24209900
G@@	O	-1	24209900
)	O	-1	24209900
in	O	-1	24209900
the	O	-1	24209900
early	O	-1	24209900
det@@	O	-1	24209900
ection	O	-1	24209900
and	O	-1	24209900
man@@	O	-1	24209900
ag@@	O	-1	24209900
ement	O	-1	24209900
of	O	-1	24209900
if@@	B-Chemical	D007069	24209900
os@@	I-Chemical	-1	24209900
f@@	I-Chemical	-1	24209900
amide	I-Chemical	-1	24209900
related	O	-1	24209900
encephalo@@	B-Disease	D001927	24209900
pathy	I-Disease	-1	24209900
.	O	-1	24209900
METHODS:	O	-1	24209900
R@@	O	-1	24209900
et@@	O	-1	24209900
ro@@	O	-1	24209900
sp@@	O	-1	24209900
ective	O	-1	24209900
ch@@	O	-1	24209900
ar@@	O	-1	24209900
t	O	-1	24209900
revie@@	O	-1	24209900
w	O	-1	24209900
including	O	-1	24209900
clinical	O	-1	24209900
data	O	-1	24209900
and	O	-1	24209900
E@@	O	-1	24209900
E@@	O	-1	24209900
G	O	-1	24209900
recor@@	O	-1	24209900
d@@	O	-1	24209900
ings	O	-1	24209900
was	O	-1	24209900
d@@	O	-1	24209900
one	O	-1	24209900
on	O	-1	24209900
five	O	-1	24209900
patients,	O	-1	24209900
ad@@	O	-1	24209900
mit@@	O	-1	24209900
ted	O	-1	24209900
to	O	-1	24209900
M@@	O	-1	24209900
D	O	-1	24209900
An@@	O	-1	24209900
der@@	O	-1	24209900
s@@	O	-1	24209900
on	O	-1	24209900
C@@	B-Disease	D009369	24209900
anc@@	I-Disease	-1	24209900
er	I-Disease	-1	24209900
C@@	O	-1	24209900
ent@@	O	-1	24209900
er	O	-1	24209900
between	O	-1	24209900
years	O	-1	24209900
20@@	O	-1	24209900
0@@	O	-1	24209900
9	O	-1	24209900
and	O	-1	24209900
20@@	O	-1	24209900
12@@	O	-1	24209900
,	O	-1	24209900
who	O	-1	24209900
developed	O	-1	24209900
if@@	B-Chemical	D007069	24209900
os@@	I-Chemical	-1	24209900
f@@	I-Chemical	-1	24209900
amide	I-Chemical	-1	24209900
related	O	-1	24209900
acute	O	-1	24209900
encephalo@@	B-Disease	D001927	24209900
pathy	I-Disease	-1	24209900
.	O	-1	24209900
RESULTS:	O	-1	24209900
All	O	-1	24209900
five	O	-1	24209900
patients	O	-1	24209900
experienced	O	-1	24209900
symptoms	O	-1	24209900
of	O	-1	24209900
encephalo@@	B-Disease	D001927	24209900
pathy	I-Disease	-1	24209900
so@@	O	-1	24209900
on	O	-1	24209900
after	O	-1	24209900
(@@	O	-1	24209900
within	O	-1	24209900
12	O	-1	24209900
h@@	O	-1	24209900
-@@	O	-1	24209900
2	O	-1	24209900
da@@	O	-1	24209900
ys@@	O	-1	24209900
)	O	-1	24209900
receiving	O	-1	24209900
if@@	B-Chemical	D007069	24209900
os@@	I-Chemical	-1	24209900
f@@	I-Chemical	-1	24209900
amide	I-Chemical	-1	24209900
.	O	-1	24209900
Two	O	-1	24209900
patients	O	-1	24209900
developed	O	-1	24209900
gener@@	O	-1	24209900
al@@	O	-1	24209900
ized	O	-1	24209900
convul@@	B-Disease	D012640	24209900
sions	I-Disease	-1	24209900
while	O	-1	24209900
one	O	-1	24209900
patient	O	-1	24209900
developed	O	-1	24209900
continu@@	O	-1	24209900
ous	O	-1	24209900
non-@@	B-Disease	D013226	24209900
convul@@	I-Disease	-1	24209900
sive	I-Disease	-1	24209900
status	I-Disease	-1	24209900
epilep@@	I-Disease	-1	24209900
tic@@	I-Disease	-1	24209900
us	I-Disease	-1	24209900
(	O	-1	24209900
N@@	B-Disease	D013226	24209900
C@@	I-Disease	-1	24209900
S@@	I-Disease	-1	24209900
E	I-Disease	-1	24209900
)	O	-1	24209900
that	O	-1	24209900
requ@@	O	-1	24209900
ired	O	-1	24209900
IC@@	O	-1	24209900
U	O	-1	24209900
ad@@	O	-1	24209900
mission	O	-1	24209900
and	O	-1	24209900
int@@	O	-1	24209900
ub@@	O	-1	24209900
ation.	O	-1	24209900
In@@	O	-1	24209900
iti@@	O	-1	24209900
al	O	-1	24209900
E@@	O	-1	24209900
E@@	O	-1	24209900
G	O	-1	24209900
showed	O	-1	24209900
epilep@@	O	-1	24209900
ti@@	O	-1	24209900
form	O	-1	24209900
dis@@	O	-1	24209900
ch@@	O	-1	24209900
arg@@	O	-1	24209900
es	O	-1	24209900
in	O	-1	24209900
three	O	-1	24209900
patient@@	O	-1	24209900
s;	O	-1	24209900
ru@@	O	-1	24209900
n	O	-1	24209900
of	O	-1	24209900
tri@@	O	-1	24209900
pha@@	O	-1	24209900
sic	O	-1	24209900
w@@	O	-1	24209900
av@@	O	-1	24209900
es	O	-1	24209900
in	O	-1	24209900
one	O	-1	24209900
patient	O	-1	24209900
and	O	-1	24209900
moder@@	O	-1	24209900
ate	O	-1	24209900
de@@	O	-1	24209900
g@@	O	-1	24209900
ree	O	-1	24209900
diff@@	O	-1	24209900
use	O	-1	24209900
gener@@	O	-1	24209900
al@@	O	-1	24209900
ized	O	-1	24209900
s@@	O	-1	24209900
low@@	O	-1	24209900
ing.	O	-1	24209900
M@@	O	-1	24209900
i@@	O	-1	24209900
x@@	O	-1	24209900
ed	O	-1	24209900
pat@@	O	-1	24209900
ter@@	O	-1	24209900
n	O	-1	24209900
with	O	-1	24209900
the	O	-1	24209900
presence	O	-1	24209900
of	O	-1	24209900
both	O	-1	24209900
sh@@	O	-1	24209900
ar@@	O	-1	24209900
p@@	O	-1	24209900
s	O	-1	24209900
and	O	-1	24209900
tri@@	O	-1	24209900
pha@@	O	-1	24209900
sic	O	-1	24209900
w@@	O	-1	24209900
av@@	O	-1	24209900
es	O	-1	24209900
were	O	-1	24209900
also	O	-1	24209900
not@@	O	-1	24209900
ed.	O	-1	24209900
R@@	O	-1	24209900
ep@@	O	-1	24209900
e@@	O	-1	24209900
at	O	-1	24209900
E@@	O	-1	24209900
E@@	O	-1	24209900
G@@	O	-1	24209900
s	O	-1	24209900
within	O	-1	24209900
2@@	O	-1	24209900
4@@	O	-1	24209900
_@@	O	-1	24209900
h	O	-1	24209900
of	O	-1	24209900
sympto@@	O	-1	24209900
m	O	-1	24209900
onset	O	-1	24209900
showed	O	-1	24209900
mark@@	O	-1	24209900
ed	O	-1	24209900
impro@@	O	-1	24209900
vement	O	-1	24209900
that	O	-1	24209900
was	O	-1	24209900
cor@@	O	-1	24209900
related	O	-1	24209900
with	O	-1	24209900
clinical	O	-1	24209900
impro@@	O	-1	24209900
ve@@	O	-1	24209900
ment.	O	-1	24209900
CONCLUSIONS:	O	-1	24209900
S@@	O	-1	24209900
e@@	O	-1	24209900
ver@@	O	-1	24209900
ity	O	-1	24209900
of	O	-1	24209900
if@@	B-Chemical	D007069	24209900
os@@	I-Chemical	-1	24209900
f@@	I-Chemical	-1	24209900
amide	I-Chemical	-1	24209900
related	O	-1	24209900
encephalo@@	B-Disease	D001927	24209900
pathy	I-Disease	-1	24209900
correl@@	O	-1	24209900
ates	O	-1	24209900
with	O	-1	24209900
E@@	O	-1	24209900
E@@	O	-1	24209900
G	O	-1	24209900
chang@@	O	-1	24209900
es.	O	-1	24209900
We	O	-1	24209900
suggest	O	-1	24209900
a	O	-1	24209900
ti@@	O	-1	24209900
me@@	O	-1	24209900
ly	O	-1	24209900
E@@	O	-1	24209900
E@@	O	-1	24209900
G	O	-1	24209900
evalu@@	O	-1	24209900
ation	O	-1	24209900
for	O	-1	24209900
patients	O	-1	24209900
receiving	O	-1	24209900
if@@	B-Chemical	D007069	24209900
os@@	I-Chemical	-1	24209900
f@@	I-Chemical	-1	24209900
amide	I-Chemical	-1	24209900
who	O	-1	24209900
deve@@	O	-1	24209900
lo@@	O	-1	24209900
p	O	-1	24209900
feat@@	O	-1	24209900
ures	O	-1	24209900
of	O	-1	24209900
encephalo@@	B-Disease	D001927	24209900
pathy	I-Disease	-1	24209900
.	O	-1	24209900

In@@	O	-1	24220752
c@@	O	-1	24220752
idence	O	-1	24220752
of	O	-1	24220752
contr@@	B-Chemical	D003287	24220752
ast	I-Chemical	-1	24220752
-induced	O	-1	24220752
nephro@@	B-Disease	D007674	24220752
pathy	I-Disease	-1	24220752
in	O	-1	24220752
hospit@@	O	-1	24220752
al@@	O	-1	24220752
is@@	O	-1	24220752
ed	O	-1	24220752
patients	O	-1	24220752
with	O	-1	24220752
cancer	B-Disease	D009369	24220752
.	O	-1	24220752
OBJECTIV@@	O	-1	24220752
E@@	O	-1	24220752
S:	O	-1	24220752
To	O	-1	24220752
determine	O	-1	24220752
the	O	-1	24220752
frequency	O	-1	24220752
of	O	-1	24220752
and	O	-1	24220752
possible	O	-1	24220752
factors	O	-1	24220752
related	O	-1	24220752
to	O	-1	24220752
contr@@	B-Chemical	D003287	24220752
ast	I-Chemical	-1	24220752
-induced	O	-1	24220752
nephro@@	B-Disease	D007674	24220752
pathy	I-Disease	-1	24220752
(C@@	O	-1	24220752
IN@@	O	-1	24220752
)	O	-1	24220752
in	O	-1	24220752
hospit@@	O	-1	24220752
al@@	O	-1	24220752
is@@	O	-1	24220752
ed	O	-1	24220752
patients	O	-1	24220752
with	O	-1	24220752
cancer	B-Disease	D009369	24220752
.	O	-1	24220752
METHODS:	O	-1	24220752
N@@	O	-1	24220752
ine@@	O	-1	24220752
t@@	O	-1	24220752
y	O	-1	24220752
ad@@	O	-1	24220752
ult	O	-1	24220752
patients	O	-1	24220752
were	O	-1	24220752
en@@	O	-1	24220752
ro@@	O	-1	24220752
l@@	O	-1	24220752
le@@	O	-1	24220752
d.	O	-1	24220752
Patients	O	-1	24220752
with	O	-1	24220752
risk	O	-1	24220752
factors	O	-1	24220752
for	O	-1	24220752
acute	B-Disease	D058186	24220752
renal	I-Disease	-1	24220752
failure	I-Disease	-1	24220752
were	O	-1	24220752
ex@@	O	-1	24220752
cl@@	O	-1	24220752
u@@	O	-1	24220752
de@@	O	-1	24220752
d.	O	-1	24220752
B@@	O	-1	24220752
lo@@	O	-1	24220752
od	O	-1	24220752
sam@@	O	-1	24220752
ple@@	O	-1	24220752
s	O	-1	24220752
were	O	-1	24220752
examined	O	-1	24220752
the	O	-1	24220752
day	O	-1	24220752
before	O	-1	24220752
contr@@	B-Chemical	D003287	24220752
ast	I-Chemical	-1	24220752
-@@	O	-1	24220752
enhanced	O	-1	24220752
comp@@	O	-1	24220752
ut@@	O	-1	24220752
ed	O	-1	24220752
to@@	O	-1	24220752
mo@@	O	-1	24220752
graph@@	O	-1	24220752
y	O	-1	24220752
(C@@	O	-1	24220752
T)	O	-1	24220752
and	O	-1	24220752
seri@@	O	-1	24220752
ally	O	-1	24220752
for	O	-1	24220752
3	O	-1	24220752
days	O	-1	24220752
the@@	O	-1	24220752
re@@	O	-1	24220752
af@@	O	-1	24220752
ter@@	O	-1	24220752
.	O	-1	24220752
CI@@	O	-1	24220752
N	O	-1	24220752
was	O	-1	24220752
def@@	O	-1	24220752
in@@	O	-1	24220752
ed	O	-1	24220752
as	O	-1	24220752
an	O	-1	24220752
increase	O	-1	24220752
in	O	-1	24220752
serum	O	-1	24220752
creatinine	B-Chemical	D003404	24220752
(	O	-1	24220752
C@@	B-Chemical	D002857	24220752
r	I-Chemical	-1	24220752
)	O	-1	24220752
of	O	-1	24220752
0.@@	O	-1	24220752
5	O	-1	24220752
mg/d@@	O	-1	24220752
l	O	-1	24220752
or	O	-1	24220752
mo@@	O	-1	24220752
re,	O	-1	24220752
or	O	-1	24220752
elev@@	O	-1	24220752
ation	O	-1	24220752
of	O	-1	24220752
C@@	B-Chemical	D002857	24220752
r	I-Chemical	-1	24220752
to	O	-1	24220752
25	O	-1	24220752
%	O	-1	24220752
over	O	-1	24220752
basel@@	O	-1	24220752
ine.	O	-1	24220752
R@@	O	-1	24220752
el@@	O	-1	24220752
ation@@	O	-1	24220752
shi@@	O	-1	24220752
p@@	O	-1	24220752
s	O	-1	24220752
between	O	-1	24220752
CI@@	O	-1	24220752
N	O	-1	24220752
and	O	-1	24220752
possible	O	-1	24220752
risk	O	-1	24220752
factors	O	-1	24220752
were	O	-1	24220752
investig@@	O	-1	24220752
ated.	O	-1	24220752
RESULTS:	O	-1	24220752
CI@@	O	-1	24220752
N	O	-1	24220752
was	O	-1	24220752
det@@	O	-1	24220752
ected	O	-1	24220752
in	O	-1	24220752
18@@	O	-1	24220752
/@@	O	-1	24220752
9@@	O	-1	24220752
0	O	-1	24220752
(2@@	O	-1	24220752
0	O	-1	24220752
%)	O	-1	24220752
patients.	O	-1	24220752
CI@@	O	-1	24220752
N	O	-1	24220752
developed	O	-1	24220752
in	O	-1	24220752
2@@	O	-1	24220752
5.@@	O	-1	24220752
5	O	-1	24220752
%	O	-1	24220752
patients	O	-1	24220752
who	O	-1	24220752
under@@	O	-1	24220752
w@@	O	-1	24220752
ent	O	-1	24220752
chemotherapy	O	-1	24220752
and	O	-1	24220752
in	O	-1	24220752
11	O	-1	24220752
%	O	-1	24220752
patients	O	-1	24220752
who	O	-1	24220752
did	O	-1	24220752
not	O	-1	24220752
(P	O	-1	24220752
=	O	-1	24220752
0.@@	O	-1	24220752
1).	O	-1	24220752
CI@@	O	-1	24220752
N	O	-1	24220752
more	O	-1	24220752
frequ@@	O	-1	24220752
ently	O	-1	24220752
developed	O	-1	24220752
in	O	-1	24220752
patients	O	-1	24220752
who	O	-1	24220752
had	O	-1	24220752
under@@	O	-1	24220752
g@@	O	-1	24220752
one	O	-1	24220752
C@@	O	-1	24220752
T	O	-1	24220752
within	O	-1	24220752
4@@	O	-1	24220752
5	O	-1	24220752
days	O	-1	24220752
after	O	-1	24220752
the	O	-1	24220752
las@@	O	-1	24220752
t	O	-1	24220752
chemotherapy	O	-1	24220752
(P	O	-1	24220752
=	O	-1	24220752
0.00@@	O	-1	24220752
5@@	O	-1	24220752
);	O	-1	24220752
it	O	-1	24220752
was	O	-1	24220752
also	O	-1	24220752
an	O	-1	24220752
in@@	O	-1	24220752
dependent	O	-1	24220752
risk	O	-1	24220752
factor	O	-1	24220752
(P	O	-1	24220752
=	O	-1	24220752
0.0@@	O	-1	24220752
17@@	O	-1	24220752
).	O	-1	24220752
CI@@	O	-1	24220752
N	O	-1	24220752
was	O	-1	24220752
significantly	O	-1	24220752
more	O	-1	24220752
after	O	-1	24220752
treatment	O	-1	24220752
with	O	-1	24220752
be@@	B-Chemical	-1	24220752
vac@@	I-Chemical	-1	24220752
iz@@	I-Chemical	-1	24220752
u@@	I-Chemical	-1	24220752
ma@@	I-Chemical	-1	24220752
b	I-Chemical	-1	24220752
/	O	-1	24220752
ir@@	B-Chemical	C051890	24220752
in@@	I-Chemical	-1	24220752
ot@@	I-Chemical	-1	24220752
ec@@	I-Chemical	-1	24220752
an	I-Chemical	-1	24220752
(P	O	-1	24220752
=	O	-1	24220752
0.0@@	O	-1	24220752
2@@	O	-1	24220752
1)	O	-1	24220752
and	O	-1	24220752
in	O	-1	24220752
patients	O	-1	24220752
with	O	-1	24220752
hypertension	B-Disease	D006973	24220752
(P	O	-1	24220752
=	O	-1	24220752
0.0@@	O	-1	24220752
4@@	O	-1	24220752
4@@	O	-1	24220752
).	O	-1	24220752
CONCLUSIONS:	O	-1	24220752
The	O	-1	24220752
incidence	O	-1	24220752
of	O	-1	24220752
CI@@	O	-1	24220752
N	O	-1	24220752
after	O	-1	24220752
C@@	O	-1	24220752
T	O	-1	24220752
in	O	-1	24220752
hospit@@	O	-1	24220752
al@@	O	-1	24220752
is@@	O	-1	24220752
ed	O	-1	24220752
on@@	O	-1	24220752
co@@	O	-1	24220752
log@@	O	-1	24220752
ical	O	-1	24220752
patients	O	-1	24220752
was	O	-1	24220752
20	O	-1	24220752
%.	O	-1	24220752
CI@@	O	-1	24220752
N	O	-1	24220752
developed	O	-1	24220752
4.@@	O	-1	24220752
5-@@	O	-1	24220752
times	O	-1	24220752
more	O	-1	24220752
frequ@@	O	-1	24220752
ently	O	-1	24220752
in	O	-1	24220752
patients	O	-1	24220752
with	O	-1	24220752
cancer	B-Disease	D009369	24220752
who	O	-1	24220752
had	O	-1	24220752
under@@	O	-1	24220752
g@@	O	-1	24220752
one	O	-1	24220752
rec@@	O	-1	24220752
ent	O	-1	24220752
chemo@@	O	-1	24220752
therapy.	O	-1	24220752
H@@	B-Disease	D006973	24220752
y@@	I-Disease	-1	24220752
per@@	I-Disease	-1	24220752
ten@@	I-Disease	-1	24220752
sion	I-Disease	-1	24220752
and	O	-1	24220752
the	O	-1	24220752
combination	O	-1	24220752
of	O	-1	24220752
be@@	B-Chemical	-1	24220752
vac@@	I-Chemical	-1	24220752
iz@@	I-Chemical	-1	24220752
u@@	I-Chemical	-1	24220752
ma@@	I-Chemical	-1	24220752
b	I-Chemical	-1	24220752
/	O	-1	24220752
ir@@	B-Chemical	C051890	24220752
in@@	I-Chemical	-1	24220752
ot@@	I-Chemical	-1	24220752
ec@@	I-Chemical	-1	24220752
an	I-Chemical	-1	24220752
may	O	-1	24220752
be	O	-1	24220752
addi@@	O	-1	24220752
tional	O	-1	24220752
risk	O	-1	24220752
factors	O	-1	24220752
for	O	-1	24220752
CI@@	O	-1	24220752
N	O	-1	24220752
develop@@	O	-1	24220752
ment.	O	-1	24220752
K@@	O	-1	24220752
E@@	O	-1	24220752
Y	O	-1	24220752
P@@	O	-1	24220752
O@@	O	-1	24220752
IN@@	O	-1	24220752
T@@	O	-1	24220752
S:	O	-1	24220752
.	O	-1	24220752
C@@	B-Chemical	D003287	24220752
ont@@	I-Chemical	-1	24220752
r@@	I-Chemical	-1	24220752
ast	I-Chemical	-1	24220752
-induced	O	-1	24220752
nephro@@	B-Disease	D007674	24220752
pathy	I-Disease	-1	24220752
(C@@	O	-1	24220752
IN@@	O	-1	24220752
)	O	-1	24220752
is	O	-1	24220752
a	O	-1	24220752
con@@	O	-1	24220752
cer@@	O	-1	24220752
n	O	-1	24220752
for	O	-1	24220752
on@@	O	-1	24220752
co@@	O	-1	24220752
log@@	O	-1	24220752
ical	O	-1	24220752
patients	O	-1	24220752
under@@	O	-1	24220752
go@@	O	-1	24220752
ing	O	-1	24220752
C@@	O	-1	24220752
T@@	O	-1	24220752
.	O	-1	24220752
.	O	-1	24220752
CI@@	O	-1	24220752
N	O	-1	24220752
occur@@	O	-1	24220752
s	O	-1	24220752
more	O	-1	24220752
often	O	-1	24220752
when	O	-1	24220752
C@@	O	-1	24220752
T	O	-1	24220752
is	O	-1	24220752
performed	O	-1	24220752
<@@	O	-1	24220752
4@@	O	-1	24220752
5	O	-1	24220752
days	O	-1	24220752
after	O	-1	24220752
chemo@@	O	-1	24220752
therapy.	O	-1	24220752
.	O	-1	24220752
H@@	B-Disease	D006973	24220752
y@@	I-Disease	-1	24220752
per@@	I-Disease	-1	24220752
ten@@	I-Disease	-1	24220752
sion	I-Disease	-1	24220752
and	O	-1	24220752
treatment	O	-1	24220752
with	O	-1	24220752
be@@	B-Chemical	-1	24220752
vac@@	I-Chemical	-1	24220752
iz@@	I-Chemical	-1	24220752
u@@	I-Chemical	-1	24220752
ma@@	I-Chemical	-1	24220752
b	I-Chemical	-1	24220752
appe@@	O	-1	24220752
ar	O	-1	24220752
to	O	-1	24220752
be	O	-1	24220752
addi@@	O	-1	24220752
tional	O	-1	24220752
risk	O	-1	24220752
fact@@	O	-1	24220752
or@@	O	-1	24220752
s.	O	-1	24220752

S@@	B-Disease	D007177	24234943
yn@@	I-Disease	-1	24234943
drom@@	I-Disease	-1	24234943
e	I-Disease	-1	24234943
of	I-Disease	-1	24234943
in@@	I-Disease	-1	24234943
appro@@	I-Disease	-1	24234943
pri@@	I-Disease	-1	24234943
ate	I-Disease	-1	24234943
anti@@	I-Disease	-1	24234943
di@@	I-Disease	-1	24234943
ure@@	I-Disease	-1	24234943
tic	I-Disease	-1	24234943
h@@	I-Disease	-1	24234943
orm@@	I-Disease	-1	24234943
one	I-Disease	-1	24234943
secre@@	O	-1	24234943
tion	O	-1	24234943
associated	O	-1	24234943
with	O	-1	24234943
des@@	B-Chemical	C086816	24234943
ven@@	I-Chemical	-1	24234943
l@@	I-Chemical	-1	24234943
af@@	I-Chemical	-1	24234943
ax@@	I-Chemical	-1	24234943
ine	I-Chemical	-1	24234943
.	O	-1	24234943
OBJECTIVE:	O	-1	24234943
To	O	-1	24234943
report	O	-1	24234943
a	O	-1	24234943
case	O	-1	24234943
of	O	-1	24234943
syndrome	B-Disease	D007177	24234943
of	I-Disease	-1	24234943
in@@	I-Disease	-1	24234943
appro@@	I-Disease	-1	24234943
pri@@	I-Disease	-1	24234943
ate	I-Disease	-1	24234943
anti@@	I-Disease	-1	24234943
-@@	I-Disease	-1	24234943
di@@	I-Disease	-1	24234943
ure@@	I-Disease	-1	24234943
tic	I-Disease	-1	24234943
h@@	I-Disease	-1	24234943
orm@@	I-Disease	-1	24234943
one	I-Disease	-1	24234943
(	O	-1	24234943
S@@	B-Disease	D007177	24234943
I@@	I-Disease	-1	24234943
AD@@	I-Disease	-1	24234943
H	I-Disease	-1	24234943
)	O	-1	24234943
secre@@	O	-1	24234943
tion	O	-1	24234943
associated	O	-1	24234943
with	O	-1	24234943
des@@	B-Chemical	C086816	24234943
ven@@	I-Chemical	-1	24234943
l@@	I-Chemical	-1	24234943
af@@	I-Chemical	-1	24234943
ax@@	I-Chemical	-1	24234943
ine	I-Chemical	-1	24234943
.	O	-1	24234943
CA@@	O	-1	24234943
S@@	O	-1	24234943
E	O	-1	24234943
S@@	O	-1	24234943
U@@	O	-1	24234943
M@@	O	-1	24234943
MA@@	O	-1	24234943
R@@	O	-1	24234943
Y@@	O	-1	24234943
:	O	-1	24234943
A	O	-1	24234943
5@@	O	-1	24234943
7-@@	O	-1	24234943
year	O	-1	24234943
old	O	-1	24234943
female	O	-1	24234943
with	O	-1	24234943
hy@@	B-Disease	D007010	24234943
p@@	I-Disease	-1	24234943
on@@	I-Disease	-1	24234943
at@@	I-Disease	-1	24234943
ra@@	I-Disease	-1	24234943
emia	I-Disease	-1	24234943
.	O	-1	24234943
H@@	O	-1	24234943
er	O	-1	24234943
medic@@	O	-1	24234943
ations	O	-1	24234943
included	O	-1	24234943
des@@	B-Chemical	C086816	24234943
ven@@	I-Chemical	-1	24234943
l@@	I-Chemical	-1	24234943
af@@	I-Chemical	-1	24234943
ax@@	I-Chemical	-1	24234943
ine	I-Chemical	-1	24234943
,	O	-1	24234943
and	O	-1	24234943
symptoms	O	-1	24234943
included	O	-1	24234943
nausea	B-Disease	D009325	24234943
,	O	-1	24234943
an@@	B-Disease	D001008	24234943
xi@@	I-Disease	-1	24234943
ety	I-Disease	-1	24234943
and	O	-1	24234943
conf@@	B-Disease	D003221	24234943
usion	I-Disease	-1	24234943
.	O	-1	24234943
The	O	-1	24234943
serum	O	-1	24234943
sodium	B-Chemical	D012964	24234943
at	O	-1	24234943
this	O	-1	24234943
time	O	-1	24234943
was	O	-1	24234943
1@@	O	-1	24234943
20	O	-1	24234943
m@@	O	-1	24234943
mol@@	O	-1	24234943
/@@	O	-1	24234943
L@@	O	-1	24234943
,	O	-1	24234943
serum	O	-1	24234943
os@@	O	-1	24234943
mol@@	O	-1	24234943
ality	O	-1	24234943
was	O	-1	24234943
2@@	O	-1	24234943
6@@	O	-1	24234943
3	O	-1	24234943
m@@	O	-1	24234943
os@@	O	-1	24234943
mol@@	O	-1	24234943
/@@	O	-1	24234943
kg@@	O	-1	24234943
,	O	-1	24234943
urine	O	-1	24234943
os@@	O	-1	24234943
mol@@	O	-1	24234943
ality	O	-1	24234943
4@@	O	-1	24234943
10	O	-1	24234943
m@@	O	-1	24234943
os@@	O	-1	24234943
mol@@	O	-1	24234943
/@@	O	-1	24234943
k@@	O	-1	24234943
g	O	-1	24234943
and	O	-1	24234943
urine	O	-1	24234943
sodium	B-Chemical	D012964	24234943
6@@	O	-1	24234943
3	O	-1	24234943
m@@	O	-1	24234943
mol@@	O	-1	24234943
/@@	O	-1	24234943
L@@	O	-1	24234943
,	O	-1	24234943
consist@@	O	-1	24234943
ent	O	-1	24234943
with	O	-1	24234943
a	O	-1	24234943
diagnosis	O	-1	24234943
of	O	-1	24234943
S@@	B-Disease	D007177	24234943
I@@	I-Disease	-1	24234943
AD@@	I-Disease	-1	24234943
H	I-Disease	-1	24234943
.	O	-1	24234943
D@@	B-Chemical	C086816	24234943
es@@	I-Chemical	-1	24234943
ven@@	I-Chemical	-1	24234943
l@@	I-Chemical	-1	24234943
af@@	I-Chemical	-1	24234943
ax@@	I-Chemical	-1	24234943
ine	I-Chemical	-1	24234943
was	O	-1	24234943
ce@@	O	-1	24234943
as@@	O	-1	24234943
ed	O	-1	24234943
and	O	-1	24234943
flu@@	O	-1	24234943
id	O	-1	24234943
re@@	O	-1	24234943
stric@@	O	-1	24234943
tion	O	-1	24234943
im@@	O	-1	24234943
ple@@	O	-1	24234943
ment@@	O	-1	24234943
ed.	O	-1	24234943
After	O	-1	24234943
4	O	-1	24234943
days	O	-1	24234943
the	O	-1	24234943
sodium	B-Chemical	D012964	24234943
increased	O	-1	24234943
to	O	-1	24234943
12@@	O	-1	24234943
8	O	-1	24234943
m@@	O	-1	24234943
mol@@	O	-1	24234943
/@@	O	-1	24234943
L	O	-1	24234943
and	O	-1	24234943
flu@@	O	-1	24234943
id	O	-1	24234943
re@@	O	-1	24234943
stric@@	O	-1	24234943
tion	O	-1	24234943
was	O	-1	24234943
rel@@	O	-1	24234943
ax@@	O	-1	24234943
ed.	O	-1	24234943
D@@	O	-1	24234943
uring	O	-1	24234943
h@@	O	-1	24234943
er	O	-1	24234943
further	O	-1	24234943
3	O	-1	24234943
weeks	O	-1	24234943
in@@	O	-1	24234943
patient	O	-1	24234943
ad@@	O	-1	24234943
mission	O	-1	24234943
the	O	-1	24234943
serum	O	-1	24234943
sodium	B-Chemical	D012964	24234943
rang@@	O	-1	24234943
ed	O	-1	24234943
from	O	-1	24234943
13@@	O	-1	24234943
4	O	-1	24234943
to	O	-1	24234943
13@@	O	-1	24234943
7	O	-1	24234943
m@@	O	-1	24234943
mol@@	O	-1	24234943
/@@	O	-1	24234943
L	O	-1	24234943
during	O	-1	24234943
treatment	O	-1	24234943
with	O	-1	24234943
m@@	B-Chemical	C035133	24234943
ir@@	I-Chemical	-1	24234943
t@@	I-Chemical	-1	24234943
az@@	I-Chemical	-1	24234943
apine	I-Chemical	-1	24234943
.	O	-1	24234943
D@@	O	-1	24234943
I@@	O	-1	24234943
S@@	O	-1	24234943
C@@	O	-1	24234943
US@@	O	-1	24234943
S@@	O	-1	24234943
ION@@	O	-1	24234943
:	O	-1	24234943
S@@	B-Disease	D007177	24234943
I@@	I-Disease	-1	24234943
AD@@	I-Disease	-1	24234943
H	I-Disease	-1	24234943
has	O	-1	24234943
been	O	-1	24234943
wi@@	O	-1	24234943
de@@	O	-1	24234943
ly	O	-1	24234943
reported	O	-1	24234943
with	O	-1	24234943
a	O	-1	24234943
range	O	-1	24234943
of	O	-1	24234943
antidepress@@	O	-1	24234943
ant@@	O	-1	24234943
s.	O	-1	24234943
This	O	-1	24234943
case	O	-1	24234943
report	O	-1	24234943
suggests	O	-1	24234943
that	O	-1	24234943
des@@	B-Chemical	C086816	24234943
ven@@	I-Chemical	-1	24234943
l@@	I-Chemical	-1	24234943
af@@	I-Chemical	-1	24234943
ax@@	I-Chemical	-1	24234943
ine	I-Chemical	-1	24234943
might	O	-1	24234943
cause	O	-1	24234943
clin@@	O	-1	24234943
ically	O	-1	24234943
significant	O	-1	24234943
hy@@	B-Disease	D007010	24234943
p@@	I-Disease	-1	24234943
on@@	I-Disease	-1	24234943
at@@	I-Disease	-1	24234943
re@@	I-Disease	-1	24234943
mia	I-Disease	-1	24234943
.	O	-1	24234943
CONCLUSIONS:	O	-1	24234943
Clin@@	O	-1	24234943
ici@@	O	-1	24234943
ans	O	-1	24234943
should	O	-1	24234943
be	O	-1	24234943
aw@@	O	-1	24234943
are	O	-1	24234943
of	O	-1	24234943
the	O	-1	24234943
potential	O	-1	24234943
for	O	-1	24234943
antidepress@@	O	-1	24234943
ants	O	-1	24234943
to	O	-1	24234943
cause	O	-1	24234943
hy@@	B-Disease	D007010	24234943
p@@	I-Disease	-1	24234943
on@@	I-Disease	-1	24234943
at@@	I-Disease	-1	24234943
re@@	I-Disease	-1	24234943
mia	I-Disease	-1	24234943
,@@	O	-1	24234943
and	O	-1	24234943
tak@@	O	-1	24234943
e	O	-1	24234943
appro@@	O	-1	24234943
pri@@	O	-1	24234943
ate	O	-1	24234943
cor@@	O	-1	24234943
rec@@	O	-1	24234943
tive	O	-1	24234943
action	O	-1	24234943
wh@@	O	-1	24234943
ere	O	-1	24234943
nec@@	O	-1	24234943
ess@@	O	-1	24234943
ar@@	O	-1	24234943
y.	O	-1	24234943

O@@	O	-1	24275640
x@@	O	-1	24275640
id@@	O	-1	24275640
ative	O	-1	24275640
stres@@	O	-1	24275640
s	O	-1	24275640
on	O	-1	24275640
cardi@@	B-Disease	D066126	24275640
otoxicity	I-Disease	-1	24275640
after	O	-1	24275640
treatment	O	-1	24275640
with	O	-1	24275640
single	O	-1	24275640
and	O	-1	24275640
multiple	O	-1	24275640
doses	O	-1	24275640
of	O	-1	24275640
dox@@	B-Chemical	D004317	24275640
orub@@	I-Chemical	-1	24275640
icin	I-Chemical	-1	24275640
.	O	-1	24275640
The	O	-1	24275640
mechanism	O	-1	24275640
of	O	-1	24275640
dox@@	B-Chemical	D004317	24275640
orub@@	I-Chemical	-1	24275640
icin	I-Chemical	-1	24275640
(	O	-1	24275640
DO@@	B-Chemical	D004317	24275640
X	I-Chemical	-1	24275640
)@@	O	-1	24275640
-induced	O	-1	24275640
cardi@@	B-Disease	D066126	24275640
otoxicity	I-Disease	-1	24275640
remain@@	O	-1	24275640
s	O	-1	24275640
contro@@	O	-1	24275640
ver@@	O	-1	24275640
si@@	O	-1	24275640
al.	O	-1	24275640
Wistar	O	-1	24275640
rats	O	-1	24275640
(n	O	-1	24275640
=	O	-1	24275640
6@@	O	-1	24275640
6@@	O	-1	24275640
)	O	-1	24275640
received	O	-1	24275640
DO@@	B-Chemical	D004317	24275640
X	I-Chemical	-1	24275640
injec@@	O	-1	24275640
tions	O	-1	24275640
intra@@	O	-1	24275640
per@@	O	-1	24275640
it@@	O	-1	24275640
one@@	O	-1	24275640
ally	O	-1	24275640
and	O	-1	24275640
were	O	-1	24275640
random@@	O	-1	24275640
ly	O	-1	24275640
as@@	O	-1	24275640
signed	O	-1	24275640
to	O	-1	24275640
2	O	-1	24275640
experimental	O	-1	24275640
pro@@	O	-1	24275640
to@@	O	-1	24275640
co@@	O	-1	24275640
l@@	O	-1	24275640
s:	O	-1	24275640
(1@@	O	-1	24275640
)	O	-1	24275640
rats	O	-1	24275640
were	O	-1	24275640
k@@	O	-1	24275640
ill@@	O	-1	24275640
ed	O	-1	24275640
before	O	-1	24275640
(-@@	O	-1	24275640
24	O	-1	24275640
h@@	O	-1	24275640
,	O	-1	24275640
n	O	-1	24275640
=	O	-1	24275640
8@@	O	-1	24275640
)	O	-1	24275640
and	O	-1	24275640
24	O	-1	24275640
h	O	-1	24275640
after	O	-1	24275640
(@@	O	-1	24275640
+@@	O	-1	24275640
24	O	-1	24275640
h@@	O	-1	24275640
,	O	-1	24275640
n	O	-1	24275640
=	O	-1	24275640
8@@	O	-1	24275640
)	O	-1	24275640
a	O	-1	24275640
single	O	-1	24275640
dose	O	-1	24275640
of	O	-1	24275640
DO@@	B-Chemical	D004317	24275640
X	I-Chemical	-1	24275640
(@@	O	-1	24275640
4	O	-1	24275640
mg/kg	O	-1	24275640
body	O	-1	24275640
weigh@@	O	-1	24275640
t@@	O	-1	24275640
)	O	-1	24275640
to	O	-1	24275640
determine	O	-1	24275640
the	O	-1	24275640
DO@@	B-Chemical	D004317	24275640
X	I-Chemical	-1	24275640
acute	O	-1	24275640
effect	O	-1	24275640
and	O	-1	24275640
(2@@	O	-1	24275640
)	O	-1	24275640
rats	O	-1	24275640
(n	O	-1	24275640
=	O	-1	24275640
5@@	O	-1	24275640
8@@	O	-1	24275640
)	O	-1	24275640
received	O	-1	24275640
4	O	-1	24275640
injec@@	O	-1	24275640
tions	O	-1	24275640
of	O	-1	24275640
DO@@	B-Chemical	D004317	24275640
X	I-Chemical	-1	24275640
(@@	O	-1	24275640
4	O	-1	24275640
mg/kg	O	-1	24275640
body	O	-1	24275640
weigh@@	O	-1	24275640
t@@	O	-1	24275640
/@@	O	-1	24275640
week@@	O	-1	24275640
)	O	-1	24275640
and	O	-1	24275640
were	O	-1	24275640
k@@	O	-1	24275640
ill@@	O	-1	24275640
ed	O	-1	24275640
before	O	-1	24275640
the	O	-1	24275640
first	O	-1	24275640
injection	O	-1	24275640
(@@	O	-1	24275640
M@@	O	-1	24275640
0@@	O	-1	24275640
)	O	-1	24275640
and	O	-1	24275640
1	O	-1	24275640
week	O	-1	24275640
after	O	-1	24275640
each	O	-1	24275640
injection	O	-1	24275640
(@@	O	-1	24275640
M@@	O	-1	24275640
1,	O	-1	24275640
M@@	O	-1	24275640
2,	O	-1	24275640
M@@	O	-1	24275640
3,	O	-1	24275640
and	O	-1	24275640
M@@	O	-1	24275640
4@@	O	-1	24275640
)	O	-1	24275640
to	O	-1	24275640
determine	O	-1	24275640
the	O	-1	24275640
chron@@	O	-1	24275640
ological	O	-1	24275640
effects.	O	-1	24275640
An@@	O	-1	24275640
im@@	O	-1	24275640
als	O	-1	24275640
used	O	-1	24275640
at	O	-1	24275640
M@@	O	-1	24275640
0	O	-1	24275640
(n	O	-1	24275640
=	O	-1	24275640
8@@	O	-1	24275640
)	O	-1	24275640
were	O	-1	24275640
also	O	-1	24275640
used	O	-1	24275640
at	O	-1	24275640
mo@@	O	-1	24275640
ment	O	-1	24275640
-@@	O	-1	24275640
24	O	-1	24275640
h	O	-1	24275640
of	O	-1	24275640
acute	O	-1	24275640
study.	O	-1	24275640
C@@	O	-1	24275640
ardi@@	O	-1	24275640
a@@	O	-1	24275640
c	O	-1	24275640
total	O	-1	24275640
anti@@	O	-1	24275640
oxid@@	O	-1	24275640
ant	O	-1	24275640
perform@@	O	-1	24275640
ance	O	-1	24275640
(T@@	O	-1	24275640
A@@	O	-1	24275640
P@@	O	-1	24275640
),	O	-1	24275640
D@@	O	-1	24275640
NA	O	-1	24275640
dam@@	O	-1	24275640
age,	O	-1	24275640
and	O	-1	24275640
morph@@	O	-1	24275640
ology	O	-1	24275640
analy@@	O	-1	24275640
ses	O	-1	24275640
were	O	-1	24275640
car@@	O	-1	24275640
ri@@	O	-1	24275640
ed	O	-1	24275640
out	O	-1	24275640
at	O	-1	24275640
each	O	-1	24275640
time	O	-1	24275640
po@@	O	-1	24275640
int@@	O	-1	24275640
.	O	-1	24275640
S@@	O	-1	24275640
ing@@	O	-1	24275640
le	O	-1	24275640
dose	O	-1	24275640
of	O	-1	24275640
DO@@	B-Chemical	D004317	24275640
X	I-Chemical	-1	24275640
was	O	-1	24275640
associated	O	-1	24275640
with	O	-1	24275640
increased	O	-1	24275640
cardiac	B-Disease	D006331	24275640
dis@@	I-Disease	-1	24275640
ar@@	I-Disease	-1	24275640
rang@@	I-Disease	-1	24275640
ement	I-Disease	-1	24275640
,	O	-1	24275640
necro@@	B-Disease	D009336	24275640
sis	I-Disease	-1	24275640
,	O	-1	24275640
and	O	-1	24275640
D@@	O	-1	24275640
NA	O	-1	24275640
damage	O	-1	24275640
(@@	O	-1	24275640
str@@	O	-1	24275640
and	O	-1	24275640
b@@	O	-1	24275640
re@@	O	-1	24275640
ak@@	O	-1	24275640
s	O	-1	24275640
(S@@	O	-1	24275640
B@@	O	-1	24275640
s)	O	-1	24275640
and	O	-1	24275640
ox@@	O	-1	24275640
i@@	O	-1	24275640
di@@	O	-1	24275640
zed	O	-1	24275640
pyri@@	O	-1	24275640
mid@@	O	-1	24275640
in@@	O	-1	24275640
es@@	O	-1	24275640
)	O	-1	24275640
and	O	-1	24275640
decreased	O	-1	24275640
TA@@	O	-1	24275640
P@@	O	-1	24275640
.	O	-1	24275640
The	O	-1	24275640
chron@@	O	-1	24275640
ological	O	-1	24275640
study	O	-1	24275640
showed	O	-1	24275640
an	O	-1	24275640
effect	O	-1	24275640
of	O	-1	24275640
a	O	-1	24275640
cum@@	O	-1	24275640
ul@@	O	-1	24275640
ative	O	-1	24275640
dose	O	-1	24275640
on	O	-1	24275640
body	O	-1	24275640
weight	O	-1	24275640
(@@	O	-1	24275640
R	O	-1	24275640
=	O	-1	24275640
-@@	O	-1	24275640
0.@@	O	-1	24275640
9@@	O	-1	24275640
9@@	O	-1	24275640
,	O	-1	24275640
p	O	-1	24275640
=	O	-1	24275640
0.0@@	O	-1	24275640
1@@	O	-1	24275640
1),	O	-1	24275640
necro@@	B-Disease	D009336	24275640
sis	I-Disease	-1	24275640
(@@	O	-1	24275640
R	O	-1	24275640
=	O	-1	24275640
1.@@	O	-1	24275640
0@@	O	-1	24275640
0@@	O	-1	24275640
,	O	-1	24275640
p	O	-1	24275640
=	O	-1	24275640
0.00@@	O	-1	24275640
4@@	O	-1	24275640
),	O	-1	24275640
TA@@	O	-1	24275640
P	O	-1	24275640
(@@	O	-1	24275640
R	O	-1	24275640
=	O	-1	24275640
0.@@	O	-1	24275640
9@@	O	-1	24275640
5,	O	-1	24275640
p	O	-1	24275640
=	O	-1	24275640
0.0@@	O	-1	24275640
4@@	O	-1	24275640
9@@	O	-1	24275640
),	O	-1	24275640
and	O	-1	24275640
D@@	O	-1	24275640
NA	O	-1	24275640
S@@	O	-1	24275640
B@@	O	-1	24275640
s	O	-1	24275640
(@@	O	-1	24275640
R	O	-1	24275640
=	O	-1	24275640
-@@	O	-1	24275640
0.@@	O	-1	24275640
9@@	O	-1	24275640
5,	O	-1	24275640
p	O	-1	24275640
=	O	-1	24275640
0.0@@	O	-1	24275640
4@@	O	-1	24275640
9@@	O	-1	24275640
).	O	-1	24275640
D@@	O	-1	24275640
NA	O	-1	24275640
S@@	O	-1	24275640
B@@	O	-1	24275640
s	O	-1	24275640
damage	O	-1	24275640
was	O	-1	24275640
neg@@	O	-1	24275640
atively	O	-1	24275640
associated	O	-1	24275640
with	O	-1	24275640
TA@@	O	-1	24275640
P	O	-1	24275640
(@@	O	-1	24275640
R	O	-1	24275640
=	O	-1	24275640
-@@	O	-1	24275640
0.@@	O	-1	24275640
9@@	O	-1	24275640
8@@	O	-1	24275640
,	O	-1	24275640
p	O	-1	24275640
=	O	-1	24275640
0.0@@	O	-1	24275640
18@@	O	-1	24275640
),	O	-1	24275640
and	O	-1	24275640
necro@@	B-Disease	D009336	24275640
sis	I-Disease	-1	24275640
(@@	O	-1	24275640
R	O	-1	24275640
=	O	-1	24275640
-@@	O	-1	24275640
0.@@	O	-1	24275640
9@@	O	-1	24275640
7@@	O	-1	24275640
,	O	-1	24275640
p	O	-1	24275640
=	O	-1	24275640
0.0@@	O	-1	24275640
27@@	O	-1	24275640
).	O	-1	24275640
Our	O	-1	24275640
results	O	-1	24275640
suggest	O	-1	24275640
that	O	-1	24275640
oxid@@	O	-1	24275640
ative	O	-1	24275640
damage	O	-1	24275640
is	O	-1	24275640
associated	O	-1	24275640
with	O	-1	24275640
acute	O	-1	24275640
cardi@@	B-Disease	D066126	24275640
otoxicity	I-Disease	-1	24275640
induced	O	-1	24275640
by	O	-1	24275640
a	O	-1	24275640
single	O	-1	24275640
dose	O	-1	24275640
of	O	-1	24275640
DO@@	B-Chemical	D004317	24275640
X	I-Chemical	-1	24275640
on@@	O	-1	24275640
ly.	O	-1	24275640
In@@	O	-1	24275640
c@@	O	-1	24275640
reas@@	O	-1	24275640
ed	O	-1	24275640
resist@@	O	-1	24275640
ance	O	-1	24275640
to	O	-1	24275640
the	O	-1	24275640
oxid@@	O	-1	24275640
ative	O	-1	24275640
stres@@	O	-1	24275640
s	O	-1	24275640
is	O	-1	24275640
pl@@	O	-1	24275640
au@@	O	-1	24275640
sible	O	-1	24275640
for	O	-1	24275640
the	O	-1	24275640
multiple	O	-1	24275640
dose	O	-1	24275640
of	O	-1	24275640
DO@@	B-Chemical	D004317	24275640
X	I-Chemical	-1	24275640
.	O	-1	24275640
Th@@	O	-1	24275640
us,	O	-1	24275640
different	O	-1	24275640
mechanisms	O	-1	24275640
may	O	-1	24275640
be	O	-1	24275640
involved	O	-1	24275640
in	O	-1	24275640
acute	O	-1	24275640
toxicity	B-Disease	D064420	24275640
versus	O	-1	24275640
chronic	O	-1	24275640
toxicity	B-Disease	D064420	24275640
.	O	-1	24275640

T@@	B-Chemical	D016559	24283660
ac@@	I-Chemical	-1	24283660
rolimus	I-Chemical	-1	24283660
-@@	O	-1	24283660
related	O	-1	24283660
seizure	B-Disease	D012640	24283660
after	O	-1	24283660
pe@@	O	-1	24283660
di@@	O	-1	24283660
atric	O	-1	24283660
liver	O	-1	24283660
transplant@@	O	-1	24283660
ation@@	O	-1	24283660
-@@	O	-1	24283660
-@@	O	-1	24283660
a	O	-1	24283660
sing@@	O	-1	24283660
le@@	O	-1	24283660
-@@	O	-1	24283660
c@@	O	-1	24283660
ent@@	O	-1	24283660
er	O	-1	24283660
experi@@	O	-1	24283660
ence@@	O	-1	24283660
.	O	-1	24283660
To	O	-1	24283660
identi@@	O	-1	24283660
f@@	O	-1	24283660
y	O	-1	24283660
the	O	-1	24283660
risk	O	-1	24283660
factors	O	-1	24283660
for	O	-1	24283660
ne@@	O	-1	24283660
w@@	O	-1	24283660
-@@	O	-1	24283660
onset	O	-1	24283660
seizures	B-Disease	D012640	24283660
after	O	-1	24283660
pe@@	O	-1	24283660
di@@	O	-1	24283660
atric	O	-1	24283660
L@@	O	-1	24283660
T	O	-1	24283660
and	O	-1	24283660
to	O	-1	24283660
ass@@	O	-1	24283660
ess	O	-1	24283660
their	O	-1	24283660
clinical	O	-1	24283660
implic@@	O	-1	24283660
ations	O	-1	24283660
and	O	-1	24283660
long-term	O	-1	24283660
pro@@	O	-1	24283660
g@@	O	-1	24283660
no@@	O	-1	24283660
sis.	O	-1	24283660
The	O	-1	24283660
clinical	O	-1	24283660
and	O	-1	24283660
labor@@	O	-1	24283660
atory	O	-1	24283660
data	O	-1	24283660
of	O	-1	24283660
2@@	O	-1	24283660
7	O	-1	24283660
con@@	O	-1	24283660
sec@@	O	-1	24283660
utive	O	-1	24283660
children	O	-1	24283660
who	O	-1	24283660
under@@	O	-1	24283660
w@@	O	-1	24283660
ent	O	-1	24283660
L@@	O	-1	24283660
T	O	-1	24283660
from	O	-1	24283660
J@@	O	-1	24283660
an@@	O	-1	24283660
u@@	O	-1	24283660
ary	O	-1	24283660
20@@	O	-1	24283660
0@@	O	-1	24283660
7	O	-1	24283660
to	O	-1	24283660
D@@	O	-1	24283660
ec@@	O	-1	24283660
emb@@	O	-1	24283660
er	O	-1	24283660
20@@	O	-1	24283660
10	O	-1	24283660
in	O	-1	24283660
our	O	-1	24283660
c@@	O	-1	24283660
ent@@	O	-1	24283660
er	O	-1	24283660
were	O	-1	24283660
analy@@	O	-1	24283660
zed	O	-1	24283660
ret@@	O	-1	24283660
ro@@	O	-1	24283660
sp@@	O	-1	24283660
ecti@@	O	-1	24283660
vel@@	O	-1	24283660
y.	O	-1	24283660
Patients	O	-1	24283660
were	O	-1	24283660
divid@@	O	-1	24283660
ed	O	-1	24283660
into	O	-1	24283660
seizures	B-Disease	D012640	24283660
group	O	-1	24283660
and	O	-1	24283660
a	O	-1	24283660
non@@	O	-1	24283660
-	O	-1	24283660
seizures	B-Disease	D012640	24283660
group.	O	-1	24283660
Pre@@	O	-1	24283660
-@@	O	-1	24283660
o@@	O	-1	24283660
per@@	O	-1	24283660
ati@@	O	-1	24283660
ve,	O	-1	24283660
intra@@	O	-1	24283660
-@@	O	-1	24283660
o@@	O	-1	24283660
per@@	O	-1	24283660
ati@@	O	-1	24283660
ve,	O	-1	24283660
and	O	-1	24283660
post@@	O	-1	24283660
-@@	O	-1	24283660
o@@	O	-1	24283660
perative	O	-1	24283660
data	O	-1	24283660
were	O	-1	24283660
coll@@	O	-1	24283660
ect@@	O	-1	24283660
ed.	O	-1	24283660
S@@	B-Disease	D012640	24283660
e@@	I-Disease	-1	24283660
iz@@	I-Disease	-1	24283660
ures	I-Disease	-1	24283660
occurred	O	-1	24283660
in	O	-1	24283660
four	O	-1	24283660
child@@	O	-1	24283660
ren@@	O	-1	24283660
,	O	-1	24283660
an	O	-1	24283660
incidence	O	-1	24283660
of	O	-1	24283660
1@@	O	-1	24283660
4.@@	O	-1	24283660
8@@	O	-1	24283660
%.	O	-1	24283660
All	O	-1	24283660
ex@@	O	-1	24283660
hib@@	O	-1	24283660
ited	O	-1	24283660
gener@@	O	-1	24283660
al@@	O	-1	24283660
ized	O	-1	24283660
t@@	B-Disease	D004830	24283660
on@@	I-Disease	-1	24283660
ic@@	I-Disease	-1	24283660
-@@	I-Disease	-1	24283660
clon@@	I-Disease	-1	24283660
ic	I-Disease	-1	24283660
seizures	I-Disease	-1	24283660
within	O	-1	24283660
the	O	-1	24283660
first	O	-1	24283660
two	O	-1	24283660
w@@	O	-1	24283660
k	O	-1	24283660
after	O	-1	24283660
LT@@	O	-1	24283660
.	O	-1	24283660
U@@	O	-1	24283660
n@@	O	-1	24283660
i@@	O	-1	24283660
vari@@	O	-1	24283660
ate	O	-1	24283660
analysis	O	-1	24283660
showed	O	-1	24283660
that	O	-1	24283660
the	O	-1	24283660
risk	O	-1	24283660
factors	O	-1	24283660
associated	O	-1	24283660
with	O	-1	24283660
seizures	B-Disease	D012640	24283660
after	O	-1	24283660
pe@@	O	-1	24283660
di@@	O	-1	24283660
atric	O	-1	24283660
L@@	O	-1	24283660
T	O	-1	24283660
included	O	-1	24283660
gen@@	O	-1	24283660
der@@	O	-1	24283660
,	O	-1	24283660
pe@@	O	-1	24283660
di@@	O	-1	24283660
atric	O	-1	24283660
en@@	B-Disease	D058625	24283660
d-@@	I-Disease	-1	24283660
st@@	I-Disease	-1	24283660
age	I-Disease	-1	24283660
liver	I-Disease	-1	24283660
disease	I-Disease	-1	24283660
scor@@	O	-1	24283660
e	O	-1	24283660
before	O	-1	24283660
surger@@	O	-1	24283660
y,	O	-1	24283660
Ch@@	O	-1	24283660
il@@	O	-1	24283660
d-@@	O	-1	24283660
P@@	O	-1	24283660
u@@	O	-1	24283660
gh	O	-1	24283660
scor@@	O	-1	24283660
e	O	-1	24283660
before	O	-1	24283660
surger@@	O	-1	24283660
y,	O	-1	24283660
serum	O	-1	24283660
total	O	-1	24283660
bil@@	B-Chemical	D001663	24283660
i@@	I-Chemical	-1	24283660
ru@@	I-Chemical	-1	24283660
bin	I-Chemical	-1	24283660
after	O	-1	24283660
surger@@	O	-1	24283660
y,	O	-1	24283660
and	O	-1	24283660
t@@	O	-1	24283660
rou@@	O	-1	24283660
gh	O	-1	24283660
TA@@	B-Chemical	D016559	24283660
C	I-Chemical	-1	24283660
level@@	O	-1	24283660
.	O	-1	24283660
M@@	O	-1	24283660
ul@@	O	-1	24283660
tiv@@	O	-1	24283660
ari@@	O	-1	24283660
ate	O	-1	24283660
analysis	O	-1	24283660
showed	O	-1	24283660
that	O	-1	24283660
t@@	O	-1	24283660
rou@@	O	-1	24283660
gh	O	-1	24283660
TA@@	B-Chemical	D016559	24283660
C	I-Chemical	-1	24283660
level	O	-1	24283660
was	O	-1	24283660
the	O	-1	24283660
only	O	-1	24283660
in@@	O	-1	24283660
dependent	O	-1	24283660
risk	O	-1	24283660
factor	O	-1	24283660
associated	O	-1	24283660
with	O	-1	24283660
the	O	-1	24283660
seizures	B-Disease	D012640	24283660
.	O	-1	24283660
All	O	-1	24283660
children	O	-1	24283660
who	O	-1	24283660
experienced	O	-1	24283660
seizures	B-Disease	D012640	24283660
sur@@	O	-1	24283660
vi@@	O	-1	24283660
ved	O	-1	24283660
with	O	-1	24283660
go@@	O	-1	24283660
od	O	-1	24283660
gra@@	O	-1	24283660
ft	O	-1	24283660
function	O	-1	24283660
and	O	-1	24283660
remained	O	-1	24283660
seizure	B-Disease	D012640	24283660
-@@	O	-1	24283660
free	O	-1	24283660
without	O	-1	24283660
anti@@	O	-1	24283660
-	O	-1	24283660
epileptic	B-Disease	D004827	24283660
drugs	O	-1	24283660
over	O	-1	24283660
a	O	-1	24283660
mean	O	-1	24283660
follow-up	O	-1	24283660
period	O	-1	24283660
of	O	-1	24283660
3@@	O	-1	24283660
3.@@	O	-1	24283660
7	O	-1	24283660
+	O	-1	24283660
1@@	O	-1	24283660
4.@@	O	-1	24283660
6	O	-1	24283660
months.	O	-1	24283660
H@@	O	-1	24283660
i@@	O	-1	24283660
gh	O	-1	24283660
t@@	O	-1	24283660
rou@@	O	-1	24283660
gh	O	-1	24283660
TA@@	B-Chemical	D016559	24283660
C	I-Chemical	-1	24283660
level	O	-1	24283660
was	O	-1	24283660
the	O	-1	24283660
pre@@	O	-1	24283660
domin@@	O	-1	24283660
ant	O	-1	24283660
factor	O	-1	24283660
that	O	-1	24283660
cont@@	O	-1	24283660
ri@@	O	-1	24283660
but@@	O	-1	24283660
ed	O	-1	24283660
to	O	-1	24283660
seizures	B-Disease	D012640	24283660
in	O	-1	24283660
the	O	-1	24283660
early	O	-1	24283660
post@@	O	-1	24283660
-@@	O	-1	24283660
o@@	O	-1	24283660
perative	O	-1	24283660
period	O	-1	24283660
after	O	-1	24283660
pe@@	O	-1	24283660
di@@	O	-1	24283660
atric	O	-1	24283660
LT@@	O	-1	24283660
.	O	-1	24283660
H@@	O	-1	24283660
i@@	O	-1	24283660
gh	O	-1	24283660
P@@	O	-1	24283660
E@@	O	-1	24283660
L@@	O	-1	24283660
D	O	-1	24283660
and	O	-1	24283660
Ch@@	O	-1	24283660
il@@	O	-1	24283660
d-@@	O	-1	24283660
P@@	O	-1	24283660
u@@	O	-1	24283660
gh	O	-1	24283660
sco@@	O	-1	24283660
res	O	-1	24283660
before	O	-1	24283660
L@@	O	-1	24283660
T	O	-1	24283660
and	O	-1	24283660
high	O	-1	24283660
post@@	O	-1	24283660
-@@	O	-1	24283660
o@@	O	-1	24283660
perative	O	-1	24283660
serum	O	-1	24283660
T@@	O	-1	24283660
b@@	O	-1	24283660
il	O	-1	24283660
may	O	-1	24283660
be	O	-1	24283660
cont@@	O	-1	24283660
ri@@	O	-1	24283660
but@@	O	-1	24283660
ory	O	-1	24283660
risk	O	-1	24283660
factors	O	-1	24283660
for	O	-1	24283660
TA@@	B-Chemical	D016559	24283660
C	I-Chemical	-1	24283660
-@@	O	-1	24283660
related	O	-1	24283660
seizures	B-Disease	D012640	24283660
.	O	-1	24283660

The	O	-1	24284476
f@@	B-Chemical	D005419	24284476
l@@	I-Chemical	-1	24284476
av@@	I-Chemical	-1	24284476
on@@	I-Chemical	-1	24284476
oid	I-Chemical	-1	24284476
ap@@	B-Chemical	D047310	24284476
i@@	I-Chemical	-1	24284476
gen@@	I-Chemical	-1	24284476
in	I-Chemical	-1	24284476
del@@	O	-1	24284476
ays	O	-1	24284476
for@@	O	-1	24284476
g@@	O	-1	24284476
et@@	O	-1	24284476
ting	O	-1	24284476
of	O	-1	24284476
p@@	O	-1	24284476
as@@	O	-1	24284476
sive	O	-1	24284476
avoid@@	O	-1	24284476
ance	O	-1	24284476
condi@@	O	-1	24284476
tion@@	O	-1	24284476
ing	O	-1	24284476
in	O	-1	24284476
rats.	O	-1	24284476
The	O	-1	24284476
present	O	-1	24284476
experim@@	O	-1	24284476
ents	O	-1	24284476
were	O	-1	24284476
performed	O	-1	24284476
to	O	-1	24284476
study	O	-1	24284476
the	O	-1	24284476
effect	O	-1	24284476
of	O	-1	24284476
the	O	-1	24284476
f@@	B-Chemical	D005419	24284476
l@@	I-Chemical	-1	24284476
av@@	I-Chemical	-1	24284476
on@@	I-Chemical	-1	24284476
oid	I-Chemical	-1	24284476
ap@@	B-Chemical	D047310	24284476
i@@	I-Chemical	-1	24284476
gen@@	I-Chemical	-1	24284476
in	I-Chemical	-1	24284476
(2@@	O	-1	24284476
0	O	-1	24284476
mg/kg	O	-1	24284476
intra@@	O	-1	24284476
per@@	O	-1	24284476
it@@	O	-1	24284476
one@@	O	-1	24284476
ally	O	-1	24284476
(@@	O	-1	24284476
i.p.@@	O	-1	24284476
),	O	-1	24284476
1	O	-1	24284476
h	O	-1	24284476
before	O	-1	24284476
ac@@	O	-1	24284476
qu@@	O	-1	24284476
i@@	O	-1	24284476
si@@	O	-1	24284476
tion@@	O	-1	24284476
),	O	-1	24284476
on	O	-1	24284476
24	O	-1	24284476
h	O	-1	24284476
re@@	O	-1	24284476
ten@@	O	-1	24284476
tion	O	-1	24284476
perform@@	O	-1	24284476
ance	O	-1	24284476
and	O	-1	24284476
for@@	O	-1	24284476
g@@	O	-1	24284476
et@@	O	-1	24284476
ting	O	-1	24284476
of	O	-1	24284476
a	O	-1	24284476
st@@	O	-1	24284476
ep@@	O	-1	24284476
-@@	O	-1	24284476
through	O	-1	24284476
p@@	O	-1	24284476
as@@	O	-1	24284476
sive	O	-1	24284476
avoid@@	O	-1	24284476
ance	O	-1	24284476
t@@	O	-1	24284476
as@@	O	-1	24284476
k@@	O	-1	24284476
,	O	-1	24284476
in	O	-1	24284476
youn@@	O	-1	24284476
g	O	-1	24284476
male	O	-1	24284476
Wistar	O	-1	24284476
rats.	O	-1	24284476
There	O	-1	24284476
were	O	-1	24284476
no	O	-1	24284476
differences	O	-1	24284476
between	O	-1	24284476
sal@@	O	-1	24284476
ine@@	O	-1	24284476
-	O	-1	24284476
and	O	-1	24284476
ap@@	B-Chemical	D047310	24284476
i@@	I-Chemical	-1	24284476
gen@@	I-Chemical	-1	24284476
in	I-Chemical	-1	24284476
-treated	O	-1	24284476
groups	O	-1	24284476
in	O	-1	24284476
the	O	-1	24284476
24	O	-1	24284476
h	O	-1	24284476
re@@	O	-1	24284476
ten@@	O	-1	24284476
tion	O	-1	24284476
tri@@	O	-1	24284476
al.	O	-1	24284476
F@@	O	-1	24284476
ur@@	O	-1	24284476
ther@@	O	-1	24284476
mo@@	O	-1	24284476
re,	O	-1	24284476
ap@@	B-Chemical	D047310	24284476
i@@	I-Chemical	-1	24284476
gen@@	I-Chemical	-1	24284476
in	I-Chemical	-1	24284476
did	O	-1	24284476
not	O	-1	24284476
prev@@	O	-1	24284476
ent	O	-1	24284476
the	O	-1	24284476
am@@	B-Disease	D000647	24284476
ne@@	I-Disease	-1	24284476
sia	I-Disease	-1	24284476
induced	O	-1	24284476
by	O	-1	24284476
scopol@@	B-Chemical	D012601	24284476
amine	I-Chemical	-1	24284476
(1@@	O	-1	24284476
mg/kg@@	O	-1	24284476
,	O	-1	24284476
i.p.@@	O	-1	24284476
,	O	-1	24284476
30	O	-1	24284476
min	O	-1	24284476
before	O	-1	24284476
the	O	-1	24284476
ac@@	O	-1	24284476
qu@@	O	-1	24284476
i@@	O	-1	24284476
si@@	O	-1	24284476
tion@@	O	-1	24284476
).	O	-1	24284476
The	O	-1	24284476
sal@@	O	-1	24284476
ine@@	O	-1	24284476
-	O	-1	24284476
and	O	-1	24284476
ap@@	B-Chemical	D047310	24284476
i@@	I-Chemical	-1	24284476
gen@@	I-Chemical	-1	24284476
in	I-Chemical	-1	24284476
-treated	O	-1	24284476
rats	O	-1	24284476
that	O	-1	24284476
did	O	-1	24284476
not	O	-1	24284476
st@@	O	-1	24284476
ep	O	-1	24284476
through	O	-1	24284476
into	O	-1	24284476
the	O	-1	24284476
d@@	O	-1	24284476
ar@@	O	-1	24284476
k	O	-1	24284476
compar@@	O	-1	24284476
t@@	O	-1	24284476
ment	O	-1	24284476
during	O	-1	24284476
the	O	-1	24284476
c@@	O	-1	24284476
ut@@	O	-1	24284476
-@@	O	-1	24284476
of@@	O	-1	24284476
f	O	-1	24284476
time	O	-1	24284476
(5@@	O	-1	24284476
40	O	-1	24284476
s)	O	-1	24284476
were	O	-1	24284476
re@@	O	-1	24284476
tested	O	-1	24284476
week@@	O	-1	24284476
ly	O	-1	24284476
for	O	-1	24284476
up	O	-1	24284476
to	O	-1	24284476
e@@	O	-1	24284476
ight	O	-1	24284476
week@@	O	-1	24284476
s.	O	-1	24284476
In	O	-1	24284476
the	O	-1	24284476
saline	O	-1	24284476
treated	O	-1	24284476
group@@	O	-1	24284476
,	O	-1	24284476
the	O	-1	24284476
first	O	-1	24284476
significant	O	-1	24284476
dec@@	O	-1	24284476
line	O	-1	24284476
in	O	-1	24284476
p@@	O	-1	24284476
as@@	O	-1	24284476
sive	O	-1	24284476
avoid@@	O	-1	24284476
ance	O	-1	24284476
response	O	-1	24284476
was	O	-1	24284476
observed	O	-1	24284476
at	O	-1	24284476
four	O	-1	24284476
week@@	O	-1	24284476
s,	O	-1	24284476
and	O	-1	24284476
complete	O	-1	24284476
memory	B-Disease	D008569	24284476
loss	I-Disease	-1	24284476
was	O	-1	24284476
found	O	-1	24284476
five	O	-1	24284476
weeks	O	-1	24284476
after	O	-1	24284476
the	O	-1	24284476
ac@@	O	-1	24284476
qu@@	O	-1	24284476
i@@	O	-1	24284476
si@@	O	-1	24284476
tion	O	-1	24284476
of	O	-1	24284476
the	O	-1	24284476
p@@	O	-1	24284476
as@@	O	-1	24284476
sive	O	-1	24284476
avoid@@	O	-1	24284476
ance	O	-1	24284476
t@@	O	-1	24284476
as@@	O	-1	24284476
k@@	O	-1	24284476
.	O	-1	24284476
A@@	O	-1	24284476
t	O	-1	24284476
the	O	-1	24284476
end	O	-1	24284476
of	O	-1	24284476
the	O	-1	24284476
experimental	O	-1	24284476
perio@@	O	-1	24284476
d,	O	-1	24284476
6@@	O	-1	24284476
0%	O	-1	24284476
of	O	-1	24284476
the	O	-1	24284476
animals	O	-1	24284476
treated	O	-1	24284476
with	O	-1	24284476
ap@@	B-Chemical	D047310	24284476
i@@	I-Chemical	-1	24284476
gen@@	I-Chemical	-1	24284476
in	I-Chemical	-1	24284476
sti@@	O	-1	24284476
ll	O	-1	24284476
did	O	-1	24284476
not	O	-1	24284476
st@@	O	-1	24284476
ep	O	-1	24284476
throu@@	O	-1	24284476
gh@@	O	-1	24284476
.	O	-1	24284476
These	O	-1	24284476
data	O	-1	24284476
suggest	O	-1	24284476
that	O	-1	24284476
1)	O	-1	24284476
ap@@	B-Chemical	D047310	24284476
i@@	I-Chemical	-1	24284476
gen@@	I-Chemical	-1	24284476
in	I-Chemical	-1	24284476
del@@	O	-1	24284476
ays	O	-1	24284476
the	O	-1	24284476
long-term	O	-1	24284476
for@@	O	-1	24284476
g@@	O	-1	24284476
et@@	O	-1	24284476
ting	O	-1	24284476
but	O	-1	24284476
did	O	-1	24284476
not	O	-1	24284476
mod@@	O	-1	24284476
ul@@	O	-1	24284476
ate	O	-1	24284476
the	O	-1	24284476
24	O	-1	24284476
h	O	-1	24284476
re@@	O	-1	24284476
ten@@	O	-1	24284476
tion	O	-1	24284476
of	O	-1	24284476
fe@@	O	-1	24284476
ar	O	-1	24284476
memory	O	-1	24284476
and	O	-1	24284476
2)	O	-1	24284476
the	O	-1	24284476
obtained	O	-1	24284476
ben@@	O	-1	24284476
e@@	O	-1	24284476
fic@@	O	-1	24284476
ial	O	-1	24284476
effect	O	-1	24284476
of	O	-1	24284476
ap@@	B-Chemical	D047310	24284476
i@@	I-Chemical	-1	24284476
gen@@	I-Chemical	-1	24284476
in	I-Chemical	-1	24284476
on	O	-1	24284476
the	O	-1	24284476
p@@	O	-1	24284476
as@@	O	-1	24284476
sive	O	-1	24284476
avoid@@	O	-1	24284476
ance	O	-1	24284476
condi@@	O	-1	24284476
tion@@	O	-1	24284476
ing	O	-1	24284476
is	O	-1	24284476
mediated	O	-1	24284476
by	O	-1	24284476
mechanisms	O	-1	24284476
that	O	-1	24284476
d@@	O	-1	24284476
o	O	-1	24284476
not	O	-1	24284476
implic@@	O	-1	24284476
ate	O	-1	24284476
its	O	-1	24284476
action	O	-1	24284476
on	O	-1	24284476
the	O	-1	24284476
mus@@	O	-1	24284476
car@@	O	-1	24284476
inic	O	-1	24284476
cholinergic	O	-1	24284476
system@@	O	-1	24284476
.	O	-1	24284476

Ch@@	B-Chemical	D012844	24309294
ol@@	I-Chemical	-1	24309294
ec@@	I-Chemical	-1	24309294
y@@	I-Chemical	-1	24309294
sto@@	I-Chemical	-1	24309294
kin@@	I-Chemical	-1	24309294
in-@@	I-Chemical	-1	24309294
oc@@	I-Chemical	-1	24309294
t@@	I-Chemical	-1	24309294
ap@@	I-Chemical	-1	24309294
ep@@	I-Chemical	-1	24309294
ti@@	I-Chemical	-1	24309294
de	I-Chemical	-1	24309294
re@@	O	-1	24309294
sto@@	O	-1	24309294
red	O	-1	24309294
morphine	B-Chemical	D009020	24309294
-induced	O	-1	24309294
hippocamp@@	O	-1	24309294
al	O	-1	24309294
long-term	O	-1	24309294
potenti@@	O	-1	24309294
ation	O	-1	24309294
impair@@	O	-1	24309294
ment	O	-1	24309294
in	O	-1	24309294
rats.	O	-1	24309294
Ch@@	B-Chemical	D012844	24309294
ol@@	I-Chemical	-1	24309294
ec@@	I-Chemical	-1	24309294
y@@	I-Chemical	-1	24309294
sto@@	I-Chemical	-1	24309294
kin@@	I-Chemical	-1	24309294
in-@@	I-Chemical	-1	24309294
oc@@	I-Chemical	-1	24309294
t@@	I-Chemical	-1	24309294
ap@@	I-Chemical	-1	24309294
ep@@	I-Chemical	-1	24309294
ti@@	I-Chemical	-1	24309294
de	I-Chemical	-1	24309294
(	O	-1	24309294
C@@	B-Chemical	D012844	24309294
C@@	I-Chemical	-1	24309294
K@@	I-Chemical	-1	24309294
-@@	I-Chemical	-1	24309294
8	I-Chemical	-1	24309294
),	O	-1	24309294
which	O	-1	24309294
is	O	-1	24309294
a	O	-1	24309294
typ@@	O	-1	24309294
ical	O	-1	24309294
bra@@	O	-1	24309294
in-@@	O	-1	24309294
gu@@	O	-1	24309294
t	O	-1	24309294
p@@	O	-1	24309294
ep@@	O	-1	24309294
ti@@	O	-1	24309294
de@@	O	-1	24309294
,	O	-1	24309294
ex@@	O	-1	24309294
er@@	O	-1	24309294
ts	O	-1	24309294
a	O	-1	24309294
w@@	O	-1	24309294
ide	O	-1	24309294
range	O	-1	24309294
of	O	-1	24309294
bio@@	O	-1	24309294
log@@	O	-1	24309294
ical	O	-1	24309294
ac@@	O	-1	24309294
ti@@	O	-1	24309294
vi@@	O	-1	24309294
ties	O	-1	24309294
on	O	-1	24309294
the	O	-1	24309294
central	O	-1	24309294
ner@@	O	-1	24309294
v@@	O	-1	24309294
ous	O	-1	24309294
system@@	O	-1	24309294
.	O	-1	24309294
We	O	-1	24309294
have	O	-1	24309294
previously	O	-1	24309294
reported	O	-1	24309294
that	O	-1	24309294
C@@	B-Chemical	D012844	24309294
C@@	I-Chemical	-1	24309294
K@@	I-Chemical	-1	24309294
-@@	I-Chemical	-1	24309294
8	I-Chemical	-1	24309294
significantly	O	-1	24309294
al@@	O	-1	24309294
le@@	O	-1	24309294
vi@@	O	-1	24309294
ated	O	-1	24309294
morphine	B-Chemical	D009020	24309294
-induced	O	-1	24309294
am@@	B-Disease	D000647	24309294
ne@@	I-Disease	-1	24309294
sia	I-Disease	-1	24309294
and	O	-1	24309294
reversed	O	-1	24309294
sp@@	O	-1	24309294
ine	O	-1	24309294
d@@	O	-1	24309294
ensity	O	-1	24309294
decreas@@	O	-1	24309294
es	O	-1	24309294
in	O	-1	24309294
the	O	-1	24309294
CA@@	O	-1	24309294
1	O	-1	24309294
regi@@	O	-1	24309294
on	O	-1	24309294
of	O	-1	24309294
the	O	-1	24309294
hippocamp@@	O	-1	24309294
us	O	-1	24309294
in	O	-1	24309294
morphine	B-Chemical	D009020	24309294
-treated	O	-1	24309294
anim@@	O	-1	24309294
al@@	O	-1	24309294
s.	O	-1	24309294
He@@	O	-1	24309294
re,	O	-1	24309294
we	O	-1	24309294
investigated	O	-1	24309294
the	O	-1	24309294
effects	O	-1	24309294
of	O	-1	24309294
C@@	B-Chemical	D012844	24309294
C@@	I-Chemical	-1	24309294
K@@	I-Chemical	-1	24309294
-@@	I-Chemical	-1	24309294
8	I-Chemical	-1	24309294
on	O	-1	24309294
long-term	O	-1	24309294
potenti@@	O	-1	24309294
ation	O	-1	24309294
(@@	O	-1	24309294
LT@@	O	-1	24309294
P)	O	-1	24309294
in	O	-1	24309294
the	O	-1	24309294
lat@@	O	-1	24309294
eral	O	-1	24309294
per@@	O	-1	24309294
for@@	O	-1	24309294
ant	O	-1	24309294
pat@@	O	-1	24309294
h	O	-1	24309294
(@@	O	-1	24309294
L@@	O	-1	24309294
P@@	O	-1	24309294
P@@	O	-1	24309294
)-@@	O	-1	24309294
gran@@	O	-1	24309294
ul@@	O	-1	24309294
e	O	-1	24309294
cell	O	-1	24309294
syn@@	O	-1	24309294
ap@@	O	-1	24309294
se	O	-1	24309294
of	O	-1	24309294
rat	O	-1	24309294
d@@	O	-1	24309294
ent@@	O	-1	24309294
ate	O	-1	24309294
g@@	O	-1	24309294
y@@	O	-1	24309294
ru@@	O	-1	24309294
s	O	-1	24309294
(D@@	O	-1	24309294
G@@	O	-1	24309294
)	O	-1	24309294
in	O	-1	24309294
acute	O	-1	24309294
saline	O	-1	24309294
or	O	-1	24309294
morphine	B-Chemical	D009020	24309294
-treated	O	-1	24309294
rats.	O	-1	24309294
P@@	O	-1	24309294
op@@	O	-1	24309294
ulation	O	-1	24309294
s@@	O	-1	24309294
pi@@	O	-1	24309294
k@@	O	-1	24309294
es	O	-1	24309294
(P@@	O	-1	24309294
S@@	O	-1	24309294
),	O	-1	24309294
which	O	-1	24309294
were	O	-1	24309294
evoked	O	-1	24309294
by	O	-1	24309294
stimulation	O	-1	24309294
of	O	-1	24309294
the	O	-1	24309294
L@@	O	-1	24309294
P@@	O	-1	24309294
P@@	O	-1	24309294
,	O	-1	24309294
were	O	-1	24309294
recor@@	O	-1	24309294
ded	O	-1	24309294
in	O	-1	24309294
the	O	-1	24309294
D@@	O	-1	24309294
G	O	-1	24309294
regi@@	O	-1	24309294
on@@	O	-1	24309294
.	O	-1	24309294
Ac@@	O	-1	24309294
ute	O	-1	24309294
morphine	B-Chemical	D009020	24309294
(3@@	O	-1	24309294
0@@	O	-1	24309294
mg/kg@@	O	-1	24309294
,	O	-1	24309294
s@@	O	-1	24309294
.@@	O	-1	24309294
c@@	O	-1	24309294
.)	O	-1	24309294
treatment	O	-1	24309294
significantly	O	-1	24309294
attenu@@	O	-1	24309294
ated	O	-1	24309294
hippocamp@@	O	-1	24309294
al	O	-1	24309294
LT@@	O	-1	24309294
P	O	-1	24309294
and	O	-1	24309294
C@@	B-Chemical	D012844	24309294
C@@	I-Chemical	-1	24309294
K@@	I-Chemical	-1	24309294
-@@	I-Chemical	-1	24309294
8	I-Chemical	-1	24309294
(1@@	O	-1	24309294
u@@	O	-1	24309294
g@@	O	-1	24309294
,	O	-1	24309294
i.@@	O	-1	24309294
c@@	O	-1	24309294
.@@	O	-1	24309294
v@@	O	-1	24309294
.)	O	-1	24309294
re@@	O	-1	24309294
sto@@	O	-1	24309294
red	O	-1	24309294
the	O	-1	24309294
am@@	O	-1	24309294
pl@@	O	-1	24309294
it@@	O	-1	24309294
ude	O	-1	24309294
of	O	-1	24309294
P@@	O	-1	24309294
S	O	-1	24309294
that	O	-1	24309294
was	O	-1	24309294
attenu@@	O	-1	24309294
ated	O	-1	24309294
by	O	-1	24309294
morphine	B-Chemical	D009020	24309294
injec@@	O	-1	24309294
tion.	O	-1	24309294
F@@	O	-1	24309294
ur@@	O	-1	24309294
ther@@	O	-1	24309294
mo@@	O	-1	24309294
re,	O	-1	24309294
micro@@	O	-1	24309294
injection	O	-1	24309294
of	O	-1	24309294
C@@	B-Chemical	D012844	24309294
C@@	I-Chemical	-1	24309294
K@@	I-Chemical	-1	24309294
-@@	I-Chemical	-1	24309294
8	I-Chemical	-1	24309294
(0.@@	O	-1	24309294
1	O	-1	24309294
and	O	-1	24309294
1@@	O	-1	24309294
u@@	O	-1	24309294
g@@	O	-1	24309294
,	O	-1	24309294
i.@@	O	-1	24309294
c@@	O	-1	24309294
.@@	O	-1	24309294
v@@	O	-1	24309294
.)	O	-1	24309294
also	O	-1	24309294
significantly	O	-1	24309294
au@@	O	-1	24309294
g@@	O	-1	24309294
ment@@	O	-1	24309294
ed	O	-1	24309294
hippocamp@@	O	-1	24309294
al	O	-1	24309294
LT@@	O	-1	24309294
P	O	-1	24309294
in	O	-1	24309294
sal@@	O	-1	24309294
ine-@@	O	-1	24309294
treated	O	-1	24309294
(1@@	O	-1	24309294
ml@@	O	-1	24309294
/@@	O	-1	24309294
kg@@	O	-1	24309294
,	O	-1	24309294
s@@	O	-1	24309294
.@@	O	-1	24309294
c@@	O	-1	24309294
.)	O	-1	24309294
rats.	O	-1	24309294
Pre@@	O	-1	24309294
-@@	O	-1	24309294
treatment	O	-1	24309294
of	O	-1	24309294
the	O	-1	24309294
C@@	O	-1	24309294
C@@	O	-1	24309294
K@@	O	-1	24309294
2	O	-1	24309294
receptor	O	-1	24309294
antagonist	O	-1	24309294
L-@@	O	-1	24309294
3@@	O	-1	24309294
6@@	O	-1	24309294
5@@	O	-1	24309294
,@@	O	-1	24309294
2@@	O	-1	24309294
60	O	-1	24309294
(@@	O	-1	24309294
10@@	O	-1	24309294
u@@	O	-1	24309294
g@@	O	-1	24309294
,	O	-1	24309294
i.@@	O	-1	24309294
c@@	O	-1	24309294
.@@	O	-1	24309294
v@@	O	-1	24309294
)	O	-1	24309294
reversed	O	-1	24309294
the	O	-1	24309294
effects	O	-1	24309294
of	O	-1	24309294
C@@	B-Chemical	D012844	24309294
C@@	I-Chemical	-1	24309294
K@@	I-Chemical	-1	24309294
-@@	I-Chemical	-1	24309294
8	I-Chemical	-1	24309294
,	O	-1	24309294
but	O	-1	24309294
the	O	-1	24309294
C@@	O	-1	24309294
C@@	O	-1	24309294
K@@	O	-1	24309294
1	O	-1	24309294
receptor	O	-1	24309294
antagonist	O	-1	24309294
L-@@	O	-1	24309294
3@@	O	-1	24309294
6@@	O	-1	24309294
4@@	O	-1	24309294
,@@	O	-1	24309294
7@@	O	-1	24309294
1@@	O	-1	24309294
8	O	-1	24309294
(@@	O	-1	24309294
10@@	O	-1	24309294
u@@	O	-1	24309294
g@@	O	-1	24309294
,	O	-1	24309294
i.@@	O	-1	24309294
c@@	O	-1	24309294
.@@	O	-1	24309294
v@@	O	-1	24309294
)	O	-1	24309294
did	O	-1	24309294
not@@	O	-1	24309294
.	O	-1	24309294
The	O	-1	24309294
present	O	-1	24309294
results	O	-1	24309294
demon@@	O	-1	24309294
st@@	O	-1	24309294
rate	O	-1	24309294
that	O	-1	24309294
C@@	B-Chemical	D012844	24309294
C@@	I-Chemical	-1	24309294
K@@	I-Chemical	-1	24309294
-@@	I-Chemical	-1	24309294
8	I-Chemical	-1	24309294
attenu@@	O	-1	24309294
ates	O	-1	24309294
the	O	-1	24309294
effect	O	-1	24309294
of	O	-1	24309294
morphine	B-Chemical	D009020	24309294
on	O	-1	24309294
hippocamp@@	O	-1	24309294
al	O	-1	24309294
LT@@	O	-1	24309294
P	O	-1	24309294
through	O	-1	24309294
C@@	O	-1	24309294
C@@	O	-1	24309294
K@@	O	-1	24309294
2	O	-1	24309294
receptors	O	-1	24309294
and	O	-1	24309294
suggest	O	-1	24309294
an	O	-1	24309294
ame@@	O	-1	24309294
li@@	O	-1	24309294
or@@	O	-1	24309294
ative	O	-1	24309294
function	O	-1	24309294
of	O	-1	24309294
C@@	B-Chemical	D012844	24309294
C@@	I-Chemical	-1	24309294
K@@	I-Chemical	-1	24309294
-@@	I-Chemical	-1	24309294
8	I-Chemical	-1	24309294
on	O	-1	24309294
morphine	B-Chemical	D009020	24309294
-induced	O	-1	24309294
memory	B-Disease	D008569	24309294
impair@@	I-Disease	-1	24309294
ment	I-Disease	-1	24309294
.	O	-1	24309294

G@@	O	-1	24333387
lial	O	-1	24333387
activation	O	-1	24333387
and	O	-1	24333387
post@@	O	-1	24333387
-@@	O	-1	24333387
syn@@	O	-1	24333387
ap@@	O	-1	24333387
tic	O	-1	24333387
neuro@@	B-Disease	D020258	24333387
toxicity	I-Disease	-1	24333387
:	O	-1	24333387
the	O	-1	24333387
ke@@	O	-1	24333387
y	O	-1	24333387
events	O	-1	24333387
in	O	-1	24333387
S@@	B-Chemical	D013311	24333387
tre@@	I-Chemical	-1	24333387
pto@@	I-Chemical	-1	24333387
z@@	I-Chemical	-1	24333387
ot@@	I-Chemical	-1	24333387
oc@@	I-Chemical	-1	24333387
in	I-Chemical	-1	24333387
(@@	O	-1	24333387
IC@@	O	-1	24333387
V@@	O	-1	24333387
)	O	-1	24333387
induced	O	-1	24333387
memory	B-Disease	D008569	24333387
impair@@	I-Disease	-1	24333387
ment	I-Disease	-1	24333387
in	O	-1	24333387
rats.	O	-1	24333387
In	O	-1	24333387
the	O	-1	24333387
present	O	-1	24333387
study	O	-1	24333387
the	O	-1	24333387
role	O	-1	24333387
of	O	-1	24333387
g@@	O	-1	24333387
lial	O	-1	24333387
activation	O	-1	24333387
and	O	-1	24333387
pos@@	O	-1	24333387
t	O	-1	24333387
syn@@	O	-1	24333387
ap@@	O	-1	24333387
tic	O	-1	24333387
toxicity	B-Disease	D064420	24333387
in	O	-1	24333387
IC@@	O	-1	24333387
V	O	-1	24333387
S@@	B-Chemical	D013311	24333387
tre@@	I-Chemical	-1	24333387
pto@@	I-Chemical	-1	24333387
z@@	I-Chemical	-1	24333387
ot@@	I-Chemical	-1	24333387
oc@@	I-Chemical	-1	24333387
in	I-Chemical	-1	24333387
(	O	-1	24333387
S@@	B-Chemical	D013311	24333387
T@@	I-Chemical	-1	24333387
Z	I-Chemical	-1	24333387
)	O	-1	24333387
induced	O	-1	24333387
memory	B-Disease	D008569	24333387
impaired	I-Disease	-1	24333387
rats	O	-1	24333387
was	O	-1	24333387
ex@@	O	-1	24333387
p@@	O	-1	24333387
lo@@	O	-1	24333387
red.	O	-1	24333387
In	O	-1	24333387
experim@@	O	-1	24333387
ent	O	-1	24333387
set	O	-1	24333387
up	O	-1	24333387
1@@	O	-1	24333387
:	O	-1	24333387
M@@	B-Disease	D008569	24333387
em@@	I-Disease	-1	24333387
ory	I-Disease	-1	24333387
defic@@	I-Disease	-1	24333387
it	I-Disease	-1	24333387
was	O	-1	24333387
found	O	-1	24333387
in	O	-1	24333387
M@@	O	-1	24333387
or@@	O	-1	24333387
ri@@	O	-1	24333387
s	O	-1	24333387
w@@	O	-1	24333387
at@@	O	-1	24333387
er	O	-1	24333387
ma@@	O	-1	24333387
ze	O	-1	24333387
test	O	-1	24333387
on	O	-1	24333387
14@@	O	-1	24333387
-1@@	O	-1	24333387
6	O	-1	24333387
days	O	-1	24333387
after	O	-1	24333387
S@@	B-Chemical	D013311	24333387
T@@	I-Chemical	-1	24333387
Z	I-Chemical	-1	24333387
(@@	O	-1	24333387
IC@@	O	-1	24333387
V@@	O	-1	24333387
;	O	-1	24333387
3@@	O	-1	24333387
mg/@@	O	-1	24333387
K@@	O	-1	24333387
g@@	O	-1	24333387
)	O	-1	24333387
administr@@	O	-1	24333387
ation.	O	-1	24333387
S@@	B-Chemical	D013311	24333387
T@@	I-Chemical	-1	24333387
Z	I-Chemical	-1	24333387
causes	O	-1	24333387
increased	O	-1	24333387
expression	O	-1	24333387
of	O	-1	24333387
GF@@	O	-1	24333387
A@@	O	-1	24333387
P@@	O	-1	24333387
,	O	-1	24333387
C@@	O	-1	24333387
D@@	O	-1	24333387
1@@	O	-1	24333387
1@@	O	-1	24333387
b	O	-1	24333387
and	O	-1	24333387
T@@	O	-1	24333387
N@@	O	-1	24333387
F@@	O	-1	24333387
-@@	O	-1	24333387
a	O	-1	24333387
indicating	O	-1	24333387
g@@	O	-1	24333387
lial	O	-1	24333387
activation	O	-1	24333387
and	O	-1	24333387
neuro@@	B-Disease	D007249	24333387
inflam@@	I-Disease	-1	24333387
m@@	I-Disease	-1	24333387
ation	I-Disease	-1	24333387
.	O	-1	24333387
S@@	B-Chemical	D013311	24333387
T@@	I-Chemical	-1	24333387
Z	I-Chemical	-1	24333387
also	O	-1	24333387
significantly	O	-1	24333387
increased	O	-1	24333387
the	O	-1	24333387
level	O	-1	24333387
of	O	-1	24333387
RO@@	O	-1	24333387
S@@	O	-1	24333387
,	O	-1	24333387
nit@@	B-Chemical	D009573	24333387
rit@@	I-Chemical	-1	24333387
e	I-Chemical	-1	24333387
,	O	-1	24333387
C@@	B-Chemical	D002118	24333387
a	I-Chemical	-1	24333387
(2@@	O	-1	24333387
+@@	O	-1	24333387
)	O	-1	24333387
and	O	-1	24333387
reduced	O	-1	24333387
the	O	-1	24333387
mitochondrial	O	-1	24333387
activity	O	-1	24333387
in	O	-1	24333387
syn@@	O	-1	24333387
ap@@	O	-1	24333387
t@@	O	-1	24333387
os@@	O	-1	24333387
om@@	O	-1	24333387
al	O	-1	24333387
pre@@	O	-1	24333387
par@@	O	-1	24333387
ation	O	-1	24333387
il@@	O	-1	24333387
lu@@	O	-1	24333387
strat@@	O	-1	24333387
ing	O	-1	24333387
free	O	-1	24333387
ra@@	O	-1	24333387
d@@	O	-1	24333387
ical	O	-1	24333387
generation	O	-1	24333387
and	O	-1	24333387
ex@@	B-Disease	D064420	24333387
cit@@	I-Disease	-1	24333387
otoxicity	I-Disease	-1	24333387
.	O	-1	24333387
In@@	O	-1	24333387
c@@	O	-1	24333387
reas@@	O	-1	24333387
ed	O	-1	24333387
expression	O	-1	24333387
and	O	-1	24333387
activity	O	-1	24333387
of	O	-1	24333387
C@@	O	-1	24333387
as@@	O	-1	24333387
p@@	O	-1	24333387
as@@	O	-1	24333387
e-@@	O	-1	24333387
3	O	-1	24333387
was	O	-1	24333387
also	O	-1	24333387
observed	O	-1	24333387
in	O	-1	24333387
S@@	B-Chemical	D013311	24333387
T@@	I-Chemical	-1	24333387
Z	I-Chemical	-1	24333387
treated	O	-1	24333387
rat	O	-1	24333387
which	O	-1	24333387
specif@@	O	-1	24333387
y	O	-1	24333387
apo@@	O	-1	24333387
pto@@	O	-1	24333387
tic	O	-1	24333387
cell	O	-1	24333387
death	O	-1	24333387
in	O	-1	24333387
hippocamp@@	O	-1	24333387
us	O	-1	24333387
and	O	-1	24333387
cor@@	O	-1	24333387
t@@	O	-1	24333387
ex@@	O	-1	24333387
.	O	-1	24333387
S@@	B-Chemical	D013311	24333387
T@@	I-Chemical	-1	24333387
Z	I-Chemical	-1	24333387
treatment	O	-1	24333387
showed	O	-1	24333387
decrease	O	-1	24333387
expression	O	-1	24333387
of	O	-1	24333387
pos@@	O	-1	24333387
t	O	-1	24333387
syn@@	O	-1	24333387
ap@@	O	-1	24333387
tic	O	-1	24333387
mark@@	O	-1	24333387
ers	O	-1	24333387
Ca@@	O	-1	24333387
M@@	O	-1	24333387
K@@	O	-1	24333387
II@@	O	-1	24333387
a	O	-1	24333387
and	O	-1	24333387
P@@	O	-1	24333387
S@@	O	-1	24333387
D-@@	O	-1	24333387
9@@	O	-1	24333387
5,	O	-1	24333387
w@@	O	-1	24333387
hi@@	O	-1	24333387
le@@	O	-1	24333387
,	O	-1	24333387
expression	O	-1	24333387
of	O	-1	24333387
pr@@	O	-1	24333387
e	O	-1	24333387
syn@@	O	-1	24333387
ap@@	O	-1	24333387
tic	O	-1	24333387
mark@@	O	-1	24333387
ers	O	-1	24333387
(@@	O	-1	24333387
syn@@	O	-1	24333387
ap@@	O	-1	24333387
to@@	O	-1	24333387
ph@@	O	-1	24333387
ys@@	O	-1	24333387
in	O	-1	24333387
and	O	-1	24333387
S@@	O	-1	24333387
N@@	O	-1	24333387
A@@	O	-1	24333387
P@@	O	-1	24333387
-@@	O	-1	24333387
25@@	O	-1	24333387
)	O	-1	24333387
remain@@	O	-1	24333387
s	O	-1	24333387
un@@	O	-1	24333387
al@@	O	-1	24333387
te@@	O	-1	24333387
red	O	-1	24333387
indicating	O	-1	24333387
selective	O	-1	24333387
pos@@	O	-1	24333387
t	O	-1	24333387
syn@@	O	-1	24333387
ap@@	O	-1	24333387
tic	O	-1	24333387
neuro@@	B-Disease	D020258	24333387
toxicity	I-Disease	-1	24333387
.	O	-1	24333387
O@@	O	-1	24333387
ral	O	-1	24333387
treatment	O	-1	24333387
with	O	-1	24333387
M@@	B-Chemical	D008559	24333387
em@@	I-Chemical	-1	24333387
ant@@	I-Chemical	-1	24333387
ine	I-Chemical	-1	24333387
(@@	O	-1	24333387
10@@	O	-1	24333387
mg/kg)	O	-1	24333387
and	O	-1	24333387
I@@	B-Chemical	D007052	24333387
bu@@	I-Chemical	-1	24333387
prof@@	I-Chemical	-1	24333387
en	I-Chemical	-1	24333387
(@@	O	-1	24333387
50	O	-1	24333387
mg/kg)	O	-1	24333387
daily	O	-1	24333387
for	O	-1	24333387
13	O	-1	24333387
days	O	-1	24333387
attenu@@	O	-1	24333387
ated	O	-1	24333387
S@@	B-Chemical	D013311	24333387
T@@	I-Chemical	-1	24333387
Z	I-Chemical	-1	24333387
induced	O	-1	24333387
g@@	O	-1	24333387
lial	O	-1	24333387
activ@@	O	-1	24333387
ation,	O	-1	24333387
apo@@	O	-1	24333387
pto@@	O	-1	24333387
tic	O	-1	24333387
cell	O	-1	24333387
death	O	-1	24333387
and	O	-1	24333387
pos@@	O	-1	24333387
t	O	-1	24333387
syn@@	O	-1	24333387
ap@@	O	-1	24333387
tic	O	-1	24333387
neuro@@	B-Disease	D020258	24333387
toxicity	I-Disease	-1	24333387
in	O	-1	24333387
rat	O	-1	24333387
bra@@	O	-1	24333387
in.	O	-1	24333387
F@@	O	-1	24333387
ur@@	O	-1	24333387
ther@@	O	-1	24333387
,	O	-1	24333387
in	O	-1	24333387
experim@@	O	-1	24333387
ent	O	-1	24333387
set	O	-1	24333387
up	O	-1	24333387
2@@	O	-1	24333387
:	O	-1	24333387
wh@@	O	-1	24333387
ere	O	-1	24333387
memory	O	-1	24333387
function	O	-1	24333387
was	O	-1	24333387
not	O	-1	24333387
affected	O	-1	24333387
i.@@	O	-1	24333387
e.	O	-1	24333387
7-@@	O	-1	24333387
9	O	-1	24333387
days	O	-1	24333387
after	O	-1	24333387
S@@	B-Chemical	D013311	24333387
T@@	I-Chemical	-1	24333387
Z	I-Chemical	-1	24333387
treatment.	O	-1	24333387
The	O	-1	24333387
level	O	-1	24333387
of	O	-1	24333387
GF@@	O	-1	24333387
A@@	O	-1	24333387
P@@	O	-1	24333387
,	O	-1	24333387
C@@	O	-1	24333387
D@@	O	-1	24333387
1@@	O	-1	24333387
1@@	O	-1	24333387
b@@	O	-1	24333387
,	O	-1	24333387
T@@	O	-1	24333387
N@@	O	-1	24333387
F@@	O	-1	24333387
-@@	O	-1	24333387
a,	O	-1	24333387
RO@@	O	-1	24333387
S	O	-1	24333387
and	O	-1	24333387
nit@@	B-Chemical	D009573	24333387
rit@@	I-Chemical	-1	24333387
e	I-Chemical	-1	24333387
levels	O	-1	24333387
were	O	-1	24333387
increas@@	O	-1	24333387
ed.	O	-1	24333387
O@@	O	-1	24333387
n	O	-1	24333387
the	O	-1	24333387
other	O	-1	24333387
h@@	O	-1	24333387
and@@	O	-1	24333387
,	O	-1	24333387
apo@@	O	-1	24333387
pto@@	O	-1	24333387
tic	O	-1	24333387
mark@@	O	-1	24333387
er,	O	-1	24333387
syn@@	O	-1	24333387
ap@@	O	-1	24333387
tic	O	-1	24333387
mark@@	O	-1	24333387
er@@	O	-1	24333387
s,	O	-1	24333387
mitochondrial	O	-1	24333387
activity	O	-1	24333387
and	O	-1	24333387
C@@	B-Chemical	D002118	24333387
a	I-Chemical	-1	24333387
(2@@	O	-1	24333387
+@@	O	-1	24333387
)	O	-1	24333387
levels	O	-1	24333387
remained	O	-1	24333387
un@@	O	-1	24333387
aff@@	O	-1	24333387
ect@@	O	-1	24333387
ed.	O	-1	24333387
C@@	O	-1	24333387
ol@@	O	-1	24333387
l@@	O	-1	24333387
ective	O	-1	24333387
data	O	-1	24333387
indic@@	O	-1	24333387
ates	O	-1	24333387
that	O	-1	24333387
neuro@@	B-Disease	D007249	24333387
inflam@@	I-Disease	-1	24333387
mat@@	I-Disease	-1	24333387
ory	I-Disease	-1	24333387
pro@@	O	-1	24333387
cess	O	-1	24333387
and	O	-1	24333387
oxid@@	O	-1	24333387
ative	O	-1	24333387
stres@@	O	-1	24333387
s	O	-1	24333387
occur@@	O	-1	24333387
s	O	-1	24333387
ear@@	O	-1	24333387
li@@	O	-1	24333387
er	O	-1	24333387
to	O	-1	24333387
apo@@	O	-1	24333387
pto@@	O	-1	24333387
sis	O	-1	24333387
and	O	-1	24333387
does	O	-1	24333387
not	O	-1	24333387
aff@@	O	-1	24333387
ect	O	-1	24333387
memory	O	-1	24333387
func@@	O	-1	24333387
tion.	O	-1	24333387
P@@	O	-1	24333387
res@@	O	-1	24333387
ent	O	-1	24333387
study	O	-1	24333387
clear@@	O	-1	24333387
ly	O	-1	24333387
suggests	O	-1	24333387
that	O	-1	24333387
g@@	O	-1	24333387
lial	O	-1	24333387
activation	O	-1	24333387
and	O	-1	24333387
pos@@	O	-1	24333387
t	O	-1	24333387
syn@@	O	-1	24333387
ap@@	O	-1	24333387
tic	O	-1	24333387
neuro@@	B-Disease	D020258	24333387
toxicity	I-Disease	-1	24333387
are	O	-1	24333387
the	O	-1	24333387
ke@@	O	-1	24333387
y	O	-1	24333387
factors	O	-1	24333387
in	O	-1	24333387
S@@	B-Chemical	D013311	24333387
T@@	I-Chemical	-1	24333387
Z	I-Chemical	-1	24333387
induced	O	-1	24333387
memory	B-Disease	D008569	24333387
impair@@	I-Disease	-1	24333387
ment	I-Disease	-1	24333387
and	O	-1	24333387
neuron@@	O	-1	24333387
al	O	-1	24333387
cell	O	-1	24333387
de@@	O	-1	24333387
ath@@	O	-1	24333387
.	O	-1	24333387

Com@@	O	-1	24341598
par@@	O	-1	24341598
ison	O	-1	24341598
of	O	-1	24341598
effects	O	-1	24341598
of	O	-1	24341598
is@@	O	-1	24341598
oton@@	O	-1	24341598
ic	O	-1	24341598
sodium	B-Chemical	D012965	24341598
chlor@@	I-Chemical	-1	24341598
ide	I-Chemical	-1	24341598
with	O	-1	24341598
di@@	B-Chemical	D004110	24341598
l@@	I-Chemical	-1	24341598
ti@@	I-Chemical	-1	24341598
az@@	I-Chemical	-1	24341598
em	I-Chemical	-1	24341598
in	O	-1	24341598
pre@@	O	-1	24341598
ven@@	O	-1	24341598
tion	O	-1	24341598
of	O	-1	24341598
contr@@	B-Chemical	D003287	24341598
ast	I-Chemical	-1	24341598
-induced	O	-1	24341598
nephro@@	B-Disease	D007674	24341598
pathy	I-Disease	-1	24341598
.	O	-1	24341598
IN@@	O	-1	24341598
T@@	O	-1	24341598
RO@@	O	-1	24341598
D@@	O	-1	24341598
U@@	O	-1	24341598
C@@	O	-1	24341598
TI@@	O	-1	24341598
O@@	O	-1	24341598
N	O	-1	24341598
AN@@	O	-1	24341598
D	O	-1	24341598
OBJECTIVE:	O	-1	24341598
C@@	B-Chemical	D003287	24341598
ont@@	I-Chemical	-1	24341598
r@@	I-Chemical	-1	24341598
ast	I-Chemical	-1	24341598
-induced	O	-1	24341598
nephro@@	B-Disease	D007674	24341598
pathy	I-Disease	-1	24341598
(C@@	O	-1	24341598
IN@@	O	-1	24341598
)	O	-1	24341598
significantly	O	-1	24341598
increases	O	-1	24341598
the	O	-1	24341598
mor@@	O	-1	24341598
b@@	O	-1	24341598
idity	O	-1	24341598
and	O	-1	24341598
mor@@	O	-1	24341598
t@@	O	-1	24341598
ality	O	-1	24341598
of	O	-1	24341598
patients.	O	-1	24341598
The	O	-1	24341598
a@@	O	-1	24341598
im	O	-1	24341598
of	O	-1	24341598
this	O	-1	24341598
study	O	-1	24341598
is	O	-1	24341598
to	O	-1	24341598
investigate	O	-1	24341598
and	O	-1	24341598
compar@@	O	-1	24341598
e	O	-1	24341598
the	O	-1	24341598
protective	O	-1	24341598
effects	O	-1	24341598
of	O	-1	24341598
is@@	O	-1	24341598
oton@@	O	-1	24341598
ic	O	-1	24341598
sodium	B-Chemical	D012965	24341598
chlor@@	I-Chemical	-1	24341598
ide	I-Chemical	-1	24341598
with	O	-1	24341598
sodium	B-Chemical	D017693	24341598
b@@	I-Chemical	-1	24341598
ic@@	I-Chemical	-1	24341598
arb@@	I-Chemical	-1	24341598
on@@	I-Chemical	-1	24341598
ate	I-Chemical	-1	24341598
infusion	O	-1	24341598
and	O	-1	24341598
is@@	O	-1	24341598
oton@@	O	-1	24341598
ic	O	-1	24341598
sodium	B-Chemical	D012965	24341598
chlor@@	I-Chemical	-1	24341598
ide	I-Chemical	-1	24341598
infusion	O	-1	24341598
with	O	-1	24341598
di@@	B-Chemical	D004110	24341598
l@@	I-Chemical	-1	24341598
ti@@	I-Chemical	-1	24341598
az@@	I-Chemical	-1	24341598
em	I-Chemical	-1	24341598
,	O	-1	24341598
a	O	-1	24341598
calcium	B-Chemical	D002118	24341598
channel	O	-1	24341598
block@@	O	-1	24341598
er,	O	-1	24341598
in	O	-1	24341598
prevent@@	O	-1	24341598
ing	O	-1	24341598
CI@@	O	-1	24341598
N@@	O	-1	24341598
.	O	-1	24341598
M@@	O	-1	24341598
AT@@	O	-1	24341598
E@@	O	-1	24341598
R@@	O	-1	24341598
I@@	O	-1	24341598
AL@@	O	-1	24341598
S	O	-1	24341598
AN@@	O	-1	24341598
D	O	-1	24341598
METHODS:	O	-1	24341598
Our	O	-1	24341598
study	O	-1	24341598
included	O	-1	24341598
patients	O	-1	24341598
who	O	-1	24341598
were	O	-1	24341598
administered	O	-1	24341598
3@@	O	-1	24341598
0-@@	O	-1	24341598
60	O	-1	24341598
m@@	O	-1	24341598
L	O	-1	24341598
of	O	-1	24341598
iod@@	O	-1	24341598
in@@	O	-1	24341598
ated	O	-1	24341598
contr@@	B-Chemical	D003287	24341598
ast	I-Chemical	-1	24341598
agent	O	-1	24341598
for	O	-1	24341598
perc@@	O	-1	24341598
utaneous	O	-1	24341598
coronary	O	-1	24341598
angio@@	O	-1	24341598
graph@@	O	-1	24341598
y	O	-1	24341598
(P@@	O	-1	24341598
CA@@	O	-1	24341598
G@@	O	-1	24341598
),	O	-1	24341598
all	O	-1	24341598
with	O	-1	24341598
creatinine	B-Chemical	D003404	24341598
values	O	-1	24341598
between	O	-1	24341598
1.@@	O	-1	24341598
1	O	-1	24341598
and	O	-1	24341598
3.@@	O	-1	24341598
1	O	-1	24341598
mg/d@@	O	-1	24341598
L@@	O	-1	24341598
.	O	-1	24341598
Patients	O	-1	24341598
were	O	-1	24341598
divid@@	O	-1	24341598
ed	O	-1	24341598
into	O	-1	24341598
three	O	-1	24341598
groups	O	-1	24341598
and	O	-1	24341598
each	O	-1	24341598
group	O	-1	24341598
had	O	-1	24341598
20	O	-1	24341598
patients.	O	-1	24341598
The	O	-1	24341598
first	O	-1	24341598
group	O	-1	24341598
of	O	-1	24341598
patients	O	-1	24341598
was	O	-1	24341598
administered	O	-1	24341598
is@@	O	-1	24341598
oton@@	O	-1	24341598
ic	O	-1	24341598
sodium	B-Chemical	D012965	24341598
chlor@@	I-Chemical	-1	24341598
ide	I-Chemical	-1	24341598
;	O	-1	24341598
the	O	-1	24341598
second	O	-1	24341598
group	O	-1	24341598
was	O	-1	24341598
administered	O	-1	24341598
a	O	-1	24341598
sol@@	O	-1	24341598
u@@	O	-1	24341598
tion	O	-1	24341598
that	O	-1	24341598
of	O	-1	24341598
5%	O	-1	24341598
de@@	B-Chemical	D005947	24341598
x@@	I-Chemical	-1	24341598
tro@@	I-Chemical	-1	24341598
se	I-Chemical	-1	24341598
and	O	-1	24341598
sodium	B-Chemical	D017693	24341598
b@@	I-Chemical	-1	24341598
ic@@	I-Chemical	-1	24341598
arb@@	I-Chemical	-1	24341598
on@@	I-Chemical	-1	24341598
ate	I-Chemical	-1	24341598
,	O	-1	24341598
while	O	-1	24341598
the	O	-1	24341598
thir@@	O	-1	24341598
d	O	-1	24341598
group	O	-1	24341598
was	O	-1	24341598
administered	O	-1	24341598
is@@	O	-1	24341598
oton@@	O	-1	24341598
ic	O	-1	24341598
sodium	B-Chemical	D012965	24341598
chlor@@	I-Chemical	-1	24341598
ide	I-Chemical	-1	24341598
before	O	-1	24341598
and	O	-1	24341598
after	O	-1	24341598
the	O	-1	24341598
contr@@	B-Chemical	D003287	24341598
ast	I-Chemical	-1	24341598
injec@@	O	-1	24341598
tion.	O	-1	24341598
The	O	-1	24341598
thir@@	O	-1	24341598
d	O	-1	24341598
group	O	-1	24341598
received	O	-1	24341598
an	O	-1	24341598
addi@@	O	-1	24341598
tional	O	-1	24341598
injection	O	-1	24341598
of	O	-1	24341598
di@@	B-Chemical	D004110	24341598
l@@	I-Chemical	-1	24341598
ti@@	I-Chemical	-1	24341598
az@@	I-Chemical	-1	24341598
em	I-Chemical	-1	24341598
the	O	-1	24341598
day	O	-1	24341598
before	O	-1	24341598
and	O	-1	24341598
first	O	-1	24341598
2	O	-1	24341598
days	O	-1	24341598
after	O	-1	24341598
the	O	-1	24341598
contr@@	B-Chemical	D003287	24341598
ast	I-Chemical	-1	24341598
injec@@	O	-1	24341598
tion.	O	-1	24341598
All	O	-1	24341598
of	O	-1	24341598
the	O	-1	24341598
patient@@	O	-1	24341598
s@@	O	-1	24341598
'	O	-1	24341598
plasma	O	-1	24341598
blood	B-Chemical	D001806	24341598
ure@@	I-Chemical	-1	24341598
a	I-Chemical	-1	24341598
nitro@@	I-Chemical	-1	24341598
gen	I-Chemical	-1	24341598
(	O	-1	24341598
B@@	B-Chemical	D001806	24341598
U@@	I-Chemical	-1	24341598
N	I-Chemical	-1	24341598
)	O	-1	24341598
and	O	-1	24341598
creatinine	B-Chemical	D003404	24341598
levels	O	-1	24341598
were	O	-1	24341598
measured	O	-1	24341598
on	O	-1	24341598
the	O	-1	24341598
second	O	-1	24341598
and	O	-1	24341598
sev@@	O	-1	24341598
ent@@	O	-1	24341598
h	O	-1	24341598
day	O	-1	24341598
after	O	-1	24341598
the	O	-1	24341598
administration	O	-1	24341598
of	O	-1	24341598
intravenous	O	-1	24341598
contr@@	B-Chemical	D003287	24341598
ast	I-Chemical	-1	24341598
mat@@	O	-1	24341598
er@@	O	-1	24341598
i@@	O	-1	24341598
al.	O	-1	24341598
RESULTS:	O	-1	24341598
The	O	-1	24341598
bas@@	O	-1	24341598
al	O	-1	24341598
creatinine	B-Chemical	D003404	24341598
levels	O	-1	24341598
were	O	-1	24341598
similar	O	-1	24341598
for	O	-1	24341598
all	O	-1	24341598
three	O	-1	24341598
groups	O	-1	24341598
(p	O	-1	24341598
>	O	-1	24341598
0.05@@	O	-1	24341598
).	O	-1	24341598
A@@	O	-1	24341598
mon@@	O	-1	24341598
g	O	-1	24341598
a	O	-1	24341598
total	O	-1	24341598
of	O	-1	24341598
60	O	-1	24341598
patients	O	-1	24341598
included	O	-1	24341598
in	O	-1	24341598
the	O	-1	24341598
study,	O	-1	24341598
16	O	-1	24341598
patients	O	-1	24341598
developed	O	-1	24341598
acute	B-Disease	D058186	24341598
renal	I-Disease	-1	24341598
failure	I-Disease	-1	24341598
(	O	-1	24341598
A@@	B-Disease	D058186	24341598
R@@	I-Disease	-1	24341598
F	I-Disease	-1	24341598
)	O	-1	24341598
on	O	-1	24341598
the	O	-1	24341598
second	O	-1	24341598
day	O	-1	24341598
after	O	-1	24341598
contr@@	B-Chemical	D003287	24341598
ast	I-Chemical	-1	24341598
mat@@	O	-1	24341598
er@@	O	-1	24341598
ial	O	-1	24341598
was	O	-1	24341598
injected	O	-1	24341598
(2@@	O	-1	24341598
6.@@	O	-1	24341598
6@@	O	-1	24341598
%).	O	-1	24341598
The	O	-1	24341598
number	O	-1	24341598
of	O	-1	24341598
patients	O	-1	24341598
who	O	-1	24341598
developed	O	-1	24341598
A@@	B-Disease	D058186	24341598
R@@	I-Disease	-1	24341598
F	I-Disease	-1	24341598
on	O	-1	24341598
the	O	-1	24341598
second	O	-1	24341598
day	O	-1	24341598
after	O	-1	24341598
the	O	-1	24341598
injection	O	-1	24341598
in	O	-1	24341598
the	O	-1	24341598
first	O	-1	24341598
group	O	-1	24341598
was	O	-1	24341598
five	O	-1	24341598
(2@@	O	-1	24341598
5@@	O	-1	24341598
%),	O	-1	24341598
in	O	-1	24341598
the	O	-1	24341598
second	O	-1	24341598
group	O	-1	24341598
was	O	-1	24341598
six	O	-1	24341598
(3@@	O	-1	24341598
0@@	O	-1	24341598
%)	O	-1	24341598
and	O	-1	24341598
the	O	-1	24341598
thir@@	O	-1	24341598
d	O	-1	24341598
group	O	-1	24341598
was	O	-1	24341598
five	O	-1	24341598
(2@@	O	-1	24341598
5@@	O	-1	24341598
%)	O	-1	24341598
(p	O	-1	24341598
>	O	-1	24341598
0.05@@	O	-1	24341598
).	O	-1	24341598
CONCLUSION:	O	-1	24341598
There	O	-1	24341598
was	O	-1	24341598
no	O	-1	24341598
significant	O	-1	24341598
difference	O	-1	24341598
between	O	-1	24341598
is@@	O	-1	24341598
oton@@	O	-1	24341598
ic	O	-1	24341598
sodium	B-Chemical	D012965	24341598
chlor@@	I-Chemical	-1	24341598
ide	I-Chemical	-1	24341598
,	O	-1	24341598
sodium	B-Chemical	D017693	24341598
b@@	I-Chemical	-1	24341598
ic@@	I-Chemical	-1	24341598
arb@@	I-Chemical	-1	24341598
on@@	I-Chemical	-1	24341598
ate	I-Chemical	-1	24341598
and	O	-1	24341598
is@@	O	-1	24341598
oton@@	O	-1	24341598
ic	O	-1	24341598
sodium	B-Chemical	D012965	24341598
chlor@@	I-Chemical	-1	24341598
ide	I-Chemical	-1	24341598
with	O	-1	24341598
di@@	B-Chemical	D004110	24341598
l@@	I-Chemical	-1	24341598
ti@@	I-Chemical	-1	24341598
az@@	I-Chemical	-1	24341598
em	I-Chemical	-1	24341598
ap@@	O	-1	24341598
plic@@	O	-1	24341598
ation	O	-1	24341598
in	O	-1	24341598
pre@@	O	-1	24341598
ven@@	O	-1	24341598
tion	O	-1	24341598
of	O	-1	24341598
CI@@	O	-1	24341598
N@@	O	-1	24341598
.	O	-1	24341598

Ne@@	O	-1	24345882
uro@@	O	-1	24345882
cognitive	O	-1	24345882
and	O	-1	24345882
neuro@@	O	-1	24345882
radi@@	O	-1	24345882
ologic	O	-1	24345882
central	O	-1	24345882
ner@@	O	-1	24345882
v@@	O	-1	24345882
ous	O	-1	24345882
system	O	-1	24345882
l@@	O	-1	24345882
ate	O	-1	24345882
effects	O	-1	24345882
in	O	-1	24345882
children	O	-1	24345882
treated	O	-1	24345882
on	O	-1	24345882
P@@	O	-1	24345882
edi@@	O	-1	24345882
atric	O	-1	24345882
On@@	O	-1	24345882
co@@	O	-1	24345882
log@@	O	-1	24345882
y	O	-1	24345882
Group	O	-1	24345882
(P@@	O	-1	24345882
O@@	O	-1	24345882
G@@	O	-1	24345882
)	O	-1	24345882
P@@	O	-1	24345882
9@@	O	-1	24345882
6@@	O	-1	24345882
0@@	O	-1	24345882
5	O	-1	24345882
(@@	O	-1	24345882
standard	O	-1	24345882
ris@@	O	-1	24345882
k@@	O	-1	24345882
)	O	-1	24345882
and	O	-1	24345882
P@@	O	-1	24345882
9@@	O	-1	24345882
20@@	O	-1	24345882
1	O	-1	24345882
(@@	O	-1	24345882
l@@	O	-1	24345882
ess@@	O	-1	24345882
er	O	-1	24345882
ris@@	O	-1	24345882
k@@	O	-1	24345882
)	O	-1	24345882
acute	B-Disease	D054198	24345882
lymph@@	I-Disease	-1	24345882
ob@@	I-Disease	-1	24345882
las@@	I-Disease	-1	24345882
tic	I-Disease	-1	24345882
leuk@@	I-Disease	-1	24345882
emia	I-Disease	-1	24345882
pro@@	O	-1	24345882
to@@	O	-1	24345882
co@@	O	-1	24345882
l@@	O	-1	24345882
s	O	-1	24345882
(@@	O	-1	24345882
AC@@	O	-1	24345882
CL@@	O	-1	24345882
0@@	O	-1	24345882
13@@	O	-1	24345882
1@@	O	-1	24345882
)@@	O	-1	24345882
:	O	-1	24345882
a	O	-1	24345882
meth@@	B-Chemical	D008727	24345882
ot@@	I-Chemical	-1	24345882
re@@	I-Chemical	-1	24345882
x@@	I-Chemical	-1	24345882
ate	I-Chemical	-1	24345882
con@@	O	-1	24345882
sequ@@	O	-1	24345882
ence@@	O	-1	24345882
?	O	-1	24345882
A	O	-1	24345882
report	O	-1	24345882
from	O	-1	24345882
the	O	-1	24345882
Ch@@	O	-1	24345882
ild@@	O	-1	24345882
ren@@	O	-1	24345882
's	O	-1	24345882
On@@	O	-1	24345882
co@@	O	-1	24345882
log@@	O	-1	24345882
y	O	-1	24345882
Grou@@	O	-1	24345882
p@@	O	-1	24345882
.	O	-1	24345882
Con@@	O	-1	24345882
cer@@	O	-1	24345882
n@@	O	-1	24345882
s	O	-1	24345882
about	O	-1	24345882
long-term	O	-1	24345882
meth@@	B-Chemical	D008727	24345882
ot@@	I-Chemical	-1	24345882
re@@	I-Chemical	-1	24345882
x@@	I-Chemical	-1	24345882
ate	I-Chemical	-1	24345882
(	O	-1	24345882
M@@	B-Chemical	D008727	24345882
T@@	I-Chemical	-1	24345882
X	I-Chemical	-1	24345882
)	O	-1	24345882
neuro@@	B-Disease	D020258	24345882
toxicity	I-Disease	-1	24345882
in	O	-1	24345882
the	O	-1	24345882
19@@	O	-1	24345882
9@@	O	-1	24345882
0@@	O	-1	24345882
s	O	-1	24345882
l@@	O	-1	24345882
ed	O	-1	24345882
to	O	-1	24345882
mo@@	O	-1	24345882
di@@	O	-1	24345882
fic@@	O	-1	24345882
ations	O	-1	24345882
in	O	-1	24345882
intra@@	O	-1	24345882
th@@	O	-1	24345882
ec@@	O	-1	24345882
al	O	-1	24345882
(@@	O	-1	24345882
I@@	O	-1	24345882
T)	O	-1	24345882
therapy,	O	-1	24345882
leu@@	O	-1	24345882
co@@	O	-1	24345882
v@@	O	-1	24345882
or@@	O	-1	24345882
in	O	-1	24345882
res@@	O	-1	24345882
c@@	O	-1	24345882
u@@	O	-1	24345882
e,	O	-1	24345882
and	O	-1	24345882
frequency	O	-1	24345882
of	O	-1	24345882
systemic	O	-1	24345882
M@@	B-Chemical	D008727	24345882
T@@	I-Chemical	-1	24345882
X	I-Chemical	-1	24345882
administration	O	-1	24345882
in	O	-1	24345882
children	O	-1	24345882
with	O	-1	24345882
acute	B-Disease	D054198	24345882
lymph@@	I-Disease	-1	24345882
ob@@	I-Disease	-1	24345882
las@@	I-Disease	-1	24345882
tic	I-Disease	-1	24345882
leuk@@	I-Disease	-1	24345882
emia	I-Disease	-1	24345882
.	O	-1	24345882
In	O	-1	24345882
this	O	-1	24345882
study,	O	-1	24345882
neuro@@	O	-1	24345882
cognitive	O	-1	24345882
outcom@@	O	-1	24345882
es	O	-1	24345882
and	O	-1	24345882
neuro@@	O	-1	24345882
radi@@	O	-1	24345882
ologic	O	-1	24345882
evidence	O	-1	24345882
of	O	-1	24345882
leuk@@	B-Disease	D056784	24345882
o@@	I-Disease	-1	24345882
encephalo@@	I-Disease	-1	24345882
pathy	I-Disease	-1	24345882
were	O	-1	24345882
compared	O	-1	24345882
in	O	-1	24345882
children	O	-1	24345882
treated	O	-1	24345882
with	O	-1	24345882
int@@	O	-1	24345882
en@@	O	-1	24345882
se	O	-1	24345882
central	O	-1	24345882
ner@@	O	-1	24345882
v@@	O	-1	24345882
ous	O	-1	24345882
system	O	-1	24345882
(C@@	O	-1	24345882
N@@	O	-1	24345882
S@@	O	-1	24345882
)-@@	O	-1	24345882
direc@@	O	-1	24345882
ted	O	-1	24345882
therapy	O	-1	24345882
(P@@	O	-1	24345882
9@@	O	-1	24345882
6@@	O	-1	24345882
0@@	O	-1	24345882
5@@	O	-1	24345882
)	O	-1	24345882
versus	O	-1	24345882
those	O	-1	24345882
receiving	O	-1	24345882
fe@@	O	-1	24345882
w@@	O	-1	24345882
er	O	-1	24345882
C@@	O	-1	24345882
N@@	O	-1	24345882
S@@	O	-1	24345882
-@@	O	-1	24345882
direc@@	O	-1	24345882
ted	O	-1	24345882
treatment	O	-1	24345882
days	O	-1	24345882
during	O	-1	24345882
int@@	O	-1	24345882
en@@	O	-1	24345882
sive	O	-1	24345882
con@@	O	-1	24345882
sol@@	O	-1	24345882
id@@	O	-1	24345882
ation	O	-1	24345882
(P@@	O	-1	24345882
9@@	O	-1	24345882
20@@	O	-1	24345882
1).	O	-1	24345882
A	O	-1	24345882
total	O	-1	24345882
of	O	-1	24345882
6@@	O	-1	24345882
6	O	-1	24345882
children	O	-1	24345882
from	O	-1	24345882
16	O	-1	24345882
P@@	O	-1	24345882
edi@@	O	-1	24345882
atric	O	-1	24345882
On@@	O	-1	24345882
co@@	O	-1	24345882
log@@	O	-1	24345882
y	O	-1	24345882
Group	O	-1	24345882
insti@@	O	-1	24345882
tu@@	O	-1	24345882
tions	O	-1	24345882
with	O	-1	24345882
"@@	O	-1	24345882
stand@@	O	-1	24345882
ar@@	O	-1	24345882
d-@@	O	-1	24345882
ris@@	O	-1	24345882
k@@	O	-1	24345882
"	O	-1	24345882
acute	B-Disease	D054198	24345882
lymph@@	I-Disease	-1	24345882
ob@@	I-Disease	-1	24345882
las@@	I-Disease	-1	24345882
tic	I-Disease	-1	24345882
leuk@@	I-Disease	-1	24345882
emia	I-Disease	-1	24345882
,	O	-1	24345882
1.@@	O	-1	24345882
00	O	-1	24345882
to	O	-1	24345882
9.@@	O	-1	24345882
9@@	O	-1	24345882
9	O	-1	24345882
years	O	-1	24345882
at	O	-1	24345882
diagno@@	O	-1	24345882
sis,	O	-1	24345882
without	O	-1	24345882
evidence	O	-1	24345882
of	O	-1	24345882
C@@	O	-1	24345882
N@@	O	-1	24345882
S	O	-1	24345882
leuk@@	B-Disease	D007938	24345882
emia	I-Disease	-1	24345882
at	O	-1	24345882
diagnosis	O	-1	24345882
were	O	-1	24345882
en@@	O	-1	24345882
ro@@	O	-1	24345882
lled	O	-1	24345882
on	O	-1	24345882
AC@@	O	-1	24345882
CL@@	O	-1	24345882
0@@	O	-1	24345882
13@@	O	-1	24345882
1@@	O	-1	24345882
:	O	-1	24345882
2@@	O	-1	24345882
8	O	-1	24345882
from	O	-1	24345882
P@@	O	-1	24345882
9@@	O	-1	24345882
20@@	O	-1	24345882
1	O	-1	24345882
and	O	-1	24345882
3@@	O	-1	24345882
8	O	-1	24345882
from	O	-1	24345882
P@@	O	-1	24345882
9@@	O	-1	24345882
6@@	O	-1	24345882
0@@	O	-1	24345882
5@@	O	-1	24345882
.	O	-1	24345882
M@@	O	-1	24345882
ag@@	O	-1	24345882
ne@@	O	-1	24345882
tic	O	-1	24345882
res@@	O	-1	24345882
on@@	O	-1	24345882
ance	O	-1	24345882
imaging	O	-1	24345882
s@@	O	-1	24345882
c@@	O	-1	24345882
ans	O	-1	24345882
and	O	-1	24345882
standard	O	-1	24345882
neuro@@	O	-1	24345882
psych@@	O	-1	24345882
ological	O	-1	24345882
tests	O	-1	24345882
were	O	-1	24345882
performed	O	-1	24345882
>@@	O	-1	24345882
2.@@	O	-1	24345882
6	O	-1	24345882
years	O	-1	24345882
after	O	-1	24345882
the	O	-1	24345882
end	O	-1	24345882
of	O	-1	24345882
treatment.	O	-1	24345882
Si@@	O	-1	24345882
gn@@	O	-1	24345882
ific@@	O	-1	24345882
ant@@	O	-1	24345882
ly	O	-1	24345882
more	O	-1	24345882
P@@	O	-1	24345882
9@@	O	-1	24345882
6@@	O	-1	24345882
0@@	O	-1	24345882
5	O	-1	24345882
patients	O	-1	24345882
developed	O	-1	24345882
leuk@@	B-Disease	D056784	24345882
o@@	I-Disease	-1	24345882
encephalo@@	I-Disease	-1	24345882
pathy	I-Disease	-1	24345882
compared	O	-1	24345882
with	O	-1	24345882
P@@	O	-1	24345882
9@@	O	-1	24345882
20@@	O	-1	24345882
1	O	-1	24345882
patients	O	-1	24345882
(6@@	O	-1	24345882
8@@	O	-1	24345882
%,	O	-1	24345882
95%	O	-1	24345882
conf@@	O	-1	24345882
idence	O	-1	24345882
interv@@	O	-1	24345882
al	O	-1	24345882
4@@	O	-1	24345882
9@@	O	-1	24345882
%@@	O	-1	24345882
-@@	O	-1	24345882
8@@	O	-1	24345882
3@@	O	-1	24345882
%	O	-1	24345882
vs.	O	-1	24345882
2@@	O	-1	24345882
2@@	O	-1	24345882
%,	O	-1	24345882
95%	O	-1	24345882
conf@@	O	-1	24345882
idence	O	-1	24345882
interv@@	O	-1	24345882
al	O	-1	24345882
5@@	O	-1	24345882
%@@	O	-1	24345882
-@@	O	-1	24345882
4@@	O	-1	24345882
4@@	O	-1	24345882
%@@	O	-1	24345882
;	O	-1	24345882
P@@	O	-1	24345882
=@@	O	-1	24345882
0.00@@	O	-1	24345882
1)	O	-1	24345882
identi@@	O	-1	24345882
fied	O	-1	24345882
as	O	-1	24345882
l@@	O	-1	24345882
ate	O	-1	24345882
as	O	-1	24345882
7.@@	O	-1	24345882
7	O	-1	24345882
years	O	-1	24345882
after	O	-1	24345882
the	O	-1	24345882
end	O	-1	24345882
of	O	-1	24345882
treatment.	O	-1	24345882
O@@	O	-1	24345882
ver@@	O	-1	24345882
all@@	O	-1	24345882
,	O	-1	24345882
4@@	O	-1	24345882
0%	O	-1	24345882
of	O	-1	24345882
patients	O	-1	24345882
sco@@	O	-1	24345882
red	O	-1	24345882
<@@	O	-1	24345882
8@@	O	-1	24345882
5	O	-1	24345882
on	O	-1	24345882
either	O	-1	24345882
V@@	O	-1	24345882
er@@	O	-1	24345882
b@@	O	-1	24345882
al	O	-1	24345882
or	O	-1	24345882
P@@	O	-1	24345882
er@@	O	-1	24345882
form@@	O	-1	24345882
ance	O	-1	24345882
I@@	O	-1	24345882
Q@@	O	-1	24345882
.	O	-1	24345882
Ch@@	O	-1	24345882
ild@@	O	-1	24345882
ren	O	-1	24345882
on	O	-1	24345882
both	O	-1	24345882
studies	O	-1	24345882
had	O	-1	24345882
significant	O	-1	24345882
atten@@	B-Disease	D003072	24345882
tion	I-Disease	-1	24345882
pro@@	I-Disease	-1	24345882
ble@@	I-Disease	-1	24345882
ms	I-Disease	-1	24345882
,	O	-1	24345882
but	O	-1	24345882
P@@	O	-1	24345882
9@@	O	-1	24345882
6@@	O	-1	24345882
0@@	O	-1	24345882
5	O	-1	24345882
children	O	-1	24345882
sco@@	O	-1	24345882
red	O	-1	24345882
be@@	O	-1	24345882
low	O	-1	24345882
average	O	-1	24345882
on	O	-1	24345882
more	O	-1	24345882
neuro@@	O	-1	24345882
cognitive	O	-1	24345882
meas@@	O	-1	24345882
ures	O	-1	24345882
than	O	-1	24345882
those	O	-1	24345882
treated	O	-1	24345882
on	O	-1	24345882
P@@	O	-1	24345882
9@@	O	-1	24345882
20@@	O	-1	24345882
1	O	-1	24345882
(@@	O	-1	24345882
8@@	O	-1	24345882
2@@	O	-1	24345882
%,	O	-1	24345882
14@@	O	-1	24345882
/@@	O	-1	24345882
17	O	-1	24345882
meas@@	O	-1	24345882
ures	O	-1	24345882
vs.	O	-1	24345882
2@@	O	-1	24345882
4@@	O	-1	24345882
%,	O	-1	24345882
4@@	O	-1	24345882
/@@	O	-1	24345882
17	O	-1	24345882
meas@@	O	-1	24345882
ures@@	O	-1	24345882
).	O	-1	24345882
This	O	-1	24345882
suppor@@	O	-1	24345882
ts	O	-1	24345882
on@@	O	-1	24345882
go@@	O	-1	24345882
ing	O	-1	24345882
con@@	O	-1	24345882
cer@@	O	-1	24345882
n@@	O	-1	24345882
s	O	-1	24345882
about	O	-1	24345882
int@@	O	-1	24345882
en@@	O	-1	24345882
sive	O	-1	24345882
M@@	B-Chemical	D008727	24345882
T@@	I-Chemical	-1	24345882
X	I-Chemical	-1	24345882
exposure	O	-1	24345882
as	O	-1	24345882
a	O	-1	24345882
major	O	-1	24345882
cont@@	O	-1	24345882
ri@@	O	-1	24345882
but@@	O	-1	24345882
or	O	-1	24345882
to	O	-1	24345882
C@@	O	-1	24345882
N@@	O	-1	24345882
S	O	-1	24345882
l@@	O	-1	24345882
ate	O	-1	24345882
effects.	O	-1	24345882

T@@	B-Chemical	D014148	24434397
ran@@	I-Chemical	-1	24434397
ex@@	I-Chemical	-1	24434397
am@@	I-Chemical	-1	24434397
ic	I-Chemical	-1	24434397
acid	I-Chemical	-1	24434397
over@@	O	-1	24434397
dos@@	O	-1	24434397
ag@@	O	-1	24434397
e@@	O	-1	24434397
-induced	O	-1	24434397
gener@@	O	-1	24434397
al@@	O	-1	24434397
ized	O	-1	24434397
seizure	B-Disease	D012640	24434397
in	O	-1	24434397
renal	B-Disease	D051437	24434397
failure	I-Disease	-1	24434397
.	O	-1	24434397
We	O	-1	24434397
report	O	-1	24434397
a	O	-1	24434397
4@@	O	-1	24434397
5-@@	O	-1	24434397
year-old	O	-1	24434397
l@@	O	-1	24434397
ad@@	O	-1	24434397
y	O	-1	24434397
with	O	-1	24434397
chronic	B-Disease	D051436	24434397
kidney	I-Disease	-1	24434397
disease	I-Disease	-1	24434397
st@@	O	-1	24434397
age	O	-1	24434397
4	O	-1	24434397
due	O	-1	24434397
to	O	-1	24434397
chronic	O	-1	24434397
tu@@	B-Disease	D004194	24434397
bu@@	I-Disease	-1	24434397
lo@@	I-Disease	-1	24434397
inter@@	I-Disease	-1	24434397
s@@	I-Disease	-1	24434397
tial	I-Disease	-1	24434397
disease	I-Disease	-1	24434397
.	O	-1	24434397
S@@	O	-1	24434397
he	O	-1	24434397
was	O	-1	24434397
ad@@	O	-1	24434397
mit@@	O	-1	24434397
ted	O	-1	24434397
to	O	-1	24434397
our	O	-1	24434397
c@@	O	-1	24434397
ent@@	O	-1	24434397
er	O	-1	24434397
for	O	-1	24434397
severe	O	-1	24434397
anemia	B-Disease	D000740	24434397
due	O	-1	24434397
to	O	-1	24434397
men@@	B-Disease	D008595	24434397
or@@	I-Disease	-1	24434397
rh@@	I-Disease	-1	24434397
ag@@	I-Disease	-1	24434397
ia	I-Disease	-1	24434397
and	O	-1	24434397
deter@@	B-Disease	D051437	24434397
i@@	I-Disease	-1	24434397
or@@	I-Disease	-1	24434397
ation	I-Disease	-1	24434397
of	I-Disease	-1	24434397
renal	I-Disease	-1	24434397
function	I-Disease	-1	24434397
.	O	-1	24434397
S@@	O	-1	24434397
he	O	-1	24434397
was	O	-1	24434397
inf@@	O	-1	24434397
used	O	-1	24434397
three	O	-1	24434397
un@@	O	-1	24434397
its	O	-1	24434397
of	O	-1	24434397
pac@@	O	-1	24434397
ked	O	-1	24434397
cells	O	-1	24434397
during	O	-1	24434397
a	O	-1	24434397
s@@	O	-1	24434397
es@@	O	-1	24434397
sion	O	-1	24434397
of	O	-1	24434397
hemo@@	O	-1	24434397
dialy@@	O	-1	24434397
sis.	O	-1	24434397
T@@	B-Chemical	D014148	24434397
ran@@	I-Chemical	-1	24434397
ex@@	I-Chemical	-1	24434397
am@@	I-Chemical	-1	24434397
ic	I-Chemical	-1	24434397
acid	I-Chemical	-1	24434397
(	O	-1	24434397
T@@	B-Chemical	D014148	24434397
NA	I-Chemical	-1	24434397
)	O	-1	24434397
1	O	-1	24434397
g	O	-1	24434397
8@@	O	-1	24434397
-@@	O	-1	24434397
hour@@	O	-1	24434397
ly	O	-1	24434397
was	O	-1	24434397
administered	O	-1	24434397
to	O	-1	24434397
h@@	O	-1	24434397
er	O	-1	24434397
to	O	-1	24434397
control	O	-1	24434397
ble@@	B-Disease	D006470	24434397
ed@@	I-Disease	-1	24434397
ing	I-Disease	-1	24434397
per	O	-1	24434397
v@@	O	-1	24434397
ag@@	O	-1	24434397
in@@	O	-1	24434397
um@@	O	-1	24434397
.	O	-1	24434397
Two	O	-1	24434397
hours	O	-1	24434397
after	O	-1	24434397
the	O	-1	24434397
si@@	O	-1	24434397
x@@	O	-1	24434397
th	O	-1	24434397
dose	O	-1	24434397
of	O	-1	24434397
T@@	B-Chemical	D014148	24434397
NA	I-Chemical	-1	24434397
,	O	-1	24434397
sh@@	O	-1	24434397
e	O	-1	24434397
had	O	-1	24434397
an	O	-1	24434397
episo@@	O	-1	24434397
de	O	-1	24434397
of	O	-1	24434397
gener@@	O	-1	24434397
al@@	O	-1	24434397
ized	O	-1	24434397
t@@	B-Disease	D004830	24434397
onic	I-Disease	-1	24434397
clon@@	I-Disease	-1	24434397
ic	I-Disease	-1	24434397
convul@@	I-Disease	-1	24434397
sions	I-Disease	-1	24434397
.	O	-1	24434397
T@@	B-Chemical	D014148	24434397
NA	I-Chemical	-1	24434397
was	O	-1	24434397
discontinu@@	O	-1	24434397
ed.	O	-1	24434397
In@@	O	-1	24434397
v@@	O	-1	24434397
estig@@	O	-1	24434397
ations	O	-1	24434397
of	O	-1	24434397
the	O	-1	24434397
patient	O	-1	24434397
revealed	O	-1	24434397
no	O	-1	24434397
bio@@	O	-1	24434397
chemical	O	-1	24434397
or	O	-1	24434397
struct@@	O	-1	24434397
ural	O	-1	24434397
central	O	-1	24434397
ner@@	B-Disease	D009421	24434397
v@@	I-Disease	-1	24434397
ous	I-Disease	-1	24434397
system	I-Disease	-1	24434397
abnormal@@	I-Disease	-1	24434397
ities	I-Disease	-1	24434397
that	O	-1	24434397
could	O	-1	24434397
have	O	-1	24434397
prov@@	O	-1	24434397
o@@	O	-1	24434397
ked	O	-1	24434397
the	O	-1	24434397
convul@@	B-Disease	D012640	24434397
sions	I-Disease	-1	24434397
.	O	-1	24434397
S@@	O	-1	24434397
he	O	-1	24434397
did	O	-1	24434397
not	O	-1	24434397
requ@@	O	-1	24434397
ir@@	O	-1	24434397
e	O	-1	24434397
any	O	-1	24434397
further	O	-1	24434397
dialy@@	O	-1	24434397
tic	O	-1	24434397
sup@@	O	-1	24434397
port@@	O	-1	24434397
.	O	-1	24434397
S@@	O	-1	24434397
he	O	-1	24434397
had	O	-1	24434397
no	O	-1	24434397
further	O	-1	24434397
episo@@	O	-1	24434397
des	O	-1	24434397
of	O	-1	24434397
convul@@	B-Disease	D012640	24434397
sion	I-Disease	-1	24434397
ti@@	O	-1	24434397
ll	O	-1	24434397
dis@@	O	-1	24434397
-@@	O	-1	24434397
ch@@	O	-1	24434397
arg@@	O	-1	24434397
e	O	-1	24434397
and	O	-1	24434397
during	O	-1	24434397
the	O	-1	24434397
two	O	-1	24434397
months	O	-1	24434397
of	O	-1	24434397
follow-@@	O	-1	24434397
up@@	O	-1	24434397
.	O	-1	24434397
Th@@	O	-1	24434397
us,	O	-1	24434397
the	O	-1	24434397
pre@@	O	-1	24434397
ci@@	O	-1	24434397
pit@@	O	-1	24434397
ating	O	-1	24434397
cause	O	-1	24434397
of	O	-1	24434397
convul@@	B-Disease	D012640	24434397
sions	I-Disease	-1	24434397
was	O	-1	24434397
be@@	O	-1	24434397
li@@	O	-1	24434397
ev@@	O	-1	24434397
ed	O	-1	24434397
to	O	-1	24434397
be	O	-1	24434397
an	O	-1	24434397
over@@	B-Disease	D062787	24434397
dose	I-Disease	-1	24434397
of	O	-1	24434397
T@@	B-Chemical	D014148	24434397
NA	I-Chemical	-1	24434397
.	O	-1	24434397

Pre@@	O	-1	24438483
-@@	O	-1	24438483
treatment	O	-1	24438483
of	O	-1	24438483
bupivac@@	B-Chemical	D002045	24438483
aine	I-Chemical	-1	24438483
-induced	O	-1	24438483
cardiovascular	B-Disease	D002318	24438483
de@@	I-Disease	-1	24438483
pression	I-Disease	-1	24438483
using	O	-1	24438483
different	O	-1	24438483
li@@	O	-1	24438483
pid	O	-1	24438483
form@@	O	-1	24438483
ul@@	O	-1	24438483
ations	O	-1	24438483
of	O	-1	24438483
pro@@	B-Chemical	D015742	24438483
po@@	I-Chemical	-1	24438483
f@@	I-Chemical	-1	24438483
ol	I-Chemical	-1	24438483
.	O	-1	24438483
BACKGROUND:	O	-1	24438483
Pre@@	O	-1	24438483
-@@	O	-1	24438483
treatment	O	-1	24438483
with	O	-1	24438483
li@@	O	-1	24438483
pid	O	-1	24438483
em@@	O	-1	24438483
ul@@	O	-1	24438483
sions	O	-1	24438483
has	O	-1	24438483
been	O	-1	24438483
shown	O	-1	24438483
to	O	-1	24438483
increase	O	-1	24438483
le@@	O	-1	24438483
th@@	O	-1	24438483
al	O	-1	24438483
doses	O	-1	24438483
of	O	-1	24438483
bupivac@@	B-Chemical	D002045	24438483
aine	I-Chemical	-1	24438483
,	O	-1	24438483
and	O	-1	24438483
the	O	-1	24438483
li@@	O	-1	24438483
pid	O	-1	24438483
cont@@	O	-1	24438483
ent	O	-1	24438483
of	O	-1	24438483
pro@@	B-Chemical	D015742	24438483
po@@	I-Chemical	-1	24438483
f@@	I-Chemical	-1	24438483
ol	I-Chemical	-1	24438483
may	O	-1	24438483
al@@	O	-1	24438483
le@@	O	-1	24438483
vi@@	O	-1	24438483
ate	O	-1	24438483
bupivac@@	B-Chemical	D002045	24438483
aine	I-Chemical	-1	24438483
-induced	O	-1	24438483
cardi@@	B-Disease	D066126	24438483
otoxicity	I-Disease	-1	24438483
.	O	-1	24438483
The	O	-1	24438483
a@@	O	-1	24438483
im	O	-1	24438483
of	O	-1	24438483
this	O	-1	24438483
study	O	-1	24438483
is	O	-1	24438483
to	O	-1	24438483
investigate	O	-1	24438483
the	O	-1	24438483
effects	O	-1	24438483
of	O	-1	24438483
pro@@	B-Chemical	D015742	24438483
po@@	I-Chemical	-1	24438483
f@@	I-Chemical	-1	24438483
ol	I-Chemical	-1	24438483
in	O	-1	24438483
int@@	O	-1	24438483
r@@	O	-1	24438483
al@@	O	-1	24438483
i@@	O	-1	24438483
pid	O	-1	24438483
or	O	-1	24438483
medi@@	O	-1	24438483
al@@	O	-1	24438483
i@@	O	-1	24438483
pid	O	-1	24438483
em@@	O	-1	24438483
ul@@	O	-1	24438483
sions	O	-1	24438483
on	O	-1	24438483
bupivac@@	B-Chemical	D002045	24438483
aine	I-Chemical	-1	24438483
-induced	O	-1	24438483
cardi@@	B-Disease	D066126	24438483
otoxicity	I-Disease	-1	24438483
.	O	-1	24438483
METHODS:	O	-1	24438483
R@@	O	-1	24438483
at@@	O	-1	24438483
s	O	-1	24438483
were	O	-1	24438483
anaesthe@@	O	-1	24438483
tis@@	O	-1	24438483
ed	O	-1	24438483
with	O	-1	24438483
k@@	B-Chemical	D007649	24438483
et@@	I-Chemical	-1	24438483
amine	I-Chemical	-1	24438483
and	O	-1	24438483
were	O	-1	24438483
given	O	-1	24438483
0.@@	O	-1	24438483
5	O	-1	24438483
mg/k@@	O	-1	24438483
g/@@	O	-1	24438483
min	O	-1	24438483
pro@@	B-Chemical	D015742	24438483
po@@	I-Chemical	-1	24438483
f@@	I-Chemical	-1	24438483
ol	I-Chemical	-1	24438483
in	O	-1	24438483
int@@	O	-1	24438483
r@@	O	-1	24438483
al@@	O	-1	24438483
i@@	O	-1	24438483
pid	O	-1	24438483
(@@	O	-1	24438483
Group	O	-1	24438483
P@@	O	-1	24438483
),	O	-1	24438483
pro@@	B-Chemical	D015742	24438483
po@@	I-Chemical	-1	24438483
f@@	I-Chemical	-1	24438483
ol	I-Chemical	-1	24438483
in	O	-1	24438483
medi@@	O	-1	24438483
al@@	O	-1	24438483
i@@	O	-1	24438483
pid	O	-1	24438483
(@@	O	-1	24438483
Group	O	-1	24438483
L@@	O	-1	24438483
),	O	-1	24438483
or	O	-1	24438483
saline	O	-1	24438483
(@@	O	-1	24438483
Group	O	-1	24438483
C@@	O	-1	24438483
)	O	-1	24438483
over	O	-1	24438483
20	O	-1	24438483
min@@	O	-1	24438483
.	O	-1	24438483
The@@	O	-1	24438483
re@@	O	-1	24438483
af@@	O	-1	24438483
ter@@	O	-1	24438483
,	O	-1	24438483
2	O	-1	24438483
mg/k@@	O	-1	24438483
g/@@	O	-1	24438483
min	O	-1	24438483
bupivac@@	B-Chemical	D002045	24438483
aine	I-Chemical	-1	24438483
0.@@	O	-1	24438483
5%	O	-1	24438483
was	O	-1	24438483
inf@@	O	-1	24438483
use@@	O	-1	24438483
d.	O	-1	24438483
We	O	-1	24438483
recor@@	O	-1	24438483
ded	O	-1	24438483
time	O	-1	24438483
to	O	-1	24438483
first	O	-1	24438483
dys@@	B-Disease	D001145	24438483
rhyth@@	I-Disease	-1	24438483
mia	I-Disease	-1	24438483
occur@@	O	-1	24438483
ren@@	O	-1	24438483
ce@@	O	-1	24438483
,	O	-1	24438483
resp@@	O	-1	24438483
ective	O	-1	24438483
times	O	-1	24438483
to	O	-1	24438483
2@@	O	-1	24438483
5%	O	-1	24438483
and	O	-1	24438483
50@@	O	-1	24438483
%	O	-1	24438483
reduction	O	-1	24438483
of	O	-1	24438483
the	O	-1	24438483
heart	O	-1	24438483
rate	O	-1	24438483
(@@	O	-1	24438483
H@@	O	-1	24438483
R@@	O	-1	24438483
)	O	-1	24438483
and	O	-1	24438483
mean	O	-1	24438483
arterial	O	-1	24438483
pressu@@	O	-1	24438483
re,	O	-1	24438483
and	O	-1	24438483
time	O	-1	24438483
to	O	-1	24438483
as@@	B-Disease	D006323	24438483
y@@	I-Disease	-1	24438483
st@@	I-Disease	-1	24438483
ole	I-Disease	-1	24438483
and	O	-1	24438483
total	O	-1	24438483
amoun@@	O	-1	24438483
t	O	-1	24438483
of	O	-1	24438483
bupivac@@	B-Chemical	D002045	24438483
aine	I-Chemical	-1	24438483
consum@@	O	-1	24438483
p@@	O	-1	24438483
tion.	O	-1	24438483
B@@	O	-1	24438483
lo@@	O	-1	24438483
od	O	-1	24438483
and	O	-1	24438483
tissue	O	-1	24438483
sam@@	O	-1	24438483
ple@@	O	-1	24438483
s	O	-1	24438483
were	O	-1	24438483
coll@@	O	-1	24438483
ected	O	-1	24438483
following	O	-1	24438483
as@@	B-Disease	D006323	24438483
y@@	I-Disease	-1	24438483
st@@	I-Disease	-1	24438483
ole	I-Disease	-1	24438483
.	O	-1	24438483
RESULTS:	O	-1	24438483
The	O	-1	24438483
time	O	-1	24438483
to	O	-1	24438483
first	O	-1	24438483
dys@@	B-Disease	D001145	24438483
rhyth@@	I-Disease	-1	24438483
mia	I-Disease	-1	24438483
occur@@	O	-1	24438483
ren@@	O	-1	24438483
ce@@	O	-1	24438483
,	O	-1	24438483
time	O	-1	24438483
to	O	-1	24438483
2@@	O	-1	24438483
5%	O	-1	24438483
and	O	-1	24438483
50@@	O	-1	24438483
%	O	-1	24438483
reduc@@	O	-1	24438483
tions	O	-1	24438483
in	O	-1	24438483
H@@	O	-1	24438483
R@@	O	-1	24438483
,	O	-1	24438483
and	O	-1	24438483
time	O	-1	24438483
to	O	-1	24438483
as@@	B-Disease	D006323	24438483
y@@	I-Disease	-1	24438483
st@@	I-Disease	-1	24438483
ole	I-Disease	-1	24438483
were	O	-1	24438483
long@@	O	-1	24438483
er	O	-1	24438483
in	O	-1	24438483
Group	O	-1	24438483
P	O	-1	24438483
than	O	-1	24438483
the	O	-1	24438483
other	O	-1	24438483
groups.	O	-1	24438483
The	O	-1	24438483
cum@@	O	-1	24438483
ul@@	O	-1	24438483
ative	O	-1	24438483
bupivac@@	B-Chemical	D002045	24438483
aine	I-Chemical	-1	24438483
dose	O	-1	24438483
given	O	-1	24438483
at	O	-1	24438483
those	O	-1	24438483
time	O	-1	24438483
po@@	O	-1	24438483
int@@	O	-1	24438483
s	O	-1	24438483
was	O	-1	24438483
higher	O	-1	24438483
in	O	-1	24438483
Group	O	-1	24438483
P@@	O	-1	24438483
.	O	-1	24438483
P@@	O	-1	24438483
las@@	O	-1	24438483
ma	O	-1	24438483
bupivac@@	B-Chemical	D002045	24438483
aine	I-Chemical	-1	24438483
levels	O	-1	24438483
were	O	-1	24438483
significantly	O	-1	24438483
lower	O	-1	24438483
in	O	-1	24438483
Group	O	-1	24438483
P	O	-1	24438483
than	O	-1	24438483
in	O	-1	24438483
Group	O	-1	24438483
C@@	O	-1	24438483
.	O	-1	24438483
B@@	B-Chemical	D002045	24438483
u@@	I-Chemical	-1	24438483
pivac@@	I-Chemical	-1	24438483
aine	I-Chemical	-1	24438483
levels	O	-1	24438483
in	O	-1	24438483
the	O	-1	24438483
brain	O	-1	24438483
and	O	-1	24438483
heart	O	-1	24438483
were	O	-1	24438483
significantly	O	-1	24438483
lower	O	-1	24438483
in	O	-1	24438483
Group	O	-1	24438483
P	O	-1	24438483
and	O	-1	24438483
Group	O	-1	24438483
L	O	-1	24438483
than	O	-1	24438483
in	O	-1	24438483
Group	O	-1	24438483
C@@	O	-1	24438483
.	O	-1	24438483
CONCLUSION:	O	-1	24438483
We	O	-1	24438483
concl@@	O	-1	24438483
ude	O	-1	24438483
that	O	-1	24438483
pre-@@	O	-1	24438483
treatment	O	-1	24438483
with	O	-1	24438483
pro@@	B-Chemical	D015742	24438483
po@@	I-Chemical	-1	24438483
f@@	I-Chemical	-1	24438483
ol	I-Chemical	-1	24438483
in	O	-1	24438483
int@@	O	-1	24438483
r@@	O	-1	24438483
al@@	O	-1	24438483
ip@@	O	-1	24438483
id@@	O	-1	24438483
,	O	-1	24438483
compared	O	-1	24438483
with	O	-1	24438483
pro@@	B-Chemical	D015742	24438483
po@@	I-Chemical	-1	24438483
f@@	I-Chemical	-1	24438483
ol	I-Chemical	-1	24438483
in	O	-1	24438483
medi@@	O	-1	24438483
al@@	O	-1	24438483
i@@	O	-1	24438483
pid	O	-1	24438483
or	O	-1	24438483
sal@@	O	-1	24438483
ine,	O	-1	24438483
del@@	O	-1	24438483
ayed	O	-1	24438483
the	O	-1	24438483
onset	O	-1	24438483
of	O	-1	24438483
bupivac@@	B-Chemical	D002045	24438483
aine	I-Chemical	-1	24438483
-induced	O	-1	24438483
cardi@@	B-Disease	D066126	24438483
ot@@	I-Disease	-1	24438483
ox@@	I-Disease	-1	24438483
ic	I-Disease	-1	24438483
effects	O	-1	24438483
as	O	-1	24438483
well	O	-1	24438483
as	O	-1	24438483
reduced	O	-1	24438483
plasma	O	-1	24438483
bupivac@@	B-Chemical	D002045	24438483
aine	I-Chemical	-1	24438483
level@@	O	-1	24438483
s.	O	-1	24438483
F@@	O	-1	24438483
urther	O	-1	24438483
studies	O	-1	24438483
are	O	-1	24438483
ne@@	O	-1	24438483
ed@@	O	-1	24438483
ed	O	-1	24438483
to	O	-1	24438483
expl@@	O	-1	24438483
or@@	O	-1	24438483
e	O	-1	24438483
tissue	O	-1	24438483
bupivac@@	B-Chemical	D002045	24438483
aine	I-Chemical	-1	24438483
levels	O	-1	24438483
of	O	-1	24438483
pro@@	B-Chemical	D015742	24438483
po@@	I-Chemical	-1	24438483
f@@	I-Chemical	-1	24438483
ol	I-Chemical	-1	24438483
in	O	-1	24438483
medi@@	O	-1	24438483
al@@	O	-1	24438483
i@@	O	-1	24438483
pid	O	-1	24438483
and	O	-1	24438483
ad@@	O	-1	24438483
ap@@	O	-1	24438483
t	O	-1	24438483
these	O	-1	24438483
results	O	-1	24438483
to	O	-1	24438483
clinical	O	-1	24438483
p@@	O	-1	24438483
rac@@	O	-1	24438483
ti@@	O	-1	24438483
ce@@	O	-1	24438483
.	O	-1	24438483

D@@	B-Disease	D056486	24451297
ru@@	I-Disease	-1	24451297
g@@	I-Disease	-1	24451297
-@@	I-Disease	-1	24451297
In@@	I-Disease	-1	24451297
duced	I-Disease	-1	24451297
Ac@@	I-Disease	-1	24451297
ute	I-Disease	-1	24451297
L@@	I-Disease	-1	24451297
i@@	I-Disease	-1	24451297
ver	I-Disease	-1	24451297
In@@	I-Disease	-1	24451297
j@@	I-Disease	-1	24451297
ur@@	I-Disease	-1	24451297
y	I-Disease	-1	24451297
W@@	O	-1	24451297
i@@	O	-1	24451297
th@@	O	-1	24451297
in	O	-1	24451297
12	O	-1	24451297
Ho@@	O	-1	24451297
ur@@	O	-1	24451297
s	O	-1	24451297
After	O	-1	24451297
F@@	B-Chemical	C065180	24451297
lu@@	I-Chemical	-1	24451297
vastatin	I-Chemical	-1	24451297
Th@@	O	-1	24451297
er@@	O	-1	24451297
ap@@	O	-1	24451297
y.	O	-1	24451297
Although	O	-1	24451297
stat@@	B-Chemical	D019161	24451297
ins	I-Chemical	-1	24451297
are	O	-1	24451297
gener@@	O	-1	24451297
ally	O	-1	24451297
we@@	O	-1	24451297
ll@@	O	-1	24451297
-@@	O	-1	24451297
toler@@	O	-1	24451297
ated	O	-1	24451297
drug@@	O	-1	24451297
s,	O	-1	24451297
rec@@	O	-1	24451297
ent	O	-1	24451297
cases	O	-1	24451297
of	O	-1	24451297
drug@@	B-Disease	D056486	24451297
-induced	I-Disease	-1	24451297
liver	I-Disease	-1	24451297
injury	I-Disease	-1	24451297
associated	O	-1	24451297
with	O	-1	24451297
their	O	-1	24451297
use	O	-1	24451297
have	O	-1	24451297
been	O	-1	24451297
repor@@	O	-1	24451297
ted.	O	-1	24451297
A	O	-1	24451297
5@@	O	-1	24451297
2-@@	O	-1	24451297
year-old	O	-1	24451297
Ch@@	O	-1	24451297
in@@	O	-1	24451297
ese	O	-1	24451297
man	O	-1	24451297
reported	O	-1	24451297
with	O	-1	24451297
liver	B-Disease	D056486	24451297
damage	I-Disease	-1	24451297
,	O	-1	24451297
which	O	-1	24451297
appe@@	O	-1	24451297
a@@	O	-1	24451297
red	O	-1	24451297
12	O	-1	24451297
hours	O	-1	24451297
after	O	-1	24451297
be@@	O	-1	24451297
g@@	O	-1	24451297
in@@	O	-1	24451297
ning	O	-1	24451297
treatment	O	-1	24451297
with	O	-1	24451297
flu@@	B-Chemical	C065180	24451297
vastatin	I-Chemical	-1	24451297
.	O	-1	24451297
Pati@@	O	-1	24451297
ent	O	-1	24451297
presented	O	-1	24451297
with	O	-1	24451297
com@@	O	-1	24451297
pl@@	O	-1	24451297
a@@	O	-1	24451297
int@@	O	-1	24451297
s	O	-1	24451297
of	O	-1	24451297
increas@@	O	-1	24451297
ing	O	-1	24451297
nausea	B-Disease	D009325	24451297
,	O	-1	24451297
an@@	B-Disease	D000855	24451297
ore@@	I-Disease	-1	24451297
x@@	I-Disease	-1	24451297
ia	I-Disease	-1	24451297
,	O	-1	24451297
and	O	-1	24451297
up@@	O	-1	24451297
per	O	-1	24451297
ab@@	B-Disease	D015746	24451297
domin@@	I-Disease	-1	24451297
al	I-Disease	-1	24451297
pain	I-Disease	-1	24451297
.	O	-1	24451297
H@@	O	-1	24451297
is	O	-1	24451297
labor@@	O	-1	24451297
atory	O	-1	24451297
values	O	-1	24451297
showed	O	-1	24451297
elevated	O	-1	24451297
creat@@	B-Chemical	D003401	24451297
ine	I-Chemical	-1	24451297
kin@@	O	-1	24451297
ase	O	-1	24451297
and	O	-1	24451297
trans@@	O	-1	24451297
amin@@	O	-1	24451297
as@@	O	-1	24451297
es.	O	-1	24451297
T@@	O	-1	24451297
est@@	O	-1	24451297
ing	O	-1	24451297
for	O	-1	24451297
auto@@	O	-1	24451297
anti@@	O	-1	24451297
bo@@	O	-1	24451297
di@@	O	-1	24451297
es	O	-1	24451297
was	O	-1	24451297
also	O	-1	24451297
neg@@	O	-1	24451297
ati@@	O	-1	24451297
ve.	O	-1	24451297
The	O	-1	24451297
liver	O	-1	24451297
bio@@	O	-1	24451297
chem@@	O	-1	24451297
ist@@	O	-1	24451297
ri@@	O	-1	24451297
es	O	-1	24451297
event@@	O	-1	24451297
ually	O	-1	24451297
normal@@	O	-1	24451297
ized	O	-1	24451297
within	O	-1	24451297
3	O	-1	24451297
weeks	O	-1	24451297
of	O	-1	24451297
sto@@	O	-1	24451297
pp@@	O	-1	24451297
ing	O	-1	24451297
the	O	-1	24451297
flu@@	B-Chemical	C065180	24451297
vastatin	I-Chemical	-1	24451297
.	O	-1	24451297
The@@	O	-1	24451297
refore,	O	-1	24451297
when	O	-1	24451297
prescri@@	O	-1	24451297
b@@	O	-1	24451297
ing	O	-1	24451297
stat@@	O	-1	24451297
in@@	O	-1	24451297
s,	O	-1	24451297
the	O	-1	24451297
possib@@	O	-1	24451297
ility	O	-1	24451297
of	O	-1	24451297
hepatic	B-Disease	D056486	24451297
damage	I-Disease	-1	24451297
should	O	-1	24451297
be	O	-1	24451297
tak@@	O	-1	24451297
en	O	-1	24451297
into	O	-1	24451297
ac@@	O	-1	24451297
coun@@	O	-1	24451297
t.	O	-1	24451297

F@@	B-Chemical	D015725	24459006
l@@	I-Chemical	-1	24459006
uc@@	I-Chemical	-1	24459006
on@@	I-Chemical	-1	24459006
azole	I-Chemical	-1	24459006
associated	O	-1	24459006
ag@@	B-Disease	D000380	24459006
ran@@	I-Disease	-1	24459006
ulo@@	I-Disease	-1	24459006
cyto@@	I-Disease	-1	24459006
sis	I-Disease	-1	24459006
and	O	-1	24459006
throm@@	B-Disease	D013921	24459006
b@@	I-Disease	-1	24459006
ocyto@@	I-Disease	-1	24459006
pen@@	I-Disease	-1	24459006
ia	I-Disease	-1	24459006
.	O	-1	24459006
CA@@	O	-1	24459006
S@@	O	-1	24459006
E:	O	-1	24459006
We	O	-1	24459006
describe	O	-1	24459006
a	O	-1	24459006
second	O	-1	24459006
case	O	-1	24459006
of	O	-1	24459006
f@@	B-Chemical	D015725	24459006
l@@	I-Chemical	-1	24459006
uc@@	I-Chemical	-1	24459006
on@@	I-Chemical	-1	24459006
azole	I-Chemical	-1	24459006
associated	O	-1	24459006
ag@@	B-Disease	D000380	24459006
ran@@	I-Disease	-1	24459006
ulo@@	I-Disease	-1	24459006
cyto@@	I-Disease	-1	24459006
sis	I-Disease	-1	24459006
with	O	-1	24459006
throm@@	B-Disease	D013921	24459006
b@@	I-Disease	-1	24459006
ocyto@@	I-Disease	-1	24459006
pen@@	I-Disease	-1	24459006
ia	I-Disease	-1	24459006
and	O	-1	24459006
recovery	O	-1	24459006
up@@	O	-1	24459006
on	O	-1	24459006
discontinu@@	O	-1	24459006
ation	O	-1	24459006
of	O	-1	24459006
therapy.	O	-1	24459006
The	O	-1	24459006
patient	O	-1	24459006
be@@	O	-1	24459006
g@@	O	-1	24459006
an	O	-1	24459006
to	O	-1	24459006
have	O	-1	24459006
changes	O	-1	24459006
in	O	-1	24459006
wh@@	O	-1	24459006
ite	O	-1	24459006
blood	O	-1	24459006
cells	O	-1	24459006
and	O	-1	24459006
platele@@	O	-1	24459006
ts	O	-1	24459006
within	O	-1	24459006
4@@	O	-1	24459006
8	O	-1	24459006
h	O	-1	24459006
of	O	-1	24459006
administration	O	-1	24459006
of	O	-1	24459006
f@@	B-Chemical	D015725	24459006
l@@	I-Chemical	-1	24459006
uc@@	I-Chemical	-1	24459006
on@@	I-Chemical	-1	24459006
azole	I-Chemical	-1	24459006
and	O	-1	24459006
be@@	O	-1	24459006
g@@	O	-1	24459006
an	O	-1	24459006
to	O	-1	24459006
reco@@	O	-1	24459006
ver	O	-1	24459006
with	O	-1	24459006
4@@	O	-1	24459006
8	O	-1	24459006
h	O	-1	24459006
of	O	-1	24459006
discontinu@@	O	-1	24459006
ation.	O	-1	24459006
This	O	-1	24459006
case	O	-1	24459006
high@@	O	-1	24459006
li@@	O	-1	24459006
gh@@	O	-1	24459006
ts	O	-1	24459006
that	O	-1	24459006
drug@@	O	-1	24459006
-induced	O	-1	24459006
blood	B-Disease	D006402	24459006
dys@@	I-Disease	-1	24459006
c@@	I-Disease	-1	24459006
ra@@	I-Disease	-1	24459006
si@@	I-Disease	-1	24459006
as	I-Disease	-1	24459006
can	O	-1	24459006
occ@@	O	-1	24459006
ur	O	-1	24459006
un@@	O	-1	24459006
ex@@	O	-1	24459006
p@@	O	-1	24459006
ect@@	O	-1	24459006
ed@@	O	-1	24459006
ly	O	-1	24459006
as	O	-1	24459006
a	O	-1	24459006
result	O	-1	24459006
of	O	-1	24459006
treatment	O	-1	24459006
with	O	-1	24459006
a	O	-1	24459006
common@@	O	-1	24459006
ly	O	-1	24459006
used	O	-1	24459006
drug	O	-1	24459006
thou@@	O	-1	24459006
ght	O	-1	24459006
to	O	-1	24459006
be	O	-1	24459006
"@@	O	-1	24459006
saf@@	O	-1	24459006
e@@	O	-1	24459006
"@@	O	-1	24459006
.	O	-1	24459006
CONCLUSION:	O	-1	24459006
Ac@@	O	-1	24459006
cor@@	O	-1	24459006
ding	O	-1	24459006
to	O	-1	24459006
N@@	O	-1	24459006
ar@@	O	-1	24459006
an@@	O	-1	24459006
j@@	O	-1	24459006
o@@	O	-1	24459006
's	O	-1	24459006
al@@	O	-1	24459006
g@@	O	-1	24459006
or@@	O	-1	24459006
i@@	O	-1	24459006
th@@	O	-1	24459006
m	O	-1	24459006
the	O	-1	24459006
lik@@	O	-1	24459006
e@@	O	-1	24459006
li@@	O	-1	24459006
ho@@	O	-1	24459006
od	O	-1	24459006
that	O	-1	24459006
our	O	-1	24459006
patient@@	O	-1	24459006
's	O	-1	24459006
ag@@	B-Disease	D000380	24459006
ran@@	I-Disease	-1	24459006
ulo@@	I-Disease	-1	24459006
cyto@@	I-Disease	-1	24459006
sis	I-Disease	-1	24459006
and	O	-1	24459006
throm@@	B-Disease	D013921	24459006
b@@	I-Disease	-1	24459006
ocyto@@	I-Disease	-1	24459006
pen@@	I-Disease	-1	24459006
ia	I-Disease	-1	24459006
occurred	O	-1	24459006
as	O	-1	24459006
a	O	-1	24459006
result	O	-1	24459006
of	O	-1	24459006
therapy	O	-1	24459006
with	O	-1	24459006
f@@	B-Chemical	D015725	24459006
l@@	I-Chemical	-1	24459006
uc@@	I-Chemical	-1	24459006
on@@	I-Chemical	-1	24459006
azole	I-Chemical	-1	24459006
is	O	-1	24459006
prob@@	O	-1	24459006
able@@	O	-1	24459006
,	O	-1	24459006
with	O	-1	24459006
a	O	-1	24459006
total	O	-1	24459006
of	O	-1	24459006
six	O	-1	24459006
po@@	O	-1	24459006
int@@	O	-1	24459006
s.	O	-1	24459006
We	O	-1	24459006
fe@@	O	-1	24459006
el	O	-1	24459006
that	O	-1	24459006
the	O	-1	24459006
weight	O	-1	24459006
of	O	-1	24459006
the	O	-1	24459006
over@@	O	-1	24459006
all	O	-1	24459006
evidence	O	-1	24459006
of	O	-1	24459006
this	O	-1	24459006
evidence	O	-1	24459006
is	O	-1	24459006
st@@	O	-1	24459006
ron@@	O	-1	24459006
g@@	O	-1	24459006
.	O	-1	24459006
In	O	-1	24459006
partic@@	O	-1	24459006
ular	O	-1	24459006
the	O	-1	24459006
tempor@@	O	-1	24459006
al	O	-1	24459006
rel@@	O	-1	24459006
ationship	O	-1	24459006
of	O	-1	24459006
b@@	B-Disease	D001855	24459006
one	I-Disease	-1	24459006
m@@	I-Disease	-1	24459006
ar@@	I-Disease	-1	24459006
ro@@	I-Disease	-1	24459006
w	I-Disease	-1	24459006
sup@@	I-Disease	-1	24459006
pression	I-Disease	-1	24459006
to	O	-1	24459006
the	O	-1	24459006
initi@@	O	-1	24459006
ation	O	-1	24459006
of	O	-1	24459006
f@@	B-Chemical	D015725	24459006
l@@	I-Chemical	-1	24459006
uc@@	I-Chemical	-1	24459006
on@@	I-Chemical	-1	24459006
azole	I-Chemical	-1	24459006
and	O	-1	24459006
the	O	-1	24459006
ab@@	O	-1	24459006
at@@	O	-1	24459006
ement	O	-1	24459006
of	O	-1	24459006
symptoms	O	-1	24459006
that	O	-1	24459006
ra@@	O	-1	24459006
pid@@	O	-1	24459006
ly	O	-1	24459006
reversed	O	-1	24459006
immedi@@	O	-1	24459006
ately	O	-1	24459006
following	O	-1	24459006
discontinu@@	O	-1	24459006
ation.	O	-1	24459006

T@@	O	-1	24464946
wo@@	O	-1	24464946
-@@	O	-1	24464946
di@@	O	-1	24464946
men@@	O	-1	24464946
sion@@	O	-1	24464946
al	O	-1	24464946
spec@@	O	-1	24464946
k@@	O	-1	24464946
le	O	-1	24464946
trac@@	O	-1	24464946
king	O	-1	24464946
echocardiograph@@	O	-1	24464946
y	O	-1	24464946
combined	O	-1	24464946
with	O	-1	24464946
high-@@	O	-1	24464946
sensitive	O	-1	24464946
cardiac	O	-1	24464946
tro@@	O	-1	24464946
p@@	O	-1	24464946
on@@	O	-1	24464946
in	O	-1	24464946
T	O	-1	24464946
in	O	-1	24464946
early	O	-1	24464946
det@@	O	-1	24464946
ection	O	-1	24464946
and	O	-1	24464946
predic@@	O	-1	24464946
tion	O	-1	24464946
of	O	-1	24464946
cardi@@	B-Disease	D066126	24464946
otoxicity	I-Disease	-1	24464946
during	O	-1	24464946
epi@@	B-Chemical	D015251	24464946
ru@@	I-Chemical	-1	24464946
b@@	I-Chemical	-1	24464946
ic@@	I-Chemical	-1	24464946
ine	I-Chemical	-1	24464946
-@@	O	-1	24464946
bas@@	O	-1	24464946
ed	O	-1	24464946
chemo@@	O	-1	24464946
therapy.	O	-1	24464946
A@@	O	-1	24464946
I@@	O	-1	24464946
M@@	O	-1	24464946
S:	O	-1	24464946
To	O	-1	24464946
investigate	O	-1	24464946
whether	O	-1	24464946
al@@	O	-1	24464946
ter@@	O	-1	24464946
ations	O	-1	24464946
of	O	-1	24464946
myocardial	B-Disease	D009202	24464946
stra@@	I-Disease	-1	24464946
in	I-Disease	-1	24464946
and	O	-1	24464946
high-@@	O	-1	24464946
sensitive	O	-1	24464946
cardiac	O	-1	24464946
tro@@	O	-1	24464946
p@@	O	-1	24464946
on@@	O	-1	24464946
in	O	-1	24464946
T	O	-1	24464946
(@@	O	-1	24464946
cTn@@	O	-1	24464946
T)	O	-1	24464946
could	O	-1	24464946
predic@@	O	-1	24464946
t	O	-1	24464946
f@@	O	-1	24464946
ut@@	O	-1	24464946
ure	O	-1	24464946
cardiac	B-Disease	D006331	24464946
dysfunction	I-Disease	-1	24464946
in	O	-1	24464946
patients	O	-1	24464946
after	O	-1	24464946
epi@@	B-Chemical	D015251	24464946
ru@@	I-Chemical	-1	24464946
b@@	I-Chemical	-1	24464946
icin	I-Chemical	-1	24464946
expos@@	O	-1	24464946
ure.	O	-1	24464946
METHODS:	O	-1	24464946
S@@	O	-1	24464946
event@@	O	-1	24464946
y-@@	O	-1	24464946
five	O	-1	24464946
patients	O	-1	24464946
with	O	-1	24464946
non-@@	B-Disease	D008228	24464946
Ho@@	I-Disease	-1	24464946
d@@	I-Disease	-1	24464946
g@@	I-Disease	-1	24464946
k@@	I-Disease	-1	24464946
in	I-Disease	-1	24464946
lymph@@	I-Disease	-1	24464946
oma	I-Disease	-1	24464946
treated	O	-1	24464946
with	O	-1	24464946
epi@@	B-Chemical	D015251	24464946
ru@@	I-Chemical	-1	24464946
b@@	I-Chemical	-1	24464946
icin	I-Chemical	-1	24464946
were	O	-1	24464946
studi@@	O	-1	24464946
ed.	O	-1	24464946
B@@	O	-1	24464946
lo@@	O	-1	24464946
od	O	-1	24464946
coll@@	O	-1	24464946
ection	O	-1	24464946
and	O	-1	24464946
echocardiograph@@	O	-1	24464946
y	O	-1	24464946
were	O	-1	24464946
performed	O	-1	24464946
at	O	-1	24464946
basel@@	O	-1	24464946
ine,	O	-1	24464946
1	O	-1	24464946
day	O	-1	24464946
after	O	-1	24464946
the	O	-1	24464946
thir@@	O	-1	24464946
d	O	-1	24464946
cyc@@	O	-1	24464946
le@@	O	-1	24464946
,	O	-1	24464946
and	O	-1	24464946
1	O	-1	24464946
day	O	-1	24464946
after	O	-1	24464946
comple@@	O	-1	24464946
tion	O	-1	24464946
of	O	-1	24464946
chemo@@	O	-1	24464946
therapy.	O	-1	24464946
Patients	O	-1	24464946
were	O	-1	24464946
studied	O	-1	24464946
using	O	-1	24464946
echocardiograph@@	O	-1	24464946
y	O	-1	24464946
during	O	-1	24464946
follow-@@	O	-1	24464946
up@@	O	-1	24464946
.	O	-1	24464946
G@@	O	-1	24464946
lo@@	O	-1	24464946
b@@	O	-1	24464946
al	O	-1	24464946
long@@	O	-1	24464946
it@@	O	-1	24464946
ud@@	O	-1	24464946
inal	O	-1	24464946
(@@	O	-1	24464946
G@@	O	-1	24464946
L@@	O	-1	24464946
S@@	O	-1	24464946
),	O	-1	24464946
cir@@	O	-1	24464946
cum@@	O	-1	24464946
fe@@	O	-1	24464946
ren@@	O	-1	24464946
tial	O	-1	24464946
(@@	O	-1	24464946
G@@	O	-1	24464946
C@@	O	-1	24464946
S@@	O	-1	24464946
),	O	-1	24464946
and	O	-1	24464946
radi@@	O	-1	24464946
al	O	-1	24464946
stra@@	O	-1	24464946
in	O	-1	24464946
(@@	O	-1	24464946
G@@	O	-1	24464946
R@@	O	-1	24464946
S)	O	-1	24464946
were	O	-1	24464946
calc@@	O	-1	24464946
ul@@	O	-1	24464946
ated	O	-1	24464946
using	O	-1	24464946
spec@@	O	-1	24464946
k@@	O	-1	24464946
le	O	-1	24464946
trac@@	O	-1	24464946
king	O	-1	24464946
echocardiograph@@	O	-1	24464946
y.	O	-1	24464946
L@@	O	-1	24464946
e@@	O	-1	24464946
ft	O	-1	24464946
ventricular	O	-1	24464946
e@@	O	-1	24464946
j@@	O	-1	24464946
ection	O	-1	24464946
frac@@	O	-1	24464946
tion	O	-1	24464946
was	O	-1	24464946
an@@	O	-1	24464946
al@@	O	-1	24464946
ys@@	O	-1	24464946
ed	O	-1	24464946
by	O	-1	24464946
re@@	O	-1	24464946
al@@	O	-1	24464946
-@@	O	-1	24464946
time	O	-1	24464946
3@@	O	-1	24464946
D	O	-1	24464946
echocardiograph@@	O	-1	24464946
y.	O	-1	24464946
C@@	B-Disease	D066126	24464946
ardi@@	I-Disease	-1	24464946
otoxicity	I-Disease	-1	24464946
was	O	-1	24464946
def@@	O	-1	24464946
in@@	O	-1	24464946
ed	O	-1	24464946
as	O	-1	24464946
a	O	-1	24464946
reduction	O	-1	24464946
of	O	-1	24464946
the	O	-1	24464946
L@@	O	-1	24464946
V@@	O	-1	24464946
E@@	O	-1	24464946
F	O	-1	24464946
of	O	-1	24464946
>@@	O	-1	24464946
5%	O	-1	24464946
to	O	-1	24464946
<@@	O	-1	24464946
5@@	O	-1	24464946
5%	O	-1	24464946
with	O	-1	24464946
symptoms	O	-1	24464946
of	O	-1	24464946
heart	B-Disease	D006333	24464946
failure	I-Disease	-1	24464946
or	O	-1	24464946
an	O	-1	24464946
as@@	O	-1	24464946
ym@@	O	-1	24464946
pto@@	O	-1	24464946
m@@	O	-1	24464946
atic	O	-1	24464946
reduction	O	-1	24464946
of	O	-1	24464946
the	O	-1	24464946
L@@	O	-1	24464946
V@@	O	-1	24464946
E@@	O	-1	24464946
F	O	-1	24464946
of	O	-1	24464946
>@@	O	-1	24464946
10@@	O	-1	24464946
%	O	-1	24464946
to	O	-1	24464946
<@@	O	-1	24464946
55@@	O	-1	24464946
%.	O	-1	24464946
RESULTS:	O	-1	24464946
F@@	O	-1	24464946
o@@	O	-1	24464946
ur@@	O	-1	24464946
te@@	O	-1	24464946
en	O	-1	24464946
patients	O	-1	24464946
(1@@	O	-1	24464946
8.@@	O	-1	24464946
6@@	O	-1	24464946
7@@	O	-1	24464946
%)	O	-1	24464946
developed	O	-1	24464946
cardi@@	B-Disease	D066126	24464946
otoxicity	I-Disease	-1	24464946
after	O	-1	24464946
treatment.	O	-1	24464946
G@@	O	-1	24464946
L@@	O	-1	24464946
S	O	-1	24464946
(@@	O	-1	24464946
-1@@	O	-1	24464946
8.@@	O	-1	24464946
4@@	O	-1	24464946
8	O	-1	24464946
+	O	-1	24464946
1.@@	O	-1	24464946
7@@	O	-1	24464946
2@@	O	-1	24464946
%	O	-1	24464946
vs.	O	-1	24464946
-1@@	O	-1	24464946
5.@@	O	-1	24464946
9@@	O	-1	24464946
6	O	-1	24464946
+	O	-1	24464946
1.@@	O	-1	24464946
6@@	O	-1	24464946
%),	O	-1	24464946
G@@	O	-1	24464946
C@@	O	-1	24464946
S	O	-1	24464946
(-@@	O	-1	24464946
2@@	O	-1	24464946
0.@@	O	-1	24464946
9@@	O	-1	24464946
3	O	-1	24464946
+	O	-1	24464946
2.@@	O	-1	24464946
8@@	O	-1	24464946
6%	O	-1	24464946
vs.	O	-1	24464946
-1@@	O	-1	24464946
9.@@	O	-1	24464946
20	O	-1	24464946
+	O	-1	24464946
3.@@	O	-1	24464946
2@@	O	-1	24464946
1@@	O	-1	24464946
%),	O	-1	24464946
and	O	-1	24464946
G@@	O	-1	24464946
R@@	O	-1	24464946
S	O	-1	24464946
(3@@	O	-1	24464946
9.@@	O	-1	24464946
2@@	O	-1	24464946
3	O	-1	24464946
+	O	-1	24464946
6.@@	O	-1	24464946
4@@	O	-1	24464946
4@@	O	-1	24464946
%	O	-1	24464946
vs.	O	-1	24464946
3@@	O	-1	24464946
4.@@	O	-1	24464946
9@@	O	-1	24464946
8	O	-1	24464946
+	O	-1	24464946
6.@@	O	-1	24464946
2@@	O	-1	24464946
%)	O	-1	24464946
were	O	-1	24464946
mark@@	O	-1	24464946
ed@@	O	-1	24464946
ly	O	-1	24464946
reduced	O	-1	24464946
and	O	-1	24464946
cTn@@	O	-1	24464946
T	O	-1	24464946
was	O	-1	24464946
elevated	O	-1	24464946
from	O	-1	24464946
0.00@@	O	-1	24464946
10	O	-1	24464946
+	O	-1	24464946
0.00@@	O	-1	24464946
20	O	-1	24464946
to	O	-1	24464946
0.00@@	O	-1	24464946
7@@	O	-1	24464946
3	O	-1	24464946
+	O	-1	24464946
0.00@@	O	-1	24464946
3@@	O	-1	24464946
8	O	-1	24464946
n@@	O	-1	24464946
g/@@	O	-1	24464946
m@@	O	-1	24464946
L	O	-1	24464946
(P	O	-1	24464946
all	O	-1	24464946
<	O	-1	24464946
0.0@@	O	-1	24464946
1)	O	-1	24464946
at	O	-1	24464946
the	O	-1	24464946
comple@@	O	-1	24464946
tion	O	-1	24464946
of	O	-1	24464946
chemotherapy	O	-1	24464946
compared	O	-1	24464946
with	O	-1	24464946
baseline	O	-1	24464946
valu@@	O	-1	24464946
es.	O	-1	24464946
A	O	-1	24464946
>@@	O	-1	24464946
1@@	O	-1	24464946
5.@@	O	-1	24464946
9@@	O	-1	24464946
%	O	-1	24464946
decrease	O	-1	24464946
in	O	-1	24464946
G@@	O	-1	24464946
L@@	O	-1	24464946
S	O	-1	24464946
[@@	O	-1	24464946
sensi@@	O	-1	24464946
tiv@@	O	-1	24464946
ity,	O	-1	24464946
8@@	O	-1	24464946
6@@	O	-1	24464946
%@@	O	-1	24464946
;	O	-1	24464946
spec@@	O	-1	24464946
ific@@	O	-1	24464946
ity,	O	-1	24464946
7@@	O	-1	24464946
5@@	O	-1	24464946
%@@	O	-1	24464946
;	O	-1	24464946
a@@	O	-1	24464946
re@@	O	-1	24464946
a	O	-1	24464946
under	O	-1	24464946
the	O	-1	24464946
cur@@	O	-1	24464946
ve	O	-1	24464946
(A@@	O	-1	24464946
U@@	O	-1	24464946
C@@	O	-1	24464946
)	O	-1	24464946
=	O	-1	24464946
0.@@	O	-1	24464946
8@@	O	-1	24464946
1@@	O	-1	24464946
5@@	O	-1	24464946
;	O	-1	24464946
P	O	-1	24464946
=	O	-1	24464946
0.00@@	O	-1	24464946
1@@	O	-1	24464946
]	O	-1	24464946
and	O	-1	24464946
a	O	-1	24464946
>@@	O	-1	24464946
0.00@@	O	-1	24464946
4	O	-1	24464946
n@@	O	-1	24464946
g/@@	O	-1	24464946
m@@	O	-1	24464946
L	O	-1	24464946
elev@@	O	-1	24464946
ation	O	-1	24464946
in	O	-1	24464946
cTn@@	O	-1	24464946
T	O	-1	24464946
(@@	O	-1	24464946
sensi@@	O	-1	24464946
tiv@@	O	-1	24464946
ity,	O	-1	24464946
7@@	O	-1	24464946
9@@	O	-1	24464946
%@@	O	-1	24464946
;	O	-1	24464946
spec@@	O	-1	24464946
ific@@	O	-1	24464946
ity,	O	-1	24464946
6@@	O	-1	24464946
4@@	O	-1	24464946
%@@	O	-1	24464946
;	O	-1	24464946
A@@	O	-1	24464946
U@@	O	-1	24464946
C	O	-1	24464946
=	O	-1	24464946
0.@@	O	-1	24464946
7@@	O	-1	24464946
5@@	O	-1	24464946
7@@	O	-1	24464946
;	O	-1	24464946
P	O	-1	24464946
=	O	-1	24464946
0.00@@	O	-1	24464946
5@@	O	-1	24464946
)	O	-1	24464946
from	O	-1	24464946
baseline	O	-1	24464946
to	O	-1	24464946
the	O	-1	24464946
thir@@	O	-1	24464946
d	O	-1	24464946
cyc@@	O	-1	24464946
le	O	-1	24464946
of	O	-1	24464946
chemotherapy	O	-1	24464946
predic@@	O	-1	24464946
ted	O	-1	24464946
lat@@	O	-1	24464946
er	O	-1	24464946
cardi@@	B-Disease	D066126	24464946
otoxicity	I-Disease	-1	24464946
.	O	-1	24464946
The	O	-1	24464946
decrease	O	-1	24464946
in	O	-1	24464946
G@@	O	-1	24464946
L@@	O	-1	24464946
S	O	-1	24464946
remained	O	-1	24464946
the	O	-1	24464946
only	O	-1	24464946
in@@	O	-1	24464946
dependent	O	-1	24464946
predic@@	O	-1	24464946
t@@	O	-1	24464946
or	O	-1	24464946
of	O	-1	24464946
cardi@@	B-Disease	D066126	24464946
otoxicity	I-Disease	-1	24464946
(P	O	-1	24464946
=	O	-1	24464946
0.00@@	O	-1	24464946
0@@	O	-1	24464946
).	O	-1	24464946
CONCLUSIONS:	O	-1	24464946
G@@	O	-1	24464946
L@@	O	-1	24464946
S	O	-1	24464946
combined	O	-1	24464946
with	O	-1	24464946
cTn@@	O	-1	24464946
T	O	-1	24464946
may	O	-1	24464946
prov@@	O	-1	24464946
ide	O	-1	24464946
a	O	-1	24464946
re@@	O	-1	24464946
li@@	O	-1	24464946
able	O	-1	24464946
and	O	-1	24464946
non-@@	O	-1	24464946
inv@@	O	-1	24464946
a@@	O	-1	24464946
sive	O	-1	24464946
meth@@	O	-1	24464946
od	O	-1	24464946
to	O	-1	24464946
predic@@	O	-1	24464946
t	O	-1	24464946
cardiac	B-Disease	D006331	24464946
dysfunction	I-Disease	-1	24464946
in	O	-1	24464946
patients	O	-1	24464946
receiving	O	-1	24464946
an@@	B-Chemical	D018943	24464946
th@@	I-Chemical	-1	24464946
rac@@	I-Chemical	-1	24464946
y@@	I-Chemical	-1	24464946
cl@@	I-Chemical	-1	24464946
ine	I-Chemical	-1	24464946
-@@	O	-1	24464946
bas@@	O	-1	24464946
ed	O	-1	24464946
chemo@@	O	-1	24464946
therapy.	O	-1	24464946

Pre@@	O	-1	24535067
ven@@	O	-1	24535067
tion	O	-1	24535067
of	O	-1	24535067
e@@	B-Chemical	D005045	24535067
to@@	I-Chemical	-1	24535067
mid@@	I-Chemical	-1	24535067
ate	I-Chemical	-1	24535067
-induced	O	-1	24535067
my@@	B-Disease	D009207	24535067
oc@@	I-Disease	-1	24535067
lon@@	I-Disease	-1	24535067
us	I-Disease	-1	24535067
:	O	-1	24535067
which	O	-1	24535067
is	O	-1	24535067
su@@	O	-1	24535067
peri@@	O	-1	24535067
or@@	O	-1	24535067
:	O	-1	24535067
F@@	B-Chemical	D005283	24535067
entan@@	I-Chemical	-1	24535067
yl	I-Chemical	-1	24535067
,	O	-1	24535067
mid@@	B-Chemical	D008874	24535067
azol@@	I-Chemical	-1	24535067
am	I-Chemical	-1	24535067
,	O	-1	24535067
or	O	-1	24535067
a	O	-1	24535067
combin@@	O	-1	24535067
ation@@	O	-1	24535067
?	O	-1	24535067
A	O	-1	24535067
R@@	O	-1	24535067
et@@	O	-1	24535067
ro@@	O	-1	24535067
sp@@	O	-1	24535067
ective	O	-1	24535067
compar@@	O	-1	24535067
ative	O	-1	24535067
study.	O	-1	24535067
BACKGROUND:	O	-1	24535067
In	O	-1	24535067
this	O	-1	24535067
ret@@	O	-1	24535067
ro@@	O	-1	24535067
sp@@	O	-1	24535067
ective	O	-1	24535067
compar@@	O	-1	24535067
ative	O	-1	24535067
study,	O	-1	24535067
we	O	-1	24535067
a@@	O	-1	24535067
im@@	O	-1	24535067
ed	O	-1	24535067
to	O	-1	24535067
compar@@	O	-1	24535067
e	O	-1	24535067
the	O	-1	24535067
eff@@	O	-1	24535067
ec@@	O	-1	24535067
tiv@@	O	-1	24535067
en@@	O	-1	24535067
ess	O	-1	24535067
of	O	-1	24535067
f@@	B-Chemical	D005283	24535067
entan@@	I-Chemical	-1	24535067
yl	I-Chemical	-1	24535067
,	O	-1	24535067
mid@@	B-Chemical	D008874	24535067
azol@@	I-Chemical	-1	24535067
am	I-Chemical	-1	24535067
,	O	-1	24535067
and	O	-1	24535067
a	O	-1	24535067
combination	O	-1	24535067
of	O	-1	24535067
f@@	B-Chemical	D005283	24535067
entan@@	I-Chemical	-1	24535067
yl	I-Chemical	-1	24535067
and	O	-1	24535067
mid@@	B-Chemical	D008874	24535067
azol@@	I-Chemical	-1	24535067
am	I-Chemical	-1	24535067
to	O	-1	24535067
prev@@	O	-1	24535067
ent	O	-1	24535067
e@@	B-Chemical	D005045	24535067
to@@	I-Chemical	-1	24535067
mid@@	I-Chemical	-1	24535067
ate	I-Chemical	-1	24535067
-induced	O	-1	24535067
my@@	B-Disease	D009207	24535067
oc@@	I-Disease	-1	24535067
lon@@	I-Disease	-1	24535067
us	I-Disease	-1	24535067
.	O	-1	24535067
M@@	O	-1	24535067
AT@@	O	-1	24535067
E@@	O	-1	24535067
R@@	O	-1	24535067
I@@	O	-1	24535067
A@@	O	-1	24535067
L	O	-1	24535067
AN@@	O	-1	24535067
D	O	-1	24535067
METHODS:	O	-1	24535067
This	O	-1	24535067
study	O	-1	24535067
was	O	-1	24535067
performed	O	-1	24535067
bas@@	O	-1	24535067
ed	O	-1	24535067
on	O	-1	24535067
anesthe@@	O	-1	24535067
sia	O	-1	24535067
recor@@	O	-1	24535067
d@@	O	-1	24535067
s.	O	-1	24535067
D@@	O	-1	24535067
ep@@	O	-1	24535067
en@@	O	-1	24535067
ding	O	-1	24535067
on	O	-1	24535067
the	O	-1	24535067
drugs	O	-1	24535067
that	O	-1	24535067
wo@@	O	-1	24535067
uld	O	-1	24535067
be	O	-1	24535067
given	O	-1	24535067
before	O	-1	24535067
the	O	-1	24535067
induction	O	-1	24535067
of	O	-1	24535067
anesthe@@	O	-1	24535067
sia	O	-1	24535067
with	O	-1	24535067
e@@	B-Chemical	D005045	24535067
to@@	I-Chemical	-1	24535067
mid@@	I-Chemical	-1	24535067
ate	I-Chemical	-1	24535067
,	O	-1	24535067
the	O	-1	24535067
patients	O	-1	24535067
were	O	-1	24535067
se@@	O	-1	24535067
par@@	O	-1	24535067
ated	O	-1	24535067
into	O	-1	24535067
4	O	-1	24535067
group@@	O	-1	24535067
s:	O	-1	24535067
no	O	-1	24535067
pretreatment	O	-1	24535067
(@@	O	-1	24535067
Group	O	-1	24535067
N@@	O	-1	24535067
P@@	O	-1	24535067
),	O	-1	24535067
f@@	B-Chemical	D005283	24535067
entan@@	I-Chemical	-1	24535067
yl	I-Chemical	-1	24535067
1	O	-1	24535067
u@@	O	-1	24535067
g@@	O	-1	24535067
.@@	O	-1	24535067
kg@@	O	-1	24535067
-1	O	-1	24535067
(@@	O	-1	24535067
Group	O	-1	24535067
F@@	O	-1	24535067
),	O	-1	24535067
mid@@	B-Chemical	D008874	24535067
azol@@	I-Chemical	-1	24535067
am	I-Chemical	-1	24535067
0.0@@	O	-1	24535067
3	O	-1	24535067
mg@@	O	-1	24535067
.@@	O	-1	24535067
kg@@	O	-1	24535067
-1	O	-1	24535067
(@@	O	-1	24535067
Group	O	-1	24535067
M@@	O	-1	24535067
),	O	-1	24535067
and	O	-1	24535067
mid@@	B-Chemical	D008874	24535067
azol@@	I-Chemical	-1	24535067
am	I-Chemical	-1	24535067
0.0@@	O	-1	24535067
15	O	-1	24535067
mg@@	O	-1	24535067
.@@	O	-1	24535067
kg@@	O	-1	24535067
-1	O	-1	24535067
+	O	-1	24535067
f@@	B-Chemical	D005283	24535067
entan@@	I-Chemical	-1	24535067
yl	I-Chemical	-1	24535067
0.@@	O	-1	24535067
5	O	-1	24535067
u@@	O	-1	24535067
g@@	O	-1	24535067
.@@	O	-1	24535067
kg@@	O	-1	24535067
-1	O	-1	24535067
(@@	O	-1	24535067
Group	O	-1	24535067
F@@	O	-1	24535067
M@@	O	-1	24535067
).	O	-1	24535067
Patients	O	-1	24535067
who	O	-1	24535067
received	O	-1	24535067
the	O	-1	24535067
same	O	-1	24535067
anesthe@@	O	-1	24535067
tic	O	-1	24535067
proce@@	O	-1	24535067
d@@	O	-1	24535067
ure	O	-1	24535067
were	O	-1	24535067
sel@@	O	-1	24535067
ect@@	O	-1	24535067
ed@@	O	-1	24535067
:	O	-1	24535067
2	O	-1	24535067
minutes	O	-1	24535067
after	O	-1	24535067
intravenous	O	-1	24535067
injec@@	O	-1	24535067
tions	O	-1	24535067
of	O	-1	24535067
the	O	-1	24535067
pretreatment	O	-1	24535067
drug@@	O	-1	24535067
s,	O	-1	24535067
anesthe@@	O	-1	24535067
sia	O	-1	24535067
is	O	-1	24535067
induced	O	-1	24535067
with	O	-1	24535067
0.@@	O	-1	24535067
3	O	-1	24535067
mg@@	O	-1	24535067
.@@	O	-1	24535067
kg@@	O	-1	24535067
-1	O	-1	24535067
e@@	B-Chemical	D005045	24535067
to@@	I-Chemical	-1	24535067
mid@@	I-Chemical	-1	24535067
ate	I-Chemical	-1	24535067
injected	O	-1	24535067
intra@@	O	-1	24535067
ven@@	O	-1	24535067
ously	O	-1	24535067
over	O	-1	24535067
a	O	-1	24535067
period	O	-1	24535067
of	O	-1	24535067
20@@	O	-1	24535067
-@@	O	-1	24535067
30	O	-1	24535067
second@@	O	-1	24535067
s.	O	-1	24535067
M@@	B-Disease	D009069	24535067
y@@	I-Disease	-1	24535067
oc@@	I-Disease	-1	24535067
lon@@	I-Disease	-1	24535067
ic	I-Disease	-1	24535067
mo@@	I-Disease	-1	24535067
ve@@	I-Disease	-1	24535067
ments	I-Disease	-1	24535067
are	O	-1	24535067
evalu@@	O	-1	24535067
at@@	O	-1	24535067
ed,	O	-1	24535067
which	O	-1	24535067
were	O	-1	24535067
observed	O	-1	24535067
and	O	-1	24535067
gra@@	O	-1	24535067
ded	O	-1	24535067
ac@@	O	-1	24535067
cor@@	O	-1	24535067
ding	O	-1	24535067
to	O	-1	24535067
clinical	O	-1	24535067
severity	O	-1	24535067
during	O	-1	24535067
the	O	-1	24535067
2	O	-1	24535067
minutes	O	-1	24535067
after	O	-1	24535067
e@@	B-Chemical	D005045	24535067
to@@	I-Chemical	-1	24535067
mid@@	I-Chemical	-1	24535067
ate	I-Chemical	-1	24535067
injec@@	O	-1	24535067
tion.	O	-1	24535067
The	O	-1	24535067
severity	O	-1	24535067
of	O	-1	24535067
pain	B-Disease	D010146	24535067
due	O	-1	24535067
to	O	-1	24535067
e@@	B-Chemical	D005045	24535067
to@@	I-Chemical	-1	24535067
mid@@	I-Chemical	-1	24535067
ate	I-Chemical	-1	24535067
injec@@	O	-1	24535067
tion,	O	-1	24535067
mean	O	-1	24535067
arterial	O	-1	24535067
pressu@@	O	-1	24535067
re,	O	-1	24535067
heart	O	-1	24535067
rat@@	O	-1	24535067
e,	O	-1	24535067
and	O	-1	24535067
adverse	O	-1	24535067
effects	O	-1	24535067
were	O	-1	24535067
also	O	-1	24535067
evalu@@	O	-1	24535067
ated.	O	-1	24535067
RESULTS:	O	-1	24535067
S@@	O	-1	24535067
t@@	O	-1	24535067
ud@@	O	-1	24535067
y	O	-1	24535067
results	O	-1	24535067
showed	O	-1	24535067
that	O	-1	24535067
my@@	B-Disease	D009207	24535067
oc@@	I-Disease	-1	24535067
lon@@	I-Disease	-1	24535067
us	I-Disease	-1	24535067
incidence	O	-1	24535067
was	O	-1	24535067
8@@	O	-1	24535067
5@@	O	-1	24535067
%,	O	-1	24535067
4@@	O	-1	24535067
0@@	O	-1	24535067
%,	O	-1	24535067
7@@	O	-1	24535067
0@@	O	-1	24535067
%,	O	-1	24535067
and	O	-1	24535067
2@@	O	-1	24535067
5%	O	-1	24535067
in	O	-1	24535067
Group	O	-1	24535067
N@@	O	-1	24535067
P@@	O	-1	24535067
,	O	-1	24535067
Group	O	-1	24535067
F@@	O	-1	24535067
,	O	-1	24535067
Group	O	-1	24535067
M@@	O	-1	24535067
,	O	-1	24535067
and	O	-1	24535067
Group	O	-1	24535067
F@@	O	-1	24535067
M@@	O	-1	24535067
,	O	-1	24535067
respectivel@@	O	-1	24535067
y,	O	-1	24535067
and	O	-1	24535067
were	O	-1	24535067
significantly	O	-1	24535067
lower	O	-1	24535067
in	O	-1	24535067
Group	O	-1	24535067
F	O	-1	24535067
and	O	-1	24535067
Group	O	-1	24535067
F@@	O	-1	24535067
M@@	O	-1	24535067
.	O	-1	24535067
CONCLUSIONS:	O	-1	24535067
We	O	-1	24535067
concl@@	O	-1	24535067
ude	O	-1	24535067
that	O	-1	24535067
pretreatment	O	-1	24535067
with	O	-1	24535067
f@@	B-Chemical	D005283	24535067
entan@@	I-Chemical	-1	24535067
yl	I-Chemical	-1	24535067
or	O	-1	24535067
combination	O	-1	24535067
of	O	-1	24535067
f@@	B-Chemical	D005283	24535067
entan@@	I-Chemical	-1	24535067
yl	I-Chemical	-1	24535067
and	O	-1	24535067
mid@@	B-Chemical	D008874	24535067
azol@@	I-Chemical	-1	24535067
am	I-Chemical	-1	24535067
was	O	-1	24535067
effective	O	-1	24535067
in	O	-1	24535067
prevent@@	O	-1	24535067
ing	O	-1	24535067
e@@	B-Chemical	D005045	24535067
to@@	I-Chemical	-1	24535067
mid@@	I-Chemical	-1	24535067
ate	I-Chemical	-1	24535067
-induced	O	-1	24535067
my@@	B-Disease	D009207	24535067
oc@@	I-Disease	-1	24535067
lon@@	I-Disease	-1	24535067
us	I-Disease	-1	24535067
.	O	-1	24535067

Ch@@	B-Disease	D002779	24554916
ol@@	I-Disease	-1	24554916
est@@	I-Disease	-1	24554916
atic	I-Disease	-1	24554916
present@@	O	-1	24554916
ation	O	-1	24554916
of	O	-1	24554916
y@@	O	-1	24554916
el@@	O	-1	24554916
low	O	-1	24554916
phosph@@	B-Chemical	D010758	24554916
or@@	I-Chemical	-1	24554916
us	I-Chemical	-1	24554916
po@@	B-Disease	D011041	24554916
is@@	I-Disease	-1	24554916
on@@	I-Disease	-1	24554916
ing	I-Disease	-1	24554916
.	O	-1	24554916
Y@@	O	-1	24554916
el@@	O	-1	24554916
low	O	-1	24554916
phosph@@	B-Chemical	D010758	24554916
or@@	I-Chemical	-1	24554916
us	I-Chemical	-1	24554916
,	O	-1	24554916
a	O	-1	24554916
comp@@	O	-1	24554916
on@@	O	-1	24554916
ent	O	-1	24554916
of	O	-1	24554916
cer@@	O	-1	24554916
t@@	O	-1	24554916
ain	O	-1	24554916
p@@	O	-1	24554916
es@@	O	-1	24554916
tic@@	O	-1	24554916
ide	O	-1	24554916
pa@@	O	-1	24554916
st@@	O	-1	24554916
es	O	-1	24554916
and	O	-1	24554916
fi@@	O	-1	24554916
re@@	O	-1	24554916
wor@@	O	-1	24554916
k@@	O	-1	24554916
s,	O	-1	24554916
is	O	-1	24554916
well	O	-1	24554916
known	O	-1	24554916
to	O	-1	24554916
cause	O	-1	24554916
hepat@@	B-Disease	D056486	24554916
otoxicity	I-Disease	-1	24554916
.	O	-1	24554916
P@@	B-Disease	D011041	24554916
o@@	I-Disease	-1	24554916
is@@	I-Disease	-1	24554916
on@@	I-Disease	-1	24554916
ing	I-Disease	-1	24554916
with	O	-1	24554916
y@@	O	-1	24554916
el@@	O	-1	24554916
low	O	-1	24554916
phosph@@	B-Chemical	D010758	24554916
or@@	I-Chemical	-1	24554916
us	I-Chemical	-1	24554916
cl@@	O	-1	24554916
assi@@	O	-1	24554916
c@@	O	-1	24554916
ally	O	-1	24554916
man@@	O	-1	24554916
if@@	O	-1	24554916
est@@	O	-1	24554916
s	O	-1	24554916
with	O	-1	24554916
acute	B-Disease	D006505	24554916
hepatitis	I-Disease	-1	24554916
lead@@	O	-1	24554916
ing	O	-1	24554916
to	O	-1	24554916
acute	B-Disease	D017114	24554916
liver	I-Disease	-1	24554916
failure	I-Disease	-1	24554916
which	O	-1	24554916
may	O	-1	24554916
need	O	-1	24554916
liver	O	-1	24554916
transplant@@	O	-1	24554916
ation.	O	-1	24554916
We	O	-1	24554916
present	O	-1	24554916
a	O	-1	24554916
case	O	-1	24554916
of	O	-1	24554916
y@@	O	-1	24554916
el@@	O	-1	24554916
low	O	-1	24554916
phosph@@	B-Chemical	D010758	24554916
or@@	I-Chemical	-1	24554916
us	I-Chemical	-1	24554916
po@@	B-Disease	D011041	24554916
is@@	I-Disease	-1	24554916
on@@	I-Disease	-1	24554916
ing	I-Disease	-1	24554916
in	O	-1	24554916
which	O	-1	24554916
a	O	-1	24554916
patient	O	-1	24554916
presented	O	-1	24554916
with	O	-1	24554916
f@@	O	-1	24554916
lor@@	O	-1	24554916
id	O	-1	24554916
clinical	O	-1	24554916
feat@@	O	-1	24554916
ures	O	-1	24554916
of	O	-1	24554916
cholest@@	B-Disease	D002779	24554916
asis	I-Disease	-1	24554916
high@@	O	-1	24554916
li@@	O	-1	24554916
gh@@	O	-1	24554916
ting	O	-1	24554916
the	O	-1	24554916
fac@@	O	-1	24554916
t	O	-1	24554916
that	O	-1	24554916
cholest@@	B-Disease	D002779	24554916
asis	I-Disease	-1	24554916
can	O	-1	24554916
ra@@	O	-1	24554916
re@@	O	-1	24554916
ly	O	-1	24554916
be	O	-1	24554916
a	O	-1	24554916
present@@	O	-1	24554916
ing	O	-1	24554916
feat@@	O	-1	24554916
ure	O	-1	24554916
of	O	-1	24554916
y@@	O	-1	24554916
el@@	O	-1	24554916
low	O	-1	24554916
phosph@@	B-Chemical	D010758	24554916
or@@	I-Chemical	-1	24554916
us	I-Chemical	-1	24554916
hepat@@	B-Disease	D056486	24554916
otoxicity	I-Disease	-1	24554916
.	O	-1	24554916

V@@	B-Disease	D019462	24571687
as@@	I-Disease	-1	24571687
o@@	I-Disease	-1	24571687
v@@	I-Disease	-1	24571687
ag@@	I-Disease	-1	24571687
al	I-Disease	-1	24571687
syn@@	I-Disease	-1	24571687
co@@	I-Disease	-1	24571687
p@@	I-Disease	-1	24571687
e	I-Disease	-1	24571687
and	O	-1	24571687
severe	O	-1	24571687
brady@@	B-Disease	D001919	24571687
cardia	I-Disease	-1	24571687
following	O	-1	24571687
int@@	O	-1	24571687
ran@@	O	-1	24571687
as@@	O	-1	24571687
al	O	-1	24571687
de@@	B-Chemical	D020927	24571687
x@@	I-Chemical	-1	24571687
me@@	I-Chemical	-1	24571687
de@@	I-Chemical	-1	24571687
to@@	I-Chemical	-1	24571687
m@@	I-Chemical	-1	24571687
idine	I-Chemical	-1	24571687
for	O	-1	24571687
pe@@	O	-1	24571687
di@@	O	-1	24571687
atric	O	-1	24571687
proce@@	O	-1	24571687
dur@@	O	-1	24571687
al	O	-1	24571687
sed@@	O	-1	24571687
ation.	O	-1	24571687
We	O	-1	24571687
report	O	-1	24571687
syn@@	B-Disease	D013575	24571687
co@@	I-Disease	-1	24571687
p@@	I-Disease	-1	24571687
e	I-Disease	-1	24571687
and	O	-1	24571687
brady@@	B-Disease	D001919	24571687
cardia	I-Disease	-1	24571687
in	O	-1	24571687
an	O	-1	24571687
1@@	O	-1	24571687
1-@@	O	-1	24571687
year-old	O	-1	24571687
gi@@	O	-1	24571687
r@@	O	-1	24571687
l	O	-1	24571687
following	O	-1	24571687
administration	O	-1	24571687
of	O	-1	24571687
int@@	O	-1	24571687
ran@@	O	-1	24571687
as@@	O	-1	24571687
al	O	-1	24571687
de@@	B-Chemical	D020927	24571687
x@@	I-Chemical	-1	24571687
me@@	I-Chemical	-1	24571687
de@@	I-Chemical	-1	24571687
to@@	I-Chemical	-1	24571687
m@@	I-Chemical	-1	24571687
idine	I-Chemical	-1	24571687
for	O	-1	24571687
sed@@	O	-1	24571687
ation	O	-1	24571687
for	O	-1	24571687
a	O	-1	24571687
v@@	O	-1	24571687
oid@@	O	-1	24571687
ing	O	-1	24571687
cy@@	O	-1	24571687
st@@	O	-1	24571687
ou@@	O	-1	24571687
re@@	O	-1	24571687
th@@	O	-1	24571687
ro@@	O	-1	24571687
gram@@	O	-1	24571687
.	O	-1	24571687
F@@	O	-1	24571687
ol@@	O	-1	24571687
low@@	O	-1	24571687
ing	O	-1	24571687
suc@@	O	-1	24571687
cess@@	O	-1	24571687
ful	O	-1	24571687
comple@@	O	-1	24571687
tion	O	-1	24571687
of	O	-1	24571687
V@@	O	-1	24571687
C@@	O	-1	24571687
U@@	O	-1	24571687
G	O	-1	24571687
and	O	-1	24571687
a	O	-1	24571687
6@@	O	-1	24571687
0-@@	O	-1	24571687
min	O	-1	24571687
recovery	O	-1	24571687
perio@@	O	-1	24571687
d,	O	-1	24571687
the	O	-1	24571687
patient@@	O	-1	24571687
's	O	-1	24571687
level	O	-1	24571687
of	O	-1	24571687
con@@	O	-1	24571687
s@@	O	-1	24571687
ci@@	O	-1	24571687
ous@@	O	-1	24571687
ness	O	-1	24571687
and	O	-1	24571687
vit@@	O	-1	24571687
al	O	-1	24571687
signs	O	-1	24571687
retur@@	O	-1	24571687
n@@	O	-1	24571687
ed	O	-1	24571687
to	O	-1	24571687
pre@@	O	-1	24571687
sed@@	O	-1	24571687
ation	O	-1	24571687
level@@	O	-1	24571687
s.	O	-1	24571687
U@@	O	-1	24571687
p@@	O	-1	24571687
on	O	-1	24571687
le@@	O	-1	24571687
a@@	O	-1	24571687
ving	O	-1	24571687
the	O	-1	24571687
sed@@	O	-1	24571687
ation	O	-1	24571687
a@@	O	-1	24571687
re@@	O	-1	24571687
a,	O	-1	24571687
the	O	-1	24571687
patient	O	-1	24571687
coll@@	O	-1	24571687
ap@@	O	-1	24571687
se@@	O	-1	24571687
d,	O	-1	24571687
with	O	-1	24571687
no	O	-1	24571687
appa@@	O	-1	24571687
rent	O	-1	24571687
inc@@	O	-1	24571687
it@@	O	-1	24571687
ing	O	-1	24571687
event@@	O	-1	24571687
.	O	-1	24571687
The	O	-1	24571687
patient	O	-1	24571687
qu@@	O	-1	24571687
ic@@	O	-1	24571687
k@@	O	-1	24571687
ly	O	-1	24571687
reg@@	O	-1	24571687
ained	O	-1	24571687
con@@	O	-1	24571687
s@@	O	-1	24571687
ci@@	O	-1	24571687
ous@@	O	-1	24571687
ness	O	-1	24571687
and	O	-1	24571687
no	O	-1	24571687
injury	O	-1	24571687
occur@@	O	-1	24571687
red.	O	-1	24571687
The	O	-1	24571687
prim@@	O	-1	24571687
ary	O	-1	24571687
abnormal@@	O	-1	24571687
ity	O	-1	24571687
found	O	-1	24571687
was	O	-1	24571687
per@@	O	-1	24571687
sist@@	O	-1	24571687
ent	O	-1	24571687
brady@@	B-Disease	D001919	24571687
cardia	I-Disease	-1	24571687
,	O	-1	24571687
and	O	-1	24571687
sh@@	O	-1	24571687
e	O	-1	24571687
was	O	-1	24571687
ad@@	O	-1	24571687
mit@@	O	-1	24571687
ted	O	-1	24571687
to	O	-1	24571687
the	O	-1	24571687
hospit@@	O	-1	24571687
al	O	-1	24571687
for	O	-1	24571687
te@@	O	-1	24571687
le@@	O	-1	24571687
me@@	O	-1	24571687
tri@@	O	-1	24571687
c	O	-1	24571687
observ@@	O	-1	24571687
ation.	O	-1	24571687
The	O	-1	24571687
brady@@	B-Disease	D001919	24571687
cardia	I-Disease	-1	24571687
l@@	O	-1	24571687
ast@@	O	-1	24571687
ed	O	-1	24571687
~@@	O	-1	24571687
2	O	-1	24571687
h@@	O	-1	24571687
,	O	-1	24571687
and	O	-1	24571687
further	O	-1	24571687
cardiac	O	-1	24571687
wor@@	O	-1	24571687
k@@	O	-1	24571687
up	O	-1	24571687
revealed	O	-1	24571687
no	O	-1	24571687
underlying	O	-1	24571687
abnormal@@	O	-1	24571687
ity.	O	-1	24571687
U@@	O	-1	24571687
n@@	O	-1	24571687
anti@@	O	-1	24571687
ci@@	O	-1	24571687
p@@	O	-1	24571687
ated	O	-1	24571687
and	O	-1	24571687
previously	O	-1	24571687
un@@	O	-1	24571687
reported	O	-1	24571687
outcom@@	O	-1	24571687
es	O	-1	24571687
may	O	-1	24571687
be	O	-1	24571687
wit@@	O	-1	24571687
n@@	O	-1	24571687
ess@@	O	-1	24571687
ed	O	-1	24571687
as	O	-1	24571687
we	O	-1	24571687
ex@@	O	-1	24571687
p@@	O	-1	24571687
and	O	-1	24571687
the	O	-1	24571687
use	O	-1	24571687
of	O	-1	24571687
cer@@	O	-1	24571687
t@@	O	-1	24571687
ain	O	-1	24571687
sed@@	O	-1	24571687
ati@@	O	-1	24571687
v@@	O	-1	24571687
es	O	-1	24571687
to	O	-1	24571687
al@@	O	-1	24571687
tern@@	O	-1	24571687
ative	O	-1	24571687
ro@@	O	-1	24571687
ut@@	O	-1	24571687
es	O	-1	24571687
of	O	-1	24571687
administr@@	O	-1	24571687
ation.	O	-1	24571687

P@@	O	-1	24582773
ar@@	O	-1	24582773
ad@@	O	-1	24582773
ox@@	O	-1	24582773
ical	O	-1	24582773
severe	O	-1	24582773
ag@@	B-Disease	D011595	24582773
it@@	I-Disease	-1	24582773
ation	I-Disease	-1	24582773
induced	O	-1	24582773
by	O	-1	24582773
ad@@	O	-1	24582773
d-@@	O	-1	24582773
on	O	-1	24582773
high-@@	O	-1	24582773
doses	O	-1	24582773
qu@@	B-Chemical	C069541	24582773
e@@	I-Chemical	-1	24582773
ti@@	I-Chemical	-1	24582773
apine	I-Chemical	-1	24582773
in	O	-1	24582773
sch@@	B-Disease	D011618	24582773
iz@@	I-Disease	-1	24582773
o@@	I-Disease	-1	24582773
-@@	I-Disease	-1	24582773
aff@@	I-Disease	-1	24582773
ective	I-Disease	-1	24582773
disor@@	I-Disease	-1	24582773
der	I-Disease	-1	24582773
.	O	-1	24582773
We	O	-1	24582773
report	O	-1	24582773
the	O	-1	24582773
case	O	-1	24582773
of	O	-1	24582773
a	O	-1	24582773
3@@	O	-1	24582773
5-@@	O	-1	24582773
year-old	O	-1	24582773
patient	O	-1	24582773
suff@@	O	-1	24582773
ering	O	-1	24582773
from	O	-1	24582773
sch@@	B-Disease	D011618	24582773
iz@@	I-Disease	-1	24582773
o@@	I-Disease	-1	24582773
-@@	I-Disease	-1	24582773
aff@@	I-Disease	-1	24582773
ective	I-Disease	-1	24582773
disor@@	I-Disease	-1	24582773
der	I-Disease	-1	24582773
s@@	O	-1	24582773
inc@@	O	-1	24582773
e	O	-1	24582773
the	O	-1	24582773
age	O	-1	24582773
of	O	-1	24582773
1@@	O	-1	24582773
9	O	-1	24582773
year@@	O	-1	24582773
s,	O	-1	24582773
treated	O	-1	24582773
by	O	-1	24582773
a	O	-1	24582773
combination	O	-1	24582773
of	O	-1	24582773
fir@@	O	-1	24582773
st@@	O	-1	24582773
-@@	O	-1	24582773
generation	O	-1	24582773
anti@@	O	-1	24582773
psycho@@	O	-1	24582773
tic@@	O	-1	24582773
s,	O	-1	24582773
z@@	B-Chemical	D003006	24582773
uc@@	I-Chemical	-1	24582773
lop@@	I-Chemical	-1	24582773
en@@	I-Chemical	-1	24582773
thi@@	I-Chemical	-1	24582773
x@@	I-Chemical	-1	24582773
ol	I-Chemical	-1	24582773
(@@	O	-1	24582773
100	O	-1	24582773
mg/@@	O	-1	24582773
day@@	O	-1	24582773
)	O	-1	24582773
and	O	-1	24582773
lithium	B-Chemical	D008094	24582773
(1@@	O	-1	24582773
2@@	O	-1	24582773
00	O	-1	24582773
mg/@@	O	-1	24582773
day@@	O	-1	24582773
)	O	-1	24582773
(@@	O	-1	24582773
serum	O	-1	24582773
lithium	B-Chemical	D008094	24582773
=@@	O	-1	24582773
0.@@	O	-1	24582773
8@@	O	-1	24582773
5	O	-1	24582773
m@@	O	-1	24582773
E@@	O	-1	24582773
q@@	O	-1	24582773
/@@	O	-1	24582773
l@@	O	-1	24582773
).	O	-1	24582773
This	O	-1	24582773
patient	O	-1	24582773
had	O	-1	24582773
no	O	-1	24582773
associated	O	-1	24582773
per@@	B-Disease	D010554	24582773
son@@	I-Disease	-1	24582773
ality	I-Disease	-1	24582773
disor@@	I-Disease	-1	24582773
der	I-Disease	-1	24582773
(@@	O	-1	24582773
partic@@	O	-1	24582773
ul@@	O	-1	24582773
arly	O	-1	24582773
no	O	-1	24582773
anti@@	B-Disease	D000987	24582773
s@@	I-Disease	-1	24582773
oci@@	I-Disease	-1	24582773
al	I-Disease	-1	24582773
disor@@	I-Disease	-1	24582773
der	I-Disease	-1	24582773
)	O	-1	24582773
and	O	-1	24582773
no	O	-1	24582773
subst@@	B-Disease	D019966	24582773
ance	I-Disease	-1	24582773
ab@@	I-Disease	-1	24582773
use	I-Disease	-1	24582773
disor@@	I-Disease	-1	24582773
der	I-Disease	-1	24582773
.	O	-1	24582773
W@@	O	-1	24582773
i@@	O	-1	24582773
th@@	O	-1	24582773
in	O	-1	24582773
the	O	-1	24582773
4@@	O	-1	24582773
8	O	-1	24582773
h	O	-1	24582773
following	O	-1	24582773
the	O	-1	24582773
gra@@	O	-1	24582773
du@@	O	-1	24582773
al	O	-1	24582773
int@@	O	-1	24582773
ro@@	O	-1	24582773
duction	O	-1	24582773
of	O	-1	24582773
qu@@	B-Chemical	C069541	24582773
e@@	I-Chemical	-1	24582773
ti@@	I-Chemical	-1	24582773
apine	I-Chemical	-1	24582773
(@@	O	-1	24582773
up	O	-1	24582773
to	O	-1	24582773
6@@	O	-1	24582773
00	O	-1	24582773
mg/@@	O	-1	24582773
day@@	O	-1	24582773
),	O	-1	24582773
the	O	-1	24582773
patient	O	-1	24582773
presented	O	-1	24582773
severe	O	-1	24582773
ag@@	B-Disease	D011595	24582773
it@@	I-Disease	-1	24582773
ation	I-Disease	-1	24582773
without	O	-1	24582773
an	O	-1	24582773
en@@	O	-1	24582773
vi@@	O	-1	24582773
ron@@	O	-1	24582773
mental	O	-1	24582773
expl@@	O	-1	24582773
an@@	O	-1	24582773
ation,	O	-1	24582773
contrast@@	O	-1	24582773
ing	O	-1	24582773
with	O	-1	24582773
the	O	-1	24582773
absence	O	-1	24582773
of	O	-1	24582773
a	O	-1	24582773
hist@@	O	-1	24582773
ory	O	-1	24582773
of	O	-1	24582773
ag@@	B-Disease	D010554	24582773
gres@@	I-Disease	-1	24582773
si@@	I-Disease	-1	24582773
ven@@	I-Disease	-1	24582773
ess	I-Disease	-1	24582773
or	O	-1	24582773
per@@	B-Disease	D010554	24582773
son@@	I-Disease	-1	24582773
ality	I-Disease	-1	24582773
disor@@	I-Disease	-1	24582773
der	I-Disease	-1	24582773
.	O	-1	24582773
The	O	-1	24582773
diagno@@	O	-1	24582773
ses	O	-1	24582773
of	O	-1	24582773
man@@	B-Disease	D001714	24582773
ic	I-Disease	-1	24582773
shi@@	O	-1	24582773
ft	O	-1	24582773
and	O	-1	24582773
ak@@	B-Disease	D017109	24582773
athi@@	I-Disease	-1	24582773
sia	I-Disease	-1	24582773
were	O	-1	24582773
dis@@	O	-1	24582773
mis@@	O	-1	24582773
sed.	O	-1	24582773
The	O	-1	24582773
withdrawal	O	-1	24582773
and	O	-1	24582773
the	O	-1	24582773
gra@@	O	-1	24582773
du@@	O	-1	24582773
al	O	-1	24582773
re@@	O	-1	24582773
int@@	O	-1	24582773
ro@@	O	-1	24582773
duction	O	-1	24582773
of	O	-1	24582773
qu@@	B-Chemical	C069541	24582773
e@@	I-Chemical	-1	24582773
ti@@	I-Chemical	-1	24582773
apine	I-Chemical	-1	24582773
2	O	-1	24582773
weeks	O	-1	24582773
lat@@	O	-1	24582773
er,	O	-1	24582773
which	O	-1	24582773
l@@	O	-1	24582773
ed	O	-1	24582773
to	O	-1	24582773
an@@	O	-1	24582773
other	O	-1	24582773
severe	O	-1	24582773
ag@@	B-Disease	D011595	24582773
it@@	I-Disease	-1	24582773
ation	I-Disease	-1	24582773
,	O	-1	24582773
en@@	O	-1	24582773
abl@@	O	-1	24582773
ed	O	-1	24582773
us	O	-1	24582773
to	O	-1	24582773
at@@	O	-1	24582773
tri@@	O	-1	24582773
b@@	O	-1	24582773
ute	O	-1	24582773
the	O	-1	24582773
ag@@	B-Disease	D011595	24582773
it@@	I-Disease	-1	24582773
ation	I-Disease	-1	24582773
spec@@	O	-1	24582773
ific@@	O	-1	24582773
ally	O	-1	24582773
to	O	-1	24582773
qu@@	B-Chemical	C069541	24582773
e@@	I-Chemical	-1	24582773
ti@@	I-Chemical	-1	24582773
apine	I-Chemical	-1	24582773
.	O	-1	24582773

An@@	O	-1	24587916
ti@@	O	-1	24587916
oxid@@	O	-1	24587916
ant	O	-1	24587916
effects	O	-1	24587916
of	O	-1	24587916
bo@@	O	-1	24587916
v@@	O	-1	24587916
ine	O	-1	24587916
l@@	O	-1	24587916
ac@@	O	-1	24587916
to@@	O	-1	24587916
fer@@	O	-1	24587916
rin	O	-1	24587916
on	O	-1	24587916
de@@	B-Chemical	D003907	24587916
xameth@@	I-Chemical	-1	24587916
as@@	I-Chemical	-1	24587916
one	I-Chemical	-1	24587916
-induced	O	-1	24587916
hypertension	B-Disease	D006973	24587916
in	O	-1	24587916
rat@@	O	-1	24587916
.	O	-1	24587916
D@@	B-Chemical	D003907	24587916
ex@@	I-Chemical	-1	24587916
ameth@@	I-Chemical	-1	24587916
as@@	I-Chemical	-1	24587916
one	I-Chemical	-1	24587916
-	O	-1	24587916
(	O	-1	24587916
De@@	B-Chemical	D003907	24587916
x	I-Chemical	-1	24587916
-@@	O	-1	24587916
)	O	-1	24587916
induced	O	-1	24587916
hypertension	B-Disease	D006973	24587916
is	O	-1	24587916
associated	O	-1	24587916
with	O	-1	24587916
enhanced	O	-1	24587916
oxid@@	O	-1	24587916
ative	O	-1	24587916
stres@@	O	-1	24587916
s.	O	-1	24587916
L@@	O	-1	24587916
ac@@	O	-1	24587916
to@@	O	-1	24587916
fer@@	O	-1	24587916
rin	O	-1	24587916
(@@	O	-1	24587916
L@@	O	-1	24587916
F@@	O	-1	24587916
)	O	-1	24587916
is	O	-1	24587916
an	O	-1	24587916
i@@	B-Chemical	D007501	24587916
ro@@	I-Chemical	-1	24587916
n	I-Chemical	-1	24587916
-@@	O	-1	24587916
b@@	O	-1	24587916
ind@@	O	-1	24587916
ing	O	-1	24587916
gly@@	O	-1	24587916
co@@	O	-1	24587916
protein	O	-1	24587916
with	O	-1	24587916
anti@@	O	-1	24587916
hypertensive	O	-1	24587916
pro@@	O	-1	24587916
per@@	O	-1	24587916
ti@@	O	-1	24587916
es.	O	-1	24587916
In	O	-1	24587916
this	O	-1	24587916
study,	O	-1	24587916
we	O	-1	24587916
investigated	O	-1	24587916
the	O	-1	24587916
effect	O	-1	24587916
of	O	-1	24587916
chronic	O	-1	24587916
administration	O	-1	24587916
of	O	-1	24587916
L@@	O	-1	24587916
F	O	-1	24587916
on	O	-1	24587916
oxid@@	O	-1	24587916
ative	O	-1	24587916
stres@@	O	-1	24587916
s	O	-1	24587916
and	O	-1	24587916
hypertension	B-Disease	D006973	24587916
up@@	O	-1	24587916
on	O	-1	24587916
De@@	B-Chemical	D003907	24587916
x	I-Chemical	-1	24587916
administr@@	O	-1	24587916
ation.	O	-1	24587916
M@@	O	-1	24587916
al@@	O	-1	24587916
e	O	-1	24587916
Wistar	O	-1	24587916
rats	O	-1	24587916
were	O	-1	24587916
treated	O	-1	24587916
by	O	-1	24587916
De@@	B-Chemical	D003907	24587916
x	I-Chemical	-1	24587916
(@@	O	-1	24587916
30	O	-1	24587916
u	O	-1	24587916
g/@@	O	-1	24587916
k@@	O	-1	24587916
g/@@	O	-1	24587916
day	O	-1	24587916
sub@@	O	-1	24587916
c@@	O	-1	24587916
ut@@	O	-1	24587916
ane@@	O	-1	24587916
ous@@	O	-1	24587916
ly@@	O	-1	24587916
)	O	-1	24587916
or	O	-1	24587916
saline	O	-1	24587916
for	O	-1	24587916
14	O	-1	24587916
days.	O	-1	24587916
O@@	O	-1	24587916
ral	O	-1	24587916
bo@@	O	-1	24587916
v@@	O	-1	24587916
ine	O	-1	24587916
L@@	O	-1	24587916
F	O	-1	24587916
(3@@	O	-1	24587916
0@@	O	-1	24587916
,	O	-1	24587916
10@@	O	-1	24587916
0@@	O	-1	24587916
,	O	-1	24587916
3@@	O	-1	24587916
00	O	-1	24587916
mg/kg)	O	-1	24587916
was	O	-1	24587916
given	O	-1	24587916
from	O	-1	24587916
day	O	-1	24587916
8	O	-1	24587916
to	O	-1	24587916
14	O	-1	24587916
in	O	-1	24587916
a	O	-1	24587916
rever@@	O	-1	24587916
s@@	O	-1	24587916
al	O	-1	24587916
study.	O	-1	24587916
In	O	-1	24587916
a	O	-1	24587916
pre@@	O	-1	24587916
ven@@	O	-1	24587916
tion	O	-1	24587916
study,	O	-1	24587916
rats	O	-1	24587916
received	O	-1	24587916
4	O	-1	24587916
days	O	-1	24587916
of	O	-1	24587916
L@@	O	-1	24587916
F	O	-1	24587916
treatment	O	-1	24587916
followed	O	-1	24587916
by	O	-1	24587916
De@@	B-Chemical	D003907	24587916
x	I-Chemical	-1	24587916
and	O	-1	24587916
continu@@	O	-1	24587916
ed	O	-1	24587916
during	O	-1	24587916
the	O	-1	24587916
test	O	-1	24587916
perio@@	O	-1	24587916
d.	O	-1	24587916
S@@	O	-1	24587916
y@@	O	-1	24587916
st@@	O	-1	24587916
olic	O	-1	24587916
blood	O	-1	24587916
pressure	O	-1	24587916
(S@@	O	-1	24587916
B@@	O	-1	24587916
P)	O	-1	24587916
was	O	-1	24587916
measured	O	-1	24587916
using	O	-1	24587916
t@@	O	-1	24587916
ail@@	O	-1	24587916
-@@	O	-1	24587916
c@@	O	-1	24587916
u@@	O	-1	24587916
f@@	O	-1	24587916
f	O	-1	24587916
meth@@	O	-1	24587916
o@@	O	-1	24587916
d.	O	-1	24587916
Th@@	O	-1	24587916
ym@@	O	-1	24587916
us	O	-1	24587916
weight	O	-1	24587916
was	O	-1	24587916
used	O	-1	24587916
as	O	-1	24587916
a	O	-1	24587916
mark@@	O	-1	24587916
er	O	-1	24587916
of	O	-1	24587916
g@@	O	-1	24587916
lu@@	O	-1	24587916
co@@	O	-1	24587916
cortico@@	O	-1	24587916
id	O	-1	24587916
activ@@	O	-1	24587916
ity.	O	-1	24587916
P@@	O	-1	24587916
las@@	O	-1	24587916
ma	O	-1	24587916
hydro@@	B-Chemical	D006861	24587916
gen	I-Chemical	-1	24587916
per@@	I-Chemical	-1	24587916
ox@@	I-Chemical	-1	24587916
ide	I-Chemical	-1	24587916
(	O	-1	24587916
H@@	B-Chemical	D006861	24587916
2@@	I-Chemical	-1	24587916
O@@	I-Chemical	-1	24587916
2	I-Chemical	-1	24587916
)	O	-1	24587916
concentration	O	-1	24587916
and	O	-1	24587916
fer@@	O	-1	24587916
ric	O	-1	24587916
reduc@@	O	-1	24587916
ing	O	-1	24587916
anti@@	O	-1	24587916
oxid@@	O	-1	24587916
ant	O	-1	24587916
po@@	O	-1	24587916
w@@	O	-1	24587916
er	O	-1	24587916
(@@	O	-1	24587916
F@@	O	-1	24587916
R@@	O	-1	24587916
A@@	O	-1	24587916
P)	O	-1	24587916
valu@@	O	-1	24587916
e	O	-1	24587916
were	O	-1	24587916
deter@@	O	-1	24587916
m@@	O	-1	24587916
ine@@	O	-1	24587916
d.	O	-1	24587916
D@@	B-Chemical	D003907	24587916
ex@@	I-Chemical	-1	24587916
ameth@@	I-Chemical	-1	24587916
as@@	I-Chemical	-1	24587916
one	I-Chemical	-1	24587916
significantly	O	-1	24587916
increased	O	-1	24587916
S@@	O	-1	24587916
B@@	O	-1	24587916
P	O	-1	24587916
and	O	-1	24587916
plasma	O	-1	24587916
H@@	B-Chemical	D006861	24587916
2@@	I-Chemical	-1	24587916
O@@	I-Chemical	-1	24587916
2	I-Chemical	-1	24587916
level	O	-1	24587916
and	O	-1	24587916
decreased	O	-1	24587916
th@@	O	-1	24587916
ym@@	O	-1	24587916
us	O	-1	24587916
and	O	-1	24587916
body	O	-1	24587916
weigh@@	O	-1	24587916
t@@	O	-1	24587916
s.	O	-1	24587916
L@@	O	-1	24587916
F	O	-1	24587916
lo@@	O	-1	24587916
we@@	O	-1	24587916
red	O	-1	24587916
(P	O	-1	24587916
<	O	-1	24587916
0.0@@	O	-1	24587916
1)	O	-1	24587916
and	O	-1	24587916
dose	O	-1	24587916
depend@@	O	-1	24587916
ently	O	-1	24587916
prevent@@	O	-1	24587916
ed	O	-1	24587916
(P	O	-1	24587916
<	O	-1	24587916
0.00@@	O	-1	24587916
1)	O	-1	24587916
De@@	B-Chemical	D003907	24587916
x	I-Chemical	-1	24587916
-induced	O	-1	24587916
hypertension	B-Disease	D006973	24587916
.	O	-1	24587916
L@@	O	-1	24587916
F	O	-1	24587916
prevent@@	O	-1	24587916
ed	O	-1	24587916
body	O	-1	24587916
weight	B-Disease	D015431	24587916
loss	I-Disease	-1	24587916
and	O	-1	24587916
significantly	O	-1	24587916
reduced	O	-1	24587916
the	O	-1	24587916
elevated	O	-1	24587916
plasma	O	-1	24587916
H@@	B-Chemical	D006861	24587916
2@@	I-Chemical	-1	24587916
O@@	I-Chemical	-1	24587916
2	I-Chemical	-1	24587916
and	O	-1	24587916
increased	O	-1	24587916
F@@	O	-1	24587916
R@@	O	-1	24587916
A@@	O	-1	24587916
P	O	-1	24587916
valu@@	O	-1	24587916
es.	O	-1	24587916
Ch@@	O	-1	24587916
ron@@	O	-1	24587916
ic	O	-1	24587916
administration	O	-1	24587916
of	O	-1	24587916
L@@	O	-1	24587916
F	O	-1	24587916
st@@	O	-1	24587916
ron@@	O	-1	24587916
g@@	O	-1	24587916
ly	O	-1	24587916
reduced	O	-1	24587916
the	O	-1	24587916
blood	O	-1	24587916
pressure	O	-1	24587916
and	O	-1	24587916
pro@@	O	-1	24587916
duction	O	-1	24587916
of	O	-1	24587916
RO@@	O	-1	24587916
S	O	-1	24587916
and	O	-1	24587916
improved	O	-1	24587916
anti@@	O	-1	24587916
oxid@@	O	-1	24587916
ant	O	-1	24587916
cap@@	O	-1	24587916
ac@@	O	-1	24587916
ity	O	-1	24587916
in	O	-1	24587916
De@@	B-Chemical	D003907	24587916
x	I-Chemical	-1	24587916
-induced	O	-1	24587916
hypertension	B-Disease	D006973	24587916
,	O	-1	24587916
suggesting	O	-1	24587916
the	O	-1	24587916
role	O	-1	24587916
of	O	-1	24587916
inhibition	O	-1	24587916
of	O	-1	24587916
oxid@@	O	-1	24587916
ative	O	-1	24587916
stres@@	O	-1	24587916
s	O	-1	24587916
as	O	-1	24587916
an@@	O	-1	24587916
other	O	-1	24587916
mechanism	O	-1	24587916
of	O	-1	24587916
anti@@	O	-1	24587916
hypertensive	O	-1	24587916
action	O	-1	24587916
of	O	-1	24587916
L@@	O	-1	24587916
F@@	O	-1	24587916
.	O	-1	24587916

The	O	-1	24588023
association	O	-1	24588023
between	O	-1	24588023
tran@@	B-Chemical	D014148	24588023
ex@@	I-Chemical	-1	24588023
am@@	I-Chemical	-1	24588023
ic	I-Chemical	-1	24588023
acid	I-Chemical	-1	24588023
and	O	-1	24588023
convul@@	B-Disease	D012640	24588023
sive	I-Disease	-1	24588023
seizures	B-Disease	D012640	24588023
after	O	-1	24588023
cardiac	O	-1	24588023
surg@@	O	-1	24588023
ery@@	O	-1	24588023
:	O	-1	24588023
a	O	-1	24588023
mul@@	O	-1	24588023
tiv@@	O	-1	24588023
ari@@	O	-1	24588023
ate	O	-1	24588023
analysis	O	-1	24588023
in	O	-1	24588023
11	O	-1	24588023
5@@	O	-1	24588023
2@@	O	-1	24588023
9	O	-1	24588023
patients.	O	-1	24588023
B@@	O	-1	24588023
ecause	O	-1	24588023
of	O	-1	24588023
a	O	-1	24588023
l@@	O	-1	24588023
ac@@	O	-1	24588023
k	O	-1	24588023
of	O	-1	24588023
cont@@	O	-1	24588023
em@@	O	-1	24588023
por@@	O	-1	24588023
ary	O	-1	24588023
data	O	-1	24588023
reg@@	O	-1	24588023
ar@@	O	-1	24588023
ding	O	-1	24588023
seizures	B-Disease	D012640	24588023
after	O	-1	24588023
cardiac	O	-1	24588023
surger@@	O	-1	24588023
y,	O	-1	24588023
we	O	-1	24588023
under@@	O	-1	24588023
to@@	O	-1	24588023
o@@	O	-1	24588023
k	O	-1	24588023
a	O	-1	24588023
ret@@	O	-1	24588023
ro@@	O	-1	24588023
sp@@	O	-1	24588023
ective	O	-1	24588023
analysis	O	-1	24588023
of	O	-1	24588023
pro@@	O	-1	24588023
sp@@	O	-1	24588023
ectively	O	-1	24588023
coll@@	O	-1	24588023
ected	O	-1	24588023
data	O	-1	24588023
from	O	-1	24588023
11	O	-1	24588023
5@@	O	-1	24588023
2@@	O	-1	24588023
9	O	-1	24588023
patients	O	-1	24588023
in	O	-1	24588023
whom	O	-1	24588023
cardio@@	O	-1	24588023
pulmonary	O	-1	24588023
b@@	O	-1	24588023
yp@@	O	-1	24588023
as@@	O	-1	24588023
s	O	-1	24588023
was	O	-1	24588023
used	O	-1	24588023
from	O	-1	24588023
J@@	O	-1	24588023
an@@	O	-1	24588023
u@@	O	-1	24588023
ary	O	-1	24588023
20@@	O	-1	24588023
0@@	O	-1	24588023
4	O	-1	24588023
to	O	-1	24588023
D@@	O	-1	24588023
ec@@	O	-1	24588023
emb@@	O	-1	24588023
er	O	-1	24588023
20@@	O	-1	24588023
10@@	O	-1	24588023
.	O	-1	24588023
A	O	-1	24588023
convul@@	B-Disease	D012640	24588023
sive	I-Disease	-1	24588023
seizure	B-Disease	D012640	24588023
was	O	-1	24588023
def@@	O	-1	24588023
in@@	O	-1	24588023
ed	O	-1	24588023
as	O	-1	24588023
a	O	-1	24588023
transi@@	O	-1	24588023
ent	O	-1	24588023
episo@@	O	-1	24588023
de	O	-1	24588023
of	O	-1	24588023
dist@@	O	-1	24588023
ur@@	O	-1	24588023
bed	O	-1	24588023
brain	O	-1	24588023
function	O	-1	24588023
character@@	O	-1	24588023
is@@	O	-1	24588023
ed	O	-1	24588023
by	O	-1	24588023
ab@@	B-Disease	D004409	24588023
normal	I-Disease	-1	24588023
invol@@	I-Disease	-1	24588023
un@@	I-Disease	-1	24588023
t@@	I-Disease	-1	24588023
ary	I-Disease	-1	24588023
motor	I-Disease	-1	24588023
mo@@	I-Disease	-1	24588023
ve@@	I-Disease	-1	24588023
ments	I-Disease	-1	24588023
.	O	-1	24588023
M@@	O	-1	24588023
ul@@	O	-1	24588023
tiv@@	O	-1	24588023
ari@@	O	-1	24588023
ate	O	-1	24588023
reg@@	O	-1	24588023
res@@	O	-1	24588023
sion	O	-1	24588023
analysis	O	-1	24588023
was	O	-1	24588023
performed	O	-1	24588023
to	O	-1	24588023
identi@@	O	-1	24588023
f@@	O	-1	24588023
y	O	-1	24588023
in@@	O	-1	24588023
dependent	O	-1	24588023
predic@@	O	-1	24588023
t@@	O	-1	24588023
ors	O	-1	24588023
of	O	-1	24588023
postoperative	O	-1	24588023
seizures	B-Disease	D012640	24588023
.	O	-1	24588023
A	O	-1	24588023
total	O	-1	24588023
of	O	-1	24588023
100	O	-1	24588023
(0.@@	O	-1	24588023
9@@	O	-1	24588023
%)	O	-1	24588023
patients	O	-1	24588023
developed	O	-1	24588023
postoperative	O	-1	24588023
convul@@	B-Disease	D012640	24588023
sive	I-Disease	-1	24588023
seizures	B-Disease	D012640	24588023
.	O	-1	24588023
G@@	B-Disease	D012640	24588023
en@@	I-Disease	-1	24588023
er@@	I-Disease	-1	24588023
al@@	I-Disease	-1	24588023
is@@	I-Disease	-1	24588023
ed	I-Disease	-1	24588023
and	I-Disease	-1	24588023
foc@@	I-Disease	-1	24588023
al	I-Disease	-1	24588023
seizures	I-Disease	-1	24588023
were	O	-1	24588023
identi@@	O	-1	24588023
fied	O	-1	24588023
in	O	-1	24588023
6@@	O	-1	24588023
8	O	-1	24588023
and	O	-1	24588023
3@@	O	-1	24588023
2	O	-1	24588023
patients,	O	-1	24588023
respectively.	O	-1	24588023
The	O	-1	24588023
median	O	-1	24588023
(@@	O	-1	24588023
I@@	O	-1	24588023
Q@@	O	-1	24588023
R	O	-1	24588023
[@@	O	-1	24588023
ran@@	O	-1	24588023
ge@@	O	-1	24588023
]@@	O	-1	24588023
)	O	-1	24588023
time	O	-1	24588023
after	O	-1	24588023
surger@@	O	-1	24588023
y	O	-1	24588023
when	O	-1	24588023
the	O	-1	24588023
seizure	B-Disease	D012640	24588023
occurred	O	-1	24588023
was	O	-1	24588023
7	O	-1	24588023
(6@@	O	-1	24588023
-1@@	O	-1	24588023
2	O	-1	24588023
[@@	O	-1	24588023
1-@@	O	-1	24588023
2@@	O	-1	24588023
1@@	O	-1	24588023
6@@	O	-1	24588023
]@@	O	-1	24588023
)	O	-1	24588023
h	O	-1	24588023
and	O	-1	24588023
8	O	-1	24588023
(6@@	O	-1	24588023
-1@@	O	-1	24588023
1	O	-1	24588023
[@@	O	-1	24588023
4@@	O	-1	24588023
-1@@	O	-1	24588023
8@@	O	-1	24588023
]@@	O	-1	24588023
)	O	-1	24588023
h@@	O	-1	24588023
,	O	-1	24588023
respectively.	O	-1	24588023
E@@	O	-1	24588023
pi@@	O	-1	24588023
le@@	O	-1	24588023
p@@	O	-1	24588023
ti@@	O	-1	24588023
form	O	-1	24588023
findings	O	-1	24588023
on	O	-1	24588023
electro@@	O	-1	24588023
encephalo@@	O	-1	24588023
graph@@	O	-1	24588023
y	O	-1	24588023
were	O	-1	24588023
seen	O	-1	24588023
in	O	-1	24588023
1@@	O	-1	24588023
9	O	-1	24588023
patients.	O	-1	24588023
In@@	O	-1	24588023
dependent	O	-1	24588023
predic@@	O	-1	24588023
t@@	O	-1	24588023
ors	O	-1	24588023
of	O	-1	24588023
postoperative	O	-1	24588023
seizures	B-Disease	D012640	24588023
included	O	-1	24588023
age,	O	-1	24588023
female	O	-1	24588023
sex@@	O	-1	24588023
,	O	-1	24588023
re@@	O	-1	24588023
d@@	O	-1	24588023
o	O	-1	24588023
cardiac	O	-1	24588023
surger@@	O	-1	24588023
y,	O	-1	24588023
calcification	O	-1	24588023
of	O	-1	24588023
as@@	O	-1	24588023
c@@	O	-1	24588023
en@@	O	-1	24588023
ding	O	-1	24588023
a@@	O	-1	24588023
ort@@	O	-1	24588023
a,	O	-1	24588023
con@@	B-Disease	D006333	24588023
g@@	I-Disease	-1	24588023
es@@	I-Disease	-1	24588023
tive	I-Disease	-1	24588023
heart	I-Disease	-1	24588023
failure	I-Disease	-1	24588023
,	O	-1	24588023
de@@	O	-1	24588023
ep	O	-1	24588023
hypo@@	B-Disease	D007035	24588023
ther@@	I-Disease	-1	24588023
mic	I-Disease	-1	24588023
cir@@	O	-1	24588023
cul@@	O	-1	24588023
atory	O	-1	24588023
ar@@	O	-1	24588023
rest@@	O	-1	24588023
,	O	-1	24588023
duration	O	-1	24588023
of	O	-1	24588023
a@@	O	-1	24588023
or@@	O	-1	24588023
tic	O	-1	24588023
cros@@	O	-1	24588023
s-@@	O	-1	24588023
cl@@	O	-1	24588023
am@@	O	-1	24588023
p	O	-1	24588023
and	O	-1	24588023
tran@@	B-Chemical	D014148	24588023
ex@@	I-Chemical	-1	24588023
am@@	I-Chemical	-1	24588023
ic	I-Chemical	-1	24588023
acid	I-Chemical	-1	24588023
.	O	-1	24588023
Whe@@	O	-1	24588023
n	O	-1	24588023
tested	O	-1	24588023
in	O	-1	24588023
a	O	-1	24588023
mul@@	O	-1	24588023
tiv@@	O	-1	24588023
ari@@	O	-1	24588023
ate	O	-1	24588023
reg@@	O	-1	24588023
res@@	O	-1	24588023
sion	O	-1	24588023
analy@@	O	-1	24588023
sis,	O	-1	24588023
tran@@	B-Chemical	D014148	24588023
ex@@	I-Chemical	-1	24588023
am@@	I-Chemical	-1	24588023
ic	I-Chemical	-1	24588023
acid	I-Chemical	-1	24588023
was	O	-1	24588023
a	O	-1	24588023
st@@	O	-1	24588023
ron@@	O	-1	24588023
g	O	-1	24588023
in@@	O	-1	24588023
dependent	O	-1	24588023
predic@@	O	-1	24588023
t@@	O	-1	24588023
or	O	-1	24588023
of	O	-1	24588023
seizures	B-Disease	D012640	24588023
(@@	O	-1	24588023
O@@	O	-1	24588023
R	O	-1	24588023
1@@	O	-1	24588023
4.@@	O	-1	24588023
3,	O	-1	24588023
95%	O	-1	24588023
C@@	O	-1	24588023
I	O	-1	24588023
5.@@	O	-1	24588023
5-@@	O	-1	24588023
3@@	O	-1	24588023
6.@@	O	-1	24588023
7@@	O	-1	24588023
;	O	-1	24588023
p	O	-1	24588023
<	O	-1	24588023
0.00@@	O	-1	24588023
1).	O	-1	24588023
Patients	O	-1	24588023
with	O	-1	24588023
convul@@	B-Disease	D012640	24588023
sive	I-Disease	-1	24588023
seizures	B-Disease	D012640	24588023
had	O	-1	24588023
2.@@	O	-1	24588023
5	O	-1	24588023
times	O	-1	24588023
higher	O	-1	24588023
in-@@	O	-1	24588023
hospit@@	O	-1	24588023
al	O	-1	24588023
mor@@	O	-1	24588023
t@@	O	-1	24588023
ality	O	-1	24588023
rat@@	O	-1	24588023
es	O	-1	24588023
and	O	-1	24588023
tw@@	O	-1	24588023
ic@@	O	-1	24588023
e	O	-1	24588023
the	O	-1	24588023
l@@	O	-1	24588023
en@@	O	-1	24588023
g@@	O	-1	24588023
th	O	-1	24588023
of	O	-1	24588023
hospit@@	O	-1	24588023
al	O	-1	24588023
st@@	O	-1	24588023
ay	O	-1	24588023
compared	O	-1	24588023
with	O	-1	24588023
patients	O	-1	24588023
without	O	-1	24588023
convul@@	B-Disease	D012640	24588023
sive	I-Disease	-1	24588023
seizures	B-Disease	D012640	24588023
.	O	-1	24588023
M@@	O	-1	24588023
e@@	O	-1	24588023
an	O	-1	24588023
(@@	O	-1	24588023
I@@	O	-1	24588023
Q@@	O	-1	24588023
R	O	-1	24588023
[@@	O	-1	24588023
ran@@	O	-1	24588023
ge@@	O	-1	24588023
]@@	O	-1	24588023
)	O	-1	24588023
l@@	O	-1	24588023
en@@	O	-1	24588023
g@@	O	-1	24588023
th	O	-1	24588023
of	O	-1	24588023
st@@	O	-1	24588023
ay	O	-1	24588023
in	O	-1	24588023
the	O	-1	24588023
int@@	O	-1	24588023
en@@	O	-1	24588023
sive	O	-1	24588023
car@@	O	-1	24588023
e	O	-1	24588023
un@@	O	-1	24588023
it	O	-1	24588023
was	O	-1	24588023
1@@	O	-1	24588023
15	O	-1	24588023
(4@@	O	-1	24588023
9@@	O	-1	24588023
-@@	O	-1	24588023
2@@	O	-1	24588023
2@@	O	-1	24588023
8	O	-1	24588023
[@@	O	-1	24588023
3@@	O	-1	24588023
2-@@	O	-1	24588023
4@@	O	-1	24588023
8@@	O	-1	24588023
1@@	O	-1	24588023
]@@	O	-1	24588023
)	O	-1	24588023
h	O	-1	24588023
in	O	-1	24588023
patients	O	-1	24588023
with	O	-1	24588023
convul@@	B-Disease	D012640	24588023
sive	I-Disease	-1	24588023
seizures	B-Disease	D012640	24588023
compared	O	-1	24588023
with	O	-1	24588023
2@@	O	-1	24588023
6	O	-1	24588023
(2@@	O	-1	24588023
2-@@	O	-1	24588023
6@@	O	-1	24588023
9	O	-1	24588023
[@@	O	-1	24588023
1@@	O	-1	24588023
4-@@	O	-1	24588023
10@@	O	-1	24588023
80@@	O	-1	24588023
]@@	O	-1	24588023
)	O	-1	24588023
h	O	-1	24588023
in	O	-1	24588023
patients	O	-1	24588023
without	O	-1	24588023
seizures	B-Disease	D012640	24588023
(p	O	-1	24588023
<	O	-1	24588023
0.00@@	O	-1	24588023
1).	O	-1	24588023
Con@@	B-Disease	D012640	24588023
vul@@	I-Disease	-1	24588023
sive	I-Disease	-1	24588023
seizures	B-Disease	D012640	24588023
are	O	-1	24588023
a	O	-1	24588023
seri@@	O	-1	24588023
ous	O	-1	24588023
postoperative	B-Disease	D011183	24588023
complication	I-Disease	-1	24588023
after	O	-1	24588023
cardiac	O	-1	24588023
surger@@	O	-1	24588023
y.	O	-1	24588023
A@@	O	-1	24588023
s	O	-1	24588023
tran@@	B-Chemical	D014148	24588023
ex@@	I-Chemical	-1	24588023
am@@	I-Chemical	-1	24588023
ic	I-Chemical	-1	24588023
acid	I-Chemical	-1	24588023
is	O	-1	24588023
the	O	-1	24588023
only	O	-1	24588023
mo@@	O	-1	24588023
di@@	O	-1	24588023
fi@@	O	-1	24588023
able	O	-1	24588023
fact@@	O	-1	24588023
or@@	O	-1	24588023
,	O	-1	24588023
its	O	-1	24588023
administr@@	O	-1	24588023
ation,	O	-1	24588023
partic@@	O	-1	24588023
ul@@	O	-1	24588023
arly	O	-1	24588023
in	O	-1	24588023
doses	O	-1	24588023
ex@@	O	-1	24588023
ce@@	O	-1	24588023
ed@@	O	-1	24588023
ing	O	-1	24588023
8@@	O	-1	24588023
0	O	-1	24588023
mg@@	O	-1	24588023
.@@	O	-1	24588023
kg@@	O	-1	24588023
(@@	O	-1	24588023
-1@@	O	-1	24588023
),	O	-1	24588023
should	O	-1	24588023
be	O	-1	24588023
weigh@@	O	-1	24588023
ed	O	-1	24588023
against	O	-1	24588023
the	O	-1	24588023
risk	O	-1	24588023
of	O	-1	24588023
postoperative	O	-1	24588023
seizures	B-Disease	D012640	24588023
.	O	-1	24588023

D@@	B-Disease	D008569	24595967
ys@@	I-Disease	-1	24595967
functional	I-Disease	-1	24595967
over@@	I-Disease	-1	24595967
n@@	I-Disease	-1	24595967
ight	I-Disease	-1	24595967
memory	I-Disease	-1	24595967
con@@	O	-1	24595967
sol@@	O	-1	24595967
id@@	O	-1	24595967
ation	O	-1	24595967
in	O	-1	24595967
ec@@	B-Chemical	D018817	24595967
st@@	I-Chemical	-1	24595967
as@@	I-Chemical	-1	24595967
y	I-Chemical	-1	24595967
us@@	O	-1	24595967
ers.	O	-1	24595967
S@@	O	-1	24595967
le@@	O	-1	24595967
ep	O	-1	24595967
pl@@	O	-1	24595967
ays	O	-1	24595967
an	O	-1	24595967
important	O	-1	24595967
role	O	-1	24595967
in	O	-1	24595967
the	O	-1	24595967
con@@	O	-1	24595967
sol@@	O	-1	24595967
id@@	O	-1	24595967
ation	O	-1	24595967
and	O	-1	24595967
in@@	O	-1	24595967
te@@	O	-1	24595967
g@@	O	-1	24595967
ration	O	-1	24595967
of	O	-1	24595967
memory	O	-1	24595967
in	O	-1	24595967
a	O	-1	24595967
pro@@	O	-1	24595967
cess	O	-1	24595967
c@@	O	-1	24595967
all@@	O	-1	24595967
ed	O	-1	24595967
over@@	O	-1	24595967
n@@	O	-1	24595967
ight	O	-1	24595967
memory	O	-1	24595967
con@@	O	-1	24595967
sol@@	O	-1	24595967
id@@	O	-1	24595967
ation.	O	-1	24595967
Pre@@	O	-1	24595967
vi@@	O	-1	24595967
ous	O	-1	24595967
studies	O	-1	24595967
indicate	O	-1	24595967
that	O	-1	24595967
ec@@	B-Chemical	D018817	24595967
st@@	I-Chemical	-1	24595967
as@@	I-Chemical	-1	24595967
y	I-Chemical	-1	24595967
users	O	-1	24595967
have	O	-1	24595967
mark@@	O	-1	24595967
ed	O	-1	24595967
and	O	-1	24595967
per@@	O	-1	24595967
sist@@	O	-1	24595967
ent	O	-1	24595967
neuro@@	O	-1	24595967
cognitive	O	-1	24595967
and	O	-1	24595967
sle@@	B-Disease	D012893	24595967
ep@@	I-Disease	-1	24595967
-@@	I-Disease	-1	24595967
related	I-Disease	-1	24595967
impair@@	I-Disease	-1	24595967
ments	I-Disease	-1	24595967
.	O	-1	24595967
We	O	-1	24595967
exten@@	O	-1	24595967
d	O	-1	24595967
p@@	O	-1	24595967
ast	O	-1	24595967
re@@	O	-1	24595967
se@@	O	-1	24595967
arc@@	O	-1	24595967
h	O	-1	24595967
by	O	-1	24595967
examin@@	O	-1	24595967
ing	O	-1	24595967
over@@	O	-1	24595967
n@@	O	-1	24595967
ight	O	-1	24595967
memory	O	-1	24595967
con@@	O	-1	24595967
sol@@	O	-1	24595967
id@@	O	-1	24595967
ation	O	-1	24595967
among	O	-1	24595967
reg@@	O	-1	24595967
ular	O	-1	24595967
ec@@	B-Chemical	D018817	24595967
st@@	I-Chemical	-1	24595967
as@@	I-Chemical	-1	24595967
y	I-Chemical	-1	24595967
users	O	-1	24595967
(n@@	O	-1	24595967
=@@	O	-1	24595967
12@@	O	-1	24595967
)	O	-1	24595967
and	O	-1	24595967
drug	O	-1	24595967
na@@	O	-1	24595967
i@@	O	-1	24595967
ve	O	-1	24595967
healthy	O	-1	24595967
controls	O	-1	24595967
(n@@	O	-1	24595967
=@@	O	-1	24595967
2@@	O	-1	24595967
6@@	O	-1	24595967
).	O	-1	24595967
M@@	O	-1	24595967
em@@	O	-1	24595967
ory	O	-1	24595967
rec@@	O	-1	24595967
all	O	-1	24595967
of	O	-1	24595967
wor@@	O	-1	24595967
d	O	-1	24595967
pa@@	O	-1	24595967
ir@@	O	-1	24595967
s	O	-1	24595967
was	O	-1	24595967
evaluated	O	-1	24595967
before	O	-1	24595967
and	O	-1	24595967
after	O	-1	24595967
a	O	-1	24595967
period	O	-1	24595967
of	O	-1	24595967
sle@@	O	-1	24595967
ep@@	O	-1	24595967
,	O	-1	24595967
with	O	-1	24595967
and	O	-1	24595967
without	O	-1	24595967
inter@@	O	-1	24595967
fe@@	O	-1	24595967
rence	O	-1	24595967
prior	O	-1	24595967
to	O	-1	24595967
test@@	O	-1	24595967
ing.	O	-1	24595967
In	O	-1	24595967
addi@@	O	-1	24595967
tion,	O	-1	24595967
we	O	-1	24595967
assessed	O	-1	24595967
neuro@@	O	-1	24595967
cognitive	O	-1	24595967
perform@@	O	-1	24595967
anc@@	O	-1	24595967
es	O	-1	24595967
ac@@	O	-1	24595967
ros@@	O	-1	24595967
s	O	-1	24595967
t@@	O	-1	24595967
as@@	O	-1	24595967
k@@	O	-1	24595967
s	O	-1	24595967
of	O	-1	24595967
lear@@	O	-1	24595967
n@@	O	-1	24595967
ing,	O	-1	24595967
memory	O	-1	24595967
and	O	-1	24595967
ex@@	O	-1	24595967
ec@@	O	-1	24595967
utive	O	-1	24595967
func@@	O	-1	24595967
tion@@	O	-1	24595967
ing.	O	-1	24595967
E@@	B-Chemical	D018817	24595967
c@@	I-Chemical	-1	24595967
st@@	I-Chemical	-1	24595967
as@@	I-Chemical	-1	24595967
y	I-Chemical	-1	24595967
users	O	-1	24595967
demonstrated	O	-1	24595967
impaired	B-Disease	D008569	24595967
over@@	I-Disease	-1	24595967
n@@	I-Disease	-1	24595967
ight	I-Disease	-1	24595967
memory	I-Disease	-1	24595967
con@@	O	-1	24595967
sol@@	O	-1	24595967
id@@	O	-1	24595967
ation,	O	-1	24595967
a	O	-1	24595967
find@@	O	-1	24595967
ing	O	-1	24595967
that	O	-1	24595967
was	O	-1	24595967
more	O	-1	24595967
p@@	O	-1	24595967
ron@@	O	-1	24595967
oun@@	O	-1	24595967
c@@	O	-1	24595967
ed	O	-1	24595967
following	O	-1	24595967
associ@@	O	-1	24595967
ative	O	-1	24595967
inter@@	O	-1	24595967
fe@@	O	-1	24595967
ren@@	O	-1	24595967
ce@@	O	-1	24595967
.	O	-1	24595967
Ad@@	O	-1	24595967
di@@	O	-1	24595967
tion@@	O	-1	24595967
ally,	O	-1	24595967
ec@@	B-Chemical	D018817	24595967
st@@	I-Chemical	-1	24595967
as@@	I-Chemical	-1	24595967
y	I-Chemical	-1	24595967
users	O	-1	24595967
demonstrated	O	-1	24595967
impair@@	O	-1	24595967
ments	O	-1	24595967
on	O	-1	24595967
t@@	O	-1	24595967
as@@	O	-1	24595967
k@@	O	-1	24595967
s	O	-1	24595967
rec@@	O	-1	24595967
ru@@	O	-1	24595967
it@@	O	-1	24595967
ing	O	-1	24595967
fron@@	O	-1	24595967
to@@	O	-1	24595967
stri@@	O	-1	24595967
atal	O	-1	24595967
and	O	-1	24595967
hippocamp@@	O	-1	24595967
al	O	-1	24595967
ne@@	O	-1	24595967
ural	O	-1	24595967
cir@@	O	-1	24595967
c@@	O	-1	24595967
u@@	O	-1	24595967
it@@	O	-1	24595967
r@@	O	-1	24595967
y,	O	-1	24595967
in	O	-1	24595967
the	O	-1	24595967
do@@	O	-1	24595967
main@@	O	-1	24595967
s	O	-1	24595967
of	O	-1	24595967
pro@@	O	-1	24595967
active	O	-1	24595967
inter@@	O	-1	24595967
fe@@	O	-1	24595967
rence	O	-1	24595967
memor@@	O	-1	24595967
y,	O	-1	24595967
long-term	O	-1	24595967
memor@@	O	-1	24595967
y,	O	-1	24595967
en@@	O	-1	24595967
co@@	O	-1	24595967
d@@	O	-1	24595967
ing,	O	-1	24595967
wor@@	O	-1	24595967
king	O	-1	24595967
memory	O	-1	24595967
and	O	-1	24595967
comple@@	O	-1	24595967
x	O	-1	24595967
pl@@	O	-1	24595967
an@@	O	-1	24595967
n@@	O	-1	24595967
ing.	O	-1	24595967
We	O	-1	24595967
suggest	O	-1	24595967
that	O	-1	24595967
ec@@	B-Chemical	D018817	24595967
st@@	I-Chemical	-1	24595967
as@@	I-Chemical	-1	24595967
y	I-Chemical	-1	24595967
-@@	O	-1	24595967
associated	O	-1	24595967
dysfunction	O	-1	24595967
in	O	-1	24595967
fron@@	O	-1	24595967
to@@	O	-1	24595967
-@@	O	-1	24595967
tempor@@	O	-1	24595967
al	O	-1	24595967
cir@@	O	-1	24595967
c@@	O	-1	24595967
u@@	O	-1	24595967
it@@	O	-1	24595967
r@@	O	-1	24595967
y	O	-1	24595967
may	O	-1	24595967
under@@	O	-1	24595967
li@@	O	-1	24595967
e	O	-1	24595967
over@@	O	-1	24595967
n@@	O	-1	24595967
ight	O	-1	24595967
con@@	O	-1	24595967
sol@@	O	-1	24595967
id@@	O	-1	24595967
ation	O	-1	24595967
memory	B-Disease	D008569	24595967
impair@@	I-Disease	-1	24595967
ments	I-Disease	-1	24595967
in	O	-1	24595967
reg@@	O	-1	24595967
ular	O	-1	24595967
ec@@	B-Chemical	D018817	24595967
st@@	I-Chemical	-1	24595967
as@@	I-Chemical	-1	24595967
y	I-Chemical	-1	24595967
us@@	O	-1	24595967
ers.	O	-1	24595967

N@@	O	-1	24614773
or@@	O	-1	24614773
mo@@	O	-1	24614773
am@@	O	-1	24614773
mon@@	O	-1	24614773
em@@	O	-1	24614773
ic	O	-1	24614773
encephalo@@	B-Disease	D001927	24614773
pathy	I-Disease	-1	24614773
:	O	-1	24614773
sol@@	O	-1	24614773
ely	O	-1	24614773
valpro@@	B-Chemical	D014635	24614773
ate	I-Chemical	-1	24614773
induced	O	-1	24614773
or	O	-1	24614773
multiple	O	-1	24614773
mechanis@@	O	-1	24614773
m@@	O	-1	24614773
s@@	O	-1	24614773
?	O	-1	24614773
A	O	-1	24614773
7@@	O	-1	24614773
7-@@	O	-1	24614773
year-old	O	-1	24614773
woman	O	-1	24614773
presented	O	-1	24614773
with	O	-1	24614773
sub@@	O	-1	24614773
acute	O	-1	24614773
onset	O	-1	24614773
progressive	O	-1	24614773
conf@@	B-Disease	D003221	24614773
usion	I-Disease	-1	24614773
,	O	-1	24614773
ag@@	B-Disease	D001523	24614773
gres@@	I-Disease	-1	24614773
sion	I-Disease	-1	24614773
,	O	-1	24614773
a@@	B-Disease	D006212	24614773
ud@@	I-Disease	-1	24614773
it@@	I-Disease	-1	24614773
ory	I-Disease	-1	24614773
h@@	I-Disease	-1	24614773
all@@	I-Disease	-1	24614773
uc@@	I-Disease	-1	24614773
in@@	I-Disease	-1	24614773
ations	I-Disease	-1	24614773
and	O	-1	24614773
de@@	B-Disease	D003072	24614773
lu@@	I-Disease	-1	24614773
sions	I-Disease	-1	24614773
.	O	-1	24614773
In	O	-1	24614773
the	O	-1	24614773
pre@@	O	-1	24614773
ce@@	O	-1	24614773
ding	O	-1	24614773
month@@	O	-1	24614773
s,	O	-1	24614773
the	O	-1	24614773
patient	O	-1	24614773
had	O	-1	24614773
a	O	-1	24614773
number	O	-1	24614773
of	O	-1	24614773
ad@@	O	-1	24614773
mis@@	O	-1	24614773
sions	O	-1	24614773
with	O	-1	24614773
transi@@	O	-1	24614773
ent	O	-1	24614773
un@@	O	-1	24614773
il@@	O	-1	24614773
ateral	O	-1	24614773
he@@	B-Disease	D010291	24614773
mi@@	I-Disease	-1	24614773
pa@@	I-Disease	-1	24614773
re@@	I-Disease	-1	24614773
sis	I-Disease	-1	24614773
with	O	-1	24614773
fac@@	O	-1	24614773
ial	O	-1	24614773
dro@@	O	-1	24614773
op@@	O	-1	24614773
,	O	-1	24614773
and	O	-1	24614773
had	O	-1	24614773
been	O	-1	24614773
star@@	O	-1	24614773
ted	O	-1	24614773
on	O	-1	24614773
valpro@@	B-Chemical	D014635	24614773
ate	I-Chemical	-1	24614773
for	O	-1	24614773
pres@@	O	-1	24614773
um@@	O	-1	24614773
ed	O	-1	24614773
he@@	B-Disease	D020325	24614773
mi@@	I-Disease	-1	24614773
ple@@	I-Disease	-1	24614773
g@@	I-Disease	-1	24614773
ic	I-Disease	-1	24614773
migra@@	I-Disease	-1	24614773
ine	I-Disease	-1	24614773
.	O	-1	24614773
V@@	B-Chemical	D014635	24614773
al@@	I-Chemical	-1	24614773
pro@@	I-Chemical	-1	24614773
ate	I-Chemical	-1	24614773
was	O	-1	24614773
withdraw@@	O	-1	24614773
n	O	-1	24614773
so@@	O	-1	24614773
on	O	-1	24614773
after	O	-1	24614773
ad@@	O	-1	24614773
mission	O	-1	24614773
and	O	-1	24614773
h@@	O	-1	24614773
er	O	-1	24614773
cognitive	O	-1	24614773
abil@@	O	-1	24614773
ities	O	-1	24614773
have	O	-1	24614773
gra@@	O	-1	24614773
du@@	O	-1	24614773
ally	O	-1	24614773
improved	O	-1	24614773
over	O	-1	24614773
3	O	-1	24614773
months	O	-1	24614773
of	O	-1	24614773
follow-@@	O	-1	24614773
up@@	O	-1	24614773
.	O	-1	24614773
V@@	B-Chemical	D014635	24614773
al@@	I-Chemical	-1	24614773
pro@@	I-Chemical	-1	24614773
ate	I-Chemical	-1	24614773
levels	O	-1	24614773
tak@@	O	-1	24614773
en	O	-1	24614773
prior	O	-1	24614773
to	O	-1	24614773
withdrawal	O	-1	24614773
were	O	-1	24614773
sub@@	O	-1	24614773
therapeutic	O	-1	24614773
and	O	-1	24614773
the	O	-1	24614773
patient	O	-1	24614773
was	O	-1	24614773
nor@@	O	-1	24614773
mo@@	O	-1	24614773
am@@	O	-1	24614773
mon@@	O	-1	24614773
a@@	O	-1	24614773
em@@	O	-1	24614773
ic@@	O	-1	24614773
.	O	-1	24614773
E@@	O	-1	24614773
E@@	O	-1	24614773
G	O	-1	24614773
under@@	O	-1	24614773
tak@@	O	-1	24614773
en	O	-1	24614773
during	O	-1	24614773
in@@	O	-1	24614773
patient	O	-1	24614773
st@@	O	-1	24614773
ay	O	-1	24614773
showed	O	-1	24614773
changes	O	-1	24614773
consist@@	O	-1	24614773
ent	O	-1	24614773
with	O	-1	24614773
encephalo@@	B-Disease	D001927	24614773
pathy	I-Disease	-1	24614773
,	O	-1	24614773
and	O	-1	24614773
low	O	-1	24614773
ti@@	O	-1	24614773
tr@@	O	-1	24614773
e	O	-1	24614773
N@@	B-Chemical	D016202	24614773
-@@	I-Chemical	-1	24614773
methyl@@	I-Chemical	-1	24614773
-@@	I-Chemical	-1	24614773
D-@@	I-Chemical	-1	24614773
as@@	I-Chemical	-1	24614773
part@@	I-Chemical	-1	24614773
ate	I-Chemical	-1	24614773
(	O	-1	24614773
N@@	B-Chemical	D016202	24614773
MD@@	I-Chemical	-1	24614773
A	I-Chemical	-1	24614773
)	O	-1	24614773
receptor	O	-1	24614773
anti@@	O	-1	24614773
bo@@	O	-1	24614773
di@@	O	-1	24614773
es	O	-1	24614773
were	O	-1	24614773
present	O	-1	24614773
in	O	-1	24614773
this	O	-1	24614773
patient@@	O	-1	24614773
.	O	-1	24614773
The	O	-1	24614773
possible	O	-1	24614773
a@@	O	-1	24614773
e@@	O	-1	24614773
ti@@	O	-1	24614773
olog@@	O	-1	24614773
i@@	O	-1	24614773
es	O	-1	24614773
of	O	-1	24614773
valpro@@	B-Chemical	D014635	24614773
ate	I-Chemical	-1	24614773
-induced	O	-1	24614773
encephalo@@	B-Disease	D001927	24614773
pathy	I-Disease	-1	24614773
and	O	-1	24614773
N@@	B-Chemical	D016202	24614773
MD@@	I-Chemical	-1	24614773
A	I-Chemical	-1	24614773
receptor@@	O	-1	24614773
-@@	O	-1	24614773
associated	O	-1	24614773
encephal@@	B-Disease	D004660	24614773
iti@@	I-Disease	-1	24614773
s	I-Disease	-1	24614773
present	O	-1	24614773
a	O	-1	24614773
diagnos@@	O	-1	24614773
tic	O	-1	24614773
di@@	O	-1	24614773
le@@	O	-1	24614773
m@@	O	-1	24614773
ma.	O	-1	24614773
We	O	-1	24614773
present	O	-1	24614773
a	O	-1	24614773
p@@	O	-1	24614773
ut@@	O	-1	24614773
ative	O	-1	24614773
combin@@	O	-1	24614773
at@@	O	-1	24614773
or@@	O	-1	24614773
ial	O	-1	24614773
hypo@@	O	-1	24614773
thesis	O	-1	24614773
to	O	-1	24614773
expl@@	O	-1	24614773
ain	O	-1	24614773
this	O	-1	24614773
patient@@	O	-1	24614773
's	O	-1	24614773
symptom@@	O	-1	24614773
s.	O	-1	24614773

C@@	B-Disease	D002526	24618873
e@@	I-Disease	-1	24618873
re@@	I-Disease	-1	24618873
bell@@	I-Disease	-1	24618873
ar	I-Disease	-1	24618873
and	I-Disease	-1	24618873
oc@@	I-Disease	-1	24618873
ulo@@	I-Disease	-1	24618873
motor	I-Disease	-1	24618873
dysfunction	I-Disease	-1	24618873
C@@	B-Disease	D005128	24618873
e@@	I-Disease	-1	24618873
re@@	I-Disease	-1	24618873
bell@@	I-Disease	-1	24618873
ar	I-Disease	-1	24618873
and	I-Disease	-1	24618873
oc@@	I-Disease	-1	24618873
ulo@@	I-Disease	-1	24618873
motor	I-Disease	-1	24618873
dysfunction	I-Disease	-1	24618873
induced	O	-1	24618873
by	O	-1	24618873
ra@@	O	-1	24618873
pid	O	-1	24618873
infusion	O	-1	24618873
of	O	-1	24618873
pe@@	B-Chemical	D008614	24618873
th@@	I-Chemical	-1	24618873
idine	I-Chemical	-1	24618873
.	O	-1	24618873
P@@	B-Chemical	D008614	24618873
eth@@	I-Chemical	-1	24618873
idine	I-Chemical	-1	24618873
is	O	-1	24618873
an	O	-1	24618873
o@@	O	-1	24618873
pi@@	O	-1	24618873
oid	O	-1	24618873
that	O	-1	24618873
g@@	O	-1	24618873
ain@@	O	-1	24618873
s	O	-1	24618873
its	O	-1	24618873
po@@	O	-1	24618873
pul@@	O	-1	24618873
ar@@	O	-1	24618873
ity	O	-1	24618873
for	O	-1	24618873
the	O	-1	24618873
effective	O	-1	24618873
pain	B-Disease	D010146	24618873
control	O	-1	24618873
through	O	-1	24618873
act@@	O	-1	24618873
ing	O	-1	24618873
on	O	-1	24618873
the	O	-1	24618873
o@@	O	-1	24618873
pi@@	O	-1	24618873
oid@@	O	-1	24618873
-@@	O	-1	24618873
receptor@@	O	-1	24618873
s.	O	-1	24618873
However,	O	-1	24618873
ra@@	O	-1	24618873
pid	O	-1	24618873
pain	B-Disease	D010146	24618873
re@@	O	-1	24618873
li@@	O	-1	24618873
e@@	O	-1	24618873
f	O	-1	24618873
so@@	O	-1	24618873
me@@	O	-1	24618873
times	O	-1	24618873
b@@	O	-1	24618873
r@@	O	-1	24618873
ings	O	-1	24618873
about	O	-1	24618873
un@@	O	-1	24618873
f@@	O	-1	24618873
av@@	O	-1	24618873
o@@	O	-1	24618873
ur@@	O	-1	24618873
able	O	-1	24618873
side	O	-1	24618873
effects	O	-1	24618873
that	O	-1	24618873
larg@@	O	-1	24618873
ely	O	-1	24618873
lim@@	O	-1	24618873
it	O	-1	24618873
its	O	-1	24618873
clinical	O	-1	24618873
u@@	O	-1	24618873
til@@	O	-1	24618873
ity.	O	-1	24618873
Com@@	O	-1	24618873
m@@	O	-1	24618873
on	O	-1	24618873
side	O	-1	24618873
effects	O	-1	24618873
includ@@	O	-1	24618873
e	O	-1	24618873
nausea	B-Disease	D009325	24618873
,	O	-1	24618873
v@@	B-Disease	D014839	24618873
om@@	I-Disease	-1	24618873
it@@	I-Disease	-1	24618873
ing	I-Disease	-1	24618873
and	O	-1	24618873
hypotension	B-Disease	D007022	24618873
.	O	-1	24618873
In	O	-1	24618873
patients	O	-1	24618873
with	O	-1	24618873
impaired	B-Disease	D051437	24618873
renal	I-Disease	-1	24618873
and	I-Disease	-1	24618873
liver	I-Disease	-1	24618873
function	I-Disease	-1	24618873
impaired	B-Disease	D017093	24618873
renal	I-Disease	-1	24618873
and	I-Disease	-1	24618873
liver	I-Disease	-1	24618873
function	I-Disease	-1	24618873
,	O	-1	24618873
and	O	-1	24618873
those	O	-1	24618873
who	O	-1	24618873
need	O	-1	24618873
long-term	O	-1	24618873
pain	B-Disease	D010146	24618873
control@@	O	-1	24618873
,	O	-1	24618873
pe@@	B-Chemical	D008614	24618873
th@@	I-Chemical	-1	24618873
idine	I-Chemical	-1	24618873
may	O	-1	24618873
cause	O	-1	24618873
ex@@	O	-1	24618873
cit@@	O	-1	24618873
atory	O	-1	24618873
central	O	-1	24618873
ner@@	O	-1	24618873
v@@	O	-1	24618873
ous	O	-1	24618873
system	O	-1	24618873
(C@@	O	-1	24618873
N@@	O	-1	24618873
S)	O	-1	24618873
effects	O	-1	24618873
through	O	-1	24618873
its	O	-1	24618873
neuro@@	B-Disease	D020258	24618873
toxic	I-Disease	-1	24618873
metabol@@	O	-1	24618873
it@@	O	-1	24618873
e,	O	-1	24618873
nor@@	B-Chemical	C002752	24618873
pe@@	I-Chemical	-1	24618873
th@@	I-Chemical	-1	24618873
idine	I-Chemical	-1	24618873
,	O	-1	24618873
result@@	O	-1	24618873
ing	O	-1	24618873
in	O	-1	24618873
ir@@	B-Disease	D001523	24618873
rit@@	I-Disease	-1	24618873
ability	I-Disease	-1	24618873
and	O	-1	24618873
seizure	B-Disease	D012640	24618873
at@@	O	-1	24618873
tac@@	O	-1	24618873
k@@	O	-1	24618873
.	O	-1	24618873
O@@	O	-1	24618873
n	O	-1	24618873
the	O	-1	24618873
contr@@	O	-1	24618873
ar@@	O	-1	24618873
y,	O	-1	24618873
though	O	-1	24618873
not	O	-1	24618873
clin@@	O	-1	24618873
ically	O	-1	24618873
appa@@	O	-1	24618873
ren@@	O	-1	24618873
t,	O	-1	24618873
pe@@	B-Chemical	D008614	24618873
th@@	I-Chemical	-1	24618873
idine	I-Chemical	-1	24618873
potenti@@	O	-1	24618873
ally	O	-1	24618873
causes	O	-1	24618873
inhibit@@	O	-1	24618873
ory	O	-1	24618873
im@@	O	-1	24618873
p@@	O	-1	24618873
act@@	O	-1	24618873
s	O	-1	24618873
on	O	-1	24618873
the	O	-1	24618873
C@@	O	-1	24618873
N@@	O	-1	24618873
S	O	-1	24618873
and	O	-1	24618873
impair@@	O	-1	24618873
s	O	-1	24618873
normal	O	-1	24618873
ce@@	O	-1	24618873
re@@	O	-1	24618873
bell@@	O	-1	24618873
ar	O	-1	24618873
and	O	-1	24618873
oc@@	O	-1	24618873
ulo@@	O	-1	24618873
motor	O	-1	24618873
function	O	-1	24618873
in	O	-1	24618873
the	O	-1	24618873
sh@@	O	-1	24618873
ort	O	-1	24618873
ter@@	O	-1	24618873
m.	O	-1	24618873
In	O	-1	24618873
this	O	-1	24618873
case	O	-1	24618873
repor@@	O	-1	24618873
t,	O	-1	24618873
we	O	-1	24618873
high@@	O	-1	24618873
li@@	O	-1	24618873
ght	O	-1	24618873
o@@	O	-1	24618873
pi@@	O	-1	24618873
oid@@	O	-1	24618873
's	O	-1	24618873
inhibit@@	O	-1	24618873
ory	O	-1	24618873
side	O	-1	24618873
effects	O	-1	24618873
on	O	-1	24618873
the	O	-1	24618873
ce@@	O	-1	24618873
re@@	O	-1	24618873
bell@@	O	-1	24618873
ar	O	-1	24618873
struct@@	O	-1	24618873
ure	O	-1	24618873
that	O	-1	24618873
causes	O	-1	24618873
dys@@	B-Disease	D002524	24618873
me@@	I-Disease	-1	24618873
tri@@	I-Disease	-1	24618873
a	I-Disease	-1	24618873
,	O	-1	24618873
dys@@	B-Disease	D004401	24618873
arth@@	I-Disease	-1	24618873
ri@@	I-Disease	-1	24618873
a	I-Disease	-1	24618873
,	O	-1	24618873
reduced	O	-1	24618873
smo@@	O	-1	24618873
oth	O	-1	24618873
pur@@	O	-1	24618873
su@@	O	-1	24618873
it	O	-1	24618873
g@@	O	-1	24618873
ain	O	-1	24618873
and	O	-1	24618873
decreased	O	-1	24618873
s@@	O	-1	24618873
ac@@	O	-1	24618873
ca@@	O	-1	24618873
di@@	O	-1	24618873
c	O	-1	24618873
ve@@	O	-1	24618873
loc@@	O	-1	24618873
ity.	O	-1	24618873

B@@	B-Disease	-1	24641119
ab@@	I-Disease	-1	24641119
o@@	I-Disease	-1	24641119
on	I-Disease	-1	24641119
syndrome	I-Disease	-1	24641119
induced	O	-1	24641119
by	O	-1	24641119
ke@@	B-Chemical	D007654	24641119
to@@	I-Chemical	-1	24641119
con@@	I-Chemical	-1	24641119
azole	I-Chemical	-1	24641119
.	O	-1	24641119
A	O	-1	24641119
27@@	O	-1	24641119
-@@	O	-1	24641119
year-old	O	-1	24641119
male	O	-1	24641119
patient	O	-1	24641119
presented	O	-1	24641119
with	O	-1	24641119
a	O	-1	24641119
mac@@	B-Disease	D003875	24641119
u@@	I-Disease	-1	24641119
lop@@	I-Disease	-1	24641119
ap@@	I-Disease	-1	24641119
ular	I-Disease	-1	24641119
er@@	I-Disease	-1	24641119
up@@	I-Disease	-1	24641119
tion	I-Disease	-1	24641119
on	O	-1	24641119
the	O	-1	24641119
f@@	O	-1	24641119
le@@	O	-1	24641119
x@@	O	-1	24641119
ural	O	-1	24641119
a@@	O	-1	24641119
reas	O	-1	24641119
and	O	-1	24641119
but@@	O	-1	24641119
t@@	O	-1	24641119
oc@@	O	-1	24641119
k@@	O	-1	24641119
s	O	-1	24641119
after	O	-1	24641119
using	O	-1	24641119
oral	O	-1	24641119
ke@@	B-Chemical	D007654	24641119
to@@	I-Chemical	-1	24641119
con@@	I-Chemical	-1	24641119
azole	I-Chemical	-1	24641119
.	O	-1	24641119
The	O	-1	24641119
patient	O	-1	24641119
was	O	-1	24641119
diagnos@@	O	-1	24641119
ed	O	-1	24641119
with	O	-1	24641119
drug@@	O	-1	24641119
-induced	O	-1	24641119
b@@	B-Disease	-1	24641119
ab@@	I-Disease	-1	24641119
o@@	I-Disease	-1	24641119
on	I-Disease	-1	24641119
syndrome	I-Disease	-1	24641119
bas@@	O	-1	24641119
ed	O	-1	24641119
on	O	-1	24641119
h@@	O	-1	24641119
is	O	-1	24641119
hist@@	O	-1	24641119
or@@	O	-1	24641119
y,	O	-1	24641119
which	O	-1	24641119
included	O	-1	24641119
prior	O	-1	24641119
sensitivity	O	-1	24641119
to	O	-1	24641119
to@@	O	-1	24641119
p@@	O	-1	24641119
ical	O	-1	24641119
ke@@	B-Chemical	D007654	24641119
to@@	I-Chemical	-1	24641119
con@@	I-Chemical	-1	24641119
azole	I-Chemical	-1	24641119
,	O	-1	24641119
a	O	-1	24641119
physi@@	O	-1	24641119
c@@	O	-1	24641119
al	O	-1	24641119
examin@@	O	-1	24641119
ation,	O	-1	24641119
and	O	-1	24641119
histo@@	O	-1	24641119
path@@	O	-1	24641119
ological	O	-1	24641119
find@@	O	-1	24641119
ing@@	O	-1	24641119
s.	O	-1	24641119
B@@	B-Disease	-1	24641119
ab@@	I-Disease	-1	24641119
o@@	I-Disease	-1	24641119
on	I-Disease	-1	24641119
syndrome	I-Disease	-1	24641119
is	O	-1	24641119
a	O	-1	24641119
drug@@	O	-1	24641119
-	O	-1	24641119
or	O	-1	24641119
cont@@	O	-1	24641119
ac@@	O	-1	24641119
t	O	-1	24641119
all@@	O	-1	24641119
er@@	O	-1	24641119
gen@@	O	-1	24641119
-@@	O	-1	24641119
related	O	-1	24641119
mac@@	B-Disease	D003875	24641119
u@@	I-Disease	-1	24641119
lop@@	I-Disease	-1	24641119
ap@@	I-Disease	-1	24641119
ular	I-Disease	-1	24641119
er@@	I-Disease	-1	24641119
up@@	I-Disease	-1	24641119
tion	I-Disease	-1	24641119
that	O	-1	24641119
typ@@	O	-1	24641119
ically	O	-1	24641119
invol@@	O	-1	24641119
v@@	O	-1	24641119
es	O	-1	24641119
the	O	-1	24641119
f@@	O	-1	24641119
le@@	O	-1	24641119
x@@	O	-1	24641119
ural	O	-1	24641119
and	O	-1	24641119
g@@	O	-1	24641119
lu@@	O	-1	24641119
te@@	O	-1	24641119
al	O	-1	24641119
a@@	O	-1	24641119
reas@@	O	-1	24641119
.	O	-1	24641119
To	O	-1	24641119
the	O	-1	24641119
b@@	O	-1	24641119
est	O	-1	24641119
of	O	-1	24641119
our	O	-1	24641119
know@@	O	-1	24641119
le@@	O	-1	24641119
d@@	O	-1	24641119
g@@	O	-1	24641119
e,	O	-1	24641119
this	O	-1	24641119
is	O	-1	24641119
the	O	-1	24641119
first	O	-1	24641119
reported	O	-1	24641119
case	O	-1	24641119
of	O	-1	24641119
ke@@	B-Chemical	D007654	24641119
to@@	I-Chemical	-1	24641119
con@@	I-Chemical	-1	24641119
azole	I-Chemical	-1	24641119
-induced	O	-1	24641119
b@@	B-Disease	-1	24641119
ab@@	I-Disease	-1	24641119
o@@	I-Disease	-1	24641119
on	I-Disease	-1	24641119
syndrome	I-Disease	-1	24641119
in	O	-1	24641119
the	O	-1	24641119
E@@	O	-1	24641119
n@@	O	-1	24641119
gl@@	O	-1	24641119
is@@	O	-1	24641119
h	O	-1	24641119
literat@@	O	-1	24641119
ure.	O	-1	24641119

A	O	-1	24653743
C@@	O	-1	24653743
ase	O	-1	24653743
of	O	-1	24653743
S@@	B-Disease	D016757	24653743
ud@@	I-Disease	-1	24653743
de@@	I-Disease	-1	24653743
n	I-Disease	-1	24653743
C@@	I-Disease	-1	24653743
ardi@@	I-Disease	-1	24653743
a@@	I-Disease	-1	24653743
c	I-Disease	-1	24653743
De@@	I-Disease	-1	24653743
ath	I-Disease	-1	24653743
due	O	-1	24653743
to	O	-1	24653743
P@@	B-Chemical	C042288	24653743
il@@	I-Chemical	-1	24653743
si@@	I-Chemical	-1	24653743
ca@@	I-Chemical	-1	24653743
in@@	I-Chemical	-1	24653743
ide	I-Chemical	-1	24653743
-@@	O	-1	24653743
In@@	O	-1	24653743
duced	O	-1	24653743
T@@	B-Disease	D016171	24653743
or@@	I-Disease	-1	24653743
sa@@	I-Disease	-1	24653743
des	I-Disease	-1	24653743
de	I-Disease	-1	24653743
P@@	I-Disease	-1	24653743
o@@	I-Disease	-1	24653743
int@@	I-Disease	-1	24653743
es	I-Disease	-1	24653743
.	O	-1	24653743
An	O	-1	24653743
8@@	O	-1	24653743
4-@@	O	-1	24653743
year-old	O	-1	24653743
male	O	-1	24653743
received	O	-1	24653743
oral	O	-1	24653743
p@@	B-Chemical	C042288	24653743
il@@	I-Chemical	-1	24653743
si@@	I-Chemical	-1	24653743
ca@@	I-Chemical	-1	24653743
in@@	I-Chemical	-1	24653743
ide	I-Chemical	-1	24653743
,	O	-1	24653743
a	O	-1	24653743
p@@	O	-1	24653743
ure	O	-1	24653743
sodium	B-Chemical	D012964	24653743
channel	O	-1	24653743
block@@	O	-1	24653743
er	O	-1	24653743
with	O	-1	24653743
s@@	O	-1	24653743
low	O	-1	24653743
recovery	O	-1	24653743
kine@@	O	-1	24653743
tic@@	O	-1	24653743
s,	O	-1	24653743
to	O	-1	24653743
conver@@	O	-1	24653743
t	O	-1	24653743
h@@	O	-1	24653743
is	O	-1	24653743
pa@@	O	-1	24653743
ro@@	O	-1	24653743
x@@	O	-1	24653743
ys@@	O	-1	24653743
m@@	O	-1	24653743
al	O	-1	24653743
atrial	B-Disease	D001281	24653743
fibrill@@	I-Disease	-1	24653743
ation	I-Disease	-1	24653743
to	O	-1	24653743
a	O	-1	24653743
s@@	O	-1	24653743
in@@	O	-1	24653743
us	O	-1	24653743
rhyth@@	O	-1	24653743
m@@	O	-1	24653743
;	O	-1	24653743
the	O	-1	24653743
patient	O	-1	24653743
developed	O	-1	24653743
su@@	B-Disease	D016757	24653743
d@@	I-Disease	-1	24653743
de@@	I-Disease	-1	24653743
n	I-Disease	-1	24653743
cardiac	I-Disease	-1	24653743
death	I-Disease	-1	24653743
two	O	-1	24653743
days	O	-1	24653743
lat@@	O	-1	24653743
er.	O	-1	24653743
The	O	-1	24653743
H@@	O	-1	24653743
ol@@	O	-1	24653743
ter	O	-1	24653743
electro@@	O	-1	24653743
cardio@@	O	-1	24653743
gram@@	O	-1	24653743
,	O	-1	24653743
which	O	-1	24653743
was	O	-1	24653743
wor@@	O	-1	24653743
n	O	-1	24653743
by	O	-1	24653743
ch@@	O	-1	24653743
ance@@	O	-1	24653743
,	O	-1	24653743
revealed	O	-1	24653743
t@@	B-Disease	D016171	24653743
or@@	I-Disease	-1	24653743
s@@	I-Disease	-1	24653743
ade	I-Disease	-1	24653743
de	I-Disease	-1	24653743
po@@	I-Disease	-1	24653743
int@@	I-Disease	-1	24653743
es	I-Disease	-1	24653743
with	O	-1	24653743
gra@@	O	-1	24653743
du@@	O	-1	24653743
ally	O	-1	24653743
prolonged	O	-1	24653743
Q@@	O	-1	24653743
T	O	-1	24653743
inter@@	O	-1	24653743
val@@	O	-1	24653743
s.	O	-1	24653743
This	O	-1	24653743
drug	O	-1	24653743
is	O	-1	24653743
ra@@	O	-1	24653743
pid@@	O	-1	24653743
ly	O	-1	24653743
abs@@	O	-1	24653743
or@@	O	-1	24653743
bed	O	-1	24653743
from	O	-1	24653743
the	O	-1	24653743
gast@@	O	-1	24653743
ro@@	O	-1	24653743
in@@	O	-1	24653743
test@@	O	-1	24653743
inal	O	-1	24653743
trac@@	O	-1	24653743
t,	O	-1	24653743
and	O	-1	24653743
most	O	-1	24653743
of	O	-1	24653743
it	O	-1	24653743
is	O	-1	24653743
ex@@	O	-1	24653743
cre@@	O	-1	24653743
ted	O	-1	24653743
from	O	-1	24653743
the	O	-1	24653743
kidne@@	O	-1	24653743
y.	O	-1	24653743
Although	O	-1	24653743
the	O	-1	24653743
patient@@	O	-1	24653743
's	O	-1	24653743
renal	O	-1	24653743
function	O	-1	24653743
was	O	-1	24653743
not	O	-1	24653743
high@@	O	-1	24653743
ly	O	-1	24653743
impaired	O	-1	24653743
and	O	-1	24653743
the	O	-1	24653743
dose	O	-1	24653743
of	O	-1	24653743
p@@	B-Chemical	C042288	24653743
il@@	I-Chemical	-1	24653743
si@@	I-Chemical	-1	24653743
ca@@	I-Chemical	-1	24653743
in@@	I-Chemical	-1	24653743
ide	I-Chemical	-1	24653743
was	O	-1	24653743
low@@	O	-1	24653743
,	O	-1	24653743
the	O	-1	24653743
plasma	O	-1	24653743
concentration	O	-1	24653743
of	O	-1	24653743
p@@	B-Chemical	C042288	24653743
il@@	I-Chemical	-1	24653743
si@@	I-Chemical	-1	24653743
ca@@	I-Chemical	-1	24653743
in@@	I-Chemical	-1	24653743
ide	I-Chemical	-1	24653743
may	O	-1	24653743
have	O	-1	24653743
been	O	-1	24653743
high@@	O	-1	24653743
,	O	-1	24653743
which	O	-1	24653743
can	O	-1	24653743
produce	O	-1	24653743
t@@	B-Disease	D016171	24653743
or@@	I-Disease	-1	24653743
sa@@	I-Disease	-1	24653743
des	I-Disease	-1	24653743
de	I-Disease	-1	24653743
po@@	I-Disease	-1	24653743
int@@	I-Disease	-1	24653743
es	I-Disease	-1	24653743
in	O	-1	24653743
the	O	-1	24653743
oc@@	O	-1	24653743
to@@	O	-1	24653743
gen@@	O	-1	24653743
ari@@	O	-1	24653743
an@@	O	-1	24653743
.	O	-1	24653743
Although	O	-1	24653743
the	O	-1	24653743
oral	O	-1	24653743
administration	O	-1	24653743
of	O	-1	24653743
cl@@	O	-1	24653743
as@@	O	-1	24653743
s	O	-1	24653743
I@@	O	-1	24653743
C	O	-1	24653743
drug@@	O	-1	24653743
s,	O	-1	24653743
including	O	-1	24653743
p@@	B-Chemical	C042288	24653743
il@@	I-Chemical	-1	24653743
si@@	I-Chemical	-1	24653743
ca@@	I-Chemical	-1	24653743
in@@	I-Chemical	-1	24653743
ide	I-Chemical	-1	24653743
,	O	-1	24653743
is	O	-1	24653743
effective	O	-1	24653743
to	O	-1	24653743
ter@@	O	-1	24653743
min@@	O	-1	24653743
ate	O	-1	24653743
atrial	B-Disease	D001281	24653743
fibrill@@	I-Disease	-1	24653743
ation	I-Disease	-1	24653743
,	O	-1	24653743
ca@@	O	-1	24653743
ref@@	O	-1	24653743
u@@	O	-1	24653743
l	O	-1	24653743
con@@	O	-1	24653743
si@@	O	-1	24653743
der@@	O	-1	24653743
ation	O	-1	24653743
mus@@	O	-1	24653743
t	O	-1	24653743
be	O	-1	24653743
tak@@	O	-1	24653743
en	O	-1	24653743
before	O	-1	24653743
gi@@	O	-1	24653743
ving	O	-1	24653743
these	O	-1	24653743
drugs	O	-1	24653743
to	O	-1	24653743
oc@@	O	-1	24653743
to@@	O	-1	24653743
gen@@	O	-1	24653743
ari@@	O	-1	24653743
an@@	O	-1	24653743
s.	O	-1	24653743

A@@	B-Chemical	D014212	24658375
ll@@	I-Chemical	-1	24658375
-@@	I-Chemical	-1	24658375
tran@@	I-Chemical	-1	24658375
s	I-Chemical	-1	24658375
ret@@	I-Chemical	-1	24658375
ino@@	I-Chemical	-1	24658375
ic	I-Chemical	-1	24658375
acid	I-Chemical	-1	24658375
-induced	O	-1	24658375
inflam@@	O	-1	24658375
mat@@	O	-1	24658375
ory	O	-1	24658375
my@@	B-Disease	D009220	24658375
o@@	I-Disease	-1	24658375
si@@	I-Disease	-1	24658375
tis	I-Disease	-1	24658375
in	O	-1	24658375
a	O	-1	24658375
patient	O	-1	24658375
with	O	-1	24658375
acute	B-Disease	D015473	24658375
pro@@	I-Disease	-1	24658375
my@@	I-Disease	-1	24658375
e@@	I-Disease	-1	24658375
lo@@	I-Disease	-1	24658375
cy@@	I-Disease	-1	24658375
tic	I-Disease	-1	24658375
leuk@@	I-Disease	-1	24658375
emia	I-Disease	-1	24658375
.	O	-1	24658375
A@@	B-Chemical	D014212	24658375
ll@@	I-Chemical	-1	24658375
-@@	I-Chemical	-1	24658375
tran@@	I-Chemical	-1	24658375
s	I-Chemical	-1	24658375
ret@@	I-Chemical	-1	24658375
ino@@	I-Chemical	-1	24658375
ic	I-Chemical	-1	24658375
acid	I-Chemical	-1	24658375
(	O	-1	24658375
AT@@	B-Chemical	D014212	24658375
R@@	I-Chemical	-1	24658375
A	I-Chemical	-1	24658375
),	O	-1	24658375
a	O	-1	24658375
comp@@	O	-1	24658375
on@@	O	-1	24658375
ent	O	-1	24658375
of	O	-1	24658375
standard	O	-1	24658375
therapy	O	-1	24658375
for	O	-1	24658375
acute	B-Disease	D015473	24658375
pro@@	I-Disease	-1	24658375
my@@	I-Disease	-1	24658375
e@@	I-Disease	-1	24658375
lo@@	I-Disease	-1	24658375
cy@@	I-Disease	-1	24658375
tic	I-Disease	-1	24658375
leuk@@	I-Disease	-1	24658375
emia	I-Disease	-1	24658375
(	O	-1	24658375
A@@	B-Disease	D015473	24658375
P@@	I-Disease	-1	24658375
L	I-Disease	-1	24658375
),	O	-1	24658375
is	O	-1	24658375
associated	O	-1	24658375
with	O	-1	24658375
potenti@@	O	-1	24658375
ally	O	-1	24658375
seri@@	O	-1	24658375
ous	O	-1	24658375
but	O	-1	24658375
treat@@	O	-1	24658375
able	O	-1	24658375
adverse	O	-1	24658375
effects	O	-1	24658375
invol@@	O	-1	24658375
ving	O	-1	24658375
n@@	O	-1	24658375
um@@	O	-1	24658375
er@@	O	-1	24658375
ous	O	-1	24658375
org@@	O	-1	24658375
an	O	-1	24658375
system@@	O	-1	24658375
s,	O	-1	24658375
including	O	-1	24658375
r@@	O	-1	24658375
are	O	-1	24658375
s@@	O	-1	24658375
ke@@	O	-1	24658375
le@@	O	-1	24658375
t@@	O	-1	24658375
al	O	-1	24658375
musc@@	O	-1	24658375
le	O	-1	24658375
invol@@	O	-1	24658375
ve@@	O	-1	24658375
ment.	O	-1	24658375
On@@	O	-1	24658375
ly	O	-1	24658375
a	O	-1	24658375
h@@	O	-1	24658375
and@@	O	-1	24658375
ful	O	-1	24658375
of	O	-1	24658375
cases	O	-1	24658375
of	O	-1	24658375
AT@@	B-Chemical	D014212	24658375
R@@	I-Chemical	-1	24658375
A	I-Chemical	-1	24658375
-induced	O	-1	24658375
my@@	B-Disease	D009220	24658375
o@@	I-Disease	-1	24658375
si@@	I-Disease	-1	24658375
tis	I-Disease	-1	24658375
in	O	-1	24658375
children	O	-1	24658375
have	O	-1	24658375
been	O	-1	24658375
repor@@	O	-1	24658375
te@@	O	-1	24658375
d,	O	-1	24658375
and	O	-1	24658375
n@@	O	-1	24658375
one	O	-1	24658375
in	O	-1	24658375
the	O	-1	24658375
radi@@	O	-1	24658375
ology	O	-1	24658375
literat@@	O	-1	24658375
ure.	O	-1	24658375
We	O	-1	24658375
present	O	-1	24658375
such	O	-1	24658375
a	O	-1	24658375
case	O	-1	24658375
in	O	-1	24658375
a	O	-1	24658375
1@@	O	-1	24658375
5-@@	O	-1	24658375
year-old	O	-1	24658375
bo@@	O	-1	24658375
y	O	-1	24658375
with	O	-1	24658375
A@@	B-Disease	D015473	24658375
P@@	I-Disease	-1	24658375
L	I-Disease	-1	24658375
,	O	-1	24658375
wh@@	O	-1	24658375
ere	O	-1	24658375
reco@@	O	-1	24658375
gn@@	O	-1	24658375
ition	O	-1	24658375
of	O	-1	24658375
imaging	O	-1	24658375
findings	O	-1	24658375
pl@@	O	-1	24658375
ayed	O	-1	24658375
a	O	-1	24658375
c@@	O	-1	24658375
r@@	O	-1	24658375
uc@@	O	-1	24658375
ial	O	-1	24658375
role	O	-1	24658375
in	O	-1	24658375
ma@@	O	-1	24658375
king	O	-1	24658375
the	O	-1	24658375
diagnosis	O	-1	24658375
and	O	-1	24658375
fac@@	O	-1	24658375
il@@	O	-1	24658375
it@@	O	-1	24658375
ated	O	-1	24658375
pro@@	O	-1	24658375
m@@	O	-1	24658375
pt@@	O	-1	24658375
,	O	-1	24658375
effective	O	-1	24658375
treatment.	O	-1	24658375

T@@	O	-1	24659727
oler@@	O	-1	24659727
ability	O	-1	24659727
of	O	-1	24659727
lo@@	B-Chemical	D008130	24659727
m@@	I-Chemical	-1	24659727
ust@@	I-Chemical	-1	24659727
ine	I-Chemical	-1	24659727
in	O	-1	24659727
combination	O	-1	24659727
with	O	-1	24659727
cyclophosph@@	B-Chemical	D003520	24659727
amide	I-Chemical	-1	24659727
in	O	-1	24659727
dog@@	O	-1	24659727
s	O	-1	24659727
with	O	-1	24659727
lymph@@	B-Disease	D008223	24659727
oma	I-Disease	-1	24659727
.	O	-1	24659727
This	O	-1	24659727
ret@@	O	-1	24659727
ro@@	O	-1	24659727
sp@@	O	-1	24659727
ective	O	-1	24659727
study	O	-1	24659727
descri@@	O	-1	24659727
b@@	O	-1	24659727
es	O	-1	24659727
toxicity	B-Disease	D064420	24659727
associated	O	-1	24659727
with	O	-1	24659727
a	O	-1	24659727
pro@@	O	-1	24659727
to@@	O	-1	24659727
co@@	O	-1	24659727
l	O	-1	24659727
of	O	-1	24659727
lo@@	B-Chemical	D008130	24659727
m@@	I-Chemical	-1	24659727
ust@@	I-Chemical	-1	24659727
ine	I-Chemical	-1	24659727
(	O	-1	24659727
C@@	B-Chemical	D008130	24659727
C@@	I-Chemical	-1	24659727
N@@	I-Chemical	-1	24659727
U	I-Chemical	-1	24659727
)	O	-1	24659727
and	O	-1	24659727
cyclophosph@@	B-Chemical	D003520	24659727
amide	I-Chemical	-1	24659727
(	O	-1	24659727
C@@	B-Chemical	D003520	24659727
T@@	I-Chemical	-1	24659727
X	I-Chemical	-1	24659727
)	O	-1	24659727
in	O	-1	24659727
dog@@	O	-1	24659727
s	O	-1	24659727
with	O	-1	24659727
lymph@@	B-Disease	D008223	24659727
oma	I-Disease	-1	24659727
.	O	-1	24659727
C@@	B-Chemical	D008130	24659727
C@@	I-Chemical	-1	24659727
N@@	I-Chemical	-1	24659727
U	I-Chemical	-1	24659727
was	O	-1	24659727
administered	O	-1	24659727
per	O	-1	24659727
o@@	O	-1	24659727
s	O	-1	24659727
(P@@	O	-1	24659727
O@@	O	-1	24659727
)	O	-1	24659727
at	O	-1	24659727
a	O	-1	24659727
t@@	O	-1	24659727
arg@@	O	-1	24659727
et@@	O	-1	24659727
ed	O	-1	24659727
dos@@	O	-1	24659727
age	O	-1	24659727
of	O	-1	24659727
60	O	-1	24659727
mg/m@@	O	-1	24659727
(2@@	O	-1	24659727
)	O	-1	24659727
body	O	-1	24659727
sur@@	O	-1	24659727
fac@@	O	-1	24659727
e	O	-1	24659727
a@@	O	-1	24659727
re@@	O	-1	24659727
a	O	-1	24659727
on	O	-1	24659727
day	O	-1	24659727
0@@	O	-1	24659727
,	O	-1	24659727
C@@	B-Chemical	D003520	24659727
T@@	I-Chemical	-1	24659727
X	I-Chemical	-1	24659727
was	O	-1	24659727
administered	O	-1	24659727
P@@	O	-1	24659727
O	O	-1	24659727
at	O	-1	24659727
a	O	-1	24659727
t@@	O	-1	24659727
arg@@	O	-1	24659727
et@@	O	-1	24659727
ed	O	-1	24659727
dos@@	O	-1	24659727
age	O	-1	24659727
of	O	-1	24659727
2@@	O	-1	24659727
50	O	-1	24659727
mg/m@@	O	-1	24659727
(2@@	O	-1	24659727
)	O	-1	24659727
divid@@	O	-1	24659727
ed	O	-1	24659727
over	O	-1	24659727
days	O	-1	24659727
0	O	-1	24659727
through	O	-1	24659727
4@@	O	-1	24659727
,	O	-1	24659727
and	O	-1	24659727
all	O	-1	24659727
dog@@	O	-1	24659727
s	O	-1	24659727
received	O	-1	24659727
pro@@	O	-1	24659727
phyl@@	O	-1	24659727
ac@@	O	-1	24659727
tic	O	-1	24659727
anti@@	O	-1	24659727
bio@@	O	-1	24659727
tic@@	O	-1	24659727
s.	O	-1	24659727
N@@	O	-1	24659727
ine@@	O	-1	24659727
t@@	O	-1	24659727
y	O	-1	24659727
treat@@	O	-1	24659727
ments	O	-1	24659727
were	O	-1	24659727
given	O	-1	24659727
to	O	-1	24659727
the	O	-1	24659727
5@@	O	-1	24659727
7	O	-1	24659727
dog@@	O	-1	24659727
s	O	-1	24659727
included	O	-1	24659727
in	O	-1	24659727
the	O	-1	24659727
study.	O	-1	24659727
Ne@@	B-Disease	D009503	24659727
ut@@	I-Disease	-1	24659727
ro@@	I-Disease	-1	24659727
pen@@	I-Disease	-1	24659727
ia	I-Disease	-1	24659727
was	O	-1	24659727
the	O	-1	24659727
pr@@	O	-1	24659727
inc@@	O	-1	24659727
ip@@	O	-1	24659727
al	O	-1	24659727
toxic	O	-1	24659727
effect@@	O	-1	24659727
,	O	-1	24659727
and	O	-1	24659727
the	O	-1	24659727
over@@	O	-1	24659727
all	O	-1	24659727
frequency	O	-1	24659727
of	O	-1	24659727
gra@@	O	-1	24659727
de	O	-1	24659727
4	O	-1	24659727
ne@@	B-Disease	D009503	24659727
ut@@	I-Disease	-1	24659727
ro@@	I-Disease	-1	24659727
pen@@	I-Disease	-1	24659727
ia	I-Disease	-1	24659727
after	O	-1	24659727
the	O	-1	24659727
first	O	-1	24659727
treatment	O	-1	24659727
of	O	-1	24659727
C@@	B-Chemical	D008130	24659727
C@@	I-Chemical	-1	24659727
N@@	I-Chemical	-1	24659727
U	I-Chemical	-1	24659727
/	O	-1	24659727
C@@	B-Chemical	D003520	24659727
T@@	I-Chemical	-1	24659727
X	I-Chemical	-1	24659727
was	O	-1	24659727
3@@	O	-1	24659727
0%	O	-1	24659727
(@@	O	-1	24659727
95%	O	-1	24659727
conf@@	O	-1	24659727
idence	O	-1	24659727
inter@@	O	-1	24659727
val@@	O	-1	24659727
,	O	-1	24659727
19@@	O	-1	24659727
-@@	O	-1	24659727
4@@	O	-1	24659727
3@@	O	-1	24659727
%).	O	-1	24659727
The	O	-1	24659727
mean	O	-1	24659727
body	O	-1	24659727
weight	O	-1	24659727
of	O	-1	24659727
dog@@	O	-1	24659727
s	O	-1	24659727
with	O	-1	24659727
gra@@	O	-1	24659727
de	O	-1	24659727
4	O	-1	24659727
ne@@	B-Disease	D009503	24659727
ut@@	I-Disease	-1	24659727
ro@@	I-Disease	-1	24659727
pen@@	I-Disease	-1	24659727
ia	I-Disease	-1	24659727
(1@@	O	-1	24659727
9.@@	O	-1	24659727
7	O	-1	24659727
k@@	O	-1	24659727
g	O	-1	24659727
+	O	-1	24659727
1@@	O	-1	24659727
3.@@	O	-1	24659727
4	O	-1	24659727
kg@@	O	-1	24659727
)	O	-1	24659727
was	O	-1	24659727
significantly	O	-1	24659727
less	O	-1	24659727
than	O	-1	24659727
the	O	-1	24659727
mean	O	-1	24659727
body	O	-1	24659727
weight	O	-1	24659727
of	O	-1	24659727
dog@@	O	-1	24659727
s	O	-1	24659727
that	O	-1	24659727
did	O	-1	24659727
not	O	-1	24659727
deve@@	O	-1	24659727
lo@@	O	-1	24659727
p	O	-1	24659727
gra@@	O	-1	24659727
de	O	-1	24659727
4	O	-1	24659727
ne@@	B-Disease	D009503	24659727
ut@@	I-Disease	-1	24659727
ro@@	I-Disease	-1	24659727
pen@@	I-Disease	-1	24659727
ia	I-Disease	-1	24659727
(3@@	O	-1	24659727
1.@@	O	-1	24659727
7	O	-1	24659727
k@@	O	-1	24659727
g	O	-1	24659727
+	O	-1	24659727
1@@	O	-1	24659727
2.@@	O	-1	24659727
4	O	-1	24659727
kg@@	O	-1	24659727
;	O	-1	24659727
P	O	-1	24659727
=	O	-1	24659727
.@@	O	-1	24659727
0@@	O	-1	24659727
0@@	O	-1	24659727
5@@	O	-1	24659727
).	O	-1	24659727
One	O	-1	24659727
do@@	O	-1	24659727
g	O	-1	24659727
(3@@	O	-1	24659727
%)	O	-1	24659727
developed	O	-1	24659727
hemat@@	O	-1	24659727
ologic	O	-1	24659727
changes	O	-1	24659727
sugg@@	O	-1	24659727
es@@	O	-1	24659727
tive	O	-1	24659727
of	O	-1	24659727
hepat@@	B-Disease	D056486	24659727
otoxicity	I-Disease	-1	24659727
.	O	-1	24659727
No	O	-1	24659727
dog@@	O	-1	24659727
s	O	-1	24659727
had	O	-1	24659727
evidence	O	-1	24659727
of	O	-1	24659727
either	O	-1	24659727
renal	B-Disease	D007674	24659727
toxicity	I-Disease	-1	24659727
or	O	-1	24659727
hemorrh@@	B-Disease	D006470	24659727
ag@@	I-Disease	-1	24659727
ic	I-Disease	-1	24659727
cys@@	I-Disease	-1	24659727
ti@@	I-Disease	-1	24659727
tis	I-Disease	-1	24659727
hemorrh@@	B-Disease	D003556	24659727
ag@@	I-Disease	-1	24659727
ic	I-Disease	-1	24659727
cys@@	I-Disease	-1	24659727
ti@@	I-Disease	-1	24659727
tis	I-Disease	-1	24659727
.	O	-1	24659727
Ad@@	O	-1	24659727
verse	O	-1	24659727
gast@@	O	-1	24659727
ro@@	O	-1	24659727
in@@	O	-1	24659727
test@@	O	-1	24659727
inal	O	-1	24659727
effects	O	-1	24659727
were	O	-1	24659727
un@@	O	-1	24659727
common@@	O	-1	24659727
.	O	-1	24659727
O@@	O	-1	24659727
n	O	-1	24659727
the	O	-1	24659727
b@@	O	-1	24659727
asis	O	-1	24659727
of	O	-1	24659727
the	O	-1	24659727
findings	O	-1	24659727
reported	O	-1	24659727
he@@	O	-1	24659727
re@@	O	-1	24659727
in,	O	-1	24659727
a	O	-1	24659727
dose	O	-1	24659727
of	O	-1	24659727
60	O	-1	24659727
mg/m@@	O	-1	24659727
(2@@	O	-1	24659727
)	O	-1	24659727
of	O	-1	24659727
C@@	B-Chemical	D008130	24659727
C@@	I-Chemical	-1	24659727
N@@	I-Chemical	-1	24659727
U	I-Chemical	-1	24659727
combined	O	-1	24659727
with	O	-1	24659727
2@@	O	-1	24659727
50	O	-1	24659727
mg/m@@	O	-1	24659727
(2@@	O	-1	24659727
)	O	-1	24659727
of	O	-1	24659727
C@@	B-Chemical	D003520	24659727
T@@	I-Chemical	-1	24659727
X	I-Chemical	-1	24659727
(@@	O	-1	24659727
divid@@	O	-1	24659727
ed	O	-1	24659727
over	O	-1	24659727
5	O	-1	24659727
da@@	O	-1	24659727
ys@@	O	-1	24659727
)	O	-1	24659727
q	O	-1	24659727
4	O	-1	24659727
w@@	O	-1	24659727
k	O	-1	24659727
is	O	-1	24659727
toler@@	O	-1	24659727
able	O	-1	24659727
in	O	-1	24659727
tumor	B-Disease	D009369	24659727
-@@	O	-1	24659727
be@@	O	-1	24659727
ar@@	O	-1	24659727
ing	O	-1	24659727
dog@@	O	-1	24659727
s.	O	-1	24659727

N@@	B-Chemical	C104457	24664478
el@@	I-Chemical	-1	24664478
ar@@	I-Chemical	-1	24664478
ab@@	I-Chemical	-1	24664478
ine	I-Chemical	-1	24664478
neuro@@	B-Disease	D020258	24664478
toxicity	I-Disease	-1	24664478
with	O	-1	24664478
con@@	O	-1	24664478
current	O	-1	24664478
intra@@	O	-1	24664478
th@@	O	-1	24664478
ec@@	O	-1	24664478
al	O	-1	24664478
chemo@@	O	-1	24664478
therap@@	O	-1	24664478
y@@	O	-1	24664478
:	O	-1	24664478
C@@	O	-1	24664478
ase	O	-1	24664478
report	O	-1	24664478
and	O	-1	24664478
revie@@	O	-1	24664478
w	O	-1	24664478
of	O	-1	24664478
literat@@	O	-1	24664478
ure.	O	-1	24664478
S@@	O	-1	24664478
ev@@	O	-1	24664478
ere	O	-1	24664478
ne@@	B-Chemical	C104457	24664478
l@@	I-Chemical	-1	24664478
ar@@	I-Chemical	-1	24664478
ab@@	I-Chemical	-1	24664478
ine	I-Chemical	-1	24664478
neuro@@	B-Disease	D020258	24664478
toxicity	I-Disease	-1	24664478
in	O	-1	24664478
a	O	-1	24664478
patient	O	-1	24664478
who	O	-1	24664478
received	O	-1	24664478
con@@	O	-1	24664478
current	O	-1	24664478
intra@@	O	-1	24664478
th@@	O	-1	24664478
ec@@	O	-1	24664478
al	O	-1	24664478
(@@	O	-1	24664478
I@@	O	-1	24664478
T)	O	-1	24664478
chemotherapy	O	-1	24664478
is	O	-1	24664478
repor@@	O	-1	24664478
ted.	O	-1	24664478
A	O	-1	24664478
3@@	O	-1	24664478
7-@@	O	-1	24664478
year-old	O	-1	24664478
Ca@@	O	-1	24664478
uc@@	O	-1	24664478
a@@	O	-1	24664478
si@@	O	-1	24664478
an	O	-1	24664478
woman	O	-1	24664478
with	O	-1	24664478
a	O	-1	24664478
hist@@	O	-1	24664478
ory	O	-1	24664478
of	O	-1	24664478
T@@	B-Disease	D054218	24664478
-@@	I-Disease	-1	24664478
cell	I-Disease	-1	24664478
lymph@@	I-Disease	-1	24664478
ob@@	I-Disease	-1	24664478
las@@	I-Disease	-1	24664478
tic	I-Disease	-1	24664478
lymph@@	I-Disease	-1	24664478
oma	I-Disease	-1	24664478
was	O	-1	24664478
ad@@	O	-1	24664478
mit@@	O	-1	24664478
ted	O	-1	24664478
for	O	-1	24664478
rel@@	O	-1	24664478
ap@@	O	-1	24664478
sed	O	-1	24664478
disease.	O	-1	24664478
S@@	O	-1	24664478
he	O	-1	24664478
was	O	-1	24664478
or@@	O	-1	24664478
ig@@	O	-1	24664478
in@@	O	-1	24664478
ally	O	-1	24664478
treated	O	-1	24664478
with	O	-1	24664478
induction	O	-1	24664478
chemotherapy	O	-1	24664478
followed	O	-1	24664478
by	O	-1	24664478
an	O	-1	24664478
auto@@	O	-1	24664478
log@@	O	-1	24664478
ous	O	-1	24664478
transplant@@	O	-1	24664478
.	O	-1	24664478
S@@	O	-1	24664478
he	O	-1	24664478
developed	O	-1	24664478
rel@@	O	-1	24664478
ap@@	O	-1	24664478
sed	O	-1	24664478
disease	O	-1	24664478
10	O	-1	24664478
months	O	-1	24664478
lat@@	O	-1	24664478
er	O	-1	24664478
with	O	-1	24664478
leuk@@	B-Disease	D007938	24664478
em@@	I-Disease	-1	24664478
ic	I-Disease	-1	24664478
invol@@	O	-1	24664478
ve@@	O	-1	24664478
ment.	O	-1	24664478
S@@	O	-1	24664478
he	O	-1	24664478
was	O	-1	24664478
re@@	O	-1	24664478
-induced	O	-1	24664478
with	O	-1	24664478
ne@@	B-Chemical	C104457	24664478
l@@	I-Chemical	-1	24664478
ar@@	I-Chemical	-1	24664478
ab@@	I-Chemical	-1	24664478
ine	I-Chemical	-1	24664478
1@@	O	-1	24664478
5@@	O	-1	24664478
00	O	-1	24664478
mg/m@@	O	-1	24664478
(2@@	O	-1	24664478
)	O	-1	24664478
on	O	-1	24664478
days	O	-1	24664478
1,	O	-1	24664478
3,	O	-1	24664478
and	O	-1	24664478
5	O	-1	24664478
with	O	-1	24664478
1	O	-1	24664478
dose	O	-1	24664478
of	O	-1	24664478
I@@	O	-1	24664478
T	O	-1	24664478
cy@@	B-Chemical	D003561	24664478
t@@	I-Chemical	-1	24664478
ar@@	I-Chemical	-1	24664478
ab@@	I-Chemical	-1	24664478
ine	I-Chemical	-1	24664478
100	O	-1	24664478
mg	O	-1	24664478
on	O	-1	24664478
day	O	-1	24664478
2	O	-1	24664478
as	O	-1	24664478
central	O	-1	24664478
ner@@	O	-1	24664478
v@@	O	-1	24664478
ous	O	-1	24664478
system	O	-1	24664478
(C@@	O	-1	24664478
N@@	O	-1	24664478
S)	O	-1	24664478
pro@@	O	-1	24664478
phyl@@	O	-1	24664478
ax@@	O	-1	24664478
i@@	O	-1	24664478
s.	O	-1	24664478
A@@	O	-1	24664478
t	O	-1	24664478
the	O	-1	24664478
time	O	-1	24664478
of	O	-1	24664478
treatment,	O	-1	24664478
sh@@	O	-1	24664478
e	O	-1	24664478
was	O	-1	24664478
on	O	-1	24664478
continu@@	O	-1	24664478
ous	O	-1	24664478
renal	O	-1	24664478
re@@	O	-1	24664478
pl@@	O	-1	24664478
ac@@	O	-1	24664478
ement	O	-1	24664478
therapy	O	-1	24664478
due	O	-1	24664478
to	O	-1	24664478
sequ@@	O	-1	24664478
el@@	O	-1	24664478
a@@	O	-1	24664478
e	O	-1	24664478
of	O	-1	24664478
tumor	B-Disease	D015275	24664478
ly@@	I-Disease	-1	24664478
sis	I-Disease	-1	24664478
syndrome	I-Disease	-1	24664478
(	O	-1	24664478
T@@	B-Disease	D015275	24664478
L@@	I-Disease	-1	24664478
S	I-Disease	-1	24664478
).	O	-1	24664478
S@@	O	-1	24664478
he	O	-1	24664478
toler@@	O	-1	24664478
ated	O	-1	24664478
therapy	O	-1	24664478
we@@	O	-1	24664478
ll@@	O	-1	24664478
,	O	-1	24664478
ent@@	O	-1	24664478
ered	O	-1	24664478
a	O	-1	24664478
complete	O	-1	24664478
re@@	O	-1	24664478
mis@@	O	-1	24664478
sion,	O	-1	24664478
and	O	-1	24664478
reco@@	O	-1	24664478
vered	O	-1	24664478
h@@	O	-1	24664478
er	O	-1	24664478
renal	O	-1	24664478
func@@	O	-1	24664478
tion.	O	-1	24664478
S@@	O	-1	24664478
he	O	-1	24664478
received	O	-1	24664478
a	O	-1	24664478
second	O	-1	24664478
cyc@@	O	-1	24664478
le	O	-1	24664478
of	O	-1	24664478
ne@@	B-Chemical	C104457	24664478
l@@	I-Chemical	-1	24664478
ar@@	I-Chemical	-1	24664478
ab@@	I-Chemical	-1	24664478
ine	I-Chemical	-1	24664478
without	O	-1	24664478
addi@@	O	-1	24664478
tional	O	-1	24664478
I@@	O	-1	24664478
T	O	-1	24664478
pro@@	O	-1	24664478
phyl@@	O	-1	24664478
ax@@	O	-1	24664478
is	O	-1	24664478
one	O	-1	24664478
mon@@	O	-1	24664478
th	O	-1	24664478
lat@@	O	-1	24664478
er.	O	-1	24664478
A	O	-1	24664478
week	O	-1	24664478
after	O	-1	24664478
this	O	-1	24664478
second	O	-1	24664478
cyc@@	O	-1	24664478
le@@	O	-1	24664478
,	O	-1	24664478
sh@@	O	-1	24664478
e	O	-1	24664478
not@@	O	-1	24664478
ed	O	-1	24664478
numb@@	O	-1	24664478
ness	O	-1	24664478
in	O	-1	24664478
h@@	O	-1	24664478
er	O	-1	24664478
lower	O	-1	24664478
ex@@	O	-1	24664478
trem@@	O	-1	24664478
iti@@	O	-1	24664478
es.	O	-1	24664478
Pre@@	O	-1	24664478
domin@@	O	-1	24664478
ant@@	O	-1	24664478
ly	O	-1	24664478
sens@@	O	-1	24664478
or@@	O	-1	24664478
y,	O	-1	24664478
though	O	-1	24664478
also	O	-1	24664478
motor	O	-1	24664478
and	O	-1	24664478
a@@	O	-1	24664478
ut@@	O	-1	24664478
on@@	O	-1	24664478
om@@	O	-1	24664478
ic@@	O	-1	24664478
,	O	-1	24664478
peripheral	B-Disease	D010523	24664478
neuropathy	I-Disease	-1	24664478
star@@	O	-1	24664478
ted	O	-1	24664478
in	O	-1	24664478
h@@	O	-1	24664478
er	O	-1	24664478
fe@@	O	-1	24664478
et@@	O	-1	24664478
,	O	-1	24664478
as@@	O	-1	24664478
c@@	O	-1	24664478
en@@	O	-1	24664478
ded	O	-1	24664478
pro@@	O	-1	24664478
xim@@	O	-1	24664478
ally	O	-1	24664478
to	O	-1	24664478
the	O	-1	24664478
mid@@	O	-1	24664478
-@@	O	-1	24664478
th@@	O	-1	24664478
or@@	O	-1	24664478
ac@@	O	-1	24664478
ic	O	-1	24664478
regi@@	O	-1	24664478
on@@	O	-1	24664478
,	O	-1	24664478
and	O	-1	24664478
event@@	O	-1	24664478
ually	O	-1	24664478
included	O	-1	24664478
h@@	O	-1	24664478
er	O	-1	24664478
dist@@	O	-1	24664478
al	O	-1	24664478
up@@	O	-1	24664478
per	O	-1	24664478
ex@@	O	-1	24664478
trem@@	O	-1	24664478
iti@@	O	-1	24664478
es.	O	-1	24664478
A	O	-1	24664478
mag@@	O	-1	24664478
ne@@	O	-1	24664478
tic	O	-1	24664478
res@@	O	-1	24664478
on@@	O	-1	24664478
ance	O	-1	24664478
imaging	O	-1	24664478
(@@	O	-1	24664478
MR@@	O	-1	24664478
I@@	O	-1	24664478
)	O	-1	24664478
of	O	-1	24664478
h@@	O	-1	24664478
er	O	-1	24664478
sp@@	O	-1	24664478
ine	O	-1	24664478
demonstrated	O	-1	24664478
changes	O	-1	24664478
from	O	-1	24664478
C@@	O	-1	24664478
2	O	-1	24664478
to	O	-1	24664478
C@@	O	-1	24664478
6	O	-1	24664478
consist@@	O	-1	24664478
ent	O	-1	24664478
with	O	-1	24664478
sub@@	O	-1	24664478
acute	O	-1	24664478
combined	O	-1	24664478
de@@	O	-1	24664478
gener@@	O	-1	24664478
ation.	O	-1	24664478
N@@	B-Chemical	C104457	24664478
el@@	I-Chemical	-1	24664478
ar@@	I-Chemical	-1	24664478
ab@@	I-Chemical	-1	24664478
ine	I-Chemical	-1	24664478
was	O	-1	24664478
f@@	O	-1	24664478
el@@	O	-1	24664478
t	O	-1	24664478
to	O	-1	24664478
be	O	-1	24664478
the	O	-1	24664478
cause	O	-1	24664478
of	O	-1	24664478
h@@	O	-1	24664478
er	O	-1	24664478
symptom@@	O	-1	24664478
s.	O	-1	24664478
H@@	O	-1	24664478
er	O	-1	24664478
neuropathy	B-Disease	D009422	24664478
st@@	O	-1	24664478
abil@@	O	-1	24664478
ized	O	-1	24664478
and	O	-1	24664478
showed	O	-1	24664478
s@@	O	-1	24664478
li@@	O	-1	24664478
ght	O	-1	24664478
impro@@	O	-1	24664478
vement	O	-1	24664478
and	O	-1	24664478
ul@@	O	-1	24664478
tim@@	O	-1	24664478
ately	O	-1	24664478
received	O	-1	24664478
an	O	-1	24664478
un@@	O	-1	24664478
rel@@	O	-1	24664478
at@@	O	-1	24664478
ed,	O	-1	24664478
reduc@@	O	-1	24664478
ed@@	O	-1	24664478
-@@	O	-1	24664478
int@@	O	-1	24664478
ensity	O	-1	24664478
al@@	O	-1	24664478
log@@	O	-1	24664478
en@@	O	-1	24664478
e@@	O	-1	24664478
ic	O	-1	24664478
transplant	O	-1	24664478
while	O	-1	24664478
in	O	-1	24664478
complete	O	-1	24664478
re@@	O	-1	24664478
mis@@	O	-1	24664478
sion,	O	-1	24664478
but	O	-1	24664478
rel@@	O	-1	24664478
ap@@	O	-1	24664478
sed	O	-1	24664478
disease	O	-1	24664478
10	O	-1	24664478
weeks	O	-1	24664478
lat@@	O	-1	24664478
er.	O	-1	24664478
S@@	O	-1	24664478
he	O	-1	24664478
is	O	-1	24664478
cur@@	O	-1	24664478
ren@@	O	-1	24664478
tly	O	-1	24664478
being	O	-1	24664478
treated	O	-1	24664478
with	O	-1	24664478
b@@	O	-1	24664478
est	O	-1	24664478
suppor@@	O	-1	24664478
tive	O	-1	24664478
ca@@	O	-1	24664478
re.	O	-1	24664478
To	O	-1	24664478
our	O	-1	24664478
know@@	O	-1	24664478
le@@	O	-1	24664478
d@@	O	-1	24664478
g@@	O	-1	24664478
e,	O	-1	24664478
this	O	-1	24664478
is	O	-1	24664478
the	O	-1	24664478
first	O	-1	24664478
pu@@	O	-1	24664478
bl@@	O	-1	24664478
ished	O	-1	24664478
case	O	-1	24664478
report	O	-1	24664478
of	O	-1	24664478
severe	O	-1	24664478
neuro@@	B-Disease	D020258	24664478
toxicity	I-Disease	-1	24664478
caused	O	-1	24664478
by	O	-1	24664478
ne@@	B-Chemical	C104457	24664478
l@@	I-Chemical	-1	24664478
ar@@	I-Chemical	-1	24664478
ab@@	I-Chemical	-1	24664478
ine	I-Chemical	-1	24664478
in	O	-1	24664478
a	O	-1	24664478
patient	O	-1	24664478
who	O	-1	24664478
received	O	-1	24664478
con@@	O	-1	24664478
current	O	-1	24664478
I@@	O	-1	24664478
T	O	-1	24664478
chemo@@	O	-1	24664478
therapy.	O	-1	24664478

V@@	B-Chemical	D014635	24665854
al@@	I-Chemical	-1	24665854
pro@@	I-Chemical	-1	24665854
ate	I-Chemical	-1	24665854
-induced	O	-1	24665854
hyper@@	B-Disease	D022124	24665854
am@@	I-Disease	-1	24665854
mon@@	I-Disease	-1	24665854
em@@	I-Disease	-1	24665854
ic	I-Disease	-1	24665854
encephalo@@	B-Disease	D001927	24665854
pathy	I-Disease	-1	24665854
in	O	-1	24665854
a	O	-1	24665854
renal	O	-1	24665854
transplant@@	O	-1	24665854
ed	O	-1	24665854
patient@@	O	-1	24665854
.	O	-1	24665854
Ne@@	B-Disease	D009422	24665854
uro@@	I-Disease	-1	24665854
log@@	I-Disease	-1	24665854
ical	I-Disease	-1	24665854
complications	I-Disease	-1	24665854
after	O	-1	24665854
renal	O	-1	24665854
transplant@@	O	-1	24665854
ation	O	-1	24665854
con@@	O	-1	24665854
sti@@	O	-1	24665854
t@@	O	-1	24665854
ute	O	-1	24665854
an	O	-1	24665854
important	O	-1	24665854
cause	O	-1	24665854
of	O	-1	24665854
mor@@	O	-1	24665854
b@@	O	-1	24665854
idity	O	-1	24665854
and	O	-1	24665854
mor@@	O	-1	24665854
t@@	O	-1	24665854
al@@	O	-1	24665854
ity.	O	-1	24665854
The@@	O	-1	24665854
ir	O	-1	24665854
differen@@	O	-1	24665854
tial	O	-1	24665854
diagnosis	O	-1	24665854
is	O	-1	24665854
diff@@	O	-1	24665854
ic@@	O	-1	24665854
ult	O	-1	24665854
and	O	-1	24665854
es@@	O	-1	24665854
sen@@	O	-1	24665854
tial	O	-1	24665854
for	O	-1	24665854
subsequ@@	O	-1	24665854
ent	O	-1	24665854
patient@@	O	-1	24665854
's	O	-1	24665854
man@@	O	-1	24665854
ag@@	O	-1	24665854
em@@	O	-1	24665854
ent@@	O	-1	24665854
.	O	-1	24665854
V@@	B-Chemical	D014635	24665854
al@@	I-Chemical	-1	24665854
pro@@	I-Chemical	-1	24665854
ate	I-Chemical	-1	24665854
-induced	O	-1	24665854
hyper@@	B-Disease	D022124	24665854
am@@	I-Disease	-1	24665854
mon@@	I-Disease	-1	24665854
em@@	I-Disease	-1	24665854
ic	I-Disease	-1	24665854
encephalo@@	B-Disease	D001927	24665854
pathy	I-Disease	-1	24665854
is	O	-1	24665854
an	O	-1	24665854
un@@	O	-1	24665854
common	O	-1	24665854
but	O	-1	24665854
seri@@	O	-1	24665854
ous	O	-1	24665854
effect	O	-1	24665854
of	O	-1	24665854
valpro@@	B-Chemical	D014635	24665854
ate	I-Chemical	-1	24665854
treatment.	O	-1	24665854
He@@	O	-1	24665854
re,	O	-1	24665854
we	O	-1	24665854
describe	O	-1	24665854
the	O	-1	24665854
case	O	-1	24665854
of	O	-1	24665854
a	O	-1	24665854
1@@	O	-1	24665854
5-@@	O	-1	24665854
year-old	O	-1	24665854
gi@@	O	-1	24665854
r@@	O	-1	24665854
l	O	-1	24665854
who	O	-1	24665854
was	O	-1	24665854
on	O	-1	24665854
a	O	-1	24665854
long-term	O	-1	24665854
therapy	O	-1	24665854
with	O	-1	24665854
valpro@@	B-Chemical	D014635	24665854
ate	I-Chemical	-1	24665854
due	O	-1	24665854
to	O	-1	24665854
epilep@@	B-Disease	D004827	24665854
sy	I-Disease	-1	24665854
and	O	-1	24665854
revealed	O	-1	24665854
impaired	B-Disease	D003244	24665854
con@@	I-Disease	-1	24665854
s@@	I-Disease	-1	24665854
ci@@	I-Disease	-1	24665854
ous@@	I-Disease	-1	24665854
ness	I-Disease	-1	24665854
with	O	-1	24665854
hyper@@	B-Disease	D022124	24665854
am@@	I-Disease	-1	24665854
mon@@	I-Disease	-1	24665854
emia	I-Disease	-1	24665854
12	O	-1	24665854
days	O	-1	24665854
after	O	-1	24665854
renal	O	-1	24665854
transplant@@	O	-1	24665854
ation.	O	-1	24665854
After	O	-1	24665854
with@@	O	-1	24665854
dra@@	O	-1	24665854
w	O	-1	24665854
of	O	-1	24665854
valpro@@	B-Chemical	D014635	24665854
ate	I-Chemical	-1	24665854
,	O	-1	24665854
patient@@	O	-1	24665854
s@@	O	-1	24665854
'	O	-1	24665854
symptoms	O	-1	24665854
resol@@	O	-1	24665854
ved	O	-1	24665854
within	O	-1	24665854
24	O	-1	24665854
h@@	O	-1	24665854
.	O	-1	24665854
Clin@@	O	-1	24665854
ici@@	O	-1	24665854
ans	O	-1	24665854
should	O	-1	24665854
increase	O	-1	24665854
their	O	-1	24665854
aw@@	O	-1	24665854
a@@	O	-1	24665854
ren@@	O	-1	24665854
ess	O	-1	24665854
for	O	-1	24665854
potential	O	-1	24665854
complication	O	-1	24665854
of	O	-1	24665854
valpro@@	B-Chemical	D014635	24665854
ate	I-Chemical	-1	24665854
,	O	-1	24665854
es@@	O	-1	24665854
p@@	O	-1	24665854
ec@@	O	-1	24665854
i@@	O	-1	24665854
ally	O	-1	24665854
in	O	-1	24665854
transplant@@	O	-1	24665854
ed	O	-1	24665854
patients.	O	-1	24665854

N@@	B-Disease	D019115	24671324
ec@@	I-Disease	-1	24671324
ro@@	I-Disease	-1	24671324
tis@@	I-Disease	-1	24671324
ing	I-Disease	-1	24671324
f@@	I-Disease	-1	24671324
as@@	I-Disease	-1	24671324
ci@@	I-Disease	-1	24671324
iti@@	I-Disease	-1	24671324
s	I-Disease	-1	24671324
after	O	-1	24671324
b@@	B-Chemical	C400082	24671324
or@@	I-Chemical	-1	24671324
te@@	I-Chemical	-1	24671324
z@@	I-Chemical	-1	24671324
om@@	I-Chemical	-1	24671324
i@@	I-Chemical	-1	24671324
b	I-Chemical	-1	24671324
and	O	-1	24671324
de@@	B-Chemical	D003907	24671324
xameth@@	I-Chemical	-1	24671324
as@@	I-Chemical	-1	24671324
one	I-Chemical	-1	24671324
-@@	O	-1	24671324
containing	O	-1	24671324
regi@@	O	-1	24671324
men	O	-1	24671324
in	O	-1	24671324
an	O	-1	24671324
el@@	O	-1	24671324
der@@	O	-1	24671324
ly	O	-1	24671324
patient	O	-1	24671324
of	O	-1	24671324
W@@	B-Disease	D008258	24671324
al@@	I-Disease	-1	24671324
d@@	I-Disease	-1	24671324
en@@	I-Disease	-1	24671324
st@@	I-Disease	-1	24671324
rom	I-Disease	-1	24671324
mac@@	I-Disease	-1	24671324
ro@@	I-Disease	-1	24671324
glo@@	I-Disease	-1	24671324
b@@	I-Disease	-1	24671324
ul@@	I-Disease	-1	24671324
in@@	I-Disease	-1	24671324
a@@	I-Disease	-1	24671324
emia	I-Disease	-1	24671324
.	O	-1	24671324
B@@	B-Chemical	C400082	24671324
or@@	I-Chemical	-1	24671324
te@@	I-Chemical	-1	24671324
z@@	I-Chemical	-1	24671324
om@@	I-Chemical	-1	24671324
i@@	I-Chemical	-1	24671324
b	I-Chemical	-1	24671324
and	O	-1	24671324
high-dose	O	-1	24671324
de@@	B-Chemical	D003907	24671324
xameth@@	I-Chemical	-1	24671324
as@@	I-Chemical	-1	24671324
one	I-Chemical	-1	24671324
-@@	O	-1	24671324
containing	O	-1	24671324
regimen@@	O	-1	24671324
s	O	-1	24671324
are	O	-1	24671324
considered	O	-1	24671324
to	O	-1	24671324
be	O	-1	24671324
gener@@	O	-1	24671324
ally	O	-1	24671324
toler@@	O	-1	24671324
able	O	-1	24671324
with	O	-1	24671324
fe@@	O	-1	24671324
w	O	-1	24671324
severe	O	-1	24671324
bac@@	B-Disease	D001424	24671324
ter@@	I-Disease	-1	24671324
ial	I-Disease	-1	24671324
inf@@	I-Disease	-1	24671324
ec@@	I-Disease	-1	24671324
tions	I-Disease	-1	24671324
in	O	-1	24671324
patients	O	-1	24671324
with	O	-1	24671324
B@@	O	-1	24671324
-@@	O	-1	24671324
cell	O	-1	24671324
mal@@	B-Disease	D009369	24671324
i@@	I-Disease	-1	24671324
gn@@	I-Disease	-1	24671324
an@@	I-Disease	-1	24671324
ci@@	I-Disease	-1	24671324
es	I-Disease	-1	24671324
.	O	-1	24671324
However,	O	-1	24671324
inf@@	O	-1	24671324
orm@@	O	-1	24671324
ation	O	-1	24671324
is	O	-1	24671324
lim@@	O	-1	24671324
ited	O	-1	24671324
con@@	O	-1	24671324
cer@@	O	-1	24671324
ning	O	-1	24671324
the	O	-1	24671324
safety	O	-1	24671324
of	O	-1	24671324
the	O	-1	24671324
regi@@	O	-1	24671324
men	O	-1	24671324
in	O	-1	24671324
el@@	O	-1	24671324
der@@	O	-1	24671324
ly	O	-1	24671324
patients.	O	-1	24671324
We	O	-1	24671324
report	O	-1	24671324
a	O	-1	24671324
case	O	-1	24671324
of	O	-1	24671324
a	O	-1	24671324
7@@	O	-1	24671324
6-@@	O	-1	24671324
year-old	O	-1	24671324
man	O	-1	24671324
with	O	-1	24671324
W@@	B-Disease	D008258	24671324
al@@	I-Disease	-1	24671324
d@@	I-Disease	-1	24671324
en@@	I-Disease	-1	24671324
st@@	I-Disease	-1	24671324
rom	I-Disease	-1	24671324
mac@@	I-Disease	-1	24671324
ro@@	I-Disease	-1	24671324
glo@@	I-Disease	-1	24671324
b@@	I-Disease	-1	24671324
ul@@	I-Disease	-1	24671324
in@@	I-Disease	-1	24671324
a@@	I-Disease	-1	24671324
emia	I-Disease	-1	24671324
who	O	-1	24671324
su@@	O	-1	24671324
ffe@@	O	-1	24671324
red	O	-1	24671324
necro@@	B-Disease	D019115	24671324
tis@@	I-Disease	-1	24671324
ing	I-Disease	-1	24671324
f@@	I-Disease	-1	24671324
as@@	I-Disease	-1	24671324
ci@@	I-Disease	-1	24671324
iti@@	I-Disease	-1	24671324
s	I-Disease	-1	24671324
without	O	-1	24671324
ne@@	B-Disease	D009503	24671324
ut@@	I-Disease	-1	24671324
ro@@	I-Disease	-1	24671324
pen@@	I-Disease	-1	24671324
ia	I-Disease	-1	24671324
after	O	-1	24671324
the	O	-1	24671324
combination	O	-1	24671324
treatment	O	-1	24671324
with	O	-1	24671324
b@@	B-Chemical	C400082	24671324
or@@	I-Chemical	-1	24671324
te@@	I-Chemical	-1	24671324
z@@	I-Chemical	-1	24671324
om@@	I-Chemical	-1	24671324
i@@	I-Chemical	-1	24671324
b	I-Chemical	-1	24671324
,	O	-1	24671324
high-dose	O	-1	24671324
de@@	B-Chemical	D003907	24671324
xameth@@	I-Chemical	-1	24671324
as@@	I-Chemical	-1	24671324
one	I-Chemical	-1	24671324
and	O	-1	24671324
rit@@	O	-1	24671324
u@@	O	-1	24671324
xim@@	O	-1	24671324
ab@@	O	-1	24671324
.	O	-1	24671324
D@@	O	-1	24671324
es@@	O	-1	24671324
pit@@	O	-1	24671324
e	O	-1	24671324
immedi@@	O	-1	24671324
ate	O	-1	24671324
intravenous	O	-1	24671324
anti@@	O	-1	24671324
micro@@	O	-1	24671324
b@@	O	-1	24671324
ial	O	-1	24671324
therapy,	O	-1	24671324
he	O	-1	24671324
suc@@	O	-1	24671324
cum@@	O	-1	24671324
bed	O	-1	24671324
2@@	O	-1	24671324
3	O	-1	24671324
h	O	-1	24671324
after	O	-1	24671324
the	O	-1	24671324
on@@	O	-1	24671324
se@@	O	-1	24671324
t.	O	-1	24671324
P@@	O	-1	24671324
hy@@	O	-1	24671324
si@@	O	-1	24671324
ci@@	O	-1	24671324
ans	O	-1	24671324
should	O	-1	24671324
reco@@	O	-1	24671324
gn@@	O	-1	24671324
is@@	O	-1	24671324
e	O	-1	24671324
the	O	-1	24671324
possib@@	O	-1	24671324
ility	O	-1	24671324
of	O	-1	24671324
f@@	O	-1	24671324
atal	O	-1	24671324
bac@@	B-Disease	D001424	24671324
ter@@	I-Disease	-1	24671324
ial	I-Disease	-1	24671324
inf@@	I-Disease	-1	24671324
ec@@	I-Disease	-1	24671324
tions	I-Disease	-1	24671324
related	O	-1	24671324
to	O	-1	24671324
b@@	B-Chemical	C400082	24671324
or@@	I-Chemical	-1	24671324
te@@	I-Chemical	-1	24671324
z@@	I-Chemical	-1	24671324
om@@	I-Chemical	-1	24671324
i@@	I-Chemical	-1	24671324
b	I-Chemical	-1	24671324
plus	O	-1	24671324
high-dose	O	-1	24671324
de@@	B-Chemical	D003907	24671324
xameth@@	I-Chemical	-1	24671324
as@@	I-Chemical	-1	24671324
one	I-Chemical	-1	24671324
in	O	-1	24671324
el@@	O	-1	24671324
der@@	O	-1	24671324
ly	O	-1	24671324
patients,	O	-1	24671324
and	O	-1	24671324
we	O	-1	24671324
be@@	O	-1	24671324
li@@	O	-1	24671324
e@@	O	-1	24671324
ve	O	-1	24671324
this	O	-1	24671324
case	O	-1	24671324
war@@	O	-1	24671324
ran@@	O	-1	24671324
ts	O	-1	24671324
further	O	-1	24671324
investig@@	O	-1	24671324
ation.	O	-1	24671324

An	O	-1	24675088
in@@	O	-1	24675088
te@@	O	-1	24675088
g@@	O	-1	24675088
r@@	O	-1	24675088
ated	O	-1	24675088
character@@	O	-1	24675088
ization	O	-1	24675088
of	O	-1	24675088
ser@@	O	-1	24675088
olog@@	O	-1	24675088
ic@@	O	-1	24675088
al,	O	-1	24675088
path@@	O	-1	24675088
olog@@	O	-1	24675088
ic@@	O	-1	24675088
al,	O	-1	24675088
and	O	-1	24675088
functional	O	-1	24675088
events	O	-1	24675088
in	O	-1	24675088
dox@@	B-Chemical	D004317	24675088
orub@@	I-Chemical	-1	24675088
icin	I-Chemical	-1	24675088
-induced	O	-1	24675088
cardi@@	B-Disease	D066126	24675088
otoxicity	I-Disease	-1	24675088
.	O	-1	24675088
M@@	O	-1	24675088
any	O	-1	24675088
efficac@@	O	-1	24675088
i@@	O	-1	24675088
ous	O	-1	24675088
cancer	B-Disease	D009369	24675088
treat@@	O	-1	24675088
ments	O	-1	24675088
cause	O	-1	24675088
significant	O	-1	24675088
cardiac	O	-1	24675088
mor@@	O	-1	24675088
b@@	O	-1	24675088
id@@	O	-1	24675088
ity,	O	-1	24675088
y@@	O	-1	24675088
et	O	-1	24675088
b@@	O	-1	24675088
i@@	O	-1	24675088
om@@	O	-1	24675088
ark@@	O	-1	24675088
ers	O	-1	24675088
or	O	-1	24675088
functional	O	-1	24675088
indic@@	O	-1	24675088
es	O	-1	24675088
of	O	-1	24675088
early	O	-1	24675088
dam@@	O	-1	24675088
age,	O	-1	24675088
which	O	-1	24675088
wo@@	O	-1	24675088
uld	O	-1	24675088
al@@	O	-1	24675088
low	O	-1	24675088
monit@@	O	-1	24675088
or@@	O	-1	24675088
ing	O	-1	24675088
and	O	-1	24675088
inter@@	O	-1	24675088
ven@@	O	-1	24675088
tion,	O	-1	24675088
are	O	-1	24675088
l@@	O	-1	24675088
ac@@	O	-1	24675088
k@@	O	-1	24675088
ing.	O	-1	24675088
In	O	-1	24675088
this	O	-1	24675088
study,	O	-1	24675088
we	O	-1	24675088
have	O	-1	24675088
u@@	O	-1	24675088
ti@@	O	-1	24675088
li@@	O	-1	24675088
zed	O	-1	24675088
a	O	-1	24675088
rat	O	-1	24675088
model	O	-1	24675088
of	O	-1	24675088
progressive	O	-1	24675088
dox@@	B-Chemical	D004317	24675088
orub@@	I-Chemical	-1	24675088
icin	I-Chemical	-1	24675088
(	O	-1	24675088
DO@@	B-Chemical	D004317	24675088
X	I-Chemical	-1	24675088
)@@	O	-1	24675088
-induced	O	-1	24675088
cardi@@	B-Disease	D009202	24675088
om@@	I-Disease	-1	24675088
yo@@	I-Disease	-1	24675088
pathy	I-Disease	-1	24675088
,	O	-1	24675088
ap@@	O	-1	24675088
pl@@	O	-1	24675088
y@@	O	-1	24675088
ing	O	-1	24675088
multiple	O	-1	24675088
appro@@	O	-1	24675088
ac@@	O	-1	24675088
h@@	O	-1	24675088
es,	O	-1	24675088
including	O	-1	24675088
cardiac	O	-1	24675088
mag@@	O	-1	24675088
ne@@	O	-1	24675088
tic	O	-1	24675088
res@@	O	-1	24675088
on@@	O	-1	24675088
ance	O	-1	24675088
imaging	O	-1	24675088
(@@	O	-1	24675088
MR@@	O	-1	24675088
I@@	O	-1	24675088
),	O	-1	24675088
to	O	-1	24675088
prov@@	O	-1	24675088
ide	O	-1	24675088
the	O	-1	24675088
most	O	-1	24675088
com@@	O	-1	24675088
pre@@	O	-1	24675088
h@@	O	-1	24675088
en@@	O	-1	24675088
sive	O	-1	24675088
character@@	O	-1	24675088
ization	O	-1	24675088
to	O	-1	24675088
d@@	O	-1	24675088
ate	O	-1	24675088
of	O	-1	24675088
the	O	-1	24675088
tim@@	O	-1	24675088
ec@@	O	-1	24675088
o@@	O	-1	24675088
ur@@	O	-1	24675088
se	O	-1	24675088
of	O	-1	24675088
ser@@	O	-1	24675088
olog@@	O	-1	24675088
ic@@	O	-1	24675088
al,	O	-1	24675088
path@@	O	-1	24675088
olog@@	O	-1	24675088
ic@@	O	-1	24675088
al,	O	-1	24675088
and	O	-1	24675088
functional	O	-1	24675088
events	O	-1	24675088
underlying	O	-1	24675088
this	O	-1	24675088
toxicity	B-Disease	D064420	24675088
.	O	-1	24675088
H@@	O	-1	24675088
an@@	O	-1	24675088
no@@	O	-1	24675088
ver	O	-1	24675088
Wistar	O	-1	24675088
rats	O	-1	24675088
were	O	-1	24675088
dos@@	O	-1	24675088
ed	O	-1	24675088
with	O	-1	24675088
1.@@	O	-1	24675088
25	O	-1	24675088
mg/kg	O	-1	24675088
DO@@	B-Chemical	D004317	24675088
X	I-Chemical	-1	24675088
week@@	O	-1	24675088
ly	O	-1	24675088
for	O	-1	24675088
8	O	-1	24675088
weeks	O	-1	24675088
followed	O	-1	24675088
by	O	-1	24675088
a	O	-1	24675088
4	O	-1	24675088
week	O	-1	24675088
o@@	O	-1	24675088
ff@@	O	-1	24675088
-@@	O	-1	24675088
dos@@	O	-1	24675088
ing	O	-1	24675088
"@@	O	-1	24675088
reco@@	O	-1	24675088
ver@@	O	-1	24675088
y@@	O	-1	24675088
"	O	-1	24675088
perio@@	O	-1	24675088
d.	O	-1	24675088
E@@	O	-1	24675088
l@@	O	-1	24675088
ect@@	O	-1	24675088
ro@@	O	-1	24675088
n	O	-1	24675088
micro@@	O	-1	24675088
sco@@	O	-1	24675088
p@@	O	-1	24675088
y	O	-1	24675088
of	O	-1	24675088
the	O	-1	24675088
myocardi@@	O	-1	24675088
um	O	-1	24675088
revealed	O	-1	24675088
sub@@	B-Disease	D009410	24675088
cell@@	I-Disease	-1	24675088
ular	I-Disease	-1	24675088
de@@	I-Disease	-1	24675088
generation	I-Disease	-1	24675088
and	O	-1	24675088
mark@@	O	-1	24675088
ed	O	-1	24675088
mitochondrial	O	-1	24675088
changes	O	-1	24675088
after	O	-1	24675088
a	O	-1	24675088
single	O	-1	24675088
dose.	O	-1	24675088
H@@	O	-1	24675088
ist@@	O	-1	24675088
o@@	O	-1	24675088
path@@	O	-1	24675088
ological	O	-1	24675088
analysis	O	-1	24675088
revealed	O	-1	24675088
progressive	O	-1	24675088
cardi@@	B-Disease	D009410	24675088
om@@	I-Disease	-1	24675088
y@@	I-Disease	-1	24675088
ocyte	I-Disease	-1	24675088
de@@	I-Disease	-1	24675088
generation	I-Disease	-1	24675088
,	O	-1	24675088
hyper@@	B-Disease	D006984	24675088
tro@@	I-Disease	-1	24675088
ph@@	I-Disease	-1	24675088
y	I-Disease	-1	24675088
/@@	O	-1	24675088
cyto@@	O	-1	24675088
me@@	O	-1	24675088
g@@	O	-1	24675088
al@@	O	-1	24675088
y,	O	-1	24675088
and	O	-1	24675088
exten@@	O	-1	24675088
sive	O	-1	24675088
vac@@	O	-1	24675088
u@@	O	-1	24675088
ol@@	O	-1	24675088
ation	O	-1	24675088
after	O	-1	24675088
two	O	-1	24675088
dos@@	O	-1	24675088
es.	O	-1	24675088
E@@	O	-1	24675088
x@@	O	-1	24675088
ten@@	O	-1	24675088
sive	O	-1	24675088
re@@	O	-1	24675088
pl@@	O	-1	24675088
ac@@	O	-1	24675088
ement	O	-1	24675088
fib@@	B-Disease	D005355	24675088
ro@@	I-Disease	-1	24675088
sis	I-Disease	-1	24675088
(@@	O	-1	24675088
qu@@	O	-1	24675088
anti@@	O	-1	24675088
fied	O	-1	24675088
by	O	-1	24675088
Si@@	O	-1	24675088
ri@@	O	-1	24675088
us	O	-1	24675088
red	O	-1	24675088
st@@	O	-1	24675088
ain@@	O	-1	24675088
ing@@	O	-1	24675088
)	O	-1	24675088
developed	O	-1	24675088
during	O	-1	24675088
the	O	-1	24675088
o@@	O	-1	24675088
ff@@	O	-1	24675088
-@@	O	-1	24675088
dos@@	O	-1	24675088
ing	O	-1	24675088
perio@@	O	-1	24675088
d.	O	-1	24675088
F@@	O	-1	24675088
unc@@	O	-1	24675088
tional	O	-1	24675088
indic@@	O	-1	24675088
es	O	-1	24675088
assessed	O	-1	24675088
by	O	-1	24675088
cardiac	O	-1	24675088
MR@@	O	-1	24675088
I	O	-1	24675088
(@@	O	-1	24675088
including	O	-1	24675088
left	O	-1	24675088
ventricular	O	-1	24675088
e@@	O	-1	24675088
j@@	O	-1	24675088
ection	O	-1	24675088
frac@@	O	-1	24675088
tion	O	-1	24675088
(@@	O	-1	24675088
L@@	O	-1	24675088
V@@	O	-1	24675088
E@@	O	-1	24675088
F@@	O	-1	24675088
),	O	-1	24675088
cardiac	O	-1	24675088
out@@	O	-1	24675088
p@@	O	-1	24675088
ut@@	O	-1	24675088
,	O	-1	24675088
and	O	-1	24675088
E@@	O	-1	24675088
/@@	O	-1	24675088
A	O	-1	24675088
rati@@	O	-1	24675088
o@@	O	-1	24675088
)	O	-1	24675088
dec@@	O	-1	24675088
lin@@	O	-1	24675088
ed	O	-1	24675088
progres@@	O	-1	24675088
si@@	O	-1	24675088
vel@@	O	-1	24675088
y,	O	-1	24675088
reac@@	O	-1	24675088
h@@	O	-1	24675088
ing	O	-1	24675088
statis@@	O	-1	24675088
tical	O	-1	24675088
signific@@	O	-1	24675088
ance	O	-1	24675088
after	O	-1	24675088
two	O	-1	24675088
doses	O	-1	24675088
and	O	-1	24675088
cul@@	O	-1	24675088
min@@	O	-1	24675088
ating	O	-1	24675088
in	O	-1	24675088
"@@	O	-1	24675088
clin@@	O	-1	24675088
ic@@	O	-1	24675088
al@@	O	-1	24675088
"	O	-1	24675088
L@@	B-Disease	D018487	24675088
V	I-Disease	-1	24675088
dysfunction	I-Disease	-1	24675088
by	O	-1	24675088
12	O	-1	24675088
week@@	O	-1	24675088
s.	O	-1	24675088
Si@@	O	-1	24675088
gn@@	O	-1	24675088
ific@@	O	-1	24675088
ant	O	-1	24675088
increases	O	-1	24675088
in	O	-1	24675088
pe@@	O	-1	24675088
a@@	O	-1	24675088
k	O	-1	24675088
myocardial	O	-1	24675088
contr@@	O	-1	24675088
ast	O	-1	24675088
enh@@	O	-1	24675088
ance@@	O	-1	24675088
ment	O	-1	24675088
and	O	-1	24675088
ser@@	O	-1	24675088
ological	O	-1	24675088
cardiac	O	-1	24675088
tro@@	O	-1	24675088
p@@	O	-1	24675088
on@@	O	-1	24675088
in	O	-1	24675088
I	O	-1	24675088
(@@	O	-1	24675088
cTn@@	O	-1	24675088
I@@	O	-1	24675088
)	O	-1	24675088
em@@	O	-1	24675088
erg@@	O	-1	24675088
ed	O	-1	24675088
after	O	-1	24675088
e@@	O	-1	24675088
ight	O	-1	24675088
dos@@	O	-1	24675088
es,	O	-1	24675088
import@@	O	-1	24675088
ant@@	O	-1	24675088
ly	O	-1	24675088
pre@@	O	-1	24675088
ce@@	O	-1	24675088
ding	O	-1	24675088
the	O	-1	24675088
L@@	O	-1	24675088
V@@	O	-1	24675088
E@@	O	-1	24675088
F	O	-1	24675088
dec@@	O	-1	24675088
line	O	-1	24675088
to	O	-1	24675088
<@@	O	-1	24675088
50@@	O	-1	24675088
%.	O	-1	24675088
T@@	O	-1	24675088
ro@@	O	-1	24675088
p@@	O	-1	24675088
on@@	O	-1	24675088
in	O	-1	24675088
I	O	-1	24675088
levels	O	-1	24675088
posi@@	O	-1	24675088
ti@@	O	-1	24675088
vely	O	-1	24675088
cor@@	O	-1	24675088
related	O	-1	24675088
with	O	-1	24675088
del@@	O	-1	24675088
ayed	O	-1	24675088
and	O	-1	24675088
pe@@	O	-1	24675088
a@@	O	-1	24675088
k	O	-1	24675088
g@@	B-Chemical	D005682	24675088
ad@@	I-Chemical	-1	24675088
ol@@	I-Chemical	-1	24675088
in@@	I-Chemical	-1	24675088
i@@	I-Chemical	-1	24675088
um	I-Chemical	-1	24675088
contr@@	O	-1	24675088
ast	O	-1	24675088
enh@@	O	-1	24675088
ance@@	O	-1	24675088
ment@@	O	-1	24675088
,	O	-1	24675088
histo@@	O	-1	24675088
path@@	O	-1	24675088
ological	O	-1	24675088
gra@@	O	-1	24675088
d@@	O	-1	24675088
ing,	O	-1	24675088
and	O	-1	24675088
di@@	B-Disease	D018754	24675088
ast@@	I-Disease	-1	24675088
olic	I-Disease	-1	24675088
dysfunction	I-Disease	-1	24675088
.	O	-1	24675088
In	O	-1	24675088
su@@	O	-1	24675088
mm@@	O	-1	24675088
ar@@	O	-1	24675088
y,	O	-1	24675088
sub@@	O	-1	24675088
cell@@	O	-1	24675088
ular	O	-1	24675088
cardi@@	B-Disease	D009410	24675088
om@@	I-Disease	-1	24675088
y@@	I-Disease	-1	24675088
ocyte	I-Disease	-1	24675088
de@@	I-Disease	-1	24675088
generation	I-Disease	-1	24675088
was	O	-1	24675088
the	O	-1	24675088
ear@@	O	-1	24675088
li@@	O	-1	24675088
est	O	-1	24675088
mark@@	O	-1	24675088
er,	O	-1	24675088
followed	O	-1	24675088
by	O	-1	24675088
progressive	O	-1	24675088
functional	O	-1	24675088
dec@@	O	-1	24675088
line	O	-1	24675088
and	O	-1	24675088
histo@@	O	-1	24675088
path@@	O	-1	24675088
ological	O	-1	24675088
man@@	O	-1	24675088
if@@	O	-1	24675088
est@@	O	-1	24675088
ations.	O	-1	24675088
M@@	O	-1	24675088
y@@	O	-1	24675088
ocardi@@	O	-1	24675088
al	O	-1	24675088
contr@@	O	-1	24675088
ast	O	-1	24675088
enh@@	O	-1	24675088
ance@@	O	-1	24675088
ment	O	-1	24675088
and	O	-1	24675088
elev@@	O	-1	24675088
ations	O	-1	24675088
in	O	-1	24675088
cTn@@	O	-1	24675088
I	O	-1	24675088
occurred	O	-1	24675088
lat@@	O	-1	24675088
er.	O	-1	24675088
However,	O	-1	24675088
all	O	-1	24675088
indic@@	O	-1	24675088
es	O	-1	24675088
pre@@	O	-1	24675088
d@@	O	-1	24675088
ated	O	-1	24675088
"@@	O	-1	24675088
clin@@	O	-1	24675088
ic@@	O	-1	24675088
al@@	O	-1	24675088
"	O	-1	24675088
L@@	B-Disease	D018487	24675088
V	I-Disease	-1	24675088
dysfunction	I-Disease	-1	24675088
and	O	-1	24675088
th@@	O	-1	24675088
us	O	-1	24675088
war@@	O	-1	24675088
ran@@	O	-1	24675088
t	O	-1	24675088
further	O	-1	24675088
evalu@@	O	-1	24675088
ation	O	-1	24675088
as	O	-1	24675088
predic@@	O	-1	24675088
tive	O	-1	24675088
b@@	O	-1	24675088
i@@	O	-1	24675088
om@@	O	-1	24675088
ark@@	O	-1	24675088
ers.	O	-1	24675088

In@@	O	-1	24684312
tra@@	O	-1	24684312
der@@	O	-1	24684312
m@@	O	-1	24684312
al	O	-1	24684312
glutamate	B-Chemical	D018698	24684312
and	O	-1	24684312
cap@@	B-Chemical	D002211	24684312
sa@@	I-Chemical	-1	24684312
icin	I-Chemical	-1	24684312
injec@@	O	-1	24684312
tion@@	O	-1	24684312
s:	O	-1	24684312
intra@@	O	-1	24684312
-	O	-1	24684312
and	O	-1	24684312
inter@@	O	-1	24684312
individ@@	O	-1	24684312
ual	O	-1	24684312
vari@@	O	-1	24684312
ability	O	-1	24684312
of	O	-1	24684312
prov@@	O	-1	24684312
o@@	O	-1	24684312
ked	O	-1	24684312
hyperalge@@	B-Disease	D006930	24684312
sia	I-Disease	-1	24684312
and	O	-1	24684312
al@@	B-Disease	D006930	24684312
lo@@	I-Disease	-1	24684312
dy@@	I-Disease	-1	24684312
n@@	I-Disease	-1	24684312
ia	I-Disease	-1	24684312
.	O	-1	24684312
In@@	O	-1	24684312
tra@@	O	-1	24684312
der@@	O	-1	24684312
m@@	O	-1	24684312
al	O	-1	24684312
injec@@	O	-1	24684312
tions	O	-1	24684312
of	O	-1	24684312
glutamate	B-Chemical	D018698	24684312
and	O	-1	24684312
cap@@	B-Chemical	D002211	24684312
sa@@	I-Chemical	-1	24684312
icin	I-Chemical	-1	24684312
are	O	-1	24684312
at@@	O	-1	24684312
trac@@	O	-1	24684312
tive	O	-1	24684312
to	O	-1	24684312
use	O	-1	24684312
in	O	-1	24684312
human	O	-1	24684312
experimental	O	-1	24684312
pain	B-Disease	D010146	24684312
models	O	-1	24684312
because	O	-1	24684312
hyperalge@@	B-Disease	D006930	24684312
sia	I-Disease	-1	24684312
and	O	-1	24684312
al@@	B-Disease	D006930	24684312
lo@@	I-Disease	-1	24684312
dy@@	I-Disease	-1	24684312
n@@	I-Disease	-1	24684312
ia	I-Disease	-1	24684312
m@@	O	-1	24684312
im@@	O	-1	24684312
ic	O	-1	24684312
isol@@	O	-1	24684312
ated	O	-1	24684312
as@@	O	-1	24684312
p@@	O	-1	24684312
ects	O	-1	24684312
of	O	-1	24684312
clinical	O	-1	24684312
pain	B-Disease	D013001	24684312
disorder@@	I-Disease	-1	24684312
s	I-Disease	-1	24684312
.	O	-1	24684312
The	O	-1	24684312
a@@	O	-1	24684312
im	O	-1	24684312
of	O	-1	24684312
the	O	-1	24684312
present	O	-1	24684312
study	O	-1	24684312
was	O	-1	24684312
to	O	-1	24684312
investigate	O	-1	24684312
the	O	-1	24684312
re@@	O	-1	24684312
produc@@	O	-1	24684312
i@@	O	-1	24684312
b@@	O	-1	24684312
ility	O	-1	24684312
of	O	-1	24684312
these	O	-1	24684312
model@@	O	-1	24684312
s.	O	-1	24684312
Tw@@	O	-1	24684312
ent@@	O	-1	24684312
y	O	-1	24684312
healthy	O	-1	24684312
male	O	-1	24684312
vol@@	O	-1	24684312
un@@	O	-1	24684312
te@@	O	-1	24684312
ers	O	-1	24684312
(@@	O	-1	24684312
mean	O	-1	24684312
age	O	-1	24684312
24	O	-1	24684312
year@@	O	-1	24684312
s;	O	-1	24684312
range	O	-1	24684312
18@@	O	-1	24684312
-@@	O	-1	24684312
3@@	O	-1	24684312
8	O	-1	24684312
year@@	O	-1	24684312
s)	O	-1	24684312
received	O	-1	24684312
intra@@	O	-1	24684312
der@@	O	-1	24684312
m@@	O	-1	24684312
al	O	-1	24684312
injec@@	O	-1	24684312
tions	O	-1	24684312
of	O	-1	24684312
glutamate	B-Chemical	D018698	24684312
and	O	-1	24684312
cap@@	B-Chemical	D002211	24684312
sa@@	I-Chemical	-1	24684312
icin	I-Chemical	-1	24684312
in	O	-1	24684312
the	O	-1	24684312
vol@@	O	-1	24684312
ar	O	-1	24684312
fo@@	O	-1	24684312
re@@	O	-1	24684312
ar@@	O	-1	24684312
m.	O	-1	24684312
M@@	O	-1	24684312
ag@@	O	-1	24684312
nit@@	O	-1	24684312
u@@	O	-1	24684312
des	O	-1	24684312
of	O	-1	24684312
secondary	O	-1	24684312
p@@	O	-1	24684312
in@@	O	-1	24684312
pr@@	O	-1	24684312
ic@@	O	-1	24684312
k	O	-1	24684312
hyperalge@@	B-Disease	D006930	24684312
sia	I-Disease	-1	24684312
and	O	-1	24684312
b@@	O	-1	24684312
r@@	O	-1	24684312
us@@	O	-1	24684312
h@@	O	-1	24684312
-@@	O	-1	24684312
evoked	O	-1	24684312
al@@	B-Disease	D006930	24684312
lo@@	I-Disease	-1	24684312
dy@@	I-Disease	-1	24684312
n@@	I-Disease	-1	24684312
ia	I-Disease	-1	24684312
were	O	-1	24684312
investigated	O	-1	24684312
using	O	-1	24684312
v@@	O	-1	24684312
on	O	-1	24684312
F@@	O	-1	24684312
re@@	O	-1	24684312
y	O	-1	24684312
f@@	O	-1	24684312
il@@	O	-1	24684312
am@@	O	-1	24684312
ents	O	-1	24684312
(@@	O	-1	24684312
g@@	O	-1	24684312
au@@	O	-1	24684312
g@@	O	-1	24684312
es	O	-1	24684312
10@@	O	-1	24684312
,	O	-1	24684312
1@@	O	-1	24684312
5,	O	-1	24684312
60	O	-1	24684312
and	O	-1	24684312
100	O	-1	24684312
g@@	O	-1	24684312
)	O	-1	24684312
and	O	-1	24684312
b@@	O	-1	24684312
r@@	O	-1	24684312
us@@	O	-1	24684312
h	O	-1	24684312
strok@@	O	-1	24684312
es.	O	-1	24684312
A@@	O	-1	24684312
reas	O	-1	24684312
of	O	-1	24684312
secondary	B-Disease	D006930	24684312
hyperalge@@	I-Disease	-1	24684312
sia	I-Disease	-1	24684312
and	O	-1	24684312
al@@	B-Disease	D006930	24684312
lo@@	I-Disease	-1	24684312
dy@@	I-Disease	-1	24684312
n@@	I-Disease	-1	24684312
ia	I-Disease	-1	24684312
were	O	-1	24684312
qu@@	O	-1	24684312
anti@@	O	-1	24684312
fied	O	-1	24684312
immedi@@	O	-1	24684312
ately	O	-1	24684312
after	O	-1	24684312
injection	O	-1	24684312
and	O	-1	24684312
after	O	-1	24684312
1@@	O	-1	24684312
5,	O	-1	24684312
30	O	-1	24684312
and	O	-1	24684312
60	O	-1	24684312
min@@	O	-1	24684312
.	O	-1	24684312
Two	O	-1	24684312
id@@	O	-1	24684312
en@@	O	-1	24684312
tical	O	-1	24684312
experim@@	O	-1	24684312
ents	O	-1	24684312
se@@	O	-1	24684312
par@@	O	-1	24684312
ated	O	-1	24684312
by	O	-1	24684312
at	O	-1	24684312
le@@	O	-1	24684312
ast	O	-1	24684312
7	O	-1	24684312
days	O	-1	24684312
were	O	-1	24684312
per@@	O	-1	24684312
for@@	O	-1	24684312
me@@	O	-1	24684312
d.	O	-1	24684312
Re@@	O	-1	24684312
produc@@	O	-1	24684312
i@@	O	-1	24684312
b@@	O	-1	24684312
ility	O	-1	24684312
ac@@	O	-1	24684312
ros@@	O	-1	24684312
s	O	-1	24684312
and	O	-1	24684312
within	O	-1	24684312
vol@@	O	-1	24684312
un@@	O	-1	24684312
te@@	O	-1	24684312
ers	O	-1	24684312
(@@	O	-1	24684312
inter@@	O	-1	24684312
-	O	-1	24684312
and	O	-1	24684312
intra@@	O	-1	24684312
-@@	O	-1	24684312
individ@@	O	-1	24684312
ual	O	-1	24684312
vari@@	O	-1	24684312
ation,	O	-1	24684312
respectivel@@	O	-1	24684312
y@@	O	-1	24684312
)	O	-1	24684312
was	O	-1	24684312
assessed	O	-1	24684312
using	O	-1	24684312
intrac@@	O	-1	24684312
las@@	O	-1	24684312
s	O	-1	24684312
correl@@	O	-1	24684312
ation	O	-1	24684312
co@@	O	-1	24684312
eff@@	O	-1	24684312
ici@@	O	-1	24684312
ent	O	-1	24684312
(@@	O	-1	24684312
IC@@	O	-1	24684312
C@@	O	-1	24684312
)	O	-1	24684312
and	O	-1	24684312
co@@	O	-1	24684312
eff@@	O	-1	24684312
ici@@	O	-1	24684312
ent	O	-1	24684312
of	O	-1	24684312
vari@@	O	-1	24684312
ation	O	-1	24684312
(C@@	O	-1	24684312
V@@	O	-1	24684312
).	O	-1	24684312
S@@	O	-1	24684312
ec@@	O	-1	24684312
ond@@	O	-1	24684312
ary	O	-1	24684312
p@@	O	-1	24684312
in@@	O	-1	24684312
pr@@	O	-1	24684312
ic@@	O	-1	24684312
k	O	-1	24684312
hyperalge@@	B-Disease	D006930	24684312
sia	I-Disease	-1	24684312
was	O	-1	24684312
observed	O	-1	24684312
as	O	-1	24684312
a	O	-1	24684312
mark@@	O	-1	24684312
ed	O	-1	24684312
increase	O	-1	24684312
in	O	-1	24684312
the	O	-1	24684312
visual	O	-1	24684312
an@@	O	-1	24684312
alo@@	O	-1	24684312
gu@@	O	-1	24684312
e	O	-1	24684312
s@@	O	-1	24684312
cal@@	O	-1	24684312
e	O	-1	24684312
(V@@	O	-1	24684312
A@@	O	-1	24684312
S)	O	-1	24684312
response	O	-1	24684312
to	O	-1	24684312
v@@	O	-1	24684312
on	O	-1	24684312
F@@	O	-1	24684312
re@@	O	-1	24684312
y	O	-1	24684312
g@@	O	-1	24684312
au@@	O	-1	24684312
g@@	O	-1	24684312
es	O	-1	24684312
60	O	-1	24684312
and	O	-1	24684312
100	O	-1	24684312
g	O	-1	24684312
(P	O	-1	24684312
<	O	-1	24684312
0.00@@	O	-1	24684312
1)	O	-1	24684312
after	O	-1	24684312
glutamate	B-Chemical	D018698	24684312
injec@@	O	-1	24684312
tion.	O	-1	24684312
F@@	O	-1	24684312
or	O	-1	24684312
cap@@	B-Chemical	D002211	24684312
sa@@	I-Chemical	-1	24684312
icin	I-Chemical	-1	24684312
,	O	-1	24684312
secondary	O	-1	24684312
p@@	O	-1	24684312
in@@	O	-1	24684312
pr@@	O	-1	24684312
ic@@	O	-1	24684312
k	O	-1	24684312
hyperalge@@	B-Disease	D006930	24684312
sia	I-Disease	-1	24684312
was	O	-1	24684312
det@@	O	-1	24684312
ected	O	-1	24684312
with	O	-1	24684312
all	O	-1	24684312
v@@	O	-1	24684312
on	O	-1	24684312
F@@	O	-1	24684312
re@@	O	-1	24684312
y	O	-1	24684312
g@@	O	-1	24684312
au@@	O	-1	24684312
g@@	O	-1	24684312
es	O	-1	24684312
(P	O	-1	24684312
<	O	-1	24684312
0.00@@	O	-1	24684312
1).	O	-1	24684312
G@@	B-Chemical	D018698	24684312
l@@	I-Chemical	-1	24684312
ut@@	I-Chemical	-1	24684312
am@@	I-Chemical	-1	24684312
ate	I-Chemical	-1	24684312
evoked	O	-1	24684312
re@@	O	-1	24684312
produc@@	O	-1	24684312
i@@	O	-1	24684312
ble	O	-1	24684312
V@@	O	-1	24684312
A@@	O	-1	24684312
S	O	-1	24684312
response	O	-1	24684312
to	O	-1	24684312
all	O	-1	24684312
v@@	O	-1	24684312
on	O	-1	24684312
F@@	O	-1	24684312
re@@	O	-1	24684312
y	O	-1	24684312
g@@	O	-1	24684312
au@@	O	-1	24684312
g@@	O	-1	24684312
es	O	-1	24684312
(@@	O	-1	24684312
IC@@	O	-1	24684312
C	O	-1	24684312
>	O	-1	24684312
0.@@	O	-1	24684312
6@@	O	-1	24684312
0@@	O	-1	24684312
)	O	-1	24684312
and	O	-1	24684312
b@@	O	-1	24684312
r@@	O	-1	24684312
us@@	O	-1	24684312
h	O	-1	24684312
strok@@	O	-1	24684312
es	O	-1	24684312
(@@	O	-1	24684312
IC@@	O	-1	24684312
C	O	-1	24684312
>	O	-1	24684312
0.@@	O	-1	24684312
8@@	O	-1	24684312
3@@	O	-1	24684312
).	O	-1	24684312
C@@	B-Chemical	D002211	24684312
ap@@	I-Chemical	-1	24684312
sa@@	I-Chemical	-1	24684312
icin	I-Chemical	-1	24684312
injection	O	-1	24684312
was	O	-1	24684312
re@@	O	-1	24684312
produc@@	O	-1	24684312
i@@	O	-1	24684312
ble	O	-1	24684312
for	O	-1	24684312
secondary	B-Disease	D006930	24684312
hyperalge@@	I-Disease	-1	24684312
sia	I-Disease	-1	24684312
(@@	O	-1	24684312
IC@@	O	-1	24684312
C	O	-1	24684312
>	O	-1	24684312
0.@@	O	-1	24684312
7@@	O	-1	24684312
0@@	O	-1	24684312
)	O	-1	24684312
and	O	-1	24684312
al@@	B-Disease	D006930	24684312
lo@@	I-Disease	-1	24684312
dy@@	I-Disease	-1	24684312
n@@	I-Disease	-1	24684312
ia	I-Disease	-1	24684312
(@@	O	-1	24684312
IC@@	O	-1	24684312
C	O	-1	24684312
>	O	-1	24684312
0.@@	O	-1	24684312
7@@	O	-1	24684312
1).	O	-1	24684312
In@@	O	-1	24684312
tra@@	O	-1	24684312
-@@	O	-1	24684312
individ@@	O	-1	24684312
ual	O	-1	24684312
vari@@	O	-1	24684312
ability	O	-1	24684312
was	O	-1	24684312
gener@@	O	-1	24684312
ally	O	-1	24684312
lower	O	-1	24684312
for	O	-1	24684312
the	O	-1	24684312
V@@	O	-1	24684312
A@@	O	-1	24684312
S	O	-1	24684312
response	O	-1	24684312
to	O	-1	24684312
v@@	O	-1	24684312
on	O	-1	24684312
F@@	O	-1	24684312
re@@	O	-1	24684312
y	O	-1	24684312
and	O	-1	24684312
b@@	O	-1	24684312
r@@	O	-1	24684312
us@@	O	-1	24684312
h	O	-1	24684312
compared	O	-1	24684312
with	O	-1	24684312
a@@	O	-1	24684312
reas	O	-1	24684312
of	O	-1	24684312
secondary	B-Disease	D006930	24684312
hyperalge@@	I-Disease	-1	24684312
sia	I-Disease	-1	24684312
and	O	-1	24684312
al@@	B-Disease	D006930	24684312
lo@@	I-Disease	-1	24684312
dy@@	I-Disease	-1	24684312
n@@	I-Disease	-1	24684312
ia	I-Disease	-1	24684312
.	O	-1	24684312
In	O	-1	24684312
concl@@	O	-1	24684312
u@@	O	-1	24684312
sion,	O	-1	24684312
glutamate	B-Chemical	D018698	24684312
and	O	-1	24684312
cap@@	B-Chemical	D002211	24684312
sa@@	I-Chemical	-1	24684312
icin	I-Chemical	-1	24684312
y@@	O	-1	24684312
i@@	O	-1	24684312
el@@	O	-1	24684312
d	O	-1	24684312
re@@	O	-1	24684312
produc@@	O	-1	24684312
i@@	O	-1	24684312
ble	O	-1	24684312
hyperalge@@	B-Disease	D006930	24684312
sic	I-Disease	-1	24684312
and	O	-1	24684312
al@@	B-Disease	D006930	24684312
lo@@	I-Disease	-1	24684312
dy@@	I-Disease	-1	24684312
n@@	I-Disease	-1	24684312
ic	I-Disease	-1	24684312
respon@@	O	-1	24684312
s@@	O	-1	24684312
es,	O	-1	24684312
and	O	-1	24684312
the	O	-1	24684312
present	O	-1	24684312
model	O	-1	24684312
is	O	-1	24684312
well	O	-1	24684312
su@@	O	-1	24684312
ited	O	-1	24684312
for	O	-1	24684312
b@@	O	-1	24684312
a@@	O	-1	24684312
sic	O	-1	24684312
re@@	O	-1	24684312
se@@	O	-1	24684312
ar@@	O	-1	24684312
ch@@	O	-1	24684312
,	O	-1	24684312
as	O	-1	24684312
well	O	-1	24684312
as	O	-1	24684312
for	O	-1	24684312
assess@@	O	-1	24684312
ing	O	-1	24684312
the	O	-1	24684312
mod@@	O	-1	24684312
ulation	O	-1	24684312
of	O	-1	24684312
central	O	-1	24684312
phen@@	O	-1	24684312
om@@	O	-1	24684312
en@@	O	-1	24684312
a.	O	-1	24684312

O@@	O	-1	24691439
cul@@	O	-1	24691439
ar@@	O	-1	24691439
-@@	O	-1	24691439
specific	O	-1	24691439
E@@	O	-1	24691439
R	O	-1	24691439
stres@@	O	-1	24691439
s	O	-1	24691439
reduction	O	-1	24691439
res@@	O	-1	24691439
c@@	O	-1	24691439
u@@	O	-1	24691439
es	O	-1	24691439
gl@@	B-Disease	D005901	24691439
au@@	I-Disease	-1	24691439
com@@	I-Disease	-1	24691439
a	I-Disease	-1	24691439
in	O	-1	24691439
m@@	O	-1	24691439
urine	O	-1	24691439
g@@	O	-1	24691439
lu@@	O	-1	24691439
co@@	O	-1	24691439
cortico@@	O	-1	24691439
id@@	O	-1	24691439
-induced	O	-1	24691439
gl@@	B-Disease	D005901	24691439
au@@	I-Disease	-1	24691439
com@@	I-Disease	-1	24691439
a	I-Disease	-1	24691439
.	O	-1	24691439
Ad@@	O	-1	24691439
minist@@	O	-1	24691439
ration	O	-1	24691439
of	O	-1	24691439
g@@	O	-1	24691439
lu@@	O	-1	24691439
co@@	O	-1	24691439
cortico@@	O	-1	24691439
id@@	O	-1	24691439
s	O	-1	24691439
induc@@	O	-1	24691439
es	O	-1	24691439
oc@@	B-Disease	D009798	24691439
ular	I-Disease	-1	24691439
hypertension	I-Disease	-1	24691439
in	O	-1	24691439
some	O	-1	24691439
patients.	O	-1	24691439
I@@	O	-1	24691439
f	O	-1	24691439
un@@	O	-1	24691439
treat@@	O	-1	24691439
ed,	O	-1	24691439
these	O	-1	24691439
patients	O	-1	24691439
can	O	-1	24691439
deve@@	O	-1	24691439
lo@@	O	-1	24691439
p	O	-1	24691439
a	O	-1	24691439
secondary	O	-1	24691439
gl@@	B-Disease	D005901	24691439
au@@	I-Disease	-1	24691439
com@@	I-Disease	-1	24691439
a	I-Disease	-1	24691439
that	O	-1	24691439
re@@	O	-1	24691439
se@@	O	-1	24691439
m@@	O	-1	24691439
ble@@	O	-1	24691439
s	O	-1	24691439
prim@@	B-Disease	C562750	24691439
ary	I-Disease	-1	24691439
o@@	I-Disease	-1	24691439
pen@@	I-Disease	-1	24691439
-@@	I-Disease	-1	24691439
ang@@	I-Disease	-1	24691439
le	I-Disease	-1	24691439
gl@@	I-Disease	-1	24691439
au@@	I-Disease	-1	24691439
com@@	I-Disease	-1	24691439
a	I-Disease	-1	24691439
(	O	-1	24691439
P@@	B-Disease	C562750	24691439
O@@	I-Disease	-1	24691439
A@@	I-Disease	-1	24691439
G	I-Disease	-1	24691439
).	O	-1	24691439
The	O	-1	24691439
underlying	O	-1	24691439
path@@	O	-1	24691439
ology	O	-1	24691439
of	O	-1	24691439
g@@	O	-1	24691439
lu@@	O	-1	24691439
co@@	O	-1	24691439
cortico@@	O	-1	24691439
id@@	O	-1	24691439
-induced	O	-1	24691439
gl@@	B-Disease	D005901	24691439
au@@	I-Disease	-1	24691439
com@@	I-Disease	-1	24691439
a	I-Disease	-1	24691439
is	O	-1	24691439
not	O	-1	24691439
ful@@	O	-1	24691439
ly	O	-1	24691439
under@@	O	-1	24691439
sto@@	O	-1	24691439
o@@	O	-1	24691439
d,	O	-1	24691439
due	O	-1	24691439
in	O	-1	24691439
par@@	O	-1	24691439
t	O	-1	24691439
to	O	-1	24691439
l@@	O	-1	24691439
ac@@	O	-1	24691439
k	O	-1	24691439
of	O	-1	24691439
an	O	-1	24691439
appro@@	O	-1	24691439
pri@@	O	-1	24691439
ate	O	-1	24691439
anim@@	O	-1	24691439
al	O	-1	24691439
model@@	O	-1	24691439
.	O	-1	24691439
He@@	O	-1	24691439
re,	O	-1	24691439
we	O	-1	24691439
developed	O	-1	24691439
a	O	-1	24691439
m@@	O	-1	24691439
urine	O	-1	24691439
model	O	-1	24691439
of	O	-1	24691439
g@@	O	-1	24691439
lu@@	O	-1	24691439
co@@	O	-1	24691439
cortico@@	O	-1	24691439
id@@	O	-1	24691439
-induced	O	-1	24691439
gl@@	B-Disease	D005901	24691439
au@@	I-Disease	-1	24691439
com@@	I-Disease	-1	24691439
a	I-Disease	-1	24691439
that	O	-1	24691439
ex@@	O	-1	24691439
hib@@	O	-1	24691439
its	O	-1	24691439
gl@@	B-Disease	D005901	24691439
au@@	I-Disease	-1	24691439
com@@	I-Disease	-1	24691439
a	I-Disease	-1	24691439
feat@@	O	-1	24691439
ures	O	-1	24691439
that	O	-1	24691439
are	O	-1	24691439
observed	O	-1	24691439
in	O	-1	24691439
patients.	O	-1	24691439
Treat@@	O	-1	24691439
ment	O	-1	24691439
of	O	-1	24691439
W@@	O	-1	24691439
T	O	-1	24691439
mice	O	-1	24691439
with	O	-1	24691439
to@@	O	-1	24691439
p@@	O	-1	24691439
ical	O	-1	24691439
oc@@	O	-1	24691439
ular	O	-1	24691439
0.@@	O	-1	24691439
1@@	O	-1	24691439
%	O	-1	24691439
de@@	B-Chemical	D003907	24691439
xameth@@	I-Chemical	-1	24691439
as@@	I-Chemical	-1	24691439
one	I-Chemical	-1	24691439
l@@	O	-1	24691439
ed	O	-1	24691439
to	O	-1	24691439
elev@@	O	-1	24691439
ation	O	-1	24691439
of	O	-1	24691439
intra@@	O	-1	24691439
oc@@	O	-1	24691439
ular	O	-1	24691439
pressure	O	-1	24691439
(@@	O	-1	24691439
I@@	O	-1	24691439
O@@	O	-1	24691439
P@@	O	-1	24691439
),	O	-1	24691439
functional	O	-1	24691439
and	O	-1	24691439
struct@@	O	-1	24691439
ural	O	-1	24691439
loss	O	-1	24691439
of	O	-1	24691439
ret@@	B-Disease	D012173	24691439
inal	I-Disease	-1	24691439
g@@	I-Disease	-1	24691439
ang@@	I-Disease	-1	24691439
li@@	I-Disease	-1	24691439
on	I-Disease	-1	24691439
cell@@	O	-1	24691439
s,	O	-1	24691439
and	O	-1	24691439
ax@@	B-Disease	D009410	24691439
on@@	I-Disease	-1	24691439
al	I-Disease	-1	24691439
de@@	I-Disease	-1	24691439
generation	I-Disease	-1	24691439
,	O	-1	24691439
re@@	O	-1	24691439
se@@	O	-1	24691439
m@@	O	-1	24691439
bl@@	O	-1	24691439
ing	O	-1	24691439
g@@	O	-1	24691439
lu@@	O	-1	24691439
co@@	O	-1	24691439
cortico@@	O	-1	24691439
id@@	O	-1	24691439
-induced	O	-1	24691439
gl@@	B-Disease	D005901	24691439
au@@	I-Disease	-1	24691439
com@@	I-Disease	-1	24691439
a	I-Disease	-1	24691439
in	O	-1	24691439
human	O	-1	24691439
patients.	O	-1	24691439
F@@	O	-1	24691439
ur@@	O	-1	24691439
ther@@	O	-1	24691439
mo@@	O	-1	24691439
re,	O	-1	24691439
de@@	B-Chemical	D003907	24691439
xameth@@	I-Chemical	-1	24691439
as@@	I-Chemical	-1	24691439
one	I-Chemical	-1	24691439
-induced	O	-1	24691439
oc@@	B-Disease	D009798	24691439
ular	I-Disease	-1	24691439
hypertension	I-Disease	-1	24691439
was	O	-1	24691439
associated	O	-1	24691439
with	O	-1	24691439
chronic	O	-1	24691439
E@@	O	-1	24691439
R	O	-1	24691439
stres@@	O	-1	24691439
s	O	-1	24691439
of	O	-1	24691439
the	O	-1	24691439
tra@@	O	-1	24691439
b@@	O	-1	24691439
ec@@	O	-1	24691439
ular	O	-1	24691439
m@@	O	-1	24691439
es@@	O	-1	24691439
h@@	O	-1	24691439
wor@@	O	-1	24691439
k	O	-1	24691439
(T@@	O	-1	24691439
M@@	O	-1	24691439
).	O	-1	24691439
S@@	O	-1	24691439
im@@	O	-1	24691439
il@@	O	-1	24691439
ar	O	-1	24691439
to	O	-1	24691439
patients,	O	-1	24691439
withdrawal	O	-1	24691439
of	O	-1	24691439
de@@	B-Chemical	D003907	24691439
xameth@@	I-Chemical	-1	24691439
as@@	I-Chemical	-1	24691439
one	I-Chemical	-1	24691439
treatment	O	-1	24691439
reduced	O	-1	24691439
elevated	O	-1	24691439
I@@	O	-1	24691439
O@@	O	-1	24691439
P	O	-1	24691439
and	O	-1	24691439
E@@	O	-1	24691439
R	O	-1	24691439
stres@@	O	-1	24691439
s	O	-1	24691439
in	O	-1	24691439
this	O	-1	24691439
anim@@	O	-1	24691439
al	O	-1	24691439
model@@	O	-1	24691439
.	O	-1	24691439
D@@	B-Chemical	D003907	24691439
ex@@	I-Chemical	-1	24691439
ameth@@	I-Chemical	-1	24691439
as@@	I-Chemical	-1	24691439
one	I-Chemical	-1	24691439
induced	O	-1	24691439
the	O	-1	24691439
trans@@	O	-1	24691439
cri@@	O	-1	24691439
p@@	O	-1	24691439
tional	O	-1	24691439
factor	O	-1	24691439
C@@	O	-1	24691439
HO@@	O	-1	24691439
P@@	O	-1	24691439
,	O	-1	24691439
a	O	-1	24691439
mark@@	O	-1	24691439
er	O	-1	24691439
for	O	-1	24691439
chronic	O	-1	24691439
E@@	O	-1	24691439
R	O	-1	24691439
stres@@	O	-1	24691439
s,	O	-1	24691439
in	O	-1	24691439
the	O	-1	24691439
an@@	O	-1	24691439
ter@@	O	-1	24691439
ior	O	-1	24691439
seg@@	O	-1	24691439
ment	O	-1	24691439
tissu@@	O	-1	24691439
es,	O	-1	24691439
and	O	-1	24691439
C@@	O	-1	24691439
ho@@	O	-1	24691439
p	O	-1	24691439
de@@	O	-1	24691439
le@@	O	-1	24691439
tion	O	-1	24691439
reduced	O	-1	24691439
E@@	O	-1	24691439
R	O	-1	24691439
stres@@	O	-1	24691439
s	O	-1	24691439
in	O	-1	24691439
these	O	-1	24691439
tissu@@	O	-1	24691439
es	O	-1	24691439
and	O	-1	24691439
prevent@@	O	-1	24691439
ed	O	-1	24691439
de@@	B-Chemical	D003907	24691439
xameth@@	I-Chemical	-1	24691439
as@@	I-Chemical	-1	24691439
one	I-Chemical	-1	24691439
-induced	O	-1	24691439
oc@@	B-Disease	D009798	24691439
ular	I-Disease	-1	24691439
hypertension	I-Disease	-1	24691439
.	O	-1	24691439
F@@	O	-1	24691439
ur@@	O	-1	24691439
ther@@	O	-1	24691439
mo@@	O	-1	24691439
re,	O	-1	24691439
reduction	O	-1	24691439
of	O	-1	24691439
E@@	O	-1	24691439
R	O	-1	24691439
stres@@	O	-1	24691439
s	O	-1	24691439
in	O	-1	24691439
the	O	-1	24691439
T@@	O	-1	24691439
M	O	-1	24691439
with	O	-1	24691439
sodium	B-Chemical	C075773	24691439
4-@@	I-Chemical	-1	24691439
phenyl@@	I-Chemical	-1	24691439
but@@	I-Chemical	-1	24691439
y@@	I-Chemical	-1	24691439
rate	I-Chemical	-1	24691439
prevent@@	O	-1	24691439
ed	O	-1	24691439
de@@	B-Chemical	D003907	24691439
xameth@@	I-Chemical	-1	24691439
as@@	I-Chemical	-1	24691439
one	I-Chemical	-1	24691439
-induced	O	-1	24691439
oc@@	B-Disease	D009798	24691439
ular	I-Disease	-1	24691439
hypertension	I-Disease	-1	24691439
in	O	-1	24691439
W@@	O	-1	24691439
T	O	-1	24691439
mice.	O	-1	24691439
Our	O	-1	24691439
data	O	-1	24691439
indicate	O	-1	24691439
that	O	-1	24691439
E@@	O	-1	24691439
R	O	-1	24691439
stres@@	O	-1	24691439
s	O	-1	24691439
cont@@	O	-1	24691439
ri@@	O	-1	24691439
but@@	O	-1	24691439
es	O	-1	24691439
to	O	-1	24691439
g@@	O	-1	24691439
lu@@	O	-1	24691439
co@@	O	-1	24691439
cortico@@	O	-1	24691439
id@@	O	-1	24691439
-induced	O	-1	24691439
oc@@	B-Disease	D009798	24691439
ular	I-Disease	-1	24691439
hypertension	I-Disease	-1	24691439
and	O	-1	24691439
suggest	O	-1	24691439
that	O	-1	24691439
reduc@@	O	-1	24691439
ing	O	-1	24691439
E@@	O	-1	24691439
R	O	-1	24691439
stres@@	O	-1	24691439
s	O	-1	24691439
has	O	-1	24691439
potential	O	-1	24691439
as	O	-1	24691439
a	O	-1	24691439
therapeutic	O	-1	24691439
strat@@	O	-1	24691439
e@@	O	-1	24691439
g@@	O	-1	24691439
y	O	-1	24691439
for	O	-1	24691439
treat@@	O	-1	24691439
ing	O	-1	24691439
g@@	O	-1	24691439
lu@@	O	-1	24691439
co@@	O	-1	24691439
cortico@@	O	-1	24691439
id@@	O	-1	24691439
-induced	O	-1	24691439
gl@@	B-Disease	D005901	24691439
au@@	I-Disease	-1	24691439
com@@	I-Disease	-1	24691439
a	I-Disease	-1	24691439
.	O	-1	24691439

Eff@@	O	-1	24709919
ects	O	-1	24709919
of	O	-1	24709919
g@@	B-Chemical	D036145	24709919
in@@	I-Chemical	-1	24709919
sen@@	I-Chemical	-1	24709919
o@@	I-Chemical	-1	24709919
side@@	I-Chemical	-1	24709919
s	I-Chemical	-1	24709919
on	O	-1	24709919
o@@	O	-1	24709919
pi@@	O	-1	24709919
oid@@	O	-1	24709919
-induced	O	-1	24709919
hyperalge@@	B-Disease	D006930	24709919
sia	I-Disease	-1	24709919
in	O	-1	24709919
mice.	O	-1	24709919
O@@	O	-1	24709919
pi@@	O	-1	24709919
oid@@	O	-1	24709919
-induced	O	-1	24709919
hyperalge@@	B-Disease	D006930	24709919
sia	I-Disease	-1	24709919
(	O	-1	24709919
O@@	B-Disease	D006930	24709919
I@@	I-Disease	-1	24709919
H	I-Disease	-1	24709919
)	O	-1	24709919
is	O	-1	24709919
character@@	O	-1	24709919
ized	O	-1	24709919
by	O	-1	24709919
n@@	O	-1	24709919
ocicep@@	O	-1	24709919
tive	O	-1	24709919
sensi@@	O	-1	24709919
tiz@@	O	-1	24709919
ation	O	-1	24709919
caused	O	-1	24709919
by	O	-1	24709919
the	O	-1	24709919
cess@@	O	-1	24709919
ation	O	-1	24709919
of	O	-1	24709919
chronic	O	-1	24709919
o@@	O	-1	24709919
pi@@	O	-1	24709919
oid	O	-1	24709919
use.	O	-1	24709919
O@@	B-Disease	D006930	24709919
I@@	I-Disease	-1	24709919
H	I-Disease	-1	24709919
can	O	-1	24709919
lim@@	O	-1	24709919
it	O	-1	24709919
the	O	-1	24709919
clinical	O	-1	24709919
use	O	-1	24709919
of	O	-1	24709919
o@@	O	-1	24709919
pi@@	O	-1	24709919
oid	O	-1	24709919
analge@@	O	-1	24709919
si@@	O	-1	24709919
c@@	O	-1	24709919
s	O	-1	24709919
and	O	-1	24709919
complic@@	O	-1	24709919
ate	O	-1	24709919
withdrawal	O	-1	24709919
from	O	-1	24709919
o@@	B-Disease	D009293	24709919
pi@@	I-Disease	-1	24709919
oid	I-Disease	-1	24709919
ad@@	I-Disease	-1	24709919
dic@@	I-Disease	-1	24709919
tion	I-Disease	-1	24709919
.	O	-1	24709919
In	O	-1	24709919
this	O	-1	24709919
study,	O	-1	24709919
we	O	-1	24709919
investigated	O	-1	24709919
the	O	-1	24709919
effects	O	-1	24709919
of	O	-1	24709919
R@@	B-Chemical	C049864	24709919
e,	I-Chemical	-1	24709919
R@@	I-Chemical	-1	24709919
g@@	I-Chemical	-1	24709919
1,	I-Chemical	-1	24709919
and	I-Chemical	-1	24709919
R@@	I-Chemical	-1	24709919
b@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
g@@	I-Chemical	-1	24709919
in@@	I-Chemical	-1	24709919
sen@@	I-Chemical	-1	24709919
o@@	I-Chemical	-1	24709919
side@@	I-Chemical	-1	24709919
s	I-Chemical	-1	24709919
R@@	B-Chemical	C035054	24709919
e,	I-Chemical	-1	24709919
R@@	I-Chemical	-1	24709919
g@@	I-Chemical	-1	24709919
1,	I-Chemical	-1	24709919
and	I-Chemical	-1	24709919
R@@	I-Chemical	-1	24709919
b@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
g@@	I-Chemical	-1	24709919
in@@	I-Chemical	-1	24709919
sen@@	I-Chemical	-1	24709919
o@@	I-Chemical	-1	24709919
side@@	I-Chemical	-1	24709919
s	I-Chemical	-1	24709919
R@@	B-Chemical	C442759	24709919
e,	I-Chemical	-1	24709919
R@@	I-Chemical	-1	24709919
g@@	I-Chemical	-1	24709919
1,	I-Chemical	-1	24709919
and	I-Chemical	-1	24709919
R@@	I-Chemical	-1	24709919
b@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
g@@	I-Chemical	-1	24709919
in@@	I-Chemical	-1	24709919
sen@@	I-Chemical	-1	24709919
o@@	I-Chemical	-1	24709919
side@@	I-Chemical	-1	24709919
s	I-Chemical	-1	24709919
,	O	-1	24709919
the	O	-1	24709919
bio@@	O	-1	24709919
active	O	-1	24709919
comp@@	O	-1	24709919
on@@	O	-1	24709919
ents	O	-1	24709919
of	O	-1	24709919
g@@	O	-1	24709919
in@@	O	-1	24709919
sen@@	O	-1	24709919
g@@	O	-1	24709919
,	O	-1	24709919
on	O	-1	24709919
O@@	B-Disease	D006930	24709919
I@@	I-Disease	-1	24709919
H	I-Disease	-1	24709919
.	O	-1	24709919
O@@	B-Disease	D006930	24709919
I@@	I-Disease	-1	24709919
H	I-Disease	-1	24709919
was	O	-1	24709919
achi@@	O	-1	24709919
ev@@	O	-1	24709919
ed	O	-1	24709919
in	O	-1	24709919
mice	O	-1	24709919
after	O	-1	24709919
sub@@	O	-1	24709919
c@@	O	-1	24709919
utaneous	O	-1	24709919
administration	O	-1	24709919
of	O	-1	24709919
morphine	B-Chemical	D009020	24709919
for	O	-1	24709919
7	O	-1	24709919
con@@	O	-1	24709919
sec@@	O	-1	24709919
utive	O	-1	24709919
days	O	-1	24709919
three	O	-1	24709919
times	O	-1	24709919
per	O	-1	24709919
da@@	O	-1	24709919
y.	O	-1	24709919
D@@	O	-1	24709919
uring	O	-1	24709919
withdrawal	O	-1	24709919
(@@	O	-1	24709919
days	O	-1	24709919
8	O	-1	24709919
and	O	-1	24709919
9@@	O	-1	24709919
),	O	-1	24709919
these	O	-1	24709919
mice	O	-1	24709919
were	O	-1	24709919
administered	O	-1	24709919
R@@	B-Chemical	C049864	24709919
e	I-Chemical	-1	24709919
,	O	-1	24709919
R@@	B-Chemical	C035054	24709919
g@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
,	O	-1	24709919
or	O	-1	24709919
R@@	B-Chemical	C442759	24709919
b@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
intra@@	O	-1	24709919
gast@@	O	-1	24709919
r@@	O	-1	24709919
ically	O	-1	24709919
two	O	-1	24709919
times	O	-1	24709919
per	O	-1	24709919
da@@	O	-1	24709919
y.	O	-1	24709919
O@@	O	-1	24709919
n	O	-1	24709919
the	O	-1	24709919
test	O	-1	24709919
day	O	-1	24709919
(@@	O	-1	24709919
day	O	-1	24709919
10@@	O	-1	24709919
),	O	-1	24709919
mice	O	-1	24709919
were	O	-1	24709919
subj@@	O	-1	24709919
ected	O	-1	24709919
to	O	-1	24709919
the	O	-1	24709919
ther@@	O	-1	24709919
m@@	O	-1	24709919
al	O	-1	24709919
sensitivity	O	-1	24709919
test	O	-1	24709919
and	O	-1	24709919
the	O	-1	24709919
ace@@	B-Chemical	D019342	24709919
tic	I-Chemical	-1	24709919
acid	I-Chemical	-1	24709919
-induced	O	-1	24709919
w@@	O	-1	24709919
ri@@	O	-1	24709919
th@@	O	-1	24709919
ing	O	-1	24709919
test@@	O	-1	24709919
.	O	-1	24709919
R@@	B-Chemical	C049864	24709919
e	I-Chemical	-1	24709919
(3@@	O	-1	24709919
00	O	-1	24709919
mg/kg)	O	-1	24709919
inhibited	O	-1	24709919
O@@	B-Disease	D006930	24709919
I@@	I-Disease	-1	24709919
H	I-Disease	-1	24709919
in	O	-1	24709919
both	O	-1	24709919
the	O	-1	24709919
ther@@	O	-1	24709919
m@@	O	-1	24709919
al	O	-1	24709919
sensitivity	O	-1	24709919
test	O	-1	24709919
and	O	-1	24709919
the	O	-1	24709919
ace@@	B-Chemical	D019342	24709919
tic	I-Chemical	-1	24709919
acid	I-Chemical	-1	24709919
-induced	O	-1	24709919
w@@	O	-1	24709919
ri@@	O	-1	24709919
th@@	O	-1	24709919
ing	O	-1	24709919
test@@	O	-1	24709919
.	O	-1	24709919
However,	O	-1	24709919
the	O	-1	24709919
R@@	B-Chemical	C035054	24709919
g@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
and	I-Chemical	-1	24709919
R@@	I-Chemical	-1	24709919
b@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
g@@	I-Chemical	-1	24709919
in@@	I-Chemical	-1	24709919
sen@@	I-Chemical	-1	24709919
o@@	I-Chemical	-1	24709919
side@@	I-Chemical	-1	24709919
s	I-Chemical	-1	24709919
R@@	B-Chemical	C442759	24709919
g@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
and	I-Chemical	-1	24709919
R@@	I-Chemical	-1	24709919
b@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
g@@	I-Chemical	-1	24709919
in@@	I-Chemical	-1	24709919
sen@@	I-Chemical	-1	24709919
o@@	I-Chemical	-1	24709919
side@@	I-Chemical	-1	24709919
s	I-Chemical	-1	24709919
fail@@	O	-1	24709919
ed	O	-1	24709919
to	O	-1	24709919
prev@@	O	-1	24709919
ent	O	-1	24709919
O@@	B-Disease	D006930	24709919
I@@	I-Disease	-1	24709919
H	I-Disease	-1	24709919
in	O	-1	24709919
either	O	-1	24709919
test@@	O	-1	24709919
.	O	-1	24709919
F@@	O	-1	24709919
ur@@	O	-1	24709919
ther@@	O	-1	24709919
mo@@	O	-1	24709919
re,	O	-1	24709919
R@@	B-Chemical	C035054	24709919
g@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
showed	O	-1	24709919
a	O	-1	24709919
ten@@	O	-1	24709919
d@@	O	-1	24709919
ency	O	-1	24709919
to	O	-1	24709919
ag@@	O	-1	24709919
gra@@	O	-1	24709919
v@@	O	-1	24709919
ate	O	-1	24709919
O@@	B-Disease	D006930	24709919
I@@	I-Disease	-1	24709919
H	I-Disease	-1	24709919
in	O	-1	24709919
the	O	-1	24709919
ace@@	B-Chemical	D019342	24709919
tic	I-Chemical	-1	24709919
acid	I-Chemical	-1	24709919
-induced	O	-1	24709919
w@@	O	-1	24709919
ri@@	O	-1	24709919
th@@	O	-1	24709919
ing	O	-1	24709919
test@@	O	-1	24709919
.	O	-1	24709919
Our	O	-1	24709919
data	O	-1	24709919
suggested	O	-1	24709919
that	O	-1	24709919
the	O	-1	24709919
g@@	B-Chemical	C049864	24709919
in@@	I-Chemical	-1	24709919
sen@@	I-Chemical	-1	24709919
o@@	I-Chemical	-1	24709919
side	I-Chemical	-1	24709919
R@@	I-Chemical	-1	24709919
e	I-Chemical	-1	24709919
,	O	-1	24709919
but	O	-1	24709919
not	O	-1	24709919
R@@	B-Chemical	C035054	24709919
g@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
or	O	-1	24709919
R@@	B-Chemical	C442759	24709919
b@@	I-Chemical	-1	24709919
1	I-Chemical	-1	24709919
,	O	-1	24709919
may	O	-1	24709919
cont@@	O	-1	24709919
rib@@	O	-1	24709919
ute	O	-1	24709919
to@@	O	-1	24709919
war@@	O	-1	24709919
d	O	-1	24709919
rever@@	O	-1	24709919
s@@	O	-1	24709919
al	O	-1	24709919
of	O	-1	24709919
O@@	B-Disease	D006930	24709919
I@@	I-Disease	-1	24709919
H	I-Disease	-1	24709919
.	O	-1	24709919

A	O	-1	24717468
compar@@	O	-1	24717468
ison	O	-1	24717468
of	O	-1	24717468
severe	O	-1	24717468
hemo@@	O	-1	24717468
dynam@@	O	-1	24717468
ic	O	-1	24717468
dist@@	O	-1	24717468
urb@@	O	-1	24717468
anc@@	O	-1	24717468
es	O	-1	24717468
between	O	-1	24717468
de@@	B-Chemical	D020927	24717468
x@@	I-Chemical	-1	24717468
me@@	I-Chemical	-1	24717468
de@@	I-Chemical	-1	24717468
to@@	I-Chemical	-1	24717468
m@@	I-Chemical	-1	24717468
idine	I-Chemical	-1	24717468
and	O	-1	24717468
pro@@	B-Chemical	D015742	24717468
po@@	I-Chemical	-1	24717468
f@@	I-Chemical	-1	24717468
ol	I-Chemical	-1	24717468
for	O	-1	24717468
sed@@	O	-1	24717468
ation	O	-1	24717468
in	O	-1	24717468
neuro@@	O	-1	24717468
cri@@	O	-1	24717468
tical	O	-1	24717468
car@@	O	-1	24717468
e	O	-1	24717468
patients.	O	-1	24717468
OBJECTIVE:	O	-1	24717468
D@@	B-Chemical	D020927	24717468
ex@@	I-Chemical	-1	24717468
me@@	I-Chemical	-1	24717468
de@@	I-Chemical	-1	24717468
to@@	I-Chemical	-1	24717468
m@@	I-Chemical	-1	24717468
idine	I-Chemical	-1	24717468
and	O	-1	24717468
pro@@	B-Chemical	D015742	24717468
po@@	I-Chemical	-1	24717468
f@@	I-Chemical	-1	24717468
ol	I-Chemical	-1	24717468
are	O	-1	24717468
common@@	O	-1	24717468
ly	O	-1	24717468
used	O	-1	24717468
sed@@	O	-1	24717468
ati@@	O	-1	24717468
v@@	O	-1	24717468
es	O	-1	24717468
in	O	-1	24717468
neuro@@	O	-1	24717468
cri@@	O	-1	24717468
tical	O	-1	24717468
car@@	O	-1	24717468
e	O	-1	24717468
as	O	-1	24717468
they	O	-1	24717468
al@@	O	-1	24717468
low	O	-1	24717468
for	O	-1	24717468
frequent	O	-1	24717468
neurolog@@	O	-1	24717468
ic	O	-1	24717468
examin@@	O	-1	24717468
ations.	O	-1	24717468
However,	O	-1	24717468
both	O	-1	24717468
agents	O	-1	24717468
are	O	-1	24717468
associated	O	-1	24717468
with	O	-1	24717468
significant	O	-1	24717468
hemo@@	O	-1	24717468
dynam@@	O	-1	24717468
ic	O	-1	24717468
side	O	-1	24717468
effects.	O	-1	24717468
The	O	-1	24717468
prim@@	O	-1	24717468
ary	O	-1	24717468
ob@@	O	-1	24717468
j@@	O	-1	24717468
ective	O	-1	24717468
of	O	-1	24717468
this	O	-1	24717468
study	O	-1	24717468
is	O	-1	24717468
to	O	-1	24717468
compar@@	O	-1	24717468
e	O	-1	24717468
the	O	-1	24717468
prev@@	O	-1	24717468
al@@	O	-1	24717468
ence	O	-1	24717468
of	O	-1	24717468
severe	O	-1	24717468
hemo@@	O	-1	24717468
dynam@@	O	-1	24717468
ic	O	-1	24717468
effects	O	-1	24717468
in	O	-1	24717468
neuro@@	O	-1	24717468
cri@@	O	-1	24717468
tical	O	-1	24717468
car@@	O	-1	24717468
e	O	-1	24717468
patients	O	-1	24717468
receiving	O	-1	24717468
de@@	B-Chemical	D020927	24717468
x@@	I-Chemical	-1	24717468
me@@	I-Chemical	-1	24717468
de@@	I-Chemical	-1	24717468
to@@	I-Chemical	-1	24717468
m@@	I-Chemical	-1	24717468
idine	I-Chemical	-1	24717468
and	O	-1	24717468
pro@@	B-Chemical	D015742	24717468
po@@	I-Chemical	-1	24717468
f@@	I-Chemical	-1	24717468
ol	I-Chemical	-1	24717468
.	O	-1	24717468
D@@	O	-1	24717468
ES@@	O	-1	24717468
I@@	O	-1	24717468
G@@	O	-1	24717468
N@@	O	-1	24717468
:	O	-1	24717468
M@@	O	-1	24717468
ul@@	O	-1	24717468
tic@@	O	-1	24717468
ent@@	O	-1	24717468
er,	O	-1	24717468
ret@@	O	-1	24717468
ro@@	O	-1	24717468
sp@@	O	-1	24717468
ecti@@	O	-1	24717468
ve,	O	-1	24717468
pro@@	O	-1	24717468
pen@@	O	-1	24717468
sit@@	O	-1	24717468
y-@@	O	-1	24717468
mat@@	O	-1	24717468
ch@@	O	-1	24717468
ed	O	-1	24717468
co@@	O	-1	24717468
h@@	O	-1	24717468
ort	O	-1	24717468
study.	O	-1	24717468
S@@	O	-1	24717468
ET@@	O	-1	24717468
TI@@	O	-1	24717468
N@@	O	-1	24717468
G@@	O	-1	24717468
:	O	-1	24717468
Ne@@	O	-1	24717468
uro@@	O	-1	24717468
cri@@	O	-1	24717468
tical	O	-1	24717468
car@@	O	-1	24717468
e	O	-1	24717468
un@@	O	-1	24717468
its	O	-1	24717468
at	O	-1	24717468
two	O	-1	24717468
ac@@	O	-1	24717468
ade@@	O	-1	24717468
mic	O	-1	24717468
med@@	O	-1	24717468
ical	O	-1	24717468
c@@	O	-1	24717468
ent@@	O	-1	24717468
ers	O	-1	24717468
with	O	-1	24717468
de@@	O	-1	24717468
dic@@	O	-1	24717468
ated	O	-1	24717468
neuro@@	O	-1	24717468
cri@@	O	-1	24717468
tical	O	-1	24717468
car@@	O	-1	24717468
e	O	-1	24717468
te@@	O	-1	24717468
am@@	O	-1	24717468
s	O	-1	24717468
and	O	-1	24717468
bo@@	O	-1	24717468
ar@@	O	-1	24717468
d-@@	O	-1	24717468
cer@@	O	-1	24717468
ti@@	O	-1	24717468
fied	O	-1	24717468
neuro@@	O	-1	24717468
int@@	O	-1	24717468
en@@	O	-1	24717468
si@@	O	-1	24717468
vi@@	O	-1	24717468
st@@	O	-1	24717468
s.	O	-1	24717468
PA@@	O	-1	24717468
TI@@	O	-1	24717468
E@@	O	-1	24717468
N@@	O	-1	24717468
T@@	O	-1	24717468
S:	O	-1	24717468
Ne@@	O	-1	24717468
uro@@	O	-1	24717468
cri@@	O	-1	24717468
tical	O	-1	24717468
car@@	O	-1	24717468
e	O	-1	24717468
patients	O	-1	24717468
ad@@	O	-1	24717468
mit@@	O	-1	24717468
ted	O	-1	24717468
between	O	-1	24717468
J@@	O	-1	24717468
ul@@	O	-1	24717468
y	O	-1	24717468
20@@	O	-1	24717468
0@@	O	-1	24717468
9	O	-1	24717468
and	O	-1	24717468
S@@	O	-1	24717468
e@@	O	-1	24717468
pt@@	O	-1	24717468
emb@@	O	-1	24717468
er	O	-1	24717468
20@@	O	-1	24717468
12	O	-1	24717468
were	O	-1	24717468
evaluated	O	-1	24717468
and	O	-1	24717468
then	O	-1	24717468
mat@@	O	-1	24717468
ch@@	O	-1	24717468
ed	O	-1	24717468
1@@	O	-1	24717468
:@@	O	-1	24717468
1	O	-1	24717468
bas@@	O	-1	24717468
ed	O	-1	24717468
on	O	-1	24717468
pro@@	O	-1	24717468
pen@@	O	-1	24717468
s@@	O	-1	24717468
ity	O	-1	24717468
scor@@	O	-1	24717468
ing	O	-1	24717468
of	O	-1	24717468
baseline	O	-1	24717468
character@@	O	-1	24717468
is@@	O	-1	24717468
tic@@	O	-1	24717468
s.	O	-1	24717468
IN@@	O	-1	24717468
TE@@	O	-1	24717468
R@@	O	-1	24717468
V@@	O	-1	24717468
E@@	O	-1	24717468
N@@	O	-1	24717468
T@@	O	-1	24717468
ION@@	O	-1	24717468
S:	O	-1	24717468
C@@	O	-1	24717468
ont@@	O	-1	24717468
in@@	O	-1	24717468
u@@	O	-1	24717468
ous	O	-1	24717468
sed@@	O	-1	24717468
ation	O	-1	24717468
with	O	-1	24717468
de@@	B-Chemical	D020927	24717468
x@@	I-Chemical	-1	24717468
me@@	I-Chemical	-1	24717468
de@@	I-Chemical	-1	24717468
to@@	I-Chemical	-1	24717468
m@@	I-Chemical	-1	24717468
idine	I-Chemical	-1	24717468
or	O	-1	24717468
pro@@	B-Chemical	D015742	24717468
po@@	I-Chemical	-1	24717468
f@@	I-Chemical	-1	24717468
ol	I-Chemical	-1	24717468
.	O	-1	24717468
M@@	O	-1	24717468
E@@	O	-1	24717468
A@@	O	-1	24717468
S@@	O	-1	24717468
U@@	O	-1	24717468
R@@	O	-1	24717468
E@@	O	-1	24717468
M@@	O	-1	24717468
E@@	O	-1	24717468
N@@	O	-1	24717468
T@@	O	-1	24717468
S	O	-1	24717468
AN@@	O	-1	24717468
D	O	-1	24717468
MA@@	O	-1	24717468
I@@	O	-1	24717468
N	O	-1	24717468
RESULTS:	O	-1	24717468
A	O	-1	24717468
total	O	-1	24717468
of	O	-1	24717468
34@@	O	-1	24717468
2	O	-1	24717468
patients	O	-1	24717468
(@@	O	-1	24717468
10@@	O	-1	24717468
5	O	-1	24717468
de@@	B-Chemical	D020927	24717468
x@@	I-Chemical	-1	24717468
me@@	I-Chemical	-1	24717468
de@@	I-Chemical	-1	24717468
to@@	I-Chemical	-1	24717468
m@@	I-Chemical	-1	24717468
idine	I-Chemical	-1	24717468
and	O	-1	24717468
2@@	O	-1	24717468
3@@	O	-1	24717468
7	O	-1	24717468
pro@@	B-Chemical	D015742	24717468
po@@	I-Chemical	-1	24717468
f@@	I-Chemical	-1	24717468
ol	I-Chemical	-1	24717468
)	O	-1	24717468
were	O	-1	24717468
included	O	-1	24717468
in	O	-1	24717468
the	O	-1	24717468
analy@@	O	-1	24717468
sis,	O	-1	24717468
with	O	-1	24717468
19@@	O	-1	24717468
0	O	-1	24717468
mat@@	O	-1	24717468
ch@@	O	-1	24717468
ed	O	-1	24717468
(@@	O	-1	24717468
9@@	O	-1	24717468
5	O	-1	24717468
in	O	-1	24717468
each	O	-1	24717468
group@@	O	-1	24717468
)	O	-1	24717468
by	O	-1	24717468
pro@@	O	-1	24717468
pen@@	O	-1	24717468
s@@	O	-1	24717468
ity	O	-1	24717468
sco@@	O	-1	24717468
re.	O	-1	24717468
The	O	-1	24717468
prim@@	O	-1	24717468
ary	O	-1	24717468
outcom@@	O	-1	24717468
e	O	-1	24717468
of	O	-1	24717468
this	O	-1	24717468
study	O	-1	24717468
was	O	-1	24717468
a	O	-1	24717468
com@@	O	-1	24717468
pos@@	O	-1	24717468
ite	O	-1	24717468
of	O	-1	24717468
severe	O	-1	24717468
hypotension	B-Disease	D007022	24717468
(@@	O	-1	24717468
mean	O	-1	24717468
arterial	O	-1	24717468
pressure	O	-1	24717468
<	O	-1	24717468
60	O	-1	24717468
mm	O	-1	24717468
H@@	O	-1	24717468
g@@	O	-1	24717468
)	O	-1	24717468
and	O	-1	24717468
brady@@	B-Disease	D001919	24717468
cardia	I-Disease	-1	24717468
(@@	O	-1	24717468
heart	O	-1	24717468
rate	O	-1	24717468
<	O	-1	24717468
50	O	-1	24717468
be@@	O	-1	24717468
at@@	O	-1	24717468
s/@@	O	-1	24717468
min@@	O	-1	24717468
)	O	-1	24717468
during	O	-1	24717468
sed@@	O	-1	24717468
ative	O	-1	24717468
infu@@	O	-1	24717468
sion.	O	-1	24717468
No	O	-1	24717468
difference	O	-1	24717468
in	O	-1	24717468
the	O	-1	24717468
prim@@	O	-1	24717468
ary	O	-1	24717468
com@@	O	-1	24717468
pos@@	O	-1	24717468
ite	O	-1	24717468
outcom@@	O	-1	24717468
e	O	-1	24717468
in	O	-1	24717468
both	O	-1	24717468
the	O	-1	24717468
un@@	O	-1	24717468
mat@@	O	-1	24717468
ch@@	O	-1	24717468
ed	O	-1	24717468
(3@@	O	-1	24717468
0%	O	-1	24717468
v@@	O	-1	24717468
s	O	-1	24717468
3@@	O	-1	24717468
0@@	O	-1	24717468
%,	O	-1	24717468
p	O	-1	24717468
=	O	-1	24717468
0.@@	O	-1	24717468
9@@	O	-1	24717468
4@@	O	-1	24717468
)	O	-1	24717468
or	O	-1	24717468
mat@@	O	-1	24717468
ch@@	O	-1	24717468
ed	O	-1	24717468
co@@	O	-1	24717468
h@@	O	-1	24717468
or@@	O	-1	24717468
ts	O	-1	24717468
(2@@	O	-1	24717468
8@@	O	-1	24717468
%	O	-1	24717468
v@@	O	-1	24717468
s	O	-1	24717468
34@@	O	-1	24717468
%,	O	-1	24717468
p	O	-1	24717468
=	O	-1	24717468
0.@@	O	-1	24717468
3@@	O	-1	24717468
5@@	O	-1	24717468
)	O	-1	24717468
could	O	-1	24717468
be	O	-1	24717468
f@@	O	-1	24717468
oun@@	O	-1	24717468
d.	O	-1	24717468
Whe@@	O	-1	24717468
n	O	-1	24717468
analy@@	O	-1	24717468
zed	O	-1	24717468
se@@	O	-1	24717468
par@@	O	-1	24717468
at@@	O	-1	24717468
el@@	O	-1	24717468
y,	O	-1	24717468
no	O	-1	24717468
differences	O	-1	24717468
could	O	-1	24717468
be	O	-1	24717468
found	O	-1	24717468
in	O	-1	24717468
the	O	-1	24717468
prev@@	O	-1	24717468
al@@	O	-1	24717468
ence	O	-1	24717468
of	O	-1	24717468
severe	O	-1	24717468
hypotension	B-Disease	D007022	24717468
or	O	-1	24717468
brady@@	B-Disease	D001919	24717468
cardia	I-Disease	-1	24717468
in	O	-1	24717468
either	O	-1	24717468
the	O	-1	24717468
un@@	O	-1	24717468
mat@@	O	-1	24717468
ch@@	O	-1	24717468
ed	O	-1	24717468
or	O	-1	24717468
mat@@	O	-1	24717468
ch@@	O	-1	24717468
ed	O	-1	24717468
co@@	O	-1	24717468
h@@	O	-1	24717468
ort@@	O	-1	24717468
s.	O	-1	24717468
CONCLUSIONS:	O	-1	24717468
S@@	O	-1	24717468
ev@@	O	-1	24717468
ere	O	-1	24717468
hypotension	B-Disease	D007022	24717468
and	O	-1	24717468
brady@@	B-Disease	D001919	24717468
cardia	I-Disease	-1	24717468
occ@@	O	-1	24717468
ur	O	-1	24717468
at	O	-1	24717468
similar	O	-1	24717468
prev@@	O	-1	24717468
al@@	O	-1	24717468
ence	O	-1	24717468
in	O	-1	24717468
neuro@@	O	-1	24717468
cri@@	O	-1	24717468
tical	O	-1	24717468
car@@	O	-1	24717468
e	O	-1	24717468
patients	O	-1	24717468
who	O	-1	24717468
recei@@	O	-1	24717468
ve	O	-1	24717468
de@@	B-Chemical	D020927	24717468
x@@	I-Chemical	-1	24717468
me@@	I-Chemical	-1	24717468
de@@	I-Chemical	-1	24717468
to@@	I-Chemical	-1	24717468
m@@	I-Chemical	-1	24717468
idine	I-Chemical	-1	24717468
or	O	-1	24717468
pro@@	B-Chemical	D015742	24717468
po@@	I-Chemical	-1	24717468
f@@	I-Chemical	-1	24717468
ol	I-Chemical	-1	24717468
.	O	-1	24717468
Pro@@	O	-1	24717468
vid@@	O	-1	24717468
ers	O	-1	24717468
should	O	-1	24717468
simil@@	O	-1	24717468
arly	O	-1	24717468
con@@	O	-1	24717468
si@@	O	-1	24717468
der	O	-1	24717468
the	O	-1	24717468
lik@@	O	-1	24717468
e@@	O	-1	24717468
li@@	O	-1	24717468
ho@@	O	-1	24717468
od	O	-1	24717468
of	O	-1	24717468
hypotension	B-Disease	D007022	24717468
or	O	-1	24717468
brady@@	B-Disease	D001919	24717468
cardia	I-Disease	-1	24717468
before	O	-1	24717468
star@@	O	-1	24717468
ting	O	-1	24717468
either	O	-1	24717468
sed@@	O	-1	24717468
ati@@	O	-1	24717468
ve.	O	-1	24717468

H@@	B-Chemical	C005975	24727461
y@@	I-Chemical	-1	24727461
dro@@	I-Chemical	-1	24727461
x@@	I-Chemical	-1	24727461
y@@	I-Chemical	-1	24727461
ty@@	I-Chemical	-1	24727461
ros@@	I-Chemical	-1	24727461
ol	I-Chemical	-1	24727461
ame@@	O	-1	24727461
li@@	O	-1	24727461
or@@	O	-1	24727461
ates	O	-1	24727461
oxid@@	O	-1	24727461
ative	O	-1	24727461
stres@@	O	-1	24727461
s	O	-1	24727461
and	O	-1	24727461
mitochondrial	B-Disease	D028361	24727461
dysfunction	I-Disease	-1	24727461
in	O	-1	24727461
dox@@	B-Chemical	D004317	24727461
orub@@	I-Chemical	-1	24727461
icin	I-Chemical	-1	24727461
-induced	O	-1	24727461
cardi@@	B-Disease	D066126	24727461
otoxicity	I-Disease	-1	24727461
in	O	-1	24727461
rats	O	-1	24727461
with	O	-1	24727461
b@@	B-Disease	D001943	24727461
reas@@	I-Disease	-1	24727461
t	I-Disease	-1	24727461
cancer	I-Disease	-1	24727461
.	O	-1	24727461
O@@	O	-1	24727461
x@@	O	-1	24727461
id@@	O	-1	24727461
ative	O	-1	24727461
stres@@	O	-1	24727461
s	O	-1	24727461
is	O	-1	24727461
involved	O	-1	24727461
in	O	-1	24727461
several	O	-1	24727461
pro@@	O	-1	24727461
ces@@	O	-1	24727461
ses	O	-1	24727461
including	O	-1	24727461
cancer	B-Disease	D009369	24727461
,	O	-1	24727461
ag@@	O	-1	24727461
ing	O	-1	24727461
and	O	-1	24727461
cardiovascular	B-Disease	D002318	24727461
disease	I-Disease	-1	24727461
,	O	-1	24727461
and	O	-1	24727461
has	O	-1	24727461
been	O	-1	24727461
shown	O	-1	24727461
to	O	-1	24727461
potenti@@	O	-1	24727461
ate	O	-1	24727461
the	O	-1	24727461
therapeutic	O	-1	24727461
effect	O	-1	24727461
of	O	-1	24727461
drugs	O	-1	24727461
such	O	-1	24727461
as	O	-1	24727461
dox@@	B-Chemical	D004317	24727461
orub@@	I-Chemical	-1	24727461
icin	I-Chemical	-1	24727461
.	O	-1	24727461
D@@	B-Chemical	D004317	24727461
ox@@	I-Chemical	-1	24727461
orub@@	I-Chemical	-1	24727461
icin	I-Chemical	-1	24727461
causes	O	-1	24727461
significant	O	-1	24727461
cardi@@	B-Disease	D066126	24727461
otoxicity	I-Disease	-1	24727461
character@@	O	-1	24727461
ized	O	-1	24727461
by	O	-1	24727461
mark@@	O	-1	24727461
ed	O	-1	24727461
increases	O	-1	24727461
in	O	-1	24727461
oxid@@	O	-1	24727461
ative	O	-1	24727461
stres@@	O	-1	24727461
s	O	-1	24727461
and	O	-1	24727461
mitochondrial	B-Disease	D028361	24727461
dysfunction	I-Disease	-1	24727461
.	O	-1	24727461
He@@	O	-1	24727461
re@@	O	-1	24727461
in,	O	-1	24727461
we	O	-1	24727461
investigate	O	-1	24727461
whether	O	-1	24727461
dox@@	B-Chemical	D004317	24727461
orub@@	I-Chemical	-1	24727461
icin	I-Chemical	-1	24727461
-@@	O	-1	24727461
associated	O	-1	24727461
chronic	O	-1	24727461
cardiac	B-Disease	D066126	24727461
toxicity	I-Disease	-1	24727461
can	O	-1	24727461
be	O	-1	24727461
ame@@	O	-1	24727461
li@@	O	-1	24727461
or@@	O	-1	24727461
ated	O	-1	24727461
with	O	-1	24727461
the	O	-1	24727461
anti@@	O	-1	24727461
oxid@@	O	-1	24727461
ant	O	-1	24727461
hydrox@@	B-Chemical	C005975	24727461
y@@	I-Chemical	-1	24727461
ty@@	I-Chemical	-1	24727461
ros@@	I-Chemical	-1	24727461
ol	I-Chemical	-1	24727461
in	O	-1	24727461
rats	O	-1	24727461
with	O	-1	24727461
b@@	B-Disease	D001943	24727461
reas@@	I-Disease	-1	24727461
t	I-Disease	-1	24727461
cancer	I-Disease	-1	24727461
.	O	-1	24727461
Th@@	O	-1	24727461
ir@@	O	-1	24727461
ty-@@	O	-1	24727461
six	O	-1	24727461
rats	O	-1	24727461
be@@	O	-1	24727461
ar@@	O	-1	24727461
ing	O	-1	24727461
b@@	B-Disease	D001943	24727461
reas@@	I-Disease	-1	24727461
t	I-Disease	-1	24727461
tu@@	I-Disease	-1	24727461
mor@@	I-Disease	-1	24727461
s	I-Disease	-1	24727461
induced	O	-1	24727461
chem@@	O	-1	24727461
ically	O	-1	24727461
were	O	-1	24727461
divid@@	O	-1	24727461
ed	O	-1	24727461
into	O	-1	24727461
4	O	-1	24727461
group@@	O	-1	24727461
s:	O	-1	24727461
control@@	O	-1	24727461
,	O	-1	24727461
hydrox@@	B-Chemical	C005975	24727461
y@@	I-Chemical	-1	24727461
ty@@	I-Chemical	-1	24727461
ros@@	I-Chemical	-1	24727461
ol	I-Chemical	-1	24727461
(0.@@	O	-1	24727461
5@@	O	-1	24727461
mg/kg@@	O	-1	24727461
,	O	-1	24727461
5@@	O	-1	24727461
da@@	O	-1	24727461
ys@@	O	-1	24727461
/@@	O	-1	24727461
week@@	O	-1	24727461
),	O	-1	24727461
dox@@	B-Chemical	D004317	24727461
orub@@	I-Chemical	-1	24727461
icin	I-Chemical	-1	24727461
(1@@	O	-1	24727461
mg/k@@	O	-1	24727461
g/@@	O	-1	24727461
week@@	O	-1	24727461
),	O	-1	24727461
and	O	-1	24727461
dox@@	B-Chemical	D004317	24727461
orub@@	I-Chemical	-1	24727461
icin	I-Chemical	-1	24727461
plus	O	-1	24727461
hydrox@@	B-Chemical	C005975	24727461
y@@	I-Chemical	-1	24727461
ty@@	I-Chemical	-1	24727461
ros@@	I-Chemical	-1	24727461
ol	I-Chemical	-1	24727461
.	O	-1	24727461
C@@	B-Disease	D006331	24727461
ardi@@	I-Disease	-1	24727461
a@@	I-Disease	-1	24727461
c	I-Disease	-1	24727461
dist@@	I-Disease	-1	24727461
urb@@	I-Disease	-1	24727461
anc@@	I-Disease	-1	24727461
es	I-Disease	-1	24727461
at	O	-1	24727461
the	O	-1	24727461
cell@@	O	-1	24727461
ular	O	-1	24727461
and	O	-1	24727461
mitochondrial	O	-1	24727461
level@@	O	-1	24727461
,	O	-1	24727461
mitochondrial	O	-1	24727461
electro@@	O	-1	24727461
n	O	-1	24727461
trans@@	O	-1	24727461
por@@	O	-1	24727461
t	O	-1	24727461
ch@@	O	-1	24727461
ain	O	-1	24727461
comple@@	O	-1	24727461
x@@	O	-1	24727461
es	O	-1	24727461
I@@	O	-1	24727461
-@@	O	-1	24727461
IV	O	-1	24727461
and	O	-1	24727461
apo@@	O	-1	24727461
pto@@	O	-1	24727461
si@@	O	-1	24727461
s-@@	O	-1	24727461
induc@@	O	-1	24727461
ing	O	-1	24727461
fact@@	O	-1	24727461
or@@	O	-1	24727461
,	O	-1	24727461
and	O	-1	24727461
oxid@@	O	-1	24727461
ative	O	-1	24727461
stres@@	O	-1	24727461
s	O	-1	24727461
mark@@	O	-1	24727461
ers	O	-1	24727461
have	O	-1	24727461
been	O	-1	24727461
analy@@	O	-1	24727461
z@@	O	-1	24727461
ed.	O	-1	24727461
H@@	B-Chemical	C005975	24727461
y@@	I-Chemical	-1	24727461
dro@@	I-Chemical	-1	24727461
x@@	I-Chemical	-1	24727461
y@@	I-Chemical	-1	24727461
ty@@	I-Chemical	-1	24727461
ros@@	I-Chemical	-1	24727461
ol	I-Chemical	-1	24727461
improved	O	-1	24727461
the	O	-1	24727461
cardiac	B-Disease	D006331	24727461
dist@@	I-Disease	-1	24727461
urb@@	I-Disease	-1	24727461
anc@@	I-Disease	-1	24727461
es	I-Disease	-1	24727461
enhanced	O	-1	24727461
by	O	-1	24727461
dox@@	B-Chemical	D004317	24727461
orub@@	I-Chemical	-1	24727461
icin	I-Chemical	-1	24727461
by	O	-1	24727461
significantly	O	-1	24727461
reduc@@	O	-1	24727461
ing	O	-1	24727461
the	O	-1	24727461
perc@@	O	-1	24727461
ent@@	O	-1	24727461
age	O	-1	24727461
of	O	-1	24727461
al@@	O	-1	24727461
te@@	O	-1	24727461
red	O	-1	24727461
mitochond@@	O	-1	24727461
ri@@	O	-1	24727461
a	O	-1	24727461
and	O	-1	24727461
oxid@@	O	-1	24727461
ative	O	-1	24727461
dam@@	O	-1	24727461
age.	O	-1	24727461
These	O	-1	24727461
results	O	-1	24727461
suggest	O	-1	24727461
that	O	-1	24727461
hydrox@@	B-Chemical	C005975	24727461
y@@	I-Chemical	-1	24727461
ty@@	I-Chemical	-1	24727461
ros@@	I-Chemical	-1	24727461
ol	I-Chemical	-1	24727461
impro@@	O	-1	24727461
ve	O	-1	24727461
the	O	-1	24727461
mitochondrial	O	-1	24727461
electro@@	O	-1	24727461
n	O	-1	24727461
trans@@	O	-1	24727461
por@@	O	-1	24727461
t	O	-1	24727461
ch@@	O	-1	24727461
ain@@	O	-1	24727461
.	O	-1	24727461
This	O	-1	24727461
study	O	-1	24727461
demon@@	O	-1	24727461
strat@@	O	-1	24727461
es	O	-1	24727461
that	O	-1	24727461
hydrox@@	B-Chemical	C005975	24727461
y@@	I-Chemical	-1	24727461
ty@@	I-Chemical	-1	24727461
ros@@	I-Chemical	-1	24727461
ol	I-Chemical	-1	24727461
prot@@	O	-1	24727461
ect	O	-1	24727461
rat	O	-1	24727461
heart	B-Disease	D006331	24727461
damage	I-Disease	-1	24727461
prov@@	O	-1	24727461
o@@	O	-1	24727461
ked	O	-1	24727461
by	O	-1	24727461
dox@@	B-Chemical	D004317	24727461
orub@@	I-Chemical	-1	24727461
icin	I-Chemical	-1	24727461
decreas@@	O	-1	24727461
ing	O	-1	24727461
oxid@@	O	-1	24727461
ative	O	-1	24727461
damage	O	-1	24727461
and	O	-1	24727461
mitochondrial	O	-1	24727461
al@@	O	-1	24727461
ter@@	O	-1	24727461
ations.	O	-1	24727461

A@@	B-Chemical	D000638	24729111
m@@	I-Chemical	-1	24729111
iodar@@	I-Chemical	-1	24729111
one	I-Chemical	-1	24729111
-induced	O	-1	24729111
my@@	B-Disease	D007037	24729111
x@@	I-Disease	-1	24729111
o@@	I-Disease	-1	24729111
e@@	I-Disease	-1	24729111
de@@	I-Disease	-1	24729111
ma	I-Disease	-1	24729111
com@@	I-Disease	-1	24729111
a	I-Disease	-1	24729111
my@@	B-Disease	D003128	24729111
x@@	I-Disease	-1	24729111
o@@	I-Disease	-1	24729111
e@@	I-Disease	-1	24729111
de@@	I-Disease	-1	24729111
ma	I-Disease	-1	24729111
com@@	I-Disease	-1	24729111
a	I-Disease	-1	24729111
.	O	-1	24729111
A	O	-1	24729111
6@@	O	-1	24729111
2-@@	O	-1	24729111
year-old	O	-1	24729111
man	O	-1	24729111
was	O	-1	24729111
found	O	-1	24729111
to	O	-1	24729111
have	O	-1	24729111
brady@@	B-Disease	D001919	24729111
cardia	I-Disease	-1	24729111
,	O	-1	24729111
hypo@@	B-Disease	D007035	24729111
ther@@	I-Disease	-1	24729111
mia	I-Disease	-1	24729111
and	O	-1	24729111
respiratory	B-Disease	D012131	24729111
failure	I-Disease	-1	24729111
3	O	-1	24729111
weeks	O	-1	24729111
after	O	-1	24729111
initi@@	O	-1	24729111
ation	O	-1	24729111
of	O	-1	24729111
am@@	B-Chemical	D000638	24729111
iodar@@	I-Chemical	-1	24729111
one	I-Chemical	-1	24729111
therapy	O	-1	24729111
for	O	-1	24729111
atrial	B-Disease	D001281	24729111
fibrill@@	I-Disease	-1	24729111
ation	I-Disease	-1	24729111
.	O	-1	24729111
Th@@	O	-1	24729111
yro@@	O	-1	24729111
id@@	O	-1	24729111
-@@	O	-1	24729111
stimul@@	O	-1	24729111
ating	O	-1	24729111
h@@	O	-1	24729111
orm@@	O	-1	24729111
one	O	-1	24729111
was	O	-1	24729111
found	O	-1	24729111
to	O	-1	24729111
be	O	-1	24729111
1@@	O	-1	24729111
6@@	O	-1	24729111
8	O	-1	24729111
u@@	O	-1	24729111
I@@	O	-1	24729111
U@@	O	-1	24729111
/@@	O	-1	24729111
m@@	O	-1	24729111
L	O	-1	24729111
(n@@	O	-1	24729111
l@@	O	-1	24729111
.	O	-1	24729111
0.@@	O	-1	24729111
3-@@	O	-1	24729111
5	O	-1	24729111
u@@	O	-1	24729111
I@@	O	-1	24729111
U@@	O	-1	24729111
/@@	O	-1	24729111
m@@	O	-1	24729111
L@@	O	-1	24729111
)	O	-1	24729111
and	O	-1	24729111
free	O	-1	24729111
th@@	B-Chemical	D013974	24729111
yro@@	I-Chemical	-1	24729111
x@@	I-Chemical	-1	24729111
ine	I-Chemical	-1	24729111
(@@	O	-1	24729111
F@@	O	-1	24729111
T@@	O	-1	24729111
4@@	O	-1	24729111
)	O	-1	24729111
was	O	-1	24729111
<@@	O	-1	24729111
0.@@	O	-1	24729111
2	O	-1	24729111
n@@	O	-1	24729111
g/@@	O	-1	24729111
d@@	O	-1	24729111
L	O	-1	24729111
(n@@	O	-1	24729111
l@@	O	-1	24729111
.	O	-1	24729111
0.@@	O	-1	24729111
8@@	O	-1	24729111
-@@	O	-1	24729111
1.@@	O	-1	24729111
8	O	-1	24729111
n@@	O	-1	24729111
g/@@	O	-1	24729111
d@@	O	-1	24729111
L@@	O	-1	24729111
).	O	-1	24729111
H@@	O	-1	24729111
e	O	-1	24729111
received	O	-1	24729111
intravenous	O	-1	24729111
flu@@	O	-1	24729111
id@@	O	-1	24729111
s,	O	-1	24729111
vas@@	O	-1	24729111
o@@	O	-1	24729111
press@@	O	-1	24729111
or	O	-1	24729111
therapy	O	-1	24729111
and	O	-1	24729111
stres@@	O	-1	24729111
s	O	-1	24729111
dose	O	-1	24729111
steroid@@	B-Chemical	D013256	24729111
s	I-Chemical	-1	24729111
;	O	-1	24729111
he	O	-1	24729111
was	O	-1	24729111
int@@	O	-1	24729111
ub@@	O	-1	24729111
ated	O	-1	24729111
and	O	-1	24729111
ad@@	O	-1	24729111
mit@@	O	-1	24729111
ted	O	-1	24729111
to	O	-1	24729111
the	O	-1	24729111
int@@	O	-1	24729111
en@@	O	-1	24729111
sive	O	-1	24729111
car@@	O	-1	24729111
e	O	-1	24729111
un@@	O	-1	24729111
it@@	O	-1	24729111
.	O	-1	24729111
H@@	O	-1	24729111
e	O	-1	24729111
received	O	-1	24729111
5@@	O	-1	24729111
00	O	-1	24729111
u@@	O	-1	24729111
g	O	-1	24729111
of	O	-1	24729111
intravenous	O	-1	24729111
levo@@	B-Chemical	D013974	24729111
th@@	I-Chemical	-1	24729111
yro@@	I-Chemical	-1	24729111
x@@	I-Chemical	-1	24729111
ine	I-Chemical	-1	24729111
in	O	-1	24729111
the	O	-1	24729111
first	O	-1	24729111
1@@	O	-1	24729111
8	O	-1	24729111
h	O	-1	24729111
of	O	-1	24729111
therapy,	O	-1	24729111
and	O	-1	24729111
1@@	O	-1	24729111
50	O	-1	24729111
u@@	O	-1	24729111
g	O	-1	24729111
intravenous	O	-1	24729111
daily	O	-1	24729111
the@@	O	-1	24729111
re@@	O	-1	24729111
af@@	O	-1	24729111
ter@@	O	-1	24729111
.	O	-1	24729111
H@@	O	-1	24729111
a@@	O	-1	24729111
em@@	O	-1	24729111
o@@	O	-1	24729111
dynam@@	O	-1	24729111
ic	O	-1	24729111
impro@@	O	-1	24729111
ve@@	O	-1	24729111
ment@@	O	-1	24729111
,	O	-1	24729111
al@@	O	-1	24729111
ong	O	-1	24729111
with	O	-1	24729111
complete	O	-1	24729111
recovery	O	-1	24729111
of	O	-1	24729111
mental	O	-1	24729111
stat@@	O	-1	24729111
us,	O	-1	24729111
occurred	O	-1	24729111
after	O	-1	24729111
4@@	O	-1	24729111
8	O	-1	24729111
h@@	O	-1	24729111
.	O	-1	24729111
T@@	O	-1	24729111
we@@	O	-1	24729111
l@@	O	-1	24729111
ve	O	-1	24729111
hours	O	-1	24729111
after	O	-1	24729111
the	O	-1	24729111
initi@@	O	-1	24729111
ation	O	-1	24729111
of	O	-1	24729111
therapy,	O	-1	24729111
F@@	O	-1	24729111
T@@	O	-1	24729111
4	O	-1	24729111
was	O	-1	24729111
0.@@	O	-1	24729111
9@@	O	-1	24729111
6	O	-1	24729111
n@@	O	-1	24729111
g/@@	O	-1	24729111
d@@	O	-1	24729111
L@@	O	-1	24729111
.	O	-1	24729111
The	O	-1	24729111
patient	O	-1	24729111
was	O	-1	24729111
maint@@	O	-1	24729111
ained	O	-1	24729111
on	O	-1	24729111
levo@@	B-Chemical	D013974	24729111
th@@	I-Chemical	-1	24729111
yro@@	I-Chemical	-1	24729111
x@@	I-Chemical	-1	24729111
ine	I-Chemical	-1	24729111
17@@	O	-1	24729111
5	O	-1	24729111
(@@	O	-1	24729111
g	O	-1	24729111
P@@	O	-1	24729111
O@@	O	-1	24729111
or@@	O	-1	24729111
ally	O	-1	24729111
da@@	O	-1	24729111
il@@	O	-1	24729111
y.	O	-1	24729111
A	O	-1	24729111
th@@	O	-1	24729111
yro@@	O	-1	24729111
id	O	-1	24729111
ult@@	O	-1	24729111
r@@	O	-1	24729111
as@@	O	-1	24729111
ound	O	-1	24729111
showed	O	-1	24729111
diff@@	O	-1	24729111
use	O	-1	24729111
he@@	O	-1	24729111
ter@@	O	-1	24729111
o@@	O	-1	24729111
gene@@	O	-1	24729111
ity.	O	-1	24729111
The	O	-1	24729111
24	O	-1	24729111
h@@	O	-1	24729111
our	O	-1	24729111
ex@@	O	-1	24729111
cre@@	O	-1	24729111
tion	O	-1	24729111
of	O	-1	24729111
iod@@	B-Chemical	D007455	24729111
ine	I-Chemical	-1	24729111
was	O	-1	24729111
3@@	O	-1	24729111
6@@	O	-1	24729111
5@@	O	-1	24729111
7	O	-1	24729111
(@@	O	-1	24729111
m@@	O	-1	24729111
c@@	O	-1	24729111
g	O	-1	24729111
(2@@	O	-1	24729111
5-@@	O	-1	24729111
7@@	O	-1	24729111
5@@	O	-1	24729111
6	O	-1	24729111
(	O	-1	24729111
m@@	O	-1	24729111
c@@	O	-1	24729111
g@@	O	-1	24729111
).	O	-1	24729111
The	O	-1	24729111
only	O	-1	24729111
two	O	-1	24729111
cases	O	-1	24729111
of	O	-1	24729111
am@@	B-Chemical	D000638	24729111
iodar@@	I-Chemical	-1	24729111
one	I-Chemical	-1	24729111
-induced	O	-1	24729111
my@@	B-Disease	D007037	24729111
x@@	I-Disease	-1	24729111
o@@	I-Disease	-1	24729111
e@@	I-Disease	-1	24729111
de@@	I-Disease	-1	24729111
ma	I-Disease	-1	24729111
com@@	I-Disease	-1	24729111
a	I-Disease	-1	24729111
my@@	B-Disease	D003128	24729111
x@@	I-Disease	-1	24729111
o@@	I-Disease	-1	24729111
e@@	I-Disease	-1	24729111
de@@	I-Disease	-1	24729111
ma	I-Disease	-1	24729111
com@@	I-Disease	-1	24729111
a	I-Disease	-1	24729111
in	O	-1	24729111
the	O	-1	24729111
literat@@	O	-1	24729111
ure	O	-1	24729111
report	O	-1	24729111
patient	O	-1	24729111
death	O	-1	24729111
des@@	O	-1	24729111
pit@@	O	-1	24729111
e	O	-1	24729111
suppor@@	O	-1	24729111
tive	O	-1	24729111
therapy	O	-1	24729111
and	O	-1	24729111
th@@	O	-1	24729111
yro@@	O	-1	24729111
id	O	-1	24729111
h@@	O	-1	24729111
orm@@	O	-1	24729111
one	O	-1	24729111
re@@	O	-1	24729111
pl@@	O	-1	24729111
ac@@	O	-1	24729111
em@@	O	-1	24729111
ent@@	O	-1	24729111
.	O	-1	24729111
This	O	-1	24729111
case	O	-1	24729111
re@@	O	-1	24729111
pres@@	O	-1	24729111
ents	O	-1	24729111
the	O	-1	24729111
most	O	-1	24729111
th@@	O	-1	24729111
o@@	O	-1	24729111
rou@@	O	-1	24729111
gh@@	O	-1	24729111
ly	O	-1	24729111
investigated	O	-1	24729111
case	O	-1	24729111
of	O	-1	24729111
am@@	B-Chemical	D000638	24729111
iodar@@	I-Chemical	-1	24729111
one	I-Chemical	-1	24729111
-induced	O	-1	24729111
my@@	B-Disease	D007037	24729111
x@@	I-Disease	-1	24729111
o@@	I-Disease	-1	24729111
e@@	I-Disease	-1	24729111
de@@	I-Disease	-1	24729111
ma	I-Disease	-1	24729111
com@@	I-Disease	-1	24729111
a	I-Disease	-1	24729111
my@@	B-Disease	D003128	24729111
x@@	I-Disease	-1	24729111
o@@	I-Disease	-1	24729111
e@@	I-Disease	-1	24729111
de@@	I-Disease	-1	24729111
ma	I-Disease	-1	24729111
com@@	I-Disease	-1	24729111
a	I-Disease	-1	24729111
with	O	-1	24729111
a	O	-1	24729111
hist@@	O	-1	24729111
ory	O	-1	24729111
significant	O	-1	24729111
for	O	-1	24729111
sub@@	O	-1	24729111
clinical	O	-1	24729111
th@@	B-Disease	D013959	24729111
yro@@	I-Disease	-1	24729111
id	I-Disease	-1	24729111
disease	I-Disease	-1	24729111
.	O	-1	24729111

U@@	O	-1	24733133
se	O	-1	24733133
of	O	-1	24733133
arg@@	B-Chemical	C031942	24733133
atro@@	I-Chemical	-1	24733133
b@@	I-Chemical	-1	24733133
an	I-Chemical	-1	24733133
and	O	-1	24733133
ca@@	O	-1	24733133
the@@	O	-1	24733133
ter@@	O	-1	24733133
-@@	O	-1	24733133
direc@@	O	-1	24733133
ted	O	-1	24733133
throm@@	B-Disease	D055499	24733133
b@@	I-Disease	-1	24733133
oly@@	I-Disease	-1	24733133
sis	I-Disease	-1	24733133
with	O	-1	24733133
al@@	O	-1	24733133
te@@	O	-1	24733133
pl@@	O	-1	24733133
ase	O	-1	24733133
in	O	-1	24733133
an	O	-1	24733133
on@@	O	-1	24733133
co@@	O	-1	24733133
log@@	O	-1	24733133
y	O	-1	24733133
patient	O	-1	24733133
with	O	-1	24733133
hepar@@	B-Chemical	D006493	24733133
in	I-Chemical	-1	24733133
-induced	O	-1	24733133
throm@@	B-Disease	D013921	24733133
b@@	I-Disease	-1	24733133
ocyto@@	I-Disease	-1	24733133
pen@@	I-Disease	-1	24733133
ia	I-Disease	-1	24733133
with	O	-1	24733133
thrombo@@	B-Disease	D013927	24733133
sis	I-Disease	-1	24733133
.	O	-1	24733133
P@@	O	-1	24733133
U@@	O	-1	24733133
R@@	O	-1	24733133
P@@	O	-1	24733133
O@@	O	-1	24733133
S@@	O	-1	24733133
E:	O	-1	24733133
The	O	-1	24733133
case	O	-1	24733133
of	O	-1	24733133
an	O	-1	24733133
on@@	O	-1	24733133
co@@	O	-1	24733133
log@@	O	-1	24733133
y	O	-1	24733133
patient	O	-1	24733133
who	O	-1	24733133
developed	O	-1	24733133
hepar@@	B-Chemical	D006493	24733133
in	I-Chemical	-1	24733133
-induced	O	-1	24733133
throm@@	B-Disease	D013921	24733133
b@@	I-Disease	-1	24733133
ocyto@@	I-Disease	-1	24733133
pen@@	I-Disease	-1	24733133
ia	I-Disease	-1	24733133
with	O	-1	24733133
thrombo@@	B-Disease	D013927	24733133
sis	I-Disease	-1	24733133
(	O	-1	24733133
H@@	B-Disease	D013921	24733133
I@@	I-Disease	-1	24733133
T@@	I-Disease	-1	24733133
T	I-Disease	-1	24733133
H@@	B-Disease	D013927	24733133
I@@	I-Disease	-1	24733133
T@@	I-Disease	-1	24733133
T	I-Disease	-1	24733133
)	O	-1	24733133
and	O	-1	24733133
was	O	-1	24733133
treated	O	-1	24733133
with	O	-1	24733133
arg@@	B-Chemical	C031942	24733133
atro@@	I-Chemical	-1	24733133
b@@	I-Chemical	-1	24733133
an	I-Chemical	-1	24733133
plus	O	-1	24733133
ca@@	O	-1	24733133
the@@	O	-1	24733133
ter@@	O	-1	24733133
-@@	O	-1	24733133
direc@@	O	-1	24733133
ted	O	-1	24733133
throm@@	B-Disease	D055499	24733133
b@@	I-Disease	-1	24733133
oly@@	I-Disease	-1	24733133
sis	I-Disease	-1	24733133
(C@@	O	-1	24733133
D@@	O	-1	24733133
T)	O	-1	24733133
with	O	-1	24733133
al@@	O	-1	24733133
te@@	O	-1	24733133
pl@@	O	-1	24733133
ase	O	-1	24733133
is	O	-1	24733133
present@@	O	-1	24733133
ed.	O	-1	24733133
S@@	O	-1	24733133
U@@	O	-1	24733133
M@@	O	-1	24733133
MA@@	O	-1	24733133
R@@	O	-1	24733133
Y@@	O	-1	24733133
:	O	-1	24733133
A	O	-1	24733133
6@@	O	-1	24733133
3-@@	O	-1	24733133
year-old	O	-1	24733133
Ca@@	O	-1	24733133
uc@@	O	-1	24733133
a@@	O	-1	24733133
si@@	O	-1	24733133
an	O	-1	24733133
man	O	-1	24733133
with	O	-1	24733133
renal	O	-1	24733133
am@@	B-Disease	D000686	24733133
y@@	I-Disease	-1	24733133
lo@@	I-Disease	-1	24733133
id@@	I-Disease	-1	24733133
o@@	I-Disease	-1	24733133
sis	I-Disease	-1	24733133
under@@	O	-1	24733133
go@@	O	-1	24733133
ing	O	-1	24733133
peripheral	O	-1	24733133
blood	O	-1	24733133
st@@	O	-1	24733133
em	O	-1	24733133
cell	O	-1	24733133
coll@@	O	-1	24733133
ection	O	-1	24733133
for	O	-1	24733133
an	O	-1	24733133
auto@@	O	-1	24733133
log@@	O	-1	24733133
ous	O	-1	24733133
st@@	O	-1	24733133
em	O	-1	24733133
cell	O	-1	24733133
transplant	O	-1	24733133
developed	O	-1	24733133
exten@@	O	-1	24733133
sive	O	-1	24733133
bil@@	O	-1	24733133
ateral	O	-1	24733133
up@@	B-Disease	D056824	24733133
per@@	I-Disease	-1	24733133
-@@	I-Disease	-1	24733133
ex@@	I-Disease	-1	24733133
trem@@	I-Disease	-1	24733133
ity	I-Disease	-1	24733133
de@@	I-Disease	-1	24733133
ep	I-Disease	-1	24733133
venous	I-Disease	-1	24733133
thrombo@@	I-Disease	-1	24733133
sis	I-Disease	-1	24733133
(	O	-1	24733133
D@@	B-Disease	D020246	24733133
V@@	I-Disease	-1	24733133
T	I-Disease	-1	24733133
)	O	-1	24733133
and	O	-1	24733133
pulmonary	B-Disease	D011655	24733133
emb@@	I-Disease	-1	24733133
ol@@	I-Disease	-1	24733133
ism	I-Disease	-1	24733133
secondary	O	-1	24733133
to	O	-1	24733133
hepar@@	B-Chemical	D006493	24733133
in	I-Chemical	-1	24733133
-induced	O	-1	24733133
throm@@	B-Disease	D013921	24733133
b@@	I-Disease	-1	24733133
ocyto@@	I-Disease	-1	24733133
pen@@	I-Disease	-1	24733133
ia	I-Disease	-1	24733133
.	O	-1	24733133
A	O	-1	24733133
continu@@	O	-1	24733133
ous	O	-1	24733133
i.v@@	O	-1	24733133
.	O	-1	24733133
infusion	O	-1	24733133
of	O	-1	24733133
arg@@	B-Chemical	C031942	24733133
atro@@	I-Chemical	-1	24733133
b@@	I-Chemical	-1	24733133
an	I-Chemical	-1	24733133
was	O	-1	24733133
initi@@	O	-1	24733133
at@@	O	-1	24733133
ed,	O	-1	24733133
and	O	-1	24733133
the	O	-1	24733133
patient	O	-1	24733133
was	O	-1	24733133
man@@	O	-1	24733133
aged	O	-1	24733133
on	O	-1	24733133
the	O	-1	24733133
gener@@	O	-1	24733133
al	O	-1	24733133
med@@	O	-1	24733133
ical	O	-1	24733133
f@@	O	-1	24733133
lo@@	O	-1	24733133
or@@	O	-1	24733133
.	O	-1	24733133
After	O	-1	24733133
one	O	-1	24733133
week	O	-1	24733133
of	O	-1	24733133
therapy,	O	-1	24733133
he	O	-1	24733133
was	O	-1	24733133
trans@@	O	-1	24733133
fer@@	O	-1	24733133
red	O	-1	24733133
to	O	-1	24733133
the	O	-1	24733133
int@@	O	-1	24733133
en@@	O	-1	24733133
sive	O	-1	24733133
car@@	O	-1	24733133
e	O	-1	24733133
un@@	O	-1	24733133
it	O	-1	24733133
with	O	-1	24733133
cardio@@	O	-1	24733133
pulmonary	O	-1	24733133
com@@	O	-1	24733133
pro@@	O	-1	24733133
mis@@	O	-1	24733133
e	O	-1	24733133
related	O	-1	24733133
to	O	-1	24733133
su@@	B-Disease	D013479	24733133
peri@@	I-Disease	-1	24733133
or	I-Disease	-1	24733133
ven@@	I-Disease	-1	24733133
a	I-Disease	-1	24733133
ca@@	I-Disease	-1	24733133
v@@	I-Disease	-1	24733133
a	I-Disease	-1	24733133
(S@@	I-Disease	-1	24733133
V@@	I-Disease	-1	24733133
C@@	I-Disease	-1	24733133
)	I-Disease	-1	24733133
syndrome	I-Disease	-1	24733133
.	O	-1	24733133
A	O	-1	24733133
perc@@	O	-1	24733133
utaneous	O	-1	24733133
mechan@@	O	-1	24733133
ical	O	-1	24733133
throm@@	O	-1	24733133
b@@	O	-1	24733133
ect@@	O	-1	24733133
om@@	O	-1	24733133
y	O	-1	24733133
and	O	-1	24733133
C@@	O	-1	24733133
D@@	O	-1	24733133
T	O	-1	24733133
with	O	-1	24733133
al@@	O	-1	24733133
te@@	O	-1	24733133
pl@@	O	-1	24733133
ase	O	-1	24733133
were	O	-1	24733133
at@@	O	-1	24733133
tem@@	O	-1	24733133
p@@	O	-1	24733133
te@@	O	-1	24733133
d,	O	-1	24733133
but	O	-1	24733133
the	O	-1	24733133
proce@@	O	-1	24733133
d@@	O	-1	24733133
ure	O	-1	24733133
was	O	-1	24733133
abor@@	O	-1	24733133
ted	O	-1	24733133
due	O	-1	24733133
to	O	-1	24733133
ep@@	B-Disease	D004844	24733133
ist@@	I-Disease	-1	24733133
ax@@	I-Disease	-1	24733133
is	I-Disease	-1	24733133
.	O	-1	24733133
The	O	-1	24733133
ep@@	B-Disease	D004844	24733133
ist@@	I-Disease	-1	24733133
ax@@	I-Disease	-1	24733133
is	I-Disease	-1	24733133
resol@@	O	-1	24733133
ved	O	-1	24733133
the	O	-1	24733133
ne@@	O	-1	24733133
x@@	O	-1	24733133
t	O	-1	24733133
da@@	O	-1	24733133
y,	O	-1	24733133
and	O	-1	24733133
the	O	-1	24733133
patient	O	-1	24733133
was	O	-1	24733133
re@@	O	-1	24733133
star@@	O	-1	24733133
ted	O	-1	24733133
on	O	-1	24733133
arg@@	B-Chemical	C031942	24733133
atro@@	I-Chemical	-1	24733133
b@@	I-Chemical	-1	24733133
an	I-Chemical	-1	24733133
.	O	-1	24733133
A	O	-1	24733133
second	O	-1	24733133
perc@@	O	-1	24733133
utaneous	O	-1	24733133
mechan@@	O	-1	24733133
ical	O	-1	24733133
throm@@	O	-1	24733133
b@@	O	-1	24733133
ect@@	O	-1	24733133
om@@	O	-1	24733133
y	O	-1	24733133
was	O	-1	24733133
performed	O	-1	24733133
six	O	-1	24733133
days	O	-1	24733133
lat@@	O	-1	24733133
er	O	-1	24733133
and	O	-1	24733133
resulted	O	-1	24733133
in	O	-1	24733133
partial	O	-1	24733133
re@@	O	-1	24733133
vas@@	O	-1	24733133
cul@@	O	-1	24733133
ar@@	O	-1	24733133
ization	O	-1	24733133
of	O	-1	24733133
the	O	-1	24733133
S@@	O	-1	24733133
V@@	O	-1	24733133
C	O	-1	24733133
and	O	-1	24733133
central	O	-1	24733133
ve@@	O	-1	24733133
in@@	O	-1	24733133
s.	O	-1	24733133
P@@	O	-1	24733133
ost@@	O	-1	24733133
throm@@	O	-1	24733133
b@@	O	-1	24733133
ect@@	O	-1	24733133
om@@	O	-1	24733133
y	O	-1	24733133
continu@@	O	-1	24733133
ous	O	-1	24733133
C@@	O	-1	24733133
D@@	O	-1	24733133
T	O	-1	24733133
with	O	-1	24733133
al@@	O	-1	24733133
te@@	O	-1	24733133
pl@@	O	-1	24733133
ase	O	-1	24733133
was	O	-1	24733133
comm@@	O	-1	24733133
enc@@	O	-1	24733133
ed	O	-1	24733133
while	O	-1	24733133
arg@@	B-Chemical	C031942	24733133
atro@@	I-Chemical	-1	24733133
b@@	I-Chemical	-1	24733133
an	I-Chemical	-1	24733133
was	O	-1	24733133
with@@	O	-1	24733133
he@@	O	-1	24733133
l@@	O	-1	24733133
d,	O	-1	24733133
and	O	-1	24733133
complete	O	-1	24733133
pat@@	O	-1	24733133
ency	O	-1	24733133
of	O	-1	24733133
the	O	-1	24733133
S@@	O	-1	24733133
V@@	O	-1	24733133
C	O	-1	24733133
and	O	-1	24733133
central	O	-1	24733133
ve@@	O	-1	24733133
ins	O	-1	24733133
was	O	-1	24733133
achi@@	O	-1	24733133
ev@@	O	-1	24733133
ed	O	-1	24733133
after	O	-1	24733133
three	O	-1	24733133
days	O	-1	24733133
of	O	-1	24733133
therapy.	O	-1	24733133
Al@@	O	-1	24733133
te@@	O	-1	24733133
pl@@	O	-1	24733133
ase	O	-1	24733133
was	O	-1	24733133
discontinu@@	O	-1	24733133
ed,	O	-1	24733133
and	O	-1	24733133
the	O	-1	24733133
patient	O	-1	24733133
was	O	-1	24733133
re@@	O	-1	24733133
initi@@	O	-1	24733133
ated	O	-1	24733133
on	O	-1	24733133
arg@@	B-Chemical	C031942	24733133
atro@@	I-Chemical	-1	24733133
b@@	I-Chemical	-1	24733133
an	I-Chemical	-1	24733133
;	O	-1	24733133
ul@@	O	-1	24733133
tim@@	O	-1	24733133
at@@	O	-1	24733133
el@@	O	-1	24733133
y,	O	-1	24733133
he	O	-1	24733133
was	O	-1	24733133
transi@@	O	-1	24733133
tion@@	O	-1	24733133
ed	O	-1	24733133
to	O	-1	24733133
war@@	B-Chemical	D014859	24733133
farin	I-Chemical	-1	24733133
for	O	-1	24733133
long-term	O	-1	24733133
anti@@	O	-1	24733133
co@@	O	-1	24733133
ag@@	O	-1	24733133
ul@@	O	-1	24733133
ation.	O	-1	24733133
Although	O	-1	24733133
the	O	-1	24733133
patient	O	-1	24733133
reco@@	O	-1	24733133
ve@@	O	-1	24733133
re@@	O	-1	24733133
d,	O	-1	24733133
he	O	-1	24733133
experienced	O	-1	24733133
per@@	O	-1	24733133
man@@	O	-1	24733133
ent	O	-1	24733133
vi@@	B-Disease	D014786	24733133
sion	I-Disease	-1	24733133
and	I-Disease	-1	24733133
hearing	I-Disease	-1	24733133
loss	I-Disease	-1	24733133
vi@@	B-Disease	D034381	24733133
sion	I-Disease	-1	24733133
and	I-Disease	-1	24733133
hearing	I-Disease	-1	24733133
loss	I-Disease	-1	24733133
,	O	-1	24733133
as	O	-1	24733133
well	O	-1	24733133
as	O	-1	24733133
en@@	B-Disease	D007676	24733133
d-@@	I-Disease	-1	24733133
st@@	I-Disease	-1	24733133
age	I-Disease	-1	24733133
renal	I-Disease	-1	24733133
disease	I-Disease	-1	24733133
.	O	-1	24733133
CONCLUSION:	O	-1	24733133
A	O	-1	24733133
6@@	O	-1	24733133
3-@@	O	-1	24733133
year-old	O	-1	24733133
man	O	-1	24733133
with	O	-1	24733133
renal	O	-1	24733133
am@@	B-Disease	D000686	24733133
y@@	I-Disease	-1	24733133
lo@@	I-Disease	-1	24733133
id@@	I-Disease	-1	24733133
o@@	I-Disease	-1	24733133
sis	I-Disease	-1	24733133
and	O	-1	24733133
S@@	B-Disease	D013479	24733133
V@@	I-Disease	-1	24733133
C	I-Disease	-1	24733133
syndrome	I-Disease	-1	24733133
secondary	O	-1	24733133
to	O	-1	24733133
H@@	B-Disease	D013921	24733133
I@@	I-Disease	-1	24733133
T@@	I-Disease	-1	24733133
T	I-Disease	-1	24733133
H@@	B-Disease	D013927	24733133
I@@	I-Disease	-1	24733133
T@@	I-Disease	-1	24733133
T	I-Disease	-1	24733133
was	O	-1	24733133
suc@@	O	-1	24733133
cess@@	O	-1	24733133
ful@@	O	-1	24733133
ly	O	-1	24733133
treated	O	-1	24733133
with	O	-1	24733133
arg@@	B-Chemical	C031942	24733133
atro@@	I-Chemical	-1	24733133
b@@	I-Chemical	-1	24733133
an	I-Chemical	-1	24733133
and	O	-1	24733133
C@@	O	-1	24733133
D@@	O	-1	24733133
T	O	-1	24733133
with	O	-1	24733133
al@@	O	-1	24733133
te@@	O	-1	24733133
plas@@	O	-1	24733133
e.	O	-1	24733133

Eff@@	O	-1	24739405
ects	O	-1	24739405
of	O	-1	24739405
de@@	B-Chemical	D003687	24739405
hydro@@	I-Chemical	-1	24739405
epi@@	I-Chemical	-1	24739405
and@@	I-Chemical	-1	24739405
ro@@	I-Chemical	-1	24739405
sterone	I-Chemical	-1	24739405
in	O	-1	24739405
amphetamine	B-Chemical	D000661	24739405
-induced	O	-1	24739405
sch@@	B-Disease	D012559	24739405
iz@@	I-Disease	-1	24739405
oph@@	I-Disease	-1	24739405
ren@@	I-Disease	-1	24739405
ia	I-Disease	-1	24739405
models	O	-1	24739405
in	O	-1	24739405
mice.	O	-1	24739405
OBJECTIVE:	O	-1	24739405
To	O	-1	24739405
ex@@	O	-1	24739405
amine	O	-1	24739405
the	O	-1	24739405
effects	O	-1	24739405
of	O	-1	24739405
de@@	B-Chemical	D003687	24739405
hydro@@	I-Chemical	-1	24739405
epi@@	I-Chemical	-1	24739405
and@@	I-Chemical	-1	24739405
ro@@	I-Chemical	-1	24739405
sterone	I-Chemical	-1	24739405
(	O	-1	24739405
D@@	B-Chemical	D003687	24739405
H@@	I-Chemical	-1	24739405
E@@	I-Chemical	-1	24739405
A	I-Chemical	-1	24739405
)	O	-1	24739405
on	O	-1	24739405
anim@@	O	-1	24739405
al	O	-1	24739405
models	O	-1	24739405
of	O	-1	24739405
sch@@	B-Disease	D012559	24739405
iz@@	I-Disease	-1	24739405
oph@@	I-Disease	-1	24739405
ren@@	I-Disease	-1	24739405
ia	I-Disease	-1	24739405
.	O	-1	24739405
METHODS:	O	-1	24739405
S@@	O	-1	24739405
event@@	O	-1	24739405
y	O	-1	24739405
S@@	O	-1	24739405
w@@	O	-1	24739405
is@@	O	-1	24739405
s	O	-1	24739405
al@@	O	-1	24739405
bin@@	O	-1	24739405
o	O	-1	24739405
female	O	-1	24739405
mice	O	-1	24739405
(2@@	O	-1	24739405
5-@@	O	-1	24739405
3@@	O	-1	24739405
5	O	-1	24739405
g@@	O	-1	24739405
)	O	-1	24739405
were	O	-1	24739405
divid@@	O	-1	24739405
ed	O	-1	24739405
into	O	-1	24739405
4	O	-1	24739405
group@@	O	-1	24739405
s:	O	-1	24739405
amphetamine	B-Chemical	D000661	24739405
-@@	O	-1	24739405
free	O	-1	24739405
(@@	O	-1	24739405
control@@	O	-1	24739405
),	O	-1	24739405
amphetamine	B-Chemical	D000661	24739405
,	O	-1	24739405
50@@	O	-1	24739405
,	O	-1	24739405
and	O	-1	24739405
100	O	-1	24739405
mg/kg	O	-1	24739405
D@@	B-Chemical	D003687	24739405
H@@	I-Chemical	-1	24739405
E@@	I-Chemical	-1	24739405
A	I-Chemical	-1	24739405
.	O	-1	24739405
The	O	-1	24739405
D@@	B-Chemical	D003687	24739405
H@@	I-Chemical	-1	24739405
E@@	I-Chemical	-1	24739405
A	I-Chemical	-1	24739405
was	O	-1	24739405
administered	O	-1	24739405
intra@@	O	-1	24739405
per@@	O	-1	24739405
it@@	O	-1	24739405
one@@	O	-1	24739405
ally	O	-1	24739405
(@@	O	-1	24739405
ip@@	O	-1	24739405
)	O	-1	24739405
for	O	-1	24739405
5	O	-1	24739405
days.	O	-1	24739405
A@@	B-Chemical	D000661	24739405
m@@	I-Chemical	-1	24739405
ph@@	I-Chemical	-1	24739405
et@@	I-Chemical	-1	24739405
amine	I-Chemical	-1	24739405
(@@	O	-1	24739405
3	O	-1	24739405
mg/kg	O	-1	24739405
ip@@	O	-1	24739405
)	O	-1	24739405
induced	O	-1	24739405
hy@@	B-Disease	D006948	24739405
per	I-Disease	-1	24739405
locom@@	O	-1	24739405
o@@	O	-1	24739405
tion,	O	-1	24739405
apo@@	B-Chemical	D001058	24739405
morphine	I-Chemical	-1	24739405
(1@@	O	-1	24739405
.@@	O	-1	24739405
5	O	-1	24739405
mg/kg	O	-1	24739405
sub@@	O	-1	24739405
c@@	O	-1	24739405
ut@@	O	-1	24739405
ane@@	O	-1	24739405
ously	O	-1	24739405
[@@	O	-1	24739405
s@@	O	-1	24739405
c@@	O	-1	24739405
]@@	O	-1	24739405
)	O	-1	24739405
induced	O	-1	24739405
cl@@	O	-1	24739405
im@@	O	-1	24739405
b@@	O	-1	24739405
ing,	O	-1	24739405
and	O	-1	24739405
haloperidol	B-Chemical	D006220	24739405
(1@@	O	-1	24739405
.@@	O	-1	24739405
5	O	-1	24739405
mg/kg	O	-1	24739405
s@@	O	-1	24739405
c@@	O	-1	24739405
)	O	-1	24739405
induced	O	-1	24739405
cat@@	B-Disease	D002375	24739405
al@@	I-Disease	-1	24739405
ep@@	I-Disease	-1	24739405
sy	I-Disease	-1	24739405
tests	O	-1	24739405
were	O	-1	24739405
used	O	-1	24739405
as	O	-1	24739405
anim@@	O	-1	24739405
al	O	-1	24739405
models	O	-1	24739405
of	O	-1	24739405
sch@@	B-Disease	D012559	24739405
iz@@	I-Disease	-1	24739405
oph@@	I-Disease	-1	24739405
ren@@	I-Disease	-1	24739405
ia	I-Disease	-1	24739405
.	O	-1	24739405
The	O	-1	24739405
study	O	-1	24739405
was	O	-1	24739405
con@@	O	-1	24739405
duc@@	O	-1	24739405
ted	O	-1	24739405
at	O	-1	24739405
the	O	-1	24739405
An@@	O	-1	24739405
im@@	O	-1	24739405
al	O	-1	24739405
E@@	O	-1	24739405
x@@	O	-1	24739405
per@@	O	-1	24739405
im@@	O	-1	24739405
ent	O	-1	24739405
L@@	O	-1	24739405
abor@@	O	-1	24739405
at@@	O	-1	24739405
or@@	O	-1	24739405
i@@	O	-1	24739405
es,	O	-1	24739405
De@@	O	-1	24739405
part@@	O	-1	24739405
ment	O	-1	24739405
of	O	-1	24739405
Ph@@	O	-1	24739405
armac@@	O	-1	24739405
olog@@	O	-1	24739405
y,	O	-1	24739405
M@@	O	-1	24739405
ed@@	O	-1	24739405
ical	O	-1	24739405
S@@	O	-1	24739405
ch@@	O	-1	24739405
o@@	O	-1	24739405
ol@@	O	-1	24739405
,	O	-1	24739405
E@@	O	-1	24739405
s@@	O	-1	24739405
k@@	O	-1	24739405
i@@	O	-1	24739405
se@@	O	-1	24739405
hi@@	O	-1	24739405
r	O	-1	24739405
O@@	O	-1	24739405
sm@@	O	-1	24739405
ang@@	O	-1	24739405
az@@	O	-1	24739405
i	O	-1	24739405
U@@	O	-1	24739405
n@@	O	-1	24739405
i@@	O	-1	24739405
ver@@	O	-1	24739405
s@@	O	-1	24739405
ity,	O	-1	24739405
E@@	O	-1	24739405
s@@	O	-1	24739405
k@@	O	-1	24739405
i@@	O	-1	24739405
se@@	O	-1	24739405
hi@@	O	-1	24739405
r@@	O	-1	24739405
,	O	-1	24739405
T@@	O	-1	24739405
ur@@	O	-1	24739405
ke@@	O	-1	24739405
y	O	-1	24739405
between	O	-1	24739405
M@@	O	-1	24739405
arc@@	O	-1	24739405
h	O	-1	24739405
and	O	-1	24739405
M@@	O	-1	24739405
ay	O	-1	24739405
20@@	O	-1	24739405
12@@	O	-1	24739405
.	O	-1	24739405
S@@	O	-1	24739405
t@@	O	-1	24739405
atis@@	O	-1	24739405
tical	O	-1	24739405
analysis	O	-1	24739405
was	O	-1	24739405
car@@	O	-1	24739405
ri@@	O	-1	24739405
ed	O	-1	24739405
out	O	-1	24739405
using	O	-1	24739405
K@@	O	-1	24739405
r@@	O	-1	24739405
us@@	O	-1	24739405
k@@	O	-1	24739405
al@@	O	-1	24739405
-@@	O	-1	24739405
W@@	O	-1	24739405
all@@	O	-1	24739405
is	O	-1	24739405
test	O	-1	24739405
for	O	-1	24739405
hy@@	B-Disease	D006948	24739405
per	I-Disease	-1	24739405
locom@@	O	-1	24739405
o@@	O	-1	24739405
tion,	O	-1	24739405
and	O	-1	24739405
on@@	O	-1	24739405
e-@@	O	-1	24739405
w@@	O	-1	24739405
ay	O	-1	24739405
AN@@	O	-1	24739405
O@@	O	-1	24739405
V@@	O	-1	24739405
A	O	-1	24739405
for	O	-1	24739405
cl@@	O	-1	24739405
im@@	O	-1	24739405
b@@	O	-1	24739405
ing	O	-1	24739405
and	O	-1	24739405
cat@@	B-Disease	D002375	24739405
al@@	I-Disease	-1	24739405
ep@@	I-Disease	-1	24739405
sy	I-Disease	-1	24739405
test@@	O	-1	24739405
s.	O	-1	24739405
RESULTS:	O	-1	24739405
In	O	-1	24739405
the	O	-1	24739405
amphetamine	B-Chemical	D000661	24739405
-induced	O	-1	24739405
locom@@	O	-1	24739405
o@@	O	-1	24739405
tion	O	-1	24739405
test@@	O	-1	24739405
,	O	-1	24739405
there	O	-1	24739405
were	O	-1	24739405
significant	O	-1	24739405
increases	O	-1	24739405
in	O	-1	24739405
all	O	-1	24739405
mo@@	O	-1	24739405
ve@@	O	-1	24739405
ments	O	-1	24739405
compared	O	-1	24739405
with	O	-1	24739405
the	O	-1	24739405
amphetamine	B-Chemical	D000661	24739405
-@@	O	-1	24739405
free	O	-1	24739405
group.	O	-1	24739405
B@@	O	-1	24739405
oth	O	-1	24739405
D@@	B-Chemical	D003687	24739405
H@@	I-Chemical	-1	24739405
E@@	I-Chemical	-1	24739405
A	I-Chemical	-1	24739405
50	O	-1	24739405
mg/kg	O	-1	24739405
(p@@	O	-1	24739405
<@@	O	-1	24739405
0.05@@	O	-1	24739405
),	O	-1	24739405
and	O	-1	24739405
100	O	-1	24739405
mg/kg	O	-1	24739405
(p@@	O	-1	24739405
<@@	O	-1	24739405
0.0@@	O	-1	24739405
1)	O	-1	24739405
significantly	O	-1	24739405
decreased	O	-1	24739405
all	O	-1	24739405
mo@@	O	-1	24739405
ve@@	O	-1	24739405
ments	O	-1	24739405
compared	O	-1	24739405
with	O	-1	24739405
the	O	-1	24739405
amphetamine	B-Chemical	D000661	24739405
-induced	O	-1	24739405
locom@@	O	-1	24739405
o@@	O	-1	24739405
tion	O	-1	24739405
group.	O	-1	24739405
There	O	-1	24739405
was	O	-1	24739405
a	O	-1	24739405
significant	O	-1	24739405
difference	O	-1	24739405
between	O	-1	24739405
groups	O	-1	24739405
in	O	-1	24739405
the	O	-1	24739405
haloperidol	B-Chemical	D006220	24739405
-induced	O	-1	24739405
cat@@	B-Disease	D002375	24739405
al@@	I-Disease	-1	24739405
ep@@	I-Disease	-1	24739405
sy	I-Disease	-1	24739405
test	O	-1	24739405
(p@@	O	-1	24739405
<@@	O	-1	24739405
0.05@@	O	-1	24739405
).	O	-1	24739405
There	O	-1	24739405
was	O	-1	24739405
no	O	-1	24739405
significant	O	-1	24739405
difference	O	-1	24739405
between	O	-1	24739405
groups	O	-1	24739405
in	O	-1	24739405
ter@@	O	-1	24739405
ms	O	-1	24739405
of	O	-1	24739405
total	O	-1	24739405
cl@@	O	-1	24739405
im@@	O	-1	24739405
b@@	O	-1	24739405
ing	O	-1	24739405
time	O	-1	24739405
in	O	-1	24739405
the	O	-1	24739405
apo@@	B-Chemical	D001058	24739405
morphine	I-Chemical	-1	24739405
-induced	O	-1	24739405
cl@@	O	-1	24739405
im@@	O	-1	24739405
b@@	O	-1	24739405
ing	O	-1	24739405
test	O	-1	24739405
(p@@	O	-1	24739405
>@@	O	-1	24739405
0.05@@	O	-1	24739405
).	O	-1	24739405
CONCLUSION:	O	-1	24739405
We	O	-1	24739405
observed	O	-1	24739405
that	O	-1	24739405
D@@	B-Chemical	D003687	24739405
H@@	I-Chemical	-1	24739405
E@@	I-Chemical	-1	24739405
A	I-Chemical	-1	24739405
reduced	O	-1	24739405
locomotor	O	-1	24739405
activity	O	-1	24739405
and	O	-1	24739405
increased	O	-1	24739405
cat@@	B-Disease	D002375	24739405
al@@	I-Disease	-1	24739405
ep@@	I-Disease	-1	24739405
sy	I-Disease	-1	24739405
at	O	-1	24739405
both	O	-1	24739405
dos@@	O	-1	24739405
es,	O	-1	24739405
while	O	-1	24739405
it	O	-1	24739405
had	O	-1	24739405
no	O	-1	24739405
effect	O	-1	24739405
on	O	-1	24739405
cl@@	O	-1	24739405
im@@	O	-1	24739405
b@@	O	-1	24739405
ing	O	-1	24739405
behavi@@	O	-1	24739405
or@@	O	-1	24739405
.	O	-1	24739405
We	O	-1	24739405
suggest	O	-1	24739405
that	O	-1	24739405
D@@	B-Chemical	D003687	24739405
H@@	I-Chemical	-1	24739405
E@@	I-Chemical	-1	24739405
A	I-Chemical	-1	24739405
dis@@	O	-1	24739405
pl@@	O	-1	24739405
ays	O	-1	24739405
typ@@	O	-1	24739405
ical	O	-1	24739405
neuro@@	O	-1	24739405
le@@	O	-1	24739405
p@@	O	-1	24739405
tic@@	O	-1	24739405
-@@	O	-1	24739405
like	O	-1	24739405
effect@@	O	-1	24739405
s,	O	-1	24739405
and	O	-1	24739405
may	O	-1	24739405
be	O	-1	24739405
used	O	-1	24739405
in	O	-1	24739405
the	O	-1	24739405
treatment	O	-1	24739405
of	O	-1	24739405
sch@@	B-Disease	D012559	24739405
iz@@	I-Disease	-1	24739405
oph@@	I-Disease	-1	24739405
ren@@	I-Disease	-1	24739405
ia	I-Disease	-1	24739405
.	O	-1	24739405

A@@	O	-1	24742750
v@@	O	-1	24742750
ail@@	O	-1	24742750
ability	O	-1	24742750
of	O	-1	24742750
human	O	-1	24742750
induced	O	-1	24742750
pl@@	O	-1	24742750
ur@@	O	-1	24742750
ip@@	O	-1	24742750
ot@@	O	-1	24742750
ent	O	-1	24742750
st@@	O	-1	24742750
em	O	-1	24742750
cell@@	O	-1	24742750
-@@	O	-1	24742750
der@@	O	-1	24742750
i@@	O	-1	24742750
ved	O	-1	24742750
cardi@@	O	-1	24742750
om@@	O	-1	24742750
y@@	O	-1	24742750
ocy@@	O	-1	24742750
tes	O	-1	24742750
in	O	-1	24742750
assess@@	O	-1	24742750
ment	O	-1	24742750
of	O	-1	24742750
drug	O	-1	24742750
potential	O	-1	24742750
for	O	-1	24742750
Q@@	B-Disease	D008133	24742750
T	I-Disease	-1	24742750
prolong@@	I-Disease	-1	24742750
ation	I-Disease	-1	24742750
.	O	-1	24742750
F@@	O	-1	24742750
i@@	O	-1	24742750
el@@	O	-1	24742750
d	O	-1	24742750
potential	O	-1	24742750
duration	O	-1	24742750
(@@	O	-1	24742750
F@@	O	-1	24742750
P@@	O	-1	24742750
D)	O	-1	24742750
in	O	-1	24742750
hum@@	O	-1	24742750
an@@	O	-1	24742750
-induced	O	-1	24742750
pl@@	O	-1	24742750
ur@@	O	-1	24742750
ip@@	O	-1	24742750
ot@@	O	-1	24742750
ent	O	-1	24742750
st@@	O	-1	24742750
em	O	-1	24742750
cell@@	O	-1	24742750
-@@	O	-1	24742750
der@@	O	-1	24742750
i@@	O	-1	24742750
ved	O	-1	24742750
cardi@@	O	-1	24742750
om@@	O	-1	24742750
y@@	O	-1	24742750
ocy@@	O	-1	24742750
tes	O	-1	24742750
(@@	O	-1	24742750
hi@@	O	-1	24742750
P@@	O	-1	24742750
S@@	O	-1	24742750
-@@	O	-1	24742750
C@@	O	-1	24742750
M@@	O	-1	24742750
s),	O	-1	24742750
which	O	-1	24742750
can	O	-1	24742750
ex@@	O	-1	24742750
pres@@	O	-1	24742750
s	O	-1	24742750
Q@@	O	-1	24742750
T	O	-1	24742750
interv@@	O	-1	24742750
al	O	-1	24742750
in	O	-1	24742750
an	O	-1	24742750
electro@@	O	-1	24742750
cardio@@	O	-1	24742750
gram@@	O	-1	24742750
,	O	-1	24742750
is	O	-1	24742750
reported	O	-1	24742750
to	O	-1	24742750
be	O	-1	24742750
a	O	-1	24742750
use@@	O	-1	24742750
ful	O	-1	24742750
to@@	O	-1	24742750
ol	O	-1	24742750
to	O	-1	24742750
predic@@	O	-1	24742750
t	O	-1	24742750
K	B-Chemical	D011188	24742750
(@@	O	-1	24742750
+@@	O	-1	24742750
)	O	-1	24742750
channel	O	-1	24742750
and	O	-1	24742750
C@@	B-Chemical	D002118	24742750
a	I-Chemical	-1	24742750
(2@@	O	-1	24742750
+@@	O	-1	24742750
)	O	-1	24742750
channel	O	-1	24742750
block@@	O	-1	24742750
er	O	-1	24742750
effects	O	-1	24742750
on	O	-1	24742750
Q@@	O	-1	24742750
T	O	-1	24742750
inter@@	O	-1	24742750
val@@	O	-1	24742750
.	O	-1	24742750
However,	O	-1	24742750
there	O	-1	24742750
is	O	-1	24742750
no	O	-1	24742750
report	O	-1	24742750
show@@	O	-1	24742750
ing	O	-1	24742750
that	O	-1	24742750
this	O	-1	24742750
t@@	O	-1	24742750
ech@@	O	-1	24742750
n@@	O	-1	24742750
i@@	O	-1	24742750
qu@@	O	-1	24742750
e	O	-1	24742750
can	O	-1	24742750
be	O	-1	24742750
used	O	-1	24742750
to	O	-1	24742750
predic@@	O	-1	24742750
t	O	-1	24742750
multi@@	O	-1	24742750
channel	O	-1	24742750
block@@	O	-1	24742750
er	O	-1	24742750
potential	O	-1	24742750
for	O	-1	24742750
Q@@	B-Disease	D008133	24742750
T	I-Disease	-1	24742750
prolong@@	I-Disease	-1	24742750
ation	I-Disease	-1	24742750
.	O	-1	24742750
The	O	-1	24742750
a@@	O	-1	24742750
im	O	-1	24742750
of	O	-1	24742750
this	O	-1	24742750
study	O	-1	24742750
is	O	-1	24742750
to	O	-1	24742750
show	O	-1	24742750
that	O	-1	24742750
F@@	O	-1	24742750
P@@	O	-1	24742750
D	O	-1	24742750
from	O	-1	24742750
M@@	O	-1	24742750
E@@	O	-1	24742750
A	O	-1	24742750
(@@	O	-1	24742750
M@@	O	-1	24742750
ul@@	O	-1	24742750
ti@@	O	-1	24742750
electro@@	O	-1	24742750
de	O	-1	24742750
ar@@	O	-1	24742750
ra@@	O	-1	24742750
y@@	O	-1	24742750
)	O	-1	24742750
of	O	-1	24742750
hi@@	O	-1	24742750
P@@	O	-1	24742750
S@@	O	-1	24742750
-@@	O	-1	24742750
C@@	O	-1	24742750
M@@	O	-1	24742750
s	O	-1	24742750
can	O	-1	24742750
det@@	O	-1	24742750
ect	O	-1	24742750
Q@@	B-Disease	D008133	24742750
T	I-Disease	-1	24742750
prolong@@	I-Disease	-1	24742750
ation	I-Disease	-1	24742750
induced	O	-1	24742750
by	O	-1	24742750
multi@@	O	-1	24742750
channel	O	-1	24742750
block@@	O	-1	24742750
ers.	O	-1	24742750
hi@@	O	-1	24742750
P@@	O	-1	24742750
S@@	O	-1	24742750
-@@	O	-1	24742750
C@@	O	-1	24742750
M@@	O	-1	24742750
s	O	-1	24742750
were	O	-1	24742750
se@@	O	-1	24742750
ed@@	O	-1	24742750
ed	O	-1	24742750
on@@	O	-1	24742750
to	O	-1	24742750
M@@	O	-1	24742750
E@@	O	-1	24742750
A	O	-1	24742750
and	O	-1	24742750
F@@	O	-1	24742750
P@@	O	-1	24742750
D	O	-1	24742750
was	O	-1	24742750
measured	O	-1	24742750
for	O	-1	24742750
2@@	O	-1	24742750
min	O	-1	24742750
every	O	-1	24742750
10@@	O	-1	24742750
min	O	-1	24742750
for	O	-1	24742750
3@@	O	-1	24742750
0@@	O	-1	24742750
min	O	-1	24742750
after	O	-1	24742750
drug	O	-1	24742750
exposure	O	-1	24742750
for	O	-1	24742750
the	O	-1	24742750
ve@@	O	-1	24742750
h@@	O	-1	24742750
ic@@	O	-1	24742750
le	O	-1	24742750
and	O	-1	24742750
each	O	-1	24742750
drug	O	-1	24742750
concentr@@	O	-1	24742750
ation.	O	-1	24742750
I@@	O	-1	24742750
K@@	O	-1	24742750
r	O	-1	24742750
and	O	-1	24742750
I@@	O	-1	24742750
K@@	O	-1	24742750
s	O	-1	24742750
block@@	O	-1	24742750
ers	O	-1	24742750
concentr@@	O	-1	24742750
ation@@	O	-1	24742750
-@@	O	-1	24742750
depend@@	O	-1	24742750
ently	O	-1	24742750
prolonged	O	-1	24742750
cor@@	O	-1	24742750
rec@@	O	-1	24742750
ted	O	-1	24742750
F@@	O	-1	24742750
P@@	O	-1	24742750
D	O	-1	24742750
(@@	O	-1	24742750
F@@	O	-1	24742750
P@@	O	-1	24742750
D@@	O	-1	24742750
c@@	O	-1	24742750
),	O	-1	24742750
whereas	O	-1	24742750
C@@	B-Chemical	D002118	24742750
a	I-Chemical	-1	24742750
(2@@	O	-1	24742750
+@@	O	-1	24742750
)	O	-1	24742750
channel	O	-1	24742750
block@@	O	-1	24742750
ers	O	-1	24742750
concentr@@	O	-1	24742750
ation@@	O	-1	24742750
-@@	O	-1	24742750
depend@@	O	-1	24742750
ently	O	-1	24742750
sh@@	O	-1	24742750
or@@	O	-1	24742750
ten@@	O	-1	24742750
ed	O	-1	24742750
F@@	O	-1	24742750
P@@	O	-1	24742750
D@@	O	-1	24742750
c@@	O	-1	24742750
.	O	-1	24742750
Al@@	O	-1	24742750
so@@	O	-1	24742750
,	O	-1	24742750
the	O	-1	24742750
multi@@	O	-1	24742750
channel	O	-1	24742750
block@@	O	-1	24742750
ers	O	-1	24742750
A@@	B-Chemical	D000638	24742750
m@@	I-Chemical	-1	24742750
iodar@@	I-Chemical	-1	24742750
one	I-Chemical	-1	24742750
,	O	-1	24742750
P@@	B-Chemical	D017374	24742750
a@@	I-Chemical	-1	24742750
ro@@	I-Chemical	-1	24742750
x@@	I-Chemical	-1	24742750
et@@	I-Chemical	-1	24742750
ine	I-Chemical	-1	24742750
,	O	-1	24742750
T@@	B-Chemical	D016593	24742750
er@@	I-Chemical	-1	24742750
f@@	I-Chemical	-1	24742750
en@@	I-Chemical	-1	24742750
ad@@	I-Chemical	-1	24742750
ine	I-Chemical	-1	24742750
and	O	-1	24742750
C@@	B-Chemical	D015283	24742750
it@@	I-Chemical	-1	24742750
alo@@	I-Chemical	-1	24742750
pra@@	I-Chemical	-1	24742750
m	I-Chemical	-1	24742750
prolonged	O	-1	24742750
F@@	O	-1	24742750
P@@	O	-1	24742750
D@@	O	-1	24742750
c	O	-1	24742750
in	O	-1	24742750
a	O	-1	24742750
concentration	O	-1	24742750
dependent	O	-1	24742750
man@@	O	-1	24742750
ner@@	O	-1	24742750
.	O	-1	24742750
F@@	O	-1	24742750
in@@	O	-1	24742750
ally,	O	-1	24742750
the	O	-1	24742750
I@@	O	-1	24742750
K@@	O	-1	24742750
r	O	-1	24742750
block@@	O	-1	24742750
er@@	O	-1	24742750
s,	O	-1	24742750
T@@	B-Chemical	D016593	24742750
er@@	I-Chemical	-1	24742750
f@@	I-Chemical	-1	24742750
en@@	I-Chemical	-1	24742750
ad@@	I-Chemical	-1	24742750
ine	I-Chemical	-1	24742750
and	O	-1	24742750
C@@	B-Chemical	D015283	24742750
it@@	I-Chemical	-1	24742750
alo@@	I-Chemical	-1	24742750
pra@@	I-Chemical	-1	24742750
m	I-Chemical	-1	24742750
,	O	-1	24742750
which	O	-1	24742750
are	O	-1	24742750
reported	O	-1	24742750
to	O	-1	24742750
cause	O	-1	24742750
T@@	B-Disease	D016171	24742750
or@@	I-Disease	-1	24742750
s@@	I-Disease	-1	24742750
ade	I-Disease	-1	24742750
de	I-Disease	-1	24742750
P@@	I-Disease	-1	24742750
o@@	I-Disease	-1	24742750
int@@	I-Disease	-1	24742750
es	I-Disease	-1	24742750
(	O	-1	24742750
T@@	B-Disease	D016171	24742750
d@@	I-Disease	-1	24742750
P	I-Disease	-1	24742750
)	O	-1	24742750
in	O	-1	24742750
clinical	O	-1	24742750
p@@	O	-1	24742750
rac@@	O	-1	24742750
ti@@	O	-1	24742750
ce@@	O	-1	24742750
,	O	-1	24742750
produced	O	-1	24742750
early	O	-1	24742750
af@@	O	-1	24742750
ter@@	O	-1	24742750
de@@	O	-1	24742750
pol@@	O	-1	24742750
ar@@	O	-1	24742750
ization	O	-1	24742750
(@@	O	-1	24742750
E@@	O	-1	24742750
AD@@	O	-1	24742750
).	O	-1	24742750
hi@@	O	-1	24742750
P@@	O	-1	24742750
S@@	O	-1	24742750
-@@	O	-1	24742750
C@@	O	-1	24742750
M@@	O	-1	24742750
s	O	-1	24742750
using	O	-1	24742750
M@@	O	-1	24742750
E@@	O	-1	24742750
A	O	-1	24742750
system	O	-1	24742750
and	O	-1	24742750
F@@	O	-1	24742750
P@@	O	-1	24742750
D@@	O	-1	24742750
c	O	-1	24742750
can	O	-1	24742750
predic@@	O	-1	24742750
t	O	-1	24742750
the	O	-1	24742750
effects	O	-1	24742750
of	O	-1	24742750
drug	O	-1	24742750
can@@	O	-1	24742750
di@@	O	-1	24742750
dat@@	O	-1	24742750
es	O	-1	24742750
on	O	-1	24742750
Q@@	O	-1	24742750
T	O	-1	24742750
inter@@	O	-1	24742750
val@@	O	-1	24742750
.	O	-1	24742750
This	O	-1	24742750
study	O	-1	24742750
also	O	-1	24742750
show@@	O	-1	24742750
s	O	-1	24742750
that	O	-1	24742750
this	O	-1	24742750
ass@@	O	-1	24742750
ay	O	-1	24742750
can	O	-1	24742750
he@@	O	-1	24742750
l@@	O	-1	24742750
p	O	-1	24742750
det@@	O	-1	24742750
ect	O	-1	24742750
E@@	O	-1	24742750
A@@	O	-1	24742750
D	O	-1	24742750
for	O	-1	24742750
drugs	O	-1	24742750
with	O	-1	24742750
T@@	B-Disease	D016171	24742750
d@@	I-Disease	-1	24742750
P	I-Disease	-1	24742750
potenti@@	O	-1	24742750
al.	O	-1	24742750

D@@	O	-1	24753331
er@@	O	-1	24753331
m@@	O	-1	24753331
al	O	-1	24753331
develop@@	O	-1	24753331
mental	O	-1	24753331
toxicity	B-Disease	D064420	24753331
of	O	-1	24753331
N@@	O	-1	24753331
-@@	O	-1	24753331
phenyl@@	O	-1	24753331
im@@	O	-1	24753331
ide	O	-1	24753331
h@@	O	-1	24753331
er@@	O	-1	24753331
b@@	O	-1	24753331
ici@@	O	-1	24753331
des	O	-1	24753331
in	O	-1	24753331
rats.	O	-1	24753331
BACKGROUND:	O	-1	24753331
S@@	B-Chemical	C106487	24753331
-@@	I-Chemical	-1	24753331
5@@	I-Chemical	-1	24753331
34@@	I-Chemical	-1	24753331
8@@	I-Chemical	-1	24753331
2	I-Chemical	-1	24753331
and	O	-1	24753331
S@@	B-Chemical	C083440	24753331
-@@	I-Chemical	-1	24753331
2@@	I-Chemical	-1	24753331
3@@	I-Chemical	-1	24753331
12@@	I-Chemical	-1	24753331
1	I-Chemical	-1	24753331
are	O	-1	24753331
N@@	O	-1	24753331
-@@	O	-1	24753331
phenyl@@	O	-1	24753331
im@@	O	-1	24753331
ide	O	-1	24753331
h@@	O	-1	24753331
er@@	O	-1	24753331
b@@	O	-1	24753331
ici@@	O	-1	24753331
des	O	-1	24753331
and	O	-1	24753331
produced	O	-1	24753331
emb@@	B-Disease	D020964	24753331
r@@	I-Disease	-1	24753331
y@@	I-Disease	-1	24753331
ol@@	I-Disease	-1	24753331
eth@@	I-Disease	-1	24753331
ality	I-Disease	-1	24753331
,	O	-1	24753331
ter@@	B-Disease	D064793	24753331
at@@	I-Disease	-1	24753331
o@@	I-Disease	-1	24753331
gen@@	I-Disease	-1	24753331
ic@@	I-Disease	-1	24753331
ity	I-Disease	-1	24753331
(@@	O	-1	24753331
main@@	O	-1	24753331
ly	O	-1	24753331
ventricular	B-Disease	D006345	24753331
se@@	I-Disease	-1	24753331
pt@@	I-Disease	-1	24753331
al	I-Disease	-1	24753331
def@@	I-Disease	-1	24753331
ects	I-Disease	-1	24753331
and	O	-1	24753331
w@@	O	-1	24753331
av@@	O	-1	24753331
y	O	-1	24753331
rib@@	O	-1	24753331
s),	O	-1	24753331
and	O	-1	24753331
growth	B-Disease	D005317	24753331
ret@@	I-Disease	-1	24753331
ar@@	I-Disease	-1	24753331
d@@	I-Disease	-1	24753331
ation	I-Disease	-1	24753331
in	O	-1	24753331
rats	O	-1	24753331
in	O	-1	24753331
con@@	O	-1	24753331
ven@@	O	-1	24753331
tional	O	-1	24753331
oral	O	-1	24753331
develop@@	O	-1	24753331
mental	O	-1	24753331
toxicity	B-Disease	D064420	24753331
studi@@	O	-1	24753331
es.	O	-1	24753331
Our	O	-1	24753331
ob@@	O	-1	24753331
j@@	O	-1	24753331
ective	O	-1	24753331
in	O	-1	24753331
this	O	-1	24753331
study	O	-1	24753331
was	O	-1	24753331
to	O	-1	24753331
investigate	O	-1	24753331
whether	O	-1	24753331
the	O	-1	24753331
comp@@	O	-1	24753331
oun@@	O	-1	24753331
ds	O	-1	24753331
induce	O	-1	24753331
develop@@	O	-1	24753331
mental	O	-1	24753331
toxicity	B-Disease	D064420	24753331
vi@@	O	-1	24753331
a	O	-1	24753331
the	O	-1	24753331
der@@	O	-1	24753331
m@@	O	-1	24753331
al	O	-1	24753331
rou@@	O	-1	24753331
te@@	O	-1	24753331
,	O	-1	24753331
which	O	-1	24753331
is	O	-1	24753331
more	O	-1	24753331
re@@	O	-1	24753331
lev@@	O	-1	24753331
ant	O	-1	24753331
to	O	-1	24753331
occ@@	O	-1	24753331
u@@	O	-1	24753331
pati@@	O	-1	24753331
on@@	O	-1	24753331
al	O	-1	24753331
expos@@	O	-1	24753331
ure,	O	-1	24753331
h@@	O	-1	24753331
ence	O	-1	24753331
bet@@	O	-1	24753331
ter	O	-1	24753331
ad@@	O	-1	24753331
d@@	O	-1	24753331
res@@	O	-1	24753331
s@@	O	-1	24753331
ing	O	-1	24753331
human	O	-1	24753331
heal@@	O	-1	24753331
th	O	-1	24753331
ris@@	O	-1	24753331
k@@	O	-1	24753331
s.	O	-1	24753331
METHODS:	O	-1	24753331
S@@	B-Chemical	C106487	24753331
-@@	I-Chemical	-1	24753331
5@@	I-Chemical	-1	24753331
34@@	I-Chemical	-1	24753331
8@@	I-Chemical	-1	24753331
2	I-Chemical	-1	24753331
was	O	-1	24753331
administered	O	-1	24753331
der@@	O	-1	24753331
m@@	O	-1	24753331
ally	O	-1	24753331
to	O	-1	24753331
rats	O	-1	24753331
at	O	-1	24753331
3@@	O	-1	24753331
0@@	O	-1	24753331
,	O	-1	24753331
10@@	O	-1	24753331
0@@	O	-1	24753331
,	O	-1	24753331
and	O	-1	24753331
3@@	O	-1	24753331
00	O	-1	24753331
mg/kg	O	-1	24753331
during	O	-1	24753331
org@@	O	-1	24753331
an@@	O	-1	24753331
o@@	O	-1	24753331
gene@@	O	-1	24753331
sis,	O	-1	24753331
and	O	-1	24753331
S@@	B-Chemical	C083440	24753331
-@@	I-Chemical	-1	24753331
2@@	I-Chemical	-1	24753331
3@@	I-Chemical	-1	24753331
12@@	I-Chemical	-1	24753331
1	I-Chemical	-1	24753331
was	O	-1	24753331
administered	O	-1	24753331
at	O	-1	24753331
20@@	O	-1	24753331
0@@	O	-1	24753331
,	O	-1	24753331
4@@	O	-1	24753331
0@@	O	-1	24753331
0@@	O	-1	24753331
,	O	-1	24753331
and	O	-1	24753331
8@@	O	-1	24753331
00	O	-1	24753331
mg/kg	O	-1	24753331
(@@	O	-1	24753331
the	O	-1	24753331
maxim@@	O	-1	24753331
um	O	-1	24753331
ap@@	O	-1	24753331
plic@@	O	-1	24753331
able	O	-1	24753331
dose	O	-1	24753331
level@@	O	-1	24753331
).	O	-1	24753331
F@@	O	-1	24753331
et@@	O	-1	24753331
u@@	O	-1	24753331
ses	O	-1	24753331
were	O	-1	24753331
obtained	O	-1	24753331
by	O	-1	24753331
a	O	-1	24753331
C@@	O	-1	24753331
es@@	O	-1	24753331
a@@	O	-1	24753331
re@@	O	-1	24753331
an	O	-1	24753331
sec@@	O	-1	24753331
tion	O	-1	24753331
and	O	-1	24753331
examined	O	-1	24753331
for	O	-1	24753331
ex@@	O	-1	24753331
tern@@	O	-1	24753331
al,	O	-1	24753331
v@@	O	-1	24753331
is@@	O	-1	24753331
cer@@	O	-1	24753331
al,	O	-1	24753331
and	O	-1	24753331
s@@	O	-1	24753331
ke@@	O	-1	24753331
le@@	O	-1	24753331
t@@	O	-1	24753331
al	O	-1	24753331
al@@	O	-1	24753331
ter@@	O	-1	24753331
ations.	O	-1	24753331
RESULTS:	O	-1	24753331
D@@	O	-1	24753331
er@@	O	-1	24753331
m@@	O	-1	24753331
al	O	-1	24753331
exposure	O	-1	24753331
of	O	-1	24753331
rats	O	-1	24753331
to	O	-1	24753331
S@@	B-Chemical	C106487	24753331
-@@	I-Chemical	-1	24753331
5@@	I-Chemical	-1	24753331
34@@	I-Chemical	-1	24753331
8@@	I-Chemical	-1	24753331
2	I-Chemical	-1	24753331
at	O	-1	24753331
3@@	O	-1	24753331
00	O	-1	24753331
mg/kg	O	-1	24753331
produced	O	-1	24753331
pat@@	O	-1	24753331
tern@@	O	-1	24753331
s	O	-1	24753331
of	O	-1	24753331
develop@@	O	-1	24753331
mental	O	-1	24753331
toxicity	B-Disease	D064420	24753331
similar	O	-1	24753331
to	O	-1	24753331
those	O	-1	24753331
result@@	O	-1	24753331
ing	O	-1	24753331
from	O	-1	24753331
oral	O	-1	24753331
expos@@	O	-1	24753331
ure.	O	-1	24753331
T@@	B-Disease	D064420	24753331
oxic@@	I-Disease	-1	24753331
ity	I-Disease	-1	24753331
included	O	-1	24753331
emb@@	B-Disease	D020964	24753331
r@@	I-Disease	-1	24753331
y@@	I-Disease	-1	24753331
ol@@	I-Disease	-1	24753331
eth@@	I-Disease	-1	24753331
ality	I-Disease	-1	24753331
,	O	-1	24753331
ter@@	B-Disease	D064793	24753331
at@@	I-Disease	-1	24753331
o@@	I-Disease	-1	24753331
gen@@	I-Disease	-1	24753331
ic@@	I-Disease	-1	24753331
ity	I-Disease	-1	24753331
,	O	-1	24753331
and	O	-1	24753331
growth	B-Disease	D005317	24753331
ret@@	I-Disease	-1	24753331
ar@@	I-Disease	-1	24753331
d@@	I-Disease	-1	24753331
ation	I-Disease	-1	24753331
.	O	-1	24753331
D@@	O	-1	24753331
er@@	O	-1	24753331
m@@	O	-1	24753331
al	O	-1	24753331
administration	O	-1	24753331
of	O	-1	24753331
S@@	B-Chemical	C083440	24753331
-@@	I-Chemical	-1	24753331
2@@	I-Chemical	-1	24753331
3@@	I-Chemical	-1	24753331
12@@	I-Chemical	-1	24753331
1	I-Chemical	-1	24753331
at	O	-1	24753331
8@@	O	-1	24753331
00	O	-1	24753331
mg/kg	O	-1	24753331
resulted	O	-1	24753331
in	O	-1	24753331
an	O	-1	24753331
increased	O	-1	24753331
incidence	O	-1	24753331
of	O	-1	24753331
emb@@	B-Disease	D020964	24753331
r@@	I-Disease	-1	24753331
y@@	I-Disease	-1	24753331
onic	I-Disease	-1	24753331
death	I-Disease	-1	24753331
and	O	-1	24753331
ventricular	B-Disease	D006345	24753331
se@@	I-Disease	-1	24753331
pt@@	I-Disease	-1	24753331
al	I-Disease	-1	24753331
def@@	I-Disease	-1	24753331
ect	I-Disease	-1	24753331
,	O	-1	24753331
but	O	-1	24753331
ret@@	O	-1	24753331
ar@@	O	-1	24753331
ded	O	-1	24753331
f@@	O	-1	24753331
et@@	O	-1	24753331
al	O	-1	24753331
growth	O	-1	24753331
was	O	-1	24753331
not	O	-1	24753331
observed	O	-1	24753331
as	O	-1	24753331
it	O	-1	24753331
was	O	-1	24753331
following	O	-1	24753331
oral	O	-1	24753331
exposure	O	-1	24753331
to	O	-1	24753331
S@@	B-Chemical	C083440	24753331
-@@	I-Chemical	-1	24753331
2@@	I-Chemical	-1	24753331
3@@	I-Chemical	-1	24753331
12@@	I-Chemical	-1	24753331
1	I-Chemical	-1	24753331
.	O	-1	24753331
CONCLUSIONS:	O	-1	24753331
B@@	O	-1	24753331
as@@	O	-1	24753331
ed	O	-1	24753331
on	O	-1	24753331
the	O	-1	24753331
result@@	O	-1	24753331
s,	O	-1	24753331
S@@	B-Chemical	C106487	24753331
-@@	I-Chemical	-1	24753331
5@@	I-Chemical	-1	24753331
34@@	I-Chemical	-1	24753331
8@@	I-Chemical	-1	24753331
2	I-Chemical	-1	24753331
and	O	-1	24753331
S@@	B-Chemical	C083440	24753331
-@@	I-Chemical	-1	24753331
2@@	I-Chemical	-1	24753331
3@@	I-Chemical	-1	24753331
12@@	I-Chemical	-1	24753331
1	I-Chemical	-1	24753331
were	O	-1	24753331
ter@@	B-Disease	D064793	24753331
at@@	I-Disease	-1	24753331
o@@	I-Disease	-1	24753331
genic	I-Disease	-1	24753331
when	O	-1	24753331
administered	O	-1	24753331
der@@	O	-1	24753331
m@@	O	-1	24753331
ally	O	-1	24753331
to	O	-1	24753331
pregn@@	O	-1	24753331
ant	O	-1	24753331
rats	O	-1	24753331
as	O	-1	24753331
were	O	-1	24753331
the	O	-1	24753331
comp@@	O	-1	24753331
oun@@	O	-1	24753331
ds	O	-1	24753331
administered	O	-1	24753331
or@@	O	-1	24753331
all@@	O	-1	24753331
y.	O	-1	24753331
Th@@	O	-1	24753331
us,	O	-1	24753331
investig@@	O	-1	24753331
ation	O	-1	24753331
of	O	-1	24753331
the	O	-1	24753331
mechanism	O	-1	24753331
and	O	-1	24753331
its	O	-1	24753331
human	O	-1	24753331
re@@	O	-1	24753331
lev@@	O	-1	24753331
anc@@	O	-1	24753331
y	O	-1	24753331
b@@	O	-1	24753331
ec@@	O	-1	24753331
ome	O	-1	24753331
more	O	-1	24753331
import@@	O	-1	24753331
ant@@	O	-1	24753331
.	O	-1	24753331

R@@	O	-1	24778426
ates	O	-1	24778426
of	O	-1	24778426
R@@	B-Disease	D007674	24778426
en@@	I-Disease	-1	24778426
al	I-Disease	-1	24778426
T@@	I-Disease	-1	24778426
oxic@@	I-Disease	-1	24778426
ity	I-Disease	-1	24778426
in	O	-1	24778426
C@@	B-Disease	D009369	24778426
anc@@	I-Disease	-1	24778426
er	I-Disease	-1	24778426
Patients	O	-1	24778426
Rec@@	O	-1	24778426
e@@	O	-1	24778426
i@@	O	-1	24778426
ving	O	-1	24778426
C@@	B-Chemical	D002945	24778426
is@@	I-Chemical	-1	24778426
pl@@	I-Chemical	-1	24778426
atin	I-Chemical	-1	24778426
W@@	O	-1	24778426
it@@	O	-1	24778426
h	O	-1	24778426
and	O	-1	24778426
W@@	O	-1	24778426
i@@	O	-1	24778426
th@@	O	-1	24778426
out	O	-1	24778426
M@@	B-Chemical	D008353	24778426
an@@	I-Chemical	-1	24778426
nit@@	I-Chemical	-1	24778426
ol	I-Chemical	-1	24778426
.	O	-1	24778426
BACKGROUND:	O	-1	24778426
C@@	B-Chemical	D002945	24778426
is@@	I-Chemical	-1	24778426
pl@@	I-Chemical	-1	24778426
atin	I-Chemical	-1	24778426
is	O	-1	24778426
a	O	-1	24778426
wi@@	O	-1	24778426
de@@	O	-1	24778426
ly	O	-1	24778426
used	O	-1	24778426
ant@@	O	-1	24778426
ine@@	O	-1	24778426
o@@	O	-1	24778426
plas@@	O	-1	24778426
tic@@	O	-1	24778426
.	O	-1	24778426
One	O	-1	24778426
of	O	-1	24778426
the	O	-1	24778426
major	O	-1	24778426
complications	O	-1	24778426
of	O	-1	24778426
cisplatin	B-Chemical	D002945	24778426
use	O	-1	24778426
is	O	-1	24778426
dose-@@	O	-1	24778426
lim@@	O	-1	24778426
it@@	O	-1	24778426
ing	O	-1	24778426
nephro@@	B-Disease	D007674	24778426
toxicity	I-Disease	-1	24778426
.	O	-1	24778426
There	O	-1	24778426
are	O	-1	24778426
man@@	O	-1	24778426
y	O	-1	24778426
strat@@	O	-1	24778426
e@@	O	-1	24778426
gi@@	O	-1	24778426
es	O	-1	24778426
to	O	-1	24778426
prev@@	O	-1	24778426
ent	O	-1	24778426
this	O	-1	24778426
toxicity	B-Disease	D064420	24778426
,	O	-1	24778426
including	O	-1	24778426
the	O	-1	24778426
use	O	-1	24778426
of	O	-1	24778426
man@@	B-Chemical	D008353	24778426
nit@@	I-Chemical	-1	24778426
ol	I-Chemical	-1	24778426
as	O	-1	24778426
a	O	-1	24778426
nephro@@	O	-1	24778426
prot@@	O	-1	24778426
ect@@	O	-1	24778426
ant	O	-1	24778426
in	O	-1	24778426
combination	O	-1	24778426
with	O	-1	24778426
hy@@	O	-1	24778426
d@@	O	-1	24778426
r@@	O	-1	24778426
ation.	O	-1	24778426
OBJECTIVE:	O	-1	24778426
We	O	-1	24778426
a@@	O	-1	24778426
im@@	O	-1	24778426
ed	O	-1	24778426
to	O	-1	24778426
evalu@@	O	-1	24778426
ate	O	-1	24778426
the	O	-1	24778426
rat@@	O	-1	24778426
es	O	-1	24778426
of	O	-1	24778426
cisplatin	B-Chemical	D002945	24778426
-induced	O	-1	24778426
nephro@@	B-Disease	D007674	24778426
toxicity	I-Disease	-1	24778426
in	O	-1	24778426
cancer	B-Disease	D009369	24778426
patients	O	-1	24778426
receiving	O	-1	24778426
sing@@	O	-1	24778426
le@@	O	-1	24778426
-@@	O	-1	24778426
agent	O	-1	24778426
cisplatin	B-Chemical	D002945	24778426
with	O	-1	24778426
and	O	-1	24778426
without	O	-1	24778426
man@@	B-Chemical	D008353	24778426
nit@@	I-Chemical	-1	24778426
ol	I-Chemical	-1	24778426
.	O	-1	24778426
METHODS:	O	-1	24778426
This	O	-1	24778426
sing@@	O	-1	24778426
le@@	O	-1	24778426
-@@	O	-1	24778426
c@@	O	-1	24778426
ent@@	O	-1	24778426
er	O	-1	24778426
ret@@	O	-1	24778426
ro@@	O	-1	24778426
sp@@	O	-1	24778426
ective	O	-1	24778426
analysis	O	-1	24778426
was	O	-1	24778426
a	O	-1	24778426
qu@@	O	-1	24778426
as@@	O	-1	24778426
i	O	-1	24778426
experim@@	O	-1	24778426
ent	O	-1	24778426
cre@@	O	-1	24778426
ated	O	-1	24778426
by	O	-1	24778426
the	O	-1	24778426
n@@	O	-1	24778426
ation@@	O	-1	24778426
al	O	-1	24778426
man@@	B-Chemical	D008353	24778426
nit@@	I-Chemical	-1	24778426
ol	I-Chemical	-1	24778426
sh@@	O	-1	24778426
ort@@	O	-1	24778426
age.	O	-1	24778426
D@@	O	-1	24778426
at@@	O	-1	24778426
a	O	-1	24778426
were	O	-1	24778426
coll@@	O	-1	24778426
ected	O	-1	24778426
on	O	-1	24778426
ad@@	O	-1	24778426
ult	O	-1	24778426
cancer	B-Disease	D009369	24778426
patients	O	-1	24778426
receiving	O	-1	24778426
sing@@	O	-1	24778426
le@@	O	-1	24778426
-@@	O	-1	24778426
agent	O	-1	24778426
cisplatin	B-Chemical	D002945	24778426
as	O	-1	24778426
an	O	-1	24778426
out@@	O	-1	24778426
patient	O	-1	24778426
from	O	-1	24778426
J@@	O	-1	24778426
an@@	O	-1	24778426
u@@	O	-1	24778426
ary	O	-1	24778426
20@@	O	-1	24778426
11	O	-1	24778426
to	O	-1	24778426
S@@	O	-1	24778426
e@@	O	-1	24778426
pt@@	O	-1	24778426
emb@@	O	-1	24778426
er	O	-1	24778426
20@@	O	-1	24778426
12@@	O	-1	24778426
.	O	-1	24778426
The	O	-1	24778426
prim@@	O	-1	24778426
ary	O	-1	24778426
outcom@@	O	-1	24778426
e	O	-1	24778426
was	O	-1	24778426
acute	B-Disease	D058186	24778426
kidney	I-Disease	-1	24778426
injury	I-Disease	-1	24778426
(	O	-1	24778426
A@@	B-Disease	D058186	24778426
K@@	I-Disease	-1	24778426
I	I-Disease	-1	24778426
).	O	-1	24778426
RESULTS:	O	-1	24778426
We	O	-1	24778426
evaluated	O	-1	24778426
14@@	O	-1	24778426
3	O	-1	24778426
patients	O	-1	24778426
who	O	-1	24778426
received	O	-1	24778426
sing@@	O	-1	24778426
le@@	O	-1	24778426
-@@	O	-1	24778426
agent	O	-1	24778426
cisplatin	B-Chemical	D002945	24778426
;	O	-1	24778426
9@@	O	-1	24778426
7.@@	O	-1	24778426
2@@	O	-1	24778426
%	O	-1	24778426
of	O	-1	24778426
patients	O	-1	24778426
had	O	-1	24778426
he@@	B-Disease	D006258	24778426
ad	I-Disease	-1	24778426
and	I-Disease	-1	24778426
nec@@	I-Disease	-1	24778426
k	I-Disease	-1	24778426
cancer	I-Disease	-1	24778426
as	O	-1	24778426
their	O	-1	24778426
prim@@	O	-1	24778426
ary	O	-1	24778426
mal@@	B-Disease	D009369	24778426
i@@	I-Disease	-1	24778426
gn@@	I-Disease	-1	24778426
anc@@	I-Disease	-1	24778426
y	I-Disease	-1	24778426
.	O	-1	24778426
Patients	O	-1	24778426
who	O	-1	24778426
did	O	-1	24778426
not	O	-1	24778426
recei@@	O	-1	24778426
ve	O	-1	24778426
man@@	B-Chemical	D008353	24778426
nit@@	I-Chemical	-1	24778426
ol	I-Chemical	-1	24778426
were	O	-1	24778426
more	O	-1	24778426
likely	O	-1	24778426
to	O	-1	24778426
deve@@	O	-1	24778426
lo@@	O	-1	24778426
p	O	-1	24778426
nephro@@	B-Disease	D007674	24778426
toxicity	I-Disease	-1	24778426
:	O	-1	24778426
o@@	O	-1	24778426
d@@	O	-1	24778426
ds	O	-1	24778426
rati@@	O	-1	24778426
o	O	-1	24778426
[@@	O	-1	24778426
O@@	O	-1	24778426
R@@	O	-1	24778426
]	O	-1	24778426
=	O	-1	24778426
2.@@	O	-1	24778426
6@@	O	-1	24778426
4@@	O	-1	24778426
6	O	-1	24778426
(@@	O	-1	24778426
95%	O	-1	24778426
C@@	O	-1	24778426
I	O	-1	24778426
=	O	-1	24778426
1.@@	O	-1	24778426
0@@	O	-1	24778426
0@@	O	-1	24778426
8@@	O	-1	24778426
,	O	-1	24778426
6.@@	O	-1	24778426
9@@	O	-1	24778426
4@@	O	-1	24778426
4@@	O	-1	24778426
;	O	-1	24778426
P	O	-1	24778426
=	O	-1	24778426
0.0@@	O	-1	24778426
4@@	O	-1	24778426
8@@	O	-1	24778426
).	O	-1	24778426
Patients	O	-1	24778426
who	O	-1	24778426
received	O	-1	24778426
the	O	-1	24778426
100	O	-1	24778426
mg/m@@	O	-1	24778426
(2@@	O	-1	24778426
)	O	-1	24778426
dos@@	O	-1	24778426
ing	O	-1	24778426
and	O	-1	24778426
patients	O	-1	24778426
who	O	-1	24778426
had	O	-1	24778426
a	O	-1	24778426
hist@@	O	-1	24778426
ory	O	-1	24778426
of	O	-1	24778426
hypertension	B-Disease	D006973	24778426
also	O	-1	24778426
had	O	-1	24778426
a	O	-1	24778426
higher	O	-1	24778426
lik@@	O	-1	24778426
e@@	O	-1	24778426
li@@	O	-1	24778426
ho@@	O	-1	24778426
od	O	-1	24778426
of	O	-1	24778426
develop@@	O	-1	24778426
ing	O	-1	24778426
nephro@@	B-Disease	D007674	24778426
toxicity	I-Disease	-1	24778426
:	O	-1	24778426
O@@	O	-1	24778426
R	O	-1	24778426
=	O	-1	24778426
1@@	O	-1	24778426
1.@@	O	-1	24778426
4@@	O	-1	24778426
9@@	O	-1	24778426
4	O	-1	24778426
(@@	O	-1	24778426
95%	O	-1	24778426
C@@	O	-1	24778426
I	O	-1	24778426
=	O	-1	24778426
4.@@	O	-1	24778426
14@@	O	-1	24778426
9@@	O	-1	24778426
,	O	-1	24778426
3@@	O	-1	24778426
2.@@	O	-1	24778426
25@@	O	-1	24778426
8@@	O	-1	24778426
;	O	-1	24778426
P	O	-1	24778426
<	O	-1	24778426
0.00@@	O	-1	24778426
0@@	O	-1	24778426
1)	O	-1	24778426
and	O	-1	24778426
O@@	O	-1	24778426
R	O	-1	24778426
=	O	-1	24778426
3.@@	O	-1	24778426
2@@	O	-1	24778426
1@@	O	-1	24778426
9	O	-1	24778426
(@@	O	-1	24778426
95%	O	-1	24778426
C@@	O	-1	24778426
I	O	-1	24778426
=	O	-1	24778426
1.@@	O	-1	24778426
2@@	O	-1	24778426
2@@	O	-1	24778426
8@@	O	-1	24778426
,	O	-1	24778426
8.@@	O	-1	24778426
4@@	O	-1	24778426
3@@	O	-1	24778426
9@@	O	-1	24778426
;	O	-1	24778426
P	O	-1	24778426
=	O	-1	24778426
0.0@@	O	-1	24778426
17@@	O	-1	24778426
),	O	-1	24778426
respectively.	O	-1	24778426
CONCLUSIONS:	O	-1	24778426
Whe@@	O	-1	24778426
n	O	-1	24778426
lim@@	O	-1	24778426
ited	O	-1	24778426
qu@@	O	-1	24778426
anti@@	O	-1	24778426
ties	O	-1	24778426
of	O	-1	24778426
man@@	B-Chemical	D008353	24778426
nit@@	I-Chemical	-1	24778426
ol	I-Chemical	-1	24778426
are	O	-1	24778426
av@@	O	-1	24778426
ail@@	O	-1	24778426
able@@	O	-1	24778426
,	O	-1	24778426
it	O	-1	24778426
should	O	-1	24778426
pre@@	O	-1	24778426
fe@@	O	-1	24778426
ren@@	O	-1	24778426
ti@@	O	-1	24778426
ally	O	-1	24778426
be	O	-1	24778426
given	O	-1	24778426
to	O	-1	24778426
patients	O	-1	24778426
at	O	-1	24778426
partic@@	O	-1	24778426
ul@@	O	-1	24778426
arly	O	-1	24778426
high	O	-1	24778426
risk	O	-1	24778426
of	O	-1	24778426
nephro@@	B-Disease	D007674	24778426
toxicity	I-Disease	-1	24778426
.	O	-1	24778426
Our	O	-1	24778426
analysis	O	-1	24778426
suggests	O	-1	24778426
that	O	-1	24778426
those	O	-1	24778426
patients	O	-1	24778426
receiving	O	-1	24778426
the	O	-1	24778426
dos@@	O	-1	24778426
ing	O	-1	24778426
sch@@	O	-1	24778426
ed@@	O	-1	24778426
ul@@	O	-1	24778426
e	O	-1	24778426
of	O	-1	24778426
100	O	-1	24778426
mg/m@@	O	-1	24778426
(2@@	O	-1	24778426
)	O	-1	24778426
cisplatin	B-Chemical	D002945	24778426
every	O	-1	24778426
3	O	-1	24778426
weeks	O	-1	24778426
and	O	-1	24778426
those	O	-1	24778426
with	O	-1	24778426
hypertension	B-Disease	D006973	24778426
are	O	-1	24778426
at	O	-1	24778426
the	O	-1	24778426
great@@	O	-1	24778426
est	O	-1	24778426
risk	O	-1	24778426
of	O	-1	24778426
nephro@@	B-Disease	D007674	24778426
toxicity	I-Disease	-1	24778426
and	O	-1	24778426
wo@@	O	-1	24778426
uld	O	-1	24778426
ben@@	O	-1	24778426
e@@	O	-1	24778426
fi@@	O	-1	24778426
t	O	-1	24778426
from	O	-1	24778426
the	O	-1	24778426
addition	O	-1	24778426
of	O	-1	24778426
man@@	B-Chemical	D008353	24778426
nit@@	I-Chemical	-1	24778426
ol	I-Chemical	-1	24778426
.	O	-1	24778426

M@@	B-Chemical	D008687	24802403
et@@	I-Chemical	-1	24802403
form@@	I-Chemical	-1	24802403
in	I-Chemical	-1	24802403
prot@@	O	-1	24802403
ects	O	-1	24802403
against	O	-1	24802403
seizures	B-Disease	D012640	24802403
,	O	-1	24802403
lear@@	B-Disease	D007859	24802403
ning	I-Disease	-1	24802403
and	I-Disease	-1	24802403
memory	I-Disease	-1	24802403
impair@@	I-Disease	-1	24802403
ments	I-Disease	-1	24802403
lear@@	B-Disease	D008569	24802403
ning	I-Disease	-1	24802403
and	I-Disease	-1	24802403
memory	I-Disease	-1	24802403
impair@@	I-Disease	-1	24802403
ments	I-Disease	-1	24802403
and	O	-1	24802403
oxid@@	O	-1	24802403
ative	O	-1	24802403
damage	O	-1	24802403
induced	O	-1	24802403
by	O	-1	24802403
pent@@	B-Chemical	D010433	24802403
yl@@	I-Chemical	-1	24802403
en@@	I-Chemical	-1	24802403
e@@	I-Chemical	-1	24802403
te@@	I-Chemical	-1	24802403
tra@@	I-Chemical	-1	24802403
z@@	I-Chemical	-1	24802403
ole	I-Chemical	-1	24802403
-induced	O	-1	24802403
k@@	O	-1	24802403
ind@@	O	-1	24802403
l@@	O	-1	24802403
ing	O	-1	24802403
in	O	-1	24802403
mice.	O	-1	24802403
C@@	B-Disease	D003072	24802403
o@@	I-Disease	-1	24802403
gn@@	I-Disease	-1	24802403
itive	I-Disease	-1	24802403
impair@@	I-Disease	-1	24802403
ment	I-Disease	-1	24802403
,	O	-1	24802403
the	O	-1	24802403
most	O	-1	24802403
common	O	-1	24802403
and	O	-1	24802403
severe	O	-1	24802403
com@@	O	-1	24802403
or@@	O	-1	24802403
b@@	O	-1	24802403
idity	O	-1	24802403
of	O	-1	24802403
epilep@@	B-Disease	D004827	24802403
sy	I-Disease	-1	24802403
,	O	-1	24802403
great@@	O	-1	24802403
ly	O	-1	24802403
di@@	O	-1	24802403
min@@	O	-1	24802403
ish@@	O	-1	24802403
es	O	-1	24802403
the	O	-1	24802403
qu@@	O	-1	24802403
ality	O	-1	24802403
of	O	-1	24802403
lif@@	O	-1	24802403
e.	O	-1	24802403
However,	O	-1	24802403
current	O	-1	24802403
therapeutic	O	-1	24802403
inter@@	O	-1	24802403
ven@@	O	-1	24802403
tions	O	-1	24802403
for	O	-1	24802403
epilep@@	B-Disease	D004827	24802403
sy	I-Disease	-1	24802403
can	O	-1	24802403
also	O	-1	24802403
cause	O	-1	24802403
un@@	O	-1	24802403
to@@	O	-1	24802403
war@@	O	-1	24802403
d	O	-1	24802403
cognitive	O	-1	24802403
effects.	O	-1	24802403
Th@@	O	-1	24802403
us,	O	-1	24802403
there	O	-1	24802403
is	O	-1	24802403
an	O	-1	24802403
ur@@	O	-1	24802403
g@@	O	-1	24802403
ent	O	-1	24802403
need	O	-1	24802403
for	O	-1	24802403
new	O	-1	24802403
k@@	O	-1	24802403
ind@@	O	-1	24802403
s	O	-1	24802403
of	O	-1	24802403
agents	O	-1	24802403
t@@	O	-1	24802403
arg@@	O	-1	24802403
et@@	O	-1	24802403
ing	O	-1	24802403
both	O	-1	24802403
seizures	B-Disease	D012640	24802403
and	O	-1	24802403
cogn@@	B-Disease	D003072	24802403
ition	I-Disease	-1	24802403
defic@@	I-Disease	-1	24802403
its	I-Disease	-1	24802403
.	O	-1	24802403
O@@	O	-1	24802403
x@@	O	-1	24802403
id@@	O	-1	24802403
ative	O	-1	24802403
stres@@	O	-1	24802403
s	O	-1	24802403
is	O	-1	24802403
considered	O	-1	24802403
to	O	-1	24802403
pl@@	O	-1	24802403
ay	O	-1	24802403
an	O	-1	24802403
important	O	-1	24802403
role	O	-1	24802403
in	O	-1	24802403
epile@@	O	-1	24802403
pto@@	O	-1	24802403
genesis	O	-1	24802403
and	O	-1	24802403
cognitive	B-Disease	D003072	24802403
defic@@	I-Disease	-1	24802403
its	I-Disease	-1	24802403
,	O	-1	24802403
and	O	-1	24802403
anti@@	O	-1	24802403
oxid@@	O	-1	24802403
ants	O	-1	24802403
have	O	-1	24802403
a	O	-1	24802403
p@@	O	-1	24802403
ut@@	O	-1	24802403
ative	O	-1	24802403
anti@@	O	-1	24802403
epileptic	O	-1	24802403
potenti@@	O	-1	24802403
al.	O	-1	24802403
M@@	B-Chemical	D008687	24802403
et@@	I-Chemical	-1	24802403
form@@	I-Chemical	-1	24802403
in	I-Chemical	-1	24802403
,	O	-1	24802403
the	O	-1	24802403
most	O	-1	24802403
common@@	O	-1	24802403
ly	O	-1	24802403
prescri@@	O	-1	24802403
bed	O	-1	24802403
anti@@	O	-1	24802403
dia@@	O	-1	24802403
be@@	O	-1	24802403
tic	O	-1	24802403
oral	O	-1	24802403
drug@@	O	-1	24802403
,	O	-1	24802403
has	O	-1	24802403
anti@@	O	-1	24802403
oxid@@	O	-1	24802403
ant	O	-1	24802403
pro@@	O	-1	24802403
per@@	O	-1	24802403
ti@@	O	-1	24802403
es.	O	-1	24802403
This	O	-1	24802403
study	O	-1	24802403
was	O	-1	24802403
de@@	O	-1	24802403
signed	O	-1	24802403
to	O	-1	24802403
evalu@@	O	-1	24802403
ate	O	-1	24802403
the	O	-1	24802403
ame@@	O	-1	24802403
li@@	O	-1	24802403
or@@	O	-1	24802403
ative	O	-1	24802403
effects	O	-1	24802403
of	O	-1	24802403
met@@	B-Chemical	D008687	24802403
form@@	I-Chemical	-1	24802403
in	I-Chemical	-1	24802403
on	O	-1	24802403
seizures	B-Disease	D012640	24802403
,	O	-1	24802403
cognitive	B-Disease	D003072	24802403
impair@@	I-Disease	-1	24802403
ment	I-Disease	-1	24802403
and	O	-1	24802403
brain	O	-1	24802403
oxid@@	O	-1	24802403
ative	O	-1	24802403
stres@@	O	-1	24802403
s	O	-1	24802403
mark@@	O	-1	24802403
ers	O	-1	24802403
observed	O	-1	24802403
in	O	-1	24802403
pent@@	B-Chemical	D010433	24802403
yl@@	I-Chemical	-1	24802403
en@@	I-Chemical	-1	24802403
e@@	I-Chemical	-1	24802403
te@@	I-Chemical	-1	24802403
tra@@	I-Chemical	-1	24802403
z@@	I-Chemical	-1	24802403
ole	I-Chemical	-1	24802403
-induced	O	-1	24802403
k@@	O	-1	24802403
ind@@	O	-1	24802403
l@@	O	-1	24802403
ing	O	-1	24802403
anim@@	O	-1	24802403
al@@	O	-1	24802403
s.	O	-1	24802403
M@@	O	-1	24802403
al@@	O	-1	24802403
e	O	-1	24802403
C@@	O	-1	24802403
5@@	O	-1	24802403
7@@	O	-1	24802403
B@@	O	-1	24802403
L@@	O	-1	24802403
/@@	O	-1	24802403
6	O	-1	24802403
mice	O	-1	24802403
were	O	-1	24802403
administered	O	-1	24802403
with	O	-1	24802403
sub@@	O	-1	24802403
convul@@	O	-1	24802403
sive	O	-1	24802403
dose	O	-1	24802403
of	O	-1	24802403
pent@@	B-Chemical	D010433	24802403
yl@@	I-Chemical	-1	24802403
en@@	I-Chemical	-1	24802403
e@@	I-Chemical	-1	24802403
te@@	I-Chemical	-1	24802403
tra@@	I-Chemical	-1	24802403
z@@	I-Chemical	-1	24802403
ole	I-Chemical	-1	24802403
(3@@	O	-1	24802403
7	O	-1	24802403
mg/kg@@	O	-1	24802403
,	O	-1	24802403
i.p.@@	O	-1	24802403
)	O	-1	24802403
every	O	-1	24802403
other	O	-1	24802403
day	O	-1	24802403
for	O	-1	24802403
14	O	-1	24802403
injec@@	O	-1	24802403
tions.	O	-1	24802403
M@@	B-Chemical	D008687	24802403
et@@	I-Chemical	-1	24802403
form@@	I-Chemical	-1	24802403
in	I-Chemical	-1	24802403
was	O	-1	24802403
injected	O	-1	24802403
intra@@	O	-1	24802403
per@@	O	-1	24802403
it@@	O	-1	24802403
one@@	O	-1	24802403
ally	O	-1	24802403
in	O	-1	24802403
dose	O	-1	24802403
of	O	-1	24802403
20@@	O	-1	24802403
0@@	O	-1	24802403
mg/kg	O	-1	24802403
al@@	O	-1	24802403
ong	O	-1	24802403
with	O	-1	24802403
al@@	O	-1	24802403
tern@@	O	-1	24802403
at@@	O	-1	24802403
e-@@	O	-1	24802403
day	O	-1	24802403
P@@	B-Chemical	D010433	24802403
T@@	I-Chemical	-1	24802403
Z	I-Chemical	-1	24802403
.	O	-1	24802403
We	O	-1	24802403
found	O	-1	24802403
that	O	-1	24802403
met@@	B-Chemical	D008687	24802403
form@@	I-Chemical	-1	24802403
in	I-Chemical	-1	24802403
sup@@	O	-1	24802403
press@@	O	-1	24802403
ed	O	-1	24802403
the	O	-1	24802403
progres@@	O	-1	24802403
sion	O	-1	24802403
of	O	-1	24802403
k@@	O	-1	24802403
ind@@	O	-1	24802403
l@@	O	-1	24802403
ing,	O	-1	24802403
ame@@	O	-1	24802403
li@@	O	-1	24802403
or@@	O	-1	24802403
ated	O	-1	24802403
the	O	-1	24802403
cognitive	B-Disease	D003072	24802403
impair@@	I-Disease	-1	24802403
ment	I-Disease	-1	24802403
and	O	-1	24802403
decreased	O	-1	24802403
brain	O	-1	24802403
oxid@@	O	-1	24802403
ative	O	-1	24802403
stres@@	O	-1	24802403
s.	O	-1	24802403
Th@@	O	-1	24802403
us	O	-1	24802403
the	O	-1	24802403
present	O	-1	24802403
study	O	-1	24802403
concl@@	O	-1	24802403
uded	O	-1	24802403
that	O	-1	24802403
met@@	B-Chemical	D008687	24802403
form@@	I-Chemical	-1	24802403
in	I-Chemical	-1	24802403
may	O	-1	24802403
be	O	-1	24802403
a	O	-1	24802403
potential	O	-1	24802403
agent	O	-1	24802403
for	O	-1	24802403
the	O	-1	24802403
treatment	O	-1	24802403
of	O	-1	24802403
epilep@@	B-Disease	D004827	24802403
sy	I-Disease	-1	24802403
as	O	-1	24802403
well	O	-1	24802403
as	O	-1	24802403
a	O	-1	24802403
protective	O	-1	24802403
medic@@	O	-1	24802403
ine	O	-1	24802403
against	O	-1	24802403
cognitive	B-Disease	D003072	24802403
impair@@	I-Disease	-1	24802403
ment	I-Disease	-1	24802403
induced	O	-1	24802403
by	O	-1	24802403
seizures	B-Disease	D012640	24802403
.	O	-1	24802403

P@@	O	-1	24812279
5@@	O	-1	24812279
3	O	-1	24812279
inhibition	O	-1	24812279
ex@@	O	-1	24812279
ac@@	O	-1	24812279
er@@	O	-1	24812279
b@@	O	-1	24812279
ates	O	-1	24812279
lat@@	O	-1	24812279
e-@@	O	-1	24812279
st@@	O	-1	24812279
age	O	-1	24812279
an@@	B-Chemical	D018943	24812279
th@@	I-Chemical	-1	24812279
rac@@	I-Chemical	-1	24812279
y@@	I-Chemical	-1	24812279
cl@@	I-Chemical	-1	24812279
ine	I-Chemical	-1	24812279
cardi@@	B-Disease	D066126	24812279
otoxicity	I-Disease	-1	24812279
.	O	-1	24812279
A@@	O	-1	24812279
I@@	O	-1	24812279
M@@	O	-1	24812279
S:	O	-1	24812279
D@@	B-Chemical	D004317	24812279
ox@@	I-Chemical	-1	24812279
orub@@	I-Chemical	-1	24812279
icin	I-Chemical	-1	24812279
(	O	-1	24812279
DO@@	B-Chemical	D004317	24812279
X	I-Chemical	-1	24812279
)	O	-1	24812279
is	O	-1	24812279
an	O	-1	24812279
effective	O	-1	24812279
anti@@	O	-1	24812279
-	O	-1	24812279
cancer	B-Disease	D009369	24812279
therapeu@@	O	-1	24812279
tic@@	O	-1	24812279
,	O	-1	24812279
but	O	-1	24812279
is	O	-1	24812279
associated	O	-1	24812279
with	O	-1	24812279
both	O	-1	24812279
acute	O	-1	24812279
and	O	-1	24812279
lat@@	O	-1	24812279
e-@@	O	-1	24812279
st@@	O	-1	24812279
age	O	-1	24812279
cardi@@	B-Disease	D066126	24812279
otoxicity	I-Disease	-1	24812279
.	O	-1	24812279
Ch@@	O	-1	24812279
ild@@	O	-1	24812279
ren	O	-1	24812279
are	O	-1	24812279
partic@@	O	-1	24812279
ul@@	O	-1	24812279
arly	O	-1	24812279
sensitive	O	-1	24812279
to	O	-1	24812279
DO@@	B-Chemical	D004317	24812279
X	I-Chemical	-1	24812279
-induced	O	-1	24812279
heart	B-Disease	D006333	24812279
failure	I-Disease	-1	24812279
.	O	-1	24812279
He@@	O	-1	24812279
re,	O	-1	24812279
the	O	-1	24812279
im@@	O	-1	24812279
pac@@	O	-1	24812279
t	O	-1	24812279
of	O	-1	24812279
p@@	O	-1	24812279
5@@	O	-1	24812279
3	O	-1	24812279
inhibition	O	-1	24812279
on	O	-1	24812279
acute	O	-1	24812279
vs.	O	-1	24812279
lat@@	O	-1	24812279
e-@@	O	-1	24812279
st@@	O	-1	24812279
age	O	-1	24812279
DO@@	B-Chemical	D004317	24812279
X	I-Chemical	-1	24812279
cardi@@	B-Disease	D066126	24812279
otoxicity	I-Disease	-1	24812279
was	O	-1	24812279
examined	O	-1	24812279
in	O	-1	24812279
a	O	-1	24812279
j@@	O	-1	24812279
u@@	O	-1	24812279
ven@@	O	-1	24812279
ile	O	-1	24812279
model@@	O	-1	24812279
.	O	-1	24812279
METHOD@@	O	-1	24812279
S	O	-1	24812279
AN@@	O	-1	24812279
D	O	-1	24812279
RESULTS:	O	-1	24812279
T@@	O	-1	24812279
wo@@	O	-1	24812279
-@@	O	-1	24812279
week@@	O	-1	24812279
-old	O	-1	24812279
M@@	O	-1	24812279
HC@@	O	-1	24812279
-@@	O	-1	24812279
C@@	O	-1	24812279
B@@	O	-1	24812279
7	O	-1	24812279
mice	O	-1	24812279
(@@	O	-1	24812279
which	O	-1	24812279
ex@@	O	-1	24812279
pres@@	O	-1	24812279
s	O	-1	24812279
domin@@	O	-1	24812279
ant@@	O	-1	24812279
-@@	O	-1	24812279
inter@@	O	-1	24812279
fer@@	O	-1	24812279
ing	O	-1	24812279
p@@	O	-1	24812279
5@@	O	-1	24812279
3	O	-1	24812279
in	O	-1	24812279
cardi@@	O	-1	24812279
om@@	O	-1	24812279
y@@	O	-1	24812279
ocy@@	O	-1	24812279
t@@	O	-1	24812279
es@@	O	-1	24812279
)	O	-1	24812279
and	O	-1	24812279
their	O	-1	24812279
non-@@	O	-1	24812279
trans@@	O	-1	24812279
genic	O	-1	24812279
(N@@	O	-1	24812279
ON@@	O	-1	24812279
-@@	O	-1	24812279
T@@	O	-1	24812279
X@@	O	-1	24812279
G@@	O	-1	24812279
)	O	-1	24812279
lit@@	O	-1	24812279
ter@@	O	-1	24812279
mat@@	O	-1	24812279
es	O	-1	24812279
received	O	-1	24812279
week@@	O	-1	24812279
ly	O	-1	24812279
DO@@	B-Chemical	D004317	24812279
X	I-Chemical	-1	24812279
injec@@	O	-1	24812279
tions	O	-1	24812279
for	O	-1	24812279
5	O	-1	24812279
weeks	O	-1	24812279
(2@@	O	-1	24812279
5	O	-1	24812279
mg/kg	O	-1	24812279
cum@@	O	-1	24812279
ul@@	O	-1	24812279
ative	O	-1	24812279
dose@@	O	-1	24812279
).	O	-1	24812279
One	O	-1	24812279
week	O	-1	24812279
after	O	-1	24812279
the	O	-1	24812279
las@@	O	-1	24812279
t	O	-1	24812279
DO@@	B-Chemical	D004317	24812279
X	I-Chemical	-1	24812279
treatment	O	-1	24812279
(@@	O	-1	24812279
acute	O	-1	24812279
st@@	O	-1	24812279
ag@@	O	-1	24812279
e@@	O	-1	24812279
),	O	-1	24812279
M@@	O	-1	24812279
HC@@	O	-1	24812279
-@@	O	-1	24812279
C@@	O	-1	24812279
B@@	O	-1	24812279
7	O	-1	24812279
mice	O	-1	24812279
ex@@	O	-1	24812279
hib@@	O	-1	24812279
ited	O	-1	24812279
improved	O	-1	24812279
cardiac	O	-1	24812279
function	O	-1	24812279
and	O	-1	24812279
lower	O	-1	24812279
levels	O	-1	24812279
of	O	-1	24812279
cardi@@	O	-1	24812279
om@@	O	-1	24812279
y@@	O	-1	24812279
ocyte	O	-1	24812279
apo@@	O	-1	24812279
pto@@	O	-1	24812279
sis	O	-1	24812279
when	O	-1	24812279
compared	O	-1	24812279
with	O	-1	24812279
the	O	-1	24812279
N@@	O	-1	24812279
ON@@	O	-1	24812279
-@@	O	-1	24812279
T@@	O	-1	24812279
X@@	O	-1	24812279
G	O	-1	24812279
mice.	O	-1	24812279
S@@	O	-1	24812279
ur@@	O	-1	24812279
p@@	O	-1	24812279
ris@@	O	-1	24812279
ing@@	O	-1	24812279
ly,	O	-1	24812279
by	O	-1	24812279
13	O	-1	24812279
weeks	O	-1	24812279
following	O	-1	24812279
the	O	-1	24812279
las@@	O	-1	24812279
t	O	-1	24812279
DO@@	B-Chemical	D004317	24812279
X	I-Chemical	-1	24812279
treatment	O	-1	24812279
(@@	O	-1	24812279
l@@	O	-1	24812279
ate	O	-1	24812279
st@@	O	-1	24812279
ag@@	O	-1	24812279
e@@	O	-1	24812279
),	O	-1	24812279
M@@	O	-1	24812279
HC@@	O	-1	24812279
-@@	O	-1	24812279
C@@	O	-1	24812279
B@@	O	-1	24812279
7	O	-1	24812279
ex@@	O	-1	24812279
hib@@	O	-1	24812279
ited	O	-1	24812279
a	O	-1	24812279
progressive	O	-1	24812279
decrease	O	-1	24812279
in	O	-1	24812279
cardiac	O	-1	24812279
function	O	-1	24812279
and	O	-1	24812279
higher	O	-1	24812279
rat@@	O	-1	24812279
es	O	-1	24812279
of	O	-1	24812279
cardi@@	O	-1	24812279
om@@	O	-1	24812279
y@@	O	-1	24812279
ocyte	O	-1	24812279
apo@@	O	-1	24812279
pto@@	O	-1	24812279
sis	O	-1	24812279
when	O	-1	24812279
compared	O	-1	24812279
with	O	-1	24812279
N@@	O	-1	24812279
ON@@	O	-1	24812279
-@@	O	-1	24812279
T@@	O	-1	24812279
X@@	O	-1	24812279
G	O	-1	24812279
mice.	O	-1	24812279
p@@	O	-1	24812279
5@@	O	-1	24812279
3	O	-1	24812279
inhibition	O	-1	24812279
block@@	O	-1	24812279
ed	O	-1	24812279
transi@@	O	-1	24812279
ent	O	-1	24812279
DO@@	B-Chemical	D004317	24812279
X	I-Chemical	-1	24812279
-induced	O	-1	24812279
S@@	O	-1	24812279
T@@	O	-1	24812279
AT@@	O	-1	24812279
3	O	-1	24812279
activation	O	-1	24812279
in	O	-1	24812279
M@@	O	-1	24812279
HC@@	O	-1	24812279
-@@	O	-1	24812279
C@@	O	-1	24812279
B@@	O	-1	24812279
7	O	-1	24812279
mic@@	O	-1	24812279
e,	O	-1	24812279
which	O	-1	24812279
was	O	-1	24812279
associated	O	-1	24812279
with	O	-1	24812279
enhanced	O	-1	24812279
induction	O	-1	24812279
of	O	-1	24812279
the	O	-1	24812279
D@@	O	-1	24812279
NA	O	-1	24812279
re@@	O	-1	24812279
pa@@	O	-1	24812279
ir	O	-1	24812279
protein@@	O	-1	24812279
s	O	-1	24812279
K@@	O	-1	24812279
u@@	O	-1	24812279
7@@	O	-1	24812279
0	O	-1	24812279
and	O	-1	24812279
K@@	O	-1	24812279
u@@	O	-1	24812279
80@@	O	-1	24812279
.	O	-1	24812279
M@@	O	-1	24812279
ic@@	O	-1	24812279
e	O	-1	24812279
with	O	-1	24812279
cardi@@	O	-1	24812279
om@@	O	-1	24812279
y@@	O	-1	24812279
ocy@@	O	-1	24812279
te@@	O	-1	24812279
-@@	O	-1	24812279
re@@	O	-1	24812279
stric@@	O	-1	24812279
ted	O	-1	24812279
de@@	O	-1	24812279
le@@	O	-1	24812279
tion	O	-1	24812279
of	O	-1	24812279
S@@	O	-1	24812279
T@@	O	-1	24812279
AT@@	O	-1	24812279
3	O	-1	24812279
ex@@	O	-1	24812279
hib@@	O	-1	24812279
ited	O	-1	24812279
wor@@	O	-1	24812279
se	O	-1	24812279
cardiac	O	-1	24812279
func@@	O	-1	24812279
tion,	O	-1	24812279
higher	O	-1	24812279
levels	O	-1	24812279
of	O	-1	24812279
cardi@@	O	-1	24812279
om@@	O	-1	24812279
y@@	O	-1	24812279
ocyte	O	-1	24812279
apo@@	O	-1	24812279
pto@@	O	-1	24812279
sis,	O	-1	24812279
and	O	-1	24812279
a	O	-1	24812279
greater	O	-1	24812279
induction	O	-1	24812279
of	O	-1	24812279
K@@	O	-1	24812279
u@@	O	-1	24812279
7@@	O	-1	24812279
0	O	-1	24812279
and	O	-1	24812279
K@@	O	-1	24812279
u@@	O	-1	24812279
8@@	O	-1	24812279
0	O	-1	24812279
in	O	-1	24812279
response	O	-1	24812279
to	O	-1	24812279
DO@@	B-Chemical	D004317	24812279
X	I-Chemical	-1	24812279
treatment	O	-1	24812279
during	O	-1	24812279
the	O	-1	24812279
acute	O	-1	24812279
st@@	O	-1	24812279
age	O	-1	24812279
when	O	-1	24812279
compared	O	-1	24812279
with	O	-1	24812279
control	O	-1	24812279
anim@@	O	-1	24812279
al@@	O	-1	24812279
s.	O	-1	24812279
CONCLUSION:	O	-1	24812279
These	O	-1	24812279
data	O	-1	24812279
suppor@@	O	-1	24812279
t	O	-1	24812279
a	O	-1	24812279
model	O	-1	24812279
whe@@	O	-1	24812279
re@@	O	-1	24812279
in	O	-1	24812279
a	O	-1	24812279
p@@	O	-1	24812279
5@@	O	-1	24812279
3-@@	O	-1	24812279
dependent	O	-1	24812279
cardio@@	O	-1	24812279
protective	O	-1	24812279
path@@	O	-1	24812279
w@@	O	-1	24812279
a@@	O	-1	24812279
y,	O	-1	24812279
mediated	O	-1	24812279
vi@@	O	-1	24812279
a	O	-1	24812279
S@@	O	-1	24812279
T@@	O	-1	24812279
AT@@	O	-1	24812279
3	O	-1	24812279
activ@@	O	-1	24812279
ation,	O	-1	24812279
m@@	O	-1	24812279
iti@@	O	-1	24812279
g@@	O	-1	24812279
ates	O	-1	24812279
DO@@	B-Chemical	D004317	24812279
X	I-Chemical	-1	24812279
-induced	O	-1	24812279
myocardial	O	-1	24812279
stres@@	O	-1	24812279
s	O	-1	24812279
during	O	-1	24812279
drug	O	-1	24812279
de@@	O	-1	24812279
li@@	O	-1	24812279
ver@@	O	-1	24812279
y.	O	-1	24812279
F@@	O	-1	24812279
ur@@	O	-1	24812279
ther@@	O	-1	24812279
mo@@	O	-1	24812279
re,	O	-1	24812279
these	O	-1	24812279
data	O	-1	24812279
suggest	O	-1	24812279
an	O	-1	24812279
expl@@	O	-1	24812279
an@@	O	-1	24812279
ation	O	-1	24812279
as	O	-1	24812279
to	O	-1	24812279
ho@@	O	-1	24812279
w	O	-1	24812279
p@@	O	-1	24812279
5@@	O	-1	24812279
3	O	-1	24812279
inhibition	O	-1	24812279
can	O	-1	24812279
result	O	-1	24812279
in	O	-1	24812279
cardio@@	O	-1	24812279
prot@@	O	-1	24812279
ection	O	-1	24812279
during	O	-1	24812279
drug	O	-1	24812279
treatment	O	-1	24812279
and@@	O	-1	24812279
,	O	-1	24812279
par@@	O	-1	24812279
ad@@	O	-1	24812279
oxic@@	O	-1	24812279
ally,	O	-1	24812279
enhanced	O	-1	24812279
cardi@@	B-Disease	D066126	24812279
otoxicity	I-Disease	-1	24812279
lon@@	O	-1	24812279
g	O	-1	24812279
after	O	-1	24812279
the	O	-1	24812279
cess@@	O	-1	24812279
ation	O	-1	24812279
of	O	-1	24812279
drug	O	-1	24812279
treatment.	O	-1	24812279

M@@	B-Chemical	D008795	24816962
et@@	I-Chemical	-1	24816962
ron@@	I-Chemical	-1	24816962
id@@	I-Chemical	-1	24816962
azole	I-Chemical	-1	24816962
-induced	O	-1	24816962
encephalo@@	B-Disease	D001927	24816962
pathy	I-Disease	-1	24816962
:	O	-1	24816962
an	O	-1	24816962
un@@	O	-1	24816962
common	O	-1	24816962
s@@	O	-1	24816962
c@@	O	-1	24816962
en@@	O	-1	24816962
ar@@	O	-1	24816962
io@@	O	-1	24816962
.	O	-1	24816962
M@@	B-Chemical	D008795	24816962
et@@	I-Chemical	-1	24816962
ron@@	I-Chemical	-1	24816962
id@@	I-Chemical	-1	24816962
azole	I-Chemical	-1	24816962
can	O	-1	24816962
produce	O	-1	24816962
neurolog@@	O	-1	24816962
ical	O	-1	24816962
complications	O	-1	24816962
although	O	-1	24816962
it	O	-1	24816962
is	O	-1	24816962
not	O	-1	24816962
a	O	-1	24816962
common	O	-1	24816962
s@@	O	-1	24816962
c@@	O	-1	24816962
en@@	O	-1	24816962
ar@@	O	-1	24816962
io@@	O	-1	24816962
.	O	-1	24816962
We	O	-1	24816962
present	O	-1	24816962
a	O	-1	24816962
case	O	-1	24816962
wh@@	O	-1	24816962
ere	O	-1	24816962
a	O	-1	24816962
patient	O	-1	24816962
developed	O	-1	24816962
feat@@	O	-1	24816962
ures	O	-1	24816962
of	O	-1	24816962
encephalo@@	B-Disease	D001927	24816962
pathy	I-Disease	-1	24816962
following	O	-1	24816962
prolonged	O	-1	24816962
met@@	B-Chemical	D008795	24816962
ron@@	I-Chemical	-1	24816962
id@@	I-Chemical	-1	24816962
azole	I-Chemical	-1	24816962
int@@	O	-1	24816962
ak@@	O	-1	24816962
e.	O	-1	24816962
M@@	O	-1	24816962
ag@@	O	-1	24816962
ne@@	O	-1	24816962
tic	O	-1	24816962
res@@	O	-1	24816962
on@@	O	-1	24816962
ance	O	-1	24816962
imaging	O	-1	24816962
(@@	O	-1	24816962
MR@@	O	-1	24816962
I@@	O	-1	24816962
)	O	-1	24816962
brain	O	-1	24816962
showed	O	-1	24816962
ab@@	O	-1	24816962
normal	O	-1	24816962
sign@@	O	-1	24816962
al	O	-1	24816962
int@@	O	-1	24816962
ensity	O	-1	24816962
invol@@	O	-1	24816962
ving	O	-1	24816962
both	O	-1	24816962
d@@	O	-1	24816962
ent@@	O	-1	24816962
ate	O	-1	24816962
nucle@@	O	-1	24816962
i	O	-1	24816962
of	O	-1	24816962
ce@@	O	-1	24816962
re@@	O	-1	24816962
bell@@	O	-1	24816962
um	O	-1	24816962
and	O	-1	24816962
s@@	O	-1	24816962
pl@@	O	-1	24816962
en@@	O	-1	24816962
i@@	O	-1	24816962
um	O	-1	24816962
of	O	-1	24816962
cor@@	O	-1	24816962
p@@	O	-1	24816962
us	O	-1	24816962
cal@@	O	-1	24816962
lo@@	O	-1	24816962
su@@	O	-1	24816962
m.	O	-1	24816962
The	O	-1	24816962
diagnosis	O	-1	24816962
of	O	-1	24816962
met@@	B-Chemical	D008795	24816962
ron@@	I-Chemical	-1	24816962
id@@	I-Chemical	-1	24816962
azole	I-Chemical	-1	24816962
toxicity	B-Disease	D064420	24816962
was	O	-1	24816962
m@@	O	-1	24816962
ade	O	-1	24816962
by	O	-1	24816962
the	O	-1	24816962
MR@@	O	-1	24816962
I	O	-1	24816962
findings	O	-1	24816962
and	O	-1	24816962
suppor@@	O	-1	24816962
ted	O	-1	24816962
clin@@	O	-1	24816962
ic@@	O	-1	24816962
all@@	O	-1	24816962
y.	O	-1	24816962

A@@	B-Chemical	D000157	24840785
con@@	I-Chemical	-1	24840785
it@@	I-Chemical	-1	24840785
ine	I-Chemical	-1	24840785
-induced	O	-1	24840785
C@@	B-Chemical	D002118	24840785
a	I-Chemical	-1	24840785
2@@	O	-1	24840785
+	O	-1	24840785
over@@	O	-1	24840785
lo@@	O	-1	24840785
ad	O	-1	24840785
causes	O	-1	24840785
arrhyth@@	B-Disease	D001145	24840785
mia	I-Disease	-1	24840785
and	O	-1	24840785
tri@@	O	-1	24840785
g@@	O	-1	24840785
g@@	O	-1	24840785
ers	O	-1	24840785
apo@@	O	-1	24840785
pto@@	O	-1	24840785
sis	O	-1	24840785
through	O	-1	24840785
p@@	O	-1	24840785
3@@	O	-1	24840785
8	O	-1	24840785
MA@@	O	-1	24840785
P@@	O	-1	24840785
K	O	-1	24840785
sign@@	O	-1	24840785
al@@	O	-1	24840785
ing	O	-1	24840785
path@@	O	-1	24840785
w@@	O	-1	24840785
ay	O	-1	24840785
in	O	-1	24840785
rats.	O	-1	24840785
A@@	B-Chemical	D000157	24840785
con@@	I-Chemical	-1	24840785
it@@	I-Chemical	-1	24840785
ine	I-Chemical	-1	24840785
is	O	-1	24840785
a	O	-1	24840785
major	O	-1	24840785
bio@@	O	-1	24840785
active	O	-1	24840785
d@@	O	-1	24840785
it@@	O	-1	24840785
er@@	O	-1	24840785
pen@@	O	-1	24840785
oid	O	-1	24840785
al@@	O	-1	24840785
k@@	O	-1	24840785
alo@@	O	-1	24840785
id	O	-1	24840785
with	O	-1	24840785
high	O	-1	24840785
cont@@	O	-1	24840785
ent	O	-1	24840785
der@@	O	-1	24840785
i@@	O	-1	24840785
ved	O	-1	24840785
from	O	-1	24840785
h@@	O	-1	24840785
er@@	O	-1	24840785
b@@	O	-1	24840785
al	O	-1	24840785
ac@@	O	-1	24840785
on@@	O	-1	24840785
it@@	O	-1	24840785
um	O	-1	24840785
pl@@	O	-1	24840785
ant@@	O	-1	24840785
s.	O	-1	24840785
E@@	O	-1	24840785
m@@	O	-1	24840785
erg@@	O	-1	24840785
ing	O	-1	24840785
evidence	O	-1	24840785
indic@@	O	-1	24840785
ates	O	-1	24840785
that	O	-1	24840785
vol@@	O	-1	24840785
t@@	O	-1	24840785
ag@@	O	-1	24840785
e-@@	O	-1	24840785
dependent	O	-1	24840785
N@@	B-Chemical	D012964	24840785
a	I-Chemical	-1	24840785
(@@	O	-1	24840785
+@@	O	-1	24840785
)	O	-1	24840785
channe@@	O	-1	24840785
l@@	O	-1	24840785
s	O	-1	24840785
have	O	-1	24840785
pi@@	O	-1	24840785
v@@	O	-1	24840785
ot@@	O	-1	24840785
al	O	-1	24840785
ro@@	O	-1	24840785
le@@	O	-1	24840785
s	O	-1	24840785
in	O	-1	24840785
the	O	-1	24840785
cardi@@	B-Disease	D066126	24840785
otoxicity	I-Disease	-1	24840785
of	O	-1	24840785
ac@@	B-Chemical	D000157	24840785
on@@	I-Chemical	-1	24840785
it@@	I-Chemical	-1	24840785
ine	I-Chemical	-1	24840785
.	O	-1	24840785
However,	O	-1	24840785
no	O	-1	24840785
reports	O	-1	24840785
are	O	-1	24840785
av@@	O	-1	24840785
ail@@	O	-1	24840785
able	O	-1	24840785
on	O	-1	24840785
the	O	-1	24840785
role	O	-1	24840785
of	O	-1	24840785
C@@	B-Chemical	D002118	24840785
a	I-Chemical	-1	24840785
(2@@	O	-1	24840785
+@@	O	-1	24840785
)	O	-1	24840785
in	O	-1	24840785
ac@@	B-Chemical	D000157	24840785
on@@	I-Chemical	-1	24840785
it@@	I-Chemical	-1	24840785
ine	I-Chemical	-1	24840785
po@@	B-Disease	D011041	24840785
is@@	I-Disease	-1	24840785
on@@	I-Disease	-1	24840785
ing	I-Disease	-1	24840785
.	O	-1	24840785
In	O	-1	24840785
this	O	-1	24840785
study,	O	-1	24840785
we	O	-1	24840785
ex@@	O	-1	24840785
p@@	O	-1	24840785
lo@@	O	-1	24840785
red	O	-1	24840785
the	O	-1	24840785
import@@	O	-1	24840785
ance	O	-1	24840785
of	O	-1	24840785
path@@	O	-1	24840785
ological	O	-1	24840785
C@@	B-Chemical	D002118	24840785
a	I-Chemical	-1	24840785
(2@@	O	-1	24840785
+@@	O	-1	24840785
)	O	-1	24840785
sign@@	O	-1	24840785
al@@	O	-1	24840785
ing	O	-1	24840785
in	O	-1	24840785
ac@@	B-Chemical	D000157	24840785
on@@	I-Chemical	-1	24840785
it@@	I-Chemical	-1	24840785
ine	I-Chemical	-1	24840785
po@@	B-Disease	D011041	24840785
is@@	I-Disease	-1	24840785
on@@	I-Disease	-1	24840785
ing	I-Disease	-1	24840785
in	O	-1	24840785
vit@@	O	-1	24840785
r@@	O	-1	24840785
o	O	-1	24840785
and	O	-1	24840785
in	O	-1	24840785
viv@@	O	-1	24840785
o@@	O	-1	24840785
.	O	-1	24840785
We	O	-1	24840785
found	O	-1	24840785
that	O	-1	24840785
C@@	B-Chemical	D002118	24840785
a	I-Chemical	-1	24840785
(2@@	O	-1	24840785
+@@	O	-1	24840785
)	O	-1	24840785
over@@	O	-1	24840785
lo@@	O	-1	24840785
ad	O	-1	24840785
le@@	O	-1	24840785
ad	O	-1	24840785
to	O	-1	24840785
ac@@	O	-1	24840785
ce@@	O	-1	24840785
l@@	O	-1	24840785
er@@	O	-1	24840785
ated	O	-1	24840785
be@@	O	-1	24840785
ating	O	-1	24840785
rhyth@@	O	-1	24840785
m	O	-1	24840785
in	O	-1	24840785
ad@@	O	-1	24840785
ult	O	-1	24840785
rat	O	-1	24840785
ventricular	O	-1	24840785
my@@	O	-1	24840785
ocy@@	O	-1	24840785
tes	O	-1	24840785
and	O	-1	24840785
caused	O	-1	24840785
arrhyth@@	B-Disease	D001145	24840785
mia	I-Disease	-1	24840785
in	O	-1	24840785
con@@	O	-1	24840785
s@@	O	-1	24840785
ci@@	O	-1	24840785
ous	O	-1	24840785
f@@	O	-1	24840785
re@@	O	-1	24840785
ely	O	-1	24840785
mo@@	O	-1	24840785
ving	O	-1	24840785
rats.	O	-1	24840785
To	O	-1	24840785
investigate	O	-1	24840785
effects	O	-1	24840785
of	O	-1	24840785
ac@@	B-Chemical	D000157	24840785
on@@	I-Chemical	-1	24840785
it@@	I-Chemical	-1	24840785
ine	I-Chemical	-1	24840785
on	O	-1	24840785
myocardial	B-Disease	D009202	24840785
injury	I-Disease	-1	24840785
,	O	-1	24840785
we	O	-1	24840785
performed	O	-1	24840785
cy@@	B-Disease	D064420	24840785
tot@@	I-Disease	-1	24840785
oxic@@	I-Disease	-1	24840785
ity	I-Disease	-1	24840785
ass@@	O	-1	24840785
ay	O	-1	24840785
in	O	-1	24840785
ne@@	O	-1	24840785
on@@	O	-1	24840785
atal	O	-1	24840785
rat	O	-1	24840785
ventricular	O	-1	24840785
my@@	O	-1	24840785
ocy@@	O	-1	24840785
tes	O	-1	24840785
(N@@	O	-1	24840785
R@@	O	-1	24840785
V@@	O	-1	24840785
M@@	O	-1	24840785
s),	O	-1	24840785
as	O	-1	24840785
well	O	-1	24840785
as	O	-1	24840785
measured	O	-1	24840785
l@@	B-Chemical	D019344	24840785
act@@	I-Chemical	-1	24840785
ate	I-Chemical	-1	24840785
de@@	O	-1	24840785
hydro@@	O	-1	24840785
gen@@	O	-1	24840785
ase	O	-1	24840785
level	O	-1	24840785
in	O	-1	24840785
the	O	-1	24840785
c@@	O	-1	24840785
ult@@	O	-1	24840785
ure	O	-1	24840785
medi@@	O	-1	24840785
um	O	-1	24840785
of	O	-1	24840785
N@@	O	-1	24840785
R@@	O	-1	24840785
V@@	O	-1	24840785
M@@	O	-1	24840785
s	O	-1	24840785
and	O	-1	24840785
ac@@	O	-1	24840785
ti@@	O	-1	24840785
vi@@	O	-1	24840785
ties	O	-1	24840785
of	O	-1	24840785
serum	O	-1	24840785
cardiac	O	-1	24840785
enzym@@	O	-1	24840785
es	O	-1	24840785
in	O	-1	24840785
rats.	O	-1	24840785
The	O	-1	24840785
results	O	-1	24840785
showed	O	-1	24840785
that	O	-1	24840785
ac@@	B-Chemical	D000157	24840785
on@@	I-Chemical	-1	24840785
it@@	I-Chemical	-1	24840785
ine	I-Chemical	-1	24840785
resulted	O	-1	24840785
in	O	-1	24840785
myocardial	B-Disease	D009202	24840785
injury	I-Disease	-1	24840785
and	O	-1	24840785
reduced	O	-1	24840785
N@@	O	-1	24840785
R@@	O	-1	24840785
V@@	O	-1	24840785
M@@	O	-1	24840785
s	O	-1	24840785
vi@@	O	-1	24840785
ability	O	-1	24840785
dose-@@	O	-1	24840785
depend@@	O	-1	24840785
ent@@	O	-1	24840785
ly.	O	-1	24840785
To	O	-1	24840785
con@@	O	-1	24840785
fir@@	O	-1	24840785
m	O	-1	24840785
the	O	-1	24840785
pro@@	O	-1	24840785
-@@	O	-1	24840785
apo@@	O	-1	24840785
pto@@	O	-1	24840785
tic	O	-1	24840785
effect@@	O	-1	24840785
s,	O	-1	24840785
we	O	-1	24840785
performed	O	-1	24840785
flow	O	-1	24840785
cyto@@	O	-1	24840785
me@@	O	-1	24840785
tri@@	O	-1	24840785
c	O	-1	24840785
det@@	O	-1	24840785
ec@@	O	-1	24840785
tion,	O	-1	24840785
cardiac	O	-1	24840785
hist@@	O	-1	24840785
olog@@	O	-1	24840785
y,	O	-1	24840785
trans@@	O	-1	24840785
mission	O	-1	24840785
electro@@	O	-1	24840785
n	O	-1	24840785
micro@@	O	-1	24840785
sco@@	O	-1	24840785
p@@	O	-1	24840785
y	O	-1	24840785
and	O	-1	24840785
ter@@	O	-1	24840785
min@@	O	-1	24840785
al	O	-1	24840785
de@@	O	-1	24840785
oxy@@	O	-1	24840785
nucle@@	O	-1	24840785
o@@	O	-1	24840785
ti@@	O	-1	24840785
dy@@	O	-1	24840785
l	O	-1	24840785
trans@@	O	-1	24840785
fer@@	O	-1	24840785
as@@	O	-1	24840785
e-@@	O	-1	24840785
mediated	O	-1	24840785
d@@	B-Chemical	-1	24840785
U@@	I-Chemical	-1	24840785
T@@	I-Chemical	-1	24840785
P	I-Chemical	-1	24840785
-	O	-1	24840785
bio@@	B-Chemical	D001710	24840785
tin	I-Chemical	-1	24840785
n@@	O	-1	24840785
ic@@	O	-1	24840785
k	O	-1	24840785
end	O	-1	24840785
l@@	O	-1	24840785
a@@	O	-1	24840785
be@@	O	-1	24840785
l@@	O	-1	24840785
ing	O	-1	24840785
ass@@	O	-1	24840785
a@@	O	-1	24840785
y.	O	-1	24840785
The	O	-1	24840785
results	O	-1	24840785
showed	O	-1	24840785
that	O	-1	24840785
ac@@	B-Chemical	D000157	24840785
on@@	I-Chemical	-1	24840785
it@@	I-Chemical	-1	24840785
ine	I-Chemical	-1	24840785
stimul@@	O	-1	24840785
ated	O	-1	24840785
apo@@	O	-1	24840785
pto@@	O	-1	24840785
sis	O	-1	24840785
ti@@	O	-1	24840785
me@@	O	-1	24840785
-@@	O	-1	24840785
depend@@	O	-1	24840785
ent@@	O	-1	24840785
ly.	O	-1	24840785
The	O	-1	24840785
expression	O	-1	24840785
analysis	O	-1	24840785
of	O	-1	24840785
C@@	B-Chemical	D002118	24840785
a	I-Chemical	-1	24840785
(2@@	O	-1	24840785
+@@	O	-1	24840785
)	O	-1	24840785
h@@	O	-1	24840785
and@@	O	-1	24840785
l@@	O	-1	24840785
ing	O	-1	24840785
protein@@	O	-1	24840785
s	O	-1	24840785
demonstrated	O	-1	24840785
that	O	-1	24840785
ac@@	B-Chemical	D000157	24840785
on@@	I-Chemical	-1	24840785
it@@	I-Chemical	-1	24840785
ine	I-Chemical	-1	24840785
pro@@	O	-1	24840785
m@@	O	-1	24840785
ot@@	O	-1	24840785
ed	O	-1	24840785
C@@	B-Chemical	D002118	24840785
a	I-Chemical	-1	24840785
(2@@	O	-1	24840785
+@@	O	-1	24840785
)	O	-1	24840785
over@@	O	-1	24840785
lo@@	O	-1	24840785
ad	O	-1	24840785
through	O	-1	24840785
the	O	-1	24840785
expression	O	-1	24840785
reg@@	O	-1	24840785
ulation	O	-1	24840785
of	O	-1	24840785
C@@	B-Chemical	D002118	24840785
a	I-Chemical	-1	24840785
(2@@	O	-1	24840785
+@@	O	-1	24840785
)	O	-1	24840785
h@@	O	-1	24840785
and@@	O	-1	24840785
l@@	O	-1	24840785
ing	O	-1	24840785
protein@@	O	-1	24840785
s.	O	-1	24840785
The	O	-1	24840785
expression	O	-1	24840785
analysis	O	-1	24840785
of	O	-1	24840785
apo@@	O	-1	24840785
pto@@	O	-1	24840785
si@@	O	-1	24840785
s-@@	O	-1	24840785
related	O	-1	24840785
protein@@	O	-1	24840785
s	O	-1	24840785
revealed	O	-1	24840785
that	O	-1	24840785
pro@@	O	-1	24840785
-@@	O	-1	24840785
apo@@	O	-1	24840785
pto@@	O	-1	24840785
tic	O	-1	24840785
protein	O	-1	24840785
expression	O	-1	24840785
was	O	-1	24840785
u@@	O	-1	24840785
pre@@	O	-1	24840785
g@@	O	-1	24840785
ul@@	O	-1	24840785
at@@	O	-1	24840785
ed,	O	-1	24840785
and	O	-1	24840785
anti@@	O	-1	24840785
-@@	O	-1	24840785
apo@@	O	-1	24840785
pto@@	O	-1	24840785
tic	O	-1	24840785
protein	O	-1	24840785
B@@	O	-1	24840785
CL@@	O	-1	24840785
-@@	O	-1	24840785
2	O	-1	24840785
expression	O	-1	24840785
was	O	-1	24840785
do@@	O	-1	24840785
w@@	O	-1	24840785
n@@	O	-1	24840785
reg@@	O	-1	24840785
ul@@	O	-1	24840785
ated.	O	-1	24840785
F@@	O	-1	24840785
ur@@	O	-1	24840785
ther@@	O	-1	24840785
mo@@	O	-1	24840785
re,	O	-1	24840785
increased	O	-1	24840785
phosph@@	O	-1	24840785
or@@	O	-1	24840785
yl@@	O	-1	24840785
ation	O	-1	24840785
of	O	-1	24840785
MA@@	O	-1	24840785
P@@	O	-1	24840785
K	O	-1	24840785
f@@	O	-1	24840785
ami@@	O	-1	24840785
ly	O	-1	24840785
memb@@	O	-1	24840785
er@@	O	-1	24840785
s,	O	-1	24840785
es@@	O	-1	24840785
p@@	O	-1	24840785
ec@@	O	-1	24840785
i@@	O	-1	24840785
ally	O	-1	24840785
the	O	-1	24840785
P@@	O	-1	24840785
-@@	O	-1	24840785
P@@	O	-1	24840785
3@@	O	-1	24840785
8@@	O	-1	24840785
/@@	O	-1	24840785
P@@	O	-1	24840785
3@@	O	-1	24840785
8	O	-1	24840785
rati@@	O	-1	24840785
o	O	-1	24840785
was	O	-1	24840785
found	O	-1	24840785
in	O	-1	24840785
cardiac	O	-1	24840785
tissu@@	O	-1	24840785
es.	O	-1	24840785
H@@	O	-1	24840785
ence@@	O	-1	24840785
,	O	-1	24840785
our	O	-1	24840785
results	O	-1	24840785
suggest	O	-1	24840785
that	O	-1	24840785
ac@@	B-Chemical	D000157	24840785
on@@	I-Chemical	-1	24840785
it@@	I-Chemical	-1	24840785
ine	I-Chemical	-1	24840785
significantly	O	-1	24840785
ag@@	O	-1	24840785
gra@@	O	-1	24840785
v@@	O	-1	24840785
ates	O	-1	24840785
C@@	B-Chemical	D002118	24840785
a	I-Chemical	-1	24840785
(2@@	O	-1	24840785
+@@	O	-1	24840785
)	O	-1	24840785
over@@	O	-1	24840785
lo@@	O	-1	24840785
ad	O	-1	24840785
and	O	-1	24840785
causes	O	-1	24840785
arrhyth@@	B-Disease	D001145	24840785
mia	I-Disease	-1	24840785
and	O	-1	24840785
f@@	O	-1	24840785
in@@	O	-1	24840785
ally	O	-1	24840785
pro@@	O	-1	24840785
m@@	O	-1	24840785
ot@@	O	-1	24840785
es	O	-1	24840785
apo@@	O	-1	24840785
pto@@	O	-1	24840785
tic	O	-1	24840785
development	O	-1	24840785
vi@@	O	-1	24840785
a	O	-1	24840785
phosph@@	O	-1	24840785
or@@	O	-1	24840785
yl@@	O	-1	24840785
ation	O	-1	24840785
of	O	-1	24840785
P@@	O	-1	24840785
3@@	O	-1	24840785
8	O	-1	24840785
mit@@	O	-1	24840785
o@@	O	-1	24840785
gen@@	O	-1	24840785
-@@	O	-1	24840785
activ@@	O	-1	24840785
ated	O	-1	24840785
protein	O	-1	24840785
kin@@	O	-1	24840785
as@@	O	-1	24840785
e.	O	-1	24840785

Ch@@	O	-1	24842192
ron@@	O	-1	24842192
ic	O	-1	24842192
treatment	O	-1	24842192
with	O	-1	24842192
met@@	B-Chemical	D008687	24842192
form@@	I-Chemical	-1	24842192
in	I-Chemical	-1	24842192
sup@@	O	-1	24842192
pres@@	O	-1	24842192
ses	O	-1	24842192
t@@	O	-1	24842192
ol@@	O	-1	24842192
l@@	O	-1	24842192
-@@	O	-1	24842192
like	O	-1	24842192
receptor	O	-1	24842192
4	O	-1	24842192
sign@@	O	-1	24842192
al@@	O	-1	24842192
ing	O	-1	24842192
and	O	-1	24842192
attenu@@	O	-1	24842192
ates	O	-1	24842192
left	B-Disease	D018487	24842192
ventricular	I-Disease	-1	24842192
dysfunction	I-Disease	-1	24842192
following	O	-1	24842192
myocardial	B-Disease	D009203	24842192
infarction	I-Disease	-1	24842192
.	O	-1	24842192
Ac@@	O	-1	24842192
ute	O	-1	24842192
treatment	O	-1	24842192
with	O	-1	24842192
met@@	B-Chemical	D008687	24842192
form@@	I-Chemical	-1	24842192
in	I-Chemical	-1	24842192
has	O	-1	24842192
a	O	-1	24842192
protective	O	-1	24842192
effect	O	-1	24842192
in	O	-1	24842192
myocardial	B-Disease	D009203	24842192
infarction	I-Disease	-1	24842192
by	O	-1	24842192
sup@@	O	-1	24842192
pression	O	-1	24842192
of	O	-1	24842192
inflam@@	O	-1	24842192
mat@@	O	-1	24842192
ory	O	-1	24842192
responses	O	-1	24842192
due	O	-1	24842192
to	O	-1	24842192
activation	O	-1	24842192
of	O	-1	24842192
AM@@	B-Chemical	D000667	24842192
P	I-Chemical	-1	24842192
-@@	O	-1	24842192
activ@@	O	-1	24842192
ated	O	-1	24842192
protein	O	-1	24842192
kin@@	O	-1	24842192
ase	O	-1	24842192
(A@@	O	-1	24842192
MP@@	O	-1	24842192
K@@	O	-1	24842192
).	O	-1	24842192
In	O	-1	24842192
the	O	-1	24842192
present	O	-1	24842192
study,	O	-1	24842192
the	O	-1	24842192
effect	O	-1	24842192
of	O	-1	24842192
chronic	O	-1	24842192
pre-@@	O	-1	24842192
treatment	O	-1	24842192
with	O	-1	24842192
met@@	B-Chemical	D008687	24842192
form@@	I-Chemical	-1	24842192
in	I-Chemical	-1	24842192
on	O	-1	24842192
cardiac	B-Disease	D006331	24842192
dysfunction	I-Disease	-1	24842192
and	O	-1	24842192
t@@	O	-1	24842192
ol@@	O	-1	24842192
l@@	O	-1	24842192
-@@	O	-1	24842192
like	O	-1	24842192
receptor	O	-1	24842192
4	O	-1	24842192
(T@@	O	-1	24842192
L@@	O	-1	24842192
R@@	O	-1	24842192
4@@	O	-1	24842192
)	O	-1	24842192
ac@@	O	-1	24842192
ti@@	O	-1	24842192
vi@@	O	-1	24842192
ties	O	-1	24842192
following	O	-1	24842192
myocardial	B-Disease	D009203	24842192
infarction	I-Disease	-1	24842192
and	O	-1	24842192
their	O	-1	24842192
rel@@	O	-1	24842192
ation	O	-1	24842192
with	O	-1	24842192
AM@@	O	-1	24842192
P@@	O	-1	24842192
K	O	-1	24842192
were	O	-1	24842192
ass@@	O	-1	24842192
es@@	O	-1	24842192
sed.	O	-1	24842192
M@@	O	-1	24842192
al@@	O	-1	24842192
e	O	-1	24842192
Wistar	O	-1	24842192
rats	O	-1	24842192
were	O	-1	24842192
random@@	O	-1	24842192
ly	O	-1	24842192
as@@	O	-1	24842192
signed	O	-1	24842192
to	O	-1	24842192
one	O	-1	24842192
of	O	-1	24842192
5	O	-1	24842192
groups	O	-1	24842192
(n@@	O	-1	24842192
=@@	O	-1	24842192
6@@	O	-1	24842192
)@@	O	-1	24842192
:	O	-1	24842192
normal	O	-1	24842192
control	O	-1	24842192
and	O	-1	24842192
groups	O	-1	24842192
were	O	-1	24842192
injected	O	-1	24842192
isoproteren@@	B-Chemical	D007545	24842192
ol	I-Chemical	-1	24842192
after	O	-1	24842192
chronic	O	-1	24842192
pre-@@	O	-1	24842192
treatment	O	-1	24842192
with	O	-1	24842192
0@@	O	-1	24842192
,	O	-1	24842192
2@@	O	-1	24842192
5,	O	-1	24842192
50@@	O	-1	24842192
,	O	-1	24842192
or	O	-1	24842192
10@@	O	-1	24842192
0@@	O	-1	24842192
mg/kg	O	-1	24842192
of	O	-1	24842192
met@@	B-Chemical	D008687	24842192
form@@	I-Chemical	-1	24842192
in	I-Chemical	-1	24842192
tw@@	O	-1	24842192
ic@@	O	-1	24842192
e	O	-1	24842192
daily	O	-1	24842192
for	O	-1	24842192
14	O	-1	24842192
days.	O	-1	24842192
I@@	B-Chemical	D007545	24842192
so@@	I-Chemical	-1	24842192
proteren@@	I-Chemical	-1	24842192
ol	I-Chemical	-1	24842192
(@@	O	-1	24842192
10@@	O	-1	24842192
0@@	O	-1	24842192
mg/kg)	O	-1	24842192
was	O	-1	24842192
injected	O	-1	24842192
sub@@	O	-1	24842192
c@@	O	-1	24842192
ut@@	O	-1	24842192
ane@@	O	-1	24842192
ously	O	-1	24842192
on	O	-1	24842192
the	O	-1	24842192
13@@	O	-1	24842192
th	O	-1	24842192
and	O	-1	24842192
14@@	O	-1	24842192
th	O	-1	24842192
days	O	-1	24842192
to	O	-1	24842192
induce	O	-1	24842192
acute	B-Disease	D009203	24842192
myocardial	I-Disease	-1	24842192
infarction	I-Disease	-1	24842192
.	O	-1	24842192
I@@	B-Chemical	D007545	24842192
so@@	I-Chemical	-1	24842192
proteren@@	I-Chemical	-1	24842192
ol	I-Chemical	-1	24842192
alone	O	-1	24842192
decreased	O	-1	24842192
left	O	-1	24842192
ventricular	O	-1	24842192
systolic	O	-1	24842192
pressure	O	-1	24842192
and	O	-1	24842192
myocardial	O	-1	24842192
contrac@@	O	-1	24842192
til@@	O	-1	24842192
ity	O	-1	24842192
in@@	O	-1	24842192
de@@	O	-1	24842192
x@@	O	-1	24842192
ed	O	-1	24842192
as	O	-1	24842192
L@@	O	-1	24842192
V@@	O	-1	24842192
d@@	O	-1	24842192
p@@	O	-1	24842192
/@@	O	-1	24842192
d@@	O	-1	24842192
t@@	O	-1	24842192
ma@@	O	-1	24842192
x	O	-1	24842192
and	O	-1	24842192
L@@	O	-1	24842192
V@@	O	-1	24842192
d@@	O	-1	24842192
p@@	O	-1	24842192
/@@	O	-1	24842192
d@@	O	-1	24842192
t@@	O	-1	24842192
min@@	O	-1	24842192
.	O	-1	24842192
The	O	-1	24842192
left	B-Disease	D018487	24842192
ventricular	I-Disease	-1	24842192
dysfunction	I-Disease	-1	24842192
was	O	-1	24842192
significantly	O	-1	24842192
lower	O	-1	24842192
in	O	-1	24842192
the	O	-1	24842192
groups	O	-1	24842192
treated	O	-1	24842192
with	O	-1	24842192
25	O	-1	24842192
and	O	-1	24842192
50@@	O	-1	24842192
mg/kg	O	-1	24842192
of	O	-1	24842192
met@@	B-Chemical	D008687	24842192
form@@	I-Chemical	-1	24842192
in	I-Chemical	-1	24842192
.	O	-1	24842192
M@@	O	-1	24842192
et@@	O	-1	24842192
f@@	O	-1	24842192
rom@@	O	-1	24842192
in	O	-1	24842192
mark@@	O	-1	24842192
ed@@	O	-1	24842192
ly	O	-1	24842192
lo@@	O	-1	24842192
we@@	O	-1	24842192
red	O	-1	24842192
isoproteren@@	B-Chemical	D007545	24842192
ol	I-Chemical	-1	24842192
-induced	O	-1	24842192
elev@@	O	-1	24842192
ation	O	-1	24842192
in	O	-1	24842192
the	O	-1	24842192
levels	O	-1	24842192
of	O	-1	24842192
T@@	O	-1	24842192
L@@	O	-1	24842192
R@@	O	-1	24842192
4	O	-1	24842192
mR@@	O	-1	24842192
N@@	O	-1	24842192
A@@	O	-1	24842192
,	O	-1	24842192
my@@	O	-1	24842192
e@@	O	-1	24842192
lo@@	O	-1	24842192
id	O	-1	24842192
differen@@	O	-1	24842192
ti@@	O	-1	24842192
ation	O	-1	24842192
protein	O	-1	24842192
8@@	O	-1	24842192
8	O	-1	24842192
(@@	O	-1	24842192
M@@	O	-1	24842192
y@@	O	-1	24842192
D@@	O	-1	24842192
8@@	O	-1	24842192
8@@	O	-1	24842192
),	O	-1	24842192
tumor	B-Disease	D009369	24842192
necro@@	B-Disease	D009336	24842192
sis	I-Disease	-1	24842192
fact@@	O	-1	24842192
or@@	O	-1	24842192
-@@	O	-1	24842192
al@@	O	-1	24842192
ph@@	O	-1	24842192
a	O	-1	24842192
(T@@	O	-1	24842192
N@@	O	-1	24842192
F@@	O	-1	24842192
-@@	O	-1	24842192
a@@	O	-1	24842192
),	O	-1	24842192
and	O	-1	24842192
inter@@	O	-1	24842192
leuk@@	O	-1	24842192
in	O	-1	24842192
6	O	-1	24842192
(@@	O	-1	24842192
I@@	O	-1	24842192
L-@@	O	-1	24842192
6@@	O	-1	24842192
)	O	-1	24842192
in	O	-1	24842192
the	O	-1	24842192
heart	O	-1	24842192
tissu@@	O	-1	24842192
es.	O	-1	24842192
S@@	O	-1	24842192
im@@	O	-1	24842192
il@@	O	-1	24842192
ar	O	-1	24842192
changes	O	-1	24842192
were	O	-1	24842192
also	O	-1	24842192
seen	O	-1	24842192
in	O	-1	24842192
the	O	-1	24842192
serum	O	-1	24842192
levels	O	-1	24842192
of	O	-1	24842192
T@@	O	-1	24842192
N@@	O	-1	24842192
F@@	O	-1	24842192
-@@	O	-1	24842192
a	O	-1	24842192
and	O	-1	24842192
I@@	O	-1	24842192
L-@@	O	-1	24842192
6@@	O	-1	24842192
.	O	-1	24842192
However,	O	-1	24842192
the	O	-1	24842192
lower	O	-1	24842192
doses	O	-1	24842192
of	O	-1	24842192
25	O	-1	24842192
and	O	-1	24842192
50@@	O	-1	24842192
mg/kg	O	-1	24842192
were	O	-1	24842192
more	O	-1	24842192
effective	O	-1	24842192
than	O	-1	24842192
10@@	O	-1	24842192
0@@	O	-1	24842192
mg/kg@@	O	-1	24842192
.	O	-1	24842192
Ph@@	O	-1	24842192
osph@@	O	-1	24842192
or@@	O	-1	24842192
yl@@	O	-1	24842192
ated	O	-1	24842192
AM@@	O	-1	24842192
P@@	O	-1	24842192
K@@	O	-1	24842192
a	O	-1	24842192
(p@@	O	-1	24842192
-@@	O	-1	24842192
AM@@	O	-1	24842192
P@@	O	-1	24842192
K@@	O	-1	24842192
)	O	-1	24842192
in	O	-1	24842192
the	O	-1	24842192
myocardi@@	O	-1	24842192
um	O	-1	24842192
was	O	-1	24842192
significantly	O	-1	24842192
elevated	O	-1	24842192
by	O	-1	24842192
25@@	O	-1	24842192
mg/kg	O	-1	24842192
of	O	-1	24842192
met@@	B-Chemical	D008687	24842192
form@@	I-Chemical	-1	24842192
in	I-Chemical	-1	24842192
,	O	-1	24842192
s@@	O	-1	24842192
li@@	O	-1	24842192
gh@@	O	-1	24842192
tly	O	-1	24842192
by	O	-1	24842192
50@@	O	-1	24842192
mg/kg@@	O	-1	24842192
,	O	-1	24842192
but	O	-1	24842192
not	O	-1	24842192
by	O	-1	24842192
10@@	O	-1	24842192
0@@	O	-1	24842192
mg/kg@@	O	-1	24842192
.	O	-1	24842192
Ch@@	O	-1	24842192
ron@@	O	-1	24842192
ic	O	-1	24842192
pre-@@	O	-1	24842192
treatment	O	-1	24842192
with	O	-1	24842192
met@@	B-Chemical	D008687	24842192
form@@	I-Chemical	-1	24842192
in	I-Chemical	-1	24842192
reduc@@	O	-1	24842192
es	O	-1	24842192
post@@	O	-1	24842192
-	O	-1	24842192
myocardial	B-Disease	D009203	24842192
infarction	I-Disease	-1	24842192
cardiac	O	-1	24842192
dysfunction	O	-1	24842192
and	O	-1	24842192
sup@@	O	-1	24842192
pres@@	O	-1	24842192
ses	O	-1	24842192
inflam@@	O	-1	24842192
mat@@	O	-1	24842192
ory	O	-1	24842192
respon@@	O	-1	24842192
s@@	O	-1	24842192
es,	O	-1	24842192
possib@@	O	-1	24842192
ly	O	-1	24842192
through	O	-1	24842192
inhibition	O	-1	24842192
of	O	-1	24842192
T@@	O	-1	24842192
L@@	O	-1	24842192
R@@	O	-1	24842192
4	O	-1	24842192
ac@@	O	-1	24842192
ti@@	O	-1	24842192
vi@@	O	-1	24842192
ti@@	O	-1	24842192
es.	O	-1	24842192
This	O	-1	24842192
mechanism	O	-1	24842192
can	O	-1	24842192
be	O	-1	24842192
considered	O	-1	24842192
as	O	-1	24842192
a	O	-1	24842192
t@@	O	-1	24842192
arg@@	O	-1	24842192
et	O	-1	24842192
to	O	-1	24842192
prot@@	O	-1	24842192
ect	O	-1	24842192
infarc@@	O	-1	24842192
ted	O	-1	24842192
myocardi@@	O	-1	24842192
um@@	O	-1	24842192
.	O	-1	24842192

Ne@@	B-Disease	D009459	24881749
uro@@	I-Disease	-1	24881749
le@@	I-Disease	-1	24881749
p@@	I-Disease	-1	24881749
tic	I-Disease	-1	24881749
mal@@	I-Disease	-1	24881749
i@@	I-Disease	-1	24881749
gn@@	I-Disease	-1	24881749
ant	I-Disease	-1	24881749
syndrome	I-Disease	-1	24881749
induced	O	-1	24881749
by	O	-1	24881749
combination	O	-1	24881749
therapy	O	-1	24881749
with	O	-1	24881749
te@@	B-Chemical	D013747	24881749
tra@@	I-Chemical	-1	24881749
ben@@	I-Chemical	-1	24881749
az@@	I-Chemical	-1	24881749
ine	I-Chemical	-1	24881749
and	O	-1	24881749
ti@@	B-Chemical	D063325	24881749
apri@@	I-Chemical	-1	24881749
de	I-Chemical	-1	24881749
in	O	-1	24881749
a	O	-1	24881749
J@@	O	-1	24881749
ap@@	O	-1	24881749
an@@	O	-1	24881749
ese	O	-1	24881749
patient	O	-1	24881749
with	O	-1	24881749
H@@	B-Disease	D006816	24881749
un@@	I-Disease	-1	24881749
t@@	I-Disease	-1	24881749
ing@@	I-Disease	-1	24881749
t@@	I-Disease	-1	24881749
on@@	I-Disease	-1	24881749
's	I-Disease	-1	24881749
disease	I-Disease	-1	24881749
at	O	-1	24881749
the	O	-1	24881749
ter@@	O	-1	24881749
min@@	O	-1	24881749
al	O	-1	24881749
st@@	O	-1	24881749
age	O	-1	24881749
of	O	-1	24881749
recur@@	O	-1	24881749
rent	O	-1	24881749
b@@	B-Disease	D001943	24881749
reas@@	I-Disease	-1	24881749
t	I-Disease	-1	24881749
cancer	I-Disease	-1	24881749
.	O	-1	24881749
We	O	-1	24881749
he@@	O	-1	24881749
re@@	O	-1	24881749
in	O	-1	24881749
describe	O	-1	24881749
the	O	-1	24881749
case	O	-1	24881749
of	O	-1	24881749
an	O	-1	24881749
8@@	O	-1	24881749
1-@@	O	-1	24881749
year-old	O	-1	24881749
J@@	O	-1	24881749
ap@@	O	-1	24881749
an@@	O	-1	24881749
ese	O	-1	24881749
woman	O	-1	24881749
with	O	-1	24881749
neuro@@	B-Disease	D009459	24881749
le@@	I-Disease	-1	24881749
p@@	I-Disease	-1	24881749
tic	I-Disease	-1	24881749
mal@@	I-Disease	-1	24881749
i@@	I-Disease	-1	24881749
gn@@	I-Disease	-1	24881749
ant	I-Disease	-1	24881749
syndrome	I-Disease	-1	24881749
that	O	-1	24881749
occurred	O	-1	24881749
3@@	O	-1	24881749
6	O	-1	24881749
days	O	-1	24881749
after	O	-1	24881749
the	O	-1	24881749
initi@@	O	-1	24881749
ation	O	-1	24881749
of	O	-1	24881749
combination	O	-1	24881749
therapy	O	-1	24881749
with	O	-1	24881749
ti@@	B-Chemical	D063325	24881749
apri@@	I-Chemical	-1	24881749
de	I-Chemical	-1	24881749
(@@	O	-1	24881749
7@@	O	-1	24881749
5	O	-1	24881749
mg/@@	O	-1	24881749
day@@	O	-1	24881749
)	O	-1	24881749
and	O	-1	24881749
te@@	B-Chemical	D013747	24881749
tra@@	I-Chemical	-1	24881749
ben@@	I-Chemical	-1	24881749
az@@	I-Chemical	-1	24881749
ine	I-Chemical	-1	24881749
(1@@	O	-1	24881749
2.@@	O	-1	24881749
5	O	-1	24881749
mg/@@	O	-1	24881749
day@@	O	-1	24881749
)	O	-1	24881749
for	O	-1	24881749
H@@	B-Disease	D006816	24881749
un@@	I-Disease	-1	24881749
t@@	I-Disease	-1	24881749
ing@@	I-Disease	-1	24881749
t@@	I-Disease	-1	24881749
on@@	I-Disease	-1	24881749
's	I-Disease	-1	24881749
disease	I-Disease	-1	24881749
.	O	-1	24881749
The	O	-1	24881749
patient	O	-1	24881749
had	O	-1	24881749
been	O	-1	24881749
treated	O	-1	24881749
with	O	-1	24881749
ti@@	B-Chemical	D063325	24881749
apri@@	I-Chemical	-1	24881749
de	I-Chemical	-1	24881749
or	O	-1	24881749
te@@	B-Chemical	D013747	24881749
tra@@	I-Chemical	-1	24881749
ben@@	I-Chemical	-1	24881749
az@@	I-Chemical	-1	24881749
ine	I-Chemical	-1	24881749
alone	O	-1	24881749
without	O	-1	24881749
any	O	-1	24881749
adverse	O	-1	24881749
effects	O	-1	24881749
before	O	-1	24881749
the	O	-1	24881749
administration	O	-1	24881749
of	O	-1	24881749
the	O	-1	24881749
combination	O	-1	24881749
therapy.	O	-1	24881749
S@@	O	-1	24881749
he	O	-1	24881749
also	O	-1	24881749
had	O	-1	24881749
adv@@	O	-1	24881749
anced	O	-1	24881749
b@@	B-Disease	D001943	24881749
reas@@	I-Disease	-1	24881749
t	I-Disease	-1	24881749
cancer	I-Disease	-1	24881749
when	O	-1	24881749
the	O	-1	24881749
combination	O	-1	24881749
therapy	O	-1	24881749
was	O	-1	24881749
initi@@	O	-1	24881749
ated.	O	-1	24881749
To	O	-1	24881749
the	O	-1	24881749
b@@	O	-1	24881749
est	O	-1	24881749
of	O	-1	24881749
our	O	-1	24881749
know@@	O	-1	24881749
le@@	O	-1	24881749
d@@	O	-1	24881749
g@@	O	-1	24881749
e,	O	-1	24881749
the	O	-1	24881749
occur@@	O	-1	24881749
rence	O	-1	24881749
of	O	-1	24881749
neuro@@	B-Disease	D009459	24881749
le@@	I-Disease	-1	24881749
p@@	I-Disease	-1	24881749
tic	I-Disease	-1	24881749
mal@@	I-Disease	-1	24881749
i@@	I-Disease	-1	24881749
gn@@	I-Disease	-1	24881749
ant	I-Disease	-1	24881749
syndrome	I-Disease	-1	24881749
due	O	-1	24881749
to	O	-1	24881749
combination	O	-1	24881749
therapy	O	-1	24881749
with	O	-1	24881749
te@@	B-Chemical	D013747	24881749
tra@@	I-Chemical	-1	24881749
ben@@	I-Chemical	-1	24881749
az@@	I-Chemical	-1	24881749
ine	I-Chemical	-1	24881749
and	O	-1	24881749
ti@@	B-Chemical	D063325	24881749
apri@@	I-Chemical	-1	24881749
de	I-Chemical	-1	24881749
has	O	-1	24881749
not	O	-1	24881749
been	O	-1	24881749
previously	O	-1	24881749
repor@@	O	-1	24881749
ted.	O	-1	24881749
T@@	B-Chemical	D013747	24881749
et@@	I-Chemical	-1	24881749
ra@@	I-Chemical	-1	24881749
ben@@	I-Chemical	-1	24881749
az@@	I-Chemical	-1	24881749
ine	I-Chemical	-1	24881749
should	O	-1	24881749
be	O	-1	24881749
administered	O	-1	24881749
very	O	-1	24881749
ca@@	O	-1	24881749
ref@@	O	-1	24881749
ul@@	O	-1	24881749
ly	O	-1	24881749
in	O	-1	24881749
combination	O	-1	24881749
with	O	-1	24881749
other	O	-1	24881749
neuro@@	B-Chemical	D014150	24881749
le@@	I-Chemical	-1	24881749
p@@	I-Chemical	-1	24881749
tic	I-Chemical	-1	24881749
drugs	I-Chemical	-1	24881749
,	O	-1	24881749
partic@@	O	-1	24881749
ul@@	O	-1	24881749
arly	O	-1	24881749
in	O	-1	24881749
patients	O	-1	24881749
with	O	-1	24881749
a	O	-1	24881749
wor@@	O	-1	24881749
sen@@	O	-1	24881749
ing	O	-1	24881749
gener@@	O	-1	24881749
al	O	-1	24881749
condi@@	O	-1	24881749
tion.	O	-1	24881749

A	O	-1	24894748
me@@	B-Chemical	D008790	24894748
to@@	I-Chemical	-1	24894748
pro@@	I-Chemical	-1	24894748
lol	I-Chemical	-1	24894748
-	O	-1	24894748
ter@@	B-Chemical	C041359	24894748
bin@@	I-Chemical	-1	24894748
af@@	I-Chemical	-1	24894748
ine	I-Chemical	-1	24894748
combination	O	-1	24894748
induced	O	-1	24894748
brady@@	B-Disease	D001919	24894748
cardia	I-Disease	-1	24894748
.	O	-1	24894748
To	O	-1	24894748
report	O	-1	24894748
a	O	-1	24894748
s@@	B-Disease	D012804	24894748
in@@	I-Disease	-1	24894748
us	I-Disease	-1	24894748
brady@@	I-Disease	-1	24894748
cardia	I-Disease	-1	24894748
induced	O	-1	24894748
by	O	-1	24894748
me@@	B-Chemical	D008790	24894748
to@@	I-Chemical	-1	24894748
pro@@	I-Chemical	-1	24894748
lol	I-Chemical	-1	24894748
and	O	-1	24894748
ter@@	B-Chemical	C041359	24894748
bin@@	I-Chemical	-1	24894748
af@@	I-Chemical	-1	24894748
ine	I-Chemical	-1	24894748
drug@@	O	-1	24894748
-@@	O	-1	24894748
drug	O	-1	24894748
inter@@	O	-1	24894748
action	O	-1	24894748
and	O	-1	24894748
its	O	-1	24894748
man@@	O	-1	24894748
ag@@	O	-1	24894748
em@@	O	-1	24894748
ent@@	O	-1	24894748
.	O	-1	24894748
A	O	-1	24894748
6@@	O	-1	24894748
3	O	-1	24894748
year-old	O	-1	24894748
Ca@@	O	-1	24894748
uc@@	O	-1	24894748
a@@	O	-1	24894748
si@@	O	-1	24894748
an	O	-1	24894748
man	O	-1	24894748
on	O	-1	24894748
me@@	B-Chemical	D008790	24894748
to@@	I-Chemical	-1	24894748
pro@@	I-Chemical	-1	24894748
lol	I-Chemical	-1	24894748
2@@	O	-1	24894748
00	O	-1	24894748
mg/@@	O	-1	24894748
day	O	-1	24894748
for	O	-1	24894748
st@@	O	-1	24894748
able	O	-1	24894748
coronary	B-Disease	D003324	24894748
artery	I-Disease	-1	24894748
disease	I-Disease	-1	24894748
was	O	-1	24894748
prescri@@	O	-1	24894748
bed	O	-1	24894748
a	O	-1	24894748
9@@	O	-1	24894748
0-@@	O	-1	24894748
day	O	-1	24894748
course	O	-1	24894748
of	O	-1	24894748
oral	O	-1	24894748
ter@@	B-Chemical	C041359	24894748
bin@@	I-Chemical	-1	24894748
af@@	I-Chemical	-1	24894748
ine	I-Chemical	-1	24894748
2@@	O	-1	24894748
50	O	-1	24894748
mg/@@	O	-1	24894748
day	O	-1	24894748
for	O	-1	24894748
on@@	B-Disease	D014009	24894748
y@@	I-Disease	-1	24894748
ch@@	I-Disease	-1	24894748
om@@	I-Disease	-1	24894748
y@@	I-Disease	-1	24894748
co@@	I-Disease	-1	24894748
sis	I-Disease	-1	24894748
.	O	-1	24894748
O@@	O	-1	24894748
n	O	-1	24894748
the	O	-1	24894748
4@@	O	-1	24894748
9@@	O	-1	24894748
th	O	-1	24894748
day	O	-1	24894748
of	O	-1	24894748
ter@@	B-Chemical	C041359	24894748
bin@@	I-Chemical	-1	24894748
af@@	I-Chemical	-1	24894748
ine	I-Chemical	-1	24894748
therapy,	O	-1	24894748
he	O	-1	24894748
was	O	-1	24894748
b@@	O	-1	24894748
rou@@	O	-1	24894748
ght	O	-1	24894748
to	O	-1	24894748
the	O	-1	24894748
em@@	O	-1	24894748
er@@	O	-1	24894748
gen@@	O	-1	24894748
c@@	O	-1	24894748
y	O	-1	24894748
ro@@	O	-1	24894748
o@@	O	-1	24894748
m	O	-1	24894748
for	O	-1	24894748
a	O	-1	24894748
decrease	O	-1	24894748
of	O	-1	24894748
h@@	O	-1	24894748
is	O	-1	24894748
glo@@	O	-1	24894748
b@@	O	-1	24894748
al	O	-1	24894748
heal@@	O	-1	24894748
th	O	-1	24894748
stat@@	O	-1	24894748
us,	O	-1	24894748
conf@@	B-Disease	D003221	24894748
usion	I-Disease	-1	24894748
and	O	-1	24894748
f@@	O	-1	24894748
all@@	O	-1	24894748
s.	O	-1	24894748
The	O	-1	24894748
electro@@	O	-1	24894748
cardio@@	O	-1	24894748
gra@@	O	-1	24894748
m	O	-1	24894748
revealed	O	-1	24894748
a	O	-1	24894748
3@@	O	-1	24894748
7	O	-1	24894748
be@@	O	-1	24894748
at@@	O	-1	24894748
s/@@	O	-1	24894748
min	O	-1	24894748
s@@	B-Disease	D012804	24894748
in@@	I-Disease	-1	24894748
us	I-Disease	-1	24894748
brady@@	I-Disease	-1	24894748
cardia	I-Disease	-1	24894748
.	O	-1	24894748
A	O	-1	24894748
scor@@	O	-1	24894748
e	O	-1	24894748
of	O	-1	24894748
7	O	-1	24894748
on	O	-1	24894748
the	O	-1	24894748
N@@	O	-1	24894748
ar@@	O	-1	24894748
an@@	O	-1	24894748
j@@	O	-1	24894748
o	O	-1	24894748
adverse	B-Disease	D064420	24894748
drug	I-Disease	-1	24894748
reaction	I-Disease	-1	24894748
prob@@	O	-1	24894748
ability	O	-1	24894748
s@@	O	-1	24894748
cal@@	O	-1	24894748
e	O	-1	24894748
indic@@	O	-1	24894748
ates	O	-1	24894748
a	O	-1	24894748
prob@@	O	-1	24894748
able	O	-1	24894748
rel@@	O	-1	24894748
ationship	O	-1	24894748
between	O	-1	24894748
the	O	-1	24894748
patient@@	O	-1	24894748
's	O	-1	24894748
s@@	B-Disease	D012804	24894748
in@@	I-Disease	-1	24894748
us	I-Disease	-1	24894748
brady@@	I-Disease	-1	24894748
cardia	I-Disease	-1	24894748
and	O	-1	24894748
the	O	-1	24894748
drug	O	-1	24894748
inter@@	O	-1	24894748
action	O	-1	24894748
between	O	-1	24894748
me@@	B-Chemical	D008790	24894748
to@@	I-Chemical	-1	24894748
pro@@	I-Chemical	-1	24894748
lol	I-Chemical	-1	24894748
and	O	-1	24894748
ter@@	B-Chemical	C041359	24894748
bin@@	I-Chemical	-1	24894748
af@@	I-Chemical	-1	24894748
ine	I-Chemical	-1	24894748
.	O	-1	24894748
The	O	-1	24894748
heart	O	-1	24894748
rate	O	-1	24894748
ame@@	O	-1	24894748
li@@	O	-1	24894748
or@@	O	-1	24894748
ated	O	-1	24894748
first	O	-1	24894748
with	O	-1	24894748
a	O	-1	24894748
decrease	O	-1	24894748
in	O	-1	24894748
the	O	-1	24894748
dose	O	-1	24894748
of	O	-1	24894748
me@@	B-Chemical	D008790	24894748
to@@	I-Chemical	-1	24894748
pro@@	I-Chemical	-1	24894748
lol	I-Chemical	-1	24894748
.	O	-1	24894748
It	O	-1	24894748
was	O	-1	24894748
subsequ@@	O	-1	24894748
ently	O	-1	24894748
chang@@	O	-1	24894748
ed	O	-1	24894748
to	O	-1	24894748
b@@	B-Chemical	D017298	24894748
iso@@	I-Chemical	-1	24894748
pro@@	I-Chemical	-1	24894748
lol	I-Chemical	-1	24894748
and	O	-1	24894748
the	O	-1	24894748
heart	O	-1	24894748
rate	O	-1	24894748
remained	O	-1	24894748
normal@@	O	-1	24894748
.	O	-1	24894748
B@@	O	-1	24894748
y	O	-1	24894748
inhibit@@	O	-1	24894748
ing	O	-1	24894748
the	O	-1	24894748
cyto@@	O	-1	24894748
ch@@	O	-1	24894748
rom@@	O	-1	24894748
e	O	-1	24894748
P@@	O	-1	24894748
4@@	O	-1	24894748
50	O	-1	24894748
2@@	O	-1	24894748
D@@	O	-1	24894748
6,	O	-1	24894748
ter@@	B-Chemical	C041359	24894748
bin@@	I-Chemical	-1	24894748
af@@	I-Chemical	-1	24894748
ine	I-Chemical	-1	24894748
had	O	-1	24894748
decreased	O	-1	24894748
me@@	B-Chemical	D008790	24894748
to@@	I-Chemical	-1	24894748
pro@@	I-Chemical	-1	24894748
lol	I-Chemical	-1	24894748
's	O	-1	24894748
clear@@	O	-1	24894748
ance@@	O	-1	24894748
,	O	-1	24894748
lead@@	O	-1	24894748
ing	O	-1	24894748
in	O	-1	24894748
me@@	B-Chemical	D008790	24894748
to@@	I-Chemical	-1	24894748
pro@@	I-Chemical	-1	24894748
lol	I-Chemical	-1	24894748
accum@@	O	-1	24894748
ulation	O	-1	24894748
which	O	-1	24894748
has	O	-1	24894748
resulted	O	-1	24894748
in	O	-1	24894748
clin@@	O	-1	24894748
ically	O	-1	24894748
significant	O	-1	24894748
s@@	B-Disease	D012804	24894748
in@@	I-Disease	-1	24894748
us	I-Disease	-1	24894748
brady@@	I-Disease	-1	24894748
cardia	I-Disease	-1	24894748
.	O	-1	24894748

O@@	O	-1	24897009
pto@@	O	-1	24897009
ch@@	O	-1	24897009
i@@	O	-1	24897009
as@@	O	-1	24897009
m@@	O	-1	24897009
atic	O	-1	24897009
and	O	-1	24897009
peripheral	B-Disease	D010523	24897009
neuropathy	I-Disease	-1	24897009
due	O	-1	24897009
to	O	-1	24897009
eth@@	B-Chemical	D004977	24897009
am@@	I-Chemical	-1	24897009
bu@@	I-Chemical	-1	24897009
to@@	I-Chemical	-1	24897009
l	I-Chemical	-1	24897009
over@@	O	-1	24897009
treatment.	O	-1	24897009
E@@	B-Chemical	D004977	24897009
th@@	I-Chemical	-1	24897009
am@@	I-Chemical	-1	24897009
bu@@	I-Chemical	-1	24897009
to@@	I-Chemical	-1	24897009
l	I-Chemical	-1	24897009
is	O	-1	24897009
known	O	-1	24897009
to	O	-1	24897009
cause	O	-1	24897009
op@@	B-Disease	D009901	24897009
tic	I-Disease	-1	24897009
neuropathy	I-Disease	-1	24897009
and@@	O	-1	24897009
,	O	-1	24897009
more	O	-1	24897009
ra@@	O	-1	24897009
rel@@	O	-1	24897009
y,	O	-1	24897009
ax@@	O	-1	24897009
on@@	O	-1	24897009
al	O	-1	24897009
poly@@	B-Disease	D011115	24897009
neuropathy	I-Disease	-1	24897009
.	O	-1	24897009
We	O	-1	24897009
character@@	O	-1	24897009
iz@@	O	-1	24897009
e	O	-1	24897009
the	O	-1	24897009
clin@@	O	-1	24897009
ic@@	O	-1	24897009
al,	O	-1	24897009
neuro@@	O	-1	24897009
physi@@	O	-1	24897009
olog@@	O	-1	24897009
ic@@	O	-1	24897009
al,	O	-1	24897009
and	O	-1	24897009
neuro@@	O	-1	24897009
imaging	O	-1	24897009
findings	O	-1	24897009
in	O	-1	24897009
a	O	-1	24897009
7@@	O	-1	24897009
2-@@	O	-1	24897009
year-old	O	-1	24897009
man	O	-1	24897009
who	O	-1	24897009
developed	O	-1	24897009
visual	B-Disease	D014786	24897009
loss	I-Disease	-1	24897009
and	O	-1	24897009
pa@@	B-Disease	D010292	24897009
res@@	I-Disease	-1	24897009
the@@	I-Disease	-1	24897009
si@@	I-Disease	-1	24897009
as	I-Disease	-1	24897009
after	O	-1	24897009
11	O	-1	24897009
weeks	O	-1	24897009
of	O	-1	24897009
exposure	O	-1	24897009
to	O	-1	24897009
a	O	-1	24897009
sup@@	O	-1	24897009
ra@@	O	-1	24897009
therapeutic	O	-1	24897009
dose	O	-1	24897009
of	O	-1	24897009
eth@@	B-Chemical	D004977	24897009
am@@	I-Chemical	-1	24897009
bu@@	I-Chemical	-1	24897009
to@@	I-Chemical	-1	24897009
l	I-Chemical	-1	24897009
.	O	-1	24897009
This	O	-1	24897009
case	O	-1	24897009
demon@@	O	-1	24897009
strat@@	O	-1	24897009
es	O	-1	24897009
the	O	-1	24897009
selective	O	-1	24897009
vul@@	O	-1	24897009
ner@@	O	-1	24897009
ability	O	-1	24897009
of	O	-1	24897009
the	O	-1	24897009
an@@	O	-1	24897009
ter@@	O	-1	24897009
ior	O	-1	24897009
visual	O	-1	24897009
path@@	O	-1	24897009
w@@	O	-1	24897009
ays	O	-1	24897009
and	O	-1	24897009
peripheral	O	-1	24897009
ner@@	O	-1	24897009
v@@	O	-1	24897009
es	O	-1	24897009
to	O	-1	24897009
eth@@	B-Chemical	D004977	24897009
am@@	I-Chemical	-1	24897009
bu@@	I-Chemical	-1	24897009
to@@	I-Chemical	-1	24897009
l	I-Chemical	-1	24897009
toxicity	B-Disease	D064420	24897009
.	O	-1	24897009

T@@	B-Chemical	D013739	24902786
est@@	I-Chemical	-1	24902786
osterone	I-Chemical	-1	24902786
ame@@	O	-1	24902786
li@@	O	-1	24902786
or@@	O	-1	24902786
ates	O	-1	24902786
st@@	B-Chemical	D013311	24902786
re@@	I-Chemical	-1	24902786
pto@@	I-Chemical	-1	24902786
z@@	I-Chemical	-1	24902786
ot@@	I-Chemical	-1	24902786
oc@@	I-Chemical	-1	24902786
in	I-Chemical	-1	24902786
-induced	O	-1	24902786
memory	B-Disease	D008569	24902786
impair@@	I-Disease	-1	24902786
ment	I-Disease	-1	24902786
in	O	-1	24902786
male	O	-1	24902786
rats.	O	-1	24902786
A@@	O	-1	24902786
I@@	O	-1	24902786
M@@	O	-1	24902786
:	O	-1	24902786
To	O	-1	24902786
study	O	-1	24902786
the	O	-1	24902786
effects	O	-1	24902786
of	O	-1	24902786
test@@	B-Chemical	D013739	24902786
osterone	I-Chemical	-1	24902786
on	O	-1	24902786
st@@	B-Chemical	D013311	24902786
re@@	I-Chemical	-1	24902786
pto@@	I-Chemical	-1	24902786
z@@	I-Chemical	-1	24902786
ot@@	I-Chemical	-1	24902786
oc@@	I-Chemical	-1	24902786
in	I-Chemical	-1	24902786
(	O	-1	24902786
S@@	B-Chemical	D013311	24902786
T@@	I-Chemical	-1	24902786
Z	I-Chemical	-1	24902786
)@@	O	-1	24902786
-induced	O	-1	24902786
memory	B-Disease	D008569	24902786
impair@@	I-Disease	-1	24902786
ment	I-Disease	-1	24902786
in	O	-1	24902786
male	O	-1	24902786
rats.	O	-1	24902786
METHODS:	O	-1	24902786
Ad@@	O	-1	24902786
ult	O	-1	24902786
male	O	-1	24902786
Wistar	O	-1	24902786
rats	O	-1	24902786
were	O	-1	24902786
intrac@@	O	-1	24902786
e@@	O	-1	24902786
reb@@	O	-1	24902786
ro@@	O	-1	24902786
ventric@@	O	-1	24902786
ul@@	O	-1	24902786
arly	O	-1	24902786
(@@	O	-1	24902786
ic@@	O	-1	24902786
v@@	O	-1	24902786
)	O	-1	24902786
inf@@	O	-1	24902786
used	O	-1	24902786
with	O	-1	24902786
S@@	B-Chemical	D013311	24902786
T@@	I-Chemical	-1	24902786
Z	I-Chemical	-1	24902786
(@@	O	-1	24902786
7@@	O	-1	24902786
50	O	-1	24902786
u@@	O	-1	24902786
g@@	O	-1	24902786
)	O	-1	24902786
on	O	-1	24902786
d	O	-1	24902786
1	O	-1	24902786
and	O	-1	24902786
d	O	-1	24902786
3,	O	-1	24902786
and	O	-1	24902786
a	O	-1	24902786
p@@	O	-1	24902786
as@@	O	-1	24902786
sive	O	-1	24902786
avoid@@	O	-1	24902786
ance	O	-1	24902786
t@@	O	-1	24902786
as@@	O	-1	24902786
k	O	-1	24902786
was	O	-1	24902786
assessed	O	-1	24902786
2	O	-1	24902786
weeks	O	-1	24902786
after	O	-1	24902786
the	O	-1	24902786
first	O	-1	24902786
injection	O	-1	24902786
of	O	-1	24902786
S@@	B-Chemical	D013311	24902786
T@@	I-Chemical	-1	24902786
Z	I-Chemical	-1	24902786
.	O	-1	24902786
C@@	O	-1	24902786
ast@@	O	-1	24902786
ration	O	-1	24902786
surger@@	O	-1	24902786
y	O	-1	24902786
was	O	-1	24902786
performed	O	-1	24902786
in	O	-1	24902786
an@@	O	-1	24902786
other	O	-1	24902786
group	O	-1	24902786
of	O	-1	24902786
rats,	O	-1	24902786
and	O	-1	24902786
the	O	-1	24902786
p@@	O	-1	24902786
as@@	O	-1	24902786
sive	O	-1	24902786
avoid@@	O	-1	24902786
ance	O	-1	24902786
t@@	O	-1	24902786
as@@	O	-1	24902786
k	O	-1	24902786
was	O	-1	24902786
assessed	O	-1	24902786
4	O	-1	24902786
weeks	O	-1	24902786
after	O	-1	24902786
the	O	-1	24902786
o@@	O	-1	24902786
per@@	O	-1	24902786
ation.	O	-1	24902786
T@@	B-Chemical	D013739	24902786
est@@	I-Chemical	-1	24902786
osterone	I-Chemical	-1	24902786
(@@	O	-1	24902786
1	O	-1	24902786
mg@@	O	-1	24902786
.@@	O	-1	24902786
kg@@	O	-1	24902786
(@@	O	-1	24902786
-1@@	O	-1	24902786
)@@	O	-1	24902786
.@@	O	-1	24902786
d@@	O	-1	24902786
(@@	O	-1	24902786
-1@@	O	-1	24902786
),	O	-1	24902786
s@@	O	-1	24902786
c@@	O	-1	24902786
),	O	-1	24902786
the	O	-1	24902786
and@@	B-Chemical	D000728	24902786
ro@@	I-Chemical	-1	24902786
gen	I-Chemical	-1	24902786
receptor	O	-1	24902786
antagonist	O	-1	24902786
f@@	B-Chemical	D005485	24902786
l@@	I-Chemical	-1	24902786
ut@@	I-Chemical	-1	24902786
amide	I-Chemical	-1	24902786
(10	O	-1	24902786
mg@@	O	-1	24902786
.@@	O	-1	24902786
kg@@	O	-1	24902786
(@@	O	-1	24902786
-1@@	O	-1	24902786
)@@	O	-1	24902786
.@@	O	-1	24902786
d@@	O	-1	24902786
(@@	O	-1	24902786
-1@@	O	-1	24902786
),	O	-1	24902786
ip@@	O	-1	24902786
),	O	-1	24902786
the	O	-1	24902786
est@@	B-Chemical	D004967	24902786
ro@@	I-Chemical	-1	24902786
gen	I-Chemical	-1	24902786
receptor	O	-1	24902786
antagonist	O	-1	24902786
t@@	B-Chemical	D013629	24902786
am@@	I-Chemical	-1	24902786
oxif@@	I-Chemical	-1	24902786
en	I-Chemical	-1	24902786
(@@	O	-1	24902786
1	O	-1	24902786
mg@@	O	-1	24902786
.@@	O	-1	24902786
kg@@	O	-1	24902786
(@@	O	-1	24902786
-1@@	O	-1	24902786
)@@	O	-1	24902786
.@@	O	-1	24902786
d@@	O	-1	24902786
(@@	O	-1	24902786
-1@@	O	-1	24902786
),	O	-1	24902786
ip@@	O	-1	24902786
)	O	-1	24902786
or	O	-1	24902786
the	O	-1	24902786
a@@	O	-1	24902786
rom@@	O	-1	24902786
at@@	O	-1	24902786
ase	O	-1	24902786
inhibitor	O	-1	24902786
le@@	B-Chemical	C067431	24902786
tro@@	I-Chemical	-1	24902786
z@@	I-Chemical	-1	24902786
ole	I-Chemical	-1	24902786
(@@	O	-1	24902786
4	O	-1	24902786
mg@@	O	-1	24902786
.@@	O	-1	24902786
kg@@	O	-1	24902786
(@@	O	-1	24902786
-1@@	O	-1	24902786
)@@	O	-1	24902786
.@@	O	-1	24902786
d@@	O	-1	24902786
(@@	O	-1	24902786
-1@@	O	-1	24902786
),	O	-1	24902786
ip@@	O	-1	24902786
)	O	-1	24902786
were	O	-1	24902786
administered	O	-1	24902786
for	O	-1	24902786
6	O	-1	24902786
d	O	-1	24902786
after	O	-1	24902786
the	O	-1	24902786
first	O	-1	24902786
injection	O	-1	24902786
of	O	-1	24902786
S@@	B-Chemical	D013311	24902786
T@@	I-Chemical	-1	24902786
Z	I-Chemical	-1	24902786
.	O	-1	24902786
RESULTS:	O	-1	24902786
S@@	B-Chemical	D013311	24902786
T@@	I-Chemical	-1	24902786
Z	I-Chemical	-1	24902786
administration	O	-1	24902786
and	O	-1	24902786
ca@@	O	-1	24902786
st@@	O	-1	24902786
ration	O	-1	24902786
mark@@	O	-1	24902786
ed@@	O	-1	24902786
ly	O	-1	24902786
decreased	O	-1	24902786
both	O	-1	24902786
S@@	O	-1	24902786
T@@	O	-1	24902786
L@@	O	-1	24902786
1	O	-1	24902786
(@@	O	-1	24902786
the	O	-1	24902786
sh@@	O	-1	24902786
ort	O	-1	24902786
memor@@	O	-1	24902786
y@@	O	-1	24902786
)	O	-1	24902786
and	O	-1	24902786
S@@	O	-1	24902786
T@@	O	-1	24902786
L@@	O	-1	24902786
2	O	-1	24902786
(@@	O	-1	24902786
the	O	-1	24902786
lon@@	O	-1	24902786
g	O	-1	24902786
memor@@	O	-1	24902786
y@@	O	-1	24902786
)	O	-1	24902786
in	O	-1	24902786
p@@	O	-1	24902786
as@@	O	-1	24902786
sive	O	-1	24902786
avoid@@	O	-1	24902786
ance	O	-1	24902786
test@@	O	-1	24902786
s.	O	-1	24902786
T@@	B-Chemical	D013739	24902786
est@@	I-Chemical	-1	24902786
osterone	I-Chemical	-1	24902786
re@@	O	-1	24902786
pl@@	O	-1	24902786
ac@@	O	-1	24902786
ement	O	-1	24902786
al@@	O	-1	24902786
most	O	-1	24902786
re@@	O	-1	24902786
sto@@	O	-1	24902786
red	O	-1	24902786
the	O	-1	24902786
S@@	O	-1	24902786
T@@	O	-1	24902786
L@@	O	-1	24902786
1	O	-1	24902786
and	O	-1	24902786
S@@	O	-1	24902786
T@@	O	-1	24902786
L@@	O	-1	24902786
2	O	-1	24902786
in	O	-1	24902786
ca@@	O	-1	24902786
strated	O	-1	24902786
rats,	O	-1	24902786
and	O	-1	24902786
significantly	O	-1	24902786
prolonged	O	-1	24902786
the	O	-1	24902786
S@@	O	-1	24902786
T@@	O	-1	24902786
L@@	O	-1	24902786
1	O	-1	24902786
and	O	-1	24902786
S@@	O	-1	24902786
T@@	O	-1	24902786
L@@	O	-1	24902786
2	O	-1	24902786
in	O	-1	24902786
S@@	B-Chemical	D013311	24902786
T@@	I-Chemical	-1	24902786
Z	I-Chemical	-1	24902786
-treated	O	-1	24902786
rats.	O	-1	24902786
Ad@@	O	-1	24902786
minist@@	O	-1	24902786
ration	O	-1	24902786
of	O	-1	24902786
f@@	B-Chemical	D005485	24902786
l@@	I-Chemical	-1	24902786
ut@@	I-Chemical	-1	24902786
amide	I-Chemical	-1	24902786
,	O	-1	24902786
le@@	B-Chemical	C067431	24902786
tro@@	I-Chemical	-1	24902786
z@@	I-Chemical	-1	24902786
ole	I-Chemical	-1	24902786
or	O	-1	24902786
t@@	B-Chemical	D013629	24902786
am@@	I-Chemical	-1	24902786
oxif@@	I-Chemical	-1	24902786
en	I-Chemical	-1	24902786
significantly	O	-1	24902786
impaired	B-Disease	D008569	24902786
the	I-Disease	-1	24902786
memory	I-Disease	-1	24902786
in	O	-1	24902786
int@@	O	-1	24902786
ac@@	O	-1	24902786
t	O	-1	24902786
rats,	O	-1	24902786
and	O	-1	24902786
significantly	O	-1	24902786
attenu@@	O	-1	24902786
ated	O	-1	24902786
the	O	-1	24902786
test@@	B-Chemical	D013739	24902786
osterone	I-Chemical	-1	24902786
re@@	O	-1	24902786
pl@@	O	-1	24902786
ac@@	O	-1	24902786
ement	O	-1	24902786
in	O	-1	24902786
impro@@	O	-1	24902786
ving	O	-1	24902786
S@@	B-Chemical	D013311	24902786
T@@	I-Chemical	-1	24902786
Z	I-Chemical	-1	24902786
-	O	-1	24902786
and	O	-1	24902786
ca@@	O	-1	24902786
str@@	O	-1	24902786
ation@@	O	-1	24902786
-induced	O	-1	24902786
memory	B-Disease	D008569	24902786
impair@@	I-Disease	-1	24902786
ment	I-Disease	-1	24902786
.	O	-1	24902786
CONCLUSION:	O	-1	24902786
T@@	B-Chemical	D013739	24902786
est@@	I-Chemical	-1	24902786
osterone	I-Chemical	-1	24902786
administration	O	-1	24902786
ame@@	O	-1	24902786
li@@	O	-1	24902786
or@@	O	-1	24902786
ates	O	-1	24902786
S@@	B-Chemical	D013311	24902786
T@@	I-Chemical	-1	24902786
Z	I-Chemical	-1	24902786
-	O	-1	24902786
and	O	-1	24902786
ca@@	O	-1	24902786
str@@	O	-1	24902786
ation@@	O	-1	24902786
-induced	O	-1	24902786
memory	B-Disease	D008569	24902786
impair@@	I-Disease	-1	24902786
ment	I-Disease	-1	24902786
in	O	-1	24902786
male	O	-1	24902786
Wistar	O	-1	24902786
rats.	O	-1	24902786

B@@	O	-1	24911645
e@@	O	-1	24911645
havi@@	O	-1	24911645
oral	O	-1	24911645
and	O	-1	24911645
neuro@@	O	-1	24911645
chemical	O	-1	24911645
studies	O	-1	24911645
in	O	-1	24911645
mice	O	-1	24911645
pre@@	O	-1	24911645
treated	O	-1	24911645
with	O	-1	24911645
g@@	B-Chemical	C573355	24911645
arc@@	I-Chemical	-1	24911645
in@@	I-Chemical	-1	24911645
i@@	I-Chemical	-1	24911645
el@@	I-Chemical	-1	24911645
li@@	I-Chemical	-1	24911645
pt@@	I-Chemical	-1	24911645
one	I-Chemical	-1	24911645
F@@	I-Chemical	-1	24911645
C	I-Chemical	-1	24911645
in	O	-1	24911645
pilocar@@	B-Chemical	D010862	24911645
pine	I-Chemical	-1	24911645
-induced	O	-1	24911645
seizures	B-Disease	D012640	24911645
.	O	-1	24911645
G@@	B-Chemical	C573355	24911645
arc@@	I-Chemical	-1	24911645
in@@	I-Chemical	-1	24911645
i@@	I-Chemical	-1	24911645
el@@	I-Chemical	-1	24911645
li@@	I-Chemical	-1	24911645
pt@@	I-Chemical	-1	24911645
one	I-Chemical	-1	24911645
F@@	I-Chemical	-1	24911645
C	I-Chemical	-1	24911645
(	O	-1	24911645
GF@@	B-Chemical	C573355	24911645
C	I-Chemical	-1	24911645
)	O	-1	24911645
isol@@	O	-1	24911645
ated	O	-1	24911645
from	O	-1	24911645
he@@	O	-1	24911645
x@@	O	-1	24911645
anic	O	-1	24911645
frac@@	O	-1	24911645
tion	O	-1	24911645
se@@	O	-1	24911645
ed	O	-1	24911645
extrac@@	O	-1	24911645
t	O	-1	24911645
of	O	-1	24911645
spec@@	O	-1	24911645
i@@	O	-1	24911645
es	O	-1	24911645
P@@	O	-1	24911645
lat@@	O	-1	24911645
on@@	O	-1	24911645
ia	O	-1	24911645
in@@	O	-1	24911645
sign@@	O	-1	24911645
is	O	-1	24911645
M@@	O	-1	24911645
ar@@	O	-1	24911645
t.	O	-1	24911645
It	O	-1	24911645
is	O	-1	24911645
wi@@	O	-1	24911645
de@@	O	-1	24911645
ly	O	-1	24911645
used	O	-1	24911645
in	O	-1	24911645
fol@@	O	-1	24911645
k	O	-1	24911645
medic@@	O	-1	24911645
ine	O	-1	24911645
to	O	-1	24911645
tre@@	O	-1	24911645
at	O	-1	24911645
s@@	B-Disease	D012871	24911645
k@@	I-Disease	-1	24911645
in	I-Disease	-1	24911645
diseas@@	I-Disease	-1	24911645
es	I-Disease	-1	24911645
in	O	-1	24911645
both	O	-1	24911645
hum@@	O	-1	24911645
ans	O	-1	24911645
and	O	-1	24911645
animals	O	-1	24911645
as	O	-1	24911645
well	O	-1	24911645
as	O	-1	24911645
the	O	-1	24911645
se@@	O	-1	24911645
ed	O	-1	24911645
dec@@	O	-1	24911645
oc@@	O	-1	24911645
tion	O	-1	24911645
has	O	-1	24911645
been	O	-1	24911645
used	O	-1	24911645
to	O	-1	24911645
tre@@	O	-1	24911645
at	O	-1	24911645
di@@	B-Disease	D003967	24911645
ar@@	I-Disease	-1	24911645
r@@	I-Disease	-1	24911645
he@@	I-Disease	-1	24911645
as	I-Disease	-1	24911645
and	O	-1	24911645
inflam@@	B-Disease	D007249	24911645
mat@@	I-Disease	-1	24911645
ory	I-Disease	-1	24911645
diseas@@	I-Disease	-1	24911645
es	I-Disease	-1	24911645
.	O	-1	24911645
However,	O	-1	24911645
there	O	-1	24911645
is	O	-1	24911645
no	O	-1	24911645
re@@	O	-1	24911645
se@@	O	-1	24911645
arc@@	O	-1	24911645
h	O	-1	24911645
on	O	-1	24911645
GF@@	B-Chemical	C573355	24911645
C	I-Chemical	-1	24911645
effects	O	-1	24911645
in	O	-1	24911645
the	O	-1	24911645
central	O	-1	24911645
ner@@	O	-1	24911645
v@@	O	-1	24911645
ous	O	-1	24911645
system	O	-1	24911645
of	O	-1	24911645
ro@@	O	-1	24911645
d@@	O	-1	24911645
ent@@	O	-1	24911645
s.	O	-1	24911645
The	O	-1	24911645
present	O	-1	24911645
study	O	-1	24911645
a@@	O	-1	24911645
im@@	O	-1	24911645
ed	O	-1	24911645
to	O	-1	24911645
evalu@@	O	-1	24911645
ate	O	-1	24911645
the	O	-1	24911645
GF@@	B-Chemical	C573355	24911645
C	I-Chemical	-1	24911645
effects	O	-1	24911645
at	O	-1	24911645
doses	O	-1	24911645
of	O	-1	24911645
2@@	O	-1	24911645
5,	O	-1	24911645
50	O	-1	24911645
or	O	-1	24911645
7@@	O	-1	24911645
5	O	-1	24911645
mg/kg	O	-1	24911645
on	O	-1	24911645
seizure	B-Disease	D012640	24911645
par@@	O	-1	24911645
ame@@	O	-1	24911645
ters	O	-1	24911645
to	O	-1	24911645
determine	O	-1	24911645
their	O	-1	24911645
anti@@	O	-1	24911645
convul@@	O	-1	24911645
s@@	O	-1	24911645
ant	O	-1	24911645
activity	O	-1	24911645
and	O	-1	24911645
its	O	-1	24911645
effects	O	-1	24911645
on	O	-1	24911645
amin@@	B-Chemical	D000596	24911645
o	I-Chemical	-1	24911645
acid	I-Chemical	-1	24911645
(	O	-1	24911645
r@@	B-Chemical	D005680	24911645
-@@	I-Chemical	-1	24911645
amin@@	I-Chemical	-1	24911645
ob@@	I-Chemical	-1	24911645
ut@@	I-Chemical	-1	24911645
y@@	I-Chemical	-1	24911645
ric	I-Chemical	-1	24911645
acid	I-Chemical	-1	24911645
(	O	-1	24911645
G@@	B-Chemical	D005680	24911645
A@@	I-Chemical	-1	24911645
B@@	I-Chemical	-1	24911645
A	I-Chemical	-1	24911645
),	O	-1	24911645
glut@@	B-Chemical	D018698	24911645
amine	I-Chemical	-1	24911645
,	O	-1	24911645
as@@	B-Chemical	D001224	24911645
part@@	I-Chemical	-1	24911645
ate	I-Chemical	-1	24911645
and	O	-1	24911645
glut@@	B-Chemical	D005978	24911645
athi@@	I-Chemical	-1	24911645
one	I-Chemical	-1	24911645
)	O	-1	24911645
levels	O	-1	24911645
as	O	-1	24911645
well	O	-1	24911645
as	O	-1	24911645
on	O	-1	24911645
acet@@	O	-1	24911645
ylchol@@	O	-1	24911645
ine@@	O	-1	24911645
ster@@	O	-1	24911645
ase	O	-1	24911645
(@@	O	-1	24911645
AC@@	O	-1	24911645
h@@	O	-1	24911645
E@@	O	-1	24911645
)	O	-1	24911645
activity	O	-1	24911645
in	O	-1	24911645
mice	O	-1	24911645
hippocamp@@	O	-1	24911645
us	O	-1	24911645
after	O	-1	24911645
seizures	B-Disease	D012640	24911645
.	O	-1	24911645
GF@@	B-Chemical	C573355	24911645
C	I-Chemical	-1	24911645
produced	O	-1	24911645
an	O	-1	24911645
increased	O	-1	24911645
lat@@	O	-1	24911645
ency	O	-1	24911645
to	O	-1	24911645
first	O	-1	24911645
seizure	B-Disease	D012640	24911645
,	O	-1	24911645
at	O	-1	24911645
doses	O	-1	24911645
25@@	O	-1	24911645
mg/kg	O	-1	24911645
(2@@	O	-1	24911645
0.@@	O	-1	24911645
12	O	-1	24911645
+	O	-1	24911645
2.@@	O	-1	24911645
20	O	-1	24911645
min@@	O	-1	24911645
),	O	-1	24911645
50@@	O	-1	24911645
mg/kg	O	-1	24911645
(2@@	O	-1	24911645
0.@@	O	-1	24911645
9@@	O	-1	24911645
5	O	-1	24911645
+	O	-1	24911645
2.@@	O	-1	24911645
21	O	-1	24911645
min@@	O	-1	24911645
)	O	-1	24911645
or	O	-1	24911645
7@@	O	-1	24911645
5	O	-1	24911645
mg/kg	O	-1	24911645
(2@@	O	-1	24911645
3.@@	O	-1	24911645
4@@	O	-1	24911645
3	O	-1	24911645
+	O	-1	24911645
1.@@	O	-1	24911645
9@@	O	-1	24911645
9	O	-1	24911645
min@@	O	-1	24911645
)	O	-1	24911645
when	O	-1	24911645
compared	O	-1	24911645
with	O	-1	24911645
seiz@@	O	-1	24911645
ed	O	-1	24911645
mice.	O	-1	24911645
In	O	-1	24911645
addi@@	O	-1	24911645
tion,	O	-1	24911645
G@@	B-Chemical	D005680	24911645
A@@	I-Chemical	-1	24911645
B@@	I-Chemical	-1	24911645
A	I-Chemical	-1	24911645
cont@@	O	-1	24911645
ent	O	-1	24911645
of	O	-1	24911645
mice	O	-1	24911645
hippocamp@@	O	-1	24911645
us	O	-1	24911645
treated	O	-1	24911645
with	O	-1	24911645
GF@@	O	-1	24911645
C@@	O	-1	24911645
7@@	O	-1	24911645
5	O	-1	24911645
plus	O	-1	24911645
P@@	O	-1	24911645
4@@	O	-1	24911645
00	O	-1	24911645
showed	O	-1	24911645
an	O	-1	24911645
increase	O	-1	24911645
of	O	-1	24911645
4@@	O	-1	24911645
6.@@	O	-1	24911645
9@@	O	-1	24911645
0%	O	-1	24911645
when	O	-1	24911645
compared	O	-1	24911645
with	O	-1	24911645
seiz@@	O	-1	24911645
ed	O	-1	24911645
mice.	O	-1	24911645
In	O	-1	24911645
as@@	B-Chemical	D001224	24911645
part@@	I-Chemical	-1	24911645
ate	I-Chemical	-1	24911645
,	O	-1	24911645
glut@@	B-Chemical	D018698	24911645
amine	I-Chemical	-1	24911645
and	O	-1	24911645
glutamate	B-Chemical	D018698	24911645
levels	O	-1	24911645
det@@	O	-1	24911645
ected	O	-1	24911645
a	O	-1	24911645
decrease	O	-1	24911645
of	O	-1	24911645
5.@@	O	-1	24911645
2@@	O	-1	24911645
1@@	O	-1	24911645
%,	O	-1	24911645
1@@	O	-1	24911645
3.@@	O	-1	24911645
5@@	O	-1	24911645
5%	O	-1	24911645
and	O	-1	24911645
2@@	O	-1	24911645
1.@@	O	-1	24911645
80@@	O	-1	24911645
%,	O	-1	24911645
respecti@@	O	-1	24911645
vely	O	-1	24911645
in	O	-1	24911645
mice	O	-1	24911645
hippocamp@@	O	-1	24911645
us	O	-1	24911645
treated	O	-1	24911645
with	O	-1	24911645
GF@@	O	-1	24911645
C@@	O	-1	24911645
7@@	O	-1	24911645
5	O	-1	24911645
plus	O	-1	24911645
P@@	O	-1	24911645
4@@	O	-1	24911645
00	O	-1	24911645
when	O	-1	24911645
compared	O	-1	24911645
with	O	-1	24911645
seiz@@	O	-1	24911645
ed	O	-1	24911645
mice.	O	-1	24911645
H@@	O	-1	24911645
ip@@	O	-1	24911645
p@@	O	-1	24911645
ocamp@@	O	-1	24911645
us	O	-1	24911645
mice	O	-1	24911645
treated	O	-1	24911645
with	O	-1	24911645
GF@@	O	-1	24911645
C@@	O	-1	24911645
7@@	O	-1	24911645
5	O	-1	24911645
plus	O	-1	24911645
P@@	O	-1	24911645
4@@	O	-1	24911645
00	O	-1	24911645
showed	O	-1	24911645
an	O	-1	24911645
increase	O	-1	24911645
in	O	-1	24911645
AC@@	O	-1	24911645
h@@	O	-1	24911645
E	O	-1	24911645
activity	O	-1	24911645
(6@@	O	-1	24911645
3.@@	O	-1	24911645
3@@	O	-1	24911645
0@@	O	-1	24911645
%)	O	-1	24911645
when	O	-1	24911645
compared	O	-1	24911645
with	O	-1	24911645
seiz@@	O	-1	24911645
ed	O	-1	24911645
mice.	O	-1	24911645
The	O	-1	24911645
results	O	-1	24911645
indicate	O	-1	24911645
that	O	-1	24911645
GF@@	B-Chemical	C573355	24911645
C	I-Chemical	-1	24911645
can	O	-1	24911645
ex@@	O	-1	24911645
er@@	O	-1	24911645
t	O	-1	24911645
anti@@	O	-1	24911645
convul@@	O	-1	24911645
s@@	O	-1	24911645
ant	O	-1	24911645
activity	O	-1	24911645
and	O	-1	24911645
re@@	O	-1	24911645
duce	O	-1	24911645
the	O	-1	24911645
frequency	O	-1	24911645
of	O	-1	24911645
in@@	O	-1	24911645
st@@	O	-1	24911645
all@@	O	-1	24911645
ation	O	-1	24911645
of	O	-1	24911645
pilocar@@	B-Chemical	D010862	24911645
pine	I-Chemical	-1	24911645
-induced	O	-1	24911645
status	B-Disease	D013226	24911645
epilep@@	I-Disease	-1	24911645
tic@@	I-Disease	-1	24911645
us	I-Disease	-1	24911645
,	O	-1	24911645
as	O	-1	24911645
demonstrated	O	-1	24911645
by	O	-1	24911645
increase	O	-1	24911645
in	O	-1	24911645
lat@@	O	-1	24911645
ency	O	-1	24911645
to	O	-1	24911645
first	O	-1	24911645
seizure	B-Disease	D012640	24911645
and	O	-1	24911645
decrease	O	-1	24911645
in	O	-1	24911645
mor@@	O	-1	24911645
t@@	O	-1	24911645
ality	O	-1	24911645
rate	O	-1	24911645
of	O	-1	24911645
anim@@	O	-1	24911645
al@@	O	-1	24911645
s.	O	-1	24911645
In	O	-1	24911645
concl@@	O	-1	24911645
u@@	O	-1	24911645
sion,	O	-1	24911645
our	O	-1	24911645
data	O	-1	24911645
suggest	O	-1	24911645
that	O	-1	24911645
GF@@	B-Chemical	C573355	24911645
C	I-Chemical	-1	24911645
may	O	-1	24911645
influence	O	-1	24911645
in	O	-1	24911645
epile@@	O	-1	24911645
pto@@	O	-1	24911645
genesis	O	-1	24911645
and	O	-1	24911645
pro@@	O	-1	24911645
m@@	O	-1	24911645
ot@@	O	-1	24911645
e	O	-1	24911645
anti@@	O	-1	24911645
convul@@	O	-1	24911645
s@@	O	-1	24911645
ant	O	-1	24911645
ac@@	O	-1	24911645
tions	O	-1	24911645
in	O	-1	24911645
pilocar@@	B-Chemical	D010862	24911645
pine	I-Chemical	-1	24911645
model	O	-1	24911645
by	O	-1	24911645
mod@@	O	-1	24911645
ul@@	O	-1	24911645
ating	O	-1	24911645
the	O	-1	24911645
G@@	B-Chemical	D005680	24911645
A@@	I-Chemical	-1	24911645
B@@	I-Chemical	-1	24911645
A	I-Chemical	-1	24911645
and	O	-1	24911645
glutamate	B-Chemical	D018698	24911645
cont@@	O	-1	24911645
ents	O	-1	24911645
and	O	-1	24911645
of	O	-1	24911645
AC@@	O	-1	24911645
h@@	O	-1	24911645
E	O	-1	24911645
activity	O	-1	24911645
in	O	-1	24911645
seiz@@	O	-1	24911645
ed	O	-1	24911645
mice	O	-1	24911645
hippocamp@@	O	-1	24911645
us.	O	-1	24911645
This	O	-1	24911645
comp@@	O	-1	24911645
ound	O	-1	24911645
may	O	-1	24911645
be	O	-1	24911645
use@@	O	-1	24911645
ful	O	-1	24911645
to	O	-1	24911645
produce	O	-1	24911645
neuron@@	O	-1	24911645
al	O	-1	24911645
prot@@	O	-1	24911645
ection	O	-1	24911645
and	O	-1	24911645
it	O	-1	24911645
can	O	-1	24911645
be	O	-1	24911645
considered	O	-1	24911645
as	O	-1	24911645
an	O	-1	24911645
anti@@	O	-1	24911645
convul@@	O	-1	24911645
s@@	O	-1	24911645
ant	O	-1	24911645
agent@@	O	-1	24911645
.	O	-1	24911645

S@@	O	-1	24923469
t@@	O	-1	24923469
and@@	O	-1	24923469
ard	O	-1	24923469
o@@	O	-1	24923469
per@@	O	-1	24923469
ating	O	-1	24923469
proce@@	O	-1	24923469
d@@	O	-1	24923469
ures	O	-1	24923469
for	O	-1	24923469
anti@@	O	-1	24923469
bio@@	O	-1	24923469
tic	O	-1	24923469
therapy	O	-1	24923469
and	O	-1	24923469
the	O	-1	24923469
occur@@	O	-1	24923469
rence	O	-1	24923469
of	O	-1	24923469
acute	B-Disease	D058186	24923469
kidney	I-Disease	-1	24923469
injury	I-Disease	-1	24923469
:	O	-1	24923469
a	O	-1	24923469
pro@@	O	-1	24923469
sp@@	O	-1	24923469
ecti@@	O	-1	24923469
ve,	O	-1	24923469
clin@@	O	-1	24923469
ic@@	O	-1	24923469
al,	O	-1	24923469
non-@@	O	-1	24923469
inter@@	O	-1	24923469
ven@@	O	-1	24923469
tion@@	O	-1	24923469
al,	O	-1	24923469
observ@@	O	-1	24923469
ation@@	O	-1	24923469
al	O	-1	24923469
study.	O	-1	24923469
IN@@	O	-1	24923469
T@@	O	-1	24923469
RO@@	O	-1	24923469
D@@	O	-1	24923469
U@@	O	-1	24923469
C@@	O	-1	24923469
T@@	O	-1	24923469
ION@@	O	-1	24923469
:	O	-1	24923469
Ac@@	B-Disease	D058186	24923469
ute	I-Disease	-1	24923469
kidney	I-Disease	-1	24923469
injury	I-Disease	-1	24923469
(	O	-1	24923469
A@@	B-Disease	D058186	24923469
K@@	I-Disease	-1	24923469
I	I-Disease	-1	24923469
)	O	-1	24923469
occur@@	O	-1	24923469
s	O	-1	24923469
in	O	-1	24923469
7@@	O	-1	24923469
%	O	-1	24923469
of	O	-1	24923469
hospit@@	O	-1	24923469
al@@	O	-1	24923469
ized	O	-1	24923469
and	O	-1	24923469
6@@	O	-1	24923469
6%	O	-1	24923469
of	O	-1	24923469
In@@	O	-1	24923469
ten@@	O	-1	24923469
sive	O	-1	24923469
C@@	O	-1	24923469
are	O	-1	24923469
U@@	O	-1	24923469
n@@	O	-1	24923469
it	O	-1	24923469
(@@	O	-1	24923469
IC@@	O	-1	24923469
U@@	O	-1	24923469
)	O	-1	24923469
patients.	O	-1	24923469
It	O	-1	24923469
increases	O	-1	24923469
mor@@	O	-1	24923469
t@@	O	-1	24923469
al@@	O	-1	24923469
ity,	O	-1	24923469
hospit@@	O	-1	24923469
al	O	-1	24923469
l@@	O	-1	24923469
en@@	O	-1	24923469
g@@	O	-1	24923469
th	O	-1	24923469
of	O	-1	24923469
st@@	O	-1	24923469
a@@	O	-1	24923469
y,	O	-1	24923469
and	O	-1	24923469
co@@	O	-1	24923469
st@@	O	-1	24923469
s.	O	-1	24923469
The	O	-1	24923469
a@@	O	-1	24923469
im	O	-1	24923469
of	O	-1	24923469
this	O	-1	24923469
study	O	-1	24923469
was	O	-1	24923469
to	O	-1	24923469
investig@@	O	-1	24923469
ate,	O	-1	24923469
whether	O	-1	24923469
there	O	-1	24923469
is	O	-1	24923469
an	O	-1	24923469
association	O	-1	24923469
between	O	-1	24923469
ad@@	O	-1	24923469
he@@	O	-1	24923469
rence	O	-1	24923469
to	O	-1	24923469
gu@@	O	-1	24923469
ide@@	O	-1	24923469
lin@@	O	-1	24923469
es	O	-1	24923469
(@@	O	-1	24923469
standard	O	-1	24923469
o@@	O	-1	24923469
per@@	O	-1	24923469
ating	O	-1	24923469
proce@@	O	-1	24923469
d@@	O	-1	24923469
ures	O	-1	24923469
(S@@	O	-1	24923469
O@@	O	-1	24923469
P@@	O	-1	24923469
)@@	O	-1	24923469
)	O	-1	24923469
for	O	-1	24923469
potenti@@	O	-1	24923469
ally	O	-1	24923469
nephro@@	B-Disease	D007674	24923469
toxic	I-Disease	-1	24923469
anti@@	O	-1	24923469
bio@@	O	-1	24923469
tics	O	-1	24923469
and	O	-1	24923469
the	O	-1	24923469
occur@@	O	-1	24923469
rence	O	-1	24923469
of	O	-1	24923469
A@@	B-Disease	D058186	24923469
K@@	I-Disease	-1	24923469
I	I-Disease	-1	24923469
.	O	-1	24923469
METHODS:	O	-1	24923469
This	O	-1	24923469
study	O	-1	24923469
was	O	-1	24923469
car@@	O	-1	24923469
ri@@	O	-1	24923469
ed	O	-1	24923469
out	O	-1	24923469
as	O	-1	24923469
a	O	-1	24923469
pro@@	O	-1	24923469
sp@@	O	-1	24923469
ecti@@	O	-1	24923469
ve,	O	-1	24923469
clin@@	O	-1	24923469
ic@@	O	-1	24923469
al,	O	-1	24923469
non-@@	O	-1	24923469
inter@@	O	-1	24923469
ven@@	O	-1	24923469
tion@@	O	-1	24923469
al,	O	-1	24923469
observ@@	O	-1	24923469
ation@@	O	-1	24923469
al	O	-1	24923469
study.	O	-1	24923469
D@@	O	-1	24923469
at@@	O	-1	24923469
a	O	-1	24923469
coll@@	O	-1	24923469
ection	O	-1	24923469
was	O	-1	24923469
performed	O	-1	24923469
over	O	-1	24923469
a	O	-1	24923469
total	O	-1	24923469
of	O	-1	24923469
17@@	O	-1	24923469
0	O	-1	24923469
days	O	-1	24923469
in	O	-1	24923469
three	O	-1	24923469
IC@@	O	-1	24923469
U@@	O	-1	24923469
s	O	-1	24923469
at	O	-1	24923469
Ch@@	O	-1	24923469
ar@@	O	-1	24923469
ite	O	-1	24923469
-	O	-1	24923469
U@@	O	-1	24923469
n@@	O	-1	24923469
i@@	O	-1	24923469
ver@@	O	-1	24923469
sit@@	O	-1	24923469
a@@	O	-1	24923469
et@@	O	-1	24923469
s@@	O	-1	24923469
medi@@	O	-1	24923469
z@@	O	-1	24923469
in	O	-1	24923469
B@@	O	-1	24923469
er@@	O	-1	24923469
l@@	O	-1	24923469
in.	O	-1	24923469
A	O	-1	24923469
total	O	-1	24923469
of	O	-1	24923469
6@@	O	-1	24923469
7@@	O	-1	24923469
5	O	-1	24923469
patients	O	-1	24923469
were	O	-1	24923469
inc@@	O	-1	24923469
lu@@	O	-1	24923469
de@@	O	-1	24923469
d@@	O	-1	24923469
;	O	-1	24923469
1@@	O	-1	24923469
6@@	O	-1	24923469
3	O	-1	24923469
of	O	-1	24923469
these	O	-1	24923469
had	O	-1	24923469
therapy	O	-1	24923469
with	O	-1	24923469
v@@	B-Chemical	D014640	24923469
an@@	I-Chemical	-1	24923469
com@@	I-Chemical	-1	24923469
ycin	I-Chemical	-1	24923469
,	O	-1	24923469
g@@	B-Chemical	D005839	24923469
ent@@	I-Chemical	-1	24923469
am@@	I-Chemical	-1	24923469
icin	I-Chemical	-1	24923469
,	O	-1	24923469
or	O	-1	24923469
to@@	B-Chemical	D014031	24923469
b@@	I-Chemical	-1	24923469
ram@@	I-Chemical	-1	24923469
ycin	I-Chemical	-1	24923469
;	O	-1	24923469
were	O	-1	24923469
>@@	O	-1	24923469
1@@	O	-1	24923469
8	O	-1	24923469
year@@	O	-1	24923469
s;	O	-1	24923469
and	O	-1	24923469
treated	O	-1	24923469
in	O	-1	24923469
the	O	-1	24923469
IC@@	O	-1	24923469
U	O	-1	24923469
for	O	-1	24923469
>@@	O	-1	24923469
24	O	-1	24923469
hour@@	O	-1	24923469
s.	O	-1	24923469
Patients	O	-1	24923469
with	O	-1	24923469
an	O	-1	24923469
ad@@	O	-1	24923469
he@@	O	-1	24923469
rence	O	-1	24923469
to	O	-1	24923469
S@@	O	-1	24923469
O@@	O	-1	24923469
P	O	-1	24923469
>@@	O	-1	24923469
7@@	O	-1	24923469
0%	O	-1	24923469
were	O	-1	24923469
cl@@	O	-1	24923469
assi@@	O	-1	24923469
fied	O	-1	24923469
into	O	-1	24923469
the	O	-1	24923469
high	O	-1	24923469
ad@@	O	-1	24923469
he@@	O	-1	24923469
rence	O	-1	24923469
group	O	-1	24923469
(@@	O	-1	24923469
H@@	O	-1	24923469
A@@	O	-1	24923469
G@@	O	-1	24923469
)	O	-1	24923469
and	O	-1	24923469
patients	O	-1	24923469
with	O	-1	24923469
an	O	-1	24923469
ad@@	O	-1	24923469
he@@	O	-1	24923469
rence	O	-1	24923469
of	O	-1	24923469
<@@	O	-1	24923469
7@@	O	-1	24923469
0%	O	-1	24923469
into	O	-1	24923469
the	O	-1	24923469
low	O	-1	24923469
ad@@	O	-1	24923469
he@@	O	-1	24923469
rence	O	-1	24923469
group	O	-1	24923469
(@@	O	-1	24923469
L@@	O	-1	24923469
A@@	O	-1	24923469
G@@	O	-1	24923469
).	O	-1	24923469
A@@	B-Disease	D058186	24923469
K@@	I-Disease	-1	24923469
I	I-Disease	-1	24923469
was	O	-1	24923469
def@@	O	-1	24923469
in@@	O	-1	24923469
ed	O	-1	24923469
ac@@	O	-1	24923469
cor@@	O	-1	24923469
ding	O	-1	24923469
to	O	-1	24923469
R@@	O	-1	24923469
I@@	O	-1	24923469
F@@	O	-1	24923469
L@@	O	-1	24923469
E	O	-1	24923469
c@@	O	-1	24923469
rit@@	O	-1	24923469
er@@	O	-1	24923469
ia.	O	-1	24923469
Ad@@	O	-1	24923469
he@@	O	-1	24923469
rence	O	-1	24923469
to	O	-1	24923469
S@@	O	-1	24923469
O@@	O	-1	24923469
P@@	O	-1	24923469
s	O	-1	24923469
was	O	-1	24923469
evaluated	O	-1	24923469
by	O	-1	24923469
ret@@	O	-1	24923469
ro@@	O	-1	24923469
sp@@	O	-1	24923469
ective	O	-1	24923469
exper@@	O	-1	24923469
t	O	-1	24923469
a@@	O	-1	24923469
ud@@	O	-1	24923469
it@@	O	-1	24923469
.	O	-1	24923469
De@@	O	-1	24923469
ve@@	O	-1	24923469
lop@@	O	-1	24923469
ment	O	-1	24923469
of	O	-1	24923469
A@@	B-Disease	D058186	24923469
K@@	I-Disease	-1	24923469
I	I-Disease	-1	24923469
was	O	-1	24923469
compared	O	-1	24923469
between	O	-1	24923469
groups	O	-1	24923469
with	O	-1	24923469
ex@@	O	-1	24923469
ac@@	O	-1	24923469
t	O	-1	24923469
C@@	O	-1	24923469
hi@@	O	-1	24923469
2-@@	O	-1	24923469
test	O	-1	24923469
and	O	-1	24923469
mul@@	O	-1	24923469
tiv@@	O	-1	24923469
ari@@	O	-1	24923469
ate	O	-1	24923469
log@@	O	-1	24923469
istic	O	-1	24923469
reg@@	O	-1	24923469
res@@	O	-1	24923469
sion	O	-1	24923469
analysis	O	-1	24923469
(@@	O	-1	24923469
tw@@	O	-1	24923469
o@@	O	-1	24923469
-@@	O	-1	24923469
si@@	O	-1	24923469
ded	O	-1	24923469
P	O	-1	24923469
<@@	O	-1	24923469
0.05@@	O	-1	24923469
).	O	-1	24923469
RESULTS:	O	-1	24923469
L@@	O	-1	24923469
A@@	O	-1	24923469
G	O	-1	24923469
consist@@	O	-1	24923469
ed	O	-1	24923469
of	O	-1	24923469
7@@	O	-1	24923469
5	O	-1	24923469
patients	O	-1	24923469
(4@@	O	-1	24923469
6@@	O	-1	24923469
%)	O	-1	24923469
versus	O	-1	24923469
8@@	O	-1	24923469
8	O	-1	24923469
H@@	O	-1	24923469
A@@	O	-1	24923469
G	O	-1	24923469
patients	O	-1	24923469
(5@@	O	-1	24923469
4@@	O	-1	24923469
%).	O	-1	24923469
A@@	B-Disease	D058186	24923469
K@@	I-Disease	-1	24923469
I	I-Disease	-1	24923469
occurred	O	-1	24923469
significantly	O	-1	24923469
more	O	-1	24923469
often	O	-1	24923469
in	O	-1	24923469
L@@	O	-1	24923469
A@@	O	-1	24923469
G	O	-1	24923469
with	O	-1	24923469
3@@	O	-1	24923469
6%	O	-1	24923469
versus	O	-1	24923469
2@@	O	-1	24923469
1@@	O	-1	24923469
%	O	-1	24923469
in	O	-1	24923469
H@@	O	-1	24923469
A@@	O	-1	24923469
G	O	-1	24923469
(P	O	-1	24923469
=	O	-1	24923469
0.0@@	O	-1	24923469
3@@	O	-1	24923469
5@@	O	-1	24923469
).	O	-1	24923469
B@@	O	-1	24923469
a@@	O	-1	24923469
sic	O	-1	24923469
character@@	O	-1	24923469
is@@	O	-1	24923469
tics	O	-1	24923469
were	O	-1	24923469
compar@@	O	-1	24923469
able@@	O	-1	24923469
,	O	-1	24923469
ex@@	O	-1	24923469
cep@@	O	-1	24923469
t	O	-1	24923469
an	O	-1	24923469
increased	O	-1	24923469
rate	O	-1	24923469
of	O	-1	24923469
so@@	O	-1	24923469
ft	O	-1	24923469
tissue	O	-1	24923469
inf@@	B-Disease	D007239	24923469
ec@@	I-Disease	-1	24923469
tions	I-Disease	-1	24923469
in	O	-1	24923469
L@@	O	-1	24923469
A@@	O	-1	24923469
G@@	O	-1	24923469
.	O	-1	24923469
M@@	O	-1	24923469
ul@@	O	-1	24923469
tiv@@	O	-1	24923469
ari@@	O	-1	24923469
ate	O	-1	24923469
analysis	O	-1	24923469
revealed	O	-1	24923469
an	O	-1	24923469
o@@	O	-1	24923469
d@@	O	-1	24923469
ds	O	-1	24923469
rati@@	O	-1	24923469
o	O	-1	24923469
of	O	-1	24923469
2.@@	O	-1	24923469
5-@@	O	-1	24923469
fol@@	O	-1	24923469
d	O	-1	24923469
for	O	-1	24923469
L@@	O	-1	24923469
A@@	O	-1	24923469
G	O	-1	24923469
to	O	-1	24923469
deve@@	O	-1	24923469
lo@@	O	-1	24923469
p	O	-1	24923469
A@@	B-Disease	D058186	24923469
K@@	I-Disease	-1	24923469
I	I-Disease	-1	24923469
compared	O	-1	24923469
with	O	-1	24923469
H@@	O	-1	24923469
A@@	O	-1	24923469
G	O	-1	24923469
(@@	O	-1	24923469
95%	O	-1	24923469
conf@@	O	-1	24923469
idence	O	-1	24923469
interv@@	O	-1	24923469
al	O	-1	24923469
1.@@	O	-1	24923469
19@@	O	-1	24923469
5	O	-1	24923469
to	O	-1	24923469
5.@@	O	-1	24923469
12@@	O	-1	24923469
4@@	O	-1	24923469
,	O	-1	24923469
P	O	-1	24923469
=	O	-1	24923469
0.0@@	O	-1	24923469
3@@	O	-1	24923469
9@@	O	-1	24923469
).	O	-1	24923469
CONCLUSION:	O	-1	24923469
L@@	O	-1	24923469
o@@	O	-1	24923469
w	O	-1	24923469
ad@@	O	-1	24923469
he@@	O	-1	24923469
rence	O	-1	24923469
to	O	-1	24923469
S@@	O	-1	24923469
O@@	O	-1	24923469
P@@	O	-1	24923469
s	O	-1	24923469
for	O	-1	24923469
potenti@@	O	-1	24923469
ally	O	-1	24923469
nephro@@	B-Disease	D007674	24923469
toxic	I-Disease	-1	24923469
anti@@	O	-1	24923469
bio@@	O	-1	24923469
tics	O	-1	24923469
was	O	-1	24923469
associated	O	-1	24923469
with	O	-1	24923469
a	O	-1	24923469
higher	O	-1	24923469
occur@@	O	-1	24923469
rence	O	-1	24923469
of	O	-1	24923469
A@@	B-Disease	D058186	24923469
K@@	I-Disease	-1	24923469
I	I-Disease	-1	24923469
.	O	-1	24923469
TR@@	O	-1	24923469
I@@	O	-1	24923469
A@@	O	-1	24923469
L	O	-1	24923469
R@@	O	-1	24923469
E@@	O	-1	24923469
G@@	O	-1	24923469
I@@	O	-1	24923469
S@@	O	-1	24923469
TR@@	O	-1	24923469
AT@@	O	-1	24923469
ION@@	O	-1	24923469
:	O	-1	24923469
C@@	O	-1	24923469
ur@@	O	-1	24923469
rent	O	-1	24923469
C@@	O	-1	24923469
ont@@	O	-1	24923469
ro@@	O	-1	24923469
lled	O	-1	24923469
T@@	O	-1	24923469
ri@@	O	-1	24923469
als	O	-1	24923469
I@@	O	-1	24923469
SR@@	O	-1	24923469
C@@	O	-1	24923469
T@@	O	-1	24923469
N@@	O	-1	24923469
5@@	O	-1	24923469
4@@	O	-1	24923469
5@@	O	-1	24923469
9@@	O	-1	24923469
8@@	O	-1	24923469
6@@	O	-1	24923469
7@@	O	-1	24923469
5@@	O	-1	24923469
.	O	-1	24923469
Re@@	O	-1	24923469
g@@	O	-1	24923469
ist@@	O	-1	24923469
ered	O	-1	24923469
17	O	-1	24923469
A@@	O	-1	24923469
u@@	O	-1	24923469
g@@	O	-1	24923469
us@@	O	-1	24923469
t	O	-1	24923469
20@@	O	-1	24923469
0@@	O	-1	24923469
7@@	O	-1	24923469
.	O	-1	24923469

R@@	B-Disease	D012206	24927617
h@@	I-Disease	-1	24927617
ab@@	I-Disease	-1	24927617
do@@	I-Disease	-1	24927617
my@@	I-Disease	-1	24927617
oly@@	I-Disease	-1	24927617
sis	I-Disease	-1	24927617
in	O	-1	24927617
a	O	-1	24927617
hepatitis	B-Disease	D006526	24927617
C	I-Disease	-1	24927617
vi@@	I-Disease	-1	24927617
ru@@	I-Disease	-1	24927617
s	I-Disease	-1	24927617
inf@@	I-Disease	-1	24927617
ected	I-Disease	-1	24927617
patient	O	-1	24927617
treated	O	-1	24927617
with	O	-1	24927617
te@@	B-Chemical	C486464	24927617
l@@	I-Chemical	-1	24927617
ap@@	I-Chemical	-1	24927617
re@@	I-Chemical	-1	24927617
vi@@	I-Chemical	-1	24927617
r	I-Chemical	-1	24927617
and	O	-1	24927617
sim@@	B-Chemical	D019821	24927617
vastatin	I-Chemical	-1	24927617
.	O	-1	24927617
A	O	-1	24927617
4@@	O	-1	24927617
6-@@	O	-1	24927617
year	O	-1	24927617
old	O	-1	24927617
man	O	-1	24927617
with	O	-1	24927617
a	O	-1	24927617
chronic	O	-1	24927617
hepatitis	B-Disease	D006526	24927617
C	I-Disease	-1	24927617
vi@@	I-Disease	-1	24927617
ru@@	I-Disease	-1	24927617
s	I-Disease	-1	24927617
inf@@	I-Disease	-1	24927617
ection	I-Disease	-1	24927617
received	O	-1	24927617
tri@@	O	-1	24927617
ple	O	-1	24927617
therapy	O	-1	24927617
with	O	-1	24927617
rib@@	B-Chemical	D012254	24927617
avi@@	I-Chemical	-1	24927617
rin	I-Chemical	-1	24927617
,	O	-1	24927617
pe@@	B-Chemical	C417083	24927617
g@@	I-Chemical	-1	24927617
yl@@	I-Chemical	-1	24927617
ated	I-Chemical	-1	24927617
inter@@	I-Chemical	-1	24927617
fer@@	I-Chemical	-1	24927617
on	I-Chemical	-1	24927617
and	O	-1	24927617
te@@	B-Chemical	C486464	24927617
l@@	I-Chemical	-1	24927617
ap@@	I-Chemical	-1	24927617
re@@	I-Chemical	-1	24927617
vi@@	I-Chemical	-1	24927617
r	I-Chemical	-1	24927617
.	O	-1	24927617
The	O	-1	24927617
patient	O	-1	24927617
also	O	-1	24927617
received	O	-1	24927617
sim@@	B-Chemical	D019821	24927617
vastatin	I-Chemical	-1	24927617
.	O	-1	24927617
One	O	-1	24927617
mon@@	O	-1	24927617
th	O	-1	24927617
after	O	-1	24927617
star@@	O	-1	24927617
ting	O	-1	24927617
the	O	-1	24927617
anti@@	O	-1	24927617
viral	O	-1	24927617
therapy,	O	-1	24927617
the	O	-1	24927617
patient	O	-1	24927617
was	O	-1	24927617
ad@@	O	-1	24927617
mit@@	O	-1	24927617
ted	O	-1	24927617
to	O	-1	24927617
the	O	-1	24927617
hospit@@	O	-1	24927617
al	O	-1	24927617
because	O	-1	24927617
he	O	-1	24927617
developed	O	-1	24927617
rh@@	B-Disease	D012206	24927617
ab@@	I-Disease	-1	24927617
do@@	I-Disease	-1	24927617
my@@	I-Disease	-1	24927617
oly@@	I-Disease	-1	24927617
sis	I-Disease	-1	24927617
.	O	-1	24927617
A@@	O	-1	24927617
t	O	-1	24927617
ad@@	O	-1	24927617
mission	O	-1	24927617
sim@@	B-Chemical	D019821	24927617
vastatin	I-Chemical	-1	24927617
and	O	-1	24927617
all	O	-1	24927617
anti@@	O	-1	24927617
viral	O	-1	24927617
drugs	O	-1	24927617
were	O	-1	24927617
discontinu@@	O	-1	24927617
ed	O	-1	24927617
because	O	-1	24927617
toxicity	B-Disease	D064420	24927617
due	O	-1	24927617
to	O	-1	24927617
a	O	-1	24927617
drug@@	O	-1	24927617
-@@	O	-1	24927617
drug	O	-1	24927617
inter@@	O	-1	24927617
action	O	-1	24927617
was	O	-1	24927617
sus@@	O	-1	24927617
p@@	O	-1	24927617
ect@@	O	-1	24927617
ed.	O	-1	24927617
The	O	-1	24927617
creat@@	B-Chemical	D003401	24927617
ine	I-Chemical	-1	24927617
kin@@	O	-1	24927617
ase	O	-1	24927617
pe@@	O	-1	24927617
ak@@	O	-1	24927617
ed	O	-1	24927617
at	O	-1	24927617
6@@	O	-1	24927617
2@@	O	-1	24927617
,@@	O	-1	24927617
2@@	O	-1	24927617
4@@	O	-1	24927617
6	O	-1	24927617
I@@	O	-1	24927617
U@@	O	-1	24927617
/@@	O	-1	24927617
L	O	-1	24927617
and	O	-1	24927617
the	O	-1	24927617
patient	O	-1	24927617
was	O	-1	24927617
treated	O	-1	24927617
with	O	-1	24927617
intravenous	O	-1	24927617
normal	O	-1	24927617
sal@@	O	-1	24927617
ine.	O	-1	24927617
The	O	-1	24927617
patient@@	O	-1	24927617
's	O	-1	24927617
renal	O	-1	24927617
function	O	-1	24927617
remained	O	-1	24927617
un@@	O	-1	24927617
aff@@	O	-1	24927617
ect@@	O	-1	24927617
ed.	O	-1	24927617
F@@	O	-1	24927617
o@@	O	-1	24927617
ur@@	O	-1	24927617
te@@	O	-1	24927617
en	O	-1	24927617
days	O	-1	24927617
after	O	-1	24927617
hospit@@	O	-1	24927617
al@@	O	-1	24927617
iz@@	O	-1	24927617
ation,	O	-1	24927617
creat@@	B-Chemical	D003401	24927617
ine	I-Chemical	-1	24927617
kin@@	O	-1	24927617
ase	O	-1	24927617
level	O	-1	24927617
had	O	-1	24927617
retur@@	O	-1	24927617
n@@	O	-1	24927617
ed	O	-1	24927617
to	O	-1	24927617
2@@	O	-1	24927617
30	O	-1	24927617
I@@	O	-1	24927617
U@@	O	-1	24927617
/@@	O	-1	24927617
L	O	-1	24927617
and	O	-1	24927617
the	O	-1	24927617
patient	O	-1	24927617
was	O	-1	24927617
dis@@	O	-1	24927617
ch@@	O	-1	24927617
arg@@	O	-1	24927617
ed.	O	-1	24927617
T@@	B-Chemical	C486464	24927617
el@@	I-Chemical	-1	24927617
ap@@	I-Chemical	-1	24927617
re@@	I-Chemical	-1	24927617
vi@@	I-Chemical	-1	24927617
r	I-Chemical	-1	24927617
was	O	-1	24927617
considered	O	-1	24927617
the	O	-1	24927617
prob@@	O	-1	24927617
able	O	-1	24927617
ca@@	O	-1	24927617
us@@	O	-1	24927617
ative	O	-1	24927617
agent	O	-1	24927617
of	O	-1	24927617
an	O	-1	24927617
inter@@	O	-1	24927617
action	O	-1	24927617
with	O	-1	24927617
sim@@	B-Chemical	D019821	24927617
vastatin	I-Chemical	-1	24927617
ac@@	O	-1	24927617
cor@@	O	-1	24927617
ding	O	-1	24927617
to	O	-1	24927617
the	O	-1	24927617
D@@	O	-1	24927617
ru@@	O	-1	24927617
g	O	-1	24927617
In@@	O	-1	24927617
ter@@	O	-1	24927617
action	O	-1	24927617
Pro@@	O	-1	24927617
b@@	O	-1	24927617
ability	O	-1	24927617
S@@	O	-1	24927617
cal@@	O	-1	24927617
e.	O	-1	24927617
The	O	-1	24927617
inter@@	O	-1	24927617
action	O	-1	24927617
is	O	-1	24927617
due	O	-1	24927617
to	O	-1	24927617
inhibition	O	-1	24927617
of	O	-1	24927617
C@@	O	-1	24927617
Y@@	O	-1	24927617
P@@	O	-1	24927617
3@@	O	-1	24927617
A@@	O	-1	24927617
4-@@	O	-1	24927617
mediated	O	-1	24927617
sim@@	B-Chemical	D019821	24927617
vastatin	I-Chemical	-1	24927617
clear@@	O	-1	24927617
ance@@	O	-1	24927617
.	O	-1	24927617
S@@	B-Chemical	D019821	24927617
im@@	I-Chemical	-1	24927617
vastatin	I-Chemical	-1	24927617
plasma	O	-1	24927617
concentration	O	-1	24927617
increased	O	-1	24927617
30	O	-1	24927617
times	O	-1	24927617
in	O	-1	24927617
this	O	-1	24927617
patient	O	-1	24927617
and	O	-1	24927617
st@@	B-Chemical	D019821	24927617
atin	I-Chemical	-1	24927617
induced	O	-1	24927617
musc@@	B-Disease	D009135	24927617
le	I-Disease	-1	24927617
toxicity	I-Disease	-1	24927617
is	O	-1	24927617
related	O	-1	24927617
to	O	-1	24927617
the	O	-1	24927617
concentration	O	-1	24927617
of	O	-1	24927617
the	O	-1	24927617
st@@	B-Chemical	D019821	24927617
atin	I-Chemical	-1	24927617
in	O	-1	24927617
blo@@	O	-1	24927617
o@@	O	-1	24927617
d.	O	-1	24927617
In	O	-1	24927617
concl@@	O	-1	24927617
u@@	O	-1	24927617
sion,	O	-1	24927617
with	O	-1	24927617
this	O	-1	24927617
case	O	-1	24927617
we	O	-1	24927617
il@@	O	-1	24927617
lu@@	O	-1	24927617
st@@	O	-1	24927617
rate	O	-1	24927617
that	O	-1	24927617
te@@	B-Chemical	C486464	24927617
l@@	I-Chemical	-1	24927617
ap@@	I-Chemical	-1	24927617
re@@	I-Chemical	-1	24927617
vi@@	I-Chemical	-1	24927617
r	I-Chemical	-1	24927617
as	O	-1	24927617
well	O	-1	24927617
as	O	-1	24927617
stat@@	B-Chemical	D019821	24927617
ins	I-Chemical	-1	24927617
are	O	-1	24927617
sus@@	O	-1	24927617
cep@@	O	-1	24927617
ti@@	O	-1	24927617
ble	O	-1	24927617
to	O	-1	24927617
clinical	O	-1	24927617
re@@	O	-1	24927617
lev@@	O	-1	24927617
ant	O	-1	24927617
drug@@	O	-1	24927617
-@@	O	-1	24927617
drug	O	-1	24927617
inter@@	O	-1	24927617
ac@@	O	-1	24927617
tions.	O	-1	24927617

Com@@	O	-1	24928523
bin@@	O	-1	24928523
ation	O	-1	24928523
of	O	-1	24928523
b@@	B-Chemical	C400082	24928523
or@@	I-Chemical	-1	24928523
te@@	I-Chemical	-1	24928523
z@@	I-Chemical	-1	24928523
om@@	I-Chemical	-1	24928523
i@@	I-Chemical	-1	24928523
b	I-Chemical	-1	24928523
,	O	-1	24928523
thal@@	B-Chemical	D013792	24928523
id@@	I-Chemical	-1	24928523
om@@	I-Chemical	-1	24928523
ide	I-Chemical	-1	24928523
,	O	-1	24928523
and	O	-1	24928523
de@@	B-Chemical	D003907	24928523
xameth@@	I-Chemical	-1	24928523
as@@	I-Chemical	-1	24928523
one	I-Chemical	-1	24928523
(V@@	O	-1	24928523
T@@	O	-1	24928523
D)	O	-1	24928523
as	O	-1	24928523
a	O	-1	24928523
con@@	O	-1	24928523
sol@@	O	-1	24928523
id@@	O	-1	24928523
ation	O	-1	24928523
therapy	O	-1	24928523
after	O	-1	24928523
auto@@	O	-1	24928523
log@@	O	-1	24928523
ous	O	-1	24928523
st@@	O	-1	24928523
em	O	-1	24928523
cell	O	-1	24928523
transplant@@	O	-1	24928523
ation	O	-1	24928523
for	O	-1	24928523
symptom@@	O	-1	24928523
atic	O	-1	24928523
multiple	B-Disease	D009101	24928523
my@@	I-Disease	-1	24928523
e@@	I-Disease	-1	24928523
lo@@	I-Disease	-1	24928523
ma	I-Disease	-1	24928523
in	O	-1	24928523
J@@	O	-1	24928523
ap@@	O	-1	24928523
an@@	O	-1	24928523
ese	O	-1	24928523
patients.	O	-1	24928523
Con@@	O	-1	24928523
sol@@	O	-1	24928523
id@@	O	-1	24928523
ation	O	-1	24928523
therapy	O	-1	24928523
for	O	-1	24928523
patients	O	-1	24928523
with	O	-1	24928523
multiple	B-Disease	D009101	24928523
my@@	I-Disease	-1	24928523
e@@	I-Disease	-1	24928523
lo@@	I-Disease	-1	24928523
ma	I-Disease	-1	24928523
(	O	-1	24928523
M@@	B-Disease	D009101	24928523
M	I-Disease	-1	24928523
)	O	-1	24928523
has	O	-1	24928523
been	O	-1	24928523
wi@@	O	-1	24928523
de@@	O	-1	24928523
ly	O	-1	24928523
ad@@	O	-1	24928523
o@@	O	-1	24928523
pt@@	O	-1	24928523
ed	O	-1	24928523
to	O	-1	24928523
impro@@	O	-1	24928523
ve	O	-1	24928523
treatment	O	-1	24928523
response	O	-1	24928523
following	O	-1	24928523
auto@@	O	-1	24928523
log@@	O	-1	24928523
ous	O	-1	24928523
st@@	O	-1	24928523
em	O	-1	24928523
cell	O	-1	24928523
transplant@@	O	-1	24928523
ation.	O	-1	24928523
In	O	-1	24928523
this	O	-1	24928523
study,	O	-1	24928523
we	O	-1	24928523
ret@@	O	-1	24928523
ro@@	O	-1	24928523
sp@@	O	-1	24928523
ectively	O	-1	24928523
analy@@	O	-1	24928523
zed	O	-1	24928523
the	O	-1	24928523
safety	O	-1	24928523
and	O	-1	24928523
efficacy	O	-1	24928523
of	O	-1	24928523
combination	O	-1	24928523
regi@@	O	-1	24928523
men	O	-1	24928523
of	O	-1	24928523
b@@	B-Chemical	C400082	24928523
or@@	I-Chemical	-1	24928523
te@@	I-Chemical	-1	24928523
z@@	I-Chemical	-1	24928523
om@@	I-Chemical	-1	24928523
i@@	I-Chemical	-1	24928523
b	I-Chemical	-1	24928523
,	O	-1	24928523
thal@@	B-Chemical	D013792	24928523
id@@	I-Chemical	-1	24928523
om@@	I-Chemical	-1	24928523
ide	I-Chemical	-1	24928523
,	O	-1	24928523
and	O	-1	24928523
de@@	B-Chemical	D003907	24928523
xameth@@	I-Chemical	-1	24928523
as@@	I-Chemical	-1	24928523
one	I-Chemical	-1	24928523
(V@@	O	-1	24928523
T@@	O	-1	24928523
D)	O	-1	24928523
as	O	-1	24928523
con@@	O	-1	24928523
sol@@	O	-1	24928523
id@@	O	-1	24928523
ation	O	-1	24928523
therapy	O	-1	24928523
in	O	-1	24928523
24	O	-1	24928523
J@@	O	-1	24928523
ap@@	O	-1	24928523
an@@	O	-1	24928523
ese	O	-1	24928523
patients	O	-1	24928523
with	O	-1	24928523
ne@@	O	-1	24928523
w@@	O	-1	24928523
ly	O	-1	24928523
diagnos@@	O	-1	24928523
ed	O	-1	24928523
M@@	B-Disease	D009101	24928523
M	I-Disease	-1	24928523
.	O	-1	24928523
V@@	O	-1	24928523
T@@	O	-1	24928523
D	O	-1	24928523
consist@@	O	-1	24928523
ed	O	-1	24928523
of	O	-1	24928523
b@@	B-Chemical	C400082	24928523
or@@	I-Chemical	-1	24928523
te@@	I-Chemical	-1	24928523
z@@	I-Chemical	-1	24928523
om@@	I-Chemical	-1	24928523
i@@	I-Chemical	-1	24928523
b	I-Chemical	-1	24928523
at	O	-1	24928523
a	O	-1	24928523
dose	O	-1	24928523
of	O	-1	24928523
1.@@	O	-1	24928523
3	O	-1	24928523
mg/m@@	O	-1	24928523
(2@@	O	-1	24928523
)	O	-1	24928523
and	O	-1	24928523
de@@	B-Chemical	D003907	24928523
xameth@@	I-Chemical	-1	24928523
as@@	I-Chemical	-1	24928523
one	I-Chemical	-1	24928523
at	O	-1	24928523
a	O	-1	24928523
dose	O	-1	24928523
of	O	-1	24928523
40	O	-1	24928523
mg/@@	O	-1	24928523
day	O	-1	24928523
on	O	-1	24928523
days	O	-1	24928523
1,	O	-1	24928523
8@@	O	-1	24928523
,	O	-1	24928523
1@@	O	-1	24928523
5,	O	-1	24928523
and	O	-1	24928523
2@@	O	-1	24928523
2	O	-1	24928523
of	O	-1	24928523
a	O	-1	24928523
3@@	O	-1	24928523
5-@@	O	-1	24928523
day	O	-1	24928523
cyc@@	O	-1	24928523
le@@	O	-1	24928523
,	O	-1	24928523
with	O	-1	24928523
daily	O	-1	24928523
oral	O	-1	24928523
thal@@	B-Chemical	D013792	24928523
id@@	I-Chemical	-1	24928523
om@@	I-Chemical	-1	24928523
ide	I-Chemical	-1	24928523
at	O	-1	24928523
a	O	-1	24928523
dose	O	-1	24928523
of	O	-1	24928523
100	O	-1	24928523
mg/@@	O	-1	24928523
da@@	O	-1	24928523
y.	O	-1	24928523
G@@	O	-1	24928523
ra@@	O	-1	24928523
de	O	-1	24928523
3-@@	O	-1	24928523
4	O	-1	24928523
ne@@	B-Disease	D009503	24928523
ut@@	I-Disease	-1	24928523
ro@@	I-Disease	-1	24928523
pen@@	I-Disease	-1	24928523
ia	I-Disease	-1	24928523
and	O	-1	24928523
throm@@	B-Disease	D013921	24928523
b@@	I-Disease	-1	24928523
ocyto@@	I-Disease	-1	24928523
pen@@	I-Disease	-1	24928523
ia	I-Disease	-1	24928523
were	O	-1	24928523
doc@@	O	-1	24928523
um@@	O	-1	24928523
ent@@	O	-1	24928523
ed	O	-1	24928523
in	O	-1	24928523
four	O	-1	24928523
and	O	-1	24928523
three	O	-1	24928523
patients	O	-1	24928523
(1@@	O	-1	24928523
7	O	-1	24928523
and	O	-1	24928523
13	O	-1	24928523
%),	O	-1	24928523
respectivel@@	O	-1	24928523
y,	O	-1	24928523
but	O	-1	24928523
drug	O	-1	24928523
dose	O	-1	24928523
reduction	O	-1	24928523
due	O	-1	24928523
to	O	-1	24928523
cyto@@	B-Disease	D006402	24928523
pen@@	I-Disease	-1	24928523
ia	I-Disease	-1	24928523
was	O	-1	24928523
not	O	-1	24928523
requ@@	O	-1	24928523
ired	O	-1	24928523
in	O	-1	24928523
any	O	-1	24928523
cas@@	O	-1	24928523
e.	O	-1	24928523
P@@	B-Disease	D010523	24928523
er@@	I-Disease	-1	24928523
i@@	I-Disease	-1	24928523
pheral	I-Disease	-1	24928523
neuropathy	I-Disease	-1	24928523
was	O	-1	24928523
common	O	-1	24928523
(6@@	O	-1	24928523
3	O	-1	24928523
%),	O	-1	24928523
but	O	-1	24928523
severe	O	-1	24928523
gra@@	O	-1	24928523
de	O	-1	24928523
3-@@	O	-1	24928523
4	O	-1	24928523
peripheral	B-Disease	D010523	24928523
neuropathy	I-Disease	-1	24928523
was	O	-1	24928523
not	O	-1	24928523
obser@@	O	-1	24928523
ved.	O	-1	24928523
V@@	O	-1	24928523
er@@	O	-1	24928523
y	O	-1	24928523
go@@	O	-1	24928523
od	O	-1	24928523
partial	O	-1	24928523
response	O	-1	24928523
or	O	-1	24928523
bet@@	O	-1	24928523
ter	O	-1	24928523
response	O	-1	24928523
(@@	O	-1	24928523
>@@	O	-1	24928523
V@@	O	-1	24928523
G@@	O	-1	24928523
P@@	O	-1	24928523
R@@	O	-1	24928523
)	O	-1	24928523
rat@@	O	-1	24928523
es	O	-1	24928523
before	O	-1	24928523
and	O	-1	24928523
after	O	-1	24928523
con@@	O	-1	24928523
sol@@	O	-1	24928523
id@@	O	-1	24928523
ation	O	-1	24928523
therapy	O	-1	24928523
were	O	-1	24928523
5@@	O	-1	24928523
4	O	-1	24928523
and	O	-1	24928523
7@@	O	-1	24928523
9	O	-1	24928523
%,	O	-1	24928523
respectively.	O	-1	24928523
Patients	O	-1	24928523
had	O	-1	24928523
a	O	-1	24928523
significant	O	-1	24928523
prob@@	O	-1	24928523
ability	O	-1	24928523
of	O	-1	24928523
impro@@	O	-1	24928523
ving	O	-1	24928523
from	O	-1	24928523
<@@	O	-1	24928523
V@@	O	-1	24928523
G@@	O	-1	24928523
P@@	O	-1	24928523
R	O	-1	24928523
before	O	-1	24928523
con@@	O	-1	24928523
sol@@	O	-1	24928523
id@@	O	-1	24928523
ation	O	-1	24928523
therapy	O	-1	24928523
to	O	-1	24928523
>@@	O	-1	24928523
V@@	O	-1	24928523
G@@	O	-1	24928523
P@@	O	-1	24928523
R	O	-1	24928523
after	O	-1	24928523
con@@	O	-1	24928523
sol@@	O	-1	24928523
id@@	O	-1	24928523
ation	O	-1	24928523
therapy	O	-1	24928523
(p	O	-1	24928523
=	O	-1	24928523
0.0@@	O	-1	24928523
4@@	O	-1	24928523
1).	O	-1	24928523
The	O	-1	24928523
V@@	O	-1	24928523
T@@	O	-1	24928523
D	O	-1	24928523
regi@@	O	-1	24928523
men	O	-1	24928523
may	O	-1	24928523
be	O	-1	24928523
saf@@	O	-1	24928523
e	O	-1	24928523
and	O	-1	24928523
effective	O	-1	24928523
as	O	-1	24928523
a	O	-1	24928523
con@@	O	-1	24928523
sol@@	O	-1	24928523
id@@	O	-1	24928523
ation	O	-1	24928523
therapy	O	-1	24928523
in	O	-1	24928523
the	O	-1	24928523
treatment	O	-1	24928523
of	O	-1	24928523
M@@	O	-1	24928523
M	O	-1	24928523
in	O	-1	24928523
J@@	O	-1	24928523
ap@@	O	-1	24928523
an@@	O	-1	24928523
ese	O	-1	24928523
po@@	O	-1	24928523
pul@@	O	-1	24928523
ation.	O	-1	24928523

Con@@	O	-1	24971338
ver@@	O	-1	24971338
sion	O	-1	24971338
to	O	-1	24971338
sirolimus	B-Chemical	D020123	24971338
ame@@	O	-1	24971338
li@@	O	-1	24971338
or@@	O	-1	24971338
ates	O	-1	24971338
cyclospor@@	B-Chemical	D016572	24971338
ine	I-Chemical	-1	24971338
-induced	O	-1	24971338
nephro@@	B-Disease	D007674	24971338
pathy	I-Disease	-1	24971338
in	O	-1	24971338
the	O	-1	24971338
rat@@	O	-1	24971338
:	O	-1	24971338
foc@@	O	-1	24971338
us	O	-1	24971338
on	O	-1	24971338
ser@@	O	-1	24971338
um,	O	-1	24971338
ur@@	O	-1	24971338
ine,	O	-1	24971338
gen@@	O	-1	24971338
e,	O	-1	24971338
and	O	-1	24971338
protein	O	-1	24971338
renal	O	-1	24971338
expression	O	-1	24971338
b@@	O	-1	24971338
i@@	O	-1	24971338
om@@	O	-1	24971338
ark@@	O	-1	24971338
ers.	O	-1	24971338
Pro@@	O	-1	24971338
to@@	O	-1	24971338
co@@	O	-1	24971338
l@@	O	-1	24971338
s	O	-1	24971338
of	O	-1	24971338
conver@@	O	-1	24971338
sion	O	-1	24971338
from	O	-1	24971338
cyclospor@@	B-Chemical	D016572	24971338
in	I-Chemical	-1	24971338
A	I-Chemical	-1	24971338
(	O	-1	24971338
C@@	B-Chemical	D016572	24971338
s@@	I-Chemical	-1	24971338
A	I-Chemical	-1	24971338
)	O	-1	24971338
to	O	-1	24971338
sirolimus	B-Chemical	D020123	24971338
(	O	-1	24971338
SR@@	B-Chemical	D020123	24971338
L	I-Chemical	-1	24971338
)	O	-1	24971338
have	O	-1	24971338
been	O	-1	24971338
wi@@	O	-1	24971338
de@@	O	-1	24971338
ly	O	-1	24971338
used	O	-1	24971338
in	O	-1	24971338
immuno@@	O	-1	24971338
therapy	O	-1	24971338
after	O	-1	24971338
transplant@@	O	-1	24971338
ation	O	-1	24971338
to	O	-1	24971338
prev@@	O	-1	24971338
ent	O	-1	24971338
C@@	B-Chemical	D016572	24971338
s@@	I-Chemical	-1	24971338
A	I-Chemical	-1	24971338
-induced	O	-1	24971338
nephro@@	B-Disease	D007674	24971338
pathy	I-Disease	-1	24971338
,	O	-1	24971338
but	O	-1	24971338
the	O	-1	24971338
mol@@	O	-1	24971338
ec@@	O	-1	24971338
ular	O	-1	24971338
mechanisms	O	-1	24971338
underlying	O	-1	24971338
these	O	-1	24971338
pro@@	O	-1	24971338
to@@	O	-1	24971338
co@@	O	-1	24971338
l@@	O	-1	24971338
s	O	-1	24971338
re@@	O	-1	24971338
ma@@	O	-1	24971338
in	O	-1	24971338
n@@	O	-1	24971338
uc@@	O	-1	24971338
lear@@	O	-1	24971338
.	O	-1	24971338
This	O	-1	24971338
study	O	-1	24971338
a@@	O	-1	24971338
im@@	O	-1	24971338
ed	O	-1	24971338
to	O	-1	24971338
identi@@	O	-1	24971338
f@@	O	-1	24971338
y	O	-1	24971338
the	O	-1	24971338
mol@@	O	-1	24971338
ec@@	O	-1	24971338
ular	O	-1	24971338
path@@	O	-1	24971338
w@@	O	-1	24971338
ays	O	-1	24971338
and	O	-1	24971338
p@@	O	-1	24971338
ut@@	O	-1	24971338
ative	O	-1	24971338
b@@	O	-1	24971338
i@@	O	-1	24971338
om@@	O	-1	24971338
ark@@	O	-1	24971338
ers	O	-1	24971338
of	O	-1	24971338
C@@	B-Chemical	D016572	24971338
s@@	I-Chemical	-1	24971338
A	I-Chemical	-1	24971338
-@@	O	-1	24971338
to@@	O	-1	24971338
-	O	-1	24971338
SR@@	B-Chemical	D020123	24971338
L	I-Chemical	-1	24971338
conver@@	O	-1	24971338
sion	O	-1	24971338
in	O	-1	24971338
a	O	-1	24971338
rat	O	-1	24971338
model@@	O	-1	24971338
.	O	-1	24971338
F@@	O	-1	24971338
our	O	-1	24971338
anim@@	O	-1	24971338
al	O	-1	24971338
groups	O	-1	24971338
(n	O	-1	24971338
=	O	-1	24971338
6@@	O	-1	24971338
)	O	-1	24971338
were	O	-1	24971338
tested	O	-1	24971338
during	O	-1	24971338
9	O	-1	24971338
week@@	O	-1	24971338
s:	O	-1	24971338
control@@	O	-1	24971338
,	O	-1	24971338
C@@	B-Chemical	D016572	24971338
s@@	I-Chemical	-1	24971338
A	I-Chemical	-1	24971338
,	O	-1	24971338
SR@@	B-Chemical	D020123	24971338
L	I-Chemical	-1	24971338
,	O	-1	24971338
and	O	-1	24971338
conver@@	O	-1	24971338
sion	O	-1	24971338
(	O	-1	24971338
C@@	B-Chemical	D016572	24971338
s@@	I-Chemical	-1	24971338
A	I-Chemical	-1	24971338
for	O	-1	24971338
3	O	-1	24971338
weeks	O	-1	24971338
followed	O	-1	24971338
by	O	-1	24971338
SR@@	B-Chemical	D020123	24971338
L	I-Chemical	-1	24971338
for	O	-1	24971338
6	O	-1	24971338
week@@	O	-1	24971338
s@@	O	-1	24971338
).	O	-1	24971338
C@@	O	-1	24971338
las@@	O	-1	24971338
si@@	O	-1	24971338
c@@	O	-1	24971338
al	O	-1	24971338
and	O	-1	24971338
em@@	O	-1	24971338
erg@@	O	-1	24971338
ent	O	-1	24971338
ser@@	O	-1	24971338
um,	O	-1	24971338
ur@@	O	-1	24971338
in@@	O	-1	24971338
ar@@	O	-1	24971338
y,	O	-1	24971338
and	O	-1	24971338
kidney	O	-1	24971338
tissue	O	-1	24971338
(@@	O	-1	24971338
gen@@	O	-1	24971338
e	O	-1	24971338
and	O	-1	24971338
protein	O	-1	24971338
ex@@	O	-1	24971338
pres@@	O	-1	24971338
sion@@	O	-1	24971338
)	O	-1	24971338
mark@@	O	-1	24971338
ers	O	-1	24971338
were	O	-1	24971338
ass@@	O	-1	24971338
es@@	O	-1	24971338
sed.	O	-1	24971338
R@@	B-Disease	D007674	24971338
en@@	I-Disease	-1	24971338
al	I-Disease	-1	24971338
lesions	I-Disease	-1	24971338
were	O	-1	24971338
analy@@	O	-1	24971338
zed	O	-1	24971338
in	O	-1	24971338
hemat@@	B-Chemical	D006416	24971338
ox@@	I-Chemical	-1	24971338
yl@@	I-Chemical	-1	24971338
in	I-Chemical	-1	24971338
and	O	-1	24971338
e@@	B-Chemical	D004801	24971338
os@@	I-Chemical	-1	24971338
in	I-Chemical	-1	24971338
,	O	-1	24971338
perio@@	O	-1	24971338
di@@	O	-1	24971338
c	O	-1	24971338
acid@@	O	-1	24971338
-@@	O	-1	24971338
S@@	O	-1	24971338
ch@@	O	-1	24971338
i@@	O	-1	24971338
ff@@	O	-1	24971338
,	O	-1	24971338
and	O	-1	24971338
M@@	O	-1	24971338
ass@@	O	-1	24971338
on@@	O	-1	24971338
's	O	-1	24971338
tr@@	O	-1	24971338
ic@@	O	-1	24971338
h@@	O	-1	24971338
rom@@	O	-1	24971338
e	O	-1	24971338
st@@	O	-1	24971338
ain@@	O	-1	24971338
s.	O	-1	24971338
SR@@	B-Chemical	D020123	24971338
L	I-Chemical	-1	24971338
-treated	O	-1	24971338
rats	O	-1	24971338
presented	O	-1	24971338
proteinuria	B-Disease	D011507	24971338
and	O	-1	24971338
N@@	O	-1	24971338
G@@	O	-1	24971338
A@@	O	-1	24971338
L	O	-1	24971338
(@@	O	-1	24971338
serum	O	-1	24971338
and	O	-1	24971338
ur@@	O	-1	24971338
in@@	O	-1	24971338
ar@@	O	-1	24971338
y@@	O	-1	24971338
)	O	-1	24971338
as	O	-1	24971338
the	O	-1	24971338
b@@	O	-1	24971338
est	O	-1	24971338
mark@@	O	-1	24971338
ers	O	-1	24971338
of	O	-1	24971338
renal	B-Disease	D007674	24971338
impair@@	I-Disease	-1	24971338
ment	I-Disease	-1	24971338
.	O	-1	24971338
S@@	O	-1	24971338
h@@	O	-1	24971338
ort	O	-1	24971338
C@@	B-Chemical	D016572	24971338
s@@	I-Chemical	-1	24971338
A	I-Chemical	-1	24971338
treatment	O	-1	24971338
presented	O	-1	24971338
s@@	O	-1	24971338
li@@	O	-1	24971338
ght	O	-1	24971338
or	O	-1	24971338
even	O	-1	24971338
abs@@	O	-1	24971338
ent	O	-1	24971338
kidney	B-Disease	D007674	24971338
lesions	I-Disease	-1	24971338
and	O	-1	24971338
T@@	O	-1	24971338
GF@@	O	-1	24971338
-@@	O	-1	24971338
b@@	O	-1	24971338
,	O	-1	24971338
N@@	O	-1	24971338
F@@	O	-1	24971338
-	O	-1	24971338
k@@	O	-1	24971338
b@@	O	-1	24971338
,	O	-1	24971338
m@@	O	-1	24971338
T@@	O	-1	24971338
O@@	O	-1	24971338
R@@	O	-1	24971338
,	O	-1	24971338
P@@	O	-1	24971338
C@@	O	-1	24971338
N@@	O	-1	24971338
A@@	O	-1	24971338
,	O	-1	24971338
T@@	O	-1	24971338
P@@	O	-1	24971338
5@@	O	-1	24971338
3,	O	-1	24971338
K@@	O	-1	24971338
I@@	O	-1	24971338
M@@	O	-1	24971338
-1@@	O	-1	24971338
,	O	-1	24971338
and	O	-1	24971338
C@@	O	-1	24971338
T@@	O	-1	24971338
G@@	O	-1	24971338
F	O	-1	24971338
as	O	-1	24971338
re@@	O	-1	24971338
lev@@	O	-1	24971338
ant	O	-1	24971338
gen@@	O	-1	24971338
e	O	-1	24971338
and	O	-1	24971338
protein	O	-1	24971338
chang@@	O	-1	24971338
es.	O	-1	24971338
Pro@@	O	-1	24971338
long@@	O	-1	24971338
ed	O	-1	24971338
C@@	B-Chemical	D016572	24971338
s@@	I-Chemical	-1	24971338
A	I-Chemical	-1	24971338
exposure	O	-1	24971338
ag@@	O	-1	24971338
gra@@	O	-1	24971338
v@@	O	-1	24971338
ated	O	-1	24971338
renal	B-Disease	D007674	24971338
damage	I-Disease	-1	24971338
,	O	-1	24971338
without	O	-1	24971338
c@@	O	-1	24971338
le@@	O	-1	24971338
ar	O	-1	24971338
changes	O	-1	24971338
on	O	-1	24971338
the	O	-1	24971338
t@@	O	-1	24971338
radi@@	O	-1	24971338
tional	O	-1	24971338
mark@@	O	-1	24971338
er@@	O	-1	24971338
s,	O	-1	24971338
but	O	-1	24971338
with	O	-1	24971338
changes	O	-1	24971338
in	O	-1	24971338
ser@@	O	-1	24971338
um@@	O	-1	24971338
s	O	-1	24971338
T@@	O	-1	24971338
GF@@	O	-1	24971338
-	O	-1	24971338
b	O	-1	24971338
and	O	-1	24971338
I@@	O	-1	24971338
L-@@	O	-1	24971338
7@@	O	-1	24971338
,	O	-1	24971338
T@@	O	-1	24971338
BA@@	O	-1	24971338
R@@	O	-1	24971338
s	O	-1	24971338
clear@@	O	-1	24971338
ance@@	O	-1	24971338
,	O	-1	24971338
and	O	-1	24971338
kidney	O	-1	24971338
T@@	O	-1	24971338
GF@@	O	-1	24971338
-@@	O	-1	24971338
b	O	-1	24971338
and	O	-1	24971338
m@@	O	-1	24971338
T@@	O	-1	24971338
O@@	O	-1	24971338
R@@	O	-1	24971338
.	O	-1	24971338
Con@@	O	-1	24971338
ver@@	O	-1	24971338
sion	O	-1	24971338
to	O	-1	24971338
SR@@	B-Chemical	D020123	24971338
L	I-Chemical	-1	24971338
prevent@@	O	-1	24971338
ed	O	-1	24971338
C@@	B-Chemical	D016572	24971338
s@@	I-Chemical	-1	24971338
A	I-Chemical	-1	24971338
-induced	O	-1	24971338
renal	B-Disease	D007674	24971338
damage	I-Disease	-1	24971338
ev@@	O	-1	24971338
ol@@	O	-1	24971338
u@@	O	-1	24971338
tion	O	-1	24971338
(@@	O	-1	24971338
abs@@	O	-1	24971338
ent@@	O	-1	24971338
/@@	O	-1	24971338
mil@@	O	-1	24971338
d	O	-1	24971338
gra@@	O	-1	24971338
de	O	-1	24971338
le@@	O	-1	24971338
sion@@	O	-1	24971338
s),	O	-1	24971338
while	O	-1	24971338
N@@	O	-1	24971338
G@@	O	-1	24971338
A@@	O	-1	24971338
L	O	-1	24971338
(@@	O	-1	24971338
serum	O	-1	24971338
versus	O	-1	24971338
ur@@	O	-1	24971338
ine@@	O	-1	24971338
)	O	-1	24971338
se@@	O	-1	24971338
em@@	O	-1	24971338
s	O	-1	24971338
to	O	-1	24971338
be	O	-1	24971338
a	O	-1	24971338
fe@@	O	-1	24971338
a@@	O	-1	24971338
sible	O	-1	24971338
b@@	O	-1	24971338
i@@	O	-1	24971338
om@@	O	-1	24971338
ark@@	O	-1	24971338
er	O	-1	24971338
of	O	-1	24971338
C@@	B-Chemical	D016572	24971338
s@@	I-Chemical	-1	24971338
A	I-Chemical	-1	24971338
re@@	O	-1	24971338
pl@@	O	-1	24971338
ac@@	O	-1	24971338
ement	O	-1	24971338
to	O	-1	24971338
SR@@	B-Chemical	D020123	24971338
L	I-Chemical	-1	24971338
.	O	-1	24971338

K@@	O	-1	24975837
in@@	O	-1	24975837
in	O	-1	24975837
B@@	O	-1	24975837
2	O	-1	24975837
receptor	O	-1	24975837
de@@	O	-1	24975837
le@@	O	-1	24975837
tion	O	-1	24975837
and	O	-1	24975837
block@@	O	-1	24975837
age	O	-1	24975837
ame@@	O	-1	24975837
li@@	O	-1	24975837
or@@	O	-1	24975837
ates	O	-1	24975837
cisplatin	B-Chemical	D002945	24975837
-induced	O	-1	24975837
acute	B-Disease	D058186	24975837
renal	I-Disease	-1	24975837
injury	I-Disease	-1	24975837
.	O	-1	24975837
C@@	B-Chemical	D002945	24975837
is@@	I-Chemical	-1	24975837
pl@@	I-Chemical	-1	24975837
atin	I-Chemical	-1	24975837
treatment	O	-1	24975837
has	O	-1	24975837
been	O	-1	24975837
ad@@	O	-1	24975837
o@@	O	-1	24975837
pt@@	O	-1	24975837
ed	O	-1	24975837
in	O	-1	24975837
some	O	-1	24975837
chemo@@	O	-1	24975837
therap@@	O	-1	24975837
i@@	O	-1	24975837
es@@	O	-1	24975837
;	O	-1	24975837
however,	O	-1	24975837
this	O	-1	24975837
drug	O	-1	24975837
can	O	-1	24975837
induce	O	-1	24975837
acute	B-Disease	D058186	24975837
kidney	I-Disease	-1	24975837
injury	I-Disease	-1	24975837
due	O	-1	24975837
its	O	-1	24975837
ability	O	-1	24975837
to	O	-1	24975837
neg@@	O	-1	24975837
atively	O	-1	24975837
aff@@	O	-1	24975837
ect	O	-1	24975837
renal	O	-1	24975837
func@@	O	-1	24975837
tion,	O	-1	24975837
au@@	O	-1	24975837
g@@	O	-1	24975837
ment	O	-1	24975837
serum	O	-1	24975837
levels	O	-1	24975837
of	O	-1	24975837
creatinine	B-Chemical	D003404	24975837
and	O	-1	24975837
ure@@	B-Chemical	D014508	24975837
a	I-Chemical	-1	24975837
,	O	-1	24975837
increase	O	-1	24975837
the	O	-1	24975837
acute	B-Disease	D007683	24975837
tub@@	I-Disease	-1	24975837
ular	I-Disease	-1	24975837
necro@@	I-Disease	-1	24975837
sis	I-Disease	-1	24975837
scor@@	O	-1	24975837
e	O	-1	24975837
and	O	-1	24975837
up@@	O	-1	24975837
-@@	O	-1	24975837
reg@@	O	-1	24975837
ul@@	O	-1	24975837
ate	O	-1	24975837
cyto@@	O	-1	24975837
kin@@	O	-1	24975837
es	O	-1	24975837
(@@	O	-1	24975837
e@@	O	-1	24975837
.@@	O	-1	24975837
g@@	O	-1	24975837
.,	O	-1	24975837
I@@	O	-1	24975837
L-@@	O	-1	24975837
1@@	O	-1	24975837
b	O	-1	24975837
and	O	-1	24975837
T@@	O	-1	24975837
N@@	O	-1	24975837
F@@	O	-1	24975837
-@@	O	-1	24975837
a@@	O	-1	24975837
).	O	-1	24975837
The	O	-1	24975837
kin@@	O	-1	24975837
in	O	-1	24975837
B@@	O	-1	24975837
2	O	-1	24975837
receptor	O	-1	24975837
has	O	-1	24975837
been	O	-1	24975837
associated	O	-1	24975837
with	O	-1	24975837
the	O	-1	24975837
inflam@@	B-Disease	D007249	24975837
m@@	I-Disease	-1	24975837
ation	I-Disease	-1	24975837
pro@@	O	-1	24975837
ces@@	O	-1	24975837
s,	O	-1	24975837
as	O	-1	24975837
well	O	-1	24975837
as	O	-1	24975837
the	O	-1	24975837
reg@@	O	-1	24975837
ulation	O	-1	24975837
of	O	-1	24975837
cyto@@	O	-1	24975837
k@@	O	-1	24975837
ine	O	-1	24975837
ex@@	O	-1	24975837
pres@@	O	-1	24975837
sion,	O	-1	24975837
and	O	-1	24975837
its	O	-1	24975837
de@@	O	-1	24975837
le@@	O	-1	24975837
tion	O	-1	24975837
resulted	O	-1	24975837
in	O	-1	24975837
an	O	-1	24975837
impro@@	O	-1	24975837
vement	O	-1	24975837
in	O	-1	24975837
the	O	-1	24975837
dia@@	B-Disease	D003928	24975837
be@@	I-Disease	-1	24975837
tic	I-Disease	-1	24975837
nephro@@	I-Disease	-1	24975837
pathy	I-Disease	-1	24975837
stat@@	O	-1	24975837
us.	O	-1	24975837
To	O	-1	24975837
ex@@	O	-1	24975837
amine	O	-1	24975837
the	O	-1	24975837
role	O	-1	24975837
of	O	-1	24975837
the	O	-1	24975837
kin@@	O	-1	24975837
in	O	-1	24975837
B@@	O	-1	24975837
2	O	-1	24975837
receptor	O	-1	24975837
in	O	-1	24975837
cisplatin	B-Chemical	D002945	24975837
-induced	O	-1	24975837
acute	B-Disease	D058186	24975837
kidney	I-Disease	-1	24975837
injury	I-Disease	-1	24975837
,	O	-1	24975837
kin@@	O	-1	24975837
in	O	-1	24975837
B@@	O	-1	24975837
2	O	-1	24975837
receptor	O	-1	24975837
k@@	O	-1	24975837
n@@	O	-1	24975837
oc@@	O	-1	24975837
k@@	O	-1	24975837
out	O	-1	24975837
mice	O	-1	24975837
were	O	-1	24975837
ch@@	O	-1	24975837
all@@	O	-1	24975837
en@@	O	-1	24975837
g@@	O	-1	24975837
ed	O	-1	24975837
with	O	-1	24975837
cisplatin	B-Chemical	D002945	24975837
.	O	-1	24975837
Ad@@	O	-1	24975837
di@@	O	-1	24975837
tion@@	O	-1	24975837
ally,	O	-1	24975837
W@@	O	-1	24975837
T	O	-1	24975837
mice	O	-1	24975837
were	O	-1	24975837
treated	O	-1	24975837
with	O	-1	24975837
a	O	-1	24975837
B@@	O	-1	24975837
2	O	-1	24975837
receptor	O	-1	24975837
antagonist	O	-1	24975837
after	O	-1	24975837
cisplatin	B-Chemical	D002945	24975837
administr@@	O	-1	24975837
ation.	O	-1	24975837
B@@	O	-1	24975837
2	O	-1	24975837
receptor@@	O	-1	24975837
-@@	O	-1	24975837
defici@@	O	-1	24975837
ent	O	-1	24975837
mice	O	-1	24975837
were	O	-1	24975837
less	O	-1	24975837
sensitive	O	-1	24975837
to	O	-1	24975837
this	O	-1	24975837
drug	O	-1	24975837
than	O	-1	24975837
the	O	-1	24975837
W@@	O	-1	24975837
T	O	-1	24975837
mic@@	O	-1	24975837
e,	O	-1	24975837
as	O	-1	24975837
shown	O	-1	24975837
by	O	-1	24975837
reduced	O	-1	24975837
weight	B-Disease	D015431	24975837
loss	I-Disease	-1	24975837
,	O	-1	24975837
bet@@	O	-1	24975837
ter	O	-1	24975837
pres@@	O	-1	24975837
er@@	O	-1	24975837
v@@	O	-1	24975837
ation	O	-1	24975837
of	O	-1	24975837
kidney	O	-1	24975837
func@@	O	-1	24975837
tion,	O	-1	24975837
do@@	O	-1	24975837
w@@	O	-1	24975837
n	O	-1	24975837
reg@@	O	-1	24975837
ulation	O	-1	24975837
of	O	-1	24975837
inflam@@	O	-1	24975837
mat@@	O	-1	24975837
ory	O	-1	24975837
cyto@@	O	-1	24975837
kin@@	O	-1	24975837
es	O	-1	24975837
and	O	-1	24975837
less	O	-1	24975837
acute	B-Disease	D007683	24975837
tub@@	I-Disease	-1	24975837
ular	I-Disease	-1	24975837
necro@@	I-Disease	-1	24975837
sis	I-Disease	-1	24975837
.	O	-1	24975837
M@@	O	-1	24975837
ore@@	O	-1	24975837
o@@	O	-1	24975837
ver,	O	-1	24975837
treatment	O	-1	24975837
with	O	-1	24975837
the	O	-1	24975837
kin@@	O	-1	24975837
in	O	-1	24975837
B@@	O	-1	24975837
2	O	-1	24975837
receptor	O	-1	24975837
antagonist	O	-1	24975837
eff@@	O	-1	24975837
ectively	O	-1	24975837
reduced	O	-1	24975837
the	O	-1	24975837
levels	O	-1	24975837
of	O	-1	24975837
serum	O	-1	24975837
creatinine	B-Chemical	D003404	24975837
and	O	-1	24975837
blood	O	-1	24975837
ure@@	B-Chemical	D014508	24975837
a	I-Chemical	-1	24975837
after	O	-1	24975837
cisplatin	B-Chemical	D002945	24975837
administr@@	O	-1	24975837
ation.	O	-1	24975837
Th@@	O	-1	24975837
us,	O	-1	24975837
our	O	-1	24975837
data	O	-1	24975837
suggest	O	-1	24975837
that	O	-1	24975837
the	O	-1	24975837
kin@@	O	-1	24975837
in	O	-1	24975837
B@@	O	-1	24975837
2	O	-1	24975837
receptor	O	-1	24975837
is	O	-1	24975837
involved	O	-1	24975837
in	O	-1	24975837
cisplatin	B-Chemical	D002945	24975837
-induced	O	-1	24975837
acute	B-Disease	D058186	24975837
kidney	I-Disease	-1	24975837
injury	I-Disease	-1	24975837
by	O	-1	24975837
medi@@	O	-1	24975837
ating	O	-1	24975837
the	O	-1	24975837
necro@@	B-Disease	D009336	24975837
tic	I-Disease	-1	24975837
pro@@	O	-1	24975837
cess	O	-1	24975837
and	O	-1	24975837
the	O	-1	24975837
expression	O	-1	24975837
of	O	-1	24975837
inflam@@	O	-1	24975837
mat@@	O	-1	24975837
ory	O	-1	24975837
cyto@@	O	-1	24975837
kin@@	O	-1	24975837
es,	O	-1	24975837
th@@	O	-1	24975837
us	O	-1	24975837
result@@	O	-1	24975837
ing	O	-1	24975837
in	O	-1	24975837
dec@@	O	-1	24975837
lin@@	O	-1	24975837
ed	O	-1	24975837
renal	O	-1	24975837
func@@	O	-1	24975837
tion.	O	-1	24975837
These	O	-1	24975837
results	O	-1	24975837
high@@	O	-1	24975837
li@@	O	-1	24975837
ght	O	-1	24975837
the	O	-1	24975837
kin@@	O	-1	24975837
in	O	-1	24975837
B@@	O	-1	24975837
2	O	-1	24975837
receptor	O	-1	24975837
antagonist	O	-1	24975837
treatment	O	-1	24975837
in	O	-1	24975837
ame@@	O	-1	24975837
li@@	O	-1	24975837
or@@	O	-1	24975837
ation	O	-1	24975837
of	O	-1	24975837
nephro@@	B-Disease	D007674	24975837
toxicity	I-Disease	-1	24975837
induced	O	-1	24975837
by	O	-1	24975837
cisplatin	B-Chemical	D002945	24975837
therapy.	O	-1	24975837

S@@	O	-1	24999722
af@@	O	-1	24999722
ety	O	-1	24999722
and	O	-1	24999722
efficacy	O	-1	24999722
of	O	-1	24999722
flu@@	B-Chemical	D005446	24999722
oc@@	I-Chemical	-1	24999722
in@@	I-Chemical	-1	24999722
ol@@	I-Chemical	-1	24999722
one	I-Chemical	-1	24999722
acet@@	I-Chemical	-1	24999722
on@@	I-Chemical	-1	24999722
ide	I-Chemical	-1	24999722
intra@@	O	-1	24999722
vit@@	O	-1	24999722
re@@	O	-1	24999722
al	O	-1	24999722
im@@	O	-1	24999722
pl@@	O	-1	24999722
ant	O	-1	24999722
(0.@@	O	-1	24999722
5@@	O	-1	24999722
9	O	-1	24999722
mg@@	O	-1	24999722
)	O	-1	24999722
in	O	-1	24999722
b@@	B-Disease	C537630	24999722
ir@@	I-Disease	-1	24999722
d@@	I-Disease	-1	24999722
sho@@	I-Disease	-1	24999722
t	I-Disease	-1	24999722
ret@@	I-Disease	-1	24999722
in@@	I-Disease	-1	24999722
och@@	I-Disease	-1	24999722
o@@	I-Disease	-1	24999722
ro@@	I-Disease	-1	24999722
id@@	I-Disease	-1	24999722
o@@	I-Disease	-1	24999722
pathy	I-Disease	-1	24999722
.	O	-1	24999722
P@@	O	-1	24999722
U@@	O	-1	24999722
R@@	O	-1	24999722
P@@	O	-1	24999722
O@@	O	-1	24999722
S@@	O	-1	24999722
E:	O	-1	24999722
To	O	-1	24999722
report	O	-1	24999722
the	O	-1	24999722
treatment	O	-1	24999722
outcom@@	O	-1	24999722
es	O	-1	24999722
of	O	-1	24999722
the	O	-1	24999722
flu@@	B-Chemical	D005446	24999722
oc@@	I-Chemical	-1	24999722
in@@	I-Chemical	-1	24999722
ol@@	I-Chemical	-1	24999722
one	I-Chemical	-1	24999722
acet@@	I-Chemical	-1	24999722
on@@	I-Chemical	-1	24999722
ide	I-Chemical	-1	24999722
intra@@	O	-1	24999722
vit@@	O	-1	24999722
re@@	O	-1	24999722
al	O	-1	24999722
im@@	O	-1	24999722
pl@@	O	-1	24999722
ant	O	-1	24999722
(0.@@	O	-1	24999722
5@@	O	-1	24999722
9	O	-1	24999722
mg@@	O	-1	24999722
)	O	-1	24999722
in	O	-1	24999722
patients	O	-1	24999722
with	O	-1	24999722
b@@	B-Disease	C537630	24999722
ir@@	I-Disease	-1	24999722
d@@	I-Disease	-1	24999722
sho@@	I-Disease	-1	24999722
t	I-Disease	-1	24999722
ret@@	I-Disease	-1	24999722
in@@	I-Disease	-1	24999722
och@@	I-Disease	-1	24999722
o@@	I-Disease	-1	24999722
ro@@	I-Disease	-1	24999722
id@@	I-Disease	-1	24999722
o@@	I-Disease	-1	24999722
pathy	I-Disease	-1	24999722
wh@@	O	-1	24999722
ose	O	-1	24999722
disease	O	-1	24999722
is	O	-1	24999722
ref@@	O	-1	24999722
rac@@	O	-1	24999722
t@@	O	-1	24999722
ory	O	-1	24999722
or	O	-1	24999722
int@@	O	-1	24999722
oler@@	O	-1	24999722
ant	O	-1	24999722
to	O	-1	24999722
con@@	O	-1	24999722
ven@@	O	-1	24999722
tional	O	-1	24999722
immuno@@	O	-1	24999722
mod@@	O	-1	24999722
ul@@	O	-1	24999722
atory	O	-1	24999722
therapy.	O	-1	24999722
METHODS:	O	-1	24999722
A	O	-1	24999722
ret@@	O	-1	24999722
ro@@	O	-1	24999722
sp@@	O	-1	24999722
ective	O	-1	24999722
case	O	-1	24999722
seri@@	O	-1	24999722
es	O	-1	24999722
invol@@	O	-1	24999722
ving	O	-1	24999722
11	O	-1	24999722
b@@	B-Disease	C537630	24999722
ir@@	I-Disease	-1	24999722
d@@	I-Disease	-1	24999722
sho@@	I-Disease	-1	24999722
t	I-Disease	-1	24999722
ret@@	I-Disease	-1	24999722
in@@	I-Disease	-1	24999722
och@@	I-Disease	-1	24999722
o@@	I-Disease	-1	24999722
ro@@	I-Disease	-1	24999722
id@@	I-Disease	-1	24999722
o@@	I-Disease	-1	24999722
pathy	I-Disease	-1	24999722
patients	O	-1	24999722
(1@@	O	-1	24999722
1	O	-1	24999722
e@@	O	-1	24999722
y@@	O	-1	24999722
es@@	O	-1	24999722
).	O	-1	24999722
E@@	O	-1	24999722
le@@	O	-1	24999722
ven	O	-1	24999722
patients	O	-1	24999722
(1@@	O	-1	24999722
1	O	-1	24999722
e@@	O	-1	24999722
y@@	O	-1	24999722
es@@	O	-1	24999722
)	O	-1	24999722
under@@	O	-1	24999722
w@@	O	-1	24999722
ent	O	-1	24999722
surger@@	O	-1	24999722
y	O	-1	24999722
for	O	-1	24999722
flu@@	B-Chemical	D005446	24999722
oc@@	I-Chemical	-1	24999722
in@@	I-Chemical	-1	24999722
ol@@	I-Chemical	-1	24999722
one	I-Chemical	-1	24999722
acet@@	I-Chemical	-1	24999722
on@@	I-Chemical	-1	24999722
ide	I-Chemical	-1	24999722
im@@	O	-1	24999722
pl@@	O	-1	24999722
ant	O	-1	24999722
(0.@@	O	-1	24999722
5@@	O	-1	24999722
9	O	-1	24999722
mg@@	O	-1	24999722
).	O	-1	24999722
Treat@@	O	-1	24999722
ment	O	-1	24999722
outcom@@	O	-1	24999722
es	O	-1	24999722
of	O	-1	24999722
in@@	O	-1	24999722
te@@	O	-1	24999722
res@@	O	-1	24999722
t	O	-1	24999722
were	O	-1	24999722
not@@	O	-1	24999722
ed	O	-1	24999722
at	O	-1	24999722
basel@@	O	-1	24999722
ine,	O	-1	24999722
before	O	-1	24999722
flu@@	B-Chemical	D005446	24999722
oc@@	I-Chemical	-1	24999722
in@@	I-Chemical	-1	24999722
ol@@	I-Chemical	-1	24999722
one	I-Chemical	-1	24999722
acet@@	I-Chemical	-1	24999722
on@@	I-Chemical	-1	24999722
ide	I-Chemical	-1	24999722
im@@	O	-1	24999722
pl@@	O	-1	24999722
ant@@	O	-1	24999722
,	O	-1	24999722
and	O	-1	24999722
then	O	-1	24999722
at	O	-1	24999722
6	O	-1	24999722
month@@	O	-1	24999722
s,	O	-1	24999722
1	O	-1	24999722
year@@	O	-1	24999722
,	O	-1	24999722
2	O	-1	24999722
year@@	O	-1	24999722
s,	O	-1	24999722
3	O	-1	24999722
year@@	O	-1	24999722
s,	O	-1	24999722
and	O	-1	24999722
be@@	O	-1	24999722
y@@	O	-1	24999722
on@@	O	-1	24999722
d	O	-1	24999722
3	O	-1	24999722
year@@	O	-1	24999722
s.	O	-1	24999722
Di@@	O	-1	24999722
se@@	O	-1	24999722
ase	O	-1	24999722
activity	O	-1	24999722
mark@@	O	-1	24999722
er@@	O	-1	24999722
s,	O	-1	24999722
including	O	-1	24999722
signs	O	-1	24999722
of	O	-1	24999722
oc@@	O	-1	24999722
ular	O	-1	24999722
inflam@@	B-Disease	D007249	24999722
m@@	I-Disease	-1	24999722
ation	I-Disease	-1	24999722
,	O	-1	24999722
evidence	O	-1	24999722
of	O	-1	24999722
ret@@	B-Disease	D031300	24999722
inal	I-Disease	-1	24999722
vas@@	I-Disease	-1	24999722
cul@@	I-Disease	-1	24999722
iti@@	I-Disease	-1	24999722
s	I-Disease	-1	24999722
,	O	-1	24999722
S@@	O	-1	24999722
we@@	O	-1	24999722
dis@@	O	-1	24999722
h	O	-1	24999722
inter@@	O	-1	24999722
active	O	-1	24999722
th@@	O	-1	24999722
res@@	O	-1	24999722
h@@	O	-1	24999722
old	O	-1	24999722
al@@	O	-1	24999722
g@@	O	-1	24999722
or@@	O	-1	24999722
i@@	O	-1	24999722
th@@	O	-1	24999722
m@@	O	-1	24999722
-@@	O	-1	24999722
sh@@	O	-1	24999722
ort	O	-1	24999722
w@@	O	-1	24999722
a@@	O	-1	24999722
vel@@	O	-1	24999722
en@@	O	-1	24999722
g@@	O	-1	24999722
th	O	-1	24999722
auto@@	O	-1	24999722
m@@	O	-1	24999722
ated	O	-1	24999722
peri@@	O	-1	24999722
met@@	O	-1	24999722
r@@	O	-1	24999722
y	O	-1	24999722
H@@	O	-1	24999722
um@@	O	-1	24999722
ph@@	O	-1	24999722
re@@	O	-1	24999722
y	O	-1	24999722
visual	O	-1	24999722
fi@@	O	-1	24999722
el@@	O	-1	24999722
d	O	-1	24999722
analy@@	O	-1	24999722
sis,	O	-1	24999722
electro@@	O	-1	24999722
ret@@	O	-1	24999722
in@@	O	-1	24999722
ograph@@	O	-1	24999722
ic	O	-1	24999722
par@@	O	-1	24999722
ame@@	O	-1	24999722
ter@@	O	-1	24999722
s,	O	-1	24999722
and	O	-1	24999722
op@@	O	-1	24999722
tical	O	-1	24999722
co@@	O	-1	24999722
he@@	O	-1	24999722
rence	O	-1	24999722
to@@	O	-1	24999722
mo@@	O	-1	24999722
graph@@	O	-1	24999722
y	O	-1	24999722
were	O	-1	24999722
recor@@	O	-1	24999722
de@@	O	-1	24999722
d.	O	-1	24999722
D@@	O	-1	24999722
at@@	O	-1	24999722
a	O	-1	24999722
on	O	-1	24999722
occur@@	O	-1	24999722
rence	O	-1	24999722
of	O	-1	24999722
cat@@	B-Disease	D002386	24999722
arac@@	I-Disease	-1	24999722
t	I-Disease	-1	24999722
and	O	-1	24999722
ra@@	B-Disease	D009798	24999722
is@@	I-Disease	-1	24999722
ed	I-Disease	-1	24999722
intra@@	I-Disease	-1	24999722
oc@@	I-Disease	-1	24999722
ular	I-Disease	-1	24999722
pressure	I-Disease	-1	24999722
were	O	-1	24999722
coll@@	O	-1	24999722
ected	O	-1	24999722
in	O	-1	24999722
all	O	-1	24999722
e@@	O	-1	24999722
y@@	O	-1	24999722
es.	O	-1	24999722
RESULTS:	O	-1	24999722
In@@	O	-1	24999722
tra@@	O	-1	24999722
oc@@	O	-1	24999722
ular	O	-1	24999722
inflam@@	B-Disease	D007249	24999722
m@@	I-Disease	-1	24999722
ation	I-Disease	-1	24999722
was	O	-1	24999722
present	O	-1	24999722
in	O	-1	24999722
5@@	O	-1	24999722
4.@@	O	-1	24999722
5,	O	-1	24999722
9.@@	O	-1	24999722
9@@	O	-1	24999722
,	O	-1	24999722
1@@	O	-1	24999722
1.@@	O	-1	24999722
1,	O	-1	24999722
and	O	-1	24999722
0%	O	-1	24999722
of	O	-1	24999722
patients	O	-1	24999722
at	O	-1	24999722
basel@@	O	-1	24999722
ine,	O	-1	24999722
6	O	-1	24999722
month@@	O	-1	24999722
s,	O	-1	24999722
1	O	-1	24999722
year@@	O	-1	24999722
,	O	-1	24999722
2	O	-1	24999722
year@@	O	-1	24999722
s,	O	-1	24999722
3	O	-1	24999722
year@@	O	-1	24999722
s,	O	-1	24999722
and	O	-1	24999722
be@@	O	-1	24999722
y@@	O	-1	24999722
on@@	O	-1	24999722
d	O	-1	24999722
3	O	-1	24999722
years	O	-1	24999722
after	O	-1	24999722
receiving	O	-1	24999722
the	O	-1	24999722
im@@	O	-1	24999722
pl@@	O	-1	24999722
ant@@	O	-1	24999722
,	O	-1	24999722
respectively.	O	-1	24999722
Ac@@	O	-1	24999722
tive	O	-1	24999722
vas@@	B-Disease	D014657	24999722
cul@@	I-Disease	-1	24999722
iti@@	I-Disease	-1	24999722
s	I-Disease	-1	24999722
was	O	-1	24999722
not@@	O	-1	24999722
ed	O	-1	24999722
in	O	-1	24999722
3@@	O	-1	24999722
6.@@	O	-1	24999722
3@@	O	-1	24999722
%	O	-1	24999722
patients	O	-1	24999722
at	O	-1	24999722
baseline	O	-1	24999722
and	O	-1	24999722
0%	O	-1	24999722
at	O	-1	24999722
3	O	-1	24999722
years	O	-1	24999722
of	O	-1	24999722
follow-@@	O	-1	24999722
up@@	O	-1	24999722
.	O	-1	24999722
M@@	O	-1	24999722
or@@	O	-1	24999722
e	O	-1	24999722
than	O	-1	24999722
20@@	O	-1	24999722
%	O	-1	24999722
(4@@	O	-1	24999722
7.@@	O	-1	24999722
6@@	O	-1	24999722
1-@@	O	-1	24999722
6@@	O	-1	24999722
7.@@	O	-1	24999722
2@@	O	-1	24999722
%)	O	-1	24999722
reduction	O	-1	24999722
in	O	-1	24999722
central	O	-1	24999722
ret@@	O	-1	24999722
inal	O	-1	24999722
th@@	O	-1	24999722
ic@@	O	-1	24999722
k@@	O	-1	24999722
ness	O	-1	24999722
was	O	-1	24999722
not@@	O	-1	24999722
ed	O	-1	24999722
in	O	-1	24999722
all	O	-1	24999722
patients	O	-1	24999722
with	O	-1	24999722
cy@@	B-Disease	D008269	24999722
sto@@	I-Disease	-1	24999722
id	I-Disease	-1	24999722
mac@@	I-Disease	-1	24999722
ular	I-Disease	-1	24999722
e@@	I-Disease	-1	24999722
de@@	I-Disease	-1	24999722
ma	I-Disease	-1	24999722
at	O	-1	24999722
6	O	-1	24999722
month@@	O	-1	24999722
s,	O	-1	24999722
1	O	-1	24999722
year@@	O	-1	24999722
,	O	-1	24999722
2	O	-1	24999722
year@@	O	-1	24999722
s,	O	-1	24999722
and	O	-1	24999722
3	O	-1	24999722
years	O	-1	24999722
pos@@	O	-1	24999722
tim@@	O	-1	24999722
pl@@	O	-1	24999722
ant@@	O	-1	24999722
.	O	-1	24999722
A@@	O	-1	24999722
t	O	-1	24999722
basel@@	O	-1	24999722
ine,	O	-1	24999722
5@@	O	-1	24999722
4.@@	O	-1	24999722
5%	O	-1	24999722
patients	O	-1	24999722
were	O	-1	24999722
on	O	-1	24999722
immuno@@	O	-1	24999722
mod@@	O	-1	24999722
ul@@	O	-1	24999722
atory	O	-1	24999722
agent@@	O	-1	24999722
s.	O	-1	24999722
This	O	-1	24999722
perc@@	O	-1	24999722
ent@@	O	-1	24999722
age	O	-1	24999722
decreased	O	-1	24999722
to	O	-1	24999722
4@@	O	-1	24999722
5.@@	O	-1	24999722
4@@	O	-1	24999722
5,	O	-1	24999722
4@@	O	-1	24999722
4.@@	O	-1	24999722
4@@	O	-1	24999722
,	O	-1	24999722
and	O	-1	24999722
1@@	O	-1	24999722
4.@@	O	-1	24999722
2@@	O	-1	24999722
8@@	O	-1	24999722
%	O	-1	24999722
at	O	-1	24999722
1	O	-1	24999722
year@@	O	-1	24999722
,	O	-1	24999722
2	O	-1	24999722
year@@	O	-1	24999722
s,	O	-1	24999722
and	O	-1	24999722
3	O	-1	24999722
years	O	-1	24999722
pos@@	O	-1	24999722
tim@@	O	-1	24999722
pl@@	O	-1	24999722
ant@@	O	-1	24999722
,	O	-1	24999722
respectively.	O	-1	24999722
Ad@@	O	-1	24999722
verse	O	-1	24999722
events	O	-1	24999722
included	O	-1	24999722
increased	B-Disease	D009798	24999722
intra@@	I-Disease	-1	24999722
oc@@	I-Disease	-1	24999722
ular	I-Disease	-1	24999722
pressure	I-Disease	-1	24999722
(5@@	O	-1	24999722
4.@@	O	-1	24999722
5@@	O	-1	24999722
%)	O	-1	24999722
and	O	-1	24999722
cat@@	B-Disease	D002386	24999722
arac@@	I-Disease	-1	24999722
t	I-Disease	-1	24999722
formation	O	-1	24999722
(@@	O	-1	24999722
10@@	O	-1	24999722
0@@	O	-1	24999722
%).	O	-1	24999722
CONCLUSION:	O	-1	24999722
The	O	-1	24999722
data	O	-1	24999722
suggest	O	-1	24999722
that	O	-1	24999722
flu@@	B-Chemical	D005446	24999722
oc@@	I-Chemical	-1	24999722
in@@	I-Chemical	-1	24999722
ol@@	I-Chemical	-1	24999722
one	I-Chemical	-1	24999722
acet@@	I-Chemical	-1	24999722
on@@	I-Chemical	-1	24999722
ide	I-Chemical	-1	24999722
im@@	O	-1	24999722
pl@@	O	-1	24999722
ant	O	-1	24999722
(0.@@	O	-1	24999722
5@@	O	-1	24999722
9	O	-1	24999722
mg@@	O	-1	24999722
)	O	-1	24999722
he@@	O	-1	24999722
l@@	O	-1	24999722
p@@	O	-1	24999722
s	O	-1	24999722
to	O	-1	24999722
control	O	-1	24999722
inflam@@	B-Disease	D007249	24999722
m@@	I-Disease	-1	24999722
ation	I-Disease	-1	24999722
in	O	-1	24999722
o@@	O	-1	24999722
ther@@	O	-1	24999722
w@@	O	-1	24999722
is@@	O	-1	24999722
e	O	-1	24999722
treatment@@	O	-1	24999722
-@@	O	-1	24999722
ref@@	O	-1	24999722
rac@@	O	-1	24999722
t@@	O	-1	24999722
ory	O	-1	24999722
cases	O	-1	24999722
of	O	-1	24999722
b@@	B-Disease	C537630	24999722
ir@@	I-Disease	-1	24999722
d@@	I-Disease	-1	24999722
sho@@	I-Disease	-1	24999722
t	I-Disease	-1	24999722
ret@@	I-Disease	-1	24999722
in@@	I-Disease	-1	24999722
och@@	I-Disease	-1	24999722
o@@	I-Disease	-1	24999722
ro@@	I-Disease	-1	24999722
id@@	I-Disease	-1	24999722
o@@	I-Disease	-1	24999722
pathy	I-Disease	-1	24999722
.	O	-1	24999722
It	O	-1	24999722
is	O	-1	24999722
associated	O	-1	24999722
with	O	-1	24999722
significant	O	-1	24999722
side	O	-1	24999722
effects	O	-1	24999722
of	O	-1	24999722
cat@@	B-Disease	D002386	24999722
arac@@	I-Disease	-1	24999722
t	I-Disease	-1	24999722
and	O	-1	24999722
oc@@	B-Disease	D009798	24999722
ular	I-Disease	-1	24999722
hypertension	I-Disease	-1	24999722
requ@@	O	-1	24999722
ir@@	O	-1	24999722
ing	O	-1	24999722
treatment.	O	-1	24999722

O@@	O	-1	25006369
p@@	O	-1	25006369
tim@@	O	-1	25006369
al	O	-1	25006369
pre@@	O	-1	25006369
cur@@	O	-1	25006369
ar@@	O	-1	25006369
iz@@	O	-1	25006369
ing	O	-1	25006369
dose	O	-1	25006369
of	O	-1	25006369
ro@@	B-Chemical	C061870	25006369
cur@@	I-Chemical	-1	25006369
oni@@	I-Chemical	-1	25006369
um	I-Chemical	-1	25006369
to	O	-1	25006369
decrease	O	-1	25006369
f@@	B-Disease	D005207	25006369
as@@	I-Disease	-1	25006369
c@@	I-Disease	-1	25006369
ic@@	I-Disease	-1	25006369
ulation	I-Disease	-1	25006369
and	O	-1	25006369
my@@	B-Disease	D063806	25006369
al@@	I-Disease	-1	25006369
g@@	I-Disease	-1	25006369
ia	I-Disease	-1	25006369
following	O	-1	25006369
suc@@	B-Chemical	D013390	25006369
cin@@	I-Chemical	-1	25006369
ylcholine	I-Chemical	-1	25006369
administr@@	O	-1	25006369
ation.	O	-1	25006369
BACKGROUND:	O	-1	25006369
S@@	B-Chemical	D013390	25006369
uc@@	I-Chemical	-1	25006369
cin@@	I-Chemical	-1	25006369
ylcholine	I-Chemical	-1	25006369
common@@	O	-1	25006369
ly	O	-1	25006369
produc@@	O	-1	25006369
es	O	-1	25006369
frequent	O	-1	25006369
adverse	O	-1	25006369
effect@@	O	-1	25006369
s,	O	-1	25006369
including	O	-1	25006369
musc@@	B-Disease	D005207	25006369
le	I-Disease	-1	25006369
f@@	I-Disease	-1	25006369
as@@	I-Disease	-1	25006369
c@@	I-Disease	-1	25006369
ic@@	I-Disease	-1	25006369
ulation	I-Disease	-1	25006369
and	O	-1	25006369
my@@	B-Disease	D063806	25006369
al@@	I-Disease	-1	25006369
g@@	I-Disease	-1	25006369
ia	I-Disease	-1	25006369
.	O	-1	25006369
The	O	-1	25006369
current	O	-1	25006369
study	O	-1	25006369
identi@@	O	-1	25006369
fied	O	-1	25006369
the	O	-1	25006369
op@@	O	-1	25006369
tim@@	O	-1	25006369
al	O	-1	25006369
dose	O	-1	25006369
of	O	-1	25006369
ro@@	B-Chemical	C061870	25006369
cur@@	I-Chemical	-1	25006369
oni@@	I-Chemical	-1	25006369
um	I-Chemical	-1	25006369
to	O	-1	25006369
prev@@	O	-1	25006369
ent	O	-1	25006369
suc@@	B-Chemical	D013390	25006369
cin@@	I-Chemical	-1	25006369
ylcholine	I-Chemical	-1	25006369
-induced	O	-1	25006369
f@@	B-Disease	D005207	25006369
as@@	I-Disease	-1	25006369
c@@	I-Disease	-1	25006369
ic@@	I-Disease	-1	25006369
ulation	I-Disease	-1	25006369
and	O	-1	25006369
my@@	B-Disease	D063806	25006369
al@@	I-Disease	-1	25006369
g@@	I-Disease	-1	25006369
ia	I-Disease	-1	25006369
and	O	-1	25006369
evaluated	O	-1	25006369
the	O	-1	25006369
influence	O	-1	25006369
of	O	-1	25006369
ro@@	B-Chemical	C061870	25006369
cur@@	I-Chemical	-1	25006369
oni@@	I-Chemical	-1	25006369
um	I-Chemical	-1	25006369
on	O	-1	25006369
the	O	-1	25006369
sp@@	O	-1	25006369
e@@	O	-1	25006369
ed	O	-1	25006369
of	O	-1	25006369
onset	O	-1	25006369
produced	O	-1	25006369
by	O	-1	25006369
suc@@	B-Chemical	D013390	25006369
cin@@	I-Chemical	-1	25006369
ylcholine	I-Chemical	-1	25006369
.	O	-1	25006369
METHODS:	O	-1	25006369
This	O	-1	25006369
random@@	O	-1	25006369
iz@@	O	-1	25006369
ed,	O	-1	25006369
double-bl@@	O	-1	25006369
ind@@	O	-1	25006369
ed	O	-1	25006369
study	O	-1	25006369
was	O	-1	25006369
con@@	O	-1	25006369
duc@@	O	-1	25006369
ted	O	-1	25006369
in	O	-1	25006369
100	O	-1	25006369
patients	O	-1	25006369
random@@	O	-1	25006369
ly	O	-1	25006369
al@@	O	-1	25006369
loc@@	O	-1	25006369
ated	O	-1	25006369
into	O	-1	25006369
five	O	-1	25006369
groups	O	-1	25006369
of	O	-1	25006369
20	O	-1	25006369
patients	O	-1	25006369
e@@	O	-1	25006369
ac@@	O	-1	25006369
h@@	O	-1	25006369
.	O	-1	25006369
Patients	O	-1	25006369
were	O	-1	25006369
randomized	O	-1	25006369
to	O	-1	25006369
recei@@	O	-1	25006369
ve	O	-1	25006369
0.0@@	O	-1	25006369
2,	O	-1	25006369
0.0@@	O	-1	25006369
3,	O	-1	25006369
0.0@@	O	-1	25006369
4@@	O	-1	25006369
,	O	-1	25006369
0.0@@	O	-1	25006369
5	O	-1	25006369
and	O	-1	25006369
0.0@@	O	-1	25006369
6	O	-1	25006369
mg/kg	O	-1	25006369
ro@@	B-Chemical	C061870	25006369
cur@@	I-Chemical	-1	25006369
oni@@	I-Chemical	-1	25006369
um	I-Chemical	-1	25006369
as	O	-1	25006369
a	O	-1	25006369
pre@@	O	-1	25006369
cur@@	O	-1	25006369
ar@@	O	-1	25006369
iz@@	O	-1	25006369
ing	O	-1	25006369
dose.	O	-1	25006369
Ne@@	O	-1	25006369
uro@@	O	-1	25006369
mus@@	O	-1	25006369
cular	O	-1	25006369
monit@@	O	-1	25006369
or@@	O	-1	25006369
ing	O	-1	25006369
after	O	-1	25006369
each	O	-1	25006369
pre@@	O	-1	25006369
cur@@	O	-1	25006369
ar@@	O	-1	25006369
iz@@	O	-1	25006369
ing	O	-1	25006369
dose	O	-1	25006369
was	O	-1	25006369
recor@@	O	-1	25006369
ded	O	-1	25006369
from	O	-1	25006369
the	O	-1	25006369
ad@@	O	-1	25006369
duc@@	O	-1	25006369
t@@	O	-1	25006369
or	O	-1	25006369
pol@@	O	-1	25006369
l@@	O	-1	25006369
ic@@	O	-1	25006369
is	O	-1	25006369
musc@@	O	-1	25006369
le	O	-1	25006369
using	O	-1	25006369
ac@@	O	-1	25006369
ce@@	O	-1	25006369
l@@	O	-1	25006369
er@@	O	-1	25006369
om@@	O	-1	25006369
y@@	O	-1	25006369
ograph@@	O	-1	25006369
y	O	-1	25006369
with	O	-1	25006369
tra@@	O	-1	25006369
in-@@	O	-1	25006369
of@@	O	-1	25006369
-@@	O	-1	25006369
four	O	-1	25006369
stimulation	O	-1	25006369
of	O	-1	25006369
the	O	-1	25006369
ul@@	O	-1	25006369
n@@	O	-1	25006369
ar	O	-1	25006369
ner@@	O	-1	25006369
ve.	O	-1	25006369
All	O	-1	25006369
patients	O	-1	25006369
received	O	-1	25006369
suc@@	B-Chemical	D013390	25006369
cin@@	I-Chemical	-1	25006369
ylcholine	I-Chemical	-1	25006369
1.@@	O	-1	25006369
5	O	-1	25006369
mg/kg	O	-1	25006369
at	O	-1	25006369
2	O	-1	25006369
minutes	O	-1	25006369
after	O	-1	25006369
the	O	-1	25006369
pre@@	O	-1	25006369
cur@@	O	-1	25006369
ar@@	O	-1	25006369
iz@@	O	-1	25006369
ation,	O	-1	25006369
and	O	-1	25006369
were	O	-1	25006369
assessed	O	-1	25006369
the	O	-1	25006369
incidence	O	-1	25006369
and	O	-1	25006369
severity	O	-1	25006369
of	O	-1	25006369
f@@	B-Disease	D005207	25006369
as@@	I-Disease	-1	25006369
c@@	I-Disease	-1	25006369
ic@@	I-Disease	-1	25006369
ul@@	I-Disease	-1	25006369
ations	I-Disease	-1	25006369
,	O	-1	25006369
while	O	-1	25006369
my@@	B-Disease	D063806	25006369
al@@	I-Disease	-1	25006369
g@@	I-Disease	-1	25006369
ia	I-Disease	-1	25006369
was	O	-1	25006369
assessed	O	-1	25006369
at	O	-1	25006369
24	O	-1	25006369
hours	O	-1	25006369
after	O	-1	25006369
surger@@	O	-1	25006369
y.	O	-1	25006369
RESULTS:	O	-1	25006369
The	O	-1	25006369
incidence	O	-1	25006369
and	O	-1	25006369
severity	O	-1	25006369
of	O	-1	25006369
vi@@	O	-1	25006369
sible	O	-1	25006369
musc@@	B-Disease	D005207	25006369
le	I-Disease	-1	25006369
f@@	I-Disease	-1	25006369
as@@	I-Disease	-1	25006369
c@@	I-Disease	-1	25006369
ic@@	I-Disease	-1	25006369
ulation	I-Disease	-1	25006369
was	O	-1	25006369
significantly	O	-1	25006369
less	O	-1	25006369
with	O	-1	25006369
increas@@	O	-1	25006369
ing	O	-1	25006369
the	O	-1	25006369
amoun@@	O	-1	25006369
t	O	-1	25006369
of	O	-1	25006369
pre@@	O	-1	25006369
cur@@	O	-1	25006369
ar@@	O	-1	25006369
iz@@	O	-1	25006369
ing	O	-1	25006369
dose	O	-1	25006369
of	O	-1	25006369
ro@@	B-Chemical	C061870	25006369
cur@@	I-Chemical	-1	25006369
oni@@	I-Chemical	-1	25006369
um	I-Chemical	-1	25006369
(P	O	-1	25006369
<	O	-1	25006369
0.00@@	O	-1	25006369
1).	O	-1	25006369
Th@@	O	-1	25006369
ose	O	-1	25006369
of	O	-1	25006369
my@@	B-Disease	D063806	25006369
al@@	I-Disease	-1	25006369
g@@	I-Disease	-1	25006369
ia	I-Disease	-1	25006369
ten@@	O	-1	25006369
d	O	-1	25006369
to	O	-1	25006369
decrease	O	-1	25006369
ac@@	O	-1	25006369
cor@@	O	-1	25006369
ding	O	-1	25006369
to	O	-1	25006369
increas@@	O	-1	25006369
ing	O	-1	25006369
the	O	-1	25006369
amoun@@	O	-1	25006369
t	O	-1	25006369
of	O	-1	25006369
pre@@	O	-1	25006369
cur@@	O	-1	25006369
ar@@	O	-1	25006369
iz@@	O	-1	25006369
ing	O	-1	25006369
dose	O	-1	25006369
of	O	-1	25006369
ro@@	B-Chemical	C061870	25006369
cur@@	I-Chemical	-1	25006369
oni@@	I-Chemical	-1	25006369
um	I-Chemical	-1	25006369
,	O	-1	25006369
but	O	-1	25006369
there	O	-1	25006369
was	O	-1	25006369
no	O	-1	25006369
signific@@	O	-1	25006369
ance	O	-1	25006369
(P	O	-1	25006369
=	O	-1	25006369
0.0@@	O	-1	25006369
7@@	O	-1	25006369
2@@	O	-1	25006369
).	O	-1	25006369
The	O	-1	25006369
onset	O	-1	25006369
time	O	-1	25006369
of	O	-1	25006369
suc@@	B-Chemical	D013390	25006369
cin@@	I-Chemical	-1	25006369
ylcholine	I-Chemical	-1	25006369
was	O	-1	25006369
significantly	O	-1	25006369
long@@	O	-1	25006369
er	O	-1	25006369
with	O	-1	25006369
increas@@	O	-1	25006369
ing	O	-1	25006369
the	O	-1	25006369
amoun@@	O	-1	25006369
t	O	-1	25006369
of	O	-1	25006369
pre@@	O	-1	25006369
cur@@	O	-1	25006369
ar@@	O	-1	25006369
iz@@	O	-1	25006369
ing	O	-1	25006369
dose	O	-1	25006369
of	O	-1	25006369
ro@@	B-Chemical	C061870	25006369
cur@@	I-Chemical	-1	25006369
oni@@	I-Chemical	-1	25006369
um	I-Chemical	-1	25006369
(P	O	-1	25006369
<	O	-1	25006369
0.00@@	O	-1	25006369
1).	O	-1	25006369
CONCLUSIONS:	O	-1	25006369
P@@	O	-1	25006369
recur@@	O	-1	25006369
ar@@	O	-1	25006369
ization	O	-1	25006369
with	O	-1	25006369
0.0@@	O	-1	25006369
4	O	-1	25006369
mg/kg	O	-1	25006369
ro@@	B-Chemical	C061870	25006369
cur@@	I-Chemical	-1	25006369
oni@@	I-Chemical	-1	25006369
um	I-Chemical	-1	25006369
was	O	-1	25006369
the	O	-1	25006369
op@@	O	-1	25006369
tim@@	O	-1	25006369
al	O	-1	25006369
dose	O	-1	25006369
con@@	O	-1	25006369
si@@	O	-1	25006369
der@@	O	-1	25006369
ing	O	-1	25006369
the	O	-1	25006369
reduction	O	-1	25006369
in	O	-1	25006369
the	O	-1	25006369
incidence	O	-1	25006369
and	O	-1	25006369
severity	O	-1	25006369
of	O	-1	25006369
f@@	B-Disease	D005207	25006369
as@@	I-Disease	-1	25006369
c@@	I-Disease	-1	25006369
ic@@	I-Disease	-1	25006369
ulation	I-Disease	-1	25006369
and	O	-1	25006369
my@@	B-Disease	D063806	25006369
al@@	I-Disease	-1	25006369
g@@	I-Disease	-1	25006369
ia	I-Disease	-1	25006369
with	O	-1	25006369
ac@@	O	-1	25006369
ce@@	O	-1	25006369
pt@@	O	-1	25006369
able	O	-1	25006369
onset	O	-1	25006369
ti@@	O	-1	25006369
me,	O	-1	25006369
and	O	-1	25006369
the	O	-1	25006369
saf@@	O	-1	25006369
e	O	-1	25006369
and	O	-1	25006369
effective	O	-1	25006369
pre@@	O	-1	25006369
cur@@	O	-1	25006369
ar@@	O	-1	25006369
iz@@	O	-1	25006369
ation.	O	-1	25006369

A@@	O	-1	25006961
b@@	O	-1	25006961
s@@	O	-1	25006961
ence	O	-1	25006961
of	O	-1	25006961
P@@	O	-1	25006961
K@@	O	-1	25006961
C@@	O	-1	25006961
-@@	O	-1	25006961
al@@	O	-1	25006961
ph@@	O	-1	25006961
a	O	-1	25006961
attenu@@	O	-1	25006961
ates	O	-1	25006961
lithium	B-Chemical	D008094	25006961
-induced	O	-1	25006961
nephro@@	B-Disease	D018500	25006961
genic	I-Disease	-1	25006961
dia@@	I-Disease	-1	25006961
bet@@	I-Disease	-1	25006961
es	I-Disease	-1	25006961
in@@	I-Disease	-1	25006961
si@@	I-Disease	-1	25006961
pid@@	I-Disease	-1	25006961
us	I-Disease	-1	25006961
.	O	-1	25006961
L@@	B-Chemical	D008094	25006961
i@@	I-Chemical	-1	25006961
thi@@	I-Chemical	-1	25006961
um	I-Chemical	-1	25006961
,	O	-1	25006961
an	O	-1	25006961
effective	O	-1	25006961
anti@@	O	-1	25006961
psycho@@	O	-1	25006961
tic@@	O	-1	25006961
,	O	-1	25006961
induc@@	O	-1	25006961
es	O	-1	25006961
nephro@@	B-Disease	D018500	25006961
genic	I-Disease	-1	25006961
dia@@	I-Disease	-1	25006961
bet@@	I-Disease	-1	25006961
es	I-Disease	-1	25006961
in@@	I-Disease	-1	25006961
si@@	I-Disease	-1	25006961
pid@@	I-Disease	-1	25006961
us	I-Disease	-1	25006961
(	O	-1	25006961
N@@	B-Disease	D018500	25006961
D@@	I-Disease	-1	25006961
I	I-Disease	-1	25006961
)	O	-1	25006961
in	O	-1	25006961
4@@	O	-1	25006961
0%	O	-1	25006961
of	O	-1	25006961
patients.	O	-1	25006961
The	O	-1	25006961
decreased	O	-1	25006961
cap@@	O	-1	25006961
ac@@	O	-1	25006961
ity	O	-1	25006961
to	O	-1	25006961
con@@	O	-1	25006961
c@@	O	-1	25006961
ent@@	O	-1	25006961
rate	O	-1	25006961
urine	O	-1	25006961
is	O	-1	25006961
likely	O	-1	25006961
due	O	-1	25006961
to	O	-1	25006961
lithium	B-Chemical	D008094	25006961
ac@@	O	-1	25006961
u@@	O	-1	25006961
te@@	O	-1	25006961
ly	O	-1	25006961
dis@@	O	-1	25006961
ru@@	O	-1	25006961
pt@@	O	-1	25006961
ing	O	-1	25006961
the	O	-1	25006961
c@@	B-Chemical	D000242	25006961
AM@@	I-Chemical	-1	25006961
P	I-Chemical	-1	25006961
path@@	O	-1	25006961
w@@	O	-1	25006961
ay	O	-1	25006961
and	O	-1	25006961
chron@@	O	-1	25006961
ically	O	-1	25006961
reduc@@	O	-1	25006961
ing	O	-1	25006961
ure@@	B-Chemical	D014508	25006961
a	I-Chemical	-1	25006961
trans@@	O	-1	25006961
por@@	O	-1	25006961
ter	O	-1	25006961
(@@	O	-1	25006961
U@@	O	-1	25006961
T@@	O	-1	25006961
-@@	O	-1	25006961
A@@	O	-1	25006961
1)	O	-1	25006961
and	O	-1	25006961
w@@	O	-1	25006961
at@@	O	-1	25006961
er	O	-1	25006961
channel	O	-1	25006961
(A@@	O	-1	25006961
Q@@	O	-1	25006961
P@@	O	-1	25006961
2)	O	-1	25006961
expression	O	-1	25006961
in	O	-1	25006961
the	O	-1	25006961
in@@	O	-1	25006961
n@@	O	-1	25006961
er	O	-1	25006961
med@@	O	-1	25006961
ul@@	O	-1	25006961
l@@	O	-1	25006961
a.	O	-1	25006961
T@@	O	-1	25006961
arg@@	O	-1	25006961
et@@	O	-1	25006961
ing	O	-1	25006961
an	O	-1	25006961
al@@	O	-1	25006961
tern@@	O	-1	25006961
ative	O	-1	25006961
sign@@	O	-1	25006961
al@@	O	-1	25006961
ing	O	-1	25006961
path@@	O	-1	25006961
w@@	O	-1	25006961
a@@	O	-1	25006961
y,	O	-1	25006961
such	O	-1	25006961
as	O	-1	25006961
P@@	O	-1	25006961
K@@	O	-1	25006961
C@@	O	-1	25006961
-@@	O	-1	25006961
mediated	O	-1	25006961
sign@@	O	-1	25006961
al@@	O	-1	25006961
ing,	O	-1	25006961
may	O	-1	25006961
be	O	-1	25006961
an	O	-1	25006961
effective	O	-1	25006961
meth@@	O	-1	25006961
od	O	-1	25006961
of	O	-1	25006961
treat@@	O	-1	25006961
ing	O	-1	25006961
lithium	B-Chemical	D008094	25006961
-induced	O	-1	25006961
poly@@	B-Disease	D011141	25006961
uria	I-Disease	-1	25006961
.	O	-1	25006961
P@@	O	-1	25006961
K@@	O	-1	25006961
C@@	O	-1	25006961
-@@	O	-1	25006961
al@@	O	-1	25006961
ph@@	O	-1	25006961
a	O	-1	25006961
n@@	O	-1	25006961
ul@@	O	-1	25006961
l	O	-1	25006961
mice	O	-1	25006961
(P@@	O	-1	25006961
K@@	O	-1	25006961
C@@	O	-1	25006961
a	O	-1	25006961
K@@	O	-1	25006961
O@@	O	-1	25006961
)	O	-1	25006961
and	O	-1	25006961
stra@@	O	-1	25006961
in-@@	O	-1	25006961
mat@@	O	-1	25006961
ch@@	O	-1	25006961
ed	O	-1	25006961
wil@@	O	-1	25006961
d	O	-1	25006961
type	O	-1	25006961
(@@	O	-1	25006961
W@@	O	-1	25006961
T)	O	-1	25006961
controls	O	-1	25006961
were	O	-1	25006961
treated	O	-1	25006961
with	O	-1	25006961
lithium	B-Chemical	D008094	25006961
for	O	-1	25006961
0@@	O	-1	25006961
,	O	-1	25006961
3	O	-1	25006961
or	O	-1	25006961
5	O	-1	25006961
days.	O	-1	25006961
W@@	O	-1	25006961
T	O	-1	25006961
mice	O	-1	25006961
had	O	-1	25006961
increased	O	-1	25006961
urine	O	-1	25006961
out@@	O	-1	25006961
pu@@	O	-1	25006961
t	O	-1	25006961
and	O	-1	25006961
lo@@	O	-1	25006961
we@@	O	-1	25006961
red	O	-1	25006961
urine	O	-1	25006961
os@@	O	-1	25006961
mol@@	O	-1	25006961
ality	O	-1	25006961
after	O	-1	25006961
3	O	-1	25006961
and	O	-1	25006961
5	O	-1	25006961
days	O	-1	25006961
of	O	-1	25006961
treatment	O	-1	25006961
whereas	O	-1	25006961
P@@	O	-1	25006961
K@@	O	-1	25006961
C@@	O	-1	25006961
a	O	-1	25006961
K@@	O	-1	25006961
O	O	-1	25006961
mice	O	-1	25006961
had	O	-1	25006961
no	O	-1	25006961
change	O	-1	25006961
in	O	-1	25006961
urine	O	-1	25006961
out@@	O	-1	25006961
pu@@	O	-1	25006961
t	O	-1	25006961
or	O	-1	25006961
concentr@@	O	-1	25006961
ation.	O	-1	25006961
W@@	O	-1	25006961
est@@	O	-1	25006961
er@@	O	-1	25006961
n	O	-1	25006961
blo@@	O	-1	25006961
t	O	-1	25006961
analysis	O	-1	25006961
revealed	O	-1	25006961
that	O	-1	25006961
A@@	O	-1	25006961
Q@@	O	-1	25006961
P@@	O	-1	25006961
2	O	-1	25006961
expression	O	-1	25006961
in	O	-1	25006961
med@@	O	-1	25006961
ul@@	O	-1	25006961
l@@	O	-1	25006961
ary	O	-1	25006961
tissu@@	O	-1	25006961
es	O	-1	25006961
was	O	-1	25006961
lo@@	O	-1	25006961
we@@	O	-1	25006961
red	O	-1	25006961
after	O	-1	25006961
3	O	-1	25006961
and	O	-1	25006961
5	O	-1	25006961
days	O	-1	25006961
in	O	-1	25006961
W@@	O	-1	25006961
T	O	-1	25006961
mic@@	O	-1	25006961
e@@	O	-1	25006961
;	O	-1	25006961
however,	O	-1	25006961
A@@	O	-1	25006961
Q@@	O	-1	25006961
P@@	O	-1	25006961
2	O	-1	25006961
was	O	-1	25006961
un@@	O	-1	25006961
chang@@	O	-1	25006961
ed	O	-1	25006961
in	O	-1	25006961
P@@	O	-1	25006961
K@@	O	-1	25006961
C@@	O	-1	25006961
a	O	-1	25006961
K@@	O	-1	25006961
O@@	O	-1	25006961
.	O	-1	25006961
S@@	O	-1	25006961
im@@	O	-1	25006961
il@@	O	-1	25006961
ar	O	-1	25006961
results	O	-1	25006961
were	O	-1	25006961
observed	O	-1	25006961
with	O	-1	25006961
U@@	O	-1	25006961
T@@	O	-1	25006961
-@@	O	-1	25006961
A@@	O	-1	25006961
1	O	-1	25006961
ex@@	O	-1	25006961
pres@@	O	-1	25006961
sion.	O	-1	25006961
An@@	O	-1	25006961
im@@	O	-1	25006961
als	O	-1	25006961
were	O	-1	25006961
also	O	-1	25006961
treated	O	-1	25006961
with	O	-1	25006961
lithium	B-Chemical	D008094	25006961
for	O	-1	25006961
6	O	-1	25006961
week@@	O	-1	25006961
s.	O	-1	25006961
L@@	B-Chemical	D008094	25006961
i@@	I-Chemical	-1	25006961
thi@@	I-Chemical	-1	25006961
um	I-Chemical	-1	25006961
-treated	O	-1	25006961
W@@	O	-1	25006961
T	O	-1	25006961
mice	O	-1	25006961
had	O	-1	25006961
19@@	O	-1	25006961
-@@	O	-1	25006961
fol@@	O	-1	25006961
d	O	-1	25006961
increased	O	-1	25006961
urine	O	-1	25006961
out@@	O	-1	25006961
pu@@	O	-1	25006961
t	O	-1	25006961
whereas	O	-1	25006961
treated	O	-1	25006961
P@@	O	-1	25006961
K@@	O	-1	25006961
C@@	O	-1	25006961
a	O	-1	25006961
K@@	O	-1	25006961
O	O	-1	25006961
animals	O	-1	25006961
had	O	-1	25006961
a	O	-1	25006961
4-@@	O	-1	25006961
fol@@	O	-1	25006961
d	O	-1	25006961
increase	O	-1	25006961
in	O	-1	25006961
out@@	O	-1	25006961
p@@	O	-1	25006961
ut@@	O	-1	25006961
.	O	-1	25006961
A@@	O	-1	25006961
Q@@	O	-1	25006961
P@@	O	-1	25006961
2	O	-1	25006961
and	O	-1	25006961
U@@	O	-1	25006961
T@@	O	-1	25006961
-@@	O	-1	25006961
A@@	O	-1	25006961
1	O	-1	25006961
expression	O	-1	25006961
was	O	-1	25006961
lo@@	O	-1	25006961
we@@	O	-1	25006961
red	O	-1	25006961
in	O	-1	25006961
6	O	-1	25006961
week	O	-1	25006961
lithium	B-Chemical	D008094	25006961
-treated	O	-1	25006961
W@@	O	-1	25006961
T	O	-1	25006961
animals	O	-1	25006961
whereas	O	-1	25006961
in	O	-1	25006961
treated	O	-1	25006961
P@@	O	-1	25006961
K@@	O	-1	25006961
C@@	O	-1	25006961
a	O	-1	25006961
K@@	O	-1	25006961
O	O	-1	25006961
mic@@	O	-1	25006961
e,	O	-1	25006961
A@@	O	-1	25006961
Q@@	O	-1	25006961
P@@	O	-1	25006961
2	O	-1	25006961
was	O	-1	25006961
only	O	-1	25006961
reduced	O	-1	25006961
by	O	-1	25006961
2-@@	O	-1	25006961
fol@@	O	-1	25006961
d	O	-1	25006961
and	O	-1	25006961
U@@	O	-1	25006961
T@@	O	-1	25006961
-@@	O	-1	25006961
A@@	O	-1	25006961
1	O	-1	25006961
expression	O	-1	25006961
was	O	-1	25006961
un@@	O	-1	25006961
aff@@	O	-1	25006961
ect@@	O	-1	25006961
ed.	O	-1	25006961
U@@	O	-1	25006961
r@@	O	-1	25006961
inary	O	-1	25006961
sodium	B-Chemical	D012964	25006961
,	O	-1	25006961
pot@@	B-Chemical	D011188	25006961
assi@@	I-Chemical	-1	25006961
um	I-Chemical	-1	25006961
and	O	-1	25006961
calcium	B-Chemical	D002118	25006961
were	O	-1	25006961
elevated	O	-1	25006961
in	O	-1	25006961
lithium	B-Chemical	D008094	25006961
-@@	O	-1	25006961
f@@	O	-1	25006961
ed	O	-1	25006961
W@@	O	-1	25006961
T	O	-1	25006961
but	O	-1	25006961
not	O	-1	25006961
in	O	-1	25006961
lithium	B-Chemical	D008094	25006961
-@@	O	-1	25006961
f@@	O	-1	25006961
ed	O	-1	25006961
P@@	O	-1	25006961
K@@	O	-1	25006961
C@@	O	-1	25006961
a	O	-1	25006961
K@@	O	-1	25006961
O	O	-1	25006961
mice.	O	-1	25006961
Our	O	-1	25006961
data	O	-1	25006961
show	O	-1	25006961
that	O	-1	25006961
abl@@	O	-1	25006961
ation	O	-1	25006961
of	O	-1	25006961
P@@	O	-1	25006961
K@@	O	-1	25006961
C@@	O	-1	25006961
a	O	-1	25006961
pres@@	O	-1	25006961
er@@	O	-1	25006961
v@@	O	-1	25006961
es	O	-1	25006961
A@@	O	-1	25006961
Q@@	O	-1	25006961
P@@	O	-1	25006961
2	O	-1	25006961
and	O	-1	25006961
U@@	O	-1	25006961
T@@	O	-1	25006961
-@@	O	-1	25006961
A@@	O	-1	25006961
1	O	-1	25006961
protein	O	-1	25006961
expression	O	-1	25006961
and	O	-1	25006961
lo@@	O	-1	25006961
cal@@	O	-1	25006961
ization	O	-1	25006961
in	O	-1	25006961
lithium	B-Chemical	D008094	25006961
-induced	O	-1	25006961
N@@	B-Disease	D018500	25006961
D@@	I-Disease	-1	25006961
I	I-Disease	-1	25006961
,	O	-1	25006961
and	O	-1	25006961
prev@@	O	-1	25006961
ents	O	-1	25006961
the	O	-1	25006961
development	O	-1	25006961
of	O	-1	25006961
the	O	-1	25006961
severe	O	-1	25006961
poly@@	B-Disease	D011141	25006961
uria	I-Disease	-1	25006961
associated	O	-1	25006961
with	O	-1	25006961
lithium	B-Chemical	D008094	25006961
therapy.	O	-1	25006961

I@@	O	-1	25031906
s	O	-1	25031906
D@@	B-Disease	D004408	25031906
ys@@	I-Disease	-1	25031906
gu@@	I-Disease	-1	25031906
e@@	I-Disease	-1	25031906
sia	I-Disease	-1	25031906
G@@	O	-1	25031906
o@@	O	-1	25031906
ing	O	-1	25031906
to	O	-1	25031906
be	O	-1	25031906
a	O	-1	25031906
R@@	O	-1	25031906
are	O	-1	25031906
or	O	-1	25031906
a	O	-1	25031906
Com@@	O	-1	25031906
m@@	O	-1	25031906
on	O	-1	25031906
S@@	O	-1	25031906
ide@@	O	-1	25031906
-@@	O	-1	25031906
effect	O	-1	25031906
of	O	-1	25031906
A@@	B-Chemical	D017311	25031906
m@@	I-Chemical	-1	25031906
lo@@	I-Chemical	-1	25031906
di@@	I-Chemical	-1	25031906
pine	I-Chemical	-1	25031906
?	O	-1	25031906
A	O	-1	25031906
very	O	-1	25031906
r@@	O	-1	25031906
are	O	-1	25031906
side@@	O	-1	25031906
-@@	O	-1	25031906
effect	O	-1	25031906
of	O	-1	25031906
am@@	B-Chemical	D017311	25031906
lo@@	I-Chemical	-1	25031906
di@@	I-Chemical	-1	25031906
pine	I-Chemical	-1	25031906
is	O	-1	25031906
dys@@	B-Disease	D004408	25031906
gu@@	I-Disease	-1	25031906
e@@	I-Disease	-1	25031906
sia	I-Disease	-1	25031906
.	O	-1	25031906
A	O	-1	25031906
revie@@	O	-1	25031906
w	O	-1	25031906
of	O	-1	25031906
the	O	-1	25031906
literat@@	O	-1	25031906
ure	O	-1	25031906
produced	O	-1	25031906
only	O	-1	25031906
one	O	-1	25031906
cas@@	O	-1	25031906
e.	O	-1	25031906
We	O	-1	25031906
report	O	-1	25031906
a	O	-1	25031906
case	O	-1	25031906
about	O	-1	25031906
a	O	-1	25031906
female	O	-1	25031906
with	O	-1	25031906
es@@	O	-1	25031906
sen@@	O	-1	25031906
tial	O	-1	25031906
hypertension	B-Disease	D006973	25031906
on	O	-1	25031906
drug	O	-1	25031906
treatment	O	-1	25031906
with	O	-1	25031906
am@@	B-Chemical	D017311	25031906
lo@@	I-Chemical	-1	25031906
di@@	I-Chemical	-1	25031906
pine	I-Chemical	-1	25031906
developed	O	-1	25031906
loss	B-Disease	D012678	25031906
of	I-Disease	-1	25031906
t@@	I-Disease	-1	25031906
ast@@	I-Disease	-1	25031906
e	I-Disease	-1	25031906
sens@@	I-Disease	-1	25031906
ation	I-Disease	-1	25031906
.	O	-1	25031906
Con@@	O	-1	25031906
di@@	O	-1	25031906
tion	O	-1	25031906
moder@@	O	-1	25031906
ately	O	-1	25031906
improved	O	-1	25031906
on	O	-1	25031906
sto@@	O	-1	25031906
pp@@	O	-1	25031906
age	O	-1	25031906
of	O	-1	25031906
the	O	-1	25031906
drug	O	-1	25031906
for	O	-1	25031906
25	O	-1	25031906
days.	O	-1	25031906
We	O	-1	25031906
concl@@	O	-1	25031906
ude	O	-1	25031906
that	O	-1	25031906
am@@	B-Chemical	D017311	25031906
lo@@	I-Chemical	-1	25031906
di@@	I-Chemical	-1	25031906
pine	I-Chemical	-1	25031906
can	O	-1	25031906
cause	O	-1	25031906
dys@@	B-Disease	D004408	25031906
gu@@	I-Disease	-1	25031906
e@@	I-Disease	-1	25031906
sia	I-Disease	-1	25031906
.	O	-1	25031906
He@@	O	-1	25031906
re,	O	-1	25031906
we	O	-1	25031906
describe	O	-1	25031906
the	O	-1	25031906
clinical	O	-1	25031906
present@@	O	-1	25031906
ation	O	-1	25031906
and	O	-1	25031906
revie@@	O	-1	25031906
w	O	-1	25031906
the	O	-1	25031906
re@@	O	-1	25031906
lev@@	O	-1	25031906
ant	O	-1	25031906
literat@@	O	-1	25031906
ure	O	-1	25031906
on	O	-1	25031906
am@@	B-Chemical	D017311	25031906
lo@@	I-Chemical	-1	25031906
di@@	I-Chemical	-1	25031906
pine	I-Chemical	-1	25031906
and	O	-1	25031906
dys@@	B-Disease	D004408	25031906
gu@@	I-Disease	-1	25031906
e@@	I-Disease	-1	25031906
sia	I-Disease	-1	25031906
.	O	-1	25031906

R@@	B-Disease	D012206	25041770
h@@	I-Disease	-1	25041770
ab@@	I-Disease	-1	25041770
do@@	I-Disease	-1	25041770
my@@	I-Disease	-1	25041770
oly@@	I-Disease	-1	25041770
sis	I-Disease	-1	25041770
in	O	-1	25041770
association	O	-1	25041770
with	O	-1	25041770
sim@@	B-Chemical	D019821	25041770
vastatin	I-Chemical	-1	25041770
and	O	-1	25041770
dos@@	O	-1	25041770
age	O	-1	25041770
inc@@	O	-1	25041770
re@@	O	-1	25041770
ment	O	-1	25041770
in	O	-1	25041770
cl@@	B-Chemical	D017291	25041770
ari@@	I-Chemical	-1	25041770
throm@@	I-Chemical	-1	25041770
ycin	I-Chemical	-1	25041770
.	O	-1	25041770
Cl@@	B-Chemical	D017291	25041770
ari@@	I-Chemical	-1	25041770
throm@@	I-Chemical	-1	25041770
ycin	I-Chemical	-1	25041770
is	O	-1	25041770
the	O	-1	25041770
most	O	-1	25041770
doc@@	O	-1	25041770
um@@	O	-1	25041770
ent@@	O	-1	25041770
ed	O	-1	25041770
cyto@@	O	-1	25041770
ch@@	O	-1	25041770
rom@@	O	-1	25041770
e	O	-1	25041770
P@@	O	-1	25041770
4@@	O	-1	25041770
50	O	-1	25041770
3@@	O	-1	25041770
A@@	O	-1	25041770
4	O	-1	25041770
(C@@	O	-1	25041770
Y@@	O	-1	25041770
P@@	O	-1	25041770
3@@	O	-1	25041770
A@@	O	-1	25041770
4@@	O	-1	25041770
)	O	-1	25041770
inhibitor	O	-1	25041770
to	O	-1	25041770
cause	O	-1	25041770
an	O	-1	25041770
adverse	O	-1	25041770
inter@@	O	-1	25041770
action	O	-1	25041770
with	O	-1	25041770
sim@@	B-Chemical	D019821	25041770
vastatin	I-Chemical	-1	25041770
.	O	-1	25041770
This	O	-1	25041770
partic@@	O	-1	25041770
ular	O	-1	25041770
case	O	-1	25041770
is	O	-1	25041770
of	O	-1	25041770
in@@	O	-1	25041770
te@@	O	-1	25041770
res@@	O	-1	25041770
t	O	-1	25041770
as	O	-1	25041770
rh@@	B-Disease	D012206	25041770
ab@@	I-Disease	-1	25041770
do@@	I-Disease	-1	25041770
my@@	I-Disease	-1	25041770
oly@@	I-Disease	-1	25041770
sis	I-Disease	-1	25041770
only	O	-1	25041770
occurred	O	-1	25041770
after	O	-1	25041770
an	O	-1	25041770
increase	O	-1	25041770
in	O	-1	25041770
the	O	-1	25041770
dose	O	-1	25041770
of	O	-1	25041770
cl@@	B-Chemical	D017291	25041770
ari@@	I-Chemical	-1	25041770
throm@@	I-Chemical	-1	25041770
ycin	I-Chemical	-1	25041770
.	O	-1	25041770
The	O	-1	25041770
patient	O	-1	25041770
developed	O	-1	25041770
ra@@	O	-1	25041770
is@@	O	-1	25041770
ed	O	-1	25041770
cardiac	O	-1	25041770
b@@	O	-1	25041770
i@@	O	-1	25041770
om@@	O	-1	25041770
ark@@	O	-1	25041770
ers	O	-1	25041770
without	O	-1	25041770
any	O	-1	25041770
ob@@	O	-1	25041770
vi@@	O	-1	25041770
ous	O	-1	25041770
cardiac	O	-1	25041770
is@@	O	-1	25041770
su@@	O	-1	25041770
es,	O	-1	25041770
a	O	-1	25041770
phen@@	O	-1	25041770
om@@	O	-1	25041770
en@@	O	-1	25041770
on	O	-1	25041770
that	O	-1	25041770
has	O	-1	25041770
been	O	-1	25041770
lin@@	O	-1	25041770
ked	O	-1	25041770
to	O	-1	25041770
rh@@	B-Disease	D012206	25041770
ab@@	I-Disease	-1	25041770
do@@	I-Disease	-1	25041770
my@@	I-Disease	-1	25041770
oly@@	I-Disease	-1	25041770
sis	I-Disease	-1	25041770
previ@@	O	-1	25041770
ous@@	O	-1	25041770
ly.	O	-1	25041770
To	O	-1	25041770
dat@@	O	-1	25041770
e,	O	-1	25041770
there	O	-1	25041770
has	O	-1	25041770
been	O	-1	25041770
no	O	-1	25041770
reported	O	-1	25041770
effect	O	-1	25041770
of	O	-1	25041770
rh@@	B-Disease	D012206	25041770
ab@@	I-Disease	-1	25041770
do@@	I-Disease	-1	25041770
my@@	I-Disease	-1	25041770
oly@@	I-Disease	-1	25041770
sis	I-Disease	-1	25041770
on	O	-1	25041770
the	O	-1	25041770
struct@@	O	-1	25041770
ure	O	-1	25041770
and	O	-1	25041770
function	O	-1	25041770
of	O	-1	25041770
cardiac	O	-1	25041770
musc@@	O	-1	25041770
le@@	O	-1	25041770
.	O	-1	25041770
Clin@@	O	-1	25041770
ici@@	O	-1	25041770
ans	O	-1	25041770
need	O	-1	25041770
to	O	-1	25041770
be	O	-1	25041770
aw@@	O	-1	25041770
are	O	-1	25041770
of	O	-1	25041770
prescri@@	O	-1	25041770
b@@	O	-1	25041770
ing	O	-1	25041770
concomit@@	O	-1	25041770
ant	O	-1	25041770
medic@@	O	-1	25041770
ations	O	-1	25041770
that	O	-1	25041770
increase	O	-1	25041770
the	O	-1	25041770
risk	O	-1	25041770
of	O	-1	25041770
my@@	B-Disease	D009135	25041770
o@@	I-Disease	-1	25041770
pathy	I-Disease	-1	25041770
or	O	-1	25041770
inhib@@	O	-1	25041770
it	O	-1	25041770
the	O	-1	25041770
C@@	O	-1	25041770
Y@@	O	-1	25041770
P@@	O	-1	25041770
3@@	O	-1	25041770
A@@	O	-1	25041770
4	O	-1	25041770
enz@@	O	-1	25041770
y@@	O	-1	25041770
me.	O	-1	25041770
Our	O	-1	25041770
case	O	-1	25041770
suggests	O	-1	25041770
that	O	-1	25041770
tro@@	O	-1	25041770
p@@	O	-1	25041770
on@@	O	-1	25041770
in	O	-1	25041770
elev@@	O	-1	25041770
ation	O	-1	25041770
could	O	-1	25041770
be	O	-1	25041770
associated	O	-1	25041770
with	O	-1	25041770
st@@	B-Chemical	D019821	25041770
atin	I-Chemical	-1	25041770
induced	O	-1	25041770
rh@@	B-Disease	D012206	25041770
ab@@	I-Disease	-1	25041770
do@@	I-Disease	-1	25041770
my@@	I-Disease	-1	25041770
oly@@	I-Disease	-1	25041770
sis	I-Disease	-1	25041770
,	O	-1	25041770
which	O	-1	25041770
may	O	-1	25041770
war@@	O	-1	25041770
ran@@	O	-1	25041770
t	O	-1	25041770
further	O	-1	25041770
studi@@	O	-1	25041770
es.	O	-1	25041770

Ch@@	O	-1	25054547
aracter@@	O	-1	25054547
ization	O	-1	25054547
of	O	-1	25054547
a	O	-1	25054547
novel	O	-1	25054547
BC@@	O	-1	25054547
H@@	O	-1	25054547
E	O	-1	25054547
"@@	O	-1	25054547
si@@	O	-1	25054547
l@@	O	-1	25054547
ent@@	O	-1	25054547
"	O	-1	25054547
al@@	O	-1	25054547
le@@	O	-1	25054547
le@@	O	-1	25054547
:	O	-1	25054547
po@@	O	-1	25054547
in@@	O	-1	25054547
t	O	-1	25054547
mut@@	O	-1	25054547
ation	O	-1	25054547
(@@	O	-1	25054547
p.@@	O	-1	25054547
V@@	O	-1	25054547
al@@	O	-1	25054547
20@@	O	-1	25054547
4@@	O	-1	25054547
A@@	O	-1	25054547
sp@@	O	-1	25054547
)	O	-1	25054547
causes	O	-1	25054547
loss	O	-1	25054547
of	O	-1	25054547
activity	O	-1	25054547
and	O	-1	25054547
prolonged	O	-1	25054547
ap@@	B-Disease	D001049	25054547
ne@@	I-Disease	-1	25054547
a	I-Disease	-1	25054547
with	O	-1	25054547
su@@	B-Chemical	D013390	25054547
xameth@@	I-Chemical	-1	25054547
oni@@	I-Chemical	-1	25054547
um	I-Chemical	-1	25054547
.	O	-1	25054547
B@@	B-Disease	C537417	25054547
ut@@	I-Disease	-1	25054547
y@@	I-Disease	-1	25054547
r@@	I-Disease	-1	25054547
ylchol@@	I-Disease	-1	25054547
ine@@	I-Disease	-1	25054547
ster@@	I-Disease	-1	25054547
ase	I-Disease	-1	25054547
defici@@	I-Disease	-1	25054547
ency	I-Disease	-1	25054547
is	O	-1	25054547
character@@	O	-1	25054547
ized	O	-1	25054547
by	O	-1	25054547
prolonged	O	-1	25054547
ap@@	B-Disease	D001049	25054547
ne@@	I-Disease	-1	25054547
a	I-Disease	-1	25054547
after	O	-1	25054547
the	O	-1	25054547
use	O	-1	25054547
of	O	-1	25054547
musc@@	O	-1	25054547
le	O	-1	25054547
rel@@	O	-1	25054547
ax@@	O	-1	25054547
ants	O	-1	25054547
(	O	-1	25054547
su@@	B-Chemical	D013390	25054547
xameth@@	I-Chemical	-1	25054547
oni@@	I-Chemical	-1	25054547
um	I-Chemical	-1	25054547
or	O	-1	25054547
mi@@	B-Chemical	C049430	25054547
vac@@	I-Chemical	-1	25054547
ur@@	I-Chemical	-1	25054547
i@@	I-Chemical	-1	25054547
um	I-Chemical	-1	25054547
)	O	-1	25054547
in	O	-1	25054547
patients	O	-1	25054547
who	O	-1	25054547
have	O	-1	25054547
mut@@	O	-1	25054547
ations	O	-1	25054547
in	O	-1	25054547
the	O	-1	25054547
BC@@	O	-1	25054547
H@@	O	-1	25054547
E	O	-1	25054547
gen@@	O	-1	25054547
e.	O	-1	25054547
He@@	O	-1	25054547
re,	O	-1	25054547
we	O	-1	25054547
report	O	-1	25054547
a	O	-1	25054547
case	O	-1	25054547
of	O	-1	25054547
prolonged	O	-1	25054547
neuro@@	O	-1	25054547
mus@@	O	-1	25054547
cular	O	-1	25054547
bloc@@	O	-1	25054547
k	O	-1	25054547
after	O	-1	25054547
administration	O	-1	25054547
of	O	-1	25054547
su@@	B-Chemical	D013390	25054547
xameth@@	I-Chemical	-1	25054547
oni@@	I-Chemical	-1	25054547
um	I-Chemical	-1	25054547
lead@@	O	-1	25054547
ing	O	-1	25054547
to	O	-1	25054547
the	O	-1	25054547
dis@@	O	-1	25054547
co@@	O	-1	25054547
very	O	-1	25054547
of	O	-1	25054547
a	O	-1	25054547
novel	O	-1	25054547
BC@@	O	-1	25054547
H@@	O	-1	25054547
E	O	-1	25054547
vari@@	O	-1	25054547
ant	O	-1	25054547
(@@	O	-1	25054547
c@@	O	-1	25054547
.@@	O	-1	25054547
6@@	O	-1	25054547
9@@	O	-1	25054547
5@@	O	-1	25054547
T@@	O	-1	25054547
>@@	O	-1	25054547
A@@	O	-1	25054547
,	O	-1	25054547
p.@@	O	-1	25054547
V@@	O	-1	25054547
al@@	O	-1	25054547
20@@	O	-1	25054547
4@@	O	-1	25054547
A@@	O	-1	25054547
sp@@	O	-1	25054547
).	O	-1	25054547
In@@	O	-1	25054547
hib@@	O	-1	25054547
ition	O	-1	25054547
studi@@	O	-1	25054547
es,	O	-1	25054547
kine@@	O	-1	25054547
tic	O	-1	25054547
analysis	O	-1	25054547
and	O	-1	25054547
mol@@	O	-1	25054547
ec@@	O	-1	25054547
ular	O	-1	25054547
dynam@@	O	-1	25054547
ic@@	O	-1	25054547
s	O	-1	25054547
were	O	-1	25054547
under@@	O	-1	25054547
tak@@	O	-1	25054547
en	O	-1	25054547
to	O	-1	25054547
under@@	O	-1	25054547
st@@	O	-1	25054547
and	O	-1	25054547
ho@@	O	-1	25054547
w	O	-1	25054547
this	O	-1	25054547
mut@@	O	-1	25054547
ation	O	-1	25054547
dis@@	O	-1	25054547
ru@@	O	-1	25054547
pt@@	O	-1	25054547
s	O	-1	25054547
the	O	-1	25054547
cat@@	O	-1	25054547
aly@@	O	-1	25054547
tic	O	-1	25054547
tri@@	O	-1	25054547
ad	O	-1	25054547
and	O	-1	25054547
determin@@	O	-1	25054547
es	O	-1	25054547
a	O	-1	25054547
"@@	O	-1	25054547
si@@	O	-1	25054547
l@@	O	-1	25054547
ent@@	O	-1	25054547
"	O	-1	25054547
phen@@	O	-1	25054547
ot@@	O	-1	25054547
yp@@	O	-1	25054547
e.	O	-1	25054547
L@@	O	-1	25054547
o@@	O	-1	25054547
w	O	-1	25054547
activity	O	-1	25054547
of	O	-1	25054547
patient	O	-1	25054547
plasma	O	-1	25054547
but@@	O	-1	25054547
y@@	O	-1	25054547
r@@	O	-1	25054547
ylchol@@	O	-1	25054547
ine@@	O	-1	25054547
ster@@	O	-1	25054547
ase	O	-1	25054547
with	O	-1	25054547
but@@	B-Chemical	D002092	25054547
y@@	I-Chemical	-1	25054547
r@@	I-Chemical	-1	25054547
yl@@	I-Chemical	-1	25054547
th@@	I-Chemical	-1	25054547
io@@	I-Chemical	-1	25054547
chol@@	I-Chemical	-1	25054547
ine	I-Chemical	-1	25054547
(	O	-1	25054547
B@@	B-Chemical	D002092	25054547
T@@	I-Chemical	-1	25054547
C	I-Chemical	-1	25054547
)	O	-1	25054547
and	O	-1	25054547
b@@	B-Chemical	D001588	25054547
enz@@	I-Chemical	-1	25054547
o@@	I-Chemical	-1	25054547
ylcholine	I-Chemical	-1	25054547
,	O	-1	25054547
and	O	-1	25054547
values	O	-1	25054547
of	O	-1	25054547
di@@	B-Chemical	D003992	25054547
b@@	I-Chemical	-1	25054547
uc@@	I-Chemical	-1	25054547
aine	I-Chemical	-1	25054547
and	O	-1	25054547
flu@@	B-Chemical	D005459	25054547
or@@	I-Chemical	-1	25054547
ide	I-Chemical	-1	25054547
numb@@	O	-1	25054547
ers	O	-1	25054547
fi@@	O	-1	25054547
t	O	-1	25054547
with	O	-1	25054547
he@@	O	-1	25054547
ter@@	O	-1	25054547
o@@	O	-1	25054547
z@@	O	-1	25054547
y@@	O	-1	25054547
g@@	O	-1	25054547
ous	O	-1	25054547
at@@	O	-1	25054547
yp@@	O	-1	25054547
ical	O	-1	25054547
si@@	O	-1	25054547
l@@	O	-1	25054547
ent	O	-1	25054547
gen@@	O	-1	25054547
ot@@	O	-1	25054547
yp@@	O	-1	25054547
e.	O	-1	25054547
E@@	O	-1	25054547
l@@	O	-1	25054547
ect@@	O	-1	25054547
ro@@	O	-1	25054547
ph@@	O	-1	25054547
ore@@	O	-1	25054547
tic	O	-1	25054547
analysis	O	-1	25054547
of	O	-1	25054547
plasma	O	-1	25054547
B@@	O	-1	25054547
Ch@@	O	-1	25054547
E	O	-1	25054547
of	O	-1	25054547
the	O	-1	25054547
prob@@	O	-1	25054547
and	O	-1	25054547
and	O	-1	25054547
h@@	O	-1	25054547
is	O	-1	25054547
mo@@	O	-1	25054547
ther	O	-1	25054547
showed	O	-1	25054547
that	O	-1	25054547
patient	O	-1	25054547
has	O	-1	25054547
a	O	-1	25054547
reduced	O	-1	25054547
amoun@@	O	-1	25054547
t	O	-1	25054547
of	O	-1	25054547
te@@	O	-1	25054547
t@@	O	-1	25054547
ram@@	O	-1	25054547
er@@	O	-1	25054547
ic	O	-1	25054547
enzyme	O	-1	25054547
in	O	-1	25054547
plasma	O	-1	25054547
and	O	-1	25054547
that	O	-1	25054547
min@@	O	-1	25054547
or	O	-1	25054547
f@@	O	-1	25054547
ast@@	O	-1	25054547
-@@	O	-1	25054547
mo@@	O	-1	25054547
ving	O	-1	25054547
B@@	O	-1	25054547
Ch@@	O	-1	25054547
E	O	-1	25054547
comp@@	O	-1	25054547
on@@	O	-1	25054547
ent@@	O	-1	25054547
s:	O	-1	25054547
mon@@	O	-1	25054547
om@@	O	-1	25054547
er,	O	-1	25054547
di@@	O	-1	25054547
mer@@	O	-1	25054547
,	O	-1	25054547
and	O	-1	25054547
mon@@	O	-1	25054547
om@@	O	-1	25054547
er@@	O	-1	25054547
-@@	O	-1	25054547
al@@	O	-1	25054547
b@@	O	-1	25054547
um@@	O	-1	25054547
in	O	-1	25054547
con@@	O	-1	25054547
j@@	O	-1	25054547
u@@	O	-1	25054547
g@@	O	-1	25054547
ate	O	-1	25054547
are	O	-1	25054547
mis@@	O	-1	25054547
sing@@	O	-1	25054547
.	O	-1	25054547
K@@	O	-1	25054547
ine@@	O	-1	25054547
tic	O	-1	25054547
analysis	O	-1	25054547
showed	O	-1	25054547
that	O	-1	25054547
the	O	-1	25054547
p.@@	O	-1	25054547
V@@	O	-1	25054547
al@@	O	-1	25054547
20@@	O	-1	25054547
4@@	O	-1	25054547
A@@	O	-1	25054547
sp@@	O	-1	25054547
/@@	O	-1	25054547
p.@@	O	-1	25054547
A@@	O	-1	25054547
sp@@	O	-1	25054547
7@@	O	-1	25054547
0@@	O	-1	25054547
G@@	O	-1	25054547
l@@	O	-1	25054547
y-@@	O	-1	25054547
p.@@	O	-1	25054547
Al@@	O	-1	25054547
a@@	O	-1	25054547
5@@	O	-1	25054547
3@@	O	-1	25054547
9@@	O	-1	25054547
Th@@	O	-1	25054547
r	O	-1	25054547
B@@	O	-1	25054547
Ch@@	O	-1	25054547
E	O	-1	25054547
dis@@	O	-1	25054547
pl@@	O	-1	25054547
ays	O	-1	25054547
a	O	-1	25054547
p@@	O	-1	25054547
ure	O	-1	25054547
M@@	O	-1	25054547
ic@@	O	-1	25054547
ha@@	O	-1	25054547
e@@	O	-1	25054547
li@@	O	-1	25054547
an	O	-1	25054547
behavi@@	O	-1	25054547
or	O	-1	25054547
with	O	-1	25054547
B@@	B-Chemical	D002092	25054547
T@@	I-Chemical	-1	25054547
C	I-Chemical	-1	25054547
as	O	-1	25054547
the	O	-1	25054547
sub@@	O	-1	25054547
strat@@	O	-1	25054547
e.	O	-1	25054547
B@@	O	-1	25054547
oth	O	-1	25054547
cat@@	O	-1	25054547
aly@@	O	-1	25054547
tic	O	-1	25054547
par@@	O	-1	25054547
ame@@	O	-1	25054547
ters	O	-1	25054547
K@@	O	-1	25054547
m	O	-1	25054547
=	O	-1	25054547
2@@	O	-1	25054547
6@@	O	-1	25054547
5	O	-1	25054547
u@@	O	-1	25054547
M	O	-1	25054547
for	O	-1	25054547
B@@	B-Chemical	D002092	25054547
T@@	I-Chemical	-1	25054547
C	I-Chemical	-1	25054547
,	O	-1	25054547
two	O	-1	25054547
times	O	-1	25054547
higher	O	-1	25054547
than	O	-1	25054547
that	O	-1	25054547
of	O	-1	25054547
the	O	-1	25054547
at@@	O	-1	25054547
yp@@	O	-1	25054547
ical	O	-1	25054547
enz@@	O	-1	25054547
y@@	O	-1	25054547
me,	O	-1	25054547
and	O	-1	25054547
a	O	-1	25054547
low	O	-1	25054547
V@@	O	-1	25054547
ma@@	O	-1	25054547
x	O	-1	25054547
are	O	-1	25054547
consist@@	O	-1	25054547
ent	O	-1	25054547
with	O	-1	25054547
the	O	-1	25054547
absence	O	-1	25054547
of	O	-1	25054547
activity	O	-1	25054547
against	O	-1	25054547
su@@	B-Chemical	D013390	25054547
xameth@@	I-Chemical	-1	25054547
oni@@	I-Chemical	-1	25054547
um	I-Chemical	-1	25054547
.	O	-1	25054547
M@@	O	-1	25054547
ol@@	O	-1	25054547
ec@@	O	-1	25054547
ular	O	-1	25054547
dynam@@	O	-1	25054547
ic	O	-1	25054547
(@@	O	-1	25054547
MD@@	O	-1	25054547
)	O	-1	25054547
si@@	O	-1	25054547
mul@@	O	-1	25054547
ations	O	-1	25054547
showed	O	-1	25054547
that	O	-1	25054547
the	O	-1	25054547
over@@	O	-1	25054547
all	O	-1	25054547
effect	O	-1	25054547
of	O	-1	25054547
the	O	-1	25054547
mut@@	O	-1	25054547
ation	O	-1	25054547
p.@@	O	-1	25054547
V@@	O	-1	25054547
al@@	O	-1	25054547
20@@	O	-1	25054547
4@@	O	-1	25054547
A@@	O	-1	25054547
s@@	O	-1	25054547
p	O	-1	25054547
is	O	-1	25054547
dis@@	O	-1	25054547
ru@@	O	-1	25054547
ption	O	-1	25054547
of	O	-1	25054547
hydro@@	B-Chemical	D006859	25054547
gen	I-Chemical	-1	25054547
b@@	O	-1	25054547
on@@	O	-1	25054547
ding	O	-1	25054547
between	O	-1	25054547
G@@	O	-1	25054547
l@@	O	-1	25054547
n@@	O	-1	25054547
2@@	O	-1	25054547
2@@	O	-1	25054547
3	O	-1	25054547
and	O	-1	25054547
G@@	O	-1	25054547
lu@@	O	-1	25054547
4@@	O	-1	25054547
4@@	O	-1	25054547
1,	O	-1	25054547
lead@@	O	-1	25054547
ing	O	-1	25054547
S@@	O	-1	25054547
er@@	O	-1	25054547
19@@	O	-1	25054547
8	O	-1	25054547
and	O	-1	25054547
H@@	O	-1	25054547
is@@	O	-1	25054547
4@@	O	-1	25054547
3@@	O	-1	25054547
8	O	-1	25054547
to	O	-1	25054547
mo@@	O	-1	25054547
ve	O	-1	25054547
aw@@	O	-1	25054547
ay	O	-1	25054547
from	O	-1	25054547
each	O	-1	25054547
other	O	-1	25054547
with	O	-1	25054547
subsequ@@	O	-1	25054547
ent	O	-1	25054547
dis@@	O	-1	25054547
ru@@	O	-1	25054547
ption	O	-1	25054547
of	O	-1	25054547
the	O	-1	25054547
cat@@	O	-1	25054547
aly@@	O	-1	25054547
tic	O	-1	25054547
tri@@	O	-1	25054547
ad	O	-1	25054547
func@@	O	-1	25054547
tion@@	O	-1	25054547
ality	O	-1	25054547
reg@@	O	-1	25054547
ar@@	O	-1	25054547
d@@	O	-1	25054547
less	O	-1	25054547
of	O	-1	25054547
the	O	-1	25054547
type	O	-1	25054547
of	O	-1	25054547
sub@@	O	-1	25054547
strat@@	O	-1	25054547
e.	O	-1	25054547
M@@	O	-1	25054547
D	O	-1	25054547
also	O	-1	25054547
showed	O	-1	25054547
that	O	-1	25054547
the	O	-1	25054547
enzyme	O	-1	25054547
volume	O	-1	25054547
is	O	-1	25054547
increas@@	O	-1	25054547
ed,	O	-1	25054547
suggesting	O	-1	25054547
a	O	-1	25054547
pre-@@	O	-1	25054547
d@@	O	-1	25054547
en@@	O	-1	25054547
at@@	O	-1	25054547
ur@@	O	-1	25054547
ation	O	-1	25054547
stat@@	O	-1	25054547
e.	O	-1	25054547
This	O	-1	25054547
f@@	O	-1	25054547
its	O	-1	25054547
with	O	-1	25054547
the	O	-1	25054547
reduced	O	-1	25054547
concentration	O	-1	25054547
of	O	-1	25054547
p.@@	O	-1	25054547
Al@@	O	-1	25054547
a@@	O	-1	25054547
20@@	O	-1	25054547
4@@	O	-1	25054547
A@@	O	-1	25054547
sp@@	O	-1	25054547
/@@	O	-1	25054547
p.@@	O	-1	25054547
A@@	O	-1	25054547
sp@@	O	-1	25054547
7@@	O	-1	25054547
0@@	O	-1	25054547
G@@	O	-1	25054547
l@@	O	-1	25054547
y-@@	O	-1	25054547
p.@@	O	-1	25054547
Al@@	O	-1	25054547
a@@	O	-1	25054547
5@@	O	-1	25054547
3@@	O	-1	25054547
9@@	O	-1	25054547
Th@@	O	-1	25054547
r	O	-1	25054547
te@@	O	-1	25054547
t@@	O	-1	25054547
ram@@	O	-1	25054547
er@@	O	-1	25054547
ic	O	-1	25054547
enzyme	O	-1	25054547
in	O	-1	25054547
the	O	-1	25054547
plasma	O	-1	25054547
and	O	-1	25054547
non-@@	O	-1	25054547
det@@	O	-1	25054547
ect@@	O	-1	25054547
able	O	-1	25054547
f@@	O	-1	25054547
ast	O	-1	25054547
mo@@	O	-1	25054547
v@@	O	-1	25054547
ing@@	O	-1	25054547
-@@	O	-1	25054547
b@@	O	-1	25054547
and@@	O	-1	25054547
s	O	-1	25054547
on	O	-1	25054547
electro@@	O	-1	25054547
ph@@	O	-1	25054547
ore@@	O	-1	25054547
sis	O	-1	25054547
g@@	O	-1	25054547
el@@	O	-1	25054547
s.	O	-1	25054547

D@@	O	-1	25071004
el@@	O	-1	25071004
ayed	O	-1	25071004
anemia	B-Disease	D000740	25071004
after	O	-1	25071004
treatment	O	-1	25071004
with	O	-1	25071004
inj@@	O	-1	25071004
ect@@	O	-1	25071004
able	O	-1	25071004
ar@@	B-Chemical	C039726	25071004
t@@	I-Chemical	-1	25071004
es@@	I-Chemical	-1	25071004
un@@	I-Chemical	-1	25071004
ate	I-Chemical	-1	25071004
in	O	-1	25071004
the	O	-1	25071004
D@@	O	-1	25071004
em@@	O	-1	25071004
oc@@	O	-1	25071004
r@@	O	-1	25071004
atic	O	-1	25071004
R@@	O	-1	25071004
ep@@	O	-1	25071004
u@@	O	-1	25071004
bl@@	O	-1	25071004
ic	O	-1	25071004
of	O	-1	25071004
the	O	-1	25071004
Con@@	O	-1	25071004
go@@	O	-1	25071004
:	O	-1	25071004
a	O	-1	25071004
man@@	O	-1	25071004
ag@@	O	-1	25071004
e@@	O	-1	25071004
able	O	-1	25071004
is@@	O	-1	25071004
su@@	O	-1	25071004
e.	O	-1	25071004
C@@	O	-1	25071004
as@@	O	-1	25071004
es	O	-1	25071004
of	O	-1	25071004
del@@	O	-1	25071004
ayed	O	-1	25071004
hemolytic	B-Disease	D000743	25071004
anemia	I-Disease	-1	25071004
have	O	-1	25071004
been	O	-1	25071004
descri@@	O	-1	25071004
bed	O	-1	25071004
after	O	-1	25071004
treatment	O	-1	25071004
with	O	-1	25071004
inj@@	O	-1	25071004
ect@@	O	-1	25071004
able	O	-1	25071004
ar@@	B-Chemical	C039726	25071004
t@@	I-Chemical	-1	25071004
es@@	I-Chemical	-1	25071004
un@@	I-Chemical	-1	25071004
ate	I-Chemical	-1	25071004
,	O	-1	25071004
the	O	-1	25071004
current	O	-1	25071004
W@@	O	-1	25071004
or@@	O	-1	25071004
l@@	O	-1	25071004
d	O	-1	25071004
He@@	O	-1	25071004
al@@	O	-1	25071004
th	O	-1	25071004
O@@	O	-1	25071004
r@@	O	-1	25071004
g@@	O	-1	25071004
an@@	O	-1	25071004
ization	O	-1	25071004
(@@	O	-1	25071004
W@@	O	-1	25071004
HO@@	O	-1	25071004
)-@@	O	-1	25071004
recomm@@	O	-1	25071004
en@@	O	-1	25071004
ded	O	-1	25071004
fir@@	O	-1	25071004
st@@	O	-1	25071004
-@@	O	-1	25071004
line	O	-1	25071004
drug	O	-1	25071004
for	O	-1	25071004
the	O	-1	25071004
treatment	O	-1	25071004
of	O	-1	25071004
severe	O	-1	25071004
mal@@	B-Disease	D008288	25071004
ar@@	I-Disease	-1	25071004
ia	I-Disease	-1	25071004
.	O	-1	25071004
A	O	-1	25071004
total	O	-1	25071004
of	O	-1	25071004
3@@	O	-1	25071004
50	O	-1	25071004
patients	O	-1	25071004
(2@@	O	-1	25071004
15	O	-1	25071004
[@@	O	-1	25071004
6@@	O	-1	25071004
1.@@	O	-1	25071004
4@@	O	-1	25071004
%@@	O	-1	25071004
]	O	-1	25071004
<	O	-1	25071004
5	O	-1	25071004
years	O	-1	25071004
of	O	-1	25071004
age	O	-1	25071004
and	O	-1	25071004
13@@	O	-1	25071004
5	O	-1	25071004
[@@	O	-1	25071004
3@@	O	-1	25071004
8.@@	O	-1	25071004
6@@	O	-1	25071004
%@@	O	-1	25071004
]	O	-1	25071004
>	O	-1	25071004
5	O	-1	25071004
years	O	-1	25071004
of	O	-1	25071004
ag@@	O	-1	25071004
e@@	O	-1	25071004
)	O	-1	25071004
were	O	-1	25071004
fol@@	O	-1	25071004
lo@@	O	-1	25071004
we@@	O	-1	25071004
d-@@	O	-1	25071004
up	O	-1	25071004
after	O	-1	25071004
treatment	O	-1	25071004
with	O	-1	25071004
inj@@	O	-1	25071004
ect@@	O	-1	25071004
able	O	-1	25071004
ar@@	B-Chemical	C039726	25071004
t@@	I-Chemical	-1	25071004
es@@	I-Chemical	-1	25071004
un@@	I-Chemical	-1	25071004
ate	I-Chemical	-1	25071004
for	O	-1	25071004
severe	O	-1	25071004
mal@@	B-Disease	D008288	25071004
ar@@	I-Disease	-1	25071004
ia	I-Disease	-1	25071004
in	O	-1	25071004
hospit@@	O	-1	25071004
als	O	-1	25071004
and	O	-1	25071004
heal@@	O	-1	25071004
th	O	-1	25071004
c@@	O	-1	25071004
ent@@	O	-1	25071004
ers	O	-1	25071004
of	O	-1	25071004
the	O	-1	25071004
D@@	O	-1	25071004
em@@	O	-1	25071004
oc@@	O	-1	25071004
r@@	O	-1	25071004
atic	O	-1	25071004
R@@	O	-1	25071004
ep@@	O	-1	25071004
u@@	O	-1	25071004
bl@@	O	-1	25071004
ic	O	-1	25071004
of	O	-1	25071004
the	O	-1	25071004
Con@@	O	-1	25071004
go@@	O	-1	25071004
.	O	-1	25071004
Com@@	O	-1	25071004
ple@@	O	-1	25071004
te	O	-1	25071004
seri@@	O	-1	25071004
es	O	-1	25071004
of	O	-1	25071004
hemo@@	O	-1	25071004
globin	O	-1	25071004
(@@	O	-1	25071004
H@@	O	-1	25071004
b@@	O	-1	25071004
)	O	-1	25071004
meas@@	O	-1	25071004
ure@@	O	-1	25071004
ments	O	-1	25071004
were	O	-1	25071004
av@@	O	-1	25071004
ail@@	O	-1	25071004
able	O	-1	25071004
for	O	-1	25071004
20@@	O	-1	25071004
1	O	-1	25071004
patients.	O	-1	25071004
A	O	-1	25071004
decrease	O	-1	25071004
in	O	-1	25071004
H@@	O	-1	25071004
b	O	-1	25071004
levels	O	-1	25071004
between	O	-1	25071004
2	O	-1	25071004
and	O	-1	25071004
5	O	-1	25071004
g/@@	O	-1	25071004
d@@	O	-1	25071004
L	O	-1	25071004
was	O	-1	25071004
det@@	O	-1	25071004
ected	O	-1	25071004
in	O	-1	25071004
2@@	O	-1	25071004
3	O	-1	25071004
(1@@	O	-1	25071004
1.@@	O	-1	25071004
4@@	O	-1	25071004
%)	O	-1	25071004
patients	O	-1	25071004
during	O	-1	25071004
the	O	-1	25071004
follow-up	O	-1	25071004
perio@@	O	-1	25071004
d.	O	-1	25071004
F@@	O	-1	25071004
or	O	-1	25071004
five	O	-1	25071004
patients,	O	-1	25071004
H@@	O	-1	25071004
b	O	-1	25071004
levels	O	-1	25071004
decreased	O	-1	25071004
be@@	O	-1	25071004
low	O	-1	25071004
5	O	-1	25071004
g/@@	O	-1	25071004
d@@	O	-1	25071004
L	O	-1	25071004
during	O	-1	25071004
at	O	-1	25071004
le@@	O	-1	25071004
ast	O	-1	25071004
one	O	-1	25071004
follow-up	O	-1	25071004
v@@	O	-1	25071004
is@@	O	-1	25071004
it@@	O	-1	25071004
.	O	-1	25071004
All	O	-1	25071004
cases	O	-1	25071004
of	O	-1	25071004
del@@	O	-1	25071004
ayed	O	-1	25071004
anemia	B-Disease	D000740	25071004
were	O	-1	25071004
clin@@	O	-1	25071004
ically	O	-1	25071004
man@@	O	-1	25071004
ag@@	O	-1	25071004
e@@	O	-1	25071004
able	O	-1	25071004
and	O	-1	25071004
resol@@	O	-1	25071004
ved	O	-1	25071004
within	O	-1	25071004
one	O	-1	25071004
month@@	O	-1	25071004
.	O	-1	25071004

Re@@	O	-1	25080425
g@@	O	-1	25080425
ulation	O	-1	25080425
of	O	-1	25080425
sign@@	O	-1	25080425
al	O	-1	25080425
trans@@	O	-1	25080425
duc@@	O	-1	25080425
er	O	-1	25080425
and	O	-1	25080425
activ@@	O	-1	25080425
at@@	O	-1	25080425
or	O	-1	25080425
of	O	-1	25080425
trans@@	O	-1	25080425
cri@@	O	-1	25080425
ption	O	-1	25080425
3	O	-1	25080425
and	O	-1	25080425
apo@@	O	-1	25080425
pto@@	O	-1	25080425
tic	O	-1	25080425
path@@	O	-1	25080425
w@@	O	-1	25080425
ays	O	-1	25080425
by	O	-1	25080425
beta@@	B-Chemical	D001622	25080425
ine	I-Chemical	-1	25080425
attenu@@	O	-1	25080425
ates	O	-1	25080425
isoproteren@@	B-Chemical	D007545	25080425
ol	I-Chemical	-1	25080425
-induced	O	-1	25080425
acute	O	-1	25080425
myocardial	B-Disease	D009202	25080425
injury	I-Disease	-1	25080425
in	O	-1	25080425
rats.	O	-1	25080425
The	O	-1	25080425
present	O	-1	25080425
study	O	-1	25080425
was	O	-1	25080425
de@@	O	-1	25080425
signed	O	-1	25080425
to	O	-1	25080425
investigate	O	-1	25080425
the	O	-1	25080425
cardio@@	O	-1	25080425
protective	O	-1	25080425
effects	O	-1	25080425
of	O	-1	25080425
beta@@	B-Chemical	D001622	25080425
ine	I-Chemical	-1	25080425
on	O	-1	25080425
acute	O	-1	25080425
myocardial	B-Disease	D017202	25080425
ischem@@	I-Disease	-1	25080425
ia	I-Disease	-1	25080425
induced	O	-1	25080425
experim@@	O	-1	25080425
ent@@	O	-1	25080425
ally	O	-1	25080425
in	O	-1	25080425
rats	O	-1	25080425
foc@@	O	-1	25080425
using	O	-1	25080425
on	O	-1	25080425
reg@@	O	-1	25080425
ulation	O	-1	25080425
of	O	-1	25080425
sign@@	O	-1	25080425
al	O	-1	25080425
trans@@	O	-1	25080425
duc@@	O	-1	25080425
er	O	-1	25080425
and	O	-1	25080425
activ@@	O	-1	25080425
at@@	O	-1	25080425
or	O	-1	25080425
of	O	-1	25080425
trans@@	O	-1	25080425
cri@@	O	-1	25080425
ption	O	-1	25080425
3	O	-1	25080425
(S@@	O	-1	25080425
T@@	O	-1	25080425
AT@@	O	-1	25080425
3@@	O	-1	25080425
)	O	-1	25080425
and	O	-1	25080425
apo@@	O	-1	25080425
pto@@	O	-1	25080425
tic	O	-1	25080425
path@@	O	-1	25080425
w@@	O	-1	25080425
ays	O	-1	25080425
as	O	-1	25080425
the	O	-1	25080425
potential	O	-1	25080425
mechanism	O	-1	25080425
underlying	O	-1	25080425
the	O	-1	25080425
drug	O	-1	25080425
effect@@	O	-1	25080425
.	O	-1	25080425
M@@	O	-1	25080425
al@@	O	-1	25080425
e	O	-1	25080425
S@@	O	-1	25080425
pra@@	O	-1	25080425
gu@@	O	-1	25080425
e	O	-1	25080425
D@@	O	-1	25080425
aw@@	O	-1	25080425
le@@	O	-1	25080425
y	O	-1	25080425
rats	O	-1	25080425
were	O	-1	25080425
treated	O	-1	25080425
with	O	-1	25080425
beta@@	B-Chemical	D001622	25080425
ine	I-Chemical	-1	25080425
(@@	O	-1	25080425
10@@	O	-1	25080425
0@@	O	-1	25080425
,	O	-1	25080425
20@@	O	-1	25080425
0@@	O	-1	25080425
,	O	-1	25080425
and	O	-1	25080425
4@@	O	-1	25080425
00	O	-1	25080425
mg/kg)	O	-1	25080425
or@@	O	-1	25080425
ally	O	-1	25080425
for	O	-1	25080425
40	O	-1	25080425
days.	O	-1	25080425
Ac@@	O	-1	25080425
ute	O	-1	25080425
myocardial	B-Disease	D017202	25080425
ischem@@	I-Disease	-1	25080425
ic	I-Disease	-1	25080425
injury	I-Disease	-1	25080425
was	O	-1	25080425
induced	O	-1	25080425
in	O	-1	25080425
rats	O	-1	25080425
by	O	-1	25080425
sub@@	O	-1	25080425
c@@	O	-1	25080425
utaneous	O	-1	25080425
injection	O	-1	25080425
of	O	-1	25080425
isoproteren@@	B-Chemical	D007545	25080425
ol	I-Chemical	-1	25080425
(@@	O	-1	25080425
8@@	O	-1	25080425
5	O	-1	25080425
mg/kg@@	O	-1	25080425
),	O	-1	25080425
for	O	-1	25080425
two	O	-1	25080425
con@@	O	-1	25080425
sec@@	O	-1	25080425
utive	O	-1	25080425
days.	O	-1	25080425
S@@	O	-1	25080425
er@@	O	-1	25080425
um	O	-1	25080425
cardiac	O	-1	25080425
mark@@	O	-1	25080425
er	O	-1	25080425
enz@@	O	-1	25080425
y@@	O	-1	25080425
me,	O	-1	25080425
histo@@	O	-1	25080425
path@@	O	-1	25080425
ological	O	-1	25080425
vari@@	O	-1	25080425
able@@	O	-1	25080425
s	O	-1	25080425
and	O	-1	25080425
expression	O	-1	25080425
of	O	-1	25080425
protein	O	-1	25080425
levels	O	-1	25080425
were	O	-1	25080425
analy@@	O	-1	25080425
z@@	O	-1	25080425
ed.	O	-1	25080425
O@@	O	-1	25080425
ral	O	-1	25080425
administration	O	-1	25080425
of	O	-1	25080425
beta@@	B-Chemical	D001622	25080425
ine	I-Chemical	-1	25080425
(2@@	O	-1	25080425
00	O	-1	25080425
and	O	-1	25080425
4@@	O	-1	25080425
00	O	-1	25080425
mg/kg)	O	-1	25080425
significantly	O	-1	25080425
reduced	O	-1	25080425
the	O	-1	25080425
level	O	-1	25080425
of	O	-1	25080425
cardiac	O	-1	25080425
mark@@	O	-1	25080425
er	O	-1	25080425
enzyme	O	-1	25080425
in	O	-1	25080425
the	O	-1	25080425
serum	O	-1	25080425
and	O	-1	25080425
prevent@@	O	-1	25080425
ed	O	-1	25080425
left	O	-1	25080425
ventricular	B-Disease	D020257	25080425
re@@	I-Disease	-1	25080425
model@@	I-Disease	-1	25080425
ing	I-Disease	-1	25080425
.	O	-1	25080425
W@@	O	-1	25080425
est@@	O	-1	25080425
er@@	O	-1	25080425
n	O	-1	25080425
blo@@	O	-1	25080425
t	O	-1	25080425
analysis	O	-1	25080425
showed	O	-1	25080425
that	O	-1	25080425
isoproteren@@	B-Chemical	D007545	25080425
ol	I-Chemical	-1	25080425
-induced	O	-1	25080425
phosph@@	O	-1	25080425
or@@	O	-1	25080425
yl@@	O	-1	25080425
ation	O	-1	25080425
of	O	-1	25080425
S@@	O	-1	25080425
T@@	O	-1	25080425
AT@@	O	-1	25080425
3	O	-1	25080425
was	O	-1	25080425
maint@@	O	-1	25080425
ained	O	-1	25080425
or	O	-1	25080425
further	O	-1	25080425
enhanced	O	-1	25080425
by	O	-1	25080425
beta@@	B-Chemical	D001622	25080425
ine	I-Chemical	-1	25080425
treatment	O	-1	25080425
in	O	-1	25080425
myocardi@@	O	-1	25080425
um@@	O	-1	25080425
.	O	-1	25080425
F@@	O	-1	25080425
ur@@	O	-1	25080425
ther@@	O	-1	25080425
mo@@	O	-1	25080425
re,	O	-1	25080425
beta@@	B-Chemical	D001622	25080425
ine	I-Chemical	-1	25080425
(2@@	O	-1	25080425
00	O	-1	25080425
and	O	-1	25080425
4@@	O	-1	25080425
00	O	-1	25080425
mg/kg)	O	-1	25080425
treatment	O	-1	25080425
increased	O	-1	25080425
the	O	-1	25080425
ventricular	O	-1	25080425
expression	O	-1	25080425
of	O	-1	25080425
B@@	O	-1	25080425
cl@@	O	-1	25080425
-@@	O	-1	25080425
2	O	-1	25080425
and	O	-1	25080425
reduced	O	-1	25080425
the	O	-1	25080425
level	O	-1	25080425
of	O	-1	25080425
B@@	O	-1	25080425
ax@@	O	-1	25080425
,	O	-1	25080425
the@@	O	-1	25080425
re@@	O	-1	25080425
fore	O	-1	25080425
ca@@	O	-1	25080425
using	O	-1	25080425
a	O	-1	25080425
significant	O	-1	25080425
increase	O	-1	25080425
in	O	-1	25080425
the	O	-1	25080425
rati@@	O	-1	25080425
o	O	-1	25080425
of	O	-1	25080425
B@@	O	-1	25080425
cl@@	O	-1	25080425
-@@	O	-1	25080425
2@@	O	-1	25080425
/@@	O	-1	25080425
B@@	O	-1	25080425
ax@@	O	-1	25080425
.	O	-1	25080425
The	O	-1	25080425
protective	O	-1	25080425
role	O	-1	25080425
of	O	-1	25080425
beta@@	B-Chemical	D001622	25080425
ine	I-Chemical	-1	25080425
on	O	-1	25080425
myocardial	B-Disease	D009202	25080425
damage	I-Disease	-1	25080425
was	O	-1	25080425
further	O	-1	25080425
con@@	O	-1	25080425
fir@@	O	-1	25080425
m@@	O	-1	25080425
ed	O	-1	25080425
by	O	-1	25080425
histo@@	O	-1	25080425
path@@	O	-1	25080425
ological	O	-1	25080425
examin@@	O	-1	25080425
ation.	O	-1	25080425
In	O	-1	25080425
su@@	O	-1	25080425
mm@@	O	-1	25080425
ar@@	O	-1	25080425
y,	O	-1	25080425
our	O	-1	25080425
results	O	-1	25080425
showed	O	-1	25080425
that	O	-1	25080425
beta@@	B-Chemical	D001622	25080425
ine	I-Chemical	-1	25080425
pretreatment	O	-1	25080425
attenu@@	O	-1	25080425
ated	O	-1	25080425
isoproteren@@	B-Chemical	D007545	25080425
ol	I-Chemical	-1	25080425
-induced	O	-1	25080425
acute	O	-1	25080425
myocardial	B-Disease	D017202	25080425
ischem@@	I-Disease	-1	25080425
ia	I-Disease	-1	25080425
vi@@	O	-1	25080425
a	O	-1	25080425
the	O	-1	25080425
reg@@	O	-1	25080425
ulation	O	-1	25080425
of	O	-1	25080425
S@@	O	-1	25080425
T@@	O	-1	25080425
AT@@	O	-1	25080425
3	O	-1	25080425
and	O	-1	25080425
apo@@	O	-1	25080425
pto@@	O	-1	25080425
tic	O	-1	25080425
path@@	O	-1	25080425
w@@	O	-1	25080425
ay@@	O	-1	25080425
s.	O	-1	25080425

Q@@	B-Chemical	C069541	25084821
u@@	I-Chemical	-1	25084821
e@@	I-Chemical	-1	25084821
ti@@	I-Chemical	-1	25084821
apine	I-Chemical	-1	25084821
-induced	O	-1	25084821
ne@@	B-Disease	D009503	25084821
ut@@	I-Disease	-1	25084821
ro@@	I-Disease	-1	25084821
pen@@	I-Disease	-1	25084821
ia	I-Disease	-1	25084821
in	O	-1	25084821
a	O	-1	25084821
b@@	B-Disease	D001714	25084821
ip@@	I-Disease	-1	25084821
ol@@	I-Disease	-1	25084821
ar	I-Disease	-1	25084821
patient	O	-1	25084821
with	O	-1	25084821
hepat@@	B-Disease	D006528	25084821
oc@@	I-Disease	-1	25084821
ell@@	I-Disease	-1	25084821
ular	I-Disease	-1	25084821
carcin@@	I-Disease	-1	25084821
oma	I-Disease	-1	25084821
.	O	-1	25084821
OBJECTIVE:	O	-1	25084821
Q@@	B-Chemical	C069541	25084821
u@@	I-Chemical	-1	25084821
e@@	I-Chemical	-1	25084821
ti@@	I-Chemical	-1	25084821
apine	I-Chemical	-1	25084821
is	O	-1	25084821
a	O	-1	25084821
di@@	O	-1	25084821
b@@	O	-1	25084821
enz@@	O	-1	25084821
o@@	O	-1	25084821
thi@@	O	-1	25084821
azepine	O	-1	25084821
der@@	O	-1	25084821
i@@	O	-1	25084821
v@@	O	-1	25084821
ati@@	O	-1	25084821
ve,	O	-1	25084821
similar	O	-1	25084821
to	O	-1	25084821
cloz@@	B-Chemical	D003024	25084821
apine	I-Chemical	-1	25084821
,	O	-1	25084821
which	O	-1	25084821
has	O	-1	25084821
the	O	-1	25084821
high@@	O	-1	25084821
est	O	-1	25084821
risk	O	-1	25084821
of	O	-1	25084821
ca@@	O	-1	25084821
using	O	-1	25084821
blood	B-Disease	D006402	25084821
dys@@	I-Disease	-1	25084821
c@@	I-Disease	-1	25084821
ra@@	I-Disease	-1	25084821
si@@	I-Disease	-1	25084821
as	I-Disease	-1	25084821
,	O	-1	25084821
es@@	O	-1	25084821
p@@	O	-1	25084821
ec@@	O	-1	25084821
i@@	O	-1	25084821
ally	O	-1	25084821
ne@@	B-Disease	D009503	25084821
ut@@	I-Disease	-1	25084821
ro@@	I-Disease	-1	25084821
pen@@	I-Disease	-1	25084821
ia	I-Disease	-1	25084821
.	O	-1	25084821
There	O	-1	25084821
are	O	-1	25084821
some	O	-1	25084821
case	O	-1	25084821
reports	O	-1	25084821
about	O	-1	25084821
this	O	-1	25084821
side	O	-1	25084821
effect	O	-1	25084821
of	O	-1	25084821
qu@@	B-Chemical	C069541	25084821
e@@	I-Chemical	-1	25084821
ti@@	I-Chemical	-1	25084821
apine	I-Chemical	-1	25084821
,	O	-1	25084821
but	O	-1	25084821
possible	O	-1	25084821
risk	O	-1	25084821
factors	O	-1	25084821
are	O	-1	25084821
sel@@	O	-1	25084821
do@@	O	-1	25084821
m	O	-1	25084821
discus@@	O	-1	25084821
sed	O	-1	25084821
and	O	-1	25084821
identi@@	O	-1	25084821
fi@@	O	-1	25084821
ed.	O	-1	25084821
A	O	-1	25084821
case	O	-1	25084821
of	O	-1	25084821
a	O	-1	25084821
patient	O	-1	25084821
with	O	-1	25084821
hepat@@	B-Disease	D006528	25084821
oc@@	I-Disease	-1	25084821
ell@@	I-Disease	-1	25084821
ular	I-Disease	-1	25084821
carcin@@	I-Disease	-1	25084821
oma	I-Disease	-1	25084821
that	O	-1	25084821
developed	O	-1	25084821
ne@@	B-Disease	D009503	25084821
ut@@	I-Disease	-1	25084821
ro@@	I-Disease	-1	25084821
pen@@	I-Disease	-1	25084821
ia	I-Disease	-1	25084821
after	O	-1	25084821
treatment	O	-1	25084821
with	O	-1	25084821
qu@@	B-Chemical	C069541	25084821
e@@	I-Chemical	-1	25084821
ti@@	I-Chemical	-1	25084821
apine	I-Chemical	-1	25084821
is	O	-1	25084821
descri@@	O	-1	25084821
bed	O	-1	25084821
he@@	O	-1	25084821
re.	O	-1	25084821
CA@@	O	-1	25084821
S@@	O	-1	25084821
E	O	-1	25084821
R@@	O	-1	25084821
EP@@	O	-1	25084821
O@@	O	-1	25084821
R@@	O	-1	25084821
T@@	O	-1	25084821
:	O	-1	25084821
A	O	-1	25084821
6@@	O	-1	25084821
2-@@	O	-1	25084821
year-old	O	-1	25084821
T@@	O	-1	25084821
a@@	O	-1	25084821
i@@	O	-1	25084821
w@@	O	-1	25084821
an@@	O	-1	25084821
ese	O	-1	25084821
w@@	O	-1	25084821
id@@	O	-1	25084821
o@@	O	-1	25084821
w	O	-1	25084821
with	O	-1	25084821
b@@	B-Disease	D001714	25084821
ip@@	I-Disease	-1	25084821
ol@@	I-Disease	-1	25084821
ar	I-Disease	-1	25084821
disor@@	I-Disease	-1	25084821
der	I-Disease	-1	25084821
was	O	-1	25084821
diagnos@@	O	-1	25084821
ed	O	-1	25084821
with	O	-1	25084821
hepat@@	B-Disease	D006528	25084821
oc@@	I-Disease	-1	25084821
ell@@	I-Disease	-1	25084821
ular	I-Disease	-1	25084821
carcin@@	I-Disease	-1	25084821
oma	I-Disease	-1	25084821
at	O	-1	25084821
age	O	-1	25084821
6@@	O	-1	25084821
0@@	O	-1	25084821
.	O	-1	25084821
S@@	O	-1	25084821
he	O	-1	25084821
developed	O	-1	25084821
leu@@	B-Disease	D007970	25084821
co@@	I-Disease	-1	25084821
pen@@	I-Disease	-1	25084821
ia	I-Disease	-1	25084821
after	O	-1	25084821
being	O	-1	25084821
treated	O	-1	25084821
with	O	-1	25084821
qu@@	B-Chemical	C069541	25084821
e@@	I-Chemical	-1	25084821
ti@@	I-Chemical	-1	25084821
apine	I-Chemical	-1	25084821
.	O	-1	25084821
After	O	-1	25084821
qu@@	B-Chemical	C069541	25084821
e@@	I-Chemical	-1	25084821
ti@@	I-Chemical	-1	25084821
apine	I-Chemical	-1	25084821
was	O	-1	25084821
discontinu@@	O	-1	25084821
ed,	O	-1	25084821
h@@	O	-1	25084821
er	O	-1	25084821
wh@@	O	-1	25084821
ite	O	-1	25084821
blood	O	-1	25084821
cell	O	-1	25084821
coun@@	O	-1	25084821
t	O	-1	25084821
retur@@	O	-1	25084821
n@@	O	-1	25084821
ed	O	-1	25084821
to	O	-1	25084821
normal@@	O	-1	25084821
.	O	-1	25084821
CONCLUSIONS:	O	-1	25084821
Although	O	-1	25084821
ne@@	B-Disease	D009503	25084821
ut@@	I-Disease	-1	25084821
ro@@	I-Disease	-1	25084821
pen@@	I-Disease	-1	25084821
ia	I-Disease	-1	25084821
is	O	-1	25084821
not	O	-1	25084821
a	O	-1	25084821
common	O	-1	25084821
side	O	-1	25084821
effect	O	-1	25084821
of	O	-1	25084821
qu@@	B-Chemical	C069541	25084821
e@@	I-Chemical	-1	25084821
ti@@	I-Chemical	-1	25084821
apine	I-Chemical	-1	25084821
,	O	-1	25084821
physi@@	O	-1	25084821
ci@@	O	-1	25084821
ans	O	-1	25084821
should	O	-1	25084821
be	O	-1	25084821
cau@@	O	-1	25084821
ti@@	O	-1	25084821
ous	O	-1	25084821
about	O	-1	25084821
its	O	-1	25084821
present@@	O	-1	25084821
ation	O	-1	25084821
and	O	-1	25084821
associated	O	-1	25084821
risk	O	-1	25084821
fact@@	O	-1	25084821
or@@	O	-1	25084821
s.	O	-1	25084821
He@@	B-Disease	D008107	25084821
pati@@	I-Disease	-1	25084821
c	I-Disease	-1	25084821
dysfunction	I-Disease	-1	25084821
may	O	-1	25084821
be	O	-1	25084821
one	O	-1	25084821
of	O	-1	25084821
the	O	-1	25084821
possible	O	-1	25084821
risk	O	-1	25084821
fact@@	O	-1	25084821
or@@	O	-1	25084821
s,	O	-1	25084821
and	O	-1	25084821
concomit@@	O	-1	25084821
ant	O	-1	25084821
f@@	B-Disease	D005334	25084821
ev@@	I-Disease	-1	25084821
er	I-Disease	-1	25084821
may	O	-1	25084821
be	O	-1	25084821
a	O	-1	25084821
diagnos@@	O	-1	25084821
tic	O	-1	25084821
mark@@	O	-1	25084821
er	O	-1	25084821
for	O	-1	25084821
adverse	O	-1	25084821
reaction	O	-1	25084821
to	O	-1	25084821
qu@@	B-Chemical	C069541	25084821
e@@	I-Chemical	-1	25084821
ti@@	I-Chemical	-1	25084821
apine	I-Chemical	-1	25084821
.	O	-1	25084821

L@@	O	-1	25096313
ateral	O	-1	25096313
an@@	O	-1	25096313
te@@	O	-1	25096313
b@@	O	-1	25096313
rac@@	O	-1	25096313
hi@@	O	-1	25096313
al	O	-1	25096313
c@@	O	-1	25096313
utaneous	O	-1	25096313
neuropathy	B-Disease	D009422	25096313
after	O	-1	25096313
ster@@	B-Chemical	D013256	25096313
oid	I-Chemical	-1	25096313
injection	O	-1	25096313
at	O	-1	25096313
lat@@	O	-1	25096313
eral	O	-1	25096313
ep@@	O	-1	25096313
ic@@	O	-1	25096313
on@@	O	-1	25096313
dy@@	O	-1	25096313
le@@	O	-1	25096313
.	O	-1	25096313
BACKGROUN@@	O	-1	25096313
D	O	-1	25096313
AN@@	O	-1	25096313
D	O	-1	25096313
OBJECTIV@@	O	-1	25096313
E@@	O	-1	25096313
S:	O	-1	25096313
This	O	-1	25096313
report	O	-1	25096313
a@@	O	-1	25096313
im@@	O	-1	25096313
ed	O	-1	25096313
to	O	-1	25096313
present	O	-1	25096313
a	O	-1	25096313
case	O	-1	25096313
of	O	-1	25096313
lat@@	O	-1	25096313
eral	O	-1	25096313
an@@	O	-1	25096313
te@@	O	-1	25096313
b@@	O	-1	25096313
rac@@	O	-1	25096313
hi@@	O	-1	25096313
al	O	-1	25096313
c@@	O	-1	25096313
utaneous	O	-1	25096313
neuropathy	B-Disease	D009422	25096313
(@@	O	-1	25096313
L@@	O	-1	25096313
AC@@	O	-1	25096313
N@@	O	-1	25096313
P)	O	-1	25096313
that	O	-1	25096313
occurred	O	-1	25096313
after	O	-1	25096313
a	O	-1	25096313
ster@@	B-Chemical	D013256	25096313
oid	I-Chemical	-1	25096313
injection	O	-1	25096313
in	O	-1	25096313
the	O	-1	25096313
lat@@	O	-1	25096313
eral	O	-1	25096313
ep@@	O	-1	25096313
ic@@	O	-1	25096313
on@@	O	-1	25096313
dy@@	O	-1	25096313
le	O	-1	25096313
to	O	-1	25096313
tre@@	O	-1	25096313
at	O	-1	25096313
lat@@	B-Disease	D013716	25096313
eral	I-Disease	-1	25096313
ep@@	I-Disease	-1	25096313
ic@@	I-Disease	-1	25096313
on@@	I-Disease	-1	25096313
dy@@	I-Disease	-1	25096313
li@@	I-Disease	-1	25096313
tis	I-Disease	-1	25096313
in	O	-1	25096313
a	O	-1	25096313
4@@	O	-1	25096313
0-@@	O	-1	25096313
year-old	O	-1	25096313
wom@@	O	-1	25096313
an@@	O	-1	25096313
.	O	-1	25096313
M@@	O	-1	25096313
AT@@	O	-1	25096313
E@@	O	-1	25096313
R@@	O	-1	25096313
I@@	O	-1	25096313
A@@	O	-1	25096313
L	O	-1	25096313
AN@@	O	-1	25096313
D	O	-1	25096313
METHOD@@	O	-1	25096313
:	O	-1	25096313
A	O	-1	25096313
4@@	O	-1	25096313
0-@@	O	-1	25096313
year-old	O	-1	25096313
woman	O	-1	25096313
presented	O	-1	25096313
with	O	-1	25096313
decreased	O	-1	25096313
sens@@	O	-1	25096313
ation	O	-1	25096313
and	O	-1	25096313
pa@@	B-Disease	D010292	25096313
res@@	I-Disease	-1	25096313
the@@	I-Disease	-1	25096313
sia	I-Disease	-1	25096313
over	O	-1	25096313
h@@	O	-1	25096313
er	O	-1	25096313
right	O	-1	25096313
lat@@	O	-1	25096313
eral	O	-1	25096313
fo@@	O	-1	25096313
re@@	O	-1	25096313
ar@@	O	-1	25096313
m@@	O	-1	25096313
;	O	-1	25096313
the	O	-1	25096313
pa@@	B-Disease	D010292	25096313
res@@	I-Disease	-1	25096313
the@@	I-Disease	-1	25096313
sia	I-Disease	-1	25096313
had	O	-1	25096313
occurred	O	-1	25096313
after	O	-1	25096313
a	O	-1	25096313
ster@@	B-Chemical	D013256	25096313
oid	I-Chemical	-1	25096313
injection	O	-1	25096313
in	O	-1	25096313
the	O	-1	25096313
right	O	-1	25096313
lat@@	O	-1	25096313
eral	O	-1	25096313
ep@@	O	-1	25096313
ic@@	O	-1	25096313
on@@	O	-1	25096313
dy@@	O	-1	25096313
le	O	-1	25096313
3	O	-1	25096313
months	O	-1	25096313
be@@	O	-1	25096313
fo@@	O	-1	25096313
re.	O	-1	25096313
H@@	O	-1	25096313
er	O	-1	25096313
sens@@	O	-1	25096313
ation	O	-1	25096313
of	O	-1	25096313
li@@	O	-1	25096313
ght	O	-1	25096313
to@@	O	-1	25096313
uc@@	O	-1	25096313
h	O	-1	25096313
and	O	-1	25096313
pain	B-Disease	D010146	25096313
was	O	-1	25096313
di@@	O	-1	25096313
min@@	O	-1	25096313
ished	O	-1	25096313
over	O	-1	25096313
the	O	-1	25096313
lat@@	O	-1	25096313
eral	O	-1	25096313
side	O	-1	25096313
of	O	-1	25096313
the	O	-1	25096313
right	O	-1	25096313
fo@@	O	-1	25096313
re@@	O	-1	25096313
ar@@	O	-1	25096313
m	O	-1	25096313
and	O	-1	25096313
w@@	O	-1	25096313
ris@@	O	-1	25096313
t	O	-1	25096313
a@@	O	-1	25096313
re@@	O	-1	25096313
a.	O	-1	25096313
RESULTS:	O	-1	25096313
The	O	-1	25096313
sens@@	O	-1	25096313
ory	O	-1	25096313
action	O	-1	25096313
potential	O	-1	25096313
am@@	O	-1	25096313
pl@@	O	-1	25096313
it@@	O	-1	25096313
ude	O	-1	25096313
of	O	-1	25096313
the	O	-1	25096313
right	O	-1	25096313
lat@@	O	-1	25096313
eral	O	-1	25096313
an@@	O	-1	25096313
te@@	O	-1	25096313
b@@	O	-1	25096313
rac@@	O	-1	25096313
hi@@	O	-1	25096313
al	O	-1	25096313
c@@	O	-1	25096313
utaneous	O	-1	25096313
nerve	O	-1	25096313
(@@	O	-1	25096313
L@@	O	-1	25096313
AC@@	O	-1	25096313
N@@	O	-1	25096313
)	O	-1	25096313
(@@	O	-1	25096313
6.@@	O	-1	25096313
2	O	-1	25096313
u@@	O	-1	25096313
V@@	O	-1	25096313
)	O	-1	25096313
was	O	-1	25096313
lower	O	-1	25096313
than	O	-1	25096313
that	O	-1	25096313
of	O	-1	25096313
the	O	-1	25096313
left	O	-1	25096313
(1@@	O	-1	25096313
3.@@	O	-1	25096313
1	O	-1	25096313
u@@	O	-1	25096313
V@@	O	-1	25096313
).	O	-1	25096313
The	O	-1	25096313
difference	O	-1	25096313
of	O	-1	25096313
am@@	O	-1	25096313
pl@@	O	-1	25096313
it@@	O	-1	25096313
ude	O	-1	25096313
between	O	-1	25096313
both	O	-1	25096313
side@@	O	-1	25096313
s	O	-1	25096313
was	O	-1	25096313
significant	O	-1	25096313
because	O	-1	25096313
there	O	-1	25096313
was	O	-1	25096313
more	O	-1	25096313
than	O	-1	25096313
a	O	-1	25096313
50@@	O	-1	25096313
%	O	-1	25096313
reduc@@	O	-1	25096313
tion.	O	-1	25096313
S@@	O	-1	25096313
he	O	-1	25096313
was	O	-1	25096313
diagnos@@	O	-1	25096313
ed	O	-1	25096313
with	O	-1	25096313
right	O	-1	25096313
L@@	O	-1	25096313
AC@@	O	-1	25096313
N@@	O	-1	25096313
P	O	-1	25096313
(@@	O	-1	25096313
main@@	O	-1	25096313
ly	O	-1	25096313
ax@@	O	-1	25096313
on@@	O	-1	25096313
al	O	-1	25096313
invol@@	O	-1	25096313
ve@@	O	-1	25096313
ment@@	O	-1	25096313
)	O	-1	25096313
on	O	-1	25096313
the	O	-1	25096313
b@@	O	-1	25096313
asis	O	-1	25096313
of	O	-1	25096313
the	O	-1	25096313
clinical	O	-1	25096313
man@@	O	-1	25096313
if@@	O	-1	25096313
est@@	O	-1	25096313
ation	O	-1	25096313
and	O	-1	25096313
the	O	-1	25096313
electro@@	O	-1	25096313
diagnos@@	O	-1	25096313
tic	O	-1	25096313
find@@	O	-1	25096313
ing@@	O	-1	25096313
s.	O	-1	25096313
H@@	O	-1	25096313
er	O	-1	25096313
symptoms	O	-1	25096313
improved	O	-1	25096313
through	O	-1	25096313
physi@@	O	-1	25096313
c@@	O	-1	25096313
al	O	-1	25096313
therapy	O	-1	25096313
but	O	-1	25096313
per@@	O	-1	25096313
sist@@	O	-1	25096313
ed	O	-1	25096313
to	O	-1	25096313
some	O	-1	25096313
de@@	O	-1	25096313
gre@@	O	-1	25096313
e.	O	-1	25096313
CONCLUSION:	O	-1	25096313
This	O	-1	25096313
report	O	-1	25096313
descri@@	O	-1	25096313
b@@	O	-1	25096313
es	O	-1	25096313
the	O	-1	25096313
case	O	-1	25096313
of	O	-1	25096313
a	O	-1	25096313
woman	O	-1	25096313
with	O	-1	25096313
L@@	O	-1	25096313
AC@@	O	-1	25096313
N@@	O	-1	25096313
P	O	-1	25096313
that	O	-1	25096313
developed	O	-1	25096313
after	O	-1	25096313
a	O	-1	25096313
ster@@	B-Chemical	D013256	25096313
oid	I-Chemical	-1	25096313
injection	O	-1	25096313
for	O	-1	25096313
the	O	-1	25096313
treatment	O	-1	25096313
of	O	-1	25096313
lat@@	B-Disease	D013716	25096313
eral	I-Disease	-1	25096313
ep@@	I-Disease	-1	25096313
ic@@	I-Disease	-1	25096313
on@@	I-Disease	-1	25096313
dy@@	I-Disease	-1	25096313
li@@	I-Disease	-1	25096313
tis	I-Disease	-1	25096313
.	O	-1	25096313
An	O	-1	25096313
electro@@	O	-1	25096313
diagnos@@	O	-1	25096313
tic	O	-1	25096313
study,	O	-1	25096313
including	O	-1	25096313
a	O	-1	25096313
nerve	O	-1	25096313
con@@	O	-1	25096313
duction	O	-1	25096313
study	O	-1	25096313
of	O	-1	25096313
the	O	-1	25096313
L@@	O	-1	25096313
AC@@	O	-1	25096313
N@@	O	-1	25096313
,	O	-1	25096313
was	O	-1	25096313
he@@	O	-1	25096313
l@@	O	-1	25096313
p@@	O	-1	25096313
ful	O	-1	25096313
to	O	-1	25096313
diag@@	O	-1	25096313
n@@	O	-1	25096313
ose	O	-1	25096313
right	O	-1	25096313
L@@	O	-1	25096313
AC@@	O	-1	25096313
N@@	O	-1	25096313
P	O	-1	25096313
and	O	-1	25096313
to	O	-1	25096313
f@@	O	-1	25096313
ind	O	-1	25096313
the	O	-1	25096313
p@@	O	-1	25096313
ass@@	O	-1	25096313
age	O	-1	25096313
of	O	-1	25096313
the	O	-1	25096313
L@@	O	-1	25096313
AC@@	O	-1	25096313
N	O	-1	25096313
on	O	-1	25096313
the	O	-1	25096313
lat@@	O	-1	25096313
eral	O	-1	25096313
ep@@	O	-1	25096313
ic@@	O	-1	25096313
on@@	O	-1	25096313
dy@@	O	-1	25096313
le@@	O	-1	25096313
.	O	-1	25096313

C@@	B-Chemical	D003474	25119790
ur@@	I-Chemical	-1	25119790
cum@@	I-Chemical	-1	25119790
in	I-Chemical	-1	25119790
prev@@	O	-1	25119790
ents	O	-1	25119790
mal@@	B-Chemical	C030272	25119790
e@@	I-Chemical	-1	25119790
ate	I-Chemical	-1	25119790
-induced	O	-1	25119790
nephro@@	B-Disease	D007674	25119790
toxicity	I-Disease	-1	25119790
:	O	-1	25119790
rel@@	O	-1	25119790
ation	O	-1	25119790
to	O	-1	25119790
hemo@@	O	-1	25119790
dynam@@	O	-1	25119790
ic	O	-1	25119790
al@@	O	-1	25119790
ter@@	O	-1	25119790
ation@@	O	-1	25119790
s,	O	-1	25119790
oxid@@	O	-1	25119790
ative	O	-1	25119790
stres@@	O	-1	25119790
s,	O	-1	25119790
mitochondrial	O	-1	25119790
oxy@@	B-Chemical	D010100	25119790
gen	I-Chemical	-1	25119790
consum@@	O	-1	25119790
ption	O	-1	25119790
and	O	-1	25119790
activity	O	-1	25119790
of	O	-1	25119790
respiratory	O	-1	25119790
comple@@	O	-1	25119790
x	O	-1	25119790
I@@	O	-1	25119790
.	O	-1	25119790
The	O	-1	25119790
potential	O	-1	25119790
protective	O	-1	25119790
effect	O	-1	25119790
of	O	-1	25119790
the	O	-1	25119790
di@@	O	-1	25119790
et@@	O	-1	25119790
ary	O	-1	25119790
anti@@	O	-1	25119790
oxid@@	O	-1	25119790
ant	O	-1	25119790
cur@@	B-Chemical	D003474	25119790
cum@@	I-Chemical	-1	25119790
in	I-Chemical	-1	25119790
(1@@	O	-1	25119790
20	O	-1	25119790
mg/@@	O	-1	25119790
K@@	O	-1	25119790
g/@@	O	-1	25119790
day	O	-1	25119790
for	O	-1	25119790
6	O	-1	25119790
da@@	O	-1	25119790
ys@@	O	-1	25119790
)	O	-1	25119790
against	O	-1	25119790
the	O	-1	25119790
renal	B-Disease	D007674	25119790
injury	I-Disease	-1	25119790
induced	O	-1	25119790
by	O	-1	25119790
mal@@	B-Chemical	C030272	25119790
e@@	I-Chemical	-1	25119790
ate	I-Chemical	-1	25119790
was	O	-1	25119790
evalu@@	O	-1	25119790
ated.	O	-1	25119790
T@@	O	-1	25119790
ub@@	O	-1	25119790
ular	O	-1	25119790
proteinuria	B-Disease	D011507	25119790
and	O	-1	25119790
oxid@@	O	-1	25119790
ative	O	-1	25119790
stres@@	O	-1	25119790
s	O	-1	25119790
were	O	-1	25119790
induced	O	-1	25119790
by	O	-1	25119790
a	O	-1	25119790
single	O	-1	25119790
injection	O	-1	25119790
of	O	-1	25119790
mal@@	B-Chemical	C030272	25119790
e@@	I-Chemical	-1	25119790
ate	I-Chemical	-1	25119790
(4@@	O	-1	25119790
00	O	-1	25119790
mg/kg)	O	-1	25119790
in	O	-1	25119790
rats.	O	-1	25119790
M@@	B-Chemical	C030272	25119790
al@@	I-Chemical	-1	25119790
e@@	I-Chemical	-1	25119790
ate	I-Chemical	-1	25119790
-induced	O	-1	25119790
renal	B-Disease	D007674	25119790
injury	I-Disease	-1	25119790
included	O	-1	25119790
increase	O	-1	25119790
in	O	-1	25119790
renal	O	-1	25119790
vascular	O	-1	25119790
resist@@	O	-1	25119790
ance	O	-1	25119790
and	O	-1	25119790
in	O	-1	25119790
the	O	-1	25119790
urinary	O	-1	25119790
ex@@	O	-1	25119790
cre@@	O	-1	25119790
tion	O	-1	25119790
of	O	-1	25119790
total	O	-1	25119790
protein@@	O	-1	25119790
,	O	-1	25119790
g@@	B-Chemical	D005947	25119790
lu@@	I-Chemical	-1	25119790
co@@	I-Chemical	-1	25119790
se	I-Chemical	-1	25119790
,	O	-1	25119790
sodium	B-Chemical	D012964	25119790
,	O	-1	25119790
ne@@	O	-1	25119790
ut@@	O	-1	25119790
ro@@	O	-1	25119790
ph@@	O	-1	25119790
il	O	-1	25119790
g@@	O	-1	25119790
el@@	O	-1	25119790
at@@	O	-1	25119790
in@@	O	-1	25119790
as@@	O	-1	25119790
e-@@	O	-1	25119790
associated	O	-1	25119790
li@@	O	-1	25119790
p@@	O	-1	25119790
oc@@	O	-1	25119790
al@@	O	-1	25119790
in	O	-1	25119790
(N@@	O	-1	25119790
G@@	O	-1	25119790
AL@@	O	-1	25119790
)	O	-1	25119790
and	O	-1	25119790
N@@	O	-1	25119790
-@@	O	-1	25119790
acet@@	O	-1	25119790
yl	O	-1	25119790
b@@	O	-1	25119790
-@@	O	-1	25119790
D-@@	O	-1	25119790
g@@	O	-1	25119790
lu@@	O	-1	25119790
co@@	O	-1	25119790
s@@	O	-1	25119790
amin@@	O	-1	25119790
id@@	O	-1	25119790
ase	O	-1	25119790
(N@@	O	-1	25119790
A@@	O	-1	25119790
G@@	O	-1	25119790
),	O	-1	25119790
u@@	O	-1	25119790
pre@@	O	-1	25119790
g@@	O	-1	25119790
ulation	O	-1	25119790
of	O	-1	25119790
kidney	B-Disease	D007674	25119790
injury	I-Disease	-1	25119790
mol@@	O	-1	25119790
ec@@	O	-1	25119790
ul@@	O	-1	25119790
e	O	-1	25119790
(@@	O	-1	25119790
K@@	O	-1	25119790
I@@	O	-1	25119790
M@@	O	-1	25119790
)@@	O	-1	25119790
-1@@	O	-1	25119790
,	O	-1	25119790
decrease	O	-1	25119790
in	O	-1	25119790
renal	O	-1	25119790
blood	O	-1	25119790
flow	O	-1	25119790
and	O	-1	25119790
cl@@	O	-1	25119790
a@@	O	-1	25119790
ud@@	O	-1	25119790
in-@@	O	-1	25119790
2	O	-1	25119790
expression	O	-1	25119790
be@@	O	-1	25119790
side@@	O	-1	25119790
s	O	-1	25119790
of	O	-1	25119790
necro@@	B-Disease	D009336	25119790
sis	I-Disease	-1	25119790
and	O	-1	25119790
apo@@	O	-1	25119790
pto@@	O	-1	25119790
sis	O	-1	25119790
of	O	-1	25119790
tub@@	O	-1	25119790
ular	O	-1	25119790
cells	O	-1	25119790
on	O	-1	25119790
24	O	-1	25119790
h@@	O	-1	25119790
.	O	-1	25119790
O@@	O	-1	25119790
x@@	O	-1	25119790
id@@	O	-1	25119790
ative	O	-1	25119790
stres@@	O	-1	25119790
s	O	-1	25119790
was	O	-1	25119790
determined	O	-1	25119790
by	O	-1	25119790
meas@@	O	-1	25119790
uring	O	-1	25119790
the	O	-1	25119790
oxid@@	O	-1	25119790
ation	O	-1	25119790
of	O	-1	25119790
li@@	O	-1	25119790
pid@@	O	-1	25119790
s	O	-1	25119790
and	O	-1	25119790
protein@@	O	-1	25119790
s	O	-1	25119790
and	O	-1	25119790
di@@	O	-1	25119790
min@@	O	-1	25119790
u@@	O	-1	25119790
tion	O	-1	25119790
in	O	-1	25119790
renal	O	-1	25119790
N@@	O	-1	25119790
r@@	O	-1	25119790
f@@	O	-1	25119790
2	O	-1	25119790
level@@	O	-1	25119790
s.	O	-1	25119790
S@@	O	-1	25119790
t@@	O	-1	25119790
udi@@	O	-1	25119790
es	O	-1	25119790
were	O	-1	25119790
also	O	-1	25119790
con@@	O	-1	25119790
duc@@	O	-1	25119790
ted	O	-1	25119790
in	O	-1	25119790
renal	O	-1	25119790
epi@@	O	-1	25119790
thelial	O	-1	25119790
L@@	O	-1	25119790
L@@	O	-1	25119790
C@@	O	-1	25119790
-@@	O	-1	25119790
P@@	O	-1	25119790
K@@	O	-1	25119790
1	O	-1	25119790
cells	O	-1	25119790
and	O	-1	25119790
in	O	-1	25119790
mitochond@@	O	-1	25119790
ri@@	O	-1	25119790
a	O	-1	25119790
isol@@	O	-1	25119790
ated	O	-1	25119790
from	O	-1	25119790
kidne@@	O	-1	25119790
ys	O	-1	25119790
of	O	-1	25119790
all	O	-1	25119790
the	O	-1	25119790
experimental	O	-1	25119790
groups.	O	-1	25119790
M@@	B-Chemical	C030272	25119790
al@@	I-Chemical	-1	25119790
e@@	I-Chemical	-1	25119790
ate	I-Chemical	-1	25119790
induced	O	-1	25119790
cell	O	-1	25119790
damage	O	-1	25119790
and	O	-1	25119790
reac@@	O	-1	25119790
tive	O	-1	25119790
oxy@@	B-Chemical	D010100	25119790
gen	I-Chemical	-1	25119790
spec@@	O	-1	25119790
i@@	O	-1	25119790
es	O	-1	25119790
(@@	O	-1	25119790
RO@@	O	-1	25119790
S)	O	-1	25119790
pro@@	O	-1	25119790
duction	O	-1	25119790
in	O	-1	25119790
L@@	O	-1	25119790
L@@	O	-1	25119790
C@@	O	-1	25119790
-@@	O	-1	25119790
P@@	O	-1	25119790
K@@	O	-1	25119790
1	O	-1	25119790
cells	O	-1	25119790
in	O	-1	25119790
c@@	O	-1	25119790
ult@@	O	-1	25119790
ure.	O	-1	25119790
In	O	-1	25119790
addi@@	O	-1	25119790
tion,	O	-1	25119790
mal@@	B-Chemical	C030272	25119790
e@@	I-Chemical	-1	25119790
ate	I-Chemical	-1	25119790
treatment	O	-1	25119790
reduced	O	-1	25119790
oxy@@	B-Chemical	D010100	25119790
gen	I-Chemical	-1	25119790
consum@@	O	-1	25119790
ption	O	-1	25119790
in	O	-1	25119790
AD@@	B-Chemical	D000244	25119790
P	I-Chemical	-1	25119790
-@@	O	-1	25119790
stimul@@	O	-1	25119790
ated	O	-1	25119790
mitochond@@	O	-1	25119790
ri@@	O	-1	25119790
a	O	-1	25119790
and	O	-1	25119790
di@@	O	-1	25119790
min@@	O	-1	25119790
ished	O	-1	25119790
respiratory	O	-1	25119790
control	O	-1	25119790
in@@	O	-1	25119790
de@@	O	-1	25119790
x	O	-1	25119790
when	O	-1	25119790
using	O	-1	25119790
mal@@	B-Chemical	C030298	25119790
ate	I-Chemical	-1	25119790
/	O	-1	25119790
glutamate	B-Chemical	D018698	25119790
as	O	-1	25119790
sub@@	O	-1	25119790
strat@@	O	-1	25119790
e.	O	-1	25119790
The	O	-1	25119790
ac@@	O	-1	25119790
ti@@	O	-1	25119790
vi@@	O	-1	25119790
ties	O	-1	25119790
of	O	-1	25119790
both	O	-1	25119790
comple@@	O	-1	25119790
x	O	-1	25119790
I	O	-1	25119790
and	O	-1	25119790
ac@@	O	-1	25119790
on@@	O	-1	25119790
it@@	O	-1	25119790
ase	O	-1	25119790
were	O	-1	25119790
also	O	-1	25119790
di@@	O	-1	25119790
min@@	O	-1	25119790
is@@	O	-1	25119790
he@@	O	-1	25119790
d.	O	-1	25119790
All	O	-1	25119790
the	O	-1	25119790
ab@@	O	-1	25119790
o@@	O	-1	25119790
ve@@	O	-1	25119790
-@@	O	-1	25119790
descri@@	O	-1	25119790
bed	O	-1	25119790
al@@	O	-1	25119790
ter@@	O	-1	25119790
ations	O	-1	25119790
were	O	-1	25119790
prevent@@	O	-1	25119790
ed	O	-1	25119790
by	O	-1	25119790
cur@@	B-Chemical	D003474	25119790
cum@@	I-Chemical	-1	25119790
in	I-Chemical	-1	25119790
.	O	-1	25119790
It	O	-1	25119790
is	O	-1	25119790
concl@@	O	-1	25119790
uded	O	-1	25119790
that	O	-1	25119790
cur@@	B-Chemical	D003474	25119790
cum@@	I-Chemical	-1	25119790
in	I-Chemical	-1	25119790
is	O	-1	25119790
able	O	-1	25119790
to	O	-1	25119790
attenu@@	O	-1	25119790
ate	O	-1	25119790
in	O	-1	25119790
viv@@	O	-1	25119790
o	O	-1	25119790
mal@@	B-Chemical	C030272	25119790
e@@	I-Chemical	-1	25119790
ate	I-Chemical	-1	25119790
-induced	O	-1	25119790
nephro@@	B-Disease	D007674	25119790
pathy	I-Disease	-1	25119790
and	O	-1	25119790
in	O	-1	25119790
vit@@	O	-1	25119790
r@@	O	-1	25119790
o	O	-1	25119790
cell	O	-1	25119790
dam@@	O	-1	25119790
age.	O	-1	25119790
The	O	-1	25119790
in	O	-1	25119790
viv@@	O	-1	25119790
o	O	-1	25119790
prot@@	O	-1	25119790
ection	O	-1	25119790
was	O	-1	25119790
associated	O	-1	25119790
to	O	-1	25119790
the	O	-1	25119790
pre@@	O	-1	25119790
ven@@	O	-1	25119790
tion	O	-1	25119790
of	O	-1	25119790
oxid@@	O	-1	25119790
ative	O	-1	25119790
stres@@	O	-1	25119790
s	O	-1	25119790
and	O	-1	25119790
pres@@	O	-1	25119790
er@@	O	-1	25119790
v@@	O	-1	25119790
ation	O	-1	25119790
of	O	-1	25119790
mitochondrial	O	-1	25119790
oxy@@	B-Chemical	D010100	25119790
gen	I-Chemical	-1	25119790
consum@@	O	-1	25119790
ption	O	-1	25119790
and	O	-1	25119790
activity	O	-1	25119790
of	O	-1	25119790
respiratory	O	-1	25119790
comple@@	O	-1	25119790
x	O	-1	25119790
I@@	O	-1	25119790
,	O	-1	25119790
and	O	-1	25119790
the	O	-1	25119790
in	O	-1	25119790
vit@@	O	-1	25119790
r@@	O	-1	25119790
o	O	-1	25119790
prot@@	O	-1	25119790
ection	O	-1	25119790
was	O	-1	25119790
associated	O	-1	25119790
to	O	-1	25119790
the	O	-1	25119790
pre@@	O	-1	25119790
ven@@	O	-1	25119790
tion	O	-1	25119790
of	O	-1	25119790
RO@@	O	-1	25119790
S	O	-1	25119790
produc@@	O	-1	25119790
tion.	O	-1	25119790

In@@	O	-1	25907210
c@@	O	-1	25907210
idence	O	-1	25907210
of	O	-1	25907210
sol@@	O	-1	25907210
id	O	-1	25907210
tu@@	B-Disease	D009369	25907210
mo@@	I-Disease	-1	25907210
ur@@	I-Disease	-1	25907210
s	I-Disease	-1	25907210
among	O	-1	25907210
p@@	O	-1	25907210
es@@	O	-1	25907210
tic@@	O	-1	25907210
ide	O	-1	25907210
ap@@	O	-1	25907210
plic@@	O	-1	25907210
at@@	O	-1	25907210
ors	O	-1	25907210
exposed	O	-1	25907210
to	O	-1	25907210
the	O	-1	25907210
org@@	B-Chemical	D010755	25907210
an@@	I-Chemical	-1	25907210
oph@@	I-Chemical	-1	25907210
osph@@	I-Chemical	-1	25907210
ate	I-Chemical	-1	25907210
in@@	O	-1	25907210
sec@@	O	-1	25907210
tic@@	O	-1	25907210
ide	O	-1	25907210
di@@	B-Chemical	D003976	25907210
az@@	I-Chemical	-1	25907210
in@@	I-Chemical	-1	25907210
on	I-Chemical	-1	25907210
in	O	-1	25907210
the	O	-1	25907210
A@@	O	-1	25907210
g@@	O	-1	25907210
r@@	O	-1	25907210
ic@@	O	-1	25907210
ult@@	O	-1	25907210
ural	O	-1	25907210
He@@	O	-1	25907210
al@@	O	-1	25907210
th	O	-1	25907210
S@@	O	-1	25907210
t@@	O	-1	25907210
ud@@	O	-1	25907210
y@@	O	-1	25907210
:	O	-1	25907210
an	O	-1	25907210
up@@	O	-1	25907210
d@@	O	-1	25907210
ated	O	-1	25907210
analy@@	O	-1	25907210
sis.	O	-1	25907210
OBJECTIVE:	O	-1	25907210
Di@@	B-Chemical	D003976	25907210
az@@	I-Chemical	-1	25907210
in@@	I-Chemical	-1	25907210
on	I-Chemical	-1	25907210
,	O	-1	25907210
a	O	-1	25907210
common	O	-1	25907210
org@@	B-Chemical	D010755	25907210
an@@	I-Chemical	-1	25907210
oph@@	I-Chemical	-1	25907210
osph@@	I-Chemical	-1	25907210
ate	I-Chemical	-1	25907210
in@@	O	-1	25907210
sec@@	O	-1	25907210
tic@@	O	-1	25907210
ide	O	-1	25907210
with	O	-1	25907210
gen@@	O	-1	25907210
ot@@	O	-1	25907210
ox@@	O	-1	25907210
ic	O	-1	25907210
pro@@	O	-1	25907210
per@@	O	-1	25907210
ti@@	O	-1	25907210
es,	O	-1	25907210
was	O	-1	25907210
previously	O	-1	25907210
associated	O	-1	25907210
with	O	-1	25907210
l@@	B-Disease	D008175	25907210
un@@	I-Disease	-1	25907210
g	I-Disease	-1	25907210
cancer	I-Disease	-1	25907210
in	O	-1	25907210
the	O	-1	25907210
A@@	O	-1	25907210
g@@	O	-1	25907210
r@@	O	-1	25907210
ic@@	O	-1	25907210
ult@@	O	-1	25907210
ural	O	-1	25907210
He@@	O	-1	25907210
al@@	O	-1	25907210
th	O	-1	25907210
S@@	O	-1	25907210
t@@	O	-1	25907210
ud@@	O	-1	25907210
y	O	-1	25907210
(A@@	O	-1	25907210
H@@	O	-1	25907210
S)	O	-1	25907210
co@@	O	-1	25907210
h@@	O	-1	25907210
ort@@	O	-1	25907210
,	O	-1	25907210
but	O	-1	25907210
fe@@	O	-1	25907210
w	O	-1	25907210
other	O	-1	25907210
epi@@	O	-1	25907210
de@@	O	-1	25907210
m@@	O	-1	25907210
io@@	O	-1	25907210
log@@	O	-1	25907210
ical	O	-1	25907210
studies	O	-1	25907210
have	O	-1	25907210
examined	O	-1	25907210
di@@	B-Chemical	D003976	25907210
az@@	I-Chemical	-1	25907210
in@@	I-Chemical	-1	25907210
on	I-Chemical	-1	25907210
-@@	O	-1	25907210
associated	O	-1	25907210
cancer	B-Disease	D009369	25907210
ris@@	O	-1	25907210
k@@	O	-1	25907210
.	O	-1	25907210
We	O	-1	25907210
used	O	-1	25907210
up@@	O	-1	25907210
d@@	O	-1	25907210
ated	O	-1	25907210
di@@	B-Chemical	D003976	25907210
az@@	I-Chemical	-1	25907210
in@@	I-Chemical	-1	25907210
on	I-Chemical	-1	25907210
exposure	O	-1	25907210
and	O	-1	25907210
cancer	B-Disease	D009369	25907210
incidence	O	-1	25907210
inf@@	O	-1	25907210
orm@@	O	-1	25907210
ation	O	-1	25907210
to	O	-1	25907210
evalu@@	O	-1	25907210
ate	O	-1	25907210
sol@@	O	-1	25907210
id	O	-1	25907210
tum@@	B-Disease	D009369	25907210
our	I-Disease	-1	25907210
risk	O	-1	25907210
in	O	-1	25907210
the	O	-1	25907210
A@@	O	-1	25907210
H@@	O	-1	25907210
S@@	O	-1	25907210
.	O	-1	25907210
METHODS:	O	-1	25907210
M@@	O	-1	25907210
al@@	O	-1	25907210
e	O	-1	25907210
p@@	O	-1	25907210
es@@	O	-1	25907210
tic@@	O	-1	25907210
ide	O	-1	25907210
ap@@	O	-1	25907210
plic@@	O	-1	25907210
at@@	O	-1	25907210
ors	O	-1	25907210
in	O	-1	25907210
I@@	O	-1	25907210
o@@	O	-1	25907210
w@@	O	-1	25907210
a	O	-1	25907210
and	O	-1	25907210
N@@	O	-1	25907210
or@@	O	-1	25907210
th	O	-1	25907210
Ca@@	O	-1	25907210
ro@@	O	-1	25907210
lin@@	O	-1	25907210
a	O	-1	25907210
reported	O	-1	25907210
li@@	O	-1	25907210
fe@@	O	-1	25907210
time	O	-1	25907210
di@@	B-Chemical	D003976	25907210
az@@	I-Chemical	-1	25907210
in@@	I-Chemical	-1	25907210
on	I-Chemical	-1	25907210
use	O	-1	25907210
at	O	-1	25907210
en@@	O	-1	25907210
ro@@	O	-1	25907210
l@@	O	-1	25907210
ment	O	-1	25907210
(1@@	O	-1	25907210
9@@	O	-1	25907210
9@@	O	-1	25907210
3@@	O	-1	25907210
-1@@	O	-1	25907210
9@@	O	-1	25907210
9@@	O	-1	25907210
7@@	O	-1	25907210
)	O	-1	25907210
and	O	-1	25907210
follow-up	O	-1	25907210
(1@@	O	-1	25907210
9@@	O	-1	25907210
9@@	O	-1	25907210
8@@	O	-1	25907210
-@@	O	-1	25907210
20@@	O	-1	25907210
0@@	O	-1	25907210
5@@	O	-1	25907210
);	O	-1	25907210
cancer	B-Disease	D009369	25907210
incidence	O	-1	25907210
was	O	-1	25907210
assessed	O	-1	25907210
through	O	-1	25907210
20@@	O	-1	25907210
10@@	O	-1	25907210
(N@@	O	-1	25907210
or@@	O	-1	25907210
th	O	-1	25907210
Ca@@	O	-1	25907210
ro@@	O	-1	25907210
lin@@	O	-1	25907210
a@@	O	-1	25907210
)@@	O	-1	25907210
/@@	O	-1	25907210
20@@	O	-1	25907210
1@@	O	-1	25907210
1@@	O	-1	25907210
(@@	O	-1	25907210
I@@	O	-1	25907210
o@@	O	-1	25907210
w@@	O	-1	25907210
a@@	O	-1	25907210
).	O	-1	25907210
A@@	O	-1	25907210
mon@@	O	-1	25907210
g	O	-1	25907210
ap@@	O	-1	25907210
plic@@	O	-1	25907210
at@@	O	-1	25907210
ors	O	-1	25907210
with	O	-1	25907210
us@@	O	-1	25907210
age	O	-1	25907210
inf@@	O	-1	25907210
orm@@	O	-1	25907210
ation	O	-1	25907210
suffici@@	O	-1	25907210
ent	O	-1	25907210
to	O	-1	25907210
evalu@@	O	-1	25907210
ate	O	-1	25907210
expos@@	O	-1	25907210
ure@@	O	-1	25907210
-@@	O	-1	25907210
response	O	-1	25907210
pat@@	O	-1	25907210
tern@@	O	-1	25907210
s,	O	-1	25907210
we	O	-1	25907210
used	O	-1	25907210
P@@	O	-1	25907210
o@@	O	-1	25907210
is@@	O	-1	25907210
s@@	O	-1	25907210
on	O	-1	25907210
reg@@	O	-1	25907210
res@@	O	-1	25907210
sion	O	-1	25907210
to	O	-1	25907210
estim@@	O	-1	25907210
ate	O	-1	25907210
adjust@@	O	-1	25907210
ed	O	-1	25907210
rate	O	-1	25907210
rati@@	O	-1	25907210
o@@	O	-1	25907210
s	O	-1	25907210
(@@	O	-1	25907210
R@@	O	-1	25907210
R@@	O	-1	25907210
s)	O	-1	25907210
and	O	-1	25907210
95%	O	-1	25907210
C@@	O	-1	25907210
I	O	-1	25907210
for	O	-1	25907210
cancer	B-Disease	D009369	25907210
sit@@	O	-1	25907210
es	O	-1	25907210
with	O	-1	25907210
>@@	O	-1	25907210
10	O	-1	25907210
exposed	O	-1	25907210
cases	O	-1	25907210
for	O	-1	25907210
both	O	-1	25907210
li@@	O	-1	25907210
fe@@	O	-1	25907210
time	O	-1	25907210
(@@	O	-1	25907210
LT@@	O	-1	25907210
)	O	-1	25907210
exposure	O	-1	25907210
days	O	-1	25907210
and	O	-1	25907210
int@@	O	-1	25907210
en@@	O	-1	25907210
sit@@	O	-1	25907210
y-@@	O	-1	25907210
weigh@@	O	-1	25907210
ted	O	-1	25907210
(@@	O	-1	25907210
I@@	O	-1	25907210
W@@	O	-1	25907210
)	O	-1	25907210
li@@	O	-1	25907210
fe@@	O	-1	25907210
time	O	-1	25907210
exposure	O	-1	25907210
days	O	-1	25907210
(@@	O	-1	25907210
ac@@	O	-1	25907210
coun@@	O	-1	25907210
ting	O	-1	25907210
for	O	-1	25907210
factors	O	-1	25907210
im@@	O	-1	25907210
p@@	O	-1	25907210
act@@	O	-1	25907210
ing	O	-1	25907210
expos@@	O	-1	25907210
ure@@	O	-1	25907210
).	O	-1	25907210
RESULTS:	O	-1	25907210
We	O	-1	25907210
observed	O	-1	25907210
elevated	O	-1	25907210
l@@	B-Disease	D008175	25907210
un@@	I-Disease	-1	25907210
g	I-Disease	-1	25907210
cancer	I-Disease	-1	25907210
ris@@	O	-1	25907210
k@@	O	-1	25907210
s	O	-1	25907210
(N@@	O	-1	25907210
=@@	O	-1	25907210
2@@	O	-1	25907210
8@@	O	-1	25907210
3@@	O	-1	25907210
)	O	-1	25907210
among	O	-1	25907210
ap@@	O	-1	25907210
plic@@	O	-1	25907210
at@@	O	-1	25907210
ors	O	-1	25907210
with	O	-1	25907210
the	O	-1	25907210
great@@	O	-1	25907210
est	O	-1	25907210
number	O	-1	25907210
of	O	-1	25907210
L@@	O	-1	25907210
T	O	-1	25907210
(@@	O	-1	25907210
R@@	O	-1	25907210
R@@	O	-1	25907210
=@@	O	-1	25907210
1.@@	O	-1	25907210
6@@	O	-1	25907210
0@@	O	-1	25907210
;	O	-1	25907210
95%	O	-1	25907210
C@@	O	-1	25907210
I	O	-1	25907210
1.@@	O	-1	25907210
11	O	-1	25907210
to	O	-1	25907210
2.@@	O	-1	25907210
3@@	O	-1	25907210
1@@	O	-1	25907210
;	O	-1	25907210
P@@	O	-1	25907210
tre@@	O	-1	25907210
n@@	O	-1	25907210
d@@	O	-1	25907210
=@@	O	-1	25907210
0.0@@	O	-1	25907210
2)	O	-1	25907210
and	O	-1	25907210
I@@	O	-1	25907210
W	O	-1	25907210
days	O	-1	25907210
of	O	-1	25907210
di@@	B-Chemical	D003976	25907210
az@@	I-Chemical	-1	25907210
in@@	I-Chemical	-1	25907210
on	I-Chemical	-1	25907210
use	O	-1	25907210
(@@	O	-1	25907210
R@@	O	-1	25907210
R@@	O	-1	25907210
=@@	O	-1	25907210
1.@@	O	-1	25907210
4@@	O	-1	25907210
1@@	O	-1	25907210
;	O	-1	25907210
95%	O	-1	25907210
C@@	O	-1	25907210
I	O	-1	25907210
0.@@	O	-1	25907210
9@@	O	-1	25907210
8	O	-1	25907210
to	O	-1	25907210
2.@@	O	-1	25907210
0@@	O	-1	25907210
4@@	O	-1	25907210
;	O	-1	25907210
P@@	O	-1	25907210
tre@@	O	-1	25907210
n@@	O	-1	25907210
d@@	O	-1	25907210
=@@	O	-1	25907210
0.0@@	O	-1	25907210
8@@	O	-1	25907210
).	O	-1	25907210
K@@	B-Disease	D007680	25907210
idne@@	I-Disease	-1	25907210
y	I-Disease	-1	25907210
cancer	I-Disease	-1	25907210
(N@@	O	-1	25907210
=@@	O	-1	25907210
9@@	O	-1	25907210
4@@	O	-1	25907210
)	O	-1	25907210
ris@@	O	-1	25907210
k@@	O	-1	25907210
s	O	-1	25907210
were	O	-1	25907210
non-@@	O	-1	25907210
significantly	O	-1	25907210
elevated	O	-1	25907210
(@@	O	-1	25907210
R@@	O	-1	25907210
R@@	O	-1	25907210
L@@	O	-1	25907210
T	O	-1	25907210
da@@	O	-1	25907210
ys@@	O	-1	25907210
=@@	O	-1	25907210
1.@@	O	-1	25907210
7@@	O	-1	25907210
7@@	O	-1	25907210
;	O	-1	25907210
95%	O	-1	25907210
C@@	O	-1	25907210
I	O	-1	25907210
0.@@	O	-1	25907210
9@@	O	-1	25907210
0	O	-1	25907210
to	O	-1	25907210
3.@@	O	-1	25907210
5@@	O	-1	25907210
1@@	O	-1	25907210
;	O	-1	25907210
P@@	O	-1	25907210
tre@@	O	-1	25907210
n@@	O	-1	25907210
d@@	O	-1	25907210
=@@	O	-1	25907210
0.0@@	O	-1	25907210
9@@	O	-1	25907210
;	O	-1	25907210
R@@	O	-1	25907210
R@@	O	-1	25907210
I@@	O	-1	25907210
W	O	-1	25907210
days	O	-1	25907210
1.@@	O	-1	25907210
3@@	O	-1	25907210
7@@	O	-1	25907210
;	O	-1	25907210
95%	O	-1	25907210
C@@	O	-1	25907210
I	O	-1	25907210
0.@@	O	-1	25907210
6@@	O	-1	25907210
4	O	-1	25907210
to	O	-1	25907210
2.@@	O	-1	25907210
9@@	O	-1	25907210
2@@	O	-1	25907210
;	O	-1	25907210
P@@	O	-1	25907210
tre@@	O	-1	25907210
n@@	O	-1	25907210
d@@	O	-1	25907210
=@@	O	-1	25907210
0.@@	O	-1	25907210
50@@	O	-1	25907210
),	O	-1	25907210
as	O	-1	25907210
were	O	-1	25907210
ris@@	O	-1	25907210
k@@	O	-1	25907210
s	O	-1	25907210
for	O	-1	25907210
ag@@	O	-1	25907210
gres@@	O	-1	25907210
sive	O	-1	25907210
pro@@	B-Disease	D011471	25907210
state	I-Disease	-1	25907210
cancer	I-Disease	-1	25907210
(N@@	O	-1	25907210
=@@	O	-1	25907210
6@@	O	-1	25907210
5@@	O	-1	25907210
6@@	O	-1	25907210
).	O	-1	25907210
CONCLUSIONS:	O	-1	25907210
Our	O	-1	25907210
up@@	O	-1	25907210
d@@	O	-1	25907210
ated	O	-1	25907210
evalu@@	O	-1	25907210
ation	O	-1	25907210
of	O	-1	25907210
di@@	B-Chemical	D003976	25907210
az@@	I-Chemical	-1	25907210
in@@	I-Chemical	-1	25907210
on	I-Chemical	-1	25907210
pro@@	O	-1	25907210
vi@@	O	-1	25907210
des	O	-1	25907210
addi@@	O	-1	25907210
tional	O	-1	25907210
evidence	O	-1	25907210
of	O	-1	25907210
an	O	-1	25907210
association	O	-1	25907210
with	O	-1	25907210
l@@	B-Disease	D008175	25907210
un@@	I-Disease	-1	25907210
g	I-Disease	-1	25907210
cancer	I-Disease	-1	25907210
ris@@	O	-1	25907210
k@@	O	-1	25907210
.	O	-1	25907210
Ne@@	O	-1	25907210
w@@	O	-1	25907210
ly	O	-1	25907210
identi@@	O	-1	25907210
fied	O	-1	25907210
lin@@	O	-1	25907210
k@@	O	-1	25907210
s	O	-1	25907210
to	O	-1	25907210
kidney	B-Disease	D007680	25907210
cancer	I-Disease	-1	25907210
and	O	-1	25907210
associ@@	O	-1	25907210
ations	O	-1	25907210
with	O	-1	25907210
ag@@	O	-1	25907210
gres@@	O	-1	25907210
sive	O	-1	25907210
pro@@	B-Disease	D011471	25907210
state	I-Disease	-1	25907210
cancer	I-Disease	-1	25907210
requ@@	O	-1	25907210
ir@@	O	-1	25907210
e	O	-1	25907210
further	O	-1	25907210
evalu@@	O	-1	25907210
ation.	O	-1	25907210

A@@	O	-1	25951420
s@@	O	-1	25951420
s@@	O	-1	25951420
oci@@	O	-1	25951420
ations	O	-1	25951420
of	O	-1	25951420
O@@	B-Chemical	D010126	25951420
z@@	I-Chemical	-1	25951420
one	I-Chemical	-1	25951420
and	O	-1	25951420
P@@	O	-1	25951420
M@@	O	-1	25951420
2.@@	O	-1	25951420
5	O	-1	25951420
Con@@	O	-1	25951420
centr@@	O	-1	25951420
ations	O	-1	25951420
W@@	O	-1	25951420
it@@	O	-1	25951420
h	O	-1	25951420
Parkinson's	B-Disease	D010300	25951420
Di@@	I-Disease	-1	25951420
se@@	I-Disease	-1	25951420
ase	I-Disease	-1	25951420
A@@	O	-1	25951420
mon@@	O	-1	25951420
g	O	-1	25951420
P@@	O	-1	25951420
ar@@	O	-1	25951420
tic@@	O	-1	25951420
ip@@	O	-1	25951420
ants	O	-1	25951420
in	O	-1	25951420
the	O	-1	25951420
A@@	O	-1	25951420
g@@	O	-1	25951420
r@@	O	-1	25951420
ic@@	O	-1	25951420
ult@@	O	-1	25951420
ural	O	-1	25951420
He@@	O	-1	25951420
al@@	O	-1	25951420
th	O	-1	25951420
S@@	O	-1	25951420
t@@	O	-1	25951420
ud@@	O	-1	25951420
y.	O	-1	25951420
OBJECTIVE:	O	-1	25951420
This	O	-1	25951420
study	O	-1	25951420
descri@@	O	-1	25951420
b@@	O	-1	25951420
es	O	-1	25951420
associ@@	O	-1	25951420
ations	O	-1	25951420
of	O	-1	25951420
o@@	B-Chemical	D010126	25951420
z@@	I-Chemical	-1	25951420
one	I-Chemical	-1	25951420
and	O	-1	25951420
f@@	O	-1	25951420
ine	O	-1	25951420
partic@@	B-Chemical	D052638	25951420
ul@@	I-Chemical	-1	25951420
ate	I-Chemical	-1	25951420
mat@@	I-Chemical	-1	25951420
ter	I-Chemical	-1	25951420
with	O	-1	25951420
Parkinson's	B-Disease	D010300	25951420
disease	I-Disease	-1	25951420
observed	O	-1	25951420
among	O	-1	25951420
far@@	O	-1	25951420
m@@	O	-1	25951420
ers	O	-1	25951420
in	O	-1	25951420
N@@	O	-1	25951420
or@@	O	-1	25951420
th	O	-1	25951420
Ca@@	O	-1	25951420
ro@@	O	-1	25951420
lin@@	O	-1	25951420
a	O	-1	25951420
and	O	-1	25951420
I@@	O	-1	25951420
o@@	O	-1	25951420
w@@	O	-1	25951420
a.	O	-1	25951420
METHODS:	O	-1	25951420
We	O	-1	25951420
used	O	-1	25951420
log@@	O	-1	25951420
istic	O	-1	25951420
reg@@	O	-1	25951420
res@@	O	-1	25951420
sion	O	-1	25951420
to	O	-1	25951420
determine	O	-1	25951420
the	O	-1	25951420
associ@@	O	-1	25951420
ations	O	-1	25951420
of	O	-1	25951420
these	O	-1	25951420
pol@@	O	-1	25951420
l@@	O	-1	25951420
ut@@	O	-1	25951420
ants	O	-1	25951420
with	O	-1	25951420
sel@@	O	-1	25951420
f@@	O	-1	25951420
-@@	O	-1	25951420
repor@@	O	-1	25951420
te@@	O	-1	25951420
d,	O	-1	25951420
doc@@	O	-1	25951420
t@@	O	-1	25951420
or@@	O	-1	25951420
-@@	O	-1	25951420
diagnos@@	O	-1	25951420
ed	O	-1	25951420
Parkinson's	B-Disease	D010300	25951420
disease	I-Disease	-1	25951420
.	O	-1	25951420
D@@	O	-1	25951420
a@@	O	-1	25951420
ily	O	-1	25951420
predic@@	O	-1	25951420
ted	O	-1	25951420
pol@@	O	-1	25951420
l@@	O	-1	25951420
ut@@	O	-1	25951420
ant	O	-1	25951420
concentrations	O	-1	25951420
were	O	-1	25951420
used	O	-1	25951420
to	O	-1	25951420
der@@	O	-1	25951420
i@@	O	-1	25951420
ve	O	-1	25951420
sur@@	O	-1	25951420
ro@@	O	-1	25951420
g@@	O	-1	25951420
ates	O	-1	25951420
of	O	-1	25951420
long-term	O	-1	25951420
exposure	O	-1	25951420
and	O	-1	25951420
lin@@	O	-1	25951420
k	O	-1	25951420
the@@	O	-1	25951420
m	O	-1	25951420
to	O	-1	25951420
study	O	-1	25951420
partic@@	O	-1	25951420
ip@@	O	-1	25951420
ant@@	O	-1	25951420
s@@	O	-1	25951420
'	O	-1	25951420
ge@@	O	-1	25951420
o@@	O	-1	25951420
co@@	O	-1	25951420
ded	O	-1	25951420
ad@@	O	-1	25951420
d@@	O	-1	25951420
res@@	O	-1	25951420
s@@	O	-1	25951420
es.	O	-1	25951420
RESULTS:	O	-1	25951420
We	O	-1	25951420
observed	O	-1	25951420
positive	O	-1	25951420
associ@@	O	-1	25951420
ations	O	-1	25951420
of	O	-1	25951420
Parkinson's	B-Disease	D010300	25951420
disease	I-Disease	-1	25951420
with	O	-1	25951420
o@@	B-Chemical	D010126	25951420
z@@	I-Chemical	-1	25951420
one	I-Chemical	-1	25951420
(@@	O	-1	25951420
o@@	O	-1	25951420
d@@	O	-1	25951420
ds	O	-1	25951420
rati@@	O	-1	25951420
o	O	-1	25951420
=	O	-1	25951420
1.@@	O	-1	25951420
3@@	O	-1	25951420
9@@	O	-1	25951420
;	O	-1	25951420
95%	O	-1	25951420
CI@@	O	-1	25951420
:	O	-1	25951420
0.@@	O	-1	25951420
9@@	O	-1	25951420
8	O	-1	25951420
to	O	-1	25951420
1.@@	O	-1	25951420
9@@	O	-1	25951420
8@@	O	-1	25951420
)	O	-1	25951420
and	O	-1	25951420
f@@	O	-1	25951420
ine	O	-1	25951420
partic@@	B-Chemical	D052638	25951420
ul@@	I-Chemical	-1	25951420
ate	I-Chemical	-1	25951420
mat@@	I-Chemical	-1	25951420
ter	I-Chemical	-1	25951420
(@@	O	-1	25951420
o@@	O	-1	25951420
d@@	O	-1	25951420
ds	O	-1	25951420
rati@@	O	-1	25951420
o	O	-1	25951420
=	O	-1	25951420
1.@@	O	-1	25951420
34@@	O	-1	25951420
;	O	-1	25951420
95%	O	-1	25951420
CI@@	O	-1	25951420
:	O	-1	25951420
0.@@	O	-1	25951420
9@@	O	-1	25951420
3	O	-1	25951420
to	O	-1	25951420
1.@@	O	-1	25951420
9@@	O	-1	25951420
3@@	O	-1	25951420
)	O	-1	25951420
in	O	-1	25951420
N@@	O	-1	25951420
or@@	O	-1	25951420
th	O	-1	25951420
Ca@@	O	-1	25951420
ro@@	O	-1	25951420
lin@@	O	-1	25951420
a	O	-1	25951420
but	O	-1	25951420
not	O	-1	25951420
in	O	-1	25951420
I@@	O	-1	25951420
o@@	O	-1	25951420
w@@	O	-1	25951420
a.	O	-1	25951420
CONCLUSIONS:	O	-1	25951420
The	O	-1	25951420
pl@@	O	-1	25951420
au@@	O	-1	25951420
sib@@	O	-1	25951420
ility	O	-1	25951420
of	O	-1	25951420
an	O	-1	25951420
effect	O	-1	25951420
of	O	-1	25951420
am@@	O	-1	25951420
b@@	O	-1	25951420
i@@	O	-1	25951420
ent	O	-1	25951420
concentrations	O	-1	25951420
of	O	-1	25951420
these	O	-1	25951420
pol@@	O	-1	25951420
l@@	O	-1	25951420
ut@@	O	-1	25951420
ants	O	-1	25951420
on	O	-1	25951420
Parkinson's	B-Disease	D010300	25951420
disease	I-Disease	-1	25951420
risk	O	-1	25951420
is	O	-1	25951420
suppor@@	O	-1	25951420
ted	O	-1	25951420
by	O	-1	25951420
experimental	O	-1	25951420
data	O	-1	25951420
demon@@	O	-1	25951420
strat@@	O	-1	25951420
ing	O	-1	25951420
damage	O	-1	25951420
to	O	-1	25951420
dop@@	O	-1	25951420
aminergic	O	-1	25951420
neuron@@	O	-1	25951420
s	O	-1	25951420
at	O	-1	25951420
re@@	O	-1	25951420
lev@@	O	-1	25951420
ant	O	-1	25951420
concentr@@	O	-1	25951420
ations.	O	-1	25951420
Ad@@	O	-1	25951420
di@@	O	-1	25951420
tional	O	-1	25951420
studies	O	-1	25951420
are	O	-1	25951420
ne@@	O	-1	25951420
ed@@	O	-1	25951420
ed	O	-1	25951420
to	O	-1	25951420
ad@@	O	-1	25951420
d@@	O	-1	25951420
res@@	O	-1	25951420
s	O	-1	25951420
unc@@	O	-1	25951420
er@@	O	-1	25951420
t@@	O	-1	25951420
ain@@	O	-1	25951420
ties	O	-1	25951420
related	O	-1	25951420
to	O	-1	25951420
conf@@	O	-1	25951420
oun@@	O	-1	25951420
ding	O	-1	25951420
and	O	-1	25951420
to	O	-1	25951420
ex@@	O	-1	25951420
amine	O	-1	25951420
tempor@@	O	-1	25951420
al	O	-1	25951420
as@@	O	-1	25951420
p@@	O	-1	25951420
ects	O	-1	25951420
of	O	-1	25951420
the	O	-1	25951420
associ@@	O	-1	25951420
ations	O	-1	25951420
we	O	-1	25951420
obser@@	O	-1	25951420
ved.	O	-1	25951420

L@@	O	-1	25986755
o@@	O	-1	25986755
w	O	-1	25986755
functional	O	-1	25986755
pro@@	O	-1	25986755
gram@@	O	-1	25986755
m@@	O	-1	25986755
ing	O	-1	25986755
of	O	-1	25986755
renal	O	-1	25986755
AT@@	O	-1	25986755
2@@	O	-1	25986755
R	O	-1	25986755
medi@@	O	-1	25986755
ates	O	-1	25986755
the	O	-1	25986755
develop@@	O	-1	25986755
mental	O	-1	25986755
or@@	O	-1	25986755
ig@@	O	-1	25986755
in	O	-1	25986755
of	O	-1	25986755
glomer@@	B-Disease	D005921	25986755
u@@	I-Disease	-1	25986755
los@@	I-Disease	-1	25986755
clero@@	I-Disease	-1	25986755
sis	I-Disease	-1	25986755
in	O	-1	25986755
ad@@	O	-1	25986755
ult	O	-1	25986755
o@@	O	-1	25986755
ff@@	O	-1	25986755
sp@@	O	-1	25986755
r@@	O	-1	25986755
ing	O	-1	25986755
induced	O	-1	25986755
by	O	-1	25986755
p@@	O	-1	25986755
ren@@	O	-1	25986755
atal	O	-1	25986755
caffe@@	B-Chemical	D002110	25986755
ine	I-Chemical	-1	25986755
expos@@	O	-1	25986755
ure.	O	-1	25986755
UN@@	O	-1	25986755
A@@	O	-1	25986755
S@@	O	-1	25986755
S@@	O	-1	25986755
I@@	O	-1	25986755
G@@	O	-1	25986755
N@@	O	-1	25986755
E@@	O	-1	25986755
D@@	O	-1	25986755
:	O	-1	25986755
Our	O	-1	25986755
previ@@	O	-1	25986755
ous	O	-1	25986755
study	O	-1	25986755
has	O	-1	25986755
indic@@	O	-1	25986755
ated	O	-1	25986755
that	O	-1	25986755
p@@	O	-1	25986755
ren@@	O	-1	25986755
atal	O	-1	25986755
caffe@@	B-Chemical	D002110	25986755
ine	I-Chemical	-1	25986755
exposure	O	-1	25986755
(P@@	O	-1	25986755
C@@	O	-1	25986755
E@@	O	-1	25986755
)	O	-1	25986755
could	O	-1	25986755
induce	O	-1	25986755
intra@@	B-Disease	D005317	25986755
u@@	I-Disease	-1	25986755
ter@@	I-Disease	-1	25986755
ine	I-Disease	-1	25986755
growth	I-Disease	-1	25986755
ret@@	I-Disease	-1	25986755
ar@@	I-Disease	-1	25986755
d@@	I-Disease	-1	25986755
ation	I-Disease	-1	25986755
(	O	-1	25986755
I@@	B-Disease	D005317	25986755
U@@	I-Disease	-1	25986755
G@@	I-Disease	-1	25986755
R	I-Disease	-1	25986755
)	O	-1	25986755
of	O	-1	25986755
o@@	O	-1	25986755
ff@@	O	-1	25986755
sp@@	O	-1	25986755
r@@	O	-1	25986755
ing.	O	-1	25986755
Rec@@	O	-1	25986755
ent	O	-1	25986755
re@@	O	-1	25986755
se@@	O	-1	25986755
arc@@	O	-1	25986755
h	O	-1	25986755
suggested	O	-1	25986755
that	O	-1	25986755
I@@	B-Disease	D005317	25986755
U@@	I-Disease	-1	25986755
G@@	I-Disease	-1	25986755
R	I-Disease	-1	25986755
is	O	-1	25986755
a	O	-1	25986755
risk	O	-1	25986755
factor	O	-1	25986755
for	O	-1	25986755
glomer@@	B-Disease	D005921	25986755
u@@	I-Disease	-1	25986755
los@@	I-Disease	-1	25986755
clero@@	I-Disease	-1	25986755
sis	I-Disease	-1	25986755
.	O	-1	25986755
However,	O	-1	25986755
whether	O	-1	25986755
P@@	O	-1	25986755
C@@	O	-1	25986755
E	O	-1	25986755
could	O	-1	25986755
induce	O	-1	25986755
glomer@@	B-Disease	D005921	25986755
u@@	I-Disease	-1	25986755
los@@	I-Disease	-1	25986755
clero@@	I-Disease	-1	25986755
sis	I-Disease	-1	25986755
and	O	-1	25986755
its	O	-1	25986755
underlying	O	-1	25986755
mechanisms	O	-1	25986755
re@@	O	-1	25986755
ma@@	O	-1	25986755
in	O	-1	25986755
un@@	O	-1	25986755
know@@	O	-1	25986755
n@@	O	-1	25986755
.	O	-1	25986755
This	O	-1	25986755
study	O	-1	25986755
a@@	O	-1	25986755
im@@	O	-1	25986755
ed	O	-1	25986755
to	O	-1	25986755
demon@@	O	-1	25986755
st@@	O	-1	25986755
rate	O	-1	25986755
the	O	-1	25986755
induction	O	-1	25986755
to	O	-1	25986755
glomer@@	B-Disease	D005921	25986755
u@@	I-Disease	-1	25986755
los@@	I-Disease	-1	25986755
clero@@	I-Disease	-1	25986755
sis	I-Disease	-1	25986755
in	O	-1	25986755
ad@@	O	-1	25986755
ult	O	-1	25986755
o@@	O	-1	25986755
ff@@	O	-1	25986755
sp@@	O	-1	25986755
r@@	O	-1	25986755
ing	O	-1	25986755
by	O	-1	25986755
P@@	O	-1	25986755
C@@	O	-1	25986755
E	O	-1	25986755
and	O	-1	25986755
its	O	-1	25986755
intra@@	O	-1	25986755
u@@	O	-1	25986755
ter@@	O	-1	25986755
ine	O	-1	25986755
pro@@	O	-1	25986755
gram@@	O	-1	25986755
m@@	O	-1	25986755
ing	O	-1	25986755
mechanis@@	O	-1	25986755
m@@	O	-1	25986755
s.	O	-1	25986755
A	O	-1	25986755
rat	O	-1	25986755
model	O	-1	25986755
of	O	-1	25986755
I@@	B-Disease	D005317	25986755
U@@	I-Disease	-1	25986755
G@@	I-Disease	-1	25986755
R	I-Disease	-1	25986755
was	O	-1	25986755
est@@	O	-1	25986755
abl@@	O	-1	25986755
ished	O	-1	25986755
by	O	-1	25986755
P@@	O	-1	25986755
C@@	O	-1	25986755
E@@	O	-1	25986755
,	O	-1	25986755
male	O	-1	25986755
f@@	O	-1	25986755
et@@	O	-1	25986755
u@@	O	-1	25986755
ses	O	-1	25986755
and	O	-1	25986755
ad@@	O	-1	25986755
ult	O	-1	25986755
o@@	O	-1	25986755
ff@@	O	-1	25986755
sp@@	O	-1	25986755
r@@	O	-1	25986755
ing	O	-1	25986755
at	O	-1	25986755
the	O	-1	25986755
age	O	-1	25986755
of	O	-1	25986755
post@@	O	-1	25986755
n@@	O	-1	25986755
atal	O	-1	25986755
week	O	-1	25986755
24	O	-1	25986755
were	O	-1	25986755
eu@@	O	-1	25986755
th@@	O	-1	25986755
an@@	O	-1	25986755
iz@@	O	-1	25986755
ed.	O	-1	25986755
The	O	-1	25986755
results	O	-1	25986755
revealed	O	-1	25986755
that	O	-1	25986755
the	O	-1	25986755
ad@@	O	-1	25986755
ult	O	-1	25986755
o@@	O	-1	25986755
ff@@	O	-1	25986755
sp@@	O	-1	25986755
r@@	O	-1	25986755
ing	O	-1	25986755
kidne@@	O	-1	25986755
ys	O	-1	25986755
in	O	-1	25986755
the	O	-1	25986755
P@@	O	-1	25986755
C@@	O	-1	25986755
E	O	-1	25986755
group	O	-1	25986755
ex@@	O	-1	25986755
hib@@	O	-1	25986755
ited	O	-1	25986755
glomer@@	B-Disease	D005921	25986755
u@@	I-Disease	-1	25986755
los@@	I-Disease	-1	25986755
clero@@	I-Disease	-1	25986755
sis	I-Disease	-1	25986755
as	O	-1	25986755
well	O	-1	25986755
as	O	-1	25986755
interstitial	B-Disease	D005355	25986755
fib@@	I-Disease	-1	25986755
ro@@	I-Disease	-1	25986755
sis	I-Disease	-1	25986755
,	O	-1	25986755
ac@@	O	-1	25986755
comp@@	O	-1	25986755
an@@	O	-1	25986755
ied	O	-1	25986755
by	O	-1	25986755
elevated	O	-1	25986755
levels	O	-1	25986755
of	O	-1	25986755
serum	O	-1	25986755
creatinine	B-Chemical	D003404	25986755
and	O	-1	25986755
urine	O	-1	25986755
protein@@	O	-1	25986755
.	O	-1	25986755
R@@	O	-1	25986755
en@@	O	-1	25986755
al	O	-1	25986755
angiotens@@	B-Chemical	D000804	25986755
in	I-Chemical	-1	25986755
II	I-Chemical	-1	25986755
receptor	O	-1	25986755
type	O	-1	25986755
2	O	-1	25986755
(A@@	O	-1	25986755
T@@	O	-1	25986755
2@@	O	-1	25986755
R@@	O	-1	25986755
)	O	-1	25986755
gen@@	O	-1	25986755
e	O	-1	25986755
expression	O	-1	25986755
in	O	-1	25986755
ad@@	O	-1	25986755
ult	O	-1	25986755
o@@	O	-1	25986755
ff@@	O	-1	25986755
sp@@	O	-1	25986755
r@@	O	-1	25986755
ing	O	-1	25986755
was	O	-1	25986755
reduced	O	-1	25986755
by	O	-1	25986755
P@@	O	-1	25986755
C@@	O	-1	25986755
E@@	O	-1	25986755
,	O	-1	25986755
whereas	O	-1	25986755
the	O	-1	25986755
renal	O	-1	25986755
angiotens@@	B-Chemical	D000804	25986755
in	I-Chemical	-1	25986755
II	I-Chemical	-1	25986755
receptor	O	-1	25986755
type	O	-1	25986755
1@@	O	-1	25986755
a	O	-1	25986755
(A@@	O	-1	25986755
T@@	O	-1	25986755
1@@	O	-1	25986755
a@@	O	-1	25986755
R@@	O	-1	25986755
)@@	O	-1	25986755
/@@	O	-1	25986755
AT@@	O	-1	25986755
2@@	O	-1	25986755
R	O	-1	25986755
expression	O	-1	25986755
rati@@	O	-1	25986755
o	O	-1	25986755
was	O	-1	25986755
increas@@	O	-1	25986755
ed.	O	-1	25986755
The	O	-1	25986755
f@@	O	-1	25986755
et@@	O	-1	25986755
al	O	-1	25986755
kidne@@	O	-1	25986755
ys	O	-1	25986755
in	O	-1	25986755
the	O	-1	25986755
P@@	O	-1	25986755
C@@	O	-1	25986755
E	O	-1	25986755
group	O	-1	25986755
dis@@	O	-1	25986755
pl@@	O	-1	25986755
ayed	O	-1	25986755
an	O	-1	25986755
en@@	O	-1	25986755
larg@@	O	-1	25986755
ed	O	-1	25986755
B@@	O	-1	25986755
o@@	O	-1	25986755
w@@	O	-1	25986755
man@@	O	-1	25986755
's	O	-1	25986755
sp@@	O	-1	25986755
ac@@	O	-1	25986755
e	O	-1	25986755
and	O	-1	25986755
a	O	-1	25986755
sh@@	O	-1	25986755
r@@	O	-1	25986755
un@@	O	-1	25986755
k@@	O	-1	25986755
en	O	-1	25986755
glomerular	O	-1	25986755
tu@@	O	-1	25986755
f@@	O	-1	25986755
t,	O	-1	25986755
ac@@	O	-1	25986755
comp@@	O	-1	25986755
an@@	O	-1	25986755
ied	O	-1	25986755
by	O	-1	25986755
a	O	-1	25986755
reduced	O	-1	25986755
cor@@	O	-1	25986755
te@@	O	-1	25986755
x	O	-1	25986755
w@@	O	-1	25986755
id@@	O	-1	25986755
th	O	-1	25986755
and	O	-1	25986755
an	O	-1	25986755
increase	O	-1	25986755
in	O	-1	25986755
the	O	-1	25986755
nephro@@	O	-1	25986755
genic	O	-1	25986755
z@@	O	-1	25986755
one@@	O	-1	25986755
/@@	O	-1	25986755
cor@@	O	-1	25986755
tical	O	-1	25986755
z@@	O	-1	25986755
one	O	-1	25986755
rati@@	O	-1	25986755
o@@	O	-1	25986755
.	O	-1	25986755
O@@	O	-1	25986755
b@@	O	-1	25986755
ser@@	O	-1	25986755
v@@	O	-1	25986755
ation	O	-1	25986755
by	O	-1	25986755
elect@@	O	-1	25986755
ron@@	O	-1	25986755
ic	O	-1	25986755
micro@@	O	-1	25986755
sco@@	O	-1	25986755
p@@	O	-1	25986755
e	O	-1	25986755
revealed	O	-1	25986755
struct@@	O	-1	25986755
ural	O	-1	25986755
damage	O	-1	25986755
of	O	-1	25986755
po@@	O	-1	25986755
d@@	O	-1	25986755
ocy@@	O	-1	25986755
t@@	O	-1	25986755
es@@	O	-1	25986755
;	O	-1	25986755
the	O	-1	25986755
reduced	O	-1	25986755
expression	O	-1	25986755
level	O	-1	25986755
of	O	-1	25986755
po@@	O	-1	25986755
d@@	O	-1	25986755
ocyte	O	-1	25986755
mark@@	O	-1	25986755
er	O	-1	25986755
gen@@	O	-1	25986755
es,	O	-1	25986755
neph@@	O	-1	25986755
rin	O	-1	25986755
and	O	-1	25986755
po@@	O	-1	25986755
doc@@	O	-1	25986755
in,	O	-1	25986755
was	O	-1	25986755
also	O	-1	25986755
det@@	O	-1	25986755
ected	O	-1	25986755
by	O	-1	25986755
q@@	O	-1	25986755
-@@	O	-1	25986755
P@@	O	-1	25986755
CR@@	O	-1	25986755
.	O	-1	25986755
M@@	O	-1	25986755
ore@@	O	-1	25986755
o@@	O	-1	25986755
ver,	O	-1	25986755
AT@@	O	-1	25986755
2@@	O	-1	25986755
R	O	-1	25986755
gen@@	O	-1	25986755
e	O	-1	25986755
and	O	-1	25986755
protein	O	-1	25986755
ex@@	O	-1	25986755
pres@@	O	-1	25986755
sions	O	-1	25986755
in	O	-1	25986755
f@@	O	-1	25986755
et@@	O	-1	25986755
al	O	-1	25986755
kidne@@	O	-1	25986755
ys	O	-1	25986755
were	O	-1	25986755
inhibited	O	-1	25986755
by	O	-1	25986755
P@@	O	-1	25986755
C@@	O	-1	25986755
E@@	O	-1	25986755
,	O	-1	25986755
associated	O	-1	25986755
with	O	-1	25986755
the	O	-1	25986755
re@@	O	-1	25986755
pression	O	-1	25986755
of	O	-1	25986755
the	O	-1	25986755
gen@@	O	-1	25986755
e	O	-1	25986755
expression	O	-1	25986755
of	O	-1	25986755
g@@	O	-1	25986755
li@@	O	-1	25986755
al@@	O	-1	25986755
-@@	O	-1	25986755
cell@@	O	-1	25986755
-@@	O	-1	25986755
l@@	O	-1	25986755
ine-@@	O	-1	25986755
der@@	O	-1	25986755
i@@	O	-1	25986755
ved	O	-1	25986755
neuro@@	O	-1	25986755
tro@@	O	-1	25986755
ph@@	O	-1	25986755
ic	O	-1	25986755
factor	O	-1	25986755
(@@	O	-1	25986755
G@@	O	-1	25986755
D@@	O	-1	25986755
N@@	O	-1	25986755
F@@	O	-1	25986755
)@@	O	-1	25986755
/	O	-1	25986755
ty@@	B-Chemical	D014443	25986755
ros@@	I-Chemical	-1	25986755
ine	I-Chemical	-1	25986755
kin@@	O	-1	25986755
ase	O	-1	25986755
receptor	O	-1	25986755
(@@	O	-1	25986755
c@@	O	-1	25986755
-@@	O	-1	25986755
R@@	O	-1	25986755
et@@	O	-1	25986755
)	O	-1	25986755
sign@@	O	-1	25986755
al@@	O	-1	25986755
ing	O	-1	25986755
path@@	O	-1	25986755
w@@	O	-1	25986755
a@@	O	-1	25986755
y.	O	-1	25986755
These	O	-1	25986755
results	O	-1	25986755
demonstrated	O	-1	25986755
that	O	-1	25986755
P@@	O	-1	25986755
C@@	O	-1	25986755
E	O	-1	25986755
could	O	-1	25986755
induce	O	-1	25986755
dys@@	B-Disease	D007674	25986755
pl@@	I-Disease	-1	25986755
a@@	I-Disease	-1	25986755
sia	I-Disease	-1	25986755
of	I-Disease	-1	25986755
f@@	I-Disease	-1	25986755
et@@	I-Disease	-1	25986755
al	I-Disease	-1	25986755
kidne@@	I-Disease	-1	25986755
ys	I-Disease	-1	25986755
as	O	-1	25986755
well	O	-1	25986755
as	O	-1	25986755
glomer@@	B-Disease	D005921	25986755
u@@	I-Disease	-1	25986755
los@@	I-Disease	-1	25986755
clero@@	I-Disease	-1	25986755
sis	I-Disease	-1	25986755
of	O	-1	25986755
ad@@	O	-1	25986755
ult	O	-1	25986755
o@@	O	-1	25986755
ff@@	O	-1	25986755
sp@@	O	-1	25986755
r@@	O	-1	25986755
ing,	O	-1	25986755
and	O	-1	25986755
the	O	-1	25986755
low	O	-1	25986755
functional	O	-1	25986755
pro@@	O	-1	25986755
gram@@	O	-1	25986755
m@@	O	-1	25986755
ing	O	-1	25986755
of	O	-1	25986755
renal	O	-1	25986755
AT@@	O	-1	25986755
2@@	O	-1	25986755
R	O	-1	25986755
might	O	-1	25986755
medi@@	O	-1	25986755
ate	O	-1	25986755
the	O	-1	25986755
develop@@	O	-1	25986755
mental	O	-1	25986755
or@@	O	-1	25986755
ig@@	O	-1	25986755
in	O	-1	25986755
of	O	-1	25986755
ad@@	O	-1	25986755
ult	O	-1	25986755
glomer@@	B-Disease	D005921	25986755
u@@	I-Disease	-1	25986755
los@@	I-Disease	-1	25986755
clero@@	I-Disease	-1	25986755
sis	I-Disease	-1	25986755
.	O	-1	25986755

1@@	B-Chemical	C031763	26002693
,@@	I-Chemical	-1	26002693
3-@@	I-Chemical	-1	26002693
B@@	I-Chemical	-1	26002693
ut@@	I-Chemical	-1	26002693
a@@	I-Chemical	-1	26002693
di@@	I-Chemical	-1	26002693
ene	I-Chemical	-1	26002693
,	O	-1	26002693
C@@	B-Disease	D015464	26002693
M@@	I-Disease	-1	26002693
L	I-Disease	-1	26002693
and	O	-1	26002693
the	O	-1	26002693
t@@	O	-1	26002693
(@@	O	-1	26002693
9@@	O	-1	26002693
:@@	O	-1	26002693
2@@	O	-1	26002693
2)	O	-1	26002693
trans@@	O	-1	26002693
loc@@	O	-1	26002693
ation@@	O	-1	26002693
:	O	-1	26002693
A	O	-1	26002693
re@@	O	-1	26002693
ality	O	-1	26002693
ch@@	O	-1	26002693
ec@@	O	-1	26002693
k@@	O	-1	26002693
.	O	-1	26002693
UN@@	O	-1	26002693
A@@	O	-1	26002693
S@@	O	-1	26002693
S@@	O	-1	26002693
I@@	O	-1	26002693
G@@	O	-1	26002693
N@@	O	-1	26002693
E@@	O	-1	26002693
D@@	O	-1	26002693
:	O	-1	26002693
E@@	O	-1	26002693
pi@@	O	-1	26002693
de@@	O	-1	26002693
m@@	O	-1	26002693
io@@	O	-1	26002693
log@@	O	-1	26002693
ical	O	-1	26002693
studies	O	-1	26002693
of	O	-1	26002693
1@@	B-Chemical	C031763	26002693
,@@	I-Chemical	-1	26002693
3-@@	I-Chemical	-1	26002693
but@@	I-Chemical	-1	26002693
a@@	I-Chemical	-1	26002693
di@@	I-Chemical	-1	26002693
ene	I-Chemical	-1	26002693
have	O	-1	26002693
suggest	O	-1	26002693
that	O	-1	26002693
expos@@	O	-1	26002693
ures	O	-1	26002693
to	O	-1	26002693
hum@@	O	-1	26002693
ans	O	-1	26002693
are	O	-1	26002693
associated	O	-1	26002693
with	O	-1	26002693
chronic	B-Disease	D015464	26002693
my@@	I-Disease	-1	26002693
e@@	I-Disease	-1	26002693
lo@@	I-Disease	-1	26002693
id	I-Disease	-1	26002693
leuk@@	I-Disease	-1	26002693
emia	I-Disease	-1	26002693
(	O	-1	26002693
C@@	B-Disease	D015464	26002693
M@@	I-Disease	-1	26002693
L	I-Disease	-1	26002693
).	O	-1	26002693
C@@	B-Disease	D015464	26002693
M@@	I-Disease	-1	26002693
L	I-Disease	-1	26002693
has	O	-1	26002693
a	O	-1	26002693
we@@	O	-1	26002693
ll@@	O	-1	26002693
-@@	O	-1	26002693
doc@@	O	-1	26002693
um@@	O	-1	26002693
ent@@	O	-1	26002693
ed	O	-1	26002693
association	O	-1	26002693
with	O	-1	26002693
i@@	O	-1	26002693
on@@	O	-1	26002693
iz@@	O	-1	26002693
ing	O	-1	26002693
radi@@	O	-1	26002693
ation,	O	-1	26002693
but	O	-1	26002693
reports	O	-1	26002693
of	O	-1	26002693
associ@@	O	-1	26002693
ations	O	-1	26002693
with	O	-1	26002693
chemical	O	-1	26002693
expos@@	O	-1	26002693
ures	O	-1	26002693
have	O	-1	26002693
been	O	-1	26002693
qu@@	O	-1	26002693
es@@	O	-1	26002693
tion@@	O	-1	26002693
ed.	O	-1	26002693
I@@	O	-1	26002693
on@@	O	-1	26002693
iz@@	O	-1	26002693
ing	O	-1	26002693
radi@@	O	-1	26002693
ation	O	-1	26002693
is	O	-1	26002693
cap@@	O	-1	26002693
able	O	-1	26002693
of	O	-1	26002693
induc@@	O	-1	26002693
ing	O	-1	26002693
the	O	-1	26002693
requ@@	O	-1	26002693
is@@	O	-1	26002693
ite	O	-1	26002693
C@@	B-Disease	D015464	26002693
M@@	I-Disease	-1	26002693
L	I-Disease	-1	26002693
-@@	O	-1	26002693
associated	O	-1	26002693
t@@	O	-1	26002693
(@@	O	-1	26002693
9@@	O	-1	26002693
:@@	O	-1	26002693
2@@	O	-1	26002693
2)	O	-1	26002693
trans@@	O	-1	26002693
loc@@	O	-1	26002693
ation	O	-1	26002693
(	O	-1	26002693
Ph@@	B-Disease	D010677	26002693
il@@	I-Disease	-1	26002693
a@@	I-Disease	-1	26002693
del@@	I-Disease	-1	26002693
ph@@	I-Disease	-1	26002693
ia	I-Disease	-1	26002693
ch@@	I-Disease	-1	26002693
rom@@	I-Disease	-1	26002693
os@@	I-Disease	-1	26002693
ome	I-Disease	-1	26002693
)	O	-1	26002693
in	O	-1	26002693
appro@@	O	-1	26002693
pri@@	O	-1	26002693
ate	O	-1	26002693
cells	O	-1	26002693
in	O	-1	26002693
vit@@	O	-1	26002693
r@@	O	-1	26002693
o	O	-1	26002693
but@@	O	-1	26002693
,	O	-1	26002693
th@@	O	-1	26002693
us	O	-1	26002693
far@@	O	-1	26002693
,	O	-1	26002693
chem@@	O	-1	26002693
ic@@	O	-1	26002693
als	O	-1	26002693
have	O	-1	26002693
not	O	-1	26002693
shown	O	-1	26002693
this	O	-1	26002693
cap@@	O	-1	26002693
ac@@	O	-1	26002693
ity.	O	-1	26002693
We	O	-1	26002693
have	O	-1	26002693
pro@@	O	-1	26002693
pos@@	O	-1	26002693
ed	O	-1	26002693
that	O	-1	26002693
1@@	B-Chemical	C031763	26002693
,@@	I-Chemical	-1	26002693
3-@@	I-Chemical	-1	26002693
but@@	I-Chemical	-1	26002693
a@@	I-Chemical	-1	26002693
di@@	I-Chemical	-1	26002693
ene	I-Chemical	-1	26002693
metabol@@	O	-1	26002693
it@@	O	-1	26002693
es	O	-1	26002693
be	O	-1	26002693
so	O	-1	26002693
tested	O	-1	26002693
as	O	-1	26002693
a	O	-1	26002693
re@@	O	-1	26002693
ality	O	-1	26002693
ch@@	O	-1	26002693
ec@@	O	-1	26002693
k	O	-1	26002693
on	O	-1	26002693
the	O	-1	26002693
epi@@	O	-1	26002693
de@@	O	-1	26002693
m@@	O	-1	26002693
io@@	O	-1	26002693
log@@	O	-1	26002693
ical	O	-1	26002693
repor@@	O	-1	26002693
t@@	O	-1	26002693
s.	O	-1	26002693
In	O	-1	26002693
or@@	O	-1	26002693
der	O	-1	26002693
to	O	-1	26002693
con@@	O	-1	26002693
duc@@	O	-1	26002693
t	O	-1	26002693
re@@	O	-1	26002693
li@@	O	-1	26002693
able	O	-1	26002693
test@@	O	-1	26002693
ing	O	-1	26002693
in	O	-1	26002693
this	O	-1	26002693
reg@@	O	-1	26002693
ar@@	O	-1	26002693
d,	O	-1	26002693
it	O	-1	26002693
is	O	-1	26002693
es@@	O	-1	26002693
sen@@	O	-1	26002693
tial	O	-1	26002693
that	O	-1	26002693
a	O	-1	26002693
positive	O	-1	26002693
control	O	-1	26002693
for	O	-1	26002693
induction	O	-1	26002693
be	O	-1	26002693
av@@	O	-1	26002693
ail@@	O	-1	26002693
able@@	O	-1	26002693
.	O	-1	26002693
We	O	-1	26002693
have	O	-1	26002693
used	O	-1	26002693
i@@	O	-1	26002693
on@@	O	-1	26002693
iz@@	O	-1	26002693
ing	O	-1	26002693
radi@@	O	-1	26002693
ation	O	-1	26002693
to	O	-1	26002693
deve@@	O	-1	26002693
lo@@	O	-1	26002693
p	O	-1	26002693
such	O	-1	26002693
a	O	-1	26002693
control@@	O	-1	26002693
.	O	-1	26002693
R@@	O	-1	26002693
es@@	O	-1	26002693
ult@@	O	-1	26002693
s	O	-1	26002693
descri@@	O	-1	26002693
bed	O	-1	26002693
h@@	O	-1	26002693
ere	O	-1	26002693
demon@@	O	-1	26002693
st@@	O	-1	26002693
rate	O	-1	26002693
that	O	-1	26002693
this	O	-1	26002693
agent	O	-1	26002693
does	O	-1	26002693
in	O	-1	26002693
fac@@	O	-1	26002693
t	O	-1	26002693
induce	O	-1	26002693
path@@	O	-1	26002693
o@@	O	-1	26002693
genic	O	-1	26002693
t@@	O	-1	26002693
(@@	O	-1	26002693
9@@	O	-1	26002693
:@@	O	-1	26002693
2@@	O	-1	26002693
2)	O	-1	26002693
trans@@	O	-1	26002693
loc@@	O	-1	26002693
ations	O	-1	26002693
in	O	-1	26002693
a	O	-1	26002693
human	O	-1	26002693
my@@	O	-1	26002693
e@@	O	-1	26002693
lo@@	O	-1	26002693
id	O	-1	26002693
cell	O	-1	26002693
line	O	-1	26002693
in	O	-1	26002693
vit@@	O	-1	26002693
ro@@	O	-1	26002693
,	O	-1	26002693
but	O	-1	26002693
does	O	-1	26002693
so	O	-1	26002693
at	O	-1	26002693
low	O	-1	26002693
frequ@@	O	-1	26002693
en@@	O	-1	26002693
ci@@	O	-1	26002693
es.	O	-1	26002693
Con@@	O	-1	26002693
di@@	O	-1	26002693
tions	O	-1	26002693
that	O	-1	26002693
wil@@	O	-1	26002693
l	O	-1	26002693
be	O	-1	26002693
requ@@	O	-1	26002693
ired	O	-1	26002693
for	O	-1	26002693
studies	O	-1	26002693
of	O	-1	26002693
1@@	B-Chemical	C031763	26002693
,@@	I-Chemical	-1	26002693
3-@@	I-Chemical	-1	26002693
but@@	I-Chemical	-1	26002693
a@@	I-Chemical	-1	26002693
di@@	I-Chemical	-1	26002693
ene	I-Chemical	-1	26002693
are	O	-1	26002693
discus@@	O	-1	26002693
sed.	O	-1	26002693

C@@	B-Disease	D009369	26033014
anc@@	I-Disease	-1	26033014
er	I-Disease	-1	26033014
incidence	O	-1	26033014
and	O	-1	26033014
met@@	B-Chemical	C051786	26033014
ol@@	I-Chemical	-1	26033014
ac@@	I-Chemical	-1	26033014
h@@	I-Chemical	-1	26033014
lo@@	I-Chemical	-1	26033014
r	I-Chemical	-1	26033014
use	O	-1	26033014
in	O	-1	26033014
the	O	-1	26033014
A@@	O	-1	26033014
g@@	O	-1	26033014
r@@	O	-1	26033014
ic@@	O	-1	26033014
ult@@	O	-1	26033014
ural	O	-1	26033014
He@@	O	-1	26033014
al@@	O	-1	26033014
th	O	-1	26033014
S@@	O	-1	26033014
t@@	O	-1	26033014
ud@@	O	-1	26033014
y@@	O	-1	26033014
:	O	-1	26033014
An	O	-1	26033014
up@@	O	-1	26033014
dat@@	O	-1	26033014
e.	O	-1	26033014
UN@@	O	-1	26033014
A@@	O	-1	26033014
S@@	O	-1	26033014
S@@	O	-1	26033014
I@@	O	-1	26033014
G@@	O	-1	26033014
N@@	O	-1	26033014
E@@	O	-1	26033014
D@@	O	-1	26033014
:	O	-1	26033014
M@@	B-Chemical	C051786	26033014
et@@	I-Chemical	-1	26033014
ol@@	I-Chemical	-1	26033014
ac@@	I-Chemical	-1	26033014
h@@	I-Chemical	-1	26033014
lo@@	I-Chemical	-1	26033014
r	I-Chemical	-1	26033014
,	O	-1	26033014
a	O	-1	26033014
wi@@	O	-1	26033014
de@@	O	-1	26033014
ly	O	-1	26033014
used	O	-1	26033014
h@@	O	-1	26033014
er@@	O	-1	26033014
b@@	O	-1	26033014
ici@@	O	-1	26033014
de@@	O	-1	26033014
,	O	-1	26033014
is	O	-1	26033014
cl@@	O	-1	26033014
assi@@	O	-1	26033014
fied	O	-1	26033014
as	O	-1	26033014
a	O	-1	26033014
Group	O	-1	26033014
C	O	-1	26033014
carcino@@	O	-1	26033014
gen	O	-1	26033014
by	O	-1	26033014
the	O	-1	26033014
U@@	O	-1	26033014
.@@	O	-1	26033014
S@@	O	-1	26033014
.	O	-1	26033014
E@@	O	-1	26033014
n@@	O	-1	26033014
vi@@	O	-1	26033014
ron@@	O	-1	26033014
mental	O	-1	26033014
Pro@@	O	-1	26033014
t@@	O	-1	26033014
ection	O	-1	26033014
A@@	O	-1	26033014
gen@@	O	-1	26033014
c@@	O	-1	26033014
y	O	-1	26033014
bas@@	O	-1	26033014
ed	O	-1	26033014
on	O	-1	26033014
increased	O	-1	26033014
liver	B-Disease	D008113	26033014
ne@@	I-Disease	-1	26033014
o@@	I-Disease	-1	26033014
plas@@	I-Disease	-1	26033014
ms	I-Disease	-1	26033014
in	O	-1	26033014
female	O	-1	26033014
rats.	O	-1	26033014
E@@	O	-1	26033014
pi@@	O	-1	26033014
de@@	O	-1	26033014
m@@	O	-1	26033014
io@@	O	-1	26033014
log@@	O	-1	26033014
ic	O	-1	26033014
studies	O	-1	26033014
of	O	-1	26033014
the	O	-1	26033014
heal@@	O	-1	26033014
th	O	-1	26033014
effects	O	-1	26033014
of	O	-1	26033014
met@@	B-Chemical	C051786	26033014
ol@@	I-Chemical	-1	26033014
ac@@	I-Chemical	-1	26033014
h@@	I-Chemical	-1	26033014
lo@@	I-Chemical	-1	26033014
r	I-Chemical	-1	26033014
have	O	-1	26033014
been	O	-1	26033014
lim@@	O	-1	26033014
it@@	O	-1	26033014
ed.	O	-1	26033014
The	O	-1	26033014
A@@	O	-1	26033014
g@@	O	-1	26033014
r@@	O	-1	26033014
ic@@	O	-1	26033014
ult@@	O	-1	26033014
ural	O	-1	26033014
He@@	O	-1	26033014
al@@	O	-1	26033014
th	O	-1	26033014
S@@	O	-1	26033014
t@@	O	-1	26033014
ud@@	O	-1	26033014
y	O	-1	26033014
(A@@	O	-1	26033014
H@@	O	-1	26033014
S)	O	-1	26033014
is	O	-1	26033014
a	O	-1	26033014
pro@@	O	-1	26033014
sp@@	O	-1	26033014
ective	O	-1	26033014
co@@	O	-1	26033014
h@@	O	-1	26033014
ort	O	-1	26033014
study	O	-1	26033014
including	O	-1	26033014
l@@	O	-1	26033014
ic@@	O	-1	26033014
en@@	O	-1	26033014
sed	O	-1	26033014
pri@@	O	-1	26033014
v@@	O	-1	26033014
ate	O	-1	26033014
and	O	-1	26033014
com@@	O	-1	26033014
mer@@	O	-1	26033014
ci@@	O	-1	26033014
al	O	-1	26033014
p@@	O	-1	26033014
es@@	O	-1	26033014
tic@@	O	-1	26033014
ide	O	-1	26033014
ap@@	O	-1	26033014
plic@@	O	-1	26033014
at@@	O	-1	26033014
ors	O	-1	26033014
in	O	-1	26033014
I@@	O	-1	26033014
o@@	O	-1	26033014
w@@	O	-1	26033014
a	O	-1	26033014
and	O	-1	26033014
N@@	O	-1	26033014
or@@	O	-1	26033014
th	O	-1	26033014
Ca@@	O	-1	26033014
ro@@	O	-1	26033014
lin@@	O	-1	26033014
a	O	-1	26033014
en@@	O	-1	26033014
ro@@	O	-1	26033014
lled	O	-1	26033014
19@@	O	-1	26033014
9@@	O	-1	26033014
3@@	O	-1	26033014
-1@@	O	-1	26033014
9@@	O	-1	26033014
9@@	O	-1	26033014
7@@	O	-1	26033014
.	O	-1	26033014
We	O	-1	26033014
evaluated	O	-1	26033014
cancer	B-Disease	D009369	26033014
incidence	O	-1	26033014
through	O	-1	26033014
20@@	O	-1	26033014
10@@	O	-1	26033014
/@@	O	-1	26033014
20@@	O	-1	26033014
11	O	-1	26033014
(N@@	O	-1	26033014
C@@	O	-1	26033014
/@@	O	-1	26033014
I@@	O	-1	26033014
A@@	O	-1	26033014
)	O	-1	26033014
for	O	-1	26033014
4@@	O	-1	26033014
9@@	O	-1	26033014
,@@	O	-1	26033014
6@@	O	-1	26033014
16	O	-1	26033014
ap@@	O	-1	26033014
plic@@	O	-1	26033014
at@@	O	-1	26033014
or@@	O	-1	26033014
s,	O	-1	26033014
5@@	O	-1	26033014
3@@	O	-1	26033014
%	O	-1	26033014
of	O	-1	26033014
whom	O	-1	26033014
reported	O	-1	26033014
ev@@	O	-1	26033014
er	O	-1	26033014
using	O	-1	26033014
met@@	B-Chemical	C051786	26033014
ol@@	I-Chemical	-1	26033014
ac@@	I-Chemical	-1	26033014
h@@	I-Chemical	-1	26033014
lo@@	I-Chemical	-1	26033014
r	I-Chemical	-1	26033014
.	O	-1	26033014
We	O	-1	26033014
used	O	-1	26033014
P@@	O	-1	26033014
o@@	O	-1	26033014
is@@	O	-1	26033014
s@@	O	-1	26033014
on	O	-1	26033014
reg@@	O	-1	26033014
res@@	O	-1	26033014
sion	O	-1	26033014
to	O	-1	26033014
evalu@@	O	-1	26033014
ate	O	-1	26033014
rel@@	O	-1	26033014
ations	O	-1	26033014
between	O	-1	26033014
two	O	-1	26033014
met@@	O	-1	26033014
r@@	O	-1	26033014
ic@@	O	-1	26033014
s	O	-1	26033014
of	O	-1	26033014
met@@	B-Chemical	C051786	26033014
ol@@	I-Chemical	-1	26033014
ac@@	I-Chemical	-1	26033014
h@@	I-Chemical	-1	26033014
lo@@	I-Chemical	-1	26033014
r	I-Chemical	-1	26033014
use	O	-1	26033014
(@@	O	-1	26033014
li@@	O	-1	26033014
fe@@	O	-1	26033014
time	O	-1	26033014
day@@	O	-1	26033014
s,	O	-1	26033014
int@@	O	-1	26033014
en@@	O	-1	26033014
sit@@	O	-1	26033014
y-@@	O	-1	26033014
weigh@@	O	-1	26033014
ted	O	-1	26033014
li@@	O	-1	26033014
fe@@	O	-1	26033014
time	O	-1	26033014
da@@	O	-1	26033014
ys@@	O	-1	26033014
)	O	-1	26033014
and	O	-1	26033014
cancer	B-Disease	D009369	26033014
inc@@	O	-1	26033014
id@@	O	-1	26033014
ence@@	O	-1	26033014
.	O	-1	26033014
We	O	-1	26033014
sa@@	O	-1	26033014
w	O	-1	26033014
no	O	-1	26033014
association	O	-1	26033014
between	O	-1	26033014
met@@	B-Chemical	C051786	26033014
ol@@	I-Chemical	-1	26033014
ac@@	I-Chemical	-1	26033014
h@@	I-Chemical	-1	26033014
lo@@	I-Chemical	-1	26033014
r	I-Chemical	-1	26033014
use	O	-1	26033014
and	O	-1	26033014
incidence	O	-1	26033014
of	O	-1	26033014
all	O	-1	26033014
canc@@	B-Disease	D009369	26033014
ers	I-Disease	-1	26033014
combined	O	-1	26033014
(n	O	-1	26033014
=	O	-1	26033014
5@@	O	-1	26033014
,@@	O	-1	26033014
7@@	O	-1	26033014
0@@	O	-1	26033014
1	O	-1	26033014
with	O	-1	26033014
a	O	-1	26033014
5-@@	O	-1	26033014
year	O	-1	26033014
l@@	O	-1	26033014
ag@@	O	-1	26033014
)	O	-1	26033014
or	O	-1	26033014
most	O	-1	26033014
sit@@	O	-1	26033014
e-@@	O	-1	26033014
specific	O	-1	26033014
canc@@	B-Disease	D009369	26033014
ers	I-Disease	-1	26033014
.	O	-1	26033014
F@@	O	-1	26033014
or	O	-1	26033014
liver	B-Disease	D008113	26033014
cancer	I-Disease	-1	26033014
,	O	-1	26033014
in	O	-1	26033014
analy@@	O	-1	26033014
ses	O	-1	26033014
re@@	O	-1	26033014
stric@@	O	-1	26033014
ted	O	-1	26033014
to	O	-1	26033014
exposed	O	-1	26033014
wor@@	O	-1	26033014
k@@	O	-1	26033014
er@@	O	-1	26033014
s,	O	-1	26033014
elev@@	O	-1	26033014
ations	O	-1	26033014
observed	O	-1	26033014
at	O	-1	26033014
higher	O	-1	26033014
c@@	O	-1	26033014
ate@@	O	-1	26033014
g@@	O	-1	26033014
or@@	O	-1	26033014
i@@	O	-1	26033014
es	O	-1	26033014
of	O	-1	26033014
use	O	-1	26033014
were	O	-1	26033014
not	O	-1	26033014
statis@@	O	-1	26033014
tically	O	-1	26033014
significant@@	O	-1	26033014
.	O	-1	26033014
However,	O	-1	26033014
tre@@	O	-1	26033014
n@@	O	-1	26033014
ds	O	-1	26033014
for	O	-1	26033014
both	O	-1	26033014
li@@	O	-1	26033014
fe@@	O	-1	26033014
time	O	-1	26033014
and	O	-1	26033014
int@@	O	-1	26033014
en@@	O	-1	26033014
sit@@	O	-1	26033014
y-@@	O	-1	26033014
weigh@@	O	-1	26033014
ted	O	-1	26033014
li@@	O	-1	26033014
fe@@	O	-1	26033014
time	O	-1	26033014
days	O	-1	26033014
of	O	-1	26033014
met@@	B-Chemical	C051786	26033014
ol@@	I-Chemical	-1	26033014
ac@@	I-Chemical	-1	26033014
h@@	I-Chemical	-1	26033014
or	I-Chemical	-1	26033014
use	O	-1	26033014
were	O	-1	26033014
positive	O	-1	26033014
and	O	-1	26033014
statis@@	O	-1	26033014
tically	O	-1	26033014
significant	O	-1	26033014
with	O	-1	26033014
an	O	-1	26033014
un@@	O	-1	26033014
exposed	O	-1	26033014
ref@@	O	-1	26033014
e@@	O	-1	26033014
rence	O	-1	26033014
group.	O	-1	26033014
A	O	-1	26033014
similar	O	-1	26033014
pat@@	O	-1	26033014
ter@@	O	-1	26033014
n	O	-1	26033014
was	O	-1	26033014
observed	O	-1	26033014
for	O	-1	26033014
fol@@	B-Disease	D008224	26033014
l@@	I-Disease	-1	26033014
ic@@	I-Disease	-1	26033014
ular	I-Disease	-1	26033014
cell	I-Disease	-1	26033014
lymph@@	I-Disease	-1	26033014
oma	I-Disease	-1	26033014
,	O	-1	26033014
but	O	-1	26033014
no	O	-1	26033014
other	O	-1	26033014
lymph@@	B-Disease	D008223	26033014
oma	I-Disease	-1	26033014
sub@@	O	-1	26033014
typ@@	O	-1	26033014
es.	O	-1	26033014
An	O	-1	26033014
ear@@	O	-1	26033014
li@@	O	-1	26033014
er	O	-1	26033014
sugg@@	O	-1	26033014
es@@	O	-1	26033014
tion	O	-1	26033014
of	O	-1	26033014
increased	O	-1	26033014
l@@	B-Disease	D008175	26033014
un@@	I-Disease	-1	26033014
g	I-Disease	-1	26033014
cancer	I-Disease	-1	26033014
risk	O	-1	26033014
at	O	-1	26033014
high	O	-1	26033014
levels	O	-1	26033014
of	O	-1	26033014
met@@	B-Chemical	C051786	26033014
ol@@	I-Chemical	-1	26033014
ac@@	I-Chemical	-1	26033014
h@@	I-Chemical	-1	26033014
lo@@	I-Chemical	-1	26033014
r	I-Chemical	-1	26033014
use	O	-1	26033014
in	O	-1	26033014
this	O	-1	26033014
co@@	O	-1	26033014
h@@	O	-1	26033014
ort	O	-1	26033014
was	O	-1	26033014
not	O	-1	26033014
con@@	O	-1	26033014
fir@@	O	-1	26033014
m@@	O	-1	26033014
ed	O	-1	26033014
in	O	-1	26033014
this	O	-1	26033014
up@@	O	-1	26033014
dat@@	O	-1	26033014
e.	O	-1	26033014
This	O	-1	26033014
sugg@@	O	-1	26033014
es@@	O	-1	26033014
tion	O	-1	26033014
of	O	-1	26033014
an	O	-1	26033014
association	O	-1	26033014
between	O	-1	26033014
met@@	B-Chemical	C051786	26033014
ol@@	I-Chemical	-1	26033014
ac@@	I-Chemical	-1	26033014
h@@	I-Chemical	-1	26033014
lo@@	I-Chemical	-1	26033014
r	I-Chemical	-1	26033014
and	O	-1	26033014
liver	B-Disease	D008113	26033014
cancer	I-Disease	-1	26033014
among	O	-1	26033014
p@@	O	-1	26033014
es@@	O	-1	26033014
tic@@	O	-1	26033014
ide	O	-1	26033014
ap@@	O	-1	26033014
plic@@	O	-1	26033014
at@@	O	-1	26033014
ors	O	-1	26033014
is	O	-1	26033014
a	O	-1	26033014
novel	O	-1	26033014
find@@	O	-1	26033014
ing	O	-1	26033014
and	O	-1	26033014
ec@@	O	-1	26033014
ho@@	O	-1	26033014
es	O	-1	26033014
observ@@	O	-1	26033014
ation	O	-1	26033014
of	O	-1	26033014
increased	O	-1	26033014
liver	B-Disease	D008113	26033014
ne@@	I-Disease	-1	26033014
o@@	I-Disease	-1	26033014
plas@@	I-Disease	-1	26033014
ms	I-Disease	-1	26033014
in	O	-1	26033014
some	O	-1	26033014
anim@@	O	-1	26033014
al	O	-1	26033014
studi@@	O	-1	26033014
es.	O	-1	26033014
However,	O	-1	26033014
our	O	-1	26033014
findings	O	-1	26033014
for	O	-1	26033014
both	O	-1	26033014
liver	B-Disease	D008113	26033014
cancer	I-Disease	-1	26033014
and	O	-1	26033014
fol@@	O	-1	26033014
l@@	O	-1	26033014
ic@@	O	-1	26033014
ular	O	-1	26033014
cell	O	-1	26033014
lymph@@	B-Disease	D008223	26033014
oma	I-Disease	-1	26033014
war@@	O	-1	26033014
ran@@	O	-1	26033014
t	O	-1	26033014
follow-up	O	-1	26033014
to	O	-1	26033014
bet@@	O	-1	26033014
ter	O	-1	26033014
differen@@	O	-1	26033014
ti@@	O	-1	26033014
ate	O	-1	26033014
effects	O	-1	26033014
of	O	-1	26033014
met@@	B-Chemical	C051786	26033014
ol@@	I-Chemical	-1	26033014
ac@@	I-Chemical	-1	26033014
h@@	I-Chemical	-1	26033014
lo@@	I-Chemical	-1	26033014
r	I-Chemical	-1	26033014
use	O	-1	26033014
from	O	-1	26033014
other	O	-1	26033014
fact@@	O	-1	26033014
or@@	O	-1	26033014
s.	O	-1	26033014

M@@	O	-1	26115410
echan@@	O	-1	26115410
is@@	O	-1	26115410
ms	O	-1	26115410
U@@	O	-1	26115410
n@@	O	-1	26115410
der@@	O	-1	26115410
ly@@	O	-1	26115410
ing	O	-1	26115410
L@@	O	-1	26115410
at@@	O	-1	26115410
ent	O	-1	26115410
Di@@	O	-1	26115410
se@@	O	-1	26115410
ase	O	-1	26115410
R@@	O	-1	26115410
is@@	O	-1	26115410
k	O	-1	26115410
A@@	O	-1	26115410
s@@	O	-1	26115410
s@@	O	-1	26115410
oci@@	O	-1	26115410
ated	O	-1	26115410
with	O	-1	26115410
E@@	O	-1	26115410
ar@@	O	-1	26115410
l@@	O	-1	26115410
y-@@	O	-1	26115410
L@@	O	-1	26115410
if@@	O	-1	26115410
e	O	-1	26115410
A@@	B-Chemical	D001151	26115410
r@@	I-Chemical	-1	26115410
sen@@	I-Chemical	-1	26115410
ic	I-Chemical	-1	26115410
E@@	O	-1	26115410
x@@	O	-1	26115410
pos@@	O	-1	26115410
ure@@	O	-1	26115410
:	O	-1	26115410
C@@	O	-1	26115410
ur@@	O	-1	26115410
rent	O	-1	26115410
R@@	O	-1	26115410
es@@	O	-1	26115410
ear@@	O	-1	26115410
ch	O	-1	26115410
T@@	O	-1	26115410
ren@@	O	-1	26115410
ds	O	-1	26115410
and	O	-1	26115410
S@@	O	-1	26115410
ci@@	O	-1	26115410
enti@@	O	-1	26115410
f@@	O	-1	26115410
ic	O	-1	26115410
G@@	O	-1	26115410
ap@@	O	-1	26115410
s.	O	-1	26115410
BACKGROUND:	O	-1	26115410
M@@	O	-1	26115410
il@@	O	-1	26115410
li@@	O	-1	26115410
ons	O	-1	26115410
of	O	-1	26115410
individ@@	O	-1	26115410
u@@	O	-1	26115410
als	O	-1	26115410
wor@@	O	-1	26115410
l@@	O	-1	26115410
d@@	O	-1	26115410
wi@@	O	-1	26115410
de@@	O	-1	26115410
,	O	-1	26115410
partic@@	O	-1	26115410
ul@@	O	-1	26115410
arly	O	-1	26115410
those	O	-1	26115410
li@@	O	-1	26115410
ving	O	-1	26115410
in	O	-1	26115410
r@@	O	-1	26115410
ural	O	-1	26115410
and	O	-1	26115410
develop@@	O	-1	26115410
ing	O	-1	26115410
a@@	O	-1	26115410
reas@@	O	-1	26115410
,	O	-1	26115410
are	O	-1	26115410
exposed	O	-1	26115410
to	O	-1	26115410
h@@	O	-1	26115410
ar@@	O	-1	26115410
m@@	O	-1	26115410
ful	O	-1	26115410
levels	O	-1	26115410
of	O	-1	26115410
in@@	B-Chemical	D001152	26115410
org@@	I-Chemical	-1	26115410
anic	I-Chemical	-1	26115410
ar@@	I-Chemical	-1	26115410
sen@@	I-Chemical	-1	26115410
ic	I-Chemical	-1	26115410
(	O	-1	26115410
i@@	B-Chemical	D001152	26115410
A@@	I-Chemical	-1	26115410
s	I-Chemical	-1	26115410
)	O	-1	26115410
in	O	-1	26115410
their	O	-1	26115410
d@@	O	-1	26115410
r@@	O	-1	26115410
in@@	O	-1	26115410
king	O	-1	26115410
w@@	O	-1	26115410
at@@	O	-1	26115410
er.	O	-1	26115410
In@@	B-Chemical	D001152	26115410
org@@	I-Chemical	-1	26115410
anic	I-Chemical	-1	26115410
A@@	I-Chemical	-1	26115410
s	I-Chemical	-1	26115410
exposure	O	-1	26115410
during	O	-1	26115410
ke@@	O	-1	26115410
y	O	-1	26115410
develop@@	O	-1	26115410
mental	O	-1	26115410
perio@@	O	-1	26115410
ds	O	-1	26115410
is	O	-1	26115410
associated	O	-1	26115410
with	O	-1	26115410
a	O	-1	26115410
vari@@	O	-1	26115410
ety	O	-1	26115410
of	O	-1	26115410
adverse	O	-1	26115410
heal@@	O	-1	26115410
th	O	-1	26115410
effects	O	-1	26115410
including	O	-1	26115410
those	O	-1	26115410
that	O	-1	26115410
are	O	-1	26115410
ev@@	O	-1	26115410
id@@	O	-1	26115410
ent	O	-1	26115410
in	O	-1	26115410
ad@@	O	-1	26115410
ul@@	O	-1	26115410
th@@	O	-1	26115410
o@@	O	-1	26115410
o@@	O	-1	26115410
d.	O	-1	26115410
There	O	-1	26115410
is	O	-1	26115410
con@@	O	-1	26115410
si@@	O	-1	26115410
der@@	O	-1	26115410
able	O	-1	26115410
in@@	O	-1	26115410
te@@	O	-1	26115410
res@@	O	-1	26115410
t	O	-1	26115410
in	O	-1	26115410
identi@@	O	-1	26115410
f@@	O	-1	26115410
y@@	O	-1	26115410
ing	O	-1	26115410
the	O	-1	26115410
mol@@	O	-1	26115410
ec@@	O	-1	26115410
ular	O	-1	26115410
mechanisms	O	-1	26115410
that	O	-1	26115410
rel@@	O	-1	26115410
ate	O	-1	26115410
ear@@	O	-1	26115410
l@@	O	-1	26115410
y-@@	O	-1	26115410
lif@@	O	-1	26115410
e	O	-1	26115410
i@@	B-Chemical	D001152	26115410
A@@	I-Chemical	-1	26115410
s	I-Chemical	-1	26115410
exposure	O	-1	26115410
to	O	-1	26115410
the	O	-1	26115410
development	O	-1	26115410
of	O	-1	26115410
these	O	-1	26115410
lat@@	O	-1	26115410
ent	O	-1	26115410
diseas@@	O	-1	26115410
es,	O	-1	26115410
partic@@	O	-1	26115410
ul@@	O	-1	26115410
arly	O	-1	26115410
in	O	-1	26115410
rel@@	O	-1	26115410
ationship	O	-1	26115410
to	O	-1	26115410
cancer	B-Disease	D009369	26115410
.	O	-1	26115410
OBJECTIV@@	O	-1	26115410
E@@	O	-1	26115410
S:	O	-1	26115410
This	O	-1	26115410
wor@@	O	-1	26115410
k	O	-1	26115410
su@@	O	-1	26115410
mm@@	O	-1	26115410
ar@@	O	-1	26115410
iz@@	O	-1	26115410
es	O	-1	26115410
re@@	O	-1	26115410
se@@	O	-1	26115410
arc@@	O	-1	26115410
h	O	-1	26115410
on	O	-1	26115410
the	O	-1	26115410
mol@@	O	-1	26115410
ec@@	O	-1	26115410
ular	O	-1	26115410
mechanisms	O	-1	26115410
that	O	-1	26115410
under@@	O	-1	26115410
li@@	O	-1	26115410
e	O	-1	26115410
the	O	-1	26115410
increased	O	-1	26115410
risk	O	-1	26115410
of	O	-1	26115410
cancer	B-Disease	D009369	26115410
development	O	-1	26115410
in	O	-1	26115410
ad@@	O	-1	26115410
ul@@	O	-1	26115410
th@@	O	-1	26115410
o@@	O	-1	26115410
od	O	-1	26115410
that	O	-1	26115410
is	O	-1	26115410
associated	O	-1	26115410
with	O	-1	26115410
ear@@	O	-1	26115410
l@@	O	-1	26115410
y-@@	O	-1	26115410
lif@@	O	-1	26115410
e	O	-1	26115410
i@@	B-Chemical	D001152	26115410
A@@	I-Chemical	-1	26115410
s	I-Chemical	-1	26115410
expos@@	O	-1	26115410
ure.	O	-1	26115410
D@@	O	-1	26115410
I@@	O	-1	26115410
S@@	O	-1	26115410
C@@	O	-1	26115410
US@@	O	-1	26115410
S@@	O	-1	26115410
ION@@	O	-1	26115410
:	O	-1	26115410
E@@	O	-1	26115410
pi@@	O	-1	26115410
gene@@	O	-1	26115410
tic	O	-1	26115410
re@@	O	-1	26115410
pro@@	O	-1	26115410
gram@@	O	-1	26115410
m@@	O	-1	26115410
ing	O	-1	26115410
that	O	-1	26115410
im@@	O	-1	26115410
par@@	O	-1	26115410
ts	O	-1	26115410
functional	O	-1	26115410
changes	O	-1	26115410
in	O	-1	26115410
gen@@	O	-1	26115410
e	O	-1	26115410
ex@@	O	-1	26115410
pres@@	O	-1	26115410
sion,	O	-1	26115410
the	O	-1	26115410
development	O	-1	26115410
of	O	-1	26115410
cancer	B-Disease	D009369	26115410
st@@	O	-1	26115410
em	O	-1	26115410
cell@@	O	-1	26115410
s,	O	-1	26115410
and	O	-1	26115410
immuno@@	O	-1	26115410
mod@@	O	-1	26115410
ulation	O	-1	26115410
are	O	-1	26115410
pl@@	O	-1	26115410
au@@	O	-1	26115410
sible	O	-1	26115410
underlying	O	-1	26115410
mechanisms	O	-1	26115410
by	O	-1	26115410
which	O	-1	26115410
ear@@	O	-1	26115410
l@@	O	-1	26115410
y-@@	O	-1	26115410
lif@@	O	-1	26115410
e	O	-1	26115410
i@@	B-Chemical	D001152	26115410
A@@	I-Chemical	-1	26115410
s	I-Chemical	-1	26115410
exposure	O	-1	26115410
el@@	O	-1	26115410
ic@@	O	-1	26115410
its	O	-1	26115410
lat@@	O	-1	26115410
ent	O	-1	26115410
carcino@@	O	-1	26115410
genic	O	-1	26115410
effects.	O	-1	26115410
CONCLUSIONS:	O	-1	26115410
E@@	O	-1	26115410
v@@	O	-1	26115410
idence	O	-1	26115410
is	O	-1	26115410
m@@	O	-1	26115410
oun@@	O	-1	26115410
ting	O	-1	26115410
that	O	-1	26115410
rel@@	O	-1	26115410
ates	O	-1	26115410
ear@@	O	-1	26115410
l@@	O	-1	26115410
y-@@	O	-1	26115410
lif@@	O	-1	26115410
e	O	-1	26115410
i@@	B-Chemical	D001152	26115410
A@@	I-Chemical	-1	26115410
s	I-Chemical	-1	26115410
exposure	O	-1	26115410
and	O	-1	26115410
cancer	B-Disease	D009369	26115410
development	O	-1	26115410
lat@@	O	-1	26115410
er	O	-1	26115410
in	O	-1	26115410
lif@@	O	-1	26115410
e.	O	-1	26115410
F@@	O	-1	26115410
ut@@	O	-1	26115410
ure	O	-1	26115410
re@@	O	-1	26115410
se@@	O	-1	26115410
arc@@	O	-1	26115410
h	O	-1	26115410
should	O	-1	26115410
includ@@	O	-1	26115410
e	O	-1	26115410
anim@@	O	-1	26115410
al	O	-1	26115410
studies	O	-1	26115410
that	O	-1	26115410
ad@@	O	-1	26115410
d@@	O	-1	26115410
res@@	O	-1	26115410
s	O	-1	26115410
mechanis@@	O	-1	26115410
tic	O	-1	26115410
hypo@@	O	-1	26115410
th@@	O	-1	26115410
es@@	O	-1	26115410
es	O	-1	26115410
and	O	-1	26115410
studies	O	-1	26115410
of	O	-1	26115410
human	O	-1	26115410
po@@	O	-1	26115410
pul@@	O	-1	26115410
ations	O	-1	26115410
that	O	-1	26115410
in@@	O	-1	26115410
te@@	O	-1	26115410
g@@	O	-1	26115410
rate	O	-1	26115410
ear@@	O	-1	26115410
l@@	O	-1	26115410
y-@@	O	-1	26115410
lif@@	O	-1	26115410
e	O	-1	26115410
expos@@	O	-1	26115410
ure,	O	-1	26115410
mol@@	O	-1	26115410
ec@@	O	-1	26115410
ular	O	-1	26115410
al@@	O	-1	26115410
ter@@	O	-1	26115410
ation@@	O	-1	26115410
s,	O	-1	26115410
and	O	-1	26115410
lat@@	O	-1	26115410
ent	O	-1	26115410
disease	O	-1	26115410
outcom@@	O	-1	26115410
es.	O	-1	26115410

O@@	O	-1	44072
n	O	-1	44072
the	O	-1	44072
anti@@	O	-1	44072
arrhyth@@	O	-1	44072
mic	O	-1	44072
activity	O	-1	44072
of	O	-1	44072
one	O	-1	44072
N@@	O	-1	44072
-@@	O	-1	44072
sub@@	O	-1	44072
sti@@	O	-1	44072
t@@	O	-1	44072
ut@@	O	-1	44072
ed	O	-1	44072
pi@@	B-Chemical	C034930	44072
per@@	I-Chemical	-1	44072
az@@	I-Chemical	-1	44072
ine	I-Chemical	-1	44072
der@@	O	-1	44072
i@@	O	-1	44072
v@@	O	-1	44072
ative	O	-1	44072
of	O	-1	44072
trans@@	B-Chemical	-1	44072
-@@	I-Chemical	-1	44072
2-@@	I-Chemical	-1	44072
amino@@	I-Chemical	-1	44072
-@@	I-Chemical	-1	44072
3-@@	I-Chemical	-1	44072
hydrox@@	I-Chemical	-1	44072
y@@	I-Chemical	-1	44072
-1@@	I-Chemical	-1	44072
,	I-Chemical	-1	44072
2,	I-Chemical	-1	44072
3,	I-Chemical	-1	44072
4-@@	I-Chemical	-1	44072
te@@	I-Chemical	-1	44072
tra@@	I-Chemical	-1	44072
hydro@@	I-Chemical	-1	44072
ana@@	I-Chemical	-1	44072
ph@@	I-Chemical	-1	44072
thal@@	I-Chemical	-1	44072
ene	I-Chemical	-1	44072
.	O	-1	44072
The	O	-1	44072
anti@@	O	-1	44072
arrhyth@@	O	-1	44072
mic	O	-1	44072
activity	O	-1	44072
of	O	-1	44072
the	O	-1	44072
comp@@	O	-1	44072
ound	O	-1	44072
N@@	B-Chemical	C013741	44072
-@@	I-Chemical	-1	44072
(@@	I-Chemical	-1	44072
trans@@	I-Chemical	-1	44072
-@@	I-Chemical	-1	44072
3-@@	I-Chemical	-1	44072
hydrox@@	I-Chemical	-1	44072
y@@	I-Chemical	-1	44072
-1@@	I-Chemical	-1	44072
,@@	I-Chemical	-1	44072
2@@	I-Chemical	-1	44072
,@@	I-Chemical	-1	44072
3@@	I-Chemical	-1	44072
,@@	I-Chemical	-1	44072
4-@@	I-Chemical	-1	44072
te@@	I-Chemical	-1	44072
tra@@	I-Chemical	-1	44072
hydro@@	I-Chemical	-1	44072
-@@	I-Chemical	-1	44072
2-@@	I-Chemical	-1	44072
na@@	I-Chemical	-1	44072
ph@@	I-Chemical	-1	44072
th@@	I-Chemical	-1	44072
yl@@	I-Chemical	-1	44072
)-@@	I-Chemical	-1	44072
N@@	I-Chemical	-1	44072
-@@	I-Chemical	-1	44072
(3@@	I-Chemical	-1	44072
-@@	I-Chemical	-1	44072
ox@@	I-Chemical	-1	44072
o@@	I-Chemical	-1	44072
-@@	I-Chemical	-1	44072
3-@@	I-Chemical	-1	44072
phenyl@@	I-Chemical	-1	44072
-@@	I-Chemical	-1	44072
2-@@	I-Chemical	-1	44072
methyl@@	I-Chemical	-1	44072
prop@@	I-Chemical	-1	44072
yl@@	I-Chemical	-1	44072
)-@@	I-Chemical	-1	44072
pi@@	I-Chemical	-1	44072
per@@	I-Chemical	-1	44072
az@@	I-Chemical	-1	44072
ine	I-Chemical	-1	44072
hydro@@	I-Chemical	-1	44072
chlor@@	I-Chemical	-1	44072
ide	I-Chemical	-1	44072
,	O	-1	44072
ref@@	O	-1	44072
er@@	O	-1	44072
red	O	-1	44072
to	O	-1	44072
as	O	-1	44072
P@@	B-Chemical	C013741	44072
11	I-Chemical	-1	44072
,	O	-1	44072
is	O	-1	44072
studied	O	-1	44072
on	O	-1	44072
anaesthe@@	O	-1	44072
si@@	O	-1	44072
zed	O	-1	44072
cat@@	O	-1	44072
s	O	-1	44072
and	O	-1	44072
Wistar	O	-1	44072
al@@	O	-1	44072
bin@@	O	-1	44072
o	O	-1	44072
rats,	O	-1	44072
as	O	-1	44072
well	O	-1	44072
as	O	-1	44072
on	O	-1	44072
non-@@	O	-1	44072
anaesthe@@	O	-1	44072
si@@	O	-1	44072
zed	O	-1	44072
ra@@	O	-1	44072
b@@	O	-1	44072
b@@	O	-1	44072
it@@	O	-1	44072
s.	O	-1	44072
F@@	O	-1	44072
our	O	-1	44072
typ@@	O	-1	44072
es	O	-1	44072
of	O	-1	44072
experimental	O	-1	44072
arrhyth@@	B-Disease	D001145	44072
mia	I-Disease	-1	44072
are	O	-1	44072
use@@	O	-1	44072
d-@@	O	-1	44072
-@@	O	-1	44072
with	O	-1	44072
B@@	B-Chemical	C024986	44072
a@@	I-Chemical	-1	44072
Cl@@	I-Chemical	-1	44072
2	I-Chemical	-1	44072
,	O	-1	44072
with	O	-1	44072
ch@@	B-Chemical	D002725	44072
loro@@	I-Chemical	-1	44072
form	I-Chemical	-1	44072
-	O	-1	44072
adren@@	B-Chemical	D004837	44072
aline	I-Chemical	-1	44072
,	O	-1	44072
with	O	-1	44072
stro@@	B-Chemical	D010042	44072
ph@@	I-Chemical	-1	44072
ant@@	I-Chemical	-1	44072
ine	I-Chemical	-1	44072
G	I-Chemical	-1	44072
and	O	-1	44072
with	O	-1	44072
ac@@	B-Chemical	D000157	44072
on@@	I-Chemical	-1	44072
it@@	I-Chemical	-1	44072
ine	I-Chemical	-1	44072
.	O	-1	44072
The	O	-1	44072
comp@@	O	-1	44072
ound	O	-1	44072
P@@	B-Chemical	C013741	44072
11	I-Chemical	-1	44072
is	O	-1	44072
int@@	O	-1	44072
ro@@	O	-1	44072
duced	O	-1	44072
in	O	-1	44072
doses	O	-1	44072
of	O	-1	44072
0.@@	O	-1	44072
25	O	-1	44072
and	O	-1	44072
0.@@	O	-1	44072
50	O	-1	44072
mg/kg	O	-1	44072
intra@@	O	-1	44072
ven@@	O	-1	44072
ously	O	-1	44072
and	O	-1	44072
10	O	-1	44072
mg/kg	O	-1	44072
or@@	O	-1	44072
all@@	O	-1	44072
y.	O	-1	44072
The	O	-1	44072
comp@@	O	-1	44072
ound	O	-1	44072
man@@	O	-1	44072
if@@	O	-1	44072
est@@	O	-1	44072
s	O	-1	44072
anti@@	O	-1	44072
arrhyth@@	O	-1	44072
mic	O	-1	44072
activity	O	-1	44072
in	O	-1	44072
all	O	-1	44072
models	O	-1	44072
of	O	-1	44072
experimental	O	-1	44072
arrhyth@@	B-Disease	D001145	44072
mia	I-Disease	-1	44072
use@@	O	-1	44072
d,	O	-1	44072
ca@@	O	-1	44072
using	O	-1	44072
great@@	O	-1	44072
est	O	-1	44072
inhibition	O	-1	44072
on	O	-1	44072
the	O	-1	44072
arrhyth@@	B-Disease	D001145	44072
mia	I-Disease	-1	44072
induced	O	-1	44072
by	O	-1	44072
ch@@	B-Chemical	D002725	44072
loro@@	I-Chemical	-1	44072
form	I-Chemical	-1	44072
-	O	-1	44072
adren@@	B-Chemical	D004837	44072
aline	I-Chemical	-1	44072
(@@	O	-1	44072
in	O	-1	44072
9@@	O	-1	44072
0	O	-1	44072
per	O	-1	44072
c@@	O	-1	44072
ent@@	O	-1	44072
)	O	-1	44072
and	O	-1	44072
with	O	-1	44072
B@@	B-Chemical	C024986	44072
a@@	I-Chemical	-1	44072
Cl@@	I-Chemical	-1	44072
2	I-Chemical	-1	44072
(@@	O	-1	44072
in	O	-1	44072
8@@	O	-1	44072
4	O	-1	44072
per	O	-1	44072
c@@	O	-1	44072
ent@@	O	-1	44072
).	O	-1	44072
The	O	-1	44072
results	O	-1	44072
obtained	O	-1	44072
are	O	-1	44072
associated	O	-1	44072
with	O	-1	44072
the	O	-1	44072
beta-@@	O	-1	44072
adren@@	O	-1	44072
ob@@	O	-1	44072
loc@@	O	-1	44072
king	O	-1	44072
and	O	-1	44072
with	O	-1	44072
the	O	-1	44072
membran@@	O	-1	44072
e-@@	O	-1	44072
st@@	O	-1	44072
abil@@	O	-1	44072
iz@@	O	-1	44072
ing	O	-1	44072
action	O	-1	44072
of	O	-1	44072
the	O	-1	44072
comp@@	O	-1	44072
oun@@	O	-1	44072
d.	O	-1	44072

E@@	O	-1	753803
x@@	O	-1	753803
per@@	O	-1	753803
im@@	O	-1	753803
ental	O	-1	753803
progressive	O	-1	753803
mus@@	B-Disease	D009136	753803
cular	I-Disease	-1	753803
dy@@	I-Disease	-1	753803
stro@@	I-Disease	-1	753803
ph@@	I-Disease	-1	753803
y	I-Disease	-1	753803
and	O	-1	753803
its	O	-1	753803
treatment	O	-1	753803
with	O	-1	753803
high	O	-1	753803
doses	O	-1	753803
an@@	O	-1	753803
abol@@	O	-1	753803
iz@@	O	-1	753803
ing	O	-1	753803
agent@@	O	-1	753803
s.	O	-1	753803
We	O	-1	753803
are	O	-1	753803
sti@@	O	-1	753803
ll	O	-1	753803
a	O	-1	753803
lon@@	O	-1	753803
g	O	-1	753803
w@@	O	-1	753803
ay	O	-1	753803
from	O	-1	753803
dis@@	O	-1	753803
co@@	O	-1	753803
ver@@	O	-1	753803
ing	O	-1	753803
an	O	-1	753803
un@@	O	-1	753803
equ@@	O	-1	753803
i@@	O	-1	753803
v@@	O	-1	753803
oc@@	O	-1	753803
al	O	-1	753803
path@@	O	-1	753803
o@@	O	-1	753803
gene@@	O	-1	753803
tic	O	-1	753803
inter@@	O	-1	753803
pre@@	O	-1	753803
t@@	O	-1	753803
ation	O	-1	753803
of	O	-1	753803
progressive	O	-1	753803
mus@@	B-Disease	D009136	753803
cular	I-Disease	-1	753803
dy@@	I-Disease	-1	753803
stro@@	I-Disease	-1	753803
ph@@	I-Disease	-1	753803
y	I-Disease	-1	753803
in	O	-1	753803
man@@	O	-1	753803
.	O	-1	753803
N@@	O	-1	753803
ot@@	O	-1	753803
e@@	O	-1	753803
wor@@	O	-1	753803
th@@	O	-1	753803
y	O	-1	753803
eff@@	O	-1	753803
or@@	O	-1	753803
ts	O	-1	753803
have	O	-1	753803
been	O	-1	753803
m@@	O	-1	753803
ade	O	-1	753803
in	O	-1	753803
the	O	-1	753803
experimental	O	-1	753803
fi@@	O	-1	753803
el@@	O	-1	753803
d@@	O	-1	753803
;	O	-1	753803
a	O	-1	753803
rec@@	O	-1	753803
es@@	O	-1	753803
sive	O	-1	753803
a@@	O	-1	753803
ut@@	O	-1	753803
os@@	O	-1	753803
om@@	O	-1	753803
ic	O	-1	753803
form	O	-1	753803
found	O	-1	753803
in	O	-1	753803
the	O	-1	753803
mouse	O	-1	753803
se@@	O	-1	753803
em@@	O	-1	753803
s	O	-1	753803
to	O	-1	753803
be@@	O	-1	753803
ar	O	-1	753803
the	O	-1	753803
c@@	O	-1	753803
los@@	O	-1	753803
est	O	-1	753803
re@@	O	-1	753803
se@@	O	-1	753803
m@@	O	-1	753803
bl@@	O	-1	753803
ance	O	-1	753803
to	O	-1	753803
the	O	-1	753803
human	O	-1	753803
form	O	-1	753803
from	O	-1	753803
the	O	-1	753803
gene@@	O	-1	753803
tic	O	-1	753803
po@@	O	-1	753803
in@@	O	-1	753803
t	O	-1	753803
of	O	-1	753803
vie@@	O	-1	753803
w@@	O	-1	753803
.	O	-1	753803
M@@	B-Disease	D009135	753803
yo@@	I-Disease	-1	753803
pathy	I-Disease	-1	753803
due	O	-1	753803
to	O	-1	753803
l@@	O	-1	753803
ac@@	O	-1	753803
k	O	-1	753803
of	O	-1	753803
vitamin	B-Chemical	D014810	753803
E	I-Chemical	-1	753803
and	O	-1	753803
my@@	B-Disease	D009135	753803
o@@	I-Disease	-1	753803
pathy	I-Disease	-1	753803
induced	O	-1	753803
by	O	-1	753803
cer@@	O	-1	753803
t@@	O	-1	753803
ain	O	-1	753803
vi@@	O	-1	753803
ru@@	O	-1	753803
ses	O	-1	753803
have	O	-1	753803
m@@	O	-1	753803
uc@@	O	-1	753803
h	O	-1	753803
in	O	-1	753803
common	O	-1	753803
an@@	O	-1	753803
at@@	O	-1	753803
om@@	O	-1	753803
ically	O	-1	753803
and	O	-1	753803
path@@	O	-1	753803
olog@@	O	-1	753803
ically	O	-1	753803
with	O	-1	753803
the	O	-1	753803
human	O	-1	753803
form@@	O	-1	753803
.	O	-1	753803
The	O	-1	753803
au@@	O	-1	753803
th@@	O	-1	753803
ors	O	-1	753803
induced	O	-1	753803
my@@	B-Disease	D009136	753803
o@@	I-Disease	-1	753803
dy@@	I-Disease	-1	753803
stro@@	I-Disease	-1	753803
ph@@	I-Disease	-1	753803
y	I-Disease	-1	753803
in	O	-1	753803
the	O	-1	753803
rat	O	-1	753803
by	O	-1	753803
gi@@	O	-1	753803
ving	O	-1	753803
it	O	-1	753803
a	O	-1	753803
diet	O	-1	753803
l@@	O	-1	753803
ac@@	O	-1	753803
king	O	-1	753803
in	O	-1	753803
vitamin	B-Chemical	D014810	753803
E	I-Chemical	-1	753803
.	O	-1	753803
The	O	-1	753803
pharmac@@	O	-1	753803
ological	O	-1	753803
character@@	O	-1	753803
is@@	O	-1	753803
tics	O	-1	753803
of	O	-1	753803
vitamin	B-Chemical	D014810	753803
E	I-Chemical	-1	753803
and	O	-1	753803
the	O	-1	753803
de@@	O	-1	753803
gener@@	O	-1	753803
ative	O	-1	753803
changes	O	-1	753803
b@@	O	-1	753803
rou@@	O	-1	753803
ght	O	-1	753803
about	O	-1	753803
by	O	-1	753803
its	O	-1	753803
defici@@	O	-1	753803
enc@@	O	-1	753803
y,	O	-1	753803
es@@	O	-1	753803
p@@	O	-1	753803
ec@@	O	-1	753803
i@@	O	-1	753803
ally	O	-1	753803
in	O	-1	753803
the	O	-1	753803
mus@@	O	-1	753803
cl@@	O	-1	753803
es,	O	-1	753803
are	O	-1	753803
il@@	O	-1	753803
lu@@	O	-1	753803
strat@@	O	-1	753803
ed.	O	-1	753803
It	O	-1	753803
is	O	-1	753803
th@@	O	-1	753803
us	O	-1	753803
con@@	O	-1	753803
fir@@	O	-1	753803
m@@	O	-1	753803
ed	O	-1	753803
that	O	-1	753803
the	O	-1	753803
hist@@	O	-1	753803
ological	O	-1	753803
character@@	O	-1	753803
is@@	O	-1	753803
tics	O	-1	753803
of	O	-1	753803
my@@	B-Disease	D009135	753803
o@@	I-Disease	-1	753803
path@@	I-Disease	-1	753803
ic	I-Disease	-1	753803
rat	O	-1	753803
musc@@	O	-1	753803
le	O	-1	753803
induced	O	-1	753803
experim@@	O	-1	753803
ent@@	O	-1	753803
ally	O	-1	753803
are	O	-1	753803
ext@@	O	-1	753803
ra@@	O	-1	753803
or@@	O	-1	753803
d@@	O	-1	753803
in@@	O	-1	753803
ari@@	O	-1	753803
ly	O	-1	753803
similar	O	-1	753803
to	O	-1	753803
those	O	-1	753803
of	O	-1	753803
human	O	-1	753803
my@@	B-Disease	D009135	753803
o@@	I-Disease	-1	753803
pathy	I-Disease	-1	753803
as	O	-1	753803
con@@	O	-1	753803
fir@@	O	-1	753803
m@@	O	-1	753803
ed	O	-1	753803
during	O	-1	753803
biop@@	O	-1	753803
si@@	O	-1	753803
es	O	-1	753803
performed	O	-1	753803
at	O	-1	753803
the	O	-1	753803
O@@	O	-1	753803
r@@	O	-1	753803
th@@	O	-1	753803
o@@	O	-1	753803
pa@@	O	-1	753803
edi@@	O	-1	753803
c	O	-1	753803
T@@	O	-1	753803
ra@@	O	-1	753803
um@@	O	-1	753803
at@@	O	-1	753803
ological	O	-1	753803
C@@	O	-1	753803
ent@@	O	-1	753803
re,	O	-1	753803
F@@	O	-1	753803
lo@@	O	-1	753803
ren@@	O	-1	753803
ce@@	O	-1	753803
.	O	-1	753803
The	O	-1	753803
en@@	O	-1	753803
cour@@	O	-1	753803
ag@@	O	-1	753803
ing	O	-1	753803
results	O	-1	753803
obtained	O	-1	753803
in	O	-1	753803
various	O	-1	753803
au@@	O	-1	753803
th@@	O	-1	753803
or@@	O	-1	753803
at@@	O	-1	753803
ative	O	-1	753803
de@@	O	-1	753803
part@@	O	-1	753803
ments	O	-1	753803
in	O	-1	753803
my@@	B-Disease	D009135	753803
o@@	I-Disease	-1	753803
path@@	I-Disease	-1	753803
ic	I-Disease	-1	753803
patients	O	-1	753803
by	O	-1	753803
using	O	-1	753803
an@@	O	-1	753803
abol@@	O	-1	753803
iz@@	O	-1	753803
ing	O	-1	753803
steroid@@	B-Chemical	D013256	753803
s	I-Chemical	-1	753803
have	O	-1	753803
en@@	O	-1	753803
cour@@	O	-1	753803
aged	O	-1	753803
the	O	-1	753803
au@@	O	-1	753803
th@@	O	-1	753803
ors	O	-1	753803
to	O	-1	753803
investigate	O	-1	753803
the	O	-1	753803
ben@@	O	-1	753803
e@@	O	-1	753803
fic@@	O	-1	753803
ial	O	-1	753803
effects	O	-1	753803
of	O	-1	753803
one	O	-1	753803
an@@	O	-1	753803
abol@@	O	-1	753803
iz@@	O	-1	753803
ing	O	-1	753803
agent	O	-1	753803
(	O	-1	753803
Di@@	B-Chemical	D008696	753803
an@@	I-Chemical	-1	753803
ab@@	I-Chemical	-1	753803
ol	I-Chemical	-1	753803
,	O	-1	753803
CI@@	B-Chemical	-1	753803
B@@	I-Chemical	-1	753803
A	I-Chemical	-1	753803
)	O	-1	753803
at	O	-1	753803
high	O	-1	753803
doses	O	-1	753803
in	O	-1	753803
rats	O	-1	753803
ren@@	O	-1	753803
de@@	O	-1	753803
red	O	-1	753803
my@@	B-Disease	D009135	753803
o@@	I-Disease	-1	753803
path@@	I-Disease	-1	753803
ic	I-Disease	-1	753803
by	O	-1	753803
a	O	-1	753803
diet	O	-1	753803
defici@@	O	-1	753803
ent	O	-1	753803
in	O	-1	753803
vitamin	B-Chemical	D014810	753803
E	I-Chemical	-1	753803
.	O	-1	753803
In	O	-1	753803
this	O	-1	753803
w@@	O	-1	753803
ay	O	-1	753803
they	O	-1	753803
obtained	O	-1	753803
ap@@	O	-1	753803
pre@@	O	-1	753803
ci@@	O	-1	753803
able	O	-1	753803
changes	O	-1	753803
in	O	-1	753803
body	O	-1	753803
weight	O	-1	753803
(@@	O	-1	753803
increased	O	-1	753803
from	O	-1	753803
50	O	-1	753803
to	O	-1	753803
7@@	O	-1	753803
0	O	-1	753803
g	O	-1	753803
after	O	-1	753803
for@@	O	-1	753803
t@@	O	-1	753803
y	O	-1	753803
days	O	-1	753803
at	O	-1	753803
a	O	-1	753803
dose	O	-1	753803
of	O	-1	753803
5	O	-1	753803
mg	O	-1	753803
per	O	-1	753803
day	O	-1	753803
of	O	-1	753803
an@@	O	-1	753803
abol@@	O	-1	753803
iz@@	O	-1	753803
ing	O	-1	753803
agent@@	O	-1	753803
),	O	-1	753803
but	O	-1	753803
most	O	-1	753803
of	O	-1	753803
all	O	-1	753803
they	O	-1	753803
found	O	-1	753803
hist@@	O	-1	753803
ological	O	-1	753803
changes	O	-1	753803
due	O	-1	753803
to	O	-1	753803
"@@	O	-1	753803
re@@	O	-1	753803
gener@@	O	-1	753803
ati@@	O	-1	753803
ve@@	O	-1	753803
"	O	-1	753803
changes	O	-1	753803
in	O	-1	753803
the	O	-1	753803
musc@@	O	-1	753803
le	O	-1	753803
tissu@@	O	-1	753803
e,	O	-1	753803
which	O	-1	753803
ho@@	O	-1	753803
we@@	O	-1	753803
ver	O	-1	753803
maint@@	O	-1	753803
ained	O	-1	753803
its	O	-1	753803
my@@	B-Disease	D009135	753803
o@@	I-Disease	-1	753803
path@@	I-Disease	-1	753803
ic	I-Disease	-1	753803
character@@	O	-1	753803
is@@	O	-1	753803
tics	O	-1	753803
in	O	-1	753803
the	O	-1	753803
control	O	-1	753803
animals	O	-1	753803
that	O	-1	753803
were	O	-1	753803
not	O	-1	753803
treated	O	-1	753803
with	O	-1	753803
the	O	-1	753803
an@@	O	-1	753803
abol@@	O	-1	753803
iz@@	O	-1	753803
ing	O	-1	753803
agent@@	O	-1	753803
.	O	-1	753803
The	O	-1	753803
au@@	O	-1	753803
th@@	O	-1	753803
ors	O	-1	753803
concl@@	O	-1	753803
ude	O	-1	753803
by	O	-1	753803
aff@@	O	-1	753803
ir@@	O	-1	753803
m@@	O	-1	753803
ing	O	-1	753803
the	O	-1	753803
un@@	O	-1	753803
dou@@	O	-1	753803
b@@	O	-1	753803
ted	O	-1	753803
efficacy	O	-1	753803
of	O	-1	753803
the	O	-1	753803
an@@	O	-1	753803
abol@@	O	-1	753803
iz@@	O	-1	753803
ing	O	-1	753803
steroid@@	B-Chemical	D013256	753803
s	I-Chemical	-1	753803
in	O	-1	753803
experimental	O	-1	753803
my@@	B-Disease	D009135	753803
o@@	I-Disease	-1	753803
path@@	I-Disease	-1	753803
ic	I-Disease	-1	753803
disease	I-Disease	-1	753803
,	O	-1	753803
but	O	-1	753803
they	O	-1	753803
have	O	-1	753803
res@@	O	-1	753803
er@@	O	-1	753803
v@@	O	-1	753803
ations	O	-1	753803
as	O	-1	753803
to	O	-1	753803
the	O	-1	753803
trans@@	O	-1	753803
f@@	O	-1	753803
er	O	-1	753803
of	O	-1	753803
the	O	-1	753803
results	O	-1	753803
into	O	-1	753803
the	O	-1	753803
human	O	-1	753803
fi@@	O	-1	753803
el@@	O	-1	753803
d,	O	-1	753803
wh@@	O	-1	753803
ere	O	-1	753803
high	O	-1	753803
dos@@	O	-1	753803
age	O	-1	753803
can@@	O	-1	753803
not	O	-1	753803
be	O	-1	753803
car@@	O	-1	753803
ri@@	O	-1	753803
ed	O	-1	753803
out	O	-1	753803
continu@@	O	-1	753803
ously	O	-1	753803
because	O	-1	753803
of	O	-1	753803
the	O	-1	753803
effects	O	-1	753803
of	O	-1	753803
the	O	-1	753803
drug	O	-1	753803
on	O	-1	753803
vi@@	O	-1	753803
ri@@	O	-1	753803
lit@@	O	-1	753803
y@@	O	-1	753803
;	O	-1	753803
because	O	-1	753803
the	O	-1	753803
tissue	O	-1	753803
injury	O	-1	753803
to@@	O	-1	753803
o	O	-1	753803
often	O	-1	753803
occur@@	O	-1	753803
s	O	-1	753803
at	O	-1	753803
an	O	-1	753803
ir@@	O	-1	753803
reversible	O	-1	753803
st@@	O	-1	753803
age	O	-1	753803
v@@	O	-1	753803
is@@	O	-1	753803
-@@	O	-1	753803
a@@	O	-1	753803
-@@	O	-1	753803
v@@	O	-1	753803
is	O	-1	753803
the	O	-1	753803
"@@	O	-1	753803
re@@	O	-1	753803
gener@@	O	-1	753803
ation@@	O	-1	753803
"	O	-1	753803
of	O	-1	753803
the	O	-1	753803
musc@@	O	-1	753803
le	O	-1	753803
tissu@@	O	-1	753803
e@@	O	-1	753803
;	O	-1	753803
and	O	-1	753803
f@@	O	-1	753803
in@@	O	-1	753803
ally	O	-1	753803
because	O	-1	753803
the	O	-1	753803
dy@@	O	-1	753803
stro@@	O	-1	753803
ph@@	O	-1	753803
ic	O	-1	753803
injur@@	O	-1	753803
i@@	O	-1	753803
ous	O	-1	753803
agent	O	-1	753803
is	O	-1	753803
cer@@	O	-1	753803
t@@	O	-1	753803
ain@@	O	-1	753803
ly	O	-1	753803
not	O	-1	753803
the	O	-1	753803
l@@	O	-1	753803
ac@@	O	-1	753803
k	O	-1	753803
of	O	-1	753803
vitamin	B-Chemical	D014810	753803
E	I-Chemical	-1	753803
but	O	-1	753803
so@@	O	-1	753803
meth@@	O	-1	753803
ing	O	-1	753803
as	O	-1	753803
y@@	O	-1	753803
et	O	-1	753803
un@@	O	-1	753803
know@@	O	-1	753803
n@@	O	-1	753803
.	O	-1	753803

F@@	O	-1	920167
et@@	O	-1	920167
al	O	-1	920167
ris@@	O	-1	920167
k@@	O	-1	920167
s	O	-1	920167
due	O	-1	920167
to	O	-1	920167
war@@	B-Chemical	D014859	920167
farin	I-Chemical	-1	920167
therapy	O	-1	920167
during	O	-1	920167
pregn@@	O	-1	920167
anc@@	O	-1	920167
y.	O	-1	920167
Two	O	-1	920167
mo@@	O	-1	920167
ther@@	O	-1	920167
s	O	-1	920167
with	O	-1	920167
heart	O	-1	920167
val@@	O	-1	920167
ve	O	-1	920167
pro@@	O	-1	920167
s@@	O	-1	920167
thesis	O	-1	920167
were	O	-1	920167
treated	O	-1	920167
with	O	-1	920167
war@@	B-Chemical	D014859	920167
farin	I-Chemical	-1	920167
during	O	-1	920167
pregn@@	O	-1	920167
anc@@	O	-1	920167
y.	O	-1	920167
In	O	-1	920167
the	O	-1	920167
first	O	-1	920167
case	O	-1	920167
a	O	-1	920167
ca@@	O	-1	920167
es@@	O	-1	920167
a@@	O	-1	920167
re@@	O	-1	920167
an	O	-1	920167
sec@@	O	-1	920167
tion	O	-1	920167
was	O	-1	920167
d@@	O	-1	920167
one	O	-1	920167
one	O	-1	920167
week	O	-1	920167
after	O	-1	920167
re@@	O	-1	920167
pl@@	O	-1	920167
ac@@	O	-1	920167
ement	O	-1	920167
of	O	-1	920167
war@@	B-Chemical	D014859	920167
farin	I-Chemical	-1	920167
with	O	-1	920167
hepar@@	B-Chemical	D006493	920167
in	I-Chemical	-1	920167
.	O	-1	920167
The	O	-1	920167
b@@	O	-1	920167
a@@	O	-1	920167
by	O	-1	920167
di@@	O	-1	920167
ed	O	-1	920167
of	O	-1	920167
cerebral	B-Disease	D002543	920167
and	I-Disease	-1	920167
pulmonary	I-Disease	-1	920167
hemorrh@@	I-Disease	-1	920167
age	I-Disease	-1	920167
cerebral	B-Disease	D008171	920167
and	I-Disease	-1	920167
pulmonary	I-Disease	-1	920167
hemorrh@@	I-Disease	-1	920167
age	I-Disease	-1	920167
cerebral	B-Disease	D006470	920167
and	I-Disease	-1	920167
pulmonary	I-Disease	-1	920167
hemorrh@@	I-Disease	-1	920167
age	I-Disease	-1	920167
.	O	-1	920167
The	O	-1	920167
second	O	-1	920167
mo@@	O	-1	920167
ther	O	-1	920167
had	O	-1	920167
a	O	-1	920167
male	O	-1	920167
inf@@	O	-1	920167
ant	O	-1	920167
by	O	-1	920167
ca@@	O	-1	920167
es@@	O	-1	920167
a@@	O	-1	920167
re@@	O	-1	920167
an	O	-1	920167
sec@@	O	-1	920167
tion.	O	-1	920167
The	O	-1	920167
b@@	O	-1	920167
a@@	O	-1	920167
by	O	-1	920167
showed	O	-1	920167
war@@	B-Chemical	D014859	920167
farin	I-Chemical	-1	920167
-induced	O	-1	920167
emb@@	B-Disease	D005315	920167
r@@	I-Disease	-1	920167
yo@@	I-Disease	-1	920167
pathy	I-Disease	-1	920167
with	O	-1	920167
n@@	B-Disease	-1	920167
as@@	I-Disease	-1	920167
al	I-Disease	-1	920167
hypo@@	I-Disease	-1	920167
pl@@	I-Disease	-1	920167
a@@	I-Disease	-1	920167
sia	I-Disease	-1	920167
and	O	-1	920167
sti@@	B-Disease	D002806	920167
p@@	I-Disease	-1	920167
pl@@	I-Disease	-1	920167
ed	I-Disease	-1	920167
epi@@	I-Disease	-1	920167
ph@@	I-Disease	-1	920167
y@@	I-Disease	-1	920167
ses	I-Disease	-1	920167
(	O	-1	920167
ch@@	B-Disease	D002806	920167
on@@	I-Disease	-1	920167
dro@@	I-Disease	-1	920167
dys@@	I-Disease	-1	920167
pl@@	I-Disease	-1	920167
a@@	I-Disease	-1	920167
sia	I-Disease	-1	920167
p@@	I-Disease	-1	920167
unc@@	I-Disease	-1	920167
t@@	I-Disease	-1	920167
at@@	I-Disease	-1	920167
a	I-Disease	-1	920167
).	O	-1	920167
N@@	B-Disease	-1	920167
as@@	I-Disease	-1	920167
al	I-Disease	-1	920167
hypo@@	I-Disease	-1	920167
pl@@	I-Disease	-1	920167
a@@	I-Disease	-1	920167
sia	I-Disease	-1	920167
with	O	-1	920167
or	O	-1	920167
without	O	-1	920167
sti@@	B-Disease	D002806	920167
p@@	I-Disease	-1	920167
pl@@	I-Disease	-1	920167
ed	I-Disease	-1	920167
epi@@	I-Disease	-1	920167
ph@@	I-Disease	-1	920167
y@@	I-Disease	-1	920167
ses	I-Disease	-1	920167
has	O	-1	920167
no@@	O	-1	920167
w	O	-1	920167
been	O	-1	920167
reported	O	-1	920167
in	O	-1	920167
11	O	-1	920167
inf@@	O	-1	920167
ants	O	-1	920167
b@@	O	-1	920167
or@@	O	-1	920167
n	O	-1	920167
to	O	-1	920167
mo@@	O	-1	920167
ther@@	O	-1	920167
s	O	-1	920167
treated	O	-1	920167
with	O	-1	920167
war@@	B-Chemical	D014859	920167
farin	I-Chemical	-1	920167
during	O	-1	920167
the	O	-1	920167
first	O	-1	920167
tri@@	O	-1	920167
me@@	O	-1	920167
ster@@	O	-1	920167
,	O	-1	920167
and	O	-1	920167
a	O	-1	920167
ca@@	O	-1	920167
us@@	O	-1	920167
al	O	-1	920167
association	O	-1	920167
is	O	-1	920167
prob@@	O	-1	920167
able@@	O	-1	920167
.	O	-1	920167
In	O	-1	920167
vie@@	O	-1	920167
w	O	-1	920167
of	O	-1	920167
the	O	-1	920167
ris@@	O	-1	920167
k@@	O	-1	920167
s	O	-1	920167
to	O	-1	920167
both	O	-1	920167
mo@@	O	-1	920167
ther	O	-1	920167
and	O	-1	920167
f@@	O	-1	920167
et@@	O	-1	920167
us	O	-1	920167
in	O	-1	920167
women	O	-1	920167
with	O	-1	920167
pro@@	O	-1	920167
s@@	O	-1	920167
thetic	O	-1	920167
cardiac	O	-1	920167
val@@	O	-1	920167
v@@	O	-1	920167
es	O	-1	920167
it	O	-1	920167
is	O	-1	920167
recomm@@	O	-1	920167
en@@	O	-1	920167
ded	O	-1	920167
that	O	-1	920167
therapeutic	O	-1	920167
abor@@	O	-1	920167
tion	O	-1	920167
be	O	-1	920167
adv@@	O	-1	920167
is@@	O	-1	920167
ed	O	-1	920167
as	O	-1	920167
the	O	-1	920167
first	O	-1	920167
al@@	O	-1	920167
tern@@	O	-1	920167
ati@@	O	-1	920167
ve.	O	-1	920167

I@@	B-Chemical	D017275	1451544
s@@	I-Chemical	-1	1451544
radi@@	I-Chemical	-1	1451544
pine	I-Chemical	-1	1451544
treatment	O	-1	1451544
for	O	-1	1451544
hypertension	B-Disease	D006973	1451544
in	O	-1	1451544
gener@@	O	-1	1451544
al	O	-1	1451544
p@@	O	-1	1451544
rac@@	O	-1	1451544
ti@@	O	-1	1451544
ce	O	-1	1451544
in	O	-1	1451544
H@@	O	-1	1451544
ong	O	-1	1451544
K@@	O	-1	1451544
on@@	O	-1	1451544
g@@	O	-1	1451544
.	O	-1	1451544
A	O	-1	1451544
6-@@	O	-1	1451544
week	O	-1	1451544
op@@	O	-1	1451544
en	O	-1	1451544
study	O	-1	1451544
of	O	-1	1451544
the	O	-1	1451544
int@@	O	-1	1451544
ro@@	O	-1	1451544
duction	O	-1	1451544
of	O	-1	1451544
is@@	B-Chemical	D017275	1451544
radi@@	I-Chemical	-1	1451544
pine	I-Chemical	-1	1451544
treatment	O	-1	1451544
was	O	-1	1451544
con@@	O	-1	1451544
duc@@	O	-1	1451544
ted	O	-1	1451544
in	O	-1	1451544
gener@@	O	-1	1451544
al	O	-1	1451544
p@@	O	-1	1451544
rac@@	O	-1	1451544
ti@@	O	-1	1451544
ce	O	-1	1451544
in	O	-1	1451544
H@@	O	-1	1451544
ong	O	-1	1451544
K@@	O	-1	1451544
on@@	O	-1	1451544
g@@	O	-1	1451544
.	O	-1	1451544
3@@	O	-1	1451544
0@@	O	-1	1451544
3	O	-1	1451544
Ch@@	O	-1	1451544
in@@	O	-1	1451544
ese	O	-1	1451544
patients	O	-1	1451544
with	O	-1	1451544
mil@@	O	-1	1451544
d	O	-1	1451544
to	O	-1	1451544
moder@@	O	-1	1451544
ate	O	-1	1451544
hypertension	B-Disease	D006973	1451544
ent@@	O	-1	1451544
ered	O	-1	1451544
the	O	-1	1451544
study.	O	-1	1451544
S@@	O	-1	1451544
ide	O	-1	1451544
effects	O	-1	1451544
were	O	-1	1451544
reported	O	-1	1451544
in	O	-1	1451544
2@@	O	-1	1451544
1@@	O	-1	1451544
%	O	-1	1451544
of	O	-1	1451544
patients	O	-1	1451544
and	O	-1	1451544
caused	O	-1	1451544
withdrawal	O	-1	1451544
from	O	-1	1451544
the	O	-1	1451544
study	O	-1	1451544
in	O	-1	1451544
3	O	-1	1451544
patients.	O	-1	1451544
The	O	-1	1451544
ma@@	O	-1	1451544
in	O	-1	1451544
side@@	O	-1	1451544
-@@	O	-1	1451544
effects	O	-1	1451544
were	O	-1	1451544
headac@@	B-Disease	D006261	1451544
he	I-Disease	-1	1451544
,	O	-1	1451544
di@@	B-Disease	D004244	1451544
z@@	I-Disease	-1	1451544
z@@	I-Disease	-1	1451544
in@@	I-Disease	-1	1451544
ess	I-Disease	-1	1451544
,	O	-1	1451544
p@@	B-Disease	-1	1451544
al@@	I-Disease	-1	1451544
pit@@	I-Disease	-1	1451544
ation	I-Disease	-1	1451544
and	O	-1	1451544
f@@	B-Disease	D005483	1451544
l@@	I-Disease	-1	1451544
us@@	I-Disease	-1	1451544
h@@	I-Disease	-1	1451544
ing	I-Disease	-1	1451544
and	O	-1	1451544
these	O	-1	1451544
were	O	-1	1451544
not	O	-1	1451544
more	O	-1	1451544
frequent	O	-1	1451544
than	O	-1	1451544
reported	O	-1	1451544
in	O	-1	1451544
other	O	-1	1451544
studies	O	-1	1451544
with	O	-1	1451544
is@@	B-Chemical	D017275	1451544
radi@@	I-Chemical	-1	1451544
pine	I-Chemical	-1	1451544
or	O	-1	1451544
with	O	-1	1451544
placebo@@	O	-1	1451544
.	O	-1	1451544
S@@	O	-1	1451544
up@@	O	-1	1451544
ine	O	-1	1451544
blood	O	-1	1451544
pressure	O	-1	1451544
was	O	-1	1451544
reduced	O	-1	1451544
(P	O	-1	1451544
less	O	-1	1451544
than	O	-1	1451544
0.0@@	O	-1	1451544
1)	O	-1	1451544
from	O	-1	1451544
17@@	O	-1	1451544
0	O	-1	1451544
+/-	O	-1	1451544
20@@	O	-1	1451544
/@@	O	-1	1451544
10@@	O	-1	1451544
2	O	-1	1451544
+/-	O	-1	1451544
6	O	-1	1451544
mm@@	O	-1	1451544
H@@	O	-1	1451544
g	O	-1	1451544
to	O	-1	1451544
1@@	O	-1	1451544
5@@	O	-1	1451544
3	O	-1	1451544
+/-	O	-1	1451544
19@@	O	-1	1451544
/@@	O	-1	1451544
9@@	O	-1	1451544
2	O	-1	1451544
+/-	O	-1	1451544
8@@	O	-1	1451544
,	O	-1	1451544
14@@	O	-1	1451544
7	O	-1	1451544
+/-	O	-1	1451544
18@@	O	-1	1451544
/@@	O	-1	1451544
8@@	O	-1	1451544
8	O	-1	1451544
+/-	O	-1	1451544
7	O	-1	1451544
and	O	-1	1451544
14@@	O	-1	1451544
4	O	-1	1451544
+/-	O	-1	1451544
14@@	O	-1	1451544
/@@	O	-1	1451544
8@@	O	-1	1451544
7	O	-1	1451544
+/-	O	-1	1451544
6	O	-1	1451544
mm@@	O	-1	1451544
H@@	O	-1	1451544
g	O	-1	1451544
at	O	-1	1451544
2,	O	-1	1451544
4	O	-1	1451544
and	O	-1	1451544
6	O	-1	1451544
weeks	O	-1	1451544
respecti@@	O	-1	1451544
vely	O	-1	1451544
in	O	-1	1451544
evalu@@	O	-1	1451544
able	O	-1	1451544
patients.	O	-1	1451544
S@@	O	-1	1451544
im@@	O	-1	1451544
il@@	O	-1	1451544
ar	O	-1	1451544
reduc@@	O	-1	1451544
tions	O	-1	1451544
occurred	O	-1	1451544
in	O	-1	1451544
stand@@	O	-1	1451544
ing	O	-1	1451544
blood	O	-1	1451544
pressure	O	-1	1451544
and	O	-1	1451544
there	O	-1	1451544
was	O	-1	1451544
no	O	-1	1451544
evidence	O	-1	1451544
of	O	-1	1451544
post@@	B-Disease	D007024	1451544
ural	I-Disease	-1	1451544
hypotension	I-Disease	-1	1451544
.	O	-1	1451544
N@@	O	-1	1451544
orm@@	O	-1	1451544
al@@	O	-1	1451544
ization	O	-1	1451544
and	O	-1	1451544
respon@@	O	-1	1451544
der	O	-1	1451544
rat@@	O	-1	1451544
es	O	-1	1451544
at	O	-1	1451544
6	O	-1	1451544
weeks	O	-1	1451544
were	O	-1	1451544
8@@	O	-1	1451544
6%	O	-1	1451544
and	O	-1	1451544
6@@	O	-1	1451544
9@@	O	-1	1451544
%	O	-1	1451544
respectively.	O	-1	1451544
D@@	O	-1	1451544
os@@	O	-1	1451544
age	O	-1	1451544
was	O	-1	1451544
increased	O	-1	1451544
from	O	-1	1451544
2.@@	O	-1	1451544
5	O	-1	1451544
mg	O	-1	1451544
b@@	O	-1	1451544
.@@	O	-1	1451544
d.	O	-1	1451544
to	O	-1	1451544
5	O	-1	1451544
mg	O	-1	1451544
b@@	O	-1	1451544
.@@	O	-1	1451544
d.	O	-1	1451544
at	O	-1	1451544
4	O	-1	1451544
weeks	O	-1	1451544
in	O	-1	1451544
patients	O	-1	1451544
with	O	-1	1451544
di@@	O	-1	1451544
ast@@	O	-1	1451544
olic	O	-1	1451544
blood	O	-1	1451544
pressure	O	-1	1451544
greater	O	-1	1451544
than	O	-1	1451544
9@@	O	-1	1451544
0	O	-1	1451544
mm@@	O	-1	1451544
H@@	O	-1	1451544
g	O	-1	1451544
and	O	-1	1451544
their	O	-1	1451544
further	O	-1	1451544
response	O	-1	1451544
was	O	-1	1451544
greater	O	-1	1451544
than	O	-1	1451544
those	O	-1	1451544
remain@@	O	-1	1451544
ing	O	-1	1451544
on	O	-1	1451544
2.@@	O	-1	1451544
5	O	-1	1451544
mg	O	-1	1451544
b@@	O	-1	1451544
.@@	O	-1	1451544
d.	O	-1	1451544

T@@	O	-1	2782734
ac@@	O	-1	2782734
hy@@	O	-1	2782734
phyl@@	O	-1	2782734
ax@@	O	-1	2782734
is	O	-1	2782734
to	O	-1	2782734
systemic	O	-1	2782734
but	O	-1	2782734
not	O	-1	2782734
to	O	-1	2782734
a@@	O	-1	2782734
ir@@	O	-1	2782734
w@@	O	-1	2782734
ay	O	-1	2782734
responses	O	-1	2782734
during	O	-1	2782734
prolonged	O	-1	2782734
therapy	O	-1	2782734
with	O	-1	2782734
high	O	-1	2782734
dose	O	-1	2782734
in@@	O	-1	2782734
h@@	O	-1	2782734
al@@	O	-1	2782734
ed	O	-1	2782734
sal@@	B-Chemical	D000420	2782734
but@@	I-Chemical	-1	2782734
am@@	I-Chemical	-1	2782734
ol	I-Chemical	-1	2782734
in	O	-1	2782734
as@@	B-Disease	D001249	2782734
th@@	I-Disease	-1	2782734
m@@	I-Disease	-1	2782734
ati@@	I-Disease	-1	2782734
c@@	I-Disease	-1	2782734
s	I-Disease	-1	2782734
.	O	-1	2782734
H@@	O	-1	2782734
i@@	O	-1	2782734
gh	O	-1	2782734
doses	O	-1	2782734
of	O	-1	2782734
in@@	O	-1	2782734
h@@	O	-1	2782734
al@@	O	-1	2782734
ed	O	-1	2782734
sal@@	B-Chemical	D000420	2782734
but@@	I-Chemical	-1	2782734
am@@	I-Chemical	-1	2782734
ol	I-Chemical	-1	2782734
produce	O	-1	2782734
subst@@	O	-1	2782734
anti@@	O	-1	2782734
al	O	-1	2782734
impro@@	O	-1	2782734
ve@@	O	-1	2782734
ments	O	-1	2782734
in	O	-1	2782734
a@@	O	-1	2782734
ir@@	O	-1	2782734
w@@	O	-1	2782734
ay	O	-1	2782734
response	O	-1	2782734
in	O	-1	2782734
patients	O	-1	2782734
with	O	-1	2782734
as@@	B-Disease	D001249	2782734
th@@	I-Disease	-1	2782734
ma	I-Disease	-1	2782734
,	O	-1	2782734
and	O	-1	2782734
are	O	-1	2782734
associated	O	-1	2782734
with	O	-1	2782734
dose-@@	O	-1	2782734
dependent	O	-1	2782734
systemic	O	-1	2782734
beta-@@	O	-1	2782734
adren@@	O	-1	2782734
oc@@	O	-1	2782734
e@@	O	-1	2782734
pt@@	O	-1	2782734
or	O	-1	2782734
respon@@	O	-1	2782734
s@@	O	-1	2782734
es.	O	-1	2782734
The	O	-1	2782734
pur@@	O	-1	2782734
p@@	O	-1	2782734
ose	O	-1	2782734
of	O	-1	2782734
the	O	-1	2782734
present	O	-1	2782734
study	O	-1	2782734
was	O	-1	2782734
to	O	-1	2782734
investigate	O	-1	2782734
whether	O	-1	2782734
tachy@@	O	-1	2782734
phyl@@	O	-1	2782734
ax@@	O	-1	2782734
is	O	-1	2782734
occur@@	O	-1	2782734
s	O	-1	2782734
during	O	-1	2782734
prolonged	O	-1	2782734
treatment	O	-1	2782734
with	O	-1	2782734
high	O	-1	2782734
dose	O	-1	2782734
in@@	O	-1	2782734
h@@	O	-1	2782734
al@@	O	-1	2782734
ed	O	-1	2782734
sal@@	B-Chemical	D000420	2782734
but@@	I-Chemical	-1	2782734
am@@	I-Chemical	-1	2782734
ol	I-Chemical	-1	2782734
.	O	-1	2782734
T@@	O	-1	2782734
we@@	O	-1	2782734
l@@	O	-1	2782734
ve	O	-1	2782734
as@@	B-Disease	D001249	2782734
th@@	I-Disease	-1	2782734
m@@	I-Disease	-1	2782734
atic	I-Disease	-1	2782734
patients	O	-1	2782734
(@@	O	-1	2782734
F@@	O	-1	2782734
E@@	O	-1	2782734
V@@	O	-1	2782734
1,	O	-1	2782734
8@@	O	-1	2782734
1	O	-1	2782734
+/-	O	-1	2782734
4@@	O	-1	2782734
%	O	-1	2782734
predic@@	O	-1	2782734
te@@	O	-1	2782734
d@@	O	-1	2782734
),	O	-1	2782734
requ@@	O	-1	2782734
ir@@	O	-1	2782734
ing	O	-1	2782734
only	O	-1	2782734
oc@@	O	-1	2782734
ca@@	O	-1	2782734
sion@@	O	-1	2782734
al	O	-1	2782734
in@@	O	-1	2782734
h@@	O	-1	2782734
al@@	O	-1	2782734
ed	O	-1	2782734
beta-@@	O	-1	2782734
agon@@	O	-1	2782734
ist@@	O	-1	2782734
s	O	-1	2782734
as	O	-1	2782734
their	O	-1	2782734
sol@@	O	-1	2782734
e	O	-1	2782734
therapy,	O	-1	2782734
were	O	-1	2782734
given	O	-1	2782734
a	O	-1	2782734
1@@	O	-1	2782734
4-@@	O	-1	2782734
day	O	-1	2782734
treatment	O	-1	2782734
with	O	-1	2782734
high	O	-1	2782734
dose	O	-1	2782734
in@@	O	-1	2782734
h@@	O	-1	2782734
al@@	O	-1	2782734
ed	O	-1	2782734
sal@@	B-Chemical	D000420	2782734
but@@	I-Chemical	-1	2782734
am@@	I-Chemical	-1	2782734
ol	I-Chemical	-1	2782734
(@@	O	-1	2782734
H@@	O	-1	2782734
D@@	O	-1	2782734
S@@	O	-1	2782734
),	O	-1	2782734
4@@	O	-1	2782734
,@@	O	-1	2782734
0@@	O	-1	2782734
00	O	-1	2782734
microgram@@	O	-1	2782734
s	O	-1	2782734
da@@	O	-1	2782734
il@@	O	-1	2782734
y,	O	-1	2782734
low	O	-1	2782734
dose	O	-1	2782734
in@@	O	-1	2782734
h@@	O	-1	2782734
al@@	O	-1	2782734
ed	O	-1	2782734
sal@@	B-Chemical	D000420	2782734
but@@	I-Chemical	-1	2782734
am@@	I-Chemical	-1	2782734
ol	I-Chemical	-1	2782734
(@@	O	-1	2782734
L@@	O	-1	2782734
D@@	O	-1	2782734
S@@	O	-1	2782734
),	O	-1	2782734
8@@	O	-1	2782734
00	O	-1	2782734
microgram@@	O	-1	2782734
s	O	-1	2782734
da@@	O	-1	2782734
il@@	O	-1	2782734
y,	O	-1	2782734
or	O	-1	2782734
placebo	O	-1	2782734
(P@@	O	-1	2782734
I@@	O	-1	2782734
)	O	-1	2782734
by	O	-1	2782734
me@@	O	-1	2782734
te@@	O	-1	2782734
re@@	O	-1	2782734
d-@@	O	-1	2782734
dose	O	-1	2782734
in@@	O	-1	2782734
h@@	O	-1	2782734
al@@	O	-1	2782734
er	O	-1	2782734
in	O	-1	2782734
a	O	-1	2782734
double-bl@@	O	-1	2782734
ind@@	O	-1	2782734
,	O	-1	2782734
randomized	O	-1	2782734
cros@@	O	-1	2782734
s@@	O	-1	2782734
over	O	-1	2782734
de@@	O	-1	2782734
sign@@	O	-1	2782734
.	O	-1	2782734
D@@	O	-1	2782734
uring	O	-1	2782734
the	O	-1	2782734
1@@	O	-1	2782734
4-@@	O	-1	2782734
day	O	-1	2782734
r@@	O	-1	2782734
un@@	O	-1	2782734
-@@	O	-1	2782734
in	O	-1	2782734
and	O	-1	2782734
during	O	-1	2782734
w@@	O	-1	2782734
as@@	O	-1	2782734
h@@	O	-1	2782734
out	O	-1	2782734
perio@@	O	-1	2782734
d@@	O	-1	2782734
s,	O	-1	2782734
in@@	O	-1	2782734
h@@	O	-1	2782734
al@@	O	-1	2782734
ed	O	-1	2782734
beta-@@	O	-1	2782734
agon@@	O	-1	2782734
ist@@	O	-1	2782734
s	O	-1	2782734
were	O	-1	2782734
with@@	O	-1	2782734
he@@	O	-1	2782734
l@@	O	-1	2782734
d	O	-1	2782734
and	O	-1	2782734
ip@@	B-Chemical	D009241	2782734
rat@@	I-Chemical	-1	2782734
ro@@	I-Chemical	-1	2782734
pi@@	I-Chemical	-1	2782734
um	I-Chemical	-1	2782734
brom@@	I-Chemical	-1	2782734
ide	I-Chemical	-1	2782734
was	O	-1	2782734
sub@@	O	-1	2782734
sti@@	O	-1	2782734
t@@	O	-1	2782734
ut@@	O	-1	2782734
ed	O	-1	2782734
for	O	-1	2782734
res@@	O	-1	2782734
c@@	O	-1	2782734
u@@	O	-1	2782734
e	O	-1	2782734
pur@@	O	-1	2782734
pos@@	O	-1	2782734
es.	O	-1	2782734
A@@	O	-1	2782734
t	O	-1	2782734
the	O	-1	2782734
end	O	-1	2782734
of	O	-1	2782734
each	O	-1	2782734
1@@	O	-1	2782734
4-@@	O	-1	2782734
day	O	-1	2782734
treatment,	O	-1	2782734
a	O	-1	2782734
dose-@@	O	-1	2782734
response	O	-1	2782734
cur@@	O	-1	2782734
ve	O	-1	2782734
(D@@	O	-1	2782734
R@@	O	-1	2782734
C@@	O	-1	2782734
)	O	-1	2782734
was	O	-1	2782734
per@@	O	-1	2782734
for@@	O	-1	2782734
me@@	O	-1	2782734
d,	O	-1	2782734
and	O	-1	2782734
a@@	O	-1	2782734
ir@@	O	-1	2782734
w@@	O	-1	2782734
ay	O	-1	2782734
(@@	O	-1	2782734
F@@	O	-1	2782734
E@@	O	-1	2782734
V@@	O	-1	2782734
1,	O	-1	2782734
F@@	O	-1	2782734
E@@	O	-1	2782734
F@@	O	-1	2782734
2@@	O	-1	2782734
5-@@	O	-1	2782734
7@@	O	-1	2782734
5@@	O	-1	2782734
)	O	-1	2782734
chron@@	O	-1	2782734
ot@@	O	-1	2782734
ro@@	O	-1	2782734
p@@	O	-1	2782734
ic	O	-1	2782734
(@@	O	-1	2782734
H@@	O	-1	2782734
R@@	O	-1	2782734
),	O	-1	2782734
trem@@	B-Disease	D014202	2782734
or	I-Disease	-1	2782734
,	O	-1	2782734
and	O	-1	2782734
met@@	O	-1	2782734
ab@@	O	-1	2782734
olic	O	-1	2782734
(	O	-1	2782734
K	B-Chemical	D011188	2782734
,	O	-1	2782734
G@@	B-Chemical	D005947	2782734
l@@	I-Chemical	-1	2782734
u	I-Chemical	-1	2782734
)	O	-1	2782734
responses	O	-1	2782734
were	O	-1	2782734
measured	O	-1	2782734
at	O	-1	2782734
each	O	-1	2782734
st@@	O	-1	2782734
ep	O	-1	2782734
(@@	O	-1	2782734
from	O	-1	2782734
100	O	-1	2782734
to	O	-1	2782734
4@@	O	-1	2782734
,@@	O	-1	2782734
0@@	O	-1	2782734
00	O	-1	2782734
microgram@@	O	-1	2782734
s@@	O	-1	2782734
).	O	-1	2782734
Treat@@	O	-1	2782734
ment	O	-1	2782734
had	O	-1	2782734
no	O	-1	2782734
significant	O	-1	2782734
effect	O	-1	2782734
on	O	-1	2782734
baseline	O	-1	2782734
valu@@	O	-1	2782734
es.	O	-1	2782734
There	O	-1	2782734
were	O	-1	2782734
dose-@@	O	-1	2782734
dependent	O	-1	2782734
increases	O	-1	2782734
in	O	-1	2782734
F@@	O	-1	2782734
E@@	O	-1	2782734
V@@	O	-1	2782734
1	O	-1	2782734
and	O	-1	2782734
F@@	O	-1	2782734
E@@	O	-1	2782734
F@@	O	-1	2782734
2@@	O	-1	2782734
5-@@	O	-1	2782734
7@@	O	-1	2782734
5	O	-1	2782734
(p	O	-1	2782734
less	O	-1	2782734
than	O	-1	2782734
0.00@@	O	-1	2782734
1),	O	-1	2782734
and	O	-1	2782734
pretreatment	O	-1	2782734
with	O	-1	2782734
H@@	O	-1	2782734
D@@	O	-1	2782734
S	O	-1	2782734
did	O	-1	2782734
not	O	-1	2782734
dis@@	O	-1	2782734
pl@@	O	-1	2782734
ac@@	O	-1	2782734
e	O	-1	2782734
the	O	-1	2782734
D@@	O	-1	2782734
R@@	O	-1	2782734
C	O	-1	2782734
to	O	-1	2782734
the	O	-1	2782734
ri@@	O	-1	2782734
gh@@	O	-1	2782734
t.	O	-1	2782734
D@@	O	-1	2782734
R@@	O	-1	2782734
C	O	-1	2782734
for	O	-1	2782734
H@@	O	-1	2782734
R	O	-1	2782734
(p	O	-1	2782734
less	O	-1	2782734
than	O	-1	2782734
0.00@@	O	-1	2782734
1),	O	-1	2782734
K	B-Chemical	D011188	2782734
(p	O	-1	2782734
less	O	-1	2782734
than	O	-1	2782734
0.00@@	O	-1	2782734
1),	O	-1	2782734
and	O	-1	2782734
G@@	B-Chemical	D005947	2782734
l@@	I-Chemical	-1	2782734
u	I-Chemical	-1	2782734
(p	O	-1	2782734
less	O	-1	2782734
than	O	-1	2782734
0.00@@	O	-1	2782734
5@@	O	-1	2782734
)	O	-1	2782734
were	O	-1	2782734
attenu@@	O	-1	2782734
ated	O	-1	2782734
after	O	-1	2782734
treatment	O	-1	2782734
with	O	-1	2782734
H@@	O	-1	2782734
D@@	O	-1	2782734
S	O	-1	2782734
compared	O	-1	2782734
with	O	-1	2782734
P@@	O	-1	2782734
I@@	O	-1	2782734
.	O	-1	2782734
There	O	-1	2782734
were	O	-1	2782734
also	O	-1	2782734
differences	O	-1	2782734
between	O	-1	2782734
H@@	O	-1	2782734
D@@	O	-1	2782734
S	O	-1	2782734
and	O	-1	2782734
L@@	O	-1	2782734
D@@	O	-1	2782734
S	O	-1	2782734
for	O	-1	2782734
H@@	O	-1	2782734
R	O	-1	2782734
(p	O	-1	2782734
less	O	-1	2782734
than	O	-1	2782734
0.00@@	O	-1	2782734
1)	O	-1	2782734
and	O	-1	2782734
G@@	B-Chemical	D005947	2782734
l@@	I-Chemical	-1	2782734
u	I-Chemical	-1	2782734
(p	O	-1	2782734
less	O	-1	2782734
than	O	-1	2782734
0.05@@	O	-1	2782734
)	O	-1	2782734
respon@@	O	-1	2782734
s@@	O	-1	2782734
es.	O	-1	2782734
F@@	O	-1	2782734
requ@@	O	-1	2782734
ency	O	-1	2782734
and	O	-1	2782734
severity	O	-1	2782734
of	O	-1	2782734
subj@@	O	-1	2782734
ective	O	-1	2782734
adverse	O	-1	2782734
effects	O	-1	2782734
were	O	-1	2782734
also	O	-1	2782734
reduced	O	-1	2782734
after	O	-1	2782734
H@@	O	-1	2782734
D@@	O	-1	2782734
S:	O	-1	2782734
trem@@	B-Disease	D014202	2782734
or	I-Disease	-1	2782734
(p	O	-1	2782734
less	O	-1	2782734
than	O	-1	2782734
0.00@@	O	-1	2782734
1),	O	-1	2782734
p@@	B-Disease	-1	2782734
al@@	I-Disease	-1	2782734
pit@@	I-Disease	-1	2782734
ations	I-Disease	-1	2782734
(p	O	-1	2782734
less	O	-1	2782734
than	O	-1	2782734
0.00@@	O	-1	2782734
1@@	O	-1	2782734
)@@	O	-1	2782734
.@@	O	-1	2782734
(A@@	O	-1	2782734
B@@	O	-1	2782734
S@@	O	-1	2782734
TR@@	O	-1	2782734
AC@@	O	-1	2782734
T	O	-1	2782734
TR@@	O	-1	2782734
UN@@	O	-1	2782734
C@@	O	-1	2782734
AT@@	O	-1	2782734
E@@	O	-1	2782734
D	O	-1	2782734
A@@	O	-1	2782734
T	O	-1	2782734
2@@	O	-1	2782734
50	O	-1	2782734
W@@	O	-1	2782734
O@@	O	-1	2782734
RD@@	O	-1	2782734
S)	O	-1	2782734

In@@	O	-1	2983630
c@@	O	-1	2983630
reas@@	O	-1	2983630
ed	O	-1	2983630
an@@	O	-1	2983630
x@@	O	-1	2983630
io@@	O	-1	2983630
genic	O	-1	2983630
effects	O	-1	2983630
of	O	-1	2983630
caffe@@	B-Chemical	D002110	2983630
ine	I-Chemical	-1	2983630
in	O	-1	2983630
p@@	B-Disease	D016584	2983630
anic	I-Disease	-1	2983630
disorder@@	I-Disease	-1	2983630
s	I-Disease	-1	2983630
.	O	-1	2983630
The	O	-1	2983630
effects	O	-1	2983630
of	O	-1	2983630
oral	O	-1	2983630
administration	O	-1	2983630
of	O	-1	2983630
caffe@@	B-Chemical	D002110	2983630
ine	I-Chemical	-1	2983630
(10	O	-1	2983630
mg/kg)	O	-1	2983630
on	O	-1	2983630
behavioral	O	-1	2983630
rat@@	O	-1	2983630
ing@@	O	-1	2983630
s,	O	-1	2983630
s@@	O	-1	2983630
om@@	O	-1	2983630
atic	O	-1	2983630
symptom@@	O	-1	2983630
s,	O	-1	2983630
blood	O	-1	2983630
pressure	O	-1	2983630
and	O	-1	2983630
plasma	O	-1	2983630
levels	O	-1	2983630
of	O	-1	2983630
3-@@	B-Chemical	D008734	2983630
meth@@	I-Chemical	-1	2983630
ox@@	I-Chemical	-1	2983630
y-@@	I-Chemical	-1	2983630
4-@@	I-Chemical	-1	2983630
hydrox@@	I-Chemical	-1	2983630
y@@	I-Chemical	-1	2983630
phen@@	I-Chemical	-1	2983630
eth@@	I-Chemical	-1	2983630
yl@@	I-Chemical	-1	2983630
en@@	I-Chemical	-1	2983630
e@@	I-Chemical	-1	2983630
gly@@	I-Chemical	-1	2983630
co@@	I-Chemical	-1	2983630
l	I-Chemical	-1	2983630
(	O	-1	2983630
M@@	B-Chemical	D008734	2983630
H@@	I-Chemical	-1	2983630
P@@	I-Chemical	-1	2983630
G	I-Chemical	-1	2983630
)	O	-1	2983630
and	O	-1	2983630
cor@@	B-Chemical	D006854	2983630
tis@@	I-Chemical	-1	2983630
ol	I-Chemical	-1	2983630
were	O	-1	2983630
determined	O	-1	2983630
in	O	-1	2983630
17	O	-1	2983630
healthy	O	-1	2983630
subjects	O	-1	2983630
and	O	-1	2983630
21	O	-1	2983630
patients	O	-1	2983630
me@@	O	-1	2983630
et@@	O	-1	2983630
ing	O	-1	2983630
D@@	O	-1	2983630
S@@	O	-1	2983630
M@@	O	-1	2983630
-@@	O	-1	2983630
I@@	O	-1	2983630
II	O	-1	2983630
c@@	O	-1	2983630
rit@@	O	-1	2983630
er@@	O	-1	2983630
ia	O	-1	2983630
for	O	-1	2983630
ag@@	B-Disease	D000379	2983630
or@@	I-Disease	-1	2983630
a@@	I-Disease	-1	2983630
ph@@	I-Disease	-1	2983630
ob@@	I-Disease	-1	2983630
ia	I-Disease	-1	2983630
with	O	-1	2983630
p@@	B-Disease	D016584	2983630
anic	I-Disease	-1	2983630
at@@	I-Disease	-1	2983630
tac@@	I-Disease	-1	2983630
k@@	I-Disease	-1	2983630
s	I-Disease	-1	2983630
or	O	-1	2983630
p@@	B-Disease	D016584	2983630
anic	I-Disease	-1	2983630
disor@@	I-Disease	-1	2983630
der	I-Disease	-1	2983630
.	O	-1	2983630
Ca@@	B-Chemical	D002110	2983630
ffe@@	I-Chemical	-1	2983630
ine	I-Chemical	-1	2983630
produced	O	-1	2983630
significantly	O	-1	2983630
greater	O	-1	2983630
increases	O	-1	2983630
in	O	-1	2983630
subj@@	O	-1	2983630
ect@@	O	-1	2983630
-@@	O	-1	2983630
r@@	O	-1	2983630
ated	O	-1	2983630
an@@	B-Disease	D001008	2983630
xi@@	I-Disease	-1	2983630
ety	I-Disease	-1	2983630
,	O	-1	2983630
ner@@	O	-1	2983630
v@@	O	-1	2983630
ous@@	O	-1	2983630
n@@	O	-1	2983630
es@@	O	-1	2983630
s,	O	-1	2983630
f@@	O	-1	2983630
ear@@	O	-1	2983630
,	O	-1	2983630
nausea	B-Disease	D009325	2983630
,	O	-1	2983630
p@@	B-Disease	-1	2983630
al@@	I-Disease	-1	2983630
pit@@	I-Disease	-1	2983630
ations	I-Disease	-1	2983630
,	O	-1	2983630
rest@@	B-Disease	D011595	2983630
l@@	I-Disease	-1	2983630
ess@@	I-Disease	-1	2983630
ness	I-Disease	-1	2983630
,	O	-1	2983630
and	O	-1	2983630
tre@@	B-Disease	D014202	2983630
mor@@	I-Disease	-1	2983630
s	I-Disease	-1	2983630
in	O	-1	2983630
the	O	-1	2983630
patients	O	-1	2983630
compared	O	-1	2983630
with	O	-1	2983630
healthy	O	-1	2983630
subj@@	O	-1	2983630
ect@@	O	-1	2983630
s.	O	-1	2983630
In	O	-1	2983630
the	O	-1	2983630
patients,	O	-1	2983630
but	O	-1	2983630
not	O	-1	2983630
the	O	-1	2983630
healthy	O	-1	2983630
subj@@	O	-1	2983630
ect@@	O	-1	2983630
s,	O	-1	2983630
these	O	-1	2983630
symptoms	O	-1	2983630
were	O	-1	2983630
significantly	O	-1	2983630
cor@@	O	-1	2983630
related	O	-1	2983630
with	O	-1	2983630
plasma	O	-1	2983630
caffe@@	B-Chemical	D002110	2983630
ine	I-Chemical	-1	2983630
level@@	O	-1	2983630
s.	O	-1	2983630
S@@	O	-1	2983630
event@@	O	-1	2983630
y-@@	O	-1	2983630
one	O	-1	2983630
perc@@	O	-1	2983630
ent	O	-1	2983630
of	O	-1	2983630
the	O	-1	2983630
patients	O	-1	2983630
reported	O	-1	2983630
that	O	-1	2983630
the	O	-1	2983630
behavioral	O	-1	2983630
effects	O	-1	2983630
of	O	-1	2983630
caffe@@	B-Chemical	D002110	2983630
ine	I-Chemical	-1	2983630
were	O	-1	2983630
similar	O	-1	2983630
to	O	-1	2983630
those	O	-1	2983630
experienced	O	-1	2983630
during	O	-1	2983630
p@@	B-Disease	D016584	2983630
anic	I-Disease	-1	2983630
at@@	I-Disease	-1	2983630
tac@@	I-Disease	-1	2983630
k@@	I-Disease	-1	2983630
s	I-Disease	-1	2983630
.	O	-1	2983630
Ca@@	B-Chemical	D002110	2983630
ffe@@	I-Chemical	-1	2983630
ine	I-Chemical	-1	2983630
did	O	-1	2983630
not	O	-1	2983630
al@@	O	-1	2983630
ter	O	-1	2983630
plasma	O	-1	2983630
M@@	B-Chemical	D008734	2983630
H@@	I-Chemical	-1	2983630
P@@	I-Chemical	-1	2983630
G	I-Chemical	-1	2983630
levels	O	-1	2983630
in	O	-1	2983630
either	O	-1	2983630
the	O	-1	2983630
healthy	O	-1	2983630
subjects	O	-1	2983630
or	O	-1	2983630
patients.	O	-1	2983630
Ca@@	B-Chemical	D002110	2983630
ffe@@	I-Chemical	-1	2983630
ine	I-Chemical	-1	2983630
increased	O	-1	2983630
plasma	O	-1	2983630
cor@@	B-Chemical	D006854	2983630
tis@@	I-Chemical	-1	2983630
ol	I-Chemical	-1	2983630
levels	O	-1	2983630
equ@@	O	-1	2983630
ally	O	-1	2983630
in	O	-1	2983630
the	O	-1	2983630
patient	O	-1	2983630
and	O	-1	2983630
healthy	O	-1	2983630
groups.	O	-1	2983630
B@@	O	-1	2983630
ecause	O	-1	2983630
caffe@@	B-Chemical	D002110	2983630
ine	I-Chemical	-1	2983630
is	O	-1	2983630
an	O	-1	2983630
aden@@	B-Chemical	D000241	2983630
os@@	I-Chemical	-1	2983630
ine	I-Chemical	-1	2983630
receptor	O	-1	2983630
antagonist@@	O	-1	2983630
,	O	-1	2983630
these	O	-1	2983630
results	O	-1	2983630
suggest	O	-1	2983630
that	O	-1	2983630
some	O	-1	2983630
p@@	B-Disease	D016584	2983630
anic	I-Disease	-1	2983630
disor@@	I-Disease	-1	2983630
der	I-Disease	-1	2983630
patients	O	-1	2983630
may	O	-1	2983630
have	O	-1	2983630
abnormal@@	B-Disease	D009421	2983630
ities	I-Disease	-1	2983630
in	I-Disease	-1	2983630
neuron@@	I-Disease	-1	2983630
al	I-Disease	-1	2983630
system@@	I-Disease	-1	2983630
s	I-Disease	-1	2983630
invol@@	O	-1	2983630
ving	O	-1	2983630
aden@@	B-Chemical	D000241	2983630
os@@	I-Chemical	-1	2983630
ine	I-Chemical	-1	2983630
.	O	-1	2983630
Patients	O	-1	2983630
with	O	-1	2983630
an@@	B-Disease	D001008	2983630
xi@@	I-Disease	-1	2983630
ety	I-Disease	-1	2983630
disorder@@	I-Disease	-1	2983630
s	I-Disease	-1	2983630
may	O	-1	2983630
ben@@	O	-1	2983630
e@@	O	-1	2983630
fi@@	O	-1	2983630
t	O	-1	2983630
by	O	-1	2983630
avoid@@	O	-1	2983630
ing	O	-1	2983630
caffe@@	B-Chemical	D002110	2983630
ine	I-Chemical	-1	2983630
-@@	O	-1	2983630
containing	O	-1	2983630
fo@@	O	-1	2983630
o@@	O	-1	2983630
ds	O	-1	2983630
and	O	-1	2983630
be@@	O	-1	2983630
ver@@	O	-1	2983630
ag@@	O	-1	2983630
es.	O	-1	2983630

H@@	O	-1	3711722
um@@	O	-1	3711722
an	O	-1	3711722
and	O	-1	3711722
can@@	O	-1	3711722
ine	O	-1	3711722
ventricular	O	-1	3711722
vas@@	O	-1	3711722
o@@	O	-1	3711722
active	O	-1	3711722
in@@	O	-1	3711722
test@@	O	-1	3711722
inal	O	-1	3711722
poly@@	O	-1	3711722
p@@	O	-1	3711722
ep@@	O	-1	3711722
ti@@	O	-1	3711722
de@@	O	-1	3711722
:	O	-1	3711722
decrease	O	-1	3711722
with	O	-1	3711722
heart	B-Disease	D006333	3711722
failure	I-Disease	-1	3711722
.	O	-1	3711722
V@@	O	-1	3711722
as@@	O	-1	3711722
o@@	O	-1	3711722
active	O	-1	3711722
in@@	O	-1	3711722
test@@	O	-1	3711722
inal	O	-1	3711722
poly@@	O	-1	3711722
p@@	O	-1	3711722
ep@@	O	-1	3711722
ti@@	O	-1	3711722
de	O	-1	3711722
(V@@	O	-1	3711722
I@@	O	-1	3711722
P)	O	-1	3711722
is	O	-1	3711722
a	O	-1	3711722
systemic	O	-1	3711722
and	O	-1	3711722
coronary	O	-1	3711722
vas@@	O	-1	3711722
odi@@	O	-1	3711722
lat@@	O	-1	3711722
or	O	-1	3711722
that	O	-1	3711722
may	O	-1	3711722
have	O	-1	3711722
positive	O	-1	3711722
in@@	O	-1	3711722
ot@@	O	-1	3711722
ro@@	O	-1	3711722
p@@	O	-1	3711722
ic	O	-1	3711722
pro@@	O	-1	3711722
per@@	O	-1	3711722
ti@@	O	-1	3711722
es.	O	-1	3711722
M@@	O	-1	3711722
y@@	O	-1	3711722
ocardi@@	O	-1	3711722
al	O	-1	3711722
levels	O	-1	3711722
of	O	-1	3711722
V@@	O	-1	3711722
I@@	O	-1	3711722
P	O	-1	3711722
were	O	-1	3711722
ass@@	O	-1	3711722
ayed	O	-1	3711722
before	O	-1	3711722
and	O	-1	3711722
after	O	-1	3711722
the	O	-1	3711722
development	O	-1	3711722
of	O	-1	3711722
heart	B-Disease	D006333	3711722
failure	I-Disease	-1	3711722
in	O	-1	3711722
two	O	-1	3711722
can@@	O	-1	3711722
ine	O	-1	3711722
model@@	O	-1	3711722
s.	O	-1	3711722
In	O	-1	3711722
the	O	-1	3711722
fir@@	O	-1	3711722
st@@	O	-1	3711722
,	O	-1	3711722
co@@	B-Chemical	D003035	3711722
b@@	I-Chemical	-1	3711722
al@@	I-Chemical	-1	3711722
t	I-Chemical	-1	3711722
cardi@@	B-Disease	D009202	3711722
om@@	I-Disease	-1	3711722
yo@@	I-Disease	-1	3711722
pathy	I-Disease	-1	3711722
was	O	-1	3711722
induced	O	-1	3711722
in	O	-1	3711722
e@@	O	-1	3711722
ight	O	-1	3711722
dog@@	O	-1	3711722
s;	O	-1	3711722
V@@	O	-1	3711722
I@@	O	-1	3711722
P	O	-1	3711722
(@@	O	-1	3711722
by	O	-1	3711722
radi@@	O	-1	3711722
o@@	O	-1	3711722
immuno@@	O	-1	3711722
ass@@	O	-1	3711722
ay@@	O	-1	3711722
)	O	-1	3711722
decreased	O	-1	3711722
from	O	-1	3711722
3@@	O	-1	3711722
5	O	-1	3711722
+/-	O	-1	3711722
11	O	-1	3711722
p@@	O	-1	3711722
g/@@	O	-1	3711722
mg	O	-1	3711722
protein	O	-1	3711722
(@@	O	-1	3711722
mean	O	-1	3711722
+/-	O	-1	3711722
S@@	O	-1	3711722
D)	O	-1	3711722
to	O	-1	3711722
5	O	-1	3711722
+/-	O	-1	3711722
4	O	-1	3711722
p@@	O	-1	3711722
g/@@	O	-1	3711722
mg	O	-1	3711722
protein	O	-1	3711722
(P	O	-1	3711722
less	O	-1	3711722
than	O	-1	3711722
0.05@@	O	-1	3711722
).	O	-1	3711722
In	O	-1	3711722
six	O	-1	3711722
dog@@	O	-1	3711722
s	O	-1	3711722
with	O	-1	3711722
dox@@	B-Chemical	D004317	3711722
orub@@	I-Chemical	-1	3711722
icin	I-Chemical	-1	3711722
-induced	O	-1	3711722
heart	B-Disease	D006333	3711722
failure	I-Disease	-1	3711722
,	O	-1	3711722
V@@	O	-1	3711722
I@@	O	-1	3711722
P	O	-1	3711722
decreased	O	-1	3711722
from	O	-1	3711722
3@@	O	-1	3711722
1	O	-1	3711722
+/-	O	-1	3711722
7	O	-1	3711722
to	O	-1	3711722
11	O	-1	3711722
+/-	O	-1	3711722
4	O	-1	3711722
p@@	O	-1	3711722
g/@@	O	-1	3711722
mg	O	-1	3711722
protein	O	-1	3711722
(P	O	-1	3711722
less	O	-1	3711722
than	O	-1	3711722
0.05@@	O	-1	3711722
).	O	-1	3711722
In	O	-1	3711722
addi@@	O	-1	3711722
tion,	O	-1	3711722
V@@	O	-1	3711722
I@@	O	-1	3711722
P	O	-1	3711722
cont@@	O	-1	3711722
ent	O	-1	3711722
of	O	-1	3711722
left	O	-1	3711722
ventricular	O	-1	3711722
musc@@	O	-1	3711722
le	O	-1	3711722
of	O	-1	3711722
res@@	O	-1	3711722
ected	O	-1	3711722
fail@@	O	-1	3711722
ing	O	-1	3711722
hear@@	O	-1	3711722
ts	O	-1	3711722
in	O	-1	3711722
10	O	-1	3711722
patients	O	-1	3711722
receiving	O	-1	3711722
a	O	-1	3711722
heart	O	-1	3711722
transplant	O	-1	3711722
was	O	-1	3711722
compared	O	-1	3711722
with	O	-1	3711722
the	O	-1	3711722
pap@@	O	-1	3711722
ill@@	O	-1	3711722
ary	O	-1	3711722
musc@@	O	-1	3711722
le@@	O	-1	3711722
s	O	-1	3711722
in	O	-1	3711722
14	O	-1	3711722
patients	O	-1	3711722
(@@	O	-1	3711722
five	O	-1	3711722
with	O	-1	3711722
r@@	B-Disease	D012216	3711722
he@@	I-Disease	-1	3711722
um@@	I-Disease	-1	3711722
atic	I-Disease	-1	3711722
disease	I-Disease	-1	3711722
,	O	-1	3711722
n@@	O	-1	3711722
ine	O	-1	3711722
with	O	-1	3711722
my@@	B-Disease	-1	3711722
x@@	I-Disease	-1	3711722
om@@	I-Disease	-1	3711722
at@@	I-Disease	-1	3711722
ous	I-Disease	-1	3711722
de@@	I-Disease	-1	3711722
generation	I-Disease	-1	3711722
)	O	-1	3711722
receiving	O	-1	3711722
mit@@	O	-1	3711722
ral	O	-1	3711722
val@@	O	-1	3711722
ve	O	-1	3711722
pro@@	O	-1	3711722
s@@	O	-1	3711722
th@@	O	-1	3711722
es@@	O	-1	3711722
es.	O	-1	3711722
The	O	-1	3711722
low@@	O	-1	3711722
est	O	-1	3711722
myocardial	O	-1	3711722
V@@	O	-1	3711722
I@@	O	-1	3711722
P	O	-1	3711722
concentration	O	-1	3711722
was	O	-1	3711722
found	O	-1	3711722
in	O	-1	3711722
the	O	-1	3711722
hear@@	O	-1	3711722
ts	O	-1	3711722
of	O	-1	3711722
patients	O	-1	3711722
with	O	-1	3711722
coronary	B-Disease	D003327	3711722
disease	I-Disease	-1	3711722
(@@	O	-1	3711722
one	O	-1	3711722
patient	O	-1	3711722
receiving	O	-1	3711722
a	O	-1	3711722
transplant	O	-1	3711722
and	O	-1	3711722
three	O	-1	3711722
receiving	O	-1	3711722
mit@@	O	-1	3711722
ral	O	-1	3711722
pro@@	O	-1	3711722
s@@	O	-1	3711722
th@@	O	-1	3711722
es@@	O	-1	3711722
es@@	O	-1	3711722
)	O	-1	3711722
(@@	O	-1	3711722
6.@@	O	-1	3711722
3	O	-1	3711722
+/-	O	-1	3711722
1.@@	O	-1	3711722
9	O	-1	3711722
p@@	O	-1	3711722
g/@@	O	-1	3711722
mg	O	-1	3711722
protein@@	O	-1	3711722
).	O	-1	3711722
The	O	-1	3711722
other	O	-1	3711722
patients	O	-1	3711722
under@@	O	-1	3711722
go@@	O	-1	3711722
ing	O	-1	3711722
transplant@@	O	-1	3711722
ation	O	-1	3711722
had	O	-1	3711722
an	O	-1	3711722
average	O	-1	3711722
e@@	O	-1	3711722
j@@	O	-1	3711722
ection	O	-1	3711722
frac@@	O	-1	3711722
tion	O	-1	3711722
of	O	-1	3711722
17@@	O	-1	3711722
%	O	-1	3711722
+/-	O	-1	3711722
6%	O	-1	3711722
and	O	-1	3711722
a	O	-1	3711722
V@@	O	-1	3711722
I@@	O	-1	3711722
P	O	-1	3711722
level	O	-1	3711722
of	O	-1	3711722
8.@@	O	-1	3711722
8	O	-1	3711722
+/-	O	-1	3711722
3.@@	O	-1	3711722
9	O	-1	3711722
p@@	O	-1	3711722
g/@@	O	-1	3711722
mg	O	-1	3711722
protein@@	O	-1	3711722
.	O	-1	3711722
The	O	-1	3711722
hear@@	O	-1	3711722
ts	O	-1	3711722
without	O	-1	3711722
coronary	B-Disease	D003324	3711722
artery	I-Disease	-1	3711722
disease	I-Disease	-1	3711722
(@@	O	-1	3711722
average	O	-1	3711722
e@@	O	-1	3711722
j@@	O	-1	3711722
ection	O	-1	3711722
frac@@	O	-1	3711722
tion	O	-1	3711722
of	O	-1	3711722
this	O	-1	3711722
group	O	-1	3711722
6@@	O	-1	3711722
2@@	O	-1	3711722
%	O	-1	3711722
+/-	O	-1	3711722
10@@	O	-1	3711722
%)	O	-1	3711722
had	O	-1	3711722
a	O	-1	3711722
V@@	O	-1	3711722
I@@	O	-1	3711722
P	O	-1	3711722
concentration	O	-1	3711722
of	O	-1	3711722
1@@	O	-1	3711722
4.@@	O	-1	3711722
1	O	-1	3711722
+/-	O	-1	3711722
7.@@	O	-1	3711722
9	O	-1	3711722
p@@	O	-1	3711722
g/@@	O	-1	3711722
mg	O	-1	3711722
protein@@	O	-1	3711722
,	O	-1	3711722
and	O	-1	3711722
this	O	-1	3711722
was	O	-1	3711722
greater	O	-1	3711722
than	O	-1	3711722
in	O	-1	3711722
hear@@	O	-1	3711722
ts	O	-1	3711722
of	O	-1	3711722
the	O	-1	3711722
patients	O	-1	3711722
with	O	-1	3711722
coronary	B-Disease	D003327	3711722
disease	I-Disease	-1	3711722
and	O	-1	3711722
the	O	-1	3711722
hear@@	O	-1	3711722
ts	O	-1	3711722
of	O	-1	3711722
patients	O	-1	3711722
receiving	O	-1	3711722
a	O	-1	3711722
transplant	O	-1	3711722
(P	O	-1	3711722
less	O	-1	3711722
than	O	-1	3711722
0.05@@	O	-1	3711722
).	O	-1	3711722
M@@	O	-1	3711722
y@@	O	-1	3711722
ocardi@@	O	-1	3711722
al	O	-1	3711722
cat@@	B-Chemical	D002395	3711722
ech@@	I-Chemical	-1	3711722
ol@@	I-Chemical	-1	3711722
amin@@	I-Chemical	-1	3711722
es	I-Chemical	-1	3711722
were	O	-1	3711722
also	O	-1	3711722
determined	O	-1	3711722
in	O	-1	3711722
14	O	-1	3711722
subj@@	O	-1	3711722
ect@@	O	-1	3711722
s;	O	-1	3711722
a	O	-1	3711722
we@@	O	-1	3711722
a@@	O	-1	3711722
k	O	-1	3711722
correl@@	O	-1	3711722
ation	O	-1	3711722
(@@	O	-1	3711722
r	O	-1	3711722
=	O	-1	3711722
0.@@	O	-1	3711722
5@@	O	-1	3711722
7@@	O	-1	3711722
,	O	-1	3711722
P	O	-1	3711722
less	O	-1	3711722
than	O	-1	3711722
0.05@@	O	-1	3711722
)	O	-1	3711722
between	O	-1	3711722
the	O	-1	3711722
tissue	O	-1	3711722
concentrations	O	-1	3711722
of	O	-1	3711722
V@@	O	-1	3711722
I@@	O	-1	3711722
P	O	-1	3711722
and	O	-1	3711722
no@@	B-Chemical	D009638	3711722
re@@	I-Chemical	-1	3711722
p@@	I-Chemical	-1	3711722
ine@@	I-Chemical	-1	3711722
phrine	I-Chemical	-1	3711722
was	O	-1	3711722
not@@	O	-1	3711722
ed@@	O	-1	3711722
.@@	O	-1	3711722
(A@@	O	-1	3711722
B@@	O	-1	3711722
S@@	O	-1	3711722
TR@@	O	-1	3711722
AC@@	O	-1	3711722
T	O	-1	3711722
TR@@	O	-1	3711722
UN@@	O	-1	3711722
C@@	O	-1	3711722
AT@@	O	-1	3711722
E@@	O	-1	3711722
D	O	-1	3711722
A@@	O	-1	3711722
T	O	-1	3711722
2@@	O	-1	3711722
50	O	-1	3711722
W@@	O	-1	3711722
O@@	O	-1	3711722
RD@@	O	-1	3711722
S)	O	-1	3711722

In@@	O	-1	6728873
ter@@	O	-1	6728873
stra@@	O	-1	6728873
in	O	-1	6728873
vari@@	O	-1	6728873
ation	O	-1	6728873
in	O	-1	6728873
acute	O	-1	6728873
toxic	O	-1	6728873
response	O	-1	6728873
to	O	-1	6728873
caffe@@	B-Chemical	D002110	6728873
ine	I-Chemical	-1	6728873
among	O	-1	6728873
in@@	O	-1	6728873
b@@	O	-1	6728873
red	O	-1	6728873
mice.	O	-1	6728873
Ac@@	O	-1	6728873
ute	O	-1	6728873
toxic	O	-1	6728873
dos@@	O	-1	6728873
ag@@	O	-1	6728873
e-@@	O	-1	6728873
dependent	O	-1	6728873
behavioral	O	-1	6728873
effects	O	-1	6728873
of	O	-1	6728873
caffe@@	B-Chemical	D002110	6728873
ine	I-Chemical	-1	6728873
were	O	-1	6728873
compared	O	-1	6728873
in	O	-1	6728873
ad@@	O	-1	6728873
ult	O	-1	6728873
mal@@	O	-1	6728873
es	O	-1	6728873
from	O	-1	6728873
seven	O	-1	6728873
in@@	O	-1	6728873
b@@	O	-1	6728873
red	O	-1	6728873
mouse	O	-1	6728873
stra@@	O	-1	6728873
ins	O	-1	6728873
(A@@	O	-1	6728873
/@@	O	-1	6728873
J@@	O	-1	6728873
,	O	-1	6728873
BA@@	O	-1	6728873
L@@	O	-1	6728873
B@@	O	-1	6728873
/@@	O	-1	6728873
c@@	O	-1	6728873
J@@	O	-1	6728873
,	O	-1	6728873
C@@	O	-1	6728873
BA@@	O	-1	6728873
/@@	O	-1	6728873
J@@	O	-1	6728873
,	O	-1	6728873
C@@	O	-1	6728873
3@@	O	-1	6728873
H@@	O	-1	6728873
/@@	O	-1	6728873
He@@	O	-1	6728873
J@@	O	-1	6728873
,	O	-1	6728873
C@@	O	-1	6728873
5@@	O	-1	6728873
7@@	O	-1	6728873
B@@	O	-1	6728873
L@@	O	-1	6728873
/@@	O	-1	6728873
6@@	O	-1	6728873
J@@	O	-1	6728873
,	O	-1	6728873
D@@	O	-1	6728873
BA@@	O	-1	6728873
/@@	O	-1	6728873
2@@	O	-1	6728873
J@@	O	-1	6728873
,	O	-1	6728873
S@@	O	-1	6728873
W@@	O	-1	6728873
R@@	O	-1	6728873
/@@	O	-1	6728873
J@@	O	-1	6728873
).	O	-1	6728873
C@@	O	-1	6728873
5@@	O	-1	6728873
7@@	O	-1	6728873
B@@	O	-1	6728873
L@@	O	-1	6728873
/@@	O	-1	6728873
6@@	O	-1	6728873
J@@	O	-1	6728873
,	O	-1	6728873
ch@@	O	-1	6728873
o@@	O	-1	6728873
se@@	O	-1	6728873
n	O	-1	6728873
as	O	-1	6728873
a	O	-1	6728873
"@@	O	-1	6728873
prot@@	O	-1	6728873
ot@@	O	-1	6728873
yp@@	O	-1	6728873
ic@@	O	-1	6728873
"	O	-1	6728873
mouse	O	-1	6728873
stra@@	O	-1	6728873
in,	O	-1	6728873
was	O	-1	6728873
used	O	-1	6728873
to	O	-1	6728873
determine	O	-1	6728873
behavioral	O	-1	6728873
responses	O	-1	6728873
to	O	-1	6728873
a	O	-1	6728873
b@@	O	-1	6728873
ro@@	O	-1	6728873
ad	O	-1	6728873
range	O	-1	6728873
(@@	O	-1	6728873
5-@@	O	-1	6728873
5@@	O	-1	6728873
00	O	-1	6728873
mg/kg)	O	-1	6728873
of	O	-1	6728873
caffe@@	B-Chemical	D002110	6728873
ine	I-Chemical	-1	6728873
dos@@	O	-1	6728873
es.	O	-1	6728873
F@@	O	-1	6728873
i@@	O	-1	6728873
ve	O	-1	6728873
phen@@	O	-1	6728873
ot@@	O	-1	6728873
yp@@	O	-1	6728873
ic	O	-1	6728873
character@@	O	-1	6728873
is@@	O	-1	6728873
tic@@	O	-1	6728873
s-@@	O	-1	6728873
-@@	O	-1	6728873
locomotor	O	-1	6728873
activ@@	O	-1	6728873
ity,	O	-1	6728873
ri@@	O	-1	6728873
gh@@	O	-1	6728873
ting	O	-1	6728873
abil@@	O	-1	6728873
ity,	O	-1	6728873
clon@@	B-Disease	D012640	6728873
ic	I-Disease	-1	6728873
seizure	I-Disease	-1	6728873
induc@@	O	-1	6728873
tion,	O	-1	6728873
stres@@	O	-1	6728873
s@@	O	-1	6728873
-induced	O	-1	6728873
le@@	O	-1	6728873
thal@@	O	-1	6728873
ity,	O	-1	6728873
death	O	-1	6728873
without	O	-1	6728873
ex@@	O	-1	6728873
tern@@	O	-1	6728873
al	O	-1	6728873
stres@@	O	-1	6728873
s-@@	O	-1	6728873
-@@	O	-1	6728873
were	O	-1	6728873
sco@@	O	-1	6728873
red	O	-1	6728873
at	O	-1	6728873
various	O	-1	6728873
caffe@@	B-Chemical	D002110	6728873
ine	I-Chemical	-1	6728873
doses	O	-1	6728873
in	O	-1	6728873
drug@@	O	-1	6728873
-@@	O	-1	6728873
na@@	O	-1	6728873
i@@	O	-1	6728873
ve	O	-1	6728873
animals	O	-1	6728873
under	O	-1	6728873
em@@	O	-1	6728873
pi@@	O	-1	6728873
r@@	O	-1	6728873
ically	O	-1	6728873
op@@	O	-1	6728873
tim@@	O	-1	6728873
iz@@	O	-1	6728873
ed,	O	-1	6728873
rig@@	O	-1	6728873
id@@	O	-1	6728873
ly	O	-1	6728873
con@@	O	-1	6728873
st@@	O	-1	6728873
ant	O	-1	6728873
experimental	O	-1	6728873
condi@@	O	-1	6728873
tions.	O	-1	6728873
M@@	O	-1	6728873
ic@@	O	-1	6728873
e	O	-1	6728873
(n	O	-1	6728873
=	O	-1	6728873
12	O	-1	6728873
for	O	-1	6728873
each	O	-1	6728873
po@@	O	-1	6728873
int@@	O	-1	6728873
)	O	-1	6728873
received	O	-1	6728873
single	O	-1	6728873
I@@	O	-1	6728873
P	O	-1	6728873
injec@@	O	-1	6728873
tions	O	-1	6728873
of	O	-1	6728873
a	O	-1	6728873
fi@@	O	-1	6728873
x@@	O	-1	6728873
ed	O	-1	6728873
vol@@	O	-1	6728873
u@@	O	-1	6728873
me@@	O	-1	6728873
/@@	O	-1	6728873
g	O	-1	6728873
body	O	-1	6728873
weight	O	-1	6728873
of	O	-1	6728873
physi@@	O	-1	6728873
ological	O	-1	6728873
saline	O	-1	6728873
car@@	O	-1	6728873
ri@@	O	-1	6728873
er	O	-1	6728873
with	O	-1	6728873
or	O	-1	6728873
without	O	-1	6728873
caffe@@	B-Chemical	D002110	6728873
ine	I-Chemical	-1	6728873
in	O	-1	6728873
doses	O	-1	6728873
rang@@	O	-1	6728873
ing	O	-1	6728873
from	O	-1	6728873
12@@	O	-1	6728873
5-@@	O	-1	6728873
5@@	O	-1	6728873
00	O	-1	6728873
mg/kg@@	O	-1	6728873
.	O	-1	6728873
L@@	O	-1	6728873
os@@	O	-1	6728873
s	O	-1	6728873
of	O	-1	6728873
ri@@	O	-1	6728873
gh@@	O	-1	6728873
ting	O	-1	6728873
ability	O	-1	6728873
was	O	-1	6728873
sco@@	O	-1	6728873
red	O	-1	6728873
at	O	-1	6728873
1,	O	-1	6728873
3,	O	-1	6728873
5	O	-1	6728873
min	O	-1	6728873
pos@@	O	-1	6728873
t	O	-1	6728873
dos@@	O	-1	6728873
ing	O	-1	6728873
and	O	-1	6728873
at	O	-1	6728873
5	O	-1	6728873
min	O	-1	6728873
interv@@	O	-1	6728873
als	O	-1	6728873
the@@	O	-1	6728873
re@@	O	-1	6728873
after	O	-1	6728873
for	O	-1	6728873
20	O	-1	6728873
min@@	O	-1	6728873
.	O	-1	6728873
In	O	-1	6728873
the	O	-1	6728873
same	O	-1	6728873
animals	O	-1	6728873
the	O	-1	6728873
occur@@	O	-1	6728873
rence	O	-1	6728873
of	O	-1	6728873
clon@@	B-Disease	D012640	6728873
ic	I-Disease	-1	6728873
seizures	I-Disease	-1	6728873
was	O	-1	6728873
sco@@	O	-1	6728873
red	O	-1	6728873
as	O	-1	6728873
to	O	-1	6728873
time	O	-1	6728873
of	O	-1	6728873
onset	O	-1	6728873
and	O	-1	6728873
severity	O	-1	6728873
for	O	-1	6728873
20	O	-1	6728873
min	O	-1	6728873
after	O	-1	6728873
drug	O	-1	6728873
administr@@	O	-1	6728873
ation.	O	-1	6728873
Whe@@	O	-1	6728873
n	O	-1	6728873
these	O	-1	6728873
proce@@	O	-1	6728873
ed@@	O	-1	6728873
ed	O	-1	6728873
to	O	-1	6728873
t@@	B-Disease	D012640	6728873
onic	I-Disease	-1	6728873
seizures	I-Disease	-1	6728873
,	O	-1	6728873
death	O	-1	6728873
occurred	O	-1	6728873
in	O	-1	6728873
less	O	-1	6728873
than	O	-1	6728873
20	O	-1	6728873
min@@	O	-1	6728873
.	O	-1	6728873
An@@	O	-1	6728873
im@@	O	-1	6728873
als	O	-1	6728873
sur@@	O	-1	6728873
vi@@	O	-1	6728873
ving	O	-1	6728873
for	O	-1	6728873
20	O	-1	6728873
min	O	-1	6728873
were	O	-1	6728873
immedi@@	O	-1	6728873
ately	O	-1	6728873
stres@@	O	-1	6728873
sed	O	-1	6728873
by	O	-1	6728873
a	O	-1	6728873
s@@	O	-1	6728873
wi@@	O	-1	6728873
m	O	-1	6728873
test	O	-1	6728873
in	O	-1	6728873
25	O	-1	6728873
de@@	O	-1	6728873
gre@@	O	-1	6728873
es	O	-1	6728873
C	O	-1	6728873
w@@	O	-1	6728873
at@@	O	-1	6728873
er,	O	-1	6728873
and	O	-1	6728873
de@@	O	-1	6728873
ath@@	O	-1	6728873
-@@	O	-1	6728873
produc@@	O	-1	6728873
ing	O	-1	6728873
t@@	B-Disease	D012640	6728873
onic	I-Disease	-1	6728873
seizures	I-Disease	-1	6728873
were	O	-1	6728873
sco@@	O	-1	6728873
red	O	-1	6728873
for	O	-1	6728873
2	O	-1	6728873
min@@	O	-1	6728873
.	O	-1	6728873
In	O	-1	6728873
other	O	-1	6728873
animals	O	-1	6728873
locomotor	O	-1	6728873
activity	O	-1	6728873
was	O	-1	6728873
measured	O	-1	6728873
15	O	-1	6728873
or	O	-1	6728873
60	O	-1	6728873
min	O	-1	6728873
after	O	-1	6728873
caffe@@	B-Chemical	D002110	6728873
ine	I-Chemical	-1	6728873
administr@@	O	-1	6728873
ation.	O	-1	6728873
B@@	O	-1	6728873
y	O	-1	6728873
any	O	-1	6728873
single	O	-1	6728873
behavioral	O	-1	6728873
c@@	O	-1	6728873
rit@@	O	-1	6728873
er@@	O	-1	6728873
i@@	O	-1	6728873
on	O	-1	6728873
or	O	-1	6728873
a	O	-1	6728873
combination	O	-1	6728873
of	O	-1	6728873
these	O	-1	6728873
c@@	O	-1	6728873
rit@@	O	-1	6728873
er@@	O	-1	6728873
ia,	O	-1	6728873
mark@@	O	-1	6728873
ed	O	-1	6728873
differences	O	-1	6728873
in	O	-1	6728873
response	O	-1	6728873
to	O	-1	6728873
toxic	O	-1	6728873
caffe@@	B-Chemical	D002110	6728873
ine	I-Chemical	-1	6728873
doses	O	-1	6728873
were	O	-1	6728873
observed	O	-1	6728873
between	O	-1	6728873
stra@@	O	-1	6728873
in@@	O	-1	6728873
s.	O	-1	6728873
These	O	-1	6728873
results	O	-1	6728873
indicate	O	-1	6728873
that	O	-1	6728873
behavioral	O	-1	6728873
toxicity	B-Disease	D064420	6728873
test@@	O	-1	6728873
ing	O	-1	6728873
of	O	-1	6728873
al@@	B-Chemical	-1	6728873
k@@	I-Chemical	-1	6728873
yl@@	I-Chemical	-1	6728873
x@@	I-Chemical	-1	6728873
an@@	I-Chemical	-1	6728873
th@@	I-Chemical	-1	6728873
in@@	I-Chemical	-1	6728873
es	I-Chemical	-1	6728873
in	O	-1	6728873
a	O	-1	6728873
single	O	-1	6728873
mouse	O	-1	6728873
stra@@	O	-1	6728873
in	O	-1	6728873
may	O	-1	6728873
be	O	-1	6728873
mis@@	O	-1	6728873
lead@@	O	-1	6728873
ing	O	-1	6728873
and	O	-1	6728873
suggest	O	-1	6728873
that	O	-1	6728873
toxic	O	-1	6728873
responses	O	-1	6728873
of	O	-1	6728873
the	O	-1	6728873
central	O	-1	6728873
ner@@	O	-1	6728873
v@@	O	-1	6728873
ous	O	-1	6728873
system	O	-1	6728873
to	O	-1	6728873
this	O	-1	6728873
cl@@	O	-1	6728873
as@@	O	-1	6728873
s	O	-1	6728873
of	O	-1	6728873
comp@@	O	-1	6728873
oun@@	O	-1	6728873
ds	O	-1	6728873
are	O	-1	6728873
gene@@	O	-1	6728873
tically	O	-1	6728873
influ@@	O	-1	6728873
enc@@	O	-1	6728873
ed	O	-1	6728873
in	O	-1	6728873
m@@	O	-1	6728873
am@@	O	-1	6728873
mal@@	O	-1	6728873
s.	O	-1	6728873

In@@	O	-1	7248895
v@@	O	-1	7248895
a@@	O	-1	7248895
sive	O	-1	7248895
carcin@@	B-Disease	D010386	7248895
oma	I-Disease	-1	7248895
of	I-Disease	-1	7248895
the	I-Disease	-1	7248895
renal	I-Disease	-1	7248895
p@@	I-Disease	-1	7248895
el@@	I-Disease	-1	7248895
v@@	I-Disease	-1	7248895
is	I-Disease	-1	7248895
following	O	-1	7248895
cyclophosph@@	B-Chemical	D003520	7248895
amide	I-Chemical	-1	7248895
therapy	O	-1	7248895
for	O	-1	7248895
non@@	O	-1	7248895
mal@@	O	-1	7248895
i@@	O	-1	7248895
gn@@	O	-1	7248895
ant	O	-1	7248895
disease.	O	-1	7248895
A	O	-1	7248895
4@@	O	-1	7248895
7-@@	O	-1	7248895
year-old	O	-1	7248895
woman	O	-1	7248895
with	O	-1	7248895
right	O	-1	7248895
hy@@	B-Disease	D006869	7248895
d@@	I-Disease	-1	7248895
rou@@	I-Disease	-1	7248895
re@@	I-Disease	-1	7248895
ter@@	I-Disease	-1	7248895
one@@	I-Disease	-1	7248895
ph@@	I-Disease	-1	7248895
ro@@	I-Disease	-1	7248895
sis	I-Disease	-1	7248895
due	O	-1	7248895
to	O	-1	7248895
ure@@	O	-1	7248895
ter@@	O	-1	7248895
o@@	O	-1	7248895
ve@@	O	-1	7248895
si@@	O	-1	7248895
c@@	O	-1	7248895
al	O	-1	7248895
j@@	O	-1	7248895
unc@@	O	-1	7248895
tion	O	-1	7248895
ob@@	O	-1	7248895
struc@@	O	-1	7248895
tion	O	-1	7248895
had	O	-1	7248895
g@@	O	-1	7248895
ros@@	O	-1	7248895
s	O	-1	7248895
hemat@@	B-Disease	D006417	7248895
uria	I-Disease	-1	7248895
after	O	-1	7248895
being	O	-1	7248895
treated	O	-1	7248895
for	O	-1	7248895
five	O	-1	7248895
years	O	-1	7248895
w@@	O	-1	7248895
ti@@	O	-1	7248895
h	O	-1	7248895
cyclophosph@@	B-Chemical	D003520	7248895
amide	I-Chemical	-1	7248895
for	O	-1	7248895
cerebral	B-Disease	D020293	7248895
vas@@	I-Disease	-1	7248895
cul@@	I-Disease	-1	7248895
iti@@	I-Disease	-1	7248895
s	I-Disease	-1	7248895
.	O	-1	7248895
A	O	-1	7248895
right	O	-1	7248895
neph@@	O	-1	7248895
rou@@	O	-1	7248895
re@@	O	-1	7248895
te@@	O	-1	7248895
rec@@	O	-1	7248895
to@@	O	-1	7248895
m@@	O	-1	7248895
y	O	-1	7248895
was	O	-1	7248895
requ@@	O	-1	7248895
ired	O	-1	7248895
for	O	-1	7248895
control	O	-1	7248895
of	O	-1	7248895
ble@@	B-Disease	D006470	7248895
ed@@	I-Disease	-1	7248895
ing	I-Disease	-1	7248895
.	O	-1	7248895
The	O	-1	7248895
path@@	O	-1	7248895
ology	O	-1	7248895
spec@@	O	-1	7248895
i@@	O	-1	7248895
men	O	-1	7248895
cont@@	O	-1	7248895
ained	O	-1	7248895
clin@@	O	-1	7248895
ically	O	-1	7248895
occ@@	O	-1	7248895
ult	O	-1	7248895
inv@@	O	-1	7248895
a@@	O	-1	7248895
sive	O	-1	7248895
carcin@@	B-Disease	D010386	7248895
oma	I-Disease	-1	7248895
of	I-Disease	-1	7248895
the	I-Disease	-1	7248895
renal	I-Disease	-1	7248895
p@@	I-Disease	-1	7248895
el@@	I-Disease	-1	7248895
v@@	I-Disease	-1	7248895
is	I-Disease	-1	7248895
.	O	-1	7248895
Although	O	-1	7248895
the	O	-1	7248895
ability	O	-1	7248895
of	O	-1	7248895
cyclophosph@@	B-Chemical	D003520	7248895
amide	I-Chemical	-1	7248895
to	O	-1	7248895
cause	O	-1	7248895
hemorrh@@	B-Disease	D006470	7248895
ag@@	I-Disease	-1	7248895
ic	I-Disease	-1	7248895
cys@@	I-Disease	-1	7248895
ti@@	I-Disease	-1	7248895
tis	I-Disease	-1	7248895
hemorrh@@	B-Disease	D003556	7248895
ag@@	I-Disease	-1	7248895
ic	I-Disease	-1	7248895
cys@@	I-Disease	-1	7248895
ti@@	I-Disease	-1	7248895
tis	I-Disease	-1	7248895
and	O	-1	7248895
urine	O	-1	7248895
cyto@@	O	-1	7248895
log@@	O	-1	7248895
ic	O	-1	7248895
abnormal@@	O	-1	7248895
ities	O	-1	7248895
in@@	O	-1	7248895
dist@@	O	-1	7248895
ing@@	O	-1	7248895
u@@	O	-1	7248895
ish@@	O	-1	7248895
able	O	-1	7248895
from	O	-1	7248895
high	O	-1	7248895
gra@@	O	-1	7248895
de	O	-1	7248895
carcin@@	B-Disease	D002277	7248895
oma	I-Disease	-1	7248895
is	O	-1	7248895
well	O	-1	7248895
know@@	O	-1	7248895
n@@	O	-1	7248895
,	O	-1	7248895
it	O	-1	7248895
is	O	-1	7248895
less	O	-1	7248895
wi@@	O	-1	7248895
de@@	O	-1	7248895
ly	O	-1	7248895
ap@@	O	-1	7248895
pre@@	O	-1	7248895
ci@@	O	-1	7248895
ated	O	-1	7248895
that	O	-1	7248895
it	O	-1	7248895
is	O	-1	7248895
also	O	-1	7248895
associated	O	-1	7248895
with	O	-1	7248895
carcin@@	B-Disease	D014571	7248895
oma	I-Disease	-1	7248895
of	I-Disease	-1	7248895
the	I-Disease	-1	7248895
urinary	I-Disease	-1	7248895
trac@@	I-Disease	-1	7248895
t	I-Disease	-1	7248895
.	O	-1	7248895
Tw@@	O	-1	7248895
ent@@	O	-1	7248895
y	O	-1	7248895
carcin@@	B-Disease	D001749	7248895
om@@	I-Disease	-1	7248895
as	I-Disease	-1	7248895
of	I-Disease	-1	7248895
the	I-Disease	-1	7248895
urinary	I-Disease	-1	7248895
bladder	I-Disease	-1	7248895
and	O	-1	7248895
one	O	-1	7248895
carcin@@	B-Disease	D011471	7248895
oma	I-Disease	-1	7248895
of	I-Disease	-1	7248895
the	I-Disease	-1	7248895
pro@@	I-Disease	-1	7248895
state	I-Disease	-1	7248895
have	O	-1	7248895
been	O	-1	7248895
reported	O	-1	7248895
in	O	-1	7248895
association	O	-1	7248895
with	O	-1	7248895
its	O	-1	7248895
use.	O	-1	7248895
The	O	-1	7248895
present	O	-1	7248895
case	O	-1	7248895
is	O	-1	7248895
the	O	-1	7248895
first	O	-1	7248895
carcin@@	B-Disease	D010386	7248895
oma	I-Disease	-1	7248895
of	I-Disease	-1	7248895
the	I-Disease	-1	7248895
renal	I-Disease	-1	7248895
p@@	I-Disease	-1	7248895
el@@	I-Disease	-1	7248895
v@@	I-Disease	-1	7248895
is	I-Disease	-1	7248895
reported	O	-1	7248895
in	O	-1	7248895
association	O	-1	7248895
with	O	-1	7248895
cyclophosph@@	B-Chemical	D003520	7248895
amide	I-Chemical	-1	7248895
treatment.	O	-1	7248895
It	O	-1	7248895
is	O	-1	7248895
the	O	-1	7248895
thir@@	O	-1	7248895
d	O	-1	7248895
urinary	B-Disease	D014571	7248895
trac@@	I-Disease	-1	7248895
t	I-Disease	-1	7248895
cancer	I-Disease	-1	7248895
reported	O	-1	7248895
in	O	-1	7248895
association	O	-1	7248895
with	O	-1	7248895
cyclophosph@@	B-Chemical	D003520	7248895
amide	I-Chemical	-1	7248895
treatment	O	-1	7248895
for	O	-1	7248895
non@@	O	-1	7248895
mal@@	O	-1	7248895
i@@	O	-1	7248895
gn@@	O	-1	7248895
ant	O	-1	7248895
disease.	O	-1	7248895
The	O	-1	7248895
association	O	-1	7248895
of	O	-1	7248895
the	O	-1	7248895
tumor	B-Disease	D009369	7248895
with	O	-1	7248895
pre@@	O	-1	7248895
ex@@	O	-1	7248895
ist@@	O	-1	7248895
ing	O	-1	7248895
hy@@	B-Disease	D006869	7248895
d@@	I-Disease	-1	7248895
rou@@	I-Disease	-1	7248895
re@@	I-Disease	-1	7248895
ter@@	I-Disease	-1	7248895
one@@	I-Disease	-1	7248895
ph@@	I-Disease	-1	7248895
ro@@	I-Disease	-1	7248895
sis	I-Disease	-1	7248895
suggests	O	-1	7248895
that	O	-1	7248895
st@@	O	-1	7248895
asis	O	-1	7248895
prolonged	O	-1	7248895
and	O	-1	7248895
int@@	O	-1	7248895
en@@	O	-1	7248895
si@@	O	-1	7248895
fied	O	-1	7248895
exposure	O	-1	7248895
of	O	-1	7248895
up@@	O	-1	7248895
per	O	-1	7248895
urinary	O	-1	7248895
trac@@	O	-1	7248895
t	O	-1	7248895
epi@@	O	-1	7248895
the@@	O	-1	7248895
li@@	O	-1	7248895
um	O	-1	7248895
to	O	-1	7248895
cyclophosph@@	B-Chemical	D003520	7248895
amide	I-Chemical	-1	7248895
.	O	-1	7248895
Patients	O	-1	7248895
who	O	-1	7248895
are	O	-1	7248895
can@@	O	-1	7248895
di@@	O	-1	7248895
dat@@	O	-1	7248895
es	O	-1	7248895
for	O	-1	7248895
long-term	O	-1	7248895
cyclophosph@@	B-Chemical	D003520	7248895
amide	I-Chemical	-1	7248895
treatment	O	-1	7248895
should	O	-1	7248895
be	O	-1	7248895
ro@@	O	-1	7248895
ut@@	O	-1	7248895
ine@@	O	-1	7248895
ly	O	-1	7248895
evaluated	O	-1	7248895
for	O	-1	7248895
ob@@	B-Disease	-1	7248895
struc@@	I-Disease	-1	7248895
tive	I-Disease	-1	7248895
uro@@	I-Disease	-1	7248895
pathy	I-Disease	-1	7248895
.	O	-1	7248895

A@@	O	-1	9578276
s@@	O	-1	9578276
c@@	O	-1	9578276
en@@	O	-1	9578276
ding	O	-1	9578276
dose	O	-1	9578276
toler@@	O	-1	9578276
ance	O	-1	9578276
study	O	-1	9578276
of	O	-1	9578276
int@@	O	-1	9578276
ram@@	O	-1	9578276
us@@	O	-1	9578276
cular	O	-1	9578276
car@@	B-Chemical	C020731	9578276
bet@@	I-Chemical	-1	9578276
oc@@	I-Chemical	-1	9578276
in	I-Chemical	-1	9578276
administered	O	-1	9578276
after	O	-1	9578276
normal	O	-1	9578276
v@@	O	-1	9578276
ag@@	O	-1	9578276
inal	O	-1	9578276
b@@	O	-1	9578276
ir@@	O	-1	9578276
th@@	O	-1	9578276
.	O	-1	9578276
OBJECTIVE:	O	-1	9578276
To	O	-1	9578276
determine	O	-1	9578276
the	O	-1	9578276
maxim@@	O	-1	9578276
um	O	-1	9578276
toler@@	O	-1	9578276
ated	O	-1	9578276
dose	O	-1	9578276
(@@	O	-1	9578276
M@@	O	-1	9578276
T@@	O	-1	9578276
D)	O	-1	9578276
of	O	-1	9578276
car@@	B-Chemical	C020731	9578276
bet@@	I-Chemical	-1	9578276
oc@@	I-Chemical	-1	9578276
in	I-Chemical	-1	9578276
(@@	O	-1	9578276
a	O	-1	9578276
long@@	O	-1	9578276
-@@	O	-1	9578276
act@@	O	-1	9578276
ing	O	-1	9578276
syn@@	O	-1	9578276
thetic	O	-1	9578276
an@@	O	-1	9578276
alo@@	O	-1	9578276
gu@@	O	-1	9578276
e	O	-1	9578276
of	O	-1	9578276
oxy@@	B-Chemical	D010121	9578276
t@@	I-Chemical	-1	9578276
oc@@	I-Chemical	-1	9578276
in	I-Chemical	-1	9578276
),	O	-1	9578276
when	O	-1	9578276
administered	O	-1	9578276
immedi@@	O	-1	9578276
ately	O	-1	9578276
after	O	-1	9578276
v@@	O	-1	9578276
ag@@	O	-1	9578276
inal	O	-1	9578276
de@@	O	-1	9578276
li@@	O	-1	9578276
very	O	-1	9578276
at	O	-1	9578276
ter@@	O	-1	9578276
m.	O	-1	9578276
M@@	O	-1	9578276
AT@@	O	-1	9578276
E@@	O	-1	9578276
R@@	O	-1	9578276
I@@	O	-1	9578276
AL@@	O	-1	9578276
S	O	-1	9578276
AN@@	O	-1	9578276
D	O	-1	9578276
METHODS:	O	-1	9578276
C@@	B-Chemical	C020731	9578276
ar@@	I-Chemical	-1	9578276
bet@@	I-Chemical	-1	9578276
oc@@	I-Chemical	-1	9578276
in	I-Chemical	-1	9578276
was	O	-1	9578276
given	O	-1	9578276
as	O	-1	9578276
an	O	-1	9578276
int@@	O	-1	9578276
ram@@	O	-1	9578276
us@@	O	-1	9578276
cular	O	-1	9578276
injection	O	-1	9578276
immedi@@	O	-1	9578276
ately	O	-1	9578276
after	O	-1	9578276
the	O	-1	9578276
b@@	O	-1	9578276
ir@@	O	-1	9578276
th	O	-1	9578276
of	O	-1	9578276
the	O	-1	9578276
inf@@	O	-1	9578276
ant	O	-1	9578276
in	O	-1	9578276
4@@	O	-1	9578276
5	O	-1	9578276
healthy	O	-1	9578276
women	O	-1	9578276
with	O	-1	9578276
normal	O	-1	9578276
sing@@	O	-1	9578276
le@@	O	-1	9578276
t@@	O	-1	9578276
on	O	-1	9578276
pregn@@	O	-1	9578276
an@@	O	-1	9578276
ci@@	O	-1	9578276
es	O	-1	9578276
who	O	-1	9578276
de@@	O	-1	9578276
li@@	O	-1	9578276
vered	O	-1	9578276
v@@	O	-1	9578276
ag@@	O	-1	9578276
in@@	O	-1	9578276
ally	O	-1	9578276
at	O	-1	9578276
ter@@	O	-1	9578276
m.	O	-1	9578276
D@@	O	-1	9578276
os@@	O	-1	9578276
age	O	-1	9578276
groups	O	-1	9578276
of	O	-1	9578276
1@@	O	-1	9578276
5,	O	-1	9578276
3@@	O	-1	9578276
0@@	O	-1	9578276
,	O	-1	9578276
50@@	O	-1	9578276
,	O	-1	9578276
7@@	O	-1	9578276
5,	O	-1	9578276
10@@	O	-1	9578276
0@@	O	-1	9578276
,	O	-1	9578276
12@@	O	-1	9578276
5,	O	-1	9578276
1@@	O	-1	9578276
50@@	O	-1	9578276
,	O	-1	9578276
17@@	O	-1	9578276
5	O	-1	9578276
or	O	-1	9578276
2@@	O	-1	9578276
00	O	-1	9578276
micro@@	O	-1	9578276
g	O	-1	9578276
car@@	B-Chemical	C020731	9578276
bet@@	I-Chemical	-1	9578276
oc@@	I-Chemical	-1	9578276
in	I-Chemical	-1	9578276
were	O	-1	9578276
as@@	O	-1	9578276
signed	O	-1	9578276
to	O	-1	9578276
block@@	O	-1	9578276
s	O	-1	9578276
of	O	-1	9578276
three	O	-1	9578276
women	O	-1	9578276
ac@@	O	-1	9578276
cor@@	O	-1	9578276
ding	O	-1	9578276
to	O	-1	9578276
the	O	-1	9578276
continu@@	O	-1	9578276
al	O	-1	9578276
reas@@	O	-1	9578276
s@@	O	-1	9578276
ess@@	O	-1	9578276
ment	O	-1	9578276
meth@@	O	-1	9578276
od	O	-1	9578276
(C@@	O	-1	9578276
R@@	O	-1	9578276
M@@	O	-1	9578276
).	O	-1	9578276
RESULTS:	O	-1	9578276
All	O	-1	9578276
dos@@	O	-1	9578276
age	O	-1	9578276
groups	O	-1	9578276
consist@@	O	-1	9578276
ed	O	-1	9578276
of	O	-1	9578276
three	O	-1	9578276
wom@@	O	-1	9578276
en@@	O	-1	9578276
,	O	-1	9578276
ex@@	O	-1	9578276
cep@@	O	-1	9578276
t	O	-1	9578276
those	O	-1	9578276
with	O	-1	9578276
100	O	-1	9578276
micro@@	O	-1	9578276
g	O	-1	9578276
(n@@	O	-1	9578276
=@@	O	-1	9578276
6@@	O	-1	9578276
)	O	-1	9578276
and	O	-1	9578276
2@@	O	-1	9578276
00	O	-1	9578276
micro@@	O	-1	9578276
g	O	-1	9578276
(n@@	O	-1	9578276
=@@	O	-1	9578276
18@@	O	-1	9578276
).	O	-1	9578276
Rec@@	O	-1	9578276
or@@	O	-1	9578276
ded	O	-1	9578276
were	O	-1	9578276
dose-@@	O	-1	9578276
lim@@	O	-1	9578276
it@@	O	-1	9578276
ing	O	-1	9578276
adverse	O	-1	9578276
event@@	O	-1	9578276
s:	O	-1	9578276
hyper@@	B-Disease	D006973	9578276
-	I-Disease	-1	9578276
or	I-Disease	-1	9578276
hypotension	I-Disease	-1	9578276
hyper@@	B-Disease	D007022	9578276
-	I-Disease	-1	9578276
or	I-Disease	-1	9578276
hypotension	I-Disease	-1	9578276
(@@	O	-1	9578276
th@@	O	-1	9578276
re@@	O	-1	9578276
e@@	O	-1	9578276
),	O	-1	9578276
severe	O	-1	9578276
ab@@	B-Disease	D015746	9578276
domin@@	I-Disease	-1	9578276
al	I-Disease	-1	9578276
pain	I-Disease	-1	9578276
(@@	O	-1	9578276
0@@	O	-1	9578276
),	O	-1	9578276
v@@	B-Disease	D014839	9578276
om@@	I-Disease	-1	9578276
it@@	I-Disease	-1	9578276
ing	I-Disease	-1	9578276
(@@	O	-1	9578276
0@@	O	-1	9578276
)	O	-1	9578276
and	O	-1	9578276
ret@@	B-Disease	D018457	9578276
ained	I-Disease	-1	9578276
pl@@	I-Disease	-1	9578276
ac@@	I-Disease	-1	9578276
ent@@	I-Disease	-1	9578276
a	I-Disease	-1	9578276
(@@	O	-1	9578276
fo@@	O	-1	9578276
ur@@	O	-1	9578276
).	O	-1	9578276
S@@	O	-1	9578276
er@@	O	-1	9578276
i@@	O	-1	9578276
ous	O	-1	9578276
adverse	O	-1	9578276
events	O	-1	9578276
occurred	O	-1	9578276
in	O	-1	9578276
seven	O	-1	9578276
wom@@	O	-1	9578276
en@@	O	-1	9578276
:	O	-1	9578276
six	O	-1	9578276
cases	O	-1	9578276
with	O	-1	9578276
blood	B-Disease	D006473	9578276
loss	I-Disease	-1	9578276
>	O	-1	9578276
or	O	-1	9578276
=	O	-1	9578276
10@@	O	-1	9578276
00	O	-1	9578276
ml@@	O	-1	9578276
,	O	-1	9578276
four	O	-1	9578276
cases	O	-1	9578276
of	O	-1	9578276
man@@	O	-1	9578276
ual	O	-1	9578276
pl@@	O	-1	9578276
ac@@	O	-1	9578276
ent@@	O	-1	9578276
a	O	-1	9578276
re@@	O	-1	9578276
mo@@	O	-1	9578276
val@@	O	-1	9578276
,	O	-1	9578276
five	O	-1	9578276
cases	O	-1	9578276
of	O	-1	9578276
addi@@	O	-1	9578276
tional	O	-1	9578276
oxy@@	O	-1	9578276
t@@	O	-1	9578276
oc@@	O	-1	9578276
ic@@	O	-1	9578276
s	O	-1	9578276
administration	O	-1	9578276
and	O	-1	9578276
five	O	-1	9578276
cases	O	-1	9578276
of	O	-1	9578276
blood	O	-1	9578276
trans@@	O	-1	9578276
fu@@	O	-1	9578276
sion.	O	-1	9578276
M@@	O	-1	9578276
ax@@	O	-1	9578276
im@@	O	-1	9578276
um	O	-1	9578276
blood	B-Disease	D006473	9578276
loss	I-Disease	-1	9578276
was	O	-1	9578276
great@@	O	-1	9578276
est	O	-1	9578276
at	O	-1	9578276
the	O	-1	9578276
up@@	O	-1	9578276
per	O	-1	9578276
and	O	-1	9578276
lower	O	-1	9578276
dose	O	-1	9578276
level@@	O	-1	9578276
s,	O	-1	9578276
and	O	-1	9578276
low@@	O	-1	9578276
est	O	-1	9578276
in	O	-1	9578276
the	O	-1	9578276
7@@	O	-1	9578276
0@@	O	-1	9578276
-1@@	O	-1	9578276
25	O	-1	9578276
micro@@	O	-1	9578276
g	O	-1	9578276
dose	O	-1	9578276
rang@@	O	-1	9578276
e.	O	-1	9578276
F@@	O	-1	9578276
our	O	-1	9578276
out	O	-1	9578276
of	O	-1	9578276
six	O	-1	9578276
cases	O	-1	9578276
with	O	-1	9578276
blood	B-Disease	D006473	9578276
loss	I-Disease	-1	9578276
>	O	-1	9578276
or	O	-1	9578276
=	O	-1	9578276
10@@	O	-1	9578276
00	O	-1	9578276
m@@	O	-1	9578276
l	O	-1	9578276
occurred	O	-1	9578276
in	O	-1	9578276
the	O	-1	9578276
2@@	O	-1	9578276
00	O	-1	9578276
micro@@	O	-1	9578276
g	O	-1	9578276
group.	O	-1	9578276
The	O	-1	9578276
maj@@	O	-1	9578276
or@@	O	-1	9578276
ity	O	-1	9578276
of	O	-1	9578276
addi@@	O	-1	9578276
tional	O	-1	9578276
administration	O	-1	9578276
of	O	-1	9578276
oxy@@	O	-1	9578276
t@@	O	-1	9578276
oc@@	O	-1	9578276
ic@@	O	-1	9578276
s	O	-1	9578276
(4@@	O	-1	9578276
/@@	O	-1	9578276
5@@	O	-1	9578276
)	O	-1	9578276
and	O	-1	9578276
blood	O	-1	9578276
trans@@	O	-1	9578276
f@@	O	-1	9578276
usion	O	-1	9578276
(3@@	O	-1	9578276
/@@	O	-1	9578276
5@@	O	-1	9578276
)	O	-1	9578276
occurred	O	-1	9578276
in	O	-1	9578276
the	O	-1	9578276
dose	O	-1	9578276
groups	O	-1	9578276
of	O	-1	9578276
2@@	O	-1	9578276
00	O	-1	9578276
micro@@	O	-1	9578276
g@@	O	-1	9578276
.	O	-1	9578276
All	O	-1	9578276
ret@@	O	-1	9578276
ained	O	-1	9578276
pl@@	O	-1	9578276
ac@@	O	-1	9578276
ent@@	O	-1	9578276
a@@	O	-1	9578276
e	O	-1	9578276
were	O	-1	9578276
found	O	-1	9578276
in	O	-1	9578276
the	O	-1	9578276
group	O	-1	9578276
of	O	-1	9578276
2@@	O	-1	9578276
00	O	-1	9578276
micro@@	O	-1	9578276
g@@	O	-1	9578276
.	O	-1	9578276
CONCLUSION:	O	-1	9578276
The	O	-1	9578276
M@@	O	-1	9578276
T@@	O	-1	9578276
D	O	-1	9578276
was	O	-1	9578276
calc@@	O	-1	9578276
ul@@	O	-1	9578276
ated	O	-1	9578276
to	O	-1	9578276
be	O	-1	9578276
at	O	-1	9578276
2@@	O	-1	9578276
00	O	-1	9578276
micro@@	O	-1	9578276
g	O	-1	9578276
car@@	B-Chemical	C020731	9578276
bet@@	I-Chemical	-1	9578276
oc@@	I-Chemical	-1	9578276
in	I-Chemical	-1	9578276
.	O	-1	9578276

A	O	-1	11423811
pilo@@	O	-1	11423811
t	O	-1	11423811
study	O	-1	11423811
to	O	-1	11423811
ass@@	O	-1	11423811
ess	O	-1	11423811
the	O	-1	11423811
safety	O	-1	11423811
of	O	-1	11423811
do@@	B-Chemical	D004280	11423811
but@@	I-Chemical	-1	11423811
amine	I-Chemical	-1	11423811
stres@@	O	-1	11423811
s	O	-1	11423811
echocardiograph@@	O	-1	11423811
y	O	-1	11423811
in	O	-1	11423811
the	O	-1	11423811
em@@	O	-1	11423811
er@@	O	-1	11423811
gen@@	O	-1	11423811
c@@	O	-1	11423811
y	O	-1	11423811
de@@	O	-1	11423811
part@@	O	-1	11423811
ment	O	-1	11423811
evalu@@	O	-1	11423811
ation	O	-1	11423811
of	O	-1	11423811
cocaine	B-Chemical	D003042	11423811
-@@	O	-1	11423811
associated	O	-1	11423811
ch@@	B-Disease	D002637	11423811
est	I-Disease	-1	11423811
pain	I-Disease	-1	11423811
.	O	-1	11423811
S@@	O	-1	11423811
T@@	O	-1	11423811
U@@	O	-1	11423811
D@@	O	-1	11423811
Y	O	-1	11423811
OBJECTIVE:	O	-1	11423811
Ch@@	B-Disease	D002637	11423811
est	I-Disease	-1	11423811
pain	I-Disease	-1	11423811
in	O	-1	11423811
the	O	-1	11423811
se@@	O	-1	11423811
t@@	O	-1	11423811
ting	O	-1	11423811
of	O	-1	11423811
cocaine	B-Chemical	D003042	11423811
use	O	-1	11423811
po@@	O	-1	11423811
ses	O	-1	11423811
a	O	-1	11423811
diagnos@@	O	-1	11423811
tic	O	-1	11423811
di@@	O	-1	11423811
le@@	O	-1	11423811
m@@	O	-1	11423811
ma.	O	-1	11423811
D@@	B-Chemical	D004280	11423811
ob@@	I-Chemical	-1	11423811
ut@@	I-Chemical	-1	11423811
amine	I-Chemical	-1	11423811
stres@@	O	-1	11423811
s	O	-1	11423811
echocardiograph@@	O	-1	11423811
y	O	-1	11423811
(D@@	O	-1	11423811
S@@	O	-1	11423811
E@@	O	-1	11423811
)	O	-1	11423811
is	O	-1	11423811
a	O	-1	11423811
wi@@	O	-1	11423811
de@@	O	-1	11423811
ly	O	-1	11423811
av@@	O	-1	11423811
ail@@	O	-1	11423811
able	O	-1	11423811
and	O	-1	11423811
sensitive	O	-1	11423811
test	O	-1	11423811
for	O	-1	11423811
evalu@@	O	-1	11423811
ating	O	-1	11423811
cardiac	O	-1	11423811
ischem@@	B-Disease	D007511	11423811
ia	I-Disease	-1	11423811
.	O	-1	11423811
B@@	O	-1	11423811
ecause	O	-1	11423811
of	O	-1	11423811
the	O	-1	11423811
the@@	O	-1	11423811
ore@@	O	-1	11423811
tical	O	-1	11423811
con@@	O	-1	11423811
cer@@	O	-1	11423811
n	O	-1	11423811
reg@@	O	-1	11423811
ar@@	O	-1	11423811
ding	O	-1	11423811
administration	O	-1	11423811
of	O	-1	11423811
do@@	B-Chemical	D004280	11423811
but@@	I-Chemical	-1	11423811
amine	I-Chemical	-1	11423811
in	O	-1	11423811
the	O	-1	11423811
se@@	O	-1	11423811
t@@	O	-1	11423811
ting	O	-1	11423811
of	O	-1	11423811
cocaine	B-Chemical	D003042	11423811
use@@	O	-1	11423811
,	O	-1	11423811
we	O	-1	11423811
con@@	O	-1	11423811
duc@@	O	-1	11423811
ted	O	-1	11423811
a	O	-1	11423811
pilo@@	O	-1	11423811
t	O	-1	11423811
study	O	-1	11423811
to	O	-1	11423811
ass@@	O	-1	11423811
ess	O	-1	11423811
the	O	-1	11423811
safety	O	-1	11423811
of	O	-1	11423811
D@@	O	-1	11423811
S@@	O	-1	11423811
E	O	-1	11423811
in	O	-1	11423811
em@@	O	-1	11423811
er@@	O	-1	11423811
gen@@	O	-1	11423811
c@@	O	-1	11423811
y	O	-1	11423811
de@@	O	-1	11423811
part@@	O	-1	11423811
ment	O	-1	11423811
patients	O	-1	11423811
with	O	-1	11423811
cocaine	B-Chemical	D003042	11423811
-@@	O	-1	11423811
associated	O	-1	11423811
ch@@	B-Disease	D002637	11423811
est	I-Disease	-1	11423811
pain	I-Disease	-1	11423811
.	O	-1	11423811
METHODS:	O	-1	11423811
A	O	-1	11423811
pro@@	O	-1	11423811
sp@@	O	-1	11423811
ective	O	-1	11423811
case	O	-1	11423811
seri@@	O	-1	11423811
es	O	-1	11423811
was	O	-1	11423811
con@@	O	-1	11423811
duc@@	O	-1	11423811
ted	O	-1	11423811
in	O	-1	11423811
the	O	-1	11423811
int@@	O	-1	11423811
en@@	O	-1	11423811
sive	O	-1	11423811
diagnos@@	O	-1	11423811
tic	O	-1	11423811
and	O	-1	11423811
treatment	O	-1	11423811
un@@	O	-1	11423811
it	O	-1	11423811
in	O	-1	11423811
the	O	-1	11423811
E@@	O	-1	11423811
D	O	-1	11423811
of	O	-1	11423811
an	O	-1	11423811
urb@@	O	-1	11423811
an	O	-1	11423811
ter@@	O	-1	11423811
ti@@	O	-1	11423811
ar@@	O	-1	11423811
y-@@	O	-1	11423811
car@@	O	-1	11423811
e	O	-1	11423811
te@@	O	-1	11423811
ac@@	O	-1	11423811
h@@	O	-1	11423811
ing	O	-1	11423811
hospit@@	O	-1	11423811
al.	O	-1	11423811
Patients	O	-1	11423811
were	O	-1	11423811
e@@	O	-1	11423811
li@@	O	-1	11423811
gi@@	O	-1	11423811
ble	O	-1	11423811
for	O	-1	11423811
D@@	O	-1	11423811
S@@	O	-1	11423811
E	O	-1	11423811
if	O	-1	11423811
they	O	-1	11423811
had	O	-1	11423811
used	O	-1	11423811
cocaine	B-Chemical	D003042	11423811
within	O	-1	11423811
24	O	-1	11423811
hours	O	-1	11423811
pre@@	O	-1	11423811
ce@@	O	-1	11423811
ding	O	-1	11423811
the	O	-1	11423811
onset	O	-1	11423811
of	O	-1	11423811
ch@@	B-Disease	D002637	11423811
est	I-Disease	-1	11423811
pain	I-Disease	-1	11423811
and	O	-1	11423811
had	O	-1	11423811
a	O	-1	11423811
normal	O	-1	11423811
EC@@	O	-1	11423811
G	O	-1	11423811
and	O	-1	11423811
tro@@	O	-1	11423811
p@@	O	-1	11423811
in@@	O	-1	11423811
in	O	-1	11423811
I	O	-1	11423811
level@@	O	-1	11423811
.	O	-1	11423811
Patients	O	-1	11423811
ex@@	O	-1	11423811
hib@@	O	-1	11423811
it@@	O	-1	11423811
ing	O	-1	11423811
signs	O	-1	11423811
of	O	-1	11423811
continu@@	O	-1	11423811
ing	O	-1	11423811
cocaine	B-Chemical	D003042	11423811
toxicity	B-Disease	D064420	11423811
were	O	-1	11423811
ex@@	O	-1	11423811
cl@@	O	-1	11423811
uded	O	-1	11423811
from	O	-1	11423811
the	O	-1	11423811
study.	O	-1	11423811
All	O	-1	11423811
patients	O	-1	11423811
were	O	-1	11423811
ad@@	O	-1	11423811
mit@@	O	-1	11423811
ted	O	-1	11423811
to	O	-1	11423811
the	O	-1	11423811
hospit@@	O	-1	11423811
al	O	-1	11423811
for	O	-1	11423811
ser@@	O	-1	11423811
ial	O	-1	11423811
test@@	O	-1	11423811
ing	O	-1	11423811
after	O	-1	11423811
the	O	-1	11423811
D@@	O	-1	11423811
S@@	O	-1	11423811
E	O	-1	11423811
test@@	O	-1	11423811
ing	O	-1	11423811
in	O	-1	11423811
the	O	-1	11423811
int@@	O	-1	11423811
en@@	O	-1	11423811
sive	O	-1	11423811
diagnos@@	O	-1	11423811
tic	O	-1	11423811
and	O	-1	11423811
treatment	O	-1	11423811
un@@	O	-1	11423811
it@@	O	-1	11423811
.	O	-1	11423811
RESULTS:	O	-1	11423811
Tw@@	O	-1	11423811
ent@@	O	-1	11423811
y-@@	O	-1	11423811
four	O	-1	11423811
patients	O	-1	11423811
were	O	-1	11423811
en@@	O	-1	11423811
ro@@	O	-1	11423811
l@@	O	-1	11423811
le@@	O	-1	11423811
d.	O	-1	11423811
Two	O	-1	11423811
patients	O	-1	11423811
had	O	-1	11423811
in@@	O	-1	11423811
ade@@	O	-1	11423811
qu@@	O	-1	11423811
ate	O	-1	11423811
rest@@	O	-1	11423811
ing	O	-1	11423811
imag@@	O	-1	11423811
es,	O	-1	11423811
one	O	-1	11423811
D@@	O	-1	11423811
S@@	O	-1	11423811
E	O	-1	11423811
was	O	-1	11423811
ter@@	O	-1	11423811
min@@	O	-1	11423811
ated	O	-1	11423811
because	O	-1	11423811
of	O	-1	11423811
inf@@	O	-1	11423811
er@@	O	-1	11423811
ior	O	-1	11423811
hypo@@	B-Disease	D018476	11423811
kine@@	I-Disease	-1	11423811
sis	I-Disease	-1	11423811
,	O	-1	11423811
an@@	O	-1	11423811
other	O	-1	11423811
D@@	O	-1	11423811
S@@	O	-1	11423811
E	O	-1	11423811
was	O	-1	11423811
ter@@	O	-1	11423811
min@@	O	-1	11423811
ated	O	-1	11423811
because	O	-1	11423811
of	O	-1	11423811
a	O	-1	11423811
rat@@	O	-1	11423811
e-@@	O	-1	11423811
related	O	-1	11423811
atrial	O	-1	11423811
con@@	O	-1	11423811
duction	O	-1	11423811
defic@@	O	-1	11423811
it@@	O	-1	11423811
,	O	-1	11423811
and	O	-1	11423811
1	O	-1	11423811
patient	O	-1	11423811
did	O	-1	11423811
not	O	-1	11423811
reac@@	O	-1	11423811
h	O	-1	11423811
the	O	-1	11423811
t@@	O	-1	11423811
arg@@	O	-1	11423811
et	O	-1	11423811
heart	O	-1	11423811
rat@@	O	-1	11423811
e.	O	-1	11423811
Th@@	O	-1	11423811
us,	O	-1	11423811
1@@	O	-1	11423811
9	O	-1	11423811
patients	O	-1	11423811
comple@@	O	-1	11423811
ted	O	-1	11423811
a	O	-1	11423811
D@@	O	-1	11423811
S@@	O	-1	11423811
E	O	-1	11423811
and	O	-1	11423811
reac@@	O	-1	11423811
h@@	O	-1	11423811
ed	O	-1	11423811
their	O	-1	11423811
t@@	O	-1	11423811
arg@@	O	-1	11423811
et	O	-1	11423811
heart	O	-1	11423811
rat@@	O	-1	11423811
es.	O	-1	11423811
N@@	O	-1	11423811
one	O	-1	11423811
of	O	-1	11423811
the	O	-1	11423811
patients	O	-1	11423811
experienced	O	-1	11423811
signs	O	-1	11423811
of	O	-1	11423811
ex@@	O	-1	11423811
ag@@	O	-1	11423811
g@@	O	-1	11423811
er@@	O	-1	11423811
ated	O	-1	11423811
adrenergic	O	-1	11423811
respon@@	O	-1	11423811
se@@	O	-1	11423811
,	O	-1	11423811
which	O	-1	11423811
was	O	-1	11423811
def@@	O	-1	11423811
in@@	O	-1	11423811
ed	O	-1	11423811
as	O	-1	11423811
a	O	-1	11423811
systolic	O	-1	11423811
blood	O	-1	11423811
pressure	O	-1	11423811
of	O	-1	11423811
greater	O	-1	11423811
than	O	-1	11423811
2@@	O	-1	11423811
00	O	-1	11423811
mm	O	-1	11423811
H@@	O	-1	11423811
g	O	-1	11423811
or	O	-1	11423811
the	O	-1	11423811
occur@@	O	-1	11423811
rence	O	-1	11423811
of	O	-1	11423811
tachy@@	B-Disease	-1	11423811
dys@@	I-Disease	-1	11423811
rhyth@@	I-Disease	-1	11423811
mi@@	I-Disease	-1	11423811
as	I-Disease	-1	11423811
(@@	O	-1	11423811
ex@@	O	-1	11423811
cl@@	O	-1	11423811
ud@@	O	-1	11423811
ing	O	-1	11423811
s@@	B-Disease	D013616	11423811
in@@	I-Disease	-1	11423811
us	I-Disease	-1	11423811
tachycardia	I-Disease	-1	11423811
).	O	-1	11423811
F@@	O	-1	11423811
urther	O	-1	11423811
suggesting	O	-1	11423811
l@@	O	-1	11423811
ac@@	O	-1	11423811
k	O	-1	11423811
of	O	-1	11423811
ex@@	O	-1	11423811
ag@@	O	-1	11423811
g@@	O	-1	11423811
er@@	O	-1	11423811
ated	O	-1	11423811
adrenergic	O	-1	11423811
respon@@	O	-1	11423811
se@@	O	-1	11423811
,	O	-1	11423811
13	O	-1	11423811
(6@@	O	-1	11423811
5@@	O	-1	11423811
%)	O	-1	11423811
of	O	-1	11423811
20	O	-1	11423811
patients	O	-1	11423811
requ@@	O	-1	11423811
ired	O	-1	11423811
sup@@	O	-1	11423811
ple@@	O	-1	11423811
mental	O	-1	11423811
atro@@	B-Chemical	D001285	11423811
pine	I-Chemical	-1	11423811
to	O	-1	11423811
reac@@	O	-1	11423811
h	O	-1	11423811
their	O	-1	11423811
t@@	O	-1	11423811
arg@@	O	-1	11423811
et	O	-1	11423811
heart	O	-1	11423811
rat@@	O	-1	11423811
es.	O	-1	11423811
CONCLUSION:	O	-1	11423811
No	O	-1	11423811
ex@@	O	-1	11423811
ag@@	O	-1	11423811
g@@	O	-1	11423811
er@@	O	-1	11423811
ated	O	-1	11423811
adrenergic	O	-1	11423811
response	O	-1	11423811
was	O	-1	11423811
det@@	O	-1	11423811
ected	O	-1	11423811
when	O	-1	11423811
do@@	B-Chemical	D004280	11423811
but@@	I-Chemical	-1	11423811
amine	I-Chemical	-1	11423811
was	O	-1	11423811
administered	O	-1	11423811
to	O	-1	11423811
patients	O	-1	11423811
with	O	-1	11423811
cocaine	B-Chemical	D003042	11423811
-@@	O	-1	11423811
related	O	-1	11423811
ch@@	B-Disease	D002637	11423811
est	I-Disease	-1	11423811
pain	I-Disease	-1	11423811
.	O	-1	11423811

A@@	B-Chemical	D000638	12678199
m@@	I-Chemical	-1	12678199
iodar@@	I-Chemical	-1	12678199
one	I-Chemical	-1	12678199
-induced	O	-1	12678199
t@@	B-Disease	D016171	12678199
or@@	I-Disease	-1	12678199
s@@	I-Disease	-1	12678199
ade	I-Disease	-1	12678199
de	I-Disease	-1	12678199
po@@	I-Disease	-1	12678199
int@@	I-Disease	-1	12678199
es	I-Disease	-1	12678199
during	O	-1	12678199
bladder	O	-1	12678199
ir@@	O	-1	12678199
rig@@	O	-1	12678199
ation@@	O	-1	12678199
:	O	-1	12678199
an	O	-1	12678199
un@@	O	-1	12678199
us@@	O	-1	12678199
ual	O	-1	12678199
present@@	O	-1	12678199
ation@@	O	-1	12678199
-@@	O	-1	12678199
-@@	O	-1	12678199
a	O	-1	12678199
case	O	-1	12678199
repor@@	O	-1	12678199
t.	O	-1	12678199
The	O	-1	12678199
au@@	O	-1	12678199
th@@	O	-1	12678199
ors	O	-1	12678199
present	O	-1	12678199
a	O	-1	12678199
case	O	-1	12678199
of	O	-1	12678199
early	O	-1	12678199
(@@	O	-1	12678199
within	O	-1	12678199
4	O	-1	12678199
da@@	O	-1	12678199
ys@@	O	-1	12678199
)	O	-1	12678199
development	O	-1	12678199
of	O	-1	12678199
t@@	B-Disease	D016171	12678199
or@@	I-Disease	-1	12678199
s@@	I-Disease	-1	12678199
ade	I-Disease	-1	12678199
de	I-Disease	-1	12678199
po@@	I-Disease	-1	12678199
int@@	I-Disease	-1	12678199
es	I-Disease	-1	12678199
(	O	-1	12678199
T@@	B-Disease	D016171	12678199
d@@	I-Disease	-1	12678199
P	I-Disease	-1	12678199
)	O	-1	12678199
associated	O	-1	12678199
with	O	-1	12678199
oral	O	-1	12678199
am@@	B-Chemical	D000638	12678199
iodar@@	I-Chemical	-1	12678199
one	I-Chemical	-1	12678199
therapy.	O	-1	12678199
Con@@	O	-1	12678199
sist@@	O	-1	12678199
ent	O	-1	12678199
with	O	-1	12678199
other	O	-1	12678199
reports	O	-1	12678199
this	O	-1	12678199
case	O	-1	12678199
of	O	-1	12678199
T@@	B-Disease	D016171	12678199
d@@	I-Disease	-1	12678199
P	I-Disease	-1	12678199
occurred	O	-1	12678199
in	O	-1	12678199
the	O	-1	12678199
cont@@	O	-1	12678199
ex@@	O	-1	12678199
t	O	-1	12678199
of	O	-1	12678199
multiple	O	-1	12678199
ex@@	O	-1	12678199
ac@@	O	-1	12678199
er@@	O	-1	12678199
b@@	O	-1	12678199
ating	O	-1	12678199
factors	O	-1	12678199
including	O	-1	12678199
hypo@@	B-Disease	D007008	12678199
k@@	I-Disease	-1	12678199
al@@	I-Disease	-1	12678199
emia	I-Disease	-1	12678199
and	O	-1	12678199
di@@	B-Chemical	D004077	12678199
g@@	I-Chemical	-1	12678199
ox@@	I-Chemical	-1	12678199
in	I-Chemical	-1	12678199
ex@@	O	-1	12678199
ces@@	O	-1	12678199
s.	O	-1	12678199
T@@	O	-1	12678199
ran@@	O	-1	12678199
si@@	O	-1	12678199
ent	O	-1	12678199
prolong@@	O	-1	12678199
ation	O	-1	12678199
of	O	-1	12678199
the	O	-1	12678199
Q@@	O	-1	12678199
T	O	-1	12678199
during	O	-1	12678199
bladder	O	-1	12678199
ir@@	O	-1	12678199
rig@@	O	-1	12678199
ation	O	-1	12678199
pro@@	O	-1	12678199
m@@	O	-1	12678199
pt@@	O	-1	12678199
ed	O	-1	12678199
the	O	-1	12678199
episo@@	O	-1	12678199
de	O	-1	12678199
of	O	-1	12678199
T@@	B-Disease	D016171	12678199
d@@	I-Disease	-1	12678199
P	I-Disease	-1	12678199
.	O	-1	12678199
It	O	-1	12678199
is	O	-1	12678199
well	O	-1	12678199
known	O	-1	12678199
that	O	-1	12678199
brady@@	B-Disease	D001919	12678199
cardia	I-Disease	-1	12678199
ex@@	O	-1	12678199
ac@@	O	-1	12678199
er@@	O	-1	12678199
b@@	O	-1	12678199
ates	O	-1	12678199
ac@@	O	-1	12678199
qu@@	O	-1	12678199
ired	O	-1	12678199
T@@	B-Disease	D016171	12678199
d@@	I-Disease	-1	12678199
P	I-Disease	-1	12678199
.	O	-1	12678199
The	O	-1	12678199
au@@	O	-1	12678199
th@@	O	-1	12678199
ors	O	-1	12678199
spec@@	O	-1	12678199
ul@@	O	-1	12678199
ate	O	-1	12678199
that	O	-1	12678199
the	O	-1	12678199
increased	O	-1	12678199
v@@	O	-1	12678199
ag@@	O	-1	12678199
al	O	-1	12678199
t@@	O	-1	12678199
one	O	-1	12678199
during	O	-1	12678199
bladder	O	-1	12678199
ir@@	O	-1	12678199
rig@@	O	-1	12678199
ation,	O	-1	12678199
a	O	-1	12678199
v@@	O	-1	12678199
ag@@	O	-1	12678199
al	O	-1	12678199
man@@	O	-1	12678199
eu@@	O	-1	12678199
ver,	O	-1	12678199
in	O	-1	12678199
the	O	-1	12678199
cont@@	O	-1	12678199
ex@@	O	-1	12678199
t	O	-1	12678199
of	O	-1	12678199
am@@	B-Chemical	D000638	12678199
iodar@@	I-Chemical	-1	12678199
one	I-Chemical	-1	12678199
therapy	O	-1	12678199
resulted	O	-1	12678199
in	O	-1	12678199
am@@	B-Chemical	D000638	12678199
iodar@@	I-Chemical	-1	12678199
one	I-Chemical	-1	12678199
-induced	O	-1	12678199
pro@@	B-Disease	-1	12678199
arrhyth@@	I-Disease	-1	12678199
mia	I-Disease	-1	12678199
.	O	-1	12678199
In	O	-1	12678199
the	O	-1	12678199
absence	O	-1	12678199
of	O	-1	12678199
am@@	B-Chemical	D000638	12678199
iodar@@	I-Chemical	-1	12678199
one	I-Chemical	-1	12678199
therapy,	O	-1	12678199
a	O	-1	12678199
second	O	-1	12678199
bladder	O	-1	12678199
ir@@	O	-1	12678199
rig@@	O	-1	12678199
ation	O	-1	12678199
did	O	-1	12678199
not	O	-1	12678199
induce	O	-1	12678199
T@@	B-Disease	D016171	12678199
d@@	I-Disease	-1	12678199
P	I-Disease	-1	12678199
des@@	O	-1	12678199
pit@@	O	-1	12678199
e	O	-1	12678199
hypo@@	B-Disease	D007008	12678199
k@@	I-Disease	-1	12678199
al@@	I-Disease	-1	12678199
emia	I-Disease	-1	12678199
and	O	-1	12678199
hypo@@	B-Disease	C537153	12678199
mag@@	I-Disease	-1	12678199
n@@	I-Disease	-1	12678199
es@@	I-Disease	-1	12678199
emia	I-Disease	-1	12678199
.	O	-1	12678199

Ac@@	B-Disease	D058186	15696449
ute	I-Disease	-1	15696449
renal	I-Disease	-1	15696449
in@@	I-Disease	-1	15696449
suffici@@	I-Disease	-1	15696449
ency	I-Disease	-1	15696449
after	O	-1	15696449
high-dose	O	-1	15696449
me@@	B-Chemical	D008558	15696449
l@@	I-Chemical	-1	15696449
ph@@	I-Chemical	-1	15696449
al@@	I-Chemical	-1	15696449
an	I-Chemical	-1	15696449
in	O	-1	15696449
patients	O	-1	15696449
with	O	-1	15696449
prim@@	B-Disease	C531616	15696449
ary	I-Disease	-1	15696449
systemic	I-Disease	-1	15696449
am@@	I-Disease	-1	15696449
y@@	I-Disease	-1	15696449
lo@@	I-Disease	-1	15696449
id@@	I-Disease	-1	15696449
o@@	I-Disease	-1	15696449
sis	I-Disease	-1	15696449
during	O	-1	15696449
st@@	O	-1	15696449
em	O	-1	15696449
cell	O	-1	15696449
transplant@@	O	-1	15696449
ation.	O	-1	15696449
BACKGROUND:	O	-1	15696449
Patients	O	-1	15696449
with	O	-1	15696449
prim@@	B-Disease	C531616	15696449
ary	I-Disease	-1	15696449
systemic	I-Disease	-1	15696449
am@@	I-Disease	-1	15696449
y@@	I-Disease	-1	15696449
lo@@	I-Disease	-1	15696449
id@@	I-Disease	-1	15696449
o@@	I-Disease	-1	15696449
sis	I-Disease	-1	15696449
(	O	-1	15696449
A@@	B-Disease	D000686	15696449
L	I-Disease	-1	15696449
)	O	-1	15696449
have	O	-1	15696449
a	O	-1	15696449
po@@	O	-1	15696449
or	O	-1	15696449
pro@@	O	-1	15696449
g@@	O	-1	15696449
no@@	O	-1	15696449
sis.	O	-1	15696449
M@@	O	-1	15696449
edi@@	O	-1	15696449
an	O	-1	15696449
sur@@	O	-1	15696449
viv@@	O	-1	15696449
al	O	-1	15696449
time	O	-1	15696449
from	O	-1	15696449
standard	O	-1	15696449
treat@@	O	-1	15696449
ments	O	-1	15696449
is	O	-1	15696449
only	O	-1	15696449
17	O	-1	15696449
months.	O	-1	15696449
H@@	O	-1	15696449
igh@@	O	-1	15696449
-@@	O	-1	15696449
dose	O	-1	15696449
intravenous	O	-1	15696449
me@@	B-Chemical	D008558	15696449
l@@	I-Chemical	-1	15696449
ph@@	I-Chemical	-1	15696449
al@@	I-Chemical	-1	15696449
an	I-Chemical	-1	15696449
followed	O	-1	15696449
by	O	-1	15696449
peripheral	O	-1	15696449
blood	O	-1	15696449
st@@	O	-1	15696449
em	O	-1	15696449
cell	O	-1	15696449
transplant	O	-1	15696449
(P@@	O	-1	15696449
B@@	O	-1	15696449
S@@	O	-1	15696449
C@@	O	-1	15696449
T)	O	-1	15696449
appear@@	O	-1	15696449
s	O	-1	15696449
to	O	-1	15696449
be	O	-1	15696449
the	O	-1	15696449
most	O	-1	15696449
pro@@	O	-1	15696449
mis@@	O	-1	15696449
ing	O	-1	15696449
therapy,	O	-1	15696449
but	O	-1	15696449
treatment	O	-1	15696449
mor@@	O	-1	15696449
t@@	O	-1	15696449
ality	O	-1	15696449
can	O	-1	15696449
be	O	-1	15696449
high@@	O	-1	15696449
.	O	-1	15696449
The	O	-1	15696449
au@@	O	-1	15696449
th@@	O	-1	15696449
ors	O	-1	15696449
have	O	-1	15696449
not@@	O	-1	15696449
ed	O	-1	15696449
the	O	-1	15696449
development	O	-1	15696449
of	O	-1	15696449
acute	B-Disease	D058186	15696449
renal	I-Disease	-1	15696449
in@@	I-Disease	-1	15696449
suffici@@	I-Disease	-1	15696449
ency	I-Disease	-1	15696449
immedi@@	O	-1	15696449
ately	O	-1	15696449
after	O	-1	15696449
me@@	B-Chemical	D008558	15696449
l@@	I-Chemical	-1	15696449
ph@@	I-Chemical	-1	15696449
al@@	I-Chemical	-1	15696449
an	I-Chemical	-1	15696449
condi@@	O	-1	15696449
tion@@	O	-1	15696449
ing.	O	-1	15696449
This	O	-1	15696449
study	O	-1	15696449
was	O	-1	15696449
under@@	O	-1	15696449
tak@@	O	-1	15696449
en	O	-1	15696449
to	O	-1	15696449
further	O	-1	15696449
ex@@	O	-1	15696449
amine	O	-1	15696449
its	O	-1	15696449
risk	O	-1	15696449
factors	O	-1	15696449
and	O	-1	15696449
im@@	O	-1	15696449
pac@@	O	-1	15696449
t	O	-1	15696449
on	O	-1	15696449
post@@	O	-1	15696449
transplant	O	-1	15696449
mor@@	O	-1	15696449
t@@	O	-1	15696449
al@@	O	-1	15696449
ity.	O	-1	15696449
METHODS:	O	-1	15696449
Con@@	O	-1	15696449
sec@@	O	-1	15696449
utive	O	-1	15696449
A@@	B-Disease	D000686	15696449
L	I-Disease	-1	15696449
patients	O	-1	15696449
who	O	-1	15696449
under@@	O	-1	15696449
w@@	O	-1	15696449
ent	O	-1	15696449
P@@	O	-1	15696449
B@@	O	-1	15696449
S@@	O	-1	15696449
C@@	O	-1	15696449
T	O	-1	15696449
were	O	-1	15696449
studied	O	-1	15696449
ret@@	O	-1	15696449
ro@@	O	-1	15696449
sp@@	O	-1	15696449
ecti@@	O	-1	15696449
vel@@	O	-1	15696449
y.	O	-1	15696449
Ac@@	B-Disease	D058186	15696449
ute	I-Disease	-1	15696449
renal	I-Disease	-1	15696449
in@@	I-Disease	-1	15696449
suffici@@	I-Disease	-1	15696449
ency	I-Disease	-1	15696449
(	O	-1	15696449
A@@	B-Disease	D058186	15696449
R@@	I-Disease	-1	15696449
I	I-Disease	-1	15696449
)	O	-1	15696449
after	O	-1	15696449
high-dose	O	-1	15696449
me@@	B-Chemical	D008558	15696449
l@@	I-Chemical	-1	15696449
ph@@	I-Chemical	-1	15696449
al@@	I-Chemical	-1	15696449
an	I-Chemical	-1	15696449
was	O	-1	15696449
def@@	O	-1	15696449
in@@	O	-1	15696449
ed	O	-1	15696449
by	O	-1	15696449
a	O	-1	15696449
minim@@	O	-1	15696449
um	O	-1	15696449
increase	O	-1	15696449
of	O	-1	15696449
0.@@	O	-1	15696449
5	O	-1	15696449
mg/d@@	O	-1	15696449
L	O	-1	15696449
(4@@	O	-1	15696449
4	O	-1	15696449
mic@@	O	-1	15696449
rom@@	O	-1	15696449
ol@@	O	-1	15696449
/@@	O	-1	15696449
L@@	O	-1	15696449
)	O	-1	15696449
in	O	-1	15696449
the	O	-1	15696449
serum	O	-1	15696449
creatinine	B-Chemical	D003404	15696449
level	O	-1	15696449
that	O	-1	15696449
is	O	-1	15696449
greater	O	-1	15696449
than	O	-1	15696449
50@@	O	-1	15696449
%	O	-1	15696449
of	O	-1	15696449
baseline	O	-1	15696449
immedi@@	O	-1	15696449
ately	O	-1	15696449
after	O	-1	15696449
condi@@	O	-1	15696449
tion@@	O	-1	15696449
ing.	O	-1	15696449
U@@	O	-1	15696449
rine	O	-1	15696449
se@@	O	-1	15696449
di@@	O	-1	15696449
ment	O	-1	15696449
scor@@	O	-1	15696449
e	O	-1	15696449
was	O	-1	15696449
the	O	-1	15696449
su@@	O	-1	15696449
m	O	-1	15696449
of	O	-1	15696449
the	O	-1	15696449
individ@@	O	-1	15696449
ual	O	-1	15696449
typ@@	O	-1	15696449
es	O	-1	15696449
of	O	-1	15696449
se@@	O	-1	15696449
di@@	O	-1	15696449
ment	O	-1	15696449
identi@@	O	-1	15696449
fied	O	-1	15696449
on	O	-1	15696449
urine	O	-1	15696449
micro@@	O	-1	15696449
sco@@	O	-1	15696449
p@@	O	-1	15696449
y.	O	-1	15696449
RESULTS:	O	-1	15696449
Of	O	-1	15696449
the	O	-1	15696449
8@@	O	-1	15696449
0	O	-1	15696449
patients	O	-1	15696449
studi@@	O	-1	15696449
ed,	O	-1	15696449
A@@	B-Disease	D058186	15696449
R@@	I-Disease	-1	15696449
I	I-Disease	-1	15696449
developed	O	-1	15696449
in	O	-1	15696449
1@@	O	-1	15696449
8.@@	O	-1	15696449
8@@	O	-1	15696449
%	O	-1	15696449
of	O	-1	15696449
the	O	-1	15696449
patients	O	-1	15696449
after	O	-1	15696449
high-dose	O	-1	15696449
me@@	B-Chemical	D008558	15696449
l@@	I-Chemical	-1	15696449
ph@@	I-Chemical	-1	15696449
al@@	I-Chemical	-1	15696449
an	I-Chemical	-1	15696449
.	O	-1	15696449
U@@	O	-1	15696449
n@@	O	-1	15696449
i@@	O	-1	15696449
vari@@	O	-1	15696449
ate	O	-1	15696449
analysis	O	-1	15696449
identi@@	O	-1	15696449
fied	O	-1	15696449
age,	O	-1	15696449
hypo@@	B-Disease	D034141	15696449
al@@	I-Disease	-1	15696449
b@@	I-Disease	-1	15696449
um@@	I-Disease	-1	15696449
ine@@	I-Disease	-1	15696449
mia	I-Disease	-1	15696449
,	O	-1	15696449
he@@	O	-1	15696449
av@@	O	-1	15696449
y	O	-1	15696449
proteinuria	B-Disease	D011507	15696449
,	O	-1	15696449
di@@	O	-1	15696449
ure@@	O	-1	15696449
tic	O	-1	15696449
use@@	O	-1	15696449
,	O	-1	15696449
and	O	-1	15696449
urine	O	-1	15696449
se@@	O	-1	15696449
di@@	O	-1	15696449
ment	O	-1	15696449
scor@@	O	-1	15696449
e	O	-1	15696449
(@@	O	-1	15696449
>@@	O	-1	15696449
3@@	O	-1	15696449
)	O	-1	15696449
as	O	-1	15696449
risk	O	-1	15696449
fact@@	O	-1	15696449
or@@	O	-1	15696449
s.	O	-1	15696449
A@@	O	-1	15696449
ge	O	-1	15696449
and	O	-1	15696449
urine	O	-1	15696449
se@@	O	-1	15696449
di@@	O	-1	15696449
ment	O	-1	15696449
scor@@	O	-1	15696449
e	O	-1	15696449
remained	O	-1	15696449
in@@	O	-1	15696449
depend@@	O	-1	15696449
ently	O	-1	15696449
significant	O	-1	15696449
risk	O	-1	15696449
factors	O	-1	15696449
in	O	-1	15696449
the	O	-1	15696449
mul@@	O	-1	15696449
tiv@@	O	-1	15696449
ari@@	O	-1	15696449
ate	O	-1	15696449
analy@@	O	-1	15696449
sis.	O	-1	15696449
Patients	O	-1	15696449
who	O	-1	15696449
had	O	-1	15696449
A@@	B-Disease	D058186	15696449
R@@	I-Disease	-1	15696449
I	I-Disease	-1	15696449
after	O	-1	15696449
high-dose	O	-1	15696449
me@@	B-Chemical	D008558	15696449
l@@	I-Chemical	-1	15696449
ph@@	I-Chemical	-1	15696449
al@@	I-Chemical	-1	15696449
an	I-Chemical	-1	15696449
under@@	O	-1	15696449
w@@	O	-1	15696449
ent	O	-1	15696449
dialy@@	O	-1	15696449
sis	O	-1	15696449
more	O	-1	15696449
often	O	-1	15696449
(P	O	-1	15696449
=	O	-1	15696449
0.00@@	O	-1	15696449
7@@	O	-1	15696449
),	O	-1	15696449
and	O	-1	15696449
had	O	-1	15696449
a	O	-1	15696449
wor@@	O	-1	15696449
se	O	-1	15696449
1-@@	O	-1	15696449
year	O	-1	15696449
sur@@	O	-1	15696449
viv@@	O	-1	15696449
al	O	-1	15696449
(P	O	-1	15696449
=	O	-1	15696449
0.0@@	O	-1	15696449
3@@	O	-1	15696449
).	O	-1	15696449
CONCLUSION:	O	-1	15696449
The	O	-1	15696449
tim@@	O	-1	15696449
ing	O	-1	15696449
of	O	-1	15696449
renal	B-Disease	D058186	15696449
injury	I-Disease	-1	15696449
st@@	O	-1	15696449
ron@@	O	-1	15696449
g@@	O	-1	15696449
ly	O	-1	15696449
suggests	O	-1	15696449
me@@	B-Chemical	D008558	15696449
l@@	I-Chemical	-1	15696449
ph@@	I-Chemical	-1	15696449
al@@	I-Chemical	-1	15696449
an	I-Chemical	-1	15696449
as	O	-1	15696449
the	O	-1	15696449
ca@@	O	-1	15696449
us@@	O	-1	15696449
ative	O	-1	15696449
agent@@	O	-1	15696449
.	O	-1	15696449
On@@	O	-1	15696449
go@@	O	-1	15696449
ing	O	-1	15696449
tub@@	B-Disease	-1	15696449
ular	I-Disease	-1	15696449
injury	I-Disease	-1	15696449
may	O	-1	15696449
be	O	-1	15696449
a	O	-1	15696449
pre@@	O	-1	15696449
requ@@	O	-1	15696449
is@@	O	-1	15696449
ite	O	-1	15696449
for	O	-1	15696449
renal	B-Disease	D058186	15696449
injury	I-Disease	-1	15696449
by	O	-1	15696449
me@@	B-Chemical	D008558	15696449
l@@	I-Chemical	-1	15696449
ph@@	I-Chemical	-1	15696449
al@@	I-Chemical	-1	15696449
an	I-Chemical	-1	15696449
as	O	-1	15696449
ev@@	O	-1	15696449
id@@	O	-1	15696449
enc@@	O	-1	15696449
ed	O	-1	15696449
by	O	-1	15696449
the	O	-1	15696449
active	O	-1	15696449
urinary	O	-1	15696449
se@@	O	-1	15696449
di@@	O	-1	15696449
ment.	O	-1	15696449
De@@	O	-1	15696449
ve@@	O	-1	15696449
lop@@	O	-1	15696449
ment	O	-1	15696449
of	O	-1	15696449
A@@	B-Disease	D058186	15696449
R@@	I-Disease	-1	15696449
I	I-Disease	-1	15696449
ad@@	O	-1	15696449
ver@@	O	-1	15696449
se@@	O	-1	15696449
ly	O	-1	15696449
affected	O	-1	15696449
the	O	-1	15696449
outcom@@	O	-1	15696449
e	O	-1	15696449
after	O	-1	15696449
P@@	O	-1	15696449
B@@	O	-1	15696449
S@@	O	-1	15696449
C@@	O	-1	15696449
T@@	O	-1	15696449
.	O	-1	15696449
Eff@@	O	-1	15696449
ective	O	-1	15696449
pre@@	O	-1	15696449
ven@@	O	-1	15696449
tive	O	-1	15696449
meas@@	O	-1	15696449
ures	O	-1	15696449
may	O	-1	15696449
he@@	O	-1	15696449
l@@	O	-1	15696449
p	O	-1	15696449
decrease	O	-1	15696449
the	O	-1	15696449
treatment	O	-1	15696449
mor@@	O	-1	15696449
t@@	O	-1	15696449
ality	O	-1	15696449
of	O	-1	15696449
P@@	O	-1	15696449
B@@	O	-1	15696449
S@@	O	-1	15696449
C@@	O	-1	15696449
T	O	-1	15696449
in	O	-1	15696449
A@@	B-Disease	D000686	15696449
L	I-Disease	-1	15696449
patients.	O	-1	15696449

Im@@	B-Disease	D001925	17554526
pa@@	I-Disease	-1	17554526
ired	I-Disease	-1	17554526
fe@@	I-Disease	-1	17554526
ar	I-Disease	-1	17554526
reco@@	I-Disease	-1	17554526
gn@@	I-Disease	-1	17554526
ition	I-Disease	-1	17554526
in	O	-1	17554526
reg@@	O	-1	17554526
ular	O	-1	17554526
rec@@	O	-1	17554526
re@@	O	-1	17554526
ation@@	O	-1	17554526
al	O	-1	17554526
cocaine	B-Chemical	D003042	17554526
us@@	O	-1	17554526
ers.	O	-1	17554526
IN@@	O	-1	17554526
T@@	O	-1	17554526
RO@@	O	-1	17554526
D@@	O	-1	17554526
U@@	O	-1	17554526
C@@	O	-1	17554526
T@@	O	-1	17554526
ION@@	O	-1	17554526
:	O	-1	17554526
The	O	-1	17554526
ability	O	-1	17554526
to	O	-1	17554526
re@@	O	-1	17554526
ad	O	-1	17554526
fac@@	O	-1	17554526
ial	O	-1	17554526
ex@@	O	-1	17554526
pres@@	O	-1	17554526
sions	O	-1	17554526
is	O	-1	17554526
es@@	O	-1	17554526
sen@@	O	-1	17554526
tial	O	-1	17554526
for	O	-1	17554526
normal	O	-1	17554526
human	O	-1	17554526
s@@	O	-1	17554526
oci@@	O	-1	17554526
al	O	-1	17554526
inter@@	O	-1	17554526
ac@@	O	-1	17554526
tion.	O	-1	17554526
The	O	-1	17554526
a@@	O	-1	17554526
im	O	-1	17554526
of	O	-1	17554526
the	O	-1	17554526
present	O	-1	17554526
study	O	-1	17554526
was	O	-1	17554526
to	O	-1	17554526
con@@	O	-1	17554526
duc@@	O	-1	17554526
t	O	-1	17554526
the	O	-1	17554526
first	O	-1	17554526
investig@@	O	-1	17554526
ation	O	-1	17554526
of	O	-1	17554526
fac@@	O	-1	17554526
ial	O	-1	17554526
expression	O	-1	17554526
reco@@	O	-1	17554526
gn@@	O	-1	17554526
ition	O	-1	17554526
perform@@	O	-1	17554526
ance	O	-1	17554526
in	O	-1	17554526
rec@@	O	-1	17554526
re@@	O	-1	17554526
ation@@	O	-1	17554526
al	O	-1	17554526
cocaine	B-Chemical	D003042	17554526
us@@	O	-1	17554526
ers.	O	-1	17554526
M@@	O	-1	17554526
AT@@	O	-1	17554526
E@@	O	-1	17554526
R@@	O	-1	17554526
I@@	O	-1	17554526
AL@@	O	-1	17554526
S	O	-1	17554526
AN@@	O	-1	17554526
D	O	-1	17554526
METHODS:	O	-1	17554526
Th@@	O	-1	17554526
ree	O	-1	17554526
group@@	O	-1	17554526
s,	O	-1	17554526
comp@@	O	-1	17554526
ris@@	O	-1	17554526
ed	O	-1	17554526
of	O	-1	17554526
21	O	-1	17554526
cocaine	B-Chemical	D003042	17554526
na@@	O	-1	17554526
i@@	O	-1	17554526
ve	O	-1	17554526
partic@@	O	-1	17554526
ip@@	O	-1	17554526
ants	O	-1	17554526
(C@@	O	-1	17554526
N@@	O	-1	17554526
),	O	-1	17554526
30	O	-1	17554526
oc@@	O	-1	17554526
ca@@	O	-1	17554526
sion@@	O	-1	17554526
al	O	-1	17554526
cocaine	B-Chemical	D003042	17554526
(@@	O	-1	17554526
O@@	O	-1	17554526
C@@	O	-1	17554526
),	O	-1	17554526
and	O	-1	17554526
4@@	O	-1	17554526
8	O	-1	17554526
reg@@	O	-1	17554526
ular	O	-1	17554526
rec@@	O	-1	17554526
re@@	O	-1	17554526
ation@@	O	-1	17554526
al	O	-1	17554526
cocaine	B-Chemical	D003042	17554526
(@@	O	-1	17554526
R@@	O	-1	17554526
C@@	O	-1	17554526
)	O	-1	17554526
us@@	O	-1	17554526
er@@	O	-1	17554526
s,	O	-1	17554526
were	O	-1	17554526
com@@	O	-1	17554526
pa@@	O	-1	17554526
red.	O	-1	17554526
An	O	-1	17554526
em@@	O	-1	17554526
o@@	O	-1	17554526
tional	O	-1	17554526
fac@@	O	-1	17554526
ial	O	-1	17554526
expression	O	-1	17554526
(@@	O	-1	17554526
E@@	O	-1	17554526
F@@	O	-1	17554526
E@@	O	-1	17554526
)	O	-1	17554526
t@@	O	-1	17554526
as@@	O	-1	17554526
k	O	-1	17554526
consist@@	O	-1	17554526
ing	O	-1	17554526
of	O	-1	17554526
a	O	-1	17554526
male	O	-1	17554526
and	O	-1	17554526
female	O	-1	17554526
fac@@	O	-1	17554526
e	O	-1	17554526
ex@@	O	-1	17554526
press@@	O	-1	17554526
ing	O	-1	17554526
six	O	-1	17554526
b@@	O	-1	17554526
a@@	O	-1	17554526
sic	O	-1	17554526
em@@	O	-1	17554526
o@@	O	-1	17554526
tions	O	-1	17554526
(@@	O	-1	17554526
h@@	O	-1	17554526
app@@	O	-1	17554526
in@@	O	-1	17554526
es@@	O	-1	17554526
s,	O	-1	17554526
sur@@	O	-1	17554526
pri@@	O	-1	17554526
se@@	O	-1	17554526
,	O	-1	17554526
s@@	O	-1	17554526
ad@@	O	-1	17554526
n@@	O	-1	17554526
es@@	O	-1	17554526
s,	O	-1	17554526
ang@@	O	-1	17554526
er,	O	-1	17554526
f@@	O	-1	17554526
ear@@	O	-1	17554526
,	O	-1	17554526
and	O	-1	17554526
dis@@	O	-1	17554526
gu@@	O	-1	17554526
st@@	O	-1	17554526
)	O	-1	17554526
was	O	-1	17554526
administ@@	O	-1	17554526
e@@	O	-1	17554526
red.	O	-1	17554526
M@@	O	-1	17554526
e@@	O	-1	17554526
an	O	-1	17554526
perc@@	O	-1	17554526
ent	O	-1	17554526
ac@@	O	-1	17554526
cur@@	O	-1	17554526
ac@@	O	-1	17554526
y	O	-1	17554526
and	O	-1	17554526
lat@@	O	-1	17554526
en@@	O	-1	17554526
ci@@	O	-1	17554526
es	O	-1	17554526
for	O	-1	17554526
cor@@	O	-1	17554526
rec@@	O	-1	17554526
t	O	-1	17554526
responses	O	-1	17554526
ac@@	O	-1	17554526
ros@@	O	-1	17554526
s	O	-1	17554526
e@@	O	-1	17554526
ight	O	-1	17554526
present@@	O	-1	17554526
ations	O	-1	17554526
of	O	-1	17554526
each	O	-1	17554526
b@@	O	-1	17554526
a@@	O	-1	17554526
sic	O	-1	17554526
em@@	O	-1	17554526
o@@	O	-1	17554526
tion	O	-1	17554526
were	O	-1	17554526
der@@	O	-1	17554526
i@@	O	-1	17554526
ved.	O	-1	17554526
P@@	O	-1	17554526
ar@@	O	-1	17554526
tic@@	O	-1	17554526
ip@@	O	-1	17554526
ants	O	-1	17554526
were	O	-1	17554526
also	O	-1	17554526
assessed	O	-1	17554526
with	O	-1	17554526
the	O	-1	17554526
"@@	O	-1	17554526
E@@	O	-1	17554526
y@@	O	-1	17554526
es	O	-1	17554526
t@@	O	-1	17554526
as@@	O	-1	17554526
k@@	O	-1	17554526
"	O	-1	17554526
to	O	-1	17554526
investigate	O	-1	17554526
their	O	-1	17554526
ability	O	-1	17554526
to	O	-1	17554526
reco@@	O	-1	17554526
gn@@	O	-1	17554526
iz@@	O	-1	17554526
e	O	-1	17554526
more	O	-1	17554526
comple@@	O	-1	17554526
x	O	-1	17554526
em@@	O	-1	17554526
o@@	O	-1	17554526
tional	O	-1	17554526
st@@	O	-1	17554526
ates	O	-1	17554526
and	O	-1	17554526
the	O	-1	17554526
S@@	O	-1	17554526
ym@@	O	-1	17554526
pto@@	O	-1	17554526
m	O	-1	17554526
Ch@@	O	-1	17554526
ec@@	O	-1	17554526
k@@	O	-1	17554526
L@@	O	-1	17554526
ist@@	O	-1	17554526
-@@	O	-1	17554526
9@@	O	-1	17554526
0-@@	O	-1	17554526
R@@	O	-1	17554526
ev@@	O	-1	17554526
is@@	O	-1	17554526
ed	O	-1	17554526
to	O	-1	17554526
meas@@	O	-1	17554526
ure	O	-1	17554526
psycho@@	O	-1	17554526
path@@	O	-1	17554526
olog@@	O	-1	17554526
y.	O	-1	17554526
RESULTS:	O	-1	17554526
There	O	-1	17554526
were	O	-1	17554526
no	O	-1	17554526
group	O	-1	17554526
differences	O	-1	17554526
in	O	-1	17554526
psycho@@	O	-1	17554526
path@@	O	-1	17554526
ology	O	-1	17554526
or	O	-1	17554526
"@@	O	-1	17554526
e@@	O	-1	17554526
y@@	O	-1	17554526
es	O	-1	17554526
t@@	O	-1	17554526
as@@	O	-1	17554526
k@@	O	-1	17554526
"	O	-1	17554526
perform@@	O	-1	17554526
ance@@	O	-1	17554526
,	O	-1	17554526
but	O	-1	17554526
the	O	-1	17554526
R@@	O	-1	17554526
C	O	-1	17554526
group@@	O	-1	17554526
,	O	-1	17554526
who	O	-1	17554526
o@@	O	-1	17554526
ther@@	O	-1	17554526
w@@	O	-1	17554526
is@@	O	-1	17554526
e	O	-1	17554526
had	O	-1	17554526
similar	O	-1	17554526
ill@@	O	-1	17554526
ic@@	O	-1	17554526
it	O	-1	17554526
subst@@	O	-1	17554526
ance	O	-1	17554526
use	O	-1	17554526
hist@@	O	-1	17554526
or@@	O	-1	17554526
i@@	O	-1	17554526
es	O	-1	17554526
to	O	-1	17554526
the	O	-1	17554526
O@@	O	-1	17554526
C	O	-1	17554526
group@@	O	-1	17554526
,	O	-1	17554526
ex@@	O	-1	17554526
hib@@	O	-1	17554526
ited	O	-1	17554526
impaired	B-Disease	D001925	17554526
fe@@	I-Disease	-1	17554526
ar	I-Disease	-1	17554526
reco@@	I-Disease	-1	17554526
gn@@	I-Disease	-1	17554526
ition	I-Disease	-1	17554526
ac@@	O	-1	17554526
cur@@	O	-1	17554526
ac@@	O	-1	17554526
y	O	-1	17554526
compared	O	-1	17554526
to	O	-1	17554526
the	O	-1	17554526
O@@	O	-1	17554526
C	O	-1	17554526
and	O	-1	17554526
C@@	O	-1	17554526
N	O	-1	17554526
groups.	O	-1	17554526
The	O	-1	17554526
R@@	O	-1	17554526
C	O	-1	17554526
group	O	-1	17554526
also	O	-1	17554526
cor@@	O	-1	17554526
rec@@	O	-1	17554526
tly	O	-1	17554526
identi@@	O	-1	17554526
fied	O	-1	17554526
ang@@	O	-1	17554526
er,	O	-1	17554526
f@@	O	-1	17554526
ear@@	O	-1	17554526
,	O	-1	17554526
h@@	O	-1	17554526
app@@	O	-1	17554526
in@@	O	-1	17554526
es@@	O	-1	17554526
s,	O	-1	17554526
and	O	-1	17554526
sur@@	O	-1	17554526
pri@@	O	-1	17554526
se@@	O	-1	17554526
,	O	-1	17554526
more	O	-1	17554526
s@@	O	-1	17554526
low@@	O	-1	17554526
ly	O	-1	17554526
than	O	-1	17554526
C@@	O	-1	17554526
N@@	O	-1	17554526
,	O	-1	17554526
but	O	-1	17554526
not	O	-1	17554526
O@@	O	-1	17554526
C	O	-1	17554526
partic@@	O	-1	17554526
ip@@	O	-1	17554526
ant@@	O	-1	17554526
s.	O	-1	17554526
The	O	-1	17554526
O@@	O	-1	17554526
C	O	-1	17554526
group	O	-1	17554526
was	O	-1	17554526
s@@	O	-1	17554526
lower	O	-1	17554526
than	O	-1	17554526
C@@	O	-1	17554526
N	O	-1	17554526
when	O	-1	17554526
cor@@	O	-1	17554526
rec@@	O	-1	17554526
tly	O	-1	17554526
identi@@	O	-1	17554526
f@@	O	-1	17554526
y@@	O	-1	17554526
ing	O	-1	17554526
dis@@	O	-1	17554526
gu@@	O	-1	17554526
st@@	O	-1	17554526
.	O	-1	17554526
The	O	-1	17554526
selective	O	-1	17554526
defic@@	B-Disease	D001925	17554526
it	I-Disease	-1	17554526
in	I-Disease	-1	17554526
fe@@	I-Disease	-1	17554526
ar	I-Disease	-1	17554526
reco@@	I-Disease	-1	17554526
gn@@	I-Disease	-1	17554526
ition	I-Disease	-1	17554526
ac@@	O	-1	17554526
cur@@	O	-1	17554526
ac@@	O	-1	17554526
y	O	-1	17554526
man@@	O	-1	17554526
if@@	O	-1	17554526
est@@	O	-1	17554526
ed	O	-1	17554526
by	O	-1	17554526
the	O	-1	17554526
R@@	O	-1	17554526
C	O	-1	17554526
group	O	-1	17554526
can@@	O	-1	17554526
not	O	-1	17554526
be	O	-1	17554526
expl@@	O	-1	17554526
ained	O	-1	17554526
by	O	-1	17554526
the	O	-1	17554526
sub@@	O	-1	17554526
acute	O	-1	17554526
effects	O	-1	17554526
of	O	-1	17554526
cocaine	B-Chemical	D003042	17554526
,	O	-1	17554526
or	O	-1	17554526
ec@@	B-Chemical	D018817	17554526
st@@	I-Chemical	-1	17554526
as@@	I-Chemical	-1	17554526
y	I-Chemical	-1	17554526
,	O	-1	17554526
because	O	-1	17554526
rec@@	O	-1	17554526
ent	O	-1	17554526
and	O	-1	17554526
less	O	-1	17554526
rec@@	O	-1	17554526
ent	O	-1	17554526
users	O	-1	17554526
of	O	-1	17554526
these	O	-1	17554526
drugs	O	-1	17554526
within	O	-1	17554526
this	O	-1	17554526
group	O	-1	17554526
were	O	-1	17554526
simil@@	O	-1	17554526
arly	O	-1	17554526
impa@@	O	-1	17554526
i@@	O	-1	17554526
red.	O	-1	17554526
P@@	O	-1	17554526
os@@	O	-1	17554526
sible	O	-1	17554526
par@@	O	-1	17554526
al@@	O	-1	17554526
le@@	O	-1	17554526
l@@	O	-1	17554526
s	O	-1	17554526
between	O	-1	17554526
R@@	O	-1	17554526
C	O	-1	17554526
users	O	-1	17554526
and	O	-1	17554526
psycho@@	B-Disease	D001523	17554526
path@@	I-Disease	-1	17554526
s	I-Disease	-1	17554526
with	O	-1	17554526
resp@@	O	-1	17554526
ect	O	-1	17554526
to	O	-1	17554526
impaired	B-Disease	D001925	17554526
fe@@	I-Disease	-1	17554526
ar	I-Disease	-1	17554526
reco@@	I-Disease	-1	17554526
gn@@	I-Disease	-1	17554526
ition	I-Disease	-1	17554526
,	O	-1	17554526
am@@	B-Disease	-1	17554526
y@@	I-Disease	-1	17554526
g@@	I-Disease	-1	17554526
d@@	I-Disease	-1	17554526
al@@	I-Disease	-1	17554526
a	I-Disease	-1	17554526
dysfunction	I-Disease	-1	17554526
,	O	-1	17554526
and	O	-1	17554526
e@@	O	-1	17554526
ti@@	O	-1	17554526
ology	O	-1	17554526
are	O	-1	17554526
discus@@	O	-1	17554526
sed.	O	-1	17554526

C@@	B-Disease	D003320	17721298
or@@	I-Disease	-1	17721298
ne@@	I-Disease	-1	17721298
al	I-Disease	-1	17721298
ul@@	I-Disease	-1	17721298
c@@	I-Disease	-1	17721298
ers	I-Disease	-1	17721298
associated	O	-1	17721298
with	O	-1	17721298
a@@	O	-1	17721298
er@@	O	-1	17721298
os@@	O	-1	17721298
ol@@	O	-1	17721298
ized	O	-1	17721298
c@@	B-Chemical	D016578	17721298
rac@@	I-Chemical	-1	17721298
k	I-Chemical	-1	17721298
cocaine	I-Chemical	-1	17721298
use.	O	-1	17721298
P@@	O	-1	17721298
U@@	O	-1	17721298
R@@	O	-1	17721298
P@@	O	-1	17721298
O@@	O	-1	17721298
S@@	O	-1	17721298
E:	O	-1	17721298
We	O	-1	17721298
report	O	-1	17721298
4	O	-1	17721298
cases	O	-1	17721298
of	O	-1	17721298
cor@@	B-Disease	D003320	17721298
ne@@	I-Disease	-1	17721298
al	I-Disease	-1	17721298
ul@@	I-Disease	-1	17721298
c@@	I-Disease	-1	17721298
ers	I-Disease	-1	17721298
associated	O	-1	17721298
with	O	-1	17721298
drug	B-Disease	D019966	17721298
ab@@	I-Disease	-1	17721298
use	I-Disease	-1	17721298
.	O	-1	17721298
The	O	-1	17721298
path@@	O	-1	17721298
o@@	O	-1	17721298
genesis	O	-1	17721298
of	O	-1	17721298
these	O	-1	17721298
ul@@	B-Disease	D014456	17721298
c@@	I-Disease	-1	17721298
ers	I-Disease	-1	17721298
and	O	-1	17721298
man@@	O	-1	17721298
ag@@	O	-1	17721298
ement	O	-1	17721298
of	O	-1	17721298
these	O	-1	17721298
patients	O	-1	17721298
are	O	-1	17721298
also	O	-1	17721298
revie@@	O	-1	17721298
we@@	O	-1	17721298
d.	O	-1	17721298
METHODS:	O	-1	17721298
Re@@	O	-1	17721298
vie@@	O	-1	17721298
w	O	-1	17721298
of	O	-1	17721298
all	O	-1	17721298
cases	O	-1	17721298
of	O	-1	17721298
cor@@	B-Disease	D003320	17721298
ne@@	I-Disease	-1	17721298
al	I-Disease	-1	17721298
ul@@	I-Disease	-1	17721298
c@@	I-Disease	-1	17721298
ers	I-Disease	-1	17721298
associated	O	-1	17721298
with	O	-1	17721298
drug	B-Disease	D019966	17721298
ab@@	I-Disease	-1	17721298
use	I-Disease	-1	17721298
seen	O	-1	17721298
at	O	-1	17721298
our	O	-1	17721298
insti@@	O	-1	17721298
tu@@	O	-1	17721298
tion	O	-1	17721298
from	O	-1	17721298
J@@	O	-1	17721298
ul@@	O	-1	17721298
y	O	-1	17721298
20@@	O	-1	17721298
0@@	O	-1	17721298
6	O	-1	17721298
to	O	-1	17721298
D@@	O	-1	17721298
ec@@	O	-1	17721298
emb@@	O	-1	17721298
er	O	-1	17721298
20@@	O	-1	17721298
0@@	O	-1	17721298
6@@	O	-1	17721298
.	O	-1	17721298
RESULTS:	O	-1	17721298
F@@	O	-1	17721298
our	O	-1	17721298
patients	O	-1	17721298
with	O	-1	17721298
cor@@	B-Disease	D003320	17721298
ne@@	I-Disease	-1	17721298
al	I-Disease	-1	17721298
ul@@	I-Disease	-1	17721298
c@@	I-Disease	-1	17721298
ers	I-Disease	-1	17721298
associated	O	-1	17721298
with	O	-1	17721298
c@@	B-Chemical	D016578	17721298
rac@@	I-Chemical	-1	17721298
k	I-Chemical	-1	17721298
cocaine	I-Chemical	-1	17721298
use	O	-1	17721298
were	O	-1	17721298
revie@@	O	-1	17721298
we@@	O	-1	17721298
d.	O	-1	17721298
All	O	-1	17721298
cor@@	B-Disease	D003320	17721298
ne@@	I-Disease	-1	17721298
al	I-Disease	-1	17721298
ul@@	I-Disease	-1	17721298
c@@	I-Disease	-1	17721298
ers	I-Disease	-1	17721298
were	O	-1	17721298
c@@	O	-1	17721298
ult@@	O	-1	17721298
ure@@	O	-1	17721298
d,	O	-1	17721298
and	O	-1	17721298
the	O	-1	17721298
patients	O	-1	17721298
were	O	-1	17721298
ad@@	O	-1	17721298
mit@@	O	-1	17721298
ted	O	-1	17721298
to	O	-1	17721298
the	O	-1	17721298
hospit@@	O	-1	17721298
al	O	-1	17721298
for	O	-1	17721298
int@@	O	-1	17721298
en@@	O	-1	17721298
sive	O	-1	17721298
to@@	O	-1	17721298
p@@	O	-1	17721298
ical	O	-1	17721298
anti@@	O	-1	17721298
bio@@	O	-1	17721298
tic	O	-1	17721298
treatment.	O	-1	17721298
E@@	O	-1	17721298
ach	O	-1	17721298
patient	O	-1	17721298
received	O	-1	17721298
com@@	O	-1	17721298
pre@@	O	-1	17721298
h@@	O	-1	17721298
en@@	O	-1	17721298
sive	O	-1	17721298
heal@@	O	-1	17721298
th	O	-1	17721298
ca@@	O	-1	17721298
re,	O	-1	17721298
including	O	-1	17721298
med@@	O	-1	17721298
ical	O	-1	17721298
and	O	-1	17721298
subst@@	B-Disease	D019966	17721298
ance	I-Disease	-1	17721298
ab@@	I-Disease	-1	17721298
use	I-Disease	-1	17721298
con@@	O	-1	17721298
s@@	O	-1	17721298
ult@@	O	-1	17721298
ations.	O	-1	17721298
S@@	O	-1	17721298
tre@@	O	-1	17721298
pto@@	O	-1	17721298
co@@	O	-1	17721298
c@@	O	-1	17721298
c@@	O	-1	17721298
al	O	-1	17721298
org@@	O	-1	17721298
an@@	O	-1	17721298
is@@	O	-1	17721298
ms	O	-1	17721298
were	O	-1	17721298
found	O	-1	17721298
in	O	-1	17721298
3	O	-1	17721298
cases	O	-1	17721298
and	O	-1	17721298
C@@	O	-1	17721298
ap@@	O	-1	17721298
n@@	O	-1	17721298
ocyto@@	O	-1	17721298
ph@@	O	-1	17721298
ag@@	O	-1	17721298
a	O	-1	17721298
and	O	-1	17721298
B@@	O	-1	17721298
re@@	O	-1	17721298
vi@@	O	-1	17721298
bac@@	O	-1	17721298
ter@@	O	-1	17721298
i@@	O	-1	17721298
um	O	-1	17721298
cas@@	O	-1	17721298
e@@	O	-1	17721298
i	O	-1	17721298
in	O	-1	17721298
1	O	-1	17721298
patient@@	O	-1	17721298
.	O	-1	17721298
The	O	-1	17721298
inf@@	B-Disease	D007239	17721298
ec@@	I-Disease	-1	17721298
tions	I-Disease	-1	17721298
respon@@	O	-1	17721298
ded	O	-1	17721298
to	O	-1	17721298
anti@@	O	-1	17721298
bio@@	O	-1	17721298
tic	O	-1	17721298
treatment.	O	-1	17721298
Two	O	-1	17721298
patients	O	-1	17721298
ne@@	O	-1	17721298
ed@@	O	-1	17721298
ed	O	-1	17721298
a	O	-1	17721298
lat@@	O	-1	17721298
eral	O	-1	17721298
t@@	O	-1	17721298
ar@@	O	-1	17721298
s@@	O	-1	17721298
or@@	O	-1	17721298
r@@	O	-1	17721298
ha@@	O	-1	17721298
ph@@	O	-1	17721298
y	O	-1	17721298
for	O	-1	17721298
per@@	O	-1	17721298
sist@@	O	-1	17721298
ent	O	-1	17721298
epi@@	B-Disease	-1	17721298
thelial	I-Disease	-1	17721298
def@@	I-Disease	-1	17721298
ects	I-Disease	-1	17721298
.	O	-1	17721298
CONCLUSIONS:	O	-1	17721298
A@@	O	-1	17721298
er@@	O	-1	17721298
os@@	O	-1	17721298
ol@@	O	-1	17721298
ized	O	-1	17721298
c@@	B-Chemical	D016578	17721298
rac@@	I-Chemical	-1	17721298
k	I-Chemical	-1	17721298
cocaine	I-Chemical	-1	17721298
use	O	-1	17721298
can	O	-1	17721298
be	O	-1	17721298
associated	O	-1	17721298
with	O	-1	17721298
the	O	-1	17721298
development	O	-1	17721298
of	O	-1	17721298
cor@@	B-Disease	D003320	17721298
ne@@	I-Disease	-1	17721298
al	I-Disease	-1	17721298
ul@@	I-Disease	-1	17721298
c@@	I-Disease	-1	17721298
ers	I-Disease	-1	17721298
.	O	-1	17721298
D@@	B-Disease	D019966	17721298
ru@@	I-Disease	-1	17721298
g	I-Disease	-1	17721298
ab@@	I-Disease	-1	17721298
use	I-Disease	-1	17721298
pro@@	O	-1	17721298
vi@@	O	-1	17721298
des	O	-1	17721298
addi@@	O	-1	17721298
tional	O	-1	17721298
ch@@	O	-1	17721298
all@@	O	-1	17721298
en@@	O	-1	17721298
g@@	O	-1	17721298
es	O	-1	17721298
for	O	-1	17721298
man@@	O	-1	17721298
ag@@	O	-1	17721298
em@@	O	-1	17721298
ent@@	O	-1	17721298
.	O	-1	17721298
N@@	O	-1	17721298
o@@	O	-1	17721298
t	O	-1	17721298
only	O	-1	17721298
treatment	O	-1	17721298
of	O	-1	17721298
their	O	-1	17721298
inf@@	B-Disease	D007239	17721298
ec@@	I-Disease	-1	17721298
tions	I-Disease	-1	17721298
but	O	-1	17721298
also	O	-1	17721298
the	O	-1	17721298
over@@	O	-1	17721298
all	O	-1	17721298
po@@	O	-1	17721298
or	O	-1	17721298
heal@@	O	-1	17721298
th	O	-1	17721298
of	O	-1	17721298
the	O	-1	17721298
patients	O	-1	17721298
and	O	-1	17721298
increased	O	-1	17721298
risk	O	-1	17721298
of	O	-1	17721298
non@@	O	-1	17721298
com@@	O	-1	17721298
pl@@	O	-1	17721298
i@@	O	-1	17721298
ance	O	-1	17721298
need	O	-1	17721298
to	O	-1	17721298
be	O	-1	17721298
ad@@	O	-1	17721298
d@@	O	-1	17721298
res@@	O	-1	17721298
sed.	O	-1	17721298
Com@@	O	-1	17721298
pre@@	O	-1	17721298
h@@	O	-1	17721298
en@@	O	-1	17721298
sive	O	-1	17721298
car@@	O	-1	17721298
e	O	-1	17721298
may	O	-1	17721298
prov@@	O	-1	17721298
ide	O	-1	17721298
the	O	-1	17721298
patient	O	-1	17721298
the	O	-1	17721298
op@@	O	-1	17721298
port@@	O	-1	17721298
un@@	O	-1	17721298
ity	O	-1	17721298
to	O	-1	17721298
discontinu@@	O	-1	17721298
e	O	-1	17721298
their	O	-1	17721298
subst@@	B-Disease	D019966	17721298
ance	I-Disease	-1	17721298
ab@@	I-Disease	-1	17721298
use	I-Disease	-1	17721298
,	O	-1	17721298
impro@@	O	-1	17721298
ve	O	-1	17721298
their	O	-1	17721298
over@@	O	-1	17721298
all	O	-1	17721298
health@@	O	-1	17721298
,	O	-1	17721298
and	O	-1	17721298
prev@@	O	-1	17721298
ent	O	-1	17721298
f@@	O	-1	17721298
ut@@	O	-1	17721298
ure	O	-1	17721298
cor@@	O	-1	17721298
ne@@	O	-1	17721298
al	O	-1	17721298
complic@@	O	-1	17721298
ations.	O	-1	17721298

L@@	B-Chemical	C026098	18341442
e@@	I-Chemical	-1	18341442
ve@@	I-Chemical	-1	18341442
ti@@	I-Chemical	-1	18341442
rac@@	I-Chemical	-1	18341442
et@@	I-Chemical	-1	18341442
am	I-Chemical	-1	18341442
as	O	-1	18341442
an	O	-1	18341442
adj@@	O	-1	18341442
unc@@	O	-1	18341442
t	O	-1	18341442
to	O	-1	18341442
phenobarbit@@	B-Chemical	D010634	18341442
al	I-Chemical	-1	18341442
treatment	O	-1	18341442
in	O	-1	18341442
cat@@	O	-1	18341442
s	O	-1	18341442
with	O	-1	18341442
sus@@	O	-1	18341442
p@@	O	-1	18341442
ected	O	-1	18341442
i@@	B-Disease	C562694	18341442
di@@	I-Disease	-1	18341442
o@@	I-Disease	-1	18341442
path@@	I-Disease	-1	18341442
ic	I-Disease	-1	18341442
epilep@@	I-Disease	-1	18341442
sy	I-Disease	-1	18341442
.	O	-1	18341442
OBJECTIVE:	O	-1	18341442
To	O	-1	18341442
ass@@	O	-1	18341442
ess	O	-1	18341442
pharmac@@	O	-1	18341442
o@@	O	-1	18341442
kine@@	O	-1	18341442
tic@@	O	-1	18341442
s,	O	-1	18341442
efficac@@	O	-1	18341442
y,	O	-1	18341442
and	O	-1	18341442
toler@@	O	-1	18341442
ability	O	-1	18341442
of	O	-1	18341442
oral	O	-1	18341442
le@@	B-Chemical	C026098	18341442
ve@@	I-Chemical	-1	18341442
ti@@	I-Chemical	-1	18341442
rac@@	I-Chemical	-1	18341442
et@@	I-Chemical	-1	18341442
am	I-Chemical	-1	18341442
administered	O	-1	18341442
as	O	-1	18341442
an	O	-1	18341442
adj@@	O	-1	18341442
unc@@	O	-1	18341442
t	O	-1	18341442
to	O	-1	18341442
phenobarbit@@	B-Chemical	D010634	18341442
al	I-Chemical	-1	18341442
treatment	O	-1	18341442
in	O	-1	18341442
cat@@	O	-1	18341442
s	O	-1	18341442
with	O	-1	18341442
po@@	O	-1	18341442
or@@	O	-1	18341442
ly	O	-1	18341442
controlled	O	-1	18341442
sus@@	O	-1	18341442
p@@	O	-1	18341442
ected	O	-1	18341442
i@@	B-Disease	C562694	18341442
di@@	I-Disease	-1	18341442
o@@	I-Disease	-1	18341442
path@@	I-Disease	-1	18341442
ic	I-Disease	-1	18341442
epilep@@	I-Disease	-1	18341442
sy	I-Disease	-1	18341442
.	O	-1	18341442
D@@	O	-1	18341442
ES@@	O	-1	18341442
I@@	O	-1	18341442
G@@	O	-1	18341442
N@@	O	-1	18341442
-@@	O	-1	18341442
O@@	O	-1	18341442
pen@@	O	-1	18341442
-@@	O	-1	18341442
l@@	O	-1	18341442
a@@	O	-1	18341442
be@@	O	-1	18341442
l@@	O	-1	18341442
,	O	-1	18341442
non@@	O	-1	18341442
compar@@	O	-1	18341442
ative	O	-1	18341442
clinical	O	-1	18341442
tri@@	O	-1	18341442
al.	O	-1	18341442
AN@@	O	-1	18341442
I@@	O	-1	18341442
MA@@	O	-1	18341442
L@@	O	-1	18341442
S:	O	-1	18341442
12	O	-1	18341442
cat@@	O	-1	18341442
s	O	-1	18341442
sus@@	O	-1	18341442
p@@	O	-1	18341442
ected	O	-1	18341442
to	O	-1	18341442
have	O	-1	18341442
i@@	B-Disease	C562694	18341442
di@@	I-Disease	-1	18341442
o@@	I-Disease	-1	18341442
path@@	I-Disease	-1	18341442
ic	I-Disease	-1	18341442
epilep@@	I-Disease	-1	18341442
sy	I-Disease	-1	18341442
that	O	-1	18341442
was	O	-1	18341442
po@@	O	-1	18341442
or@@	O	-1	18341442
ly	O	-1	18341442
controlled	O	-1	18341442
with	O	-1	18341442
phenobarbit@@	B-Chemical	D010634	18341442
al	I-Chemical	-1	18341442
or	O	-1	18341442
that	O	-1	18341442
had	O	-1	18341442
un@@	O	-1	18341442
ac@@	O	-1	18341442
ce@@	O	-1	18341442
pt@@	O	-1	18341442
able	O	-1	18341442
adverse	O	-1	18341442
effects	O	-1	18341442
when	O	-1	18341442
treated	O	-1	18341442
with	O	-1	18341442
phenobarbit@@	B-Chemical	D010634	18341442
al	I-Chemical	-1	18341442
.	O	-1	18341442
P@@	O	-1	18341442
RO@@	O	-1	18341442
C@@	O	-1	18341442
E@@	O	-1	18341442
D@@	O	-1	18341442
U@@	O	-1	18341442
R@@	O	-1	18341442
E@@	O	-1	18341442
S:	O	-1	18341442
C@@	O	-1	18341442
at@@	O	-1	18341442
s	O	-1	18341442
were	O	-1	18341442
treated	O	-1	18341442
with	O	-1	18341442
le@@	B-Chemical	C026098	18341442
ve@@	I-Chemical	-1	18341442
ti@@	I-Chemical	-1	18341442
rac@@	I-Chemical	-1	18341442
et@@	I-Chemical	-1	18341442
am	I-Chemical	-1	18341442
(2@@	O	-1	18341442
0	O	-1	18341442
mg/kg	O	-1	18341442
[@@	O	-1	18341442
9.@@	O	-1	18341442
1	O	-1	18341442
mg/@@	O	-1	18341442
l@@	O	-1	18341442
b@@	O	-1	18341442
]@@	O	-1	18341442
,	O	-1	18341442
P@@	O	-1	18341442
O@@	O	-1	18341442
,	O	-1	18341442
q	O	-1	18341442
8	O	-1	18341442
h@@	O	-1	18341442
).	O	-1	18341442
After	O	-1	18341442
a	O	-1	18341442
minim@@	O	-1	18341442
um	O	-1	18341442
of	O	-1	18341442
1	O	-1	18341442
week	O	-1	18341442
of	O	-1	18341442
treatment,	O	-1	18341442
serum	O	-1	18341442
le@@	B-Chemical	C026098	18341442
ve@@	I-Chemical	-1	18341442
ti@@	I-Chemical	-1	18341442
rac@@	I-Chemical	-1	18341442
et@@	I-Chemical	-1	18341442
am	I-Chemical	-1	18341442
concentrations	O	-1	18341442
were	O	-1	18341442
measured	O	-1	18341442
before	O	-1	18341442
and	O	-1	18341442
2,	O	-1	18341442
4@@	O	-1	18341442
,	O	-1	18341442
and	O	-1	18341442
6	O	-1	18341442
hours	O	-1	18341442
after	O	-1	18341442
drug	O	-1	18341442
administr@@	O	-1	18341442
ation,	O	-1	18341442
and	O	-1	18341442
maxim@@	O	-1	18341442
um	O	-1	18341442
and	O	-1	18341442
minim@@	O	-1	18341442
um	O	-1	18341442
serum	O	-1	18341442
concentrations	O	-1	18341442
and	O	-1	18341442
el@@	O	-1	18341442
im@@	O	-1	18341442
in@@	O	-1	18341442
ation	O	-1	18341442
h@@	O	-1	18341442
al@@	O	-1	18341442
f@@	O	-1	18341442
-@@	O	-1	18341442
lif@@	O	-1	18341442
e	O	-1	18341442
were	O	-1	18341442
calc@@	O	-1	18341442
ul@@	O	-1	18341442
ated.	O	-1	18341442
S@@	B-Disease	D012640	18341442
e@@	I-Disease	-1	18341442
iz@@	I-Disease	-1	18341442
ure	I-Disease	-1	18341442
frequ@@	O	-1	18341442
en@@	O	-1	18341442
ci@@	O	-1	18341442
es	O	-1	18341442
before	O	-1	18341442
and	O	-1	18341442
after	O	-1	18341442
initi@@	O	-1	18341442
ation	O	-1	18341442
of	O	-1	18341442
le@@	B-Chemical	C026098	18341442
ve@@	I-Chemical	-1	18341442
ti@@	I-Chemical	-1	18341442
rac@@	I-Chemical	-1	18341442
et@@	I-Chemical	-1	18341442
am	I-Chemical	-1	18341442
treatment	O	-1	18341442
were	O	-1	18341442
com@@	O	-1	18341442
pa@@	O	-1	18341442
re@@	O	-1	18341442
d,	O	-1	18341442
and	O	-1	18341442
adverse	O	-1	18341442
effects	O	-1	18341442
were	O	-1	18341442
recor@@	O	-1	18341442
de@@	O	-1	18341442
d.	O	-1	18341442
RESULTS:	O	-1	18341442
M@@	O	-1	18341442
edi@@	O	-1	18341442
an	O	-1	18341442
maxim@@	O	-1	18341442
um	O	-1	18341442
serum	O	-1	18341442
le@@	B-Chemical	C026098	18341442
ve@@	I-Chemical	-1	18341442
ti@@	I-Chemical	-1	18341442
rac@@	I-Chemical	-1	18341442
et@@	I-Chemical	-1	18341442
am	I-Chemical	-1	18341442
concentration	O	-1	18341442
was	O	-1	18341442
2@@	O	-1	18341442
5.@@	O	-1	18341442
5	O	-1	18341442
micro@@	O	-1	18341442
g/@@	O	-1	18341442
m@@	O	-1	18341442
L@@	O	-1	18341442
,	O	-1	18341442
median	O	-1	18341442
minim@@	O	-1	18341442
um	O	-1	18341442
serum	O	-1	18341442
le@@	B-Chemical	C026098	18341442
ve@@	I-Chemical	-1	18341442
ti@@	I-Chemical	-1	18341442
rac@@	I-Chemical	-1	18341442
et@@	I-Chemical	-1	18341442
am	I-Chemical	-1	18341442
concentration	O	-1	18341442
was	O	-1	18341442
8.@@	O	-1	18341442
3	O	-1	18341442
micro@@	O	-1	18341442
g/@@	O	-1	18341442
m@@	O	-1	18341442
L@@	O	-1	18341442
,	O	-1	18341442
and	O	-1	18341442
median	O	-1	18341442
el@@	O	-1	18341442
im@@	O	-1	18341442
in@@	O	-1	18341442
ation	O	-1	18341442
h@@	O	-1	18341442
al@@	O	-1	18341442
f@@	O	-1	18341442
-@@	O	-1	18341442
lif@@	O	-1	18341442
e	O	-1	18341442
was	O	-1	18341442
2.@@	O	-1	18341442
9	O	-1	18341442
hour@@	O	-1	18341442
s.	O	-1	18341442
M@@	O	-1	18341442
edi@@	O	-1	18341442
an	O	-1	18341442
seizure	B-Disease	D012640	18341442
frequency	O	-1	18341442
prior	O	-1	18341442
to	O	-1	18341442
treatment	O	-1	18341442
with	O	-1	18341442
le@@	B-Chemical	C026098	18341442
ve@@	I-Chemical	-1	18341442
ti@@	I-Chemical	-1	18341442
rac@@	I-Chemical	-1	18341442
et@@	I-Chemical	-1	18341442
am	I-Chemical	-1	18341442
(2@@	O	-1	18341442
.@@	O	-1	18341442
1	O	-1	18341442
seizures	B-Disease	D012640	18341442
/@@	O	-1	18341442
mo@@	O	-1	18341442
)	O	-1	18341442
was	O	-1	18341442
significantly	O	-1	18341442
higher	O	-1	18341442
than	O	-1	18341442
median	O	-1	18341442
seizure	B-Disease	D012640	18341442
frequency	O	-1	18341442
after	O	-1	18341442
initi@@	O	-1	18341442
ation	O	-1	18341442
of	O	-1	18341442
le@@	B-Chemical	C026098	18341442
ve@@	I-Chemical	-1	18341442
ti@@	I-Chemical	-1	18341442
rac@@	I-Chemical	-1	18341442
et@@	I-Chemical	-1	18341442
am	I-Chemical	-1	18341442
treatment	O	-1	18341442
(0.@@	O	-1	18341442
4@@	O	-1	18341442
2	O	-1	18341442
seizures	B-Disease	D012640	18341442
/@@	O	-1	18341442
mo@@	O	-1	18341442
),	O	-1	18341442
and	O	-1	18341442
7	O	-1	18341442
of	O	-1	18341442
10	O	-1	18341442
cat@@	O	-1	18341442
s	O	-1	18341442
were	O	-1	18341442
cl@@	O	-1	18341442
assi@@	O	-1	18341442
fied	O	-1	18341442
as	O	-1	18341442
ha@@	O	-1	18341442
ving	O	-1	18341442
respon@@	O	-1	18341442
ded	O	-1	18341442
to	O	-1	18341442
le@@	B-Chemical	C026098	18341442
ve@@	I-Chemical	-1	18341442
ti@@	I-Chemical	-1	18341442
rac@@	I-Chemical	-1	18341442
et@@	I-Chemical	-1	18341442
am	I-Chemical	-1	18341442
treatment	O	-1	18341442
(@@	O	-1	18341442
i@@	O	-1	18341442
e,	O	-1	18341442
reduction	O	-1	18341442
in	O	-1	18341442
seizure	B-Disease	D012640	18341442
frequency	O	-1	18341442
of	O	-1	18341442
>@@	O	-1	18341442
or@@	O	-1	18341442
=@@	O	-1	18341442
50@@	O	-1	18341442
%).	O	-1	18341442
Two	O	-1	18341442
cat@@	O	-1	18341442
s	O	-1	18341442
had	O	-1	18341442
transi@@	O	-1	18341442
ent	O	-1	18341442
le@@	B-Disease	D053609	18341442
th@@	I-Disease	-1	18341442
arg@@	I-Disease	-1	18341442
y	I-Disease	-1	18341442
and	O	-1	18341442
in@@	B-Disease	-1	18341442
app@@	I-Disease	-1	18341442
et@@	I-Disease	-1	18341442
ence	I-Disease	-1	18341442
.	O	-1	18341442
CONCLUSION@@	O	-1	18341442
S	O	-1	18341442
AN@@	O	-1	18341442
D	O	-1	18341442
CL@@	O	-1	18341442
IN@@	O	-1	18341442
I@@	O	-1	18341442
CA@@	O	-1	18341442
L	O	-1	18341442
R@@	O	-1	18341442
E@@	O	-1	18341442
L@@	O	-1	18341442
E@@	O	-1	18341442
V@@	O	-1	18341442
AN@@	O	-1	18341442
C@@	O	-1	18341442
E:	O	-1	18341442
R@@	O	-1	18341442
es@@	O	-1	18341442
ult@@	O	-1	18341442
s	O	-1	18341442
suggested	O	-1	18341442
that	O	-1	18341442
le@@	B-Chemical	C026098	18341442
ve@@	I-Chemical	-1	18341442
ti@@	I-Chemical	-1	18341442
rac@@	I-Chemical	-1	18341442
et@@	I-Chemical	-1	18341442
am	I-Chemical	-1	18341442
is	O	-1	18341442
well	O	-1	18341442
toler@@	O	-1	18341442
ated	O	-1	18341442
in	O	-1	18341442
cat@@	O	-1	18341442
s	O	-1	18341442
and	O	-1	18341442
may	O	-1	18341442
be	O	-1	18341442
use@@	O	-1	18341442
ful	O	-1	18341442
as	O	-1	18341442
an	O	-1	18341442
adj@@	O	-1	18341442
unc@@	O	-1	18341442
t	O	-1	18341442
to	O	-1	18341442
phenobarbit@@	B-Chemical	D010634	18341442
al	I-Chemical	-1	18341442
treatment	O	-1	18341442
in	O	-1	18341442
cat@@	O	-1	18341442
s	O	-1	18341442
with	O	-1	18341442
i@@	B-Disease	C562694	18341442
di@@	I-Disease	-1	18341442
o@@	I-Disease	-1	18341442
path@@	I-Disease	-1	18341442
ic	I-Disease	-1	18341442
epilep@@	I-Disease	-1	18341442
sy	I-Disease	-1	18341442
.	O	-1	18341442

B@@	O	-1	19681452
il@@	O	-1	19681452
ateral	O	-1	19681452
haem@@	B-Disease	D002543	19681452
or@@	I-Disease	-1	19681452
rh@@	I-Disease	-1	19681452
ag@@	I-Disease	-1	19681452
ic	I-Disease	-1	19681452
infarction	I-Disease	-1	19681452
of	I-Disease	-1	19681452
the	I-Disease	-1	19681452
glo@@	I-Disease	-1	19681452
bu@@	I-Disease	-1	19681452
s	I-Disease	-1	19681452
p@@	I-Disease	-1	19681452
all@@	I-Disease	-1	19681452
id@@	I-Disease	-1	19681452
us	I-Disease	-1	19681452
haem@@	B-Disease	D020520	19681452
or@@	I-Disease	-1	19681452
rh@@	I-Disease	-1	19681452
ag@@	I-Disease	-1	19681452
ic	I-Disease	-1	19681452
infarction	I-Disease	-1	19681452
of	I-Disease	-1	19681452
the	I-Disease	-1	19681452
glo@@	I-Disease	-1	19681452
bu@@	I-Disease	-1	19681452
s	I-Disease	-1	19681452
p@@	I-Disease	-1	19681452
all@@	I-Disease	-1	19681452
id@@	I-Disease	-1	19681452
us	I-Disease	-1	19681452
after	O	-1	19681452
cocaine	B-Chemical	D003042	19681452
and	O	-1	19681452
alco@@	B-Chemical	D000431	19681452
hol	I-Chemical	-1	19681452
in@@	O	-1	19681452
toxic@@	O	-1	19681452
ation.	O	-1	19681452
C@@	B-Chemical	D003042	19681452
oc@@	I-Chemical	-1	19681452
aine	I-Chemical	-1	19681452
is	O	-1	19681452
a	O	-1	19681452
risk	O	-1	19681452
factor	O	-1	19681452
for	O	-1	19681452
both	O	-1	19681452
ischem@@	B-Disease	D002544	19681452
ic	I-Disease	-1	19681452
and	I-Disease	-1	19681452
haem@@	I-Disease	-1	19681452
or@@	I-Disease	-1	19681452
rh@@	I-Disease	-1	19681452
ag@@	I-Disease	-1	19681452
ic	I-Disease	-1	19681452
strok@@	I-Disease	-1	19681452
e	I-Disease	-1	19681452
ischem@@	B-Disease	D020521	19681452
ic	I-Disease	-1	19681452
and	I-Disease	-1	19681452
haem@@	I-Disease	-1	19681452
or@@	I-Disease	-1	19681452
rh@@	I-Disease	-1	19681452
ag@@	I-Disease	-1	19681452
ic	I-Disease	-1	19681452
strok@@	I-Disease	-1	19681452
e	I-Disease	-1	19681452
.	O	-1	19681452
We	O	-1	19681452
present	O	-1	19681452
the	O	-1	19681452
case	O	-1	19681452
of	O	-1	19681452
a	O	-1	19681452
3@@	O	-1	19681452
1-@@	O	-1	19681452
year-old	O	-1	19681452
man	O	-1	19681452
with	O	-1	19681452
bil@@	O	-1	19681452
ateral	O	-1	19681452
ischem@@	B-Disease	D002545	19681452
ia	I-Disease	-1	19681452
of	I-Disease	-1	19681452
the	I-Disease	-1	19681452
glo@@	I-Disease	-1	19681452
bu@@	I-Disease	-1	19681452
s	I-Disease	-1	19681452
p@@	I-Disease	-1	19681452
all@@	I-Disease	-1	19681452
id@@	I-Disease	-1	19681452
us	I-Disease	-1	19681452
after	O	-1	19681452
ex@@	O	-1	19681452
ces@@	O	-1	19681452
sive	O	-1	19681452
alco@@	B-Chemical	D000431	19681452
hol	I-Chemical	-1	19681452
and	O	-1	19681452
int@@	O	-1	19681452
ran@@	O	-1	19681452
as@@	O	-1	19681452
al	O	-1	19681452
cocaine	B-Chemical	D003042	19681452
use.	O	-1	19681452
D@@	O	-1	19681452
ru@@	O	-1	19681452
g@@	O	-1	19681452
-@@	O	-1	19681452
related	O	-1	19681452
glo@@	B-Disease	D020520	19681452
bu@@	I-Disease	-1	19681452
s	I-Disease	-1	19681452
p@@	I-Disease	-1	19681452
all@@	I-Disease	-1	19681452
id@@	I-Disease	-1	19681452
us	I-Disease	-1	19681452
infarc@@	I-Disease	-1	19681452
tions	I-Disease	-1	19681452
are	O	-1	19681452
most	O	-1	19681452
often	O	-1	19681452
associated	O	-1	19681452
with	O	-1	19681452
h@@	B-Chemical	D003932	19681452
ero@@	I-Chemical	-1	19681452
in	I-Chemical	-1	19681452
.	O	-1	19681452
B@@	O	-1	19681452
il@@	O	-1	19681452
ateral	O	-1	19681452
bas@@	B-Disease	D020520	19681452
al	I-Disease	-1	19681452
g@@	I-Disease	-1	19681452
ang@@	I-Disease	-1	19681452
li@@	I-Disease	-1	19681452
a	I-Disease	-1	19681452
infarc@@	I-Disease	-1	19681452
ts	I-Disease	-1	19681452
after	O	-1	19681452
the	O	-1	19681452
use	O	-1	19681452
of	O	-1	19681452
cocaine	B-Chemical	D003042	19681452
,	O	-1	19681452
without	O	-1	19681452
con@@	O	-1	19681452
current	O	-1	19681452
h@@	B-Chemical	D003932	19681452
ero@@	I-Chemical	-1	19681452
in	I-Chemical	-1	19681452
use@@	O	-1	19681452
,	O	-1	19681452
have	O	-1	19681452
ne@@	O	-1	19681452
ver	O	-1	19681452
been	O	-1	19681452
repor@@	O	-1	19681452
ted.	O	-1	19681452
In	O	-1	19681452
our	O	-1	19681452
patient@@	O	-1	19681452
,	O	-1	19681452
transi@@	O	-1	19681452
ent	O	-1	19681452
cardiac	B-Disease	D001145	19681452
arrhyth@@	I-Disease	-1	19681452
mia	I-Disease	-1	19681452
or	O	-1	19681452
respiratory	B-Disease	D012131	19681452
dysfunction	I-Disease	-1	19681452
related	O	-1	19681452
to	O	-1	19681452
cocaine	B-Chemical	D003042	19681452
and/or	O	-1	19681452
eth@@	B-Chemical	D000431	19681452
an@@	I-Chemical	-1	19681452
ol	I-Chemical	-1	19681452
use	O	-1	19681452
were	O	-1	19681452
the	O	-1	19681452
most	O	-1	19681452
likely	O	-1	19681452
causes	O	-1	19681452
of	O	-1	19681452
cerebral	B-Disease	-1	19681452
hypo@@	I-Disease	-1	19681452
per@@	I-Disease	-1	19681452
f@@	I-Disease	-1	19681452
usion	I-Disease	-1	19681452
.	O	-1	19681452

Ac@@	B-Disease	D058186	20009434
ute	I-Disease	-1	20009434
renal	I-Disease	-1	20009434
failure	I-Disease	-1	20009434
after	O	-1	20009434
high-dose	O	-1	20009434
meth@@	B-Chemical	D008727	20009434
ot@@	I-Chemical	-1	20009434
re@@	I-Chemical	-1	20009434
x@@	I-Chemical	-1	20009434
ate	I-Chemical	-1	20009434
therapy	O	-1	20009434
in	O	-1	20009434
a	O	-1	20009434
patient	O	-1	20009434
with	O	-1	20009434
i@@	O	-1	20009434
le@@	O	-1	20009434
ost@@	O	-1	20009434
om@@	O	-1	20009434
y.	O	-1	20009434
H@@	O	-1	20009434
igh@@	O	-1	20009434
-@@	O	-1	20009434
dose	O	-1	20009434
meth@@	B-Chemical	D008727	20009434
ot@@	I-Chemical	-1	20009434
re@@	I-Chemical	-1	20009434
x@@	I-Chemical	-1	20009434
ate	I-Chemical	-1	20009434
(@@	O	-1	20009434
H@@	O	-1	20009434
D@@	O	-1	20009434
-	O	-1	20009434
M@@	B-Chemical	D008727	20009434
T@@	I-Chemical	-1	20009434
X	I-Chemical	-1	20009434
)	O	-1	20009434
is	O	-1	20009434
an	O	-1	20009434
important	O	-1	20009434
treatment	O	-1	20009434
for	O	-1	20009434
B@@	B-Disease	D002051	20009434
ur@@	I-Disease	-1	20009434
k@@	I-Disease	-1	20009434
it@@	I-Disease	-1	20009434
t	I-Disease	-1	20009434
lymph@@	I-Disease	-1	20009434
oma	I-Disease	-1	20009434
,	O	-1	20009434
but	O	-1	20009434
can	O	-1	20009434
cause	O	-1	20009434
hepatic	B-Disease	D056486	20009434
and	I-Disease	-1	20009434
renal	I-Disease	-1	20009434
toxicity	I-Disease	-1	20009434
hepatic	B-Disease	D007674	20009434
and	I-Disease	-1	20009434
renal	I-Disease	-1	20009434
toxicity	I-Disease	-1	20009434
when	O	-1	20009434
its	O	-1	20009434
clear@@	O	-1	20009434
ance	O	-1	20009434
is	O	-1	20009434
del@@	O	-1	20009434
ay@@	O	-1	20009434
ed.	O	-1	20009434
We	O	-1	20009434
report	O	-1	20009434
a	O	-1	20009434
case	O	-1	20009434
of	O	-1	20009434
acute	B-Disease	D058186	20009434
renal	I-Disease	-1	20009434
failure	I-Disease	-1	20009434
after	O	-1	20009434
H@@	O	-1	20009434
D@@	O	-1	20009434
-	O	-1	20009434
M@@	B-Chemical	D008727	20009434
T@@	I-Chemical	-1	20009434
X	I-Chemical	-1	20009434
therapy	O	-1	20009434
in	O	-1	20009434
a	O	-1	20009434
patient	O	-1	20009434
with	O	-1	20009434
i@@	O	-1	20009434
le@@	O	-1	20009434
ost@@	O	-1	20009434
om@@	O	-1	20009434
y,	O	-1	20009434
The	O	-1	20009434
patient	O	-1	20009434
was	O	-1	20009434
a	O	-1	20009434
3-@@	O	-1	20009434
year-old	O	-1	20009434
bo@@	O	-1	20009434
y	O	-1	20009434
who	O	-1	20009434
had	O	-1	20009434
received	O	-1	20009434
a	O	-1	20009434
li@@	O	-1	20009434
v@@	O	-1	20009434
ing@@	O	-1	20009434
-@@	O	-1	20009434
related	O	-1	20009434
liver	O	-1	20009434
transplant@@	O	-1	20009434
ation	O	-1	20009434
for	O	-1	20009434
con@@	O	-1	20009434
gen@@	O	-1	20009434
it@@	O	-1	20009434
al	O	-1	20009434
bil@@	B-Disease	D001656	20009434
i@@	I-Disease	-1	20009434
ary	I-Disease	-1	20009434
at@@	I-Disease	-1	20009434
re@@	I-Disease	-1	20009434
sia	I-Disease	-1	20009434
.	O	-1	20009434
A@@	O	-1	20009434
t	O	-1	20009434
day	O	-1	20009434
8@@	O	-1	20009434
3@@	O	-1	20009434
3	O	-1	20009434
after	O	-1	20009434
the	O	-1	20009434
transplant@@	O	-1	20009434
ation,	O	-1	20009434
he	O	-1	20009434
was	O	-1	20009434
diagnos@@	O	-1	20009434
ed	O	-1	20009434
with	O	-1	20009434
P@@	B-Disease	D008232	20009434
T@@	I-Disease	-1	20009434
L@@	I-Disease	-1	20009434
D	I-Disease	-1	20009434
(	O	-1	20009434
post@@	B-Disease	D008232	20009434
-@@	I-Disease	-1	20009434
transplant@@	I-Disease	-1	20009434
ation	I-Disease	-1	20009434
lymph@@	I-Disease	-1	20009434
o@@	I-Disease	-1	20009434
pro@@	I-Disease	-1	20009434
li@@	I-Disease	-1	20009434
fer@@	I-Disease	-1	20009434
ative	I-Disease	-1	20009434
disor@@	I-Disease	-1	20009434
der	I-Disease	-1	20009434
,	O	-1	20009434
B@@	B-Disease	D002051	20009434
ur@@	I-Disease	-1	20009434
k@@	I-Disease	-1	20009434
it@@	I-Disease	-1	20009434
t-@@	I-Disease	-1	20009434
type	I-Disease	-1	20009434
mal@@	I-Disease	-1	20009434
i@@	I-Disease	-1	20009434
gn@@	I-Disease	-1	20009434
ant	I-Disease	-1	20009434
lymph@@	I-Disease	-1	20009434
oma	I-Disease	-1	20009434
).	O	-1	20009434
D@@	O	-1	20009434
uring	O	-1	20009434
induction	O	-1	20009434
therapy,	O	-1	20009434
he	O	-1	20009434
su@@	O	-1	20009434
ffe@@	O	-1	20009434
red	O	-1	20009434
i@@	O	-1	20009434
le@@	O	-1	20009434
al	O	-1	20009434
per@@	O	-1	20009434
for@@	O	-1	20009434
ation	O	-1	20009434
and	O	-1	20009434
i@@	O	-1	20009434
le@@	O	-1	20009434
ost@@	O	-1	20009434
om@@	O	-1	20009434
y	O	-1	20009434
was	O	-1	20009434
per@@	O	-1	20009434
for@@	O	-1	20009434
me@@	O	-1	20009434
d.	O	-1	20009434
S@@	O	-1	20009434
ub@@	O	-1	20009434
sequ@@	O	-1	20009434
ent	O	-1	20009434
H@@	O	-1	20009434
D@@	O	-1	20009434
-	O	-1	20009434
M@@	B-Chemical	D008727	20009434
T@@	I-Chemical	-1	20009434
X	I-Chemical	-1	20009434
therapy	O	-1	20009434
caused	O	-1	20009434
acute	B-Disease	D058186	20009434
renal	I-Disease	-1	20009434
failure	I-Disease	-1	20009434
that	O	-1	20009434
requ@@	O	-1	20009434
ired	O	-1	20009434
continu@@	O	-1	20009434
ous	O	-1	20009434
hemo@@	O	-1	20009434
dialy@@	O	-1	20009434
sis.	O	-1	20009434
We	O	-1	20009434
sup@@	O	-1	20009434
pos@@	O	-1	20009434
ed	O	-1	20009434
that	O	-1	20009434
intra@@	O	-1	20009434
vascular	O	-1	20009434
hypo@@	B-Disease	D020896	20009434
vol@@	I-Disease	-1	20009434
emia	I-Disease	-1	20009434
due	O	-1	20009434
to	O	-1	20009434
subst@@	O	-1	20009434
anti@@	O	-1	20009434
al	O	-1	20009434
dra@@	O	-1	20009434
in@@	O	-1	20009434
age	O	-1	20009434
from	O	-1	20009434
the	O	-1	20009434
i@@	O	-1	20009434
le@@	O	-1	20009434
ost@@	O	-1	20009434
oma	O	-1	20009434
caused	O	-1	20009434
acute	B-Disease	-1	20009434
pre@@	I-Disease	-1	20009434
renal	I-Disease	-1	20009434
failure	I-Disease	-1	20009434
.	O	-1	20009434
After	O	-1	20009434
recovery	O	-1	20009434
of	O	-1	20009434
h@@	O	-1	20009434
is	O	-1	20009434
renal	O	-1	20009434
func@@	O	-1	20009434
tion,	O	-1	20009434
we	O	-1	20009434
could	O	-1	20009434
saf@@	O	-1	20009434
ely	O	-1	20009434
tre@@	O	-1	20009434
at	O	-1	20009434
the	O	-1	20009434
patient	O	-1	20009434
with	O	-1	20009434
H@@	O	-1	20009434
D@@	O	-1	20009434
-	O	-1	20009434
M@@	B-Chemical	D008727	20009434
T@@	I-Chemical	-1	20009434
X	I-Chemical	-1	20009434
therapy	O	-1	20009434
by	O	-1	20009434
contro@@	O	-1	20009434
ll@@	O	-1	20009434
ing	O	-1	20009434
dra@@	O	-1	20009434
in@@	O	-1	20009434
age	O	-1	20009434
from	O	-1	20009434
i@@	O	-1	20009434
le@@	O	-1	20009434
ost@@	O	-1	20009434
oma	O	-1	20009434
with	O	-1	20009434
total	O	-1	20009434
pa@@	O	-1	20009434
ren@@	O	-1	20009434
ter@@	O	-1	20009434
al	O	-1	20009434
n@@	O	-1	20009434
ut@@	O	-1	20009434
ri@@	O	-1	20009434
tion.	O	-1	20009434

An@@	O	-1	20431083
ti@@	O	-1	20431083
thrombotic	O	-1	20431083
drug	O	-1	20431083
use@@	O	-1	20431083
,	O	-1	20431083
cerebral	B-Disease	-1	20431083
micro@@	I-Disease	-1	20431083
ble@@	I-Disease	-1	20431083
ed@@	I-Disease	-1	20431083
s	I-Disease	-1	20431083
,	O	-1	20431083
and	O	-1	20431083
intrac@@	B-Disease	D002543	20431083
e@@	I-Disease	-1	20431083
rebral	I-Disease	-1	20431083
hemorrh@@	I-Disease	-1	20431083
age	I-Disease	-1	20431083
:	O	-1	20431083
a	O	-1	20431083
system@@	O	-1	20431083
atic	O	-1	20431083
revie@@	O	-1	20431083
w	O	-1	20431083
of	O	-1	20431083
pu@@	O	-1	20431083
bl@@	O	-1	20431083
ished	O	-1	20431083
and	O	-1	20431083
un@@	O	-1	20431083
pu@@	O	-1	20431083
bl@@	O	-1	20431083
ished	O	-1	20431083
studi@@	O	-1	20431083
es.	O	-1	20431083
BACKGROUN@@	O	-1	20431083
D	O	-1	20431083
AN@@	O	-1	20431083
D	O	-1	20431083
P@@	O	-1	20431083
U@@	O	-1	20431083
R@@	O	-1	20431083
P@@	O	-1	20431083
O@@	O	-1	20431083
S@@	O	-1	20431083
E:	O	-1	20431083
C@@	B-Disease	-1	20431083
e@@	I-Disease	-1	20431083
rebral	I-Disease	-1	20431083
micro@@	I-Disease	-1	20431083
ble@@	I-Disease	-1	20431083
ed@@	I-Disease	-1	20431083
s	I-Disease	-1	20431083
(	O	-1	20431083
M@@	B-Disease	-1	20431083
B	I-Disease	-1	20431083
)	O	-1	20431083
are	O	-1	20431083
potential	O	-1	20431083
risk	O	-1	20431083
factors	O	-1	20431083
for	O	-1	20431083
intrac@@	B-Disease	D002543	20431083
e@@	I-Disease	-1	20431083
rebral	I-Disease	-1	20431083
hemorrh@@	I-Disease	-1	20431083
age	I-Disease	-1	20431083
(	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
),	O	-1	20431083
but	O	-1	20431083
it	O	-1	20431083
is	O	-1	20431083
unc@@	O	-1	20431083
le@@	O	-1	20431083
ar	O	-1	20431083
if	O	-1	20431083
they	O	-1	20431083
are	O	-1	20431083
a	O	-1	20431083
contra@@	O	-1	20431083
indic@@	O	-1	20431083
ation	O	-1	20431083
to	O	-1	20431083
using	O	-1	20431083
anti@@	O	-1	20431083
thrombotic	O	-1	20431083
drug@@	O	-1	20431083
s.	O	-1	20431083
In@@	O	-1	20431083
si@@	O	-1	20431083
gh@@	O	-1	20431083
ts	O	-1	20431083
could	O	-1	20431083
be	O	-1	20431083
g@@	O	-1	20431083
ained	O	-1	20431083
by	O	-1	20431083
po@@	O	-1	20431083
ol@@	O	-1	20431083
ing	O	-1	20431083
data	O	-1	20431083
on	O	-1	20431083
M@@	B-Disease	-1	20431083
B	I-Disease	-1	20431083
frequency	O	-1	20431083
str@@	O	-1	20431083
ati@@	O	-1	20431083
fied	O	-1	20431083
by	O	-1	20431083
anti@@	O	-1	20431083
thrombotic	O	-1	20431083
use	O	-1	20431083
in	O	-1	20431083
co@@	O	-1	20431083
h@@	O	-1	20431083
or@@	O	-1	20431083
ts	O	-1	20431083
with	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
and	O	-1	20431083
ischem@@	B-Disease	D002544	20431083
ic	I-Disease	-1	20431083
strok@@	I-Disease	-1	20431083
e	I-Disease	-1	20431083
(	O	-1	20431083
I@@	B-Disease	D002544	20431083
S	I-Disease	-1	20431083
)@@	O	-1	20431083
/	O	-1	20431083
transi@@	B-Disease	D002546	20431083
ent	I-Disease	-1	20431083
ischem@@	I-Disease	-1	20431083
ic	I-Disease	-1	20431083
at@@	I-Disease	-1	20431083
tac@@	I-Disease	-1	20431083
k	I-Disease	-1	20431083
(	O	-1	20431083
TI@@	B-Disease	D002546	20431083
A	I-Disease	-1	20431083
).	O	-1	20431083
METHODS:	O	-1	20431083
We	O	-1	20431083
performed	O	-1	20431083
a	O	-1	20431083
system@@	O	-1	20431083
atic	O	-1	20431083
revie@@	O	-1	20431083
w	O	-1	20431083
of	O	-1	20431083
pu@@	O	-1	20431083
bl@@	O	-1	20431083
ished	O	-1	20431083
and	O	-1	20431083
un@@	O	-1	20431083
pu@@	O	-1	20431083
bl@@	O	-1	20431083
ished	O	-1	20431083
data	O	-1	20431083
from	O	-1	20431083
co@@	O	-1	20431083
h@@	O	-1	20431083
or@@	O	-1	20431083
ts	O	-1	20431083
with	O	-1	20431083
strok@@	B-Disease	D020521	20431083
e	I-Disease	-1	20431083
or	O	-1	20431083
TI@@	B-Disease	D002546	20431083
A	I-Disease	-1	20431083
to	O	-1	20431083
compar@@	O	-1	20431083
e	O	-1	20431083
the	O	-1	20431083
presence	O	-1	20431083
of	O	-1	20431083
M@@	B-Disease	-1	20431083
B	I-Disease	-1	20431083
in@@	O	-1	20431083
:	O	-1	20431083
(1@@	O	-1	20431083
)	O	-1	20431083
anti@@	O	-1	20431083
thrombotic	O	-1	20431083
users	O	-1	20431083
v@@	O	-1	20431083
s	O	-1	20431083
non@@	O	-1	20431083
anti@@	O	-1	20431083
thrombotic	O	-1	20431083
users	O	-1	20431083
with	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
;	O	-1	20431083
(2@@	O	-1	20431083
)	O	-1	20431083
anti@@	O	-1	20431083
thrombotic	O	-1	20431083
users	O	-1	20431083
v@@	O	-1	20431083
s	O	-1	20431083
non@@	O	-1	20431083
users	O	-1	20431083
with	O	-1	20431083
I@@	B-Disease	D002544	20431083
S	I-Disease	-1	20431083
/	O	-1	20431083
TI@@	B-Disease	D002546	20431083
A	I-Disease	-1	20431083
;	O	-1	20431083
and	O	-1	20431083
(3@@	O	-1	20431083
)	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
v@@	O	-1	20431083
s	O	-1	20431083
ischem@@	B-Disease	D007511	20431083
ic	I-Disease	-1	20431083
events	O	-1	20431083
str@@	O	-1	20431083
ati@@	O	-1	20431083
fied	O	-1	20431083
by	O	-1	20431083
anti@@	O	-1	20431083
thrombotic	O	-1	20431083
use.	O	-1	20431083
We	O	-1	20431083
also	O	-1	20431083
analy@@	O	-1	20431083
zed	O	-1	20431083
pu@@	O	-1	20431083
bl@@	O	-1	20431083
ished	O	-1	20431083
and	O	-1	20431083
un@@	O	-1	20431083
pu@@	O	-1	20431083
bl@@	O	-1	20431083
ished	O	-1	20431083
follow-up	O	-1	20431083
data	O	-1	20431083
to	O	-1	20431083
determine	O	-1	20431083
the	O	-1	20431083
risk	O	-1	20431083
of	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
in	O	-1	20431083
anti@@	O	-1	20431083
thrombotic	O	-1	20431083
users	O	-1	20431083
with	O	-1	20431083
M@@	B-Disease	-1	20431083
B	I-Disease	-1	20431083
.	O	-1	20431083
RESULTS:	O	-1	20431083
In	O	-1	20431083
a	O	-1	20431083
po@@	O	-1	20431083
ol@@	O	-1	20431083
ed	O	-1	20431083
analysis	O	-1	20431083
of	O	-1	20431083
14@@	O	-1	20431083
60	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
and	O	-1	20431083
3@@	O	-1	20431083
8@@	O	-1	20431083
17	O	-1	20431083
I@@	B-Disease	D002544	20431083
S	I-Disease	-1	20431083
/	O	-1	20431083
TI@@	B-Disease	D002546	20431083
A	I-Disease	-1	20431083
,	O	-1	20431083
M@@	B-Disease	-1	20431083
B	I-Disease	-1	20431083
were	O	-1	20431083
more	O	-1	20431083
frequent	O	-1	20431083
in	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
v@@	O	-1	20431083
s	O	-1	20431083
I@@	B-Disease	D002544	20431083
S	I-Disease	-1	20431083
/	O	-1	20431083
TI@@	B-Disease	D002546	20431083
A	I-Disease	-1	20431083
in	O	-1	20431083
all	O	-1	20431083
treatment	O	-1	20431083
group@@	O	-1	20431083
s,	O	-1	20431083
but	O	-1	20431083
the	O	-1	20431083
ex@@	O	-1	20431083
cess	O	-1	20431083
increased	O	-1	20431083
from	O	-1	20431083
2.@@	O	-1	20431083
8	O	-1	20431083
(@@	O	-1	20431083
o@@	O	-1	20431083
d@@	O	-1	20431083
ds	O	-1	20431083
rati@@	O	-1	20431083
o@@	O	-1	20431083
;	O	-1	20431083
rang@@	O	-1	20431083
e,	O	-1	20431083
2.@@	O	-1	20431083
3-@@	O	-1	20431083
3.@@	O	-1	20431083
5@@	O	-1	20431083
)	O	-1	20431083
in	O	-1	20431083
non@@	O	-1	20431083
anti@@	O	-1	20431083
thrombotic	O	-1	20431083
users	O	-1	20431083
to	O	-1	20431083
5.@@	O	-1	20431083
7	O	-1	20431083
(@@	O	-1	20431083
rang@@	O	-1	20431083
e,	O	-1	20431083
3.@@	O	-1	20431083
4-@@	O	-1	20431083
9.@@	O	-1	20431083
7@@	O	-1	20431083
)	O	-1	20431083
in	O	-1	20431083
anti@@	O	-1	20431083
platele@@	O	-1	20431083
t	O	-1	20431083
users	O	-1	20431083
and	O	-1	20431083
8.@@	O	-1	20431083
0	O	-1	20431083
(@@	O	-1	20431083
rang@@	O	-1	20431083
e,	O	-1	20431083
3.@@	O	-1	20431083
5-@@	O	-1	20431083
1@@	O	-1	20431083
7.@@	O	-1	20431083
8@@	O	-1	20431083
)	O	-1	20431083
in	O	-1	20431083
war@@	B-Chemical	D014859	20431083
farin	I-Chemical	-1	20431083
users	O	-1	20431083
(P	O	-1	20431083
differen@@	O	-1	20431083
ce@@	O	-1	20431083
=@@	O	-1	20431083
0.0@@	O	-1	20431083
1).	O	-1	20431083
There	O	-1	20431083
was	O	-1	20431083
also	O	-1	20431083
an	O	-1	20431083
ex@@	O	-1	20431083
cess	O	-1	20431083
of	O	-1	20431083
M@@	B-Disease	-1	20431083
B	I-Disease	-1	20431083
in	O	-1	20431083
war@@	B-Chemical	D014859	20431083
farin	I-Chemical	-1	20431083
users	O	-1	20431083
v@@	O	-1	20431083
s	O	-1	20431083
non@@	O	-1	20431083
users	O	-1	20431083
with	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
(@@	O	-1	20431083
O@@	O	-1	20431083
R@@	O	-1	20431083
,	O	-1	20431083
2.@@	O	-1	20431083
7@@	O	-1	20431083
;	O	-1	20431083
95%	O	-1	20431083
CI@@	O	-1	20431083
,	O	-1	20431083
1.@@	O	-1	20431083
6-@@	O	-1	20431083
4.@@	O	-1	20431083
4@@	O	-1	20431083
;	O	-1	20431083
P@@	O	-1	20431083
<@@	O	-1	20431083
0.00@@	O	-1	20431083
1)	O	-1	20431083
but	O	-1	20431083
n@@	O	-1	20431083
one	O	-1	20431083
in	O	-1	20431083
war@@	B-Chemical	D014859	20431083
farin	I-Chemical	-1	20431083
users	O	-1	20431083
with	O	-1	20431083
I@@	B-Disease	D002544	20431083
S	I-Disease	-1	20431083
/	O	-1	20431083
TI@@	B-Disease	D002546	20431083
A	I-Disease	-1	20431083
(@@	O	-1	20431083
O@@	O	-1	20431083
R@@	O	-1	20431083
,	O	-1	20431083
1.@@	O	-1	20431083
3@@	O	-1	20431083
;	O	-1	20431083
95%	O	-1	20431083
CI@@	O	-1	20431083
,	O	-1	20431083
0.@@	O	-1	20431083
9@@	O	-1	20431083
-@@	O	-1	20431083
1.@@	O	-1	20431083
7@@	O	-1	20431083
;	O	-1	20431083
P@@	O	-1	20431083
=@@	O	-1	20431083
0.@@	O	-1	20431083
3@@	O	-1	20431083
3@@	O	-1	20431083
;	O	-1	20431083
P	O	-1	20431083
differen@@	O	-1	20431083
ce@@	O	-1	20431083
=@@	O	-1	20431083
0.0@@	O	-1	20431083
1).	O	-1	20431083
There	O	-1	20431083
was	O	-1	20431083
a	O	-1	20431083
sm@@	O	-1	20431083
all@@	O	-1	20431083
er	O	-1	20431083
ex@@	O	-1	20431083
cess	O	-1	20431083
of	O	-1	20431083
M@@	B-Disease	-1	20431083
B	I-Disease	-1	20431083
in	O	-1	20431083
anti@@	O	-1	20431083
platele@@	O	-1	20431083
t	O	-1	20431083
users	O	-1	20431083
v@@	O	-1	20431083
s	O	-1	20431083
non@@	O	-1	20431083
users	O	-1	20431083
with	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
(@@	O	-1	20431083
O@@	O	-1	20431083
R@@	O	-1	20431083
,	O	-1	20431083
1.@@	O	-1	20431083
7@@	O	-1	20431083
;	O	-1	20431083
95%	O	-1	20431083
CI@@	O	-1	20431083
,	O	-1	20431083
1.@@	O	-1	20431083
3-@@	O	-1	20431083
2.@@	O	-1	20431083
3@@	O	-1	20431083
;	O	-1	20431083
P@@	O	-1	20431083
<@@	O	-1	20431083
0.00@@	O	-1	20431083
1),	O	-1	20431083
but	O	-1	20431083
findings	O	-1	20431083
were	O	-1	20431083
similar	O	-1	20431083
for	O	-1	20431083
anti@@	O	-1	20431083
platele@@	O	-1	20431083
t	O	-1	20431083
users	O	-1	20431083
with	O	-1	20431083
I@@	B-Disease	D002544	20431083
S	I-Disease	-1	20431083
/	O	-1	20431083
TI@@	B-Disease	D002546	20431083
A	I-Disease	-1	20431083
(@@	O	-1	20431083
O@@	O	-1	20431083
R@@	O	-1	20431083
,	O	-1	20431083
1.@@	O	-1	20431083
4@@	O	-1	20431083
;	O	-1	20431083
95%	O	-1	20431083
CI@@	O	-1	20431083
,	O	-1	20431083
1.@@	O	-1	20431083
2-@@	O	-1	20431083
1.@@	O	-1	20431083
7@@	O	-1	20431083
;	O	-1	20431083
P@@	O	-1	20431083
<@@	O	-1	20431083
0.00@@	O	-1	20431083
1@@	O	-1	20431083
;	O	-1	20431083
P	O	-1	20431083
differen@@	O	-1	20431083
ce@@	O	-1	20431083
=@@	O	-1	20431083
0.@@	O	-1	20431083
25@@	O	-1	20431083
).	O	-1	20431083
In	O	-1	20431083
po@@	O	-1	20431083
ol@@	O	-1	20431083
ed	O	-1	20431083
follow-up	O	-1	20431083
data	O	-1	20431083
for	O	-1	20431083
7@@	O	-1	20431083
6@@	O	-1	20431083
8	O	-1	20431083
anti@@	O	-1	20431083
thrombotic	O	-1	20431083
us@@	O	-1	20431083
er@@	O	-1	20431083
s,	O	-1	20431083
presence	O	-1	20431083
of	O	-1	20431083
M@@	B-Disease	-1	20431083
B	I-Disease	-1	20431083
at	O	-1	20431083
baseline	O	-1	20431083
was	O	-1	20431083
associated	O	-1	20431083
with	O	-1	20431083
a	O	-1	20431083
subst@@	O	-1	20431083
anti@@	O	-1	20431083
ally	O	-1	20431083
increased	O	-1	20431083
risk	O	-1	20431083
of	O	-1	20431083
subsequ@@	O	-1	20431083
ent	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
(@@	O	-1	20431083
O@@	O	-1	20431083
R@@	O	-1	20431083
,	O	-1	20431083
1@@	O	-1	20431083
2.@@	O	-1	20431083
1@@	O	-1	20431083
;	O	-1	20431083
95%	O	-1	20431083
CI@@	O	-1	20431083
,	O	-1	20431083
3.@@	O	-1	20431083
4-@@	O	-1	20431083
4@@	O	-1	20431083
2.@@	O	-1	20431083
5@@	O	-1	20431083
;	O	-1	20431083
P@@	O	-1	20431083
<@@	O	-1	20431083
0.00@@	O	-1	20431083
1).	O	-1	20431083
CONCLUSIONS:	O	-1	20431083
The	O	-1	20431083
ex@@	O	-1	20431083
cess	O	-1	20431083
of	O	-1	20431083
M@@	B-Disease	-1	20431083
B	I-Disease	-1	20431083
in	O	-1	20431083
war@@	B-Chemical	D014859	20431083
farin	I-Chemical	-1	20431083
users	O	-1	20431083
with	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
compared	O	-1	20431083
to	O	-1	20431083
other	O	-1	20431083
groups	O	-1	20431083
suggests	O	-1	20431083
that	O	-1	20431083
M@@	B-Disease	-1	20431083
B	I-Disease	-1	20431083
increase	O	-1	20431083
the	O	-1	20431083
risk	O	-1	20431083
of	O	-1	20431083
war@@	B-Chemical	D014859	20431083
farin	I-Chemical	-1	20431083
-@@	O	-1	20431083
associated	O	-1	20431083
IC@@	B-Disease	D002543	20431083
H	I-Disease	-1	20431083
.	O	-1	20431083
L@@	O	-1	20431083
im@@	O	-1	20431083
ited	O	-1	20431083
pro@@	O	-1	20431083
sp@@	O	-1	20431083
ective	O	-1	20431083
data	O	-1	20431083
cor@@	O	-1	20431083
ro@@	O	-1	20431083
b@@	O	-1	20431083
or@@	O	-1	20431083
ate	O	-1	20431083
these	O	-1	20431083
find@@	O	-1	20431083
ing@@	O	-1	20431083
s,	O	-1	20431083
but	O	-1	20431083
larg@@	O	-1	20431083
er	O	-1	20431083
pro@@	O	-1	20431083
sp@@	O	-1	20431083
ective	O	-1	20431083
studies	O	-1	20431083
are	O	-1	20431083
ur@@	O	-1	20431083
g@@	O	-1	20431083
ently	O	-1	20431083
requ@@	O	-1	20431083
i@@	O	-1	20431083
red.	O	-1	20431083

V@@	B-Chemical	D014700	20595935
er@@	I-Chemical	-1	20595935
ap@@	I-Chemical	-1	20595935
ami@@	I-Chemical	-1	20595935
l	I-Chemical	-1	20595935
stimulation	O	-1	20595935
test	O	-1	20595935
in	O	-1	20595935
hyper@@	B-Disease	D006966	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
ine@@	I-Disease	-1	20595935
mia	I-Disease	-1	20595935
:	O	-1	20595935
loss	O	-1	20595935
of	O	-1	20595935
prolactin	O	-1	20595935
response	O	-1	20595935
in	O	-1	20595935
an@@	O	-1	20595935
at@@	O	-1	20595935
om@@	O	-1	20595935
ic	O	-1	20595935
or	O	-1	20595935
functional	O	-1	20595935
st@@	O	-1	20595935
al@@	O	-1	20595935
k	O	-1	20595935
effect@@	O	-1	20595935
.	O	-1	20595935
A@@	O	-1	20595935
I@@	O	-1	20595935
M@@	O	-1	20595935
:	O	-1	20595935
V@@	B-Chemical	D014700	20595935
er@@	I-Chemical	-1	20595935
ap@@	I-Chemical	-1	20595935
ami@@	I-Chemical	-1	20595935
l	I-Chemical	-1	20595935
stimulation	O	-1	20595935
test	O	-1	20595935
was	O	-1	20595935
previously	O	-1	20595935
investigated	O	-1	20595935
as	O	-1	20595935
a	O	-1	20595935
to@@	O	-1	20595935
ol	O	-1	20595935
for	O	-1	20595935
differen@@	O	-1	20595935
tial	O	-1	20595935
diagnosis	O	-1	20595935
of	O	-1	20595935
hyper@@	B-Disease	D006966	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
ine@@	I-Disease	-1	20595935
mia	I-Disease	-1	20595935
,	O	-1	20595935
but	O	-1	20595935
with	O	-1	20595935
conf@@	O	-1	20595935
l@@	O	-1	20595935
ic@@	O	-1	20595935
ting	O	-1	20595935
result@@	O	-1	20595935
s.	O	-1	20595935
M@@	B-Disease	D015175	20595935
ac@@	I-Disease	-1	20595935
ro@@	I-Disease	-1	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
ine@@	I-Disease	-1	20595935
mia	I-Disease	-1	20595935
was	O	-1	20595935
ne@@	O	-1	20595935
ver	O	-1	20595935
considered	O	-1	20595935
in	O	-1	20595935
those	O	-1	20595935
previ@@	O	-1	20595935
ous	O	-1	20595935
studi@@	O	-1	20595935
es.	O	-1	20595935
He@@	O	-1	20595935
re,	O	-1	20595935
we	O	-1	20595935
a@@	O	-1	20595935
im@@	O	-1	20595935
ed	O	-1	20595935
to	O	-1	20595935
re@@	O	-1	20595935
-@@	O	-1	20595935
investigate	O	-1	20595935
the	O	-1	20595935
diagnos@@	O	-1	20595935
tic	O	-1	20595935
valu@@	O	-1	20595935
e	O	-1	20595935
of	O	-1	20595935
verap@@	B-Chemical	D014700	20595935
ami@@	I-Chemical	-1	20595935
l	I-Chemical	-1	20595935
in	O	-1	20595935
a	O	-1	20595935
po@@	O	-1	20595935
p@@	O	-1	20595935
ulation	O	-1	20595935
who	O	-1	20595935
were	O	-1	20595935
all	O	-1	20595935
s@@	O	-1	20595935
cre@@	O	-1	20595935
en@@	O	-1	20595935
ed	O	-1	20595935
for	O	-1	20595935
mac@@	B-Disease	D015175	20595935
ro@@	I-Disease	-1	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
ine@@	I-Disease	-1	20595935
mia	I-Disease	-1	20595935
.	O	-1	20595935
Pro@@	O	-1	20595935
l@@	O	-1	20595935
actin	O	-1	20595935
responses	O	-1	20595935
to	O	-1	20595935
verap@@	B-Chemical	D014700	20595935
ami@@	I-Chemical	-1	20595935
l	I-Chemical	-1	20595935
in	O	-1	20595935
6@@	O	-1	20595935
5	O	-1	20595935
female	O	-1	20595935
patients	O	-1	20595935
(@@	O	-1	20595935
ag@@	O	-1	20595935
e@@	O	-1	20595935
:	O	-1	20595935
2@@	O	-1	20595935
9.@@	O	-1	20595935
9	O	-1	20595935
+/-	O	-1	20595935
8.@@	O	-1	20595935
1	O	-1	20595935
year@@	O	-1	20595935
s)	O	-1	20595935
with	O	-1	20595935
hyper@@	B-Disease	D006966	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
ine@@	I-Disease	-1	20595935
mia	I-Disease	-1	20595935
were	O	-1	20595935
tested	O	-1	20595935
in	O	-1	20595935
a	O	-1	20595935
descri@@	O	-1	20595935
p@@	O	-1	20595935
ti@@	O	-1	20595935
ve,	O	-1	20595935
mat@@	O	-1	20595935
ch@@	O	-1	20595935
ed	O	-1	20595935
cas@@	O	-1	20595935
e-@@	O	-1	20595935
control	O	-1	20595935
study.	O	-1	20595935
METHODS:	O	-1	20595935
V@@	B-Chemical	D014700	20595935
er@@	I-Chemical	-1	20595935
ap@@	I-Chemical	-1	20595935
ami@@	I-Chemical	-1	20595935
l	I-Chemical	-1	20595935
8@@	O	-1	20595935
0	O	-1	20595935
mg@@	O	-1	20595935
,	O	-1	20595935
p.@@	O	-1	20595935
o@@	O	-1	20595935
.	O	-1	20595935
was	O	-1	20595935
administ@@	O	-1	20595935
e@@	O	-1	20595935
re@@	O	-1	20595935
d,	O	-1	20595935
and	O	-1	20595935
then	O	-1	20595935
P@@	O	-1	20595935
R@@	O	-1	20595935
L	O	-1	20595935
levels	O	-1	20595935
were	O	-1	20595935
measured	O	-1	20595935
at	O	-1	20595935
8@@	O	-1	20595935
th	O	-1	20595935
and	O	-1	20595935
1@@	O	-1	20595935
6@@	O	-1	20595935
th	O	-1	20595935
hour@@	O	-1	20595935
s,	O	-1	20595935
by	O	-1	20595935
immuno@@	O	-1	20595935
me@@	O	-1	20595935
tri@@	O	-1	20595935
c	O	-1	20595935
chem@@	O	-1	20595935
il@@	O	-1	20595935
u@@	O	-1	20595935
min@@	O	-1	20595935
es@@	O	-1	20595935
c@@	O	-1	20595935
ence@@	O	-1	20595935
.	O	-1	20595935
V@@	B-Chemical	D014700	20595935
er@@	I-Chemical	-1	20595935
ap@@	I-Chemical	-1	20595935
ami@@	I-Chemical	-1	20595935
l	I-Chemical	-1	20595935
respon@@	O	-1	20595935
si@@	O	-1	20595935
ven@@	O	-1	20595935
ess	O	-1	20595935
was	O	-1	20595935
determined	O	-1	20595935
by	O	-1	20595935
pe@@	O	-1	20595935
a@@	O	-1	20595935
k	O	-1	20595935
perc@@	O	-1	20595935
ent	O	-1	20595935
change	O	-1	20595935
in	O	-1	20595935
bas@@	O	-1	20595935
al	O	-1	20595935
prolactin	O	-1	20595935
levels	O	-1	20595935
(P@@	O	-1	20595935
R@@	O	-1	20595935
L@@	O	-1	20595935
).	O	-1	20595935
RESULTS:	O	-1	20595935
V@@	B-Chemical	D014700	20595935
er@@	I-Chemical	-1	20595935
ap@@	I-Chemical	-1	20595935
ami@@	I-Chemical	-1	20595935
l	I-Chemical	-1	20595935
significantly	O	-1	20595935
increased	O	-1	20595935
P@@	O	-1	20595935
R@@	O	-1	20595935
L	O	-1	20595935
levels	O	-1	20595935
in	O	-1	20595935
healthy	O	-1	20595935
controls	O	-1	20595935
(N@@	O	-1	20595935
.	O	-1	20595935
8@@	O	-1	20595935
,	O	-1	20595935
P@@	O	-1	20595935
R@@	O	-1	20595935
L@@	O	-1	20595935
:	O	-1	20595935
18@@	O	-1	20595935
3@@	O	-1	20595935
%),	O	-1	20595935
mac@@	B-Disease	D015175	20595935
ro@@	I-Disease	-1	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
in@@	I-Disease	-1	20595935
oma	I-Disease	-1	20595935
(N@@	O	-1	20595935
.	O	-1	20595935
8@@	O	-1	20595935
,	O	-1	20595935
P@@	O	-1	20595935
R@@	O	-1	20595935
L@@	O	-1	20595935
:	O	-1	20595935
7@@	O	-1	20595935
%),	O	-1	20595935
micro@@	B-Disease	D015175	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
in@@	I-Disease	-1	20595935
oma	I-Disease	-1	20595935
(N@@	O	-1	20595935
.	O	-1	20595935
19@@	O	-1	20595935
,	O	-1	20595935
P@@	O	-1	20595935
R@@	O	-1	20595935
L@@	O	-1	20595935
:	O	-1	20595935
2@@	O	-1	20595935
1@@	O	-1	20595935
%),	O	-1	20595935
mac@@	B-Disease	D015175	20595935
ro@@	I-Disease	-1	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
ine@@	I-Disease	-1	20595935
mia	I-Disease	-1	20595935
(N@@	O	-1	20595935
.	O	-1	20595935
2@@	O	-1	20595935
3,	O	-1	20595935
P@@	O	-1	20595935
R@@	O	-1	20595935
L@@	O	-1	20595935
:	O	-1	20595935
12@@	O	-1	20595935
6@@	O	-1	20595935
%),	O	-1	20595935
but	O	-1	20595935
not	O	-1	20595935
in	O	-1	20595935
p@@	B-Disease	-1	20595935
se@@	I-Disease	-1	20595935
u@@	I-Disease	-1	20595935
do@@	I-Disease	-1	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
in@@	I-Disease	-1	20595935
oma	I-Disease	-1	20595935
(N@@	O	-1	20595935
.	O	-1	20595935
8@@	O	-1	20595935
,	O	-1	20595935
P@@	O	-1	20595935
R@@	O	-1	20595935
L@@	O	-1	20595935
:	O	-1	20595935
0.@@	O	-1	20595935
8@@	O	-1	20595935
%),	O	-1	20595935
and	O	-1	20595935
ris@@	B-Chemical	D018967	20595935
perid@@	I-Chemical	-1	20595935
one	I-Chemical	-1	20595935
-induced	O	-1	20595935
hyper@@	B-Disease	D006966	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
ine@@	I-Disease	-1	20595935
mia	I-Disease	-1	20595935
(N@@	O	-1	20595935
.	O	-1	20595935
7@@	O	-1	20595935
,	O	-1	20595935
P@@	O	-1	20595935
R@@	O	-1	20595935
L@@	O	-1	20595935
:	O	-1	20595935
3@@	O	-1	20595935
%).	O	-1	20595935
RO@@	O	-1	20595935
C	O	-1	20595935
cur@@	O	-1	20595935
ve	O	-1	20595935
analysis	O	-1	20595935
revealed	O	-1	20595935
that	O	-1	20595935
un@@	O	-1	20595935
respon@@	O	-1	20595935
si@@	O	-1	20595935
ven@@	O	-1	20595935
ess	O	-1	20595935
to	O	-1	20595935
verap@@	B-Chemical	D014700	20595935
ami@@	I-Chemical	-1	20595935
l	I-Chemical	-1	20595935
def@@	O	-1	20595935
in@@	O	-1	20595935
ed	O	-1	20595935
as	O	-1	20595935
P@@	O	-1	20595935
R@@	O	-1	20595935
L	O	-1	20595935
<@@	O	-1	20595935
7@@	O	-1	20595935
%,	O	-1	20595935
dis@@	O	-1	20595935
cri@@	O	-1	20595935
min@@	O	-1	20595935
ated	O	-1	20595935
an@@	O	-1	20595935
at@@	O	-1	20595935
om@@	O	-1	20595935
ical	O	-1	20595935
or	O	-1	20595935
functional	O	-1	20595935
st@@	O	-1	20595935
al@@	O	-1	20595935
k	O	-1	20595935
effect	O	-1	20595935
(@@	O	-1	20595935
sensi@@	O	-1	20595935
tiv@@	O	-1	20595935
it@@	O	-1	20595935
y@@	O	-1	20595935
:	O	-1	20595935
7@@	O	-1	20595935
4@@	O	-1	20595935
%,	O	-1	20595935
spec@@	O	-1	20595935
ific@@	O	-1	20595935
it@@	O	-1	20595935
y@@	O	-1	20595935
:	O	-1	20595935
7@@	O	-1	20595935
3@@	O	-1	20595935
%,	O	-1	20595935
A@@	O	-1	20595935
U@@	O	-1	20595935
C@@	O	-1	20595935
:	O	-1	20595935
0.@@	O	-1	20595935
8@@	O	-1	20595935
55@@	O	-1	20595935
+/-@@	O	-1	20595935
0.0@@	O	-1	20595935
4@@	O	-1	20595935
,	O	-1	20595935
P	O	-1	20595935
<@@	O	-1	20595935
0.00@@	O	-1	20595935
1,	O	-1	20595935
CI@@	O	-1	20595935
:	O	-1	20595935
0.@@	O	-1	20595935
7@@	O	-1	20595935
6@@	O	-1	20595935
8@@	O	-1	20595935
-@@	O	-1	20595935
0.@@	O	-1	20595935
9@@	O	-1	20595935
4@@	O	-1	20595935
2)	O	-1	20595935
associated	O	-1	20595935
with	O	-1	20595935
p@@	B-Disease	-1	20595935
se@@	I-Disease	-1	20595935
u@@	I-Disease	-1	20595935
do@@	I-Disease	-1	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
in@@	I-Disease	-1	20595935
oma	I-Disease	-1	20595935
or	O	-1	20595935
ris@@	B-Chemical	D018967	20595935
perid@@	I-Chemical	-1	20595935
one	I-Chemical	-1	20595935
-induced	O	-1	20595935
hyper@@	B-Disease	D006966	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
ine@@	I-Disease	-1	20595935
mia	I-Disease	-1	20595935
,	O	-1	20595935
respectively.	O	-1	20595935
CONCLUSION:	O	-1	20595935
V@@	B-Chemical	D014700	20595935
er@@	I-Chemical	-1	20595935
ap@@	I-Chemical	-1	20595935
ami@@	I-Chemical	-1	20595935
l	I-Chemical	-1	20595935
respon@@	O	-1	20595935
si@@	O	-1	20595935
ven@@	O	-1	20595935
ess	O	-1	20595935
is	O	-1	20595935
not	O	-1	20595935
a	O	-1	20595935
re@@	O	-1	20595935
li@@	O	-1	20595935
able	O	-1	20595935
find@@	O	-1	20595935
ing	O	-1	20595935
for	O	-1	20595935
the	O	-1	20595935
differen@@	O	-1	20595935
tial	O	-1	20595935
diagnosis	O	-1	20595935
of	O	-1	20595935
hyper@@	B-Disease	D006966	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
ine@@	I-Disease	-1	20595935
mia	I-Disease	-1	20595935
.	O	-1	20595935
However,	O	-1	20595935
verap@@	B-Chemical	D014700	20595935
ami@@	I-Chemical	-1	20595935
l	I-Chemical	-1	20595935
un@@	O	-1	20595935
respon@@	O	-1	20595935
si@@	O	-1	20595935
ven@@	O	-1	20595935
ess	O	-1	20595935
dis@@	O	-1	20595935
cri@@	O	-1	20595935
min@@	O	-1	20595935
ates	O	-1	20595935
st@@	O	-1	20595935
al@@	O	-1	20595935
k	O	-1	20595935
effect	O	-1	20595935
(@@	O	-1	20595935
i.@@	O	-1	20595935
e@@	O	-1	20595935
.,	O	-1	20595935
an@@	O	-1	20595935
at@@	O	-1	20595935
om@@	O	-1	20595935
ically	O	-1	20595935
or	O	-1	20595935
func@@	O	-1	20595935
tion@@	O	-1	20595935
ally	O	-1	20595935
inhibited	O	-1	20595935
dop@@	O	-1	20595935
aminergic	O	-1	20595935
t@@	O	-1	20595935
on@@	O	-1	20595935
us@@	O	-1	20595935
)	O	-1	20595935
from	O	-1	20595935
other	O	-1	20595935
causes	O	-1	20595935
of	O	-1	20595935
hyper@@	B-Disease	D006966	20595935
prol@@	I-Disease	-1	20595935
act@@	I-Disease	-1	20595935
ine@@	I-Disease	-1	20595935
mia	I-Disease	-1	20595935
with	O	-1	20595935
v@@	O	-1	20595935
ar@@	O	-1	20595935
y@@	O	-1	20595935
ing	O	-1	20595935
de@@	O	-1	20595935
gre@@	O	-1	20595935
es	O	-1	20595935
of	O	-1	20595935
respon@@	O	-1	20595935
si@@	O	-1	20595935
ven@@	O	-1	20595935
es@@	O	-1	20595935
s.	O	-1	20595935

C@@	O	-1	35781
entr@@	O	-1	35781
al	O	-1	35781
action	O	-1	35781
of	O	-1	35781
n@@	O	-1	35781
ar@@	O	-1	35781
co@@	O	-1	35781
tic	O	-1	35781
analge@@	O	-1	35781
si@@	O	-1	35781
c@@	O	-1	35781
s.	O	-1	35781
P@@	O	-1	35781
ar@@	O	-1	35781
t	O	-1	35781
I@@	O	-1	35781
V@@	O	-1	35781
.	O	-1	35781
N@@	O	-1	35781
or@@	O	-1	35781
adrenergic	O	-1	35781
influ@@	O	-1	35781
enc@@	O	-1	35781
es	O	-1	35781
on	O	-1	35781
the	O	-1	35781
activity	O	-1	35781
of	O	-1	35781
analge@@	O	-1	35781
si@@	O	-1	35781
c@@	O	-1	35781
s	O	-1	35781
in	O	-1	35781
rats.	O	-1	35781
The	O	-1	35781
effect	O	-1	35781
of	O	-1	35781
clonidine	B-Chemical	D003000	35781
,	O	-1	35781
na@@	B-Chemical	D009278	35781
ph@@	I-Chemical	-1	35781
azol@@	I-Chemical	-1	35781
ine	I-Chemical	-1	35781
and	O	-1	35781
x@@	B-Chemical	C009695	35781
y@@	I-Chemical	-1	35781
lo@@	I-Chemical	-1	35781
met@@	I-Chemical	-1	35781
azol@@	I-Chemical	-1	35781
ine	I-Chemical	-1	35781
on	O	-1	35781
analge@@	O	-1	35781
sia	O	-1	35781
induced	O	-1	35781
by	O	-1	35781
morphine	B-Chemical	D009020	35781
,	O	-1	35781
co@@	B-Chemical	D003061	35781
de@@	I-Chemical	-1	35781
ine	I-Chemical	-1	35781
,	O	-1	35781
f@@	B-Chemical	D005283	35781
entan@@	I-Chemical	-1	35781
yl	I-Chemical	-1	35781
and	O	-1	35781
pent@@	B-Chemical	D010423	35781
az@@	I-Chemical	-1	35781
oc@@	I-Chemical	-1	35781
ine	I-Chemical	-1	35781
,	O	-1	35781
and	O	-1	35781
on	O	-1	35781
cat@@	B-Disease	D002375	35781
al@@	I-Disease	-1	35781
ep@@	I-Disease	-1	35781
tic	I-Disease	-1	35781
effect	O	-1	35781
of	O	-1	35781
morphine	B-Chemical	D009020	35781
,	O	-1	35781
co@@	B-Chemical	D003061	35781
d@@	I-Chemical	-1	35781
ine	I-Chemical	-1	35781
and	O	-1	35781
f@@	B-Chemical	D005283	35781
entan@@	I-Chemical	-1	35781
yl	I-Chemical	-1	35781
was	O	-1	35781
studied	O	-1	35781
in	O	-1	35781
rats.	O	-1	35781
The	O	-1	35781
bio@@	O	-1	35781
chemical	O	-1	35781
ass@@	O	-1	35781
ays	O	-1	35781
on	O	-1	35781
the	O	-1	35781
influence	O	-1	35781
of	O	-1	35781
four	O	-1	35781
analge@@	O	-1	35781
si@@	O	-1	35781
c@@	O	-1	35781
s	O	-1	35781
on	O	-1	35781
the	O	-1	35781
brain	O	-1	35781
concentration	O	-1	35781
and	O	-1	35781
t@@	O	-1	35781
ur@@	O	-1	35781
no@@	O	-1	35781
ver	O	-1	35781
of	O	-1	35781
nor@@	B-Chemical	D009638	35781
adren@@	I-Chemical	-1	35781
aline	I-Chemical	-1	35781
(	O	-1	35781
NA	B-Chemical	D009638	35781
)	O	-1	35781
were	O	-1	35781
also	O	-1	35781
per@@	O	-1	35781
for@@	O	-1	35781
me@@	O	-1	35781
d.	O	-1	35781
It	O	-1	35781
was	O	-1	35781
found	O	-1	35781
that	O	-1	35781
three	O	-1	35781
drugs	O	-1	35781
stimul@@	O	-1	35781
ating	O	-1	35781
central	O	-1	35781
NA	B-Chemical	D009638	35781
receptors	O	-1	35781
fail@@	O	-1	35781
ed	O	-1	35781
to	O	-1	35781
aff@@	O	-1	35781
ect	O	-1	35781
the	O	-1	35781
analge@@	O	-1	35781
sic	O	-1	35781
E@@	O	-1	35781
D@@	O	-1	35781
50	O	-1	35781
of	O	-1	35781
all	O	-1	35781
ant@@	O	-1	35781
in@@	O	-1	35781
ocicep@@	O	-1	35781
tive	O	-1	35781
agents	O	-1	35781
and	O	-1	35781
they	O	-1	35781
enhanced	O	-1	35781
cat@@	B-Disease	D002375	35781
al@@	I-Disease	-1	35781
ep@@	I-Disease	-1	35781
sy	I-Disease	-1	35781
induced	O	-1	35781
by	O	-1	35781
morphine	B-Chemical	D009020	35781
and	O	-1	35781
f@@	B-Chemical	D005283	35781
entan@@	I-Chemical	-1	35781
yl	I-Chemical	-1	35781
.	O	-1	35781
C@@	B-Chemical	D003061	35781
o@@	I-Chemical	-1	35781
de@@	I-Chemical	-1	35781
ine	I-Chemical	-1	35781
cat@@	B-Disease	D002375	35781
al@@	I-Disease	-1	35781
ep@@	I-Disease	-1	35781
sy	I-Disease	-1	35781
was	O	-1	35781
increased	O	-1	35781
by	O	-1	35781
clonidine	B-Chemical	D003000	35781
and	O	-1	35781
decreased	O	-1	35781
by	O	-1	35781
na@@	B-Chemical	D009278	35781
ph@@	I-Chemical	-1	35781
azol@@	I-Chemical	-1	35781
ine	I-Chemical	-1	35781
and	O	-1	35781
x@@	B-Chemical	C009695	35781
y@@	I-Chemical	-1	35781
lo@@	I-Chemical	-1	35781
met@@	I-Chemical	-1	35781
azol@@	I-Chemical	-1	35781
ine	I-Chemical	-1	35781
.	O	-1	35781
The	O	-1	35781
brain	O	-1	35781
concentration	O	-1	35781
of	O	-1	35781
NA	B-Chemical	D009638	35781
was	O	-1	35781
not	O	-1	35781
chang@@	O	-1	35781
ed	O	-1	35781
by	O	-1	35781
morphine	B-Chemical	D009020	35781
and	O	-1	35781
f@@	B-Chemical	D005283	35781
entan@@	I-Chemical	-1	35781
yl	I-Chemical	-1	35781
,	O	-1	35781
but	O	-1	35781
one	O	-1	35781
of	O	-1	35781
the	O	-1	35781
doses	O	-1	35781
of	O	-1	35781
co@@	B-Chemical	D003061	35781
de@@	I-Chemical	-1	35781
ine	I-Chemical	-1	35781
(4@@	O	-1	35781
5	O	-1	35781
mg/kg)	O	-1	35781
s@@	O	-1	35781
li@@	O	-1	35781
gh@@	O	-1	35781
tly	O	-1	35781
enhanced	O	-1	35781
it@@	O	-1	35781
.	O	-1	35781
P@@	B-Chemical	D010423	35781
ent@@	I-Chemical	-1	35781
az@@	I-Chemical	-1	35781
oc@@	I-Chemical	-1	35781
ine	I-Chemical	-1	35781
dose-@@	O	-1	35781
depend@@	O	-1	35781
ently	O	-1	35781
decreased	O	-1	35781
the	O	-1	35781
brain	O	-1	35781
level	O	-1	35781
of	O	-1	35781
NA	B-Chemical	D009638	35781
.	O	-1	35781
The	O	-1	35781
rate	O	-1	35781
of	O	-1	35781
NA	B-Chemical	D009638	35781
t@@	O	-1	35781
ur@@	O	-1	35781
no@@	O	-1	35781
ver	O	-1	35781
was	O	-1	35781
not	O	-1	35781
al@@	O	-1	35781
te@@	O	-1	35781
red	O	-1	35781
by	O	-1	35781
analge@@	O	-1	35781
si@@	O	-1	35781
c@@	O	-1	35781
s	O	-1	35781
ex@@	O	-1	35781
cep@@	O	-1	35781
t	O	-1	35781
for	O	-1	35781
the	O	-1	35781
higher	O	-1	35781
dose	O	-1	35781
of	O	-1	35781
f@@	B-Chemical	D005283	35781
entan@@	I-Chemical	-1	35781
yl	I-Chemical	-1	35781
(0.@@	O	-1	35781
2	O	-1	35781
mg/kg)	O	-1	35781
following	O	-1	35781
which	O	-1	35781
the	O	-1	35781
dis@@	O	-1	35781
appear@@	O	-1	35781
ance	O	-1	35781
of	O	-1	35781
NA	B-Chemical	D009638	35781
from	O	-1	35781
the	O	-1	35781
brain	O	-1	35781
was	O	-1	35781
di@@	O	-1	35781
min@@	O	-1	35781
is@@	O	-1	35781
he@@	O	-1	35781
d.	O	-1	35781
The	O	-1	35781
results	O	-1	35781
are	O	-1	35781
discus@@	O	-1	35781
sed	O	-1	35781
in	O	-1	35781
the	O	-1	35781
li@@	O	-1	35781
ght	O	-1	35781
of	O	-1	35781
various	O	-1	35781
and	O	-1	35781
non-@@	O	-1	35781
un@@	O	-1	35781
if@@	O	-1	35781
or@@	O	-1	35781
m	O	-1	35781
data	O	-1	35781
from	O	-1	35781
the	O	-1	35781
literat@@	O	-1	35781
ure.	O	-1	35781
It	O	-1	35781
is	O	-1	35781
suggested	O	-1	35781
that	O	-1	35781
in	O	-1	35781
rats	O	-1	35781
the	O	-1	35781
brain	O	-1	35781
NA	B-Chemical	D009638	35781
pl@@	O	-1	35781
ays	O	-1	35781
a	O	-1	35781
less	O	-1	35781
important	O	-1	35781
function	O	-1	35781
than	O	-1	35781
the	O	-1	35781
other	O	-1	35781
mon@@	B-Chemical	D015306	35781
o@@	I-Chemical	-1	35781
amin@@	I-Chemical	-1	35781
es	I-Chemical	-1	35781
in	O	-1	35781
the	O	-1	35781
behavi@@	O	-1	35781
o@@	O	-1	35781
ural	O	-1	35781
activity	O	-1	35781
of	O	-1	35781
pot@@	O	-1	35781
ent	O	-1	35781
analge@@	O	-1	35781
si@@	O	-1	35781
c@@	O	-1	35781
s.	O	-1	35781

M@@	O	-1	48835
odi@@	O	-1	48835
fic@@	O	-1	48835
ation	O	-1	48835
by	O	-1	48835
prop@@	B-Chemical	D011433	48835
ran@@	I-Chemical	-1	48835
o@@	I-Chemical	-1	48835
lol	I-Chemical	-1	48835
of	O	-1	48835
cardiovascular	O	-1	48835
effects	O	-1	48835
of	O	-1	48835
induced	O	-1	48835
hypo@@	B-Disease	D007003	48835
gly@@	I-Disease	-1	48835
ca@@	I-Disease	-1	48835
emia	I-Disease	-1	48835
.	O	-1	48835
The	O	-1	48835
cardiovascular	O	-1	48835
effects	O	-1	48835
of	O	-1	48835
hypo@@	B-Disease	D007003	48835
gly@@	I-Disease	-1	48835
ca@@	I-Disease	-1	48835
emia	I-Disease	-1	48835
,	O	-1	48835
with	O	-1	48835
and	O	-1	48835
without	O	-1	48835
beta-@@	O	-1	48835
block@@	O	-1	48835
ade@@	O	-1	48835
,	O	-1	48835
were	O	-1	48835
compared	O	-1	48835
in	O	-1	48835
fo@@	O	-1	48835
ur@@	O	-1	48835
te@@	O	-1	48835
en	O	-1	48835
healthy	O	-1	48835
men@@	O	-1	48835
.	O	-1	48835
E@@	O	-1	48835
ight	O	-1	48835
received	O	-1	48835
in@@	O	-1	48835
sul@@	O	-1	48835
in	O	-1	48835
al@@	O	-1	48835
one,	O	-1	48835
and	O	-1	48835
e@@	O	-1	48835
igh@@	O	-1	48835
t,	O	-1	48835
including	O	-1	48835
two	O	-1	48835
of	O	-1	48835
the	O	-1	48835
or@@	O	-1	48835
ig@@	O	-1	48835
inal	O	-1	48835
in@@	O	-1	48835
sul@@	O	-1	48835
in-@@	O	-1	48835
only	O	-1	48835
group@@	O	-1	48835
,	O	-1	48835
were	O	-1	48835
given	O	-1	48835
prop@@	B-Chemical	D011433	48835
ran@@	I-Chemical	-1	48835
o@@	I-Chemical	-1	48835
lol	I-Chemical	-1	48835
and	O	-1	48835
in@@	O	-1	48835
sul@@	O	-1	48835
in.	O	-1	48835
In	O	-1	48835
the	O	-1	48835
in@@	O	-1	48835
sul@@	O	-1	48835
in-@@	O	-1	48835
group	O	-1	48835
the	O	-1	48835
period	O	-1	48835
of	O	-1	48835
hypo@@	B-Disease	D007003	48835
gly@@	I-Disease	-1	48835
ca@@	I-Disease	-1	48835
emia	I-Disease	-1	48835
was	O	-1	48835
associated	O	-1	48835
with	O	-1	48835
an	O	-1	48835
increase	O	-1	48835
in	O	-1	48835
hear@@	O	-1	48835
t-@@	O	-1	48835
rate	O	-1	48835
and	O	-1	48835
a	O	-1	48835
f@@	O	-1	48835
all	O	-1	48835
in	O	-1	48835
di@@	O	-1	48835
ast@@	O	-1	48835
olic	O	-1	48835
blo@@	O	-1	48835
o@@	O	-1	48835
d-@@	O	-1	48835
pressu@@	O	-1	48835
re.	O	-1	48835
In	O	-1	48835
the	O	-1	48835
prop@@	B-Chemical	D011433	48835
ran@@	I-Chemical	-1	48835
o@@	I-Chemical	-1	48835
lol	I-Chemical	-1	48835
-@@	O	-1	48835
in@@	O	-1	48835
sul@@	O	-1	48835
in	O	-1	48835
group	O	-1	48835
there	O	-1	48835
was	O	-1	48835
a	O	-1	48835
significant	O	-1	48835
f@@	O	-1	48835
all	O	-1	48835
in	O	-1	48835
hear@@	O	-1	48835
t-@@	O	-1	48835
rate	O	-1	48835
in	O	-1	48835
most	O	-1	48835
subjects	O	-1	48835
and	O	-1	48835
an	O	-1	48835
increase	O	-1	48835
in	O	-1	48835
di@@	O	-1	48835
ast@@	O	-1	48835
olic	O	-1	48835
pressu@@	O	-1	48835
re.	O	-1	48835
T@@	O	-1	48835
yp@@	O	-1	48835
ical	O	-1	48835
S@@	O	-1	48835
-@@	O	-1	48835
T@@	O	-1	48835
/@@	O	-1	48835
T	O	-1	48835
changes	O	-1	48835
occurred	O	-1	48835
in	O	-1	48835
the	O	-1	48835
in@@	O	-1	48835
sul@@	O	-1	48835
in-@@	O	-1	48835
group	O	-1	48835
but	O	-1	48835
in	O	-1	48835
n@@	O	-1	48835
one	O	-1	48835
of	O	-1	48835
the	O	-1	48835
prop@@	B-Chemical	D011433	48835
ran@@	I-Chemical	-1	48835
o@@	I-Chemical	-1	48835
lol	I-Chemical	-1	48835
-@@	O	-1	48835
in@@	O	-1	48835
sul@@	O	-1	48835
in	O	-1	48835
group.	O	-1	48835
H@@	B-Disease	D006973	48835
y@@	I-Disease	-1	48835
per@@	I-Disease	-1	48835
ten@@	I-Disease	-1	48835
sion	I-Disease	-1	48835
in	O	-1	48835
dia@@	B-Disease	D003920	48835
be@@	I-Disease	-1	48835
tics	I-Disease	-1	48835
pr@@	O	-1	48835
one	O	-1	48835
to	O	-1	48835
hypo@@	B-Disease	D007003	48835
gly@@	I-Disease	-1	48835
ca@@	I-Disease	-1	48835
emia	I-Disease	-1	48835
at@@	O	-1	48835
tac@@	O	-1	48835
k@@	O	-1	48835
s	O	-1	48835
should	O	-1	48835
not	O	-1	48835
be	O	-1	48835
treated	O	-1	48835
with	O	-1	48835
beta-@@	O	-1	48835
block@@	O	-1	48835
ers	O	-1	48835
because	O	-1	48835
these	O	-1	48835
drugs	O	-1	48835
may	O	-1	48835
cause	O	-1	48835
a	O	-1	48835
sh@@	O	-1	48835
ar@@	O	-1	48835
p	O	-1	48835
ri@@	O	-1	48835
se	O	-1	48835
in	O	-1	48835
blo@@	O	-1	48835
o@@	O	-1	48835
d-@@	O	-1	48835
pressure	O	-1	48835
in	O	-1	48835
such	O	-1	48835
patients.	O	-1	48835

Pre@@	O	-1	89511
ven@@	O	-1	89511
tion	O	-1	89511
and	O	-1	89511
treatment	O	-1	89511
of	O	-1	89511
endo@@	B-Disease	D014591	89511
me@@	I-Disease	-1	89511
trial	I-Disease	-1	89511
disease	I-Disease	-1	89511
in	O	-1	89511
cl@@	O	-1	89511
im@@	O	-1	89511
ac@@	O	-1	89511
ter@@	O	-1	89511
ic	O	-1	89511
women	O	-1	89511
receiving	O	-1	89511
o@@	B-Chemical	D004967	89511
est@@	I-Chemical	-1	89511
ro@@	I-Chemical	-1	89511
gen	I-Chemical	-1	89511
therapy.	O	-1	89511
The	O	-1	89511
treatment	O	-1	89511
regimen@@	O	-1	89511
s	O	-1	89511
are	O	-1	89511
descri@@	O	-1	89511
bed	O	-1	89511
in	O	-1	89511
7@@	O	-1	89511
4	O	-1	89511
patients	O	-1	89511
with	O	-1	89511
endo@@	B-Disease	D014591	89511
me@@	I-Disease	-1	89511
trial	I-Disease	-1	89511
disease	I-Disease	-1	89511
among	O	-1	89511
8@@	O	-1	89511
50	O	-1	89511
cl@@	O	-1	89511
im@@	O	-1	89511
ac@@	O	-1	89511
ter@@	O	-1	89511
ic	O	-1	89511
women	O	-1	89511
receiving	O	-1	89511
o@@	B-Chemical	D004967	89511
est@@	I-Chemical	-1	89511
ro@@	I-Chemical	-1	89511
gen	I-Chemical	-1	89511
therapy.	O	-1	89511
C@@	O	-1	89511
ys@@	O	-1	89511
tic	O	-1	89511
hyper@@	B-Disease	D006965	89511
pl@@	I-Disease	-1	89511
a@@	I-Disease	-1	89511
sia	I-Disease	-1	89511
was	O	-1	89511
associated	O	-1	89511
with	O	-1	89511
un@@	O	-1	89511
op@@	O	-1	89511
pos@@	O	-1	89511
ed	O	-1	89511
o@@	B-Chemical	D004967	89511
est@@	I-Chemical	-1	89511
ro@@	I-Chemical	-1	89511
gen	I-Chemical	-1	89511
therapy	O	-1	89511
without	O	-1	89511
pro@@	B-Chemical	D011372	89511
g@@	I-Chemical	-1	89511
est@@	I-Chemical	-1	89511
ag@@	I-Chemical	-1	89511
en	I-Chemical	-1	89511
.	O	-1	89511
Two	O	-1	89511
cour@@	O	-1	89511
ses	O	-1	89511
of	O	-1	89511
21	O	-1	89511
days	O	-1	89511
of	O	-1	89511
5	O	-1	89511
mg	O	-1	89511
no@@	B-Chemical	D009640	89511
re@@	I-Chemical	-1	89511
th@@	I-Chemical	-1	89511
ist@@	I-Chemical	-1	89511
er@@	I-Chemical	-1	89511
one	I-Chemical	-1	89511
daily	O	-1	89511
caused	O	-1	89511
rever@@	O	-1	89511
sion	O	-1	89511
to	O	-1	89511
normal	O	-1	89511
in	O	-1	89511
all	O	-1	89511
5@@	O	-1	89511
7	O	-1	89511
cases	O	-1	89511
of	O	-1	89511
cys@@	O	-1	89511
tic	O	-1	89511
hyper@@	B-Disease	D006965	89511
pl@@	I-Disease	-1	89511
a@@	I-Disease	-1	89511
sia	I-Disease	-1	89511
and	O	-1	89511
6	O	-1	89511
of	O	-1	89511
the	O	-1	89511
8	O	-1	89511
cases	O	-1	89511
of	O	-1	89511
at@@	O	-1	89511
yp@@	O	-1	89511
ical	O	-1	89511
hyper@@	B-Disease	D006965	89511
pl@@	I-Disease	-1	89511
a@@	I-Disease	-1	89511
sia	I-Disease	-1	89511
.	O	-1	89511
4	O	-1	89511
cases	O	-1	89511
of	O	-1	89511
endo@@	B-Disease	D016889	89511
me@@	I-Disease	-1	89511
trial	I-Disease	-1	89511
carcin@@	I-Disease	-1	89511
oma	I-Disease	-1	89511
ref@@	O	-1	89511
er@@	O	-1	89511
red	O	-1	89511
from	O	-1	89511
el@@	O	-1	89511
se@@	O	-1	89511
wh@@	O	-1	89511
ere	O	-1	89511
demonstrated	O	-1	89511
the	O	-1	89511
pro@@	O	-1	89511
ble@@	O	-1	89511
ms	O	-1	89511
of	O	-1	89511
in@@	O	-1	89511
appro@@	O	-1	89511
pri@@	O	-1	89511
ate	O	-1	89511
and	O	-1	89511
un@@	O	-1	89511
su@@	O	-1	89511
per@@	O	-1	89511
v@@	O	-1	89511
is@@	O	-1	89511
ed	O	-1	89511
un@@	O	-1	89511
op@@	O	-1	89511
pos@@	O	-1	89511
ed	O	-1	89511
o@@	B-Chemical	D004967	89511
est@@	I-Chemical	-1	89511
ro@@	I-Chemical	-1	89511
gen	I-Chemical	-1	89511
therapy	O	-1	89511
and	O	-1	89511
the	O	-1	89511
diff@@	O	-1	89511
ic@@	O	-1	89511
ult@@	O	-1	89511
y	O	-1	89511
in	O	-1	89511
dist@@	O	-1	89511
ing@@	O	-1	89511
u@@	O	-1	89511
ish@@	O	-1	89511
ing	O	-1	89511
severe	O	-1	89511
hyper@@	B-Disease	D006965	89511
pl@@	I-Disease	-1	89511
a@@	I-Disease	-1	89511
sia	I-Disease	-1	89511
from	O	-1	89511
mal@@	B-Disease	D009369	89511
i@@	I-Disease	-1	89511
gn@@	I-Disease	-1	89511
anc@@	I-Disease	-1	89511
y	I-Disease	-1	89511
.	O	-1	89511
C@@	O	-1	89511
y@@	O	-1	89511
cl@@	O	-1	89511
ical	O	-1	89511
low@@	O	-1	89511
-@@	O	-1	89511
dose	O	-1	89511
o@@	B-Chemical	D004967	89511
est@@	I-Chemical	-1	89511
ro@@	I-Chemical	-1	89511
gen	I-Chemical	-1	89511
therapy	O	-1	89511
with	O	-1	89511
7-@@	O	-1	89511
-1@@	O	-1	89511
3	O	-1	89511
days	O	-1	89511
of	O	-1	89511
pro@@	B-Chemical	D011372	89511
g@@	I-Chemical	-1	89511
est@@	I-Chemical	-1	89511
ag@@	I-Chemical	-1	89511
en	I-Chemical	-1	89511
does	O	-1	89511
not	O	-1	89511
se@@	O	-1	89511
em	O	-1	89511
to	O	-1	89511
increase	O	-1	89511
the	O	-1	89511
risk	O	-1	89511
of	O	-1	89511
endo@@	B-Disease	D004714	89511
me@@	I-Disease	-1	89511
trial	I-Disease	-1	89511
hyper@@	I-Disease	-1	89511
pl@@	I-Disease	-1	89511
a@@	I-Disease	-1	89511
sia	I-Disease	-1	89511
or	O	-1	89511
carcin@@	B-Disease	D002277	89511
oma	I-Disease	-1	89511
.	O	-1	89511

P@@	B-Disease	D012010	146391
ure	I-Disease	-1	146391
red	I-Disease	-1	146391
cell	I-Disease	-1	146391
ap@@	I-Disease	-1	146391
l@@	I-Disease	-1	146391
a@@	I-Disease	-1	146391
sia	I-Disease	-1	146391
,	O	-1	146391
toxic	B-Disease	D003875	146391
der@@	I-Disease	-1	146391
m@@	I-Disease	-1	146391
ati@@	I-Disease	-1	146391
tis	I-Disease	-1	146391
and	O	-1	146391
lymph@@	B-Disease	D008206	146391
aden@@	I-Disease	-1	146391
o@@	I-Disease	-1	146391
pathy	I-Disease	-1	146391
in	O	-1	146391
a	O	-1	146391
patient	O	-1	146391
taking	O	-1	146391
di@@	B-Chemical	D010672	146391
phenyl@@	I-Chemical	-1	146391
hy@@	I-Chemical	-1	146391
d@@	I-Chemical	-1	146391
an@@	I-Chemical	-1	146391
to@@	I-Chemical	-1	146391
in	I-Chemical	-1	146391
.	O	-1	146391
A	O	-1	146391
patient	O	-1	146391
taking	O	-1	146391
di@@	B-Chemical	D010672	146391
phenyl@@	I-Chemical	-1	146391
hy@@	I-Chemical	-1	146391
d@@	I-Chemical	-1	146391
an@@	I-Chemical	-1	146391
to@@	I-Chemical	-1	146391
in	I-Chemical	-1	146391
for	O	-1	146391
3	O	-1	146391
weeks	O	-1	146391
developed	O	-1	146391
a	O	-1	146391
gener@@	O	-1	146391
al@@	O	-1	146391
ized	O	-1	146391
s@@	B-Disease	D005076	146391
k@@	I-Disease	-1	146391
in	I-Disease	-1	146391
r@@	I-Disease	-1	146391
as@@	I-Disease	-1	146391
h	I-Disease	-1	146391
,	O	-1	146391
lymph@@	B-Disease	D008206	146391
aden@@	I-Disease	-1	146391
o@@	I-Disease	-1	146391
pathy	I-Disease	-1	146391
and	O	-1	146391
p@@	B-Disease	D012010	146391
ure	I-Disease	-1	146391
red	I-Disease	-1	146391
cell	I-Disease	-1	146391
ap@@	I-Disease	-1	146391
l@@	I-Disease	-1	146391
a@@	I-Disease	-1	146391
sia	I-Disease	-1	146391
.	O	-1	146391
After	O	-1	146391
withdrawal	O	-1	146391
of	O	-1	146391
the	O	-1	146391
pharmac@@	O	-1	146391
on	O	-1	146391
all	O	-1	146391
symptoms	O	-1	146391
dis@@	O	-1	146391
appe@@	O	-1	146391
a@@	O	-1	146391
red	O	-1	146391
spont@@	O	-1	146391
ane@@	O	-1	146391
ous@@	O	-1	146391
ly.	O	-1	146391
S@@	B-Disease	D005076	146391
k@@	I-Disease	-1	146391
in	I-Disease	-1	146391
r@@	I-Disease	-1	146391
as@@	I-Disease	-1	146391
h	I-Disease	-1	146391
is	O	-1	146391
a	O	-1	146391
we@@	O	-1	146391
ll@@	O	-1	146391
-@@	O	-1	146391
known	O	-1	146391
complication	O	-1	146391
of	O	-1	146391
di@@	B-Chemical	D010672	146391
phenyl@@	I-Chemical	-1	146391
hy@@	I-Chemical	-1	146391
d@@	I-Chemical	-1	146391
an@@	I-Chemical	-1	146391
to@@	I-Chemical	-1	146391
in	I-Chemical	-1	146391
treatment	O	-1	146391
as	O	-1	146391
is	O	-1	146391
ben@@	O	-1	146391
ig@@	O	-1	146391
n	O	-1	146391
and	O	-1	146391
mal@@	O	-1	146391
i@@	O	-1	146391
gn@@	O	-1	146391
ant	O	-1	146391
lymph@@	B-Disease	D008206	146391
aden@@	I-Disease	-1	146391
o@@	I-Disease	-1	146391
pathy	I-Disease	-1	146391
.	O	-1	146391
P@@	B-Disease	D012010	146391
ure	I-Disease	-1	146391
red	I-Disease	-1	146391
cell	I-Disease	-1	146391
ap@@	I-Disease	-1	146391
l@@	I-Disease	-1	146391
a@@	I-Disease	-1	146391
sia	I-Disease	-1	146391
associated	O	-1	146391
with	O	-1	146391
di@@	B-Chemical	D010672	146391
phenyl@@	I-Chemical	-1	146391
hy@@	I-Chemical	-1	146391
d@@	I-Chemical	-1	146391
an@@	I-Chemical	-1	146391
to@@	I-Chemical	-1	146391
in	I-Chemical	-1	146391
medic@@	O	-1	146391
ation	O	-1	146391
has	O	-1	146391
been	O	-1	146391
reported	O	-1	146391
in	O	-1	146391
3	O	-1	146391
patients.	O	-1	146391
The	O	-1	146391
ex@@	O	-1	146391
ac@@	O	-1	146391
t	O	-1	146391
mechanism	O	-1	146391
by	O	-1	146391
which	O	-1	146391
di@@	B-Chemical	D010672	146391
phenyl@@	I-Chemical	-1	146391
hy@@	I-Chemical	-1	146391
d@@	I-Chemical	-1	146391
an@@	I-Chemical	-1	146391
to@@	I-Chemical	-1	146391
in	I-Chemical	-1	146391
ex@@	O	-1	146391
er@@	O	-1	146391
ts	O	-1	146391
its	O	-1	146391
toxic	O	-1	146391
effects	O	-1	146391
is	O	-1	146391
not	O	-1	146391
know@@	O	-1	146391
n@@	O	-1	146391
.	O	-1	146391
In	O	-1	146391
this	O	-1	146391
patient	O	-1	146391
the	O	-1	146391
time	O	-1	146391
rel@@	O	-1	146391
ation	O	-1	146391
between	O	-1	146391
the	O	-1	146391
ing@@	O	-1	146391
es@@	O	-1	146391
tion	O	-1	146391
of	O	-1	146391
di@@	B-Chemical	D010672	146391
phenyl@@	I-Chemical	-1	146391
hy@@	I-Chemical	-1	146391
d@@	I-Chemical	-1	146391
an@@	I-Chemical	-1	146391
to@@	I-Chemical	-1	146391
in	I-Chemical	-1	146391
and	O	-1	146391
the	O	-1	146391
occur@@	O	-1	146391
rence	O	-1	146391
of	O	-1	146391
the	O	-1	146391
s@@	B-Disease	D005076	146391
k@@	I-Disease	-1	146391
in	I-Disease	-1	146391
r@@	I-Disease	-1	146391
as@@	I-Disease	-1	146391
h	I-Disease	-1	146391
,	O	-1	146391
lymph@@	B-Disease	D008206	146391
aden@@	I-Disease	-1	146391
o@@	I-Disease	-1	146391
pathy	I-Disease	-1	146391
and	O	-1	146391
p@@	B-Disease	D012010	146391
ure	I-Disease	-1	146391
red	I-Disease	-1	146391
cell	I-Disease	-1	146391
ap@@	I-Disease	-1	146391
l@@	I-Disease	-1	146391
a@@	I-Disease	-1	146391
sia	I-Disease	-1	146391
is	O	-1	146391
very	O	-1	146391
sugg@@	O	-1	146391
es@@	O	-1	146391
tive	O	-1	146391
of	O	-1	146391
a	O	-1	146391
direct	O	-1	146391
con@@	O	-1	146391
nec@@	O	-1	146391
tion.	O	-1	146391

C@@	O	-1	256433
ont@@	O	-1	256433
in@@	O	-1	256433
u@@	O	-1	256433
ous	O	-1	256433
infusion	O	-1	256433
to@@	B-Chemical	D014031	256433
b@@	I-Chemical	-1	256433
ram@@	I-Chemical	-1	256433
ycin	I-Chemical	-1	256433
combined	O	-1	256433
with	O	-1	256433
carb@@	B-Chemical	D002228	256433
en@@	I-Chemical	-1	256433
icill@@	I-Chemical	-1	256433
in	I-Chemical	-1	256433
for	O	-1	256433
inf@@	B-Disease	D007239	256433
ec@@	I-Disease	-1	256433
tions	I-Disease	-1	256433
in	O	-1	256433
cancer	B-Disease	D009369	256433
patients.	O	-1	256433
The	O	-1	256433
c@@	O	-1	256433
ure	O	-1	256433
rate	O	-1	256433
of	O	-1	256433
inf@@	B-Disease	D007239	256433
ec@@	I-Disease	-1	256433
tions	I-Disease	-1	256433
in	O	-1	256433
cancer	B-Disease	D009369	256433
patients	O	-1	256433
is	O	-1	256433
ad@@	O	-1	256433
ver@@	O	-1	256433
se@@	O	-1	256433
ly	O	-1	256433
affected	O	-1	256433
by	O	-1	256433
ne@@	B-Disease	D009503	256433
ut@@	I-Disease	-1	256433
ro@@	I-Disease	-1	256433
pen@@	I-Disease	-1	256433
ia	I-Disease	-1	256433
(@@	O	-1	256433
less	O	-1	256433
than	O	-1	256433
1@@	O	-1	256433
,@@	O	-1	256433
0@@	O	-1	256433
0@@	O	-1	256433
0@@	O	-1	256433
/@@	O	-1	256433
mm@@	O	-1	256433
3@@	O	-1	256433
).	O	-1	256433
In	O	-1	256433
partic@@	O	-1	256433
ul@@	O	-1	256433
ar@@	O	-1	256433
,	O	-1	256433
patients	O	-1	256433
with	O	-1	256433
severe	O	-1	256433
ne@@	B-Disease	D009503	256433
ut@@	I-Disease	-1	256433
ro@@	I-Disease	-1	256433
pen@@	I-Disease	-1	256433
ia	I-Disease	-1	256433
(@@	O	-1	256433
less	O	-1	256433
than	O	-1	256433
10@@	O	-1	256433
0@@	O	-1	256433
/@@	O	-1	256433
mm@@	O	-1	256433
3@@	O	-1	256433
)	O	-1	256433
have	O	-1	256433
shown	O	-1	256433
a	O	-1	256433
po@@	O	-1	256433
or	O	-1	256433
response	O	-1	256433
to	O	-1	256433
anti@@	O	-1	256433
bio@@	O	-1	256433
tic@@	O	-1	256433
s.	O	-1	256433
To	O	-1	256433
over@@	O	-1	256433
com@@	O	-1	256433
e	O	-1	256433
the	O	-1	256433
adverse	O	-1	256433
effects	O	-1	256433
of	O	-1	256433
ne@@	B-Disease	D009503	256433
ut@@	I-Disease	-1	256433
ro@@	I-Disease	-1	256433
pen@@	I-Disease	-1	256433
ia	I-Disease	-1	256433
,	O	-1	256433
to@@	B-Chemical	D014031	256433
b@@	I-Chemical	-1	256433
ram@@	I-Chemical	-1	256433
ycin	I-Chemical	-1	256433
was	O	-1	256433
given	O	-1	256433
by	O	-1	256433
continu@@	O	-1	256433
ous	O	-1	256433
infusion	O	-1	256433
and	O	-1	256433
combined	O	-1	256433
with	O	-1	256433
inter@@	O	-1	256433
mit@@	O	-1	256433
t@@	O	-1	256433
ent	O	-1	256433
carb@@	B-Chemical	D002228	256433
en@@	I-Chemical	-1	256433
icill@@	I-Chemical	-1	256433
in	I-Chemical	-1	256433
.	O	-1	256433
T@@	B-Chemical	D014031	256433
ob@@	I-Chemical	-1	256433
ram@@	I-Chemical	-1	256433
ycin	I-Chemical	-1	256433
was	O	-1	256433
given	O	-1	256433
to	O	-1	256433
a	O	-1	256433
total	O	-1	256433
daily	O	-1	256433
dose	O	-1	256433
of	O	-1	256433
3@@	O	-1	256433
00	O	-1	256433
mg/m@@	O	-1	256433
2	O	-1	256433
and	O	-1	256433
carb@@	B-Chemical	D002228	256433
en@@	I-Chemical	-1	256433
icill@@	I-Chemical	-1	256433
in	I-Chemical	-1	256433
was	O	-1	256433
given	O	-1	256433
at	O	-1	256433
a	O	-1	256433
dose	O	-1	256433
of	O	-1	256433
5	O	-1	256433
g@@	O	-1	256433
m	O	-1	256433
every	O	-1	256433
four	O	-1	256433
hour@@	O	-1	256433
s.	O	-1	256433
There	O	-1	256433
were	O	-1	256433
12@@	O	-1	256433
5	O	-1	256433
inf@@	O	-1	256433
ecti@@	O	-1	256433
ous	O	-1	256433
episo@@	O	-1	256433
des	O	-1	256433
in	O	-1	256433
1@@	O	-1	256433
16	O	-1	256433
cancer	B-Disease	D009369	256433
patients	O	-1	256433
receiving	O	-1	256433
my@@	O	-1	256433
e@@	O	-1	256433
lo@@	O	-1	256433
sup@@	O	-1	256433
pressive	O	-1	256433
chemo@@	O	-1	256433
therapy.	O	-1	256433
The	O	-1	256433
over@@	O	-1	256433
all	O	-1	256433
c@@	O	-1	256433
ure	O	-1	256433
rate	O	-1	256433
was	O	-1	256433
7@@	O	-1	256433
0@@	O	-1	256433
%.	O	-1	256433
P@@	B-Disease	D011014	256433
ne@@	I-Disease	-1	256433
um@@	I-Disease	-1	256433
on@@	I-Disease	-1	256433
ia	I-Disease	-1	256433
was	O	-1	256433
the	O	-1	256433
most	O	-1	256433
common	O	-1	256433
inf@@	B-Disease	D007239	256433
ection	I-Disease	-1	256433
and	O	-1	256433
6@@	O	-1	256433
1@@	O	-1	256433
%	O	-1	256433
of	O	-1	256433
5@@	O	-1	256433
9	O	-1	256433
episo@@	O	-1	256433
des	O	-1	256433
were	O	-1	256433
c@@	O	-1	256433
ure@@	O	-1	256433
d.	O	-1	256433
G@@	O	-1	256433
ram@@	O	-1	256433
-@@	O	-1	256433
negative	O	-1	256433
bac@@	O	-1	256433
ill@@	O	-1	256433
i	O	-1	256433
were	O	-1	256433
the	O	-1	256433
most	O	-1	256433
common	O	-1	256433
ca@@	O	-1	256433
us@@	O	-1	256433
ative	O	-1	256433
org@@	O	-1	256433
an@@	O	-1	256433
is@@	O	-1	256433
ms	O	-1	256433
and	O	-1	256433
6@@	O	-1	256433
9@@	O	-1	256433
%	O	-1	256433
of	O	-1	256433
these	O	-1	256433
inf@@	B-Disease	D007239	256433
ec@@	I-Disease	-1	256433
tions	I-Disease	-1	256433
were	O	-1	256433
c@@	O	-1	256433
ure@@	O	-1	256433
d.	O	-1	256433
The	O	-1	256433
most	O	-1	256433
common	O	-1	256433
path@@	O	-1	256433
o@@	O	-1	256433
gen	O	-1	256433
was	O	-1	256433
K@@	O	-1	256433
le@@	O	-1	256433
b@@	O	-1	256433
si@@	O	-1	256433
ell@@	O	-1	256433
a	O	-1	256433
p@@	B-Disease	D011014	256433
ne@@	I-Disease	-1	256433
um@@	I-Disease	-1	256433
on@@	I-Disease	-1	256433
ia@@	I-Disease	-1	256433
e	I-Disease	-1	256433
and	O	-1	256433
th@@	O	-1	256433
is@@	O	-1	256433
,	O	-1	256433
to@@	O	-1	256433
ge@@	O	-1	256433
ther	O	-1	256433
with	O	-1	256433
E@@	O	-1	256433
sch@@	O	-1	256433
er@@	O	-1	256433
ic@@	O	-1	256433
hi@@	O	-1	256433
a	O	-1	256433
co@@	O	-1	256433
l@@	O	-1	256433
i	O	-1	256433
and	O	-1	256433
P@@	O	-1	256433
se@@	O	-1	256433
u@@	O	-1	256433
do@@	O	-1	256433
mon@@	O	-1	256433
as	O	-1	256433
a@@	O	-1	256433
er@@	O	-1	256433
u@@	O	-1	256433
g@@	O	-1	256433
in@@	O	-1	256433
os@@	O	-1	256433
a,	O	-1	256433
ac@@	O	-1	256433
coun@@	O	-1	256433
ted	O	-1	256433
for	O	-1	256433
7@@	O	-1	256433
4@@	O	-1	256433
%	O	-1	256433
of	O	-1	256433
all	O	-1	256433
gram@@	B-Disease	D016905	256433
-@@	I-Disease	-1	256433
negative	I-Disease	-1	256433
bac@@	I-Disease	-1	256433
ill@@	I-Disease	-1	256433
ary	I-Disease	-1	256433
inf@@	I-Disease	-1	256433
ec@@	I-Disease	-1	256433
tions	I-Disease	-1	256433
.	O	-1	256433
R@@	O	-1	256433
es@@	O	-1	256433
p@@	O	-1	256433
on@@	O	-1	256433
se	O	-1	256433
was	O	-1	256433
not	O	-1	256433
influ@@	O	-1	256433
enc@@	O	-1	256433
ed	O	-1	256433
by	O	-1	256433
the	O	-1	256433
initial	O	-1	256433
ne@@	O	-1	256433
ut@@	O	-1	256433
ro@@	O	-1	256433
ph@@	O	-1	256433
il	O	-1	256433
coun@@	O	-1	256433
t,	O	-1	256433
with	O	-1	256433
a	O	-1	256433
6@@	O	-1	256433
2@@	O	-1	256433
%	O	-1	256433
c@@	O	-1	256433
ure	O	-1	256433
rate	O	-1	256433
for	O	-1	256433
3@@	O	-1	256433
9	O	-1	256433
episo@@	O	-1	256433
des	O	-1	256433
associated	O	-1	256433
with	O	-1	256433
severe	O	-1	256433
ne@@	B-Disease	D009503	256433
ut@@	I-Disease	-1	256433
ro@@	I-Disease	-1	256433
pen@@	I-Disease	-1	256433
ia	I-Disease	-1	256433
.	O	-1	256433
However,	O	-1	256433
failure	O	-1	256433
of	O	-1	256433
the	O	-1	256433
ne@@	O	-1	256433
ut@@	O	-1	256433
ro@@	O	-1	256433
ph@@	O	-1	256433
il	O	-1	256433
coun@@	O	-1	256433
t	O	-1	256433
to	O	-1	256433
increase	O	-1	256433
during	O	-1	256433
therapy	O	-1	256433
ad@@	O	-1	256433
ver@@	O	-1	256433
se@@	O	-1	256433
ly	O	-1	256433
affected	O	-1	256433
respon@@	O	-1	256433
se.	O	-1	256433
A@@	B-Disease	D053099	256433
z@@	I-Disease	-1	256433
ot@@	I-Disease	-1	256433
emia	I-Disease	-1	256433
was	O	-1	256433
the	O	-1	256433
major	O	-1	256433
side	O	-1	256433
effect	O	-1	256433
reco@@	O	-1	256433
gn@@	O	-1	256433
iz@@	O	-1	256433
ed,	O	-1	256433
and	O	-1	256433
it	O	-1	256433
occurred	O	-1	256433
in	O	-1	256433
1@@	O	-1	256433
1@@	O	-1	256433
%	O	-1	256433
of	O	-1	256433
episo@@	O	-1	256433
d@@	O	-1	256433
es.	O	-1	256433
M@@	O	-1	256433
a@@	O	-1	256433
j@@	O	-1	256433
or	O	-1	256433
az@@	B-Disease	D053099	256433
ot@@	I-Disease	-1	256433
emia	I-Disease	-1	256433
(@@	O	-1	256433
serum	O	-1	256433
creatinine	B-Chemical	D003404	256433
greater	O	-1	256433
than	O	-1	256433
2.@@	O	-1	256433
5	O	-1	256433
mg/d@@	O	-1	256433
l	O	-1	256433
or	O	-1	256433
B@@	O	-1	256433
U@@	O	-1	256433
N	O	-1	256433
greater	O	-1	256433
than	O	-1	256433
50	O	-1	256433
mg/d@@	O	-1	256433
l@@	O	-1	256433
)	O	-1	256433
occurred	O	-1	256433
in	O	-1	256433
only	O	-1	256433
2@@	O	-1	256433
%.	O	-1	256433
A@@	B-Disease	D053099	256433
z@@	I-Disease	-1	256433
ot@@	I-Disease	-1	256433
emia	I-Disease	-1	256433
was	O	-1	256433
not	O	-1	256433
related	O	-1	256433
to	O	-1	256433
duration	O	-1	256433
of	O	-1	256433
therapy	O	-1	256433
or	O	-1	256433
serum	O	-1	256433
to@@	B-Chemical	D014031	256433
b@@	I-Chemical	-1	256433
ram@@	I-Chemical	-1	256433
ycin	I-Chemical	-1	256433
concentr@@	O	-1	256433
ation.	O	-1	256433
This	O	-1	256433
anti@@	O	-1	256433
bio@@	O	-1	256433
tic	O	-1	256433
regi@@	O	-1	256433
men	O	-1	256433
showed	O	-1	256433
both	O	-1	256433
therapeutic	O	-1	256433
efficacy	O	-1	256433
and	O	-1	256433
ac@@	O	-1	256433
ce@@	O	-1	256433
pt@@	O	-1	256433
able	O	-1	256433
renal	B-Disease	D007674	256433
toxicity	I-Disease	-1	256433
for	O	-1	256433
these	O	-1	256433
patients.	O	-1	256433

Rec@@	O	-1	448423
ur@@	O	-1	448423
rent	O	-1	448423
sub@@	B-Disease	D013345	448423
arac@@	I-Disease	-1	448423
h@@	I-Disease	-1	448423
no@@	I-Disease	-1	448423
id	I-Disease	-1	448423
hemorrh@@	I-Disease	-1	448423
age	I-Disease	-1	448423
associated	O	-1	448423
with	O	-1	448423
amin@@	B-Chemical	D000614	448423
oc@@	I-Chemical	-1	448423
a@@	I-Chemical	-1	448423
pro@@	I-Chemical	-1	448423
ic	I-Chemical	-1	448423
acid	I-Chemical	-1	448423
therapy	O	-1	448423
and	O	-1	448423
acute	B-Disease	D007674	448423
renal	I-Disease	-1	448423
artery	I-Disease	-1	448423
thrombo@@	I-Disease	-1	448423
sis	I-Disease	-1	448423
.	O	-1	448423
C@@	O	-1	448423
ase	O	-1	448423
repor@@	O	-1	448423
t.	O	-1	448423
E@@	B-Chemical	D015119	448423
p@@	I-Chemical	-1	448423
si@@	I-Chemical	-1	448423
l@@	I-Chemical	-1	448423
on	I-Chemical	-1	448423
amin@@	I-Chemical	-1	448423
oc@@	I-Chemical	-1	448423
a@@	I-Chemical	-1	448423
pro@@	I-Chemical	-1	448423
ic	I-Chemical	-1	448423
acid	I-Chemical	-1	448423
(	O	-1	448423
E@@	B-Chemical	D015119	448423
AC@@	I-Chemical	-1	448423
A	I-Chemical	-1	448423
)	O	-1	448423
has	O	-1	448423
been	O	-1	448423
used	O	-1	448423
to	O	-1	448423
prev@@	O	-1	448423
ent	O	-1	448423
re@@	O	-1	448423
ble@@	O	-1	448423
ed@@	O	-1	448423
ing	O	-1	448423
in	O	-1	448423
patients	O	-1	448423
with	O	-1	448423
sub@@	B-Disease	D013345	448423
arac@@	I-Disease	-1	448423
h@@	I-Disease	-1	448423
no@@	I-Disease	-1	448423
id	I-Disease	-1	448423
hemorrh@@	I-Disease	-1	448423
age	I-Disease	-1	448423
(	O	-1	448423
S@@	B-Disease	D013345	448423
A@@	I-Disease	-1	448423
H	I-Disease	-1	448423
).	O	-1	448423
Although	O	-1	448423
this	O	-1	448423
agent	O	-1	448423
does	O	-1	448423
decrease	O	-1	448423
the	O	-1	448423
frequency	O	-1	448423
of	O	-1	448423
re@@	O	-1	448423
ble@@	O	-1	448423
ed@@	O	-1	448423
ing,	O	-1	448423
several	O	-1	448423
reports	O	-1	448423
have	O	-1	448423
descri@@	O	-1	448423
bed	O	-1	448423
thrombotic	B-Disease	D013927	448423
complications	O	-1	448423
of	O	-1	448423
E@@	B-Chemical	D015119	448423
AC@@	I-Chemical	-1	448423
A	I-Chemical	-1	448423
therapy.	O	-1	448423
These	O	-1	448423
complications	O	-1	448423
have	O	-1	448423
included	O	-1	448423
clinical	O	-1	448423
deter@@	O	-1	448423
i@@	O	-1	448423
or@@	O	-1	448423
ation	O	-1	448423
and	O	-1	448423
intrac@@	B-Disease	D020767	448423
ranial	I-Disease	-1	448423
vascular	I-Disease	-1	448423
thrombo@@	I-Disease	-1	448423
sis	I-Disease	-1	448423
in	O	-1	448423
patients	O	-1	448423
with	O	-1	448423
S@@	B-Disease	D013345	448423
A@@	I-Disease	-1	448423
H	I-Disease	-1	448423
,	O	-1	448423
arter@@	O	-1	448423
i@@	O	-1	448423
ol@@	O	-1	448423
ar	O	-1	448423
and	O	-1	448423
cap@@	O	-1	448423
ill@@	O	-1	448423
ary	O	-1	448423
fib@@	O	-1	448423
rin	O	-1	448423
throm@@	B-Disease	D013927	448423
b@@	I-Disease	-1	448423
i	I-Disease	-1	448423
in	O	-1	448423
patients	O	-1	448423
with	O	-1	448423
fib@@	O	-1	448423
r@@	O	-1	448423
in@@	O	-1	448423
oly@@	O	-1	448423
tic	O	-1	448423
syndrom@@	O	-1	448423
es	O	-1	448423
treated	O	-1	448423
with	O	-1	448423
E@@	B-Chemical	D015119	448423
AC@@	I-Chemical	-1	448423
A	I-Chemical	-1	448423
,	O	-1	448423
or	O	-1	448423
other	O	-1	448423
thrombo@@	B-Disease	D013923	448423
emb@@	I-Disease	-1	448423
olic	I-Disease	-1	448423
phen@@	I-Disease	-1	448423
om@@	I-Disease	-1	448423
en@@	I-Disease	-1	448423
a	I-Disease	-1	448423
.	O	-1	448423
S@@	O	-1	448423
inc@@	O	-1	448423
e	O	-1	448423
intra@@	O	-1	448423
vascular	O	-1	448423
fib@@	O	-1	448423
rin	O	-1	448423
throm@@	B-Disease	D013927	448423
b@@	I-Disease	-1	448423
i	I-Disease	-1	448423
are	O	-1	448423
often	O	-1	448423
observed	O	-1	448423
in	O	-1	448423
patients	O	-1	448423
with	O	-1	448423
fib@@	O	-1	448423
r@@	O	-1	448423
in@@	O	-1	448423
oly@@	O	-1	448423
tic	O	-1	448423
disorder@@	O	-1	448423
s,	O	-1	448423
E@@	B-Chemical	D015119	448423
AC@@	I-Chemical	-1	448423
A	I-Chemical	-1	448423
should	O	-1	448423
not	O	-1	448423
be	O	-1	448423
implic@@	O	-1	448423
ated	O	-1	448423
in	O	-1	448423
the	O	-1	448423
path@@	O	-1	448423
o@@	O	-1	448423
genesis	O	-1	448423
of	O	-1	448423
fib@@	O	-1	448423
rin	O	-1	448423
throm@@	B-Disease	D013927	448423
b@@	I-Disease	-1	448423
i	I-Disease	-1	448423
in	O	-1	448423
patients	O	-1	448423
with	O	-1	448423
dis@@	B-Disease	D004211	448423
se@@	I-Disease	-1	448423
min@@	I-Disease	-1	448423
ated	I-Disease	-1	448423
intra@@	I-Disease	-1	448423
vascular	I-Disease	-1	448423
co@@	I-Disease	-1	448423
ag@@	I-Disease	-1	448423
ulation	I-Disease	-1	448423
or	O	-1	448423
other	O	-1	448423
"	O	-1	448423
consum@@	B-Disease	D004211	448423
ption	I-Disease	-1	448423
co@@	I-Disease	-1	448423
ag@@	I-Disease	-1	448423
ulo@@	I-Disease	-1	448423
path@@	I-Disease	-1	448423
i@@	I-Disease	-1	448423
es	I-Disease	-1	448423
.@@	O	-1	448423
"	O	-1	448423
This	O	-1	448423
report	O	-1	448423
descri@@	O	-1	448423
b@@	O	-1	448423
es	O	-1	448423
sub@@	O	-1	448423
total	O	-1	448423
infarction	B-Disease	D007238	448423
of	O	-1	448423
the	O	-1	448423
kidney	O	-1	448423
due	O	-1	448423
to	O	-1	448423
thrombo@@	B-Disease	D007674	448423
sis	I-Disease	-1	448423
of	I-Disease	-1	448423
a	I-Disease	-1	448423
normal	I-Disease	-1	448423
renal	I-Disease	-1	448423
artery	I-Disease	-1	448423
.	O	-1	448423
This	O	-1	448423
oc@@	O	-1	448423
cl@@	O	-1	448423
usion	O	-1	448423
occurred	O	-1	448423
after	O	-1	448423
E@@	B-Chemical	D015119	448423
AC@@	I-Chemical	-1	448423
A	I-Chemical	-1	448423
therapy	O	-1	448423
in	O	-1	448423
a	O	-1	448423
patient	O	-1	448423
with	O	-1	448423
S@@	B-Disease	D013345	448423
A@@	I-Disease	-1	448423
H	I-Disease	-1	448423
and	O	-1	448423
histo@@	O	-1	448423
path@@	O	-1	448423
ological	O	-1	448423
doc@@	O	-1	448423
um@@	O	-1	448423
ent@@	O	-1	448423
ation	O	-1	448423
of	O	-1	448423
recur@@	O	-1	448423
rent	O	-1	448423
S@@	B-Disease	D013345	448423
A@@	I-Disease	-1	448423
H	I-Disease	-1	448423
.	O	-1	448423
The	O	-1	448423
cor@@	O	-1	448423
respon@@	O	-1	448423
ding	O	-1	448423
clinical	O	-1	448423
ev@@	O	-1	448423
ent	O	-1	448423
was	O	-1	448423
character@@	O	-1	448423
ized	O	-1	448423
by	O	-1	448423
mark@@	O	-1	448423
ed	O	-1	448423
hypertension	B-Disease	D006973	448423
and	O	-1	448423
ab@@	O	-1	448423
ru@@	O	-1	448423
p@@	O	-1	448423
t	O	-1	448423
neurolog@@	O	-1	448423
ical	O	-1	448423
deter@@	O	-1	448423
i@@	O	-1	448423
or@@	O	-1	448423
ation.	O	-1	448423

L@@	O	-1	573555
on@@	O	-1	573555
g@@	O	-1	573555
-term	O	-1	573555
prop@@	B-Chemical	D011433	573555
ran@@	I-Chemical	-1	573555
o@@	I-Chemical	-1	573555
lol	I-Chemical	-1	573555
therapy	O	-1	573555
in	O	-1	573555
pregn@@	O	-1	573555
anc@@	O	-1	573555
y@@	O	-1	573555
:	O	-1	573555
mat@@	O	-1	573555
er@@	O	-1	573555
n@@	O	-1	573555
al	O	-1	573555
and	O	-1	573555
f@@	O	-1	573555
et@@	O	-1	573555
al	O	-1	573555
out@@	O	-1	573555
co@@	O	-1	573555
me.	O	-1	573555
Pro@@	B-Chemical	D011433	573555
p@@	I-Chemical	-1	573555
ran@@	I-Chemical	-1	573555
o@@	I-Chemical	-1	573555
lol	I-Chemical	-1	573555
,	O	-1	573555
a	O	-1	573555
beta-@@	O	-1	573555
adrenergic	O	-1	573555
block@@	O	-1	573555
ing	O	-1	573555
agent@@	O	-1	573555
,	O	-1	573555
has	O	-1	573555
found	O	-1	573555
an	O	-1	573555
important	O	-1	573555
posi@@	O	-1	573555
tion	O	-1	573555
in	O	-1	573555
the	O	-1	573555
p@@	O	-1	573555
rac@@	O	-1	573555
ti@@	O	-1	573555
ce	O	-1	573555
of	O	-1	573555
medic@@	O	-1	573555
ine.	O	-1	573555
I@@	O	-1	573555
ts	O	-1	573555
use	O	-1	573555
in	O	-1	573555
pregn@@	O	-1	573555
anc@@	O	-1	573555
y,	O	-1	573555
however,	O	-1	573555
is	O	-1	573555
an	O	-1	573555
op@@	O	-1	573555
en	O	-1	573555
qu@@	O	-1	573555
es@@	O	-1	573555
tion	O	-1	573555
as	O	-1	573555
a	O	-1	573555
number	O	-1	573555
of	O	-1	573555
de@@	O	-1	573555
tri@@	O	-1	573555
mental	O	-1	573555
side	O	-1	573555
effects	O	-1	573555
have	O	-1	573555
been	O	-1	573555
reported	O	-1	573555
in	O	-1	573555
the	O	-1	573555
f@@	O	-1	573555
et@@	O	-1	573555
us	O	-1	573555
and	O	-1	573555
ne@@	O	-1	573555
on@@	O	-1	573555
at@@	O	-1	573555
e.	O	-1	573555
T@@	O	-1	573555
en	O	-1	573555
patients	O	-1	573555
and	O	-1	573555
12	O	-1	573555
pregn@@	O	-1	573555
an@@	O	-1	573555
ci@@	O	-1	573555
es	O	-1	573555
are	O	-1	573555
reported	O	-1	573555
wh@@	O	-1	573555
ere	O	-1	573555
chronic	O	-1	573555
prop@@	B-Chemical	D011433	573555
ran@@	I-Chemical	-1	573555
o@@	I-Chemical	-1	573555
lol	I-Chemical	-1	573555
has	O	-1	573555
been	O	-1	573555
administ@@	O	-1	573555
e@@	O	-1	573555
red.	O	-1	573555
F@@	O	-1	573555
i@@	O	-1	573555
ve	O	-1	573555
patients	O	-1	573555
with	O	-1	573555
ser@@	O	-1	573555
ial	O	-1	573555
pregn@@	O	-1	573555
an@@	O	-1	573555
ci@@	O	-1	573555
es	O	-1	573555
with	O	-1	573555
and	O	-1	573555
without	O	-1	573555
prop@@	B-Chemical	D011433	573555
ran@@	I-Chemical	-1	573555
o@@	I-Chemical	-1	573555
lol	I-Chemical	-1	573555
therapy	O	-1	573555
are	O	-1	573555
also	O	-1	573555
ex@@	O	-1	573555
am@@	O	-1	573555
ine@@	O	-1	573555
d.	O	-1	573555
M@@	O	-1	573555
at@@	O	-1	573555
er@@	O	-1	573555
n@@	O	-1	573555
al,	O	-1	573555
f@@	O	-1	573555
et@@	O	-1	573555
al,	O	-1	573555
and	O	-1	573555
ne@@	O	-1	573555
on@@	O	-1	573555
atal	O	-1	573555
complications	O	-1	573555
are	O	-1	573555
ex@@	O	-1	573555
am@@	O	-1	573555
ine@@	O	-1	573555
d.	O	-1	573555
An	O	-1	573555
at@@	O	-1	573555
tem@@	O	-1	573555
p@@	O	-1	573555
t	O	-1	573555
is	O	-1	573555
m@@	O	-1	573555
ade	O	-1	573555
to	O	-1	573555
differen@@	O	-1	573555
ti@@	O	-1	573555
ate	O	-1	573555
drug@@	O	-1	573555
-@@	O	-1	573555
related	O	-1	573555
complications	O	-1	573555
from	O	-1	573555
mat@@	O	-1	573555
er@@	O	-1	573555
n@@	O	-1	573555
al	O	-1	573555
diseas@@	O	-1	573555
e-@@	O	-1	573555
-@@	O	-1	573555
related	O	-1	573555
complic@@	O	-1	573555
ations.	O	-1	573555
We	O	-1	573555
concl@@	O	-1	573555
ude	O	-1	573555
that	O	-1	573555
previously	O	-1	573555
reported	O	-1	573555
hypo@@	B-Disease	D007003	573555
gly@@	I-Disease	-1	573555
ce@@	I-Disease	-1	573555
mia	I-Disease	-1	573555
,	O	-1	573555
hyper@@	B-Disease	D006932	573555
bil@@	I-Disease	-1	573555
i@@	I-Disease	-1	573555
ru@@	I-Disease	-1	573555
b@@	I-Disease	-1	573555
ine@@	I-Disease	-1	573555
mia	I-Disease	-1	573555
,	O	-1	573555
pol@@	B-Disease	D011086	573555
yc@@	I-Disease	-1	573555
y@@	I-Disease	-1	573555
th@@	I-Disease	-1	573555
emia	I-Disease	-1	573555
,	O	-1	573555
ne@@	B-Disease	D001049	573555
on@@	I-Disease	-1	573555
atal	I-Disease	-1	573555
ap@@	I-Disease	-1	573555
ne@@	I-Disease	-1	573555
a	I-Disease	-1	573555
,	O	-1	573555
and	O	-1	573555
brady@@	B-Disease	D001919	573555
cardia	I-Disease	-1	573555
are	O	-1	573555
not	O	-1	573555
inv@@	O	-1	573555
ari@@	O	-1	573555
able	O	-1	573555
and	O	-1	573555
can@@	O	-1	573555
not	O	-1	573555
be	O	-1	573555
statis@@	O	-1	573555
tically	O	-1	573555
cor@@	O	-1	573555
related	O	-1	573555
with	O	-1	573555
chronic	O	-1	573555
prop@@	B-Chemical	D011433	573555
ran@@	I-Chemical	-1	573555
o@@	I-Chemical	-1	573555
lol	I-Chemical	-1	573555
therapy.	O	-1	573555
G@@	B-Disease	D005317	573555
row@@	I-Disease	-1	573555
th	I-Disease	-1	573555
ret@@	I-Disease	-1	573555
ar@@	I-Disease	-1	573555
d@@	I-Disease	-1	573555
ation	I-Disease	-1	573555
,	O	-1	573555
however,	O	-1	573555
appear@@	O	-1	573555
s	O	-1	573555
to	O	-1	573555
be	O	-1	573555
significant	O	-1	573555
in	O	-1	573555
both	O	-1	573555
of	O	-1	573555
our	O	-1	573555
seri@@	O	-1	573555
es.	O	-1	573555

U@@	O	-1	611664
se	O	-1	611664
of	O	-1	611664
prop@@	B-Chemical	D011433	611664
ran@@	I-Chemical	-1	611664
o@@	I-Chemical	-1	611664
lol	I-Chemical	-1	611664
in	O	-1	611664
the	O	-1	611664
treatment	O	-1	611664
of	O	-1	611664
i@@	B-Disease	C544351	611664
di@@	I-Disease	-1	611664
o@@	I-Disease	-1	611664
path@@	I-Disease	-1	611664
ic	I-Disease	-1	611664
or@@	I-Disease	-1	611664
th@@	I-Disease	-1	611664
ost@@	I-Disease	-1	611664
atic	I-Disease	-1	611664
hypotension	I-Disease	-1	611664
.	O	-1	611664
F@@	O	-1	611664
i@@	O	-1	611664
ve	O	-1	611664
patients	O	-1	611664
with	O	-1	611664
i@@	B-Disease	C544351	611664
di@@	I-Disease	-1	611664
o@@	I-Disease	-1	611664
path@@	I-Disease	-1	611664
ic	I-Disease	-1	611664
or@@	I-Disease	-1	611664
th@@	I-Disease	-1	611664
ost@@	I-Disease	-1	611664
atic	I-Disease	-1	611664
hypotension	I-Disease	-1	611664
who	O	-1	611664
had	O	-1	611664
physi@@	O	-1	611664
ologic	O	-1	611664
and	O	-1	611664
bio@@	O	-1	611664
chemical	O	-1	611664
evidence	O	-1	611664
of	O	-1	611664
severe	O	-1	611664
a@@	O	-1	611664
ut@@	O	-1	611664
on@@	O	-1	611664
om@@	O	-1	611664
ic	O	-1	611664
dysfunction	O	-1	611664
were	O	-1	611664
included	O	-1	611664
in	O	-1	611664
the	O	-1	611664
study.	O	-1	611664
The@@	O	-1	611664
y	O	-1	611664
all	O	-1	611664
ex@@	O	-1	611664
hib@@	O	-1	611664
ited	O	-1	611664
mark@@	O	-1	611664
ed@@	O	-1	611664
ly	O	-1	611664
reduced	O	-1	611664
plasma	O	-1	611664
cat@@	B-Chemical	D002395	611664
ech@@	I-Chemical	-1	611664
ol@@	I-Chemical	-1	611664
amin@@	I-Chemical	-1	611664
es	I-Chemical	-1	611664
and	O	-1	611664
plasma	O	-1	611664
ren@@	O	-1	611664
in	O	-1	611664
activity	O	-1	611664
in	O	-1	611664
both	O	-1	611664
rec@@	O	-1	611664
umb@@	O	-1	611664
ent	O	-1	611664
and	O	-1	611664
u@@	O	-1	611664
pri@@	O	-1	611664
ght	O	-1	611664
posi@@	O	-1	611664
tions	O	-1	611664
and	O	-1	611664
had	O	-1	611664
mark@@	O	-1	611664
ed	O	-1	611664
hyper@@	B-Disease	D004342	611664
sensitivity	I-Disease	-1	611664
to	O	-1	611664
the	O	-1	611664
press@@	O	-1	611664
or	O	-1	611664
effects	O	-1	611664
of	O	-1	611664
inf@@	O	-1	611664
used	O	-1	611664
no@@	B-Chemical	D009638	611664
re@@	I-Chemical	-1	611664
p@@	I-Chemical	-1	611664
ine@@	I-Chemical	-1	611664
phrine	I-Chemical	-1	611664
.	O	-1	611664
Treat@@	O	-1	611664
ment	O	-1	611664
with	O	-1	611664
prop@@	B-Chemical	D011433	611664
an@@	I-Chemical	-1	611664
o@@	I-Chemical	-1	611664
lol	I-Chemical	-1	611664
administered	O	-1	611664
intra@@	O	-1	611664
ven@@	O	-1	611664
ously	O	-1	611664
(1@@	O	-1	611664
-@@	O	-1	611664
5	O	-1	611664
mg@@	O	-1	611664
)	O	-1	611664
produced	O	-1	611664
increases	O	-1	611664
in	O	-1	611664
sup@@	O	-1	611664
ine	O	-1	611664
and	O	-1	611664
u@@	O	-1	611664
pri@@	O	-1	611664
ght	O	-1	611664
blood	O	-1	611664
pressure	O	-1	611664
in	O	-1	611664
4	O	-1	611664
of	O	-1	611664
the	O	-1	611664
5	O	-1	611664
individ@@	O	-1	611664
u@@	O	-1	611664
als	O	-1	611664
with	O	-1	611664
ri@@	O	-1	611664
ses	O	-1	611664
rang@@	O	-1	611664
ing	O	-1	611664
from	O	-1	611664
1@@	O	-1	611664
1@@	O	-1	611664
/@@	O	-1	611664
6	O	-1	611664
to	O	-1	611664
2@@	O	-1	611664
2@@	O	-1	611664
/@@	O	-1	611664
11	O	-1	611664
mm@@	O	-1	611664
H@@	O	-1	611664
g@@	O	-1	611664
.	O	-1	611664
Ch@@	O	-1	611664
ron@@	O	-1	611664
ic	O	-1	611664
oral	O	-1	611664
administration	O	-1	611664
of	O	-1	611664
prop@@	B-Chemical	D011433	611664
ran@@	I-Chemical	-1	611664
o@@	I-Chemical	-1	611664
lol	I-Chemical	-1	611664
(4@@	O	-1	611664
0@@	O	-1	611664
-1@@	O	-1	611664
60	O	-1	611664
mg/@@	O	-1	611664
day@@	O	-1	611664
)	O	-1	611664
also	O	-1	611664
elevated	O	-1	611664
the	O	-1	611664
blood	O	-1	611664
pressu@@	O	-1	611664
res	O	-1	611664
of	O	-1	611664
these	O	-1	611664
individ@@	O	-1	611664
u@@	O	-1	611664
als	O	-1	611664
with	O	-1	611664
increases	O	-1	611664
in	O	-1	611664
the	O	-1	611664
or@@	O	-1	611664
der	O	-1	611664
of	O	-1	611664
20@@	O	-1	611664
-@@	O	-1	611664
3@@	O	-1	611664
5@@	O	-1	611664
/@@	O	-1	611664
1@@	O	-1	611664
5-@@	O	-1	611664
25	O	-1	611664
m@@	O	-1	611664
mg	O	-1	611664
being	O	-1	611664
obser@@	O	-1	611664
ved.	O	-1	611664
In	O	-1	611664
1	O	-1	611664
patient@@	O	-1	611664
,	O	-1	611664
mark@@	O	-1	611664
ed	O	-1	611664
hypertension	B-Disease	D006973	611664
was	O	-1	611664
induced	O	-1	611664
by	O	-1	611664
prop@@	B-Chemical	D011433	611664
ran@@	I-Chemical	-1	611664
o@@	I-Chemical	-1	611664
lol	I-Chemical	-1	611664
and	O	-1	611664
the	O	-1	611664
drug	O	-1	611664
had	O	-1	611664
to	O	-1	611664
be	O	-1	611664
withdraw@@	O	-1	611664
n@@	O	-1	611664
.	O	-1	611664
It	O	-1	611664
o@@	O	-1	611664
ther@@	O	-1	611664
w@@	O	-1	611664
is@@	O	-1	611664
e	O	-1	611664
was	O	-1	611664
well	O	-1	611664
toler@@	O	-1	611664
ated	O	-1	611664
and	O	-1	611664
no	O	-1	611664
important	O	-1	611664
side	O	-1	611664
effects	O	-1	611664
were	O	-1	611664
obser@@	O	-1	611664
ved.	O	-1	611664
Treat@@	O	-1	611664
ment	O	-1	611664
has	O	-1	611664
been	O	-1	611664
continu@@	O	-1	611664
ed	O	-1	611664
in	O	-1	611664
3	O	-1	611664
individ@@	O	-1	611664
u@@	O	-1	611664
als	O	-1	611664
for	O	-1	611664
6@@	O	-1	611664
-1@@	O	-1	611664
3	O	-1	611664
months	O	-1	611664
with	O	-1	611664
per@@	O	-1	611664
sist@@	O	-1	611664
ence	O	-1	611664
of	O	-1	611664
the	O	-1	611664
press@@	O	-1	611664
or	O	-1	611664
effect@@	O	-1	611664
,	O	-1	611664
although	O	-1	611664
there	O	-1	611664
appear@@	O	-1	611664
s	O	-1	611664
to	O	-1	611664
have	O	-1	611664
been	O	-1	611664
some	O	-1	611664
decrease	O	-1	611664
in	O	-1	611664
the	O	-1	611664
de@@	O	-1	611664
g@@	O	-1	611664
ree	O	-1	611664
of	O	-1	611664
response	O	-1	611664
with	O	-1	611664
ti@@	O	-1	611664
me.	O	-1	611664
H@@	O	-1	611664
em@@	O	-1	611664
o@@	O	-1	611664
dynam@@	O	-1	611664
ic	O	-1	611664
meas@@	O	-1	611664
ure@@	O	-1	611664
ments	O	-1	611664
in	O	-1	611664
1	O	-1	611664
of	O	-1	611664
the	O	-1	611664
patients	O	-1	611664
demonstrated	O	-1	611664
an	O	-1	611664
increase	O	-1	611664
in	O	-1	611664
total	O	-1	611664
peripheral	O	-1	611664
resist@@	O	-1	611664
ance	O	-1	611664
and	O	-1	611664
es@@	O	-1	611664
sen@@	O	-1	611664
ti@@	O	-1	611664
ally	O	-1	611664
no	O	-1	611664
change	O	-1	611664
in	O	-1	611664
cardiac	O	-1	611664
out@@	O	-1	611664
pu@@	O	-1	611664
t	O	-1	611664
following	O	-1	611664
prop@@	B-Chemical	D011433	611664
ran@@	I-Chemical	-1	611664
o@@	I-Chemical	-1	611664
lol	I-Chemical	-1	611664
therapy.	O	-1	611664
The	O	-1	611664
studies	O	-1	611664
suggest	O	-1	611664
that	O	-1	611664
prop@@	B-Chemical	D011433	611664
ran@@	I-Chemical	-1	611664
o@@	I-Chemical	-1	611664
lol	I-Chemical	-1	611664
is	O	-1	611664
a	O	-1	611664
use@@	O	-1	611664
ful	O	-1	611664
drug	O	-1	611664
in	O	-1	611664
sel@@	O	-1	611664
ected	O	-1	611664
patients	O	-1	611664
with	O	-1	611664
severe	O	-1	611664
i@@	B-Disease	C544351	611664
di@@	I-Disease	-1	611664
o@@	I-Disease	-1	611664
path@@	I-Disease	-1	611664
ic	I-Disease	-1	611664
or@@	I-Disease	-1	611664
th@@	I-Disease	-1	611664
ost@@	I-Disease	-1	611664
atic	I-Disease	-1	611664
hypotension	I-Disease	-1	611664
.	O	-1	611664

T@@	O	-1	612112
ot@@	O	-1	612112
al	O	-1	612112
intravenous	O	-1	612112
anesthe@@	O	-1	612112
sia	O	-1	612112
with	O	-1	612112
e@@	B-Chemical	D005045	612112
to@@	I-Chemical	-1	612112
mid@@	I-Chemical	-1	612112
ate	I-Chemical	-1	612112
.	O	-1	612112
II@@	O	-1	612112
I@@	O	-1	612112
.	O	-1	612112
S@@	O	-1	612112
ome	O	-1	612112
observ@@	O	-1	612112
ations	O	-1	612112
in	O	-1	612112
ad@@	O	-1	612112
ult@@	O	-1	612112
s.	O	-1	612112
An	O	-1	612112
investig@@	O	-1	612112
ation	O	-1	612112
was	O	-1	612112
under@@	O	-1	612112
tak@@	O	-1	612112
en	O	-1	612112
to	O	-1	612112
determine	O	-1	612112
the	O	-1	612112
dos@@	O	-1	612112
age	O	-1	612112
of	O	-1	612112
e@@	B-Chemical	D005045	612112
to@@	I-Chemical	-1	612112
mid@@	I-Chemical	-1	612112
ate	I-Chemical	-1	612112
requ@@	O	-1	612112
ired	O	-1	612112
to	O	-1	612112
maint@@	O	-1	612112
ain	O	-1	612112
sleep	O	-1	612112
in	O	-1	612112
ad@@	O	-1	612112
ult@@	O	-1	612112
s	O	-1	612112
under@@	O	-1	612112
go@@	O	-1	612112
ing	O	-1	612112
surger@@	O	-1	612112
y	O	-1	612112
under	O	-1	612112
regi@@	O	-1	612112
on@@	O	-1	612112
al	O	-1	612112
loc@@	O	-1	612112
al	O	-1	612112
anesthe@@	O	-1	612112
sia.	O	-1	612112
Pre@@	O	-1	612112
medic@@	O	-1	612112
ation	O	-1	612112
of	O	-1	612112
di@@	B-Chemical	D003975	612112
az@@	I-Chemical	-1	612112
epam	I-Chemical	-1	612112
10	O	-1	612112
mg	O	-1	612112
and	O	-1	612112
atro@@	B-Chemical	D001285	612112
pine	I-Chemical	-1	612112
0.@@	O	-1	612112
5	O	-1	612112
mg	O	-1	612112
was	O	-1	612112
gi@@	O	-1	612112
ven@@	O	-1	612112
,	O	-1	612112
and	O	-1	612112
sleep	O	-1	612112
was	O	-1	612112
induced	O	-1	612112
and	O	-1	612112
maint@@	O	-1	612112
ained	O	-1	612112
by	O	-1	612112
inter@@	O	-1	612112
mit@@	O	-1	612112
t@@	O	-1	612112
ent	O	-1	612112
intravenous	O	-1	612112
injec@@	O	-1	612112
tions	O	-1	612112
of	O	-1	612112
e@@	B-Chemical	D005045	612112
to@@	I-Chemical	-1	612112
mid@@	I-Chemical	-1	612112
ate	I-Chemical	-1	612112
0.@@	O	-1	612112
1@@	O	-1	612112
/@@	O	-1	612112
mg/kg@@	O	-1	612112
,	O	-1	612112
given	O	-1	612112
wh@@	O	-1	612112
en@@	O	-1	612112
ev@@	O	-1	612112
er	O	-1	612112
the	O	-1	612112
patient	O	-1	612112
wo@@	O	-1	612112
uld	O	-1	612112
op@@	O	-1	612112
en	O	-1	612112
h@@	O	-1	612112
is	O	-1	612112
e@@	O	-1	612112
y@@	O	-1	612112
es	O	-1	612112
on	O	-1	612112
requ@@	O	-1	612112
est@@	O	-1	612112
.	O	-1	612112
A	O	-1	612112
mean	O	-1	612112
over@@	O	-1	612112
all	O	-1	612112
dose	O	-1	612112
of	O	-1	612112
e@@	B-Chemical	D005045	612112
to@@	I-Chemical	-1	612112
mid@@	I-Chemical	-1	612112
ate	I-Chemical	-1	612112
1@@	O	-1	612112
7.@@	O	-1	612112
4	O	-1	612112
microgram@@	O	-1	612112
/@@	O	-1	612112
k@@	O	-1	612112
g/@@	O	-1	612112
min@@	O	-1	612112
.	O	-1	612112
was	O	-1	612112
requ@@	O	-1	612112
ired	O	-1	612112
to	O	-1	612112
maint@@	O	-1	612112
ain	O	-1	612112
sle@@	O	-1	612112
ep@@	O	-1	612112
,	O	-1	612112
but	O	-1	612112
gre@@	O	-1	612112
at	O	-1	612112
individ@@	O	-1	612112
ual	O	-1	612112
vari@@	O	-1	612112
ation	O	-1	612112
occur@@	O	-1	612112
re@@	O	-1	612112
d,	O	-1	612112
with	O	-1	612112
ol@@	O	-1	612112
der	O	-1	612112
patients	O	-1	612112
requ@@	O	-1	612112
ir@@	O	-1	612112
ing	O	-1	612112
less	O	-1	612112
drug.	O	-1	612112
The	O	-1	612112
investig@@	O	-1	612112
ation	O	-1	612112
was	O	-1	612112
discontinu@@	O	-1	612112
ed	O	-1	612112
after	O	-1	612112
1@@	O	-1	612112
8	O	-1	612112
patients	O	-1	612112
because	O	-1	612112
of	O	-1	612112
the	O	-1	612112
frequency	O	-1	612112
and	O	-1	612112
int@@	O	-1	612112
ensity	O	-1	612112
of	O	-1	612112
side@@	O	-1	612112
-@@	O	-1	612112
effect@@	O	-1	612112
s,	O	-1	612112
partic@@	O	-1	612112
ul@@	O	-1	612112
arly	O	-1	612112
pain	B-Disease	D010146	612112
and	O	-1	612112
my@@	B-Disease	D009207	612112
oc@@	I-Disease	-1	612112
lon@@	I-Disease	-1	612112
ia	I-Disease	-1	612112
,	O	-1	612112
which	O	-1	612112
caused	O	-1	612112
the	O	-1	612112
t@@	O	-1	612112
ech@@	O	-1	612112
n@@	O	-1	612112
i@@	O	-1	612112
qu@@	O	-1	612112
e	O	-1	612112
to	O	-1	612112
be	O	-1	612112
ab@@	O	-1	612112
and@@	O	-1	612112
on@@	O	-1	612112
ed	O	-1	612112
in	O	-1	612112
two	O	-1	612112
cas@@	O	-1	612112
es.	O	-1	612112
It	O	-1	612112
is	O	-1	612112
considered	O	-1	612112
un@@	O	-1	612112
likely	O	-1	612112
that	O	-1	612112
e@@	B-Chemical	D005045	612112
to@@	I-Chemical	-1	612112
mid@@	I-Chemical	-1	612112
ate	I-Chemical	-1	612112
wil@@	O	-1	612112
l	O	-1	612112
pro@@	O	-1	612112
ve	O	-1	612112
to	O	-1	612112
be	O	-1	612112
the	O	-1	612112
hy@@	O	-1	612112
p@@	O	-1	612112
no@@	O	-1	612112
tic	O	-1	612112
of	O	-1	612112
ch@@	O	-1	612112
o@@	O	-1	612112
ic@@	O	-1	612112
e	O	-1	612112
for	O	-1	612112
a	O	-1	612112
tot@@	O	-1	612112
ally	O	-1	612112
intravenous	O	-1	612112
anesthe@@	O	-1	612112
tic	O	-1	612112
t@@	O	-1	612112
ech@@	O	-1	612112
n@@	O	-1	612112
i@@	O	-1	612112
qu@@	O	-1	612112
e	O	-1	612112
in	O	-1	612112
ad@@	O	-1	612112
ult@@	O	-1	612112
s	O	-1	612112
because	O	-1	612112
of	O	-1	612112
the	O	-1	612112
high	O	-1	612112
incidence	O	-1	612112
of	O	-1	612112
my@@	B-Disease	D009207	612112
oc@@	I-Disease	-1	612112
lon@@	I-Disease	-1	612112
ia	I-Disease	-1	612112
after	O	-1	612112
prolonged	O	-1	612112
administr@@	O	-1	612112
ation.	O	-1	612112
In	O	-1	612112
several	O	-1	612112
patients	O	-1	612112
un@@	O	-1	612112
contro@@	O	-1	612112
ll@@	O	-1	612112
able	O	-1	612112
musc@@	O	-1	612112
le	O	-1	612112
mo@@	O	-1	612112
ve@@	O	-1	612112
ments	O	-1	612112
per@@	O	-1	612112
sist@@	O	-1	612112
ed	O	-1	612112
for	O	-1	612112
man@@	O	-1	612112
y	O	-1	612112
minutes	O	-1	612112
after	O	-1	612112
complete	O	-1	612112
recovery	O	-1	612112
of	O	-1	612112
con@@	O	-1	612112
s@@	O	-1	612112
ci@@	O	-1	612112
ous@@	O	-1	612112
n@@	O	-1	612112
es@@	O	-1	612112
s.	O	-1	612112

A	O	-1	689020
meth@@	O	-1	689020
od	O	-1	689020
for	O	-1	689020
the	O	-1	689020
meas@@	O	-1	689020
ure@@	O	-1	689020
ment	O	-1	689020
of	O	-1	689020
trem@@	B-Disease	D014202	689020
or	I-Disease	-1	689020
,	O	-1	689020
and	O	-1	689020
a	O	-1	689020
compar@@	O	-1	689020
ison	O	-1	689020
of	O	-1	689020
the	O	-1	689020
effects	O	-1	689020
of	O	-1	689020
to@@	O	-1	689020
co@@	O	-1	689020
ly@@	O	-1	689020
tic	O	-1	689020
beta-@@	O	-1	689020
mi@@	O	-1	689020
me@@	O	-1	689020
tic@@	O	-1	689020
s.	O	-1	689020
A	O	-1	689020
meth@@	O	-1	689020
od	O	-1	689020
per@@	O	-1	689020
mit@@	O	-1	689020
ting	O	-1	689020
meas@@	O	-1	689020
ure@@	O	-1	689020
ment	O	-1	689020
of	O	-1	689020
f@@	O	-1	689020
ing@@	O	-1	689020
er	O	-1	689020
trem@@	B-Disease	D014202	689020
or	I-Disease	-1	689020
as	O	-1	689020
a	O	-1	689020
dis@@	O	-1	689020
pl@@	O	-1	689020
ac@@	O	-1	689020
em@@	O	-1	689020
ent@@	O	-1	689020
-@@	O	-1	689020
time	O	-1	689020
cur@@	O	-1	689020
ve	O	-1	689020
is	O	-1	689020
descri@@	O	-1	689020
be@@	O	-1	689020
d,	O	-1	689020
using	O	-1	689020
a	O	-1	689020
test	O	-1	689020
system	O	-1	689020
with	O	-1	689020
sim@@	O	-1	689020
ple	O	-1	689020
am@@	O	-1	689020
pl@@	O	-1	689020
it@@	O	-1	689020
ude	O	-1	689020
cal@@	O	-1	689020
i@@	O	-1	689020
b@@	O	-1	689020
r@@	O	-1	689020
ation.	O	-1	689020
The	O	-1	689020
co@@	O	-1	689020
or@@	O	-1	689020
d@@	O	-1	689020
in@@	O	-1	689020
ates	O	-1	689020
of	O	-1	689020
the	O	-1	689020
in@@	O	-1	689020
ver@@	O	-1	689020
sion	O	-1	689020
po@@	O	-1	689020
int@@	O	-1	689020
s	O	-1	689020
of	O	-1	689020
the	O	-1	689020
dis@@	O	-1	689020
pl@@	O	-1	689020
ac@@	O	-1	689020
em@@	O	-1	689020
ent@@	O	-1	689020
-@@	O	-1	689020
time	O	-1	689020
cur@@	O	-1	689020
v@@	O	-1	689020
es	O	-1	689020
were	O	-1	689020
trans@@	O	-1	689020
fer@@	O	-1	689020
red	O	-1	689020
through	O	-1	689020
graph@@	O	-1	689020
ical	O	-1	689020
in@@	O	-1	689020
pu@@	O	-1	689020
t	O	-1	689020
equ@@	O	-1	689020
ip@@	O	-1	689020
ment	O	-1	689020
to	O	-1	689020
p@@	O	-1	689020
un@@	O	-1	689020
ch@@	O	-1	689020
ed	O	-1	689020
t@@	O	-1	689020
ap@@	O	-1	689020
e.	O	-1	689020
B@@	O	-1	689020
y	O	-1	689020
me@@	O	-1	689020
ans	O	-1	689020
of	O	-1	689020
a	O	-1	689020
comp@@	O	-1	689020
u@@	O	-1	689020
ter	O	-1	689020
pro@@	O	-1	689020
gram@@	O	-1	689020
,	O	-1	689020
perio@@	O	-1	689020
ds	O	-1	689020
and	O	-1	689020
am@@	O	-1	689020
pl@@	O	-1	689020
it@@	O	-1	689020
u@@	O	-1	689020
des	O	-1	689020
of	O	-1	689020
trem@@	B-Disease	D014202	689020
or	I-Disease	-1	689020
os@@	O	-1	689020
c@@	O	-1	689020
ill@@	O	-1	689020
ations	O	-1	689020
were	O	-1	689020
calc@@	O	-1	689020
ul@@	O	-1	689020
ated	O	-1	689020
and	O	-1	689020
cl@@	O	-1	689020
assi@@	O	-1	689020
fi@@	O	-1	689020
ed.	O	-1	689020
The	O	-1	689020
ev@@	O	-1	689020
ent	O	-1	689020
frequency	O	-1	689020
for	O	-1	689020
each	O	-1	689020
cl@@	O	-1	689020
as@@	O	-1	689020
s	O	-1	689020
of	O	-1	689020
perio@@	O	-1	689020
ds	O	-1	689020
and	O	-1	689020
am@@	O	-1	689020
pl@@	O	-1	689020
it@@	O	-1	689020
u@@	O	-1	689020
des	O	-1	689020
was	O	-1	689020
deter@@	O	-1	689020
m@@	O	-1	689020
ine@@	O	-1	689020
d.	O	-1	689020
The	O	-1	689020
ac@@	O	-1	689020
tions	O	-1	689020
of	O	-1	689020
f@@	B-Chemical	D005280	689020
en@@	I-Chemical	-1	689020
ot@@	I-Chemical	-1	689020
er@@	I-Chemical	-1	689020
ol@@	I-Chemical	-1	689020
-@@	I-Chemical	-1	689020
hydro@@	I-Chemical	-1	689020
brom@@	I-Chemical	-1	689020
ide	I-Chemical	-1	689020
,	O	-1	689020
rit@@	B-Chemical	D012312	689020
o@@	I-Chemical	-1	689020
d@@	I-Chemical	-1	689020
r@@	I-Chemical	-1	689020
in-@@	I-Chemical	-1	689020
HC@@	I-Chemical	-1	689020
l	I-Chemical	-1	689020
and	O	-1	689020
placebo	O	-1	689020
given	O	-1	689020
to	O	-1	689020
10	O	-1	689020
healthy	O	-1	689020
subjects	O	-1	689020
by	O	-1	689020
intravenous	O	-1	689020
infusion	O	-1	689020
in	O	-1	689020
a	O	-1	689020
double-bl@@	O	-1	689020
ind	O	-1	689020
cros@@	O	-1	689020
s@@	O	-1	689020
over	O	-1	689020
study	O	-1	689020
were	O	-1	689020
tested	O	-1	689020
by	O	-1	689020
this	O	-1	689020
meth@@	O	-1	689020
o@@	O	-1	689020
d.	O	-1	689020
A@@	O	-1	689020
t	O	-1	689020
therapeutic	O	-1	689020
doses	O	-1	689020
both	O	-1	689020
subst@@	O	-1	689020
anc@@	O	-1	689020
es	O	-1	689020
ra@@	O	-1	689020
is@@	O	-1	689020
ed	O	-1	689020
the	O	-1	689020
mean	O	-1	689020
trem@@	B-Disease	D014202	689020
or	I-Disease	-1	689020
am@@	O	-1	689020
pl@@	O	-1	689020
it@@	O	-1	689020
ude	O	-1	689020
to	O	-1	689020
about	O	-1	689020
three	O	-1	689020
times	O	-1	689020
the	O	-1	689020
control	O	-1	689020
level@@	O	-1	689020
.	O	-1	689020
A@@	O	-1	689020
t	O	-1	689020
the	O	-1	689020
same	O	-1	689020
ti@@	O	-1	689020
me,	O	-1	689020
the	O	-1	689020
mean	O	-1	689020
period	O	-1	689020
within	O	-1	689020
each	O	-1	689020
cl@@	O	-1	689020
as@@	O	-1	689020
s	O	-1	689020
of	O	-1	689020
am@@	O	-1	689020
pl@@	O	-1	689020
it@@	O	-1	689020
u@@	O	-1	689020
des	O	-1	689020
sh@@	O	-1	689020
or@@	O	-1	689020
ten@@	O	-1	689020
ed	O	-1	689020
by	O	-1	689020
10-@@	O	-1	689020
-@@	O	-1	689020
20	O	-1	689020
m@@	O	-1	689020
s,	O	-1	689020
whereas	O	-1	689020
the	O	-1	689020
mean	O	-1	689020
perio@@	O	-1	689020
ds	O	-1	689020
calc@@	O	-1	689020
ul@@	O	-1	689020
ated	O	-1	689020
from	O	-1	689020
all	O	-1	689020
os@@	O	-1	689020
c@@	O	-1	689020
ill@@	O	-1	689020
ations	O	-1	689020
to@@	O	-1	689020
ge@@	O	-1	689020
ther	O	-1	689020
did	O	-1	689020
not	O	-1	689020
change	O	-1	689020
significant@@	O	-1	689020
ly.	O	-1	689020
After	O	-1	689020
the	O	-1	689020
end	O	-1	689020
of	O	-1	689020
f@@	B-Chemical	D005280	689020
en@@	I-Chemical	-1	689020
ot@@	I-Chemical	-1	689020
er@@	I-Chemical	-1	689020
ol@@	I-Chemical	-1	689020
-@@	I-Chemical	-1	689020
hydro@@	I-Chemical	-1	689020
brom@@	I-Chemical	-1	689020
ide	I-Chemical	-1	689020
infu@@	O	-1	689020
sion,	O	-1	689020
trem@@	B-Disease	D014202	689020
or	I-Disease	-1	689020
am@@	O	-1	689020
pl@@	O	-1	689020
it@@	O	-1	689020
u@@	O	-1	689020
des	O	-1	689020
decreased	O	-1	689020
significantly	O	-1	689020
f@@	O	-1	689020
ast@@	O	-1	689020
er	O	-1	689020
than	O	-1	689020
those	O	-1	689020
following	O	-1	689020
rit@@	B-Chemical	D012312	689020
o@@	I-Chemical	-1	689020
d@@	I-Chemical	-1	689020
r@@	I-Chemical	-1	689020
in-@@	I-Chemical	-1	689020
HC@@	I-Chemical	-1	689020
l	I-Chemical	-1	689020
infu@@	O	-1	689020
sion.	O	-1	689020

B@@	O	-1	733189
il@@	O	-1	733189
ateral	O	-1	733189
ret@@	B-Disease	D015356	733189
inal	I-Disease	-1	733189
artery	I-Disease	-1	733189
and	I-Disease	-1	733189
ch@@	I-Disease	-1	733189
or@@	I-Disease	-1	733189
i@@	I-Disease	-1	733189
oc@@	I-Disease	-1	733189
ap@@	I-Disease	-1	733189
ill@@	I-Disease	-1	733189
ar@@	I-Disease	-1	733189
is	I-Disease	-1	733189
oc@@	I-Disease	-1	733189
cl@@	I-Disease	-1	733189
usion	I-Disease	-1	733189
following	O	-1	733189
the	O	-1	733189
injection	O	-1	733189
of	O	-1	733189
long@@	O	-1	733189
-@@	O	-1	733189
act@@	O	-1	733189
ing	O	-1	733189
cortico@@	B-Chemical	D000305	733189
ster@@	I-Chemical	-1	733189
oid	I-Chemical	-1	733189
sus@@	O	-1	733189
pen@@	O	-1	733189
sions	O	-1	733189
in	O	-1	733189
combination	O	-1	733189
with	O	-1	733189
other	O	-1	733189
drug@@	O	-1	733189
s:	O	-1	733189
I@@	O	-1	733189
.	O	-1	733189
Clin@@	O	-1	733189
ical	O	-1	733189
studi@@	O	-1	733189
es.	O	-1	733189
Two	O	-1	733189
we@@	O	-1	733189
ll@@	O	-1	733189
-@@	O	-1	733189
doc@@	O	-1	733189
um@@	O	-1	733189
ent@@	O	-1	733189
ed	O	-1	733189
cases	O	-1	733189
of	O	-1	733189
bil@@	O	-1	733189
ateral	O	-1	733189
ret@@	B-Disease	D015356	733189
inal	I-Disease	-1	733189
artery	I-Disease	-1	733189
and	I-Disease	-1	733189
ch@@	I-Disease	-1	733189
or@@	I-Disease	-1	733189
i@@	I-Disease	-1	733189
oc@@	I-Disease	-1	733189
ap@@	I-Disease	-1	733189
ill@@	I-Disease	-1	733189
ar@@	I-Disease	-1	733189
is	I-Disease	-1	733189
oc@@	I-Disease	-1	733189
cl@@	I-Disease	-1	733189
u@@	I-Disease	-1	733189
sions	I-Disease	-1	733189
with	O	-1	733189
bl@@	B-Disease	D001766	733189
ind@@	I-Disease	-1	733189
ness	I-Disease	-1	733189
following	O	-1	733189
he@@	O	-1	733189
ad	O	-1	733189
and	O	-1	733189
nec@@	O	-1	733189
k	O	-1	733189
s@@	O	-1	733189
of@@	O	-1	733189
t-@@	O	-1	733189
tissue	O	-1	733189
injection	O	-1	733189
with	O	-1	733189
methyl@@	B-Chemical	C000873	733189
pre@@	I-Chemical	-1	733189
d@@	I-Chemical	-1	733189
n@@	I-Chemical	-1	733189
isol@@	I-Chemical	-1	733189
one	I-Chemical	-1	733189
acet@@	I-Chemical	-1	733189
ate	I-Chemical	-1	733189
in	O	-1	733189
combination	O	-1	733189
with	O	-1	733189
lidocaine	B-Chemical	D008012	733189
,	O	-1	733189
ep@@	B-Chemical	D004837	733189
ine@@	I-Chemical	-1	733189
phrine	I-Chemical	-1	733189
,	O	-1	733189
or	O	-1	733189
pen@@	B-Chemical	D010406	733189
icill@@	I-Chemical	-1	733189
in	I-Chemical	-1	733189
are	O	-1	733189
repor@@	O	-1	733189
ted.	O	-1	733189
One	O	-1	733189
case	O	-1	733189
had	O	-1	733189
only	O	-1	733189
a	O	-1	733189
un@@	O	-1	733189
il@@	O	-1	733189
ateral	O	-1	733189
injec@@	O	-1	733189
tion.	O	-1	733189
The	O	-1	733189
acute	O	-1	733189
observ@@	O	-1	733189
ations	O	-1	733189
included	O	-1	733189
ha@@	O	-1	733189
z@@	O	-1	733189
y	O	-1	733189
sens@@	O	-1	733189
or@@	O	-1	733189
i@@	O	-1	733189
um,	O	-1	733189
su@@	O	-1	733189
peri@@	O	-1	733189
or	O	-1	733189
g@@	O	-1	733189
az@@	O	-1	733189
e	O	-1	733189
p@@	B-Disease	D010243	733189
al@@	I-Disease	-1	733189
sy	I-Disease	-1	733189
,	O	-1	733189
p@@	B-Disease	D011681	733189
up@@	I-Disease	-1	733189
ill@@	I-Disease	-1	733189
ary	I-Disease	-1	733189
abnormal@@	I-Disease	-1	733189
ities	I-Disease	-1	733189
,	O	-1	733189
and	O	-1	733189
con@@	O	-1	733189
j@@	O	-1	733189
unc@@	O	-1	733189
tiv@@	O	-1	733189
al	O	-1	733189
hemorrh@@	B-Disease	D006470	733189
ages	I-Disease	-1	733189
with	O	-1	733189
e@@	B-Disease	D004487	733189
de@@	I-Disease	-1	733189
ma	I-Disease	-1	733189
.	O	-1	733189
F@@	O	-1	733189
ol@@	O	-1	733189
low@@	O	-1	733189
-@@	O	-1	733189
up	O	-1	733189
changes	O	-1	733189
showed	O	-1	733189
mark@@	O	-1	733189
ed	O	-1	733189
visual	B-Disease	D014786	733189
loss	I-Disease	-1	733189
,	O	-1	733189
con@@	O	-1	733189
stric@@	O	-1	733189
ted	O	-1	733189
visual	O	-1	733189
fi@@	O	-1	733189
el@@	O	-1	733189
d@@	O	-1	733189
s,	O	-1	733189
op@@	O	-1	733189
tic	O	-1	733189
nerve	O	-1	733189
p@@	O	-1	733189
all@@	O	-1	733189
or@@	O	-1	733189
,	O	-1	733189
vascular	O	-1	733189
attenu@@	O	-1	733189
ation,	O	-1	733189
and	O	-1	733189
ch@@	B-Disease	C566236	733189
or@@	I-Disease	-1	733189
io@@	I-Disease	-1	733189
ret@@	I-Disease	-1	733189
inal	I-Disease	-1	733189
atro@@	I-Disease	-1	733189
ph@@	I-Disease	-1	733189
y	I-Disease	-1	733189
.	O	-1	733189
The	O	-1	733189
literat@@	O	-1	733189
ure	O	-1	733189
is	O	-1	733189
revie@@	O	-1	733189
we@@	O	-1	733189
d,	O	-1	733189
and	O	-1	733189
possible	O	-1	733189
causes	O	-1	733189
are	O	-1	733189
discus@@	O	-1	733189
sed.	O	-1	733189

C@@	B-Chemical	D002512	816141
e@@	I-Chemical	-1	816141
ph@@	I-Chemical	-1	816141
alo@@	I-Chemical	-1	816141
th@@	I-Chemical	-1	816141
in	I-Chemical	-1	816141
-induced	O	-1	816141
immun@@	O	-1	816141
e	O	-1	816141
hemolytic	B-Disease	D000743	816141
anemia	I-Disease	-1	816141
.	O	-1	816141
A	O	-1	816141
patient	O	-1	816141
with	O	-1	816141
renal	B-Disease	D007674	816141
disease	I-Disease	-1	816141
developed	O	-1	816141
C@@	O	-1	816141
o@@	O	-1	816141
om@@	O	-1	816141
b@@	O	-1	816141
s-@@	O	-1	816141
positive	O	-1	816141
hemolytic	B-Disease	D000743	816141
anemia	I-Disease	-1	816141
while	O	-1	816141
receiving	O	-1	816141
ce@@	B-Chemical	D002512	816141
ph@@	I-Chemical	-1	816141
alo@@	I-Chemical	-1	816141
th@@	I-Chemical	-1	816141
in	I-Chemical	-1	816141
therapy.	O	-1	816141
An	O	-1	816141
anti@@	O	-1	816141
-	O	-1	816141
ce@@	B-Chemical	D002512	816141
ph@@	I-Chemical	-1	816141
alo@@	I-Chemical	-1	816141
th@@	I-Chemical	-1	816141
in	I-Chemical	-1	816141
I@@	O	-1	816141
g@@	O	-1	816141
G	O	-1	816141
anti@@	O	-1	816141
body	O	-1	816141
was	O	-1	816141
det@@	O	-1	816141
ected	O	-1	816141
in	O	-1	816141
the	O	-1	816141
patient@@	O	-1	816141
's	O	-1	816141
serum	O	-1	816141
and	O	-1	816141
in	O	-1	816141
the	O	-1	816141
el@@	O	-1	816141
u@@	O	-1	816141
ates	O	-1	816141
from	O	-1	816141
h@@	O	-1	816141
er	O	-1	816141
erythro@@	O	-1	816141
cy@@	O	-1	816141
t@@	O	-1	816141
es.	O	-1	816141
In	O	-1	816141
addi@@	O	-1	816141
tion,	O	-1	816141
non@@	O	-1	816141
immun@@	O	-1	816141
ologic	O	-1	816141
b@@	O	-1	816141
ind@@	O	-1	816141
ing	O	-1	816141
of	O	-1	816141
normal	O	-1	816141
and	O	-1	816141
patient@@	O	-1	816141
's	O	-1	816141
serum	O	-1	816141
protein@@	O	-1	816141
s	O	-1	816141
to	O	-1	816141
h@@	O	-1	816141
er	O	-1	816141
o@@	O	-1	816141
w@@	O	-1	816141
n	O	-1	816141
and	O	-1	816141
ce@@	B-Chemical	D002512	816141
ph@@	I-Chemical	-1	816141
alo@@	I-Chemical	-1	816141
th@@	I-Chemical	-1	816141
in	I-Chemical	-1	816141
-@@	O	-1	816141
co@@	O	-1	816141
ated	O	-1	816141
normal	O	-1	816141
red	O	-1	816141
cells	O	-1	816141
was	O	-1	816141
demon@@	O	-1	816141
strat@@	O	-1	816141
ed.	O	-1	816141
S@@	O	-1	816141
k@@	O	-1	816141
in	O	-1	816141
tests	O	-1	816141
and	O	-1	816141
in	O	-1	816141
vit@@	O	-1	816141
r@@	O	-1	816141
o	O	-1	816141
lymph@@	O	-1	816141
ocyte	O	-1	816141
stimulation	O	-1	816141
revealed	O	-1	816141
that	O	-1	816141
the	O	-1	816141
patient	O	-1	816141
was	O	-1	816141
sensi@@	O	-1	816141
tiz@@	O	-1	816141
ed	O	-1	816141
to	O	-1	816141
ce@@	B-Chemical	D002512	816141
ph@@	I-Chemical	-1	816141
alo@@	I-Chemical	-1	816141
th@@	I-Chemical	-1	816141
in	I-Chemical	-1	816141
and	O	-1	816141
also	O	-1	816141
to	O	-1	816141
amp@@	B-Chemical	D000667	816141
icill@@	I-Chemical	-1	816141
in	I-Chemical	-1	816141
.	O	-1	816141
Ca@@	O	-1	816141
ref@@	O	-1	816141
u@@	O	-1	816141
l	O	-1	816141
investig@@	O	-1	816141
ation	O	-1	816141
of	O	-1	816141
drug@@	O	-1	816141
-induced	O	-1	816141
hemolytic	B-Disease	D000743	816141
an@@	I-Disease	-1	816141
em@@	I-Disease	-1	816141
i@@	I-Disease	-1	816141
as	I-Disease	-1	816141
reve@@	O	-1	816141
als	O	-1	816141
the	O	-1	816141
comple@@	O	-1	816141
x@@	O	-1	816141
ity	O	-1	816141
of	O	-1	816141
the	O	-1	816141
immun@@	O	-1	816141
e	O	-1	816141
mechanisms	O	-1	816141
invol@@	O	-1	816141
ved.	O	-1	816141

K@@	O	-1	851038
al@@	O	-1	851038
i@@	O	-1	851038
ure@@	O	-1	851038
tic	O	-1	851038
effect	O	-1	851038
of	O	-1	851038
L-@@	B-Chemical	D007980	851038
dopa	I-Chemical	-1	851038
treatment	O	-1	851038
in	O	-1	851038
par@@	B-Disease	D010300	851038
k@@	I-Disease	-1	851038
inson@@	I-Disease	-1	851038
i@@	I-Disease	-1	851038
an	I-Disease	-1	851038
patients.	O	-1	851038
H@@	B-Disease	D007008	851038
y@@	I-Disease	-1	851038
po@@	I-Disease	-1	851038
k@@	I-Disease	-1	851038
al@@	I-Disease	-1	851038
emia	I-Disease	-1	851038
,	O	-1	851038
so@@	O	-1	851038
me@@	O	-1	851038
times	O	-1	851038
se@@	O	-1	851038
ve@@	O	-1	851038
re,	O	-1	851038
was	O	-1	851038
observed	O	-1	851038
in	O	-1	851038
some	O	-1	851038
L-@@	B-Chemical	D007980	851038
dopa	I-Chemical	-1	851038
-treated	O	-1	851038
par@@	B-Disease	D010300	851038
k@@	I-Disease	-1	851038
inson@@	I-Disease	-1	851038
i@@	I-Disease	-1	851038
an	I-Disease	-1	851038
patients.	O	-1	851038
The	O	-1	851038
influence	O	-1	851038
of	O	-1	851038
L-@@	B-Chemical	D007980	851038
dopa	I-Chemical	-1	851038
on	O	-1	851038
the	O	-1	851038
renal	O	-1	851038
ex@@	O	-1	851038
cre@@	O	-1	851038
tion	O	-1	851038
of	O	-1	851038
pot@@	B-Chemical	D011188	851038
assi@@	I-Chemical	-1	851038
um	I-Chemical	-1	851038
was	O	-1	851038
studied	O	-1	851038
in	O	-1	851038
3	O	-1	851038
patients	O	-1	851038
with	O	-1	851038
hypo@@	B-Disease	D007008	851038
k@@	I-Disease	-1	851038
al@@	I-Disease	-1	851038
emia	I-Disease	-1	851038
and	O	-1	851038
in	O	-1	851038
5	O	-1	851038
nor@@	O	-1	851038
mo@@	O	-1	851038
k@@	O	-1	851038
al@@	O	-1	851038
em@@	O	-1	851038
ic	O	-1	851038
patients	O	-1	851038
by	O	-1	851038
determin@@	O	-1	851038
ation	O	-1	851038
of	O	-1	851038
renal	O	-1	851038
plasma	O	-1	851038
f@@	O	-1	851038
low@@	O	-1	851038
,	O	-1	851038
glomerular	O	-1	851038
f@@	O	-1	851038
iltration	O	-1	851038
rat@@	O	-1	851038
e,	O	-1	851038
plasma	O	-1	851038
concentration	O	-1	851038
of	O	-1	851038
pot@@	B-Chemical	D011188	851038
assi@@	I-Chemical	-1	851038
um	I-Chemical	-1	851038
and	O	-1	851038
sodium	B-Chemical	D012964	851038
as	O	-1	851038
well	O	-1	851038
as	O	-1	851038
urinary	O	-1	851038
ex@@	O	-1	851038
cre@@	O	-1	851038
tion	O	-1	851038
of	O	-1	851038
pot@@	B-Chemical	D011188	851038
assi@@	I-Chemical	-1	851038
um	I-Chemical	-1	851038
,	O	-1	851038
sodium	B-Chemical	D012964	851038
and	O	-1	851038
al@@	B-Chemical	D000450	851038
do@@	I-Chemical	-1	851038
sterone	I-Chemical	-1	851038
.	O	-1	851038
L-@@	B-Chemical	D007980	851038
D@@	I-Chemical	-1	851038
op@@	I-Chemical	-1	851038
a	I-Chemical	-1	851038
int@@	O	-1	851038
ake	O	-1	851038
was	O	-1	851038
found	O	-1	851038
to	O	-1	851038
cause	O	-1	851038
an	O	-1	851038
increased	O	-1	851038
ex@@	O	-1	851038
cre@@	O	-1	851038
tion	O	-1	851038
of	O	-1	851038
pot@@	B-Chemical	D011188	851038
assi@@	I-Chemical	-1	851038
um	I-Chemical	-1	851038
,	O	-1	851038
and	O	-1	851038
so@@	O	-1	851038
me@@	O	-1	851038
times	O	-1	851038
also	O	-1	851038
of	O	-1	851038
sodium	B-Chemical	D012964	851038
,	O	-1	851038
in	O	-1	851038
the	O	-1	851038
hypo@@	O	-1	851038
k@@	O	-1	851038
al@@	O	-1	851038
em@@	O	-1	851038
ic	O	-1	851038
but	O	-1	851038
not	O	-1	851038
in	O	-1	851038
the	O	-1	851038
nor@@	O	-1	851038
mo@@	O	-1	851038
k@@	O	-1	851038
al@@	O	-1	851038
em@@	O	-1	851038
ic	O	-1	851038
patients.	O	-1	851038
This	O	-1	851038
effect	O	-1	851038
on	O	-1	851038
the	O	-1	851038
renal	O	-1	851038
function	O	-1	851038
could	O	-1	851038
be	O	-1	851038
pro@@	O	-1	851038
hib@@	O	-1	851038
ited	O	-1	851038
by	O	-1	851038
the	O	-1	851038
administration	O	-1	851038
of	O	-1	851038
a	O	-1	851038
peripheral	O	-1	851038
dopa	O	-1	851038
dec@@	O	-1	851038
ar@@	O	-1	851038
bo@@	O	-1	851038
d@@	O	-1	851038
yl@@	O	-1	851038
ase	O	-1	851038
inhibitor@@	O	-1	851038
.	O	-1	851038
It	O	-1	851038
is	O	-1	851038
not	O	-1	851038
known	O	-1	851038
wh@@	O	-1	851038
y	O	-1	851038
this	O	-1	851038
effect	O	-1	851038
occurred	O	-1	851038
in	O	-1	851038
some	O	-1	851038
individ@@	O	-1	851038
u@@	O	-1	851038
als	O	-1	851038
but	O	-1	851038
not	O	-1	851038
in	O	-1	851038
o@@	O	-1	851038
ther@@	O	-1	851038
s,	O	-1	851038
but	O	-1	851038
our	O	-1	851038
results	O	-1	851038
indicate	O	-1	851038
a	O	-1	851038
correl@@	O	-1	851038
ation	O	-1	851038
between	O	-1	851038
al@@	B-Chemical	D000450	851038
do@@	I-Chemical	-1	851038
sterone	I-Chemical	-1	851038
pro@@	O	-1	851038
duction	O	-1	851038
and	O	-1	851038
this	O	-1	851038
renal	O	-1	851038
effect	O	-1	851038
of	O	-1	851038
L-@@	B-Chemical	D007980	851038
dopa	I-Chemical	-1	851038
.	O	-1	851038

Ph@@	B-Chemical	D010672	891494
en@@	I-Chemical	-1	891494
y@@	I-Chemical	-1	891494
to@@	I-Chemical	-1	891494
in	I-Chemical	-1	891494
encephalo@@	B-Disease	D001927	891494
pathy	I-Disease	-1	891494
as	O	-1	891494
prob@@	O	-1	891494
able	O	-1	891494
i@@	O	-1	891494
di@@	O	-1	891494
os@@	O	-1	891494
yn@@	O	-1	891494
c@@	O	-1	891494
r@@	O	-1	891494
atic	O	-1	891494
reac@@	O	-1	891494
tion@@	O	-1	891494
:	O	-1	891494
case	O	-1	891494
repor@@	O	-1	891494
t.	O	-1	891494
A	O	-1	891494
case	O	-1	891494
of	O	-1	891494
pheny@@	B-Chemical	D010672	891494
to@@	I-Chemical	-1	891494
in	I-Chemical	-1	891494
(	O	-1	891494
D@@	B-Chemical	D010672	891494
P@@	I-Chemical	-1	891494
H	I-Chemical	-1	891494
)	O	-1	891494
encephalo@@	B-Disease	D001927	891494
pathy	I-Disease	-1	891494
with	O	-1	891494
increas@@	O	-1	891494
ing	O	-1	891494
seizures	B-Disease	D012640	891494
and	O	-1	891494
E@@	O	-1	891494
E@@	O	-1	891494
G	O	-1	891494
and	O	-1	891494
mental	O	-1	891494
changes	O	-1	891494
is	O	-1	891494
descri@@	O	-1	891494
be@@	O	-1	891494
d.	O	-1	891494
D@@	O	-1	891494
es@@	O	-1	891494
pit@@	O	-1	891494
e	O	-1	891494
ade@@	O	-1	891494
qu@@	O	-1	891494
ate	O	-1	891494
oral	O	-1	891494
dos@@	O	-1	891494
age	O	-1	891494
of	O	-1	891494
D@@	B-Chemical	D010672	891494
P@@	I-Chemical	-1	891494
H	I-Chemical	-1	891494
(@@	O	-1	891494
5	O	-1	891494
mg/k@@	O	-1	891494
g/@@	O	-1	891494
da@@	O	-1	891494
il@@	O	-1	891494
y@@	O	-1	891494
)	O	-1	891494
the	O	-1	891494
plasma	O	-1	891494
level	O	-1	891494
was	O	-1	891494
very	O	-1	891494
low	O	-1	891494
(2@@	O	-1	891494
.@@	O	-1	891494
8	O	-1	891494
microgram@@	O	-1	891494
g/@@	O	-1	891494
ml@@	O	-1	891494
).	O	-1	891494
The	O	-1	891494
encephalo@@	B-Disease	D001927	891494
pathy	I-Disease	-1	891494
was	O	-1	891494
prob@@	O	-1	891494
ably	O	-1	891494
an	O	-1	891494
i@@	O	-1	891494
di@@	O	-1	891494
os@@	O	-1	891494
yn@@	O	-1	891494
c@@	O	-1	891494
r@@	O	-1	891494
atic	O	-1	891494
and	O	-1	891494
not	O	-1	891494
toxic	O	-1	891494
or	O	-1	891494
all@@	O	-1	891494
ergic	O	-1	891494
reac@@	O	-1	891494
tion.	O	-1	891494
In	O	-1	891494
fac@@	O	-1	891494
t	O	-1	891494
the	O	-1	891494
concentration	O	-1	891494
of	O	-1	891494
free	O	-1	891494
D@@	B-Chemical	D010672	891494
P@@	I-Chemical	-1	891494
H	I-Chemical	-1	891494
was	O	-1	891494
normal@@	O	-1	891494
,	O	-1	891494
the	O	-1	891494
patient	O	-1	891494
presented	O	-1	891494
a	O	-1	891494
ret@@	O	-1	891494
ar@@	O	-1	891494
ded	O	-1	891494
mor@@	O	-1	891494
bil@@	O	-1	891494
li@@	O	-1	891494
form	O	-1	891494
r@@	B-Disease	D005076	891494
as@@	I-Disease	-1	891494
h	I-Disease	-1	891494
during	O	-1	891494
D@@	B-Chemical	D010672	891494
P@@	I-Chemical	-1	891494
H	I-Chemical	-1	891494
treatment,	O	-1	891494
the	O	-1	891494
pro@@	O	-1	891494
ti@@	O	-1	891494
do@@	O	-1	891494
gra@@	O	-1	891494
m	O	-1	891494
was	O	-1	891494
normal@@	O	-1	891494
,	O	-1	891494
and	O	-1	891494
an	O	-1	891494
intra@@	O	-1	891494
der@@	O	-1	891494
mic	O	-1	891494
D@@	B-Chemical	D010672	891494
P@@	I-Chemical	-1	891494
H	I-Chemical	-1	891494
injection	O	-1	891494
had	O	-1	891494
no	O	-1	891494
loc@@	O	-1	891494
al	O	-1	891494
effect@@	O	-1	891494
.	O	-1	891494
The	O	-1	891494
au@@	O	-1	891494
th@@	O	-1	891494
ors	O	-1	891494
concl@@	O	-1	891494
ude	O	-1	891494
that	O	-1	891494
in	O	-1	891494
a	O	-1	891494
patient	O	-1	891494
star@@	O	-1	891494
ting	O	-1	891494
D@@	B-Chemical	D010672	891494
P@@	I-Chemical	-1	891494
H	I-Chemical	-1	891494
treatment	O	-1	891494
an	O	-1	891494
un@@	O	-1	891494
ex@@	O	-1	891494
p@@	O	-1	891494
ected	O	-1	891494
increase	O	-1	891494
in	O	-1	891494
seizures	B-Disease	D012640	891494
,	O	-1	891494
with	O	-1	891494
E@@	O	-1	891494
E@@	O	-1	891494
G	O	-1	891494
and	O	-1	891494
mental	O	-1	891494
changes	O	-1	891494
occur@@	O	-1	891494
r@@	O	-1	891494
ing	O	-1	891494
sim@@	O	-1	891494
ult@@	O	-1	891494
ane@@	O	-1	891494
ous@@	O	-1	891494
ly,	O	-1	891494
should	O	-1	891494
al@@	O	-1	891494
er@@	O	-1	891494
t	O	-1	891494
the	O	-1	891494
physi@@	O	-1	891494
ci@@	O	-1	891494
an	O	-1	891494
to	O	-1	891494
the	O	-1	891494
possible	O	-1	891494
need	O	-1	891494
for	O	-1	891494
el@@	O	-1	891494
im@@	O	-1	891494
in@@	O	-1	891494
ating	O	-1	891494
D@@	B-Chemical	D010672	891494
P@@	I-Chemical	-1	891494
H	I-Chemical	-1	891494
from	O	-1	891494
the	O	-1	891494
therapeutic	O	-1	891494
regimen@@	O	-1	891494
,	O	-1	891494
even	O	-1	891494
if	O	-1	891494
plasma	O	-1	891494
concentrations	O	-1	891494
are	O	-1	891494
low@@	O	-1	891494
.	O	-1	891494

Eff@@	O	-1	895432
ects	O	-1	895432
of	O	-1	895432
ex@@	O	-1	895432
er@@	O	-1	895432
cis@@	O	-1	895432
e	O	-1	895432
on	O	-1	895432
the	O	-1	895432
severity	O	-1	895432
of	O	-1	895432
isoproteren@@	B-Chemical	D007545	895432
ol	I-Chemical	-1	895432
-induced	O	-1	895432
myocardial	B-Disease	D009203	895432
infarction	I-Disease	-1	895432
.	O	-1	895432
The	O	-1	895432
effect	O	-1	895432
of	O	-1	895432
ex@@	O	-1	895432
er@@	O	-1	895432
cis@@	O	-1	895432
e	O	-1	895432
on	O	-1	895432
the	O	-1	895432
severity	O	-1	895432
of	O	-1	895432
isoproteren@@	B-Chemical	D007545	895432
ol	I-Chemical	-1	895432
-induced	O	-1	895432
myocardial	B-Disease	D009203	895432
infarction	I-Disease	-1	895432
was	O	-1	895432
studied	O	-1	895432
in	O	-1	895432
male	O	-1	895432
rats.	O	-1	895432
N@@	O	-1	895432
ine@@	O	-1	895432
ty-@@	O	-1	895432
three	O	-1	895432
rats	O	-1	895432
were	O	-1	895432
random@@	O	-1	895432
ly	O	-1	895432
divid@@	O	-1	895432
ed	O	-1	895432
into	O	-1	895432
three	O	-1	895432
groups.	O	-1	895432
The	O	-1	895432
ex@@	O	-1	895432
er@@	O	-1	895432
ci@@	O	-1	895432
se@@	O	-1	895432
-	O	-1	895432
isoproteren@@	B-Chemical	D007545	895432
ol	I-Chemical	-1	895432
(@@	O	-1	895432
E@@	O	-1	895432
-1@@	O	-1	895432
)	O	-1	895432
and	O	-1	895432
ex@@	O	-1	895432
er@@	O	-1	895432
cis@@	O	-1	895432
e	O	-1	895432
control	O	-1	895432
(@@	O	-1	895432
EC@@	O	-1	895432
)	O	-1	895432
groups	O	-1	895432
ex@@	O	-1	895432
er@@	O	-1	895432
cis@@	O	-1	895432
ed	O	-1	895432
daily	O	-1	895432
for	O	-1	895432
thir@@	O	-1	895432
t@@	O	-1	895432
y	O	-1	895432
days	O	-1	895432
on	O	-1	895432
a	O	-1	895432
tre@@	O	-1	895432
ad@@	O	-1	895432
mil@@	O	-1	895432
l	O	-1	895432
at	O	-1	895432
1	O	-1	895432
m@@	O	-1	895432
ph@@	O	-1	895432
,	O	-1	895432
2@@	O	-1	895432
%	O	-1	895432
gra@@	O	-1	895432
de	O	-1	895432
while	O	-1	895432
animals	O	-1	895432
of	O	-1	895432
the	O	-1	895432
sed@@	O	-1	895432
ent@@	O	-1	895432
ar@@	O	-1	895432
y@@	O	-1	895432
-	O	-1	895432
isoproteren@@	B-Chemical	D007545	895432
ol	I-Chemical	-1	895432
(S@@	O	-1	895432
-@@	O	-1	895432
I@@	O	-1	895432
)	O	-1	895432
group	O	-1	895432
remained	O	-1	895432
sed@@	O	-1	895432
ent@@	O	-1	895432
ar@@	O	-1	895432
y.	O	-1	895432
E@@	O	-1	895432
ight	O	-1	895432
animals	O	-1	895432
were	O	-1	895432
as@@	O	-1	895432
signed	O	-1	895432
to	O	-1	895432
the	O	-1	895432
sed@@	O	-1	895432
ent@@	O	-1	895432
ary	O	-1	895432
control	O	-1	895432
(S@@	O	-1	895432
C@@	O	-1	895432
)	O	-1	895432
group	O	-1	895432
which	O	-1	895432
remained	O	-1	895432
sed@@	O	-1	895432
ent@@	O	-1	895432
ary	O	-1	895432
throu@@	O	-1	895432
gh@@	O	-1	895432
out	O	-1	895432
the	O	-1	895432
experimental	O	-1	895432
perio@@	O	-1	895432
d.	O	-1	895432
F@@	O	-1	895432
or@@	O	-1	895432
ty-@@	O	-1	895432
e@@	O	-1	895432
ight	O	-1	895432
hours	O	-1	895432
after	O	-1	895432
the	O	-1	895432
f@@	O	-1	895432
inal	O	-1	895432
ex@@	O	-1	895432
er@@	O	-1	895432
cis@@	O	-1	895432
e	O	-1	895432
perio@@	O	-1	895432
d,	O	-1	895432
S@@	O	-1	895432
-@@	O	-1	895432
I	O	-1	895432
and	O	-1	895432
E@@	O	-1	895432
-@@	O	-1	895432
I	O	-1	895432
animals	O	-1	895432
received	O	-1	895432
a	O	-1	895432
single	O	-1	895432
sub@@	O	-1	895432
c@@	O	-1	895432
utaneous	O	-1	895432
injection	O	-1	895432
of	O	-1	895432
isoproteren@@	B-Chemical	D007545	895432
ol	I-Chemical	-1	895432
(2@@	O	-1	895432
50	O	-1	895432
mg/kg	O	-1	895432
body	O	-1	895432
weigh@@	O	-1	895432
t@@	O	-1	895432
).	O	-1	895432
An@@	O	-1	895432
im@@	O	-1	895432
als	O	-1	895432
of	O	-1	895432
the	O	-1	895432
S@@	O	-1	895432
-@@	O	-1	895432
I	O	-1	895432
group	O	-1	895432
ex@@	O	-1	895432
hib@@	O	-1	895432
ited	O	-1	895432
significantly	O	-1	895432
(P@@	O	-1	895432
p	O	-1	895432
less	O	-1	895432
than	O	-1	895432
0.05@@	O	-1	895432
)	O	-1	895432
greater	O	-1	895432
mor@@	O	-1	895432
t@@	O	-1	895432
ality	O	-1	895432
from	O	-1	895432
the	O	-1	895432
effects	O	-1	895432
of	O	-1	895432
isoproteren@@	B-Chemical	D007545	895432
ol	I-Chemical	-1	895432
than	O	-1	895432
animals	O	-1	895432
of	O	-1	895432
the	O	-1	895432
E@@	O	-1	895432
-@@	O	-1	895432
I	O	-1	895432
group.	O	-1	895432
S@@	O	-1	895432
er@@	O	-1	895432
um	O	-1	895432
C@@	O	-1	895432
P@@	O	-1	895432
K	O	-1	895432
activity	O	-1	895432
for	O	-1	895432
E@@	O	-1	895432
-@@	O	-1	895432
I	O	-1	895432
animals	O	-1	895432
was	O	-1	895432
significantly	O	-1	895432
(p	O	-1	895432
less	O	-1	895432
than	O	-1	895432
0.05@@	O	-1	895432
)	O	-1	895432
greater	O	-1	895432
than	O	-1	895432
for	O	-1	895432
animals	O	-1	895432
in	O	-1	895432
the	O	-1	895432
S@@	O	-1	895432
-@@	O	-1	895432
I	O	-1	895432
and	O	-1	895432
E@@	O	-1	895432
C	O	-1	895432
groups	O	-1	895432
tw@@	O	-1	895432
ent@@	O	-1	895432
y	O	-1	895432
hours	O	-1	895432
following	O	-1	895432
isoproteren@@	B-Chemical	D007545	895432
ol	I-Chemical	-1	895432
injec@@	O	-1	895432
tion.	O	-1	895432
No	O	-1	895432
statis@@	O	-1	895432
tically	O	-1	895432
significant	O	-1	895432
differences	O	-1	895432
were	O	-1	895432
observed	O	-1	895432
between	O	-1	895432
the	O	-1	895432
two	O	-1	895432
isoproteren@@	B-Chemical	D007545	895432
ol	I-Chemical	-1	895432
treated	O	-1	895432
groups	O	-1	895432
for	O	-1	895432
severity	O	-1	895432
of	O	-1	895432
the	O	-1	895432
induced	O	-1	895432
le@@	O	-1	895432
sion@@	O	-1	895432
s,	O	-1	895432
changes	O	-1	895432
in	O	-1	895432
heart	O	-1	895432
weigh@@	O	-1	895432
t,	O	-1	895432
or	O	-1	895432
heart	O	-1	895432
weight	O	-1	895432
to	O	-1	895432
body	O	-1	895432
weight	O	-1	895432
rati@@	O	-1	895432
o@@	O	-1	895432
s.	O	-1	895432
The	O	-1	895432
results	O	-1	895432
indic@@	O	-1	895432
ated	O	-1	895432
that	O	-1	895432
ex@@	O	-1	895432
er@@	O	-1	895432
cis@@	O	-1	895432
e	O	-1	895432
reduced	O	-1	895432
the	O	-1	895432
mor@@	O	-1	895432
t@@	O	-1	895432
ality	O	-1	895432
associated	O	-1	895432
with	O	-1	895432
the	O	-1	895432
effects	O	-1	895432
of	O	-1	895432
larg@@	O	-1	895432
e	O	-1	895432
dos@@	O	-1	895432
ages	O	-1	895432
of	O	-1	895432
isoproteren@@	B-Chemical	D007545	895432
ol	I-Chemical	-1	895432
but	O	-1	895432
had	O	-1	895432
lit@@	O	-1	895432
t@@	O	-1	895432
le	O	-1	895432
on	O	-1	895432
the	O	-1	895432
severity	O	-1	895432
of	O	-1	895432
the	O	-1	895432
infarction	B-Disease	D007238	895432
.	O	-1	895432

Eff@@	O	-1	931801
ect	O	-1	931801
of	O	-1	931801
D-@@	B-Chemical	D005937	931801
G@@	I-Chemical	-1	931801
l@@	I-Chemical	-1	931801
uc@@	I-Chemical	-1	931801
ar@@	I-Chemical	-1	931801
ates	I-Chemical	-1	931801
on	O	-1	931801
b@@	O	-1	931801
a@@	O	-1	931801
sic	O	-1	931801
anti@@	O	-1	931801
bio@@	O	-1	931801
tic@@	O	-1	931801
-induced	O	-1	931801
renal	B-Disease	D007674	931801
damage	I-Disease	-1	931801
in	O	-1	931801
rats.	O	-1	931801
De@@	B-Disease	D003681	931801
hy@@	I-Disease	-1	931801
d@@	I-Disease	-1	931801
r@@	I-Disease	-1	931801
ated	I-Disease	-1	931801
rats	O	-1	931801
reg@@	O	-1	931801
ul@@	O	-1	931801
arly	O	-1	931801
deve@@	O	-1	931801
lo@@	O	-1	931801
p	O	-1	931801
acute	B-Disease	D058186	931801
renal	I-Disease	-1	931801
failure	I-Disease	-1	931801
following	O	-1	931801
single	O	-1	931801
injection	O	-1	931801
of	O	-1	931801
amino@@	B-Chemical	D000617	931801
gly@@	I-Chemical	-1	931801
co@@	I-Chemical	-1	931801
side	I-Chemical	-1	931801
anti@@	O	-1	931801
bio@@	O	-1	931801
tics	O	-1	931801
combined	O	-1	931801
with	O	-1	931801
de@@	O	-1	931801
x@@	O	-1	931801
tra@@	O	-1	931801
n	O	-1	931801
or	O	-1	931801
of	O	-1	931801
anti@@	O	-1	931801
bio@@	O	-1	931801
tics	O	-1	931801
on@@	O	-1	931801
ly.	O	-1	931801
O@@	O	-1	931801
ral	O	-1	931801
administration	O	-1	931801
of	O	-1	931801
2@@	B-Chemical	C038936	931801
,@@	I-Chemical	-1	931801
5-@@	I-Chemical	-1	931801
di@@	I-Chemical	-1	931801
-@@	I-Chemical	-1	931801
O@@	I-Chemical	-1	931801
-@@	I-Chemical	-1	931801
acet@@	I-Chemical	-1	931801
yl@@	I-Chemical	-1	931801
-@@	I-Chemical	-1	931801
D-@@	I-Chemical	-1	931801
gl@@	I-Chemical	-1	931801
uc@@	I-Chemical	-1	931801
a@@	I-Chemical	-1	931801
ro@@	I-Chemical	-1	931801
-1@@	I-Chemical	-1	931801
,@@	I-Chemical	-1	931801
4-@@	I-Chemical	-1	931801
6@@	I-Chemical	-1	931801
,@@	I-Chemical	-1	931801
3-@@	I-Chemical	-1	931801
di@@	I-Chemical	-1	931801
l@@	I-Chemical	-1	931801
act@@	I-Chemical	-1	931801
one	I-Chemical	-1	931801
prot@@	O	-1	931801
ected	O	-1	931801
rats	O	-1	931801
against	O	-1	931801
renal	B-Disease	D051437	931801
failure	I-Disease	-1	931801
induced	O	-1	931801
by	O	-1	931801
k@@	B-Chemical	D007612	931801
an@@	I-Chemical	-1	931801
am@@	I-Chemical	-1	931801
ycin	I-Chemical	-1	931801
-@@	O	-1	931801
de@@	O	-1	931801
x@@	O	-1	931801
tran@@	O	-1	931801
.	O	-1	931801
The	O	-1	931801
protective	O	-1	931801
effect	O	-1	931801
was	O	-1	931801
prev@@	O	-1	931801
al@@	O	-1	931801
ent	O	-1	931801
among	O	-1	931801
D-@@	B-Chemical	D005937	931801
gl@@	I-Chemical	-1	931801
uc@@	I-Chemical	-1	931801
ar@@	I-Chemical	-1	931801
ates	I-Chemical	-1	931801
,	O	-1	931801
and	O	-1	931801
also	O	-1	931801
to	O	-1	931801
other	O	-1	931801
s@@	B-Chemical	D005937	931801
ac@@	I-Chemical	-1	931801
ch@@	I-Chemical	-1	931801
ar@@	I-Chemical	-1	931801
ic	I-Chemical	-1	931801
acid	I-Chemical	-1	931801
,	O	-1	931801
he@@	B-Chemical	D006603	931801
x@@	I-Chemical	-1	931801
a@@	I-Chemical	-1	931801
uron@@	I-Chemical	-1	931801
ic	I-Chemical	-1	931801
acid@@	I-Chemical	-1	931801
s	I-Chemical	-1	931801
and	O	-1	931801
he@@	B-Chemical	-1	931801
x@@	I-Chemical	-1	931801
a@@	I-Chemical	-1	931801
al@@	I-Chemical	-1	931801
d@@	I-Chemical	-1	931801
onic	I-Chemical	-1	931801
acid@@	I-Chemical	-1	931801
s	I-Chemical	-1	931801
,	O	-1	931801
although	O	-1	931801
to	O	-1	931801
a	O	-1	931801
l@@	O	-1	931801
ess@@	O	-1	931801
er	O	-1	931801
de@@	O	-1	931801
gre@@	O	-1	931801
e,	O	-1	931801
but	O	-1	931801
not	O	-1	931801
to	O	-1	931801
a	O	-1	931801
he@@	O	-1	931801
x@@	O	-1	931801
a@@	O	-1	931801
al@@	O	-1	931801
dose@@	O	-1	931801
,	O	-1	931801
sug@@	B-Chemical	D013402	931801
ar	I-Chemical	-1	931801
alco@@	I-Chemical	-1	931801
h@@	I-Chemical	-1	931801
ol@@	I-Chemical	-1	931801
s	I-Chemical	-1	931801
,	O	-1	931801
subst@@	O	-1	931801
anc@@	O	-1	931801
es	O	-1	931801
in@@	O	-1	931801
the	O	-1	931801
T@@	B-Chemical	D002952	931801
C@@	I-Chemical	-1	931801
A	I-Chemical	-1	931801
cyc@@	O	-1	931801
le	O	-1	931801
and	O	-1	931801
other	O	-1	931801
ac@@	O	-1	931801
i@@	O	-1	931801
di@@	O	-1	931801
c	O	-1	931801
comp@@	O	-1	931801
oun@@	O	-1	931801
d@@	O	-1	931801
s.	O	-1	931801
D-@@	B-Chemical	D005937	931801
G@@	I-Chemical	-1	931801
l@@	I-Chemical	-1	931801
uc@@	I-Chemical	-1	931801
ar@@	I-Chemical	-1	931801
ates	I-Chemical	-1	931801
were	O	-1	931801
effective	O	-1	931801
against	O	-1	931801
renal	B-Disease	D007674	931801
damage	I-Disease	-1	931801
induced	O	-1	931801
by	O	-1	931801
p@@	O	-1	931801
ep@@	O	-1	931801
ti@@	O	-1	931801
de	O	-1	931801
anti@@	O	-1	931801
bio@@	O	-1	931801
tics	O	-1	931801
as	O	-1	931801
well	O	-1	931801
as	O	-1	931801
various	O	-1	931801
amino@@	B-Chemical	D000617	931801
gly@@	I-Chemical	-1	931801
co@@	I-Chemical	-1	931801
side	I-Chemical	-1	931801
anti@@	O	-1	931801
b@@	O	-1	931801
it@@	O	-1	931801
oci@@	O	-1	931801
s.	O	-1	931801
D@@	O	-1	931801
o@@	O	-1	931801
se@@	O	-1	931801
-@@	O	-1	931801
responses	O	-1	931801
were	O	-1	931801
observed	O	-1	931801
in	O	-1	931801
the	O	-1	931801
protective	O	-1	931801
effect	O	-1	931801
of	O	-1	931801
D-@@	B-Chemical	D005937	931801
G@@	I-Chemical	-1	931801
l@@	I-Chemical	-1	931801
uc@@	I-Chemical	-1	931801
ar@@	I-Chemical	-1	931801
ates	I-Chemical	-1	931801
.	O	-1	931801
W@@	O	-1	931801
it@@	O	-1	931801
h	O	-1	931801
a	O	-1	931801
D-@@	B-Chemical	D005937	931801
gl@@	I-Chemical	-1	931801
uc@@	I-Chemical	-1	931801
ar@@	I-Chemical	-1	931801
ate	I-Chemical	-1	931801
of	O	-1	931801
a	O	-1	931801
fi@@	O	-1	931801
x@@	O	-1	931801
ed	O	-1	931801
size	O	-1	931801
of	O	-1	931801
dose@@	O	-1	931801
,	O	-1	931801
appro@@	O	-1	931801
xim@@	O	-1	931801
ately	O	-1	931801
the	O	-1	931801
same	O	-1	931801
de@@	O	-1	931801
g@@	O	-1	931801
ree	O	-1	931801
of	O	-1	931801
prot@@	O	-1	931801
ection	O	-1	931801
was	O	-1	931801
obtained	O	-1	931801
against	O	-1	931801
renal	B-Disease	D007674	931801
dam@@	I-Disease	-1	931801
ages	I-Disease	-1	931801
induced	O	-1	931801
by	O	-1	931801
different	O	-1	931801
b@@	O	-1	931801
a@@	O	-1	931801
sic	O	-1	931801
anti@@	O	-1	931801
bio@@	O	-1	931801
tics	O	-1	931801
des@@	O	-1	931801
pit@@	O	-1	931801
e	O	-1	931801
larg@@	O	-1	931801
e	O	-1	931801
dis@@	O	-1	931801
par@@	O	-1	931801
ities	O	-1	931801
in	O	-1	931801
administration	O	-1	931801
doses	O	-1	931801
of	O	-1	931801
different	O	-1	931801
anti@@	O	-1	931801
bio@@	O	-1	931801
tic@@	O	-1	931801
s.	O	-1	931801
D-@@	B-Chemical	D005937	931801
G@@	I-Chemical	-1	931801
l@@	I-Chemical	-1	931801
uc@@	I-Chemical	-1	931801
ar@@	I-Chemical	-1	931801
ates	I-Chemical	-1	931801
had	O	-1	931801
the	O	-1	931801
ability	O	-1	931801
to	O	-1	931801
prev@@	O	-1	931801
ent	O	-1	931801
renal	B-Disease	D007674	931801
damage	I-Disease	-1	931801
but	O	-1	931801
not	O	-1	931801
to	O	-1	931801
c@@	O	-1	931801
ure	O	-1	931801
it@@	O	-1	931801
.	O	-1	931801
R@@	O	-1	931801
at@@	O	-1	931801
s	O	-1	931801
ex@@	O	-1	931801
cre@@	O	-1	931801
ted	O	-1	931801
ac@@	O	-1	931801
i@@	O	-1	931801
di@@	O	-1	931801
c	O	-1	931801
urine	O	-1	931801
when	O	-1	931801
they	O	-1	931801
were	O	-1	931801
s@@	O	-1	931801
pared	O	-1	931801
from	O	-1	931801
renal	B-Disease	D007674	931801
lesions	I-Disease	-1	931801
by	O	-1	931801
mon@@	B-Chemical	D009005	931801
os@@	I-Chemical	-1	931801
ac@@	I-Chemical	-1	931801
ch@@	I-Chemical	-1	931801
ari@@	I-Chemical	-1	931801
des	I-Chemical	-1	931801
.	O	-1	931801
The	O	-1	931801
reduction	O	-1	931801
effect	O	-1	931801
of	O	-1	931801
D-@@	B-Chemical	D005937	931801
gl@@	I-Chemical	-1	931801
uc@@	I-Chemical	-1	931801
ar@@	I-Chemical	-1	931801
ates	I-Chemical	-1	931801
against	O	-1	931801
nephro@@	B-Disease	D007674	931801
toxicity	I-Disease	-1	931801
of	O	-1	931801
b@@	O	-1	931801
a@@	O	-1	931801
sic	O	-1	931801
anti@@	O	-1	931801
bio@@	O	-1	931801
tics	O	-1	931801
was	O	-1	931801
discus@@	O	-1	931801
sed.	O	-1	931801

P@@	B-Disease	D010264	946593
ar@@	I-Disease	-1	946593
ap@@	I-Disease	-1	946593
le@@	I-Disease	-1	946593
g@@	I-Disease	-1	946593
ia	I-Disease	-1	946593
following	O	-1	946593
intra@@	O	-1	946593
th@@	O	-1	946593
ec@@	O	-1	946593
al	O	-1	946593
meth@@	B-Chemical	D008727	946593
ot@@	I-Chemical	-1	946593
re@@	I-Chemical	-1	946593
x@@	I-Chemical	-1	946593
ate	I-Chemical	-1	946593
:	O	-1	946593
report	O	-1	946593
of	O	-1	946593
a	O	-1	946593
case	O	-1	946593
and	O	-1	946593
revie@@	O	-1	946593
w	O	-1	946593
of	O	-1	946593
the	O	-1	946593
literat@@	O	-1	946593
ure.	O	-1	946593
A	O	-1	946593
patient	O	-1	946593
who	O	-1	946593
developed	O	-1	946593
par@@	B-Disease	D010264	946593
ap@@	I-Disease	-1	946593
le@@	I-Disease	-1	946593
g@@	I-Disease	-1	946593
ia	I-Disease	-1	946593
following	O	-1	946593
the	O	-1	946593
intra@@	O	-1	946593
th@@	O	-1	946593
ec@@	O	-1	946593
al	O	-1	946593
insti@@	O	-1	946593
ll@@	O	-1	946593
ation	O	-1	946593
of	O	-1	946593
meth@@	B-Chemical	D008727	946593
ot@@	I-Chemical	-1	946593
re@@	I-Chemical	-1	946593
x@@	I-Chemical	-1	946593
ate	I-Chemical	-1	946593
is	O	-1	946593
dis@@	O	-1	946593
cri@@	O	-1	946593
be@@	O	-1	946593
d.	O	-1	946593
The	O	-1	946593
ten	O	-1	946593
previously	O	-1	946593
reported	O	-1	946593
cases	O	-1	946593
of	O	-1	946593
this	O	-1	946593
un@@	O	-1	946593
us@@	O	-1	946593
ual	O	-1	946593
complication	O	-1	946593
are	O	-1	946593
revie@@	O	-1	946593
we@@	O	-1	946593
d.	O	-1	946593
The	O	-1	946593
following	O	-1	946593
factors	O	-1	946593
appe@@	O	-1	946593
ar	O	-1	946593
to	O	-1	946593
pre@@	O	-1	946593
dis@@	O	-1	946593
p@@	O	-1	946593
ose	O	-1	946593
to	O	-1	946593
the	O	-1	946593
development	O	-1	946593
of	O	-1	946593
this	O	-1	946593
complic@@	O	-1	946593
ation@@	O	-1	946593
:	O	-1	946593
ab@@	O	-1	946593
normal	O	-1	946593
ce@@	O	-1	946593
reb@@	O	-1	946593
ro@@	O	-1	946593
spinal	O	-1	946593
dynam@@	O	-1	946593
ic@@	O	-1	946593
s	O	-1	946593
related	O	-1	946593
to	O	-1	946593
the	O	-1	946593
presence	O	-1	946593
of	O	-1	946593
central	B-Disease	D002493	946593
ner@@	I-Disease	-1	946593
v@@	I-Disease	-1	946593
ous	I-Disease	-1	946593
system	I-Disease	-1	946593
leuk@@	I-Disease	-1	946593
emia	I-Disease	-1	946593
,	O	-1	946593
and	O	-1	946593
ep@@	O	-1	946593
id@@	O	-1	946593
ural	O	-1	946593
ce@@	O	-1	946593
reb@@	O	-1	946593
ro@@	O	-1	946593
spinal	O	-1	946593
le@@	O	-1	946593
ak@@	O	-1	946593
ag@@	O	-1	946593
e@@	O	-1	946593
;	O	-1	946593
elevated	O	-1	946593
ce@@	O	-1	946593
reb@@	O	-1	946593
ro@@	O	-1	946593
spinal	O	-1	946593
flu@@	O	-1	946593
id	O	-1	946593
meth@@	B-Chemical	D008727	946593
o@@	I-Chemical	-1	946593
th@@	I-Chemical	-1	946593
ex@@	I-Chemical	-1	946593
ate	I-Chemical	-1	946593
concentration	O	-1	946593
related	O	-1	946593
to	O	-1	946593
ab@@	O	-1	946593
normal	O	-1	946593
ce@@	O	-1	946593
reb@@	O	-1	946593
ro@@	O	-1	946593
spinal	O	-1	946593
flu@@	O	-1	946593
id	O	-1	946593
dynam@@	O	-1	946593
ic@@	O	-1	946593
s	O	-1	946593
and	O	-1	946593
to	O	-1	946593
in@@	O	-1	946593
appro@@	O	-1	946593
pri@@	O	-1	946593
ately	O	-1	946593
high	O	-1	946593
meth@@	B-Chemical	D008727	946593
ot@@	I-Chemical	-1	946593
re@@	I-Chemical	-1	946593
x@@	I-Chemical	-1	946593
ate	I-Chemical	-1	946593
doses	O	-1	946593
bas@@	O	-1	946593
ed	O	-1	946593
on	O	-1	946593
body	O	-1	946593
sur@@	O	-1	946593
fac@@	O	-1	946593
e	O	-1	946593
a@@	O	-1	946593
re@@	O	-1	946593
a	O	-1	946593
calc@@	O	-1	946593
ul@@	O	-1	946593
ations	O	-1	946593
in	O	-1	946593
ol@@	O	-1	946593
der	O	-1	946593
children	O	-1	946593
and	O	-1	946593
ad@@	O	-1	946593
ult@@	O	-1	946593
s;	O	-1	946593
the	O	-1	946593
presence	O	-1	946593
of	O	-1	946593
neuro@@	B-Disease	D020258	946593
toxic	I-Disease	-1	946593
pres@@	O	-1	946593
er@@	O	-1	946593
v@@	O	-1	946593
ati@@	O	-1	946593
v@@	O	-1	946593
es	O	-1	946593
in	O	-1	946593
com@@	O	-1	946593
mer@@	O	-1	946593
ci@@	O	-1	946593
ally	O	-1	946593
av@@	O	-1	946593
ail@@	O	-1	946593
able	O	-1	946593
meth@@	B-Chemical	D008727	946593
ot@@	I-Chemical	-1	946593
re@@	I-Chemical	-1	946593
x@@	I-Chemical	-1	946593
ate	I-Chemical	-1	946593
pre@@	O	-1	946593
par@@	O	-1	946593
ations	O	-1	946593
and	O	-1	946593
di@@	O	-1	946593
lu@@	O	-1	946593
ent@@	O	-1	946593
s;	O	-1	946593
and	O	-1	946593
the	O	-1	946593
use	O	-1	946593
of	O	-1	946593
meth@@	B-Chemical	D008727	946593
ot@@	I-Chemical	-1	946593
re@@	I-Chemical	-1	946593
x@@	I-Chemical	-1	946593
ate	I-Chemical	-1	946593
di@@	O	-1	946593
lu@@	O	-1	946593
ents	O	-1	946593
of	O	-1	946593
un@@	O	-1	946593
physi@@	O	-1	946593
ologic	O	-1	946593
p@@	O	-1	946593
H@@	O	-1	946593
,	O	-1	946593
i@@	O	-1	946593
onic	O	-1	946593
cont@@	O	-1	946593
ent	O	-1	946593
and	O	-1	946593
os@@	O	-1	946593
mol@@	O	-1	946593
ar@@	O	-1	946593
ity.	O	-1	946593
The	O	-1	946593
role	O	-1	946593
of	O	-1	946593
meth@@	B-Chemical	D008727	946593
ot@@	I-Chemical	-1	946593
re@@	I-Chemical	-1	946593
x@@	I-Chemical	-1	946593
ate	I-Chemical	-1	946593
cont@@	O	-1	946593
amin@@	O	-1	946593
ant@@	O	-1	946593
s,	O	-1	946593
loc@@	O	-1	946593
al	O	-1	946593
fol@@	B-Disease	C536409	946593
ate	I-Disease	-1	946593
defici@@	I-Disease	-1	946593
ency	I-Disease	-1	946593
,	O	-1	946593
and	O	-1	946593
c@@	O	-1	946593
ranial	O	-1	946593
ir@@	O	-1	946593
radi@@	O	-1	946593
ation	O	-1	946593
in	O	-1	946593
the	O	-1	946593
path@@	O	-1	946593
o@@	O	-1	946593
genesis	O	-1	946593
of	O	-1	946593
intra@@	O	-1	946593
th@@	O	-1	946593
ec@@	O	-1	946593
al	O	-1	946593
meth@@	B-Chemical	D008727	946593
ot@@	I-Chemical	-1	946593
re@@	I-Chemical	-1	946593
x@@	I-Chemical	-1	946593
ate	I-Chemical	-1	946593
toxicity	B-Disease	D064420	946593
is	O	-1	946593
unc@@	O	-1	946593
lear@@	O	-1	946593
.	O	-1	946593
The	O	-1	946593
incidence	O	-1	946593
of	O	-1	946593
neuro@@	B-Disease	D020258	946593
toxicity	I-Disease	-1	946593
may	O	-1	946593
be	O	-1	946593
reduced	O	-1	946593
by	O	-1	946593
em@@	O	-1	946593
p@@	O	-1	946593
lo@@	O	-1	946593
y@@	O	-1	946593
ing	O	-1	946593
lower	O	-1	946593
doses	O	-1	946593
of	O	-1	946593
meth@@	B-Chemical	D008727	946593
ot@@	I-Chemical	-1	946593
re@@	I-Chemical	-1	946593
x@@	I-Chemical	-1	946593
ate	I-Chemical	-1	946593
in	O	-1	946593
the	O	-1	946593
presence	O	-1	946593
of	O	-1	946593
central	B-Disease	D002493	946593
ner@@	I-Disease	-1	946593
v@@	I-Disease	-1	946593
ous	I-Disease	-1	946593
system	I-Disease	-1	946593
leuk@@	I-Disease	-1	946593
emia	I-Disease	-1	946593
,	O	-1	946593
in	O	-1	946593
ol@@	O	-1	946593
der	O	-1	946593
children	O	-1	946593
and	O	-1	946593
ad@@	O	-1	946593
ult@@	O	-1	946593
s,	O	-1	946593
and	O	-1	946593
in	O	-1	946593
the	O	-1	946593
presence	O	-1	946593
of	O	-1	946593
ep@@	O	-1	946593
id@@	O	-1	946593
ural	O	-1	946593
le@@	O	-1	946593
ak@@	O	-1	946593
age.	O	-1	946593
On@@	O	-1	946593
ly	O	-1	946593
pres@@	O	-1	946593
er@@	O	-1	946593
v@@	O	-1	946593
ati@@	O	-1	946593
ve@@	O	-1	946593
-@@	O	-1	946593
free	O	-1	946593
meth@@	B-Chemical	D008727	946593
ot@@	I-Chemical	-1	946593
re@@	I-Chemical	-1	946593
x@@	I-Chemical	-1	946593
ate	I-Chemical	-1	946593
in	O	-1	946593
E@@	O	-1	946593
l@@	O	-1	946593
li@@	O	-1	946593
ot@@	O	-1	946593
t@@	O	-1	946593
's	O	-1	946593
B	O	-1	946593
S@@	O	-1	946593
ol@@	O	-1	946593
u@@	O	-1	946593
tion	O	-1	946593
at	O	-1	946593
a	O	-1	946593
concentration	O	-1	946593
of	O	-1	946593
not	O	-1	946593
more	O	-1	946593
than	O	-1	946593
1	O	-1	946593
mg/m@@	O	-1	946593
l	O	-1	946593
should	O	-1	946593
be	O	-1	946593
used	O	-1	946593
for	O	-1	946593
intra@@	O	-1	946593
th@@	O	-1	946593
ec@@	O	-1	946593
al	O	-1	946593
administr@@	O	-1	946593
ation.	O	-1	946593
P@@	O	-1	946593
er@@	O	-1	946593
io@@	O	-1	946593
di@@	O	-1	946593
c	O	-1	946593
monit@@	O	-1	946593
or@@	O	-1	946593
ing	O	-1	946593
of	O	-1	946593
ce@@	O	-1	946593
reb@@	O	-1	946593
r@@	O	-1	946593
us@@	O	-1	946593
p@@	O	-1	946593
inal	O	-1	946593
flu@@	O	-1	946593
id	O	-1	946593
meth@@	B-Chemical	D008727	946593
ot@@	I-Chemical	-1	946593
re@@	I-Chemical	-1	946593
x@@	I-Chemical	-1	946593
ate	I-Chemical	-1	946593
levels	O	-1	946593
may	O	-1	946593
be	O	-1	946593
predic@@	O	-1	946593
tive	O	-1	946593
of	O	-1	946593
the	O	-1	946593
development	O	-1	946593
of	O	-1	946593
seri@@	O	-1	946593
ous	O	-1	946593
neuro@@	B-Disease	D020258	946593
toxicity	I-Disease	-1	946593
.	O	-1	946593

C@@	O	-1	978847
entr@@	O	-1	978847
ally	O	-1	978847
mediated	O	-1	978847
cardiovascular	O	-1	978847
effects	O	-1	978847
of	O	-1	978847
intrac@@	O	-1	978847
ist@@	O	-1	978847
er@@	O	-1	978847
n@@	O	-1	978847
al	O	-1	978847
ap@@	O	-1	978847
plic@@	O	-1	978847
ation	O	-1	978847
of	O	-1	978847
carb@@	B-Chemical	D002217	978847
ac@@	I-Chemical	-1	978847
hol	I-Chemical	-1	978847
in	O	-1	978847
anesthe@@	O	-1	978847
tiz@@	O	-1	978847
ed	O	-1	978847
rats.	O	-1	978847
The	O	-1	978847
press@@	O	-1	978847
or	O	-1	978847
response	O	-1	978847
to	O	-1	978847
the	O	-1	978847
intrac@@	O	-1	978847
ist@@	O	-1	978847
er@@	O	-1	978847
n@@	O	-1	978847
al	O	-1	978847
(@@	O	-1	978847
i.@@	O	-1	978847
c@@	O	-1	978847
.)	O	-1	978847
injection	O	-1	978847
of	O	-1	978847
carb@@	B-Chemical	D002217	978847
ac@@	I-Chemical	-1	978847
hol	I-Chemical	-1	978847
(@@	O	-1	978847
1	O	-1	978847
m@@	O	-1	978847
u@@	O	-1	978847
g@@	O	-1	978847
)	O	-1	978847
in	O	-1	978847
anesthe@@	O	-1	978847
tiz@@	O	-1	978847
ed	O	-1	978847
rats	O	-1	978847
was	O	-1	978847
analy@@	O	-1	978847
z@@	O	-1	978847
ed.	O	-1	978847
This	O	-1	978847
response	O	-1	978847
was	O	-1	978847
significantly	O	-1	978847
reduced	O	-1	978847
by	O	-1	978847
the	O	-1	978847
intravenous	O	-1	978847
(@@	O	-1	978847
i.v@@	O	-1	978847
.)	O	-1	978847
injection	O	-1	978847
of	O	-1	978847
gu@@	B-Chemical	D006145	978847
ane@@	I-Chemical	-1	978847
th@@	I-Chemical	-1	978847
idine	I-Chemical	-1	978847
(@@	O	-1	978847
5	O	-1	978847
mg@@	O	-1	978847
),	O	-1	978847
he@@	B-Chemical	D018738	978847
xameth@@	I-Chemical	-1	978847
oni@@	I-Chemical	-1	978847
um	I-Chemical	-1	978847
(10	O	-1	978847
mg@@	O	-1	978847
)	O	-1	978847
or	O	-1	978847
ph@@	B-Chemical	D010646	978847
ent@@	I-Chemical	-1	978847
ol@@	I-Chemical	-1	978847
amine	I-Chemical	-1	978847
(@@	O	-1	978847
5	O	-1	978847
mg@@	O	-1	978847
),	O	-1	978847
and	O	-1	978847
conver@@	O	-1	978847
sel@@	O	-1	978847
y,	O	-1	978847
potenti@@	O	-1	978847
ated	O	-1	978847
by	O	-1	978847
i.v@@	O	-1	978847
.	O	-1	978847
des@@	B-Chemical	D003891	978847
methyl@@	I-Chemical	-1	978847
im@@	I-Chemical	-1	978847
ip@@	I-Chemical	-1	978847
r@@	I-Chemical	-1	978847
amine	I-Chemical	-1	978847
(0.@@	O	-1	978847
3	O	-1	978847
mg@@	O	-1	978847
),	O	-1	978847
while	O	-1	978847
prop@@	B-Chemical	D011433	978847
ran@@	I-Chemical	-1	978847
o@@	I-Chemical	-1	978847
lol	I-Chemical	-1	978847
(0.@@	O	-1	978847
5	O	-1	978847
mg@@	O	-1	978847
)	O	-1	978847
i.v@@	O	-1	978847
.	O	-1	978847
sel@@	O	-1	978847
ectively	O	-1	978847
inhibited	O	-1	978847
the	O	-1	978847
en@@	B-Disease	D006973	978847
larg@@	I-Disease	-1	978847
ement	I-Disease	-1	978847
of	I-Disease	-1	978847
pul@@	I-Disease	-1	978847
se	I-Disease	-1	978847
pressure	I-Disease	-1	978847
and	O	-1	978847
the	O	-1	978847
tachycardia	B-Disease	D013610	978847
following	O	-1	978847
i.@@	O	-1	978847
c@@	O	-1	978847
.	O	-1	978847
carb@@	B-Chemical	D002217	978847
ac@@	I-Chemical	-1	978847
hol	I-Chemical	-1	978847
(@@	O	-1	978847
1	O	-1	978847
m@@	O	-1	978847
u@@	O	-1	978847
g@@	O	-1	978847
).	O	-1	978847
O@@	O	-1	978847
n	O	-1	978847
the	O	-1	978847
other	O	-1	978847
h@@	O	-1	978847
and@@	O	-1	978847
,	O	-1	978847
the	O	-1	978847
press@@	O	-1	978847
or	O	-1	978847
response	O	-1	978847
to	O	-1	978847
i.@@	O	-1	978847
c@@	O	-1	978847
.	O	-1	978847
carb@@	B-Chemical	D002217	978847
ac@@	I-Chemical	-1	978847
hol	I-Chemical	-1	978847
(@@	O	-1	978847
1	O	-1	978847
m@@	O	-1	978847
u@@	O	-1	978847
g@@	O	-1	978847
)	O	-1	978847
was	O	-1	978847
al@@	O	-1	978847
most	O	-1	978847
complete@@	O	-1	978847
ly	O	-1	978847
block@@	O	-1	978847
ed	O	-1	978847
by	O	-1	978847
i.@@	O	-1	978847
c@@	O	-1	978847
.	O	-1	978847
atro@@	B-Chemical	D001285	978847
pine	I-Chemical	-1	978847
(@@	O	-1	978847
3	O	-1	978847
m@@	O	-1	978847
u@@	O	-1	978847
g@@	O	-1	978847
)	O	-1	978847
or	O	-1	978847
he@@	B-Chemical	D018738	978847
xameth@@	I-Chemical	-1	978847
oni@@	I-Chemical	-1	978847
um	I-Chemical	-1	978847
(5@@	O	-1	978847
00	O	-1	978847
m@@	O	-1	978847
u@@	O	-1	978847
g@@	O	-1	978847
),	O	-1	978847
and	O	-1	978847
significantly	O	-1	978847
reduced	O	-1	978847
by	O	-1	978847
i.@@	O	-1	978847
c@@	O	-1	978847
.	O	-1	978847
chlor@@	B-Chemical	D002746	978847
pro@@	I-Chemical	-1	978847
ma@@	I-Chemical	-1	978847
z@@	I-Chemical	-1	978847
ine	I-Chemical	-1	978847
(@@	O	-1	978847
50	O	-1	978847
m@@	O	-1	978847
u@@	O	-1	978847
g@@	O	-1	978847
)	O	-1	978847
but	O	-1	978847
significantly	O	-1	978847
potenti@@	O	-1	978847
ated	O	-1	978847
by	O	-1	978847
i.@@	O	-1	978847
c@@	O	-1	978847
.	O	-1	978847
des@@	B-Chemical	D003891	978847
methyl@@	I-Chemical	-1	978847
im@@	I-Chemical	-1	978847
ip@@	I-Chemical	-1	978847
r@@	I-Chemical	-1	978847
amine	I-Chemical	-1	978847
(@@	O	-1	978847
30	O	-1	978847
m@@	O	-1	978847
u@@	O	-1	978847
g@@	O	-1	978847
).	O	-1	978847
The	O	-1	978847
press@@	O	-1	978847
or	O	-1	978847
response	O	-1	978847
to	O	-1	978847
i.@@	O	-1	978847
c@@	O	-1	978847
.	O	-1	978847
carb@@	B-Chemical	D002217	978847
ac@@	I-Chemical	-1	978847
hol	I-Chemical	-1	978847
(@@	O	-1	978847
1	O	-1	978847
m@@	O	-1	978847
u@@	O	-1	978847
g@@	O	-1	978847
)	O	-1	978847
remained	O	-1	978847
un@@	O	-1	978847
chang@@	O	-1	978847
ed	O	-1	978847
after	O	-1	978847
sec@@	O	-1	978847
tion@@	O	-1	978847
ing	O	-1	978847
of	O	-1	978847
the	O	-1	978847
bil@@	O	-1	978847
ateral	O	-1	978847
cer@@	O	-1	978847
v@@	O	-1	978847
ical	O	-1	978847
v@@	O	-1	978847
ag@@	O	-1	978847
al	O	-1	978847
ner@@	O	-1	978847
v@@	O	-1	978847
es	O	-1	978847
but	O	-1	978847
dis@@	O	-1	978847
appe@@	O	-1	978847
a@@	O	-1	978847
red	O	-1	978847
after	O	-1	978847
sec@@	O	-1	978847
tion@@	O	-1	978847
ing	O	-1	978847
of	O	-1	978847
the	O	-1	978847
spinal	O	-1	978847
cor@@	O	-1	978847
d	O	-1	978847
(C@@	O	-1	978847
7-@@	O	-1	978847
C@@	O	-1	978847
8@@	O	-1	978847
).	O	-1	978847
F@@	O	-1	978847
rom	O	-1	978847
the	O	-1	978847
ab@@	O	-1	978847
o@@	O	-1	978847
ve	O	-1	978847
result	O	-1	978847
it	O	-1	978847
is	O	-1	978847
suggested	O	-1	978847
that	O	-1	978847
the	O	-1	978847
press@@	O	-1	978847
or	O	-1	978847
response	O	-1	978847
to	O	-1	978847
i.@@	O	-1	978847
c@@	O	-1	978847
.	O	-1	978847
carb@@	B-Chemical	D002217	978847
ac@@	I-Chemical	-1	978847
hol	I-Chemical	-1	978847
ort@@	O	-1	978847
ral	O	-1	978847
and	O	-1	978847
peripheral	O	-1	978847
adrenergic	O	-1	978847
mechanis@@	O	-1	978847
m@@	O	-1	978847
s,	O	-1	978847
and	O	-1	978847
that	O	-1	978847
the	O	-1	978847
sym@@	O	-1	978847
pa@@	O	-1	978847
thetic	O	-1	978847
tr@@	O	-1	978847
un@@	O	-1	978847
k	O	-1	978847
is	O	-1	978847
the	O	-1	978847
ma@@	O	-1	978847
in	O	-1	978847
path@@	O	-1	978847
w@@	O	-1	978847
a@@	O	-1	978847
y.	O	-1	978847

H@@	B-Disease	D006943	1117341
y@@	I-Disease	-1	1117341
per@@	I-Disease	-1	1117341
gly@@	I-Disease	-1	1117341
ce@@	I-Disease	-1	1117341
mic	I-Disease	-1	1117341
effect	O	-1	1117341
of	O	-1	1117341
amin@@	B-Chemical	D015119	1117341
o	I-Chemical	-1	1117341
comp@@	O	-1	1117341
oun@@	O	-1	1117341
ds	O	-1	1117341
struct@@	O	-1	1117341
ur@@	O	-1	1117341
ally	O	-1	1117341
related	O	-1	1117341
to	O	-1	1117341
ca@@	B-Chemical	C037652	1117341
pro@@	I-Chemical	-1	1117341
ate	I-Chemical	-1	1117341
in	O	-1	1117341
rats.	O	-1	1117341
The	O	-1	1117341
chronic	O	-1	1117341
fe@@	O	-1	1117341
ed@@	O	-1	1117341
ing	O	-1	1117341
of	O	-1	1117341
sm@@	O	-1	1117341
all	O	-1	1117341
amoun@@	O	-1	1117341
ts	O	-1	1117341
(0.@@	O	-1	1117341
3-@@	O	-1	1117341
3@@	O	-1	1117341
%	O	-1	1117341
of	O	-1	1117341
diet	O	-1	1117341
weigh@@	O	-1	1117341
t@@	O	-1	1117341
)	O	-1	1117341
of	O	-1	1117341
cer@@	O	-1	1117341
t@@	O	-1	1117341
ain	O	-1	1117341
amin@@	B-Chemical	D015119	1117341
o	I-Chemical	-1	1117341
der@@	O	-1	1117341
i@@	O	-1	1117341
v@@	O	-1	1117341
ati@@	O	-1	1117341
v@@	O	-1	1117341
es	O	-1	1117341
of	O	-1	1117341
ca@@	B-Chemical	C037652	1117341
pro@@	I-Chemical	-1	1117341
ate	I-Chemical	-1	1117341
resulted	O	-1	1117341
in	O	-1	1117341
hyper@@	B-Disease	D006943	1117341
gly@@	I-Disease	-1	1117341
ce@@	I-Disease	-1	1117341
mia	I-Disease	-1	1117341
,	O	-1	1117341
an	O	-1	1117341
elevated	O	-1	1117341
g@@	B-Chemical	D005947	1117341
lu@@	I-Chemical	-1	1117341
co@@	I-Chemical	-1	1117341
se	I-Chemical	-1	1117341
toler@@	O	-1	1117341
ance	O	-1	1117341
cur@@	O	-1	1117341
ve	O	-1	1117341
and@@	O	-1	1117341
,	O	-1	1117341
oc@@	O	-1	1117341
ca@@	O	-1	1117341
sion@@	O	-1	1117341
ally,	O	-1	1117341
g@@	B-Disease	D006030	1117341
lu@@	I-Disease	-1	1117341
co@@	I-Disease	-1	1117341
sur@@	I-Disease	-1	1117341
ia	I-Disease	-1	1117341
.	O	-1	1117341
Eff@@	O	-1	1117341
ective	O	-1	1117341
comp@@	O	-1	1117341
oun@@	O	-1	1117341
ds	O	-1	1117341
included	O	-1	1117341
nor@@	B-Chemical	-1	1117341
le@@	I-Chemical	-1	1117341
uc@@	I-Chemical	-1	1117341
ine	I-Chemical	-1	1117341
,	O	-1	1117341
nor@@	B-Chemical	-1	1117341
val@@	I-Chemical	-1	1117341
ine	I-Chemical	-1	1117341
,	O	-1	1117341
glutamate	B-Chemical	D018698	1117341
,	O	-1	1117341
ep@@	B-Chemical	-1	1117341
si@@	I-Chemical	-1	1117341
lon@@	I-Chemical	-1	1117341
-@@	I-Chemical	-1	1117341
amin@@	I-Chemical	-1	1117341
oc@@	I-Chemical	-1	1117341
a@@	I-Chemical	-1	1117341
pro@@	I-Chemical	-1	1117341
ate	I-Chemical	-1	1117341
,	O	-1	1117341
meth@@	B-Chemical	D008715	1117341
i@@	I-Chemical	-1	1117341
on@@	I-Chemical	-1	1117341
ine	I-Chemical	-1	1117341
,	O	-1	1117341
and	O	-1	1117341
le@@	B-Chemical	-1	1117341
uc@@	I-Chemical	-1	1117341
ine	I-Chemical	-1	1117341
.	O	-1	1117341

F@@	B-Disease	D005234	1158089
at@@	I-Disease	-1	1158089
t@@	I-Disease	-1	1158089
y	I-Disease	-1	1158089
liver	I-Disease	-1	1158089
induced	O	-1	1158089
by	O	-1	1158089
te@@	B-Chemical	D013752	1158089
trac@@	I-Chemical	-1	1158089
y@@	I-Chemical	-1	1158089
cl@@	I-Chemical	-1	1158089
ine	I-Chemical	-1	1158089
in	O	-1	1158089
the	O	-1	1158089
rat@@	O	-1	1158089
.	O	-1	1158089
D@@	O	-1	1158089
o@@	O	-1	1158089
se@@	O	-1	1158089
-@@	O	-1	1158089
response	O	-1	1158089
rel@@	O	-1	1158089
ation@@	O	-1	1158089
shi@@	O	-1	1158089
p@@	O	-1	1158089
s	O	-1	1158089
and	O	-1	1158089
effect	O	-1	1158089
of	O	-1	1158089
sex@@	O	-1	1158089
.	O	-1	1158089
D@@	O	-1	1158089
o@@	O	-1	1158089
se@@	O	-1	1158089
-@@	O	-1	1158089
response	O	-1	1158089
rel@@	O	-1	1158089
ation@@	O	-1	1158089
shi@@	O	-1	1158089
p@@	O	-1	1158089
s,	O	-1	1158089
bio@@	O	-1	1158089
chemical	O	-1	1158089
mechanis@@	O	-1	1158089
m@@	O	-1	1158089
s,	O	-1	1158089
and	O	-1	1158089
se@@	O	-1	1158089
x	O	-1	1158089
differences	O	-1	1158089
in	O	-1	1158089
the	O	-1	1158089
experimental	O	-1	1158089
f@@	B-Disease	D005234	1158089
at@@	I-Disease	-1	1158089
t@@	I-Disease	-1	1158089
y	I-Disease	-1	1158089
liver	I-Disease	-1	1158089
induced	O	-1	1158089
by	O	-1	1158089
te@@	B-Chemical	D013752	1158089
trac@@	I-Chemical	-1	1158089
y@@	I-Chemical	-1	1158089
cl@@	I-Chemical	-1	1158089
ine	I-Chemical	-1	1158089
were	O	-1	1158089
studied	O	-1	1158089
in	O	-1	1158089
the	O	-1	1158089
int@@	O	-1	1158089
ac@@	O	-1	1158089
t	O	-1	1158089
rat	O	-1	1158089
and	O	-1	1158089
with	O	-1	1158089
the	O	-1	1158089
isol@@	O	-1	1158089
ated	O	-1	1158089
per@@	O	-1	1158089
f@@	O	-1	1158089
used	O	-1	1158089
rat	O	-1	1158089
liver	O	-1	1158089
in	O	-1	1158089
vit@@	O	-1	1158089
ro@@	O	-1	1158089
.	O	-1	1158089
In	O	-1	1158089
the	O	-1	1158089
int@@	O	-1	1158089
ac@@	O	-1	1158089
t	O	-1	1158089
male	O	-1	1158089
and	O	-1	1158089
female	O	-1	1158089
rat@@	O	-1	1158089
,	O	-1	1158089
no	O	-1	1158089
direct	O	-1	1158089
rel@@	O	-1	1158089
ationship	O	-1	1158089
was	O	-1	1158089
observed	O	-1	1158089
between	O	-1	1158089
dose	O	-1	1158089
of	O	-1	1158089
te@@	B-Chemical	D013752	1158089
trac@@	I-Chemical	-1	1158089
y@@	I-Chemical	-1	1158089
cl@@	I-Chemical	-1	1158089
ine	I-Chemical	-1	1158089
and	O	-1	1158089
hepatic	O	-1	1158089
accum@@	O	-1	1158089
ulation	O	-1	1158089
of	O	-1	1158089
tri@@	B-Chemical	D014280	1158089
glycer@@	I-Chemical	-1	1158089
ide	I-Chemical	-1	1158089
.	O	-1	1158089
W@@	O	-1	1158089
it@@	O	-1	1158089
h	O	-1	1158089
pro@@	O	-1	1158089
vi@@	O	-1	1158089
sion	O	-1	1158089
of	O	-1	1158089
ade@@	O	-1	1158089
qu@@	O	-1	1158089
ate	O	-1	1158089
ol@@	B-Chemical	D019301	1158089
e@@	I-Chemical	-1	1158089
ic	I-Chemical	-1	1158089
acid	I-Chemical	-1	1158089
as	O	-1	1158089
a	O	-1	1158089
subst@@	O	-1	1158089
rate	O	-1	1158089
for	O	-1	1158089
the	O	-1	1158089
isol@@	O	-1	1158089
ated	O	-1	1158089
per@@	O	-1	1158089
f@@	O	-1	1158089
used	O	-1	1158089
li@@	O	-1	1158089
ver,	O	-1	1158089
a	O	-1	1158089
direct	O	-1	1158089
rel@@	O	-1	1158089
ationship	O	-1	1158089
was	O	-1	1158089
observed	O	-1	1158089
between	O	-1	1158089
dose	O	-1	1158089
of	O	-1	1158089
te@@	B-Chemical	D013752	1158089
trac@@	I-Chemical	-1	1158089
y@@	I-Chemical	-1	1158089
cl@@	I-Chemical	-1	1158089
ine	I-Chemical	-1	1158089
and	O	-1	1158089
both	O	-1	1158089
accum@@	O	-1	1158089
ulation	O	-1	1158089
of	O	-1	1158089
tri@@	B-Chemical	D014280	1158089
glycer@@	I-Chemical	-1	1158089
ide	I-Chemical	-1	1158089
in	O	-1	1158089
the	O	-1	1158089
liver	O	-1	1158089
and	O	-1	1158089
de@@	B-Disease	D003866	1158089
pression	I-Disease	-1	1158089
of	O	-1	1158089
out@@	O	-1	1158089
pu@@	O	-1	1158089
t	O	-1	1158089
of	O	-1	1158089
tri@@	B-Chemical	D014280	1158089
glycer@@	I-Chemical	-1	1158089
ide	I-Chemical	-1	1158089
by	O	-1	1158089
li@@	O	-1	1158089
ver@@	O	-1	1158089
s	O	-1	1158089
from	O	-1	1158089
male	O	-1	1158089
and	O	-1	1158089
female	O	-1	1158089
rats.	O	-1	1158089
M@@	O	-1	1158089
ark@@	O	-1	1158089
ed	O	-1	1158089
differences	O	-1	1158089
were	O	-1	1158089
observed	O	-1	1158089
between	O	-1	1158089
female	O	-1	1158089
and	O	-1	1158089
male	O	-1	1158089
rats	O	-1	1158089
with	O	-1	1158089
reg@@	O	-1	1158089
ard	O	-1	1158089
to	O	-1	1158089
b@@	O	-1	1158089
ase	O	-1	1158089
line	O	-1	1158089
(@@	O	-1	1158089
control@@	O	-1	1158089
)	O	-1	1158089
hepatic	O	-1	1158089
concentration	O	-1	1158089
of	O	-1	1158089
tri@@	B-Chemical	D014280	1158089
glycer@@	I-Chemical	-1	1158089
ide	I-Chemical	-1	1158089
and	O	-1	1158089
out@@	O	-1	1158089
pu@@	O	-1	1158089
t	O	-1	1158089
of	O	-1	1158089
tri@@	B-Chemical	D014280	1158089
glycer@@	I-Chemical	-1	1158089
ide	I-Chemical	-1	1158089
.	O	-1	1158089
Ac@@	O	-1	1158089
cum@@	O	-1	1158089
ulation	O	-1	1158089
of	O	-1	1158089
hepatic	O	-1	1158089
tri@@	B-Chemical	D014280	1158089
glycer@@	I-Chemical	-1	1158089
ide	I-Chemical	-1	1158089
,	O	-1	1158089
as	O	-1	1158089
a	O	-1	1158089
per	O	-1	1158089
c@@	O	-1	1158089
ent	O	-1	1158089
of	O	-1	1158089
control	O	-1	1158089
valu@@	O	-1	1158089
es,	O	-1	1158089
in	O	-1	1158089
response	O	-1	1158089
to	O	-1	1158089
gra@@	O	-1	1158089
ded	O	-1	1158089
doses	O	-1	1158089
of	O	-1	1158089
te@@	B-Chemical	D013752	1158089
trac@@	I-Chemical	-1	1158089
y@@	I-Chemical	-1	1158089
cl@@	I-Chemical	-1	1158089
ine	I-Chemical	-1	1158089
,	O	-1	1158089
did	O	-1	1158089
not	O	-1	1158089
diff@@	O	-1	1158089
er	O	-1	1158089
significantly	O	-1	1158089
between	O	-1	1158089
mal@@	O	-1	1158089
e,	O	-1	1158089
female	O	-1	1158089
and	O	-1	1158089
pregn@@	O	-1	1158089
ant	O	-1	1158089
rat	O	-1	1158089
li@@	O	-1	1158089
ver@@	O	-1	1158089
s.	O	-1	1158089
However,	O	-1	1158089
li@@	O	-1	1158089
ver@@	O	-1	1158089
s	O	-1	1158089
from	O	-1	1158089
femal@@	O	-1	1158089
e,	O	-1	1158089
and	O	-1	1158089
es@@	O	-1	1158089
p@@	O	-1	1158089
ec@@	O	-1	1158089
i@@	O	-1	1158089
ally	O	-1	1158089
pregn@@	O	-1	1158089
ant	O	-1	1158089
female	O	-1	1158089
rats,	O	-1	1158089
were	O	-1	1158089
stri@@	O	-1	1158089
k@@	O	-1	1158089
ing@@	O	-1	1158089
ly	O	-1	1158089
resist@@	O	-1	1158089
ant	O	-1	1158089
to	O	-1	1158089
the	O	-1	1158089
effects	O	-1	1158089
of	O	-1	1158089
te@@	B-Chemical	D013752	1158089
trac@@	I-Chemical	-1	1158089
y@@	I-Chemical	-1	1158089
cl@@	I-Chemical	-1	1158089
ine	I-Chemical	-1	1158089
on	O	-1	1158089
de@@	B-Disease	D003866	1158089
pression	I-Disease	-1	1158089
of	O	-1	1158089
out@@	O	-1	1158089
pu@@	O	-1	1158089
t	O	-1	1158089
of	O	-1	1158089
tri@@	B-Chemical	D014280	1158089
glycer@@	I-Chemical	-1	1158089
ide	I-Chemical	-1	1158089
under	O	-1	1158089
these	O	-1	1158089
experimental	O	-1	1158089
condi@@	O	-1	1158089
tions.	O	-1	1158089
These	O	-1	1158089
differences	O	-1	1158089
between	O	-1	1158089
the	O	-1	1158089
sex@@	O	-1	1158089
es	O	-1	1158089
could	O	-1	1158089
not	O	-1	1158089
be	O	-1	1158089
related	O	-1	1158089
to	O	-1	1158089
al@@	O	-1	1158089
te@@	O	-1	1158089
red	O	-1	1158089
dis@@	O	-1	1158089
posi@@	O	-1	1158089
tion	O	-1	1158089
of	O	-1	1158089
te@@	B-Chemical	D013752	1158089
trac@@	I-Chemical	-1	1158089
y@@	I-Chemical	-1	1158089
cl@@	I-Chemical	-1	1158089
ine	I-Chemical	-1	1158089
or	O	-1	1158089
al@@	O	-1	1158089
te@@	O	-1	1158089
red	O	-1	1158089
u@@	O	-1	1158089
pt@@	O	-1	1158089
ake	O	-1	1158089
of	O	-1	1158089
ol@@	B-Chemical	D019301	1158089
e@@	I-Chemical	-1	1158089
ic	I-Chemical	-1	1158089
acid	I-Chemical	-1	1158089
.	O	-1	1158089
De@@	O	-1	1158089
press@@	O	-1	1158089
ed	O	-1	1158089
hepatic	O	-1	1158089
secre@@	O	-1	1158089
tion	O	-1	1158089
of	O	-1	1158089
tri@@	B-Chemical	D014280	1158089
glycer@@	I-Chemical	-1	1158089
ide	I-Chemical	-1	1158089
ac@@	O	-1	1158089
coun@@	O	-1	1158089
ted	O	-1	1158089
only	O	-1	1158089
for	O	-1	1158089
30	O	-1	1158089
to	O	-1	1158089
50@@	O	-1	1158089
%	O	-1	1158089
of	O	-1	1158089
accum@@	O	-1	1158089
ul@@	O	-1	1158089
ated	O	-1	1158089
hepatic	O	-1	1158089
tri@@	B-Chemical	D014280	1158089
glycer@@	I-Chemical	-1	1158089
ide	I-Chemical	-1	1158089
,	O	-1	1158089
indicating	O	-1	1158089
that	O	-1	1158089
addi@@	O	-1	1158089
tional	O	-1	1158089
mechanisms	O	-1	1158089
mus@@	O	-1	1158089
t	O	-1	1158089
be	O	-1	1158089
involved	O	-1	1158089
in	O	-1	1158089
the	O	-1	1158089
pro@@	O	-1	1158089
duction	O	-1	1158089
of	O	-1	1158089
the	O	-1	1158089
tri@@	B-Chemical	D014280	1158089
glycer@@	I-Chemical	-1	1158089
ide	I-Chemical	-1	1158089
-@@	O	-1	1158089
r@@	O	-1	1158089
ich	O	-1	1158089
f@@	B-Disease	D005234	1158089
at@@	I-Disease	-1	1158089
t@@	I-Disease	-1	1158089
y	I-Disease	-1	1158089
liver	I-Disease	-1	1158089
in	O	-1	1158089
response	O	-1	1158089
to	O	-1	1158089
te@@	B-Chemical	D013752	1158089
trac@@	I-Chemical	-1	1158089
y@@	I-Chemical	-1	1158089
cl@@	I-Chemical	-1	1158089
ine	I-Chemical	-1	1158089
.	O	-1	1158089

F@@	O	-1	1280054
atal	O	-1	1280054
my@@	B-Disease	D001927	1280054
e@@	I-Disease	-1	1280054
lo@@	I-Disease	-1	1280054
encephalo@@	I-Disease	-1	1280054
pathy	I-Disease	-1	1280054
due	O	-1	1280054
to	O	-1	1280054
intra@@	O	-1	1280054
th@@	O	-1	1280054
ec@@	O	-1	1280054
al	O	-1	1280054
v@@	B-Chemical	D014750	1280054
inc@@	I-Chemical	-1	1280054
ri@@	I-Chemical	-1	1280054
st@@	I-Chemical	-1	1280054
ine	I-Chemical	-1	1280054
administr@@	O	-1	1280054
ation.	O	-1	1280054
V@@	B-Chemical	D014750	1280054
inc@@	I-Chemical	-1	1280054
ri@@	I-Chemical	-1	1280054
st@@	I-Chemical	-1	1280054
ine	I-Chemical	-1	1280054
was	O	-1	1280054
ac@@	O	-1	1280054
c@@	O	-1	1280054
id@@	O	-1	1280054
ent@@	O	-1	1280054
ally	O	-1	1280054
given	O	-1	1280054
intra@@	O	-1	1280054
th@@	O	-1	1280054
ec@@	O	-1	1280054
ally	O	-1	1280054
to	O	-1	1280054
a	O	-1	1280054
ch@@	O	-1	1280054
il@@	O	-1	1280054
d	O	-1	1280054
with	O	-1	1280054
leuk@@	B-Disease	D007938	1280054
a@@	I-Disease	-1	1280054
emia	I-Disease	-1	1280054
,	O	-1	1280054
produc@@	O	-1	1280054
ing	O	-1	1280054
sens@@	B-Disease	D007049	1280054
ory	I-Disease	-1	1280054
and	I-Disease	-1	1280054
motor	I-Disease	-1	1280054
dysfunction	I-Disease	-1	1280054
followed	O	-1	1280054
by	O	-1	1280054
encephalo@@	B-Disease	D001927	1280054
pathy	I-Disease	-1	1280054
and	O	-1	1280054
de@@	O	-1	1280054
ath@@	O	-1	1280054
.	O	-1	1280054
S@@	O	-1	1280054
e@@	O	-1	1280054
par@@	O	-1	1280054
ate	O	-1	1280054
times	O	-1	1280054
for	O	-1	1280054
administ@@	O	-1	1280054
ering	O	-1	1280054
v@@	B-Chemical	D014750	1280054
inc@@	I-Chemical	-1	1280054
ri@@	I-Chemical	-1	1280054
st@@	I-Chemical	-1	1280054
ine	I-Chemical	-1	1280054
and	O	-1	1280054
intra@@	O	-1	1280054
th@@	O	-1	1280054
ec@@	O	-1	1280054
al	O	-1	1280054
therapy	O	-1	1280054
is	O	-1	1280054
recomm@@	O	-1	1280054
en@@	O	-1	1280054
de@@	O	-1	1280054
d.	O	-1	1280054

Pro@@	B-Chemical	D011374	1280707
g@@	I-Chemical	-1	1280707
est@@	I-Chemical	-1	1280707
er@@	I-Chemical	-1	1280707
one	I-Chemical	-1	1280707
potenti@@	O	-1	1280707
ation	O	-1	1280707
of	O	-1	1280707
bupivac@@	B-Chemical	D002045	1280707
aine	I-Chemical	-1	1280707
arrhyth@@	O	-1	1280707
mo@@	O	-1	1280707
gen@@	O	-1	1280707
ic@@	O	-1	1280707
ity	O	-1	1280707
in	O	-1	1280707
pent@@	B-Chemical	D010424	1280707
obarbit@@	I-Chemical	-1	1280707
al	I-Chemical	-1	1280707
-@@	O	-1	1280707
anesthe@@	O	-1	1280707
tiz@@	O	-1	1280707
ed	O	-1	1280707
rats	O	-1	1280707
and	O	-1	1280707
be@@	O	-1	1280707
ating	O	-1	1280707
rat	O	-1	1280707
heart	O	-1	1280707
cell	O	-1	1280707
c@@	O	-1	1280707
ult@@	O	-1	1280707
ures@@	O	-1	1280707
.	O	-1	1280707
The	O	-1	1280707
effects	O	-1	1280707
of	O	-1	1280707
pro@@	B-Chemical	D011374	1280707
g@@	I-Chemical	-1	1280707
est@@	I-Chemical	-1	1280707
er@@	I-Chemical	-1	1280707
one	I-Chemical	-1	1280707
treatment	O	-1	1280707
on	O	-1	1280707
bupivac@@	B-Chemical	D002045	1280707
aine	I-Chemical	-1	1280707
arrhyth@@	O	-1	1280707
mo@@	O	-1	1280707
gen@@	O	-1	1280707
ic@@	O	-1	1280707
ity	O	-1	1280707
in	O	-1	1280707
be@@	O	-1	1280707
ating	O	-1	1280707
rat	O	-1	1280707
heart	O	-1	1280707
my@@	O	-1	1280707
ocyte	O	-1	1280707
c@@	O	-1	1280707
ult@@	O	-1	1280707
ures	O	-1	1280707
and	O	-1	1280707
on	O	-1	1280707
anesthe@@	O	-1	1280707
tiz@@	O	-1	1280707
ed	O	-1	1280707
rats	O	-1	1280707
were	O	-1	1280707
deter@@	O	-1	1280707
m@@	O	-1	1280707
ine@@	O	-1	1280707
d.	O	-1	1280707
After	O	-1	1280707
determin@@	O	-1	1280707
ing	O	-1	1280707
the	O	-1	1280707
bupivac@@	B-Chemical	D002045	1280707
aine	I-Chemical	-1	1280707
AD@@	O	-1	1280707
50	O	-1	1280707
(@@	O	-1	1280707
the	O	-1	1280707
concentration	O	-1	1280707
of	O	-1	1280707
bupivac@@	B-Chemical	D002045	1280707
aine	I-Chemical	-1	1280707
that	O	-1	1280707
caused	O	-1	1280707
50@@	O	-1	1280707
%	O	-1	1280707
of	O	-1	1280707
all	O	-1	1280707
be@@	O	-1	1280707
ating	O	-1	1280707
rat	O	-1	1280707
heart	O	-1	1280707
my@@	O	-1	1280707
ocyte	O	-1	1280707
c@@	O	-1	1280707
ult@@	O	-1	1280707
ures	O	-1	1280707
to	O	-1	1280707
b@@	O	-1	1280707
ec@@	O	-1	1280707
ome	O	-1	1280707
arrhyth@@	B-Disease	D001145	1280707
mic	I-Disease	-1	1280707
),	O	-1	1280707
we	O	-1	1280707
determined	O	-1	1280707
the	O	-1	1280707
effect	O	-1	1280707
of	O	-1	1280707
1-@@	O	-1	1280707
h@@	O	-1	1280707
our	O	-1	1280707
pro@@	B-Chemical	D011374	1280707
g@@	I-Chemical	-1	1280707
est@@	I-Chemical	-1	1280707
er@@	I-Chemical	-1	1280707
one	I-Chemical	-1	1280707
HC@@	B-Chemical	D006851	1280707
l	I-Chemical	-1	1280707
exposure	O	-1	1280707
on	O	-1	1280707
my@@	O	-1	1280707
ocyte	O	-1	1280707
contrac@@	O	-1	1280707
ti@@	O	-1	1280707
le	O	-1	1280707
rhyth@@	O	-1	1280707
m.	O	-1	1280707
E@@	O	-1	1280707
ach	O	-1	1280707
concentration	O	-1	1280707
of	O	-1	1280707
pro@@	B-Chemical	D011374	1280707
g@@	I-Chemical	-1	1280707
est@@	I-Chemical	-1	1280707
er@@	I-Chemical	-1	1280707
one	I-Chemical	-1	1280707
(@@	O	-1	1280707
6.@@	O	-1	1280707
2@@	O	-1	1280707
5,	O	-1	1280707
1@@	O	-1	1280707
2.@@	O	-1	1280707
5,	O	-1	1280707
2@@	O	-1	1280707
5,	O	-1	1280707
and	O	-1	1280707
50	O	-1	1280707
microgram@@	O	-1	1280707
s/@@	O	-1	1280707
ml@@	O	-1	1280707
)	O	-1	1280707
caused	O	-1	1280707
a	O	-1	1280707
significant	O	-1	1280707
and	O	-1	1280707
concentr@@	O	-1	1280707
ation@@	O	-1	1280707
-@@	O	-1	1280707
dependent	O	-1	1280707
reduction	O	-1	1280707
in	O	-1	1280707
the	O	-1	1280707
AD@@	O	-1	1280707
50	O	-1	1280707
for	O	-1	1280707
bupivac@@	B-Chemical	D002045	1280707
aine	I-Chemical	-1	1280707
.	O	-1	1280707
E@@	B-Chemical	D004958	1280707
st@@	I-Chemical	-1	1280707
radi@@	I-Chemical	-1	1280707
ol	I-Chemical	-1	1280707
treatment	O	-1	1280707
also	O	-1	1280707
increased	O	-1	1280707
the	O	-1	1280707
arrhyth@@	O	-1	1280707
mo@@	O	-1	1280707
gen@@	O	-1	1280707
ic@@	O	-1	1280707
ity	O	-1	1280707
of	O	-1	1280707
bupivac@@	B-Chemical	D002045	1280707
aine	I-Chemical	-1	1280707
in	O	-1	1280707
my@@	O	-1	1280707
ocyte	O	-1	1280707
c@@	O	-1	1280707
ult@@	O	-1	1280707
ures@@	O	-1	1280707
,	O	-1	1280707
but	O	-1	1280707
was	O	-1	1280707
only	O	-1	1280707
one	O	-1	1280707
fo@@	O	-1	1280707
ur@@	O	-1	1280707
th	O	-1	1280707
as	O	-1	1280707
pot@@	O	-1	1280707
ent	O	-1	1280707
as	O	-1	1280707
pro@@	B-Chemical	D011374	1280707
g@@	I-Chemical	-1	1280707
est@@	I-Chemical	-1	1280707
er@@	I-Chemical	-1	1280707
one	I-Chemical	-1	1280707
.	O	-1	1280707
N@@	O	-1	1280707
either	O	-1	1280707
pro@@	B-Chemical	D011374	1280707
g@@	I-Chemical	-1	1280707
est@@	I-Chemical	-1	1280707
er@@	I-Chemical	-1	1280707
one	I-Chemical	-1	1280707
n@@	O	-1	1280707
or	O	-1	1280707
est@@	B-Chemical	D004958	1280707
radi@@	I-Chemical	-1	1280707
ol	I-Chemical	-1	1280707
effects	O	-1	1280707
on	O	-1	1280707
bupivac@@	B-Chemical	D002045	1280707
aine	I-Chemical	-1	1280707
arrhyth@@	O	-1	1280707
mo@@	O	-1	1280707
gen@@	O	-1	1280707
ic@@	O	-1	1280707
ity	O	-1	1280707
were	O	-1	1280707
potenti@@	O	-1	1280707
ated	O	-1	1280707
by	O	-1	1280707
ep@@	B-Chemical	D004837	1280707
ine@@	I-Chemical	-1	1280707
phrine	I-Chemical	-1	1280707
.	O	-1	1280707
Ch@@	O	-1	1280707
ron@@	O	-1	1280707
ic	O	-1	1280707
pro@@	B-Chemical	D011374	1280707
g@@	I-Chemical	-1	1280707
est@@	I-Chemical	-1	1280707
er@@	I-Chemical	-1	1280707
one	I-Chemical	-1	1280707
pretreatment	O	-1	1280707
(@@	O	-1	1280707
5	O	-1	1280707
mg/k@@	O	-1	1280707
g/@@	O	-1	1280707
day	O	-1	1280707
for	O	-1	1280707
21	O	-1	1280707
da@@	O	-1	1280707
ys@@	O	-1	1280707
)	O	-1	1280707
caused	O	-1	1280707
a	O	-1	1280707
significant	O	-1	1280707
increase	O	-1	1280707
in	O	-1	1280707
bupivac@@	B-Chemical	D002045	1280707
aine	I-Chemical	-1	1280707
arrhyth@@	O	-1	1280707
mo@@	O	-1	1280707
gen@@	O	-1	1280707
ic@@	O	-1	1280707
ity	O	-1	1280707
in	O	-1	1280707
int@@	O	-1	1280707
ac@@	O	-1	1280707
t	O	-1	1280707
pent@@	B-Chemical	D010424	1280707
obarbit@@	I-Chemical	-1	1280707
al	I-Chemical	-1	1280707
-@@	O	-1	1280707
anesthe@@	O	-1	1280707
tiz@@	O	-1	1280707
ed	O	-1	1280707
rats.	O	-1	1280707
There	O	-1	1280707
was	O	-1	1280707
a	O	-1	1280707
significant	O	-1	1280707
decrease	O	-1	1280707
in	O	-1	1280707
the	O	-1	1280707
time	O	-1	1280707
to	O	-1	1280707
onset	O	-1	1280707
of	O	-1	1280707
arrhyth@@	B-Disease	D001145	1280707
mia	I-Disease	-1	1280707
as	O	-1	1280707
compared	O	-1	1280707
with	O	-1	1280707
control	O	-1	1280707
non@@	O	-1	1280707
pro@@	O	-1	1280707
g@@	O	-1	1280707
est@@	O	-1	1280707
er@@	O	-1	1280707
on@@	O	-1	1280707
e-@@	O	-1	1280707
treated	O	-1	1280707
rats	O	-1	1280707
(@@	O	-1	1280707
6.@@	O	-1	1280707
2	O	-1	1280707
+/-	O	-1	1280707
1.@@	O	-1	1280707
3	O	-1	1280707
vs.	O	-1	1280707
3@@	O	-1	1280707
0.@@	O	-1	1280707
8	O	-1	1280707
+/-	O	-1	1280707
2.@@	O	-1	1280707
5	O	-1	1280707
min@@	O	-1	1280707
,	O	-1	1280707
mean	O	-1	1280707
+/-	O	-1	1280707
S@@	O	-1	1280707
E@@	O	-1	1280707
).	O	-1	1280707
The	O	-1	1280707
results	O	-1	1280707
of	O	-1	1280707
this	O	-1	1280707
study	O	-1	1280707
indicate	O	-1	1280707
that	O	-1	1280707
pro@@	B-Chemical	D011374	1280707
g@@	I-Chemical	-1	1280707
est@@	I-Chemical	-1	1280707
er@@	I-Chemical	-1	1280707
one	I-Chemical	-1	1280707
can	O	-1	1280707
potenti@@	O	-1	1280707
ate	O	-1	1280707
bupivac@@	B-Chemical	D002045	1280707
aine	I-Chemical	-1	1280707
arrhyth@@	O	-1	1280707
mo@@	O	-1	1280707
gen@@	O	-1	1280707
ic@@	O	-1	1280707
ity	O	-1	1280707
both	O	-1	1280707
in	O	-1	1280707
viv@@	O	-1	1280707
o	O	-1	1280707
and	O	-1	1280707
in	O	-1	1280707
vit@@	O	-1	1280707
ro@@	O	-1	1280707
.	O	-1	1280707
P@@	O	-1	1280707
oten@@	O	-1	1280707
ti@@	O	-1	1280707
ation	O	-1	1280707
of	O	-1	1280707
bupivac@@	B-Chemical	D002045	1280707
aine	I-Chemical	-1	1280707
arrhyth@@	B-Disease	D001145	1280707
mia	I-Disease	-1	1280707
in	O	-1	1280707
my@@	O	-1	1280707
ocyte	O	-1	1280707
c@@	O	-1	1280707
ult@@	O	-1	1280707
ures	O	-1	1280707
suggests	O	-1	1280707
that	O	-1	1280707
this	O	-1	1280707
effect	O	-1	1280707
is	O	-1	1280707
at	O	-1	1280707
le@@	O	-1	1280707
ast	O	-1	1280707
part@@	O	-1	1280707
ly	O	-1	1280707
mediated	O	-1	1280707
at	O	-1	1280707
the	O	-1	1280707
my@@	O	-1	1280707
ocyte	O	-1	1280707
level@@	O	-1	1280707
.	O	-1	1280707

Ac@@	B-Disease	D058186	1289188
ute	I-Disease	-1	1289188
renal	I-Disease	-1	1289188
failure	I-Disease	-1	1289188
occur@@	O	-1	1289188
r@@	O	-1	1289188
ing	O	-1	1289188
during	O	-1	1289188
intravenous	O	-1	1289188
des@@	B-Chemical	D003676	1289188
fer@@	I-Chemical	-1	1289188
ri@@	I-Chemical	-1	1289188
ox@@	I-Chemical	-1	1289188
amine	I-Chemical	-1	1289188
therap@@	O	-1	1289188
y@@	O	-1	1289188
:	O	-1	1289188
recovery	O	-1	1289188
after	O	-1	1289188
haem@@	O	-1	1289188
odi@@	O	-1	1289188
aly@@	O	-1	1289188
sis.	O	-1	1289188
A	O	-1	1289188
patient	O	-1	1289188
with	O	-1	1289188
trans@@	O	-1	1289188
fu@@	O	-1	1289188
sion@@	O	-1	1289188
-@@	O	-1	1289188
dependent	O	-1	1289188
thal@@	B-Disease	D013789	1289188
as@@	I-Disease	-1	1289188
se@@	I-Disease	-1	1289188
mia	I-Disease	-1	1289188
was	O	-1	1289188
under@@	O	-1	1289188
go@@	O	-1	1289188
ing	O	-1	1289188
ho@@	O	-1	1289188
m@@	O	-1	1289188
e	O	-1	1289188
intravenous	O	-1	1289188
des@@	B-Chemical	D003676	1289188
fer@@	I-Chemical	-1	1289188
ri@@	I-Chemical	-1	1289188
ox@@	I-Chemical	-1	1289188
amine	I-Chemical	-1	1289188
(	O	-1	1289188
DF@@	B-Chemical	D003676	1289188
X	I-Chemical	-1	1289188
)	O	-1	1289188
treatment	O	-1	1289188
by	O	-1	1289188
me@@	O	-1	1289188
ans	O	-1	1289188
of	O	-1	1289188
a	O	-1	1289188
tot@@	O	-1	1289188
ally	O	-1	1289188
im@@	O	-1	1289188
pl@@	O	-1	1289188
ant@@	O	-1	1289188
ed	O	-1	1289188
system	O	-1	1289188
because	O	-1	1289188
of	O	-1	1289188
h@@	O	-1	1289188
is	O	-1	1289188
po@@	O	-1	1289188
or	O	-1	1289188
com@@	O	-1	1289188
pl@@	O	-1	1289188
i@@	O	-1	1289188
ance	O	-1	1289188
with	O	-1	1289188
the	O	-1	1289188
n@@	O	-1	1289188
igh@@	O	-1	1289188
tly	O	-1	1289188
sub@@	O	-1	1289188
c@@	O	-1	1289188
utaneous	O	-1	1289188
therapy.	O	-1	1289188
D@@	O	-1	1289188
u@@	O	-1	1289188
e	O	-1	1289188
to	O	-1	1289188
an	O	-1	1289188
ac@@	O	-1	1289188
c@@	O	-1	1289188
id@@	O	-1	1289188
ental	O	-1	1289188
mal@@	O	-1	1289188
func@@	O	-1	1289188
tion@@	O	-1	1289188
ing	O	-1	1289188
of	O	-1	1289188
the	O	-1	1289188
infusion	O	-1	1289188
p@@	O	-1	1289188
um@@	O	-1	1289188
p@@	O	-1	1289188
,	O	-1	1289188
the	O	-1	1289188
patient	O	-1	1289188
was	O	-1	1289188
in@@	O	-1	1289188
ad@@	O	-1	1289188
ver@@	O	-1	1289188
t@@	O	-1	1289188
ently	O	-1	1289188
administered	O	-1	1289188
a	O	-1	1289188
toxic	O	-1	1289188
dos@@	O	-1	1289188
age	O	-1	1289188
of	O	-1	1289188
the	O	-1	1289188
drug	O	-1	1289188
which	O	-1	1289188
caused	O	-1	1289188
renal	B-Disease	D051437	1289188
in@@	I-Disease	-1	1289188
suffici@@	I-Disease	-1	1289188
ency	I-Disease	-1	1289188
.	O	-1	1289188
G@@	O	-1	1289188
i@@	O	-1	1289188
ven	O	-1	1289188
the	O	-1	1289188
progressive	O	-1	1289188
deter@@	O	-1	1289188
i@@	O	-1	1289188
or@@	O	-1	1289188
ation	O	-1	1289188
of	O	-1	1289188
the	O	-1	1289188
symptoms	O	-1	1289188
and	O	-1	1289188
of	O	-1	1289188
the	O	-1	1289188
labor@@	O	-1	1289188
atory	O	-1	1289188
valu@@	O	-1	1289188
es,	O	-1	1289188
des@@	O	-1	1289188
pit@@	O	-1	1289188
e	O	-1	1289188
ade@@	O	-1	1289188
qu@@	O	-1	1289188
ate	O	-1	1289188
med@@	O	-1	1289188
ical	O	-1	1289188
treatment,	O	-1	1289188
a	O	-1	1289188
dec@@	O	-1	1289188
i@@	O	-1	1289188
sion	O	-1	1289188
was	O	-1	1289188
m@@	O	-1	1289188
ade	O	-1	1289188
to	O	-1	1289188
int@@	O	-1	1289188
ro@@	O	-1	1289188
duce	O	-1	1289188
haem@@	O	-1	1289188
odi@@	O	-1	1289188
aly@@	O	-1	1289188
tical	O	-1	1289188
therapy	O	-1	1289188
in	O	-1	1289188
or@@	O	-1	1289188
der	O	-1	1289188
to	O	-1	1289188
re@@	O	-1	1289188
mo@@	O	-1	1289188
ve	O	-1	1289188
the	O	-1	1289188
drug	O	-1	1289188
and	O	-1	1289188
therapy	O	-1	1289188
re@@	O	-1	1289188
duce	O	-1	1289188
the	O	-1	1289188
nephro@@	B-Disease	D007674	1289188
toxicity	I-Disease	-1	1289188
.	O	-1	1289188
F@@	O	-1	1289188
rom	O	-1	1289188
the	O	-1	1289188
results	O	-1	1289188
obt@@	O	-1	1289188
a@@	O	-1	1289188
ine@@	O	-1	1289188
d,	O	-1	1289188
haem@@	O	-1	1289188
odi@@	O	-1	1289188
aly@@	O	-1	1289188
sis	O	-1	1289188
can	O	-1	1289188
the@@	O	-1	1289188
re@@	O	-1	1289188
fore	O	-1	1289188
be	O	-1	1289188
suggested	O	-1	1289188
as	O	-1	1289188
a	O	-1	1289188
use@@	O	-1	1289188
ful	O	-1	1289188
therapy	O	-1	1289188
in	O	-1	1289188
r@@	O	-1	1289188
are	O	-1	1289188
cases	O	-1	1289188
of	O	-1	1289188
progressive	O	-1	1289188
acute	B-Disease	D058186	1289188
renal	I-Disease	-1	1289188
failure	I-Disease	-1	1289188
caused	O	-1	1289188
by	O	-1	1289188
des@@	B-Chemical	D003676	1289188
fer@@	I-Chemical	-1	1289188
ri@@	I-Chemical	-1	1289188
ox@@	I-Chemical	-1	1289188
amine	I-Chemical	-1	1289188
.	O	-1	1289188

Ne@@	B-Chemical	D014150	1359137
uro@@	I-Chemical	-1	1359137
le@@	I-Chemical	-1	1359137
p@@	I-Chemical	-1	1359137
tic	I-Chemical	-1	1359137
-@@	O	-1	1359137
associated	O	-1	1359137
hyper@@	B-Disease	D006966	1359137
prol@@	I-Disease	-1	1359137
act@@	I-Disease	-1	1359137
ine@@	I-Disease	-1	1359137
mia	I-Disease	-1	1359137
.	O	-1	1359137
C@@	O	-1	1359137
an	O	-1	1359137
it	O	-1	1359137
be	O	-1	1359137
treated	O	-1	1359137
with	O	-1	1359137
brom@@	B-Chemical	D001971	1359137
oc@@	I-Chemical	-1	1359137
ript@@	I-Chemical	-1	1359137
ine	I-Chemical	-1	1359137
?	O	-1	1359137
Si@@	O	-1	1359137
x	O	-1	1359137
st@@	O	-1	1359137
able	O	-1	1359137
psych@@	O	-1	1359137
i@@	O	-1	1359137
atric	O	-1	1359137
out@@	O	-1	1359137
patients	O	-1	1359137
with	O	-1	1359137
hyper@@	B-Disease	D006966	1359137
prol@@	I-Disease	-1	1359137
act@@	I-Disease	-1	1359137
ine@@	I-Disease	-1	1359137
mia	I-Disease	-1	1359137
and	O	-1	1359137
am@@	B-Disease	D000568	1359137
en@@	I-Disease	-1	1359137
or@@	I-Disease	-1	1359137
r@@	I-Disease	-1	1359137
he@@	I-Disease	-1	1359137
a	I-Disease	-1	1359137
/	O	-1	1359137
ol@@	B-Disease	D009839	1359137
ig@@	I-Disease	-1	1359137
om@@	I-Disease	-1	1359137
en@@	I-Disease	-1	1359137
or@@	I-Disease	-1	1359137
r@@	I-Disease	-1	1359137
he@@	I-Disease	-1	1359137
a	I-Disease	-1	1359137
associated	O	-1	1359137
with	O	-1	1359137
their	O	-1	1359137
neuro@@	B-Chemical	D014150	1359137
le@@	I-Chemical	-1	1359137
p@@	I-Chemical	-1	1359137
tic	I-Chemical	-1	1359137
medic@@	I-Chemical	-1	1359137
ations	I-Chemical	-1	1359137
were	O	-1	1359137
treated	O	-1	1359137
with	O	-1	1359137
brom@@	B-Chemical	D001971	1359137
oc@@	I-Chemical	-1	1359137
ript@@	I-Chemical	-1	1359137
ine	I-Chemical	-1	1359137
.	O	-1	1359137
D@@	O	-1	1359137
a@@	O	-1	1359137
ily	O	-1	1359137
dos@@	O	-1	1359137
ages	O	-1	1359137
of	O	-1	1359137
5-@@	O	-1	1359137
10	O	-1	1359137
mg	O	-1	1359137
cor@@	O	-1	1359137
rec@@	O	-1	1359137
ted	O	-1	1359137
the	O	-1	1359137
hyper@@	B-Disease	D006966	1359137
prol@@	I-Disease	-1	1359137
act@@	I-Disease	-1	1359137
ine@@	I-Disease	-1	1359137
mia	I-Disease	-1	1359137
and	O	-1	1359137
re@@	O	-1	1359137
sto@@	O	-1	1359137
red	O	-1	1359137
men@@	O	-1	1359137
st@@	O	-1	1359137
ru@@	O	-1	1359137
ation	O	-1	1359137
in	O	-1	1359137
four	O	-1	1359137
of	O	-1	1359137
the	O	-1	1359137
six	O	-1	1359137
patients.	O	-1	1359137
One	O	-1	1359137
wom@@	O	-1	1359137
an@@	O	-1	1359137
,	O	-1	1359137
however,	O	-1	1359137
developed	O	-1	1359137
wor@@	O	-1	1359137
sen@@	O	-1	1359137
ed	O	-1	1359137
psych@@	B-Disease	D011618	1359137
i@@	I-Disease	-1	1359137
atric	I-Disease	-1	1359137
symptoms	I-Disease	-1	1359137
while	O	-1	1359137
taking	O	-1	1359137
brom@@	B-Chemical	D001971	1359137
oc@@	I-Chemical	-1	1359137
ript@@	I-Chemical	-1	1359137
ine	I-Chemical	-1	1359137
,	O	-1	1359137
and	O	-1	1359137
it	O	-1	1359137
was	O	-1	1359137
discontinu@@	O	-1	1359137
ed.	O	-1	1359137
Th@@	O	-1	1359137
us,	O	-1	1359137
three	O	-1	1359137
of	O	-1	1359137
six	O	-1	1359137
patients	O	-1	1359137
had	O	-1	1359137
their	O	-1	1359137
men@@	O	-1	1359137
st@@	O	-1	1359137
ru@@	O	-1	1359137
al	O	-1	1359137
ir@@	O	-1	1359137
reg@@	O	-1	1359137
ul@@	O	-1	1359137
ar@@	O	-1	1359137
ity	O	-1	1359137
suc@@	O	-1	1359137
cess@@	O	-1	1359137
ful@@	O	-1	1359137
ly	O	-1	1359137
cor@@	O	-1	1359137
rec@@	O	-1	1359137
ted	O	-1	1359137
with	O	-1	1359137
brom@@	B-Chemical	D001971	1359137
oc@@	I-Chemical	-1	1359137
ript@@	I-Chemical	-1	1359137
ine	I-Chemical	-1	1359137
.	O	-1	1359137
This	O	-1	1359137
suggests	O	-1	1359137
that	O	-1	1359137
brom@@	B-Chemical	D001971	1359137
oc@@	I-Chemical	-1	1359137
ript@@	I-Chemical	-1	1359137
ine	I-Chemical	-1	1359137
should	O	-1	1359137
be	O	-1	1359137
further	O	-1	1359137
evaluated	O	-1	1359137
as	O	-1	1359137
potential	O	-1	1359137
therapy	O	-1	1359137
for	O	-1	1359137
neuro@@	B-Chemical	D014150	1359137
le@@	I-Chemical	-1	1359137
p@@	I-Chemical	-1	1359137
tic	I-Chemical	-1	1359137
-@@	O	-1	1359137
associated	O	-1	1359137
hyper@@	B-Disease	D006966	1359137
prol@@	I-Disease	-1	1359137
act@@	I-Disease	-1	1359137
ine@@	I-Disease	-1	1359137
mia	I-Disease	-1	1359137
and	O	-1	1359137
am@@	B-Disease	D000568	1359137
en@@	I-Disease	-1	1359137
or@@	I-Disease	-1	1359137
r@@	I-Disease	-1	1359137
he@@	I-Disease	-1	1359137
a	I-Disease	-1	1359137
/	O	-1	1359137
g@@	B-Disease	D005687	1359137
al@@	I-Disease	-1	1359137
act@@	I-Disease	-1	1359137
or@@	I-Disease	-1	1359137
r@@	I-Disease	-1	1359137
he@@	I-Disease	-1	1359137
a	I-Disease	-1	1359137
.	O	-1	1359137

E@@	B-Chemical	D004976	1360900
th@@	I-Chemical	-1	1360900
ac@@	I-Chemical	-1	1360900
r@@	I-Chemical	-1	1360900
yn@@	I-Chemical	-1	1360900
ic	I-Chemical	-1	1360900
acid	I-Chemical	-1	1360900
-induced	O	-1	1360900
convul@@	B-Disease	D012640	1360900
sions	I-Disease	-1	1360900
and	O	-1	1360900
brain	O	-1	1360900
neuro@@	O	-1	1360900
trans@@	O	-1	1360900
mit@@	O	-1	1360900
ters	O	-1	1360900
in	O	-1	1360900
mice.	O	-1	1360900
In@@	O	-1	1360900
trac@@	O	-1	1360900
e@@	O	-1	1360900
reb@@	O	-1	1360900
ro@@	O	-1	1360900
ventricular	O	-1	1360900
injection	O	-1	1360900
of	O	-1	1360900
eth@@	B-Chemical	D004976	1360900
ac@@	I-Chemical	-1	1360900
r@@	I-Chemical	-1	1360900
yn@@	I-Chemical	-1	1360900
ic	I-Chemical	-1	1360900
acid	I-Chemical	-1	1360900
(@@	O	-1	1360900
50@@	O	-1	1360900
%	O	-1	1360900
convul@@	B-Disease	D012640	1360900
sive	I-Disease	-1	1360900
dose@@	O	-1	1360900
;	O	-1	1360900
50	O	-1	1360900
microgram@@	O	-1	1360900
s/@@	O	-1	1360900
mou@@	O	-1	1360900
se@@	O	-1	1360900
)	O	-1	1360900
ac@@	O	-1	1360900
ce@@	O	-1	1360900
l@@	O	-1	1360900
er@@	O	-1	1360900
ated	O	-1	1360900
the	O	-1	1360900
syn@@	O	-1	1360900
the@@	O	-1	1360900
si@@	O	-1	1360900
s/@@	O	-1	1360900
t@@	O	-1	1360900
ur@@	O	-1	1360900
no@@	O	-1	1360900
ver	O	-1	1360900
of	O	-1	1360900
5-@@	B-Chemical	D012701	1360900
hydrox@@	I-Chemical	-1	1360900
y@@	I-Chemical	-1	1360900
tr@@	I-Chemical	-1	1360900
y@@	I-Chemical	-1	1360900
pt@@	I-Chemical	-1	1360900
amine	I-Chemical	-1	1360900
(	O	-1	1360900
5-@@	B-Chemical	D012701	1360900
H@@	I-Chemical	-1	1360900
T	I-Chemical	-1	1360900
)	O	-1	1360900
but	O	-1	1360900
sup@@	O	-1	1360900
press@@	O	-1	1360900
ed	O	-1	1360900
the	O	-1	1360900
syn@@	O	-1	1360900
thesis	O	-1	1360900
of	O	-1	1360900
gamma@@	B-Chemical	D005680	1360900
-@@	I-Chemical	-1	1360900
amin@@	I-Chemical	-1	1360900
ob@@	I-Chemical	-1	1360900
ut@@	I-Chemical	-1	1360900
y@@	I-Chemical	-1	1360900
ric	I-Chemical	-1	1360900
acid	I-Chemical	-1	1360900
and	O	-1	1360900
acet@@	B-Chemical	D000109	1360900
ylcholine	I-Chemical	-1	1360900
in	O	-1	1360900
mouse	O	-1	1360900
bra@@	O	-1	1360900
in.	O	-1	1360900
These	O	-1	1360900
effects	O	-1	1360900
were	O	-1	1360900
complete@@	O	-1	1360900
ly	O	-1	1360900
antagon@@	O	-1	1360900
ized	O	-1	1360900
by	O	-1	1360900
pretreatment	O	-1	1360900
with	O	-1	1360900
a	O	-1	1360900
glutamate	B-Chemical	D018698	1360900
/	O	-1	1360900
N@@	B-Chemical	D016202	1360900
-@@	I-Chemical	-1	1360900
methyl@@	I-Chemical	-1	1360900
-@@	I-Chemical	-1	1360900
D-@@	I-Chemical	-1	1360900
as@@	I-Chemical	-1	1360900
part@@	I-Chemical	-1	1360900
ate	I-Chemical	-1	1360900
antagonist@@	O	-1	1360900
,	O	-1	1360900
aminoph@@	B-Chemical	-1	1360900
osph@@	I-Chemical	-1	1360900
on@@	I-Chemical	-1	1360900
o@@	I-Chemical	-1	1360900
val@@	I-Chemical	-1	1360900
er@@	I-Chemical	-1	1360900
ic	I-Chemical	-1	1360900
acid	I-Chemical	-1	1360900
.	O	-1	1360900
In	O	-1	1360900
eth@@	B-Chemical	D004976	1360900
ac@@	I-Chemical	-1	1360900
r@@	I-Chemical	-1	1360900
yn@@	I-Chemical	-1	1360900
ic	I-Chemical	-1	1360900
acid	I-Chemical	-1	1360900
-induced	O	-1	1360900
convul@@	B-Disease	D012640	1360900
sions	I-Disease	-1	1360900
,	O	-1	1360900
these	O	-1	1360900
neuro@@	O	-1	1360900
trans@@	O	-1	1360900
mit@@	O	-1	1360900
ter	O	-1	1360900
system@@	O	-1	1360900
s	O	-1	1360900
may	O	-1	1360900
be	O	-1	1360900
differen@@	O	-1	1360900
ti@@	O	-1	1360900
ally	O	-1	1360900
mod@@	O	-1	1360900
ul@@	O	-1	1360900
at@@	O	-1	1360900
ed,	O	-1	1360900
prob@@	O	-1	1360900
ably	O	-1	1360900
through	O	-1	1360900
activation	O	-1	1360900
of	O	-1	1360900
glut@@	O	-1	1360900
aminergic	O	-1	1360900
neuron@@	O	-1	1360900
s	O	-1	1360900
in	O	-1	1360900
the	O	-1	1360900
bra@@	O	-1	1360900
in.	O	-1	1360900

Ph@@	O	-1	1361574
armac@@	O	-1	1361574
ology	O	-1	1361574
of	O	-1	1361574
gamma@@	B-Chemical	D005680	1361574
-@@	I-Chemical	-1	1361574
amin@@	I-Chemical	-1	1361574
ob@@	I-Chemical	-1	1361574
ut@@	I-Chemical	-1	1361574
y@@	I-Chemical	-1	1361574
ric	I-Chemical	-1	1361574
acid	I-Chemical	-1	1361574
A	O	-1	1361574
receptor	O	-1	1361574
comple@@	O	-1	1361574
x	O	-1	1361574
after	O	-1	1361574
the	O	-1	1361574
in	O	-1	1361574
viv@@	O	-1	1361574
o	O	-1	1361574
administration	O	-1	1361574
of	O	-1	1361574
the	O	-1	1361574
an@@	O	-1	1361574
x@@	O	-1	1361574
io@@	O	-1	1361574
selective	O	-1	1361574
and	O	-1	1361574
anti@@	O	-1	1361574
convul@@	O	-1	1361574
s@@	O	-1	1361574
ant	O	-1	1361574
beta-@@	B-Chemical	D002243	1361574
carb@@	I-Chemical	-1	1361574
ol@@	I-Chemical	-1	1361574
ine	I-Chemical	-1	1361574
der@@	O	-1	1361574
i@@	O	-1	1361574
v@@	O	-1	1361574
ative	O	-1	1361574
ab@@	B-Chemical	C062769	1361574
ec@@	I-Chemical	-1	1361574
ar@@	I-Chemical	-1	1361574
n@@	I-Chemical	-1	1361574
il	I-Chemical	-1	1361574
.	O	-1	1361574
In	O	-1	1361574
ro@@	O	-1	1361574
d@@	O	-1	1361574
ent@@	O	-1	1361574
s,	O	-1	1361574
the	O	-1	1361574
effect	O	-1	1361574
of	O	-1	1361574
the	O	-1	1361574
beta-@@	B-Chemical	D002243	1361574
carb@@	I-Chemical	-1	1361574
ol@@	I-Chemical	-1	1361574
ine	I-Chemical	-1	1361574
der@@	O	-1	1361574
i@@	O	-1	1361574
v@@	O	-1	1361574
ative	O	-1	1361574
iso@@	B-Chemical	C062769	1361574
prop@@	I-Chemical	-1	1361574
yl@@	I-Chemical	-1	1361574
-@@	I-Chemical	-1	1361574
6@@	I-Chemical	-1	1361574
-	I-Chemical	-1	1361574
b@@	I-Chemical	-1	1361574
enz@@	I-Chemical	-1	1361574
y@@	I-Chemical	-1	1361574
lo@@	I-Chemical	-1	1361574
x@@	I-Chemical	-1	1361574
y-@@	I-Chemical	-1	1361574
4-@@	I-Chemical	-1	1361574
meth@@	I-Chemical	-1	1361574
oxy@@	I-Chemical	-1	1361574
methyl@@	I-Chemical	-1	1361574
-@@	I-Chemical	-1	1361574
beta-@@	I-Chemical	-1	1361574
carb@@	I-Chemical	-1	1361574
ol@@	I-Chemical	-1	1361574
ine-@@	I-Chemical	-1	1361574
3-@@	I-Chemical	-1	1361574
carb@@	I-Chemical	-1	1361574
ox@@	I-Chemical	-1	1361574
yl@@	I-Chemical	-1	1361574
ate	I-Chemical	-1	1361574
(	O	-1	1361574
ab@@	B-Chemical	C062769	1361574
ec@@	I-Chemical	-1	1361574
ar@@	I-Chemical	-1	1361574
r@@	I-Chemical	-1	1361574
n@@	I-Chemical	-1	1361574
il	I-Chemical	-1	1361574
),	O	-1	1361574
a	O	-1	1361574
new	O	-1	1361574
li@@	O	-1	1361574
g@@	O	-1	1361574
and	O	-1	1361574
for	O	-1	1361574
b@@	B-Chemical	D001569	1361574
enz@@	I-Chemical	-1	1361574
odi@@	I-Chemical	-1	1361574
azepine	I-Chemical	-1	1361574
receptors	O	-1	1361574
pos@@	O	-1	1361574
s@@	O	-1	1361574
ess@@	O	-1	1361574
ing	O	-1	1361574
an@@	O	-1	1361574
xi@@	O	-1	1361574
oly@@	O	-1	1361574
tic	O	-1	1361574
and	O	-1	1361574
anti@@	O	-1	1361574
convul@@	O	-1	1361574
s@@	O	-1	1361574
ant	O	-1	1361574
pro@@	O	-1	1361574
per@@	O	-1	1361574
ti@@	O	-1	1361574
es,	O	-1	1361574
was	O	-1	1361574
evaluated	O	-1	1361574
on	O	-1	1361574
the	O	-1	1361574
function	O	-1	1361574
of	O	-1	1361574
central	O	-1	1361574
gamma@@	B-Chemical	D005680	1361574
-@@	I-Chemical	-1	1361574
amin@@	I-Chemical	-1	1361574
ob@@	I-Chemical	-1	1361574
ut@@	I-Chemical	-1	1361574
y@@	I-Chemical	-1	1361574
ric	I-Chemical	-1	1361574
acid	I-Chemical	-1	1361574
(	O	-1	1361574
G@@	B-Chemical	D005680	1361574
A@@	I-Chemical	-1	1361574
B@@	I-Chemical	-1	1361574
A	I-Chemical	-1	1361574
)@@	O	-1	1361574
A	O	-1	1361574
receptor	O	-1	1361574
comple@@	O	-1	1361574
x@@	O	-1	1361574
,	O	-1	1361574
both	O	-1	1361574
in	O	-1	1361574
vit@@	O	-1	1361574
r@@	O	-1	1361574
o	O	-1	1361574
and	O	-1	1361574
in	O	-1	1361574
viv@@	O	-1	1361574
o@@	O	-1	1361574
.	O	-1	1361574
Ad@@	O	-1	1361574
ded	O	-1	1361574
in	O	-1	1361574
vit@@	O	-1	1361574
r@@	O	-1	1361574
o	O	-1	1361574
to	O	-1	1361574
rat	O	-1	1361574
cor@@	O	-1	1361574
tical	O	-1	1361574
membran@@	O	-1	1361574
e	O	-1	1361574
pre@@	O	-1	1361574
par@@	O	-1	1361574
ation,	O	-1	1361574
ab@@	B-Chemical	C062769	1361574
ec@@	I-Chemical	-1	1361574
ar@@	I-Chemical	-1	1361574
n@@	I-Chemical	-1	1361574
il	I-Chemical	-1	1361574
increased	O	-1	1361574
[@@	O	-1	1361574
3@@	O	-1	1361574
H@@	O	-1	1361574
]	O	-1	1361574
G@@	B-Chemical	D005680	1361574
A@@	I-Chemical	-1	1361574
B@@	I-Chemical	-1	1361574
A	I-Chemical	-1	1361574
b@@	O	-1	1361574
ind@@	O	-1	1361574
ing,	O	-1	1361574
enhanced	O	-1	1361574
musc@@	B-Chemical	D009118	1361574
im@@	I-Chemical	-1	1361574
ol	I-Chemical	-1	1361574
-@@	O	-1	1361574
stimul@@	O	-1	1361574
ated	O	-1	1361574
3@@	O	-1	1361574
6@@	O	-1	1361574
Cl@@	O	-1	1361574
-	O	-1	1361574
u@@	O	-1	1361574
pt@@	O	-1	1361574
ake	O	-1	1361574
and	O	-1	1361574
reduced	O	-1	1361574
the	O	-1	1361574
b@@	O	-1	1361574
ind@@	O	-1	1361574
ing	O	-1	1361574
of	O	-1	1361574
t-@@	B-Chemical	C037476	1361574
[@@	I-Chemical	-1	1361574
3@@	I-Chemical	-1	1361574
5@@	I-Chemical	-1	1361574
S@@	I-Chemical	-1	1361574
]@@	I-Chemical	-1	1361574
but@@	I-Chemical	-1	1361574
yl@@	I-Chemical	-1	1361574
b@@	I-Chemical	-1	1361574
ic@@	I-Chemical	-1	1361574
yc@@	I-Chemical	-1	1361574
lo@@	I-Chemical	-1	1361574
phosph@@	I-Chemical	-1	1361574
o@@	I-Chemical	-1	1361574
ro@@	I-Chemical	-1	1361574
thi@@	I-Chemical	-1	1361574
on@@	I-Chemical	-1	1361574
ate	I-Chemical	-1	1361574
(	O	-1	1361574
[@@	B-Chemical	C037476	1361574
3@@	I-Chemical	-1	1361574
5@@	I-Chemical	-1	1361574
S@@	I-Chemical	-1	1361574
]@@	I-Chemical	-1	1361574
T@@	I-Chemical	-1	1361574
B@@	I-Chemical	-1	1361574
P@@	I-Chemical	-1	1361574
S	I-Chemical	-1	1361574
).	O	-1	1361574
These	O	-1	1361574
effects	O	-1	1361574
were	O	-1	1361574
similar	O	-1	1361574
to	O	-1	1361574
those	O	-1	1361574
induced	O	-1	1361574
by	O	-1	1361574
di@@	B-Chemical	D003975	1361574
az@@	I-Chemical	-1	1361574
epam	I-Chemical	-1	1361574
,	O	-1	1361574
whereas	O	-1	1361574
the	O	-1	1361574
partial	O	-1	1361574
agon@@	O	-1	1361574
ist	O	-1	1361574
R@@	B-Chemical	C054626	1361574
o	I-Chemical	-1	1361574
1@@	I-Chemical	-1	1361574
6-@@	I-Chemical	-1	1361574
6@@	I-Chemical	-1	1361574
0@@	I-Chemical	-1	1361574
2@@	I-Chemical	-1	1361574
8	I-Chemical	-1	1361574
(	O	-1	1361574
ter@@	B-Chemical	C054626	1361574
t-@@	I-Chemical	-1	1361574
but@@	I-Chemical	-1	1361574
yl@@	I-Chemical	-1	1361574
-@@	I-Chemical	-1	1361574
(S@@	I-Chemical	-1	1361574
)-@@	I-Chemical	-1	1361574
8@@	I-Chemical	-1	1361574
-@@	I-Chemical	-1	1361574
b@@	I-Chemical	-1	1361574
ro@@	I-Chemical	-1	1361574
mo@@	I-Chemical	-1	1361574
-1@@	I-Chemical	-1	1361574
1@@	I-Chemical	-1	1361574
,@@	I-Chemical	-1	1361574
12@@	I-Chemical	-1	1361574
,@@	I-Chemical	-1	1361574
13@@	I-Chemical	-1	1361574
,@@	I-Chemical	-1	1361574
13@@	I-Chemical	-1	1361574
a@@	I-Chemical	-1	1361574
-@@	I-Chemical	-1	1361574
te@@	I-Chemical	-1	1361574
tra@@	I-Chemical	-1	1361574
hydro@@	I-Chemical	-1	1361574
-@@	I-Chemical	-1	1361574
9@@	I-Chemical	-1	1361574
-@@	I-Chemical	-1	1361574
ox@@	I-Chemical	-1	1361574
o@@	I-Chemical	-1	1361574
-@@	I-Chemical	-1	1361574
9@@	I-Chemical	-1	1361574
H@@	I-Chemical	-1	1361574
-	I-Chemical	-1	1361574
im@@	I-Chemical	-1	1361574
id@@	I-Chemical	-1	1361574
az@@	I-Chemical	-1	1361574
o@@	I-Chemical	-1	1361574
[@@	I-Chemical	-1	1361574
1@@	I-Chemical	-1	1361574
,@@	I-Chemical	-1	1361574
5-@@	I-Chemical	-1	1361574
a@@	I-Chemical	-1	1361574
]@@	I-Chemical	-1	1361574
-@@	I-Chemical	-1	1361574
py@@	I-Chemical	-1	1361574
r@@	I-Chemical	-1	1361574
ro@@	I-Chemical	-1	1361574
lo@@	I-Chemical	-1	1361574
-@@	I-Chemical	-1	1361574
[@@	I-Chemical	-1	1361574
2@@	I-Chemical	-1	1361574
,@@	I-Chemical	-1	1361574
1-@@	I-Chemical	-1	1361574
c@@	I-Chemical	-1	1361574
]@@	I-Chemical	-1	1361574
[@@	I-Chemical	-1	1361574
1@@	I-Chemical	-1	1361574
,@@	I-Chemical	-1	1361574
4@@	I-Chemical	-1	1361574
]@@	I-Chemical	-1	1361574
b@@	I-Chemical	-1	1361574
enz@@	I-Chemical	-1	1361574
odi@@	I-Chemical	-1	1361574
azep@@	I-Chemical	-1	1361574
ine-@@	I-Chemical	-1	1361574
1-@@	I-Chemical	-1	1361574
carb@@	I-Chemical	-1	1361574
ox@@	I-Chemical	-1	1361574
yl@@	I-Chemical	-1	1361574
ate	I-Chemical	-1	1361574
)	O	-1	1361574
showed	O	-1	1361574
very	O	-1	1361574
we@@	O	-1	1361574
a@@	O	-1	1361574
k	O	-1	1361574
efficacy	O	-1	1361574
in	O	-1	1361574
these	O	-1	1361574
bio@@	O	-1	1361574
chemical	O	-1	1361574
test@@	O	-1	1361574
s.	O	-1	1361574
After	O	-1	1361574
i.@@	O	-1	1361574
p@@	O	-1	1361574
.	O	-1	1361574
injection	O	-1	1361574
to	O	-1	1361574
rats,	O	-1	1361574
ab@@	B-Chemical	C062769	1361574
ec@@	I-Chemical	-1	1361574
ar@@	I-Chemical	-1	1361574
n@@	I-Chemical	-1	1361574
il	I-Chemical	-1	1361574
and	O	-1	1361574
di@@	B-Chemical	D003975	1361574
az@@	I-Chemical	-1	1361574
epam	I-Chemical	-1	1361574
decreased	O	-1	1361574
in	O	-1	1361574
a	O	-1	1361574
ti@@	O	-1	1361574
me@@	O	-1	1361574
-@@	O	-1	1361574
dependent	O	-1	1361574
and	O	-1	1361574
dose-@@	O	-1	1361574
related	O	-1	1361574
(0.@@	O	-1	1361574
2@@	O	-1	1361574
5-@@	O	-1	1361574
20	O	-1	1361574
mg/kg	O	-1	1361574
i.p.@@	O	-1	1361574
)	O	-1	1361574
man@@	O	-1	1361574
n@@	O	-1	1361574
er	O	-1	1361574
[@@	B-Chemical	C037476	1361574
3@@	I-Chemical	-1	1361574
5@@	I-Chemical	-1	1361574
S@@	I-Chemical	-1	1361574
]@@	I-Chemical	-1	1361574
T@@	I-Chemical	-1	1361574
B@@	I-Chemical	-1	1361574
P@@	I-Chemical	-1	1361574
S	I-Chemical	-1	1361574
b@@	O	-1	1361574
ind@@	O	-1	1361574
ing	O	-1	1361574
measured	O	-1	1361574
e@@	O	-1	1361574
x	O	-1	1361574
viv@@	O	-1	1361574
o	O	-1	1361574
in	O	-1	1361574
the	O	-1	1361574
cerebral	O	-1	1361574
cor@@	O	-1	1361574
t@@	O	-1	1361574
ex@@	O	-1	1361574
.	O	-1	1361574
M@@	O	-1	1361574
ore@@	O	-1	1361574
o@@	O	-1	1361574
ver,	O	-1	1361574
both	O	-1	1361574
drugs	O	-1	1361574
at	O	-1	1361574
the	O	-1	1361574
dose	O	-1	1361574
of	O	-1	1361574
0.@@	O	-1	1361574
5	O	-1	1361574
mg/kg	O	-1	1361574
antagon@@	O	-1	1361574
ized	O	-1	1361574
complete@@	O	-1	1361574
ly	O	-1	1361574
the	O	-1	1361574
convul@@	O	-1	1361574
s@@	O	-1	1361574
ant	O	-1	1361574
activity	O	-1	1361574
and	O	-1	1361574
the	O	-1	1361574
increase	O	-1	1361574
of	O	-1	1361574
[@@	B-Chemical	C037476	1361574
3@@	I-Chemical	-1	1361574
5@@	I-Chemical	-1	1361574
S@@	I-Chemical	-1	1361574
]@@	I-Chemical	-1	1361574
T@@	I-Chemical	-1	1361574
B@@	I-Chemical	-1	1361574
P@@	I-Chemical	-1	1361574
S	I-Chemical	-1	1361574
b@@	O	-1	1361574
ind@@	O	-1	1361574
ing	O	-1	1361574
induced	O	-1	1361574
by	O	-1	1361574
is@@	B-Chemical	D007538	1361574
oni@@	I-Chemical	-1	1361574
az@@	I-Chemical	-1	1361574
ide	I-Chemical	-1	1361574
(3@@	O	-1	1361574
50	O	-1	1361574
mg/kg	O	-1	1361574
s@@	O	-1	1361574
.@@	O	-1	1361574
c@@	O	-1	1361574
.)	O	-1	1361574
as	O	-1	1361574
well	O	-1	1361574
as	O	-1	1361574
the	O	-1	1361574
increase	O	-1	1361574
of	O	-1	1361574
[@@	B-Chemical	C037476	1361574
3@@	I-Chemical	-1	1361574
5@@	I-Chemical	-1	1361574
S@@	I-Chemical	-1	1361574
]@@	I-Chemical	-1	1361574
T@@	I-Chemical	-1	1361574
B@@	I-Chemical	-1	1361574
P@@	I-Chemical	-1	1361574
S	I-Chemical	-1	1361574
b@@	O	-1	1361574
ind@@	O	-1	1361574
ing	O	-1	1361574
induced	O	-1	1361574
by	O	-1	1361574
fo@@	O	-1	1361574
ot@@	O	-1	1361574
-@@	O	-1	1361574
sh@@	O	-1	1361574
oc@@	O	-1	1361574
k	O	-1	1361574
stres@@	O	-1	1361574
s.	O	-1	1361574
To	O	-1	1361574
bet@@	O	-1	1361574
ter	O	-1	1361574
correl@@	O	-1	1361574
ate	O	-1	1361574
the	O	-1	1361574
bio@@	O	-1	1361574
chemical	O	-1	1361574
and	O	-1	1361574
the	O	-1	1361574
pharmac@@	O	-1	1361574
ological	O	-1	1361574
effect@@	O	-1	1361574
s,	O	-1	1361574
we	O	-1	1361574
studied	O	-1	1361574
the	O	-1	1361574
action	O	-1	1361574
of	O	-1	1361574
ab@@	B-Chemical	C062769	1361574
ec@@	I-Chemical	-1	1361574
ar@@	I-Chemical	-1	1361574
n@@	I-Chemical	-1	1361574
il	I-Chemical	-1	1361574
on	O	-1	1361574
[@@	B-Chemical	C037476	1361574
3@@	I-Chemical	-1	1361574
5@@	I-Chemical	-1	1361574
S@@	I-Chemical	-1	1361574
]@@	I-Chemical	-1	1361574
T@@	I-Chemical	-1	1361574
B@@	I-Chemical	-1	1361574
P@@	I-Chemical	-1	1361574
S	I-Chemical	-1	1361574
b@@	O	-1	1361574
ind@@	O	-1	1361574
ing,	O	-1	1361574
expl@@	O	-1	1361574
or@@	O	-1	1361574
atory	O	-1	1361574
mo@@	O	-1	1361574
til@@	O	-1	1361574
ity	O	-1	1361574
and	O	-1	1361574
on	O	-1	1361574
is@@	B-Chemical	D007538	1361574
oni@@	I-Chemical	-1	1361574
az@@	I-Chemical	-1	1361574
id	I-Chemical	-1	1361574
-induced	O	-1	1361574
bio@@	O	-1	1361574
chemical	O	-1	1361574
and	O	-1	1361574
pharmac@@	O	-1	1361574
ological	O	-1	1361574
effects	O	-1	1361574
in	O	-1	1361574
mice.	O	-1	1361574
In	O	-1	1361574
these	O	-1	1361574
anim@@	O	-1	1361574
al@@	O	-1	1361574
s,	O	-1	1361574
ab@@	B-Chemical	C062769	1361574
ec@@	I-Chemical	-1	1361574
ar@@	I-Chemical	-1	1361574
n@@	I-Chemical	-1	1361574
il	I-Chemical	-1	1361574
produced	O	-1	1361574
a	O	-1	1361574
par@@	O	-1	1361574
al@@	O	-1	1361574
le@@	O	-1	1361574
l@@	O	-1	1361574
ed	O	-1	1361574
dose-@@	O	-1	1361574
dependent	O	-1	1361574
(@@	O	-1	1361574
0.0@@	O	-1	1361574
5-@@	O	-1	1361574
1	O	-1	1361574
mg/kg	O	-1	1361574
i.p.@@	O	-1	1361574
)	O	-1	1361574
reduction	O	-1	1361574
of	O	-1	1361574
both	O	-1	1361574
motor	O	-1	1361574
behavi@@	O	-1	1361574
or	O	-1	1361574
and	O	-1	1361574
cor@@	O	-1	1361574
tical	O	-1	1361574
[@@	O	-1	1361574
3@@	O	-1	1361574
5@@	O	-1	1361574
S@@	O	-1	1361574
]@@	O	-1	1361574
T@@	O	-1	1361574
B@@	O	-1	1361574
P@@	O	-1	1361574
S	O	-1	1361574
b@@	O	-1	1361574
ind@@	O	-1	1361574
ing.	O	-1	1361574
M@@	O	-1	1361574
ore@@	O	-1	1361574
o@@	O	-1	1361574
ver,	O	-1	1361574
0.0@@	O	-1	1361574
5	O	-1	1361574
mg/kg	O	-1	1361574
of	O	-1	1361574
this	O	-1	1361574
beta-@@	B-Chemical	D002243	1361574
carb@@	I-Chemical	-1	1361574
ol@@	I-Chemical	-1	1361574
ine	I-Chemical	-1	1361574
reduced	O	-1	1361574
mark@@	O	-1	1361574
ed@@	O	-1	1361574
ly	O	-1	1361574
the	O	-1	1361574
increase	O	-1	1361574
of	O	-1	1361574
[@@	B-Chemical	C037476	1361574
3@@	I-Chemical	-1	1361574
5@@	I-Chemical	-1	1361574
S@@	I-Chemical	-1	1361574
]@@	I-Chemical	-1	1361574
T@@	I-Chemical	-1	1361574
B@@	I-Chemical	-1	1361574
P@@	I-Chemical	-1	1361574
S	I-Chemical	-1	1361574
b@@	O	-1	1361574
ind@@	O	-1	1361574
ing	O	-1	1361574
and	O	-1	1361574
the	O	-1	1361574
convul@@	B-Disease	D012640	1361574
sions	I-Disease	-1	1361574
induced	O	-1	1361574
by	O	-1	1361574
is@@	B-Chemical	D007538	1361574
oni@@	I-Chemical	-1	1361574
az@@	I-Chemical	-1	1361574
id	I-Chemical	-1	1361574
(2@@	O	-1	1361574
00	O	-1	1361574
mg/kg	O	-1	1361574
s@@	O	-1	1361574
.@@	O	-1	1361574
c@@	O	-1	1361574
.@@	O	-1	1361574
)@@	O	-1	1361574
.@@	O	-1	1361574
(A@@	O	-1	1361574
B@@	O	-1	1361574
S@@	O	-1	1361574
TR@@	O	-1	1361574
AC@@	O	-1	1361574
T	O	-1	1361574
TR@@	O	-1	1361574
UN@@	O	-1	1361574
C@@	O	-1	1361574
AT@@	O	-1	1361574
E@@	O	-1	1361574
D	O	-1	1361574
A@@	O	-1	1361574
T	O	-1	1361574
2@@	O	-1	1361574
50	O	-1	1361574
W@@	O	-1	1361574
O@@	O	-1	1361574
RD@@	O	-1	1361574
S)	O	-1	1361574

Rec@@	O	-1	1395192
ur@@	O	-1	1395192
rent	O	-1	1395192
myocardial	B-Disease	D009203	1395192
infarction	I-Disease	-1	1395192
in	O	-1	1395192
a	O	-1	1395192
post@@	O	-1	1395192
part@@	O	-1	1395192
um	O	-1	1395192
patient	O	-1	1395192
receiving	O	-1	1395192
brom@@	B-Chemical	D001971	1395192
oc@@	I-Chemical	-1	1395192
ript@@	I-Chemical	-1	1395192
ine	I-Chemical	-1	1395192
.	O	-1	1395192
M@@	B-Disease	D009203	1395192
y@@	I-Disease	-1	1395192
ocardi@@	I-Disease	-1	1395192
al	I-Disease	-1	1395192
infarction	I-Disease	-1	1395192
in	O	-1	1395192
pu@@	O	-1	1395192
er@@	O	-1	1395192
peri@@	O	-1	1395192
um	O	-1	1395192
is	O	-1	1395192
inf@@	O	-1	1395192
requ@@	O	-1	1395192
ently	O	-1	1395192
repor@@	O	-1	1395192
ted.	O	-1	1395192
S@@	B-Disease	D013035	1395192
p@@	I-Disease	-1	1395192
as@@	I-Disease	-1	1395192
m	I-Disease	-1	1395192
,	O	-1	1395192
coronary	O	-1	1395192
dis@@	O	-1	1395192
sec@@	O	-1	1395192
tion,	O	-1	1395192
or	O	-1	1395192
a@@	O	-1	1395192
ther@@	O	-1	1395192
om@@	O	-1	1395192
at@@	O	-1	1395192
ous	O	-1	1395192
e@@	O	-1	1395192
ti@@	O	-1	1395192
ology	O	-1	1395192
has	O	-1	1395192
been	O	-1	1395192
descri@@	O	-1	1395192
be@@	O	-1	1395192
d.	O	-1	1395192
B@@	B-Chemical	D001971	1395192
rom@@	I-Chemical	-1	1395192
oc@@	I-Chemical	-1	1395192
ript@@	I-Chemical	-1	1395192
ine	I-Chemical	-1	1395192
has	O	-1	1395192
been	O	-1	1395192
implic@@	O	-1	1395192
ated	O	-1	1395192
in	O	-1	1395192
several	O	-1	1395192
previ@@	O	-1	1395192
ous	O	-1	1395192
case	O	-1	1395192
reports	O	-1	1395192
of	O	-1	1395192
myocardial	B-Disease	D009203	1395192
infarction	I-Disease	-1	1395192
in	O	-1	1395192
the	O	-1	1395192
pu@@	O	-1	1395192
er@@	O	-1	1395192
peri@@	O	-1	1395192
um@@	O	-1	1395192
.	O	-1	1395192
Our	O	-1	1395192
case	O	-1	1395192
(@@	O	-1	1395192
including	O	-1	1395192
an	O	-1	1395192
in@@	O	-1	1395192
ad@@	O	-1	1395192
ver@@	O	-1	1395192
t@@	O	-1	1395192
ent	O	-1	1395192
re@@	O	-1	1395192
ch@@	O	-1	1395192
all@@	O	-1	1395192
en@@	O	-1	1395192
ge@@	O	-1	1395192
)	O	-1	1395192
suggests	O	-1	1395192
such	O	-1	1395192
a	O	-1	1395192
rel@@	O	-1	1395192
ation@@	O	-1	1395192
shi@@	O	-1	1395192
p@@	O	-1	1395192
.	O	-1	1395192
Although	O	-1	1395192
gener@@	O	-1	1395192
ally	O	-1	1395192
reg@@	O	-1	1395192
ar@@	O	-1	1395192
ded	O	-1	1395192
as	O	-1	1395192
"@@	O	-1	1395192
saf@@	O	-1	1395192
e@@	O	-1	1395192
,@@	O	-1	1395192
"	O	-1	1395192
possible	O	-1	1395192
seri@@	O	-1	1395192
ous	O	-1	1395192
cardiac	O	-1	1395192
effects	O	-1	1395192
of	O	-1	1395192
brom@@	B-Chemical	D001971	1395192
oc@@	I-Chemical	-1	1395192
ript@@	I-Chemical	-1	1395192
ine	I-Chemical	-1	1395192
should	O	-1	1395192
be	O	-1	1395192
ac@@	O	-1	1395192
know@@	O	-1	1395192
le@@	O	-1	1395192
d@@	O	-1	1395192
g@@	O	-1	1395192
ed.	O	-1	1395192

A@@	B-Disease	D020820	1420650
ster@@	I-Disease	-1	1420650
i@@	I-Disease	-1	1420650
x@@	I-Disease	-1	1420650
is	I-Disease	-1	1420650
induced	O	-1	1420650
by	O	-1	1420650
carbamazepine	B-Chemical	D002220	1420650
therapy.	O	-1	1420650
There	O	-1	1420650
are	O	-1	1420650
very	O	-1	1420650
fe@@	O	-1	1420650
w	O	-1	1420650
reports	O	-1	1420650
about	O	-1	1420650
ast@@	B-Disease	D020820	1420650
er@@	I-Disease	-1	1420650
i@@	I-Disease	-1	1420650
x@@	I-Disease	-1	1420650
is	I-Disease	-1	1420650
as	O	-1	1420650
a	O	-1	1420650
side	O	-1	1420650
effect	O	-1	1420650
of	O	-1	1420650
treatment	O	-1	1420650
with	O	-1	1420650
psych@@	O	-1	1420650
oph@@	O	-1	1420650
armac@@	O	-1	1420650
ologic	O	-1	1420650
agent@@	O	-1	1420650
s.	O	-1	1420650
In	O	-1	1420650
this	O	-1	1420650
report	O	-1	1420650
we	O	-1	1420650
present	O	-1	1420650
four	O	-1	1420650
patients	O	-1	1420650
treated	O	-1	1420650
with	O	-1	1420650
a	O	-1	1420650
combination	O	-1	1420650
of	O	-1	1420650
different	O	-1	1420650
psych@@	O	-1	1420650
ot@@	O	-1	1420650
ro@@	O	-1	1420650
p@@	O	-1	1420650
ic	O	-1	1420650
drug@@	O	-1	1420650
s,	O	-1	1420650
in	O	-1	1420650
whom	O	-1	1420650
ast@@	B-Disease	D020820	1420650
er@@	I-Disease	-1	1420650
i@@	I-Disease	-1	1420650
x@@	I-Disease	-1	1420650
is	I-Disease	-1	1420650
was	O	-1	1420650
tri@@	O	-1	1420650
g@@	O	-1	1420650
ge@@	O	-1	1420650
red	O	-1	1420650
either	O	-1	1420650
by	O	-1	1420650
ad@@	O	-1	1420650
ding	O	-1	1420650
carbamazepine	B-Chemical	D002220	1420650
(	O	-1	1420650
C@@	B-Chemical	D002220	1420650
B@@	I-Chemical	-1	1420650
Z	I-Chemical	-1	1420650
)	O	-1	1420650
to	O	-1	1420650
a	O	-1	1420650
treatment	O	-1	1420650
regimen@@	O	-1	1420650
,	O	-1	1420650
or	O	-1	1420650
by	O	-1	1420650
increas@@	O	-1	1420650
ing	O	-1	1420650
its	O	-1	1420650
dos@@	O	-1	1420650
age.	O	-1	1420650
N@@	O	-1	1420650
either	O	-1	1420650
dos@@	O	-1	1420650
age	O	-1	1420650
n@@	O	-1	1420650
or	O	-1	1420650
serum	O	-1	1420650
levels	O	-1	1420650
of	O	-1	1420650
C@@	B-Chemical	D002220	1420650
B@@	I-Chemical	-1	1420650
Z	I-Chemical	-1	1420650
were	O	-1	1420650
in	O	-1	1420650
a	O	-1	1420650
higher	O	-1	1420650
rang@@	O	-1	1420650
e.	O	-1	1420650
We	O	-1	1420650
con@@	O	-1	1420650
si@@	O	-1	1420650
der	O	-1	1420650
ast@@	B-Disease	D020820	1420650
er@@	I-Disease	-1	1420650
i@@	I-Disease	-1	1420650
x@@	I-Disease	-1	1420650
is	I-Disease	-1	1420650
to	O	-1	1420650
be	O	-1	1420650
an	O	-1	1420650
e@@	O	-1	1420650
a@@	O	-1	1420650
si@@	O	-1	1420650
ly	O	-1	1420650
over@@	O	-1	1420650
lo@@	O	-1	1420650
o@@	O	-1	1420650
ked	O	-1	1420650
si@@	O	-1	1420650
g@@	O	-1	1420650
n	O	-1	1420650
of	O	-1	1420650
neuro@@	B-Disease	D020258	1420650
toxicity	I-Disease	-1	1420650
,	O	-1	1420650
which	O	-1	1420650
may	O	-1	1420650
occ@@	O	-1	1420650
ur	O	-1	1420650
even	O	-1	1420650
at	O	-1	1420650
low	O	-1	1420650
or	O	-1	1420650
moder@@	O	-1	1420650
ate	O	-1	1420650
dos@@	O	-1	1420650
age	O	-1	1420650
level@@	O	-1	1420650
s,	O	-1	1420650
if	O	-1	1420650
cer@@	O	-1	1420650
t@@	O	-1	1420650
ain	O	-1	1420650
drugs	O	-1	1420650
as	O	-1	1420650
lithium	B-Chemical	D008094	1420650
or	O	-1	1420650
cloz@@	B-Chemical	D003024	1420650
apine	I-Chemical	-1	1420650
are	O	-1	1420650
used	O	-1	1420650
in	O	-1	1420650
combination	O	-1	1420650
with	O	-1	1420650
C@@	B-Chemical	D002220	1420650
B@@	I-Chemical	-1	1420650
Z	I-Chemical	-1	1420650
.	O	-1	1420650

Ph@@	O	-1	1423336
armac@@	O	-1	1423336
o@@	O	-1	1423336
dynam@@	O	-1	1423336
ic@@	O	-1	1423336
s	O	-1	1423336
of	O	-1	1423336
the	O	-1	1423336
hypoten@@	B-Disease	D007022	1423336
sive	I-Disease	-1	1423336
effect	O	-1	1423336
of	O	-1	1423336
levo@@	B-Chemical	D007980	1423336
dopa	I-Chemical	-1	1423336
in	O	-1	1423336
par@@	B-Disease	D010300	1423336
k@@	I-Disease	-1	1423336
inson@@	I-Disease	-1	1423336
i@@	I-Disease	-1	1423336
an	I-Disease	-1	1423336
patients.	O	-1	1423336
B@@	O	-1	1423336
lo@@	O	-1	1423336
od	O	-1	1423336
pressure	O	-1	1423336
effects	O	-1	1423336
of	O	-1	1423336
i.v@@	O	-1	1423336
.	O	-1	1423336
levo@@	B-Chemical	D007980	1423336
dopa	I-Chemical	-1	1423336
were	O	-1	1423336
examined	O	-1	1423336
in	O	-1	1423336
par@@	B-Disease	D010300	1423336
k@@	I-Disease	-1	1423336
inson@@	I-Disease	-1	1423336
i@@	I-Disease	-1	1423336
an	I-Disease	-1	1423336
patients	O	-1	1423336
with	O	-1	1423336
st@@	O	-1	1423336
able	O	-1	1423336
and	O	-1	1423336
f@@	O	-1	1423336
l@@	O	-1	1423336
uc@@	O	-1	1423336
tu@@	O	-1	1423336
ating	O	-1	1423336
responses	O	-1	1423336
to	O	-1	1423336
levo@@	B-Chemical	D007980	1423336
dopa	I-Chemical	-1	1423336
.	O	-1	1423336
The	O	-1	1423336
mag@@	O	-1	1423336
nit@@	O	-1	1423336
ude	O	-1	1423336
of	O	-1	1423336
the	O	-1	1423336
hypoten@@	B-Disease	D007022	1423336
sive	I-Disease	-1	1423336
effect	O	-1	1423336
of	O	-1	1423336
levo@@	B-Chemical	D007980	1423336
dopa	I-Chemical	-1	1423336
was	O	-1	1423336
concentration	O	-1	1423336
dependent	O	-1	1423336
and	O	-1	1423336
was	O	-1	1423336
fi@@	O	-1	1423336
t	O	-1	1423336
to	O	-1	1423336
an	O	-1	1423336
E@@	O	-1	1423336
ma@@	O	-1	1423336
x	O	-1	1423336
model	O	-1	1423336
in	O	-1	1423336
f@@	O	-1	1423336
l@@	O	-1	1423336
uc@@	O	-1	1423336
tu@@	O	-1	1423336
ating	O	-1	1423336
respon@@	O	-1	1423336
der@@	O	-1	1423336
s.	O	-1	1423336
S@@	O	-1	1423336
t@@	O	-1	1423336
able	O	-1	1423336
respon@@	O	-1	1423336
der@@	O	-1	1423336
s	O	-1	1423336
demonstrated	O	-1	1423336
a	O	-1	1423336
sm@@	O	-1	1423336
all	O	-1	1423336
hypoten@@	B-Disease	D007022	1423336
sive	I-Disease	-1	1423336
respon@@	O	-1	1423336
se.	O	-1	1423336
B@@	O	-1	1423336
as@@	O	-1	1423336
el@@	O	-1	1423336
ine	O	-1	1423336
blood	O	-1	1423336
pressu@@	O	-1	1423336
res	O	-1	1423336
were	O	-1	1423336
higher	O	-1	1423336
in	O	-1	1423336
f@@	O	-1	1423336
l@@	O	-1	1423336
uc@@	O	-1	1423336
tu@@	O	-1	1423336
ating	O	-1	1423336
patient@@	O	-1	1423336
s;	O	-1	1423336
a	O	-1	1423336
higher	O	-1	1423336
baseline	O	-1	1423336
blood	O	-1	1423336
pressure	O	-1	1423336
cor@@	O	-1	1423336
related	O	-1	1423336
with	O	-1	1423336
greater	O	-1	1423336
hypoten@@	B-Disease	D007022	1423336
sive	I-Disease	-1	1423336
effects.	O	-1	1423336
An@@	O	-1	1423336
ti@@	O	-1	1423336
par@@	O	-1	1423336
k@@	O	-1	1423336
inson@@	O	-1	1423336
i@@	O	-1	1423336
an	O	-1	1423336
effects	O	-1	1423336
of	O	-1	1423336
levo@@	B-Chemical	D007980	1423336
dopa	I-Chemical	-1	1423336
tempor@@	O	-1	1423336
ally	O	-1	1423336
cor@@	O	-1	1423336
related	O	-1	1423336
with	O	-1	1423336
blood	O	-1	1423336
pressure	O	-1	1423336
chang@@	O	-1	1423336
es.	O	-1	1423336
Ph@@	B-Chemical	D010649	1423336
en@@	I-Chemical	-1	1423336
yl@@	I-Chemical	-1	1423336
al@@	I-Chemical	-1	1423336
an@@	I-Chemical	-1	1423336
ine	I-Chemical	-1	1423336
,	O	-1	1423336
a	O	-1	1423336
larg@@	O	-1	1423336
e	O	-1	1423336
ne@@	O	-1	1423336
ut@@	O	-1	1423336
ral	O	-1	1423336
amin@@	B-Chemical	D000596	1423336
o	I-Chemical	-1	1423336
acid	I-Chemical	-1	1423336
(@@	O	-1	1423336
L@@	O	-1	1423336
N@@	O	-1	1423336
A@@	O	-1	1423336
A@@	O	-1	1423336
)	O	-1	1423336
comp@@	O	-1	1423336
et@@	O	-1	1423336
ing	O	-1	1423336
with	O	-1	1423336
levo@@	B-Chemical	D007980	1423336
dopa	I-Chemical	-1	1423336
for	O	-1	1423336
trans@@	O	-1	1423336
por@@	O	-1	1423336
t	O	-1	1423336
ac@@	O	-1	1423336
ros@@	O	-1	1423336
s	O	-1	1423336
the	O	-1	1423336
blo@@	O	-1	1423336
o@@	O	-1	1423336
d-@@	O	-1	1423336
brain	O	-1	1423336
bar@@	O	-1	1423336
ri@@	O	-1	1423336
er,	O	-1	1423336
reduced	O	-1	1423336
the	O	-1	1423336
hypoten@@	B-Disease	D007022	1423336
sive	I-Disease	-1	1423336
and	O	-1	1423336
anti@@	O	-1	1423336
par@@	O	-1	1423336
k@@	O	-1	1423336
inson@@	O	-1	1423336
i@@	O	-1	1423336
an	O	-1	1423336
effects	O	-1	1423336
of	O	-1	1423336
levo@@	B-Chemical	D007980	1423336
dopa	I-Chemical	-1	1423336
.	O	-1	1423336
We	O	-1	1423336
concl@@	O	-1	1423336
ude	O	-1	1423336
that	O	-1	1423336
levo@@	B-Chemical	D007980	1423336
dopa	I-Chemical	-1	1423336
has	O	-1	1423336
a	O	-1	1423336
central	O	-1	1423336
hypoten@@	B-Disease	D007022	1423336
sive	I-Disease	-1	1423336
action	O	-1	1423336
that	O	-1	1423336
par@@	O	-1	1423336
al@@	O	-1	1423336
le@@	O	-1	1423336
l@@	O	-1	1423336
s	O	-1	1423336
the	O	-1	1423336
motor	O	-1	1423336
effects	O	-1	1423336
in	O	-1	1423336
f@@	O	-1	1423336
l@@	O	-1	1423336
uc@@	O	-1	1423336
tu@@	O	-1	1423336
ating	O	-1	1423336
patients.	O	-1	1423336
The	O	-1	1423336
hypoten@@	B-Disease	D007022	1423336
sive	I-Disease	-1	1423336
effect	O	-1	1423336
appear@@	O	-1	1423336
s	O	-1	1423336
to	O	-1	1423336
be	O	-1	1423336
related	O	-1	1423336
to	O	-1	1423336
the	O	-1	1423336
higher	O	-1	1423336
baseline	O	-1	1423336
blood	O	-1	1423336
pressure	O	-1	1423336
we	O	-1	1423336
observed	O	-1	1423336
in	O	-1	1423336
f@@	O	-1	1423336
l@@	O	-1	1423336
uc@@	O	-1	1423336
tu@@	O	-1	1423336
ating	O	-1	1423336
patients	O	-1	1423336
rel@@	O	-1	1423336
ative	O	-1	1423336
to	O	-1	1423336
st@@	O	-1	1423336
able	O	-1	1423336
patients.	O	-1	1423336

S@@	B-Disease	D007177	1424076
yn@@	I-Disease	-1	1424076
drom@@	I-Disease	-1	1424076
e	I-Disease	-1	1424076
of	I-Disease	-1	1424076
in@@	I-Disease	-1	1424076
appro@@	I-Disease	-1	1424076
pri@@	I-Disease	-1	1424076
ate	I-Disease	-1	1424076
secre@@	I-Disease	-1	1424076
tion	I-Disease	-1	1424076
of	I-Disease	-1	1424076
anti@@	I-Disease	-1	1424076
di@@	I-Disease	-1	1424076
ure@@	I-Disease	-1	1424076
tic	I-Disease	-1	1424076
h@@	I-Disease	-1	1424076
orm@@	I-Disease	-1	1424076
one	I-Disease	-1	1424076
after	O	-1	1424076
infu@@	O	-1	1424076
sion@@	O	-1	1424076
al	O	-1	1424076
v@@	B-Chemical	D014750	1424076
inc@@	I-Chemical	-1	1424076
ri@@	I-Chemical	-1	1424076
st@@	I-Chemical	-1	1424076
ine	I-Chemical	-1	1424076
.	O	-1	1424076
A	O	-1	1424076
7@@	O	-1	1424076
7-@@	O	-1	1424076
year-old	O	-1	1424076
woman	O	-1	1424076
with	O	-1	1424076
ref@@	O	-1	1424076
rac@@	O	-1	1424076
t@@	O	-1	1424076
ory	O	-1	1424076
multiple	B-Disease	D009101	1424076
my@@	I-Disease	-1	1424076
e@@	I-Disease	-1	1424076
lo@@	I-Disease	-1	1424076
ma	I-Disease	-1	1424076
was	O	-1	1424076
treated	O	-1	1424076
with	O	-1	1424076
a	O	-1	1424076
4-@@	O	-1	1424076
day	O	-1	1424076
continu@@	O	-1	1424076
ous	O	-1	1424076
intravenous	O	-1	1424076
infusion	O	-1	1424076
of	O	-1	1424076
v@@	B-Chemical	D014750	1424076
inc@@	I-Chemical	-1	1424076
ri@@	I-Chemical	-1	1424076
st@@	I-Chemical	-1	1424076
ine	I-Chemical	-1	1424076
and	O	-1	1424076
dox@@	B-Chemical	D004317	1424076
orub@@	I-Chemical	-1	1424076
icin	I-Chemical	-1	1424076
and	O	-1	1424076
4	O	-1	1424076
days	O	-1	1424076
of	O	-1	1424076
oral	O	-1	1424076
de@@	B-Chemical	D003907	1424076
xameth@@	I-Chemical	-1	1424076
as@@	I-Chemical	-1	1424076
one	I-Chemical	-1	1424076
.	O	-1	1424076
N@@	O	-1	1424076
ine	O	-1	1424076
days	O	-1	1424076
after	O	-1	1424076
h@@	O	-1	1424076
er	O	-1	1424076
second	O	-1	1424076
cyc@@	O	-1	1424076
le	O	-1	1424076
sh@@	O	-1	1424076
e	O	-1	1424076
presented	O	-1	1424076
with	O	-1	1424076
le@@	B-Disease	D053609	1424076
th@@	I-Disease	-1	1424076
arg@@	I-Disease	-1	1424076
y	I-Disease	-1	1424076
and	O	-1	1424076
we@@	B-Disease	D018908	1424076
ak@@	I-Disease	-1	1424076
ness	I-Disease	-1	1424076
associated	O	-1	1424076
with	O	-1	1424076
hy@@	B-Disease	D007010	1424076
p@@	I-Disease	-1	1424076
on@@	I-Disease	-1	1424076
at@@	I-Disease	-1	1424076
re@@	I-Disease	-1	1424076
mia	I-Disease	-1	1424076
.	O	-1	1424076
E@@	O	-1	1424076
valu@@	O	-1	1424076
ation	O	-1	1424076
revealed	O	-1	1424076
the	O	-1	1424076
syndrome	B-Disease	D007177	1424076
of	I-Disease	-1	1424076
in@@	I-Disease	-1	1424076
appro@@	I-Disease	-1	1424076
pri@@	I-Disease	-1	1424076
ate	I-Disease	-1	1424076
secre@@	I-Disease	-1	1424076
tion	I-Disease	-1	1424076
of	I-Disease	-1	1424076
anti@@	I-Disease	-1	1424076
di@@	I-Disease	-1	1424076
ure@@	I-Disease	-1	1424076
tic	I-Disease	-1	1424076
h@@	I-Disease	-1	1424076
orm@@	I-Disease	-1	1424076
one	I-Disease	-1	1424076
,	O	-1	1424076
which	O	-1	1424076
was	O	-1	1424076
at@@	O	-1	1424076
tri@@	O	-1	1424076
but@@	O	-1	1424076
ed	O	-1	1424076
to	O	-1	1424076
the	O	-1	1424076
v@@	B-Chemical	D014750	1424076
inc@@	I-Chemical	-1	1424076
ri@@	I-Chemical	-1	1424076
st@@	I-Chemical	-1	1424076
ine	I-Chemical	-1	1424076
infu@@	O	-1	1424076
sion.	O	-1	1424076
After	O	-1	1424076
normal	O	-1	1424076
serum	O	-1	1424076
sodium	B-Chemical	D012964	1424076
levels	O	-1	1424076
retur@@	O	-1	1424076
ne@@	O	-1	1424076
d,	O	-1	1424076
further	O	-1	1424076
dox@@	B-Chemical	D004317	1424076
orub@@	I-Chemical	-1	1424076
icin	I-Chemical	-1	1424076
and	O	-1	1424076
de@@	B-Chemical	D003907	1424076
xameth@@	I-Chemical	-1	1424076
as@@	I-Chemical	-1	1424076
one	I-Chemical	-1	1424076
chemotherapy	O	-1	1424076
without	O	-1	1424076
v@@	B-Chemical	D014750	1424076
inc@@	I-Chemical	-1	1424076
ri@@	I-Chemical	-1	1424076
st@@	I-Chemical	-1	1424076
ine	I-Chemical	-1	1424076
did	O	-1	1424076
not	O	-1	1424076
produce	O	-1	1424076
this	O	-1	1424076
complic@@	O	-1	1424076
ation.	O	-1	1424076

H@@	B-Disease	D006333	1449452
ear@@	I-Disease	-1	1449452
t	I-Disease	-1	1449452
failure	I-Disease	-1	1449452
:	O	-1	1449452
to	O	-1	1449452
di@@	O	-1	1449452
g@@	O	-1	1449452
it@@	O	-1	1449452
al@@	O	-1	1449452
is@@	O	-1	1449452
e	O	-1	1449452
or	O	-1	1449452
not@@	O	-1	1449452
?	O	-1	1449452
The	O	-1	1449452
vie@@	O	-1	1449452
w	O	-1	1449452
again@@	O	-1	1449452
st@@	O	-1	1449452
.	O	-1	1449452
D@@	O	-1	1449452
es@@	O	-1	1449452
pit@@	O	-1	1449452
e	O	-1	1449452
exten@@	O	-1	1449452
sive	O	-1	1449452
clinical	O	-1	1449452
experi@@	O	-1	1449452
ence	O	-1	1449452
the	O	-1	1449452
role	O	-1	1449452
of	O	-1	1449452
di@@	B-Chemical	D004077	1449452
g@@	I-Chemical	-1	1449452
ox@@	I-Chemical	-1	1449452
in	I-Chemical	-1	1449452
is	O	-1	1449452
sti@@	O	-1	1449452
ll	O	-1	1449452
not	O	-1	1449452
well	O	-1	1449452
def@@	O	-1	1449452
ine@@	O	-1	1449452
d.	O	-1	1449452
In	O	-1	1449452
patients	O	-1	1449452
with	O	-1	1449452
atrial	B-Disease	D001281	1449452
fibrill@@	I-Disease	-1	1449452
ation	I-Disease	-1	1449452
di@@	B-Chemical	D004077	1449452
g@@	I-Chemical	-1	1449452
ox@@	I-Chemical	-1	1449452
in	I-Chemical	-1	1449452
is	O	-1	1449452
ben@@	O	-1	1449452
e@@	O	-1	1449452
fic@@	O	-1	1449452
ial	O	-1	1449452
for	O	-1	1449452
ventricular	O	-1	1449452
rate	O	-1	1449452
control@@	O	-1	1449452
.	O	-1	1449452
F@@	O	-1	1449452
or	O	-1	1449452
patients	O	-1	1449452
in	O	-1	1449452
s@@	O	-1	1449452
in@@	O	-1	1449452
us	O	-1	1449452
rhyth@@	O	-1	1449452
m	O	-1	1449452
and	O	-1	1449452
heart	B-Disease	D006333	1449452
failure	I-Disease	-1	1449452
the	O	-1	1449452
sit@@	O	-1	1449452
u@@	O	-1	1449452
ation	O	-1	1449452
is	O	-1	1449452
less	O	-1	1449452
clear@@	O	-1	1449452
.	O	-1	1449452
D@@	B-Chemical	D004077	1449452
ig@@	I-Chemical	-1	1449452
ox@@	I-Chemical	-1	1449452
in	I-Chemical	-1	1449452
has	O	-1	1449452
a	O	-1	1449452
n@@	O	-1	1449452
ar@@	O	-1	1449452
ro@@	O	-1	1449452
w	O	-1	1449452
therapeu@@	O	-1	1449452
tic@@	O	-1	1449452
:@@	O	-1	1449452
toxic	O	-1	1449452
rati@@	O	-1	1449452
o	O	-1	1449452
and	O	-1	1449452
concentrations	O	-1	1449452
are	O	-1	1449452
affected	O	-1	1449452
by	O	-1	1449452
a	O	-1	1449452
number	O	-1	1449452
of	O	-1	1449452
drug@@	O	-1	1449452
s.	O	-1	1449452
Al@@	O	-1	1449452
so@@	O	-1	1449452
,	O	-1	1449452
di@@	B-Chemical	D004077	1449452
g@@	I-Chemical	-1	1449452
ox@@	I-Chemical	-1	1449452
in	I-Chemical	-1	1449452
has	O	-1	1449452
un@@	O	-1	1449452
desi@@	O	-1	1449452
ra@@	O	-1	1449452
ble	O	-1	1449452
effects	O	-1	1449452
such	O	-1	1449452
as	O	-1	1449452
increas@@	O	-1	1449452
ing	O	-1	1449452
peripheral	O	-1	1449452
resist@@	O	-1	1449452
ance	O	-1	1449452
and	O	-1	1449452
myocardial	O	-1	1449452
de@@	O	-1	1449452
m@@	O	-1	1449452
and@@	O	-1	1449452
s,	O	-1	1449452
and	O	-1	1449452
ca@@	O	-1	1449452
using	O	-1	1449452
arrhyth@@	B-Disease	D001145	1449452
mi@@	I-Disease	-1	1449452
as	I-Disease	-1	1449452
.	O	-1	1449452
There	O	-1	1449452
is	O	-1	1449452
a	O	-1	1449452
pa@@	O	-1	1449452
uc@@	O	-1	1449452
ity	O	-1	1449452
of	O	-1	1449452
data	O	-1	1449452
from	O	-1	1449452
we@@	O	-1	1449452
ll@@	O	-1	1449452
-@@	O	-1	1449452
de@@	O	-1	1449452
signed	O	-1	1449452
tri@@	O	-1	1449452
al@@	O	-1	1449452
s.	O	-1	1449452
The	O	-1	1449452
tri@@	O	-1	1449452
als	O	-1	1449452
that	O	-1	1449452
are	O	-1	1449452
av@@	O	-1	1449452
ail@@	O	-1	1449452
able	O	-1	1449452
are	O	-1	1449452
gener@@	O	-1	1449452
ally	O	-1	1449452
sm@@	O	-1	1449452
all	O	-1	1449452
with	O	-1	1449452
lim@@	O	-1	1449452
it@@	O	-1	1449452
ations	O	-1	1449452
in	O	-1	1449452
desi@@	O	-1	1449452
g@@	O	-1	1449452
n	O	-1	1449452
and	O	-1	1449452
these	O	-1	1449452
show	O	-1	1449452
vari@@	O	-1	1449452
ation	O	-1	1449452
in	O	-1	1449452
patient	O	-1	1449452
ben@@	O	-1	1449452
e@@	O	-1	1449452
f@@	O	-1	1449452
it@@	O	-1	1449452
.	O	-1	1449452
M@@	O	-1	1449452
or@@	O	-1	1449452
e	O	-1	1449452
con@@	O	-1	1449452
v@@	O	-1	1449452
inc@@	O	-1	1449452
ing	O	-1	1449452
evidence	O	-1	1449452
is	O	-1	1449452
requ@@	O	-1	1449452
ired	O	-1	1449452
show@@	O	-1	1449452
ing	O	-1	1449452
that	O	-1	1449452
di@@	B-Chemical	D004077	1449452
g@@	I-Chemical	-1	1449452
ox@@	I-Chemical	-1	1449452
in	I-Chemical	-1	1449452
impro@@	O	-1	1449452
v@@	O	-1	1449452
es	O	-1	1449452
symptoms	O	-1	1449452
or	O	-1	1449452
ex@@	O	-1	1449452
er@@	O	-1	1449452
cis@@	O	-1	1449452
e	O	-1	1449452
cap@@	O	-1	1449452
ac@@	O	-1	1449452
ity.	O	-1	1449452
F@@	O	-1	1449452
ur@@	O	-1	1449452
ther@@	O	-1	1449452
mo@@	O	-1	1449452
re,	O	-1	1449452
no	O	-1	1449452
trial	O	-1	1449452
has	O	-1	1449452
had	O	-1	1449452
suffici@@	O	-1	1449452
ent	O	-1	1449452
po@@	O	-1	1449452
w@@	O	-1	1449452
er	O	-1	1449452
to	O	-1	1449452
evalu@@	O	-1	1449452
ate	O	-1	1449452
mor@@	O	-1	1449452
t@@	O	-1	1449452
al@@	O	-1	1449452
ity.	O	-1	1449452
P@@	O	-1	1449452
o@@	O	-1	1449452
ol@@	O	-1	1449452
ed	O	-1	1449452
analysis	O	-1	1449452
of	O	-1	1449452
the	O	-1	1449452
effects	O	-1	1449452
of	O	-1	1449452
other	O	-1	1449452
in@@	O	-1	1449452
ot@@	O	-1	1449452
ro@@	O	-1	1449452
p@@	O	-1	1449452
ic	O	-1	1449452
drugs	O	-1	1449452
show@@	O	-1	1449452
s	O	-1	1449452
an	O	-1	1449452
ex@@	O	-1	1449452
cess	O	-1	1449452
mor@@	O	-1	1449452
t@@	O	-1	1449452
ality	O	-1	1449452
and	O	-1	1449452
there	O	-1	1449452
is	O	-1	1449452
a	O	-1	1449452
possib@@	O	-1	1449452
ility	O	-1	1449452
that	O	-1	1449452
di@@	B-Chemical	D004077	1449452
g@@	I-Chemical	-1	1449452
ox@@	I-Chemical	-1	1449452
in	I-Chemical	-1	1449452
may	O	-1	1449452
increase	O	-1	1449452
mor@@	O	-1	1449452
t@@	O	-1	1449452
ality	O	-1	1449452
after	O	-1	1449452
myocardial	B-Disease	D009203	1449452
infarction	I-Disease	-1	1449452
(	O	-1	1449452
M@@	B-Disease	D009203	1449452
I	I-Disease	-1	1449452
).	O	-1	1449452
An@@	B-Chemical	D000809	1449452
gi@@	I-Chemical	-1	1449452
otens@@	I-Chemical	-1	1449452
in	I-Chemical	-1	1449452
-@@	O	-1	1449452
conver@@	O	-1	1449452
ting	O	-1	1449452
enzyme	O	-1	1449452
(@@	O	-1	1449452
AC@@	O	-1	1449452
E@@	O	-1	1449452
)	O	-1	1449452
inhibitors	O	-1	1449452
should	O	-1	1449452
be	O	-1	1449452
used	O	-1	1449452
first	O	-1	1449452
as	O	-1	1449452
they	O	-1	1449452
are	O	-1	1449452
saf@@	O	-1	1449452
er,	O	-1	1449452
d@@	O	-1	1449452
o	O	-1	1449452
not	O	-1	1449452
requ@@	O	-1	1449452
ir@@	O	-1	1449452
e	O	-1	1449452
blood	O	-1	1449452
level	O	-1	1449452
monit@@	O	-1	1449452
or@@	O	-1	1449452
ing,	O	-1	1449452
mo@@	O	-1	1449452
di@@	O	-1	1449452
f@@	O	-1	1449452
y	O	-1	1449452
progres@@	O	-1	1449452
sion	O	-1	1449452
of	O	-1	1449452
diseas@@	O	-1	1449452
e,	O	-1	1449452
re@@	O	-1	1449452
li@@	O	-1	1449452
e@@	O	-1	1449452
ve	O	-1	1449452
symptom@@	O	-1	1449452
s,	O	-1	1449452
impro@@	O	-1	1449452
ve	O	-1	1449452
ex@@	O	-1	1449452
er@@	O	-1	1449452
cis@@	O	-1	1449452
e	O	-1	1449452
toler@@	O	-1	1449452
ance	O	-1	1449452
and	O	-1	1449452
re@@	O	-1	1449452
duce	O	-1	1449452
mor@@	O	-1	1449452
t@@	O	-1	1449452
al@@	O	-1	1449452
ity.	O	-1	1449452
C@@	O	-1	1449452
au@@	O	-1	1449452
tion	O	-1	1449452
should	O	-1	1449452
be	O	-1	1449452
ex@@	O	-1	1449452
er@@	O	-1	1449452
cis@@	O	-1	1449452
ed	O	-1	1449452
in	O	-1	1449452
using	O	-1	1449452
di@@	B-Chemical	D004077	1449452
g@@	I-Chemical	-1	1449452
ox@@	I-Chemical	-1	1449452
in	I-Chemical	-1	1449452
un@@	O	-1	1449452
ti@@	O	-1	1449452
l	O	-1	1449452
larg@@	O	-1	1449452
e	O	-1	1449452
mor@@	O	-1	1449452
t@@	O	-1	1449452
ality	O	-1	1449452
tri@@	O	-1	1449452
als	O	-1	1449452
are	O	-1	1449452
comple@@	O	-1	1449452
ted	O	-1	1449452
show@@	O	-1	1449452
ing	O	-1	1449452
either	O	-1	1449452
ben@@	O	-1	1449452
e@@	O	-1	1449452
fi@@	O	-1	1449452
t	O	-1	1449452
or	O	-1	1449452
h@@	O	-1	1449452
ar@@	O	-1	1449452
m.	O	-1	1449452
U@@	O	-1	1449452
n@@	O	-1	1449452
ti@@	O	-1	1449452
l	O	-1	1449452
then	O	-1	1449452
di@@	B-Chemical	D004077	1449452
g@@	I-Chemical	-1	1449452
ox@@	I-Chemical	-1	1449452
in	I-Chemical	-1	1449452
should	O	-1	1449452
be	O	-1	1449452
considered	O	-1	1449452
a	O	-1	1449452
thir@@	O	-1	1449452
d-@@	O	-1	1449452
line	O	-1	1449452
therapy.	O	-1	1449452

In@@	O	-1	1522360
tra@@	O	-1	1522360
vascular	O	-1	1522360
hemoly@@	B-Disease	D006461	1522360
sis	I-Disease	-1	1522360
and	O	-1	1522360
acute	B-Disease	D058186	1522360
renal	I-Disease	-1	1522360
failure	I-Disease	-1	1522360
following	O	-1	1522360
inter@@	O	-1	1522360
mit@@	O	-1	1522360
t@@	O	-1	1522360
ent	O	-1	1522360
ri@@	B-Chemical	D012293	1522360
f@@	I-Chemical	-1	1522360
amp@@	I-Chemical	-1	1522360
in	I-Chemical	-1	1522360
therapy.	O	-1	1522360
R@@	B-Disease	D051437	1522360
en@@	I-Disease	-1	1522360
al	I-Disease	-1	1522360
failure	I-Disease	-1	1522360
is	O	-1	1522360
a	O	-1	1522360
r@@	O	-1	1522360
are	O	-1	1522360
complication	O	-1	1522360
associated	O	-1	1522360
with	O	-1	1522360
the	O	-1	1522360
use	O	-1	1522360
of	O	-1	1522360
ri@@	B-Chemical	D012293	1522360
f@@	I-Chemical	-1	1522360
amp@@	I-Chemical	-1	1522360
in	I-Chemical	-1	1522360
.	O	-1	1522360
In@@	O	-1	1522360
tra@@	O	-1	1522360
vascular	O	-1	1522360
hemoly@@	B-Disease	D006461	1522360
sis	I-Disease	-1	1522360
lead@@	O	-1	1522360
ing	O	-1	1522360
to	O	-1	1522360
acute	B-Disease	D058186	1522360
renal	I-Disease	-1	1522360
failure	I-Disease	-1	1522360
following	O	-1	1522360
ri@@	B-Chemical	D012293	1522360
f@@	I-Chemical	-1	1522360
amp@@	I-Chemical	-1	1522360
in	I-Chemical	-1	1522360
therapy	O	-1	1522360
is	O	-1	1522360
ex@@	O	-1	1522360
tre@@	O	-1	1522360
me@@	O	-1	1522360
ly	O	-1	1522360
ra@@	O	-1	1522360
re.	O	-1	1522360
Two	O	-1	1522360
patients	O	-1	1522360
with	O	-1	1522360
le@@	B-Disease	D007918	1522360
pro@@	I-Disease	-1	1522360
sy	I-Disease	-1	1522360
who	O	-1	1522360
developed	O	-1	1522360
hemoly@@	B-Disease	D006461	1522360
sis	I-Disease	-1	1522360
and	O	-1	1522360
acute	B-Disease	D058186	1522360
renal	I-Disease	-1	1522360
failure	I-Disease	-1	1522360
following	O	-1	1522360
ri@@	B-Chemical	D012293	1522360
f@@	I-Chemical	-1	1522360
amp@@	I-Chemical	-1	1522360
in	I-Chemical	-1	1522360
are	O	-1	1522360
repor@@	O	-1	1522360
ted.	O	-1	1522360

Z@@	B-Chemical	D015215	1556529
id@@	I-Chemical	-1	1556529
o@@	I-Chemical	-1	1556529
vud@@	I-Chemical	-1	1556529
ine	I-Chemical	-1	1556529
-induced	O	-1	1556529
hepatitis	B-Disease	D056486	1556529
.	O	-1	1556529
A	O	-1	1556529
case	O	-1	1556529
of	O	-1	1556529
acute	O	-1	1556529
hepatitis	B-Disease	D056486	1556529
induced	O	-1	1556529
by	O	-1	1556529
z@@	B-Chemical	D015215	1556529
id@@	I-Chemical	-1	1556529
o@@	I-Chemical	-1	1556529
vud@@	I-Chemical	-1	1556529
ine	I-Chemical	-1	1556529
in	O	-1	1556529
a	O	-1	1556529
3@@	O	-1	1556529
8@@	O	-1	1556529
-@@	O	-1	1556529
year-old	O	-1	1556529
patient	O	-1	1556529
with	O	-1	1556529
A@@	B-Disease	D000163	1556529
I@@	I-Disease	-1	1556529
D@@	I-Disease	-1	1556529
S	I-Disease	-1	1556529
is	O	-1	1556529
present@@	O	-1	1556529
ed.	O	-1	1556529
The	O	-1	1556529
mechanism	O	-1	1556529
whe@@	O	-1	1556529
re@@	O	-1	1556529
by	O	-1	1556529
the	O	-1	1556529
hepatitis	B-Disease	D056486	1556529
was	O	-1	1556529
induced	O	-1	1556529
is	O	-1	1556529
not	O	-1	1556529
know@@	O	-1	1556529
n@@	O	-1	1556529
.	O	-1	1556529
However,	O	-1	1556529
the	O	-1	1556529
patient	O	-1	1556529
toler@@	O	-1	1556529
ated	O	-1	1556529
well	O	-1	1556529
an	O	-1	1556529
al@@	O	-1	1556529
tern@@	O	-1	1556529
ative	O	-1	1556529
re@@	O	-1	1556529
verse	O	-1	1556529
trans@@	O	-1	1556529
cri@@	O	-1	1556529
pt@@	O	-1	1556529
ase	O	-1	1556529
inhibitor@@	O	-1	1556529
,	O	-1	1556529
2@@	B-Chemical	D016049	1556529
'@@	I-Chemical	-1	1556529
3@@	I-Chemical	-1	1556529
'	I-Chemical	-1	1556529
di@@	I-Chemical	-1	1556529
de@@	I-Chemical	-1	1556529
oxy@@	I-Chemical	-1	1556529
in@@	I-Chemical	-1	1556529
os@@	I-Chemical	-1	1556529
ine	I-Chemical	-1	1556529
.	O	-1	1556529
P@@	O	-1	1556529
hy@@	O	-1	1556529
si@@	O	-1	1556529
ci@@	O	-1	1556529
ans	O	-1	1556529
car@@	O	-1	1556529
ing	O	-1	1556529
for	O	-1	1556529
patients	O	-1	1556529
with	O	-1	1556529
A@@	B-Disease	D000163	1556529
I@@	I-Disease	-1	1556529
D@@	I-Disease	-1	1556529
S	I-Disease	-1	1556529
should	O	-1	1556529
be	O	-1	1556529
aw@@	O	-1	1556529
are	O	-1	1556529
of	O	-1	1556529
this	O	-1	1556529
hi@@	O	-1	1556529
ther@@	O	-1	1556529
to	O	-1	1556529
ra@@	O	-1	1556529
re@@	O	-1	1556529
ly	O	-1	1556529
reported	O	-1	1556529
complic@@	O	-1	1556529
ation.	O	-1	1556529

Th@@	B-Disease	D020758	1563460
or@@	I-Disease	-1	1563460
ac@@	I-Disease	-1	1563460
ic	I-Disease	-1	1563460
hemat@@	I-Disease	-1	1563460
om@@	I-Disease	-1	1563460
ye@@	I-Disease	-1	1563460
li@@	I-Disease	-1	1563460
a	I-Disease	-1	1563460
secondary	O	-1	1563460
to	O	-1	1563460
co@@	B-Chemical	D014859	1563460
um@@	I-Chemical	-1	1563460
ad@@	I-Chemical	-1	1563460
in	I-Chemical	-1	1563460
anti@@	O	-1	1563460
co@@	O	-1	1563460
ag@@	O	-1	1563460
ul@@	O	-1	1563460
ant	O	-1	1563460
therap@@	O	-1	1563460
y@@	O	-1	1563460
:	O	-1	1563460
a	O	-1	1563460
case	O	-1	1563460
repor@@	O	-1	1563460
t.	O	-1	1563460
A	O	-1	1563460
case	O	-1	1563460
of	O	-1	1563460
th@@	B-Disease	D020758	1563460
or@@	I-Disease	-1	1563460
ac@@	I-Disease	-1	1563460
ic	I-Disease	-1	1563460
hemat@@	I-Disease	-1	1563460
om@@	I-Disease	-1	1563460
ye@@	I-Disease	-1	1563460
li@@	I-Disease	-1	1563460
a	I-Disease	-1	1563460
secondary	O	-1	1563460
to	O	-1	1563460
anti@@	O	-1	1563460
co@@	O	-1	1563460
ag@@	O	-1	1563460
ul@@	O	-1	1563460
ant	O	-1	1563460
therapy	O	-1	1563460
is	O	-1	1563460
present@@	O	-1	1563460
ed.	O	-1	1563460
Clin@@	O	-1	1563460
ical	O	-1	1563460
feat@@	O	-1	1563460
ures@@	O	-1	1563460
,	O	-1	1563460
similar	O	-1	1563460
to	O	-1	1563460
2	O	-1	1563460
other	O	-1	1563460
previously	O	-1	1563460
reported	O	-1	1563460
cas@@	O	-1	1563460
es,	O	-1	1563460
are	O	-1	1563460
discus@@	O	-1	1563460
sed.	O	-1	1563460
A	O	-1	1563460
high	O	-1	1563460
in@@	O	-1	1563460
de@@	O	-1	1563460
x	O	-1	1563460
of	O	-1	1563460
sus@@	O	-1	1563460
p@@	O	-1	1563460
ici@@	O	-1	1563460
on	O	-1	1563460
may	O	-1	1563460
le@@	O	-1	1563460
ad	O	-1	1563460
to	O	-1	1563460
a	O	-1	1563460
qu@@	O	-1	1563460
ic@@	O	-1	1563460
k	O	-1	1563460
diagnos@@	O	-1	1563460
tic	O	-1	1563460
proce@@	O	-1	1563460
d@@	O	-1	1563460
ure	O	-1	1563460
and	O	-1	1563460
suc@@	O	-1	1563460
cess@@	O	-1	1563460
ful	O	-1	1563460
dec@@	O	-1	1563460
om@@	O	-1	1563460
pressive	O	-1	1563460
surger@@	O	-1	1563460
y.	O	-1	1563460

M@@	B-Disease	D001714	1564030
an@@	I-Disease	-1	1564030
ia	I-Disease	-1	1564030
associated	O	-1	1564030
with	O	-1	1564030
flu@@	B-Chemical	D005473	1564030
ox@@	I-Chemical	-1	1564030
et@@	I-Chemical	-1	1564030
ine	I-Chemical	-1	1564030
treatment	O	-1	1564030
in	O	-1	1564030
ad@@	O	-1	1564030
ol@@	O	-1	1564030
es@@	O	-1	1564030
c@@	O	-1	1564030
ent@@	O	-1	1564030
s.	O	-1	1564030
F@@	B-Chemical	D005473	1564030
lu@@	I-Chemical	-1	1564030
ox@@	I-Chemical	-1	1564030
et@@	I-Chemical	-1	1564030
ine	I-Chemical	-1	1564030
,	O	-1	1564030
a	O	-1	1564030
selective	O	-1	1564030
seroton@@	B-Chemical	D012701	1564030
in	I-Chemical	-1	1564030
re@@	O	-1	1564030
u@@	O	-1	1564030
pt@@	O	-1	1564030
ake	O	-1	1564030
inhibitor@@	O	-1	1564030
,	O	-1	1564030
is	O	-1	1564030
g@@	O	-1	1564030
aining	O	-1	1564030
increased	O	-1	1564030
ac@@	O	-1	1564030
ce@@	O	-1	1564030
pt@@	O	-1	1564030
ance	O	-1	1564030
in	O	-1	1564030
the	O	-1	1564030
treatment	O	-1	1564030
of	O	-1	1564030
ad@@	O	-1	1564030
ol@@	O	-1	1564030
es@@	O	-1	1564030
c@@	O	-1	1564030
ent	O	-1	1564030
de@@	B-Disease	D003866	1564030
pression	I-Disease	-1	1564030
.	O	-1	1564030
G@@	O	-1	1564030
en@@	O	-1	1564030
er@@	O	-1	1564030
ally	O	-1	1564030
saf@@	O	-1	1564030
e	O	-1	1564030
and	O	-1	1564030
well	O	-1	1564030
toler@@	O	-1	1564030
ated	O	-1	1564030
by	O	-1	1564030
ad@@	O	-1	1564030
ult@@	O	-1	1564030
s,	O	-1	1564030
flu@@	B-Chemical	D005473	1564030
ox@@	I-Chemical	-1	1564030
et@@	I-Chemical	-1	1564030
ine	I-Chemical	-1	1564030
has	O	-1	1564030
been	O	-1	1564030
reported	O	-1	1564030
to	O	-1	1564030
induce	O	-1	1564030
man@@	B-Disease	D001714	1564030
ia	I-Disease	-1	1564030
.	O	-1	1564030
The	O	-1	1564030
cases	O	-1	1564030
of	O	-1	1564030
five	O	-1	1564030
depress@@	B-Disease	D003866	1564030
ed	I-Disease	-1	1564030
ad@@	O	-1	1564030
ol@@	O	-1	1564030
es@@	O	-1	1564030
c@@	O	-1	1564030
ent@@	O	-1	1564030
s,	O	-1	1564030
14@@	O	-1	1564030
-1@@	O	-1	1564030
6	O	-1	1564030
years	O	-1	1564030
of	O	-1	1564030
age,	O	-1	1564030
who	O	-1	1564030
developed	O	-1	1564030
man@@	B-Disease	D001714	1564030
ia	I-Disease	-1	1564030
during	O	-1	1564030
pharmac@@	O	-1	1564030
o@@	O	-1	1564030
therapy	O	-1	1564030
with	O	-1	1564030
flu@@	B-Chemical	D005473	1564030
ox@@	I-Chemical	-1	1564030
et@@	I-Chemical	-1	1564030
ine	I-Chemical	-1	1564030
,	O	-1	1564030
are	O	-1	1564030
reported	O	-1	1564030
he@@	O	-1	1564030
re.	O	-1	1564030
A@@	O	-1	1564030
p@@	O	-1	1564030
pa@@	O	-1	1564030
rent	O	-1	1564030
risk	O	-1	1564030
factors	O	-1	1564030
for	O	-1	1564030
the	O	-1	1564030
development	O	-1	1564030
of	O	-1	1564030
man@@	B-Disease	D001714	1564030
ia	I-Disease	-1	1564030
or	O	-1	1564030
hypo@@	B-Disease	D001714	1564030
man@@	I-Disease	-1	1564030
ia	I-Disease	-1	1564030
during	O	-1	1564030
flu@@	B-Chemical	D005473	1564030
ox@@	I-Chemical	-1	1564030
et@@	I-Chemical	-1	1564030
ine	I-Chemical	-1	1564030
pharmac@@	O	-1	1564030
o@@	O	-1	1564030
therapy	O	-1	1564030
in	O	-1	1564030
this	O	-1	1564030
po@@	O	-1	1564030
p@@	O	-1	1564030
ulation	O	-1	1564030
were	O	-1	1564030
the	O	-1	1564030
combination	O	-1	1564030
of	O	-1	1564030
atten@@	B-Disease	D001289	1564030
tion@@	I-Disease	-1	1564030
-@@	I-Disease	-1	1564030
defic@@	I-Disease	-1	1564030
it	I-Disease	-1	1564030
hyperactivity	I-Disease	-1	1564030
disor@@	I-Disease	-1	1564030
der	I-Disease	-1	1564030
and	O	-1	1564030
aff@@	O	-1	1564030
ective	O	-1	1564030
in@@	O	-1	1564030
st@@	O	-1	1564030
abil@@	O	-1	1564030
it@@	O	-1	1564030
y@@	O	-1	1564030
;	O	-1	1564030
major	O	-1	1564030
de@@	B-Disease	D003866	1564030
pression	I-Disease	-1	1564030
with	O	-1	1564030
psycho@@	B-Disease	D011618	1564030
tic	I-Disease	-1	1564030
feat@@	O	-1	1564030
ures@@	O	-1	1564030
;	O	-1	1564030
a	O	-1	1564030
f@@	O	-1	1564030
ami@@	O	-1	1564030
ly	O	-1	1564030
hist@@	O	-1	1564030
ory	O	-1	1564030
of	O	-1	1564030
aff@@	B-Disease	D019964	1564030
ective	I-Disease	-1	1564030
disor@@	I-Disease	-1	1564030
der	I-Disease	-1	1564030
,	O	-1	1564030
es@@	O	-1	1564030
p@@	O	-1	1564030
ec@@	O	-1	1564030
i@@	O	-1	1564030
ally	O	-1	1564030
b@@	B-Disease	D001714	1564030
ip@@	I-Disease	-1	1564030
ol@@	I-Disease	-1	1564030
ar	I-Disease	-1	1564030
disor@@	I-Disease	-1	1564030
der	I-Disease	-1	1564030
;	O	-1	1564030
and	O	-1	1564030
a	O	-1	1564030
diagnosis	O	-1	1564030
of	O	-1	1564030
b@@	B-Disease	D001714	1564030
ip@@	I-Disease	-1	1564030
ol@@	I-Disease	-1	1564030
ar	I-Disease	-1	1564030
disor@@	I-Disease	-1	1564030
der	I-Disease	-1	1564030
.	O	-1	1564030
F@@	O	-1	1564030
urther	O	-1	1564030
study	O	-1	1564030
is	O	-1	1564030
ne@@	O	-1	1564030
ed@@	O	-1	1564030
ed	O	-1	1564030
to	O	-1	1564030
determine	O	-1	1564030
the	O	-1	1564030
op@@	O	-1	1564030
tim@@	O	-1	1564030
al	O	-1	1564030
dos@@	O	-1	1564030
age	O	-1	1564030
and	O	-1	1564030
to	O	-1	1564030
identi@@	O	-1	1564030
f@@	O	-1	1564030
y	O	-1	1564030
risk	O	-1	1564030
factors	O	-1	1564030
that	O	-1	1564030
increase	O	-1	1564030
individ@@	O	-1	1564030
ual	O	-1	1564030
vul@@	O	-1	1564030
ner@@	O	-1	1564030
ability	O	-1	1564030
to	O	-1	1564030
flu@@	B-Chemical	D005473	1564030
ox@@	I-Chemical	-1	1564030
et@@	I-Chemical	-1	1564030
ine	I-Chemical	-1	1564030
induced	O	-1	1564030
man@@	B-Disease	D001714	1564030
ia	I-Disease	-1	1564030
in	O	-1	1564030
ad@@	O	-1	1564030
ol@@	O	-1	1564030
es@@	O	-1	1564030
c@@	O	-1	1564030
ent@@	O	-1	1564030
s.	O	-1	1564030

G@@	B-Chemical	D015248	1615846
em@@	I-Chemical	-1	1615846
fib@@	I-Chemical	-1	1615846
ro@@	I-Chemical	-1	1615846
z@@	I-Chemical	-1	1615846
il	I-Chemical	-1	1615846
-	O	-1	1615846
lo@@	B-Chemical	D008148	1615846
vastatin	I-Chemical	-1	1615846
therapy	O	-1	1615846
for	O	-1	1615846
prim@@	O	-1	1615846
ary	O	-1	1615846
hyper@@	B-Disease	D006951	1615846
li@@	I-Disease	-1	1615846
po@@	I-Disease	-1	1615846
prote@@	I-Disease	-1	1615846
ine@@	I-Disease	-1	1615846
mi@@	I-Disease	-1	1615846
as	I-Disease	-1	1615846
.	O	-1	1615846
The	O	-1	1615846
specific	O	-1	1615846
a@@	O	-1	1615846
im	O	-1	1615846
of	O	-1	1615846
this	O	-1	1615846
ret@@	O	-1	1615846
ro@@	O	-1	1615846
sp@@	O	-1	1615846
ecti@@	O	-1	1615846
ve,	O	-1	1615846
observ@@	O	-1	1615846
ation@@	O	-1	1615846
al	O	-1	1615846
study	O	-1	1615846
was	O	-1	1615846
to	O	-1	1615846
ass@@	O	-1	1615846
ess	O	-1	1615846
safety	O	-1	1615846
and	O	-1	1615846
efficacy	O	-1	1615846
of	O	-1	1615846
long-term	O	-1	1615846
(2@@	O	-1	1615846
1	O	-1	1615846
month@@	O	-1	1615846
s/@@	O	-1	1615846
patient@@	O	-1	1615846
),	O	-1	1615846
o@@	O	-1	1615846
pen@@	O	-1	1615846
-@@	O	-1	1615846
l@@	O	-1	1615846
a@@	O	-1	1615846
be@@	O	-1	1615846
l@@	O	-1	1615846
,	O	-1	1615846
g@@	B-Chemical	D015248	1615846
em@@	I-Chemical	-1	1615846
fib@@	I-Chemical	-1	1615846
ro@@	I-Chemical	-1	1615846
z@@	I-Chemical	-1	1615846
il	I-Chemical	-1	1615846
-	O	-1	1615846
lo@@	B-Chemical	D008148	1615846
vastatin	I-Chemical	-1	1615846
treatment	O	-1	1615846
in	O	-1	1615846
8@@	O	-1	1615846
0	O	-1	1615846
patients	O	-1	1615846
with	O	-1	1615846
prim@@	O	-1	1615846
ary	O	-1	1615846
mi@@	O	-1	1615846
x@@	O	-1	1615846
ed	O	-1	1615846
hyper@@	B-Disease	D006949	1615846
li@@	I-Disease	-1	1615846
pi@@	I-Disease	-1	1615846
de@@	I-Disease	-1	1615846
mia	I-Disease	-1	1615846
(6@@	O	-1	1615846
8@@	O	-1	1615846
%	O	-1	1615846
of	O	-1	1615846
whom	O	-1	1615846
had	O	-1	1615846
a@@	B-Disease	D002340	1615846
therosclero@@	I-Disease	-1	1615846
tic	I-Disease	-1	1615846
vascular	I-Disease	-1	1615846
disease	I-Disease	-1	1615846
).	O	-1	1615846
B@@	O	-1	1615846
ecause	O	-1	1615846
ide@@	O	-1	1615846
al	O	-1	1615846
li@@	O	-1	1615846
pid	O	-1	1615846
t@@	O	-1	1615846
arg@@	O	-1	1615846
et@@	O	-1	1615846
s	O	-1	1615846
were	O	-1	1615846
not	O	-1	1615846
reac@@	O	-1	1615846
h@@	O	-1	1615846
ed	O	-1	1615846
(@@	O	-1	1615846
low@@	O	-1	1615846
-@@	O	-1	1615846
d@@	O	-1	1615846
ensity	O	-1	1615846
li@@	O	-1	1615846
po@@	O	-1	1615846
protein	O	-1	1615846
(@@	O	-1	1615846
L@@	O	-1	1615846
D@@	O	-1	1615846
L@@	O	-1	1615846
)	O	-1	1615846
cholester@@	B-Chemical	D002784	1615846
ol	I-Chemical	-1	1615846
less	O	-1	1615846
than	O	-1	1615846
1@@	O	-1	1615846
30	O	-1	1615846
mg/d@@	O	-1	1615846
l@@	O	-1	1615846
,	O	-1	1615846
high-@@	O	-1	1615846
d@@	O	-1	1615846
ensity	O	-1	1615846
li@@	O	-1	1615846
po@@	O	-1	1615846
protein	O	-1	1615846
(@@	O	-1	1615846
H@@	O	-1	1615846
D@@	O	-1	1615846
L@@	O	-1	1615846
)	O	-1	1615846
cholester@@	B-Chemical	D002784	1615846
ol	I-Chemical	-1	1615846
greater	O	-1	1615846
than	O	-1	1615846
3@@	O	-1	1615846
5	O	-1	1615846
mg/d@@	O	-1	1615846
l@@	O	-1	1615846
,	O	-1	1615846
or	O	-1	1615846
total	O	-1	1615846
cholester@@	B-Chemical	D002784	1615846
ol	I-Chemical	-1	1615846
/@@	O	-1	1615846
H@@	O	-1	1615846
D@@	O	-1	1615846
L	O	-1	1615846
cholester@@	B-Chemical	D002784	1615846
ol	I-Chemical	-1	1615846
less	O	-1	1615846
than	O	-1	1615846
4.@@	O	-1	1615846
5	O	-1	1615846
mg/d@@	O	-1	1615846
l@@	O	-1	1615846
)	O	-1	1615846
with	O	-1	1615846
diet	O	-1	1615846
plus	O	-1	1615846
a	O	-1	1615846
single	O	-1	1615846
drug@@	O	-1	1615846
,	O	-1	1615846
g@@	B-Chemical	D015248	1615846
em@@	I-Chemical	-1	1615846
fib@@	I-Chemical	-1	1615846
ro@@	I-Chemical	-1	1615846
z@@	I-Chemical	-1	1615846
il	I-Chemical	-1	1615846
(1@@	O	-1	1615846
.@@	O	-1	1615846
2	O	-1	1615846
g/@@	O	-1	1615846
day@@	O	-1	1615846
)@@	O	-1	1615846
-	O	-1	1615846
lo@@	B-Chemical	D008148	1615846
vastatin	I-Chemical	-1	1615846
(@@	O	-1	1615846
prim@@	O	-1	1615846
ari@@	O	-1	1615846
ly	O	-1	1615846
20	O	-1	1615846
or	O	-1	1615846
40	O	-1	1615846
mg@@	O	-1	1615846
)	O	-1	1615846
treatment	O	-1	1615846
was	O	-1	1615846
gi@@	O	-1	1615846
ven@@	O	-1	1615846
.	O	-1	1615846
F@@	O	-1	1615846
ol@@	O	-1	1615846
low@@	O	-1	1615846
-@@	O	-1	1615846
up	O	-1	1615846
v@@	O	-1	1615846
is@@	O	-1	1615846
its	O	-1	1615846
were	O	-1	1615846
sch@@	O	-1	1615846
ed@@	O	-1	1615846
ul@@	O	-1	1615846
ed	O	-1	1615846
with	O	-1	1615846
2-@@	O	-1	1615846
drug	O	-1	1615846
therapy	O	-1	1615846
every	O	-1	1615846
6	O	-1	1615846
to	O	-1	1615846
8	O	-1	1615846
week@@	O	-1	1615846
s,	O	-1	1615846
an	O	-1	1615846
average	O	-1	1615846
of	O	-1	1615846
1@@	O	-1	1615846
0.@@	O	-1	1615846
3	O	-1	1615846
v@@	O	-1	1615846
is@@	O	-1	1615846
its	O	-1	1615846
per	O	-1	1615846
patient@@	O	-1	1615846
,	O	-1	1615846
with	O	-1	1615846
7@@	O	-1	1615846
4@@	O	-1	1615846
1	O	-1	1615846
b@@	O	-1	1615846
at@@	O	-1	1615846
ter@@	O	-1	1615846
i@@	O	-1	1615846
es	O	-1	1615846
of	O	-1	1615846
6	O	-1	1615846
liver	O	-1	1615846
function	O	-1	1615846
tests	O	-1	1615846
and	O	-1	1615846
7@@	O	-1	1615846
14	O	-1	1615846
creat@@	B-Chemical	D003401	1615846
ine	I-Chemical	-1	1615846
phosph@@	O	-1	1615846
o@@	O	-1	1615846
kin@@	O	-1	1615846
ase	O	-1	1615846
levels	O	-1	1615846
meas@@	O	-1	1615846
ure@@	O	-1	1615846
d.	O	-1	1615846
On@@	O	-1	1615846
ly	O	-1	1615846
1	O	-1	1615846
of	O	-1	1615846
the	O	-1	1615846
4@@	O	-1	1615846
,@@	O	-1	1615846
4@@	O	-1	1615846
4@@	O	-1	1615846
6	O	-1	1615846
liver	O	-1	1615846
function	O	-1	1615846
tests	O	-1	1615846
(@@	O	-1	1615846
0.0@@	O	-1	1615846
2@@	O	-1	1615846
%),	O	-1	1615846
a	O	-1	1615846
gam@@	O	-1	1615846
ma	O	-1	1615846
glutam@@	O	-1	1615846
yl	O	-1	1615846
trans@@	O	-1	1615846
fer@@	O	-1	1615846
ase,	O	-1	1615846
was	O	-1	1615846
greater	O	-1	1615846
than	O	-1	1615846
or	O	-1	1615846
equ@@	O	-1	1615846
al	O	-1	1615846
to	O	-1	1615846
3	O	-1	1615846
times	O	-1	1615846
the	O	-1	1615846
up@@	O	-1	1615846
per	O	-1	1615846
normal	O	-1	1615846
lim@@	O	-1	1615846
it@@	O	-1	1615846
.	O	-1	1615846
Of	O	-1	1615846
the	O	-1	1615846
7@@	O	-1	1615846
14	O	-1	1615846
creat@@	B-Chemical	D003401	1615846
ine	I-Chemical	-1	1615846
phosph@@	O	-1	1615846
o@@	O	-1	1615846
kin@@	O	-1	1615846
ase	O	-1	1615846
level@@	O	-1	1615846
s,	O	-1	1615846
9@@	O	-1	1615846
%	O	-1	1615846
were	O	-1	1615846
high@@	O	-1	1615846
;	O	-1	1615846
only	O	-1	1615846
1	O	-1	1615846
(0.@@	O	-1	1615846
1@@	O	-1	1615846
%)	O	-1	1615846
was	O	-1	1615846
greater	O	-1	1615846
than	O	-1	1615846
or	O	-1	1615846
equ@@	O	-1	1615846
al	O	-1	1615846
to	O	-1	1615846
3	O	-1	1615846
times	O	-1	1615846
the	O	-1	1615846
up@@	O	-1	1615846
per	O	-1	1615846
normal	O	-1	1615846
lim@@	O	-1	1615846
it@@	O	-1	1615846
.	O	-1	1615846
W@@	O	-1	1615846
it@@	O	-1	1615846
h	O	-1	1615846
2-@@	O	-1	1615846
drug	O	-1	1615846
therapy,	O	-1	1615846
mean	O	-1	1615846
total	O	-1	1615846
cholester@@	B-Chemical	D002784	1615846
ol	I-Chemical	-1	1615846
decreased	O	-1	1615846
2@@	O	-1	1615846
2@@	O	-1	1615846
%	O	-1	1615846
from	O	-1	1615846
25@@	O	-1	1615846
5	O	-1	1615846
to	O	-1	1615846
2@@	O	-1	1615846
00	O	-1	1615846
mg/d@@	O	-1	1615846
l@@	O	-1	1615846
,	O	-1	1615846
tri@@	B-Chemical	D014280	1615846
glycer@@	I-Chemical	-1	1615846
ide	I-Chemical	-1	1615846
levels	O	-1	1615846
decreased	O	-1	1615846
3@@	O	-1	1615846
5%	O	-1	1615846
from	O	-1	1615846
2@@	O	-1	1615846
3@@	O	-1	1615846
6	O	-1	1615846
to	O	-1	1615846
1@@	O	-1	1615846
5@@	O	-1	1615846
4	O	-1	1615846
mg/d@@	O	-1	1615846
l@@	O	-1	1615846
,	O	-1	1615846
L@@	O	-1	1615846
D@@	O	-1	1615846
L	O	-1	1615846
cholester@@	B-Chemical	D002784	1615846
ol	I-Chemical	-1	1615846
decreased	O	-1	1615846
2@@	O	-1	1615846
6%	O	-1	1615846
from	O	-1	1615846
17@@	O	-1	1615846
6	O	-1	1615846
to	O	-1	1615846
13@@	O	-1	1615846
1	O	-1	1615846
mg/d@@	O	-1	1615846
l@@	O	-1	1615846
,	O	-1	1615846
and	O	-1	1615846
the	O	-1	1615846
total	O	-1	1615846
cholester@@	B-Chemical	D002784	1615846
ol	I-Chemical	-1	1615846
/@@	O	-1	1615846
H@@	O	-1	1615846
D@@	O	-1	1615846
L	O	-1	1615846
cholester@@	B-Chemical	D002784	1615846
ol	I-Chemical	-1	1615846
rati@@	O	-1	1615846
o	O	-1	1615846
decreased	O	-1	1615846
2@@	O	-1	1615846
4@@	O	-1	1615846
%	O	-1	1615846
from	O	-1	1615846
7.@@	O	-1	1615846
1	O	-1	1615846
to	O	-1	1615846
5.@@	O	-1	1615846
4@@	O	-1	1615846
,	O	-1	1615846
all	O	-1	1615846
p	O	-1	1615846
less	O	-1	1615846
than	O	-1	1615846
or	O	-1	1615846
equ@@	O	-1	1615846
al	O	-1	1615846
to	O	-1	1615846
0.00@@	O	-1	1615846
0@@	O	-1	1615846
1@@	O	-1	1615846
.	O	-1	1615846
M@@	B-Disease	D009220	1615846
yo@@	I-Disease	-1	1615846
si@@	I-Disease	-1	1615846
tis	I-Disease	-1	1615846
,	O	-1	1615846
at@@	O	-1	1615846
tri@@	O	-1	1615846
but@@	O	-1	1615846
able	O	-1	1615846
to	O	-1	1615846
the	O	-1	1615846
drug	O	-1	1615846
combination	O	-1	1615846
and	O	-1	1615846
symptom@@	O	-1	1615846
atic	O	-1	1615846
en@@	O	-1	1615846
ou@@	O	-1	1615846
gh	O	-1	1615846
to	O	-1	1615846
discontinu@@	O	-1	1615846
e	O	-1	1615846
it@@	O	-1	1615846
,	O	-1	1615846
occurred	O	-1	1615846
in	O	-1	1615846
3@@	O	-1	1615846
%	O	-1	1615846
of	O	-1	1615846
patients,	O	-1	1615846
and	O	-1	1615846
in	O	-1	1615846
1@@	O	-1	1615846
%	O	-1	1615846
with	O	-1	1615846
con@@	O	-1	1615846
current	O	-1	1615846
high	O	-1	1615846
creat@@	B-Chemical	D003401	1615846
ine	I-Chemical	-1	1615846
phosph@@	O	-1	1615846
o@@	O	-1	1615846
kin@@	O	-1	1615846
ase	O	-1	1615846
(@@	O	-1	1615846
7@@	O	-1	1615846
6@@	O	-1	1615846
9	O	-1	1615846
U@@	O	-1	1615846
/@@	O	-1	1615846
liter@@	O	-1	1615846
);	O	-1	1615846
no	O	-1	1615846
patients	O	-1	1615846
had	O	-1	1615846
rh@@	B-Disease	D012206	1615846
ab@@	I-Disease	-1	1615846
do@@	I-Disease	-1	1615846
my@@	I-Disease	-1	1615846
oly@@	I-Disease	-1	1615846
sis	I-Disease	-1	1615846
or	O	-1	1615846
my@@	B-Disease	D009212	1615846
o@@	I-Disease	-1	1615846
glo@@	I-Disease	-1	1615846
bin@@	I-Disease	-1	1615846
uria	I-Disease	-1	1615846
.@@	O	-1	1615846
(A@@	O	-1	1615846
B@@	O	-1	1615846
S@@	O	-1	1615846
TR@@	O	-1	1615846
AC@@	O	-1	1615846
T	O	-1	1615846
TR@@	O	-1	1615846
UN@@	O	-1	1615846
C@@	O	-1	1615846
AT@@	O	-1	1615846
E@@	O	-1	1615846
D	O	-1	1615846
A@@	O	-1	1615846
T	O	-1	1615846
2@@	O	-1	1615846
50	O	-1	1615846
W@@	O	-1	1615846
O@@	O	-1	1615846
RD@@	O	-1	1615846
S)	O	-1	1615846

H@@	B-Disease	D006528	1655018
ep@@	I-Disease	-1	1655018
at@@	I-Disease	-1	1655018
oc@@	I-Disease	-1	1655018
ell@@	I-Disease	-1	1655018
ular	I-Disease	-1	1655018
carcin@@	I-Disease	-1	1655018
oma	I-Disease	-1	1655018
in	O	-1	1655018
F@@	B-Disease	D005199	1655018
an@@	I-Disease	-1	1655018
con@@	I-Disease	-1	1655018
i@@	I-Disease	-1	1655018
's	I-Disease	-1	1655018
anemia	I-Disease	-1	1655018
treated	O	-1	1655018
with	O	-1	1655018
and@@	B-Chemical	D000728	1655018
ro@@	I-Chemical	-1	1655018
gen	I-Chemical	-1	1655018
and	O	-1	1655018
cortico@@	B-Chemical	D000305	1655018
ster@@	I-Chemical	-1	1655018
oid	I-Chemical	-1	1655018
.	O	-1	1655018
The	O	-1	1655018
case	O	-1	1655018
of	O	-1	1655018
an	O	-1	1655018
1@@	O	-1	1655018
1-@@	O	-1	1655018
year-old	O	-1	1655018
bo@@	O	-1	1655018
y	O	-1	1655018
is	O	-1	1655018
reported	O	-1	1655018
who	O	-1	1655018
was	O	-1	1655018
known	O	-1	1655018
to	O	-1	1655018
have	O	-1	1655018
F@@	B-Disease	D005199	1655018
an@@	I-Disease	-1	1655018
con@@	I-Disease	-1	1655018
i@@	I-Disease	-1	1655018
's	I-Disease	-1	1655018
anemia	I-Disease	-1	1655018
for	O	-1	1655018
3	O	-1	1655018
years	O	-1	1655018
and	O	-1	1655018
was	O	-1	1655018
treated	O	-1	1655018
with	O	-1	1655018
and@@	B-Chemical	D000728	1655018
ro@@	I-Chemical	-1	1655018
gen@@	I-Chemical	-1	1655018
s	I-Chemical	-1	1655018
,	O	-1	1655018
cortico@@	B-Chemical	D000305	1655018
steroid@@	I-Chemical	-1	1655018
s	I-Chemical	-1	1655018
and	O	-1	1655018
trans@@	O	-1	1655018
fu@@	O	-1	1655018
sion@@	O	-1	1655018
s.	O	-1	1655018
Two	O	-1	1655018
weeks	O	-1	1655018
before	O	-1	1655018
h@@	O	-1	1655018
is	O	-1	1655018
death	O	-1	1655018
he	O	-1	1655018
was	O	-1	1655018
re@@	O	-1	1655018
ad@@	O	-1	1655018
mit@@	O	-1	1655018
ted	O	-1	1655018
because	O	-1	1655018
of	O	-1	1655018
ap@@	O	-1	1655018
las@@	O	-1	1655018
tic	O	-1	1655018
cri@@	O	-1	1655018
sis	O	-1	1655018
with	O	-1	1655018
se@@	B-Disease	D018805	1655018
p@@	I-Disease	-1	1655018
ti@@	I-Disease	-1	1655018
ce@@	I-Disease	-1	1655018
mia	I-Disease	-1	1655018
and	O	-1	1655018
mark@@	O	-1	1655018
ed	O	-1	1655018
abnormal@@	O	-1	1655018
ities	O	-1	1655018
in	O	-1	1655018
liver	O	-1	1655018
function	O	-1	1655018
and	O	-1	1655018
di@@	O	-1	1655018
ed	O	-1	1655018
of	O	-1	1655018
hemorrh@@	B-Disease	D001996	1655018
ag@@	I-Disease	-1	1655018
ic	I-Disease	-1	1655018
b@@	I-Disease	-1	1655018
ron@@	I-Disease	-1	1655018
ch@@	I-Disease	-1	1655018
op@@	I-Disease	-1	1655018
ne@@	I-Disease	-1	1655018
um@@	I-Disease	-1	1655018
on@@	I-Disease	-1	1655018
ia	I-Disease	-1	1655018
.	O	-1	1655018
A@@	O	-1	1655018
t	O	-1	1655018
auto@@	O	-1	1655018
p@@	O	-1	1655018
sy	O	-1	1655018
pe@@	B-Disease	D010382	1655018
li@@	I-Disease	-1	1655018
o@@	I-Disease	-1	1655018
sis	I-Disease	-1	1655018
and	O	-1	1655018
multiple	O	-1	1655018
hepatic	B-Disease	D008113	1655018
tu@@	I-Disease	-1	1655018
mor@@	I-Disease	-1	1655018
s	I-Disease	-1	1655018
were	O	-1	1655018
found	O	-1	1655018
which	O	-1	1655018
hist@@	O	-1	1655018
olog@@	O	-1	1655018
ically	O	-1	1655018
pro@@	O	-1	1655018
ved	O	-1	1655018
to	O	-1	1655018
be	O	-1	1655018
we@@	O	-1	1655018
ll@@	O	-1	1655018
-@@	O	-1	1655018
differen@@	O	-1	1655018
ti@@	O	-1	1655018
ated	O	-1	1655018
hepat@@	B-Disease	D006528	1655018
oc@@	I-Disease	-1	1655018
ell@@	I-Disease	-1	1655018
ular	I-Disease	-1	1655018
carcin@@	I-Disease	-1	1655018
oma	I-Disease	-1	1655018
.	O	-1	1655018
This	O	-1	1655018
case	O	-1	1655018
cont@@	O	-1	1655018
ri@@	O	-1	1655018
but@@	O	-1	1655018
es	O	-1	1655018
to	O	-1	1655018
the	O	-1	1655018
previ@@	O	-1	1655018
ous	O	-1	1655018
observ@@	O	-1	1655018
ations	O	-1	1655018
that	O	-1	1655018
non-@@	O	-1	1655018
met@@	O	-1	1655018
ast@@	O	-1	1655018
a@@	O	-1	1655018
si@@	O	-1	1655018
z@@	O	-1	1655018
ing	O	-1	1655018
hepatic	B-Disease	D008113	1655018
ne@@	I-Disease	-1	1655018
o@@	I-Disease	-1	1655018
plas@@	I-Disease	-1	1655018
ms	I-Disease	-1	1655018
and	O	-1	1655018
pe@@	B-Disease	D010382	1655018
li@@	I-Disease	-1	1655018
o@@	I-Disease	-1	1655018
sis	I-Disease	-1	1655018
can	O	-1	1655018
deve@@	O	-1	1655018
lo@@	O	-1	1655018
p	O	-1	1655018
in	O	-1	1655018
patients	O	-1	1655018
with	O	-1	1655018
and@@	B-Chemical	D000728	1655018
ro@@	I-Chemical	-1	1655018
gen	I-Chemical	-1	1655018
-	O	-1	1655018
and	O	-1	1655018
cortico@@	B-Chemical	D000305	1655018
ster@@	I-Chemical	-1	1655018
oid	I-Chemical	-1	1655018
-treated	O	-1	1655018
F@@	B-Disease	D005199	1655018
an@@	I-Disease	-1	1655018
con@@	I-Disease	-1	1655018
i@@	I-Disease	-1	1655018
's	I-Disease	-1	1655018
anemia	I-Disease	-1	1655018
.	O	-1	1655018

Ch@@	O	-1	1735570
ron@@	O	-1	1735570
ic	O	-1	1735570
le@@	O	-1	1735570
sion	O	-1	1735570
of	O	-1	1735570
ro@@	O	-1	1735570
str@@	O	-1	1735570
al	O	-1	1735570
v@@	O	-1	1735570
ent@@	O	-1	1735570
ro@@	O	-1	1735570
lat@@	O	-1	1735570
eral	O	-1	1735570
med@@	O	-1	1735570
ul@@	O	-1	1735570
l@@	O	-1	1735570
a	O	-1	1735570
in	O	-1	1735570
spont@@	O	-1	1735570
ane@@	O	-1	1735570
ously	O	-1	1735570
hypertensive	B-Disease	D006973	1735570
rats.	O	-1	1735570
We	O	-1	1735570
studied	O	-1	1735570
the	O	-1	1735570
effects	O	-1	1735570
of	O	-1	1735570
chronic	O	-1	1735570
selective	O	-1	1735570
neuron@@	O	-1	1735570
al	O	-1	1735570
le@@	O	-1	1735570
sion	O	-1	1735570
of	O	-1	1735570
ro@@	O	-1	1735570
str@@	O	-1	1735570
al	O	-1	1735570
v@@	O	-1	1735570
ent@@	O	-1	1735570
ro@@	O	-1	1735570
lat@@	O	-1	1735570
eral	O	-1	1735570
med@@	O	-1	1735570
ul@@	O	-1	1735570
l@@	O	-1	1735570
a	O	-1	1735570
on	O	-1	1735570
mean	O	-1	1735570
arterial	O	-1	1735570
pressu@@	O	-1	1735570
re,	O	-1	1735570
heart	O	-1	1735570
rat@@	O	-1	1735570
e,	O	-1	1735570
and	O	-1	1735570
neuro@@	O	-1	1735570
genic	O	-1	1735570
t@@	O	-1	1735570
one	O	-1	1735570
in	O	-1	1735570
con@@	O	-1	1735570
s@@	O	-1	1735570
ci@@	O	-1	1735570
ou@@	O	-1	1735570
s,	O	-1	1735570
un@@	O	-1	1735570
re@@	O	-1	1735570
stra@@	O	-1	1735570
in@@	O	-1	1735570
ed	O	-1	1735570
spont@@	O	-1	1735570
ane@@	O	-1	1735570
ously	O	-1	1735570
hypertensive	B-Disease	D006973	1735570
rats.	O	-1	1735570
The	O	-1	1735570
lesions	O	-1	1735570
were	O	-1	1735570
pl@@	O	-1	1735570
ac@@	O	-1	1735570
ed	O	-1	1735570
vi@@	O	-1	1735570
a	O	-1	1735570
bil@@	O	-1	1735570
ateral	O	-1	1735570
micro@@	O	-1	1735570
injec@@	O	-1	1735570
tions	O	-1	1735570
of	O	-1	1735570
30	O	-1	1735570
n@@	O	-1	1735570
mol@@	O	-1	1735570
/@@	O	-1	1735570
2@@	O	-1	1735570
00	O	-1	1735570
n@@	O	-1	1735570
l	O	-1	1735570
N@@	B-Chemical	D016202	1735570
-@@	I-Chemical	-1	1735570
methyl@@	I-Chemical	-1	1735570
-@@	I-Chemical	-1	1735570
D-@@	I-Chemical	-1	1735570
as@@	I-Chemical	-1	1735570
par@@	I-Chemical	-1	1735570
tic	I-Chemical	-1	1735570
acid	I-Chemical	-1	1735570
.	O	-1	1735570
The	O	-1	1735570
res@@	O	-1	1735570
tim@@	O	-1	1735570
ulation	O	-1	1735570
of	O	-1	1735570
this	O	-1	1735570
a@@	O	-1	1735570
re@@	O	-1	1735570
a	O	-1	1735570
with	O	-1	1735570
N@@	B-Chemical	D016202	1735570
-@@	I-Chemical	-1	1735570
methyl@@	I-Chemical	-1	1735570
-@@	I-Chemical	-1	1735570
D-@@	I-Chemical	-1	1735570
as@@	I-Chemical	-1	1735570
par@@	I-Chemical	-1	1735570
tic	I-Chemical	-1	1735570
acid	I-Chemical	-1	1735570
15	O	-1	1735570
days	O	-1	1735570
post@@	O	-1	1735570
le@@	O	-1	1735570
sion	O	-1	1735570
fail@@	O	-1	1735570
ed	O	-1	1735570
to	O	-1	1735570
produce	O	-1	1735570
a	O	-1	1735570
press@@	O	-1	1735570
or	O	-1	1735570
respon@@	O	-1	1735570
se.	O	-1	1735570
One	O	-1	1735570
day	O	-1	1735570
post@@	O	-1	1735570
le@@	O	-1	1735570
sion,	O	-1	1735570
the	O	-1	1735570
rest@@	O	-1	1735570
ing	O	-1	1735570
mean	O	-1	1735570
arterial	O	-1	1735570
pressure	O	-1	1735570
was	O	-1	1735570
significantly	O	-1	1735570
decreased	O	-1	1735570
in	O	-1	1735570
le@@	O	-1	1735570
sion@@	O	-1	1735570
ed	O	-1	1735570
rats	O	-1	1735570
when	O	-1	1735570
compared	O	-1	1735570
with	O	-1	1735570
s@@	O	-1	1735570
ha@@	O	-1	1735570
m	O	-1	1735570
rats	O	-1	1735570
(@@	O	-1	1735570
100	O	-1	1735570
+/-	O	-1	1735570
7	O	-1	1735570
versus	O	-1	1735570
17@@	O	-1	1735570
3	O	-1	1735570
+/-	O	-1	1735570
4	O	-1	1735570
mm	O	-1	1735570
H@@	O	-1	1735570
g@@	O	-1	1735570
,	O	-1	1735570
p	O	-1	1735570
less	O	-1	1735570
than	O	-1	1735570
0.05@@	O	-1	1735570
).	O	-1	1735570
F@@	O	-1	1735570
if@@	O	-1	1735570
te@@	O	-1	1735570
en	O	-1	1735570
days	O	-1	1735570
lat@@	O	-1	1735570
er,	O	-1	1735570
the	O	-1	1735570
le@@	O	-1	1735570
sion@@	O	-1	1735570
ed	O	-1	1735570
group	O	-1	1735570
sti@@	O	-1	1735570
ll	O	-1	1735570
showed	O	-1	1735570
values	O	-1	1735570
significantly	O	-1	1735570
lower	O	-1	1735570
than	O	-1	1735570
the	O	-1	1735570
s@@	O	-1	1735570
ha@@	O	-1	1735570
m	O	-1	1735570
group	O	-1	1735570
(1@@	O	-1	1735570
50	O	-1	1735570
+/-	O	-1	1735570
6	O	-1	1735570
versus	O	-1	1735570
1@@	O	-1	1735570
6@@	O	-1	1735570
7	O	-1	1735570
+/-	O	-1	1735570
5	O	-1	1735570
mm	O	-1	1735570
H@@	O	-1	1735570
g@@	O	-1	1735570
,	O	-1	1735570
p	O	-1	1735570
less	O	-1	1735570
than	O	-1	1735570
0.05@@	O	-1	1735570
).	O	-1	1735570
No	O	-1	1735570
significant	O	-1	1735570
heart	O	-1	1735570
rate	O	-1	1735570
differences	O	-1	1735570
were	O	-1	1735570
observed	O	-1	1735570
between	O	-1	1735570
the	O	-1	1735570
s@@	O	-1	1735570
ha@@	O	-1	1735570
m	O	-1	1735570
and	O	-1	1735570
le@@	O	-1	1735570
sion@@	O	-1	1735570
ed	O	-1	1735570
groups.	O	-1	1735570
The	O	-1	1735570
g@@	O	-1	1735570
ang@@	O	-1	1735570
li@@	O	-1	1735570
onic	O	-1	1735570
block@@	O	-1	1735570
er	O	-1	1735570
tri@@	B-Chemical	D014294	1735570
meth@@	I-Chemical	-1	1735570
a@@	I-Chemical	-1	1735570
ph@@	I-Chemical	-1	1735570
an	I-Chemical	-1	1735570
(@@	O	-1	1735570
5	O	-1	1735570
mg/kg	O	-1	1735570
i.v@@	O	-1	1735570
.)	O	-1	1735570
caused	O	-1	1735570
similar	O	-1	1735570
reduc@@	O	-1	1735570
tions	O	-1	1735570
in	O	-1	1735570
mean	O	-1	1735570
arterial	O	-1	1735570
pressure	O	-1	1735570
in	O	-1	1735570
both	O	-1	1735570
le@@	O	-1	1735570
sion@@	O	-1	1735570
ed	O	-1	1735570
and	O	-1	1735570
s@@	O	-1	1735570
ha@@	O	-1	1735570
m	O	-1	1735570
groups.	O	-1	1735570
The	O	-1	1735570
tri@@	B-Chemical	D014294	1735570
meth@@	I-Chemical	-1	1735570
a@@	I-Chemical	-1	1735570
ph@@	I-Chemical	-1	1735570
an	I-Chemical	-1	1735570
-induced	O	-1	1735570
hypotension	B-Disease	D007022	1735570
was	O	-1	1735570
ac@@	O	-1	1735570
comp@@	O	-1	1735570
an@@	O	-1	1735570
ied	O	-1	1735570
by	O	-1	1735570
a	O	-1	1735570
significant	O	-1	1735570
brady@@	B-Disease	D001919	1735570
cardia	I-Disease	-1	1735570
in	O	-1	1735570
le@@	O	-1	1735570
sion@@	O	-1	1735570
ed	O	-1	1735570
rats	O	-1	1735570
(-@@	O	-1	1735570
3@@	O	-1	1735570
2	O	-1	1735570
+/-	O	-1	1735570
13	O	-1	1735570
be@@	O	-1	1735570
at@@	O	-1	1735570
s	O	-1	1735570
per	O	-1	1735570
min@@	O	-1	1735570
u@@	O	-1	1735570
te@@	O	-1	1735570
)	O	-1	1735570
but	O	-1	1735570
a	O	-1	1735570
tachycardia	B-Disease	D013610	1735570
in	O	-1	1735570
s@@	O	-1	1735570
ha@@	O	-1	1735570
m	O	-1	1735570
rats	O	-1	1735570
(@@	O	-1	1735570
+@@	O	-1	1735570
3@@	O	-1	1735570
3	O	-1	1735570
+/-	O	-1	1735570
12	O	-1	1735570
be@@	O	-1	1735570
at@@	O	-1	1735570
s	O	-1	1735570
per	O	-1	1735570
min@@	O	-1	1735570
u@@	O	-1	1735570
te@@	O	-1	1735570
)	O	-1	1735570
1	O	-1	1735570
day	O	-1	1735570
post@@	O	-1	1735570
le@@	O	-1	1735570
sion.	O	-1	1735570
The@@	O	-1	1735570
refore,	O	-1	1735570
ro@@	O	-1	1735570
str@@	O	-1	1735570
al	O	-1	1735570
v@@	O	-1	1735570
ent@@	O	-1	1735570
ro@@	O	-1	1735570
lat@@	O	-1	1735570
eral	O	-1	1735570
med@@	O	-1	1735570
ul@@	O	-1	1735570
l@@	O	-1	1735570
a	O	-1	1735570
neuron@@	O	-1	1735570
s	O	-1	1735570
appe@@	O	-1	1735570
ar	O	-1	1735570
to	O	-1	1735570
pl@@	O	-1	1735570
ay	O	-1	1735570
a	O	-1	1735570
significant	O	-1	1735570
role	O	-1	1735570
in	O	-1	1735570
maint@@	O	-1	1735570
aining	O	-1	1735570
hypertension	B-Disease	D006973	1735570
in	O	-1	1735570
con@@	O	-1	1735570
s@@	O	-1	1735570
ci@@	O	-1	1735570
ous	O	-1	1735570
spont@@	O	-1	1735570
ane@@	O	-1	1735570
ously	O	-1	1735570
hypertensive	B-Disease	D006973	1735570
rats.	O	-1	1735570
S@@	O	-1	1735570
p@@	O	-1	1735570
inal	O	-1	1735570
or	O	-1	1735570
sup@@	O	-1	1735570
ra@@	O	-1	1735570
b@@	O	-1	1735570
ul@@	O	-1	1735570
b@@	O	-1	1735570
ar	O	-1	1735570
struct@@	O	-1	1735570
ures	O	-1	1735570
could	O	-1	1735570
be	O	-1	1735570
respon@@	O	-1	1735570
sible	O	-1	1735570
for	O	-1	1735570
the	O	-1	1735570
gra@@	O	-1	1735570
du@@	O	-1	1735570
al	O	-1	1735570
recovery	O	-1	1735570
of	O	-1	1735570
the	O	-1	1735570
hypertension	B-Disease	D006973	1735570
in	O	-1	1735570
the	O	-1	1735570
le@@	O	-1	1735570
sion@@	O	-1	1735570
ed	O	-1	1735570
rats.	O	-1	1735570

D@@	B-Disease	D001930	1756784
am@@	I-Disease	-1	1756784
age	I-Disease	-1	1756784
of	I-Disease	-1	1756784
subst@@	I-Disease	-1	1756784
anti@@	I-Disease	-1	1756784
a	I-Disease	-1	1756784
n@@	I-Disease	-1	1756784
ig@@	I-Disease	-1	1756784
r@@	I-Disease	-1	1756784
a	I-Disease	-1	1756784
par@@	I-Disease	-1	1756784
s	I-Disease	-1	1756784
re@@	I-Disease	-1	1756784
tic@@	I-Disease	-1	1756784
ul@@	I-Disease	-1	1756784
at@@	I-Disease	-1	1756784
a	I-Disease	-1	1756784
during	O	-1	1756784
pilocar@@	B-Chemical	D010862	1756784
pine	I-Chemical	-1	1756784
-induced	O	-1	1756784
status	B-Disease	D013226	1756784
epilep@@	I-Disease	-1	1756784
tic@@	I-Disease	-1	1756784
us	I-Disease	-1	1756784
in	O	-1	1756784
the	O	-1	1756784
rat@@	O	-1	1756784
:	O	-1	1756784
immuno@@	O	-1	1756784
histo@@	O	-1	1756784
chemical	O	-1	1756784
study	O	-1	1756784
of	O	-1	1756784
neuron@@	O	-1	1756784
s,	O	-1	1756784
ast@@	O	-1	1756784
ro@@	O	-1	1756784
cy@@	O	-1	1756784
tes	O	-1	1756784
and	O	-1	1756784
ser@@	O	-1	1756784
um@@	O	-1	1756784
-@@	O	-1	1756784
protein	O	-1	1756784
ext@@	O	-1	1756784
ra@@	O	-1	1756784
vas@@	O	-1	1756784
ation.	O	-1	1756784
The	O	-1	1756784
subst@@	O	-1	1756784
anti@@	O	-1	1756784
a	O	-1	1756784
n@@	O	-1	1756784
ig@@	O	-1	1756784
r@@	O	-1	1756784
a	O	-1	1756784
has	O	-1	1756784
a	O	-1	1756784
g@@	O	-1	1756784
ating	O	-1	1756784
function	O	-1	1756784
contro@@	O	-1	1756784
ll@@	O	-1	1756784
ing	O	-1	1756784
the	O	-1	1756784
s@@	O	-1	1756784
pre@@	O	-1	1756784
ad	O	-1	1756784
of	O	-1	1756784
epileptic	B-Disease	D004827	1756784
seizure	I-Disease	-1	1756784
activ@@	O	-1	1756784
ity.	O	-1	1756784
Ad@@	O	-1	1756784
di@@	O	-1	1756784
tion@@	O	-1	1756784
ally,	O	-1	1756784
in	O	-1	1756784
models	O	-1	1756784
of	O	-1	1756784
prolonged	B-Disease	D013226	1756784
status	I-Disease	-1	1756784
epilep@@	I-Disease	-1	1756784
tic@@	I-Disease	-1	1756784
us	I-Disease	-1	1756784
the	O	-1	1756784
par@@	O	-1	1756784
s	O	-1	1756784
re@@	O	-1	1756784
tic@@	O	-1	1756784
ul@@	O	-1	1756784
at@@	O	-1	1756784
a	O	-1	1756784
of	O	-1	1756784
subst@@	O	-1	1756784
anti@@	O	-1	1756784
a	O	-1	1756784
n@@	O	-1	1756784
ig@@	O	-1	1756784
r@@	O	-1	1756784
a	O	-1	1756784
(S@@	O	-1	1756784
N@@	O	-1	1756784
R@@	O	-1	1756784
)	O	-1	1756784
suff@@	O	-1	1756784
ers	O	-1	1756784
from	O	-1	1756784
a	O	-1	1756784
mas@@	O	-1	1756784
sive	O	-1	1756784
le@@	O	-1	1756784
sion	O	-1	1756784
which	O	-1	1756784
may	O	-1	1756784
ar@@	O	-1	1756784
is@@	O	-1	1756784
e	O	-1	1756784
from	O	-1	1756784
a	O	-1	1756784
mas@@	O	-1	1756784
sive	O	-1	1756784
met@@	B-Disease	D008659	1756784
ab@@	I-Disease	-1	1756784
olic	I-Disease	-1	1756784
der@@	I-Disease	-1	1756784
ang@@	I-Disease	-1	1756784
ement	I-Disease	-1	1756784
and	O	-1	1756784
hy@@	O	-1	1756784
pe@@	O	-1	1756784
re@@	O	-1	1756784
x@@	O	-1	1756784
cit@@	O	-1	1756784
ation	O	-1	1756784
develop@@	O	-1	1756784
ing	O	-1	1756784
in	O	-1	1756784
the	O	-1	1756784
activ@@	O	-1	1756784
ated	O	-1	1756784
S@@	O	-1	1756784
N@@	O	-1	1756784
R@@	O	-1	1756784
.	O	-1	1756784
In	O	-1	1756784
this	O	-1	1756784
study,	O	-1	1756784
status	B-Disease	D013226	1756784
epilep@@	I-Disease	-1	1756784
tic@@	I-Disease	-1	1756784
us	I-Disease	-1	1756784
was	O	-1	1756784
induced	O	-1	1756784
by	O	-1	1756784
systemic	O	-1	1756784
injection	O	-1	1756784
of	O	-1	1756784
pilocar@@	B-Chemical	D010862	1756784
pine	I-Chemical	-1	1756784
in	O	-1	1756784
rats.	O	-1	1756784
The	O	-1	1756784
neuro@@	O	-1	1756784
path@@	O	-1	1756784
ology	O	-1	1756784
of	O	-1	1756784
S@@	O	-1	1756784
N@@	O	-1	1756784
R	O	-1	1756784
was	O	-1	1756784
investigated	O	-1	1756784
using	O	-1	1756784
immuno@@	O	-1	1756784
histo@@	O	-1	1756784
chemical	O	-1	1756784
t@@	O	-1	1756784
ech@@	O	-1	1756784
n@@	O	-1	1756784
i@@	O	-1	1756784
qu@@	O	-1	1756784
es	O	-1	1756784
with	O	-1	1756784
the	O	-1	1756784
major	O	-1	1756784
em@@	O	-1	1756784
pha@@	O	-1	1756784
sis	O	-1	1756784
on	O	-1	1756784
the	O	-1	1756784
ti@@	O	-1	1756784
me@@	O	-1	1756784
-@@	O	-1	1756784
course	O	-1	1756784
of	O	-1	1756784
changes	O	-1	1756784
in	O	-1	1756784
neuron@@	O	-1	1756784
s	O	-1	1756784
and	O	-1	1756784
ast@@	O	-1	1756784
ro@@	O	-1	1756784
cy@@	O	-1	1756784
t@@	O	-1	1756784
es.	O	-1	1756784
An@@	O	-1	1756784
im@@	O	-1	1756784
als	O	-1	1756784
sur@@	O	-1	1756784
vi@@	O	-1	1756784
ving	O	-1	1756784
20@@	O	-1	1756784
,	O	-1	1756784
3@@	O	-1	1756784
0@@	O	-1	1756784
,	O	-1	1756784
4@@	O	-1	1756784
0@@	O	-1	1756784
,	O	-1	1756784
60	O	-1	1756784
min@@	O	-1	1756784
,	O	-1	1756784
2,	O	-1	1756784
3,	O	-1	1756784
6	O	-1	1756784
hour@@	O	-1	1756784
s,	O	-1	1756784
1,	O	-1	1756784
2,	O	-1	1756784
and	O	-1	1756784
3	O	-1	1756784
days	O	-1	1756784
after	O	-1	1756784
induction	O	-1	1756784
of	O	-1	1756784
status	B-Disease	D013226	1756784
epilep@@	I-Disease	-1	1756784
tic@@	I-Disease	-1	1756784
us	I-Disease	-1	1756784
were	O	-1	1756784
per@@	O	-1	1756784
fu@@	O	-1	1756784
sion@@	O	-1	1756784
-@@	O	-1	1756784
fi@@	O	-1	1756784
x@@	O	-1	1756784
ed,	O	-1	1756784
and	O	-1	1756784
bra@@	O	-1	1756784
ins	O	-1	1756784
pro@@	O	-1	1756784
cess@@	O	-1	1756784
ed	O	-1	1756784
for	O	-1	1756784
immuno@@	O	-1	1756784
histo@@	O	-1	1756784
chemical	O	-1	1756784
st@@	O	-1	1756784
aining	O	-1	1756784
of	O	-1	1756784
S@@	O	-1	1756784
N@@	O	-1	1756784
R@@	O	-1	1756784
.	O	-1	1756784
N@@	O	-1	1756784
is@@	O	-1	1756784
s@@	O	-1	1756784
l@@	O	-1	1756784
-@@	O	-1	1756784
st@@	O	-1	1756784
aining	O	-1	1756784
and	O	-1	1756784
anti@@	O	-1	1756784
bo@@	O	-1	1756784
di@@	O	-1	1756784
es	O	-1	1756784
against	O	-1	1756784
the	O	-1	1756784
neuron@@	O	-1	1756784
-@@	O	-1	1756784
specific	O	-1	1756784
calcium	B-Chemical	D002118	1756784
-@@	O	-1	1756784
b@@	O	-1	1756784
ind@@	O	-1	1756784
ing	O	-1	1756784
protein@@	O	-1	1756784
,	O	-1	1756784
par@@	O	-1	1756784
val@@	O	-1	1756784
bu@@	O	-1	1756784
min@@	O	-1	1756784
,	O	-1	1756784
ser@@	O	-1	1756784
ved	O	-1	1756784
to	O	-1	1756784
det@@	O	-1	1756784
ect	O	-1	1756784
neuron@@	B-Disease	D009422	1756784
al	I-Disease	-1	1756784
damage	I-Disease	-1	1756784
in	O	-1	1756784
S@@	O	-1	1756784
N@@	O	-1	1756784
R@@	O	-1	1756784
.	O	-1	1756784
An@@	O	-1	1756784
ti@@	O	-1	1756784
bo@@	O	-1	1756784
di@@	O	-1	1756784
es	O	-1	1756784
against	O	-1	1756784
the	O	-1	1756784
ast@@	O	-1	1756784
ro@@	O	-1	1756784
g@@	O	-1	1756784
li@@	O	-1	1756784
a@@	O	-1	1756784
-@@	O	-1	1756784
specific	O	-1	1756784
cy@@	O	-1	1756784
t@@	O	-1	1756784
os@@	O	-1	1756784
ke@@	O	-1	1756784
le@@	O	-1	1756784
t@@	O	-1	1756784
al	O	-1	1756784
protein@@	O	-1	1756784
,	O	-1	1756784
g@@	O	-1	1756784
lial	O	-1	1756784
fibrill@@	O	-1	1756784
ary	O	-1	1756784
ac@@	O	-1	1756784
i@@	O	-1	1756784
di@@	O	-1	1756784
c	O	-1	1756784
protein	O	-1	1756784
(@@	O	-1	1756784
GF@@	O	-1	1756784
A@@	O	-1	1756784
P@@	O	-1	1756784
),	O	-1	1756784
and	O	-1	1756784
against	O	-1	1756784
the	O	-1	1756784
g@@	O	-1	1756784
lial	O	-1	1756784
calcium	B-Chemical	D002118	1756784
-@@	O	-1	1756784
b@@	O	-1	1756784
ind@@	O	-1	1756784
ing	O	-1	1756784
protein@@	O	-1	1756784
,	O	-1	1756784
S@@	O	-1	1756784
-@@	O	-1	1756784
100	O	-1	1756784
protein@@	O	-1	1756784
,	O	-1	1756784
were	O	-1	1756784
used	O	-1	1756784
to	O	-1	1756784
ass@@	O	-1	1756784
ess	O	-1	1756784
the	O	-1	1756784
status	O	-1	1756784
of	O	-1	1756784
ast@@	O	-1	1756784
ro@@	O	-1	1756784
cy@@	O	-1	1756784
t@@	O	-1	1756784
es.	O	-1	1756784
Im@@	O	-1	1756784
mun@@	O	-1	1756784
o@@	O	-1	1756784
histo@@	O	-1	1756784
chemical	O	-1	1756784
st@@	O	-1	1756784
aining	O	-1	1756784
for	O	-1	1756784
ser@@	O	-1	1756784
um@@	O	-1	1756784
-@@	O	-1	1756784
al@@	O	-1	1756784
b@@	O	-1	1756784
um@@	O	-1	1756784
in	O	-1	1756784
and	O	-1	1756784
immuno@@	O	-1	1756784
glo@@	O	-1	1756784
b@@	O	-1	1756784
ul@@	O	-1	1756784
ins	O	-1	1756784
in	O	-1	1756784
brain	O	-1	1756784
tissue	O	-1	1756784
was	O	-1	1756784
tak@@	O	-1	1756784
en	O	-1	1756784
as	O	-1	1756784
indic@@	O	-1	1756784
at@@	O	-1	1756784
or	O	-1	1756784
of	O	-1	1756784
blo@@	O	-1	1756784
o@@	O	-1	1756784
d-@@	O	-1	1756784
brain	O	-1	1756784
bar@@	O	-1	1756784
ri@@	O	-1	1756784
er	O	-1	1756784
dist@@	O	-1	1756784
urb@@	O	-1	1756784
anc@@	O	-1	1756784
es	O	-1	1756784
and	O	-1	1756784
vas@@	B-Disease	D001929	1756784
o@@	I-Disease	-1	1756784
genic	I-Disease	-1	1756784
e@@	I-Disease	-1	1756784
de@@	I-Disease	-1	1756784
ma	I-Disease	-1	1756784
form@@	O	-1	1756784
ation.	O	-1	1756784
Im@@	O	-1	1756784
mun@@	O	-1	1756784
o@@	O	-1	1756784
histo@@	O	-1	1756784
chemical	O	-1	1756784
st@@	O	-1	1756784
aining	O	-1	1756784
indic@@	O	-1	1756784
ated	O	-1	1756784
loss	O	-1	1756784
of	O	-1	1756784
GF@@	O	-1	1756784
A@@	O	-1	1756784
P@@	O	-1	1756784
-@@	O	-1	1756784
st@@	O	-1	1756784
aining	O	-1	1756784
al@@	O	-1	1756784
re@@	O	-1	1756784
ad@@	O	-1	1756784
y	O	-1	1756784
at	O	-1	1756784
30	O	-1	1756784
min	O	-1	1756784
after	O	-1	1756784
induction	O	-1	1756784
of	O	-1	1756784
seizures	B-Disease	D012640	1756784
in	O	-1	1756784
an	O	-1	1756784
o@@	O	-1	1756784
v@@	O	-1	1756784
al	O	-1	1756784
foc@@	O	-1	1756784
us	O	-1	1756784
sit@@	O	-1	1756784
u@@	O	-1	1756784
ated	O	-1	1756784
in	O	-1	1756784
the	O	-1	1756784
c@@	O	-1	1756784
ent@@	O	-1	1756784
er	O	-1	1756784
of	O	-1	1756784
S@@	O	-1	1756784
N@@	O	-1	1756784
R	O	-1	1756784
while	O	-1	1756784
s@@	O	-1	1756784
par@@	O	-1	1756784
ing	O	-1	1756784
medi@@	O	-1	1756784
al	O	-1	1756784
and	O	-1	1756784
lat@@	O	-1	1756784
eral	O	-1	1756784
as@@	O	-1	1756784
p@@	O	-1	1756784
ect@@	O	-1	1756784
s.	O	-1	1756784
A@@	O	-1	1756784
t	O	-1	1756784
1	O	-1	1756784
h	O	-1	1756784
there	O	-1	1756784
was	O	-1	1756784
addi@@	O	-1	1756784
tional	O	-1	1756784
vac@@	O	-1	1756784
u@@	O	-1	1756784
ol@@	O	-1	1756784
ation	O	-1	1756784
in	O	-1	1756784
S@@	O	-1	1756784
-@@	O	-1	1756784
100	O	-1	1756784
protein	O	-1	1756784
st@@	O	-1	1756784
ain@@	O	-1	1756784
ing.	O	-1	1756784
B@@	O	-1	1756784
y	O	-1	1756784
2	O	-1	1756784
hour@@	O	-1	1756784
s,	O	-1	1756784
par@@	O	-1	1756784
val@@	O	-1	1756784
bu@@	O	-1	1756784
min@@	O	-1	1756784
-@@	O	-1	1756784
st@@	O	-1	1756784
aining	O	-1	1756784
chang@@	O	-1	1756784
ed	O	-1	1756784
in	O	-1	1756784
the	O	-1	1756784
central	O	-1	1756784
S@@	O	-1	1756784
N@@	O	-1	1756784
R	O	-1	1756784
indicating	O	-1	1756784
neuron@@	B-Disease	D009422	1756784
al	I-Disease	-1	1756784
damage	I-Disease	-1	1756784
,	O	-1	1756784
and	O	-1	1756784
N@@	O	-1	1756784
is@@	O	-1	1756784
s@@	O	-1	1756784
l@@	O	-1	1756784
-@@	O	-1	1756784
st@@	O	-1	1756784
aining	O	-1	1756784
vi@@	O	-1	1756784
su@@	O	-1	1756784
al@@	O	-1	1756784
ized	O	-1	1756784
some	O	-1	1756784
neuron@@	O	-1	1756784
al	O	-1	1756784
dist@@	O	-1	1756784
or@@	O	-1	1756784
tion.	O	-1	1756784
S@@	O	-1	1756784
t@@	O	-1	1756784
aining	O	-1	1756784
for	O	-1	1756784
ser@@	O	-1	1756784
um@@	O	-1	1756784
-@@	O	-1	1756784
protein@@	O	-1	1756784
s	O	-1	1756784
occurred	O	-1	1756784
in	O	-1	1756784
a	O	-1	1756784
pat@@	O	-1	1756784
ch@@	O	-1	1756784
y	O	-1	1756784
man@@	O	-1	1756784
n@@	O	-1	1756784
er	O	-1	1756784
throu@@	O	-1	1756784
gh@@	O	-1	1756784
out	O	-1	1756784
the	O	-1	1756784
fo@@	O	-1	1756784
re@@	O	-1	1756784
brain	O	-1	1756784
during	O	-1	1756784
the	O	-1	1756784
first	O	-1	1756784
hour@@	O	-1	1756784
s.	O	-1	1756784
B@@	O	-1	1756784
y	O	-1	1756784
6	O	-1	1756784
h@@	O	-1	1756784
,	O	-1	1756784
vas@@	B-Disease	D001929	1756784
o@@	I-Disease	-1	1756784
genic	I-Disease	-1	1756784
e@@	I-Disease	-1	1756784
de@@	I-Disease	-1	1756784
ma	I-Disease	-1	1756784
co@@	O	-1	1756784
vered	O	-1	1756784
the	O	-1	1756784
le@@	B-Disease	D001930	1756784
sion@@	I-Disease	-1	1756784
ed	I-Disease	-1	1756784
S@@	I-Disease	-1	1756784
N@@	I-Disease	-1	1756784
R	I-Disease	-1	1756784
.	O	-1	1756784
B@@	O	-1	1756784
y	O	-1	1756784
24	O	-1	1756784
h@@	O	-1	1756784
,	O	-1	1756784
g@@	O	-1	1756784
lial	O	-1	1756784
and	O	-1	1756784
neuron@@	O	-1	1756784
al	O	-1	1756784
mark@@	O	-1	1756784
ers	O	-1	1756784
indic@@	O	-1	1756784
ated	O	-1	1756784
a	O	-1	1756784
mas@@	O	-1	1756784
sive	O	-1	1756784
le@@	O	-1	1756784
sion	O	-1	1756784
in	O	-1	1756784
the	O	-1	1756784
c@@	O	-1	1756784
ent@@	O	-1	1756784
er	O	-1	1756784
of	O	-1	1756784
S@@	O	-1	1756784
N@@	O	-1	1756784
R@@	O	-1	1756784
.	O	-1	1756784
B@@	O	-1	1756784
y	O	-1	1756784
4@@	O	-1	1756784
8@@	O	-1	1756784
-@@	O	-1	1756784
7@@	O	-1	1756784
2	O	-1	1756784
h@@	O	-1	1756784
,	O	-1	1756784
ast@@	O	-1	1756784
ro@@	O	-1	1756784
cy@@	O	-1	1756784
tes	O	-1	1756784
sur@@	O	-1	1756784
ro@@	O	-1	1756784
un@@	O	-1	1756784
ding	O	-1	1756784
the	O	-1	1756784
le@@	O	-1	1756784
sion	O	-1	1756784
increased	O	-1	1756784
in	O	-1	1756784
si@@	O	-1	1756784
z@@	O	-1	1756784
e,	O	-1	1756784
and	O	-1	1756784
poly@@	O	-1	1756784
morph@@	O	-1	1756784
ic	O	-1	1756784
ph@@	O	-1	1756784
ag@@	O	-1	1756784
ocyto@@	O	-1	1756784
tic	O	-1	1756784
cells	O	-1	1756784
inv@@	O	-1	1756784
ad@@	O	-1	1756784
ed	O	-1	1756784
the	O	-1	1756784
dam@@	O	-1	1756784
aged	O	-1	1756784
a@@	O	-1	1756784
re@@	O	-1	1756784
a.	O	-1	1756784
In	O	-1	1756784
a	O	-1	1756784
further	O	-1	1756784
group	O	-1	1756784
of	O	-1	1756784
animals	O	-1	1756784
sur@@	O	-1	1756784
vi@@	O	-1	1756784
ving	O	-1	1756784
1	O	-1	1756784
to	O	-1	1756784
5	O	-1	1756784
day@@	O	-1	1756784
s,	O	-1	1756784
con@@	O	-1	1756784
ven@@	O	-1	1756784
tional	O	-1	1756784
par@@	O	-1	1756784
aff@@	O	-1	1756784
in-@@	O	-1	1756784
sec@@	O	-1	1756784
tions	O	-1	1756784
con@@	O	-1	1756784
fir@@	O	-1	1756784
m@@	O	-1	1756784
ed	O	-1	1756784
the	O	-1	1756784
neuron@@	O	-1	1756784
al	O	-1	1756784
and	O	-1	1756784
g@@	O	-1	1756784
lial	O	-1	1756784
damage	B-Disease	D001930	1756784
of	I-Disease	-1	1756784
S@@	I-Disease	-1	1756784
N@@	I-Disease	-1	1756784
R	I-Disease	-1	1756784
.	O	-1	1756784
Ad@@	O	-1	1756784
di@@	O	-1	1756784
tional	O	-1	1756784
path@@	O	-1	1756784
ology	O	-1	1756784
of	O	-1	1756784
similar	O	-1	1756784
qu@@	O	-1	1756784
ality	O	-1	1756784
was	O	-1	1756784
found	O	-1	1756784
in	O	-1	1756784
the	O	-1	1756784
glo@@	O	-1	1756784
bu@@	O	-1	1756784
s	O	-1	1756784
p@@	O	-1	1756784
all@@	O	-1	1756784
id@@	O	-1	1756784
us.	O	-1	1756784
S@@	O	-1	1756784
inc@@	O	-1	1756784
e	O	-1	1756784
ast@@	O	-1	1756784
ro@@	O	-1	1756784
cy@@	O	-1	1756784
tes	O	-1	1756784
were	O	-1	1756784
al@@	O	-1	1756784
w@@	O	-1	1756784
ays	O	-1	1756784
dam@@	O	-1	1756784
aged	O	-1	1756784
in	O	-1	1756784
par@@	O	-1	1756784
al@@	O	-1	1756784
le@@	O	-1	1756784
l	O	-1	1756784
with	O	-1	1756784
neuron@@	O	-1	1756784
s	O	-1	1756784
in	O	-1	1756784
S@@	O	-1	1756784
N@@	O	-1	1756784
R	O	-1	1756784
it	O	-1	1756784
is	O	-1	1756784
pro@@	O	-1	1756784
pos@@	O	-1	1756784
ed	O	-1	1756784
that	O	-1	1756784
the	O	-1	1756784
an@@	O	-1	1756784
at@@	O	-1	1756784
om@@	O	-1	1756784
ical	O	-1	1756784
and	O	-1	1756784
functional	O	-1	1756784
inter@@	O	-1	1756784
rel@@	O	-1	1756784
ationship	O	-1	1756784
between	O	-1	1756784
neuron@@	O	-1	1756784
s	O	-1	1756784
and	O	-1	1756784
ast@@	O	-1	1756784
ro@@	O	-1	1756784
cy@@	O	-1	1756784
tes	O	-1	1756784
is	O	-1	1756784
partic@@	O	-1	1756784
ul@@	O	-1	1756784
arly	O	-1	1756784
ti@@	O	-1	1756784
ght	O	-1	1756784
in	O	-1	1756784
S@@	O	-1	1756784
N@@	O	-1	1756784
R@@	O	-1	1756784
.	O	-1	1756784
B@@	O	-1	1756784
oth	O	-1	1756784
cell	O	-1	1756784
e@@	O	-1	1756784
le@@	O	-1	1756784
ments	O	-1	1756784
may	O	-1	1756784
suff@@	O	-1	1756784
er	O	-1	1756784
in	O	-1	1756784
common	O	-1	1756784
from	O	-1	1756784
met@@	O	-1	1756784
ab@@	O	-1	1756784
olic	O	-1	1756784
dist@@	O	-1	1756784
urb@@	O	-1	1756784
ance	O	-1	1756784
and	O	-1	1756784
neuro@@	B-Disease	D001480	1756784
trans@@	I-Disease	-1	1756784
mit@@	I-Disease	-1	1756784
ter	I-Disease	-1	1756784
dysfunction	I-Disease	-1	1756784
as	O	-1	1756784
occ@@	O	-1	1756784
ur	O	-1	1756784
during	O	-1	1756784
mas@@	O	-1	1756784
sive	O	-1	1756784
status	B-Disease	D013226	1756784
epilep@@	I-Disease	-1	1756784
tic@@	I-Disease	-1	1756784
us	I-Disease	-1	1756784
.	O	-1	1756784

Re@@	O	-1	1760851
duced	O	-1	1760851
cardi@@	B-Disease	D066126	1760851
otoxicity	I-Disease	-1	1760851
of	O	-1	1760851
dox@@	B-Chemical	D004317	1760851
orub@@	I-Chemical	-1	1760851
icin	I-Chemical	-1	1760851
given	O	-1	1760851
in	O	-1	1760851
the	O	-1	1760851
form	O	-1	1760851
of	O	-1	1760851
N@@	B-Chemical	C032976	1760851
-@@	I-Chemical	-1	1760851
(2@@	I-Chemical	-1	1760851
-@@	I-Chemical	-1	1760851
hydrox@@	I-Chemical	-1	1760851
y@@	I-Chemical	-1	1760851
prop@@	I-Chemical	-1	1760851
yl@@	I-Chemical	-1	1760851
)@@	I-Chemical	-1	1760851
meth@@	I-Chemical	-1	1760851
ac@@	I-Chemical	-1	1760851
r@@	I-Chemical	-1	1760851
yl@@	I-Chemical	-1	1760851
amide	I-Chemical	-1	1760851
con@@	O	-1	1760851
j@@	O	-1	1760851
u@@	O	-1	1760851
g@@	O	-1	1760851
at@@	O	-1	1760851
es@@	O	-1	1760851
:	O	-1	1760851
and	O	-1	1760851
experimental	O	-1	1760851
study	O	-1	1760851
in	O	-1	1760851
the	O	-1	1760851
rat@@	O	-1	1760851
.	O	-1	1760851
A	O	-1	1760851
rat	O	-1	1760851
model	O	-1	1760851
was	O	-1	1760851
used	O	-1	1760851
to	O	-1	1760851
evalu@@	O	-1	1760851
ate	O	-1	1760851
the	O	-1	1760851
gener@@	O	-1	1760851
al	O	-1	1760851
acute	O	-1	1760851
toxicity	B-Disease	D064420	1760851
and	O	-1	1760851
the	O	-1	1760851
l@@	O	-1	1760851
ate	O	-1	1760851
cardi@@	B-Disease	D066126	1760851
otoxicity	I-Disease	-1	1760851
of	O	-1	1760851
4	O	-1	1760851
mg/kg	O	-1	1760851
dox@@	B-Chemical	D004317	1760851
orub@@	I-Chemical	-1	1760851
icin	I-Chemical	-1	1760851
(	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
)	O	-1	1760851
given	O	-1	1760851
either	O	-1	1760851
as	O	-1	1760851
free	O	-1	1760851
drug	O	-1	1760851
or	O	-1	1760851
in	O	-1	1760851
the	O	-1	1760851
form	O	-1	1760851
of	O	-1	1760851
three	O	-1	1760851
N@@	B-Chemical	C032976	1760851
-@@	I-Chemical	-1	1760851
(2@@	I-Chemical	-1	1760851
-@@	I-Chemical	-1	1760851
hydrox@@	I-Chemical	-1	1760851
y@@	I-Chemical	-1	1760851
prop@@	I-Chemical	-1	1760851
yl@@	I-Chemical	-1	1760851
)@@	I-Chemical	-1	1760851
meth@@	I-Chemical	-1	1760851
ac@@	I-Chemical	-1	1760851
r@@	I-Chemical	-1	1760851
yl@@	I-Chemical	-1	1760851
amide	I-Chemical	-1	1760851
(	O	-1	1760851
H@@	B-Chemical	C032976	1760851
P@@	I-Chemical	-1	1760851
M@@	I-Chemical	-1	1760851
A	I-Chemical	-1	1760851
)	O	-1	1760851
co@@	O	-1	1760851
poly@@	O	-1	1760851
m@@	O	-1	1760851
er	O	-1	1760851
con@@	O	-1	1760851
j@@	O	-1	1760851
u@@	O	-1	1760851
g@@	O	-1	1760851
at@@	O	-1	1760851
es.	O	-1	1760851
In	O	-1	1760851
these	O	-1	1760851
H@@	B-Chemical	C032976	1760851
P@@	I-Chemical	-1	1760851
M@@	I-Chemical	-1	1760851
A	I-Chemical	-1	1760851
co@@	O	-1	1760851
poly@@	O	-1	1760851
mer@@	O	-1	1760851
s,	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
was	O	-1	1760851
co@@	O	-1	1760851
val@@	O	-1	1760851
ently	O	-1	1760851
b@@	O	-1	1760851
ound	O	-1	1760851
vi@@	O	-1	1760851
a	O	-1	1760851
p@@	O	-1	1760851
ep@@	O	-1	1760851
ti@@	O	-1	1760851
de	O	-1	1760851
lin@@	O	-1	1760851
k@@	O	-1	1760851
ages	O	-1	1760851
that	O	-1	1760851
were	O	-1	1760851
either	O	-1	1760851
non-@@	O	-1	1760851
bio@@	O	-1	1760851
de@@	O	-1	1760851
gra@@	O	-1	1760851
d@@	O	-1	1760851
able	O	-1	1760851
(@@	O	-1	1760851
G@@	O	-1	1760851
l@@	O	-1	1760851
y-@@	O	-1	1760851
G@@	O	-1	1760851
ly@@	O	-1	1760851
)	O	-1	1760851
or	O	-1	1760851
de@@	O	-1	1760851
gra@@	O	-1	1760851
d@@	O	-1	1760851
able	O	-1	1760851
by	O	-1	1760851
l@@	O	-1	1760851
ys@@	O	-1	1760851
os@@	O	-1	1760851
om@@	O	-1	1760851
al	O	-1	1760851
protein@@	O	-1	1760851
as@@	O	-1	1760851
es	O	-1	1760851
(	O	-1	1760851
G@@	B-Chemical	C504380	1760851
l@@	I-Chemical	-1	1760851
y-@@	I-Chemical	-1	1760851
P@@	I-Chemical	-1	1760851
he@@	I-Chemical	-1	1760851
-@@	I-Chemical	-1	1760851
L@@	I-Chemical	-1	1760851
eu@@	I-Chemical	-1	1760851
-@@	I-Chemical	-1	1760851
G@@	I-Chemical	-1	1760851
ly	I-Chemical	-1	1760851
).	O	-1	1760851
In	O	-1	1760851
addi@@	O	-1	1760851
tion,	O	-1	1760851
one	O	-1	1760851
bio@@	O	-1	1760851
de@@	O	-1	1760851
gra@@	O	-1	1760851
d@@	O	-1	1760851
able	O	-1	1760851
con@@	O	-1	1760851
j@@	O	-1	1760851
u@@	O	-1	1760851
g@@	O	-1	1760851
ate	O	-1	1760851
containing	O	-1	1760851
g@@	B-Chemical	D005688	1760851
al@@	I-Chemical	-1	1760851
act@@	I-Chemical	-1	1760851
os@@	I-Chemical	-1	1760851
amine	I-Chemical	-1	1760851
was	O	-1	1760851
use@@	O	-1	1760851
d@@	O	-1	1760851
;	O	-1	1760851
this	O	-1	1760851
re@@	O	-1	1760851
si@@	O	-1	1760851
due	O	-1	1760851
was	O	-1	1760851
t@@	O	-1	1760851
arg@@	O	-1	1760851
et@@	O	-1	1760851
ed	O	-1	1760851
to	O	-1	1760851
the	O	-1	1760851
li@@	O	-1	1760851
ver@@	O	-1	1760851
.	O	-1	1760851
O@@	O	-1	1760851
ver	O	-1	1760851
the	O	-1	1760851
first	O	-1	1760851
3	O	-1	1760851
weeks	O	-1	1760851
after	O	-1	1760851
the	O	-1	1760851
i.v@@	O	-1	1760851
.	O	-1	1760851
administration	O	-1	1760851
of	O	-1	1760851
free	O	-1	1760851
and	O	-1	1760851
poly@@	O	-1	1760851
mer@@	O	-1	1760851
-@@	O	-1	1760851
b@@	O	-1	1760851
ound	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
,	O	-1	1760851
all	O	-1	1760851
animals	O	-1	1760851
showed	O	-1	1760851
a	O	-1	1760851
transi@@	O	-1	1760851
ent	O	-1	1760851
reduction	O	-1	1760851
in	O	-1	1760851
body	O	-1	1760851
weigh@@	O	-1	1760851
t.	O	-1	1760851
However,	O	-1	1760851
the	O	-1	1760851
maxim@@	O	-1	1760851
al	O	-1	1760851
reduction	O	-1	1760851
in	O	-1	1760851
body	O	-1	1760851
weight	O	-1	1760851
seen	O	-1	1760851
in	O	-1	1760851
animals	O	-1	1760851
that	O	-1	1760851
received	O	-1	1760851
poly@@	O	-1	1760851
mer@@	O	-1	1760851
-@@	O	-1	1760851
b@@	O	-1	1760851
ound	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
(@@	O	-1	1760851
4	O	-1	1760851
mg/kg)	O	-1	1760851
was	O	-1	1760851
significantly	O	-1	1760851
lower	O	-1	1760851
than	O	-1	1760851
that	O	-1	1760851
observed	O	-1	1760851
in	O	-1	1760851
those	O	-1	1760851
that	O	-1	1760851
received	O	-1	1760851
free	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
(@@	O	-1	1760851
4	O	-1	1760851
mg/kg)	O	-1	1760851
or	O	-1	1760851
a	O	-1	1760851
mi@@	O	-1	1760851
x@@	O	-1	1760851
t@@	O	-1	1760851
ure	O	-1	1760851
of	O	-1	1760851
the	O	-1	1760851
un@@	O	-1	1760851
mo@@	O	-1	1760851
di@@	O	-1	1760851
fied	O	-1	1760851
pa@@	O	-1	1760851
rent	O	-1	1760851
H@@	B-Chemical	C032976	1760851
P@@	I-Chemical	-1	1760851
M@@	I-Chemical	-1	1760851
A	I-Chemical	-1	1760851
co@@	O	-1	1760851
poly@@	O	-1	1760851
m@@	O	-1	1760851
er	O	-1	1760851
and	O	-1	1760851
free	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
(@@	O	-1	1760851
4	O	-1	1760851
mg/kg@@	O	-1	1760851
;	O	-1	1760851
P	O	-1	1760851
less	O	-1	1760851
than	O	-1	1760851
0.0@@	O	-1	1760851
1).	O	-1	1760851
Th@@	O	-1	1760851
rou@@	O	-1	1760851
gh@@	O	-1	1760851
out	O	-1	1760851
the	O	-1	1760851
study	O	-1	1760851
(2@@	O	-1	1760851
0	O	-1	1760851
week@@	O	-1	1760851
s),	O	-1	1760851
de@@	O	-1	1760851
ath@@	O	-1	1760851
s	O	-1	1760851
related	O	-1	1760851
to	O	-1	1760851
cardi@@	B-Disease	D066126	1760851
otoxicity	I-Disease	-1	1760851
were	O	-1	1760851
observed	O	-1	1760851
only	O	-1	1760851
in	O	-1	1760851
animals	O	-1	1760851
that	O	-1	1760851
received	O	-1	1760851
either	O	-1	1760851
free	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
or	O	-1	1760851
the	O	-1	1760851
mi@@	O	-1	1760851
x@@	O	-1	1760851
t@@	O	-1	1760851
ure	O	-1	1760851
of	O	-1	1760851
H@@	B-Chemical	C032976	1760851
P@@	I-Chemical	-1	1760851
M@@	I-Chemical	-1	1760851
A	I-Chemical	-1	1760851
co@@	O	-1	1760851
poly@@	O	-1	1760851
m@@	O	-1	1760851
er	O	-1	1760851
and	O	-1	1760851
free	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
;	O	-1	1760851
in	O	-1	1760851
these	O	-1	1760851
cas@@	O	-1	1760851
es,	O	-1	1760851
hist@@	O	-1	1760851
ological	O	-1	1760851
investig@@	O	-1	1760851
ations	O	-1	1760851
revealed	O	-1	1760851
mark@@	O	-1	1760851
ed	O	-1	1760851
changes	O	-1	1760851
in	O	-1	1760851
the	O	-1	1760851
heart	O	-1	1760851
that	O	-1	1760851
were	O	-1	1760851
consist@@	O	-1	1760851
ent	O	-1	1760851
with	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
-induced	O	-1	1760851
cardi@@	B-Disease	D066126	1760851
otoxicity	I-Disease	-1	1760851
.	O	-1	1760851
S@@	O	-1	1760851
equ@@	O	-1	1760851
en@@	O	-1	1760851
tial	O	-1	1760851
meas@@	O	-1	1760851
ure@@	O	-1	1760851
ments	O	-1	1760851
of	O	-1	1760851
cardiac	O	-1	1760851
out@@	O	-1	1760851
pu@@	O	-1	1760851
t	O	-1	1760851
in	O	-1	1760851
sur@@	O	-1	1760851
vi@@	O	-1	1760851
ving	O	-1	1760851
animals	O	-1	1760851
that	O	-1	1760851
received	O	-1	1760851
either	O	-1	1760851
free	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
or	O	-1	1760851
the	O	-1	1760851
mi@@	O	-1	1760851
x@@	O	-1	1760851
t@@	O	-1	1760851
ure	O	-1	1760851
of	O	-1	1760851
H@@	B-Chemical	C032976	1760851
P@@	I-Chemical	-1	1760851
M@@	I-Chemical	-1	1760851
A	I-Chemical	-1	1760851
co@@	O	-1	1760851
poly@@	O	-1	1760851
m@@	O	-1	1760851
er	O	-1	1760851
and	O	-1	1760851
free	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
showed	O	-1	1760851
a	O	-1	1760851
reduction	O	-1	1760851
of	O	-1	1760851
appro@@	O	-1	1760851
xim@@	O	-1	1760851
ately	O	-1	1760851
3@@	O	-1	1760851
0%	O	-1	1760851
in	O	-1	1760851
function	O	-1	1760851
be@@	O	-1	1760851
g@@	O	-1	1760851
in@@	O	-1	1760851
ning	O	-1	1760851
at	O	-1	1760851
the	O	-1	1760851
4@@	O	-1	1760851
th	O	-1	1760851
week	O	-1	1760851
after	O	-1	1760851
drug	O	-1	1760851
administr@@	O	-1	1760851
ation.	O	-1	1760851
The	O	-1	1760851
heart	O	-1	1760851
rate	O	-1	1760851
in	O	-1	1760851
these	O	-1	1760851
animals	O	-1	1760851
was	O	-1	1760851
appro@@	O	-1	1760851
xim@@	O	-1	1760851
ately	O	-1	1760851
12@@	O	-1	1760851
%	O	-1	1760851
lower	O	-1	1760851
than	O	-1	1760851
that	O	-1	1760851
measured	O	-1	1760851
in	O	-1	1760851
ag@@	O	-1	1760851
e-@@	O	-1	1760851
mat@@	O	-1	1760851
ch@@	O	-1	1760851
ed	O	-1	1760851
control	O	-1	1760851
rats	O	-1	1760851
(P	O	-1	1760851
less	O	-1	1760851
than	O	-1	1760851
0.05@@	O	-1	1760851
).	O	-1	1760851
An@@	O	-1	1760851
im@@	O	-1	1760851
als	O	-1	1760851
that	O	-1	1760851
were	O	-1	1760851
given	O	-1	1760851
the	O	-1	1760851
H@@	B-Chemical	C032976	1760851
P@@	I-Chemical	-1	1760851
M@@	I-Chemical	-1	1760851
A	I-Chemical	-1	1760851
co@@	O	-1	1760851
poly@@	O	-1	1760851
m@@	O	-1	1760851
er	O	-1	1760851
con@@	O	-1	1760851
j@@	O	-1	1760851
u@@	O	-1	1760851
g@@	O	-1	1760851
ates	O	-1	1760851
containing	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
ex@@	O	-1	1760851
hib@@	O	-1	1760851
ited	O	-1	1760851
no	O	-1	1760851
significant	O	-1	1760851
change	O	-1	1760851
in	O	-1	1760851
cardiac	O	-1	1760851
out@@	O	-1	1760851
pu@@	O	-1	1760851
t	O	-1	1760851
throu@@	O	-1	1760851
gh@@	O	-1	1760851
out	O	-1	1760851
the	O	-1	1760851
study	O	-1	1760851
(P	O	-1	1760851
less	O	-1	1760851
than	O	-1	1760851
0.05@@	O	-1	1760851
).	O	-1	1760851
In	O	-1	1760851
addi@@	O	-1	1760851
tion,	O	-1	1760851
no	O	-1	1760851
significant	O	-1	1760851
hist@@	O	-1	1760851
ological	O	-1	1760851
change	O	-1	1760851
was	O	-1	1760851
observed	O	-1	1760851
in	O	-1	1760851
the	O	-1	1760851
heart	O	-1	1760851
of	O	-1	1760851
animals	O	-1	1760851
that	O	-1	1760851
received	O	-1	1760851
DO@@	B-Chemical	D004317	1760851
X	I-Chemical	-1	1760851
in	O	-1	1760851
the	O	-1	1760851
form	O	-1	1760851
of	O	-1	1760851
H@@	B-Chemical	C032976	1760851
P@@	I-Chemical	-1	1760851
M@@	I-Chemical	-1	1760851
A	I-Chemical	-1	1760851
co@@	O	-1	1760851
poly@@	O	-1	1760851
m@@	O	-1	1760851
er	O	-1	1760851
con@@	O	-1	1760851
j@@	O	-1	1760851
u@@	O	-1	1760851
g@@	O	-1	1760851
ates	O	-1	1760851
and	O	-1	1760851
were	O	-1	1760851
k@@	O	-1	1760851
ill@@	O	-1	1760851
ed	O	-1	1760851
at	O	-1	1760851
the	O	-1	1760851
end	O	-1	1760851
of	O	-1	1760851
the	O	-1	1760851
study.	O	-1	1760851
However,	O	-1	1760851
these	O	-1	1760851
animals	O	-1	1760851
had	O	-1	1760851
shown	O	-1	1760851
a	O	-1	1760851
significant	O	-1	1760851
increase	O	-1	1760851
in	O	-1	1760851
heart	O	-1	1760851
rate	O	-1	1760851
be@@	O	-1	1760851
g@@	O	-1	1760851
in@@	O	-1	1760851
ning	O	-1	1760851
at	O	-1	1760851
8	O	-1	1760851
weeks	O	-1	1760851
after	O	-1	1760851
drug	O	-1	1760851
administration	O	-1	1760851
(P	O	-1	1760851
less	O	-1	1760851
than	O	-1	1760851
0.0@@	O	-1	1760851
1@@	O	-1	1760851
)@@	O	-1	1760851
.@@	O	-1	1760851
(A@@	O	-1	1760851
B@@	O	-1	1760851
S@@	O	-1	1760851
TR@@	O	-1	1760851
AC@@	O	-1	1760851
T	O	-1	1760851
TR@@	O	-1	1760851
UN@@	O	-1	1760851
C@@	O	-1	1760851
AT@@	O	-1	1760851
E@@	O	-1	1760851
D	O	-1	1760851
A@@	O	-1	1760851
T	O	-1	1760851
4@@	O	-1	1760851
00	O	-1	1760851
W@@	O	-1	1760851
O@@	O	-1	1760851
RD@@	O	-1	1760851
S)	O	-1	1760851

T@@	O	-1	1779253
op@@	O	-1	1779253
ical	O	-1	1779253
0.0@@	O	-1	1779253
2@@	O	-1	1779253
5%	O	-1	1779253
cap@@	B-Chemical	D002211	1779253
sa@@	I-Chemical	-1	1779253
icin	I-Chemical	-1	1779253
in	O	-1	1779253
chronic	O	-1	1779253
post@@	B-Disease	D051474	1779253
-@@	I-Disease	-1	1779253
h@@	I-Disease	-1	1779253
er@@	I-Disease	-1	1779253
pe@@	I-Disease	-1	1779253
tic	I-Disease	-1	1779253
ne@@	I-Disease	-1	1779253
ur@@	I-Disease	-1	1779253
al@@	I-Disease	-1	1779253
g@@	I-Disease	-1	1779253
ia	I-Disease	-1	1779253
:	O	-1	1779253
efficac@@	O	-1	1779253
y,	O	-1	1779253
predic@@	O	-1	1779253
t@@	O	-1	1779253
ors	O	-1	1779253
of	O	-1	1779253
response	O	-1	1779253
and	O	-1	1779253
long-term	O	-1	1779253
cour@@	O	-1	1779253
se.	O	-1	1779253
In	O	-1	1779253
or@@	O	-1	1779253
der	O	-1	1779253
to	O	-1	1779253
evalu@@	O	-1	1779253
ate	O	-1	1779253
the	O	-1	1779253
efficac@@	O	-1	1779253
y,	O	-1	1779253
ti@@	O	-1	1779253
me@@	O	-1	1779253
-@@	O	-1	1779253
course	O	-1	1779253
of	O	-1	1779253
action	O	-1	1779253
and	O	-1	1779253
predic@@	O	-1	1779253
t@@	O	-1	1779253
ors	O	-1	1779253
of	O	-1	1779253
response	O	-1	1779253
to	O	-1	1779253
to@@	O	-1	1779253
p@@	O	-1	1779253
ical	O	-1	1779253
cap@@	B-Chemical	D002211	1779253
sa@@	I-Chemical	-1	1779253
icin	I-Chemical	-1	1779253
,	O	-1	1779253
3@@	O	-1	1779253
9	O	-1	1779253
patients	O	-1	1779253
with	O	-1	1779253
chronic	O	-1	1779253
post@@	B-Disease	D051474	1779253
-@@	I-Disease	-1	1779253
h@@	I-Disease	-1	1779253
er@@	I-Disease	-1	1779253
pe@@	I-Disease	-1	1779253
tic	I-Disease	-1	1779253
ne@@	I-Disease	-1	1779253
ur@@	I-Disease	-1	1779253
al@@	I-Disease	-1	1779253
g@@	I-Disease	-1	1779253
ia	I-Disease	-1	1779253
(	O	-1	1779253
P@@	B-Disease	D051474	1779253
H@@	I-Disease	-1	1779253
N	I-Disease	-1	1779253
),	O	-1	1779253
median	O	-1	1779253
duration	O	-1	1779253
24	O	-1	1779253
month@@	O	-1	1779253
s,	O	-1	1779253
were	O	-1	1779253
treated	O	-1	1779253
with	O	-1	1779253
0.0@@	O	-1	1779253
2@@	O	-1	1779253
5%	O	-1	1779253
cap@@	B-Chemical	D002211	1779253
sa@@	I-Chemical	-1	1779253
icin	I-Chemical	-1	1779253
cre@@	O	-1	1779253
am	O	-1	1779253
for	O	-1	1779253
8	O	-1	1779253
week@@	O	-1	1779253
s.	O	-1	1779253
D@@	O	-1	1779253
uring	O	-1	1779253
therapy	O	-1	1779253
the	O	-1	1779253
patients	O	-1	1779253
r@@	O	-1	1779253
ated	O	-1	1779253
their	O	-1	1779253
pain	B-Disease	D010146	1779253
on	O	-1	1779253
a	O	-1	1779253
visual	O	-1	1779253
an@@	O	-1	1779253
alo@@	O	-1	1779253
gu@@	O	-1	1779253
e	O	-1	1779253
s@@	O	-1	1779253
cal@@	O	-1	1779253
e	O	-1	1779253
(V@@	O	-1	1779253
A@@	O	-1	1779253
S)	O	-1	1779253
and	O	-1	1779253
a	O	-1	1779253
ver@@	O	-1	1779253
b@@	O	-1	1779253
al	O	-1	1779253
outcom@@	O	-1	1779253
e	O	-1	1779253
s@@	O	-1	1779253
cal@@	O	-1	1779253
e.	O	-1	1779253
A	O	-1	1779253
follow-up	O	-1	1779253
investig@@	O	-1	1779253
ation	O	-1	1779253
was	O	-1	1779253
performed	O	-1	1779253
10@@	O	-1	1779253
-1@@	O	-1	1779253
2	O	-1	1779253
months	O	-1	1779253
after	O	-1	1779253
study	O	-1	1779253
onset	O	-1	1779253
on	O	-1	1779253
the	O	-1	1779253
patients	O	-1	1779253
who	O	-1	1779253
had	O	-1	1779253
impro@@	O	-1	1779253
ved.	O	-1	1779253
N@@	O	-1	1779253
ine@@	O	-1	1779253
te@@	O	-1	1779253
en	O	-1	1779253
patients	O	-1	1779253
(4@@	O	-1	1779253
8.@@	O	-1	1779253
7@@	O	-1	1779253
%)	O	-1	1779253
subst@@	O	-1	1779253
anti@@	O	-1	1779253
ally	O	-1	1779253
improved	O	-1	1779253
after	O	-1	1779253
the	O	-1	1779253
8@@	O	-1	1779253
-@@	O	-1	1779253
week	O	-1	1779253
tri@@	O	-1	1779253
al@@	O	-1	1779253
;	O	-1	1779253
5	O	-1	1779253
(1@@	O	-1	1779253
2.@@	O	-1	1779253
8@@	O	-1	1779253
%)	O	-1	1779253
discontinu@@	O	-1	1779253
ed	O	-1	1779253
therapy	O	-1	1779253
due	O	-1	1779253
to	O	-1	1779253
side@@	O	-1	1779253
-@@	O	-1	1779253
effects	O	-1	1779253
such	O	-1	1779253
as	O	-1	1779253
int@@	O	-1	1779253
oler@@	O	-1	1779253
able	O	-1	1779253
cap@@	B-Chemical	D002211	1779253
sa@@	I-Chemical	-1	1779253
icin	I-Chemical	-1	1779253
-induced	O	-1	1779253
b@@	O	-1	1779253
ur@@	O	-1	1779253
ning	O	-1	1779253
sens@@	O	-1	1779253
ations	O	-1	1779253
(4@@	O	-1	1779253
)	O	-1	1779253
or	O	-1	1779253
mas@@	B-Disease	D008413	1779253
ti@@	I-Disease	-1	1779253
tis	I-Disease	-1	1779253
(1@@	O	-1	1779253
);	O	-1	1779253
15	O	-1	1779253
(3@@	O	-1	1779253
8.@@	O	-1	1779253
5@@	O	-1	1779253
%)	O	-1	1779253
reported	O	-1	1779253
no	O	-1	1779253
ben@@	O	-1	1779253
e@@	O	-1	1779253
f@@	O	-1	1779253
it@@	O	-1	1779253
.	O	-1	1779253
The	O	-1	1779253
decrease	O	-1	1779253
in	O	-1	1779253
V@@	O	-1	1779253
A@@	O	-1	1779253
S	O	-1	1779253
rat@@	O	-1	1779253
ings	O	-1	1779253
was	O	-1	1779253
significant	O	-1	1779253
after	O	-1	1779253
2	O	-1	1779253
weeks	O	-1	1779253
of	O	-1	1779253
continu@@	O	-1	1779253
ous	O	-1	1779253
ap@@	O	-1	1779253
plic@@	O	-1	1779253
ation.	O	-1	1779253
Of	O	-1	1779253
the	O	-1	1779253
respon@@	O	-1	1779253
der@@	O	-1	1779253
s	O	-1	1779253
7@@	O	-1	1779253
2.@@	O	-1	1779253
2@@	O	-1	1779253
%	O	-1	1779253
were	O	-1	1779253
sti@@	O	-1	1779253
ll	O	-1	1779253
improved	O	-1	1779253
at	O	-1	1779253
the	O	-1	1779253
follow-@@	O	-1	1779253
up@@	O	-1	1779253
;	O	-1	1779253
only	O	-1	1779253
on@@	O	-1	1779253
e-@@	O	-1	1779253
thir@@	O	-1	1779253
d	O	-1	1779253
of	O	-1	1779253
the@@	O	-1	1779253
m	O	-1	1779253
had	O	-1	1779253
continu@@	O	-1	1779253
ed	O	-1	1779253
ap@@	O	-1	1779253
plic@@	O	-1	1779253
ation	O	-1	1779253
ir@@	O	-1	1779253
reg@@	O	-1	1779253
ul@@	O	-1	1779253
ar@@	O	-1	1779253
ly.	O	-1	1779253
Treat@@	O	-1	1779253
ment	O	-1	1779253
effect	O	-1	1779253
was	O	-1	1779253
not	O	-1	1779253
dependent	O	-1	1779253
on	O	-1	1779253
patient@@	O	-1	1779253
's	O	-1	1779253
age,	O	-1	1779253
duration	O	-1	1779253
or	O	-1	1779253
lo@@	O	-1	1779253
cal@@	O	-1	1779253
ization	O	-1	1779253
of	O	-1	1779253
P@@	B-Disease	D051474	1779253
H@@	I-Disease	-1	1779253
N	I-Disease	-1	1779253
(@@	O	-1	1779253
tri@@	O	-1	1779253
g@@	O	-1	1779253
em@@	O	-1	1779253
inal	O	-1	1779253
invol@@	O	-1	1779253
vement	O	-1	1779253
was	O	-1	1779253
ex@@	O	-1	1779253
cl@@	O	-1	1779253
u@@	O	-1	1779253
de@@	O	-1	1779253
d@@	O	-1	1779253
),	O	-1	1779253
sens@@	B-Disease	-1	1779253
ory	I-Disease	-1	1779253
dist@@	I-Disease	-1	1779253
urb@@	I-Disease	-1	1779253
ance	I-Disease	-1	1779253
or	O	-1	1779253
pain	B-Disease	D010146	1779253
character@@	O	-1	1779253
.	O	-1	1779253
Treat@@	O	-1	1779253
ment	O	-1	1779253
response	O	-1	1779253
was	O	-1	1779253
not	O	-1	1779253
cor@@	O	-1	1779253
related	O	-1	1779253
with	O	-1	1779253
the	O	-1	1779253
inc@@	O	-1	1779253
id@@	O	-1	1779253
ence@@	O	-1	1779253
,	O	-1	1779253
ti@@	O	-1	1779253
me@@	O	-1	1779253
-@@	O	-1	1779253
course	O	-1	1779253
or	O	-1	1779253
severity	O	-1	1779253
of	O	-1	1779253
cap@@	B-Chemical	D002211	1779253
sa@@	I-Chemical	-1	1779253
icin	I-Chemical	-1	1779253
-induced	O	-1	1779253
b@@	O	-1	1779253
ur@@	O	-1	1779253
n@@	O	-1	1779253
ing.	O	-1	1779253
I@@	O	-1	1779253
f	O	-1	1779253
con@@	O	-1	1779253
fir@@	O	-1	1779253
m@@	O	-1	1779253
ed	O	-1	1779253
in	O	-1	1779253
controlled	O	-1	1779253
tri@@	O	-1	1779253
al@@	O	-1	1779253
s,	O	-1	1779253
the	O	-1	1779253
long-term	O	-1	1779253
results	O	-1	1779253
of	O	-1	1779253
this	O	-1	1779253
o@@	O	-1	1779253
pen@@	O	-1	1779253
,	O	-1	1779253
non-@@	O	-1	1779253
randomized	O	-1	1779253
study	O	-1	1779253
might	O	-1	1779253
indicate	O	-1	1779253
that	O	-1	1779253
the	O	-1	1779253
analge@@	O	-1	1779253
sic	O	-1	1779253
effect	O	-1	1779253
of	O	-1	1779253
cap@@	B-Chemical	D002211	1779253
sa@@	I-Chemical	-1	1779253
icin	I-Chemical	-1	1779253
in	O	-1	1779253
P@@	B-Disease	D051474	1779253
H@@	I-Disease	-1	1779253
N	I-Disease	-1	1779253
is	O	-1	1779253
mediated	O	-1	1779253
by	O	-1	1779253
both	O	-1	1779253
inter@@	O	-1	1779253
fe@@	O	-1	1779253
rence	O	-1	1779253
with	O	-1	1779253
neuro@@	O	-1	1779253
p@@	O	-1	1779253
ep@@	O	-1	1779253
ti@@	O	-1	1779253
de	O	-1	1779253
metabol@@	O	-1	1779253
ism	O	-1	1779253
and	O	-1	1779253
morph@@	O	-1	1779253
ological	O	-1	1779253
changes	O	-1	1779253
(@@	O	-1	1779253
per@@	O	-1	1779253
h@@	O	-1	1779253
ap@@	O	-1	1779253
s	O	-1	1779253
de@@	O	-1	1779253
gener@@	O	-1	1779253
ation@@	O	-1	1779253
)	O	-1	1779253
of	O	-1	1779253
n@@	O	-1	1779253
ocicep@@	O	-1	1779253
tive	O	-1	1779253
a@@	O	-1	1779253
fferen@@	O	-1	1779253
t@@	O	-1	1779253
s.	O	-1	1779253

S@@	B-Chemical	D012701	1837756
er@@	I-Chemical	-1	1837756
oton@@	I-Chemical	-1	1837756
in	I-Chemical	-1	1837756
re@@	O	-1	1837756
u@@	O	-1	1837756
pt@@	O	-1	1837756
ake	O	-1	1837756
inhibitor@@	O	-1	1837756
s,	O	-1	1837756
par@@	B-Disease	D010259	1837756
an@@	I-Disease	-1	1837756
o@@	I-Disease	-1	1837756
ia	I-Disease	-1	1837756
,	O	-1	1837756
and	O	-1	1837756
the	O	-1	1837756
ventr@@	O	-1	1837756
al	O	-1	1837756
bas@@	O	-1	1837756
al	O	-1	1837756
g@@	O	-1	1837756
ang@@	O	-1	1837756
li@@	O	-1	1837756
a.	O	-1	1837756
An@@	O	-1	1837756
ti@@	O	-1	1837756
depress@@	O	-1	1837756
ants	O	-1	1837756
have	O	-1	1837756
previously	O	-1	1837756
been	O	-1	1837756
associated	O	-1	1837756
with	O	-1	1837756
par@@	B-Disease	D010259	1837756
an@@	I-Disease	-1	1837756
oid	I-Disease	-1	1837756
reactions	O	-1	1837756
in	O	-1	1837756
psych@@	O	-1	1837756
i@@	O	-1	1837756
atric	O	-1	1837756
patients.	O	-1	1837756
F@@	O	-1	1837756
i@@	O	-1	1837756
ve	O	-1	1837756
cases	O	-1	1837756
of	O	-1	1837756
par@@	B-Disease	D010259	1837756
an@@	I-Disease	-1	1837756
oid	I-Disease	-1	1837756
ex@@	O	-1	1837756
ac@@	O	-1	1837756
er@@	O	-1	1837756
b@@	O	-1	1837756
ation	O	-1	1837756
with	O	-1	1837756
the	O	-1	1837756
seroton@@	B-Chemical	D012701	1837756
in	I-Chemical	-1	1837756
re@@	O	-1	1837756
u@@	O	-1	1837756
pt@@	O	-1	1837756
ake	O	-1	1837756
inhibitors	O	-1	1837756
flu@@	B-Chemical	D005473	1837756
ox@@	I-Chemical	-1	1837756
et@@	I-Chemical	-1	1837756
ine	I-Chemical	-1	1837756
and	O	-1	1837756
am@@	B-Chemical	D000639	1837756
it@@	I-Chemical	-1	1837756
ript@@	I-Chemical	-1	1837756
yl@@	I-Chemical	-1	1837756
ine	I-Chemical	-1	1837756
are	O	-1	1837756
reported	O	-1	1837756
he@@	O	-1	1837756
re.	O	-1	1837756
E@@	O	-1	1837756
le@@	O	-1	1837756
ments	O	-1	1837756
common	O	-1	1837756
to	O	-1	1837756
these	O	-1	1837756
cases	O	-1	1837756
included	O	-1	1837756
a	O	-1	1837756
hist@@	O	-1	1837756
ory	O	-1	1837756
of	O	-1	1837756
par@@	B-Disease	D010259	1837756
an@@	I-Disease	-1	1837756
oid	I-Disease	-1	1837756
sympto@@	O	-1	1837756
mat@@	O	-1	1837756
ology	O	-1	1837756
and	O	-1	1837756
the	O	-1	1837756
concomit@@	O	-1	1837756
ant	O	-1	1837756
occur@@	O	-1	1837756
rence	O	-1	1837756
of	O	-1	1837756
de@@	B-Disease	D003866	1837756
pressive	I-Disease	-1	1837756
and	I-Disease	-1	1837756
psycho@@	I-Disease	-1	1837756
tic	I-Disease	-1	1837756
symptoms	I-Disease	-1	1837756
de@@	B-Disease	D011618	1837756
pressive	I-Disease	-1	1837756
and	I-Disease	-1	1837756
psycho@@	I-Disease	-1	1837756
tic	I-Disease	-1	1837756
symptoms	I-Disease	-1	1837756
.	O	-1	1837756
Com@@	O	-1	1837756
plic@@	O	-1	1837756
ated	O	-1	1837756
de@@	B-Disease	D003866	1837756
pressive	I-Disease	-1	1837756
disorder@@	I-Disease	-1	1837756
s	I-Disease	-1	1837756
(@@	O	-1	1837756
including	O	-1	1837756
at@@	O	-1	1837756
yp@@	O	-1	1837756
ic@@	O	-1	1837756
ality	O	-1	1837756
of	O	-1	1837756
course	O	-1	1837756
and	O	-1	1837756
sympto@@	O	-1	1837756
mat@@	O	-1	1837756
olog@@	O	-1	1837756
y,	O	-1	1837756
chron@@	O	-1	1837756
ic@@	O	-1	1837756
ity,	O	-1	1837756
psycho@@	B-Disease	D011605	1837756
sis	I-Disease	-1	1837756
,	O	-1	1837756
b@@	O	-1	1837756
ip@@	O	-1	1837756
ol@@	O	-1	1837756
ar@@	O	-1	1837756
ity,	O	-1	1837756
and	O	-1	1837756
secondary	O	-1	1837756
onset	O	-1	1837756
in	O	-1	1837756
the	O	-1	1837756
course	O	-1	1837756
of	O	-1	1837756
a	O	-1	1837756
prim@@	O	-1	1837756
ary	O	-1	1837756
psycho@@	B-Disease	D011605	1837756
sis	I-Disease	-1	1837756
)	O	-1	1837756
may	O	-1	1837756
present	O	-1	1837756
partic@@	O	-1	1837756
ular	O	-1	1837756
vul@@	O	-1	1837756
ner@@	O	-1	1837756
ability	O	-1	1837756
to	O	-1	1837756
par@@	B-Disease	D010259	1837756
an@@	I-Disease	-1	1837756
oid	I-Disease	-1	1837756
ex@@	O	-1	1837756
ac@@	O	-1	1837756
er@@	O	-1	1837756
b@@	O	-1	1837756
ations	O	-1	1837756
associated	O	-1	1837756
with	O	-1	1837756
seroton@@	B-Chemical	D012701	1837756
in	I-Chemical	-1	1837756
re@@	O	-1	1837756
u@@	O	-1	1837756
pt@@	O	-1	1837756
ake	O	-1	1837756
inhibitor@@	O	-1	1837756
s.	O	-1	1837756
Although	O	-1	1837756
the	O	-1	1837756
pharmac@@	O	-1	1837756
ology	O	-1	1837756
and	O	-1	1837756
neuro@@	O	-1	1837756
bio@@	O	-1	1837756
log@@	O	-1	1837756
y	O	-1	1837756
of	O	-1	1837756
par@@	B-Disease	D010259	1837756
an@@	I-Disease	-1	1837756
o@@	I-Disease	-1	1837756
ia	I-Disease	-1	1837756
re@@	O	-1	1837756
ma@@	O	-1	1837756
in	O	-1	1837756
c@@	O	-1	1837756
r@@	O	-1	1837756
yp@@	O	-1	1837756
tic@@	O	-1	1837756
,	O	-1	1837756
several	O	-1	1837756
mechanis@@	O	-1	1837756
m@@	O	-1	1837756
s,	O	-1	1837756
including	O	-1	1837756
5@@	O	-1	1837756
H@@	O	-1	1837756
T@@	O	-1	1837756
3	O	-1	1837756
receptor@@	O	-1	1837756
-@@	O	-1	1837756
mediated	O	-1	1837756
dopamine	B-Chemical	D004298	1837756
rele@@	O	-1	1837756
ase,	O	-1	1837756
beta-@@	O	-1	1837756
nor@@	O	-1	1837756
adrenergic	O	-1	1837756
receptor	O	-1	1837756
do@@	O	-1	1837756
w@@	O	-1	1837756
n@@	O	-1	1837756
reg@@	O	-1	1837756
ul@@	O	-1	1837756
ation,	O	-1	1837756
or	O	-1	1837756
G@@	O	-1	1837756
A@@	O	-1	1837756
BA@@	O	-1	1837756
B	O	-1	1837756
receptor	O	-1	1837756
u@@	O	-1	1837756
pre@@	O	-1	1837756
g@@	O	-1	1837756
ulation	O	-1	1837756
act@@	O	-1	1837756
ing	O	-1	1837756
in	O	-1	1837756
the	O	-1	1837756
v@@	O	-1	1837756
ic@@	O	-1	1837756
in@@	O	-1	1837756
ity	O	-1	1837756
of	O	-1	1837756
the	O	-1	1837756
ventr@@	O	-1	1837756
al	O	-1	1837756
bas@@	O	-1	1837756
al	O	-1	1837756
g@@	O	-1	1837756
ang@@	O	-1	1837756
li@@	O	-1	1837756
a	O	-1	1837756
(@@	O	-1	1837756
possib@@	O	-1	1837756
ly	O	-1	1837756
in	O	-1	1837756
lat@@	O	-1	1837756
eral	O	-1	1837756
or@@	O	-1	1837756
b@@	O	-1	1837756
it@@	O	-1	1837756
of@@	O	-1	1837756
ron@@	O	-1	1837756
t@@	O	-1	1837756
al	O	-1	1837756
or	O	-1	1837756
an@@	O	-1	1837756
ter@@	O	-1	1837756
ior	O	-1	1837756
c@@	O	-1	1837756
ing@@	O	-1	1837756
ul@@	O	-1	1837756
ate	O	-1	1837756
cir@@	O	-1	1837756
c@@	O	-1	1837756
u@@	O	-1	1837756
it@@	O	-1	1837756
s),	O	-1	1837756
might	O	-1	1837756
app@@	O	-1	1837756
ly	O	-1	1837756
to	O	-1	1837756
this	O	-1	1837756
phen@@	O	-1	1837756
om@@	O	-1	1837756
en@@	O	-1	1837756
on@@	O	-1	1837756
.	O	-1	1837756
These	O	-1	1837756
cases	O	-1	1837756
c@@	O	-1	1837756
all	O	-1	1837756
atten@@	O	-1	1837756
tion	O	-1	1837756
to	O	-1	1837756
possible	O	-1	1837756
par@@	B-Disease	D010259	1837756
an@@	I-Disease	-1	1837756
oid	I-Disease	-1	1837756
ex@@	O	-1	1837756
ac@@	O	-1	1837756
er@@	O	-1	1837756
b@@	O	-1	1837756
ations	O	-1	1837756
with	O	-1	1837756
seroton@@	B-Chemical	D012701	1837756
in	I-Chemical	-1	1837756
re@@	O	-1	1837756
u@@	O	-1	1837756
pt@@	O	-1	1837756
ake	O	-1	1837756
block@@	O	-1	1837756
ers	O	-1	1837756
in	O	-1	1837756
sel@@	O	-1	1837756
ect	O	-1	1837756
patients	O	-1	1837756
and	O	-1	1837756
ra@@	O	-1	1837756
is@@	O	-1	1837756
e	O	-1	1837756
neuro@@	O	-1	1837756
bio@@	O	-1	1837756
log@@	O	-1	1837756
ical	O	-1	1837756
con@@	O	-1	1837756
si@@	O	-1	1837756
der@@	O	-1	1837756
ations	O	-1	1837756
reg@@	O	-1	1837756
ar@@	O	-1	1837756
ding	O	-1	1837756
par@@	B-Disease	D010259	1837756
an@@	I-Disease	-1	1837756
o@@	I-Disease	-1	1837756
ia	I-Disease	-1	1837756
.	O	-1	1837756

F@@	O	-1	1858969
i@@	O	-1	1858969
ve	O	-1	1858969
cases	O	-1	1858969
of	O	-1	1858969
encephal@@	B-Disease	D004660	1858969
iti@@	I-Disease	-1	1858969
s	I-Disease	-1	1858969
during	O	-1	1858969
treatment	O	-1	1858969
of	O	-1	1858969
lo@@	B-Disease	D008118	1858969
ia@@	I-Disease	-1	1858969
sis	I-Disease	-1	1858969
with	O	-1	1858969
di@@	B-Chemical	D004049	1858969
eth@@	I-Chemical	-1	1858969
yl@@	I-Chemical	-1	1858969
carbam@@	I-Chemical	-1	1858969
az@@	I-Chemical	-1	1858969
ine	I-Chemical	-1	1858969
.	O	-1	1858969
F@@	O	-1	1858969
i@@	O	-1	1858969
ve	O	-1	1858969
cases	O	-1	1858969
of	O	-1	1858969
encephal@@	B-Disease	D004660	1858969
iti@@	I-Disease	-1	1858969
s	I-Disease	-1	1858969
following	O	-1	1858969
treatment	O	-1	1858969
with	O	-1	1858969
di@@	B-Chemical	D004049	1858969
eth@@	I-Chemical	-1	1858969
yl@@	I-Chemical	-1	1858969
carbam@@	I-Chemical	-1	1858969
az@@	I-Chemical	-1	1858969
ine	I-Chemical	-1	1858969
(	O	-1	1858969
D@@	B-Chemical	D004049	1858969
E@@	I-Chemical	-1	1858969
C	I-Chemical	-1	1858969
)	O	-1	1858969
were	O	-1	1858969
observed	O	-1	1858969
in	O	-1	1858969
Con@@	O	-1	1858969
g@@	O	-1	1858969
ol@@	O	-1	1858969
ese	O	-1	1858969
patients	O	-1	1858969
with	O	-1	1858969
L@@	O	-1	1858969
o@@	O	-1	1858969
a	O	-1	1858969
lo@@	O	-1	1858969
a	O	-1	1858969
f@@	B-Disease	D005368	1858969
il@@	I-Disease	-1	1858969
ar@@	I-Disease	-1	1858969
ia@@	I-Disease	-1	1858969
sis	I-Disease	-1	1858969
.	O	-1	1858969
Two	O	-1	1858969
cases	O	-1	1858969
had	O	-1	1858969
a	O	-1	1858969
f@@	O	-1	1858969
atal	O	-1	1858969
outcom@@	O	-1	1858969
e	O	-1	1858969
and	O	-1	1858969
one	O	-1	1858969
resulted	O	-1	1858969
in	O	-1	1858969
severe	O	-1	1858969
sequ@@	O	-1	1858969
el@@	O	-1	1858969
a@@	O	-1	1858969
e.	O	-1	1858969
The	O	-1	1858969
not@@	O	-1	1858969
able	O	-1	1858969
fac@@	O	-1	1858969
t	O	-1	1858969
was	O	-1	1858969
that	O	-1	1858969
this	O	-1	1858969
complication	O	-1	1858969
occurred	O	-1	1858969
in	O	-1	1858969
three	O	-1	1858969
patients	O	-1	1858969
hospit@@	O	-1	1858969
al@@	O	-1	1858969
ized	O	-1	1858969
before	O	-1	1858969
treatment	O	-1	1858969
be@@	O	-1	1858969
g@@	O	-1	1858969
an@@	O	-1	1858969
,	O	-1	1858969
with	O	-1	1858969
whom	O	-1	1858969
partic@@	O	-1	1858969
ul@@	O	-1	1858969
arly	O	-1	1858969
stric@@	O	-1	1858969
t	O	-1	1858969
therapeutic	O	-1	1858969
pre@@	O	-1	1858969
cau@@	O	-1	1858969
tions	O	-1	1858969
were	O	-1	1858969
tak@@	O	-1	1858969
en@@	O	-1	1858969
,	O	-1	1858969
i.@@	O	-1	1858969
e@@	O	-1	1858969
.,	O	-1	1858969
initial	O	-1	1858969
dose	O	-1	1858969
less	O	-1	1858969
than	O	-1	1858969
10	O	-1	1858969
mg	O	-1	1858969
of	O	-1	1858969
D@@	B-Chemical	D004049	1858969
E@@	I-Chemical	-1	1858969
C	I-Chemical	-1	1858969
,	O	-1	1858969
very	O	-1	1858969
gra@@	O	-1	1858969
du@@	O	-1	1858969
al	O	-1	1858969
dose	O	-1	1858969
increas@@	O	-1	1858969
es,	O	-1	1858969
and	O	-1	1858969
associated	O	-1	1858969
anti@@	O	-1	1858969
-@@	O	-1	1858969
all@@	O	-1	1858969
ergic	O	-1	1858969
treatment.	O	-1	1858969
This	O	-1	1858969
type	O	-1	1858969
of	O	-1	1858969
drug@@	O	-1	1858969
-induced	O	-1	1858969
complication	O	-1	1858969
may	O	-1	1858969
not	O	-1	1858969
be	O	-1	1858969
that	O	-1	1858969
un@@	O	-1	1858969
common	O	-1	1858969
in	O	-1	1858969
high@@	O	-1	1858969
ly	O	-1	1858969
en@@	O	-1	1858969
de@@	O	-1	1858969
mic	O	-1	1858969
regi@@	O	-1	1858969
on@@	O	-1	1858969
s.	O	-1	1858969
It	O	-1	1858969
occur@@	O	-1	1858969
s	O	-1	1858969
prim@@	O	-1	1858969
ar@@	O	-1	1858969
il@@	O	-1	1858969
y,	O	-1	1858969
but	O	-1	1858969
not	O	-1	1858969
ex@@	O	-1	1858969
cl@@	O	-1	1858969
u@@	O	-1	1858969
si@@	O	-1	1858969
vel@@	O	-1	1858969
y,	O	-1	1858969
in	O	-1	1858969
subjects	O	-1	1858969
present@@	O	-1	1858969
ing	O	-1	1858969
with	O	-1	1858969
a	O	-1	1858969
high	O	-1	1858969
micro@@	O	-1	1858969
f@@	O	-1	1858969
il@@	O	-1	1858969
ari@@	O	-1	1858969
al	O	-1	1858969
lo@@	O	-1	1858969
ad@@	O	-1	1858969
.	O	-1	1858969
The	O	-1	1858969
rel@@	O	-1	1858969
ationship	O	-1	1858969
between	O	-1	1858969
the	O	-1	1858969
occur@@	O	-1	1858969
rence	O	-1	1858969
of	O	-1	1858969
encephal@@	B-Disease	D004660	1858969
iti@@	I-Disease	-1	1858969
s	I-Disease	-1	1858969
and	O	-1	1858969
the	O	-1	1858969
decrease	O	-1	1858969
in	O	-1	1858969
micro@@	B-Disease	-1	1858969
f@@	I-Disease	-1	1858969
il@@	I-Disease	-1	1858969
a@@	I-Disease	-1	1858969
re@@	I-Disease	-1	1858969
mia	I-Disease	-1	1858969
is	O	-1	1858969
ev@@	O	-1	1858969
id@@	O	-1	1858969
ent@@	O	-1	1858969
.	O	-1	1858969
The	O	-1	1858969
path@@	O	-1	1858969
oph@@	O	-1	1858969
ysi@@	O	-1	1858969
ological	O	-1	1858969
mechanisms	O	-1	1858969
are	O	-1	1858969
discus@@	O	-1	1858969
sed	O	-1	1858969
in	O	-1	1858969
the	O	-1	1858969
li@@	O	-1	1858969
ght	O	-1	1858969
of	O	-1	1858969
these	O	-1	1858969
observ@@	O	-1	1858969
ations	O	-1	1858969
and	O	-1	1858969
the	O	-1	1858969
fe@@	O	-1	1858969
w	O	-1	1858969
other	O	-1	1858969
comm@@	O	-1	1858969
ents	O	-1	1858969
on	O	-1	1858969
this	O	-1	1858969
subj@@	O	-1	1858969
ect	O	-1	1858969
pu@@	O	-1	1858969
bl@@	O	-1	1858969
ished	O	-1	1858969
in	O	-1	1858969
the	O	-1	1858969
literat@@	O	-1	1858969
ure.	O	-1	1858969

De@@	B-Disease	D003693	1905439
li@@	I-Disease	-1	1905439
ri@@	I-Disease	-1	1905439
um	I-Disease	-1	1905439
in	O	-1	1905439
an	O	-1	1905439
el@@	O	-1	1905439
der@@	O	-1	1905439
ly	O	-1	1905439
woman	O	-1	1905439
possib@@	O	-1	1905439
ly	O	-1	1905439
associated	O	-1	1905439
with	O	-1	1905439
administration	O	-1	1905439
of	O	-1	1905439
m@@	B-Chemical	D016595	1905439
iso@@	I-Chemical	-1	1905439
pro@@	I-Chemical	-1	1905439
st@@	I-Chemical	-1	1905439
ol	I-Chemical	-1	1905439
.	O	-1	1905439
M@@	B-Chemical	D016595	1905439
iso@@	I-Chemical	-1	1905439
pro@@	I-Chemical	-1	1905439
st@@	I-Chemical	-1	1905439
ol	I-Chemical	-1	1905439
has	O	-1	1905439
been	O	-1	1905439
associated	O	-1	1905439
with	O	-1	1905439
adverse	O	-1	1905439
reac@@	O	-1	1905439
tion@@	O	-1	1905439
s,	O	-1	1905439
including	O	-1	1905439
gast@@	O	-1	1905439
ro@@	O	-1	1905439
in@@	O	-1	1905439
test@@	O	-1	1905439
inal	O	-1	1905439
symptom@@	O	-1	1905439
s,	O	-1	1905439
g@@	O	-1	1905439
y@@	O	-1	1905439
nec@@	O	-1	1905439
ologic	O	-1	1905439
pro@@	O	-1	1905439
ble@@	O	-1	1905439
m@@	O	-1	1905439
s,	O	-1	1905439
and	O	-1	1905439
headac@@	B-Disease	D006261	1905439
he	I-Disease	-1	1905439
.	O	-1	1905439
Ch@@	O	-1	1905439
ang@@	O	-1	1905439
es	O	-1	1905439
in	O	-1	1905439
mental	O	-1	1905439
stat@@	O	-1	1905439
us,	O	-1	1905439
however,	O	-1	1905439
have	O	-1	1905439
not	O	-1	1905439
been	O	-1	1905439
repor@@	O	-1	1905439
ted.	O	-1	1905439
We	O	-1	1905439
present	O	-1	1905439
a	O	-1	1905439
case	O	-1	1905439
in	O	-1	1905439
which	O	-1	1905439
an	O	-1	1905439
8@@	O	-1	1905439
9@@	O	-1	1905439
-@@	O	-1	1905439
year-old	O	-1	1905439
woman	O	-1	1905439
in	O	-1	1905439
a	O	-1	1905439
long-term	O	-1	1905439
car@@	O	-1	1905439
e	O	-1	1905439
fac@@	O	-1	1905439
ility	O	-1	1905439
b@@	O	-1	1905439
ec@@	O	-1	1905439
am@@	O	-1	1905439
e	O	-1	1905439
conf@@	O	-1	1905439
used	O	-1	1905439
after	O	-1	1905439
the	O	-1	1905439
initi@@	O	-1	1905439
ation	O	-1	1905439
of	O	-1	1905439
m@@	B-Chemical	D016595	1905439
iso@@	I-Chemical	-1	1905439
pro@@	I-Chemical	-1	1905439
st@@	I-Chemical	-1	1905439
ol	I-Chemical	-1	1905439
therapy.	O	-1	1905439
The	O	-1	1905439
patient@@	O	-1	1905439
's	O	-1	1905439
change	O	-1	1905439
in	O	-1	1905439
mental	O	-1	1905439
status	O	-1	1905439
was	O	-1	1905439
first	O	-1	1905439
reported	O	-1	1905439
n@@	O	-1	1905439
ine	O	-1	1905439
days	O	-1	1905439
after	O	-1	1905439
the	O	-1	1905439
initi@@	O	-1	1905439
ation	O	-1	1905439
of	O	-1	1905439
therapy.	O	-1	1905439
H@@	O	-1	1905439
er	O	-1	1905439
de@@	B-Disease	D003693	1905439
li@@	I-Disease	-1	1905439
ri@@	I-Disease	-1	1905439
um	I-Disease	-1	1905439
significantly	O	-1	1905439
improved	O	-1	1905439
after	O	-1	1905439
m@@	B-Chemical	D016595	1905439
iso@@	I-Chemical	-1	1905439
pro@@	I-Chemical	-1	1905439
st@@	I-Chemical	-1	1905439
ol	I-Chemical	-1	1905439
was	O	-1	1905439
discontinu@@	O	-1	1905439
ed	O	-1	1905439
and	O	-1	1905439
h@@	O	-1	1905439
er	O	-1	1905439
mental	O	-1	1905439
status	O	-1	1905439
retur@@	O	-1	1905439
n@@	O	-1	1905439
ed	O	-1	1905439
to	O	-1	1905439
normal	O	-1	1905439
within	O	-1	1905439
a	O	-1	1905439
week@@	O	-1	1905439
.	O	-1	1905439
B@@	O	-1	1905439
ecause	O	-1	1905439
no	O	-1	1905439
other	O	-1	1905439
factors	O	-1	1905439
related	O	-1	1905439
to	O	-1	1905439
this	O	-1	1905439
patient	O	-1	1905439
chang@@	O	-1	1905439
ed	O	-1	1905439
significant@@	O	-1	1905439
ly,	O	-1	1905439
the	O	-1	1905439
de@@	B-Disease	D003693	1905439
li@@	I-Disease	-1	1905439
ri@@	I-Disease	-1	1905439
um	I-Disease	-1	1905439
experienced	O	-1	1905439
by	O	-1	1905439
this	O	-1	1905439
patient	O	-1	1905439
possib@@	O	-1	1905439
ly	O	-1	1905439
resulted	O	-1	1905439
from	O	-1	1905439
m@@	B-Chemical	D016595	1905439
iso@@	I-Chemical	-1	1905439
pro@@	I-Chemical	-1	1905439
st@@	I-Chemical	-1	1905439
ol	I-Chemical	-1	1905439
therapy.	O	-1	1905439

H@@	O	-1	1943082
ep@@	O	-1	1943082
at@@	O	-1	1943082
oc@@	O	-1	1943082
ell@@	O	-1	1943082
ular	O	-1	1943082
oxid@@	O	-1	1943082
ant	O	-1	1943082
stres@@	O	-1	1943082
s	O	-1	1943082
following	O	-1	1943082
in@@	O	-1	1943082
test@@	O	-1	1943082
inal	O	-1	1943082
ischem@@	B-Disease	D007511	1943082
ia	I-Disease	-1	1943082
-	O	-1	1943082
re@@	B-Disease	D015427	1943082
per@@	I-Disease	-1	1943082
f@@	I-Disease	-1	1943082
usion	I-Disease	-1	1943082
injury	I-Disease	-1	1943082
.	O	-1	1943082
Re@@	O	-1	1943082
per@@	O	-1	1943082
f@@	O	-1	1943082
usion	O	-1	1943082
of	O	-1	1943082
ischem@@	B-Disease	D007511	1943082
ic	I-Disease	-1	1943082
in@@	O	-1	1943082
test@@	O	-1	1943082
ine	O	-1	1943082
results	O	-1	1943082
in	O	-1	1943082
acute	O	-1	1943082
liver	B-Disease	D017093	1943082
dysfunction	I-Disease	-1	1943082
character@@	O	-1	1943082
ized	O	-1	1943082
by	O	-1	1943082
hepat@@	O	-1	1943082
oc@@	O	-1	1943082
ell@@	O	-1	1943082
ular	O	-1	1943082
enzyme	O	-1	1943082
release	O	-1	1943082
into	O	-1	1943082
plas@@	O	-1	1943082
ma@@	O	-1	1943082
,	O	-1	1943082
reduction	O	-1	1943082
in	O	-1	1943082
b@@	O	-1	1943082
ile	O	-1	1943082
flow	O	-1	1943082
rat@@	O	-1	1943082
e,	O	-1	1943082
and	O	-1	1943082
ne@@	O	-1	1943082
ut@@	O	-1	1943082
ro@@	O	-1	1943082
ph@@	O	-1	1943082
il	O	-1	1943082
sequ@@	O	-1	1943082
est@@	O	-1	1943082
ration	O	-1	1943082
within	O	-1	1943082
the	O	-1	1943082
li@@	O	-1	1943082
ver@@	O	-1	1943082
.	O	-1	1943082
The	O	-1	1943082
path@@	O	-1	1943082
oph@@	O	-1	1943082
ysi@@	O	-1	1943082
ology	O	-1	1943082
underlying	O	-1	1943082
this	O	-1	1943082
acute	O	-1	1943082
hepatic	B-Disease	D056486	1943082
injury	I-Disease	-1	1943082
is	O	-1	1943082
un@@	O	-1	1943082
know@@	O	-1	1943082
n@@	O	-1	1943082
.	O	-1	1943082
This	O	-1	1943082
study	O	-1	1943082
was	O	-1	1943082
under@@	O	-1	1943082
tak@@	O	-1	1943082
en	O	-1	1943082
to	O	-1	1943082
determine	O	-1	1943082
whether	O	-1	1943082
oxid@@	O	-1	1943082
ants	O	-1	1943082
are	O	-1	1943082
associated	O	-1	1943082
with	O	-1	1943082
the	O	-1	1943082
hepatic	B-Disease	D056486	1943082
injury	I-Disease	-1	1943082
and	O	-1	1943082
to	O	-1	1943082
determine	O	-1	1943082
the	O	-1	1943082
rel@@	O	-1	1943082
ative	O	-1	1943082
valu@@	O	-1	1943082
e	O	-1	1943082
of	O	-1	1943082
several	O	-1	1943082
in@@	O	-1	1943082
direct	O	-1	1943082
meth@@	O	-1	1943082
o@@	O	-1	1943082
ds	O	-1	1943082
of	O	-1	1943082
assess@@	O	-1	1943082
ing	O	-1	1943082
oxid@@	O	-1	1943082
ant	O	-1	1943082
exposure	O	-1	1943082
in	O	-1	1943082
viv@@	O	-1	1943082
o@@	O	-1	1943082
.	O	-1	1943082
R@@	O	-1	1943082
at@@	O	-1	1943082
s	O	-1	1943082
were	O	-1	1943082
subj@@	O	-1	1943082
ected	O	-1	1943082
to	O	-1	1943082
a	O	-1	1943082
stand@@	O	-1	1943082
ardi@@	O	-1	1943082
zed	O	-1	1943082
in@@	O	-1	1943082
test@@	O	-1	1943082
inal	O	-1	1943082
ischem@@	B-Disease	D007511	1943082
ia	I-Disease	-1	1943082
-	O	-1	1943082
re@@	B-Disease	D015427	1943082
per@@	I-Disease	-1	1943082
f@@	I-Disease	-1	1943082
usion	I-Disease	-1	1943082
injury	I-Disease	-1	1943082
.	O	-1	1943082
He@@	O	-1	1943082
pati@@	O	-1	1943082
c	O	-1	1943082
tissue	O	-1	1943082
was	O	-1	1943082
ass@@	O	-1	1943082
ayed	O	-1	1943082
for	O	-1	1943082
li@@	O	-1	1943082
pid	O	-1	1943082
per@@	O	-1	1943082
oxid@@	O	-1	1943082
ation	O	-1	1943082
produc@@	O	-1	1943082
ts	O	-1	1943082
and	O	-1	1943082
ox@@	B-Chemical	D019803	1943082
i@@	I-Chemical	-1	1943082
di@@	I-Chemical	-1	1943082
zed	I-Chemical	-1	1943082
and	I-Chemical	-1	1943082
reduced	I-Chemical	-1	1943082
glut@@	I-Chemical	-1	1943082
athi@@	I-Chemical	-1	1943082
one	I-Chemical	-1	1943082
ox@@	B-Chemical	D005978	1943082
i@@	I-Chemical	-1	1943082
di@@	I-Chemical	-1	1943082
zed	I-Chemical	-1	1943082
and	I-Chemical	-1	1943082
reduced	I-Chemical	-1	1943082
glut@@	I-Chemical	-1	1943082
athi@@	I-Chemical	-1	1943082
one	I-Chemical	-1	1943082
.	O	-1	1943082
There	O	-1	1943082
was	O	-1	1943082
no	O	-1	1943082
change	O	-1	1943082
in	O	-1	1943082
hepatic	O	-1	1943082
tissue	O	-1	1943082
total	O	-1	1943082
glut@@	B-Chemical	D005978	1943082
athi@@	I-Chemical	-1	1943082
one	I-Chemical	-1	1943082
following	O	-1	1943082
in@@	O	-1	1943082
test@@	O	-1	1943082
inal	O	-1	1943082
ischem@@	B-Disease	D007511	1943082
ia	I-Disease	-1	1943082
-	O	-1	1943082
re@@	B-Disease	D015427	1943082
per@@	I-Disease	-1	1943082
f@@	I-Disease	-1	1943082
usion	I-Disease	-1	1943082
injury	I-Disease	-1	1943082
.	O	-1	1943082
O@@	B-Chemical	D019803	1943082
xi@@	I-Chemical	-1	1943082
di@@	I-Chemical	-1	1943082
zed	I-Chemical	-1	1943082
glut@@	I-Chemical	-1	1943082
athi@@	I-Chemical	-1	1943082
one	I-Chemical	-1	1943082
(	O	-1	1943082
G@@	B-Chemical	D019803	1943082
S@@	I-Chemical	-1	1943082
S@@	I-Chemical	-1	1943082
G	I-Chemical	-1	1943082
)	O	-1	1943082
increased	O	-1	1943082
significantly	O	-1	1943082
following	O	-1	1943082
30	O	-1	1943082
and	O	-1	1943082
60	O	-1	1943082
min	O	-1	1943082
of	O	-1	1943082
re@@	O	-1	1943082
per@@	O	-1	1943082
fu@@	O	-1	1943082
sion.	O	-1	1943082
There	O	-1	1943082
was	O	-1	1943082
no	O	-1	1943082
increase	O	-1	1943082
in	O	-1	1943082
any	O	-1	1943082
of	O	-1	1943082
the	O	-1	1943082
produc@@	O	-1	1943082
ts	O	-1	1943082
of	O	-1	1943082
li@@	O	-1	1943082
pid	O	-1	1943082
per@@	O	-1	1943082
oxid@@	O	-1	1943082
ation	O	-1	1943082
associated	O	-1	1943082
with	O	-1	1943082
this	O	-1	1943082
injur@@	O	-1	1943082
y.	O	-1	1943082
An	O	-1	1943082
increase	O	-1	1943082
in	O	-1	1943082
G@@	B-Chemical	D019803	1943082
S@@	I-Chemical	-1	1943082
S@@	I-Chemical	-1	1943082
G	I-Chemical	-1	1943082
within	O	-1	1943082
hepatic	O	-1	1943082
tissue	O	-1	1943082
during	O	-1	1943082
in@@	O	-1	1943082
test@@	O	-1	1943082
inal	O	-1	1943082
re@@	O	-1	1943082
per@@	O	-1	1943082
f@@	O	-1	1943082
usion	O	-1	1943082
suggests	O	-1	1943082
exposure	O	-1	1943082
of	O	-1	1943082
hepat@@	O	-1	1943082
ocy@@	O	-1	1943082
tes	O	-1	1943082
to	O	-1	1943082
an	O	-1	1943082
oxid@@	O	-1	1943082
ant	O	-1	1943082
stres@@	O	-1	1943082
s.	O	-1	1943082
The	O	-1	1943082
l@@	O	-1	1943082
ac@@	O	-1	1943082
k	O	-1	1943082
of	O	-1	1943082
a	O	-1	1943082
significant	O	-1	1943082
increase	O	-1	1943082
in	O	-1	1943082
produc@@	O	-1	1943082
ts	O	-1	1943082
of	O	-1	1943082
li@@	O	-1	1943082
pid	O	-1	1943082
per@@	O	-1	1943082
oxid@@	O	-1	1943082
ation	O	-1	1943082
suggests	O	-1	1943082
that	O	-1	1943082
the	O	-1	1943082
oxid@@	O	-1	1943082
ant	O	-1	1943082
stres@@	O	-1	1943082
s	O	-1	1943082
is	O	-1	1943082
of	O	-1	1943082
in@@	O	-1	1943082
suffici@@	O	-1	1943082
ent	O	-1	1943082
mag@@	O	-1	1943082
nit@@	O	-1	1943082
ude	O	-1	1943082
to	O	-1	1943082
result	O	-1	1943082
in	O	-1	1943082
ir@@	O	-1	1943082
reversible	O	-1	1943082
injury	O	-1	1943082
to	O	-1	1943082
hepat@@	O	-1	1943082
ocyte	O	-1	1943082
cell	O	-1	1943082
membran@@	O	-1	1943082
es.	O	-1	1943082
These	O	-1	1943082
data	O	-1	1943082
also	O	-1	1943082
suggest	O	-1	1943082
that	O	-1	1943082
the	O	-1	1943082
meas@@	O	-1	1943082
ure@@	O	-1	1943082
ment	O	-1	1943082
of	O	-1	1943082
tissue	O	-1	1943082
G@@	B-Chemical	D019803	1943082
S@@	I-Chemical	-1	1943082
S@@	I-Chemical	-1	1943082
G	I-Chemical	-1	1943082
may	O	-1	1943082
be	O	-1	1943082
a	O	-1	1943082
more	O	-1	1943082
sensitive	O	-1	1943082
indic@@	O	-1	1943082
at@@	O	-1	1943082
or	O	-1	1943082
of	O	-1	1943082
oxid@@	O	-1	1943082
ant	O	-1	1943082
stres@@	O	-1	1943082
s	O	-1	1943082
than	O	-1	1943082
meas@@	O	-1	1943082
ure@@	O	-1	1943082
ment	O	-1	1943082
of	O	-1	1943082
produc@@	O	-1	1943082
ts	O	-1	1943082
of	O	-1	1943082
li@@	O	-1	1943082
pid	O	-1	1943082
per@@	O	-1	1943082
oxid@@	O	-1	1943082
ation.	O	-1	1943082

Di@@	B-Chemical	D004155	2021990
phen@@	I-Chemical	-1	2021990
hy@@	I-Chemical	-1	2021990
d@@	I-Chemical	-1	2021990
r@@	I-Chemical	-1	2021990
amine	I-Chemical	-1	2021990
prev@@	O	-1	2021990
ents	O	-1	2021990
the	O	-1	2021990
haem@@	O	-1	2021990
o@@	O	-1	2021990
dynam@@	O	-1	2021990
ic	O	-1	2021990
changes	O	-1	2021990
of	O	-1	2021990
cimetid@@	B-Chemical	D002927	2021990
ine	I-Chemical	-1	2021990
in	O	-1	2021990
IC@@	O	-1	2021990
U	O	-1	2021990
patients.	O	-1	2021990
C@@	B-Chemical	D002927	2021990
i@@	I-Chemical	-1	2021990
metid@@	I-Chemical	-1	2021990
ine	I-Chemical	-1	2021990
,	O	-1	2021990
a	O	-1	2021990
hist@@	B-Chemical	D006632	2021990
amine	I-Chemical	-1	2021990
2	O	-1	2021990
(@@	O	-1	2021990
H@@	O	-1	2021990
2)	O	-1	2021990
antagonist@@	O	-1	2021990
,	O	-1	2021990
produc@@	O	-1	2021990
es	O	-1	2021990
a	O	-1	2021990
decrease	O	-1	2021990
in	O	-1	2021990
arterial	O	-1	2021990
pressure	O	-1	2021990
due	O	-1	2021990
to	O	-1	2021990
vas@@	O	-1	2021990
odi@@	O	-1	2021990
lat@@	O	-1	2021990
ation,	O	-1	2021990
es@@	O	-1	2021990
p@@	O	-1	2021990
ec@@	O	-1	2021990
i@@	O	-1	2021990
ally	O	-1	2021990
in	O	-1	2021990
cri@@	O	-1	2021990
tically	O	-1	2021990
il@@	O	-1	2021990
l	O	-1	2021990
patients.	O	-1	2021990
This	O	-1	2021990
may	O	-1	2021990
be	O	-1	2021990
because	O	-1	2021990
cimetid@@	B-Chemical	D002927	2021990
ine	I-Chemical	-1	2021990
act@@	O	-1	2021990
s	O	-1	2021990
as	O	-1	2021990
a	O	-1	2021990
hist@@	B-Chemical	D006632	2021990
amine	I-Chemical	-1	2021990
agon@@	O	-1	2021990
ist@@	O	-1	2021990
.	O	-1	2021990
W@@	O	-1	2021990
e,	O	-1	2021990
the@@	O	-1	2021990
refore,	O	-1	2021990
investigated	O	-1	2021990
the	O	-1	2021990
effects	O	-1	2021990
of	O	-1	2021990
the	O	-1	2021990
hist@@	B-Chemical	D006632	2021990
amine	I-Chemical	-1	2021990
1@@	O	-1	2021990
(@@	O	-1	2021990
H@@	O	-1	2021990
1)	O	-1	2021990
receptor	O	-1	2021990
antagonist@@	O	-1	2021990
,	O	-1	2021990
di@@	B-Chemical	D004155	2021990
phen@@	I-Chemical	-1	2021990
hy@@	I-Chemical	-1	2021990
d@@	I-Chemical	-1	2021990
r@@	I-Chemical	-1	2021990
amine	I-Chemical	-1	2021990
,	O	-1	2021990
on	O	-1	2021990
the	O	-1	2021990
haem@@	O	-1	2021990
o@@	O	-1	2021990
dynam@@	O	-1	2021990
ic	O	-1	2021990
changes	O	-1	2021990
observed	O	-1	2021990
after	O	-1	2021990
cimetid@@	B-Chemical	D002927	2021990
ine	I-Chemical	-1	2021990
in	O	-1	2021990
IC@@	O	-1	2021990
U	O	-1	2021990
patients.	O	-1	2021990
E@@	O	-1	2021990
ach	O	-1	2021990
patient	O	-1	2021990
was	O	-1	2021990
studied	O	-1	2021990
on	O	-1	2021990
two	O	-1	2021990
se@@	O	-1	2021990
par@@	O	-1	2021990
ate	O	-1	2021990
days.	O	-1	2021990
In	O	-1	2021990
a	O	-1	2021990
ran@@	O	-1	2021990
do@@	O	-1	2021990
m	O	-1	2021990
f@@	O	-1	2021990
as@@	O	-1	2021990
hi@@	O	-1	2021990
on@@	O	-1	2021990
,	O	-1	2021990
they	O	-1	2021990
received	O	-1	2021990
cimetid@@	B-Chemical	D002927	2021990
ine	I-Chemical	-1	2021990
2@@	O	-1	2021990
00	O	-1	2021990
mg	O	-1	2021990
i@@	O	-1	2021990
v	O	-1	2021990
on	O	-1	2021990
one	O	-1	2021990
da@@	O	-1	2021990
y,	O	-1	2021990
and	O	-1	2021990
on	O	-1	2021990
the	O	-1	2021990
o@@	O	-1	2021990
ther@@	O	-1	2021990
,	O	-1	2021990
a	O	-1	2021990
pretreatment	O	-1	2021990
of	O	-1	2021990
di@@	B-Chemical	D004155	2021990
phen@@	I-Chemical	-1	2021990
hy@@	I-Chemical	-1	2021990
d@@	I-Chemical	-1	2021990
r@@	I-Chemical	-1	2021990
amine	I-Chemical	-1	2021990
40	O	-1	2021990
mg	O	-1	2021990
i@@	O	-1	2021990
v	O	-1	2021990
with	O	-1	2021990
cimetid@@	B-Chemical	D002927	2021990
ine	I-Chemical	-1	2021990
2@@	O	-1	2021990
00	O	-1	2021990
mg	O	-1	2021990
i@@	O	-1	2021990
v@@	O	-1	2021990
.	O	-1	2021990
In	O	-1	2021990
the	O	-1	2021990
non-@@	O	-1	2021990
pretreatment	O	-1	2021990
group@@	O	-1	2021990
,	O	-1	2021990
mean	O	-1	2021990
arterial	O	-1	2021990
pressure	O	-1	2021990
(@@	O	-1	2021990
MA@@	O	-1	2021990
P)	O	-1	2021990
decreased	O	-1	2021990
from	O	-1	2021990
10@@	O	-1	2021990
7.@@	O	-1	2021990
4	O	-1	2021990
+/-	O	-1	2021990
8.@@	O	-1	2021990
4	O	-1	2021990
mm@@	O	-1	2021990
H@@	O	-1	2021990
g	O	-1	2021990
to	O	-1	2021990
8@@	O	-1	2021990
6.@@	O	-1	2021990
7	O	-1	2021990
+/-	O	-1	2021990
1@@	O	-1	2021990
1.@@	O	-1	2021990
4	O	-1	2021990
mm@@	O	-1	2021990
H@@	O	-1	2021990
g	O	-1	2021990
(P	O	-1	2021990
less	O	-1	2021990
than	O	-1	2021990
0.0@@	O	-1	2021990
1)	O	-1	2021990
two	O	-1	2021990
minutes	O	-1	2021990
after	O	-1	2021990
cimetid@@	B-Chemical	D002927	2021990
ine	I-Chemical	-1	2021990
.	O	-1	2021990
Al@@	O	-1	2021990
so@@	O	-1	2021990
,	O	-1	2021990
systemic	O	-1	2021990
vascular	O	-1	2021990
resist@@	O	-1	2021990
ance	O	-1	2021990
(S@@	O	-1	2021990
V@@	O	-1	2021990
R@@	O	-1	2021990
)	O	-1	2021990
decreased	O	-1	2021990
during	O	-1	2021990
the	O	-1	2021990
e@@	O	-1	2021990
igh@@	O	-1	2021990
t-@@	O	-1	2021990
min@@	O	-1	2021990
ute	O	-1	2021990
observ@@	O	-1	2021990
ation	O	-1	2021990
period	O	-1	2021990
(P	O	-1	2021990
less	O	-1	2021990
than	O	-1	2021990
0.0@@	O	-1	2021990
1).	O	-1	2021990
In	O	-1	2021990
contrast@@	O	-1	2021990
,	O	-1	2021990
in	O	-1	2021990
the	O	-1	2021990
pretreatment	O	-1	2021990
group@@	O	-1	2021990
,	O	-1	2021990
lit@@	O	-1	2021990
t@@	O	-1	2021990
le	O	-1	2021990
haem@@	O	-1	2021990
o@@	O	-1	2021990
dynam@@	O	-1	2021990
ic	O	-1	2021990
change	O	-1	2021990
was	O	-1	2021990
se@@	O	-1	2021990
en@@	O	-1	2021990
.	O	-1	2021990
We	O	-1	2021990
concl@@	O	-1	2021990
ude	O	-1	2021990
that	O	-1	2021990
an	O	-1	2021990
H@@	O	-1	2021990
1	O	-1	2021990
antagonist	O	-1	2021990
may	O	-1	2021990
be	O	-1	2021990
use@@	O	-1	2021990
ful	O	-1	2021990
in	O	-1	2021990
prevent@@	O	-1	2021990
ing	O	-1	2021990
hypotension	B-Disease	D007022	2021990
caused	O	-1	2021990
by	O	-1	2021990
i@@	O	-1	2021990
v	O	-1	2021990
cimetid@@	B-Chemical	D002927	2021990
ine	I-Chemical	-1	2021990
,	O	-1	2021990
s@@	O	-1	2021990
inc@@	O	-1	2021990
e	O	-1	2021990
the	O	-1	2021990
vas@@	O	-1	2021990
odi@@	O	-1	2021990
l@@	O	-1	2021990
ating	O	-1	2021990
activity	O	-1	2021990
of	O	-1	2021990
cimetid@@	B-Chemical	D002927	2021990
ine	I-Chemical	-1	2021990
is	O	-1	2021990
medi@@	O	-1	2021990
at@@	O	-1	2021990
ed,	O	-1	2021990
in	O	-1	2021990
part@@	O	-1	2021990
,	O	-1	2021990
through	O	-1	2021990
the	O	-1	2021990
H@@	O	-1	2021990
1	O	-1	2021990
receptor@@	O	-1	2021990
.	O	-1	2021990

Ac@@	B-Disease	D058186	2083961
ute	I-Disease	-1	2083961
renal	I-Disease	-1	2083961
failure	I-Disease	-1	2083961
due	O	-1	2083961
to	O	-1	2083961
ri@@	B-Chemical	D012293	2083961
f@@	I-Chemical	-1	2083961
amp@@	I-Chemical	-1	2083961
icin	I-Chemical	-1	2083961
.	O	-1	2083961
A	O	-1	2083961
2@@	O	-1	2083961
3-@@	O	-1	2083961
year-old	O	-1	2083961
male	O	-1	2083961
patient	O	-1	2083961
with	O	-1	2083961
bac@@	O	-1	2083961
ter@@	O	-1	2083961
io@@	O	-1	2083961
log@@	O	-1	2083961
ically	O	-1	2083961
pro@@	O	-1	2083961
ven	O	-1	2083961
pulmonary	B-Disease	D014397	2083961
tub@@	I-Disease	-1	2083961
er@@	I-Disease	-1	2083961
c@@	I-Disease	-1	2083961
ulo@@	I-Disease	-1	2083961
sis	I-Disease	-1	2083961
was	O	-1	2083961
treated	O	-1	2083961
with	O	-1	2083961
the	O	-1	2083961
various	O	-1	2083961
regimen@@	O	-1	2083961
s	O	-1	2083961
of	O	-1	2083961
anti@@	O	-1	2083961
tub@@	O	-1	2083961
er@@	O	-1	2083961
c@@	O	-1	2083961
ulo@@	O	-1	2083961
sis	O	-1	2083961
drugs	O	-1	2083961
for	O	-1	2083961
ne@@	O	-1	2083961
arly	O	-1	2083961
15	O	-1	2083961
months.	O	-1	2083961
R@@	B-Chemical	D012293	2083961
if@@	I-Chemical	-1	2083961
amp@@	I-Chemical	-1	2083961
icin	I-Chemical	-1	2083961
was	O	-1	2083961
administered	O	-1	2083961
th@@	O	-1	2083961
r@@	O	-1	2083961
ic@@	O	-1	2083961
e	O	-1	2083961
as	O	-1	2083961
one	O	-1	2083961
of	O	-1	2083961
the	O	-1	2083961
3-@@	O	-1	2083961
4	O	-1	2083961
drug	O	-1	2083961
regi@@	O	-1	2083961
men	O	-1	2083961
and	O	-1	2083961
each	O	-1	2083961
time	O	-1	2083961
he	O	-1	2083961
developed	O	-1	2083961
un@@	O	-1	2083961
to@@	O	-1	2083961
war@@	O	-1	2083961
d	O	-1	2083961
side	O	-1	2083961
effects	O	-1	2083961
like	O	-1	2083961
nausea	B-Disease	D009325	2083961
,	O	-1	2083961
v@@	B-Disease	D014839	2083961
om@@	I-Disease	-1	2083961
it@@	I-Disease	-1	2083961
ing	I-Disease	-1	2083961
and	O	-1	2083961
f@@	B-Disease	D005334	2083961
ev@@	I-Disease	-1	2083961
er	I-Disease	-1	2083961
with	O	-1	2083961
ch@@	O	-1	2083961
ill@@	O	-1	2083961
s	O	-1	2083961
and	O	-1	2083961
rig@@	O	-1	2083961
or@@	O	-1	2083961
s.	O	-1	2083961
The	O	-1	2083961
las@@	O	-1	2083961
t	O	-1	2083961
such	O	-1	2083961
episo@@	O	-1	2083961
de	O	-1	2083961
was	O	-1	2083961
of	O	-1	2083961
acute	O	-1	2083961
renal	O	-1	2083961
failure	O	-1	2083961
at	O	-1	2083961
which	O	-1	2083961
st@@	O	-1	2083961
age	O	-1	2083961
the	O	-1	2083961
patient	O	-1	2083961
was	O	-1	2083961
seen	O	-1	2083961
by	O	-1	2083961
the	O	-1	2083961
au@@	O	-1	2083961
th@@	O	-1	2083961
ors	O	-1	2083961
of	O	-1	2083961
this	O	-1	2083961
repor@@	O	-1	2083961
t.	O	-1	2083961
The	O	-1	2083961
patient@@	O	-1	2083961
,	O	-1	2083961
however,	O	-1	2083961
m@@	O	-1	2083961
ade	O	-1	2083961
a	O	-1	2083961
ful@@	O	-1	2083961
l	O	-1	2083961
reco@@	O	-1	2083961
ver@@	O	-1	2083961
y.	O	-1	2083961

S@@	O	-1	2131034
ev@@	O	-1	2131034
ere	O	-1	2131034
poly@@	B-Disease	D011115	2131034
neuropathy	I-Disease	-1	2131034
and	O	-1	2131034
motor	O	-1	2131034
loss	O	-1	2131034
after	O	-1	2131034
intra@@	O	-1	2131034
th@@	O	-1	2131034
ec@@	O	-1	2131034
al	O	-1	2131034
thi@@	B-Chemical	D013852	2131034
ot@@	I-Chemical	-1	2131034
ep@@	I-Chemical	-1	2131034
a	I-Chemical	-1	2131034
combination	O	-1	2131034
chemo@@	O	-1	2131034
therap@@	O	-1	2131034
y@@	O	-1	2131034
:	O	-1	2131034
descri@@	O	-1	2131034
ption	O	-1	2131034
of	O	-1	2131034
two	O	-1	2131034
cas@@	O	-1	2131034
es.	O	-1	2131034
Two	O	-1	2131034
cases	O	-1	2131034
of	O	-1	2131034
severe	O	-1	2131034
del@@	O	-1	2131034
ayed	O	-1	2131034
neurolog@@	B-Disease	D020258	2131034
ic	I-Disease	-1	2131034
toxicity	I-Disease	-1	2131034
related	O	-1	2131034
to	O	-1	2131034
the	O	-1	2131034
administration	O	-1	2131034
of	O	-1	2131034
intra@@	O	-1	2131034
th@@	O	-1	2131034
ec@@	O	-1	2131034
al	O	-1	2131034
(@@	O	-1	2131034
I@@	O	-1	2131034
T)	O	-1	2131034
combination	O	-1	2131034
chemotherapy	O	-1	2131034
including	O	-1	2131034
thi@@	B-Chemical	D013852	2131034
ot@@	I-Chemical	-1	2131034
ep@@	I-Chemical	-1	2131034
a	I-Chemical	-1	2131034
(	O	-1	2131034
T@@	B-Chemical	D013852	2131034
S@@	I-Chemical	-1	2131034
P@@	I-Chemical	-1	2131034
A	I-Chemical	-1	2131034
)	O	-1	2131034
are	O	-1	2131034
present@@	O	-1	2131034
ed.	O	-1	2131034
B@@	O	-1	2131034
oth	O	-1	2131034
cases	O	-1	2131034
developed	O	-1	2131034
ax@@	B-Disease	D056768	2131034
on@@	I-Disease	-1	2131034
al	I-Disease	-1	2131034
neuropathy	I-Disease	-1	2131034
with	O	-1	2131034
motor	O	-1	2131034
pre@@	O	-1	2131034
domin@@	O	-1	2131034
ance	O	-1	2131034
in	O	-1	2131034
the	O	-1	2131034
lower	O	-1	2131034
ex@@	O	-1	2131034
trem@@	O	-1	2131034
ities	O	-1	2131034
1	O	-1	2131034
and	O	-1	2131034
6	O	-1	2131034
months	O	-1	2131034
after	O	-1	2131034
I@@	O	-1	2131034
T	O	-1	2131034
chemotherapy	O	-1	2131034
was	O	-1	2131034
administ@@	O	-1	2131034
e@@	O	-1	2131034
red.	O	-1	2131034
Ne@@	B-Disease	D020258	2131034
uro@@	I-Disease	-1	2131034
log@@	I-Disease	-1	2131034
ic	I-Disease	-1	2131034
toxic@@	I-Disease	-1	2131034
ities	I-Disease	-1	2131034
have	O	-1	2131034
been	O	-1	2131034
descri@@	O	-1	2131034
bed	O	-1	2131034
with	O	-1	2131034
I@@	O	-1	2131034
T@@	O	-1	2131034
-	O	-1	2131034
meth@@	B-Chemical	D008727	2131034
ot@@	I-Chemical	-1	2131034
re@@	I-Chemical	-1	2131034
x@@	I-Chemical	-1	2131034
ate	I-Chemical	-1	2131034
,	O	-1	2131034
I@@	O	-1	2131034
T@@	O	-1	2131034
-	O	-1	2131034
cy@@	B-Chemical	D003561	2131034
t@@	I-Chemical	-1	2131034
os@@	I-Chemical	-1	2131034
ine	I-Chemical	-1	2131034
ar@@	I-Chemical	-1	2131034
ab@@	I-Chemical	-1	2131034
ino@@	I-Chemical	-1	2131034
side	I-Chemical	-1	2131034
and	O	-1	2131034
I@@	O	-1	2131034
T@@	O	-1	2131034
-	O	-1	2131034
T@@	B-Chemical	D013852	2131034
S@@	I-Chemical	-1	2131034
P@@	I-Chemical	-1	2131034
A	I-Chemical	-1	2131034
.	O	-1	2131034
To	O	-1	2131034
our	O	-1	2131034
know@@	O	-1	2131034
le@@	O	-1	2131034
d@@	O	-1	2131034
g@@	O	-1	2131034
e,	O	-1	2131034
however,	O	-1	2131034
ax@@	B-Disease	D056768	2131034
on@@	I-Disease	-1	2131034
al	I-Disease	-1	2131034
neuropathy	I-Disease	-1	2131034
following	O	-1	2131034
administration	O	-1	2131034
of	O	-1	2131034
these	O	-1	2131034
three	O	-1	2131034
agents	O	-1	2131034
has	O	-1	2131034
not	O	-1	2131034
been	O	-1	2131034
previously	O	-1	2131034
descri@@	O	-1	2131034
be@@	O	-1	2131034
d.	O	-1	2131034
In	O	-1	2131034
sp@@	O	-1	2131034
ite	O	-1	2131034
of	O	-1	2131034
the	O	-1	2131034
fac@@	O	-1	2131034
t	O	-1	2131034
that	O	-1	2131034
T@@	B-Chemical	D013852	2131034
S@@	I-Chemical	-1	2131034
P@@	I-Chemical	-1	2131034
A	I-Chemical	-1	2131034
is	O	-1	2131034
a	O	-1	2131034
use@@	O	-1	2131034
ful	O	-1	2131034
I@@	O	-1	2131034
T	O	-1	2131034
agent@@	O	-1	2131034
,	O	-1	2131034
its	O	-1	2131034
combination	O	-1	2131034
with	O	-1	2131034
M@@	B-Chemical	D008727	2131034
T@@	I-Chemical	-1	2131034
X	I-Chemical	-1	2131034
,	O	-1	2131034
ar@@	B-Chemical	D003561	2131034
a@@	I-Chemical	-1	2131034
-@@	I-Chemical	-1	2131034
C	I-Chemical	-1	2131034
and	O	-1	2131034
radi@@	O	-1	2131034
o@@	O	-1	2131034
therapy	O	-1	2131034
could	O	-1	2131034
cause	O	-1	2131034
severe	O	-1	2131034
neuro@@	B-Disease	D020258	2131034
toxicity	I-Disease	-1	2131034
.	O	-1	2131034
This	O	-1	2131034
un@@	O	-1	2131034
ex@@	O	-1	2131034
p@@	O	-1	2131034
ected	O	-1	2131034
complication	O	-1	2131034
indic@@	O	-1	2131034
ates	O	-1	2131034
the	O	-1	2131034
need	O	-1	2131034
for	O	-1	2131034
further	O	-1	2131034
toxic@@	O	-1	2131034
ology	O	-1	2131034
re@@	O	-1	2131034
se@@	O	-1	2131034
arc@@	O	-1	2131034
h	O	-1	2131034
on	O	-1	2131034
I@@	O	-1	2131034
T@@	O	-1	2131034
-	O	-1	2131034
T@@	B-Chemical	D013852	2131034
S@@	I-Chemical	-1	2131034
P@@	I-Chemical	-1	2131034
A	I-Chemical	-1	2131034
.	O	-1	2131034

Eff@@	O	-1	2173761
ects	O	-1	2173761
of	O	-1	2173761
c@@	B-Chemical	D019806	2173761
ro@@	I-Chemical	-1	2173761
ma@@	I-Chemical	-1	2173761
k@@	I-Chemical	-1	2173761
al@@	I-Chemical	-1	2173761
im	I-Chemical	-1	2173761
and	O	-1	2173761
p@@	B-Chemical	D020110	2173761
in@@	I-Chemical	-1	2173761
ac@@	I-Chemical	-1	2173761
i@@	I-Chemical	-1	2173761
di@@	I-Chemical	-1	2173761
l	I-Chemical	-1	2173761
on	O	-1	2173761
larg@@	O	-1	2173761
e	O	-1	2173761
ep@@	O	-1	2173761
ic@@	O	-1	2173761
ardi@@	O	-1	2173761
al	O	-1	2173761
and	O	-1	2173761
sm@@	O	-1	2173761
all	O	-1	2173761
coronary	O	-1	2173761
arter@@	O	-1	2173761
i@@	O	-1	2173761
es	O	-1	2173761
in	O	-1	2173761
con@@	O	-1	2173761
s@@	O	-1	2173761
ci@@	O	-1	2173761
ous	O	-1	2173761
dog@@	O	-1	2173761
s.	O	-1	2173761
The	O	-1	2173761
effects	O	-1	2173761
of	O	-1	2173761
i.v@@	O	-1	2173761
.	O	-1	2173761
b@@	O	-1	2173761
ol@@	O	-1	2173761
us	O	-1	2173761
administration	O	-1	2173761
of	O	-1	2173761
c@@	B-Chemical	D019806	2173761
ro@@	I-Chemical	-1	2173761
ma@@	I-Chemical	-1	2173761
k@@	I-Chemical	-1	2173761
al@@	I-Chemical	-1	2173761
im	I-Chemical	-1	2173761
(1@@	O	-1	2173761
-@@	O	-1	2173761
10	O	-1	2173761
microgram@@	O	-1	2173761
s/@@	O	-1	2173761
kg@@	O	-1	2173761
)	O	-1	2173761
and	O	-1	2173761
p@@	B-Chemical	D020110	2173761
in@@	I-Chemical	-1	2173761
ac@@	I-Chemical	-1	2173761
i@@	I-Chemical	-1	2173761
di@@	I-Chemical	-1	2173761
l	I-Chemical	-1	2173761
(3@@	O	-1	2173761
-@@	O	-1	2173761
100	O	-1	2173761
microgram@@	O	-1	2173761
s/@@	O	-1	2173761
kg@@	O	-1	2173761
)	O	-1	2173761
on	O	-1	2173761
larg@@	O	-1	2173761
e	O	-1	2173761
(@@	O	-1	2173761
cir@@	O	-1	2173761
cum@@	O	-1	2173761
f@@	O	-1	2173761
le@@	O	-1	2173761
x	O	-1	2173761
arter@@	O	-1	2173761
y@@	O	-1	2173761
)	O	-1	2173761
and	O	-1	2173761
sm@@	O	-1	2173761
all	O	-1	2173761
coronary	O	-1	2173761
arter@@	O	-1	2173761
i@@	O	-1	2173761
es	O	-1	2173761
and	O	-1	2173761
on	O	-1	2173761
systemic	O	-1	2173761
hemo@@	O	-1	2173761
dynam@@	O	-1	2173761
ic@@	O	-1	2173761
s	O	-1	2173761
were	O	-1	2173761
investigated	O	-1	2173761
in	O	-1	2173761
chron@@	O	-1	2173761
ically	O	-1	2173761
in@@	O	-1	2173761
st@@	O	-1	2173761
ru@@	O	-1	2173761
ment@@	O	-1	2173761
ed	O	-1	2173761
con@@	O	-1	2173761
s@@	O	-1	2173761
ci@@	O	-1	2173761
ous	O	-1	2173761
dog@@	O	-1	2173761
s	O	-1	2173761
and	O	-1	2173761
compared	O	-1	2173761
to	O	-1	2173761
those	O	-1	2173761
of	O	-1	2173761
nitro@@	B-Chemical	D005996	2173761
glycer@@	I-Chemical	-1	2173761
in	I-Chemical	-1	2173761
(@@	O	-1	2173761
0.0@@	O	-1	2173761
3-@@	O	-1	2173761
10	O	-1	2173761
microgram@@	O	-1	2173761
s/@@	O	-1	2173761
kg@@	O	-1	2173761
).	O	-1	2173761
N@@	B-Chemical	D005996	2173761
it@@	I-Chemical	-1	2173761
ro@@	I-Chemical	-1	2173761
glycer@@	I-Chemical	-1	2173761
in	I-Chemical	-1	2173761
,	O	-1	2173761
up	O	-1	2173761
to	O	-1	2173761
0.@@	O	-1	2173761
3	O	-1	2173761
microgram@@	O	-1	2173761
s/@@	O	-1	2173761
kg@@	O	-1	2173761
,	O	-1	2173761
sel@@	O	-1	2173761
ectively	O	-1	2173761
increased	O	-1	2173761
cir@@	O	-1	2173761
cum@@	O	-1	2173761
f@@	O	-1	2173761
le@@	O	-1	2173761
x	O	-1	2173761
artery	O	-1	2173761
di@@	O	-1	2173761
ame@@	O	-1	2173761
ter	O	-1	2173761
(C@@	O	-1	2173761
x@@	O	-1	2173761
A@@	O	-1	2173761
D)	O	-1	2173761
without	O	-1	2173761
sim@@	O	-1	2173761
ult@@	O	-1	2173761
ane@@	O	-1	2173761
ously	O	-1	2173761
aff@@	O	-1	2173761
ect@@	O	-1	2173761
ing	O	-1	2173761
any	O	-1	2173761
other	O	-1	2173761
cardiac	O	-1	2173761
or	O	-1	2173761
systemic	O	-1	2173761
hemo@@	O	-1	2173761
dynam@@	O	-1	2173761
ic	O	-1	2173761
par@@	O	-1	2173761
ame@@	O	-1	2173761
ter@@	O	-1	2173761
.	O	-1	2173761
In	O	-1	2173761
contrast@@	O	-1	2173761
,	O	-1	2173761
c@@	B-Chemical	D019806	2173761
ro@@	I-Chemical	-1	2173761
ma@@	I-Chemical	-1	2173761
k@@	I-Chemical	-1	2173761
al@@	I-Chemical	-1	2173761
im	I-Chemical	-1	2173761
and	O	-1	2173761
p@@	B-Chemical	D020110	2173761
in@@	I-Chemical	-1	2173761
ac@@	I-Chemical	-1	2173761
i@@	I-Chemical	-1	2173761
di@@	I-Chemical	-1	2173761
l	I-Chemical	-1	2173761
at	O	-1	2173761
all	O	-1	2173761
doses	O	-1	2173761
and	O	-1	2173761
nitro@@	B-Chemical	D005996	2173761
glycer@@	I-Chemical	-1	2173761
in	I-Chemical	-1	2173761
at	O	-1	2173761
doses	O	-1	2173761
higher	O	-1	2173761
than	O	-1	2173761
0.@@	O	-1	2173761
3	O	-1	2173761
microgram@@	O	-1	2173761
s/@@	O	-1	2173761
k@@	O	-1	2173761
g	O	-1	2173761
sim@@	O	-1	2173761
ult@@	O	-1	2173761
ane@@	O	-1	2173761
ously	O	-1	2173761
and	O	-1	2173761
dose-@@	O	-1	2173761
depend@@	O	-1	2173761
ently	O	-1	2173761
increased	O	-1	2173761
C@@	O	-1	2173761
x@@	O	-1	2173761
AD@@	O	-1	2173761
,	O	-1	2173761
coronary	O	-1	2173761
blood	O	-1	2173761
flow	O	-1	2173761
and	O	-1	2173761
heart	O	-1	2173761
rate	O	-1	2173761
and	O	-1	2173761
decreased	O	-1	2173761
coronary	O	-1	2173761
vascular	O	-1	2173761
resist@@	O	-1	2173761
ance	O	-1	2173761
and	O	-1	2173761
a@@	O	-1	2173761
or@@	O	-1	2173761
tic	O	-1	2173761
pressu@@	O	-1	2173761
re.	O	-1	2173761
C@@	B-Chemical	D019806	2173761
ro@@	I-Chemical	-1	2173761
ma@@	I-Chemical	-1	2173761
k@@	I-Chemical	-1	2173761
al@@	I-Chemical	-1	2173761
im	I-Chemical	-1	2173761
was	O	-1	2173761
appro@@	O	-1	2173761
xim@@	O	-1	2173761
ately	O	-1	2173761
8@@	O	-1	2173761
-	O	-1	2173761
to	O	-1	2173761
9.@@	O	-1	2173761
5-@@	O	-1	2173761
fol@@	O	-1	2173761
d	O	-1	2173761
more	O	-1	2173761
pot@@	O	-1	2173761
ent	O	-1	2173761
than	O	-1	2173761
p@@	B-Chemical	D020110	2173761
in@@	I-Chemical	-1	2173761
ac@@	I-Chemical	-1	2173761
i@@	I-Chemical	-1	2173761
di@@	I-Chemical	-1	2173761
l	I-Chemical	-1	2173761
in	O	-1	2173761
increas@@	O	-1	2173761
ing	O	-1	2173761
C@@	O	-1	2173761
x@@	O	-1	2173761
AD@@	O	-1	2173761
.	O	-1	2173761
V@@	O	-1	2173761
as@@	O	-1	2173761
odi@@	O	-1	2173761
l@@	O	-1	2173761
ation	O	-1	2173761
of	O	-1	2173761
larg@@	O	-1	2173761
e	O	-1	2173761
and	O	-1	2173761
sm@@	O	-1	2173761
all	O	-1	2173761
coronary	O	-1	2173761
v@@	O	-1	2173761
es@@	O	-1	2173761
sel@@	O	-1	2173761
s	O	-1	2173761
and	O	-1	2173761
hypotension	B-Disease	D007022	2173761
induced	O	-1	2173761
by	O	-1	2173761
c@@	B-Chemical	D019806	2173761
ro@@	I-Chemical	-1	2173761
ma@@	I-Chemical	-1	2173761
k@@	I-Chemical	-1	2173761
al@@	I-Chemical	-1	2173761
im	I-Chemical	-1	2173761
and	O	-1	2173761
p@@	B-Chemical	D020110	2173761
in@@	I-Chemical	-1	2173761
ac@@	I-Chemical	-1	2173761
i@@	I-Chemical	-1	2173761
di@@	I-Chemical	-1	2173761
l	I-Chemical	-1	2173761
were	O	-1	2173761
not	O	-1	2173761
affected	O	-1	2173761
by	O	-1	2173761
prior	O	-1	2173761
combined	O	-1	2173761
bet@@	B-Chemical	D000319	2173761
a	I-Chemical	-1	2173761
adrenergic	I-Chemical	-1	2173761
and	I-Chemical	-1	2173761
mus@@	I-Chemical	-1	2173761
car@@	I-Chemical	-1	2173761
inic	I-Chemical	-1	2173761
receptors	I-Chemical	-1	2173761
block@@	I-Chemical	-1	2173761
ade	I-Chemical	-1	2173761
bet@@	B-Chemical	D018727	2173761
a	I-Chemical	-1	2173761
adrenergic	I-Chemical	-1	2173761
and	I-Chemical	-1	2173761
mus@@	I-Chemical	-1	2173761
car@@	I-Chemical	-1	2173761
inic	I-Chemical	-1	2173761
receptors	I-Chemical	-1	2173761
block@@	I-Chemical	-1	2173761
ade	I-Chemical	-1	2173761
but	O	-1	2173761
drug@@	O	-1	2173761
-induced	O	-1	2173761
tachycardia	B-Disease	D013610	2173761
was	O	-1	2173761
abol@@	O	-1	2173761
is@@	O	-1	2173761
he@@	O	-1	2173761
d.	O	-1	2173761
Whe@@	O	-1	2173761
n	O	-1	2173761
cir@@	O	-1	2173761
cum@@	O	-1	2173761
f@@	O	-1	2173761
le@@	O	-1	2173761
x	O	-1	2173761
artery	O	-1	2173761
blood	O	-1	2173761
flow	O	-1	2173761
was	O	-1	2173761
maint@@	O	-1	2173761
ained	O	-1	2173761
con@@	O	-1	2173761
st@@	O	-1	2173761
ant@@	O	-1	2173761
,	O	-1	2173761
the	O	-1	2173761
increases	O	-1	2173761
in	O	-1	2173761
C@@	O	-1	2173761
x@@	O	-1	2173761
A@@	O	-1	2173761
D	O	-1	2173761
induced	O	-1	2173761
by	O	-1	2173761
c@@	B-Chemical	D019806	2173761
ro@@	I-Chemical	-1	2173761
ma@@	I-Chemical	-1	2173761
k@@	I-Chemical	-1	2173761
al@@	I-Chemical	-1	2173761
im	I-Chemical	-1	2173761
(10	O	-1	2173761
microgram@@	O	-1	2173761
s/@@	O	-1	2173761
kg@@	O	-1	2173761
),	O	-1	2173761
p@@	B-Chemical	D020110	2173761
in@@	I-Chemical	-1	2173761
ac@@	I-Chemical	-1	2173761
i@@	I-Chemical	-1	2173761
di@@	I-Chemical	-1	2173761
l	I-Chemical	-1	2173761
(@@	O	-1	2173761
30	O	-1	2173761
microgram@@	O	-1	2173761
s/@@	O	-1	2173761
kg@@	O	-1	2173761
)	O	-1	2173761
and	O	-1	2173761
nitro@@	B-Chemical	D005996	2173761
glycer@@	I-Chemical	-1	2173761
in	I-Chemical	-1	2173761
(10	O	-1	2173761
microgram@@	O	-1	2173761
s/@@	O	-1	2173761
kg@@	O	-1	2173761
)	O	-1	2173761
were	O	-1	2173761
reduced	O	-1	2173761
by	O	-1	2173761
6@@	O	-1	2173761
8	O	-1	2173761
+/-	O	-1	2173761
7@@	O	-1	2173761
,	O	-1	2173761
5@@	O	-1	2173761
4	O	-1	2173761
+/-	O	-1	2173761
9	O	-1	2173761
and	O	-1	2173761
1	O	-1	2173761
+/-	O	-1	2173761
1@@	O	-1	2173761
%,	O	-1	2173761
respectively.	O	-1	2173761
Th@@	O	-1	2173761
us,	O	-1	2173761
whereas	O	-1	2173761
nitro@@	B-Chemical	D005996	2173761
glycer@@	I-Chemical	-1	2173761
in	I-Chemical	-1	2173761
pre@@	O	-1	2173761
fe@@	O	-1	2173761
ren@@	O	-1	2173761
ti@@	O	-1	2173761
ally	O	-1	2173761
and	O	-1	2173761
f@@	O	-1	2173761
low@@	O	-1	2173761
-@@	O	-1	2173761
in@@	O	-1	2173761
depend@@	O	-1	2173761
ently	O	-1	2173761
di@@	O	-1	2173761
lat@@	O	-1	2173761
es	O	-1	2173761
larg@@	O	-1	2173761
e	O	-1	2173761
coronary	O	-1	2173761
arter@@	O	-1	2173761
i@@	O	-1	2173761
es,	O	-1	2173761
c@@	B-Chemical	D019806	2173761
ro@@	I-Chemical	-1	2173761
ma@@	I-Chemical	-1	2173761
k@@	I-Chemical	-1	2173761
al@@	I-Chemical	-1	2173761
im	I-Chemical	-1	2173761
and	O	-1	2173761
p@@	B-Chemical	D020110	2173761
in@@	I-Chemical	-1	2173761
ac@@	I-Chemical	-1	2173761
i@@	I-Chemical	-1	2173761
di@@	I-Chemical	-1	2173761
l	I-Chemical	-1	2173761
di@@	O	-1	2173761
l@@	O	-1	2173761
ate	O	-1	2173761
both	O	-1	2173761
larg@@	O	-1	2173761
e	O	-1	2173761
and	O	-1	2173761
sm@@	O	-1	2173761
all	O	-1	2173761
coronary	O	-1	2173761
arter@@	O	-1	2173761
i@@	O	-1	2173761
es	O	-1	2173761
and	O	-1	2173761
this	O	-1	2173761
effect	O	-1	2173761
is	O	-1	2173761
not	O	-1	2173761
dependent	O	-1	2173761
up@@	O	-1	2173761
on	O	-1	2173761
the	O	-1	2173761
sim@@	O	-1	2173761
ult@@	O	-1	2173761
aneous	O	-1	2173761
bet@@	O	-1	2173761
a	O	-1	2173761
adren@@	O	-1	2173761
oc@@	O	-1	2173761
e@@	O	-1	2173761
pt@@	O	-1	2173761
or@@	O	-1	2173761
s-@@	O	-1	2173761
mediated	O	-1	2173761
ri@@	O	-1	2173761
se	O	-1	2173761
in	O	-1	2173761
myocardial	O	-1	2173761
met@@	O	-1	2173761
ab@@	O	-1	2173761
olic	O	-1	2173761
de@@	O	-1	2173761
man@@	O	-1	2173761
d.	O	-1	2173761
F@@	O	-1	2173761
in@@	O	-1	2173761
ally,	O	-1	2173761
two	O	-1	2173761
mechanisms	O	-1	2173761
at	O	-1	2173761
le@@	O	-1	2173761
ast@@	O	-1	2173761
,	O	-1	2173761
direct	O	-1	2173761
vas@@	O	-1	2173761
odi@@	O	-1	2173761
l@@	O	-1	2173761
ation	O	-1	2173761
and	O	-1	2173761
flow	O	-1	2173761
depend@@	O	-1	2173761
enc@@	O	-1	2173761
y,	O	-1	2173761
are	O	-1	2173761
involved	O	-1	2173761
in	O	-1	2173761
the	O	-1	2173761
c@@	B-Chemical	D019806	2173761
ro@@	I-Chemical	-1	2173761
ma@@	I-Chemical	-1	2173761
k@@	I-Chemical	-1	2173761
al@@	I-Chemical	-1	2173761
im	I-Chemical	-1	2173761
-	O	-1	2173761
and	O	-1	2173761
p@@	B-Chemical	D020110	2173761
in@@	I-Chemical	-1	2173761
ac@@	I-Chemical	-1	2173761
i@@	I-Chemical	-1	2173761
di@@	I-Chemical	-1	2173761
l	I-Chemical	-1	2173761
-induced	O	-1	2173761
increase	O	-1	2173761
in	O	-1	2173761
C@@	O	-1	2173761
x@@	O	-1	2173761
AD@@	O	-1	2173761
.	O	-1	2173761

M@@	B-Chemical	D008528	2217015
e@@	I-Chemical	-1	2217015
f@@	I-Chemical	-1	2217015
en@@	I-Chemical	-1	2217015
am@@	I-Chemical	-1	2217015
ic	I-Chemical	-1	2217015
acid	I-Chemical	-1	2217015
-induced	O	-1	2217015
ne@@	B-Disease	D009503	2217015
ut@@	I-Disease	-1	2217015
ro@@	I-Disease	-1	2217015
pen@@	I-Disease	-1	2217015
ia	I-Disease	-1	2217015
and	O	-1	2217015
renal	B-Disease	D051437	2217015
failure	I-Disease	-1	2217015
in	O	-1	2217015
el@@	O	-1	2217015
der@@	O	-1	2217015
ly	O	-1	2217015
femal@@	O	-1	2217015
es	O	-1	2217015
with	O	-1	2217015
hypo@@	B-Disease	D007037	2217015
th@@	I-Disease	-1	2217015
yro@@	I-Disease	-1	2217015
i@@	I-Disease	-1	2217015
dis@@	I-Disease	-1	2217015
m	I-Disease	-1	2217015
.	O	-1	2217015
We	O	-1	2217015
report	O	-1	2217015
me@@	B-Chemical	D008528	2217015
f@@	I-Chemical	-1	2217015
en@@	I-Chemical	-1	2217015
am@@	I-Chemical	-1	2217015
ic	I-Chemical	-1	2217015
acid	I-Chemical	-1	2217015
-induced	O	-1	2217015
non-@@	O	-1	2217015
ol@@	O	-1	2217015
ig@@	O	-1	2217015
ur@@	O	-1	2217015
ic	O	-1	2217015
renal	B-Disease	D051437	2217015
failure	I-Disease	-1	2217015
and	O	-1	2217015
severe	O	-1	2217015
ne@@	B-Disease	D009503	2217015
ut@@	I-Disease	-1	2217015
ro@@	I-Disease	-1	2217015
pen@@	I-Disease	-1	2217015
ia	I-Disease	-1	2217015
occur@@	O	-1	2217015
r@@	O	-1	2217015
ing	O	-1	2217015
sim@@	O	-1	2217015
ult@@	O	-1	2217015
ane@@	O	-1	2217015
ously	O	-1	2217015
in	O	-1	2217015
two	O	-1	2217015
el@@	O	-1	2217015
der@@	O	-1	2217015
ly	O	-1	2217015
femal@@	O	-1	2217015
es.	O	-1	2217015
The	O	-1	2217015
ne@@	B-Disease	D009503	2217015
ut@@	I-Disease	-1	2217015
ro@@	I-Disease	-1	2217015
pen@@	I-Disease	-1	2217015
ia	I-Disease	-1	2217015
was	O	-1	2217015
due	O	-1	2217015
to	O	-1	2217015
mat@@	O	-1	2217015
ur@@	O	-1	2217015
ation	O	-1	2217015
ar@@	O	-1	2217015
res@@	O	-1	2217015
t	O	-1	2217015
of	O	-1	2217015
the	O	-1	2217015
my@@	O	-1	2217015
e@@	O	-1	2217015
lo@@	O	-1	2217015
id	O	-1	2217015
seri@@	O	-1	2217015
es	O	-1	2217015
in	O	-1	2217015
one	O	-1	2217015
patient@@	O	-1	2217015
.	O	-1	2217015
B@@	O	-1	2217015
oth	O	-1	2217015
patients	O	-1	2217015
were	O	-1	2217015
also	O	-1	2217015
hypo@@	B-Disease	D007037	2217015
th@@	I-Disease	-1	2217015
yro@@	I-Disease	-1	2217015
id	I-Disease	-1	2217015
,	O	-1	2217015
but	O	-1	2217015
it	O	-1	2217015
is	O	-1	2217015
not	O	-1	2217015
c@@	O	-1	2217015
le@@	O	-1	2217015
ar	O	-1	2217015
whether	O	-1	2217015
this	O	-1	2217015
was	O	-1	2217015
a	O	-1	2217015
pre@@	O	-1	2217015
dis@@	O	-1	2217015
pos@@	O	-1	2217015
ing	O	-1	2217015
factor	O	-1	2217015
to	O	-1	2217015
the	O	-1	2217015
development	O	-1	2217015
of	O	-1	2217015
these	O	-1	2217015
adverse	O	-1	2217015
reac@@	O	-1	2217015
tions.	O	-1	2217015
However,	O	-1	2217015
it	O	-1	2217015
wo@@	O	-1	2217015
uld	O	-1	2217015
se@@	O	-1	2217015
em	O	-1	2217015
pr@@	O	-1	2217015
ud@@	O	-1	2217015
ent	O	-1	2217015
not	O	-1	2217015
to	O	-1	2217015
use	O	-1	2217015
me@@	B-Chemical	D008528	2217015
f@@	I-Chemical	-1	2217015
en@@	I-Chemical	-1	2217015
am@@	I-Chemical	-1	2217015
ic	I-Chemical	-1	2217015
acid	I-Chemical	-1	2217015
in	O	-1	2217015
hypo@@	B-Disease	D007037	2217015
th@@	I-Disease	-1	2217015
yro@@	I-Disease	-1	2217015
id	I-Disease	-1	2217015
patients	O	-1	2217015
un@@	O	-1	2217015
ti@@	O	-1	2217015
l	O	-1	2217015
the	O	-1	2217015
hypo@@	B-Disease	D007037	2217015
th@@	I-Disease	-1	2217015
yro@@	I-Disease	-1	2217015
i@@	I-Disease	-1	2217015
dis@@	I-Disease	-1	2217015
m	I-Disease	-1	2217015
has	O	-1	2217015
been	O	-1	2217015
cor@@	O	-1	2217015
rec@@	O	-1	2217015
ted.	O	-1	2217015

E@@	O	-1	2239937
ti@@	O	-1	2239937
ology	O	-1	2239937
of	O	-1	2239937
hyper@@	B-Disease	D006934	2239937
cal@@	I-Disease	-1	2239937
ce@@	I-Disease	-1	2239937
mia	I-Disease	-1	2239937
in	O	-1	2239937
hemo@@	O	-1	2239937
dialy@@	O	-1	2239937
sis	O	-1	2239937
patients	O	-1	2239937
on	O	-1	2239937
calcium	B-Chemical	D002119	2239937
carb@@	I-Chemical	-1	2239937
on@@	I-Chemical	-1	2239937
ate	I-Chemical	-1	2239937
therapy.	O	-1	2239937
F@@	O	-1	2239937
o@@	O	-1	2239937
ur@@	O	-1	2239937
te@@	O	-1	2239937
en	O	-1	2239937
of	O	-1	2239937
3@@	O	-1	2239937
9	O	-1	2239937
dialy@@	O	-1	2239937
sis	O	-1	2239937
patients	O	-1	2239937
(3@@	O	-1	2239937
6@@	O	-1	2239937
%)	O	-1	2239937
b@@	O	-1	2239937
ec@@	O	-1	2239937
am@@	O	-1	2239937
e	O	-1	2239937
hyper@@	B-Disease	D006934	2239937
cal@@	I-Disease	-1	2239937
ce@@	I-Disease	-1	2239937
mic	I-Disease	-1	2239937
after	O	-1	2239937
switch@@	O	-1	2239937
ing	O	-1	2239937
to	O	-1	2239937
calcium	B-Chemical	D002119	2239937
carb@@	I-Chemical	-1	2239937
on@@	I-Chemical	-1	2239937
ate	I-Chemical	-1	2239937
as	O	-1	2239937
their	O	-1	2239937
pr@@	O	-1	2239937
inc@@	O	-1	2239937
ip@@	O	-1	2239937
al	O	-1	2239937
phosph@@	B-Chemical	D010710	2239937
ate	I-Chemical	-1	2239937
b@@	O	-1	2239937
ind@@	O	-1	2239937
er.	O	-1	2239937
In	O	-1	2239937
or@@	O	-1	2239937
der	O	-1	2239937
to	O	-1	2239937
identi@@	O	-1	2239937
f@@	O	-1	2239937
y	O	-1	2239937
risk	O	-1	2239937
factors	O	-1	2239937
associated	O	-1	2239937
with	O	-1	2239937
the	O	-1	2239937
development	O	-1	2239937
of	O	-1	2239937
hyper@@	B-Disease	D006934	2239937
cal@@	I-Disease	-1	2239937
ce@@	I-Disease	-1	2239937
mia	I-Disease	-1	2239937
,	O	-1	2239937
in@@	O	-1	2239937
direct	O	-1	2239937
par@@	O	-1	2239937
ame@@	O	-1	2239937
ters	O	-1	2239937
of	O	-1	2239937
in@@	O	-1	2239937
test@@	O	-1	2239937
inal	O	-1	2239937
calcium	B-Chemical	D002118	2239937
re@@	O	-1	2239937
abs@@	O	-1	2239937
or@@	O	-1	2239937
ption	O	-1	2239937
and	O	-1	2239937
b@@	O	-1	2239937
one	O	-1	2239937
t@@	O	-1	2239937
ur@@	O	-1	2239937
no@@	O	-1	2239937
ver	O	-1	2239937
rate	O	-1	2239937
in	O	-1	2239937
these	O	-1	2239937
14	O	-1	2239937
patients	O	-1	2239937
were	O	-1	2239937
compared	O	-1	2239937
with	O	-1	2239937
results	O	-1	2239937
in	O	-1	2239937
14	O	-1	2239937
e@@	O	-1	2239937
uc@@	O	-1	2239937
al@@	O	-1	2239937
ce@@	O	-1	2239937
mic	O	-1	2239937
patients	O	-1	2239937
mat@@	O	-1	2239937
ch@@	O	-1	2239937
ed	O	-1	2239937
for	O	-1	2239937
age,	O	-1	2239937
sex@@	O	-1	2239937
,	O	-1	2239937
l@@	O	-1	2239937
en@@	O	-1	2239937
g@@	O	-1	2239937
th	O	-1	2239937
of	O	-1	2239937
time	O	-1	2239937
on	O	-1	2239937
dialy@@	O	-1	2239937
sis,	O	-1	2239937
and	O	-1	2239937
e@@	O	-1	2239937
ti@@	O	-1	2239937
ology	O	-1	2239937
of	O	-1	2239937
renal	B-Disease	D007674	2239937
disease	I-Disease	-1	2239937
.	O	-1	2239937
In	O	-1	2239937
addition	O	-1	2239937
to	O	-1	2239937
experienc@@	O	-1	2239937
ing	O	-1	2239937
hyper@@	B-Disease	D006934	2239937
cal@@	I-Disease	-1	2239937
ce@@	I-Disease	-1	2239937
mic	I-Disease	-1	2239937
episo@@	O	-1	2239937
des	O	-1	2239937
with	O	-1	2239937
pe@@	O	-1	2239937
a@@	O	-1	2239937
k	O	-1	2239937
calcium	B-Chemical	D002118	2239937
values	O	-1	2239937
of	O	-1	2239937
2.@@	O	-1	2239937
7	O	-1	2239937
to	O	-1	2239937
3.@@	O	-1	2239937
8	O	-1	2239937
m@@	O	-1	2239937
mol@@	O	-1	2239937
/@@	O	-1	2239937
L	O	-1	2239937
(1@@	O	-1	2239937
0.@@	O	-1	2239937
7	O	-1	2239937
to	O	-1	2239937
1@@	O	-1	2239937
5.@@	O	-1	2239937
0	O	-1	2239937
mg/d@@	O	-1	2239937
L@@	O	-1	2239937
),	O	-1	2239937
patients	O	-1	2239937
in	O	-1	2239937
the	O	-1	2239937
hyper@@	B-Disease	D006934	2239937
cal@@	I-Disease	-1	2239937
ce@@	I-Disease	-1	2239937
mic	I-Disease	-1	2239937
group	O	-1	2239937
ex@@	O	-1	2239937
hib@@	O	-1	2239937
ited	O	-1	2239937
a	O	-1	2239937
significant	O	-1	2239937
increase	O	-1	2239937
in	O	-1	2239937
the	O	-1	2239937
mean	O	-1	2239937
calcium	B-Chemical	D002118	2239937
concentration	O	-1	2239937
obtained	O	-1	2239937
during	O	-1	2239937
6	O	-1	2239937
months	O	-1	2239937
before	O	-1	2239937
the	O	-1	2239937
switch@@	O	-1	2239937
,	O	-1	2239937
compared	O	-1	2239937
with	O	-1	2239937
the	O	-1	2239937
mean	O	-1	2239937
valu@@	O	-1	2239937
e	O	-1	2239937
obtained	O	-1	2239937
during	O	-1	2239937
the	O	-1	2239937
7	O	-1	2239937
months	O	-1	2239937
of	O	-1	2239937
observ@@	O	-1	2239937
ation	O	-1	2239937
after	O	-1	2239937
the	O	-1	2239937
s@@	O	-1	2239937
wit@@	O	-1	2239937
ch	O	-1	2239937
(2@@	O	-1	2239937
.@@	O	-1	2239937
4	O	-1	2239937
+/-	O	-1	2239937
0.0@@	O	-1	2239937
3	O	-1	2239937
to	O	-1	2239937
2.@@	O	-1	2239937
5	O	-1	2239937
+/-	O	-1	2239937
0.0@@	O	-1	2239937
3	O	-1	2239937
m@@	O	-1	2239937
mol@@	O	-1	2239937
/@@	O	-1	2239937
L	O	-1	2239937
[@@	O	-1	2239937
9.@@	O	-1	2239937
7	O	-1	2239937
+/-	O	-1	2239937
0.@@	O	-1	2239937
2	O	-1	2239937
to	O	-1	2239937
1@@	O	-1	2239937
0.@@	O	-1	2239937
2	O	-1	2239937
+/-	O	-1	2239937
0.@@	O	-1	2239937
1	O	-1	2239937
mg/d@@	O	-1	2239937
L@@	O	-1	2239937
]@@	O	-1	2239937
,	O	-1	2239937
P	O	-1	2239937
=	O	-1	2239937
0.00@@	O	-1	2239937
6@@	O	-1	2239937
).	O	-1	2239937
In	O	-1	2239937
contrast@@	O	-1	2239937
,	O	-1	2239937
e@@	O	-1	2239937
uc@@	O	-1	2239937
al@@	O	-1	2239937
ce@@	O	-1	2239937
mic	O	-1	2239937
patients	O	-1	2239937
ex@@	O	-1	2239937
hib@@	O	-1	2239937
ited	O	-1	2239937
no	O	-1	2239937
change	O	-1	2239937
in	O	-1	2239937
mean	O	-1	2239937
calcium	B-Chemical	D002118	2239937
values	O	-1	2239937
over	O	-1	2239937
the	O	-1	2239937
same	O	-1	2239937
time	O	-1	2239937
period	O	-1	2239937
(2@@	O	-1	2239937
.@@	O	-1	2239937
3	O	-1	2239937
+/-	O	-1	2239937
0.0@@	O	-1	2239937
5	O	-1	2239937
to	O	-1	2239937
2.@@	O	-1	2239937
3	O	-1	2239937
+/-	O	-1	2239937
0.0@@	O	-1	2239937
5	O	-1	2239937
m@@	O	-1	2239937
mol@@	O	-1	2239937
/@@	O	-1	2239937
L	O	-1	2239937
[@@	O	-1	2239937
9.@@	O	-1	2239937
2	O	-1	2239937
+/-	O	-1	2239937
0.@@	O	-1	2239937
2	O	-1	2239937
to	O	-1	2239937
9.@@	O	-1	2239937
2	O	-1	2239937
+/-	O	-1	2239937
0.@@	O	-1	2239937
2	O	-1	2239937
mg/d@@	O	-1	2239937
L@@	O	-1	2239937
]@@	O	-1	2239937
).	O	-1	2239937
Ca@@	B-Chemical	D002119	2239937
CO@@	I-Chemical	-1	2239937
3	I-Chemical	-1	2239937
dos@@	O	-1	2239937
age,	O	-1	2239937
calc@@	O	-1	2239937
ul@@	O	-1	2239937
ated	O	-1	2239937
di@@	O	-1	2239937
et@@	O	-1	2239937
ary	O	-1	2239937
calcium	B-Chemical	D002118	2239937
int@@	O	-1	2239937
ak@@	O	-1	2239937
e,	O	-1	2239937
and	O	-1	2239937
cir@@	O	-1	2239937
cul@@	O	-1	2239937
ating	O	-1	2239937
levels	O	-1	2239937
of	O	-1	2239937
vitamin	B-Chemical	D014807	2239937
D	I-Chemical	-1	2239937
metabol@@	O	-1	2239937
it@@	O	-1	2239937
es	O	-1	2239937
were	O	-1	2239937
similar	O	-1	2239937
in	O	-1	2239937
both	O	-1	2239937
groups.	O	-1	2239937
P@@	O	-1	2239937
hy@@	O	-1	2239937
si@@	O	-1	2239937
c@@	O	-1	2239937
al	O	-1	2239937
activity	O	-1	2239937
in@@	O	-1	2239937
de@@	O	-1	2239937
x	O	-1	2239937
and	O	-1	2239937
pre@@	O	-1	2239937
dialy@@	O	-1	2239937
sis	O	-1	2239937
serum	O	-1	2239937
b@@	B-Chemical	D001639	2239937
ic@@	I-Chemical	-1	2239937
arb@@	I-Chemical	-1	2239937
on@@	I-Chemical	-1	2239937
ate	I-Chemical	-1	2239937
levels	O	-1	2239937
also	O	-1	2239937
were	O	-1	2239937
similar	O	-1	2239937
in	O	-1	2239937
both	O	-1	2239937
groups.	O	-1	2239937
However,	O	-1	2239937
there	O	-1	2239937
was	O	-1	2239937
a	O	-1	2239937
significant	O	-1	2239937
difference	O	-1	2239937
in	O	-1	2239937
par@@	O	-1	2239937
ame@@	O	-1	2239937
ters	O	-1	2239937
ref@@	O	-1	2239937
l@@	O	-1	2239937
ect@@	O	-1	2239937
ing	O	-1	2239937
b@@	O	-1	2239937
one	O	-1	2239937
t@@	O	-1	2239937
ur@@	O	-1	2239937
no@@	O	-1	2239937
ver	O	-1	2239937
rat@@	O	-1	2239937
es	O	-1	2239937
between	O	-1	2239937
group@@	O	-1	2239937
s@@	O	-1	2239937
.@@	O	-1	2239937
(A@@	O	-1	2239937
B@@	O	-1	2239937
S@@	O	-1	2239937
TR@@	O	-1	2239937
AC@@	O	-1	2239937
T	O	-1	2239937
TR@@	O	-1	2239937
UN@@	O	-1	2239937
C@@	O	-1	2239937
AT@@	O	-1	2239937
E@@	O	-1	2239937
D	O	-1	2239937
A@@	O	-1	2239937
T	O	-1	2239937
2@@	O	-1	2239937
50	O	-1	2239937
W@@	O	-1	2239937
O@@	O	-1	2239937
RD@@	O	-1	2239937
S)	O	-1	2239937

M@@	B-Chemical	D008750	2320485
eth@@	I-Chemical	-1	2320485
yl@@	I-Chemical	-1	2320485
dopa	I-Chemical	-1	2320485
-induced	O	-1	2320485
hemolytic	B-Disease	D000743	2320485
anemia	I-Disease	-1	2320485
in	O	-1	2320485
a	O	-1	2320485
15	O	-1	2320485
year	O	-1	2320485
old	O	-1	2320485
present@@	O	-1	2320485
ing	O	-1	2320485
as	O	-1	2320485
ne@@	O	-1	2320485
ar@@	O	-1	2320485
-	O	-1	2320485
syn@@	B-Disease	D013575	2320485
co@@	I-Disease	-1	2320485
p@@	I-Disease	-1	2320485
e	I-Disease	-1	2320485
.	O	-1	2320485
M@@	B-Chemical	D008750	2320485
eth@@	I-Chemical	-1	2320485
yl@@	I-Chemical	-1	2320485
dopa	I-Chemical	-1	2320485
is	O	-1	2320485
an	O	-1	2320485
anti@@	O	-1	2320485
hypertensive	O	-1	2320485
medic@@	O	-1	2320485
ation	O	-1	2320485
which	O	-1	2320485
is	O	-1	2320485
av@@	O	-1	2320485
ail@@	O	-1	2320485
able	O	-1	2320485
gener@@	O	-1	2320485
ically	O	-1	2320485
and	O	-1	2320485
under	O	-1	2320485
the	O	-1	2320485
tra@@	O	-1	2320485
de	O	-1	2320485
nam@@	O	-1	2320485
e	O	-1	2320485
Al@@	B-Chemical	D008750	2320485
do@@	I-Chemical	-1	2320485
me@@	I-Chemical	-1	2320485
t	I-Chemical	-1	2320485
that	O	-1	2320485
is	O	-1	2320485
wi@@	O	-1	2320485
de@@	O	-1	2320485
ly	O	-1	2320485
prescri@@	O	-1	2320485
bed	O	-1	2320485
in	O	-1	2320485
the	O	-1	2320485
ad@@	O	-1	2320485
ult	O	-1	2320485
po@@	O	-1	2320485
p@@	O	-1	2320485
ulation	O	-1	2320485
and	O	-1	2320485
inf@@	O	-1	2320485
requ@@	O	-1	2320485
ently	O	-1	2320485
used	O	-1	2320485
in	O	-1	2320485
child@@	O	-1	2320485
ren@@	O	-1	2320485
.	O	-1	2320485
M@@	B-Chemical	D008750	2320485
eth@@	I-Chemical	-1	2320485
yl@@	I-Chemical	-1	2320485
dopa	I-Chemical	-1	2320485
causes	O	-1	2320485
an	O	-1	2320485
auto@@	B-Disease	D000744	2320485
immun@@	I-Disease	-1	2320485
e	I-Disease	-1	2320485
hemolytic	I-Disease	-1	2320485
anemia	I-Disease	-1	2320485
in	O	-1	2320485
a	O	-1	2320485
sm@@	O	-1	2320485
all	O	-1	2320485
perc@@	O	-1	2320485
ent@@	O	-1	2320485
age	O	-1	2320485
of	O	-1	2320485
patients	O	-1	2320485
who	O	-1	2320485
tak@@	O	-1	2320485
e	O	-1	2320485
the	O	-1	2320485
drug.	O	-1	2320485
We	O	-1	2320485
report	O	-1	2320485
a	O	-1	2320485
case	O	-1	2320485
of	O	-1	2320485
methyl@@	B-Chemical	D008750	2320485
dopa	I-Chemical	-1	2320485
-induced	O	-1	2320485
hemolytic	B-Disease	D000743	2320485
anemia	I-Disease	-1	2320485
in	O	-1	2320485
a	O	-1	2320485
1@@	O	-1	2320485
5-@@	O	-1	2320485
year-old	O	-1	2320485
bo@@	O	-1	2320485
y	O	-1	2320485
who	O	-1	2320485
presented	O	-1	2320485
to	O	-1	2320485
the	O	-1	2320485
em@@	B-Disease	D004630	2320485
er@@	I-Disease	-1	2320485
gen@@	I-Disease	-1	2320485
c@@	I-Disease	-1	2320485
y	I-Disease	-1	2320485
de@@	I-Disease	-1	2320485
part@@	I-Disease	-1	2320485
ment	I-Disease	-1	2320485
with	O	-1	2320485
ne@@	O	-1	2320485
ar@@	O	-1	2320485
-	O	-1	2320485
syn@@	B-Disease	D013575	2320485
co@@	I-Disease	-1	2320485
p@@	I-Disease	-1	2320485
e	I-Disease	-1	2320485
.	O	-1	2320485
The	O	-1	2320485
bo@@	O	-1	2320485
y	O	-1	2320485
had	O	-1	2320485
been	O	-1	2320485
treated	O	-1	2320485
with	O	-1	2320485
intravenous	O	-1	2320485
methyl@@	B-Chemical	D008750	2320485
dopa	I-Chemical	-1	2320485
during	O	-1	2320485
a	O	-1	2320485
tra@@	B-Disease	D014947	2320485
um@@	I-Disease	-1	2320485
a	I-Disease	-1	2320485
ad@@	O	-1	2320485
mission	O	-1	2320485
seven	O	-1	2320485
weeks	O	-1	2320485
prior	O	-1	2320485
to	O	-1	2320485
present@@	O	-1	2320485
ation.	O	-1	2320485
E@@	O	-1	2320485
valu@@	O	-1	2320485
ation	O	-1	2320485
revealed	O	-1	2320485
a	O	-1	2320485
hemo@@	O	-1	2320485
globin	O	-1	2320485
of	O	-1	2320485
three	O	-1	2320485
gram@@	O	-1	2320485
s,	O	-1	2320485
3@@	O	-1	2320485
+	O	-1	2320485
C@@	O	-1	2320485
o@@	O	-1	2320485
om@@	O	-1	2320485
b@@	O	-1	2320485
s@@	O	-1	2320485
'	O	-1	2320485
test	O	-1	2320485
with	O	-1	2320485
pol@@	O	-1	2320485
ys@@	O	-1	2320485
p@@	O	-1	2320485
ec@@	O	-1	2320485
if@@	O	-1	2320485
ic	O	-1	2320485
anti@@	O	-1	2320485
-@@	O	-1	2320485
human	O	-1	2320485
glo@@	O	-1	2320485
b@@	O	-1	2320485
ul@@	O	-1	2320485
in	O	-1	2320485
and	O	-1	2320485
mon@@	O	-1	2320485
os@@	O	-1	2320485
p@@	O	-1	2320485
ec@@	O	-1	2320485
if@@	O	-1	2320485
ic	O	-1	2320485
I@@	O	-1	2320485
g@@	O	-1	2320485
G	O	-1	2320485
re@@	O	-1	2320485
agent@@	O	-1	2320485
s,	O	-1	2320485
and	O	-1	2320485
a	O	-1	2320485
war@@	O	-1	2320485
m	O	-1	2320485
re@@	O	-1	2320485
act@@	O	-1	2320485
ing	O	-1	2320485
auto@@	O	-1	2320485
anti@@	O	-1	2320485
bo@@	O	-1	2320485
d@@	O	-1	2320485
y.	O	-1	2320485
T@@	O	-1	2320485
ran@@	O	-1	2320485
s@@	O	-1	2320485
f@@	O	-1	2320485
usion	O	-1	2320485
and	O	-1	2320485
cortico@@	B-Chemical	D000305	2320485
ster@@	I-Chemical	-1	2320485
oid	I-Chemical	-1	2320485
therapy	O	-1	2320485
resulted	O	-1	2320485
in	O	-1	2320485
a	O	-1	2320485
complete	O	-1	2320485
recovery	O	-1	2320485
of	O	-1	2320485
the	O	-1	2320485
patient@@	O	-1	2320485
.	O	-1	2320485
E@@	O	-1	2320485
mer@@	O	-1	2320485
gen@@	O	-1	2320485
c@@	O	-1	2320485
y	O	-1	2320485
physi@@	O	-1	2320485
ci@@	O	-1	2320485
ans	O	-1	2320485
treat@@	O	-1	2320485
ing	O	-1	2320485
children	O	-1	2320485
mus@@	O	-1	2320485
t	O	-1	2320485
be	O	-1	2320485
aw@@	O	-1	2320485
are	O	-1	2320485
of	O	-1	2320485
this	O	-1	2320485
syndrome	O	-1	2320485
in	O	-1	2320485
or@@	O	-1	2320485
der	O	-1	2320485
to	O	-1	2320485
diag@@	O	-1	2320485
n@@	O	-1	2320485
ose	O	-1	2320485
and	O	-1	2320485
tre@@	O	-1	2320485
at	O	-1	2320485
it	O	-1	2320485
cor@@	O	-1	2320485
rec@@	O	-1	2320485
t@@	O	-1	2320485
ly.	O	-1	2320485
A	O	-1	2320485
b@@	O	-1	2320485
ri@@	O	-1	2320485
e@@	O	-1	2320485
f	O	-1	2320485
revie@@	O	-1	2320485
w	O	-1	2320485
of	O	-1	2320485
auto@@	O	-1	2320485
immun@@	O	-1	2320485
e	O	-1	2320485
and	O	-1	2320485
drug@@	O	-1	2320485
-induced	O	-1	2320485
hemolytic	B-Disease	D000743	2320485
an@@	I-Disease	-1	2320485
em@@	I-Disease	-1	2320485
i@@	I-Disease	-1	2320485
as	I-Disease	-1	2320485
is	O	-1	2320485
pro@@	O	-1	2320485
vi@@	O	-1	2320485
de@@	O	-1	2320485
d.	O	-1	2320485

The	O	-1	2358093
long-term	O	-1	2358093
safety	O	-1	2358093
of	O	-1	2358093
d@@	B-Chemical	D003613	2358093
an@@	I-Chemical	-1	2358093
az@@	I-Chemical	-1	2358093
ol	I-Chemical	-1	2358093
in	O	-1	2358093
women	O	-1	2358093
with	O	-1	2358093
he@@	B-Disease	D054179	2358093
re@@	I-Disease	-1	2358093
d@@	I-Disease	-1	2358093
it@@	I-Disease	-1	2358093
ary	I-Disease	-1	2358093
angio@@	I-Disease	-1	2358093
e@@	I-Disease	-1	2358093
de@@	I-Disease	-1	2358093
ma	I-Disease	-1	2358093
.	O	-1	2358093
Although	O	-1	2358093
the	O	-1	2358093
sh@@	O	-1	2358093
ort@@	O	-1	2358093
-term	O	-1	2358093
safety	O	-1	2358093
(@@	O	-1	2358093
less	O	-1	2358093
than	O	-1	2358093
or	O	-1	2358093
equ@@	O	-1	2358093
al	O	-1	2358093
to	O	-1	2358093
6	O	-1	2358093
month@@	O	-1	2358093
s)	O	-1	2358093
of	O	-1	2358093
d@@	B-Chemical	D003613	2358093
an@@	I-Chemical	-1	2358093
az@@	I-Chemical	-1	2358093
ol	I-Chemical	-1	2358093
has	O	-1	2358093
been	O	-1	2358093
est@@	O	-1	2358093
abl@@	O	-1	2358093
ished	O	-1	2358093
in	O	-1	2358093
a	O	-1	2358093
vari@@	O	-1	2358093
ety	O	-1	2358093
of	O	-1	2358093
se@@	O	-1	2358093
t@@	O	-1	2358093
t@@	O	-1	2358093
ing@@	O	-1	2358093
s,	O	-1	2358093
no	O	-1	2358093
inf@@	O	-1	2358093
orm@@	O	-1	2358093
ation	O	-1	2358093
ex@@	O	-1	2358093
ist@@	O	-1	2358093
s	O	-1	2358093
as	O	-1	2358093
to	O	-1	2358093
its	O	-1	2358093
long-term	O	-1	2358093
saf@@	O	-1	2358093
et@@	O	-1	2358093
y.	O	-1	2358093
We	O	-1	2358093
the@@	O	-1	2358093
re@@	O	-1	2358093
fore	O	-1	2358093
investigated	O	-1	2358093
the	O	-1	2358093
long-term	O	-1	2358093
safety	O	-1	2358093
of	O	-1	2358093
d@@	B-Chemical	D003613	2358093
an@@	I-Chemical	-1	2358093
az@@	I-Chemical	-1	2358093
ol	I-Chemical	-1	2358093
by	O	-1	2358093
perform@@	O	-1	2358093
ing	O	-1	2358093
a	O	-1	2358093
ret@@	O	-1	2358093
ro@@	O	-1	2358093
sp@@	O	-1	2358093
ective	O	-1	2358093
ch@@	O	-1	2358093
ar@@	O	-1	2358093
t	O	-1	2358093
revie@@	O	-1	2358093
w	O	-1	2358093
of	O	-1	2358093
60	O	-1	2358093
female	O	-1	2358093
patients	O	-1	2358093
with	O	-1	2358093
he@@	B-Disease	D054179	2358093
re@@	I-Disease	-1	2358093
d@@	I-Disease	-1	2358093
it@@	I-Disease	-1	2358093
ary	I-Disease	-1	2358093
angio@@	I-Disease	-1	2358093
e@@	I-Disease	-1	2358093
de@@	I-Disease	-1	2358093
ma	I-Disease	-1	2358093
treated	O	-1	2358093
with	O	-1	2358093
d@@	B-Chemical	D003613	2358093
an@@	I-Chemical	-1	2358093
az@@	I-Chemical	-1	2358093
ol	I-Chemical	-1	2358093
for	O	-1	2358093
a	O	-1	2358093
continu@@	O	-1	2358093
ous	O	-1	2358093
period	O	-1	2358093
of	O	-1	2358093
6	O	-1	2358093
months	O	-1	2358093
or	O	-1	2358093
long@@	O	-1	2358093
er.	O	-1	2358093
The	O	-1	2358093
mean	O	-1	2358093
age	O	-1	2358093
of	O	-1	2358093
the	O	-1	2358093
patients	O	-1	2358093
was	O	-1	2358093
3@@	O	-1	2358093
5.@@	O	-1	2358093
2	O	-1	2358093
years	O	-1	2358093
and	O	-1	2358093
the	O	-1	2358093
mean	O	-1	2358093
duration	O	-1	2358093
of	O	-1	2358093
therapy	O	-1	2358093
was	O	-1	2358093
5@@	O	-1	2358093
9.@@	O	-1	2358093
7	O	-1	2358093
months.	O	-1	2358093
V@@	O	-1	2358093
ir@@	O	-1	2358093
tu@@	O	-1	2358093
ally	O	-1	2358093
all	O	-1	2358093
patients	O	-1	2358093
experienced	O	-1	2358093
one	O	-1	2358093
or	O	-1	2358093
more	O	-1	2358093
adverse	O	-1	2358093
reac@@	O	-1	2358093
tions.	O	-1	2358093
M@@	B-Disease	D008599	2358093
en@@	I-Disease	-1	2358093
st@@	I-Disease	-1	2358093
ru@@	I-Disease	-1	2358093
al	I-Disease	-1	2358093
abnormal@@	I-Disease	-1	2358093
ities	I-Disease	-1	2358093
(@@	O	-1	2358093
7@@	O	-1	2358093
9@@	O	-1	2358093
%),	O	-1	2358093
weight	B-Disease	D015430	2358093
g@@	I-Disease	-1	2358093
ain	I-Disease	-1	2358093
(6@@	O	-1	2358093
0@@	O	-1	2358093
%),	O	-1	2358093
musc@@	B-Disease	D009120	2358093
le	I-Disease	-1	2358093
c@@	I-Disease	-1	2358093
ram@@	I-Disease	-1	2358093
p@@	I-Disease	-1	2358093
s	I-Disease	-1	2358093
/	O	-1	2358093
my@@	B-Disease	D063806	2358093
al@@	I-Disease	-1	2358093
gi@@	I-Disease	-1	2358093
as	I-Disease	-1	2358093
(4@@	O	-1	2358093
0@@	O	-1	2358093
%),	O	-1	2358093
and	O	-1	2358093
trans@@	O	-1	2358093
amin@@	O	-1	2358093
ase	O	-1	2358093
elev@@	O	-1	2358093
ations	O	-1	2358093
(4@@	O	-1	2358093
0@@	O	-1	2358093
%)	O	-1	2358093
were	O	-1	2358093
the	O	-1	2358093
most	O	-1	2358093
common	O	-1	2358093
adverse	O	-1	2358093
reac@@	O	-1	2358093
tions.	O	-1	2358093
The	O	-1	2358093
drug	O	-1	2358093
was	O	-1	2358093
discontinu@@	O	-1	2358093
ed	O	-1	2358093
due	O	-1	2358093
to	O	-1	2358093
adverse	O	-1	2358093
reactions	O	-1	2358093
in	O	-1	2358093
8	O	-1	2358093
patients.	O	-1	2358093
No	O	-1	2358093
patient	O	-1	2358093
has	O	-1	2358093
di@@	O	-1	2358093
ed	O	-1	2358093
or	O	-1	2358093
su@@	O	-1	2358093
ffe@@	O	-1	2358093
red	O	-1	2358093
any	O	-1	2358093
appa@@	O	-1	2358093
rent	O	-1	2358093
long-term	O	-1	2358093
sequ@@	O	-1	2358093
el@@	O	-1	2358093
a@@	O	-1	2358093
e	O	-1	2358093
that	O	-1	2358093
were	O	-1	2358093
direc@@	O	-1	2358093
tly	O	-1	2358093
at@@	O	-1	2358093
tri@@	O	-1	2358093
but@@	O	-1	2358093
able	O	-1	2358093
to	O	-1	2358093
the	O	-1	2358093
drug.	O	-1	2358093
We	O	-1	2358093
concl@@	O	-1	2358093
ude	O	-1	2358093
th@@	O	-1	2358093
at@@	O	-1	2358093
,	O	-1	2358093
des@@	O	-1	2358093
pit@@	O	-1	2358093
e	O	-1	2358093
a	O	-1	2358093
rel@@	O	-1	2358093
atively	O	-1	2358093
high	O	-1	2358093
incidence	O	-1	2358093
of	O	-1	2358093
adverse	O	-1	2358093
reac@@	O	-1	2358093
tion@@	O	-1	2358093
s,	O	-1	2358093
d@@	B-Chemical	D003613	2358093
an@@	I-Chemical	-1	2358093
az@@	I-Chemical	-1	2358093
ol	I-Chemical	-1	2358093
has	O	-1	2358093
pro@@	O	-1	2358093
ven	O	-1	2358093
to	O	-1	2358093
be	O	-1	2358093
re@@	O	-1	2358093
mark@@	O	-1	2358093
ably	O	-1	2358093
saf@@	O	-1	2358093
e	O	-1	2358093
over	O	-1	2358093
the	O	-1	2358093
long-term	O	-1	2358093
in	O	-1	2358093
this	O	-1	2358093
group	O	-1	2358093
of	O	-1	2358093
patients.	O	-1	2358093

Pati@@	O	-1	2383364
ent	O	-1	2383364
toler@@	O	-1	2383364
ance	O	-1	2383364
study	O	-1	2383364
of	O	-1	2383364
to@@	O	-1	2383364
p@@	O	-1	2383364
ical	O	-1	2383364
chlor@@	B-Chemical	C048279	2383364
he@@	I-Chemical	-1	2383364
x@@	I-Chemical	-1	2383364
idine	I-Chemical	-1	2383364
di@@	I-Chemical	-1	2383364
phosph@@	I-Chemical	-1	2383364
an@@	I-Chemical	-1	2383364
il@@	I-Chemical	-1	2383364
ate	I-Chemical	-1	2383364
:	O	-1	2383364
a	O	-1	2383364
new	O	-1	2383364
to@@	O	-1	2383364
p@@	O	-1	2383364
ical	O	-1	2383364
agent	O	-1	2383364
for	O	-1	2383364
b@@	B-Disease	D002056	2383364
ur@@	I-Disease	-1	2383364
n@@	I-Disease	-1	2383364
s	I-Disease	-1	2383364
.	O	-1	2383364
Eff@@	O	-1	2383364
ective	O	-1	2383364
to@@	O	-1	2383364
p@@	O	-1	2383364
ical	O	-1	2383364
anti@@	O	-1	2383364
micro@@	O	-1	2383364
b@@	O	-1	2383364
ial	O	-1	2383364
agents	O	-1	2383364
decrease	O	-1	2383364
inf@@	B-Disease	D007239	2383364
ection	I-Disease	-1	2383364
and	O	-1	2383364
mor@@	O	-1	2383364
t@@	O	-1	2383364
ality	O	-1	2383364
in	O	-1	2383364
b@@	B-Disease	D002056	2383364
ur@@	I-Disease	-1	2383364
n	I-Disease	-1	2383364
patients.	O	-1	2383364
Ch@@	B-Chemical	C048279	2383364
lor@@	I-Chemical	-1	2383364
he@@	I-Chemical	-1	2383364
x@@	I-Chemical	-1	2383364
idine	I-Chemical	-1	2383364
phosph@@	I-Chemical	-1	2383364
an@@	I-Chemical	-1	2383364
il@@	I-Chemical	-1	2383364
ate	I-Chemical	-1	2383364
(	O	-1	2383364
C@@	B-Chemical	C048279	2383364
H@@	I-Chemical	-1	2383364
P	I-Chemical	-1	2383364
),	O	-1	2383364
a	O	-1	2383364
new	O	-1	2383364
b@@	O	-1	2383364
ro@@	O	-1	2383364
ad@@	O	-1	2383364
-@@	O	-1	2383364
sp@@	O	-1	2383364
ect@@	O	-1	2383364
ru@@	O	-1	2383364
m	O	-1	2383364
anti@@	O	-1	2383364
micro@@	O	-1	2383364
b@@	O	-1	2383364
ial	O	-1	2383364
agent@@	O	-1	2383364
,	O	-1	2383364
has	O	-1	2383364
been	O	-1	2383364
evaluated	O	-1	2383364
as	O	-1	2383364
a	O	-1	2383364
to@@	O	-1	2383364
p@@	O	-1	2383364
ical	O	-1	2383364
b@@	B-Disease	D002056	2383364
ur@@	I-Disease	-1	2383364
n	I-Disease	-1	2383364
w@@	O	-1	2383364
ound	O	-1	2383364
d@@	O	-1	2383364
res@@	O	-1	2383364
s@@	O	-1	2383364
ing	O	-1	2383364
in	O	-1	2383364
cre@@	O	-1	2383364
am	O	-1	2383364
form@@	O	-1	2383364
,	O	-1	2383364
but	O	-1	2383364
pre@@	O	-1	2383364
lim@@	O	-1	2383364
inary	O	-1	2383364
clinical	O	-1	2383364
tri@@	O	-1	2383364
als	O	-1	2383364
reported	O	-1	2383364
that	O	-1	2383364
it	O	-1	2383364
was	O	-1	2383364
pa@@	O	-1	2383364
infu@@	O	-1	2383364
l	O	-1	2383364
up@@	O	-1	2383364
on	O	-1	2383364
ap@@	O	-1	2383364
plic@@	O	-1	2383364
ation.	O	-1	2383364
This	O	-1	2383364
study	O	-1	2383364
compared	O	-1	2383364
various	O	-1	2383364
concentrations	O	-1	2383364
of	O	-1	2383364
C@@	B-Chemical	C048279	2383364
H@@	I-Chemical	-1	2383364
P	I-Chemical	-1	2383364
to	O	-1	2383364
determine	O	-1	2383364
if	O	-1	2383364
a	O	-1	2383364
toler@@	O	-1	2383364
able	O	-1	2383364
concentration	O	-1	2383364
could	O	-1	2383364
be	O	-1	2383364
identi@@	O	-1	2383364
fied	O	-1	2383364
with	O	-1	2383364
re@@	O	-1	2383364
ten@@	O	-1	2383364
tion	O	-1	2383364
of	O	-1	2383364
anti@@	O	-1	2383364
micro@@	O	-1	2383364
b@@	O	-1	2383364
ial	O	-1	2383364
efficac@@	O	-1	2383364
y.	O	-1	2383364
Tw@@	O	-1	2383364
ent@@	O	-1	2383364
y-@@	O	-1	2383364
n@@	O	-1	2383364
ine	O	-1	2383364
b@@	B-Disease	D002056	2383364
ur@@	I-Disease	-1	2383364
n	I-Disease	-1	2383364
patients,	O	-1	2383364
each	O	-1	2383364
with	O	-1	2383364
two	O	-1	2383364
similar	O	-1	2383364
b@@	B-Disease	D002056	2383364
ur@@	I-Disease	-1	2383364
n@@	I-Disease	-1	2383364
s	I-Disease	-1	2383364
which	O	-1	2383364
could	O	-1	2383364
be	O	-1	2383364
se@@	O	-1	2383364
par@@	O	-1	2383364
ately	O	-1	2383364
treat@@	O	-1	2383364
ed,	O	-1	2383364
were	O	-1	2383364
given	O	-1	2383364
pa@@	O	-1	2383364
ir@@	O	-1	2383364
s	O	-1	2383364
of	O	-1	2383364
treat@@	O	-1	2383364
ments	O	-1	2383364
at	O	-1	2383364
suc@@	O	-1	2383364
ces@@	O	-1	2383364
sive	O	-1	2383364
1@@	O	-1	2383364
2-@@	O	-1	2383364
h	O	-1	2383364
interv@@	O	-1	2383364
als	O	-1	2383364
over	O	-1	2383364
a	O	-1	2383364
3-@@	O	-1	2383364
day	O	-1	2383364
perio@@	O	-1	2383364
d.	O	-1	2383364
One	O	-1	2383364
b@@	B-Disease	D002056	2383364
ur@@	I-Disease	-1	2383364
n	I-Disease	-1	2383364
sit@@	O	-1	2383364
e	O	-1	2383364
was	O	-1	2383364
treated	O	-1	2383364
with	O	-1	2383364
each	O	-1	2383364
of	O	-1	2383364
four	O	-1	2383364
different	O	-1	2383364
C@@	B-Chemical	C048279	2383364
H@@	I-Chemical	-1	2383364
P	I-Chemical	-1	2383364
concentr@@	O	-1	2383364
ation@@	O	-1	2383364
s,	O	-1	2383364
from	O	-1	2383364
0.@@	O	-1	2383364
25	O	-1	2383364
per	O	-1	2383364
c@@	O	-1	2383364
ent	O	-1	2383364
to	O	-1	2383364
2	O	-1	2383364
per	O	-1	2383364
c@@	O	-1	2383364
ent@@	O	-1	2383364
,	O	-1	2383364
their	O	-1	2383364
ve@@	O	-1	2383364
h@@	O	-1	2383364
ic@@	O	-1	2383364
le@@	O	-1	2383364
,	O	-1	2383364
and	O	-1	2383364
1	O	-1	2383364
per	O	-1	2383364
c@@	O	-1	2383364
ent	O	-1	2383364
si@@	B-Chemical	D012837	2383364
l@@	I-Chemical	-1	2383364
ver	I-Chemical	-1	2383364
sul@@	I-Chemical	-1	2383364
pha@@	I-Chemical	-1	2383364
di@@	I-Chemical	-1	2383364
az@@	I-Chemical	-1	2383364
ine	I-Chemical	-1	2383364
(	O	-1	2383364
A@@	B-Chemical	D012837	2383364
g@@	I-Chemical	-1	2383364
S@@	I-Chemical	-1	2383364
D	I-Chemical	-1	2383364
)	O	-1	2383364
cre@@	O	-1	2383364
am@@	O	-1	2383364
,	O	-1	2383364
an	O	-1	2383364
anti@@	O	-1	2383364
micro@@	O	-1	2383364
b@@	O	-1	2383364
ial	O	-1	2383364
agent	O	-1	2383364
frequ@@	O	-1	2383364
ently	O	-1	2383364
used	O	-1	2383364
for	O	-1	2383364
to@@	O	-1	2383364
p@@	O	-1	2383364
ical	O	-1	2383364
treatment	O	-1	2383364
of	O	-1	2383364
b@@	B-Disease	D002056	2383364
ur@@	I-Disease	-1	2383364
n	I-Disease	-1	2383364
w@@	O	-1	2383364
oun@@	O	-1	2383364
d@@	O	-1	2383364
s.	O	-1	2383364
The	O	-1	2383364
other	O	-1	2383364
sit@@	O	-1	2383364
e	O	-1	2383364
was	O	-1	2383364
al@@	O	-1	2383364
w@@	O	-1	2383364
ays	O	-1	2383364
treated	O	-1	2383364
with	O	-1	2383364
A@@	B-Chemical	D012837	2383364
g@@	I-Chemical	-1	2383364
S@@	I-Chemical	-1	2383364
D	I-Chemical	-1	2383364
cre@@	O	-1	2383364
am@@	O	-1	2383364
.	O	-1	2383364
There	O	-1	2383364
was	O	-1	2383364
a	O	-1	2383364
direct	O	-1	2383364
rel@@	O	-1	2383364
ationship	O	-1	2383364
between	O	-1	2383364
C@@	B-Chemical	C048279	2383364
H@@	I-Chemical	-1	2383364
P	I-Chemical	-1	2383364
concentration	O	-1	2383364
and	O	-1	2383364
patient@@	O	-1	2383364
s@@	O	-1	2383364
'	O	-1	2383364
rat@@	O	-1	2383364
ings	O	-1	2383364
of	O	-1	2383364
pain	B-Disease	D010146	2383364
on	O	-1	2383364
an	O	-1	2383364
an@@	O	-1	2383364
alo@@	O	-1	2383364
gu@@	O	-1	2383364
e	O	-1	2383364
s@@	O	-1	2383364
cal@@	O	-1	2383364
e.	O	-1	2383364
The	O	-1	2383364
0.@@	O	-1	2383364
25	O	-1	2383364
per	O	-1	2383364
c@@	O	-1	2383364
ent	O	-1	2383364
C@@	B-Chemical	C048279	2383364
H@@	I-Chemical	-1	2383364
P	I-Chemical	-1	2383364
cre@@	O	-1	2383364
am	O	-1	2383364
was	O	-1	2383364
c@@	O	-1	2383364
los@@	O	-1	2383364
est	O	-1	2383364
to	O	-1	2383364
A@@	B-Chemical	D012837	2383364
g@@	I-Chemical	-1	2383364
S@@	I-Chemical	-1	2383364
D	I-Chemical	-1	2383364
in	O	-1	2383364
pain	B-Disease	D010146	2383364
toler@@	O	-1	2383364
ance@@	O	-1	2383364
;	O	-1	2383364
however,	O	-1	2383364
n@@	O	-1	2383364
one	O	-1	2383364
of	O	-1	2383364
the	O	-1	2383364
treat@@	O	-1	2383364
ments	O	-1	2383364
di@@	O	-1	2383364
ffe@@	O	-1	2383364
red	O	-1	2383364
statis@@	O	-1	2383364
tically	O	-1	2383364
from	O	-1	2383364
A@@	B-Chemical	D012837	2383364
g@@	I-Chemical	-1	2383364
S@@	I-Chemical	-1	2383364
D	I-Chemical	-1	2383364
or	O	-1	2383364
from	O	-1	2383364
each	O	-1	2383364
o@@	O	-1	2383364
ther@@	O	-1	2383364
.	O	-1	2383364
In	O	-1	2383364
addi@@	O	-1	2383364
tion,	O	-1	2383364
e@@	O	-1	2383364
ase	O	-1	2383364
of	O	-1	2383364
ap@@	O	-1	2383364
plic@@	O	-1	2383364
ation	O	-1	2383364
of	O	-1	2383364
C@@	B-Chemical	C048279	2383364
H@@	I-Chemical	-1	2383364
P	I-Chemical	-1	2383364
cre@@	O	-1	2383364
am@@	O	-1	2383364
s	O	-1	2383364
was	O	-1	2383364
less	O	-1	2383364
s@@	O	-1	2383364
atis@@	O	-1	2383364
fact@@	O	-1	2383364
ory	O	-1	2383364
than	O	-1	2383364
that	O	-1	2383364
of	O	-1	2383364
A@@	B-Chemical	D012837	2383364
g@@	I-Chemical	-1	2383364
S@@	I-Chemical	-1	2383364
D	I-Chemical	-1	2383364
.	O	-1	2383364
It	O	-1	2383364
was	O	-1	2383364
concl@@	O	-1	2383364
uded	O	-1	2383364
that	O	-1	2383364
form@@	O	-1	2383364
ul@@	O	-1	2383364
ations	O	-1	2383364
at	O	-1	2383364
or	O	-1	2383364
be@@	O	-1	2383364
low	O	-1	2383364
0.@@	O	-1	2383364
5	O	-1	2383364
per	O	-1	2383364
c@@	O	-1	2383364
ent	O	-1	2383364
C@@	B-Chemical	C048279	2383364
H@@	I-Chemical	-1	2383364
P	I-Chemical	-1	2383364
may	O	-1	2383364
pro@@	O	-1	2383364
ve	O	-1	2383364
ac@@	O	-1	2383364
ce@@	O	-1	2383364
pt@@	O	-1	2383364
able	O	-1	2383364
for	O	-1	2383364
w@@	O	-1	2383364
ound	O	-1	2383364
ca@@	O	-1	2383364
re,	O	-1	2383364
but	O	-1	2383364
the	O	-1	2383364
ve@@	O	-1	2383364
h@@	O	-1	2383364
ic@@	O	-1	2383364
le	O	-1	2383364
system	O	-1	2383364
ne@@	O	-1	2383364
ed@@	O	-1	2383364
s	O	-1	2383364
ph@@	O	-1	2383364
ar@@	O	-1	2383364
m@@	O	-1	2383364
ace@@	O	-1	2383364
u@@	O	-1	2383364
tical	O	-1	2383364
impro@@	O	-1	2383364
vement	O	-1	2383364
to	O	-1	2383364
ren@@	O	-1	2383364
der	O	-1	2383364
it	O	-1	2383364
more	O	-1	2383364
toler@@	O	-1	2383364
able	O	-1	2383364
and	O	-1	2383364
e@@	O	-1	2383364
a@@	O	-1	2383364
si@@	O	-1	2383364
er	O	-1	2383364
to	O	-1	2383364
use.	O	-1	2383364

D@@	O	-1	2400986
o@@	O	-1	2400986
se@@	O	-1	2400986
-@@	O	-1	2400986
dependent	O	-1	2400986
neuro@@	B-Disease	D020258	2400986
toxicity	I-Disease	-1	2400986
of	O	-1	2400986
high-dose	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
in	O	-1	2400986
child@@	O	-1	2400986
ren@@	O	-1	2400986
:	O	-1	2400986
a	O	-1	2400986
clinical	O	-1	2400986
and	O	-1	2400986
pharmac@@	O	-1	2400986
ological	O	-1	2400986
study.	O	-1	2400986
B@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
is	O	-1	2400986
known	O	-1	2400986
to	O	-1	2400986
be	O	-1	2400986
neuro@@	B-Disease	D020258	2400986
toxic	I-Disease	-1	2400986
in	O	-1	2400986
animals	O	-1	2400986
and	O	-1	2400986
hum@@	O	-1	2400986
an@@	O	-1	2400986
s,	O	-1	2400986
but	O	-1	2400986
its	O	-1	2400986
acute	O	-1	2400986
neuro@@	B-Disease	D020258	2400986
toxicity	I-Disease	-1	2400986
remain@@	O	-1	2400986
s	O	-1	2400986
po@@	O	-1	2400986
or@@	O	-1	2400986
ly	O	-1	2400986
character@@	O	-1	2400986
ized	O	-1	2400986
in	O	-1	2400986
child@@	O	-1	2400986
ren@@	O	-1	2400986
.	O	-1	2400986
We	O	-1	2400986
report	O	-1	2400986
h@@	O	-1	2400986
ere	O	-1	2400986
a	O	-1	2400986
ret@@	O	-1	2400986
ro@@	O	-1	2400986
sp@@	O	-1	2400986
ective	O	-1	2400986
study	O	-1	2400986
of	O	-1	2400986
12@@	O	-1	2400986
3	O	-1	2400986
children	O	-1	2400986
(@@	O	-1	2400986
median	O	-1	2400986
age,	O	-1	2400986
6.@@	O	-1	2400986
5	O	-1	2400986
year@@	O	-1	2400986
s)	O	-1	2400986
receiving	O	-1	2400986
high-dose	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
in	O	-1	2400986
combined	O	-1	2400986
chemotherapy	O	-1	2400986
before	O	-1	2400986
b@@	O	-1	2400986
one	O	-1	2400986
m@@	O	-1	2400986
ar@@	O	-1	2400986
ro@@	O	-1	2400986
w	O	-1	2400986
transplant@@	O	-1	2400986
ation	O	-1	2400986
for	O	-1	2400986
mal@@	O	-1	2400986
i@@	O	-1	2400986
gn@@	O	-1	2400986
ant	O	-1	2400986
sol@@	O	-1	2400986
id	O	-1	2400986
tu@@	B-Disease	D009369	2400986
mor@@	I-Disease	-1	2400986
s	I-Disease	-1	2400986
,	O	-1	2400986
brain	B-Disease	D001932	2400986
tu@@	I-Disease	-1	2400986
mor@@	I-Disease	-1	2400986
s	I-Disease	-1	2400986
ex@@	O	-1	2400986
cl@@	O	-1	2400986
u@@	O	-1	2400986
de@@	O	-1	2400986
d.	O	-1	2400986
B@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
was	O	-1	2400986
given	O	-1	2400986
p.@@	O	-1	2400986
o@@	O	-1	2400986
.,	O	-1	2400986
every	O	-1	2400986
6	O	-1	2400986
hours	O	-1	2400986
for	O	-1	2400986
16	O	-1	2400986
doses	O	-1	2400986
over	O	-1	2400986
4	O	-1	2400986
days.	O	-1	2400986
Two	O	-1	2400986
total	O	-1	2400986
doses	O	-1	2400986
were	O	-1	2400986
con@@	O	-1	2400986
sec@@	O	-1	2400986
u@@	O	-1	2400986
ti@@	O	-1	2400986
vely	O	-1	2400986
use@@	O	-1	2400986
d@@	O	-1	2400986
:	O	-1	2400986
16	O	-1	2400986
mg/kg@@	O	-1	2400986
,	O	-1	2400986
then	O	-1	2400986
6@@	O	-1	2400986
00	O	-1	2400986
mg/m@@	O	-1	2400986
2@@	O	-1	2400986
.	O	-1	2400986
The	O	-1	2400986
dose	O	-1	2400986
calc@@	O	-1	2400986
ulation	O	-1	2400986
on	O	-1	2400986
the	O	-1	2400986
b@@	O	-1	2400986
asis	O	-1	2400986
of	O	-1	2400986
body	O	-1	2400986
sur@@	O	-1	2400986
fac@@	O	-1	2400986
e	O	-1	2400986
a@@	O	-1	2400986
re@@	O	-1	2400986
a	O	-1	2400986
results	O	-1	2400986
in	O	-1	2400986
higher	O	-1	2400986
doses	O	-1	2400986
in	O	-1	2400986
youn@@	O	-1	2400986
g	O	-1	2400986
children	O	-1	2400986
than	O	-1	2400986
in	O	-1	2400986
ol@@	O	-1	2400986
der	O	-1	2400986
patients	O	-1	2400986
(1@@	O	-1	2400986
6	O	-1	2400986
to	O	-1	2400986
2@@	O	-1	2400986
8	O	-1	2400986
mg/kg@@	O	-1	2400986
).	O	-1	2400986
N@@	O	-1	2400986
ine@@	O	-1	2400986
ty-@@	O	-1	2400986
six	O	-1	2400986
patients	O	-1	2400986
were	O	-1	2400986
not	O	-1	2400986
given	O	-1	2400986
anti@@	O	-1	2400986
convul@@	O	-1	2400986
sive	O	-1	2400986
pro@@	O	-1	2400986
phyl@@	O	-1	2400986
ax@@	O	-1	2400986
is@@	O	-1	2400986
;	O	-1	2400986
7	O	-1	2400986
(@@	O	-1	2400986
7.@@	O	-1	2400986
5@@	O	-1	2400986
%)	O	-1	2400986
developed	O	-1	2400986
seizures	B-Disease	D012640	2400986
during	O	-1	2400986
the	O	-1	2400986
4	O	-1	2400986
days	O	-1	2400986
of	O	-1	2400986
the	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
course	O	-1	2400986
or	O	-1	2400986
within	O	-1	2400986
24	O	-1	2400986
h	O	-1	2400986
after	O	-1	2400986
the	O	-1	2400986
las@@	O	-1	2400986
t	O	-1	2400986
dos@@	O	-1	2400986
ing.	O	-1	2400986
Whe@@	O	-1	2400986
n	O	-1	2400986
the	O	-1	2400986
total	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
dose	O	-1	2400986
was	O	-1	2400986
tak@@	O	-1	2400986
en	O	-1	2400986
into	O	-1	2400986
ac@@	O	-1	2400986
coun@@	O	-1	2400986
t,	O	-1	2400986
there	O	-1	2400986
was	O	-1	2400986
a	O	-1	2400986
significant	O	-1	2400986
difference	O	-1	2400986
in	O	-1	2400986
ter@@	O	-1	2400986
ms	O	-1	2400986
of	O	-1	2400986
neuro@@	B-Disease	D020258	2400986
toxicity	I-Disease	-1	2400986
incidence	O	-1	2400986
among	O	-1	2400986
patients	O	-1	2400986
under	O	-1	2400986
16	O	-1	2400986
mg/kg	O	-1	2400986
(@@	O	-1	2400986
1	O	-1	2400986
of	O	-1	2400986
5@@	O	-1	2400986
7@@	O	-1	2400986
,	O	-1	2400986
1.@@	O	-1	2400986
7@@	O	-1	2400986
%)	O	-1	2400986
and	O	-1	2400986
patients	O	-1	2400986
under	O	-1	2400986
6@@	O	-1	2400986
00	O	-1	2400986
mg/m@@	O	-1	2400986
2	O	-1	2400986
(@@	O	-1	2400986
6	O	-1	2400986
of	O	-1	2400986
3@@	O	-1	2400986
9@@	O	-1	2400986
,	O	-1	2400986
1@@	O	-1	2400986
5.@@	O	-1	2400986
4@@	O	-1	2400986
%)	O	-1	2400986
(P	O	-1	2400986
less	O	-1	2400986
than	O	-1	2400986
0.0@@	O	-1	2400986
2@@	O	-1	2400986
).	O	-1	2400986
Tw@@	O	-1	2400986
ent@@	O	-1	2400986
y-@@	O	-1	2400986
seven	O	-1	2400986
patients	O	-1	2400986
were	O	-1	2400986
given	O	-1	2400986
a	O	-1	2400986
6@@	O	-1	2400986
0@@	O	-1	2400986
0-@@	O	-1	2400986
mg/m@@	O	-1	2400986
2	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
total	O	-1	2400986
dose	O	-1	2400986
with	O	-1	2400986
continu@@	O	-1	2400986
ous	O	-1	2400986
i.v@@	O	-1	2400986
.	O	-1	2400986
infusion	O	-1	2400986
of	O	-1	2400986
clon@@	B-Chemical	D002998	2400986
az@@	I-Chemical	-1	2400986
epam	I-Chemical	-1	2400986
;	O	-1	2400986
n@@	O	-1	2400986
one	O	-1	2400986
had	O	-1	2400986
any	O	-1	2400986
neurolog@@	B-Disease	D009461	2400986
ical	I-Disease	-1	2400986
symptoms	I-Disease	-1	2400986
.	O	-1	2400986
B@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
levels	O	-1	2400986
were	O	-1	2400986
measured	O	-1	2400986
by	O	-1	2400986
a	O	-1	2400986
g@@	O	-1	2400986
as	O	-1	2400986
ch@@	O	-1	2400986
rom@@	O	-1	2400986
at@@	O	-1	2400986
ograph@@	O	-1	2400986
ic@@	O	-1	2400986
-@@	O	-1	2400986
mas@@	O	-1	2400986
s	O	-1	2400986
sp@@	O	-1	2400986
ect@@	O	-1	2400986
ro@@	O	-1	2400986
met@@	O	-1	2400986
r@@	O	-1	2400986
y	O	-1	2400986
ass@@	O	-1	2400986
ay	O	-1	2400986
in	O	-1	2400986
the	O	-1	2400986
plasma	O	-1	2400986
and	O	-1	2400986
ce@@	O	-1	2400986
reb@@	O	-1	2400986
ro@@	O	-1	2400986
spinal	O	-1	2400986
flu@@	O	-1	2400986
id	O	-1	2400986
of	O	-1	2400986
9	O	-1	2400986
children	O	-1	2400986
without	O	-1	2400986
central	B-Disease	D002493	2400986
ner@@	I-Disease	-1	2400986
v@@	I-Disease	-1	2400986
ous	I-Disease	-1	2400986
system	I-Disease	-1	2400986
disease	I-Disease	-1	2400986
under	O	-1	2400986
6@@	O	-1	2400986
00	O	-1	2400986
mg/m@@	O	-1	2400986
2	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
with	O	-1	2400986
clon@@	B-Chemical	D002998	2400986
az@@	I-Chemical	-1	2400986
epam	I-Chemical	-1	2400986
:	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
ce@@	O	-1	2400986
reb@@	O	-1	2400986
ro@@	O	-1	2400986
spinal	O	-1	2400986
flu@@	O	-1	2400986
id@@	O	-1	2400986
:@@	O	-1	2400986
plasma	O	-1	2400986
rati@@	O	-1	2400986
o	O	-1	2400986
was	O	-1	2400986
1.@@	O	-1	2400986
3@@	O	-1	2400986
9@@	O	-1	2400986
.	O	-1	2400986
This	O	-1	2400986
was	O	-1	2400986
significantly	O	-1	2400986
different	O	-1	2400986
(P	O	-1	2400986
less	O	-1	2400986
than	O	-1	2400986
0.0@@	O	-1	2400986
2)	O	-1	2400986
from	O	-1	2400986
the	O	-1	2400986
ce@@	O	-1	2400986
reb@@	O	-1	2400986
ro@@	O	-1	2400986
spinal	O	-1	2400986
flu@@	O	-1	2400986
id@@	O	-1	2400986
:@@	O	-1	2400986
plasma	O	-1	2400986
rati@@	O	-1	2400986
o	O	-1	2400986
previously	O	-1	2400986
def@@	O	-1	2400986
in@@	O	-1	2400986
ed	O	-1	2400986
in	O	-1	2400986
children	O	-1	2400986
receiving	O	-1	2400986
a	O	-1	2400986
1@@	O	-1	2400986
6-@@	O	-1	2400986
mg/kg	O	-1	2400986
total	O	-1	2400986
dose	O	-1	2400986
of	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
.	O	-1	2400986
This	O	-1	2400986
study	O	-1	2400986
show@@	O	-1	2400986
s	O	-1	2400986
that	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
neuro@@	B-Disease	D020258	2400986
toxicity	I-Disease	-1	2400986
is	O	-1	2400986
dose-@@	O	-1	2400986
dependent	O	-1	2400986
in	O	-1	2400986
children	O	-1	2400986
and	O	-1	2400986
eff@@	O	-1	2400986
ici@@	O	-1	2400986
ently	O	-1	2400986
prevent@@	O	-1	2400986
ed	O	-1	2400986
by	O	-1	2400986
clon@@	B-Chemical	D002998	2400986
az@@	I-Chemical	-1	2400986
epam	I-Chemical	-1	2400986
.	O	-1	2400986
A	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
dose	O	-1	2400986
calc@@	O	-1	2400986
ul@@	O	-1	2400986
ated	O	-1	2400986
on	O	-1	2400986
the	O	-1	2400986
b@@	O	-1	2400986
asis	O	-1	2400986
of	O	-1	2400986
body	O	-1	2400986
sur@@	O	-1	2400986
fac@@	O	-1	2400986
e	O	-1	2400986
a@@	O	-1	2400986
re@@	O	-1	2400986
a,	O	-1	2400986
result@@	O	-1	2400986
ing	O	-1	2400986
in	O	-1	2400986
higher	O	-1	2400986
doses	O	-1	2400986
in	O	-1	2400986
youn@@	O	-1	2400986
g	O	-1	2400986
child@@	O	-1	2400986
ren@@	O	-1	2400986
,	O	-1	2400986
was	O	-1	2400986
followed	O	-1	2400986
by	O	-1	2400986
increased	O	-1	2400986
neuro@@	B-Disease	D020258	2400986
toxicity	I-Disease	-1	2400986
,	O	-1	2400986
clo@@	O	-1	2400986
se	O	-1	2400986
to	O	-1	2400986
neuro@@	B-Disease	D020258	2400986
toxicity	I-Disease	-1	2400986
incidence	O	-1	2400986
observed	O	-1	2400986
in	O	-1	2400986
ad@@	O	-1	2400986
ult@@	O	-1	2400986
s.	O	-1	2400986
S@@	O	-1	2400986
inc@@	O	-1	2400986
e	O	-1	2400986
plasma	O	-1	2400986
pharmac@@	O	-1	2400986
o@@	O	-1	2400986
kine@@	O	-1	2400986
tic	O	-1	2400986
studies	O	-1	2400986
showed	O	-1	2400986
a	O	-1	2400986
f@@	O	-1	2400986
ast@@	O	-1	2400986
er	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
clear@@	O	-1	2400986
ance	O	-1	2400986
in	O	-1	2400986
children	O	-1	2400986
than	O	-1	2400986
in	O	-1	2400986
ad@@	O	-1	2400986
ult@@	O	-1	2400986
s,	O	-1	2400986
this	O	-1	2400986
new	O	-1	2400986
dose	O	-1	2400986
may	O	-1	2400986
appro@@	O	-1	2400986
xim@@	O	-1	2400986
ate	O	-1	2400986
more	O	-1	2400986
clo@@	O	-1	2400986
se@@	O	-1	2400986
ly	O	-1	2400986
the	O	-1	2400986
ad@@	O	-1	2400986
ult	O	-1	2400986
systemic	O	-1	2400986
exposure	O	-1	2400986
obtained	O	-1	2400986
after	O	-1	2400986
the	O	-1	2400986
us@@	O	-1	2400986
ual	O	-1	2400986
1@@	O	-1	2400986
6-@@	O	-1	2400986
mg/kg	O	-1	2400986
total	O	-1	2400986
dose@@	O	-1	2400986
,	O	-1	2400986
with	O	-1	2400986
potential	O	-1	2400986
inf@@	O	-1	2400986
e@@	O	-1	2400986
ren@@	O	-1	2400986
ces	O	-1	2400986
in	O	-1	2400986
ter@@	O	-1	2400986
ms	O	-1	2400986
of	O	-1	2400986
anti@@	O	-1	2400986
cancer	O	-1	2400986
or	O	-1	2400986
my@@	O	-1	2400986
e@@	O	-1	2400986
lo@@	O	-1	2400986
abl@@	O	-1	2400986
ative	O	-1	2400986
effects.	O	-1	2400986
The	O	-1	2400986
b@@	B-Chemical	D002066	2400986
us@@	I-Chemical	-1	2400986
ul@@	I-Chemical	-1	2400986
f@@	I-Chemical	-1	2400986
an	I-Chemical	-1	2400986
dose	O	-1	2400986
in	O	-1	2400986
children	O	-1	2400986
and	O	-1	2400986
inf@@	O	-1	2400986
ants	O	-1	2400986
under@@	O	-1	2400986
go@@	O	-1	2400986
ing	O	-1	2400986
b@@	O	-1	2400986
one	O	-1	2400986
m@@	O	-1	2400986
ar@@	O	-1	2400986
ro@@	O	-1	2400986
w	O	-1	2400986
transplant@@	O	-1	2400986
ation	O	-1	2400986
should	O	-1	2400986
be	O	-1	2400986
re@@	O	-1	2400986
considered	O	-1	2400986
on	O	-1	2400986
the	O	-1	2400986
b@@	O	-1	2400986
asis	O	-1	2400986
of	O	-1	2400986
pharmac@@	O	-1	2400986
o@@	O	-1	2400986
kine@@	O	-1	2400986
tic	O	-1	2400986
studi@@	O	-1	2400986
es.	O	-1	2400986

H@@	B-Chemical	D006632	2429800
ist@@	I-Chemical	-1	2429800
amine	I-Chemical	-1	2429800
antagonist@@	O	-1	2429800
s	O	-1	2429800
and	O	-1	2429800
d-@@	B-Chemical	D014403	2429800
tub@@	I-Chemical	-1	2429800
oc@@	I-Chemical	-1	2429800
ur@@	I-Chemical	-1	2429800
ar@@	I-Chemical	-1	2429800
ine	I-Chemical	-1	2429800
-induced	O	-1	2429800
hypotension	B-Disease	D007022	2429800
in	O	-1	2429800
cardiac	O	-1	2429800
surg@@	O	-1	2429800
ical	O	-1	2429800
patients.	O	-1	2429800
H@@	O	-1	2429800
em@@	O	-1	2429800
o@@	O	-1	2429800
dynam@@	O	-1	2429800
ic	O	-1	2429800
effects	O	-1	2429800
and	O	-1	2429800
hist@@	B-Chemical	D006632	2429800
amine	I-Chemical	-1	2429800
release	O	-1	2429800
by	O	-1	2429800
b@@	O	-1	2429800
ol@@	O	-1	2429800
us	O	-1	2429800
injection	O	-1	2429800
of	O	-1	2429800
0.@@	O	-1	2429800
3@@	O	-1	2429800
5	O	-1	2429800
mg/kg	O	-1	2429800
of	O	-1	2429800
d-@@	B-Chemical	D014403	2429800
tub@@	I-Chemical	-1	2429800
oc@@	I-Chemical	-1	2429800
ur@@	I-Chemical	-1	2429800
ar@@	I-Chemical	-1	2429800
ine	I-Chemical	-1	2429800
were	O	-1	2429800
studied	O	-1	2429800
in	O	-1	2429800
24	O	-1	2429800
patients.	O	-1	2429800
H@@	O	-1	2429800
1@@	O	-1	2429800
-	O	-1	2429800
and	O	-1	2429800
H@@	O	-1	2429800
2@@	O	-1	2429800
-	O	-1	2429800
hist@@	B-Chemical	D006632	2429800
amine	I-Chemical	-1	2429800
antagonist@@	O	-1	2429800
s	O	-1	2429800
or	O	-1	2429800
placebo	O	-1	2429800
were	O	-1	2429800
given	O	-1	2429800
before	O	-1	2429800
dos@@	O	-1	2429800
ing	O	-1	2429800
with	O	-1	2429800
d-@@	B-Chemical	D014403	2429800
tub@@	I-Chemical	-1	2429800
oc@@	I-Chemical	-1	2429800
ur@@	I-Chemical	-1	2429800
ar@@	I-Chemical	-1	2429800
ine	I-Chemical	-1	2429800
in	O	-1	2429800
a	O	-1	2429800
randomized	O	-1	2429800
double-bl@@	O	-1	2429800
ind	O	-1	2429800
f@@	O	-1	2429800
as@@	O	-1	2429800
hi@@	O	-1	2429800
on	O	-1	2429800
to	O	-1	2429800
four	O	-1	2429800
group@@	O	-1	2429800
s:	O	-1	2429800
group	O	-1	2429800
1-@@	O	-1	2429800
-@@	O	-1	2429800
placebo@@	O	-1	2429800
;	O	-1	2429800
group	O	-1	2429800
2-@@	O	-1	2429800
-	O	-1	2429800
cimetid@@	B-Chemical	D002927	2429800
ine	I-Chemical	-1	2429800
,	O	-1	2429800
4	O	-1	2429800
mg/kg@@	O	-1	2429800
,	O	-1	2429800
plus	O	-1	2429800
placebo@@	O	-1	2429800
;	O	-1	2429800
group	O	-1	2429800
3-@@	O	-1	2429800
-	O	-1	2429800
chlor@@	B-Chemical	D002744	2429800
phen@@	I-Chemical	-1	2429800
ir@@	I-Chemical	-1	2429800
amine	I-Chemical	-1	2429800
,	O	-1	2429800
0.@@	O	-1	2429800
1	O	-1	2429800
mg/kg@@	O	-1	2429800
,	O	-1	2429800
plus	O	-1	2429800
placebo@@	O	-1	2429800
;	O	-1	2429800
and	O	-1	2429800
group	O	-1	2429800
4-@@	O	-1	2429800
-	O	-1	2429800
cimetid@@	B-Chemical	D002927	2429800
ine	I-Chemical	-1	2429800
plus	O	-1	2429800
chlor@@	B-Chemical	D002744	2429800
phen@@	I-Chemical	-1	2429800
ir@@	I-Chemical	-1	2429800
amine	I-Chemical	-1	2429800
.	O	-1	2429800
H@@	B-Chemical	D006632	2429800
ist@@	I-Chemical	-1	2429800
amine	I-Chemical	-1	2429800
release	O	-1	2429800
occurred	O	-1	2429800
in	O	-1	2429800
most	O	-1	2429800
patients,	O	-1	2429800
the	O	-1	2429800
high@@	O	-1	2429800
est	O	-1	2429800
level	O	-1	2429800
2	O	-1	2429800
minutes	O	-1	2429800
after	O	-1	2429800
d-@@	B-Chemical	D014403	2429800
tub@@	I-Chemical	-1	2429800
oc@@	I-Chemical	-1	2429800
ur@@	I-Chemical	-1	2429800
ar@@	I-Chemical	-1	2429800
ine	I-Chemical	-1	2429800
dos@@	O	-1	2429800
ing.	O	-1	2429800
Group	O	-1	2429800
1	O	-1	2429800
had	O	-1	2429800
a	O	-1	2429800
moder@@	O	-1	2429800
ate	O	-1	2429800
negative	O	-1	2429800
correl@@	O	-1	2429800
ation	O	-1	2429800
between	O	-1	2429800
plasma	O	-1	2429800
hist@@	B-Chemical	D006632	2429800
amine	I-Chemical	-1	2429800
change	O	-1	2429800
and	O	-1	2429800
systemic	O	-1	2429800
vascular	O	-1	2429800
resist@@	O	-1	2429800
ance	O	-1	2429800
(@@	O	-1	2429800
r	O	-1	2429800
=	O	-1	2429800
0.@@	O	-1	2429800
5@@	O	-1	2429800
8@@	O	-1	2429800
;	O	-1	2429800
P	O	-1	2429800
less	O	-1	2429800
than	O	-1	2429800
0.05@@	O	-1	2429800
)	O	-1	2429800
not	O	-1	2429800
present	O	-1	2429800
in	O	-1	2429800
group	O	-1	2429800
4@@	O	-1	2429800
.	O	-1	2429800
P@@	O	-1	2429800
ri@@	O	-1	2429800
or	O	-1	2429800
dos@@	O	-1	2429800
ing	O	-1	2429800
with	O	-1	2429800
antagonist@@	O	-1	2429800
s	O	-1	2429800
par@@	O	-1	2429800
ti@@	O	-1	2429800
ally	O	-1	2429800
prevent@@	O	-1	2429800
ed	O	-1	2429800
the	O	-1	2429800
f@@	O	-1	2429800
all	O	-1	2429800
in	O	-1	2429800
systemic	O	-1	2429800
vascular	O	-1	2429800
resist@@	O	-1	2429800
ance@@	O	-1	2429800
.	O	-1	2429800
These	O	-1	2429800
data	O	-1	2429800
demon@@	O	-1	2429800
st@@	O	-1	2429800
rate	O	-1	2429800
that	O	-1	2429800
the	O	-1	2429800
hemo@@	O	-1	2429800
dynam@@	O	-1	2429800
ic	O	-1	2429800
changes	O	-1	2429800
associated	O	-1	2429800
with	O	-1	2429800
d-@@	B-Chemical	D014403	2429800
tub@@	I-Chemical	-1	2429800
oc@@	I-Chemical	-1	2429800
ur@@	I-Chemical	-1	2429800
ar@@	I-Chemical	-1	2429800
ine	I-Chemical	-1	2429800
dos@@	O	-1	2429800
ing	O	-1	2429800
are	O	-1	2429800
only	O	-1	2429800
par@@	O	-1	2429800
ti@@	O	-1	2429800
ally	O	-1	2429800
expl@@	O	-1	2429800
ained	O	-1	2429800
by	O	-1	2429800
hist@@	B-Chemical	D006632	2429800
amine	I-Chemical	-1	2429800
rele@@	O	-1	2429800
as@@	O	-1	2429800
e.	O	-1	2429800
Th@@	O	-1	2429800
us	O	-1	2429800
prior	O	-1	2429800
dos@@	O	-1	2429800
ing	O	-1	2429800
with	O	-1	2429800
H@@	O	-1	2429800
1@@	O	-1	2429800
-	O	-1	2429800
and	O	-1	2429800
H@@	O	-1	2429800
2-@@	O	-1	2429800
antagonist@@	O	-1	2429800
s	O	-1	2429800
pro@@	O	-1	2429800
vi@@	O	-1	2429800
des	O	-1	2429800
only	O	-1	2429800
partial	O	-1	2429800
prot@@	O	-1	2429800
ec@@	O	-1	2429800
tion.	O	-1	2429800

Con@@	O	-1	2453942
vul@@	O	-1	2453942
s@@	O	-1	2453942
ant	O	-1	2453942
effect	O	-1	2453942
of	O	-1	2453942
l@@	B-Chemical	D001556	2453942
ind@@	I-Chemical	-1	2453942
ane	I-Chemical	-1	2453942
and	O	-1	2453942
regi@@	O	-1	2453942
on@@	O	-1	2453942
al	O	-1	2453942
brain	O	-1	2453942
concentration	O	-1	2453942
of	O	-1	2453942
G@@	B-Chemical	D005680	2453942
A@@	I-Chemical	-1	2453942
B@@	I-Chemical	-1	2453942
A	I-Chemical	-1	2453942
and	O	-1	2453942
dopamine	B-Chemical	D004298	2453942
.	O	-1	2453942
L@@	B-Chemical	D001556	2453942
ind@@	I-Chemical	-1	2453942
ane	I-Chemical	-1	2453942
(	O	-1	2453942
gamma@@	B-Chemical	D001556	2453942
-@@	I-Chemical	-1	2453942
he@@	I-Chemical	-1	2453942
x@@	I-Chemical	-1	2453942
ac@@	I-Chemical	-1	2453942
h@@	I-Chemical	-1	2453942
loro@@	I-Chemical	-1	2453942
cyclo@@	I-Chemical	-1	2453942
he@@	I-Chemical	-1	2453942
x@@	I-Chemical	-1	2453942
ane	I-Chemical	-1	2453942
)	O	-1	2453942
is	O	-1	2453942
an	O	-1	2453942
org@@	O	-1	2453942
an@@	O	-1	2453942
och@@	O	-1	2453942
lor@@	O	-1	2453942
ine	O	-1	2453942
in@@	O	-1	2453942
sec@@	O	-1	2453942
tic@@	O	-1	2453942
ide	O	-1	2453942
with	O	-1	2453942
known	O	-1	2453942
neuro@@	B-Disease	D020258	2453942
toxic	I-Disease	-1	2453942
effects.	O	-1	2453942
I@@	O	-1	2453942
ts	O	-1	2453942
mechanism	O	-1	2453942
of	O	-1	2453942
action	O	-1	2453942
is	O	-1	2453942
not	O	-1	2453942
well	O	-1	2453942
under@@	O	-1	2453942
sto@@	O	-1	2453942
od	O	-1	2453942
although	O	-1	2453942
it	O	-1	2453942
has	O	-1	2453942
been	O	-1	2453942
pro@@	O	-1	2453942
pos@@	O	-1	2453942
ed	O	-1	2453942
that	O	-1	2453942
l@@	B-Chemical	D001556	2453942
ind@@	I-Chemical	-1	2453942
ane	I-Chemical	-1	2453942
act@@	O	-1	2453942
s	O	-1	2453942
as	O	-1	2453942
a	O	-1	2453942
non-@@	O	-1	2453942
comp@@	O	-1	2453942
e@@	O	-1	2453942
ti@@	O	-1	2453942
tive	O	-1	2453942
antagonist	O	-1	2453942
at	O	-1	2453942
the	O	-1	2453942
gamma@@	B-Chemical	D005680	2453942
-@@	I-Chemical	-1	2453942
amin@@	I-Chemical	-1	2453942
ob@@	I-Chemical	-1	2453942
ut@@	I-Chemical	-1	2453942
y@@	I-Chemical	-1	2453942
ric	I-Chemical	-1	2453942
acid	I-Chemical	-1	2453942
(	O	-1	2453942
G@@	B-Chemical	D005680	2453942
A@@	I-Chemical	-1	2453942
B@@	I-Chemical	-1	2453942
A	I-Chemical	-1	2453942
)-@@	O	-1	2453942
A	O	-1	2453942
receptor@@	O	-1	2453942
.	O	-1	2453942
We	O	-1	2453942
studied	O	-1	2453942
the	O	-1	2453942
effect	O	-1	2453942
of	O	-1	2453942
l@@	B-Chemical	D001556	2453942
ind@@	I-Chemical	-1	2453942
ane	I-Chemical	-1	2453942
(1@@	O	-1	2453942
50	O	-1	2453942
mg/kg)	O	-1	2453942
on	O	-1	2453942
the	O	-1	2453942
G@@	O	-1	2453942
A@@	O	-1	2453942
BA@@	O	-1	2453942
ergic	O	-1	2453942
and	O	-1	2453942
dop@@	O	-1	2453942
aminergic	O	-1	2453942
system@@	O	-1	2453942
s	O	-1	2453942
by	O	-1	2453942
meas@@	O	-1	2453942
uring	O	-1	2453942
the	O	-1	2453942
concentration	O	-1	2453942
of	O	-1	2453942
G@@	B-Chemical	D005680	2453942
A@@	I-Chemical	-1	2453942
B@@	I-Chemical	-1	2453942
A	I-Chemical	-1	2453942
,	O	-1	2453942
dopamine	B-Chemical	D004298	2453942
and	O	-1	2453942
its	O	-1	2453942
metabol@@	O	-1	2453942
it@@	O	-1	2453942
es	O	-1	2453942
in	O	-1	2453942
7	O	-1	2453942
brain	O	-1	2453942
a@@	O	-1	2453942
reas	O	-1	2453942
at	O	-1	2453942
the	O	-1	2453942
onset	O	-1	2453942
of	O	-1	2453942
seizures	B-Disease	D012640	2453942
.	O	-1	2453942
All	O	-1	2453942
animals	O	-1	2453942
su@@	O	-1	2453942
ffe@@	O	-1	2453942
red	O	-1	2453942
t@@	O	-1	2453942
onic	O	-1	2453942
convul@@	B-Disease	D012640	2453942
sions	I-Disease	-1	2453942
at	O	-1	2453942
1@@	O	-1	2453942
8.@@	O	-1	2453942
3	O	-1	2453942
+/-	O	-1	2453942
1.@@	O	-1	2453942
4	O	-1	2453942
min	O	-1	2453942
after	O	-1	2453942
l@@	B-Chemical	D001556	2453942
ind@@	I-Chemical	-1	2453942
ane	I-Chemical	-1	2453942
administr@@	O	-1	2453942
ation.	O	-1	2453942
The	O	-1	2453942
concentration	O	-1	2453942
of	O	-1	2453942
G@@	B-Chemical	D005680	2453942
A@@	I-Chemical	-1	2453942
B@@	I-Chemical	-1	2453942
A	I-Chemical	-1	2453942
was	O	-1	2453942
only	O	-1	2453942
s@@	O	-1	2453942
li@@	O	-1	2453942
gh@@	O	-1	2453942
tly	O	-1	2453942
but	O	-1	2453942
significantly	O	-1	2453942
decreased	O	-1	2453942
in	O	-1	2453942
the	O	-1	2453942
coll@@	O	-1	2453942
ic@@	O	-1	2453942
ul@@	O	-1	2453942
i	O	-1	2453942
without	O	-1	2453942
mo@@	O	-1	2453942
di@@	O	-1	2453942
fic@@	O	-1	2453942
ations	O	-1	2453942
in	O	-1	2453942
the	O	-1	2453942
other	O	-1	2453942
a@@	O	-1	2453942
reas@@	O	-1	2453942
.	O	-1	2453942
The	O	-1	2453942
concentration	O	-1	2453942
of	O	-1	2453942
dopamine	B-Chemical	D004298	2453942
was	O	-1	2453942
increased	O	-1	2453942
in	O	-1	2453942
the	O	-1	2453942
m@@	O	-1	2453942
es@@	O	-1	2453942
encephal@@	O	-1	2453942
on	O	-1	2453942
and	O	-1	2453942
that	O	-1	2453942
of	O	-1	2453942
its	O	-1	2453942
metabol@@	O	-1	2453942
ite	O	-1	2453942
DO@@	B-Chemical	D015102	2453942
PA@@	I-Chemical	-1	2453942
C	I-Chemical	-1	2453942
was	O	-1	2453942
also	O	-1	2453942
increased	O	-1	2453942
in	O	-1	2453942
the	O	-1	2453942
m@@	O	-1	2453942
es@@	O	-1	2453942
encephal@@	O	-1	2453942
on	O	-1	2453942
and	O	-1	2453942
the	O	-1	2453942
striat@@	O	-1	2453942
um@@	O	-1	2453942
.	O	-1	2453942

U@@	O	-1	2484903
n@@	O	-1	2484903
us@@	O	-1	2484903
ual	O	-1	2484903
complications	O	-1	2484903
of	O	-1	2484903
anti@@	O	-1	2484903
th@@	O	-1	2484903
yro@@	O	-1	2484903
id	O	-1	2484903
drug	O	-1	2484903
therap@@	O	-1	2484903
y@@	O	-1	2484903
:	O	-1	2484903
four	O	-1	2484903
case	O	-1	2484903
reports	O	-1	2484903
and	O	-1	2484903
revie@@	O	-1	2484903
w	O	-1	2484903
of	O	-1	2484903
literat@@	O	-1	2484903
ure.	O	-1	2484903
Two	O	-1	2484903
cases	O	-1	2484903
of	O	-1	2484903
prop@@	B-Chemical	D011441	2484903
yl@@	I-Chemical	-1	2484903
th@@	I-Chemical	-1	2484903
io@@	I-Chemical	-1	2484903
urac@@	I-Chemical	-1	2484903
il	I-Chemical	-1	2484903
-@@	O	-1	2484903
associated	O	-1	2484903
acute	O	-1	2484903
hepatitis	B-Disease	D056486	2484903
,	O	-1	2484903
one	O	-1	2484903
case	O	-1	2484903
of	O	-1	2484903
f@@	O	-1	2484903
atal	O	-1	2484903
meth@@	B-Chemical	D008713	2484903
im@@	I-Chemical	-1	2484903
azole	I-Chemical	-1	2484903
-@@	O	-1	2484903
associated	O	-1	2484903
hepat@@	B-Disease	D047508	2484903
oc@@	I-Disease	-1	2484903
ell@@	I-Disease	-1	2484903
ular	I-Disease	-1	2484903
necro@@	I-Disease	-1	2484903
sis	I-Disease	-1	2484903
and	O	-1	2484903
one	O	-1	2484903
case	O	-1	2484903
of	O	-1	2484903
prop@@	B-Chemical	D011441	2484903
yl@@	I-Chemical	-1	2484903
th@@	I-Chemical	-1	2484903
io@@	I-Chemical	-1	2484903
urac@@	I-Chemical	-1	2484903
il	I-Chemical	-1	2484903
-@@	O	-1	2484903
associated	O	-1	2484903
lu@@	B-Disease	D008180	2484903
p@@	I-Disease	-1	2484903
us@@	I-Disease	-1	2484903
-@@	I-Disease	-1	2484903
like	I-Disease	-1	2484903
syndrome	I-Disease	-1	2484903
are	O	-1	2484903
descri@@	O	-1	2484903
be@@	O	-1	2484903
d.	O	-1	2484903
The	O	-1	2484903
literat@@	O	-1	2484903
ure	O	-1	2484903
related	O	-1	2484903
to	O	-1	2484903
anti@@	O	-1	2484903
th@@	O	-1	2484903
yro@@	O	-1	2484903
id	O	-1	2484903
drug	O	-1	2484903
side	O	-1	2484903
effects	O	-1	2484903
and	O	-1	2484903
the	O	-1	2484903
mechanisms	O	-1	2484903
for	O	-1	2484903
their	O	-1	2484903
occur@@	O	-1	2484903
rence	O	-1	2484903
are	O	-1	2484903
revie@@	O	-1	2484903
w@@	O	-1	2484903
ed	O	-1	2484903
and	O	-1	2484903
the	O	-1	2484903
efficacy	O	-1	2484903
and	O	-1	2484903
complications	O	-1	2484903
of	O	-1	2484903
th@@	O	-1	2484903
yro@@	O	-1	2484903
id@@	O	-1	2484903
ect@@	O	-1	2484903
om@@	O	-1	2484903
y	O	-1	2484903
and	O	-1	2484903
radi@@	O	-1	2484903
o@@	O	-1	2484903
iod@@	O	-1	2484903
ine	O	-1	2484903
compared	O	-1	2484903
to	O	-1	2484903
those	O	-1	2484903
of	O	-1	2484903
anti@@	O	-1	2484903
th@@	O	-1	2484903
yro@@	O	-1	2484903
id	O	-1	2484903
drug@@	O	-1	2484903
s.	O	-1	2484903
It	O	-1	2484903
is	O	-1	2484903
concl@@	O	-1	2484903
uded	O	-1	2484903
that	O	-1	2484903
in	O	-1	2484903
most	O	-1	2484903
cir@@	O	-1	2484903
cum@@	O	-1	2484903
st@@	O	-1	2484903
anc@@	O	-1	2484903
es	O	-1	2484903
13@@	O	-1	2484903
1@@	O	-1	2484903
I	O	-1	2484903
is	O	-1	2484903
the	O	-1	2484903
therapy	O	-1	2484903
of	O	-1	2484903
ch@@	O	-1	2484903
o@@	O	-1	2484903
ic@@	O	-1	2484903
e	O	-1	2484903
for	O	-1	2484903
hyper@@	B-Disease	D006980	2484903
th@@	I-Disease	-1	2484903
yro@@	I-Disease	-1	2484903
i@@	I-Disease	-1	2484903
dis@@	I-Disease	-1	2484903
m	I-Disease	-1	2484903
.	O	-1	2484903

An@@	O	-1	2553470
ti@@	O	-1	2553470
convul@@	O	-1	2553470
s@@	O	-1	2553470
ant	O	-1	2553470
ac@@	O	-1	2553470
tions	O	-1	2553470
of	O	-1	2553470
M@@	B-Chemical	D016291	2553470
K@@	I-Chemical	-1	2553470
-@@	I-Chemical	-1	2553470
80@@	I-Chemical	-1	2553470
1	I-Chemical	-1	2553470
on	O	-1	2553470
the	O	-1	2553470
lithium	B-Chemical	D008094	2553470
-	O	-1	2553470
pilocar@@	B-Chemical	D010862	2553470
pine	I-Chemical	-1	2553470
model	O	-1	2553470
of	O	-1	2553470
status	B-Disease	D013226	2553470
epilep@@	I-Disease	-1	2553470
tic@@	I-Disease	-1	2553470
us	I-Disease	-1	2553470
in	O	-1	2553470
rats.	O	-1	2553470
M@@	B-Chemical	D016291	2553470
K@@	I-Chemical	-1	2553470
-@@	I-Chemical	-1	2553470
80@@	I-Chemical	-1	2553470
1	I-Chemical	-1	2553470
,	O	-1	2553470
a	O	-1	2553470
non@@	O	-1	2553470
comp@@	O	-1	2553470
e@@	O	-1	2553470
ti@@	O	-1	2553470
tive	O	-1	2553470
N@@	B-Chemical	D016202	2553470
-@@	I-Chemical	-1	2553470
methyl@@	I-Chemical	-1	2553470
-@@	I-Chemical	-1	2553470
D-@@	I-Chemical	-1	2553470
as@@	I-Chemical	-1	2553470
part@@	I-Chemical	-1	2553470
ate	I-Chemical	-1	2553470
(	O	-1	2553470
N@@	B-Chemical	D016202	2553470
MD@@	I-Chemical	-1	2553470
A	I-Chemical	-1	2553470
)	O	-1	2553470
receptor	O	-1	2553470
antagonist@@	O	-1	2553470
,	O	-1	2553470
was	O	-1	2553470
tested	O	-1	2553470
for	O	-1	2553470
anti@@	O	-1	2553470
convul@@	O	-1	2553470
s@@	O	-1	2553470
ant	O	-1	2553470
effects	O	-1	2553470
in	O	-1	2553470
rats	O	-1	2553470
using	O	-1	2553470
two	O	-1	2553470
seizure	B-Disease	D012640	2553470
model@@	O	-1	2553470
s,	O	-1	2553470
co@@	O	-1	2553470
administration	O	-1	2553470
of	O	-1	2553470
lithium	B-Chemical	D008094	2553470
and	O	-1	2553470
pilocar@@	B-Chemical	D010862	2553470
pine	I-Chemical	-1	2553470
and	O	-1	2553470
administration	O	-1	2553470
of	O	-1	2553470
a	O	-1	2553470
high	O	-1	2553470
dose	O	-1	2553470
of	O	-1	2553470
pilocar@@	B-Chemical	D010862	2553470
pine	I-Chemical	-1	2553470
al@@	O	-1	2553470
one.	O	-1	2553470
Th@@	O	-1	2553470
ree	O	-1	2553470
major	O	-1	2553470
results	O	-1	2553470
are	O	-1	2553470
repor@@	O	-1	2553470
ted.	O	-1	2553470
F@@	O	-1	2553470
ir@@	O	-1	2553470
st@@	O	-1	2553470
,	O	-1	2553470
pretreatment	O	-1	2553470
with	O	-1	2553470
M@@	B-Chemical	D016291	2553470
K@@	I-Chemical	-1	2553470
-@@	I-Chemical	-1	2553470
80@@	I-Chemical	-1	2553470
1	I-Chemical	-1	2553470
produced	O	-1	2553470
an	O	-1	2553470
effective	O	-1	2553470
and	O	-1	2553470
dose-@@	O	-1	2553470
dependent	O	-1	2553470
anti@@	O	-1	2553470
convul@@	O	-1	2553470
s@@	O	-1	2553470
ant	O	-1	2553470
action	O	-1	2553470
with	O	-1	2553470
the	O	-1	2553470
lithium	B-Chemical	D008094	2553470
-	O	-1	2553470
pilocar@@	B-Chemical	D010862	2553470
pine	I-Chemical	-1	2553470
model	O	-1	2553470
but	O	-1	2553470
not	O	-1	2553470
with	O	-1	2553470
rats	O	-1	2553470
treated	O	-1	2553470
with	O	-1	2553470
pilocar@@	B-Chemical	D010862	2553470
pine	I-Chemical	-1	2553470
al@@	O	-1	2553470
one,	O	-1	2553470
suggesting	O	-1	2553470
that	O	-1	2553470
different	O	-1	2553470
bio@@	O	-1	2553470
chemical	O	-1	2553470
mechanisms	O	-1	2553470
control	O	-1	2553470
seizures	B-Disease	D012640	2553470
in	O	-1	2553470
these	O	-1	2553470
two	O	-1	2553470
model@@	O	-1	2553470
s.	O	-1	2553470
S@@	O	-1	2553470
ec@@	O	-1	2553470
on@@	O	-1	2553470
d,	O	-1	2553470
the	O	-1	2553470
anti@@	O	-1	2553470
convul@@	O	-1	2553470
s@@	O	-1	2553470
ant	O	-1	2553470
effect	O	-1	2553470
of	O	-1	2553470
M@@	B-Chemical	D016291	2553470
K@@	I-Chemical	-1	2553470
-@@	I-Chemical	-1	2553470
80@@	I-Chemical	-1	2553470
1	I-Chemical	-1	2553470
in	O	-1	2553470
the	O	-1	2553470
lithium	B-Chemical	D008094	2553470
-	O	-1	2553470
pilocar@@	B-Chemical	D010862	2553470
pine	I-Chemical	-1	2553470
model	O	-1	2553470
only	O	-1	2553470
occurred	O	-1	2553470
after	O	-1	2553470
initial	O	-1	2553470
perio@@	O	-1	2553470
ds	O	-1	2553470
of	O	-1	2553470
seizure	B-Disease	D012640	2553470
activ@@	O	-1	2553470
ity.	O	-1	2553470
This	O	-1	2553470
observ@@	O	-1	2553470
ation	O	-1	2553470
is	O	-1	2553470
suggested	O	-1	2553470
to	O	-1	2553470
be	O	-1	2553470
an	O	-1	2553470
in	O	-1	2553470
viv@@	O	-1	2553470
o	O	-1	2553470
demon@@	O	-1	2553470
st@@	O	-1	2553470
ration	O	-1	2553470
of	O	-1	2553470
the	O	-1	2553470
concl@@	O	-1	2553470
usion	O	-1	2553470
der@@	O	-1	2553470
i@@	O	-1	2553470
ved	O	-1	2553470
from	O	-1	2553470
in	O	-1	2553470
vit@@	O	-1	2553470
r@@	O	-1	2553470
o	O	-1	2553470
experim@@	O	-1	2553470
ents	O	-1	2553470
that	O	-1	2553470
M@@	B-Chemical	D016291	2553470
K@@	I-Chemical	-1	2553470
-@@	I-Chemical	-1	2553470
80@@	I-Chemical	-1	2553470
1	I-Chemical	-1	2553470
b@@	O	-1	2553470
ind@@	O	-1	2553470
ing	O	-1	2553470
requ@@	O	-1	2553470
i@@	O	-1	2553470
res	O	-1	2553470
agon@@	O	-1	2553470
ist@@	O	-1	2553470
-induced	O	-1	2553470
o@@	O	-1	2553470
pen@@	O	-1	2553470
ing	O	-1	2553470
of	O	-1	2553470
the	O	-1	2553470
channel	O	-1	2553470
sit@@	O	-1	2553470
es	O	-1	2553470
of	O	-1	2553470
the	O	-1	2553470
N@@	B-Chemical	D016202	2553470
MD@@	I-Chemical	-1	2553470
A	I-Chemical	-1	2553470
receptor@@	O	-1	2553470
.	O	-1	2553470
Th@@	O	-1	2553470
ir@@	O	-1	2553470
d,	O	-1	2553470
although	O	-1	2553470
it	O	-1	2553470
is	O	-1	2553470
rel@@	O	-1	2553470
atively	O	-1	2553470
e@@	O	-1	2553470
as@@	O	-1	2553470
y	O	-1	2553470
to	O	-1	2553470
bloc@@	O	-1	2553470
k	O	-1	2553470
seizures	B-Disease	D012640	2553470
induced	O	-1	2553470
by	O	-1	2553470
lithium	B-Chemical	D008094	2553470
and	O	-1	2553470
pilocar@@	B-Chemical	D010862	2553470
pine	I-Chemical	-1	2553470
by	O	-1	2553470
administration	O	-1	2553470
of	O	-1	2553470
anti@@	O	-1	2553470
convul@@	O	-1	2553470
s@@	O	-1	2553470
ants	O	-1	2553470
prior	O	-1	2553470
to	O	-1	2553470
pilocar@@	B-Chemical	D010862	2553470
pine	I-Chemical	-1	2553470
,	O	-1	2553470
it	O	-1	2553470
is	O	-1	2553470
more	O	-1	2553470
diff@@	O	-1	2553470
ic@@	O	-1	2553470
ult	O	-1	2553470
to	O	-1	2553470
ter@@	O	-1	2553470
min@@	O	-1	2553470
ate	O	-1	2553470
on@@	O	-1	2553470
go@@	O	-1	2553470
ing	O	-1	2553470
status	B-Disease	D013226	2553470
epilep@@	I-Disease	-1	2553470
tic@@	I-Disease	-1	2553470
us	I-Disease	-1	2553470
and	O	-1	2553470
bloc@@	O	-1	2553470
k	O	-1	2553470
the	O	-1	2553470
le@@	O	-1	2553470
thal@@	O	-1	2553470
ity	O	-1	2553470
of	O	-1	2553470
the	O	-1	2553470
seizures	B-Disease	D012640	2553470
.	O	-1	2553470
Ad@@	O	-1	2553470
minist@@	O	-1	2553470
ration	O	-1	2553470
of	O	-1	2553470
M@@	B-Chemical	D016291	2553470
K@@	I-Chemical	-1	2553470
-@@	I-Chemical	-1	2553470
80@@	I-Chemical	-1	2553470
1	I-Chemical	-1	2553470
30	O	-1	2553470
or	O	-1	2553470
60	O	-1	2553470
min	O	-1	2553470
after	O	-1	2553470
pilocar@@	B-Chemical	D010862	2553470
pine	I-Chemical	-1	2553470
,	O	-1	2553470
i.@@	O	-1	2553470
e@@	O	-1	2553470
.,	O	-1	2553470
during	O	-1	2553470
status	B-Disease	D013226	2553470
epilep@@	I-Disease	-1	2553470
tic@@	I-Disease	-1	2553470
us	I-Disease	-1	2553470
,	O	-1	2553470
gra@@	O	-1	2553470
du@@	O	-1	2553470
ally	O	-1	2553470
reduced	O	-1	2553470
elect@@	O	-1	2553470
r@@	O	-1	2553470
ical	O	-1	2553470
and	O	-1	2553470
behavioral	O	-1	2553470
seizure	B-Disease	D012640	2553470
activity	O	-1	2553470
and	O	-1	2553470
great@@	O	-1	2553470
ly	O	-1	2553470
enhanced	O	-1	2553470
the	O	-1	2553470
sur@@	O	-1	2553470
viv@@	O	-1	2553470
al	O	-1	2553470
rat@@	O	-1	2553470
e.	O	-1	2553470
These	O	-1	2553470
results	O	-1	2553470
suggest	O	-1	2553470
that	O	-1	2553470
activation	O	-1	2553470
of	O	-1	2553470
N@@	B-Chemical	D016202	2553470
MD@@	I-Chemical	-1	2553470
A	I-Chemical	-1	2553470
receptors	O	-1	2553470
pl@@	O	-1	2553470
ays	O	-1	2553470
an	O	-1	2553470
important	O	-1	2553470
role	O	-1	2553470
in	O	-1	2553470
status	B-Disease	D013226	2553470
epilep@@	I-Disease	-1	2553470
tic@@	I-Disease	-1	2553470
us	I-Disease	-1	2553470
and	O	-1	2553470
brain	B-Disease	D001930	2553470
damage	I-Disease	-1	2553470
in	O	-1	2553470
the	O	-1	2553470
lithium	B-Chemical	D008094	2553470
-	O	-1	2553470
pilocar@@	B-Chemical	D010862	2553470
pine	I-Chemical	-1	2553470
model@@	O	-1	2553470
.	O	-1	2553470
This	O	-1	2553470
was	O	-1	2553470
further	O	-1	2553470
suppor@@	O	-1	2553470
ted	O	-1	2553470
by	O	-1	2553470
results	O	-1	2553470
show@@	O	-1	2553470
ing	O	-1	2553470
that	O	-1	2553470
non@@	O	-1	2553470
convul@@	O	-1	2553470
sive	O	-1	2553470
doses	O	-1	2553470
of	O	-1	2553470
N@@	B-Chemical	D016202	2553470
MD@@	I-Chemical	-1	2553470
A	I-Chemical	-1	2553470
and	O	-1	2553470
pilocar@@	B-Chemical	D010862	2553470
pine	I-Chemical	-1	2553470
were	O	-1	2553470
syn@@	O	-1	2553470
erg@@	O	-1	2553470
is@@	O	-1	2553470
tic@@	O	-1	2553470
,	O	-1	2553470
result@@	O	-1	2553470
ing	O	-1	2553470
in	O	-1	2553470
status	B-Disease	D013226	2553470
epilep@@	I-Disease	-1	2553470
tic@@	I-Disease	-1	2553470
us	I-Disease	-1	2553470
and	O	-1	2553470
subsequ@@	O	-1	2553470
ent	O	-1	2553470
mor@@	O	-1	2553470
t@@	O	-1	2553470
al@@	O	-1	2553470
ity.	O	-1	2553470

N@@	B-Chemical	D009543	2614930
if@@	I-Chemical	-1	2614930
edi@@	I-Chemical	-1	2614930
pine	I-Chemical	-1	2614930
induced	O	-1	2614930
brady@@	B-Disease	D001919	2614930
cardia	I-Disease	-1	2614930
in	O	-1	2614930
a	O	-1	2614930
patient	O	-1	2614930
with	O	-1	2614930
a@@	B-Disease	D009422	2614930
ut@@	I-Disease	-1	2614930
on@@	I-Disease	-1	2614930
om@@	I-Disease	-1	2614930
ic	I-Disease	-1	2614930
neuropathy	I-Disease	-1	2614930
.	O	-1	2614930
An	O	-1	2614930
8@@	O	-1	2614930
0	O	-1	2614930
year	O	-1	2614930
old	O	-1	2614930
dia@@	B-Disease	D003920	2614930
be@@	I-Disease	-1	2614930
tic	I-Disease	-1	2614930
male	O	-1	2614930
with	O	-1	2614930
evidence	O	-1	2614930
of	O	-1	2614930
peripheral	B-Disease	D010523	2614930
and	I-Disease	-1	2614930
a@@	I-Disease	-1	2614930
ut@@	I-Disease	-1	2614930
on@@	I-Disease	-1	2614930
om@@	I-Disease	-1	2614930
ic	I-Disease	-1	2614930
neuropathy	I-Disease	-1	2614930
peripheral	B-Disease	D009422	2614930
and	I-Disease	-1	2614930
a@@	I-Disease	-1	2614930
ut@@	I-Disease	-1	2614930
on@@	I-Disease	-1	2614930
om@@	I-Disease	-1	2614930
ic	I-Disease	-1	2614930
neuropathy	I-Disease	-1	2614930
was	O	-1	2614930
ad@@	O	-1	2614930
mit@@	O	-1	2614930
ted	O	-1	2614930
with	O	-1	2614930
ch@@	B-Disease	D002637	2614930
est	I-Disease	-1	2614930
pain	I-Disease	-1	2614930
.	O	-1	2614930
H@@	O	-1	2614930
e	O	-1	2614930
was	O	-1	2614930
found	O	-1	2614930
to	O	-1	2614930
have	O	-1	2614930
atrial	B-Disease	D001282	2614930
f@@	I-Disease	-1	2614930
l@@	I-Disease	-1	2614930
ut@@	I-Disease	-1	2614930
ter	I-Disease	-1	2614930
at	O	-1	2614930
a	O	-1	2614930
ventricular	O	-1	2614930
rate	O	-1	2614930
of	O	-1	2614930
7@@	O	-1	2614930
0@@	O	-1	2614930
/@@	O	-1	2614930
min	O	-1	2614930
which	O	-1	2614930
s@@	O	-1	2614930
low@@	O	-1	2614930
ed	O	-1	2614930
do@@	O	-1	2614930
w@@	O	-1	2614930
n	O	-1	2614930
to	O	-1	2614930
3@@	O	-1	2614930
0-@@	O	-1	2614930
4@@	O	-1	2614930
0@@	O	-1	2614930
/@@	O	-1	2614930
min	O	-1	2614930
when	O	-1	2614930
n@@	B-Chemical	D009543	2614930
if@@	I-Chemical	-1	2614930
edi@@	I-Chemical	-1	2614930
pine	I-Chemical	-1	2614930
(@@	O	-1	2614930
60	O	-1	2614930
mg@@	O	-1	2614930
)	O	-1	2614930
in	O	-1	2614930
3	O	-1	2614930
divid@@	O	-1	2614930
ed	O	-1	2614930
dos@@	O	-1	2614930
es,	O	-1	2614930
during	O	-1	2614930
which	O	-1	2614930
he	O	-1	2614930
was	O	-1	2614930
pac@@	O	-1	2614930
ed	O	-1	2614930
at	O	-1	2614930
a	O	-1	2614930
rate	O	-1	2614930
of	O	-1	2614930
7@@	O	-1	2614930
0@@	O	-1	2614930
/@@	O	-1	2614930
min@@	O	-1	2614930
.	O	-1	2614930
This	O	-1	2614930
is	O	-1	2614930
in@@	O	-1	2614930
consist@@	O	-1	2614930
ent	O	-1	2614930
with	O	-1	2614930
the	O	-1	2614930
we@@	O	-1	2614930
ll@@	O	-1	2614930
-@@	O	-1	2614930
est@@	O	-1	2614930
abl@@	O	-1	2614930
ished	O	-1	2614930
find@@	O	-1	2614930
ing	O	-1	2614930
that	O	-1	2614930
n@@	B-Chemical	D009543	2614930
if@@	I-Chemical	-1	2614930
edi@@	I-Chemical	-1	2614930
pine	I-Chemical	-1	2614930
induc@@	O	-1	2614930
es	O	-1	2614930
tachycardia	B-Disease	D013610	2614930
in	O	-1	2614930
norm@@	O	-1	2614930
ally	O	-1	2614930
in@@	O	-1	2614930
ner@@	O	-1	2614930
v@@	O	-1	2614930
ated	O	-1	2614930
hear@@	O	-1	2614930
t@@	O	-1	2614930
s.	O	-1	2614930
However,	O	-1	2614930
in	O	-1	2614930
hear@@	O	-1	2614930
ts	O	-1	2614930
de@@	O	-1	2614930
pri@@	O	-1	2614930
ved	O	-1	2614930
of	O	-1	2614930
com@@	O	-1	2614930
pen@@	O	-1	2614930
s@@	O	-1	2614930
atory	O	-1	2614930
sym@@	O	-1	2614930
pa@@	O	-1	2614930
thetic	O	-1	2614930
d@@	O	-1	2614930
ri@@	O	-1	2614930
ve,	O	-1	2614930
it	O	-1	2614930
may	O	-1	2614930
le@@	O	-1	2614930
ad	O	-1	2614930
to	O	-1	2614930
brady@@	B-Disease	D001919	2614930
cardia	I-Disease	-1	2614930
.	O	-1	2614930

The	O	-1	2625524
effect	O	-1	2625524
of	O	-1	2625524
haloperidol	B-Chemical	D006220	2625524
in	O	-1	2625524
cocaine	B-Chemical	D003042	2625524
and	O	-1	2625524
amphetamine	B-Chemical	D000661	2625524
in@@	O	-1	2625524
toxic@@	O	-1	2625524
ation.	O	-1	2625524
The	O	-1	2625524
eff@@	O	-1	2625524
ec@@	O	-1	2625524
tiv@@	O	-1	2625524
en@@	O	-1	2625524
ess	O	-1	2625524
of	O	-1	2625524
haloperidol	B-Chemical	D006220	2625524
pretreatment	O	-1	2625524
in	O	-1	2625524
prevent@@	O	-1	2625524
ing	O	-1	2625524
the	O	-1	2625524
toxic	O	-1	2625524
effects	O	-1	2625524
of	O	-1	2625524
high	O	-1	2625524
doses	O	-1	2625524
of	O	-1	2625524
amphetamine	B-Chemical	D000661	2625524
and	O	-1	2625524
cocaine	B-Chemical	D003042	2625524
was	O	-1	2625524
studied	O	-1	2625524
in	O	-1	2625524
rats.	O	-1	2625524
In	O	-1	2625524
this	O	-1	2625524
model@@	O	-1	2625524
,	O	-1	2625524
toxic	O	-1	2625524
effects	O	-1	2625524
were	O	-1	2625524
induced	O	-1	2625524
by	O	-1	2625524
intra@@	O	-1	2625524
per@@	O	-1	2625524
it@@	O	-1	2625524
one@@	O	-1	2625524
al	O	-1	2625524
(@@	O	-1	2625524
i.p.@@	O	-1	2625524
)	O	-1	2625524
injection	O	-1	2625524
of	O	-1	2625524
amphetamine	B-Chemical	D000661	2625524
7@@	O	-1	2625524
5	O	-1	2625524
mg/kg	O	-1	2625524
(@@	O	-1	2625524
10@@	O	-1	2625524
0%	O	-1	2625524
death	O	-1	2625524
rat@@	O	-1	2625524
e@@	O	-1	2625524
)	O	-1	2625524
or	O	-1	2625524
cocaine	B-Chemical	D003042	2625524
7@@	O	-1	2625524
0	O	-1	2625524
mg/kg	O	-1	2625524
(@@	O	-1	2625524
8@@	O	-1	2625524
2@@	O	-1	2625524
%	O	-1	2625524
death	O	-1	2625524
rat@@	O	-1	2625524
e@@	O	-1	2625524
).	O	-1	2625524
H@@	B-Chemical	D006220	2625524
alo@@	I-Chemical	-1	2625524
perid@@	I-Chemical	-1	2625524
ol	I-Chemical	-1	2625524
fail@@	O	-1	2625524
ed	O	-1	2625524
to	O	-1	2625524
prev@@	O	-1	2625524
ent	O	-1	2625524
amphetamine	B-Chemical	D000661	2625524
-induced	O	-1	2625524
seizures	B-Disease	D012640	2625524
,	O	-1	2625524
but	O	-1	2625524
did	O	-1	2625524
lower	O	-1	2625524
the	O	-1	2625524
mor@@	O	-1	2625524
t@@	O	-1	2625524
ality	O	-1	2625524
rate	O	-1	2625524
at	O	-1	2625524
most	O	-1	2625524
doses	O	-1	2625524
test@@	O	-1	2625524
ed.	O	-1	2625524
H@@	B-Chemical	D006220	2625524
alo@@	I-Chemical	-1	2625524
perid@@	I-Chemical	-1	2625524
ol	I-Chemical	-1	2625524
decreased	O	-1	2625524
the	O	-1	2625524
incidence	O	-1	2625524
of	O	-1	2625524
cocaine	B-Chemical	D003042	2625524
-induced	O	-1	2625524
seizures	B-Disease	D012640	2625524
at	O	-1	2625524
the	O	-1	2625524
two	O	-1	2625524
high@@	O	-1	2625524
est	O	-1	2625524
dos@@	O	-1	2625524
es,	O	-1	2625524
but	O	-1	2625524
the	O	-1	2625524
low@@	O	-1	2625524
ering	O	-1	2625524
of	O	-1	2625524
the	O	-1	2625524
mor@@	O	-1	2625524
t@@	O	-1	2625524
ality	O	-1	2625524
rate	O	-1	2625524
did	O	-1	2625524
not	O	-1	2625524
reac@@	O	-1	2625524
h	O	-1	2625524
statis@@	O	-1	2625524
tical	O	-1	2625524
signific@@	O	-1	2625524
ance	O	-1	2625524
at	O	-1	2625524
any	O	-1	2625524
dose.	O	-1	2625524
These	O	-1	2625524
data	O	-1	2625524
suggest	O	-1	2625524
a	O	-1	2625524
protective	O	-1	2625524
role	O	-1	2625524
for	O	-1	2625524
the	O	-1	2625524
central	O	-1	2625524
dopamine	B-Chemical	D004298	2625524
block@@	O	-1	2625524
er	O	-1	2625524
haloperidol	B-Chemical	D006220	2625524
against	O	-1	2625524
death	O	-1	2625524
from	O	-1	2625524
high-dose	O	-1	2625524
amphetamine	B-Chemical	D000661	2625524
exposure	O	-1	2625524
without	O	-1	2625524
reduc@@	O	-1	2625524
ing	O	-1	2625524
the	O	-1	2625524
incidence	O	-1	2625524
of	O	-1	2625524
seizures	B-Disease	D012640	2625524
.	O	-1	2625524
In	O	-1	2625524
contrast@@	O	-1	2625524
,	O	-1	2625524
haloperidol	B-Chemical	D006220	2625524
demonstrated	O	-1	2625524
an	O	-1	2625524
ability	O	-1	2625524
to	O	-1	2625524
re@@	O	-1	2625524
duce	O	-1	2625524
cocaine	B-Chemical	D003042	2625524
-induced	O	-1	2625524
seizures	B-Disease	D012640	2625524
without	O	-1	2625524
significantly	O	-1	2625524
reduc@@	O	-1	2625524
ing	O	-1	2625524
mor@@	O	-1	2625524
t@@	O	-1	2625524
al@@	O	-1	2625524
ity.	O	-1	2625524

A@@	O	-1	2650911
ut@@	O	-1	2650911
or@@	O	-1	2650911
a@@	O	-1	2650911
di@@	O	-1	2650911
ograph@@	O	-1	2650911
ic	O	-1	2650911
evidence	O	-1	2650911
of	O	-1	2650911
est@@	B-Chemical	D004967	2650911
ro@@	I-Chemical	-1	2650911
gen	I-Chemical	-1	2650911
b@@	O	-1	2650911
ind@@	O	-1	2650911
ing	O	-1	2650911
sit@@	O	-1	2650911
es	O	-1	2650911
in	O	-1	2650911
nucle@@	O	-1	2650911
i	O	-1	2650911
of	O	-1	2650911
di@@	B-Chemical	D004054	2650911
eth@@	I-Chemical	-1	2650911
yl@@	I-Chemical	-1	2650911
sti@@	I-Chemical	-1	2650911
l@@	I-Chemical	-1	2650911
be@@	I-Chemical	-1	2650911
ster@@	I-Chemical	-1	2650911
ol	I-Chemical	-1	2650911
induced	O	-1	2650911
h@@	O	-1	2650911
am@@	O	-1	2650911
st@@	O	-1	2650911
er	O	-1	2650911
renal	B-Disease	D002292	2650911
carcin@@	I-Disease	-1	2650911
om@@	I-Disease	-1	2650911
as	I-Disease	-1	2650911
.	O	-1	2650911
E@@	B-Chemical	D004967	2650911
stro@@	I-Chemical	-1	2650911
gen	I-Chemical	-1	2650911
b@@	O	-1	2650911
ind@@	O	-1	2650911
ing	O	-1	2650911
sit@@	O	-1	2650911
es	O	-1	2650911
were	O	-1	2650911
demonstrated	O	-1	2650911
by	O	-1	2650911
a@@	O	-1	2650911
ut@@	O	-1	2650911
or@@	O	-1	2650911
a@@	O	-1	2650911
di@@	O	-1	2650911
ograph@@	O	-1	2650911
y	O	-1	2650911
in	O	-1	2650911
one	O	-1	2650911
transplant@@	O	-1	2650911
able	O	-1	2650911
and	O	-1	2650911
five	O	-1	2650911
prim@@	O	-1	2650911
ary	O	-1	2650911
di@@	B-Chemical	D004054	2650911
eth@@	I-Chemical	-1	2650911
yl@@	I-Chemical	-1	2650911
sti@@	I-Chemical	-1	2650911
l@@	I-Chemical	-1	2650911
be@@	I-Chemical	-1	2650911
ster@@	I-Chemical	-1	2650911
ol	I-Chemical	-1	2650911
induced	O	-1	2650911
renal	B-Disease	D002292	2650911
carcin@@	I-Disease	-1	2650911
om@@	I-Disease	-1	2650911
as	I-Disease	-1	2650911
in	O	-1	2650911
three	O	-1	2650911
h@@	O	-1	2650911
am@@	O	-1	2650911
ster@@	O	-1	2650911
s.	O	-1	2650911
R@@	O	-1	2650911
a@@	O	-1	2650911
di@@	O	-1	2650911
ol@@	O	-1	2650911
a@@	O	-1	2650911
bell@@	O	-1	2650911
ing,	O	-1	2650911
following	O	-1	2650911
the	O	-1	2650911
in	O	-1	2650911
viv@@	O	-1	2650911
o	O	-1	2650911
injection	O	-1	2650911
of	O	-1	2650911
3@@	O	-1	2650911
H@@	O	-1	2650911
-1@@	O	-1	2650911
7	O	-1	2650911
bet@@	O	-1	2650911
a	O	-1	2650911
est@@	B-Chemical	D004958	2650911
radi@@	I-Chemical	-1	2650911
ol	I-Chemical	-1	2650911
,	O	-1	2650911
was	O	-1	2650911
increased	O	-1	2650911
only	O	-1	2650911
over	O	-1	2650911
the	O	-1	2650911
nucle@@	O	-1	2650911
i	O	-1	2650911
of	O	-1	2650911
tumor	B-Disease	D009369	2650911
cell@@	O	-1	2650911
s;	O	-1	2650911
ste@@	O	-1	2650911
re@@	O	-1	2650911
ologic	O	-1	2650911
analysis	O	-1	2650911
revealed	O	-1	2650911
a	O	-1	2650911
4.@@	O	-1	2650911
5@@	O	-1	2650911
-	O	-1	2650911
to	O	-1	2650911
6.@@	O	-1	2650911
7-@@	O	-1	2650911
times	O	-1	2650911
higher	O	-1	2650911
concentration	O	-1	2650911
of	O	-1	2650911
reduced	O	-1	2650911
si@@	B-Chemical	D012834	2650911
l@@	I-Chemical	-1	2650911
ver	I-Chemical	-1	2650911
gra@@	O	-1	2650911
ins	O	-1	2650911
over	O	-1	2650911
nucle@@	O	-1	2650911
i	O	-1	2650911
than	O	-1	2650911
cyto@@	O	-1	2650911
plas@@	O	-1	2650911
m	O	-1	2650911
of	O	-1	2650911
these	O	-1	2650911
cell@@	O	-1	2650911
s.	O	-1	2650911
D@@	O	-1	2650911
es@@	O	-1	2650911
pit@@	O	-1	2650911
e	O	-1	2650911
ra@@	O	-1	2650911
pid	O	-1	2650911
tub@@	O	-1	2650911
ular	O	-1	2650911
ex@@	O	-1	2650911
cre@@	O	-1	2650911
tion	O	-1	2650911
of	O	-1	2650911
est@@	B-Chemical	D004958	2650911
radi@@	I-Chemical	-1	2650911
ol	I-Chemical	-1	2650911
which	O	-1	2650911
pe@@	O	-1	2650911
ak@@	O	-1	2650911
ed	O	-1	2650911
in	O	-1	2650911
less	O	-1	2650911
than	O	-1	2650911
1	O	-1	2650911
h@@	O	-1	2650911
,	O	-1	2650911
the	O	-1	2650911
normal	O	-1	2650911
cells	O	-1	2650911
did	O	-1	2650911
not	O	-1	2650911
appe@@	O	-1	2650911
ar	O	-1	2650911
to	O	-1	2650911
bin@@	O	-1	2650911
d	O	-1	2650911
the	O	-1	2650911
li@@	O	-1	2650911
g@@	O	-1	2650911
an@@	O	-1	2650911
d.	O	-1	2650911
This	O	-1	2650911
is	O	-1	2650911
the	O	-1	2650911
first	O	-1	2650911
pu@@	O	-1	2650911
bl@@	O	-1	2650911
ished	O	-1	2650911
report	O	-1	2650911
doc@@	O	-1	2650911
um@@	O	-1	2650911
ent@@	O	-1	2650911
ing	O	-1	2650911
the	O	-1	2650911
pre@@	O	-1	2650911
fe@@	O	-1	2650911
ren@@	O	-1	2650911
tial	O	-1	2650911
in	O	-1	2650911
viv@@	O	-1	2650911
o	O	-1	2650911
b@@	O	-1	2650911
ind@@	O	-1	2650911
ing	O	-1	2650911
of	O	-1	2650911
est@@	B-Chemical	D004967	2650911
ro@@	I-Chemical	-1	2650911
gen	I-Chemical	-1	2650911
to	O	-1	2650911
nucle@@	O	-1	2650911
i	O	-1	2650911
of	O	-1	2650911
cells	O	-1	2650911
in	O	-1	2650911
est@@	B-Chemical	D004967	2650911
ro@@	I-Chemical	-1	2650911
gen	I-Chemical	-1	2650911
induced	O	-1	2650911
h@@	O	-1	2650911
am@@	O	-1	2650911
st@@	O	-1	2650911
er	O	-1	2650911
renal	B-Disease	D002292	2650911
carcin@@	I-Disease	-1	2650911
om@@	I-Disease	-1	2650911
as	I-Disease	-1	2650911
.	O	-1	2650911

B@@	B-Disease	D001919	2710809
ra@@	I-Disease	-1	2710809
dy@@	I-Disease	-1	2710809
cardia	I-Disease	-1	2710809
due	O	-1	2710809
to	O	-1	2710809
b@@	B-Chemical	D001712	2710809
i@@	I-Chemical	-1	2710809
peri@@	I-Chemical	-1	2710809
de@@	I-Chemical	-1	2710809
n	I-Chemical	-1	2710809
.	O	-1	2710809
In	O	-1	2710809
a	O	-1	2710809
3@@	O	-1	2710809
8@@	O	-1	2710809
-@@	O	-1	2710809
year-old	O	-1	2710809
male	O	-1	2710809
patient	O	-1	2710809
suff@@	O	-1	2710809
ering	O	-1	2710809
from	O	-1	2710809
a	O	-1	2710809
severe	O	-1	2710809
post@@	B-Disease	D006562	2710809
z@@	I-Disease	-1	2710809
o@@	I-Disease	-1	2710809
ster@@	I-Disease	-1	2710809
ic	I-Disease	-1	2710809
tri@@	B-Disease	D014277	2710809
g@@	I-Disease	-1	2710809
em@@	I-Disease	-1	2710809
inal	I-Disease	-1	2710809
ne@@	I-Disease	-1	2710809
ur@@	I-Disease	-1	2710809
al@@	I-Disease	-1	2710809
g@@	I-Disease	-1	2710809
ia	I-Disease	-1	2710809
,	O	-1	2710809
intravenous	O	-1	2710809
ap@@	O	-1	2710809
plic@@	O	-1	2710809
ation	O	-1	2710809
of	O	-1	2710809
10	O	-1	2710809
mg	O	-1	2710809
b@@	B-Chemical	C036432	2710809
i@@	I-Chemical	-1	2710809
peri@@	I-Chemical	-1	2710809
de@@	I-Chemical	-1	2710809
n	I-Chemical	-1	2710809
l@@	I-Chemical	-1	2710809
act@@	I-Chemical	-1	2710809
ate	I-Chemical	-1	2710809
l@@	O	-1	2710809
ed	O	-1	2710809
to	O	-1	2710809
a	O	-1	2710809
long@@	O	-1	2710809
-@@	O	-1	2710809
l@@	O	-1	2710809
ast@@	O	-1	2710809
ing	O	-1	2710809
par@@	O	-1	2710809
ad@@	O	-1	2710809
ox@@	O	-1	2710809
ical	O	-1	2710809
reaction	O	-1	2710809
character@@	O	-1	2710809
ized	O	-1	2710809
by	O	-1	2710809
con@@	O	-1	2710809
si@@	O	-1	2710809
der@@	O	-1	2710809
able	O	-1	2710809
brady@@	B-Disease	D001919	2710809
cardia	I-Disease	-1	2710809
,	O	-1	2710809
dys@@	B-Disease	D004401	2710809
arth@@	I-Disease	-1	2710809
ri@@	I-Disease	-1	2710809
a	I-Disease	-1	2710809
,	O	-1	2710809
and	O	-1	2710809
dys@@	B-Disease	D003680	2710809
ph@@	I-Disease	-1	2710809
ag@@	I-Disease	-1	2710809
ia	I-Disease	-1	2710809
.	O	-1	2710809
The	O	-1	2710809
heart	O	-1	2710809
rate	O	-1	2710809
was	O	-1	2710809
bac@@	O	-1	2710809
k	O	-1	2710809
to	O	-1	2710809
normal	O	-1	2710809
within	O	-1	2710809
12	O	-1	2710809
hours	O	-1	2710809
up@@	O	-1	2710809
on	O	-1	2710809
administration	O	-1	2710809
of	O	-1	2710809
or@@	B-Chemical	D009921	2710809
ci@@	I-Chemical	-1	2710809
p@@	I-Chemical	-1	2710809
ren@@	I-Chemical	-1	2710809
aline	I-Chemical	-1	2710809
under	O	-1	2710809
cardiac	O	-1	2710809
monit@@	O	-1	2710809
or@@	O	-1	2710809
ing	O	-1	2710809
in	O	-1	2710809
an	O	-1	2710809
int@@	O	-1	2710809
en@@	O	-1	2710809
sive	O	-1	2710809
car@@	O	-1	2710809
e	O	-1	2710809
un@@	O	-1	2710809
it@@	O	-1	2710809
.	O	-1	2710809
B@@	B-Disease	D001919	2710809
ra@@	I-Disease	-1	2710809
dy@@	I-Disease	-1	2710809
cardia	I-Disease	-1	2710809
induced	O	-1	2710809
by	O	-1	2710809
b@@	B-Chemical	D001712	2710809
i@@	I-Chemical	-1	2710809
peri@@	I-Chemical	-1	2710809
de@@	I-Chemical	-1	2710809
n	I-Chemical	-1	2710809
is	O	-1	2710809
at@@	O	-1	2710809
tri@@	O	-1	2710809
but@@	O	-1	2710809
ed	O	-1	2710809
to	O	-1	2710809
the	O	-1	2710809
sp@@	O	-1	2710809
e@@	O	-1	2710809
ed	O	-1	2710809
of	O	-1	2710809
injection	O	-1	2710809
and	O	-1	2710809
to	O	-1	2710809
a	O	-1	2710809
dose-@@	O	-1	2710809
related	O	-1	2710809
du@@	O	-1	2710809
al	O	-1	2710809
effect	O	-1	2710809
of	O	-1	2710809
atro@@	B-Chemical	D001285	2710809
pine	I-Chemical	-1	2710809
-@@	O	-1	2710809
like	O	-1	2710809
drugs	O	-1	2710809
on	O	-1	2710809
mus@@	B-Chemical	D009116	2710809
car@@	I-Chemical	-1	2710809
ine	I-Chemical	-1	2710809
receptor@@	O	-1	2710809
s.	O	-1	2710809

De@@	O	-1	2718706
li@@	O	-1	2718706
b@@	O	-1	2718706
er@@	O	-1	2718706
ate	O	-1	2718706
hypotension	B-Disease	D007022	2718706
induced	O	-1	2718706
by	O	-1	2718706
l@@	B-Chemical	D007741	2718706
a@@	I-Chemical	-1	2718706
bet@@	I-Chemical	-1	2718706
al@@	I-Chemical	-1	2718706
ol	I-Chemical	-1	2718706
with	O	-1	2718706
halo@@	B-Chemical	D006221	2718706
th@@	I-Chemical	-1	2718706
ane	I-Chemical	-1	2718706
,	O	-1	2718706
en@@	B-Chemical	D004737	2718706
f@@	I-Chemical	-1	2718706
lur@@	I-Chemical	-1	2718706
ane	I-Chemical	-1	2718706
or	O	-1	2718706
iso@@	B-Chemical	D007530	2718706
f@@	I-Chemical	-1	2718706
lur@@	I-Chemical	-1	2718706
ane	I-Chemical	-1	2718706
for	O	-1	2718706
mid@@	O	-1	2718706
d@@	O	-1	2718706
le@@	O	-1	2718706
-@@	O	-1	2718706
e@@	O	-1	2718706
ar	O	-1	2718706
surger@@	O	-1	2718706
y.	O	-1	2718706
The	O	-1	2718706
fe@@	O	-1	2718706
a@@	O	-1	2718706
sib@@	O	-1	2718706
ility	O	-1	2718706
of	O	-1	2718706
using	O	-1	2718706
l@@	B-Chemical	D007741	2718706
a@@	I-Chemical	-1	2718706
bet@@	I-Chemical	-1	2718706
al@@	I-Chemical	-1	2718706
ol	I-Chemical	-1	2718706
,	O	-1	2718706
an	O	-1	2718706
alpha@@	O	-1	2718706
-	O	-1	2718706
and	O	-1	2718706
beta-@@	O	-1	2718706
adrenergic	O	-1	2718706
block@@	O	-1	2718706
ing	O	-1	2718706
agent@@	O	-1	2718706
,	O	-1	2718706
as	O	-1	2718706
a	O	-1	2718706
hypoten@@	B-Disease	D007022	2718706
sive	I-Disease	-1	2718706
agent	O	-1	2718706
in	O	-1	2718706
combination	O	-1	2718706
with	O	-1	2718706
in@@	O	-1	2718706
h@@	O	-1	2718706
al@@	O	-1	2718706
ation	O	-1	2718706
anaesthe@@	O	-1	2718706
tics	O	-1	2718706
(	O	-1	2718706
halo@@	B-Chemical	D006221	2718706
th@@	I-Chemical	-1	2718706
ane	I-Chemical	-1	2718706
,	O	-1	2718706
en@@	B-Chemical	D004737	2718706
f@@	I-Chemical	-1	2718706
lur@@	I-Chemical	-1	2718706
ane	I-Chemical	-1	2718706
or	O	-1	2718706
iso@@	B-Chemical	D007530	2718706
f@@	I-Chemical	-1	2718706
lur@@	I-Chemical	-1	2718706
ane	I-Chemical	-1	2718706
)	O	-1	2718706
was	O	-1	2718706
studied	O	-1	2718706
in	O	-1	2718706
2@@	O	-1	2718706
3	O	-1	2718706
ad@@	O	-1	2718706
ult	O	-1	2718706
patients	O	-1	2718706
under@@	O	-1	2718706
go@@	O	-1	2718706
ing	O	-1	2718706
mid@@	O	-1	2718706
d@@	O	-1	2718706
le@@	O	-1	2718706
-@@	O	-1	2718706
e@@	O	-1	2718706
ar	O	-1	2718706
surger@@	O	-1	2718706
y.	O	-1	2718706
The	O	-1	2718706
mean	O	-1	2718706
arterial	O	-1	2718706
pressure	O	-1	2718706
was	O	-1	2718706
decreased	O	-1	2718706
from	O	-1	2718706
8@@	O	-1	2718706
6	O	-1	2718706
+/-	O	-1	2718706
5	O	-1	2718706
(@@	O	-1	2718706
s@@	O	-1	2718706
.@@	O	-1	2718706
e.	O	-1	2718706
me@@	O	-1	2718706
an@@	O	-1	2718706
)	O	-1	2718706
mm@@	O	-1	2718706
H@@	O	-1	2718706
g	O	-1	2718706
to	O	-1	2718706
5@@	O	-1	2718706
2	O	-1	2718706
+/-	O	-1	2718706
1	O	-1	2718706
mm@@	O	-1	2718706
H@@	O	-1	2718706
g	O	-1	2718706
(1@@	O	-1	2718706
1.@@	O	-1	2718706
5	O	-1	2718706
+/-	O	-1	2718706
0.@@	O	-1	2718706
7	O	-1	2718706
to	O	-1	2718706
6.@@	O	-1	2718706
9	O	-1	2718706
+/-	O	-1	2718706
0.@@	O	-1	2718706
1	O	-1	2718706
k@@	O	-1	2718706
P@@	O	-1	2718706
a@@	O	-1	2718706
)	O	-1	2718706
for	O	-1	2718706
9@@	O	-1	2718706
8	O	-1	2718706
+/-	O	-1	2718706
10	O	-1	2718706
min	O	-1	2718706
in	O	-1	2718706
the	O	-1	2718706
halo@@	B-Chemical	D006221	2718706
th@@	I-Chemical	-1	2718706
ane	I-Chemical	-1	2718706
(	O	-1	2718706
H	B-Chemical	D006221	2718706
)	O	-1	2718706
group@@	O	-1	2718706
,	O	-1	2718706
from	O	-1	2718706
7@@	O	-1	2718706
9	O	-1	2718706
+/-	O	-1	2718706
5	O	-1	2718706
to	O	-1	2718706
5@@	O	-1	2718706
3	O	-1	2718706
+/-	O	-1	2718706
1	O	-1	2718706
mm@@	O	-1	2718706
H@@	O	-1	2718706
g	O	-1	2718706
(1@@	O	-1	2718706
0.@@	O	-1	2718706
5	O	-1	2718706
+/-	O	-1	2718706
0.@@	O	-1	2718706
7	O	-1	2718706
to	O	-1	2718706
7.@@	O	-1	2718706
1	O	-1	2718706
+/-	O	-1	2718706
0.@@	O	-1	2718706
1	O	-1	2718706
k@@	O	-1	2718706
P@@	O	-1	2718706
a@@	O	-1	2718706
)	O	-1	2718706
for	O	-1	2718706
12@@	O	-1	2718706
9	O	-1	2718706
+/-	O	-1	2718706
11	O	-1	2718706
min	O	-1	2718706
in	O	-1	2718706
the	O	-1	2718706
en@@	B-Chemical	D004737	2718706
f@@	I-Chemical	-1	2718706
lur@@	I-Chemical	-1	2718706
ane	I-Chemical	-1	2718706
(	O	-1	2718706
E	B-Chemical	D004737	2718706
)	O	-1	2718706
group@@	O	-1	2718706
,	O	-1	2718706
and	O	-1	2718706
from	O	-1	2718706
8@@	O	-1	2718706
0	O	-1	2718706
+/-	O	-1	2718706
4	O	-1	2718706
to	O	-1	2718706
4@@	O	-1	2718706
9	O	-1	2718706
+/-	O	-1	2718706
1	O	-1	2718706
mm@@	O	-1	2718706
H@@	O	-1	2718706
g	O	-1	2718706
(1@@	O	-1	2718706
0.@@	O	-1	2718706
7	O	-1	2718706
+/-	O	-1	2718706
0.@@	O	-1	2718706
5	O	-1	2718706
to	O	-1	2718706
6.@@	O	-1	2718706
5	O	-1	2718706
+/-	O	-1	2718706
0.@@	O	-1	2718706
1	O	-1	2718706
k@@	O	-1	2718706
P@@	O	-1	2718706
a@@	O	-1	2718706
)	O	-1	2718706
for	O	-1	2718706
13@@	O	-1	2718706
5	O	-1	2718706
+/-	O	-1	2718706
15	O	-1	2718706
min	O	-1	2718706
in	O	-1	2718706
the	O	-1	2718706
iso@@	B-Chemical	D007530	2718706
f@@	I-Chemical	-1	2718706
lur@@	I-Chemical	-1	2718706
ane	I-Chemical	-1	2718706
(	O	-1	2718706
I	B-Chemical	D007530	2718706
)	O	-1	2718706
group.	O	-1	2718706
The	O	-1	2718706
mean	O	-1	2718706
H	B-Chemical	D006221	2718706
concentration	O	-1	2718706
during	O	-1	2718706
hypotension	B-Disease	D007022	2718706
in	O	-1	2718706
the	O	-1	2718706
in@@	O	-1	2718706
s@@	O	-1	2718706
piratory	O	-1	2718706
g@@	O	-1	2718706
as	O	-1	2718706
was	O	-1	2718706
0.@@	O	-1	2718706
7	O	-1	2718706
+/-	O	-1	2718706
0.@@	O	-1	2718706
1	O	-1	2718706
vol@@	O	-1	2718706
%,	O	-1	2718706
the	O	-1	2718706
mean	O	-1	2718706
E	B-Chemical	D004737	2718706
concentration	O	-1	2718706
1.@@	O	-1	2718706
6	O	-1	2718706
+/-	O	-1	2718706
0.@@	O	-1	2718706
2	O	-1	2718706
vol@@	O	-1	2718706
%,	O	-1	2718706
and	O	-1	2718706
the	O	-1	2718706
mean	O	-1	2718706
I	B-Chemical	D007530	2718706
concentration	O	-1	2718706
1.@@	O	-1	2718706
0	O	-1	2718706
+/-	O	-1	2718706
0.@@	O	-1	2718706
1	O	-1	2718706
vol@@	O	-1	2718706
%.	O	-1	2718706
In	O	-1	2718706
addi@@	O	-1	2718706
tion,	O	-1	2718706
the	O	-1	2718706
patients	O	-1	2718706
received	O	-1	2718706
f@@	B-Chemical	D005283	2718706
entan@@	I-Chemical	-1	2718706
yl	I-Chemical	-1	2718706
and	O	-1	2718706
d-@@	B-Chemical	D014403	2718706
tub@@	I-Chemical	-1	2718706
oc@@	I-Chemical	-1	2718706
ur@@	I-Chemical	-1	2718706
ar@@	I-Chemical	-1	2718706
ine	I-Chemical	-1	2718706
.	O	-1	2718706
The	O	-1	2718706
initial	O	-1	2718706
dose	O	-1	2718706
of	O	-1	2718706
l@@	B-Chemical	D007741	2718706
a@@	I-Chemical	-1	2718706
bet@@	I-Chemical	-1	2718706
al@@	I-Chemical	-1	2718706
ol	I-Chemical	-1	2718706
for	O	-1	2718706
low@@	O	-1	2718706
ering	O	-1	2718706
blood	O	-1	2718706
pressure	O	-1	2718706
was	O	-1	2718706
simil@@	O	-1	2718706
ar@@	O	-1	2718706
,	O	-1	2718706
0.@@	O	-1	2718706
5@@	O	-1	2718706
2-@@	O	-1	2718706
0.@@	O	-1	2718706
5@@	O	-1	2718706
9	O	-1	2718706
mg/kg@@	O	-1	2718706
,	O	-1	2718706
in	O	-1	2718706
all	O	-1	2718706
the	O	-1	2718706
groups.	O	-1	2718706
D@@	O	-1	2718706
uring	O	-1	2718706
hypotension	B-Disease	D007022	2718706
,	O	-1	2718706
the	O	-1	2718706
heart	O	-1	2718706
rate	O	-1	2718706
was	O	-1	2718706
st@@	O	-1	2718706
able	O	-1	2718706
without	O	-1	2718706
tachy@@	B-Disease	D013610	2718706
-	I-Disease	-1	2718706
or	I-Disease	-1	2718706
brady@@	I-Disease	-1	2718706
cardia	I-Disease	-1	2718706
tachy@@	B-Disease	D001919	2718706
-	I-Disease	-1	2718706
or	I-Disease	-1	2718706
brady@@	I-Disease	-1	2718706
cardia	I-Disease	-1	2718706
.	O	-1	2718706
The	O	-1	2718706
o@@	O	-1	2718706
per@@	O	-1	2718706
ating	O	-1	2718706
condi@@	O	-1	2718706
tions	O	-1	2718706
reg@@	O	-1	2718706
ar@@	O	-1	2718706
ding	O	-1	2718706
ble@@	B-Disease	D006470	2718706
ed@@	I-Disease	-1	2718706
ing	I-Disease	-1	2718706
were	O	-1	2718706
estim@@	O	-1	2718706
ated	O	-1	2718706
in	O	-1	2718706
a	O	-1	2718706
double-bl@@	O	-1	2718706
ind	O	-1	2718706
man@@	O	-1	2718706
ner@@	O	-1	2718706
,	O	-1	2718706
and	O	-1	2718706
did	O	-1	2718706
not	O	-1	2718706
diff@@	O	-1	2718706
er	O	-1	2718706
significantly	O	-1	2718706
between	O	-1	2718706
the	O	-1	2718706
groups.	O	-1	2718706
D@@	O	-1	2718706
uring	O	-1	2718706
hypotension	B-Disease	D007022	2718706
,	O	-1	2718706
the	O	-1	2718706
serum	O	-1	2718706
creatinine	B-Chemical	D003404	2718706
concentration	O	-1	2718706
ro@@	O	-1	2718706
se	O	-1	2718706
significantly	O	-1	2718706
in	O	-1	2718706
all	O	-1	2718706
groups	O	-1	2718706
from	O	-1	2718706
the	O	-1	2718706
values	O	-1	2718706
before	O	-1	2718706
hypotension	B-Disease	D007022	2718706
and	O	-1	2718706
retur@@	O	-1	2718706
n@@	O	-1	2718706
ed	O	-1	2718706
posto@@	O	-1	2718706
per@@	O	-1	2718706
atively	O	-1	2718706
to	O	-1	2718706
the	O	-1	2718706
initial	O	-1	2718706
level	O	-1	2718706
in	O	-1	2718706
the	O	-1	2718706
other	O	-1	2718706
group@@	O	-1	2718706
s,	O	-1	2718706
ex@@	O	-1	2718706
cep@@	O	-1	2718706
t	O	-1	2718706
the	O	-1	2718706
iso@@	B-Chemical	D007530	2718706
f@@	I-Chemical	-1	2718706
lur@@	I-Chemical	-1	2718706
ane	I-Chemical	-1	2718706
group.	O	-1	2718706
After	O	-1	2718706
hypotension	B-Disease	D007022	2718706
there	O	-1	2718706
was	O	-1	2718706
no	O	-1	2718706
reb@@	O	-1	2718706
ound	O	-1	2718706
phen@@	O	-1	2718706
om@@	O	-1	2718706
en@@	O	-1	2718706
on	O	-1	2718706
in	O	-1	2718706
either	O	-1	2718706
blood	O	-1	2718706
pressure	O	-1	2718706
or	O	-1	2718706
heart	O	-1	2718706
rat@@	O	-1	2718706
e.	O	-1	2718706
These	O	-1	2718706
results	O	-1	2718706
indicate	O	-1	2718706
that	O	-1	2718706
l@@	B-Chemical	D007741	2718706
a@@	I-Chemical	-1	2718706
bet@@	I-Chemical	-1	2718706
al@@	I-Chemical	-1	2718706
ol	I-Chemical	-1	2718706
induc@@	O	-1	2718706
es	O	-1	2718706
e@@	O	-1	2718706
a@@	O	-1	2718706
si@@	O	-1	2718706
ly	O	-1	2718706
adjust@@	O	-1	2718706
able	O	-1	2718706
hypotension	B-Disease	D007022	2718706
without	O	-1	2718706
com@@	O	-1	2718706
pen@@	O	-1	2718706
s@@	O	-1	2718706
atory	O	-1	2718706
tachycardia	B-Disease	D013610	2718706
and	O	-1	2718706
reb@@	O	-1	2718706
ound	O	-1	2718706
hypertension	B-Disease	D006973	2718706
.	O	-1	2718706

Con@@	B-Disease	D012640	2765447
vul@@	I-Disease	-1	2765447
sion	I-Disease	-1	2765447
following	O	-1	2765447
intravenous	O	-1	2765447
fluo@@	B-Chemical	D019793	2765447
res@@	I-Chemical	-1	2765447
ce@@	I-Chemical	-1	2765447
in	I-Chemical	-1	2765447
angio@@	O	-1	2765447
graph@@	O	-1	2765447
y.	O	-1	2765447
T@@	B-Disease	D004830	2765447
on@@	I-Disease	-1	2765447
ic@@	I-Disease	-1	2765447
-@@	I-Disease	-1	2765447
clon@@	I-Disease	-1	2765447
ic	I-Disease	-1	2765447
seizures	I-Disease	-1	2765447
followed	O	-1	2765447
intravenous	O	-1	2765447
fluo@@	B-Chemical	D019793	2765447
res@@	I-Chemical	-1	2765447
ce@@	I-Chemical	-1	2765447
in	I-Chemical	-1	2765447
injection	O	-1	2765447
for	O	-1	2765447
f@@	O	-1	2765447
und@@	O	-1	2765447
us	O	-1	2765447
angio@@	O	-1	2765447
graph@@	O	-1	2765447
y	O	-1	2765447
in	O	-1	2765447
a	O	-1	2765447
4@@	O	-1	2765447
7-@@	O	-1	2765447
year-old	O	-1	2765447
mal@@	O	-1	2765447
e.	O	-1	2765447
D@@	O	-1	2765447
es@@	O	-1	2765447
pit@@	O	-1	2765447
e	O	-1	2765447
pre@@	O	-1	2765447
cau@@	O	-1	2765447
tions	O	-1	2765447
this	O	-1	2765447
adverse	O	-1	2765447
reaction	O	-1	2765447
recur@@	O	-1	2765447
red	O	-1	2765447
on	O	-1	2765447
re@@	O	-1	2765447
-@@	O	-1	2765447
exposure	O	-1	2765447
to	O	-1	2765447
intravenous	O	-1	2765447
fluo@@	B-Chemical	D019793	2765447
res@@	I-Chemical	-1	2765447
ce@@	I-Chemical	-1	2765447
in	I-Chemical	-1	2765447
.	O	-1	2765447

Ph@@	O	-1	2767010
armac@@	O	-1	2767010
ology	O	-1	2767010
of	O	-1	2767010
AC@@	B-Chemical	C043114	2767010
C@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
9@@	I-Chemical	-1	2767010
6@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
3	I-Chemical	-1	2767010
(	O	-1	2767010
pheny@@	B-Chemical	D010672	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
pro@@	O	-1	2767010
drug@@	O	-1	2767010
).	O	-1	2767010
AC@@	B-Chemical	C043114	2767010
C@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
9@@	I-Chemical	-1	2767010
6@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
3	I-Chemical	-1	2767010
,	O	-1	2767010
the	O	-1	2767010
dis@@	B-Chemical	-1	2767010
odium	I-Chemical	-1	2767010
phosph@@	I-Chemical	-1	2767010
ate	I-Chemical	-1	2767010
est@@	I-Chemical	-1	2767010
er	I-Chemical	-1	2767010
of	O	-1	2767010
3-@@	B-Chemical	C043104	2767010
hydrox@@	I-Chemical	-1	2767010
y@@	I-Chemical	-1	2767010
methyl@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
,@@	I-Chemical	-1	2767010
5-@@	I-Chemical	-1	2767010
di@@	I-Chemical	-1	2767010
phenyl@@	I-Chemical	-1	2767010
hy@@	I-Chemical	-1	2767010
d@@	I-Chemical	-1	2767010
an@@	I-Chemical	-1	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
,	O	-1	2767010
is	O	-1	2767010
a	O	-1	2767010
pro@@	O	-1	2767010
drug	O	-1	2767010
of	O	-1	2767010
pheny@@	B-Chemical	D010672	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
with	O	-1	2767010
adv@@	O	-1	2767010
ant@@	O	-1	2767010
ag@@	O	-1	2767010
e@@	O	-1	2767010
ous	O	-1	2767010
physi@@	O	-1	2767010
co@@	O	-1	2767010
chemical	O	-1	2767010
pro@@	O	-1	2767010
per@@	O	-1	2767010
ti@@	O	-1	2767010
es.	O	-1	2767010
AC@@	B-Chemical	C043114	2767010
C@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
9@@	I-Chemical	-1	2767010
6@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
3	I-Chemical	-1	2767010
is	O	-1	2767010
ra@@	O	-1	2767010
pid@@	O	-1	2767010
ly	O	-1	2767010
conver@@	O	-1	2767010
ted	O	-1	2767010
enzym@@	O	-1	2767010
ati@@	O	-1	2767010
c@@	O	-1	2767010
ally	O	-1	2767010
to	O	-1	2767010
pheny@@	B-Chemical	D010672	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
in	O	-1	2767010
viv@@	O	-1	2767010
o@@	O	-1	2767010
.	O	-1	2767010
AC@@	B-Chemical	C043114	2767010
C@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
9@@	I-Chemical	-1	2767010
6@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
3	I-Chemical	-1	2767010
and	O	-1	2767010
pheny@@	B-Chemical	C043114	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
sodium	I-Chemical	-1	2767010
have	O	-1	2767010
equ@@	O	-1	2767010
i@@	O	-1	2767010
val@@	O	-1	2767010
ent	O	-1	2767010
anti@@	O	-1	2767010
convul@@	O	-1	2767010
s@@	O	-1	2767010
ant	O	-1	2767010
activity	O	-1	2767010
against	O	-1	2767010
seizures	B-Disease	D012640	2767010
induced	O	-1	2767010
by	O	-1	2767010
maxim@@	O	-1	2767010
al	O	-1	2767010
electro@@	O	-1	2767010
sh@@	O	-1	2767010
oc@@	O	-1	2767010
k	O	-1	2767010
(@@	O	-1	2767010
M@@	O	-1	2767010
ES@@	O	-1	2767010
)	O	-1	2767010
in	O	-1	2767010
mice	O	-1	2767010
following	O	-1	2767010
i.p.@@	O	-1	2767010
,	O	-1	2767010
or@@	O	-1	2767010
al,	O	-1	2767010
or	O	-1	2767010
i.v@@	O	-1	2767010
.	O	-1	2767010
administr@@	O	-1	2767010
ation.	O	-1	2767010
The	O	-1	2767010
E@@	O	-1	2767010
D@@	O	-1	2767010
50	O	-1	2767010
doses	O	-1	2767010
were	O	-1	2767010
16	O	-1	2767010
mg/kg	O	-1	2767010
for	O	-1	2767010
i.v@@	O	-1	2767010
.	O	-1	2767010
AC@@	B-Chemical	C043114	2767010
C@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
9@@	I-Chemical	-1	2767010
6@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
3	I-Chemical	-1	2767010
and	O	-1	2767010
8	O	-1	2767010
mg/kg	O	-1	2767010
for	O	-1	2767010
i.v@@	O	-1	2767010
.	O	-1	2767010
pheny@@	B-Chemical	C043114	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
sodium	I-Chemical	-1	2767010
.	O	-1	2767010
AC@@	B-Chemical	C043114	2767010
C@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
9@@	I-Chemical	-1	2767010
6@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
3	I-Chemical	-1	2767010
and	O	-1	2767010
pheny@@	B-Chemical	C043114	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
sodium	I-Chemical	-1	2767010
have	O	-1	2767010
similar	O	-1	2767010
anti@@	O	-1	2767010
arrhyth@@	O	-1	2767010
mic	O	-1	2767010
activity	O	-1	2767010
against	O	-1	2767010
ou@@	B-Chemical	D010042	2767010
ab@@	I-Chemical	-1	2767010
ain	I-Chemical	-1	2767010
-induced	O	-1	2767010
ventricular	B-Disease	D017180	2767010
tachycardia	I-Disease	-1	2767010
in	O	-1	2767010
anesthe@@	O	-1	2767010
tiz@@	O	-1	2767010
ed	O	-1	2767010
dog@@	O	-1	2767010
s.	O	-1	2767010
The	O	-1	2767010
total	O	-1	2767010
doses	O	-1	2767010
of	O	-1	2767010
AC@@	B-Chemical	C043114	2767010
C@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
9@@	I-Chemical	-1	2767010
6@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
3	I-Chemical	-1	2767010
or	O	-1	2767010
pheny@@	B-Chemical	C043114	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
sodium	I-Chemical	-1	2767010
nec@@	O	-1	2767010
ess@@	O	-1	2767010
ary	O	-1	2767010
to	O	-1	2767010
conver@@	O	-1	2767010
t	O	-1	2767010
the	O	-1	2767010
arrhyth@@	B-Disease	D001145	2767010
mia	I-Disease	-1	2767010
to	O	-1	2767010
a	O	-1	2767010
normal	O	-1	2767010
s@@	O	-1	2767010
in@@	O	-1	2767010
us	O	-1	2767010
rhyth@@	O	-1	2767010
m	O	-1	2767010
were	O	-1	2767010
24	O	-1	2767010
+/-	O	-1	2767010
6	O	-1	2767010
and	O	-1	2767010
14	O	-1	2767010
+/-	O	-1	2767010
3	O	-1	2767010
mg/kg@@	O	-1	2767010
,	O	-1	2767010
respectively.	O	-1	2767010
On@@	O	-1	2767010
ly	O	-1	2767010
pheny@@	B-Chemical	C043114	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
sodium	I-Chemical	-1	2767010
dis@@	O	-1	2767010
pl@@	O	-1	2767010
ayed	O	-1	2767010
in	O	-1	2767010
vit@@	O	-1	2767010
r@@	O	-1	2767010
o	O	-1	2767010
anti@@	O	-1	2767010
arrhyth@@	O	-1	2767010
mic	O	-1	2767010
activity	O	-1	2767010
against	O	-1	2767010
stro@@	B-Chemical	D013327	2767010
ph@@	I-Chemical	-1	2767010
an@@	I-Chemical	-1	2767010
th@@	I-Chemical	-1	2767010
id@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
-induced	O	-1	2767010
arrhyth@@	B-Disease	D001145	2767010
mi@@	I-Disease	-1	2767010
as	I-Disease	-1	2767010
in	O	-1	2767010
gu@@	O	-1	2767010
ine@@	O	-1	2767010
a	O	-1	2767010
pi@@	O	-1	2767010
g	O	-1	2767010
right	O	-1	2767010
atri@@	O	-1	2767010
a.	O	-1	2767010
In	O	-1	2767010
anesthe@@	O	-1	2767010
tiz@@	O	-1	2767010
ed	O	-1	2767010
dog@@	O	-1	2767010
s,	O	-1	2767010
a	O	-1	2767010
high	O	-1	2767010
dose	O	-1	2767010
of	O	-1	2767010
AC@@	B-Chemical	C043114	2767010
C@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
9@@	I-Chemical	-1	2767010
6@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
3	I-Chemical	-1	2767010
(3@@	O	-1	2767010
1	O	-1	2767010
mg/kg)	O	-1	2767010
was	O	-1	2767010
inf@@	O	-1	2767010
used	O	-1	2767010
over	O	-1	2767010
1@@	O	-1	2767010
5,	O	-1	2767010
20@@	O	-1	2767010
,	O	-1	2767010
and	O	-1	2767010
30	O	-1	2767010
min	O	-1	2767010
and	O	-1	2767010
the	O	-1	2767010
responses	O	-1	2767010
were	O	-1	2767010
compared	O	-1	2767010
to	O	-1	2767010
an	O	-1	2767010
equ@@	O	-1	2767010
im@@	O	-1	2767010
ol@@	O	-1	2767010
ar	O	-1	2767010
dose	O	-1	2767010
of	O	-1	2767010
pheny@@	B-Chemical	C043114	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
sodium	I-Chemical	-1	2767010
(2@@	O	-1	2767010
1	O	-1	2767010
mg/kg@@	O	-1	2767010
).	O	-1	2767010
The	O	-1	2767010
AC@@	B-Chemical	C043114	2767010
C@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
9@@	I-Chemical	-1	2767010
6@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
3	I-Chemical	-1	2767010
and	O	-1	2767010
pheny@@	B-Chemical	C043114	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
sodium	I-Chemical	-1	2767010
treat@@	O	-1	2767010
ments	O	-1	2767010
produced	O	-1	2767010
similar	O	-1	2767010
mark@@	O	-1	2767010
ed	O	-1	2767010
reduc@@	O	-1	2767010
tions	O	-1	2767010
in	O	-1	2767010
di@@	O	-1	2767010
ast@@	O	-1	2767010
olic	O	-1	2767010
blood	O	-1	2767010
pressure	O	-1	2767010
and	O	-1	2767010
contrac@@	O	-1	2767010
ti@@	O	-1	2767010
le	O	-1	2767010
for@@	O	-1	2767010
ce	O	-1	2767010
(@@	O	-1	2767010
L@@	O	-1	2767010
V@@	O	-1	2767010
d@@	O	-1	2767010
P@@	O	-1	2767010
/@@	O	-1	2767010
d@@	O	-1	2767010
t@@	O	-1	2767010
).	O	-1	2767010
The	O	-1	2767010
maxim@@	O	-1	2767010
um	O	-1	2767010
effects	O	-1	2767010
of	O	-1	2767010
each	O	-1	2767010
treatment	O	-1	2767010
occurred	O	-1	2767010
at	O	-1	2767010
the	O	-1	2767010
time	O	-1	2767010
of	O	-1	2767010
maxim@@	O	-1	2767010
um	O	-1	2767010
pheny@@	B-Chemical	C043114	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
sodium	I-Chemical	-1	2767010
level@@	O	-1	2767010
s.	O	-1	2767010
Ac@@	O	-1	2767010
ute	O	-1	2767010
toxicity	B-Disease	D064420	2767010
studies	O	-1	2767010
of	O	-1	2767010
AC@@	B-Chemical	C043114	2767010
C@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
9@@	I-Chemical	-1	2767010
6@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
3	I-Chemical	-1	2767010
and	O	-1	2767010
pheny@@	B-Chemical	C043114	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
sodium	I-Chemical	-1	2767010
were	O	-1	2767010
car@@	O	-1	2767010
ri@@	O	-1	2767010
ed	O	-1	2767010
out	O	-1	2767010
in	O	-1	2767010
mic@@	O	-1	2767010
e,	O	-1	2767010
rats,	O	-1	2767010
ra@@	O	-1	2767010
b@@	O	-1	2767010
b@@	O	-1	2767010
it@@	O	-1	2767010
s,	O	-1	2767010
and	O	-1	2767010
dog@@	O	-1	2767010
s	O	-1	2767010
by	O	-1	2767010
i.v@@	O	-1	2767010
.,	O	-1	2767010
i.@@	O	-1	2767010
m@@	O	-1	2767010
.,	O	-1	2767010
and	O	-1	2767010
i.@@	O	-1	2767010
p@@	O	-1	2767010
.	O	-1	2767010
ro@@	O	-1	2767010
ut@@	O	-1	2767010
es	O	-1	2767010
of	O	-1	2767010
administr@@	O	-1	2767010
ation.	O	-1	2767010
The	O	-1	2767010
systemic	O	-1	2767010
toxic	O	-1	2767010
signs	O	-1	2767010
of	O	-1	2767010
both	O	-1	2767010
agents	O	-1	2767010
were	O	-1	2767010
similar	O	-1	2767010
and	O	-1	2767010
occurred	O	-1	2767010
at	O	-1	2767010
appro@@	O	-1	2767010
xim@@	O	-1	2767010
ately	O	-1	2767010
equ@@	O	-1	2767010
i@@	O	-1	2767010
val@@	O	-1	2767010
ent	O	-1	2767010
dos@@	O	-1	2767010
es.	O	-1	2767010
Im@@	O	-1	2767010
port@@	O	-1	2767010
ant@@	O	-1	2767010
ly,	O	-1	2767010
the	O	-1	2767010
loc@@	O	-1	2767010
al	O	-1	2767010
ir@@	O	-1	2767010
rit@@	O	-1	2767010
ation	O	-1	2767010
of	O	-1	2767010
AC@@	B-Chemical	C043114	2767010
C@@	I-Chemical	-1	2767010
-@@	I-Chemical	-1	2767010
9@@	I-Chemical	-1	2767010
6@@	I-Chemical	-1	2767010
5@@	I-Chemical	-1	2767010
3	I-Chemical	-1	2767010
was	O	-1	2767010
mark@@	O	-1	2767010
ed@@	O	-1	2767010
ly	O	-1	2767010
less	O	-1	2767010
than	O	-1	2767010
pheny@@	B-Chemical	C043114	2767010
to@@	I-Chemical	-1	2767010
in	I-Chemical	-1	2767010
sodium	I-Chemical	-1	2767010
following	O	-1	2767010
i.@@	O	-1	2767010
m.	O	-1	2767010
administr@@	O	-1	2767010
ation@@	O	-1	2767010
.@@	O	-1	2767010
(A@@	O	-1	2767010
B@@	O	-1	2767010
S@@	O	-1	2767010
TR@@	O	-1	2767010
AC@@	O	-1	2767010
T	O	-1	2767010
TR@@	O	-1	2767010
UN@@	O	-1	2767010
C@@	O	-1	2767010
AT@@	O	-1	2767010
E@@	O	-1	2767010
D	O	-1	2767010
A@@	O	-1	2767010
T	O	-1	2767010
2@@	O	-1	2767010
50	O	-1	2767010
W@@	O	-1	2767010
O@@	O	-1	2767010
RD@@	O	-1	2767010
S)	O	-1	2767010

Ph@@	B-Chemical	D010672	2818777
en@@	I-Chemical	-1	2818777
y@@	I-Chemical	-1	2818777
to@@	I-Chemical	-1	2818777
in	I-Chemical	-1	2818777
induced	O	-1	2818777
f@@	O	-1	2818777
atal	O	-1	2818777
hepatic	B-Disease	D056486	2818777
injury	I-Disease	-1	2818777
.	O	-1	2818777
A	O	-1	2818777
6@@	O	-1	2818777
1	O	-1	2818777
year	O	-1	2818777
old	O	-1	2818777
female	O	-1	2818777
developed	O	-1	2818777
f@@	O	-1	2818777
atal	O	-1	2818777
hepatic	B-Disease	D017093	2818777
failure	I-Disease	-1	2818777
after	O	-1	2818777
pheny@@	B-Chemical	D010672	2818777
to@@	I-Chemical	-1	2818777
in	I-Chemical	-1	2818777
administr@@	O	-1	2818777
ation.	O	-1	2818777
A	O	-1	2818777
typ@@	O	-1	2818777
ical	O	-1	2818777
multi@@	O	-1	2818777
system	O	-1	2818777
clinical	O	-1	2818777
pat@@	O	-1	2818777
ter@@	O	-1	2818777
n	O	-1	2818777
pre@@	O	-1	2818777
ce@@	O	-1	2818777
des	O	-1	2818777
the	O	-1	2818777
man@@	O	-1	2818777
if@@	O	-1	2818777
est@@	O	-1	2818777
ations	O	-1	2818777
of	O	-1	2818777
hepatic	B-Disease	D056486	2818777
injury	I-Disease	-1	2818777
.	O	-1	2818777
The	O	-1	2818777
hemat@@	O	-1	2818777
olog@@	O	-1	2818777
ic@@	O	-1	2818777
,	O	-1	2818777
bio@@	O	-1	2818777
chemical	O	-1	2818777
and	O	-1	2818777
path@@	O	-1	2818777
ologic	O	-1	2818777
feat@@	O	-1	2818777
ures	O	-1	2818777
indicate	O	-1	2818777
a	O	-1	2818777
mi@@	O	-1	2818777
x@@	O	-1	2818777
ed	O	-1	2818777
hepat@@	B-Disease	D056486	2818777
oc@@	I-Disease	-1	2818777
ell@@	I-Disease	-1	2818777
ular	I-Disease	-1	2818777
damage	I-Disease	-1	2818777
due	O	-1	2818777
to	O	-1	2818777
drug	B-Disease	D004342	2818777
hyper@@	I-Disease	-1	2818777
sensitivity	I-Disease	-1	2818777
.	O	-1	2818777
In	O	-1	2818777
a	O	-1	2818777
patient	O	-1	2818777
receiving	O	-1	2818777
pheny@@	B-Chemical	D010672	2818777
to@@	I-Chemical	-1	2818777
in	I-Chemical	-1	2818777
who	O	-1	2818777
pres@@	O	-1	2818777
ents	O	-1	2818777
a	O	-1	2818777
vi@@	O	-1	2818777
r@@	O	-1	2818777
al@@	O	-1	2818777
-@@	O	-1	2818777
like	O	-1	2818777
ill@@	O	-1	2818777
n@@	O	-1	2818777
es@@	O	-1	2818777
s,	O	-1	2818777
early	O	-1	2818777
reco@@	O	-1	2818777
gn@@	O	-1	2818777
ition	O	-1	2818777
and	O	-1	2818777
discontinu@@	O	-1	2818777
ation	O	-1	2818777
of	O	-1	2818777
the	O	-1	2818777
drug	O	-1	2818777
are	O	-1	2818777
m@@	O	-1	2818777
and@@	O	-1	2818777
at@@	O	-1	2818777
or@@	O	-1	2818777
y.	O	-1	2818777

Treat@@	O	-1	2884595
ment	O	-1	2884595
of	O	-1	2884595
le@@	O	-1	2884595
th@@	O	-1	2884595
al	O	-1	2884595
per@@	B-Chemical	D010567	2884595
t@@	I-Chemical	-1	2884595
us@@	I-Chemical	-1	2884595
sis	I-Chemical	-1	2884595
vac@@	I-Chemical	-1	2884595
c@@	I-Chemical	-1	2884595
ine	I-Chemical	-1	2884595
reaction	O	-1	2884595
with	O	-1	2884595
hist@@	B-Chemical	D006632	2884595
amine	I-Chemical	-1	2884595
H@@	O	-1	2884595
1	O	-1	2884595
antagonist@@	O	-1	2884595
s.	O	-1	2884595
We	O	-1	2884595
studied	O	-1	2884595
mor@@	O	-1	2884595
t@@	O	-1	2884595
ality	O	-1	2884595
after	O	-1	2884595
per@@	B-Disease	D014917	2884595
t@@	I-Disease	-1	2884595
us@@	I-Disease	-1	2884595
sis	I-Disease	-1	2884595
immun@@	O	-1	2884595
ization	O	-1	2884595
in	O	-1	2884595
the	O	-1	2884595
mou@@	O	-1	2884595
se.	O	-1	2884595
W@@	O	-1	2884595
i@@	O	-1	2884595
th@@	O	-1	2884595
out	O	-1	2884595
treatment,	O	-1	2884595
7@@	O	-1	2884595
3	O	-1	2884595
of	O	-1	2884595
9@@	O	-1	2884595
2	O	-1	2884595
animals	O	-1	2884595
(@@	O	-1	2884595
80@@	O	-1	2884595
%)	O	-1	2884595
di@@	O	-1	2884595
ed	O	-1	2884595
after	O	-1	2884595
injection	O	-1	2884595
of	O	-1	2884595
bo@@	O	-1	2884595
v@@	O	-1	2884595
ine	O	-1	2884595
serum	O	-1	2884595
al@@	O	-1	2884595
b@@	O	-1	2884595
um@@	O	-1	2884595
in	O	-1	2884595
(B@@	O	-1	2884595
S@@	O	-1	2884595
A@@	O	-1	2884595
)	O	-1	2884595
on	O	-1	2884595
day	O	-1	2884595
+@@	O	-1	2884595
7	O	-1	2884595
of	O	-1	2884595
per@@	B-Disease	D014917	2884595
t@@	I-Disease	-1	2884595
us@@	I-Disease	-1	2884595
sis	I-Disease	-1	2884595
immun@@	O	-1	2884595
iz@@	O	-1	2884595
ation.	O	-1	2884595
After	O	-1	2884595
pretreatment	O	-1	2884595
with	O	-1	2884595
3	O	-1	2884595
mg	O	-1	2884595
of	O	-1	2884595
cy@@	B-Chemical	D003533	2884595
pro@@	I-Chemical	-1	2884595
he@@	I-Chemical	-1	2884595
pt@@	I-Chemical	-1	2884595
ad@@	I-Chemical	-1	2884595
ine	I-Chemical	-1	2884595
,	O	-1	2884595
2	O	-1	2884595
mg	O	-1	2884595
mi@@	B-Chemical	D008803	2884595
an@@	I-Chemical	-1	2884595
ser@@	I-Chemical	-1	2884595
in	I-Chemical	-1	2884595
,	O	-1	2884595
or	O	-1	2884595
2	O	-1	2884595
mg	O	-1	2884595
chlor@@	B-Chemical	D002744	2884595
phen@@	I-Chemical	-1	2884595
ir@@	I-Chemical	-1	2884595
amine	I-Chemical	-1	2884595
,	O	-1	2884595
only	O	-1	2884595
5	O	-1	2884595
of	O	-1	2884595
10@@	O	-1	2884595
5	O	-1	2884595
animals	O	-1	2884595
(5@@	O	-1	2884595
%)	O	-1	2884595
di@@	O	-1	2884595
ed	O	-1	2884595
after	O	-1	2884595
receiving	O	-1	2884595
B@@	O	-1	2884595
S@@	O	-1	2884595
A	O	-1	2884595
on	O	-1	2884595
day	O	-1	2884595
+@@	O	-1	2884595
7	O	-1	2884595
(p	O	-1	2884595
less	O	-1	2884595
than	O	-1	2884595
0.00@@	O	-1	2884595
1).	O	-1	2884595
B@@	O	-1	2884595
loc@@	O	-1	2884595
k@@	O	-1	2884595
ade	O	-1	2884595
of	O	-1	2884595
hist@@	B-Chemical	D006632	2884595
amine	I-Chemical	-1	2884595
H@@	O	-1	2884595
1	O	-1	2884595
receptors	O	-1	2884595
may	O	-1	2884595
re@@	O	-1	2884595
duce	O	-1	2884595
mor@@	O	-1	2884595
t@@	O	-1	2884595
ality	O	-1	2884595
in	O	-1	2884595
per@@	B-Disease	D014917	2884595
t@@	I-Disease	-1	2884595
us@@	I-Disease	-1	2884595
sis	I-Disease	-1	2884595
immun@@	O	-1	2884595
iz@@	O	-1	2884595
ation@@	O	-1	2884595
-induced	O	-1	2884595
encephalo@@	B-Disease	D001927	2884595
pathy	I-Disease	-1	2884595
in	O	-1	2884595
mice.	O	-1	2884595

S@@	O	-1	2904523
up@@	O	-1	2904523
por@@	O	-1	2904523
t	O	-1	2904523
for	O	-1	2904523
adren@@	B-Chemical	D004837	2904523
aline	I-Chemical	-1	2904523
-	O	-1	2904523
hypertension	B-Disease	D006973	2904523
hypo@@	O	-1	2904523
the@@	O	-1	2904523
si@@	O	-1	2904523
s:	O	-1	2904523
1@@	O	-1	2904523
8	O	-1	2904523
h@@	O	-1	2904523
our	O	-1	2904523
press@@	O	-1	2904523
or	O	-1	2904523
effect	O	-1	2904523
after	O	-1	2904523
6	O	-1	2904523
hours	O	-1	2904523
adren@@	B-Chemical	D004837	2904523
aline	I-Chemical	-1	2904523
infu@@	O	-1	2904523
sion.	O	-1	2904523
In	O	-1	2904523
a	O	-1	2904523
dou@@	O	-1	2904523
ble	O	-1	2904523
bl@@	O	-1	2904523
ind@@	O	-1	2904523
,	O	-1	2904523
cros@@	O	-1	2904523
s@@	O	-1	2904523
over	O	-1	2904523
study	O	-1	2904523
6	O	-1	2904523
h	O	-1	2904523
infu@@	O	-1	2904523
sions	O	-1	2904523
of	O	-1	2904523
adren@@	B-Chemical	D004837	2904523
aline	I-Chemical	-1	2904523
(1@@	O	-1	2904523
5	O	-1	2904523
n@@	O	-1	2904523
g/@@	O	-1	2904523
k@@	O	-1	2904523
g/@@	O	-1	2904523
min@@	O	-1	2904523
;	O	-1	2904523
1	O	-1	2904523
n@@	O	-1	2904523
g	O	-1	2904523
=	O	-1	2904523
5.@@	O	-1	2904523
4@@	O	-1	2904523
5@@	O	-1	2904523
8	O	-1	2904523
p@@	O	-1	2904523
mol@@	O	-1	2904523
),	O	-1	2904523
nor@@	B-Chemical	D009638	2904523
adren@@	I-Chemical	-1	2904523
aline	I-Chemical	-1	2904523
(@@	O	-1	2904523
30	O	-1	2904523
n@@	O	-1	2904523
g/@@	O	-1	2904523
k@@	O	-1	2904523
g/@@	O	-1	2904523
min@@	O	-1	2904523
;	O	-1	2904523
1	O	-1	2904523
n@@	O	-1	2904523
g	O	-1	2904523
=	O	-1	2904523
5.@@	O	-1	2904523
9@@	O	-1	2904523
11	O	-1	2904523
p@@	O	-1	2904523
mol@@	O	-1	2904523
),	O	-1	2904523
and	O	-1	2904523
a	O	-1	2904523
5%	O	-1	2904523
de@@	B-Chemical	D005947	2904523
x@@	I-Chemical	-1	2904523
tro@@	I-Chemical	-1	2904523
se	I-Chemical	-1	2904523
sol@@	O	-1	2904523
u@@	O	-1	2904523
tion	O	-1	2904523
(@@	O	-1	2904523
5.@@	O	-1	2904523
4	O	-1	2904523
ml@@	O	-1	2904523
/@@	O	-1	2904523
h@@	O	-1	2904523
),	O	-1	2904523
were	O	-1	2904523
given	O	-1	2904523
to	O	-1	2904523
ten	O	-1	2904523
healthy	O	-1	2904523
vol@@	O	-1	2904523
un@@	O	-1	2904523
te@@	O	-1	2904523
ers	O	-1	2904523
in	O	-1	2904523
ran@@	O	-1	2904523
do@@	O	-1	2904523
m	O	-1	2904523
or@@	O	-1	2904523
der	O	-1	2904523
2	O	-1	2904523
weeks	O	-1	2904523
ap@@	O	-1	2904523
ar@@	O	-1	2904523
t.	O	-1	2904523
B@@	O	-1	2904523
y	O	-1	2904523
me@@	O	-1	2904523
ans	O	-1	2904523
of	O	-1	2904523
intra@@	O	-1	2904523
-@@	O	-1	2904523
arterial	O	-1	2904523
am@@	O	-1	2904523
b@@	O	-1	2904523
ul@@	O	-1	2904523
atory	O	-1	2904523
monit@@	O	-1	2904523
or@@	O	-1	2904523
ing	O	-1	2904523
the	O	-1	2904523
haem@@	O	-1	2904523
o@@	O	-1	2904523
dynam@@	O	-1	2904523
ic	O	-1	2904523
effects	O	-1	2904523
were	O	-1	2904523
followed	O	-1	2904523
for	O	-1	2904523
1@@	O	-1	2904523
8	O	-1	2904523
h	O	-1	2904523
after	O	-1	2904523
the	O	-1	2904523
infu@@	O	-1	2904523
sions	O	-1	2904523
were	O	-1	2904523
sto@@	O	-1	2904523
pp@@	O	-1	2904523
ed.	O	-1	2904523
Ad@@	B-Chemical	D004837	2904523
ren@@	I-Chemical	-1	2904523
aline	I-Chemical	-1	2904523
,	O	-1	2904523
but	O	-1	2904523
not	O	-1	2904523
nor@@	B-Chemical	D009638	2904523
adren@@	I-Chemical	-1	2904523
aline	I-Chemical	-1	2904523
,	O	-1	2904523
caused	O	-1	2904523
a	O	-1	2904523
del@@	O	-1	2904523
ayed	O	-1	2904523
and	O	-1	2904523
prot@@	O	-1	2904523
rac@@	O	-1	2904523
ted	O	-1	2904523
press@@	O	-1	2904523
or	O	-1	2904523
effect@@	O	-1	2904523
.	O	-1	2904523
O@@	O	-1	2904523
ver	O	-1	2904523
the	O	-1	2904523
total	O	-1	2904523
post@@	O	-1	2904523
infusion	O	-1	2904523
period	O	-1	2904523
systolic	O	-1	2904523
and	O	-1	2904523
di@@	O	-1	2904523
ast@@	O	-1	2904523
olic	O	-1	2904523
arterial	O	-1	2904523
pressure	O	-1	2904523
were	O	-1	2904523
6	O	-1	2904523
(S@@	O	-1	2904523
E@@	O	-1	2904523
M	O	-1	2904523
2@@	O	-1	2904523
)@@	O	-1	2904523
%	O	-1	2904523
and	O	-1	2904523
7	O	-1	2904523
(2@@	O	-1	2904523
)@@	O	-1	2904523
%,	O	-1	2904523
respectivel@@	O	-1	2904523
y,	O	-1	2904523
higher	O	-1	2904523
than	O	-1	2904523
after	O	-1	2904523
de@@	B-Chemical	D005947	2904523
x@@	I-Chemical	-1	2904523
tro@@	I-Chemical	-1	2904523
se	I-Chemical	-1	2904523
infusion	O	-1	2904523
(A@@	O	-1	2904523
NO@@	O	-1	2904523
V@@	O	-1	2904523
A@@	O	-1	2904523
,	O	-1	2904523
p	O	-1	2904523
less	O	-1	2904523
than	O	-1	2904523
0.00@@	O	-1	2904523
1).	O	-1	2904523
Th@@	O	-1	2904523
us,	O	-1	2904523
"@@	O	-1	2904523
stres@@	O	-1	2904523
s@@	O	-1	2904523
"	O	-1	2904523
levels	O	-1	2904523
of	O	-1	2904523
adren@@	B-Chemical	D004837	2904523
aline	I-Chemical	-1	2904523
(2@@	O	-1	2904523
30	O	-1	2904523
p@@	O	-1	2904523
g/@@	O	-1	2904523
ml@@	O	-1	2904523
)	O	-1	2904523
for	O	-1	2904523
6	O	-1	2904523
h	O	-1	2904523
cause	O	-1	2904523
a	O	-1	2904523
del@@	O	-1	2904523
ayed	O	-1	2904523
and	O	-1	2904523
prot@@	O	-1	2904523
rac@@	O	-1	2904523
ted	O	-1	2904523
press@@	O	-1	2904523
or	O	-1	2904523
effect@@	O	-1	2904523
.	O	-1	2904523
These	O	-1	2904523
findings	O	-1	2904523
are	O	-1	2904523
st@@	O	-1	2904523
ron@@	O	-1	2904523
g	O	-1	2904523
suppor@@	O	-1	2904523
t	O	-1	2904523
for	O	-1	2904523
the	O	-1	2904523
adren@@	B-Chemical	D004837	2904523
aline	I-Chemical	-1	2904523
-	O	-1	2904523
hypertension	B-Disease	D006973	2904523
hypo@@	O	-1	2904523
thesis	O	-1	2904523
in	O	-1	2904523
man@@	O	-1	2904523
.	O	-1	2904523

Eff@@	O	-1	2907577
ect	O	-1	2907577
of	O	-1	2907577
al@@	B-Chemical	-1	2907577
k@@	I-Chemical	-1	2907577
yl@@	I-Chemical	-1	2907577
x@@	I-Chemical	-1	2907577
an@@	I-Chemical	-1	2907577
th@@	I-Chemical	-1	2907577
in@@	I-Chemical	-1	2907577
es	I-Chemical	-1	2907577
on	O	-1	2907577
g@@	B-Chemical	D005839	2907577
ent@@	I-Chemical	-1	2907577
am@@	I-Chemical	-1	2907577
icin	I-Chemical	-1	2907577
-induced	O	-1	2907577
acute	B-Disease	D058186	2907577
renal	I-Disease	-1	2907577
failure	I-Disease	-1	2907577
in	O	-1	2907577
the	O	-1	2907577
rat@@	O	-1	2907577
.	O	-1	2907577
Ad@@	B-Chemical	D000241	2907577
en@@	I-Chemical	-1	2907577
os@@	I-Chemical	-1	2907577
ine	I-Chemical	-1	2907577
antagonist@@	O	-1	2907577
s	O	-1	2907577
have	O	-1	2907577
been	O	-1	2907577
previously	O	-1	2907577
shown	O	-1	2907577
to	O	-1	2907577
be	O	-1	2907577
of	O	-1	2907577
ben@@	O	-1	2907577
e@@	O	-1	2907577
fi@@	O	-1	2907577
t	O	-1	2907577
in	O	-1	2907577
some	O	-1	2907577
is@@	B-Disease	D007511	2907577
ch@@	I-Disease	-1	2907577
a@@	I-Disease	-1	2907577
em@@	I-Disease	-1	2907577
ic	I-Disease	-1	2907577
and	O	-1	2907577
nephro@@	B-Disease	D007674	2907577
toxic	I-Disease	-1	2907577
models	O	-1	2907577
of	O	-1	2907577
acute	B-Disease	D058186	2907577
renal	I-Disease	-1	2907577
failure	I-Disease	-1	2907577
(	O	-1	2907577
A@@	B-Disease	D058186	2907577
R@@	I-Disease	-1	2907577
F	I-Disease	-1	2907577
).	O	-1	2907577
In	O	-1	2907577
the	O	-1	2907577
present	O	-1	2907577
study,	O	-1	2907577
the	O	-1	2907577
effects	O	-1	2907577
of	O	-1	2907577
three	O	-1	2907577
al@@	B-Chemical	-1	2907577
k@@	I-Chemical	-1	2907577
yl@@	I-Chemical	-1	2907577
x@@	I-Chemical	-1	2907577
an@@	I-Chemical	-1	2907577
th@@	I-Chemical	-1	2907577
in@@	I-Chemical	-1	2907577
es	I-Chemical	-1	2907577
with	O	-1	2907577
different	O	-1	2907577
poten@@	O	-1	2907577
ci@@	O	-1	2907577
es	O	-1	2907577
as	O	-1	2907577
aden@@	B-Chemical	D000241	2907577
os@@	I-Chemical	-1	2907577
ine	I-Chemical	-1	2907577
antagonist@@	O	-1	2907577
s	O	-1	2907577
8@@	B-Chemical	C028322	2907577
-@@	I-Chemical	-1	2907577
phenyl@@	I-Chemical	-1	2907577
the@@	I-Chemical	-1	2907577
oph@@	I-Chemical	-1	2907577
yl@@	I-Chemical	-1	2907577
line	I-Chemical	-1	2907577
,	O	-1	2907577
the@@	B-Chemical	D013806	2907577
oph@@	I-Chemical	-1	2907577
yl@@	I-Chemical	-1	2907577
line	I-Chemical	-1	2907577
and	O	-1	2907577
en@@	B-Chemical	C034347	2907577
prof@@	I-Chemical	-1	2907577
yl@@	I-Chemical	-1	2907577
line	I-Chemical	-1	2907577
,	O	-1	2907577
were	O	-1	2907577
examined	O	-1	2907577
in	O	-1	2907577
rats	O	-1	2907577
develop@@	O	-1	2907577
ing	O	-1	2907577
acute	B-Disease	D058186	2907577
renal	I-Disease	-1	2907577
failure	I-Disease	-1	2907577
after	O	-1	2907577
4	O	-1	2907577
daily	O	-1	2907577
injec@@	O	-1	2907577
tions	O	-1	2907577
of	O	-1	2907577
g@@	B-Chemical	D005839	2907577
ent@@	I-Chemical	-1	2907577
am@@	I-Chemical	-1	2907577
icin	I-Chemical	-1	2907577
(2@@	O	-1	2907577
00	O	-1	2907577
mg	O	-1	2907577
kg@@	O	-1	2907577
-1@@	O	-1	2907577
).	O	-1	2907577
R@@	O	-1	2907577
en@@	O	-1	2907577
al	O	-1	2907577
function	O	-1	2907577
was	O	-1	2907577
assessed	O	-1	2907577
by	O	-1	2907577
bio@@	O	-1	2907577
chemical	O	-1	2907577
(@@	O	-1	2907577
plasma	O	-1	2907577
ure@@	B-Chemical	D014508	2907577
a	I-Chemical	-1	2907577
and	O	-1	2907577
creatinine	B-Chemical	D003404	2907577
),	O	-1	2907577
functional	O	-1	2907577
(@@	O	-1	2907577
urine	O	-1	2907577
analysis	O	-1	2907577
and	O	-1	2907577
[@@	O	-1	2907577
3@@	O	-1	2907577
H@@	O	-1	2907577
]@@	O	-1	2907577
in@@	O	-1	2907577
ul@@	O	-1	2907577
in	O	-1	2907577
and	O	-1	2907577
[@@	O	-1	2907577
14@@	O	-1	2907577
C@@	O	-1	2907577
]	O	-1	2907577
p@@	B-Chemical	D010130	2907577
-@@	I-Chemical	-1	2907577
amino@@	I-Chemical	-1	2907577
hi@@	I-Chemical	-1	2907577
pp@@	I-Chemical	-1	2907577
ur@@	I-Chemical	-1	2907577
ic	I-Chemical	-1	2907577
acid	I-Chemical	-1	2907577
clear@@	O	-1	2907577
anc@@	O	-1	2907577
es@@	O	-1	2907577
)	O	-1	2907577
and	O	-1	2907577
morph@@	O	-1	2907577
ological	O	-1	2907577
(@@	O	-1	2907577
de@@	O	-1	2907577
g@@	O	-1	2907577
ree	O	-1	2907577
of	O	-1	2907577
necro@@	B-Disease	D009336	2907577
sis	I-Disease	-1	2907577
)	O	-1	2907577
indic@@	O	-1	2907577
es.	O	-1	2907577
The	O	-1	2907577
various	O	-1	2907577
drug	O	-1	2907577
treat@@	O	-1	2907577
ments	O	-1	2907577
produced	O	-1	2907577
impro@@	O	-1	2907577
ve@@	O	-1	2907577
ments	O	-1	2907577
in	O	-1	2907577
so@@	O	-1	2907577
me,	O	-1	2907577
but	O	-1	2907577
not	O	-1	2907577
all@@	O	-1	2907577
,	O	-1	2907577
meas@@	O	-1	2907577
ure@@	O	-1	2907577
ments	O	-1	2907577
of	O	-1	2907577
renal	O	-1	2907577
func@@	O	-1	2907577
tion.	O	-1	2907577
However,	O	-1	2907577
any	O	-1	2907577
impro@@	O	-1	2907577
vement	O	-1	2907577
produced	O	-1	2907577
by	O	-1	2907577
drug	O	-1	2907577
treatment	O	-1	2907577
was	O	-1	2907577
larg@@	O	-1	2907577
ely	O	-1	2907577
a	O	-1	2907577
result	O	-1	2907577
of	O	-1	2907577
a	O	-1	2907577
ben@@	O	-1	2907577
e@@	O	-1	2907577
fic@@	O	-1	2907577
ial	O	-1	2907577
effect	O	-1	2907577
ex@@	O	-1	2907577
er@@	O	-1	2907577
ted	O	-1	2907577
by	O	-1	2907577
its	O	-1	2907577
ve@@	O	-1	2907577
h@@	O	-1	2907577
ic@@	O	-1	2907577
le	O	-1	2907577
(	O	-1	2907577
poly@@	B-Chemical	D011092	2907577
eth@@	I-Chemical	-1	2907577
yl@@	I-Chemical	-1	2907577
ene	I-Chemical	-1	2907577
gly@@	I-Chemical	-1	2907577
co@@	I-Chemical	-1	2907577
l	I-Chemical	-1	2907577
and	O	-1	2907577
Na@@	B-Chemical	D012972	2907577
O@@	I-Chemical	-1	2907577
H	I-Chemical	-1	2907577
).	O	-1	2907577
The	O	-1	2907577
l@@	O	-1	2907577
ac@@	O	-1	2907577
k	O	-1	2907577
of	O	-1	2907577
any	O	-1	2907577
consist@@	O	-1	2907577
ent	O	-1	2907577
protective	O	-1	2907577
effect	O	-1	2907577
not@@	O	-1	2907577
ed	O	-1	2907577
with	O	-1	2907577
the	O	-1	2907577
al@@	B-Chemical	-1	2907577
k@@	I-Chemical	-1	2907577
yl@@	I-Chemical	-1	2907577
x@@	I-Chemical	-1	2907577
an@@	I-Chemical	-1	2907577
th@@	I-Chemical	-1	2907577
in@@	I-Chemical	-1	2907577
es	I-Chemical	-1	2907577
tested	O	-1	2907577
in	O	-1	2907577
the	O	-1	2907577
present	O	-1	2907577
study	O	-1	2907577
indic@@	O	-1	2907577
ates	O	-1	2907577
that	O	-1	2907577
aden@@	B-Chemical	D000241	2907577
os@@	I-Chemical	-1	2907577
ine	I-Chemical	-1	2907577
pl@@	O	-1	2907577
ays	O	-1	2907577
lit@@	O	-1	2907577
t@@	O	-1	2907577
le@@	O	-1	2907577
,	O	-1	2907577
if	O	-1	2907577
an@@	O	-1	2907577
y,	O	-1	2907577
path@@	O	-1	2907577
oph@@	O	-1	2907577
ysi@@	O	-1	2907577
ological	O	-1	2907577
role	O	-1	2907577
in	O	-1	2907577
g@@	B-Chemical	D005839	2907577
ent@@	I-Chemical	-1	2907577
am@@	I-Chemical	-1	2907577
icin	I-Chemical	-1	2907577
-induced	O	-1	2907577
A@@	B-Disease	D058186	2907577
R@@	I-Disease	-1	2907577
F	I-Disease	-1	2907577
.	O	-1	2907577

Ad@@	O	-1	2931989
verse	O	-1	2931989
oc@@	O	-1	2931989
ular	O	-1	2931989
reactions	O	-1	2931989
possib@@	O	-1	2931989
ly	O	-1	2931989
associated	O	-1	2931989
with	O	-1	2931989
is@@	B-Chemical	D015474	2931989
ot@@	I-Chemical	-1	2931989
ret@@	I-Chemical	-1	2931989
ino@@	I-Chemical	-1	2931989
in	I-Chemical	-1	2931989
.	O	-1	2931989
A	O	-1	2931989
total	O	-1	2931989
of	O	-1	2931989
2@@	O	-1	2931989
6@@	O	-1	2931989
1	O	-1	2931989
adverse	O	-1	2931989
oc@@	O	-1	2931989
ular	O	-1	2931989
reactions	O	-1	2931989
occurred	O	-1	2931989
in	O	-1	2931989
2@@	O	-1	2931989
3@@	O	-1	2931989
7	O	-1	2931989
patients	O	-1	2931989
who	O	-1	2931989
received	O	-1	2931989
is@@	B-Chemical	D015474	2931989
ot@@	I-Chemical	-1	2931989
ret@@	I-Chemical	-1	2931989
ino@@	I-Chemical	-1	2931989
in	I-Chemical	-1	2931989
,	O	-1	2931989
a	O	-1	2931989
common@@	O	-1	2931989
ly	O	-1	2931989
used	O	-1	2931989
drug	O	-1	2931989
in	O	-1	2931989
the	O	-1	2931989
treatment	O	-1	2931989
of	O	-1	2931989
severe	O	-1	2931989
cys@@	O	-1	2931989
tic	O	-1	2931989
ac@@	B-Disease	D000152	2931989
n@@	I-Disease	-1	2931989
e	I-Disease	-1	2931989
.	O	-1	2931989
B@@	B-Disease	D003231	2931989
le@@	I-Disease	-1	2931989
pha@@	I-Disease	-1	2931989
ro@@	I-Disease	-1	2931989
con@@	I-Disease	-1	2931989
j@@	I-Disease	-1	2931989
unc@@	I-Disease	-1	2931989
ti@@	I-Disease	-1	2931989
vi@@	I-Disease	-1	2931989
tis	I-Disease	-1	2931989
,	O	-1	2931989
subj@@	O	-1	2931989
ective	O	-1	2931989
com@@	O	-1	2931989
pl@@	O	-1	2931989
a@@	O	-1	2931989
int@@	O	-1	2931989
s	O	-1	2931989
of	O	-1	2931989
d@@	B-Disease	D014985	2931989
r@@	I-Disease	-1	2931989
y	I-Disease	-1	2931989
e@@	I-Disease	-1	2931989
y@@	I-Disease	-1	2931989
es	I-Disease	-1	2931989
,	O	-1	2931989
bl@@	B-Disease	D014786	2931989
ur@@	I-Disease	-1	2931989
red	I-Disease	-1	2931989
vi@@	I-Disease	-1	2931989
sion	I-Disease	-1	2931989
,	O	-1	2931989
cont@@	O	-1	2931989
ac@@	O	-1	2931989
t	O	-1	2931989
l@@	O	-1	2931989
en@@	O	-1	2931989
s	O	-1	2931989
int@@	O	-1	2931989
oler@@	O	-1	2931989
ance@@	O	-1	2931989
,	O	-1	2931989
and	O	-1	2931989
ph@@	B-Disease	D010787	2931989
ot@@	I-Disease	-1	2931989
o@@	I-Disease	-1	2931989
der@@	I-Disease	-1	2931989
m@@	I-Disease	-1	2931989
ati@@	I-Disease	-1	2931989
tis	I-Disease	-1	2931989
are	O	-1	2931989
reversible	O	-1	2931989
side	O	-1	2931989
effects.	O	-1	2931989
M@@	O	-1	2931989
or@@	O	-1	2931989
e	O	-1	2931989
seri@@	O	-1	2931989
ous	O	-1	2931989
oc@@	O	-1	2931989
ular	O	-1	2931989
adverse	O	-1	2931989
reactions	O	-1	2931989
includ@@	O	-1	2931989
e	O	-1	2931989
pap@@	B-Disease	D010211	2931989
il@@	I-Disease	-1	2931989
le@@	I-Disease	-1	2931989
de@@	I-Disease	-1	2931989
ma	I-Disease	-1	2931989
,	O	-1	2931989
p@@	B-Disease	D011559	2931989
se@@	I-Disease	-1	2931989
ud@@	I-Disease	-1	2931989
ot@@	I-Disease	-1	2931989
um@@	I-Disease	-1	2931989
or	I-Disease	-1	2931989
ce@@	I-Disease	-1	2931989
reb@@	I-Disease	-1	2931989
r@@	I-Disease	-1	2931989
i	I-Disease	-1	2931989
,	O	-1	2931989
and	O	-1	2931989
wh@@	O	-1	2931989
ite	O	-1	2931989
or	O	-1	2931989
gra@@	O	-1	2931989
y	O	-1	2931989
su@@	O	-1	2931989
be@@	O	-1	2931989
pi@@	O	-1	2931989
thelial	O	-1	2931989
cor@@	B-Disease	D003318	2931989
ne@@	I-Disease	-1	2931989
al	I-Disease	-1	2931989
op@@	I-Disease	-1	2931989
ac@@	I-Disease	-1	2931989
ities	I-Disease	-1	2931989
;	O	-1	2931989
all	O	-1	2931989
of	O	-1	2931989
these	O	-1	2931989
are	O	-1	2931989
reversible	O	-1	2931989
if	O	-1	2931989
the	O	-1	2931989
drug	O	-1	2931989
is	O	-1	2931989
discontinu@@	O	-1	2931989
ed.	O	-1	2931989
Re@@	O	-1	2931989
por@@	O	-1	2931989
ted	O	-1	2931989
cases	O	-1	2931989
of	O	-1	2931989
decreased	O	-1	2931989
d@@	O	-1	2931989
ar@@	O	-1	2931989
k	O	-1	2931989
ad@@	O	-1	2931989
ap@@	O	-1	2931989
t@@	O	-1	2931989
ation	O	-1	2931989
are	O	-1	2931989
under	O	-1	2931989
investig@@	O	-1	2931989
ation.	O	-1	2931989
I@@	B-Chemical	D015474	2931989
s@@	I-Chemical	-1	2931989
ot@@	I-Chemical	-1	2931989
ret@@	I-Chemical	-1	2931989
ino@@	I-Chemical	-1	2931989
in	I-Chemical	-1	2931989
is	O	-1	2931989
contra@@	O	-1	2931989
indic@@	O	-1	2931989
ated	O	-1	2931989
in	O	-1	2931989
pregn@@	O	-1	2931989
anc@@	O	-1	2931989
y	O	-1	2931989
because	O	-1	2931989
of	O	-1	2931989
the	O	-1	2931989
man@@	O	-1	2931989
y	O	-1	2931989
reported	O	-1	2931989
con@@	B-Disease	D000013	2931989
gen@@	I-Disease	-1	2931989
it@@	I-Disease	-1	2931989
al	I-Disease	-1	2931989
abnormal@@	I-Disease	-1	2931989
ities	I-Disease	-1	2931989
after	O	-1	2931989
mat@@	O	-1	2931989
er@@	O	-1	2931989
n@@	O	-1	2931989
al	O	-1	2931989
use	O	-1	2931989
(@@	O	-1	2931989
including	O	-1	2931989
micro@@	B-Disease	D008850	2931989
ph@@	I-Disease	-1	2931989
thal@@	I-Disease	-1	2931989
mo@@	I-Disease	-1	2931989
s	I-Disease	-1	2931989
,	O	-1	2931989
or@@	O	-1	2931989
b@@	O	-1	2931989
it@@	O	-1	2931989
al	O	-1	2931989
hyper@@	B-Disease	D006972	2931989
te@@	I-Disease	-1	2931989
lor@@	I-Disease	-1	2931989
ism	I-Disease	-1	2931989
,	O	-1	2931989
and	O	-1	2931989
op@@	B-Disease	C563492	2931989
tic	I-Disease	-1	2931989
nerve	I-Disease	-1	2931989
hypo@@	I-Disease	-1	2931989
pl@@	I-Disease	-1	2931989
a@@	I-Disease	-1	2931989
sia	I-Disease	-1	2931989
).	O	-1	2931989

Pro@@	B-Chemical	D017265	2933998
cat@@	I-Chemical	-1	2933998
er@@	I-Chemical	-1	2933998
ol	I-Chemical	-1	2933998
and	O	-1	2933998
ter@@	B-Chemical	D013726	2933998
but@@	I-Chemical	-1	2933998
aline	I-Chemical	-1	2933998
in	O	-1	2933998
b@@	B-Disease	D001249	2933998
ron@@	I-Disease	-1	2933998
ch@@	I-Disease	-1	2933998
ial	I-Disease	-1	2933998
as@@	I-Disease	-1	2933998
th@@	I-Disease	-1	2933998
ma	I-Disease	-1	2933998
.	O	-1	2933998
A	O	-1	2933998
double-bl@@	O	-1	2933998
ind@@	O	-1	2933998
,	O	-1	2933998
placebo@@	O	-1	2933998
-@@	O	-1	2933998
control@@	O	-1	2933998
le@@	O	-1	2933998
d,	O	-1	2933998
cros@@	O	-1	2933998
s-@@	O	-1	2933998
over	O	-1	2933998
study.	O	-1	2933998
Pro@@	B-Chemical	D017265	2933998
cat@@	I-Chemical	-1	2933998
er@@	I-Chemical	-1	2933998
ol	I-Chemical	-1	2933998
,	O	-1	2933998
a	O	-1	2933998
new	O	-1	2933998
beta-@@	O	-1	2933998
2	O	-1	2933998
adren@@	O	-1	2933998
oc@@	O	-1	2933998
e@@	O	-1	2933998
pt@@	O	-1	2933998
or	O	-1	2933998
stimul@@	O	-1	2933998
ant@@	O	-1	2933998
,	O	-1	2933998
was	O	-1	2933998
studied	O	-1	2933998
in	O	-1	2933998
a	O	-1	2933998
double-bl@@	O	-1	2933998
ind@@	O	-1	2933998
,	O	-1	2933998
placebo@@	O	-1	2933998
-@@	O	-1	2933998
control@@	O	-1	2933998
le@@	O	-1	2933998
d,	O	-1	2933998
cros@@	O	-1	2933998
s-@@	O	-1	2933998
over	O	-1	2933998
trial	O	-1	2933998
in	O	-1	2933998
patients	O	-1	2933998
with	O	-1	2933998
b@@	B-Disease	D001249	2933998
ron@@	I-Disease	-1	2933998
ch@@	I-Disease	-1	2933998
ial	I-Disease	-1	2933998
as@@	I-Disease	-1	2933998
th@@	I-Disease	-1	2933998
ma	I-Disease	-1	2933998
.	O	-1	2933998
O@@	O	-1	2933998
ral	O	-1	2933998
pro@@	B-Chemical	D017265	2933998
cat@@	I-Chemical	-1	2933998
er@@	I-Chemical	-1	2933998
ol	I-Chemical	-1	2933998
50	O	-1	2933998
microgram@@	O	-1	2933998
s	O	-1	2933998
b@@	O	-1	2933998
.@@	O	-1	2933998
d@@	O	-1	2933998
.,	O	-1	2933998
pro@@	B-Chemical	D017265	2933998
cat@@	I-Chemical	-1	2933998
er@@	I-Chemical	-1	2933998
ol	I-Chemical	-1	2933998
100	O	-1	2933998
microgram@@	O	-1	2933998
s	O	-1	2933998
b@@	O	-1	2933998
.@@	O	-1	2933998
d@@	O	-1	2933998
.,	O	-1	2933998
and	O	-1	2933998
ter@@	B-Chemical	D013726	2933998
but@@	I-Chemical	-1	2933998
aline	I-Chemical	-1	2933998
5	O	-1	2933998
mg	O	-1	2933998
t@@	O	-1	2933998
.@@	O	-1	2933998
i.@@	O	-1	2933998
d@@	O	-1	2933998
.,	O	-1	2933998
were	O	-1	2933998
compared	O	-1	2933998
when	O	-1	2933998
given	O	-1	2933998
random@@	O	-1	2933998
ly	O	-1	2933998
in	O	-1	2933998
1-@@	O	-1	2933998
week	O	-1	2933998
treatment	O	-1	2933998
perio@@	O	-1	2933998
d@@	O	-1	2933998
s.	O	-1	2933998
The	O	-1	2933998
b@@	O	-1	2933998
est	O	-1	2933998
clinical	O	-1	2933998
effect	O	-1	2933998
was	O	-1	2933998
found	O	-1	2933998
with	O	-1	2933998
ter@@	B-Chemical	D013726	2933998
but@@	I-Chemical	-1	2933998
aline	I-Chemical	-1	2933998
.	O	-1	2933998
B@@	O	-1	2933998
oth	O	-1	2933998
anti@@	O	-1	2933998
-	O	-1	2933998
as@@	B-Disease	D001249	2933998
th@@	I-Disease	-1	2933998
m@@	I-Disease	-1	2933998
atic	I-Disease	-1	2933998
and	O	-1	2933998
tre@@	B-Disease	D014202	2933998
mor@@	I-Disease	-1	2933998
genic	I-Disease	-1	2933998
effects	O	-1	2933998
of	O	-1	2933998
pro@@	B-Chemical	D017265	2933998
cat@@	I-Chemical	-1	2933998
er@@	I-Chemical	-1	2933998
ol	I-Chemical	-1	2933998
were	O	-1	2933998
dose-@@	O	-1	2933998
rel@@	O	-1	2933998
ated.	O	-1	2933998
Pro@@	B-Chemical	D017265	2933998
cat@@	I-Chemical	-1	2933998
er@@	I-Chemical	-1	2933998
ol	I-Chemical	-1	2933998
appe@@	O	-1	2933998
a@@	O	-1	2933998
red	O	-1	2933998
effective	O	-1	2933998
in	O	-1	2933998
the	O	-1	2933998
doses	O	-1	2933998
test@@	O	-1	2933998
ed,	O	-1	2933998
and	O	-1	2933998
a	O	-1	2933998
tw@@	O	-1	2933998
ic@@	O	-1	2933998
e	O	-1	2933998
daily	O	-1	2933998
regi@@	O	-1	2933998
men	O	-1	2933998
wo@@	O	-1	2933998
uld	O	-1	2933998
appe@@	O	-1	2933998
ar	O	-1	2933998
to	O	-1	2933998
be	O	-1	2933998
su@@	O	-1	2933998
it@@	O	-1	2933998
able	O	-1	2933998
with	O	-1	2933998
this	O	-1	2933998
drug.	O	-1	2933998

S@@	O	-1	2974281
ub@@	O	-1	2974281
acute	O	-1	2974281
effects	O	-1	2974281
of	O	-1	2974281
prop@@	B-Chemical	D011433	2974281
ran@@	I-Chemical	-1	2974281
o@@	I-Chemical	-1	2974281
lol	I-Chemical	-1	2974281
and	O	-1	2974281
B	O	-1	2974281
2@@	O	-1	2974281
4@@	O	-1	2974281
/@@	O	-1	2974281
7@@	O	-1	2974281
6	O	-1	2974281
on	O	-1	2974281
isoproteren@@	B-Chemical	D007545	2974281
ol	I-Chemical	-1	2974281
-induced	O	-1	2974281
rat	O	-1	2974281
heart	B-Disease	D006332	2974281
hyper@@	I-Disease	-1	2974281
tro@@	I-Disease	-1	2974281
ph@@	I-Disease	-1	2974281
y	I-Disease	-1	2974281
in	O	-1	2974281
correl@@	O	-1	2974281
ation	O	-1	2974281
with	O	-1	2974281
blood	O	-1	2974281
pressu@@	O	-1	2974281
re.	O	-1	2974281
We	O	-1	2974281
compared	O	-1	2974281
the	O	-1	2974281
potential	O	-1	2974281
beta-@@	O	-1	2974281
receptor	O	-1	2974281
block@@	O	-1	2974281
er,	O	-1	2974281
B	O	-1	2974281
2@@	O	-1	2974281
4@@	O	-1	2974281
/@@	O	-1	2974281
7@@	O	-1	2974281
6	O	-1	2974281
i.@@	O	-1	2974281
e.	O	-1	2974281
1-@@	O	-1	2974281
(2@@	O	-1	2974281
,@@	O	-1	2974281
4-@@	O	-1	2974281
dic@@	O	-1	2974281
h@@	O	-1	2974281
loro@@	O	-1	2974281
phen@@	O	-1	2974281
oxy@@	O	-1	2974281
)-@@	O	-1	2974281
3@@	O	-1	2974281
[@@	O	-1	2974281
2-@@	O	-1	2974281
3@@	O	-1	2974281
,@@	O	-1	2974281
4-@@	O	-1	2974281
di@@	O	-1	2974281
meth@@	O	-1	2974281
oxy@@	O	-1	2974281
phenyl@@	O	-1	2974281
)@@	O	-1	2974281
eth@@	O	-1	2974281
an@@	O	-1	2974281
ol@@	O	-1	2974281
amino@@	O	-1	2974281
]@@	O	-1	2974281
-@@	O	-1	2974281
pro@@	O	-1	2974281
p	O	-1	2974281
an@@	O	-1	2974281
-@@	O	-1	2974281
2-@@	O	-1	2974281
ol@@	O	-1	2974281
,	O	-1	2974281
which	O	-1	2974281
is	O	-1	2974281
character@@	O	-1	2974281
ized	O	-1	2974281
by	O	-1	2974281
bet@@	O	-1	2974281
a	O	-1	2974281
1-@@	O	-1	2974281
adren@@	O	-1	2974281
oc@@	O	-1	2974281
e@@	O	-1	2974281
pt@@	O	-1	2974281
or	O	-1	2974281
block@@	O	-1	2974281
ing	O	-1	2974281
and	O	-1	2974281
bet@@	O	-1	2974281
a	O	-1	2974281
2-@@	O	-1	2974281
adren@@	O	-1	2974281
oc@@	O	-1	2974281
e@@	O	-1	2974281
pt@@	O	-1	2974281
or	O	-1	2974281
stimul@@	O	-1	2974281
ating	O	-1	2974281
pro@@	O	-1	2974281
per@@	O	-1	2974281
ties	O	-1	2974281
with	O	-1	2974281
prop@@	B-Chemical	D011433	2974281
ran@@	I-Chemical	-1	2974281
o@@	I-Chemical	-1	2974281
lol	I-Chemical	-1	2974281
.	O	-1	2974281
The	O	-1	2974281
studies	O	-1	2974281
were	O	-1	2974281
performed	O	-1	2974281
using	O	-1	2974281
an	O	-1	2974281
experimental	O	-1	2974281
model	O	-1	2974281
of	O	-1	2974281
isoproteren@@	B-Chemical	D007545	2974281
ol	I-Chemical	-1	2974281
-induced	O	-1	2974281
heart	B-Disease	D006332	2974281
hyper@@	I-Disease	-1	2974281
tro@@	I-Disease	-1	2974281
ph@@	I-Disease	-1	2974281
y	I-Disease	-1	2974281
in	O	-1	2974281
rats.	O	-1	2974281
A	O	-1	2974281
correl@@	O	-1	2974281
ation	O	-1	2974281
of	O	-1	2974281
the	O	-1	2974281
blood	O	-1	2974281
pressure	O	-1	2974281
was	O	-1	2974281
ne@@	O	-1	2974281
ither	O	-1	2974281
found	O	-1	2974281
in	O	-1	2974281
the	O	-1	2974281
development	O	-1	2974281
n@@	O	-1	2974281
or	O	-1	2974281
in	O	-1	2974281
the	O	-1	2974281
at@@	O	-1	2974281
tem@@	O	-1	2974281
p@@	O	-1	2974281
t	O	-1	2974281
to	O	-1	2974281
sup@@	O	-1	2974281
pres@@	O	-1	2974281
s	O	-1	2974281
the	O	-1	2974281
development	O	-1	2974281
of	O	-1	2974281
heart	B-Disease	D006332	2974281
hyper@@	I-Disease	-1	2974281
tro@@	I-Disease	-1	2974281
ph@@	I-Disease	-1	2974281
y	I-Disease	-1	2974281
with	O	-1	2974281
the	O	-1	2974281
two	O	-1	2974281
beta-@@	O	-1	2974281
receptor	O	-1	2974281
block@@	O	-1	2974281
ers.	O	-1	2974281
B@@	O	-1	2974281
oth	O	-1	2974281
beta-@@	O	-1	2974281
block@@	O	-1	2974281
ers	O	-1	2974281
influ@@	O	-1	2974281
enc@@	O	-1	2974281
ed	O	-1	2974281
the	O	-1	2974281
development	O	-1	2974281
of	O	-1	2974281
hyper@@	B-Disease	D006984	2974281
tro@@	I-Disease	-1	2974281
ph@@	I-Disease	-1	2974281
y	I-Disease	-1	2974281
to	O	-1	2974281
a	O	-1	2974281
differen@@	O	-1	2974281
t,	O	-1	2974281
but	O	-1	2974281
not	O	-1	2974281
re@@	O	-1	2974281
produc@@	O	-1	2974281
i@@	O	-1	2974281
ble	O	-1	2974281
ext@@	O	-1	2974281
ent@@	O	-1	2974281
.	O	-1	2974281
It	O	-1	2974281
was	O	-1	2974281
possible	O	-1	2974281
to	O	-1	2974281
sup@@	O	-1	2974281
pres@@	O	-1	2974281
s	O	-1	2974281
the	O	-1	2974281
increased	O	-1	2974281
or@@	B-Chemical	D009952	2974281
n@@	I-Chemical	-1	2974281
i@@	I-Chemical	-1	2974281
th@@	I-Chemical	-1	2974281
ine	I-Chemical	-1	2974281
dec@@	O	-1	2974281
arb@@	O	-1	2974281
ox@@	O	-1	2974281
yl@@	O	-1	2974281
ase	O	-1	2974281
activity	O	-1	2974281
with	O	-1	2974281
both	O	-1	2974281
beta-@@	O	-1	2974281
block@@	O	-1	2974281
ers	O	-1	2974281
in	O	-1	2974281
hyper@@	B-Disease	D006332	2974281
tro@@	I-Disease	-1	2974281
ph@@	I-Disease	-1	2974281
ied	I-Disease	-1	2974281
hear@@	I-Disease	-1	2974281
ts	I-Disease	-1	2974281
,	O	-1	2974281
but	O	-1	2974281
there	O	-1	2974281
was	O	-1	2974281
no	O	-1	2974281
effect	O	-1	2974281
on	O	-1	2974281
the	O	-1	2974281
heart	O	-1	2974281
mas@@	O	-1	2974281
s.	O	-1	2974281
N@@	O	-1	2974281
either	O	-1	2974281
prop@@	B-Chemical	D011433	2974281
ran@@	I-Chemical	-1	2974281
o@@	I-Chemical	-1	2974281
lol	I-Chemical	-1	2974281
n@@	O	-1	2974281
or	O	-1	2974281
B	O	-1	2974281
2@@	O	-1	2974281
4@@	O	-1	2974281
/@@	O	-1	2974281
7@@	O	-1	2974281
6	O	-1	2974281
could	O	-1	2974281
sto@@	O	-1	2974281
p	O	-1	2974281
the	O	-1	2974281
changes	O	-1	2974281
in	O	-1	2974281
the	O	-1	2974281
character@@	O	-1	2974281
istic	O	-1	2974281
my@@	O	-1	2974281
os@@	O	-1	2974281
in	O	-1	2974281
iso@@	O	-1	2974281
enzyme	O	-1	2974281
pat@@	O	-1	2974281
ter@@	O	-1	2974281
n	O	-1	2974281
of	O	-1	2974281
the	O	-1	2974281
hyper@@	B-Disease	D006984	2974281
tro@@	I-Disease	-1	2974281
ph@@	I-Disease	-1	2974281
ied	I-Disease	-1	2974281
rat	O	-1	2974281
hear@@	O	-1	2974281
t.	O	-1	2974281
Th@@	O	-1	2974281
us,	O	-1	2974281
the	O	-1	2974281
investig@@	O	-1	2974281
ations	O	-1	2974281
did	O	-1	2974281
not	O	-1	2974281
prov@@	O	-1	2974281
ide	O	-1	2974281
any	O	-1	2974281
evidence	O	-1	2974281
that	O	-1	2974281
the	O	-1	2974281
beta-@@	O	-1	2974281
receptor	O	-1	2974281
block@@	O	-1	2974281
ers	O	-1	2974281
prop@@	B-Chemical	D011433	2974281
ran@@	I-Chemical	-1	2974281
o@@	I-Chemical	-1	2974281
lol	I-Chemical	-1	2974281
and	O	-1	2974281
B	O	-1	2974281
2@@	O	-1	2974281
4@@	O	-1	2974281
/@@	O	-1	2974281
7@@	O	-1	2974281
6	O	-1	2974281
have	O	-1	2974281
the	O	-1	2974281
poten@@	O	-1	2974281
c@@	O	-1	2974281
y	O	-1	2974281
to	O	-1	2974281
prev@@	O	-1	2974281
ent	O	-1	2974281
isoproteren@@	B-Chemical	D007545	2974281
ol	I-Chemical	-1	2974281
from	O	-1	2974281
produc@@	O	-1	2974281
ing	O	-1	2974281
heart	B-Disease	D006332	2974281
hyper@@	I-Disease	-1	2974281
tro@@	I-Disease	-1	2974281
ph@@	I-Disease	-1	2974281
y	I-Disease	-1	2974281
.	O	-1	2974281

Com@@	O	-1	3074291
par@@	O	-1	3074291
ison	O	-1	3074291
of	O	-1	3074291
the	O	-1	3074291
effect	O	-1	3074291
of	O	-1	3074291
ox@@	B-Chemical	C017590	3074291
it@@	I-Chemical	-1	3074291
ro@@	I-Chemical	-1	3074291
pi@@	I-Chemical	-1	3074291
um	I-Chemical	-1	3074291
brom@@	I-Chemical	-1	3074291
ide	I-Chemical	-1	3074291
and	O	-1	3074291
of	O	-1	3074291
s@@	O	-1	3074291
low@@	O	-1	3074291
-@@	O	-1	3074291
release	O	-1	3074291
the@@	B-Chemical	D013806	3074291
oph@@	I-Chemical	-1	3074291
yl@@	I-Chemical	-1	3074291
line	I-Chemical	-1	3074291
on	O	-1	3074291
n@@	O	-1	3074291
oc@@	O	-1	3074291
t@@	O	-1	3074291
ur@@	O	-1	3074291
n@@	O	-1	3074291
al	O	-1	3074291
as@@	B-Disease	D001249	3074291
th@@	I-Disease	-1	3074291
ma	I-Disease	-1	3074291
.	O	-1	3074291
The	O	-1	3074291
effects	O	-1	3074291
of	O	-1	3074291
a	O	-1	3074291
new	O	-1	3074291
in@@	O	-1	3074291
h@@	O	-1	3074291
al@@	O	-1	3074291
ed	O	-1	3074291
anti@@	O	-1	3074291
mus@@	O	-1	3074291
car@@	O	-1	3074291
inic	O	-1	3074291
drug@@	O	-1	3074291
,	O	-1	3074291
ox@@	B-Chemical	C017590	3074291
it@@	I-Chemical	-1	3074291
ro@@	I-Chemical	-1	3074291
pi@@	I-Chemical	-1	3074291
um	I-Chemical	-1	3074291
brom@@	I-Chemical	-1	3074291
ide	I-Chemical	-1	3074291
,	O	-1	3074291
and	O	-1	3074291
of	O	-1	3074291
a	O	-1	3074291
s@@	O	-1	3074291
low@@	O	-1	3074291
-@@	O	-1	3074291
release	O	-1	3074291
the@@	B-Chemical	D013806	3074291
oph@@	I-Chemical	-1	3074291
yl@@	I-Chemical	-1	3074291
line	I-Chemical	-1	3074291
pre@@	O	-1	3074291
par@@	O	-1	3074291
ation	O	-1	3074291
up@@	O	-1	3074291
on	O	-1	3074291
n@@	O	-1	3074291
oc@@	O	-1	3074291
t@@	O	-1	3074291
ur@@	O	-1	3074291
n@@	O	-1	3074291
al	O	-1	3074291
as@@	B-Disease	D001249	3074291
th@@	I-Disease	-1	3074291
ma	I-Disease	-1	3074291
were	O	-1	3074291
compared	O	-1	3074291
in	O	-1	3074291
a	O	-1	3074291
placebo@@	O	-1	3074291
-@@	O	-1	3074291
controlled	O	-1	3074291
double-bl@@	O	-1	3074291
ind	O	-1	3074291
study.	O	-1	3074291
Two	O	-1	3074291
sam@@	O	-1	3074291
ple@@	O	-1	3074291
s	O	-1	3074291
were	O	-1	3074291
studi@@	O	-1	3074291
ed@@	O	-1	3074291
:	O	-1	3074291
12	O	-1	3074291
patients	O	-1	3074291
received	O	-1	3074291
ox@@	B-Chemical	C017590	3074291
it@@	I-Chemical	-1	3074291
ro@@	I-Chemical	-1	3074291
pi@@	I-Chemical	-1	3074291
um	I-Chemical	-1	3074291
at	O	-1	3074291
6@@	O	-1	3074291
00	O	-1	3074291
microgram@@	O	-1	3074291
s	O	-1	3074291
(@@	O	-1	3074291
6	O	-1	3074291
subj@@	O	-1	3074291
ect@@	O	-1	3074291
s)	O	-1	3074291
or	O	-1	3074291
at	O	-1	3074291
4@@	O	-1	3074291
00	O	-1	3074291
microgram@@	O	-1	3074291
s	O	-1	3074291
t@@	O	-1	3074291
.@@	O	-1	3074291
i.@@	O	-1	3074291
d.	O	-1	3074291
(@@	O	-1	3074291
6	O	-1	3074291
subj@@	O	-1	3074291
ect@@	O	-1	3074291
s)	O	-1	3074291
whereas	O	-1	3074291
11	O	-1	3074291
received	O	-1	3074291
the@@	B-Chemical	D013806	3074291
oph@@	I-Chemical	-1	3074291
yl@@	I-Chemical	-1	3074291
line	I-Chemical	-1	3074291
at	O	-1	3074291
3@@	O	-1	3074291
00	O	-1	3074291
mg	O	-1	3074291
b@@	O	-1	3074291
.@@	O	-1	3074291
i.@@	O	-1	3074291
d.	O	-1	3074291
M@@	O	-1	3074291
or@@	O	-1	3074291
ning	O	-1	3074291
di@@	O	-1	3074291
pp@@	O	-1	3074291
ing,	O	-1	3074291
assessed	O	-1	3074291
by	O	-1	3074291
the	O	-1	3074291
f@@	O	-1	3074291
all	O	-1	3074291
in	O	-1	3074291
pe@@	O	-1	3074291
a@@	O	-1	3074291
k	O	-1	3074291
flow	O	-1	3074291
over@@	O	-1	3074291
n@@	O	-1	3074291
igh@@	O	-1	3074291
t,	O	-1	3074291
was	O	-1	3074291
significantly	O	-1	3074291
reduced	O	-1	3074291
in	O	-1	3074291
the	O	-1	3074291
perio@@	O	-1	3074291
ds	O	-1	3074291
when	O	-1	3074291
either	O	-1	3074291
active	O	-1	3074291
drug	O	-1	3074291
was	O	-1	3074291
tak@@	O	-1	3074291
en@@	O	-1	3074291
,	O	-1	3074291
whereas	O	-1	3074291
no	O	-1	3074291
difference	O	-1	3074291
was	O	-1	3074291
no@@	O	-1	3074291
tic@@	O	-1	3074291
ed	O	-1	3074291
during	O	-1	3074291
the	O	-1	3074291
placebo	O	-1	3074291
administr@@	O	-1	3074291
ation.	O	-1	3074291
No	O	-1	3074291
significant	O	-1	3074291
difference	O	-1	3074291
was	O	-1	3074291
no@@	O	-1	3074291
tic@@	O	-1	3074291
ed	O	-1	3074291
between	O	-1	3074291
results	O	-1	3074291
obtained	O	-1	3074291
with	O	-1	3074291
either	O	-1	3074291
active	O	-1	3074291
drug@@	O	-1	3074291
,	O	-1	3074291
as	O	-1	3074291
well	O	-1	3074291
as	O	-1	3074291
with	O	-1	3074291
either	O	-1	3074291
dos@@	O	-1	3074291
age	O	-1	3074291
of	O	-1	3074291
ox@@	B-Chemical	C017590	3074291
it@@	I-Chemical	-1	3074291
ro@@	I-Chemical	-1	3074291
pi@@	I-Chemical	-1	3074291
um	I-Chemical	-1	3074291
.	O	-1	3074291
No	O	-1	3074291
subj@@	O	-1	3074291
ect	O	-1	3074291
reported	O	-1	3074291
side	O	-1	3074291
effects	O	-1	3074291
of	O	-1	3074291
ox@@	B-Chemical	C017590	3074291
it@@	I-Chemical	-1	3074291
ro@@	I-Chemical	-1	3074291
pi@@	I-Chemical	-1	3074291
um	I-Chemical	-1	3074291
,	O	-1	3074291
as	O	-1	3074291
compared	O	-1	3074291
to	O	-1	3074291
three	O	-1	3074291
subjects	O	-1	3074291
repor@@	O	-1	3074291
ting	O	-1	3074291
nausea	B-Disease	D009325	3074291
,	O	-1	3074291
v@@	B-Disease	D014839	3074291
om@@	I-Disease	-1	3074291
it@@	I-Disease	-1	3074291
ing	I-Disease	-1	3074291
and	O	-1	3074291
tre@@	B-Disease	D014202	3074291
mor@@	I-Disease	-1	3074291
s	I-Disease	-1	3074291
after	O	-1	3074291
the@@	B-Chemical	D013806	3074291
oph@@	I-Chemical	-1	3074291
yl@@	I-Chemical	-1	3074291
line	I-Chemical	-1	3074291
.	O	-1	3074291
O@@	B-Chemical	C017590	3074291
x@@	I-Chemical	-1	3074291
it@@	I-Chemical	-1	3074291
ro@@	I-Chemical	-1	3074291
pi@@	I-Chemical	-1	3074291
um	I-Chemical	-1	3074291
prov@@	O	-1	3074291
es	O	-1	3074291
to	O	-1	3074291
be	O	-1	3074291
a	O	-1	3074291
valu@@	O	-1	3074291
able	O	-1	3074291
al@@	O	-1	3074291
tern@@	O	-1	3074291
ative	O	-1	3074291
to	O	-1	3074291
the@@	B-Chemical	D013806	3074291
oph@@	I-Chemical	-1	3074291
yl@@	I-Chemical	-1	3074291
line	I-Chemical	-1	3074291
in	O	-1	3074291
n@@	O	-1	3074291
oc@@	O	-1	3074291
t@@	O	-1	3074291
ur@@	O	-1	3074291
n@@	O	-1	3074291
al	O	-1	3074291
as@@	B-Disease	D001249	3074291
th@@	I-Disease	-1	3074291
ma	I-Disease	-1	3074291
,	O	-1	3074291
s@@	O	-1	3074291
inc@@	O	-1	3074291
e	O	-1	3074291
it	O	-1	3074291
is	O	-1	3074291
equ@@	O	-1	3074291
ally	O	-1	3074291
pot@@	O	-1	3074291
ent@@	O	-1	3074291
,	O	-1	3074291
saf@@	O	-1	3074291
er	O	-1	3074291
and	O	-1	3074291
does	O	-1	3074291
not	O	-1	3074291
requ@@	O	-1	3074291
ir@@	O	-1	3074291
e	O	-1	3074291
the	O	-1	3074291
ti@@	O	-1	3074291
t@@	O	-1	3074291
ration	O	-1	3074291
of	O	-1	3074291
dos@@	O	-1	3074291
age.	O	-1	3074291

P@@	B-Chemical	D010406	3083835
en@@	I-Chemical	-1	3083835
icill@@	I-Chemical	-1	3083835
in	I-Chemical	-1	3083835
ana@@	B-Disease	D000707	3083835
phyl@@	I-Disease	-1	3083835
ax@@	I-Disease	-1	3083835
is	I-Disease	-1	3083835
.	O	-1	3083835
A	O	-1	3083835
case	O	-1	3083835
of	O	-1	3083835
oral	O	-1	3083835
pen@@	B-Chemical	D010406	3083835
icill@@	I-Chemical	-1	3083835
in	I-Chemical	-1	3083835
ana@@	B-Disease	D000707	3083835
phyl@@	I-Disease	-1	3083835
ax@@	I-Disease	-1	3083835
is	I-Disease	-1	3083835
is	O	-1	3083835
descri@@	O	-1	3083835
be@@	O	-1	3083835
d,	O	-1	3083835
and	O	-1	3083835
the	O	-1	3083835
ter@@	O	-1	3083835
min@@	O	-1	3083835
olog@@	O	-1	3083835
y,	O	-1	3083835
occur@@	O	-1	3083835
ren@@	O	-1	3083835
ce@@	O	-1	3083835
,	O	-1	3083835
clinical	O	-1	3083835
man@@	O	-1	3083835
if@@	O	-1	3083835
est@@	O	-1	3083835
ation@@	O	-1	3083835
s,	O	-1	3083835
path@@	O	-1	3083835
o@@	O	-1	3083835
gene@@	O	-1	3083835
sis,	O	-1	3083835
pre@@	O	-1	3083835
ven@@	O	-1	3083835
tion,	O	-1	3083835
and	O	-1	3083835
treatment	O	-1	3083835
of	O	-1	3083835
ana@@	B-Disease	D000707	3083835
phyl@@	I-Disease	-1	3083835
ax@@	I-Disease	-1	3083835
is	I-Disease	-1	3083835
are	O	-1	3083835
revie@@	O	-1	3083835
we@@	O	-1	3083835
d.	O	-1	3083835
E@@	O	-1	3083835
mer@@	O	-1	3083835
gen@@	O	-1	3083835
c@@	O	-1	3083835
y	O	-1	3083835
physi@@	O	-1	3083835
ci@@	O	-1	3083835
ans	O	-1	3083835
should	O	-1	3083835
be	O	-1	3083835
aw@@	O	-1	3083835
are	O	-1	3083835
of	O	-1	3083835
oral	O	-1	3083835
pen@@	B-Chemical	D010406	3083835
icill@@	I-Chemical	-1	3083835
in	I-Chemical	-1	3083835
ana@@	B-Disease	D000707	3083835
phyl@@	I-Disease	-1	3083835
ax@@	I-Disease	-1	3083835
is	I-Disease	-1	3083835
in	O	-1	3083835
or@@	O	-1	3083835
der	O	-1	3083835
to	O	-1	3083835
prev@@	O	-1	3083835
ent	O	-1	3083835
its	O	-1	3083835
occur@@	O	-1	3083835
rence	O	-1	3083835
by	O	-1	3083835
prescri@@	O	-1	3083835
b@@	O	-1	3083835
ing	O	-1	3083835
the	O	-1	3083835
anti@@	O	-1	3083835
bio@@	O	-1	3083835
tic	O	-1	3083835
j@@	O	-1	3083835
ud@@	O	-1	3083835
ici@@	O	-1	3083835
ously	O	-1	3083835
and	O	-1	3083835
know@@	O	-1	3083835
le@@	O	-1	3083835
d@@	O	-1	3083835
ge@@	O	-1	3083835
ably	O	-1	3083835
and	O	-1	3083835
to	O	-1	3083835
o@@	O	-1	3083835
ff@@	O	-1	3083835
er	O	-1	3083835
op@@	O	-1	3083835
tim@@	O	-1	3083835
al	O	-1	3083835
med@@	O	-1	3083835
ical	O	-1	3083835
therapy	O	-1	3083835
on@@	O	-1	3083835
ce	O	-1	3083835
this	O	-1	3083835
lif@@	O	-1	3083835
e-@@	O	-1	3083835
th@@	O	-1	3083835
reat@@	O	-1	3083835
en@@	O	-1	3083835
ing	O	-1	3083835
reaction	O	-1	3083835
has	O	-1	3083835
be@@	O	-1	3083835
g@@	O	-1	3083835
un@@	O	-1	3083835
.	O	-1	3083835

Re@@	O	-1	3084231
ver@@	O	-1	3084231
sible	O	-1	3084231
valpro@@	B-Chemical	D014635	3084231
ic	I-Chemical	-1	3084231
acid	I-Chemical	-1	3084231
-induced	O	-1	3084231
de@@	B-Disease	D003704	3084231
m@@	I-Disease	-1	3084231
enti@@	I-Disease	-1	3084231
a	I-Disease	-1	3084231
:	O	-1	3084231
a	O	-1	3084231
case	O	-1	3084231
repor@@	O	-1	3084231
t.	O	-1	3084231
Re@@	O	-1	3084231
ver@@	O	-1	3084231
sible	O	-1	3084231
valpro@@	B-Chemical	D014635	3084231
ic	I-Chemical	-1	3084231
acid	I-Chemical	-1	3084231
-induced	O	-1	3084231
de@@	B-Disease	D003704	3084231
m@@	I-Disease	-1	3084231
enti@@	I-Disease	-1	3084231
a	I-Disease	-1	3084231
was	O	-1	3084231
doc@@	O	-1	3084231
um@@	O	-1	3084231
ent@@	O	-1	3084231
ed	O	-1	3084231
in	O	-1	3084231
a	O	-1	3084231
2@@	O	-1	3084231
1-@@	O	-1	3084231
year-old	O	-1	3084231
man	O	-1	3084231
with	O	-1	3084231
epilep@@	B-Disease	D004827	3084231
sy	I-Disease	-1	3084231
who	O	-1	3084231
had	O	-1	3084231
a	O	-1	3084231
3-@@	O	-1	3084231
year	O	-1	3084231
hist@@	O	-1	3084231
ory	O	-1	3084231
of	O	-1	3084231
in@@	O	-1	3084231
si@@	O	-1	3084231
di@@	O	-1	3084231
ous	O	-1	3084231
progressive	O	-1	3084231
dec@@	O	-1	3084231
line	O	-1	3084231
in	O	-1	3084231
glo@@	O	-1	3084231
b@@	O	-1	3084231
al	O	-1	3084231
cognitive	O	-1	3084231
abil@@	O	-1	3084231
ities	O	-1	3084231
doc@@	O	-1	3084231
um@@	O	-1	3084231
ent@@	O	-1	3084231
ed	O	-1	3084231
by	O	-1	3084231
ser@@	O	-1	3084231
ial	O	-1	3084231
neuro@@	O	-1	3084231
psych@@	O	-1	3084231
ological	O	-1	3084231
studi@@	O	-1	3084231
es.	O	-1	3084231
R@@	O	-1	3084231
ep@@	O	-1	3084231
e@@	O	-1	3084231
at	O	-1	3084231
neuro@@	O	-1	3084231
psych@@	O	-1	3084231
ological	O	-1	3084231
test@@	O	-1	3084231
ing	O	-1	3084231
7	O	-1	3084231
weeks	O	-1	3084231
after	O	-1	3084231
discontinu@@	O	-1	3084231
ation	O	-1	3084231
of	O	-1	3084231
the	O	-1	3084231
drug	O	-1	3084231
revealed	O	-1	3084231
d@@	O	-1	3084231
ram@@	O	-1	3084231
atic	O	-1	3084231
impro@@	O	-1	3084231
vement	O	-1	3084231
in	O	-1	3084231
I@@	O	-1	3084231
Q@@	O	-1	3084231
,	O	-1	3084231
memor@@	O	-1	3084231
y,	O	-1	3084231
nam@@	O	-1	3084231
ing,	O	-1	3084231
and	O	-1	3084231
other	O	-1	3084231
t@@	O	-1	3084231
as@@	O	-1	3084231
k@@	O	-1	3084231
s	O	-1	3084231
comm@@	O	-1	3084231
en@@	O	-1	3084231
sur@@	O	-1	3084231
ate	O	-1	3084231
with	O	-1	3084231
clinical	O	-1	3084231
recovery	O	-1	3084231
in	O	-1	3084231
h@@	O	-1	3084231
is	O	-1	3084231
in@@	O	-1	3084231
te@@	O	-1	3084231
ll@@	O	-1	3084231
ect@@	O	-1	3084231
ual	O	-1	3084231
cap@@	O	-1	3084231
ac@@	O	-1	3084231
ity.	O	-1	3084231
P@@	O	-1	3084231
os@@	O	-1	3084231
sible	O	-1	3084231
path@@	O	-1	3084231
oph@@	O	-1	3084231
ysi@@	O	-1	3084231
ological	O	-1	3084231
mechanisms	O	-1	3084231
which	O	-1	3084231
may	O	-1	3084231
have	O	-1	3084231
been	O	-1	3084231
o@@	O	-1	3084231
perative	O	-1	3084231
in	O	-1	3084231
this	O	-1	3084231
case	O	-1	3084231
inc@@	O	-1	3084231
lu@@	O	-1	3084231
de@@	O	-1	3084231
:	O	-1	3084231
a	O	-1	3084231
direct	O	-1	3084231
central	O	-1	3084231
ner@@	O	-1	3084231
v@@	O	-1	3084231
ous	O	-1	3084231
system	O	-1	3084231
(C@@	O	-1	3084231
N@@	O	-1	3084231
S)	O	-1	3084231
toxic	O	-1	3084231
effect	O	-1	3084231
of	O	-1	3084231
valpro@@	B-Chemical	D014635	3084231
ic	I-Chemical	-1	3084231
acid	I-Chemical	-1	3084231
;	O	-1	3084231
a	O	-1	3084231
par@@	O	-1	3084231
ad@@	O	-1	3084231
ox@@	O	-1	3084231
ical	O	-1	3084231
epile@@	O	-1	3084231
pto@@	O	-1	3084231
genic	O	-1	3084231
effect	O	-1	3084231
secondary	O	-1	3084231
to	O	-1	3084231
the	O	-1	3084231
drug@@	O	-1	3084231
;	O	-1	3084231
and	O	-1	3084231
an	O	-1	3084231
in@@	O	-1	3084231
direct	O	-1	3084231
C@@	O	-1	3084231
N@@	O	-1	3084231
S	O	-1	3084231
toxic	O	-1	3084231
effect	O	-1	3084231
mediated	O	-1	3084231
through	O	-1	3084231
valpro@@	B-Chemical	D014635	3084231
ic	I-Chemical	-1	3084231
acid	I-Chemical	-1	3084231
-induced	O	-1	3084231
hyper@@	B-Disease	D022124	3084231
am@@	I-Disease	-1	3084231
mon@@	I-Disease	-1	3084231
emia	I-Disease	-1	3084231
.	O	-1	3084231

Re@@	O	-1	3088653
ver@@	O	-1	3088653
s@@	O	-1	3088653
al	O	-1	3088653
of	O	-1	3088653
scopol@@	B-Chemical	D012601	3088653
amine	I-Chemical	-1	3088653
-induced	O	-1	3088653
am@@	B-Disease	D000647	3088653
ne@@	I-Disease	-1	3088653
sia	I-Disease	-1	3088653
of	O	-1	3088653
p@@	O	-1	3088653
as@@	O	-1	3088653
sive	O	-1	3088653
avoid@@	O	-1	3088653
ance	O	-1	3088653
by	O	-1	3088653
pre@@	O	-1	3088653
-	O	-1	3088653
and	O	-1	3088653
post@@	O	-1	3088653
-@@	O	-1	3088653
tra@@	O	-1	3088653
in@@	O	-1	3088653
ing	O	-1	3088653
n@@	B-Chemical	D009270	3088653
al@@	I-Chemical	-1	3088653
ox@@	I-Chemical	-1	3088653
one	I-Chemical	-1	3088653
.	O	-1	3088653
In	O	-1	3088653
a	O	-1	3088653
seri@@	O	-1	3088653
es	O	-1	3088653
of	O	-1	3088653
five	O	-1	3088653
experim@@	O	-1	3088653
ent@@	O	-1	3088653
s,	O	-1	3088653
the	O	-1	3088653
mod@@	O	-1	3088653
ul@@	O	-1	3088653
ating	O	-1	3088653
role	O	-1	3088653
of	O	-1	3088653
n@@	B-Chemical	D009270	3088653
al@@	I-Chemical	-1	3088653
ox@@	I-Chemical	-1	3088653
one	I-Chemical	-1	3088653
on	O	-1	3088653
a	O	-1	3088653
scopol@@	B-Chemical	D012601	3088653
amine	I-Chemical	-1	3088653
-induced	O	-1	3088653
re@@	B-Disease	D008569	3088653
ten@@	I-Disease	-1	3088653
tion	I-Disease	-1	3088653
defic@@	I-Disease	-1	3088653
it	I-Disease	-1	3088653
in	O	-1	3088653
a	O	-1	3088653
p@@	O	-1	3088653
as@@	O	-1	3088653
sive	O	-1	3088653
avoid@@	O	-1	3088653
ance	O	-1	3088653
par@@	O	-1	3088653
a@@	O	-1	3088653
di@@	O	-1	3088653
g@@	O	-1	3088653
m	O	-1	3088653
was	O	-1	3088653
investigated	O	-1	3088653
in	O	-1	3088653
mice.	O	-1	3088653
S@@	B-Chemical	D012601	3088653
co@@	I-Chemical	-1	3088653
pol@@	I-Chemical	-1	3088653
amine	I-Chemical	-1	3088653
,	O	-1	3088653
but	O	-1	3088653
not	O	-1	3088653
meth@@	B-Chemical	D019832	3088653
yl	I-Chemical	-1	3088653
scopol@@	I-Chemical	-1	3088653
amine	I-Chemical	-1	3088653
(@@	O	-1	3088653
1	O	-1	3088653
and	O	-1	3088653
3	O	-1	3088653
mg/kg@@	O	-1	3088653
),	O	-1	3088653
induced	O	-1	3088653
an	O	-1	3088653
am@@	B-Disease	D000647	3088653
ne@@	I-Disease	-1	3088653
sia	I-Disease	-1	3088653
as	O	-1	3088653
measured	O	-1	3088653
by	O	-1	3088653
lat@@	O	-1	3088653
ency	O	-1	3088653
and	O	-1	3088653
duration	O	-1	3088653
par@@	O	-1	3088653
ame@@	O	-1	3088653
ter@@	O	-1	3088653
s.	O	-1	3088653
N@@	B-Chemical	D009270	3088653
al@@	I-Chemical	-1	3088653
ox@@	I-Chemical	-1	3088653
one	I-Chemical	-1	3088653
(0.@@	O	-1	3088653
3,	O	-1	3088653
1,	O	-1	3088653
3,	O	-1	3088653
and	O	-1	3088653
10	O	-1	3088653
mg/kg)	O	-1	3088653
injected	O	-1	3088653
prior	O	-1	3088653
to	O	-1	3088653
tra@@	O	-1	3088653
in@@	O	-1	3088653
ing	O	-1	3088653
attenu@@	O	-1	3088653
ated	O	-1	3088653
the	O	-1	3088653
re@@	B-Disease	D008569	3088653
ten@@	I-Disease	-1	3088653
tion	I-Disease	-1	3088653
defic@@	I-Disease	-1	3088653
it	I-Disease	-1	3088653
with	O	-1	3088653
a	O	-1	3088653
pe@@	O	-1	3088653
a@@	O	-1	3088653
k	O	-1	3088653
of	O	-1	3088653
activity	O	-1	3088653
at	O	-1	3088653
3	O	-1	3088653
mg/kg@@	O	-1	3088653
.	O	-1	3088653
The	O	-1	3088653
effect	O	-1	3088653
of	O	-1	3088653
n@@	B-Chemical	D009270	3088653
al@@	I-Chemical	-1	3088653
ox@@	I-Chemical	-1	3088653
one	I-Chemical	-1	3088653
could	O	-1	3088653
be	O	-1	3088653
antagon@@	O	-1	3088653
ized	O	-1	3088653
with	O	-1	3088653
morphine	B-Chemical	D009020	3088653
(1@@	O	-1	3088653
,	O	-1	3088653
3,	O	-1	3088653
and	O	-1	3088653
10	O	-1	3088653
mg/kg@@	O	-1	3088653
),	O	-1	3088653
demon@@	O	-1	3088653
strat@@	O	-1	3088653
ing	O	-1	3088653
the	O	-1	3088653
o@@	O	-1	3088653
pi@@	O	-1	3088653
oid	O	-1	3088653
spec@@	O	-1	3088653
ific@@	O	-1	3088653
ity	O	-1	3088653
of	O	-1	3088653
the	O	-1	3088653
n@@	B-Chemical	D009270	3088653
al@@	I-Chemical	-1	3088653
ox@@	I-Chemical	-1	3088653
one	I-Chemical	-1	3088653
effect@@	O	-1	3088653
.	O	-1	3088653
P@@	O	-1	3088653
ost@@	O	-1	3088653
-@@	O	-1	3088653
tra@@	O	-1	3088653
in@@	O	-1	3088653
ing	O	-1	3088653
administration	O	-1	3088653
of	O	-1	3088653
n@@	B-Chemical	D009270	3088653
al@@	I-Chemical	-1	3088653
ox@@	I-Chemical	-1	3088653
one	I-Chemical	-1	3088653
(@@	O	-1	3088653
3	O	-1	3088653
mg/kg)	O	-1	3088653
as	O	-1	3088653
a	O	-1	3088653
single	O	-1	3088653
or	O	-1	3088653
as	O	-1	3088653
a	O	-1	3088653
s@@	O	-1	3088653
pl@@	O	-1	3088653
it	O	-1	3088653
dose	O	-1	3088653
also	O	-1	3088653
attenu@@	O	-1	3088653
ated	O	-1	3088653
the	O	-1	3088653
scopol@@	B-Chemical	D012601	3088653
amine	I-Chemical	-1	3088653
-induced	O	-1	3088653
am@@	B-Disease	D000647	3088653
ne@@	I-Disease	-1	3088653
sia	I-Disease	-1	3088653
.	O	-1	3088653
C@@	O	-1	3088653
ont@@	O	-1	3088653
ro@@	O	-1	3088653
l	O	-1	3088653
experim@@	O	-1	3088653
ents	O	-1	3088653
indic@@	O	-1	3088653
ated	O	-1	3088653
that	O	-1	3088653
ne@@	O	-1	3088653
ither	O	-1	3088653
an	O	-1	3088653
increase	O	-1	3088653
in	O	-1	3088653
pain	B-Disease	D010146	3088653
sensitivity	O	-1	3088653
(@@	O	-1	3088653
pre-@@	O	-1	3088653
tra@@	O	-1	3088653
in@@	O	-1	3088653
ing	O	-1	3088653
n@@	B-Chemical	D009270	3088653
al@@	I-Chemical	-1	3088653
ox@@	I-Chemical	-1	3088653
one	I-Chemical	-1	3088653
)	O	-1	3088653
n@@	O	-1	3088653
or	O	-1	3088653
an	O	-1	3088653
induced	O	-1	3088653
aver@@	O	-1	3088653
sive	O	-1	3088653
state	O	-1	3088653
(@@	O	-1	3088653
post@@	O	-1	3088653
-@@	O	-1	3088653
tra@@	O	-1	3088653
in@@	O	-1	3088653
ing	O	-1	3088653
n@@	B-Chemical	D009270	3088653
al@@	I-Chemical	-1	3088653
ox@@	I-Chemical	-1	3088653
one	I-Chemical	-1	3088653
)	O	-1	3088653
appe@@	O	-1	3088653
ar	O	-1	3088653
to	O	-1	3088653
be	O	-1	3088653
respon@@	O	-1	3088653
sible	O	-1	3088653
for	O	-1	3088653
the	O	-1	3088653
influence	O	-1	3088653
of	O	-1	3088653
n@@	B-Chemical	D009270	3088653
al@@	I-Chemical	-1	3088653
ox@@	I-Chemical	-1	3088653
one	I-Chemical	-1	3088653
on	O	-1	3088653
the	O	-1	3088653
scopol@@	B-Chemical	D012601	3088653
amine	I-Chemical	-1	3088653
-induced	O	-1	3088653
re@@	B-Disease	D008569	3088653
ten@@	I-Disease	-1	3088653
tion	I-Disease	-1	3088653
defic@@	I-Disease	-1	3088653
it	I-Disease	-1	3088653
.	O	-1	3088653
These	O	-1	3088653
results	O	-1	3088653
exten@@	O	-1	3088653
d	O	-1	3088653
previ@@	O	-1	3088653
ous	O	-1	3088653
findings	O	-1	3088653
implic@@	O	-1	3088653
ating	O	-1	3088653
a	O	-1	3088653
chol@@	O	-1	3088653
in@@	O	-1	3088653
erg@@	O	-1	3088653
ic@@	O	-1	3088653
-@@	O	-1	3088653
o@@	O	-1	3088653
pi@@	O	-1	3088653
oid	O	-1	3088653
inter@@	O	-1	3088653
action	O	-1	3088653
in	O	-1	3088653
memory	O	-1	3088653
pro@@	O	-1	3088653
cess@@	O	-1	3088653
es.	O	-1	3088653
A	O	-1	3088653
possible	O	-1	3088653
mechanism	O	-1	3088653
for	O	-1	3088653
this	O	-1	3088653
inter@@	O	-1	3088653
action	O	-1	3088653
invol@@	O	-1	3088653
ving	O	-1	3088653
the	O	-1	3088653
se@@	O	-1	3088653
pto@@	O	-1	3088653
-@@	O	-1	3088653
hippocamp@@	O	-1	3088653
al	O	-1	3088653
cholinergic	O	-1	3088653
path@@	O	-1	3088653
w@@	O	-1	3088653
ay	O	-1	3088653
is	O	-1	3088653
discus@@	O	-1	3088653
sed.	O	-1	3088653

E@@	O	-1	3109094
l@@	O	-1	3109094
ect@@	O	-1	3109094
ro@@	O	-1	3109094
n	O	-1	3109094
micro@@	O	-1	3109094
sco@@	O	-1	3109094
p@@	O	-1	3109094
ic	O	-1	3109094
investig@@	O	-1	3109094
ations	O	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
cyclophosph@@	B-Chemical	D003520	3109094
amide	I-Chemical	-1	3109094
-induced	O	-1	3109094
lesions	B-Disease	D001745	3109094
of	I-Disease	-1	3109094
the	I-Disease	-1	3109094
urinary	I-Disease	-1	3109094
bladder	I-Disease	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
rat	O	-1	3109094
and	O	-1	3109094
their	O	-1	3109094
pre@@	O	-1	3109094
ven@@	O	-1	3109094
tion	O	-1	3109094
by	O	-1	3109094
m@@	B-Chemical	D015080	3109094
es@@	I-Chemical	-1	3109094
n@@	I-Chemical	-1	3109094
a	I-Chemical	-1	3109094
.	O	-1	3109094
F@@	O	-1	3109094
ul@@	O	-1	3109094
ly	O	-1	3109094
developed	O	-1	3109094
cyclophosph@@	B-Chemical	D003520	3109094
amide	I-Chemical	-1	3109094
-induced	O	-1	3109094
cys@@	B-Disease	D003556	3109094
ti@@	I-Disease	-1	3109094
tis	I-Disease	-1	3109094
is	O	-1	3109094
character@@	O	-1	3109094
ized	O	-1	3109094
by	O	-1	3109094
ne@@	O	-1	3109094
arly	O	-1	3109094
complete	O	-1	3109094
de@@	O	-1	3109094
tac@@	O	-1	3109094
h@@	O	-1	3109094
ment	O	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
uro@@	O	-1	3109094
the@@	O	-1	3109094
li@@	O	-1	3109094
um,	O	-1	3109094
severe	O	-1	3109094
sub@@	O	-1	3109094
m@@	O	-1	3109094
u@@	O	-1	3109094
co@@	O	-1	3109094
s@@	O	-1	3109094
al	O	-1	3109094
e@@	B-Disease	D004487	3109094
de@@	I-Disease	-1	3109094
ma	I-Disease	-1	3109094
o@@	O	-1	3109094
w@@	O	-1	3109094
ing	O	-1	3109094
to	O	-1	3109094
damage	O	-1	3109094
to	O	-1	3109094
the	O	-1	3109094
micro@@	O	-1	3109094
vascular	O	-1	3109094
bed	O	-1	3109094
and	O	-1	3109094
foc@@	O	-1	3109094
al	O	-1	3109094
musc@@	O	-1	3109094
le	O	-1	3109094
necro@@	B-Disease	D009336	3109094
ses	I-Disease	-1	3109094
.	O	-1	3109094
The	O	-1	3109094
initial	O	-1	3109094
response	O	-1	3109094
to	O	-1	3109094
the	O	-1	3109094
prim@@	O	-1	3109094
ary	O	-1	3109094
at@@	O	-1	3109094
tac@@	O	-1	3109094
k	O	-1	3109094
by	O	-1	3109094
the	O	-1	3109094
cyclophosph@@	B-Chemical	D003520	3109094
amide	I-Chemical	-1	3109094
metabol@@	O	-1	3109094
it@@	O	-1	3109094
es	O	-1	3109094
se@@	O	-1	3109094
em@@	O	-1	3109094
s	O	-1	3109094
to	O	-1	3109094
be	O	-1	3109094
f@@	O	-1	3109094
ra@@	O	-1	3109094
g@@	O	-1	3109094
ment@@	O	-1	3109094
ation	O	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
lu@@	B-Chemical	D010634	3109094
min@@	I-Chemical	-1	3109094
al	I-Chemical	-1	3109094
membran@@	O	-1	3109094
e.	O	-1	3109094
This	O	-1	3109094
dam@@	O	-1	3109094
ages	O	-1	3109094
the	O	-1	3109094
cell@@	O	-1	3109094
ular	O	-1	3109094
bar@@	O	-1	3109094
ri@@	O	-1	3109094
er	O	-1	3109094
against	O	-1	3109094
the	O	-1	3109094
hyper@@	O	-1	3109094
t@@	O	-1	3109094
onic	O	-1	3109094
ur@@	O	-1	3109094
ine.	O	-1	3109094
S@@	O	-1	3109094
ub@@	O	-1	3109094
sequ@@	O	-1	3109094
ent	O	-1	3109094
b@@	O	-1	3109094
re@@	O	-1	3109094
ak@@	O	-1	3109094
s	O	-1	3109094
in	O	-1	3109094
the	O	-1	3109094
lat@@	O	-1	3109094
eral	O	-1	3109094
cell	O	-1	3109094
membran@@	O	-1	3109094
es	O	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
su@@	O	-1	3109094
per@@	O	-1	3109094
fic@@	O	-1	3109094
ial	O	-1	3109094
cells	O	-1	3109094
and	O	-1	3109094
in	O	-1	3109094
all	O	-1	3109094
the	O	-1	3109094
plasma	O	-1	3109094
membran@@	O	-1	3109094
es	O	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
inter@@	O	-1	3109094
medi@@	O	-1	3109094
ate	O	-1	3109094
and	O	-1	3109094
bas@@	O	-1	3109094
al	O	-1	3109094
cell@@	O	-1	3109094
s,	O	-1	3109094
inter@@	O	-1	3109094
cell@@	O	-1	3109094
ular	O	-1	3109094
and	O	-1	3109094
intrac@@	O	-1	3109094
ell@@	O	-1	3109094
ular	O	-1	3109094
e@@	B-Disease	D004487	3109094
de@@	I-Disease	-1	3109094
ma	I-Disease	-1	3109094
and	O	-1	3109094
dis@@	O	-1	3109094
in@@	O	-1	3109094
te@@	O	-1	3109094
g@@	O	-1	3109094
ration	O	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
des@@	O	-1	3109094
m@@	O	-1	3109094
os@@	O	-1	3109094
om@@	O	-1	3109094
es	O	-1	3109094
and	O	-1	3109094
hem@@	O	-1	3109094
id@@	O	-1	3109094
es@@	O	-1	3109094
m@@	O	-1	3109094
os@@	O	-1	3109094
om@@	O	-1	3109094
es	O	-1	3109094
le@@	O	-1	3109094
ad	O	-1	3109094
to	O	-1	3109094
progressive	O	-1	3109094
de@@	O	-1	3109094
generation	O	-1	3109094
and	O	-1	3109094
de@@	O	-1	3109094
tac@@	O	-1	3109094
h@@	O	-1	3109094
ment	O	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
epi@@	O	-1	3109094
thelial	O	-1	3109094
cells	O	-1	3109094
with	O	-1	3109094
exposure	O	-1	3109094
and	O	-1	3109094
s@@	O	-1	3109094
pl@@	O	-1	3109094
it@@	O	-1	3109094
ting	O	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
bas@@	O	-1	3109094
al	O	-1	3109094
membran@@	O	-1	3109094
e.	O	-1	3109094
The	O	-1	3109094
morph@@	O	-1	3109094
ological	O	-1	3109094
changes	O	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
endothelial	O	-1	3109094
cell@@	O	-1	3109094
s,	O	-1	3109094
which	O	-1	3109094
b@@	O	-1	3109094
ec@@	O	-1	3109094
ome	O	-1	3109094
more	O	-1	3109094
p@@	O	-1	3109094
ron@@	O	-1	3109094
oun@@	O	-1	3109094
c@@	O	-1	3109094
ed	O	-1	3109094
in	O	-1	3109094
the	O	-1	3109094
lat@@	O	-1	3109094
er	O	-1	3109094
st@@	O	-1	3109094
ages	O	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
experim@@	O	-1	3109094
ent@@	O	-1	3109094
,	O	-1	3109094
the	O	-1	3109094
invol@@	O	-1	3109094
vement	O	-1	3109094
of	O	-1	3109094
blood	O	-1	3109094
v@@	O	-1	3109094
es@@	O	-1	3109094
sel@@	O	-1	3109094
s	O	-1	3109094
reg@@	O	-1	3109094
ar@@	O	-1	3109094
d@@	O	-1	3109094
less	O	-1	3109094
of	O	-1	3109094
their	O	-1	3109094
di@@	O	-1	3109094
ame@@	O	-1	3109094
ter	O	-1	3109094
and	O	-1	3109094
the	O	-1	3109094
loc@@	O	-1	3109094
ation@@	O	-1	3109094
-@@	O	-1	3109094
dependent	O	-1	3109094
ext@@	O	-1	3109094
ent	O	-1	3109094
of	O	-1	3109094
the	O	-1	3109094
damage	O	-1	3109094
indicate	O	-1	3109094
a	O	-1	3109094
direct	O	-1	3109094
type	O	-1	3109094
of	O	-1	3109094
damage	O	-1	3109094
which	O	-1	3109094
is	O	-1	3109094
pre@@	O	-1	3109094
ce@@	O	-1	3109094
ded	O	-1	3109094
by	O	-1	3109094
a	O	-1	3109094
medi@@	O	-1	3109094
at@@	O	-1	3109094
or@@	O	-1	3109094
-induced	O	-1	3109094
increase	O	-1	3109094
in	O	-1	3109094
per@@	O	-1	3109094
me@@	O	-1	3109094
abil@@	O	-1	3109094
ity,	O	-1	3109094
the	O	-1	3109094
morph@@	O	-1	3109094
ological	O	-1	3109094
correl@@	O	-1	3109094
ate	O	-1	3109094
of	O	-1	3109094
which	O	-1	3109094
is	O	-1	3109094
the	O	-1	3109094
formation	O	-1	3109094
of	O	-1	3109094
g@@	O	-1	3109094
ap@@	O	-1	3109094
s	O	-1	3109094
in	O	-1	3109094
the	O	-1	3109094
in@@	O	-1	3109094
te@@	O	-1	3109094
ren@@	O	-1	3109094
do@@	O	-1	3109094
thelial	O	-1	3109094
cell	O	-1	3109094
con@@	O	-1	3109094
nec@@	O	-1	3109094
tions	O	-1	3109094
on	O	-1	3109094
the	O	-1	3109094
ven@@	O	-1	3109094
ul@@	O	-1	3109094
es.	O	-1	3109094
These	O	-1	3109094
changes	O	-1	3109094
can	O	-1	3109094
be	O	-1	3109094
eff@@	O	-1	3109094
ectively	O	-1	3109094
prevent@@	O	-1	3109094
ed	O	-1	3109094
by	O	-1	3109094
m@@	B-Chemical	D015080	3109094
es@@	I-Chemical	-1	3109094
n@@	I-Chemical	-1	3109094
a	I-Chemical	-1	3109094
.	O	-1	3109094
The	O	-1	3109094
only	O	-1	3109094
si@@	O	-1	3109094
g@@	O	-1	3109094
n	O	-1	3109094
of	O	-1	3109094
a	O	-1	3109094
possible	O	-1	3109094
invol@@	O	-1	3109094
vement	O	-1	3109094
is	O	-1	3109094
the	O	-1	3109094
increase	O	-1	3109094
in	O	-1	3109094
the	O	-1	3109094
number	O	-1	3109094
of	O	-1	3109094
specific	O	-1	3109094
gran@@	O	-1	3109094
ul@@	O	-1	3109094
es	O	-1	3109094
with	O	-1	3109094
a	O	-1	3109094
pres@@	O	-1	3109094
um@@	O	-1	3109094
ed	O	-1	3109094
l@@	O	-1	3109094
ys@@	O	-1	3109094
os@@	O	-1	3109094
om@@	O	-1	3109094
al	O	-1	3109094
function	O	-1	3109094
in	O	-1	3109094
the	O	-1	3109094
su@@	O	-1	3109094
per@@	O	-1	3109094
fic@@	O	-1	3109094
ial	O	-1	3109094
cell@@	O	-1	3109094
s.	O	-1	3109094

In@@	O	-1	3125850
c@@	O	-1	3125850
reas@@	O	-1	3125850
e	O	-1	3125850
in	O	-1	3125850
intra@@	O	-1	3125850
gast@@	O	-1	3125850
ric	O	-1	3125850
pressure	O	-1	3125850
during	O	-1	3125850
su@@	B-Chemical	D013390	3125850
xameth@@	I-Chemical	-1	3125850
oni@@	I-Chemical	-1	3125850
um	I-Chemical	-1	3125850
-induced	O	-1	3125850
musc@@	B-Disease	D005207	3125850
le	I-Disease	-1	3125850
f@@	I-Disease	-1	3125850
as@@	I-Disease	-1	3125850
c@@	I-Disease	-1	3125850
ic@@	I-Disease	-1	3125850
ul@@	I-Disease	-1	3125850
ations	I-Disease	-1	3125850
in	O	-1	3125850
child@@	O	-1	3125850
ren@@	O	-1	3125850
:	O	-1	3125850
inhibition	O	-1	3125850
by	O	-1	3125850
al@@	B-Chemical	D015760	3125850
f@@	I-Chemical	-1	3125850
entan@@	I-Chemical	-1	3125850
il	I-Chemical	-1	3125850
.	O	-1	3125850
Ch@@	O	-1	3125850
ang@@	O	-1	3125850
es	O	-1	3125850
in	O	-1	3125850
intra@@	O	-1	3125850
gast@@	O	-1	3125850
ric	O	-1	3125850
pressure	O	-1	3125850
after	O	-1	3125850
the	O	-1	3125850
administration	O	-1	3125850
of	O	-1	3125850
su@@	B-Chemical	D013390	3125850
xameth@@	I-Chemical	-1	3125850
oni@@	I-Chemical	-1	3125850
um	I-Chemical	-1	3125850
1.@@	O	-1	3125850
5	O	-1	3125850
mg	O	-1	3125850
kg@@	O	-1	3125850
-1	O	-1	3125850
i.v@@	O	-1	3125850
.	O	-1	3125850
were	O	-1	3125850
studied	O	-1	3125850
in	O	-1	3125850
3@@	O	-1	3125850
2	O	-1	3125850
children	O	-1	3125850
(@@	O	-1	3125850
mean	O	-1	3125850
age	O	-1	3125850
6.@@	O	-1	3125850
9	O	-1	3125850
y@@	O	-1	3125850
r@@	O	-1	3125850
)	O	-1	3125850
pre@@	O	-1	3125850
treated	O	-1	3125850
with	O	-1	3125850
either	O	-1	3125850
physi@@	O	-1	3125850
ological	O	-1	3125850
saline	O	-1	3125850
or	O	-1	3125850
al@@	B-Chemical	D015760	3125850
f@@	I-Chemical	-1	3125850
entan@@	I-Chemical	-1	3125850
il	I-Chemical	-1	3125850
50	O	-1	3125850
microgram@@	O	-1	3125850
s	O	-1	3125850
kg@@	O	-1	3125850
-1@@	O	-1	3125850
.	O	-1	3125850
An@@	O	-1	3125850
a@@	O	-1	3125850
esthe@@	O	-1	3125850
sia	O	-1	3125850
was	O	-1	3125850
induced	O	-1	3125850
with	O	-1	3125850
th@@	B-Chemical	D013874	3125850
io@@	I-Chemical	-1	3125850
pent@@	I-Chemical	-1	3125850
one	I-Chemical	-1	3125850
5	O	-1	3125850
mg	O	-1	3125850
kg@@	O	-1	3125850
-1@@	O	-1	3125850
.	O	-1	3125850
The	O	-1	3125850
incidence	O	-1	3125850
and	O	-1	3125850
int@@	O	-1	3125850
ensity	O	-1	3125850
of	O	-1	3125850
musc@@	B-Disease	D005207	3125850
le	I-Disease	-1	3125850
f@@	I-Disease	-1	3125850
as@@	I-Disease	-1	3125850
c@@	I-Disease	-1	3125850
ic@@	I-Disease	-1	3125850
ul@@	I-Disease	-1	3125850
ations	I-Disease	-1	3125850
caused	O	-1	3125850
by	O	-1	3125850
su@@	B-Chemical	D013390	3125850
xameth@@	I-Chemical	-1	3125850
oni@@	I-Chemical	-1	3125850
um	I-Chemical	-1	3125850
were	O	-1	3125850
significantly	O	-1	3125850
greater	O	-1	3125850
in	O	-1	3125850
the	O	-1	3125850
control	O	-1	3125850
than	O	-1	3125850
in	O	-1	3125850
the	O	-1	3125850
al@@	B-Chemical	D015760	3125850
f@@	I-Chemical	-1	3125850
entan@@	I-Chemical	-1	3125850
il	I-Chemical	-1	3125850
group.	O	-1	3125850
The	O	-1	3125850
intra@@	O	-1	3125850
gast@@	O	-1	3125850
ric	O	-1	3125850
pressure	O	-1	3125850
during	O	-1	3125850
musc@@	B-Disease	D005207	3125850
le	I-Disease	-1	3125850
f@@	I-Disease	-1	3125850
as@@	I-Disease	-1	3125850
c@@	I-Disease	-1	3125850
ic@@	I-Disease	-1	3125850
ul@@	I-Disease	-1	3125850
ations	I-Disease	-1	3125850
was	O	-1	3125850
significantly	O	-1	3125850
higher	O	-1	3125850
in	O	-1	3125850
the	O	-1	3125850
control	O	-1	3125850
group	O	-1	3125850
(1@@	O	-1	3125850
6	O	-1	3125850
+/-	O	-1	3125850
0.@@	O	-1	3125850
7	O	-1	3125850
(S@@	O	-1	3125850
E@@	O	-1	3125850
M@@	O	-1	3125850
)	O	-1	3125850
c@@	O	-1	3125850
m	O	-1	3125850
H@@	B-Chemical	D014867	3125850
2@@	I-Chemical	-1	3125850
O	I-Chemical	-1	3125850
)	O	-1	3125850
than	O	-1	3125850
in	O	-1	3125850
the	O	-1	3125850
al@@	B-Chemical	D015760	3125850
f@@	I-Chemical	-1	3125850
entan@@	I-Chemical	-1	3125850
il	I-Chemical	-1	3125850
group	O	-1	3125850
(@@	O	-1	3125850
7.@@	O	-1	3125850
7	O	-1	3125850
+/-	O	-1	3125850
1.@@	O	-1	3125850
5	O	-1	3125850
(S@@	O	-1	3125850
E@@	O	-1	3125850
M@@	O	-1	3125850
)	O	-1	3125850
c@@	O	-1	3125850
m	O	-1	3125850
H@@	B-Chemical	D014867	3125850
2@@	I-Chemical	-1	3125850
O	I-Chemical	-1	3125850
).	O	-1	3125850
The	O	-1	3125850
increase	O	-1	3125850
in	O	-1	3125850
intra@@	O	-1	3125850
gast@@	O	-1	3125850
ric	O	-1	3125850
pressure	O	-1	3125850
was	O	-1	3125850
direc@@	O	-1	3125850
tly	O	-1	3125850
related	O	-1	3125850
to	O	-1	3125850
the	O	-1	3125850
int@@	O	-1	3125850
ensity	O	-1	3125850
of	O	-1	3125850
musc@@	B-Disease	D005207	3125850
le	I-Disease	-1	3125850
f@@	I-Disease	-1	3125850
as@@	I-Disease	-1	3125850
c@@	I-Disease	-1	3125850
ic@@	I-Disease	-1	3125850
ul@@	I-Disease	-1	3125850
ations	I-Disease	-1	3125850
(@@	O	-1	3125850
reg@@	O	-1	3125850
res@@	O	-1	3125850
sion	O	-1	3125850
l@@	O	-1	3125850
ine@@	O	-1	3125850
:	O	-1	3125850
y	O	-1	3125850
=	O	-1	3125850
0.@@	O	-1	3125850
5	O	-1	3125850
+	O	-1	3125850
4.@@	O	-1	3125850
7@@	O	-1	3125850
8@@	O	-1	3125850
x	O	-1	3125850
with	O	-1	3125850
r	O	-1	3125850
of	O	-1	3125850
0.@@	O	-1	3125850
7@@	O	-1	3125850
8@@	O	-1	3125850
).	O	-1	3125850
It	O	-1	3125850
is	O	-1	3125850
concl@@	O	-1	3125850
uded	O	-1	3125850
that	O	-1	3125850
intra@@	O	-1	3125850
gast@@	O	-1	3125850
ric	O	-1	3125850
pressure	O	-1	3125850
increases	O	-1	3125850
significantly	O	-1	3125850
during	O	-1	3125850
musc@@	B-Disease	D005207	3125850
le	I-Disease	-1	3125850
f@@	I-Disease	-1	3125850
as@@	I-Disease	-1	3125850
c@@	I-Disease	-1	3125850
ic@@	I-Disease	-1	3125850
ul@@	I-Disease	-1	3125850
ations	I-Disease	-1	3125850
caused	O	-1	3125850
by	O	-1	3125850
su@@	B-Chemical	D013390	3125850
xameth@@	I-Chemical	-1	3125850
oni@@	I-Chemical	-1	3125850
um	I-Chemical	-1	3125850
in	O	-1	3125850
healthy	O	-1	3125850
child@@	O	-1	3125850
ren@@	O	-1	3125850
.	O	-1	3125850
Al@@	B-Chemical	D015760	3125850
f@@	I-Chemical	-1	3125850
entan@@	I-Chemical	-1	3125850
il	I-Chemical	-1	3125850
50	O	-1	3125850
microgram@@	O	-1	3125850
s	O	-1	3125850
kg@@	O	-1	3125850
-1	O	-1	3125850
eff@@	O	-1	3125850
ectively	O	-1	3125850
inhibit@@	O	-1	3125850
s	O	-1	3125850
the	O	-1	3125850
incidence	O	-1	3125850
and	O	-1	3125850
int@@	O	-1	3125850
ensity	O	-1	3125850
of	O	-1	3125850
su@@	B-Chemical	D013390	3125850
xameth@@	I-Chemical	-1	3125850
oni@@	I-Chemical	-1	3125850
um	I-Chemical	-1	3125850
-induced	O	-1	3125850
musc@@	B-Disease	D005207	3125850
le	I-Disease	-1	3125850
f@@	I-Disease	-1	3125850
as@@	I-Disease	-1	3125850
c@@	I-Disease	-1	3125850
ic@@	I-Disease	-1	3125850
ul@@	I-Disease	-1	3125850
ations	I-Disease	-1	3125850
;	O	-1	3125850
mo@@	O	-1	3125850
re@@	O	-1	3125850
o@@	O	-1	3125850
ver,	O	-1	3125850
intra@@	O	-1	3125850
gast@@	O	-1	3125850
ric	O	-1	3125850
pressure	O	-1	3125850
remain@@	O	-1	3125850
s	O	-1	3125850
at	O	-1	3125850
its	O	-1	3125850
control	O	-1	3125850
valu@@	O	-1	3125850
e.	O	-1	3125850

Ac@@	O	-1	3155884
ute	O	-1	3155884
in@@	O	-1	3155884
sul@@	O	-1	3155884
in	O	-1	3155884
treatment	O	-1	3155884
normal@@	O	-1	3155884
iz@@	O	-1	3155884
es	O	-1	3155884
the	O	-1	3155884
resist@@	O	-1	3155884
ance	O	-1	3155884
to	O	-1	3155884
the	O	-1	3155884
cardi@@	B-Disease	D066126	3155884
ot@@	I-Disease	-1	3155884
ox@@	I-Disease	-1	3155884
ic	I-Disease	-1	3155884
effect	O	-1	3155884
of	O	-1	3155884
isoproteren@@	B-Chemical	D007545	3155884
ol	I-Chemical	-1	3155884
in	O	-1	3155884
st@@	B-Chemical	D013311	3155884
re@@	I-Chemical	-1	3155884
pto@@	I-Chemical	-1	3155884
z@@	I-Chemical	-1	3155884
ot@@	I-Chemical	-1	3155884
oc@@	I-Chemical	-1	3155884
in	I-Chemical	-1	3155884
dia@@	B-Disease	D003920	3155884
be@@	I-Disease	-1	3155884
tic	I-Disease	-1	3155884
rats.	O	-1	3155884
A	O	-1	3155884
morph@@	O	-1	3155884
o@@	O	-1	3155884
me@@	O	-1	3155884
tri@@	O	-1	3155884
c	O	-1	3155884
study	O	-1	3155884
of	O	-1	3155884
isoproteren@@	B-Chemical	D007545	3155884
ol	I-Chemical	-1	3155884
induced	O	-1	3155884
myocardial	O	-1	3155884
fib@@	B-Disease	D005355	3155884
ro@@	I-Disease	-1	3155884
sis	I-Disease	-1	3155884
.	O	-1	3155884
The	O	-1	3155884
acute	O	-1	3155884
effect	O	-1	3155884
of	O	-1	3155884
in@@	O	-1	3155884
sul@@	O	-1	3155884
in	O	-1	3155884
treatment	O	-1	3155884
on	O	-1	3155884
the	O	-1	3155884
ear@@	O	-1	3155884
li@@	O	-1	3155884
er	O	-1	3155884
reported	O	-1	3155884
protective	O	-1	3155884
effect	O	-1	3155884
of	O	-1	3155884
st@@	B-Chemical	D013311	3155884
re@@	I-Chemical	-1	3155884
pto@@	I-Chemical	-1	3155884
z@@	I-Chemical	-1	3155884
ot@@	I-Chemical	-1	3155884
oc@@	I-Chemical	-1	3155884
in	I-Chemical	-1	3155884
dia@@	B-Disease	D003920	3155884
bet@@	I-Disease	-1	3155884
es	I-Disease	-1	3155884
against	O	-1	3155884
the	O	-1	3155884
cardi@@	B-Disease	D066126	3155884
ot@@	I-Disease	-1	3155884
ox@@	I-Disease	-1	3155884
ic	I-Disease	-1	3155884
effect	O	-1	3155884
of	O	-1	3155884
high	O	-1	3155884
doses	O	-1	3155884
of	O	-1	3155884
isoproteren@@	B-Chemical	D007545	3155884
ol	I-Chemical	-1	3155884
(	O	-1	3155884
I@@	B-Chemical	D007545	3155884
S@@	I-Chemical	-1	3155884
O	I-Chemical	-1	3155884
)	O	-1	3155884
was	O	-1	3155884
investigated	O	-1	3155884
in	O	-1	3155884
rats.	O	-1	3155884
Th@@	O	-1	3155884
ir@@	O	-1	3155884
t@@	O	-1	3155884
y	O	-1	3155884
to	O	-1	3155884
13@@	O	-1	3155884
5	O	-1	3155884
min	O	-1	3155884
after	O	-1	3155884
the	O	-1	3155884
injection	O	-1	3155884
of	O	-1	3155884
c@@	O	-1	3155884
r@@	O	-1	3155884
y@@	O	-1	3155884
st@@	O	-1	3155884
all@@	O	-1	3155884
ine	O	-1	3155884
in@@	O	-1	3155884
sul@@	O	-1	3155884
in,	O	-1	3155884
I@@	B-Chemical	D007545	3155884
S@@	I-Chemical	-1	3155884
O	I-Chemical	-1	3155884
was	O	-1	3155884
given	O	-1	3155884
sub@@	O	-1	3155884
c@@	O	-1	3155884
ut@@	O	-1	3155884
ane@@	O	-1	3155884
ously	O	-1	3155884
and	O	-1	3155884
when	O	-1	3155884
I@@	B-Chemical	D007545	3155884
S@@	I-Chemical	-1	3155884
O	I-Chemical	-1	3155884
induced	O	-1	3155884
fib@@	B-Disease	D005355	3155884
ro@@	I-Disease	-1	3155884
sis	I-Disease	-1	3155884
in	O	-1	3155884
the	O	-1	3155884
myocardi@@	O	-1	3155884
um	O	-1	3155884
was	O	-1	3155884
morph@@	O	-1	3155884
o@@	O	-1	3155884
met@@	O	-1	3155884
r@@	O	-1	3155884
ically	O	-1	3155884
analy@@	O	-1	3155884
zed	O	-1	3155884
7	O	-1	3155884
days	O	-1	3155884
lat@@	O	-1	3155884
er,	O	-1	3155884
a	O	-1	3155884
high@@	O	-1	3155884
ly	O	-1	3155884
significant	O	-1	3155884
correl@@	O	-1	3155884
ation	O	-1	3155884
(@@	O	-1	3155884
r	O	-1	3155884
=	O	-1	3155884
0.@@	O	-1	3155884
8@@	O	-1	3155884
3,	O	-1	3155884
2	O	-1	3155884
p	O	-1	3155884
=	O	-1	3155884
0.00@@	O	-1	3155884
6@@	O	-1	3155884
)	O	-1	3155884
to	O	-1	3155884
the	O	-1	3155884
s@@	O	-1	3155884
lop@@	O	-1	3155884
e	O	-1	3155884
of	O	-1	3155884
the	O	-1	3155884
f@@	O	-1	3155884
all	O	-1	3155884
in	O	-1	3155884
blood	O	-1	3155884
g@@	B-Chemical	D005947	3155884
lu@@	I-Chemical	-1	3155884
co@@	I-Chemical	-1	3155884
se	I-Chemical	-1	3155884
after	O	-1	3155884
in@@	O	-1	3155884
sul@@	O	-1	3155884
in	O	-1	3155884
treatment	O	-1	3155884
appe@@	O	-1	3155884
a@@	O	-1	3155884
red.	O	-1	3155884
The	O	-1	3155884
myocardial	O	-1	3155884
cont@@	O	-1	3155884
ent	O	-1	3155884
of	O	-1	3155884
cat@@	B-Chemical	D002395	3155884
ech@@	I-Chemical	-1	3155884
ol@@	I-Chemical	-1	3155884
amin@@	I-Chemical	-1	3155884
es	I-Chemical	-1	3155884
was	O	-1	3155884
estim@@	O	-1	3155884
ated	O	-1	3155884
in	O	-1	3155884
these	O	-1	3155884
8	O	-1	3155884
day	O	-1	3155884
dia@@	B-Disease	D003920	3155884
be@@	I-Disease	-1	3155884
tic	I-Disease	-1	3155884
rats.	O	-1	3155884
The	O	-1	3155884
no@@	B-Chemical	D009638	3155884
re@@	I-Chemical	-1	3155884
p@@	I-Chemical	-1	3155884
ine@@	I-Chemical	-1	3155884
phrine	I-Chemical	-1	3155884
cont@@	O	-1	3155884
ent	O	-1	3155884
was	O	-1	3155884
significantly	O	-1	3155884
increased	O	-1	3155884
while	O	-1	3155884
ep@@	B-Chemical	D004837	3155884
ine@@	I-Chemical	-1	3155884
phrine	I-Chemical	-1	3155884
remained	O	-1	3155884
un@@	O	-1	3155884
chang@@	O	-1	3155884
ed.	O	-1	3155884
An	O	-1	3155884
enhanced	O	-1	3155884
sym@@	O	-1	3155884
pa@@	O	-1	3155884
thetic	O	-1	3155884
ner@@	O	-1	3155884
v@@	O	-1	3155884
ous	O	-1	3155884
system	O	-1	3155884
activity	O	-1	3155884
with	O	-1	3155884
a	O	-1	3155884
con@@	O	-1	3155884
sequ@@	O	-1	3155884
ent	O	-1	3155884
do@@	O	-1	3155884
w@@	O	-1	3155884
n	O	-1	3155884
reg@@	O	-1	3155884
ulation	O	-1	3155884
of	O	-1	3155884
the	O	-1	3155884
myocardial	O	-1	3155884
beta-@@	O	-1	3155884
adrenergic	O	-1	3155884
receptors	O	-1	3155884
co@@	O	-1	3155884
ul@@	O	-1	3155884
d,	O	-1	3155884
the@@	O	-1	3155884
refore,	O	-1	3155884
expl@@	O	-1	3155884
ain	O	-1	3155884
this	O	-1	3155884
cat@@	B-Chemical	D002395	3155884
ech@@	I-Chemical	-1	3155884
ol@@	I-Chemical	-1	3155884
amine	I-Chemical	-1	3155884
resist@@	O	-1	3155884
ance@@	O	-1	3155884
.	O	-1	3155884
The	O	-1	3155884
ra@@	O	-1	3155884
pid	O	-1	3155884
rever@@	O	-1	3155884
sion	O	-1	3155884
after	O	-1	3155884
in@@	O	-1	3155884
sul@@	O	-1	3155884
in	O	-1	3155884
treatment	O	-1	3155884
ex@@	O	-1	3155884
cl@@	O	-1	3155884
u@@	O	-1	3155884
des	O	-1	3155884
the	O	-1	3155884
possib@@	O	-1	3155884
ility	O	-1	3155884
that	O	-1	3155884
st@@	B-Chemical	D013311	3155884
re@@	I-Chemical	-1	3155884
pto@@	I-Chemical	-1	3155884
z@@	I-Chemical	-1	3155884
ot@@	I-Chemical	-1	3155884
oc@@	I-Chemical	-1	3155884
in	I-Chemical	-1	3155884
in	O	-1	3155884
it@@	O	-1	3155884
sel@@	O	-1	3155884
f	O	-1	3155884
causes	O	-1	3155884
the	O	-1	3155884
I@@	B-Chemical	D007545	3155884
S@@	I-Chemical	-1	3155884
O	I-Chemical	-1	3155884
resist@@	O	-1	3155884
ance	O	-1	3155884
and	O	-1	3155884
po@@	O	-1	3155884
int@@	O	-1	3155884
s	O	-1	3155884
to@@	O	-1	3155884
war@@	O	-1	3155884
ds	O	-1	3155884
a	O	-1	3155884
direct	O	-1	3155884
in@@	O	-1	3155884
sul@@	O	-1	3155884
in	O	-1	3155884
effect	O	-1	3155884
on	O	-1	3155884
myocardial	O	-1	3155884
cat@@	B-Chemical	D002395	3155884
ech@@	I-Chemical	-1	3155884
ol@@	I-Chemical	-1	3155884
amine	I-Chemical	-1	3155884
sensitivity	O	-1	3155884
in	O	-1	3155884
dia@@	B-Disease	D003920	3155884
be@@	I-Disease	-1	3155884
tic	I-Disease	-1	3155884
rats.	O	-1	3155884
The	O	-1	3155884
phen@@	O	-1	3155884
om@@	O	-1	3155884
en@@	O	-1	3155884
on	O	-1	3155884
descri@@	O	-1	3155884
bed	O	-1	3155884
might	O	-1	3155884
el@@	O	-1	3155884
uc@@	O	-1	3155884
id@@	O	-1	3155884
ate	O	-1	3155884
path@@	O	-1	3155884
o@@	O	-1	3155884
gene@@	O	-1	3155884
tic	O	-1	3155884
mechanisms	O	-1	3155884
be@@	O	-1	3155884
h@@	O	-1	3155884
ind	O	-1	3155884
toxic	O	-1	3155884
myocardial	O	-1	3155884
cell	O	-1	3155884
de@@	O	-1	3155884
generation	O	-1	3155884
and	O	-1	3155884
may	O	-1	3155884
possib@@	O	-1	3155884
ly	O	-1	3155884
have	O	-1	3155884
re@@	O	-1	3155884
lev@@	O	-1	3155884
ance	O	-1	3155884
for	O	-1	3155884
acute	O	-1	3155884
cardiovascular	O	-1	3155884
complications	O	-1	3155884
in	O	-1	3155884
dia@@	B-Disease	D003920	3155884
be@@	I-Disease	-1	3155884
tic	I-Disease	-1	3155884
patients.	O	-1	3155884

Di@@	O	-1	3191389
fferen@@	O	-1	3191389
tial	O	-1	3191389
effects	O	-1	3191389
of	O	-1	3191389
non-@@	O	-1	3191389
steroid@@	O	-1	3191389
al	O	-1	3191389
anti@@	O	-1	3191389
-@@	O	-1	3191389
inflam@@	O	-1	3191389
mat@@	O	-1	3191389
ory	O	-1	3191389
drugs	O	-1	3191389
on	O	-1	3191389
seizures	B-Disease	D012640	3191389
produced	O	-1	3191389
by	O	-1	3191389
pilocar@@	B-Chemical	D010862	3191389
pine	I-Chemical	-1	3191389
in	O	-1	3191389
rats.	O	-1	3191389
The	O	-1	3191389
mus@@	O	-1	3191389
car@@	O	-1	3191389
inic	O	-1	3191389
cholinergic	O	-1	3191389
agon@@	O	-1	3191389
ist	O	-1	3191389
pilocar@@	B-Chemical	D010862	3191389
pine	I-Chemical	-1	3191389
induc@@	O	-1	3191389
es	O	-1	3191389
in	O	-1	3191389
rats	O	-1	3191389
seizures	B-Disease	D012640	3191389
and	O	-1	3191389
status	B-Disease	D013226	3191389
epilep@@	I-Disease	-1	3191389
tic@@	I-Disease	-1	3191389
us	I-Disease	-1	3191389
followed	O	-1	3191389
by	O	-1	3191389
w@@	O	-1	3191389
id@@	O	-1	3191389
es@@	O	-1	3191389
pre@@	O	-1	3191389
ad	O	-1	3191389
damage	O	-1	3191389
to	O	-1	3191389
the	O	-1	3191389
fo@@	O	-1	3191389
re@@	O	-1	3191389
bra@@	O	-1	3191389
in.	O	-1	3191389
The	O	-1	3191389
present	O	-1	3191389
study	O	-1	3191389
was	O	-1	3191389
de@@	O	-1	3191389
signed	O	-1	3191389
to	O	-1	3191389
investigate	O	-1	3191389
the	O	-1	3191389
effect	O	-1	3191389
of	O	-1	3191389
5	O	-1	3191389
non-@@	O	-1	3191389
steroid@@	O	-1	3191389
al	O	-1	3191389
anti@@	O	-1	3191389
-@@	O	-1	3191389
inflam@@	O	-1	3191389
mat@@	O	-1	3191389
ory	O	-1	3191389
drug@@	O	-1	3191389
s,	O	-1	3191389
sodium	B-Chemical	D012980	3191389
sal@@	I-Chemical	-1	3191389
ic@@	I-Chemical	-1	3191389
yl@@	I-Chemical	-1	3191389
ate	I-Chemical	-1	3191389
,	O	-1	3191389
phenyl@@	B-Chemical	D010653	3191389
but@@	I-Chemical	-1	3191389
az@@	I-Chemical	-1	3191389
one	I-Chemical	-1	3191389
,	O	-1	3191389
in@@	B-Chemical	D007213	3191389
do@@	I-Chemical	-1	3191389
meth@@	I-Chemical	-1	3191389
ac@@	I-Chemical	-1	3191389
in	I-Chemical	-1	3191389
,	O	-1	3191389
i@@	B-Chemical	D007052	3191389
bu@@	I-Chemical	-1	3191389
prof@@	I-Chemical	-1	3191389
en	I-Chemical	-1	3191389
and	O	-1	3191389
me@@	B-Chemical	D008528	3191389
f@@	I-Chemical	-1	3191389
en@@	I-Chemical	-1	3191389
am@@	I-Chemical	-1	3191389
ic	I-Chemical	-1	3191389
acid	I-Chemical	-1	3191389
,	O	-1	3191389
on	O	-1	3191389
seizures	B-Disease	D012640	3191389
produced	O	-1	3191389
by	O	-1	3191389
pilocar@@	B-Chemical	D010862	3191389
pine	I-Chemical	-1	3191389
.	O	-1	3191389
Pre@@	O	-1	3191389
treatment	O	-1	3191389
of	O	-1	3191389
rats	O	-1	3191389
with	O	-1	3191389
sodium	B-Chemical	D012980	3191389
sal@@	I-Chemical	-1	3191389
ic@@	I-Chemical	-1	3191389
yl@@	I-Chemical	-1	3191389
ate	I-Chemical	-1	3191389
,	O	-1	3191389
E@@	O	-1	3191389
D@@	O	-1	3191389
50	O	-1	3191389
10@@	O	-1	3191389
3	O	-1	3191389
mg/kg	O	-1	3191389
(6@@	O	-1	3191389
0@@	O	-1	3191389
-1@@	O	-1	3191389
7@@	O	-1	3191389
4@@	O	-1	3191389
),	O	-1	3191389
and	O	-1	3191389
phenyl@@	B-Chemical	D010653	3191389
but@@	I-Chemical	-1	3191389
az@@	I-Chemical	-1	3191389
one	I-Chemical	-1	3191389
,	O	-1	3191389
5@@	O	-1	3191389
9	O	-1	3191389
mg/kg	O	-1	3191389
(@@	O	-1	3191389
50@@	O	-1	3191389
-@@	O	-1	3191389
7@@	O	-1	3191389
0@@	O	-1	3191389
)	O	-1	3191389
conver@@	O	-1	3191389
ted	O	-1	3191389
the	O	-1	3191389
non-@@	O	-1	3191389
convul@@	O	-1	3191389
s@@	O	-1	3191389
ant	O	-1	3191389
dose	O	-1	3191389
of	O	-1	3191389
pilocar@@	B-Chemical	D010862	3191389
pine	I-Chemical	-1	3191389
,	O	-1	3191389
2@@	O	-1	3191389
00	O	-1	3191389
mg/kg@@	O	-1	3191389
,	O	-1	3191389
to	O	-1	3191389
a	O	-1	3191389
convul@@	O	-1	3191389
s@@	O	-1	3191389
ant	O	-1	3191389
one.	O	-1	3191389
In@@	B-Chemical	D007213	3191389
do@@	I-Chemical	-1	3191389
meth@@	I-Chemical	-1	3191389
ac@@	I-Chemical	-1	3191389
in	I-Chemical	-1	3191389
,	O	-1	3191389
1-@@	O	-1	3191389
10	O	-1	3191389
mg/kg@@	O	-1	3191389
,	O	-1	3191389
and	O	-1	3191389
i@@	B-Chemical	D007052	3191389
bu@@	I-Chemical	-1	3191389
prof@@	I-Chemical	-1	3191389
en	I-Chemical	-1	3191389
,	O	-1	3191389
10-@@	O	-1	3191389
100	O	-1	3191389
mg/kg@@	O	-1	3191389
,	O	-1	3191389
fail@@	O	-1	3191389
ed	O	-1	3191389
to	O	-1	3191389
mod@@	O	-1	3191389
ul@@	O	-1	3191389
ate	O	-1	3191389
seizures	B-Disease	D012640	3191389
produced	O	-1	3191389
by	O	-1	3191389
pilocar@@	B-Chemical	D010862	3191389
pine	I-Chemical	-1	3191389
.	O	-1	3191389
M@@	B-Chemical	D008528	3191389
e@@	I-Chemical	-1	3191389
f@@	I-Chemical	-1	3191389
en@@	I-Chemical	-1	3191389
am@@	I-Chemical	-1	3191389
ic	I-Chemical	-1	3191389
acid	I-Chemical	-1	3191389
,	O	-1	3191389
2@@	O	-1	3191389
6	O	-1	3191389
(2@@	O	-1	3191389
2-@@	O	-1	3191389
3@@	O	-1	3191389
0@@	O	-1	3191389
)	O	-1	3191389
mg/kg@@	O	-1	3191389
,	O	-1	3191389
prevent@@	O	-1	3191389
ed	O	-1	3191389
seizures	B-Disease	D012640	3191389
and	O	-1	3191389
prot@@	O	-1	3191389
ected	O	-1	3191389
rats	O	-1	3191389
from	O	-1	3191389
seizure	B-Disease	D012640	3191389
-@@	O	-1	3191389
related	O	-1	3191389
brain	B-Disease	D001930	3191389
damage	I-Disease	-1	3191389
induced	O	-1	3191389
by	O	-1	3191389
pilocar@@	B-Chemical	D010862	3191389
pine	I-Chemical	-1	3191389
,	O	-1	3191389
3@@	O	-1	3191389
8@@	O	-1	3191389
0	O	-1	3191389
mg/kg@@	O	-1	3191389
.	O	-1	3191389
These	O	-1	3191389
results	O	-1	3191389
indicate	O	-1	3191389
that	O	-1	3191389
non-@@	O	-1	3191389
steroid@@	O	-1	3191389
al	O	-1	3191389
anti@@	O	-1	3191389
-@@	O	-1	3191389
inflam@@	O	-1	3191389
mat@@	O	-1	3191389
ory	O	-1	3191389
drugs	O	-1	3191389
differen@@	O	-1	3191389
ti@@	O	-1	3191389
ally	O	-1	3191389
mod@@	O	-1	3191389
ul@@	O	-1	3191389
ate	O	-1	3191389
the	O	-1	3191389
th@@	O	-1	3191389
res@@	O	-1	3191389
h@@	O	-1	3191389
old	O	-1	3191389
for	O	-1	3191389
pilocar@@	B-Chemical	D010862	3191389
pine	I-Chemical	-1	3191389
-induced	O	-1	3191389
seizures	B-Disease	D012640	3191389
.	O	-1	3191389

Ac@@	B-Disease	D009422	3289726
ute	I-Disease	-1	3289726
neurolog@@	I-Disease	-1	3289726
ic	I-Disease	-1	3289726
dysfunction	I-Disease	-1	3289726
after	O	-1	3289726
high-dose	O	-1	3289726
e@@	B-Chemical	D005047	3289726
to@@	I-Chemical	-1	3289726
po@@	I-Chemical	-1	3289726
side	I-Chemical	-1	3289726
therapy	O	-1	3289726
for	O	-1	3289726
mal@@	B-Disease	D005910	3289726
i@@	I-Disease	-1	3289726
gn@@	I-Disease	-1	3289726
ant	I-Disease	-1	3289726
g@@	I-Disease	-1	3289726
li@@	I-Disease	-1	3289726
oma	I-Disease	-1	3289726
.	O	-1	3289726
E@@	B-Chemical	D005047	3289726
to@@	I-Chemical	-1	3289726
po@@	I-Chemical	-1	3289726
side	I-Chemical	-1	3289726
(	O	-1	3289726
V@@	B-Chemical	D005047	3289726
P@@	I-Chemical	-1	3289726
-1@@	I-Chemical	-1	3289726
6-@@	I-Chemical	-1	3289726
2@@	I-Chemical	-1	3289726
13	I-Chemical	-1	3289726
)	O	-1	3289726
has	O	-1	3289726
been	O	-1	3289726
used	O	-1	3289726
in	O	-1	3289726
the	O	-1	3289726
treatment	O	-1	3289726
of	O	-1	3289726
man@@	O	-1	3289726
y	O	-1	3289726
sol@@	O	-1	3289726
id	O	-1	3289726
tu@@	B-Disease	D009369	3289726
mor@@	I-Disease	-1	3289726
s	I-Disease	-1	3289726
and	O	-1	3289726
hemat@@	B-Disease	D019337	3289726
ologic	I-Disease	-1	3289726
mal@@	I-Disease	-1	3289726
i@@	I-Disease	-1	3289726
gn@@	I-Disease	-1	3289726
an@@	I-Disease	-1	3289726
ci@@	I-Disease	-1	3289726
es	I-Disease	-1	3289726
.	O	-1	3289726
Whe@@	O	-1	3289726
n	O	-1	3289726
used	O	-1	3289726
in	O	-1	3289726
high	O	-1	3289726
doses	O	-1	3289726
and	O	-1	3289726
in	O	-1	3289726
con@@	O	-1	3289726
j@@	O	-1	3289726
unc@@	O	-1	3289726
tion	O	-1	3289726
with	O	-1	3289726
auto@@	O	-1	3289726
log@@	O	-1	3289726
ous	O	-1	3289726
b@@	O	-1	3289726
one	O	-1	3289726
m@@	O	-1	3289726
ar@@	O	-1	3289726
ro@@	O	-1	3289726
w	O	-1	3289726
transplant@@	O	-1	3289726
ation,	O	-1	3289726
this	O	-1	3289726
agent	O	-1	3289726
has	O	-1	3289726
activity	O	-1	3289726
against	O	-1	3289726
several	O	-1	3289726
treatment@@	O	-1	3289726
-@@	O	-1	3289726
resist@@	O	-1	3289726
ant	O	-1	3289726
canc@@	B-Disease	D009369	3289726
ers	I-Disease	-1	3289726
including	O	-1	3289726
mal@@	B-Disease	D005910	3289726
i@@	I-Disease	-1	3289726
gn@@	I-Disease	-1	3289726
ant	I-Disease	-1	3289726
g@@	I-Disease	-1	3289726
li@@	I-Disease	-1	3289726
oma	I-Disease	-1	3289726
.	O	-1	3289726
In	O	-1	3289726
six	O	-1	3289726
of	O	-1	3289726
e@@	O	-1	3289726
ight	O	-1	3289726
patients	O	-1	3289726
(@@	O	-1	3289726
7@@	O	-1	3289726
5@@	O	-1	3289726
%)	O	-1	3289726
who	O	-1	3289726
we	O	-1	3289726
treated	O	-1	3289726
for	O	-1	3289726
recur@@	O	-1	3289726
rent	O	-1	3289726
or	O	-1	3289726
resist@@	O	-1	3289726
ant	O	-1	3289726
g@@	B-Disease	D005910	3289726
li@@	I-Disease	-1	3289726
oma	I-Disease	-1	3289726
,	O	-1	3289726
su@@	O	-1	3289726
d@@	O	-1	3289726
de@@	O	-1	3289726
n	O	-1	3289726
severe	O	-1	3289726
neurolog@@	B-Disease	D009422	3289726
ic	I-Disease	-1	3289726
deter@@	I-Disease	-1	3289726
i@@	I-Disease	-1	3289726
or@@	I-Disease	-1	3289726
ation	I-Disease	-1	3289726
occur@@	O	-1	3289726
red.	O	-1	3289726
This	O	-1	3289726
developed	O	-1	3289726
a	O	-1	3289726
median	O	-1	3289726
of	O	-1	3289726
9	O	-1	3289726
days	O	-1	3289726
after	O	-1	3289726
initi@@	O	-1	3289726
ation	O	-1	3289726
of	O	-1	3289726
high-dose	O	-1	3289726
e@@	B-Chemical	D005047	3289726
to@@	I-Chemical	-1	3289726
po@@	I-Chemical	-1	3289726
side	I-Chemical	-1	3289726
therapy.	O	-1	3289726
Si@@	O	-1	3289726
gn@@	O	-1	3289726
ific@@	O	-1	3289726
ant	O	-1	3289726
clinical	O	-1	3289726
man@@	O	-1	3289726
if@@	O	-1	3289726
est@@	O	-1	3289726
ations	O	-1	3289726
have	O	-1	3289726
included	O	-1	3289726
conf@@	B-Disease	D003221	3289726
usion	I-Disease	-1	3289726
,	O	-1	3289726
pap@@	B-Disease	D010211	3289726
il@@	I-Disease	-1	3289726
le@@	I-Disease	-1	3289726
de@@	I-Disease	-1	3289726
ma	I-Disease	-1	3289726
,	O	-1	3289726
s@@	B-Disease	D006970	3289726
om@@	I-Disease	-1	3289726
n@@	I-Disease	-1	3289726
ol@@	I-Disease	-1	3289726
ence	I-Disease	-1	3289726
,	O	-1	3289726
ex@@	O	-1	3289726
ac@@	O	-1	3289726
er@@	O	-1	3289726
b@@	O	-1	3289726
ation	O	-1	3289726
of	O	-1	3289726
motor	B-Disease	-1	3289726
defic@@	I-Disease	-1	3289726
its	I-Disease	-1	3289726
,	O	-1	3289726
and	O	-1	3289726
sh@@	O	-1	3289726
ar@@	O	-1	3289726
p	O	-1	3289726
increase	O	-1	3289726
in	O	-1	3289726
seizure	B-Disease	D012640	3289726
activ@@	O	-1	3289726
ity.	O	-1	3289726
These	O	-1	3289726
abnormal@@	O	-1	3289726
ities	O	-1	3289726
resol@@	O	-1	3289726
ved	O	-1	3289726
ra@@	O	-1	3289726
pid@@	O	-1	3289726
ly	O	-1	3289726
after	O	-1	3289726
initi@@	O	-1	3289726
ation	O	-1	3289726
of	O	-1	3289726
high-dose	O	-1	3289726
intravenous	O	-1	3289726
de@@	B-Chemical	D003907	3289726
xameth@@	I-Chemical	-1	3289726
as@@	I-Chemical	-1	3289726
one	I-Chemical	-1	3289726
therapy.	O	-1	3289726
In	O	-1	3289726
all	O	-1	3289726
patients,	O	-1	3289726
comp@@	O	-1	3289726
u@@	O	-1	3289726
ter@@	O	-1	3289726
ized	O	-1	3289726
to@@	O	-1	3289726
mo@@	O	-1	3289726
graph@@	O	-1	3289726
ic	O	-1	3289726
(C@@	O	-1	3289726
T)	O	-1	3289726
brain	O	-1	3289726
s@@	O	-1	3289726
c@@	O	-1	3289726
ans	O	-1	3289726
demonstrated	O	-1	3289726
st@@	O	-1	3289726
ability	O	-1	3289726
in	O	-1	3289726
tumor	B-Disease	D009369	3289726
size	O	-1	3289726
and	O	-1	3289726
per@@	O	-1	3289726
it@@	O	-1	3289726
um@@	O	-1	3289726
or	O	-1	3289726
e@@	B-Disease	D004487	3289726
de@@	I-Disease	-1	3289726
ma	I-Disease	-1	3289726
when	O	-1	3289726
compared	O	-1	3289726
with	O	-1	3289726
pre@@	O	-1	3289726
transplant	O	-1	3289726
s@@	O	-1	3289726
can@@	O	-1	3289726
s.	O	-1	3289726
This	O	-1	3289726
complication	O	-1	3289726
appear@@	O	-1	3289726
s	O	-1	3289726
to	O	-1	3289726
re@@	O	-1	3289726
present	O	-1	3289726
a	O	-1	3289726
significant	O	-1	3289726
new	O	-1	3289726
toxicity	B-Disease	D064420	3289726
of	O	-1	3289726
high-dose	O	-1	3289726
e@@	B-Chemical	D005047	3289726
to@@	I-Chemical	-1	3289726
po@@	I-Chemical	-1	3289726
side	I-Chemical	-1	3289726
therapy	O	-1	3289726
for	O	-1	3289726
mal@@	B-Disease	D005910	3289726
i@@	I-Disease	-1	3289726
gn@@	I-Disease	-1	3289726
ant	I-Disease	-1	3289726
g@@	I-Disease	-1	3289726
li@@	I-Disease	-1	3289726
oma	I-Disease	-1	3289726
.	O	-1	3289726

Pro@@	O	-1	3297909
gres@@	O	-1	3297909
sive	O	-1	3297909
b@@	B-Disease	D001649	3297909
ile	I-Disease	-1	3297909
duc@@	I-Disease	-1	3297909
t	I-Disease	-1	3297909
injury	I-Disease	-1	3297909
after	O	-1	3297909
thi@@	B-Chemical	D013827	3297909
ab@@	I-Chemical	-1	3297909
en@@	I-Chemical	-1	3297909
da@@	I-Chemical	-1	3297909
z@@	I-Chemical	-1	3297909
ole	I-Chemical	-1	3297909
administr@@	O	-1	3297909
ation.	O	-1	3297909
A	O	-1	3297909
27@@	O	-1	3297909
-@@	O	-1	3297909
y@@	O	-1	3297909
r@@	O	-1	3297909
-old	O	-1	3297909
man	O	-1	3297909
developed	O	-1	3297909
j@@	B-Disease	D007565	3297909
a@@	I-Disease	-1	3297909
un@@	I-Disease	-1	3297909
dic@@	I-Disease	-1	3297909
e	I-Disease	-1	3297909
2	O	-1	3297909
w@@	O	-1	3297909
k	O	-1	3297909
after	O	-1	3297909
exposure	O	-1	3297909
to	O	-1	3297909
thi@@	B-Chemical	D013827	3297909
ab@@	I-Chemical	-1	3297909
en@@	I-Chemical	-1	3297909
da@@	I-Chemical	-1	3297909
z@@	I-Chemical	-1	3297909
ole	I-Chemical	-1	3297909
.	O	-1	3297909
Ch@@	B-Disease	D002779	3297909
ol@@	I-Disease	-1	3297909
est@@	I-Disease	-1	3297909
asis	I-Disease	-1	3297909
per@@	O	-1	3297909
sist@@	O	-1	3297909
ed	O	-1	3297909
for	O	-1	3297909
3	O	-1	3297909
y@@	O	-1	3297909
r@@	O	-1	3297909
,	O	-1	3297909
at	O	-1	3297909
which	O	-1	3297909
time	O	-1	3297909
a	O	-1	3297909
liver	O	-1	3297909
transplant	O	-1	3297909
was	O	-1	3297909
per@@	O	-1	3297909
for@@	O	-1	3297909
me@@	O	-1	3297909
d.	O	-1	3297909
Two	O	-1	3297909
liver	O	-1	3297909
biop@@	O	-1	3297909
sy	O	-1	3297909
spec@@	O	-1	3297909
imen@@	O	-1	3297909
s	O	-1	3297909
and	O	-1	3297909
the	O	-1	3297909
hepat@@	O	-1	3297909
ect@@	O	-1	3297909
om@@	O	-1	3297909
y	O	-1	3297909
spec@@	O	-1	3297909
i@@	O	-1	3297909
men	O	-1	3297909
were	O	-1	3297909
re@@	O	-1	3297909
mark@@	O	-1	3297909
able	O	-1	3297909
for	O	-1	3297909
al@@	O	-1	3297909
most	O	-1	3297909
complete	O	-1	3297909
dis@@	O	-1	3297909
appear@@	O	-1	3297909
ance	O	-1	3297909
of	O	-1	3297909
inter@@	O	-1	3297909
lo@@	O	-1	3297909
b@@	O	-1	3297909
ular	O	-1	3297909
b@@	O	-1	3297909
ile	O	-1	3297909
duc@@	O	-1	3297909
t@@	O	-1	3297909
s.	O	-1	3297909
Pro@@	O	-1	3297909
min@@	O	-1	3297909
ent	O	-1	3297909
fib@@	B-Disease	D005355	3297909
ro@@	I-Disease	-1	3297909
sis	I-Disease	-1	3297909
and	O	-1	3297909
hepat@@	O	-1	3297909
oc@@	O	-1	3297909
ell@@	O	-1	3297909
ular	O	-1	3297909
re@@	O	-1	3297909
generation	O	-1	3297909
were	O	-1	3297909
also	O	-1	3297909
present@@	O	-1	3297909
;	O	-1	3297909
however,	O	-1	3297909
the	O	-1	3297909
lo@@	O	-1	3297909
b@@	O	-1	3297909
ular	O	-1	3297909
ar@@	O	-1	3297909
ch@@	O	-1	3297909
it@@	O	-1	3297909
ect@@	O	-1	3297909
ure	O	-1	3297909
was	O	-1	3297909
pres@@	O	-1	3297909
er@@	O	-1	3297909
ved.	O	-1	3297909
This	O	-1	3297909
case	O	-1	3297909
re@@	O	-1	3297909
pres@@	O	-1	3297909
ents	O	-1	3297909
an	O	-1	3297909
ex@@	O	-1	3297909
am@@	O	-1	3297909
ple	O	-1	3297909
of	O	-1	3297909
"@@	O	-1	3297909
i@@	O	-1	3297909
di@@	O	-1	3297909
os@@	O	-1	3297909
yn@@	O	-1	3297909
c@@	O	-1	3297909
rati@@	O	-1	3297909
c@@	O	-1	3297909
"	O	-1	3297909
drug@@	B-Disease	D056486	3297909
-induced	I-Disease	-1	3297909
liver	I-Disease	-1	3297909
damage	I-Disease	-1	3297909
in	O	-1	3297909
which	O	-1	3297909
the	O	-1	3297909
prim@@	O	-1	3297909
ary	O	-1	3297909
t@@	O	-1	3297909
arg@@	O	-1	3297909
et	O	-1	3297909
of	O	-1	3297909
injury	O	-1	3297909
is	O	-1	3297909
the	O	-1	3297909
b@@	O	-1	3297909
ile	O	-1	3297909
duc@@	O	-1	3297909
t.	O	-1	3297909
An	O	-1	3297909
auto@@	O	-1	3297909
immun@@	O	-1	3297909
e	O	-1	3297909
path@@	O	-1	3297909
o@@	O	-1	3297909
genesis	O	-1	3297909
of	O	-1	3297909
the	O	-1	3297909
b@@	B-Disease	D001649	3297909
ile	I-Disease	-1	3297909
duc@@	I-Disease	-1	3297909
t	I-Disease	-1	3297909
de@@	I-Disease	-1	3297909
struc@@	I-Disease	-1	3297909
tion	I-Disease	-1	3297909
is	O	-1	3297909
suggest@@	O	-1	3297909
ed.	O	-1	3297909

Di@@	O	-1	3323259
fferen@@	O	-1	3323259
tial	O	-1	3323259
effects	O	-1	3323259
of	O	-1	3323259
1@@	B-Chemical	C038806	3323259
,@@	I-Chemical	-1	3323259
4-@@	I-Chemical	-1	3323259
di@@	I-Chemical	-1	3323259
hydro@@	I-Chemical	-1	3323259
pyri@@	I-Chemical	-1	3323259
d@@	I-Chemical	-1	3323259
ine	I-Chemical	-1	3323259
calcium	B-Chemical	D002121	3323259
channel	I-Chemical	-1	3323259
block@@	I-Chemical	-1	3323259
ers	I-Chemical	-1	3323259
:	O	-1	3323259
therapeutic	O	-1	3323259
implic@@	O	-1	3323259
ations.	O	-1	3323259
In@@	O	-1	3323259
c@@	O	-1	3323259
reas@@	O	-1	3323259
ing	O	-1	3323259
reco@@	O	-1	3323259
gn@@	O	-1	3323259
ition	O	-1	3323259
of	O	-1	3323259
the	O	-1	3323259
import@@	O	-1	3323259
ance	O	-1	3323259
of	O	-1	3323259
calcium	B-Chemical	D002118	3323259
in	O	-1	3323259
the	O	-1	3323259
path@@	O	-1	3323259
o@@	O	-1	3323259
genesis	O	-1	3323259
of	O	-1	3323259
cardiovascular	B-Disease	D002318	3323259
disease	I-Disease	-1	3323259
has	O	-1	3323259
stimul@@	O	-1	3323259
ated	O	-1	3323259
re@@	O	-1	3323259
se@@	O	-1	3323259
arc@@	O	-1	3323259
h	O	-1	3323259
into	O	-1	3323259
the	O	-1	3323259
use	O	-1	3323259
of	O	-1	3323259
calcium	B-Chemical	D002121	3323259
channel	I-Chemical	-1	3323259
block@@	I-Chemical	-1	3323259
ing	I-Chemical	-1	3323259
agents	I-Chemical	-1	3323259
for	O	-1	3323259
treatment	O	-1	3323259
of	O	-1	3323259
a	O	-1	3323259
vari@@	O	-1	3323259
ety	O	-1	3323259
of	O	-1	3323259
cardiovascular	B-Disease	D002318	3323259
diseas@@	I-Disease	-1	3323259
es	I-Disease	-1	3323259
.	O	-1	3323259
The	O	-1	3323259
f@@	O	-1	3323259
av@@	O	-1	3323259
or@@	O	-1	3323259
able	O	-1	3323259
efficacy	O	-1	3323259
and	O	-1	3323259
toler@@	O	-1	3323259
ability	O	-1	3323259
pro@@	O	-1	3323259
fi@@	O	-1	3323259
le@@	O	-1	3323259
s	O	-1	3323259
of	O	-1	3323259
these	O	-1	3323259
agents	O	-1	3323259
ma@@	O	-1	3323259
k@@	O	-1	3323259
e	O	-1	3323259
the@@	O	-1	3323259
m	O	-1	3323259
at@@	O	-1	3323259
trac@@	O	-1	3323259
tive	O	-1	3323259
therapeutic	O	-1	3323259
mod@@	O	-1	3323259
al@@	O	-1	3323259
iti@@	O	-1	3323259
es.	O	-1	3323259
Clin@@	O	-1	3323259
ical	O	-1	3323259
ap@@	O	-1	3323259
plic@@	O	-1	3323259
ations	O	-1	3323259
of	O	-1	3323259
calcium	B-Chemical	D002121	3323259
channel	I-Chemical	-1	3323259
block@@	I-Chemical	-1	3323259
ers	I-Chemical	-1	3323259
par@@	O	-1	3323259
al@@	O	-1	3323259
le@@	O	-1	3323259
l	O	-1	3323259
their	O	-1	3323259
tissue	O	-1	3323259
sel@@	O	-1	3323259
ec@@	O	-1	3323259
tiv@@	O	-1	3323259
ity.	O	-1	3323259
In	O	-1	3323259
contr@@	O	-1	3323259
ast	O	-1	3323259
to	O	-1	3323259
verap@@	B-Chemical	D014700	3323259
ami@@	I-Chemical	-1	3323259
l	I-Chemical	-1	3323259
and	O	-1	3323259
di@@	B-Chemical	D004110	3323259
l@@	I-Chemical	-1	3323259
ti@@	I-Chemical	-1	3323259
az@@	I-Chemical	-1	3323259
em	I-Chemical	-1	3323259
,	O	-1	3323259
which	O	-1	3323259
are	O	-1	3323259
rou@@	O	-1	3323259
gh@@	O	-1	3323259
ly	O	-1	3323259
equ@@	O	-1	3323259
ip@@	O	-1	3323259
ot@@	O	-1	3323259
ent	O	-1	3323259
in	O	-1	3323259
their	O	-1	3323259
ac@@	O	-1	3323259
tions	O	-1	3323259
on	O	-1	3323259
the	O	-1	3323259
heart	O	-1	3323259
and	O	-1	3323259
vascular	O	-1	3323259
smo@@	O	-1	3323259
oth	O	-1	3323259
musc@@	O	-1	3323259
le@@	O	-1	3323259
,	O	-1	3323259
the	O	-1	3323259
di@@	B-Chemical	C038806	3323259
hydro@@	I-Chemical	-1	3323259
pyri@@	I-Chemical	-1	3323259
d@@	I-Chemical	-1	3323259
ine	I-Chemical	-1	3323259
calcium	B-Chemical	D002121	3323259
channel	I-Chemical	-1	3323259
block@@	I-Chemical	-1	3323259
ers	I-Chemical	-1	3323259
are	O	-1	3323259
a	O	-1	3323259
group	O	-1	3323259
of	O	-1	3323259
pot@@	O	-1	3323259
ent	O	-1	3323259
peripheral	O	-1	3323259
vas@@	O	-1	3323259
odi@@	O	-1	3323259
lat@@	O	-1	3323259
or	O	-1	3323259
agents	O	-1	3323259
that	O	-1	3323259
ex@@	O	-1	3323259
er@@	O	-1	3323259
t	O	-1	3323259
minim@@	O	-1	3323259
al	O	-1	3323259
electro@@	O	-1	3323259
physi@@	O	-1	3323259
ologic	O	-1	3323259
effects	O	-1	3323259
on	O	-1	3323259
cardiac	O	-1	3323259
no@@	O	-1	3323259
d@@	O	-1	3323259
al	O	-1	3323259
or	O	-1	3323259
con@@	O	-1	3323259
duction	O	-1	3323259
tissu@@	O	-1	3323259
e.	O	-1	3323259
A@@	O	-1	3323259
s	O	-1	3323259
the	O	-1	3323259
first	O	-1	3323259
di@@	B-Chemical	C038806	3323259
hydro@@	I-Chemical	-1	3323259
pyri@@	I-Chemical	-1	3323259
d@@	I-Chemical	-1	3323259
ine	I-Chemical	-1	3323259
av@@	O	-1	3323259
ail@@	O	-1	3323259
able	O	-1	3323259
for	O	-1	3323259
use	O	-1	3323259
in	O	-1	3323259
the	O	-1	3323259
U@@	O	-1	3323259
nit@@	O	-1	3323259
ed	O	-1	3323259
S@@	O	-1	3323259
t@@	O	-1	3323259
at@@	O	-1	3323259
es,	O	-1	3323259
n@@	B-Chemical	D009543	3323259
if@@	I-Chemical	-1	3323259
edi@@	I-Chemical	-1	3323259
pine	I-Chemical	-1	3323259
controls	O	-1	3323259
ang@@	B-Disease	D000787	3323259
in@@	I-Disease	-1	3323259
a	I-Disease	-1	3323259
and	O	-1	3323259
hypertension	B-Disease	D006973	3323259
with	O	-1	3323259
minim@@	O	-1	3323259
al	O	-1	3323259
de@@	O	-1	3323259
pression	O	-1	3323259
of	O	-1	3323259
cardiac	O	-1	3323259
func@@	O	-1	3323259
tion.	O	-1	3323259
Ad@@	O	-1	3323259
di@@	O	-1	3323259
tional	O	-1	3323259
memb@@	O	-1	3323259
ers	O	-1	3323259
of	O	-1	3323259
this	O	-1	3323259
group	O	-1	3323259
of	O	-1	3323259
calcium	B-Chemical	D002121	3323259
channel	I-Chemical	-1	3323259
block@@	I-Chemical	-1	3323259
ers	I-Chemical	-1	3323259
have	O	-1	3323259
been	O	-1	3323259
studied	O	-1	3323259
for	O	-1	3323259
a	O	-1	3323259
vari@@	O	-1	3323259
ety	O	-1	3323259
of	O	-1	3323259
indic@@	O	-1	3323259
ations	O	-1	3323259
for	O	-1	3323259
which	O	-1	3323259
they	O	-1	3323259
may	O	-1	3323259
o@@	O	-1	3323259
ff@@	O	-1	3323259
er	O	-1	3323259
adv@@	O	-1	3323259
ant@@	O	-1	3323259
ages	O	-1	3323259
over	O	-1	3323259
current	O	-1	3323259
therapy.	O	-1	3323259
On@@	O	-1	3323259
ce	O	-1	3323259
or	O	-1	3323259
tw@@	O	-1	3323259
ic@@	O	-1	3323259
e	O	-1	3323259
daily	O	-1	3323259
dos@@	O	-1	3323259
age	O	-1	3323259
possible	O	-1	3323259
with	O	-1	3323259
nit@@	B-Chemical	D009568	3323259
ren@@	I-Chemical	-1	3323259
di@@	I-Chemical	-1	3323259
pine	I-Chemical	-1	3323259
and	O	-1	3323259
n@@	B-Chemical	D015737	3323259
isol@@	I-Chemical	-1	3323259
di@@	I-Chemical	-1	3323259
pine	I-Chemical	-1	3323259
o@@	O	-1	3323259
ff@@	O	-1	3323259
ers	O	-1	3323259
a	O	-1	3323259
con@@	O	-1	3323259
ven@@	O	-1	3323259
i@@	O	-1	3323259
ent	O	-1	3323259
administration	O	-1	3323259
sch@@	O	-1	3323259
ed@@	O	-1	3323259
ul@@	O	-1	3323259
e,	O	-1	3323259
which	O	-1	3323259
en@@	O	-1	3323259
cour@@	O	-1	3323259
ages	O	-1	3323259
patient	O	-1	3323259
com@@	O	-1	3323259
pl@@	O	-1	3323259
i@@	O	-1	3323259
ance	O	-1	3323259
in	O	-1	3323259
long-term	O	-1	3323259
therapy	O	-1	3323259
of	O	-1	3323259
hypertension	B-Disease	D006973	3323259
.	O	-1	3323259
The	O	-1	3323259
coronary	O	-1	3323259
vas@@	O	-1	3323259
odi@@	O	-1	3323259
l@@	O	-1	3323259
ating	O	-1	3323259
pro@@	O	-1	3323259
per@@	O	-1	3323259
ties	O	-1	3323259
of	O	-1	3323259
n@@	B-Chemical	D015737	3323259
isol@@	I-Chemical	-1	3323259
di@@	I-Chemical	-1	3323259
pine	I-Chemical	-1	3323259
have	O	-1	3323259
l@@	O	-1	3323259
ed	O	-1	3323259
to	O	-1	3323259
the	O	-1	3323259
investig@@	O	-1	3323259
ation	O	-1	3323259
of	O	-1	3323259
this	O	-1	3323259
agent	O	-1	3323259
for	O	-1	3323259
use	O	-1	3323259
in	O	-1	3323259
ang@@	B-Disease	D000787	3323259
in@@	I-Disease	-1	3323259
a	I-Disease	-1	3323259
.	O	-1	3323259
S@@	O	-1	3323259
el@@	O	-1	3323259
ec@@	O	-1	3323259
tivity	O	-1	3323259
for	O	-1	3323259
the	O	-1	3323259
ce@@	O	-1	3323259
reb@@	O	-1	3323259
ro@@	O	-1	3323259
vascular	O	-1	3323259
bed	O	-1	3323259
ma@@	O	-1	3323259
k@@	O	-1	3323259
es	O	-1	3323259
n@@	B-Chemical	D009553	3323259
im@@	I-Chemical	-1	3323259
odi@@	I-Chemical	-1	3323259
pine	I-Chemical	-1	3323259
potenti@@	O	-1	3323259
ally	O	-1	3323259
use@@	O	-1	3323259
ful	O	-1	3323259
in	O	-1	3323259
the	O	-1	3323259
treatment	O	-1	3323259
of	O	-1	3323259
sub@@	B-Disease	D013345	3323259
arac@@	I-Disease	-1	3323259
h@@	I-Disease	-1	3323259
no@@	I-Disease	-1	3323259
id	I-Disease	-1	3323259
hemorrh@@	I-Disease	-1	3323259
age	I-Disease	-1	3323259
,	O	-1	3323259
migra@@	B-Disease	D008881	3323259
ine	I-Disease	-1	3323259
headac@@	I-Disease	-1	3323259
he	I-Disease	-1	3323259
,	O	-1	3323259
de@@	B-Disease	D003704	3323259
m@@	I-Disease	-1	3323259
enti@@	I-Disease	-1	3323259
a	I-Disease	-1	3323259
,	O	-1	3323259
and	O	-1	3323259
strok@@	B-Disease	D020521	3323259
e	I-Disease	-1	3323259
.	O	-1	3323259
In	O	-1	3323259
gener@@	O	-1	3323259
al,	O	-1	3323259
the	O	-1	3323259
di@@	B-Chemical	C038806	3323259
hydro@@	I-Chemical	-1	3323259
pyri@@	I-Chemical	-1	3323259
d@@	I-Chemical	-1	3323259
ine	I-Chemical	-1	3323259
calcium	B-Chemical	D002121	3323259
channel	I-Chemical	-1	3323259
block@@	I-Chemical	-1	3323259
ers	I-Chemical	-1	3323259
are	O	-1	3323259
us@@	O	-1	3323259
ually	O	-1	3323259
well	O	-1	3323259
toler@@	O	-1	3323259
at@@	O	-1	3323259
ed,	O	-1	3323259
with	O	-1	3323259
headac@@	B-Disease	D006261	3323259
he	I-Disease	-1	3323259
,	O	-1	3323259
fac@@	O	-1	3323259
ial	O	-1	3323259
f@@	B-Disease	D005483	3323259
l@@	I-Disease	-1	3323259
us@@	I-Disease	-1	3323259
h@@	I-Disease	-1	3323259
ing	I-Disease	-1	3323259
,	O	-1	3323259
p@@	B-Disease	-1	3323259
al@@	I-Disease	-1	3323259
pit@@	I-Disease	-1	3323259
ations	I-Disease	-1	3323259
,	O	-1	3323259
e@@	B-Disease	D004487	3323259
de@@	I-Disease	-1	3323259
ma	I-Disease	-1	3323259
,	O	-1	3323259
nausea	B-Disease	D009325	3323259
,	O	-1	3323259
an@@	B-Disease	D000855	3323259
ore@@	I-Disease	-1	3323259
x@@	I-Disease	-1	3323259
ia	I-Disease	-1	3323259
,	O	-1	3323259
and	O	-1	3323259
di@@	B-Disease	D004244	3323259
z@@	I-Disease	-1	3323259
z@@	I-Disease	-1	3323259
in@@	I-Disease	-1	3323259
ess	I-Disease	-1	3323259
being	O	-1	3323259
the	O	-1	3323259
more	O	-1	3323259
common	O	-1	3323259
adverse	O	-1	3323259
effects.	O	-1	3323259

The	O	-1	3323599
enh@@	O	-1	3323599
ance@@	O	-1	3323599
ment	O	-1	3323599
of	O	-1	3323599
amin@@	B-Chemical	D011692	3323599
on@@	I-Chemical	-1	3323599
ucle@@	I-Chemical	-1	3323599
o@@	I-Chemical	-1	3323599
side	I-Chemical	-1	3323599
nephro@@	B-Disease	D009401	3323599
sis	I-Disease	-1	3323599
by	O	-1	3323599
the	O	-1	3323599
co-@@	O	-1	3323599
administration	O	-1	3323599
of	O	-1	3323599
prot@@	O	-1	3323599
am@@	O	-1	3323599
ine.	O	-1	3323599
An	O	-1	3323599
experimental	O	-1	3323599
model	O	-1	3323599
of	O	-1	3323599
foc@@	B-Disease	D005923	3323599
al	I-Disease	-1	3323599
seg@@	I-Disease	-1	3323599
mental	I-Disease	-1	3323599
glomerular	I-Disease	-1	3323599
s@@	I-Disease	-1	3323599
clero@@	I-Disease	-1	3323599
sis	I-Disease	-1	3323599
(	O	-1	3323599
F@@	B-Disease	D005923	3323599
S@@	I-Disease	-1	3323599
G@@	I-Disease	-1	3323599
S	I-Disease	-1	3323599
)	O	-1	3323599
was	O	-1	3323599
developed	O	-1	3323599
in	O	-1	3323599
rats	O	-1	3323599
by	O	-1	3323599
the	O	-1	3323599
combined	O	-1	3323599
administration	O	-1	3323599
of	O	-1	3323599
p@@	B-Chemical	D011692	3323599
uro@@	I-Chemical	-1	3323599
m@@	I-Chemical	-1	3323599
yc@@	I-Chemical	-1	3323599
in-@@	I-Chemical	-1	3323599
amin@@	I-Chemical	-1	3323599
on@@	I-Chemical	-1	3323599
ucle@@	I-Chemical	-1	3323599
o@@	I-Chemical	-1	3323599
side	I-Chemical	-1	3323599
(	O	-1	3323599
AM@@	B-Chemical	D011692	3323599
N@@	I-Chemical	-1	3323599
S	I-Chemical	-1	3323599
)	O	-1	3323599
and	O	-1	3323599
prot@@	B-Chemical	D011479	3323599
amine	I-Chemical	-1	3323599
sulf@@	I-Chemical	-1	3323599
ate	I-Chemical	-1	3323599
(	O	-1	3323599
P@@	B-Chemical	D011479	3323599
S	I-Chemical	-1	3323599
).	O	-1	3323599
M@@	O	-1	3323599
al@@	O	-1	3323599
e	O	-1	3323599
S@@	O	-1	3323599
pra@@	O	-1	3323599
gu@@	O	-1	3323599
e-@@	O	-1	3323599
D@@	O	-1	3323599
aw@@	O	-1	3323599
le@@	O	-1	3323599
y	O	-1	3323599
rats,	O	-1	3323599
un@@	O	-1	3323599
ine@@	O	-1	3323599
ph@@	O	-1	3323599
rec@@	O	-1	3323599
to@@	O	-1	3323599
m@@	O	-1	3323599
ized	O	-1	3323599
three	O	-1	3323599
weeks	O	-1	3323599
be@@	O	-1	3323599
fo@@	O	-1	3323599
re,	O	-1	3323599
received	O	-1	3323599
daily	O	-1	3323599
injec@@	O	-1	3323599
tions	O	-1	3323599
of	O	-1	3323599
sub@@	O	-1	3323599
c@@	O	-1	3323599
utaneous	O	-1	3323599
AM@@	B-Chemical	D011692	3323599
N@@	I-Chemical	-1	3323599
S	I-Chemical	-1	3323599
(@@	O	-1	3323599
1	O	-1	3323599
mg/@@	O	-1	3323599
100	O	-1	3323599
g	O	-1	3323599
body	O	-1	3323599
w@@	O	-1	3323599
t@@	O	-1	3323599
)	O	-1	3323599
and	O	-1	3323599
intravenous	O	-1	3323599
P@@	B-Chemical	D011479	3323599
S	I-Chemical	-1	3323599
(@@	O	-1	3323599
2	O	-1	3323599
se@@	O	-1	3323599
par@@	O	-1	3323599
ated	O	-1	3323599
doses	O	-1	3323599
of	O	-1	3323599
2.@@	O	-1	3323599
5	O	-1	3323599
mg/@@	O	-1	3323599
100	O	-1	3323599
g	O	-1	3323599
body	O	-1	3323599
w@@	O	-1	3323599
t@@	O	-1	3323599
)	O	-1	3323599
for	O	-1	3323599
four	O	-1	3323599
days.	O	-1	3323599
The	O	-1	3323599
seri@@	O	-1	3323599
es	O	-1	3323599
of	O	-1	3323599
injec@@	O	-1	3323599
tions	O	-1	3323599
were	O	-1	3323599
repe@@	O	-1	3323599
ated	O	-1	3323599
an@@	O	-1	3323599
other	O	-1	3323599
three	O	-1	3323599
times	O	-1	3323599
at	O	-1	3323599
10	O	-1	3323599
day	O	-1	3323599
inter@@	O	-1	3323599
val@@	O	-1	3323599
s.	O	-1	3323599
The	O	-1	3323599
animals	O	-1	3323599
were	O	-1	3323599
s@@	O	-1	3323599
ac@@	O	-1	3323599
ri@@	O	-1	3323599
fic@@	O	-1	3323599
ed	O	-1	3323599
on	O	-1	3323599
days	O	-1	3323599
2@@	O	-1	3323599
4@@	O	-1	3323599
,	O	-1	3323599
5@@	O	-1	3323599
2,	O	-1	3323599
and	O	-1	3323599
80@@	O	-1	3323599
.	O	-1	3323599
The@@	O	-1	3323599
y	O	-1	3323599
developed	O	-1	3323599
nephro@@	B-Disease	D009404	3323599
tic	I-Disease	-1	3323599
syndrome	I-Disease	-1	3323599
and	O	-1	3323599
f@@	O	-1	3323599
in@@	O	-1	3323599
ally	O	-1	3323599
renal	B-Disease	D051437	3323599
failure	I-Disease	-1	3323599
.	O	-1	3323599
The	O	-1	3323599
ti@@	O	-1	3323599
me@@	O	-1	3323599
-@@	O	-1	3323599
course	O	-1	3323599
cur@@	O	-1	3323599
ve	O	-1	3323599
of	O	-1	3323599
creatinine	B-Chemical	D003404	3323599
clear@@	O	-1	3323599
ance	O	-1	3323599
dro@@	O	-1	3323599
pp@@	O	-1	3323599
ed	O	-1	3323599
and	O	-1	3323599
showed	O	-1	3323599
significant	O	-1	3323599
difference	O	-1	3323599
(P	O	-1	3323599
less	O	-1	3323599
than	O	-1	3323599
0.0@@	O	-1	3323599
1)	O	-1	3323599
from	O	-1	3323599
that	O	-1	3323599
of	O	-1	3323599
each	O	-1	3323599
control	O	-1	3323599
group@@	O	-1	3323599
,	O	-1	3323599
such	O	-1	3323599
as@@	O	-1	3323599
,	O	-1	3323599
AM@@	B-Chemical	D011692	3323599
N@@	I-Chemical	-1	3323599
S	I-Chemical	-1	3323599
al@@	O	-1	3323599
one,	O	-1	3323599
P@@	B-Chemical	D011479	3323599
S	I-Chemical	-1	3323599
alone	O	-1	3323599
or	O	-1	3323599
saline	O	-1	3323599
inj@@	O	-1	3323599
ect@@	O	-1	3323599
ed.	O	-1	3323599
The@@	O	-1	3323599
ir	O	-1	3323599
glomerul@@	O	-1	3323599
i	O	-1	3323599
showed	O	-1	3323599
changes	O	-1	3323599
of	O	-1	3323599
progressive	O	-1	3323599
F@@	B-Disease	D005923	3323599
S@@	I-Disease	-1	3323599
G@@	I-Disease	-1	3323599
S	I-Disease	-1	3323599
.	O	-1	3323599
The	O	-1	3323599
ult@@	O	-1	3323599
ra@@	O	-1	3323599
struct@@	O	-1	3323599
ural	O	-1	3323599
studies	O	-1	3323599
in	O	-1	3323599
the	O	-1	3323599
initial	O	-1	3323599
st@@	O	-1	3323599
age	O	-1	3323599
revealed	O	-1	3323599
significant	O	-1	3323599
l@@	O	-1	3323599
ac@@	O	-1	3323599
k	O	-1	3323599
of	O	-1	3323599
partic@@	O	-1	3323599
le@@	O	-1	3323599
s	O	-1	3323599
of	O	-1	3323599
per@@	O	-1	3323599
f@@	O	-1	3323599
used	O	-1	3323599
ru@@	B-Chemical	D012428	3323599
th@@	I-Chemical	-1	3323599
en@@	I-Chemical	-1	3323599
i@@	I-Chemical	-1	3323599
um	I-Chemical	-1	3323599
red	O	-1	3323599
on	O	-1	3323599
the	O	-1	3323599
l@@	O	-1	3323599
amin@@	O	-1	3323599
a	O	-1	3323599
r@@	O	-1	3323599
ar@@	O	-1	3323599
a	O	-1	3323599
ex@@	O	-1	3323599
tern@@	O	-1	3323599
a	O	-1	3323599
and	O	-1	3323599
mark@@	O	-1	3323599
ed	O	-1	3323599
changes	O	-1	3323599
in	O	-1	3323599
epi@@	O	-1	3323599
thelial	O	-1	3323599
cell	O	-1	3323599
cyto@@	O	-1	3323599
plas@@	O	-1	3323599
m.	O	-1	3323599
The@@	O	-1	3323599
refore,	O	-1	3323599
it	O	-1	3323599
is	O	-1	3323599
suggested	O	-1	3323599
that	O	-1	3323599
the	O	-1	3323599
administration	O	-1	3323599
of	O	-1	3323599
P@@	B-Chemical	D011479	3323599
S	I-Chemical	-1	3323599
enh@@	O	-1	3323599
anc@@	O	-1	3323599
es	O	-1	3323599
the	O	-1	3323599
toxicity	B-Disease	D064420	3323599
of	O	-1	3323599
AM@@	B-Chemical	D011692	3323599
N@@	I-Chemical	-1	3323599
S	I-Chemical	-1	3323599
on	O	-1	3323599
the	O	-1	3323599
glomerul@@	O	-1	3323599
us	O	-1	3323599
and	O	-1	3323599
re@@	O	-1	3323599
a@@	O	-1	3323599
di@@	O	-1	3323599
ly	O	-1	3323599
produc@@	O	-1	3323599
es	O	-1	3323599
progressive	O	-1	3323599
F@@	B-Disease	D005923	3323599
S@@	I-Disease	-1	3323599
G@@	I-Disease	-1	3323599
S	I-Disease	-1	3323599
in	O	-1	3323599
rats	O	-1	3323599
result@@	O	-1	3323599
ing	O	-1	3323599
in	O	-1	3323599
the	O	-1	3323599
en@@	B-Disease	D007676	3323599
d-@@	I-Disease	-1	3323599
st@@	I-Disease	-1	3323599
age	I-Disease	-1	3323599
renal	I-Disease	-1	3323599
disease	I-Disease	-1	3323599
.	O	-1	3323599

The@@	B-Chemical	D013806	3339945
oph@@	I-Chemical	-1	3339945
yl@@	I-Chemical	-1	3339945
line	I-Chemical	-1	3339945
neuro@@	B-Disease	D020258	3339945
toxicity	I-Disease	-1	3339945
in	O	-1	3339945
pregn@@	O	-1	3339945
ant	O	-1	3339945
rats.	O	-1	3339945
The	O	-1	3339945
pur@@	O	-1	3339945
p@@	O	-1	3339945
ose	O	-1	3339945
of	O	-1	3339945
this	O	-1	3339945
investig@@	O	-1	3339945
ation	O	-1	3339945
was	O	-1	3339945
to	O	-1	3339945
determine	O	-1	3339945
whether	O	-1	3339945
the	O	-1	3339945
neuro@@	B-Disease	D020258	3339945
toxicity	I-Disease	-1	3339945
of	O	-1	3339945
the@@	B-Chemical	D013806	3339945
oph@@	I-Chemical	-1	3339945
yl@@	I-Chemical	-1	3339945
line	I-Chemical	-1	3339945
is	O	-1	3339945
al@@	O	-1	3339945
te@@	O	-1	3339945
red	O	-1	3339945
in	O	-1	3339945
adv@@	O	-1	3339945
anced	O	-1	3339945
pregn@@	O	-1	3339945
anc@@	O	-1	3339945
y.	O	-1	3339945
S@@	O	-1	3339945
pra@@	O	-1	3339945
gu@@	O	-1	3339945
e-@@	O	-1	3339945
D@@	O	-1	3339945
aw@@	O	-1	3339945
le@@	O	-1	3339945
y	O	-1	3339945
rats	O	-1	3339945
that	O	-1	3339945
were	O	-1	3339945
20	O	-1	3339945
days	O	-1	3339945
pregn@@	O	-1	3339945
ant	O	-1	3339945
and	O	-1	3339945
non@@	O	-1	3339945
pregn@@	O	-1	3339945
ant	O	-1	3339945
rats	O	-1	3339945
of	O	-1	3339945
the	O	-1	3339945
same	O	-1	3339945
age	O	-1	3339945
and	O	-1	3339945
stra@@	O	-1	3339945
in	O	-1	3339945
received	O	-1	3339945
infu@@	O	-1	3339945
sions	O	-1	3339945
of	O	-1	3339945
aminoph@@	B-Chemical	D000628	3339945
yl@@	I-Chemical	-1	3339945
line	I-Chemical	-1	3339945
un@@	O	-1	3339945
ti@@	O	-1	3339945
l	O	-1	3339945
onset	O	-1	3339945
of	O	-1	3339945
maxim@@	O	-1	3339945
al	O	-1	3339945
seizures	B-Disease	D012640	3339945
which	O	-1	3339945
occurred	O	-1	3339945
after	O	-1	3339945
2@@	O	-1	3339945
8	O	-1	3339945
and	O	-1	3339945
30	O	-1	3339945
minutes	O	-1	3339945
respectively.	O	-1	3339945
The@@	B-Chemical	D013806	3339945
oph@@	I-Chemical	-1	3339945
yl@@	I-Chemical	-1	3339945
line	I-Chemical	-1	3339945
concentrations	O	-1	3339945
at	O	-1	3339945
this	O	-1	3339945
en@@	O	-1	3339945
d@@	O	-1	3339945
po@@	O	-1	3339945
in@@	O	-1	3339945
t	O	-1	3339945
in	O	-1	3339945
serum	O	-1	3339945
(@@	O	-1	3339945
tot@@	O	-1	3339945
al@@	O	-1	3339945
)	O	-1	3339945
and	O	-1	3339945
C@@	O	-1	3339945
S@@	O	-1	3339945
F	O	-1	3339945
were	O	-1	3339945
similar	O	-1	3339945
but	O	-1	3339945
serum	O	-1	3339945
(@@	O	-1	3339945
f@@	O	-1	3339945
re@@	O	-1	3339945
e@@	O	-1	3339945
)	O	-1	3339945
and	O	-1	3339945
brain	O	-1	3339945
concentrations	O	-1	3339945
were	O	-1	3339945
s@@	O	-1	3339945
li@@	O	-1	3339945
gh@@	O	-1	3339945
tly	O	-1	3339945
different	O	-1	3339945
in	O	-1	3339945
pregn@@	O	-1	3339945
ant	O	-1	3339945
rats.	O	-1	3339945
The@@	B-Chemical	D013806	3339945
oph@@	I-Chemical	-1	3339945
yl@@	I-Chemical	-1	3339945
line	I-Chemical	-1	3339945
serum	O	-1	3339945
protein	O	-1	3339945
b@@	O	-1	3339945
ind@@	O	-1	3339945
ing	O	-1	3339945
determined	O	-1	3339945
by	O	-1	3339945
equ@@	O	-1	3339945
il@@	O	-1	3339945
i@@	O	-1	3339945
b@@	O	-1	3339945
ri@@	O	-1	3339945
um	O	-1	3339945
dialy@@	O	-1	3339945
sis	O	-1	3339945
was	O	-1	3339945
lower	O	-1	3339945
in	O	-1	3339945
pregn@@	O	-1	3339945
ant	O	-1	3339945
rats.	O	-1	3339945
F@@	O	-1	3339945
et@@	O	-1	3339945
al	O	-1	3339945
serum	O	-1	3339945
concentrations	O	-1	3339945
at	O	-1	3339945
onset	O	-1	3339945
of	O	-1	3339945
seizures	B-Disease	D012640	3339945
in	O	-1	3339945
the	O	-1	3339945
mo@@	O	-1	3339945
ther	O	-1	3339945
were	O	-1	3339945
similar	O	-1	3339945
to	O	-1	3339945
mat@@	O	-1	3339945
er@@	O	-1	3339945
n@@	O	-1	3339945
al	O	-1	3339945
brain	O	-1	3339945
and	O	-1	3339945
C@@	O	-1	3339945
S@@	O	-1	3339945
F	O	-1	3339945
concentrations	O	-1	3339945
and	O	-1	3339945
cor@@	O	-1	3339945
related	O	-1	3339945
significantly	O	-1	3339945
with	O	-1	3339945
the	O	-1	3339945
form@@	O	-1	3339945
er.	O	-1	3339945
It	O	-1	3339945
is	O	-1	3339945
concl@@	O	-1	3339945
uded	O	-1	3339945
that	O	-1	3339945
adv@@	O	-1	3339945
anced	O	-1	3339945
pregn@@	O	-1	3339945
anc@@	O	-1	3339945
y	O	-1	3339945
has	O	-1	3339945
a	O	-1	3339945
neg@@	O	-1	3339945
li@@	O	-1	3339945
gi@@	O	-1	3339945
ble	O	-1	3339945
effect	O	-1	3339945
on	O	-1	3339945
the	O	-1	3339945
neuro@@	B-Disease	D020258	3339945
toxic	I-Disease	-1	3339945
response	O	-1	3339945
to	O	-1	3339945
the@@	B-Chemical	D013806	3339945
oph@@	I-Chemical	-1	3339945
yl@@	I-Chemical	-1	3339945
line	I-Chemical	-1	3339945
in	O	-1	3339945
rats.	O	-1	3339945

H@@	B-Disease	D006947	3375885
y@@	I-Disease	-1	3375885
per@@	I-Disease	-1	3375885
k@@	I-Disease	-1	3375885
al@@	I-Disease	-1	3375885
emia	I-Disease	-1	3375885
induced	O	-1	3375885
by	O	-1	3375885
in@@	B-Chemical	D007213	3375885
do@@	I-Chemical	-1	3375885
meth@@	I-Chemical	-1	3375885
ac@@	I-Chemical	-1	3375885
in	I-Chemical	-1	3375885
and	O	-1	3375885
na@@	B-Chemical	D009288	3375885
pro@@	I-Chemical	-1	3375885
x@@	I-Chemical	-1	3375885
en	I-Chemical	-1	3375885
and	O	-1	3375885
reversed	O	-1	3375885
by	O	-1	3375885
f@@	B-Chemical	D005438	3375885
lud@@	I-Chemical	-1	3375885
ro@@	I-Chemical	-1	3375885
cor@@	I-Chemical	-1	3375885
tis@@	I-Chemical	-1	3375885
one	I-Chemical	-1	3375885
.	O	-1	3375885
We	O	-1	3375885
have	O	-1	3375885
descri@@	O	-1	3375885
bed	O	-1	3375885
a	O	-1	3375885
patient	O	-1	3375885
with	O	-1	3375885
severe	O	-1	3375885
r@@	B-Disease	D001172	3375885
he@@	I-Disease	-1	3375885
um@@	I-Disease	-1	3375885
at@@	I-Disease	-1	3375885
oid	I-Disease	-1	3375885
arth@@	I-Disease	-1	3375885
ritis	I-Disease	-1	3375885
and	O	-1	3375885
a	O	-1	3375885
hist@@	O	-1	3375885
ory	O	-1	3375885
of	O	-1	3375885
me@@	B-Chemical	D008528	3375885
f@@	I-Chemical	-1	3375885
en@@	I-Chemical	-1	3375885
am@@	I-Chemical	-1	3375885
ic	I-Chemical	-1	3375885
acid	I-Chemical	-1	3375885
nephro@@	B-Disease	D007674	3375885
pathy	I-Disease	-1	3375885
in	O	-1	3375885
whom	O	-1	3375885
hyper@@	B-Disease	D006947	3375885
k@@	I-Disease	-1	3375885
al@@	I-Disease	-1	3375885
emia	I-Disease	-1	3375885
and	O	-1	3375885
in@@	O	-1	3375885
appro@@	O	-1	3375885
pri@@	O	-1	3375885
ate	O	-1	3375885
hypo@@	B-Disease	D006994	3375885
al@@	I-Disease	-1	3375885
do@@	I-Disease	-1	3375885
ster@@	I-Disease	-1	3375885
on@@	I-Disease	-1	3375885
ism	I-Disease	-1	3375885
were	O	-1	3375885
caused	O	-1	3375885
by	O	-1	3375885
both	O	-1	3375885
in@@	B-Chemical	D007213	3375885
do@@	I-Chemical	-1	3375885
meth@@	I-Chemical	-1	3375885
ac@@	I-Chemical	-1	3375885
in	I-Chemical	-1	3375885
and	O	-1	3375885
na@@	B-Chemical	D009288	3375885
pro@@	I-Chemical	-1	3375885
x@@	I-Chemical	-1	3375885
en	I-Chemical	-1	3375885
,	O	-1	3375885
without	O	-1	3375885
major	O	-1	3375885
dec@@	O	-1	3375885
line	O	-1	3375885
in	O	-1	3375885
renal	O	-1	3375885
func@@	O	-1	3375885
tion.	O	-1	3375885
It	O	-1	3375885
is	O	-1	3375885
likely	O	-1	3375885
that	O	-1	3375885
pre@@	O	-1	3375885
ex@@	O	-1	3375885
ist@@	O	-1	3375885
ing	O	-1	3375885
renal	B-Disease	D007674	3375885
disease	I-Disease	-1	3375885
pre@@	O	-1	3375885
dis@@	O	-1	3375885
pos@@	O	-1	3375885
ed	O	-1	3375885
this	O	-1	3375885
patient	O	-1	3375885
to	O	-1	3375885
type	B-Disease	D006994	3375885
IV	I-Disease	-1	3375885
renal	I-Disease	-1	3375885
tub@@	I-Disease	-1	3375885
ular	I-Disease	-1	3375885
acid@@	I-Disease	-1	3375885
o@@	I-Disease	-1	3375885
sis	I-Disease	-1	3375885
with	O	-1	3375885
pro@@	B-Chemical	D011453	3375885
st@@	I-Chemical	-1	3375885
ag@@	I-Chemical	-1	3375885
l@@	I-Chemical	-1	3375885
and@@	I-Chemical	-1	3375885
in	I-Chemical	-1	3375885
syn@@	O	-1	3375885
the@@	O	-1	3375885
t@@	O	-1	3375885
ase	O	-1	3375885
inhibitor@@	O	-1	3375885
s.	O	-1	3375885
B@@	O	-1	3375885
ecause	O	-1	3375885
he	O	-1	3375885
was	O	-1	3375885
un@@	O	-1	3375885
able	O	-1	3375885
to	O	-1	3375885
discontinu@@	O	-1	3375885
e	O	-1	3375885
non@@	O	-1	3375885
steroid@@	O	-1	3375885
al	O	-1	3375885
anti@@	O	-1	3375885
-@@	O	-1	3375885
inflam@@	O	-1	3375885
mat@@	O	-1	3375885
ory	O	-1	3375885
drug	O	-1	3375885
therapy,	O	-1	3375885
f@@	B-Chemical	D005438	3375885
lud@@	I-Chemical	-1	3375885
ro@@	I-Chemical	-1	3375885
cor@@	I-Chemical	-1	3375885
tis@@	I-Chemical	-1	3375885
one	I-Chemical	-1	3375885
was	O	-1	3375885
ad@@	O	-1	3375885
de@@	O	-1	3375885
d,	O	-1	3375885
cor@@	O	-1	3375885
rec@@	O	-1	3375885
ting	O	-1	3375885
the	O	-1	3375885
hyper@@	B-Disease	D006947	3375885
k@@	I-Disease	-1	3375885
al@@	I-Disease	-1	3375885
emia	I-Disease	-1	3375885
and	O	-1	3375885
al@@	O	-1	3375885
low@@	O	-1	3375885
ing	O	-1	3375885
in@@	B-Chemical	D007213	3375885
do@@	I-Chemical	-1	3375885
meth@@	I-Chemical	-1	3375885
ac@@	I-Chemical	-1	3375885
in	I-Chemical	-1	3375885
therapy	O	-1	3375885
to	O	-1	3375885
be	O	-1	3375885
continu@@	O	-1	3375885
ed	O	-1	3375885
saf@@	O	-1	3375885
el@@	O	-1	3375885
y.	O	-1	3375885

H@@	B-Disease	D007022	3383127
y@@	I-Disease	-1	3383127
poten@@	I-Disease	-1	3383127
sion	I-Disease	-1	3383127
as	O	-1	3383127
a	O	-1	3383127
man@@	O	-1	3383127
if@@	O	-1	3383127
est@@	O	-1	3383127
ation	O	-1	3383127
of	O	-1	3383127
cardi@@	B-Disease	D066126	3383127
otoxicity	I-Disease	-1	3383127
in	O	-1	3383127
three	O	-1	3383127
patients	O	-1	3383127
receiving	O	-1	3383127
cisplatin	B-Chemical	D002945	3383127
and	O	-1	3383127
5-@@	B-Chemical	D005472	3383127
fluoro@@	I-Chemical	-1	3383127
urac@@	I-Chemical	-1	3383127
il	I-Chemical	-1	3383127
.	O	-1	3383127
C@@	O	-1	3383127
ardi@@	O	-1	3383127
a@@	O	-1	3383127
c	O	-1	3383127
symptom@@	O	-1	3383127
s,	O	-1	3383127
including	O	-1	3383127
hypotension	B-Disease	D007022	3383127
,	O	-1	3383127
developed	O	-1	3383127
in	O	-1	3383127
three	O	-1	3383127
patients	O	-1	3383127
with	O	-1	3383127
adv@@	O	-1	3383127
anced	O	-1	3383127
co@@	B-Disease	D015179	3383127
lo@@	I-Disease	-1	3383127
rec@@	I-Disease	-1	3383127
t@@	I-Disease	-1	3383127
al	I-Disease	-1	3383127
carcin@@	I-Disease	-1	3383127
oma	I-Disease	-1	3383127
while	O	-1	3383127
being	O	-1	3383127
treated	O	-1	3383127
with	O	-1	3383127
cisplatin	B-Chemical	D002945	3383127
(	O	-1	3383127
C@@	B-Chemical	D002945	3383127
D@@	I-Chemical	-1	3383127
D@@	I-Chemical	-1	3383127
P	I-Chemical	-1	3383127
)	O	-1	3383127
and	O	-1	3383127
5-@@	B-Chemical	D005472	3383127
fluoro@@	I-Chemical	-1	3383127
urac@@	I-Chemical	-1	3383127
il	I-Chemical	-1	3383127
(	O	-1	3383127
5-@@	B-Chemical	D005472	3383127
F@@	I-Chemical	-1	3383127
U	I-Chemical	-1	3383127
).	O	-1	3383127
In	O	-1	3383127
two	O	-1	3383127
patients,	O	-1	3383127
hypotension	B-Disease	D007022	3383127
was	O	-1	3383127
associated	O	-1	3383127
with	O	-1	3383127
severe	O	-1	3383127
left	B-Disease	D018487	3383127
ventricular	I-Disease	-1	3383127
dysfunction	I-Disease	-1	3383127
.	O	-1	3383127
All	O	-1	3383127
three	O	-1	3383127
patients	O	-1	3383127
requ@@	O	-1	3383127
ired	O	-1	3383127
therapy	O	-1	3383127
discontinu@@	O	-1	3383127
ation.	O	-1	3383127
C@@	O	-1	3383127
ardi@@	O	-1	3383127
a@@	O	-1	3383127
c	O	-1	3383127
enzym@@	O	-1	3383127
es	O	-1	3383127
remained	O	-1	3383127
normal	O	-1	3383127
des@@	O	-1	3383127
pit@@	O	-1	3383127
e	O	-1	3383127
transi@@	O	-1	3383127
ent	O	-1	3383127
electro@@	O	-1	3383127
cardio@@	O	-1	3383127
graph@@	O	-1	3383127
ic	O	-1	3383127
(@@	O	-1	3383127
E@@	O	-1	3383127
KG@@	O	-1	3383127
)	O	-1	3383127
chang@@	O	-1	3383127
es.	O	-1	3383127
The	O	-1	3383127
present@@	O	-1	3383127
ation	O	-1	3383127
and	O	-1	3383127
cardiac	O	-1	3383127
evalu@@	O	-1	3383127
ation	O	-1	3383127
(@@	O	-1	3383127
hemo@@	O	-1	3383127
dynam@@	O	-1	3383127
ic@@	O	-1	3383127
,	O	-1	3383127
echocardiograph@@	O	-1	3383127
ic@@	O	-1	3383127
,	O	-1	3383127
and	O	-1	3383127
s@@	O	-1	3383127
cin@@	O	-1	3383127
ti@@	O	-1	3383127
graph@@	O	-1	3383127
ic@@	O	-1	3383127
)	O	-1	3383127
of	O	-1	3383127
these	O	-1	3383127
patients	O	-1	3383127
suggest	O	-1	3383127
new	O	-1	3383127
man@@	O	-1	3383127
if@@	O	-1	3383127
est@@	O	-1	3383127
ations	O	-1	3383127
of	O	-1	3383127
5-@@	B-Chemical	D005472	3383127
F@@	I-Chemical	-1	3383127
U	I-Chemical	-1	3383127
cardi@@	B-Disease	D066126	3383127
otoxicity	I-Disease	-1	3383127
that	O	-1	3383127
may	O	-1	3383127
be	O	-1	3383127
influ@@	O	-1	3383127
enc@@	O	-1	3383127
ed	O	-1	3383127
by	O	-1	3383127
C@@	B-Chemical	D002945	3383127
D@@	I-Chemical	-1	3383127
D@@	I-Chemical	-1	3383127
P	I-Chemical	-1	3383127
.	O	-1	3383127
The	O	-1	3383127
possible	O	-1	3383127
path@@	O	-1	3383127
oph@@	O	-1	3383127
ysi@@	O	-1	3383127
ologic	O	-1	3383127
mechanisms	O	-1	3383127
are	O	-1	3383127
discus@@	O	-1	3383127
sed.	O	-1	3383127

F@@	O	-1	3409843
atal	O	-1	3409843
ap@@	B-Disease	D000741	3409843
las@@	I-Disease	-1	3409843
tic	I-Disease	-1	3409843
anemia	I-Disease	-1	3409843
in	O	-1	3409843
a	O	-1	3409843
patient	O	-1	3409843
treated	O	-1	3409843
with	O	-1	3409843
carbamazepine	B-Chemical	D002220	3409843
.	O	-1	3409843
A	O	-1	3409843
case	O	-1	3409843
of	O	-1	3409843
f@@	O	-1	3409843
atal	O	-1	3409843
ap@@	B-Disease	D000741	3409843
las@@	I-Disease	-1	3409843
tic	I-Disease	-1	3409843
anemia	I-Disease	-1	3409843
due	O	-1	3409843
to	O	-1	3409843
carbamazepine	B-Chemical	D002220	3409843
treatment	O	-1	3409843
in	O	-1	3409843
an	O	-1	3409843
epileptic	B-Disease	D004827	3409843
woman	O	-1	3409843
is	O	-1	3409843
repor@@	O	-1	3409843
ted.	O	-1	3409843
D@@	O	-1	3409843
es@@	O	-1	3409843
pit@@	O	-1	3409843
e	O	-1	3409843
con@@	O	-1	3409843
cer@@	O	-1	3409843
n@@	O	-1	3409843
s	O	-1	3409843
of	O	-1	3409843
f@@	O	-1	3409843
atal	O	-1	3409843
b@@	B-Disease	D001855	3409843
one	I-Disease	-1	3409843
m@@	I-Disease	-1	3409843
ar@@	I-Disease	-1	3409843
ro@@	I-Disease	-1	3409843
w	I-Disease	-1	3409843
toxicity	I-Disease	-1	3409843
due	O	-1	3409843
to	O	-1	3409843
carbamazepine	B-Chemical	D002220	3409843
,	O	-1	3409843
this	O	-1	3409843
is	O	-1	3409843
only	O	-1	3409843
the	O	-1	3409843
fo@@	O	-1	3409843
ur@@	O	-1	3409843
th	O	-1	3409843
doc@@	O	-1	3409843
um@@	O	-1	3409843
ent@@	O	-1	3409843
ed	O	-1	3409843
and	O	-1	3409843
pu@@	O	-1	3409843
bl@@	O	-1	3409843
ished	O	-1	3409843
repor@@	O	-1	3409843
t.	O	-1	3409843
C@@	B-Chemical	D002220	3409843
arb@@	I-Chemical	-1	3409843
am@@	I-Chemical	-1	3409843
azepine	I-Chemical	-1	3409843
is	O	-1	3409843
a	O	-1	3409843
saf@@	O	-1	3409843
e	O	-1	3409843
drug@@	O	-1	3409843
,	O	-1	3409843
but	O	-1	3409843
physi@@	O	-1	3409843
ci@@	O	-1	3409843
ans	O	-1	3409843
and	O	-1	3409843
patients	O	-1	3409843
should	O	-1	3409843
be	O	-1	3409843
aw@@	O	-1	3409843
are	O	-1	3409843
of	O	-1	3409843
the	O	-1	3409843
ex@@	O	-1	3409843
ce@@	O	-1	3409843
ed@@	O	-1	3409843
ing@@	O	-1	3409843
ly	O	-1	3409843
r@@	O	-1	3409843
are	O	-1	3409843
but	O	-1	3409843
potenti@@	O	-1	3409843
ally	O	-1	3409843
f@@	O	-1	3409843
atal	O	-1	3409843
side	O	-1	3409843
effect@@	O	-1	3409843
s,	O	-1	3409843
bet@@	O	-1	3409843
ter	O	-1	3409843
prevent@@	O	-1	3409843
ed	O	-1	3409843
by	O	-1	3409843
clinical	O	-1	3409843
than	O	-1	3409843
by	O	-1	3409843
labor@@	O	-1	3409843
atory	O	-1	3409843
monit@@	O	-1	3409843
or@@	O	-1	3409843
ing.	O	-1	3409843

P@@	O	-1	3423103
ar@@	O	-1	3423103
tic@@	O	-1	3423103
ip@@	O	-1	3423103
ation	O	-1	3423103
of	O	-1	3423103
a	O	-1	3423103
b@@	O	-1	3423103
ul@@	O	-1	3423103
b@@	O	-1	3423103
os@@	O	-1	3423103
p@@	O	-1	3423103
inal	O	-1	3423103
seroton@@	O	-1	3423103
ergic	O	-1	3423103
path@@	O	-1	3423103
w@@	O	-1	3423103
ay	O	-1	3423103
in	O	-1	3423103
the	O	-1	3423103
rat	O	-1	3423103
brain	O	-1	3423103
in	O	-1	3423103
clonidine	B-Chemical	D003000	3423103
-induced	O	-1	3423103
hypotension	B-Disease	D007022	3423103
and	O	-1	3423103
brady@@	B-Disease	D001919	3423103
cardia	I-Disease	-1	3423103
.	O	-1	3423103
The	O	-1	3423103
effects	O	-1	3423103
of	O	-1	3423103
micro@@	O	-1	3423103
injection	O	-1	3423103
of	O	-1	3423103
clonidine	B-Chemical	D003000	3423103
(1@@	O	-1	3423103
-@@	O	-1	3423103
10	O	-1	3423103
microgram@@	O	-1	3423103
s	O	-1	3423103
in	O	-1	3423103
1	O	-1	3423103
micro@@	O	-1	3423103
liter@@	O	-1	3423103
)	O	-1	3423103
into	O	-1	3423103
a	O	-1	3423103
regi@@	O	-1	3423103
on	O	-1	3423103
adj@@	O	-1	3423103
ac@@	O	-1	3423103
ent	O	-1	3423103
to	O	-1	3423103
the	O	-1	3423103
v@@	O	-1	3423103
ent@@	O	-1	3423103
ro@@	O	-1	3423103
lat@@	O	-1	3423103
eral	O	-1	3423103
sur@@	O	-1	3423103
fac@@	O	-1	3423103
e	O	-1	3423103
of	O	-1	3423103
the	O	-1	3423103
med@@	O	-1	3423103
ul@@	O	-1	3423103
l@@	O	-1	3423103
a	O	-1	3423103
ob@@	O	-1	3423103
long@@	O	-1	3423103
at@@	O	-1	3423103
a	O	-1	3423103
on	O	-1	3423103
cardiovascular	O	-1	3423103
function	O	-1	3423103
were	O	-1	3423103
assessed	O	-1	3423103
in	O	-1	3423103
ure@@	B-Chemical	D014520	3423103
th@@	I-Chemical	-1	3423103
ane	I-Chemical	-1	3423103
-@@	O	-1	3423103
anesthe@@	O	-1	3423103
tiz@@	O	-1	3423103
ed	O	-1	3423103
rats.	O	-1	3423103
In@@	O	-1	3423103
t@@	O	-1	3423103
ram@@	O	-1	3423103
ed@@	O	-1	3423103
ul@@	O	-1	3423103
l@@	O	-1	3423103
ary	O	-1	3423103
administration	O	-1	3423103
of	O	-1	3423103
clonidine	B-Chemical	D003000	3423103
,	O	-1	3423103
but	O	-1	3423103
not	O	-1	3423103
saline	O	-1	3423103
ve@@	O	-1	3423103
h@@	O	-1	3423103
ic@@	O	-1	3423103
le@@	O	-1	3423103
,	O	-1	3423103
caused	O	-1	3423103
a	O	-1	3423103
dose-@@	O	-1	3423103
dependent	O	-1	3423103
decrease	O	-1	3423103
in	O	-1	3423103
both	O	-1	3423103
the	O	-1	3423103
mean	O	-1	3423103
arterial	O	-1	3423103
pressure	O	-1	3423103
and	O	-1	3423103
the	O	-1	3423103
heart	O	-1	3423103
rat@@	O	-1	3423103
e.	O	-1	3423103
The	O	-1	3423103
clonidine	B-Chemical	D003000	3423103
-induced	O	-1	3423103
hypotension	B-Disease	D007022	3423103
was	O	-1	3423103
antagon@@	O	-1	3423103
ized	O	-1	3423103
by	O	-1	3423103
prior	O	-1	3423103
spinal	O	-1	3423103
trans@@	O	-1	3423103
ec@@	O	-1	3423103
tion,	O	-1	3423103
but	O	-1	3423103
not	O	-1	3423103
bil@@	O	-1	3423103
ateral	O	-1	3423103
v@@	O	-1	3423103
ag@@	O	-1	3423103
ot@@	O	-1	3423103
om@@	O	-1	3423103
y.	O	-1	3423103
O@@	O	-1	3423103
n	O	-1	3423103
the	O	-1	3423103
other	O	-1	3423103
h@@	O	-1	3423103
and@@	O	-1	3423103
,	O	-1	3423103
the	O	-1	3423103
clonidine	B-Chemical	D003000	3423103
-induced	O	-1	3423103
brady@@	B-Disease	D001919	3423103
cardia	I-Disease	-1	3423103
was	O	-1	3423103
antagon@@	O	-1	3423103
ized	O	-1	3423103
by	O	-1	3423103
prior	O	-1	3423103
bil@@	O	-1	3423103
ateral	O	-1	3423103
v@@	O	-1	3423103
ag@@	O	-1	3423103
ot@@	O	-1	3423103
om@@	O	-1	3423103
y,	O	-1	3423103
but	O	-1	3423103
not	O	-1	3423103
spinal	O	-1	3423103
trans@@	O	-1	3423103
ec@@	O	-1	3423103
tion.	O	-1	3423103
F@@	O	-1	3423103
ur@@	O	-1	3423103
ther@@	O	-1	3423103
mo@@	O	-1	3423103
re,	O	-1	3423103
selective	O	-1	3423103
de@@	O	-1	3423103
struc@@	O	-1	3423103
tion	O	-1	3423103
of	O	-1	3423103
the	O	-1	3423103
spinal	O	-1	3423103
5-@@	B-Chemical	D012701	3423103
H@@	I-Chemical	-1	3423103
T	I-Chemical	-1	3423103
ner@@	O	-1	3423103
v@@	O	-1	3423103
es,	O	-1	3423103
produced	O	-1	3423103
by	O	-1	3423103
bil@@	O	-1	3423103
ateral	O	-1	3423103
spinal	O	-1	3423103
injection	O	-1	3423103
of	O	-1	3423103
5@@	B-Chemical	D015116	3423103
,@@	I-Chemical	-1	3423103
7-@@	I-Chemical	-1	3423103
di@@	I-Chemical	-1	3423103
hydrox@@	I-Chemical	-1	3423103
y@@	I-Chemical	-1	3423103
tr@@	I-Chemical	-1	3423103
y@@	I-Chemical	-1	3423103
pt@@	I-Chemical	-1	3423103
amine	I-Chemical	-1	3423103
,	O	-1	3423103
reduced	O	-1	3423103
the	O	-1	3423103
mag@@	O	-1	3423103
nit@@	O	-1	3423103
ude	O	-1	3423103
of	O	-1	3423103
the	O	-1	3423103
vas@@	O	-1	3423103
o@@	O	-1	3423103
depress@@	O	-1	3423103
or	O	-1	3423103
or	O	-1	3423103
the	O	-1	3423103
brady@@	B-Disease	D001919	3423103
cardiac	I-Disease	-1	3423103
responses	O	-1	3423103
to	O	-1	3423103
clonidine	B-Chemical	D003000	3423103
micro@@	O	-1	3423103
injected	O	-1	3423103
into	O	-1	3423103
the	O	-1	3423103
a@@	O	-1	3423103
re@@	O	-1	3423103
a	O	-1	3423103
ne@@	O	-1	3423103
ar	O	-1	3423103
the	O	-1	3423103
v@@	O	-1	3423103
ent@@	O	-1	3423103
ro@@	O	-1	3423103
lat@@	O	-1	3423103
eral	O	-1	3423103
sur@@	O	-1	3423103
fac@@	O	-1	3423103
e	O	-1	3423103
of	O	-1	3423103
the	O	-1	3423103
med@@	O	-1	3423103
ul@@	O	-1	3423103
l@@	O	-1	3423103
a	O	-1	3423103
ob@@	O	-1	3423103
long@@	O	-1	3423103
at@@	O	-1	3423103
a	O	-1	3423103
in	O	-1	3423103
rats.	O	-1	3423103
The	O	-1	3423103
data	O	-1	3423103
indicate	O	-1	3423103
that	O	-1	3423103
a	O	-1	3423103
b@@	O	-1	3423103
ul@@	O	-1	3423103
b@@	O	-1	3423103
os@@	O	-1	3423103
p@@	O	-1	3423103
inal	O	-1	3423103
seroton@@	O	-1	3423103
ergic	O	-1	3423103
path@@	O	-1	3423103
w@@	O	-1	3423103
ay	O	-1	3423103
is	O	-1	3423103
involved	O	-1	3423103
in	O	-1	3423103
development	O	-1	3423103
of	O	-1	3423103
clonidine	B-Chemical	D003000	3423103
-induced	O	-1	3423103
hypotension	B-Disease	D007022	3423103
and	O	-1	3423103
brady@@	B-Disease	D001919	3423103
cardia	I-Disease	-1	3423103
.	O	-1	3423103
The	O	-1	3423103
induced	O	-1	3423103
hypotension	B-Disease	D007022	3423103
is	O	-1	3423103
b@@	O	-1	3423103
rou@@	O	-1	3423103
ght	O	-1	3423103
about	O	-1	3423103
by	O	-1	3423103
a	O	-1	3423103
decrease	O	-1	3423103
in	O	-1	3423103
sym@@	O	-1	3423103
pa@@	O	-1	3423103
thetic	O	-1	3423103
eff@@	O	-1	3423103
e@@	O	-1	3423103
rent	O	-1	3423103
activ@@	O	-1	3423103
ity,	O	-1	3423103
whereas	O	-1	3423103
the	O	-1	3423103
induced	O	-1	3423103
brady@@	B-Disease	D001919	3423103
cardia	I-Disease	-1	3423103
was	O	-1	3423103
due	O	-1	3423103
to	O	-1	3423103
an	O	-1	3423103
increase	O	-1	3423103
in	O	-1	3423103
v@@	O	-1	3423103
ag@@	O	-1	3423103
al	O	-1	3423103
eff@@	O	-1	3423103
e@@	O	-1	3423103
rent	O	-1	3423103
activ@@	O	-1	3423103
ity.	O	-1	3423103

H@@	B-Disease	D006973	3439580
y@@	I-Disease	-1	3439580
per@@	I-Disease	-1	3439580
ten@@	I-Disease	-1	3439580
sion	I-Disease	-1	3439580
in	O	-1	3439580
neuro@@	B-Disease	D009447	3439580
bl@@	I-Disease	-1	3439580
ast@@	I-Disease	-1	3439580
oma	I-Disease	-1	3439580
induced	O	-1	3439580
by	O	-1	3439580
im@@	B-Chemical	D007099	3439580
ip@@	I-Chemical	-1	3439580
r@@	I-Chemical	-1	3439580
amine	I-Chemical	-1	3439580
.	O	-1	3439580
H@@	B-Disease	D006973	3439580
y@@	I-Disease	-1	3439580
per@@	I-Disease	-1	3439580
ten@@	I-Disease	-1	3439580
sion	I-Disease	-1	3439580
is	O	-1	3439580
a	O	-1	3439580
we@@	O	-1	3439580
ll@@	O	-1	3439580
-@@	O	-1	3439580
known	O	-1	3439580
find@@	O	-1	3439580
ing	O	-1	3439580
in	O	-1	3439580
some	O	-1	3439580
patients	O	-1	3439580
with	O	-1	3439580
neuro@@	B-Disease	D009447	3439580
bl@@	I-Disease	-1	3439580
ast@@	I-Disease	-1	3439580
oma	I-Disease	-1	3439580
.	O	-1	3439580
However,	O	-1	3439580
it	O	-1	3439580
has	O	-1	3439580
not	O	-1	3439580
previously	O	-1	3439580
been	O	-1	3439580
descri@@	O	-1	3439580
bed	O	-1	3439580
in	O	-1	3439580
association	O	-1	3439580
with	O	-1	3439580
the	O	-1	3439580
use	O	-1	3439580
of	O	-1	3439580
I@@	B-Chemical	D007099	3439580
mi@@	I-Chemical	-1	3439580
pramine	I-Chemical	-1	3439580
.	O	-1	3439580
We	O	-1	3439580
report	O	-1	3439580
the	O	-1	3439580
occur@@	O	-1	3439580
rence	O	-1	3439580
of	O	-1	3439580
severe	O	-1	3439580
hypertension	B-Disease	D006973	3439580
(@@	O	-1	3439580
blood	O	-1	3439580
pressure	O	-1	3439580
19@@	O	-1	3439580
0@@	O	-1	3439580
/@@	O	-1	3439580
1@@	O	-1	3439580
6@@	O	-1	3439580
0@@	O	-1	3439580
)	O	-1	3439580
in	O	-1	3439580
a	O	-1	3439580
4-@@	O	-1	3439580
year-old	O	-1	3439580
gi@@	O	-1	3439580
r@@	O	-1	3439580
l	O	-1	3439580
with	O	-1	3439580
neuro@@	B-Disease	D009447	3439580
bl@@	I-Disease	-1	3439580
ast@@	I-Disease	-1	3439580
oma	I-Disease	-1	3439580
who	O	-1	3439580
was	O	-1	3439580
given	O	-1	3439580
I@@	B-Chemical	D007099	3439580
mi@@	I-Chemical	-1	3439580
pramine	I-Chemical	-1	3439580
to	O	-1	3439580
control	O	-1	3439580
a	O	-1	3439580
behavi@@	B-Disease	D002653	3439580
or	I-Disease	-1	3439580
disor@@	I-Disease	-1	3439580
der	I-Disease	-1	3439580
.	O	-1	3439580
It	O	-1	3439580
was	O	-1	3439580
determined	O	-1	3439580
lat@@	O	-1	3439580
er	O	-1	3439580
that	O	-1	3439580
this	O	-1	3439580
patient@@	O	-1	3439580
's	O	-1	3439580
tumor	B-Disease	D009369	3439580
was	O	-1	3439580
recur@@	O	-1	3439580
r@@	O	-1	3439580
ing	O	-1	3439580
at	O	-1	3439580
the	O	-1	3439580
time	O	-1	3439580
of	O	-1	3439580
h@@	O	-1	3439580
er	O	-1	3439580
hypertensive	B-Disease	D006973	3439580
episo@@	O	-1	3439580
de@@	O	-1	3439580
.	O	-1	3439580
S@@	O	-1	3439580
inc@@	O	-1	3439580
e	O	-1	3439580
sh@@	O	-1	3439580
e	O	-1	3439580
had	O	-1	3439580
no	O	-1	3439580
blood	O	-1	3439580
pressure	O	-1	3439580
elev@@	O	-1	3439580
ation	O	-1	3439580
at	O	-1	3439580
initial	O	-1	3439580
diagnosis	O	-1	3439580
and	O	-1	3439580
n@@	O	-1	3439580
one	O	-1	3439580
following	O	-1	3439580
discontinu@@	O	-1	3439580
ation	O	-1	3439580
of	O	-1	3439580
the	O	-1	3439580
I@@	B-Chemical	D007099	3439580
mi@@	I-Chemical	-1	3439580
pramine	I-Chemical	-1	3439580
(@@	O	-1	3439580
when	O	-1	3439580
sh@@	O	-1	3439580
e	O	-1	3439580
was	O	-1	3439580
in	O	-1	3439580
f@@	O	-1	3439580
lor@@	O	-1	3439580
id	O	-1	3439580
rel@@	O	-1	3439580
ap@@	O	-1	3439580
se@@	O	-1	3439580
),	O	-1	3439580
we	O	-1	3439580
be@@	O	-1	3439580
li@@	O	-1	3439580
e@@	O	-1	3439580
ve	O	-1	3439580
that	O	-1	3439580
this	O	-1	3439580
drug	O	-1	3439580
ra@@	O	-1	3439580
ther	O	-1	3439580
than	O	-1	3439580
h@@	O	-1	3439580
er	O	-1	3439580
underlying	O	-1	3439580
disease	O	-1	3439580
alone	O	-1	3439580
caused	O	-1	3439580
h@@	O	-1	3439580
er	O	-1	3439580
hypertension	B-Disease	D006973	3439580
.	O	-1	3439580
The	O	-1	3439580
mechanism	O	-1	3439580
for	O	-1	3439580
this	O	-1	3439580
reaction	O	-1	3439580
is	O	-1	3439580
be@@	O	-1	3439580
li@@	O	-1	3439580
ev@@	O	-1	3439580
ed	O	-1	3439580
to	O	-1	3439580
be	O	-1	3439580
increased	O	-1	3439580
levels	O	-1	3439580
of	O	-1	3439580
vas@@	O	-1	3439580
o@@	O	-1	3439580
active	O	-1	3439580
cat@@	B-Chemical	D002395	3439580
ech@@	I-Chemical	-1	3439580
ol@@	I-Chemical	-1	3439580
amin@@	I-Chemical	-1	3439580
es	I-Chemical	-1	3439580
due	O	-1	3439580
to	O	-1	3439580
inter@@	O	-1	3439580
fe@@	O	-1	3439580
rence	O	-1	3439580
of	O	-1	3439580
their	O	-1	3439580
physi@@	O	-1	3439580
ologic	O	-1	3439580
in@@	O	-1	3439580
activation	O	-1	3439580
by	O	-1	3439580
I@@	B-Chemical	D007099	3439580
mi@@	I-Chemical	-1	3439580
pramine	I-Chemical	-1	3439580
.	O	-1	3439580
F@@	O	-1	3439580
rom	O	-1	3439580
this	O	-1	3439580
experi@@	O	-1	3439580
ence@@	O	-1	3439580
,	O	-1	3439580
we	O	-1	3439580
ur@@	O	-1	3439580
ge	O	-1	3439580
ex@@	O	-1	3439580
trem@@	O	-1	3439580
e	O	-1	3439580
cau@@	O	-1	3439580
tion	O	-1	3439580
in	O	-1	3439580
the	O	-1	3439580
use	O	-1	3439580
of	O	-1	3439580
tr@@	O	-1	3439580
ic@@	O	-1	3439580
y@@	O	-1	3439580
cl@@	O	-1	3439580
ic	O	-1	3439580
antidepress@@	O	-1	3439580
ants	O	-1	3439580
in	O	-1	3439580
children	O	-1	3439580
with	O	-1	3439580
active	O	-1	3439580
neuro@@	B-Disease	D009447	3439580
bl@@	I-Disease	-1	3439580
ast@@	I-Disease	-1	3439580
oma	I-Disease	-1	3439580
.	O	-1	3439580

R@@	O	-1	3475563
ech@@	O	-1	3475563
all@@	O	-1	3475563
enge	O	-1	3475563
of	O	-1	3475563
patients	O	-1	3475563
who	O	-1	3475563
developed	O	-1	3475563
oral	B-Disease	D002180	3475563
can@@	I-Disease	-1	3475563
di@@	I-Disease	-1	3475563
dia@@	I-Disease	-1	3475563
sis	I-Disease	-1	3475563
or	O	-1	3475563
ho@@	B-Disease	D006685	3475563
ar@@	I-Disease	-1	3475563
sen@@	I-Disease	-1	3475563
ess	I-Disease	-1	3475563
with	O	-1	3475563
b@@	B-Chemical	D001507	3475563
ec@@	I-Chemical	-1	3475563
lo@@	I-Chemical	-1	3475563
meth@@	I-Chemical	-1	3475563
as@@	I-Chemical	-1	3475563
one	I-Chemical	-1	3475563
di@@	I-Chemical	-1	3475563
pro@@	I-Chemical	-1	3475563
pi@@	I-Chemical	-1	3475563
on@@	I-Chemical	-1	3475563
ate	I-Chemical	-1	3475563
.	O	-1	3475563
Of	O	-1	3475563
1@@	O	-1	3475563
5@@	O	-1	3475563
8	O	-1	3475563
as@@	B-Disease	D001249	3475563
th@@	I-Disease	-1	3475563
m@@	I-Disease	-1	3475563
atic	I-Disease	-1	3475563
patients	O	-1	3475563
who	O	-1	3475563
were	O	-1	3475563
pl@@	O	-1	3475563
ac@@	O	-1	3475563
ed	O	-1	3475563
on	O	-1	3475563
in@@	O	-1	3475563
h@@	O	-1	3475563
al@@	O	-1	3475563
ed	O	-1	3475563
b@@	B-Chemical	D001507	3475563
ec@@	I-Chemical	-1	3475563
lo@@	I-Chemical	-1	3475563
meth@@	I-Chemical	-1	3475563
as@@	I-Chemical	-1	3475563
one	I-Chemical	-1	3475563
,	O	-1	3475563
15	O	-1	3475563
(@@	O	-1	3475563
9.@@	O	-1	3475563
5@@	O	-1	3475563
%)	O	-1	3475563
developed	O	-1	3475563
either	O	-1	3475563
ho@@	B-Disease	D006685	3475563
ar@@	I-Disease	-1	3475563
sen@@	I-Disease	-1	3475563
ess	I-Disease	-1	3475563
(@@	O	-1	3475563
8@@	O	-1	3475563
),	O	-1	3475563
oral	O	-1	3475563
th@@	B-Disease	D002180	3475563
r@@	I-Disease	-1	3475563
us@@	I-Disease	-1	3475563
h	I-Disease	-1	3475563
(6@@	O	-1	3475563
),	O	-1	3475563
or	O	-1	3475563
both	O	-1	3475563
(1@@	O	-1	3475563
).	O	-1	3475563
Whe@@	O	-1	3475563
n	O	-1	3475563
their	O	-1	3475563
adverse	O	-1	3475563
reactions	O	-1	3475563
sub@@	O	-1	3475563
side@@	O	-1	3475563
d,	O	-1	3475563
seven	O	-1	3475563
of	O	-1	3475563
these	O	-1	3475563
15	O	-1	3475563
patients	O	-1	3475563
were	O	-1	3475563
re@@	O	-1	3475563
ch@@	O	-1	3475563
all@@	O	-1	3475563
en@@	O	-1	3475563
g@@	O	-1	3475563
ed	O	-1	3475563
with	O	-1	3475563
in@@	O	-1	3475563
h@@	O	-1	3475563
al@@	O	-1	3475563
ed	O	-1	3475563
b@@	B-Chemical	D001507	3475563
ec@@	I-Chemical	-1	3475563
lo@@	I-Chemical	-1	3475563
meth@@	I-Chemical	-1	3475563
as@@	I-Chemical	-1	3475563
one	I-Chemical	-1	3475563
.	O	-1	3475563
These	O	-1	3475563
included	O	-1	3475563
five	O	-1	3475563
cases	O	-1	3475563
who	O	-1	3475563
developed	O	-1	3475563
ho@@	B-Disease	D006685	3475563
ar@@	I-Disease	-1	3475563
sen@@	I-Disease	-1	3475563
ess	I-Disease	-1	3475563
and	O	-1	3475563
three	O	-1	3475563
who	O	-1	3475563
developed	O	-1	3475563
C@@	B-Disease	D002177	3475563
an@@	I-Disease	-1	3475563
di@@	I-Disease	-1	3475563
dia@@	I-Disease	-1	3475563
sis	I-Disease	-1	3475563
.	O	-1	3475563
One	O	-1	3475563
patient	O	-1	3475563
had	O	-1	3475563
bo@@	O	-1	3475563
th@@	O	-1	3475563
.	O	-1	3475563
O@@	O	-1	3475563
ral	O	-1	3475563
th@@	B-Disease	D002180	3475563
r@@	I-Disease	-1	3475563
us@@	I-Disease	-1	3475563
h	I-Disease	-1	3475563
did	O	-1	3475563
not	O	-1	3475563
recur@@	O	-1	3475563
,	O	-1	3475563
but	O	-1	3475563
6@@	O	-1	3475563
0%	O	-1	3475563
(3@@	O	-1	3475563
/@@	O	-1	3475563
5@@	O	-1	3475563
)	O	-1	3475563
of	O	-1	3475563
patients	O	-1	3475563
with	O	-1	3475563
ho@@	B-Disease	D006685	3475563
ar@@	I-Disease	-1	3475563
sen@@	I-Disease	-1	3475563
ess	I-Disease	-1	3475563
had	O	-1	3475563
recur@@	O	-1	3475563
ren@@	O	-1	3475563
ce@@	O	-1	3475563
.	O	-1	3475563
We	O	-1	3475563
concl@@	O	-1	3475563
ude	O	-1	3475563
that	O	-1	3475563
patients	O	-1	3475563
may	O	-1	3475563
be	O	-1	3475563
re@@	O	-1	3475563
star@@	O	-1	3475563
ted	O	-1	3475563
on	O	-1	3475563
in@@	O	-1	3475563
h@@	O	-1	3475563
al@@	O	-1	3475563
ed	O	-1	3475563
b@@	B-Chemical	D001507	3475563
ec@@	I-Chemical	-1	3475563
lo@@	I-Chemical	-1	3475563
meth@@	I-Chemical	-1	3475563
as@@	I-Chemical	-1	3475563
one	I-Chemical	-1	3475563
when	O	-1	3475563
clin@@	O	-1	3475563
ically	O	-1	3475563
indic@@	O	-1	3475563
ated@@	O	-1	3475563
;	O	-1	3475563
however,	O	-1	3475563
because	O	-1	3475563
of	O	-1	3475563
the	O	-1	3475563
high	O	-1	3475563
recur@@	O	-1	3475563
rence	O	-1	3475563
rat@@	O	-1	3475563
e,	O	-1	3475563
patients	O	-1	3475563
who	O	-1	3475563
deve@@	O	-1	3475563
lo@@	O	-1	3475563
p	O	-1	3475563
ho@@	B-Disease	D006685	3475563
ar@@	I-Disease	-1	3475563
sen@@	I-Disease	-1	3475563
ess	I-Disease	-1	3475563
should	O	-1	3475563
not	O	-1	3475563
be	O	-1	3475563
re@@	O	-1	3475563
-@@	O	-1	3475563
ch@@	O	-1	3475563
all@@	O	-1	3475563
en@@	O	-1	3475563
g@@	O	-1	3475563
ed.	O	-1	3475563
Con@@	O	-1	3475563
comit@@	O	-1	3475563
ant	O	-1	3475563
use	O	-1	3475563
of	O	-1	3475563
oral	O	-1	3475563
pre@@	B-Chemical	D011241	3475563
d@@	I-Chemical	-1	3475563
n@@	I-Chemical	-1	3475563
is@@	I-Chemical	-1	3475563
one	I-Chemical	-1	3475563
and	O	-1	3475563
to@@	O	-1	3475563
p@@	O	-1	3475563
ical	O	-1	3475563
b@@	B-Chemical	D001507	3475563
ec@@	I-Chemical	-1	3475563
lo@@	I-Chemical	-1	3475563
meth@@	I-Chemical	-1	3475563
as@@	I-Chemical	-1	3475563
one	I-Chemical	-1	3475563
may	O	-1	3475563
increase	O	-1	3475563
the	O	-1	3475563
risk	O	-1	3475563
of	O	-1	3475563
develop@@	O	-1	3475563
ing	O	-1	3475563
ho@@	B-Disease	D006685	3475563
ar@@	I-Disease	-1	3475563
sen@@	I-Disease	-1	3475563
ess	I-Disease	-1	3475563
or	O	-1	3475563
can@@	B-Disease	D002177	3475563
di@@	I-Disease	-1	3475563
dia@@	I-Disease	-1	3475563
sis	I-Disease	-1	3475563
.	O	-1	3475563

C@@	B-Chemical	D003520	3533179
yc@@	I-Chemical	-1	3533179
lo@@	I-Chemical	-1	3533179
phosph@@	I-Chemical	-1	3533179
amide	I-Chemical	-1	3533179
cardi@@	B-Disease	D066126	3533179
otoxicity	I-Disease	-1	3533179
:	O	-1	3533179
an	O	-1	3533179
analysis	O	-1	3533179
of	O	-1	3533179
dos@@	O	-1	3533179
ing	O	-1	3533179
as	O	-1	3533179
a	O	-1	3533179
risk	O	-1	3533179
fact@@	O	-1	3533179
or@@	O	-1	3533179
.	O	-1	3533179
Patients	O	-1	3533179
who	O	-1	3533179
under@@	O	-1	3533179
g@@	O	-1	3533179
o	O	-1	3533179
b@@	O	-1	3533179
one	O	-1	3533179
m@@	O	-1	3533179
ar@@	O	-1	3533179
ro@@	O	-1	3533179
w	O	-1	3533179
transplant@@	O	-1	3533179
ation	O	-1	3533179
are	O	-1	3533179
gener@@	O	-1	3533179
ally	O	-1	3533179
immunosup@@	O	-1	3533179
press@@	O	-1	3533179
ed	O	-1	3533179
with	O	-1	3533179
a	O	-1	3533179
dose	O	-1	3533179
of	O	-1	3533179
cyclophosph@@	B-Chemical	D003520	3533179
amide	I-Chemical	-1	3533179
(	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
)	O	-1	3533179
which	O	-1	3533179
is	O	-1	3533179
us@@	O	-1	3533179
ually	O	-1	3533179
calc@@	O	-1	3533179
ul@@	O	-1	3533179
ated	O	-1	3533179
bas@@	O	-1	3533179
ed	O	-1	3533179
on	O	-1	3533179
the	O	-1	3533179
patient@@	O	-1	3533179
's	O	-1	3533179
weigh@@	O	-1	3533179
t.	O	-1	3533179
A@@	O	-1	3533179
t	O	-1	3533179
these	O	-1	3533179
high	O	-1	3533179
doses	O	-1	3533179
of	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
,	O	-1	3533179
seri@@	O	-1	3533179
ous	O	-1	3533179
cardi@@	B-Disease	D066126	3533179
otoxicity	I-Disease	-1	3533179
may	O	-1	3533179
occur@@	O	-1	3533179
,	O	-1	3533179
but	O	-1	3533179
def@@	O	-1	3533179
in@@	O	-1	3533179
itive	O	-1	3533179
risk	O	-1	3533179
factors	O	-1	3533179
for	O	-1	3533179
the	O	-1	3533179
development	O	-1	3533179
of	O	-1	3533179
such	O	-1	3533179
cardi@@	B-Disease	D066126	3533179
otoxicity	I-Disease	-1	3533179
have	O	-1	3533179
not	O	-1	3533179
been	O	-1	3533179
descri@@	O	-1	3533179
be@@	O	-1	3533179
d.	O	-1	3533179
S@@	O	-1	3533179
inc@@	O	-1	3533179
e	O	-1	3533179
chemo@@	O	-1	3533179
therapeutic	O	-1	3533179
agent	O	-1	3533179
toxicity	B-Disease	D064420	3533179
gener@@	O	-1	3533179
ally	O	-1	3533179
correl@@	O	-1	3533179
ates	O	-1	3533179
with	O	-1	3533179
dose	O	-1	3533179
per	O	-1	3533179
body	O	-1	3533179
sur@@	O	-1	3533179
fac@@	O	-1	3533179
e	O	-1	3533179
a@@	O	-1	3533179
re@@	O	-1	3533179
a,	O	-1	3533179
we	O	-1	3533179
ret@@	O	-1	3533179
ro@@	O	-1	3533179
sp@@	O	-1	3533179
ectively	O	-1	3533179
calc@@	O	-1	3533179
ul@@	O	-1	3533179
ated	O	-1	3533179
the	O	-1	3533179
dose	O	-1	3533179
of	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
in	O	-1	3533179
patients	O	-1	3533179
transplant@@	O	-1	3533179
ed	O	-1	3533179
at	O	-1	3533179
our	O	-1	3533179
insti@@	O	-1	3533179
tu@@	O	-1	3533179
tion	O	-1	3533179
to	O	-1	3533179
determine	O	-1	3533179
whether	O	-1	3533179
the	O	-1	3533179
incidence	O	-1	3533179
of	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
cardi@@	B-Disease	D066126	3533179
otoxicity	I-Disease	-1	3533179
cor@@	O	-1	3533179
related	O	-1	3533179
with	O	-1	3533179
the	O	-1	3533179
dose	O	-1	3533179
per	O	-1	3533179
body	O	-1	3533179
sur@@	O	-1	3533179
fac@@	O	-1	3533179
e	O	-1	3533179
a@@	O	-1	3533179
re@@	O	-1	3533179
a.	O	-1	3533179
E@@	O	-1	3533179
igh@@	O	-1	3533179
t@@	O	-1	3533179
y	O	-1	3533179
patients	O	-1	3533179
who	O	-1	3533179
were	O	-1	3533179
to	O	-1	3533179
recei@@	O	-1	3533179
ve	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
50	O	-1	3533179
mg/k@@	O	-1	3533179
g/@@	O	-1	3533179
d	O	-1	3533179
for	O	-1	3533179
four	O	-1	3533179
days	O	-1	3533179
as	O	-1	3533179
pre@@	O	-1	3533179
par@@	O	-1	3533179
ation	O	-1	3533179
for	O	-1	3533179
m@@	O	-1	3533179
ar@@	O	-1	3533179
ro@@	O	-1	3533179
w	O	-1	3533179
gra@@	O	-1	3533179
f@@	O	-1	3533179
ting	O	-1	3533179
under@@	O	-1	3533179
w@@	O	-1	3533179
ent	O	-1	3533179
a	O	-1	3533179
total	O	-1	3533179
of	O	-1	3533179
8@@	O	-1	3533179
4	O	-1	3533179
transplant@@	O	-1	3533179
s	O	-1	3533179
for	O	-1	3533179
ap@@	B-Disease	D000741	3533179
las@@	I-Disease	-1	3533179
tic	I-Disease	-1	3533179
anemia	I-Disease	-1	3533179
,	O	-1	3533179
W@@	B-Disease	D014923	3533179
is@@	I-Disease	-1	3533179
k@@	I-Disease	-1	3533179
ot@@	I-Disease	-1	3533179
t-@@	I-Disease	-1	3533179
Al@@	I-Disease	-1	3533179
d@@	I-Disease	-1	3533179
r@@	I-Disease	-1	3533179
ich	I-Disease	-1	3533179
syndrome	I-Disease	-1	3533179
,	O	-1	3533179
or	O	-1	3533179
severe	B-Disease	D016511	3533179
combined	I-Disease	-1	3533179
immuno@@	I-Disease	-1	3533179
defici@@	I-Disease	-1	3533179
ency	I-Disease	-1	3533179
syndrome	I-Disease	-1	3533179
.	O	-1	3533179
F@@	O	-1	3533179
o@@	O	-1	3533179
ur@@	O	-1	3533179
te@@	O	-1	3533179
en	O	-1	3533179
of	O	-1	3533179
8@@	O	-1	3533179
4	O	-1	3533179
(1@@	O	-1	3533179
7@@	O	-1	3533179
%)	O	-1	3533179
patients	O	-1	3533179
had	O	-1	3533179
symptoms	O	-1	3533179
and	O	-1	3533179
signs	O	-1	3533179
consist@@	O	-1	3533179
ent	O	-1	3533179
with	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
cardi@@	B-Disease	D066126	3533179
otoxicity	I-Disease	-1	3533179
within	O	-1	3533179
ten	O	-1	3533179
days	O	-1	3533179
of	O	-1	3533179
receiving	O	-1	3533179
1	O	-1	3533179
to	O	-1	3533179
4	O	-1	3533179
doses	O	-1	3533179
of	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
.	O	-1	3533179
Si@@	O	-1	3533179
x	O	-1	3533179
of	O	-1	3533179
the	O	-1	3533179
14	O	-1	3533179
patients	O	-1	3533179
di@@	O	-1	3533179
ed	O	-1	3533179
with	O	-1	3533179
con@@	B-Disease	D006333	3533179
g@@	I-Disease	-1	3533179
es@@	I-Disease	-1	3533179
tive	I-Disease	-1	3533179
heart	I-Disease	-1	3533179
failure	I-Disease	-1	3533179
.	O	-1	3533179
The	O	-1	3533179
dose	O	-1	3533179
of	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
per	O	-1	3533179
body	O	-1	3533179
sur@@	O	-1	3533179
fac@@	O	-1	3533179
e	O	-1	3533179
a@@	O	-1	3533179
re@@	O	-1	3533179
a	O	-1	3533179
was	O	-1	3533179
calc@@	O	-1	3533179
ul@@	O	-1	3533179
ated	O	-1	3533179
for	O	-1	3533179
all	O	-1	3533179
patients	O	-1	3533179
and	O	-1	3533179
the	O	-1	3533179
patients	O	-1	3533179
were	O	-1	3533179
divid@@	O	-1	3533179
ed	O	-1	3533179
into	O	-1	3533179
two	O	-1	3533179
groups	O	-1	3533179
bas@@	O	-1	3533179
ed	O	-1	3533179
on	O	-1	3533179
daily	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
dose@@	O	-1	3533179
:	O	-1	3533179
Group	O	-1	3533179
1,	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
less	O	-1	3533179
than	O	-1	3533179
or	O	-1	3533179
equ@@	O	-1	3533179
al	O	-1	3533179
to	O	-1	3533179
1.@@	O	-1	3533179
5@@	O	-1	3533179
5	O	-1	3533179
g/@@	O	-1	3533179
m@@	O	-1	3533179
2@@	O	-1	3533179
/@@	O	-1	3533179
d@@	O	-1	3533179
;	O	-1	3533179
Group	O	-1	3533179
2,	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
greater	O	-1	3533179
than	O	-1	3533179
1.@@	O	-1	3533179
5@@	O	-1	3533179
5	O	-1	3533179
g/@@	O	-1	3533179
m@@	O	-1	3533179
2@@	O	-1	3533179
/@@	O	-1	3533179
d.	O	-1	3533179
C@@	B-Disease	D066126	3533179
ardi@@	I-Disease	-1	3533179
otoxicity	I-Disease	-1	3533179
that	O	-1	3533179
was	O	-1	3533179
thou@@	O	-1	3533179
ght	O	-1	3533179
to	O	-1	3533179
be	O	-1	3533179
related	O	-1	3533179
to	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
occurred	O	-1	3533179
in	O	-1	3533179
1@@	O	-1	3533179
/@@	O	-1	3533179
3@@	O	-1	3533179
2	O	-1	3533179
(3@@	O	-1	3533179
%)	O	-1	3533179
of	O	-1	3533179
patients	O	-1	3533179
in	O	-1	3533179
Group	O	-1	3533179
1	O	-1	3533179
and	O	-1	3533179
in	O	-1	3533179
13@@	O	-1	3533179
/@@	O	-1	3533179
5@@	O	-1	3533179
2	O	-1	3533179
(2@@	O	-1	3533179
5@@	O	-1	3533179
%)	O	-1	3533179
patients	O	-1	3533179
in	O	-1	3533179
Group	O	-1	3533179
2	O	-1	3533179
(P	O	-1	3533179
less	O	-1	3533179
than	O	-1	3533179
0.0@@	O	-1	3533179
25@@	O	-1	3533179
).	O	-1	3533179
Con@@	B-Disease	D006333	3533179
g@@	I-Disease	-1	3533179
es@@	I-Disease	-1	3533179
tive	I-Disease	-1	3533179
heart	I-Disease	-1	3533179
failure	I-Disease	-1	3533179
caused	O	-1	3533179
or	O	-1	3533179
cont@@	O	-1	3533179
ri@@	O	-1	3533179
but@@	O	-1	3533179
ed	O	-1	3533179
to	O	-1	3533179
death	O	-1	3533179
in	O	-1	3533179
0@@	O	-1	3533179
/@@	O	-1	3533179
3@@	O	-1	3533179
2	O	-1	3533179
patients	O	-1	3533179
in	O	-1	3533179
Group	O	-1	3533179
1	O	-1	3533179
v	O	-1	3533179
6@@	O	-1	3533179
/@@	O	-1	3533179
5@@	O	-1	3533179
2	O	-1	3533179
(1@@	O	-1	3533179
2@@	O	-1	3533179
%)	O	-1	3533179
of	O	-1	3533179
patients	O	-1	3533179
in	O	-1	3533179
Group	O	-1	3533179
2	O	-1	3533179
(P	O	-1	3533179
less	O	-1	3533179
than	O	-1	3533179
0.@@	O	-1	3533179
25@@	O	-1	3533179
).	O	-1	3533179
There	O	-1	3533179
was	O	-1	3533179
no	O	-1	3533179
difference	O	-1	3533179
in	O	-1	3533179
the	O	-1	3533179
rate	O	-1	3533179
of	O	-1	3533179
en@@	O	-1	3533179
gra@@	O	-1	3533179
f@@	O	-1	3533179
t@@	O	-1	3533179
ment	O	-1	3533179
of	O	-1	3533179
evalu@@	O	-1	3533179
able	O	-1	3533179
patients	O	-1	3533179
in	O	-1	3533179
the	O	-1	3533179
two	O	-1	3533179
groups	O	-1	3533179
(P	O	-1	3533179
greater	O	-1	3533179
than	O	-1	3533179
0.@@	O	-1	3533179
5@@	O	-1	3533179
).	O	-1	3533179
We	O	-1	3533179
concl@@	O	-1	3533179
ude	O	-1	3533179
that	O	-1	3533179
the	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
cardi@@	B-Disease	D066126	3533179
otoxicity	I-Disease	-1	3533179
correl@@	O	-1	3533179
ates	O	-1	3533179
with	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
dos@@	O	-1	3533179
age	O	-1	3533179
as	O	-1	3533179
calc@@	O	-1	3533179
ul@@	O	-1	3533179
ated	O	-1	3533179
by	O	-1	3533179
body	O	-1	3533179
sur@@	O	-1	3533179
fac@@	O	-1	3533179
e	O	-1	3533179
a@@	O	-1	3533179
re@@	O	-1	3533179
a,	O	-1	3533179
and	O	-1	3533179
that	O	-1	3533179
patients	O	-1	3533179
with	O	-1	3533179
ap@@	B-Disease	D000741	3533179
las@@	I-Disease	-1	3533179
tic	I-Disease	-1	3533179
anemia	I-Disease	-1	3533179
and	O	-1	3533179
immuno@@	B-Disease	D007153	3533179
defici@@	I-Disease	-1	3533179
en@@	I-Disease	-1	3533179
ci@@	I-Disease	-1	3533179
es	I-Disease	-1	3533179
can	O	-1	3533179
be	O	-1	3533179
eff@@	O	-1	3533179
ectively	O	-1	3533179
pre@@	O	-1	3533179
pared	O	-1	3533179
for	O	-1	3533179
b@@	O	-1	3533179
one	O	-1	3533179
m@@	O	-1	3533179
ar@@	O	-1	3533179
ro@@	O	-1	3533179
w	O	-1	3533179
gra@@	O	-1	3533179
f@@	O	-1	3533179
ting	O	-1	3533179
at	O	-1	3533179
a	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
dose	O	-1	3533179
of	O	-1	3533179
1.@@	O	-1	3533179
5@@	O	-1	3533179
5	O	-1	3533179
g/@@	O	-1	3533179
m@@	O	-1	3533179
2@@	O	-1	3533179
/@@	O	-1	3533179
d	O	-1	3533179
for	O	-1	3533179
four	O	-1	3533179
days	O	-1	3533179
with	O	-1	3533179
a	O	-1	3533179
lower	O	-1	3533179
incidence	O	-1	3533179
of	O	-1	3533179
cardi@@	B-Disease	D066126	3533179
otoxicity	I-Disease	-1	3533179
than	O	-1	3533179
patients	O	-1	3533179
wh@@	O	-1	3533179
ose	O	-1	3533179
C@@	B-Chemical	D003520	3533179
Y@@	I-Chemical	-1	3533179
A	I-Chemical	-1	3533179
dos@@	O	-1	3533179
age	O	-1	3533179
is	O	-1	3533179
calc@@	O	-1	3533179
ul@@	O	-1	3533179
ated	O	-1	3533179
bas@@	O	-1	3533179
ed	O	-1	3533179
on	O	-1	3533179
weigh@@	O	-1	3533179
t.	O	-1	3533179
This	O	-1	3533179
study	O	-1	3533179
re@@	O	-1	3533179
aff@@	O	-1	3533179
ir@@	O	-1	3533179
ms	O	-1	3533179
the	O	-1	3533179
pr@@	O	-1	3533179
inc@@	O	-1	3533179
i@@	O	-1	3533179
ple	O	-1	3533179
that	O	-1	3533179
drug	O	-1	3533179
toxicity	B-Disease	D064420	3533179
correl@@	O	-1	3533179
ates	O	-1	3533179
with	O	-1	3533179
dose	O	-1	3533179
per	O	-1	3533179
body	O	-1	3533179
sur@@	O	-1	3533179
fac@@	O	-1	3533179
e	O	-1	3533179
a@@	O	-1	3533179
re@@	O	-1	3533179
a.	O	-1	3533179

S@@	O	-1	3538855
t@@	O	-1	3538855
udi@@	O	-1	3538855
es	O	-1	3538855
of	O	-1	3538855
risk	O	-1	3538855
factors	O	-1	3538855
for	O	-1	3538855
amino@@	B-Chemical	D000617	3538855
gly@@	I-Chemical	-1	3538855
co@@	I-Chemical	-1	3538855
side	I-Chemical	-1	3538855
nephro@@	B-Disease	D007674	3538855
toxicity	I-Disease	-1	3538855
.	O	-1	3538855
The	O	-1	3538855
epi@@	O	-1	3538855
de@@	O	-1	3538855
m@@	O	-1	3538855
io@@	O	-1	3538855
log@@	O	-1	3538855
y	O	-1	3538855
of	O	-1	3538855
amino@@	B-Chemical	D000617	3538855
gly@@	I-Chemical	-1	3538855
co@@	I-Chemical	-1	3538855
side	I-Chemical	-1	3538855
-induced	O	-1	3538855
nephro@@	B-Disease	D007674	3538855
toxicity	I-Disease	-1	3538855
is	O	-1	3538855
not	O	-1	3538855
ful@@	O	-1	3538855
ly	O	-1	3538855
under@@	O	-1	3538855
sto@@	O	-1	3538855
o@@	O	-1	3538855
d.	O	-1	3538855
E@@	O	-1	3538855
x@@	O	-1	3538855
per@@	O	-1	3538855
im@@	O	-1	3538855
ental	O	-1	3538855
studies	O	-1	3538855
in	O	-1	3538855
healthy	O	-1	3538855
human	O	-1	3538855
vol@@	O	-1	3538855
un@@	O	-1	3538855
te@@	O	-1	3538855
ers	O	-1	3538855
indicate	O	-1	3538855
amino@@	B-Chemical	D000617	3538855
gly@@	I-Chemical	-1	3538855
co@@	I-Chemical	-1	3538855
side@@	I-Chemical	-1	3538855
s	I-Chemical	-1	3538855
cause	O	-1	3538855
pro@@	O	-1	3538855
xim@@	O	-1	3538855
al	O	-1	3538855
tub@@	O	-1	3538855
ular	O	-1	3538855
damage	O	-1	3538855
in	O	-1	3538855
most	O	-1	3538855
patients,	O	-1	3538855
but	O	-1	3538855
ra@@	O	-1	3538855
rel@@	O	-1	3538855
y,	O	-1	3538855
if	O	-1	3538855
e@@	O	-1	3538855
ver,	O	-1	3538855
cause	O	-1	3538855
glomerular	B-Disease	D007674	3538855
or	I-Disease	-1	3538855
tub@@	I-Disease	-1	3538855
ular	I-Disease	-1	3538855
dysfunction	I-Disease	-1	3538855
.	O	-1	3538855
Clin@@	O	-1	3538855
ical	O	-1	3538855
tri@@	O	-1	3538855
als	O	-1	3538855
of	O	-1	3538855
amino@@	B-Chemical	D000617	3538855
gly@@	I-Chemical	-1	3538855
co@@	I-Chemical	-1	3538855
side@@	I-Chemical	-1	3538855
s	I-Chemical	-1	3538855
in	O	-1	3538855
seri@@	O	-1	3538855
ously	O	-1	3538855
il@@	O	-1	3538855
l	O	-1	3538855
patients	O	-1	3538855
indicate	O	-1	3538855
that	O	-1	3538855
the	O	-1	3538855
rel@@	O	-1	3538855
ative	O	-1	3538855
risk	O	-1	3538855
for	O	-1	3538855
develop@@	O	-1	3538855
ing	O	-1	3538855
acute	B-Disease	D058186	3538855
renal	I-Disease	-1	3538855
failure	I-Disease	-1	3538855
during	O	-1	3538855
therapy	O	-1	3538855
rang@@	O	-1	3538855
es	O	-1	3538855
from	O	-1	3538855
8	O	-1	3538855
to	O	-1	3538855
10	O	-1	3538855
and	O	-1	3538855
that	O	-1	3538855
the	O	-1	3538855
at@@	O	-1	3538855
tri@@	O	-1	3538855
but@@	O	-1	3538855
able	O	-1	3538855
risk	O	-1	3538855
is	O	-1	3538855
7@@	O	-1	3538855
0%	O	-1	3538855
to	O	-1	3538855
80@@	O	-1	3538855
%.	O	-1	3538855
F@@	O	-1	3538855
urther	O	-1	3538855
analysis	O	-1	3538855
of	O	-1	3538855
these	O	-1	3538855
data	O	-1	3538855
suggests	O	-1	3538855
that	O	-1	3538855
the	O	-1	3538855
duration	O	-1	3538855
of	O	-1	3538855
therapy,	O	-1	3538855
plasma	O	-1	3538855
amino@@	B-Chemical	D000617	3538855
gly@@	I-Chemical	-1	3538855
co@@	I-Chemical	-1	3538855
side	I-Chemical	-1	3538855
level@@	O	-1	3538855
s,	O	-1	3538855
liver	B-Disease	D008107	3538855
disease	I-Disease	-1	3538855
,	O	-1	3538855
adv@@	O	-1	3538855
anced	O	-1	3538855
age,	O	-1	3538855
high	O	-1	3538855
initial	O	-1	3538855
estim@@	O	-1	3538855
ated	O	-1	3538855
creatinine	B-Chemical	D003404	3538855
clear@@	O	-1	3538855
ance	O	-1	3538855
and@@	O	-1	3538855
,	O	-1	3538855
possib@@	O	-1	3538855
ly,	O	-1	3538855
female	O	-1	3538855
gen@@	O	-1	3538855
der	O	-1	3538855
all	O	-1	3538855
increase	O	-1	3538855
the	O	-1	3538855
risk	O	-1	3538855
for	O	-1	3538855
nephro@@	B-Disease	D007674	3538855
toxicity	I-Disease	-1	3538855
.	O	-1	3538855
O@@	O	-1	3538855
ther	O	-1	3538855
causes	O	-1	3538855
of	O	-1	3538855
acute	B-Disease	D058186	3538855
renal	I-Disease	-1	3538855
failure	I-Disease	-1	3538855
,	O	-1	3538855
such	O	-1	3538855
as	O	-1	3538855
sh@@	B-Disease	D012769	3538855
oc@@	I-Disease	-1	3538855
k	I-Disease	-1	3538855
,	O	-1	3538855
appe@@	O	-1	3538855
ar	O	-1	3538855
to	O	-1	3538855
have	O	-1	3538855
an	O	-1	3538855
addi@@	O	-1	3538855
tive	O	-1	3538855
effect@@	O	-1	3538855
.	O	-1	3538855
Pre@@	O	-1	3538855
dic@@	O	-1	3538855
tive	O	-1	3538855
models	O	-1	3538855
have	O	-1	3538855
been	O	-1	3538855
developed	O	-1	3538855
from	O	-1	3538855
these	O	-1	3538855
analy@@	O	-1	3538855
ses	O	-1	3538855
that	O	-1	3538855
should	O	-1	3538855
be	O	-1	3538855
use@@	O	-1	3538855
ful	O	-1	3538855
for	O	-1	3538855
identi@@	O	-1	3538855
f@@	O	-1	3538855
y@@	O	-1	3538855
ing	O	-1	3538855
patients	O	-1	3538855
at	O	-1	3538855
high	O	-1	3538855
ris@@	O	-1	3538855
k@@	O	-1	3538855
.	O	-1	3538855
These	O	-1	3538855
models	O	-1	3538855
may	O	-1	3538855
also	O	-1	3538855
be	O	-1	3538855
use@@	O	-1	3538855
ful	O	-1	3538855
in	O	-1	3538855
develop@@	O	-1	3538855
ing	O	-1	3538855
in@@	O	-1	3538855
si@@	O	-1	3538855
gh@@	O	-1	3538855
ts	O	-1	3538855
into	O	-1	3538855
the	O	-1	3538855
path@@	O	-1	3538855
oph@@	O	-1	3538855
ysi@@	O	-1	3538855
ology	O	-1	3538855
of	O	-1	3538855
amino@@	B-Chemical	D000617	3538855
gly@@	I-Chemical	-1	3538855
co@@	I-Chemical	-1	3538855
side	I-Chemical	-1	3538855
-induced	O	-1	3538855
nephro@@	B-Disease	D007674	3538855
toxicity	I-Disease	-1	3538855
.	O	-1	3538855

F@@	B-Chemical	D005481	3685052
l@@	I-Chemical	-1	3685052
uro@@	I-Chemical	-1	3685052
th@@	I-Chemical	-1	3685052
yl	I-Chemical	-1	3685052
seizure	B-Disease	D012640	3685052
th@@	O	-1	3685052
res@@	O	-1	3685052
h@@	O	-1	3685052
ol@@	O	-1	3685052
ds	O	-1	3685052
in	O	-1	3685052
mice	O	-1	3685052
treated	O	-1	3685052
ne@@	O	-1	3685052
on@@	O	-1	3685052
at@@	O	-1	3685052
ally	O	-1	3685052
with	O	-1	3685052
a	O	-1	3685052
single	O	-1	3685052
injection	O	-1	3685052
of	O	-1	3685052
mon@@	B-Chemical	D012970	3685052
os@@	I-Chemical	-1	3685052
odium	I-Chemical	-1	3685052
glutamate	I-Chemical	-1	3685052
(	O	-1	3685052
M@@	B-Chemical	D012970	3685052
S@@	I-Chemical	-1	3685052
G	I-Chemical	-1	3685052
)@@	O	-1	3685052
:	O	-1	3685052
evalu@@	O	-1	3685052
ation	O	-1	3685052
of	O	-1	3685052
experimental	O	-1	3685052
par@@	O	-1	3685052
ame@@	O	-1	3685052
ters	O	-1	3685052
in	O	-1	3685052
f@@	B-Chemical	D005481	3685052
l@@	I-Chemical	-1	3685052
uro@@	I-Chemical	-1	3685052
th@@	I-Chemical	-1	3685052
yl	I-Chemical	-1	3685052
seizure	B-Disease	D012640	3685052
test@@	O	-1	3685052
ing.	O	-1	3685052
M@@	B-Chemical	D012970	3685052
on@@	I-Chemical	-1	3685052
os@@	I-Chemical	-1	3685052
odium	I-Chemical	-1	3685052
glutamate	I-Chemical	-1	3685052
(	O	-1	3685052
M@@	B-Chemical	D012970	3685052
S@@	I-Chemical	-1	3685052
G	I-Chemical	-1	3685052
)	O	-1	3685052
administration	O	-1	3685052
to	O	-1	3685052
ne@@	O	-1	3685052
on@@	O	-1	3685052
atal	O	-1	3685052
ro@@	O	-1	3685052
d@@	O	-1	3685052
ents	O	-1	3685052
produc@@	O	-1	3685052
es	O	-1	3685052
convul@@	B-Disease	D012640	3685052
sions	I-Disease	-1	3685052
and	O	-1	3685052
results	O	-1	3685052
in	O	-1	3685052
n@@	O	-1	3685052
um@@	O	-1	3685052
er@@	O	-1	3685052
ous	O	-1	3685052
bio@@	O	-1	3685052
chemical	O	-1	3685052
and	O	-1	3685052
behavioral	O	-1	3685052
defic@@	O	-1	3685052
it@@	O	-1	3685052
s.	O	-1	3685052
These	O	-1	3685052
studies	O	-1	3685052
were	O	-1	3685052
under@@	O	-1	3685052
tak@@	O	-1	3685052
en	O	-1	3685052
to	O	-1	3685052
determine	O	-1	3685052
if	O	-1	3685052
ne@@	O	-1	3685052
on@@	O	-1	3685052
atal	O	-1	3685052
administration	O	-1	3685052
of	O	-1	3685052
M@@	B-Chemical	D012970	3685052
S@@	I-Chemical	-1	3685052
G	I-Chemical	-1	3685052
produced	O	-1	3685052
per@@	O	-1	3685052
man@@	O	-1	3685052
ent	O	-1	3685052
al@@	O	-1	3685052
ter@@	O	-1	3685052
ations	O	-1	3685052
in	O	-1	3685052
seizure	B-Disease	D012640	3685052
sus@@	O	-1	3685052
cep@@	O	-1	3685052
ti@@	O	-1	3685052
bil@@	O	-1	3685052
ity,	O	-1	3685052
s@@	O	-1	3685052
inc@@	O	-1	3685052
e	O	-1	3685052
previ@@	O	-1	3685052
ous	O	-1	3685052
investig@@	O	-1	3685052
ations	O	-1	3685052
were	O	-1	3685052
in@@	O	-1	3685052
concl@@	O	-1	3685052
u@@	O	-1	3685052
si@@	O	-1	3685052
ve.	O	-1	3685052
A	O	-1	3685052
f@@	B-Chemical	D005481	3685052
l@@	I-Chemical	-1	3685052
uro@@	I-Chemical	-1	3685052
th@@	I-Chemical	-1	3685052
yl	I-Chemical	-1	3685052
e@@	B-Chemical	D004986	3685052
ther	I-Chemical	-1	3685052
seizure	B-Disease	D012640	3685052
s@@	O	-1	3685052
cre@@	O	-1	3685052
en@@	O	-1	3685052
ing	O	-1	3685052
t@@	O	-1	3685052
ech@@	O	-1	3685052
n@@	O	-1	3685052
i@@	O	-1	3685052
qu@@	O	-1	3685052
e	O	-1	3685052
was	O	-1	3685052
used	O	-1	3685052
to	O	-1	3685052
evalu@@	O	-1	3685052
ate	O	-1	3685052
seizure	B-Disease	D012640	3685052
sus@@	O	-1	3685052
cep@@	O	-1	3685052
ti@@	O	-1	3685052
b@@	O	-1	3685052
ility	O	-1	3685052
in	O	-1	3685052
ad@@	O	-1	3685052
ult	O	-1	3685052
mice	O	-1	3685052
that	O	-1	3685052
received	O	-1	3685052
ne@@	O	-1	3685052
on@@	O	-1	3685052
atal	O	-1	3685052
injec@@	O	-1	3685052
tions	O	-1	3685052
of	O	-1	3685052
M@@	B-Chemical	D012970	3685052
S@@	I-Chemical	-1	3685052
G	I-Chemical	-1	3685052
(@@	O	-1	3685052
4	O	-1	3685052
mg/@@	O	-1	3685052
g	O	-1	3685052
and	O	-1	3685052
1	O	-1	3685052
mg/@@	O	-1	3685052
g@@	O	-1	3685052
).	O	-1	3685052
M@@	B-Chemical	D012970	3685052
S@@	I-Chemical	-1	3685052
G	I-Chemical	-1	3685052
treatment	O	-1	3685052
resulted	O	-1	3685052
in	O	-1	3685052
significant	O	-1	3685052
reduc@@	O	-1	3685052
tions	O	-1	3685052
in	O	-1	3685052
wh@@	O	-1	3685052
ole	O	-1	3685052
brain	O	-1	3685052
weight	O	-1	3685052
but	O	-1	3685052
did	O	-1	3685052
not	O	-1	3685052
al@@	O	-1	3685052
ter	O	-1	3685052
seizure	B-Disease	D012640	3685052
th@@	O	-1	3685052
res@@	O	-1	3685052
h@@	O	-1	3685052
ol@@	O	-1	3685052
d.	O	-1	3685052
A	O	-1	3685052
n@@	B-Chemical	D009270	3685052
al@@	I-Chemical	-1	3685052
ox@@	I-Chemical	-1	3685052
one	I-Chemical	-1	3685052
(@@	O	-1	3685052
5	O	-1	3685052
mg/kg)	O	-1	3685052
ch@@	O	-1	3685052
all@@	O	-1	3685052
enge	O	-1	3685052
was	O	-1	3685052
also	O	-1	3685052
ine@@	O	-1	3685052
ff@@	O	-1	3685052
ective	O	-1	3685052
in	O	-1	3685052
al@@	O	-1	3685052
ter@@	O	-1	3685052
ing	O	-1	3685052
the	O	-1	3685052
seizure	B-Disease	D012640	3685052
th@@	O	-1	3685052
res@@	O	-1	3685052
h@@	O	-1	3685052
ol@@	O	-1	3685052
ds	O	-1	3685052
of	O	-1	3685052
either	O	-1	3685052
control	O	-1	3685052
of	O	-1	3685052
M@@	B-Chemical	D012970	3685052
S@@	I-Chemical	-1	3685052
G	I-Chemical	-1	3685052
-treated	O	-1	3685052
mice.	O	-1	3685052
F@@	B-Chemical	D005481	3685052
l@@	I-Chemical	-1	3685052
uro@@	I-Chemical	-1	3685052
th@@	I-Chemical	-1	3685052
yl	I-Chemical	-1	3685052
e@@	B-Chemical	D004986	3685052
ther	I-Chemical	-1	3685052
produced	O	-1	3685052
hypo@@	B-Disease	D007035	3685052
ther@@	I-Disease	-1	3685052
mia	I-Disease	-1	3685052
which	O	-1	3685052
was	O	-1	3685052
cor@@	O	-1	3685052
related	O	-1	3685052
with	O	-1	3685052
the	O	-1	3685052
duration	O	-1	3685052
of	O	-1	3685052
f@@	B-Chemical	D005481	3685052
l@@	I-Chemical	-1	3685052
uro@@	I-Chemical	-1	3685052
th@@	I-Chemical	-1	3685052
yl	I-Chemical	-1	3685052
expos@@	O	-1	3685052
ure@@	O	-1	3685052
;	O	-1	3685052
however,	O	-1	3685052
the	O	-1	3685052
rel@@	O	-1	3685052
ationship	O	-1	3685052
of	O	-1	3685052
hypo@@	B-Disease	D007035	3685052
ther@@	I-Disease	-1	3685052
mia	I-Disease	-1	3685052
to	O	-1	3685052
seizure	B-Disease	D012640	3685052
induction	O	-1	3685052
was	O	-1	3685052
unc@@	O	-1	3685052
lear@@	O	-1	3685052
.	O	-1	3685052
F@@	B-Chemical	D005481	3685052
l@@	I-Chemical	-1	3685052
uro@@	I-Chemical	-1	3685052
th@@	I-Chemical	-1	3685052
yl	I-Chemical	-1	3685052
seizure	B-Disease	D012640	3685052
test@@	O	-1	3685052
ing	O	-1	3685052
pro@@	O	-1	3685052
ved	O	-1	3685052
to	O	-1	3685052
be	O	-1	3685052
a	O	-1	3685052
ra@@	O	-1	3685052
pid	O	-1	3685052
and	O	-1	3685052
re@@	O	-1	3685052
li@@	O	-1	3685052
able	O	-1	3685052
t@@	O	-1	3685052
ech@@	O	-1	3685052
n@@	O	-1	3685052
i@@	O	-1	3685052
qu@@	O	-1	3685052
e	O	-1	3685052
with	O	-1	3685052
which	O	-1	3685052
to	O	-1	3685052
evalu@@	O	-1	3685052
ate	O	-1	3685052
seizure	B-Disease	D012640	3685052
sus@@	O	-1	3685052
cep@@	O	-1	3685052
ti@@	O	-1	3685052
bil@@	O	-1	3685052
ity.	O	-1	3685052

S@@	O	-1	3708328
us@@	O	-1	3708328
cep@@	O	-1	3708328
ti@@	O	-1	3708328
b@@	O	-1	3708328
ility	O	-1	3708328
to	O	-1	3708328
seizures	B-Disease	D012640	3708328
produced	O	-1	3708328
by	O	-1	3708328
pilocar@@	B-Chemical	D010862	3708328
pine	I-Chemical	-1	3708328
in	O	-1	3708328
rats	O	-1	3708328
after	O	-1	3708328
micro@@	O	-1	3708328
injection	O	-1	3708328
of	O	-1	3708328
is@@	B-Chemical	D007538	3708328
oni@@	I-Chemical	-1	3708328
az@@	I-Chemical	-1	3708328
id	I-Chemical	-1	3708328
or	O	-1	3708328
gamma@@	B-Chemical	D020888	3708328
-@@	I-Chemical	-1	3708328
v@@	I-Chemical	-1	3708328
in@@	I-Chemical	-1	3708328
yl@@	I-Chemical	-1	3708328
-@@	I-Chemical	-1	3708328
G@@	I-Chemical	-1	3708328
A@@	I-Chemical	-1	3708328
B@@	I-Chemical	-1	3708328
A	I-Chemical	-1	3708328
into	O	-1	3708328
the	O	-1	3708328
subst@@	O	-1	3708328
anti@@	O	-1	3708328
a	O	-1	3708328
n@@	O	-1	3708328
i@@	O	-1	3708328
gra@@	O	-1	3708328
.	O	-1	3708328
P@@	B-Chemical	D010862	3708328
i@@	I-Chemical	-1	3708328
lo@@	I-Chemical	-1	3708328
car@@	I-Chemical	-1	3708328
pine	I-Chemical	-1	3708328
,	O	-1	3708328
given	O	-1	3708328
intra@@	O	-1	3708328
per@@	O	-1	3708328
it@@	O	-1	3708328
one@@	O	-1	3708328
ally	O	-1	3708328
to	O	-1	3708328
rats,	O	-1	3708328
re@@	O	-1	3708328
produc@@	O	-1	3708328
es	O	-1	3708328
the	O	-1	3708328
neuro@@	O	-1	3708328
path@@	O	-1	3708328
ological	O	-1	3708328
sequ@@	O	-1	3708328
el@@	O	-1	3708328
a@@	O	-1	3708328
e	O	-1	3708328
of	O	-1	3708328
tempor@@	B-Disease	D004833	3708328
al	I-Disease	-1	3708328
lo@@	I-Disease	-1	3708328
be	I-Disease	-1	3708328
epilep@@	I-Disease	-1	3708328
sy	I-Disease	-1	3708328
and	O	-1	3708328
pro@@	O	-1	3708328
vi@@	O	-1	3708328
des	O	-1	3708328
a	O	-1	3708328
re@@	O	-1	3708328
lev@@	O	-1	3708328
ant	O	-1	3708328
anim@@	O	-1	3708328
al	O	-1	3708328
model	O	-1	3708328
for	O	-1	3708328
stud@@	O	-1	3708328
y@@	O	-1	3708328
ing	O	-1	3708328
mechanisms	O	-1	3708328
of	O	-1	3708328
bu@@	O	-1	3708328
il@@	O	-1	3708328
du@@	O	-1	3708328
p	O	-1	3708328
of	O	-1	3708328
convul@@	B-Disease	D012640	3708328
sive	I-Disease	-1	3708328
activity	O	-1	3708328
and	O	-1	3708328
path@@	O	-1	3708328
w@@	O	-1	3708328
ays	O	-1	3708328
o@@	O	-1	3708328
perative	O	-1	3708328
in	O	-1	3708328
the	O	-1	3708328
gener@@	O	-1	3708328
al@@	O	-1	3708328
ization	O	-1	3708328
and	O	-1	3708328
prop@@	O	-1	3708328
ag@@	O	-1	3708328
ation	O	-1	3708328
of	O	-1	3708328
seizures	B-Disease	D012640	3708328
within	O	-1	3708328
the	O	-1	3708328
fo@@	O	-1	3708328
re@@	O	-1	3708328
bra@@	O	-1	3708328
in.	O	-1	3708328
In	O	-1	3708328
the	O	-1	3708328
present	O	-1	3708328
study,	O	-1	3708328
the	O	-1	3708328
effects	O	-1	3708328
of	O	-1	3708328
man@@	O	-1	3708328
ip@@	O	-1	3708328
ul@@	O	-1	3708328
ating	O	-1	3708328
the	O	-1	3708328
activity	O	-1	3708328
of	O	-1	3708328
the	O	-1	3708328
gamma@@	B-Chemical	D005680	3708328
-@@	I-Chemical	-1	3708328
amin@@	I-Chemical	-1	3708328
ob@@	I-Chemical	-1	3708328
ut@@	I-Chemical	-1	3708328
y@@	I-Chemical	-1	3708328
ric	I-Chemical	-1	3708328
acid	I-Chemical	-1	3708328
(	O	-1	3708328
G@@	B-Chemical	D005680	3708328
A@@	I-Chemical	-1	3708328
B@@	I-Chemical	-1	3708328
A	I-Chemical	-1	3708328
)-@@	O	-1	3708328
mediated	O	-1	3708328
syn@@	O	-1	3708328
ap@@	O	-1	3708328
tic	O	-1	3708328
inhibition	O	-1	3708328
within	O	-1	3708328
the	O	-1	3708328
subst@@	O	-1	3708328
anti@@	O	-1	3708328
a	O	-1	3708328
n@@	O	-1	3708328
ig@@	O	-1	3708328
r@@	O	-1	3708328
a	O	-1	3708328
on	O	-1	3708328
seizures	B-Disease	D012640	3708328
produced	O	-1	3708328
by	O	-1	3708328
pilocar@@	B-Chemical	D010862	3708328
pine	I-Chemical	-1	3708328
in	O	-1	3708328
rats,	O	-1	3708328
were	O	-1	3708328
investig@@	O	-1	3708328
ated.	O	-1	3708328
In	O	-1	3708328
animals	O	-1	3708328
pre@@	O	-1	3708328
treated	O	-1	3708328
with	O	-1	3708328
micro@@	O	-1	3708328
injec@@	O	-1	3708328
tions	O	-1	3708328
of	O	-1	3708328
is@@	B-Chemical	D007538	3708328
oni@@	I-Chemical	-1	3708328
az@@	I-Chemical	-1	3708328
id	I-Chemical	-1	3708328
,	O	-1	3708328
1@@	O	-1	3708328
50	O	-1	3708328
microgram@@	O	-1	3708328
s,	O	-1	3708328
an	O	-1	3708328
inhibitor	O	-1	3708328
of	O	-1	3708328
activity	O	-1	3708328
of	O	-1	3708328
the	O	-1	3708328
G@@	B-Chemical	D005680	3708328
A@@	I-Chemical	-1	3708328
B@@	I-Chemical	-1	3708328
A	I-Chemical	-1	3708328
-@@	O	-1	3708328
syn@@	O	-1	3708328
the@@	O	-1	3708328
si@@	O	-1	3708328
z@@	O	-1	3708328
ing	O	-1	3708328
enz@@	O	-1	3708328
y@@	O	-1	3708328
me,	O	-1	3708328
L-@@	B-Chemical	D018698	3708328
glutam@@	I-Chemical	-1	3708328
ic	I-Chemical	-1	3708328
acid	I-Chemical	-1	3708328
dec@@	O	-1	3708328
arb@@	O	-1	3708328
ox@@	O	-1	3708328
yl@@	O	-1	3708328
ase,	O	-1	3708328
into	O	-1	3708328
the	O	-1	3708328
subst@@	O	-1	3708328
anti@@	O	-1	3708328
a	O	-1	3708328
n@@	O	-1	3708328
ig@@	O	-1	3708328
r@@	O	-1	3708328
a	O	-1	3708328
par@@	O	-1	3708328
s	O	-1	3708328
re@@	O	-1	3708328
tic@@	O	-1	3708328
ul@@	O	-1	3708328
at@@	O	-1	3708328
a	O	-1	3708328
(S@@	O	-1	3708328
N@@	O	-1	3708328
R@@	O	-1	3708328
),	O	-1	3708328
bil@@	O	-1	3708328
at@@	O	-1	3708328
er@@	O	-1	3708328
ally,	O	-1	3708328
non-@@	O	-1	3708328
convul@@	O	-1	3708328
s@@	O	-1	3708328
ant	O	-1	3708328
doses	O	-1	3708328
of	O	-1	3708328
pilocar@@	B-Chemical	D010862	3708328
pine	I-Chemical	-1	3708328
,	O	-1	3708328
100	O	-1	3708328
and	O	-1	3708328
2@@	O	-1	3708328
00	O	-1	3708328
mg/kg@@	O	-1	3708328
,	O	-1	3708328
resulted	O	-1	3708328
in	O	-1	3708328
severe	O	-1	3708328
motor	O	-1	3708328
lim@@	O	-1	3708328
b@@	O	-1	3708328
ic	O	-1	3708328
seizures	B-Disease	D012640	3708328
and	O	-1	3708328
status	B-Disease	D013226	3708328
epilep@@	I-Disease	-1	3708328
tic@@	I-Disease	-1	3708328
us	I-Disease	-1	3708328
.	O	-1	3708328
E@@	O	-1	3708328
l@@	O	-1	3708328
ect@@	O	-1	3708328
ro@@	O	-1	3708328
encephalo@@	O	-1	3708328
graph@@	O	-1	3708328
ic	O	-1	3708328
and	O	-1	3708328
behavioral	O	-1	3708328
monit@@	O	-1	3708328
or@@	O	-1	3708328
ing	O	-1	3708328
revealed	O	-1	3708328
a	O	-1	3708328
pro@@	O	-1	3708328
found	O	-1	3708328
reduction	O	-1	3708328
of	O	-1	3708328
the	O	-1	3708328
th@@	O	-1	3708328
res@@	O	-1	3708328
h@@	O	-1	3708328
old	O	-1	3708328
for	O	-1	3708328
pilocar@@	B-Chemical	D010862	3708328
pine	I-Chemical	-1	3708328
-induced	O	-1	3708328
convul@@	B-Disease	D012640	3708328
sions	I-Disease	-1	3708328
.	O	-1	3708328
M@@	O	-1	3708328
or@@	O	-1	3708328
ph@@	O	-1	3708328
ological	O	-1	3708328
analysis	O	-1	3708328
of	O	-1	3708328
fron@@	O	-1	3708328
t@@	O	-1	3708328
al	O	-1	3708328
fo@@	O	-1	3708328
re@@	O	-1	3708328
brain	O	-1	3708328
sec@@	O	-1	3708328
tions	O	-1	3708328
with	O	-1	3708328
li@@	O	-1	3708328
ght	O	-1	3708328
micro@@	O	-1	3708328
sco@@	O	-1	3708328
p@@	O	-1	3708328
y	O	-1	3708328
revealed	O	-1	3708328
seizure	B-Disease	D012640	3708328
-@@	O	-1	3708328
related	O	-1	3708328
damage	O	-1	3708328
to	O	-1	3708328
the	O	-1	3708328
hippocamp@@	O	-1	3708328
al	O	-1	3708328
form@@	O	-1	3708328
ation,	O	-1	3708328
thal@@	O	-1	3708328
am@@	O	-1	3708328
us,	O	-1	3708328
am@@	O	-1	3708328
y@@	O	-1	3708328
g@@	O	-1	3708328
d@@	O	-1	3708328
al@@	O	-1	3708328
a,	O	-1	3708328
ol@@	O	-1	3708328
fact@@	O	-1	3708328
ory	O	-1	3708328
cor@@	O	-1	3708328
t@@	O	-1	3708328
ex@@	O	-1	3708328
,	O	-1	3708328
subst@@	O	-1	3708328
anti@@	O	-1	3708328
a	O	-1	3708328
n@@	O	-1	3708328
ig@@	O	-1	3708328
r@@	O	-1	3708328
a	O	-1	3708328
and	O	-1	3708328
ne@@	O	-1	3708328
oc@@	O	-1	3708328
ort@@	O	-1	3708328
ex@@	O	-1	3708328
,	O	-1	3708328
which	O	-1	3708328
is	O	-1	3708328
typ@@	O	-1	3708328
ically	O	-1	3708328
observed	O	-1	3708328
with	O	-1	3708328
pilocar@@	B-Chemical	D010862	3708328
pine	I-Chemical	-1	3708328
in	O	-1	3708328
doses	O	-1	3708328
ex@@	O	-1	3708328
ce@@	O	-1	3708328
ed@@	O	-1	3708328
ing	O	-1	3708328
3@@	O	-1	3708328
50	O	-1	3708328
mg/kg@@	O	-1	3708328
.	O	-1	3708328
B@@	O	-1	3708328
il@@	O	-1	3708328
ateral	O	-1	3708328
intra@@	O	-1	3708328
stri@@	O	-1	3708328
atal	O	-1	3708328
injec@@	O	-1	3708328
tions	O	-1	3708328
of	O	-1	3708328
is@@	B-Chemical	D007538	3708328
oni@@	I-Chemical	-1	3708328
az@@	I-Chemical	-1	3708328
id	I-Chemical	-1	3708328
did	O	-1	3708328
not	O	-1	3708328
au@@	O	-1	3708328
g@@	O	-1	3708328
ment	O	-1	3708328
seizures	B-Disease	D012640	3708328
produced	O	-1	3708328
by	O	-1	3708328
pilocar@@	B-Chemical	D010862	3708328
pine	I-Chemical	-1	3708328
,	O	-1	3708328
2@@	O	-1	3708328
00	O	-1	3708328
mg/kg@@	O	-1	3708328
.	O	-1	3708328
A@@	O	-1	3708328
p@@	O	-1	3708328
plic@@	O	-1	3708328
ation	O	-1	3708328
of	O	-1	3708328
an	O	-1	3708328
ir@@	O	-1	3708328
reversible	O	-1	3708328
inhibitor	O	-1	3708328
of	O	-1	3708328
G@@	B-Chemical	D005680	3708328
A@@	I-Chemical	-1	3708328
B@@	I-Chemical	-1	3708328
A	I-Chemical	-1	3708328
trans@@	O	-1	3708328
amin@@	O	-1	3708328
ase,	O	-1	3708328
gamma@@	B-Chemical	D020888	3708328
-@@	I-Chemical	-1	3708328
v@@	I-Chemical	-1	3708328
in@@	I-Chemical	-1	3708328
yl@@	I-Chemical	-1	3708328
-@@	I-Chemical	-1	3708328
G@@	I-Chemical	-1	3708328
A@@	I-Chemical	-1	3708328
B@@	I-Chemical	-1	3708328
A	I-Chemical	-1	3708328
(	O	-1	3708328
D@@	B-Chemical	D020888	3708328
,@@	I-Chemical	-1	3708328
L-@@	I-Chemical	-1	3708328
4-@@	I-Chemical	-1	3708328
amino@@	I-Chemical	-1	3708328
-@@	I-Chemical	-1	3708328
he@@	I-Chemical	-1	3708328
x@@	I-Chemical	-1	3708328
-@@	I-Chemical	-1	3708328
5-@@	I-Chemical	-1	3708328
en@@	I-Chemical	-1	3708328
o@@	I-Chemical	-1	3708328
ic	I-Chemical	-1	3708328
acid	I-Chemical	-1	3708328
),	O	-1	3708328
5	O	-1	3708328
microgram@@	O	-1	3708328
s,	O	-1	3708328
into	O	-1	3708328
the	O	-1	3708328
S@@	O	-1	3708328
N@@	O	-1	3708328
R@@	O	-1	3708328
,	O	-1	3708328
bil@@	O	-1	3708328
at@@	O	-1	3708328
er@@	O	-1	3708328
ally,	O	-1	3708328
sup@@	O	-1	3708328
press@@	O	-1	3708328
ed	O	-1	3708328
the	O	-1	3708328
appear@@	O	-1	3708328
ance	O	-1	3708328
of	O	-1	3708328
electro@@	O	-1	3708328
graph@@	O	-1	3708328
ic	O	-1	3708328
and	O	-1	3708328
behavioral	O	-1	3708328
seizures	B-Disease	D012640	3708328
produced	O	-1	3708328
by	O	-1	3708328
pilocar@@	B-Chemical	D010862	3708328
pine	I-Chemical	-1	3708328
,	O	-1	3708328
3@@	O	-1	3708328
8@@	O	-1	3708328
0	O	-1	3708328
mg/kg@@	O	-1	3708328
.	O	-1	3708328
This	O	-1	3708328
treatment	O	-1	3708328
was	O	-1	3708328
also	O	-1	3708328
suffici@@	O	-1	3708328
ent	O	-1	3708328
to	O	-1	3708328
prot@@	O	-1	3708328
ect	O	-1	3708328
animals	O	-1	3708328
from	O	-1	3708328
the	O	-1	3708328
occur@@	O	-1	3708328
rence	O	-1	3708328
of	O	-1	3708328
brain	B-Disease	D001930	3708328
damage	I-Disease	-1	3708328
.	O	-1	3708328
M@@	O	-1	3708328
ic@@	O	-1	3708328
ro@@	O	-1	3708328
injec@@	O	-1	3708328
tions	O	-1	3708328
of	O	-1	3708328
gamma@@	B-Chemical	D020888	3708328
-@@	I-Chemical	-1	3708328
v@@	I-Chemical	-1	3708328
in@@	I-Chemical	-1	3708328
yl@@	I-Chemical	-1	3708328
-@@	I-Chemical	-1	3708328
G@@	I-Chemical	-1	3708328
A@@	I-Chemical	-1	3708328
B@@	I-Chemical	-1	3708328
A	I-Chemical	-1	3708328
,	O	-1	3708328
5	O	-1	3708328
microgram@@	O	-1	3708328
s,	O	-1	3708328
into	O	-1	3708328
the	O	-1	3708328
d@@	O	-1	3708328
or@@	O	-1	3708328
s@@	O	-1	3708328
al	O	-1	3708328
striat@@	O	-1	3708328
um,	O	-1	3708328
bil@@	O	-1	3708328
at@@	O	-1	3708328
er@@	O	-1	3708328
ally,	O	-1	3708328
fail@@	O	-1	3708328
ed	O	-1	3708328
to	O	-1	3708328
prev@@	O	-1	3708328
ent	O	-1	3708328
the	O	-1	3708328
development	O	-1	3708328
of	O	-1	3708328
convul@@	B-Disease	D012640	3708328
sions	I-Disease	-1	3708328
produced	O	-1	3708328
by	O	-1	3708328
pilocar@@	B-Chemical	D010862	3708328
pine	I-Chemical	-1	3708328
,	O	-1	3708328
3@@	O	-1	3708328
8@@	O	-1	3708328
0	O	-1	3708328
mg/kg@@	O	-1	3708328
.	O	-1	3708328
The	O	-1	3708328
results	O	-1	3708328
demon@@	O	-1	3708328
st@@	O	-1	3708328
rate	O	-1	3708328
that	O	-1	3708328
the	O	-1	3708328
th@@	O	-1	3708328
res@@	O	-1	3708328
h@@	O	-1	3708328
old	O	-1	3708328
for	O	-1	3708328
pilocar@@	B-Chemical	D010862	3708328
pine	I-Chemical	-1	3708328
-induced	O	-1	3708328
seizures	B-Disease	D012640	3708328
in	O	-1	3708328
rats	O	-1	3708328
is	O	-1	3708328
subj@@	O	-1	3708328
ected	O	-1	3708328
to	O	-1	3708328
the	O	-1	3708328
reg@@	O	-1	3708328
ulation	O	-1	3708328
of	O	-1	3708328
the	O	-1	3708328
G@@	B-Chemical	D005680	3708328
A@@	I-Chemical	-1	3708328
B@@	I-Chemical	-1	3708328
A	I-Chemical	-1	3708328
-@@	O	-1	3708328
mediated	O	-1	3708328
syn@@	O	-1	3708328
ap@@	O	-1	3708328
tic	O	-1	3708328
inhibition	O	-1	3708328
within	O	-1	3708328
the	O	-1	3708328
subst@@	O	-1	3708328
anti@@	O	-1	3708328
a	O	-1	3708328
n@@	O	-1	3708328
i@@	O	-1	3708328
gra@@	O	-1	3708328
.	O	-1	3708328

N@@	O	-1	3746148
on@@	O	-1	3746148
-@@	O	-1	3746148
inv@@	O	-1	3746148
a@@	O	-1	3746148
sive	O	-1	3746148
det@@	O	-1	3746148
ection	O	-1	3746148
of	O	-1	3746148
coronary	B-Disease	D003324	3746148
artery	I-Disease	-1	3746148
disease	I-Disease	-1	3746148
by	O	-1	3746148
body	O	-1	3746148
sur@@	O	-1	3746148
fac@@	O	-1	3746148
e	O	-1	3746148
electro@@	O	-1	3746148
cardio@@	O	-1	3746148
graph@@	O	-1	3746148
ic	O	-1	3746148
m@@	O	-1	3746148
app@@	O	-1	3746148
ing	O	-1	3746148
after	O	-1	3746148
di@@	B-Chemical	D004176	3746148
pyri@@	I-Chemical	-1	3746148
dam@@	I-Chemical	-1	3746148
ole	I-Chemical	-1	3746148
infu@@	O	-1	3746148
sion.	O	-1	3746148
E@@	O	-1	3746148
l@@	O	-1	3746148
ect@@	O	-1	3746148
ro@@	O	-1	3746148
cardio@@	O	-1	3746148
graph@@	O	-1	3746148
ic	O	-1	3746148
changes	O	-1	3746148
after	O	-1	3746148
di@@	B-Chemical	D004176	3746148
pyri@@	I-Chemical	-1	3746148
dam@@	I-Chemical	-1	3746148
ole	I-Chemical	-1	3746148
infusion	O	-1	3746148
(0.@@	O	-1	3746148
5@@	O	-1	3746148
6@@	O	-1	3746148
8	O	-1	3746148
mg/k@@	O	-1	3746148
g/@@	O	-1	3746148
4	O	-1	3746148
min@@	O	-1	3746148
)	O	-1	3746148
were	O	-1	3746148
studied	O	-1	3746148
in	O	-1	3746148
4@@	O	-1	3746148
1	O	-1	3746148
patients	O	-1	3746148
with	O	-1	3746148
coronary	B-Disease	D003324	3746148
artery	I-Disease	-1	3746148
disease	I-Disease	-1	3746148
and	O	-1	3746148
compared	O	-1	3746148
with	O	-1	3746148
those	O	-1	3746148
after	O	-1	3746148
sub@@	O	-1	3746148
maxim@@	O	-1	3746148
al	O	-1	3746148
tre@@	O	-1	3746148
ad@@	O	-1	3746148
mil@@	O	-1	3746148
l	O	-1	3746148
ex@@	O	-1	3746148
er@@	O	-1	3746148
cis@@	O	-1	3746148
e	O	-1	3746148
by	O	-1	3746148
use	O	-1	3746148
of	O	-1	3746148
the	O	-1	3746148
body	O	-1	3746148
sur@@	O	-1	3746148
fac@@	O	-1	3746148
e	O	-1	3746148
m@@	O	-1	3746148
app@@	O	-1	3746148
ing	O	-1	3746148
t@@	O	-1	3746148
ech@@	O	-1	3746148
n@@	O	-1	3746148
i@@	O	-1	3746148
qu@@	O	-1	3746148
e.	O	-1	3746148
Patients	O	-1	3746148
were	O	-1	3746148
divid@@	O	-1	3746148
ed	O	-1	3746148
into	O	-1	3746148
three	O	-1	3746148
group@@	O	-1	3746148
s;	O	-1	3746148
1@@	O	-1	3746148
9	O	-1	3746148
patients	O	-1	3746148
without	O	-1	3746148
myocardial	B-Disease	D009203	3746148
infarction	I-Disease	-1	3746148
(@@	O	-1	3746148
non@@	O	-1	3746148
-	O	-1	3746148
M@@	B-Disease	D009203	3746148
I	I-Disease	-1	3746148
group@@	O	-1	3746148
),	O	-1	3746148
14	O	-1	3746148
with	O	-1	3746148
an@@	B-Disease	D056988	3746148
ter@@	I-Disease	-1	3746148
ior	I-Disease	-1	3746148
infarction	I-Disease	-1	3746148
(	O	-1	3746148
AN@@	B-Disease	D056988	3746148
T@@	I-Disease	-1	3746148
-@@	I-Disease	-1	3746148
M@@	I-Disease	-1	3746148
I	I-Disease	-1	3746148
)	O	-1	3746148
and	O	-1	3746148
e@@	O	-1	3746148
ight	O	-1	3746148
with	O	-1	3746148
inf@@	B-Disease	D056989	3746148
er@@	I-Disease	-1	3746148
ior	I-Disease	-1	3746148
infarction	I-Disease	-1	3746148
(	O	-1	3746148
IN@@	B-Disease	D056989	3746148
F@@	I-Disease	-1	3746148
-@@	I-Disease	-1	3746148
M@@	I-Disease	-1	3746148
I	I-Disease	-1	3746148
).	O	-1	3746148
E@@	O	-1	3746148
igh@@	O	-1	3746148
ty-@@	O	-1	3746148
seven	O	-1	3746148
un@@	O	-1	3746148
ip@@	O	-1	3746148
ol@@	O	-1	3746148
ar	O	-1	3746148
electro@@	O	-1	3746148
cardio@@	O	-1	3746148
gram@@	O	-1	3746148
s	O	-1	3746148
(@@	O	-1	3746148
EC@@	O	-1	3746148
G@@	O	-1	3746148
s)	O	-1	3746148
di@@	O	-1	3746148
stri@@	O	-1	3746148
but@@	O	-1	3746148
ed	O	-1	3746148
over	O	-1	3746148
the	O	-1	3746148
enti@@	O	-1	3746148
r@@	O	-1	3746148
e	O	-1	3746148
th@@	O	-1	3746148
or@@	O	-1	3746148
ac@@	O	-1	3746148
ic	O	-1	3746148
sur@@	O	-1	3746148
fac@@	O	-1	3746148
e	O	-1	3746148
were	O	-1	3746148
sim@@	O	-1	3746148
ult@@	O	-1	3746148
ane@@	O	-1	3746148
ously	O	-1	3746148
recor@@	O	-1	3746148
de@@	O	-1	3746148
d.	O	-1	3746148
After	O	-1	3746148
di@@	B-Chemical	D004176	3746148
pyri@@	I-Chemical	-1	3746148
dam@@	I-Chemical	-1	3746148
ole	I-Chemical	-1	3746148
,	O	-1	3746148
ischem@@	B-Disease	D007511	3746148
ic	I-Disease	-1	3746148
S@@	O	-1	3746148
T@@	O	-1	3746148
-@@	O	-1	3746148
seg@@	O	-1	3746148
ment	O	-1	3746148
de@@	B-Disease	D003866	3746148
pression	I-Disease	-1	3746148
(@@	O	-1	3746148
0.0@@	O	-1	3746148
5	O	-1	3746148
m@@	O	-1	3746148
V	O	-1	3746148
or	O	-1	3746148
mo@@	O	-1	3746148
re@@	O	-1	3746148
)	O	-1	3746148
was	O	-1	3746148
observed	O	-1	3746148
in	O	-1	3746148
8@@	O	-1	3746148
4@@	O	-1	3746148
%	O	-1	3746148
of	O	-1	3746148
the	O	-1	3746148
non@@	O	-1	3746148
-	O	-1	3746148
M@@	B-Disease	D009203	3746148
I	I-Disease	-1	3746148
group@@	O	-1	3746148
,	O	-1	3746148
2@@	O	-1	3746148
9@@	O	-1	3746148
%	O	-1	3746148
of	O	-1	3746148
the	O	-1	3746148
AN@@	B-Disease	D056988	3746148
T@@	I-Disease	-1	3746148
-@@	I-Disease	-1	3746148
M@@	I-Disease	-1	3746148
I	I-Disease	-1	3746148
group@@	O	-1	3746148
,	O	-1	3746148
6@@	O	-1	3746148
3@@	O	-1	3746148
%	O	-1	3746148
of	O	-1	3746148
the	O	-1	3746148
IN@@	B-Disease	D056989	3746148
F@@	I-Disease	-1	3746148
-@@	I-Disease	-1	3746148
M@@	I-Disease	-1	3746148
I	I-Disease	-1	3746148
group	O	-1	3746148
and	O	-1	3746148
6@@	O	-1	3746148
1@@	O	-1	3746148
%	O	-1	3746148
of	O	-1	3746148
the	O	-1	3746148
total	O	-1	3746148
po@@	O	-1	3746148
pul@@	O	-1	3746148
ation.	O	-1	3746148
E@@	O	-1	3746148
x@@	O	-1	3746148
er@@	O	-1	3746148
ci@@	O	-1	3746148
se@@	O	-1	3746148
-induced	O	-1	3746148
S@@	O	-1	3746148
T	O	-1	3746148
de@@	B-Disease	D003866	3746148
pression	I-Disease	-1	3746148
was	O	-1	3746148
observed	O	-1	3746148
in	O	-1	3746148
8@@	O	-1	3746148
4@@	O	-1	3746148
%	O	-1	3746148
of	O	-1	3746148
the	O	-1	3746148
non@@	O	-1	3746148
-	O	-1	3746148
M@@	B-Disease	D009203	3746148
I	I-Disease	-1	3746148
group@@	O	-1	3746148
,	O	-1	3746148
4@@	O	-1	3746148
3@@	O	-1	3746148
%	O	-1	3746148
of	O	-1	3746148
the	O	-1	3746148
AN@@	B-Disease	D056988	3746148
T@@	I-Disease	-1	3746148
-@@	I-Disease	-1	3746148
M@@	I-Disease	-1	3746148
I	I-Disease	-1	3746148
group@@	O	-1	3746148
,	O	-1	3746148
3@@	O	-1	3746148
8@@	O	-1	3746148
%	O	-1	3746148
of	O	-1	3746148
the	O	-1	3746148
IN@@	B-Disease	D056989	3746148
F@@	I-Disease	-1	3746148
-@@	I-Disease	-1	3746148
M@@	I-Disease	-1	3746148
I	I-Disease	-1	3746148
group	O	-1	3746148
and	O	-1	3746148
6@@	O	-1	3746148
1@@	O	-1	3746148
%	O	-1	3746148
of	O	-1	3746148
the	O	-1	3746148
tot@@	O	-1	3746148
al.	O	-1	3746148
F@@	O	-1	3746148
or	O	-1	3746148
individ@@	O	-1	3746148
ual	O	-1	3746148
patients,	O	-1	3746148
there	O	-1	3746148
were	O	-1	3746148
no	O	-1	3746148
ob@@	O	-1	3746148
vi@@	O	-1	3746148
ous	O	-1	3746148
differences	O	-1	3746148
between	O	-1	3746148
the	O	-1	3746148
body	O	-1	3746148
sur@@	O	-1	3746148
fac@@	O	-1	3746148
e	O	-1	3746148
di@@	O	-1	3746148
stri@@	O	-1	3746148
bu@@	O	-1	3746148
tion	O	-1	3746148
of	O	-1	3746148
S@@	O	-1	3746148
T	O	-1	3746148
de@@	B-Disease	D003866	3746148
pression	I-Disease	-1	3746148
in	O	-1	3746148
both	O	-1	3746148
test@@	O	-1	3746148
s.	O	-1	3746148
The	O	-1	3746148
increase	O	-1	3746148
in	O	-1	3746148
pressure	O	-1	3746148
rate	O	-1	3746148
produc@@	O	-1	3746148
t	O	-1	3746148
after	O	-1	3746148
di@@	B-Chemical	D004176	3746148
pyri@@	I-Chemical	-1	3746148
dam@@	I-Chemical	-1	3746148
ole	I-Chemical	-1	3746148
was	O	-1	3746148
significantly	O	-1	3746148
less	O	-1	3746148
than	O	-1	3746148
that	O	-1	3746148
during	O	-1	3746148
the	O	-1	3746148
tre@@	O	-1	3746148
ad@@	O	-1	3746148
mil@@	O	-1	3746148
l	O	-1	3746148
ex@@	O	-1	3746148
er@@	O	-1	3746148
ci@@	O	-1	3746148
se.	O	-1	3746148
The	O	-1	3746148
data	O	-1	3746148
suggest	O	-1	3746148
that	O	-1	3746148
the	O	-1	3746148
di@@	B-Chemical	D004176	3746148
pyri@@	I-Chemical	-1	3746148
dam@@	I-Chemical	-1	3746148
ole	I-Chemical	-1	3746148
-induced	O	-1	3746148
myocardial	B-Disease	D017202	3746148
ischem@@	I-Disease	-1	3746148
ia	I-Disease	-1	3746148
is	O	-1	3746148
caused	O	-1	3746148
by	O	-1	3746148
the	O	-1	3746148
in@@	O	-1	3746148
ho@@	O	-1	3746148
mo@@	O	-1	3746148
gen@@	O	-1	3746148
ous	O	-1	3746148
di@@	O	-1	3746148
stri@@	O	-1	3746148
bu@@	O	-1	3746148
tion	O	-1	3746148
of	O	-1	3746148
myocardial	O	-1	3746148
blood	O	-1	3746148
f@@	O	-1	3746148
low@@	O	-1	3746148
.	O	-1	3746148
We	O	-1	3746148
concl@@	O	-1	3746148
ude	O	-1	3746148
that	O	-1	3746148
the	O	-1	3746148
di@@	B-Chemical	D004176	3746148
pyri@@	I-Chemical	-1	3746148
dam@@	I-Chemical	-1	3746148
ole	I-Chemical	-1	3746148
EC@@	O	-1	3746148
G	O	-1	3746148
test	O	-1	3746148
is	O	-1	3746148
as	O	-1	3746148
use@@	O	-1	3746148
ful	O	-1	3746148
as	O	-1	3746148
the	O	-1	3746148
ex@@	O	-1	3746148
er@@	O	-1	3746148
cis@@	O	-1	3746148
e	O	-1	3746148
EC@@	O	-1	3746148
G	O	-1	3746148
test	O	-1	3746148
for	O	-1	3746148
the	O	-1	3746148
assess@@	O	-1	3746148
ment	O	-1	3746148
of	O	-1	3746148
coronary	B-Disease	D003324	3746148
artery	I-Disease	-1	3746148
disease	I-Disease	-1	3746148
.	O	-1	3746148

B@@	B-Disease	D001919	3798047
ra@@	I-Disease	-1	3798047
dy@@	I-Disease	-1	3798047
cardia	I-Disease	-1	3798047
after	O	-1	3798047
high-dose	O	-1	3798047
intravenous	O	-1	3798047
methyl@@	B-Chemical	D008775	3798047
pre@@	I-Chemical	-1	3798047
d@@	I-Chemical	-1	3798047
n@@	I-Chemical	-1	3798047
isol@@	I-Chemical	-1	3798047
one	I-Chemical	-1	3798047
therapy.	O	-1	3798047
In	O	-1	3798047
5	O	-1	3798047
con@@	O	-1	3798047
sec@@	O	-1	3798047
utive	O	-1	3798047
patients	O	-1	3798047
with	O	-1	3798047
r@@	B-Disease	D001172	3798047
he@@	I-Disease	-1	3798047
um@@	I-Disease	-1	3798047
at@@	I-Disease	-1	3798047
oid	I-Disease	-1	3798047
arth@@	I-Disease	-1	3798047
ritis	I-Disease	-1	3798047
who	O	-1	3798047
received	O	-1	3798047
intravenous	O	-1	3798047
high-dose	O	-1	3798047
methyl@@	B-Chemical	D008775	3798047
pre@@	I-Chemical	-1	3798047
d@@	I-Chemical	-1	3798047
n@@	I-Chemical	-1	3798047
isol@@	I-Chemical	-1	3798047
one	I-Chemical	-1	3798047
(	O	-1	3798047
M@@	B-Chemical	D008775	3798047
P	I-Chemical	-1	3798047
)	O	-1	3798047
therapy	O	-1	3798047
(@@	O	-1	3798047
1	O	-1	3798047
g	O	-1	3798047
daily	O	-1	3798047
for	O	-1	3798047
2	O	-1	3798047
or	O	-1	3798047
3	O	-1	3798047
con@@	O	-1	3798047
sec@@	O	-1	3798047
utive	O	-1	3798047
da@@	O	-1	3798047
ys@@	O	-1	3798047
),	O	-1	3798047
a	O	-1	3798047
dec@@	O	-1	3798047
line	O	-1	3798047
in	O	-1	3798047
pul@@	O	-1	3798047
se	O	-1	3798047
rate	O	-1	3798047
was	O	-1	3798047
obser@@	O	-1	3798047
ve@@	O	-1	3798047
d,	O	-1	3798047
most	O	-1	3798047
p@@	O	-1	3798047
ron@@	O	-1	3798047
oun@@	O	-1	3798047
c@@	O	-1	3798047
ed	O	-1	3798047
on	O	-1	3798047
day	O	-1	3798047
4@@	O	-1	3798047
.	O	-1	3798047
In	O	-1	3798047
one	O	-1	3798047
of	O	-1	3798047
the	O	-1	3798047
5	O	-1	3798047
patients	O	-1	3798047
the	O	-1	3798047
brady@@	B-Disease	D001919	3798047
cardia	I-Disease	-1	3798047
was	O	-1	3798047
associated	O	-1	3798047
with	O	-1	3798047
com@@	O	-1	3798047
pl@@	O	-1	3798047
a@@	O	-1	3798047
int@@	O	-1	3798047
s	O	-1	3798047
of	O	-1	3798047
sub@@	O	-1	3798047
ster@@	O	-1	3798047
n@@	O	-1	3798047
al	O	-1	3798047
pressu@@	O	-1	3798047
re.	O	-1	3798047
Re@@	O	-1	3798047
ver@@	O	-1	3798047
s@@	O	-1	3798047
al	O	-1	3798047
to	O	-1	3798047
normal	O	-1	3798047
heart	O	-1	3798047
rate	O	-1	3798047
was	O	-1	3798047
found	O	-1	3798047
on	O	-1	3798047
day	O	-1	3798047
7@@	O	-1	3798047
.	O	-1	3798047
E@@	O	-1	3798047
l@@	O	-1	3798047
ect@@	O	-1	3798047
ro@@	O	-1	3798047
cardio@@	O	-1	3798047
graph@@	O	-1	3798047
ic	O	-1	3798047
reg@@	O	-1	3798047
ist@@	O	-1	3798047
r@@	O	-1	3798047
ations	O	-1	3798047
showed	O	-1	3798047
s@@	B-Disease	D012804	3798047
in@@	I-Disease	-1	3798047
us	I-Disease	-1	3798047
brady@@	I-Disease	-1	3798047
cardia	I-Disease	-1	3798047
in	O	-1	3798047
all	O	-1	3798047
cas@@	O	-1	3798047
es.	O	-1	3798047
No	O	-1	3798047
significant	O	-1	3798047
changes	O	-1	3798047
in	O	-1	3798047
plasma	O	-1	3798047
concentrations	O	-1	3798047
of	O	-1	3798047
electro@@	O	-1	3798047
ly@@	O	-1	3798047
tes	O	-1	3798047
were	O	-1	3798047
f@@	O	-1	3798047
oun@@	O	-1	3798047
d.	O	-1	3798047
Ca@@	O	-1	3798047
ref@@	O	-1	3798047
u@@	O	-1	3798047
l	O	-1	3798047
observ@@	O	-1	3798047
ation	O	-1	3798047
of	O	-1	3798047
patients	O	-1	3798047
receiving	O	-1	3798047
high-dose	O	-1	3798047
M@@	B-Chemical	D008775	3798047
P	I-Chemical	-1	3798047
is	O	-1	3798047
recomm@@	O	-1	3798047
en@@	O	-1	3798047
de@@	O	-1	3798047
d.	O	-1	3798047
H@@	O	-1	3798047
igh@@	O	-1	3798047
-@@	O	-1	3798047
dose	O	-1	3798047
M@@	B-Chemical	D008775	3798047
P	I-Chemical	-1	3798047
may	O	-1	3798047
be	O	-1	3798047
contra@@	O	-1	3798047
indic@@	O	-1	3798047
ated	O	-1	3798047
in	O	-1	3798047
patients	O	-1	3798047
with	O	-1	3798047
known	O	-1	3798047
heart	B-Disease	D006331	3798047
disease	I-Disease	-1	3798047
.	O	-1	3798047

Two	O	-1	3812624
cases	O	-1	3812624
of	O	-1	3812624
do@@	B-Disease	D009759	3812624
w@@	I-Disease	-1	3812624
n@@	I-Disease	-1	3812624
be@@	I-Disease	-1	3812624
at	I-Disease	-1	3812624
n@@	I-Disease	-1	3812624
y@@	I-Disease	-1	3812624
st@@	I-Disease	-1	3812624
ag@@	I-Disease	-1	3812624
m@@	I-Disease	-1	3812624
us	I-Disease	-1	3812624
and	O	-1	3812624
os@@	B-Disease	D015835	3812624
c@@	I-Disease	-1	3812624
il@@	I-Disease	-1	3812624
lop@@	I-Disease	-1	3812624
sia	I-Disease	-1	3812624
associated	O	-1	3812624
with	O	-1	3812624
carbamazepine	B-Chemical	D002220	3812624
.	O	-1	3812624
D@@	B-Disease	D009759	3812624
o@@	I-Disease	-1	3812624
w@@	I-Disease	-1	3812624
n@@	I-Disease	-1	3812624
be@@	I-Disease	-1	3812624
at	I-Disease	-1	3812624
n@@	I-Disease	-1	3812624
y@@	I-Disease	-1	3812624
st@@	I-Disease	-1	3812624
ag@@	I-Disease	-1	3812624
m@@	I-Disease	-1	3812624
us	I-Disease	-1	3812624
is	O	-1	3812624
often	O	-1	3812624
associated	O	-1	3812624
with	O	-1	3812624
struct@@	O	-1	3812624
ural	O	-1	3812624
lesions	O	-1	3812624
at	O	-1	3812624
the	O	-1	3812624
c@@	O	-1	3812624
ran@@	O	-1	3812624
i@@	O	-1	3812624
oc@@	O	-1	3812624
er@@	O	-1	3812624
v@@	O	-1	3812624
ical	O	-1	3812624
j@@	O	-1	3812624
unc@@	O	-1	3812624
tion,	O	-1	3812624
but	O	-1	3812624
has	O	-1	3812624
oc@@	O	-1	3812624
ca@@	O	-1	3812624
sion@@	O	-1	3812624
ally	O	-1	3812624
been	O	-1	3812624
reported	O	-1	3812624
as	O	-1	3812624
a	O	-1	3812624
man@@	O	-1	3812624
if@@	O	-1	3812624
est@@	O	-1	3812624
ation	O	-1	3812624
of	O	-1	3812624
met@@	O	-1	3812624
ab@@	O	-1	3812624
olic	O	-1	3812624
im@@	O	-1	3812624
b@@	O	-1	3812624
al@@	O	-1	3812624
ance	O	-1	3812624
or	O	-1	3812624
drug	O	-1	3812624
in@@	O	-1	3812624
toxic@@	O	-1	3812624
ation.	O	-1	3812624
We	O	-1	3812624
recor@@	O	-1	3812624
ded	O	-1	3812624
the	O	-1	3812624
e@@	O	-1	3812624
y@@	O	-1	3812624
e	O	-1	3812624
mo@@	O	-1	3812624
ve@@	O	-1	3812624
ments	O	-1	3812624
of	O	-1	3812624
two	O	-1	3812624
patients	O	-1	3812624
with	O	-1	3812624
reversible	O	-1	3812624
do@@	B-Disease	D009759	3812624
w@@	I-Disease	-1	3812624
n@@	I-Disease	-1	3812624
be@@	I-Disease	-1	3812624
at	I-Disease	-1	3812624
n@@	I-Disease	-1	3812624
y@@	I-Disease	-1	3812624
st@@	I-Disease	-1	3812624
ag@@	I-Disease	-1	3812624
m@@	I-Disease	-1	3812624
us	I-Disease	-1	3812624
related	O	-1	3812624
to	O	-1	3812624
carbamazepine	B-Chemical	D002220	3812624
therapy.	O	-1	3812624
The	O	-1	3812624
n@@	B-Disease	D009759	3812624
y@@	I-Disease	-1	3812624
st@@	I-Disease	-1	3812624
ag@@	I-Disease	-1	3812624
m@@	I-Disease	-1	3812624
us	I-Disease	-1	3812624
of	O	-1	3812624
both	O	-1	3812624
patients	O	-1	3812624
resol@@	O	-1	3812624
ved	O	-1	3812624
after	O	-1	3812624
reduction	O	-1	3812624
of	O	-1	3812624
the	O	-1	3812624
serum	O	-1	3812624
carbamazepine	B-Chemical	D002220	3812624
level@@	O	-1	3812624
s.	O	-1	3812624
Ne@@	O	-1	3812624
uro@@	O	-1	3812624
radi@@	O	-1	3812624
ologic	O	-1	3812624
investig@@	O	-1	3812624
ations	O	-1	3812624
including	O	-1	3812624
mag@@	O	-1	3812624
ne@@	O	-1	3812624
tic	O	-1	3812624
res@@	O	-1	3812624
on@@	O	-1	3812624
ance	O	-1	3812624
imaging	O	-1	3812624
s@@	O	-1	3812624
c@@	O	-1	3812624
ans	O	-1	3812624
in	O	-1	3812624
both	O	-1	3812624
patients	O	-1	3812624
showed	O	-1	3812624
no	O	-1	3812624
evidence	O	-1	3812624
of	O	-1	3812624
intrac@@	O	-1	3812624
ranial	O	-1	3812624
abnormal@@	O	-1	3812624
ity.	O	-1	3812624
In	O	-1	3812624
patients	O	-1	3812624
with	O	-1	3812624
do@@	B-Disease	D009759	3812624
w@@	I-Disease	-1	3812624
n@@	I-Disease	-1	3812624
be@@	I-Disease	-1	3812624
at	I-Disease	-1	3812624
n@@	I-Disease	-1	3812624
y@@	I-Disease	-1	3812624
st@@	I-Disease	-1	3812624
ag@@	I-Disease	-1	3812624
m@@	I-Disease	-1	3812624
us	I-Disease	-1	3812624
who	O	-1	3812624
are	O	-1	3812624
taking	O	-1	3812624
anti@@	O	-1	3812624
convul@@	O	-1	3812624
s@@	O	-1	3812624
ant	O	-1	3812624
medic@@	O	-1	3812624
ation@@	O	-1	3812624
s,	O	-1	3812624
con@@	O	-1	3812624
si@@	O	-1	3812624
der@@	O	-1	3812624
ation	O	-1	3812624
should	O	-1	3812624
be	O	-1	3812624
given	O	-1	3812624
to	O	-1	3812624
reduction	O	-1	3812624
in	O	-1	3812624
dose	O	-1	3812624
before	O	-1	3812624
further	O	-1	3812624
investig@@	O	-1	3812624
ation	O	-1	3812624
is	O	-1	3812624
under@@	O	-1	3812624
tak@@	O	-1	3812624
en@@	O	-1	3812624
.	O	-1	3812624

Im@@	O	-1	3831029
pro@@	O	-1	3831029
vement	O	-1	3831029
by	O	-1	3831029
d@@	B-Chemical	C037293	3831029
en@@	I-Chemical	-1	3831029
op@@	I-Chemical	-1	3831029
amine	I-Chemical	-1	3831029
(	O	-1	3831029
TA@@	B-Chemical	C037293	3831029
-@@	I-Chemical	-1	3831029
0@@	I-Chemical	-1	3831029
6@@	I-Chemical	-1	3831029
4	I-Chemical	-1	3831029
)	O	-1	3831029
of	O	-1	3831029
pent@@	B-Chemical	D010424	3831029
obarbit@@	I-Chemical	-1	3831029
al	I-Chemical	-1	3831029
-induced	O	-1	3831029
cardiac	B-Disease	D006333	3831029
failure	I-Disease	-1	3831029
in	O	-1	3831029
the	O	-1	3831029
do@@	O	-1	3831029
g	O	-1	3831029
hear@@	O	-1	3831029
t-@@	O	-1	3831029
l@@	O	-1	3831029
un@@	O	-1	3831029
g	O	-1	3831029
pre@@	O	-1	3831029
par@@	O	-1	3831029
ation.	O	-1	3831029
The	O	-1	3831029
efficacy	O	-1	3831029
of	O	-1	3831029
d@@	B-Chemical	C037293	3831029
en@@	I-Chemical	-1	3831029
op@@	I-Chemical	-1	3831029
amine	I-Chemical	-1	3831029
,	O	-1	3831029
an	O	-1	3831029
or@@	O	-1	3831029
ally	O	-1	3831029
active	O	-1	3831029
bet@@	O	-1	3831029
a	O	-1	3831029
1-@@	O	-1	3831029
adren@@	O	-1	3831029
oc@@	O	-1	3831029
e@@	O	-1	3831029
pt@@	O	-1	3831029
or	O	-1	3831029
agon@@	O	-1	3831029
ist@@	O	-1	3831029
,	O	-1	3831029
in	O	-1	3831029
impro@@	O	-1	3831029
ving	O	-1	3831029
cardiac	B-Disease	D006333	3831029
failure	I-Disease	-1	3831029
was	O	-1	3831029
assessed	O	-1	3831029
in	O	-1	3831029
do@@	O	-1	3831029
g	O	-1	3831029
hear@@	O	-1	3831029
t-@@	O	-1	3831029
l@@	O	-1	3831029
un@@	O	-1	3831029
g	O	-1	3831029
pre@@	O	-1	3831029
par@@	O	-1	3831029
ations.	O	-1	3831029
C@@	O	-1	3831029
ardi@@	O	-1	3831029
a@@	O	-1	3831029
c	O	-1	3831029
func@@	O	-1	3831029
tions	O	-1	3831029
depress@@	O	-1	3831029
ed	O	-1	3831029
by	O	-1	3831029
pent@@	B-Chemical	D010424	3831029
obarbit@@	I-Chemical	-1	3831029
al	I-Chemical	-1	3831029
(1@@	O	-1	3831029
1@@	O	-1	3831029
8	O	-1	3831029
+/-	O	-1	3831029
2@@	O	-1	3831029
8	O	-1	3831029
mg@@	O	-1	3831029
;	O	-1	3831029
mean	O	-1	3831029
valu@@	O	-1	3831029
e	O	-1	3831029
+/-	O	-1	3831029
S@@	O	-1	3831029
D)	O	-1	3831029
such	O	-1	3831029
that	O	-1	3831029
cardiac	O	-1	3831029
out@@	O	-1	3831029
pu@@	O	-1	3831029
t	O	-1	3831029
and	O	-1	3831029
maxim@@	O	-1	3831029
um	O	-1	3831029
rate	O	-1	3831029
of	O	-1	3831029
ri@@	O	-1	3831029
se	O	-1	3831029
of	O	-1	3831029
left	O	-1	3831029
ventricular	O	-1	3831029
pressure	O	-1	3831029
(@@	O	-1	3831029
L@@	O	-1	3831029
V	O	-1	3831029
d@@	O	-1	3831029
P@@	O	-1	3831029
/@@	O	-1	3831029
d@@	O	-1	3831029
t	O	-1	3831029
ma@@	O	-1	3831029
x@@	O	-1	3831029
)	O	-1	3831029
had	O	-1	3831029
been	O	-1	3831029
reduced	O	-1	3831029
by	O	-1	3831029
about	O	-1	3831029
3@@	O	-1	3831029
5%	O	-1	3831029
and	O	-1	3831029
2@@	O	-1	3831029
6%	O	-1	3831029
of	O	-1	3831029
the	O	-1	3831029
resp@@	O	-1	3831029
ective	O	-1	3831029
controls	O	-1	3831029
were	O	-1	3831029
improved	O	-1	3831029
by	O	-1	3831029
d@@	B-Chemical	C037293	3831029
en@@	I-Chemical	-1	3831029
op@@	I-Chemical	-1	3831029
amine	I-Chemical	-1	3831029
(@@	O	-1	3831029
10-@@	O	-1	3831029
3@@	O	-1	3831029
00	O	-1	3831029
microgram@@	O	-1	3831029
s)	O	-1	3831029
in	O	-1	3831029
a	O	-1	3831029
dose-@@	O	-1	3831029
dependent	O	-1	3831029
man@@	O	-1	3831029
ner@@	O	-1	3831029
.	O	-1	3831029
W@@	O	-1	3831029
it@@	O	-1	3831029
h	O	-1	3831029
100	O	-1	3831029
microgram@@	O	-1	3831029
s	O	-1	3831029
d@@	B-Chemical	C037293	3831029
en@@	I-Chemical	-1	3831029
op@@	I-Chemical	-1	3831029
amine	I-Chemical	-1	3831029
,	O	-1	3831029
al@@	O	-1	3831029
most	O	-1	3831029
complete	O	-1	3831029
rest@@	O	-1	3831029
or@@	O	-1	3831029
ation	O	-1	3831029
of	O	-1	3831029
cardiac	O	-1	3831029
perform@@	O	-1	3831029
ance	O	-1	3831029
was	O	-1	3831029
at@@	O	-1	3831029
t@@	O	-1	3831029
a@@	O	-1	3831029
ine@@	O	-1	3831029
d,	O	-1	3831029
associated	O	-1	3831029
with	O	-1	3831029
a	O	-1	3831029
s@@	O	-1	3831029
li@@	O	-1	3831029
ght	O	-1	3831029
increase	O	-1	3831029
in	O	-1	3831029
heart	O	-1	3831029
rat@@	O	-1	3831029
e.	O	-1	3831029
No	O	-1	3831029
arrhyth@@	B-Disease	D001145	3831029
mi@@	I-Disease	-1	3831029
as	I-Disease	-1	3831029
were	O	-1	3831029
induced	O	-1	3831029
by	O	-1	3831029
these	O	-1	3831029
doses	O	-1	3831029
of	O	-1	3831029
d@@	B-Chemical	C037293	3831029
en@@	I-Chemical	-1	3831029
op@@	I-Chemical	-1	3831029
amine	I-Chemical	-1	3831029
.	O	-1	3831029
The	O	-1	3831029
results	O	-1	3831029
war@@	O	-1	3831029
ran@@	O	-1	3831029
t	O	-1	3831029
clinical	O	-1	3831029
tri@@	O	-1	3831029
als	O	-1	3831029
of	O	-1	3831029
d@@	B-Chemical	C037293	3831029
en@@	I-Chemical	-1	3831029
op@@	I-Chemical	-1	3831029
amine	I-Chemical	-1	3831029
in	O	-1	3831029
the	O	-1	3831029
treatment	O	-1	3831029
of	O	-1	3831029
cardiac	B-Disease	D006333	3831029
failure	I-Disease	-1	3831029
.	O	-1	3831029

C@@	B-Chemical	D002998	3832950
lon@@	I-Chemical	-1	3832950
az@@	I-Chemical	-1	3832950
epam	I-Chemical	-1	3832950
mon@@	O	-1	3832950
o@@	O	-1	3832950
therapy	O	-1	3832950
for	O	-1	3832950
epilep@@	B-Disease	D004827	3832950
sy	I-Disease	-1	3832950
in	O	-1	3832950
child@@	O	-1	3832950
ho@@	O	-1	3832950
o@@	O	-1	3832950
d.	O	-1	3832950
Si@@	O	-1	3832950
x@@	O	-1	3832950
t@@	O	-1	3832950
y	O	-1	3832950
patients	O	-1	3832950
(@@	O	-1	3832950
ag@@	O	-1	3832950
e-@@	O	-1	3832950
range	O	-1	3832950
one	O	-1	3832950
mon@@	O	-1	3832950
th	O	-1	3832950
to	O	-1	3832950
14	O	-1	3832950
year@@	O	-1	3832950
s)	O	-1	3832950
with	O	-1	3832950
other	O	-1	3832950
typ@@	O	-1	3832950
es	O	-1	3832950
of	O	-1	3832950
epilep@@	B-Disease	D004827	3832950
sy	I-Disease	-1	3832950
than	O	-1	3832950
inf@@	B-Disease	D013036	3832950
anti@@	I-Disease	-1	3832950
le	I-Disease	-1	3832950
sp@@	I-Disease	-1	3832950
as@@	I-Disease	-1	3832950
ms	I-Disease	-1	3832950
were	O	-1	3832950
treated	O	-1	3832950
with	O	-1	3832950
clon@@	B-Chemical	D002998	3832950
az@@	I-Chemical	-1	3832950
epam	I-Chemical	-1	3832950
.	O	-1	3832950
D@@	O	-1	3832950
is@@	O	-1	3832950
appear@@	O	-1	3832950
ance	O	-1	3832950
of	O	-1	3832950
seizures	B-Disease	D012640	3832950
and	O	-1	3832950
normal@@	O	-1	3832950
ization	O	-1	3832950
of	O	-1	3832950
ab@@	O	-1	3832950
normal	O	-1	3832950
E@@	O	-1	3832950
E@@	O	-1	3832950
G	O	-1	3832950
with	O	-1	3832950
dis@@	O	-1	3832950
appear@@	O	-1	3832950
ance	O	-1	3832950
of	O	-1	3832950
seizures	B-Disease	D012640	3832950
were	O	-1	3832950
reco@@	O	-1	3832950
gn@@	O	-1	3832950
ized	O	-1	3832950
in	O	-1	3832950
7@@	O	-1	3832950
7@@	O	-1	3832950
%	O	-1	3832950
and	O	-1	3832950
50@@	O	-1	3832950
%,	O	-1	3832950
respectively.	O	-1	3832950
S@@	B-Disease	D012640	3832950
e@@	I-Disease	-1	3832950
iz@@	I-Disease	-1	3832950
ures	I-Disease	-1	3832950
dis@@	O	-1	3832950
appe@@	O	-1	3832950
a@@	O	-1	3832950
red	O	-1	3832950
in	O	-1	3832950
7@@	O	-1	3832950
1@@	O	-1	3832950
%	O	-1	3832950
of	O	-1	3832950
the	O	-1	3832950
patients	O	-1	3832950
with	O	-1	3832950
gener@@	O	-1	3832950
al@@	O	-1	3832950
ized	O	-1	3832950
seizures	B-Disease	D012640	3832950
and	O	-1	3832950
8@@	O	-1	3832950
9@@	O	-1	3832950
%	O	-1	3832950
of	O	-1	3832950
partial	O	-1	3832950
seizures	B-Disease	D012640	3832950
.	O	-1	3832950
Im@@	O	-1	3832950
pro@@	O	-1	3832950
vement	O	-1	3832950
of	O	-1	3832950
ab@@	O	-1	3832950
normal	O	-1	3832950
E@@	O	-1	3832950
E@@	O	-1	3832950
G	O	-1	3832950
was	O	-1	3832950
no@@	O	-1	3832950
tic@@	O	-1	3832950
ed	O	-1	3832950
in	O	-1	3832950
7@@	O	-1	3832950
6%	O	-1	3832950
of	O	-1	3832950
diff@@	O	-1	3832950
use	O	-1	3832950
pa@@	O	-1	3832950
ro@@	O	-1	3832950
x@@	O	-1	3832950
ys@@	O	-1	3832950
ms	O	-1	3832950
and	O	-1	3832950
in	O	-1	3832950
6@@	O	-1	3832950
7@@	O	-1	3832950
%	O	-1	3832950
of	O	-1	3832950
foc@@	O	-1	3832950
al	O	-1	3832950
pa@@	O	-1	3832950
ro@@	O	-1	3832950
x@@	O	-1	3832950
ys@@	O	-1	3832950
m@@	O	-1	3832950
s.	O	-1	3832950
In	O	-1	3832950
ex@@	O	-1	3832950
cell@@	O	-1	3832950
ent	O	-1	3832950
cas@@	O	-1	3832950
es,	O	-1	3832950
mean	O	-1	3832950
effective	O	-1	3832950
dos@@	O	-1	3832950
ages	O	-1	3832950
were	O	-1	3832950
0.0@@	O	-1	3832950
8@@	O	-1	3832950
6	O	-1	3832950
+/-	O	-1	3832950
0.0@@	O	-1	3832950
21	O	-1	3832950
mg/k@@	O	-1	3832950
g/@@	O	-1	3832950
day	O	-1	3832950
in	O	-1	3832950
inf@@	O	-1	3832950
ants	O	-1	3832950
and	O	-1	3832950
0.05@@	O	-1	3832950
7	O	-1	3832950
+/-	O	-1	3832950
0.0@@	O	-1	3832950
2@@	O	-1	3832950
2	O	-1	3832950
mg/k@@	O	-1	3832950
g/@@	O	-1	3832950
day	O	-1	3832950
in	O	-1	3832950
sch@@	O	-1	3832950
o@@	O	-1	3832950
ol@@	O	-1	3832950
child@@	O	-1	3832950
ren@@	O	-1	3832950
,	O	-1	3832950
this	O	-1	3832950
difference	O	-1	3832950
was	O	-1	3832950
statis@@	O	-1	3832950
tically	O	-1	3832950
significant	O	-1	3832950
(p	O	-1	3832950
less	O	-1	3832950
than	O	-1	3832950
0.00@@	O	-1	3832950
5@@	O	-1	3832950
).	O	-1	3832950
The	O	-1	3832950
incidence	O	-1	3832950
of	O	-1	3832950
side	O	-1	3832950
effects	O	-1	3832950
such	O	-1	3832950
as	O	-1	3832950
dro@@	B-Disease	D006970	3832950
w@@	I-Disease	-1	3832950
s@@	I-Disease	-1	3832950
in@@	I-Disease	-1	3832950
ess	I-Disease	-1	3832950
and	O	-1	3832950
at@@	B-Disease	D001259	3832950
ax@@	I-Disease	-1	3832950
ia	I-Disease	-1	3832950
was	O	-1	3832950
only	O	-1	3832950
5@@	O	-1	3832950
%.	O	-1	3832950

P@@	O	-1	3833372
ost@@	O	-1	3833372
mark@@	O	-1	3833372
et@@	O	-1	3833372
ing	O	-1	3833372
study	O	-1	3833372
of	O	-1	3833372
ti@@	B-Chemical	D013999	3833372
mo@@	I-Chemical	-1	3833372
lol	I-Chemical	-1	3833372
-	O	-1	3833372
hydro@@	B-Chemical	D006852	3833372
ch@@	I-Chemical	-1	3833372
loro@@	I-Chemical	-1	3833372
thi@@	I-Chemical	-1	3833372
az@@	I-Chemical	-1	3833372
ide	I-Chemical	-1	3833372
anti@@	O	-1	3833372
hypertensive	O	-1	3833372
therapy.	O	-1	3833372
A	O	-1	3833372
post@@	O	-1	3833372
mark@@	O	-1	3833372
et@@	O	-1	3833372
ing	O	-1	3833372
sur@@	O	-1	3833372
ve@@	O	-1	3833372
ill@@	O	-1	3833372
ance	O	-1	3833372
study	O	-1	3833372
was	O	-1	3833372
con@@	O	-1	3833372
duc@@	O	-1	3833372
ted	O	-1	3833372
to	O	-1	3833372
determine	O	-1	3833372
the	O	-1	3833372
safety	O	-1	3833372
and	O	-1	3833372
efficacy	O	-1	3833372
of	O	-1	3833372
a	O	-1	3833372
fi@@	O	-1	3833372
x@@	O	-1	3833372
ed@@	O	-1	3833372
-@@	O	-1	3833372
rati@@	O	-1	3833372
o	O	-1	3833372
combination	O	-1	3833372
containing	O	-1	3833372
10	O	-1	3833372
mg	O	-1	3833372
of	O	-1	3833372
ti@@	B-Chemical	D013999	3833372
mo@@	I-Chemical	-1	3833372
lol	I-Chemical	-1	3833372
mal@@	I-Chemical	-1	3833372
e@@	I-Chemical	-1	3833372
ate	I-Chemical	-1	3833372
and	O	-1	3833372
25	O	-1	3833372
mg	O	-1	3833372
of	O	-1	3833372
hydro@@	B-Chemical	D006852	3833372
ch@@	I-Chemical	-1	3833372
loro@@	I-Chemical	-1	3833372
thi@@	I-Chemical	-1	3833372
az@@	I-Chemical	-1	3833372
ide	I-Chemical	-1	3833372
,	O	-1	3833372
administered	O	-1	3833372
tw@@	O	-1	3833372
ic@@	O	-1	3833372
e	O	-1	3833372
daily	O	-1	3833372
for	O	-1	3833372
one	O	-1	3833372
mon@@	O	-1	3833372
th	O	-1	3833372
to	O	-1	3833372
hypertensive	B-Disease	D006973	3833372
patients.	O	-1	3833372
D@@	O	-1	3833372
at@@	O	-1	3833372
a	O	-1	3833372
on	O	-1	3833372
9@@	O	-1	3833372
,@@	O	-1	3833372
0@@	O	-1	3833372
3@@	O	-1	3833372
7	O	-1	3833372
patients	O	-1	3833372
were	O	-1	3833372
coll@@	O	-1	3833372
ected	O	-1	3833372
by	O	-1	3833372
1@@	O	-1	3833372
,@@	O	-1	3833372
4@@	O	-1	3833372
5@@	O	-1	3833372
5	O	-1	3833372
partic@@	O	-1	3833372
ip@@	O	-1	3833372
ating	O	-1	3833372
physi@@	O	-1	3833372
ci@@	O	-1	3833372
an@@	O	-1	3833372
s.	O	-1	3833372
M@@	O	-1	3833372
e@@	O	-1	3833372
an	O	-1	3833372
systolic	O	-1	3833372
blood	O	-1	3833372
pressure	O	-1	3833372
decreased	O	-1	3833372
25	O	-1	3833372
mm@@	O	-1	3833372
H@@	O	-1	3833372
g	O	-1	3833372
and	O	-1	3833372
mean	O	-1	3833372
di@@	O	-1	3833372
ast@@	O	-1	3833372
olic	O	-1	3833372
blood	O	-1	3833372
pressure	O	-1	3833372
dec@@	O	-1	3833372
lin@@	O	-1	3833372
ed	O	-1	3833372
15	O	-1	3833372
mm@@	O	-1	3833372
H@@	O	-1	3833372
g	O	-1	3833372
after	O	-1	3833372
one	O	-1	3833372
mon@@	O	-1	3833372
th	O	-1	3833372
of	O	-1	3833372
ti@@	B-Chemical	D013999	3833372
mo@@	I-Chemical	-1	3833372
lol	I-Chemical	-1	3833372
-	O	-1	3833372
hydro@@	B-Chemical	D006852	3833372
ch@@	I-Chemical	-1	3833372
loro@@	I-Chemical	-1	3833372
thi@@	I-Chemical	-1	3833372
az@@	I-Chemical	-1	3833372
ide	I-Chemical	-1	3833372
therapy	O	-1	3833372
(P	O	-1	3833372
less	O	-1	3833372
than	O	-1	3833372
0.0@@	O	-1	3833372
1,	O	-1	3833372
both	O	-1	3833372
compar@@	O	-1	3833372
is@@	O	-1	3833372
on@@	O	-1	3833372
s@@	O	-1	3833372
).	O	-1	3833372
A@@	O	-1	3833372
g@@	O	-1	3833372
e,	O	-1	3833372
rac@@	O	-1	3833372
e,	O	-1	3833372
and	O	-1	3833372
se@@	O	-1	3833372
x	O	-1	3833372
appe@@	O	-1	3833372
a@@	O	-1	3833372
red	O	-1	3833372
to	O	-1	3833372
have	O	-1	3833372
no	O	-1	3833372
influence	O	-1	3833372
on	O	-1	3833372
the	O	-1	3833372
decrease	O	-1	3833372
in	O	-1	3833372
blood	O	-1	3833372
pressu@@	O	-1	3833372
re.	O	-1	3833372
The	O	-1	3833372
anti@@	O	-1	3833372
hypertensive	O	-1	3833372
effect	O	-1	3833372
of	O	-1	3833372
the	O	-1	3833372
drug	O	-1	3833372
was	O	-1	3833372
greater	O	-1	3833372
in	O	-1	3833372
patients	O	-1	3833372
with	O	-1	3833372
more	O	-1	3833372
severe	O	-1	3833372
hypertension	B-Disease	D006973	3833372
.	O	-1	3833372
O@@	O	-1	3833372
ver@@	O	-1	3833372
all@@	O	-1	3833372
,	O	-1	3833372
1@@	O	-1	3833372
,@@	O	-1	3833372
4@@	O	-1	3833372
5@@	O	-1	3833372
3	O	-1	3833372
patients	O	-1	3833372
experienced	O	-1	3833372
a	O	-1	3833372
total	O	-1	3833372
of	O	-1	3833372
2@@	O	-1	3833372
,@@	O	-1	3833372
6@@	O	-1	3833372
5@@	O	-1	3833372
8	O	-1	3833372
adverse	O	-1	3833372
event@@	O	-1	3833372
s,	O	-1	3833372
the	O	-1	3833372
most	O	-1	3833372
common	O	-1	3833372
being	O	-1	3833372
f@@	B-Disease	D005221	3833372
ati@@	I-Disease	-1	3833372
gu@@	I-Disease	-1	3833372
e	I-Disease	-1	3833372
,	O	-1	3833372
di@@	B-Disease	D004244	3833372
z@@	I-Disease	-1	3833372
z@@	I-Disease	-1	3833372
in@@	I-Disease	-1	3833372
ess	I-Disease	-1	3833372
,	O	-1	3833372
and	O	-1	3833372
we@@	B-Disease	D018908	3833372
ak@@	I-Disease	-1	3833372
ness	I-Disease	-1	3833372
.	O	-1	3833372
Treat@@	O	-1	3833372
ment	O	-1	3833372
in	O	-1	3833372
5@@	O	-1	3833372
9@@	O	-1	3833372
0	O	-1	3833372
patients	O	-1	3833372
was	O	-1	3833372
discontinu@@	O	-1	3833372
ed	O	-1	3833372
because	O	-1	3833372
of	O	-1	3833372
adverse	O	-1	3833372
event@@	O	-1	3833372
s.	O	-1	3833372

S@@	B-Chemical	D012459	3864191
al@@	I-Chemical	-1	3864191
ic@@	I-Chemical	-1	3864191
yl@@	I-Chemical	-1	3864191
ate	I-Chemical	-1	3864191
nephro@@	B-Disease	D007674	3864191
pathy	I-Disease	-1	3864191
in	O	-1	3864191
the	O	-1	3864191
G@@	O	-1	3864191
un@@	O	-1	3864191
n	O	-1	3864191
rat@@	O	-1	3864191
:	O	-1	3864191
potential	O	-1	3864191
role	O	-1	3864191
of	O	-1	3864191
pro@@	B-Chemical	D011453	3864191
st@@	I-Chemical	-1	3864191
ag@@	I-Chemical	-1	3864191
l@@	I-Chemical	-1	3864191
and@@	I-Chemical	-1	3864191
ins	I-Chemical	-1	3864191
.	O	-1	3864191
We	O	-1	3864191
examined	O	-1	3864191
the	O	-1	3864191
potential	O	-1	3864191
role	O	-1	3864191
of	O	-1	3864191
pro@@	B-Chemical	D011453	3864191
st@@	I-Chemical	-1	3864191
ag@@	I-Chemical	-1	3864191
l@@	I-Chemical	-1	3864191
and@@	I-Chemical	-1	3864191
ins	I-Chemical	-1	3864191
in	O	-1	3864191
the	O	-1	3864191
development	O	-1	3864191
of	O	-1	3864191
analge@@	O	-1	3864191
sic	O	-1	3864191
nephro@@	B-Disease	D007674	3864191
pathy	I-Disease	-1	3864191
in	O	-1	3864191
the	O	-1	3864191
G@@	O	-1	3864191
un@@	O	-1	3864191
n	O	-1	3864191
stra@@	O	-1	3864191
in	O	-1	3864191
of	O	-1	3864191
rat@@	O	-1	3864191
.	O	-1	3864191
The	O	-1	3864191
ho@@	O	-1	3864191
mo@@	O	-1	3864191
z@@	O	-1	3864191
y@@	O	-1	3864191
g@@	O	-1	3864191
ous	O	-1	3864191
G@@	O	-1	3864191
un@@	O	-1	3864191
n	O	-1	3864191
rats	O	-1	3864191
have	O	-1	3864191
un@@	O	-1	3864191
con@@	O	-1	3864191
j@@	O	-1	3864191
u@@	O	-1	3864191
g@@	O	-1	3864191
ated	O	-1	3864191
hyper@@	B-Disease	D006932	3864191
bil@@	I-Disease	-1	3864191
i@@	I-Disease	-1	3864191
ru@@	I-Disease	-1	3864191
b@@	I-Disease	-1	3864191
ine@@	I-Disease	-1	3864191
mia	I-Disease	-1	3864191
due	O	-1	3864191
to	O	-1	3864191
the	O	-1	3864191
absence	O	-1	3864191
of	O	-1	3864191
gl@@	B-Chemical	-1	3864191
uc@@	I-Chemical	-1	3864191
uron@@	I-Chemical	-1	3864191
yl	I-Chemical	-1	3864191
trans@@	O	-1	3864191
fer@@	O	-1	3864191
ase,	O	-1	3864191
lead@@	O	-1	3864191
ing	O	-1	3864191
to	O	-1	3864191
mark@@	O	-1	3864191
ed	O	-1	3864191
bil@@	B-Chemical	D001663	3864191
i@@	I-Chemical	-1	3864191
ru@@	I-Chemical	-1	3864191
bin	I-Chemical	-1	3864191
de@@	O	-1	3864191
posi@@	O	-1	3864191
tion	O	-1	3864191
in	O	-1	3864191
renal	O	-1	3864191
med@@	O	-1	3864191
ul@@	O	-1	3864191
l@@	O	-1	3864191
a	O	-1	3864191
and	O	-1	3864191
pap@@	O	-1	3864191
ill@@	O	-1	3864191
a.	O	-1	3864191
These	O	-1	3864191
rats	O	-1	3864191
are	O	-1	3864191
also	O	-1	3864191
high@@	O	-1	3864191
ly	O	-1	3864191
sus@@	O	-1	3864191
cep@@	O	-1	3864191
ti@@	O	-1	3864191
ble	O	-1	3864191
to	O	-1	3864191
deve@@	O	-1	3864191
lo@@	O	-1	3864191
p	O	-1	3864191
pap@@	B-Disease	D007681	3864191
ill@@	I-Disease	-1	3864191
ary	I-Disease	-1	3864191
necro@@	I-Disease	-1	3864191
sis	I-Disease	-1	3864191
with	O	-1	3864191
analge@@	O	-1	3864191
sic	O	-1	3864191
administr@@	O	-1	3864191
ation.	O	-1	3864191
We	O	-1	3864191
used	O	-1	3864191
ho@@	O	-1	3864191
mo@@	O	-1	3864191
z@@	O	-1	3864191
y@@	O	-1	3864191
g@@	O	-1	3864191
ous	O	-1	3864191
(@@	O	-1	3864191
j@@	O	-1	3864191
j@@	O	-1	3864191
)	O	-1	3864191
and	O	-1	3864191
phen@@	O	-1	3864191
ot@@	O	-1	3864191
yp@@	O	-1	3864191
ically	O	-1	3864191
normal	O	-1	3864191
he@@	O	-1	3864191
ter@@	O	-1	3864191
o@@	O	-1	3864191
z@@	O	-1	3864191
y@@	O	-1	3864191
g@@	O	-1	3864191
ous	O	-1	3864191
(@@	O	-1	3864191
j@@	O	-1	3864191
J@@	O	-1	3864191
)	O	-1	3864191
anim@@	O	-1	3864191
al@@	O	-1	3864191
s.	O	-1	3864191
F@@	O	-1	3864191
our	O	-1	3864191
groups	O	-1	3864191
of	O	-1	3864191
rats	O	-1	3864191
(n	O	-1	3864191
=	O	-1	3864191
7@@	O	-1	3864191
)	O	-1	3864191
were	O	-1	3864191
studi@@	O	-1	3864191
ed@@	O	-1	3864191
:	O	-1	3864191
j@@	O	-1	3864191
j	O	-1	3864191
and	O	-1	3864191
j@@	O	-1	3864191
J	O	-1	3864191
rats	O	-1	3864191
treated	O	-1	3864191
either	O	-1	3864191
with	O	-1	3864191
as@@	B-Chemical	D001241	3864191
pi@@	I-Chemical	-1	3864191
rin	I-Chemical	-1	3864191
3@@	O	-1	3864191
00	O	-1	3864191
mg/kg	O	-1	3864191
every	O	-1	3864191
other	O	-1	3864191
day	O	-1	3864191
or	O	-1	3864191
sh@@	O	-1	3864191
am@@	O	-1	3864191
-@@	O	-1	3864191
treat@@	O	-1	3864191
ed.	O	-1	3864191
After	O	-1	3864191
one	O	-1	3864191
week@@	O	-1	3864191
,	O	-1	3864191
s@@	O	-1	3864191
l@@	O	-1	3864191
ic@@	O	-1	3864191
es	O	-1	3864191
of	O	-1	3864191
cor@@	O	-1	3864191
t@@	O	-1	3864191
ex@@	O	-1	3864191
,	O	-1	3864191
ou@@	O	-1	3864191
ter	O	-1	3864191
and	O	-1	3864191
in@@	O	-1	3864191
n@@	O	-1	3864191
er	O	-1	3864191
med@@	O	-1	3864191
ul@@	O	-1	3864191
l@@	O	-1	3864191
a	O	-1	3864191
from	O	-1	3864191
one	O	-1	3864191
kidney	O	-1	3864191
were	O	-1	3864191
inc@@	O	-1	3864191
ub@@	O	-1	3864191
ated	O	-1	3864191
in	O	-1	3864191
bu@@	O	-1	3864191
ff@@	O	-1	3864191
er	O	-1	3864191
and	O	-1	3864191
pro@@	B-Chemical	D011453	3864191
st@@	I-Chemical	-1	3864191
ag@@	I-Chemical	-1	3864191
l@@	I-Chemical	-1	3864191
and@@	I-Chemical	-1	3864191
in	I-Chemical	-1	3864191
syn@@	O	-1	3864191
thesis	O	-1	3864191
was	O	-1	3864191
determined	O	-1	3864191
by	O	-1	3864191
radi@@	O	-1	3864191
o@@	O	-1	3864191
immuno@@	O	-1	3864191
ass@@	O	-1	3864191
a@@	O	-1	3864191
y.	O	-1	3864191
The	O	-1	3864191
other	O	-1	3864191
kidney	O	-1	3864191
was	O	-1	3864191
examined	O	-1	3864191
hist@@	O	-1	3864191
olog@@	O	-1	3864191
ic@@	O	-1	3864191
all@@	O	-1	3864191
y.	O	-1	3864191
A	O	-1	3864191
mark@@	O	-1	3864191
ed	O	-1	3864191
cortico@@	O	-1	3864191
med@@	O	-1	3864191
ul@@	O	-1	3864191
l@@	O	-1	3864191
ary	O	-1	3864191
gra@@	O	-1	3864191
di@@	O	-1	3864191
ent	O	-1	3864191
of	O	-1	3864191
pro@@	B-Chemical	D011453	3864191
st@@	I-Chemical	-1	3864191
ag@@	I-Chemical	-1	3864191
l@@	I-Chemical	-1	3864191
and@@	I-Chemical	-1	3864191
in	I-Chemical	-1	3864191
syn@@	O	-1	3864191
thesis	O	-1	3864191
was	O	-1	3864191
observed	O	-1	3864191
in	O	-1	3864191
all	O	-1	3864191
groups.	O	-1	3864191
PG@@	B-Chemical	D015232	3864191
E@@	I-Chemical	-1	3864191
2	I-Chemical	-1	3864191
syn@@	O	-1	3864191
thesis	O	-1	3864191
was	O	-1	3864191
significantly	O	-1	3864191
higher	O	-1	3864191
in	O	-1	3864191
ou@@	O	-1	3864191
ter	O	-1	3864191
med@@	O	-1	3864191
ul@@	O	-1	3864191
l@@	O	-1	3864191
a,	O	-1	3864191
but	O	-1	3864191
not	O	-1	3864191
cor@@	O	-1	3864191
te@@	O	-1	3864191
x	O	-1	3864191
or	O	-1	3864191
in@@	O	-1	3864191
n@@	O	-1	3864191
er	O	-1	3864191
med@@	O	-1	3864191
ul@@	O	-1	3864191
l@@	O	-1	3864191
a,	O	-1	3864191
of	O	-1	3864191
j@@	O	-1	3864191
j	O	-1	3864191
(3@@	O	-1	3864191
8	O	-1	3864191
+/-	O	-1	3864191
6	O	-1	3864191
n@@	O	-1	3864191
g/@@	O	-1	3864191
mg	O	-1	3864191
prot@@	O	-1	3864191
)	O	-1	3864191
than	O	-1	3864191
j@@	O	-1	3864191
J	O	-1	3864191
rats	O	-1	3864191
(1@@	O	-1	3864191
5	O	-1	3864191
+/-	O	-1	3864191
3@@	O	-1	3864191
)	O	-1	3864191
(p	O	-1	3864191
less	O	-1	3864191
than	O	-1	3864191
0.0@@	O	-1	3864191
1).	O	-1	3864191
A@@	B-Chemical	D001241	3864191
s@@	I-Chemical	-1	3864191
pi@@	I-Chemical	-1	3864191
rin	I-Chemical	-1	3864191
treatment	O	-1	3864191
reduced	O	-1	3864191
PG@@	B-Chemical	D015232	3864191
E@@	I-Chemical	-1	3864191
2	I-Chemical	-1	3864191
syn@@	O	-1	3864191
thesis	O	-1	3864191
in	O	-1	3864191
all	O	-1	3864191
regi@@	O	-1	3864191
on@@	O	-1	3864191
s,	O	-1	3864191
but	O	-1	3864191
ou@@	O	-1	3864191
ter	O	-1	3864191
med@@	O	-1	3864191
ul@@	O	-1	3864191
l@@	O	-1	3864191
ary	O	-1	3864191
PG@@	B-Chemical	D015232	3864191
E@@	I-Chemical	-1	3864191
2	I-Chemical	-1	3864191
remained	O	-1	3864191
higher	O	-1	3864191
in	O	-1	3864191
j@@	O	-1	3864191
j	O	-1	3864191
(1@@	O	-1	3864191
8	O	-1	3864191
+/-	O	-1	3864191
3@@	O	-1	3864191
)	O	-1	3864191
than	O	-1	3864191
j@@	O	-1	3864191
J	O	-1	3864191
rats	O	-1	3864191
(@@	O	-1	3864191
9	O	-1	3864191
+/-	O	-1	3864191
2)	O	-1	3864191
(p	O	-1	3864191
less	O	-1	3864191
than	O	-1	3864191
0.05@@	O	-1	3864191
).	O	-1	3864191
PG@@	B-Chemical	D015237	3864191
F@@	I-Chemical	-1	3864191
2	I-Chemical	-1	3864191
al@@	I-Chemical	-1	3864191
ph@@	I-Chemical	-1	3864191
a	I-Chemical	-1	3864191
was	O	-1	3864191
also	O	-1	3864191
significantly	O	-1	3864191
higher	O	-1	3864191
in	O	-1	3864191
the	O	-1	3864191
ou@@	O	-1	3864191
ter	O	-1	3864191
med@@	O	-1	3864191
ul@@	O	-1	3864191
l@@	O	-1	3864191
a	O	-1	3864191
of	O	-1	3864191
j@@	O	-1	3864191
j	O	-1	3864191
rats	O	-1	3864191
with	O	-1	3864191
and	O	-1	3864191
without	O	-1	3864191
as@@	B-Chemical	D001241	3864191
pi@@	I-Chemical	-1	3864191
rin	I-Chemical	-1	3864191
administration	O	-1	3864191
(p	O	-1	3864191
less	O	-1	3864191
than	O	-1	3864191
0.05@@	O	-1	3864191
).	O	-1	3864191
The	O	-1	3864191
changes	O	-1	3864191
in	O	-1	3864191
renal	O	-1	3864191
pro@@	B-Chemical	D011453	3864191
st@@	I-Chemical	-1	3864191
ag@@	I-Chemical	-1	3864191
l@@	I-Chemical	-1	3864191
and@@	I-Chemical	-1	3864191
in	I-Chemical	-1	3864191
syn@@	O	-1	3864191
thesis	O	-1	3864191
were	O	-1	3864191
ac@@	O	-1	3864191
comp@@	O	-1	3864191
an@@	O	-1	3864191
ied	O	-1	3864191
by	O	-1	3864191
evidence	O	-1	3864191
of	O	-1	3864191
renal	B-Disease	D007674	3864191
damage	I-Disease	-1	3864191
in	O	-1	3864191
as@@	B-Chemical	D001241	3864191
pi@@	I-Chemical	-1	3864191
rin	I-Chemical	-1	3864191
-treated	O	-1	3864191
j@@	O	-1	3864191
j	O	-1	3864191
but	O	-1	3864191
not	O	-1	3864191
j@@	O	-1	3864191
J	O	-1	3864191
rats	O	-1	3864191
as	O	-1	3864191
ev@@	O	-1	3864191
id@@	O	-1	3864191
enc@@	O	-1	3864191
ed	O	-1	3864191
b@@	O	-1	3864191
y@@	O	-1	3864191
:	O	-1	3864191
increased	O	-1	3864191
incidence	O	-1	3864191
and	O	-1	3864191
severity	O	-1	3864191
of	O	-1	3864191
hemat@@	B-Disease	D006417	3864191
uria	I-Disease	-1	3864191
(p	O	-1	3864191
less	O	-1	3864191
than	O	-1	3864191
0.0@@	O	-1	3864191
1@@	O	-1	3864191
);	O	-1	3864191
increased	O	-1	3864191
serum	O	-1	3864191
creatinine	B-Chemical	D003404	3864191
(p	O	-1	3864191
less	O	-1	3864191
than	O	-1	3864191
0.05@@	O	-1	3864191
);	O	-1	3864191
and	O	-1	3864191
increase	O	-1	3864191
in	O	-1	3864191
ou@@	O	-1	3864191
ter	O	-1	3864191
med@@	O	-1	3864191
ul@@	O	-1	3864191
l@@	O	-1	3864191
ary	O	-1	3864191
histo@@	O	-1	3864191
path@@	O	-1	3864191
ologic	O	-1	3864191
lesions	O	-1	3864191
(p	O	-1	3864191
less	O	-1	3864191
than	O	-1	3864191
0.00@@	O	-1	3864191
5	O	-1	3864191
compared	O	-1	3864191
to	O	-1	3864191
either	O	-1	3864191
sh@@	O	-1	3864191
am@@	O	-1	3864191
-treated	O	-1	3864191
j@@	O	-1	3864191
j	O	-1	3864191
or	O	-1	3864191
as@@	B-Chemical	D001241	3864191
pi@@	I-Chemical	-1	3864191
rin	I-Chemical	-1	3864191
-treated	O	-1	3864191
j@@	O	-1	3864191
J@@	O	-1	3864191
).	O	-1	3864191
These	O	-1	3864191
results	O	-1	3864191
suggest	O	-1	3864191
that	O	-1	3864191
enhanced	O	-1	3864191
pro@@	B-Chemical	D011453	3864191
st@@	I-Chemical	-1	3864191
ag@@	I-Chemical	-1	3864191
l@@	I-Chemical	-1	3864191
and@@	I-Chemical	-1	3864191
in	I-Chemical	-1	3864191
syn@@	O	-1	3864191
thesis	O	-1	3864191
cont@@	O	-1	3864191
ri@@	O	-1	3864191
but@@	O	-1	3864191
es	O	-1	3864191
to	O	-1	3864191
maint@@	O	-1	3864191
en@@	O	-1	3864191
ance	O	-1	3864191
of	O	-1	3864191
renal	O	-1	3864191
function	O	-1	3864191
and	O	-1	3864191
morph@@	O	-1	3864191
ological	O	-1	3864191
in@@	O	-1	3864191
te@@	O	-1	3864191
g@@	O	-1	3864191
r@@	O	-1	3864191
ity,	O	-1	3864191
and	O	-1	3864191
that	O	-1	3864191
inhibition	O	-1	3864191
of	O	-1	3864191
pro@@	B-Chemical	D011453	3864191
st@@	I-Chemical	-1	3864191
ag@@	I-Chemical	-1	3864191
l@@	I-Chemical	-1	3864191
and@@	I-Chemical	-1	3864191
in	I-Chemical	-1	3864191
syn@@	O	-1	3864191
thesis	O	-1	3864191
may	O	-1	3864191
le@@	O	-1	3864191
ad	O	-1	3864191
to	O	-1	3864191
path@@	B-Disease	D058186	3864191
ological	I-Disease	-1	3864191
renal	I-Disease	-1	3864191
med@@	I-Disease	-1	3864191
ul@@	I-Disease	-1	3864191
l@@	I-Disease	-1	3864191
ary	I-Disease	-1	3864191
lesions	I-Disease	-1	3864191
and	O	-1	3864191
deter@@	B-Disease	D007674	3864191
i@@	I-Disease	-1	3864191
or@@	I-Disease	-1	3864191
ation	I-Disease	-1	3864191
of	I-Disease	-1	3864191
renal	I-Disease	-1	3864191
function	I-Disease	-1	3864191
.	O	-1	3864191

Pro@@	O	-1	3895875
phyl@@	O	-1	3895875
ac@@	O	-1	3895875
tic	O	-1	3895875
lidocaine	B-Chemical	D008012	3895875
in	O	-1	3895875
the	O	-1	3895875
early	O	-1	3895875
phase	O	-1	3895875
of	O	-1	3895875
sus@@	O	-1	3895875
p@@	O	-1	3895875
ected	O	-1	3895875
myocardial	B-Disease	D009203	3895875
infarction	I-Disease	-1	3895875
.	O	-1	3895875
F@@	O	-1	3895875
our	O	-1	3895875
h@@	O	-1	3895875
und@@	O	-1	3895875
red	O	-1	3895875
two	O	-1	3895875
patients	O	-1	3895875
with	O	-1	3895875
sus@@	O	-1	3895875
p@@	O	-1	3895875
ected	O	-1	3895875
myocardial	B-Disease	D009203	3895875
infarction	I-Disease	-1	3895875
seen	O	-1	3895875
within	O	-1	3895875
6	O	-1	3895875
hours	O	-1	3895875
of	O	-1	3895875
the	O	-1	3895875
onset	O	-1	3895875
of	O	-1	3895875
symptoms	O	-1	3895875
ent@@	O	-1	3895875
ered	O	-1	3895875
a	O	-1	3895875
double-bl@@	O	-1	3895875
ind	O	-1	3895875
randomized	O	-1	3895875
trial	O	-1	3895875
of	O	-1	3895875
lidocaine	B-Chemical	D008012	3895875
v@@	O	-1	3895875
s	O	-1	3895875
placebo@@	O	-1	3895875
.	O	-1	3895875
D@@	O	-1	3895875
uring	O	-1	3895875
the	O	-1	3895875
1	O	-1	3895875
h@@	O	-1	3895875
our	O	-1	3895875
after	O	-1	3895875
administration	O	-1	3895875
of	O	-1	3895875
the	O	-1	3895875
drug	O	-1	3895875
the	O	-1	3895875
incidence	O	-1	3895875
of	O	-1	3895875
ventricular	B-Disease	D014693	3895875
fibrill@@	I-Disease	-1	3895875
ation	I-Disease	-1	3895875
or	O	-1	3895875
su@@	O	-1	3895875
st@@	O	-1	3895875
ained	O	-1	3895875
ventricular	B-Disease	D017180	3895875
tachycardia	I-Disease	-1	3895875
among	O	-1	3895875
the	O	-1	3895875
20@@	O	-1	3895875
4	O	-1	3895875
patients	O	-1	3895875
with	O	-1	3895875
acute	O	-1	3895875
myocardial	B-Disease	D009203	3895875
infarction	I-Disease	-1	3895875
was	O	-1	3895875
low@@	O	-1	3895875
,	O	-1	3895875
1.@@	O	-1	3895875
5@@	O	-1	3895875
%.	O	-1	3895875
L@@	B-Chemical	D008012	3895875
idoc@@	I-Chemical	-1	3895875
aine	I-Chemical	-1	3895875
,	O	-1	3895875
given	O	-1	3895875
in	O	-1	3895875
a	O	-1	3895875
3@@	O	-1	3895875
00	O	-1	3895875
mg	O	-1	3895875
dose	O	-1	3895875
int@@	O	-1	3895875
ram@@	O	-1	3895875
us@@	O	-1	3895875
cul@@	O	-1	3895875
arly	O	-1	3895875
followed	O	-1	3895875
by	O	-1	3895875
100	O	-1	3895875
mg	O	-1	3895875
intra@@	O	-1	3895875
ven@@	O	-1	3895875
ous@@	O	-1	3895875
ly,	O	-1	3895875
did	O	-1	3895875
not	O	-1	3895875
prev@@	O	-1	3895875
ent	O	-1	3895875
su@@	O	-1	3895875
st@@	O	-1	3895875
ained	O	-1	3895875
ventricular	B-Disease	D017180	3895875
tachycardia	I-Disease	-1	3895875
,	O	-1	3895875
although	O	-1	3895875
there	O	-1	3895875
was	O	-1	3895875
a	O	-1	3895875
significant	O	-1	3895875
reduction	O	-1	3895875
in	O	-1	3895875
the	O	-1	3895875
number	O	-1	3895875
of	O	-1	3895875
patients	O	-1	3895875
with	O	-1	3895875
war@@	O	-1	3895875
ning	O	-1	3895875
arrhyth@@	B-Disease	D001145	3895875
mi@@	I-Disease	-1	3895875
as	I-Disease	-1	3895875
between	O	-1	3895875
15	O	-1	3895875
and	O	-1	3895875
4@@	O	-1	3895875
5	O	-1	3895875
minutes	O	-1	3895875
after	O	-1	3895875
the	O	-1	3895875
administration	O	-1	3895875
of	O	-1	3895875
lidocaine	B-Chemical	D008012	3895875
(p	O	-1	3895875
less	O	-1	3895875
than	O	-1	3895875
0.05@@	O	-1	3895875
).	O	-1	3895875
The	O	-1	3895875
average	O	-1	3895875
plasma	O	-1	3895875
lidocaine	B-Chemical	D008012	3895875
level	O	-1	3895875
10	O	-1	3895875
minutes	O	-1	3895875
after	O	-1	3895875
administration	O	-1	3895875
for	O	-1	3895875
patients	O	-1	3895875
without	O	-1	3895875
a	O	-1	3895875
myocardial	B-Disease	D009203	3895875
infarction	I-Disease	-1	3895875
was	O	-1	3895875
significantly	O	-1	3895875
higher	O	-1	3895875
than	O	-1	3895875
that	O	-1	3895875
for	O	-1	3895875
patients	O	-1	3895875
with	O	-1	3895875
an	O	-1	3895875
acute	O	-1	3895875
infarction	B-Disease	D007238	3895875
.	O	-1	3895875
The	O	-1	3895875
mean	O	-1	3895875
plasma	O	-1	3895875
lidocaine	B-Chemical	D008012	3895875
level	O	-1	3895875
of	O	-1	3895875
patients	O	-1	3895875
on	O	-1	3895875
beta-@@	O	-1	3895875
block@@	O	-1	3895875
ing	O	-1	3895875
agents	O	-1	3895875
was	O	-1	3895875
no	O	-1	3895875
different	O	-1	3895875
from	O	-1	3895875
that	O	-1	3895875
in	O	-1	3895875
patients	O	-1	3895875
not	O	-1	3895875
on	O	-1	3895875
bet@@	O	-1	3895875
a	O	-1	3895875
block@@	O	-1	3895875
ing	O	-1	3895875
agent@@	O	-1	3895875
s.	O	-1	3895875
D@@	O	-1	3895875
uring	O	-1	3895875
the	O	-1	3895875
1-@@	O	-1	3895875
h@@	O	-1	3895875
our	O	-1	3895875
study	O	-1	3895875
perio@@	O	-1	3895875
d,	O	-1	3895875
the	O	-1	3895875
incidence	O	-1	3895875
of	O	-1	3895875
central	O	-1	3895875
ner@@	O	-1	3895875
v@@	O	-1	3895875
ous	O	-1	3895875
system	O	-1	3895875
side	O	-1	3895875
effects	O	-1	3895875
was	O	-1	3895875
significantly	O	-1	3895875
greater	O	-1	3895875
in	O	-1	3895875
the	O	-1	3895875
lidocaine	B-Chemical	D008012	3895875
group@@	O	-1	3895875
,	O	-1	3895875
hypotension	B-Disease	D007022	3895875
occurred	O	-1	3895875
in	O	-1	3895875
11	O	-1	3895875
patients,	O	-1	3895875
n@@	O	-1	3895875
ine	O	-1	3895875
of	O	-1	3895875
whom	O	-1	3895875
had	O	-1	3895875
received	O	-1	3895875
lidocaine	B-Chemical	D008012	3895875
,	O	-1	3895875
and	O	-1	3895875
four	O	-1	3895875
patients	O	-1	3895875
di@@	O	-1	3895875
ed	O	-1	3895875
from	O	-1	3895875
as@@	B-Disease	D006323	3895875
y@@	I-Disease	-1	3895875
st@@	I-Disease	-1	3895875
ole	I-Disease	-1	3895875
,	O	-1	3895875
three	O	-1	3895875
of	O	-1	3895875
whom	O	-1	3895875
had	O	-1	3895875
had	O	-1	3895875
lidocaine	B-Chemical	D008012	3895875
.	O	-1	3895875
We	O	-1	3895875
can@@	O	-1	3895875
not	O	-1	3895875
adv@@	O	-1	3895875
oc@@	O	-1	3895875
ate	O	-1	3895875
the	O	-1	3895875
administration	O	-1	3895875
of	O	-1	3895875
lidocaine	B-Chemical	D008012	3895875
pro@@	O	-1	3895875
phyl@@	O	-1	3895875
ac@@	O	-1	3895875
tically	O	-1	3895875
in	O	-1	3895875
the	O	-1	3895875
early	O	-1	3895875
hours	O	-1	3895875
of	O	-1	3895875
sus@@	O	-1	3895875
p@@	O	-1	3895875
ected	O	-1	3895875
myocardial	B-Disease	D009203	3895875
infarction	I-Disease	-1	3895875
.	O	-1	3895875

E@@	O	-1	3925479
v@@	O	-1	3925479
idence	O	-1	3925479
for	O	-1	3925479
a	O	-1	3925479
cholinergic	O	-1	3925479
role	O	-1	3925479
in	O	-1	3925479
haloperidol	B-Chemical	D006220	3925479
-induced	O	-1	3925479
cat@@	B-Disease	D002375	3925479
al@@	I-Disease	-1	3925479
ep@@	I-Disease	-1	3925479
sy	I-Disease	-1	3925479
.	O	-1	3925479
E@@	O	-1	3925479
x@@	O	-1	3925479
per@@	O	-1	3925479
im@@	O	-1	3925479
ents	O	-1	3925479
in	O	-1	3925479
mice	O	-1	3925479
tested	O	-1	3925479
previ@@	O	-1	3925479
ous	O	-1	3925479
evidence	O	-1	3925479
that	O	-1	3925479
activation	O	-1	3925479
of	O	-1	3925479
cholinergic	O	-1	3925479
system@@	O	-1	3925479
s	O	-1	3925479
pro@@	O	-1	3925479
m@@	O	-1	3925479
ot@@	O	-1	3925479
es	O	-1	3925479
cat@@	B-Disease	D002375	3925479
al@@	I-Disease	-1	3925479
ep@@	I-Disease	-1	3925479
sy	I-Disease	-1	3925479
and	O	-1	3925479
that	O	-1	3925479
cholinergic	O	-1	3925479
mechanisms	O	-1	3925479
need	O	-1	3925479
to	O	-1	3925479
be	O	-1	3925479
int@@	O	-1	3925479
ac@@	O	-1	3925479
t	O	-1	3925479
for	O	-1	3925479
ful@@	O	-1	3925479
l	O	-1	3925479
expression	O	-1	3925479
of	O	-1	3925479
neuro@@	B-Chemical	D014150	3925479
le@@	I-Chemical	-1	3925479
p@@	I-Chemical	-1	3925479
tic	I-Chemical	-1	3925479
-induced	O	-1	3925479
cat@@	B-Disease	D002375	3925479
al@@	I-Disease	-1	3925479
ep@@	I-Disease	-1	3925479
sy	I-Disease	-1	3925479
.	O	-1	3925479
L@@	O	-1	3925479
arg@@	O	-1	3925479
e	O	-1	3925479
doses	O	-1	3925479
of	O	-1	3925479
the	O	-1	3925479
chol@@	O	-1	3925479
in@@	O	-1	3925479
om@@	O	-1	3925479
i@@	O	-1	3925479
me@@	O	-1	3925479
tic@@	O	-1	3925479
,	O	-1	3925479
pilocar@@	B-Chemical	D010862	3925479
pine	I-Chemical	-1	3925479
,	O	-1	3925479
could	O	-1	3925479
induce	O	-1	3925479
cat@@	B-Disease	D002375	3925479
al@@	I-Disease	-1	3925479
ep@@	I-Disease	-1	3925479
sy	I-Disease	-1	3925479
when	O	-1	3925479
peripheral	O	-1	3925479
cholinergic	O	-1	3925479
receptors	O	-1	3925479
were	O	-1	3925479
block@@	O	-1	3925479
ed.	O	-1	3925479
L@@	O	-1	3925479
o@@	O	-1	3925479
w	O	-1	3925479
doses	O	-1	3925479
of	O	-1	3925479
pilocar@@	B-Chemical	D010862	3925479
pine	I-Chemical	-1	3925479
caused	O	-1	3925479
a	O	-1	3925479
p@@	O	-1	3925479
ron@@	O	-1	3925479
oun@@	O	-1	3925479
c@@	O	-1	3925479
ed	O	-1	3925479
enh@@	O	-1	3925479
ance@@	O	-1	3925479
ment	O	-1	3925479
of	O	-1	3925479
the	O	-1	3925479
cat@@	B-Disease	D002375	3925479
al@@	I-Disease	-1	3925479
ep@@	I-Disease	-1	3925479
sy	I-Disease	-1	3925479
that	O	-1	3925479
was	O	-1	3925479
induced	O	-1	3925479
by	O	-1	3925479
the	O	-1	3925479
dop@@	O	-1	3925479
aminergic	O	-1	3925479
block@@	O	-1	3925479
er,	O	-1	3925479
haloperidol	B-Chemical	D006220	3925479
.	O	-1	3925479
A	O	-1	3925479
mus@@	O	-1	3925479
car@@	O	-1	3925479
inic	O	-1	3925479
receptor	O	-1	3925479
block@@	O	-1	3925479
er,	O	-1	3925479
atro@@	B-Chemical	D001285	3925479
pine	I-Chemical	-1	3925479
,	O	-1	3925479
dis@@	O	-1	3925479
ru@@	O	-1	3925479
pt@@	O	-1	3925479
ed	O	-1	3925479
haloperidol	B-Chemical	D006220	3925479
-induced	O	-1	3925479
cat@@	B-Disease	D002375	3925479
al@@	I-Disease	-1	3925479
ep@@	I-Disease	-1	3925479
sy	I-Disease	-1	3925479
.	O	-1	3925479
In@@	O	-1	3925479
trac@@	O	-1	3925479
ranial	O	-1	3925479
injection	O	-1	3925479
of	O	-1	3925479
an	O	-1	3925479
acet@@	B-Chemical	D000109	3925479
ylcholine	I-Chemical	-1	3925479
-@@	O	-1	3925479
syn@@	O	-1	3925479
thesis	O	-1	3925479
inhibitor@@	O	-1	3925479
,	O	-1	3925479
he@@	B-Chemical	D006426	3925479
mic@@	I-Chemical	-1	3925479
h@@	I-Chemical	-1	3925479
ol@@	I-Chemical	-1	3925479
in@@	I-Chemical	-1	3925479
i@@	I-Chemical	-1	3925479
um	I-Chemical	-1	3925479
,	O	-1	3925479
prevent@@	O	-1	3925479
ed	O	-1	3925479
the	O	-1	3925479
cat@@	B-Disease	D002375	3925479
al@@	I-Disease	-1	3925479
ep@@	I-Disease	-1	3925479
sy	I-Disease	-1	3925479
that	O	-1	3925479
is	O	-1	3925479
us@@	O	-1	3925479
ually	O	-1	3925479
induced	O	-1	3925479
by	O	-1	3925479
haloperidol	B-Chemical	D006220	3925479
.	O	-1	3925479
These	O	-1	3925479
findings	O	-1	3925479
suggest	O	-1	3925479
the	O	-1	3925479
hypo@@	O	-1	3925479
thesis	O	-1	3925479
that	O	-1	3925479
the	O	-1	3925479
cat@@	B-Disease	D002375	3925479
al@@	I-Disease	-1	3925479
ep@@	I-Disease	-1	3925479
sy	I-Disease	-1	3925479
that	O	-1	3925479
is	O	-1	3925479
produced	O	-1	3925479
by	O	-1	3925479
neuro@@	B-Chemical	D014150	3925479
le@@	I-Chemical	-1	3925479
p@@	I-Chemical	-1	3925479
tics	I-Chemical	-1	3925479
such	O	-1	3925479
as	O	-1	3925479
haloperidol	B-Chemical	D006220	3925479
is	O	-1	3925479
act@@	O	-1	3925479
ually	O	-1	3925479
mediated	O	-1	3925479
by	O	-1	3925479
int@@	O	-1	3925479
r@@	O	-1	3925479
in@@	O	-1	3925479
sic	O	-1	3925479
central	O	-1	3925479
cholinergic	O	-1	3925479
system@@	O	-1	3925479
s.	O	-1	3925479
Al@@	O	-1	3925479
tern@@	O	-1	3925479
ati@@	O	-1	3925479
vel@@	O	-1	3925479
y,	O	-1	3925479
activation	O	-1	3925479
of	O	-1	3925479
central	O	-1	3925479
cholinergic	O	-1	3925479
system@@	O	-1	3925479
s	O	-1	3925479
could	O	-1	3925479
pro@@	O	-1	3925479
m@@	O	-1	3925479
ot@@	O	-1	3925479
e	O	-1	3925479
cat@@	B-Disease	D002375	3925479
al@@	I-Disease	-1	3925479
ep@@	I-Disease	-1	3925479
sy	I-Disease	-1	3925479
by	O	-1	3925479
sup@@	O	-1	3925479
pression	O	-1	3925479
of	O	-1	3925479
dop@@	O	-1	3925479
aminergic	O	-1	3925479
system@@	O	-1	3925479
s.	O	-1	3925479

C@@	B-Disease	D002318	3975902
ardi@@	I-Disease	-1	3975902
o@@	I-Disease	-1	3975902
vascular	I-Disease	-1	3975902
dysfunction	I-Disease	-1	3975902
and	O	-1	3975902
hyper@@	B-Disease	D004342	3975902
sensitivity	I-Disease	-1	3975902
to	O	-1	3975902
sodium	B-Chemical	D010424	3975902
pent@@	I-Chemical	-1	3975902
obarbit@@	I-Chemical	-1	3975902
al	I-Chemical	-1	3975902
induced	O	-1	3975902
by	O	-1	3975902
chronic	O	-1	3975902
b@@	B-Chemical	C024986	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
chlor@@	I-Chemical	-1	3975902
ide	I-Chemical	-1	3975902
ing@@	O	-1	3975902
es@@	O	-1	3975902
tion.	O	-1	3975902
B@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
-@@	O	-1	3975902
sup@@	O	-1	3975902
ple@@	O	-1	3975902
ment@@	O	-1	3975902
ed	O	-1	3975902
L@@	O	-1	3975902
on@@	O	-1	3975902
g@@	O	-1	3975902
-@@	O	-1	3975902
E@@	O	-1	3975902
v@@	O	-1	3975902
ans	O	-1	3975902
ho@@	O	-1	3975902
o@@	O	-1	3975902
ded	O	-1	3975902
rats	O	-1	3975902
were	O	-1	3975902
character@@	O	-1	3975902
ized	O	-1	3975902
by	O	-1	3975902
a	O	-1	3975902
per@@	O	-1	3975902
sist@@	O	-1	3975902
ent	O	-1	3975902
hypertension	B-Disease	D006973	3975902
that	O	-1	3975902
was	O	-1	3975902
ev@@	O	-1	3975902
id@@	O	-1	3975902
ent	O	-1	3975902
after	O	-1	3975902
1	O	-1	3975902
mon@@	O	-1	3975902
th	O	-1	3975902
of	O	-1	3975902
b@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
(@@	O	-1	3975902
100	O	-1	3975902
microgram@@	O	-1	3975902
s/@@	O	-1	3975902
m@@	O	-1	3975902
l	O	-1	3975902
min@@	O	-1	3975902
eral	O	-1	3975902
for@@	O	-1	3975902
ti@@	O	-1	3975902
fied	O	-1	3975902
w@@	O	-1	3975902
at@@	O	-1	3975902
er@@	O	-1	3975902
)	O	-1	3975902
treatment.	O	-1	3975902
An@@	O	-1	3975902
aly@@	O	-1	3975902
sis	O	-1	3975902
of	O	-1	3975902
in	O	-1	3975902
viv@@	O	-1	3975902
o	O	-1	3975902
myocardial	O	-1	3975902
ex@@	O	-1	3975902
cit@@	O	-1	3975902
abil@@	O	-1	3975902
ity,	O	-1	3975902
contrac@@	O	-1	3975902
ti@@	O	-1	3975902
lit@@	O	-1	3975902
y,	O	-1	3975902
and	O	-1	3975902
met@@	O	-1	3975902
ab@@	O	-1	3975902
olic	O	-1	3975902
character@@	O	-1	3975902
is@@	O	-1	3975902
tics	O	-1	3975902
at	O	-1	3975902
16	O	-1	3975902
months	O	-1	3975902
revealed	O	-1	3975902
other	O	-1	3975902
significant	O	-1	3975902
b@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
-induced	O	-1	3975902
dist@@	B-Disease	D002318	3975902
urb@@	I-Disease	-1	3975902
anc@@	I-Disease	-1	3975902
es	I-Disease	-1	3975902
within	I-Disease	-1	3975902
the	I-Disease	-1	3975902
cardiovascular	I-Disease	-1	3975902
system	I-Disease	-1	3975902
.	O	-1	3975902
The	O	-1	3975902
most	O	-1	3975902
dist@@	O	-1	3975902
inc@@	O	-1	3975902
tive	O	-1	3975902
as@@	O	-1	3975902
p@@	O	-1	3975902
ect	O	-1	3975902
of	O	-1	3975902
the	O	-1	3975902
b@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
effect	O	-1	3975902
was	O	-1	3975902
a	O	-1	3975902
demonstrated	O	-1	3975902
hyper@@	B-Disease	D004342	3975902
sensitivity	I-Disease	-1	3975902
of	O	-1	3975902
the	O	-1	3975902
cardiovascular	O	-1	3975902
system	O	-1	3975902
to	O	-1	3975902
sodium	B-Chemical	D010424	3975902
pent@@	I-Chemical	-1	3975902
obarbit@@	I-Chemical	-1	3975902
al	I-Chemical	-1	3975902
.	O	-1	3975902
U@@	O	-1	3975902
n@@	O	-1	3975902
der	O	-1	3975902
b@@	B-Chemical	C032232	3975902
arbit@@	I-Chemical	-1	3975902
ur@@	I-Chemical	-1	3975902
ate	I-Chemical	-1	3975902
anesthe@@	O	-1	3975902
si@@	O	-1	3975902
a,	O	-1	3975902
vi@@	O	-1	3975902
r@@	O	-1	3975902
tu@@	O	-1	3975902
ally	O	-1	3975902
all	O	-1	3975902
of	O	-1	3975902
the	O	-1	3975902
myocardial	O	-1	3975902
contrac@@	O	-1	3975902
ti@@	O	-1	3975902
le	O	-1	3975902
indic@@	O	-1	3975902
es	O	-1	3975902
were	O	-1	3975902
depress@@	O	-1	3975902
ed	O	-1	3975902
significantly	O	-1	3975902
in	O	-1	3975902
b@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
-@@	O	-1	3975902
exposed	O	-1	3975902
rats	O	-1	3975902
rel@@	O	-1	3975902
ative	O	-1	3975902
to	O	-1	3975902
the	O	-1	3975902
cor@@	O	-1	3975902
respon@@	O	-1	3975902
ding	O	-1	3975902
control@@	O	-1	3975902
-@@	O	-1	3975902
f@@	O	-1	3975902
ed	O	-1	3975902
rats.	O	-1	3975902
The	O	-1	3975902
l@@	O	-1	3975902
ac@@	O	-1	3975902
k	O	-1	3975902
of	O	-1	3975902
a	O	-1	3975902
similar	O	-1	3975902
response	O	-1	3975902
to	O	-1	3975902
k@@	B-Chemical	D007649	3975902
et@@	I-Chemical	-1	3975902
amine	I-Chemical	-1	3975902
and	O	-1	3975902
x@@	B-Chemical	D014991	3975902
yl@@	I-Chemical	-1	3975902
az@@	I-Chemical	-1	3975902
ine	I-Chemical	-1	3975902
anesthe@@	O	-1	3975902
sia	O	-1	3975902
revealed	O	-1	3975902
that	O	-1	3975902
the	O	-1	3975902
cardiovascular	O	-1	3975902
ac@@	O	-1	3975902
tions	O	-1	3975902
of	O	-1	3975902
sodium	B-Chemical	D010424	3975902
pent@@	I-Chemical	-1	3975902
obarbit@@	I-Chemical	-1	3975902
al	I-Chemical	-1	3975902
in	O	-1	3975902
b@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
-treated	O	-1	3975902
rats	O	-1	3975902
were	O	-1	3975902
lin@@	O	-1	3975902
ked	O	-1	3975902
spec@@	O	-1	3975902
ific@@	O	-1	3975902
ally	O	-1	3975902
to	O	-1	3975902
this	O	-1	3975902
anesthe@@	O	-1	3975902
tic@@	O	-1	3975902
,	O	-1	3975902
and	O	-1	3975902
were	O	-1	3975902
not	O	-1	3975902
re@@	O	-1	3975902
present@@	O	-1	3975902
ative	O	-1	3975902
of	O	-1	3975902
a	O	-1	3975902
gener@@	O	-1	3975902
al@@	O	-1	3975902
ized	O	-1	3975902
anesthe@@	O	-1	3975902
tic	O	-1	3975902
respon@@	O	-1	3975902
se.	O	-1	3975902
O@@	O	-1	3975902
ther	O	-1	3975902
myocardial	O	-1	3975902
path@@	O	-1	3975902
oph@@	O	-1	3975902
ysi@@	O	-1	3975902
ologic	O	-1	3975902
and	O	-1	3975902
met@@	O	-1	3975902
ab@@	O	-1	3975902
olic	O	-1	3975902
changes	O	-1	3975902
induced	O	-1	3975902
by	O	-1	3975902
b@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
were	O	-1	3975902
man@@	O	-1	3975902
if@@	O	-1	3975902
est@@	O	-1	3975902
,	O	-1	3975902
ir@@	O	-1	3975902
resp@@	O	-1	3975902
ective	O	-1	3975902
of	O	-1	3975902
the	O	-1	3975902
anesthe@@	O	-1	3975902
tic	O	-1	3975902
em@@	O	-1	3975902
p@@	O	-1	3975902
lo@@	O	-1	3975902
y@@	O	-1	3975902
ed.	O	-1	3975902
The	O	-1	3975902
contrac@@	O	-1	3975902
ti@@	O	-1	3975902
le	O	-1	3975902
e@@	O	-1	3975902
le@@	O	-1	3975902
ment	O	-1	3975902
sh@@	O	-1	3975902
or@@	O	-1	3975902
ten@@	O	-1	3975902
ing	O	-1	3975902
ve@@	O	-1	3975902
loc@@	O	-1	3975902
ity	O	-1	3975902
of	O	-1	3975902
the	O	-1	3975902
cardiac	O	-1	3975902
musc@@	O	-1	3975902
le	O	-1	3975902
fib@@	O	-1	3975902
ers	O	-1	3975902
was	O	-1	3975902
significantly	O	-1	3975902
s@@	O	-1	3975902
lower	O	-1	3975902
in	O	-1	3975902
both	O	-1	3975902
groups	O	-1	3975902
of	O	-1	3975902
b@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
-treated	O	-1	3975902
rats	O	-1	3975902
rel@@	O	-1	3975902
ative	O	-1	3975902
to	O	-1	3975902
the	O	-1	3975902
control	O	-1	3975902
group@@	O	-1	3975902
s,	O	-1	3975902
ir@@	O	-1	3975902
resp@@	O	-1	3975902
ective	O	-1	3975902
of	O	-1	3975902
the	O	-1	3975902
anesthe@@	O	-1	3975902
tic	O	-1	3975902
regimen@@	O	-1	3975902
.	O	-1	3975902
S@@	O	-1	3975902
im@@	O	-1	3975902
il@@	O	-1	3975902
ar@@	O	-1	3975902
ly,	O	-1	3975902
significant	O	-1	3975902
dist@@	O	-1	3975902
urb@@	O	-1	3975902
anc@@	O	-1	3975902
es	O	-1	3975902
in	O	-1	3975902
myocardial	O	-1	3975902
en@@	O	-1	3975902
erg@@	O	-1	3975902
y	O	-1	3975902
metabol@@	O	-1	3975902
ism	O	-1	3975902
were	O	-1	3975902
det@@	O	-1	3975902
ected	O	-1	3975902
in	O	-1	3975902
the	O	-1	3975902
b@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
-@@	O	-1	3975902
exposed	O	-1	3975902
rats	O	-1	3975902
which	O	-1	3975902
were	O	-1	3975902
consist@@	O	-1	3975902
ent	O	-1	3975902
with	O	-1	3975902
the	O	-1	3975902
reduced	O	-1	3975902
contrac@@	O	-1	3975902
ti@@	O	-1	3975902
le	O	-1	3975902
e@@	O	-1	3975902
le@@	O	-1	3975902
ment	O	-1	3975902
sh@@	O	-1	3975902
or@@	O	-1	3975902
ten@@	O	-1	3975902
ing	O	-1	3975902
ve@@	O	-1	3975902
loc@@	O	-1	3975902
ity.	O	-1	3975902
In	O	-1	3975902
addi@@	O	-1	3975902
tion,	O	-1	3975902
the	O	-1	3975902
ex@@	O	-1	3975902
cit@@	O	-1	3975902
ability	O	-1	3975902
of	O	-1	3975902
the	O	-1	3975902
cardiac	O	-1	3975902
con@@	O	-1	3975902
duction	O	-1	3975902
system	O	-1	3975902
was	O	-1	3975902
depress@@	O	-1	3975902
ed	O	-1	3975902
pre@@	O	-1	3975902
fe@@	O	-1	3975902
ren@@	O	-1	3975902
ti@@	O	-1	3975902
ally	O	-1	3975902
in	O	-1	3975902
the	O	-1	3975902
atri@@	O	-1	3975902
o@@	O	-1	3975902
ventricular	O	-1	3975902
no@@	O	-1	3975902
d@@	O	-1	3975902
al	O	-1	3975902
regi@@	O	-1	3975902
on	O	-1	3975902
of	O	-1	3975902
hear@@	O	-1	3975902
ts	O	-1	3975902
from	O	-1	3975902
b@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
-@@	O	-1	3975902
exposed	O	-1	3975902
rats.	O	-1	3975902
O@@	O	-1	3975902
ver@@	O	-1	3975902
all@@	O	-1	3975902
,	O	-1	3975902
the	O	-1	3975902
al@@	O	-1	3975902
te@@	O	-1	3975902
red	O	-1	3975902
cardiac	O	-1	3975902
contrac@@	O	-1	3975902
til@@	O	-1	3975902
ity	O	-1	3975902
and	O	-1	3975902
ex@@	O	-1	3975902
cit@@	O	-1	3975902
ability	O	-1	3975902
character@@	O	-1	3975902
is@@	O	-1	3975902
tic@@	O	-1	3975902
s,	O	-1	3975902
the	O	-1	3975902
myocardial	O	-1	3975902
met@@	B-Disease	D008659	3975902
ab@@	I-Disease	-1	3975902
olic	I-Disease	-1	3975902
dist@@	I-Disease	-1	3975902
urb@@	I-Disease	-1	3975902
anc@@	I-Disease	-1	3975902
es	I-Disease	-1	3975902
,	O	-1	3975902
and	O	-1	3975902
the	O	-1	3975902
hyper@@	B-Disease	D004342	3975902
sensitivity	I-Disease	-1	3975902
of	O	-1	3975902
the	O	-1	3975902
cardiovascular	O	-1	3975902
system	O	-1	3975902
to	O	-1	3975902
sodium	B-Chemical	D010424	3975902
pent@@	I-Chemical	-1	3975902
obarbit@@	I-Chemical	-1	3975902
al	I-Chemical	-1	3975902
suggest	O	-1	3975902
the	O	-1	3975902
ex@@	O	-1	3975902
ist@@	O	-1	3975902
ence	O	-1	3975902
of	O	-1	3975902
a	O	-1	3975902
he@@	O	-1	3975902
re@@	O	-1	3975902
to@@	O	-1	3975902
fore	O	-1	3975902
un@@	O	-1	3975902
descri@@	O	-1	3975902
bed	O	-1	3975902
cardi@@	B-Disease	D009202	3975902
om@@	I-Disease	-1	3975902
yo@@	I-Disease	-1	3975902
path@@	I-Disease	-1	3975902
ic	I-Disease	-1	3975902
disor@@	I-Disease	-1	3975902
der	I-Disease	-1	3975902
induced	O	-1	3975902
by	O	-1	3975902
chronic	O	-1	3975902
b@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
expos@@	O	-1	3975902
ure.	O	-1	3975902
These	O	-1	3975902
experimental	O	-1	3975902
findings	O	-1	3975902
re@@	O	-1	3975902
present	O	-1	3975902
the	O	-1	3975902
first	O	-1	3975902
indic@@	O	-1	3975902
ation	O	-1	3975902
that	O	-1	3975902
lif@@	O	-1	3975902
e-@@	O	-1	3975902
lon@@	O	-1	3975902
g	O	-1	3975902
b@@	B-Chemical	D001464	3975902
ari@@	I-Chemical	-1	3975902
um	I-Chemical	-1	3975902
ing@@	O	-1	3975902
es@@	O	-1	3975902
tion	O	-1	3975902
may	O	-1	3975902
have	O	-1	3975902
significant	O	-1	3975902
adverse	O	-1	3975902
effects	O	-1	3975902
on	O	-1	3975902
the	O	-1	3975902
m@@	O	-1	3975902
am@@	O	-1	3975902
mal@@	O	-1	3975902
i@@	O	-1	3975902
an	O	-1	3975902
cardiovascular	O	-1	3975902
system@@	O	-1	3975902
.	O	-1	3975902

Pro@@	B-Chemical	D011433	3987172
p@@	I-Chemical	-1	3987172
ran@@	I-Chemical	-1	3987172
o@@	I-Chemical	-1	3987172
lol	I-Chemical	-1	3987172
antagon@@	O	-1	3987172
ism	O	-1	3987172
of	O	-1	3987172
phenyl@@	B-Chemical	D010665	3987172
prop@@	I-Chemical	-1	3987172
an@@	I-Chemical	-1	3987172
ol@@	I-Chemical	-1	3987172
amine	I-Chemical	-1	3987172
-induced	O	-1	3987172
hypertension	B-Disease	D006973	3987172
.	O	-1	3987172
Ph@@	B-Chemical	D010665	3987172
en@@	I-Chemical	-1	3987172
yl@@	I-Chemical	-1	3987172
prop@@	I-Chemical	-1	3987172
an@@	I-Chemical	-1	3987172
ol@@	I-Chemical	-1	3987172
amine	I-Chemical	-1	3987172
(	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
)	O	-1	3987172
over@@	B-Disease	D062787	3987172
dose	I-Disease	-1	3987172
can	O	-1	3987172
cause	O	-1	3987172
severe	O	-1	3987172
hypertension	B-Disease	D006973	3987172
,	O	-1	3987172
intrac@@	B-Disease	D002543	3987172
e@@	I-Disease	-1	3987172
rebral	I-Disease	-1	3987172
hemorrh@@	I-Disease	-1	3987172
age	I-Disease	-1	3987172
,	O	-1	3987172
and	O	-1	3987172
de@@	O	-1	3987172
ath@@	O	-1	3987172
.	O	-1	3987172
We	O	-1	3987172
studied	O	-1	3987172
the	O	-1	3987172
efficacy	O	-1	3987172
and	O	-1	3987172
safety	O	-1	3987172
of	O	-1	3987172
prop@@	B-Chemical	D011433	3987172
ran@@	I-Chemical	-1	3987172
o@@	I-Chemical	-1	3987172
lol	I-Chemical	-1	3987172
in	O	-1	3987172
the	O	-1	3987172
treatment	O	-1	3987172
of	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
-induced	O	-1	3987172
hypertension	B-Disease	D006973	3987172
.	O	-1	3987172
S@@	O	-1	3987172
ub@@	O	-1	3987172
j@@	O	-1	3987172
ects	O	-1	3987172
received	O	-1	3987172
prop@@	B-Chemical	D011433	3987172
ran@@	I-Chemical	-1	3987172
o@@	I-Chemical	-1	3987172
lol	I-Chemical	-1	3987172
either	O	-1	3987172
by	O	-1	3987172
mou@@	O	-1	3987172
th	O	-1	3987172
for	O	-1	3987172
4@@	O	-1	3987172
8	O	-1	3987172
hours	O	-1	3987172
before	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
or	O	-1	3987172
as	O	-1	3987172
a	O	-1	3987172
ra@@	O	-1	3987172
pid	O	-1	3987172
intravenous	O	-1	3987172
infusion	O	-1	3987172
after	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
.	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
,	O	-1	3987172
7@@	O	-1	3987172
5	O	-1	3987172
mg	O	-1	3987172
al@@	O	-1	3987172
one,	O	-1	3987172
increased	O	-1	3987172
blood	O	-1	3987172
pressure	O	-1	3987172
(3@@	O	-1	3987172
1	O	-1	3987172
+/-	O	-1	3987172
14	O	-1	3987172
mm	O	-1	3987172
H@@	O	-1	3987172
g	O	-1	3987172
syst@@	O	-1	3987172
ol@@	O	-1	3987172
ic@@	O	-1	3987172
,	O	-1	3987172
20	O	-1	3987172
+/-	O	-1	3987172
5	O	-1	3987172
mm	O	-1	3987172
H@@	O	-1	3987172
g	O	-1	3987172
di@@	O	-1	3987172
ast@@	O	-1	3987172
ol@@	O	-1	3987172
ic@@	O	-1	3987172
),	O	-1	3987172
and	O	-1	3987172
prop@@	B-Chemical	D011433	3987172
ran@@	I-Chemical	-1	3987172
o@@	I-Chemical	-1	3987172
lol	I-Chemical	-1	3987172
pretreatment	O	-1	3987172
antagon@@	O	-1	3987172
ized	O	-1	3987172
this	O	-1	3987172
increase	O	-1	3987172
(1@@	O	-1	3987172
2	O	-1	3987172
+/-	O	-1	3987172
10	O	-1	3987172
mm	O	-1	3987172
H@@	O	-1	3987172
g	O	-1	3987172
syst@@	O	-1	3987172
ol@@	O	-1	3987172
ic@@	O	-1	3987172
,	O	-1	3987172
10	O	-1	3987172
+/-	O	-1	3987172
7	O	-1	3987172
mm	O	-1	3987172
H@@	O	-1	3987172
g	O	-1	3987172
di@@	O	-1	3987172
ast@@	O	-1	3987172
ol@@	O	-1	3987172
ic@@	O	-1	3987172
).	O	-1	3987172
In@@	O	-1	3987172
tra@@	O	-1	3987172
venous	O	-1	3987172
prop@@	B-Chemical	D011433	3987172
ran@@	I-Chemical	-1	3987172
o@@	I-Chemical	-1	3987172
lol	I-Chemical	-1	3987172
after	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
also	O	-1	3987172
decreased	O	-1	3987172
blood	O	-1	3987172
pressu@@	O	-1	3987172
re.	O	-1	3987172
L@@	O	-1	3987172
e@@	O	-1	3987172
ft	O	-1	3987172
ventricular	O	-1	3987172
function	O	-1	3987172
(@@	O	-1	3987172
assessed	O	-1	3987172
by	O	-1	3987172
echocardiograph@@	O	-1	3987172
y@@	O	-1	3987172
)	O	-1	3987172
showed	O	-1	3987172
that	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
increased	O	-1	3987172
the	O	-1	3987172
strok@@	B-Disease	D020521	3987172
e	I-Disease	-1	3987172
volume	O	-1	3987172
3@@	O	-1	3987172
0%	O	-1	3987172
(@@	O	-1	3987172
from	O	-1	3987172
6@@	O	-1	3987172
2.@@	O	-1	3987172
5	O	-1	3987172
+/-	O	-1	3987172
2@@	O	-1	3987172
0.@@	O	-1	3987172
9	O	-1	3987172
to	O	-1	3987172
8@@	O	-1	3987172
0.@@	O	-1	3987172
8	O	-1	3987172
+/-	O	-1	3987172
2@@	O	-1	3987172
2.@@	O	-1	3987172
4	O	-1	3987172
ml@@	O	-1	3987172
),	O	-1	3987172
the	O	-1	3987172
e@@	O	-1	3987172
j@@	O	-1	3987172
ection	O	-1	3987172
frac@@	O	-1	3987172
tion	O	-1	3987172
9@@	O	-1	3987172
%	O	-1	3987172
(@@	O	-1	3987172
from	O	-1	3987172
6@@	O	-1	3987172
4@@	O	-1	3987172
%	O	-1	3987172
+/-	O	-1	3987172
10@@	O	-1	3987172
%	O	-1	3987172
to	O	-1	3987172
7@@	O	-1	3987172
0%	O	-1	3987172
+/-	O	-1	3987172
7@@	O	-1	3987172
%),	O	-1	3987172
and	O	-1	3987172
cardiac	O	-1	3987172
out@@	O	-1	3987172
pu@@	O	-1	3987172
t	O	-1	3987172
14@@	O	-1	3987172
%	O	-1	3987172
(@@	O	-1	3987172
from	O	-1	3987172
3.@@	O	-1	3987172
6	O	-1	3987172
+/-	O	-1	3987172
0.@@	O	-1	3987172
6	O	-1	3987172
to	O	-1	3987172
4.@@	O	-1	3987172
1	O	-1	3987172
+/-	O	-1	3987172
1.@@	O	-1	3987172
0	O	-1	3987172
L@@	O	-1	3987172
/@@	O	-1	3987172
min@@	O	-1	3987172
).	O	-1	3987172
In@@	O	-1	3987172
tra@@	O	-1	3987172
venous	O	-1	3987172
prop@@	B-Chemical	D011433	3987172
ran@@	I-Chemical	-1	3987172
o@@	I-Chemical	-1	3987172
lol	I-Chemical	-1	3987172
reversed	O	-1	3987172
these	O	-1	3987172
effects.	O	-1	3987172
S@@	O	-1	3987172
y@@	O	-1	3987172
st@@	O	-1	3987172
em@@	O	-1	3987172
ic	O	-1	3987172
vascular	O	-1	3987172
resist@@	O	-1	3987172
ance	O	-1	3987172
was	O	-1	3987172
increased	O	-1	3987172
by	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
2@@	O	-1	3987172
8@@	O	-1	3987172
%	O	-1	3987172
(@@	O	-1	3987172
from	O	-1	3987172
17@@	O	-1	3987172
10	O	-1	3987172
+/-	O	-1	3987172
2@@	O	-1	3987172
00	O	-1	3987172
to	O	-1	3987172
2@@	O	-1	3987172
19@@	O	-1	3987172
0	O	-1	3987172
+/-	O	-1	3987172
7@@	O	-1	3987172
00	O	-1	3987172
dy@@	O	-1	3987172
n@@	O	-1	3987172
e	O	-1	3987172
X	O	-1	3987172
sec@@	O	-1	3987172
/@@	O	-1	3987172
c@@	O	-1	3987172
m@@	O	-1	3987172
5@@	O	-1	3987172
)	O	-1	3987172
and	O	-1	3987172
was	O	-1	3987172
further	O	-1	3987172
increased	O	-1	3987172
by	O	-1	3987172
prop@@	B-Chemical	D011433	3987172
ran@@	I-Chemical	-1	3987172
o@@	I-Chemical	-1	3987172
lol	I-Chemical	-1	3987172
2@@	O	-1	3987172
2@@	O	-1	3987172
%	O	-1	3987172
(@@	O	-1	3987172
to	O	-1	3987172
2@@	O	-1	3987172
6@@	O	-1	3987172
60	O	-1	3987172
+/-	O	-1	3987172
12@@	O	-1	3987172
00	O	-1	3987172
dy@@	O	-1	3987172
n@@	O	-1	3987172
e	O	-1	3987172
X	O	-1	3987172
sec@@	O	-1	3987172
/@@	O	-1	3987172
c@@	O	-1	3987172
m@@	O	-1	3987172
5@@	O	-1	3987172
).	O	-1	3987172
We	O	-1	3987172
concl@@	O	-1	3987172
ude	O	-1	3987172
that	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
increases	O	-1	3987172
blood	O	-1	3987172
pressure	O	-1	3987172
by	O	-1	3987172
increas@@	O	-1	3987172
ing	O	-1	3987172
systemic	O	-1	3987172
vascular	O	-1	3987172
resist@@	O	-1	3987172
ance	O	-1	3987172
and	O	-1	3987172
cardiac	O	-1	3987172
out@@	O	-1	3987172
p@@	O	-1	3987172
ut@@	O	-1	3987172
,	O	-1	3987172
and	O	-1	3987172
that	O	-1	3987172
prop@@	B-Chemical	D011433	3987172
ran@@	I-Chemical	-1	3987172
o@@	I-Chemical	-1	3987172
lol	I-Chemical	-1	3987172
antagon@@	O	-1	3987172
iz@@	O	-1	3987172
es	O	-1	3987172
this	O	-1	3987172
increase	O	-1	3987172
by	O	-1	3987172
rever@@	O	-1	3987172
s@@	O	-1	3987172
ing	O	-1	3987172
the	O	-1	3987172
effect	O	-1	3987172
of	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
on	O	-1	3987172
cardiac	O	-1	3987172
out@@	O	-1	3987172
p@@	O	-1	3987172
ut@@	O	-1	3987172
.	O	-1	3987172
Th@@	O	-1	3987172
at	O	-1	3987172
prop@@	B-Chemical	D011433	3987172
ran@@	I-Chemical	-1	3987172
o@@	I-Chemical	-1	3987172
lol	I-Chemical	-1	3987172
antagon@@	O	-1	3987172
iz@@	O	-1	3987172
es	O	-1	3987172
the	O	-1	3987172
press@@	O	-1	3987172
or	O	-1	3987172
effect	O	-1	3987172
of	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
is	O	-1	3987172
in	O	-1	3987172
contr@@	O	-1	3987172
ast	O	-1	3987172
to	O	-1	3987172
the	O	-1	3987172
inter@@	O	-1	3987172
action	O	-1	3987172
in	O	-1	3987172
which	O	-1	3987172
prop@@	B-Chemical	D011433	3987172
ran@@	I-Chemical	-1	3987172
o@@	I-Chemical	-1	3987172
lol	I-Chemical	-1	3987172
enh@@	O	-1	3987172
anc@@	O	-1	3987172
es	O	-1	3987172
the	O	-1	3987172
press@@	O	-1	3987172
or	O	-1	3987172
effect	O	-1	3987172
of	O	-1	3987172
no@@	B-Chemical	D009638	3987172
re@@	I-Chemical	-1	3987172
p@@	I-Chemical	-1	3987172
ine@@	I-Chemical	-1	3987172
phrine	I-Chemical	-1	3987172
.	O	-1	3987172
This	O	-1	3987172
is	O	-1	3987172
prob@@	O	-1	3987172
ably	O	-1	3987172
because	O	-1	3987172
P@@	B-Chemical	D010665	3987172
P@@	I-Chemical	-1	3987172
A	I-Chemical	-1	3987172
has	O	-1	3987172
less	O	-1	3987172
bet@@	O	-1	3987172
a	O	-1	3987172
2	O	-1	3987172
activity	O	-1	3987172
than	O	-1	3987172
does	O	-1	3987172
no@@	B-Chemical	D009638	3987172
re@@	I-Chemical	-1	3987172
p@@	I-Chemical	-1	3987172
ine@@	I-Chemical	-1	3987172
phrine	I-Chemical	-1	3987172
.	O	-1	3987172

M@@	O	-1	3990093
es@@	O	-1	3990093
ang@@	O	-1	3990093
ial	O	-1	3990093
function	O	-1	3990093
and	O	-1	3990093
glomerular	B-Disease	D007674	3990093
s@@	I-Disease	-1	3990093
clero@@	I-Disease	-1	3990093
sis	I-Disease	-1	3990093
in	O	-1	3990093
rats	O	-1	3990093
with	O	-1	3990093
amin@@	B-Chemical	D011692	3990093
on@@	I-Chemical	-1	3990093
ucle@@	I-Chemical	-1	3990093
o@@	I-Chemical	-1	3990093
side	I-Chemical	-1	3990093
nephro@@	B-Disease	D009401	3990093
sis	I-Disease	-1	3990093
.	O	-1	3990093
The	O	-1	3990093
possible	O	-1	3990093
rel@@	O	-1	3990093
ationship	O	-1	3990093
between	O	-1	3990093
m@@	B-Disease	D007674	3990093
es@@	I-Disease	-1	3990093
ang@@	I-Disease	-1	3990093
ial	I-Disease	-1	3990093
dysfunction	I-Disease	-1	3990093
and	O	-1	3990093
development	O	-1	3990093
of	O	-1	3990093
glomerular	B-Disease	D007674	3990093
s@@	I-Disease	-1	3990093
clero@@	I-Disease	-1	3990093
sis	I-Disease	-1	3990093
was	O	-1	3990093
studied	O	-1	3990093
in	O	-1	3990093
the	O	-1	3990093
p@@	B-Chemical	D011692	3990093
uro@@	I-Chemical	-1	3990093
m@@	I-Chemical	-1	3990093
ycin	I-Chemical	-1	3990093
amin@@	I-Chemical	-1	3990093
on@@	I-Chemical	-1	3990093
ucle@@	I-Chemical	-1	3990093
o@@	I-Chemical	-1	3990093
side	I-Chemical	-1	3990093
(	O	-1	3990093
PA@@	B-Chemical	D011692	3990093
N	I-Chemical	-1	3990093
)	O	-1	3990093
model@@	O	-1	3990093
.	O	-1	3990093
F@@	O	-1	3990093
i@@	O	-1	3990093
ve	O	-1	3990093
male	O	-1	3990093
Wistar	O	-1	3990093
rats	O	-1	3990093
received	O	-1	3990093
repe@@	O	-1	3990093
ated	O	-1	3990093
sub@@	O	-1	3990093
c@@	O	-1	3990093
utaneous	O	-1	3990093
PA@@	B-Chemical	D011692	3990093
N	I-Chemical	-1	3990093
injec@@	O	-1	3990093
tion@@	O	-1	3990093
s;	O	-1	3990093
five	O	-1	3990093
controls	O	-1	3990093
received	O	-1	3990093
saline	O	-1	3990093
on@@	O	-1	3990093
ly.	O	-1	3990093
After	O	-1	3990093
4	O	-1	3990093
weeks	O	-1	3990093
the	O	-1	3990093
PA@@	B-Chemical	D011692	3990093
N	I-Chemical	-1	3990093
rats	O	-1	3990093
were	O	-1	3990093
se@@	O	-1	3990093
ve@@	O	-1	3990093
re@@	O	-1	3990093
ly	O	-1	3990093
protein@@	B-Disease	D011507	3990093
ur@@	I-Disease	-1	3990093
ic	I-Disease	-1	3990093
(1@@	O	-1	3990093
9@@	O	-1	3990093
0	O	-1	3990093
+/-	O	-1	3990093
8@@	O	-1	3990093
0	O	-1	3990093
mg/@@	O	-1	3990093
24	O	-1	3990093
h@@	O	-1	3990093
r@@	O	-1	3990093
),	O	-1	3990093
and	O	-1	3990093
all	O	-1	3990093
rats	O	-1	3990093
were	O	-1	3990093
given	O	-1	3990093
co@@	O	-1	3990093
l@@	O	-1	3990093
lo@@	O	-1	3990093
idal	O	-1	3990093
carb@@	B-Chemical	D002244	3990093
on	I-Chemical	-1	3990093
(C@@	O	-1	3990093
C@@	O	-1	3990093
)	O	-1	3990093
intra@@	O	-1	3990093
ven@@	O	-1	3990093
ous@@	O	-1	3990093
ly.	O	-1	3990093
A@@	O	-1	3990093
t	O	-1	3990093
5	O	-1	3990093
months	O	-1	3990093
glomerular	B-Disease	D007674	3990093
s@@	I-Disease	-1	3990093
clero@@	I-Disease	-1	3990093
sis	I-Disease	-1	3990093
was	O	-1	3990093
found	O	-1	3990093
in	O	-1	3990093
7.@@	O	-1	3990093
6	O	-1	3990093
+/-	O	-1	3990093
3.@@	O	-1	3990093
4@@	O	-1	3990093
%	O	-1	3990093
of	O	-1	3990093
the	O	-1	3990093
glomerul@@	O	-1	3990093
i	O	-1	3990093
of	O	-1	3990093
PA@@	B-Chemical	D011692	3990093
N	I-Chemical	-1	3990093
rat@@	O	-1	3990093
s;	O	-1	3990093
glomerul@@	O	-1	3990093
i	O	-1	3990093
of	O	-1	3990093
the	O	-1	3990093
controls	O	-1	3990093
were	O	-1	3990093
normal@@	O	-1	3990093
.	O	-1	3990093
G@@	O	-1	3990093
lo@@	O	-1	3990093
mer@@	O	-1	3990093
ul@@	O	-1	3990093
i	O	-1	3990093
of	O	-1	3990093
PA@@	B-Chemical	D011692	3990093
N	I-Chemical	-1	3990093
rats	O	-1	3990093
cont@@	O	-1	3990093
ained	O	-1	3990093
significantly	O	-1	3990093
more	O	-1	3990093
C@@	O	-1	3990093
C	O	-1	3990093
than	O	-1	3990093
glomerul@@	O	-1	3990093
i	O	-1	3990093
of	O	-1	3990093
controls.	O	-1	3990093
G@@	O	-1	3990093
lo@@	O	-1	3990093
mer@@	O	-1	3990093
ul@@	O	-1	3990093
i	O	-1	3990093
with	O	-1	3990093
s@@	B-Disease	D012598	3990093
clero@@	I-Disease	-1	3990093
sis	I-Disease	-1	3990093
cont@@	O	-1	3990093
ained	O	-1	3990093
significantly	O	-1	3990093
more	O	-1	3990093
C@@	O	-1	3990093
C	O	-1	3990093
than	O	-1	3990093
non-@@	O	-1	3990093
s@@	O	-1	3990093
clero@@	O	-1	3990093
tic	O	-1	3990093
glomerul@@	O	-1	3990093
i	O	-1	3990093
in	O	-1	3990093
the	O	-1	3990093
same	O	-1	3990093
kidne@@	O	-1	3990093
y@@	O	-1	3990093
s.	O	-1	3990093
C@@	O	-1	3990093
C	O	-1	3990093
was	O	-1	3990093
pre@@	O	-1	3990093
fe@@	O	-1	3990093
ren@@	O	-1	3990093
ti@@	O	-1	3990093
ally	O	-1	3990093
lo@@	O	-1	3990093
cal@@	O	-1	3990093
ized	O	-1	3990093
within	O	-1	3990093
the	O	-1	3990093
s@@	O	-1	3990093
clero@@	O	-1	3990093
tic	O	-1	3990093
a@@	O	-1	3990093
reas	O	-1	3990093
of	O	-1	3990093
the	O	-1	3990093
affected	O	-1	3990093
glomerul@@	O	-1	3990093
i@@	O	-1	3990093
.	O	-1	3990093
S@@	O	-1	3990093
inc@@	O	-1	3990093
e	O	-1	3990093
m@@	O	-1	3990093
es@@	O	-1	3990093
ang@@	O	-1	3990093
ial	O	-1	3990093
C@@	O	-1	3990093
C	O	-1	3990093
clear@@	O	-1	3990093
ance	O	-1	3990093
from	O	-1	3990093
the	O	-1	3990093
m@@	O	-1	3990093
es@@	O	-1	3990093
angi@@	O	-1	3990093
um	O	-1	3990093
did	O	-1	3990093
not	O	-1	3990093
change	O	-1	3990093
during	O	-1	3990093
chronic	O	-1	3990093
PA@@	B-Chemical	D011692	3990093
N	I-Chemical	-1	3990093
treatment,	O	-1	3990093
we	O	-1	3990093
concl@@	O	-1	3990093
ude	O	-1	3990093
that	O	-1	3990093
this	O	-1	3990093
pre@@	O	-1	3990093
fe@@	O	-1	3990093
ren@@	O	-1	3990093
tial	O	-1	3990093
C@@	O	-1	3990093
C	O	-1	3990093
lo@@	O	-1	3990093
cal@@	O	-1	3990093
ization	O	-1	3990093
within	O	-1	3990093
the	O	-1	3990093
lesions	O	-1	3990093
is	O	-1	3990093
caused	O	-1	3990093
by	O	-1	3990093
an	O	-1	3990093
increased	O	-1	3990093
C@@	O	-1	3990093
C	O	-1	3990093
u@@	O	-1	3990093
pt@@	O	-1	3990093
ake	O	-1	3990093
sh@@	O	-1	3990093
ort@@	O	-1	3990093
ly	O	-1	3990093
after	O	-1	3990093
injection	O	-1	3990093
in	O	-1	3990093
appa@@	O	-1	3990093
rent	O	-1	3990093
vul@@	O	-1	3990093
ner@@	O	-1	3990093
able	O	-1	3990093
a@@	O	-1	3990093
reas	O	-1	3990093
wh@@	O	-1	3990093
ere	O	-1	3990093
s@@	B-Disease	D012598	3990093
clero@@	I-Disease	-1	3990093
sis	I-Disease	-1	3990093
wil@@	O	-1	3990093
l	O	-1	3990093
deve@@	O	-1	3990093
lo@@	O	-1	3990093
p	O	-1	3990093
subsequ@@	O	-1	3990093
ent@@	O	-1	3990093
ly.	O	-1	3990093
C@@	O	-1	3990093
lu@@	O	-1	3990093
st@@	O	-1	3990093
er	O	-1	3990093
analysis	O	-1	3990093
showed	O	-1	3990093
a	O	-1	3990093
ran@@	O	-1	3990093
do@@	O	-1	3990093
m	O	-1	3990093
di@@	O	-1	3990093
stri@@	O	-1	3990093
bu@@	O	-1	3990093
tion	O	-1	3990093
of	O	-1	3990093
lesions	O	-1	3990093
in	O	-1	3990093
the	O	-1	3990093
PA@@	B-Chemical	D011692	3990093
N	I-Chemical	-1	3990093
glomerul@@	O	-1	3990093
i	O	-1	3990093
in	O	-1	3990093
con@@	O	-1	3990093
cor@@	O	-1	3990093
d@@	O	-1	3990093
ance	O	-1	3990093
with	O	-1	3990093
the	O	-1	3990093
ran@@	O	-1	3990093
do@@	O	-1	3990093
m	O	-1	3990093
lo@@	O	-1	3990093
cal@@	O	-1	3990093
ization	O	-1	3990093
of	O	-1	3990093
m@@	O	-1	3990093
es@@	O	-1	3990093
ang@@	O	-1	3990093
ial	O	-1	3990093
a@@	O	-1	3990093
reas	O	-1	3990093
with	O	-1	3990093
dysfunction	O	-1	3990093
in	O	-1	3990093
this	O	-1	3990093
model@@	O	-1	3990093
.	O	-1	3990093
S@@	O	-1	3990093
im@@	O	-1	3990093
il@@	O	-1	3990093
ar	O	-1	3990093
to	O	-1	3990093
the	O	-1	3990093
re@@	O	-1	3990093
m@@	O	-1	3990093
n@@	O	-1	3990093
ant	O	-1	3990093
kidney	O	-1	3990093
model	O	-1	3990093
in	O	-1	3990093
PA@@	B-Chemical	D011692	3990093
N	I-Chemical	-1	3990093
nephro@@	B-Disease	D009401	3990093
sis	I-Disease	-1	3990093
the	O	-1	3990093
development	O	-1	3990093
of	O	-1	3990093
glomerular	B-Disease	D007674	3990093
s@@	I-Disease	-1	3990093
clero@@	I-Disease	-1	3990093
sis	I-Disease	-1	3990093
may	O	-1	3990093
be	O	-1	3990093
related	O	-1	3990093
to	O	-1	3990093
"@@	O	-1	3990093
m@@	O	-1	3990093
es@@	O	-1	3990093
ang@@	O	-1	3990093
ial	O	-1	3990093
over@@	O	-1	3990093
lo@@	O	-1	3990093
ad@@	O	-1	3990093
ing@@	O	-1	3990093
.@@	O	-1	3990093
"	O	-1	3990093

R@@	O	-1	4010471
el@@	O	-1	4010471
ationship	O	-1	4010471
between	O	-1	4010471
nicotine	B-Chemical	D009538	4010471
-induced	O	-1	4010471
seizures	B-Disease	D012640	4010471
and	O	-1	4010471
hippocamp@@	O	-1	4010471
al	O	-1	4010471
nicot@@	O	-1	4010471
inic	O	-1	4010471
receptor@@	O	-1	4010471
s.	O	-1	4010471
A	O	-1	4010471
contro@@	O	-1	4010471
ver@@	O	-1	4010471
sy	O	-1	4010471
has	O	-1	4010471
ex@@	O	-1	4010471
ist@@	O	-1	4010471
ed	O	-1	4010471
for	O	-1	4010471
several	O	-1	4010471
years	O	-1	4010471
con@@	O	-1	4010471
cer@@	O	-1	4010471
ning	O	-1	4010471
the	O	-1	4010471
physi@@	O	-1	4010471
ological	O	-1	4010471
re@@	O	-1	4010471
lev@@	O	-1	4010471
ance	O	-1	4010471
of	O	-1	4010471
the	O	-1	4010471
nicot@@	O	-1	4010471
inic	O	-1	4010471
receptor	O	-1	4010471
measured	O	-1	4010471
by	O	-1	4010471
alpha-@@	O	-1	4010471
b@@	O	-1	4010471
un@@	O	-1	4010471
g@@	O	-1	4010471
a@@	O	-1	4010471
ro@@	O	-1	4010471
tox@@	O	-1	4010471
in	O	-1	4010471
b@@	O	-1	4010471
ind@@	O	-1	4010471
ing.	O	-1	4010471
U@@	O	-1	4010471
s@@	O	-1	4010471
ing	O	-1	4010471
mice	O	-1	4010471
der@@	O	-1	4010471
i@@	O	-1	4010471
ved	O	-1	4010471
from	O	-1	4010471
a	O	-1	4010471
cl@@	O	-1	4010471
assi@@	O	-1	4010471
c@@	O	-1	4010471
al	O	-1	4010471
F@@	O	-1	4010471
2	O	-1	4010471
and	O	-1	4010471
bac@@	O	-1	4010471
k@@	O	-1	4010471
cros@@	O	-1	4010471
s	O	-1	4010471
gene@@	O	-1	4010471
tic	O	-1	4010471
de@@	O	-1	4010471
sign@@	O	-1	4010471
,	O	-1	4010471
a	O	-1	4010471
rel@@	O	-1	4010471
ationship	O	-1	4010471
between	O	-1	4010471
nicotine	B-Chemical	D009538	4010471
-induced	O	-1	4010471
seizures	B-Disease	D012640	4010471
and	O	-1	4010471
alpha-@@	O	-1	4010471
b@@	O	-1	4010471
un@@	O	-1	4010471
g@@	O	-1	4010471
a@@	O	-1	4010471
ro@@	O	-1	4010471
tox@@	O	-1	4010471
in	O	-1	4010471
nicot@@	O	-1	4010471
inic	O	-1	4010471
receptor	O	-1	4010471
concentration	O	-1	4010471
was	O	-1	4010471
f@@	O	-1	4010471
oun@@	O	-1	4010471
d.	O	-1	4010471
M@@	O	-1	4010471
ic@@	O	-1	4010471
e	O	-1	4010471
sensitive	O	-1	4010471
to	O	-1	4010471
the	O	-1	4010471
convul@@	O	-1	4010471
s@@	O	-1	4010471
ant	O	-1	4010471
effects	O	-1	4010471
of	O	-1	4010471
nicotine	B-Chemical	D009538	4010471
had	O	-1	4010471
greater	O	-1	4010471
alpha-@@	O	-1	4010471
b@@	O	-1	4010471
un@@	O	-1	4010471
g@@	O	-1	4010471
a@@	O	-1	4010471
ro@@	O	-1	4010471
tox@@	O	-1	4010471
in	O	-1	4010471
b@@	O	-1	4010471
ind@@	O	-1	4010471
ing	O	-1	4010471
in	O	-1	4010471
the	O	-1	4010471
hippocamp@@	O	-1	4010471
us	O	-1	4010471
than	O	-1	4010471
seizure	B-Disease	D012640	4010471
in@@	O	-1	4010471
sensitive	O	-1	4010471
mice.	O	-1	4010471
The	O	-1	4010471
b@@	O	-1	4010471
ind@@	O	-1	4010471
ing	O	-1	4010471
sit@@	O	-1	4010471
es	O	-1	4010471
from	O	-1	4010471
seizure	B-Disease	D012640	4010471
sensitive	O	-1	4010471
and	O	-1	4010471
resist@@	O	-1	4010471
ant	O	-1	4010471
mice	O	-1	4010471
were	O	-1	4010471
equ@@	O	-1	4010471
ally	O	-1	4010471
affected	O	-1	4010471
by	O	-1	4010471
treatment	O	-1	4010471
with	O	-1	4010471
di@@	B-Chemical	D004229	4010471
th@@	I-Chemical	-1	4010471
io@@	I-Chemical	-1	4010471
th@@	I-Chemical	-1	4010471
re@@	I-Chemical	-1	4010471
it@@	I-Chemical	-1	4010471
ol	I-Chemical	-1	4010471
,	O	-1	4010471
tr@@	O	-1	4010471
yp@@	O	-1	4010471
s@@	O	-1	4010471
in	O	-1	4010471
or	O	-1	4010471
he@@	O	-1	4010471
at@@	O	-1	4010471
.	O	-1	4010471
Th@@	O	-1	4010471
us	O	-1	4010471
it	O	-1	4010471
appear@@	O	-1	4010471
s	O	-1	4010471
that	O	-1	4010471
the	O	-1	4010471
difference	O	-1	4010471
between	O	-1	4010471
seizure	B-Disease	D012640	4010471
sensitive	O	-1	4010471
and	O	-1	4010471
in@@	O	-1	4010471
sensitive	O	-1	4010471
animals	O	-1	4010471
may	O	-1	4010471
be	O	-1	4010471
due	O	-1	4010471
to	O	-1	4010471
a	O	-1	4010471
difference	O	-1	4010471
in	O	-1	4010471
hippocamp@@	O	-1	4010471
al	O	-1	4010471
nicot@@	O	-1	4010471
inic	O	-1	4010471
receptor	O	-1	4010471
concentration	O	-1	4010471
as	O	-1	4010471
measured	O	-1	4010471
with	O	-1	4010471
alpha-@@	O	-1	4010471
b@@	O	-1	4010471
un@@	O	-1	4010471
g@@	O	-1	4010471
a@@	O	-1	4010471
ro@@	O	-1	4010471
tox@@	O	-1	4010471
in	O	-1	4010471
b@@	O	-1	4010471
ind@@	O	-1	4010471
ing.	O	-1	4010471

The	O	-1	4082192
role	O	-1	4082192
of	O	-1	4082192
p@@	B-Chemical	C026729	4082192
-@@	I-Chemical	-1	4082192
amino@@	I-Chemical	-1	4082192
phen@@	I-Chemical	-1	4082192
ol	I-Chemical	-1	4082192
in	O	-1	4082192
acet@@	B-Chemical	D000082	4082192
aminoph@@	I-Chemical	-1	4082192
en	I-Chemical	-1	4082192
-induced	O	-1	4082192
nephro@@	B-Disease	D007674	4082192
toxicity	I-Disease	-1	4082192
:	O	-1	4082192
effect	O	-1	4082192
of	O	-1	4082192
b@@	B-Chemical	C002887	4082192
is@@	I-Chemical	-1	4082192
(p@@	I-Chemical	-1	4082192
-@@	I-Chemical	-1	4082192
nitro@@	I-Chemical	-1	4082192
phenyl@@	I-Chemical	-1	4082192
)	I-Chemical	-1	4082192
phosph@@	I-Chemical	-1	4082192
ate	I-Chemical	-1	4082192
on	O	-1	4082192
acet@@	B-Chemical	D000082	4082192
aminoph@@	I-Chemical	-1	4082192
en	I-Chemical	-1	4082192
and	O	-1	4082192
p@@	B-Chemical	C026729	4082192
-@@	I-Chemical	-1	4082192
amino@@	I-Chemical	-1	4082192
phen@@	I-Chemical	-1	4082192
ol	I-Chemical	-1	4082192
nephro@@	B-Disease	D007674	4082192
toxicity	I-Disease	-1	4082192
and	O	-1	4082192
metabol@@	O	-1	4082192
ism	O	-1	4082192
in	O	-1	4082192
F@@	O	-1	4082192
is@@	O	-1	4082192
ch@@	O	-1	4082192
er	O	-1	4082192
34@@	O	-1	4082192
4	O	-1	4082192
rats.	O	-1	4082192
A@@	B-Chemical	D000082	4082192
ce@@	I-Chemical	-1	4082192
t@@	I-Chemical	-1	4082192
aminoph@@	I-Chemical	-1	4082192
en	I-Chemical	-1	4082192
(	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
)	O	-1	4082192
produc@@	O	-1	4082192
es	O	-1	4082192
pro@@	O	-1	4082192
xim@@	O	-1	4082192
al	O	-1	4082192
tub@@	B-Disease	D007683	4082192
ular	I-Disease	-1	4082192
necro@@	I-Disease	-1	4082192
sis	I-Disease	-1	4082192
in	O	-1	4082192
F@@	O	-1	4082192
is@@	O	-1	4082192
ch@@	O	-1	4082192
er	O	-1	4082192
34@@	O	-1	4082192
4	O	-1	4082192
(@@	O	-1	4082192
F@@	O	-1	4082192
34@@	O	-1	4082192
4@@	O	-1	4082192
)	O	-1	4082192
rats.	O	-1	4082192
Rec@@	O	-1	4082192
ent@@	O	-1	4082192
ly,	O	-1	4082192
p@@	B-Chemical	C026729	4082192
-@@	I-Chemical	-1	4082192
amino@@	I-Chemical	-1	4082192
phen@@	I-Chemical	-1	4082192
ol	I-Chemical	-1	4082192
(	O	-1	4082192
PA@@	B-Chemical	C026729	4082192
P	I-Chemical	-1	4082192
),	O	-1	4082192
a	O	-1	4082192
known	O	-1	4082192
pot@@	O	-1	4082192
ent	O	-1	4082192
nephro@@	O	-1	4082192
toxic@@	O	-1	4082192
ant@@	O	-1	4082192
,	O	-1	4082192
was	O	-1	4082192
identi@@	O	-1	4082192
fied	O	-1	4082192
as	O	-1	4082192
a	O	-1	4082192
metabol@@	O	-1	4082192
ite	O	-1	4082192
of	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
in	O	-1	4082192
F@@	O	-1	4082192
34@@	O	-1	4082192
4	O	-1	4082192
rats.	O	-1	4082192
The	O	-1	4082192
pur@@	O	-1	4082192
p@@	O	-1	4082192
ose	O	-1	4082192
of	O	-1	4082192
this	O	-1	4082192
study	O	-1	4082192
was	O	-1	4082192
to	O	-1	4082192
determine	O	-1	4082192
if	O	-1	4082192
PA@@	B-Chemical	C026729	4082192
P	I-Chemical	-1	4082192
formation	O	-1	4082192
is	O	-1	4082192
a	O	-1	4082192
requ@@	O	-1	4082192
is@@	O	-1	4082192
ite	O	-1	4082192
st@@	O	-1	4082192
ep	O	-1	4082192
in	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
-induced	O	-1	4082192
nephro@@	B-Disease	D007674	4082192
toxicity	I-Disease	-1	4082192
.	O	-1	4082192
The@@	O	-1	4082192
refore,	O	-1	4082192
the	O	-1	4082192
effect	O	-1	4082192
of	O	-1	4082192
b@@	B-Chemical	C002887	4082192
is@@	I-Chemical	-1	4082192
(p@@	I-Chemical	-1	4082192
-@@	I-Chemical	-1	4082192
nitro@@	I-Chemical	-1	4082192
phenyl@@	I-Chemical	-1	4082192
)	I-Chemical	-1	4082192
phosph@@	I-Chemical	-1	4082192
ate	I-Chemical	-1	4082192
(	O	-1	4082192
B@@	B-Chemical	C002887	4082192
N@@	I-Chemical	-1	4082192
P@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
),	O	-1	4082192
an	O	-1	4082192
ac@@	O	-1	4082192
yl@@	O	-1	4082192
am@@	O	-1	4082192
id@@	O	-1	4082192
ase	O	-1	4082192
inhibitor@@	O	-1	4082192
,	O	-1	4082192
on	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
and	O	-1	4082192
PA@@	B-Chemical	C026729	4082192
P	I-Chemical	-1	4082192
nephro@@	B-Disease	D007674	4082192
toxicity	I-Disease	-1	4082192
and	O	-1	4082192
metabol@@	O	-1	4082192
ism	O	-1	4082192
was	O	-1	4082192
deter@@	O	-1	4082192
m@@	O	-1	4082192
ine@@	O	-1	4082192
d.	O	-1	4082192
B@@	B-Chemical	C002887	4082192
N@@	I-Chemical	-1	4082192
P@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
(@@	O	-1	4082192
1	O	-1	4082192
to	O	-1	4082192
8	O	-1	4082192
m@@	O	-1	4082192
M@@	O	-1	4082192
)	O	-1	4082192
reduced	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
de@@	O	-1	4082192
acet@@	O	-1	4082192
yl@@	O	-1	4082192
ation	O	-1	4082192
and	O	-1	4082192
co@@	O	-1	4082192
val@@	O	-1	4082192
ent	O	-1	4082192
b@@	O	-1	4082192
ind@@	O	-1	4082192
ing	O	-1	4082192
in	O	-1	4082192
F@@	O	-1	4082192
34@@	O	-1	4082192
4	O	-1	4082192
renal	O	-1	4082192
cor@@	O	-1	4082192
tical	O	-1	4082192
ho@@	O	-1	4082192
mo@@	O	-1	4082192
gen@@	O	-1	4082192
ates	O	-1	4082192
in	O	-1	4082192
a	O	-1	4082192
concentr@@	O	-1	4082192
ation@@	O	-1	4082192
-@@	O	-1	4082192
dependent	O	-1	4082192
man@@	O	-1	4082192
ner@@	O	-1	4082192
.	O	-1	4082192
Pre@@	O	-1	4082192
treatment	O	-1	4082192
of	O	-1	4082192
animals	O	-1	4082192
with	O	-1	4082192
B@@	B-Chemical	C002887	4082192
N@@	I-Chemical	-1	4082192
P@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
prior	O	-1	4082192
to	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
or	O	-1	4082192
PA@@	B-Chemical	C026729	4082192
P	I-Chemical	-1	4082192
administration	O	-1	4082192
resulted	O	-1	4082192
in	O	-1	4082192
mark@@	O	-1	4082192
ed	O	-1	4082192
reduction	O	-1	4082192
of	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
(@@	O	-1	4082192
9@@	O	-1	4082192
00	O	-1	4082192
mg/kg)	O	-1	4082192
nephro@@	B-Disease	D007674	4082192
toxicity	I-Disease	-1	4082192
but	O	-1	4082192
not	O	-1	4082192
PA@@	B-Chemical	C026729	4082192
P	I-Chemical	-1	4082192
nephro@@	B-Disease	D007674	4082192
toxicity	I-Disease	-1	4082192
.	O	-1	4082192
This	O	-1	4082192
result	O	-1	4082192
was	O	-1	4082192
not	O	-1	4082192
due	O	-1	4082192
to	O	-1	4082192
al@@	O	-1	4082192
te@@	O	-1	4082192
red	O	-1	4082192
dis@@	O	-1	4082192
posi@@	O	-1	4082192
tion	O	-1	4082192
of	O	-1	4082192
either	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
or	O	-1	4082192
acet@@	O	-1	4082192
yl@@	O	-1	4082192
ated	O	-1	4082192
metabol@@	O	-1	4082192
it@@	O	-1	4082192
es	O	-1	4082192
in	O	-1	4082192
plasma	O	-1	4082192
or	O	-1	4082192
renal	O	-1	4082192
cor@@	O	-1	4082192
tical	O	-1	4082192
and	O	-1	4082192
hepatic	O	-1	4082192
tissu@@	O	-1	4082192
e.	O	-1	4082192
R@@	O	-1	4082192
a@@	O	-1	4082192
ther@@	O	-1	4082192
,	O	-1	4082192
B@@	B-Chemical	C002887	4082192
N@@	I-Chemical	-1	4082192
P@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
pretreatment	O	-1	4082192
reduced	O	-1	4082192
the	O	-1	4082192
frac@@	O	-1	4082192
tion	O	-1	4082192
of	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
ex@@	O	-1	4082192
cre@@	O	-1	4082192
ted	O	-1	4082192
as	O	-1	4082192
PA@@	B-Chemical	C026729	4082192
P	I-Chemical	-1	4082192
by	O	-1	4082192
6@@	O	-1	4082192
4	O	-1	4082192
and	O	-1	4082192
7@@	O	-1	4082192
5%	O	-1	4082192
after	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
doses	O	-1	4082192
of	O	-1	4082192
7@@	O	-1	4082192
50	O	-1	4082192
and	O	-1	4082192
9@@	O	-1	4082192
00	O	-1	4082192
mg/kg@@	O	-1	4082192
.	O	-1	4082192
B@@	B-Chemical	C002887	4082192
N@@	I-Chemical	-1	4082192
P@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
did	O	-1	4082192
not	O	-1	4082192
al@@	O	-1	4082192
ter	O	-1	4082192
the	O	-1	4082192
ex@@	O	-1	4082192
cre@@	O	-1	4082192
tion	O	-1	4082192
of	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
or	O	-1	4082192
any	O	-1	4082192
of	O	-1	4082192
its	O	-1	4082192
non-@@	O	-1	4082192
de@@	O	-1	4082192
acet@@	O	-1	4082192
yl@@	O	-1	4082192
ated	O	-1	4082192
metabol@@	O	-1	4082192
it@@	O	-1	4082192
es	O	-1	4082192
n@@	O	-1	4082192
or	O	-1	4082192
did	O	-1	4082192
B@@	B-Chemical	C002887	4082192
N@@	I-Chemical	-1	4082192
P@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
al@@	O	-1	4082192
ter	O	-1	4082192
ex@@	O	-1	4082192
cre@@	O	-1	4082192
tion	O	-1	4082192
of	O	-1	4082192
PA@@	B-Chemical	C026729	4082192
P	I-Chemical	-1	4082192
or	O	-1	4082192
its	O	-1	4082192
metabol@@	O	-1	4082192
it@@	O	-1	4082192
es	O	-1	4082192
after	O	-1	4082192
PA@@	B-Chemical	C026729	4082192
P	I-Chemical	-1	4082192
doses	O	-1	4082192
of	O	-1	4082192
1@@	O	-1	4082192
50	O	-1	4082192
and	O	-1	4082192
3@@	O	-1	4082192
00	O	-1	4082192
mg/kg@@	O	-1	4082192
.	O	-1	4082192
The@@	O	-1	4082192
refore,	O	-1	4082192
the	O	-1	4082192
B@@	B-Chemical	C002887	4082192
N@@	I-Chemical	-1	4082192
P@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
-induced	O	-1	4082192
reduction	O	-1	4082192
in	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
-induced	O	-1	4082192
nephro@@	B-Disease	D007674	4082192
toxicity	I-Disease	-1	4082192
appear@@	O	-1	4082192
s	O	-1	4082192
to	O	-1	4082192
be	O	-1	4082192
due	O	-1	4082192
to	O	-1	4082192
inhibition	O	-1	4082192
of	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
de@@	O	-1	4082192
acet@@	O	-1	4082192
yl@@	O	-1	4082192
ation.	O	-1	4082192
It	O	-1	4082192
is	O	-1	4082192
concl@@	O	-1	4082192
uded	O	-1	4082192
that	O	-1	4082192
PA@@	B-Chemical	C026729	4082192
P	I-Chemical	-1	4082192
form@@	O	-1	4082192
ation,	O	-1	4082192
in	O	-1	4082192
viv@@	O	-1	4082192
o@@	O	-1	4082192
,	O	-1	4082192
ac@@	O	-1	4082192
coun@@	O	-1	4082192
t@@	O	-1	4082192
s,	O	-1	4082192
at	O	-1	4082192
le@@	O	-1	4082192
ast	O	-1	4082192
in	O	-1	4082192
part@@	O	-1	4082192
,	O	-1	4082192
for	O	-1	4082192
A@@	B-Chemical	D000082	4082192
PA@@	I-Chemical	-1	4082192
P	I-Chemical	-1	4082192
-induced	O	-1	4082192
renal	B-Disease	D007683	4082192
tub@@	I-Disease	-1	4082192
ular	I-Disease	-1	4082192
necro@@	I-Disease	-1	4082192
sis	I-Disease	-1	4082192
.	O	-1	4082192

M@@	B-Chemical	D009020	4082466
or@@	I-Chemical	-1	4082466
ph@@	I-Chemical	-1	4082466
ine	I-Chemical	-1	4082466
-induced	O	-1	4082466
seizures	B-Disease	D012640	4082466
in	O	-1	4082466
ne@@	O	-1	4082466
w@@	O	-1	4082466
b@@	O	-1	4082466
or@@	O	-1	4082466
n	O	-1	4082466
inf@@	O	-1	4082466
ant@@	O	-1	4082466
s.	O	-1	4082466
Two	O	-1	4082466
ne@@	O	-1	4082466
on@@	O	-1	4082466
ates	O	-1	4082466
su@@	O	-1	4082466
ffe@@	O	-1	4082466
red	O	-1	4082466
from	O	-1	4082466
gener@@	O	-1	4082466
al@@	O	-1	4082466
ized	O	-1	4082466
seizures	B-Disease	D012640	4082466
during	O	-1	4082466
the	O	-1	4082466
course	O	-1	4082466
of	O	-1	4082466
intravenous	O	-1	4082466
morphine	B-Chemical	D009020	4082466
sulf@@	I-Chemical	-1	4082466
ate	I-Chemical	-1	4082466
for	O	-1	4082466
post@@	O	-1	4082466
-@@	O	-1	4082466
o@@	O	-1	4082466
perative	O	-1	4082466
analge@@	O	-1	4082466
sia.	O	-1	4082466
The@@	O	-1	4082466
y	O	-1	4082466
received	O	-1	4082466
morphine	B-Chemical	D009020	4082466
in	O	-1	4082466
doses	O	-1	4082466
of	O	-1	4082466
3@@	O	-1	4082466
2	O	-1	4082466
microgram@@	O	-1	4082466
s/@@	O	-1	4082466
k@@	O	-1	4082466
g/@@	O	-1	4082466
h@@	O	-1	4082466
r	O	-1	4082466
and	O	-1	4082466
40	O	-1	4082466
microgram@@	O	-1	4082466
s/@@	O	-1	4082466
k@@	O	-1	4082466
g/@@	O	-1	4082466
h@@	O	-1	4082466
r	O	-1	4082466
larg@@	O	-1	4082466
er	O	-1	4082466
than	O	-1	4082466
a	O	-1	4082466
group	O	-1	4082466
of	O	-1	4082466
10	O	-1	4082466
ne@@	O	-1	4082466
on@@	O	-1	4082466
ates	O	-1	4082466
who	O	-1	4082466
received	O	-1	4082466
6-@@	O	-1	4082466
24	O	-1	4082466
microgram@@	O	-1	4082466
s/@@	O	-1	4082466
k@@	O	-1	4082466
g/@@	O	-1	4082466
h@@	O	-1	4082466
r	O	-1	4082466
and	O	-1	4082466
had	O	-1	4082466
no	O	-1	4082466
seizures	B-Disease	D012640	4082466
.	O	-1	4082466
P@@	O	-1	4082466
las@@	O	-1	4082466
ma	O	-1	4082466
concentrations	O	-1	4082466
of	O	-1	4082466
morphine	B-Chemical	D009020	4082466
in	O	-1	4082466
these	O	-1	4082466
ne@@	O	-1	4082466
on@@	O	-1	4082466
ates	O	-1	4082466
was	O	-1	4082466
ex@@	O	-1	4082466
ces@@	O	-1	4082466
sive	O	-1	4082466
(@@	O	-1	4082466
60	O	-1	4082466
and	O	-1	4082466
9@@	O	-1	4082466
0	O	-1	4082466
mg/m@@	O	-1	4082466
l@@	O	-1	4082466
).	O	-1	4082466
O@@	O	-1	4082466
ther	O	-1	4082466
known	O	-1	4082466
reas@@	O	-1	4082466
ons	O	-1	4082466
for	O	-1	4082466
seizures	B-Disease	D012640	4082466
were	O	-1	4082466
r@@	O	-1	4082466
ul@@	O	-1	4082466
ed	O	-1	4082466
out	O	-1	4082466
and	O	-1	4082466
the	O	-1	4082466
convul@@	B-Disease	D012640	4082466
sions	I-Disease	-1	4082466
sto@@	O	-1	4082466
pp@@	O	-1	4082466
ed	O	-1	4082466
a	O	-1	4082466
fe@@	O	-1	4082466
w	O	-1	4082466
hours	O	-1	4082466
after	O	-1	4082466
cess@@	O	-1	4082466
ation	O	-1	4082466
of	O	-1	4082466
morphine	B-Chemical	D009020	4082466
and	O	-1	4082466
did	O	-1	4082466
not	O	-1	4082466
re@@	O	-1	4082466
occ@@	O	-1	4082466
ur	O	-1	4082466
in	O	-1	4082466
the	O	-1	4082466
subsequ@@	O	-1	4082466
ent	O	-1	4082466
8	O	-1	4082466
months.	O	-1	4082466
It	O	-1	4082466
is	O	-1	4082466
suggested	O	-1	4082466
that	O	-1	4082466
post@@	O	-1	4082466
-@@	O	-1	4082466
o@@	O	-1	4082466
perative	O	-1	4082466
intravenous	O	-1	4082466
morphine	B-Chemical	D009020	4082466
should	O	-1	4082466
not	O	-1	4082466
ex@@	O	-1	4082466
ce@@	O	-1	4082466
ed	O	-1	4082466
20	O	-1	4082466
microgram@@	O	-1	4082466
s/@@	O	-1	4082466
k@@	O	-1	4082466
g/@@	O	-1	4082466
m@@	O	-1	4082466
l	O	-1	4082466
in	O	-1	4082466
ne@@	O	-1	4082466
on@@	O	-1	4082466
at@@	O	-1	4082466
es.	O	-1	4082466

Eff@@	O	-1	4631913
ect	O	-1	4631913
of	O	-1	4631913
v@@	B-Chemical	D014750	4631913
inc@@	I-Chemical	-1	4631913
ri@@	I-Chemical	-1	4631913
st@@	I-Chemical	-1	4631913
ine	I-Chemical	-1	4631913
sulf@@	I-Chemical	-1	4631913
ate	I-Chemical	-1	4631913
on	O	-1	4631913
P@@	B-Disease	D011552	4631913
se@@	I-Disease	-1	4631913
u@@	I-Disease	-1	4631913
do@@	I-Disease	-1	4631913
mon@@	I-Disease	-1	4631913
as	I-Disease	-1	4631913
inf@@	I-Disease	-1	4631913
ec@@	I-Disease	-1	4631913
tions	I-Disease	-1	4631913
in	O	-1	4631913
mon@@	O	-1	4631913
ke@@	O	-1	4631913
y@@	O	-1	4631913
s.	O	-1	4631913
In	O	-1	4631913
rh@@	O	-1	4631913
es@@	O	-1	4631913
us	O	-1	4631913
mon@@	O	-1	4631913
ke@@	O	-1	4631913
y@@	O	-1	4631913
s,	O	-1	4631913
intravenous	O	-1	4631913
ch@@	O	-1	4631913
all@@	O	-1	4631913
enge	O	-1	4631913
with	O	-1	4631913
0.@@	O	-1	4631913
6	O	-1	4631913
x	O	-1	4631913
10@@	O	-1	4631913
(@@	O	-1	4631913
10@@	O	-1	4631913
)	O	-1	4631913
to	O	-1	4631913
2.@@	O	-1	4631913
2	O	-1	4631913
x	O	-1	4631913
10@@	O	-1	4631913
(@@	O	-1	4631913
10@@	O	-1	4631913
)@@	O	-1	4631913
P@@	O	-1	4631913
se@@	O	-1	4631913
u@@	O	-1	4631913
do@@	O	-1	4631913
mon@@	O	-1	4631913
as	O	-1	4631913
a@@	O	-1	4631913
er@@	O	-1	4631913
u@@	O	-1	4631913
g@@	O	-1	4631913
in@@	O	-1	4631913
os@@	O	-1	4631913
a	O	-1	4631913
org@@	O	-1	4631913
an@@	O	-1	4631913
is@@	O	-1	4631913
ms	O	-1	4631913
caused	O	-1	4631913
acute	O	-1	4631913
ill@@	O	-1	4631913
ness	O	-1	4631913
of	O	-1	4631913
4	O	-1	4631913
to	O	-1	4631913
5	O	-1	4631913
da@@	O	-1	4631913
ys@@	O	-1	4631913
'	O	-1	4631913
duration	O	-1	4631913
with	O	-1	4631913
spont@@	O	-1	4631913
aneous	O	-1	4631913
recovery	O	-1	4631913
in	O	-1	4631913
13	O	-1	4631913
of	O	-1	4631913
15	O	-1	4631913
mon@@	O	-1	4631913
ke@@	O	-1	4631913
ys@@	O	-1	4631913
;	O	-1	4631913
blood	O	-1	4631913
c@@	O	-1	4631913
ult@@	O	-1	4631913
ures	O	-1	4631913
b@@	O	-1	4631913
ec@@	O	-1	4631913
am@@	O	-1	4631913
e	O	-1	4631913
negative	O	-1	4631913
3	O	-1	4631913
to	O	-1	4631913
17	O	-1	4631913
days	O	-1	4631913
after	O	-1	4631913
ch@@	O	-1	4631913
all@@	O	-1	4631913
en@@	O	-1	4631913
g@@	O	-1	4631913
e.	O	-1	4631913
L@@	B-Disease	D007964	4631913
eu@@	I-Disease	-1	4631913
k@@	I-Disease	-1	4631913
ocyto@@	I-Disease	-1	4631913
sis	I-Disease	-1	4631913
was	O	-1	4631913
observed	O	-1	4631913
in	O	-1	4631913
all	O	-1	4631913
mon@@	O	-1	4631913
ke@@	O	-1	4631913
y@@	O	-1	4631913
s.	O	-1	4631913
In@@	O	-1	4631913
tra@@	O	-1	4631913
venous	O	-1	4631913
or	O	-1	4631913
int@@	O	-1	4631913
rat@@	O	-1	4631913
rac@@	O	-1	4631913
he@@	O	-1	4631913
al	O	-1	4631913
in@@	O	-1	4631913
oc@@	O	-1	4631913
ulation	O	-1	4631913
of	O	-1	4631913
2.@@	O	-1	4631913
0	O	-1	4631913
to	O	-1	4631913
2.@@	O	-1	4631913
5	O	-1	4631913
mg	O	-1	4631913
of	O	-1	4631913
v@@	B-Chemical	D014750	4631913
inc@@	I-Chemical	-1	4631913
ri@@	I-Chemical	-1	4631913
st@@	I-Chemical	-1	4631913
ine	I-Chemical	-1	4631913
sulf@@	I-Chemical	-1	4631913
ate	I-Chemical	-1	4631913
was	O	-1	4631913
followed	O	-1	4631913
by	O	-1	4631913
leuk@@	B-Disease	D007970	4631913
o@@	I-Disease	-1	4631913
pen@@	I-Disease	-1	4631913
ia	I-Disease	-1	4631913
in	O	-1	4631913
4	O	-1	4631913
to	O	-1	4631913
5	O	-1	4631913
days.	O	-1	4631913
In@@	O	-1	4631913
tra@@	O	-1	4631913
venous	O	-1	4631913
in@@	O	-1	4631913
oc@@	O	-1	4631913
ulation	O	-1	4631913
of	O	-1	4631913
4.@@	O	-1	4631913
2	O	-1	4631913
x	O	-1	4631913
10@@	O	-1	4631913
(@@	O	-1	4631913
10@@	O	-1	4631913
)	O	-1	4631913
to	O	-1	4631913
7.@@	O	-1	4631913
8	O	-1	4631913
x	O	-1	4631913
10@@	O	-1	4631913
(@@	O	-1	4631913
10@@	O	-1	4631913
)	O	-1	4631913
py@@	O	-1	4631913
oc@@	O	-1	4631913
in	O	-1	4631913
type	O	-1	4631913
6	O	-1	4631913
P@@	O	-1	4631913
se@@	O	-1	4631913
u@@	O	-1	4631913
do@@	O	-1	4631913
mon@@	O	-1	4631913
as	O	-1	4631913
org@@	O	-1	4631913
an@@	O	-1	4631913
is@@	O	-1	4631913
ms	O	-1	4631913
in	O	-1	4631913
mon@@	O	-1	4631913
ke@@	O	-1	4631913
ys	O	-1	4631913
given	O	-1	4631913
v@@	B-Chemical	D014750	4631913
inc@@	I-Chemical	-1	4631913
ri@@	I-Chemical	-1	4631913
st@@	I-Chemical	-1	4631913
ine	I-Chemical	-1	4631913
sulf@@	I-Chemical	-1	4631913
ate	I-Chemical	-1	4631913
4	O	-1	4631913
days	O	-1	4631913
previously	O	-1	4631913
resulted	O	-1	4631913
in	O	-1	4631913
f@@	O	-1	4631913
atal	O	-1	4631913
inf@@	B-Disease	D007239	4631913
ection	I-Disease	-1	4631913
in	O	-1	4631913
11	O	-1	4631913
of	O	-1	4631913
14	O	-1	4631913
mon@@	O	-1	4631913
ke@@	O	-1	4631913
y@@	O	-1	4631913
s,	O	-1	4631913
whereas	O	-1	4631913
n@@	O	-1	4631913
one	O	-1	4631913
of	O	-1	4631913
four	O	-1	4631913
receiving	O	-1	4631913
P@@	O	-1	4631913
se@@	O	-1	4631913
u@@	O	-1	4631913
do@@	O	-1	4631913
mon@@	O	-1	4631913
as	O	-1	4631913
alone	O	-1	4631913
di@@	O	-1	4631913
ed.	O	-1	4631913
These	O	-1	4631913
studies	O	-1	4631913
suggest	O	-1	4631913
that	O	-1	4631913
an	O	-1	4631913
anti@@	O	-1	4631913
metabol@@	O	-1	4631913
it@@	O	-1	4631913
e@@	O	-1	4631913
-induced	O	-1	4631913
leuk@@	B-Disease	D007970	4631913
o@@	I-Disease	-1	4631913
pen@@	I-Disease	-1	4631913
ia	I-Disease	-1	4631913
pre@@	O	-1	4631913
dis@@	O	-1	4631913
po@@	O	-1	4631913
ses	O	-1	4631913
to	O	-1	4631913
severe	O	-1	4631913
P@@	O	-1	4631913
se@@	O	-1	4631913
u@@	O	-1	4631913
do@@	O	-1	4631913
mon@@	O	-1	4631913
as	O	-1	4631913
se@@	B-Disease	D018805	4631913
p@@	I-Disease	-1	4631913
sis	I-Disease	-1	4631913
and	O	-1	4631913
that	O	-1	4631913
such	O	-1	4631913
mon@@	O	-1	4631913
ke@@	O	-1	4631913
ys	O	-1	4631913
may	O	-1	4631913
ser@@	O	-1	4631913
ve	O	-1	4631913
as	O	-1	4631913
a	O	-1	4631913
bio@@	O	-1	4631913
log@@	O	-1	4631913
ical	O	-1	4631913
model	O	-1	4631913
for	O	-1	4631913
study	O	-1	4631913
of	O	-1	4631913
compar@@	O	-1	4631913
ative	O	-1	4631913
efficacy	O	-1	4631913
of	O	-1	4631913
anti@@	O	-1	4631913
micro@@	O	-1	4631913
b@@	O	-1	4631913
ial	O	-1	4631913
agent@@	O	-1	4631913
s.	O	-1	4631913

C@@	O	-1	6106951
entr@@	O	-1	6106951
al	O	-1	6106951
ex@@	O	-1	6106951
cit@@	O	-1	6106951
atory	O	-1	6106951
ac@@	O	-1	6106951
tions	O	-1	6106951
of	O	-1	6106951
f@@	B-Chemical	D005479	6106951
lur@@	I-Chemical	-1	6106951
az@@	I-Chemical	-1	6106951
epam	I-Chemical	-1	6106951
.	O	-1	6106951
T@@	O	-1	6106951
ox@@	O	-1	6106951
ic	O	-1	6106951
ac@@	O	-1	6106951
tions	O	-1	6106951
of	O	-1	6106951
f@@	B-Chemical	D005479	6106951
lur@@	I-Chemical	-1	6106951
az@@	I-Chemical	-1	6106951
epam	I-Chemical	-1	6106951
(	O	-1	6106951
F@@	B-Chemical	D005479	6106951
Z@@	I-Chemical	-1	6106951
P	I-Chemical	-1	6106951
)	O	-1	6106951
were	O	-1	6106951
studied	O	-1	6106951
in	O	-1	6106951
cat@@	O	-1	6106951
s,	O	-1	6106951
mice	O	-1	6106951
and	O	-1	6106951
rats.	O	-1	6106951
H@@	O	-1	6106951
i@@	O	-1	6106951
gh	O	-1	6106951
doses	O	-1	6106951
caused	O	-1	6106951
an	O	-1	6106951
appa@@	O	-1	6106951
rent	O	-1	6106951
central	O	-1	6106951
ex@@	O	-1	6106951
cit@@	O	-1	6106951
ation,	O	-1	6106951
most	O	-1	6106951
clear@@	O	-1	6106951
ly	O	-1	6106951
seen	O	-1	6106951
as	O	-1	6106951
clon@@	O	-1	6106951
ic	O	-1	6106951
convul@@	B-Disease	D012640	6106951
sions	I-Disease	-1	6106951
,	O	-1	6106951
su@@	O	-1	6106951
per@@	O	-1	6106951
im@@	O	-1	6106951
pos@@	O	-1	6106951
ed	O	-1	6106951
on	O	-1	6106951
gener@@	O	-1	6106951
al	O	-1	6106951
de@@	B-Disease	D003866	6106951
pression	I-Disease	-1	6106951
.	O	-1	6106951
F@@	O	-1	6106951
ol@@	O	-1	6106951
low@@	O	-1	6106951
ing	O	-1	6106951
a	O	-1	6106951
le@@	O	-1	6106951
th@@	O	-1	6106951
al	O	-1	6106951
dose@@	O	-1	6106951
,	O	-1	6106951
death	O	-1	6106951
was	O	-1	6106951
al@@	O	-1	6106951
w@@	O	-1	6106951
ays	O	-1	6106951
associated	O	-1	6106951
with	O	-1	6106951
convul@@	B-Disease	D012640	6106951
sions	I-Disease	-1	6106951
.	O	-1	6106951
Com@@	O	-1	6106951
par@@	O	-1	6106951
ing	O	-1	6106951
the	O	-1	6106951
rel@@	O	-1	6106951
ative	O	-1	6106951
sensitivity	O	-1	6106951
to	O	-1	6106951
central	O	-1	6106951
de@@	B-Disease	D003866	6106951
pression	I-Disease	-1	6106951
and	O	-1	6106951
ex@@	O	-1	6106951
cit@@	O	-1	6106951
ation	O	-1	6106951
revealed	O	-1	6106951
that	O	-1	6106951
rats	O	-1	6106951
were	O	-1	6106951
le@@	O	-1	6106951
ast	O	-1	6106951
likely	O	-1	6106951
to	O	-1	6106951
have	O	-1	6106951
convul@@	B-Disease	D012640	6106951
sions	I-Disease	-1	6106951
at	O	-1	6106951
doses	O	-1	6106951
that	O	-1	6106951
did	O	-1	6106951
not	O	-1	6106951
first	O	-1	6106951
cause	O	-1	6106951
loss	B-Disease	D014474	6106951
of	I-Disease	-1	6106951
con@@	I-Disease	-1	6106951
s@@	I-Disease	-1	6106951
ci@@	I-Disease	-1	6106951
ous@@	I-Disease	-1	6106951
ness	I-Disease	-1	6106951
,	O	-1	6106951
while	O	-1	6106951
cat@@	O	-1	6106951
s	O	-1	6106951
most	O	-1	6106951
clear@@	O	-1	6106951
ly	O	-1	6106951
showed	O	-1	6106951
mark@@	O	-1	6106951
ed	O	-1	6106951
central	O	-1	6106951
ex@@	O	-1	6106951
cit@@	O	-1	6106951
atory	O	-1	6106951
ac@@	O	-1	6106951
tions.	O	-1	6106951
Si@@	O	-1	6106951
gn@@	O	-1	6106951
s	O	-1	6106951
of	O	-1	6106951
F@@	B-Chemical	D005479	6106951
Z@@	I-Chemical	-1	6106951
P	I-Chemical	-1	6106951
tox@@	B-Disease	D064420	6106951
oc@@	I-Disease	-1	6106951
ity	I-Disease	-1	6106951
in	O	-1	6106951
cat@@	O	-1	6106951
s	O	-1	6106951
included	O	-1	6106951
ex@@	O	-1	6106951
ces@@	O	-1	6106951
sive	O	-1	6106951
sal@@	B-Disease	D012798	6106951
i@@	I-Disease	-1	6106951
v@@	I-Disease	-1	6106951
ation	I-Disease	-1	6106951
,	O	-1	6106951
ex@@	O	-1	6106951
trem@@	O	-1	6106951
e	O	-1	6106951
ap@@	O	-1	6106951
pre@@	O	-1	6106951
h@@	O	-1	6106951
en@@	O	-1	6106951
sive	O	-1	6106951
behavi@@	O	-1	6106951
or@@	O	-1	6106951
,	O	-1	6106951
ret@@	O	-1	6106951
ch@@	O	-1	6106951
ing,	O	-1	6106951
musc@@	B-Disease	D014202	6106951
le	I-Disease	-1	6106951
tre@@	I-Disease	-1	6106951
mor@@	I-Disease	-1	6106951
s	I-Disease	-1	6106951
and	O	-1	6106951
convul@@	B-Disease	D012640	6106951
sions	I-Disease	-1	6106951
.	O	-1	6106951
An	O	-1	6106951
inter@@	O	-1	6106951
action	O	-1	6106951
between	O	-1	6106951
F@@	B-Chemical	D005479	6106951
Z@@	I-Chemical	-1	6106951
P	I-Chemical	-1	6106951
and	O	-1	6106951
pent@@	B-Chemical	D010433	6106951
yl@@	I-Chemical	-1	6106951
en@@	I-Chemical	-1	6106951
e@@	I-Chemical	-1	6106951
te@@	I-Chemical	-1	6106951
tra@@	I-Chemical	-1	6106951
z@@	I-Chemical	-1	6106951
ol	I-Chemical	-1	6106951
(	O	-1	6106951
P@@	B-Chemical	D010433	6106951
T@@	I-Chemical	-1	6106951
Z	I-Chemical	-1	6106951
)	O	-1	6106951
was	O	-1	6106951
shown	O	-1	6106951
by	O	-1	6106951
pre@@	O	-1	6106951
treat@@	O	-1	6106951
ing	O	-1	6106951
mice	O	-1	6106951
with	O	-1	6106951
F@@	B-Chemical	D005479	6106951
Z@@	I-Chemical	-1	6106951
P	I-Chemical	-1	6106951
before	O	-1	6106951
P@@	B-Chemical	D010433	6106951
T@@	I-Chemical	-1	6106951
Z	I-Chemical	-1	6106951
ch@@	O	-1	6106951
all@@	O	-1	6106951
en@@	O	-1	6106951
g@@	O	-1	6106951
e.	O	-1	6106951
A@@	O	-1	6106951
s	O	-1	6106951
a	O	-1	6106951
function	O	-1	6106951
of	O	-1	6106951
dose@@	O	-1	6106951
,	O	-1	6106951
F@@	B-Chemical	D005479	6106951
Z@@	I-Chemical	-1	6106951
P	I-Chemical	-1	6106951
first	O	-1	6106951
prot@@	O	-1	6106951
ected	O	-1	6106951
against	O	-1	6106951
convul@@	B-Disease	D012640	6106951
sions	I-Disease	-1	6106951
and	O	-1	6106951
de@@	O	-1	6106951
ath@@	O	-1	6106951
.	O	-1	6106951
A@@	O	-1	6106951
t	O	-1	6106951
higher	O	-1	6106951
dos@@	O	-1	6106951
es,	O	-1	6106951
however,	O	-1	6106951
convul@@	B-Disease	D012640	6106951
sions	I-Disease	-1	6106951
ag@@	O	-1	6106951
ain	O	-1	6106951
em@@	O	-1	6106951
erg@@	O	-1	6106951
ed.	O	-1	6106951
These	O	-1	6106951
doses	O	-1	6106951
of	O	-1	6106951
F@@	B-Chemical	D005479	6106951
Z@@	I-Chemical	-1	6106951
P	I-Chemical	-1	6106951
were	O	-1	6106951
lower	O	-1	6106951
than	O	-1	6106951
those	O	-1	6106951
that	O	-1	6106951
wo@@	O	-1	6106951
uld	O	-1	6106951
alone	O	-1	6106951
cause	O	-1	6106951
convul@@	B-Disease	D012640	6106951
sions	I-Disease	-1	6106951
.	O	-1	6106951
These	O	-1	6106951
results	O	-1	6106951
may	O	-1	6106951
be	O	-1	6106951
re@@	O	-1	6106951
lev@@	O	-1	6106951
ant	O	-1	6106951
to	O	-1	6106951
the	O	-1	6106951
use	O	-1	6106951
of	O	-1	6106951
F@@	B-Chemical	D005479	6106951
Z@@	I-Chemical	-1	6106951
P	I-Chemical	-1	6106951
in	O	-1	6106951
clinical	O	-1	6106951
sit@@	O	-1	6106951
u@@	O	-1	6106951
ations	O	-1	6106951
in	O	-1	6106951
which	O	-1	6106951
there	O	-1	6106951
is	O	-1	6106951
increased	O	-1	6106951
ne@@	O	-1	6106951
ural	O	-1	6106951
ex@@	O	-1	6106951
cit@@	O	-1	6106951
abil@@	O	-1	6106951
ity,	O	-1	6106951
such	O	-1	6106951
as	O	-1	6106951
epilep@@	B-Disease	D004827	6106951
sy	I-Disease	-1	6106951
or	O	-1	6106951
sed@@	O	-1	6106951
ati@@	O	-1	6106951
ve@@	O	-1	6106951
-@@	O	-1	6106951
hy@@	O	-1	6106951
p@@	O	-1	6106951
no@@	O	-1	6106951
tic	O	-1	6106951
drug	O	-1	6106951
withdraw@@	O	-1	6106951
al.	O	-1	6106951

E@@	O	-1	6299641
v@@	O	-1	6299641
idence	O	-1	6299641
for	O	-1	6299641
cardiac	O	-1	6299641
bet@@	O	-1	6299641
a	O	-1	6299641
2-@@	O	-1	6299641
adren@@	O	-1	6299641
oc@@	O	-1	6299641
e@@	O	-1	6299641
pt@@	O	-1	6299641
ors	O	-1	6299641
in	O	-1	6299641
man@@	O	-1	6299641
.	O	-1	6299641
We	O	-1	6299641
compared	O	-1	6299641
the	O	-1	6299641
effects	O	-1	6299641
of	O	-1	6299641
single	O	-1	6299641
doses	O	-1	6299641
of	O	-1	6299641
50	O	-1	6299641
mg	O	-1	6299641
at@@	B-Chemical	D001262	6299641
en@@	I-Chemical	-1	6299641
o@@	I-Chemical	-1	6299641
lol	I-Chemical	-1	6299641
(@@	O	-1	6299641
cardio@@	O	-1	6299641
sel@@	O	-1	6299641
ecti@@	O	-1	6299641
ve@@	O	-1	6299641
),	O	-1	6299641
40	O	-1	6299641
mg	O	-1	6299641
prop@@	B-Chemical	D011433	6299641
ran@@	I-Chemical	-1	6299641
o@@	I-Chemical	-1	6299641
lol	I-Chemical	-1	6299641
(@@	O	-1	6299641
non@@	O	-1	6299641
sel@@	O	-1	6299641
ecti@@	O	-1	6299641
ve@@	O	-1	6299641
),	O	-1	6299641
and	O	-1	6299641
placebo	O	-1	6299641
on	O	-1	6299641
both	O	-1	6299641
ex@@	O	-1	6299641
er@@	O	-1	6299641
ci@@	O	-1	6299641
se@@	O	-1	6299641
-	O	-1	6299641
and	O	-1	6299641
isoproteren@@	B-Chemical	D007545	6299641
ol	I-Chemical	-1	6299641
-induced	O	-1	6299641
tachycardia	B-Disease	D013610	6299641
in	O	-1	6299641
two	O	-1	6299641
experim@@	O	-1	6299641
ents	O	-1	6299641
invol@@	O	-1	6299641
ving	O	-1	6299641
n@@	O	-1	6299641
ine	O	-1	6299641
normal	O	-1	6299641
subj@@	O	-1	6299641
ect@@	O	-1	6299641
s.	O	-1	6299641
M@@	O	-1	6299641
ax@@	O	-1	6299641
im@@	O	-1	6299641
al	O	-1	6299641
ex@@	O	-1	6299641
er@@	O	-1	6299641
cis@@	O	-1	6299641
e	O	-1	6299641
heart	O	-1	6299641
rate	O	-1	6299641
was	O	-1	6299641
reduced	O	-1	6299641
from	O	-1	6299641
18@@	O	-1	6299641
7	O	-1	6299641
+/-	O	-1	6299641
4@@	O	-1	6299641
(S@@	O	-1	6299641
E@@	O	-1	6299641
M@@	O	-1	6299641
)	O	-1	6299641
after	O	-1	6299641
placebo	O	-1	6299641
to	O	-1	6299641
14@@	O	-1	6299641
6	O	-1	6299641
+/-	O	-1	6299641
7	O	-1	6299641
b@@	O	-1	6299641
p@@	O	-1	6299641
m	O	-1	6299641
after	O	-1	6299641
at@@	B-Chemical	D001262	6299641
en@@	I-Chemical	-1	6299641
o@@	I-Chemical	-1	6299641
lol	I-Chemical	-1	6299641
and	O	-1	6299641
13@@	O	-1	6299641
8	O	-1	6299641
+/-	O	-1	6299641
6	O	-1	6299641
b@@	O	-1	6299641
p@@	O	-1	6299641
m	O	-1	6299641
after	O	-1	6299641
prop@@	B-Chemical	D011433	6299641
ran@@	I-Chemical	-1	6299641
o@@	I-Chemical	-1	6299641
lol	I-Chemical	-1	6299641
,	O	-1	6299641
but	O	-1	6299641
there	O	-1	6299641
were	O	-1	6299641
no	O	-1	6299641
differences	O	-1	6299641
between	O	-1	6299641
the	O	-1	6299641
drug@@	O	-1	6299641
s.	O	-1	6299641
The	O	-1	6299641
effects	O	-1	6299641
on	O	-1	6299641
isoproteren@@	B-Chemical	D007545	6299641
ol	I-Chemical	-1	6299641
tachycardia	B-Disease	D013610	6299641
were	O	-1	6299641
determined	O	-1	6299641
before	O	-1	6299641
and	O	-1	6299641
after	O	-1	6299641
atro@@	B-Chemical	D001285	6299641
pine	I-Chemical	-1	6299641
(@@	O	-1	6299641
0.0@@	O	-1	6299641
4	O	-1	6299641
mg/kg	O	-1	6299641
I@@	O	-1	6299641
V@@	O	-1	6299641
).	O	-1	6299641
I@@	B-Chemical	D007545	6299641
so@@	I-Chemical	-1	6299641
proteren@@	I-Chemical	-1	6299641
ol	I-Chemical	-1	6299641
sensitivity	O	-1	6299641
was	O	-1	6299641
determined	O	-1	6299641
as	O	-1	6299641
the	O	-1	6299641
intravenous	O	-1	6299641
dose	O	-1	6299641
that	O	-1	6299641
increased	O	-1	6299641
heart	O	-1	6299641
rate	O	-1	6299641
by	O	-1	6299641
25	O	-1	6299641
b@@	O	-1	6299641
p@@	O	-1	6299641
m	O	-1	6299641
(C@@	O	-1	6299641
D@@	O	-1	6299641
25@@	O	-1	6299641
)	O	-1	6299641
and	O	-1	6299641
this	O	-1	6299641
was	O	-1	6299641
increased	O	-1	6299641
from	O	-1	6299641
1.@@	O	-1	6299641
8	O	-1	6299641
+/-	O	-1	6299641
0.@@	O	-1	6299641
3	O	-1	6299641
microgram@@	O	-1	6299641
s	O	-1	6299641
after	O	-1	6299641
placebo	O	-1	6299641
to	O	-1	6299641
3@@	O	-1	6299641
8.@@	O	-1	6299641
9	O	-1	6299641
+/-	O	-1	6299641
8.@@	O	-1	6299641
3	O	-1	6299641
microgram@@	O	-1	6299641
s	O	-1	6299641
after	O	-1	6299641
prop@@	B-Chemical	D011433	6299641
ran@@	I-Chemical	-1	6299641
o@@	I-Chemical	-1	6299641
lol	I-Chemical	-1	6299641
and	O	-1	6299641
8.@@	O	-1	6299641
3	O	-1	6299641
+/-	O	-1	6299641
1.@@	O	-1	6299641
7	O	-1	6299641
microgram@@	O	-1	6299641
s	O	-1	6299641
after	O	-1	6299641
at@@	B-Chemical	D001262	6299641
en@@	I-Chemical	-1	6299641
o@@	I-Chemical	-1	6299641
lol	I-Chemical	-1	6299641
.	O	-1	6299641
The	O	-1	6299641
difference	O	-1	6299641
in	O	-1	6299641
the	O	-1	6299641
effects	O	-1	6299641
of	O	-1	6299641
the	O	-1	6299641
two	O	-1	6299641
was	O	-1	6299641
significant@@	O	-1	6299641
.	O	-1	6299641
After	O	-1	6299641
atro@@	B-Chemical	D001285	6299641
pine	I-Chemical	-1	6299641
the	O	-1	6299641
C@@	O	-1	6299641
D@@	O	-1	6299641
25	O	-1	6299641
was	O	-1	6299641
un@@	O	-1	6299641
chang@@	O	-1	6299641
ed	O	-1	6299641
after	O	-1	6299641
placebo	O	-1	6299641
(2@@	O	-1	6299641
.@@	O	-1	6299641
3	O	-1	6299641
+/-	O	-1	6299641
0.@@	O	-1	6299641
3	O	-1	6299641
microgram@@	O	-1	6299641
s)	O	-1	6299641
and	O	-1	6299641
at@@	B-Chemical	D001262	6299641
en@@	I-Chemical	-1	6299641
o@@	I-Chemical	-1	6299641
lol	I-Chemical	-1	6299641
(@@	O	-1	6299641
7.@@	O	-1	6299641
7	O	-1	6299641
+/-	O	-1	6299641
1.@@	O	-1	6299641
3	O	-1	6299641
microgram@@	O	-1	6299641
s@@	O	-1	6299641
);	O	-1	6299641
it	O	-1	6299641
was	O	-1	6299641
reduced	O	-1	6299641
after	O	-1	6299641
prop@@	B-Chemical	D011433	6299641
ran@@	I-Chemical	-1	6299641
o@@	I-Chemical	-1	6299641
lol	I-Chemical	-1	6299641
(2@@	O	-1	6299641
4.@@	O	-1	6299641
8	O	-1	6299641
+/-	O	-1	6299641
5.@@	O	-1	6299641
0	O	-1	6299641
microgram@@	O	-1	6299641
s),	O	-1	6299641
but	O	-1	6299641
remained	O	-1	6299641
different	O	-1	6299641
from	O	-1	6299641
at@@	B-Chemical	D001262	6299641
en@@	I-Chemical	-1	6299641
o@@	I-Chemical	-1	6299641
lol	I-Chemical	-1	6299641
.	O	-1	6299641
This	O	-1	6299641
change	O	-1	6299641
with	O	-1	6299641
prop@@	B-Chemical	D011433	6299641
ran@@	I-Chemical	-1	6299641
o@@	I-Chemical	-1	6299641
lol	I-Chemical	-1	6299641
sensitivity	O	-1	6299641
was	O	-1	6299641
calc@@	O	-1	6299641
ul@@	O	-1	6299641
ated	O	-1	6299641
as	O	-1	6299641
the	O	-1	6299641
appa@@	O	-1	6299641
rent	O	-1	6299641
K@@	O	-1	6299641
a,	O	-1	6299641
this	O	-1	6299641
was	O	-1	6299641
un@@	O	-1	6299641
chang@@	O	-1	6299641
ed	O	-1	6299641
by	O	-1	6299641
atro@@	B-Chemical	D001285	6299641
pine	I-Chemical	-1	6299641
(1@@	O	-1	6299641
1.@@	O	-1	6299641
7	O	-1	6299641
+/-	O	-1	6299641
2.@@	O	-1	6299641
1	O	-1	6299641
and	O	-1	6299641
1@@	O	-1	6299641
0.@@	O	-1	6299641
1	O	-1	6299641
+/-	O	-1	6299641
2.@@	O	-1	6299641
5	O	-1	6299641
ml@@	O	-1	6299641
/@@	O	-1	6299641
n@@	O	-1	6299641
g@@	O	-1	6299641
).	O	-1	6299641
These	O	-1	6299641
data	O	-1	6299641
are	O	-1	6299641
consist@@	O	-1	6299641
ent	O	-1	6299641
with	O	-1	6299641
the	O	-1	6299641
hypo@@	O	-1	6299641
thesis	O	-1	6299641
that	O	-1	6299641
ex@@	O	-1	6299641
er@@	O	-1	6299641
ci@@	O	-1	6299641
se@@	O	-1	6299641
-induced	O	-1	6299641
tachycardia	B-Disease	D013610	6299641
results	O	-1	6299641
larg@@	O	-1	6299641
ely	O	-1	6299641
from	O	-1	6299641
bet@@	O	-1	6299641
a	O	-1	6299641
1-@@	O	-1	6299641
receptor	O	-1	6299641
activation	O	-1	6299641
that	O	-1	6299641
is	O	-1	6299641
block@@	O	-1	6299641
ed	O	-1	6299641
by	O	-1	6299641
both	O	-1	6299641
cardio@@	O	-1	6299641
selective	O	-1	6299641
and	O	-1	6299641
non@@	O	-1	6299641
selective	O	-1	6299641
drug@@	O	-1	6299641
s,	O	-1	6299641
whereas	O	-1	6299641
isoproteren@@	B-Chemical	D007545	6299641
ol	I-Chemical	-1	6299641
activ@@	O	-1	6299641
ates	O	-1	6299641
both	O	-1	6299641
bet@@	O	-1	6299641
a	O	-1	6299641
1@@	O	-1	6299641
-	O	-1	6299641
and	O	-1	6299641
bet@@	O	-1	6299641
a	O	-1	6299641
2-@@	O	-1	6299641
receptors	O	-1	6299641
so	O	-1	6299641
that	O	-1	6299641
after	O	-1	6299641
cardio@@	O	-1	6299641
selective	O	-1	6299641
block@@	O	-1	6299641
ade	O	-1	6299641
there	O	-1	6299641
remain@@	O	-1	6299641
s	O	-1	6299641
a	O	-1	6299641
bet@@	O	-1	6299641
a	O	-1	6299641
2-@@	O	-1	6299641
comp@@	O	-1	6299641
on@@	O	-1	6299641
ent	O	-1	6299641
that	O	-1	6299641
can	O	-1	6299641
be	O	-1	6299641
block@@	O	-1	6299641
ed	O	-1	6299641
with	O	-1	6299641
a	O	-1	6299641
non@@	O	-1	6299641
selective	O	-1	6299641
drug.	O	-1	6299641
W@@	O	-1	6299641
h@@	O	-1	6299641
ile	O	-1	6299641
there	O	-1	6299641
appe@@	O	-1	6299641
ar	O	-1	6299641
to	O	-1	6299641
be	O	-1	6299641
bet@@	O	-1	6299641
a	O	-1	6299641
2-@@	O	-1	6299641
receptors	O	-1	6299641
in	O	-1	6299641
the	O	-1	6299641
human	O	-1	6299641
hear@@	O	-1	6299641
t,	O	-1	6299641
their	O	-1	6299641
physi@@	O	-1	6299641
ologic	O	-1	6299641
or	O	-1	6299641
path@@	O	-1	6299641
ologic	O	-1	6299641
ro@@	O	-1	6299641
le@@	O	-1	6299641
s	O	-1	6299641
re@@	O	-1	6299641
ma@@	O	-1	6299641
in	O	-1	6299641
to	O	-1	6299641
be	O	-1	6299641
def@@	O	-1	6299641
ine@@	O	-1	6299641
d.	O	-1	6299641

H@@	O	-1	6305660
orm@@	O	-1	6305660
on@@	O	-1	6305660
es	O	-1	6305660
and	O	-1	6305660
risk	O	-1	6305660
of	O	-1	6305660
b@@	B-Disease	D001943	6305660
reas@@	I-Disease	-1	6305660
t	I-Disease	-1	6305660
cancer	I-Disease	-1	6305660
.	O	-1	6305660
This	O	-1	6305660
pap@@	O	-1	6305660
er	O	-1	6305660
reports	O	-1	6305660
the	O	-1	6305660
results	O	-1	6305660
of	O	-1	6305660
a	O	-1	6305660
study	O	-1	6305660
of	O	-1	6305660
50	O	-1	6305660
men@@	O	-1	6305660
o@@	O	-1	6305660
pa@@	O	-1	6305660
us@@	O	-1	6305660
al	O	-1	6305660
women	O	-1	6305660
receiving	O	-1	6305660
h@@	O	-1	6305660
orm@@	O	-1	6305660
on@@	O	-1	6305660
al	O	-1	6305660
re@@	O	-1	6305660
pl@@	O	-1	6305660
ac@@	O	-1	6305660
ement	O	-1	6305660
therapy.	O	-1	6305660
The	O	-1	6305660
maj@@	O	-1	6305660
or@@	O	-1	6305660
ity	O	-1	6305660
(2@@	O	-1	6305660
9@@	O	-1	6305660
)	O	-1	6305660
had	O	-1	6305660
surg@@	O	-1	6305660
ical	O	-1	6305660
men@@	O	-1	6305660
o@@	O	-1	6305660
pa@@	O	-1	6305660
use@@	O	-1	6305660
;	O	-1	6305660
their	O	-1	6305660
mean	O	-1	6305660
age	O	-1	6305660
was	O	-1	6305660
4@@	O	-1	6305660
5.@@	O	-1	6305660
7	O	-1	6305660
year@@	O	-1	6305660
s.	O	-1	6305660
It	O	-1	6305660
was	O	-1	6305660
hypo@@	O	-1	6305660
the@@	O	-1	6305660
si@@	O	-1	6305660
zed	O	-1	6305660
that	O	-1	6305660
pro@@	B-Chemical	D011372	6305660
g@@	I-Chemical	-1	6305660
est@@	I-Chemical	-1	6305660
ins	I-Chemical	-1	6305660
could	O	-1	6305660
equ@@	O	-1	6305660
il@@	O	-1	6305660
i@@	O	-1	6305660
b@@	O	-1	6305660
rate	O	-1	6305660
the	O	-1	6305660
effects	O	-1	6305660
of	O	-1	6305660
the	O	-1	6305660
est@@	O	-1	6305660
ro@@	O	-1	6305660
genic	O	-1	6305660
stimulation	O	-1	6305660
on	O	-1	6305660
the	O	-1	6305660
m@@	O	-1	6305660
am@@	O	-1	6305660
m@@	O	-1	6305660
ary	O	-1	6305660
and	O	-1	6305660
endo@@	O	-1	6305660
me@@	O	-1	6305660
trial	O	-1	6305660
t@@	O	-1	6305660
arg@@	O	-1	6305660
et	O	-1	6305660
tissu@@	O	-1	6305660
es	O	-1	6305660
of	O	-1	6305660
women	O	-1	6305660
on	O	-1	6305660
h@@	O	-1	6305660
orm@@	O	-1	6305660
on@@	O	-1	6305660
al	O	-1	6305660
re@@	O	-1	6305660
pl@@	O	-1	6305660
ac@@	O	-1	6305660
ement	O	-1	6305660
therapy.	O	-1	6305660
The	O	-1	6305660
treatment	O	-1	6305660
sch@@	O	-1	6305660
ed@@	O	-1	6305660
ul@@	O	-1	6305660
e	O	-1	6305660
consist@@	O	-1	6305660
ed	O	-1	6305660
of	O	-1	6305660
con@@	B-Chemical	D004966	6305660
j@@	I-Chemical	-1	6305660
u@@	I-Chemical	-1	6305660
g@@	I-Chemical	-1	6305660
ated	I-Chemical	-1	6305660
est@@	I-Chemical	-1	6305660
ro@@	I-Chemical	-1	6305660
gen@@	I-Chemical	-1	6305660
s	I-Chemical	-1	6305660
(	O	-1	6305660
Pre@@	B-Chemical	D004966	6305660
m@@	I-Chemical	-1	6305660
ar@@	I-Chemical	-1	6305660
in	I-Chemical	-1	6305660
)	O	-1	6305660
1.@@	O	-1	6305660
25	O	-1	6305660
mg/@@	O	-1	6305660
day	O	-1	6305660
for	O	-1	6305660
21	O	-1	6305660
days	O	-1	6305660
and	O	-1	6305660
M@@	B-Chemical	D017258	6305660
ed@@	I-Chemical	-1	6305660
ro@@	I-Chemical	-1	6305660
x@@	I-Chemical	-1	6305660
y@@	I-Chemical	-1	6305660
pro@@	I-Chemical	-1	6305660
g@@	I-Chemical	-1	6305660
est@@	I-Chemical	-1	6305660
er@@	I-Chemical	-1	6305660
one	I-Chemical	-1	6305660
acet@@	I-Chemical	-1	6305660
ate	I-Chemical	-1	6305660
10	O	-1	6305660
mg/@@	O	-1	6305660
day	O	-1	6305660
for	O	-1	6305660
10	O	-1	6305660
days	O	-1	6305660
in	O	-1	6305660
each	O	-1	6305660
month@@	O	-1	6305660
.	O	-1	6305660
The	O	-1	6305660
mean	O	-1	6305660
treatment	O	-1	6305660
period	O	-1	6305660
was	O	-1	6305660
1@@	O	-1	6305660
8	O	-1	6305660
months.	O	-1	6305660
D@@	O	-1	6305660
uring	O	-1	6305660
the	O	-1	6305660
follow-up	O	-1	6305660
perio@@	O	-1	6305660
d,	O	-1	6305660
atten@@	O	-1	6305660
tion	O	-1	6305660
was	O	-1	6305660
pa@@	O	-1	6305660
id	O	-1	6305660
to	O	-1	6305660
b@@	O	-1	6305660
reas@@	O	-1	6305660
t	O	-1	6305660
mo@@	O	-1	6305660
di@@	O	-1	6305660
fic@@	O	-1	6305660
ations	O	-1	6305660
as	O	-1	6305660
ev@@	O	-1	6305660
id@@	O	-1	6305660
enc@@	O	-1	6305660
ed	O	-1	6305660
by	O	-1	6305660
sympto@@	O	-1	6305660
mat@@	O	-1	6305660
olog@@	O	-1	6305660
y,	O	-1	6305660
physi@@	O	-1	6305660
c@@	O	-1	6305660
al	O	-1	6305660
examin@@	O	-1	6305660
ation,	O	-1	6305660
and	O	-1	6305660
pl@@	O	-1	6305660
ate	O	-1	6305660
ther@@	O	-1	6305660
mo@@	O	-1	6305660
graph@@	O	-1	6305660
y.	O	-1	6305660
M@@	B-Disease	D059373	6305660
ast@@	I-Disease	-1	6305660
o@@	I-Disease	-1	6305660
dy@@	I-Disease	-1	6305660
n@@	I-Disease	-1	6305660
ia	I-Disease	-1	6305660
was	O	-1	6305660
reported	O	-1	6305660
by	O	-1	6305660
21	O	-1	6305660
patients,	O	-1	6305660
and	O	-1	6305660
physi@@	O	-1	6305660
c@@	O	-1	6305660
al	O	-1	6305660
examin@@	O	-1	6305660
ation	O	-1	6305660
revealed	O	-1	6305660
a	O	-1	6305660
li@@	O	-1	6305660
ght	O	-1	6305660
increase	O	-1	6305660
in	O	-1	6305660
b@@	O	-1	6305660
reas@@	O	-1	6305660
t	O	-1	6305660
fir@@	O	-1	6305660
m@@	O	-1	6305660
ness	O	-1	6305660
in	O	-1	6305660
12	O	-1	6305660
women	O	-1	6305660
and	O	-1	6305660
a	O	-1	6305660
moder@@	O	-1	6305660
ate	O	-1	6305660
increase	O	-1	6305660
in	O	-1	6305660
b@@	O	-1	6305660
reas@@	O	-1	6305660
t	O	-1	6305660
no@@	O	-1	6305660
d@@	O	-1	6305660
ul@@	O	-1	6305660
ar@@	O	-1	6305660
ity	O	-1	6305660
in	O	-1	6305660
2	O	-1	6305660
wom@@	O	-1	6305660
en@@	O	-1	6305660
.	O	-1	6305660
Th@@	O	-1	6305660
em@@	O	-1	6305660
ograph@@	O	-1	6305660
y	O	-1	6305660
con@@	O	-1	6305660
fir@@	O	-1	6305660
m@@	O	-1	6305660
ed	O	-1	6305660
the	O	-1	6305660
ex@@	O	-1	6305660
ist@@	O	-1	6305660
ence	O	-1	6305660
of	O	-1	6305660
an	O	-1	6305660
ex@@	O	-1	6305660
ces@@	O	-1	6305660
sive	O	-1	6305660
b@@	O	-1	6305660
reas@@	O	-1	6305660
t	O	-1	6305660
stimulation	O	-1	6305660
in	O	-1	6305660
1	O	-1	6305660
women	O	-1	6305660
who	O	-1	6305660
com@@	O	-1	6305660
pl@@	O	-1	6305660
ained	O	-1	6305660
of	O	-1	6305660
moder@@	O	-1	6305660
ate	O	-1	6305660
ma@@	B-Disease	D059373	6305660
sto@@	I-Disease	-1	6305660
dy@@	I-Disease	-1	6305660
n@@	I-Disease	-1	6305660
ia	I-Disease	-1	6305660
and	O	-1	6305660
in	O	-1	6305660
5	O	-1	6305660
of	O	-1	6305660
the	O	-1	6305660
7	O	-1	6305660
women	O	-1	6305660
who	O	-1	6305660
com@@	O	-1	6305660
pl@@	O	-1	6305660
ained	O	-1	6305660
of	O	-1	6305660
severe	O	-1	6305660
ma@@	B-Disease	D059373	6305660
sto@@	I-Disease	-1	6305660
dy@@	I-Disease	-1	6305660
n@@	I-Disease	-1	6305660
ia	I-Disease	-1	6305660
.	O	-1	6305660
N@@	O	-1	6305660
orm@@	O	-1	6305660
al@@	O	-1	6305660
ization	O	-1	6305660
was	O	-1	6305660
obtained	O	-1	6305660
by	O	-1	6305660
h@@	O	-1	6305660
al@@	O	-1	6305660
ving	O	-1	6305660
the	O	-1	6305660
est@@	B-Chemical	D004967	6305660
ro@@	I-Chemical	-1	6305660
gen	I-Chemical	-1	6305660
dose.	O	-1	6305660
These	O	-1	6305660
results	O	-1	6305660
suggest	O	-1	6305660
that	O	-1	6305660
h@@	O	-1	6305660
orm@@	O	-1	6305660
on@@	O	-1	6305660
al	O	-1	6305660
re@@	O	-1	6305660
pl@@	O	-1	6305660
ac@@	O	-1	6305660
ement	O	-1	6305660
therapy	O	-1	6305660
can	O	-1	6305660
be	O	-1	6305660
saf@@	O	-1	6305660
ely	O	-1	6305660
prescri@@	O	-1	6305660
bed	O	-1	6305660
if	O	-1	6305660
the	O	-1	6305660
following	O	-1	6305660
c@@	O	-1	6305660
rit@@	O	-1	6305660
er@@	O	-1	6305660
ia	O	-1	6305660
are	O	-1	6305660
s@@	O	-1	6305660
atis@@	O	-1	6305660
fi@@	O	-1	6305660
ed@@	O	-1	6305660
:	O	-1	6305660
1)	O	-1	6305660
pre@@	O	-1	6305660
lim@@	O	-1	6305660
inary	O	-1	6305660
evalu@@	O	-1	6305660
ation	O	-1	6305660
of	O	-1	6305660
patients	O	-1	6305660
from	O	-1	6305660
a	O	-1	6305660
clin@@	O	-1	6305660
ic@@	O	-1	6305660
al,	O	-1	6305660
metabol@@	O	-1	6305660
ic@@	O	-1	6305660
,	O	-1	6305660
cyto@@	O	-1	6305660
log@@	O	-1	6305660
ic@@	O	-1	6305660
,	O	-1	6305660
and	O	-1	6305660
m@@	O	-1	6305660
am@@	O	-1	6305660
mo@@	O	-1	6305660
graph@@	O	-1	6305660
ic	O	-1	6305660
per@@	O	-1	6305660
sp@@	O	-1	6305660
ecti@@	O	-1	6305660
ve@@	O	-1	6305660
;	O	-1	6305660
2)	O	-1	6305660
cy@@	O	-1	6305660
cl@@	O	-1	6305660
ic	O	-1	6305660
treatment	O	-1	6305660
sch@@	O	-1	6305660
ed@@	O	-1	6305660
ul@@	O	-1	6305660
e,	O	-1	6305660
with	O	-1	6305660
a	O	-1	6305660
pro@@	O	-1	6305660
g@@	O	-1	6305660
est@@	O	-1	6305660
ative	O	-1	6305660
phase	O	-1	6305660
of	O	-1	6305660
10	O	-1	6305660
da@@	O	-1	6305660
ys@@	O	-1	6305660
;	O	-1	6305660
and	O	-1	6305660
3@@	O	-1	6305660
)	O	-1	6305660
perio@@	O	-1	6305660
di@@	O	-1	6305660
c	O	-1	6305660
complete	O	-1	6305660
follow-@@	O	-1	6305660
up@@	O	-1	6305660
,	O	-1	6305660
with	O	-1	6305660
ac@@	O	-1	6305660
cur@@	O	-1	6305660
ate	O	-1	6305660
ther@@	O	-1	6305660
mo@@	O	-1	6305660
graph@@	O	-1	6305660
ic	O	-1	6305660
evalu@@	O	-1	6305660
ation	O	-1	6305660
of	O	-1	6305660
the	O	-1	6305660
b@@	O	-1	6305660
reas@@	O	-1	6305660
t	O	-1	6305660
t@@	O	-1	6305660
arg@@	O	-1	6305660
et	O	-1	6305660
tissu@@	O	-1	6305660
es.	O	-1	6305660

E@@	O	-1	6310832
arly	O	-1	6310832
inf@@	B-Disease	D007239	6310832
ec@@	I-Disease	-1	6310832
tions	I-Disease	-1	6310832
in	O	-1	6310832
kidne@@	O	-1	6310832
y,	O	-1	6310832
hear@@	O	-1	6310832
t,	O	-1	6310832
and	O	-1	6310832
liver	O	-1	6310832
transplant	O	-1	6310832
re@@	O	-1	6310832
ci@@	O	-1	6310832
pi@@	O	-1	6310832
ents	O	-1	6310832
on	O	-1	6310832
cyclospor@@	B-Chemical	D016572	6310832
ine	I-Chemical	-1	6310832
.	O	-1	6310832
E@@	O	-1	6310832
igh@@	O	-1	6310832
ty-@@	O	-1	6310832
one	O	-1	6310832
ren@@	O	-1	6310832
al,	O	-1	6310832
sev@@	O	-1	6310832
ent@@	O	-1	6310832
e@@	O	-1	6310832
en	O	-1	6310832
hear@@	O	-1	6310832
t,	O	-1	6310832
and	O	-1	6310832
tw@@	O	-1	6310832
ent@@	O	-1	6310832
y-@@	O	-1	6310832
four	O	-1	6310832
liver	O	-1	6310832
transplant	O	-1	6310832
patients	O	-1	6310832
were	O	-1	6310832
followed	O	-1	6310832
for	O	-1	6310832
inf@@	B-Disease	D007239	6310832
ection	I-Disease	-1	6310832
.	O	-1	6310832
S@@	O	-1	6310832
event@@	O	-1	6310832
e@@	O	-1	6310832
en	O	-1	6310832
renal	O	-1	6310832
patients	O	-1	6310832
received	O	-1	6310832
az@@	B-Chemical	D001379	6310832
ath@@	I-Chemical	-1	6310832
io@@	I-Chemical	-1	6310832
p@@	I-Chemical	-1	6310832
rine	I-Chemical	-1	6310832
(	O	-1	6310832
A@@	B-Chemical	D001379	6310832
z@@	I-Chemical	-1	6310832
a	I-Chemical	-1	6310832
)	O	-1	6310832
and	O	-1	6310832
pre@@	B-Chemical	D011241	6310832
d@@	I-Chemical	-1	6310832
n@@	I-Chemical	-1	6310832
is@@	I-Chemical	-1	6310832
one	I-Chemical	-1	6310832
as	O	-1	6310832
par@@	O	-1	6310832
t	O	-1	6310832
of	O	-1	6310832
a	O	-1	6310832
randomized	O	-1	6310832
trial	O	-1	6310832
of	O	-1	6310832
immunosup@@	O	-1	6310832
pression	O	-1	6310832
with	O	-1	6310832
21	O	-1	6310832
cyclospor@@	B-Chemical	D016572	6310832
ine	I-Chemical	-1	6310832
-@@	O	-1	6310832
and@@	O	-1	6310832
-	O	-1	6310832
pre@@	B-Chemical	D011241	6310832
d@@	I-Chemical	-1	6310832
n@@	I-Chemical	-1	6310832
is@@	I-Chemical	-1	6310832
one	I-Chemical	-1	6310832
-treated	O	-1	6310832
renal	O	-1	6310832
transplant	O	-1	6310832
patients.	O	-1	6310832
All	O	-1	6310832
o@@	O	-1	6310832
ther@@	O	-1	6310832
s	O	-1	6310832
received	O	-1	6310832
cyclospor@@	B-Chemical	D016572	6310832
ine	I-Chemical	-1	6310832
and	O	-1	6310832
pre@@	B-Chemical	D011241	6310832
d@@	I-Chemical	-1	6310832
n@@	I-Chemical	-1	6310832
is@@	I-Chemical	-1	6310832
one	I-Chemical	-1	6310832
.	O	-1	6310832
The	O	-1	6310832
randomized	O	-1	6310832
A@@	B-Chemical	D001379	6310832
z@@	I-Chemical	-1	6310832
a	I-Chemical	-1	6310832
patients	O	-1	6310832
had	O	-1	6310832
more	O	-1	6310832
over@@	O	-1	6310832
all	O	-1	6310832
inf@@	B-Disease	D007239	6310832
ec@@	I-Disease	-1	6310832
tions	I-Disease	-1	6310832
(P	O	-1	6310832
less	O	-1	6310832
than	O	-1	6310832
0.05@@	O	-1	6310832
)	O	-1	6310832
and	O	-1	6310832
more	O	-1	6310832
non@@	O	-1	6310832
viral	O	-1	6310832
inf@@	B-Disease	D007239	6310832
ec@@	I-Disease	-1	6310832
tions	I-Disease	-1	6310832
(P	O	-1	6310832
less	O	-1	6310832
than	O	-1	6310832
0.0@@	O	-1	6310832
2)	O	-1	6310832
than	O	-1	6310832
the	O	-1	6310832
randomized	O	-1	6310832
cyclospor@@	B-Chemical	D016572	6310832
ine	I-Chemical	-1	6310832
patients.	O	-1	6310832
H@@	O	-1	6310832
ear@@	O	-1	6310832
t	O	-1	6310832
and	O	-1	6310832
liver	O	-1	6310832
patients	O	-1	6310832
had	O	-1	6310832
more	O	-1	6310832
inf@@	B-Disease	D007239	6310832
ec@@	I-Disease	-1	6310832
tions	I-Disease	-1	6310832
than	O	-1	6310832
cyclospor@@	B-Chemical	D016572	6310832
ine	I-Chemical	-1	6310832
renal	O	-1	6310832
patients	O	-1	6310832
but	O	-1	6310832
fe@@	O	-1	6310832
w@@	O	-1	6310832
er	O	-1	6310832
inf@@	B-Disease	D007239	6310832
ec@@	I-Disease	-1	6310832
tions	I-Disease	-1	6310832
than	O	-1	6310832
the	O	-1	6310832
A@@	B-Chemical	D001379	6310832
z@@	I-Chemical	-1	6310832
a	I-Chemical	-1	6310832
renal	O	-1	6310832
patients.	O	-1	6310832
There	O	-1	6310832
were	O	-1	6310832
no	O	-1	6310832
inf@@	O	-1	6310832
ecti@@	O	-1	6310832
ous	O	-1	6310832
de@@	O	-1	6310832
ath@@	O	-1	6310832
s	O	-1	6310832
in	O	-1	6310832
renal	O	-1	6310832
transplant	O	-1	6310832
patients	O	-1	6310832
on	O	-1	6310832
cyclospor@@	B-Chemical	D016572	6310832
ine	I-Chemical	-1	6310832
or	O	-1	6310832
A@@	B-Chemical	D001379	6310832
z@@	I-Chemical	-1	6310832
a	I-Chemical	-1	6310832
,	O	-1	6310832
but	O	-1	6310832
inf@@	B-Disease	D007239	6310832
ection	I-Disease	-1	6310832
pl@@	O	-1	6310832
ayed	O	-1	6310832
a	O	-1	6310832
major	O	-1	6310832
role	O	-1	6310832
in	O	-1	6310832
3	O	-1	6310832
out	O	-1	6310832
of	O	-1	6310832
6	O	-1	6310832
cardiac	O	-1	6310832
transplant	O	-1	6310832
de@@	O	-1	6310832
ath@@	O	-1	6310832
s	O	-1	6310832
and	O	-1	6310832
in	O	-1	6310832
8	O	-1	6310832
out	O	-1	6310832
of	O	-1	6310832
9	O	-1	6310832
liver	O	-1	6310832
transplant	O	-1	6310832
de@@	O	-1	6310832
ath@@	O	-1	6310832
s.	O	-1	6310832
R@@	O	-1	6310832
en@@	O	-1	6310832
al	O	-1	6310832
patients	O	-1	6310832
on	O	-1	6310832
cyclospor@@	B-Chemical	D016572	6310832
ine	I-Chemical	-1	6310832
had	O	-1	6310832
the	O	-1	6310832
fe@@	O	-1	6310832
w@@	O	-1	6310832
est	O	-1	6310832
bac@@	B-Disease	D016470	6310832
te@@	I-Disease	-1	6310832
re@@	I-Disease	-1	6310832
mi@@	I-Disease	-1	6310832
as	I-Disease	-1	6310832
.	O	-1	6310832
An@@	O	-1	6310832
aly@@	O	-1	6310832
sis	O	-1	6310832
of	O	-1	6310832
sit@@	O	-1	6310832
e	O	-1	6310832
of	O	-1	6310832
inf@@	B-Disease	D007239	6310832
ection	I-Disease	-1	6310832
showed	O	-1	6310832
a	O	-1	6310832
pre@@	O	-1	6310832
p@@	O	-1	6310832
on@@	O	-1	6310832
der@@	O	-1	6310832
ance	O	-1	6310832
of	O	-1	6310832
ab@@	B-Disease	D059413	6310832
domin@@	I-Disease	-1	6310832
al	I-Disease	-1	6310832
inf@@	I-Disease	-1	6310832
ec@@	I-Disease	-1	6310832
tions	I-Disease	-1	6310832
in	O	-1	6310832
liver	O	-1	6310832
patients,	O	-1	6310832
intra@@	O	-1	6310832
th@@	O	-1	6310832
or@@	O	-1	6310832
ac@@	O	-1	6310832
ic	O	-1	6310832
inf@@	B-Disease	D007239	6310832
ec@@	I-Disease	-1	6310832
tions	I-Disease	-1	6310832
in	O	-1	6310832
heart	O	-1	6310832
patients,	O	-1	6310832
and	O	-1	6310832
urinary	B-Disease	D014552	6310832
trac@@	I-Disease	-1	6310832
t	I-Disease	-1	6310832
inf@@	I-Disease	-1	6310832
ec@@	I-Disease	-1	6310832
tions	I-Disease	-1	6310832
in	O	-1	6310832
renal	O	-1	6310832
patients.	O	-1	6310832
P@@	O	-1	6310832
ul@@	O	-1	6310832
monary	O	-1	6310832
inf@@	B-Disease	D007239	6310832
ec@@	I-Disease	-1	6310832
tions	I-Disease	-1	6310832
were	O	-1	6310832
less	O	-1	6310832
common	O	-1	6310832
in	O	-1	6310832
cyclospor@@	B-Chemical	D016572	6310832
ine	I-Chemical	-1	6310832
-treated	O	-1	6310832
renal	O	-1	6310832
patients	O	-1	6310832
than	O	-1	6310832
in	O	-1	6310832
A@@	B-Chemical	D001379	6310832
z@@	I-Chemical	-1	6310832
a	I-Chemical	-1	6310832
-treated	O	-1	6310832
patients	O	-1	6310832
(P	O	-1	6310832
less	O	-1	6310832
than	O	-1	6310832
0.05@@	O	-1	6310832
).	O	-1	6310832
A@@	B-Chemical	D001379	6310832
z@@	I-Chemical	-1	6310832
a	I-Chemical	-1	6310832
patients	O	-1	6310832
had	O	-1	6310832
significantly	O	-1	6310832
more	O	-1	6310832
st@@	B-Disease	D013203	6310832
a@@	I-Disease	-1	6310832
ph@@	I-Disease	-1	6310832
y@@	I-Disease	-1	6310832
lo@@	I-Disease	-1	6310832
co@@	I-Disease	-1	6310832
c@@	I-Disease	-1	6310832
c@@	I-Disease	-1	6310832
al	I-Disease	-1	6310832
inf@@	I-Disease	-1	6310832
ec@@	I-Disease	-1	6310832
tions	I-Disease	-1	6310832
than	O	-1	6310832
all	O	-1	6310832
other	O	-1	6310832
transplant	O	-1	6310832
groups	O	-1	6310832
(P	O	-1	6310832
less	O	-1	6310832
than	O	-1	6310832
0.00@@	O	-1	6310832
5@@	O	-1	6310832
),	O	-1	6310832
and	O	-1	6310832
systemic	O	-1	6310832
f@@	B-Disease	D009181	6310832
un@@	I-Disease	-1	6310832
g@@	I-Disease	-1	6310832
al	I-Disease	-1	6310832
inf@@	I-Disease	-1	6310832
ec@@	I-Disease	-1	6310832
tions	I-Disease	-1	6310832
occurred	O	-1	6310832
only	O	-1	6310832
in	O	-1	6310832
the	O	-1	6310832
liver	O	-1	6310832
transplant	O	-1	6310832
group.	O	-1	6310832
C@@	O	-1	6310832
y@@	O	-1	6310832
to@@	O	-1	6310832
me@@	O	-1	6310832
g@@	O	-1	6310832
alo@@	O	-1	6310832
vi@@	O	-1	6310832
ru@@	O	-1	6310832
s	O	-1	6310832
(C@@	O	-1	6310832
M@@	O	-1	6310832
V@@	O	-1	6310832
)	O	-1	6310832
s@@	O	-1	6310832
he@@	O	-1	6310832
d@@	O	-1	6310832
ding	O	-1	6310832
or	O	-1	6310832
ser@@	O	-1	6310832
ological	O	-1	6310832
ri@@	O	-1	6310832
ses	O	-1	6310832
in	O	-1	6310832
anti@@	O	-1	6310832
body	O	-1	6310832
ti@@	O	-1	6310832
ter@@	O	-1	6310832
,	O	-1	6310832
or	O	-1	6310832
both	O	-1	6310832
occurred	O	-1	6310832
in	O	-1	6310832
7@@	O	-1	6310832
8@@	O	-1	6310832
%	O	-1	6310832
of	O	-1	6310832
cyclospor@@	B-Chemical	D016572	6310832
ine	I-Chemical	-1	6310832
patients	O	-1	6310832
and	O	-1	6310832
7@@	O	-1	6310832
6%	O	-1	6310832
of	O	-1	6310832
A@@	B-Chemical	D001379	6310832
z@@	I-Chemical	-1	6310832
a	I-Chemical	-1	6310832
patients.	O	-1	6310832
Of	O	-1	6310832
the	O	-1	6310832
cyclospor@@	B-Chemical	D016572	6310832
ine	I-Chemical	-1	6310832
patients,	O	-1	6310832
1@@	O	-1	6310832
5%	O	-1	6310832
had	O	-1	6310832
symptoms	O	-1	6310832
related	O	-1	6310832
to	O	-1	6310832
C@@	B-Disease	D003586	6310832
M@@	I-Disease	-1	6310832
V	I-Disease	-1	6310832
inf@@	I-Disease	-1	6310832
ection	I-Disease	-1	6310832
.	O	-1	6310832
S@@	O	-1	6310832
er@@	O	-1	6310832
ological	O	-1	6310832
evidence	O	-1	6310832
for	O	-1	6310832
E@@	B-Disease	D020031	6310832
p@@	I-Disease	-1	6310832
ste@@	I-Disease	-1	6310832
in	I-Disease	-1	6310832
B@@	I-Disease	-1	6310832
ar@@	I-Disease	-1	6310832
r	I-Disease	-1	6310832
V@@	I-Disease	-1	6310832
i@@	I-Disease	-1	6310832
ru@@	I-Disease	-1	6310832
s	I-Disease	-1	6310832
inf@@	I-Disease	-1	6310832
ection	I-Disease	-1	6310832
was	O	-1	6310832
found	O	-1	6310832
in	O	-1	6310832
20@@	O	-1	6310832
%	O	-1	6310832
of	O	-1	6310832
6@@	O	-1	6310832
5	O	-1	6310832
cyclospor@@	B-Chemical	D016572	6310832
ine	I-Chemical	-1	6310832
patients	O	-1	6310832
studi@@	O	-1	6310832
ed.	O	-1	6310832
Th@@	O	-1	6310832
ree	O	-1	6310832
had	O	-1	6310832
associated	O	-1	6310832
symptom@@	O	-1	6310832
s,	O	-1	6310832
and	O	-1	6310832
one	O	-1	6310832
developed	O	-1	6310832
a	O	-1	6310832
lymph@@	B-Disease	D008223	6310832
oma	I-Disease	-1	6310832
.	O	-1	6310832

S@@	O	-1	6316193
tr@@	O	-1	6316193
uc@@	O	-1	6316193
t@@	O	-1	6316193
ure@@	O	-1	6316193
-@@	O	-1	6316193
activity	O	-1	6316193
and	O	-1	6316193
dose-@@	O	-1	6316193
effect	O	-1	6316193
rel@@	O	-1	6316193
ation@@	O	-1	6316193
shi@@	O	-1	6316193
p@@	O	-1	6316193
s	O	-1	6316193
of	O	-1	6316193
the	O	-1	6316193
antagon@@	O	-1	6316193
ism	O	-1	6316193
of	O	-1	6316193
p@@	B-Chemical	D010852	6316193
ic@@	I-Chemical	-1	6316193
ro@@	I-Chemical	-1	6316193
tox@@	I-Chemical	-1	6316193
in	I-Chemical	-1	6316193
-induced	O	-1	6316193
seizures	B-Disease	D012640	6316193
by	O	-1	6316193
chol@@	B-Chemical	D002766	6316193
ec@@	I-Chemical	-1	6316193
y@@	I-Chemical	-1	6316193
sto@@	I-Chemical	-1	6316193
kin@@	I-Chemical	-1	6316193
in	I-Chemical	-1	6316193
,	O	-1	6316193
f@@	O	-1	6316193
ra@@	O	-1	6316193
g@@	O	-1	6316193
ments	O	-1	6316193
and	O	-1	6316193
an@@	O	-1	6316193
alo@@	O	-1	6316193
gu@@	O	-1	6316193
es	O	-1	6316193
of	O	-1	6316193
chol@@	B-Chemical	D002766	6316193
ec@@	I-Chemical	-1	6316193
y@@	I-Chemical	-1	6316193
sto@@	I-Chemical	-1	6316193
kin@@	I-Chemical	-1	6316193
in	I-Chemical	-1	6316193
in	O	-1	6316193
mice.	O	-1	6316193
In@@	O	-1	6316193
tra@@	O	-1	6316193
per@@	O	-1	6316193
it@@	O	-1	6316193
one@@	O	-1	6316193
al	O	-1	6316193
administration	O	-1	6316193
of	O	-1	6316193
chol@@	B-Chemical	D012844	6316193
ec@@	I-Chemical	-1	6316193
y@@	I-Chemical	-1	6316193
sto@@	I-Chemical	-1	6316193
kin@@	I-Chemical	-1	6316193
in	I-Chemical	-1	6316193
oc@@	I-Chemical	-1	6316193
t@@	I-Chemical	-1	6316193
ap@@	I-Chemical	-1	6316193
ep@@	I-Chemical	-1	6316193
ti@@	I-Chemical	-1	6316193
de	I-Chemical	-1	6316193
sul@@	O	-1	6316193
ph@@	O	-1	6316193
ate	O	-1	6316193
est@@	O	-1	6316193
er	O	-1	6316193
(	O	-1	6316193
C@@	B-Chemical	D012844	6316193
C@@	I-Chemical	-1	6316193
K@@	I-Chemical	-1	6316193
-@@	I-Chemical	-1	6316193
8	I-Chemical	-1	6316193
-@@	O	-1	6316193
S@@	O	-1	6316193
E@@	O	-1	6316193
)	O	-1	6316193
and	O	-1	6316193
non@@	O	-1	6316193
sul@@	O	-1	6316193
ph@@	O	-1	6316193
ated	O	-1	6316193
chol@@	B-Chemical	D012844	6316193
ec@@	I-Chemical	-1	6316193
y@@	I-Chemical	-1	6316193
sto@@	I-Chemical	-1	6316193
kin@@	I-Chemical	-1	6316193
in	I-Chemical	-1	6316193
oc@@	I-Chemical	-1	6316193
t@@	I-Chemical	-1	6316193
ap@@	I-Chemical	-1	6316193
ep@@	I-Chemical	-1	6316193
ti@@	I-Chemical	-1	6316193
de	I-Chemical	-1	6316193
(	O	-1	6316193
C@@	B-Chemical	D012844	6316193
C@@	I-Chemical	-1	6316193
K@@	I-Chemical	-1	6316193
-@@	I-Chemical	-1	6316193
8	I-Chemical	-1	6316193
-@@	O	-1	6316193
N@@	O	-1	6316193
S)	O	-1	6316193
enhanced	O	-1	6316193
the	O	-1	6316193
lat@@	O	-1	6316193
ency	O	-1	6316193
of	O	-1	6316193
seizures	B-Disease	D012640	6316193
induced	O	-1	6316193
by	O	-1	6316193
p@@	B-Chemical	D010852	6316193
ic@@	I-Chemical	-1	6316193
ro@@	I-Chemical	-1	6316193
tox@@	I-Chemical	-1	6316193
in	I-Chemical	-1	6316193
in	O	-1	6316193
mice.	O	-1	6316193
E@@	O	-1	6316193
x@@	O	-1	6316193
per@@	O	-1	6316193
im@@	O	-1	6316193
ents	O	-1	6316193
with	O	-1	6316193
N@@	O	-1	6316193
-	O	-1	6316193
and	O	-1	6316193
C@@	O	-1	6316193
-@@	O	-1	6316193
ter@@	O	-1	6316193
min@@	O	-1	6316193
al	O	-1	6316193
f@@	O	-1	6316193
ra@@	O	-1	6316193
g@@	O	-1	6316193
ments	O	-1	6316193
revealed	O	-1	6316193
that	O	-1	6316193
the	O	-1	6316193
C@@	O	-1	6316193
-@@	O	-1	6316193
ter@@	O	-1	6316193
min@@	O	-1	6316193
al	O	-1	6316193
te@@	O	-1	6316193
tra@@	O	-1	6316193
p@@	O	-1	6316193
ep@@	O	-1	6316193
ti@@	O	-1	6316193
de	O	-1	6316193
(C@@	O	-1	6316193
C@@	O	-1	6316193
K@@	O	-1	6316193
-@@	O	-1	6316193
5-@@	O	-1	6316193
8@@	O	-1	6316193
)	O	-1	6316193
was	O	-1	6316193
the	O	-1	6316193
active	O	-1	6316193
centr@@	O	-1	6316193
e	O	-1	6316193
of	O	-1	6316193
the	O	-1	6316193
C@@	O	-1	6316193
C@@	O	-1	6316193
K	O	-1	6316193
oc@@	O	-1	6316193
t@@	O	-1	6316193
ap@@	O	-1	6316193
ep@@	O	-1	6316193
ti@@	O	-1	6316193
de	O	-1	6316193
mol@@	O	-1	6316193
ec@@	O	-1	6316193
ul@@	O	-1	6316193
e.	O	-1	6316193
The	O	-1	6316193
an@@	O	-1	6316193
alo@@	O	-1	6316193
gu@@	O	-1	6316193
es	O	-1	6316193
C@@	B-Chemical	D012844	6316193
C@@	I-Chemical	-1	6316193
K@@	I-Chemical	-1	6316193
-@@	I-Chemical	-1	6316193
8	I-Chemical	-1	6316193
-@@	O	-1	6316193
S@@	O	-1	6316193
E	O	-1	6316193
and	O	-1	6316193
C@@	B-Chemical	D012844	6316193
C@@	I-Chemical	-1	6316193
K@@	I-Chemical	-1	6316193
-@@	I-Chemical	-1	6316193
8	I-Chemical	-1	6316193
-@@	O	-1	6316193
N@@	O	-1	6316193
S	O	-1	6316193
(@@	O	-1	6316193
dose	O	-1	6316193
range	O	-1	6316193
0.@@	O	-1	6316193
2-@@	O	-1	6316193
6.@@	O	-1	6316193
4	O	-1	6316193
m@@	O	-1	6316193
um@@	O	-1	6316193
ol@@	O	-1	6316193
/@@	O	-1	6316193
kg@@	O	-1	6316193
)	O	-1	6316193
and	O	-1	6316193
ca@@	B-Chemical	D002108	6316193
er@@	I-Chemical	-1	6316193
ul@@	I-Chemical	-1	6316193
e@@	I-Chemical	-1	6316193
in	I-Chemical	-1	6316193
dose	O	-1	6316193
range	O	-1	6316193
0.@@	O	-1	6316193
1-@@	O	-1	6316193
0.@@	O	-1	6316193
8	O	-1	6316193
m@@	O	-1	6316193
um@@	O	-1	6316193
ol@@	O	-1	6316193
/@@	O	-1	6316193
kg@@	O	-1	6316193
)	O	-1	6316193
showed	O	-1	6316193
bell@@	O	-1	6316193
-@@	O	-1	6316193
sh@@	O	-1	6316193
ap@@	O	-1	6316193
ed	O	-1	6316193
dose-@@	O	-1	6316193
effect	O	-1	6316193
cur@@	O	-1	6316193
v@@	O	-1	6316193
es,	O	-1	6316193
with	O	-1	6316193
the	O	-1	6316193
great@@	O	-1	6316193
est	O	-1	6316193
maxim@@	O	-1	6316193
um	O	-1	6316193
inhibition	O	-1	6316193
for	O	-1	6316193
C@@	B-Chemical	D012844	6316193
C@@	I-Chemical	-1	6316193
K@@	I-Chemical	-1	6316193
-@@	I-Chemical	-1	6316193
8	I-Chemical	-1	6316193
-@@	O	-1	6316193
N@@	O	-1	6316193
S@@	O	-1	6316193
.	O	-1	6316193
The	O	-1	6316193
p@@	O	-1	6316193
ep@@	O	-1	6316193
ti@@	O	-1	6316193
de	O	-1	6316193
C@@	O	-1	6316193
C@@	O	-1	6316193
K@@	O	-1	6316193
-@@	O	-1	6316193
5-@@	O	-1	6316193
8	O	-1	6316193
had	O	-1	6316193
we@@	O	-1	6316193
a@@	O	-1	6316193
k	O	-1	6316193
anti@@	O	-1	6316193
convul@@	O	-1	6316193
s@@	O	-1	6316193
ant	O	-1	6316193
activity	O	-1	6316193
in	O	-1	6316193
compar@@	O	-1	6316193
ison	O	-1	6316193
to	O	-1	6316193
the	O	-1	6316193
oc@@	O	-1	6316193
t@@	O	-1	6316193
ap@@	O	-1	6316193
ep@@	O	-1	6316193
tid@@	O	-1	6316193
es,	O	-1	6316193
3.@@	O	-1	6316193
2	O	-1	6316193
m@@	O	-1	6316193
um@@	O	-1	6316193
ol@@	O	-1	6316193
/@@	O	-1	6316193
k@@	O	-1	6316193
g	O	-1	6316193
and	O	-1	6316193
larg@@	O	-1	6316193
er	O	-1	6316193
doses	O	-1	6316193
of	O	-1	6316193
the	O	-1	6316193
ref@@	O	-1	6316193
e@@	O	-1	6316193
rence	O	-1	6316193
drug@@	O	-1	6316193
,	O	-1	6316193
di@@	B-Chemical	D003975	6316193
az@@	I-Chemical	-1	6316193
epam	I-Chemical	-1	6316193
,	O	-1	6316193
tot@@	O	-1	6316193
ally	O	-1	6316193
prevent@@	O	-1	6316193
ed	O	-1	6316193
p@@	B-Chemical	D010852	6316193
ic@@	I-Chemical	-1	6316193
ro@@	I-Chemical	-1	6316193
tox@@	I-Chemical	-1	6316193
in	I-Chemical	-1	6316193
-induced	O	-1	6316193
seizures	B-Disease	D012640	6316193
and	O	-1	6316193
mor@@	O	-1	6316193
t@@	O	-1	6316193
al@@	O	-1	6316193
ity.	O	-1	6316193
The	O	-1	6316193
maxim@@	O	-1	6316193
um	O	-1	6316193
effect	O	-1	6316193
of	O	-1	6316193
the	O	-1	6316193
p@@	O	-1	6316193
ep@@	O	-1	6316193
ti@@	O	-1	6316193
des	O	-1	6316193
tested	O	-1	6316193
was	O	-1	6316193
less	O	-1	6316193
than	O	-1	6316193
that	O	-1	6316193
of	O	-1	6316193
di@@	B-Chemical	D003975	6316193
az@@	I-Chemical	-1	6316193
epam	I-Chemical	-1	6316193
.	O	-1	6316193
E@@	O	-1	6316193
x@@	O	-1	6316193
per@@	O	-1	6316193
im@@	O	-1	6316193
ents	O	-1	6316193
with	O	-1	6316193
an@@	O	-1	6316193
alo@@	O	-1	6316193
gu@@	O	-1	6316193
es	O	-1	6316193
and	O	-1	6316193
der@@	O	-1	6316193
i@@	O	-1	6316193
v@@	O	-1	6316193
ati@@	O	-1	6316193
v@@	O	-1	6316193
es	O	-1	6316193
of	O	-1	6316193
C@@	O	-1	6316193
C@@	O	-1	6316193
K@@	O	-1	6316193
-@@	O	-1	6316193
5-@@	O	-1	6316193
8	O	-1	6316193
demonstrated	O	-1	6316193
that	O	-1	6316193
the	O	-1	6316193
eff@@	O	-1	6316193
ec@@	O	-1	6316193
tiv@@	O	-1	6316193
en@@	O	-1	6316193
ess	O	-1	6316193
of	O	-1	6316193
the	O	-1	6316193
beta-@@	O	-1	6316193
al@@	O	-1	6316193
an@@	O	-1	6316193
yl	O	-1	6316193
der@@	O	-1	6316193
i@@	O	-1	6316193
v@@	O	-1	6316193
ati@@	O	-1	6316193
v@@	O	-1	6316193
es	O	-1	6316193
of	O	-1	6316193
C@@	O	-1	6316193
C@@	O	-1	6316193
K@@	O	-1	6316193
-@@	O	-1	6316193
5-@@	O	-1	6316193
8	O	-1	6316193
were	O	-1	6316193
enhanced	O	-1	6316193
and	O	-1	6316193
that	O	-1	6316193
they	O	-1	6316193
were	O	-1	6316193
equ@@	O	-1	6316193
ip@@	O	-1	6316193
ot@@	O	-1	6316193
ent	O	-1	6316193
with	O	-1	6316193
C@@	B-Chemical	D012844	6316193
C@@	I-Chemical	-1	6316193
K@@	I-Chemical	-1	6316193
-@@	I-Chemical	-1	6316193
8	I-Chemical	-1	6316193
-@@	O	-1	6316193
S@@	O	-1	6316193
E@@	O	-1	6316193
.	O	-1	6316193
Of	O	-1	6316193
the	O	-1	6316193
C@@	O	-1	6316193
C@@	O	-1	6316193
K@@	O	-1	6316193
-@@	O	-1	6316193
2-@@	O	-1	6316193
8	O	-1	6316193
an@@	O	-1	6316193
alo@@	O	-1	6316193
gu@@	O	-1	6316193
es,	O	-1	6316193
S@@	O	-1	6316193
er@@	O	-1	6316193
(S@@	O	-1	6316193
O@@	O	-1	6316193
3@@	O	-1	6316193
H@@	O	-1	6316193
)@@	O	-1	6316193
7-@@	O	-1	6316193
Ac@@	O	-1	6316193
-@@	O	-1	6316193
C@@	O	-1	6316193
C@@	O	-1	6316193
K@@	O	-1	6316193
-@@	O	-1	6316193
2-@@	O	-1	6316193
8@@	O	-1	6316193
-@@	O	-1	6316193
S@@	O	-1	6316193
E	O	-1	6316193
and	O	-1	6316193
Th@@	O	-1	6316193
r@@	O	-1	6316193
(S@@	O	-1	6316193
O@@	O	-1	6316193
3@@	O	-1	6316193
H@@	O	-1	6316193
)@@	O	-1	6316193
7-@@	O	-1	6316193
Ac@@	O	-1	6316193
-@@	O	-1	6316193
C@@	O	-1	6316193
C@@	O	-1	6316193
K@@	O	-1	6316193
-@@	O	-1	6316193
2-@@	O	-1	6316193
8@@	O	-1	6316193
-@@	O	-1	6316193
S@@	O	-1	6316193
E	O	-1	6316193
and	O	-1	6316193
H@@	O	-1	6316193
yp@@	O	-1	6316193
(S@@	O	-1	6316193
O@@	O	-1	6316193
3@@	O	-1	6316193
H@@	O	-1	6316193
)-@@	O	-1	6316193
Ac@@	O	-1	6316193
-@@	O	-1	6316193
C@@	O	-1	6316193
C@@	O	-1	6316193
K@@	O	-1	6316193
-@@	O	-1	6316193
2-@@	O	-1	6316193
8@@	O	-1	6316193
-@@	O	-1	6316193
S@@	O	-1	6316193
E	O	-1	6316193
were	O	-1	6316193
s@@	O	-1	6316193
li@@	O	-1	6316193
gh@@	O	-1	6316193
tly	O	-1	6316193
more	O	-1	6316193
active	O	-1	6316193
than	O	-1	6316193
C@@	B-Chemical	D012844	6316193
C@@	I-Chemical	-1	6316193
K@@	I-Chemical	-1	6316193
-@@	I-Chemical	-1	6316193
8	I-Chemical	-1	6316193
-@@	O	-1	6316193
S@@	O	-1	6316193
E@@	O	-1	6316193
.	O	-1	6316193

V@@	B-Chemical	D014667	6321816
as@@	I-Chemical	-1	6321816
o@@	I-Chemical	-1	6321816
press@@	I-Chemical	-1	6321816
in	I-Chemical	-1	6321816
as	O	-1	6321816
a	O	-1	6321816
possible	O	-1	6321816
cont@@	O	-1	6321816
ri@@	O	-1	6321816
but@@	O	-1	6321816
or	O	-1	6321816
to	O	-1	6321816
hypertension	B-Disease	D006973	6321816
.	O	-1	6321816
The	O	-1	6321816
role	O	-1	6321816
of	O	-1	6321816
vas@@	B-Chemical	D014667	6321816
o@@	I-Chemical	-1	6321816
press@@	I-Chemical	-1	6321816
in	I-Chemical	-1	6321816
as	O	-1	6321816
a	O	-1	6321816
press@@	O	-1	6321816
or	O	-1	6321816
agent	O	-1	6321816
to	O	-1	6321816
the	O	-1	6321816
hypertensive	B-Disease	D006973	6321816
pro@@	O	-1	6321816
cess	O	-1	6321816
was	O	-1	6321816
ex@@	O	-1	6321816
am@@	O	-1	6321816
ine@@	O	-1	6321816
d.	O	-1	6321816
V@@	B-Chemical	D014667	6321816
as@@	I-Chemical	-1	6321816
o@@	I-Chemical	-1	6321816
press@@	I-Chemical	-1	6321816
in	I-Chemical	-1	6321816
pl@@	O	-1	6321816
ays	O	-1	6321816
a	O	-1	6321816
major	O	-1	6321816
role	O	-1	6321816
in	O	-1	6321816
the	O	-1	6321816
path@@	O	-1	6321816
o@@	O	-1	6321816
genesis	O	-1	6321816
of	O	-1	6321816
DO@@	B-Chemical	D003900	6321816
C@@	I-Chemical	-1	6321816
A	I-Chemical	-1	6321816
-@@	O	-1	6321816
sal@@	O	-1	6321816
t	O	-1	6321816
hypertension	B-Disease	D006973	6321816
,	O	-1	6321816
s@@	O	-1	6321816
inc@@	O	-1	6321816
e	O	-1	6321816
the	O	-1	6321816
elev@@	O	-1	6321816
ation	O	-1	6321816
of	O	-1	6321816
blood	O	-1	6321816
pressure	O	-1	6321816
was	O	-1	6321816
not	O	-1	6321816
subst@@	O	-1	6321816
anti@@	O	-1	6321816
al	O	-1	6321816
in	O	-1	6321816
the	O	-1	6321816
rats	O	-1	6321816
with	O	-1	6321816
lithium	B-Chemical	D008094	6321816
-treated	O	-1	6321816
dia@@	B-Disease	D003919	6321816
bet@@	I-Disease	-1	6321816
es	I-Disease	-1	6321816
in@@	I-Disease	-1	6321816
si@@	I-Disease	-1	6321816
pid@@	I-Disease	-1	6321816
us	I-Disease	-1	6321816
after	O	-1	6321816
DO@@	B-Chemical	D003900	6321816
C@@	I-Chemical	-1	6321816
A	I-Chemical	-1	6321816
-@@	O	-1	6321816
sal@@	O	-1	6321816
t	O	-1	6321816
treatment.	O	-1	6321816
Ad@@	O	-1	6321816
minist@@	O	-1	6321816
ration	O	-1	6321816
of	O	-1	6321816
D@@	B-Chemical	D003894	6321816
D@@	I-Chemical	-1	6321816
A@@	I-Chemical	-1	6321816
V@@	I-Chemical	-1	6321816
P	I-Chemical	-1	6321816
which	O	-1	6321816
has	O	-1	6321816
anti@@	O	-1	6321816
di@@	O	-1	6321816
ure@@	O	-1	6321816
tic	O	-1	6321816
action	O	-1	6321816
but	O	-1	6321816
minim@@	O	-1	6321816
al	O	-1	6321816
vas@@	O	-1	6321816
o@@	O	-1	6321816
press@@	O	-1	6321816
or	O	-1	6321816
effect	O	-1	6321816
fail@@	O	-1	6321816
ed	O	-1	6321816
to	O	-1	6321816
increase	O	-1	6321816
blood	O	-1	6321816
pressure	O	-1	6321816
to	O	-1	6321816
the	O	-1	6321816
levels	O	-1	6321816
observed	O	-1	6321816
after	O	-1	6321816
administration	O	-1	6321816
of	O	-1	6321816
A@@	O	-1	6321816
V@@	O	-1	6321816
P@@	O	-1	6321816
.	O	-1	6321816
F@@	O	-1	6321816
ur@@	O	-1	6321816
ther@@	O	-1	6321816
mo@@	O	-1	6321816
re,	O	-1	6321816
the	O	-1	6321816
press@@	O	-1	6321816
or	O	-1	6321816
action	O	-1	6321816
of	O	-1	6321816
vas@@	B-Chemical	D014667	6321816
o@@	I-Chemical	-1	6321816
press@@	I-Chemical	-1	6321816
in	I-Chemical	-1	6321816
appear@@	O	-1	6321816
s	O	-1	6321816
to	O	-1	6321816
be	O	-1	6321816
important	O	-1	6321816
in	O	-1	6321816
the	O	-1	6321816
development	O	-1	6321816
of	O	-1	6321816
this	O	-1	6321816
model	O	-1	6321816
of	O	-1	6321816
hypertension	B-Disease	D006973	6321816
,	O	-1	6321816
s@@	O	-1	6321816
inc@@	O	-1	6321816
e	O	-1	6321816
the	O	-1	6321816
enhanced	O	-1	6321816
press@@	O	-1	6321816
or	O	-1	6321816
respon@@	O	-1	6321816
si@@	O	-1	6321816
ven@@	O	-1	6321816
ess	O	-1	6321816
to	O	-1	6321816
the	O	-1	6321816
h@@	O	-1	6321816
orm@@	O	-1	6321816
one	O	-1	6321816
was	O	-1	6321816
observed	O	-1	6321816
in	O	-1	6321816
the	O	-1	6321816
initial	O	-1	6321816
st@@	O	-1	6321816
age	O	-1	6321816
of	O	-1	6321816
hypertension	B-Disease	D006973	6321816
.	O	-1	6321816
In@@	O	-1	6321816
c@@	O	-1	6321816
reas@@	O	-1	6321816
ed	O	-1	6321816
secre@@	O	-1	6321816
tion	O	-1	6321816
of	O	-1	6321816
vas@@	B-Chemical	D014667	6321816
o@@	I-Chemical	-1	6321816
press@@	I-Chemical	-1	6321816
in	I-Chemical	-1	6321816
from	O	-1	6321816
neuro@@	O	-1	6321816
hypo@@	O	-1	6321816
ph@@	O	-1	6321816
y@@	O	-1	6321816
sis	O	-1	6321816
also	O	-1	6321816
pro@@	O	-1	6321816
m@@	O	-1	6321816
ot@@	O	-1	6321816
es	O	-1	6321816
the	O	-1	6321816
function	O	-1	6321816
of	O	-1	6321816
the	O	-1	6321816
h@@	O	-1	6321816
orm@@	O	-1	6321816
one	O	-1	6321816
as	O	-1	6321816
a	O	-1	6321816
path@@	O	-1	6321816
o@@	O	-1	6321816
gene@@	O	-1	6321816
tic	O	-1	6321816
factor	O	-1	6321816
in	O	-1	6321816
hypertension	B-Disease	D006973	6321816
.	O	-1	6321816
An	O	-1	6321816
un@@	O	-1	6321816
pro@@	O	-1	6321816
por@@	O	-1	6321816
tional	O	-1	6321816
release	O	-1	6321816
of	O	-1	6321816
vas@@	B-Chemical	D014667	6321816
o@@	I-Chemical	-1	6321816
press@@	I-Chemical	-1	6321816
in	I-Chemical	-1	6321816
compared	O	-1	6321816
to	O	-1	6321816
plasma	O	-1	6321816
os@@	O	-1	6321816
mol@@	O	-1	6321816
ality	O	-1	6321816
may	O	-1	6321816
be	O	-1	6321816
induced	O	-1	6321816
by	O	-1	6321816
the	O	-1	6321816
absence	O	-1	6321816
of	O	-1	6321816
an	O	-1	6321816
adjust@@	O	-1	6321816
ing	O	-1	6321816
control	O	-1	6321816
of	O	-1	6321816
angiotens@@	B-Chemical	D000809	6321816
in	I-Chemical	-1	6321816
II	O	-1	6321816
form@@	O	-1	6321816
ing	O	-1	6321816
and	O	-1	6321816
receptor	O	-1	6321816
b@@	O	-1	6321816
ind@@	O	-1	6321816
ing	O	-1	6321816
cap@@	O	-1	6321816
ac@@	O	-1	6321816
ity	O	-1	6321816
for	O	-1	6321816
sodium	B-Chemical	D012964	6321816
b@@	O	-1	6321816
al@@	O	-1	6321816
ance	O	-1	6321816
in	O	-1	6321816
the	O	-1	6321816
bra@@	O	-1	6321816
in.	O	-1	6321816
However,	O	-1	6321816
the	O	-1	6321816
role	O	-1	6321816
of	O	-1	6321816
vas@@	B-Chemical	D014667	6321816
o@@	I-Chemical	-1	6321816
press@@	I-Chemical	-1	6321816
in	I-Chemical	-1	6321816
remain@@	O	-1	6321816
s	O	-1	6321816
to	O	-1	6321816
be	O	-1	6321816
determined	O	-1	6321816
in	O	-1	6321816
human	O	-1	6321816
es@@	O	-1	6321816
sen@@	O	-1	6321816
tial	O	-1	6321816
hypertension	B-Disease	D006973	6321816
.	O	-1	6321816

T@@	B-Disease	D056486	6453500
ox@@	I-Disease	-1	6453500
ic	I-Disease	-1	6453500
hepatitis	I-Disease	-1	6453500
induced	O	-1	6453500
by	O	-1	6453500
dis@@	B-Chemical	D004221	6453500
ul@@	I-Chemical	-1	6453500
fi@@	I-Chemical	-1	6453500
ra@@	I-Chemical	-1	6453500
m	I-Chemical	-1	6453500
in	O	-1	6453500
a	O	-1	6453500
non-@@	O	-1	6453500
alco@@	O	-1	6453500
h@@	O	-1	6453500
ol@@	O	-1	6453500
ic@@	O	-1	6453500
.	O	-1	6453500
A	O	-1	6453500
reversible	O	-1	6453500
toxic	B-Disease	D056486	6453500
liver	I-Disease	-1	6453500
damage	I-Disease	-1	6453500
was	O	-1	6453500
observed	O	-1	6453500
in	O	-1	6453500
a	O	-1	6453500
non-@@	O	-1	6453500
alco@@	O	-1	6453500
h@@	O	-1	6453500
olic	O	-1	6453500
woman	O	-1	6453500
treated	O	-1	6453500
with	O	-1	6453500
dis@@	B-Chemical	D004221	6453500
ul@@	I-Chemical	-1	6453500
fi@@	I-Chemical	-1	6453500
ra@@	I-Chemical	-1	6453500
m	I-Chemical	-1	6453500
.	O	-1	6453500
The	O	-1	6453500
ca@@	O	-1	6453500
us@@	O	-1	6453500
ative	O	-1	6453500
rel@@	O	-1	6453500
ationship	O	-1	6453500
was	O	-1	6453500
pro@@	O	-1	6453500
ven	O	-1	6453500
by	O	-1	6453500
ch@@	O	-1	6453500
all@@	O	-1	6453500
en@@	O	-1	6453500
g@@	O	-1	6453500
e.	O	-1	6453500

A@@	B-Disease	D003328	6517710
trial	I-Disease	-1	6517710
thrombo@@	I-Disease	-1	6517710
sis	I-Disease	-1	6517710
invol@@	O	-1	6517710
ving	O	-1	6517710
the	O	-1	6517710
heart	O	-1	6517710
of	O	-1	6517710
F@@	O	-1	6517710
-@@	O	-1	6517710
34@@	O	-1	6517710
4	O	-1	6517710
rats	O	-1	6517710
ing@@	O	-1	6517710
est@@	O	-1	6517710
ing	O	-1	6517710
qu@@	B-Chemical	D011796	6517710
in@@	I-Chemical	-1	6517710
ac@@	I-Chemical	-1	6517710
rine	I-Chemical	-1	6517710
hydro@@	I-Chemical	-1	6517710
chlor@@	I-Chemical	-1	6517710
ide	I-Chemical	-1	6517710
.	O	-1	6517710
Q@@	B-Chemical	D011796	6517710
u@@	I-Chemical	-1	6517710
in@@	I-Chemical	-1	6517710
ac@@	I-Chemical	-1	6517710
rine	I-Chemical	-1	6517710
hydro@@	I-Chemical	-1	6517710
chlor@@	I-Chemical	-1	6517710
ide	I-Chemical	-1	6517710
is	O	-1	6517710
toxic	O	-1	6517710
for	O	-1	6517710
the	O	-1	6517710
heart	O	-1	6517710
of	O	-1	6517710
F@@	O	-1	6517710
-@@	O	-1	6517710
34@@	O	-1	6517710
4	O	-1	6517710
rats.	O	-1	6517710
R@@	O	-1	6517710
at@@	O	-1	6517710
s	O	-1	6517710
treated	O	-1	6517710
with	O	-1	6517710
5@@	O	-1	6517710
00	O	-1	6517710
pp@@	O	-1	6517710
m	O	-1	6517710
qu@@	B-Chemical	D011796	6517710
in@@	I-Chemical	-1	6517710
ac@@	I-Chemical	-1	6517710
rine	I-Chemical	-1	6517710
hydro@@	I-Chemical	-1	6517710
chlor@@	I-Chemical	-1	6517710
ide	I-Chemical	-1	6517710
in	O	-1	6517710
the	O	-1	6517710
diet	O	-1	6517710
all	O	-1	6517710
developed	O	-1	6517710
a	O	-1	6517710
high	O	-1	6517710
incidence	O	-1	6517710
of	O	-1	6517710
left	O	-1	6517710
atrial	B-Disease	D003328	6517710
thrombo@@	I-Disease	-1	6517710
sis	I-Disease	-1	6517710
.	O	-1	6517710
The	O	-1	6517710
le@@	O	-1	6517710
sion	O	-1	6517710
was	O	-1	6517710
associated	O	-1	6517710
with	O	-1	6517710
cardiac	B-Disease	D006332	6517710
hyper@@	I-Disease	-1	6517710
tro@@	I-Disease	-1	6517710
ph@@	I-Disease	-1	6517710
y	I-Disease	-1	6517710
and	O	-1	6517710
di@@	O	-1	6517710
lat@@	O	-1	6517710
ation	O	-1	6517710
and	O	-1	6517710
foc@@	O	-1	6517710
al	O	-1	6517710
myocardial	B-Disease	D009202	6517710
de@@	I-Disease	-1	6517710
generation	I-Disease	-1	6517710
.	O	-1	6517710
R@@	O	-1	6517710
at@@	O	-1	6517710
s	O	-1	6517710
di@@	O	-1	6517710
ed	O	-1	6517710
from	O	-1	6517710
cardiac	B-Disease	D006332	6517710
hyper@@	I-Disease	-1	6517710
tro@@	I-Disease	-1	6517710
ph@@	I-Disease	-1	6517710
y	I-Disease	-1	6517710
with	O	-1	6517710
severe	O	-1	6517710
acute	O	-1	6517710
and	O	-1	6517710
chronic	O	-1	6517710
con@@	O	-1	6517710
g@@	O	-1	6517710
es@@	O	-1	6517710
tion	O	-1	6517710
of	O	-1	6517710
the	O	-1	6517710
l@@	O	-1	6517710
un@@	O	-1	6517710
g@@	O	-1	6517710
s,	O	-1	6517710
li@@	O	-1	6517710
ver,	O	-1	6517710
and	O	-1	6517710
other	O	-1	6517710
org@@	O	-1	6517710
an@@	O	-1	6517710
s.	O	-1	6517710
S@@	O	-1	6517710
event@@	O	-1	6517710
y	O	-1	6517710
perc@@	O	-1	6517710
ent	O	-1	6517710
of	O	-1	6517710
rats	O	-1	6517710
given	O	-1	6517710
2@@	O	-1	6517710
50	O	-1	6517710
pp@@	O	-1	6517710
m	O	-1	6517710
qu@@	B-Chemical	D011796	6517710
in@@	I-Chemical	-1	6517710
ac@@	I-Chemical	-1	6517710
rine	I-Chemical	-1	6517710
hydro@@	I-Chemical	-1	6517710
chlor@@	I-Chemical	-1	6517710
ide	I-Chemical	-1	6517710
and	O	-1	6517710
1@@	O	-1	6517710
,@@	O	-1	6517710
0@@	O	-1	6517710
00	O	-1	6517710
pp@@	O	-1	6517710
m	O	-1	6517710
sodium	B-Chemical	D012977	6517710
nit@@	I-Chemical	-1	6517710
rit@@	I-Chemical	-1	6517710
e	I-Chemical	-1	6517710
sim@@	O	-1	6517710
ult@@	O	-1	6517710
ane@@	O	-1	6517710
ously	O	-1	6517710
in	O	-1	6517710
the	O	-1	6517710
diet	O	-1	6517710
had	O	-1	6517710
thrombo@@	B-Disease	D013927	6517710
sis	I-Disease	-1	6517710
of	O	-1	6517710
the	O	-1	6517710
atri@@	O	-1	6517710
a	O	-1	6517710
of	O	-1	6517710
the	O	-1	6517710
hear@@	O	-1	6517710
t,	O	-1	6517710
while	O	-1	6517710
un@@	O	-1	6517710
treated	O	-1	6517710
control	O	-1	6517710
rats	O	-1	6517710
in	O	-1	6517710
this	O	-1	6517710
labor@@	O	-1	6517710
atory	O	-1	6517710
did	O	-1	6517710
not	O	-1	6517710
have	O	-1	6517710
atrial	B-Disease	D003328	6517710
thrombo@@	I-Disease	-1	6517710
sis	I-Disease	-1	6517710
.	O	-1	6517710
S@@	B-Chemical	D012977	6517710
odium	I-Chemical	-1	6517710
nit@@	I-Chemical	-1	6517710
rit@@	I-Chemical	-1	6517710
e	I-Chemical	-1	6517710
in	O	-1	6517710
combination	O	-1	6517710
with	O	-1	6517710
qu@@	B-Chemical	D011796	6517710
in@@	I-Chemical	-1	6517710
ac@@	I-Chemical	-1	6517710
rine	I-Chemical	-1	6517710
hydro@@	I-Chemical	-1	6517710
chlor@@	I-Chemical	-1	6517710
ide	I-Chemical	-1	6517710
appe@@	O	-1	6517710
a@@	O	-1	6517710
red	O	-1	6517710
to	O	-1	6517710
have	O	-1	6517710
no	O	-1	6517710
addi@@	O	-1	6517710
tional	O	-1	6517710
effect@@	O	-1	6517710
.	O	-1	6517710

Al@@	B-Disease	D001146	6529939
tern@@	I-Disease	-1	6529939
ating	I-Disease	-1	6529939
s@@	I-Disease	-1	6529939
in@@	I-Disease	-1	6529939
us	I-Disease	-1	6529939
rhyth@@	I-Disease	-1	6529939
m	I-Disease	-1	6529939
and	O	-1	6529939
inter@@	O	-1	6529939
mit@@	O	-1	6529939
t@@	O	-1	6529939
ent	O	-1	6529939
s@@	B-Disease	D012848	6529939
ino@@	I-Disease	-1	6529939
atrial	I-Disease	-1	6529939
bloc@@	I-Disease	-1	6529939
k	I-Disease	-1	6529939
induced	O	-1	6529939
by	O	-1	6529939
prop@@	B-Chemical	D011433	6529939
ran@@	I-Chemical	-1	6529939
o@@	I-Chemical	-1	6529939
lol	I-Chemical	-1	6529939
.	O	-1	6529939
Al@@	B-Disease	D001146	6529939
tern@@	I-Disease	-1	6529939
ating	I-Disease	-1	6529939
s@@	I-Disease	-1	6529939
in@@	I-Disease	-1	6529939
us	I-Disease	-1	6529939
rhyth@@	I-Disease	-1	6529939
m	I-Disease	-1	6529939
and	O	-1	6529939
inter@@	O	-1	6529939
mit@@	O	-1	6529939
t@@	O	-1	6529939
ent	O	-1	6529939
s@@	B-Disease	D012848	6529939
ino@@	I-Disease	-1	6529939
atrial	I-Disease	-1	6529939
(S@@	I-Disease	-1	6529939
-@@	I-Disease	-1	6529939
A@@	I-Disease	-1	6529939
)	I-Disease	-1	6529939
bloc@@	I-Disease	-1	6529939
k	I-Disease	-1	6529939
was	O	-1	6529939
observed	O	-1	6529939
in	O	-1	6529939
a	O	-1	6529939
5@@	O	-1	6529939
7-@@	O	-1	6529939
year-old	O	-1	6529939
wom@@	O	-1	6529939
an@@	O	-1	6529939
,	O	-1	6529939
under	O	-1	6529939
treatment	O	-1	6529939
for	O	-1	6529939
ang@@	B-Disease	D000787	6529939
in@@	I-Disease	-1	6529939
a	I-Disease	-1	6529939
with	O	-1	6529939
8@@	O	-1	6529939
0	O	-1	6529939
mg	O	-1	6529939
prop@@	B-Chemical	D011433	6529939
ran@@	I-Chemical	-1	6529939
o@@	I-Chemical	-1	6529939
lol	I-Chemical	-1	6529939
da@@	O	-1	6529939
il@@	O	-1	6529939
y.	O	-1	6529939
The	O	-1	6529939
electro@@	O	-1	6529939
cardio@@	O	-1	6529939
gra@@	O	-1	6529939
m	O	-1	6529939
showed	O	-1	6529939
al@@	O	-1	6529939
tern@@	O	-1	6529939
ation	O	-1	6529939
of	O	-1	6529939
lon@@	O	-1	6529939
g	O	-1	6529939
and	O	-1	6529939
sh@@	O	-1	6529939
ort	O	-1	6529939
P@@	O	-1	6529939
-@@	O	-1	6529939
P	O	-1	6529939
interv@@	O	-1	6529939
als	O	-1	6529939
and	O	-1	6529939
oc@@	O	-1	6529939
ca@@	O	-1	6529939
sion@@	O	-1	6529939
al	O	-1	6529939
pa@@	O	-1	6529939
us@@	O	-1	6529939
es.	O	-1	6529939
These	O	-1	6529939
pa@@	O	-1	6529939
u@@	O	-1	6529939
ses	O	-1	6529939
were	O	-1	6529939
al@@	O	-1	6529939
w@@	O	-1	6529939
ays	O	-1	6529939
pre@@	O	-1	6529939
ce@@	O	-1	6529939
ded	O	-1	6529939
by	O	-1	6529939
the	O	-1	6529939
sh@@	O	-1	6529939
ort	O	-1	6529939
P@@	O	-1	6529939
-@@	O	-1	6529939
P	O	-1	6529939
interv@@	O	-1	6529939
als	O	-1	6529939
and	O	-1	6529939
were	O	-1	6529939
us@@	O	-1	6529939
ually	O	-1	6529939
followed	O	-1	6529939
by	O	-1	6529939
one	O	-1	6529939
or	O	-1	6529939
two	O	-1	6529939
P@@	O	-1	6529939
-@@	O	-1	6529939
P	O	-1	6529939
interv@@	O	-1	6529939
als	O	-1	6529939
of	O	-1	6529939
0.@@	O	-1	6529939
9@@	O	-1	6529939
2-@@	O	-1	6529939
0.@@	O	-1	6529939
9@@	O	-1	6529939
5	O	-1	6529939
s	O	-1	6529939
re@@	O	-1	6529939
present@@	O	-1	6529939
ing	O	-1	6529939
the	O	-1	6529939
b@@	O	-1	6529939
a@@	O	-1	6529939
sic	O	-1	6529939
s@@	O	-1	6529939
in@@	O	-1	6529939
us	O	-1	6529939
cyc@@	O	-1	6529939
le@@	O	-1	6529939
.	O	-1	6529939
F@@	O	-1	6529939
ol@@	O	-1	6529939
low@@	O	-1	6529939
ing	O	-1	6529939
these	O	-1	6529939
b@@	O	-1	6529939
a@@	O	-1	6529939
sic	O	-1	6529939
s@@	O	-1	6529939
in@@	O	-1	6529939
us	O	-1	6529939
cy@@	O	-1	6529939
cl@@	O	-1	6529939
es,	O	-1	6529939
al@@	B-Disease	D001146	6529939
tern@@	I-Disease	-1	6529939
ating	I-Disease	-1	6529939
rhyth@@	I-Disease	-1	6529939
m	I-Disease	-1	6529939
star@@	O	-1	6529939
ted	O	-1	6529939
with	O	-1	6529939
the	O	-1	6529939
long@@	O	-1	6529939
er	O	-1	6529939
P@@	O	-1	6529939
-@@	O	-1	6529939
P	O	-1	6529939
inter@@	O	-1	6529939
val@@	O	-1	6529939
.	O	-1	6529939
The	O	-1	6529939
lon@@	O	-1	6529939
g	O	-1	6529939
P@@	O	-1	6529939
-@@	O	-1	6529939
P	O	-1	6529939
interv@@	O	-1	6529939
als	O	-1	6529939
rang@@	O	-1	6529939
ed	O	-1	6529939
between	O	-1	6529939
1.@@	O	-1	6529939
0@@	O	-1	6529939
4-@@	O	-1	6529939
1.@@	O	-1	6529939
12	O	-1	6529939
s	O	-1	6529939
and	O	-1	6529939
the	O	-1	6529939
sh@@	O	-1	6529939
ort	O	-1	6529939
P@@	O	-1	6529939
-@@	O	-1	6529939
P	O	-1	6529939
interv@@	O	-1	6529939
als	O	-1	6529939
between	O	-1	6529939
0.@@	O	-1	6529939
8@@	O	-1	6529939
0-@@	O	-1	6529939
0.@@	O	-1	6529939
8@@	O	-1	6529939
4	O	-1	6529939
s,	O	-1	6529939
respectively.	O	-1	6529939
The	O	-1	6529939
duration	O	-1	6529939
of	O	-1	6529939
the	O	-1	6529939
pa@@	O	-1	6529939
u@@	O	-1	6529939
ses	O	-1	6529939
were	O	-1	6529939
equ@@	O	-1	6529939
al	O	-1	6529939
or	O	-1	6529939
al@@	O	-1	6529939
most	O	-1	6529939
equ@@	O	-1	6529939
al	O	-1	6529939
to	O	-1	6529939
one	O	-1	6529939
sh@@	O	-1	6529939
ort	O	-1	6529939
plus	O	-1	6529939
one	O	-1	6529939
lon@@	O	-1	6529939
g	O	-1	6529939
P@@	O	-1	6529939
-@@	O	-1	6529939
P	O	-1	6529939
interv@@	O	-1	6529939
al	O	-1	6529939
or	O	-1	6529939
to	O	-1	6529939
tw@@	O	-1	6529939
ic@@	O	-1	6529939
e	O	-1	6529939
the	O	-1	6529939
b@@	O	-1	6529939
a@@	O	-1	6529939
sic	O	-1	6529939
s@@	O	-1	6529939
in@@	O	-1	6529939
us	O	-1	6529939
cyc@@	O	-1	6529939
le@@	O	-1	6529939
.	O	-1	6529939
In	O	-1	6529939
one	O	-1	6529939
recor@@	O	-1	6529939
ding	O	-1	6529939
a	O	-1	6529939
sh@@	O	-1	6529939
ort	O	-1	6529939
period	O	-1	6529939
of	O	-1	6529939
reg@@	O	-1	6529939
ular	O	-1	6529939
s@@	O	-1	6529939
in@@	O	-1	6529939
us	O	-1	6529939
rhyth@@	O	-1	6529939
m	O	-1	6529939
with	O	-1	6529939
inter@@	O	-1	6529939
mit@@	O	-1	6529939
t@@	O	-1	6529939
ent	O	-1	6529939
2@@	O	-1	6529939
/@@	O	-1	6529939
1	O	-1	6529939
S@@	B-Disease	D012848	6529939
-@@	I-Disease	-1	6529939
A	I-Disease	-1	6529939
bloc@@	I-Disease	-1	6529939
k	I-Disease	-1	6529939
was	O	-1	6529939
obser@@	O	-1	6529939
ved.	O	-1	6529939
This	O	-1	6529939
sh@@	O	-1	6529939
ort	O	-1	6529939
period	O	-1	6529939
of	O	-1	6529939
s@@	O	-1	6529939
in@@	O	-1	6529939
us	O	-1	6529939
rhyth@@	O	-1	6529939
m	O	-1	6529939
was	O	-1	6529939
inter@@	O	-1	6529939
ru@@	O	-1	6529939
pt@@	O	-1	6529939
ed	O	-1	6529939
by	O	-1	6529939
su@@	O	-1	6529939
d@@	O	-1	6529939
de@@	O	-1	6529939
n	O	-1	6529939
prolong@@	O	-1	6529939
ation	O	-1	6529939
of	O	-1	6529939
the	O	-1	6529939
P@@	O	-1	6529939
-@@	O	-1	6529939
P	O	-1	6529939
interv@@	O	-1	6529939
al	O	-1	6529939
star@@	O	-1	6529939
ting	O	-1	6529939
the	O	-1	6529939
al@@	O	-1	6529939
tern@@	O	-1	6529939
ative	O	-1	6529939
rhyth@@	O	-1	6529939
m.	O	-1	6529939
There	O	-1	6529939
were	O	-1	6529939
sm@@	O	-1	6529939
all	O	-1	6529939
changes	O	-1	6529939
in	O	-1	6529939
the	O	-1	6529939
sh@@	O	-1	6529939
ap@@	O	-1	6529939
e	O	-1	6529939
of	O	-1	6529939
the	O	-1	6529939
P	O	-1	6529939
w@@	O	-1	6529939
av@@	O	-1	6529939
es	O	-1	6529939
and	O	-1	6529939
P@@	O	-1	6529939
-@@	O	-1	6529939
R	O	-1	6529939
inter@@	O	-1	6529939
val@@	O	-1	6529939
s.	O	-1	6529939
S@@	O	-1	6529939
-@@	O	-1	6529939
A	O	-1	6529939
con@@	O	-1	6529939
duction	O	-1	6529939
through	O	-1	6529939
two	O	-1	6529939
path@@	O	-1	6529939
w@@	O	-1	6529939
ay@@	O	-1	6529939
s,	O	-1	6529939
the	O	-1	6529939
first	O	-1	6529939
with	O	-1	6529939
2@@	O	-1	6529939
/@@	O	-1	6529939
1	O	-1	6529939
bloc@@	O	-1	6529939
k	O	-1	6529939
the	O	-1	6529939
second	O	-1	6529939
ha@@	O	-1	6529939
ving	O	-1	6529939
0.@@	O	-1	6529939
1@@	O	-1	6529939
2-@@	O	-1	6529939
0.@@	O	-1	6529939
14	O	-1	6529939
s	O	-1	6529939
long@@	O	-1	6529939
er	O	-1	6529939
con@@	O	-1	6529939
duction	O	-1	6529939
time	O	-1	6529939
and	O	-1	6529939
with	O	-1	6529939
oc@@	O	-1	6529939
ca@@	O	-1	6529939
sion@@	O	-1	6529939
al	O	-1	6529939
2@@	O	-1	6529939
/@@	O	-1	6529939
1	O	-1	6529939
bloc@@	O	-1	6529939
k	O	-1	6529939
was	O	-1	6529939
pro@@	O	-1	6529939
pos@@	O	-1	6529939
ed	O	-1	6529939
for	O	-1	6529939
the	O	-1	6529939
expl@@	O	-1	6529939
an@@	O	-1	6529939
ation	O	-1	6529939
of	O	-1	6529939
the	O	-1	6529939
al@@	O	-1	6529939
tern@@	O	-1	6529939
ating	O	-1	6529939
P@@	O	-1	6529939
-@@	O	-1	6529939
P	O	-1	6529939
interv@@	O	-1	6529939
al	O	-1	6529939
and	O	-1	6529939
other	O	-1	6529939
electro@@	O	-1	6529939
cardio@@	O	-1	6529939
graph@@	O	-1	6529939
ic	O	-1	6529939
feat@@	O	-1	6529939
ures	O	-1	6529939
se@@	O	-1	6529939
en@@	O	-1	6529939
.	O	-1	6529939
A@@	B-Chemical	D001285	6529939
tro@@	I-Chemical	-1	6529939
pine	I-Chemical	-1	6529939
1	O	-1	6529939
mg	O	-1	6529939
given	O	-1	6529939
intra@@	O	-1	6529939
ven@@	O	-1	6529939
ously	O	-1	6529939
resulted	O	-1	6529939
in	O	-1	6529939
sh@@	O	-1	6529939
or@@	O	-1	6529939
ten@@	O	-1	6529939
ing	O	-1	6529939
of	O	-1	6529939
all	O	-1	6529939
P@@	O	-1	6529939
-@@	O	-1	6529939
P	O	-1	6529939
interv@@	O	-1	6529939
als	O	-1	6529939
without	O	-1	6529939
chang@@	O	-1	6529939
ing	O	-1	6529939
the	O	-1	6529939
rhyth@@	O	-1	6529939
m.	O	-1	6529939
The	O	-1	6529939
ab@@	O	-1	6529939
normal	O	-1	6529939
rhyth@@	O	-1	6529939
m	O	-1	6529939
dis@@	O	-1	6529939
appe@@	O	-1	6529939
a@@	O	-1	6529939
red	O	-1	6529939
with	O	-1	6529939
the	O	-1	6529939
withdrawal	O	-1	6529939
of	O	-1	6529939
prop@@	B-Chemical	D011433	6529939
ran@@	I-Chemical	-1	6529939
o@@	I-Chemical	-1	6529939
lol	I-Chemical	-1	6529939
and	O	-1	6529939
when	O	-1	6529939
the	O	-1	6529939
drug	O	-1	6529939
was	O	-1	6529939
re@@	O	-1	6529939
star@@	O	-1	6529939
ted	O	-1	6529939
a	O	-1	6529939
2@@	O	-1	6529939
/@@	O	-1	6529939
1	O	-1	6529939
S@@	B-Disease	D012848	6529939
-@@	I-Disease	-1	6529939
A	I-Disease	-1	6529939
bloc@@	I-Disease	-1	6529939
k	I-Disease	-1	6529939
was	O	-1	6529939
se@@	O	-1	6529939
en@@	O	-1	6529939
.	O	-1	6529939
This	O	-1	6529939
was	O	-1	6529939
ac@@	O	-1	6529939
ce@@	O	-1	6529939
pt@@	O	-1	6529939
ed	O	-1	6529939
as	O	-1	6529939
evidence	O	-1	6529939
for	O	-1	6529939
prop@@	B-Chemical	D011433	6529939
ran@@	I-Chemical	-1	6529939
o@@	I-Chemical	-1	6529939
lol	I-Chemical	-1	6529939
being	O	-1	6529939
the	O	-1	6529939
cause	O	-1	6529939
of	O	-1	6529939
this	O	-1	6529939
con@@	B-Disease	D019955	6529939
duction	I-Disease	-1	6529939
disor@@	I-Disease	-1	6529939
der	I-Disease	-1	6529939
.	O	-1	6529939

An@@	O	-1	6585590
ti@@	O	-1	6585590
tumor	O	-1	6585590
effect@@	O	-1	6585590
,	O	-1	6585590
cardi@@	B-Disease	D066126	6585590
otoxicity	I-Disease	-1	6585590
,	O	-1	6585590
and	O	-1	6585590
nephro@@	B-Disease	D007674	6585590
toxicity	I-Disease	-1	6585590
of	O	-1	6585590
dox@@	B-Chemical	D004317	6585590
orub@@	I-Chemical	-1	6585590
icin	I-Chemical	-1	6585590
in	O	-1	6585590
the	O	-1	6585590
I@@	O	-1	6585590
g@@	O	-1	6585590
M	O	-1	6585590
sol@@	O	-1	6585590
id	O	-1	6585590
immun@@	B-Disease	-1	6585590
ocyto@@	I-Disease	-1	6585590
ma	I-Disease	-1	6585590
-@@	O	-1	6585590
be@@	O	-1	6585590
ar@@	O	-1	6585590
ing	O	-1	6585590
L@@	O	-1	6585590
O@@	O	-1	6585590
U@@	O	-1	6585590
/@@	O	-1	6585590
M@@	O	-1	6585590
/@@	O	-1	6585590
W@@	O	-1	6585590
S@@	O	-1	6585590
L	O	-1	6585590
rat@@	O	-1	6585590
.	O	-1	6585590
An@@	O	-1	6585590
ti@@	O	-1	6585590
tumor	O	-1	6585590
activ@@	O	-1	6585590
ity,	O	-1	6585590
cardi@@	B-Disease	D066126	6585590
otoxicity	I-Disease	-1	6585590
,	O	-1	6585590
and	O	-1	6585590
nephro@@	B-Disease	D007674	6585590
toxicity	I-Disease	-1	6585590
induced	O	-1	6585590
by	O	-1	6585590
dox@@	B-Chemical	D004317	6585590
orub@@	I-Chemical	-1	6585590
icin	I-Chemical	-1	6585590
were	O	-1	6585590
studied	O	-1	6585590
in	O	-1	6585590
L@@	O	-1	6585590
O@@	O	-1	6585590
U@@	O	-1	6585590
/@@	O	-1	6585590
M@@	O	-1	6585590
/@@	O	-1	6585590
W@@	O	-1	6585590
S@@	O	-1	6585590
L	O	-1	6585590
in@@	O	-1	6585590
b@@	O	-1	6585590
red	O	-1	6585590
rats	O	-1	6585590
each	O	-1	6585590
be@@	O	-1	6585590
ar@@	O	-1	6585590
ing	O	-1	6585590
a	O	-1	6585590
transplant@@	O	-1	6585590
able	O	-1	6585590
sol@@	O	-1	6585590
id	O	-1	6585590
I@@	O	-1	6585590
g@@	O	-1	6585590
M	O	-1	6585590
immun@@	B-Disease	-1	6585590
ocyto@@	I-Disease	-1	6585590
ma	I-Disease	-1	6585590
.	O	-1	6585590
An@@	O	-1	6585590
im@@	O	-1	6585590
als	O	-1	6585590
with	O	-1	6585590
a	O	-1	6585590
tumor	B-Disease	D009369	6585590
(@@	O	-1	6585590
di@@	O	-1	6585590
ame@@	O	-1	6585590
ter@@	O	-1	6585590
,	O	-1	6585590
1@@	O	-1	6585590
5.@@	O	-1	6585590
8	O	-1	6585590
+/-	O	-1	6585590
3.@@	O	-1	6585590
3	O	-1	6585590
mm@@	O	-1	6585590
)	O	-1	6585590
were	O	-1	6585590
treated	O	-1	6585590
with	O	-1	6585590
i@@	O	-1	6585590
v	O	-1	6585590
injec@@	O	-1	6585590
tions	O	-1	6585590
of	O	-1	6585590
dox@@	B-Chemical	D004317	6585590
orub@@	I-Chemical	-1	6585590
icin	I-Chemical	-1	6585590
on	O	-1	6585590
5	O	-1	6585590
con@@	O	-1	6585590
sec@@	O	-1	6585590
utive	O	-1	6585590
day@@	O	-1	6585590
s,	O	-1	6585590
followed	O	-1	6585590
by	O	-1	6585590
1	O	-1	6585590
week@@	O	-1	6585590
ly	O	-1	6585590
injection	O	-1	6585590
for	O	-1	6585590
7	O	-1	6585590
weeks	O	-1	6585590
(@@	O	-1	6585590
dose	O	-1	6585590
rang@@	O	-1	6585590
e,	O	-1	6585590
0.0@@	O	-1	6585590
1@@	O	-1	6585590
5-@@	O	-1	6585590
4.@@	O	-1	6585590
0	O	-1	6585590
mg/kg	O	-1	6585590
body	O	-1	6585590
w@@	O	-1	6585590
t@@	O	-1	6585590
).	O	-1	6585590
T@@	B-Disease	D009369	6585590
um@@	I-Disease	-1	6585590
or	I-Disease	-1	6585590
reg@@	O	-1	6585590
res@@	O	-1	6585590
sion	O	-1	6585590
was	O	-1	6585590
observed	O	-1	6585590
with	O	-1	6585590
0.@@	O	-1	6585590
5	O	-1	6585590
mg	O	-1	6585590
dox@@	B-Chemical	D004317	6585590
orub@@	I-Chemical	-1	6585590
icin	I-Chemical	-1	6585590
/@@	O	-1	6585590
kg@@	O	-1	6585590
.	O	-1	6585590
Com@@	O	-1	6585590
ple@@	O	-1	6585590
te	O	-1	6585590
dis@@	O	-1	6585590
appear@@	O	-1	6585590
ance	O	-1	6585590
of	O	-1	6585590
the	O	-1	6585590
tumor	B-Disease	D009369	6585590
was	O	-1	6585590
induced	O	-1	6585590
with	O	-1	6585590
1.@@	O	-1	6585590
0	O	-1	6585590
mg	O	-1	6585590
dox@@	B-Chemical	D004317	6585590
orub@@	I-Chemical	-1	6585590
icin	I-Chemical	-1	6585590
/@@	O	-1	6585590
kg@@	O	-1	6585590
.	O	-1	6585590
H@@	O	-1	6585590
ist@@	O	-1	6585590
ologic	O	-1	6585590
evidence	O	-1	6585590
of	O	-1	6585590
cardi@@	B-Disease	D066126	6585590
otoxicity	I-Disease	-1	6585590
sco@@	O	-1	6585590
red	O	-1	6585590
as	O	-1	6585590
gra@@	O	-1	6585590
de	O	-1	6585590
I@@	O	-1	6585590
II	O	-1	6585590
was	O	-1	6585590
only	O	-1	6585590
observed	O	-1	6585590
at	O	-1	6585590
a	O	-1	6585590
dose	O	-1	6585590
of	O	-1	6585590
1.@@	O	-1	6585590
0	O	-1	6585590
mg	O	-1	6585590
dox@@	B-Chemical	D004317	6585590
orub@@	I-Chemical	-1	6585590
icin	I-Chemical	-1	6585590
/@@	O	-1	6585590
kg@@	O	-1	6585590
.	O	-1	6585590
L@@	O	-1	6585590
ight	O	-1	6585590
micro@@	O	-1	6585590
sco@@	O	-1	6585590
p@@	O	-1	6585590
ic	O	-1	6585590
evidence	O	-1	6585590
of	O	-1	6585590
renal	B-Disease	D007674	6585590
damage	I-Disease	-1	6585590
was	O	-1	6585590
seen	O	-1	6585590
ab@@	O	-1	6585590
o@@	O	-1	6585590
ve	O	-1	6585590
a	O	-1	6585590
dose	O	-1	6585590
of	O	-1	6585590
0.@@	O	-1	6585590
5	O	-1	6585590
mg	O	-1	6585590
dox@@	B-Chemical	D004317	6585590
orub@@	I-Chemical	-1	6585590
icin	I-Chemical	-1	6585590
/@@	O	-1	6585590
kg@@	O	-1	6585590
,	O	-1	6585590
which	O	-1	6585590
resulted	O	-1	6585590
in	O	-1	6585590
al@@	B-Disease	D000419	6585590
bu@@	I-Disease	-1	6585590
min@@	I-Disease	-1	6585590
uria	I-Disease	-1	6585590
and	O	-1	6585590
very	O	-1	6585590
low	O	-1	6585590
serum	O	-1	6585590
al@@	O	-1	6585590
b@@	O	-1	6585590
um@@	O	-1	6585590
in	O	-1	6585590
level@@	O	-1	6585590
s.	O	-1	6585590
In	O	-1	6585590
the	O	-1	6585590
group	O	-1	6585590
that	O	-1	6585590
received	O	-1	6585590
1.@@	O	-1	6585590
0	O	-1	6585590
mg	O	-1	6585590
dox@@	B-Chemical	D004317	6585590
orub@@	I-Chemical	-1	6585590
icin	I-Chemical	-1	6585590
/@@	O	-1	6585590
kg@@	O	-1	6585590
,	O	-1	6585590
the	O	-1	6585590
serum	O	-1	6585590
al@@	O	-1	6585590
b@@	O	-1	6585590
um@@	O	-1	6585590
in	O	-1	6585590
level	O	-1	6585590
decreased	O	-1	6585590
from	O	-1	6585590
3@@	O	-1	6585590
3.@@	O	-1	6585590
6	O	-1	6585590
+/-	O	-1	6585590
4.@@	O	-1	6585590
1	O	-1	6585590
to	O	-1	6585590
1.@@	O	-1	6585590
5	O	-1	6585590
+/-	O	-1	6585590
0.@@	O	-1	6585590
5	O	-1	6585590
g/@@	O	-1	6585590
liter@@	O	-1	6585590
.	O	-1	6585590
A@@	B-Disease	D001201	6585590
s@@	I-Disease	-1	6585590
cit@@	I-Disease	-1	6585590
es	I-Disease	-1	6585590
and	O	-1	6585590
hydro@@	B-Disease	D006876	6585590
th@@	I-Disease	-1	6585590
or@@	I-Disease	-1	6585590
a@@	I-Disease	-1	6585590
x	I-Disease	-1	6585590
were	O	-1	6585590
observed	O	-1	6585590
sim@@	O	-1	6585590
ult@@	O	-1	6585590
ane@@	O	-1	6585590
ous@@	O	-1	6585590
ly.	O	-1	6585590
The	O	-1	6585590
same	O	-1	6585590
experim@@	O	-1	6585590
ents	O	-1	6585590
were	O	-1	6585590
performed	O	-1	6585590
with	O	-1	6585590
non@@	O	-1	6585590
-	O	-1	6585590
tumor	B-Disease	D009369	6585590
-@@	O	-1	6585590
be@@	O	-1	6585590
ar@@	O	-1	6585590
ing	O	-1	6585590
rats,	O	-1	6585590
in	O	-1	6585590
which	O	-1	6585590
no	O	-1	6585590
major	O	-1	6585590
differences	O	-1	6585590
were	O	-1	6585590
obser@@	O	-1	6585590
ved.	O	-1	6585590
In	O	-1	6585590
concl@@	O	-1	6585590
u@@	O	-1	6585590
sion,	O	-1	6585590
anti@@	O	-1	6585590
tumor	O	-1	6585590
activ@@	O	-1	6585590
ity,	O	-1	6585590
cardi@@	B-Disease	D066126	6585590
otoxicity	I-Disease	-1	6585590
,	O	-1	6585590
and	O	-1	6585590
nephro@@	B-Disease	D007674	6585590
toxicity	I-Disease	-1	6585590
were	O	-1	6585590
studied	O	-1	6585590
sim@@	O	-1	6585590
ult@@	O	-1	6585590
ane@@	O	-1	6585590
ously	O	-1	6585590
in	O	-1	6585590
the	O	-1	6585590
same	O	-1	6585590
L@@	O	-1	6585590
O@@	O	-1	6585590
U@@	O	-1	6585590
/@@	O	-1	6585590
M@@	O	-1	6585590
/@@	O	-1	6585590
W@@	O	-1	6585590
S@@	O	-1	6585590
L	O	-1	6585590
rat@@	O	-1	6585590
.	O	-1	6585590
Al@@	B-Disease	D000419	6585590
bu@@	I-Disease	-1	6585590
min@@	I-Disease	-1	6585590
uria	I-Disease	-1	6585590
due	O	-1	6585590
to	O	-1	6585590
renal	B-Disease	D007674	6585590
damage	I-Disease	-1	6585590
l@@	O	-1	6585590
ed	O	-1	6585590
to	O	-1	6585590
ex@@	O	-1	6585590
tre@@	O	-1	6585590
me@@	O	-1	6585590
ly	O	-1	6585590
low	O	-1	6585590
serum	O	-1	6585590
al@@	O	-1	6585590
b@@	O	-1	6585590
um@@	O	-1	6585590
in	O	-1	6585590
level@@	O	-1	6585590
s,	O	-1	6585590
so	O	-1	6585590
as@@	B-Disease	D001201	6585590
cit@@	I-Disease	-1	6585590
es	I-Disease	-1	6585590
and	O	-1	6585590
hydro@@	B-Disease	D006876	6585590
th@@	I-Disease	-1	6585590
or@@	I-Disease	-1	6585590
a@@	I-Disease	-1	6585590
x	I-Disease	-1	6585590
were	O	-1	6585590
not	O	-1	6585590
nec@@	O	-1	6585590
ess@@	O	-1	6585590
ari@@	O	-1	6585590
ly	O	-1	6585590
a	O	-1	6585590
con@@	O	-1	6585590
sequ@@	O	-1	6585590
ence	O	-1	6585590
of	O	-1	6585590
the	O	-1	6585590
observed	O	-1	6585590
cardi@@	B-Disease	D009202	6585590
om@@	I-Disease	-1	6585590
yo@@	I-Disease	-1	6585590
pathy	I-Disease	-1	6585590
.	O	-1	6585590

In@@	O	-1	6615679
tra@@	O	-1	6615679
o@@	O	-1	6615679
perative	O	-1	6615679
brady@@	B-Disease	D001919	6615679
cardia	I-Disease	-1	6615679
and	O	-1	6615679
hypotension	B-Disease	D007022	6615679
associated	O	-1	6615679
with	O	-1	6615679
ti@@	B-Chemical	D013999	6615679
mo@@	I-Chemical	-1	6615679
lol	I-Chemical	-1	6615679
and	O	-1	6615679
pilocar@@	B-Chemical	D010862	6615679
pine	I-Chemical	-1	6615679
e@@	O	-1	6615679
y@@	O	-1	6615679
e	O	-1	6615679
dro@@	O	-1	6615679
p@@	O	-1	6615679
s.	O	-1	6615679
A	O	-1	6615679
6@@	O	-1	6615679
9@@	O	-1	6615679
-@@	O	-1	6615679
y@@	O	-1	6615679
r@@	O	-1	6615679
-old	O	-1	6615679
man@@	O	-1	6615679
,	O	-1	6615679
who	O	-1	6615679
was	O	-1	6615679
con@@	O	-1	6615679
cur@@	O	-1	6615679
ren@@	O	-1	6615679
tly	O	-1	6615679
being	O	-1	6615679
treated	O	-1	6615679
with	O	-1	6615679
pilocar@@	B-Chemical	D010862	6615679
pine	I-Chemical	-1	6615679
nit@@	I-Chemical	-1	6615679
rate	I-Chemical	-1	6615679
and	O	-1	6615679
ti@@	B-Chemical	D013999	6615679
mo@@	I-Chemical	-1	6615679
lol	I-Chemical	-1	6615679
mal@@	I-Chemical	-1	6615679
e@@	I-Chemical	-1	6615679
ate	I-Chemical	-1	6615679
e@@	O	-1	6615679
y@@	O	-1	6615679
e	O	-1	6615679
dro@@	O	-1	6615679
p@@	O	-1	6615679
s,	O	-1	6615679
developed	O	-1	6615679
a	O	-1	6615679
brady@@	B-Disease	D001919	6615679
cardia	I-Disease	-1	6615679
and	O	-1	6615679
b@@	O	-1	6615679
ec@@	O	-1	6615679
am@@	O	-1	6615679
e	O	-1	6615679
hypoten@@	B-Disease	D007022	6615679
sive	I-Disease	-1	6615679
during	O	-1	6615679
halo@@	B-Chemical	D006221	6615679
th@@	I-Chemical	-1	6615679
ane	I-Chemical	-1	6615679
anaesthe@@	O	-1	6615679
sia.	O	-1	6615679
B@@	O	-1	6615679
oth	O	-1	6615679
ti@@	B-Chemical	D013999	6615679
mo@@	I-Chemical	-1	6615679
lol	I-Chemical	-1	6615679
and	O	-1	6615679
pilocar@@	B-Chemical	D010862	6615679
pine	I-Chemical	-1	6615679
were	O	-1	6615679
subsequ@@	O	-1	6615679
ently	O	-1	6615679
identi@@	O	-1	6615679
fied	O	-1	6615679
in	O	-1	6615679
a	O	-1	6615679
2@@	O	-1	6615679
4-@@	O	-1	6615679
h	O	-1	6615679
coll@@	O	-1	6615679
ection	O	-1	6615679
of	O	-1	6615679
ur@@	O	-1	6615679
ine.	O	-1	6615679
T@@	B-Chemical	D013999	6615679
im@@	I-Chemical	-1	6615679
o@@	I-Chemical	-1	6615679
lol	I-Chemical	-1	6615679
(@@	O	-1	6615679
but	O	-1	6615679
not	O	-1	6615679
pilocar@@	B-Chemical	D010862	6615679
pine	I-Chemical	-1	6615679
)	O	-1	6615679
was	O	-1	6615679
det@@	O	-1	6615679
ected	O	-1	6615679
in	O	-1	6615679
a	O	-1	6615679
sam@@	O	-1	6615679
ple	O	-1	6615679
of	O	-1	6615679
plasma	O	-1	6615679
re@@	O	-1	6615679
mo@@	O	-1	6615679
ved	O	-1	6615679
during	O	-1	6615679
surg@@	O	-1	6615679
ery@@	O	-1	6615679
;	O	-1	6615679
the	O	-1	6615679
plasma	O	-1	6615679
concentration	O	-1	6615679
of	O	-1	6615679
ti@@	B-Chemical	D013999	6615679
mo@@	I-Chemical	-1	6615679
lol	I-Chemical	-1	6615679
(2@@	O	-1	6615679
.@@	O	-1	6615679
6	O	-1	6615679
n@@	O	-1	6615679
g	O	-1	6615679
ml@@	O	-1	6615679
-1@@	O	-1	6615679
)	O	-1	6615679
was	O	-1	6615679
consist@@	O	-1	6615679
ent	O	-1	6615679
with	O	-1	6615679
partial	O	-1	6615679
beta-@@	O	-1	6615679
adren@@	O	-1	6615679
oc@@	O	-1	6615679
e@@	O	-1	6615679
pt@@	O	-1	6615679
or	O	-1	6615679
block@@	O	-1	6615679
ade@@	O	-1	6615679
.	O	-1	6615679
It	O	-1	6615679
is	O	-1	6615679
post@@	O	-1	6615679
ul@@	O	-1	6615679
ated	O	-1	6615679
that	O	-1	6615679
this	O	-1	6615679
action	O	-1	6615679
may	O	-1	6615679
have	O	-1	6615679
been	O	-1	6615679
enhanced	O	-1	6615679
during	O	-1	6615679
halo@@	B-Chemical	D006221	6615679
th@@	I-Chemical	-1	6615679
ane	I-Chemical	-1	6615679
anaesthe@@	O	-1	6615679
sia	O	-1	6615679
with	O	-1	6615679
result@@	O	-1	6615679
ant	O	-1	6615679
brady@@	B-Disease	D001919	6615679
cardia	I-Disease	-1	6615679
and	O	-1	6615679
hypotension	B-Disease	D007022	6615679
.	O	-1	6615679
P@@	B-Chemical	D010862	6615679
i@@	I-Chemical	-1	6615679
lo@@	I-Chemical	-1	6615679
car@@	I-Chemical	-1	6615679
pine	I-Chemical	-1	6615679
may	O	-1	6615679
have	O	-1	6615679
had	O	-1	6615679
a	O	-1	6615679
cont@@	O	-1	6615679
ri@@	O	-1	6615679
but@@	O	-1	6615679
ory	O	-1	6615679
effect@@	O	-1	6615679
.	O	-1	6615679

S@@	B-Chemical	D013390	6627074
uc@@	I-Chemical	-1	6627074
cin@@	I-Chemical	-1	6627074
ylcholine	I-Chemical	-1	6627074
ap@@	B-Disease	D001049	6627074
no@@	I-Disease	-1	6627074
e@@	I-Disease	-1	6627074
a	I-Disease	-1	6627074
:	O	-1	6627074
at@@	O	-1	6627074
tem@@	O	-1	6627074
pt@@	O	-1	6627074
ed	O	-1	6627074
rever@@	O	-1	6627074
s@@	O	-1	6627074
al	O	-1	6627074
with	O	-1	6627074
anti@@	O	-1	6627074
chol@@	O	-1	6627074
ine@@	O	-1	6627074
ster@@	O	-1	6627074
as@@	O	-1	6627074
es.	O	-1	6627074
An@@	O	-1	6627074
ti@@	O	-1	6627074
chol@@	O	-1	6627074
ine@@	O	-1	6627074
ster@@	O	-1	6627074
as@@	O	-1	6627074
es	O	-1	6627074
were	O	-1	6627074
administered	O	-1	6627074
in	O	-1	6627074
an	O	-1	6627074
at@@	O	-1	6627074
tem@@	O	-1	6627074
p@@	O	-1	6627074
t	O	-1	6627074
to	O	-1	6627074
antagon@@	O	-1	6627074
iz@@	O	-1	6627074
e	O	-1	6627074
prolonged	O	-1	6627074
neuro@@	B-Disease	D020879	6627074
mus@@	I-Disease	-1	6627074
cular	I-Disease	-1	6627074
block@@	I-Disease	-1	6627074
ade	I-Disease	-1	6627074
following	O	-1	6627074
the	O	-1	6627074
administration	O	-1	6627074
of	O	-1	6627074
suc@@	B-Chemical	D013390	6627074
cin@@	I-Chemical	-1	6627074
ylcholine	I-Chemical	-1	6627074
in	O	-1	6627074
a	O	-1	6627074
patient	O	-1	6627074
lat@@	O	-1	6627074
er	O	-1	6627074
found	O	-1	6627074
to	O	-1	6627074
be	O	-1	6627074
ho@@	O	-1	6627074
mo@@	O	-1	6627074
z@@	O	-1	6627074
y@@	O	-1	6627074
g@@	O	-1	6627074
ous	O	-1	6627074
for	O	-1	6627074
at@@	O	-1	6627074
yp@@	O	-1	6627074
ical	O	-1	6627074
plasma	O	-1	6627074
chol@@	O	-1	6627074
ine@@	O	-1	6627074
ster@@	O	-1	6627074
as@@	O	-1	6627074
e.	O	-1	6627074
E@@	B-Chemical	D004491	6627074
dro@@	I-Chemical	-1	6627074
ph@@	I-Chemical	-1	6627074
oni@@	I-Chemical	-1	6627074
um	I-Chemical	-1	6627074
10	O	-1	6627074
mg@@	O	-1	6627074
,	O	-1	6627074
given	O	-1	6627074
7@@	O	-1	6627074
4	O	-1	6627074
min	O	-1	6627074
after	O	-1	6627074
suc@@	B-Chemical	D013390	6627074
cin@@	I-Chemical	-1	6627074
ylcholine	I-Chemical	-1	6627074
,	O	-1	6627074
when	O	-1	6627074
tra@@	O	-1	6627074
in-@@	O	-1	6627074
of@@	O	-1	6627074
-@@	O	-1	6627074
four	O	-1	6627074
stimulation	O	-1	6627074
was	O	-1	6627074
character@@	O	-1	6627074
istic	O	-1	6627074
of	O	-1	6627074
phase	O	-1	6627074
II	O	-1	6627074
block@@	O	-1	6627074
,	O	-1	6627074
produced	O	-1	6627074
partial	O	-1	6627074
antagon@@	O	-1	6627074
ism	O	-1	6627074
which	O	-1	6627074
was	O	-1	6627074
not	O	-1	6627074
su@@	O	-1	6627074
st@@	O	-1	6627074
a@@	O	-1	6627074
ine@@	O	-1	6627074
d.	O	-1	6627074
R@@	O	-1	6627074
ep@@	O	-1	6627074
e@@	O	-1	6627074
ated	O	-1	6627074
doses	O	-1	6627074
of	O	-1	6627074
ed@@	B-Chemical	D004491	6627074
ro@@	I-Chemical	-1	6627074
ph@@	I-Chemical	-1	6627074
oni@@	I-Chemical	-1	6627074
um	I-Chemical	-1	6627074
to	O	-1	6627074
7@@	O	-1	6627074
0	O	-1	6627074
mg	O	-1	6627074
and	O	-1	6627074
ne@@	B-Chemical	D009388	6627074
os@@	I-Chemical	-1	6627074
tig@@	I-Chemical	-1	6627074
mine	I-Chemical	-1	6627074
to	O	-1	6627074
2.@@	O	-1	6627074
5	O	-1	6627074
mg	O	-1	6627074
did	O	-1	6627074
not	O	-1	6627074
antagon@@	O	-1	6627074
iz@@	O	-1	6627074
e	O	-1	6627074
or	O	-1	6627074
au@@	O	-1	6627074
g@@	O	-1	6627074
ment	O	-1	6627074
the	O	-1	6627074
block@@	O	-1	6627074
.	O	-1	6627074
S@@	O	-1	6627074
p@@	O	-1	6627074
ont@@	O	-1	6627074
aneous	O	-1	6627074
res@@	O	-1	6627074
pi@@	O	-1	6627074
ration	O	-1	6627074
recomm@@	O	-1	6627074
enc@@	O	-1	6627074
ed	O	-1	6627074
2@@	O	-1	6627074
00	O	-1	6627074
min	O	-1	6627074
after	O	-1	6627074
suc@@	B-Chemical	D013390	6627074
cin@@	I-Chemical	-1	6627074
ylcholine	I-Chemical	-1	6627074
administr@@	O	-1	6627074
ation.	O	-1	6627074
It	O	-1	6627074
is	O	-1	6627074
concl@@	O	-1	6627074
uded	O	-1	6627074
that	O	-1	6627074
anti@@	O	-1	6627074
chol@@	O	-1	6627074
ine@@	O	-1	6627074
ster@@	O	-1	6627074
as@@	O	-1	6627074
es	O	-1	6627074
are	O	-1	6627074
only	O	-1	6627074
par@@	O	-1	6627074
ti@@	O	-1	6627074
ally	O	-1	6627074
effective	O	-1	6627074
in	O	-1	6627074
rest@@	O	-1	6627074
or@@	O	-1	6627074
ing	O	-1	6627074
neuro@@	O	-1	6627074
mus@@	O	-1	6627074
cular	O	-1	6627074
function	O	-1	6627074
in	O	-1	6627074
suc@@	B-Chemical	D013390	6627074
cin@@	I-Chemical	-1	6627074
ylcholine	I-Chemical	-1	6627074
ap@@	B-Disease	D001049	6627074
no@@	I-Disease	-1	6627074
e@@	I-Disease	-1	6627074
a	I-Disease	-1	6627074
des@@	O	-1	6627074
pit@@	O	-1	6627074
e	O	-1	6627074
musc@@	O	-1	6627074
le	O	-1	6627074
t@@	O	-1	6627074
wit@@	O	-1	6627074
ch	O	-1	6627074
activity	O	-1	6627074
typ@@	O	-1	6627074
ical	O	-1	6627074
of	O	-1	6627074
phase	O	-1	6627074
II	O	-1	6627074
block@@	O	-1	6627074
.	O	-1	6627074

Eff@@	O	-1	6631522
ect	O	-1	6631522
of	O	-1	6631522
dox@@	B-Chemical	D004317	6631522
orub@@	I-Chemical	-1	6631522
icin	I-Chemical	-1	6631522
on	O	-1	6631522
[@@	B-Chemical	C013102	6631522
o@@	I-Chemical	-1	6631522
me@@	I-Chemical	-1	6631522
g@@	I-Chemical	-1	6631522
a@@	I-Chemical	-1	6631522
-@@	I-Chemical	-1	6631522
I@@	I-Chemical	-1	6631522
-1@@	I-Chemical	-1	6631522
3@@	I-Chemical	-1	6631522
1@@	I-Chemical	-1	6631522
]@@	I-Chemical	-1	6631522
he@@	I-Chemical	-1	6631522
pt@@	I-Chemical	-1	6631522
ad@@	I-Chemical	-1	6631522
ec@@	I-Chemical	-1	6631522
an@@	I-Chemical	-1	6631522
o@@	I-Chemical	-1	6631522
ic	I-Chemical	-1	6631522
acid	I-Chemical	-1	6631522
myocardial	O	-1	6631522
s@@	O	-1	6631522
cin@@	O	-1	6631522
ti@@	O	-1	6631522
graph@@	O	-1	6631522
y	O	-1	6631522
and	O	-1	6631522
echocardiograph@@	O	-1	6631522
y	O	-1	6631522
in	O	-1	6631522
dog@@	O	-1	6631522
s.	O	-1	6631522
The	O	-1	6631522
effects	O	-1	6631522
of	O	-1	6631522
ser@@	O	-1	6631522
ial	O	-1	6631522
treatment	O	-1	6631522
with	O	-1	6631522
dox@@	B-Chemical	D004317	6631522
orub@@	I-Chemical	-1	6631522
icin	I-Chemical	-1	6631522
on	O	-1	6631522
dynam@@	O	-1	6631522
ic	O	-1	6631522
myocardial	O	-1	6631522
s@@	O	-1	6631522
cin@@	O	-1	6631522
ti@@	O	-1	6631522
graph@@	O	-1	6631522
y	O	-1	6631522
with	O	-1	6631522
[@@	B-Chemical	C013102	6631522
o@@	I-Chemical	-1	6631522
me@@	I-Chemical	-1	6631522
g@@	I-Chemical	-1	6631522
a@@	I-Chemical	-1	6631522
-@@	I-Chemical	-1	6631522
I@@	I-Chemical	-1	6631522
-1@@	I-Chemical	-1	6631522
3@@	I-Chemical	-1	6631522
1@@	I-Chemical	-1	6631522
]@@	I-Chemical	-1	6631522
he@@	I-Chemical	-1	6631522
pt@@	I-Chemical	-1	6631522
ad@@	I-Chemical	-1	6631522
ec@@	I-Chemical	-1	6631522
an@@	I-Chemical	-1	6631522
o@@	I-Chemical	-1	6631522
ic	I-Chemical	-1	6631522
acid	I-Chemical	-1	6631522
(	O	-1	6631522
I@@	B-Chemical	C013102	6631522
-1@@	I-Chemical	-1	6631522
3@@	I-Chemical	-1	6631522
1	I-Chemical	-1	6631522
H@@	I-Chemical	-1	6631522
A	I-Chemical	-1	6631522
),	O	-1	6631522
and	O	-1	6631522
on	O	-1	6631522
glo@@	O	-1	6631522
b@@	O	-1	6631522
al	O	-1	6631522
le@@	O	-1	6631522
f@@	O	-1	6631522
t-@@	O	-1	6631522
ventricular	O	-1	6631522
function	O	-1	6631522
determined	O	-1	6631522
echocardiograph@@	O	-1	6631522
ic@@	O	-1	6631522
ally,	O	-1	6631522
were	O	-1	6631522
studied	O	-1	6631522
in	O	-1	6631522
a	O	-1	6631522
group	O	-1	6631522
of	O	-1	6631522
n@@	O	-1	6631522
ine	O	-1	6631522
mon@@	O	-1	6631522
gre@@	O	-1	6631522
l	O	-1	6631522
dog@@	O	-1	6631522
s.	O	-1	6631522
T@@	O	-1	6631522
ot@@	O	-1	6631522
al	O	-1	6631522
extrac@@	O	-1	6631522
t@@	O	-1	6631522
able	O	-1	6631522
myocardial	O	-1	6631522
li@@	O	-1	6631522
pid	O	-1	6631522
was	O	-1	6631522
compared	O	-1	6631522
post@@	O	-1	6631522
mor@@	O	-1	6631522
te@@	O	-1	6631522
m	O	-1	6631522
between	O	-1	6631522
a	O	-1	6631522
group	O	-1	6631522
of	O	-1	6631522
control	O	-1	6631522
dog@@	O	-1	6631522
s	O	-1	6631522
and	O	-1	6631522
dox@@	B-Chemical	D004317	6631522
orub@@	I-Chemical	-1	6631522
icin	I-Chemical	-1	6631522
-treated	O	-1	6631522
dog@@	O	-1	6631522
s.	O	-1	6631522
A	O	-1	6631522
significant	O	-1	6631522
and	O	-1	6631522
then	O	-1	6631522
progressive	O	-1	6631522
f@@	O	-1	6631522
all	O	-1	6631522
in	O	-1	6631522
glo@@	O	-1	6631522
b@@	O	-1	6631522
al	O	-1	6631522
L@@	O	-1	6631522
V	O	-1	6631522
function	O	-1	6631522
was	O	-1	6631522
observed	O	-1	6631522
at	O	-1	6631522
a	O	-1	6631522
cum@@	O	-1	6631522
ul@@	O	-1	6631522
ative	O	-1	6631522
dox@@	B-Chemical	D004317	6631522
orub@@	I-Chemical	-1	6631522
icin	I-Chemical	-1	6631522
dose	O	-1	6631522
of	O	-1	6631522
4	O	-1	6631522
mg/kg@@	O	-1	6631522
.	O	-1	6631522
A	O	-1	6631522
significant	O	-1	6631522
increase	O	-1	6631522
in	O	-1	6631522
the	O	-1	6631522
myocardial	O	-1	6631522
t@@	O	-1	6631522
1@@	O	-1	6631522
/@@	O	-1	6631522
2	O	-1	6631522
of	O	-1	6631522
the	O	-1	6631522
I@@	B-Chemical	C013102	6631522
-1@@	I-Chemical	-1	6631522
3@@	I-Chemical	-1	6631522
1	I-Chemical	-1	6631522
H@@	I-Chemical	-1	6631522
A	I-Chemical	-1	6631522
was	O	-1	6631522
observed	O	-1	6631522
only	O	-1	6631522
at	O	-1	6631522
a	O	-1	6631522
higher	O	-1	6631522
cum@@	O	-1	6631522
ul@@	O	-1	6631522
ative	O	-1	6631522
dose@@	O	-1	6631522
,	O	-1	6631522
10	O	-1	6631522
mg/kg@@	O	-1	6631522
.	O	-1	6631522
No	O	-1	6631522
significant	O	-1	6631522
al@@	O	-1	6631522
ter@@	O	-1	6631522
ation	O	-1	6631522
in	O	-1	6631522
total	O	-1	6631522
extrac@@	O	-1	6631522
t@@	O	-1	6631522
able	O	-1	6631522
myocardial	O	-1	6631522
li@@	O	-1	6631522
pid@@	O	-1	6631522
s	O	-1	6631522
was	O	-1	6631522
observed	O	-1	6631522
between	O	-1	6631522
control	O	-1	6631522
dog@@	O	-1	6631522
s	O	-1	6631522
and	O	-1	6631522
those	O	-1	6631522
treated	O	-1	6631522
with	O	-1	6631522
dox@@	B-Chemical	D004317	6631522
orub@@	I-Chemical	-1	6631522
icin	I-Chemical	-1	6631522
.	O	-1	6631522
Our	O	-1	6631522
findings	O	-1	6631522
suggest	O	-1	6631522
that	O	-1	6631522
the	O	-1	6631522
changes	O	-1	6631522
lead@@	O	-1	6631522
ing	O	-1	6631522
to	O	-1	6631522
an	O	-1	6631522
al@@	O	-1	6631522
ter@@	O	-1	6631522
ation	O	-1	6631522
of	O	-1	6631522
myocardial	O	-1	6631522
dynam@@	O	-1	6631522
ic	O	-1	6631522
imaging	O	-1	6631522
with	O	-1	6631522
I@@	B-Chemical	C013102	6631522
-1@@	I-Chemical	-1	6631522
3@@	I-Chemical	-1	6631522
1	I-Chemical	-1	6631522
H@@	I-Chemical	-1	6631522
A	I-Chemical	-1	6631522
are	O	-1	6631522
not	O	-1	6631522
the	O	-1	6631522
initi@@	O	-1	6631522
ating	O	-1	6631522
factor	O	-1	6631522
in	O	-1	6631522
dox@@	B-Chemical	D004317	6631522
orub@@	I-Chemical	-1	6631522
icin	I-Chemical	-1	6631522
cardi@@	B-Disease	D066126	6631522
otoxicity	I-Disease	-1	6631522
.	O	-1	6631522

H@@	O	-1	6673474
em@@	O	-1	6673474
o@@	O	-1	6673474
dynam@@	O	-1	6673474
ic@@	O	-1	6673474
s	O	-1	6673474
and	O	-1	6673474
myocardial	O	-1	6673474
metabol@@	O	-1	6673474
ism	O	-1	6673474
under	O	-1	6673474
de@@	O	-1	6673474
li@@	O	-1	6673474
b@@	O	-1	6673474
er@@	O	-1	6673474
ate	O	-1	6673474
hypotension	B-Disease	D007022	6673474
.	O	-1	6673474
An	O	-1	6673474
experimental	O	-1	6673474
study	O	-1	6673474
in	O	-1	6673474
dog@@	O	-1	6673474
s.	O	-1	6673474
C@@	O	-1	6673474
or@@	O	-1	6673474
onary	O	-1	6673474
blood	O	-1	6673474
f@@	O	-1	6673474
low@@	O	-1	6673474
,	O	-1	6673474
cardiac	O	-1	6673474
wor@@	O	-1	6673474
k	O	-1	6673474
and	O	-1	6673474
metabol@@	O	-1	6673474
ism	O	-1	6673474
were	O	-1	6673474
studied	O	-1	6673474
in	O	-1	6673474
dog@@	O	-1	6673474
s	O	-1	6673474
under	O	-1	6673474
sodium	B-Chemical	D009599	6673474
nitro@@	I-Chemical	-1	6673474
pr@@	I-Chemical	-1	6673474
us@@	I-Chemical	-1	6673474
side	I-Chemical	-1	6673474
(	O	-1	6673474
S@@	B-Chemical	D009599	6673474
N@@	I-Chemical	-1	6673474
P	I-Chemical	-1	6673474
)	O	-1	6673474
and	O	-1	6673474
tri@@	B-Chemical	D014294	6673474
met@@	I-Chemical	-1	6673474
a@@	I-Chemical	-1	6673474
ph@@	I-Chemical	-1	6673474
an	I-Chemical	-1	6673474
(	O	-1	6673474
T@@	B-Chemical	D014294	6673474
M@@	I-Chemical	-1	6673474
P	I-Chemical	-1	6673474
)	O	-1	6673474
de@@	O	-1	6673474
li@@	O	-1	6673474
b@@	O	-1	6673474
er@@	O	-1	6673474
ate	O	-1	6673474
hypotension	B-Disease	D007022	6673474
(2@@	O	-1	6673474
0%	O	-1	6673474
and	O	-1	6673474
4@@	O	-1	6673474
0%	O	-1	6673474
mean	O	-1	6673474
pressure	O	-1	6673474
decrease	O	-1	6673474
from	O	-1	6673474
basel@@	O	-1	6673474
ine@@	O	-1	6673474
).	O	-1	6673474
Re@@	O	-1	6673474
g@@	O	-1	6673474
ar@@	O	-1	6673474
ding	O	-1	6673474
the	O	-1	6673474
effects	O	-1	6673474
of	O	-1	6673474
drug@@	O	-1	6673474
-induced	O	-1	6673474
hypotension	B-Disease	D007022	6673474
on	O	-1	6673474
coronary	O	-1	6673474
blood	O	-1	6673474
f@@	O	-1	6673474
low@@	O	-1	6673474
,	O	-1	6673474
a@@	O	-1	6673474
or@@	O	-1	6673474
tic	O	-1	6673474
and	O	-1	6673474
coronary	O	-1	6673474
s@@	O	-1	6673474
in@@	O	-1	6673474
us	O	-1	6673474
met@@	O	-1	6673474
ab@@	O	-1	6673474
olic	O	-1	6673474
data	O	-1	6673474
(p@@	O	-1	6673474
H@@	O	-1	6673474
,	O	-1	6673474
p@@	O	-1	6673474
O@@	O	-1	6673474
2,	O	-1	6673474
p@@	O	-1	6673474
CO@@	O	-1	6673474
2)	O	-1	6673474
we	O	-1	6673474
could	O	-1	6673474
con@@	O	-1	6673474
fir@@	O	-1	6673474
m	O	-1	6673474
that	O	-1	6673474
nitro@@	B-Chemical	D009599	6673474
pr@@	I-Chemical	-1	6673474
us@@	I-Chemical	-1	6673474
side	I-Chemical	-1	6673474
hypotension	B-Disease	D007022	6673474
could	O	-1	6673474
be	O	-1	6673474
saf@@	O	-1	6673474
ely	O	-1	6673474
used	O	-1	6673474
to	O	-1	6673474
3@@	O	-1	6673474
0%	O	-1	6673474
mean	O	-1	6673474
blood	O	-1	6673474
pressure	O	-1	6673474
decrease	O	-1	6673474
from	O	-1	6673474
control@@	O	-1	6673474
,	O	-1	6673474
tri@@	B-Chemical	D014294	6673474
met@@	I-Chemical	-1	6673474
a@@	I-Chemical	-1	6673474
ph@@	I-Chemical	-1	6673474
an	I-Chemical	-1	6673474
hypotension	B-Disease	D007022	6673474
to	O	-1	6673474
20@@	O	-1	6673474
%	O	-1	6673474
mean	O	-1	6673474
blood	O	-1	6673474
pressure	O	-1	6673474
decreas@@	O	-1	6673474
e.	O	-1	6673474
C@@	O	-1	6673474
ardi@@	O	-1	6673474
a@@	O	-1	6673474
c	O	-1	6673474
wor@@	O	-1	6673474
k	O	-1	6673474
was	O	-1	6673474
significantly	O	-1	6673474
reduced	O	-1	6673474
during	O	-1	6673474
S@@	B-Chemical	D009599	6673474
N@@	I-Chemical	-1	6673474
P	I-Chemical	-1	6673474
hypotension	B-Disease	D007022	6673474
.	O	-1	6673474
M@@	O	-1	6673474
y@@	O	-1	6673474
ocardi@@	O	-1	6673474
al	O	-1	6673474
O@@	B-Chemical	D010100	6673474
2	I-Chemical	-1	6673474
consum@@	O	-1	6673474
ption	O	-1	6673474
and	O	-1	6673474
O@@	B-Chemical	D010100	6673474
2	I-Chemical	-1	6673474
av@@	O	-1	6673474
ail@@	O	-1	6673474
ability	O	-1	6673474
were	O	-1	6673474
direc@@	O	-1	6673474
tly	O	-1	6673474
dependent	O	-1	6673474
on	O	-1	6673474
the	O	-1	6673474
coronary	O	-1	6673474
per@@	O	-1	6673474
fu@@	O	-1	6673474
sion.	O	-1	6673474
Ca@@	O	-1	6673474
ref@@	O	-1	6673474
u@@	O	-1	6673474
l	O	-1	6673474
inv@@	O	-1	6673474
a@@	O	-1	6673474
sive	O	-1	6673474
monit@@	O	-1	6673474
or@@	O	-1	6673474
ing	O	-1	6673474
of	O	-1	6673474
the	O	-1	6673474
blood	O	-1	6673474
pressu@@	O	-1	6673474
re,	O	-1	6673474
blood	O	-1	6673474
g@@	O	-1	6673474
as@@	O	-1	6673474
es	O	-1	6673474
and	O	-1	6673474
of	O	-1	6673474
the	O	-1	6673474
EC@@	O	-1	6673474
G	O	-1	6673474
S@@	O	-1	6673474
T@@	O	-1	6673474
-@@	O	-1	6673474
T	O	-1	6673474
seg@@	O	-1	6673474
ment	O	-1	6673474
is	O	-1	6673474
m@@	O	-1	6673474
and@@	O	-1	6673474
at@@	O	-1	6673474
or@@	O	-1	6673474
y.	O	-1	6673474

E@@	O	-1	6687006
v@@	O	-1	6687006
idence	O	-1	6687006
for	O	-1	6687006
a	O	-1	6687006
selective	O	-1	6687006
brain	O	-1	6687006
nor@@	O	-1	6687006
adrenergic	O	-1	6687006
invol@@	O	-1	6687006
vement	O	-1	6687006
in	O	-1	6687006
the	O	-1	6687006
locomotor	O	-1	6687006
stimul@@	O	-1	6687006
ant	O	-1	6687006
effects	O	-1	6687006
of	O	-1	6687006
amphetamine	B-Chemical	D000661	6687006
in	O	-1	6687006
the	O	-1	6687006
rat@@	O	-1	6687006
.	O	-1	6687006
M@@	O	-1	6687006
al@@	O	-1	6687006
e	O	-1	6687006
rats	O	-1	6687006
received	O	-1	6687006
the	O	-1	6687006
nor@@	B-Chemical	D009638	6687006
adren@@	I-Chemical	-1	6687006
aline	I-Chemical	-1	6687006
neuro@@	O	-1	6687006
tox@@	O	-1	6687006
in	O	-1	6687006
D@@	B-Chemical	C012102	6687006
S@@	I-Chemical	-1	6687006
P@@	I-Chemical	-1	6687006
4	I-Chemical	-1	6687006
(@@	O	-1	6687006
50	O	-1	6687006
mg/kg)	O	-1	6687006
7	O	-1	6687006
days	O	-1	6687006
prior	O	-1	6687006
to	O	-1	6687006
injection	O	-1	6687006
of	O	-1	6687006
D-@@	B-Chemical	D003913	6687006
amphetamine	I-Chemical	-1	6687006
(10	O	-1	6687006
or	O	-1	6687006
40	O	-1	6687006
m@@	O	-1	6687006
um@@	O	-1	6687006
ol@@	O	-1	6687006
/@@	O	-1	6687006
k@@	O	-1	6687006
g	O	-1	6687006
i.p.@@	O	-1	6687006
).	O	-1	6687006
The	O	-1	6687006
hyperactivity	B-Disease	D006948	6687006
induced	O	-1	6687006
by	O	-1	6687006
D-@@	B-Chemical	D003913	6687006
amphetamine	I-Chemical	-1	6687006
(10	O	-1	6687006
m@@	O	-1	6687006
um@@	O	-1	6687006
ol@@	O	-1	6687006
/@@	O	-1	6687006
kg@@	O	-1	6687006
)	O	-1	6687006
was	O	-1	6687006
significantly	O	-1	6687006
reduced	O	-1	6687006
by	O	-1	6687006
D@@	B-Chemical	C012102	6687006
S@@	I-Chemical	-1	6687006
P@@	I-Chemical	-1	6687006
4	I-Chemical	-1	6687006
pre@@	O	-1	6687006
treatment.	O	-1	6687006
However,	O	-1	6687006
the	O	-1	6687006
increased	O	-1	6687006
re@@	O	-1	6687006
ar@@	O	-1	6687006
ings	O	-1	6687006
and	O	-1	6687006
the	O	-1	6687006
amphetamine	B-Chemical	D000661	6687006
-induced	O	-1	6687006
ste@@	B-Disease	D019956	6687006
re@@	I-Disease	-1	6687006
ot@@	I-Disease	-1	6687006
y@@	I-Disease	-1	6687006
pi@@	I-Disease	-1	6687006
es	I-Disease	-1	6687006
were	O	-1	6687006
not	O	-1	6687006
block@@	O	-1	6687006
ed	O	-1	6687006
by	O	-1	6687006
pretreatment	O	-1	6687006
with	O	-1	6687006
D@@	B-Chemical	C012102	6687006
S@@	I-Chemical	-1	6687006
P@@	I-Chemical	-1	6687006
4	I-Chemical	-1	6687006
.	O	-1	6687006
The	O	-1	6687006
reduction	O	-1	6687006
of	O	-1	6687006
amphetamine	B-Chemical	D000661	6687006
hyperactivity	B-Disease	D006948	6687006
induced	O	-1	6687006
by	O	-1	6687006
D@@	B-Chemical	C012102	6687006
S@@	I-Chemical	-1	6687006
P@@	I-Chemical	-1	6687006
4	I-Chemical	-1	6687006
was	O	-1	6687006
block@@	O	-1	6687006
ed	O	-1	6687006
by	O	-1	6687006
pretreatment	O	-1	6687006
with	O	-1	6687006
the	O	-1	6687006
nor@@	B-Chemical	D009638	6687006
adren@@	I-Chemical	-1	6687006
aline	I-Chemical	-1	6687006
-@@	O	-1	6687006
u@@	O	-1	6687006
pt@@	O	-1	6687006
ake	O	-1	6687006
block@@	O	-1	6687006
ing	O	-1	6687006
agent@@	O	-1	6687006
,	O	-1	6687006
desi@@	B-Chemical	D003891	6687006
pramine	I-Chemical	-1	6687006
,	O	-1	6687006
which	O	-1	6687006
prev@@	O	-1	6687006
ents	O	-1	6687006
the	O	-1	6687006
neuro@@	B-Disease	D020258	6687006
toxic	I-Disease	-1	6687006
action	O	-1	6687006
of	O	-1	6687006
D@@	B-Chemical	C012102	6687006
S@@	I-Chemical	-1	6687006
P@@	I-Chemical	-1	6687006
4	I-Chemical	-1	6687006
.	O	-1	6687006
The	O	-1	6687006
present	O	-1	6687006
results	O	-1	6687006
suggest	O	-1	6687006
a	O	-1	6687006
selective	O	-1	6687006
invol@@	O	-1	6687006
vement	O	-1	6687006
of	O	-1	6687006
central	O	-1	6687006
nor@@	O	-1	6687006
adrenergic	O	-1	6687006
neuron@@	O	-1	6687006
es	O	-1	6687006
in	O	-1	6687006
the	O	-1	6687006
locomotor	O	-1	6687006
stimul@@	O	-1	6687006
ant	O	-1	6687006
effect	O	-1	6687006
of	O	-1	6687006
amphetamine	B-Chemical	D000661	6687006
in	O	-1	6687006
the	O	-1	6687006
rat@@	O	-1	6687006
.	O	-1	6687006

Ac@@	B-Disease	D001145	6695685
ce@@	I-Disease	-1	6695685
l@@	I-Disease	-1	6695685
er@@	I-Disease	-1	6695685
ated	I-Disease	-1	6695685
j@@	I-Disease	-1	6695685
unc@@	I-Disease	-1	6695685
tional	I-Disease	-1	6695685
rhyth@@	I-Disease	-1	6695685
ms	I-Disease	-1	6695685
during	O	-1	6695685
oral	O	-1	6695685
verap@@	B-Chemical	D014700	6695685
ami@@	I-Chemical	-1	6695685
l	I-Chemical	-1	6695685
therapy.	O	-1	6695685
This	O	-1	6695685
study	O	-1	6695685
examined	O	-1	6695685
the	O	-1	6695685
frequency	O	-1	6695685
of	O	-1	6695685
atri@@	O	-1	6695685
o@@	O	-1	6695685
ventricular	O	-1	6695685
(A@@	O	-1	6695685
V@@	O	-1	6695685
)	O	-1	6695685
dis@@	O	-1	6695685
s@@	O	-1	6695685
oci@@	O	-1	6695685
ation	O	-1	6695685
and	O	-1	6695685
ac@@	B-Disease	D001145	6695685
ce@@	I-Disease	-1	6695685
l@@	I-Disease	-1	6695685
er@@	I-Disease	-1	6695685
ated	I-Disease	-1	6695685
j@@	I-Disease	-1	6695685
unc@@	I-Disease	-1	6695685
tional	I-Disease	-1	6695685
rhyth@@	I-Disease	-1	6695685
ms	I-Disease	-1	6695685
in	O	-1	6695685
5@@	O	-1	6695685
9	O	-1	6695685
patients	O	-1	6695685
receiving	O	-1	6695685
oral	O	-1	6695685
verap@@	B-Chemical	D014700	6695685
ami@@	I-Chemical	-1	6695685
l	I-Chemical	-1	6695685
.	O	-1	6695685
Ac@@	B-Disease	D001145	6695685
ce@@	I-Disease	-1	6695685
l@@	I-Disease	-1	6695685
er@@	I-Disease	-1	6695685
ated	I-Disease	-1	6695685
j@@	I-Disease	-1	6695685
unc@@	I-Disease	-1	6695685
tional	I-Disease	-1	6695685
rhyth@@	I-Disease	-1	6695685
ms	I-Disease	-1	6695685
and	O	-1	6695685
A@@	O	-1	6695685
V	O	-1	6695685
dis@@	O	-1	6695685
s@@	O	-1	6695685
oci@@	O	-1	6695685
ation	O	-1	6695685
were	O	-1	6695685
frequent	O	-1	6695685
in	O	-1	6695685
patients	O	-1	6695685
with	O	-1	6695685
sup@@	B-Disease	D013617	6695685
ra@@	I-Disease	-1	6695685
ventricular	I-Disease	-1	6695685
tachy@@	I-Disease	-1	6695685
arrhyth@@	I-Disease	-1	6695685
mi@@	I-Disease	-1	6695685
as	I-Disease	-1	6695685
,	O	-1	6695685
partic@@	O	-1	6695685
ul@@	O	-1	6695685
arly	O	-1	6695685
A@@	O	-1	6695685
V	O	-1	6695685
no@@	O	-1	6695685
d@@	O	-1	6695685
al	O	-1	6695685
re@@	O	-1	6695685
entr@@	O	-1	6695685
y.	O	-1	6695685
V@@	B-Chemical	D014700	6695685
er@@	I-Chemical	-1	6695685
ap@@	I-Chemical	-1	6695685
ami@@	I-Chemical	-1	6695685
l	I-Chemical	-1	6695685
administration	O	-1	6695685
to	O	-1	6695685
these	O	-1	6695685
patients	O	-1	6695685
l@@	O	-1	6695685
ed	O	-1	6695685
to	O	-1	6695685
an	O	-1	6695685
as@@	O	-1	6695685
ym@@	O	-1	6695685
pto@@	O	-1	6695685
m@@	O	-1	6695685
atic	O	-1	6695685
increase	O	-1	6695685
in	O	-1	6695685
activity	O	-1	6695685
of	O	-1	6695685
these	O	-1	6695685
j@@	O	-1	6695685
unc@@	O	-1	6695685
tional	O	-1	6695685
pac@@	O	-1	6695685
em@@	O	-1	6695685
ak@@	O	-1	6695685
ers.	O	-1	6695685
In	O	-1	6695685
patients	O	-1	6695685
with	O	-1	6695685
various	O	-1	6695685
ch@@	B-Disease	D002637	6695685
est	I-Disease	-1	6695685
pain	I-Disease	-1	6695685
syndrom@@	O	-1	6695685
es,	O	-1	6695685
verap@@	B-Chemical	D014700	6695685
ami@@	I-Chemical	-1	6695685
l	I-Chemical	-1	6695685
ne@@	O	-1	6695685
ither	O	-1	6695685
increased	O	-1	6695685
the	O	-1	6695685
frequency	O	-1	6695685
of	O	-1	6695685
j@@	O	-1	6695685
unc@@	O	-1	6695685
tional	O	-1	6695685
rhyth@@	O	-1	6695685
ms	O	-1	6695685
n@@	O	-1	6695685
or	O	-1	6695685
sup@@	O	-1	6695685
press@@	O	-1	6695685
ed	O	-1	6695685
their	O	-1	6695685
role	O	-1	6695685
as	O	-1	6695685
es@@	O	-1	6695685
cap@@	O	-1	6695685
e	O	-1	6695685
rhyth@@	O	-1	6695685
ms	O	-1	6695685
under	O	-1	6695685
physi@@	O	-1	6695685
olog@@	O	-1	6695685
ically	O	-1	6695685
appro@@	O	-1	6695685
pri@@	O	-1	6695685
ate	O	-1	6695685
cir@@	O	-1	6695685
cum@@	O	-1	6695685
st@@	O	-1	6695685
anc@@	O	-1	6695685
es.	O	-1	6695685

Treat@@	O	-1	6806735
ment	O	-1	6806735
of	O	-1	6806735
o@@	B-Disease	D010051	6806735
vari@@	I-Disease	-1	6806735
an	I-Disease	-1	6806735
cancer	I-Disease	-1	6806735
with	O	-1	6806735
a	O	-1	6806735
combination	O	-1	6806735
of	O	-1	6806735
cis@@	B-Chemical	D002945	6806735
-@@	I-Chemical	-1	6806735
pl@@	I-Chemical	-1	6806735
at@@	I-Chemical	-1	6806735
in@@	I-Chemical	-1	6806735
um	I-Chemical	-1	6806735
,	O	-1	6806735
adriam@@	B-Chemical	D004317	6806735
ycin	I-Chemical	-1	6806735
,	O	-1	6806735
cyclophosph@@	B-Chemical	D003520	6806735
amide	I-Chemical	-1	6806735
and	O	-1	6806735
he@@	B-Chemical	D006585	6806735
xameth@@	I-Chemical	-1	6806735
yl@@	I-Chemical	-1	6806735
me@@	I-Chemical	-1	6806735
l@@	I-Chemical	-1	6806735
amine	I-Chemical	-1	6806735
.	O	-1	6806735
D@@	O	-1	6806735
uring	O	-1	6806735
the	O	-1	6806735
las@@	O	-1	6806735
t	O	-1	6806735
2	O	-1	6806735
1@@	O	-1	6806735
/@@	O	-1	6806735
2	O	-1	6806735
year@@	O	-1	6806735
s,	O	-1	6806735
3@@	O	-1	6806735
8	O	-1	6806735
patients	O	-1	6806735
with	O	-1	6806735
o@@	B-Disease	D010051	6806735
vari@@	I-Disease	-1	6806735
an	I-Disease	-1	6806735
cancer	I-Disease	-1	6806735
were	O	-1	6806735
treated	O	-1	6806735
with	O	-1	6806735
a	O	-1	6806735
combination	O	-1	6806735
of	O	-1	6806735
cispl@@	B-Chemical	D002945	6806735
at@@	I-Chemical	-1	6806735
in@@	I-Chemical	-1	6806735
um	I-Chemical	-1	6806735
(	O	-1	6806735
C@@	B-Chemical	C034868	6806735
P@@	I-Chemical	-1	6806735
D@@	I-Chemical	-1	6806735
D	I-Chemical	-1	6806735
),	O	-1	6806735
50	O	-1	6806735
mg/m@@	O	-1	6806735
2,	O	-1	6806735
adriam@@	B-Chemical	D004317	6806735
ycin	I-Chemical	-1	6806735
,	O	-1	6806735
30	O	-1	6806735
mg/m@@	O	-1	6806735
2,	O	-1	6806735
cyclophosph@@	B-Chemical	D003520	6806735
amide	I-Chemical	-1	6806735
,	O	-1	6806735
3@@	O	-1	6806735
00	O	-1	6806735
mg/m@@	O	-1	6806735
2,	O	-1	6806735
on	O	-1	6806735
day	O	-1	6806735
1@@	O	-1	6806735
;	O	-1	6806735
and	O	-1	6806735
he@@	B-Chemical	D006585	6806735
xameth@@	I-Chemical	-1	6806735
yl@@	I-Chemical	-1	6806735
me@@	I-Chemical	-1	6806735
l@@	I-Chemical	-1	6806735
amine	I-Chemical	-1	6806735
(	O	-1	6806735
H@@	B-Chemical	D006585	6806735
M@@	I-Chemical	-1	6806735
M	I-Chemical	-1	6806735
),	O	-1	6806735
6	O	-1	6806735
mg/kg	O	-1	6806735
da@@	O	-1	6806735
il@@	O	-1	6806735
y,	O	-1	6806735
for	O	-1	6806735
14	O	-1	6806735
days.	O	-1	6806735
E@@	O	-1	6806735
ach	O	-1	6806735
course	O	-1	6806735
was	O	-1	6806735
repe@@	O	-1	6806735
ated	O	-1	6806735
month@@	O	-1	6806735
ly.	O	-1	6806735
2	O	-1	6806735
patients	O	-1	6806735
had	O	-1	6806735
st@@	O	-1	6806735
age	O	-1	6806735
II@@	O	-1	6806735
,	O	-1	6806735
14	O	-1	6806735
st@@	O	-1	6806735
age	O	-1	6806735
I@@	O	-1	6806735
II	O	-1	6806735
and	O	-1	6806735
2@@	O	-1	6806735
2	O	-1	6806735
st@@	O	-1	6806735
age	O	-1	6806735
IV	O	-1	6806735
disease.	O	-1	6806735
14	O	-1	6806735
of	O	-1	6806735
the	O	-1	6806735
3@@	O	-1	6806735
8	O	-1	6806735
patients	O	-1	6806735
were	O	-1	6806735
previously	O	-1	6806735
treated	O	-1	6806735
with	O	-1	6806735
chemo@@	O	-1	6806735
therapy,	O	-1	6806735
1	O	-1	6806735
with	O	-1	6806735
radi@@	O	-1	6806735
ation,	O	-1	6806735
6	O	-1	6806735
with	O	-1	6806735
both	O	-1	6806735
chemotherapy	O	-1	6806735
and	O	-1	6806735
radi@@	O	-1	6806735
ation,	O	-1	6806735
and	O	-1	6806735
17	O	-1	6806735
did	O	-1	6806735
not	O	-1	6806735
have	O	-1	6806735
any	O	-1	6806735
treatment	O	-1	6806735
before	O	-1	6806735
C@@	B-Chemical	C034868	6806735
P@@	I-Chemical	-1	6806735
D@@	I-Chemical	-1	6806735
D	I-Chemical	-1	6806735
combin@@	O	-1	6806735
ation.	O	-1	6806735
3@@	O	-1	6806735
1	O	-1	6806735
of	O	-1	6806735
the	O	-1	6806735
3@@	O	-1	6806735
8	O	-1	6806735
cases	O	-1	6806735
(@@	O	-1	6806735
8@@	O	-1	6806735
1.@@	O	-1	6806735
5@@	O	-1	6806735
%)	O	-1	6806735
demonstrated	O	-1	6806735
ob@@	O	-1	6806735
j@@	O	-1	6806735
ective	O	-1	6806735
responses	O	-1	6806735
l@@	O	-1	6806735
ast@@	O	-1	6806735
ing	O	-1	6806735
for	O	-1	6806735
2	O	-1	6806735
months	O	-1	6806735
or	O	-1	6806735
mo@@	O	-1	6806735
re.	O	-1	6806735
These	O	-1	6806735
responses	O	-1	6806735
were	O	-1	6806735
partial	O	-1	6806735
in	O	-1	6806735
1@@	O	-1	6806735
9	O	-1	6806735
and	O	-1	6806735
complete	O	-1	6806735
in	O	-1	6806735
12	O	-1	6806735
cas@@	O	-1	6806735
es.	O	-1	6806735
H@@	B-Disease	D006402	6806735
em@@	I-Disease	-1	6806735
at@@	I-Disease	-1	6806735
ologic	I-Disease	-1	6806735
toxicity	I-Disease	-1	6806735
was	O	-1	6806735
moder@@	O	-1	6806735
ate	O	-1	6806735
and	O	-1	6806735
with	O	-1	6806735
reversible	O	-1	6806735
anemia	B-Disease	D000740	6806735
develop@@	O	-1	6806735
ing	O	-1	6806735
in	O	-1	6806735
7@@	O	-1	6806735
1@@	O	-1	6806735
%	O	-1	6806735
of	O	-1	6806735
patients.	O	-1	6806735
G@@	O	-1	6806735
ast@@	O	-1	6806735
ro@@	O	-1	6806735
in@@	O	-1	6806735
test@@	O	-1	6806735
inal	O	-1	6806735
side	O	-1	6806735
effects	O	-1	6806735
from	O	-1	6806735
C@@	B-Chemical	C034868	6806735
P@@	I-Chemical	-1	6806735
D@@	I-Chemical	-1	6806735
D	I-Chemical	-1	6806735
were	O	-1	6806735
un@@	O	-1	6806735
i@@	O	-1	6806735
ver@@	O	-1	6806735
sal@@	O	-1	6806735
.	O	-1	6806735
H@@	B-Chemical	D006585	6806735
M@@	I-Chemical	-1	6806735
M	I-Chemical	-1	6806735
gast@@	B-Disease	D005767	6806735
ro@@	I-Disease	-1	6806735
in@@	I-Disease	-1	6806735
test@@	I-Disease	-1	6806735
inal	I-Disease	-1	6806735
toxicity	I-Disease	-1	6806735
nec@@	O	-1	6806735
ess@@	O	-1	6806735
it@@	O	-1	6806735
ated	O	-1	6806735
discontinu@@	O	-1	6806735
ation	O	-1	6806735
of	O	-1	6806735
the	O	-1	6806735
drug	O	-1	6806735
in	O	-1	6806735
5	O	-1	6806735
patients.	O	-1	6806735
S@@	O	-1	6806735
ev@@	O	-1	6806735
ere	O	-1	6806735
nephro@@	B-Disease	D007674	6806735
toxicity	I-Disease	-1	6806735
was	O	-1	6806735
observed	O	-1	6806735
in	O	-1	6806735
2	O	-1	6806735
patients	O	-1	6806735
but	O	-1	6806735
was	O	-1	6806735
rever@@	O	-1	6806735
sib@@	O	-1	6806735
le@@	O	-1	6806735
.	O	-1	6806735
There	O	-1	6806735
were	O	-1	6806735
no	O	-1	6806735
drug@@	O	-1	6806735
-@@	O	-1	6806735
related	O	-1	6806735
de@@	O	-1	6806735
ath@@	O	-1	6806735
s.	O	-1	6806735

N@@	O	-1	6884395
ont@@	O	-1	6884395
ra@@	O	-1	6884395
um@@	O	-1	6884395
atic	O	-1	6884395
dis@@	B-Disease	D000784	6884395
s@@	I-Disease	-1	6884395
ect@@	I-Disease	-1	6884395
ing	I-Disease	-1	6884395
aneurys@@	I-Disease	-1	6884395
m	I-Disease	-1	6884395
of	O	-1	6884395
the	O	-1	6884395
b@@	O	-1	6884395
a@@	O	-1	6884395
si@@	O	-1	6884395
l@@	O	-1	6884395
ar	O	-1	6884395
arter@@	O	-1	6884395
y.	O	-1	6884395
A	O	-1	6884395
case	O	-1	6884395
of	O	-1	6884395
non@@	O	-1	6884395
tra@@	O	-1	6884395
um@@	O	-1	6884395
atic	O	-1	6884395
dis@@	B-Disease	D000784	6884395
s@@	I-Disease	-1	6884395
ect@@	I-Disease	-1	6884395
ing	I-Disease	-1	6884395
aneurys@@	I-Disease	-1	6884395
m	I-Disease	-1	6884395
of	O	-1	6884395
the	O	-1	6884395
b@@	O	-1	6884395
a@@	O	-1	6884395
si@@	O	-1	6884395
l@@	O	-1	6884395
ar	O	-1	6884395
artery	O	-1	6884395
in	O	-1	6884395
association	O	-1	6884395
with	O	-1	6884395
hypertension	B-Disease	D006973	6884395
,	O	-1	6884395
smo@@	O	-1	6884395
k@@	O	-1	6884395
e,	O	-1	6884395
and	O	-1	6884395
oral	B-Chemical	D003276	6884395
contrac@@	I-Chemical	-1	6884395
ep@@	I-Chemical	-1	6884395
tiv@@	I-Chemical	-1	6884395
es	I-Chemical	-1	6884395
is	O	-1	6884395
reported	O	-1	6884395
in	O	-1	6884395
a	O	-1	6884395
youn@@	O	-1	6884395
g	O	-1	6884395
female	O	-1	6884395
patient	O	-1	6884395
with	O	-1	6884395
a	O	-1	6884395
loc@@	B-Disease	D011782	6884395
k@@	I-Disease	-1	6884395
ed@@	I-Disease	-1	6884395
-@@	I-Disease	-1	6884395
in	I-Disease	-1	6884395
syndrome	I-Disease	-1	6884395
.	O	-1	6884395

Pro@@	B-Chemical	D011441	6893265
p@@	I-Chemical	-1	6893265
yl@@	I-Chemical	-1	6893265
th@@	I-Chemical	-1	6893265
io@@	I-Chemical	-1	6893265
urac@@	I-Chemical	-1	6893265
il	I-Chemical	-1	6893265
-induced	O	-1	6893265
hepatic	B-Disease	D056486	6893265
damage	I-Disease	-1	6893265
.	O	-1	6893265
Two	O	-1	6893265
cases	O	-1	6893265
of	O	-1	6893265
prop@@	B-Chemical	D011441	6893265
yl@@	I-Chemical	-1	6893265
th@@	I-Chemical	-1	6893265
io@@	I-Chemical	-1	6893265
urac@@	I-Chemical	-1	6893265
il	I-Chemical	-1	6893265
-induced	O	-1	6893265
liver	B-Disease	D056486	6893265
damage	I-Disease	-1	6893265
have	O	-1	6893265
been	O	-1	6893265
obser@@	O	-1	6893265
ved.	O	-1	6893265
The	O	-1	6893265
first	O	-1	6893265
case	O	-1	6893265
is	O	-1	6893265
of	O	-1	6893265
an	O	-1	6893265
acute	O	-1	6893265
type	O	-1	6893265
of	O	-1	6893265
dam@@	O	-1	6893265
age,	O	-1	6893265
pro@@	O	-1	6893265
ven	O	-1	6893265
by	O	-1	6893265
re@@	O	-1	6893265
ch@@	O	-1	6893265
all@@	O	-1	6893265
en@@	O	-1	6893265
ge@@	O	-1	6893265
;	O	-1	6893265
the	O	-1	6893265
second	O	-1	6893265
pres@@	O	-1	6893265
ents	O	-1	6893265
a	O	-1	6893265
clinical	O	-1	6893265
and	O	-1	6893265
hist@@	O	-1	6893265
ologic	O	-1	6893265
p@@	O	-1	6893265
ic@@	O	-1	6893265
t@@	O	-1	6893265
ure	O	-1	6893265
re@@	O	-1	6893265
se@@	O	-1	6893265
m@@	O	-1	6893265
bl@@	O	-1	6893265
ing	O	-1	6893265
chronic	B-Disease	D006521	6893265
active	I-Disease	-1	6893265
hepatitis	I-Disease	-1	6893265
,	O	-1	6893265
with	O	-1	6893265
spont@@	O	-1	6893265
aneous	O	-1	6893265
re@@	O	-1	6893265
mis@@	O	-1	6893265
sion.	O	-1	6893265

S@@	O	-1	6985297
t@@	O	-1	6985297
udi@@	O	-1	6985297
es	O	-1	6985297
on	O	-1	6985297
the	O	-1	6985297
brady@@	B-Disease	D001919	6985297
cardia	I-Disease	-1	6985297
induced	O	-1	6985297
by	O	-1	6985297
be@@	B-Chemical	D015764	6985297
pri@@	I-Chemical	-1	6985297
di@@	I-Chemical	-1	6985297
l	I-Chemical	-1	6985297
.	O	-1	6985297
B@@	B-Chemical	D015764	6985297
ep@@	I-Chemical	-1	6985297
ri@@	I-Chemical	-1	6985297
di@@	I-Chemical	-1	6985297
l	I-Chemical	-1	6985297
,	O	-1	6985297
a	O	-1	6985297
novel	O	-1	6985297
active	O	-1	6985297
comp@@	O	-1	6985297
ound	O	-1	6985297
for	O	-1	6985297
pro@@	O	-1	6985297
phyl@@	O	-1	6985297
ac@@	O	-1	6985297
tic	O	-1	6985297
treatment	O	-1	6985297
of	O	-1	6985297
ang@@	B-Disease	D000787	6985297
inal	I-Disease	-1	6985297
at@@	I-Disease	-1	6985297
tac@@	I-Disease	-1	6985297
k@@	I-Disease	-1	6985297
s	I-Disease	-1	6985297
,	O	-1	6985297
induced	O	-1	6985297
per@@	O	-1	6985297
sist@@	O	-1	6985297
ent	O	-1	6985297
brady@@	B-Disease	D001919	6985297
cardia	I-Disease	-1	6985297
and	O	-1	6985297
a	O	-1	6985297
non-@@	O	-1	6985297
specific	O	-1	6985297
anti@@	O	-1	6985297
-	O	-1	6985297
tachy@@	B-Disease	D013610	6985297
cardi@@	I-Disease	-1	6985297
al	I-Disease	-1	6985297
effect@@	O	-1	6985297
,	O	-1	6985297
the	O	-1	6985297
mechanisms	O	-1	6985297
of	O	-1	6985297
which	O	-1	6985297
were	O	-1	6985297
investigated	O	-1	6985297
in	O	-1	6985297
vit@@	O	-1	6985297
r@@	O	-1	6985297
o	O	-1	6985297
and	O	-1	6985297
in	O	-1	6985297
viv@@	O	-1	6985297
o@@	O	-1	6985297
.	O	-1	6985297
In	O	-1	6985297
vit@@	O	-1	6985297
r@@	O	-1	6985297
o	O	-1	6985297
per@@	O	-1	6985297
f@@	O	-1	6985297
usion	O	-1	6985297
of	O	-1	6985297
be@@	B-Chemical	D015764	6985297
pri@@	I-Chemical	-1	6985297
di@@	I-Chemical	-1	6985297
l	I-Chemical	-1	6985297
in	O	-1	6985297
the	O	-1	6985297
lif@@	O	-1	6985297
e-@@	O	-1	6985297
suppor@@	O	-1	6985297
t	O	-1	6985297
medi@@	O	-1	6985297
um	O	-1	6985297
for	O	-1	6985297
isol@@	O	-1	6985297
ated	O	-1	6985297
s@@	O	-1	6985297
ino@@	O	-1	6985297
-@@	O	-1	6985297
atrial	O	-1	6985297
tissue	O	-1	6985297
from	O	-1	6985297
ra@@	O	-1	6985297
b@@	O	-1	6985297
b@@	O	-1	6985297
it	O	-1	6985297
hear@@	O	-1	6985297
t,	O	-1	6985297
caused	O	-1	6985297
a	O	-1	6985297
reduction	O	-1	6985297
in	O	-1	6985297
action	O	-1	6985297
potential	O	-1	6985297
(A@@	O	-1	6985297
P)	O	-1	6985297
s@@	O	-1	6985297
pi@@	O	-1	6985297
k@@	O	-1	6985297
e	O	-1	6985297
frequency	O	-1	6985297
(@@	O	-1	6985297
recor@@	O	-1	6985297
ded	O	-1	6985297
by	O	-1	6985297
K@@	B-Chemical	D011189	6985297
C@@	I-Chemical	-1	6985297
l	I-Chemical	-1	6985297
micro@@	O	-1	6985297
electro@@	O	-1	6985297
des@@	O	-1	6985297
)	O	-1	6985297
star@@	O	-1	6985297
ting	O	-1	6985297
at	O	-1	6985297
doses	O	-1	6985297
of	O	-1	6985297
5	O	-1	6985297
X	O	-1	6985297
10@@	O	-1	6985297
(-@@	O	-1	6985297
6@@	O	-1	6985297
)	O	-1	6985297
M@@	O	-1	6985297
.	O	-1	6985297
This	O	-1	6985297
effect	O	-1	6985297
was	O	-1	6985297
dose-@@	O	-1	6985297
dependent	O	-1	6985297
up	O	-1	6985297
to	O	-1	6985297
concentrations	O	-1	6985297
of	O	-1	6985297
5	O	-1	6985297
X	O	-1	6985297
10@@	O	-1	6985297
(-@@	O	-1	6985297
5@@	O	-1	6985297
)	O	-1	6985297
M@@	O	-1	6985297
,	O	-1	6985297
whe@@	O	-1	6985297
re@@	O	-1	6985297
up@@	O	-1	6985297
on	O	-1	6985297
block@@	O	-1	6985297
ade	O	-1	6985297
of	O	-1	6985297
s@@	O	-1	6985297
in@@	O	-1	6985297
us	O	-1	6985297
activity	O	-1	6985297
set	O	-1	6985297
in.	O	-1	6985297
B@@	B-Chemical	D015764	6985297
ep@@	I-Chemical	-1	6985297
ri@@	I-Chemical	-1	6985297
di@@	I-Chemical	-1	6985297
l	I-Chemical	-1	6985297
at	O	-1	6985297
a	O	-1	6985297
dose	O	-1	6985297
of	O	-1	6985297
5	O	-1	6985297
X	O	-1	6985297
10@@	O	-1	6985297
(-@@	O	-1	6985297
6@@	O	-1	6985297
)	O	-1	6985297
M@@	O	-1	6985297
,	O	-1	6985297
induced	O	-1	6985297
a	O	-1	6985297
concomit@@	O	-1	6985297
ant	O	-1	6985297
reduction	O	-1	6985297
in	O	-1	6985297
A@@	O	-1	6985297
P	O	-1	6985297
am@@	O	-1	6985297
pl@@	O	-1	6985297
it@@	O	-1	6985297
ude	O	-1	6985297
(@@	O	-1	6985297
f@@	O	-1	6985297
all@@	O	-1	6985297
ing	O	-1	6985297
from	O	-1	6985297
7@@	O	-1	6985297
1	O	-1	6985297
+/-	O	-1	6985297
8	O	-1	6985297
m@@	O	-1	6985297
V	O	-1	6985297
to	O	-1	6985297
4@@	O	-1	6985297
7	O	-1	6985297
+/-	O	-1	6985297
6	O	-1	6985297
m@@	O	-1	6985297
V@@	O	-1	6985297
),	O	-1	6985297
maxim@@	O	-1	6985297
um	O	-1	6985297
systolic	O	-1	6985297
de@@	O	-1	6985297
pol@@	O	-1	6985297
ar@@	O	-1	6985297
ization	O	-1	6985297
ve@@	O	-1	6985297
loc@@	O	-1	6985297
ity	O	-1	6985297
(@@	O	-1	6985297
phase	O	-1	6985297
0@@	O	-1	6985297
)	O	-1	6985297
which	O	-1	6985297
f@@	O	-1	6985297
el@@	O	-1	6985297
l	O	-1	6985297
from	O	-1	6985297
1.@@	O	-1	6985297
8@@	O	-1	6985297
5	O	-1	6985297
+/-	O	-1	6985297
0.@@	O	-1	6985297
3@@	O	-1	6985297
5	O	-1	6985297
V@@	O	-1	6985297
/@@	O	-1	6985297
s	O	-1	6985297
to	O	-1	6985297
0.@@	O	-1	6985297
8@@	O	-1	6985297
4	O	-1	6985297
+/-	O	-1	6985297
0.@@	O	-1	6985297
2@@	O	-1	6985297
8	O	-1	6985297
V@@	O	-1	6985297
/@@	O	-1	6985297
s,	O	-1	6985297
to@@	O	-1	6985297
ge@@	O	-1	6985297
ther	O	-1	6985297
with	O	-1	6985297
maxim@@	O	-1	6985297
um	O	-1	6985297
di@@	O	-1	6985297
ast@@	O	-1	6985297
olic	O	-1	6985297
de@@	O	-1	6985297
pol@@	O	-1	6985297
ar@@	O	-1	6985297
ization	O	-1	6985297
ve@@	O	-1	6985297
loc@@	O	-1	6985297
ity	O	-1	6985297
(@@	O	-1	6985297
phase	O	-1	6985297
4@@	O	-1	6985297
)	O	-1	6985297
which	O	-1	6985297
f@@	O	-1	6985297
el@@	O	-1	6985297
l	O	-1	6985297
from	O	-1	6985297
3@@	O	-1	6985297
8	O	-1	6985297
+/-	O	-1	6985297
3	O	-1	6985297
m@@	O	-1	6985297
V@@	O	-1	6985297
/@@	O	-1	6985297
s	O	-1	6985297
to	O	-1	6985297
24	O	-1	6985297
+/-	O	-1	6985297
5	O	-1	6985297
m@@	O	-1	6985297
V@@	O	-1	6985297
/@@	O	-1	6985297
s.	O	-1	6985297
In	O	-1	6985297
viv@@	O	-1	6985297
o	O	-1	6985297
injection	O	-1	6985297
of	O	-1	6985297
be@@	B-Chemical	D015764	6985297
pri@@	I-Chemical	-1	6985297
di@@	I-Chemical	-1	6985297
l	I-Chemical	-1	6985297
at	O	-1	6985297
a	O	-1	6985297
dose	O	-1	6985297
of	O	-1	6985297
5	O	-1	6985297
mg/kg	O	-1	6985297
(@@	O	-1	6985297
i.v@@	O	-1	6985297
.)	O	-1	6985297
into	O	-1	6985297
6	O	-1	6985297
anaesthe@@	O	-1	6985297
tiz@@	O	-1	6985297
ed	O	-1	6985297
dog@@	O	-1	6985297
s	O	-1	6985297
which	O	-1	6985297
had	O	-1	6985297
under@@	O	-1	6985297
g@@	O	-1	6985297
one	O	-1	6985297
abl@@	O	-1	6985297
ation	O	-1	6985297
of	O	-1	6985297
all	O	-1	6985297
the	O	-1	6985297
ext@@	O	-1	6985297
r@@	O	-1	6985297
in@@	O	-1	6985297
sic	O	-1	6985297
cardiac	O	-1	6985297
a@@	O	-1	6985297
fferen@@	O	-1	6985297
t	O	-1	6985297
nerve	O	-1	6985297
sup@@	O	-1	6985297
pl@@	O	-1	6985297
y,	O	-1	6985297
to@@	O	-1	6985297
ge@@	O	-1	6985297
ther	O	-1	6985297
with	O	-1	6985297
a	O	-1	6985297
bil@@	O	-1	6985297
ateral	O	-1	6985297
med@@	O	-1	6985297
ul@@	O	-1	6985297
lo@@	O	-1	6985297
-@@	O	-1	6985297
adren@@	O	-1	6985297
al@@	O	-1	6985297
ect@@	O	-1	6985297
om@@	O	-1	6985297
y,	O	-1	6985297
caused	O	-1	6985297
a	O	-1	6985297
mark@@	O	-1	6985297
ed	O	-1	6985297
reduction	O	-1	6985297
in	O	-1	6985297
heart	O	-1	6985297
rate	O	-1	6985297
which	O	-1	6985297
f@@	O	-1	6985297
el@@	O	-1	6985297
l	O	-1	6985297
from	O	-1	6985297
9@@	O	-1	6985297
8.@@	O	-1	6985297
7	O	-1	6985297
+/-	O	-1	6985297
4.@@	O	-1	6985297
2	O	-1	6985297
be@@	O	-1	6985297
at@@	O	-1	6985297
s/@@	O	-1	6985297
min	O	-1	6985297
to	O	-1	6985297
7@@	O	-1	6985297
6	O	-1	6985297
+/-	O	-1	6985297
5.@@	O	-1	6985297
3	O	-1	6985297
be@@	O	-1	6985297
at@@	O	-1	6985297
s/@@	O	-1	6985297
min	O	-1	6985297
su@@	O	-1	6985297
st@@	O	-1	6985297
ained	O	-1	6985297
for	O	-1	6985297
more	O	-1	6985297
than	O	-1	6985297
4@@	O	-1	6985297
5	O	-1	6985297
min@@	O	-1	6985297
.	O	-1	6985297
It	O	-1	6985297
is	O	-1	6985297
concl@@	O	-1	6985297
uded	O	-1	6985297
that	O	-1	6985297
be@@	B-Chemical	D015764	6985297
pri@@	I-Chemical	-1	6985297
di@@	I-Chemical	-1	6985297
l	I-Chemical	-1	6985297
reduc@@	O	-1	6985297
es	O	-1	6985297
heart	O	-1	6985297
rate	O	-1	6985297
by	O	-1	6985297
act@@	O	-1	6985297
ing	O	-1	6985297
direc@@	O	-1	6985297
tly	O	-1	6985297
on	O	-1	6985297
the	O	-1	6985297
s@@	O	-1	6985297
in@@	O	-1	6985297
us	O	-1	6985297
no@@	O	-1	6985297
de@@	O	-1	6985297
.	O	-1	6985297
This	O	-1	6985297
effect@@	O	-1	6985297
,	O	-1	6985297
which	O	-1	6985297
results	O	-1	6985297
in	O	-1	6985297
a	O	-1	6985297
f@@	O	-1	6985297
lat@@	O	-1	6985297
ten@@	O	-1	6985297
ing	O	-1	6985297
of	O	-1	6985297
the	O	-1	6985297
phase	O	-1	6985297
0	O	-1	6985297
and	O	-1	6985297
phase	O	-1	6985297
4	O	-1	6985297
s@@	O	-1	6985297
lop@@	O	-1	6985297
e,	O	-1	6985297
to@@	O	-1	6985297
ge@@	O	-1	6985297
ther	O	-1	6985297
with	O	-1	6985297
a	O	-1	6985297
long@@	O	-1	6985297
er	O	-1	6985297
A@@	O	-1	6985297
P	O	-1	6985297
dur@@	O	-1	6985297
ation,	O	-1	6985297
may	O	-1	6985297
be	O	-1	6985297
due	O	-1	6985297
to	O	-1	6985297
an	O	-1	6985297
increase	O	-1	6985297
in	O	-1	6985297
the	O	-1	6985297
time	O	-1	6985297
con@@	O	-1	6985297
st@@	O	-1	6985297
ants	O	-1	6985297
of	O	-1	6985297
s@@	O	-1	6985297
low	O	-1	6985297
in@@	O	-1	6985297
war@@	O	-1	6985297
d	O	-1	6985297
i@@	O	-1	6985297
onic	O	-1	6985297
cur@@	O	-1	6985297
ren@@	O	-1	6985297
ts	O	-1	6985297
(@@	O	-1	6985297
al@@	O	-1	6985297
re@@	O	-1	6985297
ad@@	O	-1	6985297
y	O	-1	6985297
demonstrated	O	-1	6985297
el@@	O	-1	6985297
se@@	O	-1	6985297
whe@@	O	-1	6985297
re@@	O	-1	6985297
),	O	-1	6985297
but	O	-1	6985297
also	O	-1	6985297
to	O	-1	6985297
an	O	-1	6985297
increased	O	-1	6985297
time	O	-1	6985297
con@@	O	-1	6985297
st@@	O	-1	6985297
ant	O	-1	6985297
for	O	-1	6985297
de@@	O	-1	6985297
activation	O	-1	6985297
of	O	-1	6985297
the	O	-1	6985297
ou@@	O	-1	6985297
tw@@	O	-1	6985297
ard	O	-1	6985297
pot@@	B-Chemical	D011188	6985297
assi@@	I-Chemical	-1	6985297
um	I-Chemical	-1	6985297
current	O	-1	6985297
(@@	O	-1	6985297
I@@	O	-1	6985297
p@@	O	-1	6985297
).	O	-1	6985297

He@@	B-Disease	D056486	6985498
pati@@	I-Disease	-1	6985498
tis	I-Disease	-1	6985498
and	O	-1	6985498
renal	B-Disease	D000141	6985498
tub@@	I-Disease	-1	6985498
ular	I-Disease	-1	6985498
acid@@	I-Disease	-1	6985498
o@@	I-Disease	-1	6985498
sis	I-Disease	-1	6985498
after	O	-1	6985498
anesthe@@	O	-1	6985498
sia	O	-1	6985498
with	O	-1	6985498
meth@@	B-Chemical	D008733	6985498
oxy@@	I-Chemical	-1	6985498
f@@	I-Chemical	-1	6985498
lur@@	I-Chemical	-1	6985498
ane	I-Chemical	-1	6985498
.	O	-1	6985498
A	O	-1	6985498
6@@	O	-1	6985498
9@@	O	-1	6985498
-@@	O	-1	6985498
year-old	O	-1	6985498
man	O	-1	6985498
o@@	O	-1	6985498
per@@	O	-1	6985498
ated	O	-1	6985498
for	O	-1	6985498
acute	B-Disease	D041881	6985498
chol@@	I-Disease	-1	6985498
ec@@	I-Disease	-1	6985498
ys@@	I-Disease	-1	6985498
ti@@	I-Disease	-1	6985498
tis	I-Disease	-1	6985498
under	O	-1	6985498
meth@@	B-Chemical	D008733	6985498
oxy@@	I-Chemical	-1	6985498
f@@	I-Chemical	-1	6985498
lur@@	I-Chemical	-1	6985498
ane	I-Chemical	-1	6985498
anesthe@@	O	-1	6985498
sia	O	-1	6985498
developed	O	-1	6985498
posto@@	O	-1	6985498
per@@	O	-1	6985498
atively	O	-1	6985498
a	O	-1	6985498
hepatic	B-Disease	D048550	6985498
in@@	I-Disease	-1	6985498
suffici@@	I-Disease	-1	6985498
ency	I-Disease	-1	6985498
syndrome	I-Disease	-1	6985498
and	O	-1	6985498
renal	B-Disease	D000141	6985498
tub@@	I-Disease	-1	6985498
ular	I-Disease	-1	6985498
acid@@	I-Disease	-1	6985498
o@@	I-Disease	-1	6985498
sis	I-Disease	-1	6985498
.	O	-1	6985498
M@@	O	-1	6985498
as@@	O	-1	6985498
sive	O	-1	6985498
ble@@	B-Disease	D006470	6985498
ed@@	I-Disease	-1	6985498
ing	I-Disease	-1	6985498
appe@@	O	-1	6985498
a@@	O	-1	6985498
red	O	-1	6985498
during	O	-1	6985498
surger@@	O	-1	6985498
y	O	-1	6985498
which	O	-1	6985498
l@@	O	-1	6985498
ast@@	O	-1	6985498
ed	O	-1	6985498
for	O	-1	6985498
six	O	-1	6985498
hour@@	O	-1	6985498
s.	O	-1	6985498
P@@	O	-1	6985498
o@@	O	-1	6985498
sto@@	O	-1	6985498
perative	O	-1	6985498
ev@@	O	-1	6985498
ol@@	O	-1	6985498
u@@	O	-1	6985498
tion	O	-1	6985498
under	O	-1	6985498
suppor@@	O	-1	6985498
tive	O	-1	6985498
therapy	O	-1	6985498
was	O	-1	6985498
f@@	O	-1	6985498
av@@	O	-1	6985498
o@@	O	-1	6985498
ur@@	O	-1	6985498
able@@	O	-1	6985498
.	O	-1	6985498
Com@@	O	-1	6985498
ple@@	O	-1	6985498
te	O	-1	6985498
recovery	O	-1	6985498
was	O	-1	6985498
con@@	O	-1	6985498
fir@@	O	-1	6985498
m@@	O	-1	6985498
ed	O	-1	6985498
by	O	-1	6985498
repe@@	O	-1	6985498
ated	O	-1	6985498
controls	O	-1	6985498
performed	O	-1	6985498
over	O	-1	6985498
a	O	-1	6985498
period	O	-1	6985498
of	O	-1	6985498
one	O	-1	6985498
year	O	-1	6985498
after	O	-1	6985498
surger@@	O	-1	6985498
y.	O	-1	6985498

P@@	O	-1	7018927
it@@	O	-1	7018927
u@@	O	-1	7018927
it@@	O	-1	7018927
ary	O	-1	7018927
response	O	-1	7018927
to	O	-1	7018927
lu@@	O	-1	7018927
te@@	O	-1	7018927
in@@	O	-1	7018927
iz@@	O	-1	7018927
ing	O	-1	7018927
h@@	O	-1	7018927
orm@@	O	-1	7018927
on@@	O	-1	7018927
e-@@	O	-1	7018927
rele@@	O	-1	7018927
as@@	O	-1	7018927
ing	O	-1	7018927
h@@	O	-1	7018927
orm@@	O	-1	7018927
one	O	-1	7018927
during	O	-1	7018927
haloperidol	B-Chemical	D006220	7018927
-induced	O	-1	7018927
hyper@@	B-Disease	D006966	7018927
prol@@	I-Disease	-1	7018927
act@@	I-Disease	-1	7018927
ine@@	I-Disease	-1	7018927
mia	I-Disease	-1	7018927
.	O	-1	7018927
The	O	-1	7018927
effects	O	-1	7018927
of	O	-1	7018927
a	O	-1	7018927
6-@@	O	-1	7018927
h@@	O	-1	7018927
our	O	-1	7018927
infusion	O	-1	7018927
with	O	-1	7018927
haloperidol	B-Chemical	D006220	7018927
on	O	-1	7018927
serum	O	-1	7018927
prolactin	O	-1	7018927
and	O	-1	7018927
lu@@	O	-1	7018927
te@@	O	-1	7018927
in@@	O	-1	7018927
iz@@	O	-1	7018927
ing	O	-1	7018927
h@@	O	-1	7018927
orm@@	O	-1	7018927
one	O	-1	7018927
(@@	O	-1	7018927
L@@	O	-1	7018927
H@@	O	-1	7018927
)	O	-1	7018927
levels	O	-1	7018927
was	O	-1	7018927
studied	O	-1	7018927
in	O	-1	7018927
a	O	-1	7018927
group	O	-1	7018927
of	O	-1	7018927
male	O	-1	7018927
subj@@	O	-1	7018927
ect@@	O	-1	7018927
s.	O	-1	7018927
F@@	O	-1	7018927
i@@	O	-1	7018927
ve	O	-1	7018927
hours	O	-1	7018927
after	O	-1	7018927
star@@	O	-1	7018927
ting	O	-1	7018927
the	O	-1	7018927
infu@@	O	-1	7018927
sion@@	O	-1	7018927
s,	O	-1	7018927
a	O	-1	7018927
study	O	-1	7018927
of	O	-1	7018927
the	O	-1	7018927
pit@@	O	-1	7018927
u@@	O	-1	7018927
it@@	O	-1	7018927
ary	O	-1	7018927
responses	O	-1	7018927
to	O	-1	7018927
L@@	O	-1	7018927
H@@	O	-1	7018927
-@@	O	-1	7018927
rele@@	O	-1	7018927
as@@	O	-1	7018927
ing	O	-1	7018927
h@@	O	-1	7018927
orm@@	O	-1	7018927
one	O	-1	7018927
(@@	O	-1	7018927
L@@	O	-1	7018927
H@@	O	-1	7018927
-@@	O	-1	7018927
R@@	O	-1	7018927
H@@	O	-1	7018927
)	O	-1	7018927
was	O	-1	7018927
car@@	O	-1	7018927
ri@@	O	-1	7018927
ed	O	-1	7018927
out@@	O	-1	7018927
.	O	-1	7018927
C@@	O	-1	7018927
ont@@	O	-1	7018927
ro@@	O	-1	7018927
l	O	-1	7018927
patients	O	-1	7018927
received	O	-1	7018927
infu@@	O	-1	7018927
sions	O	-1	7018927
of	O	-1	7018927
0.@@	O	-1	7018927
9@@	O	-1	7018927
%	O	-1	7018927
Na@@	B-Chemical	D012965	7018927
C@@	I-Chemical	-1	7018927
l	I-Chemical	-1	7018927
sol@@	O	-1	7018927
u@@	O	-1	7018927
tion.	O	-1	7018927
D@@	O	-1	7018927
uring	O	-1	7018927
the	O	-1	7018927
course	O	-1	7018927
of	O	-1	7018927
haloperidol	B-Chemical	D006220	7018927
infu@@	O	-1	7018927
sion@@	O	-1	7018927
s,	O	-1	7018927
significant	O	-1	7018927
hyper@@	B-Disease	D006966	7018927
prol@@	I-Disease	-1	7018927
act@@	I-Disease	-1	7018927
ine@@	I-Disease	-1	7018927
mia	I-Disease	-1	7018927
was	O	-1	7018927
f@@	O	-1	7018927
oun@@	O	-1	7018927
d,	O	-1	7018927
to@@	O	-1	7018927
ge@@	O	-1	7018927
ther	O	-1	7018927
with	O	-1	7018927
an	O	-1	7018927
abol@@	O	-1	7018927
ished	O	-1	7018927
pit@@	O	-1	7018927
u@@	O	-1	7018927
it@@	O	-1	7018927
ary	O	-1	7018927
response	O	-1	7018927
to	O	-1	7018927
L@@	O	-1	7018927
H@@	O	-1	7018927
-@@	O	-1	7018927
R@@	O	-1	7018927
H@@	O	-1	7018927
,	O	-1	7018927
as	O	-1	7018927
compared	O	-1	7018927
with	O	-1	7018927
responses	O	-1	7018927
of	O	-1	7018927
control	O	-1	7018927
subj@@	O	-1	7018927
ect@@	O	-1	7018927
s.	O	-1	7018927

An@@	O	-1	7121659
ti@@	O	-1	7121659
ri@@	O	-1	7121659
f@@	O	-1	7121659
amp@@	O	-1	7121659
icin	O	-1	7121659
anti@@	O	-1	7121659
bo@@	O	-1	7121659
di@@	O	-1	7121659
es	O	-1	7121659
in	O	-1	7121659
acute	O	-1	7121659
ri@@	B-Chemical	D012293	7121659
f@@	I-Chemical	-1	7121659
amp@@	I-Chemical	-1	7121659
icin	I-Chemical	-1	7121659
-@@	O	-1	7121659
associated	O	-1	7121659
renal	B-Disease	D051437	7121659
failure	I-Disease	-1	7121659
.	O	-1	7121659
5	O	-1	7121659
patients	O	-1	7121659
with	O	-1	7121659
acute	B-Disease	D058186	7121659
renal	I-Disease	-1	7121659
failure	I-Disease	-1	7121659
(@@	O	-1	7121659
3	O	-1	7121659
with	O	-1	7121659
thrombo@@	B-Disease	D013921	7121659
pen@@	I-Disease	-1	7121659
ia	I-Disease	-1	7121659
and	O	-1	7121659
hemoly@@	B-Disease	D006461	7121659
sis	I-Disease	-1	7121659
)	O	-1	7121659
induced	O	-1	7121659
by	O	-1	7121659
the	O	-1	7121659
re@@	O	-1	7121659
int@@	O	-1	7121659
ro@@	O	-1	7121659
duction	O	-1	7121659
of	O	-1	7121659
ri@@	B-Chemical	D012293	7121659
f@@	I-Chemical	-1	7121659
amp@@	I-Chemical	-1	7121659
icin	I-Chemical	-1	7121659
are	O	-1	7121659
descri@@	O	-1	7121659
be@@	O	-1	7121659
d.	O	-1	7121659
No	O	-1	7121659
correl@@	O	-1	7121659
ation	O	-1	7121659
was	O	-1	7121659
found	O	-1	7121659
between	O	-1	7121659
the	O	-1	7121659
severity	O	-1	7121659
of	O	-1	7121659
clinical	O	-1	7121659
man@@	O	-1	7121659
if@@	O	-1	7121659
est@@	O	-1	7121659
ations	O	-1	7121659
and	O	-1	7121659
the	O	-1	7121659
total	O	-1	7121659
dose	O	-1	7121659
tak@@	O	-1	7121659
en	O	-1	7121659
by	O	-1	7121659
the	O	-1	7121659
patients.	O	-1	7121659
In	O	-1	7121659
all	O	-1	7121659
but	O	-1	7121659
1	O	-1	7121659
patient@@	O	-1	7121659
,	O	-1	7121659
anti@@	O	-1	7121659
ri@@	O	-1	7121659
f@@	O	-1	7121659
amp@@	O	-1	7121659
icin	O	-1	7121659
anti@@	O	-1	7121659
bo@@	O	-1	7121659
di@@	O	-1	7121659
es	O	-1	7121659
were	O	-1	7121659
det@@	O	-1	7121659
ect@@	O	-1	7121659
ed.	O	-1	7121659
An@@	O	-1	7121659
ti@@	O	-1	7121659
bo@@	O	-1	7121659
di@@	O	-1	7121659
es	O	-1	7121659
suggested	O	-1	7121659
to	O	-1	7121659
be	O	-1	7121659
of	O	-1	7121659
the	O	-1	7121659
I@@	O	-1	7121659
g@@	O	-1	7121659
M	O	-1	7121659
cl@@	O	-1	7121659
as@@	O	-1	7121659
s	O	-1	7121659
were	O	-1	7121659
det@@	O	-1	7121659
ected	O	-1	7121659
in	O	-1	7121659
all	O	-1	7121659
3	O	-1	7121659
patients	O	-1	7121659
with	O	-1	7121659
hemat@@	B-Disease	D006402	7121659
ological	I-Disease	-1	7121659
disorder@@	I-Disease	-1	7121659
s	I-Disease	-1	7121659
.	O	-1	7121659
The	O	-1	7121659
pat@@	O	-1	7121659
ter@@	O	-1	7121659
n	O	-1	7121659
of	O	-1	7121659
non-@@	O	-1	7121659
specific	O	-1	7121659
acute	B-Disease	D007683	7121659
tub@@	I-Disease	-1	7121659
ular	I-Disease	-1	7121659
necro@@	I-Disease	-1	7121659
sis	I-Disease	-1	7121659
found	O	-1	7121659
in	O	-1	7121659
the	O	-1	7121659
2	O	-1	7121659
biop@@	O	-1	7121659
si@@	O	-1	7121659
ed	O	-1	7121659
patients,	O	-1	7121659
in@@	O	-1	7121659
dist@@	O	-1	7121659
ing@@	O	-1	7121659
u@@	O	-1	7121659
ish@@	O	-1	7121659
able	O	-1	7121659
from	O	-1	7121659
that	O	-1	7121659
of	O	-1	7121659
ischem@@	O	-1	7121659
ic	O	-1	7121659
or@@	O	-1	7121659
ig@@	O	-1	7121659
in,	O	-1	7121659
ra@@	O	-1	7121659
is@@	O	-1	7121659
ed	O	-1	7121659
the	O	-1	7121659
possib@@	O	-1	7121659
ility	O	-1	7121659
of	O	-1	7121659
a	O	-1	7121659
vas@@	O	-1	7121659
cul@@	O	-1	7121659
ar@@	O	-1	7121659
-@@	O	-1	7121659
mediated	O	-1	7121659
dam@@	O	-1	7121659
age.	O	-1	7121659
In	O	-1	7121659
3	O	-1	7121659
patients,	O	-1	7121659
the	O	-1	7121659
possib@@	O	-1	7121659
ility	O	-1	7121659
of	O	-1	7121659
a	O	-1	7121659
tri@@	O	-1	7121659
g@@	O	-1	7121659
g@@	O	-1	7121659
ering	O	-1	7121659
immuno@@	O	-1	7121659
all@@	O	-1	7121659
ergic	O	-1	7121659
mechanism	O	-1	7121659
is	O	-1	7121659
discus@@	O	-1	7121659
sed.	O	-1	7121659

C@@	O	-1	7147232
ardi@@	O	-1	7147232
o@@	O	-1	7147232
vascular	O	-1	7147232
effects	O	-1	7147232
of	O	-1	7147232
hypotension	B-Disease	D007022	7147232
induced	O	-1	7147232
by	O	-1	7147232
aden@@	B-Chemical	D000255	7147232
os@@	I-Chemical	-1	7147232
ine	I-Chemical	-1	7147232
tri@@	I-Chemical	-1	7147232
phosph@@	I-Chemical	-1	7147232
ate	I-Chemical	-1	7147232
and	O	-1	7147232
sodium	B-Chemical	D009599	7147232
nitro@@	I-Chemical	-1	7147232
pr@@	I-Chemical	-1	7147232
us@@	I-Chemical	-1	7147232
side	I-Chemical	-1	7147232
on	O	-1	7147232
dog@@	O	-1	7147232
s	O	-1	7147232
with	O	-1	7147232
d@@	O	-1	7147232
en@@	O	-1	7147232
er@@	O	-1	7147232
v@@	O	-1	7147232
ated	O	-1	7147232
hear@@	O	-1	7147232
t@@	O	-1	7147232
s.	O	-1	7147232
Ad@@	B-Chemical	D000255	7147232
en@@	I-Chemical	-1	7147232
os@@	I-Chemical	-1	7147232
ine	I-Chemical	-1	7147232
tri@@	I-Chemical	-1	7147232
phosph@@	I-Chemical	-1	7147232
ate	I-Chemical	-1	7147232
(	O	-1	7147232
AT@@	B-Chemical	D000255	7147232
P	I-Chemical	-1	7147232
)	O	-1	7147232
and	O	-1	7147232
sodium	B-Chemical	D009599	7147232
nitro@@	I-Chemical	-1	7147232
pr@@	I-Chemical	-1	7147232
us@@	I-Chemical	-1	7147232
side	I-Chemical	-1	7147232
(	O	-1	7147232
S@@	B-Chemical	D009599	7147232
N@@	I-Chemical	-1	7147232
P	I-Chemical	-1	7147232
)	O	-1	7147232
are	O	-1	7147232
administered	O	-1	7147232
to	O	-1	7147232
patients	O	-1	7147232
to	O	-1	7147232
induce	O	-1	7147232
and	O	-1	7147232
control	O	-1	7147232
hypotension	B-Disease	D007022	7147232
during	O	-1	7147232
anesthe@@	O	-1	7147232
sia.	O	-1	7147232
S@@	B-Chemical	D009599	7147232
N@@	I-Chemical	-1	7147232
P	I-Chemical	-1	7147232
is	O	-1	7147232
au@@	O	-1	7147232
th@@	O	-1	7147232
or@@	O	-1	7147232
ized	O	-1	7147232
for	O	-1	7147232
clinical	O	-1	7147232
use	O	-1	7147232
in	O	-1	7147232
US@@	O	-1	7147232
A	O	-1	7147232
and	O	-1	7147232
U@@	O	-1	7147232
K@@	O	-1	7147232
,	O	-1	7147232
and	O	-1	7147232
AT@@	B-Chemical	D000255	7147232
P	I-Chemical	-1	7147232
is	O	-1	7147232
clin@@	O	-1	7147232
ically	O	-1	7147232
used	O	-1	7147232
in	O	-1	7147232
other	O	-1	7147232
coun@@	O	-1	7147232
tri@@	O	-1	7147232
es	O	-1	7147232
such	O	-1	7147232
as	O	-1	7147232
J@@	O	-1	7147232
ap@@	O	-1	7147232
an@@	O	-1	7147232
.	O	-1	7147232
We	O	-1	7147232
investigated	O	-1	7147232
ho@@	O	-1	7147232
w	O	-1	7147232
these	O	-1	7147232
two	O	-1	7147232
drugs	O	-1	7147232
ac@@	O	-1	7147232
t	O	-1	7147232
on	O	-1	7147232
the	O	-1	7147232
cardiovascular	O	-1	7147232
system@@	O	-1	7147232
s	O	-1	7147232
of	O	-1	7147232
20	O	-1	7147232
dog@@	O	-1	7147232
s	O	-1	7147232
wh@@	O	-1	7147232
ose	O	-1	7147232
hear@@	O	-1	7147232
ts	O	-1	7147232
had	O	-1	7147232
been	O	-1	7147232
d@@	O	-1	7147232
en@@	O	-1	7147232
er@@	O	-1	7147232
v@@	O	-1	7147232
ated	O	-1	7147232
by	O	-1	7147232
a	O	-1	7147232
proce@@	O	-1	7147232
d@@	O	-1	7147232
ure	O	-1	7147232
we	O	-1	7147232
had	O	-1	7147232
de@@	O	-1	7147232
vi@@	O	-1	7147232
sed.	O	-1	7147232
AT@@	B-Chemical	D000255	7147232
P	I-Chemical	-1	7147232
(10	O	-1	7147232
dog@@	O	-1	7147232
s)	O	-1	7147232
or	O	-1	7147232
S@@	B-Chemical	D009599	7147232
N@@	I-Chemical	-1	7147232
P	I-Chemical	-1	7147232
(10	O	-1	7147232
dog@@	O	-1	7147232
s)	O	-1	7147232
was	O	-1	7147232
administered	O	-1	7147232
to	O	-1	7147232
re@@	O	-1	7147232
duce	O	-1	7147232
mean	O	-1	7147232
arterial	O	-1	7147232
pressure	O	-1	7147232
by	O	-1	7147232
3@@	O	-1	7147232
0%	O	-1	7147232
to	O	-1	7147232
7@@	O	-1	7147232
0%	O	-1	7147232
of	O	-1	7147232
control@@	O	-1	7147232
.	O	-1	7147232
B@@	O	-1	7147232
e@@	O	-1	7147232
fo@@	O	-1	7147232
re,	O	-1	7147232
during	O	-1	7147232
and	O	-1	7147232
after	O	-1	7147232
induced	O	-1	7147232
hypotension	B-Disease	D007022	7147232
,	O	-1	7147232
we	O	-1	7147232
measured	O	-1	7147232
major	O	-1	7147232
cardiovascular	O	-1	7147232
par@@	O	-1	7147232
ame@@	O	-1	7147232
ter@@	O	-1	7147232
s.	O	-1	7147232
H@@	B-Disease	D007022	7147232
y@@	I-Disease	-1	7147232
poten@@	I-Disease	-1	7147232
sion	I-Disease	-1	7147232
induced	O	-1	7147232
by	O	-1	7147232
AT@@	B-Chemical	D000255	7147232
P	I-Chemical	-1	7147232
was	O	-1	7147232
ac@@	O	-1	7147232
comp@@	O	-1	7147232
an@@	O	-1	7147232
ied	O	-1	7147232
by	O	-1	7147232
significant	O	-1	7147232
decreas@@	O	-1	7147232
es	O	-1	7147232
in	O	-1	7147232
mean	O	-1	7147232
pulmonary	O	-1	7147232
arterial	O	-1	7147232
pressure	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.00@@	O	-1	7147232
1),	O	-1	7147232
central	O	-1	7147232
venous	O	-1	7147232
pressure	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.00@@	O	-1	7147232
1),	O	-1	7147232
left	O	-1	7147232
ventricular	O	-1	7147232
en@@	O	-1	7147232
d-@@	O	-1	7147232
di@@	O	-1	7147232
ast@@	O	-1	7147232
olic	O	-1	7147232
pressure	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.00@@	O	-1	7147232
1),	O	-1	7147232
total	O	-1	7147232
peripheral	O	-1	7147232
resist@@	O	-1	7147232
ance	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.00@@	O	-1	7147232
1),	O	-1	7147232
rate	O	-1	7147232
pressure	O	-1	7147232
produc@@	O	-1	7147232
t	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.00@@	O	-1	7147232
1),	O	-1	7147232
total	O	-1	7147232
body	O	-1	7147232
oxy@@	B-Chemical	D010100	7147232
gen	I-Chemical	-1	7147232
consum@@	O	-1	7147232
ption	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.05@@	O	-1	7147232
),	O	-1	7147232
and	O	-1	7147232
heart	O	-1	7147232
rate	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.00@@	O	-1	7147232
1@@	O	-1	7147232
);	O	-1	7147232
all	O	-1	7147232
these	O	-1	7147232
vari@@	O	-1	7147232
able@@	O	-1	7147232
s	O	-1	7147232
retur@@	O	-1	7147232
n@@	O	-1	7147232
ed	O	-1	7147232
normal	O	-1	7147232
within	O	-1	7147232
30	O	-1	7147232
min	O	-1	7147232
after	O	-1	7147232
AT@@	B-Chemical	D000255	7147232
P	I-Chemical	-1	7147232
was	O	-1	7147232
sto@@	O	-1	7147232
pp@@	O	-1	7147232
ed.	O	-1	7147232
C@@	O	-1	7147232
ardi@@	O	-1	7147232
a@@	O	-1	7147232
c	O	-1	7147232
out@@	O	-1	7147232
pu@@	O	-1	7147232
t	O	-1	7147232
did	O	-1	7147232
not	O	-1	7147232
chang@@	O	-1	7147232
e.	O	-1	7147232
D@@	O	-1	7147232
uring	O	-1	7147232
hypotension	B-Disease	D007022	7147232
produced	O	-1	7147232
by	O	-1	7147232
S@@	B-Chemical	D009599	7147232
N@@	I-Chemical	-1	7147232
P	I-Chemical	-1	7147232
similar	O	-1	7147232
decreas@@	O	-1	7147232
es	O	-1	7147232
were	O	-1	7147232
observed	O	-1	7147232
in	O	-1	7147232
mean	O	-1	7147232
pulmonary	O	-1	7147232
arterial	O	-1	7147232
pressure	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.0@@	O	-1	7147232
1),	O	-1	7147232
central	O	-1	7147232
venous	O	-1	7147232
pressure	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.00@@	O	-1	7147232
1),	O	-1	7147232
left	O	-1	7147232
ventricular	O	-1	7147232
en@@	O	-1	7147232
d-@@	O	-1	7147232
di@@	O	-1	7147232
ast@@	O	-1	7147232
olic	O	-1	7147232
pressure	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.0@@	O	-1	7147232
1),	O	-1	7147232
total	O	-1	7147232
peripheral	O	-1	7147232
resist@@	O	-1	7147232
ance	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.00@@	O	-1	7147232
1),	O	-1	7147232
rate	O	-1	7147232
pressure	O	-1	7147232
produc@@	O	-1	7147232
t	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.00@@	O	-1	7147232
1),	O	-1	7147232
and	O	-1	7147232
oxy@@	B-Chemical	D010100	7147232
gen	I-Chemical	-1	7147232
cont@@	O	-1	7147232
ent	O	-1	7147232
difference	O	-1	7147232
between	O	-1	7147232
arterial	O	-1	7147232
and	O	-1	7147232
mi@@	O	-1	7147232
x@@	O	-1	7147232
ed	O	-1	7147232
venous	O	-1	7147232
blood	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.05@@	O	-1	7147232
),	O	-1	7147232
while	O	-1	7147232
heart	O	-1	7147232
rate	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.00@@	O	-1	7147232
1)	O	-1	7147232
and	O	-1	7147232
cardiac	O	-1	7147232
out@@	O	-1	7147232
pu@@	O	-1	7147232
t	O	-1	7147232
(p	O	-1	7147232
less	O	-1	7147232
than	O	-1	7147232
0.05@@	O	-1	7147232
)	O	-1	7147232
were	O	-1	7147232
increas@@	O	-1	7147232
ed.	O	-1	7147232
Rec@@	O	-1	7147232
over@@	O	-1	7147232
i@@	O	-1	7147232
es	O	-1	7147232
of	O	-1	7147232
heart	O	-1	7147232
rate	O	-1	7147232
and	O	-1	7147232
left	O	-1	7147232
ventricular	O	-1	7147232
en@@	O	-1	7147232
d-@@	O	-1	7147232
di@@	O	-1	7147232
ast@@	O	-1	7147232
olic	O	-1	7147232
pressure	O	-1	7147232
were	O	-1	7147232
not	O	-1	7147232
shown	O	-1	7147232
within	O	-1	7147232
60	O	-1	7147232
min	O	-1	7147232
after	O	-1	7147232
S@@	B-Chemical	D009599	7147232
N@@	I-Chemical	-1	7147232
P	I-Chemical	-1	7147232
had	O	-1	7147232
been	O	-1	7147232
sto@@	O	-1	7147232
pp@@	O	-1	7147232
ed.	O	-1	7147232
B@@	O	-1	7147232
oth	O	-1	7147232
AT@@	B-Chemical	D000255	7147232
P	I-Chemical	-1	7147232
and	O	-1	7147232
S@@	B-Chemical	D009599	7147232
N@@	I-Chemical	-1	7147232
P	I-Chemical	-1	7147232
should	O	-1	7147232
ac@@	O	-1	7147232
t	O	-1	7147232
on	O	-1	7147232
the	O	-1	7147232
pac@@	O	-1	7147232
em@@	O	-1	7147232
ak@@	O	-1	7147232
er	O	-1	7147232
tissue	O	-1	7147232
of	O	-1	7147232
the	O	-1	7147232
hear@@	O	-1	7147232
t.	O	-1	7147232

Com@@	O	-1	7173007
par@@	O	-1	7173007
ative	O	-1	7173007
stud@@	O	-1	7173007
y@@	O	-1	7173007
:	O	-1	7173007
E@@	B-Chemical	C006753	7173007
n@@	I-Chemical	-1	7173007
do@@	I-Chemical	-1	7173007
gra@@	I-Chemical	-1	7173007
f@@	I-Chemical	-1	7173007
ine	I-Chemical	-1	7173007
(	O	-1	7173007
di@@	B-Chemical	D003973	7173007
atri@@	I-Chemical	-1	7173007
z@@	I-Chemical	-1	7173007
o@@	I-Chemical	-1	7173007
ate	I-Chemical	-1	7173007
),	O	-1	7173007
V@@	B-Chemical	D000100	7173007
as@@	I-Chemical	-1	7173007
ur@@	I-Chemical	-1	7173007
i@@	I-Chemical	-1	7173007
x	I-Chemical	-1	7173007
poly@@	I-Chemical	-1	7173007
vid@@	I-Chemical	-1	7173007
one	I-Chemical	-1	7173007
(	O	-1	7173007
acet@@	B-Chemical	D000100	7173007
ri@@	I-Chemical	-1	7173007
z@@	I-Chemical	-1	7173007
o@@	I-Chemical	-1	7173007
ate	I-Chemical	-1	7173007
),	O	-1	7173007
D@@	B-Chemical	C025504	7173007
im@@	I-Chemical	-1	7173007
er@@	I-Chemical	-1	7173007
-@@	I-Chemical	-1	7173007
X	I-Chemical	-1	7173007
(	O	-1	7173007
i@@	B-Chemical	C025504	7173007
oc@@	I-Chemical	-1	7173007
ar@@	I-Chemical	-1	7173007
m@@	I-Chemical	-1	7173007
ate	I-Chemical	-1	7173007
)	O	-1	7173007
and	O	-1	7173007
H@@	B-Chemical	D007485	7173007
ex@@	I-Chemical	-1	7173007
ab@@	I-Chemical	-1	7173007
ri@@	I-Chemical	-1	7173007
x	I-Chemical	-1	7173007
(	O	-1	7173007
io@@	B-Chemical	D007485	7173007
x@@	I-Chemical	-1	7173007
ag@@	I-Chemical	-1	7173007
l@@	I-Chemical	-1	7173007
ate	I-Chemical	-1	7173007
)	O	-1	7173007
in	O	-1	7173007
hy@@	O	-1	7173007
ster@@	O	-1	7173007
os@@	O	-1	7173007
al@@	O	-1	7173007
p@@	O	-1	7173007
ing@@	O	-1	7173007
ograph@@	O	-1	7173007
y.	O	-1	7173007
S@@	O	-1	7173007
ide	O	-1	7173007
effects	O	-1	7173007
of	O	-1	7173007
hy@@	O	-1	7173007
ster@@	O	-1	7173007
os@@	O	-1	7173007
al@@	O	-1	7173007
p@@	O	-1	7173007
ing@@	O	-1	7173007
ograph@@	O	-1	7173007
y	O	-1	7173007
with	O	-1	7173007
D@@	B-Chemical	C025504	7173007
im@@	I-Chemical	-1	7173007
er@@	I-Chemical	-1	7173007
-@@	I-Chemical	-1	7173007
X	I-Chemical	-1	7173007
,	O	-1	7173007
H@@	B-Chemical	D007485	7173007
ex@@	I-Chemical	-1	7173007
ab@@	I-Chemical	-1	7173007
ri@@	I-Chemical	-1	7173007
x	I-Chemical	-1	7173007
,	O	-1	7173007
V@@	B-Chemical	D000100	7173007
as@@	I-Chemical	-1	7173007
ur@@	I-Chemical	-1	7173007
i@@	I-Chemical	-1	7173007
x	I-Chemical	-1	7173007
poly@@	I-Chemical	-1	7173007
vid@@	I-Chemical	-1	7173007
one	I-Chemical	-1	7173007
and	O	-1	7173007
E@@	B-Chemical	C006753	7173007
n@@	I-Chemical	-1	7173007
do@@	I-Chemical	-1	7173007
gra@@	I-Chemical	-1	7173007
f@@	I-Chemical	-1	7173007
ine	I-Chemical	-1	7173007
in	O	-1	7173007
14@@	O	-1	7173007
2	O	-1	7173007
con@@	O	-1	7173007
sec@@	O	-1	7173007
utive	O	-1	7173007
patients,	O	-1	7173007
receiving	O	-1	7173007
one	O	-1	7173007
of	O	-1	7173007
the	O	-1	7173007
four	O	-1	7173007
tested	O	-1	7173007
medi@@	O	-1	7173007
a	O	-1	7173007
were	O	-1	7173007
evaluated	O	-1	7173007
from	O	-1	7173007
re@@	O	-1	7173007
pl@@	O	-1	7173007
i@@	O	-1	7173007
es	O	-1	7173007
to	O	-1	7173007
post@@	O	-1	7173007
al	O	-1	7173007
qu@@	O	-1	7173007
es@@	O	-1	7173007
tion@@	O	-1	7173007
na@@	O	-1	7173007
i@@	O	-1	7173007
res@@	O	-1	7173007
.	O	-1	7173007
The	O	-1	7173007
D@@	B-Chemical	C025504	7173007
im@@	I-Chemical	-1	7173007
er@@	I-Chemical	-1	7173007
-@@	I-Chemical	-1	7173007
X	I-Chemical	-1	7173007
group	O	-1	7173007
had	O	-1	7173007
a	O	-1	7173007
higher	O	-1	7173007
incidence	O	-1	7173007
of	O	-1	7173007
nausea	B-Disease	D009325	7173007
and	O	-1	7173007
di@@	B-Disease	D004244	7173007
z@@	I-Disease	-1	7173007
z@@	I-Disease	-1	7173007
in@@	I-Disease	-1	7173007
ess	I-Disease	-1	7173007
.	O	-1	7173007
The	O	-1	7173007
E@@	B-Chemical	C006753	7173007
n@@	I-Chemical	-1	7173007
do@@	I-Chemical	-1	7173007
gra@@	I-Chemical	-1	7173007
f@@	I-Chemical	-1	7173007
ine	I-Chemical	-1	7173007
group	O	-1	7173007
had	O	-1	7173007
a	O	-1	7173007
higher	O	-1	7173007
incidence	O	-1	7173007
of	O	-1	7173007
ab@@	B-Disease	D015746	7173007
domin@@	I-Disease	-1	7173007
al	I-Disease	-1	7173007
pain	I-Disease	-1	7173007
.	O	-1	7173007
These	O	-1	7173007
differences	O	-1	7173007
occ@@	O	-1	7173007
ur	O	-1	7173007
es@@	O	-1	7173007
p@@	O	-1	7173007
ec@@	O	-1	7173007
i@@	O	-1	7173007
ally	O	-1	7173007
in	O	-1	7173007
the	O	-1	7173007
age	O	-1	7173007
groups	O	-1	7173007
under	O	-1	7173007
30	O	-1	7173007
year@@	O	-1	7173007
s.	O	-1	7173007
H@@	B-Chemical	D007485	7173007
ex@@	I-Chemical	-1	7173007
ab@@	I-Chemical	-1	7173007
ri@@	I-Chemical	-1	7173007
x	I-Chemical	-1	7173007
and	O	-1	7173007
V@@	B-Chemical	D000100	7173007
as@@	I-Chemical	-1	7173007
ur@@	I-Chemical	-1	7173007
i@@	I-Chemical	-1	7173007
x	I-Chemical	-1	7173007
poly@@	I-Chemical	-1	7173007
vid@@	I-Chemical	-1	7173007
one	I-Chemical	-1	7173007
are	O	-1	7173007
considered	O	-1	7173007
the	O	-1	7173007
b@@	O	-1	7173007
est	O	-1	7173007
contr@@	B-Chemical	D003287	7173007
ast	I-Chemical	-1	7173007
medi@@	I-Chemical	-1	7173007
a	I-Chemical	-1	7173007
for	O	-1	7173007
hy@@	O	-1	7173007
ster@@	O	-1	7173007
os@@	O	-1	7173007
al@@	O	-1	7173007
p@@	O	-1	7173007
ing@@	O	-1	7173007
ograph@@	O	-1	7173007
y	O	-1	7173007
and	O	-1	7173007
per@@	O	-1	7173007
h@@	O	-1	7173007
ap@@	O	-1	7173007
s	O	-1	7173007
because	O	-1	7173007
of	O	-1	7173007
its	O	-1	7173007
low	O	-1	7173007
toxicity	B-Disease	D064420	7173007
H@@	B-Chemical	D007485	7173007
ex@@	I-Chemical	-1	7173007
ab@@	I-Chemical	-1	7173007
ri@@	I-Chemical	-1	7173007
x	I-Chemical	-1	7173007
should	O	-1	7173007
be	O	-1	7173007
pre@@	O	-1	7173007
fer@@	O	-1	7173007
red.	O	-1	7173007

P@@	O	-1	7176945
ost@@	O	-1	7176945
-	O	-1	7176945
su@@	B-Chemical	D013390	7176945
xameth@@	I-Chemical	-1	7176945
oni@@	I-Chemical	-1	7176945
um	I-Chemical	-1	7176945
pa@@	B-Disease	D010146	7176945
ins	I-Disease	-1	7176945
in	O	-1	7176945
N@@	O	-1	7176945
ig@@	O	-1	7176945
er@@	O	-1	7176945
i@@	O	-1	7176945
an	O	-1	7176945
surg@@	O	-1	7176945
ical	O	-1	7176945
patients.	O	-1	7176945
C@@	O	-1	7176945
ont@@	O	-1	7176945
r@@	O	-1	7176945
ary	O	-1	7176945
to	O	-1	7176945
an	O	-1	7176945
ear@@	O	-1	7176945
li@@	O	-1	7176945
er	O	-1	7176945
report	O	-1	7176945
by	O	-1	7176945
C@@	O	-1	7176945
ox@@	O	-1	7176945
on@@	O	-1	7176945
,	O	-1	7176945
sco@@	B-Chemical	D013390	7176945
line	I-Chemical	-1	7176945
pain	B-Disease	D010146	7176945
occur@@	O	-1	7176945
s	O	-1	7176945
in	O	-1	7176945
Af@@	O	-1	7176945
r@@	O	-1	7176945
ic@@	O	-1	7176945
an	O	-1	7176945
neg@@	O	-1	7176945
ro@@	O	-1	7176945
es.	O	-1	7176945
I@@	O	-1	7176945
ts	O	-1	7176945
incidence	O	-1	7176945
was	O	-1	7176945
determined	O	-1	7176945
in	O	-1	7176945
a	O	-1	7176945
pro@@	O	-1	7176945
sp@@	O	-1	7176945
ective	O	-1	7176945
study	O	-1	7176945
invol@@	O	-1	7176945
ving	O	-1	7176945
a	O	-1	7176945
total	O	-1	7176945
of	O	-1	7176945
100	O	-1	7176945
N@@	O	-1	7176945
ig@@	O	-1	7176945
er@@	O	-1	7176945
i@@	O	-1	7176945
an	O	-1	7176945
patients	O	-1	7176945
(@@	O	-1	7176945
50	O	-1	7176945
out@@	O	-1	7176945
-@@	O	-1	7176945
patients	O	-1	7176945
and	O	-1	7176945
50	O	-1	7176945
in-@@	O	-1	7176945
patient@@	O	-1	7176945
s@@	O	-1	7176945
).	O	-1	7176945
A@@	O	-1	7176945
b@@	O	-1	7176945
out	O	-1	7176945
6@@	O	-1	7176945
2@@	O	-1	7176945
%	O	-1	7176945
of	O	-1	7176945
the	O	-1	7176945
out@@	O	-1	7176945
-@@	O	-1	7176945
patients	O	-1	7176945
developed	O	-1	7176945
sco@@	B-Chemical	D013390	7176945
line	I-Chemical	-1	7176945
pain	B-Disease	D010146	7176945
as	O	-1	7176945
compared	O	-1	7176945
with	O	-1	7176945
about	O	-1	7176945
2@@	O	-1	7176945
6%	O	-1	7176945
among	O	-1	7176945
the	O	-1	7176945
in-@@	O	-1	7176945
patients.	O	-1	7176945
The	O	-1	7176945
abol@@	O	-1	7176945
ition	O	-1	7176945
of	O	-1	7176945
musc@@	O	-1	7176945
le	O	-1	7176945
f@@	B-Disease	D005207	7176945
as@@	I-Disease	-1	7176945
c@@	I-Disease	-1	7176945
ic@@	I-Disease	-1	7176945
ul@@	I-Disease	-1	7176945
ations	I-Disease	-1	7176945
(@@	O	-1	7176945
by	O	-1	7176945
0.0@@	O	-1	7176945
7@@	O	-1	7176945
5@@	O	-1	7176945
mg/kg	O	-1	7176945
dose	O	-1	7176945
of	O	-1	7176945
F@@	B-Chemical	C084773	7176945
az@@	I-Chemical	-1	7176945
ad@@	I-Chemical	-1	7176945
in@@	I-Chemical	-1	7176945
i@@	I-Chemical	-1	7176945
um	I-Chemical	-1	7176945
)	O	-1	7176945
did	O	-1	7176945
not	O	-1	7176945
influence	O	-1	7176945
the	O	-1	7176945
occur@@	O	-1	7176945
rence	O	-1	7176945
of	O	-1	7176945
sco@@	B-Chemical	D013390	7176945
line	I-Chemical	-1	7176945
pain	B-Disease	D010146	7176945
.	O	-1	7176945
N@@	O	-1	7176945
either	O	-1	7176945
the	O	-1	7176945
type	O	-1	7176945
of	O	-1	7176945
induction	O	-1	7176945
agent	O	-1	7176945
(	O	-1	7176945
Al@@	B-Chemical	D000530	7176945
th@@	I-Chemical	-1	7176945
es@@	I-Chemical	-1	7176945
in	I-Chemical	-1	7176945
or	O	-1	7176945
Th@@	B-Chemical	D013874	7176945
io@@	I-Chemical	-1	7176945
pent@@	I-Chemical	-1	7176945
one	I-Chemical	-1	7176945
)	O	-1	7176945
n@@	O	-1	7176945
or	O	-1	7176945
the	O	-1	7176945
sal@@	O	-1	7176945
t	O	-1	7176945
pre@@	O	-1	7176945
par@@	O	-1	7176945
ation	O	-1	7176945
of	O	-1	7176945
su@@	B-Chemical	D013390	7176945
xameth@@	I-Chemical	-1	7176945
oni@@	I-Chemical	-1	7176945
um	I-Chemical	-1	7176945
used	O	-1	7176945
(	O	-1	7176945
chlor@@	B-Chemical	D002712	7176945
ide	I-Chemical	-1	7176945
or	O	-1	7176945
brom@@	B-Chemical	D001965	7176945
ide	I-Chemical	-1	7176945
),	O	-1	7176945
affected	O	-1	7176945
the	O	-1	7176945
incidence	O	-1	7176945
of	O	-1	7176945
sco@@	B-Chemical	D013390	7176945
line	I-Chemical	-1	7176945
pain	B-Disease	D010146	7176945
.	O	-1	7176945

M@@	O	-1	7315949
edi@@	O	-1	7315949
al	O	-1	7315949
changes	O	-1	7315949
in	O	-1	7315949
arterial	O	-1	7315949
sp@@	B-Disease	D013035	7315949
as@@	I-Disease	-1	7315949
m	I-Disease	-1	7315949
induced	O	-1	7315949
by	O	-1	7315949
L-@@	B-Chemical	D009638	7315949
no@@	I-Chemical	-1	7315949
re@@	I-Chemical	-1	7315949
p@@	I-Chemical	-1	7315949
ine@@	I-Chemical	-1	7315949
phrine	I-Chemical	-1	7315949
.	O	-1	7315949
In	O	-1	7315949
normal	O	-1	7315949
rats,	O	-1	7315949
the	O	-1	7315949
medi@@	O	-1	7315949
a	O	-1	7315949
of	O	-1	7315949
sm@@	O	-1	7315949
all	O	-1	7315949
arter@@	O	-1	7315949
i@@	O	-1	7315949
es	O	-1	7315949
(0.@@	O	-1	7315949
4-@@	O	-1	7315949
-@@	O	-1	7315949
0.@@	O	-1	7315949
2	O	-1	7315949
mm	O	-1	7315949
in	O	-1	7315949
di@@	O	-1	7315949
ame@@	O	-1	7315949
ter@@	O	-1	7315949
)	O	-1	7315949
previously	O	-1	7315949
was	O	-1	7315949
shown	O	-1	7315949
to	O	-1	7315949
cont@@	O	-1	7315949
ain	O	-1	7315949
intrac@@	O	-1	7315949
ell@@	O	-1	7315949
ular	O	-1	7315949
vac@@	O	-1	7315949
u@@	O	-1	7315949
ol@@	O	-1	7315949
es,	O	-1	7315949
identi@@	O	-1	7315949
fied	O	-1	7315949
ult@@	O	-1	7315949
ra@@	O	-1	7315949
struct@@	O	-1	7315949
ur@@	O	-1	7315949
ally	O	-1	7315949
as	O	-1	7315949
h@@	O	-1	7315949
er@@	O	-1	7315949
n@@	O	-1	7315949
i@@	O	-1	7315949
ations	O	-1	7315949
of	O	-1	7315949
one	O	-1	7315949
smo@@	O	-1	7315949
oth	O	-1	7315949
musc@@	O	-1	7315949
le	O	-1	7315949
cell	O	-1	7315949
into	O	-1	7315949
an@@	O	-1	7315949
o@@	O	-1	7315949
ther@@	O	-1	7315949
.	O	-1	7315949
The	O	-1	7315949
hypo@@	O	-1	7315949
thesis	O	-1	7315949
that	O	-1	7315949
int@@	O	-1	7315949
en@@	O	-1	7315949
se	O	-1	7315949
vas@@	O	-1	7315949
o@@	O	-1	7315949
con@@	O	-1	7315949
stric@@	O	-1	7315949
tion	O	-1	7315949
wo@@	O	-1	7315949
uld	O	-1	7315949
increase	O	-1	7315949
the	O	-1	7315949
number	O	-1	7315949
of	O	-1	7315949
such	O	-1	7315949
vac@@	O	-1	7315949
u@@	O	-1	7315949
ol@@	O	-1	7315949
es	O	-1	7315949
has	O	-1	7315949
been	O	-1	7315949
test@@	O	-1	7315949
ed.	O	-1	7315949
In	O	-1	7315949
the	O	-1	7315949
medi@@	O	-1	7315949
a	O	-1	7315949
of	O	-1	7315949
the	O	-1	7315949
sa@@	O	-1	7315949
phen@@	O	-1	7315949
ous	O	-1	7315949
artery	O	-1	7315949
and	O	-1	7315949
its	O	-1	7315949
dist@@	O	-1	7315949
al	O	-1	7315949
b@@	O	-1	7315949
ran@@	O	-1	7315949
ch@@	O	-1	7315949
,	O	-1	7315949
vas@@	O	-1	7315949
o@@	O	-1	7315949
con@@	O	-1	7315949
stric@@	O	-1	7315949
tion	O	-1	7315949
induced	O	-1	7315949
by	O	-1	7315949
L-@@	B-Chemical	D009638	7315949
no@@	I-Chemical	-1	7315949
re@@	I-Chemical	-1	7315949
p@@	I-Chemical	-1	7315949
ine@@	I-Chemical	-1	7315949
phrine	I-Chemical	-1	7315949
produced	O	-1	7315949
man@@	O	-1	7315949
y	O	-1	7315949
cell@@	O	-1	7315949
-@@	O	-1	7315949
to@@	O	-1	7315949
-@@	O	-1	7315949
cell	O	-1	7315949
h@@	B-Disease	D006547	7315949
er@@	I-Disease	-1	7315949
n@@	I-Disease	-1	7315949
i@@	I-Disease	-1	7315949
as	I-Disease	-1	7315949
within	O	-1	7315949
15	O	-1	7315949
minut@@	O	-1	7315949
es.	O	-1	7315949
A@@	O	-1	7315949
t	O	-1	7315949
1	O	-1	7315949
day	O	-1	7315949
their	O	-1	7315949
number	O	-1	7315949
was	O	-1	7315949
reduced	O	-1	7315949
to	O	-1	7315949
about	O	-1	7315949
1@@	O	-1	7315949
/@@	O	-1	7315949
10	O	-1	7315949
of	O	-1	7315949
the	O	-1	7315949
or@@	O	-1	7315949
ig@@	O	-1	7315949
inal	O	-1	7315949
numb@@	O	-1	7315949
er.	O	-1	7315949
B@@	O	-1	7315949
y	O	-1	7315949
7	O	-1	7315949
days	O	-1	7315949
the	O	-1	7315949
v@@	O	-1	7315949
es@@	O	-1	7315949
se@@	O	-1	7315949
l	O	-1	7315949
was	O	-1	7315949
al@@	O	-1	7315949
most	O	-1	7315949
re@@	O	-1	7315949
sto@@	O	-1	7315949
red	O	-1	7315949
to	O	-1	7315949
normal@@	O	-1	7315949
.	O	-1	7315949
T@@	O	-1	7315949
ri@@	O	-1	7315949
ple	O	-1	7315949
stimulation	O	-1	7315949
over	O	-1	7315949
1	O	-1	7315949
day	O	-1	7315949
induced	O	-1	7315949
more	O	-1	7315949
severe	O	-1	7315949
changes	O	-1	7315949
in	O	-1	7315949
the	O	-1	7315949
medi@@	O	-1	7315949
a.	O	-1	7315949
These	O	-1	7315949
findings	O	-1	7315949
suggest	O	-1	7315949
that	O	-1	7315949
smo@@	O	-1	7315949
oth	O	-1	7315949
musc@@	O	-1	7315949
le	O	-1	7315949
cells	O	-1	7315949
are	O	-1	7315949
sus@@	O	-1	7315949
cep@@	O	-1	7315949
ti@@	O	-1	7315949
ble	O	-1	7315949
to	O	-1	7315949
damage	O	-1	7315949
in	O	-1	7315949
the	O	-1	7315949
course	O	-1	7315949
of	O	-1	7315949
their	O	-1	7315949
specific	O	-1	7315949
func@@	O	-1	7315949
tion.	O	-1	7315949
The	O	-1	7315949
experimental	O	-1	7315949
data	O	-1	7315949
are	O	-1	7315949
discus@@	O	-1	7315949
sed	O	-1	7315949
in	O	-1	7315949
rel@@	O	-1	7315949
ation	O	-1	7315949
to	O	-1	7315949
medi@@	O	-1	7315949
al	O	-1	7315949
changes	O	-1	7315949
observed	O	-1	7315949
in	O	-1	7315949
other	O	-1	7315949
in@@	O	-1	7315949
st@@	O	-1	7315949
anc@@	O	-1	7315949
es	O	-1	7315949
of	O	-1	7315949
arterial	O	-1	7315949
sp@@	B-Disease	D013035	7315949
as@@	I-Disease	-1	7315949
m	I-Disease	-1	7315949
.	O	-1	7315949
E@@	O	-1	7315949
n@@	O	-1	7315949
do@@	O	-1	7315949
thelial	O	-1	7315949
changes	O	-1	7315949
that	O	-1	7315949
developed	O	-1	7315949
in	O	-1	7315949
the	O	-1	7315949
same	O	-1	7315949
experimental	O	-1	7315949
model	O	-1	7315949
were	O	-1	7315949
descri@@	O	-1	7315949
bed	O	-1	7315949
in	O	-1	7315949
a	O	-1	7315949
previ@@	O	-1	7315949
ous	O	-1	7315949
pa@@	O	-1	7315949
per@@	O	-1	7315949
.	O	-1	7315949

A@@	O	-1	7369302
b@@	O	-1	7369302
normal@@	O	-1	7369302
ities	O	-1	7369302
of	O	-1	7369302
the	O	-1	7369302
pu@@	O	-1	7369302
pi@@	O	-1	7369302
l	O	-1	7369302
and	O	-1	7369302
vi@@	O	-1	7369302
su@@	O	-1	7369302
al@@	O	-1	7369302
-@@	O	-1	7369302
evoked	O	-1	7369302
potential	O	-1	7369302
in	O	-1	7369302
qu@@	B-Chemical	D011803	7369302
inine	I-Chemical	-1	7369302
am@@	B-Disease	D000550	7369302
bl@@	I-Disease	-1	7369302
yo@@	I-Disease	-1	7369302
pi@@	I-Disease	-1	7369302
a	I-Disease	-1	7369302
.	O	-1	7369302
T@@	O	-1	7369302
ot@@	O	-1	7369302
al	O	-1	7369302
bl@@	B-Disease	D001766	7369302
ind@@	I-Disease	-1	7369302
ness	I-Disease	-1	7369302
with	O	-1	7369302
a	O	-1	7369302
transi@@	O	-1	7369302
ent	O	-1	7369302
t@@	B-Disease	D015845	7369302
onic	I-Disease	-1	7369302
p@@	I-Disease	-1	7369302
up@@	I-Disease	-1	7369302
ill@@	I-Disease	-1	7369302
ary	I-Disease	-1	7369302
respon@@	O	-1	7369302
se@@	O	-1	7369302
,	O	-1	7369302
d@@	O	-1	7369302
en@@	O	-1	7369302
er@@	O	-1	7369302
v@@	O	-1	7369302
ation	O	-1	7369302
su@@	O	-1	7369302
per@@	O	-1	7369302
sensi@@	O	-1	7369302
tiv@@	O	-1	7369302
ity,	O	-1	7369302
and	O	-1	7369302
ab@@	O	-1	7369302
normal	O	-1	7369302
vi@@	O	-1	7369302
su@@	O	-1	7369302
al@@	O	-1	7369302
-@@	O	-1	7369302
evoked	O	-1	7369302
potenti@@	O	-1	7369302
als	O	-1	7369302
developed	O	-1	7369302
in	O	-1	7369302
a	O	-1	7369302
5@@	O	-1	7369302
4-@@	O	-1	7369302
year-old	O	-1	7369302
man	O	-1	7369302
after	O	-1	7369302
the	O	-1	7369302
use	O	-1	7369302
of	O	-1	7369302
qu@@	B-Chemical	D011803	7369302
inine	I-Chemical	-1	7369302
sulf@@	I-Chemical	-1	7369302
ate	I-Chemical	-1	7369302
for	O	-1	7369302
le@@	B-Disease	D009120	7369302
g	I-Disease	-1	7369302
c@@	I-Disease	-1	7369302
ram@@	I-Disease	-1	7369302
p@@	I-Disease	-1	7369302
s	I-Disease	-1	7369302
.	O	-1	7369302
H@@	O	-1	7369302
e	O	-1	7369302
lat@@	O	-1	7369302
er	O	-1	7369302
reco@@	O	-1	7369302
vered	O	-1	7369302
normal	O	-1	7369302
visual	O	-1	7369302
ac@@	O	-1	7369302
u@@	O	-1	7369302
ity.	O	-1	7369302
A	O	-1	7369302
transi@@	O	-1	7369302
ent	O	-1	7369302
t@@	B-Disease	D015845	7369302
onic	I-Disease	-1	7369302
p@@	I-Disease	-1	7369302
up@@	I-Disease	-1	7369302
ill@@	I-Disease	-1	7369302
ary	I-Disease	-1	7369302
respon@@	O	-1	7369302
se@@	O	-1	7369302
,	O	-1	7369302
d@@	O	-1	7369302
en@@	O	-1	7369302
er@@	O	-1	7369302
v@@	O	-1	7369302
ation	O	-1	7369302
su@@	O	-1	7369302
per@@	O	-1	7369302
sensi@@	O	-1	7369302
tiv@@	O	-1	7369302
ity,	O	-1	7369302
and	O	-1	7369302
ab@@	O	-1	7369302
normal	O	-1	7369302
vi@@	O	-1	7369302
su@@	O	-1	7369302
al@@	O	-1	7369302
-@@	O	-1	7369302
evoked	O	-1	7369302
potenti@@	O	-1	7369302
als	O	-1	7369302
in	O	-1	7369302
qu@@	B-Chemical	D011803	7369302
inine	I-Chemical	-1	7369302
toxicity	B-Disease	D064420	7369302
,	O	-1	7369302
to	O	-1	7369302
our	O	-1	7369302
know@@	O	-1	7369302
le@@	O	-1	7369302
d@@	O	-1	7369302
g@@	O	-1	7369302
e,	O	-1	7369302
have	O	-1	7369302
not	O	-1	7369302
been	O	-1	7369302
previously	O	-1	7369302
repor@@	O	-1	7369302
ted.	O	-1	7369302

S@@	B-Chemical	D013390	7378868
u@@	I-Chemical	-1	7378868
xameth@@	I-Chemical	-1	7378868
oni@@	I-Chemical	-1	7378868
um	I-Chemical	-1	7378868
-induced	O	-1	7378868
j@@	B-Disease	D014313	7378868
a@@	I-Disease	-1	7378868
w	I-Disease	-1	7378868
sti@@	I-Disease	-1	7378868
ff@@	I-Disease	-1	7378868
ness	I-Disease	-1	7378868
and	O	-1	7378868
my@@	B-Disease	D063806	7378868
al@@	I-Disease	-1	7378868
g@@	I-Disease	-1	7378868
ia	I-Disease	-1	7378868
associated	O	-1	7378868
with	O	-1	7378868
at@@	O	-1	7378868
yp@@	O	-1	7378868
ical	O	-1	7378868
chol@@	O	-1	7378868
ine@@	O	-1	7378868
ster@@	O	-1	7378868
as@@	O	-1	7378868
e@@	O	-1	7378868
:	O	-1	7378868
case	O	-1	7378868
repor@@	O	-1	7378868
t.	O	-1	7378868
An	O	-1	7378868
1@@	O	-1	7378868
1-@@	O	-1	7378868
year-old	O	-1	7378868
bo@@	O	-1	7378868
y	O	-1	7378868
was	O	-1	7378868
given	O	-1	7378868
halo@@	B-Chemical	D006221	7378868
th@@	I-Chemical	-1	7378868
ane	I-Chemical	-1	7378868
,	O	-1	7378868
nit@@	B-Chemical	D009609	7378868
rou@@	I-Chemical	-1	7378868
s	I-Chemical	-1	7378868
ox@@	I-Chemical	-1	7378868
ide	I-Chemical	-1	7378868
and	O	-1	7378868
oxy@@	B-Chemical	D010100	7378868
gen	I-Chemical	-1	7378868
,	O	-1	7378868
p@@	B-Chemical	D010197	7378868
an@@	I-Chemical	-1	7378868
cur@@	I-Chemical	-1	7378868
oni@@	I-Chemical	-1	7378868
um	I-Chemical	-1	7378868
0.@@	O	-1	7378868
4	O	-1	7378868
mg	O	-1	7378868
and	O	-1	7378868
su@@	B-Chemical	D013390	7378868
xameth@@	I-Chemical	-1	7378868
oni@@	I-Chemical	-1	7378868
um	I-Chemical	-1	7378868
100	O	-1	7378868
mg	O	-1	7378868
for	O	-1	7378868
induction	O	-1	7378868
of	O	-1	7378868
anaesthe@@	O	-1	7378868
sia.	O	-1	7378868
In	O	-1	7378868
response	O	-1	7378868
to	O	-1	7378868
this	O	-1	7378868
a	O	-1	7378868
mark@@	O	-1	7378868
ed	O	-1	7378868
j@@	B-Disease	D014313	7378868
a@@	I-Disease	-1	7378868
w	I-Disease	-1	7378868
sti@@	I-Disease	-1	7378868
ff@@	I-Disease	-1	7378868
ness	I-Disease	-1	7378868
occurred	O	-1	7378868
which	O	-1	7378868
l@@	O	-1	7378868
ast@@	O	-1	7378868
ed	O	-1	7378868
for	O	-1	7378868
two	O	-1	7378868
minutes	O	-1	7378868
and	O	-1	7378868
the	O	-1	7378868
anaesthe@@	O	-1	7378868
sia	O	-1	7378868
were	O	-1	7378868
ter@@	O	-1	7378868
min@@	O	-1	7378868
ated.	O	-1	7378868
F@@	O	-1	7378868
our	O	-1	7378868
hours	O	-1	7378868
of	O	-1	7378868
ap@@	B-Disease	D001049	7378868
no@@	I-Disease	-1	7378868
e@@	I-Disease	-1	7378868
a	I-Disease	-1	7378868
en@@	O	-1	7378868
su@@	O	-1	7378868
ed	O	-1	7378868
and	O	-1	7378868
he	O	-1	7378868
su@@	O	-1	7378868
ffe@@	O	-1	7378868
red	O	-1	7378868
gener@@	O	-1	7378868
al@@	O	-1	7378868
ized	O	-1	7378868
severe	O	-1	7378868
my@@	B-Disease	D063806	7378868
al@@	I-Disease	-1	7378868
g@@	I-Disease	-1	7378868
ia	I-Disease	-1	7378868
l@@	O	-1	7378868
ast@@	O	-1	7378868
ing	O	-1	7378868
for	O	-1	7378868
one	O	-1	7378868
week@@	O	-1	7378868
.	O	-1	7378868
H@@	O	-1	7378868
e	O	-1	7378868
was	O	-1	7378868
found	O	-1	7378868
to	O	-1	7378868
have	O	-1	7378868
at@@	O	-1	7378868
yp@@	O	-1	7378868
ical	O	-1	7378868
plasma	O	-1	7378868
chol@@	O	-1	7378868
ine@@	O	-1	7378868
ster@@	O	-1	7378868
ase	O	-1	7378868
with	O	-1	7378868
a	O	-1	7378868
di@@	B-Chemical	D003992	7378868
b@@	I-Chemical	-1	7378868
uc@@	I-Chemical	-1	7378868
aine	I-Chemical	-1	7378868
number	O	-1	7378868
of	O	-1	7378868
12@@	O	-1	7378868
,	O	-1	7378868
indicating	O	-1	7378868
ho@@	O	-1	7378868
mo@@	O	-1	7378868
z@@	O	-1	7378868
y@@	O	-1	7378868
g@@	O	-1	7378868
oc@@	O	-1	7378868
ity.	O	-1	7378868
This	O	-1	7378868
was	O	-1	7378868
ver@@	O	-1	7378868
if@@	O	-1	7378868
ied	O	-1	7378868
by	O	-1	7378868
study	O	-1	7378868
of	O	-1	7378868
the	O	-1	7378868
f@@	O	-1	7378868
am@@	O	-1	7378868
il@@	O	-1	7378868
y.	O	-1	7378868
The	O	-1	7378868
case	O	-1	7378868
show@@	O	-1	7378868
s	O	-1	7378868
that	O	-1	7378868
prolonged	B-Disease	D014313	7378868
j@@	I-Disease	-1	7378868
a@@	I-Disease	-1	7378868
w	I-Disease	-1	7378868
rig@@	I-Disease	-1	7378868
idity	I-Disease	-1	7378868
and	O	-1	7378868
my@@	B-Disease	D063806	7378868
al@@	I-Disease	-1	7378868
g@@	I-Disease	-1	7378868
ia	I-Disease	-1	7378868
may	O	-1	7378868
occ@@	O	-1	7378868
ur	O	-1	7378868
after	O	-1	7378868
su@@	B-Chemical	D013390	7378868
xameth@@	I-Chemical	-1	7378868
oni@@	I-Chemical	-1	7378868
um	I-Chemical	-1	7378868
in	O	-1	7378868
patients	O	-1	7378868
with	O	-1	7378868
at@@	O	-1	7378868
yp@@	O	-1	7378868
ical	O	-1	7378868
chol@@	O	-1	7378868
ine@@	O	-1	7378868
ster@@	O	-1	7378868
ase	O	-1	7378868
des@@	O	-1	7378868
pit@@	O	-1	7378868
e	O	-1	7378868
pretreatment	O	-1	7378868
with	O	-1	7378868
p@@	B-Chemical	D010197	7378868
an@@	I-Chemical	-1	7378868
cur@@	I-Chemical	-1	7378868
oni@@	I-Chemical	-1	7378868
um	I-Chemical	-1	7378868
.	O	-1	7378868

In@@	B-Chemical	D007213	7411769
do@@	I-Chemical	-1	7411769
meth@@	I-Chemical	-1	7411769
ac@@	I-Chemical	-1	7411769
in	I-Chemical	-1	7411769
-induced	O	-1	7411769
hyper@@	B-Disease	D006947	7411769
k@@	I-Disease	-1	7411769
al@@	I-Disease	-1	7411769
emia	I-Disease	-1	7411769
in	O	-1	7411769
three	O	-1	7411769
patients	O	-1	7411769
with	O	-1	7411769
g@@	B-Disease	D015210	7411769
out@@	I-Disease	-1	7411769
y	I-Disease	-1	7411769
arth@@	I-Disease	-1	7411769
ritis	I-Disease	-1	7411769
.	O	-1	7411769
We	O	-1	7411769
describe	O	-1	7411769
three	O	-1	7411769
patients	O	-1	7411769
in	O	-1	7411769
whom	O	-1	7411769
se@@	O	-1	7411769
ve@@	O	-1	7411769
re,	O	-1	7411769
lif@@	O	-1	7411769
e-@@	O	-1	7411769
th@@	O	-1	7411769
reat@@	O	-1	7411769
en@@	O	-1	7411769
ing	O	-1	7411769
hyper@@	B-Disease	D006947	7411769
k@@	I-Disease	-1	7411769
al@@	I-Disease	-1	7411769
emia	I-Disease	-1	7411769
and	O	-1	7411769
renal	B-Disease	D051437	7411769
in@@	I-Disease	-1	7411769
suffici@@	I-Disease	-1	7411769
ency	I-Disease	-1	7411769
developed	O	-1	7411769
after	O	-1	7411769
treatment	O	-1	7411769
of	O	-1	7411769
acute	O	-1	7411769
g@@	B-Disease	D015210	7411769
out@@	I-Disease	-1	7411769
y	I-Disease	-1	7411769
arth@@	I-Disease	-1	7411769
ritis	I-Disease	-1	7411769
with	O	-1	7411769
in@@	B-Chemical	D007213	7411769
do@@	I-Chemical	-1	7411769
meth@@	I-Chemical	-1	7411769
ac@@	I-Chemical	-1	7411769
in	I-Chemical	-1	7411769
.	O	-1	7411769
This	O	-1	7411769
complication	O	-1	7411769
may	O	-1	7411769
result	O	-1	7411769
from	O	-1	7411769
an	O	-1	7411769
inhibition	O	-1	7411769
of	O	-1	7411769
pro@@	B-Chemical	D011453	7411769
st@@	I-Chemical	-1	7411769
ag@@	I-Chemical	-1	7411769
l@@	I-Chemical	-1	7411769
and@@	I-Chemical	-1	7411769
in	I-Chemical	-1	7411769
syn@@	O	-1	7411769
thesis	O	-1	7411769
and	O	-1	7411769
con@@	O	-1	7411769
sequ@@	O	-1	7411769
ent	O	-1	7411769
hypo@@	B-Disease	D006994	7411769
ren@@	I-Disease	-1	7411769
ine@@	I-Disease	-1	7411769
mic	I-Disease	-1	7411769
hypo@@	I-Disease	-1	7411769
a@@	I-Disease	-1	7411769
id@@	I-Disease	-1	7411769
o@@	I-Disease	-1	7411769
ster@@	I-Disease	-1	7411769
on@@	I-Disease	-1	7411769
ism	I-Disease	-1	7411769
.	O	-1	7411769
Ca@@	O	-1	7411769
ref@@	O	-1	7411769
u@@	O	-1	7411769
l	O	-1	7411769
atten@@	O	-1	7411769
tion	O	-1	7411769
to	O	-1	7411769
renal	O	-1	7411769
function	O	-1	7411769
and	O	-1	7411769
pot@@	B-Chemical	D011188	7411769
assi@@	I-Chemical	-1	7411769
um	I-Chemical	-1	7411769
b@@	O	-1	7411769
al@@	O	-1	7411769
ance	O	-1	7411769
in	O	-1	7411769
patients	O	-1	7411769
receiving	O	-1	7411769
in@@	B-Chemical	D007213	7411769
do@@	I-Chemical	-1	7411769
meth@@	I-Chemical	-1	7411769
ac@@	I-Chemical	-1	7411769
in	I-Chemical	-1	7411769
or	O	-1	7411769
other	O	-1	7411769
non@@	O	-1	7411769
steroid@@	O	-1	7411769
al	O	-1	7411769
anti@@	O	-1	7411769
-@@	O	-1	7411769
inflam@@	O	-1	7411769
mat@@	O	-1	7411769
ory	O	-1	7411769
agent@@	O	-1	7411769
s,	O	-1	7411769
partic@@	O	-1	7411769
ul@@	O	-1	7411769
arly	O	-1	7411769
in	O	-1	7411769
those	O	-1	7411769
patients	O	-1	7411769
with	O	-1	7411769
dia@@	B-Disease	D003920	7411769
bet@@	I-Disease	-1	7411769
es	I-Disease	-1	7411769
me@@	I-Disease	-1	7411769
ll@@	I-Disease	-1	7411769
it@@	I-Disease	-1	7411769
us	I-Disease	-1	7411769
or	O	-1	7411769
pre@@	O	-1	7411769
ex@@	O	-1	7411769
ist@@	O	-1	7411769
ing	O	-1	7411769
renal	B-Disease	D007674	7411769
disease	I-Disease	-1	7411769
,	O	-1	7411769
wil@@	O	-1	7411769
l	O	-1	7411769
he@@	O	-1	7411769
l@@	O	-1	7411769
p	O	-1	7411769
prev@@	O	-1	7411769
ent	O	-1	7411769
this	O	-1	7411769
potenti@@	O	-1	7411769
ally	O	-1	7411769
seri@@	O	-1	7411769
ous	O	-1	7411769
complic@@	O	-1	7411769
ation.	O	-1	7411769

E@@	B-Chemical	D005045	7457821
to@@	I-Chemical	-1	7457821
mid@@	I-Chemical	-1	7457821
ate	I-Chemical	-1	7457821
:	O	-1	7457821
a	O	-1	7457821
fo@@	O	-1	7457821
res@@	O	-1	7457821
h@@	O	-1	7457821
or@@	O	-1	7457821
ten@@	O	-1	7457821
ed	O	-1	7457821
clinical	O	-1	7457821
tri@@	O	-1	7457821
al.	O	-1	7457821
A	O	-1	7457821
clinical	O	-1	7457821
evalu@@	O	-1	7457821
ation	O	-1	7457821
of	O	-1	7457821
e@@	B-Chemical	D005045	7457821
to@@	I-Chemical	-1	7457821
mid@@	I-Chemical	-1	7457821
ate	I-Chemical	-1	7457821
for	O	-1	7457821
out@@	O	-1	7457821
patient	O	-1	7457821
cy@@	O	-1	7457821
st@@	O	-1	7457821
os@@	O	-1	7457821
co@@	O	-1	7457821
p@@	O	-1	7457821
y	O	-1	7457821
was	O	-1	7457821
emb@@	O	-1	7457821
ark@@	O	-1	7457821
ed	O	-1	7457821
up@@	O	-1	7457821
on@@	O	-1	7457821
.	O	-1	7457821
U@@	O	-1	7457821
n@@	O	-1	7457821
pre@@	O	-1	7457821
medic@@	O	-1	7457821
ated	O	-1	7457821
patients	O	-1	7457821
were	O	-1	7457821
given	O	-1	7457821
f@@	B-Chemical	D005283	7457821
entan@@	I-Chemical	-1	7457821
yl	I-Chemical	-1	7457821
1	O	-1	7457821
microgram@@	O	-1	7457821
/@@	O	-1	7457821
k@@	O	-1	7457821
g	O	-1	7457821
followed	O	-1	7457821
by	O	-1	7457821
e@@	B-Chemical	D005045	7457821
to@@	I-Chemical	-1	7457821
mid@@	I-Chemical	-1	7457821
ate	I-Chemical	-1	7457821
0.@@	O	-1	7457821
3	O	-1	7457821
mg/kg@@	O	-1	7457821
.	O	-1	7457821
An@@	O	-1	7457821
a@@	O	-1	7457821
esthe@@	O	-1	7457821
sia	O	-1	7457821
was	O	-1	7457821
maint@@	O	-1	7457821
ained	O	-1	7457821
with	O	-1	7457821
inter@@	O	-1	7457821
mit@@	O	-1	7457821
t@@	O	-1	7457821
ent	O	-1	7457821
e@@	B-Chemical	D005045	7457821
to@@	I-Chemical	-1	7457821
mid@@	I-Chemical	-1	7457821
ate	I-Chemical	-1	7457821
in	O	-1	7457821
2-@@	O	-1	7457821
4	O	-1	7457821
mg	O	-1	7457821
dos@@	O	-1	7457821
es.	O	-1	7457821
Patients	O	-1	7457821
were	O	-1	7457821
inter@@	O	-1	7457821
vie@@	O	-1	7457821
w@@	O	-1	7457821
ed	O	-1	7457821
per@@	O	-1	7457821
son@@	O	-1	7457821
ally	O	-1	7457821
lat@@	O	-1	7457821
er	O	-1	7457821
the	O	-1	7457821
same	O	-1	7457821
da@@	O	-1	7457821
y,	O	-1	7457821
and	O	-1	7457821
by	O	-1	7457821
qu@@	O	-1	7457821
es@@	O	-1	7457821
tion@@	O	-1	7457821
na@@	O	-1	7457821
ir@@	O	-1	7457821
e	O	-1	7457821
three	O	-1	7457821
to	O	-1	7457821
four	O	-1	7457821
weeks	O	-1	7457821
lat@@	O	-1	7457821
er.	O	-1	7457821
The	O	-1	7457821
trial	O	-1	7457821
was	O	-1	7457821
discontinu@@	O	-1	7457821
ed	O	-1	7457821
after	O	-1	7457821
20	O	-1	7457821
cases	O	-1	7457821
because	O	-1	7457821
of	O	-1	7457821
an	O	-1	7457821
un@@	O	-1	7457821
ac@@	O	-1	7457821
ce@@	O	-1	7457821
pt@@	O	-1	7457821
able	O	-1	7457821
incidence	O	-1	7457821
of	O	-1	7457821
side	O	-1	7457821
effects.	O	-1	7457821
V@@	O	-1	7457821
en@@	O	-1	7457821
ous	O	-1	7457821
pain	B-Disease	D010146	7457821
occurred	O	-1	7457821
in	O	-1	7457821
6@@	O	-1	7457821
8@@	O	-1	7457821
%	O	-1	7457821
of	O	-1	7457821
patients	O	-1	7457821
and	O	-1	7457821
50@@	O	-1	7457821
%	O	-1	7457821
had	O	-1	7457821
re@@	O	-1	7457821
d@@	O	-1	7457821
n@@	O	-1	7457821
es@@	O	-1	7457821
s,	O	-1	7457821
pain	B-Disease	D010146	7457821
or	O	-1	7457821
s@@	B-Disease	D004487	7457821
we@@	I-Disease	-1	7457821
ll@@	I-Disease	-1	7457821
ing	I-Disease	-1	7457821
related	O	-1	7457821
to	O	-1	7457821
the	O	-1	7457821
injection	O	-1	7457821
sit@@	O	-1	7457821
e,	O	-1	7457821
in	O	-1	7457821
some	O	-1	7457821
cases	O	-1	7457821
l@@	O	-1	7457821
ast@@	O	-1	7457821
ing	O	-1	7457821
up	O	-1	7457821
to	O	-1	7457821
three	O	-1	7457821
weeks	O	-1	7457821
after	O	-1	7457821
anaesthe@@	O	-1	7457821
sia.	O	-1	7457821
S@@	O	-1	7457821
ke@@	O	-1	7457821
le@@	O	-1	7457821
t@@	O	-1	7457821
al	O	-1	7457821
mo@@	O	-1	7457821
ve@@	O	-1	7457821
ments	O	-1	7457821
occurred	O	-1	7457821
in	O	-1	7457821
50@@	O	-1	7457821
%	O	-1	7457821
of	O	-1	7457821
patient@@	O	-1	7457821
s;	O	-1	7457821
3@@	O	-1	7457821
0%	O	-1	7457821
experienced	O	-1	7457821
respiratory	B-Disease	D012140	7457821
up@@	I-Disease	-1	7457821
set	I-Disease	-1	7457821
,	O	-1	7457821
one	O	-1	7457821
suffici@@	O	-1	7457821
ently	O	-1	7457821
severe	O	-1	7457821
to	O	-1	7457821
nec@@	O	-1	7457821
ess@@	O	-1	7457821
it@@	O	-1	7457821
ate	O	-1	7457821
ab@@	O	-1	7457821
and@@	O	-1	7457821
on@@	O	-1	7457821
ing	O	-1	7457821
the	O	-1	7457821
t@@	O	-1	7457821
ech@@	O	-1	7457821
n@@	O	-1	7457821
i@@	O	-1	7457821
qu@@	O	-1	7457821
e.	O	-1	7457821
Na@@	B-Disease	D009325	7457821
use@@	I-Disease	-1	7457821
a	I-Disease	-1	7457821
and	O	-1	7457821
v@@	B-Disease	D014839	7457821
om@@	I-Disease	-1	7457821
it@@	I-Disease	-1	7457821
ing	I-Disease	-1	7457821
occurred	O	-1	7457821
in	O	-1	7457821
4@@	O	-1	7457821
0%	O	-1	7457821
and	O	-1	7457821
2@@	O	-1	7457821
5%	O	-1	7457821
had	O	-1	7457821
dist@@	O	-1	7457821
urb@@	O	-1	7457821
ing	O	-1	7457821
em@@	O	-1	7457821
er@@	O	-1	7457821
gen@@	O	-1	7457821
ce	O	-1	7457821
psycho@@	B-Disease	D011605	7457821
ses	I-Disease	-1	7457821
.	O	-1	7457821

L@@	B-Chemical	D007980	7477981
evo@@	I-Chemical	-1	7477981
dopa	I-Chemical	-1	7477981
-induced	O	-1	7477981
dyskine@@	B-Disease	D004409	7477981
si@@	I-Disease	-1	7477981
as	I-Disease	-1	7477981
are	O	-1	7477981
improved	O	-1	7477981
by	O	-1	7477981
flu@@	B-Chemical	D005473	7477981
ox@@	I-Chemical	-1	7477981
et@@	I-Chemical	-1	7477981
ine	I-Chemical	-1	7477981
.	O	-1	7477981
We	O	-1	7477981
evaluated	O	-1	7477981
the	O	-1	7477981
severity	O	-1	7477981
of	O	-1	7477981
motor	B-Disease	D009069	7477981
dis@@	I-Disease	-1	7477981
ability	I-Disease	-1	7477981
and	O	-1	7477981
dyskine@@	B-Disease	D004409	7477981
si@@	I-Disease	-1	7477981
as	I-Disease	-1	7477981
in	O	-1	7477981
seven	O	-1	7477981
levo@@	B-Chemical	D007980	7477981
dopa	I-Chemical	-1	7477981
-@@	O	-1	7477981
respon@@	O	-1	7477981
sive	O	-1	7477981
patients	O	-1	7477981
with	O	-1	7477981
Parkinson's	B-Disease	D010300	7477981
disease	I-Disease	-1	7477981
after	O	-1	7477981
an	O	-1	7477981
acute	O	-1	7477981
ch@@	O	-1	7477981
all@@	O	-1	7477981
enge	O	-1	7477981
with	O	-1	7477981
the	O	-1	7477981
mi@@	O	-1	7477981
x@@	O	-1	7477981
ed	O	-1	7477981
dopamine	B-Chemical	D004298	7477981
agon@@	O	-1	7477981
ist@@	O	-1	7477981
,	O	-1	7477981
apo@@	B-Chemical	D001058	7477981
morphine	I-Chemical	-1	7477981
,	O	-1	7477981
before	O	-1	7477981
and	O	-1	7477981
after	O	-1	7477981
the	O	-1	7477981
administration	O	-1	7477981
of	O	-1	7477981
flu@@	B-Chemical	D005473	7477981
ox@@	I-Chemical	-1	7477981
et@@	I-Chemical	-1	7477981
ine	I-Chemical	-1	7477981
(2@@	O	-1	7477981
0	O	-1	7477981
mg	O	-1	7477981
tw@@	O	-1	7477981
ic@@	O	-1	7477981
e	O	-1	7477981
per	O	-1	7477981
day@@	O	-1	7477981
)	O	-1	7477981
for	O	-1	7477981
11	O	-1	7477981
+/-	O	-1	7477981
1	O	-1	7477981
days.	O	-1	7477981
After	O	-1	7477981
flu@@	B-Chemical	D005473	7477981
ox@@	I-Chemical	-1	7477981
et@@	I-Chemical	-1	7477981
ine	I-Chemical	-1	7477981
treatment,	O	-1	7477981
there	O	-1	7477981
was	O	-1	7477981
a	O	-1	7477981
significant	O	-1	7477981
4@@	O	-1	7477981
7@@	O	-1	7477981
%	O	-1	7477981
impro@@	O	-1	7477981
vement	O	-1	7477981
(p	O	-1	7477981
<	O	-1	7477981
0.05@@	O	-1	7477981
)	O	-1	7477981
of	O	-1	7477981
apo@@	B-Chemical	D001058	7477981
morphine	I-Chemical	-1	7477981
-induced	O	-1	7477981
dyskine@@	B-Disease	D004409	7477981
si@@	I-Disease	-1	7477981
as	I-Disease	-1	7477981
without	O	-1	7477981
mo@@	O	-1	7477981
di@@	O	-1	7477981
fic@@	O	-1	7477981
ation	O	-1	7477981
of	O	-1	7477981
par@@	B-Disease	D010300	7477981
k@@	I-Disease	-1	7477981
inson@@	I-Disease	-1	7477981
i@@	I-Disease	-1	7477981
an	I-Disease	-1	7477981
motor	B-Disease	D009069	7477981
dis@@	I-Disease	-1	7477981
ability	I-Disease	-1	7477981
.	O	-1	7477981
The	O	-1	7477981
dyskine@@	B-Disease	D004409	7477981
si@@	I-Disease	-1	7477981
as	I-Disease	-1	7477981
were	O	-1	7477981
reduced	O	-1	7477981
pre@@	O	-1	7477981
domin@@	O	-1	7477981
ant@@	O	-1	7477981
ly	O	-1	7477981
in	O	-1	7477981
the	O	-1	7477981
lower	O	-1	7477981
lim@@	O	-1	7477981
b@@	O	-1	7477981
s	O	-1	7477981
during	O	-1	7477981
the	O	-1	7477981
onset	O	-1	7477981
and	O	-1	7477981
dis@@	O	-1	7477981
appear@@	O	-1	7477981
ance	O	-1	7477981
of	O	-1	7477981
dy@@	B-Disease	D020821	7477981
st@@	I-Disease	-1	7477981
onic	I-Disease	-1	7477981
dyskine@@	I-Disease	-1	7477981
si@@	I-Disease	-1	7477981
as	I-Disease	-1	7477981
dy@@	B-Disease	D004409	7477981
st@@	I-Disease	-1	7477981
onic	I-Disease	-1	7477981
dyskine@@	I-Disease	-1	7477981
si@@	I-Disease	-1	7477981
as	I-Disease	-1	7477981
(@@	O	-1	7477981
on@@	O	-1	7477981
se@@	O	-1	7477981
t@@	O	-1	7477981
-	O	-1	7477981
and	O	-1	7477981
en@@	O	-1	7477981
d-@@	O	-1	7477981
of@@	O	-1	7477981
-@@	O	-1	7477981
dose	O	-1	7477981
dyskine@@	B-Disease	D004409	7477981
si@@	I-Disease	-1	7477981
as	I-Disease	-1	7477981
)	O	-1	7477981
and	O	-1	7477981
in	O	-1	7477981
the	O	-1	7477981
up@@	O	-1	7477981
per	O	-1	7477981
lim@@	O	-1	7477981
b@@	O	-1	7477981
s	O	-1	7477981
during	O	-1	7477981
ch@@	B-Disease	D002819	7477981
ore@@	I-Disease	-1	7477981
ic	I-Disease	-1	7477981
mid@@	I-Disease	-1	7477981
-@@	I-Disease	-1	7477981
dose	I-Disease	-1	7477981
dyskine@@	I-Disease	-1	7477981
si@@	I-Disease	-1	7477981
as	I-Disease	-1	7477981
ch@@	B-Disease	D004409	7477981
ore@@	I-Disease	-1	7477981
ic	I-Disease	-1	7477981
mid@@	I-Disease	-1	7477981
-@@	I-Disease	-1	7477981
dose	I-Disease	-1	7477981
dyskine@@	I-Disease	-1	7477981
si@@	I-Disease	-1	7477981
as	I-Disease	-1	7477981
.	O	-1	7477981
The	O	-1	7477981
results	O	-1	7477981
suggest	O	-1	7477981
that	O	-1	7477981
increased	O	-1	7477981
brain	O	-1	7477981
seroton@@	O	-1	7477981
inergic	O	-1	7477981
trans@@	O	-1	7477981
mission	O	-1	7477981
with	O	-1	7477981
flu@@	B-Chemical	D005473	7477981
ox@@	I-Chemical	-1	7477981
et@@	I-Chemical	-1	7477981
ine	I-Chemical	-1	7477981
may	O	-1	7477981
re@@	O	-1	7477981
duce	O	-1	7477981
levo@@	B-Chemical	D007980	7477981
dopa	I-Chemical	-1	7477981
-	O	-1	7477981
or	O	-1	7477981
dopamine	B-Chemical	D004298	7477981
agon@@	O	-1	7477981
ist@@	O	-1	7477981
-induced	O	-1	7477981
dyskine@@	B-Disease	D004409	7477981
si@@	I-Disease	-1	7477981
as	I-Disease	-1	7477981
without	O	-1	7477981
ag@@	O	-1	7477981
gra@@	O	-1	7477981
v@@	O	-1	7477981
ating	O	-1	7477981
par@@	B-Disease	D010300	7477981
k@@	I-Disease	-1	7477981
inson@@	I-Disease	-1	7477981
i@@	I-Disease	-1	7477981
an	I-Disease	-1	7477981
motor	B-Disease	D009069	7477981
dis@@	I-Disease	-1	7477981
ability	I-Disease	-1	7477981
.	O	-1	7477981

A	O	-1	7479194
larg@@	O	-1	7479194
e	O	-1	7479194
po@@	O	-1	7479194
pul@@	O	-1	7479194
ation@@	O	-1	7479194
-@@	O	-1	7479194
bas@@	O	-1	7479194
ed	O	-1	7479194
follow-up	O	-1	7479194
study	O	-1	7479194
of	O	-1	7479194
tri@@	B-Chemical	D015662	7479194
meth@@	I-Chemical	-1	7479194
o@@	I-Chemical	-1	7479194
prim@@	I-Chemical	-1	7479194
-@@	I-Chemical	-1	7479194
sulf@@	I-Chemical	-1	7479194
ameth@@	I-Chemical	-1	7479194
ox@@	I-Chemical	-1	7479194
azole	I-Chemical	-1	7479194
,	O	-1	7479194
tri@@	B-Chemical	D014295	7479194
meth@@	I-Chemical	-1	7479194
o@@	I-Chemical	-1	7479194
pri@@	I-Chemical	-1	7479194
m	I-Chemical	-1	7479194
,	O	-1	7479194
and	O	-1	7479194
ce@@	B-Chemical	D002506	7479194
ph@@	I-Chemical	-1	7479194
al@@	I-Chemical	-1	7479194
ex@@	I-Chemical	-1	7479194
in	I-Chemical	-1	7479194
for	O	-1	7479194
un@@	O	-1	7479194
common	O	-1	7479194
seri@@	O	-1	7479194
ous	O	-1	7479194
drug	B-Disease	D064420	7479194
toxicity	I-Disease	-1	7479194
.	O	-1	7479194
We	O	-1	7479194
con@@	O	-1	7479194
duc@@	O	-1	7479194
ted	O	-1	7479194
a	O	-1	7479194
po@@	O	-1	7479194
pul@@	O	-1	7479194
ation@@	O	-1	7479194
-@@	O	-1	7479194
bas@@	O	-1	7479194
ed	O	-1	7479194
4@@	O	-1	7479194
5-@@	O	-1	7479194
day	O	-1	7479194
follow-up	O	-1	7479194
study	O	-1	7479194
of	O	-1	7479194
2@@	O	-1	7479194
3@@	O	-1	7479194
2@@	O	-1	7479194
,@@	O	-1	7479194
3@@	O	-1	7479194
9@@	O	-1	7479194
0	O	-1	7479194
pe@@	O	-1	7479194
o@@	O	-1	7479194
ple	O	-1	7479194
who	O	-1	7479194
were	O	-1	7479194
prescri@@	O	-1	7479194
bed	O	-1	7479194
tri@@	B-Chemical	D015662	7479194
meth@@	I-Chemical	-1	7479194
o@@	I-Chemical	-1	7479194
prim@@	I-Chemical	-1	7479194
-@@	I-Chemical	-1	7479194
sulf@@	I-Chemical	-1	7479194
ameth@@	I-Chemical	-1	7479194
ox@@	I-Chemical	-1	7479194
azole	I-Chemical	-1	7479194
(	O	-1	7479194
T@@	B-Chemical	D015662	7479194
MP@@	I-Chemical	-1	7479194
-@@	I-Chemical	-1	7479194
S@@	I-Chemical	-1	7479194
M@@	I-Chemical	-1	7479194
Z	I-Chemical	-1	7479194
),	O	-1	7479194
2@@	O	-1	7479194
6@@	O	-1	7479194
6@@	O	-1	7479194
,@@	O	-1	7479194
9@@	O	-1	7479194
5@@	O	-1	7479194
1	O	-1	7479194
prescri@@	O	-1	7479194
bed	O	-1	7479194
tri@@	B-Chemical	D014295	7479194
meth@@	I-Chemical	-1	7479194
o@@	I-Chemical	-1	7479194
pri@@	I-Chemical	-1	7479194
m	I-Chemical	-1	7479194
al@@	O	-1	7479194
one,	O	-1	7479194
and	O	-1	7479194
19@@	O	-1	7479194
6@@	O	-1	7479194
,@@	O	-1	7479194
3@@	O	-1	7479194
9@@	O	-1	7479194
7	O	-1	7479194
prescri@@	O	-1	7479194
bed	O	-1	7479194
ce@@	B-Chemical	D002506	7479194
ph@@	I-Chemical	-1	7479194
al@@	I-Chemical	-1	7479194
ex@@	I-Chemical	-1	7479194
in	I-Chemical	-1	7479194
,	O	-1	7479194
to	O	-1	7479194
estim@@	O	-1	7479194
ate	O	-1	7479194
the	O	-1	7479194
risk	O	-1	7479194
of	O	-1	7479194
seri@@	O	-1	7479194
ous	O	-1	7479194
li@@	B-Disease	D008107	7479194
ver,	I-Disease	-1	7479194
blo@@	I-Disease	-1	7479194
o@@	I-Disease	-1	7479194
d,	I-Disease	-1	7479194
s@@	I-Disease	-1	7479194
k@@	I-Disease	-1	7479194
in,	I-Disease	-1	7479194
and	I-Disease	-1	7479194
renal	I-Disease	-1	7479194
disorder@@	I-Disease	-1	7479194
s	I-Disease	-1	7479194
li@@	B-Disease	D006402	7479194
ver,	I-Disease	-1	7479194
blo@@	I-Disease	-1	7479194
o@@	I-Disease	-1	7479194
d,	I-Disease	-1	7479194
s@@	I-Disease	-1	7479194
k@@	I-Disease	-1	7479194
in,	I-Disease	-1	7479194
and	I-Disease	-1	7479194
renal	I-Disease	-1	7479194
disorder@@	I-Disease	-1	7479194
s	I-Disease	-1	7479194
li@@	B-Disease	D012871	7479194
ver,	I-Disease	-1	7479194
blo@@	I-Disease	-1	7479194
o@@	I-Disease	-1	7479194
d,	I-Disease	-1	7479194
s@@	I-Disease	-1	7479194
k@@	I-Disease	-1	7479194
in,	I-Disease	-1	7479194
and	I-Disease	-1	7479194
renal	I-Disease	-1	7479194
disorder@@	I-Disease	-1	7479194
s	I-Disease	-1	7479194
li@@	B-Disease	D007674	7479194
ver,	I-Disease	-1	7479194
blo@@	I-Disease	-1	7479194
o@@	I-Disease	-1	7479194
d,	I-Disease	-1	7479194
s@@	I-Disease	-1	7479194
k@@	I-Disease	-1	7479194
in,	I-Disease	-1	7479194
and	I-Disease	-1	7479194
renal	I-Disease	-1	7479194
disorder@@	I-Disease	-1	7479194
s	I-Disease	-1	7479194
result@@	O	-1	7479194
ing	O	-1	7479194
in	O	-1	7479194
ref@@	O	-1	7479194
er@@	O	-1	7479194
ral	O	-1	7479194
or	O	-1	7479194
hospit@@	O	-1	7479194
al@@	O	-1	7479194
ization	O	-1	7479194
associated	O	-1	7479194
with	O	-1	7479194
these	O	-1	7479194
drug@@	O	-1	7479194
s.	O	-1	7479194
The	O	-1	7479194
results	O	-1	7479194
were	O	-1	7479194
bas@@	O	-1	7479194
ed	O	-1	7479194
on	O	-1	7479194
inf@@	O	-1	7479194
orm@@	O	-1	7479194
ation	O	-1	7479194
recor@@	O	-1	7479194
ded	O	-1	7479194
on	O	-1	7479194
o@@	O	-1	7479194
ff@@	O	-1	7479194
ic@@	O	-1	7479194
e	O	-1	7479194
comp@@	O	-1	7479194
u@@	O	-1	7479194
ters	O	-1	7479194
by	O	-1	7479194
sel@@	O	-1	7479194
ected	O	-1	7479194
gener@@	O	-1	7479194
al	O	-1	7479194
p@@	O	-1	7479194
rac@@	O	-1	7479194
ti@@	O	-1	7479194
tion@@	O	-1	7479194
ers	O	-1	7479194
in	O	-1	7479194
the	O	-1	7479194
U@@	O	-1	7479194
nit@@	O	-1	7479194
ed	O	-1	7479194
K@@	O	-1	7479194
ing@@	O	-1	7479194
dom@@	O	-1	7479194
,	O	-1	7479194
to@@	O	-1	7479194
ge@@	O	-1	7479194
ther	O	-1	7479194
with	O	-1	7479194
a	O	-1	7479194
revie@@	O	-1	7479194
w	O	-1	7479194
of	O	-1	7479194
clinical	O	-1	7479194
recor@@	O	-1	7479194
d@@	O	-1	7479194
s.	O	-1	7479194
The	O	-1	7479194
risk	O	-1	7479194
of	O	-1	7479194
clin@@	O	-1	7479194
ically	O	-1	7479194
important	O	-1	7479194
i@@	O	-1	7479194
di@@	O	-1	7479194
o@@	O	-1	7479194
path@@	O	-1	7479194
ic	O	-1	7479194
liver	B-Disease	D008107	7479194
disease	I-Disease	-1	7479194
was	O	-1	7479194
similar	O	-1	7479194
for	O	-1	7479194
per@@	O	-1	7479194
son@@	O	-1	7479194
s	O	-1	7479194
prescri@@	O	-1	7479194
bed	O	-1	7479194
T@@	B-Chemical	D015662	7479194
MP@@	I-Chemical	-1	7479194
-@@	I-Chemical	-1	7479194
S@@	I-Chemical	-1	7479194
M@@	I-Chemical	-1	7479194
Z	I-Chemical	-1	7479194
(@@	O	-1	7479194
5.@@	O	-1	7479194
2@@	O	-1	7479194
/@@	O	-1	7479194
10@@	O	-1	7479194
0@@	O	-1	7479194
,@@	O	-1	7479194
0@@	O	-1	7479194
0@@	O	-1	7479194
0@@	O	-1	7479194
)	O	-1	7479194
and	O	-1	7479194
those	O	-1	7479194
prescri@@	O	-1	7479194
bed	O	-1	7479194
tri@@	B-Chemical	D014295	7479194
meth@@	I-Chemical	-1	7479194
o@@	I-Chemical	-1	7479194
pri@@	I-Chemical	-1	7479194
m	I-Chemical	-1	7479194
alone	O	-1	7479194
(@@	O	-1	7479194
3.@@	O	-1	7479194
8@@	O	-1	7479194
/@@	O	-1	7479194
10@@	O	-1	7479194
0@@	O	-1	7479194
,@@	O	-1	7479194
0@@	O	-1	7479194
0@@	O	-1	7479194
0@@	O	-1	7479194
).	O	-1	7479194
The	O	-1	7479194
risk	O	-1	7479194
for	O	-1	7479194
those	O	-1	7479194
prescri@@	O	-1	7479194
bed	O	-1	7479194
ce@@	B-Chemical	D002506	7479194
ph@@	I-Chemical	-1	7479194
al@@	I-Chemical	-1	7479194
ex@@	I-Chemical	-1	7479194
in	I-Chemical	-1	7479194
was	O	-1	7479194
so@@	O	-1	7479194
me@@	O	-1	7479194
wh@@	O	-1	7479194
at	O	-1	7479194
lower	O	-1	7479194
(2@@	O	-1	7479194
.@@	O	-1	7479194
0@@	O	-1	7479194
/@@	O	-1	7479194
10@@	O	-1	7479194
0@@	O	-1	7479194
,@@	O	-1	7479194
0@@	O	-1	7479194
0@@	O	-1	7479194
0@@	O	-1	7479194
).	O	-1	7479194
On@@	O	-1	7479194
ly	O	-1	7479194
five	O	-1	7479194
patients	O	-1	7479194
experienced	O	-1	7479194
blood	O	-1	7479194
disorder@@	O	-1	7479194
s,	O	-1	7479194
one	O	-1	7479194
of	O	-1	7479194
whom	O	-1	7479194
was	O	-1	7479194
exposed	O	-1	7479194
to	O	-1	7479194
T@@	B-Chemical	D015662	7479194
MP@@	I-Chemical	-1	7479194
-@@	I-Chemical	-1	7479194
S@@	I-Chemical	-1	7479194
M@@	I-Chemical	-1	7479194
Z	I-Chemical	-1	7479194
;	O	-1	7479194
of	O	-1	7479194
seven	O	-1	7479194
with	O	-1	7479194
eryth@@	B-Disease	D004892	7479194
em@@	I-Disease	-1	7479194
a	I-Disease	-1	7479194
multi@@	I-Disease	-1	7479194
form@@	I-Disease	-1	7479194
e	I-Disease	-1	7479194
and	O	-1	7479194
S@@	B-Disease	D013262	7479194
te@@	I-Disease	-1	7479194
ven@@	I-Disease	-1	7479194
s-@@	I-Disease	-1	7479194
J@@	I-Disease	-1	7479194
o@@	I-Disease	-1	7479194
h@@	I-Disease	-1	7479194
n@@	I-Disease	-1	7479194
s@@	I-Disease	-1	7479194
on	I-Disease	-1	7479194
syndrome	I-Disease	-1	7479194
,	O	-1	7479194
four	O	-1	7479194
were	O	-1	7479194
exposed	O	-1	7479194
to	O	-1	7479194
T@@	B-Chemical	D015662	7479194
MP@@	I-Chemical	-1	7479194
-@@	I-Chemical	-1	7479194
S@@	I-Chemical	-1	7479194
M@@	I-Chemical	-1	7479194
Z	I-Chemical	-1	7479194
.	O	-1	7479194
The	O	-1	7479194
one	O	-1	7479194
case	O	-1	7479194
of	O	-1	7479194
toxic	B-Disease	D013262	7479194
ep@@	I-Disease	-1	7479194
id@@	I-Disease	-1	7479194
er@@	I-Disease	-1	7479194
m@@	I-Disease	-1	7479194
al	I-Disease	-1	7479194
necro@@	I-Disease	-1	7479194
ly@@	I-Disease	-1	7479194
sis	I-Disease	-1	7479194
occurred	O	-1	7479194
in	O	-1	7479194
a	O	-1	7479194
patient	O	-1	7479194
who	O	-1	7479194
to@@	O	-1	7479194
o@@	O	-1	7479194
k	O	-1	7479194
ce@@	B-Chemical	D002506	7479194
ph@@	I-Chemical	-1	7479194
al@@	I-Chemical	-1	7479194
ex@@	I-Chemical	-1	7479194
in	I-Chemical	-1	7479194
.	O	-1	7479194
F@@	O	-1	7479194
in@@	O	-1	7479194
ally,	O	-1	7479194
only	O	-1	7479194
five	O	-1	7479194
cases	O	-1	7479194
of	O	-1	7479194
acute	O	-1	7479194
pa@@	O	-1	7479194
ren@@	O	-1	7479194
ch@@	O	-1	7479194
ym@@	O	-1	7479194
al	O	-1	7479194
renal	B-Disease	D007674	7479194
disease	I-Disease	-1	7479194
occur@@	O	-1	7479194
re@@	O	-1	7479194
d,	O	-1	7479194
n@@	O	-1	7479194
one	O	-1	7479194
likely	O	-1	7479194
to	O	-1	7479194
be	O	-1	7479194
caused	O	-1	7479194
by	O	-1	7479194
a	O	-1	7479194
study	O	-1	7479194
drug.	O	-1	7479194
We	O	-1	7479194
concl@@	O	-1	7479194
ude	O	-1	7479194
that	O	-1	7479194
the	O	-1	7479194
risk	O	-1	7479194
of	O	-1	7479194
the	O	-1	7479194
seri@@	O	-1	7479194
ous	O	-1	7479194
diseas@@	O	-1	7479194
es	O	-1	7479194
studied	O	-1	7479194
is	O	-1	7479194
sm@@	O	-1	7479194
all	O	-1	7479194
for	O	-1	7479194
the	O	-1	7479194
three	O	-1	7479194
agent@@	O	-1	7479194
s,	O	-1	7479194
and	O	-1	7479194
com@@	O	-1	7479194
pa@@	O	-1	7479194
res	O	-1	7479194
reas@@	O	-1	7479194
on@@	O	-1	7479194
ably	O	-1	7479194
with	O	-1	7479194
the	O	-1	7479194
risk	O	-1	7479194
for	O	-1	7479194
man@@	O	-1	7479194
y	O	-1	7479194
other	O	-1	7479194
anti@@	O	-1	7479194
bio@@	O	-1	7479194
tic@@	O	-1	7479194
s.	O	-1	7479194

Clin@@	O	-1	7492040
ical	O	-1	7492040
safety	O	-1	7492040
of	O	-1	7492040
lidocaine	B-Chemical	D008012	7492040
in	O	-1	7492040
patients	O	-1	7492040
with	O	-1	7492040
cocaine	B-Chemical	D003042	7492040
-@@	O	-1	7492040
associated	O	-1	7492040
myocardial	B-Disease	D009203	7492040
infarction	I-Disease	-1	7492040
.	O	-1	7492040
S@@	O	-1	7492040
T@@	O	-1	7492040
U@@	O	-1	7492040
D@@	O	-1	7492040
Y	O	-1	7492040
OBJECTIVE:	O	-1	7492040
To	O	-1	7492040
evalu@@	O	-1	7492040
ate	O	-1	7492040
the	O	-1	7492040
safety	O	-1	7492040
of	O	-1	7492040
lidocaine	B-Chemical	D008012	7492040
in	O	-1	7492040
the	O	-1	7492040
se@@	O	-1	7492040
t@@	O	-1	7492040
ting	O	-1	7492040
of	O	-1	7492040
cocaine	B-Chemical	D003042	7492040
-induced	O	-1	7492040
myocardial	B-Disease	D009203	7492040
infarction	I-Disease	-1	7492040
(	O	-1	7492040
M@@	B-Disease	D009203	7492040
I	I-Disease	-1	7492040
).	O	-1	7492040
D@@	O	-1	7492040
ES@@	O	-1	7492040
I@@	O	-1	7492040
G@@	O	-1	7492040
N@@	O	-1	7492040
:	O	-1	7492040
A	O	-1	7492040
ret@@	O	-1	7492040
ro@@	O	-1	7492040
sp@@	O	-1	7492040
ecti@@	O	-1	7492040
ve,	O	-1	7492040
mul@@	O	-1	7492040
tic@@	O	-1	7492040
ent@@	O	-1	7492040
er	O	-1	7492040
study.	O	-1	7492040
S@@	O	-1	7492040
ET@@	O	-1	7492040
TI@@	O	-1	7492040
N@@	O	-1	7492040
G@@	O	-1	7492040
:	O	-1	7492040
Tw@@	O	-1	7492040
ent@@	O	-1	7492040
y-@@	O	-1	7492040
n@@	O	-1	7492040
ine	O	-1	7492040
un@@	O	-1	7492040
i@@	O	-1	7492040
ver@@	O	-1	7492040
s@@	O	-1	7492040
ity,	O	-1	7492040
un@@	O	-1	7492040
i@@	O	-1	7492040
ver@@	O	-1	7492040
sit@@	O	-1	7492040
y-@@	O	-1	7492040
aff@@	O	-1	7492040
il@@	O	-1	7492040
i@@	O	-1	7492040
at@@	O	-1	7492040
ed,	O	-1	7492040
or	O	-1	7492040
com@@	O	-1	7492040
mun@@	O	-1	7492040
ity	O	-1	7492040
hospit@@	O	-1	7492040
als	O	-1	7492040
during	O	-1	7492040
a	O	-1	7492040
6-@@	O	-1	7492040
year	O	-1	7492040
period	O	-1	7492040
(@@	O	-1	7492040
total	O	-1	7492040
of	O	-1	7492040
1@@	O	-1	7492040
17	O	-1	7492040
cum@@	O	-1	7492040
ul@@	O	-1	7492040
ative	O	-1	7492040
hospit@@	O	-1	7492040
al@@	O	-1	7492040
-@@	O	-1	7492040
year@@	O	-1	7492040
s@@	O	-1	7492040
).	O	-1	7492040
PA@@	O	-1	7492040
R@@	O	-1	7492040
TI@@	O	-1	7492040
CI@@	O	-1	7492040
PA@@	O	-1	7492040
N@@	O	-1	7492040
T@@	O	-1	7492040
S:	O	-1	7492040
Patients	O	-1	7492040
with	O	-1	7492040
cocaine	B-Chemical	D003042	7492040
-@@	O	-1	7492040
associated	O	-1	7492040
M@@	B-Disease	D009203	7492040
I	I-Disease	-1	7492040
who	O	-1	7492040
received	O	-1	7492040
lidocaine	B-Chemical	D008012	7492040
in	O	-1	7492040
the	O	-1	7492040
em@@	O	-1	7492040
er@@	O	-1	7492040
gen@@	O	-1	7492040
c@@	O	-1	7492040
y	O	-1	7492040
de@@	O	-1	7492040
part@@	O	-1	7492040
ment.	O	-1	7492040
RESULTS:	O	-1	7492040
Of	O	-1	7492040
2@@	O	-1	7492040
9	O	-1	7492040
patients	O	-1	7492040
who	O	-1	7492040
received	O	-1	7492040
lidocaine	B-Chemical	D008012	7492040
in	O	-1	7492040
the	O	-1	7492040
se@@	O	-1	7492040
t@@	O	-1	7492040
ting	O	-1	7492040
of	O	-1	7492040
cocaine	B-Chemical	D003042	7492040
-@@	O	-1	7492040
associated	O	-1	7492040
M@@	B-Disease	D009203	7492040
I	I-Disease	-1	7492040
,	O	-1	7492040
no	O	-1	7492040
patient	O	-1	7492040
di@@	O	-1	7492040
ed@@	O	-1	7492040
;	O	-1	7492040
ex@@	O	-1	7492040
hib@@	O	-1	7492040
ited	O	-1	7492040
brady@@	B-Disease	D001919	7492040
dys@@	I-Disease	-1	7492040
rhyth@@	I-Disease	-1	7492040
mi@@	I-Disease	-1	7492040
as	I-Disease	-1	7492040
,	O	-1	7492040
ventricular	B-Disease	D017180	7492040
tachycardia	I-Disease	-1	7492040
,	O	-1	7492040
or	O	-1	7492040
ventricular	B-Disease	D014693	7492040
fibrill@@	I-Disease	-1	7492040
ation	I-Disease	-1	7492040
;	O	-1	7492040
or	O	-1	7492040
experienced	O	-1	7492040
seizures	B-Disease	D012640	7492040
after	O	-1	7492040
administration	O	-1	7492040
of	O	-1	7492040
lidocaine	B-Chemical	D008012	7492040
(@@	O	-1	7492040
95%	O	-1	7492040
conf@@	O	-1	7492040
idence	O	-1	7492040
inter@@	O	-1	7492040
val@@	O	-1	7492040
,	O	-1	7492040
0%	O	-1	7492040
to	O	-1	7492040
1@@	O	-1	7492040
1@@	O	-1	7492040
%).	O	-1	7492040
CONCLUSION:	O	-1	7492040
D@@	O	-1	7492040
es@@	O	-1	7492040
pit@@	O	-1	7492040
e	O	-1	7492040
the@@	O	-1	7492040
ore@@	O	-1	7492040
tical	O	-1	7492040
con@@	O	-1	7492040
cer@@	O	-1	7492040
n@@	O	-1	7492040
s	O	-1	7492040
that	O	-1	7492040
lidocaine	B-Chemical	D008012	7492040
may	O	-1	7492040
enh@@	O	-1	7492040
ance	O	-1	7492040
cocaine	B-Chemical	D003042	7492040
toxicity	B-Disease	D064420	7492040
,	O	-1	7492040
the	O	-1	7492040
use	O	-1	7492040
of	O	-1	7492040
lidocaine	B-Chemical	D008012	7492040
in	O	-1	7492040
patients	O	-1	7492040
with	O	-1	7492040
cocaine	B-Chemical	D003042	7492040
-@@	O	-1	7492040
associated	O	-1	7492040
M@@	B-Disease	D009203	7492040
I	I-Disease	-1	7492040
was	O	-1	7492040
not	O	-1	7492040
associated	O	-1	7492040
with	O	-1	7492040
significant	O	-1	7492040
cardiovascular	B-Disease	D002318	7492040
or	I-Disease	-1	7492040
central	I-Disease	-1	7492040
ner@@	I-Disease	-1	7492040
v@@	I-Disease	-1	7492040
ous	I-Disease	-1	7492040
system	I-Disease	-1	7492040
toxicity	I-Disease	-1	7492040
cardiovascular	B-Disease	D002493	7492040
or	I-Disease	-1	7492040
central	I-Disease	-1	7492040
ner@@	I-Disease	-1	7492040
v@@	I-Disease	-1	7492040
ous	I-Disease	-1	7492040
system	I-Disease	-1	7492040
toxicity	I-Disease	-1	7492040
.	O	-1	7492040

P@@	B-Chemical	D017239	7644931
ac@@	I-Chemical	-1	7644931
litax@@	I-Chemical	-1	7644931
el	I-Chemical	-1	7644931
3-@@	O	-1	7644931
h@@	O	-1	7644931
our	O	-1	7644931
infusion	O	-1	7644931
given	O	-1	7644931
alone	O	-1	7644931
and	O	-1	7644931
combined	O	-1	7644931
with	O	-1	7644931
car@@	B-Chemical	D016190	7644931
bo@@	I-Chemical	-1	7644931
pl@@	I-Chemical	-1	7644931
atin	I-Chemical	-1	7644931
:	O	-1	7644931
pre@@	O	-1	7644931
lim@@	O	-1	7644931
inary	O	-1	7644931
results	O	-1	7644931
of	O	-1	7644931
dose-@@	O	-1	7644931
es@@	O	-1	7644931
cal@@	O	-1	7644931
ation	O	-1	7644931
tri@@	O	-1	7644931
al@@	O	-1	7644931
s.	O	-1	7644931
P@@	B-Chemical	D017239	7644931
ac@@	I-Chemical	-1	7644931
litax@@	I-Chemical	-1	7644931
el	I-Chemical	-1	7644931
(	O	-1	7644931
T@@	B-Chemical	D017239	7644931
ax@@	I-Chemical	-1	7644931
ol	I-Chemical	-1	7644931
;	O	-1	7644931
B@@	O	-1	7644931
ri@@	O	-1	7644931
st@@	O	-1	7644931
ol@@	O	-1	7644931
-@@	O	-1	7644931
M@@	O	-1	7644931
y@@	O	-1	7644931
ers	O	-1	7644931
S@@	O	-1	7644931
qu@@	O	-1	7644931
i@@	O	-1	7644931
b@@	O	-1	7644931
b	O	-1	7644931
Com@@	O	-1	7644931
p@@	O	-1	7644931
an@@	O	-1	7644931
y,	O	-1	7644931
P@@	O	-1	7644931
r@@	O	-1	7644931
in@@	O	-1	7644931
ce@@	O	-1	7644931
t@@	O	-1	7644931
on@@	O	-1	7644931
,	O	-1	7644931
N@@	O	-1	7644931
J@@	O	-1	7644931
)	O	-1	7644931
by	O	-1	7644931
3-@@	O	-1	7644931
h@@	O	-1	7644931
our	O	-1	7644931
infusion	O	-1	7644931
was	O	-1	7644931
combined	O	-1	7644931
with	O	-1	7644931
car@@	B-Chemical	D016190	7644931
bo@@	I-Chemical	-1	7644931
pl@@	I-Chemical	-1	7644931
atin	I-Chemical	-1	7644931
in	O	-1	7644931
a	O	-1	7644931
phase	O	-1	7644931
I@@	O	-1	7644931
/@@	O	-1	7644931
II	O	-1	7644931
study	O	-1	7644931
direc@@	O	-1	7644931
ted	O	-1	7644931
to	O	-1	7644931
patients	O	-1	7644931
with	O	-1	7644931
non-@@	B-Disease	D002289	7644931
sm@@	I-Disease	-1	7644931
all	I-Disease	-1	7644931
cell	I-Disease	-1	7644931
l@@	I-Disease	-1	7644931
un@@	I-Disease	-1	7644931
g	I-Disease	-1	7644931
cancer	I-Disease	-1	7644931
.	O	-1	7644931
C@@	B-Chemical	D016190	7644931
ar@@	I-Chemical	-1	7644931
bo@@	I-Chemical	-1	7644931
pl@@	I-Chemical	-1	7644931
atin	I-Chemical	-1	7644931
was	O	-1	7644931
given	O	-1	7644931
at	O	-1	7644931
a	O	-1	7644931
fi@@	O	-1	7644931
x@@	O	-1	7644931
ed	O	-1	7644931
t@@	O	-1	7644931
arg@@	O	-1	7644931
et	O	-1	7644931
a@@	O	-1	7644931
re@@	O	-1	7644931
a	O	-1	7644931
under	O	-1	7644931
the	O	-1	7644931
concentr@@	O	-1	7644931
ation@@	O	-1	7644931
-@@	O	-1	7644931
time	O	-1	7644931
cur@@	O	-1	7644931
ve	O	-1	7644931
of	O	-1	7644931
6.@@	O	-1	7644931
0	O	-1	7644931
by	O	-1	7644931
the	O	-1	7644931
C@@	O	-1	7644931
al@@	O	-1	7644931
ver@@	O	-1	7644931
t	O	-1	7644931
form@@	O	-1	7644931
ul@@	O	-1	7644931
a,	O	-1	7644931
whereas	O	-1	7644931
paclitax@@	B-Chemical	D017239	7644931
el	I-Chemical	-1	7644931
was	O	-1	7644931
es@@	O	-1	7644931
cal@@	O	-1	7644931
ated	O	-1	7644931
in	O	-1	7644931
patient	O	-1	7644931
co@@	O	-1	7644931
h@@	O	-1	7644931
or@@	O	-1	7644931
ts	O	-1	7644931
from	O	-1	7644931
1@@	O	-1	7644931
50	O	-1	7644931
mg/m@@	O	-1	7644931
2	O	-1	7644931
(@@	O	-1	7644931
dose	O	-1	7644931
level	O	-1	7644931
I@@	O	-1	7644931
)	O	-1	7644931
to	O	-1	7644931
17@@	O	-1	7644931
5,	O	-1	7644931
20@@	O	-1	7644931
0@@	O	-1	7644931
,	O	-1	7644931
2@@	O	-1	7644931
2@@	O	-1	7644931
5,	O	-1	7644931
and	O	-1	7644931
2@@	O	-1	7644931
50	O	-1	7644931
mg/m@@	O	-1	7644931
2@@	O	-1	7644931
.	O	-1	7644931
The	O	-1	7644931
2@@	O	-1	7644931
25	O	-1	7644931
mg/m@@	O	-1	7644931
2	O	-1	7644931
level	O	-1	7644931
was	O	-1	7644931
ex@@	O	-1	7644931
p@@	O	-1	7644931
and@@	O	-1	7644931
ed	O	-1	7644931
for	O	-1	7644931
the	O	-1	7644931
phase	O	-1	7644931
II	O	-1	7644931
study	O	-1	7644931
s@@	O	-1	7644931
inc@@	O	-1	7644931
e	O	-1	7644931
the	O	-1	7644931
high@@	O	-1	7644931
est	O	-1	7644931
level	O	-1	7644931
achi@@	O	-1	7644931
ev@@	O	-1	7644931
ed	O	-1	7644931
(2@@	O	-1	7644931
50	O	-1	7644931
mg/m@@	O	-1	7644931
2)	O	-1	7644931
requ@@	O	-1	7644931
ired	O	-1	7644931
mo@@	O	-1	7644931
di@@	O	-1	7644931
fic@@	O	-1	7644931
ation	O	-1	7644931
because	O	-1	7644931
of	O	-1	7644931
non@@	O	-1	7644931
hemat@@	O	-1	7644931
ologic	O	-1	7644931
toxic@@	B-Disease	D064420	7644931
ities	I-Disease	-1	7644931
(	O	-1	7644931
arth@@	B-Disease	D018771	7644931
r@@	I-Disease	-1	7644931
al@@	I-Disease	-1	7644931
g@@	I-Disease	-1	7644931
ia	I-Disease	-1	7644931
and	O	-1	7644931
sens@@	B-Disease	D012678	7644931
ory	I-Disease	-1	7644931
neuropathy	I-Disease	-1	7644931
).	O	-1	7644931
Th@@	O	-1	7644931
er@@	O	-1	7644931
ap@@	O	-1	7644931
eu@@	O	-1	7644931
tic	O	-1	7644931
effects	O	-1	7644931
were	O	-1	7644931
not@@	O	-1	7644931
ed	O	-1	7644931
at	O	-1	7644931
all	O	-1	7644931
dose	O	-1	7644931
level@@	O	-1	7644931
s,	O	-1	7644931
with	O	-1	7644931
ob@@	O	-1	7644931
j@@	O	-1	7644931
ective	O	-1	7644931
responses	O	-1	7644931
in	O	-1	7644931
17	O	-1	7644931
(@@	O	-1	7644931
two	O	-1	7644931
complete	O	-1	7644931
and	O	-1	7644931
15	O	-1	7644931
partial	O	-1	7644931
reg@@	O	-1	7644931
res@@	O	-1	7644931
sion@@	O	-1	7644931
s)	O	-1	7644931
of	O	-1	7644931
4@@	O	-1	7644931
1	O	-1	7644931
previously	O	-1	7644931
un@@	O	-1	7644931
treated	O	-1	7644931
patients.	O	-1	7644931
T@@	B-Disease	D064420	7644931
oxic@@	I-Disease	-1	7644931
ities	I-Disease	-1	7644931
were	O	-1	7644931
compared	O	-1	7644931
with	O	-1	7644931
a	O	-1	7644931
co@@	O	-1	7644931
h@@	O	-1	7644931
ort	O	-1	7644931
of	O	-1	7644931
patients	O	-1	7644931
in	O	-1	7644931
a	O	-1	7644931
phase	O	-1	7644931
I	O	-1	7644931
trial	O	-1	7644931
of	O	-1	7644931
paclitax@@	B-Chemical	D017239	7644931
el	I-Chemical	-1	7644931
alone	O	-1	7644931
at	O	-1	7644931
id@@	O	-1	7644931
en@@	O	-1	7644931
tical	O	-1	7644931
dose	O	-1	7644931
level@@	O	-1	7644931
s.	O	-1	7644931
C@@	B-Chemical	D016190	7644931
ar@@	I-Chemical	-1	7644931
bo@@	I-Chemical	-1	7644931
pl@@	I-Chemical	-1	7644931
atin	I-Chemical	-1	7644931
did	O	-1	7644931
not	O	-1	7644931
appe@@	O	-1	7644931
ar	O	-1	7644931
to	O	-1	7644931
ad@@	O	-1	7644931
d	O	-1	7644931
to	O	-1	7644931
the	O	-1	7644931
hemat@@	B-Disease	D006402	7644931
ologic	I-Disease	-1	7644931
toxic@@	I-Disease	-1	7644931
ities	I-Disease	-1	7644931
obser@@	O	-1	7644931
ve@@	O	-1	7644931
d,	O	-1	7644931
and	O	-1	7644931
the	O	-1	7644931
paclitax@@	B-Chemical	D017239	7644931
el	I-Chemical	-1	7644931
/	O	-1	7644931
car@@	B-Chemical	D016190	7644931
bo@@	I-Chemical	-1	7644931
pl@@	I-Chemical	-1	7644931
atin	I-Chemical	-1	7644931
combination	O	-1	7644931
could	O	-1	7644931
be	O	-1	7644931
dos@@	O	-1	7644931
ed	O	-1	7644931
every	O	-1	7644931
3	O	-1	7644931
week@@	O	-1	7644931
s.	O	-1	7644931

The	O	-1	7661171
dose-@@	O	-1	7661171
dependent	O	-1	7661171
effect	O	-1	7661171
of	O	-1	7661171
m@@	B-Chemical	D016595	7661171
iso@@	I-Chemical	-1	7661171
pro@@	I-Chemical	-1	7661171
st@@	I-Chemical	-1	7661171
ol	I-Chemical	-1	7661171
on	O	-1	7661171
in@@	B-Chemical	D007213	7661171
do@@	I-Chemical	-1	7661171
meth@@	I-Chemical	-1	7661171
ac@@	I-Chemical	-1	7661171
in	I-Chemical	-1	7661171
-induced	O	-1	7661171
renal	B-Disease	D007674	7661171
dysfunction	I-Disease	-1	7661171
in	O	-1	7661171
well	O	-1	7661171
com@@	O	-1	7661171
pen@@	O	-1	7661171
s@@	O	-1	7661171
ated	O	-1	7661171
cir@@	B-Disease	D005355	7661171
r@@	I-Disease	-1	7661171
ho@@	I-Disease	-1	7661171
sis	I-Disease	-1	7661171
.	O	-1	7661171
M@@	B-Chemical	D016595	7661171
iso@@	I-Chemical	-1	7661171
pro@@	I-Chemical	-1	7661171
st@@	I-Chemical	-1	7661171
ol	I-Chemical	-1	7661171
(2@@	O	-1	7661171
00	O	-1	7661171
microgram@@	O	-1	7661171
s)	O	-1	7661171
has	O	-1	7661171
been	O	-1	7661171
shown	O	-1	7661171
to	O	-1	7661171
ac@@	O	-1	7661171
u@@	O	-1	7661171
te@@	O	-1	7661171
ly	O	-1	7661171
coun@@	O	-1	7661171
ter@@	O	-1	7661171
ac@@	O	-1	7661171
t	O	-1	7661171
the	O	-1	7661171
in@@	B-Chemical	D007213	7661171
do@@	I-Chemical	-1	7661171
meth@@	I-Chemical	-1	7661171
ac@@	I-Chemical	-1	7661171
in	I-Chemical	-1	7661171
-induced	O	-1	7661171
renal	B-Disease	D007674	7661171
dysfunction	I-Disease	-1	7661171
in	O	-1	7661171
well	O	-1	7661171
com@@	O	-1	7661171
pen@@	O	-1	7661171
s@@	O	-1	7661171
ated	O	-1	7661171
cir@@	B-Disease	D005355	7661171
r@@	I-Disease	-1	7661171
ho@@	I-Disease	-1	7661171
tic	I-Disease	-1	7661171
patients.	O	-1	7661171
The	O	-1	7661171
a@@	O	-1	7661171
im	O	-1	7661171
of	O	-1	7661171
this	O	-1	7661171
study	O	-1	7661171
was	O	-1	7661171
to	O	-1	7661171
determine	O	-1	7661171
if	O	-1	7661171
the	O	-1	7661171
pro@@	O	-1	7661171
phyl@@	O	-1	7661171
ac@@	O	-1	7661171
tic	O	-1	7661171
valu@@	O	-1	7661171
e	O	-1	7661171
of	O	-1	7661171
m@@	B-Chemical	D016595	7661171
iso@@	I-Chemical	-1	7661171
pro@@	I-Chemical	-1	7661171
st@@	I-Chemical	-1	7661171
ol	I-Chemical	-1	7661171
was	O	-1	7661171
dose-@@	O	-1	7661171
depend@@	O	-1	7661171
ent@@	O	-1	7661171
.	O	-1	7661171
P@@	O	-1	7661171
ar@@	O	-1	7661171
ame@@	O	-1	7661171
ters	O	-1	7661171
of	O	-1	7661171
renal	O	-1	7661171
hemo@@	O	-1	7661171
dynam@@	O	-1	7661171
ic@@	O	-1	7661171
s	O	-1	7661171
and	O	-1	7661171
tub@@	O	-1	7661171
ular	O	-1	7661171
sodium	B-Chemical	D012964	7661171
and	O	-1	7661171
w@@	O	-1	7661171
at@@	O	-1	7661171
er	O	-1	7661171
h@@	O	-1	7661171
and@@	O	-1	7661171
l@@	O	-1	7661171
ing	O	-1	7661171
were	O	-1	7661171
assessed	O	-1	7661171
by	O	-1	7661171
clear@@	O	-1	7661171
ance	O	-1	7661171
t@@	O	-1	7661171
ech@@	O	-1	7661171
n@@	O	-1	7661171
i@@	O	-1	7661171
qu@@	O	-1	7661171
es	O	-1	7661171
in	O	-1	7661171
2@@	O	-1	7661171
6	O	-1	7661171
well	O	-1	7661171
com@@	O	-1	7661171
pen@@	O	-1	7661171
s@@	O	-1	7661171
ated	O	-1	7661171
cir@@	B-Disease	D005355	7661171
r@@	I-Disease	-1	7661171
ho@@	I-Disease	-1	7661171
tic	I-Disease	-1	7661171
patients	O	-1	7661171
before	O	-1	7661171
and	O	-1	7661171
after	O	-1	7661171
an	O	-1	7661171
oral	O	-1	7661171
combination	O	-1	7661171
of	O	-1	7661171
50	O	-1	7661171
mg	O	-1	7661171
of	O	-1	7661171
in@@	B-Chemical	D007213	7661171
do@@	I-Chemical	-1	7661171
meth@@	I-Chemical	-1	7661171
ac@@	I-Chemical	-1	7661171
in	I-Chemical	-1	7661171
and	O	-1	7661171
various	O	-1	7661171
doses	O	-1	7661171
of	O	-1	7661171
m@@	B-Chemical	D016595	7661171
iso@@	I-Chemical	-1	7661171
pro@@	I-Chemical	-1	7661171
st@@	I-Chemical	-1	7661171
ol	I-Chemical	-1	7661171
.	O	-1	7661171
The	O	-1	7661171
20@@	O	-1	7661171
0-@@	O	-1	7661171
microgram@@	O	-1	7661171
s	O	-1	7661171
dose	O	-1	7661171
was	O	-1	7661171
able	O	-1	7661171
to	O	-1	7661171
tot@@	O	-1	7661171
ally	O	-1	7661171
abol@@	O	-1	7661171
is@@	O	-1	7661171
h	O	-1	7661171
the	O	-1	7661171
de@@	O	-1	7661171
le@@	O	-1	7661171
ter@@	O	-1	7661171
i@@	O	-1	7661171
ous	O	-1	7661171
renal	O	-1	7661171
effects	O	-1	7661171
of	O	-1	7661171
in@@	B-Chemical	D007213	7661171
do@@	I-Chemical	-1	7661171
meth@@	I-Chemical	-1	7661171
ac@@	I-Chemical	-1	7661171
in	I-Chemical	-1	7661171
,	O	-1	7661171
whereas	O	-1	7661171
the	O	-1	7661171
80@@	O	-1	7661171
0-@@	O	-1	7661171
microgram@@	O	-1	7661171
s	O	-1	7661171
dose	O	-1	7661171
resulted	O	-1	7661171
in	O	-1	7661171
significant	O	-1	7661171
wor@@	O	-1	7661171
sen@@	O	-1	7661171
ing	O	-1	7661171
of	O	-1	7661171
renal	O	-1	7661171
hemo@@	O	-1	7661171
dynam@@	O	-1	7661171
ic@@	O	-1	7661171
s	O	-1	7661171
and	O	-1	7661171
sodium	B-Chemical	D012964	7661171
re@@	O	-1	7661171
ten@@	O	-1	7661171
tion.	O	-1	7661171
These	O	-1	7661171
changes	O	-1	7661171
were	O	-1	7661171
maxim@@	O	-1	7661171
al	O	-1	7661171
in	O	-1	7661171
the	O	-1	7661171
h@@	O	-1	7661171
our	O	-1	7661171
immedi@@	O	-1	7661171
ately	O	-1	7661171
after	O	-1	7661171
medic@@	O	-1	7661171
ations	O	-1	7661171
and	O	-1	7661171
s@@	O	-1	7661171
low@@	O	-1	7661171
ly	O	-1	7661171
retur@@	O	-1	7661171
n@@	O	-1	7661171
ed	O	-1	7661171
to@@	O	-1	7661171
war@@	O	-1	7661171
d	O	-1	7661171
bas@@	O	-1	7661171
e-@@	O	-1	7661171
line	O	-1	7661171
levels	O	-1	7661171
the@@	O	-1	7661171
re@@	O	-1	7661171
af@@	O	-1	7661171
ter@@	O	-1	7661171
.	O	-1	7661171
These	O	-1	7661171
results	O	-1	7661171
suggest	O	-1	7661171
that	O	-1	7661171
the	O	-1	7661171
renal	O	-1	7661171
protective	O	-1	7661171
effects	O	-1	7661171
of	O	-1	7661171
m@@	B-Chemical	D016595	7661171
iso@@	I-Chemical	-1	7661171
pro@@	I-Chemical	-1	7661171
st@@	I-Chemical	-1	7661171
ol	I-Chemical	-1	7661171
is	O	-1	7661171
dose-@@	O	-1	7661171
depend@@	O	-1	7661171
ent@@	O	-1	7661171
.	O	-1	7661171
However,	O	-1	7661171
un@@	O	-1	7661171
ti@@	O	-1	7661171
l	O	-1	7661171
this	O	-1	7661171
appa@@	O	-1	7661171
rent	O	-1	7661171
ability	O	-1	7661171
of	O	-1	7661171
2@@	O	-1	7661171
00	O	-1	7661171
microgram@@	O	-1	7661171
s	O	-1	7661171
of	O	-1	7661171
m@@	B-Chemical	D016595	7661171
iso@@	I-Chemical	-1	7661171
pro@@	I-Chemical	-1	7661171
st@@	I-Chemical	-1	7661171
ol	I-Chemical	-1	7661171
to	O	-1	7661171
prev@@	O	-1	7661171
ent	O	-1	7661171
the	O	-1	7661171
adverse	O	-1	7661171
effects	O	-1	7661171
of	O	-1	7661171
in@@	B-Chemical	D007213	7661171
do@@	I-Chemical	-1	7661171
meth@@	I-Chemical	-1	7661171
ac@@	I-Chemical	-1	7661171
in	I-Chemical	-1	7661171
on	O	-1	7661171
renal	O	-1	7661171
function	O	-1	7661171
is	O	-1	7661171
con@@	O	-1	7661171
fir@@	O	-1	7661171
m@@	O	-1	7661171
ed	O	-1	7661171
with	O	-1	7661171
chronic	O	-1	7661171
frequent	O	-1	7661171
dos@@	O	-1	7661171
ing,	O	-1	7661171
it	O	-1	7661171
wo@@	O	-1	7661171
uld	O	-1	7661171
be	O	-1	7661171
pr@@	O	-1	7661171
ud@@	O	-1	7661171
ent	O	-1	7661171
to	O	-1	7661171
av@@	O	-1	7661171
oid	O	-1	7661171
non@@	O	-1	7661171
steroid@@	O	-1	7661171
al	O	-1	7661171
anti@@	O	-1	7661171
-@@	O	-1	7661171
inflam@@	O	-1	7661171
mat@@	O	-1	7661171
ory	O	-1	7661171
therapy	O	-1	7661171
in	O	-1	7661171
patients	O	-1	7661171
with	O	-1	7661171
cir@@	B-Disease	D005355	7661171
r@@	I-Disease	-1	7661171
ho@@	I-Disease	-1	7661171
sis	I-Disease	-1	7661171
.	O	-1	7661171

In@@	O	-1	7671401
c@@	O	-1	7671401
reas@@	O	-1	7671401
ed	O	-1	7671401
frequency	O	-1	7671401
and	O	-1	7671401
severity	O	-1	7671401
of	O	-1	7671401
angio@@	B-Disease	D000799	7671401
-@@	I-Disease	-1	7671401
o@@	I-Disease	-1	7671401
e@@	I-Disease	-1	7671401
de@@	I-Disease	-1	7671401
ma	I-Disease	-1	7671401
related	O	-1	7671401
to	O	-1	7671401
long-term	O	-1	7671401
therapy	O	-1	7671401
with	O	-1	7671401
angiotens@@	B-Chemical	D000806	7671401
in-@@	I-Chemical	-1	7671401
conver@@	I-Chemical	-1	7671401
ting	I-Chemical	-1	7671401
enzyme	I-Chemical	-1	7671401
inhibitor	I-Chemical	-1	7671401
in	O	-1	7671401
two	O	-1	7671401
patients.	O	-1	7671401
Ad@@	O	-1	7671401
verse	O	-1	7671401
reactions	O	-1	7671401
to	O	-1	7671401
drugs	O	-1	7671401
are	O	-1	7671401
well	O	-1	7671401
reco@@	O	-1	7671401
gn@@	O	-1	7671401
ized	O	-1	7671401
as	O	-1	7671401
a	O	-1	7671401
cause	O	-1	7671401
of	O	-1	7671401
acute	O	-1	7671401
or	O	-1	7671401
chronic	O	-1	7671401
ur@@	B-Disease	D014581	7671401
ti@@	I-Disease	-1	7671401
car@@	I-Disease	-1	7671401
ia	I-Disease	-1	7671401
,	O	-1	7671401
and	O	-1	7671401
angio@@	B-Disease	D000799	7671401
-@@	I-Disease	-1	7671401
o@@	I-Disease	-1	7671401
e@@	I-Disease	-1	7671401
de@@	I-Disease	-1	7671401
ma	I-Disease	-1	7671401
.	O	-1	7671401
An@@	B-Chemical	D000806	7671401
gi@@	I-Chemical	-1	7671401
otens@@	I-Chemical	-1	7671401
in-@@	I-Chemical	-1	7671401
conver@@	I-Chemical	-1	7671401
ting	I-Chemical	-1	7671401
enzyme	I-Chemical	-1	7671401
(@@	I-Chemical	-1	7671401
AC@@	I-Chemical	-1	7671401
E@@	I-Chemical	-1	7671401
)	I-Chemical	-1	7671401
inhibitors	I-Chemical	-1	7671401
,	O	-1	7671401
used	O	-1	7671401
to	O	-1	7671401
tre@@	O	-1	7671401
at	O	-1	7671401
hypertension	B-Disease	D006973	7671401
and	O	-1	7671401
con@@	B-Disease	D006333	7671401
g@@	I-Disease	-1	7671401
es@@	I-Disease	-1	7671401
tive	I-Disease	-1	7671401
heart	I-Disease	-1	7671401
failure	I-Disease	-1	7671401
,	O	-1	7671401
were	O	-1	7671401
int@@	O	-1	7671401
ro@@	O	-1	7671401
duced	O	-1	7671401
in	O	-1	7671401
E@@	O	-1	7671401
uro@@	O	-1	7671401
p@@	O	-1	7671401
e	O	-1	7671401
in	O	-1	7671401
the	O	-1	7671401
mid@@	O	-1	7671401
d@@	O	-1	7671401
le	O	-1	7671401
of	O	-1	7671401
the	O	-1	7671401
e@@	O	-1	7671401
igh@@	O	-1	7671401
ti@@	O	-1	7671401
es,	O	-1	7671401
and	O	-1	7671401
the	O	-1	7671401
use	O	-1	7671401
of	O	-1	7671401
these	O	-1	7671401
drugs	O	-1	7671401
has	O	-1	7671401
increased	O	-1	7671401
progres@@	O	-1	7671401
si@@	O	-1	7671401
vel@@	O	-1	7671401
y.	O	-1	7671401
S@@	O	-1	7671401
o@@	O	-1	7671401
on	O	-1	7671401
after	O	-1	7671401
the	O	-1	7671401
int@@	O	-1	7671401
ro@@	O	-1	7671401
duction	O	-1	7671401
of	O	-1	7671401
AC@@	B-Chemical	D000806	7671401
E	I-Chemical	-1	7671401
inhibitors	I-Chemical	-1	7671401
,	O	-1	7671401
acute	O	-1	7671401
b@@	O	-1	7671401
ou@@	O	-1	7671401
ts	O	-1	7671401
of	O	-1	7671401
angio@@	B-Disease	D000799	7671401
-@@	I-Disease	-1	7671401
o@@	I-Disease	-1	7671401
e@@	I-Disease	-1	7671401
de@@	I-Disease	-1	7671401
ma	I-Disease	-1	7671401
were	O	-1	7671401
reported	O	-1	7671401
in	O	-1	7671401
association	O	-1	7671401
with	O	-1	7671401
the	O	-1	7671401
use	O	-1	7671401
of	O	-1	7671401
these	O	-1	7671401
drug@@	O	-1	7671401
s.	O	-1	7671401
We	O	-1	7671401
w@@	O	-1	7671401
is@@	O	-1	7671401
h	O	-1	7671401
to	O	-1	7671401
dra@@	O	-1	7671401
w	O	-1	7671401
atten@@	O	-1	7671401
tion	O	-1	7671401
to	O	-1	7671401
the	O	-1	7671401
possib@@	O	-1	7671401
ility	O	-1	7671401
of	O	-1	7671401
adverse	O	-1	7671401
reactions	O	-1	7671401
to	O	-1	7671401
AC@@	B-Chemical	D000806	7671401
E	I-Chemical	-1	7671401
inhibitors	I-Chemical	-1	7671401
after	O	-1	7671401
long-term	O	-1	7671401
use	O	-1	7671401
and	O	-1	7671401
in	O	-1	7671401
patients	O	-1	7671401
with	O	-1	7671401
pre-@@	O	-1	7671401
ex@@	O	-1	7671401
ist@@	O	-1	7671401
ing	O	-1	7671401
angio@@	B-Disease	D000799	7671401
-@@	I-Disease	-1	7671401
o@@	I-Disease	-1	7671401
e@@	I-Disease	-1	7671401
de@@	I-Disease	-1	7671401
ma	I-Disease	-1	7671401
.	O	-1	7671401

M@@	B-Disease	D009207	7727612
y@@	I-Disease	-1	7727612
oc@@	I-Disease	-1	7727612
lon@@	I-Disease	-1	7727612
us	I-Disease	-1	7727612
associated	O	-1	7727612
with	O	-1	7727612
lor@@	B-Chemical	D008140	7727612
az@@	I-Chemical	-1	7727612
epam	I-Chemical	-1	7727612
therapy	O	-1	7727612
in	O	-1	7727612
ver@@	O	-1	7727612
y-@@	O	-1	7727612
low@@	O	-1	7727612
-@@	O	-1	7727612
b@@	O	-1	7727612
ir@@	O	-1	7727612
th@@	O	-1	7727612
-@@	O	-1	7727612
weight	O	-1	7727612
inf@@	O	-1	7727612
ant@@	O	-1	7727612
s.	O	-1	7727612
L@@	B-Chemical	D008140	7727612
or@@	I-Chemical	-1	7727612
az@@	I-Chemical	-1	7727612
epam	I-Chemical	-1	7727612
is	O	-1	7727612
being	O	-1	7727612
used	O	-1	7727612
with	O	-1	7727612
increas@@	O	-1	7727612
ing	O	-1	7727612
frequency	O	-1	7727612
as	O	-1	7727612
a	O	-1	7727612
sed@@	O	-1	7727612
ative	O	-1	7727612
in	O	-1	7727612
the	O	-1	7727612
ne@@	O	-1	7727612
w@@	O	-1	7727612
b@@	O	-1	7727612
or@@	O	-1	7727612
n	O	-1	7727612
and	O	-1	7727612
the	O	-1	7727612
youn@@	O	-1	7727612
g	O	-1	7727612
inf@@	O	-1	7727612
ant@@	O	-1	7727612
.	O	-1	7727612
Con@@	O	-1	7727612
cer@@	O	-1	7727612
n	O	-1	7727612
has	O	-1	7727612
been	O	-1	7727612
ra@@	O	-1	7727612
is@@	O	-1	7727612
ed	O	-1	7727612
with	O	-1	7727612
reg@@	O	-1	7727612
ard	O	-1	7727612
to	O	-1	7727612
the	O	-1	7727612
safety	O	-1	7727612
of	O	-1	7727612
lor@@	B-Chemical	D008140	7727612
az@@	I-Chemical	-1	7727612
epam	I-Chemical	-1	7727612
in	O	-1	7727612
this	O	-1	7727612
age	O	-1	7727612
group@@	O	-1	7727612
,	O	-1	7727612
es@@	O	-1	7727612
p@@	O	-1	7727612
ec@@	O	-1	7727612
i@@	O	-1	7727612
ally	O	-1	7727612
in	O	-1	7727612
ver@@	O	-1	7727612
y-@@	O	-1	7727612
low@@	O	-1	7727612
-@@	O	-1	7727612
b@@	O	-1	7727612
ir@@	O	-1	7727612
th@@	O	-1	7727612
-@@	O	-1	7727612
weight	O	-1	7727612
(V@@	O	-1	7727612
L@@	O	-1	7727612
B@@	O	-1	7727612
W@@	O	-1	7727612
;	O	-1	7727612
<	O	-1	7727612
1@@	O	-1	7727612
,@@	O	-1	7727612
5@@	O	-1	7727612
00	O	-1	7727612
g@@	O	-1	7727612
)	O	-1	7727612
inf@@	O	-1	7727612
ant@@	O	-1	7727612
s.	O	-1	7727612
Th@@	O	-1	7727612
ree	O	-1	7727612
youn@@	O	-1	7727612
g	O	-1	7727612
inf@@	O	-1	7727612
ant@@	O	-1	7727612
s,	O	-1	7727612
all	O	-1	7727612
of	O	-1	7727612
b@@	O	-1	7727612
ir@@	O	-1	7727612
th	O	-1	7727612
weight	O	-1	7727612
<	O	-1	7727612
1@@	O	-1	7727612
,@@	O	-1	7727612
5@@	O	-1	7727612
00	O	-1	7727612
g@@	O	-1	7727612
,	O	-1	7727612
experienced	O	-1	7727612
my@@	B-Disease	D009207	7727612
oc@@	I-Disease	-1	7727612
lon@@	I-Disease	-1	7727612
us	I-Disease	-1	7727612
following	O	-1	7727612
the	O	-1	7727612
intravenous	O	-1	7727612
administration	O	-1	7727612
of	O	-1	7727612
lor@@	B-Chemical	D008140	7727612
az@@	I-Chemical	-1	7727612
epam	I-Chemical	-1	7727612
.	O	-1	7727612
The	O	-1	7727612
potential	O	-1	7727612
neuro@@	B-Disease	D020258	7727612
toxic	I-Disease	-1	7727612
effects	O	-1	7727612
of	O	-1	7727612
the	O	-1	7727612
drug	O	-1	7727612
(@@	O	-1	7727612
and	O	-1	7727612
its	O	-1	7727612
ve@@	O	-1	7727612
h@@	O	-1	7727612
ic@@	O	-1	7727612
le@@	O	-1	7727612
)	O	-1	7727612
in	O	-1	7727612
this	O	-1	7727612
po@@	O	-1	7727612
p@@	O	-1	7727612
ulation	O	-1	7727612
are	O	-1	7727612
discus@@	O	-1	7727612
sed.	O	-1	7727612
In@@	O	-1	7727612
j@@	O	-1	7727612
ect@@	O	-1	7727612
able	O	-1	7727612
lor@@	B-Chemical	D008140	7727612
az@@	I-Chemical	-1	7727612
epam	I-Chemical	-1	7727612
should	O	-1	7727612
be	O	-1	7727612
used	O	-1	7727612
with	O	-1	7727612
cau@@	O	-1	7727612
tion	O	-1	7727612
in	O	-1	7727612
V@@	O	-1	7727612
L@@	O	-1	7727612
B@@	O	-1	7727612
W	O	-1	7727612
inf@@	O	-1	7727612
ant@@	O	-1	7727612
s.	O	-1	7727612

T@@	O	-1	7739955
ran@@	O	-1	7739955
s@@	O	-1	7739955
venous	O	-1	7739955
right	O	-1	7739955
ventricular	O	-1	7739955
pac@@	O	-1	7739955
ing	O	-1	7739955
during	O	-1	7739955
cardio@@	O	-1	7739955
pulmonary	O	-1	7739955
res@@	O	-1	7739955
us@@	O	-1	7739955
cit@@	O	-1	7739955
ation	O	-1	7739955
of	O	-1	7739955
pe@@	O	-1	7739955
di@@	O	-1	7739955
atric	O	-1	7739955
patients	O	-1	7739955
with	O	-1	7739955
acute	O	-1	7739955
cardi@@	B-Disease	D009202	7739955
om@@	I-Disease	-1	7739955
yo@@	I-Disease	-1	7739955
pathy	I-Disease	-1	7739955
.	O	-1	7739955
We	O	-1	7739955
describe	O	-1	7739955
the	O	-1	7739955
cardio@@	O	-1	7739955
pulmonary	O	-1	7739955
res@@	O	-1	7739955
us@@	O	-1	7739955
cit@@	O	-1	7739955
ation	O	-1	7739955
eff@@	O	-1	7739955
or@@	O	-1	7739955
ts	O	-1	7739955
on	O	-1	7739955
five	O	-1	7739955
patients	O	-1	7739955
who	O	-1	7739955
presented	O	-1	7739955
in	O	-1	7739955
acute	O	-1	7739955
cir@@	B-Disease	D012769	7739955
cul@@	I-Disease	-1	7739955
atory	I-Disease	-1	7739955
failure	I-Disease	-1	7739955
from	O	-1	7739955
myocardial	B-Disease	D009202	7739955
dysfunction	I-Disease	-1	7739955
.	O	-1	7739955
Th@@	O	-1	7739955
ree	O	-1	7739955
patients	O	-1	7739955
had	O	-1	7739955
acute	O	-1	7739955
viral	O	-1	7739955
myocardi@@	B-Disease	D009205	7739955
tis	I-Disease	-1	7739955
,	O	-1	7739955
one	O	-1	7739955
had	O	-1	7739955
a	O	-1	7739955
carbamazepine	B-Chemical	D002220	7739955
-induced	O	-1	7739955
acute	O	-1	7739955
e@@	B-Disease	D004802	7739955
os@@	I-Disease	-1	7739955
in@@	I-Disease	-1	7739955
oph@@	I-Disease	-1	7739955
il@@	I-Disease	-1	7739955
ic	I-Disease	-1	7739955
myocardi@@	I-Disease	-1	7739955
tis	I-Disease	-1	7739955
e@@	B-Disease	D009205	7739955
os@@	I-Disease	-1	7739955
in@@	I-Disease	-1	7739955
oph@@	I-Disease	-1	7739955
il@@	I-Disease	-1	7739955
ic	I-Disease	-1	7739955
myocardi@@	I-Disease	-1	7739955
tis	I-Disease	-1	7739955
,	O	-1	7739955
and	O	-1	7739955
one	O	-1	7739955
had	O	-1	7739955
cardiac	O	-1	7739955
hemo@@	O	-1	7739955
si@@	O	-1	7739955
der@@	O	-1	7739955
o@@	O	-1	7739955
sis	O	-1	7739955
result@@	O	-1	7739955
ing	O	-1	7739955
in	O	-1	7739955
acute	O	-1	7739955
cardio@@	B-Disease	D012770	7739955
genic	I-Disease	-1	7739955
sh@@	I-Disease	-1	7739955
oc@@	I-Disease	-1	7739955
k	I-Disease	-1	7739955
.	O	-1	7739955
All	O	-1	7739955
patients	O	-1	7739955
were	O	-1	7739955
continu@@	O	-1	7739955
ously	O	-1	7739955
monit@@	O	-1	7739955
o@@	O	-1	7739955
red	O	-1	7739955
with	O	-1	7739955
central	O	-1	7739955
venous	O	-1	7739955
and	O	-1	7739955
arterial	O	-1	7739955
ca@@	O	-1	7739955
the@@	O	-1	7739955
ters	O	-1	7739955
in	O	-1	7739955
addition	O	-1	7739955
to	O	-1	7739955
ro@@	O	-1	7739955
ut@@	O	-1	7739955
ine	O	-1	7739955
non@@	O	-1	7739955
inv@@	O	-1	7739955
a@@	O	-1	7739955
sive	O	-1	7739955
monit@@	O	-1	7739955
or@@	O	-1	7739955
ing.	O	-1	7739955
An	O	-1	7739955
int@@	O	-1	7739955
ro@@	O	-1	7739955
duc@@	O	-1	7739955
er	O	-1	7739955
s@@	O	-1	7739955
he@@	O	-1	7739955
ath@@	O	-1	7739955
,	O	-1	7739955
a	O	-1	7739955
pac@@	O	-1	7739955
em@@	O	-1	7739955
ak@@	O	-1	7739955
er,	O	-1	7739955
and	O	-1	7739955
ster@@	O	-1	7739955
ile	O	-1	7739955
pac@@	O	-1	7739955
ing	O	-1	7739955
wi@@	O	-1	7739955
res	O	-1	7739955
were	O	-1	7739955
m@@	O	-1	7739955
ade	O	-1	7739955
re@@	O	-1	7739955
a@@	O	-1	7739955
di@@	O	-1	7739955
ly	O	-1	7739955
av@@	O	-1	7739955
ail@@	O	-1	7739955
able	O	-1	7739955
for	O	-1	7739955
the	O	-1	7739955
patients,	O	-1	7739955
should	O	-1	7739955
the	O	-1	7739955
need	O	-1	7739955
ar@@	O	-1	7739955
is@@	O	-1	7739955
e	O	-1	7739955
to	O	-1	7739955
ter@@	O	-1	7739955
min@@	O	-1	7739955
ate	O	-1	7739955
resist@@	O	-1	7739955
ant	O	-1	7739955
cardiac	O	-1	7739955
dys@@	B-Disease	D001145	7739955
rhyth@@	I-Disease	-1	7739955
mi@@	I-Disease	-1	7739955
as	I-Disease	-1	7739955
.	O	-1	7739955
All	O	-1	7739955
patients	O	-1	7739955
developed	O	-1	7739955
cardi@@	O	-1	7739955
oci@@	O	-1	7739955
r@@	O	-1	7739955
cul@@	O	-1	7739955
atory	O	-1	7739955
ar@@	O	-1	7739955
res@@	O	-1	7739955
t	O	-1	7739955
associated	O	-1	7739955
with	O	-1	7739955
ex@@	O	-1	7739955
trem@@	O	-1	7739955
e	O	-1	7739955
hypotension	B-Disease	D007022	7739955
and	O	-1	7739955
dys@@	B-Disease	D001145	7739955
rhyth@@	I-Disease	-1	7739955
mi@@	I-Disease	-1	7739955
as	I-Disease	-1	7739955
within	O	-1	7739955
the	O	-1	7739955
first	O	-1	7739955
4@@	O	-1	7739955
8	O	-1	7739955
hours	O	-1	7739955
of	O	-1	7739955
their	O	-1	7739955
ad@@	O	-1	7739955
mission	O	-1	7739955
to	O	-1	7739955
the	O	-1	7739955
pe@@	O	-1	7739955
di@@	O	-1	7739955
atric	O	-1	7739955
int@@	O	-1	7739955
en@@	O	-1	7739955
sive	O	-1	7739955
car@@	O	-1	7739955
e	O	-1	7739955
un@@	O	-1	7739955
it	O	-1	7739955
(P@@	O	-1	7739955
IC@@	O	-1	7739955
U@@	O	-1	7739955
).	O	-1	7739955
R@@	O	-1	7739955
ight	O	-1	7739955
ventricular	O	-1	7739955
pac@@	O	-1	7739955
em@@	O	-1	7739955
ak@@	O	-1	7739955
er	O	-1	7739955
wi@@	O	-1	7739955
res	O	-1	7739955
were	O	-1	7739955
in@@	O	-1	7739955
ser@@	O	-1	7739955
ted	O	-1	7739955
in	O	-1	7739955
all	O	-1	7739955
of	O	-1	7739955
the@@	O	-1	7739955
m	O	-1	7739955
during	O	-1	7739955
cardio@@	O	-1	7739955
pulmonary	O	-1	7739955
res@@	O	-1	7739955
us@@	O	-1	7739955
cit@@	O	-1	7739955
ation	O	-1	7739955
(C@@	O	-1	7739955
P@@	O	-1	7739955
R@@	O	-1	7739955
).	O	-1	7739955
In	O	-1	7739955
four	O	-1	7739955
patients,	O	-1	7739955
cardiac	O	-1	7739955
pac@@	O	-1	7739955
ing	O	-1	7739955
was	O	-1	7739955
use@@	O	-1	7739955
d,	O	-1	7739955
result@@	O	-1	7739955
ing	O	-1	7739955
in	O	-1	7739955
a	O	-1	7739955
tempor@@	O	-1	7739955
ary	O	-1	7739955
cap@@	O	-1	7739955
t@@	O	-1	7739955
ured	O	-1	7739955
rhyth@@	O	-1	7739955
m	O	-1	7739955
and	O	-1	7739955
rest@@	O	-1	7739955
or@@	O	-1	7739955
ation	O	-1	7739955
of	O	-1	7739955
their	O	-1	7739955
cardiac	O	-1	7739955
out@@	O	-1	7739955
p@@	O	-1	7739955
ut@@	O	-1	7739955
.	O	-1	7739955
These	O	-1	7739955
patients	O	-1	7739955
had	O	-1	7739955
a	O	-1	7739955
second	O	-1	7739955
ev@@	O	-1	7739955
ent	O	-1	7739955
of	O	-1	7739955
cardiac	B-Disease	D006323	7739955
ar@@	I-Disease	-1	7739955
res@@	I-Disease	-1	7739955
t	I-Disease	-1	7739955
,	O	-1	7739955
result@@	O	-1	7739955
ing	O	-1	7739955
in	O	-1	7739955
de@@	O	-1	7739955
ath@@	O	-1	7739955
,	O	-1	7739955
within	O	-1	7739955
10	O	-1	7739955
to	O	-1	7739955
60	O	-1	7739955
minut@@	O	-1	7739955
es.	O	-1	7739955
In	O	-1	7739955
one	O	-1	7739955
patient@@	O	-1	7739955
,	O	-1	7739955
cardiac	O	-1	7739955
pac@@	O	-1	7739955
ing	O	-1	7739955
was	O	-1	7739955
not	O	-1	7739955
use@@	O	-1	7739955
d,	O	-1	7739955
because	O	-1	7739955
he	O	-1	7739955
conver@@	O	-1	7739955
ted	O	-1	7739955
to	O	-1	7739955
normal	O	-1	7739955
s@@	O	-1	7739955
in@@	O	-1	7739955
us	O	-1	7739955
rhyth@@	O	-1	7739955
m	O	-1	7739955
by	O	-1	7739955
elect@@	O	-1	7739955
r@@	O	-1	7739955
ical	O	-1	7739955
de@@	O	-1	7739955
fibrill@@	O	-1	7739955
ation	O	-1	7739955
within	O	-1	7739955
three	O	-1	7739955
minutes	O	-1	7739955
of	O	-1	7739955
initi@@	O	-1	7739955
ating	O	-1	7739955
C@@	O	-1	7739955
P@@	O	-1	7739955
R@@	O	-1	7739955
.	O	-1	7739955
We	O	-1	7739955
concl@@	O	-1	7739955
ude	O	-1	7739955
that	O	-1	7739955
cardiac	O	-1	7739955
pac@@	O	-1	7739955
ing	O	-1	7739955
during	O	-1	7739955
res@@	O	-1	7739955
us@@	O	-1	7739955
cit@@	O	-1	7739955
ative	O	-1	7739955
eff@@	O	-1	7739955
or@@	O	-1	7739955
ts	O	-1	7739955
in	O	-1	7739955
pe@@	O	-1	7739955
di@@	O	-1	7739955
atric	O	-1	7739955
patients	O	-1	7739955
suff@@	O	-1	7739955
ering	O	-1	7739955
from	O	-1	7739955
acute	O	-1	7739955
myocardial	B-Disease	D009202	7739955
dysfunction	I-Disease	-1	7739955
may	O	-1	7739955
not	O	-1	7739955
have	O	-1	7739955
long-term	O	-1	7739955
valu@@	O	-1	7739955
e	O	-1	7739955
in	O	-1	7739955
and	O	-1	7739955
of	O	-1	7739955
it@@	O	-1	7739955
sel@@	O	-1	7739955
f@@	O	-1	7739955
;	O	-1	7739955
however,	O	-1	7739955
if	O	-1	7739955
tempor@@	O	-1	7739955
ary	O	-1	7739955
hemo@@	O	-1	7739955
dynam@@	O	-1	7739955
ic	O	-1	7739955
st@@	O	-1	7739955
ability	O	-1	7739955
is	O	-1	7739955
achi@@	O	-1	7739955
ev@@	O	-1	7739955
ed	O	-1	7739955
by	O	-1	7739955
this	O	-1	7739955
proce@@	O	-1	7739955
d@@	O	-1	7739955
ure,	O	-1	7739955
it	O	-1	7739955
may	O	-1	7739955
prov@@	O	-1	7739955
ide	O	-1	7739955
addi@@	O	-1	7739955
tional	O	-1	7739955
time	O	-1	7739955
ne@@	O	-1	7739955
ed@@	O	-1	7739955
ed	O	-1	7739955
to	O	-1	7739955
insti@@	O	-1	7739955
t@@	O	-1	7739955
ute	O	-1	7739955
other	O	-1	7739955
therapeutic	O	-1	7739955
mod@@	O	-1	7739955
al@@	O	-1	7739955
iti@@	O	-1	7739955
es.	O	-1	7739955

Eff@@	O	-1	7931490
icac@@	O	-1	7931490
y	O	-1	7931490
and	O	-1	7931490
safety	O	-1	7931490
of	O	-1	7931490
gran@@	B-Chemical	D017829	7931490
i@@	I-Chemical	-1	7931490
se@@	I-Chemical	-1	7931490
tro@@	I-Chemical	-1	7931490
n	I-Chemical	-1	7931490
,	O	-1	7931490
a	O	-1	7931490
selective	O	-1	7931490
5-@@	B-Chemical	D012701	7931490
hydrox@@	I-Chemical	-1	7931490
y@@	I-Chemical	-1	7931490
tr@@	I-Chemical	-1	7931490
y@@	I-Chemical	-1	7931490
pt@@	I-Chemical	-1	7931490
amine	I-Chemical	-1	7931490
-@@	O	-1	7931490
3	O	-1	7931490
receptor	O	-1	7931490
antagonist@@	O	-1	7931490
,	O	-1	7931490
in	O	-1	7931490
the	O	-1	7931490
pre@@	O	-1	7931490
ven@@	O	-1	7931490
tion	O	-1	7931490
of	O	-1	7931490
nausea	B-Disease	D009325	7931490
and	O	-1	7931490
v@@	B-Disease	D014839	7931490
om@@	I-Disease	-1	7931490
it@@	I-Disease	-1	7931490
ing	I-Disease	-1	7931490
induced	O	-1	7931490
by	O	-1	7931490
high-dose	O	-1	7931490
cisplatin	B-Chemical	D002945	7931490
.	O	-1	7931490
P@@	O	-1	7931490
U@@	O	-1	7931490
R@@	O	-1	7931490
P@@	O	-1	7931490
O@@	O	-1	7931490
S@@	O	-1	7931490
E:	O	-1	7931490
To	O	-1	7931490
ass@@	O	-1	7931490
ess	O	-1	7931490
the	O	-1	7931490
anti@@	O	-1	7931490
e@@	O	-1	7931490
me@@	O	-1	7931490
tic	O	-1	7931490
effects	O	-1	7931490
and	O	-1	7931490
safety	O	-1	7931490
prof@@	O	-1	7931490
ile	O	-1	7931490
of	O	-1	7931490
four	O	-1	7931490
different	O	-1	7931490
doses	O	-1	7931490
of	O	-1	7931490
gran@@	B-Chemical	D017829	7931490
i@@	I-Chemical	-1	7931490
se@@	I-Chemical	-1	7931490
tro@@	I-Chemical	-1	7931490
n	I-Chemical	-1	7931490
(	O	-1	7931490
K@@	B-Chemical	D017829	7931490
y@@	I-Chemical	-1	7931490
tri@@	I-Chemical	-1	7931490
l	I-Chemical	-1	7931490
;	O	-1	7931490
S@@	O	-1	7931490
mi@@	O	-1	7931490
th@@	O	-1	7931490
K@@	O	-1	7931490
line	O	-1	7931490
B@@	O	-1	7931490
e@@	O	-1	7931490
ec@@	O	-1	7931490
ha@@	O	-1	7931490
m	O	-1	7931490
Ph@@	O	-1	7931490
ar@@	O	-1	7931490
m@@	O	-1	7931490
ace@@	O	-1	7931490
u@@	O	-1	7931490
tic@@	O	-1	7931490
al@@	O	-1	7931490
s,	O	-1	7931490
Ph@@	O	-1	7931490
il@@	O	-1	7931490
a@@	O	-1	7931490
del@@	O	-1	7931490
ph@@	O	-1	7931490
ia,	O	-1	7931490
PA@@	O	-1	7931490
)	O	-1	7931490
when	O	-1	7931490
administered	O	-1	7931490
as	O	-1	7931490
a	O	-1	7931490
single	O	-1	7931490
intravenous	O	-1	7931490
(@@	O	-1	7931490
I@@	O	-1	7931490
V@@	O	-1	7931490
)	O	-1	7931490
dose	O	-1	7931490
for	O	-1	7931490
pro@@	O	-1	7931490
phyl@@	O	-1	7931490
ax@@	O	-1	7931490
is	O	-1	7931490
of	O	-1	7931490
cisplatin	B-Chemical	D002945	7931490
-induced	O	-1	7931490
nausea	B-Disease	D009325	7931490
and	O	-1	7931490
v@@	B-Disease	D014839	7931490
om@@	I-Disease	-1	7931490
it@@	I-Disease	-1	7931490
ing	I-Disease	-1	7931490
.	O	-1	7931490
PA@@	O	-1	7931490
TI@@	O	-1	7931490
E@@	O	-1	7931490
N@@	O	-1	7931490
T@@	O	-1	7931490
S	O	-1	7931490
AN@@	O	-1	7931490
D	O	-1	7931490
METHODS:	O	-1	7931490
One	O	-1	7931490
h@@	O	-1	7931490
und@@	O	-1	7931490
red	O	-1	7931490
e@@	O	-1	7931490
igh@@	O	-1	7931490
ty-@@	O	-1	7931490
four	O	-1	7931490
chemo@@	O	-1	7931490
therap@@	O	-1	7931490
y-@@	O	-1	7931490
na@@	O	-1	7931490
i@@	O	-1	7931490
ve	O	-1	7931490
patients	O	-1	7931490
receiving	O	-1	7931490
high-dose	O	-1	7931490
cisplatin	B-Chemical	D002945	7931490
(@@	O	-1	7931490
8@@	O	-1	7931490
1	O	-1	7931490
to	O	-1	7931490
1@@	O	-1	7931490
20	O	-1	7931490
mg/m@@	O	-1	7931490
2)	O	-1	7931490
were	O	-1	7931490
randomized	O	-1	7931490
to	O	-1	7931490
recei@@	O	-1	7931490
ve	O	-1	7931490
one	O	-1	7931490
of	O	-1	7931490
four	O	-1	7931490
gran@@	B-Chemical	D017829	7931490
i@@	I-Chemical	-1	7931490
se@@	I-Chemical	-1	7931490
tro@@	I-Chemical	-1	7931490
n	I-Chemical	-1	7931490
doses	O	-1	7931490
(5@@	O	-1	7931490
,	O	-1	7931490
10@@	O	-1	7931490
,	O	-1	7931490
20@@	O	-1	7931490
,	O	-1	7931490
or	O	-1	7931490
40	O	-1	7931490
microgram@@	O	-1	7931490
s/@@	O	-1	7931490
kg@@	O	-1	7931490
)	O	-1	7931490
administered	O	-1	7931490
before	O	-1	7931490
chemo@@	O	-1	7931490
therapy.	O	-1	7931490
Patients	O	-1	7931490
were	O	-1	7931490
observed	O	-1	7931490
on	O	-1	7931490
an	O	-1	7931490
in@@	O	-1	7931490
patient	O	-1	7931490
b@@	O	-1	7931490
asis	O	-1	7931490
for	O	-1	7931490
1@@	O	-1	7931490
8	O	-1	7931490
to	O	-1	7931490
24	O	-1	7931490
hour@@	O	-1	7931490
s,	O	-1	7931490
and	O	-1	7931490
vit@@	O	-1	7931490
al	O	-1	7931490
sign@@	O	-1	7931490
s,	O	-1	7931490
nausea	B-Disease	D009325	7931490
,	O	-1	7931490
v@@	B-Disease	D014839	7931490
om@@	I-Disease	-1	7931490
it@@	I-Disease	-1	7931490
ing	I-Disease	-1	7931490
,	O	-1	7931490
ret@@	O	-1	7931490
ch@@	O	-1	7931490
ing,	O	-1	7931490
and	O	-1	7931490
appe@@	O	-1	7931490
ti@@	O	-1	7931490
te	O	-1	7931490
were	O	-1	7931490
ass@@	O	-1	7931490
es@@	O	-1	7931490
sed.	O	-1	7931490
S@@	O	-1	7931490
af@@	O	-1	7931490
ety	O	-1	7931490
analy@@	O	-1	7931490
ses	O	-1	7931490
included	O	-1	7931490
incidence	O	-1	7931490
of	O	-1	7931490
adverse	O	-1	7931490
experienc@@	O	-1	7931490
es	O	-1	7931490
and	O	-1	7931490
labor@@	O	-1	7931490
atory	O	-1	7931490
par@@	O	-1	7931490
ame@@	O	-1	7931490
ter	O	-1	7931490
chang@@	O	-1	7931490
es.	O	-1	7931490
RESULTS:	O	-1	7931490
After	O	-1	7931490
gran@@	B-Chemical	D017829	7931490
i@@	I-Chemical	-1	7931490
se@@	I-Chemical	-1	7931490
tro@@	I-Chemical	-1	7931490
n	I-Chemical	-1	7931490
doses	O	-1	7931490
of	O	-1	7931490
5,	O	-1	7931490
10@@	O	-1	7931490
,	O	-1	7931490
20@@	O	-1	7931490
,	O	-1	7931490
and	O	-1	7931490
40	O	-1	7931490
microgram@@	O	-1	7931490
s/@@	O	-1	7931490
kg@@	O	-1	7931490
,	O	-1	7931490
a	O	-1	7931490
major	O	-1	7931490
response	O	-1	7931490
(@@	O	-1	7931490
<	O	-1	7931490
or	O	-1	7931490
=	O	-1	7931490
two	O	-1	7931490
v@@	B-Disease	D014839	7931490
om@@	I-Disease	-1	7931490
it@@	I-Disease	-1	7931490
ing	I-Disease	-1	7931490
or	O	-1	7931490
ret@@	O	-1	7931490
ch@@	O	-1	7931490
ing	O	-1	7931490
episo@@	O	-1	7931490
d@@	O	-1	7931490
es,	O	-1	7931490
and	O	-1	7931490
no	O	-1	7931490
anti@@	O	-1	7931490
e@@	O	-1	7931490
me@@	O	-1	7931490
tic	O	-1	7931490
res@@	O	-1	7931490
c@@	O	-1	7931490
u@@	O	-1	7931490
e@@	O	-1	7931490
)	O	-1	7931490
was	O	-1	7931490
recor@@	O	-1	7931490
ded	O	-1	7931490
in	O	-1	7931490
2@@	O	-1	7931490
3@@	O	-1	7931490
%,	O	-1	7931490
5@@	O	-1	7931490
7@@	O	-1	7931490
%,	O	-1	7931490
5@@	O	-1	7931490
8@@	O	-1	7931490
%,	O	-1	7931490
and	O	-1	7931490
6@@	O	-1	7931490
0%	O	-1	7931490
of	O	-1	7931490
patients,	O	-1	7931490
respectivel@@	O	-1	7931490
y,	O	-1	7931490
and	O	-1	7931490
a	O	-1	7931490
complete	O	-1	7931490
response	O	-1	7931490
(@@	O	-1	7931490
no	O	-1	7931490
v@@	B-Disease	D014839	7931490
om@@	I-Disease	-1	7931490
it@@	I-Disease	-1	7931490
ing	I-Disease	-1	7931490
or	O	-1	7931490
ret@@	O	-1	7931490
ch@@	O	-1	7931490
ing,	O	-1	7931490
and	O	-1	7931490
no	O	-1	7931490
anti@@	O	-1	7931490
e@@	O	-1	7931490
me@@	O	-1	7931490
tic	O	-1	7931490
res@@	O	-1	7931490
c@@	O	-1	7931490
u@@	O	-1	7931490
e@@	O	-1	7931490
)	O	-1	7931490
in	O	-1	7931490
18@@	O	-1	7931490
%,	O	-1	7931490
4@@	O	-1	7931490
1@@	O	-1	7931490
%,	O	-1	7931490
4@@	O	-1	7931490
0@@	O	-1	7931490
%,	O	-1	7931490
and	O	-1	7931490
4@@	O	-1	7931490
7@@	O	-1	7931490
%	O	-1	7931490
of	O	-1	7931490
patients,	O	-1	7931490
respectively.	O	-1	7931490
There	O	-1	7931490
was	O	-1	7931490
a	O	-1	7931490
statis@@	O	-1	7931490
tically	O	-1	7931490
long@@	O	-1	7931490
er	O	-1	7931490
time	O	-1	7931490
to	O	-1	7931490
first	O	-1	7931490
episo@@	O	-1	7931490
de	O	-1	7931490
of	O	-1	7931490
nausea	B-Disease	D009325	7931490
(P	O	-1	7931490
=	O	-1	7931490
.@@	O	-1	7931490
0@@	O	-1	7931490
0@@	O	-1	7931490
1@@	O	-1	7931490
5@@	O	-1	7931490
)	O	-1	7931490
and	O	-1	7931490
v@@	B-Disease	D014839	7931490
om@@	I-Disease	-1	7931490
it@@	I-Disease	-1	7931490
ing	I-Disease	-1	7931490
(P	O	-1	7931490
=	O	-1	7931490
.@@	O	-1	7931490
0@@	O	-1	7931490
0@@	O	-1	7931490
0@@	O	-1	7931490
1),	O	-1	7931490
and	O	-1	7931490
fe@@	O	-1	7931490
w@@	O	-1	7931490
er	O	-1	7931490
patients	O	-1	7931490
were	O	-1	7931490
administered	O	-1	7931490
addi@@	O	-1	7931490
tional	O	-1	7931490
anti@@	O	-1	7931490
e@@	O	-1	7931490
me@@	O	-1	7931490
tic	O	-1	7931490
medic@@	O	-1	7931490
ation	O	-1	7931490
in	O	-1	7931490
the	O	-1	7931490
10-@@	O	-1	7931490
microgram@@	O	-1	7931490
s/@@	O	-1	7931490
k@@	O	-1	7931490
g	O	-1	7931490
dos@@	O	-1	7931490
ing	O	-1	7931490
groups	O	-1	7931490
than	O	-1	7931490
in	O	-1	7931490
the	O	-1	7931490
5-@@	O	-1	7931490
microgram@@	O	-1	7931490
s/@@	O	-1	7931490
k@@	O	-1	7931490
g	O	-1	7931490
dos@@	O	-1	7931490
ing	O	-1	7931490
group.	O	-1	7931490
A@@	O	-1	7931490
s	O	-1	7931490
gran@@	B-Chemical	D017829	7931490
i@@	I-Chemical	-1	7931490
se@@	I-Chemical	-1	7931490
tro@@	I-Chemical	-1	7931490
n	I-Chemical	-1	7931490
dose	O	-1	7931490
increas@@	O	-1	7931490
ed,	O	-1	7931490
appe@@	O	-1	7931490
ti@@	O	-1	7931490
te	O	-1	7931490
retur@@	O	-1	7931490
n	O	-1	7931490
increased	O	-1	7931490
(P	O	-1	7931490
=	O	-1	7931490
.@@	O	-1	7931490
0@@	O	-1	7931490
4@@	O	-1	7931490
0@@	O	-1	7931490
).	O	-1	7931490
He@@	B-Disease	D006261	7931490
ad@@	I-Disease	-1	7931490
ac@@	I-Disease	-1	7931490
he	I-Disease	-1	7931490
was	O	-1	7931490
the	O	-1	7931490
most	O	-1	7931490
frequ@@	O	-1	7931490
ently	O	-1	7931490
reported	O	-1	7931490
adverse	O	-1	7931490
ev@@	O	-1	7931490
ent	O	-1	7931490
(2@@	O	-1	7931490
0@@	O	-1	7931490
%).	O	-1	7931490
CONCLUSION:	O	-1	7931490
A	O	-1	7931490
single	O	-1	7931490
10-@@	O	-1	7931490
,	O	-1	7931490
20@@	O	-1	7931490
-@@	O	-1	7931490
,	O	-1	7931490
or	O	-1	7931490
4@@	O	-1	7931490
0-@@	O	-1	7931490
microgram@@	O	-1	7931490
s/@@	O	-1	7931490
k@@	O	-1	7931490
g	O	-1	7931490
dose	O	-1	7931490
of	O	-1	7931490
gran@@	B-Chemical	D017829	7931490
i@@	I-Chemical	-1	7931490
se@@	I-Chemical	-1	7931490
tro@@	I-Chemical	-1	7931490
n	I-Chemical	-1	7931490
was	O	-1	7931490
effective	O	-1	7931490
in	O	-1	7931490
contro@@	O	-1	7931490
ll@@	O	-1	7931490
ing	O	-1	7931490
v@@	B-Disease	D014839	7931490
om@@	I-Disease	-1	7931490
it@@	I-Disease	-1	7931490
ing	I-Disease	-1	7931490
in	O	-1	7931490
5@@	O	-1	7931490
7@@	O	-1	7931490
%	O	-1	7931490
to	O	-1	7931490
6@@	O	-1	7931490
0%	O	-1	7931490
of	O	-1	7931490
patients	O	-1	7931490
who	O	-1	7931490
received	O	-1	7931490
cisplatin	B-Chemical	D002945	7931490
at	O	-1	7931490
doses	O	-1	7931490
greater	O	-1	7931490
than	O	-1	7931490
8@@	O	-1	7931490
1	O	-1	7931490
mg/m@@	O	-1	7931490
2	O	-1	7931490
and	O	-1	7931490
tot@@	O	-1	7931490
ally	O	-1	7931490
prevent@@	O	-1	7931490
ed	O	-1	7931490
v@@	B-Disease	D014839	7931490
om@@	I-Disease	-1	7931490
it@@	I-Disease	-1	7931490
ing	I-Disease	-1	7931490
in	O	-1	7931490
4@@	O	-1	7931490
0%	O	-1	7931490
to	O	-1	7931490
4@@	O	-1	7931490
7@@	O	-1	7931490
%	O	-1	7931490
of	O	-1	7931490
patients.	O	-1	7931490
There	O	-1	7931490
were	O	-1	7931490
no	O	-1	7931490
statis@@	O	-1	7931490
tically	O	-1	7931490
significant	O	-1	7931490
differences	O	-1	7931490
in	O	-1	7931490
efficacy	O	-1	7931490
between	O	-1	7931490
the	O	-1	7931490
10-@@	O	-1	7931490
microgram@@	O	-1	7931490
s/@@	O	-1	7931490
k@@	O	-1	7931490
g	O	-1	7931490
dose	O	-1	7931490
and	O	-1	7931490
the	O	-1	7931490
20@@	O	-1	7931490
-	O	-1	7931490
and	O	-1	7931490
4@@	O	-1	7931490
0-@@	O	-1	7931490
microgram@@	O	-1	7931490
s/@@	O	-1	7931490
k@@	O	-1	7931490
g	O	-1	7931490
dos@@	O	-1	7931490
es.	O	-1	7931490
G@@	B-Chemical	D017829	7931490
ran@@	I-Chemical	-1	7931490
i@@	I-Chemical	-1	7931490
se@@	I-Chemical	-1	7931490
tro@@	I-Chemical	-1	7931490
n	I-Chemical	-1	7931490
was	O	-1	7931490
well	O	-1	7931490
toler@@	O	-1	7931490
ated	O	-1	7931490
at	O	-1	7931490
all	O	-1	7931490
dos@@	O	-1	7931490
es.	O	-1	7931490

Ad@@	O	-1	7949506
verse	O	-1	7949506
inter@@	O	-1	7949506
action	O	-1	7949506
between	O	-1	7949506
clonidine	B-Chemical	D003000	7949506
and	O	-1	7949506
verap@@	B-Chemical	D014700	7949506
ami@@	I-Chemical	-1	7949506
l	I-Chemical	-1	7949506
.	O	-1	7949506
OBJECTIVE:	O	-1	7949506
To	O	-1	7949506
report	O	-1	7949506
two	O	-1	7949506
cases	O	-1	7949506
of	O	-1	7949506
a	O	-1	7949506
possible	O	-1	7949506
adverse	O	-1	7949506
inter@@	O	-1	7949506
action	O	-1	7949506
between	O	-1	7949506
clonidine	B-Chemical	D003000	7949506
and	O	-1	7949506
verap@@	B-Chemical	D014700	7949506
ami@@	I-Chemical	-1	7949506
l	I-Chemical	-1	7949506
result@@	O	-1	7949506
ing	O	-1	7949506
in	O	-1	7949506
atri@@	B-Disease	D054537	7949506
o@@	I-Disease	-1	7949506
ventricular	I-Disease	-1	7949506
(A@@	I-Disease	-1	7949506
V@@	I-Disease	-1	7949506
)	I-Disease	-1	7949506
bloc@@	I-Disease	-1	7949506
k	I-Disease	-1	7949506
in	O	-1	7949506
both	O	-1	7949506
patients	O	-1	7949506
and	O	-1	7949506
severe	O	-1	7949506
hypotension	B-Disease	D007022	7949506
in	O	-1	7949506
one	O	-1	7949506
patient@@	O	-1	7949506
.	O	-1	7949506
CA@@	O	-1	7949506
S@@	O	-1	7949506
E	O	-1	7949506
S@@	O	-1	7949506
U@@	O	-1	7949506
M@@	O	-1	7949506
MA@@	O	-1	7949506
R@@	O	-1	7949506
I@@	O	-1	7949506
E@@	O	-1	7949506
S:	O	-1	7949506
A	O	-1	7949506
5@@	O	-1	7949506
4-@@	O	-1	7949506
year-old	O	-1	7949506
woman	O	-1	7949506
with	O	-1	7949506
hyper@@	B-Disease	D006929	7949506
al@@	I-Disease	-1	7949506
do@@	I-Disease	-1	7949506
ster@@	I-Disease	-1	7949506
on@@	I-Disease	-1	7949506
ism	I-Disease	-1	7949506
was	O	-1	7949506
treated	O	-1	7949506
with	O	-1	7949506
verap@@	B-Chemical	D014700	7949506
ami@@	I-Chemical	-1	7949506
l	I-Chemical	-1	7949506
4@@	O	-1	7949506
8@@	O	-1	7949506
0	O	-1	7949506
mg/@@	O	-1	7949506
d	O	-1	7949506
and	O	-1	7949506
s@@	B-Chemical	D013148	7949506
pi@@	I-Chemical	-1	7949506
ron@@	I-Chemical	-1	7949506
ol@@	I-Chemical	-1	7949506
act@@	I-Chemical	-1	7949506
one	I-Chemical	-1	7949506
100	O	-1	7949506
mg/@@	O	-1	7949506
d.	O	-1	7949506
After	O	-1	7949506
the	O	-1	7949506
addition	O	-1	7949506
of	O	-1	7949506
a	O	-1	7949506
minim@@	O	-1	7949506
al	O	-1	7949506
dose	O	-1	7949506
of	O	-1	7949506
clonidine	B-Chemical	D003000	7949506
(0.@@	O	-1	7949506
15	O	-1	7949506
mg	O	-1	7949506
b@@	O	-1	7949506
id@@	O	-1	7949506
),	O	-1	7949506
sh@@	O	-1	7949506
e	O	-1	7949506
developed	O	-1	7949506
complete	O	-1	7949506
A@@	B-Disease	D054537	7949506
V	I-Disease	-1	7949506
bloc@@	I-Disease	-1	7949506
k	I-Disease	-1	7949506
and	O	-1	7949506
severe	O	-1	7949506
hypotension	B-Disease	D007022	7949506
,	O	-1	7949506
which	O	-1	7949506
resol@@	O	-1	7949506
ved	O	-1	7949506
up@@	O	-1	7949506
on	O	-1	7949506
cess@@	O	-1	7949506
ation	O	-1	7949506
of	O	-1	7949506
all	O	-1	7949506
medic@@	O	-1	7949506
ations.	O	-1	7949506
A	O	-1	7949506
6@@	O	-1	7949506
5-@@	O	-1	7949506
year-old	O	-1	7949506
woman	O	-1	7949506
was	O	-1	7949506
treated	O	-1	7949506
with	O	-1	7949506
exten@@	O	-1	7949506
de@@	O	-1	7949506
d-@@	O	-1	7949506
release	O	-1	7949506
verap@@	B-Chemical	D014700	7949506
ami@@	I-Chemical	-1	7949506
l	I-Chemical	-1	7949506
2@@	O	-1	7949506
40	O	-1	7949506
mg/@@	O	-1	7949506
d.	O	-1	7949506
After	O	-1	7949506
the	O	-1	7949506
addition	O	-1	7949506
of	O	-1	7949506
clonidine	B-Chemical	D003000	7949506
0.@@	O	-1	7949506
15	O	-1	7949506
mg	O	-1	7949506
b@@	O	-1	7949506
id	O	-1	7949506
sh@@	O	-1	7949506
e	O	-1	7949506
developed	O	-1	7949506
complete	O	-1	7949506
A@@	B-Disease	D054537	7949506
V	I-Disease	-1	7949506
bloc@@	I-Disease	-1	7949506
k	I-Disease	-1	7949506
,	O	-1	7949506
which	O	-1	7949506
resol@@	O	-1	7949506
ved	O	-1	7949506
after	O	-1	7949506
all	O	-1	7949506
therapy	O	-1	7949506
was	O	-1	7949506
sto@@	O	-1	7949506
pp@@	O	-1	7949506
ed.	O	-1	7949506
D@@	O	-1	7949506
I@@	O	-1	7949506
S@@	O	-1	7949506
C@@	O	-1	7949506
US@@	O	-1	7949506
S@@	O	-1	7949506
ION@@	O	-1	7949506
:	O	-1	7949506
An	O	-1	7949506
adverse	O	-1	7949506
inter@@	O	-1	7949506
action	O	-1	7949506
between	O	-1	7949506
clonidine	B-Chemical	D003000	7949506
and	O	-1	7949506
verap@@	B-Chemical	D014700	7949506
ami@@	I-Chemical	-1	7949506
l	I-Chemical	-1	7949506
has	O	-1	7949506
not	O	-1	7949506
been	O	-1	7949506
reported	O	-1	7949506
previ@@	O	-1	7949506
ous@@	O	-1	7949506
ly.	O	-1	7949506
We	O	-1	7949506
describe	O	-1	7949506
two	O	-1	7949506
such	O	-1	7949506
cases	O	-1	7949506
and	O	-1	7949506
discus@@	O	-1	7949506
s	O	-1	7949506
the	O	-1	7949506
various	O	-1	7949506
mechanisms	O	-1	7949506
that	O	-1	7949506
might	O	-1	7949506
cause	O	-1	7949506
such	O	-1	7949506
an	O	-1	7949506
inter@@	O	-1	7949506
ac@@	O	-1	7949506
tion.	O	-1	7949506
Clin@@	O	-1	7949506
ici@@	O	-1	7949506
ans	O	-1	7949506
should	O	-1	7949506
be	O	-1	7949506
ac@@	O	-1	7949506
qu@@	O	-1	7949506
a@@	O	-1	7949506
int@@	O	-1	7949506
ed	O	-1	7949506
with	O	-1	7949506
this	O	-1	7949506
possib@@	O	-1	7949506
ly	O	-1	7949506
f@@	O	-1	7949506
atal	O	-1	7949506
inter@@	O	-1	7949506
action	O	-1	7949506
between	O	-1	7949506
two	O	-1	7949506
common@@	O	-1	7949506
ly	O	-1	7949506
used	O	-1	7949506
anti@@	O	-1	7949506
hypertensive	O	-1	7949506
drug@@	O	-1	7949506
s.	O	-1	7949506
CONCLUSIONS:	O	-1	7949506
C@@	O	-1	7949506
au@@	O	-1	7949506
tion	O	-1	7949506
is	O	-1	7949506
recomm@@	O	-1	7949506
en@@	O	-1	7949506
ded	O	-1	7949506
in	O	-1	7949506
combin@@	O	-1	7949506
ing	O	-1	7949506
clonidine	B-Chemical	D003000	7949506
and	O	-1	7949506
verap@@	B-Chemical	D014700	7949506
ami@@	I-Chemical	-1	7949506
l	I-Chemical	-1	7949506
therapy,	O	-1	7949506
even	O	-1	7949506
in	O	-1	7949506
patients	O	-1	7949506
who	O	-1	7949506
d@@	O	-1	7949506
o	O	-1	7949506
not	O	-1	7949506
have	O	-1	7949506
s@@	O	-1	7949506
in@@	O	-1	7949506
us	O	-1	7949506
or	O	-1	7949506
A@@	O	-1	7949506
V	O	-1	7949506
no@@	O	-1	7949506
de	O	-1	7949506
dysfunc@@	O	-1	7949506
tion.	O	-1	7949506
The	O	-1	7949506
two	O	-1	7949506
drugs	O	-1	7949506
may	O	-1	7949506
ac@@	O	-1	7949506
t	O	-1	7949506
syn@@	O	-1	7949506
erg@@	O	-1	7949506
is@@	O	-1	7949506
tically	O	-1	7949506
on	O	-1	7949506
both	O	-1	7949506
the	O	-1	7949506
A@@	O	-1	7949506
V	O	-1	7949506
no@@	O	-1	7949506
de	O	-1	7949506
and	O	-1	7949506
the	O	-1	7949506
peripheral	O	-1	7949506
cir@@	O	-1	7949506
cul@@	O	-1	7949506
ation.	O	-1	7949506

Ph@@	O	-1	7967231
armac@@	O	-1	7967231
ological	O	-1	7967231
studies	O	-1	7967231
on	O	-1	7967231
a	O	-1	7967231
new	O	-1	7967231
di@@	B-Chemical	-1	7967231
hydro@@	I-Chemical	-1	7967231
thi@@	I-Chemical	-1	7967231
en@@	I-Chemical	-1	7967231
o@@	I-Chemical	-1	7967231
pyri@@	I-Chemical	-1	7967231
d@@	I-Chemical	-1	7967231
ine	I-Chemical	-1	7967231
calcium	I-Chemical	-1	7967231
antagonist@@	O	-1	7967231
,	O	-1	7967231
S@@	B-Chemical	C059447	7967231
-@@	I-Chemical	-1	7967231
3@@	I-Chemical	-1	7967231
1@@	I-Chemical	-1	7967231
2-@@	I-Chemical	-1	7967231
d	I-Chemical	-1	7967231
.	O	-1	7967231
5@@	O	-1	7967231
th	O	-1	7967231
com@@	O	-1	7967231
mun@@	O	-1	7967231
ic@@	O	-1	7967231
ation@@	O	-1	7967231
:	O	-1	7967231
anti@@	O	-1	7967231
convul@@	O	-1	7967231
s@@	O	-1	7967231
ant	O	-1	7967231
effects	O	-1	7967231
in	O	-1	7967231
mice.	O	-1	7967231
S@@	B-Chemical	C059447	7967231
-@@	I-Chemical	-1	7967231
3@@	I-Chemical	-1	7967231
12	I-Chemical	-1	7967231
,	O	-1	7967231
S@@	B-Chemical	C059447	7967231
-@@	I-Chemical	-1	7967231
3@@	I-Chemical	-1	7967231
1@@	I-Chemical	-1	7967231
2-@@	I-Chemical	-1	7967231
d	I-Chemical	-1	7967231
,	O	-1	7967231
but	O	-1	7967231
not	O	-1	7967231
S@@	B-Chemical	-1	7967231
-@@	I-Chemical	-1	7967231
3@@	I-Chemical	-1	7967231
1@@	I-Chemical	-1	7967231
2-@@	I-Chemical	-1	7967231
l	I-Chemical	-1	7967231
,	O	-1	7967231
L-@@	O	-1	7967231
type	O	-1	7967231
calcium	B-Chemical	D002118	7967231
channel	O	-1	7967231
antagonist@@	O	-1	7967231
s,	O	-1	7967231
showed	O	-1	7967231
anti@@	O	-1	7967231
convul@@	O	-1	7967231
s@@	O	-1	7967231
ant	O	-1	7967231
effects	O	-1	7967231
on	O	-1	7967231
the	O	-1	7967231
a@@	B-Disease	D020195	7967231
udi@@	I-Disease	-1	7967231
o@@	I-Disease	-1	7967231
genic	I-Disease	-1	7967231
t@@	I-Disease	-1	7967231
onic	I-Disease	-1	7967231
convul@@	I-Disease	-1	7967231
sions	I-Disease	-1	7967231
in	O	-1	7967231
D@@	O	-1	7967231
BA@@	O	-1	7967231
/@@	O	-1	7967231
2	O	-1	7967231
mic@@	O	-1	7967231
e@@	O	-1	7967231
;	O	-1	7967231
and	O	-1	7967231
their	O	-1	7967231
E@@	O	-1	7967231
D@@	O	-1	7967231
50	O	-1	7967231
values	O	-1	7967231
were	O	-1	7967231
1@@	O	-1	7967231
8.@@	O	-1	7967231
4	O	-1	7967231
(1@@	O	-1	7967231
2.@@	O	-1	7967231
8@@	O	-1	7967231
-@@	O	-1	7967231
2@@	O	-1	7967231
7.@@	O	-1	7967231
1)	O	-1	7967231
mg/kg@@	O	-1	7967231
,	O	-1	7967231
p.@@	O	-1	7967231
o@@	O	-1	7967231
.	O	-1	7967231
and	O	-1	7967231
1@@	O	-1	7967231
5.@@	O	-1	7967231
0	O	-1	7967231
(1@@	O	-1	7967231
0.@@	O	-1	7967231
2-@@	O	-1	7967231
2@@	O	-1	7967231
3.@@	O	-1	7967231
7@@	O	-1	7967231
)	O	-1	7967231
mg/kg@@	O	-1	7967231
,	O	-1	7967231
p.@@	O	-1	7967231
o@@	O	-1	7967231
.,	O	-1	7967231
respectivel@@	O	-1	7967231
y,	O	-1	7967231
while	O	-1	7967231
that	O	-1	7967231
of	O	-1	7967231
f@@	B-Chemical	D005444	7967231
l@@	I-Chemical	-1	7967231
un@@	I-Chemical	-1	7967231
ar@@	I-Chemical	-1	7967231
iz@@	I-Chemical	-1	7967231
ine	I-Chemical	-1	7967231
was	O	-1	7967231
3@@	O	-1	7967231
4.@@	O	-1	7967231
0	O	-1	7967231
(2@@	O	-1	7967231
6.@@	O	-1	7967231
0-@@	O	-1	7967231
4@@	O	-1	7967231
4.@@	O	-1	7967231
8@@	O	-1	7967231
)	O	-1	7967231
mg/kg@@	O	-1	7967231
,	O	-1	7967231
p.@@	O	-1	7967231
o@@	O	-1	7967231
.	O	-1	7967231
Although	O	-1	7967231
moder@@	O	-1	7967231
ate	O	-1	7967231
anti@@	O	-1	7967231
convul@@	O	-1	7967231
s@@	O	-1	7967231
ant	O	-1	7967231
effects	O	-1	7967231
of	O	-1	7967231
S@@	B-Chemical	C059447	7967231
-@@	I-Chemical	-1	7967231
3@@	I-Chemical	-1	7967231
1@@	I-Chemical	-1	7967231
2-@@	I-Chemical	-1	7967231
d	I-Chemical	-1	7967231
in	O	-1	7967231
higher	O	-1	7967231
doses	O	-1	7967231
were	O	-1	7967231
observed	O	-1	7967231
against	O	-1	7967231
the	O	-1	7967231
clon@@	O	-1	7967231
ic	O	-1	7967231
convul@@	B-Disease	D012640	7967231
sions	I-Disease	-1	7967231
induced	O	-1	7967231
by	O	-1	7967231
pent@@	B-Chemical	D010433	7967231
yl@@	I-Chemical	-1	7967231
en@@	I-Chemical	-1	7967231
e@@	I-Chemical	-1	7967231
te@@	I-Chemical	-1	7967231
tra@@	I-Chemical	-1	7967231
z@@	I-Chemical	-1	7967231
ole	I-Chemical	-1	7967231
(@@	O	-1	7967231
8@@	O	-1	7967231
5	O	-1	7967231
mg/kg@@	O	-1	7967231
,	O	-1	7967231
s@@	O	-1	7967231
.@@	O	-1	7967231
c@@	O	-1	7967231
.)	O	-1	7967231
or	O	-1	7967231
be@@	B-Chemical	D001534	7967231
me@@	I-Chemical	-1	7967231
g@@	I-Chemical	-1	7967231
ri@@	I-Chemical	-1	7967231
de	I-Chemical	-1	7967231
(@@	O	-1	7967231
40	O	-1	7967231
mg/kg@@	O	-1	7967231
,	O	-1	7967231
s@@	O	-1	7967231
.@@	O	-1	7967231
c@@	O	-1	7967231
.@@	O	-1	7967231
),	O	-1	7967231
no	O	-1	7967231
effects	O	-1	7967231
were	O	-1	7967231
observed	O	-1	7967231
in	O	-1	7967231
convul@@	B-Disease	D012640	7967231
sions	I-Disease	-1	7967231
induced	O	-1	7967231
by	O	-1	7967231
N@@	B-Chemical	D016202	7967231
-@@	I-Chemical	-1	7967231
methyl@@	I-Chemical	-1	7967231
-@@	I-Chemical	-1	7967231
D-@@	I-Chemical	-1	7967231
as@@	I-Chemical	-1	7967231
part@@	I-Chemical	-1	7967231
ate	I-Chemical	-1	7967231
,	O	-1	7967231
p@@	B-Chemical	D010852	7967231
ic@@	I-Chemical	-1	7967231
ro@@	I-Chemical	-1	7967231
tox@@	I-Chemical	-1	7967231
in	I-Chemical	-1	7967231
,	O	-1	7967231
or	O	-1	7967231
electro@@	O	-1	7967231
sh@@	O	-1	7967231
oc@@	O	-1	7967231
k	O	-1	7967231
in	O	-1	7967231
S@@	O	-1	7967231
l@@	O	-1	7967231
c@@	O	-1	7967231
:@@	O	-1	7967231
d@@	O	-1	7967231
d@@	O	-1	7967231
Y	O	-1	7967231
mice.	O	-1	7967231
S@@	B-Chemical	C059447	7967231
-@@	I-Chemical	-1	7967231
3@@	I-Chemical	-1	7967231
1@@	I-Chemical	-1	7967231
2-@@	I-Chemical	-1	7967231
d	I-Chemical	-1	7967231
may	O	-1	7967231
be	O	-1	7967231
use@@	O	-1	7967231
ful	O	-1	7967231
in	O	-1	7967231
the	O	-1	7967231
therapy	O	-1	7967231
of	O	-1	7967231
cer@@	O	-1	7967231
t@@	O	-1	7967231
ain	O	-1	7967231
typ@@	O	-1	7967231
es	O	-1	7967231
of	O	-1	7967231
human	O	-1	7967231
epilep@@	B-Disease	D004827	7967231
sy	I-Disease	-1	7967231
.	O	-1	7967231

T@@	O	-1	8096565
ran@@	O	-1	8096565
sm@@	O	-1	8096565
ural	O	-1	8096565
myocardial	B-Disease	D009203	8096565
infarction	I-Disease	-1	8096565
with	O	-1	8096565
su@@	B-Chemical	D018170	8096565
mat@@	I-Chemical	-1	8096565
ript@@	I-Chemical	-1	8096565
an	I-Chemical	-1	8096565
.	O	-1	8096565
F@@	O	-1	8096565
or	O	-1	8096565
su@@	B-Chemical	D018170	8096565
mat@@	I-Chemical	-1	8096565
ript@@	I-Chemical	-1	8096565
an	I-Chemical	-1	8096565
,	O	-1	8096565
ti@@	O	-1	8096565
gh@@	O	-1	8096565
t@@	O	-1	8096565
ness	O	-1	8096565
in	O	-1	8096565
the	O	-1	8096565
ch@@	O	-1	8096565
est	O	-1	8096565
caused	O	-1	8096565
by	O	-1	8096565
an	O	-1	8096565
un@@	O	-1	8096565
known	O	-1	8096565
mechanism	O	-1	8096565
has	O	-1	8096565
been	O	-1	8096565
reported	O	-1	8096565
in	O	-1	8096565
3-@@	O	-1	8096565
5%	O	-1	8096565
of	O	-1	8096565
us@@	O	-1	8096565
ers.	O	-1	8096565
We	O	-1	8096565
describe	O	-1	8096565
a	O	-1	8096565
4@@	O	-1	8096565
7-@@	O	-1	8096565
year-old	O	-1	8096565
woman	O	-1	8096565
with	O	-1	8096565
an	O	-1	8096565
acute	O	-1	8096565
myocardial	B-Disease	D009203	8096565
infarction	I-Disease	-1	8096565
after	O	-1	8096565
administration	O	-1	8096565
of	O	-1	8096565
su@@	B-Chemical	D018170	8096565
mat@@	I-Chemical	-1	8096565
ript@@	I-Chemical	-1	8096565
an	I-Chemical	-1	8096565
6	O	-1	8096565
mg	O	-1	8096565
sub@@	O	-1	8096565
c@@	O	-1	8096565
ut@@	O	-1	8096565
ane@@	O	-1	8096565
ously	O	-1	8096565
for	O	-1	8096565
cl@@	B-Disease	D003027	8096565
ust@@	I-Disease	-1	8096565
er	I-Disease	-1	8096565
headac@@	I-Disease	-1	8096565
he	I-Disease	-1	8096565
.	O	-1	8096565
The	O	-1	8096565
patient	O	-1	8096565
had	O	-1	8096565
no	O	-1	8096565
hist@@	O	-1	8096565
ory	O	-1	8096565
of	O	-1	8096565
underlying	O	-1	8096565
is@@	B-Disease	D017202	8096565
ch@@	I-Disease	-1	8096565
a@@	I-Disease	-1	8096565
em@@	I-Disease	-1	8096565
ic	I-Disease	-1	8096565
heart	I-Disease	-1	8096565
disease	I-Disease	-1	8096565
or	O	-1	8096565
P@@	B-Disease	D000788	8096565
r@@	I-Disease	-1	8096565
in@@	I-Disease	-1	8096565
z@@	I-Disease	-1	8096565
met@@	I-Disease	-1	8096565
al@@	I-Disease	-1	8096565
's	I-Disease	-1	8096565
ang@@	I-Disease	-1	8096565
in@@	I-Disease	-1	8096565
a	I-Disease	-1	8096565
.	O	-1	8096565
S@@	O	-1	8096565
he	O	-1	8096565
reco@@	O	-1	8096565
vered	O	-1	8096565
without	O	-1	8096565
complic@@	O	-1	8096565
ations.	O	-1	8096565

F@@	B-Chemical	D005442	8135424
lu@@	I-Chemical	-1	8135424
ma@@	I-Chemical	-1	8135424
z@@	I-Chemical	-1	8135424
en@@	I-Chemical	-1	8135424
il	I-Chemical	-1	8135424
induc@@	O	-1	8135424
es	O	-1	8135424
seizures	B-Disease	D012640	8135424
and	O	-1	8135424
death	O	-1	8135424
in	O	-1	8135424
mi@@	O	-1	8135424
x@@	O	-1	8135424
ed	O	-1	8135424
cocaine	B-Chemical	D003042	8135424
-	O	-1	8135424
di@@	B-Chemical	D003975	8135424
az@@	I-Chemical	-1	8135424
epam	I-Chemical	-1	8135424
in@@	O	-1	8135424
toxic@@	O	-1	8135424
ations.	O	-1	8135424
S@@	O	-1	8135424
T@@	O	-1	8135424
U@@	O	-1	8135424
D@@	O	-1	8135424
Y	O	-1	8135424
H@@	O	-1	8135424
Y@@	O	-1	8135424
P@@	O	-1	8135424
O@@	O	-1	8135424
T@@	O	-1	8135424
H@@	O	-1	8135424
ES@@	O	-1	8135424
I@@	O	-1	8135424
S:	O	-1	8135424
Ad@@	O	-1	8135424
minist@@	O	-1	8135424
ration	O	-1	8135424
of	O	-1	8135424
the	O	-1	8135424
b@@	B-Chemical	D001569	8135424
enz@@	I-Chemical	-1	8135424
odi@@	I-Chemical	-1	8135424
azepine	I-Chemical	-1	8135424
antagonist	O	-1	8135424
flu@@	B-Chemical	D005442	8135424
ma@@	I-Chemical	-1	8135424
z@@	I-Chemical	-1	8135424
en@@	I-Chemical	-1	8135424
il	I-Chemical	-1	8135424
may	O	-1	8135424
un@@	O	-1	8135424
mas@@	O	-1	8135424
k	O	-1	8135424
seizures	B-Disease	D012640	8135424
in	O	-1	8135424
mi@@	O	-1	8135424
x@@	O	-1	8135424
ed	O	-1	8135424
cocaine	B-Chemical	D003042	8135424
-	O	-1	8135424
b@@	B-Chemical	D001569	8135424
enz@@	I-Chemical	-1	8135424
odi@@	I-Chemical	-1	8135424
azepine	I-Chemical	-1	8135424
in@@	O	-1	8135424
toxic@@	O	-1	8135424
ation.	O	-1	8135424
D@@	O	-1	8135424
ES@@	O	-1	8135424
I@@	O	-1	8135424
G@@	O	-1	8135424
N@@	O	-1	8135424
:	O	-1	8135424
M@@	O	-1	8135424
al@@	O	-1	8135424
e	O	-1	8135424
S@@	O	-1	8135424
pra@@	O	-1	8135424
gu@@	O	-1	8135424
e-@@	O	-1	8135424
D@@	O	-1	8135424
aw@@	O	-1	8135424
le@@	O	-1	8135424
y	O	-1	8135424
rats	O	-1	8135424
received	O	-1	8135424
100	O	-1	8135424
mg/kg	O	-1	8135424
cocaine	B-Chemical	D003042	8135424
I@@	O	-1	8135424
P	O	-1	8135424
al@@	O	-1	8135424
one,	O	-1	8135424
5	O	-1	8135424
mg/kg	O	-1	8135424
di@@	B-Chemical	D003975	8135424
az@@	I-Chemical	-1	8135424
epam	I-Chemical	-1	8135424
al@@	O	-1	8135424
one,	O	-1	8135424
or	O	-1	8135424
a	O	-1	8135424
combination	O	-1	8135424
of	O	-1	8135424
di@@	B-Chemical	D003975	8135424
az@@	I-Chemical	-1	8135424
epam	I-Chemical	-1	8135424
and	O	-1	8135424
cocaine	B-Chemical	D003042	8135424
.	O	-1	8135424
Th@@	O	-1	8135424
ree	O	-1	8135424
minutes	O	-1	8135424
lat@@	O	-1	8135424
er,	O	-1	8135424
groups	O	-1	8135424
were	O	-1	8135424
ch@@	O	-1	8135424
all@@	O	-1	8135424
en@@	O	-1	8135424
g@@	O	-1	8135424
ed	O	-1	8135424
with	O	-1	8135424
ve@@	O	-1	8135424
h@@	O	-1	8135424
ic@@	O	-1	8135424
le	O	-1	8135424
or	O	-1	8135424
flu@@	B-Chemical	D005442	8135424
ma@@	I-Chemical	-1	8135424
z@@	I-Chemical	-1	8135424
en@@	I-Chemical	-1	8135424
il	I-Chemical	-1	8135424
5	O	-1	8135424
or	O	-1	8135424
10	O	-1	8135424
mg/kg	O	-1	8135424
I@@	O	-1	8135424
P@@	O	-1	8135424
.	O	-1	8135424
An@@	O	-1	8135424
im@@	O	-1	8135424
al	O	-1	8135424
behavi@@	O	-1	8135424
or@@	O	-1	8135424
,	O	-1	8135424
seizures	B-Disease	D012640	8135424
(@@	O	-1	8135424
time	O	-1	8135424
to	O	-1	8135424
and	O	-1	8135424
inc@@	O	-1	8135424
id@@	O	-1	8135424
ence@@	O	-1	8135424
),	O	-1	8135424
death	O	-1	8135424
(@@	O	-1	8135424
time	O	-1	8135424
to	O	-1	8135424
and	O	-1	8135424
inc@@	O	-1	8135424
id@@	O	-1	8135424
ence@@	O	-1	8135424
),	O	-1	8135424
and	O	-1	8135424
cor@@	O	-1	8135424
tical	O	-1	8135424
E@@	O	-1	8135424
E@@	O	-1	8135424
G	O	-1	8135424
trac@@	O	-1	8135424
ings	O	-1	8135424
were	O	-1	8135424
recor@@	O	-1	8135424
de@@	O	-1	8135424
d.	O	-1	8135424
IN@@	O	-1	8135424
TE@@	O	-1	8135424
R@@	O	-1	8135424
V@@	O	-1	8135424
E@@	O	-1	8135424
N@@	O	-1	8135424
T@@	O	-1	8135424
ION@@	O	-1	8135424
S:	O	-1	8135424
Ad@@	O	-1	8135424
minist@@	O	-1	8135424
ration	O	-1	8135424
of	O	-1	8135424
flu@@	B-Chemical	D005442	8135424
ma@@	I-Chemical	-1	8135424
z@@	I-Chemical	-1	8135424
en@@	I-Chemical	-1	8135424
il	I-Chemical	-1	8135424
to	O	-1	8135424
animals	O	-1	8135424
after	O	-1	8135424
they	O	-1	8135424
had	O	-1	8135424
received	O	-1	8135424
a	O	-1	8135424
combination	O	-1	8135424
dose	O	-1	8135424
of	O	-1	8135424
cocaine	B-Chemical	D003042	8135424
and	O	-1	8135424
di@@	B-Chemical	D003975	8135424
az@@	I-Chemical	-1	8135424
epam	I-Chemical	-1	8135424
.	O	-1	8135424
RESULTS:	O	-1	8135424
In	O	-1	8135424
group	O	-1	8135424
1,	O	-1	8135424
animals	O	-1	8135424
received	O	-1	8135424
cocaine	B-Chemical	D003042	8135424
followed	O	-1	8135424
by	O	-1	8135424
ve@@	O	-1	8135424
h@@	O	-1	8135424
ic@@	O	-1	8135424
le@@	O	-1	8135424
.	O	-1	8135424
This	O	-1	8135424
resulted	O	-1	8135424
in	O	-1	8135424
10@@	O	-1	8135424
0%	O	-1	8135424
develop@@	O	-1	8135424
ing	O	-1	8135424
seizures	B-Disease	D012640	8135424
and	O	-1	8135424
de@@	O	-1	8135424
ath@@	O	-1	8135424
.	O	-1	8135424
Group	O	-1	8135424
2	O	-1	8135424
received	O	-1	8135424
di@@	B-Chemical	D003975	8135424
az@@	I-Chemical	-1	8135424
epam	I-Chemical	-1	8135424
alone	O	-1	8135424
followed	O	-1	8135424
by	O	-1	8135424
ve@@	O	-1	8135424
h@@	O	-1	8135424
ic@@	O	-1	8135424
le@@	O	-1	8135424
.	O	-1	8135424
An@@	O	-1	8135424
im@@	O	-1	8135424
als	O	-1	8135424
b@@	O	-1	8135424
ec@@	O	-1	8135424
am@@	O	-1	8135424
e	O	-1	8135424
s@@	O	-1	8135424
om@@	O	-1	8135424
n@@	O	-1	8135424
ol@@	O	-1	8135424
ent	O	-1	8135424
and	O	-1	8135424
n@@	O	-1	8135424
one	O	-1	8135424
di@@	O	-1	8135424
ed.	O	-1	8135424
Group	O	-1	8135424
3	O	-1	8135424
received	O	-1	8135424
di@@	B-Chemical	D003975	8135424
az@@	I-Chemical	-1	8135424
epam	I-Chemical	-1	8135424
followed	O	-1	8135424
by	O	-1	8135424
5	O	-1	8135424
mg/kg	O	-1	8135424
flu@@	B-Chemical	D005442	8135424
ma@@	I-Chemical	-1	8135424
z@@	I-Chemical	-1	8135424
en@@	I-Chemical	-1	8135424
il	I-Chemical	-1	8135424
.	O	-1	8135424
An@@	O	-1	8135424
im@@	O	-1	8135424
als	O	-1	8135424
b@@	O	-1	8135424
ec@@	O	-1	8135424
am@@	O	-1	8135424
e	O	-1	8135424
s@@	O	-1	8135424
om@@	O	-1	8135424
n@@	O	-1	8135424
ol@@	O	-1	8135424
ent	O	-1	8135424
after	O	-1	8135424
di@@	B-Chemical	D003975	8135424
az@@	I-Chemical	-1	8135424
epam	I-Chemical	-1	8135424
and	O	-1	8135424
then	O	-1	8135424
active	O	-1	8135424
after	O	-1	8135424
flu@@	B-Chemical	D005442	8135424
ma@@	I-Chemical	-1	8135424
z@@	I-Chemical	-1	8135424
en@@	I-Chemical	-1	8135424
il	I-Chemical	-1	8135424
administr@@	O	-1	8135424
ation.	O	-1	8135424
In	O	-1	8135424
group	O	-1	8135424
4@@	O	-1	8135424
,	O	-1	8135424
a	O	-1	8135424
combination	O	-1	8135424
of	O	-1	8135424
cocaine	B-Chemical	D003042	8135424
and	O	-1	8135424
di@@	B-Chemical	D003975	8135424
az@@	I-Chemical	-1	8135424
epam	I-Chemical	-1	8135424
was	O	-1	8135424
administered	O	-1	8135424
sim@@	O	-1	8135424
ult@@	O	-1	8135424
ane@@	O	-1	8135424
ous@@	O	-1	8135424
ly.	O	-1	8135424
This	O	-1	8135424
resulted	O	-1	8135424
in	O	-1	8135424
no	O	-1	8135424
over@@	O	-1	8135424
t	O	-1	8135424
or	O	-1	8135424
E@@	O	-1	8135424
E@@	O	-1	8135424
G@@	O	-1	8135424
-@@	O	-1	8135424
det@@	O	-1	8135424
ect@@	O	-1	8135424
able	O	-1	8135424
seizures	B-Disease	D012640	8135424
and	O	-1	8135424
a	O	-1	8135424
50@@	O	-1	8135424
%	O	-1	8135424
incidence	O	-1	8135424
of	O	-1	8135424
de@@	O	-1	8135424
ath@@	O	-1	8135424
.	O	-1	8135424
Group	O	-1	8135424
5	O	-1	8135424
received	O	-1	8135424
a	O	-1	8135424
similar	O	-1	8135424
combination	O	-1	8135424
of	O	-1	8135424
cocaine	B-Chemical	D003042	8135424
and	O	-1	8135424
di@@	B-Chemical	D003975	8135424
az@@	I-Chemical	-1	8135424
epam	I-Chemical	-1	8135424
,	O	-1	8135424
followed	O	-1	8135424
lat@@	O	-1	8135424
er	O	-1	8135424
by	O	-1	8135424
5	O	-1	8135424
mg/kg	O	-1	8135424
flu@@	B-Chemical	D005442	8135424
ma@@	I-Chemical	-1	8135424
z@@	I-Chemical	-1	8135424
en@@	I-Chemical	-1	8135424
il	I-Chemical	-1	8135424
.	O	-1	8135424
This	O	-1	8135424
resulted	O	-1	8135424
in	O	-1	8135424
an	O	-1	8135424
increased	O	-1	8135424
incidence	O	-1	8135424
of	O	-1	8135424
seizures	B-Disease	D012640	8135424
,	O	-1	8135424
9@@	O	-1	8135424
0%	O	-1	8135424
(P	O	-1	8135424
<	O	-1	8135424
.@@	O	-1	8135424
0@@	O	-1	8135424
1),	O	-1	8135424
and	O	-1	8135424
de@@	O	-1	8135424
ath@@	O	-1	8135424
,	O	-1	8135424
10@@	O	-1	8135424
0%	O	-1	8135424
(P	O	-1	8135424
<	O	-1	8135424
or	O	-1	8135424
=	O	-1	8135424
.@@	O	-1	8135424
0@@	O	-1	8135424
1),	O	-1	8135424
compared	O	-1	8135424
with	O	-1	8135424
group	O	-1	8135424
4@@	O	-1	8135424
.	O	-1	8135424
Group	O	-1	8135424
6	O	-1	8135424
received	O	-1	8135424
cocaine	B-Chemical	D003042	8135424
and	O	-1	8135424
di@@	B-Chemical	D003975	8135424
az@@	I-Chemical	-1	8135424
epam	I-Chemical	-1	8135424
followed	O	-1	8135424
by	O	-1	8135424
10	O	-1	8135424
mg/kg	O	-1	8135424
flu@@	B-Chemical	D005442	8135424
ma@@	I-Chemical	-1	8135424
z@@	I-Chemical	-1	8135424
en@@	I-Chemical	-1	8135424
il	I-Chemical	-1	8135424
.	O	-1	8135424
This	O	-1	8135424
also	O	-1	8135424
resulted	O	-1	8135424
in	O	-1	8135424
an	O	-1	8135424
increased	O	-1	8135424
incidence	O	-1	8135424
of	O	-1	8135424
seizures	B-Disease	D012640	8135424
,	O	-1	8135424
9@@	O	-1	8135424
0%	O	-1	8135424
(P	O	-1	8135424
<	O	-1	8135424
or	O	-1	8135424
=	O	-1	8135424
.@@	O	-1	8135424
0@@	O	-1	8135424
1),	O	-1	8135424
and	O	-1	8135424
de@@	O	-1	8135424
ath@@	O	-1	8135424
,	O	-1	8135424
9@@	O	-1	8135424
0%	O	-1	8135424
(P	O	-1	8135424
<	O	-1	8135424
or	O	-1	8135424
=	O	-1	8135424
.@@	O	-1	8135424
0@@	O	-1	8135424
5@@	O	-1	8135424
),	O	-1	8135424
compared	O	-1	8135424
with	O	-1	8135424
group	O	-1	8135424
4@@	O	-1	8135424
.	O	-1	8135424
CONCLUSION:	O	-1	8135424
F@@	B-Chemical	D005442	8135424
lu@@	I-Chemical	-1	8135424
ma@@	I-Chemical	-1	8135424
z@@	I-Chemical	-1	8135424
en@@	I-Chemical	-1	8135424
il	I-Chemical	-1	8135424
can	O	-1	8135424
un@@	O	-1	8135424
mas@@	O	-1	8135424
k	O	-1	8135424
seizures	B-Disease	D012640	8135424
and	O	-1	8135424
increase	O	-1	8135424
the	O	-1	8135424
incidence	O	-1	8135424
of	O	-1	8135424
death	O	-1	8135424
in	O	-1	8135424
a	O	-1	8135424
model	O	-1	8135424
of	O	-1	8135424
combined	O	-1	8135424
cocaine	B-Chemical	D003042	8135424
-	O	-1	8135424
di@@	B-Chemical	D003975	8135424
az@@	I-Chemical	-1	8135424
epam	I-Chemical	-1	8135424
in@@	O	-1	8135424
toxic@@	O	-1	8135424
ations.	O	-1	8135424

M@@	O	-1	8160791
echan@@	O	-1	8160791
is@@	O	-1	8160791
ms	O	-1	8160791
for	O	-1	8160791
protective	O	-1	8160791
effects	O	-1	8160791
of	O	-1	8160791
free	O	-1	8160791
ra@@	O	-1	8160791
d@@	O	-1	8160791
ical	O	-1	8160791
s@@	O	-1	8160791
ca@@	O	-1	8160791
ven@@	O	-1	8160791
g@@	O	-1	8160791
ers	O	-1	8160791
on	O	-1	8160791
g@@	B-Chemical	D005839	8160791
ent@@	I-Chemical	-1	8160791
am@@	I-Chemical	-1	8160791
icin	I-Chemical	-1	8160791
-@@	O	-1	8160791
mediated	O	-1	8160791
nephro@@	B-Disease	D007674	8160791
pathy	I-Disease	-1	8160791
in	O	-1	8160791
rats.	O	-1	8160791
S@@	O	-1	8160791
t@@	O	-1	8160791
udi@@	O	-1	8160791
es	O	-1	8160791
were	O	-1	8160791
performed	O	-1	8160791
to	O	-1	8160791
ex@@	O	-1	8160791
amine	O	-1	8160791
the	O	-1	8160791
mechanisms	O	-1	8160791
for	O	-1	8160791
the	O	-1	8160791
protective	O	-1	8160791
effects	O	-1	8160791
of	O	-1	8160791
free	O	-1	8160791
ra@@	O	-1	8160791
d@@	O	-1	8160791
ical	O	-1	8160791
s@@	O	-1	8160791
ca@@	O	-1	8160791
ven@@	O	-1	8160791
g@@	O	-1	8160791
ers	O	-1	8160791
on	O	-1	8160791
g@@	B-Chemical	D005839	8160791
ent@@	I-Chemical	-1	8160791
am@@	I-Chemical	-1	8160791
icin	I-Chemical	-1	8160791
(	O	-1	8160791
G@@	B-Chemical	D005839	8160791
M	I-Chemical	-1	8160791
)-@@	O	-1	8160791
mediated	O	-1	8160791
nephro@@	B-Disease	D007674	8160791
pathy	I-Disease	-1	8160791
.	O	-1	8160791
Ad@@	O	-1	8160791
minist@@	O	-1	8160791
ration	O	-1	8160791
of	O	-1	8160791
G@@	B-Chemical	D005839	8160791
M	I-Chemical	-1	8160791
at	O	-1	8160791
40	O	-1	8160791
mg/kg	O	-1	8160791
s@@	O	-1	8160791
c	O	-1	8160791
for	O	-1	8160791
13	O	-1	8160791
days	O	-1	8160791
to	O	-1	8160791
rats	O	-1	8160791
induced	O	-1	8160791
a	O	-1	8160791
significant	O	-1	8160791
reduction	O	-1	8160791
in	O	-1	8160791
renal	O	-1	8160791
blood	O	-1	8160791
flow	O	-1	8160791
(@@	O	-1	8160791
R@@	O	-1	8160791
B@@	O	-1	8160791
F@@	O	-1	8160791
)	O	-1	8160791
and	O	-1	8160791
in@@	O	-1	8160791
ul@@	O	-1	8160791
in	O	-1	8160791
clear@@	O	-1	8160791
ance	O	-1	8160791
(C@@	O	-1	8160791
In@@	O	-1	8160791
)	O	-1	8160791
as	O	-1	8160791
well	O	-1	8160791
as	O	-1	8160791
mark@@	O	-1	8160791
ed	O	-1	8160791
tub@@	B-Disease	D007674	8160791
ular	I-Disease	-1	8160791
damage	I-Disease	-1	8160791
.	O	-1	8160791
A	O	-1	8160791
significant	O	-1	8160791
reduction	O	-1	8160791
in	O	-1	8160791
urinary	O	-1	8160791
gu@@	B-Chemical	D006152	8160791
an@@	I-Chemical	-1	8160791
os@@	I-Chemical	-1	8160791
ine	I-Chemical	-1	8160791
3@@	I-Chemical	-1	8160791
'@@	I-Chemical	-1	8160791
,@@	I-Chemical	-1	8160791
5@@	I-Chemical	-1	8160791
'@@	I-Chemical	-1	8160791
-@@	I-Chemical	-1	8160791
cy@@	I-Chemical	-1	8160791
cl@@	I-Chemical	-1	8160791
ic	I-Chemical	-1	8160791
mon@@	I-Chemical	-1	8160791
oph@@	I-Chemical	-1	8160791
osph@@	I-Chemical	-1	8160791
ate	I-Chemical	-1	8160791
(	O	-1	8160791
c@@	B-Chemical	D006152	8160791
G@@	I-Chemical	-1	8160791
M@@	I-Chemical	-1	8160791
P	I-Chemical	-1	8160791
)	O	-1	8160791
ex@@	O	-1	8160791
cre@@	O	-1	8160791
tion	O	-1	8160791
and	O	-1	8160791
a	O	-1	8160791
significant	O	-1	8160791
increase	O	-1	8160791
in	O	-1	8160791
renal	O	-1	8160791
cor@@	O	-1	8160791
tical	O	-1	8160791
ren@@	O	-1	8160791
in	O	-1	8160791
and	O	-1	8160791
endo@@	O	-1	8160791
the@@	O	-1	8160791
l@@	O	-1	8160791
in-@@	O	-1	8160791
1	O	-1	8160791
cont@@	O	-1	8160791
ents	O	-1	8160791
were	O	-1	8160791
also	O	-1	8160791
observed	O	-1	8160791
in	O	-1	8160791
G@@	B-Chemical	D005839	8160791
M	I-Chemical	-1	8160791
-@@	O	-1	8160791
mediated	O	-1	8160791
nephro@@	B-Disease	D007674	8160791
pathy	I-Disease	-1	8160791
.	O	-1	8160791
S@@	B-Chemical	D013481	8160791
u@@	I-Chemical	-1	8160791
per@@	I-Chemical	-1	8160791
ox@@	I-Chemical	-1	8160791
ide	I-Chemical	-1	8160791
dis@@	O	-1	8160791
mut@@	O	-1	8160791
ase	O	-1	8160791
(S@@	O	-1	8160791
O@@	O	-1	8160791
D)	O	-1	8160791
or	O	-1	8160791
di@@	B-Chemical	C038983	8160791
methyl@@	I-Chemical	-1	8160791
thi@@	I-Chemical	-1	8160791
ou@@	I-Chemical	-1	8160791
re@@	I-Chemical	-1	8160791
a	I-Chemical	-1	8160791
(	O	-1	8160791
D@@	B-Chemical	C038983	8160791
M@@	I-Chemical	-1	8160791
T@@	I-Chemical	-1	8160791
U	I-Chemical	-1	8160791
)	O	-1	8160791
significantly	O	-1	8160791
l@@	O	-1	8160791
es@@	O	-1	8160791
sen@@	O	-1	8160791
ed	O	-1	8160791
the	O	-1	8160791
G@@	B-Chemical	D005839	8160791
M	I-Chemical	-1	8160791
-induced	O	-1	8160791
dec@@	O	-1	8160791
re@@	O	-1	8160791
ment	O	-1	8160791
in	O	-1	8160791
C@@	O	-1	8160791
In@@	O	-1	8160791
.	O	-1	8160791
The	O	-1	8160791
S@@	O	-1	8160791
O@@	O	-1	8160791
D@@	O	-1	8160791
-induced	O	-1	8160791
increase	O	-1	8160791
in	O	-1	8160791
glomerular	O	-1	8160791
f@@	O	-1	8160791
iltration	O	-1	8160791
rate	O	-1	8160791
was	O	-1	8160791
associated	O	-1	8160791
with	O	-1	8160791
a	O	-1	8160791
mark@@	O	-1	8160791
ed	O	-1	8160791
impro@@	O	-1	8160791
vement	O	-1	8160791
in	O	-1	8160791
R@@	O	-1	8160791
B@@	O	-1	8160791
F@@	O	-1	8160791
,	O	-1	8160791
an	O	-1	8160791
increase	O	-1	8160791
in	O	-1	8160791
urinary	O	-1	8160791
c@@	B-Chemical	D006152	8160791
G@@	I-Chemical	-1	8160791
M@@	I-Chemical	-1	8160791
P	I-Chemical	-1	8160791
ex@@	O	-1	8160791
cre@@	O	-1	8160791
tion,	O	-1	8160791
and	O	-1	8160791
a	O	-1	8160791
decrease	O	-1	8160791
in	O	-1	8160791
renal	O	-1	8160791
ren@@	O	-1	8160791
in	O	-1	8160791
and	O	-1	8160791
endo@@	O	-1	8160791
the@@	O	-1	8160791
l@@	O	-1	8160791
in-@@	O	-1	8160791
1	O	-1	8160791
cont@@	O	-1	8160791
ent@@	O	-1	8160791
.	O	-1	8160791
S@@	O	-1	8160791
O@@	O	-1	8160791
D	O	-1	8160791
did	O	-1	8160791
not	O	-1	8160791
attenu@@	O	-1	8160791
ate	O	-1	8160791
the	O	-1	8160791
tub@@	B-Disease	D007674	8160791
ular	I-Disease	-1	8160791
damage	I-Disease	-1	8160791
.	O	-1	8160791
In	O	-1	8160791
contrast@@	O	-1	8160791
,	O	-1	8160791
D@@	B-Chemical	C038983	8160791
M@@	I-Chemical	-1	8160791
T@@	I-Chemical	-1	8160791
U	I-Chemical	-1	8160791
significantly	O	-1	8160791
reduced	O	-1	8160791
the	O	-1	8160791
tub@@	B-Disease	D007674	8160791
ular	I-Disease	-1	8160791
damage	I-Disease	-1	8160791
and	O	-1	8160791
li@@	O	-1	8160791
pid	O	-1	8160791
per@@	O	-1	8160791
oxid@@	O	-1	8160791
ation,	O	-1	8160791
but	O	-1	8160791
it	O	-1	8160791
did	O	-1	8160791
not	O	-1	8160791
aff@@	O	-1	8160791
ect	O	-1	8160791
renal	O	-1	8160791
hemo@@	O	-1	8160791
dynam@@	O	-1	8160791
ic@@	O	-1	8160791
s	O	-1	8160791
and	O	-1	8160791
vas@@	O	-1	8160791
o@@	O	-1	8160791
active	O	-1	8160791
subst@@	O	-1	8160791
anc@@	O	-1	8160791
es.	O	-1	8160791
N@@	O	-1	8160791
either	O	-1	8160791
S@@	O	-1	8160791
O@@	O	-1	8160791
D	O	-1	8160791
n@@	O	-1	8160791
or	O	-1	8160791
D@@	B-Chemical	C038983	8160791
M@@	I-Chemical	-1	8160791
T@@	I-Chemical	-1	8160791
U	I-Chemical	-1	8160791
affected	O	-1	8160791
the	O	-1	8160791
renal	O	-1	8160791
cor@@	O	-1	8160791
tical	O	-1	8160791
G@@	B-Chemical	D005839	8160791
M	I-Chemical	-1	8160791
cont@@	O	-1	8160791
ent	O	-1	8160791
in	O	-1	8160791
G@@	B-Chemical	D005839	8160791
M	I-Chemical	-1	8160791
-treated	O	-1	8160791
rats.	O	-1	8160791
These	O	-1	8160791
results	O	-1	8160791
suggest	O	-1	8160791
that	O	-1	8160791
1)	O	-1	8160791
both	O	-1	8160791
S@@	O	-1	8160791
O@@	O	-1	8160791
D	O	-1	8160791
and	O	-1	8160791
D@@	B-Chemical	C038983	8160791
M@@	I-Chemical	-1	8160791
T@@	I-Chemical	-1	8160791
U	I-Chemical	-1	8160791
have	O	-1	8160791
protective	O	-1	8160791
effects	O	-1	8160791
on	O	-1	8160791
G@@	B-Chemical	D005839	8160791
M	I-Chemical	-1	8160791
-@@	O	-1	8160791
mediated	O	-1	8160791
nephro@@	B-Disease	D007674	8160791
pathy	I-Disease	-1	8160791
,	O	-1	8160791
2)	O	-1	8160791
the	O	-1	8160791
mechanisms	O	-1	8160791
for	O	-1	8160791
the	O	-1	8160791
protective	O	-1	8160791
effects	O	-1	8160791
diff@@	O	-1	8160791
er	O	-1	8160791
for	O	-1	8160791
S@@	O	-1	8160791
O@@	O	-1	8160791
D	O	-1	8160791
and	O	-1	8160791
D@@	B-Chemical	C038983	8160791
M@@	I-Chemical	-1	8160791
T@@	I-Chemical	-1	8160791
U	I-Chemical	-1	8160791
,	O	-1	8160791
and	O	-1	8160791
3@@	O	-1	8160791
)	O	-1	8160791
su@@	B-Chemical	D013481	8160791
per@@	I-Chemical	-1	8160791
ox@@	I-Chemical	-1	8160791
ide	I-Chemical	-1	8160791
an@@	O	-1	8160791
i@@	O	-1	8160791
ons	O	-1	8160791
pl@@	O	-1	8160791
ay	O	-1	8160791
a	O	-1	8160791
cri@@	O	-1	8160791
tical	O	-1	8160791
role	O	-1	8160791
in	O	-1	8160791
G@@	B-Chemical	D005839	8160791
M	I-Chemical	-1	8160791
-induced	O	-1	8160791
renal	O	-1	8160791
vas@@	O	-1	8160791
o@@	O	-1	8160791
con@@	O	-1	8160791
stric@@	O	-1	8160791
tion.	O	-1	8160791

A@@	O	-1	8184922
s@@	O	-1	8184922
s@@	O	-1	8184922
ess@@	O	-1	8184922
ment	O	-1	8184922
of	O	-1	8184922
cardi@@	O	-1	8184922
om@@	O	-1	8184922
y@@	O	-1	8184922
ocyte	O	-1	8184922
D@@	O	-1	8184922
NA	O	-1	8184922
syn@@	O	-1	8184922
thesis	O	-1	8184922
during	O	-1	8184922
hyper@@	B-Disease	D006984	8184922
tro@@	I-Disease	-1	8184922
ph@@	I-Disease	-1	8184922
y	I-Disease	-1	8184922
in	O	-1	8184922
ad@@	O	-1	8184922
ult	O	-1	8184922
mice.	O	-1	8184922
The	O	-1	8184922
ability	O	-1	8184922
of	O	-1	8184922
cardi@@	O	-1	8184922
om@@	O	-1	8184922
y@@	O	-1	8184922
ocy@@	O	-1	8184922
tes	O	-1	8184922
to	O	-1	8184922
syn@@	O	-1	8184922
the@@	O	-1	8184922
size	O	-1	8184922
D@@	O	-1	8184922
NA	O	-1	8184922
in	O	-1	8184922
response	O	-1	8184922
to	O	-1	8184922
experim@@	O	-1	8184922
ent@@	O	-1	8184922
ally	O	-1	8184922
induced	O	-1	8184922
cardiac	B-Disease	D006332	8184922
hyper@@	I-Disease	-1	8184922
tro@@	I-Disease	-1	8184922
ph@@	I-Disease	-1	8184922
y	I-Disease	-1	8184922
was	O	-1	8184922
assessed	O	-1	8184922
in	O	-1	8184922
ad@@	O	-1	8184922
ult	O	-1	8184922
mice.	O	-1	8184922
I@@	B-Chemical	D007545	8184922
so@@	I-Chemical	-1	8184922
proteren@@	I-Chemical	-1	8184922
ol	I-Chemical	-1	8184922
de@@	O	-1	8184922
li@@	O	-1	8184922
vered	O	-1	8184922
by	O	-1	8184922
os@@	O	-1	8184922
mo@@	O	-1	8184922
tic	O	-1	8184922
min@@	O	-1	8184922
ip@@	O	-1	8184922
um@@	O	-1	8184922
p	O	-1	8184922
im@@	O	-1	8184922
pl@@	O	-1	8184922
ant@@	O	-1	8184922
ation	O	-1	8184922
in	O	-1	8184922
ad@@	O	-1	8184922
ult	O	-1	8184922
C@@	O	-1	8184922
3@@	O	-1	8184922
He@@	O	-1	8184922
b@@	O	-1	8184922
/@@	O	-1	8184922
F@@	O	-1	8184922
e@@	O	-1	8184922
J	O	-1	8184922
mice	O	-1	8184922
resulted	O	-1	8184922
in	O	-1	8184922
a	O	-1	8184922
4@@	O	-1	8184922
6%	O	-1	8184922
increase	O	-1	8184922
in	O	-1	8184922
heart	O	-1	8184922
weight	O	-1	8184922
and	O	-1	8184922
a	O	-1	8184922
19@@	O	-1	8184922
.@@	O	-1	8184922
3@@	O	-1	8184922
%	O	-1	8184922
increase	O	-1	8184922
in	O	-1	8184922
cardi@@	O	-1	8184922
om@@	O	-1	8184922
y@@	O	-1	8184922
ocyte	O	-1	8184922
a@@	O	-1	8184922
re@@	O	-1	8184922
a.	O	-1	8184922
No	O	-1	8184922
D@@	O	-1	8184922
NA	O	-1	8184922
syn@@	O	-1	8184922
the@@	O	-1	8184922
sis,	O	-1	8184922
as	O	-1	8184922
assessed	O	-1	8184922
by	O	-1	8184922
a@@	O	-1	8184922
ut@@	O	-1	8184922
or@@	O	-1	8184922
a@@	O	-1	8184922
di@@	O	-1	8184922
ograph@@	O	-1	8184922
ic	O	-1	8184922
analysis	O	-1	8184922
of	O	-1	8184922
isol@@	O	-1	8184922
ated	O	-1	8184922
cardi@@	O	-1	8184922
om@@	O	-1	8184922
y@@	O	-1	8184922
ocy@@	O	-1	8184922
t@@	O	-1	8184922
es,	O	-1	8184922
was	O	-1	8184922
observed	O	-1	8184922
in	O	-1	8184922
control	O	-1	8184922
or	O	-1	8184922
hyper@@	B-Disease	D006332	8184922
tro@@	I-Disease	-1	8184922
ph@@	I-Disease	-1	8184922
ic	I-Disease	-1	8184922
hear@@	I-Disease	-1	8184922
ts	I-Disease	-1	8184922
.	O	-1	8184922
A	O	-1	8184922
sur@@	O	-1	8184922
ve@@	O	-1	8184922
y	O	-1	8184922
of	O	-1	8184922
15	O	-1	8184922
in@@	O	-1	8184922
dependent	O	-1	8184922
in@@	O	-1	8184922
b@@	O	-1	8184922
red	O	-1	8184922
stra@@	O	-1	8184922
ins	O	-1	8184922
of	O	-1	8184922
mice	O	-1	8184922
revealed	O	-1	8184922
that	O	-1	8184922
ventricular	O	-1	8184922
cardi@@	O	-1	8184922
om@@	O	-1	8184922
y@@	O	-1	8184922
ocyte	O	-1	8184922
nucle@@	O	-1	8184922
ar	O	-1	8184922
number	O	-1	8184922
rang@@	O	-1	8184922
ed	O	-1	8184922
from	O	-1	8184922
3	O	-1	8184922
to	O	-1	8184922
13@@	O	-1	8184922
%	O	-1	8184922
mon@@	O	-1	8184922
on@@	O	-1	8184922
ucle@@	O	-1	8184922
ate,	O	-1	8184922
suggesting	O	-1	8184922
that	O	-1	8184922
cardi@@	O	-1	8184922
om@@	O	-1	8184922
y@@	O	-1	8184922
ocyte	O	-1	8184922
ter@@	O	-1	8184922
min@@	O	-1	8184922
al	O	-1	8184922
differen@@	O	-1	8184922
ti@@	O	-1	8184922
ation	O	-1	8184922
is	O	-1	8184922
influ@@	O	-1	8184922
enc@@	O	-1	8184922
ed	O	-1	8184922
direc@@	O	-1	8184922
tly	O	-1	8184922
or	O	-1	8184922
in@@	O	-1	8184922
direc@@	O	-1	8184922
tly	O	-1	8184922
by	O	-1	8184922
gene@@	O	-1	8184922
tic	O	-1	8184922
bac@@	O	-1	8184922
kg@@	O	-1	8184922
ro@@	O	-1	8184922
un@@	O	-1	8184922
d.	O	-1	8184922
To	O	-1	8184922
determine	O	-1	8184922
whether	O	-1	8184922
the	O	-1	8184922
cap@@	O	-1	8184922
ac@@	O	-1	8184922
ity	O	-1	8184922
for	O	-1	8184922
reac@@	O	-1	8184922
tive	O	-1	8184922
D@@	O	-1	8184922
NA	O	-1	8184922
syn@@	O	-1	8184922
thesis	O	-1	8184922
was	O	-1	8184922
also	O	-1	8184922
subj@@	O	-1	8184922
ect	O	-1	8184922
to	O	-1	8184922
gene@@	O	-1	8184922
tic	O	-1	8184922
reg@@	O	-1	8184922
ul@@	O	-1	8184922
ation,	O	-1	8184922
cardiac	B-Disease	D006332	8184922
hyper@@	I-Disease	-1	8184922
tro@@	I-Disease	-1	8184922
ph@@	I-Disease	-1	8184922
y	I-Disease	-1	8184922
was	O	-1	8184922
induced	O	-1	8184922
in	O	-1	8184922
the	O	-1	8184922
stra@@	O	-1	8184922
ins	O	-1	8184922
of	O	-1	8184922
mice	O	-1	8184922
comp@@	O	-1	8184922
ris@@	O	-1	8184922
ing	O	-1	8184922
the	O	-1	8184922
ex@@	O	-1	8184922
trem@@	O	-1	8184922
es	O	-1	8184922
of	O	-1	8184922
the	O	-1	8184922
nucle@@	O	-1	8184922
ar	O	-1	8184922
number	O	-1	8184922
sur@@	O	-1	8184922
ve@@	O	-1	8184922
y.	O	-1	8184922
These	O	-1	8184922
data	O	-1	8184922
indicate	O	-1	8184922
that	O	-1	8184922
ad@@	O	-1	8184922
ult	O	-1	8184922
mouse	O	-1	8184922
atrial	O	-1	8184922
and	O	-1	8184922
ventricular	O	-1	8184922
cardi@@	O	-1	8184922
om@@	O	-1	8184922
y@@	O	-1	8184922
ocy@@	O	-1	8184922
tes	O	-1	8184922
d@@	O	-1	8184922
o	O	-1	8184922
not	O	-1	8184922
syn@@	O	-1	8184922
the@@	O	-1	8184922
size	O	-1	8184922
D@@	O	-1	8184922
NA	O	-1	8184922
in	O	-1	8184922
response	O	-1	8184922
to	O	-1	8184922
isoproteren@@	B-Chemical	D007545	8184922
ol	I-Chemical	-1	8184922
-induced	O	-1	8184922
cardiac	B-Disease	D006332	8184922
hyper@@	I-Disease	-1	8184922
tro@@	I-Disease	-1	8184922
ph@@	I-Disease	-1	8184922
y	I-Disease	-1	8184922
.	O	-1	8184922

C@@	O	-1	8188982
entr@@	O	-1	8188982
al	O	-1	8188982
cardiovascular	O	-1	8188982
effects	O	-1	8188982
of	O	-1	8188982
A@@	B-Chemical	D001127	8188982
V@@	I-Chemical	-1	8188982
P	I-Chemical	-1	8188982
and	O	-1	8188982
AN@@	O	-1	8188982
P	O	-1	8188982
in	O	-1	8188982
norm@@	O	-1	8188982
oten@@	O	-1	8188982
sive	O	-1	8188982
and	O	-1	8188982
spont@@	O	-1	8188982
ane@@	O	-1	8188982
ously	O	-1	8188982
hypertensive	B-Disease	D006973	8188982
rats.	O	-1	8188982
The	O	-1	8188982
pur@@	O	-1	8188982
p@@	O	-1	8188982
ose	O	-1	8188982
of	O	-1	8188982
the	O	-1	8188982
present	O	-1	8188982
study	O	-1	8188982
was	O	-1	8188982
to	O	-1	8188982
compar@@	O	-1	8188982
e	O	-1	8188982
influence	O	-1	8188982
of	O	-1	8188982
central	O	-1	8188982
arg@@	B-Chemical	D001127	8188982
inine	I-Chemical	-1	8188982
vas@@	I-Chemical	-1	8188982
o@@	I-Chemical	-1	8188982
press@@	I-Chemical	-1	8188982
in	I-Chemical	-1	8188982
(	O	-1	8188982
A@@	B-Chemical	D001127	8188982
V@@	I-Chemical	-1	8188982
P	I-Chemical	-1	8188982
)	O	-1	8188982
and	O	-1	8188982
of	O	-1	8188982
atrial	O	-1	8188982
n@@	O	-1	8188982
atri@@	O	-1	8188982
ure@@	O	-1	8188982
tic	O	-1	8188982
p@@	O	-1	8188982
ep@@	O	-1	8188982
ti@@	O	-1	8188982
de	O	-1	8188982
(A@@	O	-1	8188982
N@@	O	-1	8188982
P)	O	-1	8188982
on	O	-1	8188982
control	O	-1	8188982
of	O	-1	8188982
arterial	O	-1	8188982
blood	O	-1	8188982
pressure	O	-1	8188982
(@@	O	-1	8188982
MA@@	O	-1	8188982
P)	O	-1	8188982
and	O	-1	8188982
heart	O	-1	8188982
rate	O	-1	8188982
(@@	O	-1	8188982
H@@	O	-1	8188982
R@@	O	-1	8188982
)	O	-1	8188982
in	O	-1	8188982
norm@@	O	-1	8188982
oten@@	O	-1	8188982
sive	O	-1	8188982
(@@	O	-1	8188982
W@@	O	-1	8188982
K@@	O	-1	8188982
Y@@	O	-1	8188982
)	O	-1	8188982
and	O	-1	8188982
spont@@	O	-1	8188982
ane@@	O	-1	8188982
ously	O	-1	8188982
hypertensive	B-Disease	D006973	8188982
(S@@	O	-1	8188982
H@@	O	-1	8188982
R@@	O	-1	8188982
)	O	-1	8188982
rats.	O	-1	8188982
Th@@	O	-1	8188982
ree	O	-1	8188982
seri@@	O	-1	8188982
es	O	-1	8188982
of	O	-1	8188982
experim@@	O	-1	8188982
ents	O	-1	8188982
were	O	-1	8188982
performed	O	-1	8188982
on	O	-1	8188982
30	O	-1	8188982
W@@	O	-1	8188982
K@@	O	-1	8188982
Y	O	-1	8188982
and	O	-1	8188982
30	O	-1	8188982
S@@	O	-1	8188982
H@@	O	-1	8188982
R@@	O	-1	8188982
,	O	-1	8188982
chron@@	O	-1	8188982
ically	O	-1	8188982
in@@	O	-1	8188982
st@@	O	-1	8188982
ru@@	O	-1	8188982
ment@@	O	-1	8188982
ed	O	-1	8188982
with	O	-1	8188982
gu@@	O	-1	8188982
ide	O	-1	8188982
tub@@	O	-1	8188982
es	O	-1	8188982
in	O	-1	8188982
the	O	-1	8188982
lat@@	O	-1	8188982
eral	O	-1	8188982
ventric@@	O	-1	8188982
le	O	-1	8188982
(@@	O	-1	8188982
L@@	O	-1	8188982
V@@	O	-1	8188982
)	O	-1	8188982
and	O	-1	8188982
arterial	O	-1	8188982
and	O	-1	8188982
venous	O	-1	8188982
ca@@	O	-1	8188982
the@@	O	-1	8188982
ter@@	O	-1	8188982
s.	O	-1	8188982
MA@@	O	-1	8188982
P	O	-1	8188982
and	O	-1	8188982
H@@	O	-1	8188982
R	O	-1	8188982
were	O	-1	8188982
monit@@	O	-1	8188982
o@@	O	-1	8188982
red	O	-1	8188982
before	O	-1	8188982
and	O	-1	8188982
after	O	-1	8188982
i.v@@	O	-1	8188982
.	O	-1	8188982
injec@@	O	-1	8188982
tions	O	-1	8188982
of	O	-1	8188982
either	O	-1	8188982
ve@@	O	-1	8188982
h@@	O	-1	8188982
ic@@	O	-1	8188982
le	O	-1	8188982
or	O	-1	8188982
1,	O	-1	8188982
10	O	-1	8188982
and	O	-1	8188982
50	O	-1	8188982
n@@	O	-1	8188982
g	O	-1	8188982
of	O	-1	8188982
A@@	B-Chemical	D001127	8188982
V@@	I-Chemical	-1	8188982
P	I-Chemical	-1	8188982
and	O	-1	8188982
2@@	O	-1	8188982
5,	O	-1	8188982
12@@	O	-1	8188982
5	O	-1	8188982
and	O	-1	8188982
5@@	O	-1	8188982
00	O	-1	8188982
n@@	O	-1	8188982
g	O	-1	8188982
of	O	-1	8188982
AN@@	O	-1	8188982
P@@	O	-1	8188982
.	O	-1	8188982
S@@	O	-1	8188982
en@@	O	-1	8188982
si@@	O	-1	8188982
tivity	O	-1	8188982
of	O	-1	8188982
cardiac	O	-1	8188982
comp@@	O	-1	8188982
on@@	O	-1	8188982
ent	O	-1	8188982
of	O	-1	8188982
b@@	O	-1	8188982
a@@	O	-1	8188982
ro@@	O	-1	8188982
ref@@	O	-1	8188982
le@@	O	-1	8188982
x	O	-1	8188982
(C@@	O	-1	8188982
C@@	O	-1	8188982
B@@	O	-1	8188982
),	O	-1	8188982
ex@@	O	-1	8188982
press@@	O	-1	8188982
ed	O	-1	8188982
as	O	-1	8188982
a	O	-1	8188982
s@@	O	-1	8188982
lop@@	O	-1	8188982
e	O	-1	8188982
of	O	-1	8188982
the	O	-1	8188982
reg@@	O	-1	8188982
res@@	O	-1	8188982
sion	O	-1	8188982
line	O	-1	8188982
was	O	-1	8188982
determined	O	-1	8188982
from	O	-1	8188982
rel@@	O	-1	8188982
ation@@	O	-1	8188982
shi@@	O	-1	8188982
p@@	O	-1	8188982
s	O	-1	8188982
between	O	-1	8188982
systolic	O	-1	8188982
arterial	O	-1	8188982
pressure	O	-1	8188982
(S@@	O	-1	8188982
A@@	O	-1	8188982
P)	O	-1	8188982
and	O	-1	8188982
H@@	O	-1	8188982
R	O	-1	8188982
period	O	-1	8188982
(@@	O	-1	8188982
H@@	O	-1	8188982
R@@	O	-1	8188982
p@@	O	-1	8188982
)	O	-1	8188982
during	O	-1	8188982
pheny@@	B-Chemical	D010656	8188982
le@@	I-Chemical	-1	8188982
phrine	I-Chemical	-1	8188982
(	O	-1	8188982
P@@	B-Chemical	D010656	8188982
he	I-Chemical	-1	8188982
)@@	O	-1	8188982
-induced	O	-1	8188982
hypertension	B-Disease	D006973	8188982
and	O	-1	8188982
sodium	B-Chemical	D009599	8188982
nitro@@	I-Chemical	-1	8188982
pr@@	I-Chemical	-1	8188982
us@@	I-Chemical	-1	8188982
side	I-Chemical	-1	8188982
(	O	-1	8188982
S@@	B-Chemical	D009599	8188982
N	I-Chemical	-1	8188982
)@@	O	-1	8188982
-induced	O	-1	8188982
hypotension	B-Disease	D007022	8188982
.	O	-1	8188982
C@@	O	-1	8188982
C@@	O	-1	8188982
B	O	-1	8188982
was	O	-1	8188982
measured	O	-1	8188982
before	O	-1	8188982
and	O	-1	8188982
after	O	-1	8188982
administration	O	-1	8188982
of	O	-1	8188982
either	O	-1	8188982
ve@@	O	-1	8188982
h@@	O	-1	8188982
ic@@	O	-1	8188982
le@@	O	-1	8188982
,	O	-1	8188982
A@@	B-Chemical	D001127	8188982
V@@	I-Chemical	-1	8188982
P	I-Chemical	-1	8188982
,	O	-1	8188982
AN@@	O	-1	8188982
P@@	O	-1	8188982
,	O	-1	8188982
or	O	-1	8188982
both	O	-1	8188982
p@@	O	-1	8188982
ep@@	O	-1	8188982
ti@@	O	-1	8188982
des	O	-1	8188982
to@@	O	-1	8188982
ge@@	O	-1	8188982
ther@@	O	-1	8188982
.	O	-1	8188982
In@@	O	-1	8188982
c@@	O	-1	8188982
reas@@	O	-1	8188982
es	O	-1	8188982
of	O	-1	8188982
MA@@	O	-1	8188982
P	O	-1	8188982
occurred	O	-1	8188982
after	O	-1	8188982
L@@	O	-1	8188982
V	O	-1	8188982
administration	O	-1	8188982
of	O	-1	8188982
1,	O	-1	8188982
10	O	-1	8188982
and	O	-1	8188982
50	O	-1	8188982
n@@	O	-1	8188982
g	O	-1	8188982
of	O	-1	8188982
A@@	B-Chemical	D001127	8188982
V@@	I-Chemical	-1	8188982
P	I-Chemical	-1	8188982
in	O	-1	8188982
W@@	O	-1	8188982
K@@	O	-1	8188982
Y	O	-1	8188982
and	O	-1	8188982
of	O	-1	8188982
10	O	-1	8188982
and	O	-1	8188982
50	O	-1	8188982
n@@	O	-1	8188982
g	O	-1	8188982
in	O	-1	8188982
S@@	O	-1	8188982
H@@	O	-1	8188982
R@@	O	-1	8188982
.	O	-1	8188982
AN@@	O	-1	8188982
P	O	-1	8188982
did	O	-1	8188982
not	O	-1	8188982
cause	O	-1	8188982
significant	O	-1	8188982
changes	O	-1	8188982
in	O	-1	8188982
MA@@	O	-1	8188982
P	O	-1	8188982
in	O	-1	8188982
both	O	-1	8188982
stra@@	O	-1	8188982
ins	O	-1	8188982
as	O	-1	8188982
compared	O	-1	8188982
to	O	-1	8188982
ve@@	O	-1	8188982
h@@	O	-1	8188982
ic@@	O	-1	8188982
le@@	O	-1	8188982
,	O	-1	8188982
but	O	-1	8188982
it	O	-1	8188982
abol@@	O	-1	8188982
ished	O	-1	8188982
A@@	B-Chemical	D001127	8188982
V@@	I-Chemical	-1	8188982
P	I-Chemical	-1	8188982
-induced	O	-1	8188982
MA@@	O	-1	8188982
P	O	-1	8188982
increase	O	-1	8188982
in	O	-1	8188982
W@@	O	-1	8188982
K@@	O	-1	8188982
Y	O	-1	8188982
and	O	-1	8188982
S@@	O	-1	8188982
H@@	O	-1	8188982
R@@	O	-1	8188982
.	O	-1	8188982
C@@	O	-1	8188982
C@@	O	-1	8188982
B	O	-1	8188982
was	O	-1	8188982
reduced	O	-1	8188982
in	O	-1	8188982
W@@	O	-1	8188982
K@@	O	-1	8188982
Y	O	-1	8188982
and	O	-1	8188982
S@@	O	-1	8188982
H@@	O	-1	8188982
R	O	-1	8188982
after	O	-1	8188982
L@@	O	-1	8188982
V	O	-1	8188982
administration	O	-1	8188982
of	O	-1	8188982
A@@	B-Chemical	D001127	8188982
V@@	I-Chemical	-1	8188982
P	I-Chemical	-1	8188982
during	O	-1	8188982
S@@	B-Chemical	D009599	8188982
N	I-Chemical	-1	8188982
-induced	O	-1	8188982
hypotension	B-Disease	D007022	8188982
.	O	-1	8188982
In	O	-1	8188982
S@@	O	-1	8188982
H@@	O	-1	8188982
R	O	-1	8188982
but	O	-1	8188982
not	O	-1	8188982
in	O	-1	8188982
W@@	O	-1	8188982
K@@	O	-1	8188982
Y	O	-1	8188982
administration	O	-1	8188982
of	O	-1	8188982
AN@@	O	-1	8188982
P@@	O	-1	8188982
,	O	-1	8188982
A@@	B-Chemical	D001127	8188982
V@@	I-Chemical	-1	8188982
P	I-Chemical	-1	8188982
and	O	-1	8188982
AN@@	O	-1	8188982
P	O	-1	8188982
+	O	-1	8188982
A@@	B-Chemical	D001127	8188982
V@@	I-Chemical	-1	8188982
P	I-Chemical	-1	8188982
decreased	O	-1	8188982
C@@	O	-1	8188982
C@@	O	-1	8188982
B	O	-1	8188982
during	O	-1	8188982
P@@	B-Chemical	D010656	8188982
he	I-Chemical	-1	8188982
-induced	O	-1	8188982
MA@@	O	-1	8188982
P	O	-1	8188982
elev@@	O	-1	8188982
ation.	O	-1	8188982
The	O	-1	8188982
results	O	-1	8188982
indicate	O	-1	8188982
that	O	-1	8188982
centr@@	O	-1	8188982
ally	O	-1	8188982
ap@@	O	-1	8188982
pl@@	O	-1	8188982
ied	O	-1	8188982
A@@	B-Chemical	D001127	8188982
V@@	I-Chemical	-1	8188982
P	I-Chemical	-1	8188982
and	O	-1	8188982
AN@@	O	-1	8188982
P	O	-1	8188982
ex@@	O	-1	8188982
er@@	O	-1	8188982
t	O	-1	8188982
differen@@	O	-1	8188982
tial	O	-1	8188982
effects	O	-1	8188982
on	O	-1	8188982
blood	O	-1	8188982
pressure	O	-1	8188982
and	O	-1	8188982
b@@	O	-1	8188982
a@@	O	-1	8188982
ro@@	O	-1	8188982
ref@@	O	-1	8188982
le@@	O	-1	8188982
x	O	-1	8188982
control	O	-1	8188982
of	O	-1	8188982
heart	O	-1	8188982
rate	O	-1	8188982
in	O	-1	8188982
W@@	O	-1	8188982
K@@	O	-1	8188982
Y	O	-1	8188982
and	O	-1	8188982
S@@	O	-1	8188982
H@@	O	-1	8188982
R	O	-1	8188982
and	O	-1	8188982
suggest	O	-1	8188982
inter@@	O	-1	8188982
action	O	-1	8188982
of	O	-1	8188982
these	O	-1	8188982
two	O	-1	8188982
p@@	O	-1	8188982
ep@@	O	-1	8188982
ti@@	O	-1	8188982
des	O	-1	8188982
in	O	-1	8188982
blood	O	-1	8188982
pressure	O	-1	8188982
reg@@	O	-1	8188982
ulation	O	-1	8188982
at	O	-1	8188982
the	O	-1	8188982
level	O	-1	8188982
of	O	-1	8188982
central	O	-1	8188982
ner@@	O	-1	8188982
v@@	O	-1	8188982
ous	O	-1	8188982
system@@	O	-1	8188982
.	O	-1	8188982

C@@	O	-1	8308951
utaneous	O	-1	8308951
exposure	O	-1	8308951
to	O	-1	8308951
war@@	B-Chemical	D014859	8308951
farin	I-Chemical	-1	8308951
-@@	O	-1	8308951
like	O	-1	8308951
anti@@	O	-1	8308951
co@@	O	-1	8308951
ag@@	O	-1	8308951
ul@@	O	-1	8308951
ant	O	-1	8308951
ca@@	O	-1	8308951
using	O	-1	8308951
an	O	-1	8308951
intrac@@	B-Disease	D002543	8308951
e@@	I-Disease	-1	8308951
rebral	I-Disease	-1	8308951
hemorrh@@	I-Disease	-1	8308951
age	I-Disease	-1	8308951
:	O	-1	8308951
a	O	-1	8308951
case	O	-1	8308951
repor@@	O	-1	8308951
t.	O	-1	8308951
A	O	-1	8308951
case	O	-1	8308951
of	O	-1	8308951
inter@@	O	-1	8308951
cerebral	O	-1	8308951
hemat@@	B-Disease	D006406	8308951
oma	I-Disease	-1	8308951
due	O	-1	8308951
to	O	-1	8308951
war@@	B-Chemical	D014859	8308951
farin	I-Chemical	-1	8308951
-induced	O	-1	8308951
co@@	B-Disease	D001778	8308951
ag@@	I-Disease	-1	8308951
ulo@@	I-Disease	-1	8308951
pathy	I-Disease	-1	8308951
is	O	-1	8308951
present@@	O	-1	8308951
ed.	O	-1	8308951
The	O	-1	8308951
3@@	O	-1	8308951
9@@	O	-1	8308951
-@@	O	-1	8308951
year-old	O	-1	8308951
woman	O	-1	8308951
had	O	-1	8308951
s@@	O	-1	8308951
pre@@	O	-1	8308951
ad	O	-1	8308951
a	O	-1	8308951
war@@	B-Chemical	D014859	8308951
farin	I-Chemical	-1	8308951
-@@	O	-1	8308951
type	O	-1	8308951
rat	O	-1	8308951
po@@	O	-1	8308951
ison	O	-1	8308951
a@@	O	-1	8308951
ro@@	O	-1	8308951
un@@	O	-1	8308951
d	O	-1	8308951
h@@	O	-1	8308951
er	O	-1	8308951
h@@	O	-1	8308951
ou@@	O	-1	8308951
se	O	-1	8308951
week@@	O	-1	8308951
ly	O	-1	8308951
using	O	-1	8308951
h@@	O	-1	8308951
er	O	-1	8308951
b@@	O	-1	8308951
are	O	-1	8308951
h@@	O	-1	8308951
and@@	O	-1	8308951
s,	O	-1	8308951
with	O	-1	8308951
no	O	-1	8308951
w@@	O	-1	8308951
as@@	O	-1	8308951
h@@	O	-1	8308951
ing	O	-1	8308951
pos@@	O	-1	8308951
t	O	-1	8308951
ap@@	O	-1	8308951
plic@@	O	-1	8308951
ation.	O	-1	8308951
P@@	O	-1	8308951
er@@	O	-1	8308951
c@@	O	-1	8308951
utaneous	O	-1	8308951
abs@@	O	-1	8308951
or@@	O	-1	8308951
ption	O	-1	8308951
of	O	-1	8308951
war@@	B-Chemical	D014859	8308951
farin	I-Chemical	-1	8308951
ca@@	O	-1	8308951
using	O	-1	8308951
co@@	B-Disease	D001778	8308951
ag@@	I-Disease	-1	8308951
ulo@@	I-Disease	-1	8308951
pathy	I-Disease	-1	8308951
,	O	-1	8308951
reported	O	-1	8308951
three	O	-1	8308951
times	O	-1	8308951
in	O	-1	8308951
the	O	-1	8308951
pa@@	O	-1	8308951
st@@	O	-1	8308951
,	O	-1	8308951
is	O	-1	8308951
a	O	-1	8308951
significant	O	-1	8308951
risk	O	-1	8308951
if	O	-1	8308951
protective	O	-1	8308951
meas@@	O	-1	8308951
ures@@	O	-1	8308951
,	O	-1	8308951
such	O	-1	8308951
as	O	-1	8308951
glo@@	O	-1	8308951
v@@	O	-1	8308951
es,	O	-1	8308951
are	O	-1	8308951
not	O	-1	8308951
use@@	O	-1	8308951
d.	O	-1	8308951
An	O	-1	8308951
adverse	O	-1	8308951
drug	O	-1	8308951
inter@@	O	-1	8308951
action	O	-1	8308951
with	O	-1	8308951
pi@@	B-Chemical	D010894	8308951
ro@@	I-Chemical	-1	8308951
x@@	I-Chemical	-1	8308951
ic@@	I-Chemical	-1	8308951
am	I-Chemical	-1	8308951
,	O	-1	8308951
which	O	-1	8308951
sh@@	O	-1	8308951
e	O	-1	8308951
to@@	O	-1	8308951
o@@	O	-1	8308951
k	O	-1	8308951
oc@@	O	-1	8308951
ca@@	O	-1	8308951
sion@@	O	-1	8308951
ally,	O	-1	8308951
may	O	-1	8308951
have	O	-1	8308951
ex@@	O	-1	8308951
ac@@	O	-1	8308951
er@@	O	-1	8308951
b@@	O	-1	8308951
ated	O	-1	8308951
the	O	-1	8308951
co@@	B-Disease	D001778	8308951
ag@@	I-Disease	-1	8308951
ulo@@	I-Disease	-1	8308951
pathy	I-Disease	-1	8308951
.	O	-1	8308951

P@@	O	-1	8312343
edi@@	O	-1	8312343
atric	O	-1	8312343
heart	O	-1	8312343
transplant@@	O	-1	8312343
ation	O	-1	8312343
without	O	-1	8312343
chronic	O	-1	8312343
maint@@	O	-1	8312343
en@@	O	-1	8312343
ance	O	-1	8312343
steroid@@	B-Chemical	D013256	8312343
s	I-Chemical	-1	8312343
.	O	-1	8312343
F@@	O	-1	8312343
rom	O	-1	8312343
19@@	O	-1	8312343
8@@	O	-1	8312343
6	O	-1	8312343
to	O	-1	8312343
F@@	O	-1	8312343
e@@	O	-1	8312343
b@@	O	-1	8312343
ru@@	O	-1	8312343
ary	O	-1	8312343
19@@	O	-1	8312343
9@@	O	-1	8312343
3,	O	-1	8312343
40	O	-1	8312343
children	O	-1	8312343
aged	O	-1	8312343
2	O	-1	8312343
months	O	-1	8312343
to	O	-1	8312343
1@@	O	-1	8312343
8	O	-1	8312343
years	O	-1	8312343
(@@	O	-1	8312343
average	O	-1	8312343
age	O	-1	8312343
1@@	O	-1	8312343
0.@@	O	-1	8312343
4	O	-1	8312343
+/-	O	-1	8312343
5.@@	O	-1	8312343
8	O	-1	8312343
year@@	O	-1	8312343
s)	O	-1	8312343
under@@	O	-1	8312343
w@@	O	-1	8312343
ent	O	-1	8312343
heart	O	-1	8312343
transplant@@	O	-1	8312343
ation.	O	-1	8312343
In@@	O	-1	8312343
dic@@	O	-1	8312343
ations	O	-1	8312343
for	O	-1	8312343
transplant@@	O	-1	8312343
ation	O	-1	8312343
were	O	-1	8312343
i@@	B-Disease	D002311	8312343
di@@	I-Disease	-1	8312343
o@@	I-Disease	-1	8312343
path@@	I-Disease	-1	8312343
ic	I-Disease	-1	8312343
cardi@@	I-Disease	-1	8312343
om@@	I-Disease	-1	8312343
yo@@	I-Disease	-1	8312343
pathy	I-Disease	-1	8312343
(5@@	O	-1	8312343
2@@	O	-1	8312343
%),	O	-1	8312343
con@@	B-Disease	D006331	8312343
gen@@	I-Disease	-1	8312343
it@@	I-Disease	-1	8312343
al	I-Disease	-1	8312343
heart	I-Disease	-1	8312343
disease	I-Disease	-1	8312343
(3@@	O	-1	8312343
5@@	O	-1	8312343
%)	O	-1	8312343
with	O	-1	8312343
and	O	-1	8312343
without	O	-1	8312343
prior	O	-1	8312343
re@@	O	-1	8312343
pa@@	O	-1	8312343
ir	O	-1	8312343
(@@	O	-1	8312343
7@@	O	-1	8312343
1@@	O	-1	8312343
%	O	-1	8312343
and	O	-1	8312343
2@@	O	-1	8312343
9@@	O	-1	8312343
%,	O	-1	8312343
respectivel@@	O	-1	8312343
y@@	O	-1	8312343
),	O	-1	8312343
hyper@@	B-Disease	D002312	8312343
tro@@	I-Disease	-1	8312343
ph@@	I-Disease	-1	8312343
ic	I-Disease	-1	8312343
cardi@@	I-Disease	-1	8312343
om@@	I-Disease	-1	8312343
yo@@	I-Disease	-1	8312343
pathy	I-Disease	-1	8312343
(5@@	O	-1	8312343
%),	O	-1	8312343
val@@	B-Disease	D006349	8312343
v@@	I-Disease	-1	8312343
ular	I-Disease	-1	8312343
heart	I-Disease	-1	8312343
disease	I-Disease	-1	8312343
(3@@	O	-1	8312343
%),	O	-1	8312343
and	O	-1	8312343
dox@@	B-Chemical	D004317	8312343
orub@@	I-Chemical	-1	8312343
icin	I-Chemical	-1	8312343
cardi@@	B-Disease	D009202	8312343
om@@	I-Disease	-1	8312343
yo@@	I-Disease	-1	8312343
pathy	I-Disease	-1	8312343
(5@@	O	-1	8312343
%).	O	-1	8312343
Patients	O	-1	8312343
were	O	-1	8312343
man@@	O	-1	8312343
aged	O	-1	8312343
with	O	-1	8312343
cyclospor@@	B-Chemical	D016572	8312343
ine	I-Chemical	-1	8312343
and	O	-1	8312343
az@@	B-Chemical	D001379	8312343
ath@@	I-Chemical	-1	8312343
io@@	I-Chemical	-1	8312343
p@@	I-Chemical	-1	8312343
rine	I-Chemical	-1	8312343
.	O	-1	8312343
No	O	-1	8312343
pro@@	O	-1	8312343
phyl@@	O	-1	8312343
ax@@	O	-1	8312343
is	O	-1	8312343
with	O	-1	8312343
anti@@	O	-1	8312343
lymph@@	O	-1	8312343
ocyte	O	-1	8312343
glo@@	O	-1	8312343
b@@	O	-1	8312343
ul@@	O	-1	8312343
in	O	-1	8312343
was	O	-1	8312343
use@@	O	-1	8312343
d.	O	-1	8312343
S@@	B-Chemical	D013256	8312343
ter@@	I-Chemical	-1	8312343
oid@@	I-Chemical	-1	8312343
s	I-Chemical	-1	8312343
were	O	-1	8312343
given	O	-1	8312343
to	O	-1	8312343
3@@	O	-1	8312343
9@@	O	-1	8312343
%	O	-1	8312343
of	O	-1	8312343
patients	O	-1	8312343
for	O	-1	8312343
ref@@	O	-1	8312343
rac@@	O	-1	8312343
t@@	O	-1	8312343
ory	O	-1	8312343
re@@	O	-1	8312343
j@@	O	-1	8312343
ec@@	O	-1	8312343
tion,	O	-1	8312343
but	O	-1	8312343
we@@	O	-1	8312343
an@@	O	-1	8312343
ing	O	-1	8312343
was	O	-1	8312343
al@@	O	-1	8312343
w@@	O	-1	8312343
ays	O	-1	8312343
at@@	O	-1	8312343
tem@@	O	-1	8312343
pt@@	O	-1	8312343
ed	O	-1	8312343
and	O	-1	8312343
gener@@	O	-1	8312343
ally	O	-1	8312343
suc@@	O	-1	8312343
cess@@	O	-1	8312343
ful	O	-1	8312343
(6@@	O	-1	8312343
4@@	O	-1	8312343
%).	O	-1	8312343
F@@	O	-1	8312343
i@@	O	-1	8312343
ve	O	-1	8312343
patients	O	-1	8312343
(1@@	O	-1	8312343
4@@	O	-1	8312343
%)	O	-1	8312343
received	O	-1	8312343
maint@@	O	-1	8312343
en@@	O	-1	8312343
ance	O	-1	8312343
steroid@@	B-Chemical	D013256	8312343
s	I-Chemical	-1	8312343
.	O	-1	8312343
F@@	O	-1	8312343
our	O	-1	8312343
patients	O	-1	8312343
di@@	O	-1	8312343
ed	O	-1	8312343
in	O	-1	8312343
the	O	-1	8312343
perio@@	O	-1	8312343
perative	O	-1	8312343
period	O	-1	8312343
and	O	-1	8312343
one	O	-1	8312343
di@@	O	-1	8312343
ed	O	-1	8312343
4	O	-1	8312343
months	O	-1	8312343
lat@@	O	-1	8312343
er.	O	-1	8312343
There	O	-1	8312343
have	O	-1	8312343
been	O	-1	8312343
no	O	-1	8312343
de@@	O	-1	8312343
ath@@	O	-1	8312343
s	O	-1	8312343
related	O	-1	8312343
to	O	-1	8312343
re@@	O	-1	8312343
j@@	O	-1	8312343
ection	O	-1	8312343
or	O	-1	8312343
inf@@	B-Disease	D007239	8312343
ection	I-Disease	-1	8312343
.	O	-1	8312343
A@@	O	-1	8312343
ver@@	O	-1	8312343
age	O	-1	8312343
follow-up	O	-1	8312343
was	O	-1	8312343
3@@	O	-1	8312343
6	O	-1	8312343
+/-	O	-1	8312343
1@@	O	-1	8312343
9	O	-1	8312343
months	O	-1	8312343
(@@	O	-1	8312343
range	O	-1	8312343
1	O	-1	8312343
to	O	-1	8312343
6@@	O	-1	8312343
5	O	-1	8312343
month@@	O	-1	8312343
s@@	O	-1	8312343
).	O	-1	8312343
C@@	O	-1	8312343
um@@	O	-1	8312343
ul@@	O	-1	8312343
ative	O	-1	8312343
sur@@	O	-1	8312343
viv@@	O	-1	8312343
al	O	-1	8312343
is	O	-1	8312343
8@@	O	-1	8312343
8@@	O	-1	8312343
%	O	-1	8312343
at	O	-1	8312343
5	O	-1	8312343
year@@	O	-1	8312343
s.	O	-1	8312343
In	O	-1	8312343
patients	O	-1	8312343
less	O	-1	8312343
than	O	-1	8312343
7	O	-1	8312343
years	O	-1	8312343
of	O	-1	8312343
age,	O	-1	8312343
re@@	O	-1	8312343
j@@	O	-1	8312343
ection	O	-1	8312343
was	O	-1	8312343
monit@@	O	-1	8312343
o@@	O	-1	8312343
red	O	-1	8312343
non@@	O	-1	8312343
inv@@	O	-1	8312343
a@@	O	-1	8312343
si@@	O	-1	8312343
vel@@	O	-1	8312343
y.	O	-1	8312343
In	O	-1	8312343
the	O	-1	8312343
first	O	-1	8312343
postoperative	O	-1	8312343
month@@	O	-1	8312343
,	O	-1	8312343
8@@	O	-1	8312343
9@@	O	-1	8312343
%	O	-1	8312343
of	O	-1	8312343
patients	O	-1	8312343
were	O	-1	8312343
treated	O	-1	8312343
for	O	-1	8312343
re@@	O	-1	8312343
j@@	O	-1	8312343
ec@@	O	-1	8312343
tion.	O	-1	8312343
F@@	O	-1	8312343
re@@	O	-1	8312343
e@@	O	-1	8312343
do@@	O	-1	8312343
m	O	-1	8312343
from	O	-1	8312343
seri@@	O	-1	8312343
ous	O	-1	8312343
inf@@	B-Disease	D007239	8312343
ec@@	I-Disease	-1	8312343
tions	I-Disease	-1	8312343
was	O	-1	8312343
8@@	O	-1	8312343
3@@	O	-1	8312343
%	O	-1	8312343
at	O	-1	8312343
1	O	-1	8312343
mon@@	O	-1	8312343
th	O	-1	8312343
and	O	-1	8312343
6@@	O	-1	8312343
5%	O	-1	8312343
at	O	-1	8312343
1	O	-1	8312343
year@@	O	-1	8312343
.	O	-1	8312343
C@@	B-Disease	D003586	8312343
y@@	I-Disease	-1	8312343
to@@	I-Disease	-1	8312343
me@@	I-Disease	-1	8312343
g@@	I-Disease	-1	8312343
alo@@	I-Disease	-1	8312343
vi@@	I-Disease	-1	8312343
ru@@	I-Disease	-1	8312343
s	I-Disease	-1	8312343
inf@@	I-Disease	-1	8312343
ec@@	I-Disease	-1	8312343
tions	I-Disease	-1	8312343
were	O	-1	8312343
treated	O	-1	8312343
suc@@	O	-1	8312343
cess@@	O	-1	8312343
ful@@	O	-1	8312343
ly	O	-1	8312343
with	O	-1	8312343
g@@	B-Chemical	D015774	8312343
anc@@	I-Chemical	-1	8312343
ic@@	I-Chemical	-1	8312343
lo@@	I-Chemical	-1	8312343
vi@@	I-Chemical	-1	8312343
r	I-Chemical	-1	8312343
in	O	-1	8312343
11	O	-1	8312343
patients.	O	-1	8312343
No	O	-1	8312343
impair@@	O	-1	8312343
ment	O	-1	8312343
of	O	-1	8312343
growth	O	-1	8312343
was	O	-1	8312343
observed	O	-1	8312343
in	O	-1	8312343
children	O	-1	8312343
who	O	-1	8312343
under@@	O	-1	8312343
w@@	O	-1	8312343
ent	O	-1	8312343
transplant@@	O	-1	8312343
ation	O	-1	8312343
compared	O	-1	8312343
with	O	-1	8312343
a	O	-1	8312343
control	O	-1	8312343
po@@	O	-1	8312343
pul@@	O	-1	8312343
ation.	O	-1	8312343
Tw@@	O	-1	8312343
ent@@	O	-1	8312343
y-@@	O	-1	8312343
one	O	-1	8312343
patients	O	-1	8312343
(6@@	O	-1	8312343
0@@	O	-1	8312343
%)	O	-1	8312343
have	O	-1	8312343
under@@	O	-1	8312343
g@@	O	-1	8312343
one	O	-1	8312343
an@@	O	-1	8312343
n@@	O	-1	8312343
ual	O	-1	8312343
ca@@	O	-1	8312343
the@@	O	-1	8312343
ter@@	O	-1	8312343
iz@@	O	-1	8312343
ations	O	-1	8312343
and	O	-1	8312343
no	O	-1	8312343
si@@	O	-1	8312343
g@@	O	-1	8312343
n	O	-1	8312343
of	O	-1	8312343
gra@@	O	-1	8312343
ft	O	-1	8312343
a@@	B-Disease	D050197	8312343
therosclero@@	I-Disease	-1	8312343
sis	I-Disease	-1	8312343
has	O	-1	8312343
been	O	-1	8312343
obser@@	O	-1	8312343
ved.	O	-1	8312343
S@@	B-Disease	D012640	8312343
e@@	I-Disease	-1	8312343
iz@@	I-Disease	-1	8312343
ures	I-Disease	-1	8312343
occurred	O	-1	8312343
in	O	-1	8312343
five	O	-1	8312343
patients	O	-1	8312343
(1@@	O	-1	8312343
4@@	O	-1	8312343
%)	O	-1	8312343
and	O	-1	8312343
hypertension	B-Disease	D006973	8312343
was	O	-1	8312343
treated	O	-1	8312343
in	O	-1	8312343
10	O	-1	8312343
patients	O	-1	8312343
(2@@	O	-1	8312343
8@@	O	-1	8312343
%).	O	-1	8312343
No	O	-1	8312343
patient	O	-1	8312343
was	O	-1	8312343
dis@@	O	-1	8312343
abl@@	O	-1	8312343
ed	O	-1	8312343
and	O	-1	8312343
no	O	-1	8312343
lymph@@	B-Disease	D008232	8312343
o@@	I-Disease	-1	8312343
pro@@	I-Disease	-1	8312343
li@@	I-Disease	-1	8312343
fer@@	I-Disease	-1	8312343
ative	I-Disease	-1	8312343
disor@@	I-Disease	-1	8312343
der	I-Disease	-1	8312343
was	O	-1	8312343
obser@@	O	-1	8312343
ve@@	O	-1	8312343
d@@	O	-1	8312343
.@@	O	-1	8312343
(A@@	O	-1	8312343
B@@	O	-1	8312343
S@@	O	-1	8312343
TR@@	O	-1	8312343
AC@@	O	-1	8312343
T	O	-1	8312343
TR@@	O	-1	8312343
UN@@	O	-1	8312343
C@@	O	-1	8312343
AT@@	O	-1	8312343
E@@	O	-1	8312343
D	O	-1	8312343
A@@	O	-1	8312343
T	O	-1	8312343
2@@	O	-1	8312343
50	O	-1	8312343
W@@	O	-1	8312343
O@@	O	-1	8312343
RD@@	O	-1	8312343
S)	O	-1	8312343

De@@	B-Disease	D003693	8312983
li@@	I-Disease	-1	8312983
ri@@	I-Disease	-1	8312983
um	I-Disease	-1	8312983
during	O	-1	8312983
flu@@	B-Chemical	D005473	8312983
ox@@	I-Chemical	-1	8312983
et@@	I-Chemical	-1	8312983
ine	I-Chemical	-1	8312983
treatment.	O	-1	8312983
A	O	-1	8312983
case	O	-1	8312983
repor@@	O	-1	8312983
t.	O	-1	8312983
The	O	-1	8312983
correl@@	O	-1	8312983
ation	O	-1	8312983
between	O	-1	8312983
high	O	-1	8312983
serum	O	-1	8312983
tr@@	O	-1	8312983
ic@@	O	-1	8312983
y@@	O	-1	8312983
cl@@	O	-1	8312983
ic	O	-1	8312983
antidepress@@	O	-1	8312983
ant	O	-1	8312983
concentrations	O	-1	8312983
and	O	-1	8312983
central	O	-1	8312983
ner@@	O	-1	8312983
v@@	O	-1	8312983
ous	O	-1	8312983
system	O	-1	8312983
side	O	-1	8312983
effects	O	-1	8312983
has	O	-1	8312983
been	O	-1	8312983
well	O	-1	8312983
est@@	O	-1	8312983
abl@@	O	-1	8312983
is@@	O	-1	8312983
he@@	O	-1	8312983
d.	O	-1	8312983
On@@	O	-1	8312983
ly	O	-1	8312983
a	O	-1	8312983
fe@@	O	-1	8312983
w	O	-1	8312983
reports	O	-1	8312983
ex@@	O	-1	8312983
ist@@	O	-1	8312983
,	O	-1	8312983
however,	O	-1	8312983
on	O	-1	8312983
the	O	-1	8312983
rel@@	O	-1	8312983
ationship	O	-1	8312983
between	O	-1	8312983
the	O	-1	8312983
serum	O	-1	8312983
concentrations	O	-1	8312983
of	O	-1	8312983
selective	O	-1	8312983
seroton@@	B-Chemical	D012701	8312983
in	I-Chemical	-1	8312983
re@@	O	-1	8312983
u@@	O	-1	8312983
pt@@	O	-1	8312983
ake	O	-1	8312983
inhibitors	O	-1	8312983
(S@@	O	-1	8312983
SR@@	O	-1	8312983
I@@	O	-1	8312983
s)	O	-1	8312983
and	O	-1	8312983
their	O	-1	8312983
toxic	O	-1	8312983
effects.	O	-1	8312983
In	O	-1	8312983
some	O	-1	8312983
cas@@	O	-1	8312983
es,	O	-1	8312983
a	O	-1	8312983
high	O	-1	8312983
serum	O	-1	8312983
concentration	O	-1	8312983
of	O	-1	8312983
cit@@	B-Chemical	D015283	8312983
alo@@	I-Chemical	-1	8312983
pra@@	I-Chemical	-1	8312983
m	I-Chemical	-1	8312983
(@@	O	-1	8312983
>	O	-1	8312983
6@@	O	-1	8312983
00	O	-1	8312983
n@@	O	-1	8312983
mol@@	O	-1	8312983
/@@	O	-1	8312983
L@@	O	-1	8312983
)	O	-1	8312983
in	O	-1	8312983
el@@	O	-1	8312983
der@@	O	-1	8312983
ly	O	-1	8312983
patients	O	-1	8312983
has	O	-1	8312983
been	O	-1	8312983
associated	O	-1	8312983
with	O	-1	8312983
increased	O	-1	8312983
s@@	B-Disease	D006970	8312983
om@@	I-Disease	-1	8312983
n@@	I-Disease	-1	8312983
ol@@	I-Disease	-1	8312983
ence	I-Disease	-1	8312983
and	O	-1	8312983
mo@@	B-Disease	D020820	8312983
vement	I-Disease	-1	8312983
diff@@	I-Disease	-1	8312983
ic@@	I-Disease	-1	8312983
ul@@	I-Disease	-1	8312983
ties	I-Disease	-1	8312983
.	O	-1	8312983
W@@	O	-1	8312983
id@@	O	-1	8312983
es@@	O	-1	8312983
pre@@	O	-1	8312983
ad	O	-1	8312983
cognitive	B-Disease	D003072	8312983
disorder@@	I-Disease	-1	8312983
s	I-Disease	-1	8312983
,	O	-1	8312983
such	O	-1	8312983
as	O	-1	8312983
de@@	B-Disease	D003693	8312983
li@@	I-Disease	-1	8312983
ri@@	I-Disease	-1	8312983
um	I-Disease	-1	8312983
,	O	-1	8312983
have	O	-1	8312983
not	O	-1	8312983
been	O	-1	8312983
previously	O	-1	8312983
lin@@	O	-1	8312983
ked	O	-1	8312983
with	O	-1	8312983
high	O	-1	8312983
blood	O	-1	8312983
levels	O	-1	8312983
of	O	-1	8312983
S@@	O	-1	8312983
SR@@	O	-1	8312983
I@@	O	-1	8312983
s.	O	-1	8312983
In	O	-1	8312983
this	O	-1	8312983
repor@@	O	-1	8312983
t,	O	-1	8312983
we	O	-1	8312983
describe	O	-1	8312983
a	O	-1	8312983
patient	O	-1	8312983
with	O	-1	8312983
acute	O	-1	8312983
hyper@@	B-Disease	D006948	8312983
kine@@	I-Disease	-1	8312983
tic	I-Disease	-1	8312983
de@@	B-Disease	D003693	8312983
li@@	I-Disease	-1	8312983
ri@@	I-Disease	-1	8312983
um	I-Disease	-1	8312983
con@@	O	-1	8312983
n@@	O	-1	8312983
ected	O	-1	8312983
with	O	-1	8312983
a	O	-1	8312983
high	O	-1	8312983
serum	O	-1	8312983
total	O	-1	8312983
flu@@	B-Chemical	D005473	8312983
ox@@	I-Chemical	-1	8312983
et@@	I-Chemical	-1	8312983
ine	I-Chemical	-1	8312983
(	O	-1	8312983
flu@@	B-Chemical	D005473	8312983
ox@@	I-Chemical	-1	8312983
et@@	I-Chemical	-1	8312983
ine	I-Chemical	-1	8312983
plus	O	-1	8312983
des@@	B-Chemical	C036139	8312983
methyl@@	I-Chemical	-1	8312983
flu@@	I-Chemical	-1	8312983
ox@@	I-Chemical	-1	8312983
et@@	I-Chemical	-1	8312983
ine	I-Chemical	-1	8312983
)	O	-1	8312983
concentr@@	O	-1	8312983
ation.	O	-1	8312983

P@@	B-Disease	D011654	8318674
ul@@	I-Disease	-1	8318674
monary	I-Disease	-1	8318674
e@@	I-Disease	-1	8318674
de@@	I-Disease	-1	8318674
ma	I-Disease	-1	8318674
and	O	-1	8318674
sh@@	B-Disease	D012769	8318674
oc@@	I-Disease	-1	8318674
k	I-Disease	-1	8318674
after	O	-1	8318674
high-dose	O	-1	8318674
arac@@	B-Chemical	D003561	8318674
y@@	I-Chemical	-1	8318674
t@@	I-Chemical	-1	8318674
ine-@@	I-Chemical	-1	8318674
C	I-Chemical	-1	8318674
for	O	-1	8318674
lymph@@	B-Disease	D008223	8318674
oma	I-Disease	-1	8318674
;	O	-1	8318674
possible	O	-1	8318674
role	O	-1	8318674
of	O	-1	8318674
T@@	O	-1	8318674
N@@	O	-1	8318674
F@@	O	-1	8318674
-@@	O	-1	8318674
al@@	O	-1	8318674
ph@@	O	-1	8318674
a	O	-1	8318674
and	O	-1	8318674
PA@@	O	-1	8318674
F@@	O	-1	8318674
.	O	-1	8318674
F@@	O	-1	8318674
our	O	-1	8318674
out	O	-1	8318674
of	O	-1	8318674
2@@	O	-1	8318674
3	O	-1	8318674
con@@	O	-1	8318674
sec@@	O	-1	8318674
utive	O	-1	8318674
patients	O	-1	8318674
treated	O	-1	8318674
with	O	-1	8318674
high-dose	O	-1	8318674
A@@	B-Chemical	D003561	8318674
ra@@	I-Chemical	-1	8318674
-@@	I-Chemical	-1	8318674
C	I-Chemical	-1	8318674
for	O	-1	8318674
lymph@@	B-Disease	D008223	8318674
om@@	I-Disease	-1	8318674
as	I-Disease	-1	8318674
in	O	-1	8318674
our	O	-1	8318674
insti@@	O	-1	8318674
tu@@	O	-1	8318674
tion	O	-1	8318674
developed	O	-1	8318674
a	O	-1	8318674
stri@@	O	-1	8318674
k@@	O	-1	8318674
ing@@	O	-1	8318674
ly	O	-1	8318674
similar	O	-1	8318674
syndrome	O	-1	8318674
during	O	-1	8318674
the	O	-1	8318674
per@@	O	-1	8318674
fu@@	O	-1	8318674
sion.	O	-1	8318674
It	O	-1	8318674
was	O	-1	8318674
character@@	O	-1	8318674
ized	O	-1	8318674
by	O	-1	8318674
the	O	-1	8318674
onset	O	-1	8318674
of	O	-1	8318674
f@@	B-Disease	D005334	8318674
ev@@	I-Disease	-1	8318674
er	I-Disease	-1	8318674
,	O	-1	8318674
di@@	B-Disease	D003967	8318674
ar@@	I-Disease	-1	8318674
r@@	I-Disease	-1	8318674
he@@	I-Disease	-1	8318674
a	I-Disease	-1	8318674
,	O	-1	8318674
sh@@	B-Disease	D012769	8318674
oc@@	I-Disease	-1	8318674
k	I-Disease	-1	8318674
,	O	-1	8318674
pulmonary	B-Disease	D011654	8318674
e@@	I-Disease	-1	8318674
de@@	I-Disease	-1	8318674
ma	I-Disease	-1	8318674
,	O	-1	8318674
acute	B-Disease	D058186	8318674
renal	I-Disease	-1	8318674
failure	I-Disease	-1	8318674
,	O	-1	8318674
met@@	B-Disease	D000138	8318674
ab@@	I-Disease	-1	8318674
olic	I-Disease	-1	8318674
acid@@	I-Disease	-1	8318674
o@@	I-Disease	-1	8318674
sis	I-Disease	-1	8318674
,	O	-1	8318674
weight	B-Disease	D015430	8318674
g@@	I-Disease	-1	8318674
ain	I-Disease	-1	8318674
and	O	-1	8318674
leuk@@	B-Disease	D007964	8318674
ocyto@@	I-Disease	-1	8318674
sis	I-Disease	-1	8318674
.	O	-1	8318674
Th@@	O	-1	8318674
o@@	O	-1	8318674
rou@@	O	-1	8318674
gh	O	-1	8318674
bac@@	O	-1	8318674
ter@@	O	-1	8318674
io@@	O	-1	8318674
log@@	O	-1	8318674
ical	O	-1	8318674
s@@	O	-1	8318674
cre@@	O	-1	8318674
en@@	O	-1	8318674
ing	O	-1	8318674
fail@@	O	-1	8318674
ed	O	-1	8318674
to	O	-1	8318674
prov@@	O	-1	8318674
ide	O	-1	8318674
evidence	O	-1	8318674
of	O	-1	8318674
inf@@	B-Disease	D007239	8318674
ection	I-Disease	-1	8318674
.	O	-1	8318674
S@@	O	-1	8318674
equ@@	O	-1	8318674
en@@	O	-1	8318674
tial	O	-1	8318674
bio@@	O	-1	8318674
log@@	O	-1	8318674
ical	O	-1	8318674
ass@@	O	-1	8318674
ays	O	-1	8318674
of	O	-1	8318674
I@@	O	-1	8318674
L-@@	O	-1	8318674
1,	O	-1	8318674
I@@	O	-1	8318674
L-@@	O	-1	8318674
2,	O	-1	8318674
T@@	O	-1	8318674
N@@	O	-1	8318674
F	O	-1	8318674
and	O	-1	8318674
PA@@	O	-1	8318674
F	O	-1	8318674
were	O	-1	8318674
performed	O	-1	8318674
during	O	-1	8318674
A@@	B-Chemical	D003561	8318674
ra@@	I-Chemical	-1	8318674
-@@	I-Chemical	-1	8318674
C	I-Chemical	-1	8318674
infusion	O	-1	8318674
to	O	-1	8318674
ten	O	-1	8318674
patients,	O	-1	8318674
including	O	-1	8318674
the	O	-1	8318674
four	O	-1	8318674
who	O	-1	8318674
developed	O	-1	8318674
the	O	-1	8318674
syndro@@	O	-1	8318674
me.	O	-1	8318674
T@@	O	-1	8318674
N@@	O	-1	8318674
F	O	-1	8318674
and	O	-1	8318674
PA@@	O	-1	8318674
F	O	-1	8318674
activity	O	-1	8318674
was	O	-1	8318674
found	O	-1	8318674
in	O	-1	8318674
the	O	-1	8318674
serum	O	-1	8318674
of	O	-1	8318674
respecti@@	O	-1	8318674
vely	O	-1	8318674
two	O	-1	8318674
and	O	-1	8318674
four	O	-1	8318674
of	O	-1	8318674
the	O	-1	8318674
cas@@	O	-1	8318674
es,	O	-1	8318674
but	O	-1	8318674
not	O	-1	8318674
in	O	-1	8318674
the	O	-1	8318674
six	O	-1	8318674
controls.	O	-1	8318674
A@@	O	-1	8318674
s	O	-1	8318674
T@@	O	-1	8318674
N@@	O	-1	8318674
F	O	-1	8318674
and	O	-1	8318674
PA@@	O	-1	8318674
F	O	-1	8318674
are	O	-1	8318674
thou@@	O	-1	8318674
ght	O	-1	8318674
to	O	-1	8318674
be	O	-1	8318674
involved	O	-1	8318674
in	O	-1	8318674
the	O	-1	8318674
development	O	-1	8318674
of	O	-1	8318674
se@@	O	-1	8318674
p@@	O	-1	8318674
tic	O	-1	8318674
sh@@	B-Disease	D012769	8318674
oc@@	I-Disease	-1	8318674
k	I-Disease	-1	8318674
and	O	-1	8318674
ad@@	B-Disease	D012128	8318674
ult	I-Disease	-1	8318674
respiratory	I-Disease	-1	8318674
dist@@	I-Disease	-1	8318674
res@@	I-Disease	-1	8318674
s	I-Disease	-1	8318674
syndrome	I-Disease	-1	8318674
,	O	-1	8318674
we	O	-1	8318674
hypo@@	O	-1	8318674
the@@	O	-1	8318674
size	O	-1	8318674
that	O	-1	8318674
high-dose	O	-1	8318674
A@@	B-Chemical	D003561	8318674
ra@@	I-Chemical	-1	8318674
-@@	I-Chemical	-1	8318674
C	I-Chemical	-1	8318674
may	O	-1	8318674
be	O	-1	8318674
associated	O	-1	8318674
with	O	-1	8318674
cyto@@	O	-1	8318674
k@@	O	-1	8318674
ine	O	-1	8318674
rele@@	O	-1	8318674
as@@	O	-1	8318674
e.	O	-1	8318674

Pro@@	O	-1	8392553
t@@	O	-1	8392553
ective	O	-1	8392553
effect	O	-1	8392553
of	O	-1	8392553
cl@@	B-Chemical	C056595	8392553
enti@@	I-Chemical	-1	8392553
az@@	I-Chemical	-1	8392553
em	I-Chemical	-1	8392553
against	O	-1	8392553
ep@@	B-Chemical	D004837	8392553
ine@@	I-Chemical	-1	8392553
phrine	I-Chemical	-1	8392553
-induced	O	-1	8392553
cardiac	B-Disease	D006331	8392553
injury	I-Disease	-1	8392553
in	O	-1	8392553
rats.	O	-1	8392553
We	O	-1	8392553
investigated	O	-1	8392553
the	O	-1	8392553
effects	O	-1	8392553
of	O	-1	8392553
cl@@	B-Chemical	C056595	8392553
enti@@	I-Chemical	-1	8392553
az@@	I-Chemical	-1	8392553
em	I-Chemical	-1	8392553
,	O	-1	8392553
a	O	-1	8392553
1@@	B-Chemical	C106746	8392553
,@@	I-Chemical	-1	8392553
5-@@	I-Chemical	-1	8392553
b@@	I-Chemical	-1	8392553
enz@@	I-Chemical	-1	8392553
o@@	I-Chemical	-1	8392553
thi@@	I-Chemical	-1	8392553
azepine	I-Chemical	-1	8392553
calcium	B-Chemical	D002118	8392553
antagonist@@	O	-1	8392553
,	O	-1	8392553
on	O	-1	8392553
ep@@	B-Chemical	D004837	8392553
ine@@	I-Chemical	-1	8392553
phrine	I-Chemical	-1	8392553
-induced	O	-1	8392553
cardi@@	B-Disease	D009202	8392553
om@@	I-Disease	-1	8392553
yo@@	I-Disease	-1	8392553
pathy	I-Disease	-1	8392553
in	O	-1	8392553
rats.	O	-1	8392553
W@@	O	-1	8392553
it@@	O	-1	8392553
h	O	-1	8392553
2-@@	O	-1	8392553
week	O	-1	8392553
chronic	O	-1	8392553
ep@@	B-Chemical	D004837	8392553
ine@@	I-Chemical	-1	8392553
phrine	I-Chemical	-1	8392553
infu@@	O	-1	8392553
sion,	O	-1	8392553
16	O	-1	8392553
of	O	-1	8392553
30	O	-1	8392553
rats	O	-1	8392553
di@@	O	-1	8392553
ed	O	-1	8392553
within	O	-1	8392553
4	O	-1	8392553
day@@	O	-1	8392553
s,	O	-1	8392553
and	O	-1	8392553
severe	O	-1	8392553
ischem@@	B-Disease	D007511	8392553
ic	I-Disease	-1	8392553
lesions	I-Disease	-1	8392553
and	O	-1	8392553
fib@@	B-Disease	D005355	8392553
ro@@	I-Disease	-1	8392553
sis	I-Disease	-1	8392553
of	O	-1	8392553
the	O	-1	8392553
left	O	-1	8392553
ventric@@	O	-1	8392553
le@@	O	-1	8392553
s	O	-1	8392553
were	O	-1	8392553
obser@@	O	-1	8392553
ved.	O	-1	8392553
In	O	-1	8392553
ep@@	B-Chemical	D004837	8392553
ine@@	I-Chemical	-1	8392553
phrine	I-Chemical	-1	8392553
-treated	O	-1	8392553
rats,	O	-1	8392553
left	O	-1	8392553
atrial	O	-1	8392553
and	O	-1	8392553
left	O	-1	8392553
ventricular	O	-1	8392553
pap@@	O	-1	8392553
ill@@	O	-1	8392553
ary	O	-1	8392553
musc@@	O	-1	8392553
le	O	-1	8392553
contrac@@	O	-1	8392553
ti@@	O	-1	8392553
le	O	-1	8392553
responses	O	-1	8392553
to	O	-1	8392553
isoproteren@@	B-Chemical	D007545	8392553
ol	I-Chemical	-1	8392553
were	O	-1	8392553
reduc@@	O	-1	8392553
ed,	O	-1	8392553
but	O	-1	8392553
responses	O	-1	8392553
to	O	-1	8392553
calcium	B-Chemical	D002118	8392553
were	O	-1	8392553
normal	O	-1	8392553
or	O	-1	8392553
enhanced	O	-1	8392553
compared	O	-1	8392553
to	O	-1	8392553
controls.	O	-1	8392553
L@@	O	-1	8392553
e@@	O	-1	8392553
ft	O	-1	8392553
ventricular	O	-1	8392553
al@@	O	-1	8392553
ph@@	O	-1	8392553
a	O	-1	8392553
and	O	-1	8392553
bet@@	O	-1	8392553
a	O	-1	8392553
adren@@	O	-1	8392553
oc@@	O	-1	8392553
e@@	O	-1	8392553
pt@@	O	-1	8392553
or	O	-1	8392553
d@@	O	-1	8392553
en@@	O	-1	8392553
si@@	O	-1	8392553
ties	O	-1	8392553
were	O	-1	8392553
also	O	-1	8392553
reduced	O	-1	8392553
compared	O	-1	8392553
to	O	-1	8392553
controls.	O	-1	8392553
Treat@@	O	-1	8392553
ment	O	-1	8392553
with	O	-1	8392553
cl@@	B-Chemical	C056595	8392553
enti@@	I-Chemical	-1	8392553
az@@	I-Chemical	-1	8392553
em	I-Chemical	-1	8392553
prevent@@	O	-1	8392553
ed	O	-1	8392553
ep@@	B-Chemical	D004837	8392553
ine@@	I-Chemical	-1	8392553
phrine	I-Chemical	-1	8392553
-induced	O	-1	8392553
death	O	-1	8392553
(P	O	-1	8392553
<	O	-1	8392553
.@@	O	-1	8392553
0@@	O	-1	8392553
5@@	O	-1	8392553
),	O	-1	8392553
and	O	-1	8392553
attenu@@	O	-1	8392553
ated	O	-1	8392553
the	O	-1	8392553
ventricular	O	-1	8392553
ischem@@	B-Disease	D007511	8392553
ic	I-Disease	-1	8392553
lesions	I-Disease	-1	8392553
and	O	-1	8392553
fib@@	B-Disease	D005355	8392553
ro@@	I-Disease	-1	8392553
sis	I-Disease	-1	8392553
,	O	-1	8392553
in	O	-1	8392553
a	O	-1	8392553
dose-@@	O	-1	8392553
dependent	O	-1	8392553
man@@	O	-1	8392553
ner@@	O	-1	8392553
.	O	-1	8392553
L@@	O	-1	8392553
e@@	O	-1	8392553
ft	O	-1	8392553
atrial	O	-1	8392553
and	O	-1	8392553
left	O	-1	8392553
ventricular	O	-1	8392553
pap@@	O	-1	8392553
ill@@	O	-1	8392553
ary	O	-1	8392553
musc@@	O	-1	8392553
le	O	-1	8392553
contrac@@	O	-1	8392553
ti@@	O	-1	8392553
le	O	-1	8392553
responses	O	-1	8392553
to	O	-1	8392553
isoproteren@@	B-Chemical	D007545	8392553
ol	I-Chemical	-1	8392553
were	O	-1	8392553
reduced	O	-1	8392553
compared	O	-1	8392553
to	O	-1	8392553
controls	O	-1	8392553
in	O	-1	8392553
groups	O	-1	8392553
treated	O	-1	8392553
with	O	-1	8392553
cl@@	B-Chemical	C056595	8392553
enti@@	I-Chemical	-1	8392553
az@@	I-Chemical	-1	8392553
em	I-Chemical	-1	8392553
al@@	O	-1	8392553
one,	O	-1	8392553
but	O	-1	8392553
combined	O	-1	8392553
with	O	-1	8392553
ep@@	B-Chemical	D004837	8392553
ine@@	I-Chemical	-1	8392553
phrine	I-Chemical	-1	8392553
,	O	-1	8392553
cl@@	B-Chemical	C056595	8392553
enti@@	I-Chemical	-1	8392553
az@@	I-Chemical	-1	8392553
em	I-Chemical	-1	8392553
re@@	O	-1	8392553
sto@@	O	-1	8392553
red	O	-1	8392553
left	O	-1	8392553
atrial	O	-1	8392553
responses	O	-1	8392553
and	O	-1	8392553
enhanced	O	-1	8392553
left	O	-1	8392553
ventricular	O	-1	8392553
pap@@	O	-1	8392553
ill@@	O	-1	8392553
ary	O	-1	8392553
responses	O	-1	8392553
to	O	-1	8392553
isoproteren@@	B-Chemical	D007545	8392553
ol	I-Chemical	-1	8392553
.	O	-1	8392553
O@@	O	-1	8392553
n	O	-1	8392553
the	O	-1	8392553
other	O	-1	8392553
h@@	O	-1	8392553
and	O	-1	8392553
cl@@	B-Chemical	C056595	8392553
enti@@	I-Chemical	-1	8392553
az@@	I-Chemical	-1	8392553
em	I-Chemical	-1	8392553
did	O	-1	8392553
not	O	-1	8392553
prev@@	O	-1	8392553
ent	O	-1	8392553
ep@@	B-Chemical	D004837	8392553
ine@@	I-Chemical	-1	8392553
phrine	I-Chemical	-1	8392553
-induced	O	-1	8392553
do@@	O	-1	8392553
w@@	O	-1	8392553
n@@	O	-1	8392553
-@@	O	-1	8392553
reg@@	O	-1	8392553
ulation	O	-1	8392553
of	O	-1	8392553
al@@	O	-1	8392553
ph@@	O	-1	8392553
a	O	-1	8392553
and	O	-1	8392553
bet@@	O	-1	8392553
a	O	-1	8392553
adren@@	O	-1	8392553
oc@@	O	-1	8392553
e@@	O	-1	8392553
pt@@	O	-1	8392553
or@@	O	-1	8392553
s.	O	-1	8392553
In@@	O	-1	8392553
te@@	O	-1	8392553
rest@@	O	-1	8392553
ing@@	O	-1	8392553
ly,	O	-1	8392553
cl@@	B-Chemical	C056595	8392553
enti@@	I-Chemical	-1	8392553
az@@	I-Chemical	-1	8392553
em	I-Chemical	-1	8392553
,	O	-1	8392553
inf@@	O	-1	8392553
used	O	-1	8392553
al@@	O	-1	8392553
one,	O	-1	8392553
resulted	O	-1	8392553
in	O	-1	8392553
decreased	O	-1	8392553
adrenergic	O	-1	8392553
receptor	O	-1	8392553
d@@	O	-1	8392553
en@@	O	-1	8392553
si@@	O	-1	8392553
ties	O	-1	8392553
in	O	-1	8392553
the	O	-1	8392553
left	O	-1	8392553
ventric@@	O	-1	8392553
le@@	O	-1	8392553
.	O	-1	8392553
Cl@@	B-Chemical	C056595	8392553
enti@@	I-Chemical	-1	8392553
az@@	I-Chemical	-1	8392553
em	I-Chemical	-1	8392553
also	O	-1	8392553
did	O	-1	8392553
not	O	-1	8392553
prev@@	O	-1	8392553
ent	O	-1	8392553
the	O	-1	8392553
enhanced	O	-1	8392553
responses	O	-1	8392553
to	O	-1	8392553
calcium	B-Chemical	D002118	8392553
seen	O	-1	8392553
in	O	-1	8392553
the	O	-1	8392553
ep@@	B-Chemical	D004837	8392553
ine@@	I-Chemical	-1	8392553
phrine	I-Chemical	-1	8392553
-treated	O	-1	8392553
anim@@	O	-1	8392553
al@@	O	-1	8392553
s,	O	-1	8392553
although	O	-1	8392553
the	O	-1	8392553
high	O	-1	8392553
dose	O	-1	8392553
of	O	-1	8392553
cl@@	B-Chemical	C056595	8392553
enti@@	I-Chemical	-1	8392553
az@@	I-Chemical	-1	8392553
em	I-Chemical	-1	8392553
par@@	O	-1	8392553
ti@@	O	-1	8392553
ally	O	-1	8392553
attenu@@	O	-1	8392553
ated	O	-1	8392553
the	O	-1	8392553
maxim@@	O	-1	8392553
al	O	-1	8392553
response	O	-1	8392553
to	O	-1	8392553
calcium	B-Chemical	D002118	8392553
compared	O	-1	8392553
to	O	-1	8392553
ep@@	B-Chemical	D004837	8392553
ine@@	I-Chemical	-1	8392553
phrine	I-Chemical	-1	8392553
-treated	O	-1	8392553
anim@@	O	-1	8392553
al@@	O	-1	8392553
s.	O	-1	8392553
In	O	-1	8392553
concl@@	O	-1	8392553
u@@	O	-1	8392553
sion,	O	-1	8392553
cl@@	B-Chemical	C056595	8392553
enti@@	I-Chemical	-1	8392553
az@@	I-Chemical	-1	8392553
em	I-Chemical	-1	8392553
attenu@@	O	-1	8392553
ated	O	-1	8392553
ep@@	B-Chemical	D004837	8392553
ine@@	I-Chemical	-1	8392553
phrine	I-Chemical	-1	8392553
-induced	O	-1	8392553
cardiac	B-Disease	D006331	8392553
injury	I-Disease	-1	8392553
,	O	-1	8392553
possib@@	O	-1	8392553
ly	O	-1	8392553
through	O	-1	8392553
its	O	-1	8392553
effect	O	-1	8392553
on	O	-1	8392553
the	O	-1	8392553
adrenergic	O	-1	8392553
path@@	O	-1	8392553
w@@	O	-1	8392553
a@@	O	-1	8392553
y.	O	-1	8392553

C@@	B-Chemical	D003042	8511251
oc@@	I-Chemical	-1	8511251
aine	I-Chemical	-1	8511251
induced	O	-1	8511251
myocardial	B-Disease	D017202	8511251
ischem@@	I-Disease	-1	8511251
ia	I-Disease	-1	8511251
.	O	-1	8511251
We	O	-1	8511251
report	O	-1	8511251
a	O	-1	8511251
case	O	-1	8511251
of	O	-1	8511251
myocardial	B-Disease	D017202	8511251
ischem@@	I-Disease	-1	8511251
ia	I-Disease	-1	8511251
induced	O	-1	8511251
by	O	-1	8511251
cocaine	B-Chemical	D003042	8511251
.	O	-1	8511251
The	O	-1	8511251
ischem@@	B-Disease	D007511	8511251
ia	I-Disease	-1	8511251
prob@@	O	-1	8511251
ably	O	-1	8511251
induced	O	-1	8511251
by	O	-1	8511251
coronary	B-Disease	D003329	8511251
artery	I-Disease	-1	8511251
sp@@	I-Disease	-1	8511251
as@@	I-Disease	-1	8511251
m	I-Disease	-1	8511251
was	O	-1	8511251
reversed	O	-1	8511251
by	O	-1	8511251
nitro@@	B-Chemical	D005996	8511251
glycer@@	I-Chemical	-1	8511251
in	I-Chemical	-1	8511251
and	O	-1	8511251
calcium	B-Chemical	D002118	8511251
block@@	O	-1	8511251
ing	O	-1	8511251
agent@@	O	-1	8511251
s.	O	-1	8511251

D@@	B-Chemical	D004317	8603459
ox@@	I-Chemical	-1	8603459
orub@@	I-Chemical	-1	8603459
icin	I-Chemical	-1	8603459
-induced	O	-1	8603459
cardi@@	B-Disease	D066126	8603459
otoxicity	I-Disease	-1	8603459
monit@@	O	-1	8603459
o@@	O	-1	8603459
red	O	-1	8603459
by	O	-1	8603459
EC@@	O	-1	8603459
G	O	-1	8603459
in	O	-1	8603459
f@@	O	-1	8603459
re@@	O	-1	8603459
ely	O	-1	8603459
mo@@	O	-1	8603459
ving	O	-1	8603459
mice.	O	-1	8603459
A	O	-1	8603459
new	O	-1	8603459
model	O	-1	8603459
to	O	-1	8603459
test	O	-1	8603459
potential	O	-1	8603459
prot@@	O	-1	8603459
ect@@	O	-1	8603459
or@@	O	-1	8603459
s.	O	-1	8603459
In	O	-1	8603459
labor@@	O	-1	8603459
atory	O	-1	8603459
anim@@	O	-1	8603459
al@@	O	-1	8603459
s,	O	-1	8603459
hist@@	O	-1	8603459
ology	O	-1	8603459
is	O	-1	8603459
most	O	-1	8603459
common@@	O	-1	8603459
ly	O	-1	8603459
used	O	-1	8603459
to	O	-1	8603459
study	O	-1	8603459
dox@@	B-Chemical	D004317	8603459
orub@@	I-Chemical	-1	8603459
icin	I-Chemical	-1	8603459
-induced	O	-1	8603459
cardi@@	B-Disease	D066126	8603459
otoxicity	I-Disease	-1	8603459
.	O	-1	8603459
However,	O	-1	8603459
for	O	-1	8603459
monit@@	O	-1	8603459
or@@	O	-1	8603459
ing	O	-1	8603459
during	O	-1	8603459
treatment,	O	-1	8603459
larg@@	O	-1	8603459
e	O	-1	8603459
numb@@	O	-1	8603459
ers	O	-1	8603459
of	O	-1	8603459
animals	O	-1	8603459
are	O	-1	8603459
ne@@	O	-1	8603459
e@@	O	-1	8603459
de@@	O	-1	8603459
d.	O	-1	8603459
Rec@@	O	-1	8603459
ently	O	-1	8603459
we	O	-1	8603459
developed	O	-1	8603459
a	O	-1	8603459
new	O	-1	8603459
meth@@	O	-1	8603459
od	O	-1	8603459
to	O	-1	8603459
meas@@	O	-1	8603459
ure	O	-1	8603459
EC@@	O	-1	8603459
G	O	-1	8603459
values	O	-1	8603459
in	O	-1	8603459
f@@	O	-1	8603459
re@@	O	-1	8603459
ely	O	-1	8603459
mo@@	O	-1	8603459
ving	O	-1	8603459
mice	O	-1	8603459
by	O	-1	8603459
te@@	O	-1	8603459
le@@	O	-1	8603459
met@@	O	-1	8603459
r@@	O	-1	8603459
y.	O	-1	8603459
W@@	O	-1	8603459
it@@	O	-1	8603459
h	O	-1	8603459
this	O	-1	8603459
model	O	-1	8603459
we	O	-1	8603459
investigated	O	-1	8603459
the	O	-1	8603459
effect	O	-1	8603459
of	O	-1	8603459
chronic	O	-1	8603459
dox@@	B-Chemical	D004317	8603459
orub@@	I-Chemical	-1	8603459
icin	I-Chemical	-1	8603459
administration	O	-1	8603459
on	O	-1	8603459
the	O	-1	8603459
EC@@	O	-1	8603459
G	O	-1	8603459
of	O	-1	8603459
f@@	O	-1	8603459
re@@	O	-1	8603459
ely	O	-1	8603459
mo@@	O	-1	8603459
ving	O	-1	8603459
BA@@	O	-1	8603459
L@@	O	-1	8603459
B@@	O	-1	8603459
/@@	O	-1	8603459
c	O	-1	8603459
mice	O	-1	8603459
and	O	-1	8603459
the	O	-1	8603459
efficacy	O	-1	8603459
of	O	-1	8603459
I@@	B-Chemical	D064730	8603459
CR@@	I-Chemical	-1	8603459
F@@	I-Chemical	-1	8603459
-1@@	I-Chemical	-1	8603459
8@@	I-Chemical	-1	8603459
7	I-Chemical	-1	8603459
as	O	-1	8603459
a	O	-1	8603459
protective	O	-1	8603459
agent@@	O	-1	8603459
.	O	-1	8603459
The	O	-1	8603459
S@@	O	-1	8603459
T	O	-1	8603459
interv@@	O	-1	8603459
al	O	-1	8603459
significantly	O	-1	8603459
w@@	O	-1	8603459
id@@	O	-1	8603459
en@@	O	-1	8603459
ed	O	-1	8603459
from	O	-1	8603459
1@@	O	-1	8603459
5.@@	O	-1	8603459
0	O	-1	8603459
+/-	O	-1	8603459
1.@@	O	-1	8603459
5	O	-1	8603459
to	O	-1	8603459
5@@	O	-1	8603459
6.@@	O	-1	8603459
8	O	-1	8603459
+/-	O	-1	8603459
1@@	O	-1	8603459
1.@@	O	-1	8603459
8	O	-1	8603459
ms	O	-1	8603459
in	O	-1	8603459
week	O	-1	8603459
10	O	-1	8603459
(@@	O	-1	8603459
7	O	-1	8603459
week@@	O	-1	8603459
ly	O	-1	8603459
doses	O	-1	8603459
of	O	-1	8603459
4	O	-1	8603459
mg/kg	O	-1	8603459
dox@@	B-Chemical	D004317	8603459
orub@@	I-Chemical	-1	8603459
icin	I-Chemical	-1	8603459
given	O	-1	8603459
i.v@@	O	-1	8603459
.	O	-1	8603459
plus	O	-1	8603459
3	O	-1	8603459
weeks	O	-1	8603459
of	O	-1	8603459
observ@@	O	-1	8603459
ation@@	O	-1	8603459
).	O	-1	8603459
The	O	-1	8603459
EC@@	O	-1	8603459
G	O	-1	8603459
of	O	-1	8603459
the	O	-1	8603459
control	O	-1	8603459
animals	O	-1	8603459
did	O	-1	8603459
not	O	-1	8603459
change	O	-1	8603459
during	O	-1	8603459
the	O	-1	8603459
enti@@	O	-1	8603459
r@@	O	-1	8603459
e	O	-1	8603459
study.	O	-1	8603459
After	O	-1	8603459
s@@	O	-1	8603459
ac@@	O	-1	8603459
ri@@	O	-1	8603459
fic@@	O	-1	8603459
e	O	-1	8603459
the	O	-1	8603459
hear@@	O	-1	8603459
ts	O	-1	8603459
of	O	-1	8603459
dox@@	B-Chemical	D004317	8603459
orub@@	I-Chemical	-1	8603459
icin	I-Chemical	-1	8603459
-treated	O	-1	8603459
animals	O	-1	8603459
were	O	-1	8603459
en@@	O	-1	8603459
larg@@	O	-1	8603459
ed	O	-1	8603459
and	O	-1	8603459
the	O	-1	8603459
atri@@	O	-1	8603459
a	O	-1	8603459
were	O	-1	8603459
hyper@@	B-Disease	D006984	8603459
tro@@	I-Disease	-1	8603459
ph@@	I-Disease	-1	8603459
ic	I-Disease	-1	8603459
.	O	-1	8603459
A@@	O	-1	8603459
s	O	-1	8603459
this	O	-1	8603459
sch@@	O	-1	8603459
ed@@	O	-1	8603459
ul@@	O	-1	8603459
e	O	-1	8603459
ex@@	O	-1	8603459
er@@	O	-1	8603459
ted	O	-1	8603459
more	O	-1	8603459
toxicity	B-Disease	D064420	8603459
than	O	-1	8603459
ne@@	O	-1	8603459
ed@@	O	-1	8603459
ed	O	-1	8603459
to	O	-1	8603459
investigate	O	-1	8603459
protective	O	-1	8603459
agent@@	O	-1	8603459
s,	O	-1	8603459
the	O	-1	8603459
prot@@	O	-1	8603459
ection	O	-1	8603459
of	O	-1	8603459
I@@	B-Chemical	D064730	8603459
CR@@	I-Chemical	-1	8603459
F@@	I-Chemical	-1	8603459
-1@@	I-Chemical	-1	8603459
8@@	I-Chemical	-1	8603459
7	I-Chemical	-1	8603459
was	O	-1	8603459
determined	O	-1	8603459
using	O	-1	8603459
a	O	-1	8603459
dose	O	-1	8603459
sch@@	O	-1	8603459
ed@@	O	-1	8603459
ul@@	O	-1	8603459
e	O	-1	8603459
with	O	-1	8603459
lower	O	-1	8603459
gener@@	O	-1	8603459
al	O	-1	8603459
toxicity	B-Disease	D064420	8603459
(@@	O	-1	8603459
6	O	-1	8603459
week@@	O	-1	8603459
ly	O	-1	8603459
doses	O	-1	8603459
of	O	-1	8603459
4	O	-1	8603459
mg/kg	O	-1	8603459
dox@@	B-Chemical	D004317	8603459
orub@@	I-Chemical	-1	8603459
icin	I-Chemical	-1	8603459
given	O	-1	8603459
i.v@@	O	-1	8603459
.	O	-1	8603459
plus	O	-1	8603459
2	O	-1	8603459
weeks	O	-1	8603459
of	O	-1	8603459
observ@@	O	-1	8603459
ation@@	O	-1	8603459
).	O	-1	8603459
O@@	O	-1	8603459
n	O	-1	8603459
this	O	-1	8603459
sch@@	O	-1	8603459
ed@@	O	-1	8603459
ul@@	O	-1	8603459
e,	O	-1	8603459
the	O	-1	8603459
anim@@	O	-1	8603459
al@@	O	-1	8603459
s@@	O	-1	8603459
'	O	-1	8603459
hear@@	O	-1	8603459
ts	O	-1	8603459
appe@@	O	-1	8603459
a@@	O	-1	8603459
red	O	-1	8603459
normal	O	-1	8603459
after	O	-1	8603459
s@@	O	-1	8603459
ac@@	O	-1	8603459
ri@@	O	-1	8603459
fic@@	O	-1	8603459
e	O	-1	8603459
and	O	-1	8603459
I@@	B-Chemical	D064730	8603459
CR@@	I-Chemical	-1	8603459
F@@	I-Chemical	-1	8603459
-1@@	I-Chemical	-1	8603459
8@@	I-Chemical	-1	8603459
7	I-Chemical	-1	8603459
(@@	O	-1	8603459
50	O	-1	8603459
mg/kg	O	-1	8603459
given	O	-1	8603459
i.@@	O	-1	8603459
p@@	O	-1	8603459
.	O	-1	8603459
1	O	-1	8603459
h	O	-1	8603459
before	O	-1	8603459
dox@@	B-Chemical	D004317	8603459
orub@@	I-Chemical	-1	8603459
icin	I-Chemical	-1	8603459
)	O	-1	8603459
pro@@	O	-1	8603459
vid@@	O	-1	8603459
ed	O	-1	8603459
al@@	O	-1	8603459
most	O	-1	8603459
ful@@	O	-1	8603459
l	O	-1	8603459
prot@@	O	-1	8603459
ec@@	O	-1	8603459
tion.	O	-1	8603459
These	O	-1	8603459
data	O	-1	8603459
were	O	-1	8603459
con@@	O	-1	8603459
fir@@	O	-1	8603459
m@@	O	-1	8603459
ed	O	-1	8603459
by	O	-1	8603459
hist@@	O	-1	8603459
olog@@	O	-1	8603459
y.	O	-1	8603459
The	O	-1	8603459
results	O	-1	8603459
indicate	O	-1	8603459
that	O	-1	8603459
this	O	-1	8603459
new	O	-1	8603459
model	O	-1	8603459
is	O	-1	8603459
very	O	-1	8603459
sensitive	O	-1	8603459
and	O	-1	8603459
en@@	O	-1	8603459
able@@	O	-1	8603459
s	O	-1	8603459
monit@@	O	-1	8603459
or@@	O	-1	8603459
ing	O	-1	8603459
of	O	-1	8603459
the	O	-1	8603459
development	O	-1	8603459
of	O	-1	8603459
cardi@@	B-Disease	D066126	8603459
otoxicity	I-Disease	-1	8603459
with	O	-1	8603459
ti@@	O	-1	8603459
me.	O	-1	8603459
These	O	-1	8603459
findings	O	-1	8603459
result	O	-1	8603459
in	O	-1	8603459
a	O	-1	8603459
model	O	-1	8603459
that	O	-1	8603459
al@@	O	-1	8603459
low@@	O	-1	8603459
s	O	-1	8603459
the	O	-1	8603459
test@@	O	-1	8603459
ing	O	-1	8603459
of	O	-1	8603459
prot@@	O	-1	8603459
ect@@	O	-1	8603459
ors	O	-1	8603459
against	O	-1	8603459
dox@@	B-Chemical	D004317	8603459
orub@@	I-Chemical	-1	8603459
icin	I-Chemical	-1	8603459
-induced	O	-1	8603459
cardi@@	B-Disease	D066126	8603459
otoxicity	I-Disease	-1	8603459
as	O	-1	8603459
demonstrated	O	-1	8603459
by	O	-1	8603459
the	O	-1	8603459
prot@@	O	-1	8603459
ection	O	-1	8603459
pro@@	O	-1	8603459
vid@@	O	-1	8603459
ed	O	-1	8603459
by	O	-1	8603459
I@@	B-Chemical	D064730	8603459
CR@@	I-Chemical	-1	8603459
F@@	I-Chemical	-1	8603459
-1@@	I-Chemical	-1	8603459
8@@	I-Chemical	-1	8603459
7	I-Chemical	-1	8603459
.	O	-1	8603459

E@@	B-Chemical	D004837	8659767
p@@	I-Chemical	-1	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
dys@@	O	-1	8659767
rhyth@@	O	-1	8659767
mo@@	O	-1	8659767
gen@@	O	-1	8659767
ic@@	O	-1	8659767
ity	O	-1	8659767
is	O	-1	8659767
not	O	-1	8659767
enhanced	O	-1	8659767
by	O	-1	8659767
sub@@	O	-1	8659767
toxic	O	-1	8659767
bupivac@@	B-Chemical	D002045	8659767
aine	I-Chemical	-1	8659767
in	O	-1	8659767
dog@@	O	-1	8659767
s.	O	-1	8659767
S@@	O	-1	8659767
inc@@	O	-1	8659767
e	O	-1	8659767
bupivac@@	B-Chemical	D002045	8659767
aine	I-Chemical	-1	8659767
and	O	-1	8659767
ep@@	B-Chemical	D004837	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
may	O	-1	8659767
both	O	-1	8659767
pre@@	O	-1	8659767
ci@@	O	-1	8659767
pit@@	O	-1	8659767
ate	O	-1	8659767
dys@@	B-Disease	D001145	8659767
rhyth@@	I-Disease	-1	8659767
mi@@	I-Disease	-1	8659767
as	I-Disease	-1	8659767
,	O	-1	8659767
cir@@	O	-1	8659767
cul@@	O	-1	8659767
ating	O	-1	8659767
bupivac@@	B-Chemical	D002045	8659767
aine	I-Chemical	-1	8659767
during	O	-1	8659767
regi@@	O	-1	8659767
on@@	O	-1	8659767
al	O	-1	8659767
anesthe@@	O	-1	8659767
sia	O	-1	8659767
could	O	-1	8659767
potenti@@	O	-1	8659767
ate	O	-1	8659767
dys@@	O	-1	8659767
rhyth@@	O	-1	8659767
mo@@	O	-1	8659767
genic	O	-1	8659767
effects	O	-1	8659767
of	O	-1	8659767
ep@@	B-Chemical	D004837	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
.	O	-1	8659767
We	O	-1	8659767
the@@	O	-1	8659767
re@@	O	-1	8659767
fore	O	-1	8659767
examined	O	-1	8659767
whether	O	-1	8659767
bupivac@@	B-Chemical	D002045	8659767
aine	I-Chemical	-1	8659767
al@@	O	-1	8659767
ters	O	-1	8659767
the	O	-1	8659767
dys@@	O	-1	8659767
rhyth@@	O	-1	8659767
mo@@	O	-1	8659767
gen@@	O	-1	8659767
ic@@	O	-1	8659767
ity	O	-1	8659767
of	O	-1	8659767
subsequ@@	O	-1	8659767
ent	O	-1	8659767
administration	O	-1	8659767
of	O	-1	8659767
ep@@	B-Chemical	D004837	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
in	O	-1	8659767
con@@	O	-1	8659767
s@@	O	-1	8659767
ci@@	O	-1	8659767
ou@@	O	-1	8659767
s,	O	-1	8659767
healthy	O	-1	8659767
dog@@	O	-1	8659767
s	O	-1	8659767
and	O	-1	8659767
in	O	-1	8659767
anesthe@@	O	-1	8659767
tiz@@	O	-1	8659767
ed	O	-1	8659767
dog@@	O	-1	8659767
s	O	-1	8659767
with	O	-1	8659767
myocardial	B-Disease	D009203	8659767
infarction	I-Disease	-1	8659767
.	O	-1	8659767
F@@	O	-1	8659767
or@@	O	-1	8659767
ty-@@	O	-1	8659767
one	O	-1	8659767
con@@	O	-1	8659767
s@@	O	-1	8659767
ci@@	O	-1	8659767
ous	O	-1	8659767
dog@@	O	-1	8659767
s	O	-1	8659767
received	O	-1	8659767
10	O	-1	8659767
microgram@@	O	-1	8659767
s@@	O	-1	8659767
.@@	O	-1	8659767
kg@@	O	-1	8659767
-@@	O	-1	8659767
1.@@	O	-1	8659767
min@@	O	-1	8659767
-1	O	-1	8659767
ep@@	B-Chemical	D004837	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
.	O	-1	8659767
S@@	O	-1	8659767
event@@	O	-1	8659767
e@@	O	-1	8659767
en	O	-1	8659767
animals	O	-1	8659767
respon@@	O	-1	8659767
ded	O	-1	8659767
with	O	-1	8659767
ventricular	B-Disease	D017180	8659767
tachycardia	I-Disease	-1	8659767
(	O	-1	8659767
V@@	B-Disease	D017180	8659767
T	I-Disease	-1	8659767
)	O	-1	8659767
within	O	-1	8659767
3	O	-1	8659767
min@@	O	-1	8659767
.	O	-1	8659767
After	O	-1	8659767
3	O	-1	8659767
h@@	O	-1	8659767
,	O	-1	8659767
these	O	-1	8659767
respon@@	O	-1	8659767
der@@	O	-1	8659767
s	O	-1	8659767
random@@	O	-1	8659767
ly	O	-1	8659767
received	O	-1	8659767
1	O	-1	8659767
or	O	-1	8659767
2	O	-1	8659767
mg/kg	O	-1	8659767
bupivac@@	B-Chemical	D002045	8659767
aine	I-Chemical	-1	8659767
or	O	-1	8659767
saline	O	-1	8659767
over	O	-1	8659767
5	O	-1	8659767
min@@	O	-1	8659767
,	O	-1	8659767
followed	O	-1	8659767
by	O	-1	8659767
10	O	-1	8659767
microgram@@	O	-1	8659767
s@@	O	-1	8659767
.@@	O	-1	8659767
kg@@	O	-1	8659767
-@@	O	-1	8659767
1.@@	O	-1	8659767
min@@	O	-1	8659767
-1	O	-1	8659767
ep@@	B-Chemical	D004837	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
.	O	-1	8659767
In	O	-1	8659767
the	O	-1	8659767
bupivac@@	B-Chemical	D002045	8659767
aine	I-Chemical	-1	8659767
group@@	O	-1	8659767
s,	O	-1	8659767
ep@@	B-Chemical	D004837	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
caused	O	-1	8659767
fe@@	O	-1	8659767
w@@	O	-1	8659767
er	O	-1	8659767
pro@@	O	-1	8659767
dys@@	O	-1	8659767
rhyth@@	O	-1	8659767
mic	O	-1	8659767
effects	O	-1	8659767
than	O	-1	8659767
without	O	-1	8659767
bupivac@@	B-Chemical	D002045	8659767
aine	I-Chemical	-1	8659767
.	O	-1	8659767
V@@	B-Disease	D017180	8659767
T	I-Disease	-1	8659767
appe@@	O	-1	8659767
a@@	O	-1	8659767
red	O	-1	8659767
in	O	-1	8659767
fe@@	O	-1	8659767
w@@	O	-1	8659767
er	O	-1	8659767
dog@@	O	-1	8659767
s	O	-1	8659767
and	O	-1	8659767
at	O	-1	8659767
a	O	-1	8659767
lat@@	O	-1	8659767
er	O	-1	8659767
ti@@	O	-1	8659767
me,	O	-1	8659767
and	O	-1	8659767
there	O	-1	8659767
were	O	-1	8659767
more	O	-1	8659767
s@@	O	-1	8659767
ino@@	O	-1	8659767
atrial	O	-1	8659767
be@@	O	-1	8659767
at@@	O	-1	8659767
s	O	-1	8659767
and	O	-1	8659767
less	O	-1	8659767
ect@@	O	-1	8659767
o@@	O	-1	8659767
pi@@	O	-1	8659767
es.	O	-1	8659767
E@@	B-Chemical	D004837	8659767
p@@	I-Chemical	-1	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
sh@@	O	-1	8659767
or@@	O	-1	8659767
ten@@	O	-1	8659767
ed	O	-1	8659767
Q@@	O	-1	8659767
T	O	-1	8659767
less	O	-1	8659767
after	O	-1	8659767
bupivac@@	B-Chemical	D002045	8659767
aine	I-Chemical	-1	8659767
than	O	-1	8659767
in	O	-1	8659767
control	O	-1	8659767
anim@@	O	-1	8659767
al@@	O	-1	8659767
s.	O	-1	8659767
One	O	-1	8659767
day	O	-1	8659767
after	O	-1	8659767
experimental	O	-1	8659767
myocardial	B-Disease	D009203	8659767
infarction	I-Disease	-1	8659767
,	O	-1	8659767
six	O	-1	8659767
addi@@	O	-1	8659767
tional	O	-1	8659767
halo@@	B-Chemical	D006221	8659767
th@@	I-Chemical	-1	8659767
ane	I-Chemical	-1	8659767
-@@	O	-1	8659767
anesthe@@	O	-1	8659767
tiz@@	O	-1	8659767
ed	O	-1	8659767
dog@@	O	-1	8659767
s	O	-1	8659767
received	O	-1	8659767
4	O	-1	8659767
microgram@@	O	-1	8659767
s@@	O	-1	8659767
.@@	O	-1	8659767
kg@@	O	-1	8659767
-@@	O	-1	8659767
1.@@	O	-1	8659767
min@@	O	-1	8659767
-1	O	-1	8659767
ep@@	B-Chemical	D004837	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
un@@	O	-1	8659767
ti@@	O	-1	8659767
l	O	-1	8659767
V@@	B-Disease	D017180	8659767
T	I-Disease	-1	8659767
appe@@	O	-1	8659767
a@@	O	-1	8659767
red.	O	-1	8659767
After	O	-1	8659767
4@@	O	-1	8659767
5	O	-1	8659767
min@@	O	-1	8659767
,	O	-1	8659767
1	O	-1	8659767
mg/kg	O	-1	8659767
bupivac@@	B-Chemical	D002045	8659767
aine	I-Chemical	-1	8659767
was	O	-1	8659767
injected	O	-1	8659767
over	O	-1	8659767
5	O	-1	8659767
min@@	O	-1	8659767
,	O	-1	8659767
ag@@	O	-1	8659767
ain	O	-1	8659767
followed	O	-1	8659767
by	O	-1	8659767
4	O	-1	8659767
microgram@@	O	-1	8659767
s@@	O	-1	8659767
.@@	O	-1	8659767
kg@@	O	-1	8659767
-@@	O	-1	8659767
1.@@	O	-1	8659767
min@@	O	-1	8659767
-1	O	-1	8659767
ep@@	B-Chemical	D004837	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
.	O	-1	8659767
In	O	-1	8659767
these	O	-1	8659767
dog@@	O	-1	8659767
s,	O	-1	8659767
the	O	-1	8659767
pro@@	O	-1	8659767
dys@@	O	-1	8659767
rhyth@@	O	-1	8659767
mic	O	-1	8659767
response	O	-1	8659767
to	O	-1	8659767
ep@@	B-Chemical	D004837	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
was	O	-1	8659767
also	O	-1	8659767
m@@	O	-1	8659767
iti@@	O	-1	8659767
g@@	O	-1	8659767
ated	O	-1	8659767
by	O	-1	8659767
pre@@	O	-1	8659767
ce@@	O	-1	8659767
ding	O	-1	8659767
bupivac@@	B-Chemical	D002045	8659767
aine	I-Chemical	-1	8659767
.	O	-1	8659767
B@@	B-Chemical	D002045	8659767
u@@	I-Chemical	-1	8659767
pivac@@	I-Chemical	-1	8659767
aine	I-Chemical	-1	8659767
antagon@@	O	-1	8659767
iz@@	O	-1	8659767
es	O	-1	8659767
ep@@	B-Chemical	D004837	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
dys@@	O	-1	8659767
rhyth@@	O	-1	8659767
mo@@	O	-1	8659767
gen@@	O	-1	8659767
ic@@	O	-1	8659767
ity	O	-1	8659767
in	O	-1	8659767
con@@	O	-1	8659767
s@@	O	-1	8659767
ci@@	O	-1	8659767
ous	O	-1	8659767
dog@@	O	-1	8659767
s	O	-1	8659767
sus@@	O	-1	8659767
cep@@	O	-1	8659767
ti@@	O	-1	8659767
ble	O	-1	8659767
to	O	-1	8659767
V@@	B-Disease	D017180	8659767
T	I-Disease	-1	8659767
and	O	-1	8659767
in	O	-1	8659767
anesthe@@	O	-1	8659767
tiz@@	O	-1	8659767
ed	O	-1	8659767
dog@@	O	-1	8659767
s	O	-1	8659767
with	O	-1	8659767
spont@@	O	-1	8659767
aneous	O	-1	8659767
post@@	O	-1	8659767
infarc@@	O	-1	8659767
t	O	-1	8659767
dys@@	B-Disease	D001145	8659767
rhyth@@	I-Disease	-1	8659767
mi@@	I-Disease	-1	8659767
as	I-Disease	-1	8659767
.	O	-1	8659767
There	O	-1	8659767
is	O	-1	8659767
no	O	-1	8659767
evidence	O	-1	8659767
that	O	-1	8659767
systemic	O	-1	8659767
sub@@	O	-1	8659767
toxic	O	-1	8659767
bupivac@@	B-Chemical	D002045	8659767
aine	I-Chemical	-1	8659767
administration	O	-1	8659767
enh@@	O	-1	8659767
anc@@	O	-1	8659767
es	O	-1	8659767
the	O	-1	8659767
dys@@	O	-1	8659767
rhyth@@	O	-1	8659767
mo@@	O	-1	8659767
gen@@	O	-1	8659767
ic@@	O	-1	8659767
ity	O	-1	8659767
of	O	-1	8659767
subsequ@@	O	-1	8659767
ent	O	-1	8659767
ep@@	B-Chemical	D004837	8659767
ine@@	I-Chemical	-1	8659767
phrine	I-Chemical	-1	8659767
.	O	-1	8659767

M@@	B-Disease	D006934	8667442
il@@	I-Disease	-1	8667442
k@@	I-Disease	-1	8667442
-@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
k@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
i	I-Disease	-1	8667442
syndrome	I-Disease	-1	8667442
induced	O	-1	8667442
by	O	-1	8667442
1@@	B-Chemical	D002117	8667442
,@@	I-Chemical	-1	8667442
25@@	I-Chemical	-1	8667442
(@@	I-Chemical	-1	8667442
O@@	I-Chemical	-1	8667442
H@@	I-Chemical	-1	8667442
)@@	I-Chemical	-1	8667442
2@@	I-Chemical	-1	8667442
D	I-Chemical	-1	8667442
in	O	-1	8667442
a	O	-1	8667442
patient	O	-1	8667442
with	O	-1	8667442
hypo@@	B-Disease	D007011	8667442
par@@	I-Disease	-1	8667442
ath@@	I-Disease	-1	8667442
yro@@	I-Disease	-1	8667442
i@@	I-Disease	-1	8667442
dis@@	I-Disease	-1	8667442
m	I-Disease	-1	8667442
.	O	-1	8667442
M@@	B-Disease	D006934	8667442
il@@	I-Disease	-1	8667442
k@@	I-Disease	-1	8667442
-@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
k@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
i	I-Disease	-1	8667442
syndrome	I-Disease	-1	8667442
was	O	-1	8667442
first	O	-1	8667442
descri@@	O	-1	8667442
bed	O	-1	8667442
7@@	O	-1	8667442
0	O	-1	8667442
years	O	-1	8667442
ag@@	O	-1	8667442
o	O	-1	8667442
in	O	-1	8667442
the	O	-1	8667442
cont@@	O	-1	8667442
ex@@	O	-1	8667442
t	O	-1	8667442
of	O	-1	8667442
the	O	-1	8667442
treatment	O	-1	8667442
of	O	-1	8667442
p@@	B-Disease	D010437	8667442
ep@@	I-Disease	-1	8667442
tic	I-Disease	-1	8667442
ul@@	I-Disease	-1	8667442
c@@	I-Disease	-1	8667442
er	I-Disease	-1	8667442
disease	I-Disease	-1	8667442
with	O	-1	8667442
larg@@	O	-1	8667442
e	O	-1	8667442
amoun@@	O	-1	8667442
ts	O	-1	8667442
of	O	-1	8667442
calcium	B-Chemical	D002118	8667442
and	O	-1	8667442
al@@	B-Chemical	D000468	8667442
k@@	I-Chemical	-1	8667442
al@@	I-Chemical	-1	8667442
i	I-Chemical	-1	8667442
.	O	-1	8667442
Although	O	-1	8667442
with	O	-1	8667442
current	O	-1	8667442
ul@@	B-Disease	D014456	8667442
c@@	I-Disease	-1	8667442
er	I-Disease	-1	8667442
therapy	O	-1	8667442
(@@	O	-1	8667442
H@@	O	-1	8667442
-@@	O	-1	8667442
2	O	-1	8667442
block@@	O	-1	8667442
er@@	O	-1	8667442
s,	O	-1	8667442
o@@	B-Chemical	D009853	8667442
me@@	I-Chemical	-1	8667442
praz@@	I-Chemical	-1	8667442
ole	I-Chemical	-1	8667442
,	O	-1	8667442
and	O	-1	8667442
suc@@	B-Chemical	D013392	8667442
r@@	I-Chemical	-1	8667442
al@@	I-Chemical	-1	8667442
f@@	I-Chemical	-1	8667442
ate	I-Chemical	-1	8667442
),	O	-1	8667442
the	O	-1	8667442
frequency	O	-1	8667442
of	O	-1	8667442
mil@@	B-Disease	D006934	8667442
k@@	I-Disease	-1	8667442
-@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
k@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
i	I-Disease	-1	8667442
syndrome	I-Disease	-1	8667442
has	O	-1	8667442
decreased	O	-1	8667442
significant@@	O	-1	8667442
ly,	O	-1	8667442
the	O	-1	8667442
cl@@	O	-1	8667442
as@@	O	-1	8667442
sic	O	-1	8667442
tri@@	O	-1	8667442
ad	O	-1	8667442
of	O	-1	8667442
hyper@@	B-Disease	D006934	8667442
cal@@	I-Disease	-1	8667442
ce@@	I-Disease	-1	8667442
mia	I-Disease	-1	8667442
,	O	-1	8667442
al@@	B-Disease	D000471	8667442
k@@	I-Disease	-1	8667442
alo@@	I-Disease	-1	8667442
sis	I-Disease	-1	8667442
,	O	-1	8667442
and	O	-1	8667442
renal	B-Disease	D051437	8667442
impair@@	I-Disease	-1	8667442
ment	I-Disease	-1	8667442
remain@@	O	-1	8667442
s	O	-1	8667442
the	O	-1	8667442
h@@	O	-1	8667442
all@@	O	-1	8667442
m@@	O	-1	8667442
ar@@	O	-1	8667442
k	O	-1	8667442
of	O	-1	8667442
the	O	-1	8667442
syndro@@	O	-1	8667442
me.	O	-1	8667442
M@@	B-Disease	D006934	8667442
il@@	I-Disease	-1	8667442
k@@	I-Disease	-1	8667442
-@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
k@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
i	I-Disease	-1	8667442
syndrome	I-Disease	-1	8667442
can	O	-1	8667442
present	O	-1	8667442
seri@@	O	-1	8667442
ous	O	-1	8667442
and	O	-1	8667442
oc@@	O	-1	8667442
ca@@	O	-1	8667442
sion@@	O	-1	8667442
ally	O	-1	8667442
lif@@	O	-1	8667442
e-@@	O	-1	8667442
th@@	O	-1	8667442
reat@@	O	-1	8667442
en@@	O	-1	8667442
ing	O	-1	8667442
ill@@	O	-1	8667442
ness	O	-1	8667442
un@@	O	-1	8667442
less	O	-1	8667442
diagnos@@	O	-1	8667442
ed	O	-1	8667442
and	O	-1	8667442
treated	O	-1	8667442
appro@@	O	-1	8667442
pri@@	O	-1	8667442
at@@	O	-1	8667442
el@@	O	-1	8667442
y.	O	-1	8667442
This	O	-1	8667442
ar@@	O	-1	8667442
tic@@	O	-1	8667442
le	O	-1	8667442
pres@@	O	-1	8667442
ents	O	-1	8667442
a	O	-1	8667442
patient	O	-1	8667442
with	O	-1	8667442
hypo@@	B-Disease	D007011	8667442
par@@	I-Disease	-1	8667442
ath@@	I-Disease	-1	8667442
yro@@	I-Disease	-1	8667442
i@@	I-Disease	-1	8667442
dis@@	I-Disease	-1	8667442
m	I-Disease	-1	8667442
who	O	-1	8667442
was	O	-1	8667442
treated	O	-1	8667442
with	O	-1	8667442
calcium	B-Chemical	D002119	8667442
carb@@	I-Chemical	-1	8667442
on@@	I-Chemical	-1	8667442
ate	I-Chemical	-1	8667442
and	O	-1	8667442
calc@@	B-Chemical	D002117	8667442
it@@	I-Chemical	-1	8667442
ri@@	I-Chemical	-1	8667442
ol	I-Chemical	-1	8667442
result@@	O	-1	8667442
ing	O	-1	8667442
in	O	-1	8667442
two	O	-1	8667442
ad@@	O	-1	8667442
mis@@	O	-1	8667442
sions	O	-1	8667442
to	O	-1	8667442
the	O	-1	8667442
hospit@@	O	-1	8667442
al	O	-1	8667442
for	O	-1	8667442
mil@@	B-Disease	D006934	8667442
k@@	I-Disease	-1	8667442
-@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
k@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
i	I-Disease	-1	8667442
syndrome	I-Disease	-1	8667442
.	O	-1	8667442
The	O	-1	8667442
patient	O	-1	8667442
was	O	-1	8667442
suc@@	O	-1	8667442
cess@@	O	-1	8667442
ful@@	O	-1	8667442
ly	O	-1	8667442
treated	O	-1	8667442
with	O	-1	8667442
intravenous	O	-1	8667442
p@@	B-Chemical	C019248	8667442
am@@	I-Chemical	-1	8667442
id@@	I-Chemical	-1	8667442
ron@@	I-Chemical	-1	8667442
ate	I-Chemical	-1	8667442
on	O	-1	8667442
h@@	O	-1	8667442
is	O	-1	8667442
first	O	-1	8667442
ad@@	O	-1	8667442
mission	O	-1	8667442
and	O	-1	8667442
with	O	-1	8667442
hydro@@	B-Chemical	D006854	8667442
cor@@	I-Chemical	-1	8667442
tis@@	I-Chemical	-1	8667442
one	I-Chemical	-1	8667442
on	O	-1	8667442
the	O	-1	8667442
secon@@	O	-1	8667442
d.	O	-1	8667442
This	O	-1	8667442
il@@	O	-1	8667442
lu@@	O	-1	8667442
strat@@	O	-1	8667442
es	O	-1	8667442
intravenous	O	-1	8667442
p@@	B-Chemical	C019248	8667442
am@@	I-Chemical	-1	8667442
id@@	I-Chemical	-1	8667442
ron@@	I-Chemical	-1	8667442
ate	I-Chemical	-1	8667442
as	O	-1	8667442
a	O	-1	8667442
valu@@	O	-1	8667442
able	O	-1	8667442
therapeutic	O	-1	8667442
to@@	O	-1	8667442
ol	O	-1	8667442
when	O	-1	8667442
mil@@	B-Disease	D006934	8667442
k@@	I-Disease	-1	8667442
-@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
k@@	I-Disease	-1	8667442
al@@	I-Disease	-1	8667442
i	I-Disease	-1	8667442
syndrome	I-Disease	-1	8667442
pres@@	O	-1	8667442
ents	O	-1	8667442
as	O	-1	8667442
hyper@@	B-Disease	D006934	8667442
cal@@	I-Disease	-1	8667442
ce@@	I-Disease	-1	8667442
mic	I-Disease	-1	8667442
em@@	I-Disease	-1	8667442
er@@	I-Disease	-1	8667442
gen@@	I-Disease	-1	8667442
c@@	I-Disease	-1	8667442
y	I-Disease	-1	8667442
.	O	-1	8667442

E@@	B-Disease	D001927	8748050
n@@	I-Disease	-1	8748050
ce@@	I-Disease	-1	8748050
ph@@	I-Disease	-1	8748050
alo@@	I-Disease	-1	8748050
pathy	I-Disease	-1	8748050
during	O	-1	8748050
am@@	B-Chemical	D000639	8748050
it@@	I-Chemical	-1	8748050
ript@@	I-Chemical	-1	8748050
yl@@	I-Chemical	-1	8748050
ine	I-Chemical	-1	8748050
therap@@	O	-1	8748050
y@@	O	-1	8748050
:	O	-1	8748050
are	O	-1	8748050
neuro@@	B-Disease	D009459	8748050
le@@	I-Disease	-1	8748050
p@@	I-Disease	-1	8748050
tic	I-Disease	-1	8748050
mal@@	I-Disease	-1	8748050
i@@	I-Disease	-1	8748050
gn@@	I-Disease	-1	8748050
ant	I-Disease	-1	8748050
syndrome	I-Disease	-1	8748050
and	O	-1	8748050
seroton@@	B-Disease	D020230	8748050
in	I-Disease	-1	8748050
syndrome	I-Disease	-1	8748050
sp@@	O	-1	8748050
ect@@	O	-1	8748050
ru@@	O	-1	8748050
m	O	-1	8748050
disorder@@	O	-1	8748050
s@@	O	-1	8748050
?	O	-1	8748050
This	O	-1	8748050
report	O	-1	8748050
descri@@	O	-1	8748050
b@@	O	-1	8748050
es	O	-1	8748050
a	O	-1	8748050
case	O	-1	8748050
of	O	-1	8748050
encephalo@@	B-Disease	D001927	8748050
pathy	I-Disease	-1	8748050
developed	O	-1	8748050
in	O	-1	8748050
the	O	-1	8748050
course	O	-1	8748050
of	O	-1	8748050
am@@	B-Chemical	D000639	8748050
it@@	I-Chemical	-1	8748050
ript@@	I-Chemical	-1	8748050
yl@@	I-Chemical	-1	8748050
ine	I-Chemical	-1	8748050
therapy,	O	-1	8748050
during	O	-1	8748050
a	O	-1	8748050
re@@	O	-1	8748050
mission	O	-1	8748050
of	O	-1	8748050
un@@	B-Disease	D003866	8748050
ip@@	I-Disease	-1	8748050
ol@@	I-Disease	-1	8748050
ar	I-Disease	-1	8748050
de@@	I-Disease	-1	8748050
pression	I-Disease	-1	8748050
.	O	-1	8748050
This	O	-1	8748050
patient	O	-1	8748050
could	O	-1	8748050
have	O	-1	8748050
been	O	-1	8748050
diagnos@@	O	-1	8748050
ed	O	-1	8748050
as	O	-1	8748050
ha@@	O	-1	8748050
ving	O	-1	8748050
either	O	-1	8748050
neuro@@	B-Disease	D009459	8748050
le@@	I-Disease	-1	8748050
p@@	I-Disease	-1	8748050
tic	I-Disease	-1	8748050
mal@@	I-Disease	-1	8748050
i@@	I-Disease	-1	8748050
gn@@	I-Disease	-1	8748050
ant	I-Disease	-1	8748050
syndrome	I-Disease	-1	8748050
(	O	-1	8748050
N@@	B-Disease	D009459	8748050
M@@	I-Disease	-1	8748050
S	I-Disease	-1	8748050
)	O	-1	8748050
or	O	-1	8748050
seroton@@	B-Disease	D020230	8748050
in	I-Disease	-1	8748050
syndrome	I-Disease	-1	8748050
(	O	-1	8748050
S@@	B-Disease	D020230	8748050
S	I-Disease	-1	8748050
).	O	-1	8748050
The	O	-1	8748050
major	O	-1	8748050
determin@@	O	-1	8748050
ant	O	-1	8748050
of	O	-1	8748050
the	O	-1	8748050
symptoms	O	-1	8748050
may	O	-1	8748050
have	O	-1	8748050
been	O	-1	8748050
dopamine	B-Chemical	D004298	8748050
/	O	-1	8748050
seroton@@	B-Chemical	D012701	8748050
in	I-Chemical	-1	8748050
im@@	O	-1	8748050
b@@	O	-1	8748050
al@@	O	-1	8748050
ance	O	-1	8748050
in	O	-1	8748050
the	O	-1	8748050
central	O	-1	8748050
ner@@	O	-1	8748050
v@@	O	-1	8748050
ous	O	-1	8748050
system@@	O	-1	8748050
.	O	-1	8748050
The	O	-1	8748050
N@@	B-Disease	D009459	8748050
M@@	I-Disease	-1	8748050
S	I-Disease	-1	8748050
-@@	O	-1	8748050
like	O	-1	8748050
encephalo@@	B-Disease	D001927	8748050
pathy	I-Disease	-1	8748050
that	O	-1	8748050
develop@@	O	-1	8748050
s	O	-1	8748050
in	O	-1	8748050
association	O	-1	8748050
with	O	-1	8748050
the	O	-1	8748050
use	O	-1	8748050
of	O	-1	8748050
antidepress@@	O	-1	8748050
ants	O	-1	8748050
indic@@	O	-1	8748050
ates	O	-1	8748050
that	O	-1	8748050
N@@	B-Disease	D009459	8748050
M@@	I-Disease	-1	8748050
S	I-Disease	-1	8748050
and	O	-1	8748050
S@@	B-Disease	D020230	8748050
S	I-Disease	-1	8748050
are	O	-1	8748050
sp@@	O	-1	8748050
ect@@	O	-1	8748050
ru@@	O	-1	8748050
m	O	-1	8748050
disorder@@	O	-1	8748050
s	O	-1	8748050
induced	O	-1	8748050
by	O	-1	8748050
drugs	O	-1	8748050
with	O	-1	8748050
both	O	-1	8748050
anti@@	O	-1	8748050
dop@@	O	-1	8748050
aminergic	O	-1	8748050
and	O	-1	8748050
seroton@@	O	-1	8748050
ergic	O	-1	8748050
effects.	O	-1	8748050

G@@	O	-1	8755612
en@@	O	-1	8755612
e@@	O	-1	8755612
tic	O	-1	8755612
se@@	O	-1	8755612
par@@	O	-1	8755612
ation	O	-1	8755612
of	O	-1	8755612
tumor	B-Disease	D009369	8755612
growth	O	-1	8755612
and	O	-1	8755612
hemorrh@@	B-Disease	D006470	8755612
ag@@	I-Disease	-1	8755612
ic	I-Disease	-1	8755612
phen@@	O	-1	8755612
ot@@	O	-1	8755612
yp@@	O	-1	8755612
es	O	-1	8755612
in	O	-1	8755612
an	O	-1	8755612
est@@	B-Chemical	D004967	8755612
ro@@	I-Chemical	-1	8755612
gen	I-Chemical	-1	8755612
-induced	O	-1	8755612
tumor	B-Disease	D009369	8755612
.	O	-1	8755612
Ch@@	O	-1	8755612
ron@@	O	-1	8755612
ic	O	-1	8755612
administration	O	-1	8755612
of	O	-1	8755612
est@@	B-Chemical	D004967	8755612
ro@@	I-Chemical	-1	8755612
gen	I-Chemical	-1	8755612
to	O	-1	8755612
the	O	-1	8755612
F@@	O	-1	8755612
is@@	O	-1	8755612
ch@@	O	-1	8755612
er	O	-1	8755612
34@@	O	-1	8755612
4	O	-1	8755612
(@@	O	-1	8755612
F@@	O	-1	8755612
34@@	O	-1	8755612
4@@	O	-1	8755612
)	O	-1	8755612
rat	O	-1	8755612
induc@@	O	-1	8755612
es	O	-1	8755612
growth	O	-1	8755612
of	O	-1	8755612
larg@@	O	-1	8755612
e,	O	-1	8755612
hemorrh@@	B-Disease	D006470	8755612
ag@@	I-Disease	-1	8755612
ic	I-Disease	-1	8755612
pit@@	B-Disease	D010911	8755612
u@@	I-Disease	-1	8755612
it@@	I-Disease	-1	8755612
ary	I-Disease	-1	8755612
tu@@	I-Disease	-1	8755612
mor@@	I-Disease	-1	8755612
s	I-Disease	-1	8755612
.	O	-1	8755612
T@@	O	-1	8755612
en	O	-1	8755612
weeks	O	-1	8755612
of	O	-1	8755612
di@@	B-Chemical	D004054	8755612
eth@@	I-Chemical	-1	8755612
yl@@	I-Chemical	-1	8755612
sti@@	I-Chemical	-1	8755612
l@@	I-Chemical	-1	8755612
be@@	I-Chemical	-1	8755612
stro@@	I-Chemical	-1	8755612
l	I-Chemical	-1	8755612
(	O	-1	8755612
D@@	B-Chemical	D004054	8755612
E@@	I-Chemical	-1	8755612
S	I-Chemical	-1	8755612
)	O	-1	8755612
treatment	O	-1	8755612
caused	O	-1	8755612
female	O	-1	8755612
F@@	O	-1	8755612
34@@	O	-1	8755612
4	O	-1	8755612
rat	O	-1	8755612
pit@@	O	-1	8755612
u@@	O	-1	8755612
it@@	O	-1	8755612
ari@@	O	-1	8755612
es	O	-1	8755612
to	O	-1	8755612
g@@	O	-1	8755612
ro@@	O	-1	8755612
w	O	-1	8755612
to	O	-1	8755612
an	O	-1	8755612
average	O	-1	8755612
of	O	-1	8755612
10@@	O	-1	8755612
9.@@	O	-1	8755612
2	O	-1	8755612
+/-	O	-1	8755612
6.@@	O	-1	8755612
3	O	-1	8755612
mg	O	-1	8755612
(@@	O	-1	8755612
mean	O	-1	8755612
+/-	O	-1	8755612
S@@	O	-1	8755612
E@@	O	-1	8755612
)	O	-1	8755612
versus	O	-1	8755612
1@@	O	-1	8755612
1.@@	O	-1	8755612
3	O	-1	8755612
+/-	O	-1	8755612
1.@@	O	-1	8755612
4	O	-1	8755612
mg	O	-1	8755612
for	O	-1	8755612
un@@	O	-1	8755612
treated	O	-1	8755612
rats,	O	-1	8755612
and	O	-1	8755612
to	O	-1	8755612
b@@	O	-1	8755612
ec@@	O	-1	8755612
ome	O	-1	8755612
high@@	O	-1	8755612
ly	O	-1	8755612
hemorrh@@	B-Disease	D006470	8755612
ag@@	I-Disease	-1	8755612
ic	I-Disease	-1	8755612
.	O	-1	8755612
The	O	-1	8755612
same	O	-1	8755612
D@@	B-Chemical	D004054	8755612
E@@	I-Chemical	-1	8755612
S	I-Chemical	-1	8755612
treatment	O	-1	8755612
produced	O	-1	8755612
no	O	-1	8755612
significant	O	-1	8755612
growth	O	-1	8755612
(@@	O	-1	8755612
8.@@	O	-1	8755612
9	O	-1	8755612
+/-	O	-1	8755612
0.@@	O	-1	8755612
5	O	-1	8755612
mg	O	-1	8755612
for	O	-1	8755612
treated	O	-1	8755612
femal@@	O	-1	8755612
es	O	-1	8755612
versus	O	-1	8755612
8.@@	O	-1	8755612
7	O	-1	8755612
+/-	O	-1	8755612
1.@@	O	-1	8755612
1	O	-1	8755612
for	O	-1	8755612
un@@	O	-1	8755612
treated	O	-1	8755612
femal@@	O	-1	8755612
es@@	O	-1	8755612
)	O	-1	8755612
or	O	-1	8755612
morph@@	O	-1	8755612
ological	O	-1	8755612
changes	O	-1	8755612
in	O	-1	8755612
B@@	O	-1	8755612
row@@	O	-1	8755612
n	O	-1	8755612
N@@	O	-1	8755612
or@@	O	-1	8755612
w@@	O	-1	8755612
ay	O	-1	8755612
(B@@	O	-1	8755612
N@@	O	-1	8755612
)	O	-1	8755612
rat	O	-1	8755612
pit@@	O	-1	8755612
u@@	O	-1	8755612
it@@	O	-1	8755612
ari@@	O	-1	8755612
es.	O	-1	8755612
An	O	-1	8755612
F@@	O	-1	8755612
1	O	-1	8755612
hy@@	O	-1	8755612
b@@	O	-1	8755612
ri@@	O	-1	8755612
d	O	-1	8755612
of	O	-1	8755612
F@@	O	-1	8755612
34@@	O	-1	8755612
4	O	-1	8755612
and	O	-1	8755612
B@@	O	-1	8755612
N	O	-1	8755612
ex@@	O	-1	8755612
hib@@	O	-1	8755612
ited	O	-1	8755612
significant	O	-1	8755612
pit@@	O	-1	8755612
u@@	O	-1	8755612
it@@	O	-1	8755612
ary	O	-1	8755612
growth	O	-1	8755612
after	O	-1	8755612
10	O	-1	8755612
weeks	O	-1	8755612
of	O	-1	8755612
D@@	B-Chemical	D004054	8755612
E@@	I-Chemical	-1	8755612
S	I-Chemical	-1	8755612
treatment	O	-1	8755612
with	O	-1	8755612
an	O	-1	8755612
average	O	-1	8755612
mas@@	O	-1	8755612
s	O	-1	8755612
of	O	-1	8755612
2@@	O	-1	8755612
6.@@	O	-1	8755612
3	O	-1	8755612
+/-	O	-1	8755612
0.@@	O	-1	8755612
7	O	-1	8755612
mg	O	-1	8755612
compared	O	-1	8755612
with	O	-1	8755612
8.@@	O	-1	8755612
6	O	-1	8755612
+/-	O	-1	8755612
0.@@	O	-1	8755612
9	O	-1	8755612
mg	O	-1	8755612
for	O	-1	8755612
un@@	O	-1	8755612
treated	O	-1	8755612
rats.	O	-1	8755612
S@@	O	-1	8755612
ur@@	O	-1	8755612
p@@	O	-1	8755612
ris@@	O	-1	8755612
ing@@	O	-1	8755612
ly,	O	-1	8755612
the	O	-1	8755612
F@@	O	-1	8755612
1	O	-1	8755612
hy@@	O	-1	8755612
b@@	O	-1	8755612
ri@@	O	-1	8755612
d	O	-1	8755612
tu@@	B-Disease	D009369	8755612
mor@@	I-Disease	-1	8755612
s	I-Disease	-1	8755612
were	O	-1	8755612
not	O	-1	8755612
hemorrh@@	B-Disease	D006470	8755612
ag@@	I-Disease	-1	8755612
ic	I-Disease	-1	8755612
and	O	-1	8755612
had	O	-1	8755612
hemo@@	O	-1	8755612
globin	O	-1	8755612
cont@@	O	-1	8755612
ent	O	-1	8755612
and	O	-1	8755612
ou@@	O	-1	8755612
tw@@	O	-1	8755612
ard	O	-1	8755612
appear@@	O	-1	8755612
ance	O	-1	8755612
id@@	O	-1	8755612
en@@	O	-1	8755612
tical	O	-1	8755612
to	O	-1	8755612
that	O	-1	8755612
of	O	-1	8755612
B@@	O	-1	8755612
N@@	O	-1	8755612
.	O	-1	8755612
E@@	O	-1	8755612
x@@	O	-1	8755612
pression	O	-1	8755612
of	O	-1	8755612
both	O	-1	8755612
growth	O	-1	8755612
and	O	-1	8755612
morph@@	O	-1	8755612
ological	O	-1	8755612
changes	O	-1	8755612
is	O	-1	8755612
due	O	-1	8755612
to	O	-1	8755612
multiple	O	-1	8755612
gen@@	O	-1	8755612
es.	O	-1	8755612
However,	O	-1	8755612
while	O	-1	8755612
D@@	B-Chemical	D004054	8755612
E@@	I-Chemical	-1	8755612
S	I-Chemical	-1	8755612
-induced	O	-1	8755612
pit@@	O	-1	8755612
u@@	O	-1	8755612
it@@	O	-1	8755612
ary	O	-1	8755612
growth	O	-1	8755612
ex@@	O	-1	8755612
hib@@	O	-1	8755612
ited	O	-1	8755612
qu@@	O	-1	8755612
anti@@	O	-1	8755612
t@@	O	-1	8755612
ati@@	O	-1	8755612
ve,	O	-1	8755612
addi@@	O	-1	8755612
tive	O	-1	8755612
in@@	O	-1	8755612
h@@	O	-1	8755612
er@@	O	-1	8755612
it@@	O	-1	8755612
ance@@	O	-1	8755612
,	O	-1	8755612
the	O	-1	8755612
hemorrh@@	B-Disease	D006470	8755612
ag@@	I-Disease	-1	8755612
ic	I-Disease	-1	8755612
phen@@	O	-1	8755612
ot@@	O	-1	8755612
yp@@	O	-1	8755612
e	O	-1	8755612
ex@@	O	-1	8755612
hib@@	O	-1	8755612
ited	O	-1	8755612
rec@@	O	-1	8755612
es@@	O	-1	8755612
si@@	O	-1	8755612
ve,	O	-1	8755612
ep@@	O	-1	8755612
ist@@	O	-1	8755612
atic	O	-1	8755612
in@@	O	-1	8755612
h@@	O	-1	8755612
er@@	O	-1	8755612
it@@	O	-1	8755612
ance@@	O	-1	8755612
.	O	-1	8755612
On@@	O	-1	8755612
ly	O	-1	8755612
5	O	-1	8755612
of	O	-1	8755612
the	O	-1	8755612
1@@	O	-1	8755612
60	O	-1	8755612
F@@	O	-1	8755612
2	O	-1	8755612
pit@@	O	-1	8755612
u@@	O	-1	8755612
it@@	O	-1	8755612
ari@@	O	-1	8755612
es	O	-1	8755612
ex@@	O	-1	8755612
hib@@	O	-1	8755612
ited	O	-1	8755612
the	O	-1	8755612
hemorrh@@	B-Disease	D006470	8755612
ag@@	I-Disease	-1	8755612
ic	I-Disease	-1	8755612
phen@@	O	-1	8755612
ot@@	O	-1	8755612
y@@	O	-1	8755612
pe@@	O	-1	8755612
;	O	-1	8755612
3@@	O	-1	8755612
6	O	-1	8755612
of	O	-1	8755612
the	O	-1	8755612
1@@	O	-1	8755612
60	O	-1	8755612
F@@	O	-1	8755612
2	O	-1	8755612
pit@@	O	-1	8755612
u@@	O	-1	8755612
it@@	O	-1	8755612
ari@@	O	-1	8755612
es	O	-1	8755612
were	O	-1	8755612
in	O	-1	8755612
the	O	-1	8755612
F@@	O	-1	8755612
34@@	O	-1	8755612
4	O	-1	8755612
range	O	-1	8755612
of	O	-1	8755612
mas@@	O	-1	8755612
s,	O	-1	8755612
but	O	-1	8755612
3@@	O	-1	8755612
1	O	-1	8755612
of	O	-1	8755612
these	O	-1	8755612
were	O	-1	8755612
not	O	-1	8755612
hemorrh@@	B-Disease	D006470	8755612
ag@@	I-Disease	-1	8755612
ic	I-Disease	-1	8755612
,	O	-1	8755612
indicating	O	-1	8755612
that	O	-1	8755612
the	O	-1	8755612
hemorrh@@	B-Disease	D006470	8755612
ag@@	I-Disease	-1	8755612
ic	I-Disease	-1	8755612
phen@@	O	-1	8755612
ot@@	O	-1	8755612
yp@@	O	-1	8755612
e	O	-1	8755612
is	O	-1	8755612
not	O	-1	8755612
me@@	O	-1	8755612
re@@	O	-1	8755612
ly	O	-1	8755612
a	O	-1	8755612
con@@	O	-1	8755612
sequ@@	O	-1	8755612
ence	O	-1	8755612
of	O	-1	8755612
exten@@	O	-1	8755612
sive	O	-1	8755612
grow@@	O	-1	8755612
th@@	O	-1	8755612
.	O	-1	8755612
The	O	-1	8755612
hemorrh@@	B-Disease	D006470	8755612
ag@@	I-Disease	-1	8755612
ic	I-Disease	-1	8755612
F@@	O	-1	8755612
2	O	-1	8755612
pit@@	O	-1	8755612
u@@	O	-1	8755612
it@@	O	-1	8755612
ari@@	O	-1	8755612
es	O	-1	8755612
were	O	-1	8755612
all	O	-1	8755612
among	O	-1	8755612
the	O	-1	8755612
most	O	-1	8755612
mas@@	O	-1	8755612
si@@	O	-1	8755612
ve,	O	-1	8755612
indicating	O	-1	8755612
that	O	-1	8755612
some	O	-1	8755612
of	O	-1	8755612
the	O	-1	8755612
gen@@	O	-1	8755612
es	O	-1	8755612
reg@@	O	-1	8755612
ul@@	O	-1	8755612
ate	O	-1	8755612
both	O	-1	8755612
phen@@	O	-1	8755612
ot@@	O	-1	8755612
yp@@	O	-1	8755612
es.	O	-1	8755612

In@@	O	-1	8808730
c@@	O	-1	8808730
reas@@	O	-1	8808730
ed	O	-1	8808730
expression	O	-1	8808730
of	O	-1	8808730
neuron@@	O	-1	8808730
al	O	-1	8808730
nit@@	B-Chemical	D009569	8808730
ric	I-Chemical	-1	8808730
ox@@	I-Chemical	-1	8808730
ide	I-Chemical	-1	8808730
syn@@	O	-1	8808730
th@@	O	-1	8808730
ase	O	-1	8808730
in	O	-1	8808730
bladder	O	-1	8808730
a@@	O	-1	8808730
fferen@@	O	-1	8808730
t	O	-1	8808730
path@@	O	-1	8808730
w@@	O	-1	8808730
ays	O	-1	8808730
following	O	-1	8808730
chronic	O	-1	8808730
bladder	B-Disease	D001745	8808730
ir@@	I-Disease	-1	8808730
rit@@	I-Disease	-1	8808730
ation	I-Disease	-1	8808730
.	O	-1	8808730
Im@@	O	-1	8808730
mun@@	O	-1	8808730
ocyto@@	O	-1	8808730
chemical	O	-1	8808730
t@@	O	-1	8808730
ech@@	O	-1	8808730
n@@	O	-1	8808730
i@@	O	-1	8808730
qu@@	O	-1	8808730
es	O	-1	8808730
were	O	-1	8808730
used	O	-1	8808730
to	O	-1	8808730
ex@@	O	-1	8808730
amine	O	-1	8808730
al@@	O	-1	8808730
ter@@	O	-1	8808730
ations	O	-1	8808730
in	O	-1	8808730
the	O	-1	8808730
expression	O	-1	8808730
of	O	-1	8808730
neuron@@	O	-1	8808730
al	O	-1	8808730
nit@@	B-Chemical	D009569	8808730
ric	I-Chemical	-1	8808730
ox@@	I-Chemical	-1	8808730
ide	I-Chemical	-1	8808730
syn@@	O	-1	8808730
th@@	O	-1	8808730
ase	O	-1	8808730
(N@@	O	-1	8808730
O@@	O	-1	8808730
S)	O	-1	8808730
in	O	-1	8808730
bladder	O	-1	8808730
path@@	O	-1	8808730
w@@	O	-1	8808730
ays	O	-1	8808730
following	O	-1	8808730
acute	O	-1	8808730
and	O	-1	8808730
chronic	O	-1	8808730
ir@@	B-Disease	D014570	8808730
rit@@	I-Disease	-1	8808730
ation	I-Disease	-1	8808730
of	I-Disease	-1	8808730
the	I-Disease	-1	8808730
urinary	I-Disease	-1	8808730
trac@@	I-Disease	-1	8808730
t	I-Disease	-1	8808730
of	O	-1	8808730
the	O	-1	8808730
rat@@	O	-1	8808730
.	O	-1	8808730
C@@	O	-1	8808730
hem@@	O	-1	8808730
ical	O	-1	8808730
cys@@	B-Disease	D003556	8808730
ti@@	I-Disease	-1	8808730
tis	I-Disease	-1	8808730
was	O	-1	8808730
induced	O	-1	8808730
by	O	-1	8808730
cyclophosph@@	B-Chemical	D003520	8808730
amide	I-Chemical	-1	8808730
(	O	-1	8808730
C@@	B-Chemical	D003520	8808730
Y@@	I-Chemical	-1	8808730
P	I-Chemical	-1	8808730
)	O	-1	8808730
which	O	-1	8808730
is	O	-1	8808730
metabol@@	O	-1	8808730
ized	O	-1	8808730
to	O	-1	8808730
ac@@	B-Chemical	D000171	8808730
ro@@	I-Chemical	-1	8808730
le@@	I-Chemical	-1	8808730
in	I-Chemical	-1	8808730
,	O	-1	8808730
an	O	-1	8808730
ir@@	O	-1	8808730
rit@@	O	-1	8808730
ant	O	-1	8808730
el@@	O	-1	8808730
im@@	O	-1	8808730
in@@	O	-1	8808730
ated	O	-1	8808730
in	O	-1	8808730
the	O	-1	8808730
ur@@	O	-1	8808730
ine.	O	-1	8808730
In@@	O	-1	8808730
j@@	O	-1	8808730
ection	O	-1	8808730
of	O	-1	8808730
C@@	B-Chemical	D003520	8808730
Y@@	I-Chemical	-1	8808730
P	I-Chemical	-1	8808730
(n	O	-1	8808730
=	O	-1	8808730
10@@	O	-1	8808730
,	O	-1	8808730
7@@	O	-1	8808730
5	O	-1	8808730
mg/kg@@	O	-1	8808730
,	O	-1	8808730
i.p.@@	O	-1	8808730
)	O	-1	8808730
2	O	-1	8808730
hours	O	-1	8808730
prior	O	-1	8808730
to	O	-1	8808730
per@@	O	-1	8808730
f@@	O	-1	8808730
usion	O	-1	8808730
(@@	O	-1	8808730
acute	O	-1	8808730
treatment@@	O	-1	8808730
)	O	-1	8808730
of	O	-1	8808730
the	O	-1	8808730
animals	O	-1	8808730
increased	O	-1	8808730
F@@	O	-1	8808730
os@@	O	-1	8808730
-@@	O	-1	8808730
immuno@@	O	-1	8808730
re@@	O	-1	8808730
activity	O	-1	8808730
(@@	O	-1	8808730
I@@	O	-1	8808730
R@@	O	-1	8808730
)	O	-1	8808730
in	O	-1	8808730
neuron@@	O	-1	8808730
s	O	-1	8808730
in	O	-1	8808730
the	O	-1	8808730
d@@	O	-1	8808730
or@@	O	-1	8808730
s@@	O	-1	8808730
al	O	-1	8808730
comm@@	O	-1	8808730
is@@	O	-1	8808730
su@@	O	-1	8808730
re,	O	-1	8808730
d@@	O	-1	8808730
or@@	O	-1	8808730
s@@	O	-1	8808730
al	O	-1	8808730
h@@	O	-1	8808730
or@@	O	-1	8808730
n@@	O	-1	8808730
,	O	-1	8808730
and	O	-1	8808730
a@@	O	-1	8808730
ut@@	O	-1	8808730
on@@	O	-1	8808730
om@@	O	-1	8808730
ic	O	-1	8808730
regi@@	O	-1	8808730
ons	O	-1	8808730
of	O	-1	8808730
spinal	O	-1	8808730
seg@@	O	-1	8808730
ments	O	-1	8808730
(@@	O	-1	8808730
L@@	O	-1	8808730
1-@@	O	-1	8808730
L@@	O	-1	8808730
2	O	-1	8808730
and	O	-1	8808730
L@@	O	-1	8808730
6-@@	O	-1	8808730
S@@	O	-1	8808730
1)	O	-1	8808730
which	O	-1	8808730
recei@@	O	-1	8808730
ve	O	-1	8808730
a@@	O	-1	8808730
fferen@@	O	-1	8808730
t	O	-1	8808730
in@@	O	-1	8808730
p@@	O	-1	8808730
ut@@	O	-1	8808730
s	O	-1	8808730
from	O	-1	8808730
the	O	-1	8808730
blad@@	O	-1	8808730
der@@	O	-1	8808730
,	O	-1	8808730
ure@@	O	-1	8808730
th@@	O	-1	8808730
ra@@	O	-1	8808730
,	O	-1	8808730
and	O	-1	8808730
ure@@	O	-1	8808730
ter@@	O	-1	8808730
.	O	-1	8808730
F@@	O	-1	8808730
os@@	O	-1	8808730
-@@	O	-1	8808730
I@@	O	-1	8808730
R	O	-1	8808730
in	O	-1	8808730
the	O	-1	8808730
spinal	O	-1	8808730
cor@@	O	-1	8808730
d	O	-1	8808730
was	O	-1	8808730
not	O	-1	8808730
chang@@	O	-1	8808730
ed	O	-1	8808730
in	O	-1	8808730
rats	O	-1	8808730
receiving	O	-1	8808730
chronic	O	-1	8808730
C@@	B-Chemical	D003520	8808730
Y@@	I-Chemical	-1	8808730
P	I-Chemical	-1	8808730
treatment	O	-1	8808730
(n	O	-1	8808730
=	O	-1	8808730
1@@	O	-1	8808730
5,	O	-1	8808730
7@@	O	-1	8808730
5	O	-1	8808730
mg/kg@@	O	-1	8808730
,	O	-1	8808730
i.p.@@	O	-1	8808730
,	O	-1	8808730
every	O	-1	8808730
3@@	O	-1	8808730
r@@	O	-1	8808730
d	O	-1	8808730
day	O	-1	8808730
for	O	-1	8808730
2	O	-1	8808730
week@@	O	-1	8808730
s@@	O	-1	8808730
).	O	-1	8808730
In	O	-1	8808730
control	O	-1	8808730
animals	O	-1	8808730
and	O	-1	8808730
in	O	-1	8808730
animals	O	-1	8808730
treated	O	-1	8808730
ac@@	O	-1	8808730
u@@	O	-1	8808730
te@@	O	-1	8808730
ly	O	-1	8808730
with	O	-1	8808730
C@@	B-Chemical	D003520	8808730
Y@@	I-Chemical	-1	8808730
P	I-Chemical	-1	8808730
,	O	-1	8808730
only	O	-1	8808730
sm@@	O	-1	8808730
all	O	-1	8808730
numb@@	O	-1	8808730
ers	O	-1	8808730
of	O	-1	8808730
NO@@	O	-1	8808730
S@@	O	-1	8808730
-@@	O	-1	8808730
I@@	O	-1	8808730
R	O	-1	8808730
cells	O	-1	8808730
(0.@@	O	-1	8808730
5-@@	O	-1	8808730
0.@@	O	-1	8808730
7	O	-1	8808730
cell	O	-1	8808730
prof@@	O	-1	8808730
il@@	O	-1	8808730
es@@	O	-1	8808730
/@@	O	-1	8808730
sec@@	O	-1	8808730
tion@@	O	-1	8808730
s)	O	-1	8808730
were	O	-1	8808730
det@@	O	-1	8808730
ected	O	-1	8808730
in	O	-1	8808730
the	O	-1	8808730
L@@	O	-1	8808730
6-@@	O	-1	8808730
S@@	O	-1	8808730
1	O	-1	8808730
d@@	O	-1	8808730
or@@	O	-1	8808730
s@@	O	-1	8808730
al	O	-1	8808730
ro@@	O	-1	8808730
o@@	O	-1	8808730
t	O	-1	8808730
g@@	O	-1	8808730
ang@@	O	-1	8808730
li@@	O	-1	8808730
a	O	-1	8808730
(D@@	O	-1	8808730
R@@	O	-1	8808730
G@@	O	-1	8808730
).	O	-1	8808730
Ch@@	O	-1	8808730
ron@@	O	-1	8808730
ic	O	-1	8808730
C@@	B-Chemical	D003520	8808730
Y@@	I-Chemical	-1	8808730
P	I-Chemical	-1	8808730
administration	O	-1	8808730
significantly	O	-1	8808730
(P	O	-1	8808730
<	O	-1	8808730
or	O	-1	8808730
=	O	-1	8808730
.@@	O	-1	8808730
0@@	O	-1	8808730
0@@	O	-1	8808730
2)	O	-1	8808730
increased	O	-1	8808730
bladder	O	-1	8808730
weight	O	-1	8808730
by	O	-1	8808730
6@@	O	-1	8808730
0%	O	-1	8808730
and	O	-1	8808730
increased	O	-1	8808730
(@@	O	-1	8808730
7@@	O	-1	8808730
-	O	-1	8808730
to	O	-1	8808730
1@@	O	-1	8808730
1-@@	O	-1	8808730
fol@@	O	-1	8808730
d@@	O	-1	8808730
)	O	-1	8808730
the	O	-1	8808730
numb@@	O	-1	8808730
ers	O	-1	8808730
of	O	-1	8808730
NO@@	O	-1	8808730
S@@	O	-1	8808730
-@@	O	-1	8808730
immuno@@	O	-1	8808730
reac@@	O	-1	8808730
tive	O	-1	8808730
(@@	O	-1	8808730
I@@	O	-1	8808730
R@@	O	-1	8808730
)	O	-1	8808730
a@@	O	-1	8808730
fferen@@	O	-1	8808730
t	O	-1	8808730
neuron@@	O	-1	8808730
s	O	-1	8808730
in	O	-1	8808730
the	O	-1	8808730
L@@	O	-1	8808730
6-@@	O	-1	8808730
S@@	O	-1	8808730
1	O	-1	8808730
D@@	O	-1	8808730
R@@	O	-1	8808730
G@@	O	-1	8808730
.	O	-1	8808730
A	O	-1	8808730
sm@@	O	-1	8808730
all	O	-1	8808730
increase	O	-1	8808730
(1@@	O	-1	8808730
.@@	O	-1	8808730
5-@@	O	-1	8808730
fol@@	O	-1	8808730
d@@	O	-1	8808730
)	O	-1	8808730
also	O	-1	8808730
occurred	O	-1	8808730
in	O	-1	8808730
the	O	-1	8808730
L@@	O	-1	8808730
1	O	-1	8808730
D@@	O	-1	8808730
R@@	O	-1	8808730
G@@	O	-1	8808730
,	O	-1	8808730
but	O	-1	8808730
no	O	-1	8808730
change	O	-1	8808730
was	O	-1	8808730
det@@	O	-1	8808730
ected	O	-1	8808730
in	O	-1	8808730
the	O	-1	8808730
L@@	O	-1	8808730
2	O	-1	8808730
and	O	-1	8808730
L@@	O	-1	8808730
5	O	-1	8808730
D@@	O	-1	8808730
R@@	O	-1	8808730
G@@	O	-1	8808730
.	O	-1	8808730
B@@	O	-1	8808730
l@@	O	-1	8808730
ad@@	O	-1	8808730
der	O	-1	8808730
a@@	O	-1	8808730
fferen@@	O	-1	8808730
t	O	-1	8808730
cells	O	-1	8808730
in	O	-1	8808730
the	O	-1	8808730
L@@	O	-1	8808730
6-@@	O	-1	8808730
S@@	O	-1	8808730
1	O	-1	8808730
D@@	O	-1	8808730
R@@	O	-1	8808730
G	O	-1	8808730
l@@	O	-1	8808730
a@@	O	-1	8808730
be@@	O	-1	8808730
l@@	O	-1	8808730
ed	O	-1	8808730
by	O	-1	8808730
F@@	O	-1	8808730
lu@@	O	-1	8808730
o@@	O	-1	8808730
ro@@	O	-1	8808730
g@@	O	-1	8808730
old	O	-1	8808730
(@@	O	-1	8808730
40	O	-1	8808730
micro@@	O	-1	8808730
liter@@	O	-1	8808730
s)	O	-1	8808730
injected	O	-1	8808730
into	O	-1	8808730
the	O	-1	8808730
bladder	O	-1	8808730
w@@	O	-1	8808730
all	O	-1	8808730
did	O	-1	8808730
not	O	-1	8808730
ex@@	O	-1	8808730
hib@@	O	-1	8808730
it	O	-1	8808730
NO@@	O	-1	8808730
S@@	O	-1	8808730
-@@	O	-1	8808730
I@@	O	-1	8808730
R	O	-1	8808730
in	O	-1	8808730
control	O	-1	8808730
anim@@	O	-1	8808730
al@@	O	-1	8808730
s;	O	-1	8808730
however,	O	-1	8808730
following	O	-1	8808730
chronic	O	-1	8808730
C@@	B-Chemical	D003520	8808730
Y@@	I-Chemical	-1	8808730
P	I-Chemical	-1	8808730
administr@@	O	-1	8808730
ation,	O	-1	8808730
a	O	-1	8808730
significant	O	-1	8808730
perc@@	O	-1	8808730
ent@@	O	-1	8808730
age	O	-1	8808730
of	O	-1	8808730
bladder	O	-1	8808730
a@@	O	-1	8808730
fferen@@	O	-1	8808730
t	O	-1	8808730
neuron@@	O	-1	8808730
s	O	-1	8808730
were	O	-1	8808730
NO@@	O	-1	8808730
S@@	O	-1	8808730
-@@	O	-1	8808730
I@@	O	-1	8808730
R@@	O	-1	8808730
:	O	-1	8808730
L@@	O	-1	8808730
6	O	-1	8808730
(1@@	O	-1	8808730
9.@@	O	-1	8808730
8	O	-1	8808730
+/-	O	-1	8808730
4.@@	O	-1	8808730
6@@	O	-1	8808730
%)	O	-1	8808730
and	O	-1	8808730
S@@	O	-1	8808730
1	O	-1	8808730
(2@@	O	-1	8808730
5.@@	O	-1	8808730
3	O	-1	8808730
+/-	O	-1	8808730
2.@@	O	-1	8808730
9@@	O	-1	8808730
%).	O	-1	8808730
These	O	-1	8808730
results	O	-1	8808730
indicate	O	-1	8808730
that	O	-1	8808730
neuron@@	O	-1	8808730
al	O	-1	8808730
gen@@	O	-1	8808730
e	O	-1	8808730
expression	O	-1	8808730
in	O	-1	8808730
v@@	O	-1	8808730
is@@	O	-1	8808730
c@@	O	-1	8808730
eral	O	-1	8808730
sens@@	O	-1	8808730
ory	O	-1	8808730
path@@	O	-1	8808730
w@@	O	-1	8808730
ays	O	-1	8808730
can	O	-1	8808730
be	O	-1	8808730
u@@	O	-1	8808730
pre@@	O	-1	8808730
g@@	O	-1	8808730
ul@@	O	-1	8808730
ated	O	-1	8808730
by	O	-1	8808730
chemical	O	-1	8808730
ir@@	O	-1	8808730
rit@@	O	-1	8808730
ation	O	-1	8808730
of	O	-1	8808730
a@@	O	-1	8808730
fferen@@	O	-1	8808730
t	O	-1	8808730
receptors	O	-1	8808730
in	O	-1	8808730
the	O	-1	8808730
urinary	O	-1	8808730
trac@@	O	-1	8808730
t	O	-1	8808730
and/or	O	-1	8808730
that	O	-1	8808730
path@@	O	-1	8808730
ological	O	-1	8808730
changes	O	-1	8808730
in	O	-1	8808730
the	O	-1	8808730
urinary	O	-1	8808730
trac@@	O	-1	8808730
t	O	-1	8808730
can	O	-1	8808730
initi@@	O	-1	8808730
ate	O	-1	8808730
chemical	O	-1	8808730
sign@@	O	-1	8808730
als	O	-1	8808730
that	O	-1	8808730
al@@	O	-1	8808730
ter	O	-1	8808730
the	O	-1	8808730
chemical	O	-1	8808730
pro@@	O	-1	8808730
per@@	O	-1	8808730
ties	O	-1	8808730
of	O	-1	8808730
v@@	O	-1	8808730
is@@	O	-1	8808730
c@@	O	-1	8808730
eral	O	-1	8808730
a@@	O	-1	8808730
fferen@@	O	-1	8808730
t	O	-1	8808730
neuron@@	O	-1	8808730
s.	O	-1	8808730

Eff@@	O	-1	8819482
ects	O	-1	8819482
of	O	-1	8819482
a	O	-1	8819482
new	O	-1	8819482
calcium	B-Chemical	D002118	8819482
antagonist@@	O	-1	8819482
,	O	-1	8819482
C@@	B-Chemical	C082828	8819482
D-@@	I-Chemical	-1	8819482
8@@	I-Chemical	-1	8819482
3@@	I-Chemical	-1	8819482
2	I-Chemical	-1	8819482
,	O	-1	8819482
on	O	-1	8819482
isoproteren@@	B-Chemical	D007545	8819482
ol	I-Chemical	-1	8819482
-induced	O	-1	8819482
myocardial	B-Disease	D017202	8819482
ischem@@	I-Disease	-1	8819482
ia	I-Disease	-1	8819482
in	O	-1	8819482
dog@@	O	-1	8819482
s	O	-1	8819482
with	O	-1	8819482
partial	O	-1	8819482
coronary	B-Disease	D023921	8819482
st@@	I-Disease	-1	8819482
en@@	I-Disease	-1	8819482
o@@	I-Disease	-1	8819482
sis	I-Disease	-1	8819482
.	O	-1	8819482
Eff@@	O	-1	8819482
ects	O	-1	8819482
of	O	-1	8819482
C@@	B-Chemical	C082828	8819482
D-@@	I-Chemical	-1	8819482
8@@	I-Chemical	-1	8819482
3@@	I-Chemical	-1	8819482
2	I-Chemical	-1	8819482
on	O	-1	8819482
isoproteren@@	B-Chemical	D007545	8819482
ol	I-Chemical	-1	8819482
(	O	-1	8819482
I@@	B-Chemical	D007545	8819482
S@@	I-Chemical	-1	8819482
O	I-Chemical	-1	8819482
)@@	O	-1	8819482
-induced	O	-1	8819482
myocardial	B-Disease	D017202	8819482
ischem@@	I-Disease	-1	8819482
ia	I-Disease	-1	8819482
were	O	-1	8819482
studied	O	-1	8819482
in	O	-1	8819482
dog@@	O	-1	8819482
s	O	-1	8819482
with	O	-1	8819482
partial	O	-1	8819482
coronary	B-Disease	D023921	8819482
st@@	I-Disease	-1	8819482
en@@	I-Disease	-1	8819482
o@@	I-Disease	-1	8819482
sis	I-Disease	-1	8819482
of	O	-1	8819482
the	O	-1	8819482
left	O	-1	8819482
cir@@	O	-1	8819482
cum@@	O	-1	8819482
f@@	O	-1	8819482
le@@	O	-1	8819482
x	O	-1	8819482
coronary	O	-1	8819482
artery	O	-1	8819482
and	O	-1	8819482
findings	O	-1	8819482
were	O	-1	8819482
compared	O	-1	8819482
with	O	-1	8819482
those	O	-1	8819482
for	O	-1	8819482
n@@	B-Chemical	D009543	8819482
if@@	I-Chemical	-1	8819482
edi@@	I-Chemical	-1	8819482
pine	I-Chemical	-1	8819482
or	O	-1	8819482
di@@	B-Chemical	D004110	8819482
l@@	I-Chemical	-1	8819482
ti@@	I-Chemical	-1	8819482
az@@	I-Chemical	-1	8819482
em	I-Chemical	-1	8819482
.	O	-1	8819482
In	O	-1	8819482
the	O	-1	8819482
presence	O	-1	8819482
of	O	-1	8819482
coronary	B-Disease	D023921	8819482
artery	I-Disease	-1	8819482
st@@	I-Disease	-1	8819482
en@@	I-Disease	-1	8819482
o@@	I-Disease	-1	8819482
sis	I-Disease	-1	8819482
,	O	-1	8819482
3-@@	O	-1	8819482
min	O	-1	8819482
perio@@	O	-1	8819482
ds	O	-1	8819482
of	O	-1	8819482
intrac@@	O	-1	8819482
or@@	O	-1	8819482
onary	O	-1	8819482
I@@	B-Chemical	D007545	8819482
S@@	I-Chemical	-1	8819482
O	I-Chemical	-1	8819482
infusion	O	-1	8819482
(10	O	-1	8819482
n@@	O	-1	8819482
g/@@	O	-1	8819482
k@@	O	-1	8819482
g/@@	O	-1	8819482
min@@	O	-1	8819482
)	O	-1	8819482
increased	O	-1	8819482
heart	O	-1	8819482
rate	O	-1	8819482
and	O	-1	8819482
maxim@@	O	-1	8819482
al	O	-1	8819482
rate	O	-1	8819482
of	O	-1	8819482
left	O	-1	8819482
ventricular	O	-1	8819482
pressure	O	-1	8819482
ri@@	O	-1	8819482
se@@	O	-1	8819482
,	O	-1	8819482
which	O	-1	8819482
resulted	O	-1	8819482
in	O	-1	8819482
a	O	-1	8819482
decrease	O	-1	8819482
in	O	-1	8819482
perc@@	O	-1	8819482
ent@@	O	-1	8819482
age	O	-1	8819482
seg@@	O	-1	8819482
mental	O	-1	8819482
sh@@	O	-1	8819482
or@@	O	-1	8819482
ten@@	O	-1	8819482
ing	O	-1	8819482
and	O	-1	8819482
S@@	O	-1	8819482
T@@	O	-1	8819482
-@@	O	-1	8819482
seg@@	O	-1	8819482
ment	O	-1	8819482
elev@@	O	-1	8819482
ation	O	-1	8819482
of	O	-1	8819482
the	O	-1	8819482
ep@@	O	-1	8819482
ic@@	O	-1	8819482
ardi@@	O	-1	8819482
al	O	-1	8819482
electro@@	O	-1	8819482
cardio@@	O	-1	8819482
gram@@	O	-1	8819482
.	O	-1	8819482
After	O	-1	8819482
the	O	-1	8819482
control	O	-1	8819482
I@@	B-Chemical	D007545	8819482
S@@	I-Chemical	-1	8819482
O	I-Chemical	-1	8819482
infusion	O	-1	8819482
with	O	-1	8819482
st@@	B-Disease	D003251	8819482
en@@	I-Disease	-1	8819482
o@@	I-Disease	-1	8819482
sis	I-Disease	-1	8819482
was	O	-1	8819482
per@@	O	-1	8819482
for@@	O	-1	8819482
me@@	O	-1	8819482
d,	O	-1	8819482
equ@@	O	-1	8819482
i@@	O	-1	8819482
hypoten@@	O	-1	8819482
sive	O	-1	8819482
doses	O	-1	8819482
of	O	-1	8819482
C@@	B-Chemical	C082828	8819482
D-@@	I-Chemical	-1	8819482
8@@	I-Chemical	-1	8819482
3@@	I-Chemical	-1	8819482
2	I-Chemical	-1	8819482
(@@	O	-1	8819482
3	O	-1	8819482
and	O	-1	8819482
10	O	-1	8819482
microgram@@	O	-1	8819482
s/@@	O	-1	8819482
k@@	O	-1	8819482
g/@@	O	-1	8819482
min@@	O	-1	8819482
,	O	-1	8819482
n	O	-1	8819482
=	O	-1	8819482
7@@	O	-1	8819482
),	O	-1	8819482
n@@	B-Chemical	D009543	8819482
if@@	I-Chemical	-1	8819482
edi@@	I-Chemical	-1	8819482
pine	I-Chemical	-1	8819482
(@@	O	-1	8819482
1	O	-1	8819482
and	O	-1	8819482
3	O	-1	8819482
microgram@@	O	-1	8819482
s/@@	O	-1	8819482
k@@	O	-1	8819482
g/@@	O	-1	8819482
min@@	O	-1	8819482
,	O	-1	8819482
n	O	-1	8819482
=	O	-1	8819482
9@@	O	-1	8819482
)	O	-1	8819482
or	O	-1	8819482
di@@	B-Chemical	D004110	8819482
l@@	I-Chemical	-1	8819482
ti@@	I-Chemical	-1	8819482
az@@	I-Chemical	-1	8819482
em	I-Chemical	-1	8819482
(10	O	-1	8819482
and	O	-1	8819482
30	O	-1	8819482
microgram@@	O	-1	8819482
s/@@	O	-1	8819482
k@@	O	-1	8819482
g/@@	O	-1	8819482
min@@	O	-1	8819482
,	O	-1	8819482
n	O	-1	8819482
=	O	-1	8819482
7@@	O	-1	8819482
)	O	-1	8819482
were	O	-1	8819482
inf@@	O	-1	8819482
used	O	-1	8819482
5	O	-1	8819482
min	O	-1	8819482
before	O	-1	8819482
and	O	-1	8819482
during	O	-1	8819482
the	O	-1	8819482
second	O	-1	8819482
and	O	-1	8819482
thir@@	O	-1	8819482
d	O	-1	8819482
I@@	B-Chemical	D007545	8819482
S@@	I-Chemical	-1	8819482
O	I-Chemical	-1	8819482
infu@@	O	-1	8819482
sion.	O	-1	8819482
B@@	O	-1	8819482
oth	O	-1	8819482
C@@	B-Chemical	C082828	8819482
D-@@	I-Chemical	-1	8819482
8@@	I-Chemical	-1	8819482
3@@	I-Chemical	-1	8819482
2	I-Chemical	-1	8819482
and	O	-1	8819482
di@@	B-Chemical	D004110	8819482
l@@	I-Chemical	-1	8819482
ti@@	I-Chemical	-1	8819482
az@@	I-Chemical	-1	8819482
em	I-Chemical	-1	8819482
,	O	-1	8819482
but	O	-1	8819482
not	O	-1	8819482
n@@	B-Chemical	D009543	8819482
if@@	I-Chemical	-1	8819482
edi@@	I-Chemical	-1	8819482
pine	I-Chemical	-1	8819482
,	O	-1	8819482
significantly	O	-1	8819482
reduced	O	-1	8819482
the	O	-1	8819482
increase	O	-1	8819482
in	O	-1	8819482
heart	O	-1	8819482
rate	O	-1	8819482
induced	O	-1	8819482
by	O	-1	8819482
I@@	B-Chemical	D007545	8819482
S@@	I-Chemical	-1	8819482
O	I-Chemical	-1	8819482
infu@@	O	-1	8819482
sion.	O	-1	8819482
In	O	-1	8819482
contr@@	O	-1	8819482
ast	O	-1	8819482
to	O	-1	8819482
n@@	B-Chemical	D009543	8819482
if@@	I-Chemical	-1	8819482
edi@@	I-Chemical	-1	8819482
pine	I-Chemical	-1	8819482
,	O	-1	8819482
C@@	B-Chemical	C082828	8819482
D-@@	I-Chemical	-1	8819482
8@@	I-Chemical	-1	8819482
3@@	I-Chemical	-1	8819482
2	I-Chemical	-1	8819482
(10	O	-1	8819482
microgram@@	O	-1	8819482
s/@@	O	-1	8819482
k@@	O	-1	8819482
g/@@	O	-1	8819482
min@@	O	-1	8819482
)	O	-1	8819482
prevent@@	O	-1	8819482
ed	O	-1	8819482
the	O	-1	8819482
decrease	O	-1	8819482
in	O	-1	8819482
perc@@	O	-1	8819482
ent@@	O	-1	8819482
age	O	-1	8819482
seg@@	O	-1	8819482
mental	O	-1	8819482
sh@@	O	-1	8819482
or@@	O	-1	8819482
ten@@	O	-1	8819482
ing	O	-1	8819482
from	O	-1	8819482
3@@	O	-1	8819482
2	O	-1	8819482
+/-	O	-1	8819482
12@@	O	-1	8819482
%	O	-1	8819482
to	O	-1	8819482
1@@	O	-1	8819482
15	O	-1	8819482
+/-	O	-1	8819482
2@@	O	-1	8819482
6%	O	-1	8819482
of	O	-1	8819482
the	O	-1	8819482
control	O	-1	8819482
valu@@	O	-1	8819482
e	O	-1	8819482
(P	O	-1	8819482
<	O	-1	8819482
.@@	O	-1	8819482
0@@	O	-1	8819482
1)	O	-1	8819482
and	O	-1	8819482
S@@	O	-1	8819482
T@@	O	-1	8819482
-@@	O	-1	8819482
seg@@	O	-1	8819482
ment	O	-1	8819482
elev@@	O	-1	8819482
ation	O	-1	8819482
from	O	-1	8819482
5.@@	O	-1	8819482
6	O	-1	8819482
+/-	O	-1	8819482
1.@@	O	-1	8819482
0	O	-1	8819482
m@@	O	-1	8819482
V	O	-1	8819482
to	O	-1	8819482
1.@@	O	-1	8819482
6	O	-1	8819482
+/-	O	-1	8819482
1.@@	O	-1	8819482
3	O	-1	8819482
m@@	O	-1	8819482
V	O	-1	8819482
(P	O	-1	8819482
<	O	-1	8819482
.@@	O	-1	8819482
0@@	O	-1	8819482
1)	O	-1	8819482
at	O	-1	8819482
3	O	-1	8819482
min	O	-1	8819482
after	O	-1	8819482
I@@	B-Chemical	D007545	8819482
S@@	I-Chemical	-1	8819482
O	I-Chemical	-1	8819482
infusion	O	-1	8819482
with	O	-1	8819482
st@@	B-Disease	D003251	8819482
en@@	I-Disease	-1	8819482
o@@	I-Disease	-1	8819482
sis	I-Disease	-1	8819482
.	O	-1	8819482
D@@	B-Chemical	D004110	8819482
il@@	I-Chemical	-1	8819482
ti@@	I-Chemical	-1	8819482
az@@	I-Chemical	-1	8819482
em	I-Chemical	-1	8819482
(@@	O	-1	8819482
30	O	-1	8819482
microgram@@	O	-1	8819482
s/@@	O	-1	8819482
k@@	O	-1	8819482
g/@@	O	-1	8819482
min@@	O	-1	8819482
)	O	-1	8819482
also	O	-1	8819482
prevent@@	O	-1	8819482
ed	O	-1	8819482
the	O	-1	8819482
decrease	O	-1	8819482
in	O	-1	8819482
perc@@	O	-1	8819482
ent@@	O	-1	8819482
age	O	-1	8819482
seg@@	O	-1	8819482
mental	O	-1	8819482
sh@@	O	-1	8819482
or@@	O	-1	8819482
ten@@	O	-1	8819482
ing	O	-1	8819482
from	O	-1	8819482
3@@	O	-1	8819482
4	O	-1	8819482
+/-	O	-1	8819482
14@@	O	-1	8819482
%	O	-1	8819482
to	O	-1	8819482
6@@	O	-1	8819482
3	O	-1	8819482
+/-	O	-1	8819482
18@@	O	-1	8819482
%	O	-1	8819482
of	O	-1	8819482
the	O	-1	8819482
control	O	-1	8819482
valu@@	O	-1	8819482
e	O	-1	8819482
(P	O	-1	8819482
<	O	-1	8819482
.@@	O	-1	8819482
0@@	O	-1	8819482
5@@	O	-1	8819482
)	O	-1	8819482
and	O	-1	8819482
S@@	O	-1	8819482
T@@	O	-1	8819482
-@@	O	-1	8819482
seg@@	O	-1	8819482
ment	O	-1	8819482
elev@@	O	-1	8819482
ation	O	-1	8819482
from	O	-1	8819482
4.@@	O	-1	8819482
7	O	-1	8819482
+/-	O	-1	8819482
0.@@	O	-1	8819482
7	O	-1	8819482
m@@	O	-1	8819482
V	O	-1	8819482
to	O	-1	8819482
2.@@	O	-1	8819482
1	O	-1	8819482
+/-	O	-1	8819482
0.@@	O	-1	8819482
7	O	-1	8819482
m@@	O	-1	8819482
V	O	-1	8819482
(P	O	-1	8819482
<	O	-1	8819482
.@@	O	-1	8819482
0@@	O	-1	8819482
1)	O	-1	8819482
at	O	-1	8819482
3	O	-1	8819482
min	O	-1	8819482
after	O	-1	8819482
I@@	B-Chemical	D007545	8819482
S@@	I-Chemical	-1	8819482
O	I-Chemical	-1	8819482
infusion	O	-1	8819482
with	O	-1	8819482
st@@	B-Disease	D003251	8819482
en@@	I-Disease	-1	8819482
o@@	I-Disease	-1	8819482
sis	I-Disease	-1	8819482
.	O	-1	8819482
These	O	-1	8819482
data	O	-1	8819482
show	O	-1	8819482
that	O	-1	8819482
C@@	B-Chemical	C082828	8819482
D-@@	I-Chemical	-1	8819482
8@@	I-Chemical	-1	8819482
3@@	I-Chemical	-1	8819482
2	I-Chemical	-1	8819482
impro@@	O	-1	8819482
v@@	O	-1	8819482
es	O	-1	8819482
myocardial	B-Disease	D017202	8819482
ischem@@	I-Disease	-1	8819482
ia	I-Disease	-1	8819482
during	O	-1	8819482
I@@	B-Chemical	D007545	8819482
S@@	I-Chemical	-1	8819482
O	I-Chemical	-1	8819482
infusion	O	-1	8819482
with	O	-1	8819482
st@@	B-Disease	D003251	8819482
en@@	I-Disease	-1	8819482
o@@	I-Disease	-1	8819482
sis	I-Disease	-1	8819482
and	O	-1	8819482
suggest	O	-1	8819482
that	O	-1	8819482
the	O	-1	8819482
negative	O	-1	8819482
chron@@	O	-1	8819482
ot@@	O	-1	8819482
ro@@	O	-1	8819482
p@@	O	-1	8819482
ic	O	-1	8819482
pro@@	O	-1	8819482
per@@	O	-1	8819482
t@@	O	-1	8819482
y	O	-1	8819482
of	O	-1	8819482
C@@	B-Chemical	C082828	8819482
D-@@	I-Chemical	-1	8819482
8@@	I-Chemical	-1	8819482
3@@	I-Chemical	-1	8819482
2	I-Chemical	-1	8819482
pl@@	O	-1	8819482
ays	O	-1	8819482
a	O	-1	8819482
major	O	-1	8819482
role	O	-1	8819482
in	O	-1	8819482
the	O	-1	8819482
ben@@	O	-1	8819482
e@@	O	-1	8819482
fic@@	O	-1	8819482
ial	O	-1	8819482
effects	O	-1	8819482
of	O	-1	8819482
C@@	B-Chemical	C082828	8819482
D-@@	I-Chemical	-1	8819482
8@@	I-Chemical	-1	8819482
3@@	I-Chemical	-1	8819482
2	I-Chemical	-1	8819482
.	O	-1	8819482

The	O	-1	8825380
effect	O	-1	8825380
of	O	-1	8825380
re@@	O	-1	8825380
combin@@	O	-1	8825380
ant	O	-1	8825380
human	O	-1	8825380
in@@	O	-1	8825380
sul@@	O	-1	8825380
in-@@	O	-1	8825380
like	O	-1	8825380
growth	O	-1	8825380
fact@@	O	-1	8825380
or@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
on	O	-1	8825380
chronic	O	-1	8825380
p@@	B-Chemical	D011692	8825380
uro@@	I-Chemical	-1	8825380
m@@	I-Chemical	-1	8825380
ycin	I-Chemical	-1	8825380
amin@@	I-Chemical	-1	8825380
on@@	I-Chemical	-1	8825380
ucle@@	I-Chemical	-1	8825380
o@@	I-Chemical	-1	8825380
side	I-Chemical	-1	8825380
nephro@@	B-Disease	D007674	8825380
pathy	I-Disease	-1	8825380
in	O	-1	8825380
rats.	O	-1	8825380
We	O	-1	8825380
rec@@	O	-1	8825380
ently	O	-1	8825380
demonstrated	O	-1	8825380
that	O	-1	8825380
re@@	O	-1	8825380
combin@@	O	-1	8825380
ant	O	-1	8825380
h@@	O	-1	8825380
G@@	O	-1	8825380
H	O	-1	8825380
ex@@	O	-1	8825380
ac@@	O	-1	8825380
er@@	O	-1	8825380
b@@	O	-1	8825380
ates	O	-1	8825380
renal	O	-1	8825380
functional	O	-1	8825380
and	O	-1	8825380
struct@@	O	-1	8825380
ural	O	-1	8825380
injury	O	-1	8825380
in	O	-1	8825380
chronic	O	-1	8825380
p@@	B-Chemical	D011692	8825380
uro@@	I-Chemical	-1	8825380
m@@	I-Chemical	-1	8825380
ycin	I-Chemical	-1	8825380
amin@@	I-Chemical	-1	8825380
on@@	I-Chemical	-1	8825380
ucle@@	I-Chemical	-1	8825380
o@@	I-Chemical	-1	8825380
side	I-Chemical	-1	8825380
(	O	-1	8825380
PA@@	B-Chemical	D011692	8825380
N	I-Chemical	-1	8825380
)	O	-1	8825380
nephro@@	B-Disease	D007674	8825380
pathy	I-Disease	-1	8825380
,	O	-1	8825380
an	O	-1	8825380
experimental	O	-1	8825380
model	O	-1	8825380
of	O	-1	8825380
glomerular	B-Disease	D007674	8825380
disease	I-Disease	-1	8825380
.	O	-1	8825380
The@@	O	-1	8825380
refore,	O	-1	8825380
we	O	-1	8825380
examined	O	-1	8825380
whether	O	-1	8825380
re@@	O	-1	8825380
combin@@	O	-1	8825380
ant	O	-1	8825380
human	O	-1	8825380
(@@	O	-1	8825380
rh@@	O	-1	8825380
)	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
is	O	-1	8825380
a	O	-1	8825380
saf@@	O	-1	8825380
er	O	-1	8825380
al@@	O	-1	8825380
tern@@	O	-1	8825380
ative	O	-1	8825380
for	O	-1	8825380
the	O	-1	8825380
treatment	O	-1	8825380
of	O	-1	8825380
growth	B-Disease	D006130	8825380
failure	I-Disease	-1	8825380
in	O	-1	8825380
rats	O	-1	8825380
with	O	-1	8825380
chronic	O	-1	8825380
PA@@	B-Chemical	D011692	8825380
N	I-Chemical	-1	8825380
nephro@@	B-Disease	D007674	8825380
pathy	I-Disease	-1	8825380
.	O	-1	8825380
The	O	-1	8825380
glomer@@	B-Disease	D007674	8825380
ulo@@	I-Disease	-1	8825380
pathy	I-Disease	-1	8825380
was	O	-1	8825380
induced	O	-1	8825380
by	O	-1	8825380
seven	O	-1	8825380
ser@@	O	-1	8825380
ial	O	-1	8825380
injec@@	O	-1	8825380
tions	O	-1	8825380
of	O	-1	8825380
PA@@	B-Chemical	D011692	8825380
N	I-Chemical	-1	8825380
over	O	-1	8825380
12	O	-1	8825380
w@@	O	-1	8825380
k@@	O	-1	8825380
.	O	-1	8825380
E@@	O	-1	8825380
x@@	O	-1	8825380
per@@	O	-1	8825380
im@@	O	-1	8825380
ental	O	-1	8825380
animals	O	-1	8825380
(n	O	-1	8825380
=	O	-1	8825380
6@@	O	-1	8825380
)	O	-1	8825380
received	O	-1	8825380
rh@@	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I@@	O	-1	8825380
,	O	-1	8825380
4@@	O	-1	8825380
00	O	-1	8825380
microgram@@	O	-1	8825380
s/@@	O	-1	8825380
d,	O	-1	8825380
whereas	O	-1	8825380
control	O	-1	8825380
rats	O	-1	8825380
(n	O	-1	8825380
=	O	-1	8825380
6@@	O	-1	8825380
)	O	-1	8825380
received	O	-1	8825380
the	O	-1	8825380
ve@@	O	-1	8825380
h@@	O	-1	8825380
ic@@	O	-1	8825380
le@@	O	-1	8825380
.	O	-1	8825380
rh@@	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
improved	O	-1	8825380
weight	O	-1	8825380
g@@	O	-1	8825380
ain	O	-1	8825380
by	O	-1	8825380
14@@	O	-1	8825380
%	O	-1	8825380
(p	O	-1	8825380
<	O	-1	8825380
0.05@@	O	-1	8825380
),	O	-1	8825380
without	O	-1	8825380
al@@	O	-1	8825380
ter@@	O	-1	8825380
ing	O	-1	8825380
hemat@@	O	-1	8825380
oc@@	O	-1	8825380
ri@@	O	-1	8825380
t	O	-1	8825380
or	O	-1	8825380
blood	O	-1	8825380
pressure	O	-1	8825380
in	O	-1	8825380
rats	O	-1	8825380
with	O	-1	8825380
renal	B-Disease	D007674	8825380
disease	I-Disease	-1	8825380
.	O	-1	8825380
U@@	O	-1	8825380
r@@	O	-1	8825380
inary	O	-1	8825380
protein	O	-1	8825380
ex@@	O	-1	8825380
cre@@	O	-1	8825380
tion	O	-1	8825380
was	O	-1	8825380
un@@	O	-1	8825380
al@@	O	-1	8825380
te@@	O	-1	8825380
red	O	-1	8825380
by	O	-1	8825380
rh@@	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
treatment	O	-1	8825380
in	O	-1	8825380
rats	O	-1	8825380
with	O	-1	8825380
chronic	O	-1	8825380
PA@@	B-Chemical	D011692	8825380
N	I-Chemical	-1	8825380
nephro@@	B-Disease	D007674	8825380
pathy	I-Disease	-1	8825380
.	O	-1	8825380
After	O	-1	8825380
12	O	-1	8825380
w@@	O	-1	8825380
k@@	O	-1	8825380
,	O	-1	8825380
the	O	-1	8825380
in@@	O	-1	8825380
ul@@	O	-1	8825380
in	O	-1	8825380
clear@@	O	-1	8825380
ance	O	-1	8825380
was	O	-1	8825380
higher	O	-1	8825380
in	O	-1	8825380
rh@@	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I@@	O	-1	8825380
-treated	O	-1	8825380
rats,	O	-1	8825380
0.@@	O	-1	8825380
4@@	O	-1	8825380
8	O	-1	8825380
+/-	O	-1	8825380
0.0@@	O	-1	8825380
8	O	-1	8825380
versus	O	-1	8825380
0.@@	O	-1	8825380
24	O	-1	8825380
+/-	O	-1	8825380
0.0@@	O	-1	8825380
6	O	-1	8825380
m@@	O	-1	8825380
L@@	O	-1	8825380
/@@	O	-1	8825380
min@@	O	-1	8825380
/@@	O	-1	8825380
100	O	-1	8825380
g	O	-1	8825380
of	O	-1	8825380
body	O	-1	8825380
weight	O	-1	8825380
in	O	-1	8825380
un@@	O	-1	8825380
treated	O	-1	8825380
PA@@	B-Chemical	D011692	8825380
N	I-Chemical	-1	8825380
nephro@@	B-Disease	D007674	8825380
pathy	I-Disease	-1	8825380
anim@@	O	-1	8825380
al@@	O	-1	8825380
s,	O	-1	8825380
p	O	-1	8825380
<	O	-1	8825380
0.05@@	O	-1	8825380
.	O	-1	8825380
The	O	-1	8825380
impro@@	O	-1	8825380
vement	O	-1	8825380
in	O	-1	8825380
GF@@	O	-1	8825380
R	O	-1	8825380
was	O	-1	8825380
not	O	-1	8825380
associated	O	-1	8825380
with	O	-1	8825380
enhanced	O	-1	8825380
glomerular	B-Disease	D007674	8825380
hyper@@	I-Disease	-1	8825380
tro@@	I-Disease	-1	8825380
ph@@	I-Disease	-1	8825380
y	I-Disease	-1	8825380
or	O	-1	8825380
increased	O	-1	8825380
seg@@	O	-1	8825380
mental	O	-1	8825380
glomer@@	B-Disease	D005921	8825380
u@@	I-Disease	-1	8825380
los@@	I-Disease	-1	8825380
clero@@	I-Disease	-1	8825380
sis	I-Disease	-1	8825380
,	O	-1	8825380
tu@@	B-Disease	-1	8825380
bu@@	I-Disease	-1	8825380
lo@@	I-Disease	-1	8825380
interstitial	I-Disease	-1	8825380
injury	I-Disease	-1	8825380
,	O	-1	8825380
or	O	-1	8825380
renal	O	-1	8825380
cor@@	O	-1	8825380
tical	O	-1	8825380
mal@@	B-Chemical	D008315	8825380
on@@	I-Chemical	-1	8825380
di@@	I-Chemical	-1	8825380
al@@	I-Chemical	-1	8825380
de@@	I-Chemical	-1	8825380
hy@@	I-Chemical	-1	8825380
de	I-Chemical	-1	8825380
cont@@	O	-1	8825380
ent@@	O	-1	8825380
.	O	-1	8825380
In	O	-1	8825380
rats	O	-1	8825380
with	O	-1	8825380
PA@@	B-Chemical	D011692	8825380
N	I-Chemical	-1	8825380
nephro@@	B-Disease	D007674	8825380
pathy	I-Disease	-1	8825380
,	O	-1	8825380
administration	O	-1	8825380
of	O	-1	8825380
rh@@	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
increased	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
and	O	-1	8825380
G@@	O	-1	8825380
H	O	-1	8825380
receptor	O	-1	8825380
gen@@	O	-1	8825380
e	O	-1	8825380
ex@@	O	-1	8825380
pres@@	O	-1	8825380
sion,	O	-1	8825380
without	O	-1	8825380
al@@	O	-1	8825380
ter@@	O	-1	8825380
ing	O	-1	8825380
the	O	-1	8825380
ste@@	O	-1	8825380
ad@@	O	-1	8825380
y	O	-1	8825380
state	O	-1	8825380
level	O	-1	8825380
of	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
receptor	O	-1	8825380
mR@@	O	-1	8825380
N@@	O	-1	8825380
A@@	O	-1	8825380
.	O	-1	8825380
In	O	-1	8825380
normal	O	-1	8825380
rats	O	-1	8825380
with	O	-1	8825380
int@@	O	-1	8825380
ac@@	O	-1	8825380
t	O	-1	8825380
kidne@@	O	-1	8825380
y@@	O	-1	8825380
s,	O	-1	8825380
rh@@	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
administration	O	-1	8825380
(n	O	-1	8825380
=	O	-1	8825380
4@@	O	-1	8825380
)	O	-1	8825380
did	O	-1	8825380
not	O	-1	8825380
al@@	O	-1	8825380
ter	O	-1	8825380
weight	O	-1	8825380
g@@	O	-1	8825380
ain@@	O	-1	8825380
,	O	-1	8825380
blood	O	-1	8825380
pressu@@	O	-1	8825380
re,	O	-1	8825380
proteinuria	B-Disease	D011507	8825380
,	O	-1	8825380
GF@@	O	-1	8825380
R@@	O	-1	8825380
,	O	-1	8825380
glomerular	O	-1	8825380
pl@@	O	-1	8825380
an@@	O	-1	8825380
ar	O	-1	8825380
a@@	O	-1	8825380
re@@	O	-1	8825380
a,	O	-1	8825380
renal	O	-1	8825380
cor@@	O	-1	8825380
tical	O	-1	8825380
mal@@	B-Chemical	D008315	8825380
on@@	I-Chemical	-1	8825380
di@@	I-Chemical	-1	8825380
al@@	I-Chemical	-1	8825380
de@@	I-Chemical	-1	8825380
hy@@	I-Chemical	-1	8825380
de	I-Chemical	-1	8825380
cont@@	O	-1	8825380
ent@@	O	-1	8825380
,	O	-1	8825380
or	O	-1	8825380
glomerular	O	-1	8825380
or	O	-1	8825380
tu@@	B-Disease	D007674	8825380
bu@@	I-Disease	-1	8825380
lo@@	I-Disease	-1	8825380
interstitial	I-Disease	-1	8825380
damage	I-Disease	-1	8825380
,	O	-1	8825380
compared	O	-1	8825380
with	O	-1	8825380
un@@	O	-1	8825380
treated	O	-1	8825380
animals	O	-1	8825380
(n	O	-1	8825380
=	O	-1	8825380
4@@	O	-1	8825380
).	O	-1	8825380
rh@@	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
treatment	O	-1	8825380
reduced	O	-1	8825380
the	O	-1	8825380
ste@@	O	-1	8825380
ad@@	O	-1	8825380
y	O	-1	8825380
state	O	-1	8825380
renal	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
mRNA	O	-1	8825380
level	O	-1	8825380
but	O	-1	8825380
did	O	-1	8825380
not	O	-1	8825380
mo@@	O	-1	8825380
di@@	O	-1	8825380
f@@	O	-1	8825380
y	O	-1	8825380
gen@@	O	-1	8825380
e	O	-1	8825380
expression	O	-1	8825380
of	O	-1	8825380
the	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
or	O	-1	8825380
G@@	O	-1	8825380
H	O	-1	8825380
receptor@@	O	-1	8825380
s.	O	-1	8825380
We	O	-1	8825380
concl@@	O	-1	8825380
ude	O	-1	8825380
th@@	O	-1	8825380
at@@	O	-1	8825380
:	O	-1	8825380
1)	O	-1	8825380
administration	O	-1	8825380
of	O	-1	8825380
rh@@	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
impro@@	O	-1	8825380
v@@	O	-1	8825380
es	O	-1	8825380
growth	O	-1	8825380
and	O	-1	8825380
GF@@	O	-1	8825380
R	O	-1	8825380
in	O	-1	8825380
rats	O	-1	8825380
with	O	-1	8825380
chronic	O	-1	8825380
PA@@	B-Chemical	D011692	8825380
N	I-Chemical	-1	8825380
nephro@@	B-Disease	D007674	8825380
pathy	I-Disease	-1	8825380
and	O	-1	8825380
2)	O	-1	8825380
un@@	O	-1	8825380
like	O	-1	8825380
rh@@	O	-1	8825380
G@@	O	-1	8825380
H@@	O	-1	8825380
,	O	-1	8825380
long-term	O	-1	8825380
use	O	-1	8825380
of	O	-1	8825380
rh@@	O	-1	8825380
I@@	O	-1	8825380
GF@@	O	-1	8825380
-@@	O	-1	8825380
I	O	-1	8825380
does	O	-1	8825380
not	O	-1	8825380
wor@@	O	-1	8825380
se@@	O	-1	8825380
n	O	-1	8825380
renal	O	-1	8825380
functional	O	-1	8825380
and	O	-1	8825380
struct@@	O	-1	8825380
ural	O	-1	8825380
injury	O	-1	8825380
in	O	-1	8825380
this	O	-1	8825380
disease	O	-1	8825380
model@@	O	-1	8825380
.	O	-1	8825380

Ne@@	B-Chemical	C058876	8829135
fi@@	I-Chemical	-1	8829135
rac@@	I-Chemical	-1	8829135
et@@	I-Chemical	-1	8829135
am	I-Chemical	-1	8829135
(	O	-1	8829135
D@@	B-Chemical	C058876	8829135
M@@	I-Chemical	-1	8829135
-@@	I-Chemical	-1	8829135
9@@	I-Chemical	-1	8829135
3@@	I-Chemical	-1	8829135
8@@	I-Chemical	-1	8829135
4	I-Chemical	-1	8829135
)	O	-1	8829135
rever@@	O	-1	8829135
ses	O	-1	8829135
apo@@	B-Chemical	D001058	8829135
morphine	I-Chemical	-1	8829135
-induced	O	-1	8829135
am@@	B-Disease	D000647	8829135
ne@@	I-Disease	-1	8829135
sia	I-Disease	-1	8829135
of	O	-1	8829135
a	O	-1	8829135
p@@	O	-1	8829135
as@@	O	-1	8829135
sive	O	-1	8829135
avoid@@	O	-1	8829135
ance	O	-1	8829135
respon@@	O	-1	8829135
se@@	O	-1	8829135
:	O	-1	8829135
del@@	O	-1	8829135
ayed	O	-1	8829135
em@@	O	-1	8829135
er@@	O	-1	8829135
gen@@	O	-1	8829135
ce	O	-1	8829135
of	O	-1	8829135
the	O	-1	8829135
memory	O	-1	8829135
re@@	O	-1	8829135
ten@@	O	-1	8829135
tion	O	-1	8829135
effects.	O	-1	8829135
Ne@@	B-Chemical	C058876	8829135
fi@@	I-Chemical	-1	8829135
rac@@	I-Chemical	-1	8829135
et@@	I-Chemical	-1	8829135
am	I-Chemical	-1	8829135
is	O	-1	8829135
a	O	-1	8829135
novel	O	-1	8829135
py@@	B-Chemical	D011760	8829135
r@@	I-Chemical	-1	8829135
ro@@	I-Chemical	-1	8829135
l@@	I-Chemical	-1	8829135
id@@	I-Chemical	-1	8829135
one	I-Chemical	-1	8829135
der@@	O	-1	8829135
i@@	O	-1	8829135
v@@	O	-1	8829135
ative	O	-1	8829135
which	O	-1	8829135
attenu@@	O	-1	8829135
ates	O	-1	8829135
scopol@@	B-Chemical	D012601	8829135
amine	I-Chemical	-1	8829135
-induced	O	-1	8829135
lear@@	B-Disease	D007859	8829135
ning	I-Disease	-1	8829135
and	I-Disease	-1	8829135
post@@	I-Disease	-1	8829135
-@@	I-Disease	-1	8829135
tra@@	I-Disease	-1	8829135
in@@	I-Disease	-1	8829135
ing	I-Disease	-1	8829135
con@@	I-Disease	-1	8829135
sol@@	I-Disease	-1	8829135
id@@	I-Disease	-1	8829135
ation	I-Disease	-1	8829135
defic@@	I-Disease	-1	8829135
its	I-Disease	-1	8829135
.	O	-1	8829135
G@@	O	-1	8829135
i@@	O	-1	8829135
ven	O	-1	8829135
that	O	-1	8829135
apo@@	B-Chemical	D001058	8829135
morphine	I-Chemical	-1	8829135
inhibit@@	O	-1	8829135
s	O	-1	8829135
p@@	O	-1	8829135
as@@	O	-1	8829135
sive	O	-1	8829135
avoid@@	O	-1	8829135
ance	O	-1	8829135
re@@	O	-1	8829135
ten@@	O	-1	8829135
tion	O	-1	8829135
when	O	-1	8829135
given	O	-1	8829135
during	O	-1	8829135
tra@@	O	-1	8829135
in@@	O	-1	8829135
ing	O	-1	8829135
or	O	-1	8829135
in	O	-1	8829135
a	O	-1	8829135
def@@	O	-1	8829135
in@@	O	-1	8829135
ed	O	-1	8829135
10@@	O	-1	8829135
-1@@	O	-1	8829135
2@@	O	-1	8829135
h	O	-1	8829135
post@@	O	-1	8829135
-@@	O	-1	8829135
tra@@	O	-1	8829135
in@@	O	-1	8829135
ing	O	-1	8829135
perio@@	O	-1	8829135
d,	O	-1	8829135
we	O	-1	8829135
evaluated	O	-1	8829135
the	O	-1	8829135
ability	O	-1	8829135
of	O	-1	8829135
ne@@	B-Chemical	C058876	8829135
fi@@	I-Chemical	-1	8829135
rac@@	I-Chemical	-1	8829135
et@@	I-Chemical	-1	8829135
am	I-Chemical	-1	8829135
to	O	-1	8829135
attenu@@	O	-1	8829135
ate	O	-1	8829135
am@@	B-Disease	D000647	8829135
ne@@	I-Disease	-1	8829135
sia	I-Disease	-1	8829135
induced	O	-1	8829135
by	O	-1	8829135
dop@@	O	-1	8829135
aminergic	O	-1	8829135
agon@@	O	-1	8829135
is@@	O	-1	8829135
m.	O	-1	8829135
A	O	-1	8829135
st@@	O	-1	8829135
ep@@	O	-1	8829135
-@@	O	-1	8829135
do@@	O	-1	8829135
w@@	O	-1	8829135
n	O	-1	8829135
p@@	O	-1	8829135
as@@	O	-1	8829135
sive	O	-1	8829135
avoid@@	O	-1	8829135
ance	O	-1	8829135
par@@	O	-1	8829135
a@@	O	-1	8829135
di@@	O	-1	8829135
g@@	O	-1	8829135
m	O	-1	8829135
was	O	-1	8829135
em@@	O	-1	8829135
p@@	O	-1	8829135
lo@@	O	-1	8829135
y@@	O	-1	8829135
ed	O	-1	8829135
and	O	-1	8829135
ne@@	B-Chemical	C058876	8829135
fi@@	I-Chemical	-1	8829135
rac@@	I-Chemical	-1	8829135
et@@	I-Chemical	-1	8829135
am	I-Chemical	-1	8829135
(@@	O	-1	8829135
3	O	-1	8829135
mg/kg)	O	-1	8829135
and	O	-1	8829135
apo@@	B-Chemical	D001058	8829135
morphine	I-Chemical	-1	8829135
(0.@@	O	-1	8829135
5	O	-1	8829135
mg/kg)	O	-1	8829135
were	O	-1	8829135
given	O	-1	8829135
alone	O	-1	8829135
or	O	-1	8829135
in	O	-1	8829135
combination	O	-1	8829135
during	O	-1	8829135
tra@@	O	-1	8829135
in@@	O	-1	8829135
ing	O	-1	8829135
and	O	-1	8829135
at	O	-1	8829135
the	O	-1	8829135
10@@	O	-1	8829135
-1@@	O	-1	8829135
2@@	O	-1	8829135
h	O	-1	8829135
post@@	O	-1	8829135
-@@	O	-1	8829135
tra@@	O	-1	8829135
in@@	O	-1	8829135
ing	O	-1	8829135
period	O	-1	8829135
of	O	-1	8829135
con@@	O	-1	8829135
sol@@	O	-1	8829135
id@@	O	-1	8829135
ation.	O	-1	8829135
C@@	O	-1	8829135
o@@	O	-1	8829135
-@@	O	-1	8829135
administration	O	-1	8829135
of	O	-1	8829135
ne@@	B-Chemical	C058876	8829135
fi@@	I-Chemical	-1	8829135
rac@@	I-Chemical	-1	8829135
et@@	I-Chemical	-1	8829135
am	I-Chemical	-1	8829135
and	O	-1	8829135
apo@@	B-Chemical	D001058	8829135
morphine	I-Chemical	-1	8829135
during	O	-1	8829135
tra@@	O	-1	8829135
in@@	O	-1	8829135
ing	O	-1	8829135
or	O	-1	8829135
10@@	O	-1	8829135
h	O	-1	8829135
the@@	O	-1	8829135
re@@	O	-1	8829135
after	O	-1	8829135
produced	O	-1	8829135
no	O	-1	8829135
significant	O	-1	8829135
anti@@	O	-1	8829135
-@@	O	-1	8829135
am@@	O	-1	8829135
ne@@	O	-1	8829135
sic	O	-1	8829135
effect@@	O	-1	8829135
.	O	-1	8829135
However,	O	-1	8829135
administration	O	-1	8829135
of	O	-1	8829135
ne@@	B-Chemical	C058876	8829135
fi@@	I-Chemical	-1	8829135
rac@@	I-Chemical	-1	8829135
et@@	I-Chemical	-1	8829135
am	I-Chemical	-1	8829135
during	O	-1	8829135
tra@@	O	-1	8829135
in@@	O	-1	8829135
ing	O	-1	8829135
complete@@	O	-1	8829135
ly	O	-1	8829135
reversed	O	-1	8829135
the	O	-1	8829135
am@@	B-Disease	D000647	8829135
ne@@	I-Disease	-1	8829135
sia	I-Disease	-1	8829135
induced	O	-1	8829135
by	O	-1	8829135
apo@@	B-Chemical	D001058	8829135
morphine	I-Chemical	-1	8829135
at	O	-1	8829135
the	O	-1	8829135
10@@	O	-1	8829135
h	O	-1	8829135
post@@	O	-1	8829135
-@@	O	-1	8829135
tra@@	O	-1	8829135
in@@	O	-1	8829135
ing	O	-1	8829135
time	O	-1	8829135
and	O	-1	8829135
the	O	-1	8829135
con@@	O	-1	8829135
verse	O	-1	8829135
was	O	-1	8829135
also	O	-1	8829135
t@@	O	-1	8829135
ru@@	O	-1	8829135
e.	O	-1	8829135
These	O	-1	8829135
effects	O	-1	8829135
were	O	-1	8829135
not	O	-1	8829135
mediated	O	-1	8829135
by	O	-1	8829135
a	O	-1	8829135
dop@@	O	-1	8829135
aminergic	O	-1	8829135
mechanism	O	-1	8829135
as	O	-1	8829135
ne@@	B-Chemical	C058876	8829135
fi@@	I-Chemical	-1	8829135
rac@@	I-Chemical	-1	8829135
et@@	I-Chemical	-1	8829135
am	I-Chemical	-1	8829135
,	O	-1	8829135
at	O	-1	8829135
mil@@	O	-1	8829135
lim@@	O	-1	8829135
ol@@	O	-1	8829135
ar	O	-1	8829135
concentr@@	O	-1	8829135
ation@@	O	-1	8829135
s,	O	-1	8829135
fail@@	O	-1	8829135
ed	O	-1	8829135
to	O	-1	8829135
dis@@	O	-1	8829135
pl@@	O	-1	8829135
ac@@	O	-1	8829135
e	O	-1	8829135
either	O	-1	8829135
[@@	O	-1	8829135
3@@	O	-1	8829135
H@@	O	-1	8829135
]	O	-1	8829135
S@@	B-Chemical	C534628	8829135
C@@	I-Chemical	-1	8829135
H	I-Chemical	-1	8829135
2@@	I-Chemical	-1	8829135
3@@	I-Chemical	-1	8829135
3@@	I-Chemical	-1	8829135
9@@	I-Chemical	-1	8829135
0	I-Chemical	-1	8829135
or	O	-1	8829135
[@@	O	-1	8829135
3@@	O	-1	8829135
H@@	O	-1	8829135
]	O	-1	8829135
s@@	B-Chemical	D013134	8829135
pi@@	I-Chemical	-1	8829135
per@@	I-Chemical	-1	8829135
one	I-Chemical	-1	8829135
b@@	O	-1	8829135
ind@@	O	-1	8829135
ing	O	-1	8829135
from	O	-1	8829135
D@@	O	-1	8829135
1	O	-1	8829135
or	O	-1	8829135
D2	O	-1	8829135
dopamine	B-Chemical	D004298	8829135
receptor	O	-1	8829135
sub@@	O	-1	8829135
typ@@	O	-1	8829135
es,	O	-1	8829135
respectively.	O	-1	8829135
It	O	-1	8829135
is	O	-1	8829135
suggested	O	-1	8829135
that	O	-1	8829135
ne@@	B-Chemical	C058876	8829135
fi@@	I-Chemical	-1	8829135
rac@@	I-Chemical	-1	8829135
et@@	I-Chemical	-1	8829135
am	I-Chemical	-1	8829135
au@@	O	-1	8829135
g@@	O	-1	8829135
ments	O	-1	8829135
mol@@	O	-1	8829135
ec@@	O	-1	8829135
ular	O	-1	8829135
pro@@	O	-1	8829135
ces@@	O	-1	8829135
ses	O	-1	8829135
in	O	-1	8829135
the	O	-1	8829135
early	O	-1	8829135
st@@	O	-1	8829135
ages	O	-1	8829135
of	O	-1	8829135
events	O	-1	8829135
which	O	-1	8829135
ul@@	O	-1	8829135
tim@@	O	-1	8829135
ately	O	-1	8829135
le@@	O	-1	8829135
ad	O	-1	8829135
to	O	-1	8829135
con@@	O	-1	8829135
sol@@	O	-1	8829135
id@@	O	-1	8829135
ation	O	-1	8829135
of	O	-1	8829135
memor@@	O	-1	8829135
y.	O	-1	8829135

H@@	O	-1	8957205
um@@	O	-1	8957205
an	O	-1	8957205
cortico@@	B-Chemical	D000324	8957205
tro@@	I-Chemical	-1	8957205
p@@	I-Chemical	-1	8957205
in	I-Chemical	-1	8957205
-@@	O	-1	8957205
rele@@	O	-1	8957205
as@@	O	-1	8957205
ing	O	-1	8957205
h@@	O	-1	8957205
orm@@	O	-1	8957205
one	O	-1	8957205
and	O	-1	8957205
th@@	B-Chemical	D013972	8957205
yro@@	I-Chemical	-1	8957205
tro@@	I-Chemical	-1	8957205
p@@	I-Chemical	-1	8957205
in	I-Chemical	-1	8957205
-@@	O	-1	8957205
rele@@	O	-1	8957205
as@@	O	-1	8957205
ing	O	-1	8957205
h@@	O	-1	8957205
orm@@	O	-1	8957205
one	O	-1	8957205
mod@@	O	-1	8957205
ul@@	O	-1	8957205
ate	O	-1	8957205
the	O	-1	8957205
hyper@@	B-Disease	D006935	8957205
cap@@	I-Disease	-1	8957205
n@@	I-Disease	-1	8957205
ic	I-Disease	-1	8957205
ven@@	O	-1	8957205
ti@@	O	-1	8957205
lat@@	O	-1	8957205
ory	O	-1	8957205
response	O	-1	8957205
in	O	-1	8957205
hum@@	O	-1	8957205
an@@	O	-1	8957205
s.	O	-1	8957205
H@@	O	-1	8957205
um@@	O	-1	8957205
an	O	-1	8957205
cortico@@	B-Chemical	D000324	8957205
tro@@	I-Chemical	-1	8957205
p@@	I-Chemical	-1	8957205
in	I-Chemical	-1	8957205
-@@	O	-1	8957205
rele@@	O	-1	8957205
as@@	O	-1	8957205
ing	O	-1	8957205
h@@	O	-1	8957205
orm@@	O	-1	8957205
one	O	-1	8957205
(@@	O	-1	8957205
h@@	O	-1	8957205
CR@@	O	-1	8957205
H@@	O	-1	8957205
)	O	-1	8957205
and	O	-1	8957205
th@@	B-Chemical	D013972	8957205
yro@@	I-Chemical	-1	8957205
tro@@	I-Chemical	-1	8957205
p@@	I-Chemical	-1	8957205
in	I-Chemical	-1	8957205
-@@	O	-1	8957205
rele@@	O	-1	8957205
as@@	O	-1	8957205
ing	O	-1	8957205
h@@	O	-1	8957205
orm@@	O	-1	8957205
one	O	-1	8957205
(@@	O	-1	8957205
TR@@	O	-1	8957205
H@@	O	-1	8957205
)	O	-1	8957205
are	O	-1	8957205
known	O	-1	8957205
to	O	-1	8957205
stimul@@	O	-1	8957205
ate	O	-1	8957205
ven@@	O	-1	8957205
til@@	O	-1	8957205
ation	O	-1	8957205
after	O	-1	8957205
i.v@@	O	-1	8957205
.	O	-1	8957205
administration	O	-1	8957205
in	O	-1	8957205
hum@@	O	-1	8957205
an@@	O	-1	8957205
s.	O	-1	8957205
In	O	-1	8957205
a	O	-1	8957205
placebo@@	O	-1	8957205
-@@	O	-1	8957205
control@@	O	-1	8957205
le@@	O	-1	8957205
d,	O	-1	8957205
sing@@	O	-1	8957205
le@@	O	-1	8957205
-@@	O	-1	8957205
bl@@	O	-1	8957205
ind	O	-1	8957205
study	O	-1	8957205
we	O	-1	8957205
a@@	O	-1	8957205
im@@	O	-1	8957205
ed	O	-1	8957205
to	O	-1	8957205
cl@@	O	-1	8957205
ar@@	O	-1	8957205
if@@	O	-1	8957205
y	O	-1	8957205
if	O	-1	8957205
both	O	-1	8957205
p@@	O	-1	8957205
ep@@	O	-1	8957205
ti@@	O	-1	8957205
des	O	-1	8957205
ac@@	O	-1	8957205
t	O	-1	8957205
by	O	-1	8957205
al@@	O	-1	8957205
ter@@	O	-1	8957205
ing	O	-1	8957205
central	O	-1	8957205
chem@@	O	-1	8957205
os@@	O	-1	8957205
en@@	O	-1	8957205
si@@	O	-1	8957205
tiv@@	O	-1	8957205
ity.	O	-1	8957205
Two	O	-1	8957205
subsequ@@	O	-1	8957205
ent	O	-1	8957205
CO@@	B-Chemical	D002245	8957205
2	I-Chemical	-1	8957205
-@@	O	-1	8957205
reb@@	O	-1	8957205
re@@	O	-1	8957205
ath@@	O	-1	8957205
ing	O	-1	8957205
tests	O	-1	8957205
were	O	-1	8957205
performed	O	-1	8957205
in	O	-1	8957205
healthy	O	-1	8957205
youn@@	O	-1	8957205
g	O	-1	8957205
vol@@	O	-1	8957205
un@@	O	-1	8957205
te@@	O	-1	8957205
ers.	O	-1	8957205
D@@	O	-1	8957205
uring	O	-1	8957205
the	O	-1	8957205
first	O	-1	8957205
test	O	-1	8957205
0.@@	O	-1	8957205
9@@	O	-1	8957205
%	O	-1	8957205
Na@@	B-Chemical	D012965	8957205
C@@	I-Chemical	-1	8957205
l	I-Chemical	-1	8957205
was	O	-1	8957205
given	O	-1	8957205
i.v@@	O	-1	8957205
.@@	O	-1	8957205
;	O	-1	8957205
during	O	-1	8957205
the	O	-1	8957205
second	O	-1	8957205
test	O	-1	8957205
2@@	O	-1	8957205
00	O	-1	8957205
microgram@@	O	-1	8957205
s	O	-1	8957205
of	O	-1	8957205
h@@	O	-1	8957205
CR@@	O	-1	8957205
H	O	-1	8957205
(n	O	-1	8957205
=	O	-1	8957205
12@@	O	-1	8957205
)	O	-1	8957205
or	O	-1	8957205
4@@	O	-1	8957205
00	O	-1	8957205
microgram@@	O	-1	8957205
s	O	-1	8957205
of	O	-1	8957205
TR@@	O	-1	8957205
H	O	-1	8957205
(n	O	-1	8957205
=	O	-1	8957205
6@@	O	-1	8957205
)	O	-1	8957205
was	O	-1	8957205
administered	O	-1	8957205
i.v@@	O	-1	8957205
.	O	-1	8957205
N@@	O	-1	8957205
ine	O	-1	8957205
subjects	O	-1	8957205
received	O	-1	8957205
0.@@	O	-1	8957205
9@@	O	-1	8957205
%	O	-1	8957205
Na@@	B-Chemical	D012965	8957205
C@@	I-Chemical	-1	8957205
l	I-Chemical	-1	8957205
i.v@@	O	-1	8957205
.	O	-1	8957205
during	O	-1	8957205
both	O	-1	8957205
reb@@	O	-1	8957205
re@@	O	-1	8957205
ath@@	O	-1	8957205
ing	O	-1	8957205
man@@	O	-1	8957205
o@@	O	-1	8957205
eu@@	O	-1	8957205
v@@	O	-1	8957205
res@@	O	-1	8957205
.	O	-1	8957205
The	O	-1	8957205
CO@@	B-Chemical	D002245	8957205
2	I-Chemical	-1	8957205
-@@	O	-1	8957205
response	O	-1	8957205
cur@@	O	-1	8957205
v@@	O	-1	8957205
es	O	-1	8957205
for	O	-1	8957205
the	O	-1	8957205
two	O	-1	8957205
tests	O	-1	8957205
were	O	-1	8957205
compared	O	-1	8957205
within	O	-1	8957205
the	O	-1	8957205
same	O	-1	8957205
subj@@	O	-1	8957205
ect@@	O	-1	8957205
.	O	-1	8957205
In	O	-1	8957205
the	O	-1	8957205
h@@	O	-1	8957205
CR@@	O	-1	8957205
H	O	-1	8957205
group	O	-1	8957205
a	O	-1	8957205
mark@@	O	-1	8957205
ed	O	-1	8957205
par@@	O	-1	8957205
al@@	O	-1	8957205
le@@	O	-1	8957205
l	O	-1	8957205
shi@@	O	-1	8957205
ft	O	-1	8957205
of	O	-1	8957205
the	O	-1	8957205
CO@@	B-Chemical	D002245	8957205
2	I-Chemical	-1	8957205
-@@	O	-1	8957205
response	O	-1	8957205
cur@@	O	-1	8957205
ve	O	-1	8957205
to	O	-1	8957205
the	O	-1	8957205
left	O	-1	8957205
was	O	-1	8957205
observed	O	-1	8957205
after	O	-1	8957205
h@@	O	-1	8957205
CR@@	O	-1	8957205
H	O	-1	8957205
(P	O	-1	8957205
<	O	-1	8957205
0.0@@	O	-1	8957205
1).	O	-1	8957205
The	O	-1	8957205
same	O	-1	8957205
effect	O	-1	8957205
occurred	O	-1	8957205
following	O	-1	8957205
TR@@	O	-1	8957205
H	O	-1	8957205
but	O	-1	8957205
was	O	-1	8957205
less	O	-1	8957205
stri@@	O	-1	8957205
king	O	-1	8957205
(P	O	-1	8957205
=	O	-1	8957205
0.05@@	O	-1	8957205
).	O	-1	8957205
h@@	O	-1	8957205
CR@@	O	-1	8957205
H	O	-1	8957205
and	O	-1	8957205
TR@@	O	-1	8957205
H	O	-1	8957205
caused	O	-1	8957205
a	O	-1	8957205
reduction	O	-1	8957205
in	O	-1	8957205
the	O	-1	8957205
CO@@	B-Chemical	D002245	8957205
2	I-Chemical	-1	8957205
th@@	O	-1	8957205
res@@	O	-1	8957205
h@@	O	-1	8957205
ol@@	O	-1	8957205
d.	O	-1	8957205
The	O	-1	8957205
CO@@	B-Chemical	D002245	8957205
2	I-Chemical	-1	8957205
-@@	O	-1	8957205
response	O	-1	8957205
cur@@	O	-1	8957205
v@@	O	-1	8957205
es	O	-1	8957205
in	O	-1	8957205
the	O	-1	8957205
control	O	-1	8957205
group	O	-1	8957205
were	O	-1	8957205
ne@@	O	-1	8957205
arly	O	-1	8957205
id@@	O	-1	8957205
en@@	O	-1	8957205
tic@@	O	-1	8957205
al.	O	-1	8957205
The	O	-1	8957205
results	O	-1	8957205
indicate	O	-1	8957205
an	O	-1	8957205
addi@@	O	-1	8957205
tive	O	-1	8957205
effect	O	-1	8957205
of	O	-1	8957205
both	O	-1	8957205
rele@@	O	-1	8957205
as@@	O	-1	8957205
ing	O	-1	8957205
h@@	O	-1	8957205
orm@@	O	-1	8957205
on@@	O	-1	8957205
es	O	-1	8957205
on	O	-1	8957205
the	O	-1	8957205
hyper@@	B-Disease	D006935	8957205
cap@@	I-Disease	-1	8957205
n@@	I-Disease	-1	8957205
ic	I-Disease	-1	8957205
ven@@	O	-1	8957205
ti@@	O	-1	8957205
lat@@	O	-1	8957205
ory	O	-1	8957205
response	O	-1	8957205
in	O	-1	8957205
hum@@	O	-1	8957205
an@@	O	-1	8957205
s,	O	-1	8957205
pres@@	O	-1	8957205
um@@	O	-1	8957205
ably	O	-1	8957205
in@@	O	-1	8957205
dependent	O	-1	8957205
of	O	-1	8957205
central	O	-1	8957205
chem@@	O	-1	8957205
os@@	O	-1	8957205
en@@	O	-1	8957205
si@@	O	-1	8957205
tiv@@	O	-1	8957205
ity.	O	-1	8957205

L@@	B-Chemical	D019259	8985298
amivud@@	I-Chemical	-1	8985298
ine	I-Chemical	-1	8985298
is	O	-1	8985298
effective	O	-1	8985298
in	O	-1	8985298
sup@@	O	-1	8985298
press@@	O	-1	8985298
ing	O	-1	8985298
hepatitis	B-Disease	D006509	8985298
B	I-Disease	-1	8985298
vi@@	O	-1	8985298
ru@@	O	-1	8985298
s	O	-1	8985298
D@@	O	-1	8985298
NA	O	-1	8985298
in	O	-1	8985298
Ch@@	O	-1	8985298
in@@	O	-1	8985298
ese	O	-1	8985298
hepatitis	B-Chemical	D006514	8985298
B	I-Chemical	-1	8985298
sur@@	I-Chemical	-1	8985298
fac@@	I-Chemical	-1	8985298
e	I-Chemical	-1	8985298
anti@@	I-Chemical	-1	8985298
gen	I-Chemical	-1	8985298
car@@	O	-1	8985298
ri@@	O	-1	8985298
er@@	O	-1	8985298
s:	O	-1	8985298
a	O	-1	8985298
placebo@@	O	-1	8985298
-@@	O	-1	8985298
controlled	O	-1	8985298
tri@@	O	-1	8985298
al.	O	-1	8985298
L@@	B-Chemical	D019259	8985298
amivud@@	I-Chemical	-1	8985298
ine	I-Chemical	-1	8985298
is	O	-1	8985298
a	O	-1	8985298
novel	O	-1	8985298
2@@	B-Chemical	D019259	8985298
'@@	I-Chemical	-1	8985298
,@@	I-Chemical	-1	8985298
3@@	I-Chemical	-1	8985298
'@@	I-Chemical	-1	8985298
-@@	I-Chemical	-1	8985298
di@@	I-Chemical	-1	8985298
de@@	I-Chemical	-1	8985298
ox@@	I-Chemical	-1	8985298
y	I-Chemical	-1	8985298
cy@@	I-Chemical	-1	8985298
t@@	I-Chemical	-1	8985298
os@@	I-Chemical	-1	8985298
ine	I-Chemical	-1	8985298
an@@	O	-1	8985298
alo@@	O	-1	8985298
gu@@	O	-1	8985298
e	O	-1	8985298
that	O	-1	8985298
has	O	-1	8985298
pot@@	O	-1	8985298
ent	O	-1	8985298
inhibit@@	O	-1	8985298
ory	O	-1	8985298
effects	O	-1	8985298
on	O	-1	8985298
hepatitis	B-Disease	D006509	8985298
B	I-Disease	-1	8985298
vi@@	O	-1	8985298
ru@@	O	-1	8985298
s	O	-1	8985298
re@@	O	-1	8985298
plic@@	O	-1	8985298
ation	O	-1	8985298
in	O	-1	8985298
vit@@	O	-1	8985298
r@@	O	-1	8985298
o	O	-1	8985298
and	O	-1	8985298
in	O	-1	8985298
viv@@	O	-1	8985298
o@@	O	-1	8985298
.	O	-1	8985298
We	O	-1	8985298
performed	O	-1	8985298
a	O	-1	8985298
sing@@	O	-1	8985298
le@@	O	-1	8985298
-@@	O	-1	8985298
bl@@	O	-1	8985298
ind@@	O	-1	8985298
,	O	-1	8985298
placebo@@	O	-1	8985298
-@@	O	-1	8985298
controlled	O	-1	8985298
study	O	-1	8985298
to	O	-1	8985298
ass@@	O	-1	8985298
ess	O	-1	8985298
its	O	-1	8985298
eff@@	O	-1	8985298
ec@@	O	-1	8985298
tiv@@	O	-1	8985298
en@@	O	-1	8985298
ess	O	-1	8985298
and	O	-1	8985298
safety	O	-1	8985298
in	O	-1	8985298
Ch@@	O	-1	8985298
in@@	O	-1	8985298
ese	O	-1	8985298
hepatitis	B-Chemical	D006514	8985298
B	I-Chemical	-1	8985298
sur@@	I-Chemical	-1	8985298
fac@@	I-Chemical	-1	8985298
e	I-Chemical	-1	8985298
anti@@	I-Chemical	-1	8985298
gen	I-Chemical	-1	8985298
(	O	-1	8985298
HB@@	B-Chemical	D006514	8985298
s@@	I-Chemical	-1	8985298
A@@	I-Chemical	-1	8985298
g	I-Chemical	-1	8985298
)	O	-1	8985298
car@@	O	-1	8985298
ri@@	O	-1	8985298
ers.	O	-1	8985298
F@@	O	-1	8985298
or@@	O	-1	8985298
ty-@@	O	-1	8985298
two	O	-1	8985298
Ch@@	O	-1	8985298
in@@	O	-1	8985298
ese	O	-1	8985298
HB@@	B-Chemical	D006514	8985298
s@@	I-Chemical	-1	8985298
A@@	I-Chemical	-1	8985298
g	I-Chemical	-1	8985298
car@@	O	-1	8985298
ri@@	O	-1	8985298
ers	O	-1	8985298
were	O	-1	8985298
randomized	O	-1	8985298
to	O	-1	8985298
recei@@	O	-1	8985298
ve	O	-1	8985298
placebo	O	-1	8985298
(@@	O	-1	8985298
6	O	-1	8985298
patient@@	O	-1	8985298
s)	O	-1	8985298
or	O	-1	8985298
lamivud@@	B-Chemical	D019259	8985298
ine	I-Chemical	-1	8985298
or@@	O	-1	8985298
ally	O	-1	8985298
in	O	-1	8985298
dos@@	O	-1	8985298
ages	O	-1	8985298
of	O	-1	8985298
25	O	-1	8985298
mg@@	O	-1	8985298
,	O	-1	8985298
100	O	-1	8985298
mg@@	O	-1	8985298
,	O	-1	8985298
or	O	-1	8985298
3@@	O	-1	8985298
00	O	-1	8985298
mg	O	-1	8985298
daily	O	-1	8985298
(1@@	O	-1	8985298
2	O	-1	8985298
patients	O	-1	8985298
for	O	-1	8985298
each	O	-1	8985298
dos@@	O	-1	8985298
ag@@	O	-1	8985298
e@@	O	-1	8985298
).	O	-1	8985298
The	O	-1	8985298
drug	O	-1	8985298
was	O	-1	8985298
given	O	-1	8985298
for	O	-1	8985298
4	O	-1	8985298
week@@	O	-1	8985298
s.	O	-1	8985298
The	O	-1	8985298
patients	O	-1	8985298
were	O	-1	8985298
clo@@	O	-1	8985298
se@@	O	-1	8985298
ly	O	-1	8985298
monit@@	O	-1	8985298
o@@	O	-1	8985298
red	O	-1	8985298
clin@@	O	-1	8985298
ic@@	O	-1	8985298
ally,	O	-1	8985298
bio@@	O	-1	8985298
chem@@	O	-1	8985298
ic@@	O	-1	8985298
ally,	O	-1	8985298
and	O	-1	8985298
ser@@	O	-1	8985298
olog@@	O	-1	8985298
ically	O	-1	8985298
up	O	-1	8985298
to	O	-1	8985298
4	O	-1	8985298
weeks	O	-1	8985298
after	O	-1	8985298
drug	O	-1	8985298
treatment.	O	-1	8985298
All	O	-1	8985298
3@@	O	-1	8985298
6	O	-1	8985298
patients	O	-1	8985298
receiving	O	-1	8985298
lamivud@@	B-Chemical	D019259	8985298
ine	I-Chemical	-1	8985298
had	O	-1	8985298
a	O	-1	8985298
decrease	O	-1	8985298
in	O	-1	8985298
hepatitis	B-Disease	D006509	8985298
B	I-Disease	-1	8985298
vi@@	O	-1	8985298
ru@@	O	-1	8985298
s	O	-1	8985298
(@@	O	-1	8985298
HB@@	O	-1	8985298
V@@	O	-1	8985298
)	O	-1	8985298
D@@	O	-1	8985298
NA	O	-1	8985298
values	O	-1	8985298
of	O	-1	8985298
>@@	O	-1	8985298
9@@	O	-1	8985298
0%	O	-1	8985298
(P	O	-1	8985298
<	O	-1	8985298
.@@	O	-1	8985298
0@@	O	-1	8985298
0@@	O	-1	8985298
1	O	-1	8985298
compared	O	-1	8985298
with	O	-1	8985298
placebo@@	O	-1	8985298
).	O	-1	8985298
Although	O	-1	8985298
25	O	-1	8985298
mg	O	-1	8985298
of	O	-1	8985298
lamivud@@	B-Chemical	D019259	8985298
ine	I-Chemical	-1	8985298
was	O	-1	8985298
s@@	O	-1	8985298
li@@	O	-1	8985298
gh@@	O	-1	8985298
tly	O	-1	8985298
less	O	-1	8985298
effective	O	-1	8985298
than	O	-1	8985298
100	O	-1	8985298
mg	O	-1	8985298
(P	O	-1	8985298
=	O	-1	8985298
.@@	O	-1	8985298
0@@	O	-1	8985298
1@@	O	-1	8985298
1)	O	-1	8985298
and	O	-1	8985298
3@@	O	-1	8985298
00	O	-1	8985298
mg	O	-1	8985298
(P	O	-1	8985298
=	O	-1	8985298
.@@	O	-1	8985298
0@@	O	-1	8985298
0@@	O	-1	8985298
5@@	O	-1	8985298
),	O	-1	8985298
it	O	-1	8985298
sti@@	O	-1	8985298
ll	O	-1	8985298
induced	O	-1	8985298
9@@	O	-1	8985298
4@@	O	-1	8985298
%	O	-1	8985298
sup@@	O	-1	8985298
pression	O	-1	8985298
of	O	-1	8985298
HBV	O	-1	8985298
D@@	O	-1	8985298
NA	O	-1	8985298
after	O	-1	8985298
the	O	-1	8985298
fo@@	O	-1	8985298
ur@@	O	-1	8985298
th	O	-1	8985298
week	O	-1	8985298
of	O	-1	8985298
therapy.	O	-1	8985298
HBV	O	-1	8985298
D@@	O	-1	8985298
NA	O	-1	8985298
values	O	-1	8985298
retur@@	O	-1	8985298
n@@	O	-1	8985298
ed	O	-1	8985298
to	O	-1	8985298
pretreatment	O	-1	8985298
levels	O	-1	8985298
within	O	-1	8985298
4	O	-1	8985298
weeks	O	-1	8985298
of	O	-1	8985298
cess@@	O	-1	8985298
ation	O	-1	8985298
of	O	-1	8985298
therapy.	O	-1	8985298
There	O	-1	8985298
was	O	-1	8985298
no	O	-1	8985298
change	O	-1	8985298
in	O	-1	8985298
the	O	-1	8985298
hepatitis	B-Disease	D006509	8985298
B	I-Disease	-1	8985298
e	O	-1	8985298
anti@@	O	-1	8985298
gen	O	-1	8985298
status	O	-1	8985298
or	O	-1	8985298
in	O	-1	8985298
amin@@	O	-1	8985298
ot@@	O	-1	8985298
ran@@	O	-1	8985298
s@@	O	-1	8985298
fer@@	O	-1	8985298
ase	O	-1	8985298
level@@	O	-1	8985298
s.	O	-1	8985298
No	O	-1	8985298
seri@@	O	-1	8985298
ous	O	-1	8985298
adverse	O	-1	8985298
events	O	-1	8985298
were	O	-1	8985298
obser@@	O	-1	8985298
ved.	O	-1	8985298
In	O	-1	8985298
concl@@	O	-1	8985298
u@@	O	-1	8985298
sion,	O	-1	8985298
a	O	-1	8985298
4-@@	O	-1	8985298
week	O	-1	8985298
course	O	-1	8985298
of	O	-1	8985298
lamivud@@	B-Chemical	D019259	8985298
ine	I-Chemical	-1	8985298
was	O	-1	8985298
saf@@	O	-1	8985298
e	O	-1	8985298
and	O	-1	8985298
effective	O	-1	8985298
in	O	-1	8985298
sup@@	O	-1	8985298
pression	O	-1	8985298
of	O	-1	8985298
HBV	O	-1	8985298
D@@	O	-1	8985298
NA	O	-1	8985298
in	O	-1	8985298
Ch@@	O	-1	8985298
in@@	O	-1	8985298
ese	O	-1	8985298
HB@@	B-Chemical	D006514	8985298
s@@	I-Chemical	-1	8985298
A@@	I-Chemical	-1	8985298
g	I-Chemical	-1	8985298
car@@	O	-1	8985298
ri@@	O	-1	8985298
ers.	O	-1	8985298
The	O	-1	8985298
sup@@	O	-1	8985298
pression	O	-1	8985298
was	O	-1	8985298
>@@	O	-1	8985298
9@@	O	-1	8985298
0%	O	-1	8985298
but	O	-1	8985298
rever@@	O	-1	8985298
sib@@	O	-1	8985298
le@@	O	-1	8985298
.	O	-1	8985298
S@@	O	-1	8985298
t@@	O	-1	8985298
udi@@	O	-1	8985298
es	O	-1	8985298
with	O	-1	8985298
long-term	O	-1	8985298
lamivud@@	B-Chemical	D019259	8985298
ine	I-Chemical	-1	8985298
administration	O	-1	8985298
should	O	-1	8985298
be	O	-1	8985298
performed	O	-1	8985298
to	O	-1	8985298
determine	O	-1	8985298
if	O	-1	8985298
prolonged	O	-1	8985298
sup@@	O	-1	8985298
pression	O	-1	8985298
of	O	-1	8985298
HBV	O	-1	8985298
D@@	O	-1	8985298
NA	O	-1	8985298
can	O	-1	8985298
be	O	-1	8985298
achi@@	O	-1	8985298
e@@	O	-1	8985298
ved.	O	-1	8985298

P@@	O	-1	8996419
o@@	O	-1	8996419
pul@@	O	-1	8996419
ation@@	O	-1	8996419
-@@	O	-1	8996419
bas@@	O	-1	8996419
ed	O	-1	8996419
study	O	-1	8996419
of	O	-1	8996419
risk	O	-1	8996419
of	O	-1	8996419
venous	B-Disease	D054556	8996419
thrombo@@	I-Disease	-1	8996419
emb@@	I-Disease	-1	8996419
ol@@	I-Disease	-1	8996419
ism	I-Disease	-1	8996419
associated	O	-1	8996419
with	O	-1	8996419
various	O	-1	8996419
oral	B-Chemical	D003276	8996419
contrac@@	I-Chemical	-1	8996419
ep@@	I-Chemical	-1	8996419
tiv@@	I-Chemical	-1	8996419
es	I-Chemical	-1	8996419
.	O	-1	8996419
BACKGROUND:	O	-1	8996419
F@@	O	-1	8996419
our	O	-1	8996419
studies	O	-1	8996419
pu@@	O	-1	8996419
bl@@	O	-1	8996419
ished	O	-1	8996419
s@@	O	-1	8996419
inc@@	O	-1	8996419
e	O	-1	8996419
D@@	O	-1	8996419
ec@@	O	-1	8996419
emb@@	O	-1	8996419
er,	O	-1	8996419
19@@	O	-1	8996419
9@@	O	-1	8996419
5,	O	-1	8996419
reported	O	-1	8996419
that	O	-1	8996419
the	O	-1	8996419
incidence	O	-1	8996419
of	O	-1	8996419
venous	B-Disease	D054556	8996419
thrombo@@	I-Disease	-1	8996419
emb@@	I-Disease	-1	8996419
ol@@	I-Disease	-1	8996419
ism	I-Disease	-1	8996419
(	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
)	O	-1	8996419
was	O	-1	8996419
higher	O	-1	8996419
in	O	-1	8996419
women	O	-1	8996419
who	O	-1	8996419
used	O	-1	8996419
oral	B-Chemical	D003276	8996419
contrac@@	I-Chemical	-1	8996419
ep@@	I-Chemical	-1	8996419
tiv@@	I-Chemical	-1	8996419
es	I-Chemical	-1	8996419
(	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
)	O	-1	8996419
containing	O	-1	8996419
the	O	-1	8996419
thir@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
pro@@	B-Chemical	D011374	8996419
g@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
ag@@	I-Chemical	-1	8996419
en@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
g@@	B-Chemical	C033273	8996419
est@@	I-Chemical	-1	8996419
o@@	I-Chemical	-1	8996419
d@@	I-Chemical	-1	8996419
ene	I-Chemical	-1	8996419
or	O	-1	8996419
des@@	B-Chemical	D017135	8996419
o@@	I-Chemical	-1	8996419
g@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
re@@	I-Chemical	-1	8996419
l	I-Chemical	-1	8996419
than	O	-1	8996419
in	O	-1	8996419
users	O	-1	8996419
of	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
containing	O	-1	8996419
secon@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
pro@@	B-Chemical	D011374	8996419
g@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
ag@@	I-Chemical	-1	8996419
en@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
.	O	-1	8996419
However,	O	-1	8996419
conf@@	O	-1	8996419
oun@@	O	-1	8996419
ding	O	-1	8996419
and	O	-1	8996419
b@@	O	-1	8996419
i@@	O	-1	8996419
as	O	-1	8996419
in	O	-1	8996419
the	O	-1	8996419
desi@@	O	-1	8996419
g@@	O	-1	8996419
n	O	-1	8996419
of	O	-1	8996419
these	O	-1	8996419
studies	O	-1	8996419
may	O	-1	8996419
have	O	-1	8996419
affected	O	-1	8996419
the	O	-1	8996419
find@@	O	-1	8996419
ing@@	O	-1	8996419
s.	O	-1	8996419
The	O	-1	8996419
a@@	O	-1	8996419
im	O	-1	8996419
of	O	-1	8996419
our	O	-1	8996419
study	O	-1	8996419
was	O	-1	8996419
to	O	-1	8996419
re@@	O	-1	8996419
-@@	O	-1	8996419
ex@@	O	-1	8996419
amine	O	-1	8996419
the	O	-1	8996419
association	O	-1	8996419
between	O	-1	8996419
risk	O	-1	8996419
of	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
and	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C	I-Chemical	-1	8996419
use	O	-1	8996419
with	O	-1	8996419
a	O	-1	8996419
different	O	-1	8996419
study	O	-1	8996419
desi@@	O	-1	8996419
g@@	O	-1	8996419
n	O	-1	8996419
and	O	-1	8996419
analysis	O	-1	8996419
to	O	-1	8996419
av@@	O	-1	8996419
oid	O	-1	8996419
some	O	-1	8996419
of	O	-1	8996419
the	O	-1	8996419
b@@	O	-1	8996419
i@@	O	-1	8996419
as	O	-1	8996419
and	O	-1	8996419
conf@@	O	-1	8996419
oun@@	O	-1	8996419
ding	O	-1	8996419
of	O	-1	8996419
the	O	-1	8996419
ear@@	O	-1	8996419
li@@	O	-1	8996419
er	O	-1	8996419
studi@@	O	-1	8996419
es.	O	-1	8996419
METHODS:	O	-1	8996419
We	O	-1	8996419
used	O	-1	8996419
comp@@	O	-1	8996419
u@@	O	-1	8996419
ter	O	-1	8996419
recor@@	O	-1	8996419
ds	O	-1	8996419
of	O	-1	8996419
patients	O	-1	8996419
from	O	-1	8996419
14@@	O	-1	8996419
3	O	-1	8996419
gener@@	O	-1	8996419
al	O	-1	8996419
p@@	O	-1	8996419
rac@@	O	-1	8996419
tic@@	O	-1	8996419
es	O	-1	8996419
in	O	-1	8996419
the	O	-1	8996419
U@@	O	-1	8996419
K@@	O	-1	8996419
.	O	-1	8996419
The	O	-1	8996419
study	O	-1	8996419
was	O	-1	8996419
bas@@	O	-1	8996419
ed	O	-1	8996419
on	O	-1	8996419
the	O	-1	8996419
med@@	O	-1	8996419
ical	O	-1	8996419
recor@@	O	-1	8996419
ds	O	-1	8996419
of	O	-1	8996419
about	O	-1	8996419
5@@	O	-1	8996419
4@@	O	-1	8996419
0@@	O	-1	8996419
,@@	O	-1	8996419
0@@	O	-1	8996419
00	O	-1	8996419
women	O	-1	8996419
b@@	O	-1	8996419
or@@	O	-1	8996419
n	O	-1	8996419
between	O	-1	8996419
19@@	O	-1	8996419
4@@	O	-1	8996419
1	O	-1	8996419
and	O	-1	8996419
19@@	O	-1	8996419
8@@	O	-1	8996419
1@@	O	-1	8996419
.	O	-1	8996419
All	O	-1	8996419
women	O	-1	8996419
who	O	-1	8996419
had	O	-1	8996419
a	O	-1	8996419
recor@@	O	-1	8996419
ded	O	-1	8996419
diagnosis	O	-1	8996419
of	O	-1	8996419
de@@	B-Disease	D020246	8996419
ep@@	I-Disease	-1	8996419
-@@	I-Disease	-1	8996419
ve@@	I-Disease	-1	8996419
in	I-Disease	-1	8996419
thrombo@@	I-Disease	-1	8996419
sis	I-Disease	-1	8996419
,	O	-1	8996419
venous	B-Disease	D020246	8996419
thrombo@@	I-Disease	-1	8996419
sis	I-Disease	-1	8996419
not	O	-1	8996419
o@@	O	-1	8996419
ther@@	O	-1	8996419
w@@	O	-1	8996419
is@@	O	-1	8996419
e	O	-1	8996419
specif@@	O	-1	8996419
i@@	O	-1	8996419
ed,	O	-1	8996419
or	O	-1	8996419
pulmonary	O	-1	8996419
emb@@	O	-1	8996419
ol@@	O	-1	8996419
us	O	-1	8996419
during	O	-1	8996419
the	O	-1	8996419
study	O	-1	8996419
perio@@	O	-1	8996419
d,	O	-1	8996419
and	O	-1	8996419
who	O	-1	8996419
had	O	-1	8996419
been	O	-1	8996419
treated	O	-1	8996419
with	O	-1	8996419
an	O	-1	8996419
anti@@	O	-1	8996419
co@@	O	-1	8996419
ag@@	O	-1	8996419
ul@@	O	-1	8996419
ant	O	-1	8996419
were	O	-1	8996419
identi@@	O	-1	8996419
fied	O	-1	8996419
as	O	-1	8996419
potential	O	-1	8996419
cases	O	-1	8996419
of	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
.	O	-1	8996419
We	O	-1	8996419
did	O	-1	8996419
a	O	-1	8996419
co@@	O	-1	8996419
h@@	O	-1	8996419
ort	O	-1	8996419
analysis	O	-1	8996419
to	O	-1	8996419
estim@@	O	-1	8996419
ate	O	-1	8996419
and	O	-1	8996419
compar@@	O	-1	8996419
e	O	-1	8996419
incidence	O	-1	8996419
of	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
in	O	-1	8996419
users	O	-1	8996419
of	O	-1	8996419
the	O	-1	8996419
ma@@	O	-1	8996419
in	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C	I-Chemical	-1	8996419
pre@@	O	-1	8996419
par@@	O	-1	8996419
ation@@	O	-1	8996419
s,	O	-1	8996419
and	O	-1	8996419
a	O	-1	8996419
ne@@	O	-1	8996419
st@@	O	-1	8996419
ed	O	-1	8996419
cas@@	O	-1	8996419
e-@@	O	-1	8996419
control	O	-1	8996419
study	O	-1	8996419
to	O	-1	8996419
calc@@	O	-1	8996419
ul@@	O	-1	8996419
ate	O	-1	8996419
the	O	-1	8996419
o@@	O	-1	8996419
d@@	O	-1	8996419
ds	O	-1	8996419
rati@@	O	-1	8996419
o@@	O	-1	8996419
s	O	-1	8996419
of	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
associated	O	-1	8996419
with	O	-1	8996419
use	O	-1	8996419
of	O	-1	8996419
different	O	-1	8996419
typ@@	O	-1	8996419
es	O	-1	8996419
of	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C	I-Chemical	-1	8996419
,	O	-1	8996419
after	O	-1	8996419
adjust@@	O	-1	8996419
ment	O	-1	8996419
for	O	-1	8996419
potential	O	-1	8996419
conf@@	O	-1	8996419
oun@@	O	-1	8996419
ding	O	-1	8996419
fact@@	O	-1	8996419
or@@	O	-1	8996419
s.	O	-1	8996419
In	O	-1	8996419
the	O	-1	8996419
cas@@	O	-1	8996419
e-@@	O	-1	8996419
control	O	-1	8996419
study,	O	-1	8996419
we	O	-1	8996419
mat@@	O	-1	8996419
ch@@	O	-1	8996419
ed	O	-1	8996419
cases	O	-1	8996419
to	O	-1	8996419
controls	O	-1	8996419
by	O	-1	8996419
ex@@	O	-1	8996419
ac@@	O	-1	8996419
t	O	-1	8996419
year	O	-1	8996419
of	O	-1	8996419
b@@	O	-1	8996419
ir@@	O	-1	8996419
th@@	O	-1	8996419
,	O	-1	8996419
p@@	O	-1	8996419
rac@@	O	-1	8996419
ti@@	O	-1	8996419
ce@@	O	-1	8996419
,	O	-1	8996419
and	O	-1	8996419
current	O	-1	8996419
use	O	-1	8996419
of	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
.	O	-1	8996419
We	O	-1	8996419
used	O	-1	8996419
a	O	-1	8996419
multiple	O	-1	8996419
log@@	O	-1	8996419
istic	O	-1	8996419
reg@@	O	-1	8996419
res@@	O	-1	8996419
sion	O	-1	8996419
model	O	-1	8996419
that	O	-1	8996419
included	O	-1	8996419
bo@@	O	-1	8996419
dy@@	O	-1	8996419
-@@	O	-1	8996419
mas@@	O	-1	8996419
s	O	-1	8996419
in@@	O	-1	8996419
de@@	O	-1	8996419
x@@	O	-1	8996419
,	O	-1	8996419
number	O	-1	8996419
of	O	-1	8996419
cy@@	O	-1	8996419
cl@@	O	-1	8996419
es,	O	-1	8996419
change	O	-1	8996419
in	O	-1	8996419
type	O	-1	8996419
of	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C	I-Chemical	-1	8996419
prescri@@	O	-1	8996419
bed	O	-1	8996419
within	O	-1	8996419
3	O	-1	8996419
months	O	-1	8996419
of	O	-1	8996419
the	O	-1	8996419
event@@	O	-1	8996419
,	O	-1	8996419
previ@@	O	-1	8996419
ous	O	-1	8996419
pregn@@	O	-1	8996419
anc@@	O	-1	8996419
y,	O	-1	8996419
and	O	-1	8996419
con@@	O	-1	8996419
current	O	-1	8996419
disease.	O	-1	8996419
F@@	O	-1	8996419
IN@@	O	-1	8996419
D@@	O	-1	8996419
IN@@	O	-1	8996419
G@@	O	-1	8996419
S:	O	-1	8996419
8@@	O	-1	8996419
5	O	-1	8996419
women	O	-1	8996419
me@@	O	-1	8996419
t	O	-1	8996419
the	O	-1	8996419
inc@@	O	-1	8996419
lu@@	O	-1	8996419
sion	O	-1	8996419
c@@	O	-1	8996419
rit@@	O	-1	8996419
er@@	O	-1	8996419
ia	O	-1	8996419
for	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
,	O	-1	8996419
two	O	-1	8996419
of	O	-1	8996419
whom	O	-1	8996419
were	O	-1	8996419
users	O	-1	8996419
of	O	-1	8996419
pro@@	B-Chemical	D011372	8996419
g@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
ag@@	I-Chemical	-1	8996419
en	I-Chemical	-1	8996419
-@@	O	-1	8996419
only	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
.	O	-1	8996419
Of	O	-1	8996419
the	O	-1	8996419
8@@	O	-1	8996419
3	O	-1	8996419
cases	O	-1	8996419
of	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
associated	O	-1	8996419
with	O	-1	8996419
use	O	-1	8996419
of	O	-1	8996419
combined	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
,	O	-1	8996419
4@@	O	-1	8996419
3	O	-1	8996419
were	O	-1	8996419
recor@@	O	-1	8996419
ded	O	-1	8996419
as	O	-1	8996419
de@@	B-Disease	D020246	8996419
ep@@	I-Disease	-1	8996419
-@@	I-Disease	-1	8996419
ve@@	I-Disease	-1	8996419
in	I-Disease	-1	8996419
thrombo@@	I-Disease	-1	8996419
sis	I-Disease	-1	8996419
,	O	-1	8996419
3@@	O	-1	8996419
5	O	-1	8996419
as	O	-1	8996419
pulmonary	O	-1	8996419
thrombo@@	B-Disease	D013927	8996419
sis	I-Disease	-1	8996419
,	O	-1	8996419
and	O	-1	8996419
five	O	-1	8996419
as	O	-1	8996419
venous	B-Disease	D020246	8996419
thrombo@@	I-Disease	-1	8996419
sis	I-Disease	-1	8996419
not	O	-1	8996419
o@@	O	-1	8996419
ther@@	O	-1	8996419
w@@	O	-1	8996419
is@@	O	-1	8996419
e	O	-1	8996419
specif@@	O	-1	8996419
i@@	O	-1	8996419
ed.	O	-1	8996419
The	O	-1	8996419
c@@	O	-1	8996419
r@@	O	-1	8996419
ude	O	-1	8996419
rate	O	-1	8996419
of	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
per	O	-1	8996419
10@@	O	-1	8996419
,@@	O	-1	8996419
0@@	O	-1	8996419
00	O	-1	8996419
wom@@	O	-1	8996419
an@@	O	-1	8996419
-@@	O	-1	8996419
years	O	-1	8996419
was	O	-1	8996419
4.@@	O	-1	8996419
10	O	-1	8996419
in	O	-1	8996419
current	O	-1	8996419
users	O	-1	8996419
of	O	-1	8996419
any	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C	I-Chemical	-1	8996419
,	O	-1	8996419
3.@@	O	-1	8996419
10	O	-1	8996419
in	O	-1	8996419
users	O	-1	8996419
of	O	-1	8996419
secon@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
,	O	-1	8996419
and	O	-1	8996419
4.@@	O	-1	8996419
9@@	O	-1	8996419
6	O	-1	8996419
in	O	-1	8996419
users	O	-1	8996419
of	O	-1	8996419
thir@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
pre@@	O	-1	8996419
par@@	O	-1	8996419
ations.	O	-1	8996419
After	O	-1	8996419
adjust@@	O	-1	8996419
ment	O	-1	8996419
for	O	-1	8996419
age,	O	-1	8996419
the	O	-1	8996419
rate	O	-1	8996419
rati@@	O	-1	8996419
o	O	-1	8996419
of	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
in	O	-1	8996419
users	O	-1	8996419
of	O	-1	8996419
thir@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
rel@@	O	-1	8996419
ative	O	-1	8996419
to	O	-1	8996419
secon@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
was	O	-1	8996419
1.@@	O	-1	8996419
6@@	O	-1	8996419
8	O	-1	8996419
(@@	O	-1	8996419
95%	O	-1	8996419
C@@	O	-1	8996419
I	O	-1	8996419
1.@@	O	-1	8996419
0@@	O	-1	8996419
4-@@	O	-1	8996419
2.@@	O	-1	8996419
7@@	O	-1	8996419
5@@	O	-1	8996419
).	O	-1	8996419
L@@	O	-1	8996419
o@@	O	-1	8996419
g@@	O	-1	8996419
istic	O	-1	8996419
reg@@	O	-1	8996419
res@@	O	-1	8996419
sion	O	-1	8996419
showed	O	-1	8996419
no	O	-1	8996419
significant	O	-1	8996419
difference	O	-1	8996419
in	O	-1	8996419
the	O	-1	8996419
risk	O	-1	8996419
of	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
between	O	-1	8996419
users	O	-1	8996419
of	O	-1	8996419
thir@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
and	O	-1	8996419
secon@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
.	O	-1	8996419
A@@	O	-1	8996419
mon@@	O	-1	8996419
g	O	-1	8996419
users	O	-1	8996419
of	O	-1	8996419
thir@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
pro@@	B-Chemical	D011374	8996419
g@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
ag@@	I-Chemical	-1	8996419
en@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
,	O	-1	8996419
the	O	-1	8996419
risk	O	-1	8996419
of	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
was	O	-1	8996419
higher	O	-1	8996419
in	O	-1	8996419
users	O	-1	8996419
of	O	-1	8996419
des@@	B-Chemical	D017135	8996419
o@@	I-Chemical	-1	8996419
g@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
re@@	I-Chemical	-1	8996419
l	I-Chemical	-1	8996419
with	O	-1	8996419
20	O	-1	8996419
g	O	-1	8996419
eth@@	B-Chemical	D004997	8996419
in@@	I-Chemical	-1	8996419
y@@	I-Chemical	-1	8996419
lo@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
radi@@	I-Chemical	-1	8996419
ol	I-Chemical	-1	8996419
than	O	-1	8996419
in	O	-1	8996419
users	O	-1	8996419
of	O	-1	8996419
g@@	B-Chemical	C033273	8996419
est@@	I-Chemical	-1	8996419
o@@	I-Chemical	-1	8996419
d@@	I-Chemical	-1	8996419
ene	I-Chemical	-1	8996419
or	O	-1	8996419
des@@	B-Chemical	D017135	8996419
o@@	I-Chemical	-1	8996419
g@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
re@@	I-Chemical	-1	8996419
l	I-Chemical	-1	8996419
with	O	-1	8996419
30	O	-1	8996419
g	O	-1	8996419
eth@@	B-Chemical	D004997	8996419
in@@	I-Chemical	-1	8996419
y@@	I-Chemical	-1	8996419
lo@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
radi@@	I-Chemical	-1	8996419
ol	I-Chemical	-1	8996419
.	O	-1	8996419
W@@	O	-1	8996419
it@@	O	-1	8996419
h	O	-1	8996419
all	O	-1	8996419
secon@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
as	O	-1	8996419
the	O	-1	8996419
ref@@	O	-1	8996419
e@@	O	-1	8996419
ren@@	O	-1	8996419
ce@@	O	-1	8996419
,	O	-1	8996419
the	O	-1	8996419
o@@	O	-1	8996419
d@@	O	-1	8996419
ds	O	-1	8996419
rati@@	O	-1	8996419
o@@	O	-1	8996419
s	O	-1	8996419
for	O	-1	8996419
V@@	B-Disease	D054556	8996419
T@@	I-Disease	-1	8996419
E	I-Disease	-1	8996419
were	O	-1	8996419
3.@@	O	-1	8996419
4@@	O	-1	8996419
9	O	-1	8996419
(1@@	O	-1	8996419
.@@	O	-1	8996419
2@@	O	-1	8996419
1@@	O	-1	8996419
-1@@	O	-1	8996419
0.@@	O	-1	8996419
12@@	O	-1	8996419
)	O	-1	8996419
for	O	-1	8996419
des@@	B-Chemical	D017135	8996419
o@@	I-Chemical	-1	8996419
g@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
re@@	I-Chemical	-1	8996419
l	I-Chemical	-1	8996419
plus	O	-1	8996419
20	O	-1	8996419
g	O	-1	8996419
eth@@	B-Chemical	D004997	8996419
in@@	I-Chemical	-1	8996419
y@@	I-Chemical	-1	8996419
lo@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
radi@@	I-Chemical	-1	8996419
ol	I-Chemical	-1	8996419
and	O	-1	8996419
1.@@	O	-1	8996419
1@@	O	-1	8996419
8	O	-1	8996419
(0.@@	O	-1	8996419
6@@	O	-1	8996419
6-@@	O	-1	8996419
2.@@	O	-1	8996419
17@@	O	-1	8996419
)	O	-1	8996419
for	O	-1	8996419
the	O	-1	8996419
other	O	-1	8996419
thir@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
pro@@	B-Chemical	D011374	8996419
g@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
ag@@	I-Chemical	-1	8996419
en@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
.	O	-1	8996419
IN@@	O	-1	8996419
TE@@	O	-1	8996419
R@@	O	-1	8996419
P@@	O	-1	8996419
R@@	O	-1	8996419
ET@@	O	-1	8996419
AT@@	O	-1	8996419
ION@@	O	-1	8996419
:	O	-1	8996419
The	O	-1	8996419
previously	O	-1	8996419
reported	O	-1	8996419
increase	O	-1	8996419
in	O	-1	8996419
o@@	O	-1	8996419
d@@	O	-1	8996419
ds	O	-1	8996419
rati@@	O	-1	8996419
o	O	-1	8996419
associated	O	-1	8996419
with	O	-1	8996419
thir@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
O@@	B-Chemical	D003276	8996419
C@@	I-Chemical	-1	8996419
s	I-Chemical	-1	8996419
when	O	-1	8996419
compared	O	-1	8996419
with	O	-1	8996419
secon@@	O	-1	8996419
d-@@	O	-1	8996419
generation	O	-1	8996419
produc@@	O	-1	8996419
ts	O	-1	8996419
is	O	-1	8996419
likely	O	-1	8996419
to	O	-1	8996419
have	O	-1	8996419
been	O	-1	8996419
the	O	-1	8996419
result	O	-1	8996419
of	O	-1	8996419
re@@	O	-1	8996419
si@@	O	-1	8996419
du@@	O	-1	8996419
al	O	-1	8996419
conf@@	O	-1	8996419
oun@@	O	-1	8996419
ding	O	-1	8996419
by	O	-1	8996419
age.	O	-1	8996419
The	O	-1	8996419
increased	O	-1	8996419
o@@	O	-1	8996419
d@@	O	-1	8996419
ds	O	-1	8996419
rati@@	O	-1	8996419
o	O	-1	8996419
associated	O	-1	8996419
with	O	-1	8996419
produc@@	O	-1	8996419
ts	O	-1	8996419
containing	O	-1	8996419
20	O	-1	8996419
microgram@@	O	-1	8996419
s	O	-1	8996419
eth@@	B-Chemical	D004997	8996419
in@@	I-Chemical	-1	8996419
y@@	I-Chemical	-1	8996419
lo@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
radi@@	I-Chemical	-1	8996419
ol	I-Chemical	-1	8996419
and	O	-1	8996419
des@@	B-Chemical	D017135	8996419
o@@	I-Chemical	-1	8996419
g@@	I-Chemical	-1	8996419
est@@	I-Chemical	-1	8996419
re@@	I-Chemical	-1	8996419
l	I-Chemical	-1	8996419
compared	O	-1	8996419
with	O	-1	8996419
the	O	-1	8996419
30	O	-1	8996419
microgram@@	O	-1	8996419
s	O	-1	8996419
produc@@	O	-1	8996419
t	O	-1	8996419
is	O	-1	8996419
bio@@	O	-1	8996419
log@@	O	-1	8996419
ically	O	-1	8996419
im@@	O	-1	8996419
pl@@	O	-1	8996419
au@@	O	-1	8996419
sib@@	O	-1	8996419
le@@	O	-1	8996419
,	O	-1	8996419
and	O	-1	8996419
is	O	-1	8996419
likely	O	-1	8996419
to	O	-1	8996419
be	O	-1	8996419
the	O	-1	8996419
result	O	-1	8996419
of	O	-1	8996419
pre@@	O	-1	8996419
fe@@	O	-1	8996419
ren@@	O	-1	8996419
tial	O	-1	8996419
prescri@@	O	-1	8996419
b@@	O	-1	8996419
ing	O	-1	8996419
and@@	O	-1	8996419
,	O	-1	8996419
th@@	O	-1	8996419
us,	O	-1	8996419
conf@@	O	-1	8996419
oun@@	O	-1	8996419
d@@	O	-1	8996419
ing.	O	-1	8996419

M@@	B-Chemical	D016291	9061777
K@@	I-Chemical	-1	9061777
-@@	I-Chemical	-1	9061777
80@@	I-Chemical	-1	9061777
1	I-Chemical	-1	9061777
au@@	O	-1	9061777
g@@	O	-1	9061777
ments	O	-1	9061777
pilocar@@	B-Chemical	D010862	9061777
pine	I-Chemical	-1	9061777
-induced	O	-1	9061777
electro@@	O	-1	9061777
graph@@	O	-1	9061777
ic	O	-1	9061777
seizure	B-Disease	D012640	9061777
but	O	-1	9061777
prot@@	O	-1	9061777
ects	O	-1	9061777
against	O	-1	9061777
brain	B-Disease	D001930	9061777
damage	I-Disease	-1	9061777
in	O	-1	9061777
rats.	O	-1	9061777
1@@	O	-1	9061777
.	O	-1	9061777
The	O	-1	9061777
au@@	O	-1	9061777
th@@	O	-1	9061777
ors	O	-1	9061777
examined	O	-1	9061777
the	O	-1	9061777
anti@@	O	-1	9061777
convul@@	O	-1	9061777
s@@	O	-1	9061777
ant	O	-1	9061777
effects	O	-1	9061777
of	O	-1	9061777
M@@	B-Chemical	D016291	9061777
K@@	I-Chemical	-1	9061777
-@@	I-Chemical	-1	9061777
80@@	I-Chemical	-1	9061777
1	I-Chemical	-1	9061777
on	O	-1	9061777
the	O	-1	9061777
pilocar@@	B-Chemical	D010862	9061777
pine	I-Chemical	-1	9061777
-induced	O	-1	9061777
seizure	B-Disease	D012640	9061777
model@@	O	-1	9061777
.	O	-1	9061777
In@@	O	-1	9061777
tra@@	O	-1	9061777
per@@	O	-1	9061777
it@@	O	-1	9061777
one@@	O	-1	9061777
al	O	-1	9061777
injection	O	-1	9061777
of	O	-1	9061777
pilocar@@	B-Chemical	D010862	9061777
pine	I-Chemical	-1	9061777
(4@@	O	-1	9061777
00	O	-1	9061777
mg/kg)	O	-1	9061777
induced	O	-1	9061777
t@@	B-Disease	D012640	9061777
onic	I-Disease	-1	9061777
and	I-Disease	-1	9061777
clon@@	I-Disease	-1	9061777
ic	I-Disease	-1	9061777
seizure	I-Disease	-1	9061777
.	O	-1	9061777
S@@	B-Chemical	D012601	9061777
co@@	I-Chemical	-1	9061777
pol@@	I-Chemical	-1	9061777
amine	I-Chemical	-1	9061777
(10	O	-1	9061777
mg/kg)	O	-1	9061777
and	O	-1	9061777
pent@@	B-Chemical	D010424	9061777
obarbit@@	I-Chemical	-1	9061777
al	I-Chemical	-1	9061777
(@@	O	-1	9061777
5	O	-1	9061777
mg/kg)	O	-1	9061777
prevent@@	O	-1	9061777
ed	O	-1	9061777
development	O	-1	9061777
of	O	-1	9061777
pilocar@@	B-Chemical	D010862	9061777
pine	I-Chemical	-1	9061777
-induced	O	-1	9061777
behavioral	O	-1	9061777
seizure	B-Disease	D012640	9061777
but	O	-1	9061777
M@@	B-Chemical	D016291	9061777
K@@	I-Chemical	-1	9061777
-@@	I-Chemical	-1	9061777
80@@	I-Chemical	-1	9061777
1	I-Chemical	-1	9061777
(0.@@	O	-1	9061777
5	O	-1	9061777
mg/kg)	O	-1	9061777
did	O	-1	9061777
not@@	O	-1	9061777
.	O	-1	9061777
2@@	O	-1	9061777
.	O	-1	9061777
An	O	-1	9061777
elect@@	O	-1	9061777
r@@	O	-1	9061777
ical	O	-1	9061777
seizure	B-Disease	D012640	9061777
measured	O	-1	9061777
with	O	-1	9061777
hippocamp@@	O	-1	9061777
al	O	-1	9061777
E@@	O	-1	9061777
E@@	O	-1	9061777
G	O	-1	9061777
appe@@	O	-1	9061777
a@@	O	-1	9061777
red	O	-1	9061777
in	O	-1	9061777
the	O	-1	9061777
pilocar@@	B-Chemical	D010862	9061777
pine	I-Chemical	-1	9061777
-treated	O	-1	9061777
group.	O	-1	9061777
S@@	B-Chemical	D012601	9061777
co@@	I-Chemical	-1	9061777
pol@@	I-Chemical	-1	9061777
amine	I-Chemical	-1	9061777
and	O	-1	9061777
pent@@	B-Chemical	D010424	9061777
obarbit@@	I-Chemical	-1	9061777
al	I-Chemical	-1	9061777
block@@	O	-1	9061777
ed	O	-1	9061777
the	O	-1	9061777
pilocar@@	B-Chemical	D010862	9061777
pine	I-Chemical	-1	9061777
-induced	O	-1	9061777
electro@@	O	-1	9061777
graph@@	O	-1	9061777
ic	O	-1	9061777
seizure	B-Disease	D012640	9061777
,	O	-1	9061777
M@@	B-Chemical	D016291	9061777
K@@	I-Chemical	-1	9061777
-@@	I-Chemical	-1	9061777
80@@	I-Chemical	-1	9061777
1	I-Chemical	-1	9061777
treatment	O	-1	9061777
au@@	O	-1	9061777
g@@	O	-1	9061777
ment@@	O	-1	9061777
ed	O	-1	9061777
the	O	-1	9061777
electro@@	O	-1	9061777
graph@@	O	-1	9061777
ic	O	-1	9061777
seizure	B-Disease	D012640	9061777
induced	O	-1	9061777
by	O	-1	9061777
pilocar@@	B-Chemical	D010862	9061777
pine	I-Chemical	-1	9061777
.	O	-1	9061777
3@@	O	-1	9061777
.	O	-1	9061777
B@@	B-Disease	D001930	9061777
ra@@	I-Disease	-1	9061777
in	I-Disease	-1	9061777
damage	I-Disease	-1	9061777
was	O	-1	9061777
assessed	O	-1	9061777
by	O	-1	9061777
examin@@	O	-1	9061777
ing	O	-1	9061777
the	O	-1	9061777
hippocamp@@	O	-1	9061777
us	O	-1	9061777
micro@@	O	-1	9061777
sco@@	O	-1	9061777
p@@	O	-1	9061777
ic@@	O	-1	9061777
all@@	O	-1	9061777
y.	O	-1	9061777
P@@	B-Chemical	D010862	9061777
i@@	I-Chemical	-1	9061777
lo@@	I-Chemical	-1	9061777
car@@	I-Chemical	-1	9061777
pine	I-Chemical	-1	9061777
produced	O	-1	9061777
neuron@@	B-Disease	D009410	9061777
al	I-Disease	-1	9061777
death	I-Disease	-1	9061777
in	O	-1	9061777
the	O	-1	9061777
hippocamp@@	O	-1	9061777
us,	O	-1	9061777
which	O	-1	9061777
showed	O	-1	9061777
py@@	O	-1	9061777
k@@	O	-1	9061777
no@@	O	-1	9061777
tic	O	-1	9061777
chang@@	O	-1	9061777
es.	O	-1	9061777
P@@	B-Chemical	D010424	9061777
ent@@	I-Chemical	-1	9061777
obarbit@@	I-Chemical	-1	9061777
al	I-Chemical	-1	9061777
,	O	-1	9061777
scopol@@	B-Chemical	D012601	9061777
amine	I-Chemical	-1	9061777
and	O	-1	9061777
M@@	B-Chemical	D016291	9061777
K@@	I-Chemical	-1	9061777
-@@	I-Chemical	-1	9061777
80@@	I-Chemical	-1	9061777
1	I-Chemical	-1	9061777
prot@@	O	-1	9061777
ected	O	-1	9061777
the	O	-1	9061777
brain	B-Disease	D001930	9061777
damage	I-Disease	-1	9061777
by	O	-1	9061777
pilocar@@	B-Chemical	D010862	9061777
pine	I-Chemical	-1	9061777
,	O	-1	9061777
though	O	-1	9061777
in	O	-1	9061777
the	O	-1	9061777
M@@	B-Chemical	D016291	9061777
K@@	I-Chemical	-1	9061777
-@@	I-Chemical	-1	9061777
80@@	I-Chemical	-1	9061777
1	I-Chemical	-1	9061777
-treated	O	-1	9061777
group@@	O	-1	9061777
,	O	-1	9061777
the	O	-1	9061777
py@@	O	-1	9061777
ram@@	O	-1	9061777
idal	O	-1	9061777
cells	O	-1	9061777
of	O	-1	9061777
hippocamp@@	O	-1	9061777
us	O	-1	9061777
appe@@	O	-1	9061777
a@@	O	-1	9061777
red	O	-1	9061777
d@@	O	-1	9061777
ark@@	O	-1	9061777
er	O	-1	9061777
than	O	-1	9061777
normal@@	O	-1	9061777
.	O	-1	9061777
In	O	-1	9061777
all	O	-1	9061777
treatment@@	O	-1	9061777
s,	O	-1	9061777
gran@@	O	-1	9061777
ul@@	O	-1	9061777
e	O	-1	9061777
cells	O	-1	9061777
of	O	-1	9061777
the	O	-1	9061777
d@@	O	-1	9061777
ent@@	O	-1	9061777
ate	O	-1	9061777
g@@	O	-1	9061777
y@@	O	-1	9061777
ru@@	O	-1	9061777
s	O	-1	9061777
were	O	-1	9061777
not	O	-1	9061777
aff@@	O	-1	9061777
ect@@	O	-1	9061777
ed.	O	-1	9061777
4@@	O	-1	9061777
.	O	-1	9061777
These	O	-1	9061777
results	O	-1	9061777
indicate	O	-1	9061777
that	O	-1	9061777
status	B-Disease	D013226	9061777
epilep@@	I-Disease	-1	9061777
tic@@	I-Disease	-1	9061777
us	I-Disease	-1	9061777
induced	O	-1	9061777
by	O	-1	9061777
pilocar@@	B-Chemical	D010862	9061777
pine	I-Chemical	-1	9061777
is	O	-1	9061777
initi@@	O	-1	9061777
ated	O	-1	9061777
by	O	-1	9061777
cholinergic	O	-1	9061777
over@@	O	-1	9061777
stimulation	O	-1	9061777
and	O	-1	9061777
prop@@	O	-1	9061777
ag@@	O	-1	9061777
ated	O	-1	9061777
by	O	-1	9061777
glutam@@	O	-1	9061777
at@@	O	-1	9061777
ergic	O	-1	9061777
trans@@	O	-1	9061777
mis@@	O	-1	9061777
sion,	O	-1	9061777
the	O	-1	9061777
elev@@	O	-1	9061777
ation	O	-1	9061777
of	O	-1	9061777
which	O	-1	9061777
may	O	-1	9061777
cause	O	-1	9061777
brain	B-Disease	D001930	9061777
damage	I-Disease	-1	9061777
through	O	-1	9061777
an	O	-1	9061777
ex@@	O	-1	9061777
cit@@	O	-1	9061777
atory	O	-1	9061777
N@@	B-Chemical	D016202	9061777
MD@@	I-Chemical	-1	9061777
A	I-Chemical	-1	9061777
receptor@@	O	-1	9061777
-@@	O	-1	9061777
mediated	O	-1	9061777
mechanis@@	O	-1	9061777
m.	O	-1	9061777

P@@	B-Chemical	D017239	9071336
ac@@	I-Chemical	-1	9071336
litax@@	I-Chemical	-1	9071336
el	I-Chemical	-1	9071336
,	O	-1	9071336
5-@@	B-Chemical	D005472	9071336
fluoro@@	I-Chemical	-1	9071336
urac@@	I-Chemical	-1	9071336
il	I-Chemical	-1	9071336
,	O	-1	9071336
and	O	-1	9071336
fol@@	B-Chemical	D002955	9071336
inic	I-Chemical	-1	9071336
acid	I-Chemical	-1	9071336
in	O	-1	9071336
met@@	O	-1	9071336
ast@@	O	-1	9071336
atic	O	-1	9071336
b@@	B-Disease	D001943	9071336
reas@@	I-Disease	-1	9071336
t	I-Disease	-1	9071336
cancer	I-Disease	-1	9071336
:	O	-1	9071336
B@@	O	-1	9071336
R@@	O	-1	9071336
E@@	O	-1	9071336
-@@	O	-1	9071336
2@@	O	-1	9071336
6,	O	-1	9071336
a	O	-1	9071336
phase	O	-1	9071336
II	O	-1	9071336
tri@@	O	-1	9071336
al.	O	-1	9071336
5-@@	B-Chemical	D005472	9071336
F@@	I-Chemical	-1	9071336
lu@@	I-Chemical	-1	9071336
o@@	I-Chemical	-1	9071336
ro@@	I-Chemical	-1	9071336
urac@@	I-Chemical	-1	9071336
il	I-Chemical	-1	9071336
plus	O	-1	9071336
fol@@	B-Chemical	D002955	9071336
inic	I-Chemical	-1	9071336
acid	I-Chemical	-1	9071336
and	O	-1	9071336
paclitax@@	B-Chemical	D017239	9071336
el	I-Chemical	-1	9071336
(	O	-1	9071336
T@@	B-Chemical	D017239	9071336
ax@@	I-Chemical	-1	9071336
ol	I-Chemical	-1	9071336
;	O	-1	9071336
B@@	O	-1	9071336
ri@@	O	-1	9071336
st@@	O	-1	9071336
ol@@	O	-1	9071336
-@@	O	-1	9071336
M@@	O	-1	9071336
y@@	O	-1	9071336
ers	O	-1	9071336
S@@	O	-1	9071336
qu@@	O	-1	9071336
i@@	O	-1	9071336
b@@	O	-1	9071336
b	O	-1	9071336
Com@@	O	-1	9071336
p@@	O	-1	9071336
an@@	O	-1	9071336
y,	O	-1	9071336
P@@	O	-1	9071336
r@@	O	-1	9071336
in@@	O	-1	9071336
ce@@	O	-1	9071336
t@@	O	-1	9071336
on@@	O	-1	9071336
,	O	-1	9071336
N@@	O	-1	9071336
J@@	O	-1	9071336
)	O	-1	9071336
are	O	-1	9071336
effective	O	-1	9071336
sal@@	O	-1	9071336
v@@	O	-1	9071336
age	O	-1	9071336
therap@@	O	-1	9071336
i@@	O	-1	9071336
es	O	-1	9071336
for	O	-1	9071336
met@@	O	-1	9071336
ast@@	O	-1	9071336
atic	O	-1	9071336
b@@	B-Disease	D001943	9071336
reas@@	I-Disease	-1	9071336
t	I-Disease	-1	9071336
cancer	I-Disease	-1	9071336
patients.	O	-1	9071336
P@@	B-Chemical	D017239	9071336
ac@@	I-Chemical	-1	9071336
litax@@	I-Chemical	-1	9071336
el	I-Chemical	-1	9071336
and	O	-1	9071336
5-@@	B-Chemical	D005472	9071336
fluoro@@	I-Chemical	-1	9071336
urac@@	I-Chemical	-1	9071336
il	I-Chemical	-1	9071336
have	O	-1	9071336
addi@@	O	-1	9071336
tive	O	-1	9071336
cy@@	B-Disease	D064420	9071336
tot@@	I-Disease	-1	9071336
oxic@@	I-Disease	-1	9071336
ity	I-Disease	-1	9071336
in	O	-1	9071336
M@@	O	-1	9071336
C@@	O	-1	9071336
F@@	O	-1	9071336
-@@	O	-1	9071336
7	O	-1	9071336
cell	O	-1	9071336
lin@@	O	-1	9071336
es.	O	-1	9071336
We	O	-1	9071336
performed	O	-1	9071336
a	O	-1	9071336
phase	O	-1	9071336
II	O	-1	9071336
trial	O	-1	9071336
of	O	-1	9071336
paclitax@@	B-Chemical	D017239	9071336
el	I-Chemical	-1	9071336
17@@	O	-1	9071336
5	O	-1	9071336
mg/m@@	O	-1	9071336
2	O	-1	9071336
over	O	-1	9071336
3	O	-1	9071336
hours	O	-1	9071336
on	O	-1	9071336
day	O	-1	9071336
I	O	-1	9071336
followed	O	-1	9071336
by	O	-1	9071336
fol@@	B-Chemical	D002955	9071336
inic	I-Chemical	-1	9071336
acid	I-Chemical	-1	9071336
3@@	O	-1	9071336
00	O	-1	9071336
mg	O	-1	9071336
over	O	-1	9071336
1	O	-1	9071336
h@@	O	-1	9071336
our	O	-1	9071336
before	O	-1	9071336
5-@@	B-Chemical	D005472	9071336
fluoro@@	I-Chemical	-1	9071336
urac@@	I-Chemical	-1	9071336
il	I-Chemical	-1	9071336
3@@	O	-1	9071336
50	O	-1	9071336
mg/m@@	O	-1	9071336
2	O	-1	9071336
on	O	-1	9071336
days	O	-1	9071336
1	O	-1	9071336
to	O	-1	9071336
3	O	-1	9071336
every	O	-1	9071336
2@@	O	-1	9071336
8	O	-1	9071336
days	O	-1	9071336
(T@@	O	-1	9071336
F@@	O	-1	9071336
L@@	O	-1	9071336
)	O	-1	9071336
in	O	-1	9071336
women	O	-1	9071336
with	O	-1	9071336
met@@	O	-1	9071336
ast@@	O	-1	9071336
atic	O	-1	9071336
b@@	B-Disease	D001943	9071336
reas@@	I-Disease	-1	9071336
t	I-Disease	-1	9071336
cancer	I-Disease	-1	9071336
.	O	-1	9071336
An@@	O	-1	9071336
aly@@	O	-1	9071336
sis	O	-1	9071336
is	O	-1	9071336
reported	O	-1	9071336
on	O	-1	9071336
3@@	O	-1	9071336
7	O	-1	9071336
patients	O	-1	9071336
with	O	-1	9071336
a	O	-1	9071336
minim@@	O	-1	9071336
um	O	-1	9071336
of	O	-1	9071336
6	O	-1	9071336
months	O	-1	9071336
follow-up	O	-1	9071336
who	O	-1	9071336
received	O	-1	9071336
a	O	-1	9071336
total	O	-1	9071336
of	O	-1	9071336
19@@	O	-1	9071336
2	O	-1	9071336
cyc@@	O	-1	9071336
le@@	O	-1	9071336
s	O	-1	9071336
of	O	-1	9071336
T@@	O	-1	9071336
F@@	O	-1	9071336
L@@	O	-1	9071336
:	O	-1	9071336
n@@	O	-1	9071336
ine	O	-1	9071336
cyc@@	O	-1	9071336
le@@	O	-1	9071336
s	O	-1	9071336
(5@@	O	-1	9071336
%)	O	-1	9071336
were	O	-1	9071336
associated	O	-1	9071336
with	O	-1	9071336
gra@@	O	-1	9071336
de	O	-1	9071336
3@@	O	-1	9071336
/@@	O	-1	9071336
4	O	-1	9071336
ne@@	B-Disease	D009503	9071336
ut@@	I-Disease	-1	9071336
ro@@	I-Disease	-1	9071336
pen@@	I-Disease	-1	9071336
ia	I-Disease	-1	9071336
requ@@	O	-1	9071336
ir@@	O	-1	9071336
ing	O	-1	9071336
hospit@@	O	-1	9071336
al@@	O	-1	9071336
iz@@	O	-1	9071336
ation@@	O	-1	9071336
;	O	-1	9071336
seven	O	-1	9071336
(4@@	O	-1	9071336
%)	O	-1	9071336
cyc@@	O	-1	9071336
le@@	O	-1	9071336
s	O	-1	9071336
in	O	-1	9071336
two	O	-1	9071336
patients	O	-1	9071336
requ@@	O	-1	9071336
ired	O	-1	9071336
gran@@	B-Chemical	D016179	9071336
ulo@@	I-Chemical	-1	9071336
cy@@	I-Chemical	-1	9071336
te	I-Chemical	-1	9071336
co@@	I-Chemical	-1	9071336
lon@@	I-Chemical	-1	9071336
y-@@	I-Chemical	-1	9071336
stimul@@	I-Chemical	-1	9071336
ating	I-Chemical	-1	9071336
factor	I-Chemical	-1	9071336
due	O	-1	9071336
to	O	-1	9071336
ne@@	B-Disease	D009503	9071336
ut@@	I-Disease	-1	9071336
ro@@	I-Disease	-1	9071336
pen@@	I-Disease	-1	9071336
ia	I-Disease	-1	9071336
;	O	-1	9071336
no	O	-1	9071336
patient	O	-1	9071336
requ@@	O	-1	9071336
ired	O	-1	9071336
platele@@	O	-1	9071336
t	O	-1	9071336
trans@@	O	-1	9071336
fu@@	O	-1	9071336
sion@@	O	-1	9071336
s.	O	-1	9071336
G@@	O	-1	9071336
ra@@	O	-1	9071336
de	O	-1	9071336
3@@	O	-1	9071336
/@@	O	-1	9071336
4	O	-1	9071336
non@@	O	-1	9071336
hemat@@	O	-1	9071336
ologic	O	-1	9071336
toxic@@	B-Disease	D064420	9071336
ities	I-Disease	-1	9071336
were	O	-1	9071336
un@@	O	-1	9071336
common@@	O	-1	9071336
.	O	-1	9071336
A@@	O	-1	9071336
mon@@	O	-1	9071336
g	O	-1	9071336
the	O	-1	9071336
3@@	O	-1	9071336
4	O	-1	9071336
patients	O	-1	9071336
evalu@@	O	-1	9071336
able	O	-1	9071336
for	O	-1	9071336
respon@@	O	-1	9071336
se@@	O	-1	9071336
,	O	-1	9071336
there	O	-1	9071336
were	O	-1	9071336
three	O	-1	9071336
complete	O	-1	9071336
responses	O	-1	9071336
(@@	O	-1	9071336
9@@	O	-1	9071336
%)	O	-1	9071336
and	O	-1	9071336
1@@	O	-1	9071336
8	O	-1	9071336
partial	O	-1	9071336
responses	O	-1	9071336
(5@@	O	-1	9071336
3@@	O	-1	9071336
%)	O	-1	9071336
for	O	-1	9071336
an	O	-1	9071336
over@@	O	-1	9071336
all	O	-1	9071336
response	O	-1	9071336
rate	O	-1	9071336
of	O	-1	9071336
6@@	O	-1	9071336
2@@	O	-1	9071336
%.	O	-1	9071336
Of	O	-1	9071336
the	O	-1	9071336
1@@	O	-1	9071336
9	O	-1	9071336
evalu@@	O	-1	9071336
able	O	-1	9071336
patients	O	-1	9071336
with	O	-1	9071336
prior	O	-1	9071336
dox@@	B-Chemical	D004317	9071336
orub@@	I-Chemical	-1	9071336
icin	I-Chemical	-1	9071336
expos@@	O	-1	9071336
ure,	O	-1	9071336
11	O	-1	9071336
(5@@	O	-1	9071336
8@@	O	-1	9071336
%)	O	-1	9071336
respon@@	O	-1	9071336
ded	O	-1	9071336
compared	O	-1	9071336
with	O	-1	9071336
n@@	O	-1	9071336
ine	O	-1	9071336
of	O	-1	9071336
15	O	-1	9071336
(6@@	O	-1	9071336
0@@	O	-1	9071336
%)	O	-1	9071336
without	O	-1	9071336
prior	O	-1	9071336
dox@@	B-Chemical	D004317	9071336
orub@@	I-Chemical	-1	9071336
icin	I-Chemical	-1	9071336
.	O	-1	9071336
P@@	O	-1	9071336
las@@	O	-1	9071336
ma	O	-1	9071336
paclitax@@	B-Chemical	D017239	9071336
el	I-Chemical	-1	9071336
concentrations	O	-1	9071336
were	O	-1	9071336
measured	O	-1	9071336
at	O	-1	9071336
the	O	-1	9071336
comple@@	O	-1	9071336
tion	O	-1	9071336
of	O	-1	9071336
paclitax@@	B-Chemical	D017239	9071336
el	I-Chemical	-1	9071336
infusion	O	-1	9071336
and	O	-1	9071336
at	O	-1	9071336
24	O	-1	9071336
hours	O	-1	9071336
in	O	-1	9071336
1@@	O	-1	9071336
9	O	-1	9071336
patients.	O	-1	9071336
T@@	O	-1	9071336
F@@	O	-1	9071336
L	O	-1	9071336
is	O	-1	9071336
an	O	-1	9071336
ac@@	O	-1	9071336
ti@@	O	-1	9071336
ve,	O	-1	9071336
we@@	O	-1	9071336
ll@@	O	-1	9071336
-@@	O	-1	9071336
toler@@	O	-1	9071336
ated	O	-1	9071336
regi@@	O	-1	9071336
men	O	-1	9071336
in	O	-1	9071336
met@@	O	-1	9071336
ast@@	O	-1	9071336
atic	O	-1	9071336
b@@	B-Disease	D001943	9071336
reas@@	I-Disease	-1	9071336
t	I-Disease	-1	9071336
cancer	I-Disease	-1	9071336
.	O	-1	9071336

Eff@@	O	-1	9125676
icac@@	O	-1	9125676
y	O	-1	9125676
and	O	-1	9125676
pro@@	B-Disease	-1	9125676
arrhyth@@	I-Disease	-1	9125676
mia	I-Disease	-1	9125676
with	O	-1	9125676
the	O	-1	9125676
use	O	-1	9125676
of	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
for	O	-1	9125676
su@@	O	-1	9125676
st@@	O	-1	9125676
ained	O	-1	9125676
ventricular	B-Disease	D017180	9125676
tachy@@	I-Disease	-1	9125676
arrhyth@@	I-Disease	-1	9125676
mi@@	I-Disease	-1	9125676
as	I-Disease	-1	9125676
.	O	-1	9125676
This	O	-1	9125676
study	O	-1	9125676
pro@@	O	-1	9125676
sp@@	O	-1	9125676
ectively	O	-1	9125676
evaluated	O	-1	9125676
the	O	-1	9125676
clinical	O	-1	9125676
efficac@@	O	-1	9125676
y,	O	-1	9125676
the	O	-1	9125676
incidence	O	-1	9125676
of	O	-1	9125676
t@@	B-Disease	D016171	9125676
or@@	I-Disease	-1	9125676
sa@@	I-Disease	-1	9125676
des	I-Disease	-1	9125676
de	I-Disease	-1	9125676
po@@	I-Disease	-1	9125676
int@@	I-Disease	-1	9125676
es	I-Disease	-1	9125676
,	O	-1	9125676
and	O	-1	9125676
the	O	-1	9125676
pres@@	O	-1	9125676
um@@	O	-1	9125676
able	O	-1	9125676
risk	O	-1	9125676
factors	O	-1	9125676
for	O	-1	9125676
t@@	B-Disease	D016171	9125676
or@@	I-Disease	-1	9125676
sa@@	I-Disease	-1	9125676
des	I-Disease	-1	9125676
de	I-Disease	-1	9125676
po@@	I-Disease	-1	9125676
int@@	I-Disease	-1	9125676
es	I-Disease	-1	9125676
in	O	-1	9125676
patients	O	-1	9125676
treated	O	-1	9125676
with	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
for	O	-1	9125676
su@@	O	-1	9125676
st@@	O	-1	9125676
ained	O	-1	9125676
ventricular	B-Disease	D017180	9125676
tachy@@	I-Disease	-1	9125676
arrhyth@@	I-Disease	-1	9125676
mi@@	I-Disease	-1	9125676
as	I-Disease	-1	9125676
.	O	-1	9125676
E@@	O	-1	9125676
igh@@	O	-1	9125676
ty-@@	O	-1	9125676
one	O	-1	9125676
con@@	O	-1	9125676
sec@@	O	-1	9125676
utive	O	-1	9125676
patients	O	-1	9125676
(5@@	O	-1	9125676
4	O	-1	9125676
with	O	-1	9125676
coronary	B-Disease	D003324	9125676
artery	I-Disease	-1	9125676
disease	I-Disease	-1	9125676
,	O	-1	9125676
and	O	-1	9125676
20	O	-1	9125676
with	O	-1	9125676
di@@	B-Disease	D002311	9125676
l@@	I-Disease	-1	9125676
ated	I-Disease	-1	9125676
cardi@@	I-Disease	-1	9125676
om@@	I-Disease	-1	9125676
yo@@	I-Disease	-1	9125676
pathy	I-Disease	-1	9125676
)	O	-1	9125676
with	O	-1	9125676
induc@@	O	-1	9125676
i@@	O	-1	9125676
ble	O	-1	9125676
su@@	O	-1	9125676
st@@	O	-1	9125676
ained	O	-1	9125676
ventricular	B-Disease	D017180	9125676
tachycardia	I-Disease	-1	9125676
or	O	-1	9125676
ventricular	B-Disease	D014693	9125676
fibrill@@	I-Disease	-1	9125676
ation	I-Disease	-1	9125676
received	O	-1	9125676
oral	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
to	O	-1	9125676
prev@@	O	-1	9125676
ent	O	-1	9125676
induction	O	-1	9125676
of	O	-1	9125676
the	O	-1	9125676
ventricular	B-Disease	D017180	9125676
tachy@@	I-Disease	-1	9125676
arrhyth@@	I-Disease	-1	9125676
mia	I-Disease	-1	9125676
.	O	-1	9125676
D@@	O	-1	9125676
uring	O	-1	9125676
oral	O	-1	9125676
lo@@	O	-1	9125676
ad@@	O	-1	9125676
ing	O	-1	9125676
with	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
,	O	-1	9125676
continu@@	O	-1	9125676
ous	O	-1	9125676
electro@@	O	-1	9125676
cardio@@	O	-1	9125676
graph@@	O	-1	9125676
ic	O	-1	9125676
(@@	O	-1	9125676
EC@@	O	-1	9125676
G@@	O	-1	9125676
)	O	-1	9125676
monit@@	O	-1	9125676
or@@	O	-1	9125676
ing	O	-1	9125676
was	O	-1	9125676
per@@	O	-1	9125676
for@@	O	-1	9125676
me@@	O	-1	9125676
d.	O	-1	9125676
Th@@	O	-1	9125676
ose	O	-1	9125676
patients	O	-1	9125676
in	O	-1	9125676
whom	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
prevent@@	O	-1	9125676
ed	O	-1	9125676
induction	O	-1	9125676
of	O	-1	9125676
ventricular	B-Disease	D017180	9125676
tachycardia	I-Disease	-1	9125676
or	O	-1	9125676
ventricular	B-Disease	D014693	9125676
fibrill@@	I-Disease	-1	9125676
ation	I-Disease	-1	9125676
were	O	-1	9125676
dis@@	O	-1	9125676
ch@@	O	-1	9125676
arg@@	O	-1	9125676
ed	O	-1	9125676
with	O	-1	9125676
the	O	-1	9125676
drug	O	-1	9125676
and	O	-1	9125676
followed	O	-1	9125676
up	O	-1	9125676
on	O	-1	9125676
an	O	-1	9125676
out@@	O	-1	9125676
patient	O	-1	9125676
b@@	O	-1	9125676
asis	O	-1	9125676
for	O	-1	9125676
21	O	-1	9125676
+/-	O	-1	9125676
1@@	O	-1	9125676
8	O	-1	9125676
months.	O	-1	9125676
In@@	O	-1	9125676
duction	O	-1	9125676
of	O	-1	9125676
the	O	-1	9125676
ventricular	B-Disease	D017180	9125676
tachy@@	I-Disease	-1	9125676
arrhyth@@	I-Disease	-1	9125676
mia	I-Disease	-1	9125676
was	O	-1	9125676
prevent@@	O	-1	9125676
ed	O	-1	9125676
by	O	-1	9125676
oral	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
in	O	-1	9125676
3@@	O	-1	9125676
5	O	-1	9125676
(4@@	O	-1	9125676
3@@	O	-1	9125676
%)	O	-1	9125676
patient@@	O	-1	9125676
s;	O	-1	9125676
the	O	-1	9125676
ventricular	B-Disease	D017180	9125676
tachy@@	I-Disease	-1	9125676
arrhyth@@	I-Disease	-1	9125676
mia	I-Disease	-1	9125676
remained	O	-1	9125676
induc@@	O	-1	9125676
i@@	O	-1	9125676
ble	O	-1	9125676
in	O	-1	9125676
40	O	-1	9125676
(4@@	O	-1	9125676
9@@	O	-1	9125676
%)	O	-1	9125676
patient@@	O	-1	9125676
s;	O	-1	9125676
and	O	-1	9125676
two	O	-1	9125676
(2@@	O	-1	9125676
.@@	O	-1	9125676
5@@	O	-1	9125676
%)	O	-1	9125676
patients	O	-1	9125676
did	O	-1	9125676
not	O	-1	9125676
toler@@	O	-1	9125676
ate	O	-1	9125676
even	O	-1	9125676
40	O	-1	9125676
mg	O	-1	9125676
of	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
on@@	O	-1	9125676
ce	O	-1	9125676
da@@	O	-1	9125676
il@@	O	-1	9125676
y.	O	-1	9125676
F@@	O	-1	9125676
our	O	-1	9125676
(5@@	O	-1	9125676
%)	O	-1	9125676
patients	O	-1	9125676
had	O	-1	9125676
from	O	-1	9125676
t@@	B-Disease	D016171	9125676
or@@	I-Disease	-1	9125676
sa@@	I-Disease	-1	9125676
des	I-Disease	-1	9125676
de	I-Disease	-1	9125676
po@@	I-Disease	-1	9125676
int@@	I-Disease	-1	9125676
es	I-Disease	-1	9125676
during	O	-1	9125676
the	O	-1	9125676
initial	O	-1	9125676
oral	O	-1	9125676
treatment	O	-1	9125676
with	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
.	O	-1	9125676
N@@	O	-1	9125676
either	O	-1	9125676
EC@@	O	-1	9125676
G	O	-1	9125676
[@@	O	-1	9125676
s@@	O	-1	9125676
in@@	O	-1	9125676
us@@	O	-1	9125676
-@@	O	-1	9125676
cyc@@	O	-1	9125676
le	O	-1	9125676
l@@	O	-1	9125676
en@@	O	-1	9125676
g@@	O	-1	9125676
th	O	-1	9125676
(S@@	O	-1	9125676
CL@@	O	-1	9125676
),	O	-1	9125676
Q@@	O	-1	9125676
T	O	-1	9125676
or	O	-1	9125676
Q@@	O	-1	9125676
T@@	O	-1	9125676
c	O	-1	9125676
inter@@	O	-1	9125676
val@@	O	-1	9125676
,	O	-1	9125676
or	O	-1	9125676
U	O	-1	9125676
w@@	O	-1	9125676
a@@	O	-1	9125676
ve@@	O	-1	9125676
]	O	-1	9125676
n@@	O	-1	9125676
or	O	-1	9125676
clinical	O	-1	9125676
par@@	O	-1	9125676
ame@@	O	-1	9125676
ters	O	-1	9125676
identi@@	O	-1	9125676
fied	O	-1	9125676
patients	O	-1	9125676
at	O	-1	9125676
risk	O	-1	9125676
for	O	-1	9125676
t@@	B-Disease	D016171	9125676
or@@	I-Disease	-1	9125676
sa@@	I-Disease	-1	9125676
des	I-Disease	-1	9125676
de	I-Disease	-1	9125676
po@@	I-Disease	-1	9125676
int@@	I-Disease	-1	9125676
es	I-Disease	-1	9125676
.	O	-1	9125676
However,	O	-1	9125676
the	O	-1	9125676
oral	O	-1	9125676
dose	O	-1	9125676
of	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
was	O	-1	9125676
significantly	O	-1	9125676
lower	O	-1	9125676
in	O	-1	9125676
patients	O	-1	9125676
with	O	-1	9125676
t@@	B-Disease	D016171	9125676
or@@	I-Disease	-1	9125676
sa@@	I-Disease	-1	9125676
des	I-Disease	-1	9125676
de	I-Disease	-1	9125676
po@@	I-Disease	-1	9125676
int@@	I-Disease	-1	9125676
es	I-Disease	-1	9125676
(2@@	O	-1	9125676
00	O	-1	9125676
+/-	O	-1	9125676
4@@	O	-1	9125676
6	O	-1	9125676
vs.	O	-1	9125676
3@@	O	-1	9125676
2@@	O	-1	9125676
8	O	-1	9125676
+/-	O	-1	9125676
5@@	O	-1	9125676
3	O	-1	9125676
mg/@@	O	-1	9125676
day@@	O	-1	9125676
;	O	-1	9125676
p	O	-1	9125676
=	O	-1	9125676
0.00@@	O	-1	9125676
17@@	O	-1	9125676
).	O	-1	9125676
R@@	O	-1	9125676
is@@	O	-1	9125676
k	O	-1	9125676
factors	O	-1	9125676
associated	O	-1	9125676
with	O	-1	9125676
the	O	-1	9125676
development	O	-1	9125676
of	O	-1	9125676
t@@	B-Disease	D016171	9125676
or@@	I-Disease	-1	9125676
sa@@	I-Disease	-1	9125676
des	I-Disease	-1	9125676
de	I-Disease	-1	9125676
po@@	I-Disease	-1	9125676
int@@	I-Disease	-1	9125676
es	I-Disease	-1	9125676
were	O	-1	9125676
the	O	-1	9125676
appear@@	O	-1	9125676
ance	O	-1	9125676
of	O	-1	9125676
an	O	-1	9125676
U	O	-1	9125676
w@@	O	-1	9125676
a@@	O	-1	9125676
ve	O	-1	9125676
(p	O	-1	9125676
=	O	-1	9125676
0.0@@	O	-1	9125676
4@@	O	-1	9125676
9@@	O	-1	9125676
),	O	-1	9125676
female	O	-1	9125676
gen@@	O	-1	9125676
der	O	-1	9125676
(p	O	-1	9125676
=	O	-1	9125676
0.0@@	O	-1	9125676
1@@	O	-1	9125676
5@@	O	-1	9125676
),	O	-1	9125676
and	O	-1	9125676
significant	O	-1	9125676
dose-@@	O	-1	9125676
cor@@	O	-1	9125676
rec@@	O	-1	9125676
ted	O	-1	9125676
changes	O	-1	9125676
of	O	-1	9125676
S@@	O	-1	9125676
CL@@	O	-1	9125676
,	O	-1	9125676
Q@@	O	-1	9125676
T	O	-1	9125676
inter@@	O	-1	9125676
val@@	O	-1	9125676
,	O	-1	9125676
and	O	-1	9125676
Q@@	O	-1	9125676
T@@	O	-1	9125676
c	O	-1	9125676
interv@@	O	-1	9125676
al	O	-1	9125676
(p	O	-1	9125676
<	O	-1	9125676
0.05@@	O	-1	9125676
).	O	-1	9125676
D@@	O	-1	9125676
uring	O	-1	9125676
follow-@@	O	-1	9125676
up@@	O	-1	9125676
,	O	-1	9125676
seven	O	-1	9125676
(2@@	O	-1	9125676
0@@	O	-1	9125676
%)	O	-1	9125676
patients	O	-1	9125676
had	O	-1	9125676
a	O	-1	9125676
non@@	O	-1	9125676
f@@	O	-1	9125676
atal	O	-1	9125676
ventricular	B-Disease	D017180	9125676
tachycardia	I-Disease	-1	9125676
recur@@	O	-1	9125676
ren@@	O	-1	9125676
ce@@	O	-1	9125676
,	O	-1	9125676
and	O	-1	9125676
two	O	-1	9125676
(6@@	O	-1	9125676
%)	O	-1	9125676
patients	O	-1	9125676
di@@	O	-1	9125676
ed	O	-1	9125676
su@@	O	-1	9125676
d@@	O	-1	9125676
d@@	O	-1	9125676
en@@	O	-1	9125676
ly.	O	-1	9125676
One	O	-1	9125676
female	O	-1	9125676
patient	O	-1	9125676
with	O	-1	9125676
st@@	O	-1	9125676
able	O	-1	9125676
cardiac	B-Disease	D006331	9125676
disease	I-Disease	-1	9125676
had	O	-1	9125676
recur@@	O	-1	9125676
rent	O	-1	9125676
t@@	B-Disease	D016171	9125676
or@@	I-Disease	-1	9125676
sa@@	I-Disease	-1	9125676
des	I-Disease	-1	9125676
de	I-Disease	-1	9125676
po@@	I-Disease	-1	9125676
int@@	I-Disease	-1	9125676
es	I-Disease	-1	9125676
after	O	-1	9125676
2	O	-1	9125676
years	O	-1	9125676
of	O	-1	9125676
suc@@	O	-1	9125676
cess@@	O	-1	9125676
ful	O	-1	9125676
treatment	O	-1	9125676
with	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
.	O	-1	9125676
T@@	B-Disease	D016171	9125676
or@@	I-Disease	-1	9125676
sa@@	I-Disease	-1	9125676
des	I-Disease	-1	9125676
de	I-Disease	-1	9125676
po@@	I-Disease	-1	9125676
int@@	I-Disease	-1	9125676
es	I-Disease	-1	9125676
occurred	O	-1	9125676
early	O	-1	9125676
during	O	-1	9125676
treatment	O	-1	9125676
even	O	-1	9125676
with	O	-1	9125676
low	O	-1	9125676
doses	O	-1	9125676
of	O	-1	9125676
oral	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
.	O	-1	9125676
P@@	O	-1	9125676
ron@@	O	-1	9125676
oun@@	O	-1	9125676
c@@	O	-1	9125676
ed	O	-1	9125676
changes	O	-1	9125676
in	O	-1	9125676
the	O	-1	9125676
sur@@	O	-1	9125676
fac@@	O	-1	9125676
e	O	-1	9125676
EC@@	O	-1	9125676
G	O	-1	9125676
(@@	O	-1	9125676
cyc@@	O	-1	9125676
le	O	-1	9125676
l@@	O	-1	9125676
en@@	O	-1	9125676
g@@	O	-1	9125676
th@@	O	-1	9125676
,	O	-1	9125676
Q@@	O	-1	9125676
T@@	O	-1	9125676
,	O	-1	9125676
and	O	-1	9125676
Q@@	O	-1	9125676
T@@	O	-1	9125676
c@@	O	-1	9125676
)	O	-1	9125676
in	O	-1	9125676
rel@@	O	-1	9125676
ation	O	-1	9125676
to	O	-1	9125676
the	O	-1	9125676
dose	O	-1	9125676
of	O	-1	9125676
oral	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
might	O	-1	9125676
identi@@	O	-1	9125676
f@@	O	-1	9125676
y	O	-1	9125676
a	O	-1	9125676
sub@@	O	-1	9125676
group	O	-1	9125676
of	O	-1	9125676
patients	O	-1	9125676
with	O	-1	9125676
an	O	-1	9125676
increased	O	-1	9125676
risk	O	-1	9125676
for	O	-1	9125676
t@@	B-Disease	D016171	9125676
or@@	I-Disease	-1	9125676
sa@@	I-Disease	-1	9125676
des	I-Disease	-1	9125676
de	I-Disease	-1	9125676
po@@	I-Disease	-1	9125676
int@@	I-Disease	-1	9125676
es	I-Disease	-1	9125676
.	O	-1	9125676
O@@	O	-1	9125676
ther	O	-1	9125676
EC@@	O	-1	9125676
G	O	-1	9125676
par@@	O	-1	9125676
ame@@	O	-1	9125676
ters	O	-1	9125676
before	O	-1	9125676
the	O	-1	9125676
ap@@	O	-1	9125676
plic@@	O	-1	9125676
ation	O	-1	9125676
of	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
did	O	-1	9125676
not	O	-1	9125676
identi@@	O	-1	9125676
f@@	O	-1	9125676
y	O	-1	9125676
patients	O	-1	9125676
at	O	-1	9125676
increased	O	-1	9125676
risk	O	-1	9125676
for	O	-1	9125676
t@@	B-Disease	D016171	9125676
or@@	I-Disease	-1	9125676
sa@@	I-Disease	-1	9125676
des	I-Disease	-1	9125676
de	I-Disease	-1	9125676
po@@	I-Disease	-1	9125676
int@@	I-Disease	-1	9125676
es	I-Disease	-1	9125676
.	O	-1	9125676
Rec@@	O	-1	9125676
ur@@	O	-1	9125676
rence	O	-1	9125676
rat@@	O	-1	9125676
es	O	-1	9125676
of	O	-1	9125676
ventricular	B-Disease	D017180	9125676
tachy@@	I-Disease	-1	9125676
arrhyth@@	I-Disease	-1	9125676
mi@@	I-Disease	-1	9125676
as	I-Disease	-1	9125676
are	O	-1	9125676
high	O	-1	9125676
des@@	O	-1	9125676
pit@@	O	-1	9125676
e	O	-1	9125676
complete	O	-1	9125676
sup@@	O	-1	9125676
pression	O	-1	9125676
of	O	-1	9125676
the	O	-1	9125676
arrhyth@@	B-Disease	D001145	9125676
mia	I-Disease	-1	9125676
during	O	-1	9125676
pro@@	O	-1	9125676
gram@@	O	-1	9125676
m@@	O	-1	9125676
ed	O	-1	9125676
stimul@@	O	-1	9125676
ation.	O	-1	9125676
The@@	O	-1	9125676
re@@	O	-1	9125676
fore	O	-1	9125676
pro@@	O	-1	9125676
gram@@	O	-1	9125676
m@@	O	-1	9125676
ed	O	-1	9125676
elect@@	O	-1	9125676
r@@	O	-1	9125676
ical	O	-1	9125676
stimulation	O	-1	9125676
in	O	-1	9125676
the	O	-1	9125676
case	O	-1	9125676
of	O	-1	9125676
d@@	B-Chemical	D013015	9125676
,@@	I-Chemical	-1	9125676
l@@	I-Chemical	-1	9125676
-@@	I-Chemical	-1	9125676
s@@	I-Chemical	-1	9125676
ot@@	I-Chemical	-1	9125676
al@@	I-Chemical	-1	9125676
ol	I-Chemical	-1	9125676
se@@	O	-1	9125676
em@@	O	-1	9125676
s	O	-1	9125676
to	O	-1	9125676
be	O	-1	9125676
of	O	-1	9125676
lim@@	O	-1	9125676
ited	O	-1	9125676
pro@@	O	-1	9125676
gn@@	O	-1	9125676
os@@	O	-1	9125676
tic	O	-1	9125676
valu@@	O	-1	9125676
e.	O	-1	9125676

Ch@@	O	-1	9128918
ron@@	O	-1	9128918
ic	O	-1	9128918
hyper@@	B-Disease	D006966	9128918
prol@@	I-Disease	-1	9128918
act@@	I-Disease	-1	9128918
ine@@	I-Disease	-1	9128918
mia	I-Disease	-1	9128918
and	O	-1	9128918
changes	O	-1	9128918
in	O	-1	9128918
dopamine	B-Chemical	D004298	9128918
neuron@@	O	-1	9128918
s.	O	-1	9128918
The	O	-1	9128918
tub@@	O	-1	9128918
ero@@	O	-1	9128918
inf@@	O	-1	9128918
un@@	O	-1	9128918
di@@	O	-1	9128918
b@@	O	-1	9128918
ular	O	-1	9128918
dop@@	O	-1	9128918
aminergic	O	-1	9128918
(@@	O	-1	9128918
TI@@	O	-1	9128918
D@@	O	-1	9128918
A@@	O	-1	9128918
)	O	-1	9128918
system	O	-1	9128918
is	O	-1	9128918
known	O	-1	9128918
to	O	-1	9128918
inhib@@	O	-1	9128918
it	O	-1	9128918
prolactin	O	-1	9128918
(P@@	O	-1	9128918
R@@	O	-1	9128918
L@@	O	-1	9128918
)	O	-1	9128918
secre@@	O	-1	9128918
tion.	O	-1	9128918
In	O	-1	9128918
youn@@	O	-1	9128918
g	O	-1	9128918
animals	O	-1	9128918
this	O	-1	9128918
system	O	-1	9128918
respon@@	O	-1	9128918
ds	O	-1	9128918
to	O	-1	9128918
acute	O	-1	9128918
elev@@	O	-1	9128918
ations	O	-1	9128918
in	O	-1	9128918
serum	O	-1	9128918
P@@	O	-1	9128918
R@@	O	-1	9128918
L	O	-1	9128918
by	O	-1	9128918
increas@@	O	-1	9128918
ing	O	-1	9128918
its	O	-1	9128918
activ@@	O	-1	9128918
ity.	O	-1	9128918
However,	O	-1	9128918
this	O	-1	9128918
respon@@	O	-1	9128918
si@@	O	-1	9128918
ven@@	O	-1	9128918
ess	O	-1	9128918
is	O	-1	9128918
lo@@	O	-1	9128918
st	O	-1	9128918
in	O	-1	9128918
ag@@	O	-1	9128918
ing	O	-1	9128918
rats	O	-1	9128918
with	O	-1	9128918
chron@@	O	-1	9128918
ically	O	-1	9128918
high	O	-1	9128918
serum	O	-1	9128918
P@@	O	-1	9128918
R@@	O	-1	9128918
L	O	-1	9128918
level@@	O	-1	9128918
s.	O	-1	9128918
The	O	-1	9128918
pur@@	O	-1	9128918
p@@	O	-1	9128918
ose	O	-1	9128918
of	O	-1	9128918
this	O	-1	9128918
study	O	-1	9128918
was	O	-1	9128918
to	O	-1	9128918
induce	O	-1	9128918
hyper@@	B-Disease	D006966	9128918
prol@@	I-Disease	-1	9128918
act@@	I-Disease	-1	9128918
ine@@	I-Disease	-1	9128918
mia	I-Disease	-1	9128918
in	O	-1	9128918
rats	O	-1	9128918
for	O	-1	9128918
exten@@	O	-1	9128918
ded	O	-1	9128918
perio@@	O	-1	9128918
ds	O	-1	9128918
of	O	-1	9128918
time	O	-1	9128918
and	O	-1	9128918
ex@@	O	-1	9128918
amine	O	-1	9128918
its	O	-1	9128918
effects	O	-1	9128918
on	O	-1	9128918
dop@@	O	-1	9128918
aminergic	O	-1	9128918
system@@	O	-1	9128918
s	O	-1	9128918
in	O	-1	9128918
the	O	-1	9128918
bra@@	O	-1	9128918
in.	O	-1	9128918
H@@	B-Disease	D006966	9128918
y@@	I-Disease	-1	9128918
per@@	I-Disease	-1	9128918
prol@@	I-Disease	-1	9128918
act@@	I-Disease	-1	9128918
ine@@	I-Disease	-1	9128918
mia	I-Disease	-1	9128918
was	O	-1	9128918
induced	O	-1	9128918
by	O	-1	9128918
treatment	O	-1	9128918
with	O	-1	9128918
haloperidol	B-Chemical	D006220	9128918
,	O	-1	9128918
a	O	-1	9128918
dopamine	B-Chemical	D004298	9128918
receptor	O	-1	9128918
antagonist@@	O	-1	9128918
,	O	-1	9128918
and	O	-1	9128918
P@@	O	-1	9128918
al@@	O	-1	9128918
k@@	O	-1	9128918
o@@	O	-1	9128918
vit@@	O	-1	9128918
s@@	O	-1	9128918
'	O	-1	9128918
micro@@	O	-1	9128918
dis@@	O	-1	9128918
sec@@	O	-1	9128918
tion	O	-1	9128918
t@@	O	-1	9128918
ech@@	O	-1	9128918
n@@	O	-1	9128918
i@@	O	-1	9128918
qu@@	O	-1	9128918
e	O	-1	9128918
in	O	-1	9128918
combination	O	-1	9128918
with	O	-1	9128918
high-@@	O	-1	9128918
perform@@	O	-1	9128918
ance	O	-1	9128918
li@@	O	-1	9128918
qu@@	O	-1	9128918
id	O	-1	9128918
ch@@	O	-1	9128918
rom@@	O	-1	9128918
at@@	O	-1	9128918
ograph@@	O	-1	9128918
y	O	-1	9128918
was	O	-1	9128918
used	O	-1	9128918
to	O	-1	9128918
meas@@	O	-1	9128918
ure	O	-1	9128918
neuro@@	O	-1	9128918
trans@@	O	-1	9128918
mit@@	O	-1	9128918
ter	O	-1	9128918
concentrations	O	-1	9128918
in	O	-1	9128918
several	O	-1	9128918
a@@	O	-1	9128918
reas	O	-1	9128918
of	O	-1	9128918
the	O	-1	9128918
bra@@	O	-1	9128918
in.	O	-1	9128918
After	O	-1	9128918
6	O	-1	9128918
months	O	-1	9128918
of	O	-1	9128918
hyper@@	B-Disease	D006966	9128918
prol@@	I-Disease	-1	9128918
act@@	I-Disease	-1	9128918
ine@@	I-Disease	-1	9128918
mia	I-Disease	-1	9128918
,	O	-1	9128918
dopamine	B-Chemical	D004298	9128918
(	O	-1	9128918
D@@	B-Chemical	D004298	9128918
A	I-Chemical	-1	9128918
)	O	-1	9128918
concentrations	O	-1	9128918
in	O	-1	9128918
the	O	-1	9128918
median	O	-1	9128918
em@@	O	-1	9128918
in@@	O	-1	9128918
ence	O	-1	9128918
(@@	O	-1	9128918
M@@	O	-1	9128918
E@@	O	-1	9128918
)	O	-1	9128918
increased	O	-1	9128918
by	O	-1	9128918
8@@	O	-1	9128918
4@@	O	-1	9128918
%	O	-1	9128918
over	O	-1	9128918
the	O	-1	9128918
control	O	-1	9128918
group.	O	-1	9128918
N@@	O	-1	9128918
ine	O	-1	9128918
months	O	-1	9128918
of	O	-1	9128918
hyper@@	B-Disease	D006966	9128918
prol@@	I-Disease	-1	9128918
act@@	I-Disease	-1	9128918
ine@@	I-Disease	-1	9128918
mia	I-Disease	-1	9128918
produced	O	-1	9128918
a	O	-1	9128918
50@@	O	-1	9128918
%	O	-1	9128918
increase	O	-1	9128918
in	O	-1	9128918
D@@	B-Chemical	D004298	9128918
A	I-Chemical	-1	9128918
concentrations	O	-1	9128918
in	O	-1	9128918
the	O	-1	9128918
M@@	O	-1	9128918
E	O	-1	9128918
over	O	-1	9128918
the	O	-1	9128918
control	O	-1	9128918
group.	O	-1	9128918
However,	O	-1	9128918
D@@	B-Chemical	D004298	9128918
A	I-Chemical	-1	9128918
response	O	-1	9128918
was	O	-1	9128918
lo@@	O	-1	9128918
st	O	-1	9128918
if	O	-1	9128918
a	O	-1	9128918
9@@	O	-1	9128918
-@@	O	-1	9128918
mon@@	O	-1	9128918
th	O	-1	9128918
lon@@	O	-1	9128918
g	O	-1	9128918
haloperidol	B-Chemical	D006220	9128918
-induced	O	-1	9128918
hyper@@	B-Disease	D006966	9128918
prol@@	I-Disease	-1	9128918
act@@	I-Disease	-1	9128918
ine@@	I-Disease	-1	9128918
mia	I-Disease	-1	9128918
was	O	-1	9128918
followed	O	-1	9128918
by	O	-1	9128918
a	O	-1	9128918
1	O	-1	9128918
1@@	O	-1	9128918
/@@	O	-1	9128918
2	O	-1	9128918
month@@	O	-1	9128918
-@@	O	-1	9128918
lon@@	O	-1	9128918
g	O	-1	9128918
ex@@	O	-1	9128918
tre@@	O	-1	9128918
me@@	O	-1	9128918
ly	O	-1	9128918
high	O	-1	9128918
increase	O	-1	9128918
in	O	-1	9128918
serum	O	-1	9128918
P@@	O	-1	9128918
R@@	O	-1	9128918
L	O	-1	9128918
levels	O	-1	9128918
produced	O	-1	9128918
by	O	-1	9128918
im@@	O	-1	9128918
pl@@	O	-1	9128918
ant@@	O	-1	9128918
ation	O	-1	9128918
of	O	-1	9128918
M@@	O	-1	9128918
M@@	O	-1	9128918
Q	O	-1	9128918
cells	O	-1	9128918
under	O	-1	9128918
the	O	-1	9128918
kidney	O	-1	9128918
cap@@	O	-1	9128918
sul@@	O	-1	9128918
e.	O	-1	9128918
There	O	-1	9128918
was	O	-1	9128918
no	O	-1	9128918
change	O	-1	9128918
in	O	-1	9128918
the	O	-1	9128918
levels	O	-1	9128918
of	O	-1	9128918
D@@	B-Chemical	D004298	9128918
A	I-Chemical	-1	9128918
,	O	-1	9128918
no@@	B-Chemical	D009638	9128918
re@@	I-Chemical	-1	9128918
p@@	I-Chemical	-1	9128918
ine@@	I-Chemical	-1	9128918
phrine	I-Chemical	-1	9128918
(	O	-1	9128918
N@@	B-Chemical	D009638	9128918
E	I-Chemical	-1	9128918
),	O	-1	9128918
seroton@@	B-Chemical	D012701	9128918
in	I-Chemical	-1	9128918
(	O	-1	9128918
5-@@	B-Chemical	D012701	9128918
H@@	I-Chemical	-1	9128918
T	I-Chemical	-1	9128918
),	O	-1	9128918
or	O	-1	9128918
their	O	-1	9128918
metabol@@	O	-1	9128918
it@@	O	-1	9128918
es	O	-1	9128918
in	O	-1	9128918
the	O	-1	9128918
arc@@	O	-1	9128918
u@@	O	-1	9128918
ate	O	-1	9128918
nucle@@	O	-1	9128918
us	O	-1	9128918
(A@@	O	-1	9128918
N@@	O	-1	9128918
),	O	-1	9128918
medi@@	O	-1	9128918
al	O	-1	9128918
pre@@	O	-1	9128918
op@@	O	-1	9128918
tic	O	-1	9128918
a@@	O	-1	9128918
re@@	O	-1	9128918
a	O	-1	9128918
(@@	O	-1	9128918
M@@	O	-1	9128918
PA@@	O	-1	9128918
),	O	-1	9128918
ca@@	O	-1	9128918
ud@@	O	-1	9128918
ate	O	-1	9128918
p@@	O	-1	9128918
ut@@	O	-1	9128918
am@@	O	-1	9128918
en	O	-1	9128918
(C@@	O	-1	9128918
P@@	O	-1	9128918
),	O	-1	9128918
subst@@	O	-1	9128918
anti@@	O	-1	9128918
a	O	-1	9128918
n@@	O	-1	9128918
ig@@	O	-1	9128918
r@@	O	-1	9128918
a	O	-1	9128918
(S@@	O	-1	9128918
N@@	O	-1	9128918
),	O	-1	9128918
and	O	-1	9128918
z@@	O	-1	9128918
on@@	O	-1	9128918
a	O	-1	9128918
inc@@	O	-1	9128918
er@@	O	-1	9128918
t@@	O	-1	9128918
a	O	-1	9128918
(@@	O	-1	9128918
Z@@	O	-1	9128918
I@@	O	-1	9128918
),	O	-1	9128918
ex@@	O	-1	9128918
cep@@	O	-1	9128918
t	O	-1	9128918
for	O	-1	9128918
a	O	-1	9128918
decrease	O	-1	9128918
in	O	-1	9128918
5-@@	B-Chemical	D006897	9128918
hydrox@@	I-Chemical	-1	9128918
y@@	I-Chemical	-1	9128918
ind@@	I-Chemical	-1	9128918
ol@@	I-Chemical	-1	9128918
e@@	I-Chemical	-1	9128918
ace@@	I-Chemical	-1	9128918
tic	I-Chemical	-1	9128918
acid	I-Chemical	-1	9128918
(	O	-1	9128918
5-@@	B-Chemical	D006897	9128918
H@@	I-Chemical	-1	9128918
I@@	I-Chemical	-1	9128918
A@@	I-Chemical	-1	9128918
A	I-Chemical	-1	9128918
)	O	-1	9128918
in	O	-1	9128918
the	O	-1	9128918
A@@	O	-1	9128918
N	O	-1	9128918
after	O	-1	9128918
6-@@	O	-1	9128918
months	O	-1	9128918
of	O	-1	9128918
hyper@@	B-Disease	D006966	9128918
prol@@	I-Disease	-1	9128918
act@@	I-Disease	-1	9128918
ine@@	I-Disease	-1	9128918
mia	I-Disease	-1	9128918
and	O	-1	9128918
an	O	-1	9128918
increase	O	-1	9128918
in	O	-1	9128918
D@@	B-Chemical	D004298	9128918
A	I-Chemical	-1	9128918
concentrations	O	-1	9128918
in	O	-1	9128918
the	O	-1	9128918
A@@	O	-1	9128918
N	O	-1	9128918
after	O	-1	9128918
9@@	O	-1	9128918
-@@	O	-1	9128918
months	O	-1	9128918
of	O	-1	9128918
hyper@@	B-Disease	D006966	9128918
prol@@	I-Disease	-1	9128918
act@@	I-Disease	-1	9128918
ine@@	I-Disease	-1	9128918
mia	I-Disease	-1	9128918
.	O	-1	9128918
These	O	-1	9128918
results	O	-1	9128918
demon@@	O	-1	9128918
st@@	O	-1	9128918
rate	O	-1	9128918
that	O	-1	9128918
hyper@@	B-Disease	D006966	9128918
prol@@	I-Disease	-1	9128918
act@@	I-Disease	-1	9128918
ine@@	I-Disease	-1	9128918
mia	I-Disease	-1	9128918
spec@@	O	-1	9128918
ific@@	O	-1	9128918
ally	O	-1	9128918
aff@@	O	-1	9128918
ects	O	-1	9128918
TI@@	O	-1	9128918
D@@	O	-1	9128918
A	O	-1	9128918
neuron@@	O	-1	9128918
s	O	-1	9128918
and	O	-1	9128918
these	O	-1	9128918
effects	O	-1	9128918
v@@	O	-1	9128918
ar@@	O	-1	9128918
y,	O	-1	9128918
depend@@	O	-1	9128918
ing	O	-1	9128918
on	O	-1	9128918
the	O	-1	9128918
duration	O	-1	9128918
and	O	-1	9128918
int@@	O	-1	9128918
ensity	O	-1	9128918
of	O	-1	9128918
hyper@@	B-Disease	D006966	9128918
prol@@	I-Disease	-1	9128918
act@@	I-Disease	-1	9128918
ine@@	I-Disease	-1	9128918
mia	I-Disease	-1	9128918
.	O	-1	9128918
The	O	-1	9128918
ag@@	O	-1	9128918
e-@@	O	-1	9128918
related	O	-1	9128918
decrease	O	-1	9128918
in	O	-1	9128918
hypo@@	O	-1	9128918
thal@@	O	-1	9128918
am@@	O	-1	9128918
ic	O	-1	9128918
dopamine	B-Chemical	D004298	9128918
function	O	-1	9128918
may	O	-1	9128918
be	O	-1	9128918
associated	O	-1	9128918
with	O	-1	9128918
increases	O	-1	9128918
in	O	-1	9128918
P@@	O	-1	9128918
R@@	O	-1	9128918
L	O	-1	9128918
secre@@	O	-1	9128918
tion.	O	-1	9128918

Treat@@	O	-1	9132810
ment@@	O	-1	9132810
-@@	O	-1	9132810
related	O	-1	9132810
dis@@	O	-1	9132810
se@@	O	-1	9132810
min@@	O	-1	9132810
ated	O	-1	9132810
necro@@	O	-1	9132810
tiz@@	O	-1	9132810
ing	O	-1	9132810
leuk@@	B-Disease	D056784	9132810
o@@	I-Disease	-1	9132810
encephalo@@	I-Disease	-1	9132810
pathy	I-Disease	-1	9132810
with	O	-1	9132810
character@@	O	-1	9132810
istic	O	-1	9132810
contr@@	O	-1	9132810
ast	O	-1	9132810
enh@@	O	-1	9132810
ance@@	O	-1	9132810
ment	O	-1	9132810
of	O	-1	9132810
the	O	-1	9132810
wh@@	O	-1	9132810
ite	O	-1	9132810
mat@@	O	-1	9132810
ter@@	O	-1	9132810
.	O	-1	9132810
This	O	-1	9132810
report	O	-1	9132810
descri@@	O	-1	9132810
b@@	O	-1	9132810
es	O	-1	9132810
un@@	O	-1	9132810
i@@	O	-1	9132810
qu@@	O	-1	9132810
e	O	-1	9132810
contr@@	O	-1	9132810
ast	O	-1	9132810
enh@@	O	-1	9132810
ance@@	O	-1	9132810
ment	O	-1	9132810
of	O	-1	9132810
the	O	-1	9132810
wh@@	O	-1	9132810
ite	O	-1	9132810
mat@@	O	-1	9132810
ter	O	-1	9132810
on	O	-1	9132810
T@@	O	-1	9132810
1-@@	O	-1	9132810
weigh@@	O	-1	9132810
ted	O	-1	9132810
mag@@	O	-1	9132810
ne@@	O	-1	9132810
tic	O	-1	9132810
res@@	O	-1	9132810
on@@	O	-1	9132810
ance	O	-1	9132810
imag@@	O	-1	9132810
es	O	-1	9132810
of	O	-1	9132810
two	O	-1	9132810
patients	O	-1	9132810
with	O	-1	9132810
dis@@	O	-1	9132810
se@@	O	-1	9132810
min@@	O	-1	9132810
ated	O	-1	9132810
necro@@	O	-1	9132810
tiz@@	O	-1	9132810
ing	O	-1	9132810
leuk@@	B-Disease	D056784	9132810
o@@	I-Disease	-1	9132810
encephalo@@	I-Disease	-1	9132810
pathy	I-Disease	-1	9132810
,	O	-1	9132810
which	O	-1	9132810
developed	O	-1	9132810
from	O	-1	9132810
acute	B-Disease	D054198	9132810
lymph@@	I-Disease	-1	9132810
ob@@	I-Disease	-1	9132810
las@@	I-Disease	-1	9132810
tic	I-Disease	-1	9132810
leuk@@	I-Disease	-1	9132810
emia	I-Disease	-1	9132810
treated	O	-1	9132810
with	O	-1	9132810
high-dose	O	-1	9132810
meth@@	B-Chemical	D008727	9132810
ot@@	I-Chemical	-1	9132810
re@@	I-Chemical	-1	9132810
x@@	I-Chemical	-1	9132810
ate	I-Chemical	-1	9132810
.	O	-1	9132810
In	O	-1	9132810
both	O	-1	9132810
patients,	O	-1	9132810
the	O	-1	9132810
enh@@	O	-1	9132810
ance@@	O	-1	9132810
ment	O	-1	9132810
was	O	-1	9132810
more	O	-1	9132810
p@@	O	-1	9132810
ron@@	O	-1	9132810
oun@@	O	-1	9132810
c@@	O	-1	9132810
ed	O	-1	9132810
ne@@	O	-1	9132810
ar	O	-1	9132810
the	O	-1	9132810
b@@	O	-1	9132810
ase	O	-1	9132810
of	O	-1	9132810
the	O	-1	9132810
brain	O	-1	9132810
than	O	-1	9132810
at	O	-1	9132810
the	O	-1	9132810
ver@@	O	-1	9132810
t@@	O	-1	9132810
ex@@	O	-1	9132810
.	O	-1	9132810
N@@	O	-1	9132810
ec@@	O	-1	9132810
ro@@	O	-1	9132810
p@@	O	-1	9132810
sy	O	-1	9132810
of	O	-1	9132810
the	O	-1	9132810
first	O	-1	9132810
case	O	-1	9132810
revealed	O	-1	9132810
loss	B-Disease	D003711	9132810
of	I-Disease	-1	9132810
my@@	I-Disease	-1	9132810
el@@	I-Disease	-1	9132810
in@@	I-Disease	-1	9132810
ation	I-Disease	-1	9132810
and	O	-1	9132810
necro@@	B-Disease	D009336	9132810
sis	I-Disease	-1	9132810
of	O	-1	9132810
the	O	-1	9132810
wh@@	O	-1	9132810
ite	O	-1	9132810
mat@@	O	-1	9132810
ter@@	O	-1	9132810
.	O	-1	9132810
P@@	O	-1	9132810
os@@	O	-1	9132810
sible	O	-1	9132810
mechanisms	O	-1	9132810
ca@@	O	-1	9132810
using	O	-1	9132810
such	O	-1	9132810
a	O	-1	9132810
leuk@@	B-Disease	D056784	9132810
o@@	I-Disease	-1	9132810
encephalo@@	I-Disease	-1	9132810
pathy	I-Disease	-1	9132810
are	O	-1	9132810
discus@@	O	-1	9132810
sed.	O	-1	9132810

Th@@	B-Disease	D013927	9158667
rom@@	I-Disease	-1	9158667
bo@@	I-Disease	-1	9158667
tic	I-Disease	-1	9158667
complications	O	-1	9158667
in	O	-1	9158667
acute	B-Disease	D015473	9158667
pro@@	I-Disease	-1	9158667
my@@	I-Disease	-1	9158667
e@@	I-Disease	-1	9158667
lo@@	I-Disease	-1	9158667
cy@@	I-Disease	-1	9158667
tic	I-Disease	-1	9158667
leuk@@	I-Disease	-1	9158667
emia	I-Disease	-1	9158667
during	O	-1	9158667
all@@	B-Chemical	D014212	9158667
-@@	I-Chemical	-1	9158667
trans@@	I-Chemical	-1	9158667
-@@	I-Chemical	-1	9158667
ret@@	I-Chemical	-1	9158667
ino@@	I-Chemical	-1	9158667
ic	I-Chemical	-1	9158667
acid	I-Chemical	-1	9158667
therapy.	O	-1	9158667
A	O	-1	9158667
case	O	-1	9158667
of	O	-1	9158667
acute	B-Disease	D058186	9158667
renal	I-Disease	-1	9158667
failure	I-Disease	-1	9158667
,	O	-1	9158667
due	O	-1	9158667
to	O	-1	9158667
oc@@	B-Disease	-1	9158667
cl@@	I-Disease	-1	9158667
usion	I-Disease	-1	9158667
of	I-Disease	-1	9158667
renal	I-Disease	-1	9158667
v@@	I-Disease	-1	9158667
es@@	I-Disease	-1	9158667
sel@@	I-Disease	-1	9158667
s	I-Disease	-1	9158667
in	O	-1	9158667
a	O	-1	9158667
patient	O	-1	9158667
with	O	-1	9158667
acute	B-Disease	D015473	9158667
pro@@	I-Disease	-1	9158667
my@@	I-Disease	-1	9158667
e@@	I-Disease	-1	9158667
lo@@	I-Disease	-1	9158667
cy@@	I-Disease	-1	9158667
tic	I-Disease	-1	9158667
leuk@@	I-Disease	-1	9158667
emia	I-Disease	-1	9158667
(	O	-1	9158667
A@@	B-Disease	D015473	9158667
P@@	I-Disease	-1	9158667
L	I-Disease	-1	9158667
)	O	-1	9158667
treated	O	-1	9158667
with	O	-1	9158667
all@@	B-Chemical	D014212	9158667
-@@	I-Chemical	-1	9158667
trans@@	I-Chemical	-1	9158667
-@@	I-Chemical	-1	9158667
ret@@	I-Chemical	-1	9158667
ino@@	I-Chemical	-1	9158667
ic	I-Chemical	-1	9158667
acid	I-Chemical	-1	9158667
(	O	-1	9158667
AT@@	B-Chemical	D014212	9158667
R@@	I-Chemical	-1	9158667
A	I-Chemical	-1	9158667
)	O	-1	9158667
and	O	-1	9158667
tran@@	B-Chemical	D014148	9158667
ex@@	I-Chemical	-1	9158667
am@@	I-Chemical	-1	9158667
ic	I-Chemical	-1	9158667
acid	I-Chemical	-1	9158667
has	O	-1	9158667
been	O	-1	9158667
descri@@	O	-1	9158667
bed	O	-1	9158667
rec@@	O	-1	9158667
ent@@	O	-1	9158667
ly.	O	-1	9158667
We	O	-1	9158667
report	O	-1	9158667
a	O	-1	9158667
case	O	-1	9158667
of	O	-1	9158667
acute	B-Disease	D058186	9158667
renal	I-Disease	-1	9158667
failure	I-Disease	-1	9158667
in	O	-1	9158667
an	O	-1	9158667
A@@	B-Disease	D015473	9158667
P@@	I-Disease	-1	9158667
L	I-Disease	-1	9158667
patient	O	-1	9158667
treated	O	-1	9158667
with	O	-1	9158667
AT@@	B-Chemical	D014212	9158667
R@@	I-Chemical	-1	9158667
A	I-Chemical	-1	9158667
al@@	O	-1	9158667
one.	O	-1	9158667
This	O	-1	9158667
case	O	-1	9158667
further	O	-1	9158667
suppor@@	O	-1	9158667
ts	O	-1	9158667
the	O	-1	9158667
con@@	O	-1	9158667
cer@@	O	-1	9158667
n	O	-1	9158667
about	O	-1	9158667
thrombo@@	B-Disease	D013923	9158667
emb@@	I-Disease	-1	9158667
olic	I-Disease	-1	9158667
complications	O	-1	9158667
associated	O	-1	9158667
with	O	-1	9158667
AT@@	B-Chemical	D014212	9158667
R@@	I-Chemical	-1	9158667
A	I-Chemical	-1	9158667
therapy	O	-1	9158667
in	O	-1	9158667
A@@	B-Disease	D015473	9158667
P@@	I-Disease	-1	9158667
L	I-Disease	-1	9158667
patients.	O	-1	9158667
The	O	-1	9158667
patients,	O	-1	9158667
a	O	-1	9158667
4@@	O	-1	9158667
3-@@	O	-1	9158667
year-old	O	-1	9158667
man@@	O	-1	9158667
,	O	-1	9158667
presented	O	-1	9158667
all	O	-1	9158667
the	O	-1	9158667
signs	O	-1	9158667
and	O	-1	9158667
symptoms	O	-1	9158667
of	O	-1	9158667
A@@	B-Disease	D015473	9158667
P@@	I-Disease	-1	9158667
L	I-Disease	-1	9158667
and	O	-1	9158667
was	O	-1	9158667
included	O	-1	9158667
in	O	-1	9158667
a	O	-1	9158667
treatment	O	-1	9158667
pro@@	O	-1	9158667
to@@	O	-1	9158667
co@@	O	-1	9158667
l	O	-1	9158667
with	O	-1	9158667
AT@@	B-Chemical	D014212	9158667
R@@	I-Chemical	-1	9158667
A	I-Chemical	-1	9158667
.	O	-1	9158667
After	O	-1	9158667
10	O	-1	9158667
days	O	-1	9158667
of	O	-1	9158667
treatment,	O	-1	9158667
he	O	-1	9158667
developed	O	-1	9158667
acute	B-Disease	D058186	9158667
renal	I-Disease	-1	9158667
failure	I-Disease	-1	9158667
that	O	-1	9158667
was	O	-1	9158667
complete@@	O	-1	9158667
ly	O	-1	9158667
reversible	O	-1	9158667
after	O	-1	9158667
complete	O	-1	9158667
re@@	O	-1	9158667
mission	O	-1	9158667
of	O	-1	9158667
A@@	B-Disease	D015473	9158667
P@@	I-Disease	-1	9158667
L	I-Disease	-1	9158667
was	O	-1	9158667
achi@@	O	-1	9158667
ev@@	O	-1	9158667
ed	O	-1	9158667
and	O	-1	9158667
therapy	O	-1	9158667
discontinu@@	O	-1	9158667
ed.	O	-1	9158667
We	O	-1	9158667
concl@@	O	-1	9158667
ude	O	-1	9158667
that	O	-1	9158667
AT@@	B-Chemical	D014212	9158667
R@@	I-Chemical	-1	9158667
A	I-Chemical	-1	9158667
is	O	-1	9158667
a	O	-1	9158667
val@@	O	-1	9158667
id	O	-1	9158667
therapeutic	O	-1	9158667
ch@@	O	-1	9158667
o@@	O	-1	9158667
ic@@	O	-1	9158667
e	O	-1	9158667
for	O	-1	9158667
patients	O	-1	9158667
with	O	-1	9158667
A@@	B-Disease	D015473	9158667
P@@	I-Disease	-1	9158667
L	I-Disease	-1	9158667
,	O	-1	9158667
although	O	-1	9158667
the	O	-1	9158667
pro@@	O	-1	9158667
co@@	O	-1	9158667
ag@@	O	-1	9158667
ul@@	O	-1	9158667
ant	O	-1	9158667
ten@@	O	-1	9158667
d@@	O	-1	9158667
ency	O	-1	9158667
is	O	-1	9158667
not	O	-1	9158667
complete@@	O	-1	9158667
ly	O	-1	9158667
cor@@	O	-1	9158667
rec@@	O	-1	9158667
ted.	O	-1	9158667
Th@@	B-Disease	D013927	9158667
rom@@	I-Disease	-1	9158667
bo@@	I-Disease	-1	9158667
tic	I-Disease	-1	9158667
event@@	O	-1	9158667
s,	O	-1	9158667
however,	O	-1	9158667
could	O	-1	9158667
be	O	-1	9158667
avoid@@	O	-1	9158667
ed	O	-1	9158667
by	O	-1	9158667
using	O	-1	9158667
low@@	O	-1	9158667
-@@	O	-1	9158667
dose	O	-1	9158667
hepar@@	B-Chemical	D006493	9158667
in	I-Chemical	-1	9158667
.	O	-1	9158667

P@@	O	-1	9197951
up@@	O	-1	9197951
ill@@	O	-1	9197951
ary	O	-1	9197951
changes	O	-1	9197951
associated	O	-1	9197951
with	O	-1	9197951
the	O	-1	9197951
development	O	-1	9197951
of	O	-1	9197951
stimul@@	O	-1	9197951
ant@@	O	-1	9197951
-induced	O	-1	9197951
man@@	B-Disease	D001714	9197951
ia	I-Disease	-1	9197951
:	O	-1	9197951
a	O	-1	9197951
case	O	-1	9197951
repor@@	O	-1	9197951
t.	O	-1	9197951
A	O	-1	9197951
3@@	O	-1	9197951
0-@@	O	-1	9197951
year-old	O	-1	9197951
cocaine	B-Chemical	D003042	9197951
-@@	O	-1	9197951
dependent	O	-1	9197951
man	O	-1	9197951
who	O	-1	9197951
was	O	-1	9197951
a	O	-1	9197951
subj@@	O	-1	9197951
ect	O	-1	9197951
in	O	-1	9197951
a	O	-1	9197951
study	O	-1	9197951
evalu@@	O	-1	9197951
ating	O	-1	9197951
the	O	-1	9197951
anti@@	O	-1	9197951
c@@	O	-1	9197951
ra@@	O	-1	9197951
ving	O	-1	9197951
efficacy	O	-1	9197951
of	O	-1	9197951
the	O	-1	9197951
stimul@@	O	-1	9197951
ant	O	-1	9197951
medic@@	O	-1	9197951
ation	O	-1	9197951
di@@	B-Chemical	D004053	9197951
eth@@	I-Chemical	-1	9197951
yl@@	I-Chemical	-1	9197951
pro@@	I-Chemical	-1	9197951
pi@@	I-Chemical	-1	9197951
on	I-Chemical	-1	9197951
(	O	-1	9197951
D@@	B-Chemical	D004053	9197951
E@@	I-Chemical	-1	9197951
P	I-Chemical	-1	9197951
)	O	-1	9197951
b@@	O	-1	9197951
ec@@	O	-1	9197951
am@@	O	-1	9197951
e	O	-1	9197951
man@@	B-Disease	D001714	9197951
ic	I-Disease	-1	9197951
during	O	-1	9197951
h@@	O	-1	9197951
is	O	-1	9197951
second	O	-1	9197951
week	O	-1	9197951
on	O	-1	9197951
the	O	-1	9197951
study	O	-1	9197951
drug.	O	-1	9197951
P@@	O	-1	9197951
up@@	O	-1	9197951
il@@	O	-1	9197951
lo@@	O	-1	9197951
me@@	O	-1	9197951
tri@@	O	-1	9197951
c	O	-1	9197951
changes	O	-1	9197951
while	O	-1	9197951
on	O	-1	9197951
D@@	B-Chemical	D004053	9197951
E@@	I-Chemical	-1	9197951
P	I-Chemical	-1	9197951
,	O	-1	9197951
es@@	O	-1	9197951
p@@	O	-1	9197951
ec@@	O	-1	9197951
i@@	O	-1	9197951
ally	O	-1	9197951
changes	O	-1	9197951
in	O	-1	9197951
the	O	-1	9197951
total	O	-1	9197951
po@@	O	-1	9197951
w@@	O	-1	9197951
er	O	-1	9197951
of	O	-1	9197951
p@@	B-Disease	D011681	9197951
up@@	I-Disease	-1	9197951
ill@@	I-Disease	-1	9197951
ary	I-Disease	-1	9197951
os@@	I-Disease	-1	9197951
c@@	I-Disease	-1	9197951
ill@@	I-Disease	-1	9197951
ation	I-Disease	-1	9197951
,	O	-1	9197951
were	O	-1	9197951
d@@	O	-1	9197951
ram@@	O	-1	9197951
ati@@	O	-1	9197951
c@@	O	-1	9197951
ally	O	-1	9197951
different	O	-1	9197951
than	O	-1	9197951
those	O	-1	9197951
observed	O	-1	9197951
in	O	-1	9197951
the	O	-1	9197951
e@@	O	-1	9197951
ight	O	-1	9197951
other	O	-1	9197951
study	O	-1	9197951
subjects	O	-1	9197951
who	O	-1	9197951
did	O	-1	9197951
not	O	-1	9197951
b@@	O	-1	9197951
ec@@	O	-1	9197951
ome	O	-1	9197951
man@@	B-Disease	D001714	9197951
ic	I-Disease	-1	9197951
.	O	-1	9197951
The	O	-1	9197951
larg@@	O	-1	9197951
e	O	-1	9197951
changes	O	-1	9197951
in	O	-1	9197951
total	O	-1	9197951
po@@	O	-1	9197951
w@@	O	-1	9197951
er	O	-1	9197951
of	O	-1	9197951
p@@	B-Disease	D011681	9197951
up@@	I-Disease	-1	9197951
ill@@	I-Disease	-1	9197951
ary	I-Disease	-1	9197951
os@@	I-Disease	-1	9197951
c@@	I-Disease	-1	9197951
ill@@	I-Disease	-1	9197951
ation	I-Disease	-1	9197951
occurred	O	-1	9197951
a	O	-1	9197951
fe@@	O	-1	9197951
w	O	-1	9197951
days	O	-1	9197951
before	O	-1	9197951
the	O	-1	9197951
patient	O	-1	9197951
b@@	O	-1	9197951
ec@@	O	-1	9197951
am@@	O	-1	9197951
e	O	-1	9197951
ful@@	O	-1	9197951
ly	O	-1	9197951
man@@	B-Disease	D001714	9197951
ic	I-Disease	-1	9197951
.	O	-1	9197951
S@@	O	-1	9197951
uc@@	O	-1	9197951
h	O	-1	9197951
medic@@	O	-1	9197951
ation@@	O	-1	9197951
-@@	O	-1	9197951
associated	O	-1	9197951
changes	O	-1	9197951
in	O	-1	9197951
the	O	-1	9197951
total	O	-1	9197951
po@@	O	-1	9197951
w@@	O	-1	9197951
er	O	-1	9197951
of	O	-1	9197951
p@@	B-Disease	D011681	9197951
up@@	I-Disease	-1	9197951
ill@@	I-Disease	-1	9197951
ary	I-Disease	-1	9197951
os@@	I-Disease	-1	9197951
c@@	I-Disease	-1	9197951
ill@@	I-Disease	-1	9197951
ation	I-Disease	-1	9197951
might	O	-1	9197951
be	O	-1	9197951
of	O	-1	9197951
u@@	O	-1	9197951
til@@	O	-1	9197951
ity	O	-1	9197951
in	O	-1	9197951
identi@@	O	-1	9197951
f@@	O	-1	9197951
y@@	O	-1	9197951
ing	O	-1	9197951
per@@	O	-1	9197951
son@@	O	-1	9197951
s	O	-1	9197951
at	O	-1	9197951
risk	O	-1	9197951
for	O	-1	9197951
man@@	B-Disease	D001714	9197951
ic	I-Disease	-1	9197951
-@@	O	-1	9197951
like	O	-1	9197951
adverse	O	-1	9197951
effects	O	-1	9197951
during	O	-1	9197951
the	O	-1	9197951
med@@	O	-1	9197951
ical	O	-1	9197951
use	O	-1	9197951
of	O	-1	9197951
psych@@	O	-1	9197951
om@@	O	-1	9197951
otor	O	-1	9197951
stimul@@	O	-1	9197951
ants	O	-1	9197951
or	O	-1	9197951
sym@@	O	-1	9197951
path@@	O	-1	9197951
om@@	O	-1	9197951
i@@	O	-1	9197951
me@@	O	-1	9197951
tic	O	-1	9197951
agent@@	O	-1	9197951
s.	O	-1	9197951

The	O	-1	9272404
negative	O	-1	9272404
m@@	O	-1	9272404
u@@	O	-1	9272404
co@@	O	-1	9272404
s@@	O	-1	9272404
al	O	-1	9272404
potenti@@	O	-1	9272404
al@@	O	-1	9272404
:	O	-1	9272404
se@@	O	-1	9272404
par@@	O	-1	9272404
ating	O	-1	9272404
central	O	-1	9272404
and	O	-1	9272404
peripheral	O	-1	9272404
effects	O	-1	9272404
of	O	-1	9272404
N@@	O	-1	9272404
S@@	O	-1	9272404
A@@	O	-1	9272404
I@@	O	-1	9272404
D@@	O	-1	9272404
s	O	-1	9272404
in	O	-1	9272404
man@@	O	-1	9272404
.	O	-1	9272404
OBJECTIVE:	O	-1	9272404
We	O	-1	9272404
w@@	O	-1	9272404
ant@@	O	-1	9272404
ed	O	-1	9272404
to	O	-1	9272404
test	O	-1	9272404
whether	O	-1	9272404
assess@@	O	-1	9272404
ment	O	-1	9272404
of	O	-1	9272404
both	O	-1	9272404
a	O	-1	9272404
central	O	-1	9272404
pain	B-Disease	D010146	9272404
-@@	O	-1	9272404
related	O	-1	9272404
sign@@	O	-1	9272404
al	O	-1	9272404
(@@	O	-1	9272404
chemo@@	O	-1	9272404
-@@	O	-1	9272404
s@@	O	-1	9272404
om@@	O	-1	9272404
at@@	O	-1	9272404
os@@	O	-1	9272404
ens@@	O	-1	9272404
ory	O	-1	9272404
evoked	O	-1	9272404
potenti@@	O	-1	9272404
al,	O	-1	9272404
C@@	O	-1	9272404
S@@	O	-1	9272404
S@@	O	-1	9272404
E@@	O	-1	9272404
P)	O	-1	9272404
and	O	-1	9272404
a	O	-1	9272404
concomit@@	O	-1	9272404
ant@@	O	-1	9272404
ly	O	-1	9272404
recor@@	O	-1	9272404
ded	O	-1	9272404
peripheral	O	-1	9272404
sign@@	O	-1	9272404
al	O	-1	9272404
(@@	O	-1	9272404
negative	O	-1	9272404
m@@	O	-1	9272404
u@@	O	-1	9272404
co@@	O	-1	9272404
s@@	O	-1	9272404
al	O	-1	9272404
potenti@@	O	-1	9272404
al,	O	-1	9272404
N@@	O	-1	9272404
M@@	O	-1	9272404
P)	O	-1	9272404
al@@	O	-1	9272404
low@@	O	-1	9272404
s	O	-1	9272404
for	O	-1	9272404
se@@	O	-1	9272404
par@@	O	-1	9272404
ation	O	-1	9272404
of	O	-1	9272404
central	O	-1	9272404
and	O	-1	9272404
peripheral	O	-1	9272404
effects	O	-1	9272404
of	O	-1	9272404
N@@	O	-1	9272404
S@@	O	-1	9272404
A@@	O	-1	9272404
I@@	O	-1	9272404
D@@	O	-1	9272404
s.	O	-1	9272404
F@@	O	-1	9272404
or	O	-1	9272404
this	O	-1	9272404
pur@@	O	-1	9272404
po@@	O	-1	9272404
se@@	O	-1	9272404
,	O	-1	9272404
experimental	O	-1	9272404
condi@@	O	-1	9272404
tions	O	-1	9272404
were	O	-1	9272404
cre@@	O	-1	9272404
ated	O	-1	9272404
in	O	-1	9272404
which	O	-1	9272404
N@@	O	-1	9272404
S@@	O	-1	9272404
A@@	O	-1	9272404
I@@	O	-1	9272404
D@@	O	-1	9272404
s	O	-1	9272404
had	O	-1	9272404
previously	O	-1	9272404
been	O	-1	9272404
observed	O	-1	9272404
to	O	-1	9272404
produce	O	-1	9272404
effects	O	-1	9272404
on	O	-1	9272404
pha@@	O	-1	9272404
sic	O	-1	9272404
and	O	-1	9272404
t@@	O	-1	9272404
onic	O	-1	9272404
pain	B-Disease	D010146	9272404
by	O	-1	9272404
either	O	-1	9272404
central	O	-1	9272404
or	O	-1	9272404
peripheral	O	-1	9272404
mechanis@@	O	-1	9272404
m@@	O	-1	9272404
s.	O	-1	9272404
METHODS:	O	-1	9272404
Ac@@	O	-1	9272404
cor@@	O	-1	9272404
ding	O	-1	9272404
to	O	-1	9272404
a	O	-1	9272404
double-bl@@	O	-1	9272404
ind@@	O	-1	9272404
,	O	-1	9272404
ran@@	O	-1	9272404
do@@	O	-1	9272404
mi@@	O	-1	9272404
se@@	O	-1	9272404
d,	O	-1	9272404
control@@	O	-1	9272404
le@@	O	-1	9272404
d,	O	-1	9272404
th@@	O	-1	9272404
re@@	O	-1	9272404
e@@	O	-1	9272404
fol@@	O	-1	9272404
d	O	-1	9272404
cros@@	O	-1	9272404
s-@@	O	-1	9272404
over	O	-1	9272404
de@@	O	-1	9272404
sign@@	O	-1	9272404
,	O	-1	9272404
1@@	O	-1	9272404
8	O	-1	9272404
healthy	O	-1	9272404
subjects	O	-1	9272404
(1@@	O	-1	9272404
1	O	-1	9272404
mal@@	O	-1	9272404
es,	O	-1	9272404
7	O	-1	9272404
femal@@	O	-1	9272404
es@@	O	-1	9272404
;	O	-1	9272404
mean	O	-1	9272404
age	O	-1	9272404
2@@	O	-1	9272404
6	O	-1	9272404
year@@	O	-1	9272404
s)	O	-1	9272404
received	O	-1	9272404
either	O	-1	9272404
placebo@@	O	-1	9272404
,	O	-1	9272404
4@@	O	-1	9272404
00	O	-1	9272404
mg	O	-1	9272404
i@@	B-Chemical	D007052	9272404
bu@@	I-Chemical	-1	9272404
prof@@	I-Chemical	-1	9272404
en	I-Chemical	-1	9272404
,	O	-1	9272404
or	O	-1	9272404
8@@	O	-1	9272404
00	O	-1	9272404
mg	O	-1	9272404
i@@	B-Chemical	D007052	9272404
bu@@	I-Chemical	-1	9272404
prof@@	I-Chemical	-1	9272404
en	I-Chemical	-1	9272404
.	O	-1	9272404
P@@	O	-1	9272404
ha@@	O	-1	9272404
sic	O	-1	9272404
pain	B-Disease	D010146	9272404
was	O	-1	9272404
ap@@	O	-1	9272404
pl@@	O	-1	9272404
ied	O	-1	9272404
by	O	-1	9272404
me@@	O	-1	9272404
ans	O	-1	9272404
of	O	-1	9272404
sh@@	O	-1	9272404
ort	O	-1	9272404
pul@@	O	-1	9272404
ses	O	-1	9272404
of	O	-1	9272404
CO@@	B-Chemical	D002245	9272404
2	I-Chemical	-1	9272404
to	O	-1	9272404
the	O	-1	9272404
n@@	O	-1	9272404
as@@	O	-1	9272404
al	O	-1	9272404
m@@	O	-1	9272404
u@@	O	-1	9272404
co@@	O	-1	9272404
s@@	O	-1	9272404
a	O	-1	9272404
(@@	O	-1	9272404
stimul@@	O	-1	9272404
us	O	-1	9272404
duration	O	-1	9272404
5@@	O	-1	9272404
00	O	-1	9272404
m@@	O	-1	9272404
s,	O	-1	9272404
interv@@	O	-1	9272404
al	O	-1	9272404
appro@@	O	-1	9272404
xim@@	O	-1	9272404
ately	O	-1	9272404
60	O	-1	9272404
s),	O	-1	9272404
and	O	-1	9272404
t@@	O	-1	9272404
onic	O	-1	9272404
pain	B-Disease	D010146	9272404
was	O	-1	9272404
induced	O	-1	9272404
in	O	-1	9272404
the	O	-1	9272404
n@@	O	-1	9272404
as@@	O	-1	9272404
al	O	-1	9272404
ca@@	O	-1	9272404
v@@	O	-1	9272404
ity	O	-1	9272404
by	O	-1	9272404
me@@	O	-1	9272404
ans	O	-1	9272404
of	O	-1	9272404
d@@	O	-1	9272404
r@@	O	-1	9272404
y	O	-1	9272404
a@@	O	-1	9272404
ir	O	-1	9272404
of	O	-1	9272404
controlled	O	-1	9272404
tem@@	O	-1	9272404
per@@	O	-1	9272404
at@@	O	-1	9272404
ure,	O	-1	9272404
hum@@	O	-1	9272404
idity	O	-1	9272404
and	O	-1	9272404
flow	O	-1	9272404
rate	O	-1	9272404
(2@@	O	-1	9272404
2	O	-1	9272404
de@@	O	-1	9272404
gre@@	O	-1	9272404
es	O	-1	9272404
C@@	O	-1	9272404
,	O	-1	9272404
0%	O	-1	9272404
rel@@	O	-1	9272404
ative	O	-1	9272404
hum@@	O	-1	9272404
id@@	O	-1	9272404
ity,	O	-1	9272404
14@@	O	-1	9272404
5	O	-1	9272404
ml@@	O	-1	9272404
.@@	O	-1	9272404
s@@	O	-1	9272404
-1@@	O	-1	9272404
).	O	-1	9272404
B@@	O	-1	9272404
oth	O	-1	9272404
C@@	O	-1	9272404
S@@	O	-1	9272404
S@@	O	-1	9272404
EP@@	O	-1	9272404
s	O	-1	9272404
as	O	-1	9272404
central	O	-1	9272404
and	O	-1	9272404
N@@	O	-1	9272404
MP@@	O	-1	9272404
s	O	-1	9272404
as	O	-1	9272404
peripheral	O	-1	9272404
correl@@	O	-1	9272404
ates	O	-1	9272404
of	O	-1	9272404
pain	B-Disease	D010146	9272404
were	O	-1	9272404
obtained	O	-1	9272404
in	O	-1	9272404
response	O	-1	9272404
to	O	-1	9272404
the	O	-1	9272404
CO@@	B-Chemical	D002245	9272404
2	I-Chemical	-1	9272404
stimul@@	O	-1	9272404
i@@	O	-1	9272404
.	O	-1	9272404
Ad@@	O	-1	9272404
di@@	O	-1	9272404
tion@@	O	-1	9272404
ally,	O	-1	9272404
the	O	-1	9272404
subjects	O	-1	9272404
r@@	O	-1	9272404
ated	O	-1	9272404
the	O	-1	9272404
int@@	O	-1	9272404
ensity	O	-1	9272404
of	O	-1	9272404
both	O	-1	9272404
pha@@	O	-1	9272404
sic	O	-1	9272404
and	O	-1	9272404
t@@	O	-1	9272404
onic	O	-1	9272404
pain	B-Disease	D010146	9272404
by	O	-1	9272404
me@@	O	-1	9272404
ans	O	-1	9272404
of	O	-1	9272404
visual	O	-1	9272404
an@@	O	-1	9272404
alo@@	O	-1	9272404
gu@@	O	-1	9272404
e	O	-1	9272404
s@@	O	-1	9272404
cal@@	O	-1	9272404
es.	O	-1	9272404
RESULTS:	O	-1	9272404
A@@	O	-1	9272404
s	O	-1	9272404
descri@@	O	-1	9272404
bed	O	-1	9272404
ear@@	O	-1	9272404
li@@	O	-1	9272404
er,	O	-1	9272404
administration	O	-1	9272404
of	O	-1	9272404
i@@	B-Chemical	D007052	9272404
bu@@	I-Chemical	-1	9272404
prof@@	I-Chemical	-1	9272404
en	I-Chemical	-1	9272404
was	O	-1	9272404
followed	O	-1	9272404
by	O	-1	9272404
a	O	-1	9272404
decrease	O	-1	9272404
in	O	-1	9272404
t@@	O	-1	9272404
onic	O	-1	9272404
pain	B-Disease	D010146	9272404
but@@	O	-1	9272404
-@@	O	-1	9272404
rel@@	O	-1	9272404
ative	O	-1	9272404
to	O	-1	9272404
placebo@@	O	-1	9272404
-@@	O	-1	9272404
an	O	-1	9272404
increase	O	-1	9272404
in	O	-1	9272404
correl@@	O	-1	9272404
ates	O	-1	9272404
of	O	-1	9272404
pha@@	O	-1	9272404
sic	O	-1	9272404
pain	B-Disease	D010146	9272404
,	O	-1	9272404
indicating	O	-1	9272404
a	O	-1	9272404
specific	O	-1	9272404
effect	O	-1	9272404
of	O	-1	9272404
i@@	B-Chemical	D007052	9272404
bu@@	I-Chemical	-1	9272404
prof@@	I-Chemical	-1	9272404
en	I-Chemical	-1	9272404
on	O	-1	9272404
the	O	-1	9272404
inter@@	O	-1	9272404
action	O	-1	9272404
between	O	-1	9272404
the	O	-1	9272404
pain	B-Disease	D010146	9272404
stimul@@	O	-1	9272404
i	O	-1	9272404
under	O	-1	9272404
these	O	-1	9272404
spec@@	O	-1	9272404
ial	O	-1	9272404
experimental	O	-1	9272404
condi@@	O	-1	9272404
tions.	O	-1	9272404
B@@	O	-1	9272404
as@@	O	-1	9272404
ed	O	-1	9272404
on	O	-1	9272404
the	O	-1	9272404
similar	O	-1	9272404
behavi@@	O	-1	9272404
our	O	-1	9272404
of	O	-1	9272404
C@@	O	-1	9272404
S@@	O	-1	9272404
S@@	O	-1	9272404
E@@	O	-1	9272404
P	O	-1	9272404
and	O	-1	9272404
N@@	O	-1	9272404
MP@@	O	-1	9272404
,	O	-1	9272404
it	O	-1	9272404
was	O	-1	9272404
concl@@	O	-1	9272404
uded	O	-1	9272404
that	O	-1	9272404
the	O	-1	9272404
pharmac@@	O	-1	9272404
ological	O	-1	9272404
pro@@	O	-1	9272404
cess	O	-1	9272404
underlying	O	-1	9272404
this	O	-1	9272404
phen@@	O	-1	9272404
om@@	O	-1	9272404
en@@	O	-1	9272404
on	O	-1	9272404
was	O	-1	9272404
lo@@	O	-1	9272404
cal@@	O	-1	9272404
is@@	O	-1	9272404
ed	O	-1	9272404
in	O	-1	9272404
the	O	-1	9272404
peri@@	O	-1	9272404
ph@@	O	-1	9272404
er@@	O	-1	9272404
y.	O	-1	9272404
B@@	O	-1	9272404
y	O	-1	9272404
me@@	O	-1	9272404
ans	O	-1	9272404
of	O	-1	9272404
the	O	-1	9272404
sim@@	O	-1	9272404
ult@@	O	-1	9272404
aneous	O	-1	9272404
recor@@	O	-1	9272404
ding	O	-1	9272404
of	O	-1	9272404
inter@@	O	-1	9272404
related	O	-1	9272404
peripheral	O	-1	9272404
and	O	-1	9272404
central	O	-1	9272404
electro@@	O	-1	9272404
physi@@	O	-1	9272404
ologic	O	-1	9272404
correl@@	O	-1	9272404
ates	O	-1	9272404
of	O	-1	9272404
n@@	O	-1	9272404
ocicep@@	O	-1	9272404
tion,	O	-1	9272404
it	O	-1	9272404
was	O	-1	9272404
possible	O	-1	9272404
to	O	-1	9272404
se@@	O	-1	9272404
par@@	O	-1	9272404
ate	O	-1	9272404
central	O	-1	9272404
and	O	-1	9272404
peripheral	O	-1	9272404
effects	O	-1	9272404
of	O	-1	9272404
an	O	-1	9272404
N@@	O	-1	9272404
S@@	O	-1	9272404
A@@	O	-1	9272404
I@@	O	-1	9272404
D@@	O	-1	9272404
.	O	-1	9272404
The	O	-1	9272404
major	O	-1	9272404
adv@@	O	-1	9272404
ant@@	O	-1	9272404
age	O	-1	9272404
of	O	-1	9272404
this	O	-1	9272404
pain	B-Disease	D010146	9272404
model	O	-1	9272404
is	O	-1	9272404
the	O	-1	9272404
possib@@	O	-1	9272404
ility	O	-1	9272404
of	O	-1	9272404
obt@@	O	-1	9272404
aining	O	-1	9272404
peripheral	O	-1	9272404
pain	B-Disease	D010146	9272404
-@@	O	-1	9272404
related	O	-1	9272404
activity	O	-1	9272404
direc@@	O	-1	9272404
tly	O	-1	9272404
using	O	-1	9272404
a	O	-1	9272404
non-@@	O	-1	9272404
inv@@	O	-1	9272404
a@@	O	-1	9272404
sive	O	-1	9272404
t@@	O	-1	9272404
ech@@	O	-1	9272404
n@@	O	-1	9272404
i@@	O	-1	9272404
qu@@	O	-1	9272404
e	O	-1	9272404
in	O	-1	9272404
hum@@	O	-1	9272404
an@@	O	-1	9272404
s.	O	-1	9272404

Ac@@	O	-1	9323412
ute	O	-1	9323412
severe	O	-1	9323412
de@@	B-Disease	D003866	9323412
pression	I-Disease	-1	9323412
following	O	-1	9323412
peri@@	O	-1	9323412
-@@	O	-1	9323412
o@@	O	-1	9323412
perative	O	-1	9323412
ond@@	B-Chemical	D017294	9323412
an@@	I-Chemical	-1	9323412
se@@	I-Chemical	-1	9323412
tro@@	I-Chemical	-1	9323412
n	I-Chemical	-1	9323412
.	O	-1	9323412
A	O	-1	9323412
4@@	O	-1	9323412
1-@@	O	-1	9323412
year-old	O	-1	9323412
woman	O	-1	9323412
with	O	-1	9323412
a	O	-1	9323412
st@@	O	-1	9323412
ron@@	O	-1	9323412
g	O	-1	9323412
hist@@	O	-1	9323412
ory	O	-1	9323412
of	O	-1	9323412
postoperative	B-Disease	D020250	9323412
nausea	I-Disease	-1	9323412
and	I-Disease	-1	9323412
v@@	I-Disease	-1	9323412
om@@	I-Disease	-1	9323412
it@@	I-Disease	-1	9323412
ing	I-Disease	-1	9323412
presented	O	-1	9323412
for	O	-1	9323412
ab@@	O	-1	9323412
domin@@	O	-1	9323412
al	O	-1	9323412
hy@@	O	-1	9323412
ste@@	O	-1	9323412
rec@@	O	-1	9323412
to@@	O	-1	9323412
m@@	O	-1	9323412
y	O	-1	9323412
3	O	-1	9323412
months	O	-1	9323412
after	O	-1	9323412
a	O	-1	9323412
previ@@	O	-1	9323412
ous	O	-1	9323412
anaesthe@@	O	-1	9323412
tic	O	-1	9323412
wh@@	O	-1	9323412
ere	O	-1	9323412
ond@@	B-Chemical	D017294	9323412
an@@	I-Chemical	-1	9323412
se@@	I-Chemical	-1	9323412
tro@@	I-Chemical	-1	9323412
n	I-Chemical	-1	9323412
pro@@	O	-1	9323412
phyl@@	O	-1	9323412
ax@@	O	-1	9323412
is	O	-1	9323412
had	O	-1	9323412
been	O	-1	9323412
use@@	O	-1	9323412
d.	O	-1	9323412
S@@	O	-1	9323412
he	O	-1	9323412
had	O	-1	9323412
developed	O	-1	9323412
a	O	-1	9323412
severe	O	-1	9323412
acute	O	-1	9323412
major	B-Disease	D003865	9323412
de@@	I-Disease	-1	9323412
pression	I-Disease	-1	9323412
disor@@	I-Disease	-1	9323412
der	I-Disease	-1	9323412
al@@	O	-1	9323412
most	O	-1	9323412
immedi@@	O	-1	9323412
ately	O	-1	9323412
the@@	O	-1	9323412
re@@	O	-1	9323412
af@@	O	-1	9323412
ter@@	O	-1	9323412
,	O	-1	9323412
possib@@	O	-1	9323412
ly	O	-1	9323412
related	O	-1	9323412
to	O	-1	9323412
the	O	-1	9323412
use	O	-1	9323412
of	O	-1	9323412
a	O	-1	9323412
seroton@@	B-Chemical	D012701	9323412
in	I-Chemical	-1	9323412
antagonist@@	O	-1	9323412
.	O	-1	9323412
N@@	O	-1	9323412
ine	O	-1	9323412
years	O	-1	9323412
before	O	-1	9323412
sh@@	O	-1	9323412
e	O	-1	9323412
had	O	-1	9323412
experienced	O	-1	9323412
a	O	-1	9323412
sel@@	O	-1	9323412
f@@	O	-1	9323412
-@@	O	-1	9323412
lim@@	O	-1	9323412
ited	O	-1	9323412
pu@@	O	-1	9323412
er@@	O	-1	9323412
per@@	O	-1	9323412
al	O	-1	9323412
de@@	B-Disease	D003866	9323412
pressive	I-Disease	-1	9323412
episo@@	I-Disease	-1	9323412
de	I-Disease	-1	9323412
.	O	-1	9323412
An@@	O	-1	9323412
a@@	O	-1	9323412
esthe@@	O	-1	9323412
sia	O	-1	9323412
with	O	-1	9323412
a	O	-1	9323412
pro@@	B-Chemical	D015742	9323412
po@@	I-Chemical	-1	9323412
f@@	I-Chemical	-1	9323412
ol	I-Chemical	-1	9323412
infusion	O	-1	9323412
and	O	-1	9323412
avoid@@	O	-1	9323412
ance	O	-1	9323412
of	O	-1	9323412
seroton@@	B-Chemical	D012701	9323412
in	I-Chemical	-1	9323412
antagonist@@	O	-1	9323412
s	O	-1	9323412
pro@@	O	-1	9323412
vid@@	O	-1	9323412
ed	O	-1	9323412
a	O	-1	9323412
nausea	B-Disease	D009325	9323412
-@@	O	-1	9323412
free	O	-1	9323412
postoperative	O	-1	9323412
course	O	-1	9323412
without	O	-1	9323412
ex@@	O	-1	9323412
ac@@	O	-1	9323412
er@@	O	-1	9323412
b@@	O	-1	9323412
ation	O	-1	9323412
of	O	-1	9323412
the	O	-1	9323412
de@@	B-Disease	D003866	9323412
pression	I-Disease	-1	9323412
disor@@	I-Disease	-1	9323412
der	I-Disease	-1	9323412
.	O	-1	9323412

H@@	B-Disease	D006973	9382023
y@@	I-Disease	-1	9382023
per@@	I-Disease	-1	9382023
ten@@	I-Disease	-1	9382023
sive	I-Disease	-1	9382023
response	O	-1	9382023
during	O	-1	9382023
do@@	B-Chemical	D004280	9382023
but@@	I-Chemical	-1	9382023
amine	I-Chemical	-1	9382023
stres@@	O	-1	9382023
s	O	-1	9382023
echocardiograph@@	O	-1	9382023
y.	O	-1	9382023
A@@	O	-1	9382023
mon@@	O	-1	9382023
g	O	-1	9382023
3@@	O	-1	9382023
,@@	O	-1	9382023
12@@	O	-1	9382023
9	O	-1	9382023
do@@	B-Chemical	D004280	9382023
but@@	I-Chemical	-1	9382023
amine	I-Chemical	-1	9382023
stres@@	O	-1	9382023
s	O	-1	9382023
echocardiograph@@	O	-1	9382023
ic	O	-1	9382023
studi@@	O	-1	9382023
es,	O	-1	9382023
a	O	-1	9382023
hypertensive	B-Disease	D006973	9382023
respon@@	O	-1	9382023
se@@	O	-1	9382023
,	O	-1	9382023
def@@	O	-1	9382023
in@@	O	-1	9382023
ed	O	-1	9382023
as	O	-1	9382023
systolic	O	-1	9382023
blood	O	-1	9382023
pressure	O	-1	9382023
(B@@	O	-1	9382023
P)	O	-1	9382023
>	O	-1	9382023
or	O	-1	9382023
=	O	-1	9382023
2@@	O	-1	9382023
20	O	-1	9382023
mm	O	-1	9382023
H@@	O	-1	9382023
g	O	-1	9382023
and/or	O	-1	9382023
di@@	O	-1	9382023
ast@@	O	-1	9382023
olic	O	-1	9382023
B@@	O	-1	9382023
P	O	-1	9382023
>	O	-1	9382023
or	O	-1	9382023
=	O	-1	9382023
1@@	O	-1	9382023
10	O	-1	9382023
mm	O	-1	9382023
H@@	O	-1	9382023
g@@	O	-1	9382023
,	O	-1	9382023
occurred	O	-1	9382023
in	O	-1	9382023
30	O	-1	9382023
patients	O	-1	9382023
(1@@	O	-1	9382023
%).	O	-1	9382023
Patients	O	-1	9382023
with	O	-1	9382023
this	O	-1	9382023
response	O	-1	9382023
more	O	-1	9382023
often	O	-1	9382023
had	O	-1	9382023
a	O	-1	9382023
hist@@	O	-1	9382023
ory	O	-1	9382023
of	O	-1	9382023
hypertension	B-Disease	D006973	9382023
and	O	-1	9382023
had	O	-1	9382023
higher	O	-1	9382023
rest@@	O	-1	9382023
ing	O	-1	9382023
systolic	O	-1	9382023
and	O	-1	9382023
di@@	O	-1	9382023
ast@@	O	-1	9382023
olic	O	-1	9382023
B@@	O	-1	9382023
P	O	-1	9382023
before	O	-1	9382023
do@@	B-Chemical	D004280	9382023
but@@	I-Chemical	-1	9382023
amine	I-Chemical	-1	9382023
infu@@	O	-1	9382023
sion.	O	-1	9382023

C@@	O	-1	9428298
ont@@	O	-1	9428298
in@@	O	-1	9428298
u@@	O	-1	9428298
ously	O	-1	9428298
ne@@	O	-1	9428298
b@@	O	-1	9428298
ul@@	O	-1	9428298
ized	O	-1	9428298
al@@	B-Chemical	D000420	9428298
bu@@	I-Chemical	-1	9428298
ter@@	I-Chemical	-1	9428298
ol	I-Chemical	-1	9428298
in	O	-1	9428298
severe	O	-1	9428298
ex@@	O	-1	9428298
ac@@	O	-1	9428298
er@@	O	-1	9428298
b@@	O	-1	9428298
ations	O	-1	9428298
of	O	-1	9428298
as@@	B-Disease	D001249	9428298
th@@	I-Disease	-1	9428298
ma	I-Disease	-1	9428298
in	O	-1	9428298
ad@@	O	-1	9428298
ult@@	O	-1	9428298
s:	O	-1	9428298
a	O	-1	9428298
cas@@	O	-1	9428298
e-@@	O	-1	9428298
controlled	O	-1	9428298
study.	O	-1	9428298
A	O	-1	9428298
ret@@	O	-1	9428298
ro@@	O	-1	9428298
sp@@	O	-1	9428298
ecti@@	O	-1	9428298
ve,	O	-1	9428298
cas@@	O	-1	9428298
e-@@	O	-1	9428298
controlled	O	-1	9428298
analysis	O	-1	9428298
compar@@	O	-1	9428298
ing	O	-1	9428298
patients	O	-1	9428298
ad@@	O	-1	9428298
mit@@	O	-1	9428298
ted	O	-1	9428298
to	O	-1	9428298
a	O	-1	9428298
med@@	O	-1	9428298
ical	O	-1	9428298
int@@	O	-1	9428298
en@@	O	-1	9428298
sive	O	-1	9428298
car@@	O	-1	9428298
e	O	-1	9428298
un@@	O	-1	9428298
it	O	-1	9428298
with	O	-1	9428298
severe	O	-1	9428298
ex@@	O	-1	9428298
ac@@	O	-1	9428298
er@@	O	-1	9428298
b@@	O	-1	9428298
ations	O	-1	9428298
of	O	-1	9428298
as@@	B-Disease	D001249	9428298
th@@	I-Disease	-1	9428298
ma	I-Disease	-1	9428298
who	O	-1	9428298
received	O	-1	9428298
continu@@	O	-1	9428298
ously	O	-1	9428298
ne@@	O	-1	9428298
b@@	O	-1	9428298
ul@@	O	-1	9428298
ized	O	-1	9428298
al@@	B-Chemical	D000420	9428298
bu@@	I-Chemical	-1	9428298
ter@@	I-Chemical	-1	9428298
ol	I-Chemical	-1	9428298
(C@@	O	-1	9428298
N@@	O	-1	9428298
A@@	O	-1	9428298
)	O	-1	9428298
versus	O	-1	9428298
inter@@	O	-1	9428298
mit@@	O	-1	9428298
t@@	O	-1	9428298
ent	O	-1	9428298
al@@	B-Chemical	D000420	9428298
bu@@	I-Chemical	-1	9428298
ter@@	I-Chemical	-1	9428298
ol	I-Chemical	-1	9428298
(@@	O	-1	9428298
IN@@	O	-1	9428298
A@@	O	-1	9428298
)	O	-1	9428298
treat@@	O	-1	9428298
ments	O	-1	9428298
is	O	-1	9428298
repor@@	O	-1	9428298
ted.	O	-1	9428298
F@@	O	-1	9428298
ort@@	O	-1	9428298
y	O	-1	9428298
mat@@	O	-1	9428298
ch@@	O	-1	9428298
ed	O	-1	9428298
pa@@	O	-1	9428298
ir@@	O	-1	9428298
s	O	-1	9428298
of	O	-1	9428298
patients	O	-1	9428298
with	O	-1	9428298
as@@	B-Disease	D001249	9428298
th@@	I-Disease	-1	9428298
ma	I-Disease	-1	9428298
are	O	-1	9428298
com@@	O	-1	9428298
pa@@	O	-1	9428298
red.	O	-1	9428298
C@@	O	-1	9428298
NA	O	-1	9428298
was	O	-1	9428298
administered	O	-1	9428298
for	O	-1	9428298
a	O	-1	9428298
mean	O	-1	9428298
of	O	-1	9428298
11	O	-1	9428298
+/-	O	-1	9428298
10	O	-1	9428298
h@@	O	-1	9428298
r@@	O	-1	9428298
.	O	-1	9428298
The	O	-1	9428298
incidence	O	-1	9428298
of	O	-1	9428298
cardiac	B-Disease	D001145	9428298
dys@@	I-Disease	-1	9428298
rhyth@@	I-Disease	-1	9428298
mi@@	I-Disease	-1	9428298
as	I-Disease	-1	9428298
was	O	-1	9428298
similar	O	-1	9428298
between	O	-1	9428298
groups.	O	-1	9428298
S@@	O	-1	9428298
ym@@	O	-1	9428298
pto@@	O	-1	9428298
m@@	O	-1	9428298
atic	O	-1	9428298
hypo@@	B-Disease	D007008	9428298
k@@	I-Disease	-1	9428298
al@@	I-Disease	-1	9428298
emia	I-Disease	-1	9428298
did	O	-1	9428298
not	O	-1	9428298
occur@@	O	-1	9428298
.	O	-1	9428298
C@@	O	-1	9428298
NA	O	-1	9428298
patients	O	-1	9428298
had	O	-1	9428298
higher	O	-1	9428298
heart	O	-1	9428298
rat@@	O	-1	9428298
es	O	-1	9428298
during	O	-1	9428298
treatment,	O	-1	9428298
which	O	-1	9428298
may	O	-1	9428298
ref@@	O	-1	9428298
l@@	O	-1	9428298
ect	O	-1	9428298
severity	O	-1	9428298
of	O	-1	9428298
ill@@	O	-1	9428298
n@@	O	-1	9428298
es@@	O	-1	9428298
s.	O	-1	9428298
The	O	-1	9428298
incidence	O	-1	9428298
of	O	-1	9428298
int@@	O	-1	9428298
ub@@	O	-1	9428298
ation	O	-1	9428298
was	O	-1	9428298
simil@@	O	-1	9428298
ar@@	O	-1	9428298
.	O	-1	9428298
We	O	-1	9428298
concl@@	O	-1	9428298
ude	O	-1	9428298
that	O	-1	9428298
C@@	O	-1	9428298
NA	O	-1	9428298
and	O	-1	9428298
I@@	O	-1	9428298
NA	O	-1	9428298
demonstrated	O	-1	9428298
similar	O	-1	9428298
pro@@	O	-1	9428298
fi@@	O	-1	9428298
le@@	O	-1	9428298
s	O	-1	9428298
with	O	-1	9428298
reg@@	O	-1	9428298
ard	O	-1	9428298
to	O	-1	9428298
saf@@	O	-1	9428298
et@@	O	-1	9428298
y,	O	-1	9428298
mor@@	O	-1	9428298
b@@	O	-1	9428298
id@@	O	-1	9428298
ity,	O	-1	9428298
and	O	-1	9428298
mor@@	O	-1	9428298
t@@	O	-1	9428298
al@@	O	-1	9428298
ity.	O	-1	9428298

H@@	B-Disease	D006944	9538487
y@@	I-Disease	-1	9538487
per@@	I-Disease	-1	9538487
os@@	I-Disease	-1	9538487
mol@@	I-Disease	-1	9538487
ar	I-Disease	-1	9538487
non@@	I-Disease	-1	9538487
ke@@	I-Disease	-1	9538487
to@@	I-Disease	-1	9538487
tic	I-Disease	-1	9538487
com@@	I-Disease	-1	9538487
a	I-Disease	-1	9538487
pre@@	O	-1	9538487
ci@@	O	-1	9538487
pit@@	O	-1	9538487
ated	O	-1	9538487
by	O	-1	9538487
lithium	B-Chemical	D008094	9538487
-induced	O	-1	9538487
nephro@@	B-Disease	D018500	9538487
genic	I-Disease	-1	9538487
dia@@	I-Disease	-1	9538487
bet@@	I-Disease	-1	9538487
es	I-Disease	-1	9538487
in@@	I-Disease	-1	9538487
si@@	I-Disease	-1	9538487
pid@@	I-Disease	-1	9538487
us	I-Disease	-1	9538487
.	O	-1	9538487
A	O	-1	9538487
4@@	O	-1	9538487
5-@@	O	-1	9538487
year-old	O	-1	9538487
man@@	O	-1	9538487
,	O	-1	9538487
with	O	-1	9538487
a	O	-1	9538487
10-@@	O	-1	9538487
year	O	-1	9538487
hist@@	O	-1	9538487
ory	O	-1	9538487
of	O	-1	9538487
man@@	B-Disease	D001714	9538487
ic	I-Disease	-1	9538487
de@@	I-Disease	-1	9538487
pression	I-Disease	-1	9538487
treated	O	-1	9538487
with	O	-1	9538487
lithium	B-Chemical	D008094	9538487
,	O	-1	9538487
was	O	-1	9538487
ad@@	O	-1	9538487
mit@@	O	-1	9538487
ted	O	-1	9538487
with	O	-1	9538487
hyper@@	B-Disease	D006944	9538487
os@@	I-Disease	-1	9538487
mol@@	I-Disease	-1	9538487
ar@@	I-Disease	-1	9538487
,	I-Disease	-1	9538487
non@@	I-Disease	-1	9538487
ke@@	I-Disease	-1	9538487
to@@	I-Disease	-1	9538487
tic	I-Disease	-1	9538487
com@@	I-Disease	-1	9538487
a	I-Disease	-1	9538487
.	O	-1	9538487
H@@	O	-1	9538487
e	O	-1	9538487
g@@	O	-1	9538487
a@@	O	-1	9538487
ve	O	-1	9538487
a	O	-1	9538487
fi@@	O	-1	9538487
ve@@	O	-1	9538487
-@@	O	-1	9538487
year	O	-1	9538487
hist@@	O	-1	9538487
ory	O	-1	9538487
of	O	-1	9538487
poly@@	B-Disease	D011141	9538487
uria	I-Disease	-1	9538487
and	O	-1	9538487
poly@@	B-Disease	D059606	9538487
di@@	I-Disease	-1	9538487
p@@	I-Disease	-1	9538487
sia	I-Disease	-1	9538487
,	O	-1	9538487
during	O	-1	9538487
which	O	-1	9538487
time	O	-1	9538487
ur@@	O	-1	9538487
in@@	O	-1	9538487
aly@@	O	-1	9538487
sis	O	-1	9538487
had	O	-1	9538487
been	O	-1	9538487
negative	O	-1	9538487
for	O	-1	9538487
g@@	B-Chemical	D005947	9538487
lu@@	I-Chemical	-1	9538487
co@@	I-Chemical	-1	9538487
se	I-Chemical	-1	9538487
.	O	-1	9538487
After	O	-1	9538487
recovery	O	-1	9538487
from	O	-1	9538487
hyper@@	B-Disease	-1	9538487
gly@@	I-Disease	-1	9538487
ca@@	I-Disease	-1	9538487
emia	I-Disease	-1	9538487
,	O	-1	9538487
he	O	-1	9538487
remained	O	-1	9538487
poly@@	B-Disease	D011141	9538487
ur@@	I-Disease	-1	9538487
ic	I-Disease	-1	9538487
des@@	O	-1	9538487
pit@@	O	-1	9538487
e	O	-1	9538487
normal	O	-1	9538487
blood	O	-1	9538487
g@@	B-Chemical	D005947	9538487
lu@@	I-Chemical	-1	9538487
co@@	I-Chemical	-1	9538487
se	I-Chemical	-1	9538487
concentr@@	O	-1	9538487
ation@@	O	-1	9538487
s;	O	-1	9538487
w@@	O	-1	9538487
at@@	O	-1	9538487
er	O	-1	9538487
de@@	O	-1	9538487
pri@@	O	-1	9538487
v@@	O	-1	9538487
ation	O	-1	9538487
test@@	O	-1	9538487
ing	O	-1	9538487
indic@@	O	-1	9538487
ated	O	-1	9538487
nephro@@	B-Disease	D018500	9538487
genic	I-Disease	-1	9538487
dia@@	I-Disease	-1	9538487
bet@@	I-Disease	-1	9538487
es	I-Disease	-1	9538487
in@@	I-Disease	-1	9538487
si@@	I-Disease	-1	9538487
pid@@	I-Disease	-1	9538487
us	I-Disease	-1	9538487
,	O	-1	9538487
likely	O	-1	9538487
to	O	-1	9538487
be	O	-1	9538487
lithium	B-Chemical	D008094	9538487
-@@	O	-1	9538487
induc@@	O	-1	9538487
ed.	O	-1	9538487
We	O	-1	9538487
hypo@@	O	-1	9538487
the@@	O	-1	9538487
size	O	-1	9538487
that	O	-1	9538487
when	O	-1	9538487
this	O	-1	9538487
man	O	-1	9538487
developed	O	-1	9538487
type	B-Disease	D003924	9538487
2	I-Disease	-1	9538487
dia@@	I-Disease	-1	9538487
bet@@	I-Disease	-1	9538487
es	I-Disease	-1	9538487
,	O	-1	9538487
chronic	O	-1	9538487
poly@@	B-Disease	D011141	9538487
uria	I-Disease	-1	9538487
due	O	-1	9538487
to	O	-1	9538487
nephro@@	B-Disease	D018500	9538487
genic	I-Disease	-1	9538487
dia@@	I-Disease	-1	9538487
bet@@	I-Disease	-1	9538487
es	I-Disease	-1	9538487
in@@	I-Disease	-1	9538487
si@@	I-Disease	-1	9538487
pid@@	I-Disease	-1	9538487
us	I-Disease	-1	9538487
was	O	-1	9538487
suffici@@	O	-1	9538487
ent	O	-1	9538487
to	O	-1	9538487
pre@@	O	-1	9538487
ci@@	O	-1	9538487
pit@@	O	-1	9538487
ate	O	-1	9538487
hyper@@	O	-1	9538487
os@@	O	-1	9538487
mol@@	O	-1	9538487
ar	O	-1	9538487
de@@	B-Disease	D003681	9538487
hy@@	I-Disease	-1	9538487
d@@	I-Disease	-1	9538487
ration	I-Disease	-1	9538487
.	O	-1	9538487

Eff@@	O	-1	9570197
ects	O	-1	9570197
of	O	-1	9570197
the	O	-1	9570197
intrac@@	O	-1	9570197
or@@	O	-1	9570197
onary	O	-1	9570197
infusion	O	-1	9570197
of	O	-1	9570197
cocaine	B-Chemical	D003042	9570197
on	O	-1	9570197
left	O	-1	9570197
ventricular	O	-1	9570197
systolic	O	-1	9570197
and	O	-1	9570197
di@@	O	-1	9570197
ast@@	O	-1	9570197
olic	O	-1	9570197
function	O	-1	9570197
in	O	-1	9570197
hum@@	O	-1	9570197
an@@	O	-1	9570197
s.	O	-1	9570197
BACKGROUND:	O	-1	9570197
In	O	-1	9570197
dog@@	O	-1	9570197
s,	O	-1	9570197
a	O	-1	9570197
larg@@	O	-1	9570197
e	O	-1	9570197
amoun@@	O	-1	9570197
t	O	-1	9570197
of	O	-1	9570197
intravenous	O	-1	9570197
cocaine	B-Chemical	D003042	9570197
causes	O	-1	9570197
a	O	-1	9570197
pro@@	O	-1	9570197
found	O	-1	9570197
deter@@	B-Disease	D018487	9570197
i@@	I-Disease	-1	9570197
or@@	I-Disease	-1	9570197
ation	I-Disease	-1	9570197
of	I-Disease	-1	9570197
left	I-Disease	-1	9570197
ventricular	I-Disease	-1	9570197
(@@	I-Disease	-1	9570197
L@@	I-Disease	-1	9570197
V@@	I-Disease	-1	9570197
)	I-Disease	-1	9570197
systolic	I-Disease	-1	9570197
function	I-Disease	-1	9570197
and	O	-1	9570197
an	O	-1	9570197
increase	O	-1	9570197
in	O	-1	9570197
L@@	O	-1	9570197
V	O	-1	9570197
en@@	O	-1	9570197
d-@@	O	-1	9570197
di@@	O	-1	9570197
ast@@	O	-1	9570197
olic	O	-1	9570197
pressu@@	O	-1	9570197
re.	O	-1	9570197
This	O	-1	9570197
study	O	-1	9570197
was	O	-1	9570197
d@@	O	-1	9570197
one	O	-1	9570197
to	O	-1	9570197
ass@@	O	-1	9570197
ess	O	-1	9570197
the	O	-1	9570197
influence	O	-1	9570197
of	O	-1	9570197
a	O	-1	9570197
high	O	-1	9570197
intrac@@	O	-1	9570197
or@@	O	-1	9570197
onary	O	-1	9570197
cocaine	B-Chemical	D003042	9570197
concentration	O	-1	9570197
on	O	-1	9570197
L@@	O	-1	9570197
V	O	-1	9570197
systolic	O	-1	9570197
and	O	-1	9570197
di@@	O	-1	9570197
ast@@	O	-1	9570197
olic	O	-1	9570197
function	O	-1	9570197
in	O	-1	9570197
hum@@	O	-1	9570197
an@@	O	-1	9570197
s.	O	-1	9570197
METHOD@@	O	-1	9570197
S	O	-1	9570197
AN@@	O	-1	9570197
D	O	-1	9570197
RESULTS:	O	-1	9570197
In	O	-1	9570197
20	O	-1	9570197
patients	O	-1	9570197
(1@@	O	-1	9570197
4	O	-1	9570197
men	O	-1	9570197
and	O	-1	9570197
6	O	-1	9570197
women	O	-1	9570197
aged	O	-1	9570197
3@@	O	-1	9570197
9	O	-1	9570197
to	O	-1	9570197
7@@	O	-1	9570197
2	O	-1	9570197
year@@	O	-1	9570197
s)	O	-1	9570197
ref@@	O	-1	9570197
er@@	O	-1	9570197
red	O	-1	9570197
for	O	-1	9570197
cardiac	O	-1	9570197
ca@@	O	-1	9570197
the@@	O	-1	9570197
ter@@	O	-1	9570197
ization	O	-1	9570197
for	O	-1	9570197
the	O	-1	9570197
evalu@@	O	-1	9570197
ation	O	-1	9570197
of	O	-1	9570197
ch@@	B-Disease	D002637	9570197
est	I-Disease	-1	9570197
pain	I-Disease	-1	9570197
,	O	-1	9570197
we	O	-1	9570197
measured	O	-1	9570197
heart	O	-1	9570197
rat@@	O	-1	9570197
e,	O	-1	9570197
systemic	O	-1	9570197
arterial	O	-1	9570197
pressu@@	O	-1	9570197
re,	O	-1	9570197
L@@	O	-1	9570197
V	O	-1	9570197
pressure	O	-1	9570197
and	O	-1	9570197
its	O	-1	9570197
first	O	-1	9570197
der@@	O	-1	9570197
i@@	O	-1	9570197
v@@	O	-1	9570197
ative	O	-1	9570197
(@@	O	-1	9570197
d@@	O	-1	9570197
P@@	O	-1	9570197
/@@	O	-1	9570197
d@@	O	-1	9570197
t@@	O	-1	9570197
),	O	-1	9570197
and	O	-1	9570197
L@@	O	-1	9570197
V	O	-1	9570197
volum@@	O	-1	9570197
es	O	-1	9570197
and	O	-1	9570197
e@@	O	-1	9570197
j@@	O	-1	9570197
ection	O	-1	9570197
frac@@	O	-1	9570197
tion	O	-1	9570197
before	O	-1	9570197
and	O	-1	9570197
during	O	-1	9570197
the	O	-1	9570197
f@@	O	-1	9570197
inal	O	-1	9570197
2	O	-1	9570197
to	O	-1	9570197
3	O	-1	9570197
minutes	O	-1	9570197
of	O	-1	9570197
a	O	-1	9570197
1@@	O	-1	9570197
5-@@	O	-1	9570197
min@@	O	-1	9570197
ute	O	-1	9570197
intrac@@	O	-1	9570197
or@@	O	-1	9570197
onary	O	-1	9570197
infusion	O	-1	9570197
of	O	-1	9570197
saline	O	-1	9570197
(n@@	O	-1	9570197
=@@	O	-1	9570197
10@@	O	-1	9570197
,	O	-1	9570197
control	O	-1	9570197
subj@@	O	-1	9570197
ect@@	O	-1	9570197
s)	O	-1	9570197
or	O	-1	9570197
cocaine	B-Chemical	D003042	9570197
hydro@@	I-Chemical	-1	9570197
chlor@@	I-Chemical	-1	9570197
ide	I-Chemical	-1	9570197
1	O	-1	9570197
mg/@@	O	-1	9570197
min	O	-1	9570197
(n@@	O	-1	9570197
=@@	O	-1	9570197
10@@	O	-1	9570197
).	O	-1	9570197
No	O	-1	9570197
vari@@	O	-1	9570197
able	O	-1	9570197
chang@@	O	-1	9570197
ed	O	-1	9570197
with	O	-1	9570197
sal@@	O	-1	9570197
ine.	O	-1	9570197
W@@	O	-1	9570197
it@@	O	-1	9570197
h	O	-1	9570197
cocaine	B-Chemical	D003042	9570197
,	O	-1	9570197
the	O	-1	9570197
drug	O	-1	9570197
concentration	O	-1	9570197
in	O	-1	9570197
blood	O	-1	9570197
obtained	O	-1	9570197
from	O	-1	9570197
the	O	-1	9570197
coronary	O	-1	9570197
s@@	O	-1	9570197
in@@	O	-1	9570197
us	O	-1	9570197
was	O	-1	9570197
3.@@	O	-1	9570197
0@@	O	-1	9570197
+/-@@	O	-1	9570197
0.@@	O	-1	9570197
4	O	-1	9570197
(@@	O	-1	9570197
me@@	O	-1	9570197
an@@	O	-1	9570197
+/-@@	O	-1	9570197
S@@	O	-1	9570197
D)	O	-1	9570197
mg/@@	O	-1	9570197
L@@	O	-1	9570197
,	O	-1	9570197
similar	O	-1	9570197
in	O	-1	9570197
mag@@	O	-1	9570197
nit@@	O	-1	9570197
ude	O	-1	9570197
to	O	-1	9570197
the	O	-1	9570197
blood	O	-1	9570197
cocaine	B-Chemical	D003042	9570197
concentration	O	-1	9570197
reported	O	-1	9570197
in	O	-1	9570197
ab@@	O	-1	9570197
users	O	-1	9570197
dy@@	O	-1	9570197
ing	O	-1	9570197
of	O	-1	9570197
cocaine	B-Chemical	D003042	9570197
in@@	O	-1	9570197
toxic@@	O	-1	9570197
ation.	O	-1	9570197
C@@	B-Chemical	D003042	9570197
oc@@	I-Chemical	-1	9570197
aine	I-Chemical	-1	9570197
induced	O	-1	9570197
no	O	-1	9570197
significant	O	-1	9570197
change	O	-1	9570197
in	O	-1	9570197
heart	O	-1	9570197
rat@@	O	-1	9570197
e,	O	-1	9570197
L@@	O	-1	9570197
V	O	-1	9570197
d@@	O	-1	9570197
P@@	O	-1	9570197
/@@	O	-1	9570197
d@@	O	-1	9570197
t	O	-1	9570197
(@@	O	-1	9570197
positive	O	-1	9570197
or	O	-1	9570197
neg@@	O	-1	9570197
ati@@	O	-1	9570197
ve@@	O	-1	9570197
),	O	-1	9570197
or	O	-1	9570197
L@@	O	-1	9570197
V	O	-1	9570197
en@@	O	-1	9570197
d-@@	O	-1	9570197
di@@	O	-1	9570197
ast@@	O	-1	9570197
olic	O	-1	9570197
vol@@	O	-1	9570197
u@@	O	-1	9570197
me,	O	-1	9570197
but	O	-1	9570197
it	O	-1	9570197
caused	O	-1	9570197
an	O	-1	9570197
increase	O	-1	9570197
in	O	-1	9570197
systolic	O	-1	9570197
and	O	-1	9570197
mean	O	-1	9570197
arterial	O	-1	9570197
pressu@@	O	-1	9570197
res@@	O	-1	9570197
,	O	-1	9570197
L@@	O	-1	9570197
V	O	-1	9570197
en@@	O	-1	9570197
d-@@	O	-1	9570197
di@@	O	-1	9570197
ast@@	O	-1	9570197
olic	O	-1	9570197
pressu@@	O	-1	9570197
re,	O	-1	9570197
and	O	-1	9570197
L@@	O	-1	9570197
V	O	-1	9570197
en@@	O	-1	9570197
d-@@	O	-1	9570197
systolic	O	-1	9570197
vol@@	O	-1	9570197
u@@	O	-1	9570197
me,	O	-1	9570197
as	O	-1	9570197
well	O	-1	9570197
as	O	-1	9570197
a	O	-1	9570197
decrease	O	-1	9570197
in	O	-1	9570197
L@@	O	-1	9570197
V	O	-1	9570197
e@@	O	-1	9570197
j@@	O	-1	9570197
ection	O	-1	9570197
frac@@	O	-1	9570197
tion.	O	-1	9570197
CONCLUSIONS:	O	-1	9570197
In	O	-1	9570197
hum@@	O	-1	9570197
an@@	O	-1	9570197
s,	O	-1	9570197
the	O	-1	9570197
intrac@@	O	-1	9570197
or@@	O	-1	9570197
onary	O	-1	9570197
infusion	O	-1	9570197
of	O	-1	9570197
cocaine	B-Chemical	D003042	9570197
suffici@@	O	-1	9570197
ent	O	-1	9570197
in	O	-1	9570197
amoun@@	O	-1	9570197
t	O	-1	9570197
to	O	-1	9570197
achi@@	O	-1	9570197
e@@	O	-1	9570197
ve	O	-1	9570197
a	O	-1	9570197
high	O	-1	9570197
drug	O	-1	9570197
concentration	O	-1	9570197
in	O	-1	9570197
coronary	O	-1	9570197
s@@	O	-1	9570197
in@@	O	-1	9570197
us	O	-1	9570197
blood	O	-1	9570197
causes	O	-1	9570197
a	O	-1	9570197
deter@@	B-Disease	D018487	9570197
i@@	I-Disease	-1	9570197
or@@	I-Disease	-1	9570197
ation	I-Disease	-1	9570197
of	I-Disease	-1	9570197
L@@	I-Disease	-1	9570197
V	I-Disease	-1	9570197
systolic	I-Disease	-1	9570197
and	I-Disease	-1	9570197
di@@	I-Disease	-1	9570197
ast@@	I-Disease	-1	9570197
olic	I-Disease	-1	9570197
perform@@	I-Disease	-1	9570197
ance	I-Disease	-1	9570197
.	O	-1	9570197

He@@	B-Chemical	D006493	9646784
par@@	I-Chemical	-1	9646784
in	I-Chemical	-1	9646784
-induced	O	-1	9646784
throm@@	B-Disease	D013921	9646784
b@@	I-Disease	-1	9646784
ocyto@@	I-Disease	-1	9646784
pen@@	I-Disease	-1	9646784
ia	I-Disease	-1	9646784
,	O	-1	9646784
par@@	O	-1	9646784
ad@@	O	-1	9646784
ox@@	O	-1	9646784
ical	O	-1	9646784
thrombo@@	B-Disease	D013923	9646784
emb@@	I-Disease	-1	9646784
ol@@	I-Disease	-1	9646784
ism	I-Disease	-1	9646784
,	O	-1	9646784
and	O	-1	9646784
other	O	-1	9646784
side	O	-1	9646784
effects	O	-1	9646784
of	O	-1	9646784
hepar@@	B-Chemical	D006493	9646784
in	I-Chemical	-1	9646784
therapy.	O	-1	9646784
Although	O	-1	9646784
several	O	-1	9646784
new	O	-1	9646784
anti@@	O	-1	9646784
co@@	O	-1	9646784
ag@@	O	-1	9646784
ul@@	O	-1	9646784
ant	O	-1	9646784
drugs	O	-1	9646784
are	O	-1	9646784
in	O	-1	9646784
develop@@	O	-1	9646784
ment@@	O	-1	9646784
,	O	-1	9646784
hepar@@	B-Chemical	D006493	9646784
in	I-Chemical	-1	9646784
remain@@	O	-1	9646784
s	O	-1	9646784
the	O	-1	9646784
drug	O	-1	9646784
of	O	-1	9646784
ch@@	O	-1	9646784
o@@	O	-1	9646784
ic@@	O	-1	9646784
e	O	-1	9646784
for	O	-1	9646784
most	O	-1	9646784
anti@@	O	-1	9646784
co@@	O	-1	9646784
ag@@	O	-1	9646784
ulation	O	-1	9646784
ne@@	O	-1	9646784
ed@@	O	-1	9646784
s.	O	-1	9646784
The	O	-1	9646784
clinical	O	-1	9646784
effects	O	-1	9646784
of	O	-1	9646784
hepar@@	B-Chemical	D006493	9646784
in	I-Chemical	-1	9646784
are	O	-1	9646784
mer@@	O	-1	9646784
it@@	O	-1	9646784
or@@	O	-1	9646784
i@@	O	-1	9646784
ou@@	O	-1	9646784
s,	O	-1	9646784
but	O	-1	9646784
side	O	-1	9646784
effects	O	-1	9646784
d@@	O	-1	9646784
o	O	-1	9646784
ex@@	O	-1	9646784
ist@@	O	-1	9646784
.	O	-1	9646784
Im@@	O	-1	9646784
port@@	O	-1	9646784
ant	O	-1	9646784
un@@	O	-1	9646784
to@@	O	-1	9646784
war@@	O	-1	9646784
d	O	-1	9646784
effects	O	-1	9646784
of	O	-1	9646784
hepar@@	B-Chemical	D006493	9646784
in	I-Chemical	-1	9646784
therapy	O	-1	9646784
including	O	-1	9646784
hepar@@	B-Chemical	D006493	9646784
in	I-Chemical	-1	9646784
-induced	O	-1	9646784
throm@@	B-Disease	D013921	9646784
b@@	I-Disease	-1	9646784
ocyto@@	I-Disease	-1	9646784
pen@@	I-Disease	-1	9646784
ia	I-Disease	-1	9646784
,	O	-1	9646784
hepar@@	B-Chemical	D006493	9646784
in	I-Chemical	-1	9646784
-@@	O	-1	9646784
associated	O	-1	9646784
ost@@	B-Disease	D010024	9646784
e@@	I-Disease	-1	9646784
o@@	I-Disease	-1	9646784
po@@	I-Disease	-1	9646784
ro@@	I-Disease	-1	9646784
sis	I-Disease	-1	9646784
,	O	-1	9646784
e@@	B-Disease	D004802	9646784
os@@	I-Disease	-1	9646784
in@@	I-Disease	-1	9646784
oph@@	I-Disease	-1	9646784
il@@	I-Disease	-1	9646784
ia	I-Disease	-1	9646784
,	O	-1	9646784
s@@	B-Disease	D012871	9646784
k@@	I-Disease	-1	9646784
in	I-Disease	-1	9646784
reactions	I-Disease	-1	9646784
,	O	-1	9646784
all@@	B-Disease	D004342	9646784
ergic	I-Disease	-1	9646784
reactions	I-Disease	-1	9646784
other	O	-1	9646784
than	O	-1	9646784
throm@@	B-Disease	D013921	9646784
b@@	I-Disease	-1	9646784
ocyto@@	I-Disease	-1	9646784
pen@@	I-Disease	-1	9646784
ia	I-Disease	-1	9646784
and	O	-1	9646784
alo@@	B-Disease	D000505	9646784
p@@	I-Disease	-1	9646784
ec@@	I-Disease	-1	9646784
ia	I-Disease	-1	9646784
wil@@	O	-1	9646784
l	O	-1	9646784
be	O	-1	9646784
discus@@	O	-1	9646784
sed	O	-1	9646784
in	O	-1	9646784
this	O	-1	9646784
ar@@	O	-1	9646784
tic@@	O	-1	9646784
le@@	O	-1	9646784
.	O	-1	9646784

N@@	O	-1	9725303
on@@	O	-1	9725303
o@@	O	-1	9725303
pa@@	O	-1	9725303
qu@@	O	-1	9725303
e	O	-1	9725303
c@@	O	-1	9725303
r@@	O	-1	9725303
y@@	O	-1	9725303
st@@	O	-1	9725303
al	O	-1	9725303
de@@	O	-1	9725303
posi@@	O	-1	9725303
tion	O	-1	9725303
ca@@	O	-1	9725303
using	O	-1	9725303
ure@@	B-Disease	D014517	9725303
ter@@	I-Disease	-1	9725303
ic	I-Disease	-1	9725303
ob@@	I-Disease	-1	9725303
struc@@	I-Disease	-1	9725303
tion	I-Disease	-1	9725303
in	O	-1	9725303
patients	O	-1	9725303
with	O	-1	9725303
H@@	O	-1	9725303
IV	O	-1	9725303
under@@	O	-1	9725303
go@@	O	-1	9725303
ing	O	-1	9725303
ind@@	B-Chemical	D019469	9725303
in@@	I-Chemical	-1	9725303
avi@@	I-Chemical	-1	9725303
r	I-Chemical	-1	9725303
therapy.	O	-1	9725303
OBJECTIVE:	O	-1	9725303
We	O	-1	9725303
describe	O	-1	9725303
the	O	-1	9725303
un@@	O	-1	9725303
i@@	O	-1	9725303
qu@@	O	-1	9725303
e	O	-1	9725303
C@@	O	-1	9725303
T	O	-1	9725303
feat@@	O	-1	9725303
ures	O	-1	9725303
of	O	-1	9725303
ure@@	B-Disease	D014514	9725303
ter@@	I-Disease	-1	9725303
ic	I-Disease	-1	9725303
calc@@	I-Disease	-1	9725303
ul@@	I-Disease	-1	9725303
i	I-Disease	-1	9725303
in	O	-1	9725303
six	O	-1	9725303
H@@	B-Disease	D015658	9725303
I@@	I-Disease	-1	9725303
V@@	I-Disease	-1	9725303
-@@	I-Disease	-1	9725303
inf@@	I-Disease	-1	9725303
ected	I-Disease	-1	9725303
patients	O	-1	9725303
receiving	O	-1	9725303
ind@@	B-Chemical	D019469	9725303
in@@	I-Chemical	-1	9725303
avi@@	I-Chemical	-1	9725303
r	I-Chemical	-1	9725303
,	O	-1	9725303
the	O	-1	9725303
most	O	-1	9725303
common@@	O	-1	9725303
ly	O	-1	9725303
used	O	-1	9725303
H@@	O	-1	9725303
IV	O	-1	9725303
prote@@	O	-1	9725303
ase	O	-1	9725303
inhibitor@@	O	-1	9725303
,	O	-1	9725303
which	O	-1	9725303
is	O	-1	9725303
associated	O	-1	9725303
with	O	-1	9725303
an	O	-1	9725303
increased	O	-1	9725303
incidence	O	-1	9725303
of	O	-1	9725303
uro@@	B-Disease	D052878	9725303
li@@	I-Disease	-1	9725303
th@@	I-Disease	-1	9725303
ia@@	I-Disease	-1	9725303
sis	I-Disease	-1	9725303
.	O	-1	9725303
CONCLUSION:	O	-1	9725303
U@@	B-Disease	D014517	9725303
re@@	I-Disease	-1	9725303
ter@@	I-Disease	-1	9725303
ic	I-Disease	-1	9725303
ob@@	I-Disease	-1	9725303
struc@@	I-Disease	-1	9725303
tion	I-Disease	-1	9725303
caused	O	-1	9725303
by	O	-1	9725303
pre@@	O	-1	9725303
ci@@	O	-1	9725303
pit@@	O	-1	9725303
ated	O	-1	9725303
ind@@	B-Chemical	D019469	9725303
in@@	I-Chemical	-1	9725303
avi@@	I-Chemical	-1	9725303
r	I-Chemical	-1	9725303
c@@	O	-1	9725303
r@@	O	-1	9725303
y@@	O	-1	9725303
st@@	O	-1	9725303
als	O	-1	9725303
may	O	-1	9725303
be	O	-1	9725303
diff@@	O	-1	9725303
ic@@	O	-1	9725303
ult	O	-1	9725303
to	O	-1	9725303
diag@@	O	-1	9725303
n@@	O	-1	9725303
ose	O	-1	9725303
with	O	-1	9725303
un@@	O	-1	9725303
enhanced	O	-1	9725303
C@@	O	-1	9725303
T@@	O	-1	9725303
.	O	-1	9725303
The	O	-1	9725303
calc@@	O	-1	9725303
ul@@	O	-1	9725303
i	O	-1	9725303
are	O	-1	9725303
not	O	-1	9725303
o@@	O	-1	9725303
pa@@	O	-1	9725303
qu@@	O	-1	9725303
e,	O	-1	9725303
and	O	-1	9725303
secondary	O	-1	9725303
signs	O	-1	9725303
of	O	-1	9725303
ob@@	O	-1	9725303
struc@@	O	-1	9725303
tion	O	-1	9725303
may	O	-1	9725303
be	O	-1	9725303
abs@@	O	-1	9725303
ent	O	-1	9725303
or	O	-1	9725303
minim@@	O	-1	9725303
al	O	-1	9725303
and	O	-1	9725303
should	O	-1	9725303
be	O	-1	9725303
s@@	O	-1	9725303
ou@@	O	-1	9725303
ght	O	-1	9725303
ca@@	O	-1	9725303
ref@@	O	-1	9725303
ul@@	O	-1	9725303
ly.	O	-1	9725303
I@@	O	-1	9725303
mag@@	O	-1	9725303
es	O	-1	9725303
may	O	-1	9725303
need	O	-1	9725303
to	O	-1	9725303
be	O	-1	9725303
obtained	O	-1	9725303
using	O	-1	9725303
i.v@@	O	-1	9725303
.	O	-1	9725303
contr@@	O	-1	9725303
ast	O	-1	9725303
mat@@	O	-1	9725303
er@@	O	-1	9725303
ial	O	-1	9725303
to	O	-1	9725303
en@@	O	-1	9725303
able	O	-1	9725303
diagnosis	O	-1	9725303
of	O	-1	9725303
ure@@	B-Disease	D014514	9725303
ter@@	I-Disease	-1	9725303
ic	I-Disease	-1	9725303
ston@@	I-Disease	-1	9725303
es	I-Disease	-1	9725303
or	I-Disease	-1	9725303
ob@@	I-Disease	-1	9725303
struc@@	I-Disease	-1	9725303
tion	I-Disease	-1	9725303
ure@@	B-Disease	D014517	9725303
ter@@	I-Disease	-1	9725303
ic	I-Disease	-1	9725303
ston@@	I-Disease	-1	9725303
es	I-Disease	-1	9725303
or	I-Disease	-1	9725303
ob@@	I-Disease	-1	9725303
struc@@	I-Disease	-1	9725303
tion	I-Disease	-1	9725303
in	O	-1	9725303
patients	O	-1	9725303
with	O	-1	9725303
H@@	B-Disease	D015658	9725303
IV	I-Disease	-1	9725303
inf@@	I-Disease	-1	9725303
ection	I-Disease	-1	9725303
who	O	-1	9725303
recei@@	O	-1	9725303
ve	O	-1	9725303
ind@@	B-Chemical	D019469	9725303
in@@	I-Chemical	-1	9725303
avi@@	I-Chemical	-1	9725303
r	I-Chemical	-1	9725303
therapy.	O	-1	9725303

I@@	B-Disease	D017091	9759693
s@@	I-Disease	-1	9759693
chem@@	I-Disease	-1	9759693
ic	I-Disease	-1	9759693
co@@	I-Disease	-1	9759693
li@@	I-Disease	-1	9759693
tis	I-Disease	-1	9759693
and	O	-1	9759693
su@@	B-Chemical	D018170	9759693
mat@@	I-Chemical	-1	9759693
ript@@	I-Chemical	-1	9759693
an	I-Chemical	-1	9759693
use.	O	-1	9759693
S@@	B-Chemical	D018170	9759693
um@@	I-Chemical	-1	9759693
atri@@	I-Chemical	-1	9759693
pt@@	I-Chemical	-1	9759693
an	I-Chemical	-1	9759693
suc@@	I-Chemical	-1	9759693
cin@@	I-Chemical	-1	9759693
ate	I-Chemical	-1	9759693
,	O	-1	9759693
a	O	-1	9759693
seroton@@	B-Chemical	D012701	9759693
in	I-Chemical	-1	9759693
-1	O	-1	9759693
(	O	-1	9759693
5-@@	B-Chemical	D012701	9759693
hydrox@@	I-Chemical	-1	9759693
y@@	I-Chemical	-1	9759693
tr@@	I-Chemical	-1	9759693
y@@	I-Chemical	-1	9759693
pt@@	I-Chemical	-1	9759693
amine	I-Chemical	-1	9759693
-1@@	O	-1	9759693
)	O	-1	9759693
receptor	O	-1	9759693
agon@@	O	-1	9759693
ist@@	O	-1	9759693
,	O	-1	9759693
is	O	-1	9759693
an	O	-1	9759693
anti@@	O	-1	9759693
migra@@	O	-1	9759693
ine	O	-1	9759693
drug	O	-1	9759693
that	O	-1	9759693
is	O	-1	9759693
reported	O	-1	9759693
to	O	-1	9759693
ac@@	O	-1	9759693
t	O	-1	9759693
by	O	-1	9759693
sel@@	O	-1	9759693
ectively	O	-1	9759693
con@@	O	-1	9759693
stric@@	O	-1	9759693
ting	O	-1	9759693
intrac@@	O	-1	9759693
ranial	O	-1	9759693
arter@@	O	-1	9759693
i@@	O	-1	9759693
es.	O	-1	9759693
Rec@@	O	-1	9759693
ent@@	O	-1	9759693
ly,	O	-1	9759693
vas@@	O	-1	9759693
o@@	O	-1	9759693
press@@	O	-1	9759693
or	O	-1	9759693
responses	O	-1	9759693
that	O	-1	9759693
are	O	-1	9759693
dist@@	O	-1	9759693
inc@@	O	-1	9759693
t	O	-1	9759693
from	O	-1	9759693
the	O	-1	9759693
c@@	O	-1	9759693
ranial	O	-1	9759693
cir@@	O	-1	9759693
c@@	O	-1	9759693
ulation	O	-1	9759693
have	O	-1	9759693
been	O	-1	9759693
demonstrated	O	-1	9759693
to	O	-1	9759693
occ@@	O	-1	9759693
ur	O	-1	9759693
in	O	-1	9759693
the	O	-1	9759693
system@@	O	-1	9759693
ic@@	O	-1	9759693
,	O	-1	9759693
pul@@	O	-1	9759693
mon@@	O	-1	9759693
ar@@	O	-1	9759693
y,	O	-1	9759693
and	O	-1	9759693
coronary	O	-1	9759693
cir@@	O	-1	9759693
cul@@	O	-1	9759693
ations.	O	-1	9759693
C@@	O	-1	9759693
as@@	O	-1	9759693
es	O	-1	9759693
have	O	-1	9759693
been	O	-1	9759693
pu@@	O	-1	9759693
bl@@	O	-1	9759693
ished	O	-1	9759693
of	O	-1	9759693
coronary	B-Disease	D003329	9759693
vas@@	I-Disease	-1	9759693
os@@	I-Disease	-1	9759693
p@@	I-Disease	-1	9759693
as@@	I-Disease	-1	9759693
m	I-Disease	-1	9759693
,	O	-1	9759693
myocardial	B-Disease	D017202	9759693
ischem@@	I-Disease	-1	9759693
ia	I-Disease	-1	9759693
,	O	-1	9759693
and	O	-1	9759693
myocardial	B-Disease	D009203	9759693
infarction	I-Disease	-1	9759693
occur@@	O	-1	9759693
r@@	O	-1	9759693
ing	O	-1	9759693
after	O	-1	9759693
su@@	B-Chemical	D018170	9759693
mat@@	I-Chemical	-1	9759693
ript@@	I-Chemical	-1	9759693
an	I-Chemical	-1	9759693
use.	O	-1	9759693
We	O	-1	9759693
report	O	-1	9759693
on	O	-1	9759693
the	O	-1	9759693
development	O	-1	9759693
of	O	-1	9759693
8	O	-1	9759693
seri@@	O	-1	9759693
ous	O	-1	9759693
cases	O	-1	9759693
of	O	-1	9759693
ischem@@	B-Disease	D017091	9759693
ic	I-Disease	-1	9759693
co@@	I-Disease	-1	9759693
li@@	I-Disease	-1	9759693
tis	I-Disease	-1	9759693
in	O	-1	9759693
patients	O	-1	9759693
with	O	-1	9759693
migra@@	B-Disease	D008881	9759693
ine	I-Disease	-1	9759693
treated	O	-1	9759693
with	O	-1	9759693
su@@	B-Chemical	D018170	9759693
mat@@	I-Chemical	-1	9759693
ript@@	I-Chemical	-1	9759693
an	I-Chemical	-1	9759693
.	O	-1	9759693

P@@	O	-1	9782254
all@@	O	-1	9782254
id@@	O	-1	9782254
ot@@	O	-1	9782254
om@@	O	-1	9782254
y	O	-1	9782254
with	O	-1	9782254
the	O	-1	9782254
gam@@	O	-1	9782254
ma	O	-1	9782254
k@@	O	-1	9782254
n@@	O	-1	9782254
if@@	O	-1	9782254
e@@	O	-1	9782254
:	O	-1	9782254
a	O	-1	9782254
positive	O	-1	9782254
experi@@	O	-1	9782254
ence@@	O	-1	9782254
.	O	-1	9782254
5@@	O	-1	9782254
1	O	-1	9782254
patients	O	-1	9782254
with	O	-1	9782254
medic@@	O	-1	9782254
ally	O	-1	9782254
ref@@	O	-1	9782254
rac@@	O	-1	9782254
t@@	O	-1	9782254
ory	O	-1	9782254
Parkinson's	B-Disease	D010300	9782254
disease	I-Disease	-1	9782254
under@@	O	-1	9782254
w@@	O	-1	9782254
ent	O	-1	9782254
ste@@	O	-1	9782254
re@@	O	-1	9782254
ot@@	O	-1	9782254
ac@@	O	-1	9782254
tic	O	-1	9782254
po@@	O	-1	9782254
ster@@	O	-1	9782254
o@@	O	-1	9782254
medi@@	O	-1	9782254
al	O	-1	9782254
p@@	O	-1	9782254
all@@	O	-1	9782254
id@@	O	-1	9782254
ot@@	O	-1	9782254
om@@	O	-1	9782254
y	O	-1	9782254
between	O	-1	9782254
A@@	O	-1	9782254
u@@	O	-1	9782254
g@@	O	-1	9782254
us@@	O	-1	9782254
t	O	-1	9782254
19@@	O	-1	9782254
9@@	O	-1	9782254
3	O	-1	9782254
and	O	-1	9782254
F@@	O	-1	9782254
e@@	O	-1	9782254
b@@	O	-1	9782254
ru@@	O	-1	9782254
ary	O	-1	9782254
19@@	O	-1	9782254
9@@	O	-1	9782254
7	O	-1	9782254
for	O	-1	9782254
treatment	O	-1	9782254
of	O	-1	9782254
brady@@	B-Disease	D018476	9782254
kine@@	I-Disease	-1	9782254
sia	I-Disease	-1	9782254
,	O	-1	9782254
rig@@	B-Disease	D009127	9782254
idity	I-Disease	-1	9782254
,	O	-1	9782254
and	O	-1	9782254
L-@@	B-Chemical	D007980	9782254
DO@@	I-Chemical	-1	9782254
P@@	I-Chemical	-1	9782254
A	I-Chemical	-1	9782254
-induced	O	-1	9782254
dyskine@@	B-Disease	D004409	9782254
si@@	I-Disease	-1	9782254
as	I-Disease	-1	9782254
.	O	-1	9782254
In	O	-1	9782254
2@@	O	-1	9782254
9	O	-1	9782254
patients,	O	-1	9782254
the	O	-1	9782254
p@@	O	-1	9782254
all@@	O	-1	9782254
id@@	O	-1	9782254
ot@@	O	-1	9782254
om@@	O	-1	9782254
i@@	O	-1	9782254
es	O	-1	9782254
were	O	-1	9782254
performed	O	-1	9782254
with	O	-1	9782254
the	O	-1	9782254
L@@	O	-1	9782254
e@@	O	-1	9782254
k@@	O	-1	9782254
se@@	O	-1	9782254
ll	O	-1	9782254
G@@	O	-1	9782254
am@@	O	-1	9782254
ma	O	-1	9782254
K@@	O	-1	9782254
n@@	O	-1	9782254
if@@	O	-1	9782254
e	O	-1	9782254
and	O	-1	9782254
in	O	-1	9782254
2@@	O	-1	9782254
2	O	-1	9782254
they	O	-1	9782254
were	O	-1	9782254
performed	O	-1	9782254
with	O	-1	9782254
the	O	-1	9782254
standard	O	-1	9782254
radi@@	O	-1	9782254
o@@	O	-1	9782254
frequency	O	-1	9782254
(@@	O	-1	9782254
R@@	O	-1	9782254
F@@	O	-1	9782254
)	O	-1	9782254
meth@@	O	-1	9782254
o@@	O	-1	9782254
d.	O	-1	9782254
Clin@@	O	-1	9782254
ical	O	-1	9782254
assess@@	O	-1	9782254
ment	O	-1	9782254
as	O	-1	9782254
well	O	-1	9782254
as	O	-1	9782254
bl@@	O	-1	9782254
ind@@	O	-1	9782254
ed	O	-1	9782254
rat@@	O	-1	9782254
ings	O	-1	9782254
of	O	-1	9782254
U@@	O	-1	9782254
n@@	O	-1	9782254
if@@	O	-1	9782254
ied	O	-1	9782254
Parkinson's	B-Disease	D010300	9782254
Di@@	I-Disease	-1	9782254
se@@	I-Disease	-1	9782254
ase	I-Disease	-1	9782254
R@@	O	-1	9782254
ating	O	-1	9782254
S@@	O	-1	9782254
cal@@	O	-1	9782254
e	O	-1	9782254
(@@	O	-1	9782254
U@@	O	-1	9782254
P@@	O	-1	9782254
D@@	O	-1	9782254
R@@	O	-1	9782254
S)	O	-1	9782254
sco@@	O	-1	9782254
res	O	-1	9782254
were	O	-1	9782254
car@@	O	-1	9782254
ri@@	O	-1	9782254
ed	O	-1	9782254
out	O	-1	9782254
pre@@	O	-1	9782254
-	O	-1	9782254
and	O	-1	9782254
posto@@	O	-1	9782254
per@@	O	-1	9782254
ati@@	O	-1	9782254
vel@@	O	-1	9782254
y.	O	-1	9782254
M@@	O	-1	9782254
e@@	O	-1	9782254
an	O	-1	9782254
follow-up	O	-1	9782254
time	O	-1	9782254
is	O	-1	9782254
2@@	O	-1	9782254
0.@@	O	-1	9782254
6	O	-1	9782254
months	O	-1	9782254
(@@	O	-1	9782254
range	O	-1	9782254
6-@@	O	-1	9782254
4@@	O	-1	9782254
8@@	O	-1	9782254
)	O	-1	9782254
and	O	-1	9782254
all	O	-1	9782254
ex@@	O	-1	9782254
cep@@	O	-1	9782254
t	O	-1	9782254
4	O	-1	9782254
patients	O	-1	9782254
have	O	-1	9782254
been	O	-1	9782254
followed	O	-1	9782254
more	O	-1	9782254
than	O	-1	9782254
one	O	-1	9782254
year@@	O	-1	9782254
.	O	-1	9782254
8@@	O	-1	9782254
5	O	-1	9782254
perc@@	O	-1	9782254
ent	O	-1	9782254
of	O	-1	9782254
patients	O	-1	9782254
with	O	-1	9782254
dyskine@@	B-Disease	D004409	9782254
si@@	I-Disease	-1	9782254
as	I-Disease	-1	9782254
were	O	-1	9782254
re@@	O	-1	9782254
li@@	O	-1	9782254
ev@@	O	-1	9782254
ed	O	-1	9782254
of	O	-1	9782254
symptom@@	O	-1	9782254
s,	O	-1	9782254
reg@@	O	-1	9782254
ar@@	O	-1	9782254
d@@	O	-1	9782254
less	O	-1	9782254
of	O	-1	9782254
whether	O	-1	9782254
the	O	-1	9782254
p@@	O	-1	9782254
all@@	O	-1	9782254
id@@	O	-1	9782254
ot@@	O	-1	9782254
om@@	O	-1	9782254
i@@	O	-1	9782254
es	O	-1	9782254
were	O	-1	9782254
performed	O	-1	9782254
with	O	-1	9782254
the	O	-1	9782254
G@@	O	-1	9782254
am@@	O	-1	9782254
ma	O	-1	9782254
K@@	O	-1	9782254
n@@	O	-1	9782254
if@@	O	-1	9782254
e	O	-1	9782254
or	O	-1	9782254
radi@@	O	-1	9782254
o@@	O	-1	9782254
frequency	O	-1	9782254
meth@@	O	-1	9782254
o@@	O	-1	9782254
d@@	O	-1	9782254
s.	O	-1	9782254
A@@	O	-1	9782254
b@@	O	-1	9782254
out	O	-1	9782254
2@@	O	-1	9782254
/@@	O	-1	9782254
3	O	-1	9782254
of	O	-1	9782254
the	O	-1	9782254
patients	O	-1	9782254
in	O	-1	9782254
both	O	-1	9782254
G@@	O	-1	9782254
am@@	O	-1	9782254
ma	O	-1	9782254
K@@	O	-1	9782254
n@@	O	-1	9782254
if@@	O	-1	9782254
e	O	-1	9782254
and	O	-1	9782254
radi@@	O	-1	9782254
o@@	O	-1	9782254
frequency	O	-1	9782254
groups	O	-1	9782254
showed	O	-1	9782254
impro@@	O	-1	9782254
ve@@	O	-1	9782254
ments	O	-1	9782254
in	O	-1	9782254
brady@@	B-Disease	D018476	9782254
kine@@	I-Disease	-1	9782254
sia	I-Disease	-1	9782254
and	O	-1	9782254
rig@@	B-Disease	D009127	9782254
idity	I-Disease	-1	9782254
,	O	-1	9782254
although	O	-1	9782254
when	O	-1	9782254
considered	O	-1	9782254
as	O	-1	9782254
a	O	-1	9782254
group	O	-1	9782254
ne@@	O	-1	9782254
ither	O	-1	9782254
the	O	-1	9782254
G@@	O	-1	9782254
am@@	O	-1	9782254
ma	O	-1	9782254
K@@	O	-1	9782254
n@@	O	-1	9782254
if@@	O	-1	9782254
e	O	-1	9782254
n@@	O	-1	9782254
or	O	-1	9782254
the	O	-1	9782254
radi@@	O	-1	9782254
o@@	O	-1	9782254
frequency	O	-1	9782254
group	O	-1	9782254
showed	O	-1	9782254
statis@@	O	-1	9782254
tically	O	-1	9782254
significant	O	-1	9782254
impro@@	O	-1	9782254
ve@@	O	-1	9782254
ments	O	-1	9782254
in	O	-1	9782254
U@@	O	-1	9782254
P@@	O	-1	9782254
D@@	O	-1	9782254
R@@	O	-1	9782254
S	O	-1	9782254
sco@@	O	-1	9782254
res@@	O	-1	9782254
.	O	-1	9782254
One	O	-1	9782254
patient	O	-1	9782254
in	O	-1	9782254
the	O	-1	9782254
G@@	O	-1	9782254
am@@	O	-1	9782254
ma	O	-1	9782254
K@@	O	-1	9782254
n@@	O	-1	9782254
if@@	O	-1	9782254
e	O	-1	9782254
group	O	-1	9782254
(@@	O	-1	9782254
3.@@	O	-1	9782254
4@@	O	-1	9782254
%)	O	-1	9782254
developed	O	-1	9782254
a	O	-1	9782254
ho@@	B-Disease	D006423	9782254
mon@@	I-Disease	-1	9782254
ym@@	I-Disease	-1	9782254
ous	I-Disease	-1	9782254
he@@	I-Disease	-1	9782254
mi@@	I-Disease	-1	9782254
an@@	I-Disease	-1	9782254
op@@	I-Disease	-1	9782254
sia	I-Disease	-1	9782254
9	O	-1	9782254
months	O	-1	9782254
following	O	-1	9782254
treatment	O	-1	9782254
and	O	-1	9782254
5	O	-1	9782254
patients	O	-1	9782254
(2@@	O	-1	9782254
7.@@	O	-1	9782254
7@@	O	-1	9782254
%)	O	-1	9782254
in	O	-1	9782254
the	O	-1	9782254
radi@@	O	-1	9782254
o@@	O	-1	9782254
frequency	O	-1	9782254
group	O	-1	9782254
b@@	O	-1	9782254
ec@@	O	-1	9782254
am@@	O	-1	9782254
e	O	-1	9782254
transi@@	O	-1	9782254
ently	O	-1	9782254
conf@@	O	-1	9782254
used	O	-1	9782254
posto@@	O	-1	9782254
per@@	O	-1	9782254
ati@@	O	-1	9782254
vel@@	O	-1	9782254
y.	O	-1	9782254
No	O	-1	9782254
other	O	-1	9782254
complications	O	-1	9782254
were	O	-1	9782254
se@@	O	-1	9782254
en@@	O	-1	9782254
.	O	-1	9782254
G@@	O	-1	9782254
am@@	O	-1	9782254
ma	O	-1	9782254
K@@	O	-1	9782254
n@@	O	-1	9782254
if@@	O	-1	9782254
e	O	-1	9782254
p@@	O	-1	9782254
all@@	O	-1	9782254
id@@	O	-1	9782254
ot@@	O	-1	9782254
om@@	O	-1	9782254
y	O	-1	9782254
is	O	-1	9782254
as	O	-1	9782254
effective	O	-1	9782254
as	O	-1	9782254
radi@@	O	-1	9782254
o@@	O	-1	9782254
frequency	O	-1	9782254
p@@	O	-1	9782254
all@@	O	-1	9782254
id@@	O	-1	9782254
ot@@	O	-1	9782254
om@@	O	-1	9782254
y	O	-1	9782254
in	O	-1	9782254
contro@@	O	-1	9782254
ll@@	O	-1	9782254
ing	O	-1	9782254
cer@@	O	-1	9782254
t@@	O	-1	9782254
ain	O	-1	9782254
of	O	-1	9782254
the	O	-1	9782254
symptoms	O	-1	9782254
of	O	-1	9782254
Parkinson's	B-Disease	D010300	9782254
disease	I-Disease	-1	9782254
.	O	-1	9782254
It	O	-1	9782254
may	O	-1	9782254
be	O	-1	9782254
the	O	-1	9782254
only	O	-1	9782254
p@@	O	-1	9782254
rac@@	O	-1	9782254
tical	O	-1	9782254
t@@	O	-1	9782254
ech@@	O	-1	9782254
n@@	O	-1	9782254
i@@	O	-1	9782254
qu@@	O	-1	9782254
e	O	-1	9782254
av@@	O	-1	9782254
ail@@	O	-1	9782254
able	O	-1	9782254
in	O	-1	9782254
cer@@	O	-1	9782254
t@@	O	-1	9782254
ain	O	-1	9782254
patients,	O	-1	9782254
such	O	-1	9782254
as	O	-1	9782254
those	O	-1	9782254
who	O	-1	9782254
tak@@	O	-1	9782254
e	O	-1	9782254
anti@@	O	-1	9782254
co@@	O	-1	9782254
ag@@	O	-1	9782254
ul@@	O	-1	9782254
ant@@	O	-1	9782254
s,	O	-1	9782254
have	O	-1	9782254
ble@@	B-Disease	D006470	9782254
ed@@	I-Disease	-1	9782254
ing	I-Disease	-1	9782254
dia@@	O	-1	9782254
th@@	O	-1	9782254
es@@	O	-1	9782254
es	O	-1	9782254
or	O	-1	9782254
seri@@	O	-1	9782254
ous	O	-1	9782254
systemic	O	-1	9782254
med@@	O	-1	9782254
ical	O	-1	9782254
ill@@	O	-1	9782254
n@@	O	-1	9782254
ess@@	O	-1	9782254
es.	O	-1	9782254
It	O	-1	9782254
is	O	-1	9782254
a	O	-1	9782254
vi@@	O	-1	9782254
able	O	-1	9782254
op@@	O	-1	9782254
tion	O	-1	9782254
for	O	-1	9782254
other	O	-1	9782254
patients	O	-1	9782254
as	O	-1	9782254
we@@	O	-1	9782254
ll@@	O	-1	9782254
.	O	-1	9782254

Ne@@	B-Disease	D009459	9831002
uro@@	I-Disease	-1	9831002
le@@	I-Disease	-1	9831002
p@@	I-Disease	-1	9831002
tic	I-Disease	-1	9831002
mal@@	I-Disease	-1	9831002
i@@	I-Disease	-1	9831002
gn@@	I-Disease	-1	9831002
ant	I-Disease	-1	9831002
syndrome	I-Disease	-1	9831002
and	O	-1	9831002
methyl@@	B-Chemical	D008774	9831002
phen@@	I-Chemical	-1	9831002
id@@	I-Chemical	-1	9831002
ate	I-Chemical	-1	9831002
.	O	-1	9831002
A	O	-1	9831002
1-@@	O	-1	9831002
year-old	O	-1	9831002
female	O	-1	9831002
presented	O	-1	9831002
with	O	-1	9831002
neuro@@	B-Disease	D009459	9831002
le@@	I-Disease	-1	9831002
p@@	I-Disease	-1	9831002
tic	I-Disease	-1	9831002
mal@@	I-Disease	-1	9831002
i@@	I-Disease	-1	9831002
gn@@	I-Disease	-1	9831002
ant	I-Disease	-1	9831002
syndrome	I-Disease	-1	9831002
prob@@	O	-1	9831002
ably	O	-1	9831002
caused	O	-1	9831002
by	O	-1	9831002
methyl@@	B-Chemical	D008774	9831002
phen@@	I-Chemical	-1	9831002
id@@	I-Chemical	-1	9831002
ate	I-Chemical	-1	9831002
.	O	-1	9831002
S@@	O	-1	9831002
he	O	-1	9831002
had	O	-1	9831002
def@@	O	-1	9831002
ects	O	-1	9831002
in	O	-1	9831002
the	O	-1	9831002
sup@@	O	-1	9831002
rat@@	O	-1	9831002
ent@@	O	-1	9831002
or@@	O	-1	9831002
ial	O	-1	9831002
brain	O	-1	9831002
including	O	-1	9831002
the	O	-1	9831002
bas@@	O	-1	9831002
al	O	-1	9831002
g@@	O	-1	9831002
ang@@	O	-1	9831002
li@@	O	-1	9831002
a	O	-1	9831002
and	O	-1	9831002
the	O	-1	9831002
striat@@	O	-1	9831002
um	O	-1	9831002
(	O	-1	9831002
mul@@	B-Disease	D004678	9831002
tic@@	I-Disease	-1	9831002
ys@@	I-Disease	-1	9831002
tic	I-Disease	-1	9831002
encephal@@	I-Disease	-1	9831002
om@@	I-Disease	-1	9831002
al@@	I-Disease	-1	9831002
ac@@	I-Disease	-1	9831002
ia	I-Disease	-1	9831002
)	O	-1	9831002
due	O	-1	9831002
to	O	-1	9831002
severe	O	-1	9831002
per@@	O	-1	9831002
in@@	O	-1	9831002
atal	O	-1	9831002
hypo@@	B-Disease	D020925	9831002
x@@	I-Disease	-1	9831002
ic@@	I-Disease	-1	9831002
-@@	I-Disease	-1	9831002
ischem@@	I-Disease	-1	9831002
ic	I-Disease	-1	9831002
encephalo@@	I-Disease	-1	9831002
pathy	I-Disease	-1	9831002
,	O	-1	9831002
which	O	-1	9831002
was	O	-1	9831002
considered	O	-1	9831002
to	O	-1	9831002
be	O	-1	9831002
a	O	-1	9831002
possible	O	-1	9831002
pre@@	O	-1	9831002
dis@@	O	-1	9831002
pos@@	O	-1	9831002
ing	O	-1	9831002
factor	O	-1	9831002
ca@@	O	-1	9831002
using	O	-1	9831002
neuro@@	B-Disease	D009459	9831002
le@@	I-Disease	-1	9831002
p@@	I-Disease	-1	9831002
tic	I-Disease	-1	9831002
mal@@	I-Disease	-1	9831002
i@@	I-Disease	-1	9831002
gn@@	I-Disease	-1	9831002
ant	I-Disease	-1	9831002
syndrome	I-Disease	-1	9831002
.	O	-1	9831002
A	O	-1	9831002
dop@@	O	-1	9831002
aminergic	O	-1	9831002
block@@	O	-1	9831002
ade	O	-1	9831002
mechanism	O	-1	9831002
gener@@	O	-1	9831002
ally	O	-1	9831002
is	O	-1	9831002
ac@@	O	-1	9831002
ce@@	O	-1	9831002
pt@@	O	-1	9831002
ed	O	-1	9831002
as	O	-1	9831002
the	O	-1	9831002
path@@	O	-1	9831002
o@@	O	-1	9831002
genesis	O	-1	9831002
of	O	-1	9831002
this	O	-1	9831002
syndro@@	O	-1	9831002
me.	O	-1	9831002
However,	O	-1	9831002
methyl@@	B-Chemical	D008774	9831002
phen@@	I-Chemical	-1	9831002
id@@	I-Chemical	-1	9831002
ate	I-Chemical	-1	9831002
is	O	-1	9831002
a	O	-1	9831002
dopamine	B-Chemical	D004298	9831002
agon@@	O	-1	9831002
ist	O	-1	9831002
vi@@	O	-1	9831002
a	O	-1	9831002
the	O	-1	9831002
inhibition	O	-1	9831002
of	O	-1	9831002
u@@	O	-1	9831002
pt@@	O	-1	9831002
ake	O	-1	9831002
of	O	-1	9831002
dopamine	B-Chemical	D004298	9831002
,	O	-1	9831002
and	O	-1	9831002
the@@	O	-1	9831002
re@@	O	-1	9831002
fore	O	-1	9831002
dop@@	O	-1	9831002
aminergic	O	-1	9831002
system@@	O	-1	9831002
s	O	-1	9831002
in	O	-1	9831002
the	O	-1	9831002
bra@@	O	-1	9831002
in@@	O	-1	9831002
st@@	O	-1	9831002
em	O	-1	9831002
(@@	O	-1	9831002
main@@	O	-1	9831002
ly	O	-1	9831002
the	O	-1	9831002
mid@@	O	-1	9831002
bra@@	O	-1	9831002
in@@	O	-1	9831002
)	O	-1	9831002
and	O	-1	9831002
the	O	-1	9831002
spinal	O	-1	9831002
cor@@	O	-1	9831002
d	O	-1	9831002
were	O	-1	9831002
un@@	O	-1	9831002
likely	O	-1	9831002
to	O	-1	9831002
partic@@	O	-1	9831002
ip@@	O	-1	9831002
ate	O	-1	9831002
in	O	-1	9831002
the	O	-1	9831002
onset	O	-1	9831002
of	O	-1	9831002
this	O	-1	9831002
syndro@@	O	-1	9831002
me.	O	-1	9831002
A	O	-1	9831002
rel@@	O	-1	9831002
ative	O	-1	9831002
gamma@@	B-Chemical	D005680	9831002
-@@	I-Chemical	-1	9831002
amin@@	I-Chemical	-1	9831002
ob@@	I-Chemical	-1	9831002
ut@@	I-Chemical	-1	9831002
y@@	I-Chemical	-1	9831002
ric	I-Chemical	-1	9831002
acid	I-Chemical	-1	9831002
-@@	O	-1	9831002
ergic	O	-1	9831002
defici@@	O	-1	9831002
ency	O	-1	9831002
might	O	-1	9831002
occ@@	O	-1	9831002
ur	O	-1	9831002
because	O	-1	9831002
di@@	B-Chemical	D003975	9831002
az@@	I-Chemical	-1	9831002
epam	I-Chemical	-1	9831002
,	O	-1	9831002
a	O	-1	9831002
gamma@@	B-Chemical	D005680	9831002
-@@	I-Chemical	-1	9831002
amin@@	I-Chemical	-1	9831002
ob@@	I-Chemical	-1	9831002
ut@@	I-Chemical	-1	9831002
y@@	I-Chemical	-1	9831002
ric	I-Chemical	-1	9831002
acid	I-Chemical	-1	9831002
-@@	O	-1	9831002
mi@@	O	-1	9831002
me@@	O	-1	9831002
tic	O	-1	9831002
agent@@	O	-1	9831002
,	O	-1	9831002
was	O	-1	9831002
stri@@	O	-1	9831002
k@@	O	-1	9831002
ing@@	O	-1	9831002
ly	O	-1	9831002
eff@@	O	-1	9831002
ecti@@	O	-1	9831002
ve.	O	-1	9831002
This	O	-1	9831002
is	O	-1	9831002
the	O	-1	9831002
first	O	-1	9831002
reported	O	-1	9831002
patient	O	-1	9831002
with	O	-1	9831002
neuro@@	B-Disease	D009459	9831002
le@@	I-Disease	-1	9831002
p@@	I-Disease	-1	9831002
tic	I-Disease	-1	9831002
mal@@	I-Disease	-1	9831002
i@@	I-Disease	-1	9831002
gn@@	I-Disease	-1	9831002
ant	I-Disease	-1	9831002
syndrome	I-Disease	-1	9831002
prob@@	O	-1	9831002
ably	O	-1	9831002
caused	O	-1	9831002
by	O	-1	9831002
methyl@@	B-Chemical	D008774	9831002
phen@@	I-Chemical	-1	9831002
id@@	I-Chemical	-1	9831002
ate	I-Chemical	-1	9831002
.	O	-1	9831002

Di@@	O	-1	9869655
fferen@@	O	-1	9869655
tial	O	-1	9869655
effects	O	-1	9869655
of	O	-1	9869655
17@@	B-Chemical	D004997	9869655
alpha-@@	I-Chemical	-1	9869655
eth@@	I-Chemical	-1	9869655
in@@	I-Chemical	-1	9869655
y@@	I-Chemical	-1	9869655
le@@	I-Chemical	-1	9869655
st@@	I-Chemical	-1	9869655
radi@@	I-Chemical	-1	9869655
ol	I-Chemical	-1	9869655
on	O	-1	9869655
the	O	-1	9869655
ne@@	O	-1	9869655
ut@@	O	-1	9869655
ral	O	-1	9869655
and	O	-1	9869655
ac@@	O	-1	9869655
i@@	O	-1	9869655
di@@	O	-1	9869655
c	O	-1	9869655
path@@	O	-1	9869655
w@@	O	-1	9869655
ays	O	-1	9869655
of	O	-1	9869655
b@@	B-Chemical	D001647	9869655
ile	I-Chemical	-1	9869655
sal@@	I-Chemical	-1	9869655
t	I-Chemical	-1	9869655
syn@@	O	-1	9869655
thesis	O	-1	9869655
in	O	-1	9869655
the	O	-1	9869655
rat@@	O	-1	9869655
.	O	-1	9869655
Eff@@	O	-1	9869655
ects	O	-1	9869655
of	O	-1	9869655
17@@	B-Chemical	D004997	9869655
alpha-@@	I-Chemical	-1	9869655
eth@@	I-Chemical	-1	9869655
in@@	I-Chemical	-1	9869655
y@@	I-Chemical	-1	9869655
le@@	I-Chemical	-1	9869655
st@@	I-Chemical	-1	9869655
radi@@	I-Chemical	-1	9869655
ol	I-Chemical	-1	9869655
(	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
)	O	-1	9869655
on	O	-1	9869655
the	O	-1	9869655
ne@@	O	-1	9869655
ut@@	O	-1	9869655
ral	O	-1	9869655
and	O	-1	9869655
ac@@	O	-1	9869655
i@@	O	-1	9869655
di@@	O	-1	9869655
c	O	-1	9869655
b@@	O	-1	9869655
i@@	O	-1	9869655
os@@	O	-1	9869655
yn@@	O	-1	9869655
thetic	O	-1	9869655
path@@	O	-1	9869655
w@@	O	-1	9869655
ays	O	-1	9869655
of	O	-1	9869655
b@@	B-Chemical	D001647	9869655
ile	I-Chemical	-1	9869655
sal@@	I-Chemical	-1	9869655
t	I-Chemical	-1	9869655
(	O	-1	9869655
B@@	B-Chemical	D001647	9869655
S	I-Chemical	-1	9869655
)	O	-1	9869655
syn@@	O	-1	9869655
thesis	O	-1	9869655
were	O	-1	9869655
evaluated	O	-1	9869655
in	O	-1	9869655
rats	O	-1	9869655
with	O	-1	9869655
an	O	-1	9869655
int@@	O	-1	9869655
ac@@	O	-1	9869655
t	O	-1	9869655
ent@@	O	-1	9869655
ero@@	O	-1	9869655
hepatic	O	-1	9869655
cir@@	O	-1	9869655
c@@	O	-1	9869655
ulation	O	-1	9869655
and	O	-1	9869655
in	O	-1	9869655
rats	O	-1	9869655
with	O	-1	9869655
long-term	O	-1	9869655
b@@	O	-1	9869655
ile	O	-1	9869655
di@@	O	-1	9869655
ver@@	O	-1	9869655
sion	O	-1	9869655
to	O	-1	9869655
induce	O	-1	9869655
B@@	B-Chemical	D001647	9869655
S	I-Chemical	-1	9869655
syn@@	O	-1	9869655
the@@	O	-1	9869655
sis.	O	-1	9869655
F@@	O	-1	9869655
or	O	-1	9869655
this	O	-1	9869655
pur@@	O	-1	9869655
po@@	O	-1	9869655
se@@	O	-1	9869655
,	O	-1	9869655
b@@	B-Chemical	D001647	9869655
ile	I-Chemical	-1	9869655
sal@@	I-Chemical	-1	9869655
t	I-Chemical	-1	9869655
po@@	O	-1	9869655
ol	O	-1	9869655
com@@	O	-1	9869655
posi@@	O	-1	9869655
tion,	O	-1	9869655
syn@@	O	-1	9869655
thesis	O	-1	9869655
of	O	-1	9869655
individ@@	O	-1	9869655
ual	O	-1	9869655
B@@	B-Chemical	D001647	9869655
S	I-Chemical	-1	9869655
in	O	-1	9869655
viv@@	O	-1	9869655
o@@	O	-1	9869655
,	O	-1	9869655
hepatic	O	-1	9869655
ac@@	O	-1	9869655
ti@@	O	-1	9869655
vi@@	O	-1	9869655
ti@@	O	-1	9869655
es,	O	-1	9869655
and	O	-1	9869655
expression	O	-1	9869655
levels	O	-1	9869655
of	O	-1	9869655
cholester@@	B-Chemical	D002784	9869655
ol	I-Chemical	-1	9869655
7@@	O	-1	9869655
alpha-@@	O	-1	9869655
hydrox@@	O	-1	9869655
yl@@	O	-1	9869655
ase	O	-1	9869655
(C@@	O	-1	9869655
Y@@	O	-1	9869655
P@@	O	-1	9869655
7@@	O	-1	9869655
A@@	O	-1	9869655
),	O	-1	9869655
and	O	-1	9869655
ster@@	B-Chemical	D013261	9869655
ol	I-Chemical	-1	9869655
27@@	O	-1	9869655
-@@	O	-1	9869655
hydrox@@	O	-1	9869655
yl@@	O	-1	9869655
ase	O	-1	9869655
(C@@	O	-1	9869655
Y@@	O	-1	9869655
P@@	O	-1	9869655
27@@	O	-1	9869655
),	O	-1	9869655
as	O	-1	9869655
well	O	-1	9869655
as	O	-1	9869655
of	O	-1	9869655
other	O	-1	9869655
enzym@@	O	-1	9869655
es	O	-1	9869655
involved	O	-1	9869655
in	O	-1	9869655
B@@	B-Chemical	D001647	9869655
S	I-Chemical	-1	9869655
syn@@	O	-1	9869655
the@@	O	-1	9869655
sis,	O	-1	9869655
were	O	-1	9869655
analy@@	O	-1	9869655
zed	O	-1	9869655
in	O	-1	9869655
rats	O	-1	9869655
treated	O	-1	9869655
with	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
(@@	O	-1	9869655
5	O	-1	9869655
mg/kg@@	O	-1	9869655
,	O	-1	9869655
3	O	-1	9869655
da@@	O	-1	9869655
ys@@	O	-1	9869655
)	O	-1	9869655
or	O	-1	9869655
its	O	-1	9869655
ve@@	O	-1	9869655
h@@	O	-1	9869655
ic@@	O	-1	9869655
le@@	O	-1	9869655
.	O	-1	9869655
B@@	B-Chemical	D001647	9869655
S	I-Chemical	-1	9869655
po@@	O	-1	9869655
ol	O	-1	9869655
size	O	-1	9869655
was	O	-1	9869655
decreased	O	-1	9869655
by	O	-1	9869655
27@@	O	-1	9869655
%	O	-1	9869655
but	O	-1	9869655
total	O	-1	9869655
B@@	B-Chemical	D001647	9869655
S	I-Chemical	-1	9869655
syn@@	O	-1	9869655
thesis	O	-1	9869655
was	O	-1	9869655
not	O	-1	9869655
affected	O	-1	9869655
by	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
in	O	-1	9869655
int@@	O	-1	9869655
ac@@	O	-1	9869655
t	O	-1	9869655
rats.	O	-1	9869655
S@@	O	-1	9869655
yn@@	O	-1	9869655
thesis	O	-1	9869655
of	O	-1	9869655
chol@@	B-Chemical	D020355	9869655
ate	I-Chemical	-1	9869655
was	O	-1	9869655
reduced	O	-1	9869655
by	O	-1	9869655
6@@	O	-1	9869655
8@@	O	-1	9869655
%	O	-1	9869655
in	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
-treated	O	-1	9869655
rats,	O	-1	9869655
while	O	-1	9869655
that	O	-1	9869655
of	O	-1	9869655
ch@@	B-Chemical	D002635	9869655
en@@	I-Chemical	-1	9869655
o@@	I-Chemical	-1	9869655
de@@	I-Chemical	-1	9869655
oxy@@	I-Chemical	-1	9869655
chol@@	I-Chemical	-1	9869655
ate	I-Chemical	-1	9869655
was	O	-1	9869655
increased	O	-1	9869655
by	O	-1	9869655
6@@	O	-1	9869655
0@@	O	-1	9869655
%.	O	-1	9869655
The	O	-1	9869655
rec@@	O	-1	9869655
ently	O	-1	9869655
identi@@	O	-1	9869655
fied	O	-1	9869655
D@@	O	-1	9869655
el@@	O	-1	9869655
t@@	O	-1	9869655
a@@	O	-1	9869655
2@@	O	-1	9869655
2-@@	O	-1	9869655
is@@	O	-1	9869655
om@@	O	-1	9869655
er	O	-1	9869655
of	O	-1	9869655
beta-@@	O	-1	9869655
m@@	O	-1	9869655
ur@@	O	-1	9869655
ic@@	O	-1	9869655
h@@	O	-1	9869655
ol@@	O	-1	9869655
ate	O	-1	9869655
cont@@	O	-1	9869655
ri@@	O	-1	9869655
but@@	O	-1	9869655
ed	O	-1	9869655
for	O	-1	9869655
5.@@	O	-1	9869655
4@@	O	-1	9869655
%	O	-1	9869655
and	O	-1	9869655
1@@	O	-1	9869655
8.@@	O	-1	9869655
3	O	-1	9869655
%	O	-1	9869655
(P	O	-1	9869655
<	O	-1	9869655
0.0@@	O	-1	9869655
1)	O	-1	9869655
to	O	-1	9869655
the	O	-1	9869655
po@@	O	-1	9869655
ol	O	-1	9869655
in	O	-1	9869655
control	O	-1	9869655
and	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
-treated	O	-1	9869655
rats,	O	-1	9869655
respectivel@@	O	-1	9869655
y,	O	-1	9869655
but	O	-1	9869655
could	O	-1	9869655
not	O	-1	9869655
be	O	-1	9869655
det@@	O	-1	9869655
ected	O	-1	9869655
in	O	-1	9869655
b@@	O	-1	9869655
ile	O	-1	9869655
after	O	-1	9869655
ex@@	O	-1	9869655
ha@@	O	-1	9869655
us@@	O	-1	9869655
tion	O	-1	9869655
of	O	-1	9869655
the	O	-1	9869655
po@@	O	-1	9869655
ol@@	O	-1	9869655
.	O	-1	9869655
A	O	-1	9869655
c@@	O	-1	9869655
le@@	O	-1	9869655
ar	O	-1	9869655
reduction	O	-1	9869655
of	O	-1	9869655
B@@	B-Chemical	D001647	9869655
S	I-Chemical	-1	9869655
syn@@	O	-1	9869655
thesis	O	-1	9869655
was	O	-1	9869655
found	O	-1	9869655
in	O	-1	9869655
b@@	O	-1	9869655
i@@	O	-1	9869655
le@@	O	-1	9869655
-@@	O	-1	9869655
di@@	O	-1	9869655
ver@@	O	-1	9869655
ted	O	-1	9869655
rats	O	-1	9869655
treated	O	-1	9869655
with	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
,	O	-1	9869655
y@@	O	-1	9869655
et	O	-1	9869655
bil@@	O	-1	9869655
i@@	O	-1	9869655
ary	O	-1	9869655
B@@	B-Chemical	D001647	9869655
S	I-Chemical	-1	9869655
com@@	O	-1	9869655
posi@@	O	-1	9869655
tion	O	-1	9869655
was	O	-1	9869655
only	O	-1	9869655
minim@@	O	-1	9869655
ally	O	-1	9869655
aff@@	O	-1	9869655
ect@@	O	-1	9869655
ed.	O	-1	9869655
Ac@@	O	-1	9869655
tivity	O	-1	9869655
of	O	-1	9869655
C@@	O	-1	9869655
Y@@	O	-1	9869655
P@@	O	-1	9869655
7@@	O	-1	9869655
A	O	-1	9869655
was	O	-1	9869655
decreased	O	-1	9869655
by	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
in	O	-1	9869655
both	O	-1	9869655
int@@	O	-1	9869655
ac@@	O	-1	9869655
t	O	-1	9869655
and	O	-1	9869655
b@@	O	-1	9869655
i@@	O	-1	9869655
le@@	O	-1	9869655
-@@	O	-1	9869655
di@@	O	-1	9869655
ver@@	O	-1	9869655
ted	O	-1	9869655
rats,	O	-1	9869655
whereas	O	-1	9869655
the	O	-1	9869655
activity	O	-1	9869655
of	O	-1	9869655
the	O	-1	9869655
C@@	O	-1	9869655
Y@@	O	-1	9869655
P@@	O	-1	9869655
2@@	O	-1	9869655
7	O	-1	9869655
was	O	-1	9869655
not	O	-1	9869655
aff@@	O	-1	9869655
ect@@	O	-1	9869655
ed.	O	-1	9869655
He@@	O	-1	9869655
pati@@	O	-1	9869655
c	O	-1	9869655
mRNA	O	-1	9869655
levels	O	-1	9869655
of	O	-1	9869655
C@@	O	-1	9869655
Y@@	O	-1	9869655
P@@	O	-1	9869655
7@@	O	-1	9869655
A	O	-1	9869655
were	O	-1	9869655
significantly	O	-1	9869655
reduced	O	-1	9869655
by	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
in	O	-1	9869655
b@@	O	-1	9869655
i@@	O	-1	9869655
le@@	O	-1	9869655
-@@	O	-1	9869655
di@@	O	-1	9869655
ver@@	O	-1	9869655
ted	O	-1	9869655
rats	O	-1	9869655
on@@	O	-1	9869655
ly@@	O	-1	9869655
;	O	-1	9869655
C@@	O	-1	9869655
Y@@	O	-1	9869655
P@@	O	-1	9869655
2@@	O	-1	9869655
7	O	-1	9869655
mRNA	O	-1	9869655
levels	O	-1	9869655
were	O	-1	9869655
not	O	-1	9869655
affected	O	-1	9869655
by	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
.	O	-1	9869655
In	O	-1	9869655
addi@@	O	-1	9869655
tion,	O	-1	9869655
mRNA	O	-1	9869655
levels	O	-1	9869655
of	O	-1	9869655
ster@@	B-Chemical	D013261	9869655
ol	I-Chemical	-1	9869655
12@@	O	-1	9869655
alpha-@@	O	-1	9869655
hydrox@@	O	-1	9869655
yl@@	O	-1	9869655
ase	O	-1	9869655
and	O	-1	9869655
li@@	O	-1	9869655
th@@	O	-1	9869655
o@@	O	-1	9869655
chol@@	O	-1	9869655
ate	O	-1	9869655
6@@	O	-1	9869655
beta-@@	O	-1	9869655
hydrox@@	O	-1	9869655
yl@@	O	-1	9869655
ase	O	-1	9869655
were	O	-1	9869655
increased	O	-1	9869655
by	O	-1	9869655
b@@	O	-1	9869655
ile	O	-1	9869655
di@@	O	-1	9869655
ver@@	O	-1	9869655
sion	O	-1	9869655
and	O	-1	9869655
sup@@	O	-1	9869655
press@@	O	-1	9869655
ed	O	-1	9869655
by	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
.	O	-1	9869655
This	O	-1	9869655
study	O	-1	9869655
show@@	O	-1	9869655
s	O	-1	9869655
that	O	-1	9869655
17@@	B-Chemical	D004997	9869655
alpha-@@	I-Chemical	-1	9869655
eth@@	I-Chemical	-1	9869655
in@@	I-Chemical	-1	9869655
y@@	I-Chemical	-1	9869655
le@@	I-Chemical	-1	9869655
st@@	I-Chemical	-1	9869655
radi@@	I-Chemical	-1	9869655
ol	I-Chemical	-1	9869655
(	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
)@@	O	-1	9869655
-induced	O	-1	9869655
intra@@	B-Disease	D002780	9869655
hepatic	I-Disease	-1	9869655
cholest@@	I-Disease	-1	9869655
asis	I-Disease	-1	9869655
in	O	-1	9869655
rats	O	-1	9869655
is	O	-1	9869655
associated	O	-1	9869655
with	O	-1	9869655
selective	O	-1	9869655
inhibition	O	-1	9869655
of	O	-1	9869655
the	O	-1	9869655
ne@@	O	-1	9869655
ut@@	O	-1	9869655
ral	O	-1	9869655
path@@	O	-1	9869655
w@@	O	-1	9869655
ay	O	-1	9869655
of	O	-1	9869655
b@@	B-Chemical	D001647	9869655
ile	I-Chemical	-1	9869655
sal@@	I-Chemical	-1	9869655
t	I-Chemical	-1	9869655
(	O	-1	9869655
B@@	B-Chemical	D001647	9869655
S	I-Chemical	-1	9869655
)	O	-1	9869655
syn@@	O	-1	9869655
the@@	O	-1	9869655
sis.	O	-1	9869655
S@@	O	-1	9869655
im@@	O	-1	9869655
ult@@	O	-1	9869655
aneous	O	-1	9869655
impair@@	O	-1	9869655
ment	O	-1	9869655
of	O	-1	9869655
other	O	-1	9869655
enzym@@	O	-1	9869655
es	O	-1	9869655
in	O	-1	9869655
the	O	-1	9869655
B@@	B-Chemical	D001647	9869655
S	I-Chemical	-1	9869655
b@@	O	-1	9869655
i@@	O	-1	9869655
os@@	O	-1	9869655
yn@@	O	-1	9869655
thetic	O	-1	9869655
path@@	O	-1	9869655
w@@	O	-1	9869655
ays	O	-1	9869655
may	O	-1	9869655
cont@@	O	-1	9869655
rib@@	O	-1	9869655
ute	O	-1	9869655
to	O	-1	9869655
over@@	O	-1	9869655
all	O	-1	9869655
effects	O	-1	9869655
of	O	-1	9869655
E@@	B-Chemical	D004997	9869655
E	I-Chemical	-1	9869655
on	O	-1	9869655
B@@	B-Chemical	D001647	9869655
S	I-Chemical	-1	9869655
syn@@	O	-1	9869655
the@@	O	-1	9869655
sis.	O	-1	9869655

G@@	B-Chemical	D005905	9881641
li@@	I-Chemical	-1	9881641
ben@@	I-Chemical	-1	9881641
cl@@	I-Chemical	-1	9881641
amide	I-Chemical	-1	9881641
-@@	O	-1	9881641
sensitive	O	-1	9881641
hypotension	B-Disease	D007022	9881641
produced	O	-1	9881641
by	O	-1	9881641
he@@	B-Chemical	C040442	9881641
lo@@	I-Chemical	-1	9881641
der@@	I-Chemical	-1	9881641
min	I-Chemical	-1	9881641
assessed	O	-1	9881641
in	O	-1	9881641
the	O	-1	9881641
rat@@	O	-1	9881641
.	O	-1	9881641
The	O	-1	9881641
effects	O	-1	9881641
of	O	-1	9881641
he@@	B-Chemical	C040442	9881641
lo@@	I-Chemical	-1	9881641
der@@	I-Chemical	-1	9881641
min	I-Chemical	-1	9881641
,	O	-1	9881641
a	O	-1	9881641
b@@	O	-1	9881641
a@@	O	-1	9881641
sic	O	-1	9881641
3@@	O	-1	9881641
5@@	O	-1	9881641
-	O	-1	9881641
amin@@	B-Chemical	D000596	9881641
o	I-Chemical	-1	9881641
acid	I-Chemical	-1	9881641
p@@	O	-1	9881641
ep@@	O	-1	9881641
ti@@	O	-1	9881641
de	O	-1	9881641
isol@@	O	-1	9881641
ated	O	-1	9881641
from	O	-1	9881641
the	O	-1	9881641
ven@@	O	-1	9881641
o@@	O	-1	9881641
m	O	-1	9881641
of	O	-1	9881641
a	O	-1	9881641
li@@	O	-1	9881641
z@@	O	-1	9881641
ard	O	-1	9881641
sal@@	O	-1	9881641
i@@	O	-1	9881641
v@@	O	-1	9881641
ary	O	-1	9881641
gl@@	O	-1	9881641
and@@	O	-1	9881641
,	O	-1	9881641
on	O	-1	9881641
arterial	O	-1	9881641
blood	O	-1	9881641
pressure	O	-1	9881641
and	O	-1	9881641
heart	O	-1	9881641
rate	O	-1	9881641
were	O	-1	9881641
examined	O	-1	9881641
in	O	-1	9881641
the	O	-1	9881641
rat@@	O	-1	9881641
,	O	-1	9881641
foc@@	O	-1	9881641
using	O	-1	9881641
on	O	-1	9881641
the	O	-1	9881641
possib@@	O	-1	9881641
ility	O	-1	9881641
that	O	-1	9881641
activation	O	-1	9881641
of	O	-1	9881641
AT@@	B-Chemical	D000255	9881641
P	I-Chemical	-1	9881641
sensitive	O	-1	9881641
K	B-Chemical	D011188	9881641
+	O	-1	9881641
(	O	-1	9881641
K	B-Chemical	D011188	9881641
(	O	-1	9881641
AT@@	B-Chemical	D000255	9881641
P	I-Chemical	-1	9881641
)@@	O	-1	9881641
)	O	-1	9881641
channe@@	O	-1	9881641
l@@	O	-1	9881641
s	O	-1	9881641
is	O	-1	9881641
involved	O	-1	9881641
in	O	-1	9881641
the	O	-1	9881641
respon@@	O	-1	9881641
s@@	O	-1	9881641
es.	O	-1	9881641
The	O	-1	9881641
results	O	-1	9881641
were	O	-1	9881641
also	O	-1	9881641
compared	O	-1	9881641
with	O	-1	9881641
those	O	-1	9881641
of	O	-1	9881641
vas@@	O	-1	9881641
o@@	O	-1	9881641
active	O	-1	9881641
in@@	O	-1	9881641
test@@	O	-1	9881641
inal	O	-1	9881641
poly@@	O	-1	9881641
p@@	O	-1	9881641
ep@@	O	-1	9881641
ti@@	O	-1	9881641
de	O	-1	9881641
(V@@	O	-1	9881641
I@@	O	-1	9881641
P@@	O	-1	9881641
).	O	-1	9881641
He@@	B-Chemical	C040442	9881641
lo@@	I-Chemical	-1	9881641
der@@	I-Chemical	-1	9881641
min	I-Chemical	-1	9881641
produced	O	-1	9881641
hypotension	B-Disease	D007022	9881641
in	O	-1	9881641
a	O	-1	9881641
dose-@@	O	-1	9881641
dependent	O	-1	9881641
man@@	O	-1	9881641
n@@	O	-1	9881641
er	O	-1	9881641
with	O	-1	9881641
appro@@	O	-1	9881641
xim@@	O	-1	9881641
ately	O	-1	9881641
similar	O	-1	9881641
poten@@	O	-1	9881641
c@@	O	-1	9881641
y	O	-1	9881641
and	O	-1	9881641
duration	O	-1	9881641
to	O	-1	9881641
V@@	O	-1	9881641
I@@	O	-1	9881641
P@@	O	-1	9881641
.	O	-1	9881641
H@@	B-Disease	D007022	9881641
y@@	I-Disease	-1	9881641
poten@@	I-Disease	-1	9881641
sion	I-Disease	-1	9881641
induced	O	-1	9881641
by	O	-1	9881641
both	O	-1	9881641
p@@	O	-1	9881641
ep@@	O	-1	9881641
ti@@	O	-1	9881641
des	O	-1	9881641
was	O	-1	9881641
significantly	O	-1	9881641
attenu@@	O	-1	9881641
ated	O	-1	9881641
by	O	-1	9881641
g@@	B-Chemical	D005905	9881641
li@@	I-Chemical	-1	9881641
ben@@	I-Chemical	-1	9881641
cl@@	I-Chemical	-1	9881641
amide	I-Chemical	-1	9881641
,	O	-1	9881641
which	O	-1	9881641
abol@@	O	-1	9881641
ished	O	-1	9881641
a	O	-1	9881641
lev@@	B-Chemical	D019806	9881641
c@@	I-Chemical	-1	9881641
ro@@	I-Chemical	-1	9881641
ma@@	I-Chemical	-1	9881641
k@@	I-Chemical	-1	9881641
al@@	I-Chemical	-1	9881641
im	I-Chemical	-1	9881641
-@@	O	-1	9881641
produced	O	-1	9881641
decrease	O	-1	9881641
in	O	-1	9881641
arterial	O	-1	9881641
blood	O	-1	9881641
pressu@@	O	-1	9881641
re.	O	-1	9881641
O@@	O	-1	9881641
x@@	O	-1	9881641
y@@	O	-1	9881641
hemo@@	O	-1	9881641
globin	O	-1	9881641
did	O	-1	9881641
not	O	-1	9881641
aff@@	O	-1	9881641
ect	O	-1	9881641
he@@	B-Chemical	C040442	9881641
lo@@	I-Chemical	-1	9881641
der@@	I-Chemical	-1	9881641
min	I-Chemical	-1	9881641
-induced	O	-1	9881641
hypotension	B-Disease	D007022	9881641
,	O	-1	9881641
whereas	O	-1	9881641
it	O	-1	9881641
sh@@	O	-1	9881641
or@@	O	-1	9881641
ten@@	O	-1	9881641
ed	O	-1	9881641
the	O	-1	9881641
duration	O	-1	9881641
of	O	-1	9881641
acet@@	B-Chemical	D000109	9881641
ylcholine	I-Chemical	-1	9881641
(	O	-1	9881641
AC@@	B-Chemical	D000109	9881641
h	I-Chemical	-1	9881641
)-@@	O	-1	9881641
produced	O	-1	9881641
hypotension	B-Disease	D007022	9881641
.	O	-1	9881641
These	O	-1	9881641
findings	O	-1	9881641
suggest	O	-1	9881641
that	O	-1	9881641
he@@	B-Chemical	C040442	9881641
lo@@	I-Chemical	-1	9881641
der@@	I-Chemical	-1	9881641
min	I-Chemical	-1	9881641
-@@	O	-1	9881641
produced	O	-1	9881641
hypotension	B-Disease	D007022	9881641
is	O	-1	9881641
part@@	O	-1	9881641
ly	O	-1	9881641
at@@	O	-1	9881641
tri@@	O	-1	9881641
but@@	O	-1	9881641
able	O	-1	9881641
to	O	-1	9881641
the	O	-1	9881641
activation	O	-1	9881641
of	O	-1	9881641
g@@	B-Chemical	D005905	9881641
li@@	I-Chemical	-1	9881641
ben@@	I-Chemical	-1	9881641
cl@@	I-Chemical	-1	9881641
amide	I-Chemical	-1	9881641
-@@	O	-1	9881641
sensitive	O	-1	9881641
K	B-Chemical	D011188	9881641
+	O	-1	9881641
channe@@	O	-1	9881641
l@@	O	-1	9881641
s	O	-1	9881641
(	O	-1	9881641
K	B-Chemical	D011188	9881641
(	O	-1	9881641
AT@@	B-Chemical	D000255	9881641
P	I-Chemical	-1	9881641
)	O	-1	9881641
channe@@	O	-1	9881641
l@@	O	-1	9881641
s),	O	-1	9881641
which	O	-1	9881641
pres@@	O	-1	9881641
um@@	O	-1	9881641
ably	O	-1	9881641
ex@@	O	-1	9881641
ist	O	-1	9881641
on	O	-1	9881641
arterial	O	-1	9881641
smo@@	O	-1	9881641
oth	O	-1	9881641
musc@@	O	-1	9881641
le	O	-1	9881641
cell@@	O	-1	9881641
s.	O	-1	9881641
E@@	O	-1	9881641
D@@	O	-1	9881641
R@@	O	-1	9881641
F	O	-1	9881641
(@@	O	-1	9881641
endo@@	O	-1	9881641
the@@	O	-1	9881641
li@@	O	-1	9881641
um@@	O	-1	9881641
-@@	O	-1	9881641
der@@	O	-1	9881641
i@@	O	-1	9881641
ved	O	-1	9881641
rel@@	O	-1	9881641
ax@@	O	-1	9881641
ing	O	-1	9881641
fact@@	O	-1	9881641
or@@	O	-1	9881641
)@@	O	-1	9881641
/	O	-1	9881641
nit@@	B-Chemical	D009569	9881641
ric	I-Chemical	-1	9881641
ox@@	I-Chemical	-1	9881641
ide	I-Chemical	-1	9881641
does	O	-1	9881641
not	O	-1	9881641
se@@	O	-1	9881641
em	O	-1	9881641
to	O	-1	9881641
pl@@	O	-1	9881641
ay	O	-1	9881641
an	O	-1	9881641
important	O	-1	9881641
role	O	-1	9881641
in	O	-1	9881641
the	O	-1	9881641
p@@	O	-1	9881641
ep@@	O	-1	9881641
ti@@	O	-1	9881641
de@@	O	-1	9881641
-@@	O	-1	9881641
produced	O	-1	9881641
hypotension	B-Disease	D007022	9881641
.	O	-1	9881641

L@@	O	-1	9889429
on@@	O	-1	9889429
g@@	O	-1	9889429
-term	O	-1	9889429
efficacy	O	-1	9889429
and	O	-1	9889429
adverse	O	-1	9889429
ev@@	O	-1	9889429
ent	O	-1	9889429
of	O	-1	9889429
n@@	B-Chemical	D009543	9889429
if@@	I-Chemical	-1	9889429
edi@@	I-Chemical	-1	9889429
pine	I-Chemical	-1	9889429
su@@	O	-1	9889429
st@@	O	-1	9889429
a@@	O	-1	9889429
ine@@	O	-1	9889429
d-@@	O	-1	9889429
release	O	-1	9889429
t@@	O	-1	9889429
able@@	O	-1	9889429
ts	O	-1	9889429
for	O	-1	9889429
cyclospor@@	B-Chemical	D016572	9889429
in	I-Chemical	-1	9889429
A	I-Chemical	-1	9889429
-induced	O	-1	9889429
hypertension	B-Disease	D006973	9889429
in	O	-1	9889429
patients	O	-1	9889429
with	O	-1	9889429
p@@	B-Disease	D011565	9889429
s@@	I-Disease	-1	9889429
or@@	I-Disease	-1	9889429
ia@@	I-Disease	-1	9889429
sis	I-Disease	-1	9889429
.	O	-1	9889429
Th@@	O	-1	9889429
ir@@	O	-1	9889429
te@@	O	-1	9889429
en	O	-1	9889429
p@@	B-Disease	D011565	9889429
s@@	I-Disease	-1	9889429
or@@	I-Disease	-1	9889429
i@@	I-Disease	-1	9889429
atic	I-Disease	-1	9889429
patients	O	-1	9889429
with	O	-1	9889429
hypertension	B-Disease	D006973	9889429
during	O	-1	9889429
the	O	-1	9889429
course	O	-1	9889429
of	O	-1	9889429
cyclospor@@	B-Chemical	D016572	9889429
in	I-Chemical	-1	9889429
A	I-Chemical	-1	9889429
therapy	O	-1	9889429
were	O	-1	9889429
treated	O	-1	9889429
for	O	-1	9889429
25	O	-1	9889429
months	O	-1	9889429
with	O	-1	9889429
a	O	-1	9889429
calcium	B-Chemical	D002118	9889429
channel	O	-1	9889429
block@@	O	-1	9889429
er,	O	-1	9889429
su@@	O	-1	9889429
st@@	O	-1	9889429
a@@	O	-1	9889429
ine@@	O	-1	9889429
d-@@	O	-1	9889429
release	O	-1	9889429
n@@	B-Chemical	D009543	9889429
if@@	I-Chemical	-1	9889429
edi@@	I-Chemical	-1	9889429
pine	I-Chemical	-1	9889429
,	O	-1	9889429
to	O	-1	9889429
study	O	-1	9889429
the	O	-1	9889429
clinical	O	-1	9889429
anti@@	O	-1	9889429
hypertensive	O	-1	9889429
effects	O	-1	9889429
and	O	-1	9889429
adverse	O	-1	9889429
events	O	-1	9889429
during	O	-1	9889429
treatment	O	-1	9889429
with	O	-1	9889429
both	O	-1	9889429
drug@@	O	-1	9889429
s.	O	-1	9889429
S@@	O	-1	9889429
even	O	-1	9889429
of	O	-1	9889429
the	O	-1	9889429
13	O	-1	9889429
patients	O	-1	9889429
had	O	-1	9889429
ex@@	O	-1	9889429
hib@@	O	-1	9889429
ited	O	-1	9889429
a	O	-1	9889429
sub@@	O	-1	9889429
clinical	O	-1	9889429
hypertensive	B-Disease	D006973	9889429
state	O	-1	9889429
before	O	-1	9889429
cyclospor@@	B-Chemical	D016572	9889429
in	I-Chemical	-1	9889429
A	I-Chemical	-1	9889429
therapy.	O	-1	9889429
B@@	O	-1	9889429
oth	O	-1	9889429
systolic	O	-1	9889429
and	O	-1	9889429
di@@	O	-1	9889429
ast@@	O	-1	9889429
olic	O	-1	9889429
blood	O	-1	9889429
pressu@@	O	-1	9889429
res	O	-1	9889429
of	O	-1	9889429
these	O	-1	9889429
13	O	-1	9889429
patients	O	-1	9889429
were	O	-1	9889429
decreased	O	-1	9889429
significantly	O	-1	9889429
after	O	-1	9889429
4	O	-1	9889429
weeks	O	-1	9889429
of	O	-1	9889429
n@@	B-Chemical	D009543	9889429
if@@	I-Chemical	-1	9889429
edi@@	I-Chemical	-1	9889429
pine	I-Chemical	-1	9889429
therapy,	O	-1	9889429
and	O	-1	9889429
blood	O	-1	9889429
pressure	O	-1	9889429
was	O	-1	9889429
maint@@	O	-1	9889429
ained	O	-1	9889429
within	O	-1	9889429
the	O	-1	9889429
normal	O	-1	9889429
range	O	-1	9889429
the@@	O	-1	9889429
re@@	O	-1	9889429
after	O	-1	9889429
for	O	-1	9889429
25	O	-1	9889429
months.	O	-1	9889429
The	O	-1	9889429
adverse	O	-1	9889429
events	O	-1	9889429
during	O	-1	9889429
combined	O	-1	9889429
therapy	O	-1	9889429
with	O	-1	9889429
cyclospor@@	B-Chemical	D016572	9889429
in	I-Chemical	-1	9889429
A	I-Chemical	-1	9889429
and	O	-1	9889429
n@@	B-Chemical	D009543	9889429
if@@	I-Chemical	-1	9889429
edi@@	I-Chemical	-1	9889429
pine	I-Chemical	-1	9889429
included	O	-1	9889429
an	O	-1	9889429
increase	O	-1	9889429
in	O	-1	9889429
blood	B-Chemical	D001806	9889429
ure@@	I-Chemical	-1	9889429
a	I-Chemical	-1	9889429
nitro@@	I-Chemical	-1	9889429
gen	I-Chemical	-1	9889429
levels	O	-1	9889429
in	O	-1	9889429
9	O	-1	9889429
of	O	-1	9889429
the	O	-1	9889429
13	O	-1	9889429
patients	O	-1	9889429
and	O	-1	9889429
development	O	-1	9889429
of	O	-1	9889429
g@@	B-Disease	D005885	9889429
ing@@	I-Disease	-1	9889429
i@@	I-Disease	-1	9889429
v@@	I-Disease	-1	9889429
al	I-Disease	-1	9889429
hyper@@	I-Disease	-1	9889429
pl@@	I-Disease	-1	9889429
a@@	I-Disease	-1	9889429
sia	I-Disease	-1	9889429
in	O	-1	9889429
2	O	-1	9889429
of	O	-1	9889429
the	O	-1	9889429
13	O	-1	9889429
patients.	O	-1	9889429
Our	O	-1	9889429
findings	O	-1	9889429
indicate	O	-1	9889429
that	O	-1	9889429
su@@	O	-1	9889429
st@@	O	-1	9889429
a@@	O	-1	9889429
ine@@	O	-1	9889429
d-@@	O	-1	9889429
release	O	-1	9889429
n@@	B-Chemical	D009543	9889429
if@@	I-Chemical	-1	9889429
edi@@	I-Chemical	-1	9889429
pine	I-Chemical	-1	9889429
is	O	-1	9889429
use@@	O	-1	9889429
ful	O	-1	9889429
for	O	-1	9889429
hypertensive	B-Disease	D006973	9889429
p@@	B-Disease	D011565	9889429
s@@	I-Disease	-1	9889429
or@@	I-Disease	-1	9889429
i@@	I-Disease	-1	9889429
atic	I-Disease	-1	9889429
patients	O	-1	9889429
under	O	-1	9889429
long-term	O	-1	9889429
treatment	O	-1	9889429
with	O	-1	9889429
cyclospor@@	B-Chemical	D016572	9889429
in	I-Chemical	-1	9889429
A	I-Chemical	-1	9889429
,	O	-1	9889429
but	O	-1	9889429
that	O	-1	9889429
these	O	-1	9889429
patients	O	-1	9889429
should	O	-1	9889429
be	O	-1	9889429
monit@@	O	-1	9889429
o@@	O	-1	9889429
red	O	-1	9889429
for	O	-1	9889429
g@@	B-Disease	D005885	9889429
ing@@	I-Disease	-1	9889429
i@@	I-Disease	-1	9889429
v@@	I-Disease	-1	9889429
al	I-Disease	-1	9889429
hyper@@	I-Disease	-1	9889429
pl@@	I-Disease	-1	9889429
a@@	I-Disease	-1	9889429
sia	I-Disease	-1	9889429
.	O	-1	9889429

T@@	B-Disease	D016171	10087562
or@@	I-Disease	-1	10087562
s@@	I-Disease	-1	10087562
ade	I-Disease	-1	10087562
de	I-Disease	-1	10087562
po@@	I-Disease	-1	10087562
int@@	I-Disease	-1	10087562
es	I-Disease	-1	10087562
ventricular	B-Disease	D017180	10087562
tachycardia	I-Disease	-1	10087562
during	O	-1	10087562
low	O	-1	10087562
dose	O	-1	10087562
inter@@	O	-1	10087562
mit@@	O	-1	10087562
t@@	O	-1	10087562
ent	O	-1	10087562
do@@	B-Chemical	D004280	10087562
but@@	I-Chemical	-1	10087562
amine	I-Chemical	-1	10087562
treatment	O	-1	10087562
in	O	-1	10087562
a	O	-1	10087562
patient	O	-1	10087562
with	O	-1	10087562
di@@	B-Disease	D002311	10087562
l@@	I-Disease	-1	10087562
ated	I-Disease	-1	10087562
cardi@@	I-Disease	-1	10087562
om@@	I-Disease	-1	10087562
yo@@	I-Disease	-1	10087562
pathy	I-Disease	-1	10087562
and	O	-1	10087562
con@@	B-Disease	D006333	10087562
g@@	I-Disease	-1	10087562
es@@	I-Disease	-1	10087562
tive	I-Disease	-1	10087562
heart	I-Disease	-1	10087562
failure	I-Disease	-1	10087562
.	O	-1	10087562
The	O	-1	10087562
au@@	O	-1	10087562
th@@	O	-1	10087562
ors	O	-1	10087562
describe	O	-1	10087562
the	O	-1	10087562
case	O	-1	10087562
of	O	-1	10087562
a	O	-1	10087562
5@@	O	-1	10087562
6-@@	O	-1	10087562
year-old	O	-1	10087562
woman	O	-1	10087562
with	O	-1	10087562
chron@@	O	-1	10087562
ic@@	O	-1	10087562
,	O	-1	10087562
severe	O	-1	10087562
heart	B-Disease	D006333	10087562
failure	I-Disease	-1	10087562
secondary	O	-1	10087562
to	O	-1	10087562
di@@	B-Disease	D002311	10087562
l@@	I-Disease	-1	10087562
ated	I-Disease	-1	10087562
cardi@@	I-Disease	-1	10087562
om@@	I-Disease	-1	10087562
yo@@	I-Disease	-1	10087562
pathy	I-Disease	-1	10087562
and	O	-1	10087562
absence	O	-1	10087562
of	O	-1	10087562
significant	O	-1	10087562
ventricular	B-Disease	D001145	10087562
arrhyth@@	I-Disease	-1	10087562
mi@@	I-Disease	-1	10087562
as	I-Disease	-1	10087562
who	O	-1	10087562
developed	O	-1	10087562
Q@@	B-Disease	D008133	10087562
T	I-Disease	-1	10087562
prolong@@	I-Disease	-1	10087562
ation	I-Disease	-1	10087562
and	O	-1	10087562
t@@	B-Disease	D016171	10087562
or@@	I-Disease	-1	10087562
s@@	I-Disease	-1	10087562
ade	I-Disease	-1	10087562
de	I-Disease	-1	10087562
po@@	I-Disease	-1	10087562
int@@	I-Disease	-1	10087562
es	I-Disease	-1	10087562
ventricular	B-Disease	D017180	10087562
tachycardia	I-Disease	-1	10087562
during	O	-1	10087562
one	O	-1	10087562
cyc@@	O	-1	10087562
le	O	-1	10087562
of	O	-1	10087562
inter@@	O	-1	10087562
mit@@	O	-1	10087562
t@@	O	-1	10087562
ent	O	-1	10087562
low	O	-1	10087562
dose	O	-1	10087562
(2@@	O	-1	10087562
.@@	O	-1	10087562
5	O	-1	10087562
m@@	O	-1	10087562
c@@	O	-1	10087562
g/@@	O	-1	10087562
k@@	O	-1	10087562
g	O	-1	10087562
per	O	-1	10087562
min@@	O	-1	10087562
)	O	-1	10087562
do@@	B-Chemical	D004280	10087562
but@@	I-Chemical	-1	10087562
amine	I-Chemical	-1	10087562
.	O	-1	10087562
This	O	-1	10087562
report	O	-1	10087562
of	O	-1	10087562
t@@	B-Disease	D016171	10087562
or@@	I-Disease	-1	10087562
s@@	I-Disease	-1	10087562
ade	I-Disease	-1	10087562
de	I-Disease	-1	10087562
po@@	I-Disease	-1	10087562
int@@	I-Disease	-1	10087562
es	I-Disease	-1	10087562
ventricular	B-Disease	D017180	10087562
tachycardia	I-Disease	-1	10087562
during	O	-1	10087562
inter@@	O	-1	10087562
mit@@	O	-1	10087562
t@@	O	-1	10087562
ent	O	-1	10087562
do@@	B-Chemical	D004280	10087562
but@@	I-Chemical	-1	10087562
amine	I-Chemical	-1	10087562
suppor@@	O	-1	10087562
ts	O	-1	10087562
the	O	-1	10087562
hypo@@	O	-1	10087562
thesis	O	-1	10087562
that	O	-1	10087562
un@@	O	-1	10087562
predic@@	O	-1	10087562
t@@	O	-1	10087562
able	O	-1	10087562
f@@	O	-1	10087562
atal	O	-1	10087562
arrhyth@@	B-Disease	D001145	10087562
mi@@	I-Disease	-1	10087562
as	I-Disease	-1	10087562
may	O	-1	10087562
occ@@	O	-1	10087562
ur	O	-1	10087562
even	O	-1	10087562
with	O	-1	10087562
low	O	-1	10087562
doses	O	-1	10087562
and	O	-1	10087562
in	O	-1	10087562
patients	O	-1	10087562
with	O	-1	10087562
no	O	-1	10087562
hist@@	O	-1	10087562
ory	O	-1	10087562
of	O	-1	10087562
significant	O	-1	10087562
rhyth@@	O	-1	10087562
m	O	-1	10087562
dist@@	O	-1	10087562
urb@@	O	-1	10087562
anc@@	O	-1	10087562
es.	O	-1	10087562
The	O	-1	10087562
mechanisms	O	-1	10087562
of	O	-1	10087562
pro@@	O	-1	10087562
arrhyth@@	O	-1	10087562
mic	O	-1	10087562
effects	O	-1	10087562
of	O	-1	10087562
D@@	B-Chemical	D004280	10087562
ub@@	I-Chemical	-1	10087562
ut@@	I-Chemical	-1	10087562
amine	I-Chemical	-1	10087562
are	O	-1	10087562
discus@@	O	-1	10087562
sed.	O	-1	10087562

P@@	O	-1	10219427
o@@	O	-1	10219427
si@@	O	-1	10219427
tive	O	-1	10219427
s@@	O	-1	10219427
k@@	O	-1	10219427
in	O	-1	10219427
tests	O	-1	10219427
in	O	-1	10219427
l@@	O	-1	10219427
ate	O	-1	10219427
reactions	O	-1	10219427
to	O	-1	10219427
radi@@	O	-1	10219427
ograph@@	O	-1	10219427
ic	O	-1	10219427
contr@@	B-Chemical	D003287	10219427
ast	I-Chemical	-1	10219427
medi@@	I-Chemical	-1	10219427
a	I-Chemical	-1	10219427
.	O	-1	10219427
In	O	-1	10219427
the	O	-1	10219427
las@@	O	-1	10219427
t	O	-1	10219427
fe@@	O	-1	10219427
w	O	-1	10219427
years	O	-1	10219427
del@@	O	-1	10219427
ayed	O	-1	10219427
reactions	O	-1	10219427
several	O	-1	10219427
hours	O	-1	10219427
after	O	-1	10219427
the	O	-1	10219427
injection	O	-1	10219427
of	O	-1	10219427
radi@@	O	-1	10219427
ograph@@	O	-1	10219427
ic	O	-1	10219427
and	O	-1	10219427
contr@@	B-Chemical	D003287	10219427
ast	I-Chemical	-1	10219427
mat@@	I-Chemical	-1	10219427
er@@	I-Chemical	-1	10219427
i@@	I-Chemical	-1	10219427
als	I-Chemical	-1	10219427
(	O	-1	10219427
P@@	B-Chemical	D003287	10219427
R@@	I-Chemical	-1	10219427
C	I-Chemical	-1	10219427
)	O	-1	10219427
have	O	-1	10219427
been	O	-1	10219427
descri@@	O	-1	10219427
bed	O	-1	10219427
with	O	-1	10219427
increas@@	O	-1	10219427
ing	O	-1	10219427
frequ@@	O	-1	10219427
enc@@	O	-1	10219427
y.	O	-1	10219427
The	O	-1	10219427
au@@	O	-1	10219427
th@@	O	-1	10219427
ors	O	-1	10219427
report	O	-1	10219427
two	O	-1	10219427
observ@@	O	-1	10219427
ations	O	-1	10219427
on	O	-1	10219427
patients	O	-1	10219427
with	O	-1	10219427
del@@	O	-1	10219427
ayed	O	-1	10219427
reactions	O	-1	10219427
in	O	-1	10219427
whom	O	-1	10219427
intra@@	O	-1	10219427
der@@	O	-1	10219427
mo@@	O	-1	10219427
reactions	O	-1	10219427
(@@	O	-1	10219427
I@@	O	-1	10219427
D@@	O	-1	10219427
R@@	O	-1	10219427
)	O	-1	10219427
and	O	-1	10219427
pat@@	O	-1	10219427
ch	O	-1	10219427
tests	O	-1	10219427
to	O	-1	10219427
a	O	-1	10219427
seri@@	O	-1	10219427
es	O	-1	10219427
of	O	-1	10219427
i@@	O	-1	10219427
onic	O	-1	10219427
and	O	-1	10219427
n@@	O	-1	10219427
on	O	-1	10219427
i@@	O	-1	10219427
onic	O	-1	10219427
P@@	B-Chemical	D003287	10219427
R@@	I-Chemical	-1	10219427
C	I-Chemical	-1	10219427
were	O	-1	10219427
studi@@	O	-1	10219427
ed.	O	-1	10219427
After	O	-1	10219427
angio@@	O	-1	10219427
graph@@	O	-1	10219427
y	O	-1	10219427
by	O	-1	10219427
the	O	-1	10219427
venous	O	-1	10219427
ro@@	O	-1	10219427
ute	O	-1	10219427
in	O	-1	10219427
patient	O	-1	10219427
n	O	-1	10219427
de@@	O	-1	10219427
g@@	O	-1	10219427
ree	O	-1	10219427
1	O	-1	10219427
a	O	-1	10219427
b@@	O	-1	10219427
i@@	O	-1	10219427
pha@@	O	-1	10219427
sic	O	-1	10219427
reaction	O	-1	10219427
with	O	-1	10219427
an	O	-1	10219427
immedi@@	O	-1	10219427
ate	O	-1	10219427
reaction	O	-1	10219427
(	O	-1	10219427
dys@@	B-Disease	D004417	10219427
p@@	I-Disease	-1	10219427
ne@@	I-Disease	-1	10219427
a	I-Disease	-1	10219427
,	O	-1	10219427
loss	B-Disease	D014474	10219427
of	I-Disease	-1	10219427
con@@	I-Disease	-1	10219427
s@@	I-Disease	-1	10219427
ci@@	I-Disease	-1	10219427
ous@@	I-Disease	-1	10219427
ness	I-Disease	-1	10219427
)	O	-1	10219427
and	O	-1	10219427
del@@	O	-1	10219427
ayed	O	-1	10219427
mac@@	B-Disease	D003875	10219427
ro@@	I-Disease	-1	10219427
-@@	I-Disease	-1	10219427
pap@@	I-Disease	-1	10219427
ular	I-Disease	-1	10219427
r@@	I-Disease	-1	10219427
as@@	I-Disease	-1	10219427
h	I-Disease	-1	10219427
appe@@	O	-1	10219427
a@@	O	-1	10219427
re@@	O	-1	10219427
d,	O	-1	10219427
wh@@	O	-1	10219427
il@@	O	-1	10219427
st	O	-1	10219427
patient	O	-1	10219427
n	O	-1	10219427
de@@	O	-1	10219427
g@@	O	-1	10219427
ree	O	-1	10219427
2	O	-1	10219427
developed	O	-1	10219427
a	O	-1	10219427
gener@@	O	-1	10219427
al@@	O	-1	10219427
is@@	O	-1	10219427
ed	O	-1	10219427
sens@@	O	-1	10219427
ation	O	-1	10219427
of	O	-1	10219427
he@@	O	-1	10219427
at@@	O	-1	10219427
,	O	-1	10219427
per@@	O	-1	10219427
sist@@	O	-1	10219427
ent	O	-1	10219427
pain	B-Disease	D010146	10219427
at	O	-1	10219427
the	O	-1	10219427
sit@@	O	-1	10219427
e	O	-1	10219427
of	O	-1	10219427
injection	O	-1	10219427
immedi@@	O	-1	10219427
ately	O	-1	10219427
and	O	-1	10219427
a	O	-1	10219427
gener@@	O	-1	10219427
al@@	O	-1	10219427
is@@	O	-1	10219427
ed	O	-1	10219427
mac@@	O	-1	10219427
ro@@	O	-1	10219427
-@@	O	-1	10219427
pap@@	O	-1	10219427
ular	O	-1	10219427
reaction	O	-1	10219427
after	O	-1	10219427
24	O	-1	10219427
hour@@	O	-1	10219427
s.	O	-1	10219427
The	O	-1	10219427
s@@	O	-1	10219427
k@@	O	-1	10219427
in	O	-1	10219427
tests	O	-1	10219427
revealed	O	-1	10219427
positive	O	-1	10219427
del@@	O	-1	10219427
ayed	O	-1	10219427
reactions	O	-1	10219427
of	O	-1	10219427
24	O	-1	10219427
hours	O	-1	10219427
and	O	-1	10219427
4@@	O	-1	10219427
8	O	-1	10219427
hours	O	-1	10219427
by	O	-1	10219427
I@@	O	-1	10219427
D@@	O	-1	10219427
R	O	-1	10219427
and	O	-1	10219427
pat@@	O	-1	10219427
ch	O	-1	10219427
tests	O	-1	10219427
to	O	-1	10219427
only	O	-1	10219427
some	O	-1	10219427
P@@	B-Chemical	D003287	10219427
R@@	I-Chemical	-1	10219427
C	I-Chemical	-1	10219427
with	O	-1	10219427
common	O	-1	10219427
ch@@	O	-1	10219427
ain@@	O	-1	10219427
s	O	-1	10219427
in	O	-1	10219427
their	O	-1	10219427
struc@@	O	-1	10219427
tu@@	O	-1	10219427
res@@	O	-1	10219427
.	O	-1	10219427
The	O	-1	10219427
positive	O	-1	10219427
s@@	O	-1	10219427
k@@	O	-1	10219427
in	O	-1	10219427
tests	O	-1	10219427
are	O	-1	10219427
in	O	-1	10219427
f@@	O	-1	10219427
av@@	O	-1	10219427
our	O	-1	10219427
of	O	-1	10219427
immun@@	O	-1	10219427
ological	O	-1	10219427
reactions	O	-1	10219427
and	O	-1	10219427
may	O	-1	10219427
he@@	O	-1	10219427
l@@	O	-1	10219427
p	O	-1	10219427
in	O	-1	10219427
diagnosis	O	-1	10219427
of	O	-1	10219427
all@@	B-Disease	D004342	10219427
erg@@	I-Disease	-1	10219427
y	I-Disease	-1	10219427
in	O	-1	10219427
the	O	-1	10219427
patients.	O	-1	10219427

R@@	O	-1	10327032
is@@	O	-1	10327032
k	O	-1	10327032
of	O	-1	10327032
transi@@	O	-1	10327032
ent	O	-1	10327032
hyper@@	B-Disease	D022124	10327032
am@@	I-Disease	-1	10327032
mon@@	I-Disease	-1	10327032
em@@	I-Disease	-1	10327032
ic	I-Disease	-1	10327032
encephalo@@	I-Disease	-1	10327032
pathy	I-Disease	-1	10327032
hyper@@	B-Disease	D001927	10327032
am@@	I-Disease	-1	10327032
mon@@	I-Disease	-1	10327032
em@@	I-Disease	-1	10327032
ic	I-Disease	-1	10327032
encephalo@@	I-Disease	-1	10327032
pathy	I-Disease	-1	10327032
in	O	-1	10327032
cancer	B-Disease	D009369	10327032
patients	O	-1	10327032
who	O	-1	10327032
received	O	-1	10327032
continu@@	O	-1	10327032
ous	O	-1	10327032
infusion	O	-1	10327032
of	O	-1	10327032
5-@@	B-Chemical	D005472	10327032
fluoro@@	I-Chemical	-1	10327032
urac@@	I-Chemical	-1	10327032
il	I-Chemical	-1	10327032
with	O	-1	10327032
the	O	-1	10327032
complication	O	-1	10327032
of	O	-1	10327032
de@@	B-Disease	D003681	10327032
hy@@	I-Disease	-1	10327032
d@@	I-Disease	-1	10327032
ration	I-Disease	-1	10327032
and	O	-1	10327032
inf@@	B-Disease	D007239	10327032
ection	I-Disease	-1	10327032
.	O	-1	10327032
F@@	O	-1	10327032
rom	O	-1	10327032
19@@	O	-1	10327032
8@@	O	-1	10327032
6	O	-1	10327032
to	O	-1	10327032
19@@	O	-1	10327032
9@@	O	-1	10327032
8@@	O	-1	10327032
,	O	-1	10327032
2@@	O	-1	10327032
9	O	-1	10327032
cancer	B-Disease	D009369	10327032
patients	O	-1	10327032
who	O	-1	10327032
had	O	-1	10327032
3@@	O	-1	10327032
2	O	-1	10327032
episo@@	O	-1	10327032
des	O	-1	10327032
of	O	-1	10327032
transi@@	O	-1	10327032
ent	O	-1	10327032
hyper@@	B-Disease	D022124	10327032
am@@	I-Disease	-1	10327032
mon@@	I-Disease	-1	10327032
em@@	I-Disease	-1	10327032
ic	I-Disease	-1	10327032
encephalo@@	I-Disease	-1	10327032
pathy	I-Disease	-1	10327032
hyper@@	B-Disease	D001927	10327032
am@@	I-Disease	-1	10327032
mon@@	I-Disease	-1	10327032
em@@	I-Disease	-1	10327032
ic	I-Disease	-1	10327032
encephalo@@	I-Disease	-1	10327032
pathy	I-Disease	-1	10327032
related	O	-1	10327032
to	O	-1	10327032
continu@@	O	-1	10327032
ous	O	-1	10327032
infusion	O	-1	10327032
of	O	-1	10327032
5-@@	B-Chemical	D005472	10327032
fluoro@@	I-Chemical	-1	10327032
urac@@	I-Chemical	-1	10327032
il	I-Chemical	-1	10327032
(	O	-1	10327032
5-@@	B-Chemical	D005472	10327032
F@@	I-Chemical	-1	10327032
U	I-Chemical	-1	10327032
)	O	-1	10327032
were	O	-1	10327032
identi@@	O	-1	10327032
fi@@	O	-1	10327032
ed.	O	-1	10327032
N@@	O	-1	10327032
one	O	-1	10327032
of	O	-1	10327032
the	O	-1	10327032
patients	O	-1	10327032
had	O	-1	10327032
dec@@	O	-1	10327032
om@@	O	-1	10327032
pen@@	O	-1	10327032
s@@	O	-1	10327032
ated	O	-1	10327032
liver	B-Disease	D008107	10327032
disease	I-Disease	-1	10327032
.	O	-1	10327032
On@@	O	-1	10327032
set	O	-1	10327032
of	O	-1	10327032
hyper@@	B-Disease	D022124	10327032
am@@	I-Disease	-1	10327032
mon@@	I-Disease	-1	10327032
em@@	I-Disease	-1	10327032
ic	I-Disease	-1	10327032
encephalo@@	I-Disease	-1	10327032
pathy	I-Disease	-1	10327032
hyper@@	B-Disease	D001927	10327032
am@@	I-Disease	-1	10327032
mon@@	I-Disease	-1	10327032
em@@	I-Disease	-1	10327032
ic	I-Disease	-1	10327032
encephalo@@	I-Disease	-1	10327032
pathy	I-Disease	-1	10327032
vari@@	O	-1	10327032
ed	O	-1	10327032
from	O	-1	10327032
0.@@	O	-1	10327032
5	O	-1	10327032
to	O	-1	10327032
5	O	-1	10327032
days	O	-1	10327032
(@@	O	-1	10327032
me@@	O	-1	10327032
an@@	O	-1	10327032
:	O	-1	10327032
2.@@	O	-1	10327032
6	O	-1	10327032
+/-	O	-1	10327032
1.@@	O	-1	10327032
3	O	-1	10327032
da@@	O	-1	10327032
ys@@	O	-1	10327032
)	O	-1	10327032
after	O	-1	10327032
the	O	-1	10327032
initi@@	O	-1	10327032
ation	O	-1	10327032
of	O	-1	10327032
chemo@@	O	-1	10327032
therapy.	O	-1	10327032
P@@	O	-1	10327032
las@@	O	-1	10327032
ma	O	-1	10327032
am@@	B-Chemical	D000644	10327032
mon@@	I-Chemical	-1	10327032
i@@	I-Chemical	-1	10327032
um	I-Chemical	-1	10327032
level	O	-1	10327032
rang@@	O	-1	10327032
ed	O	-1	10327032
from	O	-1	10327032
2@@	O	-1	10327032
4@@	O	-1	10327032
8	O	-1	10327032
to	O	-1	10327032
2@@	O	-1	10327032
3@@	O	-1	10327032
8@@	O	-1	10327032
7	O	-1	10327032
micro@@	O	-1	10327032
g@@	O	-1	10327032
%	O	-1	10327032
(@@	O	-1	10327032
me@@	O	-1	10327032
an@@	O	-1	10327032
:	O	-1	10327032
6@@	O	-1	10327032
2@@	O	-1	10327032
6	O	-1	10327032
+/-	O	-1	10327032
4@@	O	-1	10327032
3@@	O	-1	10327032
1	O	-1	10327032
micro@@	O	-1	10327032
g@@	O	-1	10327032
%).	O	-1	10327032
A@@	O	-1	10327032
mon@@	O	-1	10327032
g	O	-1	10327032
the	O	-1	10327032
3@@	O	-1	10327032
2	O	-1	10327032
episo@@	O	-1	10327032
d@@	O	-1	10327032
es,	O	-1	10327032
2@@	O	-1	10327032
6	O	-1	10327032
(@@	O	-1	10327032
8@@	O	-1	10327032
1@@	O	-1	10327032
%)	O	-1	10327032
had	O	-1	10327032
various	O	-1	10327032
de@@	O	-1	10327032
gre@@	O	-1	10327032
es	O	-1	10327032
of	O	-1	10327032
az@@	B-Disease	D053099	10327032
ot@@	I-Disease	-1	10327032
emia	I-Disease	-1	10327032
,	O	-1	10327032
1@@	O	-1	10327032
8	O	-1	10327032
(5@@	O	-1	10327032
6@@	O	-1	10327032
%)	O	-1	10327032
occurred	O	-1	10327032
during	O	-1	10327032
bac@@	B-Disease	D001424	10327032
ter@@	I-Disease	-1	10327032
ial	I-Disease	-1	10327032
inf@@	I-Disease	-1	10327032
ec@@	I-Disease	-1	10327032
tions	I-Disease	-1	10327032
and	O	-1	10327032
14	O	-1	10327032
(4@@	O	-1	10327032
4@@	O	-1	10327032
%)	O	-1	10327032
without	O	-1	10327032
inf@@	B-Disease	D007239	10327032
ection	I-Disease	-1	10327032
occurred	O	-1	10327032
during	O	-1	10327032
perio@@	O	-1	10327032
ds	O	-1	10327032
of	O	-1	10327032
de@@	B-Disease	D003681	10327032
hy@@	I-Disease	-1	10327032
d@@	I-Disease	-1	10327032
ration	I-Disease	-1	10327032
.	O	-1	10327032
H@@	O	-1	10327032
igh@@	O	-1	10327032
er	O	-1	10327032
plasma	O	-1	10327032
am@@	B-Chemical	D000644	10327032
mon@@	I-Chemical	-1	10327032
i@@	I-Chemical	-1	10327032
um	I-Chemical	-1	10327032
levels	O	-1	10327032
and	O	-1	10327032
more	O	-1	10327032
ra@@	O	-1	10327032
pid	O	-1	10327032
onset	O	-1	10327032
of	O	-1	10327032
hyper@@	B-Disease	D022124	10327032
am@@	I-Disease	-1	10327032
mon@@	I-Disease	-1	10327032
emia	I-Disease	-1	10327032
were	O	-1	10327032
seen	O	-1	10327032
in	O	-1	10327032
1@@	O	-1	10327032
8	O	-1	10327032
patients	O	-1	10327032
with	O	-1	10327032
bac@@	B-Disease	D001424	10327032
ter@@	I-Disease	-1	10327032
ial	I-Disease	-1	10327032
inf@@	I-Disease	-1	10327032
ec@@	I-Disease	-1	10327032
tions	I-Disease	-1	10327032
(p@@	O	-1	10327032
=@@	O	-1	10327032
0.00@@	O	-1	10327032
3	O	-1	10327032
and	O	-1	10327032
0.00@@	O	-1	10327032
0@@	O	-1	10327032
6,	O	-1	10327032
respectivel@@	O	-1	10327032
y@@	O	-1	10327032
)	O	-1	10327032
and	O	-1	10327032
in	O	-1	10327032
n@@	O	-1	10327032
ine	O	-1	10327032
patients	O	-1	10327032
receiving	O	-1	10327032
high	O	-1	10327032
daily	O	-1	10327032
doses	O	-1	10327032
(2@@	O	-1	10327032
6@@	O	-1	10327032
00	O	-1	10327032
or	O	-1	10327032
18@@	O	-1	10327032
00	O	-1	10327032
mg/m@@	O	-1	10327032
2)	O	-1	10327032
of	O	-1	10327032
5-@@	B-Chemical	D005472	10327032
F@@	I-Chemical	-1	10327032
U	I-Chemical	-1	10327032
(p@@	O	-1	10327032
=@@	O	-1	10327032
0.00@@	O	-1	10327032
0@@	O	-1	10327032
1	O	-1	10327032
and	O	-1	10327032
<	O	-1	10327032
0.00@@	O	-1	10327032
0@@	O	-1	10327032
1,	O	-1	10327032
respectivel@@	O	-1	10327032
y@@	O	-1	10327032
).	O	-1	10327032
In	O	-1	10327032
25	O	-1	10327032
out	O	-1	10327032
of	O	-1	10327032
3@@	O	-1	10327032
2	O	-1	10327032
episo@@	O	-1	10327032
des	O	-1	10327032
(@@	O	-1	10327032
7@@	O	-1	10327032
8@@	O	-1	10327032
%),	O	-1	10327032
plasma	O	-1	10327032
am@@	B-Chemical	D000644	10327032
mon@@	I-Chemical	-1	10327032
i@@	I-Chemical	-1	10327032
um	I-Chemical	-1	10327032
levels	O	-1	10327032
and	O	-1	10327032
mental	O	-1	10327032
status	O	-1	10327032
retur@@	O	-1	10327032
n@@	O	-1	10327032
ed	O	-1	10327032
to	O	-1	10327032
normal	O	-1	10327032
within	O	-1	10327032
2	O	-1	10327032
days	O	-1	10327032
after	O	-1	10327032
ade@@	O	-1	10327032
qu@@	O	-1	10327032
ate	O	-1	10327032
man@@	O	-1	10327032
ag@@	O	-1	10327032
em@@	O	-1	10327032
ent@@	O	-1	10327032
.	O	-1	10327032
In	O	-1	10327032
concl@@	O	-1	10327032
u@@	O	-1	10327032
sion,	O	-1	10327032
hyper@@	B-Disease	D022124	10327032
am@@	I-Disease	-1	10327032
mon@@	I-Disease	-1	10327032
em@@	I-Disease	-1	10327032
ic	I-Disease	-1	10327032
encephalo@@	I-Disease	-1	10327032
pathy	I-Disease	-1	10327032
hyper@@	B-Disease	D001927	10327032
am@@	I-Disease	-1	10327032
mon@@	I-Disease	-1	10327032
em@@	I-Disease	-1	10327032
ic	I-Disease	-1	10327032
encephalo@@	I-Disease	-1	10327032
pathy	I-Disease	-1	10327032
can	O	-1	10327032
occ@@	O	-1	10327032
ur	O	-1	10327032
in	O	-1	10327032
patients	O	-1	10327032
receiving	O	-1	10327032
continu@@	O	-1	10327032
ous	O	-1	10327032
infusion	O	-1	10327032
of	O	-1	10327032
5-@@	B-Chemical	D005472	10327032
F@@	I-Chemical	-1	10327032
U	I-Chemical	-1	10327032
.	O	-1	10327032
A@@	B-Disease	D053099	10327032
z@@	I-Disease	-1	10327032
ot@@	I-Disease	-1	10327032
emia	I-Disease	-1	10327032
,	O	-1	10327032
body	O	-1	10327032
flu@@	O	-1	10327032
id	O	-1	10327032
in@@	O	-1	10327032
suffici@@	O	-1	10327032
ency	O	-1	10327032
and	O	-1	10327032
bac@@	B-Disease	D001424	10327032
ter@@	I-Disease	-1	10327032
ial	I-Disease	-1	10327032
inf@@	I-Disease	-1	10327032
ec@@	I-Disease	-1	10327032
tions	I-Disease	-1	10327032
were	O	-1	10327032
frequ@@	O	-1	10327032
ently	O	-1	10327032
found	O	-1	10327032
in	O	-1	10327032
these	O	-1	10327032
patients.	O	-1	10327032
It	O	-1	10327032
is	O	-1	10327032
the@@	O	-1	10327032
re@@	O	-1	10327032
fore	O	-1	10327032
important	O	-1	10327032
to	O	-1	10327032
reco@@	O	-1	10327032
gn@@	O	-1	10327032
iz@@	O	-1	10327032
e	O	-1	10327032
this	O	-1	10327032
condi@@	O	-1	10327032
tion	O	-1	10327032
in	O	-1	10327032
patients	O	-1	10327032
receiving	O	-1	10327032
continu@@	O	-1	10327032
ous	O	-1	10327032
infusion	O	-1	10327032
of	O	-1	10327032
5-@@	B-Chemical	D005472	10327032
F@@	I-Chemical	-1	10327032
U	I-Chemical	-1	10327032
.	O	-1	10327032

The	O	-1	10390729
effects	O	-1	10390729
of	O	-1	10390729
qu@@	B-Chemical	D011803	10390729
inine	I-Chemical	-1	10390729
and	O	-1	10390729
4-@@	B-Chemical	D015761	10390729
amino@@	I-Chemical	-1	10390729
pyri@@	I-Chemical	-1	10390729
d@@	I-Chemical	-1	10390729
ine	I-Chemical	-1	10390729
on	O	-1	10390729
condi@@	O	-1	10390729
tion@@	O	-1	10390729
ed	O	-1	10390729
pl@@	O	-1	10390729
ac@@	O	-1	10390729
e	O	-1	10390729
pre@@	O	-1	10390729
fe@@	O	-1	10390729
rence	O	-1	10390729
and	O	-1	10390729
changes	O	-1	10390729
in	O	-1	10390729
motor	O	-1	10390729
activity	O	-1	10390729
induced	O	-1	10390729
by	O	-1	10390729
morphine	B-Chemical	D009020	10390729
in	O	-1	10390729
rats.	O	-1	10390729
1@@	O	-1	10390729
.	O	-1	10390729
The	O	-1	10390729
effects	O	-1	10390729
of	O	-1	10390729
two	O	-1	10390729
un@@	O	-1	10390729
selective	O	-1	10390729
pot@@	B-Chemical	D011188	10390729
assi@@	I-Chemical	-1	10390729
um	I-Chemical	-1	10390729
(	O	-1	10390729
K	B-Chemical	D011188	10390729
(@@	O	-1	10390729
+@@	O	-1	10390729
)-@@	O	-1	10390729
)	O	-1	10390729
channel	O	-1	10390729
block@@	O	-1	10390729
er@@	O	-1	10390729
s,	O	-1	10390729
qu@@	B-Chemical	D011803	10390729
inine	I-Chemical	-1	10390729
(1@@	O	-1	10390729
2.@@	O	-1	10390729
5,	O	-1	10390729
25	O	-1	10390729
and	O	-1	10390729
50	O	-1	10390729
mg/kg)	O	-1	10390729
and	O	-1	10390729
4-@@	B-Chemical	D015761	10390729
amino@@	I-Chemical	-1	10390729
pyri@@	I-Chemical	-1	10390729
d@@	I-Chemical	-1	10390729
ine	I-Chemical	-1	10390729
(@@	O	-1	10390729
1	O	-1	10390729
and	O	-1	10390729
2	O	-1	10390729
mg/kg@@	O	-1	10390729
),	O	-1	10390729
on	O	-1	10390729
condi@@	O	-1	10390729
tion@@	O	-1	10390729
ed	O	-1	10390729
pl@@	O	-1	10390729
ac@@	O	-1	10390729
e	O	-1	10390729
pre@@	O	-1	10390729
fe@@	O	-1	10390729
rence	O	-1	10390729
and	O	-1	10390729
b@@	O	-1	10390729
i@@	O	-1	10390729
pha@@	O	-1	10390729
sic	O	-1	10390729
changes	O	-1	10390729
in	O	-1	10390729
motor	O	-1	10390729
activity	O	-1	10390729
induced	O	-1	10390729
by	O	-1	10390729
morphine	B-Chemical	D009020	10390729
(10	O	-1	10390729
mg/kg)	O	-1	10390729
were	O	-1	10390729
tested	O	-1	10390729
in	O	-1	10390729
Wistar	O	-1	10390729
rats.	O	-1	10390729
Q@@	B-Chemical	D011803	10390729
u@@	I-Chemical	-1	10390729
inine	I-Chemical	-1	10390729
is	O	-1	10390729
known	O	-1	10390729
to	O	-1	10390729
bloc@@	O	-1	10390729
k	O	-1	10390729
vol@@	O	-1	10390729
t@@	O	-1	10390729
ag@@	O	-1	10390729
e-@@	O	-1	10390729
,	O	-1	10390729
calcium	B-Chemical	D002118	10390729
-	O	-1	10390729
and	O	-1	10390729
AT@@	B-Chemical	D000255	10390729
P	I-Chemical	-1	10390729
-@@	O	-1	10390729
sensitive	O	-1	10390729
K	B-Chemical	D011188	10390729
(@@	O	-1	10390729
+@@	O	-1	10390729
)-@@	O	-1	10390729
channe@@	O	-1	10390729
l@@	O	-1	10390729
s	O	-1	10390729
while	O	-1	10390729
4-@@	B-Chemical	D015761	10390729
amino@@	I-Chemical	-1	10390729
pyri@@	I-Chemical	-1	10390729
d@@	I-Chemical	-1	10390729
ine	I-Chemical	-1	10390729
is	O	-1	10390729
known	O	-1	10390729
to	O	-1	10390729
bloc@@	O	-1	10390729
k	O	-1	10390729
vol@@	O	-1	10390729
t@@	O	-1	10390729
ag@@	O	-1	10390729
e-@@	O	-1	10390729
sensitive	O	-1	10390729
K	B-Chemical	D011188	10390729
(@@	O	-1	10390729
+@@	O	-1	10390729
)-@@	O	-1	10390729
channe@@	O	-1	10390729
l@@	O	-1	10390729
s.	O	-1	10390729
2@@	O	-1	10390729
.	O	-1	10390729
In	O	-1	10390729
the	O	-1	10390729
coun@@	O	-1	10390729
ter@@	O	-1	10390729
b@@	O	-1	10390729
al@@	O	-1	10390729
anced	O	-1	10390729
meth@@	O	-1	10390729
o@@	O	-1	10390729
d,	O	-1	10390729
qu@@	B-Chemical	D011803	10390729
inine	I-Chemical	-1	10390729
attenu@@	O	-1	10390729
ated	O	-1	10390729
morphine	B-Chemical	D009020	10390729
-induced	O	-1	10390729
pl@@	O	-1	10390729
ac@@	O	-1	10390729
e	O	-1	10390729
pre@@	O	-1	10390729
fe@@	O	-1	10390729
ren@@	O	-1	10390729
ce@@	O	-1	10390729
,	O	-1	10390729
whereas	O	-1	10390729
4-@@	B-Chemical	D015761	10390729
amino@@	I-Chemical	-1	10390729
pyri@@	I-Chemical	-1	10390729
d@@	I-Chemical	-1	10390729
ine	I-Chemical	-1	10390729
was	O	-1	10390729
ine@@	O	-1	10390729
ff@@	O	-1	10390729
ecti@@	O	-1	10390729
ve.	O	-1	10390729
In	O	-1	10390729
the	O	-1	10390729
motor	O	-1	10390729
activity	O	-1	10390729
test	O	-1	10390729
measured	O	-1	10390729
with	O	-1	10390729
an	O	-1	10390729
An@@	O	-1	10390729
i@@	O	-1	10390729
me@@	O	-1	10390729
x@@	O	-1	10390729
-@@	O	-1	10390729
activity	O	-1	10390729
me@@	O	-1	10390729
ter	O	-1	10390729
ne@@	O	-1	10390729
ither	O	-1	10390729
of	O	-1	10390729
the	O	-1	10390729
K	B-Chemical	D011188	10390729
(@@	O	-1	10390729
+@@	O	-1	10390729
)-@@	O	-1	10390729
channel	O	-1	10390729
block@@	O	-1	10390729
ers	O	-1	10390729
affected	O	-1	10390729
morphine	B-Chemical	D009020	10390729
-induced	O	-1	10390729
hypo@@	B-Disease	D009069	10390729
activity	I-Disease	-1	10390729
,	O	-1	10390729
but	O	-1	10390729
both	O	-1	10390729
K	B-Chemical	D011188	10390729
(@@	O	-1	10390729
+@@	O	-1	10390729
)-@@	O	-1	10390729
channel	O	-1	10390729
block@@	O	-1	10390729
ers	O	-1	10390729
prevent@@	O	-1	10390729
ed	O	-1	10390729
morphine	B-Chemical	D009020	10390729
-induced	O	-1	10390729
secondary	O	-1	10390729
hyperactivity	B-Disease	D006948	10390729
.	O	-1	10390729
3@@	O	-1	10390729
.	O	-1	10390729
These	O	-1	10390729
results	O	-1	10390729
suggest	O	-1	10390729
the	O	-1	10390729
invol@@	O	-1	10390729
vement	O	-1	10390729
of	O	-1	10390729
qu@@	B-Chemical	D011803	10390729
inine	I-Chemical	-1	10390729
-@@	O	-1	10390729
sensitive	O	-1	10390729
but	O	-1	10390729
not	O	-1	10390729
4-@@	B-Chemical	D015761	10390729
amino@@	I-Chemical	-1	10390729
pyri@@	I-Chemical	-1	10390729
d@@	I-Chemical	-1	10390729
ine	I-Chemical	-1	10390729
-@@	O	-1	10390729
sensitive	O	-1	10390729
K	B-Chemical	D011188	10390729
(@@	O	-1	10390729
+@@	O	-1	10390729
)-@@	O	-1	10390729
channe@@	O	-1	10390729
l@@	O	-1	10390729
s	O	-1	10390729
in	O	-1	10390729
morphine	B-Chemical	D009020	10390729
re@@	O	-1	10390729
war@@	O	-1	10390729
d.	O	-1	10390729
It	O	-1	10390729
is	O	-1	10390729
also	O	-1	10390729
suggested	O	-1	10390729
that	O	-1	10390729
the	O	-1	10390729
block@@	O	-1	10390729
ade	O	-1	10390729
of	O	-1	10390729
K	B-Chemical	D011188	10390729
(@@	O	-1	10390729
+@@	O	-1	10390729
)-@@	O	-1	10390729
channe@@	O	-1	10390729
l@@	O	-1	10390729
s	O	-1	10390729
sensitive	O	-1	10390729
to	O	-1	10390729
these	O	-1	10390729
block@@	O	-1	10390729
ers	O	-1	10390729
is	O	-1	10390729
not	O	-1	10390729
suffici@@	O	-1	10390729
ent	O	-1	10390729
to	O	-1	10390729
prev@@	O	-1	10390729
ent	O	-1	10390729
morphine	B-Chemical	D009020	10390729
-induced	O	-1	10390729
hypo@@	B-Disease	D009069	10390729
activity	I-Disease	-1	10390729
whereas	O	-1	10390729
morphine	B-Chemical	D009020	10390729
-induced	O	-1	10390729
hyperactivity	B-Disease	D006948	10390729
se@@	O	-1	10390729
em@@	O	-1	10390729
s	O	-1	10390729
to	O	-1	10390729
be	O	-1	10390729
con@@	O	-1	10390729
n@@	O	-1	10390729
ected	O	-1	10390729
to	O	-1	10390729
both	O	-1	10390729
qu@@	B-Chemical	D011803	10390729
inine	I-Chemical	-1	10390729
-	O	-1	10390729
and	O	-1	10390729
4-@@	B-Chemical	D015761	10390729
amino@@	I-Chemical	-1	10390729
pyri@@	I-Chemical	-1	10390729
d@@	I-Chemical	-1	10390729
ine	I-Chemical	-1	10390729
-@@	O	-1	10390729
sensitive	O	-1	10390729
K	B-Chemical	D011188	10390729
(@@	O	-1	10390729
+@@	O	-1	10390729
)-@@	O	-1	10390729
channe@@	O	-1	10390729
l@@	O	-1	10390729
s.	O	-1	10390729

N@@	B-Chemical	C096012	10401555
ocicep@@	I-Chemical	-1	10401555
tin	I-Chemical	-1	10401555
/	O	-1	10401555
or@@	B-Chemical	C096012	10401555
ph@@	I-Chemical	-1	10401555
an@@	I-Chemical	-1	10401555
in	I-Chemical	-1	10401555
F@@	I-Chemical	-1	10401555
Q	I-Chemical	-1	10401555
and	O	-1	10401555
n@@	B-Chemical	C111148	10401555
oc@@	I-Chemical	-1	10401555
ist@@	I-Chemical	-1	10401555
atin	I-Chemical	-1	10401555
on	O	-1	10401555
lear@@	B-Disease	D007859	10401555
ning	I-Disease	-1	10401555
and	I-Disease	-1	10401555
memory	I-Disease	-1	10401555
impair@@	I-Disease	-1	10401555
ment	I-Disease	-1	10401555
lear@@	B-Disease	D008569	10401555
ning	I-Disease	-1	10401555
and	I-Disease	-1	10401555
memory	I-Disease	-1	10401555
impair@@	I-Disease	-1	10401555
ment	I-Disease	-1	10401555
induced	O	-1	10401555
by	O	-1	10401555
scopol@@	B-Chemical	D012601	10401555
amine	I-Chemical	-1	10401555
in	O	-1	10401555
mice.	O	-1	10401555
1@@	O	-1	10401555
.	O	-1	10401555
N@@	B-Chemical	C096012	10401555
ocicep@@	I-Chemical	-1	10401555
tin	I-Chemical	-1	10401555
,	O	-1	10401555
also	O	-1	10401555
known	O	-1	10401555
as	O	-1	10401555
or@@	B-Chemical	C096012	10401555
ph@@	I-Chemical	-1	10401555
an@@	I-Chemical	-1	10401555
in	I-Chemical	-1	10401555
F@@	I-Chemical	-1	10401555
Q	I-Chemical	-1	10401555
,	O	-1	10401555
is	O	-1	10401555
an	O	-1	10401555
endo@@	O	-1	10401555
gen@@	O	-1	10401555
ous	O	-1	10401555
li@@	O	-1	10401555
g@@	O	-1	10401555
and	O	-1	10401555
for	O	-1	10401555
the	O	-1	10401555
or@@	O	-1	10401555
ph@@	O	-1	10401555
an	O	-1	10401555
o@@	O	-1	10401555
pi@@	O	-1	10401555
oid	O	-1	10401555
receptor@@	O	-1	10401555
-@@	O	-1	10401555
like	O	-1	10401555
receptor	O	-1	10401555
1	O	-1	10401555
(@@	O	-1	10401555
O@@	O	-1	10401555
R@@	O	-1	10401555
L@@	O	-1	10401555
1)	O	-1	10401555
and	O	-1	10401555
invol@@	O	-1	10401555
v@@	O	-1	10401555
es	O	-1	10401555
in	O	-1	10401555
various	O	-1	10401555
func@@	O	-1	10401555
tions	O	-1	10401555
in	O	-1	10401555
the	O	-1	10401555
central	O	-1	10401555
ner@@	O	-1	10401555
v@@	O	-1	10401555
ous	O	-1	10401555
system	O	-1	10401555
(C@@	O	-1	10401555
N@@	O	-1	10401555
S@@	O	-1	10401555
).	O	-1	10401555
O@@	O	-1	10401555
n	O	-1	10401555
the	O	-1	10401555
other	O	-1	10401555
h@@	O	-1	10401555
and@@	O	-1	10401555
,	O	-1	10401555
n@@	B-Chemical	C111148	10401555
oc@@	I-Chemical	-1	10401555
ist@@	I-Chemical	-1	10401555
atin	I-Chemical	-1	10401555
is	O	-1	10401555
rec@@	O	-1	10401555
ently	O	-1	10401555
isol@@	O	-1	10401555
ated	O	-1	10401555
from	O	-1	10401555
the	O	-1	10401555
same	O	-1	10401555
pre@@	O	-1	10401555
cur@@	O	-1	10401555
s@@	O	-1	10401555
or	O	-1	10401555
as	O	-1	10401555
n@@	B-Chemical	C096012	10401555
ocicep@@	I-Chemical	-1	10401555
tin	I-Chemical	-1	10401555
and	O	-1	10401555
block@@	O	-1	10401555
s	O	-1	10401555
n@@	B-Chemical	C096012	10401555
ocicep@@	I-Chemical	-1	10401555
tin	I-Chemical	-1	10401555
-induced	O	-1	10401555
al@@	B-Disease	D006930	10401555
lo@@	I-Disease	-1	10401555
dy@@	I-Disease	-1	10401555
n@@	I-Disease	-1	10401555
ia	I-Disease	-1	10401555
and	O	-1	10401555
hyperalge@@	B-Disease	D006930	10401555
sia	I-Disease	-1	10401555
.	O	-1	10401555
2@@	O	-1	10401555
.	O	-1	10401555
Although	O	-1	10401555
O@@	O	-1	10401555
R@@	O	-1	10401555
L@@	O	-1	10401555
1	O	-1	10401555
receptors	O	-1	10401555
which	O	-1	10401555
dis@@	O	-1	10401555
pl@@	O	-1	10401555
ay	O	-1	10401555
a	O	-1	10401555
high	O	-1	10401555
de@@	O	-1	10401555
g@@	O	-1	10401555
ree	O	-1	10401555
of	O	-1	10401555
sequ@@	O	-1	10401555
ence	O	-1	10401555
ho@@	O	-1	10401555
mo@@	O	-1	10401555
log@@	O	-1	10401555
y	O	-1	10401555
with	O	-1	10401555
cl@@	O	-1	10401555
assi@@	O	-1	10401555
c@@	O	-1	10401555
al	O	-1	10401555
o@@	O	-1	10401555
pi@@	O	-1	10401555
oid	O	-1	10401555
receptors	O	-1	10401555
are	O	-1	10401555
ab@@	O	-1	10401555
und@@	O	-1	10401555
ant	O	-1	10401555
in	O	-1	10401555
the	O	-1	10401555
hippocamp@@	O	-1	10401555
us,	O	-1	10401555
lit@@	O	-1	10401555
t@@	O	-1	10401555
le	O	-1	10401555
is	O	-1	10401555
known	O	-1	10401555
reg@@	O	-1	10401555
ar@@	O	-1	10401555
ding	O	-1	10401555
their	O	-1	10401555
role	O	-1	10401555
in	O	-1	10401555
lear@@	O	-1	10401555
ning	O	-1	10401555
and	O	-1	10401555
memor@@	O	-1	10401555
y.	O	-1	10401555
3@@	O	-1	10401555
.	O	-1	10401555
The	O	-1	10401555
present	O	-1	10401555
study	O	-1	10401555
was	O	-1	10401555
de@@	O	-1	10401555
signed	O	-1	10401555
to	O	-1	10401555
investigate	O	-1	10401555
whether	O	-1	10401555
n@@	B-Chemical	C096012	10401555
ocicep@@	I-Chemical	-1	10401555
tin	I-Chemical	-1	10401555
/	O	-1	10401555
or@@	B-Chemical	C096012	10401555
ph@@	I-Chemical	-1	10401555
an@@	I-Chemical	-1	10401555
in	I-Chemical	-1	10401555
F@@	I-Chemical	-1	10401555
Q	I-Chemical	-1	10401555
and	O	-1	10401555
n@@	B-Chemical	C111148	10401555
oc@@	I-Chemical	-1	10401555
ist@@	I-Chemical	-1	10401555
atin	I-Chemical	-1	10401555
could	O	-1	10401555
mod@@	O	-1	10401555
ul@@	O	-1	10401555
ate	O	-1	10401555
impair@@	B-Disease	D007859	10401555
ment	I-Disease	-1	10401555
of	I-Disease	-1	10401555
lear@@	I-Disease	-1	10401555
ning	I-Disease	-1	10401555
and	I-Disease	-1	10401555
memory	I-Disease	-1	10401555
impair@@	B-Disease	D008569	10401555
ment	I-Disease	-1	10401555
of	I-Disease	-1	10401555
lear@@	I-Disease	-1	10401555
ning	I-Disease	-1	10401555
and	I-Disease	-1	10401555
memory	I-Disease	-1	10401555
induced	O	-1	10401555
by	O	-1	10401555
scopol@@	B-Chemical	D012601	10401555
amine	I-Chemical	-1	10401555
,	O	-1	10401555
a	O	-1	10401555
mus@@	O	-1	10401555
car@@	O	-1	10401555
inic	O	-1	10401555
cholinergic	O	-1	10401555
receptor	O	-1	10401555
antagonist@@	O	-1	10401555
,	O	-1	10401555
using	O	-1	10401555
spont@@	O	-1	10401555
aneous	O	-1	10401555
al@@	O	-1	10401555
tern@@	O	-1	10401555
ation	O	-1	10401555
of	O	-1	10401555
Y@@	O	-1	10401555
-@@	O	-1	10401555
ma@@	O	-1	10401555
ze	O	-1	10401555
and	O	-1	10401555
st@@	O	-1	10401555
ep@@	O	-1	10401555
-@@	O	-1	10401555
do@@	O	-1	10401555
w@@	O	-1	10401555
n	O	-1	10401555
type	O	-1	10401555
p@@	O	-1	10401555
as@@	O	-1	10401555
sive	O	-1	10401555
avoid@@	O	-1	10401555
ance	O	-1	10401555
t@@	O	-1	10401555
as@@	O	-1	10401555
k@@	O	-1	10401555
s	O	-1	10401555
in	O	-1	10401555
mice.	O	-1	10401555
4@@	O	-1	10401555
.	O	-1	10401555
W@@	O	-1	10401555
h@@	O	-1	10401555
ile	O	-1	10401555
n@@	B-Chemical	C111148	10401555
oc@@	I-Chemical	-1	10401555
ist@@	I-Chemical	-1	10401555
atin	I-Chemical	-1	10401555
(0.@@	O	-1	10401555
5-@@	O	-1	10401555
5.@@	O	-1	10401555
0	O	-1	10401555
n@@	O	-1	10401555
mo@@	O	-1	10401555
l	O	-1	10401555
mou@@	O	-1	10401555
se@@	O	-1	10401555
-1@@	O	-1	10401555
,	O	-1	10401555
i.@@	O	-1	10401555
c@@	O	-1	10401555
.@@	O	-1	10401555
v@@	O	-1	10401555
.)	O	-1	10401555
administered	O	-1	10401555
30	O	-1	10401555
min	O	-1	10401555
before	O	-1	10401555
spont@@	O	-1	10401555
aneous	O	-1	10401555
al@@	O	-1	10401555
tern@@	O	-1	10401555
ation	O	-1	10401555
perform@@	O	-1	10401555
ance	O	-1	10401555
or	O	-1	10401555
the	O	-1	10401555
tra@@	O	-1	10401555
in@@	O	-1	10401555
ing	O	-1	10401555
s@@	O	-1	10401555
es@@	O	-1	10401555
sion	O	-1	10401555
of	O	-1	10401555
the	O	-1	10401555
p@@	O	-1	10401555
as@@	O	-1	10401555
sive	O	-1	10401555
avoid@@	O	-1	10401555
ance	O	-1	10401555
t@@	O	-1	10401555
as@@	O	-1	10401555
k@@	O	-1	10401555
,	O	-1	10401555
had	O	-1	10401555
no	O	-1	10401555
effect	O	-1	10401555
on	O	-1	10401555
spont@@	O	-1	10401555
aneous	O	-1	10401555
al@@	O	-1	10401555
tern@@	O	-1	10401555
ation	O	-1	10401555
or	O	-1	10401555
p@@	O	-1	10401555
as@@	O	-1	10401555
sive	O	-1	10401555
avoid@@	O	-1	10401555
ance	O	-1	10401555
behavi@@	O	-1	10401555
o@@	O	-1	10401555
ur@@	O	-1	10401555
s,	O	-1	10401555
a	O	-1	10401555
lower	O	-1	10401555
per	O	-1	10401555
c@@	O	-1	10401555
ent	O	-1	10401555
al@@	O	-1	10401555
tern@@	O	-1	10401555
ation	O	-1	10401555
and	O	-1	10401555
sh@@	O	-1	10401555
or@@	O	-1	10401555
ter	O	-1	10401555
median	O	-1	10401555
st@@	O	-1	10401555
ep@@	O	-1	10401555
-@@	O	-1	10401555
do@@	O	-1	10401555
w@@	O	-1	10401555
n	O	-1	10401555
lat@@	O	-1	10401555
ency	O	-1	10401555
in	O	-1	10401555
the	O	-1	10401555
re@@	O	-1	10401555
ten@@	O	-1	10401555
tion	O	-1	10401555
test	O	-1	10401555
were	O	-1	10401555
obtained	O	-1	10401555
in	O	-1	10401555
n@@	B-Chemical	C096012	10401555
ocicep@@	I-Chemical	-1	10401555
tin	I-Chemical	-1	10401555
(1@@	O	-1	10401555
.@@	O	-1	10401555
5	O	-1	10401555
and/or	O	-1	10401555
5.@@	O	-1	10401555
0	O	-1	10401555
n@@	O	-1	10401555
mo@@	O	-1	10401555
l	O	-1	10401555
mou@@	O	-1	10401555
se@@	O	-1	10401555
-1@@	O	-1	10401555
,	O	-1	10401555
i.@@	O	-1	10401555
c@@	O	-1	10401555
.@@	O	-1	10401555
v@@	O	-1	10401555
.@@	O	-1	10401555
)-@@	O	-1	10401555
treated	O	-1	10401555
normal	O	-1	10401555
mice.	O	-1	10401555
5@@	O	-1	10401555
.	O	-1	10401555
Ad@@	O	-1	10401555
minist@@	O	-1	10401555
ration	O	-1	10401555
of	O	-1	10401555
n@@	B-Chemical	C111148	10401555
oc@@	I-Chemical	-1	10401555
ist@@	I-Chemical	-1	10401555
atin	I-Chemical	-1	10401555
(1@@	O	-1	10401555
.@@	O	-1	10401555
5	O	-1	10401555
and/or	O	-1	10401555
5.@@	O	-1	10401555
0	O	-1	10401555
n@@	O	-1	10401555
mo@@	O	-1	10401555
l	O	-1	10401555
mou@@	O	-1	10401555
se@@	O	-1	10401555
-1@@	O	-1	10401555
,	O	-1	10401555
i.@@	O	-1	10401555
c@@	O	-1	10401555
.@@	O	-1	10401555
v@@	O	-1	10401555
.)	O	-1	10401555
30	O	-1	10401555
min	O	-1	10401555
before	O	-1	10401555
spont@@	O	-1	10401555
aneous	O	-1	10401555
al@@	O	-1	10401555
tern@@	O	-1	10401555
ation	O	-1	10401555
perform@@	O	-1	10401555
ance	O	-1	10401555
or	O	-1	10401555
the	O	-1	10401555
tra@@	O	-1	10401555
in@@	O	-1	10401555
ing	O	-1	10401555
s@@	O	-1	10401555
es@@	O	-1	10401555
sion	O	-1	10401555
of	O	-1	10401555
the	O	-1	10401555
p@@	O	-1	10401555
as@@	O	-1	10401555
sive	O	-1	10401555
avoid@@	O	-1	10401555
ance	O	-1	10401555
t@@	O	-1	10401555
as@@	O	-1	10401555
k@@	O	-1	10401555
,	O	-1	10401555
attenu@@	O	-1	10401555
ated	O	-1	10401555
the	O	-1	10401555
scopol@@	B-Chemical	D012601	10401555
amine	I-Chemical	-1	10401555
-induced	O	-1	10401555
impair@@	O	-1	10401555
ment	O	-1	10401555
of	O	-1	10401555
spont@@	O	-1	10401555
aneous	O	-1	10401555
al@@	O	-1	10401555
tern@@	O	-1	10401555
ation	O	-1	10401555
and	O	-1	10401555
p@@	O	-1	10401555
as@@	O	-1	10401555
sive	O	-1	10401555
avoid@@	O	-1	10401555
ance	O	-1	10401555
behavi@@	O	-1	10401555
o@@	O	-1	10401555
ur@@	O	-1	10401555
s.	O	-1	10401555
6@@	O	-1	10401555
.	O	-1	10401555
These	O	-1	10401555
results	O	-1	10401555
indic@@	O	-1	10401555
ated	O	-1	10401555
that	O	-1	10401555
n@@	B-Chemical	C111148	10401555
oc@@	I-Chemical	-1	10401555
ist@@	I-Chemical	-1	10401555
atin	I-Chemical	-1	10401555
,	O	-1	10401555
a	O	-1	10401555
new	O	-1	10401555
bio@@	O	-1	10401555
log@@	O	-1	10401555
ically	O	-1	10401555
active	O	-1	10401555
p@@	O	-1	10401555
ep@@	O	-1	10401555
ti@@	O	-1	10401555
de@@	O	-1	10401555
,	O	-1	10401555
ame@@	O	-1	10401555
li@@	O	-1	10401555
or@@	O	-1	10401555
ates	O	-1	10401555
impair@@	O	-1	10401555
ments	O	-1	10401555
of	O	-1	10401555
spont@@	O	-1	10401555
aneous	O	-1	10401555
al@@	O	-1	10401555
tern@@	O	-1	10401555
ation	O	-1	10401555
and	O	-1	10401555
p@@	O	-1	10401555
as@@	O	-1	10401555
sive	O	-1	10401555
avoid@@	O	-1	10401555
ance	O	-1	10401555
induced	O	-1	10401555
by	O	-1	10401555
scopol@@	B-Chemical	D012601	10401555
amine	I-Chemical	-1	10401555
,	O	-1	10401555
and	O	-1	10401555
suggested	O	-1	10401555
that	O	-1	10401555
these	O	-1	10401555
p@@	O	-1	10401555
ep@@	O	-1	10401555
ti@@	O	-1	10401555
des	O	-1	10401555
pl@@	O	-1	10401555
ay	O	-1	10401555
op@@	O	-1	10401555
pos@@	O	-1	10401555
ite	O	-1	10401555
ro@@	O	-1	10401555
le@@	O	-1	10401555
s	O	-1	10401555
in	O	-1	10401555
lear@@	O	-1	10401555
ning	O	-1	10401555
and	O	-1	10401555
memor@@	O	-1	10401555
y.	O	-1	10401555

M@@	B-Chemical	C065757	10427794
e@@	I-Chemical	-1	10427794
lo@@	I-Chemical	-1	10427794
x@@	I-Chemical	-1	10427794
ic@@	I-Chemical	-1	10427794
am	I-Chemical	-1	10427794
-induced	O	-1	10427794
liver	B-Disease	D056486	10427794
toxicity	I-Disease	-1	10427794
.	O	-1	10427794
We	O	-1	10427794
report	O	-1	10427794
the	O	-1	10427794
case	O	-1	10427794
of	O	-1	10427794
a	O	-1	10427794
female	O	-1	10427794
patient	O	-1	10427794
with	O	-1	10427794
r@@	B-Disease	D001172	10427794
he@@	I-Disease	-1	10427794
um@@	I-Disease	-1	10427794
at@@	I-Disease	-1	10427794
oid	I-Disease	-1	10427794
arth@@	I-Disease	-1	10427794
ritis	I-Disease	-1	10427794
who	O	-1	10427794
developed	O	-1	10427794
acute	O	-1	10427794
cy@@	O	-1	10427794
t@@	O	-1	10427794
oly@@	O	-1	10427794
tic	O	-1	10427794
hepatitis	B-Disease	D056486	10427794
due	O	-1	10427794
to	O	-1	10427794
me@@	B-Chemical	C065757	10427794
lo@@	I-Chemical	-1	10427794
x@@	I-Chemical	-1	10427794
ic@@	I-Chemical	-1	10427794
am	I-Chemical	-1	10427794
.	O	-1	10427794
Rec@@	O	-1	10427794
ently	O	-1	10427794
int@@	O	-1	10427794
ro@@	O	-1	10427794
duced	O	-1	10427794
in	O	-1	10427794
B@@	O	-1	10427794
el@@	O	-1	10427794
gi@@	O	-1	10427794
um,	O	-1	10427794
me@@	B-Chemical	C065757	10427794
lo@@	I-Chemical	-1	10427794
x@@	I-Chemical	-1	10427794
ic@@	I-Chemical	-1	10427794
am	I-Chemical	-1	10427794
is	O	-1	10427794
the	O	-1	10427794
first	O	-1	10427794
non@@	O	-1	10427794
steroid@@	O	-1	10427794
al	O	-1	10427794
anti@@	O	-1	10427794
inflam@@	O	-1	10427794
mat@@	O	-1	10427794
ory	O	-1	10427794
drug	O	-1	10427794
with	O	-1	10427794
selective	O	-1	10427794
action	O	-1	10427794
on	O	-1	10427794
the	O	-1	10427794
induc@@	O	-1	10427794
i@@	O	-1	10427794
ble	O	-1	10427794
form	O	-1	10427794
of	O	-1	10427794
cyclo@@	O	-1	10427794
oxy@@	O	-1	10427794
gen@@	O	-1	10427794
ase	O	-1	10427794
2@@	O	-1	10427794
.	O	-1	10427794
The	O	-1	10427794
acute	O	-1	10427794
cy@@	O	-1	10427794
t@@	O	-1	10427794
oly@@	O	-1	10427794
tic	O	-1	10427794
hepatitis	B-Disease	D056486	10427794
occurred	O	-1	10427794
ra@@	O	-1	10427794
pid@@	O	-1	10427794
ly	O	-1	10427794
after	O	-1	10427794
me@@	B-Chemical	C065757	10427794
lo@@	I-Chemical	-1	10427794
x@@	I-Chemical	-1	10427794
ic@@	I-Chemical	-1	10427794
am	I-Chemical	-1	10427794
administration	O	-1	10427794
and	O	-1	10427794
was	O	-1	10427794
associated	O	-1	10427794
with	O	-1	10427794
the	O	-1	10427794
development	O	-1	10427794
of	O	-1	10427794
ant@@	O	-1	10427794
in@@	O	-1	10427794
ucle@@	O	-1	10427794
ar	O	-1	10427794
anti@@	O	-1	10427794
bo@@	O	-1	10427794
di@@	O	-1	10427794
es	O	-1	10427794
suggesting	O	-1	10427794
a	O	-1	10427794
hyper@@	B-Disease	D004342	10427794
sensitivity	I-Disease	-1	10427794
mechanis@@	O	-1	10427794
m.	O	-1	10427794
This	O	-1	10427794
first	O	-1	10427794
case	O	-1	10427794
of	O	-1	10427794
me@@	B-Chemical	C065757	10427794
lo@@	I-Chemical	-1	10427794
x@@	I-Chemical	-1	10427794
ic@@	I-Chemical	-1	10427794
am	I-Chemical	-1	10427794
related	O	-1	10427794
liver	B-Disease	D056486	10427794
toxicity	I-Disease	-1	10427794
demon@@	O	-1	10427794
strat@@	O	-1	10427794
es	O	-1	10427794
the	O	-1	10427794
potential	O	-1	10427794
of	O	-1	10427794
this	O	-1	10427794
drug	O	-1	10427794
to	O	-1	10427794
induce	O	-1	10427794
hepatic	B-Disease	D056486	10427794
damage	I-Disease	-1	10427794
.	O	-1	10427794

In@@	O	-1	10462057
duction	O	-1	10462057
of	O	-1	10462057
apo@@	O	-1	10462057
pto@@	O	-1	10462057
sis	O	-1	10462057
by	O	-1	10462057
re@@	B-Chemical	D017330	10462057
mo@@	I-Chemical	-1	10462057
xi@@	I-Chemical	-1	10462057
pri@@	I-Chemical	-1	10462057
de	I-Chemical	-1	10462057
metabol@@	O	-1	10462057
it@@	O	-1	10462057
es	O	-1	10462057
in	O	-1	10462057
H@@	O	-1	10462057
L@@	O	-1	10462057
60	O	-1	10462057
and	O	-1	10462057
C@@	O	-1	10462057
D@@	O	-1	10462057
34@@	O	-1	10462057
+/@@	O	-1	10462057
C@@	O	-1	10462057
D@@	O	-1	10462057
19@@	O	-1	10462057
-	O	-1	10462057
human	O	-1	10462057
b@@	O	-1	10462057
one	O	-1	10462057
m@@	O	-1	10462057
ar@@	O	-1	10462057
ro@@	O	-1	10462057
w	O	-1	10462057
pro@@	O	-1	10462057
gen@@	O	-1	10462057
it@@	O	-1	10462057
or	O	-1	10462057
cell@@	O	-1	10462057
s:	O	-1	10462057
potential	O	-1	10462057
re@@	O	-1	10462057
lev@@	O	-1	10462057
ance	O	-1	10462057
to	O	-1	10462057
re@@	B-Chemical	D017330	10462057
mo@@	I-Chemical	-1	10462057
xi@@	I-Chemical	-1	10462057
pri@@	I-Chemical	-1	10462057
de	I-Chemical	-1	10462057
-induced	O	-1	10462057
ap@@	B-Disease	D000741	10462057
las@@	I-Disease	-1	10462057
tic	I-Disease	-1	10462057
anemia	I-Disease	-1	10462057
.	O	-1	10462057
The	O	-1	10462057
anti@@	O	-1	10462057
psycho@@	O	-1	10462057
tic	O	-1	10462057
agent@@	O	-1	10462057
,	O	-1	10462057
re@@	B-Chemical	D017330	10462057
mo@@	I-Chemical	-1	10462057
xi@@	I-Chemical	-1	10462057
pri@@	I-Chemical	-1	10462057
de	I-Chemical	-1	10462057
[	O	-1	10462057
(S@@	B-Chemical	D017330	10462057
)-@@	I-Chemical	-1	10462057
(-@@	I-Chemical	-1	10462057
)-@@	I-Chemical	-1	10462057
3-@@	I-Chemical	-1	10462057
b@@	I-Chemical	-1	10462057
ro@@	I-Chemical	-1	10462057
mo@@	I-Chemical	-1	10462057
-@@	I-Chemical	-1	10462057
N@@	I-Chemical	-1	10462057
-@@	I-Chemical	-1	10462057
[@@	I-Chemical	-1	10462057
(1@@	I-Chemical	-1	10462057
-@@	I-Chemical	-1	10462057
eth@@	I-Chemical	-1	10462057
yl@@	I-Chemical	-1	10462057
-@@	I-Chemical	-1	10462057
2-@@	I-Chemical	-1	10462057
py@@	I-Chemical	-1	10462057
r@@	I-Chemical	-1	10462057
ro@@	I-Chemical	-1	10462057
l@@	I-Chemical	-1	10462057
id@@	I-Chemical	-1	10462057
in@@	I-Chemical	-1	10462057
yl@@	I-Chemical	-1	10462057
)@@	I-Chemical	-1	10462057
methyl@@	I-Chemical	-1	10462057
]@@	I-Chemical	-1	10462057
-@@	I-Chemical	-1	10462057
2@@	I-Chemical	-1	10462057
,@@	I-Chemical	-1	10462057
6-@@	I-Chemical	-1	10462057
di@@	I-Chemical	-1	10462057
meth@@	I-Chemical	-1	10462057
oxy@@	I-Chemical	-1	10462057
ben@@	I-Chemical	-1	10462057
z	I-Chemical	-1	10462057
amide	I-Chemical	-1	10462057
]	O	-1	10462057
has	O	-1	10462057
been	O	-1	10462057
associated	O	-1	10462057
with	O	-1	10462057
ac@@	O	-1	10462057
qu@@	O	-1	10462057
ired	O	-1	10462057
ap@@	B-Disease	D000741	10462057
las@@	I-Disease	-1	10462057
tic	I-Disease	-1	10462057
anemia	I-Disease	-1	10462057
.	O	-1	10462057
We	O	-1	10462057
have	O	-1	10462057
examined	O	-1	10462057
the	O	-1	10462057
ability	O	-1	10462057
of	O	-1	10462057
re@@	B-Chemical	D017330	10462057
mo@@	I-Chemical	-1	10462057
xi@@	I-Chemical	-1	10462057
pri@@	I-Chemical	-1	10462057
de	I-Chemical	-1	10462057
,	O	-1	10462057
three	O	-1	10462057
py@@	B-Chemical	C032519	10462057
r@@	I-Chemical	-1	10462057
ro@@	I-Chemical	-1	10462057
l@@	I-Chemical	-1	10462057
idine	I-Chemical	-1	10462057
r@@	O	-1	10462057
ing	O	-1	10462057
metabol@@	O	-1	10462057
it@@	O	-1	10462057
es	O	-1	10462057
and	O	-1	10462057
five	O	-1	10462057
a@@	O	-1	10462057
rom@@	O	-1	10462057
atic	O	-1	10462057
r@@	O	-1	10462057
ing	O	-1	10462057
metabol@@	O	-1	10462057
it@@	O	-1	10462057
es	O	-1	10462057
of	O	-1	10462057
the	O	-1	10462057
pa@@	O	-1	10462057
rent	O	-1	10462057
comp@@	O	-1	10462057
ound	O	-1	10462057
to	O	-1	10462057
induce	O	-1	10462057
apo@@	O	-1	10462057
pto@@	O	-1	10462057
sis	O	-1	10462057
in	O	-1	10462057
H@@	O	-1	10462057
L@@	O	-1	10462057
60	O	-1	10462057
cells	O	-1	10462057
and	O	-1	10462057
human	O	-1	10462057
b@@	O	-1	10462057
one	O	-1	10462057
m@@	O	-1	10462057
ar@@	O	-1	10462057
ro@@	O	-1	10462057
w	O	-1	10462057
pro@@	O	-1	10462057
gen@@	O	-1	10462057
it@@	O	-1	10462057
or	O	-1	10462057
(@@	O	-1	10462057
HB@@	O	-1	10462057
M@@	O	-1	10462057
P)	O	-1	10462057
cell@@	O	-1	10462057
s.	O	-1	10462057
C@@	O	-1	10462057
ell@@	O	-1	10462057
s	O	-1	10462057
were	O	-1	10462057
treated	O	-1	10462057
for	O	-1	10462057
0-@@	O	-1	10462057
24	O	-1	10462057
h	O	-1	10462057
with	O	-1	10462057
each	O	-1	10462057
comp@@	O	-1	10462057
ound	O	-1	10462057
(@@	O	-1	10462057
0-@@	O	-1	10462057
2@@	O	-1	10462057
00	O	-1	10462057
micro@@	O	-1	10462057
M@@	O	-1	10462057
).	O	-1	10462057
A@@	O	-1	10462057
po@@	O	-1	10462057
pto@@	O	-1	10462057
sis	O	-1	10462057
was	O	-1	10462057
assessed	O	-1	10462057
by	O	-1	10462057
fluo@@	O	-1	10462057
res@@	O	-1	10462057
c@@	O	-1	10462057
ence	O	-1	10462057
micro@@	O	-1	10462057
sco@@	O	-1	10462057
p@@	O	-1	10462057
y	O	-1	10462057
in	O	-1	10462057
Ho@@	B-Chemical	C017807	10462057
ech@@	I-Chemical	-1	10462057
st	I-Chemical	-1	10462057
3@@	I-Chemical	-1	10462057
3@@	I-Chemical	-1	10462057
34@@	I-Chemical	-1	10462057
2	I-Chemical	-1	10462057
-	O	-1	10462057
and	O	-1	10462057
pro@@	B-Chemical	D011419	10462057
pi@@	I-Chemical	-1	10462057
di@@	I-Chemical	-1	10462057
um	I-Chemical	-1	10462057
io@@	I-Chemical	-1	10462057
di@@	I-Chemical	-1	10462057
de	I-Chemical	-1	10462057
st@@	O	-1	10462057
ained	O	-1	10462057
cell	O	-1	10462057
sam@@	O	-1	10462057
pl@@	O	-1	10462057
es.	O	-1	10462057
R@@	O	-1	10462057
es@@	O	-1	10462057
ult@@	O	-1	10462057
s	O	-1	10462057
were	O	-1	10462057
con@@	O	-1	10462057
fir@@	O	-1	10462057
m@@	O	-1	10462057
ed	O	-1	10462057
by	O	-1	10462057
determin@@	O	-1	10462057
ation	O	-1	10462057
of	O	-1	10462057
inter@@	O	-1	10462057
nucle@@	O	-1	10462057
os@@	O	-1	10462057
om@@	O	-1	10462057
al	O	-1	10462057
D@@	O	-1	10462057
NA	O	-1	10462057
f@@	O	-1	10462057
ra@@	O	-1	10462057
g@@	O	-1	10462057
ment@@	O	-1	10462057
ation	O	-1	10462057
using	O	-1	10462057
ge@@	O	-1	10462057
l	O	-1	10462057
electro@@	O	-1	10462057
ph@@	O	-1	10462057
ore@@	O	-1	10462057
sis	O	-1	10462057
for	O	-1	10462057
H@@	O	-1	10462057
L@@	O	-1	10462057
60	O	-1	10462057
cell	O	-1	10462057
sam@@	O	-1	10462057
ple@@	O	-1	10462057
s	O	-1	10462057
and	O	-1	10462057
ter@@	O	-1	10462057
min@@	O	-1	10462057
al	O	-1	10462057
de@@	O	-1	10462057
oxy@@	O	-1	10462057
nucle@@	O	-1	10462057
o@@	O	-1	10462057
ti@@	O	-1	10462057
dy@@	O	-1	10462057
l	O	-1	10462057
trans@@	O	-1	10462057
fer@@	O	-1	10462057
ase	O	-1	10462057
ass@@	O	-1	10462057
ay	O	-1	10462057
in	O	-1	10462057
HB@@	O	-1	10462057
M@@	O	-1	10462057
P	O	-1	10462057
cell@@	O	-1	10462057
s.	O	-1	10462057
The	O	-1	10462057
cat@@	B-Chemical	C034221	10462057
ec@@	I-Chemical	-1	10462057
hol	I-Chemical	-1	10462057
and	O	-1	10462057
hydro@@	B-Chemical	C031927	10462057
qu@@	I-Chemical	-1	10462057
in@@	I-Chemical	-1	10462057
one	I-Chemical	-1	10462057
metabol@@	O	-1	10462057
it@@	O	-1	10462057
es,	O	-1	10462057
N@@	B-Chemical	C084325	10462057
C@@	I-Chemical	-1	10462057
Q@@	I-Chemical	-1	10462057
4@@	I-Chemical	-1	10462057
3@@	I-Chemical	-1	10462057
6	I-Chemical	-1	10462057
and	O	-1	10462057
N@@	B-Chemical	C112341	10462057
C@@	I-Chemical	-1	10462057
Q@@	I-Chemical	-1	10462057
34@@	I-Chemical	-1	10462057
4	I-Chemical	-1	10462057
,	O	-1	10462057
induced	O	-1	10462057
apo@@	O	-1	10462057
pto@@	O	-1	10462057
sis	O	-1	10462057
in	O	-1	10462057
H@@	O	-1	10462057
L@@	O	-1	10462057
60	O	-1	10462057
and	O	-1	10462057
HB@@	O	-1	10462057
M@@	O	-1	10462057
P	O	-1	10462057
cells	O	-1	10462057
in	O	-1	10462057
a	O	-1	10462057
ti@@	O	-1	10462057
me@@	O	-1	10462057
-	O	-1	10462057
and	O	-1	10462057
concentration	O	-1	10462057
dependent	O	-1	10462057
man@@	O	-1	10462057
ner@@	O	-1	10462057
,	O	-1	10462057
while	O	-1	10462057
the	O	-1	10462057
phen@@	B-Chemical	D010636	10462057
ol@@	I-Chemical	-1	10462057
s	I-Chemical	-1	10462057
,	O	-1	10462057
N@@	O	-1	10462057
CR@@	O	-1	10462057
18@@	O	-1	10462057
1,	O	-1	10462057
F@@	O	-1	10462057
L@@	O	-1	10462057
A@@	O	-1	10462057
8@@	O	-1	10462057
7@@	O	-1	10462057
3,	O	-1	10462057
and	O	-1	10462057
F@@	B-Chemical	C050313	10462057
L@@	I-Chemical	-1	10462057
A@@	I-Chemical	-1	10462057
7@@	I-Chemical	-1	10462057
9@@	I-Chemical	-1	10462057
7	I-Chemical	-1	10462057
,	O	-1	10462057
and	O	-1	10462057
the	O	-1	10462057
der@@	O	-1	10462057
i@@	O	-1	10462057
v@@	O	-1	10462057
ati@@	O	-1	10462057
v@@	O	-1	10462057
es	O	-1	10462057
form@@	O	-1	10462057
ed	O	-1	10462057
by	O	-1	10462057
oxid@@	O	-1	10462057
ation	O	-1	10462057
of	O	-1	10462057
the	O	-1	10462057
py@@	B-Chemical	C032519	10462057
r@@	I-Chemical	-1	10462057
ro@@	I-Chemical	-1	10462057
l@@	I-Chemical	-1	10462057
idine	I-Chemical	-1	10462057
r@@	O	-1	10462057
ing,	O	-1	10462057
F@@	O	-1	10462057
L@@	O	-1	10462057
A@@	O	-1	10462057
8@@	O	-1	10462057
3@@	O	-1	10462057
8@@	O	-1	10462057
,	O	-1	10462057
N@@	O	-1	10462057
C@@	O	-1	10462057
M@@	O	-1	10462057
0@@	O	-1	10462057
0@@	O	-1	10462057
1,	O	-1	10462057
and	O	-1	10462057
N@@	O	-1	10462057
CL@@	O	-1	10462057
1@@	O	-1	10462057
18@@	O	-1	10462057
,	O	-1	10462057
had	O	-1	10462057
no	O	-1	10462057
effect@@	O	-1	10462057
.	O	-1	10462057
No	O	-1	10462057
necro@@	B-Disease	D009336	10462057
sis	I-Disease	-1	10462057
was	O	-1	10462057
observed	O	-1	10462057
in	O	-1	10462057
cells	O	-1	10462057
treated	O	-1	10462057
with	O	-1	10462057
N@@	B-Chemical	C084325	10462057
C@@	I-Chemical	-1	10462057
Q@@	I-Chemical	-1	10462057
4@@	I-Chemical	-1	10462057
3@@	I-Chemical	-1	10462057
6	I-Chemical	-1	10462057
but	O	-1	10462057
N@@	B-Chemical	C112341	10462057
C@@	I-Chemical	-1	10462057
Q@@	I-Chemical	-1	10462057
34@@	I-Chemical	-1	10462057
4	I-Chemical	-1	10462057
had	O	-1	10462057
a	O	-1	10462057
b@@	O	-1	10462057
i@@	O	-1	10462057
pha@@	O	-1	10462057
sic	O	-1	10462057
effect	O	-1	10462057
in	O	-1	10462057
both	O	-1	10462057
cell	O	-1	10462057
typ@@	O	-1	10462057
es,	O	-1	10462057
induc@@	O	-1	10462057
ing	O	-1	10462057
apo@@	O	-1	10462057
pto@@	O	-1	10462057
sis	O	-1	10462057
at	O	-1	10462057
lower	O	-1	10462057
concentrations	O	-1	10462057
and	O	-1	10462057
necro@@	B-Disease	D009336	10462057
sis	I-Disease	-1	10462057
at	O	-1	10462057
higher	O	-1	10462057
concentr@@	O	-1	10462057
ations.	O	-1	10462057
These	O	-1	10462057
data	O	-1	10462057
show	O	-1	10462057
that	O	-1	10462057
the	O	-1	10462057
cat@@	B-Chemical	C034221	10462057
ec@@	I-Chemical	-1	10462057
hol	I-Chemical	-1	10462057
and	O	-1	10462057
hydro@@	B-Chemical	C031927	10462057
qu@@	I-Chemical	-1	10462057
in@@	I-Chemical	-1	10462057
one	I-Chemical	-1	10462057
metabol@@	O	-1	10462057
it@@	O	-1	10462057
es	O	-1	10462057
of	O	-1	10462057
re@@	B-Chemical	D017330	10462057
mo@@	I-Chemical	-1	10462057
xi@@	I-Chemical	-1	10462057
pri@@	I-Chemical	-1	10462057
de	I-Chemical	-1	10462057
have	O	-1	10462057
direct	O	-1	10462057
toxic	O	-1	10462057
effects	O	-1	10462057
in	O	-1	10462057
H@@	O	-1	10462057
L@@	O	-1	10462057
60	O	-1	10462057
and	O	-1	10462057
HB@@	O	-1	10462057
M@@	O	-1	10462057
P	O	-1	10462057
cell@@	O	-1	10462057
s,	O	-1	10462057
lead@@	O	-1	10462057
ing	O	-1	10462057
to	O	-1	10462057
apo@@	O	-1	10462057
pto@@	O	-1	10462057
sis,	O	-1	10462057
while	O	-1	10462057
the	O	-1	10462057
phen@@	B-Chemical	D019800	10462057
ol	I-Chemical	-1	10462057
metabol@@	O	-1	10462057
it@@	O	-1	10462057
es	O	-1	10462057
were	O	-1	10462057
in@@	O	-1	10462057
ac@@	O	-1	10462057
ti@@	O	-1	10462057
ve.	O	-1	10462057
S@@	O	-1	10462057
im@@	O	-1	10462057
il@@	O	-1	10462057
ar@@	O	-1	10462057
ly,	O	-1	10462057
b@@	B-Chemical	D001554	10462057
enz@@	I-Chemical	-1	10462057
ene	I-Chemical	-1	10462057
-@@	O	-1	10462057
der@@	O	-1	10462057
i@@	O	-1	10462057
ved	O	-1	10462057
cat@@	B-Chemical	C034221	10462057
ec@@	I-Chemical	-1	10462057
hol	I-Chemical	-1	10462057
and	O	-1	10462057
hydro@@	B-Chemical	C031927	10462057
qu@@	I-Chemical	-1	10462057
in@@	I-Chemical	-1	10462057
one	I-Chemical	-1	10462057
,	O	-1	10462057
but	O	-1	10462057
not	O	-1	10462057
phen@@	B-Chemical	D019800	10462057
ol	I-Chemical	-1	10462057
,	O	-1	10462057
induce	O	-1	10462057
apo@@	O	-1	10462057
pto@@	O	-1	10462057
sis	O	-1	10462057
in	O	-1	10462057
HB@@	O	-1	10462057
M@@	O	-1	10462057
P	O	-1	10462057
cells	O	-1	10462057
[@@	O	-1	10462057
M@@	O	-1	10462057
or@@	O	-1	10462057
an	O	-1	10462057
et	O	-1	10462057
al@@	O	-1	10462057
.,	O	-1	10462057
M@@	O	-1	10462057
ol@@	O	-1	10462057
.	O	-1	10462057
Ph@@	O	-1	10462057
armac@@	O	-1	10462057
ol@@	O	-1	10462057
.,	O	-1	10462057
50	O	-1	10462057
(1@@	O	-1	10462057
9@@	O	-1	10462057
9@@	O	-1	10462057
6@@	O	-1	10462057
)	O	-1	10462057
6@@	O	-1	10462057
10-@@	O	-1	10462057
6@@	O	-1	10462057
1@@	O	-1	10462057
5@@	O	-1	10462057
]@@	O	-1	10462057
.	O	-1	10462057
We	O	-1	10462057
prop@@	O	-1	10462057
ose	O	-1	10462057
that	O	-1	10462057
re@@	B-Chemical	D017330	10462057
mo@@	I-Chemical	-1	10462057
xi@@	I-Chemical	-1	10462057
pri@@	I-Chemical	-1	10462057
de	I-Chemical	-1	10462057
and	O	-1	10462057
b@@	B-Chemical	D001554	10462057
enz@@	I-Chemical	-1	10462057
ene	I-Chemical	-1	10462057
may	O	-1	10462057
induce	O	-1	10462057
ap@@	B-Disease	D000741	10462057
las@@	I-Disease	-1	10462057
tic	I-Disease	-1	10462057
anemia	I-Disease	-1	10462057
vi@@	O	-1	10462057
a	O	-1	10462057
pro@@	O	-1	10462057
duction	O	-1	10462057
of	O	-1	10462057
similar	O	-1	10462057
reac@@	O	-1	10462057
tive	O	-1	10462057
metabol@@	O	-1	10462057
it@@	O	-1	10462057
es	O	-1	10462057
and	O	-1	10462057
that	O	-1	10462057
the	O	-1	10462057
ability	O	-1	10462057
of	O	-1	10462057
N@@	B-Chemical	C084325	10462057
C@@	I-Chemical	-1	10462057
Q@@	I-Chemical	-1	10462057
4@@	I-Chemical	-1	10462057
3@@	I-Chemical	-1	10462057
6	I-Chemical	-1	10462057
and	O	-1	10462057
N@@	B-Chemical	C112341	10462057
C@@	I-Chemical	-1	10462057
Q@@	I-Chemical	-1	10462057
34@@	I-Chemical	-1	10462057
4	I-Chemical	-1	10462057
to	O	-1	10462057
induce	O	-1	10462057
apo@@	O	-1	10462057
pto@@	O	-1	10462057
sis	O	-1	10462057
in	O	-1	10462057
HB@@	O	-1	10462057
M@@	O	-1	10462057
P	O	-1	10462057
cells	O	-1	10462057
may	O	-1	10462057
cont@@	O	-1	10462057
rib@@	O	-1	10462057
ute	O	-1	10462057
to	O	-1	10462057
the	O	-1	10462057
mechanism	O	-1	10462057
underlying	O	-1	10462057
ac@@	O	-1	10462057
qu@@	O	-1	10462057
ired	O	-1	10462057
ap@@	B-Disease	D000741	10462057
las@@	I-Disease	-1	10462057
tic	I-Disease	-1	10462057
anemia	I-Disease	-1	10462057
that	O	-1	10462057
has	O	-1	10462057
been	O	-1	10462057
associated	O	-1	10462057
with	O	-1	10462057
re@@	B-Chemical	D017330	10462057
mo@@	I-Chemical	-1	10462057
xi@@	I-Chemical	-1	10462057
pri@@	I-Chemical	-1	10462057
de	I-Chemical	-1	10462057
.	O	-1	10462057

S@@	O	-1	10510854
yn@@	O	-1	10510854
thesis	O	-1	10510854
and	O	-1	10510854
pre@@	O	-1	10510854
lim@@	O	-1	10510854
inary	O	-1	10510854
pharmac@@	O	-1	10510854
ological	O	-1	10510854
investig@@	O	-1	10510854
ations	O	-1	10510854
of	O	-1	10510854
1-@@	B-Chemical	-1	10510854
(1@@	I-Chemical	-1	10510854
,@@	I-Chemical	-1	10510854
2-@@	I-Chemical	-1	10510854
di@@	I-Chemical	-1	10510854
hydro@@	I-Chemical	-1	10510854
-@@	I-Chemical	-1	10510854
2-@@	I-Chemical	-1	10510854
ac@@	I-Chemical	-1	10510854
en@@	I-Chemical	-1	10510854
a@@	I-Chemical	-1	10510854
ph@@	I-Chemical	-1	10510854
th@@	I-Chemical	-1	10510854
yl@@	I-Chemical	-1	10510854
en@@	I-Chemical	-1	10510854
yl@@	I-Chemical	-1	10510854
)@@	I-Chemical	-1	10510854
pi@@	I-Chemical	-1	10510854
per@@	I-Chemical	-1	10510854
az@@	I-Chemical	-1	10510854
ine	I-Chemical	-1	10510854
der@@	O	-1	10510854
i@@	O	-1	10510854
v@@	O	-1	10510854
ati@@	O	-1	10510854
v@@	O	-1	10510854
es	O	-1	10510854
as	O	-1	10510854
potential	O	-1	10510854
at@@	O	-1	10510854
yp@@	O	-1	10510854
ical	O	-1	10510854
anti@@	O	-1	10510854
psycho@@	O	-1	10510854
tic	O	-1	10510854
agents	O	-1	10510854
in	O	-1	10510854
mice.	O	-1	10510854
In	O	-1	10510854
re@@	O	-1	10510854
se@@	O	-1	10510854
arc@@	O	-1	10510854
h	O	-1	10510854
to@@	O	-1	10510854
war@@	O	-1	10510854
ds	O	-1	10510854
the	O	-1	10510854
development	O	-1	10510854
of	O	-1	10510854
new	O	-1	10510854
at@@	O	-1	10510854
yp@@	O	-1	10510854
ical	O	-1	10510854
anti@@	O	-1	10510854
psycho@@	O	-1	10510854
tic	O	-1	10510854
agent@@	O	-1	10510854
s,	O	-1	10510854
one	O	-1	10510854
strat@@	O	-1	10510854
e@@	O	-1	10510854
g@@	O	-1	10510854
y	O	-1	10510854
is	O	-1	10510854
that	O	-1	10510854
the	O	-1	10510854
dop@@	O	-1	10510854
aminergic	O	-1	10510854
system	O	-1	10510854
can	O	-1	10510854
be	O	-1	10510854
mod@@	O	-1	10510854
ul@@	O	-1	10510854
ated	O	-1	10510854
through	O	-1	10510854
man@@	O	-1	10510854
ip@@	O	-1	10510854
ulation	O	-1	10510854
of	O	-1	10510854
the	O	-1	10510854
seroton@@	O	-1	10510854
ergic	O	-1	10510854
system@@	O	-1	10510854
.	O	-1	10510854
The	O	-1	10510854
syn@@	O	-1	10510854
thesis	O	-1	10510854
and	O	-1	10510854
pre@@	O	-1	10510854
lim@@	O	-1	10510854
inary	O	-1	10510854
pharmac@@	O	-1	10510854
ological	O	-1	10510854
evalu@@	O	-1	10510854
ation	O	-1	10510854
of	O	-1	10510854
a	O	-1	10510854
seri@@	O	-1	10510854
es	O	-1	10510854
of	O	-1	10510854
potential	O	-1	10510854
at@@	O	-1	10510854
yp@@	O	-1	10510854
ical	O	-1	10510854
anti@@	O	-1	10510854
psycho@@	O	-1	10510854
tic	O	-1	10510854
agents	O	-1	10510854
bas@@	O	-1	10510854
ed	O	-1	10510854
on	O	-1	10510854
the	O	-1	10510854
struct@@	O	-1	10510854
ure	O	-1	10510854
of	O	-1	10510854
1-@@	B-Chemical	-1	10510854
(1@@	I-Chemical	-1	10510854
,@@	I-Chemical	-1	10510854
2-@@	I-Chemical	-1	10510854
di@@	I-Chemical	-1	10510854
hydro@@	I-Chemical	-1	10510854
-@@	I-Chemical	-1	10510854
2-@@	I-Chemical	-1	10510854
ac@@	I-Chemical	-1	10510854
en@@	I-Chemical	-1	10510854
a@@	I-Chemical	-1	10510854
ph@@	I-Chemical	-1	10510854
th@@	I-Chemical	-1	10510854
yl@@	I-Chemical	-1	10510854
en@@	I-Chemical	-1	10510854
yl@@	I-Chemical	-1	10510854
)@@	I-Chemical	-1	10510854
pi@@	I-Chemical	-1	10510854
per@@	I-Chemical	-1	10510854
az@@	I-Chemical	-1	10510854
ine	I-Chemical	-1	10510854
(@@	O	-1	10510854
7@@	O	-1	10510854
)	O	-1	10510854
is	O	-1	10510854
descri@@	O	-1	10510854
be@@	O	-1	10510854
d.	O	-1	10510854
Com@@	O	-1	10510854
p@@	O	-1	10510854
ound	O	-1	10510854
7@@	O	-1	10510854
e,	O	-1	10510854
5-@@	B-Chemical	-1	10510854
{@@	I-Chemical	-1	10510854
2-@@	I-Chemical	-1	10510854
[@@	I-Chemical	-1	10510854
4-@@	I-Chemical	-1	10510854
(1@@	I-Chemical	-1	10510854
,@@	I-Chemical	-1	10510854
2-@@	I-Chemical	-1	10510854
di@@	I-Chemical	-1	10510854
hydro@@	I-Chemical	-1	10510854
-@@	I-Chemical	-1	10510854
2-@@	I-Chemical	-1	10510854
ac@@	I-Chemical	-1	10510854
en@@	I-Chemical	-1	10510854
a@@	I-Chemical	-1	10510854
ph@@	I-Chemical	-1	10510854
th@@	I-Chemical	-1	10510854
yl@@	I-Chemical	-1	10510854
en@@	I-Chemical	-1	10510854
yl@@	I-Chemical	-1	10510854
)@@	I-Chemical	-1	10510854
pi@@	I-Chemical	-1	10510854
per@@	I-Chemical	-1	10510854
az@@	I-Chemical	-1	10510854
in@@	I-Chemical	-1	10510854
yl@@	I-Chemical	-1	10510854
]@@	I-Chemical	-1	10510854
eth@@	I-Chemical	-1	10510854
yl@@	I-Chemical	-1	10510854
}@@	I-Chemical	-1	10510854
-@@	I-Chemical	-1	10510854
2@@	I-Chemical	-1	10510854
,@@	I-Chemical	-1	10510854
3-@@	I-Chemical	-1	10510854
di@@	I-Chemical	-1	10510854
h@@	I-Chemical	-1	10510854
y	I-Chemical	-1	10510854
dro@@	I-Chemical	-1	10510854
-1@@	I-Chemical	-1	10510854
H@@	I-Chemical	-1	10510854
-	I-Chemical	-1	10510854
ind@@	I-Chemical	-1	10510854
ol@@	I-Chemical	-1	10510854
-@@	I-Chemical	-1	10510854
2-@@	I-Chemical	-1	10510854
one	I-Chemical	-1	10510854
,	O	-1	10510854
from	O	-1	10510854
this	O	-1	10510854
seri@@	O	-1	10510854
es	O	-1	10510854
showed	O	-1	10510854
significant	O	-1	10510854
aff@@	O	-1	10510854
initi@@	O	-1	10510854
es	O	-1	10510854
at	O	-1	10510854
the	O	-1	10510854
5-@@	O	-1	10510854
H@@	O	-1	10510854
T@@	O	-1	10510854
1@@	O	-1	10510854
A	O	-1	10510854
and	O	-1	10510854
5-@@	O	-1	10510854
H@@	O	-1	10510854
T@@	O	-1	10510854
2@@	O	-1	10510854
A	O	-1	10510854
receptors	O	-1	10510854
and	O	-1	10510854
moder@@	O	-1	10510854
ate	O	-1	10510854
aff@@	O	-1	10510854
in@@	O	-1	10510854
ity	O	-1	10510854
at	O	-1	10510854
the	O	-1	10510854
D2	O	-1	10510854
receptor@@	O	-1	10510854
.	O	-1	10510854
7@@	O	-1	10510854
e	O	-1	10510854
ex@@	O	-1	10510854
hib@@	O	-1	10510854
its	O	-1	10510854
a	O	-1	10510854
high	O	-1	10510854
rever@@	O	-1	10510854
s@@	O	-1	10510854
al	O	-1	10510854
of	O	-1	10510854
cat@@	B-Disease	D002375	10510854
al@@	I-Disease	-1	10510854
ep@@	I-Disease	-1	10510854
sy	I-Disease	-1	10510854
induced	O	-1	10510854
by	O	-1	10510854
haloperidol	B-Chemical	D006220	10510854
indicating	O	-1	10510854
its	O	-1	10510854
at@@	O	-1	10510854
yp@@	O	-1	10510854
ical	O	-1	10510854
anti@@	O	-1	10510854
psycho@@	O	-1	10510854
tic	O	-1	10510854
n@@	O	-1	10510854
at@@	O	-1	10510854
ure.	O	-1	10510854

S@@	O	-1	10672628
ub@@	O	-1	10672628
-@@	O	-1	10672628
chronic	O	-1	10672628
inhibition	O	-1	10672628
of	O	-1	10672628
nit@@	B-Chemical	D009569	10672628
r@@	I-Chemical	-1	10672628
ic@@	I-Chemical	-1	10672628
-@@	I-Chemical	-1	10672628
ox@@	I-Chemical	-1	10672628
ide	I-Chemical	-1	10672628
syn@@	O	-1	10672628
thesis	O	-1	10672628
mo@@	O	-1	10672628
di@@	O	-1	10672628
fi@@	O	-1	10672628
es	O	-1	10672628
haloperidol	B-Chemical	D006220	10672628
-induced	O	-1	10672628
cat@@	B-Disease	D002375	10672628
al@@	I-Disease	-1	10672628
ep@@	I-Disease	-1	10672628
sy	I-Disease	-1	10672628
and	O	-1	10672628
the	O	-1	10672628
number	O	-1	10672628
of	O	-1	10672628
N@@	B-Chemical	D009249	10672628
AD@@	I-Chemical	-1	10672628
P@@	I-Chemical	-1	10672628
H	I-Chemical	-1	10672628
-@@	O	-1	10672628
dia@@	O	-1	10672628
ph@@	O	-1	10672628
or@@	O	-1	10672628
ase	O	-1	10672628
neuron@@	O	-1	10672628
s	O	-1	10672628
in	O	-1	10672628
mice.	O	-1	10672628
R@@	O	-1	10672628
AT@@	O	-1	10672628
ION@@	O	-1	10672628
AL@@	O	-1	10672628
E:	O	-1	10672628
N@@	B-Chemical	D019335	10672628
G@@	I-Chemical	-1	10672628
-@@	I-Chemical	-1	10672628
nitro@@	I-Chemical	-1	10672628
-@@	I-Chemical	-1	10672628
L-@@	I-Chemical	-1	10672628
arg@@	I-Chemical	-1	10672628
inine	I-Chemical	-1	10672628
(	O	-1	10672628
L-@@	B-Chemical	D019335	10672628
NO@@	I-Chemical	-1	10672628
A@@	I-Chemical	-1	10672628
R@@	I-Chemical	-1	10672628
G	I-Chemical	-1	10672628
),	O	-1	10672628
an	O	-1	10672628
inhibitor	O	-1	10672628
of	O	-1	10672628
nit@@	B-Chemical	D009569	10672628
r@@	I-Chemical	-1	10672628
ic@@	I-Chemical	-1	10672628
-@@	I-Chemical	-1	10672628
ox@@	I-Chemical	-1	10672628
ide	I-Chemical	-1	10672628
syn@@	O	-1	10672628
th@@	O	-1	10672628
ase	O	-1	10672628
(N@@	O	-1	10672628
O@@	O	-1	10672628
S@@	O	-1	10672628
),	O	-1	10672628
induc@@	O	-1	10672628
es	O	-1	10672628
cat@@	B-Disease	D002375	10672628
al@@	I-Disease	-1	10672628
ep@@	I-Disease	-1	10672628
sy	I-Disease	-1	10672628
in	O	-1	10672628
mice.	O	-1	10672628
This	O	-1	10672628
effect	O	-1	10672628
under@@	O	-1	10672628
go@@	O	-1	10672628
es	O	-1	10672628
ra@@	O	-1	10672628
pid	O	-1	10672628
toler@@	O	-1	10672628
ance@@	O	-1	10672628
,	O	-1	10672628
show@@	O	-1	10672628
ing	O	-1	10672628
a	O	-1	10672628
significant	O	-1	10672628
decrease	O	-1	10672628
after	O	-1	10672628
2	O	-1	10672628
days	O	-1	10672628
of	O	-1	10672628
sub@@	O	-1	10672628
-@@	O	-1	10672628
chronic	O	-1	10672628
L-@@	B-Chemical	D019335	10672628
NO@@	I-Chemical	-1	10672628
A@@	I-Chemical	-1	10672628
R@@	I-Chemical	-1	10672628
G	I-Chemical	-1	10672628
treatment.	O	-1	10672628
N@@	B-Chemical	D009569	10672628
it@@	I-Chemical	-1	10672628
ric	I-Chemical	-1	10672628
ox@@	I-Chemical	-1	10672628
ide	I-Chemical	-1	10672628
(	O	-1	10672628
N@@	B-Chemical	D009569	10672628
O	I-Chemical	-1	10672628
)	O	-1	10672628
has	O	-1	10672628
been	O	-1	10672628
shown	O	-1	10672628
to	O	-1	10672628
influence	O	-1	10672628
dop@@	O	-1	10672628
aminergic	O	-1	10672628
neuro@@	O	-1	10672628
trans@@	O	-1	10672628
mission	O	-1	10672628
in	O	-1	10672628
the	O	-1	10672628
striat@@	O	-1	10672628
um@@	O	-1	10672628
.	O	-1	10672628
Ne@@	O	-1	10672628
uro@@	O	-1	10672628
le@@	O	-1	10672628
p@@	O	-1	10672628
tic	O	-1	10672628
drugs	O	-1	10672628
such	O	-1	10672628
as	O	-1	10672628
haloperidol	B-Chemical	D006220	10672628
,	O	-1	10672628
which	O	-1	10672628
bloc@@	O	-1	10672628
k	O	-1	10672628
dopamine	B-Chemical	D004298	10672628
receptor@@	O	-1	10672628
s,	O	-1	10672628
also	O	-1	10672628
cause	O	-1	10672628
cat@@	B-Disease	D002375	10672628
al@@	I-Disease	-1	10672628
ep@@	I-Disease	-1	10672628
sy	I-Disease	-1	10672628
in	O	-1	10672628
ro@@	O	-1	10672628
d@@	O	-1	10672628
ent@@	O	-1	10672628
s.	O	-1	10672628
OBJECTIV@@	O	-1	10672628
E@@	O	-1	10672628
S:	O	-1	10672628
To	O	-1	10672628
investigate	O	-1	10672628
the	O	-1	10672628
effects	O	-1	10672628
of	O	-1	10672628
sub@@	O	-1	10672628
chronic	O	-1	10672628
L-@@	B-Chemical	D019335	10672628
NO@@	I-Chemical	-1	10672628
A@@	I-Chemical	-1	10672628
R@@	I-Chemical	-1	10672628
G	I-Chemical	-1	10672628
treatment	O	-1	10672628
in	O	-1	10672628
haloperidol	B-Chemical	D006220	10672628
-induced	O	-1	10672628
cat@@	B-Disease	D002375	10672628
al@@	I-Disease	-1	10672628
ep@@	I-Disease	-1	10672628
sy	I-Disease	-1	10672628
and	O	-1	10672628
the	O	-1	10672628
number	O	-1	10672628
of	O	-1	10672628
NO@@	O	-1	10672628
S	O	-1	10672628
neuron@@	O	-1	10672628
s	O	-1	10672628
in	O	-1	10672628
a@@	O	-1	10672628
reas	O	-1	10672628
related	O	-1	10672628
to	O	-1	10672628
motor	O	-1	10672628
control@@	O	-1	10672628
.	O	-1	10672628
METHODS:	O	-1	10672628
M@@	O	-1	10672628
al@@	O	-1	10672628
e	O	-1	10672628
al@@	O	-1	10672628
bin@@	O	-1	10672628
o	O	-1	10672628
S@@	O	-1	10672628
w@@	O	-1	10672628
is@@	O	-1	10672628
s	O	-1	10672628
mice	O	-1	10672628
were	O	-1	10672628
treated	O	-1	10672628
sub@@	O	-1	10672628
-@@	O	-1	10672628
chron@@	O	-1	10672628
ically	O	-1	10672628
(@@	O	-1	10672628
tw@@	O	-1	10672628
ic@@	O	-1	10672628
e	O	-1	10672628
a	O	-1	10672628
day	O	-1	10672628
for	O	-1	10672628
4	O	-1	10672628
da@@	O	-1	10672628
ys@@	O	-1	10672628
)	O	-1	10672628
with	O	-1	10672628
L-@@	B-Chemical	D019335	10672628
NO@@	I-Chemical	-1	10672628
A@@	I-Chemical	-1	10672628
R@@	I-Chemical	-1	10672628
G	I-Chemical	-1	10672628
(@@	O	-1	10672628
40	O	-1	10672628
mg/kg	O	-1	10672628
i.p.@@	O	-1	10672628
)	O	-1	10672628
or	O	-1	10672628
haloperidol	B-Chemical	D006220	10672628
(@@	O	-1	10672628
1	O	-1	10672628
mg/kg	O	-1	10672628
i.p.@@	O	-1	10672628
).	O	-1	10672628
C@@	B-Disease	D002375	10672628
at@@	I-Disease	-1	10672628
al@@	I-Disease	-1	10672628
ep@@	I-Disease	-1	10672628
sy	I-Disease	-1	10672628
was	O	-1	10672628
evaluated	O	-1	10672628
at	O	-1	10672628
the	O	-1	10672628
be@@	O	-1	10672628
g@@	O	-1	10672628
in@@	O	-1	10672628
ning	O	-1	10672628
and	O	-1	10672628
the	O	-1	10672628
end	O	-1	10672628
of	O	-1	10672628
the	O	-1	10672628
treatment@@	O	-1	10672628
s.	O	-1	10672628
Re@@	O	-1	10672628
duced	O	-1	10672628
nicot@@	B-Chemical	D009249	10672628
in@@	I-Chemical	-1	10672628
amide	I-Chemical	-1	10672628
aden@@	I-Chemical	-1	10672628
ine	I-Chemical	-1	10672628
d@@	I-Chemical	-1	10672628
in@@	I-Chemical	-1	10672628
ucle@@	I-Chemical	-1	10672628
o@@	I-Chemical	-1	10672628
ti@@	I-Chemical	-1	10672628
de	I-Chemical	-1	10672628
phosph@@	I-Chemical	-1	10672628
ate	I-Chemical	-1	10672628
-@@	O	-1	10672628
dia@@	O	-1	10672628
ph@@	O	-1	10672628
or@@	O	-1	10672628
ase	O	-1	10672628
(	O	-1	10672628
N@@	B-Chemical	D009249	10672628
AD@@	I-Chemical	-1	10672628
P@@	I-Chemical	-1	10672628
H	I-Chemical	-1	10672628
-@@	O	-1	10672628
d@@	O	-1	10672628
)	O	-1	10672628
histo@@	O	-1	10672628
chem@@	O	-1	10672628
ist@@	O	-1	10672628
r@@	O	-1	10672628
y	O	-1	10672628
was	O	-1	10672628
also	O	-1	10672628
em@@	O	-1	10672628
p@@	O	-1	10672628
lo@@	O	-1	10672628
y@@	O	-1	10672628
ed	O	-1	10672628
to	O	-1	10672628
vi@@	O	-1	10672628
su@@	O	-1	10672628
al@@	O	-1	10672628
iz@@	O	-1	10672628
e	O	-1	10672628
NO@@	O	-1	10672628
S	O	-1	10672628
as	O	-1	10672628
an	O	-1	10672628
in@@	O	-1	10672628
de@@	O	-1	10672628
x	O	-1	10672628
of	O	-1	10672628
enzyme	O	-1	10672628
expression	O	-1	10672628
in	O	-1	10672628
mice	O	-1	10672628
brain	O	-1	10672628
regi@@	O	-1	10672628
ons	O	-1	10672628
related	O	-1	10672628
to	O	-1	10672628
motor	O	-1	10672628
control@@	O	-1	10672628
.	O	-1	10672628
RESULTS:	O	-1	10672628
L-@@	B-Chemical	D019335	10672628
NO@@	I-Chemical	-1	10672628
A@@	I-Chemical	-1	10672628
R@@	I-Chemical	-1	10672628
G	I-Chemical	-1	10672628
sub@@	O	-1	10672628
-@@	O	-1	10672628
chronic	O	-1	10672628
administration	O	-1	10672628
produced	O	-1	10672628
toler@@	O	-1	10672628
ance	O	-1	10672628
of	O	-1	10672628
L-@@	B-Chemical	D019335	10672628
NO@@	I-Chemical	-1	10672628
A@@	I-Chemical	-1	10672628
R@@	I-Chemical	-1	10672628
G	I-Chemical	-1	10672628
and	O	-1	10672628
of	O	-1	10672628
haloperidol	B-Chemical	D006220	10672628
-induced	O	-1	10672628
cat@@	B-Disease	D002375	10672628
al@@	I-Disease	-1	10672628
ep@@	I-Disease	-1	10672628
sy	I-Disease	-1	10672628
.	O	-1	10672628
It	O	-1	10672628
also	O	-1	10672628
induced	O	-1	10672628
an	O	-1	10672628
increase	O	-1	10672628
in	O	-1	10672628
the	O	-1	10672628
number	O	-1	10672628
of	O	-1	10672628
N@@	B-Chemical	D009249	10672628
AD@@	I-Chemical	-1	10672628
P@@	I-Chemical	-1	10672628
H	I-Chemical	-1	10672628
-@@	O	-1	10672628
d-@@	O	-1	10672628
positive	O	-1	10672628
cells	O	-1	10672628
in	O	-1	10672628
the	O	-1	10672628
d@@	O	-1	10672628
or@@	O	-1	10672628
s@@	O	-1	10672628
al	O	-1	10672628
par@@	O	-1	10672628
t	O	-1	10672628
of	O	-1	10672628
the	O	-1	10672628
ca@@	O	-1	10672628
ud@@	O	-1	10672628
ate	O	-1	10672628
and	O	-1	10672628
accum@@	O	-1	10672628
ben@@	O	-1	10672628
s	O	-1	10672628
nucle@@	O	-1	10672628
i	O	-1	10672628
compared	O	-1	10672628
with	O	-1	10672628
haloperidol	B-Chemical	D006220	10672628
and	O	-1	10672628
in	O	-1	10672628
the	O	-1	10672628
p@@	O	-1	10672628
ed@@	O	-1	10672628
unc@@	O	-1	10672628
u@@	O	-1	10672628
lop@@	O	-1	10672628
ont@@	O	-1	10672628
ine	O	-1	10672628
te@@	O	-1	10672628
g@@	O	-1	10672628
mental	O	-1	10672628
nucle@@	O	-1	10672628
us	O	-1	10672628
compared	O	-1	10672628
with	O	-1	10672628
sal@@	O	-1	10672628
ine.	O	-1	10672628
In	O	-1	10672628
contrast@@	O	-1	10672628
,	O	-1	10672628
there	O	-1	10672628
was	O	-1	10672628
a	O	-1	10672628
decrease	O	-1	10672628
in	O	-1	10672628
N@@	B-Chemical	D009249	10672628
AD@@	I-Chemical	-1	10672628
P@@	I-Chemical	-1	10672628
H	I-Chemical	-1	10672628
-@@	O	-1	10672628
d	O	-1	10672628
neuro@@	O	-1	10672628
n	O	-1	10672628
number	O	-1	10672628
in	O	-1	10672628
the	O	-1	10672628
subst@@	O	-1	10672628
anti@@	O	-1	10672628
a	O	-1	10672628
n@@	O	-1	10672628
i@@	O	-1	10672628
gra@@	O	-1	10672628
,	O	-1	10672628
par@@	O	-1	10672628
s	O	-1	10672628
comp@@	O	-1	10672628
act@@	O	-1	10672628
a	O	-1	10672628
in	O	-1	10672628
both	O	-1	10672628
haloperidol	B-Chemical	D006220	10672628
-treated	O	-1	10672628
and	O	-1	10672628
L-@@	B-Chemical	D019335	10672628
NO@@	I-Chemical	-1	10672628
A@@	I-Chemical	-1	10672628
R@@	I-Chemical	-1	10672628
G	I-Chemical	-1	10672628
-treated	O	-1	10672628
anim@@	O	-1	10672628
al@@	O	-1	10672628
s.	O	-1	10672628
CONCLUSIONS:	O	-1	10672628
The	O	-1	10672628
results	O	-1	10672628
gi@@	O	-1	10672628
ve	O	-1	10672628
further	O	-1	10672628
suppor@@	O	-1	10672628
t	O	-1	10672628
to	O	-1	10672628
the	O	-1	10672628
hypo@@	O	-1	10672628
thesis	O	-1	10672628
that	O	-1	10672628
N@@	B-Chemical	D009569	10672628
O	I-Chemical	-1	10672628
pl@@	O	-1	10672628
ays	O	-1	10672628
a	O	-1	10672628
role	O	-1	10672628
in	O	-1	10672628
motor	O	-1	10672628
behavi@@	O	-1	10672628
or	O	-1	10672628
control	O	-1	10672628
and	O	-1	10672628
suggest	O	-1	10672628
that	O	-1	10672628
it	O	-1	10672628
may	O	-1	10672628
tak@@	O	-1	10672628
e	O	-1	10672628
par@@	O	-1	10672628
t	O	-1	10672628
in	O	-1	10672628
the	O	-1	10672628
syn@@	O	-1	10672628
ap@@	O	-1	10672628
tic	O	-1	10672628
changes	O	-1	10672628
produced	O	-1	10672628
by	O	-1	10672628
anti@@	O	-1	10672628
psycho@@	O	-1	10672628
tic	O	-1	10672628
treatment.	O	-1	10672628

Pro@@	O	-1	10677406
long@@	O	-1	10677406
ed	O	-1	10677406
left	B-Disease	D018487	10677406
ventricular	I-Disease	-1	10677406
dysfunction	I-Disease	-1	10677406
occur@@	O	-1	10677406
s	O	-1	10677406
in	O	-1	10677406
patients	O	-1	10677406
with	O	-1	10677406
coronary	B-Disease	D003324	10677406
artery	I-Disease	-1	10677406
disease	I-Disease	-1	10677406
after	O	-1	10677406
both	O	-1	10677406
do@@	B-Chemical	D004280	10677406
but@@	I-Chemical	-1	10677406
amine	I-Chemical	-1	10677406
and	O	-1	10677406
ex@@	O	-1	10677406
er@@	O	-1	10677406
cis@@	O	-1	10677406
e	O	-1	10677406
induced	O	-1	10677406
myocardial	B-Disease	D017202	10677406
is@@	I-Disease	-1	10677406
ch@@	I-Disease	-1	10677406
a@@	I-Disease	-1	10677406
emia	I-Disease	-1	10677406
.	O	-1	10677406
OBJECTIVE:	O	-1	10677406
To	O	-1	10677406
determine	O	-1	10677406
whether	O	-1	10677406
pharmac@@	O	-1	10677406
ological	O	-1	10677406
stres@@	O	-1	10677406
s	O	-1	10677406
lead@@	O	-1	10677406
s	O	-1	10677406
to	O	-1	10677406
prolonged	O	-1	10677406
but	O	-1	10677406
reversible	O	-1	10677406
left	B-Disease	D018487	10677406
ventricular	I-Disease	-1	10677406
dysfunction	I-Disease	-1	10677406
in	O	-1	10677406
patients	O	-1	10677406
with	O	-1	10677406
coronary	B-Disease	D003324	10677406
artery	I-Disease	-1	10677406
disease	I-Disease	-1	10677406
,	O	-1	10677406
similar	O	-1	10677406
to	O	-1	10677406
that	O	-1	10677406
seen	O	-1	10677406
after	O	-1	10677406
ex@@	O	-1	10677406
er@@	O	-1	10677406
ci@@	O	-1	10677406
se.	O	-1	10677406
D@@	O	-1	10677406
ES@@	O	-1	10677406
I@@	O	-1	10677406
G@@	O	-1	10677406
N@@	O	-1	10677406
:	O	-1	10677406
A	O	-1	10677406
random@@	O	-1	10677406
is@@	O	-1	10677406
ed	O	-1	10677406
cros@@	O	-1	10677406
s@@	O	-1	10677406
over	O	-1	10677406
study	O	-1	10677406
of	O	-1	10677406
recovery	O	-1	10677406
time	O	-1	10677406
of	O	-1	10677406
systolic	O	-1	10677406
and	O	-1	10677406
di@@	O	-1	10677406
ast@@	O	-1	10677406
olic	O	-1	10677406
left	O	-1	10677406
ventricular	O	-1	10677406
function	O	-1	10677406
after	O	-1	10677406
ex@@	O	-1	10677406
er@@	O	-1	10677406
cis@@	O	-1	10677406
e	O	-1	10677406
and	O	-1	10677406
do@@	B-Chemical	D004280	10677406
but@@	I-Chemical	-1	10677406
amine	I-Chemical	-1	10677406
induced	O	-1	10677406
is@@	B-Disease	D007511	10677406
ch@@	I-Disease	-1	10677406
a@@	I-Disease	-1	10677406
emia	I-Disease	-1	10677406
.	O	-1	10677406
S@@	O	-1	10677406
U@@	O	-1	10677406
B@@	O	-1	10677406
J@@	O	-1	10677406
EC@@	O	-1	10677406
T@@	O	-1	10677406
S:	O	-1	10677406
10	O	-1	10677406
patients	O	-1	10677406
with	O	-1	10677406
st@@	B-Disease	D060050	10677406
able	I-Disease	-1	10677406
ang@@	I-Disease	-1	10677406
in@@	I-Disease	-1	10677406
a	I-Disease	-1	10677406
,	O	-1	10677406
angio@@	O	-1	10677406
graph@@	O	-1	10677406
ically	O	-1	10677406
pro@@	O	-1	10677406
ven	O	-1	10677406
coronary	B-Disease	D003324	10677406
artery	I-Disease	-1	10677406
disease	I-Disease	-1	10677406
,	O	-1	10677406
and	O	-1	10677406
normal	O	-1	10677406
left	O	-1	10677406
ventricular	O	-1	10677406
func@@	O	-1	10677406
tion.	O	-1	10677406
IN@@	O	-1	10677406
TE@@	O	-1	10677406
R@@	O	-1	10677406
V@@	O	-1	10677406
E@@	O	-1	10677406
N@@	O	-1	10677406
T@@	O	-1	10677406
ION@@	O	-1	10677406
S:	O	-1	10677406
T@@	O	-1	10677406
re@@	O	-1	10677406
ad@@	O	-1	10677406
mil@@	O	-1	10677406
l	O	-1	10677406
ex@@	O	-1	10677406
er@@	O	-1	10677406
cis@@	O	-1	10677406
e	O	-1	10677406
and	O	-1	10677406
do@@	B-Chemical	D004280	10677406
but@@	I-Chemical	-1	10677406
amine	I-Chemical	-1	10677406
stres@@	O	-1	10677406
s	O	-1	10677406
were	O	-1	10677406
performed	O	-1	10677406
on	O	-1	10677406
different	O	-1	10677406
days.	O	-1	10677406
Q@@	O	-1	10677406
u@@	O	-1	10677406
anti@@	O	-1	10677406
t@@	O	-1	10677406
ative	O	-1	10677406
assess@@	O	-1	10677406
ment	O	-1	10677406
of	O	-1	10677406
systolic	O	-1	10677406
and	O	-1	10677406
di@@	O	-1	10677406
ast@@	O	-1	10677406
olic	O	-1	10677406
left	O	-1	10677406
ventricular	O	-1	10677406
function	O	-1	10677406
was	O	-1	10677406
performed	O	-1	10677406
using	O	-1	10677406
trans@@	O	-1	10677406
th@@	O	-1	10677406
or@@	O	-1	10677406
ac@@	O	-1	10677406
ic	O	-1	10677406
echocardiograph@@	O	-1	10677406
y	O	-1	10677406
at	O	-1	10677406
baseline	O	-1	10677406
and	O	-1	10677406
at	O	-1	10677406
reg@@	O	-1	10677406
ular	O	-1	10677406
interv@@	O	-1	10677406
als	O	-1	10677406
after	O	-1	10677406
each	O	-1	10677406
test@@	O	-1	10677406
.	O	-1	10677406
RESULTS:	O	-1	10677406
B@@	O	-1	10677406
oth	O	-1	10677406
form@@	O	-1	10677406
s	O	-1	10677406
of	O	-1	10677406
stres@@	O	-1	10677406
s	O	-1	10677406
l@@	O	-1	10677406
ed	O	-1	10677406
to	O	-1	10677406
prolonged	O	-1	10677406
but	O	-1	10677406
reversible	O	-1	10677406
systolic	O	-1	10677406
and	O	-1	10677406
di@@	O	-1	10677406
ast@@	O	-1	10677406
olic	O	-1	10677406
dysfunc@@	O	-1	10677406
tion.	O	-1	10677406
There	O	-1	10677406
was	O	-1	10677406
no	O	-1	10677406
difference	O	-1	10677406
in	O	-1	10677406
the	O	-1	10677406
maxim@@	O	-1	10677406
um	O	-1	10677406
dou@@	O	-1	10677406
ble	O	-1	10677406
produc@@	O	-1	10677406
t	O	-1	10677406
(p	O	-1	10677406
=	O	-1	10677406
0.@@	O	-1	10677406
5@@	O	-1	10677406
3@@	O	-1	10677406
)	O	-1	10677406
or	O	-1	10677406
S@@	O	-1	10677406
T	O	-1	10677406
de@@	B-Disease	D003866	10677406
pression	I-Disease	-1	10677406
(p	O	-1	10677406
=	O	-1	10677406
0.@@	O	-1	10677406
6@@	O	-1	10677406
3@@	O	-1	10677406
)	O	-1	10677406
with	O	-1	10677406
either	O	-1	10677406
form	O	-1	10677406
of	O	-1	10677406
stres@@	O	-1	10677406
s.	O	-1	10677406
After	O	-1	10677406
ex@@	O	-1	10677406
er@@	O	-1	10677406
ci@@	O	-1	10677406
se@@	O	-1	10677406
,	O	-1	10677406
e@@	O	-1	10677406
j@@	O	-1	10677406
ection	O	-1	10677406
frac@@	O	-1	10677406
tion	O	-1	10677406
was	O	-1	10677406
reduced	O	-1	10677406
at	O	-1	10677406
15	O	-1	10677406
and	O	-1	10677406
30	O	-1	10677406
minutes	O	-1	10677406
compared	O	-1	10677406
with	O	-1	10677406
baseline	O	-1	10677406
(@@	O	-1	10677406
mean	O	-1	10677406
(S@@	O	-1	10677406
E@@	O	-1	10677406
M@@	O	-1	10677406
),	O	-1	10677406
-@@	O	-1	10677406
5.@@	O	-1	10677406
6	O	-1	10677406
(1@@	O	-1	10677406
.@@	O	-1	10677406
5@@	O	-1	10677406
)@@	O	-1	10677406
%,	O	-1	10677406
p	O	-1	10677406
<	O	-1	10677406
0.05@@	O	-1	10677406
;	O	-1	10677406
and	O	-1	10677406
-@@	O	-1	10677406
6.@@	O	-1	10677406
1	O	-1	10677406
(2@@	O	-1	10677406
.@@	O	-1	10677406
2@@	O	-1	10677406
)@@	O	-1	10677406
%,	O	-1	10677406
p	O	-1	10677406
<	O	-1	10677406
0@@	O	-1	10677406
.	O	-1	10677406
0@@	O	-1	10677406
1),	O	-1	10677406
and	O	-1	10677406
at	O	-1	10677406
30	O	-1	10677406
and	O	-1	10677406
4@@	O	-1	10677406
5	O	-1	10677406
minutes	O	-1	10677406
after	O	-1	10677406
do@@	B-Chemical	D004280	10677406
but@@	I-Chemical	-1	10677406
amine	I-Chemical	-1	10677406
(@@	O	-1	10677406
-1@@	O	-1	10677406
0.@@	O	-1	10677406
8	O	-1	10677406
(1@@	O	-1	10677406
.@@	O	-1	10677406
8@@	O	-1	10677406
)@@	O	-1	10677406
%	O	-1	10677406
and	O	-1	10677406
-@@	O	-1	10677406
5@@	O	-1	10677406
.	O	-1	10677406
5	O	-1	10677406
(1@@	O	-1	10677406
.@@	O	-1	10677406
8@@	O	-1	10677406
)@@	O	-1	10677406
%,	O	-1	10677406
both	O	-1	10677406
p	O	-1	10677406
<	O	-1	10677406
0.0@@	O	-1	10677406
1).	O	-1	10677406
Re@@	O	-1	10677406
gi@@	O	-1	10677406
on@@	O	-1	10677406
al	O	-1	10677406
analysis	O	-1	10677406
showed	O	-1	10677406
a	O	-1	10677406
reduction	O	-1	10677406
in	O	-1	10677406
the	O	-1	10677406
wor@@	O	-1	10677406
st	O	-1	10677406
affected	O	-1	10677406
seg@@	O	-1	10677406
ment	O	-1	10677406
15	O	-1	10677406
and	O	-1	10677406
30	O	-1	10677406
minutes	O	-1	10677406
after	O	-1	10677406
ex@@	O	-1	10677406
er@@	O	-1	10677406
cis@@	O	-1	10677406
e	O	-1	10677406
(-@@	O	-1	10677406
2@@	O	-1	10677406
7.@@	O	-1	10677406
9	O	-1	10677406
(@@	O	-1	10677406
7.@@	O	-1	10677406
2@@	O	-1	10677406
)@@	O	-1	10677406
%	O	-1	10677406
and	O	-1	10677406
-@@	O	-1	10677406
2@@	O	-1	10677406
8.@@	O	-1	10677406
6	O	-1	10677406
(@@	O	-1	10677406
5.@@	O	-1	10677406
7@@	O	-1	10677406
)@@	O	-1	10677406
%,	O	-1	10677406
both	O	-1	10677406
p	O	-1	10677406
<	O	-1	10677406
0.0@@	O	-1	10677406
1),	O	-1	10677406
and	O	-1	10677406
at	O	-1	10677406
30	O	-1	10677406
minutes	O	-1	10677406
after	O	-1	10677406
do@@	B-Chemical	D004280	10677406
but@@	I-Chemical	-1	10677406
amine	I-Chemical	-1	10677406
(-@@	O	-1	10677406
3@@	O	-1	10677406
2	O	-1	10677406
(@@	O	-1	10677406
5.@@	O	-1	10677406
3@@	O	-1	10677406
)@@	O	-1	10677406
%,	O	-1	10677406
p	O	-1	10677406
<	O	-1	10677406
0.0@@	O	-1	10677406
1).	O	-1	10677406
The	O	-1	10677406
iso@@	O	-1	10677406
volum@@	O	-1	10677406
ic	O	-1	10677406
rel@@	O	-1	10677406
ax@@	O	-1	10677406
ation	O	-1	10677406
period	O	-1	10677406
was	O	-1	10677406
prolonged	O	-1	10677406
4@@	O	-1	10677406
5	O	-1	10677406
minutes	O	-1	10677406
after	O	-1	10677406
each	O	-1	10677406
form	O	-1	10677406
of	O	-1	10677406
stres@@	O	-1	10677406
s	O	-1	10677406
(p	O	-1	10677406
<	O	-1	10677406
0.05@@	O	-1	10677406
).	O	-1	10677406
CONCLUSIONS:	O	-1	10677406
In	O	-1	10677406
patients	O	-1	10677406
with	O	-1	10677406
coronary	B-Disease	D003324	10677406
artery	I-Disease	-1	10677406
disease	I-Disease	-1	10677406
,	O	-1	10677406
do@@	B-Chemical	D004280	10677406
but@@	I-Chemical	-1	10677406
amine	I-Chemical	-1	10677406
induced	O	-1	10677406
is@@	B-Disease	D007511	10677406
ch@@	I-Disease	-1	10677406
a@@	I-Disease	-1	10677406
emia	I-Disease	-1	10677406
results	O	-1	10677406
in	O	-1	10677406
prolonged	O	-1	10677406
reversible	O	-1	10677406
left	B-Disease	D018487	10677406
ventricular	I-Disease	-1	10677406
dysfunction	I-Disease	-1	10677406
,	O	-1	10677406
pres@@	O	-1	10677406
um@@	O	-1	10677406
ed	O	-1	10677406
to	O	-1	10677406
be	O	-1	10677406
myocardial	B-Disease	D017682	10677406
st@@	I-Disease	-1	10677406
un@@	I-Disease	-1	10677406
ning	I-Disease	-1	10677406
,	O	-1	10677406
similar	O	-1	10677406
to	O	-1	10677406
that	O	-1	10677406
seen	O	-1	10677406
after	O	-1	10677406
ex@@	O	-1	10677406
er@@	O	-1	10677406
ci@@	O	-1	10677406
se.	O	-1	10677406
D@@	B-Chemical	D004280	10677406
ob@@	I-Chemical	-1	10677406
ut@@	I-Chemical	-1	10677406
amine	I-Chemical	-1	10677406
induced	O	-1	10677406
is@@	B-Disease	D007511	10677406
ch@@	I-Disease	-1	10677406
a@@	I-Disease	-1	10677406
emia	I-Disease	-1	10677406
could	O	-1	10677406
the@@	O	-1	10677406
re@@	O	-1	10677406
fore	O	-1	10677406
be	O	-1	10677406
used	O	-1	10677406
to	O	-1	10677406
study	O	-1	10677406
the	O	-1	10677406
path@@	O	-1	10677406
oph@@	O	-1	10677406
ysi@@	O	-1	10677406
ology	O	-1	10677406
of	O	-1	10677406
this	O	-1	10677406
phen@@	O	-1	10677406
om@@	O	-1	10677406
en@@	O	-1	10677406
on	O	-1	10677406
further	O	-1	10677406
in	O	-1	10677406
patients	O	-1	10677406
with	O	-1	10677406
coronary	B-Disease	D003324	10677406
artery	I-Disease	-1	10677406
disease	I-Disease	-1	10677406
.	O	-1	10677406

A@@	O	-1	10713017
no@@	O	-1	10713017
re@@	O	-1	10713017
xi@@	O	-1	10713017
gen@@	O	-1	10713017
s	O	-1	10713017
and	O	-1	10713017
pulmonary	B-Disease	D006976	10713017
hypertension	I-Disease	-1	10713017
in	O	-1	10713017
the	O	-1	10713017
U@@	O	-1	10713017
nit@@	O	-1	10713017
ed	O	-1	10713017
S@@	O	-1	10713017
t@@	O	-1	10713017
at@@	O	-1	10713017
es@@	O	-1	10713017
:	O	-1	10713017
results	O	-1	10713017
from	O	-1	10713017
the	O	-1	10713017
sur@@	O	-1	10713017
ve@@	O	-1	10713017
ill@@	O	-1	10713017
ance	O	-1	10713017
of	O	-1	10713017
N@@	O	-1	10713017
or@@	O	-1	10713017
th	O	-1	10713017
A@@	O	-1	10713017
mer@@	O	-1	10713017
ic@@	O	-1	10713017
an	O	-1	10713017
pulmonary	B-Disease	D006976	10713017
hypertension	I-Disease	-1	10713017
.	O	-1	10713017
BACKGROUND:	O	-1	10713017
The	O	-1	10713017
use	O	-1	10713017
of	O	-1	10713017
appe@@	O	-1	10713017
ti@@	O	-1	10713017
te	O	-1	10713017
sup@@	O	-1	10713017
press@@	O	-1	10713017
ants	O	-1	10713017
in	O	-1	10713017
E@@	O	-1	10713017
uro@@	O	-1	10713017
p@@	O	-1	10713017
e	O	-1	10713017
has	O	-1	10713017
been	O	-1	10713017
associated	O	-1	10713017
with	O	-1	10713017
the	O	-1	10713017
development	O	-1	10713017
of	O	-1	10713017
prim@@	B-Disease	D006976	10713017
ary	I-Disease	-1	10713017
pulmonary	I-Disease	-1	10713017
hypertension	I-Disease	-1	10713017
(	O	-1	10713017
P@@	B-Disease	D006976	10713017
P@@	I-Disease	-1	10713017
H	I-Disease	-1	10713017
).	O	-1	10713017
Rec@@	O	-1	10713017
ent@@	O	-1	10713017
ly,	O	-1	10713017
f@@	B-Chemical	D005277	10713017
en@@	I-Chemical	-1	10713017
f@@	I-Chemical	-1	10713017
lur@@	I-Chemical	-1	10713017
amine	I-Chemical	-1	10713017
appe@@	O	-1	10713017
ti@@	O	-1	10713017
te	O	-1	10713017
sup@@	O	-1	10713017
press@@	O	-1	10713017
ants	O	-1	10713017
b@@	O	-1	10713017
ec@@	O	-1	10713017
am@@	O	-1	10713017
e	O	-1	10713017
wi@@	O	-1	10713017
de@@	O	-1	10713017
ly	O	-1	10713017
used	O	-1	10713017
in	O	-1	10713017
the	O	-1	10713017
U@@	O	-1	10713017
nit@@	O	-1	10713017
ed	O	-1	10713017
S@@	O	-1	10713017
t@@	O	-1	10713017
ates	O	-1	10713017
but	O	-1	10713017
were	O	-1	10713017
withdraw@@	O	-1	10713017
n	O	-1	10713017
in	O	-1	10713017
S@@	O	-1	10713017
e@@	O	-1	10713017
pt@@	O	-1	10713017
emb@@	O	-1	10713017
er	O	-1	10713017
19@@	O	-1	10713017
9@@	O	-1	10713017
7	O	-1	10713017
because	O	-1	10713017
of	O	-1	10713017
con@@	O	-1	10713017
cer@@	O	-1	10713017
n@@	O	-1	10713017
s	O	-1	10713017
over	O	-1	10713017
adverse	O	-1	10713017
effects.	O	-1	10713017
M@@	O	-1	10713017
AT@@	O	-1	10713017
E@@	O	-1	10713017
R@@	O	-1	10713017
I@@	O	-1	10713017
AL@@	O	-1	10713017
S	O	-1	10713017
AN@@	O	-1	10713017
D	O	-1	10713017
METHODS:	O	-1	10713017
We	O	-1	10713017
con@@	O	-1	10713017
duc@@	O	-1	10713017
ted	O	-1	10713017
a	O	-1	10713017
pro@@	O	-1	10713017
sp@@	O	-1	10713017
ective	O	-1	10713017
sur@@	O	-1	10713017
ve@@	O	-1	10713017
ill@@	O	-1	10713017
ance	O	-1	10713017
study	O	-1	10713017
on	O	-1	10713017
patients	O	-1	10713017
diagnos@@	O	-1	10713017
ed	O	-1	10713017
with	O	-1	10713017
pulmonary	B-Disease	D006976	10713017
hypertension	I-Disease	-1	10713017
at	O	-1	10713017
12	O	-1	10713017
larg@@	O	-1	10713017
e	O	-1	10713017
ref@@	O	-1	10713017
er@@	O	-1	10713017
ral	O	-1	10713017
c@@	O	-1	10713017
ent@@	O	-1	10713017
ers	O	-1	10713017
in	O	-1	10713017
N@@	O	-1	10713017
or@@	O	-1	10713017
th	O	-1	10713017
A@@	O	-1	10713017
mer@@	O	-1	10713017
ic@@	O	-1	10713017
a.	O	-1	10713017
D@@	O	-1	10713017
at@@	O	-1	10713017
a	O	-1	10713017
coll@@	O	-1	10713017
ected	O	-1	10713017
on	O	-1	10713017
patients	O	-1	10713017
seen	O	-1	10713017
from	O	-1	10713017
S@@	O	-1	10713017
e@@	O	-1	10713017
pt@@	O	-1	10713017
emb@@	O	-1	10713017
er	O	-1	10713017
1,	O	-1	10713017
19@@	O	-1	10713017
9@@	O	-1	10713017
6,	O	-1	10713017
to	O	-1	10713017
D@@	O	-1	10713017
ec@@	O	-1	10713017
emb@@	O	-1	10713017
er	O	-1	10713017
3@@	O	-1	10713017
1,	O	-1	10713017
19@@	O	-1	10713017
9@@	O	-1	10713017
7@@	O	-1	10713017
,	O	-1	10713017
included	O	-1	10713017
the	O	-1	10713017
cause	O	-1	10713017
of	O	-1	10713017
the	O	-1	10713017
pulmonary	B-Disease	D006976	10713017
hypertension	I-Disease	-1	10713017
and	O	-1	10713017
its	O	-1	10713017
sever@@	O	-1	10713017
ity.	O	-1	10713017
Patients	O	-1	10713017
with	O	-1	10713017
no	O	-1	10713017
identi@@	O	-1	10713017
fi@@	O	-1	10713017
able	O	-1	10713017
cause	O	-1	10713017
of	O	-1	10713017
pulmonary	B-Disease	D006976	10713017
hypertension	I-Disease	-1	10713017
were	O	-1	10713017
cl@@	O	-1	10713017
ass@@	O	-1	10713017
ed	O	-1	10713017
as	O	-1	10713017
P@@	B-Disease	D006976	10713017
P@@	I-Disease	-1	10713017
H	I-Disease	-1	10713017
.	O	-1	10713017
A	O	-1	10713017
hist@@	O	-1	10713017
ory	O	-1	10713017
of	O	-1	10713017
drug	O	-1	10713017
exposure	O	-1	10713017
also	O	-1	10713017
was	O	-1	10713017
tak@@	O	-1	10713017
en	O	-1	10713017
with	O	-1	10713017
spec@@	O	-1	10713017
ial	O	-1	10713017
atten@@	O	-1	10713017
tion	O	-1	10713017
on	O	-1	10713017
the	O	-1	10713017
use	O	-1	10713017
of	O	-1	10713017
antidepress@@	O	-1	10713017
ant@@	O	-1	10713017
s,	O	-1	10713017
an@@	O	-1	10713017
ore@@	O	-1	10713017
xi@@	O	-1	10713017
gen@@	O	-1	10713017
s,	O	-1	10713017
and	O	-1	10713017
amphet@@	B-Chemical	D000662	10713017
amin@@	I-Chemical	-1	10713017
es	I-Chemical	-1	10713017
.	O	-1	10713017
RESULTS:	O	-1	10713017
F@@	O	-1	10713017
i@@	O	-1	10713017
ve	O	-1	10713017
h@@	O	-1	10713017
und@@	O	-1	10713017
red	O	-1	10713017
sev@@	O	-1	10713017
ent@@	O	-1	10713017
y-@@	O	-1	10713017
n@@	O	-1	10713017
ine	O	-1	10713017
patients	O	-1	10713017
were	O	-1	10713017
studi@@	O	-1	10713017
ed,	O	-1	10713017
20@@	O	-1	10713017
5	O	-1	10713017
with	O	-1	10713017
P@@	B-Disease	D006976	10713017
P@@	I-Disease	-1	10713017
H	I-Disease	-1	10713017
and	O	-1	10713017
3@@	O	-1	10713017
7@@	O	-1	10713017
4	O	-1	10713017
with	O	-1	10713017
pulmonary	B-Disease	D006976	10713017
hypertension	I-Disease	-1	10713017
from	O	-1	10713017
other	O	-1	10713017
causes	O	-1	10713017
(@@	O	-1	10713017
secondary	O	-1	10713017
pulmonary	B-Disease	D006976	10713017
hypertension	I-Disease	-1	10713017
[@@	O	-1	10713017
S@@	O	-1	10713017
P@@	O	-1	10713017
H@@	O	-1	10713017
]@@	O	-1	10713017
).	O	-1	10713017
The	O	-1	10713017
use	O	-1	10713017
of	O	-1	10713017
an@@	O	-1	10713017
ore@@	O	-1	10713017
xi@@	O	-1	10713017
gen@@	O	-1	10713017
s	O	-1	10713017
was	O	-1	10713017
common	O	-1	10713017
in	O	-1	10713017
both	O	-1	10713017
groups.	O	-1	10713017
However,	O	-1	10713017
of	O	-1	10713017
the	O	-1	10713017
medic@@	O	-1	10713017
ations	O	-1	10713017
sur@@	O	-1	10713017
ve@@	O	-1	10713017
y@@	O	-1	10713017
ed,	O	-1	10713017
only	O	-1	10713017
the	O	-1	10713017
f@@	B-Chemical	D005277	10713017
en@@	I-Chemical	-1	10713017
f@@	I-Chemical	-1	10713017
lur@@	I-Chemical	-1	10713017
amin@@	I-Chemical	-1	10713017
es	I-Chemical	-1	10713017
had	O	-1	10713017
a	O	-1	10713017
significant	O	-1	10713017
pre@@	O	-1	10713017
fe@@	O	-1	10713017
ren@@	O	-1	10713017
tial	O	-1	10713017
association	O	-1	10713017
with	O	-1	10713017
P@@	B-Disease	D006976	10713017
P@@	I-Disease	-1	10713017
H	I-Disease	-1	10713017
as	O	-1	10713017
compared	O	-1	10713017
with	O	-1	10713017
S@@	O	-1	10713017
P@@	O	-1	10713017
H	O	-1	10713017
(@@	O	-1	10713017
adjust@@	O	-1	10713017
ed	O	-1	10713017
o@@	O	-1	10713017
d@@	O	-1	10713017
ds	O	-1	10713017
rati@@	O	-1	10713017
o	O	-1	10713017
for	O	-1	10713017
use	O	-1	10713017
>	O	-1	10713017
6	O	-1	10713017
month@@	O	-1	10713017
s,	O	-1	10713017
7.@@	O	-1	10713017
5@@	O	-1	10713017
;	O	-1	10713017
95%	O	-1	10713017
conf@@	O	-1	10713017
idence	O	-1	10713017
inter@@	O	-1	10713017
val@@	O	-1	10713017
,	O	-1	10713017
1.@@	O	-1	10713017
7	O	-1	10713017
to	O	-1	10713017
3@@	O	-1	10713017
2.@@	O	-1	10713017
4@@	O	-1	10713017
).	O	-1	10713017
The	O	-1	10713017
association	O	-1	10713017
was	O	-1	10713017
st@@	O	-1	10713017
ron@@	O	-1	10713017
g@@	O	-1	10713017
er	O	-1	10713017
with	O	-1	10713017
long@@	O	-1	10713017
er	O	-1	10713017
duration	O	-1	10713017
of	O	-1	10713017
use	O	-1	10713017
when	O	-1	10713017
compared	O	-1	10713017
to	O	-1	10713017
sh@@	O	-1	10713017
or@@	O	-1	10713017
ter	O	-1	10713017
duration	O	-1	10713017
of	O	-1	10713017
use	O	-1	10713017
and	O	-1	10713017
was	O	-1	10713017
more	O	-1	10713017
p@@	O	-1	10713017
ron@@	O	-1	10713017
oun@@	O	-1	10713017
c@@	O	-1	10713017
ed	O	-1	10713017
in	O	-1	10713017
rec@@	O	-1	10713017
ent	O	-1	10713017
users	O	-1	10713017
than	O	-1	10713017
in	O	-1	10713017
re@@	O	-1	10713017
m@@	O	-1	10713017
ot@@	O	-1	10713017
e	O	-1	10713017
us@@	O	-1	10713017
ers.	O	-1	10713017
An	O	-1	10713017
un@@	O	-1	10713017
ex@@	O	-1	10713017
p@@	O	-1	10713017
ect@@	O	-1	10713017
ed@@	O	-1	10713017
ly	O	-1	10713017
high	O	-1	10713017
(1@@	O	-1	10713017
1.@@	O	-1	10713017
4@@	O	-1	10713017
%)	O	-1	10713017
number	O	-1	10713017
of	O	-1	10713017
patients	O	-1	10713017
with	O	-1	10713017
S@@	O	-1	10713017
P@@	O	-1	10713017
H	O	-1	10713017
had	O	-1	10713017
used	O	-1	10713017
an@@	O	-1	10713017
ore@@	O	-1	10713017
xi@@	O	-1	10713017
gen@@	O	-1	10713017
s.	O	-1	10713017
CONCLUSION:	O	-1	10713017
The	O	-1	10713017
mag@@	O	-1	10713017
nit@@	O	-1	10713017
ude	O	-1	10713017
of	O	-1	10713017
the	O	-1	10713017
association	O	-1	10713017
with	O	-1	10713017
P@@	B-Disease	D006976	10713017
P@@	I-Disease	-1	10713017
H	I-Disease	-1	10713017
,	O	-1	10713017
the	O	-1	10713017
increase	O	-1	10713017
of	O	-1	10713017
association	O	-1	10713017
with	O	-1	10713017
increas@@	O	-1	10713017
ing	O	-1	10713017
duration	O	-1	10713017
of	O	-1	10713017
use@@	O	-1	10713017
,	O	-1	10713017
and	O	-1	10713017
the	O	-1	10713017
spec@@	O	-1	10713017
ific@@	O	-1	10713017
ity	O	-1	10713017
for	O	-1	10713017
f@@	B-Chemical	D005277	10713017
en@@	I-Chemical	-1	10713017
f@@	I-Chemical	-1	10713017
lur@@	I-Chemical	-1	10713017
amin@@	I-Chemical	-1	10713017
es	I-Chemical	-1	10713017
are	O	-1	10713017
consist@@	O	-1	10713017
ent	O	-1	10713017
with	O	-1	10713017
previ@@	O	-1	10713017
ous	O	-1	10713017
studies	O	-1	10713017
indicating	O	-1	10713017
that	O	-1	10713017
f@@	B-Chemical	D005277	10713017
en@@	I-Chemical	-1	10713017
f@@	I-Chemical	-1	10713017
lur@@	I-Chemical	-1	10713017
amin@@	I-Chemical	-1	10713017
es	I-Chemical	-1	10713017
are	O	-1	10713017
ca@@	O	-1	10713017
us@@	O	-1	10713017
ally	O	-1	10713017
related	O	-1	10713017
to	O	-1	10713017
P@@	B-Disease	D006976	10713017
P@@	I-Disease	-1	10713017
H	I-Disease	-1	10713017
.	O	-1	10713017
The	O	-1	10713017
high	O	-1	10713017
prev@@	O	-1	10713017
al@@	O	-1	10713017
ence	O	-1	10713017
of	O	-1	10713017
an@@	O	-1	10713017
ore@@	O	-1	10713017
xi@@	O	-1	10713017
gen	O	-1	10713017
use	O	-1	10713017
in	O	-1	10713017
patients	O	-1	10713017
with	O	-1	10713017
S@@	O	-1	10713017
P@@	O	-1	10713017
H	O	-1	10713017
also	O	-1	10713017
ra@@	O	-1	10713017
i@@	O	-1	10713017
ses	O	-1	10713017
the	O	-1	10713017
possib@@	O	-1	10713017
ility	O	-1	10713017
that	O	-1	10713017
these	O	-1	10713017
drugs	O	-1	10713017
pre@@	O	-1	10713017
ci@@	O	-1	10713017
pit@@	O	-1	10713017
ate	O	-1	10713017
pulmonary	B-Disease	D006976	10713017
hypertension	I-Disease	-1	10713017
in	O	-1	10713017
patients	O	-1	10713017
with	O	-1	10713017
underlying	O	-1	10713017
condi@@	O	-1	10713017
tions	O	-1	10713017
associated	O	-1	10713017
with	O	-1	10713017
S@@	O	-1	10713017
P@@	O	-1	10713017
H@@	O	-1	10713017
.	O	-1	10713017

Clin@@	O	-1	10726030
ical	O	-1	10726030
as@@	O	-1	10726030
p@@	O	-1	10726030
ects	O	-1	10726030
of	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
in	I-Chemical	-1	10726030
-induced	O	-1	10726030
throm@@	B-Disease	D013921	10726030
b@@	I-Disease	-1	10726030
ocyto@@	I-Disease	-1	10726030
pen@@	I-Disease	-1	10726030
ia	I-Disease	-1	10726030
and	O	-1	10726030
thrombo@@	B-Disease	D013927	10726030
sis	I-Disease	-1	10726030
and	O	-1	10726030
other	O	-1	10726030
side	O	-1	10726030
effects	O	-1	10726030
of	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
in	I-Chemical	-1	10726030
therapy.	O	-1	10726030
He@@	B-Chemical	D006493	10726030
par@@	I-Chemical	-1	10726030
in	I-Chemical	-1	10726030
,	O	-1	10726030
first	O	-1	10726030
used	O	-1	10726030
to	O	-1	10726030
prev@@	O	-1	10726030
ent	O	-1	10726030
the	O	-1	10726030
clo@@	O	-1	10726030
t@@	O	-1	10726030
ting	O	-1	10726030
of	O	-1	10726030
blood	O	-1	10726030
in	O	-1	10726030
vit@@	O	-1	10726030
ro@@	O	-1	10726030
,	O	-1	10726030
has	O	-1	10726030
been	O	-1	10726030
clin@@	O	-1	10726030
ically	O	-1	10726030
used	O	-1	10726030
to	O	-1	10726030
tre@@	O	-1	10726030
at	O	-1	10726030
thrombo@@	B-Disease	D013927	10726030
sis	I-Disease	-1	10726030
for	O	-1	10726030
more	O	-1	10726030
than	O	-1	10726030
50	O	-1	10726030
year@@	O	-1	10726030
s.	O	-1	10726030
Although	O	-1	10726030
several	O	-1	10726030
new	O	-1	10726030
anti@@	O	-1	10726030
co@@	O	-1	10726030
ag@@	O	-1	10726030
ul@@	O	-1	10726030
ant	O	-1	10726030
drugs	O	-1	10726030
are	O	-1	10726030
in	O	-1	10726030
develop@@	O	-1	10726030
ment@@	O	-1	10726030
,	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
in	I-Chemical	-1	10726030
remain@@	O	-1	10726030
s	O	-1	10726030
the	O	-1	10726030
anti@@	O	-1	10726030
co@@	O	-1	10726030
ag@@	O	-1	10726030
ul@@	O	-1	10726030
ant	O	-1	10726030
of	O	-1	10726030
ch@@	O	-1	10726030
o@@	O	-1	10726030
ic@@	O	-1	10726030
e	O	-1	10726030
to	O	-1	10726030
tre@@	O	-1	10726030
at	O	-1	10726030
acute	O	-1	10726030
thrombotic	B-Disease	D013927	10726030
episo@@	O	-1	10726030
d@@	O	-1	10726030
es.	O	-1	10726030
The	O	-1	10726030
clinical	O	-1	10726030
effects	O	-1	10726030
of	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
in	I-Chemical	-1	10726030
are	O	-1	10726030
mer@@	O	-1	10726030
it@@	O	-1	10726030
or@@	O	-1	10726030
i@@	O	-1	10726030
ou@@	O	-1	10726030
s,	O	-1	10726030
but	O	-1	10726030
side	O	-1	10726030
effects	O	-1	10726030
d@@	O	-1	10726030
o	O	-1	10726030
ex@@	O	-1	10726030
ist@@	O	-1	10726030
.	O	-1	10726030
B@@	B-Disease	D006470	10726030
le@@	I-Disease	-1	10726030
ed@@	I-Disease	-1	10726030
ing	I-Disease	-1	10726030
is	O	-1	10726030
the	O	-1	10726030
prim@@	O	-1	10726030
ary	O	-1	10726030
un@@	O	-1	10726030
to@@	O	-1	10726030
war@@	O	-1	10726030
d	O	-1	10726030
effect	O	-1	10726030
of	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
in	I-Chemical	-1	10726030
.	O	-1	10726030
M@@	O	-1	10726030
a@@	O	-1	10726030
j@@	O	-1	10726030
or	O	-1	10726030
ble@@	B-Disease	D006470	10726030
ed@@	I-Disease	-1	10726030
ing	I-Disease	-1	10726030
is	O	-1	10726030
of	O	-1	10726030
prim@@	O	-1	10726030
ary	O	-1	10726030
con@@	O	-1	10726030
cer@@	O	-1	10726030
n	O	-1	10726030
in	O	-1	10726030
patients	O	-1	10726030
receiving	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
in	I-Chemical	-1	10726030
therapy.	O	-1	10726030
However,	O	-1	10726030
addi@@	O	-1	10726030
tional	O	-1	10726030
important	O	-1	10726030
un@@	O	-1	10726030
to@@	O	-1	10726030
war@@	O	-1	10726030
d	O	-1	10726030
effects	O	-1	10726030
of	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
in	I-Chemical	-1	10726030
therapy	O	-1	10726030
includ@@	O	-1	10726030
e	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
in	I-Chemical	-1	10726030
-induced	O	-1	10726030
throm@@	B-Disease	D013921	10726030
b@@	I-Disease	-1	10726030
ocyto@@	I-Disease	-1	10726030
pen@@	I-Disease	-1	10726030
ia	I-Disease	-1	10726030
,	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
in	I-Chemical	-1	10726030
-@@	O	-1	10726030
associated	O	-1	10726030
ost@@	B-Disease	D010024	10726030
e@@	I-Disease	-1	10726030
o@@	I-Disease	-1	10726030
po@@	I-Disease	-1	10726030
ro@@	I-Disease	-1	10726030
sis	I-Disease	-1	10726030
,	O	-1	10726030
e@@	B-Disease	D004802	10726030
os@@	I-Disease	-1	10726030
in@@	I-Disease	-1	10726030
oph@@	I-Disease	-1	10726030
il@@	I-Disease	-1	10726030
ia	I-Disease	-1	10726030
,	O	-1	10726030
s@@	B-Disease	D012871	10726030
k@@	I-Disease	-1	10726030
in	I-Disease	-1	10726030
reactions	I-Disease	-1	10726030
,	O	-1	10726030
all@@	B-Disease	D004342	10726030
ergic	I-Disease	-1	10726030
reactions	I-Disease	-1	10726030
other	O	-1	10726030
than	O	-1	10726030
throm@@	B-Disease	D013921	10726030
b@@	I-Disease	-1	10726030
ocyto@@	I-Disease	-1	10726030
pen@@	I-Disease	-1	10726030
ia	I-Disease	-1	10726030
,	O	-1	10726030
alo@@	B-Disease	D000505	10726030
p@@	I-Disease	-1	10726030
ec@@	I-Disease	-1	10726030
ia	I-Disease	-1	10726030
,	O	-1	10726030
trans@@	O	-1	10726030
amin@@	O	-1	10726030
as@@	O	-1	10726030
em@@	O	-1	10726030
ia,	O	-1	10726030
hyper@@	B-Disease	D006947	10726030
k@@	I-Disease	-1	10726030
al@@	I-Disease	-1	10726030
emia	I-Disease	-1	10726030
,	O	-1	10726030
hypo@@	B-Disease	D006994	10726030
al@@	I-Disease	-1	10726030
do@@	I-Disease	-1	10726030
ster@@	I-Disease	-1	10726030
on@@	I-Disease	-1	10726030
ism	I-Disease	-1	10726030
,	O	-1	10726030
and	O	-1	10726030
pri@@	B-Disease	D011317	10726030
ap@@	I-Disease	-1	10726030
ism	I-Disease	-1	10726030
.	O	-1	10726030
These	O	-1	10726030
side	O	-1	10726030
effects	O	-1	10726030
are	O	-1	10726030
rel@@	O	-1	10726030
atively	O	-1	10726030
r@@	O	-1	10726030
are	O	-1	10726030
in	O	-1	10726030
a	O	-1	10726030
given	O	-1	10726030
individ@@	O	-1	10726030
u@@	O	-1	10726030
al,	O	-1	10726030
but	O	-1	10726030
given	O	-1	10726030
the	O	-1	10726030
ex@@	O	-1	10726030
tre@@	O	-1	10726030
me@@	O	-1	10726030
ly	O	-1	10726030
w@@	O	-1	10726030
id@@	O	-1	10726030
es@@	O	-1	10726030
pre@@	O	-1	10726030
ad	O	-1	10726030
use	O	-1	10726030
of	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
in	I-Chemical	-1	10726030
,	O	-1	10726030
some	O	-1	10726030
are	O	-1	10726030
qu@@	O	-1	10726030
ite	O	-1	10726030
common@@	O	-1	10726030
,	O	-1	10726030
partic@@	O	-1	10726030
ul@@	O	-1	10726030
arly	O	-1	10726030
H@@	B-Disease	D013921	10726030
I@@	I-Disease	-1	10726030
T@@	I-Disease	-1	10726030
T	I-Disease	-1	10726030
H@@	B-Disease	D013927	10726030
I@@	I-Disease	-1	10726030
T@@	I-Disease	-1	10726030
T	I-Disease	-1	10726030
and	O	-1	10726030
ost@@	B-Disease	D010024	10726030
e@@	I-Disease	-1	10726030
o@@	I-Disease	-1	10726030
po@@	I-Disease	-1	10726030
ro@@	I-Disease	-1	10726030
sis	I-Disease	-1	10726030
.	O	-1	10726030
Although	O	-1	10726030
reas@@	O	-1	10726030
on@@	O	-1	10726030
able	O	-1	10726030
inc@@	O	-1	10726030
id@@	O	-1	10726030
enc@@	O	-1	10726030
es	O	-1	10726030
of	O	-1	10726030
man@@	O	-1	10726030
y	O	-1	10726030
of	O	-1	10726030
these	O	-1	10726030
side	O	-1	10726030
effects	O	-1	10726030
can	O	-1	10726030
be	O	-1	10726030
"@@	O	-1	10726030
s@@	O	-1	10726030
of@@	O	-1	10726030
t@@	O	-1	10726030
ly@@	O	-1	10726030
"	O	-1	10726030
de@@	O	-1	10726030
duced	O	-1	10726030
from	O	-1	10726030
current	O	-1	10726030
reports	O	-1	10726030
de@@	O	-1	10726030
al@@	O	-1	10726030
ing	O	-1	10726030
with	O	-1	10726030
un@@	O	-1	10726030
frac@@	O	-1	10726030
tion@@	O	-1	10726030
ated	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
in	I-Chemical	-1	10726030
,	O	-1	10726030
at	O	-1	10726030
present	O	-1	10726030
the	O	-1	10726030
inc@@	O	-1	10726030
id@@	O	-1	10726030
enc@@	O	-1	10726030
es	O	-1	10726030
of	O	-1	10726030
these	O	-1	10726030
side	O	-1	10726030
effects	O	-1	10726030
with	O	-1	10726030
ne@@	O	-1	10726030
w@@	O	-1	10726030
er	O	-1	10726030
low	O	-1	10726030
mol@@	O	-1	10726030
ec@@	O	-1	10726030
ular	O	-1	10726030
weight	O	-1	10726030
hepar@@	B-Chemical	D006493	10726030
ins	I-Chemical	-1	10726030
appe@@	O	-1	10726030
ar	O	-1	10726030
to	O	-1	10726030
be	O	-1	10726030
m@@	O	-1	10726030
uc@@	O	-1	10726030
h	O	-1	10726030
less	O	-1	10726030
common@@	O	-1	10726030
.	O	-1	10726030
However,	O	-1	10726030
only	O	-1	10726030
long@@	O	-1	10726030
er	O	-1	10726030
experi@@	O	-1	10726030
ence	O	-1	10726030
wil@@	O	-1	10726030
l	O	-1	10726030
more	O	-1	10726030
clear@@	O	-1	10726030
ly	O	-1	10726030
def@@	O	-1	10726030
ine	O	-1	10726030
the	O	-1	10726030
incidence	O	-1	10726030
of	O	-1	10726030
each	O	-1	10726030
side	O	-1	10726030
effect	O	-1	10726030
with	O	-1	10726030
low	O	-1	10726030
mol@@	O	-1	10726030
ec@@	O	-1	10726030
ular	O	-1	10726030
weight	O	-1	10726030
pre@@	O	-1	10726030
par@@	O	-1	10726030
ations.	O	-1	10726030

A	O	-1	10764869
case	O	-1	10764869
of	O	-1	10764869
bil@@	O	-1	10764869
ateral	O	-1	10764869
op@@	B-Disease	D009901	10764869
tic	I-Disease	-1	10764869
neuropathy	I-Disease	-1	10764869
in	O	-1	10764869
a	O	-1	10764869
patient	O	-1	10764869
on	O	-1	10764869
tacrolimus	B-Chemical	D016559	10764869
(	O	-1	10764869
FK50@@	B-Chemical	D016559	10764869
6	I-Chemical	-1	10764869
)	O	-1	10764869
therapy	O	-1	10764869
after	O	-1	10764869
liver	O	-1	10764869
transplant@@	O	-1	10764869
ation.	O	-1	10764869
P@@	O	-1	10764869
U@@	O	-1	10764869
R@@	O	-1	10764869
P@@	O	-1	10764869
O@@	O	-1	10764869
S@@	O	-1	10764869
E:	O	-1	10764869
To	O	-1	10764869
report	O	-1	10764869
a	O	-1	10764869
case	O	-1	10764869
of	O	-1	10764869
bil@@	O	-1	10764869
ateral	O	-1	10764869
op@@	B-Disease	D009901	10764869
tic	I-Disease	-1	10764869
neuropathy	I-Disease	-1	10764869
in	O	-1	10764869
a	O	-1	10764869
patient	O	-1	10764869
receiving	O	-1	10764869
tacrolimus	B-Chemical	D016559	10764869
(	O	-1	10764869
F@@	B-Chemical	D016559	10764869
K	I-Chemical	-1	10764869
50@@	I-Chemical	-1	10764869
6	I-Chemical	-1	10764869
,	O	-1	10764869
Pro@@	O	-1	10764869
gra@@	O	-1	10764869
f@@	O	-1	10764869
;	O	-1	10764869
F@@	O	-1	10764869
u@@	O	-1	10764869
j@@	O	-1	10764869
is@@	O	-1	10764869
aw@@	O	-1	10764869
a	O	-1	10764869
US@@	O	-1	10764869
A@@	O	-1	10764869
,	O	-1	10764869
In@@	O	-1	10764869
c@@	O	-1	10764869
,	O	-1	10764869
De@@	O	-1	10764869
er@@	O	-1	10764869
fi@@	O	-1	10764869
el@@	O	-1	10764869
d,	O	-1	10764869
I@@	O	-1	10764869
ll@@	O	-1	10764869
ino@@	O	-1	10764869
is@@	O	-1	10764869
)	O	-1	10764869
for	O	-1	10764869
immunosup@@	O	-1	10764869
pression	O	-1	10764869
after	O	-1	10764869
or@@	O	-1	10764869
th@@	O	-1	10764869
ot@@	O	-1	10764869
ro@@	O	-1	10764869
p@@	O	-1	10764869
ic	O	-1	10764869
liver	O	-1	10764869
transplant@@	O	-1	10764869
ation.	O	-1	10764869
METHOD@@	O	-1	10764869
:	O	-1	10764869
C@@	O	-1	10764869
ase	O	-1	10764869
repor@@	O	-1	10764869
t.	O	-1	10764869
In	O	-1	10764869
a	O	-1	10764869
5@@	O	-1	10764869
8@@	O	-1	10764869
-@@	O	-1	10764869
year-old	O	-1	10764869
man	O	-1	10764869
receiving	O	-1	10764869
tacrolimus	B-Chemical	D016559	10764869
after	O	-1	10764869
or@@	O	-1	10764869
th@@	O	-1	10764869
ot@@	O	-1	10764869
ro@@	O	-1	10764869
p@@	O	-1	10764869
ic	O	-1	10764869
liver	O	-1	10764869
transplant@@	O	-1	10764869
ation,	O	-1	10764869
ser@@	O	-1	10764869
ial	O	-1	10764869
neuro@@	O	-1	10764869
-@@	O	-1	10764869
oph@@	O	-1	10764869
thal@@	O	-1	10764869
mo@@	O	-1	10764869
log@@	O	-1	10764869
ic	O	-1	10764869
examin@@	O	-1	10764869
ations	O	-1	10764869
and	O	-1	10764869
labor@@	O	-1	10764869
atory	O	-1	10764869
studies	O	-1	10764869
were	O	-1	10764869
per@@	O	-1	10764869
for@@	O	-1	10764869
me@@	O	-1	10764869
d.	O	-1	10764869
RESULTS:	O	-1	10764869
The	O	-1	10764869
patient	O	-1	10764869
had	O	-1	10764869
ep@@	O	-1	10764869
is@@	O	-1	10764869
odi@@	O	-1	10764869
c	O	-1	10764869
deter@@	O	-1	10764869
i@@	O	-1	10764869
or@@	O	-1	10764869
ation	O	-1	10764869
of	O	-1	10764869
vi@@	O	-1	10764869
sion	O	-1	10764869
in	O	-1	10764869
both	O	-1	10764869
e@@	O	-1	10764869
y@@	O	-1	10764869
es,	O	-1	10764869
with	O	-1	10764869
clinical	O	-1	10764869
feat@@	O	-1	10764869
ures	O	-1	10764869
re@@	O	-1	10764869
se@@	O	-1	10764869
m@@	O	-1	10764869
bl@@	O	-1	10764869
ing	O	-1	10764869
ischem@@	B-Disease	D018917	10764869
ic	I-Disease	-1	10764869
op@@	I-Disease	-1	10764869
tic	I-Disease	-1	10764869
neuro@@	I-Disease	-1	10764869
path@@	I-Disease	-1	10764869
i@@	I-Disease	-1	10764869
es	I-Disease	-1	10764869
.	O	-1	10764869
De@@	B-Disease	D015354	10764869
ter@@	I-Disease	-1	10764869
i@@	I-Disease	-1	10764869
or@@	I-Disease	-1	10764869
ation	I-Disease	-1	10764869
of	I-Disease	-1	10764869
vi@@	I-Disease	-1	10764869
sion	I-Disease	-1	10764869
occurred	O	-1	10764869
des@@	O	-1	10764869
pit@@	O	-1	10764869
e	O	-1	10764869
discontinu@@	O	-1	10764869
ation	O	-1	10764869
of	O	-1	10764869
the	O	-1	10764869
tacrolimus	B-Chemical	D016559	10764869
.	O	-1	10764869
CONCLUSION:	O	-1	10764869
T@@	B-Chemical	D016559	10764869
ac@@	I-Chemical	-1	10764869
rolimus	I-Chemical	-1	10764869
and	O	-1	10764869
other	O	-1	10764869
immunosup@@	O	-1	10764869
pressive	O	-1	10764869
agents	O	-1	10764869
may	O	-1	10764869
be	O	-1	10764869
associated	O	-1	10764869
with	O	-1	10764869
op@@	B-Disease	D009901	10764869
tic	I-Disease	-1	10764869
nerve	I-Disease	-1	10764869
toxicity	I-Disease	-1	10764869
.	O	-1	10764869

H@@	B-Disease	D006934	10770468
y@@	I-Disease	-1	10770468
per@@	I-Disease	-1	10770468
cal@@	I-Disease	-1	10770468
ce@@	I-Disease	-1	10770468
mia	I-Disease	-1	10770468
,	O	-1	10770468
arrhyth@@	B-Disease	D001145	10770468
mia	I-Disease	-1	10770468
,	O	-1	10770468
and	O	-1	10770468
mo@@	O	-1	10770468
od	O	-1	10770468
st@@	O	-1	10770468
abil@@	O	-1	10770468
iz@@	O	-1	10770468
ers.	O	-1	10770468
Rec@@	O	-1	10770468
ent	O	-1	10770468
findings	O	-1	10770468
in	O	-1	10770468
a	O	-1	10770468
b@@	B-Disease	D001714	10770468
ip@@	I-Disease	-1	10770468
ol@@	I-Disease	-1	10770468
ar	I-Disease	-1	10770468
patient	O	-1	10770468
receiving	O	-1	10770468
maint@@	O	-1	10770468
en@@	O	-1	10770468
ance	O	-1	10770468
lithium	B-Chemical	D008094	10770468
therapy	O	-1	10770468
who	O	-1	10770468
developed	O	-1	10770468
hyper@@	B-Disease	D006934	10770468
cal@@	I-Disease	-1	10770468
ce@@	I-Disease	-1	10770468
mia	I-Disease	-1	10770468
and	O	-1	10770468
severe	O	-1	10770468
brady@@	B-Disease	D001919	10770468
arrhyth@@	I-Disease	-1	10770468
mia	I-Disease	-1	10770468
pro@@	O	-1	10770468
m@@	O	-1	10770468
pt@@	O	-1	10770468
ed	O	-1	10770468
the	O	-1	10770468
au@@	O	-1	10770468
th@@	O	-1	10770468
ors	O	-1	10770468
to	O	-1	10770468
con@@	O	-1	10770468
duc@@	O	-1	10770468
t	O	-1	10770468
a	O	-1	10770468
ret@@	O	-1	10770468
ro@@	O	-1	10770468
sp@@	O	-1	10770468
ective	O	-1	10770468
study	O	-1	10770468
of	O	-1	10770468
b@@	B-Disease	D001714	10770468
ip@@	I-Disease	-1	10770468
ol@@	I-Disease	-1	10770468
ar	I-Disease	-1	10770468
patients	O	-1	10770468
with	O	-1	10770468
lithium	B-Chemical	D008094	10770468
-@@	O	-1	10770468
associated	O	-1	10770468
hyper@@	B-Disease	D006934	10770468
cal@@	I-Disease	-1	10770468
ce@@	I-Disease	-1	10770468
mia	I-Disease	-1	10770468
.	O	-1	10770468
A	O	-1	10770468
pr@@	O	-1	10770468
int@@	O	-1	10770468
out	O	-1	10770468
of	O	-1	10770468
all	O	-1	10770468
cases	O	-1	10770468
of	O	-1	10770468
hyper@@	B-Disease	D006934	10770468
cal@@	I-Disease	-1	10770468
ce@@	I-Disease	-1	10770468
mia	I-Disease	-1	10770468
that	O	-1	10770468
presented	O	-1	10770468
during	O	-1	10770468
a	O	-1	10770468
1-@@	O	-1	10770468
year	O	-1	10770468
period	O	-1	10770468
was	O	-1	10770468
gener@@	O	-1	10770468
ated.	O	-1	10770468
After	O	-1	10770468
el@@	O	-1	10770468
im@@	O	-1	10770468
in@@	O	-1	10770468
ating	O	-1	10770468
sp@@	O	-1	10770468
ur@@	O	-1	10770468
i@@	O	-1	10770468
ous	O	-1	10770468
hyper@@	B-Disease	D006934	10770468
cal@@	I-Disease	-1	10770468
ce@@	I-Disease	-1	10770468
mi@@	I-Disease	-1	10770468
as	I-Disease	-1	10770468
or	O	-1	10770468
those	O	-1	10770468
associated	O	-1	10770468
with	O	-1	10770468
intravenous	O	-1	10770468
flu@@	O	-1	10770468
id@@	O	-1	10770468
s,	O	-1	10770468
the	O	-1	10770468
au@@	O	-1	10770468
th@@	O	-1	10770468
ors	O	-1	10770468
identi@@	O	-1	10770468
fied	O	-1	10770468
1@@	O	-1	10770468
8	O	-1	10770468
non@@	O	-1	10770468
-	O	-1	10770468
lithium	B-Chemical	D008094	10770468
-treated	O	-1	10770468
patients	O	-1	10770468
with	O	-1	10770468
hyper@@	B-Disease	D006934	10770468
cal@@	I-Disease	-1	10770468
ce@@	I-Disease	-1	10770468
mi@@	I-Disease	-1	10770468
as	I-Disease	-1	10770468
related	O	-1	10770468
to	O	-1	10770468
mal@@	B-Disease	D009369	10770468
i@@	I-Disease	-1	10770468
gn@@	I-Disease	-1	10770468
an@@	I-Disease	-1	10770468
ci@@	I-Disease	-1	10770468
es	I-Disease	-1	10770468
and	O	-1	10770468
other	O	-1	10770468
med@@	O	-1	10770468
ical	O	-1	10770468
condi@@	O	-1	10770468
tions	O	-1	10770468
(@@	O	-1	10770468
group	O	-1	10770468
A@@	O	-1	10770468
)	O	-1	10770468
and	O	-1	10770468
12	O	-1	10770468
patients	O	-1	10770468
with	O	-1	10770468
lithium	B-Chemical	D008094	10770468
-@@	O	-1	10770468
associated	O	-1	10770468
hyper@@	B-Disease	D006934	10770468
cal@@	I-Disease	-1	10770468
ce@@	I-Disease	-1	10770468
mia	I-Disease	-1	10770468
(@@	O	-1	10770468
group	O	-1	10770468
B@@	O	-1	10770468
).	O	-1	10770468
Patients	O	-1	10770468
in	O	-1	10770468
group	O	-1	10770468
B	O	-1	10770468
were	O	-1	10770468
not	O	-1	10770468
compar@@	O	-1	10770468
able	O	-1	10770468
to	O	-1	10770468
those	O	-1	10770468
in	O	-1	10770468
group	O	-1	10770468
A@@	O	-1	10770468
,	O	-1	10770468
as	O	-1	10770468
the	O	-1	10770468
lat@@	O	-1	10770468
ter	O	-1	10770468
were	O	-1	10770468
medic@@	O	-1	10770468
ally	O	-1	10770468
com@@	O	-1	10770468
pro@@	O	-1	10770468
mis@@	O	-1	10770468
ed	O	-1	10770468
and	O	-1	10770468
were	O	-1	10770468
receiving	O	-1	10770468
multiple	O	-1	10770468
pharmac@@	O	-1	10770468
o@@	O	-1	10770468
therap@@	O	-1	10770468
i@@	O	-1	10770468
es.	O	-1	10770468
Th@@	O	-1	10770468
us,	O	-1	10770468
two	O	-1	10770468
control	O	-1	10770468
groups	O	-1	10770468
were	O	-1	10770468
gener@@	O	-1	10770468
ated@@	O	-1	10770468
:	O	-1	10770468
group	O	-1	10770468
C@@	O	-1	10770468
1,	O	-1	10770468
which	O	-1	10770468
included	O	-1	10770468
ag@@	O	-1	10770468
e@@	O	-1	10770468
-	O	-1	10770468
and	O	-1	10770468
sex@@	O	-1	10770468
-@@	O	-1	10770468
compar@@	O	-1	10770468
able	O	-1	10770468
lithium	B-Chemical	D008094	10770468
-treated	O	-1	10770468
b@@	B-Disease	D001714	10770468
ip@@	I-Disease	-1	10770468
ol@@	I-Disease	-1	10770468
ar	I-Disease	-1	10770468
norm@@	O	-1	10770468
oc@@	O	-1	10770468
al@@	O	-1	10770468
ce@@	O	-1	10770468
mic	O	-1	10770468
patients,	O	-1	10770468
and	O	-1	10770468
group	O	-1	10770468
C@@	O	-1	10770468
2,	O	-1	10770468
which	O	-1	10770468
included	O	-1	10770468
b@@	B-Disease	D001714	10770468
ip@@	I-Disease	-1	10770468
ol@@	I-Disease	-1	10770468
ar	I-Disease	-1	10770468
norm@@	O	-1	10770468
oc@@	O	-1	10770468
al@@	O	-1	10770468
ce@@	O	-1	10770468
mic	O	-1	10770468
patients	O	-1	10770468
treated	O	-1	10770468
with	O	-1	10770468
anti@@	O	-1	10770468
convul@@	O	-1	10770468
s@@	O	-1	10770468
ant	O	-1	10770468
mo@@	O	-1	10770468
od	O	-1	10770468
st@@	O	-1	10770468
abil@@	O	-1	10770468
iz@@	O	-1	10770468
ers.	O	-1	10770468
The	O	-1	10770468
electro@@	O	-1	10770468
cardio@@	O	-1	10770468
graph@@	O	-1	10770468
ic	O	-1	10770468
(@@	O	-1	10770468
EC@@	O	-1	10770468
G@@	O	-1	10770468
)	O	-1	10770468
findings	O	-1	10770468
for	O	-1	10770468
patients	O	-1	10770468
in	O	-1	10770468
group	O	-1	10770468
B	O	-1	10770468
were	O	-1	10770468
compared	O	-1	10770468
with	O	-1	10770468
those	O	-1	10770468
of	O	-1	10770468
patients	O	-1	10770468
in	O	-1	10770468
groups	O	-1	10770468
C@@	O	-1	10770468
1	O	-1	10770468
and	O	-1	10770468
C@@	O	-1	10770468
2@@	O	-1	10770468
.	O	-1	10770468
It	O	-1	10770468
was	O	-1	10770468
found	O	-1	10770468
that	O	-1	10770468
these	O	-1	10770468
groups	O	-1	10770468
did	O	-1	10770468
not	O	-1	10770468
diff@@	O	-1	10770468
er	O	-1	10770468
in	O	-1	10770468
their	O	-1	10770468
over@@	O	-1	10770468
all	O	-1	10770468
frequency	O	-1	10770468
of	O	-1	10770468
EC@@	O	-1	10770468
G	O	-1	10770468
abnormal@@	O	-1	10770468
iti@@	O	-1	10770468
es@@	O	-1	10770468
;	O	-1	10770468
however,	O	-1	10770468
there	O	-1	10770468
were	O	-1	10770468
significant	O	-1	10770468
differences	O	-1	10770468
in	O	-1	10770468
the	O	-1	10770468
frequency	O	-1	10770468
of	O	-1	10770468
con@@	O	-1	10770468
duction	O	-1	10770468
def@@	O	-1	10770468
ect@@	O	-1	10770468
s.	O	-1	10770468
Patients	O	-1	10770468
with	O	-1	10770468
hyper@@	B-Disease	D006934	10770468
cal@@	I-Disease	-1	10770468
ce@@	I-Disease	-1	10770468
mia	I-Disease	-1	10770468
result@@	O	-1	10770468
ing	O	-1	10770468
from	O	-1	10770468
med@@	O	-1	10770468
ical	O	-1	10770468
diseas@@	O	-1	10770468
es	O	-1	10770468
and	O	-1	10770468
b@@	B-Disease	D001714	10770468
ip@@	I-Disease	-1	10770468
ol@@	I-Disease	-1	10770468
ar	I-Disease	-1	10770468
patients	O	-1	10770468
with	O	-1	10770468
lithium	B-Chemical	D008094	10770468
-@@	O	-1	10770468
associated	O	-1	10770468
hyper@@	B-Disease	D006934	10770468
cal@@	I-Disease	-1	10770468
ce@@	I-Disease	-1	10770468
mia	I-Disease	-1	10770468
had	O	-1	10770468
significantly	O	-1	10770468
higher	O	-1	10770468
frequ@@	O	-1	10770468
en@@	O	-1	10770468
ci@@	O	-1	10770468
es	O	-1	10770468
of	O	-1	10770468
con@@	O	-1	10770468
duction	O	-1	10770468
def@@	O	-1	10770468
ect@@	O	-1	10770468
s.	O	-1	10770468
Patients	O	-1	10770468
in	O	-1	10770468
group	O	-1	10770468
A	O	-1	10770468
had	O	-1	10770468
significant	O	-1	10770468
mor@@	O	-1	10770468
t@@	O	-1	10770468
ality	O	-1	10770468
at	O	-1	10770468
2-@@	O	-1	10770468
year	O	-1	10770468
follow-up	O	-1	10770468
(2@@	O	-1	10770468
8@@	O	-1	10770468
%),	O	-1	10770468
in	O	-1	10770468
contr@@	O	-1	10770468
ast	O	-1	10770468
to	O	-1	10770468
z@@	O	-1	10770468
er@@	O	-1	10770468
o	O	-1	10770468
mor@@	O	-1	10770468
t@@	O	-1	10770468
ality	O	-1	10770468
in	O	-1	10770468
the	O	-1	10770468
other	O	-1	10770468
three	O	-1	10770468
groups.	O	-1	10770468
The	O	-1	10770468
clinical	O	-1	10770468
implic@@	O	-1	10770468
ations	O	-1	10770468
of	O	-1	10770468
these	O	-1	10770468
findings	O	-1	10770468
are	O	-1	10770468
discus@@	O	-1	10770468
sed.	O	-1	10770468

A@@	O	-1	10933650
t@@	O	-1	10933650
ten@@	O	-1	10933650
u@@	O	-1	10933650
ation	O	-1	10933650
of	O	-1	10933650
nephro@@	B-Disease	D007674	10933650
toxicity	I-Disease	-1	10933650
by	O	-1	10933650
a	O	-1	10933650
novel	O	-1	10933650
li@@	O	-1	10933650
pid	O	-1	10933650
n@@	O	-1	10933650
an@@	O	-1	10933650
osph@@	O	-1	10933650
ere	O	-1	10933650
(N@@	O	-1	10933650
S@@	O	-1	10933650
-@@	O	-1	10933650
7@@	O	-1	10933650
18@@	O	-1	10933650
)	O	-1	10933650
inc@@	O	-1	10933650
or@@	O	-1	10933650
por@@	O	-1	10933650
ating	O	-1	10933650
amph@@	B-Chemical	D000666	10933650
ot@@	I-Chemical	-1	10933650
er@@	I-Chemical	-1	10933650
icin	I-Chemical	-1	10933650
B	I-Chemical	-1	10933650
.	O	-1	10933650
N@@	O	-1	10933650
S@@	O	-1	10933650
-@@	O	-1	10933650
7@@	O	-1	10933650
18@@	O	-1	10933650
,	O	-1	10933650
a	O	-1	10933650
li@@	O	-1	10933650
pid	O	-1	10933650
n@@	O	-1	10933650
an@@	O	-1	10933650
osph@@	O	-1	10933650
ere	O	-1	10933650
inc@@	O	-1	10933650
or@@	O	-1	10933650
por@@	O	-1	10933650
ating	O	-1	10933650
amph@@	B-Chemical	D000666	10933650
ot@@	I-Chemical	-1	10933650
er@@	I-Chemical	-1	10933650
icin	I-Chemical	-1	10933650
B	I-Chemical	-1	10933650
,	O	-1	10933650
is	O	-1	10933650
effective	O	-1	10933650
against	O	-1	10933650
path@@	O	-1	10933650
o@@	O	-1	10933650
genic	O	-1	10933650
f@@	O	-1	10933650
un@@	O	-1	10933650
g@@	O	-1	10933650
i	O	-1	10933650
and	O	-1	10933650
has	O	-1	10933650
low	O	-1	10933650
toxicity	B-Disease	D064420	10933650
.	O	-1	10933650
We	O	-1	10933650
compared	O	-1	10933650
the	O	-1	10933650
toxicity	B-Disease	D064420	10933650
of	O	-1	10933650
N@@	O	-1	10933650
S@@	O	-1	10933650
-@@	O	-1	10933650
7@@	O	-1	10933650
1@@	O	-1	10933650
8	O	-1	10933650
with	O	-1	10933650
that	O	-1	10933650
of	O	-1	10933650
F@@	B-Chemical	D000666	10933650
un@@	I-Chemical	-1	10933650
g@@	I-Chemical	-1	10933650
iz@@	I-Chemical	-1	10933650
one	I-Chemical	-1	10933650
(	O	-1	10933650
amph@@	B-Chemical	C059765	10933650
ot@@	I-Chemical	-1	10933650
er@@	I-Chemical	-1	10933650
icin	I-Chemical	-1	10933650
B@@	I-Chemical	-1	10933650
-@@	I-Chemical	-1	10933650
sodium	I-Chemical	-1	10933650
de@@	I-Chemical	-1	10933650
oxy@@	I-Chemical	-1	10933650
chol@@	I-Chemical	-1	10933650
ate	I-Chemical	-1	10933650
;	O	-1	10933650
D-@@	B-Chemical	C059765	10933650
A@@	I-Chemical	-1	10933650
m@@	I-Chemical	-1	10933650
B	I-Chemical	-1	10933650
)	O	-1	10933650
in	O	-1	10933650
vit@@	O	-1	10933650
r@@	O	-1	10933650
o	O	-1	10933650
using	O	-1	10933650
renal	O	-1	10933650
cell	O	-1	10933650
c@@	O	-1	10933650
ult@@	O	-1	10933650
ures	O	-1	10933650
and	O	-1	10933650
in	O	-1	10933650
viv@@	O	-1	10933650
o	O	-1	10933650
by	O	-1	10933650
bio@@	O	-1	10933650
chemical	O	-1	10933650
analy@@	O	-1	10933650
sis,	O	-1	10933650
histo@@	O	-1	10933650
path@@	O	-1	10933650
ological	O	-1	10933650
study	O	-1	10933650
of	O	-1	10933650
the	O	-1	10933650
kidney	O	-1	10933650
and	O	-1	10933650
pharmac@@	O	-1	10933650
o@@	O	-1	10933650
kine@@	O	-1	10933650
tic	O	-1	10933650
study	O	-1	10933650
of	O	-1	10933650
amph@@	B-Chemical	D000666	10933650
ot@@	I-Chemical	-1	10933650
er@@	I-Chemical	-1	10933650
icin	I-Chemical	-1	10933650
B	I-Chemical	-1	10933650
following	O	-1	10933650
intravenous	O	-1	10933650
infusion	O	-1	10933650
of	O	-1	10933650
the	O	-1	10933650
form@@	O	-1	10933650
ulation	O	-1	10933650
in	O	-1	10933650
rats.	O	-1	10933650
In@@	O	-1	10933650
c@@	O	-1	10933650
ub@@	O	-1	10933650
ation	O	-1	10933650
with	O	-1	10933650
N@@	O	-1	10933650
S@@	O	-1	10933650
-@@	O	-1	10933650
7@@	O	-1	10933650
1@@	O	-1	10933650
8	O	-1	10933650
resulted	O	-1	10933650
in	O	-1	10933650
significantly	O	-1	10933650
less	O	-1	10933650
damage	O	-1	10933650
of	O	-1	10933650
c@@	O	-1	10933650
ult@@	O	-1	10933650
ured	O	-1	10933650
human	O	-1	10933650
renal	O	-1	10933650
pro@@	O	-1	10933650
xim@@	O	-1	10933650
al	O	-1	10933650
tub@@	O	-1	10933650
ular	O	-1	10933650
epi@@	O	-1	10933650
thelial	O	-1	10933650
cells	O	-1	10933650
compared	O	-1	10933650
with	O	-1	10933650
D-@@	B-Chemical	C059765	10933650
A@@	I-Chemical	-1	10933650
m@@	I-Chemical	-1	10933650
B	I-Chemical	-1	10933650
.	O	-1	10933650
S@@	O	-1	10933650
er@@	O	-1	10933650
um	O	-1	10933650
blood	O	-1	10933650
ure@@	B-Chemical	D014508	10933650
a	I-Chemical	-1	10933650
and	O	-1	10933650
creatinine	B-Chemical	D003404	10933650
concentrations	O	-1	10933650
increased	O	-1	10933650
significantly	O	-1	10933650
in	O	-1	10933650
rats	O	-1	10933650
given	O	-1	10933650
an	O	-1	10933650
i@@	O	-1	10933650
v	O	-1	10933650
infusion	O	-1	10933650
of	O	-1	10933650
D-@@	B-Chemical	C059765	10933650
A@@	I-Chemical	-1	10933650
m@@	I-Chemical	-1	10933650
B	I-Chemical	-1	10933650
3	O	-1	10933650
mg/kg	O	-1	10933650
but	O	-1	10933650
not	O	-1	10933650
in	O	-1	10933650
those	O	-1	10933650
given	O	-1	10933650
the	O	-1	10933650
same	O	-1	10933650
dose	O	-1	10933650
of	O	-1	10933650
N@@	O	-1	10933650
S@@	O	-1	10933650
-@@	O	-1	10933650
7@@	O	-1	10933650
18@@	O	-1	10933650
.	O	-1	10933650
H@@	O	-1	10933650
ist@@	O	-1	10933650
o@@	O	-1	10933650
path@@	O	-1	10933650
ological	O	-1	10933650
examin@@	O	-1	10933650
ation	O	-1	10933650
of	O	-1	10933650
the	O	-1	10933650
kidney	O	-1	10933650
showed	O	-1	10933650
tub@@	B-Disease	D007683	10933650
ular	I-Disease	-1	10933650
necro@@	I-Disease	-1	10933650
sis	I-Disease	-1	10933650
in	O	-1	10933650
D-@@	B-Chemical	C059765	10933650
A@@	I-Chemical	-1	10933650
m@@	I-Chemical	-1	10933650
B	I-Chemical	-1	10933650
-treated	O	-1	10933650
rats	O	-1	10933650
but	O	-1	10933650
no	O	-1	10933650
change	O	-1	10933650
in	O	-1	10933650
N@@	O	-1	10933650
S@@	O	-1	10933650
-@@	O	-1	10933650
7@@	O	-1	10933650
18@@	O	-1	10933650
-treated	O	-1	10933650
rats.	O	-1	10933650
A@@	B-Chemical	D000666	10933650
m@@	I-Chemical	-1	10933650
ph@@	I-Chemical	-1	10933650
ot@@	I-Chemical	-1	10933650
er@@	I-Chemical	-1	10933650
icin	I-Chemical	-1	10933650
B	I-Chemical	-1	10933650
concentrations	O	-1	10933650
in	O	-1	10933650
the	O	-1	10933650
kidney	O	-1	10933650
in	O	-1	10933650
N@@	O	-1	10933650
S@@	O	-1	10933650
-@@	O	-1	10933650
7@@	O	-1	10933650
18@@	O	-1	10933650
-treated	O	-1	10933650
rats	O	-1	10933650
were	O	-1	10933650
higher	O	-1	10933650
than	O	-1	10933650
those	O	-1	10933650
in	O	-1	10933650
D-@@	B-Chemical	C059765	10933650
A@@	I-Chemical	-1	10933650
m@@	I-Chemical	-1	10933650
B	I-Chemical	-1	10933650
-treated	O	-1	10933650
rats.	O	-1	10933650
Our	O	-1	10933650
in	O	-1	10933650
vit@@	O	-1	10933650
r@@	O	-1	10933650
o	O	-1	10933650
and	O	-1	10933650
in	O	-1	10933650
viv@@	O	-1	10933650
o	O	-1	10933650
results	O	-1	10933650
suggest	O	-1	10933650
that	O	-1	10933650
inc@@	O	-1	10933650
or@@	O	-1	10933650
por@@	O	-1	10933650
ation	O	-1	10933650
of	O	-1	10933650
amph@@	B-Chemical	D000666	10933650
ot@@	I-Chemical	-1	10933650
er@@	I-Chemical	-1	10933650
icin	I-Chemical	-1	10933650
B	I-Chemical	-1	10933650
into	O	-1	10933650
li@@	O	-1	10933650
pid	O	-1	10933650
n@@	O	-1	10933650
an@@	O	-1	10933650
osph@@	O	-1	10933650
e@@	O	-1	10933650
res	O	-1	10933650
of	O	-1	10933650
N@@	O	-1	10933650
S@@	O	-1	10933650
-@@	O	-1	10933650
7@@	O	-1	10933650
1@@	O	-1	10933650
8	O	-1	10933650
attenu@@	O	-1	10933650
ates	O	-1	10933650
the	O	-1	10933650
nephro@@	B-Disease	D007674	10933650
toxicity	I-Disease	-1	10933650
of	O	-1	10933650
amph@@	B-Chemical	D000666	10933650
ot@@	I-Chemical	-1	10933650
er@@	I-Chemical	-1	10933650
icin	I-Chemical	-1	10933650
B	I-Chemical	-1	10933650
.	O	-1	10933650

P@@	O	-1	10939760
at@@	O	-1	10939760
tern@@	O	-1	10939760
s	O	-1	10939760
of	O	-1	10939760
sulf@@	B-Chemical	D013411	10939760
a@@	I-Chemical	-1	10939760
di@@	I-Chemical	-1	10939760
az@@	I-Chemical	-1	10939760
ine	I-Chemical	-1	10939760
acute	B-Disease	D058186	10939760
nephro@@	I-Disease	-1	10939760
toxicity	I-Disease	-1	10939760
.	O	-1	10939760
S@@	B-Chemical	D013411	10939760
ul@@	I-Chemical	-1	10939760
f@@	I-Chemical	-1	10939760
a@@	I-Chemical	-1	10939760
di@@	I-Chemical	-1	10939760
az@@	I-Chemical	-1	10939760
ine	I-Chemical	-1	10939760
acute	B-Disease	D058186	10939760
nephro@@	I-Disease	-1	10939760
toxicity	I-Disease	-1	10939760
is	O	-1	10939760
re@@	O	-1	10939760
vi@@	O	-1	10939760
ving	O	-1	10939760
spec@@	O	-1	10939760
i@@	O	-1	10939760
ally	O	-1	10939760
because	O	-1	10939760
of	O	-1	10939760
its	O	-1	10939760
use	O	-1	10939760
in	O	-1	10939760
tox@@	B-Disease	D014123	10939760
o@@	I-Disease	-1	10939760
plas@@	I-Disease	-1	10939760
mo@@	I-Disease	-1	10939760
sis	I-Disease	-1	10939760
in	O	-1	10939760
H@@	O	-1	10939760
I@@	O	-1	10939760
V@@	O	-1	10939760
-@@	O	-1	10939760
positive	O	-1	10939760
patients.	O	-1	10939760
We	O	-1	10939760
report	O	-1	10939760
4	O	-1	10939760
cas@@	O	-1	10939760
es,	O	-1	10939760
one	O	-1	10939760
of	O	-1	10939760
the@@	O	-1	10939760
m	O	-1	10939760
in	O	-1	10939760
a	O	-1	10939760
previously	O	-1	10939760
healthy	O	-1	10939760
per@@	O	-1	10939760
son@@	O	-1	10939760
.	O	-1	10939760
U@@	O	-1	10939760
n@@	O	-1	10939760
der	O	-1	10939760
treatment	O	-1	10939760
with	O	-1	10939760
sulf@@	B-Chemical	D013411	10939760
a@@	I-Chemical	-1	10939760
di@@	I-Chemical	-1	10939760
az@@	I-Chemical	-1	10939760
ine	I-Chemical	-1	10939760
they	O	-1	10939760
developed	O	-1	10939760
ol@@	B-Disease	D009846	10939760
ig@@	I-Disease	-1	10939760
uria	I-Disease	-1	10939760
,	O	-1	10939760
ab@@	B-Disease	D015746	10939760
domin@@	I-Disease	-1	10939760
al	I-Disease	-1	10939760
pain	I-Disease	-1	10939760
,	O	-1	10939760
renal	B-Disease	D051437	10939760
failure	I-Disease	-1	10939760
and	O	-1	10939760
showed	O	-1	10939760
multiple	O	-1	10939760
radi@@	O	-1	10939760
ol@@	O	-1	10939760
uc@@	O	-1	10939760
ent	O	-1	10939760
renal	B-Disease	D007669	10939760
calc@@	I-Disease	-1	10939760
ul@@	I-Disease	-1	10939760
i	I-Disease	-1	10939760
in	O	-1	10939760
ec@@	O	-1	10939760
ho@@	O	-1	10939760
graph@@	O	-1	10939760
y.	O	-1	10939760
All	O	-1	10939760
patients	O	-1	10939760
reco@@	O	-1	10939760
vered	O	-1	10939760
their	O	-1	10939760
previ@@	O	-1	10939760
ous	O	-1	10939760
normal	O	-1	10939760
renal	O	-1	10939760
function	O	-1	10939760
after	O	-1	10939760
ade@@	O	-1	10939760
qu@@	O	-1	10939760
ate	O	-1	10939760
hy@@	O	-1	10939760
d@@	O	-1	10939760
ration	O	-1	10939760
and	O	-1	10939760
al@@	O	-1	10939760
cal@@	O	-1	10939760
in@@	O	-1	10939760
iz@@	O	-1	10939760
ation.	O	-1	10939760
A	O	-1	10939760
nephro@@	O	-1	10939760
st@@	O	-1	10939760
om@@	O	-1	10939760
y	O	-1	10939760
tu@@	O	-1	10939760
be	O	-1	10939760
had	O	-1	10939760
to	O	-1	10939760
be	O	-1	10939760
pl@@	O	-1	10939760
ac@@	O	-1	10939760
ed	O	-1	10939760
in	O	-1	10939760
one	O	-1	10939760
of	O	-1	10939760
the	O	-1	10939760
patients	O	-1	10939760
for	O	-1	10939760
ure@@	B-Disease	D052878	10939760
ter@@	I-Disease	-1	10939760
al	I-Disease	-1	10939760
li@@	I-Disease	-1	10939760
th@@	I-Disease	-1	10939760
ia@@	I-Disease	-1	10939760
sis	I-Disease	-1	10939760
in	O	-1	10939760
a	O	-1	10939760
single	O	-1	10939760
functional	O	-1	10939760
kidne@@	O	-1	10939760
y.	O	-1	10939760
N@@	O	-1	10939760
one	O	-1	10939760
of	O	-1	10939760
the@@	O	-1	10939760
m	O	-1	10939760
ne@@	O	-1	10939760
ed@@	O	-1	10939760
ed	O	-1	10939760
dialy@@	O	-1	10939760
sis	O	-1	10939760
or	O	-1	10939760
a	O	-1	10939760
renal	O	-1	10939760
biop@@	O	-1	10939760
sy	O	-1	10939760
because	O	-1	10939760
of	O	-1	10939760
a	O	-1	10939760
typ@@	O	-1	10939760
ical	O	-1	10939760
ben@@	O	-1	10939760
ig@@	O	-1	10939760
n	O	-1	10939760
cour@@	O	-1	10939760
se.	O	-1	10939760
Treat@@	O	-1	10939760
ment	O	-1	10939760
with	O	-1	10939760
sulf@@	B-Chemical	D013411	10939760
a@@	I-Chemical	-1	10939760
di@@	I-Chemical	-1	10939760
az@@	I-Chemical	-1	10939760
ine	I-Chemical	-1	10939760
requ@@	O	-1	10939760
i@@	O	-1	10939760
res	O	-1	10939760
ex@@	O	-1	10939760
qu@@	O	-1	10939760
is@@	O	-1	10939760
ite	O	-1	10939760
control	O	-1	10939760
of	O	-1	10939760
renal	O	-1	10939760
func@@	O	-1	10939760
tion,	O	-1	10939760
an	O	-1	10939760
increase	O	-1	10939760
in	O	-1	10939760
w@@	O	-1	10939760
at@@	O	-1	10939760
er	O	-1	10939760
ing@@	O	-1	10939760
es@@	O	-1	10939760
tion	O	-1	10939760
and	O	-1	10939760
possib@@	O	-1	10939760
ly	O	-1	10939760
the	O	-1	10939760
al@@	O	-1	10939760
cal@@	O	-1	10939760
in@@	O	-1	10939760
ization	O	-1	10939760
of	O	-1	10939760
the	O	-1	10939760
ur@@	O	-1	10939760
ine.	O	-1	10939760
We	O	-1	10939760
com@@	O	-1	10939760
mun@@	O	-1	10939760
ic@@	O	-1	10939760
ate	O	-1	10939760
a	O	-1	10939760
case	O	-1	10939760
in	O	-1	10939760
a	O	-1	10939760
previously	O	-1	10939760
healthy	O	-1	10939760
per@@	O	-1	10939760
son@@	O	-1	10939760
,	O	-1	10939760
a	O	-1	10939760
fac@@	O	-1	10939760
t	O	-1	10939760
not	O	-1	10939760
found	O	-1	10939760
in	O	-1	10939760
the	O	-1	10939760
rec@@	O	-1	10939760
ent	O	-1	10939760
literat@@	O	-1	10939760
ure.	O	-1	10939760
Pro@@	O	-1	10939760
b@@	O	-1	10939760
ably	O	-1	10939760
man@@	O	-1	10939760
y	O	-1	10939760
more	O	-1	10939760
cases	O	-1	10939760
are	O	-1	10939760
not	O	-1	10939760
det@@	O	-1	10939760
ect@@	O	-1	10939760
ed.	O	-1	10939760
We	O	-1	10939760
th@@	O	-1	10939760
in@@	O	-1	10939760
k	O	-1	10939760
that	O	-1	10939760
a	O	-1	10939760
pro@@	O	-1	10939760
sp@@	O	-1	10939760
ective	O	-1	10939760
study	O	-1	10939760
wo@@	O	-1	10939760
uld	O	-1	10939760
be	O	-1	10939760
use@@	O	-1	10939760
ful@@	O	-1	10939760
.	O	-1	10939760

D@@	B-Disease	D009759	10960401
o@@	I-Disease	-1	10960401
w@@	I-Disease	-1	10960401
n@@	I-Disease	-1	10960401
be@@	I-Disease	-1	10960401
at	I-Disease	-1	10960401
n@@	I-Disease	-1	10960401
y@@	I-Disease	-1	10960401
st@@	I-Disease	-1	10960401
ag@@	I-Disease	-1	10960401
m@@	I-Disease	-1	10960401
us	I-Disease	-1	10960401
associated	O	-1	10960401
with	O	-1	10960401
intravenous	O	-1	10960401
patient@@	O	-1	10960401
-@@	O	-1	10960401
controlled	O	-1	10960401
administration	O	-1	10960401
of	O	-1	10960401
morphine	B-Chemical	D009020	10960401
.	O	-1	10960401
I@@	O	-1	10960401
MP@@	O	-1	10960401
L@@	O	-1	10960401
IC@@	O	-1	10960401
AT@@	O	-1	10960401
ION@@	O	-1	10960401
S:	O	-1	10960401
This	O	-1	10960401
case	O	-1	10960401
doc@@	O	-1	10960401
um@@	O	-1	10960401
ents	O	-1	10960401
a	O	-1	10960401
patient	O	-1	10960401
who	O	-1	10960401
developed	O	-1	10960401
di@@	B-Disease	D004244	10960401
z@@	I-Disease	-1	10960401
z@@	I-Disease	-1	10960401
in@@	I-Disease	-1	10960401
ess	I-Disease	-1	10960401
with	O	-1	10960401
do@@	B-Disease	D009759	10960401
w@@	I-Disease	-1	10960401
n@@	I-Disease	-1	10960401
be@@	I-Disease	-1	10960401
ating	I-Disease	-1	10960401
n@@	I-Disease	-1	10960401
y@@	I-Disease	-1	10960401
st@@	I-Disease	-1	10960401
ag@@	I-Disease	-1	10960401
m@@	I-Disease	-1	10960401
us	I-Disease	-1	10960401
while	O	-1	10960401
receiving	O	-1	10960401
a	O	-1	10960401
rel@@	O	-1	10960401
atively	O	-1	10960401
larg@@	O	-1	10960401
e	O	-1	10960401
dose	O	-1	10960401
of	O	-1	10960401
IV	O	-1	10960401
patient@@	O	-1	10960401
-@@	O	-1	10960401
controlled	O	-1	10960401
analge@@	O	-1	10960401
sia	O	-1	10960401
morphine	B-Chemical	D009020	10960401
.	O	-1	10960401
Although	O	-1	10960401
there	O	-1	10960401
have	O	-1	10960401
been	O	-1	10960401
case	O	-1	10960401
reports	O	-1	10960401
of	O	-1	10960401
ep@@	O	-1	10960401
id@@	O	-1	10960401
ural	O	-1	10960401
morphine	B-Chemical	D009020	10960401
with	O	-1	10960401
these	O	-1	10960401
symptoms	O	-1	10960401
and	O	-1	10960401
sign@@	O	-1	10960401
s,	O	-1	10960401
this	O	-1	10960401
has	O	-1	10960401
not	O	-1	10960401
been	O	-1	10960401
previously	O	-1	10960401
doc@@	O	-1	10960401
um@@	O	-1	10960401
ent@@	O	-1	10960401
ed	O	-1	10960401
with	O	-1	10960401
IV	O	-1	10960401
or	O	-1	10960401
patient@@	O	-1	10960401
-@@	O	-1	10960401
controlled	O	-1	10960401
analge@@	O	-1	10960401
sia	O	-1	10960401
morphine	B-Chemical	D009020	10960401
.	O	-1	10960401

H@@	O	-1	10975596
em@@	O	-1	10975596
o@@	O	-1	10975596
dynam@@	O	-1	10975596
ic	O	-1	10975596
and	O	-1	10975596
anti@@	O	-1	10975596
adrenergic	O	-1	10975596
effects	O	-1	10975596
of	O	-1	10975596
d@@	B-Chemical	C118667	10975596
ron@@	I-Chemical	-1	10975596
ed@@	I-Chemical	-1	10975596
ar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
and	O	-1	10975596
am@@	B-Chemical	D000638	10975596
iodar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
in	O	-1	10975596
animals	O	-1	10975596
with	O	-1	10975596
a	O	-1	10975596
heal@@	O	-1	10975596
ed	O	-1	10975596
myocardial	B-Disease	D009203	10975596
infarction	I-Disease	-1	10975596
.	O	-1	10975596
The	O	-1	10975596
hemo@@	O	-1	10975596
dynam@@	O	-1	10975596
ic	O	-1	10975596
and	O	-1	10975596
anti@@	O	-1	10975596
adrenergic	O	-1	10975596
effects	O	-1	10975596
of	O	-1	10975596
d@@	B-Chemical	C118667	10975596
ron@@	I-Chemical	-1	10975596
ed@@	I-Chemical	-1	10975596
ar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
,	O	-1	10975596
a	O	-1	10975596
non@@	O	-1	10975596
iod@@	O	-1	10975596
in@@	O	-1	10975596
ated	O	-1	10975596
comp@@	O	-1	10975596
ound	O	-1	10975596
struct@@	O	-1	10975596
ur@@	O	-1	10975596
ally	O	-1	10975596
related	O	-1	10975596
to	O	-1	10975596
am@@	B-Chemical	D000638	10975596
iodar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
,	O	-1	10975596
were	O	-1	10975596
compared	O	-1	10975596
with	O	-1	10975596
those	O	-1	10975596
of	O	-1	10975596
am@@	B-Chemical	D000638	10975596
iodar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
after	O	-1	10975596
prolonged	O	-1	10975596
oral	O	-1	10975596
administr@@	O	-1	10975596
ation,	O	-1	10975596
both	O	-1	10975596
at	O	-1	10975596
res@@	O	-1	10975596
t	O	-1	10975596
and	O	-1	10975596
during	O	-1	10975596
sym@@	O	-1	10975596
pa@@	O	-1	10975596
thetic	O	-1	10975596
stimulation	O	-1	10975596
in	O	-1	10975596
con@@	O	-1	10975596
s@@	O	-1	10975596
ci@@	O	-1	10975596
ous	O	-1	10975596
dog@@	O	-1	10975596
s	O	-1	10975596
with	O	-1	10975596
a	O	-1	10975596
heal@@	O	-1	10975596
ed	O	-1	10975596
myocardial	B-Disease	D009203	10975596
infarction	I-Disease	-1	10975596
.	O	-1	10975596
All	O	-1	10975596
dog@@	O	-1	10975596
s	O	-1	10975596
(n	O	-1	10975596
=	O	-1	10975596
6@@	O	-1	10975596
)	O	-1	10975596
random@@	O	-1	10975596
ly	O	-1	10975596
received	O	-1	10975596
or@@	O	-1	10975596
ally	O	-1	10975596
d@@	B-Chemical	C118667	10975596
ron@@	I-Chemical	-1	10975596
ed@@	I-Chemical	-1	10975596
ar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
(10	O	-1	10975596
and	O	-1	10975596
30	O	-1	10975596
mg/kg@@	O	-1	10975596
),	O	-1	10975596
am@@	B-Chemical	D000638	10975596
iodar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
(10	O	-1	10975596
and	O	-1	10975596
30	O	-1	10975596
mg/kg@@	O	-1	10975596
),	O	-1	10975596
and	O	-1	10975596
placebo	O	-1	10975596
tw@@	O	-1	10975596
ic@@	O	-1	10975596
e	O	-1	10975596
daily	O	-1	10975596
for	O	-1	10975596
7	O	-1	10975596
day@@	O	-1	10975596
s,	O	-1	10975596
with	O	-1	10975596
a	O	-1	10975596
3-@@	O	-1	10975596
week	O	-1	10975596
w@@	O	-1	10975596
as@@	O	-1	10975596
h@@	O	-1	10975596
out	O	-1	10975596
between	O	-1	10975596
con@@	O	-1	10975596
sec@@	O	-1	10975596
utive	O	-1	10975596
treatment@@	O	-1	10975596
s.	O	-1	10975596
H@@	O	-1	10975596
ear@@	O	-1	10975596
t	O	-1	10975596
rate	O	-1	10975596
(@@	O	-1	10975596
H@@	O	-1	10975596
R@@	O	-1	10975596
),	O	-1	10975596
mean	O	-1	10975596
arterial	O	-1	10975596
pressure	O	-1	10975596
(@@	O	-1	10975596
M@@	O	-1	10975596
B@@	O	-1	10975596
P@@	O	-1	10975596
),	O	-1	10975596
positive	O	-1	10975596
rate	O	-1	10975596
of	O	-1	10975596
increase	O	-1	10975596
of	O	-1	10975596
left	O	-1	10975596
ventricular	O	-1	10975596
pressure	O	-1	10975596
(@@	O	-1	10975596
+@@	O	-1	10975596
L@@	O	-1	10975596
V@@	O	-1	10975596
d@@	O	-1	10975596
P@@	O	-1	10975596
/@@	O	-1	10975596
d@@	O	-1	10975596
t@@	O	-1	10975596
),	O	-1	10975596
echocardiograph@@	O	-1	10975596
ically	O	-1	10975596
assessed	O	-1	10975596
left	O	-1	10975596
ventricular	O	-1	10975596
e@@	O	-1	10975596
j@@	O	-1	10975596
ection	O	-1	10975596
frac@@	O	-1	10975596
tion	O	-1	10975596
(@@	O	-1	10975596
L@@	O	-1	10975596
V@@	O	-1	10975596
E@@	O	-1	10975596
F@@	O	-1	10975596
),	O	-1	10975596
and	O	-1	10975596
frac@@	O	-1	10975596
tional	O	-1	10975596
sh@@	O	-1	10975596
or@@	O	-1	10975596
ten@@	O	-1	10975596
ing	O	-1	10975596
(@@	O	-1	10975596
F@@	O	-1	10975596
S@@	O	-1	10975596
),	O	-1	10975596
as	O	-1	10975596
well	O	-1	10975596
as	O	-1	10975596
chron@@	O	-1	10975596
ot@@	O	-1	10975596
ro@@	O	-1	10975596
p@@	O	-1	10975596
ic	O	-1	10975596
response	O	-1	10975596
to	O	-1	10975596
isoproteren@@	B-Chemical	D007545	10975596
ol	I-Chemical	-1	10975596
and	O	-1	10975596
ex@@	O	-1	10975596
er@@	O	-1	10975596
ci@@	O	-1	10975596
se@@	O	-1	10975596
-induced	O	-1	10975596
sym@@	O	-1	10975596
pa@@	O	-1	10975596
thetic	O	-1	10975596
stimulation	O	-1	10975596
were	O	-1	10975596
evaluated	O	-1	10975596
under	O	-1	10975596
baseline	O	-1	10975596
and	O	-1	10975596
post@@	O	-1	10975596
treatment	O	-1	10975596
condi@@	O	-1	10975596
tions.	O	-1	10975596
R@@	O	-1	10975596
est@@	O	-1	10975596
ing	O	-1	10975596
values	O	-1	10975596
of	O	-1	10975596
L@@	O	-1	10975596
V@@	O	-1	10975596
E@@	O	-1	10975596
F@@	O	-1	10975596
,	O	-1	10975596
F@@	O	-1	10975596
S@@	O	-1	10975596
,	O	-1	10975596
+@@	O	-1	10975596
L@@	O	-1	10975596
V@@	O	-1	10975596
d@@	O	-1	10975596
P@@	O	-1	10975596
/@@	O	-1	10975596
d@@	O	-1	10975596
t,	O	-1	10975596
and	O	-1	10975596
M@@	O	-1	10975596
B@@	O	-1	10975596
P	O	-1	10975596
remained	O	-1	10975596
un@@	O	-1	10975596
chang@@	O	-1	10975596
ed	O	-1	10975596
wh@@	O	-1	10975596
at@@	O	-1	10975596
ev@@	O	-1	10975596
er	O	-1	10975596
the	O	-1	10975596
drug	O	-1	10975596
and	O	-1	10975596
the	O	-1	10975596
dos@@	O	-1	10975596
ing	O	-1	10975596
regimen@@	O	-1	10975596
,	O	-1	10975596
whereas	O	-1	10975596
rest@@	O	-1	10975596
ing	O	-1	10975596
H@@	O	-1	10975596
R	O	-1	10975596
was	O	-1	10975596
significantly	O	-1	10975596
and	O	-1	10975596
dose-@@	O	-1	10975596
depend@@	O	-1	10975596
ently	O	-1	10975596
lo@@	O	-1	10975596
we@@	O	-1	10975596
red	O	-1	10975596
after	O	-1	10975596
d@@	B-Chemical	C118667	10975596
ron@@	I-Chemical	-1	10975596
ed@@	I-Chemical	-1	10975596
ar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
and	O	-1	10975596
to	O	-1	10975596
a	O	-1	10975596
l@@	O	-1	10975596
ess@@	O	-1	10975596
er	O	-1	10975596
ext@@	O	-1	10975596
ent	O	-1	10975596
after	O	-1	10975596
am@@	B-Chemical	D000638	10975596
iodar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
.	O	-1	10975596
B@@	O	-1	10975596
oth	O	-1	10975596
d@@	B-Chemical	C118667	10975596
ron@@	I-Chemical	-1	10975596
ed@@	I-Chemical	-1	10975596
ar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
and	O	-1	10975596
am@@	B-Chemical	D000638	10975596
iodar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
significantly	O	-1	10975596
reduced	O	-1	10975596
the	O	-1	10975596
ex@@	O	-1	10975596
er@@	O	-1	10975596
ci@@	O	-1	10975596
se@@	O	-1	10975596
-induced	O	-1	10975596
tachycardia	B-Disease	D013610	10975596
and@@	O	-1	10975596
,	O	-1	10975596
at	O	-1	10975596
the	O	-1	10975596
high@@	O	-1	10975596
est	O	-1	10975596
dose@@	O	-1	10975596
,	O	-1	10975596
decreased	O	-1	10975596
the	O	-1	10975596
isoproteren@@	B-Chemical	D007545	10975596
ol	I-Chemical	-1	10975596
-induced	O	-1	10975596
tachycardia	B-Disease	D013610	10975596
.	O	-1	10975596
Th@@	O	-1	10975596
us,	O	-1	10975596
d@@	B-Chemical	C118667	10975596
ron@@	I-Chemical	-1	10975596
ed@@	I-Chemical	-1	10975596
ar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
and	O	-1	10975596
am@@	B-Chemical	D000638	10975596
iodar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
dis@@	O	-1	10975596
pl@@	O	-1	10975596
ayed	O	-1	10975596
a	O	-1	10975596
similar	O	-1	10975596
level	O	-1	10975596
of	O	-1	10975596
anti@@	O	-1	10975596
adrenergic	O	-1	10975596
effect	O	-1	10975596
and	O	-1	10975596
did	O	-1	10975596
not	O	-1	10975596
impa@@	O	-1	10975596
ir	O	-1	10975596
the	O	-1	10975596
rest@@	O	-1	10975596
ing	O	-1	10975596
left	O	-1	10975596
ventricular	O	-1	10975596
func@@	O	-1	10975596
tion.	O	-1	10975596
Con@@	O	-1	10975596
sequ@@	O	-1	10975596
ent@@	O	-1	10975596
ly,	O	-1	10975596
d@@	B-Chemical	C118667	10975596
ron@@	I-Chemical	-1	10975596
ed@@	I-Chemical	-1	10975596
ar@@	I-Chemical	-1	10975596
one	I-Chemical	-1	10975596
might	O	-1	10975596
be	O	-1	10975596
partic@@	O	-1	10975596
ul@@	O	-1	10975596
arly	O	-1	10975596
su@@	O	-1	10975596
it@@	O	-1	10975596
able	O	-1	10975596
for	O	-1	10975596
the	O	-1	10975596
treatment	O	-1	10975596
and	O	-1	10975596
pre@@	O	-1	10975596
ven@@	O	-1	10975596
tion	O	-1	10975596
of	O	-1	10975596
various	O	-1	10975596
clinical	O	-1	10975596
arrhyth@@	B-Disease	D001145	10975596
mi@@	I-Disease	-1	10975596
as	I-Disease	-1	10975596
,	O	-1	10975596
without	O	-1	10975596
com@@	O	-1	10975596
pro@@	O	-1	10975596
mis@@	O	-1	10975596
ing	O	-1	10975596
the	O	-1	10975596
left	O	-1	10975596
ventricular	O	-1	10975596
func@@	O	-1	10975596
tion.	O	-1	10975596

Ph@@	O	-1	10985896
ase	O	-1	10985896
2	O	-1	10985896
trial	O	-1	10985896
of	O	-1	10985896
li@@	O	-1	10985896
pos@@	O	-1	10985896
om@@	O	-1	10985896
al	O	-1	10985896
dox@@	B-Chemical	D004317	10985896
orub@@	I-Chemical	-1	10985896
icin	I-Chemical	-1	10985896
(@@	O	-1	10985896
40	O	-1	10985896
mg/m@@	O	-1	10985896
(2@@	O	-1	10985896
)@@	O	-1	10985896
)	O	-1	10985896
in	O	-1	10985896
pl@@	B-Chemical	D010984	10985896
at@@	I-Chemical	-1	10985896
in@@	I-Chemical	-1	10985896
um	I-Chemical	-1	10985896
/	O	-1	10985896
paclitax@@	B-Chemical	D017239	10985896
el	I-Chemical	-1	10985896
-@@	O	-1	10985896
ref@@	O	-1	10985896
rac@@	O	-1	10985896
t@@	O	-1	10985896
ory	O	-1	10985896
o@@	B-Disease	D010051	10985896
vari@@	I-Disease	-1	10985896
an	I-Disease	-1	10985896
and	I-Disease	-1	10985896
f@@	I-Disease	-1	10985896
al@@	I-Disease	-1	10985896
lo@@	I-Disease	-1	10985896
pi@@	I-Disease	-1	10985896
an	I-Disease	-1	10985896
tu@@	I-Disease	-1	10985896
be	I-Disease	-1	10985896
canc@@	I-Disease	-1	10985896
ers	I-Disease	-1	10985896
o@@	B-Disease	D005185	10985896
vari@@	I-Disease	-1	10985896
an	I-Disease	-1	10985896
and	I-Disease	-1	10985896
f@@	I-Disease	-1	10985896
al@@	I-Disease	-1	10985896
lo@@	I-Disease	-1	10985896
pi@@	I-Disease	-1	10985896
an	I-Disease	-1	10985896
tu@@	I-Disease	-1	10985896
be	I-Disease	-1	10985896
canc@@	I-Disease	-1	10985896
ers	I-Disease	-1	10985896
and	O	-1	10985896
prim@@	O	-1	10985896
ary	O	-1	10985896
carcin@@	B-Disease	D010534	10985896
oma	I-Disease	-1	10985896
of	I-Disease	-1	10985896
the	I-Disease	-1	10985896
per@@	I-Disease	-1	10985896
it@@	I-Disease	-1	10985896
one@@	I-Disease	-1	10985896
um	I-Disease	-1	10985896
.	O	-1	10985896
BACKGROUND:	O	-1	10985896
S@@	O	-1	10985896
e@@	O	-1	10985896
ver@@	O	-1	10985896
al	O	-1	10985896
studies	O	-1	10985896
have	O	-1	10985896
demonstrated	O	-1	10985896
li@@	O	-1	10985896
pos@@	O	-1	10985896
om@@	O	-1	10985896
al	O	-1	10985896
dox@@	B-Chemical	D004317	10985896
orub@@	I-Chemical	-1	10985896
icin	I-Chemical	-1	10985896
(	O	-1	10985896
D@@	B-Chemical	D004317	10985896
ox@@	I-Chemical	-1	10985896
il	I-Chemical	-1	10985896
)	O	-1	10985896
to	O	-1	10985896
be	O	-1	10985896
an	O	-1	10985896
active	O	-1	10985896
ant@@	O	-1	10985896
ine@@	O	-1	10985896
o@@	O	-1	10985896
plas@@	O	-1	10985896
tic	O	-1	10985896
agent	O	-1	10985896
in	O	-1	10985896
pl@@	B-Chemical	D010984	10985896
at@@	I-Chemical	-1	10985896
in@@	I-Chemical	-1	10985896
um	I-Chemical	-1	10985896
-@@	O	-1	10985896
resist@@	O	-1	10985896
ant	O	-1	10985896
o@@	B-Disease	D010051	10985896
vari@@	I-Disease	-1	10985896
an	I-Disease	-1	10985896
cancer	I-Disease	-1	10985896
,	O	-1	10985896
with	O	-1	10985896
dose	O	-1	10985896
lim@@	O	-1	10985896
it@@	O	-1	10985896
ing	O	-1	10985896
toxicity	B-Disease	D064420	10985896
of	O	-1	10985896
the	O	-1	10985896
standard	O	-1	10985896
dos@@	O	-1	10985896
ing	O	-1	10985896
regi@@	O	-1	10985896
men	O	-1	10985896
(@@	O	-1	10985896
50	O	-1	10985896
mg/m@@	O	-1	10985896
(2@@	O	-1	10985896
)	O	-1	10985896
q	O	-1	10985896
4	O	-1	10985896
week@@	O	-1	10985896
s)	O	-1	10985896
being	O	-1	10985896
severe	O	-1	10985896
erythro@@	B-Disease	D060831	10985896
dys@@	I-Disease	-1	10985896
esthe@@	I-Disease	-1	10985896
sia	I-Disease	-1	10985896
(@@	O	-1	10985896
"	O	-1	10985896
h@@	B-Disease	D060831	10985896
and@@	I-Disease	-1	10985896
-@@	I-Disease	-1	10985896
fo@@	I-Disease	-1	10985896
o@@	I-Disease	-1	10985896
t	I-Disease	-1	10985896
syndrome	I-Disease	-1	10985896
"@@	O	-1	10985896
)	O	-1	10985896
and	O	-1	10985896
st@@	B-Disease	D013280	10985896
om@@	I-Disease	-1	10985896
ati@@	I-Disease	-1	10985896
tis	I-Disease	-1	10985896
.	O	-1	10985896
We	O	-1	10985896
w@@	O	-1	10985896
ished	O	-1	10985896
to	O	-1	10985896
deve@@	O	-1	10985896
lo@@	O	-1	10985896
p	O	-1	10985896
a	O	-1	10985896
more	O	-1	10985896
toler@@	O	-1	10985896
able	O	-1	10985896
li@@	O	-1	10985896
pos@@	O	-1	10985896
om@@	O	-1	10985896
al	O	-1	10985896
dox@@	B-Chemical	D004317	10985896
orub@@	I-Chemical	-1	10985896
icin	I-Chemical	-1	10985896
treatment	O	-1	10985896
regi@@	O	-1	10985896
men	O	-1	10985896
and	O	-1	10985896
doc@@	O	-1	10985896
u@@	O	-1	10985896
ment	O	-1	10985896
its	O	-1	10985896
level	O	-1	10985896
of	O	-1	10985896
activity	O	-1	10985896
in	O	-1	10985896
a	O	-1	10985896
we@@	O	-1	10985896
ll@@	O	-1	10985896
-@@	O	-1	10985896
def@@	O	-1	10985896
in@@	O	-1	10985896
ed	O	-1	10985896
patient	O	-1	10985896
po@@	O	-1	10985896
p@@	O	-1	10985896
ulation	O	-1	10985896
with	O	-1	10985896
pl@@	B-Chemical	D010984	10985896
at@@	I-Chemical	-1	10985896
in@@	I-Chemical	-1	10985896
um	I-Chemical	-1	10985896
/	O	-1	10985896
paclitax@@	B-Chemical	D017239	10985896
el	I-Chemical	-1	10985896
-@@	O	-1	10985896
ref@@	O	-1	10985896
rac@@	O	-1	10985896
t@@	O	-1	10985896
ory	O	-1	10985896
disease.	O	-1	10985896
METHOD@@	O	-1	10985896
S	O	-1	10985896
AN@@	O	-1	10985896
D	O	-1	10985896
M@@	O	-1	10985896
AT@@	O	-1	10985896
E@@	O	-1	10985896
R@@	O	-1	10985896
I@@	O	-1	10985896
AL@@	O	-1	10985896
S:	O	-1	10985896
Patients	O	-1	10985896
with	O	-1	10985896
o@@	B-Disease	D010051	10985896
vari@@	I-Disease	-1	10985896
an	I-Disease	-1	10985896
or	I-Disease	-1	10985896
f@@	I-Disease	-1	10985896
al@@	I-Disease	-1	10985896
lo@@	I-Disease	-1	10985896
pi@@	I-Disease	-1	10985896
an	I-Disease	-1	10985896
tu@@	I-Disease	-1	10985896
be	I-Disease	-1	10985896
canc@@	I-Disease	-1	10985896
ers	I-Disease	-1	10985896
o@@	B-Disease	D005185	10985896
vari@@	I-Disease	-1	10985896
an	I-Disease	-1	10985896
or	I-Disease	-1	10985896
f@@	I-Disease	-1	10985896
al@@	I-Disease	-1	10985896
lo@@	I-Disease	-1	10985896
pi@@	I-Disease	-1	10985896
an	I-Disease	-1	10985896
tu@@	I-Disease	-1	10985896
be	I-Disease	-1	10985896
canc@@	I-Disease	-1	10985896
ers	I-Disease	-1	10985896
or	O	-1	10985896
prim@@	O	-1	10985896
ary	O	-1	10985896
per@@	B-Disease	D010534	10985896
it@@	I-Disease	-1	10985896
one@@	I-Disease	-1	10985896
al	I-Disease	-1	10985896
carcin@@	I-Disease	-1	10985896
oma	I-Disease	-1	10985896
with	O	-1	10985896
pl@@	B-Chemical	D010984	10985896
at@@	I-Chemical	-1	10985896
in@@	I-Chemical	-1	10985896
um	I-Chemical	-1	10985896
/	O	-1	10985896
paclitax@@	B-Chemical	D017239	10985896
el	I-Chemical	-1	10985896
-@@	O	-1	10985896
ref@@	O	-1	10985896
rac@@	O	-1	10985896
t@@	O	-1	10985896
ory	O	-1	10985896
disease	O	-1	10985896
(@@	O	-1	10985896
st@@	O	-1	10985896
able	O	-1	10985896
or	O	-1	10985896
progressive	O	-1	10985896
disease	O	-1	10985896
following	O	-1	10985896
treatment	O	-1	10985896
with	O	-1	10985896
these	O	-1	10985896
agents	O	-1	10985896
or	O	-1	10985896
previ@@	O	-1	10985896
ous	O	-1	10985896
ob@@	O	-1	10985896
j@@	O	-1	10985896
ective	O	-1	10985896
response	O	-1	10985896
<@@	O	-1	10985896
3	O	-1	10985896
months	O	-1	10985896
in	O	-1	10985896
dur@@	O	-1	10985896
ation@@	O	-1	10985896
)	O	-1	10985896
were	O	-1	10985896
treated	O	-1	10985896
with	O	-1	10985896
li@@	O	-1	10985896
pos@@	O	-1	10985896
om@@	O	-1	10985896
al	O	-1	10985896
dox@@	B-Chemical	D004317	10985896
orub@@	I-Chemical	-1	10985896
icin	I-Chemical	-1	10985896
at	O	-1	10985896
a	O	-1	10985896
dose	O	-1	10985896
of	O	-1	10985896
40	O	-1	10985896
mg/m@@	O	-1	10985896
(2@@	O	-1	10985896
)	O	-1	10985896
q	O	-1	10985896
4	O	-1	10985896
week@@	O	-1	10985896
s.	O	-1	10985896
RESULTS:	O	-1	10985896
A	O	-1	10985896
total	O	-1	10985896
of	O	-1	10985896
4@@	O	-1	10985896
9	O	-1	10985896
patients	O	-1	10985896
(@@	O	-1	10985896
median	O	-1	10985896
ag@@	O	-1	10985896
e@@	O	-1	10985896
:	O	-1	10985896
6@@	O	-1	10985896
0@@	O	-1	10985896
;	O	-1	10985896
range	O	-1	10985896
4@@	O	-1	10985896
1-@@	O	-1	10985896
8@@	O	-1	10985896
1)	O	-1	10985896
ent@@	O	-1	10985896
ered	O	-1	10985896
this	O	-1	10985896
phase	O	-1	10985896
2	O	-1	10985896
tri@@	O	-1	10985896
al.	O	-1	10985896
The	O	-1	10985896
median	O	-1	10985896
number	O	-1	10985896
of	O	-1	10985896
prior	O	-1	10985896
regimen@@	O	-1	10985896
s	O	-1	10985896
was	O	-1	10985896
2	O	-1	10985896
(@@	O	-1	10985896
ran@@	O	-1	10985896
ge@@	O	-1	10985896
:	O	-1	10985896
1-@@	O	-1	10985896
6@@	O	-1	10985896
).	O	-1	10985896
Si@@	O	-1	10985896
x	O	-1	10985896
(1@@	O	-1	10985896
2@@	O	-1	10985896
%)	O	-1	10985896
and	O	-1	10985896
4	O	-1	10985896
(@@	O	-1	10985896
8@@	O	-1	10985896
%)	O	-1	10985896
patients	O	-1	10985896
experienced	O	-1	10985896
gra@@	O	-1	10985896
de	O	-1	10985896
2	O	-1	10985896
h@@	B-Disease	D060831	10985896
and@@	I-Disease	-1	10985896
-@@	I-Disease	-1	10985896
fo@@	I-Disease	-1	10985896
o@@	I-Disease	-1	10985896
t	I-Disease	-1	10985896
syndrome	I-Disease	-1	10985896
and	O	-1	10985896
st@@	B-Disease	D013280	10985896
om@@	I-Disease	-1	10985896
ati@@	I-Disease	-1	10985896
tis	I-Disease	-1	10985896
,	O	-1	10985896
respecti@@	O	-1	10985896
vely	O	-1	10985896
(@@	O	-1	10985896
no	O	-1	10985896
episo@@	O	-1	10985896
des	O	-1	10985896
of	O	-1	10985896
gra@@	O	-1	10985896
de	O	-1	10985896
3@@	O	-1	10985896
).	O	-1	10985896
One	O	-1	10985896
patient	O	-1	10985896
developed	O	-1	10985896
gra@@	O	-1	10985896
de	O	-1	10985896
3	O	-1	10985896
di@@	B-Disease	D003967	10985896
ar@@	I-Disease	-1	10985896
r@@	I-Disease	-1	10985896
he@@	I-Disease	-1	10985896
a	I-Disease	-1	10985896
requ@@	O	-1	10985896
ir@@	O	-1	10985896
ing	O	-1	10985896
hospit@@	O	-1	10985896
al@@	O	-1	10985896
ization	O	-1	10985896
for	O	-1	10985896
hy@@	O	-1	10985896
d@@	O	-1	10985896
r@@	O	-1	10985896
ation.	O	-1	10985896
Si@@	O	-1	10985896
x	O	-1	10985896
(1@@	O	-1	10985896
2@@	O	-1	10985896
%)	O	-1	10985896
individ@@	O	-1	10985896
u@@	O	-1	10985896
als	O	-1	10985896
requ@@	O	-1	10985896
ired	O	-1	10985896
dose	O	-1	10985896
reduc@@	O	-1	10985896
tions.	O	-1	10985896
The	O	-1	10985896
median	O	-1	10985896
number	O	-1	10985896
of	O	-1	10985896
cour@@	O	-1	10985896
ses	O	-1	10985896
of	O	-1	10985896
li@@	O	-1	10985896
pos@@	O	-1	10985896
om@@	O	-1	10985896
al	O	-1	10985896
dox@@	B-Chemical	D004317	10985896
orub@@	I-Chemical	-1	10985896
icin	I-Chemical	-1	10985896
administered	O	-1	10985896
on	O	-1	10985896
this	O	-1	10985896
pro@@	O	-1	10985896
to@@	O	-1	10985896
co@@	O	-1	10985896
l	O	-1	10985896
was	O	-1	10985896
2	O	-1	10985896
(@@	O	-1	10985896
ran@@	O	-1	10985896
ge@@	O	-1	10985896
:	O	-1	10985896
1@@	O	-1	10985896
-1@@	O	-1	10985896
2@@	O	-1	10985896
).	O	-1	10985896
F@@	O	-1	10985896
our	O	-1	10985896
of	O	-1	10985896
4@@	O	-1	10985896
4	O	-1	10985896
patients	O	-1	10985896
(@@	O	-1	10985896
9@@	O	-1	10985896
%)	O	-1	10985896
evalu@@	O	-1	10985896
able	O	-1	10985896
for	O	-1	10985896
response	O	-1	10985896
ex@@	O	-1	10985896
hib@@	O	-1	10985896
ited	O	-1	10985896
ob@@	O	-1	10985896
j@@	O	-1	10985896
ective	O	-1	10985896
and	O	-1	10985896
subj@@	O	-1	10985896
ective	O	-1	10985896
evidence	O	-1	10985896
of	O	-1	10985896
an	O	-1	10985896
ant@@	O	-1	10985896
ine@@	O	-1	10985896
o@@	O	-1	10985896
plas@@	O	-1	10985896
tic	O	-1	10985896
effect	O	-1	10985896
of	O	-1	10985896
therapy.	O	-1	10985896
CONCLUSION:	O	-1	10985896
This	O	-1	10985896
mo@@	O	-1	10985896
di@@	O	-1	10985896
fied	O	-1	10985896
li@@	O	-1	10985896
pos@@	O	-1	10985896
om@@	O	-1	10985896
al	O	-1	10985896
dox@@	B-Chemical	D004317	10985896
orub@@	I-Chemical	-1	10985896
icin	I-Chemical	-1	10985896
regi@@	O	-1	10985896
men	O	-1	10985896
results	O	-1	10985896
in	O	-1	10985896
less	O	-1	10985896
toxicity	B-Disease	D064420	10985896
(	O	-1	10985896
st@@	B-Disease	D013280	10985896
om@@	I-Disease	-1	10985896
ati@@	I-Disease	-1	10985896
tis	I-Disease	-1	10985896
,	O	-1	10985896
h@@	B-Disease	D060831	10985896
and@@	I-Disease	-1	10985896
-@@	I-Disease	-1	10985896
fo@@	I-Disease	-1	10985896
o@@	I-Disease	-1	10985896
t	I-Disease	-1	10985896
syndrome	I-Disease	-1	10985896
)	O	-1	10985896
than	O	-1	10985896
the	O	-1	10985896
standard	O	-1	10985896
F@@	O	-1	10985896
D@@	O	-1	10985896
A@@	O	-1	10985896
-@@	O	-1	10985896
appro@@	O	-1	10985896
ved	O	-1	10985896
dose	O	-1	10985896
sch@@	O	-1	10985896
ed@@	O	-1	10985896
ul@@	O	-1	10985896
e.	O	-1	10985896
De@@	O	-1	10985896
f@@	O	-1	10985896
in@@	O	-1	10985896
it@@	O	-1	10985896
e,	O	-1	10985896
although	O	-1	10985896
lim@@	O	-1	10985896
it@@	O	-1	10985896
ed,	O	-1	10985896
ant@@	O	-1	10985896
ine@@	O	-1	10985896
o@@	O	-1	10985896
plas@@	O	-1	10985896
tic	O	-1	10985896
activity	O	-1	10985896
is	O	-1	10985896
observed	O	-1	10985896
in	O	-1	10985896
patients	O	-1	10985896
with	O	-1	10985896
we@@	O	-1	10985896
ll@@	O	-1	10985896
-@@	O	-1	10985896
def@@	O	-1	10985896
in@@	O	-1	10985896
ed	O	-1	10985896
pl@@	B-Chemical	D010984	10985896
at@@	I-Chemical	-1	10985896
in@@	I-Chemical	-1	10985896
um	I-Chemical	-1	10985896
-	O	-1	10985896
and	O	-1	10985896
paclitax@@	B-Chemical	D017239	10985896
el	I-Chemical	-1	10985896
-@@	O	-1	10985896
ref@@	O	-1	10985896
rac@@	O	-1	10985896
t@@	O	-1	10985896
ory	O	-1	10985896
o@@	B-Disease	D010051	10985896
vari@@	I-Disease	-1	10985896
an	I-Disease	-1	10985896
cancer	I-Disease	-1	10985896
.	O	-1	10985896

Eff@@	O	-1	10986547
icac@@	O	-1	10986547
y	O	-1	10986547
of	O	-1	10986547
ol@@	B-Chemical	C076029	10986547
an@@	I-Chemical	-1	10986547
z@@	I-Chemical	-1	10986547
apine	I-Chemical	-1	10986547
in	O	-1	10986547
acute	O	-1	10986547
b@@	B-Disease	D001714	10986547
ip@@	I-Disease	-1	10986547
ol@@	I-Disease	-1	10986547
ar	I-Disease	-1	10986547
man@@	I-Disease	-1	10986547
ia	I-Disease	-1	10986547
:	O	-1	10986547
a	O	-1	10986547
double-bl@@	O	-1	10986547
ind@@	O	-1	10986547
,	O	-1	10986547
placebo@@	O	-1	10986547
-@@	O	-1	10986547
controlled	O	-1	10986547
study.	O	-1	10986547
The	O	-1	10986547
O@@	B-Chemical	C076029	10986547
l@@	I-Chemical	-1	10986547
an@@	I-Chemical	-1	10986547
z@@	I-Chemical	-1	10986547
ip@@	I-Chemical	-1	10986547
ine	I-Chemical	-1	10986547
H@@	O	-1	10986547
G@@	O	-1	10986547
G@@	O	-1	10986547
W	O	-1	10986547
S@@	O	-1	10986547
t@@	O	-1	10986547
ud@@	O	-1	10986547
y	O	-1	10986547
Grou@@	O	-1	10986547
p@@	O	-1	10986547
.	O	-1	10986547
BACKGROUND:	O	-1	10986547
We	O	-1	10986547
compared	O	-1	10986547
the	O	-1	10986547
efficacy	O	-1	10986547
and	O	-1	10986547
safety	O	-1	10986547
of	O	-1	10986547
ol@@	B-Chemical	C076029	10986547
an@@	I-Chemical	-1	10986547
z@@	I-Chemical	-1	10986547
apine	I-Chemical	-1	10986547
v@@	O	-1	10986547
s	O	-1	10986547
placebo	O	-1	10986547
for	O	-1	10986547
the	O	-1	10986547
treatment	O	-1	10986547
of	O	-1	10986547
acute	O	-1	10986547
b@@	B-Disease	D001714	10986547
ip@@	I-Disease	-1	10986547
ol@@	I-Disease	-1	10986547
ar	I-Disease	-1	10986547
man@@	I-Disease	-1	10986547
ia	I-Disease	-1	10986547
.	O	-1	10986547
METHODS:	O	-1	10986547
F@@	O	-1	10986547
o@@	O	-1	10986547
ur@@	O	-1	10986547
-@@	O	-1	10986547
week@@	O	-1	10986547
,	O	-1	10986547
random@@	O	-1	10986547
iz@@	O	-1	10986547
ed,	O	-1	10986547
double-bl@@	O	-1	10986547
ind@@	O	-1	10986547
,	O	-1	10986547
par@@	O	-1	10986547
al@@	O	-1	10986547
le@@	O	-1	10986547
l	O	-1	10986547
study.	O	-1	10986547
A	O	-1	10986547
total	O	-1	10986547
of	O	-1	10986547
1@@	O	-1	10986547
15	O	-1	10986547
patients	O	-1	10986547
with	O	-1	10986547
a	O	-1	10986547
D@@	O	-1	10986547
S@@	O	-1	10986547
M@@	O	-1	10986547
-@@	O	-1	10986547
IV	O	-1	10986547
diagnosis	O	-1	10986547
of	O	-1	10986547
b@@	B-Disease	D001714	10986547
ip@@	I-Disease	-1	10986547
ol@@	I-Disease	-1	10986547
ar	I-Disease	-1	10986547
disor@@	I-Disease	-1	10986547
der	I-Disease	-1	10986547
,	O	-1	10986547
man@@	B-Disease	D001714	10986547
ic	I-Disease	-1	10986547
or	O	-1	10986547
mi@@	O	-1	10986547
x@@	O	-1	10986547
ed,	O	-1	10986547
were	O	-1	10986547
randomized	O	-1	10986547
to	O	-1	10986547
ol@@	B-Chemical	C076029	10986547
an@@	I-Chemical	-1	10986547
z@@	I-Chemical	-1	10986547
apine	I-Chemical	-1	10986547
,	O	-1	10986547
5	O	-1	10986547
to	O	-1	10986547
20	O	-1	10986547
mg/@@	O	-1	10986547
d	O	-1	10986547
(n	O	-1	10986547
=	O	-1	10986547
55@@	O	-1	10986547
),	O	-1	10986547
or	O	-1	10986547
placebo	O	-1	10986547
(n	O	-1	10986547
=	O	-1	10986547
6@@	O	-1	10986547
0@@	O	-1	10986547
).	O	-1	10986547
The	O	-1	10986547
prim@@	O	-1	10986547
ary	O	-1	10986547
efficacy	O	-1	10986547
meas@@	O	-1	10986547
ure	O	-1	10986547
was	O	-1	10986547
the	O	-1	10986547
Y@@	O	-1	10986547
oun@@	O	-1	10986547
g@@	O	-1	10986547
-	O	-1	10986547
M@@	B-Disease	D001714	10986547
an@@	I-Disease	-1	10986547
ia	I-Disease	-1	10986547
R@@	O	-1	10986547
ating	O	-1	10986547
S@@	O	-1	10986547
cal@@	O	-1	10986547
e	O	-1	10986547
(@@	O	-1	10986547
Y@@	O	-1	10986547
-@@	O	-1	10986547
MR@@	O	-1	10986547
S)	O	-1	10986547
total	O	-1	10986547
sco@@	O	-1	10986547
re.	O	-1	10986547
R@@	O	-1	10986547
es@@	O	-1	10986547
p@@	O	-1	10986547
on@@	O	-1	10986547
se	O	-1	10986547
and	O	-1	10986547
eu@@	O	-1	10986547
th@@	O	-1	10986547
ym@@	O	-1	10986547
ia	O	-1	10986547
were	O	-1	10986547
def@@	O	-1	10986547
ine@@	O	-1	10986547
d,	O	-1	10986547
a	O	-1	10986547
pri@@	O	-1	10986547
or@@	O	-1	10986547
i@@	O	-1	10986547
,	O	-1	10986547
as	O	-1	10986547
at	O	-1	10986547
le@@	O	-1	10986547
ast	O	-1	10986547
a	O	-1	10986547
50@@	O	-1	10986547
%	O	-1	10986547
impro@@	O	-1	10986547
vement	O	-1	10986547
from	O	-1	10986547
baseline	O	-1	10986547
to	O	-1	10986547
end	O	-1	10986547
po@@	O	-1	10986547
in@@	O	-1	10986547
t	O	-1	10986547
and	O	-1	10986547
as	O	-1	10986547
a	O	-1	10986547
scor@@	O	-1	10986547
e	O	-1	10986547
of	O	-1	10986547
no	O	-1	10986547
less	O	-1	10986547
than	O	-1	10986547
12	O	-1	10986547
at	O	-1	10986547
end	O	-1	10986547
po@@	O	-1	10986547
in@@	O	-1	10986547
t	O	-1	10986547
in	O	-1	10986547
the	O	-1	10986547
Y@@	O	-1	10986547
-@@	O	-1	10986547
MR@@	O	-1	10986547
S	O	-1	10986547
total	O	-1	10986547
sco@@	O	-1	10986547
re,	O	-1	10986547
respectively.	O	-1	10986547
S@@	O	-1	10986547
af@@	O	-1	10986547
ety	O	-1	10986547
was	O	-1	10986547
assessed	O	-1	10986547
using	O	-1	10986547
adverse	O	-1	10986547
event@@	O	-1	10986547
s,	O	-1	10986547
E@@	B-Disease	D001480	10986547
x@@	I-Disease	-1	10986547
tra@@	I-Disease	-1	10986547
py@@	I-Disease	-1	10986547
ram@@	I-Disease	-1	10986547
idal	I-Disease	-1	10986547
S@@	I-Disease	-1	10986547
ym@@	I-Disease	-1	10986547
pto@@	I-Disease	-1	10986547
m	I-Disease	-1	10986547
(	O	-1	10986547
EP@@	B-Disease	D001480	10986547
S	I-Disease	-1	10986547
)	O	-1	10986547
rat@@	O	-1	10986547
ing	O	-1	10986547
s@@	O	-1	10986547
cal@@	O	-1	10986547
es,	O	-1	10986547
labor@@	O	-1	10986547
atory	O	-1	10986547
valu@@	O	-1	10986547
es,	O	-1	10986547
electro@@	O	-1	10986547
cardio@@	O	-1	10986547
gram@@	O	-1	10986547
s,	O	-1	10986547
vit@@	O	-1	10986547
al	O	-1	10986547
sign@@	O	-1	10986547
s,	O	-1	10986547
and	O	-1	10986547
weight	O	-1	10986547
chang@@	O	-1	10986547
e.	O	-1	10986547
RESULTS:	O	-1	10986547
O@@	B-Chemical	C076029	10986547
l@@	I-Chemical	-1	10986547
an@@	I-Chemical	-1	10986547
z@@	I-Chemical	-1	10986547
apine	I-Chemical	-1	10986547
-treated	O	-1	10986547
patients	O	-1	10986547
demonstrated	O	-1	10986547
a	O	-1	10986547
statis@@	O	-1	10986547
tically	O	-1	10986547
significant	O	-1	10986547
greater	O	-1	10986547
mean	O	-1	10986547
(@@	O	-1	10986547
+/-	O	-1	10986547
S@@	O	-1	10986547
D)	O	-1	10986547
impro@@	O	-1	10986547
vement	O	-1	10986547
in	O	-1	10986547
Y@@	O	-1	10986547
-@@	O	-1	10986547
MR@@	O	-1	10986547
S	O	-1	10986547
total	O	-1	10986547
scor@@	O	-1	10986547
e	O	-1	10986547
than	O	-1	10986547
placebo@@	O	-1	10986547
-treated	O	-1	10986547
patients	O	-1	10986547
(@@	O	-1	10986547
-1@@	O	-1	10986547
4.@@	O	-1	10986547
8	O	-1	10986547
+/-	O	-1	10986547
1@@	O	-1	10986547
2.@@	O	-1	10986547
5	O	-1	10986547
and	O	-1	10986547
-@@	O	-1	10986547
8.@@	O	-1	10986547
1	O	-1	10986547
+/-	O	-1	10986547
1@@	O	-1	10986547
2.@@	O	-1	10986547
7@@	O	-1	10986547
,	O	-1	10986547
respectivel@@	O	-1	10986547
y@@	O	-1	10986547
;	O	-1	10986547
P@@	O	-1	10986547
<@@	O	-1	10986547
.@@	O	-1	10986547
0@@	O	-1	10986547
0@@	O	-1	10986547
1),	O	-1	10986547
which	O	-1	10986547
was	O	-1	10986547
ev@@	O	-1	10986547
id@@	O	-1	10986547
ent	O	-1	10986547
at	O	-1	10986547
the	O	-1	10986547
first	O	-1	10986547
post@@	O	-1	10986547
baseline	O	-1	10986547
observ@@	O	-1	10986547
ation	O	-1	10986547
1	O	-1	10986547
week	O	-1	10986547
after	O	-1	10986547
random@@	O	-1	10986547
ization	O	-1	10986547
and	O	-1	10986547
was	O	-1	10986547
maint@@	O	-1	10986547
ained	O	-1	10986547
throu@@	O	-1	10986547
gh@@	O	-1	10986547
out	O	-1	10986547
the	O	-1	10986547
study	O	-1	10986547
(@@	O	-1	10986547
las@@	O	-1	10986547
t	O	-1	10986547
observ@@	O	-1	10986547
ation	O	-1	10986547
car@@	O	-1	10986547
ri@@	O	-1	10986547
ed	O	-1	10986547
for@@	O	-1	10986547
war@@	O	-1	10986547
d@@	O	-1	10986547
).	O	-1	10986547
O@@	B-Chemical	C076029	10986547
l@@	I-Chemical	-1	10986547
an@@	I-Chemical	-1	10986547
z@@	I-Chemical	-1	10986547
apine	I-Chemical	-1	10986547
-treated	O	-1	10986547
patients	O	-1	10986547
demonstrated	O	-1	10986547
a	O	-1	10986547
higher	O	-1	10986547
rate	O	-1	10986547
of	O	-1	10986547
response	O	-1	10986547
(6@@	O	-1	10986547
5%	O	-1	10986547
v@@	O	-1	10986547
s	O	-1	10986547
4@@	O	-1	10986547
3@@	O	-1	10986547
%,	O	-1	10986547
respectivel@@	O	-1	10986547
y@@	O	-1	10986547
;	O	-1	10986547
P	O	-1	10986547
=@@	O	-1	10986547
.@@	O	-1	10986547
0@@	O	-1	10986547
2)	O	-1	10986547
and	O	-1	10986547
eu@@	O	-1	10986547
th@@	O	-1	10986547
ym@@	O	-1	10986547
ia	O	-1	10986547
(6@@	O	-1	10986547
1@@	O	-1	10986547
%	O	-1	10986547
v@@	O	-1	10986547
s	O	-1	10986547
3@@	O	-1	10986547
6@@	O	-1	10986547
%,	O	-1	10986547
respectivel@@	O	-1	10986547
y@@	O	-1	10986547
;	O	-1	10986547
P	O	-1	10986547
=@@	O	-1	10986547
.	O	-1	10986547
0@@	O	-1	10986547
1)	O	-1	10986547
than	O	-1	10986547
placebo@@	O	-1	10986547
-treated	O	-1	10986547
patients.	O	-1	10986547
There	O	-1	10986547
were	O	-1	10986547
no	O	-1	10986547
statis@@	O	-1	10986547
tically	O	-1	10986547
significant	O	-1	10986547
differences	O	-1	10986547
in	O	-1	10986547
EP@@	B-Disease	D001480	10986547
S@@	I-Disease	-1	10986547
s	I-Disease	-1	10986547
between	O	-1	10986547
groups.	O	-1	10986547
However,	O	-1	10986547
ol@@	B-Chemical	C076029	10986547
an@@	I-Chemical	-1	10986547
z@@	I-Chemical	-1	10986547
apine	I-Chemical	-1	10986547
-treated	O	-1	10986547
patients	O	-1	10986547
had	O	-1	10986547
a	O	-1	10986547
statis@@	O	-1	10986547
tically	O	-1	10986547
significant	O	-1	10986547
greater	O	-1	10986547
mean	O	-1	10986547
(@@	O	-1	10986547
+/-	O	-1	10986547
S@@	O	-1	10986547
D)	O	-1	10986547
weight	B-Disease	D015430	10986547
g@@	I-Disease	-1	10986547
ain	I-Disease	-1	10986547
than	O	-1	10986547
placebo@@	O	-1	10986547
-treated	O	-1	10986547
patients	O	-1	10986547
(2@@	O	-1	10986547
.@@	O	-1	10986547
1	O	-1	10986547
+/-	O	-1	10986547
2.@@	O	-1	10986547
8	O	-1	10986547
v@@	O	-1	10986547
s	O	-1	10986547
0.@@	O	-1	10986547
4@@	O	-1	10986547
5	O	-1	10986547
+/-	O	-1	10986547
2.@@	O	-1	10986547
3	O	-1	10986547
kg@@	O	-1	10986547
,	O	-1	10986547
respectivel@@	O	-1	10986547
y@@	O	-1	10986547
)	O	-1	10986547
and	O	-1	10986547
also	O	-1	10986547
experienced	O	-1	10986547
more	O	-1	10986547
treatment@@	O	-1	10986547
-@@	O	-1	10986547
em@@	O	-1	10986547
erg@@	O	-1	10986547
ent	O	-1	10986547
s@@	B-Disease	D006970	10986547
om@@	I-Disease	-1	10986547
n@@	I-Disease	-1	10986547
ol@@	I-Disease	-1	10986547
ence	I-Disease	-1	10986547
(2@@	O	-1	10986547
1	O	-1	10986547
patients	O	-1	10986547
[@@	O	-1	10986547
3@@	O	-1	10986547
8.@@	O	-1	10986547
2@@	O	-1	10986547
%@@	O	-1	10986547
]	O	-1	10986547
v@@	O	-1	10986547
s	O	-1	10986547
5	O	-1	10986547
[@@	O	-1	10986547
8.@@	O	-1	10986547
3@@	O	-1	10986547
%	O	-1	10986547
]@@	O	-1	10986547
,	O	-1	10986547
respectivel@@	O	-1	10986547
y@@	O	-1	10986547
).	O	-1	10986547
CONCLUSION:	O	-1	10986547
O@@	B-Chemical	C076029	10986547
l@@	I-Chemical	-1	10986547
an@@	I-Chemical	-1	10986547
z@@	I-Chemical	-1	10986547
apine	I-Chemical	-1	10986547
demonstrated	O	-1	10986547
greater	O	-1	10986547
efficacy	O	-1	10986547
than	O	-1	10986547
placebo	O	-1	10986547
in	O	-1	10986547
the	O	-1	10986547
treatment	O	-1	10986547
of	O	-1	10986547
acute	O	-1	10986547
b@@	B-Disease	D001714	10986547
ip@@	I-Disease	-1	10986547
ol@@	I-Disease	-1	10986547
ar	I-Disease	-1	10986547
man@@	I-Disease	-1	10986547
ia	I-Disease	-1	10986547
and	O	-1	10986547
was	O	-1	10986547
gener@@	O	-1	10986547
ally	O	-1	10986547
well	O	-1	10986547
toler@@	O	-1	10986547
ated.	O	-1	10986547

The	O	-1	11026989
effect	O	-1	11026989
of	O	-1	11026989
pu@@	B-Disease	D015878	11026989
pi@@	I-Disease	-1	11026989
l	I-Disease	-1	11026989
di@@	I-Disease	-1	11026989
l@@	I-Disease	-1	11026989
ation	I-Disease	-1	11026989
with	O	-1	11026989
tro@@	B-Chemical	D014331	11026989
p@@	I-Chemical	-1	11026989
ic@@	I-Chemical	-1	11026989
amide	I-Chemical	-1	11026989
on	O	-1	11026989
vi@@	O	-1	11026989
sion	O	-1	11026989
and	O	-1	11026989
d@@	O	-1	11026989
ri@@	O	-1	11026989
ving	O	-1	11026989
si@@	O	-1	11026989
mul@@	O	-1	11026989
at@@	O	-1	11026989
or	O	-1	11026989
perform@@	O	-1	11026989
ance@@	O	-1	11026989
.	O	-1	11026989
P@@	O	-1	11026989
U@@	O	-1	11026989
R@@	O	-1	11026989
P@@	O	-1	11026989
O@@	O	-1	11026989
S@@	O	-1	11026989
E:	O	-1	11026989
To	O	-1	11026989
ass@@	O	-1	11026989
ess	O	-1	11026989
the	O	-1	11026989
effect	O	-1	11026989
of	O	-1	11026989
pu@@	B-Disease	D015878	11026989
pi@@	I-Disease	-1	11026989
l	I-Disease	-1	11026989
di@@	I-Disease	-1	11026989
l@@	I-Disease	-1	11026989
ation	I-Disease	-1	11026989
on	O	-1	11026989
vi@@	O	-1	11026989
sion	O	-1	11026989
and	O	-1	11026989
d@@	O	-1	11026989
ri@@	O	-1	11026989
ving	O	-1	11026989
abil@@	O	-1	11026989
ity.	O	-1	11026989
METHODS:	O	-1	11026989
A	O	-1	11026989
seri@@	O	-1	11026989
es	O	-1	11026989
of	O	-1	11026989
tests	O	-1	11026989
on	O	-1	11026989
various	O	-1	11026989
par@@	O	-1	11026989
ame@@	O	-1	11026989
ters	O	-1	11026989
of	O	-1	11026989
visual	O	-1	11026989
function	O	-1	11026989
and	O	-1	11026989
d@@	O	-1	11026989
ri@@	O	-1	11026989
ving	O	-1	11026989
si@@	O	-1	11026989
mul@@	O	-1	11026989
at@@	O	-1	11026989
or	O	-1	11026989
perform@@	O	-1	11026989
ance	O	-1	11026989
were	O	-1	11026989
performed	O	-1	11026989
on	O	-1	11026989
12	O	-1	11026989
healthy	O	-1	11026989
d@@	O	-1	11026989
ri@@	O	-1	11026989
ver@@	O	-1	11026989
s,	O	-1	11026989
before	O	-1	11026989
and	O	-1	11026989
after	O	-1	11026989
pu@@	B-Disease	D015878	11026989
pi@@	I-Disease	-1	11026989
l	I-Disease	-1	11026989
di@@	I-Disease	-1	11026989
l@@	I-Disease	-1	11026989
ation	I-Disease	-1	11026989
using	O	-1	11026989
g@@	O	-1	11026989
ut@@	O	-1	11026989
t@@	O	-1	11026989
a@@	O	-1	11026989
e	O	-1	11026989
tro@@	B-Chemical	D014331	11026989
p@@	I-Chemical	-1	11026989
ic@@	I-Chemical	-1	11026989
amide	I-Chemical	-1	11026989
1@@	O	-1	11026989
%.	O	-1	11026989
A	O	-1	11026989
d@@	O	-1	11026989
ri@@	O	-1	11026989
ving	O	-1	11026989
si@@	O	-1	11026989
mul@@	O	-1	11026989
at@@	O	-1	11026989
or	O	-1	11026989
(T@@	O	-1	11026989
ran@@	O	-1	11026989
s@@	O	-1	11026989
por@@	O	-1	11026989
t	O	-1	11026989
R@@	O	-1	11026989
es@@	O	-1	11026989
ear@@	O	-1	11026989
ch	O	-1	11026989
L@@	O	-1	11026989
abor@@	O	-1	11026989
at@@	O	-1	11026989
or@@	O	-1	11026989
y@@	O	-1	11026989
)	O	-1	11026989
was	O	-1	11026989
used	O	-1	11026989
to	O	-1	11026989
meas@@	O	-1	11026989
ure	O	-1	11026989
reaction	O	-1	11026989
time	O	-1	11026989
(@@	O	-1	11026989
R@@	O	-1	11026989
T@@	O	-1	11026989
),	O	-1	11026989
sp@@	O	-1	11026989
e@@	O	-1	11026989
ed	O	-1	11026989
maint@@	O	-1	11026989
en@@	O	-1	11026989
ance	O	-1	11026989
and	O	-1	11026989
ste@@	O	-1	11026989
ering	O	-1	11026989
ac@@	O	-1	11026989
cur@@	O	-1	11026989
ac@@	O	-1	11026989
y.	O	-1	11026989
T@@	O	-1	11026989
est@@	O	-1	11026989
s	O	-1	11026989
of	O	-1	11026989
b@@	O	-1	11026989
a@@	O	-1	11026989
sic	O	-1	11026989
visual	O	-1	11026989
function	O	-1	11026989
included	O	-1	11026989
high@@	O	-1	11026989
-	O	-1	11026989
and	O	-1	11026989
low@@	O	-1	11026989
-@@	O	-1	11026989
contr@@	O	-1	11026989
ast	O	-1	11026989
visual	O	-1	11026989
ac@@	O	-1	11026989
u@@	O	-1	11026989
ity	O	-1	11026989
(@@	O	-1	11026989
HC@@	O	-1	11026989
V@@	O	-1	11026989
A	O	-1	11026989
and	O	-1	11026989
L@@	O	-1	11026989
C@@	O	-1	11026989
V@@	O	-1	11026989
A@@	O	-1	11026989
),	O	-1	11026989
P@@	O	-1	11026989
el@@	O	-1	11026989
li@@	O	-1	11026989
-@@	O	-1	11026989
R@@	O	-1	11026989
ob@@	O	-1	11026989
s@@	O	-1	11026989
on	O	-1	11026989
contr@@	O	-1	11026989
ast	O	-1	11026989
th@@	O	-1	11026989
res@@	O	-1	11026989
h@@	O	-1	11026989
old	O	-1	11026989
(C@@	O	-1	11026989
T)	O	-1	11026989
and	O	-1	11026989
G@@	O	-1	11026989
ol@@	O	-1	11026989
d@@	O	-1	11026989
man@@	O	-1	11026989
n	O	-1	11026989
peri@@	O	-1	11026989
met@@	O	-1	11026989
r@@	O	-1	11026989
y	O	-1	11026989
(@@	O	-1	11026989
F@@	O	-1	11026989
I@@	O	-1	11026989
E@@	O	-1	11026989
L@@	O	-1	11026989
D@@	O	-1	11026989
S@@	O	-1	11026989
).	O	-1	11026989
U@@	O	-1	11026989
se@@	O	-1	11026989
ful	O	-1	11026989
F@@	O	-1	11026989
i@@	O	-1	11026989
el@@	O	-1	11026989
d	O	-1	11026989
of	O	-1	11026989
V@@	O	-1	11026989
i@@	O	-1	11026989
e@@	O	-1	11026989
w	O	-1	11026989
(@@	O	-1	11026989
U@@	O	-1	11026989
F@@	O	-1	11026989
O@@	O	-1	11026989
V@@	O	-1	11026989
-@@	O	-1	11026989
-@@	O	-1	11026989
a	O	-1	11026989
test	O	-1	11026989
of	O	-1	11026989
visual	O	-1	11026989
atten@@	O	-1	11026989
tion@@	O	-1	11026989
)	O	-1	11026989
was	O	-1	11026989
also	O	-1	11026989
under@@	O	-1	11026989
tak@@	O	-1	11026989
en@@	O	-1	11026989
.	O	-1	11026989
The	O	-1	11026989
mean	O	-1	11026989
differences	O	-1	11026989
in	O	-1	11026989
the	O	-1	11026989
pre@@	O	-1	11026989
-	O	-1	11026989
and	O	-1	11026989
post@@	O	-1	11026989
-@@	O	-1	11026989
di@@	O	-1	11026989
lat@@	O	-1	11026989
ation	O	-1	11026989
meas@@	O	-1	11026989
ure@@	O	-1	11026989
ments	O	-1	11026989
were	O	-1	11026989
tested	O	-1	11026989
for	O	-1	11026989
statis@@	O	-1	11026989
tical	O	-1	11026989
signific@@	O	-1	11026989
ance	O	-1	11026989
at	O	-1	11026989
the	O	-1	11026989
95%	O	-1	11026989
level	O	-1	11026989
using	O	-1	11026989
on@@	O	-1	11026989
e-@@	O	-1	11026989
t@@	O	-1	11026989
a@@	O	-1	11026989
il	O	-1	11026989
pa@@	O	-1	11026989
ired	O	-1	11026989
t-@@	O	-1	11026989
test@@	O	-1	11026989
s.	O	-1	11026989
RESULTS:	O	-1	11026989
P@@	B-Disease	D015878	11026989
up@@	I-Disease	-1	11026989
ill@@	I-Disease	-1	11026989
ary	I-Disease	-1	11026989
di@@	I-Disease	-1	11026989
l@@	I-Disease	-1	11026989
ation	I-Disease	-1	11026989
resulted	O	-1	11026989
in	O	-1	11026989
a	O	-1	11026989
statis@@	O	-1	11026989
tically	O	-1	11026989
significant	O	-1	11026989
deter@@	O	-1	11026989
i@@	O	-1	11026989
or@@	O	-1	11026989
ation	O	-1	11026989
in	O	-1	11026989
C@@	O	-1	11026989
T	O	-1	11026989
and	O	-1	11026989
HC@@	O	-1	11026989
V@@	O	-1	11026989
A	O	-1	11026989
on@@	O	-1	11026989
ly.	O	-1	11026989
F@@	O	-1	11026989
i@@	O	-1	11026989
ve	O	-1	11026989
of	O	-1	11026989
12	O	-1	11026989
d@@	O	-1	11026989
ri@@	O	-1	11026989
ver@@	O	-1	11026989
s	O	-1	11026989
also	O	-1	11026989
ex@@	O	-1	11026989
hib@@	O	-1	11026989
ited	O	-1	11026989
deter@@	O	-1	11026989
i@@	O	-1	11026989
or@@	O	-1	11026989
ation	O	-1	11026989
in	O	-1	11026989
L@@	O	-1	11026989
C@@	O	-1	11026989
V@@	O	-1	11026989
A@@	O	-1	11026989
,	O	-1	11026989
C@@	O	-1	11026989
T	O	-1	11026989
and	O	-1	11026989
R@@	O	-1	11026989
T@@	O	-1	11026989
.	O	-1	11026989
L@@	O	-1	11026989
it@@	O	-1	11026989
t@@	O	-1	11026989
le	O	-1	11026989
evidence	O	-1	11026989
em@@	O	-1	11026989
erg@@	O	-1	11026989
ed	O	-1	11026989
for	O	-1	11026989
deter@@	O	-1	11026989
i@@	O	-1	11026989
or@@	O	-1	11026989
ation	O	-1	11026989
in	O	-1	11026989
F@@	O	-1	11026989
I@@	O	-1	11026989
E@@	O	-1	11026989
L@@	O	-1	11026989
D@@	O	-1	11026989
S	O	-1	11026989
and	O	-1	11026989
U@@	O	-1	11026989
F@@	O	-1	11026989
O@@	O	-1	11026989
V@@	O	-1	11026989
.	O	-1	11026989
Al@@	O	-1	11026989
so@@	O	-1	11026989
,	O	-1	11026989
7	O	-1	11026989
of	O	-1	11026989
12	O	-1	11026989
d@@	O	-1	11026989
ri@@	O	-1	11026989
ver@@	O	-1	11026989
s	O	-1	11026989
appe@@	O	-1	11026989
a@@	O	-1	11026989
red	O	-1	11026989
to	O	-1	11026989
adj@@	O	-1	11026989
us@@	O	-1	11026989
t	O	-1	11026989
their	O	-1	11026989
d@@	O	-1	11026989
ri@@	O	-1	11026989
ving	O	-1	11026989
behavi@@	O	-1	11026989
our	O	-1	11026989
by	O	-1	11026989
reduc@@	O	-1	11026989
ing	O	-1	11026989
their	O	-1	11026989
sp@@	O	-1	11026989
e@@	O	-1	11026989
ed	O	-1	11026989
on	O	-1	11026989
the	O	-1	11026989
d@@	O	-1	11026989
ri@@	O	-1	11026989
ving	O	-1	11026989
si@@	O	-1	11026989
mul@@	O	-1	11026989
at@@	O	-1	11026989
or@@	O	-1	11026989
,	O	-1	11026989
lead@@	O	-1	11026989
ing	O	-1	11026989
to	O	-1	11026989
improved	O	-1	11026989
ste@@	O	-1	11026989
ering	O	-1	11026989
ac@@	O	-1	11026989
cur@@	O	-1	11026989
ac@@	O	-1	11026989
y.	O	-1	11026989
CONCLUSIONS:	O	-1	11026989
P@@	B-Disease	D015878	11026989
up@@	I-Disease	-1	11026989
ill@@	I-Disease	-1	11026989
ary	I-Disease	-1	11026989
di@@	I-Disease	-1	11026989
l@@	I-Disease	-1	11026989
ation	I-Disease	-1	11026989
may	O	-1	11026989
le@@	O	-1	11026989
ad	O	-1	11026989
to	O	-1	11026989
a	O	-1	11026989
decrease	O	-1	11026989
in	O	-1	11026989
vi@@	O	-1	11026989
sion	O	-1	11026989
and	O	-1	11026989
day@@	O	-1	11026989
li@@	O	-1	11026989
ght	O	-1	11026989
d@@	O	-1	11026989
ri@@	O	-1	11026989
ving	O	-1	11026989
perform@@	O	-1	11026989
ance	O	-1	11026989
in	O	-1	11026989
youn@@	O	-1	11026989
g	O	-1	11026989
pe@@	O	-1	11026989
o@@	O	-1	11026989
ple@@	O	-1	11026989
.	O	-1	11026989
A	O	-1	11026989
larg@@	O	-1	11026989
er	O	-1	11026989
study,	O	-1	11026989
including	O	-1	11026989
a	O	-1	11026989
b@@	O	-1	11026989
ro@@	O	-1	11026989
ad@@	O	-1	11026989
er	O	-1	11026989
sp@@	O	-1	11026989
ect@@	O	-1	11026989
ru@@	O	-1	11026989
m	O	-1	11026989
of	O	-1	11026989
subj@@	O	-1	11026989
ect@@	O	-1	11026989
s,	O	-1	11026989
is	O	-1	11026989
war@@	O	-1	11026989
ran@@	O	-1	11026989
ted	O	-1	11026989
before	O	-1	11026989
gu@@	O	-1	11026989
ide@@	O	-1	11026989
lin@@	O	-1	11026989
es	O	-1	11026989
can	O	-1	11026989
be	O	-1	11026989
recomm@@	O	-1	11026989
en@@	O	-1	11026989
de@@	O	-1	11026989
d.	O	-1	11026989

A	O	-1	11105626
case	O	-1	11105626
of	O	-1	11105626
is@@	B-Disease	C535670	11105626
ot@@	I-Disease	-1	11105626
ret@@	I-Disease	-1	11105626
ino@@	I-Disease	-1	11105626
in	I-Disease	-1	11105626
emb@@	I-Disease	-1	11105626
r@@	I-Disease	-1	11105626
yo@@	I-Disease	-1	11105626
pathy	I-Disease	-1	11105626
with	O	-1	11105626
bil@@	O	-1	11105626
ateral	O	-1	11105626
an@@	B-Disease	D065817	11105626
o@@	I-Disease	-1	11105626
ti@@	I-Disease	-1	11105626
a	I-Disease	-1	11105626
and	O	-1	11105626
T@@	B-Disease	D004310	11105626
a@@	I-Disease	-1	11105626
us@@	I-Disease	-1	11105626
si@@	I-Disease	-1	11105626
g@@	I-Disease	-1	11105626
-@@	I-Disease	-1	11105626
B@@	I-Disease	-1	11105626
ing	I-Disease	-1	11105626
mal@@	I-Disease	-1	11105626
formation	I-Disease	-1	11105626
.	O	-1	11105626
We	O	-1	11105626
report	O	-1	11105626
a	O	-1	11105626
ne@@	O	-1	11105626
w@@	O	-1	11105626
b@@	O	-1	11105626
or@@	O	-1	11105626
n	O	-1	11105626
inf@@	O	-1	11105626
ant	O	-1	11105626
with	O	-1	11105626
multiple	O	-1	11105626
con@@	O	-1	11105626
gen@@	O	-1	11105626
it@@	O	-1	11105626
al	O	-1	11105626
an@@	O	-1	11105626
om@@	O	-1	11105626
al@@	O	-1	11105626
i@@	O	-1	11105626
es	O	-1	11105626
(	O	-1	11105626
an@@	B-Disease	D065817	11105626
o@@	I-Disease	-1	11105626
ti@@	I-Disease	-1	11105626
a	I-Disease	-1	11105626
and	O	-1	11105626
T@@	B-Disease	D004310	11105626
a@@	I-Disease	-1	11105626
us@@	I-Disease	-1	11105626
si@@	I-Disease	-1	11105626
g@@	I-Disease	-1	11105626
-@@	I-Disease	-1	11105626
B@@	I-Disease	-1	11105626
ing	I-Disease	-1	11105626
mal@@	I-Disease	-1	11105626
formation	I-Disease	-1	11105626
)	O	-1	11105626
due	O	-1	11105626
to	O	-1	11105626
exposure	O	-1	11105626
to	O	-1	11105626
is@@	B-Chemical	D015474	11105626
ot@@	I-Chemical	-1	11105626
ret@@	I-Chemical	-1	11105626
ino@@	I-Chemical	-1	11105626
in	I-Chemical	-1	11105626
within	O	-1	11105626
the	O	-1	11105626
first	O	-1	11105626
tri@@	O	-1	11105626
me@@	O	-1	11105626
ster@@	O	-1	11105626
.	O	-1	11105626
In	O	-1	11105626
this	O	-1	11105626
pap@@	O	-1	11105626
er	O	-1	11105626
we	O	-1	11105626
a@@	O	-1	11105626
im	O	-1	11105626
to	O	-1	11105626
dra@@	O	-1	11105626
w	O	-1	11105626
to	O	-1	11105626
the	O	-1	11105626
fac@@	O	-1	11105626
t	O	-1	11105626
that	O	-1	11105626
cau@@	O	-1	11105626
tion	O	-1	11105626
is	O	-1	11105626
ne@@	O	-1	11105626
ed@@	O	-1	11105626
ed	O	-1	11105626
when	O	-1	11105626
prescri@@	O	-1	11105626
b@@	O	-1	11105626
ing	O	-1	11105626
vitamin	B-Chemical	D014801	11105626
A	I-Chemical	-1	11105626
-@@	O	-1	11105626
containing	O	-1	11105626
drugs	O	-1	11105626
to	O	-1	11105626
women	O	-1	11105626
of	O	-1	11105626
child@@	O	-1	11105626
be@@	O	-1	11105626
ar@@	O	-1	11105626
ing	O	-1	11105626
year@@	O	-1	11105626
s.	O	-1	11105626

Eff@@	O	-1	11135381
ect	O	-1	11135381
of	O	-1	11135381
meth@@	B-Chemical	D008729	11135381
ox@@	I-Chemical	-1	11135381
amine	I-Chemical	-1	11135381
on	O	-1	11135381
maxim@@	O	-1	11135381
um	O	-1	11135381
ure@@	O	-1	11135381
th@@	O	-1	11135381
ral	O	-1	11135381
pressure	O	-1	11135381
in	O	-1	11135381
women	O	-1	11135381
with	O	-1	11135381
gen@@	O	-1	11135381
u@@	O	-1	11135381
ine	O	-1	11135381
stres@@	B-Disease	D014550	11135381
s	I-Disease	-1	11135381
in@@	I-Disease	-1	11135381
contin@@	I-Disease	-1	11135381
ence	I-Disease	-1	11135381
:	O	-1	11135381
a	O	-1	11135381
placebo@@	O	-1	11135381
-@@	O	-1	11135381
control@@	O	-1	11135381
le@@	O	-1	11135381
d,	O	-1	11135381
double-bl@@	O	-1	11135381
ind	O	-1	11135381
cros@@	O	-1	11135381
s@@	O	-1	11135381
over	O	-1	11135381
study.	O	-1	11135381
The	O	-1	11135381
a@@	O	-1	11135381
im	O	-1	11135381
of	O	-1	11135381
the	O	-1	11135381
study	O	-1	11135381
was	O	-1	11135381
to	O	-1	11135381
evalu@@	O	-1	11135381
ate	O	-1	11135381
the	O	-1	11135381
potential	O	-1	11135381
role	O	-1	11135381
for	O	-1	11135381
a	O	-1	11135381
selective	O	-1	11135381
alpha@@	O	-1	11135381
1-@@	O	-1	11135381
adren@@	O	-1	11135381
oc@@	O	-1	11135381
e@@	O	-1	11135381
pt@@	O	-1	11135381
or	O	-1	11135381
agon@@	O	-1	11135381
ist	O	-1	11135381
in	O	-1	11135381
the	O	-1	11135381
treatment	O	-1	11135381
of	O	-1	11135381
urinary	B-Disease	D014550	11135381
stres@@	I-Disease	-1	11135381
s	I-Disease	-1	11135381
in@@	I-Disease	-1	11135381
contin@@	I-Disease	-1	11135381
ence	I-Disease	-1	11135381
.	O	-1	11135381
A	O	-1	11135381
ran@@	O	-1	11135381
do@@	O	-1	11135381
mi@@	O	-1	11135381
se@@	O	-1	11135381
d,	O	-1	11135381
double-bl@@	O	-1	11135381
ind@@	O	-1	11135381
,	O	-1	11135381
placebo@@	O	-1	11135381
-@@	O	-1	11135381
control@@	O	-1	11135381
le@@	O	-1	11135381
d,	O	-1	11135381
cros@@	O	-1	11135381
s@@	O	-1	11135381
over	O	-1	11135381
study	O	-1	11135381
desi@@	O	-1	11135381
g@@	O	-1	11135381
n	O	-1	11135381
was	O	-1	11135381
em@@	O	-1	11135381
p@@	O	-1	11135381
lo@@	O	-1	11135381
y@@	O	-1	11135381
ed.	O	-1	11135381
H@@	O	-1	11135381
al@@	O	-1	11135381
f	O	-1	11135381
lo@@	O	-1	11135381
g	O	-1	11135381
inc@@	O	-1	11135381
re@@	O	-1	11135381
mental	O	-1	11135381
doses	O	-1	11135381
of	O	-1	11135381
intravenous	O	-1	11135381
meth@@	B-Chemical	D008729	11135381
ox@@	I-Chemical	-1	11135381
amine	I-Chemical	-1	11135381
or	O	-1	11135381
placebo	O	-1	11135381
(@@	O	-1	11135381
sal@@	O	-1	11135381
ine@@	O	-1	11135381
)	O	-1	11135381
were	O	-1	11135381
administered	O	-1	11135381
to	O	-1	11135381
a	O	-1	11135381
group	O	-1	11135381
of	O	-1	11135381
women	O	-1	11135381
with	O	-1	11135381
gen@@	O	-1	11135381
u@@	O	-1	11135381
ine	O	-1	11135381
stres@@	B-Disease	D014550	11135381
s	I-Disease	-1	11135381
in@@	I-Disease	-1	11135381
contin@@	I-Disease	-1	11135381
ence	I-Disease	-1	11135381
while	O	-1	11135381
meas@@	O	-1	11135381
uring	O	-1	11135381
maxim@@	O	-1	11135381
um	O	-1	11135381
ure@@	O	-1	11135381
th@@	O	-1	11135381
ral	O	-1	11135381
pressure	O	-1	11135381
(@@	O	-1	11135381
M@@	O	-1	11135381
U@@	O	-1	11135381
P@@	O	-1	11135381
),	O	-1	11135381
blood	O	-1	11135381
pressu@@	O	-1	11135381
re,	O	-1	11135381
heart	O	-1	11135381
rat@@	O	-1	11135381
e,	O	-1	11135381
and	O	-1	11135381
symptom@@	O	-1	11135381
atic	O	-1	11135381
side	O	-1	11135381
effects.	O	-1	11135381
M@@	B-Chemical	D008729	11135381
eth@@	I-Chemical	-1	11135381
ox@@	I-Chemical	-1	11135381
amine	I-Chemical	-1	11135381
evoked	O	-1	11135381
non-@@	O	-1	11135381
significant	O	-1	11135381
increases	O	-1	11135381
in	O	-1	11135381
M@@	O	-1	11135381
U@@	O	-1	11135381
P	O	-1	11135381
and	O	-1	11135381
di@@	O	-1	11135381
ast@@	O	-1	11135381
olic	O	-1	11135381
blood	O	-1	11135381
pressure	O	-1	11135381
but	O	-1	11135381
caused	O	-1	11135381
a	B-Disease	D006973	11135381
significant	I-Disease	-1	11135381
ri@@	I-Disease	-1	11135381
se	I-Disease	-1	11135381
in	I-Disease	-1	11135381
systolic	I-Disease	-1	11135381
blood	I-Disease	-1	11135381
pressure	I-Disease	-1	11135381
and	O	-1	11135381
significant	O	-1	11135381
f@@	O	-1	11135381
all	O	-1	11135381
in	O	-1	11135381
heart	O	-1	11135381
rate	O	-1	11135381
at	O	-1	11135381
maxim@@	O	-1	11135381
um	O	-1	11135381
dos@@	O	-1	11135381
age.	O	-1	11135381
S@@	O	-1	11135381
y@@	O	-1	11135381
st@@	O	-1	11135381
em@@	O	-1	11135381
ic	O	-1	11135381
side	O	-1	11135381
effects	O	-1	11135381
including	O	-1	11135381
pilo@@	O	-1	11135381
e@@	O	-1	11135381
rec@@	O	-1	11135381
tion,	O	-1	11135381
headac@@	B-Disease	D006261	11135381
he	I-Disease	-1	11135381
,	O	-1	11135381
and	O	-1	11135381
co@@	O	-1	11135381
l@@	O	-1	11135381
d	O	-1	11135381
ex@@	O	-1	11135381
trem@@	O	-1	11135381
ities	O	-1	11135381
were	O	-1	11135381
experienced	O	-1	11135381
in	O	-1	11135381
all	O	-1	11135381
subj@@	O	-1	11135381
ect@@	O	-1	11135381
s.	O	-1	11135381
The	O	-1	11135381
results	O	-1	11135381
indicate	O	-1	11135381
that	O	-1	11135381
the	O	-1	11135381
clinical	O	-1	11135381
use@@	O	-1	11135381
ful@@	O	-1	11135381
ness	O	-1	11135381
of	O	-1	11135381
direc@@	O	-1	11135381
t,	O	-1	11135381
peri@@	O	-1	11135381
ph@@	O	-1	11135381
er@@	O	-1	11135381
ally	O	-1	11135381
act@@	O	-1	11135381
ing	O	-1	11135381
sub@@	O	-1	11135381
-@@	O	-1	11135381
ty@@	O	-1	11135381
pe@@	O	-1	11135381
-@@	O	-1	11135381
selective	O	-1	11135381
alpha@@	O	-1	11135381
1-@@	O	-1	11135381
adren@@	O	-1	11135381
oc@@	O	-1	11135381
e@@	O	-1	11135381
pt@@	O	-1	11135381
or	O	-1	11135381
agon@@	O	-1	11135381
ist@@	O	-1	11135381
s	O	-1	11135381
in	O	-1	11135381
the	O	-1	11135381
med@@	O	-1	11135381
ical	O	-1	11135381
treatment	O	-1	11135381
of	O	-1	11135381
stres@@	B-Disease	D014550	11135381
s	I-Disease	-1	11135381
in@@	I-Disease	-1	11135381
contin@@	I-Disease	-1	11135381
ence	I-Disease	-1	11135381
may	O	-1	11135381
be	O	-1	11135381
lim@@	O	-1	11135381
ited	O	-1	11135381
by	O	-1	11135381
associated	O	-1	11135381
pilo@@	O	-1	11135381
e@@	O	-1	11135381
rec@@	O	-1	11135381
tion	O	-1	11135381
and	O	-1	11135381
cardiovascular	O	-1	11135381
side	O	-1	11135381
effects.	O	-1	11135381

T@@	O	-1	11176729
oler@@	O	-1	11176729
ation	O	-1	11176729
of	O	-1	11176729
high	O	-1	11176729
doses	O	-1	11176729
of	O	-1	11176729
angiotens@@	B-Chemical	D000806	11176729
in-@@	I-Chemical	-1	11176729
conver@@	I-Chemical	-1	11176729
ting	I-Chemical	-1	11176729
enzyme	I-Chemical	-1	11176729
inhibitors	I-Chemical	-1	11176729
in	O	-1	11176729
patients	O	-1	11176729
with	O	-1	11176729
chronic	O	-1	11176729
heart	B-Disease	D006333	11176729
failure	I-Disease	-1	11176729
:	O	-1	11176729
results	O	-1	11176729
from	O	-1	11176729
the	O	-1	11176729
AT@@	O	-1	11176729
L@@	O	-1	11176729
A@@	O	-1	11176729
S	O	-1	11176729
tri@@	O	-1	11176729
al.	O	-1	11176729
The	O	-1	11176729
A@@	O	-1	11176729
s@@	O	-1	11176729
s@@	O	-1	11176729
ess@@	O	-1	11176729
ment	O	-1	11176729
of	O	-1	11176729
Treat@@	O	-1	11176729
ment	O	-1	11176729
with	O	-1	11176729
L@@	B-Chemical	D017706	11176729
is@@	I-Chemical	-1	11176729
ino@@	I-Chemical	-1	11176729
pri@@	I-Chemical	-1	11176729
l	I-Chemical	-1	11176729
and	O	-1	11176729
S@@	O	-1	11176729
ur@@	O	-1	11176729
vi@@	O	-1	11176729
val@@	O	-1	11176729
.	O	-1	11176729
BACKGROUND:	O	-1	11176729
Treat@@	O	-1	11176729
ment	O	-1	11176729
with	O	-1	11176729
angiotens@@	B-Chemical	D000806	11176729
in-@@	I-Chemical	-1	11176729
conver@@	I-Chemical	-1	11176729
ting	I-Chemical	-1	11176729
enzyme	I-Chemical	-1	11176729
(@@	I-Chemical	-1	11176729
AC@@	I-Chemical	-1	11176729
E@@	I-Chemical	-1	11176729
)	I-Chemical	-1	11176729
inhibitors	I-Chemical	-1	11176729
reduc@@	O	-1	11176729
es	O	-1	11176729
mor@@	O	-1	11176729
t@@	O	-1	11176729
ality	O	-1	11176729
and	O	-1	11176729
mor@@	O	-1	11176729
b@@	O	-1	11176729
idity	O	-1	11176729
in	O	-1	11176729
patients	O	-1	11176729
with	O	-1	11176729
chronic	O	-1	11176729
heart	B-Disease	D006333	11176729
failure	I-Disease	-1	11176729
(	O	-1	11176729
C@@	B-Disease	D006333	11176729
H@@	I-Disease	-1	11176729
F	I-Disease	-1	11176729
),	O	-1	11176729
but	O	-1	11176729
most	O	-1	11176729
affected	O	-1	11176729
patients	O	-1	11176729
are	O	-1	11176729
not	O	-1	11176729
receiving	O	-1	11176729
these	O	-1	11176729
agents	O	-1	11176729
or	O	-1	11176729
are	O	-1	11176729
being	O	-1	11176729
treated	O	-1	11176729
with	O	-1	11176729
doses	O	-1	11176729
lower	O	-1	11176729
than	O	-1	11176729
those	O	-1	11176729
found	O	-1	11176729
to	O	-1	11176729
be	O	-1	11176729
efficac@@	O	-1	11176729
i@@	O	-1	11176729
ous	O	-1	11176729
in	O	-1	11176729
tri@@	O	-1	11176729
al@@	O	-1	11176729
s,	O	-1	11176729
prim@@	O	-1	11176729
ari@@	O	-1	11176729
ly	O	-1	11176729
because	O	-1	11176729
of	O	-1	11176729
con@@	O	-1	11176729
cer@@	O	-1	11176729
n@@	O	-1	11176729
s	O	-1	11176729
about	O	-1	11176729
the	O	-1	11176729
safety	O	-1	11176729
and	O	-1	11176729
toler@@	O	-1	11176729
ability	O	-1	11176729
of	O	-1	11176729
these	O	-1	11176729
agent@@	O	-1	11176729
s,	O	-1	11176729
es@@	O	-1	11176729
p@@	O	-1	11176729
ec@@	O	-1	11176729
i@@	O	-1	11176729
ally	O	-1	11176729
at	O	-1	11176729
the	O	-1	11176729
recomm@@	O	-1	11176729
en@@	O	-1	11176729
ded	O	-1	11176729
dos@@	O	-1	11176729
es.	O	-1	11176729
The	O	-1	11176729
present	O	-1	11176729
study	O	-1	11176729
examin@@	O	-1	11176729
es	O	-1	11176729
the	O	-1	11176729
safety	O	-1	11176729
and	O	-1	11176729
toler@@	O	-1	11176729
ability	O	-1	11176729
of	O	-1	11176729
high@@	O	-1	11176729
-	O	-1	11176729
compared	O	-1	11176729
with	O	-1	11176729
low@@	O	-1	11176729
-@@	O	-1	11176729
dose	O	-1	11176729
l@@	B-Chemical	D017706	11176729
is@@	I-Chemical	-1	11176729
ino@@	I-Chemical	-1	11176729
pri@@	I-Chemical	-1	11176729
l	I-Chemical	-1	11176729
in	O	-1	11176729
C@@	B-Disease	D006333	11176729
H@@	I-Disease	-1	11176729
F	I-Disease	-1	11176729
.	O	-1	11176729
METHODS:	O	-1	11176729
The	O	-1	11176729
A@@	O	-1	11176729
s@@	O	-1	11176729
s@@	O	-1	11176729
ess@@	O	-1	11176729
ment	O	-1	11176729
of	O	-1	11176729
L@@	B-Chemical	D017706	11176729
is@@	I-Chemical	-1	11176729
ino@@	I-Chemical	-1	11176729
pri@@	I-Chemical	-1	11176729
l	I-Chemical	-1	11176729
and	O	-1	11176729
S@@	O	-1	11176729
ur@@	O	-1	11176729
viv@@	O	-1	11176729
al	O	-1	11176729
study	O	-1	11176729
was	O	-1	11176729
a	O	-1	11176729
mul@@	O	-1	11176729
tic@@	O	-1	11176729
ent@@	O	-1	11176729
er,	O	-1	11176729
random@@	O	-1	11176729
iz@@	O	-1	11176729
ed,	O	-1	11176729
double-bl@@	O	-1	11176729
ind	O	-1	11176729
trial	O	-1	11176729
in	O	-1	11176729
which	O	-1	11176729
patients	O	-1	11176729
with	O	-1	11176729
or	O	-1	11176729
without	O	-1	11176729
previ@@	O	-1	11176729
ous	O	-1	11176729
AC@@	B-Chemical	D000806	11176729
E	I-Chemical	-1	11176729
inhibitor	I-Chemical	-1	11176729
treatment	O	-1	11176729
were	O	-1	11176729
st@@	O	-1	11176729
abil@@	O	-1	11176729
ized	O	-1	11176729
receiving	O	-1	11176729
medi@@	O	-1	11176729
um@@	O	-1	11176729
-@@	O	-1	11176729
dose	O	-1	11176729
l@@	B-Chemical	D017706	11176729
is@@	I-Chemical	-1	11176729
ino@@	I-Chemical	-1	11176729
pri@@	I-Chemical	-1	11176729
l	I-Chemical	-1	11176729
(1@@	O	-1	11176729
2.@@	O	-1	11176729
5	O	-1	11176729
or	O	-1	11176729
1@@	O	-1	11176729
5.@@	O	-1	11176729
0	O	-1	11176729
mg	O	-1	11176729
on@@	O	-1	11176729
ce	O	-1	11176729
daily	O	-1	11176729
[@@	O	-1	11176729
O@@	O	-1	11176729
D@@	O	-1	11176729
]@@	O	-1	11176729
)	O	-1	11176729
for	O	-1	11176729
2	O	-1	11176729
to	O	-1	11176729
4	O	-1	11176729
weeks	O	-1	11176729
and	O	-1	11176729
then	O	-1	11176729
randomized	O	-1	11176729
to	O	-1	11176729
high@@	O	-1	11176729
-	O	-1	11176729
(3@@	O	-1	11176729
5.@@	O	-1	11176729
0	O	-1	11176729
or	O	-1	11176729
3@@	O	-1	11176729
2.@@	O	-1	11176729
5	O	-1	11176729
mg	O	-1	11176729
O@@	O	-1	11176729
D)	O	-1	11176729
or	O	-1	11176729
low@@	O	-1	11176729
-@@	O	-1	11176729
dose	O	-1	11176729
(@@	O	-1	11176729
5.@@	O	-1	11176729
0	O	-1	11176729
or	O	-1	11176729
2.@@	O	-1	11176729
5	O	-1	11176729
mg	O	-1	11176729
O@@	O	-1	11176729
D)	O	-1	11176729
groups.	O	-1	11176729
Patients	O	-1	11176729
with	O	-1	11176729
Ne@@	O	-1	11176729
w	O	-1	11176729
Y@@	O	-1	11176729
or@@	O	-1	11176729
k	O	-1	11176729
H@@	O	-1	11176729
ear@@	O	-1	11176729
t	O	-1	11176729
A@@	O	-1	11176729
s@@	O	-1	11176729
s@@	O	-1	11176729
oci@@	O	-1	11176729
ation	O	-1	11176729
cl@@	O	-1	11176729
as@@	O	-1	11176729
ses	O	-1	11176729
II	O	-1	11176729
to	O	-1	11176729
IV	O	-1	11176729
C@@	B-Disease	D006333	11176729
H@@	I-Disease	-1	11176729
F	I-Disease	-1	11176729
and	O	-1	11176729
left	O	-1	11176729
ventricular	O	-1	11176729
e@@	O	-1	11176729
j@@	O	-1	11176729
ection	O	-1	11176729
frac@@	O	-1	11176729
tions	O	-1	11176729
of	O	-1	11176729
no	O	-1	11176729
greater	O	-1	11176729
than	O	-1	11176729
0.@@	O	-1	11176729
30	O	-1	11176729
(n	O	-1	11176729
=	O	-1	11176729
3@@	O	-1	11176729
1@@	O	-1	11176729
6@@	O	-1	11176729
4@@	O	-1	11176729
)	O	-1	11176729
were	O	-1	11176729
randomized	O	-1	11176729
and	O	-1	11176729
followed	O	-1	11176729
up	O	-1	11176729
for	O	-1	11176729
a	O	-1	11176729
median	O	-1	11176729
of	O	-1	11176729
4@@	O	-1	11176729
6	O	-1	11176729
months.	O	-1	11176729
We	O	-1	11176729
examined	O	-1	11176729
the	O	-1	11176729
occur@@	O	-1	11176729
rence	O	-1	11176729
of	O	-1	11176729
adverse	O	-1	11176729
events	O	-1	11176729
and	O	-1	11176729
the	O	-1	11176729
need	O	-1	11176729
for	O	-1	11176729
discontinu@@	O	-1	11176729
ation	O	-1	11176729
and	O	-1	11176729
dose	O	-1	11176729
reduction	O	-1	11176729
during	O	-1	11176729
treatment,	O	-1	11176729
with	O	-1	11176729
a	O	-1	11176729
foc@@	O	-1	11176729
us	O	-1	11176729
on	O	-1	11176729
hypotension	B-Disease	D007022	11176729
and	O	-1	11176729
renal	B-Disease	D007674	11176729
dysfunction	I-Disease	-1	11176729
.	O	-1	11176729
RESULTS:	O	-1	11176729
Of	O	-1	11176729
4@@	O	-1	11176729
0@@	O	-1	11176729
5	O	-1	11176729
patients	O	-1	11176729
not	O	-1	11176729
previously	O	-1	11176729
receiving	O	-1	11176729
an	O	-1	11176729
AC@@	B-Chemical	D000806	11176729
E	I-Chemical	-1	11176729
inhibitor	I-Chemical	-1	11176729
,	O	-1	11176729
doses	O	-1	11176729
in	O	-1	11176729
only	O	-1	11176729
4.@@	O	-1	11176729
2@@	O	-1	11176729
%	O	-1	11176729
could	O	-1	11176729
not	O	-1	11176729
be	O	-1	11176729
ti@@	O	-1	11176729
tr@@	O	-1	11176729
ated	O	-1	11176729
to	O	-1	11176729
the	O	-1	11176729
medi@@	O	-1	11176729
um	O	-1	11176729
doses	O	-1	11176729
requ@@	O	-1	11176729
ired	O	-1	11176729
for	O	-1	11176729
random@@	O	-1	11176729
ization	O	-1	11176729
because	O	-1	11176729
of	O	-1	11176729
symptoms	O	-1	11176729
possib@@	O	-1	11176729
ly	O	-1	11176729
related	O	-1	11176729
to	O	-1	11176729
hypotension	B-Disease	D007022	11176729
(2@@	O	-1	11176729
.@@	O	-1	11176729
0@@	O	-1	11176729
%)	O	-1	11176729
or	O	-1	11176729
because	O	-1	11176729
of	O	-1	11176729
renal	B-Disease	D007674	11176729
dysfunction	I-Disease	-1	11176729
or	O	-1	11176729
hyper@@	B-Disease	D006947	11176729
k@@	I-Disease	-1	11176729
al@@	I-Disease	-1	11176729
emia	I-Disease	-1	11176729
(2@@	O	-1	11176729
.@@	O	-1	11176729
3@@	O	-1	11176729
%).	O	-1	11176729
D@@	O	-1	11176729
o@@	O	-1	11176729
ses	O	-1	11176729
in	O	-1	11176729
more	O	-1	11176729
than	O	-1	11176729
9@@	O	-1	11176729
0%	O	-1	11176729
of	O	-1	11176729
randomized	O	-1	11176729
patients	O	-1	11176729
in	O	-1	11176729
the	O	-1	11176729
high@@	O	-1	11176729
-	O	-1	11176729
and	O	-1	11176729
low@@	O	-1	11176729
-@@	O	-1	11176729
dose	O	-1	11176729
groups	O	-1	11176729
were	O	-1	11176729
ti@@	O	-1	11176729
tr@@	O	-1	11176729
ated	O	-1	11176729
to	O	-1	11176729
their	O	-1	11176729
as@@	O	-1	11176729
signed	O	-1	11176729
t@@	O	-1	11176729
arg@@	O	-1	11176729
et@@	O	-1	11176729
,	O	-1	11176729
and	O	-1	11176729
the	O	-1	11176729
mean	O	-1	11176729
doses	O	-1	11176729
of	O	-1	11176729
bl@@	O	-1	11176729
ind@@	O	-1	11176729
ed	O	-1	11176729
medic@@	O	-1	11176729
ation	O	-1	11176729
in	O	-1	11176729
both	O	-1	11176729
groups	O	-1	11176729
remained	O	-1	11176729
similar	O	-1	11176729
throu@@	O	-1	11176729
gh@@	O	-1	11176729
out	O	-1	11176729
the	O	-1	11176729
study.	O	-1	11176729
W@@	O	-1	11176729
i@@	O	-1	11176729
th@@	O	-1	11176729
draw@@	O	-1	11176729
als	O	-1	11176729
occurred	O	-1	11176729
in	O	-1	11176729
2@@	O	-1	11176729
7.@@	O	-1	11176729
1@@	O	-1	11176729
%	O	-1	11176729
of	O	-1	11176729
the	O	-1	11176729
high@@	O	-1	11176729
-	O	-1	11176729
and	O	-1	11176729
3@@	O	-1	11176729
0.@@	O	-1	11176729
7@@	O	-1	11176729
%	O	-1	11176729
of	O	-1	11176729
the	O	-1	11176729
low@@	O	-1	11176729
-@@	O	-1	11176729
dose	O	-1	11176729
groups.	O	-1	11176729
S@@	O	-1	11176729
ub@@	O	-1	11176729
groups	O	-1	11176729
pres@@	O	-1	11176729
um@@	O	-1	11176729
ed	O	-1	11176729
to	O	-1	11176729
be	O	-1	11176729
at	O	-1	11176729
higher	O	-1	11176729
risk	O	-1	11176729
for	O	-1	11176729
AC@@	B-Chemical	D000806	11176729
E	I-Chemical	-1	11176729
inhibitor	I-Chemical	-1	11176729
int@@	O	-1	11176729
oler@@	O	-1	11176729
ance	O	-1	11176729
(@@	O	-1	11176729
blood	O	-1	11176729
pressu@@	O	-1	11176729
re,	O	-1	11176729
<@@	O	-1	11176729
1@@	O	-1	11176729
20	O	-1	11176729
mm	O	-1	11176729
H@@	O	-1	11176729
g@@	O	-1	11176729
;	O	-1	11176729
creatinine	B-Chemical	D003404	11176729
,	O	-1	11176729
>	O	-1	11176729
or	O	-1	11176729
=@@	O	-1	11176729
13@@	O	-1	11176729
2.@@	O	-1	11176729
6	O	-1	11176729
mic@@	O	-1	11176729
rom@@	O	-1	11176729
ol@@	O	-1	11176729
/@@	O	-1	11176729
L	O	-1	11176729
[@@	O	-1	11176729
>	O	-1	11176729
or	O	-1	11176729
=@@	O	-1	11176729
1.@@	O	-1	11176729
5	O	-1	11176729
mg/d@@	O	-1	11176729
L@@	O	-1	11176729
]@@	O	-1	11176729
;	O	-1	11176729
age,	O	-1	11176729
>	O	-1	11176729
or	O	-1	11176729
=@@	O	-1	11176729
7@@	O	-1	11176729
0	O	-1	11176729
year@@	O	-1	11176729
s;	O	-1	11176729
and	O	-1	11176729
patients	O	-1	11176729
with	O	-1	11176729
dia@@	B-Disease	D003920	11176729
bet@@	I-Disease	-1	11176729
es	I-Disease	-1	11176729
)	O	-1	11176729
gener@@	O	-1	11176729
ally	O	-1	11176729
toler@@	O	-1	11176729
ated	O	-1	11176729
the	O	-1	11176729
high-dose	O	-1	11176729
strat@@	O	-1	11176729
e@@	O	-1	11176729
g@@	O	-1	11176729
y.	O	-1	11176729
CONCLUSIONS:	O	-1	11176729
These	O	-1	11176729
findings	O	-1	11176729
demon@@	O	-1	11176729
st@@	O	-1	11176729
rate	O	-1	11176729
that	O	-1	11176729
AC@@	B-Chemical	D000806	11176729
E	I-Chemical	-1	11176729
inhibitor	I-Chemical	-1	11176729
therapy	O	-1	11176729
in	O	-1	11176729
most	O	-1	11176729
patients	O	-1	11176729
with	O	-1	11176729
C@@	B-Disease	D006333	11176729
H@@	I-Disease	-1	11176729
F	I-Disease	-1	11176729
can	O	-1	11176729
be	O	-1	11176729
suc@@	O	-1	11176729
cess@@	O	-1	11176729
ful@@	O	-1	11176729
ly	O	-1	11176729
ti@@	O	-1	11176729
tr@@	O	-1	11176729
ated	O	-1	11176729
to	O	-1	11176729
and	O	-1	11176729
maint@@	O	-1	11176729
ained	O	-1	11176729
at	O	-1	11176729
high	O	-1	11176729
dos@@	O	-1	11176729
es,	O	-1	11176729
and	O	-1	11176729
that	O	-1	11176729
more	O	-1	11176729
ag@@	O	-1	11176729
gres@@	O	-1	11176729
sive	O	-1	11176729
use	O	-1	11176729
of	O	-1	11176729
these	O	-1	11176729
agents	O	-1	11176729
is	O	-1	11176729
war@@	O	-1	11176729
ran@@	O	-1	11176729
ted.	O	-1	11176729

C@@	B-Chemical	D003042	11229942
oc@@	I-Chemical	-1	11229942
aine	I-Chemical	-1	11229942
,	O	-1	11229942
eth@@	B-Chemical	D000431	11229942
an@@	I-Chemical	-1	11229942
ol	I-Chemical	-1	11229942
,	O	-1	11229942
and	O	-1	11229942
coca@@	B-Chemical	C066444	11229942
eth@@	I-Chemical	-1	11229942
yl@@	I-Chemical	-1	11229942
ene	I-Chemical	-1	11229942
cardi@@	B-Disease	D066126	11229942
ot@@	I-Disease	-1	11229942
ox@@	I-Disease	-1	11229942
ity	I-Disease	-1	11229942
in	O	-1	11229942
an	O	-1	11229942
anim@@	O	-1	11229942
al	O	-1	11229942
model	O	-1	11229942
of	O	-1	11229942
cocaine	B-Disease	D019970	11229942
and	I-Disease	-1	11229942
eth@@	I-Disease	-1	11229942
an@@	I-Disease	-1	11229942
ol	I-Disease	-1	11229942
ab@@	I-Disease	-1	11229942
use	I-Disease	-1	11229942
cocaine	B-Disease	D000437	11229942
and	I-Disease	-1	11229942
eth@@	I-Disease	-1	11229942
an@@	I-Disease	-1	11229942
ol	I-Disease	-1	11229942
ab@@	I-Disease	-1	11229942
use	I-Disease	-1	11229942
.	O	-1	11229942
OBJECTIV@@	O	-1	11229942
E@@	O	-1	11229942
S:	O	-1	11229942
S@@	O	-1	11229942
im@@	O	-1	11229942
ult@@	O	-1	11229942
aneous	O	-1	11229942
ab@@	B-Disease	D019970	11229942
use	I-Disease	-1	11229942
of	I-Disease	-1	11229942
cocaine	I-Disease	-1	11229942
and	I-Disease	-1	11229942
eth@@	I-Disease	-1	11229942
an@@	I-Disease	-1	11229942
ol	I-Disease	-1	11229942
ab@@	B-Disease	D000437	11229942
use	I-Disease	-1	11229942
of	I-Disease	-1	11229942
cocaine	I-Disease	-1	11229942
and	I-Disease	-1	11229942
eth@@	I-Disease	-1	11229942
an@@	I-Disease	-1	11229942
ol	I-Disease	-1	11229942
aff@@	O	-1	11229942
ects	O	-1	11229942
12	O	-1	11229942
mil@@	O	-1	11229942
li@@	O	-1	11229942
on	O	-1	11229942
A@@	O	-1	11229942
mer@@	O	-1	11229942
ic@@	O	-1	11229942
ans	O	-1	11229942
an@@	O	-1	11229942
n@@	O	-1	11229942
u@@	O	-1	11229942
all@@	O	-1	11229942
y.	O	-1	11229942
In	O	-1	11229942
combin@@	O	-1	11229942
ation,	O	-1	11229942
these	O	-1	11229942
subst@@	O	-1	11229942
anc@@	O	-1	11229942
es	O	-1	11229942
are	O	-1	11229942
subst@@	O	-1	11229942
anti@@	O	-1	11229942
ally	O	-1	11229942
more	O	-1	11229942
toxic	O	-1	11229942
than	O	-1	11229942
either	O	-1	11229942
drug	O	-1	11229942
al@@	O	-1	11229942
one.	O	-1	11229942
The@@	O	-1	11229942
ir	O	-1	11229942
combined	O	-1	11229942
cardiac	B-Disease	D066126	11229942
toxicity	I-Disease	-1	11229942
may	O	-1	11229942
be	O	-1	11229942
due	O	-1	11229942
to	O	-1	11229942
in@@	O	-1	11229942
dependent	O	-1	11229942
effects	O	-1	11229942
of	O	-1	11229942
each	O	-1	11229942
drug@@	O	-1	11229942
;	O	-1	11229942
however,	O	-1	11229942
they	O	-1	11229942
may	O	-1	11229942
also	O	-1	11229942
be	O	-1	11229942
due	O	-1	11229942
to	O	-1	11229942
coca@@	B-Chemical	C066444	11229942
eth@@	I-Chemical	-1	11229942
yl@@	I-Chemical	-1	11229942
ene	I-Chemical	-1	11229942
(	O	-1	11229942
C@@	B-Chemical	C066444	11229942
E	I-Chemical	-1	11229942
),	O	-1	11229942
a	O	-1	11229942
cocaine	B-Chemical	D003042	11229942
metabol@@	O	-1	11229942
ite	O	-1	11229942
form@@	O	-1	11229942
ed	O	-1	11229942
only	O	-1	11229942
in	O	-1	11229942
the	O	-1	11229942
presence	O	-1	11229942
of	O	-1	11229942
eth@@	B-Chemical	D000431	11229942
an@@	I-Chemical	-1	11229942
ol	I-Chemical	-1	11229942
.	O	-1	11229942
The	O	-1	11229942
pur@@	O	-1	11229942
p@@	O	-1	11229942
ose	O	-1	11229942
of	O	-1	11229942
this	O	-1	11229942
study	O	-1	11229942
was	O	-1	11229942
to	O	-1	11229942
del@@	O	-1	11229942
ine@@	O	-1	11229942
ate	O	-1	11229942
the	O	-1	11229942
role	O	-1	11229942
of	O	-1	11229942
C@@	B-Chemical	C066444	11229942
E	I-Chemical	-1	11229942
in	O	-1	11229942
the	O	-1	11229942
combined	O	-1	11229942
cardi@@	B-Disease	D066126	11229942
otoxicity	I-Disease	-1	11229942
of	O	-1	11229942
cocaine	B-Chemical	D003042	11229942
and	O	-1	11229942
eth@@	B-Chemical	D000431	11229942
an@@	I-Chemical	-1	11229942
ol	I-Chemical	-1	11229942
in	O	-1	11229942
a	O	-1	11229942
model	O	-1	11229942
si@@	O	-1	11229942
mul@@	O	-1	11229942
ating	O	-1	11229942
their	O	-1	11229942
ab@@	O	-1	11229942
use.	O	-1	11229942
METHODS:	O	-1	11229942
Tw@@	O	-1	11229942
ent@@	O	-1	11229942
y-@@	O	-1	11229942
three	O	-1	11229942
dog@@	O	-1	11229942
s	O	-1	11229942
were	O	-1	11229942
randomized	O	-1	11229942
to	O	-1	11229942
recei@@	O	-1	11229942
ve	O	-1	11229942
either	O	-1	11229942
1)	O	-1	11229942
three	O	-1	11229942
intravenous	O	-1	11229942
(@@	O	-1	11229942
I@@	O	-1	11229942
V@@	O	-1	11229942
)	O	-1	11229942
b@@	O	-1	11229942
ol@@	O	-1	11229942
u@@	O	-1	11229942
ses	O	-1	11229942
of	O	-1	11229942
cocaine	B-Chemical	D003042	11229942
7.@@	O	-1	11229942
5	O	-1	11229942
mg/kg	O	-1	11229942
with	O	-1	11229942
eth@@	B-Chemical	D000431	11229942
an@@	I-Chemical	-1	11229942
ol	I-Chemical	-1	11229942
(@@	O	-1	11229942
1	O	-1	11229942
g/@@	O	-1	11229942
kg@@	O	-1	11229942
)	O	-1	11229942
as	O	-1	11229942
an	O	-1	11229942
IV	O	-1	11229942
infusion	O	-1	11229942
(C@@	O	-1	11229942
+@@	O	-1	11229942
E@@	O	-1	11229942
,	O	-1	11229942
n	O	-1	11229942
=	O	-1	11229942
8@@	O	-1	11229942
),	O	-1	11229942
2)	O	-1	11229942
three	O	-1	11229942
cocaine	B-Chemical	D003042	11229942
b@@	O	-1	11229942
ol@@	O	-1	11229942
u@@	O	-1	11229942
ses	O	-1	11229942
only	O	-1	11229942
(C@@	O	-1	11229942
,	O	-1	11229942
n	O	-1	11229942
=	O	-1	11229942
6@@	O	-1	11229942
),	O	-1	11229942
3@@	O	-1	11229942
)	O	-1	11229942
eth@@	B-Chemical	D000431	11229942
an@@	I-Chemical	-1	11229942
ol	I-Chemical	-1	11229942
infusion	O	-1	11229942
only	O	-1	11229942
(@@	O	-1	11229942
E@@	O	-1	11229942
,	O	-1	11229942
n	O	-1	11229942
=	O	-1	11229942
5@@	O	-1	11229942
),	O	-1	11229942
or	O	-1	11229942
4@@	O	-1	11229942
)	O	-1	11229942
placebo	O	-1	11229942
b@@	O	-1	11229942
ol@@	O	-1	11229942
u@@	O	-1	11229942
ses	O	-1	11229942
and	O	-1	11229942
infusion	O	-1	11229942
(n	O	-1	11229942
=	O	-1	11229942
4@@	O	-1	11229942
).	O	-1	11229942
H@@	O	-1	11229942
em@@	O	-1	11229942
o@@	O	-1	11229942
dynam@@	O	-1	11229942
ic	O	-1	11229942
meas@@	O	-1	11229942
ure@@	O	-1	11229942
ment@@	O	-1	11229942
s,	O	-1	11229942
electro@@	O	-1	11229942
cardio@@	O	-1	11229942
gram@@	O	-1	11229942
s,	O	-1	11229942
and	O	-1	11229942
serum	O	-1	11229942
drug	O	-1	11229942
concentrations	O	-1	11229942
were	O	-1	11229942
obtained	O	-1	11229942
at	O	-1	11229942
basel@@	O	-1	11229942
ine,	O	-1	11229942
and	O	-1	11229942
then	O	-1	11229942
at	O	-1	11229942
fi@@	O	-1	11229942
x@@	O	-1	11229942
ed	O	-1	11229942
time	O	-1	11229942
interv@@	O	-1	11229942
als	O	-1	11229942
after	O	-1	11229942
each	O	-1	11229942
drug	O	-1	11229942
was	O	-1	11229942
administ@@	O	-1	11229942
e@@	O	-1	11229942
red.	O	-1	11229942
RESULTS:	O	-1	11229942
Two	O	-1	11229942
of	O	-1	11229942
e@@	O	-1	11229942
ight	O	-1	11229942
dog@@	O	-1	11229942
s	O	-1	11229942
in	O	-1	11229942
the	O	-1	11229942
C@@	O	-1	11229942
+@@	O	-1	11229942
E	O	-1	11229942
group	O	-1	11229942
experienced	O	-1	11229942
cardiovascular	B-Disease	-1	11229942
coll@@	I-Disease	-1	11229942
ap@@	I-Disease	-1	11229942
se	I-Disease	-1	11229942
.	O	-1	11229942
The	O	-1	11229942
most	O	-1	11229942
d@@	O	-1	11229942
ram@@	O	-1	11229942
atic	O	-1	11229942
hemo@@	O	-1	11229942
dynam@@	O	-1	11229942
ic	O	-1	11229942
changes	O	-1	11229942
occurred	O	-1	11229942
after	O	-1	11229942
each	O	-1	11229942
cocaine	B-Chemical	D003042	11229942
b@@	O	-1	11229942
ol@@	O	-1	11229942
us	O	-1	11229942
in	O	-1	11229942
the	O	-1	11229942
C@@	O	-1	11229942
+@@	O	-1	11229942
E	O	-1	11229942
and	O	-1	11229942
C	O	-1	11229942
only	O	-1	11229942
group@@	O	-1	11229942
s;	O	-1	11229942
however,	O	-1	11229942
per@@	O	-1	11229942
sist@@	O	-1	11229942
ent	O	-1	11229942
hemo@@	O	-1	11229942
dynam@@	O	-1	11229942
ic	O	-1	11229942
changes	O	-1	11229942
occurred	O	-1	11229942
in	O	-1	11229942
the	O	-1	11229942
C@@	O	-1	11229942
+@@	O	-1	11229942
E	O	-1	11229942
group.	O	-1	11229942
P@@	O	-1	11229942
e@@	O	-1	11229942
a@@	O	-1	11229942
k	O	-1	11229942
C@@	B-Chemical	C066444	11229942
E	I-Chemical	-1	11229942
levels	O	-1	11229942
were	O	-1	11229942
associated	O	-1	11229942
with	O	-1	11229942
a	O	-1	11229942
4@@	O	-1	11229942
5%	O	-1	11229942
(S@@	O	-1	11229942
D	O	-1	11229942
+/-	O	-1	11229942
2@@	O	-1	11229942
2@@	O	-1	11229942
%,	O	-1	11229942
95%	O	-1	11229942
C@@	O	-1	11229942
I	O	-1	11229942
=	O	-1	11229942
2@@	O	-1	11229942
2@@	O	-1	11229942
%	O	-1	11229942
to	O	-1	11229942
6@@	O	-1	11229942
9@@	O	-1	11229942
%)	O	-1	11229942
decrease	B-Disease	D002303	11229942
in	I-Disease	-1	11229942
cardiac	I-Disease	-1	11229942
out@@	I-Disease	-1	11229942
pu@@	I-Disease	-1	11229942
t	I-Disease	-1	11229942
(p	O	-1	11229942
<	O	-1	11229942
0.05@@	O	-1	11229942
),	O	-1	11229942
a	O	-1	11229942
5@@	O	-1	11229942
6%	O	-1	11229942
(S@@	O	-1	11229942
D	O	-1	11229942
+/-	O	-1	11229942
2@@	O	-1	11229942
3@@	O	-1	11229942
%,	O	-1	11229942
95%	O	-1	11229942
C@@	O	-1	11229942
I	O	-1	11229942
=	O	-1	11229942
3@@	O	-1	11229942
2@@	O	-1	11229942
%	O	-1	11229942
to	O	-1	11229942
80@@	O	-1	11229942
%)	O	-1	11229942
decrease	O	-1	11229942
in	O	-1	11229942
d@@	O	-1	11229942
P@@	O	-1	11229942
/@@	O	-1	11229942
d@@	O	-1	11229942
t@@	O	-1	11229942
(@@	O	-1	11229942
ma@@	O	-1	11229942
x@@	O	-1	11229942
)	O	-1	11229942
(p	O	-1	11229942
<@@	O	-1	11229942
.@@	O	-1	11229942
0@@	O	-1	11229942
0@@	O	-1	11229942
6@@	O	-1	11229942
),	O	-1	11229942
and	O	-1	11229942
a	O	-1	11229942
2@@	O	-1	11229942
3@@	O	-1	11229942
%	O	-1	11229942
(S@@	O	-1	11229942
D	O	-1	11229942
+/-	O	-1	11229942
1@@	O	-1	11229942
5@@	O	-1	11229942
%,	O	-1	11229942
95%	O	-1	11229942
C@@	O	-1	11229942
I	O	-1	11229942
=	O	-1	11229942
7@@	O	-1	11229942
%	O	-1	11229942
to	O	-1	11229942
4@@	O	-1	11229942
9@@	O	-1	11229942
%)	O	-1	11229942
decrease	O	-1	11229942
in	O	-1	11229942
S@@	O	-1	11229942
V@@	O	-1	11229942
O@@	O	-1	11229942
(2@@	O	-1	11229942
)	O	-1	11229942
(p	O	-1	11229942
<	O	-1	11229942
0.0@@	O	-1	11229942
25@@	O	-1	11229942
).	O	-1	11229942
V@@	B-Disease	D001145	11229942
entr@@	I-Disease	-1	11229942
ic@@	I-Disease	-1	11229942
ular	I-Disease	-1	11229942
arrhyth@@	I-Disease	-1	11229942
mi@@	I-Disease	-1	11229942
as	I-Disease	-1	11229942
were	O	-1	11229942
prim@@	O	-1	11229942
ari@@	O	-1	11229942
ly	O	-1	11229942
observed	O	-1	11229942
in	O	-1	11229942
the	O	-1	11229942
C@@	O	-1	11229942
+@@	O	-1	11229942
E	O	-1	11229942
group@@	O	-1	11229942
,	O	-1	11229942
in	O	-1	11229942
which	O	-1	11229942
four	O	-1	11229942
of	O	-1	11229942
e@@	O	-1	11229942
ight	O	-1	11229942
dog@@	O	-1	11229942
s	O	-1	11229942
experienced	O	-1	11229942
ventricular	B-Disease	D017180	11229942
tachycardia	I-Disease	-1	11229942
.	O	-1	11229942
CONCLUSIONS:	O	-1	11229942
C@@	B-Chemical	D003042	11229942
oc@@	I-Chemical	-1	11229942
aine	I-Chemical	-1	11229942
and	O	-1	11229942
eth@@	B-Chemical	D000431	11229942
an@@	I-Chemical	-1	11229942
ol	I-Chemical	-1	11229942
in	O	-1	11229942
combination	O	-1	11229942
were	O	-1	11229942
more	O	-1	11229942
toxic	O	-1	11229942
than	O	-1	11229942
either	O	-1	11229942
subst@@	O	-1	11229942
ance	O	-1	11229942
al@@	O	-1	11229942
one.	O	-1	11229942
C@@	O	-1	11229942
o@@	O	-1	11229942
-@@	O	-1	11229942
administration	O	-1	11229942
resulted	O	-1	11229942
in	O	-1	11229942
prolonged	O	-1	11229942
cardiac	B-Disease	D066126	11229942
toxicity	I-Disease	-1	11229942
and	O	-1	11229942
was	O	-1	11229942
dys@@	O	-1	11229942
rhyth@@	O	-1	11229942
mo@@	O	-1	11229942
gen@@	O	-1	11229942
ic@@	O	-1	11229942
.	O	-1	11229942
P@@	O	-1	11229942
e@@	O	-1	11229942
a@@	O	-1	11229942
k	O	-1	11229942
serum	O	-1	11229942
coca@@	B-Chemical	C066444	11229942
eth@@	I-Chemical	-1	11229942
yl@@	I-Chemical	-1	11229942
ene	I-Chemical	-1	11229942
concentrations	O	-1	11229942
were	O	-1	11229942
associated	O	-1	11229942
with	O	-1	11229942
prolonged	O	-1	11229942
myocardial	B-Disease	D009202	11229942
de@@	I-Disease	-1	11229942
pression	I-Disease	-1	11229942
.	O	-1	11229942

W@@	O	-1	11299446
or@@	O	-1	11299446
sen@@	O	-1	11299446
ing	O	-1	11299446
of	O	-1	11299446
Parkinson@@	B-Disease	D010302	11299446
ism	I-Disease	-1	11299446
after	O	-1	11299446
the	O	-1	11299446
use	O	-1	11299446
of	O	-1	11299446
ver@@	B-Chemical	C027429	11299446
al@@	I-Chemical	-1	11299446
i@@	I-Chemical	-1	11299446
pri@@	I-Chemical	-1	11299446
de	I-Chemical	-1	11299446
for	O	-1	11299446
treatment	O	-1	11299446
of	O	-1	11299446
men@@	O	-1	11299446
o@@	O	-1	11299446
pa@@	O	-1	11299446
use@@	O	-1	11299446
:	O	-1	11299446
case	O	-1	11299446
repor@@	O	-1	11299446
t.	O	-1	11299446
We	O	-1	11299446
describe	O	-1	11299446
a	O	-1	11299446
female	O	-1	11299446
patient	O	-1	11299446
with	O	-1	11299446
st@@	O	-1	11299446
able	O	-1	11299446
Parkinson's	B-Disease	D010302	11299446
disease	I-Disease	-1	11299446
who	O	-1	11299446
has	O	-1	11299446
shown	O	-1	11299446
a	O	-1	11299446
mark@@	O	-1	11299446
ed	O	-1	11299446
wor@@	O	-1	11299446
sen@@	O	-1	11299446
ing	O	-1	11299446
of	O	-1	11299446
h@@	O	-1	11299446
er	O	-1	11299446
motor	O	-1	11299446
func@@	O	-1	11299446
tions	O	-1	11299446
following	O	-1	11299446
therapy	O	-1	11299446
of	O	-1	11299446
men@@	O	-1	11299446
o@@	O	-1	11299446
pa@@	O	-1	11299446
use	O	-1	11299446
related	O	-1	11299446
symptoms	O	-1	11299446
with	O	-1	11299446
ver@@	B-Chemical	C027429	11299446
al@@	I-Chemical	-1	11299446
i@@	I-Chemical	-1	11299446
pri@@	I-Chemical	-1	11299446
de	I-Chemical	-1	11299446
,	O	-1	11299446
as	O	-1	11299446
well	O	-1	11299446
as	O	-1	11299446
the	O	-1	11299446
impro@@	O	-1	11299446
vement	O	-1	11299446
of	O	-1	11299446
h@@	O	-1	11299446
er	O	-1	11299446
symptoms	O	-1	11299446
bac@@	O	-1	11299446
k	O	-1	11299446
to	O	-1	11299446
baseline	O	-1	11299446
after	O	-1	11299446
discontinu@@	O	-1	11299446
ation	O	-1	11299446
of	O	-1	11299446
the	O	-1	11299446
drug.	O	-1	11299446
We	O	-1	11299446
em@@	O	-1	11299446
pha@@	O	-1	11299446
size	O	-1	11299446
the	O	-1	11299446
anti@@	O	-1	11299446
-@@	O	-1	11299446
dop@@	O	-1	11299446
aminergic	O	-1	11299446
effect	O	-1	11299446
of	O	-1	11299446
ver@@	B-Chemical	C027429	11299446
al@@	I-Chemical	-1	11299446
i@@	I-Chemical	-1	11299446
pri@@	I-Chemical	-1	11299446
de	I-Chemical	-1	11299446
.	O	-1	11299446

V@@	B-Chemical	D019888	11366874
i@@	I-Chemical	-1	11366874
rac@@	I-Chemical	-1	11366874
ep@@	I-Chemical	-1	11366874
t	I-Chemical	-1	11366874
and	O	-1	11366874
ir@@	B-Disease	D001145	11366874
reg@@	I-Disease	-1	11366874
ular	I-Disease	-1	11366874
hear@@	I-Disease	-1	11366874
t@@	I-Disease	-1	11366874
be@@	I-Disease	-1	11366874
at	I-Disease	-1	11366874
war@@	O	-1	11366874
n@@	O	-1	11366874
ing.	O	-1	11366874
A	O	-1	11366874
group	O	-1	11366874
of	O	-1	11366874
doc@@	O	-1	11366874
t@@	O	-1	11366874
ors	O	-1	11366874
in	O	-1	11366874
B@@	O	-1	11366874
ost@@	O	-1	11366874
on	O	-1	11366874
war@@	O	-1	11366874
n	O	-1	11366874
that	O	-1	11366874
the	O	-1	11366874
prote@@	O	-1	11366874
ase	O	-1	11366874
inhibitor	O	-1	11366874
V@@	B-Chemical	D019888	11366874
i@@	I-Chemical	-1	11366874
rac@@	I-Chemical	-1	11366874
ep@@	I-Chemical	-1	11366874
t	I-Chemical	-1	11366874
may	O	-1	11366874
cause	O	-1	11366874
an	O	-1	11366874
ir@@	B-Disease	D001145	11366874
reg@@	I-Disease	-1	11366874
ular	I-Disease	-1	11366874
heart	I-Disease	-1	11366874
be@@	I-Disease	-1	11366874
at	I-Disease	-1	11366874
,	O	-1	11366874
known	O	-1	11366874
as	O	-1	11366874
brady@@	B-Disease	D001919	11366874
cardia	I-Disease	-1	11366874
,	O	-1	11366874
in	O	-1	11366874
pe@@	O	-1	11366874
o@@	O	-1	11366874
ple	O	-1	11366874
with	O	-1	11366874
H@@	O	-1	11366874
I@@	O	-1	11366874
V@@	O	-1	11366874
.	O	-1	11366874
B@@	B-Disease	D001919	11366874
ra@@	I-Disease	-1	11366874
dy@@	I-Disease	-1	11366874
cardia	I-Disease	-1	11366874
occurred	O	-1	11366874
in	O	-1	11366874
a	O	-1	11366874
4@@	O	-1	11366874
5-@@	O	-1	11366874
year-old	O	-1	11366874
male	O	-1	11366874
patient	O	-1	11366874
who	O	-1	11366874
was	O	-1	11366874
V@@	B-Chemical	D019888	11366874
i@@	I-Chemical	-1	11366874
rac@@	I-Chemical	-1	11366874
ep@@	I-Chemical	-1	11366874
t	I-Chemical	-1	11366874
in	O	-1	11366874
combination	O	-1	11366874
with	O	-1	11366874
other	O	-1	11366874
anti@@	O	-1	11366874
-H@@	O	-1	11366874
IV	O	-1	11366874
drug@@	O	-1	11366874
s.	O	-1	11366874
The	O	-1	11366874
symptoms	O	-1	11366874
ce@@	O	-1	11366874
as@@	O	-1	11366874
ed	O	-1	11366874
after	O	-1	11366874
switch@@	O	-1	11366874
ing	O	-1	11366874
to	O	-1	11366874
an@@	O	-1	11366874
other	O	-1	11366874
drug	O	-1	11366874
combin@@	O	-1	11366874
ation.	O	-1	11366874

F@@	O	-1	11380496
requ@@	O	-1	11380496
ency	O	-1	11380496
of	O	-1	11380496
appear@@	O	-1	11380496
ance	O	-1	11380496
of	O	-1	11380496
my@@	O	-1	11380496
e@@	O	-1	11380496
lo@@	O	-1	11380496
per@@	O	-1	11380496
oxid@@	O	-1	11380496
as@@	O	-1	11380496
e-@@	O	-1	11380496
ant@@	O	-1	11380496
ine@@	O	-1	11380496
ut@@	O	-1	11380496
ro@@	O	-1	11380496
ph@@	O	-1	11380496
il	O	-1	11380496
cyto@@	O	-1	11380496
plas@@	O	-1	11380496
mic	O	-1	11380496
anti@@	O	-1	11380496
body	O	-1	11380496
(@@	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
CA@@	O	-1	11380496
)	O	-1	11380496
in	O	-1	11380496
G@@	B-Disease	D006111	11380496
ra@@	I-Disease	-1	11380496
v@@	I-Disease	-1	11380496
es@@	I-Disease	-1	11380496
'	I-Disease	-1	11380496
disease	I-Disease	-1	11380496
patients	O	-1	11380496
treated	O	-1	11380496
with	O	-1	11380496
prop@@	B-Chemical	D011441	11380496
yl@@	I-Chemical	-1	11380496
th@@	I-Chemical	-1	11380496
io@@	I-Chemical	-1	11380496
urac@@	I-Chemical	-1	11380496
il	I-Chemical	-1	11380496
and	O	-1	11380496
the	O	-1	11380496
rel@@	O	-1	11380496
ationship	O	-1	11380496
between	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
and	O	-1	11380496
clinical	O	-1	11380496
man@@	O	-1	11380496
if@@	O	-1	11380496
est@@	O	-1	11380496
ations.	O	-1	11380496
OBJECTIVE:	O	-1	11380496
M@@	O	-1	11380496
ye@@	O	-1	11380496
lo@@	O	-1	11380496
per@@	O	-1	11380496
oxid@@	O	-1	11380496
ase	O	-1	11380496
ant@@	O	-1	11380496
ine@@	O	-1	11380496
ut@@	O	-1	11380496
ro@@	O	-1	11380496
ph@@	O	-1	11380496
il	O	-1	11380496
cyto@@	O	-1	11380496
plas@@	O	-1	11380496
mic	O	-1	11380496
anti@@	O	-1	11380496
body	O	-1	11380496
(@@	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
CA@@	O	-1	11380496
)-@@	O	-1	11380496
positive	O	-1	11380496
vas@@	B-Disease	D014657	11380496
cul@@	I-Disease	-1	11380496
iti@@	I-Disease	-1	11380496
s	I-Disease	-1	11380496
has	O	-1	11380496
been	O	-1	11380496
reported	O	-1	11380496
in	O	-1	11380496
patients	O	-1	11380496
with	O	-1	11380496
G@@	B-Disease	D006111	11380496
ra@@	I-Disease	-1	11380496
v@@	I-Disease	-1	11380496
es@@	I-Disease	-1	11380496
'	I-Disease	-1	11380496
disease	I-Disease	-1	11380496
who	O	-1	11380496
were	O	-1	11380496
treated	O	-1	11380496
with	O	-1	11380496
prop@@	B-Chemical	D011441	11380496
yl@@	I-Chemical	-1	11380496
th@@	I-Chemical	-1	11380496
io@@	I-Chemical	-1	11380496
urac@@	I-Chemical	-1	11380496
il	I-Chemical	-1	11380496
(	O	-1	11380496
P@@	B-Chemical	D011441	11380496
T@@	I-Chemical	-1	11380496
U	I-Chemical	-1	11380496
).	O	-1	11380496
The	O	-1	11380496
appear@@	O	-1	11380496
ance	O	-1	11380496
of	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
in	O	-1	11380496
these	O	-1	11380496
cases	O	-1	11380496
was	O	-1	11380496
sus@@	O	-1	11380496
p@@	O	-1	11380496
ected	O	-1	11380496
of	O	-1	11380496
being	O	-1	11380496
related	O	-1	11380496
to	O	-1	11380496
P@@	B-Chemical	D011441	11380496
T@@	I-Chemical	-1	11380496
U	I-Chemical	-1	11380496
because	O	-1	11380496
the	O	-1	11380496
ti@@	O	-1	11380496
tre@@	O	-1	11380496
s	O	-1	11380496
of	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
decreased	O	-1	11380496
when	O	-1	11380496
P@@	B-Chemical	D011441	11380496
T@@	I-Chemical	-1	11380496
U	I-Chemical	-1	11380496
was	O	-1	11380496
sto@@	O	-1	11380496
pp@@	O	-1	11380496
ed.	O	-1	11380496
Ne@@	O	-1	11380496
ver@@	O	-1	11380496
the@@	O	-1	11380496
l@@	O	-1	11380496
es@@	O	-1	11380496
s,	O	-1	11380496
there	O	-1	11380496
have	O	-1	11380496
been	O	-1	11380496
no	O	-1	11380496
studies	O	-1	11380496
on	O	-1	11380496
the	O	-1	11380496
tempor@@	O	-1	11380496
al	O	-1	11380496
rel@@	O	-1	11380496
ationship	O	-1	11380496
between	O	-1	11380496
the	O	-1	11380496
appear@@	O	-1	11380496
ance	O	-1	11380496
of	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
and	O	-1	11380496
vas@@	B-Disease	D014657	11380496
cul@@	I-Disease	-1	11380496
iti@@	I-Disease	-1	11380496
s	I-Disease	-1	11380496
during	O	-1	11380496
P@@	B-Chemical	D011441	11380496
T@@	I-Chemical	-1	11380496
U	I-Chemical	-1	11380496
therapy,	O	-1	11380496
or	O	-1	11380496
on	O	-1	11380496
the	O	-1	11380496
incidence	O	-1	11380496
of	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
in	O	-1	11380496
un@@	O	-1	11380496
treated	O	-1	11380496
G@@	B-Disease	D006111	11380496
ra@@	I-Disease	-1	11380496
v@@	I-Disease	-1	11380496
es@@	I-Disease	-1	11380496
'	I-Disease	-1	11380496
disease	I-Disease	-1	11380496
patients.	O	-1	11380496
The@@	O	-1	11380496
refore,	O	-1	11380496
we	O	-1	11380496
s@@	O	-1	11380496
ou@@	O	-1	11380496
ght	O	-1	11380496
to	O	-1	11380496
ad@@	O	-1	11380496
d@@	O	-1	11380496
res@@	O	-1	11380496
s	O	-1	11380496
these	O	-1	11380496
par@@	O	-1	11380496
ame@@	O	-1	11380496
ters	O	-1	11380496
in	O	-1	11380496
patients	O	-1	11380496
with	O	-1	11380496
G@@	B-Disease	D006111	11380496
ra@@	I-Disease	-1	11380496
v@@	I-Disease	-1	11380496
es@@	I-Disease	-1	11380496
'	I-Disease	-1	11380496
disease	I-Disease	-1	11380496
.	O	-1	11380496
PA@@	O	-1	11380496
TI@@	O	-1	11380496
E@@	O	-1	11380496
N@@	O	-1	11380496
T@@	O	-1	11380496
S:	O	-1	11380496
We	O	-1	11380496
investigated	O	-1	11380496
10@@	O	-1	11380496
2	O	-1	11380496
un@@	O	-1	11380496
treated	O	-1	11380496
patients	O	-1	11380496
with	O	-1	11380496
hyper@@	B-Disease	D006980	11380496
th@@	I-Disease	-1	11380496
yro@@	I-Disease	-1	11380496
i@@	I-Disease	-1	11380496
dis@@	I-Disease	-1	11380496
m	I-Disease	-1	11380496
due	O	-1	11380496
to	O	-1	11380496
G@@	B-Disease	D006111	11380496
ra@@	I-Disease	-1	11380496
v@@	I-Disease	-1	11380496
es@@	I-Disease	-1	11380496
'	I-Disease	-1	11380496
disease	I-Disease	-1	11380496
for	O	-1	11380496
the	O	-1	11380496
presence	O	-1	11380496
of	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
CA@@	O	-1	11380496
,	O	-1	11380496
and	O	-1	11380496
for	O	-1	11380496
the	O	-1	11380496
development	O	-1	11380496
vas@@	B-Disease	D014657	11380496
cul@@	I-Disease	-1	11380496
iti@@	I-Disease	-1	11380496
s	I-Disease	-1	11380496
after	O	-1	11380496
star@@	O	-1	11380496
ting	O	-1	11380496
P@@	B-Chemical	D011441	11380496
T@@	I-Chemical	-1	11380496
U	I-Chemical	-1	11380496
therapy.	O	-1	11380496
Tw@@	O	-1	11380496
ent@@	O	-1	11380496
y-@@	O	-1	11380496
n@@	O	-1	11380496
ine	O	-1	11380496
of	O	-1	11380496
the@@	O	-1	11380496
m	O	-1	11380496
were	O	-1	11380496
lat@@	O	-1	11380496
er	O	-1	11380496
ex@@	O	-1	11380496
cl@@	O	-1	11380496
uded	O	-1	11380496
because	O	-1	11380496
of	O	-1	11380496
adverse	O	-1	11380496
effects	O	-1	11380496
of	O	-1	11380496
P@@	B-Chemical	D011441	11380496
T@@	I-Chemical	-1	11380496
U	I-Chemical	-1	11380496
or	O	-1	11380496
because	O	-1	11380496
the	O	-1	11380496
observ@@	O	-1	11380496
ation	O	-1	11380496
period	O	-1	11380496
was	O	-1	11380496
less	O	-1	11380496
than	O	-1	11380496
3	O	-1	11380496
months.	O	-1	11380496
The	O	-1	11380496
remain@@	O	-1	11380496
ing	O	-1	11380496
7@@	O	-1	11380496
3	O	-1	11380496
patients	O	-1	11380496
(5@@	O	-1	11380496
5	O	-1	11380496
women	O	-1	11380496
and	O	-1	11380496
1@@	O	-1	11380496
8	O	-1	11380496
men@@	O	-1	11380496
),	O	-1	11380496
all	O	-1	11380496
of	O	-1	11380496
whom	O	-1	11380496
were	O	-1	11380496
examined	O	-1	11380496
for	O	-1	11380496
more	O	-1	11380496
than	O	-1	11380496
3	O	-1	11380496
month@@	O	-1	11380496
s,	O	-1	11380496
were	O	-1	11380496
ad@@	O	-1	11380496
o@@	O	-1	11380496
pt@@	O	-1	11380496
ed	O	-1	11380496
as	O	-1	11380496
the	O	-1	11380496
subjects	O	-1	11380496
of	O	-1	11380496
the	O	-1	11380496
investig@@	O	-1	11380496
ation.	O	-1	11380496
The	O	-1	11380496
median	O	-1	11380496
observ@@	O	-1	11380496
ation	O	-1	11380496
period	O	-1	11380496
was	O	-1	11380496
2@@	O	-1	11380496
3.@@	O	-1	11380496
6	O	-1	11380496
months	O	-1	11380496
(@@	O	-1	11380496
ran@@	O	-1	11380496
ge@@	O	-1	11380496
:	O	-1	11380496
3-@@	O	-1	11380496
3@@	O	-1	11380496
7	O	-1	11380496
month@@	O	-1	11380496
s@@	O	-1	11380496
).	O	-1	11380496
M@@	O	-1	11380496
E@@	O	-1	11380496
A@@	O	-1	11380496
S@@	O	-1	11380496
U@@	O	-1	11380496
R@@	O	-1	11380496
E@@	O	-1	11380496
M@@	O	-1	11380496
E@@	O	-1	11380496
N@@	O	-1	11380496
T@@	O	-1	11380496
S:	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
was	O	-1	11380496
measured	O	-1	11380496
at	O	-1	11380496
interv@@	O	-1	11380496
als	O	-1	11380496
of	O	-1	11380496
2-@@	O	-1	11380496
6	O	-1	11380496
months.	O	-1	11380496
RESULTS:	O	-1	11380496
B@@	O	-1	11380496
e@@	O	-1	11380496
fore	O	-1	11380496
treatment,	O	-1	11380496
the	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
ti@@	O	-1	11380496
tre@@	O	-1	11380496
s	O	-1	11380496
of	O	-1	11380496
all	O	-1	11380496
10@@	O	-1	11380496
2	O	-1	11380496
un@@	O	-1	11380496
treated	O	-1	11380496
G@@	B-Disease	D006111	11380496
ra@@	I-Disease	-1	11380496
v@@	I-Disease	-1	11380496
es@@	I-Disease	-1	11380496
'	I-Disease	-1	11380496
disease	I-Disease	-1	11380496
patients	O	-1	11380496
were	O	-1	11380496
within	O	-1	11380496
the	O	-1	11380496
ref@@	O	-1	11380496
e@@	O	-1	11380496
rence	O	-1	11380496
range	O	-1	11380496
(@@	O	-1	11380496
be@@	O	-1	11380496
low	O	-1	11380496
10	O	-1	11380496
U@@	O	-1	11380496
/@@	O	-1	11380496
ml@@	O	-1	11380496
).	O	-1	11380496
Th@@	O	-1	11380496
ree	O	-1	11380496
(@@	O	-1	11380496
4.@@	O	-1	11380496
1@@	O	-1	11380496
%)	O	-1	11380496
of	O	-1	11380496
the	O	-1	11380496
7@@	O	-1	11380496
3	O	-1	11380496
patients	O	-1	11380496
were	O	-1	11380496
positive	O	-1	11380496
for	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
at	O	-1	11380496
13@@	O	-1	11380496
,	O	-1	11380496
16	O	-1	11380496
and	O	-1	11380496
17	O	-1	11380496
month@@	O	-1	11380496
s,	O	-1	11380496
respectivel@@	O	-1	11380496
y,	O	-1	11380496
after	O	-1	11380496
the	O	-1	11380496
star@@	O	-1	11380496
t	O	-1	11380496
of	O	-1	11380496
P@@	B-Chemical	D011441	11380496
T@@	I-Chemical	-1	11380496
U	I-Chemical	-1	11380496
therapy.	O	-1	11380496
In	O	-1	11380496
two	O	-1	11380496
of	O	-1	11380496
th@@	O	-1	11380496
em@@	O	-1	11380496
,	O	-1	11380496
the	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
ti@@	O	-1	11380496
tre@@	O	-1	11380496
s	O	-1	11380496
transi@@	O	-1	11380496
ently	O	-1	11380496
increased	O	-1	11380496
to	O	-1	11380496
1@@	O	-1	11380496
2.@@	O	-1	11380496
8	O	-1	11380496
and	O	-1	11380496
1@@	O	-1	11380496
5.@@	O	-1	11380496
0	O	-1	11380496
U@@	O	-1	11380496
/@@	O	-1	11380496
ml@@	O	-1	11380496
,	O	-1	11380496
respectivel@@	O	-1	11380496
y,	O	-1	11380496
des@@	O	-1	11380496
pit@@	O	-1	11380496
e	O	-1	11380496
continu@@	O	-1	11380496
ed	O	-1	11380496
P@@	B-Chemical	D011441	11380496
T@@	I-Chemical	-1	11380496
U	I-Chemical	-1	11380496
therapy,	O	-1	11380496
but	O	-1	11380496
no	O	-1	11380496
vas@@	B-Disease	D014652	11380496
cul@@	I-Disease	-1	11380496
i@@	I-Disease	-1	11380496
tic	I-Disease	-1	11380496
disorder@@	I-Disease	-1	11380496
s	I-Disease	-1	11380496
develop@@	O	-1	11380496
ed.	O	-1	11380496
In	O	-1	11380496
the	O	-1	11380496
thir@@	O	-1	11380496
d	O	-1	11380496
patient@@	O	-1	11380496
,	O	-1	11380496
the	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
ti@@	O	-1	11380496
tr@@	O	-1	11380496
e	O	-1	11380496
increased	O	-1	11380496
to	O	-1	11380496
20@@	O	-1	11380496
4	O	-1	11380496
U@@	O	-1	11380496
/@@	O	-1	11380496
m@@	O	-1	11380496
l	O	-1	11380496
and	O	-1	11380496
sh@@	O	-1	11380496
e	O	-1	11380496
developed	O	-1	11380496
a	O	-1	11380496
higher	O	-1	11380496
f@@	B-Disease	D005334	11380496
ev@@	I-Disease	-1	11380496
er	I-Disease	-1	11380496
,	O	-1	11380496
oral	B-Disease	D019226	11380496
ul@@	I-Disease	-1	11380496
c@@	I-Disease	-1	11380496
ers	I-Disease	-1	11380496
and	O	-1	11380496
poly@@	B-Disease	D018771	11380496
arth@@	I-Disease	-1	11380496
r@@	I-Disease	-1	11380496
al@@	I-Disease	-1	11380496
g@@	I-Disease	-1	11380496
ia	I-Disease	-1	11380496
,	O	-1	11380496
but	O	-1	11380496
the	O	-1	11380496
symptoms	O	-1	11380496
resol@@	O	-1	11380496
ved	O	-1	11380496
2	O	-1	11380496
weeks	O	-1	11380496
after	O	-1	11380496
sto@@	O	-1	11380496
pp@@	O	-1	11380496
ing	O	-1	11380496
P@@	B-Chemical	D011441	11380496
T@@	I-Chemical	-1	11380496
U	I-Chemical	-1	11380496
therapy,	O	-1	11380496
and	O	-1	11380496
the	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
ti@@	O	-1	11380496
tr@@	O	-1	11380496
e	O	-1	11380496
decreased	O	-1	11380496
to	O	-1	11380496
2@@	O	-1	11380496
0.@@	O	-1	11380496
7	O	-1	11380496
U@@	O	-1	11380496
/@@	O	-1	11380496
m@@	O	-1	11380496
l	O	-1	11380496
by	O	-1	11380496
4	O	-1	11380496
months	O	-1	11380496
after	O	-1	11380496
discontinu@@	O	-1	11380496
ing	O	-1	11380496
P@@	B-Chemical	D011441	11380496
T@@	I-Chemical	-1	11380496
U	I-Chemical	-1	11380496
.	O	-1	11380496
CONCLUSIONS:	O	-1	11380496
P@@	B-Chemical	D011441	11380496
T@@	I-Chemical	-1	11380496
U	I-Chemical	-1	11380496
therapy	O	-1	11380496
may	O	-1	11380496
be	O	-1	11380496
related	O	-1	11380496
to	O	-1	11380496
the	O	-1	11380496
appear@@	O	-1	11380496
ance	O	-1	11380496
of	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
CA@@	O	-1	11380496
,	O	-1	11380496
but	O	-1	11380496
MP@@	O	-1	11380496
O@@	O	-1	11380496
-@@	O	-1	11380496
AN@@	O	-1	11380496
C@@	O	-1	11380496
A	O	-1	11380496
does	O	-1	11380496
not	O	-1	11380496
appe@@	O	-1	11380496
ar	O	-1	11380496
to	O	-1	11380496
be	O	-1	11380496
clo@@	O	-1	11380496
se@@	O	-1	11380496
ly	O	-1	11380496
related	O	-1	11380496
to	O	-1	11380496
vas@@	B-Disease	D014657	11380496
cul@@	I-Disease	-1	11380496
iti@@	I-Disease	-1	11380496
s	I-Disease	-1	11380496
.	O	-1	11380496

Pre@@	O	-1	11385188
val@@	O	-1	11385188
ence	O	-1	11385188
of	O	-1	11385188
heart	B-Disease	D006331	11385188
disease	I-Disease	-1	11385188
in	O	-1	11385188
as@@	O	-1	11385188
ym@@	O	-1	11385188
pto@@	O	-1	11385188
m@@	O	-1	11385188
atic	O	-1	11385188
chronic	O	-1	11385188
cocaine	B-Chemical	D003042	11385188
us@@	O	-1	11385188
ers.	O	-1	11385188
To	O	-1	11385188
determine	O	-1	11385188
the	O	-1	11385188
prev@@	O	-1	11385188
al@@	O	-1	11385188
ence	O	-1	11385188
of	O	-1	11385188
heart	B-Disease	D006331	11385188
disease	I-Disease	-1	11385188
in	O	-1	11385188
out@@	O	-1	11385188
patient	O	-1	11385188
youn@@	O	-1	11385188
g	O	-1	11385188
as@@	O	-1	11385188
ym@@	O	-1	11385188
pto@@	O	-1	11385188
m@@	O	-1	11385188
atic	O	-1	11385188
chronic	O	-1	11385188
cocaine	B-Chemical	D003042	11385188
us@@	O	-1	11385188
er@@	O	-1	11385188
s,	O	-1	11385188
3@@	O	-1	11385188
5	O	-1	11385188
cocaine	B-Chemical	D003042	11385188
users	O	-1	11385188
and	O	-1	11385188
3@@	O	-1	11385188
2	O	-1	11385188
ag@@	O	-1	11385188
e-@@	O	-1	11385188
mat@@	O	-1	11385188
ch@@	O	-1	11385188
ed	O	-1	11385188
controls	O	-1	11385188
under@@	O	-1	11385188
w@@	O	-1	11385188
ent	O	-1	11385188
rest@@	O	-1	11385188
ing	O	-1	11385188
and	O	-1	11385188
ex@@	O	-1	11385188
er@@	O	-1	11385188
cis@@	O	-1	11385188
e	O	-1	11385188
electro@@	O	-1	11385188
cardio@@	O	-1	11385188
graph@@	O	-1	11385188
y	O	-1	11385188
(@@	O	-1	11385188
EC@@	O	-1	11385188
G@@	O	-1	11385188
)	O	-1	11385188
and	O	-1	11385188
D@@	O	-1	11385188
op@@	O	-1	11385188
pl@@	O	-1	11385188
er	O	-1	11385188
echocardiograph@@	O	-1	11385188
y.	O	-1	11385188
F@@	O	-1	11385188
ind@@	O	-1	11385188
ings	O	-1	11385188
consist@@	O	-1	11385188
ent	O	-1	11385188
with	O	-1	11385188
coronary	B-Disease	D003324	11385188
artery	I-Disease	-1	11385188
disease	I-Disease	-1	11385188
were	O	-1	11385188
det@@	O	-1	11385188
ected	O	-1	11385188
in	O	-1	11385188
12	O	-1	11385188
(3@@	O	-1	11385188
4@@	O	-1	11385188
%)	O	-1	11385188
patients	O	-1	11385188
and	O	-1	11385188
3	O	-1	11385188
(@@	O	-1	11385188
9@@	O	-1	11385188
%)	O	-1	11385188
controls	O	-1	11385188
(p	O	-1	11385188
=	O	-1	11385188
0.0@@	O	-1	11385188
1).	O	-1	11385188
D@@	O	-1	11385188
ec@@	O	-1	11385188
reas@@	O	-1	11385188
ed	O	-1	11385188
left	O	-1	11385188
ventricular	O	-1	11385188
systolic	O	-1	11385188
function	O	-1	11385188
was	O	-1	11385188
demonstrated	O	-1	11385188
in	O	-1	11385188
5	O	-1	11385188
(1@@	O	-1	11385188
4@@	O	-1	11385188
%)	O	-1	11385188
patients,	O	-1	11385188
but	O	-1	11385188
in	O	-1	11385188
n@@	O	-1	11385188
one	O	-1	11385188
of	O	-1	11385188
the	O	-1	11385188
controls	O	-1	11385188
(p	O	-1	11385188
=	O	-1	11385188
0.05@@	O	-1	11385188
5@@	O	-1	11385188
).	O	-1	11385188
F@@	O	-1	11385188
in@@	O	-1	11385188
ally,	O	-1	11385188
rest@@	O	-1	11385188
ing	O	-1	11385188
and	O	-1	11385188
pe@@	O	-1	11385188
a@@	O	-1	11385188
k	O	-1	11385188
ex@@	O	-1	11385188
er@@	O	-1	11385188
cis@@	O	-1	11385188
e	O	-1	11385188
ab@@	B-Disease	D018487	11385188
normal	I-Disease	-1	11385188
left	I-Disease	-1	11385188
ventricular	I-Disease	-1	11385188
f@@	I-Disease	-1	11385188
ill@@	I-Disease	-1	11385188
ing	I-Disease	-1	11385188
was	O	-1	11385188
det@@	O	-1	11385188
ected	O	-1	11385188
in	O	-1	11385188
3@@	O	-1	11385188
8	O	-1	11385188
and	O	-1	11385188
3@@	O	-1	11385188
5%	O	-1	11385188
of	O	-1	11385188
patients	O	-1	11385188
as	O	-1	11385188
compared	O	-1	11385188
to	O	-1	11385188
1@@	O	-1	11385188
9	O	-1	11385188
and	O	-1	11385188
9@@	O	-1	11385188
%	O	-1	11385188
of	O	-1	11385188
control@@	O	-1	11385188
s,	O	-1	11385188
respecti@@	O	-1	11385188
vely	O	-1	11385188
(p	O	-1	11385188
=	O	-1	11385188
0.@@	O	-1	11385188
11	O	-1	11385188
and	O	-1	11385188
0.0@@	O	-1	11385188
2,	O	-1	11385188
respectivel@@	O	-1	11385188
y@@	O	-1	11385188
).	O	-1	11385188
We	O	-1	11385188
concl@@	O	-1	11385188
ude	O	-1	11385188
that	O	-1	11385188
coronary	B-Disease	D003324	11385188
artery	I-Disease	-1	11385188
or	I-Disease	-1	11385188
myocardial	I-Disease	-1	11385188
disease	I-Disease	-1	11385188
coronary	B-Disease	D009202	11385188
artery	I-Disease	-1	11385188
or	I-Disease	-1	11385188
myocardial	I-Disease	-1	11385188
disease	I-Disease	-1	11385188
is	O	-1	11385188
common	O	-1	11385188
(3@@	O	-1	11385188
8@@	O	-1	11385188
%)	O	-1	11385188
in	O	-1	11385188
youn@@	O	-1	11385188
g	O	-1	11385188
as@@	O	-1	11385188
ym@@	O	-1	11385188
pto@@	O	-1	11385188
m@@	O	-1	11385188
atic	O	-1	11385188
chronic	O	-1	11385188
cocaine	B-Chemical	D003042	11385188
us@@	O	-1	11385188
ers.	O	-1	11385188
The@@	O	-1	11385188
refore,	O	-1	11385188
s@@	O	-1	11385188
cre@@	O	-1	11385188
en@@	O	-1	11385188
ing	O	-1	11385188
EC@@	O	-1	11385188
G	O	-1	11385188
and	O	-1	11385188
echocardiograph@@	O	-1	11385188
y	O	-1	11385188
may	O	-1	11385188
be	O	-1	11385188
war@@	O	-1	11385188
ran@@	O	-1	11385188
ted	O	-1	11385188
in	O	-1	11385188
these	O	-1	11385188
patients.	O	-1	11385188

C@@	O	-1	11395263
ardi@@	O	-1	11395263
o@@	O	-1	11395263
protective	O	-1	11395263
effects	O	-1	11395263
of	O	-1	11395263
P@@	O	-1	11395263
ic@@	O	-1	11395263
ro@@	O	-1	11395263
r@@	O	-1	11395263
r@@	O	-1	11395263
hi@@	O	-1	11395263
z@@	O	-1	11395263
a	O	-1	11395263
k@@	O	-1	11395263
ur@@	O	-1	11395263
ro@@	O	-1	11395263
a	O	-1	11395263
against	O	-1	11395263
isoproteren@@	B-Chemical	D007545	11395263
ol	I-Chemical	-1	11395263
-induced	O	-1	11395263
myocardial	O	-1	11395263
stres@@	O	-1	11395263
s	O	-1	11395263
in	O	-1	11395263
rats.	O	-1	11395263
The	O	-1	11395263
cardio@@	O	-1	11395263
protective	O	-1	11395263
effect	O	-1	11395263
of	O	-1	11395263
the	O	-1	11395263
eth@@	B-Chemical	D000431	11395263
an@@	I-Chemical	-1	11395263
ol	I-Chemical	-1	11395263
extrac@@	O	-1	11395263
t	O	-1	11395263
of	O	-1	11395263
P@@	O	-1	11395263
ic@@	O	-1	11395263
ro@@	O	-1	11395263
r@@	O	-1	11395263
r@@	O	-1	11395263
hi@@	O	-1	11395263
z@@	O	-1	11395263
a	O	-1	11395263
k@@	O	-1	11395263
ur@@	O	-1	11395263
ro@@	O	-1	11395263
a	O	-1	11395263
r@@	O	-1	11395263
hi@@	O	-1	11395263
z@@	O	-1	11395263
om@@	O	-1	11395263
es	O	-1	11395263
and	O	-1	11395263
ro@@	O	-1	11395263
ot@@	O	-1	11395263
s	O	-1	11395263
(P@@	O	-1	11395263
K@@	O	-1	11395263
)	O	-1	11395263
on	O	-1	11395263
isoproteren@@	B-Chemical	D007545	11395263
ol	I-Chemical	-1	11395263
-induced	O	-1	11395263
myocardial	B-Disease	D009203	11395263
infarction	I-Disease	-1	11395263
in	O	-1	11395263
rats	O	-1	11395263
with	O	-1	11395263
resp@@	O	-1	11395263
ect	O	-1	11395263
to	O	-1	11395263
li@@	O	-1	11395263
pid	O	-1	11395263
metabol@@	O	-1	11395263
ism	O	-1	11395263
in	O	-1	11395263
serum	O	-1	11395263
and	O	-1	11395263
heart	O	-1	11395263
tissue	O	-1	11395263
has	O	-1	11395263
been	O	-1	11395263
investig@@	O	-1	11395263
ated.	O	-1	11395263
O@@	O	-1	11395263
ral	O	-1	11395263
pre-@@	O	-1	11395263
treatment	O	-1	11395263
with	O	-1	11395263
P@@	O	-1	11395263
K	O	-1	11395263
(@@	O	-1	11395263
8@@	O	-1	11395263
0	O	-1	11395263
mg	O	-1	11395263
kg@@	O	-1	11395263
(@@	O	-1	11395263
-1@@	O	-1	11395263
)	O	-1	11395263
day@@	O	-1	11395263
(@@	O	-1	11395263
-1@@	O	-1	11395263
)	O	-1	11395263
for	O	-1	11395263
15	O	-1	11395263
da@@	O	-1	11395263
ys@@	O	-1	11395263
)	O	-1	11395263
significantly	O	-1	11395263
prevent@@	O	-1	11395263
ed	O	-1	11395263
the	O	-1	11395263
isoproteren@@	B-Chemical	D007545	11395263
ol	I-Chemical	-1	11395263
-induced	O	-1	11395263
myocardial	B-Disease	D009203	11395263
infarction	I-Disease	-1	11395263
and	O	-1	11395263
maint@@	O	-1	11395263
ained	O	-1	11395263
the	O	-1	11395263
rats	O	-1	11395263
at	O	-1	11395263
ne@@	O	-1	11395263
ar	O	-1	11395263
normal	O	-1	11395263
stat@@	O	-1	11395263
us.	O	-1	11395263

Ph@@	O	-1	11401944
ase	O	-1	11401944
2	O	-1	11401944
early	O	-1	11401944
af@@	O	-1	11401944
ter@@	O	-1	11401944
de@@	O	-1	11401944
pol@@	O	-1	11401944
ar@@	O	-1	11401944
ization	O	-1	11401944
as	O	-1	11401944
a	O	-1	11401944
tri@@	O	-1	11401944
g@@	O	-1	11401944
g@@	O	-1	11401944
er	O	-1	11401944
of	O	-1	11401944
poly@@	O	-1	11401944
morph@@	O	-1	11401944
ic	O	-1	11401944
ventricular	B-Disease	D017180	11401944
tachycardia	I-Disease	-1	11401944
in	O	-1	11401944
ac@@	O	-1	11401944
qu@@	O	-1	11401944
ired	O	-1	11401944
long@@	B-Disease	D008133	11401944
-@@	I-Disease	-1	11401944
Q@@	I-Disease	-1	11401944
T	I-Disease	-1	11401944
syndrome	I-Disease	-1	11401944
:	O	-1	11401944
direct	O	-1	11401944
evidence	O	-1	11401944
from	O	-1	11401944
intrac@@	O	-1	11401944
ell@@	O	-1	11401944
ular	O	-1	11401944
recor@@	O	-1	11401944
d@@	O	-1	11401944
ings	O	-1	11401944
in	O	-1	11401944
the	O	-1	11401944
int@@	O	-1	11401944
ac@@	O	-1	11401944
t	O	-1	11401944
left	O	-1	11401944
ventricular	O	-1	11401944
w@@	O	-1	11401944
all@@	O	-1	11401944
.	O	-1	11401944
BACKGROUND:	O	-1	11401944
This	O	-1	11401944
study	O	-1	11401944
examined	O	-1	11401944
the	O	-1	11401944
role	O	-1	11401944
of	O	-1	11401944
phase	O	-1	11401944
2	O	-1	11401944
early	O	-1	11401944
af@@	O	-1	11401944
ter@@	O	-1	11401944
de@@	O	-1	11401944
pol@@	O	-1	11401944
ar@@	O	-1	11401944
ization	O	-1	11401944
(@@	O	-1	11401944
E@@	O	-1	11401944
A@@	O	-1	11401944
D)	O	-1	11401944
in	O	-1	11401944
produc@@	O	-1	11401944
ing	O	-1	11401944
a	O	-1	11401944
tri@@	O	-1	11401944
g@@	O	-1	11401944
g@@	O	-1	11401944
er	O	-1	11401944
to	O	-1	11401944
initi@@	O	-1	11401944
ate	O	-1	11401944
t@@	B-Disease	D016171	11401944
or@@	I-Disease	-1	11401944
s@@	I-Disease	-1	11401944
ade	I-Disease	-1	11401944
de	I-Disease	-1	11401944
po@@	I-Disease	-1	11401944
int@@	I-Disease	-1	11401944
es	I-Disease	-1	11401944
(	O	-1	11401944
T@@	B-Disease	D016171	11401944
d@@	I-Disease	-1	11401944
P	I-Disease	-1	11401944
)	O	-1	11401944
with	O	-1	11401944
Q@@	B-Disease	D008133	11401944
T	I-Disease	-1	11401944
prolong@@	I-Disease	-1	11401944
ation	I-Disease	-1	11401944
induced	O	-1	11401944
by	O	-1	11401944
d@@	O	-1	11401944
l@@	O	-1	11401944
-	O	-1	11401944
s@@	B-Chemical	D013015	11401944
ot@@	I-Chemical	-1	11401944
al@@	I-Chemical	-1	11401944
ol	I-Chemical	-1	11401944
and	O	-1	11401944
az@@	B-Chemical	C086123	11401944
im@@	I-Chemical	-1	11401944
il@@	I-Chemical	-1	11401944
ide	I-Chemical	-1	11401944
.	O	-1	11401944
The	O	-1	11401944
cont@@	O	-1	11401944
ri@@	O	-1	11401944
bu@@	O	-1	11401944
tion	O	-1	11401944
of	O	-1	11401944
trans@@	O	-1	11401944
m@@	O	-1	11401944
ural	O	-1	11401944
dis@@	O	-1	11401944
per@@	O	-1	11401944
sion	O	-1	11401944
of	O	-1	11401944
re@@	O	-1	11401944
pol@@	O	-1	11401944
ar@@	O	-1	11401944
ization	O	-1	11401944
(T@@	O	-1	11401944
D@@	O	-1	11401944
R@@	O	-1	11401944
)	O	-1	11401944
to	O	-1	11401944
trans@@	O	-1	11401944
m@@	O	-1	11401944
ural	O	-1	11401944
prop@@	O	-1	11401944
ag@@	O	-1	11401944
ation	O	-1	11401944
of	O	-1	11401944
E@@	O	-1	11401944
A@@	O	-1	11401944
D	O	-1	11401944
and	O	-1	11401944
the	O	-1	11401944
maint@@	O	-1	11401944
en@@	O	-1	11401944
ance	O	-1	11401944
of	O	-1	11401944
T@@	B-Disease	D016171	11401944
d@@	I-Disease	-1	11401944
P	I-Disease	-1	11401944
was	O	-1	11401944
also	O	-1	11401944
evalu@@	O	-1	11401944
ated.	O	-1	11401944
METHOD@@	O	-1	11401944
S	O	-1	11401944
AN@@	O	-1	11401944
D	O	-1	11401944
RESULTS:	O	-1	11401944
T@@	O	-1	11401944
ran@@	O	-1	11401944
s@@	O	-1	11401944
membran@@	O	-1	11401944
e	O	-1	11401944
action	O	-1	11401944
potenti@@	O	-1	11401944
als	O	-1	11401944
from	O	-1	11401944
ep@@	O	-1	11401944
ic@@	O	-1	11401944
ardi@@	O	-1	11401944
um,	O	-1	11401944
mid@@	O	-1	11401944
myocardi@@	O	-1	11401944
um,	O	-1	11401944
and	O	-1	11401944
en@@	O	-1	11401944
d@@	O	-1	11401944
ocardi@@	O	-1	11401944
um	O	-1	11401944
were	O	-1	11401944
recor@@	O	-1	11401944
ded	O	-1	11401944
sim@@	O	-1	11401944
ult@@	O	-1	11401944
ane@@	O	-1	11401944
ous@@	O	-1	11401944
ly,	O	-1	11401944
to@@	O	-1	11401944
ge@@	O	-1	11401944
ther	O	-1	11401944
with	O	-1	11401944
a	O	-1	11401944
trans@@	O	-1	11401944
m@@	O	-1	11401944
ural	O	-1	11401944
EC@@	O	-1	11401944
G@@	O	-1	11401944
,	O	-1	11401944
in	O	-1	11401944
arter@@	O	-1	11401944
i@@	O	-1	11401944
ally	O	-1	11401944
per@@	O	-1	11401944
f@@	O	-1	11401944
used	O	-1	11401944
can@@	O	-1	11401944
ine	O	-1	11401944
and	O	-1	11401944
ra@@	O	-1	11401944
b@@	O	-1	11401944
b@@	O	-1	11401944
it	O	-1	11401944
left	O	-1	11401944
ventricular	O	-1	11401944
pre@@	O	-1	11401944
par@@	O	-1	11401944
ations.	O	-1	11401944
d@@	O	-1	11401944
l@@	O	-1	11401944
-	O	-1	11401944
S@@	B-Chemical	D013015	11401944
ot@@	I-Chemical	-1	11401944
al@@	I-Chemical	-1	11401944
ol	I-Chemical	-1	11401944
pre@@	O	-1	11401944
fe@@	O	-1	11401944
ren@@	O	-1	11401944
ti@@	O	-1	11401944
ally	O	-1	11401944
prolonged	O	-1	11401944
action	O	-1	11401944
potential	O	-1	11401944
duration	O	-1	11401944
(A@@	O	-1	11401944
P@@	O	-1	11401944
D)	O	-1	11401944
in	O	-1	11401944
M	O	-1	11401944
cells	O	-1	11401944
dose-@@	O	-1	11401944
depend@@	O	-1	11401944
ently	O	-1	11401944
(@@	O	-1	11401944
1	O	-1	11401944
to	O	-1	11401944
100	O	-1	11401944
mic@@	O	-1	11401944
rom@@	O	-1	11401944
ol@@	O	-1	11401944
/@@	O	-1	11401944
L@@	O	-1	11401944
),	O	-1	11401944
lead@@	O	-1	11401944
ing	O	-1	11401944
to	O	-1	11401944
Q@@	B-Disease	D008133	11401944
T	I-Disease	-1	11401944
prolong@@	I-Disease	-1	11401944
ation	I-Disease	-1	11401944
and	O	-1	11401944
an	O	-1	11401944
increase	O	-1	11401944
in	O	-1	11401944
T@@	O	-1	11401944
D@@	O	-1	11401944
R@@	O	-1	11401944
.	O	-1	11401944
A@@	B-Chemical	C086123	11401944
z@@	I-Chemical	-1	11401944
im@@	I-Chemical	-1	11401944
il@@	I-Chemical	-1	11401944
ide	I-Chemical	-1	11401944
,	O	-1	11401944
however,	O	-1	11401944
significantly	O	-1	11401944
prolonged	O	-1	11401944
A@@	O	-1	11401944
P@@	O	-1	11401944
D	O	-1	11401944
and	O	-1	11401944
Q@@	O	-1	11401944
T	O	-1	11401944
interv@@	O	-1	11401944
al	O	-1	11401944
at	O	-1	11401944
concentrations	O	-1	11401944
from	O	-1	11401944
0.@@	O	-1	11401944
1	O	-1	11401944
to	O	-1	11401944
10	O	-1	11401944
mic@@	O	-1	11401944
rom@@	O	-1	11401944
ol@@	O	-1	11401944
/@@	O	-1	11401944
L	O	-1	11401944
but	O	-1	11401944
sh@@	O	-1	11401944
or@@	O	-1	11401944
ten@@	O	-1	11401944
ed	O	-1	11401944
the@@	O	-1	11401944
m	O	-1	11401944
at	O	-1	11401944
30	O	-1	11401944
mic@@	O	-1	11401944
rom@@	O	-1	11401944
ol@@	O	-1	11401944
/@@	O	-1	11401944
L@@	O	-1	11401944
.	O	-1	11401944
U@@	O	-1	11401944
n@@	O	-1	11401944
like	O	-1	11401944
d@@	O	-1	11401944
l@@	O	-1	11401944
-	O	-1	11401944
s@@	B-Chemical	D013015	11401944
ot@@	I-Chemical	-1	11401944
al@@	I-Chemical	-1	11401944
ol	I-Chemical	-1	11401944
,	O	-1	11401944
az@@	B-Chemical	C086123	11401944
im@@	I-Chemical	-1	11401944
il@@	I-Chemical	-1	11401944
ide	I-Chemical	-1	11401944
(@@	O	-1	11401944
>@@	O	-1	11401944
3	O	-1	11401944
mic@@	O	-1	11401944
rom@@	O	-1	11401944
ol@@	O	-1	11401944
/@@	O	-1	11401944
L@@	O	-1	11401944
)	O	-1	11401944
increased	O	-1	11401944
ep@@	O	-1	11401944
ic@@	O	-1	11401944
ardi@@	O	-1	11401944
al	O	-1	11401944
A@@	O	-1	11401944
P@@	O	-1	11401944
D	O	-1	11401944
mark@@	O	-1	11401944
ed@@	O	-1	11401944
ly,	O	-1	11401944
ca@@	O	-1	11401944
using	O	-1	11401944
a	O	-1	11401944
di@@	O	-1	11401944
min@@	O	-1	11401944
ished	O	-1	11401944
T@@	O	-1	11401944
D@@	O	-1	11401944
R@@	O	-1	11401944
.	O	-1	11401944
Although	O	-1	11401944
both	O	-1	11401944
d@@	O	-1	11401944
l@@	O	-1	11401944
-	O	-1	11401944
s@@	B-Chemical	D013015	11401944
ot@@	I-Chemical	-1	11401944
al@@	I-Chemical	-1	11401944
ol	I-Chemical	-1	11401944
and	O	-1	11401944
az@@	B-Chemical	C086123	11401944
im@@	I-Chemical	-1	11401944
il@@	I-Chemical	-1	11401944
ide	I-Chemical	-1	11401944
ra@@	O	-1	11401944
re@@	O	-1	11401944
ly	O	-1	11401944
induced	O	-1	11401944
E@@	O	-1	11401944
AD@@	O	-1	11401944
s	O	-1	11401944
in	O	-1	11401944
can@@	O	-1	11401944
ine	O	-1	11401944
left	O	-1	11401944
ventric@@	O	-1	11401944
l@@	O	-1	11401944
es,	O	-1	11401944
they	O	-1	11401944
produced	O	-1	11401944
frequent	O	-1	11401944
E@@	O	-1	11401944
AD@@	O	-1	11401944
s	O	-1	11401944
in	O	-1	11401944
ra@@	O	-1	11401944
b@@	O	-1	11401944
b@@	O	-1	11401944
it@@	O	-1	11401944
s,	O	-1	11401944
in	O	-1	11401944
which	O	-1	11401944
more	O	-1	11401944
p@@	O	-1	11401944
ron@@	O	-1	11401944
oun@@	O	-1	11401944
c@@	O	-1	11401944
ed	O	-1	11401944
Q@@	B-Disease	D008133	11401944
T	I-Disease	-1	11401944
prolong@@	I-Disease	-1	11401944
ation	I-Disease	-1	11401944
was	O	-1	11401944
se@@	O	-1	11401944
en@@	O	-1	11401944
.	O	-1	11401944
An	O	-1	11401944
increase	O	-1	11401944
in	O	-1	11401944
T@@	O	-1	11401944
D@@	O	-1	11401944
R	O	-1	11401944
by	O	-1	11401944
d@@	O	-1	11401944
l@@	O	-1	11401944
-	O	-1	11401944
s@@	B-Chemical	D013015	11401944
ot@@	I-Chemical	-1	11401944
al@@	I-Chemical	-1	11401944
ol	I-Chemical	-1	11401944
fac@@	O	-1	11401944
il@@	O	-1	11401944
it@@	O	-1	11401944
ated	O	-1	11401944
trans@@	O	-1	11401944
m@@	O	-1	11401944
ural	O	-1	11401944
prop@@	O	-1	11401944
ag@@	O	-1	11401944
ation	O	-1	11401944
of	O	-1	11401944
E@@	O	-1	11401944
AD@@	O	-1	11401944
s	O	-1	11401944
that	O	-1	11401944
initi@@	O	-1	11401944
ated	O	-1	11401944
multiple	O	-1	11401944
episo@@	O	-1	11401944
des	O	-1	11401944
of	O	-1	11401944
spont@@	O	-1	11401944
aneous	O	-1	11401944
T@@	B-Disease	D016171	11401944
d@@	I-Disease	-1	11401944
P	I-Disease	-1	11401944
in	O	-1	11401944
3	O	-1	11401944
of	O	-1	11401944
6	O	-1	11401944
ra@@	O	-1	11401944
b@@	O	-1	11401944
b@@	O	-1	11401944
it	O	-1	11401944
left	O	-1	11401944
ventric@@	O	-1	11401944
l@@	O	-1	11401944
es.	O	-1	11401944
Of	O	-1	11401944
not@@	O	-1	11401944
e,	O	-1	11401944
although	O	-1	11401944
az@@	B-Chemical	C086123	11401944
im@@	I-Chemical	-1	11401944
il@@	I-Chemical	-1	11401944
ide	I-Chemical	-1	11401944
(@@	O	-1	11401944
3	O	-1	11401944
to	O	-1	11401944
10	O	-1	11401944
mic@@	O	-1	11401944
rom@@	O	-1	11401944
ol@@	O	-1	11401944
/@@	O	-1	11401944
L@@	O	-1	11401944
)	O	-1	11401944
increased	O	-1	11401944
A@@	O	-1	11401944
P@@	O	-1	11401944
D	O	-1	11401944
more	O	-1	11401944
than	O	-1	11401944
d@@	O	-1	11401944
l@@	O	-1	11401944
-	O	-1	11401944
s@@	B-Chemical	D013015	11401944
ot@@	I-Chemical	-1	11401944
al@@	I-Chemical	-1	11401944
ol	I-Chemical	-1	11401944
,	O	-1	11401944
its	O	-1	11401944
E@@	O	-1	11401944
AD@@	O	-1	11401944
s	O	-1	11401944
often	O	-1	11401944
fail@@	O	-1	11401944
ed	O	-1	11401944
to	O	-1	11401944
prop@@	O	-1	11401944
ag@@	O	-1	11401944
ate	O	-1	11401944
trans@@	O	-1	11401944
m@@	O	-1	11401944
ur@@	O	-1	11401944
ally,	O	-1	11401944
prob@@	O	-1	11401944
ably	O	-1	11401944
because	O	-1	11401944
of	O	-1	11401944
a	O	-1	11401944
di@@	O	-1	11401944
min@@	O	-1	11401944
ished	O	-1	11401944
T@@	O	-1	11401944
D@@	O	-1	11401944
R@@	O	-1	11401944
.	O	-1	11401944
CONCLUSIONS:	O	-1	11401944
This	O	-1	11401944
study	O	-1	11401944
pro@@	O	-1	11401944
vi@@	O	-1	11401944
des	O	-1	11401944
the	O	-1	11401944
first	O	-1	11401944
direct	O	-1	11401944
evidence	O	-1	11401944
from	O	-1	11401944
intrac@@	O	-1	11401944
ell@@	O	-1	11401944
ular	O	-1	11401944
action	O	-1	11401944
potential	O	-1	11401944
recor@@	O	-1	11401944
d@@	O	-1	11401944
ings	O	-1	11401944
that	O	-1	11401944
phase	O	-1	11401944
2	O	-1	11401944
E@@	O	-1	11401944
A@@	O	-1	11401944
D	O	-1	11401944
can	O	-1	11401944
be	O	-1	11401944
gener@@	O	-1	11401944
ated	O	-1	11401944
from	O	-1	11401944
int@@	O	-1	11401944
ac@@	O	-1	11401944
t	O	-1	11401944
ventricular	O	-1	11401944
w@@	O	-1	11401944
all	O	-1	11401944
and	O	-1	11401944
produce	O	-1	11401944
a	O	-1	11401944
tri@@	O	-1	11401944
g@@	O	-1	11401944
g@@	O	-1	11401944
er	O	-1	11401944
to	O	-1	11401944
initi@@	O	-1	11401944
ate	O	-1	11401944
the	O	-1	11401944
onset	O	-1	11401944
of	O	-1	11401944
T@@	B-Disease	D016171	11401944
d@@	I-Disease	-1	11401944
P	I-Disease	-1	11401944
under	O	-1	11401944
Q@@	B-Disease	D008133	11401944
T	I-Disease	-1	11401944
prolong@@	I-Disease	-1	11401944
ation	I-Disease	-1	11401944
.	O	-1	11401944

P@@	O	-1	11425091
ren@@	O	-1	11425091
atal	O	-1	11425091
cocaine	B-Chemical	D003042	11425091
exposure	O	-1	11425091
and	O	-1	11425091
c@@	O	-1	11425091
ranial	O	-1	11425091
son@@	O	-1	11425091
ograph@@	O	-1	11425091
ic	O	-1	11425091
findings	O	-1	11425091
in	O	-1	11425091
pre@@	B-Disease	D007235	11425091
term	I-Disease	-1	11425091
inf@@	I-Disease	-1	11425091
ants	I-Disease	-1	11425091
.	O	-1	11425091
P@@	O	-1	11425091
U@@	O	-1	11425091
R@@	O	-1	11425091
P@@	O	-1	11425091
O@@	O	-1	11425091
S@@	O	-1	11425091
E:	O	-1	11425091
P@@	O	-1	11425091
ren@@	O	-1	11425091
atal	O	-1	11425091
cocaine	B-Chemical	D003042	11425091
exposure	O	-1	11425091
has	O	-1	11425091
been	O	-1	11425091
lin@@	O	-1	11425091
ked	O	-1	11425091
with	O	-1	11425091
su@@	O	-1	11425091
be@@	O	-1	11425091
pen@@	O	-1	11425091
d@@	O	-1	11425091
ym@@	O	-1	11425091
al	O	-1	11425091
hemorrh@@	B-Disease	D006470	11425091
age	I-Disease	-1	11425091
and	O	-1	11425091
the	O	-1	11425091
formation	O	-1	11425091
of	O	-1	11425091
cy@@	B-Disease	D003560	11425091
st@@	I-Disease	-1	11425091
s	I-Disease	-1	11425091
that	O	-1	11425091
are	O	-1	11425091
det@@	O	-1	11425091
ect@@	O	-1	11425091
able	O	-1	11425091
on	O	-1	11425091
c@@	O	-1	11425091
ranial	O	-1	11425091
son@@	O	-1	11425091
ograph@@	O	-1	11425091
y	O	-1	11425091
in	O	-1	11425091
ne@@	O	-1	11425091
on@@	O	-1	11425091
ates	O	-1	11425091
b@@	O	-1	11425091
or@@	O	-1	11425091
n	O	-1	11425091
at	O	-1	11425091
ter@@	O	-1	11425091
m.	O	-1	11425091
We	O	-1	11425091
s@@	O	-1	11425091
ou@@	O	-1	11425091
ght	O	-1	11425091
to	O	-1	11425091
determine	O	-1	11425091
if	O	-1	11425091
p@@	O	-1	11425091
ren@@	O	-1	11425091
atal	O	-1	11425091
cocaine	B-Chemical	D003042	11425091
exposure	O	-1	11425091
increases	O	-1	11425091
the	O	-1	11425091
incidence	O	-1	11425091
of	O	-1	11425091
su@@	B-Disease	D001927	11425091
be@@	I-Disease	-1	11425091
pen@@	I-Disease	-1	11425091
d@@	I-Disease	-1	11425091
ym@@	I-Disease	-1	11425091
al	I-Disease	-1	11425091
cy@@	I-Disease	-1	11425091
st@@	I-Disease	-1	11425091
s	I-Disease	-1	11425091
su@@	B-Disease	D003560	11425091
be@@	I-Disease	-1	11425091
pen@@	I-Disease	-1	11425091
d@@	I-Disease	-1	11425091
ym@@	I-Disease	-1	11425091
al	I-Disease	-1	11425091
cy@@	I-Disease	-1	11425091
st@@	I-Disease	-1	11425091
s	I-Disease	-1	11425091
in	O	-1	11425091
pre@@	B-Disease	D007235	11425091
term	I-Disease	-1	11425091
inf@@	I-Disease	-1	11425091
ants	I-Disease	-1	11425091
.	O	-1	11425091
METHODS:	O	-1	11425091
We	O	-1	11425091
ret@@	O	-1	11425091
ro@@	O	-1	11425091
sp@@	O	-1	11425091
ectively	O	-1	11425091
revie@@	O	-1	11425091
w@@	O	-1	11425091
ed	O	-1	11425091
the	O	-1	11425091
med@@	O	-1	11425091
ical	O	-1	11425091
recor@@	O	-1	11425091
ds	O	-1	11425091
and	O	-1	11425091
c@@	O	-1	11425091
ranial	O	-1	11425091
son@@	O	-1	11425091
o@@	O	-1	11425091
gram@@	O	-1	11425091
s	O	-1	11425091
obtained	O	-1	11425091
during	O	-1	11425091
a	O	-1	11425091
1-@@	O	-1	11425091
year	O	-1	11425091
period	O	-1	11425091
on	O	-1	11425091
12@@	O	-1	11425091
2	O	-1	11425091
pre@@	B-Disease	D007235	11425091
mat@@	I-Disease	-1	11425091
ure	I-Disease	-1	11425091
(@@	I-Disease	-1	11425091
<	I-Disease	-1	11425091
3@@	I-Disease	-1	11425091
6	I-Disease	-1	11425091
weeks	I-Disease	-1	11425091
of	I-Disease	-1	11425091
g@@	I-Disease	-1	11425091
est@@	I-Disease	-1	11425091
ation@@	I-Disease	-1	11425091
)	I-Disease	-1	11425091
inf@@	I-Disease	-1	11425091
ants	I-Disease	-1	11425091
.	O	-1	11425091
In@@	O	-1	11425091
f@@	O	-1	11425091
ants	O	-1	11425091
were	O	-1	11425091
c@@	O	-1	11425091
ate@@	O	-1	11425091
g@@	O	-1	11425091
or@@	O	-1	11425091
ized	O	-1	11425091
into	O	-1	11425091
1	O	-1	11425091
of	O	-1	11425091
2	O	-1	11425091
group@@	O	-1	11425091
s:	O	-1	11425091
those	O	-1	11425091
exposed	O	-1	11425091
to	O	-1	11425091
cocaine	B-Chemical	D003042	11425091
and	O	-1	11425091
those	O	-1	11425091
not	O	-1	11425091
exposed	O	-1	11425091
to	O	-1	11425091
cocaine	B-Chemical	D003042	11425091
.	O	-1	11425091
In@@	O	-1	11425091
f@@	O	-1	11425091
ants	O	-1	11425091
were	O	-1	11425091
as@@	O	-1	11425091
signed	O	-1	11425091
to	O	-1	11425091
the	O	-1	11425091
cocaine	B-Chemical	D003042	11425091
-@@	O	-1	11425091
exposed	O	-1	11425091
group	O	-1	11425091
if	O	-1	11425091
there	O	-1	11425091
was	O	-1	11425091
a	O	-1	11425091
mat@@	O	-1	11425091
er@@	O	-1	11425091
n@@	O	-1	11425091
al	O	-1	11425091
hist@@	O	-1	11425091
ory	O	-1	11425091
of	O	-1	11425091
cocaine	B-Disease	D019970	11425091
ab@@	I-Disease	-1	11425091
use	I-Disease	-1	11425091
during	O	-1	11425091
pregn@@	O	-1	11425091
anc@@	O	-1	11425091
y	O	-1	11425091
or	O	-1	11425091
if	O	-1	11425091
mat@@	O	-1	11425091
er@@	O	-1	11425091
n@@	O	-1	11425091
al	O	-1	11425091
or	O	-1	11425091
ne@@	O	-1	11425091
on@@	O	-1	11425091
atal	O	-1	11425091
urine	O	-1	11425091
toxic@@	O	-1	11425091
ology	O	-1	11425091
results	O	-1	11425091
were	O	-1	11425091
positive	O	-1	11425091
at	O	-1	11425091
the	O	-1	11425091
time	O	-1	11425091
of	O	-1	11425091
de@@	O	-1	11425091
li@@	O	-1	11425091
ver@@	O	-1	11425091
y.	O	-1	11425091
RESULTS:	O	-1	11425091
F@@	O	-1	11425091
i@@	O	-1	11425091
ve	O	-1	11425091
of	O	-1	11425091
the	O	-1	11425091
12@@	O	-1	11425091
2	O	-1	11425091
inf@@	O	-1	11425091
ants	O	-1	11425091
were	O	-1	11425091
ex@@	O	-1	11425091
cl@@	O	-1	11425091
uded	O	-1	11425091
from	O	-1	11425091
the	O	-1	11425091
study	O	-1	11425091
because	O	-1	11425091
of	O	-1	11425091
in@@	O	-1	11425091
suffici@@	O	-1	11425091
ent	O	-1	11425091
med@@	O	-1	11425091
ical	O	-1	11425091
and	O	-1	11425091
drug	O	-1	11425091
hist@@	O	-1	11425091
or@@	O	-1	11425091
i@@	O	-1	11425091
es.	O	-1	11425091
The	O	-1	11425091
incidence	O	-1	11425091
of	O	-1	11425091
su@@	B-Disease	D001927	11425091
be@@	I-Disease	-1	11425091
pen@@	I-Disease	-1	11425091
d@@	I-Disease	-1	11425091
ym@@	I-Disease	-1	11425091
al	I-Disease	-1	11425091
cy@@	I-Disease	-1	11425091
st@@	I-Disease	-1	11425091
s	I-Disease	-1	11425091
su@@	B-Disease	D003560	11425091
be@@	I-Disease	-1	11425091
pen@@	I-Disease	-1	11425091
d@@	I-Disease	-1	11425091
ym@@	I-Disease	-1	11425091
al	I-Disease	-1	11425091
cy@@	I-Disease	-1	11425091
st@@	I-Disease	-1	11425091
s	I-Disease	-1	11425091
in	O	-1	11425091
the	O	-1	11425091
1@@	O	-1	11425091
17	O	-1	11425091
remain@@	O	-1	11425091
ing	O	-1	11425091
inf@@	O	-1	11425091
ants	O	-1	11425091
was	O	-1	11425091
14@@	O	-1	11425091
%	O	-1	11425091
(1@@	O	-1	11425091
6	O	-1	11425091
of	O	-1	11425091
1@@	O	-1	11425091
17@@	O	-1	11425091
).	O	-1	11425091
The	O	-1	11425091
incidence	O	-1	11425091
of	O	-1	11425091
su@@	B-Disease	D001927	11425091
be@@	I-Disease	-1	11425091
pen@@	I-Disease	-1	11425091
d@@	I-Disease	-1	11425091
ym@@	I-Disease	-1	11425091
al	I-Disease	-1	11425091
cy@@	I-Disease	-1	11425091
st@@	I-Disease	-1	11425091
s	I-Disease	-1	11425091
su@@	B-Disease	D003560	11425091
be@@	I-Disease	-1	11425091
pen@@	I-Disease	-1	11425091
d@@	I-Disease	-1	11425091
ym@@	I-Disease	-1	11425091
al	I-Disease	-1	11425091
cy@@	I-Disease	-1	11425091
st@@	I-Disease	-1	11425091
s	I-Disease	-1	11425091
in	O	-1	11425091
inf@@	O	-1	11425091
ants	O	-1	11425091
exposed	O	-1	11425091
to	O	-1	11425091
cocaine	B-Chemical	D003042	11425091
p@@	O	-1	11425091
ren@@	O	-1	11425091
at@@	O	-1	11425091
ally	O	-1	11425091
was	O	-1	11425091
4@@	O	-1	11425091
4@@	O	-1	11425091
%	O	-1	11425091
(@@	O	-1	11425091
8	O	-1	11425091
of	O	-1	11425091
18@@	O	-1	11425091
)	O	-1	11425091
compared	O	-1	11425091
with	O	-1	11425091
8@@	O	-1	11425091
%	O	-1	11425091
(@@	O	-1	11425091
8	O	-1	11425091
of	O	-1	11425091
9@@	O	-1	11425091
9@@	O	-1	11425091
)	O	-1	11425091
in	O	-1	11425091
the	O	-1	11425091
un@@	O	-1	11425091
exposed	O	-1	11425091
group	O	-1	11425091
(p	O	-1	11425091
<	O	-1	11425091
0.0@@	O	-1	11425091
1).	O	-1	11425091
CONCLUSIONS:	O	-1	11425091
We	O	-1	11425091
found	O	-1	11425091
an	O	-1	11425091
increased	O	-1	11425091
incidence	O	-1	11425091
of	O	-1	11425091
su@@	B-Disease	D001927	11425091
be@@	I-Disease	-1	11425091
pen@@	I-Disease	-1	11425091
d@@	I-Disease	-1	11425091
ym@@	I-Disease	-1	11425091
al	I-Disease	-1	11425091
cys@@	I-Disease	-1	11425091
t	I-Disease	-1	11425091
su@@	B-Disease	D003560	11425091
be@@	I-Disease	-1	11425091
pen@@	I-Disease	-1	11425091
d@@	I-Disease	-1	11425091
ym@@	I-Disease	-1	11425091
al	I-Disease	-1	11425091
cys@@	I-Disease	-1	11425091
t	I-Disease	-1	11425091
formation	O	-1	11425091
in	O	-1	11425091
pre@@	B-Disease	D007235	11425091
term	I-Disease	-1	11425091
inf@@	I-Disease	-1	11425091
ants	I-Disease	-1	11425091
who	O	-1	11425091
were	O	-1	11425091
exposed	O	-1	11425091
to	O	-1	11425091
cocaine	B-Chemical	D003042	11425091
p@@	O	-1	11425091
ren@@	O	-1	11425091
at@@	O	-1	11425091
all@@	O	-1	11425091
y.	O	-1	11425091
This	O	-1	11425091
result	O	-1	11425091
is	O	-1	11425091
consist@@	O	-1	11425091
ent	O	-1	11425091
with	O	-1	11425091
results	O	-1	11425091
of	O	-1	11425091
similar	O	-1	11425091
studies	O	-1	11425091
in	O	-1	11425091
term	O	-1	11425091
inf@@	O	-1	11425091
ant@@	O	-1	11425091
s.	O	-1	11425091

Th@@	B-Chemical	D013792	11439380
al@@	I-Chemical	-1	11439380
id@@	I-Chemical	-1	11439380
om@@	I-Chemical	-1	11439380
ide	I-Chemical	-1	11439380
neuropathy	B-Disease	D009422	11439380
in	O	-1	11439380
patients	O	-1	11439380
treated	O	-1	11439380
for	O	-1	11439380
met@@	O	-1	11439380
ast@@	O	-1	11439380
atic	O	-1	11439380
pro@@	B-Disease	D011471	11439380
state	I-Disease	-1	11439380
cancer	I-Disease	-1	11439380
.	O	-1	11439380
We	O	-1	11439380
pro@@	O	-1	11439380
sp@@	O	-1	11439380
ectively	O	-1	11439380
evaluated	O	-1	11439380
thal@@	B-Chemical	D013792	11439380
id@@	I-Chemical	-1	11439380
om@@	I-Chemical	-1	11439380
ide	I-Chemical	-1	11439380
-induced	O	-1	11439380
neuropathy	B-Disease	D009422	11439380
using	O	-1	11439380
electro@@	O	-1	11439380
diagnos@@	O	-1	11439380
tic	O	-1	11439380
studi@@	O	-1	11439380
es.	O	-1	11439380
Si@@	O	-1	11439380
x@@	O	-1	11439380
ty-@@	O	-1	11439380
seven	O	-1	11439380
men	O	-1	11439380
with	O	-1	11439380
met@@	O	-1	11439380
ast@@	O	-1	11439380
atic	O	-1	11439380
and@@	B-Chemical	D000728	11439380
ro@@	I-Chemical	-1	11439380
gen	I-Chemical	-1	11439380
-@@	O	-1	11439380
in@@	O	-1	11439380
dependent	O	-1	11439380
pro@@	B-Disease	D011471	11439380
state	I-Disease	-1	11439380
cancer	I-Disease	-1	11439380
in	O	-1	11439380
an	O	-1	11439380
o@@	O	-1	11439380
pen@@	O	-1	11439380
-@@	O	-1	11439380
l@@	O	-1	11439380
a@@	O	-1	11439380
be@@	O	-1	11439380
l	O	-1	11439380
trial	O	-1	11439380
of	O	-1	11439380
oral	O	-1	11439380
thal@@	B-Chemical	D013792	11439380
id@@	I-Chemical	-1	11439380
om@@	I-Chemical	-1	11439380
ide	I-Chemical	-1	11439380
under@@	O	-1	11439380
w@@	O	-1	11439380
ent	O	-1	11439380
neurolog@@	O	-1	11439380
ic	O	-1	11439380
examin@@	O	-1	11439380
ations	O	-1	11439380
and	O	-1	11439380
nerve	O	-1	11439380
con@@	O	-1	11439380
duction	O	-1	11439380
studies	O	-1	11439380
(N@@	O	-1	11439380
C@@	O	-1	11439380
S)	O	-1	11439380
prior	O	-1	11439380
to	O	-1	11439380
and	O	-1	11439380
at	O	-1	11439380
3-@@	O	-1	11439380
mon@@	O	-1	11439380
th	O	-1	11439380
interv@@	O	-1	11439380
als	O	-1	11439380
during	O	-1	11439380
treatment.	O	-1	11439380
N@@	O	-1	11439380
C@@	O	-1	11439380
S	O	-1	11439380
included	O	-1	11439380
recor@@	O	-1	11439380
ding	O	-1	11439380
of	O	-1	11439380
sens@@	O	-1	11439380
ory	O	-1	11439380
nerve	O	-1	11439380
action	O	-1	11439380
potenti@@	O	-1	11439380
als	O	-1	11439380
(S@@	O	-1	11439380
N@@	O	-1	11439380
A@@	O	-1	11439380
P@@	O	-1	11439380
s)	O	-1	11439380
from	O	-1	11439380
medi@@	O	-1	11439380
an@@	O	-1	11439380
,	O	-1	11439380
radi@@	O	-1	11439380
al,	O	-1	11439380
ul@@	O	-1	11439380
n@@	O	-1	11439380
ar@@	O	-1	11439380
,	O	-1	11439380
and	O	-1	11439380
sur@@	O	-1	11439380
al	O	-1	11439380
ner@@	O	-1	11439380
v@@	O	-1	11439380
es.	O	-1	11439380
S@@	O	-1	11439380
N@@	O	-1	11439380
A@@	O	-1	11439380
P	O	-1	11439380
am@@	O	-1	11439380
pl@@	O	-1	11439380
it@@	O	-1	11439380
u@@	O	-1	11439380
des	O	-1	11439380
for	O	-1	11439380
each	O	-1	11439380
nerve	O	-1	11439380
were	O	-1	11439380
ex@@	O	-1	11439380
press@@	O	-1	11439380
ed	O	-1	11439380
as	O	-1	11439380
the	O	-1	11439380
perc@@	O	-1	11439380
ent@@	O	-1	11439380
age	O	-1	11439380
of	O	-1	11439380
its	O	-1	11439380
basel@@	O	-1	11439380
ine,	O	-1	11439380
and	O	-1	11439380
the	O	-1	11439380
mean	O	-1	11439380
of	O	-1	11439380
the	O	-1	11439380
four	O	-1	11439380
was	O	-1	11439380
ter@@	O	-1	11439380
m@@	O	-1	11439380
ed	O	-1	11439380
the	O	-1	11439380
S@@	O	-1	11439380
N@@	O	-1	11439380
A@@	O	-1	11439380
P	O	-1	11439380
in@@	O	-1	11439380
de@@	O	-1	11439380
x@@	O	-1	11439380
.	O	-1	11439380
A	O	-1	11439380
4@@	O	-1	11439380
0%	O	-1	11439380
dec@@	O	-1	11439380
line	O	-1	11439380
in	O	-1	11439380
the	O	-1	11439380
S@@	O	-1	11439380
N@@	O	-1	11439380
A@@	O	-1	11439380
P	O	-1	11439380
in@@	O	-1	11439380
de@@	O	-1	11439380
x	O	-1	11439380
was	O	-1	11439380
considered	O	-1	11439380
clin@@	O	-1	11439380
ically	O	-1	11439380
significant@@	O	-1	11439380
.	O	-1	11439380
Th@@	B-Chemical	D013792	11439380
al@@	I-Chemical	-1	11439380
id@@	I-Chemical	-1	11439380
om@@	I-Chemical	-1	11439380
ide	I-Chemical	-1	11439380
was	O	-1	11439380
discontinu@@	O	-1	11439380
ed	O	-1	11439380
in	O	-1	11439380
5@@	O	-1	11439380
5	O	-1	11439380
patients	O	-1	11439380
for	O	-1	11439380
l@@	O	-1	11439380
ac@@	O	-1	11439380
k	O	-1	11439380
of	O	-1	11439380
therapeutic	O	-1	11439380
respon@@	O	-1	11439380
se.	O	-1	11439380
Of	O	-1	11439380
6@@	O	-1	11439380
7	O	-1	11439380
patients	O	-1	11439380
initi@@	O	-1	11439380
ally	O	-1	11439380
en@@	O	-1	11439380
ro@@	O	-1	11439380
l@@	O	-1	11439380
le@@	O	-1	11439380
d,	O	-1	11439380
24	O	-1	11439380
remained	O	-1	11439380
on	O	-1	11439380
thal@@	B-Chemical	D013792	11439380
id@@	I-Chemical	-1	11439380
om@@	I-Chemical	-1	11439380
ide	I-Chemical	-1	11439380
for	O	-1	11439380
3	O	-1	11439380
month@@	O	-1	11439380
s,	O	-1	11439380
8	O	-1	11439380
remained	O	-1	11439380
at	O	-1	11439380
6	O	-1	11439380
month@@	O	-1	11439380
s,	O	-1	11439380
and	O	-1	11439380
3	O	-1	11439380
remained	O	-1	11439380
at	O	-1	11439380
9	O	-1	11439380
months.	O	-1	11439380
Si@@	O	-1	11439380
x	O	-1	11439380
patients	O	-1	11439380
developed	O	-1	11439380
neuropathy	B-Disease	D009422	11439380
.	O	-1	11439380
Clin@@	O	-1	11439380
ical	O	-1	11439380
symptoms	O	-1	11439380
and	O	-1	11439380
a	O	-1	11439380
dec@@	O	-1	11439380
line	O	-1	11439380
in	O	-1	11439380
the	O	-1	11439380
S@@	O	-1	11439380
N@@	O	-1	11439380
A@@	O	-1	11439380
P	O	-1	11439380
in@@	O	-1	11439380
de@@	O	-1	11439380
x	O	-1	11439380
occurred	O	-1	11439380
con@@	O	-1	11439380
cur@@	O	-1	11439380
ren@@	O	-1	11439380
t@@	O	-1	11439380
ly.	O	-1	11439380
O@@	O	-1	11439380
l@@	O	-1	11439380
der	O	-1	11439380
age	O	-1	11439380
and	O	-1	11439380
cum@@	O	-1	11439380
ul@@	O	-1	11439380
ative	O	-1	11439380
dose	O	-1	11439380
were	O	-1	11439380
possible	O	-1	11439380
cont@@	O	-1	11439380
ri@@	O	-1	11439380
but@@	O	-1	11439380
ing	O	-1	11439380
fact@@	O	-1	11439380
or@@	O	-1	11439380
s.	O	-1	11439380
Ne@@	B-Disease	D009422	11439380
uro@@	I-Disease	-1	11439380
pathy	I-Disease	-1	11439380
may	O	-1	11439380
th@@	O	-1	11439380
us	O	-1	11439380
be	O	-1	11439380
a	O	-1	11439380
common	O	-1	11439380
complication	O	-1	11439380
of	O	-1	11439380
thal@@	B-Chemical	D013792	11439380
id@@	I-Chemical	-1	11439380
om@@	I-Chemical	-1	11439380
ide	I-Chemical	-1	11439380
in	O	-1	11439380
ol@@	O	-1	11439380
der	O	-1	11439380
patients.	O	-1	11439380
The	O	-1	11439380
S@@	O	-1	11439380
N@@	O	-1	11439380
A@@	O	-1	11439380
P	O	-1	11439380
in@@	O	-1	11439380
de@@	O	-1	11439380
x	O	-1	11439380
can	O	-1	11439380
be	O	-1	11439380
used	O	-1	11439380
to	O	-1	11439380
monit@@	O	-1	11439380
or	O	-1	11439380
peripheral	B-Disease	D010523	11439380
neuropathy	I-Disease	-1	11439380
,	O	-1	11439380
but	O	-1	11439380
not	O	-1	11439380
for	O	-1	11439380
early	O	-1	11439380
det@@	O	-1	11439380
ec@@	O	-1	11439380
tion.	O	-1	11439380

O@@	O	-1	11474137
ve@@	O	-1	11474137
re@@	O	-1	11474137
x@@	O	-1	11474137
pression	O	-1	11474137
of	O	-1	11474137
co@@	B-Chemical	D003300	11474137
p@@	I-Chemical	-1	11474137
per	I-Chemical	-1	11474137
/	O	-1	11474137
z@@	B-Chemical	D015032	11474137
in@@	I-Chemical	-1	11474137
c	I-Chemical	-1	11474137
-	O	-1	11474137
su@@	B-Chemical	D013481	11474137
per@@	I-Chemical	-1	11474137
ox@@	I-Chemical	-1	11474137
ide	I-Chemical	-1	11474137
dis@@	O	-1	11474137
mut@@	O	-1	11474137
ase	O	-1	11474137
prot@@	O	-1	11474137
ects	O	-1	11474137
from	O	-1	11474137
k@@	B-Chemical	D007612	11474137
an@@	I-Chemical	-1	11474137
am@@	I-Chemical	-1	11474137
ycin	I-Chemical	-1	11474137
-induced	O	-1	11474137
hearing	B-Disease	D034381	11474137
loss	I-Disease	-1	11474137
.	O	-1	11474137
The	O	-1	11474137
partic@@	O	-1	11474137
ip@@	O	-1	11474137
ation	O	-1	11474137
of	O	-1	11474137
reac@@	O	-1	11474137
tive	O	-1	11474137
oxy@@	B-Chemical	D010100	11474137
gen	I-Chemical	-1	11474137
spec@@	O	-1	11474137
i@@	O	-1	11474137
es	O	-1	11474137
in	O	-1	11474137
amino@@	B-Chemical	D000617	11474137
gly@@	I-Chemical	-1	11474137
co@@	I-Chemical	-1	11474137
side	I-Chemical	-1	11474137
-induced	O	-1	11474137
ot@@	B-Disease	D006311	11474137
otoxicity	I-Disease	-1	11474137
has	O	-1	11474137
been	O	-1	11474137
de@@	O	-1	11474137
duced	O	-1	11474137
from	O	-1	11474137
observ@@	O	-1	11474137
ations	O	-1	11474137
that	O	-1	11474137
amino@@	B-Chemical	D000617	11474137
gly@@	I-Chemical	-1	11474137
co@@	I-Chemical	-1	11474137
side	I-Chemical	-1	11474137
-	O	-1	11474137
i@@	B-Chemical	D007501	11474137
ro@@	I-Chemical	-1	11474137
n	I-Chemical	-1	11474137
comple@@	O	-1	11474137
x@@	O	-1	11474137
es	O	-1	11474137
cat@@	O	-1	11474137
aly@@	O	-1	11474137
ze	O	-1	11474137
the	O	-1	11474137
formation	O	-1	11474137
of	O	-1	11474137
su@@	B-Chemical	D013481	11474137
per@@	I-Chemical	-1	11474137
ox@@	I-Chemical	-1	11474137
ide	I-Chemical	-1	11474137
ra@@	O	-1	11474137
dic@@	O	-1	11474137
als	O	-1	11474137
in	O	-1	11474137
vit@@	O	-1	11474137
r@@	O	-1	11474137
o	O	-1	11474137
and	O	-1	11474137
that	O	-1	11474137
anti@@	O	-1	11474137
oxid@@	O	-1	11474137
ants	O	-1	11474137
attenu@@	O	-1	11474137
ate	O	-1	11474137
ot@@	B-Disease	D006311	11474137
otoxicity	I-Disease	-1	11474137
in	O	-1	11474137
viv@@	O	-1	11474137
o@@	O	-1	11474137
.	O	-1	11474137
We	O	-1	11474137
the@@	O	-1	11474137
re@@	O	-1	11474137
fore	O	-1	11474137
hypo@@	O	-1	11474137
the@@	O	-1	11474137
si@@	O	-1	11474137
zed	O	-1	11474137
that	O	-1	11474137
o@@	O	-1	11474137
ve@@	O	-1	11474137
re@@	O	-1	11474137
x@@	O	-1	11474137
pression	O	-1	11474137
of	O	-1	11474137
C@@	B-Chemical	D003300	11474137
u	I-Chemical	-1	11474137
/	O	-1	11474137
Z@@	B-Chemical	D015032	11474137
n	I-Chemical	-1	11474137
-	O	-1	11474137
su@@	B-Chemical	D013481	11474137
per@@	I-Chemical	-1	11474137
ox@@	I-Chemical	-1	11474137
ide	I-Chemical	-1	11474137
dis@@	O	-1	11474137
mut@@	O	-1	11474137
ase	O	-1	11474137
(@@	O	-1	11474137
h@@	O	-1	11474137
-@@	O	-1	11474137
S@@	O	-1	11474137
O@@	O	-1	11474137
D@@	O	-1	11474137
1)	O	-1	11474137
should	O	-1	11474137
prot@@	O	-1	11474137
ect	O	-1	11474137
trans@@	O	-1	11474137
genic	O	-1	11474137
mice	O	-1	11474137
from	O	-1	11474137
ot@@	B-Disease	D006311	11474137
otoxicity	I-Disease	-1	11474137
.	O	-1	11474137
Im@@	O	-1	11474137
mun@@	O	-1	11474137
ocyto@@	O	-1	11474137
chem@@	O	-1	11474137
ist@@	O	-1	11474137
r@@	O	-1	11474137
y	O	-1	11474137
con@@	O	-1	11474137
fir@@	O	-1	11474137
m@@	O	-1	11474137
ed	O	-1	11474137
expression	O	-1	11474137
of	O	-1	11474137
h@@	O	-1	11474137
-@@	O	-1	11474137
S@@	O	-1	11474137
O@@	O	-1	11474137
D@@	O	-1	11474137
1	O	-1	11474137
in	O	-1	11474137
in@@	O	-1	11474137
n@@	O	-1	11474137
er	O	-1	11474137
e@@	O	-1	11474137
ar	O	-1	11474137
tissu@@	O	-1	11474137
es	O	-1	11474137
of	O	-1	11474137
trans@@	O	-1	11474137
genic	O	-1	11474137
C@@	O	-1	11474137
5@@	O	-1	11474137
7@@	O	-1	11474137
B@@	O	-1	11474137
L@@	O	-1	11474137
/@@	O	-1	11474137
6-@@	O	-1	11474137
T@@	O	-1	11474137
g@@	O	-1	11474137
N@@	O	-1	11474137
[@@	O	-1	11474137
S@@	O	-1	11474137
O@@	O	-1	11474137
D@@	O	-1	11474137
1@@	O	-1	11474137
]@@	O	-1	11474137
3@@	O	-1	11474137
C@@	O	-1	11474137
j@@	O	-1	11474137
e	O	-1	11474137
mice.	O	-1	11474137
T@@	O	-1	11474137
ran@@	O	-1	11474137
s@@	O	-1	11474137
genic	O	-1	11474137
and	O	-1	11474137
non@@	O	-1	11474137
trans@@	O	-1	11474137
genic	O	-1	11474137
lit@@	O	-1	11474137
ter@@	O	-1	11474137
mat@@	O	-1	11474137
es	O	-1	11474137
received	O	-1	11474137
k@@	B-Chemical	D007612	11474137
an@@	I-Chemical	-1	11474137
am@@	I-Chemical	-1	11474137
ycin	I-Chemical	-1	11474137
(4@@	O	-1	11474137
00	O	-1	11474137
mg/kg	O	-1	11474137
body	O	-1	11474137
weigh@@	O	-1	11474137
t@@	O	-1	11474137
/@@	O	-1	11474137
day@@	O	-1	11474137
)	O	-1	11474137
for	O	-1	11474137
10	O	-1	11474137
days	O	-1	11474137
be@@	O	-1	11474137
g@@	O	-1	11474137
in@@	O	-1	11474137
ning	O	-1	11474137
on	O	-1	11474137
day	O	-1	11474137
10	O	-1	11474137
after	O	-1	11474137
b@@	O	-1	11474137
ir@@	O	-1	11474137
th@@	O	-1	11474137
.	O	-1	11474137
A@@	O	-1	11474137
ud@@	O	-1	11474137
it@@	O	-1	11474137
ory	O	-1	11474137
th@@	O	-1	11474137
res@@	O	-1	11474137
h@@	O	-1	11474137
ol@@	O	-1	11474137
ds	O	-1	11474137
were	O	-1	11474137
tested	O	-1	11474137
by	O	-1	11474137
evoked	O	-1	11474137
a@@	O	-1	11474137
ud@@	O	-1	11474137
it@@	O	-1	11474137
ory	O	-1	11474137
brain	O	-1	11474137
st@@	O	-1	11474137
em	O	-1	11474137
responses	O	-1	11474137
at	O	-1	11474137
1	O	-1	11474137
mon@@	O	-1	11474137
th	O	-1	11474137
after	O	-1	11474137
b@@	O	-1	11474137
ir@@	O	-1	11474137
th@@	O	-1	11474137
.	O	-1	11474137
In	O	-1	11474137
non@@	O	-1	11474137
trans@@	O	-1	11474137
genic	O	-1	11474137
anim@@	O	-1	11474137
al@@	O	-1	11474137
s,	O	-1	11474137
the	O	-1	11474137
th@@	O	-1	11474137
res@@	O	-1	11474137
h@@	O	-1	11474137
old	O	-1	11474137
in	O	-1	11474137
the	O	-1	11474137
k@@	B-Chemical	D007612	11474137
an@@	I-Chemical	-1	11474137
am@@	I-Chemical	-1	11474137
ycin	I-Chemical	-1	11474137
-treated	O	-1	11474137
group	O	-1	11474137
was	O	-1	11474137
4@@	O	-1	11474137
5-@@	O	-1	11474137
50	O	-1	11474137
d@@	O	-1	11474137
B	O	-1	11474137
higher	O	-1	11474137
than	O	-1	11474137
in	O	-1	11474137
sal@@	O	-1	11474137
ine-@@	O	-1	11474137
injected	O	-1	11474137
controls.	O	-1	11474137
In	O	-1	11474137
the	O	-1	11474137
trans@@	O	-1	11474137
genic	O	-1	11474137
group@@	O	-1	11474137
,	O	-1	11474137
k@@	B-Chemical	D007612	11474137
an@@	I-Chemical	-1	11474137
am@@	I-Chemical	-1	11474137
ycin	I-Chemical	-1	11474137
increased	O	-1	11474137
the	O	-1	11474137
th@@	O	-1	11474137
res@@	O	-1	11474137
h@@	O	-1	11474137
old	O	-1	11474137
by	O	-1	11474137
only	O	-1	11474137
15	O	-1	11474137
d@@	O	-1	11474137
B	O	-1	11474137
over	O	-1	11474137
the	O	-1	11474137
resp@@	O	-1	11474137
ective	O	-1	11474137
controls.	O	-1	11474137
The	O	-1	11474137
effects	O	-1	11474137
were	O	-1	11474137
similar	O	-1	11474137
at	O	-1	11474137
12	O	-1	11474137
and	O	-1	11474137
24	O	-1	11474137
k@@	O	-1	11474137
H@@	O	-1	11474137
z@@	O	-1	11474137
.	O	-1	11474137
The	O	-1	11474137
prot@@	O	-1	11474137
ection	O	-1	11474137
by	O	-1	11474137
o@@	O	-1	11474137
ve@@	O	-1	11474137
re@@	O	-1	11474137
x@@	O	-1	11474137
pression	O	-1	11474137
of	O	-1	11474137
su@@	B-Chemical	D013481	11474137
per@@	I-Chemical	-1	11474137
ox@@	I-Chemical	-1	11474137
ide	I-Chemical	-1	11474137
dis@@	O	-1	11474137
mut@@	O	-1	11474137
ase	O	-1	11474137
suppor@@	O	-1	11474137
ts	O	-1	11474137
the	O	-1	11474137
hypo@@	O	-1	11474137
thesis	O	-1	11474137
that	O	-1	11474137
oxid@@	O	-1	11474137
ant	O	-1	11474137
stres@@	O	-1	11474137
s	O	-1	11474137
pl@@	O	-1	11474137
ays	O	-1	11474137
a	O	-1	11474137
significant	O	-1	11474137
role	O	-1	11474137
in	O	-1	11474137
amino@@	B-Chemical	D000617	11474137
gly@@	I-Chemical	-1	11474137
co@@	I-Chemical	-1	11474137
side	I-Chemical	-1	11474137
-induced	O	-1	11474137
ot@@	B-Disease	D006311	11474137
otoxicity	I-Disease	-1	11474137
.	O	-1	11474137
The	O	-1	11474137
results	O	-1	11474137
also	O	-1	11474137
suggest	O	-1	11474137
trans@@	O	-1	11474137
genic	O	-1	11474137
animals	O	-1	11474137
as	O	-1	11474137
su@@	O	-1	11474137
it@@	O	-1	11474137
able	O	-1	11474137
models	O	-1	11474137
to	O	-1	11474137
investigate	O	-1	11474137
the	O	-1	11474137
underlying	O	-1	11474137
mechanisms	O	-1	11474137
and	O	-1	11474137
possible	O	-1	11474137
strat@@	O	-1	11474137
e@@	O	-1	11474137
gi@@	O	-1	11474137
es	O	-1	11474137
for	O	-1	11474137
pre@@	O	-1	11474137
ven@@	O	-1	11474137
tion.	O	-1	11474137

Pre@@	B-Chemical	D011241	11708428
d@@	I-Chemical	-1	11708428
n@@	I-Chemical	-1	11708428
is@@	I-Chemical	-1	11708428
one	I-Chemical	-1	11708428
induc@@	O	-1	11708428
es	O	-1	11708428
an@@	B-Disease	D001008	11708428
xi@@	I-Disease	-1	11708428
ety	I-Disease	-1	11708428
and	O	-1	11708428
g@@	O	-1	11708428
lial	O	-1	11708428
cerebral	O	-1	11708428
changes	O	-1	11708428
in	O	-1	11708428
rats.	O	-1	11708428
OBJECTIVE:	O	-1	11708428
To	O	-1	11708428
ass@@	O	-1	11708428
ess	O	-1	11708428
whether	O	-1	11708428
pre@@	B-Chemical	D011241	11708428
d@@	I-Chemical	-1	11708428
n@@	I-Chemical	-1	11708428
is@@	I-Chemical	-1	11708428
one	I-Chemical	-1	11708428
(	O	-1	11708428
P@@	B-Chemical	D011241	11708428
D@@	I-Chemical	-1	11708428
N	I-Chemical	-1	11708428
)	O	-1	11708428
produc@@	O	-1	11708428
es	O	-1	11708428
an@@	B-Disease	D001008	11708428
xi@@	I-Disease	-1	11708428
ety	I-Disease	-1	11708428
and/or	O	-1	11708428
cerebral	O	-1	11708428
g@@	O	-1	11708428
lial	O	-1	11708428
changes	O	-1	11708428
in	O	-1	11708428
rats.	O	-1	11708428
METHODS:	O	-1	11708428
M@@	O	-1	11708428
al@@	O	-1	11708428
e	O	-1	11708428
Wistar	O	-1	11708428
rats	O	-1	11708428
were	O	-1	11708428
studied	O	-1	11708428
and	O	-1	11708428
3	O	-1	11708428
groups	O	-1	11708428
were	O	-1	11708428
form@@	O	-1	11708428
ed	O	-1	11708428
(@@	O	-1	11708428
8	O	-1	11708428
rats	O	-1	11708428
per	O	-1	11708428
group@@	O	-1	11708428
).	O	-1	11708428
The	O	-1	11708428
moder@@	O	-1	11708428
at@@	O	-1	11708428
e-@@	O	-1	11708428
dose	O	-1	11708428
group	O	-1	11708428
received	O	-1	11708428
5	O	-1	11708428
mg/k@@	O	-1	11708428
g/@@	O	-1	11708428
day	O	-1	11708428
P@@	B-Chemical	D011241	11708428
D@@	I-Chemical	-1	11708428
N	I-Chemical	-1	11708428
rele@@	O	-1	11708428
as@@	O	-1	11708428
ed	O	-1	11708428
from	O	-1	11708428
a	O	-1	11708428
sub@@	O	-1	11708428
c@@	O	-1	11708428
utaneous	O	-1	11708428
im@@	O	-1	11708428
pl@@	O	-1	11708428
ant@@	O	-1	11708428
.	O	-1	11708428
In	O	-1	11708428
the	O	-1	11708428
high-dose	O	-1	11708428
group@@	O	-1	11708428
,	O	-1	11708428
im@@	O	-1	11708428
pl@@	O	-1	11708428
ants	O	-1	11708428
containing	O	-1	11708428
P@@	B-Chemical	D011241	11708428
D@@	I-Chemical	-1	11708428
N	I-Chemical	-1	11708428
equ@@	O	-1	11708428
i@@	O	-1	11708428
val@@	O	-1	11708428
ent	O	-1	11708428
to	O	-1	11708428
60	O	-1	11708428
mg/k@@	O	-1	11708428
g/@@	O	-1	11708428
day	O	-1	11708428
were	O	-1	11708428
ap@@	O	-1	11708428
pl@@	O	-1	11708428
i@@	O	-1	11708428
ed.	O	-1	11708428
In	O	-1	11708428
the	O	-1	11708428
control	O	-1	11708428
group	O	-1	11708428
im@@	O	-1	11708428
pl@@	O	-1	11708428
ants	O	-1	11708428
cont@@	O	-1	11708428
ained	O	-1	11708428
no	O	-1	11708428
P@@	B-Chemical	D011241	11708428
D@@	I-Chemical	-1	11708428
N	I-Chemical	-1	11708428
.	O	-1	11708428
An@@	B-Disease	D001008	11708428
xi@@	I-Disease	-1	11708428
ety	I-Disease	-1	11708428
was	O	-1	11708428
assessed	O	-1	11708428
using	O	-1	11708428
an	O	-1	11708428
op@@	O	-1	11708428
en	O	-1	11708428
fi@@	O	-1	11708428
el@@	O	-1	11708428
d	O	-1	11708428
and	O	-1	11708428
elevated	O	-1	11708428
pl@@	O	-1	11708428
us@@	O	-1	11708428
-@@	O	-1	11708428
ma@@	O	-1	11708428
ze	O	-1	11708428
de@@	O	-1	11708428
v@@	O	-1	11708428
ic@@	O	-1	11708428
es.	O	-1	11708428
The	O	-1	11708428
number	O	-1	11708428
of	O	-1	11708428
cells	O	-1	11708428
and	O	-1	11708428
cyto@@	O	-1	11708428
plas@@	O	-1	11708428
mic	O	-1	11708428
trans@@	O	-1	11708428
formation	O	-1	11708428
of	O	-1	11708428
ast@@	O	-1	11708428
ro@@	O	-1	11708428
cy@@	O	-1	11708428
tes	O	-1	11708428
and	O	-1	11708428
micro@@	O	-1	11708428
g@@	O	-1	11708428
li@@	O	-1	11708428
a	O	-1	11708428
cells	O	-1	11708428
were	O	-1	11708428
assessed	O	-1	11708428
by	O	-1	11708428
immuno@@	O	-1	11708428
histo@@	O	-1	11708428
chemical	O	-1	11708428
an@@	O	-1	11708428
al@@	O	-1	11708428
ys@@	O	-1	11708428
es.	O	-1	11708428
RESULTS:	O	-1	11708428
An@@	B-Disease	D001008	11708428
xi@@	I-Disease	-1	11708428
ety	I-Disease	-1	11708428
was	O	-1	11708428
doc@@	O	-1	11708428
um@@	O	-1	11708428
ent@@	O	-1	11708428
ed	O	-1	11708428
in	O	-1	11708428
both	O	-1	11708428
groups	O	-1	11708428
of	O	-1	11708428
P@@	B-Chemical	D011241	11708428
D@@	I-Chemical	-1	11708428
N	I-Chemical	-1	11708428
treated	O	-1	11708428
rats	O	-1	11708428
compared	O	-1	11708428
with	O	-1	11708428
controls.	O	-1	11708428
The	O	-1	11708428
mag@@	O	-1	11708428
nit@@	O	-1	11708428
ude	O	-1	11708428
of	O	-1	11708428
trans@@	O	-1	11708428
formation	O	-1	11708428
of	O	-1	11708428
the	O	-1	11708428
micro@@	O	-1	11708428
g@@	O	-1	11708428
li@@	O	-1	11708428
a	O	-1	11708428
assessed	O	-1	11708428
by	O	-1	11708428
the	O	-1	11708428
number	O	-1	11708428
of	O	-1	11708428
inter@@	O	-1	11708428
sec@@	O	-1	11708428
tions	O	-1	11708428
was	O	-1	11708428
significantly	O	-1	11708428
higher	O	-1	11708428
in	O	-1	11708428
the	O	-1	11708428
P@@	B-Chemical	D011241	11708428
D@@	I-Chemical	-1	11708428
N	I-Chemical	-1	11708428
groups	O	-1	11708428
than	O	-1	11708428
in	O	-1	11708428
controls	O	-1	11708428
in	O	-1	11708428
the	O	-1	11708428
pre@@	O	-1	11708428
fron@@	O	-1	11708428
t@@	O	-1	11708428
al	O	-1	11708428
cor@@	O	-1	11708428
te@@	O	-1	11708428
x	O	-1	11708428
(@@	O	-1	11708428
moder@@	O	-1	11708428
at@@	O	-1	11708428
e-@@	O	-1	11708428
dose@@	O	-1	11708428
,	O	-1	11708428
2@@	O	-1	11708428
4.@@	O	-1	11708428
1@@	O	-1	11708428
;	O	-1	11708428
high-@@	O	-1	11708428
dose@@	O	-1	11708428
,	O	-1	11708428
2@@	O	-1	11708428
3.@@	O	-1	11708428
6@@	O	-1	11708428
;	O	-1	11708428
controls	O	-1	11708428
1@@	O	-1	11708428
8.@@	O	-1	11708428
7@@	O	-1	11708428
;	O	-1	11708428
p	O	-1	11708428
<	O	-1	11708428
0.0@@	O	-1	11708428
1)	O	-1	11708428
and	O	-1	11708428
striat@@	O	-1	11708428
um	O	-1	11708428
(@@	O	-1	11708428
moder@@	O	-1	11708428
at@@	O	-1	11708428
e-@@	O	-1	11708428
dose	O	-1	11708428
2@@	O	-1	11708428
5.@@	O	-1	11708428
6@@	O	-1	11708428
;	O	-1	11708428
high-dose	O	-1	11708428
2@@	O	-1	11708428
6.@@	O	-1	11708428
3@@	O	-1	11708428
;	O	-1	11708428
controls	O	-1	11708428
1@@	O	-1	11708428
8.@@	O	-1	11708428
9@@	O	-1	11708428
;	O	-1	11708428
p	O	-1	11708428
<	O	-1	11708428
0.0@@	O	-1	11708428
1),	O	-1	11708428
but	O	-1	11708428
not	O	-1	11708428
in	O	-1	11708428
hippocamp@@	O	-1	11708428
us.	O	-1	11708428
The	O	-1	11708428
number	O	-1	11708428
of	O	-1	11708428
st@@	O	-1	11708428
ained	O	-1	11708428
micro@@	O	-1	11708428
g@@	O	-1	11708428
li@@	O	-1	11708428
a	O	-1	11708428
cells	O	-1	11708428
was	O	-1	11708428
significantly	O	-1	11708428
higher	O	-1	11708428
in	O	-1	11708428
the	O	-1	11708428
P@@	B-Chemical	D011241	11708428
D@@	I-Chemical	-1	11708428
N	I-Chemical	-1	11708428
treated	O	-1	11708428
groups	O	-1	11708428
in	O	-1	11708428
the	O	-1	11708428
pre@@	O	-1	11708428
fron@@	O	-1	11708428
t@@	O	-1	11708428
al	O	-1	11708428
cor@@	O	-1	11708428
te@@	O	-1	11708428
x	O	-1	11708428
than	O	-1	11708428
in	O	-1	11708428
controls	O	-1	11708428
(@@	O	-1	11708428
moder@@	O	-1	11708428
at@@	O	-1	11708428
e-@@	O	-1	11708428
dose@@	O	-1	11708428
,	O	-1	11708428
2@@	O	-1	11708428
9.@@	O	-1	11708428
1@@	O	-1	11708428
;	O	-1	11708428
high-@@	O	-1	11708428
dose@@	O	-1	11708428
,	O	-1	11708428
2@@	O	-1	11708428
8.@@	O	-1	11708428
4@@	O	-1	11708428
;	O	-1	11708428
control@@	O	-1	11708428
,	O	-1	11708428
1@@	O	-1	11708428
7.@@	O	-1	11708428
7	O	-1	11708428
cells	O	-1	11708428
per	O	-1	11708428
fi@@	O	-1	11708428
el@@	O	-1	11708428
d@@	O	-1	11708428
;	O	-1	11708428
p	O	-1	11708428
<	O	-1	11708428
0.0@@	O	-1	11708428
1).	O	-1	11708428
S@@	O	-1	11708428
t@@	O	-1	11708428
ained	O	-1	11708428
micro@@	O	-1	11708428
g@@	O	-1	11708428
li@@	O	-1	11708428
a	O	-1	11708428
cells	O	-1	11708428
were	O	-1	11708428
significantly	O	-1	11708428
more	O	-1	11708428
n@@	O	-1	11708428
um@@	O	-1	11708428
er@@	O	-1	11708428
ous	O	-1	11708428
striat@@	O	-1	11708428
um	O	-1	11708428
and	O	-1	11708428
hippocamp@@	O	-1	11708428
us	O	-1	11708428
in	O	-1	11708428
the	O	-1	11708428
high-dose	O	-1	11708428
group	O	-1	11708428
compared	O	-1	11708428
to	O	-1	11708428
controls.	O	-1	11708428
CONCLUSION:	O	-1	11708428
S@@	O	-1	11708428
ub@@	O	-1	11708428
acute	O	-1	11708428
exposure	O	-1	11708428
to	O	-1	11708428
P@@	B-Chemical	D011241	11708428
D@@	I-Chemical	-1	11708428
N	I-Chemical	-1	11708428
induced	O	-1	11708428
an@@	B-Disease	D001008	11708428
xi@@	I-Disease	-1	11708428
ety	I-Disease	-1	11708428
and	O	-1	11708428
re@@	O	-1	11708428
activity	O	-1	11708428
of	O	-1	11708428
micro@@	O	-1	11708428
g@@	O	-1	11708428
li@@	O	-1	11708428
a.	O	-1	11708428
The	O	-1	11708428
re@@	O	-1	11708428
lev@@	O	-1	11708428
ance	O	-1	11708428
of	O	-1	11708428
these	O	-1	11708428
feat@@	O	-1	11708428
ures	O	-1	11708428
for	O	-1	11708428
patients	O	-1	11708428
using	O	-1	11708428
P@@	B-Chemical	D011241	11708428
D@@	I-Chemical	-1	11708428
N	I-Chemical	-1	11708428
remain@@	O	-1	11708428
s	O	-1	11708428
to	O	-1	11708428
be	O	-1	11708428
el@@	O	-1	11708428
uc@@	O	-1	11708428
id@@	O	-1	11708428
ated.	O	-1	11708428

Ph@@	O	-1	11745287
ase	O	-1	11745287
II	O	-1	11745287
study	O	-1	11745287
of	O	-1	11745287
car@@	B-Chemical	D016190	11745287
bo@@	I-Chemical	-1	11745287
pl@@	I-Chemical	-1	11745287
atin	I-Chemical	-1	11745287
and	O	-1	11745287
li@@	O	-1	11745287
pos@@	O	-1	11745287
om@@	O	-1	11745287
al	O	-1	11745287
dox@@	B-Chemical	D004317	11745287
orub@@	I-Chemical	-1	11745287
icin	I-Chemical	-1	11745287
in	O	-1	11745287
patients	O	-1	11745287
with	O	-1	11745287
recur@@	O	-1	11745287
rent	O	-1	11745287
s@@	B-Disease	D002294	11745287
qu@@	I-Disease	-1	11745287
am@@	I-Disease	-1	11745287
ous	I-Disease	-1	11745287
cell	I-Disease	-1	11745287
carcin@@	I-Disease	-1	11745287
oma	I-Disease	-1	11745287
of	I-Disease	-1	11745287
the	I-Disease	-1	11745287
cer@@	I-Disease	-1	11745287
vi@@	I-Disease	-1	11745287
x	I-Disease	-1	11745287
s@@	B-Disease	D002583	11745287
qu@@	I-Disease	-1	11745287
am@@	I-Disease	-1	11745287
ous	I-Disease	-1	11745287
cell	I-Disease	-1	11745287
carcin@@	I-Disease	-1	11745287
oma	I-Disease	-1	11745287
of	I-Disease	-1	11745287
the	I-Disease	-1	11745287
cer@@	I-Disease	-1	11745287
vi@@	I-Disease	-1	11745287
x	I-Disease	-1	11745287
.	O	-1	11745287
BACKGROUND:	O	-1	11745287
The	O	-1	11745287
activity	O	-1	11745287
of	O	-1	11745287
the	O	-1	11745287
combination	O	-1	11745287
of	O	-1	11745287
car@@	B-Chemical	D016190	11745287
bo@@	I-Chemical	-1	11745287
pl@@	I-Chemical	-1	11745287
atin	I-Chemical	-1	11745287
and	O	-1	11745287
li@@	O	-1	11745287
pos@@	O	-1	11745287
om@@	O	-1	11745287
al	O	-1	11745287
dox@@	B-Chemical	D004317	11745287
orub@@	I-Chemical	-1	11745287
icin	I-Chemical	-1	11745287
was	O	-1	11745287
tested	O	-1	11745287
in	O	-1	11745287
a	O	-1	11745287
Ph@@	O	-1	11745287
ase	O	-1	11745287
II	O	-1	11745287
study	O	-1	11745287
of	O	-1	11745287
patients	O	-1	11745287
with	O	-1	11745287
recur@@	O	-1	11745287
rent	O	-1	11745287
cer@@	B-Disease	D002583	11745287
v@@	I-Disease	-1	11745287
ical	I-Disease	-1	11745287
carcin@@	I-Disease	-1	11745287
oma	I-Disease	-1	11745287
.	O	-1	11745287
METHODS:	O	-1	11745287
The	O	-1	11745287
combination	O	-1	11745287
of	O	-1	11745287
car@@	B-Chemical	D016190	11745287
bo@@	I-Chemical	-1	11745287
pl@@	I-Chemical	-1	11745287
atin	I-Chemical	-1	11745287
(@@	O	-1	11745287
a@@	O	-1	11745287
re@@	O	-1	11745287
a	O	-1	11745287
under	O	-1	11745287
the	O	-1	11745287
concentration	O	-1	11745287
cur@@	O	-1	11745287
ve	O	-1	11745287
[@@	O	-1	11745287
A@@	O	-1	11745287
U@@	O	-1	11745287
C@@	O	-1	11745287
]@@	O	-1	11745287
,	O	-1	11745287
5@@	O	-1	11745287
)	O	-1	11745287
and	O	-1	11745287
li@@	O	-1	11745287
pos@@	O	-1	11745287
om@@	O	-1	11745287
al	O	-1	11745287
dox@@	B-Chemical	D004317	11745287
orub@@	I-Chemical	-1	11745287
icin	I-Chemical	-1	11745287
(	O	-1	11745287
D@@	B-Chemical	D004317	11745287
ox@@	I-Chemical	-1	11745287
il	I-Chemical	-1	11745287
;	O	-1	11745287
star@@	O	-1	11745287
ting	O	-1	11745287
dose@@	O	-1	11745287
,	O	-1	11745287
40	O	-1	11745287
mg/m@@	O	-1	11745287
(2@@	O	-1	11745287
)@@	O	-1	11745287
)	O	-1	11745287
was	O	-1	11745287
administered	O	-1	11745287
intra@@	O	-1	11745287
ven@@	O	-1	11745287
ously	O	-1	11745287
every	O	-1	11745287
2@@	O	-1	11745287
8	O	-1	11745287
days	O	-1	11745287
to	O	-1	11745287
3@@	O	-1	11745287
7	O	-1	11745287
patients	O	-1	11745287
with	O	-1	11745287
recur@@	O	-1	11745287
rent	O	-1	11745287
s@@	B-Disease	D002294	11745287
qu@@	I-Disease	-1	11745287
am@@	I-Disease	-1	11745287
ous	I-Disease	-1	11745287
cell	I-Disease	-1	11745287
cer@@	I-Disease	-1	11745287
v@@	I-Disease	-1	11745287
ical	I-Disease	-1	11745287
carcin@@	I-Disease	-1	11745287
oma	I-Disease	-1	11745287
s@@	B-Disease	D002583	11745287
qu@@	I-Disease	-1	11745287
am@@	I-Disease	-1	11745287
ous	I-Disease	-1	11745287
cell	I-Disease	-1	11745287
cer@@	I-Disease	-1	11745287
v@@	I-Disease	-1	11745287
ical	I-Disease	-1	11745287
carcin@@	I-Disease	-1	11745287
oma	I-Disease	-1	11745287
to	O	-1	11745287
determine	O	-1	11745287
anti@@	O	-1	11745287
tumor	O	-1	11745287
activity	O	-1	11745287
and	O	-1	11745287
toxicity	B-Disease	D064420	11745287
pro@@	O	-1	11745287
fi@@	O	-1	11745287
le@@	O	-1	11745287
.	O	-1	11745287
RESULTS:	O	-1	11745287
Tw@@	O	-1	11745287
ent@@	O	-1	11745287
y-@@	O	-1	11745287
n@@	O	-1	11745287
ine	O	-1	11745287
patients	O	-1	11745287
were	O	-1	11745287
assess@@	O	-1	11745287
able	O	-1	11745287
for	O	-1	11745287
respon@@	O	-1	11745287
se@@	O	-1	11745287
,	O	-1	11745287
and	O	-1	11745287
3@@	O	-1	11745287
5	O	-1	11745287
patients	O	-1	11745287
were	O	-1	11745287
assess@@	O	-1	11745287
able	O	-1	11745287
for	O	-1	11745287
toxicity	B-Disease	D064420	11745287
.	O	-1	11745287
The	O	-1	11745287
over@@	O	-1	11745287
all	O	-1	11745287
response	O	-1	11745287
rate	O	-1	11745287
was	O	-1	11745287
3@@	O	-1	11745287
8@@	O	-1	11745287
%,	O	-1	11745287
the	O	-1	11745287
median	O	-1	11745287
time	O	-1	11745287
to	O	-1	11745287
response	O	-1	11745287
was	O	-1	11745287
10	O	-1	11745287
week@@	O	-1	11745287
s,	O	-1	11745287
the	O	-1	11745287
median	O	-1	11745287
duration	O	-1	11745287
of	O	-1	11745287
response	O	-1	11745287
was	O	-1	11745287
2@@	O	-1	11745287
6	O	-1	11745287
week@@	O	-1	11745287
s,	O	-1	11745287
and	O	-1	11745287
the	O	-1	11745287
median	O	-1	11745287
sur@@	O	-1	11745287
viv@@	O	-1	11745287
al	O	-1	11745287
was	O	-1	11745287
3@@	O	-1	11745287
7	O	-1	11745287
week@@	O	-1	11745287
s.	O	-1	11745287
The	O	-1	11745287
ma@@	O	-1	11745287
in	O	-1	11745287
toxic	O	-1	11745287
effect	O	-1	11745287
was	O	-1	11745287
my@@	B-Disease	D001855	11745287
e@@	I-Disease	-1	11745287
lo@@	I-Disease	-1	11745287
sup@@	I-Disease	-1	11745287
pression	I-Disease	-1	11745287
,	O	-1	11745287
with	O	-1	11745287
G@@	O	-1	11745287
ra@@	O	-1	11745287
de	O	-1	11745287
3	O	-1	11745287
and	O	-1	11745287
4	O	-1	11745287
ne@@	B-Disease	D009503	11745287
ut@@	I-Disease	-1	11745287
ro@@	I-Disease	-1	11745287
pen@@	I-Disease	-1	11745287
ia	I-Disease	-1	11745287
in	O	-1	11745287
16	O	-1	11745287
patients,	O	-1	11745287
anemia	B-Disease	D000740	11745287
in	O	-1	11745287
12	O	-1	11745287
patients,	O	-1	11745287
throm@@	B-Disease	D013921	11745287
b@@	I-Disease	-1	11745287
ocyto@@	I-Disease	-1	11745287
pen@@	I-Disease	-1	11745287
ia	I-Disease	-1	11745287
in	O	-1	11745287
11	O	-1	11745287
patients,	O	-1	11745287
and	O	-1	11745287
ne@@	B-Disease	D009503	11745287
ut@@	I-Disease	-1	11745287
ro@@	I-Disease	-1	11745287
pen@@	I-Disease	-1	11745287
ic	I-Disease	-1	11745287
f@@	I-Disease	-1	11745287
ev@@	I-Disease	-1	11745287
er	I-Disease	-1	11745287
ne@@	B-Disease	D005334	11745287
ut@@	I-Disease	-1	11745287
ro@@	I-Disease	-1	11745287
pen@@	I-Disease	-1	11745287
ic	I-Disease	-1	11745287
f@@	I-Disease	-1	11745287
ev@@	I-Disease	-1	11745287
er	I-Disease	-1	11745287
in	O	-1	11745287
3	O	-1	11745287
patients.	O	-1	11745287
F@@	O	-1	11745287
our	O	-1	11745287
patients	O	-1	11745287
had	O	-1	11745287
five	O	-1	11745287
infu@@	O	-1	11745287
sion@@	O	-1	11745287
-@@	O	-1	11745287
related	O	-1	11745287
reactions	O	-1	11745287
during	O	-1	11745287
the	O	-1	11745287
infusion	O	-1	11745287
of	O	-1	11745287
li@@	O	-1	11745287
pos@@	O	-1	11745287
om@@	O	-1	11745287
al	O	-1	11745287
dox@@	B-Chemical	D004317	11745287
orub@@	I-Chemical	-1	11745287
icin	I-Chemical	-1	11745287
,	O	-1	11745287
lead@@	O	-1	11745287
ing	O	-1	11745287
to	O	-1	11745287
treatment	O	-1	11745287
discontinu@@	O	-1	11745287
ation	O	-1	11745287
in	O	-1	11745287
three	O	-1	11745287
patients.	O	-1	11745287
G@@	O	-1	11745287
ra@@	O	-1	11745287
de	O	-1	11745287
>	O	-1	11745287
or	O	-1	11745287
=	O	-1	11745287
2	O	-1	11745287
non@@	O	-1	11745287
hemat@@	O	-1	11745287
ologic	O	-1	11745287
toxicity	B-Disease	D064420	11745287
included	O	-1	11745287
nausea	B-Disease	D009325	11745287
in	O	-1	11745287
17	O	-1	11745287
patients,	O	-1	11745287
e@@	B-Disease	D014839	11745287
me@@	I-Disease	-1	11745287
sis	I-Disease	-1	11745287
in	O	-1	11745287
14	O	-1	11745287
patients,	O	-1	11745287
f@@	B-Disease	D005221	11745287
ati@@	I-Disease	-1	11745287
gu@@	I-Disease	-1	11745287
e	I-Disease	-1	11745287
in	O	-1	11745287
9	O	-1	11745287
patients,	O	-1	11745287
m@@	B-Disease	D052016	11745287
u@@	I-Disease	-1	11745287
co@@	I-Disease	-1	11745287
si@@	I-Disease	-1	11745287
tis	I-Disease	-1	11745287
and/or	O	-1	11745287
st@@	B-Disease	D013280	11745287
om@@	I-Disease	-1	11745287
ati@@	I-Disease	-1	11745287
tis	I-Disease	-1	11745287
in	O	-1	11745287
8	O	-1	11745287
patients,	O	-1	11745287
con@@	B-Disease	D003248	11745287
sti@@	I-Disease	-1	11745287
p@@	I-Disease	-1	11745287
ation	I-Disease	-1	11745287
in	O	-1	11745287
6	O	-1	11745287
patients,	O	-1	11745287
weight	B-Disease	D015431	11745287
loss	I-Disease	-1	11745287
in	O	-1	11745287
5	O	-1	11745287
patients,	O	-1	11745287
h@@	B-Disease	D060831	11745287
and@@	I-Disease	-1	11745287
-@@	I-Disease	-1	11745287
fo@@	I-Disease	-1	11745287
o@@	I-Disease	-1	11745287
t	I-Disease	-1	11745287
syndrome	I-Disease	-1	11745287
in	O	-1	11745287
2	O	-1	11745287
patients,	O	-1	11745287
and	O	-1	11745287
s@@	B-Disease	D012871	11745287
k@@	I-Disease	-1	11745287
in	I-Disease	-1	11745287
reactions	I-Disease	-1	11745287
in	O	-1	11745287
3	O	-1	11745287
patients.	O	-1	11745287
CONCLUSIONS:	O	-1	11745287
The	O	-1	11745287
combination	O	-1	11745287
of	O	-1	11745287
car@@	B-Chemical	D016190	11745287
bo@@	I-Chemical	-1	11745287
pl@@	I-Chemical	-1	11745287
atin	I-Chemical	-1	11745287
and	O	-1	11745287
li@@	O	-1	11745287
pos@@	O	-1	11745287
om@@	O	-1	11745287
al	O	-1	11745287
dox@@	B-Chemical	D004317	11745287
orub@@	I-Chemical	-1	11745287
icin	I-Chemical	-1	11745287
has	O	-1	11745287
mod@@	O	-1	11745287
est	O	-1	11745287
activity	O	-1	11745287
in	O	-1	11745287
patients	O	-1	11745287
with	O	-1	11745287
recur@@	O	-1	11745287
rent	O	-1	11745287
cer@@	B-Disease	D002583	11745287
v@@	I-Disease	-1	11745287
ical	I-Disease	-1	11745287
carcin@@	I-Disease	-1	11745287
oma	I-Disease	-1	11745287
.	O	-1	11745287

An@@	O	-1	11799346
ti@@	O	-1	11799346
micro@@	O	-1	11799346
b@@	O	-1	11799346
i@@	O	-1	11799346
al@@	O	-1	11799346
-induced	O	-1	11799346
man@@	B-Disease	D001714	11799346
ia	I-Disease	-1	11799346
(	O	-1	11799346
anti@@	B-Disease	D001714	11799346
b@@	I-Disease	-1	11799346
i@@	I-Disease	-1	11799346
om@@	I-Disease	-1	11799346
an@@	I-Disease	-1	11799346
ia	I-Disease	-1	11799346
)@@	O	-1	11799346
:	O	-1	11799346
a	O	-1	11799346
revie@@	O	-1	11799346
w	O	-1	11799346
of	O	-1	11799346
spont@@	O	-1	11799346
aneous	O	-1	11799346
repor@@	O	-1	11799346
t@@	O	-1	11799346
s.	O	-1	11799346
The	O	-1	11799346
au@@	O	-1	11799346
th@@	O	-1	11799346
ors	O	-1	11799346
revie@@	O	-1	11799346
w@@	O	-1	11799346
ed	O	-1	11799346
reported	O	-1	11799346
cases	O	-1	11799346
of	O	-1	11799346
anti@@	O	-1	11799346
bio@@	O	-1	11799346
tic@@	O	-1	11799346
-induced	O	-1	11799346
man@@	B-Disease	D001714	11799346
ic	I-Disease	-1	11799346
episo@@	O	-1	11799346
des	O	-1	11799346
by	O	-1	11799346
me@@	O	-1	11799346
ans	O	-1	11799346
of	O	-1	11799346
a	O	-1	11799346
M@@	O	-1	11799346
E@@	O	-1	11799346
D@@	O	-1	11799346
L@@	O	-1	11799346
IN@@	O	-1	11799346
E	O	-1	11799346
and	O	-1	11799346
P@@	O	-1	11799346
sy@@	O	-1	11799346
ch@@	O	-1	11799346
L@@	O	-1	11799346
it	O	-1	11799346
se@@	O	-1	11799346
arc@@	O	-1	11799346
h	O	-1	11799346
for	O	-1	11799346
reports	O	-1	11799346
of	O	-1	11799346
anti@@	O	-1	11799346
bio@@	O	-1	11799346
tic@@	O	-1	11799346
-induced	O	-1	11799346
man@@	B-Disease	D001714	11799346
ia	I-Disease	-1	11799346
.	O	-1	11799346
U@@	O	-1	11799346
n@@	O	-1	11799346
pu@@	O	-1	11799346
bl@@	O	-1	11799346
ished	O	-1	11799346
reports	O	-1	11799346
were	O	-1	11799346
requ@@	O	-1	11799346
est@@	O	-1	11799346
ed	O	-1	11799346
from	O	-1	11799346
the	O	-1	11799346
W@@	O	-1	11799346
or@@	O	-1	11799346
l@@	O	-1	11799346
d	O	-1	11799346
He@@	O	-1	11799346
al@@	O	-1	11799346
th	O	-1	11799346
O@@	O	-1	11799346
r@@	O	-1	11799346
g@@	O	-1	11799346
an@@	O	-1	11799346
ization	O	-1	11799346
(@@	O	-1	11799346
W@@	O	-1	11799346
HO@@	O	-1	11799346
)	O	-1	11799346
and	O	-1	11799346
the	O	-1	11799346
F@@	O	-1	11799346
o@@	O	-1	11799346
od	O	-1	11799346
and	O	-1	11799346
D@@	O	-1	11799346
ru@@	O	-1	11799346
g	O	-1	11799346
Ad@@	O	-1	11799346
minist@@	O	-1	11799346
ration	O	-1	11799346
(@@	O	-1	11799346
F@@	O	-1	11799346
D@@	O	-1	11799346
A@@	O	-1	11799346
).	O	-1	11799346
Tw@@	O	-1	11799346
ent@@	O	-1	11799346
y-@@	O	-1	11799346
one	O	-1	11799346
reports	O	-1	11799346
of	O	-1	11799346
anti@@	O	-1	11799346
micro@@	O	-1	11799346
b@@	O	-1	11799346
i@@	O	-1	11799346
al@@	O	-1	11799346
-induced	O	-1	11799346
man@@	B-Disease	D001714	11799346
ia	I-Disease	-1	11799346
were	O	-1	11799346
found	O	-1	11799346
in	O	-1	11799346
the	O	-1	11799346
literat@@	O	-1	11799346
ure.	O	-1	11799346
There	O	-1	11799346
were	O	-1	11799346
6	O	-1	11799346
cases	O	-1	11799346
implic@@	O	-1	11799346
ating	O	-1	11799346
cl@@	B-Chemical	D017291	11799346
ari@@	I-Chemical	-1	11799346
throm@@	I-Chemical	-1	11799346
ycin	I-Chemical	-1	11799346
,	O	-1	11799346
13	O	-1	11799346
implic@@	O	-1	11799346
ating	O	-1	11799346
is@@	B-Chemical	D007538	11799346
oni@@	I-Chemical	-1	11799346
az@@	I-Chemical	-1	11799346
id	I-Chemical	-1	11799346
,	O	-1	11799346
and	O	-1	11799346
1	O	-1	11799346
case	O	-1	11799346
each	O	-1	11799346
implic@@	O	-1	11799346
ating	O	-1	11799346
ery@@	B-Chemical	D004917	11799346
throm@@	I-Chemical	-1	11799346
ycin	I-Chemical	-1	11799346
and	O	-1	11799346
am@@	B-Chemical	D000658	11799346
oxic@@	I-Chemical	-1	11799346
ill@@	I-Chemical	-1	11799346
in	I-Chemical	-1	11799346
.	O	-1	11799346
The	O	-1	11799346
W@@	O	-1	11799346
H@@	O	-1	11799346
O	O	-1	11799346
reported	O	-1	11799346
8@@	O	-1	11799346
2	O	-1	11799346
cas@@	O	-1	11799346
es.	O	-1	11799346
Of	O	-1	11799346
th@@	O	-1	11799346
es@@	O	-1	11799346
e,	O	-1	11799346
cl@@	B-Chemical	D017291	11799346
ari@@	I-Chemical	-1	11799346
throm@@	I-Chemical	-1	11799346
ycin	I-Chemical	-1	11799346
was	O	-1	11799346
implic@@	O	-1	11799346
ated	O	-1	11799346
in	O	-1	11799346
2@@	O	-1	11799346
3	O	-1	11799346
(2@@	O	-1	11799346
7.@@	O	-1	11799346
6@@	O	-1	11799346
%)	O	-1	11799346
cas@@	O	-1	11799346
es,	O	-1	11799346
ci@@	B-Chemical	D002939	11799346
prof@@	I-Chemical	-1	11799346
lo@@	I-Chemical	-1	11799346
x@@	I-Chemical	-1	11799346
ac@@	I-Chemical	-1	11799346
in	I-Chemical	-1	11799346
in	O	-1	11799346
12	O	-1	11799346
(1@@	O	-1	11799346
4.@@	O	-1	11799346
4@@	O	-1	11799346
%)	O	-1	11799346
cas@@	O	-1	11799346
es,	O	-1	11799346
and	O	-1	11799346
of@@	B-Chemical	D015242	11799346
lo@@	I-Chemical	-1	11799346
x@@	I-Chemical	-1	11799346
ac@@	I-Chemical	-1	11799346
in	I-Chemical	-1	11799346
in	O	-1	11799346
10	O	-1	11799346
(1@@	O	-1	11799346
2@@	O	-1	11799346
%)	O	-1	11799346
cas@@	O	-1	11799346
es.	O	-1	11799346
C@@	B-Chemical	D015662	11799346
ot@@	I-Chemical	-1	11799346
ri@@	I-Chemical	-1	11799346
mo@@	I-Chemical	-1	11799346
x@@	I-Chemical	-1	11799346
azole	I-Chemical	-1	11799346
,	O	-1	11799346
met@@	B-Chemical	D008795	11799346
ron@@	I-Chemical	-1	11799346
id@@	I-Chemical	-1	11799346
azole	I-Chemical	-1	11799346
,	O	-1	11799346
and	O	-1	11799346
ery@@	B-Chemical	D004917	11799346
throm@@	I-Chemical	-1	11799346
ycin	I-Chemical	-1	11799346
were	O	-1	11799346
involved	O	-1	11799346
in	O	-1	11799346
15	O	-1	11799346
reported	O	-1	11799346
man@@	B-Disease	D001714	11799346
ic	I-Disease	-1	11799346
episo@@	O	-1	11799346
d@@	O	-1	11799346
es.	O	-1	11799346
C@@	O	-1	11799346
as@@	O	-1	11799346
es	O	-1	11799346
reported	O	-1	11799346
by	O	-1	11799346
the	O	-1	11799346
F@@	O	-1	11799346
D@@	O	-1	11799346
A	O	-1	11799346
showed	O	-1	11799346
cl@@	B-Chemical	D017291	11799346
ari@@	I-Chemical	-1	11799346
throm@@	I-Chemical	-1	11799346
ycin	I-Chemical	-1	11799346
and	O	-1	11799346
ci@@	B-Chemical	D002939	11799346
prof@@	I-Chemical	-1	11799346
lo@@	I-Chemical	-1	11799346
x@@	I-Chemical	-1	11799346
ac@@	I-Chemical	-1	11799346
in	I-Chemical	-1	11799346
to	O	-1	11799346
be	O	-1	11799346
the	O	-1	11799346
most	O	-1	11799346
frequ@@	O	-1	11799346
ently	O	-1	11799346
associated	O	-1	11799346
with	O	-1	11799346
the	O	-1	11799346
development	O	-1	11799346
of	O	-1	11799346
man@@	B-Disease	D001714	11799346
ia	I-Disease	-1	11799346
.	O	-1	11799346
S@@	O	-1	11799346
t@@	O	-1	11799346
atis@@	O	-1	11799346
tical	O	-1	11799346
analysis	O	-1	11799346
of	O	-1	11799346
the	O	-1	11799346
data	O	-1	11799346
wo@@	O	-1	11799346
uld	O	-1	11799346
not	O	-1	11799346
have	O	-1	11799346
demonstrated	O	-1	11799346
a	O	-1	11799346
significant	O	-1	11799346
statis@@	O	-1	11799346
tical	O	-1	11799346
correl@@	O	-1	11799346
ative	O	-1	11799346
risk	O	-1	11799346
and	O	-1	11799346
was	O	-1	11799346
the@@	O	-1	11799346
re@@	O	-1	11799346
fore	O	-1	11799346
not	O	-1	11799346
under@@	O	-1	11799346
tak@@	O	-1	11799346
en@@	O	-1	11799346
.	O	-1	11799346
Patients	O	-1	11799346
have	O	-1	11799346
an	O	-1	11799346
increased	O	-1	11799346
risk	O	-1	11799346
of	O	-1	11799346
develop@@	O	-1	11799346
ing	O	-1	11799346
man@@	B-Disease	D001714	11799346
ia	I-Disease	-1	11799346
while	O	-1	11799346
being	O	-1	11799346
treated	O	-1	11799346
with	O	-1	11799346
anti@@	O	-1	11799346
micro@@	O	-1	11799346
b@@	O	-1	11799346
i@@	O	-1	11799346
al@@	O	-1	11799346
s.	O	-1	11799346
Although	O	-1	11799346
this	O	-1	11799346
is	O	-1	11799346
not	O	-1	11799346
a	O	-1	11799346
statis@@	O	-1	11799346
tically	O	-1	11799346
significant	O	-1	11799346
ris@@	O	-1	11799346
k@@	O	-1	11799346
,	O	-1	11799346
physi@@	O	-1	11799346
ci@@	O	-1	11799346
ans	O	-1	11799346
mus@@	O	-1	11799346
t	O	-1	11799346
be	O	-1	11799346
aw@@	O	-1	11799346
are	O	-1	11799346
of	O	-1	11799346
the	O	-1	11799346
effect	O	-1	11799346
and	O	-1	11799346
rever@@	O	-1	11799346
sib@@	O	-1	11799346
il@@	O	-1	11799346
ity.	O	-1	11799346
F@@	O	-1	11799346
urther	O	-1	11799346
re@@	O	-1	11799346
se@@	O	-1	11799346
arc@@	O	-1	11799346
h	O	-1	11799346
clear@@	O	-1	11799346
ly	O	-1	11799346
is	O	-1	11799346
requ@@	O	-1	11799346
ired	O	-1	11799346
to	O	-1	11799346
determine	O	-1	11799346
the	O	-1	11799346
incidence	O	-1	11799346
of	O	-1	11799346
anti@@	O	-1	11799346
micro@@	O	-1	11799346
b@@	O	-1	11799346
i@@	O	-1	11799346
al@@	O	-1	11799346
-induced	O	-1	11799346
man@@	B-Disease	D001714	11799346
ia	I-Disease	-1	11799346
,	O	-1	11799346
the	O	-1	11799346
rel@@	O	-1	11799346
ative	O	-1	11799346
risk	O	-1	11799346
factors	O	-1	11799346
of	O	-1	11799346
develop@@	O	-1	11799346
ing	O	-1	11799346
an	O	-1	11799346
anti@@	O	-1	11799346
micro@@	O	-1	11799346
b@@	O	-1	11799346
i@@	O	-1	11799346
al@@	O	-1	11799346
-induced	O	-1	11799346
man@@	B-Disease	D001714	11799346
ic	I-Disease	-1	11799346
episo@@	O	-1	11799346
de	O	-1	11799346
among	O	-1	11799346
various	O	-1	11799346
de@@	O	-1	11799346
mo@@	O	-1	11799346
graph@@	O	-1	11799346
ic	O	-1	11799346
po@@	O	-1	11799346
pul@@	O	-1	11799346
ation@@	O	-1	11799346
s,	O	-1	11799346
and	O	-1	11799346
the	O	-1	11799346
incidence	O	-1	11799346
of	O	-1	11799346
patients	O	-1	11799346
who	O	-1	11799346
continu@@	O	-1	11799346
e	O	-1	11799346
to	O	-1	11799346
have	O	-1	11799346
per@@	O	-1	11799346
sist@@	O	-1	11799346
ent	O	-1	11799346
aff@@	O	-1	11799346
ective	O	-1	11799346
disorder@@	O	-1	11799346
s	O	-1	11799346
on@@	O	-1	11799346
ce	O	-1	11799346
the	O	-1	11799346
initial	O	-1	11799346
episo@@	O	-1	11799346
de@@	O	-1	11799346
,	O	-1	11799346
which	O	-1	11799346
occur@@	O	-1	11799346
s	O	-1	11799346
while	O	-1	11799346
the	O	-1	11799346
patient	O	-1	11799346
is	O	-1	11799346
taking	O	-1	11799346
anti@@	O	-1	11799346
bio@@	O	-1	11799346
tic@@	O	-1	11799346
s,	O	-1	11799346
sub@@	O	-1	11799346
si@@	O	-1	11799346
d@@	O	-1	11799346
es.	O	-1	11799346
The	O	-1	11799346
au@@	O	-1	11799346
th@@	O	-1	11799346
ors	O	-1	11799346
el@@	O	-1	11799346
ected	O	-1	11799346
to	O	-1	11799346
nam@@	O	-1	11799346
e	O	-1	11799346
this	O	-1	11799346
syndrome	O	-1	11799346
"	O	-1	11799346
anti@@	B-Disease	D001714	11799346
b@@	I-Disease	-1	11799346
i@@	I-Disease	-1	11799346
om@@	I-Disease	-1	11799346
an@@	I-Disease	-1	11799346
ia	I-Disease	-1	11799346
.@@	O	-1	11799346
"	O	-1	11799346

L@@	B-Chemical	D007980	11835460
evo@@	I-Chemical	-1	11835460
dopa	I-Chemical	-1	11835460
-induced	O	-1	11835460
oc@@	B-Disease	D015835	11835460
ular	I-Disease	-1	11835460
dyskine@@	I-Disease	-1	11835460
si@@	I-Disease	-1	11835460
as	I-Disease	-1	11835460
in	O	-1	11835460
Parkinson's	B-Disease	D010300	11835460
disease	I-Disease	-1	11835460
.	O	-1	11835460
L@@	B-Chemical	D007980	11835460
evo@@	I-Chemical	-1	11835460
dopa	I-Chemical	-1	11835460
-induced	O	-1	11835460
oc@@	B-Disease	D015835	11835460
ular	I-Disease	-1	11835460
dyskine@@	I-Disease	-1	11835460
si@@	I-Disease	-1	11835460
as	I-Disease	-1	11835460
are	O	-1	11835460
very	O	-1	11835460
un@@	O	-1	11835460
common@@	O	-1	11835460
.	O	-1	11835460
U@@	O	-1	11835460
su@@	O	-1	11835460
ally	O	-1	11835460
they	O	-1	11835460
occ@@	O	-1	11835460
ur	O	-1	11835460
sim@@	O	-1	11835460
ult@@	O	-1	11835460
ane@@	O	-1	11835460
ously	O	-1	11835460
with	O	-1	11835460
lim@@	O	-1	11835460
b	O	-1	11835460
pe@@	O	-1	11835460
ak@@	O	-1	11835460
-@@	O	-1	11835460
dose	O	-1	11835460
ch@@	B-Disease	D002819	11835460
ore@@	I-Disease	-1	11835460
atic	I-Disease	-1	11835460
dyskine@@	I-Disease	-1	11835460
si@@	I-Disease	-1	11835460
as	I-Disease	-1	11835460
.	O	-1	11835460
We	O	-1	11835460
report	O	-1	11835460
on	O	-1	11835460
a	O	-1	11835460
patient	O	-1	11835460
with	O	-1	11835460
le@@	O	-1	11835460
f@@	O	-1	11835460
tw@@	O	-1	11835460
ard	O	-1	11835460
and	O	-1	11835460
up@@	O	-1	11835460
war@@	O	-1	11835460
d	O	-1	11835460
de@@	O	-1	11835460
vi@@	O	-1	11835460
ations	O	-1	11835460
of	O	-1	11835460
g@@	O	-1	11835460
az@@	O	-1	11835460
e	O	-1	11835460
during	O	-1	11835460
the	O	-1	11835460
pe@@	O	-1	11835460
a@@	O	-1	11835460
k	O	-1	11835460
effect	O	-1	11835460
of	O	-1	11835460
levo@@	B-Chemical	D007980	11835460
dopa	I-Chemical	-1	11835460
,	O	-1	11835460
and	O	-1	11835460
hypo@@	O	-1	11835460
the@@	O	-1	11835460
size	O	-1	11835460
that	O	-1	11835460
a	O	-1	11835460
severe	O	-1	11835460
dop@@	O	-1	11835460
aminergic	O	-1	11835460
d@@	O	-1	11835460
en@@	O	-1	11835460
er@@	O	-1	11835460
v@@	O	-1	11835460
ation	O	-1	11835460
in	O	-1	11835460
the	O	-1	11835460
ca@@	O	-1	11835460
ud@@	O	-1	11835460
ate	O	-1	11835460
nucle@@	O	-1	11835460
us	O	-1	11835460
is	O	-1	11835460
ne@@	O	-1	11835460
ed@@	O	-1	11835460
ed	O	-1	11835460
for	O	-1	11835460
the	O	-1	11835460
appear@@	O	-1	11835460
ance	O	-1	11835460
of	O	-1	11835460
these	O	-1	11835460
levo@@	B-Chemical	D007980	11835460
dopa	I-Chemical	-1	11835460
-@@	O	-1	11835460
induce	O	-1	11835460
oc@@	B-Disease	D015835	11835460
ular	I-Disease	-1	11835460
dyskine@@	I-Disease	-1	11835460
si@@	I-Disease	-1	11835460
as	I-Disease	-1	11835460
.	O	-1	11835460

A	O	-1	11915580
compar@@	O	-1	11915580
ison	O	-1	11915580
of	O	-1	11915580
glyc@@	B-Chemical	D005996	11915580
ery@@	I-Chemical	-1	11915580
l	I-Chemical	-1	11915580
tr@@	I-Chemical	-1	11915580
in@@	I-Chemical	-1	11915580
it@@	I-Chemical	-1	11915580
rate	I-Chemical	-1	11915580
with	O	-1	11915580
dic@@	B-Chemical	D004008	11915580
lo@@	I-Chemical	-1	11915580
f@@	I-Chemical	-1	11915580
en@@	I-Chemical	-1	11915580
a@@	I-Chemical	-1	11915580
c	I-Chemical	-1	11915580
for	O	-1	11915580
the	O	-1	11915580
treatment	O	-1	11915580
of	O	-1	11915580
prim@@	O	-1	11915580
ary	O	-1	11915580
dys@@	B-Disease	D004412	11915580
men@@	I-Disease	-1	11915580
or@@	I-Disease	-1	11915580
r@@	I-Disease	-1	11915580
he@@	I-Disease	-1	11915580
a	I-Disease	-1	11915580
:	O	-1	11915580
an	O	-1	11915580
o@@	O	-1	11915580
pen@@	O	-1	11915580
,	O	-1	11915580
random@@	O	-1	11915580
iz@@	O	-1	11915580
ed,	O	-1	11915580
cros@@	O	-1	11915580
s-@@	O	-1	11915580
over	O	-1	11915580
tri@@	O	-1	11915580
al.	O	-1	11915580
P@@	O	-1	11915580
ri@@	O	-1	11915580
m@@	O	-1	11915580
ary	O	-1	11915580
dys@@	B-Disease	D004412	11915580
men@@	I-Disease	-1	11915580
or@@	I-Disease	-1	11915580
r@@	I-Disease	-1	11915580
he@@	I-Disease	-1	11915580
a	I-Disease	-1	11915580
is	O	-1	11915580
a	O	-1	11915580
syndrome	O	-1	11915580
character@@	O	-1	11915580
ized	O	-1	11915580
by	O	-1	11915580
pa@@	O	-1	11915580
infu@@	O	-1	11915580
l	O	-1	11915580
u@@	O	-1	11915580
ter@@	O	-1	11915580
ine	O	-1	11915580
contrac@@	O	-1	11915580
til@@	O	-1	11915580
ity	O	-1	11915580
caused	O	-1	11915580
by	O	-1	11915580
a	O	-1	11915580
hyper@@	O	-1	11915580
secre@@	O	-1	11915580
tion	O	-1	11915580
of	O	-1	11915580
endo@@	O	-1	11915580
me@@	O	-1	11915580
trial	O	-1	11915580
pro@@	B-Chemical	D011453	11915580
st@@	I-Chemical	-1	11915580
ag@@	I-Chemical	-1	11915580
l@@	I-Chemical	-1	11915580
and@@	I-Chemical	-1	11915580
ins	I-Chemical	-1	11915580
;	O	-1	11915580
non-@@	O	-1	11915580
steroid@@	O	-1	11915580
al	O	-1	11915580
anti@@	O	-1	11915580
-@@	O	-1	11915580
inflam@@	O	-1	11915580
mat@@	O	-1	11915580
ory	O	-1	11915580
drugs	O	-1	11915580
are	O	-1	11915580
the	O	-1	11915580
first	O	-1	11915580
ch@@	O	-1	11915580
o@@	O	-1	11915580
ic@@	O	-1	11915580
e	O	-1	11915580
for	O	-1	11915580
its	O	-1	11915580
treatment.	O	-1	11915580
However,	O	-1	11915580
in	O	-1	11915580
viv@@	O	-1	11915580
o	O	-1	11915580
and	O	-1	11915580
in	O	-1	11915580
vit@@	O	-1	11915580
r@@	O	-1	11915580
o	O	-1	11915580
studies	O	-1	11915580
have	O	-1	11915580
demonstrated	O	-1	11915580
that	O	-1	11915580
my@@	O	-1	11915580
o@@	O	-1	11915580
me@@	O	-1	11915580
trial	O	-1	11915580
cells	O	-1	11915580
are	O	-1	11915580
also	O	-1	11915580
t@@	O	-1	11915580
arg@@	O	-1	11915580
et@@	O	-1	11915580
s	O	-1	11915580
of	O	-1	11915580
the	O	-1	11915580
rel@@	O	-1	11915580
ax@@	O	-1	11915580
ant	O	-1	11915580
effects	O	-1	11915580
of	O	-1	11915580
nit@@	B-Chemical	D009569	11915580
ric	I-Chemical	-1	11915580
ox@@	I-Chemical	-1	11915580
ide	I-Chemical	-1	11915580
(	O	-1	11915580
N@@	B-Chemical	D009569	11915580
O	I-Chemical	-1	11915580
).	O	-1	11915580
The	O	-1	11915580
a@@	O	-1	11915580
im	O	-1	11915580
of	O	-1	11915580
the	O	-1	11915580
present	O	-1	11915580
study	O	-1	11915580
was	O	-1	11915580
to	O	-1	11915580
determine	O	-1	11915580
the	O	-1	11915580
efficacy	O	-1	11915580
of	O	-1	11915580
glyc@@	B-Chemical	D005996	11915580
ery@@	I-Chemical	-1	11915580
l	I-Chemical	-1	11915580
tr@@	I-Chemical	-1	11915580
in@@	I-Chemical	-1	11915580
it@@	I-Chemical	-1	11915580
rate	I-Chemical	-1	11915580
(	O	-1	11915580
G@@	B-Chemical	D005996	11915580
T@@	I-Chemical	-1	11915580
N	I-Chemical	-1	11915580
),	O	-1	11915580
an	O	-1	11915580
N@@	B-Chemical	D009569	11915580
O	I-Chemical	-1	11915580
d@@	O	-1	11915580
on@@	O	-1	11915580
or@@	O	-1	11915580
,	O	-1	11915580
in	O	-1	11915580
the	O	-1	11915580
resol@@	O	-1	11915580
u@@	O	-1	11915580
tion	O	-1	11915580
of	O	-1	11915580
prim@@	O	-1	11915580
ary	O	-1	11915580
dys@@	B-Disease	D004412	11915580
men@@	I-Disease	-1	11915580
or@@	I-Disease	-1	11915580
r@@	I-Disease	-1	11915580
he@@	I-Disease	-1	11915580
a	I-Disease	-1	11915580
in	O	-1	11915580
compar@@	O	-1	11915580
ison	O	-1	11915580
with	O	-1	11915580
dic@@	B-Chemical	D004008	11915580
lo@@	I-Chemical	-1	11915580
f@@	I-Chemical	-1	11915580
en@@	I-Chemical	-1	11915580
a@@	I-Chemical	-1	11915580
c	I-Chemical	-1	11915580
(	O	-1	11915580
D@@	B-Chemical	D004008	11915580
C@@	I-Chemical	-1	11915580
F	I-Chemical	-1	11915580
).	O	-1	11915580
A	O	-1	11915580
total	O	-1	11915580
of	O	-1	11915580
24	O	-1	11915580
patients	O	-1	11915580
with	O	-1	11915580
the	O	-1	11915580
diagnosis	O	-1	11915580
of	O	-1	11915580
severe	O	-1	11915580
prim@@	O	-1	11915580
ary	O	-1	11915580
dys@@	B-Disease	D004412	11915580
men@@	I-Disease	-1	11915580
or@@	I-Disease	-1	11915580
r@@	I-Disease	-1	11915580
he@@	I-Disease	-1	11915580
a	I-Disease	-1	11915580
were	O	-1	11915580
studied	O	-1	11915580
during	O	-1	11915580
two	O	-1	11915580
con@@	O	-1	11915580
sec@@	O	-1	11915580
utive	O	-1	11915580
men@@	O	-1	11915580
st@@	O	-1	11915580
ru@@	O	-1	11915580
al	O	-1	11915580
cy@@	O	-1	11915580
cl@@	O	-1	11915580
es.	O	-1	11915580
In	O	-1	11915580
an	O	-1	11915580
o@@	O	-1	11915580
pen@@	O	-1	11915580
,	O	-1	11915580
cros@@	O	-1	11915580
s-@@	O	-1	11915580
o@@	O	-1	11915580
ver,	O	-1	11915580
controlled	O	-1	11915580
de@@	O	-1	11915580
sign@@	O	-1	11915580
,	O	-1	11915580
patients	O	-1	11915580
were	O	-1	11915580
randomized	O	-1	11915580
to	O	-1	11915580
recei@@	O	-1	11915580
ve	O	-1	11915580
either	O	-1	11915580
D@@	B-Chemical	D004008	11915580
C@@	I-Chemical	-1	11915580
F	I-Chemical	-1	11915580
per	O	-1	11915580
o@@	O	-1	11915580
s	O	-1	11915580
or	O	-1	11915580
G@@	B-Chemical	D005996	11915580
T@@	I-Chemical	-1	11915580
N	I-Chemical	-1	11915580
pat@@	O	-1	11915580
ch@@	O	-1	11915580
es	O	-1	11915580
the	O	-1	11915580
first	O	-1	11915580
days	O	-1	11915580
of	O	-1	11915580
m@@	O	-1	11915580
ens@@	O	-1	11915580
es,	O	-1	11915580
when	O	-1	11915580
men@@	O	-1	11915580
st@@	O	-1	11915580
ru@@	O	-1	11915580
al	O	-1	11915580
c@@	O	-1	11915580
ram@@	O	-1	11915580
p@@	O	-1	11915580
s	O	-1	11915580
b@@	O	-1	11915580
ec@@	O	-1	11915580
am@@	O	-1	11915580
e	O	-1	11915580
un@@	O	-1	11915580
en@@	O	-1	11915580
dur@@	O	-1	11915580
able@@	O	-1	11915580
.	O	-1	11915580
In	O	-1	11915580
the	O	-1	11915580
subsequ@@	O	-1	11915580
ent	O	-1	11915580
cyc@@	O	-1	11915580
le	O	-1	11915580
the	O	-1	11915580
other	O	-1	11915580
treatment	O	-1	11915580
was	O	-1	11915580
use@@	O	-1	11915580
d.	O	-1	11915580
Patients	O	-1	11915580
received	O	-1	11915580
up	O	-1	11915580
to	O	-1	11915580
3	O	-1	11915580
dos@@	O	-1	11915580
es@@	O	-1	11915580
/@@	O	-1	11915580
day	O	-1	11915580
of	O	-1	11915580
50	O	-1	11915580
mg	O	-1	11915580
D@@	B-Chemical	D004008	11915580
C@@	I-Chemical	-1	11915580
F	I-Chemical	-1	11915580
or	O	-1	11915580
2.@@	O	-1	11915580
5	O	-1	11915580
mg/@@	O	-1	11915580
24	O	-1	11915580
h	O	-1	11915580
trans@@	O	-1	11915580
der@@	O	-1	11915580
m@@	O	-1	11915580
al	O	-1	11915580
G@@	B-Chemical	D005996	11915580
T@@	I-Chemical	-1	11915580
N	I-Chemical	-1	11915580
for	O	-1	11915580
the	O	-1	11915580
first	O	-1	11915580
3	O	-1	11915580
days	O	-1	11915580
of	O	-1	11915580
the	O	-1	11915580
cyc@@	O	-1	11915580
le@@	O	-1	11915580
,	O	-1	11915580
ac@@	O	-1	11915580
cor@@	O	-1	11915580
ding	O	-1	11915580
to	O	-1	11915580
their	O	-1	11915580
ne@@	O	-1	11915580
ed@@	O	-1	11915580
s.	O	-1	11915580
The	O	-1	11915580
partic@@	O	-1	11915580
ip@@	O	-1	11915580
ants	O	-1	11915580
recor@@	O	-1	11915580
ded	O	-1	11915580
men@@	O	-1	11915580
st@@	O	-1	11915580
ru@@	O	-1	11915580
al	O	-1	11915580
symptoms	O	-1	11915580
and	O	-1	11915580
possible	O	-1	11915580
side@@	O	-1	11915580
-@@	O	-1	11915580
effects	O	-1	11915580
at	O	-1	11915580
different	O	-1	11915580
times	O	-1	11915580
(@@	O	-1	11915580
0@@	O	-1	11915580
,	O	-1	11915580
3@@	O	-1	11915580
0@@	O	-1	11915580
,	O	-1	11915580
6@@	O	-1	11915580
0@@	O	-1	11915580
,	O	-1	11915580
1@@	O	-1	11915580
20	O	-1	11915580
minut@@	O	-1	11915580
es@@	O	-1	11915580
)	O	-1	11915580
after	O	-1	11915580
the	O	-1	11915580
first	O	-1	11915580
dose	O	-1	11915580
of	O	-1	11915580
medic@@	O	-1	11915580
ation	O	-1	11915580
on	O	-1	11915580
the	O	-1	11915580
first	O	-1	11915580
day	O	-1	11915580
of	O	-1	11915580
the	O	-1	11915580
cyc@@	O	-1	11915580
le@@	O	-1	11915580
,	O	-1	11915580
with	O	-1	11915580
both	O	-1	11915580
drug@@	O	-1	11915580
s.	O	-1	11915580
The	O	-1	11915580
difference	O	-1	11915580
in	O	-1	11915580
pain	B-Disease	D010146	11915580
int@@	O	-1	11915580
ensity	O	-1	11915580
scor@@	O	-1	11915580
e	O	-1	11915580
(D@@	O	-1	11915580
P@@	O	-1	11915580
I@@	O	-1	11915580
)	O	-1	11915580
was	O	-1	11915580
the	O	-1	11915580
ma@@	O	-1	11915580
in	O	-1	11915580
outcom@@	O	-1	11915580
e	O	-1	11915580
vari@@	O	-1	11915580
able@@	O	-1	11915580
.	O	-1	11915580
B@@	O	-1	11915580
oth	O	-1	11915580
treat@@	O	-1	11915580
ments	O	-1	11915580
significantly	O	-1	11915580
reduced	O	-1	11915580
D@@	O	-1	11915580
P@@	O	-1	11915580
I	O	-1	11915580
by	O	-1	11915580
the	O	-1	11915580
3@@	O	-1	11915580
0@@	O	-1	11915580
th	O	-1	11915580
min@@	O	-1	11915580
ute	O	-1	11915580
(	O	-1	11915580
G@@	B-Chemical	D005996	11915580
T@@	I-Chemical	-1	11915580
N	I-Chemical	-1	11915580
,	O	-1	11915580
-1@@	O	-1	11915580
2.@@	O	-1	11915580
8	O	-1	11915580
+/-	O	-1	11915580
1@@	O	-1	11915580
7.@@	O	-1	11915580
9@@	O	-1	11915580
;	O	-1	11915580
D@@	B-Chemical	D004008	11915580
C@@	I-Chemical	-1	11915580
F	I-Chemical	-1	11915580
,	O	-1	11915580
-1@@	O	-1	11915580
8.@@	O	-1	11915580
9	O	-1	11915580
+/-	O	-1	11915580
1@@	O	-1	11915580
6.@@	O	-1	11915580
6@@	O	-1	11915580
).	O	-1	11915580
However,	O	-1	11915580
D@@	B-Chemical	D004008	11915580
C@@	I-Chemical	-1	11915580
F	I-Chemical	-1	11915580
continu@@	O	-1	11915580
ed	O	-1	11915580
to	O	-1	11915580
be	O	-1	11915580
effective	O	-1	11915580
in	O	-1	11915580
reduc@@	O	-1	11915580
ing	O	-1	11915580
p@@	B-Disease	D017699	11915580
el@@	I-Disease	-1	11915580
v@@	I-Disease	-1	11915580
ic	I-Disease	-1	11915580
pain	I-Disease	-1	11915580
for	O	-1	11915580
two	O	-1	11915580
hour@@	O	-1	11915580
s,	O	-1	11915580
whereas	O	-1	11915580
G@@	B-Chemical	D005996	11915580
T@@	I-Chemical	-1	11915580
N	I-Chemical	-1	11915580
sco@@	O	-1	11915580
res	O	-1	11915580
remained	O	-1	11915580
more	O	-1	11915580
or	O	-1	11915580
less	O	-1	11915580
st@@	O	-1	11915580
able	O	-1	11915580
after	O	-1	11915580
30	O	-1	11915580
min	O	-1	11915580
and	O	-1	11915580
significantly	O	-1	11915580
higher	O	-1	11915580
than	O	-1	11915580
those	O	-1	11915580
for	O	-1	11915580
DF@@	O	-1	11915580
C	O	-1	11915580
(@@	O	-1	11915580
after	O	-1	11915580
one	O	-1	11915580
hour@@	O	-1	11915580
:	O	-1	11915580
G@@	B-Chemical	D005996	11915580
T@@	I-Chemical	-1	11915580
N	I-Chemical	-1	11915580
,	O	-1	11915580
-1@@	O	-1	11915580
2.@@	O	-1	11915580
8	O	-1	11915580
+/-	O	-1	11915580
1@@	O	-1	11915580
7.@@	O	-1	11915580
9@@	O	-1	11915580
;	O	-1	11915580
DF@@	O	-1	11915580
C@@	O	-1	11915580
,	O	-1	11915580
-1@@	O	-1	11915580
8.@@	O	-1	11915580
9	O	-1	11915580
+/-	O	-1	11915580
1@@	O	-1	11915580
6.@@	O	-1	11915580
6	O	-1	11915580
and	O	-1	11915580
after	O	-1	11915580
two	O	-1	11915580
hour@@	O	-1	11915580
s:	O	-1	11915580
G@@	B-Chemical	D005996	11915580
T@@	I-Chemical	-1	11915580
N	I-Chemical	-1	11915580
,	O	-1	11915580
-@@	O	-1	11915580
2@@	O	-1	11915580
3.@@	O	-1	11915580
7	O	-1	11915580
+/-	O	-1	11915580
2@@	O	-1	11915580
0.@@	O	-1	11915580
5@@	O	-1	11915580
;	O	-1	11915580
DF@@	O	-1	11915580
C@@	O	-1	11915580
,	O	-1	11915580
-@@	O	-1	11915580
5@@	O	-1	11915580
9.@@	O	-1	11915580
7	O	-1	11915580
+/-	O	-1	11915580
1@@	O	-1	11915580
7.@@	O	-1	11915580
9@@	O	-1	11915580
,	O	-1	11915580
p	O	-1	11915580
=	O	-1	11915580
0.00@@	O	-1	11915580
0@@	O	-1	11915580
1).	O	-1	11915580
L@@	B-Disease	D017116	11915580
o@@	I-Disease	-1	11915580
w	I-Disease	-1	11915580
bac@@	I-Disease	-1	11915580
k	I-Disease	-1	11915580
pain	I-Disease	-1	11915580
was	O	-1	11915580
also	O	-1	11915580
re@@	O	-1	11915580
li@@	O	-1	11915580
ev@@	O	-1	11915580
ed	O	-1	11915580
by	O	-1	11915580
both	O	-1	11915580
drug@@	O	-1	11915580
s.	O	-1	11915580
He@@	B-Disease	D006261	11915580
ad@@	I-Disease	-1	11915580
ac@@	I-Disease	-1	11915580
he	I-Disease	-1	11915580
was	O	-1	11915580
significantly	O	-1	11915580
increased	O	-1	11915580
by	O	-1	11915580
G@@	B-Chemical	D005996	11915580
T@@	I-Chemical	-1	11915580
N	I-Chemical	-1	11915580
but	O	-1	11915580
not	O	-1	11915580
by	O	-1	11915580
D@@	B-Chemical	D004008	11915580
C@@	I-Chemical	-1	11915580
F	I-Chemical	-1	11915580
.	O	-1	11915580
E@@	O	-1	11915580
ight	O	-1	11915580
patients	O	-1	11915580
sto@@	O	-1	11915580
pp@@	O	-1	11915580
ed	O	-1	11915580
using	O	-1	11915580
G@@	B-Chemical	D005996	11915580
T@@	I-Chemical	-1	11915580
N	I-Chemical	-1	11915580
because	O	-1	11915580
headac@@	B-Disease	D006261	11915580
he	I-Disease	-1	11915580
-@@	O	-1	11915580
-@@	O	-1	11915580
at@@	O	-1	11915580
tri@@	O	-1	11915580
but@@	O	-1	11915580
ed	O	-1	11915580
to	O	-1	11915580
its	O	-1	11915580
use@@	O	-1	11915580
-@@	O	-1	11915580
-@@	O	-1	11915580
b@@	O	-1	11915580
ec@@	O	-1	11915580
am@@	O	-1	11915580
e	O	-1	11915580
int@@	O	-1	11915580
oler@@	O	-1	11915580
able@@	O	-1	11915580
.	O	-1	11915580
These	O	-1	11915580
findings	O	-1	11915580
indicate	O	-1	11915580
that	O	-1	11915580
G@@	B-Chemical	D005996	11915580
T@@	I-Chemical	-1	11915580
N	I-Chemical	-1	11915580
has	O	-1	11915580
a	O	-1	11915580
reduced	O	-1	11915580
efficacy	O	-1	11915580
and	O	-1	11915580
toler@@	O	-1	11915580
ability	O	-1	11915580
by	O	-1	11915580
compar@@	O	-1	11915580
ison	O	-1	11915580
with	O	-1	11915580
D@@	B-Chemical	D004008	11915580
C@@	I-Chemical	-1	11915580
F	I-Chemical	-1	11915580
in	O	-1	11915580
the	O	-1	11915580
treatment	O	-1	11915580
of	O	-1	11915580
prim@@	O	-1	11915580
ary	O	-1	11915580
dys@@	B-Disease	D004412	11915580
men@@	I-Disease	-1	11915580
or@@	I-Disease	-1	11915580
r@@	I-Disease	-1	11915580
he@@	I-Disease	-1	11915580
a	I-Disease	-1	11915580
.	O	-1	11915580

T@@	B-Chemical	C055603	11936424
em@@	I-Chemical	-1	11936424
oc@@	I-Chemical	-1	11936424
apri@@	I-Chemical	-1	11936424
l	I-Chemical	-1	11936424
,	O	-1	11936424
a	O	-1	11936424
long@@	O	-1	11936424
-@@	O	-1	11936424
act@@	O	-1	11936424
ing	O	-1	11936424
non-@@	O	-1	11936424
S@@	O	-1	11936424
H	O	-1	11936424
group	O	-1	11936424
angiotens@@	B-Chemical	D000809	11936424
in	I-Chemical	-1	11936424
conver@@	O	-1	11936424
ting	O	-1	11936424
enzyme	O	-1	11936424
inhibitor@@	O	-1	11936424
,	O	-1	11936424
mod@@	O	-1	11936424
ul@@	O	-1	11936424
ates	O	-1	11936424
glomerular	B-Disease	D007674	11936424
injury	I-Disease	-1	11936424
in	O	-1	11936424
chronic	O	-1	11936424
p@@	B-Chemical	D011692	11936424
uro@@	I-Chemical	-1	11936424
m@@	I-Chemical	-1	11936424
ycin	I-Chemical	-1	11936424
amin@@	I-Chemical	-1	11936424
on@@	I-Chemical	-1	11936424
ucle@@	I-Chemical	-1	11936424
o@@	I-Chemical	-1	11936424
side	I-Chemical	-1	11936424
nephro@@	B-Disease	D009401	11936424
sis	I-Disease	-1	11936424
.	O	-1	11936424
The	O	-1	11936424
pur@@	O	-1	11936424
p@@	O	-1	11936424
ose	O	-1	11936424
of	O	-1	11936424
the	O	-1	11936424
present	O	-1	11936424
study	O	-1	11936424
was	O	-1	11936424
to	O	-1	11936424
determine	O	-1	11936424
whether	O	-1	11936424
chronic	O	-1	11936424
administration	O	-1	11936424
of	O	-1	11936424
tem@@	B-Chemical	C055603	11936424
oc@@	I-Chemical	-1	11936424
apri@@	I-Chemical	-1	11936424
l	I-Chemical	-1	11936424
,	O	-1	11936424
a	O	-1	11936424
long@@	O	-1	11936424
-@@	O	-1	11936424
act@@	O	-1	11936424
ing	O	-1	11936424
non-@@	O	-1	11936424
S@@	O	-1	11936424
H	O	-1	11936424
group	O	-1	11936424
angiotens@@	B-Chemical	D000809	11936424
in	I-Chemical	-1	11936424
conver@@	O	-1	11936424
ting	O	-1	11936424
enzyme	O	-1	11936424
(@@	O	-1	11936424
AC@@	O	-1	11936424
E@@	O	-1	11936424
)	O	-1	11936424
inhibitor@@	O	-1	11936424
,	O	-1	11936424
reduced	O	-1	11936424
proteinuria	B-Disease	D011507	11936424
,	O	-1	11936424
inhibited	O	-1	11936424
glomerular	O	-1	11936424
hyper@@	B-Disease	D006984	11936424
tro@@	I-Disease	-1	11936424
ph@@	I-Disease	-1	11936424
y	I-Disease	-1	11936424
and	O	-1	11936424
prevent@@	O	-1	11936424
ed	O	-1	11936424
glomer@@	B-Disease	D005921	11936424
u@@	I-Disease	-1	11936424
los@@	I-Disease	-1	11936424
clero@@	I-Disease	-1	11936424
sis	I-Disease	-1	11936424
in	O	-1	11936424
chronic	O	-1	11936424
p@@	B-Chemical	D011692	11936424
uro@@	I-Chemical	-1	11936424
m@@	I-Chemical	-1	11936424
ycin	I-Chemical	-1	11936424
amin@@	I-Chemical	-1	11936424
on@@	I-Chemical	-1	11936424
ucle@@	I-Chemical	-1	11936424
o@@	I-Chemical	-1	11936424
side	I-Chemical	-1	11936424
(	O	-1	11936424
PA@@	B-Chemical	D011692	11936424
N	I-Chemical	-1	11936424
)	O	-1	11936424
-	O	-1	11936424
induced	O	-1	11936424
nephro@@	B-Disease	D009404	11936424
tic	I-Disease	-1	11936424
rats.	O	-1	11936424
Ne@@	B-Disease	D009401	11936424
ph@@	I-Disease	-1	11936424
ro@@	I-Disease	-1	11936424
sis	I-Disease	-1	11936424
was	O	-1	11936424
induced	O	-1	11936424
by	O	-1	11936424
injection	O	-1	11936424
of	O	-1	11936424
PA@@	B-Chemical	D011692	11936424
N	I-Chemical	-1	11936424
(1@@	O	-1	11936424
5@@	O	-1	11936424
mg/@@	O	-1	11936424
10@@	O	-1	11936424
0@@	O	-1	11936424
g	O	-1	11936424
body	O	-1	11936424
weigh@@	O	-1	11936424
t@@	O	-1	11936424
)	O	-1	11936424
in	O	-1	11936424
male	O	-1	11936424
S@@	O	-1	11936424
pra@@	O	-1	11936424
gu@@	O	-1	11936424
e-@@	O	-1	11936424
D@@	O	-1	11936424
aw@@	O	-1	11936424
le@@	O	-1	11936424
y	O	-1	11936424
(S@@	O	-1	11936424
D)	O	-1	11936424
rats.	O	-1	11936424
F@@	O	-1	11936424
our	O	-1	11936424
groups	O	-1	11936424
were	O	-1	11936424
use@@	O	-1	11936424
d,	O	-1	11936424
i@@	O	-1	11936424
)	O	-1	11936424
the	O	-1	11936424
PA@@	B-Chemical	D011692	11936424
N	I-Chemical	-1	11936424
group	O	-1	11936424
(1@@	O	-1	11936424
4@@	O	-1	11936424
),	O	-1	11936424
i@@	O	-1	11936424
i@@	O	-1	11936424
)	O	-1	11936424
PA@@	B-Chemical	D011692	11936424
N	I-Chemical	-1	11936424
/	O	-1	11936424
tem@@	B-Chemical	C055603	11936424
oc@@	I-Chemical	-1	11936424
apri@@	I-Chemical	-1	11936424
l	I-Chemical	-1	11936424
(1@@	O	-1	11936424
3@@	O	-1	11936424
),	O	-1	11936424
i@@	O	-1	11936424
i@@	O	-1	11936424
i@@	O	-1	11936424
)	O	-1	11936424
tem@@	B-Chemical	C055603	11936424
oc@@	I-Chemical	-1	11936424
apri@@	I-Chemical	-1	11936424
l	I-Chemical	-1	11936424
(1@@	O	-1	11936424
4@@	O	-1	11936424
)	O	-1	11936424
and	O	-1	11936424
i@@	O	-1	11936424
v@@	O	-1	11936424
)	O	-1	11936424
un@@	O	-1	11936424
treated	O	-1	11936424
controls	O	-1	11936424
(1@@	O	-1	11936424
5@@	O	-1	11936424
).	O	-1	11936424
T@@	B-Chemical	C055603	11936424
em@@	I-Chemical	-1	11936424
oc@@	I-Chemical	-1	11936424
apri@@	I-Chemical	-1	11936424
l	I-Chemical	-1	11936424
(@@	O	-1	11936424
8	O	-1	11936424
mg/k@@	O	-1	11936424
g/@@	O	-1	11936424
day@@	O	-1	11936424
)	O	-1	11936424
was	O	-1	11936424
administered	O	-1	11936424
to	O	-1	11936424
the	O	-1	11936424
rats	O	-1	11936424
which	O	-1	11936424
were	O	-1	11936424
k@@	O	-1	11936424
ill@@	O	-1	11936424
ed	O	-1	11936424
at	O	-1	11936424
weeks	O	-1	11936424
4@@	O	-1	11936424
,	O	-1	11936424
14	O	-1	11936424
or	O	-1	11936424
20@@	O	-1	11936424
.	O	-1	11936424
A@@	O	-1	11936424
t	O	-1	11936424
each	O	-1	11936424
time	O	-1	11936424
po@@	O	-1	11936424
int@@	O	-1	11936424
,	O	-1	11936424
systolic	O	-1	11936424
blood	O	-1	11936424
pressure	O	-1	11936424
(B@@	O	-1	11936424
P@@	O	-1	11936424
),	O	-1	11936424
urinary	O	-1	11936424
protein	O	-1	11936424
ex@@	O	-1	11936424
cre@@	O	-1	11936424
tion	O	-1	11936424
and	O	-1	11936424
renal	O	-1	11936424
histo@@	O	-1	11936424
path@@	O	-1	11936424
ological	O	-1	11936424
findings	O	-1	11936424
were	O	-1	11936424
evalu@@	O	-1	11936424
at@@	O	-1	11936424
ed,	O	-1	11936424
and	O	-1	11936424
morph@@	O	-1	11936424
o@@	O	-1	11936424
me@@	O	-1	11936424
tri@@	O	-1	11936424
c	O	-1	11936424
im@@	O	-1	11936424
age	O	-1	11936424
analysis	O	-1	11936424
was	O	-1	11936424
d@@	O	-1	11936424
one.	O	-1	11936424
S@@	O	-1	11936424
y@@	O	-1	11936424
st@@	O	-1	11936424
olic	O	-1	11936424
B@@	O	-1	11936424
P	O	-1	11936424
in	O	-1	11936424
the	O	-1	11936424
PA@@	B-Chemical	D011692	11936424
N	I-Chemical	-1	11936424
group	O	-1	11936424
was	O	-1	11936424
significantly	O	-1	11936424
high	O	-1	11936424
at	O	-1	11936424
4@@	O	-1	11936424
,	O	-1	11936424
14	O	-1	11936424
and	O	-1	11936424
20	O	-1	11936424
week@@	O	-1	11936424
s,	O	-1	11936424
but	O	-1	11936424
was	O	-1	11936424
normal	O	-1	11936424
in	O	-1	11936424
the	O	-1	11936424
PA@@	B-Chemical	D011692	11936424
N	I-Chemical	-1	11936424
/	O	-1	11936424
tem@@	B-Chemical	C055603	11936424
oc@@	I-Chemical	-1	11936424
apri@@	I-Chemical	-1	11936424
l	I-Chemical	-1	11936424
group.	O	-1	11936424
U@@	O	-1	11936424
r@@	O	-1	11936424
inary	O	-1	11936424
protein	O	-1	11936424
ex@@	O	-1	11936424
cre@@	O	-1	11936424
tion	O	-1	11936424
in	O	-1	11936424
the	O	-1	11936424
PA@@	B-Chemical	D011692	11936424
N	I-Chemical	-1	11936424
group	O	-1	11936424
increased	O	-1	11936424
significant@@	O	-1	11936424
ly,	O	-1	11936424
pe@@	O	-1	11936424
ak@@	O	-1	11936424
ing	O	-1	11936424
at	O	-1	11936424
8	O	-1	11936424
day@@	O	-1	11936424
s,	O	-1	11936424
then	O	-1	11936424
decreased	O	-1	11936424
at	O	-1	11936424
4	O	-1	11936424
week@@	O	-1	11936424
s,	O	-1	11936424
but	O	-1	11936424
ro@@	O	-1	11936424
se	O	-1	11936424
ag@@	O	-1	11936424
ain	O	-1	11936424
significantly	O	-1	11936424
at	O	-1	11936424
14	O	-1	11936424
and	O	-1	11936424
20	O	-1	11936424
week@@	O	-1	11936424
s.	O	-1	11936424
T@@	B-Chemical	C055603	11936424
em@@	I-Chemical	-1	11936424
oc@@	I-Chemical	-1	11936424
apri@@	I-Chemical	-1	11936424
l	I-Chemical	-1	11936424
did	O	-1	11936424
not	O	-1	11936424
attenu@@	O	-1	11936424
ate	O	-1	11936424
proteinuria	B-Disease	D011507	11936424
at	O	-1	11936424
8	O	-1	11936424
day@@	O	-1	11936424
s,	O	-1	11936424
but	O	-1	11936424
it	O	-1	11936424
did	O	-1	11936424
mark@@	O	-1	11936424
ed@@	O	-1	11936424
ly	O	-1	11936424
lower	O	-1	11936424
it	O	-1	11936424
from	O	-1	11936424
weeks	O	-1	11936424
4	O	-1	11936424
to	O	-1	11936424
20@@	O	-1	11936424
.	O	-1	11936424
The	O	-1	11936424
glomer@@	B-Disease	D005921	11936424
u@@	I-Disease	-1	11936424
los@@	I-Disease	-1	11936424
clero@@	I-Disease	-1	11936424
sis	I-Disease	-1	11936424
in@@	O	-1	11936424
de@@	O	-1	11936424
x	O	-1	11936424
(@@	O	-1	11936424
G@@	O	-1	11936424
S@@	O	-1	11936424
I@@	O	-1	11936424
)	O	-1	11936424
was	O	-1	11936424
6.@@	O	-1	11936424
21	O	-1	11936424
%	O	-1	11936424
at	O	-1	11936424
4	O	-1	11936424
weeks	O	-1	11936424
and	O	-1	11936424
respecti@@	O	-1	11936424
vely	O	-1	11936424
2@@	O	-1	11936424
5.@@	O	-1	11936424
3@@	O	-1	11936424
5	O	-1	11936424
%	O	-1	11936424
and	O	-1	11936424
3@@	O	-1	11936424
0.@@	O	-1	11936424
4@@	O	-1	11936424
9	O	-1	11936424
%	O	-1	11936424
at	O	-1	11936424
14	O	-1	11936424
and	O	-1	11936424
20	O	-1	11936424
weeks	O	-1	11936424
in	O	-1	11936424
the	O	-1	11936424
PA@@	B-Chemical	D011692	11936424
N	I-Chemical	-1	11936424
group.	O	-1	11936424
There	O	-1	11936424
was	O	-1	11936424
a	O	-1	11936424
significant	O	-1	11936424
correl@@	O	-1	11936424
ation	O	-1	11936424
between	O	-1	11936424
urinary	O	-1	11936424
protein	O	-1	11936424
ex@@	O	-1	11936424
cre@@	O	-1	11936424
tion	O	-1	11936424
and	O	-1	11936424
G@@	O	-1	11936424
S@@	O	-1	11936424
I	O	-1	11936424
(@@	O	-1	11936424
r	O	-1	11936424
=	O	-1	11936424
0.@@	O	-1	11936424
80@@	O	-1	11936424
8@@	O	-1	11936424
,	O	-1	11936424
p	O	-1	11936424
<	O	-1	11936424
0.00@@	O	-1	11936424
0@@	O	-1	11936424
1).	O	-1	11936424
The	O	-1	11936424
rati@@	O	-1	11936424
o	O	-1	11936424
of	O	-1	11936424
glomerular	O	-1	11936424
tu@@	O	-1	11936424
ft	O	-1	11936424
a@@	O	-1	11936424
re@@	O	-1	11936424
a	O	-1	11936424
to	O	-1	11936424
the	O	-1	11936424
a@@	O	-1	11936424
re@@	O	-1	11936424
a	O	-1	11936424
of	O	-1	11936424
B@@	O	-1	11936424
o@@	O	-1	11936424
w@@	O	-1	11936424
man@@	O	-1	11936424
's	O	-1	11936424
cap@@	O	-1	11936424
sul@@	O	-1	11936424
es	O	-1	11936424
(@@	O	-1	11936424
G@@	O	-1	11936424
T@@	O	-1	11936424
/@@	O	-1	11936424
BC@@	O	-1	11936424
)	O	-1	11936424
in	O	-1	11936424
the	O	-1	11936424
PA@@	B-Chemical	D011692	11936424
N	I-Chemical	-1	11936424
group	O	-1	11936424
was	O	-1	11936424
significantly	O	-1	11936424
increas@@	O	-1	11936424
ed,	O	-1	11936424
but	O	-1	11936424
it	O	-1	11936424
was	O	-1	11936424
significantly	O	-1	11936424
lower	O	-1	11936424
in	O	-1	11936424
the	O	-1	11936424
PA@@	B-Chemical	D011692	11936424
N	I-Chemical	-1	11936424
/	O	-1	11936424
tem@@	B-Chemical	C055603	11936424
oc@@	I-Chemical	-1	11936424
apri@@	I-Chemical	-1	11936424
l	I-Chemical	-1	11936424
group.	O	-1	11936424
It	O	-1	11936424
appear@@	O	-1	11936424
s	O	-1	11936424
that	O	-1	11936424
tem@@	B-Chemical	C055603	11936424
oc@@	I-Chemical	-1	11936424
apri@@	I-Chemical	-1	11936424
l	I-Chemical	-1	11936424
was	O	-1	11936424
effective	O	-1	11936424
in	O	-1	11936424
ret@@	O	-1	11936424
ar@@	O	-1	11936424
ding	O	-1	11936424
renal	O	-1	11936424
progres@@	O	-1	11936424
sion	O	-1	11936424
and	O	-1	11936424
prot@@	O	-1	11936424
ected	O	-1	11936424
renal	O	-1	11936424
function	O	-1	11936424
in	O	-1	11936424
PA@@	B-Chemical	D011692	11936424
N	I-Chemical	-1	11936424
ne@@	B-Disease	D009401	11936424
pro@@	I-Disease	-1	11936424
tic	I-Disease	-1	11936424
rats.	O	-1	11936424

P@@	B-Disease	D006976	11988250
ul@@	I-Disease	-1	11988250
monary	I-Disease	-1	11988250
hypertension	I-Disease	-1	11988250
after	O	-1	11988250
i@@	B-Chemical	D007052	11988250
bu@@	I-Chemical	-1	11988250
prof@@	I-Chemical	-1	11988250
en	I-Chemical	-1	11988250
pro@@	O	-1	11988250
phyl@@	O	-1	11988250
ax@@	O	-1	11988250
is	O	-1	11988250
in	O	-1	11988250
very	O	-1	11988250
pre@@	O	-1	11988250
term	O	-1	11988250
inf@@	O	-1	11988250
ant@@	O	-1	11988250
s.	O	-1	11988250
We	O	-1	11988250
report	O	-1	11988250
three	O	-1	11988250
cases	O	-1	11988250
of	O	-1	11988250
severe	O	-1	11988250
hypo@@	B-Disease	D000860	11988250
x@@	I-Disease	-1	11988250
a@@	I-Disease	-1	11988250
emia	I-Disease	-1	11988250
after	O	-1	11988250
i@@	B-Chemical	D007052	11988250
bu@@	I-Chemical	-1	11988250
prof@@	I-Chemical	-1	11988250
en	I-Chemical	-1	11988250
administration	O	-1	11988250
during	O	-1	11988250
a	O	-1	11988250
random@@	O	-1	11988250
is@@	O	-1	11988250
ed	O	-1	11988250
controlled	O	-1	11988250
trial	O	-1	11988250
of	O	-1	11988250
pro@@	O	-1	11988250
phyl@@	O	-1	11988250
ac@@	O	-1	11988250
tic	O	-1	11988250
treatment	O	-1	11988250
of	O	-1	11988250
pat@@	B-Disease	D004374	11988250
ent	I-Disease	-1	11988250
duc@@	I-Disease	-1	11988250
t@@	I-Disease	-1	11988250
us	I-Disease	-1	11988250
arter@@	I-Disease	-1	11988250
i@@	I-Disease	-1	11988250
os@@	I-Disease	-1	11988250
us	I-Disease	-1	11988250
with	O	-1	11988250
i@@	B-Chemical	D007052	11988250
bu@@	I-Chemical	-1	11988250
prof@@	I-Chemical	-1	11988250
en	I-Chemical	-1	11988250
in	O	-1	11988250
pre@@	O	-1	11988250
mat@@	O	-1	11988250
ure	O	-1	11988250
inf@@	O	-1	11988250
ants	O	-1	11988250
b@@	O	-1	11988250
or@@	O	-1	11988250
n	O	-1	11988250
at	O	-1	11988250
less	O	-1	11988250
than	O	-1	11988250
2@@	O	-1	11988250
8	O	-1	11988250
weeks	O	-1	11988250
of	O	-1	11988250
g@@	O	-1	11988250
est@@	O	-1	11988250
ation.	O	-1	11988250
E@@	O	-1	11988250
ch@@	O	-1	11988250
ocardiograph@@	O	-1	11988250
y	O	-1	11988250
showed	O	-1	11988250
se@@	O	-1	11988250
ve@@	O	-1	11988250
re@@	O	-1	11988250
ly	O	-1	11988250
decreased	O	-1	11988250
pulmonary	O	-1	11988250
blood	O	-1	11988250
f@@	O	-1	11988250
low@@	O	-1	11988250
.	O	-1	11988250
H@@	B-Disease	D000860	11988250
y@@	I-Disease	-1	11988250
po@@	I-Disease	-1	11988250
x@@	I-Disease	-1	11988250
a@@	I-Disease	-1	11988250
emia	I-Disease	-1	11988250
resol@@	O	-1	11988250
ved	O	-1	11988250
qu@@	O	-1	11988250
ic@@	O	-1	11988250
k@@	O	-1	11988250
ly	O	-1	11988250
on	O	-1	11988250
in@@	O	-1	11988250
h@@	O	-1	11988250
al@@	O	-1	11988250
ed	O	-1	11988250
nit@@	B-Chemical	D009569	11988250
ric	I-Chemical	-1	11988250
ox@@	I-Chemical	-1	11988250
ide	I-Chemical	-1	11988250
therapy.	O	-1	11988250
We	O	-1	11988250
suggest	O	-1	11988250
that	O	-1	11988250
investig@@	O	-1	11988250
at@@	O	-1	11988250
ors	O	-1	11988250
involved	O	-1	11988250
in	O	-1	11988250
similar	O	-1	11988250
tri@@	O	-1	11988250
als	O	-1	11988250
pa@@	O	-1	11988250
y	O	-1	11988250
clo@@	O	-1	11988250
se	O	-1	11988250
atten@@	O	-1	11988250
tion	O	-1	11988250
to	O	-1	11988250
pulmonary	O	-1	11988250
pressure	O	-1	11988250
if	O	-1	11988250
hypo@@	B-Disease	D000860	11988250
x@@	I-Disease	-1	11988250
a@@	I-Disease	-1	11988250
emia	I-Disease	-1	11988250
occur@@	O	-1	11988250
s	O	-1	11988250
after	O	-1	11988250
pro@@	O	-1	11988250
phyl@@	O	-1	11988250
ac@@	O	-1	11988250
tic	O	-1	11988250
administration	O	-1	11988250
of	O	-1	11988250
i@@	B-Chemical	D007052	11988250
bu@@	I-Chemical	-1	11988250
prof@@	I-Chemical	-1	11988250
en	I-Chemical	-1	11988250
.	O	-1	11988250

H@@	B-Disease	D007010	12051122
yp@@	I-Disease	-1	12051122
on@@	I-Disease	-1	12051122
at@@	I-Disease	-1	12051122
re@@	I-Disease	-1	12051122
mia	I-Disease	-1	12051122
and	O	-1	12051122
syndrome	B-Disease	D007177	12051122
of	I-Disease	-1	12051122
in@@	I-Disease	-1	12051122
appro@@	I-Disease	-1	12051122
pri@@	I-Disease	-1	12051122
ate	I-Disease	-1	12051122
anti@@	I-Disease	-1	12051122
-@@	I-Disease	-1	12051122
di@@	I-Disease	-1	12051122
ure@@	I-Disease	-1	12051122
tic	I-Disease	-1	12051122
h@@	I-Disease	-1	12051122
orm@@	I-Disease	-1	12051122
one	I-Disease	-1	12051122
reported	O	-1	12051122
with	O	-1	12051122
the	O	-1	12051122
use	O	-1	12051122
of	O	-1	12051122
V@@	B-Chemical	D014750	12051122
inc@@	I-Chemical	-1	12051122
ri@@	I-Chemical	-1	12051122
st@@	I-Chemical	-1	12051122
ine	I-Chemical	-1	12051122
:	O	-1	12051122
an	O	-1	12051122
over@@	O	-1	12051122
-@@	O	-1	12051122
re@@	O	-1	12051122
present@@	O	-1	12051122
ation	O	-1	12051122
of	O	-1	12051122
A@@	O	-1	12051122
si@@	O	-1	12051122
an@@	O	-1	12051122
s@@	O	-1	12051122
?	O	-1	12051122
P@@	O	-1	12051122
U@@	O	-1	12051122
R@@	O	-1	12051122
P@@	O	-1	12051122
O@@	O	-1	12051122
S@@	O	-1	12051122
E:	O	-1	12051122
This	O	-1	12051122
ret@@	O	-1	12051122
ro@@	O	-1	12051122
sp@@	O	-1	12051122
ective	O	-1	12051122
study	O	-1	12051122
used	O	-1	12051122
a	O	-1	12051122
ph@@	O	-1	12051122
ar@@	O	-1	12051122
m@@	O	-1	12051122
ace@@	O	-1	12051122
u@@	O	-1	12051122
tical	O	-1	12051122
comp@@	O	-1	12051122
an@@	O	-1	12051122
y@@	O	-1	12051122
's	O	-1	12051122
glo@@	O	-1	12051122
b@@	O	-1	12051122
al	O	-1	12051122
safety	O	-1	12051122
dat@@	O	-1	12051122
ab@@	O	-1	12051122
ase	O	-1	12051122
to	O	-1	12051122
determine	O	-1	12051122
the	O	-1	12051122
repor@@	O	-1	12051122
ting	O	-1	12051122
rate	O	-1	12051122
of	O	-1	12051122
hy@@	B-Disease	D007010	12051122
p@@	I-Disease	-1	12051122
on@@	I-Disease	-1	12051122
at@@	I-Disease	-1	12051122
re@@	I-Disease	-1	12051122
mia	I-Disease	-1	12051122
and/or	O	-1	12051122
syndrome	B-Disease	D007177	12051122
of	I-Disease	-1	12051122
in@@	I-Disease	-1	12051122
appro@@	I-Disease	-1	12051122
pri@@	I-Disease	-1	12051122
ate	I-Disease	-1	12051122
secre@@	I-Disease	-1	12051122
tion	I-Disease	-1	12051122
of	I-Disease	-1	12051122
anti@@	I-Disease	-1	12051122
-@@	I-Disease	-1	12051122
di@@	I-Disease	-1	12051122
ure@@	I-Disease	-1	12051122
tic	I-Disease	-1	12051122
h@@	I-Disease	-1	12051122
orm@@	I-Disease	-1	12051122
one	I-Disease	-1	12051122
(	O	-1	12051122
S@@	B-Disease	D007177	12051122
I@@	I-Disease	-1	12051122
AD@@	I-Disease	-1	12051122
H	I-Disease	-1	12051122
)	O	-1	12051122
among	O	-1	12051122
v@@	B-Chemical	D014750	12051122
inc@@	I-Chemical	-1	12051122
ri@@	I-Chemical	-1	12051122
st@@	I-Chemical	-1	12051122
ine	I-Chemical	-1	12051122
-treated	O	-1	12051122
patients	O	-1	12051122
and	O	-1	12051122
to	O	-1	12051122
expl@@	O	-1	12051122
or@@	O	-1	12051122
e	O	-1	12051122
the	O	-1	12051122
possib@@	O	-1	12051122
ility	O	-1	12051122
of	O	-1	12051122
at@@	O	-1	12051122
-@@	O	-1	12051122
risk	O	-1	12051122
po@@	O	-1	12051122
p@@	O	-1	12051122
ulation	O	-1	12051122
sub@@	O	-1	12051122
groups.	O	-1	12051122
METHOD@@	O	-1	12051122
:	O	-1	12051122
We	O	-1	12051122
se@@	O	-1	12051122
ar@@	O	-1	12051122
ch@@	O	-1	12051122
ed	O	-1	12051122
the	O	-1	12051122
E@@	O	-1	12051122
l@@	O	-1	12051122
i	O	-1	12051122
L@@	O	-1	12051122
il@@	O	-1	12051122
ly	O	-1	12051122
and	O	-1	12051122
Com@@	O	-1	12051122
p@@	O	-1	12051122
an@@	O	-1	12051122
y@@	O	-1	12051122
's	O	-1	12051122
comp@@	O	-1	12051122
u@@	O	-1	12051122
ter@@	O	-1	12051122
ized	O	-1	12051122
adverse	O	-1	12051122
ev@@	O	-1	12051122
ent	O	-1	12051122
dat@@	O	-1	12051122
ab@@	O	-1	12051122
ase	O	-1	12051122
for	O	-1	12051122
all	O	-1	12051122
reported	O	-1	12051122
cases	O	-1	12051122
of	O	-1	12051122
hy@@	B-Disease	D007010	12051122
p@@	I-Disease	-1	12051122
on@@	I-Disease	-1	12051122
at@@	I-Disease	-1	12051122
re@@	I-Disease	-1	12051122
mia	I-Disease	-1	12051122
and/or	O	-1	12051122
S@@	B-Disease	D007177	12051122
I@@	I-Disease	-1	12051122
AD@@	I-Disease	-1	12051122
H	I-Disease	-1	12051122
as	O	-1	12051122
of	O	-1	12051122
1	O	-1	12051122
N@@	O	-1	12051122
o@@	O	-1	12051122
ve@@	O	-1	12051122
mb@@	O	-1	12051122
er	O	-1	12051122
19@@	O	-1	12051122
9@@	O	-1	12051122
9	O	-1	12051122
that	O	-1	12051122
had	O	-1	12051122
been	O	-1	12051122
reported	O	-1	12051122
during	O	-1	12051122
the	O	-1	12051122
use	O	-1	12051122
of	O	-1	12051122
v@@	B-Chemical	D014750	12051122
inc@@	I-Chemical	-1	12051122
ri@@	I-Chemical	-1	12051122
st@@	I-Chemical	-1	12051122
ine	I-Chemical	-1	12051122
.	O	-1	12051122
RESULTS:	O	-1	12051122
A	O	-1	12051122
total	O	-1	12051122
of	O	-1	12051122
7@@	O	-1	12051122
6	O	-1	12051122
cases	O	-1	12051122
of	O	-1	12051122
hy@@	B-Disease	D007010	12051122
p@@	I-Disease	-1	12051122
on@@	I-Disease	-1	12051122
at@@	I-Disease	-1	12051122
re@@	I-Disease	-1	12051122
mia	I-Disease	-1	12051122
and/or	O	-1	12051122
S@@	B-Disease	D007177	12051122
I@@	I-Disease	-1	12051122
AD@@	I-Disease	-1	12051122
H	I-Disease	-1	12051122
associated	O	-1	12051122
with	O	-1	12051122
v@@	B-Chemical	D014750	12051122
inc@@	I-Chemical	-1	12051122
ri@@	I-Chemical	-1	12051122
st@@	I-Chemical	-1	12051122
ine	I-Chemical	-1	12051122
use	O	-1	12051122
were	O	-1	12051122
identi@@	O	-1	12051122
fi@@	O	-1	12051122
ed.	O	-1	12051122
The	O	-1	12051122
over@@	O	-1	12051122
all	O	-1	12051122
repor@@	O	-1	12051122
ting	O	-1	12051122
rate	O	-1	12051122
was	O	-1	12051122
estim@@	O	-1	12051122
ated	O	-1	12051122
to	O	-1	12051122
be	O	-1	12051122
1.@@	O	-1	12051122
3@@	O	-1	12051122
/@@	O	-1	12051122
10@@	O	-1	12051122
0@@	O	-1	12051122
,@@	O	-1	12051122
0@@	O	-1	12051122
00	O	-1	12051122
treated	O	-1	12051122
patients.	O	-1	12051122
The	O	-1	12051122
average	O	-1	12051122
age	O	-1	12051122
of	O	-1	12051122
patients	O	-1	12051122
was	O	-1	12051122
3@@	O	-1	12051122
5.@@	O	-1	12051122
6	O	-1	12051122
+/-	O	-1	12051122
2@@	O	-1	12051122
8.@@	O	-1	12051122
3	O	-1	12051122
year@@	O	-1	12051122
s,	O	-1	12051122
and	O	-1	12051122
6@@	O	-1	12051122
2@@	O	-1	12051122
%	O	-1	12051122
were	O	-1	12051122
mal@@	O	-1	12051122
es.	O	-1	12051122
A@@	O	-1	12051122
p@@	O	-1	12051122
pro@@	O	-1	12051122
xim@@	O	-1	12051122
ately	O	-1	12051122
7@@	O	-1	12051122
5%	O	-1	12051122
of	O	-1	12051122
the	O	-1	12051122
patients	O	-1	12051122
were	O	-1	12051122
receiving	O	-1	12051122
treatment	O	-1	12051122
for	O	-1	12051122
leuk@@	B-Disease	D007938	12051122
emia	I-Disease	-1	12051122
or	O	-1	12051122
lymph@@	B-Disease	D008223	12051122
oma	I-Disease	-1	12051122
.	O	-1	12051122
A@@	O	-1	12051122
mon@@	O	-1	12051122
g	O	-1	12051122
the	O	-1	12051122
3@@	O	-1	12051122
9	O	-1	12051122
reports	O	-1	12051122
that	O	-1	12051122
included	O	-1	12051122
inf@@	O	-1	12051122
orm@@	O	-1	12051122
ation	O	-1	12051122
on	O	-1	12051122
rac@@	O	-1	12051122
e,	O	-1	12051122
the	O	-1	12051122
rac@@	O	-1	12051122
ial	O	-1	12051122
di@@	O	-1	12051122
stri@@	O	-1	12051122
bu@@	O	-1	12051122
tion	O	-1	12051122
w@@	O	-1	12051122
as@@	O	-1	12051122
:	O	-1	12051122
1	O	-1	12051122
B@@	O	-1	12051122
l@@	O	-1	12051122
ac@@	O	-1	12051122
k@@	O	-1	12051122
,	O	-1	12051122
3	O	-1	12051122
Ca@@	O	-1	12051122
uc@@	O	-1	12051122
a@@	O	-1	12051122
si@@	O	-1	12051122
an@@	O	-1	12051122
,	O	-1	12051122
and	O	-1	12051122
3@@	O	-1	12051122
5	O	-1	12051122
A@@	O	-1	12051122
si@@	O	-1	12051122
an@@	O	-1	12051122
.	O	-1	12051122
CONCLUSION:	O	-1	12051122
Our	O	-1	12051122
data	O	-1	12051122
suggest	O	-1	12051122
that	O	-1	12051122
A@@	O	-1	12051122
si@@	O	-1	12051122
an	O	-1	12051122
patients	O	-1	12051122
may	O	-1	12051122
be	O	-1	12051122
at	O	-1	12051122
increased	O	-1	12051122
risk	O	-1	12051122
of	O	-1	12051122
hy@@	B-Disease	D007010	12051122
p@@	I-Disease	-1	12051122
on@@	I-Disease	-1	12051122
at@@	I-Disease	-1	12051122
re@@	I-Disease	-1	12051122
mia	I-Disease	-1	12051122
and/or	O	-1	12051122
S@@	B-Disease	D007177	12051122
I@@	I-Disease	-1	12051122
AD@@	I-Disease	-1	12051122
H	I-Disease	-1	12051122
associated	O	-1	12051122
with	O	-1	12051122
v@@	B-Chemical	D014750	12051122
inc@@	I-Chemical	-1	12051122
ri@@	I-Chemical	-1	12051122
st@@	I-Chemical	-1	12051122
ine	I-Chemical	-1	12051122
use.	O	-1	12051122
Although	O	-1	12051122
the	O	-1	12051122
over@@	O	-1	12051122
all	O	-1	12051122
reported	O	-1	12051122
rate	O	-1	12051122
of	O	-1	12051122
S@@	B-Disease	D007177	12051122
I@@	I-Disease	-1	12051122
AD@@	I-Disease	-1	12051122
H	I-Disease	-1	12051122
associated	O	-1	12051122
with	O	-1	12051122
v@@	B-Chemical	D014750	12051122
inc@@	I-Chemical	-1	12051122
ri@@	I-Chemical	-1	12051122
st@@	I-Chemical	-1	12051122
ine	I-Chemical	-1	12051122
is	O	-1	12051122
very	O	-1	12051122
low@@	O	-1	12051122
,	O	-1	12051122
physi@@	O	-1	12051122
ci@@	O	-1	12051122
ans	O	-1	12051122
car@@	O	-1	12051122
ing	O	-1	12051122
for	O	-1	12051122
A@@	O	-1	12051122
si@@	O	-1	12051122
an	O	-1	12051122
on@@	O	-1	12051122
co@@	O	-1	12051122
log@@	O	-1	12051122
y	O	-1	12051122
patients	O	-1	12051122
should	O	-1	12051122
be	O	-1	12051122
aw@@	O	-1	12051122
are	O	-1	12051122
of	O	-1	12051122
this	O	-1	12051122
potential	O	-1	12051122
seri@@	O	-1	12051122
ous	O	-1	12051122
but	O	-1	12051122
reversible	O	-1	12051122
adverse	O	-1	12051122
event@@	O	-1	12051122
.	O	-1	12051122

D@@	O	-1	12059909
el@@	O	-1	12059909
ayed	O	-1	12059909
toxicity	B-Disease	D064420	12059909
of	O	-1	12059909
cyclophosph@@	B-Chemical	D003520	12059909
amide	I-Chemical	-1	12059909
on	O	-1	12059909
the	O	-1	12059909
bladder	O	-1	12059909
of	O	-1	12059909
D@@	O	-1	12059909
BA@@	O	-1	12059909
/@@	O	-1	12059909
2	O	-1	12059909
and	O	-1	12059909
C@@	O	-1	12059909
5@@	O	-1	12059909
7@@	O	-1	12059909
B@@	O	-1	12059909
L@@	O	-1	12059909
/@@	O	-1	12059909
6	O	-1	12059909
female	O	-1	12059909
mou@@	O	-1	12059909
se.	O	-1	12059909
The	O	-1	12059909
present	O	-1	12059909
study	O	-1	12059909
descri@@	O	-1	12059909
b@@	O	-1	12059909
es	O	-1	12059909
the	O	-1	12059909
del@@	O	-1	12059909
ayed	O	-1	12059909
development	O	-1	12059909
of	O	-1	12059909
a	O	-1	12059909
severe	O	-1	12059909
bladder	O	-1	12059909
path@@	O	-1	12059909
ology	O	-1	12059909
in	O	-1	12059909
a	O	-1	12059909
sus@@	O	-1	12059909
cep@@	O	-1	12059909
ti@@	O	-1	12059909
ble	O	-1	12059909
stra@@	O	-1	12059909
in	O	-1	12059909
of	O	-1	12059909
mice	O	-1	12059909
(D@@	O	-1	12059909
BA@@	O	-1	12059909
/@@	O	-1	12059909
2)	O	-1	12059909
but	O	-1	12059909
not	O	-1	12059909
in	O	-1	12059909
a	O	-1	12059909
resist@@	O	-1	12059909
ant	O	-1	12059909
stra@@	O	-1	12059909
in	O	-1	12059909
(C@@	O	-1	12059909
5@@	O	-1	12059909
7@@	O	-1	12059909
B@@	O	-1	12059909
L@@	O	-1	12059909
/@@	O	-1	12059909
6@@	O	-1	12059909
)	O	-1	12059909
when	O	-1	12059909
both	O	-1	12059909
were	O	-1	12059909
treated	O	-1	12059909
with	O	-1	12059909
a	O	-1	12059909
single	O	-1	12059909
3@@	O	-1	12059909
00	O	-1	12059909
mg/kg	O	-1	12059909
dose	O	-1	12059909
of	O	-1	12059909
cyclophosph@@	B-Chemical	D003520	12059909
amide	I-Chemical	-1	12059909
(	O	-1	12059909
C@@	B-Chemical	D003520	12059909
Y	I-Chemical	-1	12059909
).	O	-1	12059909
In@@	O	-1	12059909
b@@	O	-1	12059909
red	O	-1	12059909
D@@	O	-1	12059909
BA@@	O	-1	12059909
/@@	O	-1	12059909
2	O	-1	12059909
and	O	-1	12059909
C@@	O	-1	12059909
5@@	O	-1	12059909
7@@	O	-1	12059909
B@@	O	-1	12059909
L@@	O	-1	12059909
/@@	O	-1	12059909
6	O	-1	12059909
female	O	-1	12059909
mice	O	-1	12059909
were	O	-1	12059909
injected	O	-1	12059909
with	O	-1	12059909
C@@	B-Chemical	D003520	12059909
Y	I-Chemical	-1	12059909
,	O	-1	12059909
and	O	-1	12059909
the	O	-1	12059909
effect	O	-1	12059909
of	O	-1	12059909
the	O	-1	12059909
drug	O	-1	12059909
on	O	-1	12059909
the	O	-1	12059909
bladder	O	-1	12059909
was	O	-1	12059909
assessed	O	-1	12059909
during	O	-1	12059909
100	O	-1	12059909
days	O	-1	12059909
by	O	-1	12059909
li@@	O	-1	12059909
ght	O	-1	12059909
micro@@	O	-1	12059909
sco@@	O	-1	12059909
p@@	O	-1	12059909
y	O	-1	12059909
using	O	-1	12059909
different	O	-1	12059909
st@@	O	-1	12059909
aining	O	-1	12059909
proce@@	O	-1	12059909
du@@	O	-1	12059909
res@@	O	-1	12059909
,	O	-1	12059909
and	O	-1	12059909
after	O	-1	12059909
30	O	-1	12059909
days	O	-1	12059909
by	O	-1	12059909
con@@	O	-1	12059909
ven@@	O	-1	12059909
tional	O	-1	12059909
electro@@	O	-1	12059909
n	O	-1	12059909
micro@@	O	-1	12059909
sco@@	O	-1	12059909
p@@	O	-1	12059909
y.	O	-1	12059909
E@@	O	-1	12059909
arly	O	-1	12059909
C@@	B-Chemical	D003520	12059909
Y	I-Chemical	-1	12059909
toxicity	B-Disease	D064420	12059909
caused	O	-1	12059909
a	O	-1	12059909
typ@@	O	-1	12059909
ical	O	-1	12059909
haem@@	B-Disease	D006470	12059909
or@@	I-Disease	-1	12059909
rh@@	I-Disease	-1	12059909
ag@@	I-Disease	-1	12059909
ic	I-Disease	-1	12059909
cys@@	B-Disease	D003556	12059909
ti@@	I-Disease	-1	12059909
tis	I-Disease	-1	12059909
in	O	-1	12059909
both	O	-1	12059909
stra@@	O	-1	12059909
ins	O	-1	12059909
that	O	-1	12059909
was	O	-1	12059909
complete@@	O	-1	12059909
ly	O	-1	12059909
re@@	O	-1	12059909
pa@@	O	-1	12059909
ired	O	-1	12059909
in	O	-1	12059909
about	O	-1	12059909
7-@@	O	-1	12059909
10	O	-1	12059909
days.	O	-1	12059909
After	O	-1	12059909
30	O	-1	12059909
days	O	-1	12059909
of	O	-1	12059909
C@@	B-Chemical	D003520	12059909
Y	I-Chemical	-1	12059909
injection	O	-1	12059909
ul@@	O	-1	12059909
cer@@	O	-1	12059909
ous	O	-1	12059909
and	O	-1	12059909
non-@@	O	-1	12059909
ul@@	O	-1	12059909
cer@@	O	-1	12059909
ous	O	-1	12059909
form@@	O	-1	12059909
s	O	-1	12059909
of	O	-1	12059909
chronic	O	-1	12059909
cys@@	B-Disease	D003556	12059909
ti@@	I-Disease	-1	12059909
tis	I-Disease	-1	12059909
appe@@	O	-1	12059909
a@@	O	-1	12059909
red	O	-1	12059909
in	O	-1	12059909
8@@	O	-1	12059909
6%	O	-1	12059909
of	O	-1	12059909
D@@	O	-1	12059909
BA@@	O	-1	12059909
/@@	O	-1	12059909
2	O	-1	12059909
mice	O	-1	12059909
but	O	-1	12059909
only	O	-1	12059909
in	O	-1	12059909
4@@	O	-1	12059909
%	O	-1	12059909
of	O	-1	12059909
C@@	O	-1	12059909
5@@	O	-1	12059909
7@@	O	-1	12059909
B@@	O	-1	12059909
L@@	O	-1	12059909
/@@	O	-1	12059909
6	O	-1	12059909
mice.	O	-1	12059909
D@@	O	-1	12059909
el@@	O	-1	12059909
ayed	O	-1	12059909
cys@@	B-Disease	D003556	12059909
ti@@	I-Disease	-1	12059909
tis	I-Disease	-1	12059909
was	O	-1	12059909
character@@	O	-1	12059909
ized	O	-1	12059909
by	O	-1	12059909
inf@@	O	-1	12059909
iltration	O	-1	12059909
and	O	-1	12059909
tran@@	O	-1	12059909
se@@	O	-1	12059909
pi@@	O	-1	12059909
thelial	O	-1	12059909
p@@	O	-1	12059909
ass@@	O	-1	12059909
age	O	-1	12059909
into	O	-1	12059909
the	O	-1	12059909
lu@@	O	-1	12059909
men	O	-1	12059909
of	O	-1	12059909
inflam@@	O	-1	12059909
mat@@	O	-1	12059909
ory	O	-1	12059909
cells	O	-1	12059909
and	O	-1	12059909
by	O	-1	12059909
frequent	O	-1	12059909
ex@@	O	-1	12059909
fol@@	O	-1	12059909
i@@	O	-1	12059909
ation	O	-1	12059909
of	O	-1	12059909
the	O	-1	12059909
uro@@	O	-1	12059909
the@@	O	-1	12059909
li@@	O	-1	12059909
um@@	O	-1	12059909
.	O	-1	12059909
M@@	O	-1	12059909
ast	O	-1	12059909
cells	O	-1	12059909
appe@@	O	-1	12059909
a@@	O	-1	12059909
red	O	-1	12059909
in	O	-1	12059909
the	O	-1	12059909
con@@	O	-1	12059909
n@@	O	-1	12059909
ective	O	-1	12059909
and	O	-1	12059909
mus@@	O	-1	12059909
cular	O	-1	12059909
l@@	O	-1	12059909
ay@@	O	-1	12059909
ers	O	-1	12059909
of	O	-1	12059909
the	O	-1	12059909
bladder	O	-1	12059909
at	O	-1	12059909
a	O	-1	12059909
m@@	O	-1	12059909
uc@@	O	-1	12059909
h	O	-1	12059909
higher	O	-1	12059909
number	O	-1	12059909
in	O	-1	12059909
D@@	O	-1	12059909
BA@@	O	-1	12059909
/@@	O	-1	12059909
2	O	-1	12059909
mice	O	-1	12059909
than	O	-1	12059909
in	O	-1	12059909
C@@	O	-1	12059909
5@@	O	-1	12059909
7@@	O	-1	12059909
B@@	O	-1	12059909
L@@	O	-1	12059909
/@@	O	-1	12059909
6	O	-1	12059909
mice	O	-1	12059909
or	O	-1	12059909
un@@	O	-1	12059909
treated	O	-1	12059909
controls.	O	-1	12059909
E@@	O	-1	12059909
l@@	O	-1	12059909
ect@@	O	-1	12059909
ro@@	O	-1	12059909
n	O	-1	12059909
micro@@	O	-1	12059909
sco@@	O	-1	12059909
p@@	O	-1	12059909
y	O	-1	12059909
disc@@	O	-1	12059909
los@@	O	-1	12059909
ed	O	-1	12059909
the	O	-1	12059909
absence	O	-1	12059909
of	O	-1	12059909
the	O	-1	12059909
typ@@	O	-1	12059909
ical	O	-1	12059909
dis@@	O	-1	12059909
co@@	O	-1	12059909
idal	O	-1	12059909
ve@@	O	-1	12059909
si@@	O	-1	12059909
c@@	O	-1	12059909
le@@	O	-1	12059909
s	O	-1	12059909
norm@@	O	-1	12059909
ally	O	-1	12059909
present	O	-1	12059909
in	O	-1	12059909
the	O	-1	12059909
cyto@@	O	-1	12059909
plas@@	O	-1	12059909
m	O	-1	12059909
of	O	-1	12059909
sur@@	O	-1	12059909
fac@@	O	-1	12059909
e	O	-1	12059909
cell@@	O	-1	12059909
s.	O	-1	12059909
In@@	O	-1	12059909
ste@@	O	-1	12059909
ad@@	O	-1	12059909
,	O	-1	12059909
n@@	O	-1	12059909
um@@	O	-1	12059909
er@@	O	-1	12059909
ous	O	-1	12059909
ab@@	O	-1	12059909
normal	O	-1	12059909
ve@@	O	-1	12059909
si@@	O	-1	12059909
c@@	O	-1	12059909
le@@	O	-1	12059909
s	O	-1	12059909
containing	O	-1	12059909
one	O	-1	12059909
or	O	-1	12059909
several	O	-1	12059909
d@@	O	-1	12059909
ar@@	O	-1	12059909
k	O	-1	12059909
gran@@	O	-1	12059909
ul@@	O	-1	12059909
es	O	-1	12059909
were	O	-1	12059909
observed	O	-1	12059909
in	O	-1	12059909
the	O	-1	12059909
cyto@@	O	-1	12059909
plas@@	O	-1	12059909
m	O	-1	12059909
of	O	-1	12059909
cells	O	-1	12059909
from	O	-1	12059909
all	O	-1	12059909
the	O	-1	12059909
epi@@	O	-1	12059909
thelial	O	-1	12059909
l@@	O	-1	12059909
ay@@	O	-1	12059909
ers.	O	-1	12059909
D@@	O	-1	12059909
el@@	O	-1	12059909
ayed	O	-1	12059909
cys@@	B-Disease	D003556	12059909
ti@@	I-Disease	-1	12059909
tis	I-Disease	-1	12059909
sti@@	O	-1	12059909
ll	O	-1	12059909
per@@	O	-1	12059909
sist@@	O	-1	12059909
ed	O	-1	12059909
in	O	-1	12059909
D@@	O	-1	12059909
BA@@	O	-1	12059909
/@@	O	-1	12059909
2	O	-1	12059909
mice	O	-1	12059909
100	O	-1	12059909
days	O	-1	12059909
after	O	-1	12059909
treatment.	O	-1	12059909
These	O	-1	12059909
results	O	-1	12059909
indicate	O	-1	12059909
that	O	-1	12059909
del@@	O	-1	12059909
ayed	O	-1	12059909
toxicity	B-Disease	D064420	12059909
of	O	-1	12059909
C@@	B-Chemical	D003520	12059909
Y	I-Chemical	-1	12059909
in	O	-1	12059909
female	O	-1	12059909
D@@	O	-1	12059909
BA@@	O	-1	12059909
/@@	O	-1	12059909
2	O	-1	12059909
mice	O	-1	12059909
causes	O	-1	12059909
a	O	-1	12059909
bladder	O	-1	12059909
path@@	O	-1	12059909
ology	O	-1	12059909
that	O	-1	12059909
is	O	-1	12059909
not	O	-1	12059909
observed	O	-1	12059909
in	O	-1	12059909
C@@	O	-1	12059909
5@@	O	-1	12059909
7@@	O	-1	12059909
B@@	O	-1	12059909
L@@	O	-1	12059909
/@@	O	-1	12059909
6	O	-1	12059909
mice.	O	-1	12059909
This	O	-1	12059909
path@@	O	-1	12059909
ology	O	-1	12059909
re@@	O	-1	12059909
se@@	O	-1	12059909
m@@	O	-1	12059909
ble@@	O	-1	12059909
s	O	-1	12059909
interstitial	B-Disease	D018856	12059909
cys@@	I-Disease	-1	12059909
ti@@	I-Disease	-1	12059909
tis	I-Disease	-1	12059909
in	O	-1	12059909
hum@@	O	-1	12059909
ans	O	-1	12059909
and	O	-1	12059909
could	O	-1	12059909
per@@	O	-1	12059909
h@@	O	-1	12059909
ap@@	O	-1	12059909
s	O	-1	12059909
be	O	-1	12059909
used	O	-1	12059909
as	O	-1	12059909
an	O	-1	12059909
anim@@	O	-1	12059909
al	O	-1	12059909
model	O	-1	12059909
for	O	-1	12059909
studies	O	-1	12059909
on	O	-1	12059909
the	O	-1	12059909
disease.	O	-1	12059909

H@@	O	-1	12119460
igh@@	O	-1	12119460
-@@	O	-1	12119460
dose	O	-1	12119460
5-@@	B-Chemical	D005472	12119460
fluoro@@	I-Chemical	-1	12119460
urac@@	I-Chemical	-1	12119460
il	I-Chemical	-1	12119460
/	O	-1	12119460
fol@@	B-Chemical	D002955	12119460
inic	I-Chemical	-1	12119460
acid	I-Chemical	-1	12119460
in	O	-1	12119460
combination	O	-1	12119460
with	O	-1	12119460
th@@	O	-1	12119460
re@@	O	-1	12119460
e-@@	O	-1	12119460
week@@	O	-1	12119460
ly	O	-1	12119460
mit@@	B-Chemical	D016685	12119460
om@@	I-Chemical	-1	12119460
ycin	I-Chemical	-1	12119460
C	I-Chemical	-1	12119460
in	O	-1	12119460
the	O	-1	12119460
treatment	O	-1	12119460
of	O	-1	12119460
adv@@	O	-1	12119460
anced	O	-1	12119460
gast@@	B-Disease	D013274	12119460
ric	I-Disease	-1	12119460
cancer	I-Disease	-1	12119460
.	O	-1	12119460
A	O	-1	12119460
phase	O	-1	12119460
II	O	-1	12119460
study.	O	-1	12119460
BACKGROUND:	O	-1	12119460
The	O	-1	12119460
2@@	O	-1	12119460
4-@@	O	-1	12119460
h@@	O	-1	12119460
our	O	-1	12119460
continu@@	O	-1	12119460
ous	O	-1	12119460
infusion	O	-1	12119460
of	O	-1	12119460
5-@@	B-Chemical	D005472	12119460
fluoro@@	I-Chemical	-1	12119460
urac@@	I-Chemical	-1	12119460
il	I-Chemical	-1	12119460
(	O	-1	12119460
5-@@	B-Chemical	D005472	12119460
F@@	I-Chemical	-1	12119460
U	I-Chemical	-1	12119460
)	O	-1	12119460
and	O	-1	12119460
fol@@	B-Chemical	D002955	12119460
inic	I-Chemical	-1	12119460
acid	I-Chemical	-1	12119460
(	O	-1	12119460
F@@	B-Chemical	D002955	12119460
A	I-Chemical	-1	12119460
)	O	-1	12119460
as	O	-1	12119460
par@@	O	-1	12119460
t	O	-1	12119460
of	O	-1	12119460
several	O	-1	12119460
new	O	-1	12119460
multi@@	O	-1	12119460
drug	O	-1	12119460
chemotherapy	O	-1	12119460
regimen@@	O	-1	12119460
s	O	-1	12119460
in	O	-1	12119460
adv@@	O	-1	12119460
anced	O	-1	12119460
gast@@	B-Disease	D013274	12119460
ric	I-Disease	-1	12119460
cancer	I-Disease	-1	12119460
(	O	-1	12119460
A@@	B-Disease	D013274	12119460
G@@	I-Disease	-1	12119460
C	I-Disease	-1	12119460
)	O	-1	12119460
has	O	-1	12119460
shown	O	-1	12119460
to	O	-1	12119460
be	O	-1	12119460
eff@@	O	-1	12119460
ecti@@	O	-1	12119460
ve,	O	-1	12119460
with	O	-1	12119460
low	O	-1	12119460
toxicity	B-Disease	D064420	12119460
.	O	-1	12119460
In	O	-1	12119460
a	O	-1	12119460
previ@@	O	-1	12119460
ous	O	-1	12119460
phase	O	-1	12119460
II	O	-1	12119460
study	O	-1	12119460
with	O	-1	12119460
3-@@	O	-1	12119460
week@@	O	-1	12119460
ly	O	-1	12119460
b@@	O	-1	12119460
ol@@	O	-1	12119460
us	O	-1	12119460
5-@@	B-Chemical	D005472	12119460
F@@	I-Chemical	-1	12119460
U	I-Chemical	-1	12119460
,	O	-1	12119460
F@@	B-Chemical	D002955	12119460
A	I-Chemical	-1	12119460
and	O	-1	12119460
mit@@	B-Chemical	D016685	12119460
om@@	I-Chemical	-1	12119460
ycin	I-Chemical	-1	12119460
C	I-Chemical	-1	12119460
(	O	-1	12119460
M@@	B-Chemical	D016685	12119460
M@@	I-Chemical	-1	12119460
C	I-Chemical	-1	12119460
)	O	-1	12119460
we	O	-1	12119460
found	O	-1	12119460
a	O	-1	12119460
low	O	-1	12119460
toxicity	B-Disease	D064420	12119460
rate	O	-1	12119460
and	O	-1	12119460
response	O	-1	12119460
rat@@	O	-1	12119460
es	O	-1	12119460
compar@@	O	-1	12119460
able	O	-1	12119460
to	O	-1	12119460
those	O	-1	12119460
of	O	-1	12119460
regimen@@	O	-1	12119460
s	O	-1	12119460
such	O	-1	12119460
as	O	-1	12119460
E@@	O	-1	12119460
L@@	O	-1	12119460
F@@	O	-1	12119460
,	O	-1	12119460
F@@	O	-1	12119460
A@@	O	-1	12119460
M	O	-1	12119460
or	O	-1	12119460
F@@	O	-1	12119460
AM@@	O	-1	12119460
T@@	O	-1	12119460
X@@	O	-1	12119460
,	O	-1	12119460
and	O	-1	12119460
a	O	-1	12119460
pro@@	O	-1	12119460
mis@@	O	-1	12119460
ing	O	-1	12119460
median	O	-1	12119460
over@@	O	-1	12119460
all	O	-1	12119460
sur@@	O	-1	12119460
vi@@	O	-1	12119460
val@@	O	-1	12119460
.	O	-1	12119460
In	O	-1	12119460
or@@	O	-1	12119460
der	O	-1	12119460
to	O	-1	12119460
impro@@	O	-1	12119460
ve	O	-1	12119460
this	O	-1	12119460
M@@	B-Chemical	D016685	12119460
M@@	I-Chemical	-1	12119460
C	I-Chemical	-1	12119460
-@@	O	-1	12119460
dependent	O	-1	12119460
sch@@	O	-1	12119460
ed@@	O	-1	12119460
ul@@	O	-1	12119460
e	O	-1	12119460
we	O	-1	12119460
initi@@	O	-1	12119460
ated	O	-1	12119460
a	O	-1	12119460
phase	O	-1	12119460
II	O	-1	12119460
study	O	-1	12119460
with	O	-1	12119460
high-dose	O	-1	12119460
5-@@	B-Chemical	D005472	12119460
F@@	I-Chemical	-1	12119460
U	I-Chemical	-1	12119460
/	O	-1	12119460
F@@	B-Chemical	D002955	12119460
A	I-Chemical	-1	12119460
and	O	-1	12119460
3-@@	O	-1	12119460
week@@	O	-1	12119460
ly	O	-1	12119460
b@@	O	-1	12119460
ol@@	O	-1	12119460
us	O	-1	12119460
M@@	B-Chemical	D016685	12119460
M@@	I-Chemical	-1	12119460
C	I-Chemical	-1	12119460
.	O	-1	12119460
PA@@	O	-1	12119460
TI@@	O	-1	12119460
E@@	O	-1	12119460
N@@	O	-1	12119460
T@@	O	-1	12119460
S	O	-1	12119460
AN@@	O	-1	12119460
D	O	-1	12119460
METHODS:	O	-1	12119460
F@@	O	-1	12119460
rom	O	-1	12119460
F@@	O	-1	12119460
e@@	O	-1	12119460
b@@	O	-1	12119460
ru@@	O	-1	12119460
ar@@	O	-1	12119460
y,	O	-1	12119460
19@@	O	-1	12119460
9@@	O	-1	12119460
8	O	-1	12119460
to	O	-1	12119460
S@@	O	-1	12119460
e@@	O	-1	12119460
pt@@	O	-1	12119460
emb@@	O	-1	12119460
er,	O	-1	12119460
20@@	O	-1	12119460
00	O	-1	12119460
we	O	-1	12119460
rec@@	O	-1	12119460
ru@@	O	-1	12119460
ited	O	-1	12119460
3@@	O	-1	12119460
3	O	-1	12119460
patients	O	-1	12119460
with	O	-1	12119460
A@@	B-Disease	D013274	12119460
G@@	I-Disease	-1	12119460
C	I-Disease	-1	12119460
to	O	-1	12119460
recei@@	O	-1	12119460
ve	O	-1	12119460
week@@	O	-1	12119460
ly	O	-1	12119460
2@@	O	-1	12119460
4-@@	O	-1	12119460
h@@	O	-1	12119460
our	O	-1	12119460
5-@@	B-Chemical	D005472	12119460
F@@	I-Chemical	-1	12119460
U	I-Chemical	-1	12119460
2@@	O	-1	12119460
,@@	O	-1	12119460
6@@	O	-1	12119460
00	O	-1	12119460
mg/m@@	O	-1	12119460
(2@@	O	-1	12119460
)	O	-1	12119460
pre@@	O	-1	12119460
ce@@	O	-1	12119460
ded	O	-1	12119460
by	O	-1	12119460
2-@@	O	-1	12119460
h@@	O	-1	12119460
our	O	-1	12119460
F@@	B-Chemical	D002955	12119460
A	I-Chemical	-1	12119460
5@@	O	-1	12119460
00	O	-1	12119460
mg/m@@	O	-1	12119460
(2@@	O	-1	12119460
)	O	-1	12119460
for	O	-1	12119460
6	O	-1	12119460
week@@	O	-1	12119460
s,	O	-1	12119460
followed	O	-1	12119460
by	O	-1	12119460
a	O	-1	12119460
2-@@	O	-1	12119460
week	O	-1	12119460
res@@	O	-1	12119460
t	O	-1	12119460
perio@@	O	-1	12119460
d.	O	-1	12119460
B@@	O	-1	12119460
ol@@	O	-1	12119460
us	O	-1	12119460
M@@	B-Chemical	D016685	12119460
M@@	I-Chemical	-1	12119460
C	I-Chemical	-1	12119460
10	O	-1	12119460
mg/m@@	O	-1	12119460
(2@@	O	-1	12119460
)	O	-1	12119460
was	O	-1	12119460
ad@@	O	-1	12119460
ded	O	-1	12119460
in	O	-1	12119460
3-@@	O	-1	12119460
week@@	O	-1	12119460
ly	O	-1	12119460
inter@@	O	-1	12119460
val@@	O	-1	12119460
s.	O	-1	12119460
Treat@@	O	-1	12119460
ment	O	-1	12119460
given	O	-1	12119460
on	O	-1	12119460
an	O	-1	12119460
out@@	O	-1	12119460
patient	O	-1	12119460
b@@	O	-1	12119460
a@@	O	-1	12119460
sis,	O	-1	12119460
using	O	-1	12119460
port@@	O	-1	12119460
able	O	-1	12119460
p@@	O	-1	12119460
um@@	O	-1	12119460
p	O	-1	12119460
system@@	O	-1	12119460
s,	O	-1	12119460
was	O	-1	12119460
repe@@	O	-1	12119460
ated	O	-1	12119460
on	O	-1	12119460
day	O	-1	12119460
5@@	O	-1	12119460
7@@	O	-1	12119460
.	O	-1	12119460
Pati@@	O	-1	12119460
ent@@	O	-1	12119460
s@@	O	-1	12119460
'	O	-1	12119460
character@@	O	-1	12119460
is@@	O	-1	12119460
tics	O	-1	12119460
we@@	O	-1	12119460
re@@	O	-1	12119460
:	O	-1	12119460
mal@@	O	-1	12119460
e@@	O	-1	12119460
/@@	O	-1	12119460
female	O	-1	12119460
rati@@	O	-1	12119460
o	O	-1	12119460
20@@	O	-1	12119460
/@@	O	-1	12119460
13@@	O	-1	12119460
;	O	-1	12119460
median	O	-1	12119460
age	O	-1	12119460
5@@	O	-1	12119460
7	O	-1	12119460
(2@@	O	-1	12119460
7-@@	O	-1	12119460
7@@	O	-1	12119460
5@@	O	-1	12119460
)	O	-1	12119460
year@@	O	-1	12119460
s;	O	-1	12119460
median	O	-1	12119460
W@@	O	-1	12119460
H@@	O	-1	12119460
O	O	-1	12119460
status	O	-1	12119460
1	O	-1	12119460
(@@	O	-1	12119460
0-@@	O	-1	12119460
2@@	O	-1	12119460
).	O	-1	12119460
1@@	O	-1	12119460
8	O	-1	12119460
patients	O	-1	12119460
had	O	-1	12119460
a	O	-1	12119460
prim@@	O	-1	12119460
ary	O	-1	12119460
A@@	B-Disease	D013274	12119460
G@@	I-Disease	-1	12119460
C	I-Disease	-1	12119460
,	O	-1	12119460
and	O	-1	12119460
15	O	-1	12119460
showed	O	-1	12119460
a	O	-1	12119460
rel@@	O	-1	12119460
ap@@	O	-1	12119460
sed	O	-1	12119460
A@@	B-Disease	D013274	12119460
G@@	I-Disease	-1	12119460
C	I-Disease	-1	12119460
.	O	-1	12119460
M@@	O	-1	12119460
edi@@	O	-1	12119460
an	O	-1	12119460
follow-up	O	-1	12119460
was	O	-1	12119460
1@@	O	-1	12119460
1.@@	O	-1	12119460
8	O	-1	12119460
months	O	-1	12119460
(@@	O	-1	12119460
range	O	-1	12119460
of	O	-1	12119460
those	O	-1	12119460
sur@@	O	-1	12119460
viv@@	O	-1	12119460
ing@@	O	-1	12119460
:	O	-1	12119460
2.@@	O	-1	12119460
7@@	O	-1	12119460
-1@@	O	-1	12119460
1.@@	O	-1	12119460
8	O	-1	12119460
month@@	O	-1	12119460
s@@	O	-1	12119460
).	O	-1	12119460
RESULTS:	O	-1	12119460
3@@	O	-1	12119460
2	O	-1	12119460
patients	O	-1	12119460
were	O	-1	12119460
evalu@@	O	-1	12119460
able	O	-1	12119460
for	O	-1	12119460
response	O	-1	12119460
-	O	-1	12119460
complete	O	-1	12119460
re@@	O	-1	12119460
mission	O	-1	12119460
9.@@	O	-1	12119460
1@@	O	-1	12119460
%	O	-1	12119460
(n	O	-1	12119460
=	O	-1	12119460
3@@	O	-1	12119460
),	O	-1	12119460
partial	O	-1	12119460
re@@	O	-1	12119460
mission	O	-1	12119460
4@@	O	-1	12119460
5.@@	O	-1	12119460
5%	O	-1	12119460
(n	O	-1	12119460
=	O	-1	12119460
1@@	O	-1	12119460
5@@	O	-1	12119460
),	O	-1	12119460
no	O	-1	12119460
change	O	-1	12119460
2@@	O	-1	12119460
7.@@	O	-1	12119460
3@@	O	-1	12119460
%	O	-1	12119460
(n	O	-1	12119460
=	O	-1	12119460
9@@	O	-1	12119460
),	O	-1	12119460
progressive	O	-1	12119460
disease	O	-1	12119460
1@@	O	-1	12119460
5.@@	O	-1	12119460
1@@	O	-1	12119460
%	O	-1	12119460
(n	O	-1	12119460
=	O	-1	12119460
5@@	O	-1	12119460
).	O	-1	12119460
M@@	O	-1	12119460
edi@@	O	-1	12119460
an	O	-1	12119460
over@@	O	-1	12119460
all	O	-1	12119460
sur@@	O	-1	12119460
viv@@	O	-1	12119460
al	O	-1	12119460
time	O	-1	12119460
was	O	-1	12119460
1@@	O	-1	12119460
0.@@	O	-1	12119460
2	O	-1	12119460
months	O	-1	12119460
[@@	O	-1	12119460
95%	O	-1	12119460
conf@@	O	-1	12119460
idence	O	-1	12119460
interv@@	O	-1	12119460
al	O	-1	12119460
(C@@	O	-1	12119460
I@@	O	-1	12119460
)@@	O	-1	12119460
:	O	-1	12119460
8.@@	O	-1	12119460
7@@	O	-1	12119460
-1@@	O	-1	12119460
1.@@	O	-1	12119460
6@@	O	-1	12119460
]@@	O	-1	12119460
,	O	-1	12119460
and	O	-1	12119460
median	O	-1	12119460
progres@@	O	-1	12119460
sion@@	O	-1	12119460
-@@	O	-1	12119460
free	O	-1	12119460
sur@@	O	-1	12119460
viv@@	O	-1	12119460
al	O	-1	12119460
time	O	-1	12119460
was	O	-1	12119460
7.@@	O	-1	12119460
6	O	-1	12119460
months	O	-1	12119460
(@@	O	-1	12119460
95%	O	-1	12119460
CI@@	O	-1	12119460
:	O	-1	12119460
4.@@	O	-1	12119460
4@@	O	-1	12119460
-1@@	O	-1	12119460
0.@@	O	-1	12119460
9@@	O	-1	12119460
).	O	-1	12119460
The	O	-1	12119460
wor@@	O	-1	12119460
st	O	-1	12119460
toxic@@	B-Disease	D064420	12119460
ities	I-Disease	-1	12119460
(@@	O	-1	12119460
%)	O	-1	12119460
observed	O	-1	12119460
were	O	-1	12119460
(C@@	O	-1	12119460
T@@	O	-1	12119460
C@@	O	-1	12119460
-@@	O	-1	12119460
N@@	O	-1	12119460
C@@	O	-1	12119460
I	O	-1	12119460
1@@	O	-1	12119460
/@@	O	-1	12119460
2@@	O	-1	12119460
/@@	O	-1	12119460
3@@	O	-1	12119460
)@@	O	-1	12119460
:	O	-1	12119460
leuk@@	B-Disease	D007970	12119460
o@@	I-Disease	-1	12119460
pen@@	I-Disease	-1	12119460
ia	I-Disease	-1	12119460
4@@	O	-1	12119460
5.@@	O	-1	12119460
5@@	O	-1	12119460
/@@	O	-1	12119460
1@@	O	-1	12119460
8.@@	O	-1	12119460
2@@	O	-1	12119460
/@@	O	-1	12119460
6.@@	O	-1	12119460
1,	O	-1	12119460
throm@@	B-Disease	D013921	12119460
b@@	I-Disease	-1	12119460
ocyto@@	I-Disease	-1	12119460
pen@@	I-Disease	-1	12119460
ia	I-Disease	-1	12119460
3@@	O	-1	12119460
3.@@	O	-1	12119460
3@@	O	-1	12119460
/@@	O	-1	12119460
9.@@	O	-1	12119460
1@@	O	-1	12119460
/@@	O	-1	12119460
6.@@	O	-1	12119460
1,	O	-1	12119460
v@@	B-Disease	D014839	12119460
om@@	I-Disease	-1	12119460
it@@	I-Disease	-1	12119460
us	I-Disease	-1	12119460
2@@	O	-1	12119460
4.@@	O	-1	12119460
2@@	O	-1	12119460
/@@	O	-1	12119460
9.@@	O	-1	12119460
1@@	O	-1	12119460
/@@	O	-1	12119460
0@@	O	-1	12119460
,	O	-1	12119460
di@@	B-Disease	D003967	12119460
ar@@	I-Disease	-1	12119460
r@@	I-Disease	-1	12119460
he@@	I-Disease	-1	12119460
a	I-Disease	-1	12119460
3@@	O	-1	12119460
6.@@	O	-1	12119460
4@@	O	-1	12119460
/@@	O	-1	12119460
6.@@	O	-1	12119460
1@@	O	-1	12119460
/@@	O	-1	12119460
3.@@	O	-1	12119460
0@@	O	-1	12119460
,	O	-1	12119460
st@@	B-Disease	D013280	12119460
om@@	I-Disease	-1	12119460
ati@@	I-Disease	-1	12119460
tis	I-Disease	-1	12119460
1@@	O	-1	12119460
8.@@	O	-1	12119460
2@@	O	-1	12119460
/@@	O	-1	12119460
9.@@	O	-1	12119460
1@@	O	-1	12119460
/@@	O	-1	12119460
0@@	O	-1	12119460
,	O	-1	12119460
h@@	B-Disease	D060831	12119460
and@@	I-Disease	-1	12119460
-@@	I-Disease	-1	12119460
fo@@	I-Disease	-1	12119460
o@@	I-Disease	-1	12119460
t	I-Disease	-1	12119460
syndrome	I-Disease	-1	12119460
1@@	O	-1	12119460
2.@@	O	-1	12119460
1@@	O	-1	12119460
/@@	O	-1	12119460
0@@	O	-1	12119460
/@@	O	-1	12119460
0@@	O	-1	12119460
.	O	-1	12119460
Two	O	-1	12119460
patients	O	-1	12119460
developed	O	-1	12119460
hemoly@@	B-Disease	D006463	12119460
tic@@	I-Disease	-1	12119460
-@@	I-Disease	-1	12119460
ure@@	I-Disease	-1	12119460
mic	I-Disease	-1	12119460
syndrome	I-Disease	-1	12119460
(	O	-1	12119460
H@@	B-Disease	D006463	12119460
U@@	I-Disease	-1	12119460
S	I-Disease	-1	12119460
).	O	-1	12119460
CONCLUSIONS:	O	-1	12119460
H@@	O	-1	12119460
igh@@	O	-1	12119460
-@@	O	-1	12119460
dose	O	-1	12119460
5-@@	B-Chemical	D005472	12119460
F@@	I-Chemical	-1	12119460
U	I-Chemical	-1	12119460
/	O	-1	12119460
F@@	B-Chemical	D002955	12119460
A	I-Chemical	-1	12119460
/	O	-1	12119460
M@@	B-Chemical	D016685	12119460
M@@	I-Chemical	-1	12119460
C	I-Chemical	-1	12119460
is	O	-1	12119460
an	O	-1	12119460
effective	O	-1	12119460
and	O	-1	12119460
we@@	O	-1	12119460
ll@@	O	-1	12119460
-@@	O	-1	12119460
toler@@	O	-1	12119460
ated	O	-1	12119460
out@@	O	-1	12119460
patient	O	-1	12119460
regi@@	O	-1	12119460
men	O	-1	12119460
for	O	-1	12119460
A@@	B-Disease	D013274	12119460
G@@	I-Disease	-1	12119460
C	I-Disease	-1	12119460
(@@	O	-1	12119460
ob@@	O	-1	12119460
j@@	O	-1	12119460
ective	O	-1	12119460
response	O	-1	12119460
rate	O	-1	12119460
5@@	O	-1	12119460
4.@@	O	-1	12119460
6@@	O	-1	12119460
%).	O	-1	12119460
It	O	-1	12119460
may	O	-1	12119460
ser@@	O	-1	12119460
ve	O	-1	12119460
as	O	-1	12119460
an	O	-1	12119460
al@@	O	-1	12119460
tern@@	O	-1	12119460
ative	O	-1	12119460
to	O	-1	12119460
cisplatin	B-Chemical	D002945	12119460
-@@	O	-1	12119460
containing	O	-1	12119460
reg@@	O	-1	12119460
im@@	O	-1	12119460
ens@@	O	-1	12119460
;	O	-1	12119460
however,	O	-1	12119460
it	O	-1	12119460
has	O	-1	12119460
to	O	-1	12119460
be	O	-1	12119460
considered	O	-1	12119460
that	O	-1	12119460
possib@@	O	-1	12119460
ly	O	-1	12119460
H@@	B-Disease	D006463	12119460
U@@	I-Disease	-1	12119460
S	I-Disease	-1	12119460
may	O	-1	12119460
occur@@	O	-1	12119460
.	O	-1	12119460

P@@	O	-1	12165618
er@@	O	-1	12165618
sist@@	O	-1	12165618
ent	O	-1	12165618
ster@@	O	-1	12165618
ile	O	-1	12165618
leuk@@	B-Disease	-1	12165618
ocy@@	I-Disease	-1	12165618
t@@	I-Disease	-1	12165618
uria	I-Disease	-1	12165618
is	O	-1	12165618
associated	O	-1	12165618
with	O	-1	12165618
impaired	B-Disease	D007674	12165618
renal	I-Disease	-1	12165618
function	I-Disease	-1	12165618
in	O	-1	12165618
human	B-Disease	D015658	12165618
immuno@@	I-Disease	-1	12165618
defici@@	I-Disease	-1	12165618
ency	I-Disease	-1	12165618
vi@@	I-Disease	-1	12165618
ru@@	I-Disease	-1	12165618
s	I-Disease	-1	12165618
type	I-Disease	-1	12165618
1-@@	I-Disease	-1	12165618
inf@@	I-Disease	-1	12165618
ected	I-Disease	-1	12165618
children	O	-1	12165618
treated	O	-1	12165618
with	O	-1	12165618
ind@@	B-Chemical	D019469	12165618
in@@	I-Chemical	-1	12165618
avi@@	I-Chemical	-1	12165618
r	I-Chemical	-1	12165618
.	O	-1	12165618
BACKGROUND:	O	-1	12165618
Pro@@	O	-1	12165618
long@@	O	-1	12165618
ed	O	-1	12165618
administration	O	-1	12165618
of	O	-1	12165618
ind@@	B-Chemical	D019469	12165618
in@@	I-Chemical	-1	12165618
avi@@	I-Chemical	-1	12165618
r	I-Chemical	-1	12165618
is	O	-1	12165618
associated	O	-1	12165618
with	O	-1	12165618
the	O	-1	12165618
occur@@	O	-1	12165618
rence	O	-1	12165618
of	O	-1	12165618
a	O	-1	12165618
vari@@	O	-1	12165618
ety	O	-1	12165618
of	O	-1	12165618
renal	O	-1	12165618
complications	O	-1	12165618
in	O	-1	12165618
ad@@	O	-1	12165618
ult@@	O	-1	12165618
s.	O	-1	12165618
These	O	-1	12165618
we@@	O	-1	12165618
ll@@	O	-1	12165618
-@@	O	-1	12165618
doc@@	O	-1	12165618
um@@	O	-1	12165618
ent@@	O	-1	12165618
ed	O	-1	12165618
side	O	-1	12165618
effects	O	-1	12165618
have	O	-1	12165618
re@@	O	-1	12165618
stric@@	O	-1	12165618
ted	O	-1	12165618
the	O	-1	12165618
use	O	-1	12165618
of	O	-1	12165618
this	O	-1	12165618
pot@@	O	-1	12165618
ent	O	-1	12165618
prote@@	O	-1	12165618
ase	O	-1	12165618
inhibitor	O	-1	12165618
in	O	-1	12165618
child@@	O	-1	12165618
ren@@	O	-1	12165618
.	O	-1	12165618
D@@	O	-1	12165618
ES@@	O	-1	12165618
I@@	O	-1	12165618
G@@	O	-1	12165618
N@@	O	-1	12165618
:	O	-1	12165618
A	O	-1	12165618
pro@@	O	-1	12165618
sp@@	O	-1	12165618
ective	O	-1	12165618
study	O	-1	12165618
to	O	-1	12165618
monit@@	O	-1	12165618
or	O	-1	12165618
ind@@	B-Chemical	D019469	12165618
in@@	I-Chemical	-1	12165618
avi@@	I-Chemical	-1	12165618
r	I-Chemical	-1	12165618
-@@	O	-1	12165618
related	O	-1	12165618
nephro@@	B-Disease	D007674	12165618
toxicity	I-Disease	-1	12165618
in	O	-1	12165618
a	O	-1	12165618
co@@	O	-1	12165618
h@@	O	-1	12165618
ort	O	-1	12165618
of	O	-1	12165618
30	O	-1	12165618
human	B-Disease	D015658	12165618
immuno@@	I-Disease	-1	12165618
defici@@	I-Disease	-1	12165618
ency	I-Disease	-1	12165618
vi@@	I-Disease	-1	12165618
ru@@	I-Disease	-1	12165618
s	I-Disease	-1	12165618
type	I-Disease	-1	12165618
1-@@	I-Disease	-1	12165618
inf@@	I-Disease	-1	12165618
ected	I-Disease	-1	12165618
children	O	-1	12165618
treated	O	-1	12165618
with	O	-1	12165618
ind@@	B-Chemical	D019469	12165618
in@@	I-Chemical	-1	12165618
avi@@	I-Chemical	-1	12165618
r	I-Chemical	-1	12165618
.	O	-1	12165618
METHODS:	O	-1	12165618
U@@	O	-1	12165618
r@@	O	-1	12165618
inary	O	-1	12165618
p@@	O	-1	12165618
H@@	O	-1	12165618
,	O	-1	12165618
al@@	O	-1	12165618
bu@@	O	-1	12165618
min@@	O	-1	12165618
,	O	-1	12165618
creatinine	B-Chemical	D003404	12165618
,	O	-1	12165618
the	O	-1	12165618
presence	O	-1	12165618
of	O	-1	12165618
erythro@@	O	-1	12165618
cy@@	O	-1	12165618
t@@	O	-1	12165618
es,	O	-1	12165618
leuk@@	O	-1	12165618
ocy@@	O	-1	12165618
t@@	O	-1	12165618
es,	O	-1	12165618
bac@@	O	-1	12165618
ter@@	O	-1	12165618
ia	O	-1	12165618
and	O	-1	12165618
c@@	O	-1	12165618
r@@	O	-1	12165618
y@@	O	-1	12165618
st@@	O	-1	12165618
al@@	O	-1	12165618
s,	O	-1	12165618
and	O	-1	12165618
c@@	O	-1	12165618
ult@@	O	-1	12165618
ure	O	-1	12165618
were	O	-1	12165618
analy@@	O	-1	12165618
zed	O	-1	12165618
every	O	-1	12165618
3	O	-1	12165618
months	O	-1	12165618
for	O	-1	12165618
9@@	O	-1	12165618
6	O	-1	12165618
week@@	O	-1	12165618
s.	O	-1	12165618
S@@	O	-1	12165618
er@@	O	-1	12165618
um	O	-1	12165618
creatinine	B-Chemical	D003404	12165618
levels	O	-1	12165618
were	O	-1	12165618
ro@@	O	-1	12165618
ut@@	O	-1	12165618
ine@@	O	-1	12165618
ly	O	-1	12165618
determined	O	-1	12165618
at	O	-1	12165618
the	O	-1	12165618
same	O	-1	12165618
time	O	-1	12165618
po@@	O	-1	12165618
int@@	O	-1	12165618
s.	O	-1	12165618
S@@	O	-1	12165618
te@@	O	-1	12165618
ad@@	O	-1	12165618
y-@@	O	-1	12165618
state	O	-1	12165618
pharmac@@	O	-1	12165618
o@@	O	-1	12165618
kine@@	O	-1	12165618
tics	O	-1	12165618
of	O	-1	12165618
ind@@	B-Chemical	D019469	12165618
in@@	I-Chemical	-1	12165618
avi@@	I-Chemical	-1	12165618
r	I-Chemical	-1	12165618
were	O	-1	12165618
d@@	O	-1	12165618
one	O	-1	12165618
at	O	-1	12165618
week	O	-1	12165618
4	O	-1	12165618
after	O	-1	12165618
the	O	-1	12165618
initi@@	O	-1	12165618
ation	O	-1	12165618
of	O	-1	12165618
ind@@	B-Chemical	D019469	12165618
in@@	I-Chemical	-1	12165618
avi@@	I-Chemical	-1	12165618
r	I-Chemical	-1	12165618
.	O	-1	12165618
RESULTS:	O	-1	12165618
The	O	-1	12165618
cum@@	O	-1	12165618
ul@@	O	-1	12165618
ative	O	-1	12165618
incidence	O	-1	12165618
of	O	-1	12165618
per@@	O	-1	12165618
sist@@	O	-1	12165618
ent	O	-1	12165618
ster@@	O	-1	12165618
ile	O	-1	12165618
leuk@@	B-Disease	-1	12165618
ocy@@	I-Disease	-1	12165618
t@@	I-Disease	-1	12165618
uria	I-Disease	-1	12165618
(@@	O	-1	12165618
>	O	-1	12165618
or	O	-1	12165618
=@@	O	-1	12165618
7@@	O	-1	12165618
5	O	-1	12165618
cell@@	O	-1	12165618
s@@	O	-1	12165618
/	O	-1	12165618
mic@@	O	-1	12165618
r@@	O	-1	12165618
o	O	-1	12165618
L	O	-1	12165618
in	O	-1	12165618
at	O	-1	12165618
le@@	O	-1	12165618
ast	O	-1	12165618
2	O	-1	12165618
con@@	O	-1	12165618
sec@@	O	-1	12165618
utive	O	-1	12165618
v@@	O	-1	12165618
is@@	O	-1	12165618
it@@	O	-1	12165618
s)	O	-1	12165618
after	O	-1	12165618
9@@	O	-1	12165618
6	O	-1	12165618
weeks	O	-1	12165618
was	O	-1	12165618
5@@	O	-1	12165618
3@@	O	-1	12165618
%.	O	-1	12165618
P@@	O	-1	12165618
er@@	O	-1	12165618
sist@@	O	-1	12165618
ent	O	-1	12165618
ster@@	O	-1	12165618
ile	O	-1	12165618
leuk@@	B-Disease	-1	12165618
ocy@@	I-Disease	-1	12165618
t@@	I-Disease	-1	12165618
uria	I-Disease	-1	12165618
was	O	-1	12165618
frequ@@	O	-1	12165618
ently	O	-1	12165618
associated	O	-1	12165618
with	O	-1	12165618
a	O	-1	12165618
mil@@	O	-1	12165618
d	O	-1	12165618
increase	O	-1	12165618
in	O	-1	12165618
the	O	-1	12165618
urine	O	-1	12165618
al@@	O	-1	12165618
bu@@	O	-1	12165618
min@@	O	-1	12165618
/	O	-1	12165618
creatinine	B-Chemical	D003404	12165618
rati@@	O	-1	12165618
o	O	-1	12165618
and	O	-1	12165618
by	O	-1	12165618
micro@@	O	-1	12165618
sco@@	O	-1	12165618
p@@	O	-1	12165618
ic	O	-1	12165618
hemat@@	B-Disease	D006417	12165618
uria	I-Disease	-1	12165618
.	O	-1	12165618
The	O	-1	12165618
cum@@	O	-1	12165618
ul@@	O	-1	12165618
ative	O	-1	12165618
incidence	O	-1	12165618
of	O	-1	12165618
serum	O	-1	12165618
creatinine	B-Chemical	D003404	12165618
levels	O	-1	12165618
>@@	O	-1	12165618
50@@	O	-1	12165618
%	O	-1	12165618
ab@@	O	-1	12165618
o@@	O	-1	12165618
ve	O	-1	12165618
normal	O	-1	12165618
was	O	-1	12165618
3@@	O	-1	12165618
3@@	O	-1	12165618
%	O	-1	12165618
after	O	-1	12165618
9@@	O	-1	12165618
6	O	-1	12165618
week@@	O	-1	12165618
s.	O	-1	12165618
Ch@@	O	-1	12165618
ild@@	O	-1	12165618
ren	O	-1	12165618
with	O	-1	12165618
per@@	O	-1	12165618
sist@@	O	-1	12165618
ent	O	-1	12165618
ster@@	O	-1	12165618
ile	O	-1	12165618
leuk@@	B-Disease	-1	12165618
ocy@@	I-Disease	-1	12165618
t@@	I-Disease	-1	12165618
uria	I-Disease	-1	12165618
more	O	-1	12165618
frequ@@	O	-1	12165618
ently	O	-1	12165618
had	O	-1	12165618
serum	O	-1	12165618
creatinine	B-Chemical	D003404	12165618
levels	O	-1	12165618
of	O	-1	12165618
50@@	O	-1	12165618
%	O	-1	12165618
ab@@	O	-1	12165618
o@@	O	-1	12165618
ve	O	-1	12165618
normal	O	-1	12165618
than	O	-1	12165618
those	O	-1	12165618
children	O	-1	12165618
without	O	-1	12165618
per@@	O	-1	12165618
sist@@	O	-1	12165618
ent	O	-1	12165618
ster@@	O	-1	12165618
ile	O	-1	12165618
leuk@@	B-Disease	-1	12165618
ocy@@	I-Disease	-1	12165618
t@@	I-Disease	-1	12165618
uria	I-Disease	-1	12165618
.	O	-1	12165618
In	O	-1	12165618
children	O	-1	12165618
youn@@	O	-1	12165618
g@@	O	-1	12165618
er	O	-1	12165618
than	O	-1	12165618
5.@@	O	-1	12165618
6	O	-1	12165618
year@@	O	-1	12165618
s,	O	-1	12165618
per@@	O	-1	12165618
sist@@	O	-1	12165618
ent	O	-1	12165618
ster@@	O	-1	12165618
ile	O	-1	12165618
leuk@@	B-Disease	-1	12165618
ocy@@	I-Disease	-1	12165618
t@@	I-Disease	-1	12165618
uria	I-Disease	-1	12165618
was	O	-1	12165618
significantly	O	-1	12165618
more	O	-1	12165618
frequent	O	-1	12165618
than	O	-1	12165618
in	O	-1	12165618
ol@@	O	-1	12165618
der	O	-1	12165618
child@@	O	-1	12165618
ren@@	O	-1	12165618
.	O	-1	12165618
A	O	-1	12165618
higher	O	-1	12165618
cum@@	O	-1	12165618
ul@@	O	-1	12165618
ative	O	-1	12165618
incidence	O	-1	12165618
of	O	-1	12165618
per@@	O	-1	12165618
sist@@	O	-1	12165618
ent	O	-1	12165618
leuk@@	B-Disease	-1	12165618
ocy@@	I-Disease	-1	12165618
t@@	I-Disease	-1	12165618
uria	I-Disease	-1	12165618
was	O	-1	12165618
found	O	-1	12165618
in	O	-1	12165618
children	O	-1	12165618
with	O	-1	12165618
an	O	-1	12165618
a@@	O	-1	12165618
re@@	O	-1	12165618
a	O	-1	12165618
under	O	-1	12165618
the	O	-1	12165618
cur@@	O	-1	12165618
ve	O	-1	12165618
>@@	O	-1	12165618
1@@	O	-1	12165618
9	O	-1	12165618
mg/@@	O	-1	12165618
L	O	-1	12165618
x	O	-1	12165618
h	O	-1	12165618
or	O	-1	12165618
a	O	-1	12165618
pe@@	O	-1	12165618
a@@	O	-1	12165618
k	O	-1	12165618
serum	O	-1	12165618
level	O	-1	12165618
of	O	-1	12165618
ind@@	B-Chemical	D019469	12165618
in@@	I-Chemical	-1	12165618
avi@@	I-Chemical	-1	12165618
r	I-Chemical	-1	12165618
>@@	O	-1	12165618
12	O	-1	12165618
mg/@@	O	-1	12165618
L@@	O	-1	12165618
.	O	-1	12165618
In	O	-1	12165618
4	O	-1	12165618
child@@	O	-1	12165618
ren@@	O	-1	12165618
,	O	-1	12165618
ind@@	B-Chemical	D019469	12165618
in@@	I-Chemical	-1	12165618
avi@@	I-Chemical	-1	12165618
r	I-Chemical	-1	12165618
was	O	-1	12165618
discontinu@@	O	-1	12165618
ed	O	-1	12165618
because	O	-1	12165618
of	O	-1	12165618
nephro@@	B-Disease	D007674	12165618
toxicity	I-Disease	-1	12165618
.	O	-1	12165618
S@@	O	-1	12165618
ub@@	O	-1	12165618
sequ@@	O	-1	12165618
ent@@	O	-1	12165618
ly,	O	-1	12165618
the	O	-1	12165618
serum	O	-1	12165618
creatinine	B-Chemical	D003404	12165618
levels	O	-1	12165618
decreas@@	O	-1	12165618
ed,	O	-1	12165618
the	O	-1	12165618
urine	O	-1	12165618
al@@	O	-1	12165618
bu@@	O	-1	12165618
min@@	O	-1	12165618
/	O	-1	12165618
creatinine	B-Chemical	D003404	12165618
rati@@	O	-1	12165618
o@@	O	-1	12165618
s	O	-1	12165618
retur@@	O	-1	12165618
n@@	O	-1	12165618
ed	O	-1	12165618
to	O	-1	12165618
z@@	O	-1	12165618
ero@@	O	-1	12165618
,	O	-1	12165618
and	O	-1	12165618
the	O	-1	12165618
leuk@@	B-Disease	-1	12165618
ocy@@	I-Disease	-1	12165618
t@@	I-Disease	-1	12165618
uria	I-Disease	-1	12165618
dis@@	O	-1	12165618
appe@@	O	-1	12165618
a@@	O	-1	12165618
red	O	-1	12165618
within	O	-1	12165618
3	O	-1	12165618
months.	O	-1	12165618
CONCLUSIONS:	O	-1	12165618
Ch@@	O	-1	12165618
ild@@	O	-1	12165618
ren	O	-1	12165618
treated	O	-1	12165618
with	O	-1	12165618
ind@@	B-Chemical	D019469	12165618
in@@	I-Chemical	-1	12165618
avi@@	I-Chemical	-1	12165618
r	I-Chemical	-1	12165618
have	O	-1	12165618
a	O	-1	12165618
high	O	-1	12165618
cum@@	O	-1	12165618
ul@@	O	-1	12165618
ative	O	-1	12165618
incidence	O	-1	12165618
of	O	-1	12165618
per@@	O	-1	12165618
sist@@	O	-1	12165618
ent	O	-1	12165618
ster@@	O	-1	12165618
ile	O	-1	12165618
leuk@@	B-Disease	-1	12165618
ocy@@	I-Disease	-1	12165618
t@@	I-Disease	-1	12165618
uria	I-Disease	-1	12165618
.	O	-1	12165618
Ch@@	O	-1	12165618
ild@@	O	-1	12165618
ren	O	-1	12165618
with	O	-1	12165618
per@@	O	-1	12165618
sist@@	O	-1	12165618
ent	O	-1	12165618
ster@@	O	-1	12165618
ile	O	-1	12165618
leuk@@	B-Disease	-1	12165618
ocy@@	I-Disease	-1	12165618
t@@	I-Disease	-1	12165618
uria	I-Disease	-1	12165618
more	O	-1	12165618
frequ@@	O	-1	12165618
ently	O	-1	12165618
had	O	-1	12165618
an	O	-1	12165618
increase	O	-1	12165618
in	O	-1	12165618
serum	O	-1	12165618
creatinine	B-Chemical	D003404	12165618
levels	O	-1	12165618
of	O	-1	12165618
>@@	O	-1	12165618
50@@	O	-1	12165618
%	O	-1	12165618
ab@@	O	-1	12165618
o@@	O	-1	12165618
ve	O	-1	12165618
normal@@	O	-1	12165618
.	O	-1	12165618
Y@@	O	-1	12165618
oun@@	O	-1	12165618
g@@	O	-1	12165618
er	O	-1	12165618
children	O	-1	12165618
have	O	-1	12165618
an	O	-1	12165618
addi@@	O	-1	12165618
tional	O	-1	12165618
risk	O	-1	12165618
for	O	-1	12165618
renal	O	-1	12165618
complic@@	O	-1	12165618
ations.	O	-1	12165618
The	O	-1	12165618
impair@@	B-Disease	D007674	12165618
ment	I-Disease	-1	12165618
of	I-Disease	-1	12165618
the	I-Disease	-1	12165618
renal	I-Disease	-1	12165618
function	I-Disease	-1	12165618
in	O	-1	12165618
these	O	-1	12165618
children	O	-1	12165618
occurred	O	-1	12165618
in	O	-1	12165618
the	O	-1	12165618
absence	O	-1	12165618
of	O	-1	12165618
clinical	O	-1	12165618
symptoms	O	-1	12165618
of	O	-1	12165618
nephro@@	B-Disease	D053040	12165618
li@@	I-Disease	-1	12165618
th@@	I-Disease	-1	12165618
ia@@	I-Disease	-1	12165618
sis	I-Disease	-1	12165618
.	O	-1	12165618
In@@	B-Chemical	D019469	12165618
d@@	I-Chemical	-1	12165618
in@@	I-Chemical	-1	12165618
avi@@	I-Chemical	-1	12165618
r	I-Chemical	-1	12165618
-@@	O	-1	12165618
associated	O	-1	12165618
nephro@@	B-Disease	D007674	12165618
toxicity	I-Disease	-1	12165618
mus@@	O	-1	12165618
t	O	-1	12165618
be	O	-1	12165618
monit@@	O	-1	12165618
o@@	O	-1	12165618
red	O	-1	12165618
clo@@	O	-1	12165618
sel@@	O	-1	12165618
y,	O	-1	12165618
es@@	O	-1	12165618
p@@	O	-1	12165618
ec@@	O	-1	12165618
i@@	O	-1	12165618
ally	O	-1	12165618
in	O	-1	12165618
children	O	-1	12165618
with	O	-1	12165618
risk	O	-1	12165618
factors	O	-1	12165618
such	O	-1	12165618
as	O	-1	12165618
per@@	O	-1	12165618
sist@@	O	-1	12165618
ent	O	-1	12165618
ster@@	O	-1	12165618
ile	O	-1	12165618
leuk@@	B-Disease	-1	12165618
ocy@@	I-Disease	-1	12165618
t@@	I-Disease	-1	12165618
uria	I-Disease	-1	12165618
,	O	-1	12165618
age	O	-1	12165618
<@@	O	-1	12165618
5.@@	O	-1	12165618
6	O	-1	12165618
year@@	O	-1	12165618
s,	O	-1	12165618
an	O	-1	12165618
a@@	O	-1	12165618
re@@	O	-1	12165618
a	O	-1	12165618
under	O	-1	12165618
the	O	-1	12165618
cur@@	O	-1	12165618
ve	O	-1	12165618
of	O	-1	12165618
ind@@	B-Chemical	D019469	12165618
in@@	I-Chemical	-1	12165618
avi@@	I-Chemical	-1	12165618
r	I-Chemical	-1	12165618
>@@	O	-1	12165618
1@@	O	-1	12165618
9	O	-1	12165618
mg/@@	O	-1	12165618
L	O	-1	12165618
x	O	-1	12165618
h@@	O	-1	12165618
,	O	-1	12165618
and	O	-1	12165618
a	O	-1	12165618
C@@	O	-1	12165618
(@@	O	-1	12165618
ma@@	O	-1	12165618
x@@	O	-1	12165618
)	O	-1	12165618
>@@	O	-1	12165618
12	O	-1	12165618
mg/@@	O	-1	12165618
L@@	O	-1	12165618
.	O	-1	12165618

U@@	O	-1	12359538
til@@	O	-1	12359538
ity	O	-1	12359538
of	O	-1	12359538
tro@@	O	-1	12359538
p@@	O	-1	12359538
on@@	O	-1	12359538
in	O	-1	12359538
I	O	-1	12359538
in	O	-1	12359538
patients	O	-1	12359538
with	O	-1	12359538
cocaine	B-Chemical	D003042	12359538
-@@	O	-1	12359538
associated	O	-1	12359538
ch@@	B-Disease	D002637	12359538
est	I-Disease	-1	12359538
pain	I-Disease	-1	12359538
.	O	-1	12359538
B@@	O	-1	12359538
as@@	O	-1	12359538
el@@	O	-1	12359538
ine	O	-1	12359538
electro@@	O	-1	12359538
cardio@@	O	-1	12359538
gra@@	O	-1	12359538
m	O	-1	12359538
abnormal@@	O	-1	12359538
ities	O	-1	12359538
and	O	-1	12359538
mark@@	O	-1	12359538
et	O	-1	12359538
elev@@	O	-1	12359538
ations	O	-1	12359538
not	O	-1	12359538
associated	O	-1	12359538
with	O	-1	12359538
myocardial	B-Disease	D009202	12359538
necro@@	I-Disease	-1	12359538
sis	I-Disease	-1	12359538
ma@@	O	-1	12359538
k@@	O	-1	12359538
e	O	-1	12359538
ac@@	O	-1	12359538
cur@@	O	-1	12359538
ate	O	-1	12359538
diagnosis	O	-1	12359538
of	O	-1	12359538
myocardial	B-Disease	D009203	12359538
infarction	I-Disease	-1	12359538
(	O	-1	12359538
M@@	B-Disease	D009203	12359538
I	I-Disease	-1	12359538
)	O	-1	12359538
diff@@	O	-1	12359538
ic@@	O	-1	12359538
ult	O	-1	12359538
in	O	-1	12359538
patients	O	-1	12359538
with	O	-1	12359538
cocaine	B-Chemical	D003042	12359538
-@@	O	-1	12359538
associated	O	-1	12359538
ch@@	B-Disease	D002637	12359538
est	I-Disease	-1	12359538
pain	I-Disease	-1	12359538
.	O	-1	12359538
T@@	O	-1	12359538
ro@@	O	-1	12359538
p@@	O	-1	12359538
on@@	O	-1	12359538
in	O	-1	12359538
sam@@	O	-1	12359538
pl@@	O	-1	12359538
ing	O	-1	12359538
may	O	-1	12359538
o@@	O	-1	12359538
ff@@	O	-1	12359538
er	O	-1	12359538
greater	O	-1	12359538
diagnos@@	O	-1	12359538
tic	O	-1	12359538
u@@	O	-1	12359538
til@@	O	-1	12359538
ity	O	-1	12359538
in	O	-1	12359538
these	O	-1	12359538
patients.	O	-1	12359538
OBJECTIVE:	O	-1	12359538
To	O	-1	12359538
ass@@	O	-1	12359538
ess	O	-1	12359538
outcom@@	O	-1	12359538
es	O	-1	12359538
bas@@	O	-1	12359538
ed	O	-1	12359538
on	O	-1	12359538
tro@@	O	-1	12359538
p@@	O	-1	12359538
on@@	O	-1	12359538
in	O	-1	12359538
posi@@	O	-1	12359538
tivity	O	-1	12359538
in	O	-1	12359538
patients	O	-1	12359538
with	O	-1	12359538
cocaine	B-Chemical	D003042	12359538
ch@@	B-Disease	D002637	12359538
est	I-Disease	-1	12359538
pain	I-Disease	-1	12359538
ad@@	O	-1	12359538
mit@@	O	-1	12359538
ted	O	-1	12359538
for	O	-1	12359538
ex@@	O	-1	12359538
cl@@	O	-1	12359538
usion	O	-1	12359538
of	O	-1	12359538
M@@	B-Disease	D009203	12359538
I	I-Disease	-1	12359538
.	O	-1	12359538
METHODS:	O	-1	12359538
O@@	O	-1	12359538
ut@@	O	-1	12359538
com@@	O	-1	12359538
es	O	-1	12359538
were	O	-1	12359538
examined	O	-1	12359538
in	O	-1	12359538
patients	O	-1	12359538
ad@@	O	-1	12359538
mit@@	O	-1	12359538
ted	O	-1	12359538
for	O	-1	12359538
possible	O	-1	12359538
M@@	B-Disease	D009203	12359538
I	I-Disease	-1	12359538
after	O	-1	12359538
cocaine	B-Chemical	D003042	12359538
use.	O	-1	12359538
All	O	-1	12359538
patients	O	-1	12359538
under@@	O	-1	12359538
w@@	O	-1	12359538
ent	O	-1	12359538
a	O	-1	12359538
ra@@	O	-1	12359538
pid	O	-1	12359538
r@@	O	-1	12359538
ul@@	O	-1	12359538
e-@@	O	-1	12359538
in	O	-1	12359538
pro@@	O	-1	12359538
to@@	O	-1	12359538
co@@	O	-1	12359538
l	O	-1	12359538
that	O	-1	12359538
included	O	-1	12359538
ser@@	O	-1	12359538
ial	O	-1	12359538
sam@@	O	-1	12359538
pl@@	O	-1	12359538
ing	O	-1	12359538
of	O	-1	12359538
creat@@	B-Chemical	D003401	12359538
ine	I-Chemical	-1	12359538
kin@@	O	-1	12359538
ase	O	-1	12359538
(C@@	O	-1	12359538
K@@	O	-1	12359538
),	O	-1	12359538
C@@	O	-1	12359538
K@@	O	-1	12359538
-@@	O	-1	12359538
M@@	O	-1	12359538
B@@	O	-1	12359538
,	O	-1	12359538
and	O	-1	12359538
cardiac	O	-1	12359538
tro@@	O	-1	12359538
p@@	O	-1	12359538
on@@	O	-1	12359538
in	O	-1	12359538
I	O	-1	12359538
(@@	O	-1	12359538
cTn@@	O	-1	12359538
I@@	O	-1	12359538
)	O	-1	12359538
over	O	-1	12359538
e@@	O	-1	12359538
ight	O	-1	12359538
hour@@	O	-1	12359538
s.	O	-1	12359538
O@@	O	-1	12359538
ut@@	O	-1	12359538
com@@	O	-1	12359538
es	O	-1	12359538
included	O	-1	12359538
C@@	O	-1	12359538
K@@	O	-1	12359538
-@@	O	-1	12359538
M@@	O	-1	12359538
B	O	-1	12359538
M@@	B-Disease	D009203	12359538
I	I-Disease	-1	12359538
(C@@	O	-1	12359538
K@@	O	-1	12359538
-@@	O	-1	12359538
M@@	O	-1	12359538
B	O	-1	12359538
>@@	O	-1	12359538
or@@	O	-1	12359538
=	O	-1	12359538
8	O	-1	12359538
n@@	O	-1	12359538
g/@@	O	-1	12359538
m@@	O	-1	12359538
L	O	-1	12359538
with	O	-1	12359538
a	O	-1	12359538
rel@@	O	-1	12359538
ative	O	-1	12359538
in@@	O	-1	12359538
de@@	O	-1	12359538
x	O	-1	12359538
[@@	O	-1	12359538
(C@@	O	-1	12359538
K@@	O	-1	12359538
-@@	O	-1	12359538
M@@	O	-1	12359538
B	O	-1	12359538
x	O	-1	12359538
10@@	O	-1	12359538
0@@	O	-1	12359538
)@@	O	-1	12359538
/@@	O	-1	12359538
total	O	-1	12359538
C@@	O	-1	12359538
K@@	O	-1	12359538
]	O	-1	12359538
>@@	O	-1	12359538
or@@	O	-1	12359538
=	O	-1	12359538
4@@	O	-1	12359538
,	O	-1	12359538
cardiac	B-Disease	D003643	12359538
death	I-Disease	-1	12359538
,	O	-1	12359538
and	O	-1	12359538
significant	O	-1	12359538
coronary	B-Disease	D003327	12359538
disease	I-Disease	-1	12359538
(@@	O	-1	12359538
>@@	O	-1	12359538
or@@	O	-1	12359538
=@@	O	-1	12359538
50@@	O	-1	12359538
%).	O	-1	12359538
RESULTS:	O	-1	12359538
Of	O	-1	12359538
the	O	-1	12359538
2@@	O	-1	12359538
4@@	O	-1	12359538
6	O	-1	12359538
ad@@	O	-1	12359538
mit@@	O	-1	12359538
ted	O	-1	12359538
patients,	O	-1	12359538
3@@	O	-1	12359538
4	O	-1	12359538
(1@@	O	-1	12359538
4@@	O	-1	12359538
%)	O	-1	12359538
me@@	O	-1	12359538
t	O	-1	12359538
C@@	O	-1	12359538
K@@	O	-1	12359538
-@@	O	-1	12359538
M@@	O	-1	12359538
B	O	-1	12359538
c@@	O	-1	12359538
rit@@	O	-1	12359538
er@@	O	-1	12359538
ia	O	-1	12359538
for	O	-1	12359538
M@@	B-Disease	D009203	12359538
I	I-Disease	-1	12359538
and	O	-1	12359538
3@@	O	-1	12359538
8	O	-1	12359538
(1@@	O	-1	12359538
6@@	O	-1	12359538
%)	O	-1	12359538
had	O	-1	12359538
cTn@@	O	-1	12359538
I	O	-1	12359538
elev@@	O	-1	12359538
ations.	O	-1	12359538
An@@	O	-1	12359538
g@@	O	-1	12359538
io@@	O	-1	12359538
graph@@	O	-1	12359538
y	O	-1	12359538
was	O	-1	12359538
performed	O	-1	12359538
in	O	-1	12359538
2@@	O	-1	12359538
9	O	-1	12359538
of	O	-1	12359538
3@@	O	-1	12359538
8	O	-1	12359538
patients	O	-1	12359538
who	O	-1	12359538
were	O	-1	12359538
cTn@@	O	-1	12359538
I@@	O	-1	12359538
-@@	O	-1	12359538
posi@@	O	-1	12359538
ti@@	O	-1	12359538
ve,	O	-1	12359538
with	O	-1	12359538
significant	O	-1	12359538
disease	O	-1	12359538
present	O	-1	12359538
in	O	-1	12359538
25	O	-1	12359538
(@@	O	-1	12359538
8@@	O	-1	12359538
6@@	O	-1	12359538
%).	O	-1	12359538
Th@@	O	-1	12359538
ree	O	-1	12359538
of	O	-1	12359538
the	O	-1	12359538
four	O	-1	12359538
patients	O	-1	12359538
without	O	-1	12359538
significant	O	-1	12359538
disease	O	-1	12359538
who	O	-1	12359538
had	O	-1	12359538
cTn@@	O	-1	12359538
I	O	-1	12359538
elev@@	O	-1	12359538
ations	O	-1	12359538
me@@	O	-1	12359538
t	O	-1	12359538
C@@	O	-1	12359538
K@@	O	-1	12359538
-@@	O	-1	12359538
M@@	O	-1	12359538
B	O	-1	12359538
c@@	O	-1	12359538
rit@@	O	-1	12359538
er@@	O	-1	12359538
ia	O	-1	12359538
for	O	-1	12359538
M@@	B-Disease	D009203	12359538
I	I-Disease	-1	12359538
,	O	-1	12359538
and	O	-1	12359538
the	O	-1	12359538
other	O	-1	12359538
had	O	-1	12359538
a	O	-1	12359538
pe@@	O	-1	12359538
a@@	O	-1	12359538
k	O	-1	12359538
C@@	O	-1	12359538
K@@	O	-1	12359538
-@@	O	-1	12359538
M@@	O	-1	12359538
B	O	-1	12359538
level	O	-1	12359538
of	O	-1	12359538
13	O	-1	12359538
n@@	O	-1	12359538
g/@@	O	-1	12359538
m@@	O	-1	12359538
L@@	O	-1	12359538
.	O	-1	12359538
S@@	O	-1	12359538
en@@	O	-1	12359538
si@@	O	-1	12359538
ti@@	O	-1	12359538
vi@@	O	-1	12359538
ti@@	O	-1	12359538
es,	O	-1	12359538
spec@@	O	-1	12359538
ific@@	O	-1	12359538
iti@@	O	-1	12359538
es,	O	-1	12359538
and	O	-1	12359538
positive	O	-1	12359538
and	O	-1	12359538
negative	O	-1	12359538
lik@@	O	-1	12359538
e@@	O	-1	12359538
li@@	O	-1	12359538
ho@@	O	-1	12359538
od	O	-1	12359538
rati@@	O	-1	12359538
o@@	O	-1	12359538
s	O	-1	12359538
for	O	-1	12359538
predic@@	O	-1	12359538
ting	O	-1	12359538
cardiac	B-Disease	D003643	12359538
death	I-Disease	-1	12359538
or	O	-1	12359538
significant	O	-1	12359538
disease	O	-1	12359538
were	O	-1	12359538
high	O	-1	12359538
for	O	-1	12359538
both	O	-1	12359538
C@@	O	-1	12359538
K@@	O	-1	12359538
-@@	O	-1	12359538
M@@	O	-1	12359538
B	O	-1	12359538
M@@	B-Disease	D009203	12359538
I	I-Disease	-1	12359538
and	O	-1	12359538
cTn@@	O	-1	12359538
I	O	-1	12359538
and	O	-1	12359538
were	O	-1	12359538
not	O	-1	12359538
significantly	O	-1	12359538
differen@@	O	-1	12359538
t.	O	-1	12359538
CONCLUSIONS:	O	-1	12359538
M@@	O	-1	12359538
ost	O	-1	12359538
patients	O	-1	12359538
with	O	-1	12359538
cTn@@	O	-1	12359538
I	O	-1	12359538
elev@@	O	-1	12359538
ations	O	-1	12359538
me@@	O	-1	12359538
et	O	-1	12359538
C@@	O	-1	12359538
K@@	O	-1	12359538
-@@	O	-1	12359538
M@@	O	-1	12359538
B	O	-1	12359538
c@@	O	-1	12359538
rit@@	O	-1	12359538
er@@	O	-1	12359538
ia	O	-1	12359538
for	O	-1	12359538
M@@	B-Disease	D009203	12359538
I	I-Disease	-1	12359538
,	O	-1	12359538
as	O	-1	12359538
well	O	-1	12359538
as	O	-1	12359538
have	O	-1	12359538
a	O	-1	12359538
high	O	-1	12359538
incidence	O	-1	12359538
of	O	-1	12359538
underlying	O	-1	12359538
significant	O	-1	12359538
disease.	O	-1	12359538
T@@	O	-1	12359538
ro@@	O	-1	12359538
p@@	O	-1	12359538
on@@	O	-1	12359538
in	O	-1	12359538
appear@@	O	-1	12359538
s	O	-1	12359538
to	O	-1	12359538
have	O	-1	12359538
an	O	-1	12359538
equ@@	O	-1	12359538
i@@	O	-1	12359538
val@@	O	-1	12359538
ent	O	-1	12359538
diagnos@@	O	-1	12359538
tic	O	-1	12359538
ac@@	O	-1	12359538
cur@@	O	-1	12359538
ac@@	O	-1	12359538
y	O	-1	12359538
compared	O	-1	12359538
with	O	-1	12359538
C@@	O	-1	12359538
K@@	O	-1	12359538
-@@	O	-1	12359538
M@@	O	-1	12359538
B	O	-1	12359538
for	O	-1	12359538
diagnos@@	O	-1	12359538
ing	O	-1	12359538
necro@@	B-Disease	D009336	12359538
sis	I-Disease	-1	12359538
in	O	-1	12359538
patients	O	-1	12359538
with	O	-1	12359538
cocaine	B-Chemical	D003042	12359538
-@@	O	-1	12359538
associated	O	-1	12359538
ch@@	B-Disease	D002637	12359538
est	I-Disease	-1	12359538
pain	I-Disease	-1	12359538
and	O	-1	12359538
sus@@	O	-1	12359538
p@@	O	-1	12359538
ected	O	-1	12359538
M@@	B-Disease	D009203	12359538
I	I-Disease	-1	12359538
.	O	-1	12359538

Ac@@	O	-1	12372954
ute	O	-1	12372954
interstitial	B-Disease	D009395	12372954
neph@@	I-Disease	-1	12372954
ritis	I-Disease	-1	12372954
due	O	-1	12372954
to	O	-1	12372954
n@@	B-Chemical	D009530	12372954
ic@@	I-Chemical	-1	12372954
erg@@	I-Chemical	-1	12372954
ol@@	I-Chemical	-1	12372954
ine	I-Chemical	-1	12372954
(	O	-1	12372954
S@@	B-Chemical	D009530	12372954
er@@	I-Chemical	-1	12372954
mi@@	I-Chemical	-1	12372954
on	I-Chemical	-1	12372954
).	O	-1	12372954
We	O	-1	12372954
report	O	-1	12372954
a	O	-1	12372954
case	O	-1	12372954
of	O	-1	12372954
acute	O	-1	12372954
interstitial	B-Disease	D009395	12372954
neph@@	I-Disease	-1	12372954
ritis	I-Disease	-1	12372954
(	O	-1	12372954
A@@	B-Disease	D009395	12372954
I@@	I-Disease	-1	12372954
N	I-Disease	-1	12372954
)	O	-1	12372954
due	O	-1	12372954
to	O	-1	12372954
n@@	B-Chemical	D009530	12372954
ic@@	I-Chemical	-1	12372954
erg@@	I-Chemical	-1	12372954
ol@@	I-Chemical	-1	12372954
ine	I-Chemical	-1	12372954
(	O	-1	12372954
S@@	B-Chemical	D009530	12372954
er@@	I-Chemical	-1	12372954
mi@@	I-Chemical	-1	12372954
on	I-Chemical	-1	12372954
).	O	-1	12372954
A	O	-1	12372954
50@@	O	-1	12372954
-@@	O	-1	12372954
year-old	O	-1	12372954
patient	O	-1	12372954
ad@@	O	-1	12372954
mit@@	O	-1	12372954
ted	O	-1	12372954
to	O	-1	12372954
our	O	-1	12372954
hospit@@	O	-1	12372954
al	O	-1	12372954
for	O	-1	12372954
f@@	B-Disease	D005334	12372954
ev@@	I-Disease	-1	12372954
er	I-Disease	-1	12372954
and	O	-1	12372954
acute	B-Disease	D058186	12372954
renal	I-Disease	-1	12372954
failure	I-Disease	-1	12372954
.	O	-1	12372954
B@@	O	-1	12372954
e@@	O	-1	12372954
fore	O	-1	12372954
ad@@	O	-1	12372954
mis@@	O	-1	12372954
sion,	O	-1	12372954
he	O	-1	12372954
had	O	-1	12372954
been	O	-1	12372954
taking	O	-1	12372954
n@@	B-Chemical	D009530	12372954
ic@@	I-Chemical	-1	12372954
erg@@	I-Chemical	-1	12372954
ol@@	I-Chemical	-1	12372954
ine	I-Chemical	-1	12372954
and	O	-1	12372954
ben@@	B-Chemical	C036067	12372954
da@@	I-Chemical	-1	12372954
z@@	I-Chemical	-1	12372954
a@@	I-Chemical	-1	12372954
c	I-Chemical	-1	12372954
l@@	I-Chemical	-1	12372954
ys@@	I-Chemical	-1	12372954
ine	I-Chemical	-1	12372954
due	O	-1	12372954
to	O	-1	12372954
ret@@	B-Disease	D012170	12372954
inal	I-Disease	-1	12372954
ve@@	I-Disease	-1	12372954
in	I-Disease	-1	12372954
oc@@	I-Disease	-1	12372954
cl@@	I-Disease	-1	12372954
usion	I-Disease	-1	12372954
at	O	-1	12372954
oph@@	O	-1	12372954
thal@@	O	-1	12372954
mo@@	O	-1	12372954
log@@	O	-1	12372954
ic	O	-1	12372954
de@@	O	-1	12372954
part@@	O	-1	12372954
ment.	O	-1	12372954
The@@	O	-1	12372954
re@@	O	-1	12372954
af@@	O	-1	12372954
ter@@	O	-1	12372954
,	O	-1	12372954
he	O	-1	12372954
experienced	O	-1	12372954
inter@@	O	-1	12372954
mit@@	O	-1	12372954
t@@	O	-1	12372954
ent	O	-1	12372954
f@@	B-Disease	D005334	12372954
ev@@	I-Disease	-1	12372954
er	I-Disease	-1	12372954
and	O	-1	12372954
s@@	B-Disease	D005076	12372954
k@@	I-Disease	-1	12372954
in	I-Disease	-1	12372954
r@@	I-Disease	-1	12372954
as@@	I-Disease	-1	12372954
h	I-Disease	-1	12372954
.	O	-1	12372954
O@@	O	-1	12372954
n	O	-1	12372954
ad@@	O	-1	12372954
mis@@	O	-1	12372954
sion,	O	-1	12372954
clinical	O	-1	12372954
symptoms	O	-1	12372954
(@@	O	-1	12372954
i.@@	O	-1	12372954
e.	O	-1	12372954
arth@@	B-Disease	D018771	12372954
r@@	I-Disease	-1	12372954
al@@	I-Disease	-1	12372954
g@@	I-Disease	-1	12372954
ia	I-Disease	-1	12372954
and	O	-1	12372954
f@@	B-Disease	D005334	12372954
ev@@	I-Disease	-1	12372954
er	I-Disease	-1	12372954
)	O	-1	12372954
and	O	-1	12372954
labor@@	O	-1	12372954
atory	O	-1	12372954
findings	O	-1	12372954
(@@	O	-1	12372954
i.@@	O	-1	12372954
e.	O	-1	12372954
e@@	B-Disease	D004802	12372954
os@@	I-Disease	-1	12372954
in@@	I-Disease	-1	12372954
oph@@	I-Disease	-1	12372954
il@@	I-Disease	-1	12372954
ia	I-Disease	-1	12372954
and	O	-1	12372954
renal	B-Disease	D051437	12372954
failure	I-Disease	-1	12372954
)	O	-1	12372954
suggested	O	-1	12372954
A@@	B-Disease	D009395	12372954
I@@	I-Disease	-1	12372954
N	I-Disease	-1	12372954
,	O	-1	12372954
and	O	-1	12372954
which	O	-1	12372954
was	O	-1	12372954
con@@	O	-1	12372954
fir@@	O	-1	12372954
m@@	O	-1	12372954
ed	O	-1	12372954
by	O	-1	12372954
path@@	O	-1	12372954
ologic	O	-1	12372954
findings	O	-1	12372954
on	O	-1	12372954
renal	O	-1	12372954
bio@@	O	-1	12372954
psy@@	O	-1	12372954
.	O	-1	12372954
A	O	-1	12372954
lymph@@	O	-1	12372954
ocyte	O	-1	12372954
trans@@	O	-1	12372954
formation	O	-1	12372954
test	O	-1	12372954
demonstrated	O	-1	12372954
a	O	-1	12372954
positive	O	-1	12372954
result	O	-1	12372954
against	O	-1	12372954
n@@	B-Chemical	D009530	12372954
ic@@	I-Chemical	-1	12372954
erg@@	I-Chemical	-1	12372954
ol@@	I-Chemical	-1	12372954
ine	I-Chemical	-1	12372954
.	O	-1	12372954
Treat@@	O	-1	12372954
ment	O	-1	12372954
was	O	-1	12372954
consist@@	O	-1	12372954
ed	O	-1	12372954
of	O	-1	12372954
withdrawal	O	-1	12372954
of	O	-1	12372954
n@@	B-Chemical	D009530	12372954
ic@@	I-Chemical	-1	12372954
erg@@	I-Chemical	-1	12372954
ol@@	I-Chemical	-1	12372954
ine	I-Chemical	-1	12372954
and	O	-1	12372954
intravenous	O	-1	12372954
methyl@@	B-Chemical	D008775	12372954
pre@@	I-Chemical	-1	12372954
d@@	I-Chemical	-1	12372954
n@@	I-Chemical	-1	12372954
isol@@	I-Chemical	-1	12372954
one	I-Chemical	-1	12372954
,	O	-1	12372954
and	O	-1	12372954
h@@	O	-1	12372954
is	O	-1	12372954
renal	O	-1	12372954
function	O	-1	12372954
was	O	-1	12372954
complete@@	O	-1	12372954
ly	O	-1	12372954
reco@@	O	-1	12372954
ve@@	O	-1	12372954
red.	O	-1	12372954
To	O	-1	12372954
our	O	-1	12372954
know@@	O	-1	12372954
le@@	O	-1	12372954
d@@	O	-1	12372954
g@@	O	-1	12372954
e,	O	-1	12372954
this	O	-1	12372954
is	O	-1	12372954
the	O	-1	12372954
first	O	-1	12372954
report	O	-1	12372954
of	O	-1	12372954
n@@	B-Chemical	D009530	12372954
ic@@	I-Chemical	-1	12372954
erg@@	I-Chemical	-1	12372954
ol@@	I-Chemical	-1	12372954
ine	I-Chemical	-1	12372954
-@@	O	-1	12372954
associated	O	-1	12372954
A@@	B-Disease	D009395	12372954
I@@	I-Disease	-1	12372954
N	I-Disease	-1	12372954
.	O	-1	12372954

Ne@@	B-Disease	D009459	12452552
uro@@	I-Disease	-1	12452552
le@@	I-Disease	-1	12452552
p@@	I-Disease	-1	12452552
tic	I-Disease	-1	12452552
mal@@	I-Disease	-1	12452552
i@@	I-Disease	-1	12452552
gn@@	I-Disease	-1	12452552
ant	I-Disease	-1	12452552
syndrome	I-Disease	-1	12452552
complic@@	O	-1	12452552
ated	O	-1	12452552
by	O	-1	12452552
mas@@	O	-1	12452552
sive	O	-1	12452552
in@@	O	-1	12452552
test@@	O	-1	12452552
inal	O	-1	12452552
ble@@	B-Disease	D006470	12452552
ed@@	I-Disease	-1	12452552
ing	I-Disease	-1	12452552
in	O	-1	12452552
a	O	-1	12452552
patient	O	-1	12452552
with	O	-1	12452552
chronic	B-Disease	D007676	12452552
renal	I-Disease	-1	12452552
failure	I-Disease	-1	12452552
.	O	-1	12452552
A	O	-1	12452552
patient	O	-1	12452552
with	O	-1	12452552
chronic	B-Disease	D007676	12452552
renal	I-Disease	-1	12452552
failure	I-Disease	-1	12452552
(	O	-1	12452552
CR@@	B-Disease	D007676	12452552
F	I-Disease	-1	12452552
)	O	-1	12452552
developed	O	-1	12452552
neuro@@	B-Disease	D009459	12452552
le@@	I-Disease	-1	12452552
p@@	I-Disease	-1	12452552
tic	I-Disease	-1	12452552
mal@@	I-Disease	-1	12452552
i@@	I-Disease	-1	12452552
gn@@	I-Disease	-1	12452552
ant	I-Disease	-1	12452552
syndrome	I-Disease	-1	12452552
(	O	-1	12452552
N@@	B-Disease	D009459	12452552
M@@	I-Disease	-1	12452552
S	I-Disease	-1	12452552
)	O	-1	12452552
after	O	-1	12452552
administration	O	-1	12452552
of	O	-1	12452552
ris@@	B-Chemical	D018967	12452552
perid@@	I-Chemical	-1	12452552
one	I-Chemical	-1	12452552
and	O	-1	12452552
levo@@	B-Chemical	D008728	12452552
me@@	I-Chemical	-1	12452552
pro@@	I-Chemical	-1	12452552
ma@@	I-Chemical	-1	12452552
z@@	I-Chemical	-1	12452552
ine	I-Chemical	-1	12452552
.	O	-1	12452552
In	O	-1	12452552
addition	O	-1	12452552
to	O	-1	12452552
the	O	-1	12452552
typ@@	O	-1	12452552
ical	O	-1	12452552
symptoms	O	-1	12452552
of	O	-1	12452552
N@@	B-Disease	D009459	12452552
M@@	I-Disease	-1	12452552
S	I-Disease	-1	12452552
,	O	-1	12452552
mas@@	O	-1	12452552
sive	O	-1	12452552
in@@	O	-1	12452552
test@@	O	-1	12452552
inal	O	-1	12452552
ble@@	B-Disease	D006470	12452552
ed@@	I-Disease	-1	12452552
ing	I-Disease	-1	12452552
was	O	-1	12452552
observed	O	-1	12452552
during	O	-1	12452552
the	O	-1	12452552
episo@@	O	-1	12452552
de@@	O	-1	12452552
.	O	-1	12452552
This	O	-1	12452552
report	O	-1	12452552
suggests	O	-1	12452552
that	O	-1	12452552
N@@	B-Disease	D009459	12452552
M@@	I-Disease	-1	12452552
S	I-Disease	-1	12452552
in	O	-1	12452552
a	O	-1	12452552
patient	O	-1	12452552
with	O	-1	12452552
CR@@	B-Disease	D007676	12452552
F	I-Disease	-1	12452552
may	O	-1	12452552
be	O	-1	12452552
complic@@	O	-1	12452552
ated	O	-1	12452552
by	O	-1	12452552
in@@	O	-1	12452552
test@@	O	-1	12452552
inal	O	-1	12452552
ble@@	B-Disease	D006470	12452552
ed@@	I-Disease	-1	12452552
ing	I-Disease	-1	12452552
and	O	-1	12452552
ne@@	O	-1	12452552
ed@@	O	-1	12452552
s	O	-1	12452552
spec@@	O	-1	12452552
ial	O	-1	12452552
cau@@	O	-1	12452552
tion	O	-1	12452552
for	O	-1	12452552
this	O	-1	12452552
complic@@	O	-1	12452552
ation.	O	-1	12452552

B@@	O	-1	12487093
lo@@	O	-1	12487093
od	O	-1	12487093
brain	O	-1	12487093
bar@@	O	-1	12487093
ri@@	O	-1	12487093
er	O	-1	12487093
in	O	-1	12487093
ri@@	O	-1	12487093
gh@@	O	-1	12487093
t@@	O	-1	12487093
-	O	-1	12487093
and	O	-1	12487093
le@@	O	-1	12487093
f@@	O	-1	12487093
t-@@	O	-1	12487093
pa@@	O	-1	12487093
w@@	O	-1	12487093
ed	O	-1	12487093
female	O	-1	12487093
rats	O	-1	12487093
assessed	O	-1	12487093
by	O	-1	12487093
a	O	-1	12487093
new	O	-1	12487093
st@@	O	-1	12487093
aining	O	-1	12487093
meth@@	O	-1	12487093
o@@	O	-1	12487093
d.	O	-1	12487093
The	O	-1	12487093
as@@	O	-1	12487093
ym@@	O	-1	12487093
met@@	O	-1	12487093
r@@	O	-1	12487093
ical	O	-1	12487093
b@@	O	-1	12487093
re@@	O	-1	12487093
ak@@	O	-1	12487093
do@@	O	-1	12487093
w@@	O	-1	12487093
n	O	-1	12487093
of	O	-1	12487093
the	O	-1	12487093
blo@@	O	-1	12487093
o@@	O	-1	12487093
d-@@	O	-1	12487093
brain	O	-1	12487093
bar@@	O	-1	12487093
ri@@	O	-1	12487093
er	O	-1	12487093
(B@@	O	-1	12487093
B@@	O	-1	12487093
B@@	O	-1	12487093
)	O	-1	12487093
was	O	-1	12487093
studied	O	-1	12487093
in	O	-1	12487093
female	O	-1	12487093
rats.	O	-1	12487093
P@@	O	-1	12487093
a@@	O	-1	12487093
w	O	-1	12487093
pre@@	O	-1	12487093
fe@@	O	-1	12487093
rence	O	-1	12487093
was	O	-1	12487093
assessed	O	-1	12487093
by	O	-1	12487093
a	O	-1	12487093
fo@@	O	-1	12487093
od	O	-1	12487093
reac@@	O	-1	12487093
h@@	O	-1	12487093
ing	O	-1	12487093
test@@	O	-1	12487093
.	O	-1	12487093
Ad@@	B-Chemical	D004837	12487093
ren@@	I-Chemical	-1	12487093
aline	I-Chemical	-1	12487093
-induced	O	-1	12487093
hypertension	B-Disease	D006973	12487093
was	O	-1	12487093
used	O	-1	12487093
to	O	-1	12487093
de@@	O	-1	12487093
stro@@	O	-1	12487093
y	O	-1	12487093
the	O	-1	12487093
B@@	O	-1	12487093
B@@	O	-1	12487093
B@@	O	-1	12487093
,	O	-1	12487093
which	O	-1	12487093
was	O	-1	12487093
evaluated	O	-1	12487093
using	O	-1	12487093
tri@@	B-Chemical	C009591	12487093
phenyl@@	I-Chemical	-1	12487093
te@@	I-Chemical	-1	12487093
tra@@	I-Chemical	-1	12487093
z@@	I-Chemical	-1	12487093
ol@@	I-Chemical	-1	12487093
i@@	I-Chemical	-1	12487093
um	I-Chemical	-1	12487093
(	O	-1	12487093
T@@	B-Chemical	C009591	12487093
T@@	I-Chemical	-1	12487093
C	I-Chemical	-1	12487093
)	O	-1	12487093
st@@	O	-1	12487093
aining	O	-1	12487093
of	O	-1	12487093
the	O	-1	12487093
brain	O	-1	12487093
s@@	O	-1	12487093
l@@	O	-1	12487093
ic@@	O	-1	12487093
es	O	-1	12487093
j@@	O	-1	12487093
us@@	O	-1	12487093
t	O	-1	12487093
after	O	-1	12487093
gi@@	O	-1	12487093
ving	O	-1	12487093
adren@@	B-Chemical	D004837	12487093
aline	I-Chemical	-1	12487093
for	O	-1	12487093
30	O	-1	12487093
s.	O	-1	12487093
In	O	-1	12487093
normal	O	-1	12487093
rats,	O	-1	12487093
the	O	-1	12487093
wh@@	O	-1	12487093
ole	O	-1	12487093
brain	O	-1	12487093
sec@@	O	-1	12487093
tions	O	-1	12487093
ex@@	O	-1	12487093
hib@@	O	-1	12487093
ited	O	-1	12487093
complete	O	-1	12487093
st@@	O	-1	12487093
aining	O	-1	12487093
with	O	-1	12487093
T@@	B-Chemical	C009591	12487093
T@@	I-Chemical	-1	12487093
C	I-Chemical	-1	12487093
.	O	-1	12487093
After	O	-1	12487093
adren@@	B-Chemical	D004837	12487093
aline	I-Chemical	-1	12487093
infusion	O	-1	12487093
for	O	-1	12487093
30	O	-1	12487093
s,	O	-1	12487093
there	O	-1	12487093
were	O	-1	12487093
larg@@	O	-1	12487093
e	O	-1	12487093
un@@	O	-1	12487093
st@@	O	-1	12487093
ained	O	-1	12487093
a@@	O	-1	12487093
reas	O	-1	12487093
in	O	-1	12487093
the	O	-1	12487093
left	O	-1	12487093
brain	O	-1	12487093
in	O	-1	12487093
ri@@	O	-1	12487093
gh@@	O	-1	12487093
t-@@	O	-1	12487093
pa@@	O	-1	12487093
w@@	O	-1	12487093
ed	O	-1	12487093
anim@@	O	-1	12487093
al@@	O	-1	12487093
s,	O	-1	12487093
and	O	-1	12487093
v@@	O	-1	12487093
ic@@	O	-1	12487093
e	O	-1	12487093
ver@@	O	-1	12487093
s@@	O	-1	12487093
a	O	-1	12487093
in	O	-1	12487093
le@@	O	-1	12487093
f@@	O	-1	12487093
t-@@	O	-1	12487093
pa@@	O	-1	12487093
w@@	O	-1	12487093
ed	O	-1	12487093
anim@@	O	-1	12487093
al@@	O	-1	12487093
s.	O	-1	12487093
S@@	O	-1	12487093
im@@	O	-1	12487093
il@@	O	-1	12487093
ar	O	-1	12487093
results	O	-1	12487093
were	O	-1	12487093
obtained	O	-1	12487093
in	O	-1	12487093
seizure	B-Disease	D012640	12487093
-induced	O	-1	12487093
b@@	O	-1	12487093
re@@	O	-1	12487093
ak@@	O	-1	12487093
do@@	O	-1	12487093
w@@	O	-1	12487093
n	O	-1	12487093
of	O	-1	12487093
B@@	O	-1	12487093
B@@	O	-1	12487093
B@@	O	-1	12487093
.	O	-1	12487093
These	O	-1	12487093
results	O	-1	12487093
were	O	-1	12487093
expl@@	O	-1	12487093
ained	O	-1	12487093
by	O	-1	12487093
an	O	-1	12487093
as@@	O	-1	12487093
ym@@	O	-1	12487093
me@@	O	-1	12487093
tri@@	O	-1	12487093
c	O	-1	12487093
cerebral	O	-1	12487093
blood	O	-1	12487093
flow	O	-1	12487093
depend@@	O	-1	12487093
ing	O	-1	12487093
up@@	O	-1	12487093
on	O	-1	12487093
the	O	-1	12487093
pa@@	O	-1	12487093
w	O	-1	12487093
pre@@	O	-1	12487093
fe@@	O	-1	12487093
rence	O	-1	12487093
in	O	-1	12487093
rats.	O	-1	12487093
It	O	-1	12487093
was	O	-1	12487093
suggested	O	-1	12487093
that	O	-1	12487093
this	O	-1	12487093
new	O	-1	12487093
meth@@	O	-1	12487093
od	O	-1	12487093
and	O	-1	12487093
the	O	-1	12487093
results	O	-1	12487093
are	O	-1	12487093
consist@@	O	-1	12487093
ent	O	-1	12487093
with	O	-1	12487093
contr@@	O	-1	12487093
al@@	O	-1	12487093
ateral	O	-1	12487093
motor	O	-1	12487093
control	O	-1	12487093
that	O	-1	12487093
may	O	-1	12487093
be	O	-1	12487093
important	O	-1	12487093
in	O	-1	12487093
determin@@	O	-1	12487093
ing	O	-1	12487093
the	O	-1	12487093
domin@@	O	-1	12487093
ant	O	-1	12487093
cerebral	O	-1	12487093
he@@	O	-1	12487093
mis@@	O	-1	12487093
ph@@	O	-1	12487093
ere	O	-1	12487093
in	O	-1	12487093
anim@@	O	-1	12487093
al@@	O	-1	12487093
s.	O	-1	12487093

C@@	B-Chemical	C043211	12498738
ar@@	I-Chemical	-1	12498738
ve@@	I-Chemical	-1	12498738
di@@	I-Chemical	-1	12498738
lol	I-Chemical	-1	12498738
prot@@	O	-1	12498738
ects	O	-1	12498738
against	O	-1	12498738
dox@@	B-Chemical	D004317	12498738
orub@@	I-Chemical	-1	12498738
icin	I-Chemical	-1	12498738
-induced	O	-1	12498738
mitochondrial	O	-1	12498738
cardi@@	B-Disease	D009202	12498738
om@@	I-Disease	-1	12498738
yo@@	I-Disease	-1	12498738
pathy	I-Disease	-1	12498738
.	O	-1	12498738
S@@	O	-1	12498738
e@@	O	-1	12498738
ver@@	O	-1	12498738
al	O	-1	12498738
cyto@@	O	-1	12498738
path@@	O	-1	12498738
ic	O	-1	12498738
mechanisms	O	-1	12498738
have	O	-1	12498738
been	O	-1	12498738
suggested	O	-1	12498738
to	O	-1	12498738
medi@@	O	-1	12498738
ate	O	-1	12498738
the	O	-1	12498738
dose-@@	O	-1	12498738
lim@@	O	-1	12498738
it@@	O	-1	12498738
ing	O	-1	12498738
cum@@	O	-1	12498738
ul@@	O	-1	12498738
ative	O	-1	12498738
and	O	-1	12498738
ir@@	O	-1	12498738
reversible	O	-1	12498738
cardi@@	B-Disease	D009202	12498738
om@@	I-Disease	-1	12498738
yo@@	I-Disease	-1	12498738
pathy	I-Disease	-1	12498738
caused	O	-1	12498738
by	O	-1	12498738
dox@@	B-Chemical	D004317	12498738
orub@@	I-Chemical	-1	12498738
icin	I-Chemical	-1	12498738
.	O	-1	12498738
Rec@@	O	-1	12498738
ent	O	-1	12498738
evidence	O	-1	12498738
indic@@	O	-1	12498738
ates	O	-1	12498738
that	O	-1	12498738
oxid@@	O	-1	12498738
ative	O	-1	12498738
stres@@	O	-1	12498738
s	O	-1	12498738
and	O	-1	12498738
mitochondrial	B-Disease	D028361	12498738
dysfunction	I-Disease	-1	12498738
are	O	-1	12498738
ke@@	O	-1	12498738
y	O	-1	12498738
factors	O	-1	12498738
in	O	-1	12498738
the	O	-1	12498738
path@@	O	-1	12498738
o@@	O	-1	12498738
genic	O	-1	12498738
pro@@	O	-1	12498738
ces@@	O	-1	12498738
s.	O	-1	12498738
The	O	-1	12498738
ob@@	O	-1	12498738
j@@	O	-1	12498738
ective	O	-1	12498738
of	O	-1	12498738
this	O	-1	12498738
investig@@	O	-1	12498738
ation	O	-1	12498738
was	O	-1	12498738
to	O	-1	12498738
test	O	-1	12498738
the	O	-1	12498738
hypo@@	O	-1	12498738
thesis	O	-1	12498738
that	O	-1	12498738
car@@	B-Chemical	C043211	12498738
ve@@	I-Chemical	-1	12498738
di@@	I-Chemical	-1	12498738
lol	I-Chemical	-1	12498738
,	O	-1	12498738
a	O	-1	12498738
non@@	O	-1	12498738
selective	O	-1	12498738
beta-@@	O	-1	12498738
adrenergic	O	-1	12498738
receptor	O	-1	12498738
antagonist	O	-1	12498738
with	O	-1	12498738
pot@@	O	-1	12498738
ent	O	-1	12498738
anti@@	O	-1	12498738
oxid@@	O	-1	12498738
ant	O	-1	12498738
pro@@	O	-1	12498738
per@@	O	-1	12498738
ti@@	O	-1	12498738
es,	O	-1	12498738
prot@@	O	-1	12498738
ects	O	-1	12498738
against	O	-1	12498738
the	O	-1	12498738
cardiac	O	-1	12498738
and	O	-1	12498738
hepatic	O	-1	12498738
mitochondrial	O	-1	12498738
bio@@	O	-1	12498738
en@@	O	-1	12498738
erg@@	O	-1	12498738
e@@	O	-1	12498738
tic	O	-1	12498738
dysfunction	O	-1	12498738
associated	O	-1	12498738
with	O	-1	12498738
sub@@	O	-1	12498738
chronic	O	-1	12498738
dox@@	B-Chemical	D004317	12498738
orub@@	I-Chemical	-1	12498738
icin	I-Chemical	-1	12498738
toxicity	B-Disease	D064420	12498738
.	O	-1	12498738
H@@	O	-1	12498738
ear@@	O	-1	12498738
t	O	-1	12498738
and	O	-1	12498738
liver	O	-1	12498738
mitochond@@	O	-1	12498738
ri@@	O	-1	12498738
a	O	-1	12498738
were	O	-1	12498738
isol@@	O	-1	12498738
ated	O	-1	12498738
from	O	-1	12498738
rats	O	-1	12498738
treated	O	-1	12498738
for	O	-1	12498738
7	O	-1	12498738
weeks	O	-1	12498738
with	O	-1	12498738
dox@@	B-Chemical	D004317	12498738
orub@@	I-Chemical	-1	12498738
icin	I-Chemical	-1	12498738
(@@	O	-1	12498738
2	O	-1	12498738
mg/kg	O	-1	12498738
s@@	O	-1	12498738
c@@	O	-1	12498738
/@@	O	-1	12498738
week@@	O	-1	12498738
),	O	-1	12498738
car@@	B-Chemical	C043211	12498738
ve@@	I-Chemical	-1	12498738
di@@	I-Chemical	-1	12498738
lol	I-Chemical	-1	12498738
(@@	O	-1	12498738
1	O	-1	12498738
mg/kg	O	-1	12498738
ip@@	O	-1	12498738
/@@	O	-1	12498738
week@@	O	-1	12498738
),	O	-1	12498738
or	O	-1	12498738
the	O	-1	12498738
combination	O	-1	12498738
of	O	-1	12498738
the	O	-1	12498738
two	O	-1	12498738
drug@@	O	-1	12498738
s.	O	-1	12498738
H@@	O	-1	12498738
ear@@	O	-1	12498738
t	O	-1	12498738
mitochond@@	O	-1	12498738
ri@@	O	-1	12498738
a	O	-1	12498738
isol@@	O	-1	12498738
ated	O	-1	12498738
from	O	-1	12498738
dox@@	B-Chemical	D004317	12498738
orub@@	I-Chemical	-1	12498738
icin	I-Chemical	-1	12498738
-treated	O	-1	12498738
rats	O	-1	12498738
ex@@	O	-1	12498738
hib@@	O	-1	12498738
ited	O	-1	12498738
depress@@	O	-1	12498738
ed	O	-1	12498738
rat@@	O	-1	12498738
es	O	-1	12498738
for	O	-1	12498738
state	O	-1	12498738
3	O	-1	12498738
res@@	O	-1	12498738
pi@@	O	-1	12498738
ration	O	-1	12498738
(3@@	O	-1	12498738
3@@	O	-1	12498738
6	O	-1	12498738
+/-	O	-1	12498738
2@@	O	-1	12498738
6	O	-1	12498738
versus	O	-1	12498738
4@@	O	-1	12498738
25	O	-1	12498738
+/-	O	-1	12498738
5@@	O	-1	12498738
3	O	-1	12498738
n@@	O	-1	12498738
at@@	O	-1	12498738
o@@	O	-1	12498738
m	O	-1	12498738
O@@	O	-1	12498738
/@@	O	-1	12498738
min@@	O	-1	12498738
/@@	O	-1	12498738
mg	O	-1	12498738
protein@@	O	-1	12498738
)	O	-1	12498738
and	O	-1	12498738
a	O	-1	12498738
lower	O	-1	12498738
respiratory	O	-1	12498738
control	O	-1	12498738
rati@@	O	-1	12498738
o	O	-1	12498738
(@@	O	-1	12498738
R@@	O	-1	12498738
CR@@	O	-1	12498738
)	O	-1	12498738
(@@	O	-1	12498738
4.@@	O	-1	12498738
3	O	-1	12498738
+/-	O	-1	12498738
0.@@	O	-1	12498738
6	O	-1	12498738
versus	O	-1	12498738
5.@@	O	-1	12498738
8	O	-1	12498738
+/-	O	-1	12498738
0.@@	O	-1	12498738
4@@	O	-1	12498738
)	O	-1	12498738
compared	O	-1	12498738
with	O	-1	12498738
cardiac	O	-1	12498738
mitochond@@	O	-1	12498738
ri@@	O	-1	12498738
a	O	-1	12498738
isol@@	O	-1	12498738
ated	O	-1	12498738
from	O	-1	12498738
sal@@	O	-1	12498738
ine-@@	O	-1	12498738
treated	O	-1	12498738
rats.	O	-1	12498738
M@@	O	-1	12498738
it@@	O	-1	12498738
ochond@@	O	-1	12498738
rial	O	-1	12498738
calcium	B-Chemical	D002118	12498738
-@@	O	-1	12498738
lo@@	O	-1	12498738
ad@@	O	-1	12498738
ing	O	-1	12498738
cap@@	O	-1	12498738
ac@@	O	-1	12498738
ity	O	-1	12498738
and	O	-1	12498738
the	O	-1	12498738
activity	O	-1	12498738
of	O	-1	12498738
N@@	O	-1	12498738
AD@@	O	-1	12498738
H@@	O	-1	12498738
-@@	O	-1	12498738
de@@	O	-1	12498738
hydro@@	O	-1	12498738
gen@@	O	-1	12498738
ase	O	-1	12498738
were	O	-1	12498738
also	O	-1	12498738
sup@@	O	-1	12498738
press@@	O	-1	12498738
ed	O	-1	12498738
in	O	-1	12498738
cardiac	O	-1	12498738
mitochond@@	O	-1	12498738
ri@@	O	-1	12498738
a	O	-1	12498738
from	O	-1	12498738
dox@@	B-Chemical	D004317	12498738
orub@@	I-Chemical	-1	12498738
icin	I-Chemical	-1	12498738
-treated	O	-1	12498738
rats.	O	-1	12498738
D@@	B-Chemical	D004317	12498738
ox@@	I-Chemical	-1	12498738
orub@@	I-Chemical	-1	12498738
icin	I-Chemical	-1	12498738
treatment	O	-1	12498738
also	O	-1	12498738
caused	O	-1	12498738
a	O	-1	12498738
decrease	O	-1	12498738
in	O	-1	12498738
R@@	O	-1	12498738
C@@	O	-1	12498738
R	O	-1	12498738
for	O	-1	12498738
liver	O	-1	12498738
mitochond@@	O	-1	12498738
ri@@	O	-1	12498738
a	O	-1	12498738
(@@	O	-1	12498738
3.@@	O	-1	12498738
9	O	-1	12498738
+/-	O	-1	12498738
0.@@	O	-1	12498738
9	O	-1	12498738
versus	O	-1	12498738
5.@@	O	-1	12498738
6	O	-1	12498738
+/-	O	-1	12498738
0.@@	O	-1	12498738
7	O	-1	12498738
for	O	-1	12498738
control	O	-1	12498738
rat@@	O	-1	12498738
s)	O	-1	12498738
and	O	-1	12498738
inhibition	O	-1	12498738
of	O	-1	12498738
hepatic	O	-1	12498738
cyto@@	O	-1	12498738
ch@@	O	-1	12498738
rom@@	O	-1	12498738
e	O	-1	12498738
oxid@@	O	-1	12498738
ase	O	-1	12498738
activ@@	O	-1	12498738
ity.	O	-1	12498738
C@@	O	-1	12498738
o@@	O	-1	12498738
administration	O	-1	12498738
of	O	-1	12498738
car@@	B-Chemical	C043211	12498738
ve@@	I-Chemical	-1	12498738
di@@	I-Chemical	-1	12498738
lol	I-Chemical	-1	12498738
decreased	O	-1	12498738
the	O	-1	12498738
ext@@	O	-1	12498738
ent	O	-1	12498738
of	O	-1	12498738
cell@@	O	-1	12498738
ular	O	-1	12498738
vac@@	O	-1	12498738
u@@	O	-1	12498738
ol@@	O	-1	12498738
ization	O	-1	12498738
in	O	-1	12498738
cardiac	O	-1	12498738
my@@	O	-1	12498738
ocy@@	O	-1	12498738
tes	O	-1	12498738
and	O	-1	12498738
prevent@@	O	-1	12498738
ed	O	-1	12498738
the	O	-1	12498738
inhibit@@	O	-1	12498738
ory	O	-1	12498738
effect	O	-1	12498738
of	O	-1	12498738
dox@@	B-Chemical	D004317	12498738
orub@@	I-Chemical	-1	12498738
icin	I-Chemical	-1	12498738
on	O	-1	12498738
mitochondrial	O	-1	12498738
res@@	O	-1	12498738
pi@@	O	-1	12498738
ration	O	-1	12498738
in	O	-1	12498738
both	O	-1	12498738
heart	O	-1	12498738
and	O	-1	12498738
li@@	O	-1	12498738
ver@@	O	-1	12498738
.	O	-1	12498738
C@@	B-Chemical	C043211	12498738
ar@@	I-Chemical	-1	12498738
ve@@	I-Chemical	-1	12498738
di@@	I-Chemical	-1	12498738
lol	I-Chemical	-1	12498738
also	O	-1	12498738
prevent@@	O	-1	12498738
ed	O	-1	12498738
the	O	-1	12498738
decrease	O	-1	12498738
in	O	-1	12498738
mitochondrial	O	-1	12498738
C@@	B-Chemical	D002118	12498738
a	I-Chemical	-1	12498738
(2@@	O	-1	12498738
+@@	O	-1	12498738
)	O	-1	12498738
lo@@	O	-1	12498738
ad@@	O	-1	12498738
ing	O	-1	12498738
cap@@	O	-1	12498738
ac@@	O	-1	12498738
ity	O	-1	12498738
and	O	-1	12498738
the	O	-1	12498738
inhibition	O	-1	12498738
of	O	-1	12498738
the	O	-1	12498738
respiratory	O	-1	12498738
comple@@	O	-1	12498738
x@@	O	-1	12498738
es	O	-1	12498738
of	O	-1	12498738
heart	O	-1	12498738
mitochond@@	O	-1	12498738
ri@@	O	-1	12498738
a	O	-1	12498738
caused	O	-1	12498738
by	O	-1	12498738
dox@@	B-Chemical	D004317	12498738
orub@@	I-Chemical	-1	12498738
icin	I-Chemical	-1	12498738
.	O	-1	12498738
C@@	B-Chemical	C043211	12498738
ar@@	I-Chemical	-1	12498738
ve@@	I-Chemical	-1	12498738
di@@	I-Chemical	-1	12498738
lol	I-Chemical	-1	12498738
by	O	-1	12498738
it@@	O	-1	12498738
sel@@	O	-1	12498738
f	O	-1	12498738
did	O	-1	12498738
not	O	-1	12498738
aff@@	O	-1	12498738
ect	O	-1	12498738
any	O	-1	12498738
of	O	-1	12498738
the	O	-1	12498738
par@@	O	-1	12498738
ame@@	O	-1	12498738
ters	O	-1	12498738
measured	O	-1	12498738
for	O	-1	12498738
heart	O	-1	12498738
or	O	-1	12498738
liver	O	-1	12498738
mitochond@@	O	-1	12498738
ri@@	O	-1	12498738
a.	O	-1	12498738
It	O	-1	12498738
is	O	-1	12498738
concl@@	O	-1	12498738
uded	O	-1	12498738
that	O	-1	12498738
this	O	-1	12498738
prot@@	O	-1	12498738
ection	O	-1	12498738
by	O	-1	12498738
car@@	B-Chemical	C043211	12498738
ve@@	I-Chemical	-1	12498738
di@@	I-Chemical	-1	12498738
lol	I-Chemical	-1	12498738
against	O	-1	12498738
both	O	-1	12498738
the	O	-1	12498738
struct@@	O	-1	12498738
ural	O	-1	12498738
and	O	-1	12498738
functional	O	-1	12498738
cardiac	O	-1	12498738
tissue	O	-1	12498738
damage	O	-1	12498738
may	O	-1	12498738
aff@@	O	-1	12498738
or@@	O	-1	12498738
d	O	-1	12498738
significant	O	-1	12498738
clinical	O	-1	12498738
adv@@	O	-1	12498738
ant@@	O	-1	12498738
age	O	-1	12498738
in	O	-1	12498738
minim@@	O	-1	12498738
iz@@	O	-1	12498738
ing	O	-1	12498738
the	O	-1	12498738
dose-@@	O	-1	12498738
lim@@	O	-1	12498738
it@@	O	-1	12498738
ing	O	-1	12498738
mitochondrial	B-Disease	D028361	12498738
dysfunction	I-Disease	-1	12498738
and	O	-1	12498738
cardi@@	B-Disease	D009202	12498738
om@@	I-Disease	-1	12498738
yo@@	I-Disease	-1	12498738
pathy	I-Disease	-1	12498738
that	O	-1	12498738
ac@@	O	-1	12498738
comp@@	O	-1	12498738
an@@	O	-1	12498738
i@@	O	-1	12498738
es	O	-1	12498738
long-term	O	-1	12498738
dox@@	B-Chemical	D004317	12498738
orub@@	I-Chemical	-1	12498738
icin	I-Chemical	-1	12498738
therapy	O	-1	12498738
in	O	-1	12498738
cancer	B-Disease	D009369	12498738
patients.	O	-1	12498738

C@@	B-Chemical	D003042	12523489
oc@@	I-Chemical	-1	12523489
aine	I-Chemical	-1	12523489
-induced	O	-1	12523489
hyperactivity	B-Disease	D006948	12523489
is	O	-1	12523489
more	O	-1	12523489
influ@@	O	-1	12523489
enc@@	O	-1	12523489
ed	O	-1	12523489
by	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
receptor	O	-1	12523489
agon@@	O	-1	12523489
ist@@	O	-1	12523489
s	O	-1	12523489
than	O	-1	12523489
amphetamine	B-Chemical	D000661	12523489
-induced	O	-1	12523489
hyperactivity	B-Disease	D006948	12523489
.	O	-1	12523489
The	O	-1	12523489
influence	O	-1	12523489
of	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
receptor	O	-1	12523489
agon@@	O	-1	12523489
ist@@	O	-1	12523489
s	O	-1	12523489
and	O	-1	12523489
antagonist@@	O	-1	12523489
s	O	-1	12523489
on	O	-1	12523489
cocaine	B-Chemical	D003042	12523489
-@@	O	-1	12523489
and	O	-1	12523489
amphetamine	B-Chemical	D000661	12523489
-induced	O	-1	12523489
hyperactivity	B-Disease	D006948	12523489
was	O	-1	12523489
examined	O	-1	12523489
in	O	-1	12523489
mice.	O	-1	12523489
All	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
receptor	O	-1	12523489
agon@@	O	-1	12523489
ist@@	O	-1	12523489
s	O	-1	12523489
significantly	O	-1	12523489
decreased	B-Disease	D004409	12523489
the	I-Disease	-1	12523489
locomotor	I-Disease	-1	12523489
activity	I-Disease	-1	12523489
in	O	-1	12523489
mic@@	O	-1	12523489
e,	O	-1	12523489
and	O	-1	12523489
the	O	-1	12523489
effects	O	-1	12523489
were	O	-1	12523489
dose-@@	O	-1	12523489
depend@@	O	-1	12523489
ent@@	O	-1	12523489
.	O	-1	12523489
It	O	-1	12523489
se@@	O	-1	12523489
em@@	O	-1	12523489
s	O	-1	12523489
that	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
A@@	O	-1	12523489
1	O	-1	12523489
and	O	-1	12523489
A@@	O	-1	12523489
2	O	-1	12523489
receptors	O	-1	12523489
might	O	-1	12523489
be	O	-1	12523489
involved	O	-1	12523489
in	O	-1	12523489
this	O	-1	12523489
reac@@	O	-1	12523489
tion.	O	-1	12523489
M@@	O	-1	12523489
ore@@	O	-1	12523489
o@@	O	-1	12523489
ver,	O	-1	12523489
all	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
receptor	O	-1	12523489
agon@@	O	-1	12523489
ist@@	O	-1	12523489
s:	O	-1	12523489
2-@@	B-Chemical	C061282	12523489
p@@	I-Chemical	-1	12523489
-@@	I-Chemical	-1	12523489
(2@@	I-Chemical	-1	12523489
-@@	I-Chemical	-1	12523489
carb@@	I-Chemical	-1	12523489
oxy@@	I-Chemical	-1	12523489
eth@@	I-Chemical	-1	12523489
yl@@	I-Chemical	-1	12523489
)@@	I-Chemical	-1	12523489
phen@@	I-Chemical	-1	12523489
eth@@	I-Chemical	-1	12523489
yl@@	I-Chemical	-1	12523489
amino@@	I-Chemical	-1	12523489
-@@	I-Chemical	-1	12523489
5@@	I-Chemical	-1	12523489
'@@	I-Chemical	-1	12523489
-@@	I-Chemical	-1	12523489
N@@	I-Chemical	-1	12523489
-@@	I-Chemical	-1	12523489
eth@@	I-Chemical	-1	12523489
yl@@	I-Chemical	-1	12523489
carb@@	I-Chemical	-1	12523489
ox@@	I-Chemical	-1	12523489
am@@	I-Chemical	-1	12523489
id@@	I-Chemical	-1	12523489
o@@	I-Chemical	-1	12523489
aden@@	I-Chemical	-1	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
(	O	-1	12523489
C@@	B-Chemical	C061282	12523489
G@@	I-Chemical	-1	12523489
S	I-Chemical	-1	12523489
2@@	I-Chemical	-1	12523489
1@@	I-Chemical	-1	12523489
6@@	I-Chemical	-1	12523489
8@@	I-Chemical	-1	12523489
0	I-Chemical	-1	12523489
),	O	-1	12523489
A@@	O	-1	12523489
2@@	O	-1	12523489
A	O	-1	12523489
receptor	O	-1	12523489
agon@@	O	-1	12523489
ist@@	O	-1	12523489
,	O	-1	12523489
N@@	B-Chemical	C048599	12523489
6-@@	I-Chemical	-1	12523489
cyc@@	I-Chemical	-1	12523489
lop@@	I-Chemical	-1	12523489
ent@@	I-Chemical	-1	12523489
yl@@	I-Chemical	-1	12523489
aden@@	I-Chemical	-1	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
(	O	-1	12523489
C@@	B-Chemical	C048599	12523489
P@@	I-Chemical	-1	12523489
A	I-Chemical	-1	12523489
),	O	-1	12523489
A@@	O	-1	12523489
1	O	-1	12523489
receptor	O	-1	12523489
agon@@	O	-1	12523489
ist@@	O	-1	12523489
,	O	-1	12523489
and	O	-1	12523489
5@@	B-Chemical	D019830	12523489
'@@	I-Chemical	-1	12523489
-@@	I-Chemical	-1	12523489
N@@	I-Chemical	-1	12523489
-@@	I-Chemical	-1	12523489
eth@@	I-Chemical	-1	12523489
yl@@	I-Chemical	-1	12523489
carb@@	I-Chemical	-1	12523489
ox@@	I-Chemical	-1	12523489
am@@	I-Chemical	-1	12523489
id@@	I-Chemical	-1	12523489
o@@	I-Chemical	-1	12523489
aden@@	I-Chemical	-1	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
(	O	-1	12523489
N@@	B-Chemical	D019830	12523489
EC@@	I-Chemical	-1	12523489
A	I-Chemical	-1	12523489
),	O	-1	12523489
A@@	O	-1	12523489
2@@	O	-1	12523489
/@@	O	-1	12523489
A@@	O	-1	12523489
1	O	-1	12523489
receptor	O	-1	12523489
agon@@	O	-1	12523489
ist	O	-1	12523489
significantly	O	-1	12523489
and	O	-1	12523489
dose-@@	O	-1	12523489
depend@@	O	-1	12523489
ently	O	-1	12523489
decreased	O	-1	12523489
cocaine	B-Chemical	D003042	12523489
-induced	O	-1	12523489
locomotor	O	-1	12523489
activ@@	O	-1	12523489
ity.	O	-1	12523489
C@@	B-Chemical	C048599	12523489
P@@	I-Chemical	-1	12523489
A	I-Chemical	-1	12523489
reduced	O	-1	12523489
cocaine	B-Chemical	D003042	12523489
action	O	-1	12523489
at	O	-1	12523489
the	O	-1	12523489
doses	O	-1	12523489
wh@@	O	-1	12523489
ic@@	O	-1	12523489
h@@	O	-1	12523489
,	O	-1	12523489
given	O	-1	12523489
al@@	O	-1	12523489
one,	O	-1	12523489
did	O	-1	12523489
not	O	-1	12523489
influence	O	-1	12523489
mo@@	O	-1	12523489
ti@@	O	-1	12523489
lit@@	O	-1	12523489
y,	O	-1	12523489
while	O	-1	12523489
C@@	B-Chemical	C061282	12523489
G@@	I-Chemical	-1	12523489
S	I-Chemical	-1	12523489
2@@	I-Chemical	-1	12523489
1@@	I-Chemical	-1	12523489
6@@	I-Chemical	-1	12523489
8@@	I-Chemical	-1	12523489
0	I-Chemical	-1	12523489
and	O	-1	12523489
N@@	B-Chemical	D019830	12523489
EC@@	I-Chemical	-1	12523489
A	I-Chemical	-1	12523489
decreased	O	-1	12523489
the	O	-1	12523489
action	O	-1	12523489
of	O	-1	12523489
cocaine	B-Chemical	D003042	12523489
at	O	-1	12523489
the	O	-1	12523489
doses	O	-1	12523489
wh@@	O	-1	12523489
ic@@	O	-1	12523489
h@@	O	-1	12523489
,	O	-1	12523489
given	O	-1	12523489
al@@	O	-1	12523489
one,	O	-1	12523489
decreased	O	-1	12523489
locomotor	O	-1	12523489
activity	O	-1	12523489
in	O	-1	12523489
anim@@	O	-1	12523489
al@@	O	-1	12523489
s.	O	-1	12523489
These	O	-1	12523489
results	O	-1	12523489
suggest	O	-1	12523489
the	O	-1	12523489
invol@@	O	-1	12523489
vement	O	-1	12523489
of	O	-1	12523489
both	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
receptors	O	-1	12523489
in	O	-1	12523489
the	O	-1	12523489
action	O	-1	12523489
of	O	-1	12523489
cocaine	B-Chemical	D003042	12523489
although	O	-1	12523489
agon@@	O	-1	12523489
ist@@	O	-1	12523489
s	O	-1	12523489
of	O	-1	12523489
A@@	O	-1	12523489
1	O	-1	12523489
receptors	O	-1	12523489
se@@	O	-1	12523489
em	O	-1	12523489
to	O	-1	12523489
have	O	-1	12523489
st@@	O	-1	12523489
ron@@	O	-1	12523489
g@@	O	-1	12523489
er	O	-1	12523489
influence	O	-1	12523489
on	O	-1	12523489
it@@	O	-1	12523489
.	O	-1	12523489
The	O	-1	12523489
selective	O	-1	12523489
block@@	O	-1	12523489
ade	O	-1	12523489
of	O	-1	12523489
A@@	O	-1	12523489
2	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
receptor	O	-1	12523489
by	O	-1	12523489
D@@	B-Chemical	C057837	12523489
MP@@	I-Chemical	-1	12523489
X	I-Chemical	-1	12523489
(	O	-1	12523489
3@@	B-Chemical	C057837	12523489
,@@	I-Chemical	-1	12523489
7-@@	I-Chemical	-1	12523489
di@@	I-Chemical	-1	12523489
methyl@@	I-Chemical	-1	12523489
-1@@	I-Chemical	-1	12523489
-@@	I-Chemical	-1	12523489
pro@@	I-Chemical	-1	12523489
par@@	I-Chemical	-1	12523489
g@@	I-Chemical	-1	12523489
yl@@	I-Chemical	-1	12523489
x@@	I-Chemical	-1	12523489
an@@	I-Chemical	-1	12523489
th@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
)	O	-1	12523489
significantly	O	-1	12523489
enhanced	O	-1	12523489
cocaine	B-Chemical	D003042	12523489
-induced	O	-1	12523489
locomotor	O	-1	12523489
activity	O	-1	12523489
of	O	-1	12523489
anim@@	O	-1	12523489
al@@	O	-1	12523489
s.	O	-1	12523489
Ca@@	B-Chemical	D002110	12523489
ffe@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
had	O	-1	12523489
similar	O	-1	12523489
action	O	-1	12523489
but	O	-1	12523489
the	O	-1	12523489
effect	O	-1	12523489
was	O	-1	12523489
not	O	-1	12523489
significant@@	O	-1	12523489
.	O	-1	12523489
C@@	B-Chemical	C053907	12523489
P@@	I-Chemical	-1	12523489
T	I-Chemical	-1	12523489
(	O	-1	12523489
8@@	B-Chemical	C053907	12523489
-@@	I-Chemical	-1	12523489
cyc@@	I-Chemical	-1	12523489
lop@@	I-Chemical	-1	12523489
ent@@	I-Chemical	-1	12523489
yl@@	I-Chemical	-1	12523489
the@@	I-Chemical	-1	12523489
oph@@	I-Chemical	-1	12523489
yl@@	I-Chemical	-1	12523489
line	I-Chemical	-1	12523489
)-@@	O	-1	12523489
-@@	O	-1	12523489
A@@	O	-1	12523489
1	O	-1	12523489
receptor	O	-1	12523489
antagonist@@	O	-1	12523489
,	O	-1	12523489
did	O	-1	12523489
not	O	-1	12523489
show	O	-1	12523489
any	O	-1	12523489
influence	O	-1	12523489
in	O	-1	12523489
this	O	-1	12523489
test@@	O	-1	12523489
.	O	-1	12523489
S@@	O	-1	12523489
im@@	O	-1	12523489
il@@	O	-1	12523489
ar@@	O	-1	12523489
ly,	O	-1	12523489
all	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
receptor	O	-1	12523489
agon@@	O	-1	12523489
ist@@	O	-1	12523489
s	O	-1	12523489
decreased	O	-1	12523489
amphetamine	B-Chemical	D000661	12523489
-induced	O	-1	12523489
hyperactivity	B-Disease	D006948	12523489
,	O	-1	12523489
but	O	-1	12523489
at	O	-1	12523489
the	O	-1	12523489
higher	O	-1	12523489
doses	O	-1	12523489
than	O	-1	12523489
those	O	-1	12523489
which	O	-1	12523489
were	O	-1	12523489
active	O	-1	12523489
in	O	-1	12523489
cocaine	B-Chemical	D003042	12523489
-induced	O	-1	12523489
hyperactivity	B-Disease	D006948	12523489
.	O	-1	12523489
The	O	-1	12523489
selective	O	-1	12523489
block@@	O	-1	12523489
ade	O	-1	12523489
of	O	-1	12523489
A@@	O	-1	12523489
2	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
receptors	O	-1	12523489
(	O	-1	12523489
D@@	B-Chemical	C057837	12523489
MP@@	I-Chemical	-1	12523489
X	I-Chemical	-1	12523489
)	O	-1	12523489
and	O	-1	12523489
non-@@	O	-1	12523489
selective	O	-1	12523489
block@@	O	-1	12523489
ade	O	-1	12523489
of	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
receptors	O	-1	12523489
(	O	-1	12523489
caffe@@	B-Chemical	D002110	12523489
ine	I-Chemical	-1	12523489
)	O	-1	12523489
significantly	O	-1	12523489
increased	O	-1	12523489
the	O	-1	12523489
action	O	-1	12523489
of	O	-1	12523489
amphetamine	B-Chemical	D000661	12523489
in	O	-1	12523489
the	O	-1	12523489
locomotor	O	-1	12523489
activity	O	-1	12523489
test@@	O	-1	12523489
.	O	-1	12523489
Our	O	-1	12523489
results	O	-1	12523489
have	O	-1	12523489
shown	O	-1	12523489
that	O	-1	12523489
all	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
receptor	O	-1	12523489
agon@@	O	-1	12523489
ist@@	O	-1	12523489
s	O	-1	12523489
(A@@	O	-1	12523489
1	O	-1	12523489
and	O	-1	12523489
A@@	O	-1	12523489
2)	O	-1	12523489
re@@	O	-1	12523489
duce	O	-1	12523489
cocaine	B-Chemical	D003042	12523489
-	O	-1	12523489
and	O	-1	12523489
amphetamine	B-Chemical	D000661	12523489
-induced	O	-1	12523489
locomotor	O	-1	12523489
activity	O	-1	12523489
and	O	-1	12523489
indicate	O	-1	12523489
that	O	-1	12523489
cocaine	B-Chemical	D003042	12523489
-induced	O	-1	12523489
hyperactivity	B-Disease	D006948	12523489
is	O	-1	12523489
more	O	-1	12523489
influ@@	O	-1	12523489
enc@@	O	-1	12523489
ed	O	-1	12523489
by	O	-1	12523489
aden@@	B-Chemical	D000241	12523489
os@@	I-Chemical	-1	12523489
ine	I-Chemical	-1	12523489
receptor	O	-1	12523489
agon@@	O	-1	12523489
ist@@	O	-1	12523489
s	O	-1	12523489
(@@	O	-1	12523489
partic@@	O	-1	12523489
ul@@	O	-1	12523489
arly	O	-1	12523489
A@@	O	-1	12523489
1	O	-1	12523489
receptor@@	O	-1	12523489
s)	O	-1	12523489
than	O	-1	12523489
amphetamine	B-Chemical	D000661	12523489
-induced	O	-1	12523489
hyperactivity	B-Disease	D006948	12523489
.	O	-1	12523489

A@@	B-Chemical	D000638	12535818
m@@	I-Chemical	-1	12535818
iodar@@	I-Chemical	-1	12535818
one	I-Chemical	-1	12535818
and	O	-1	12535818
the	O	-1	12535818
risk	O	-1	12535818
of	O	-1	12535818
brady@@	B-Disease	D001919	12535818
arrhyth@@	I-Disease	-1	12535818
mia	I-Disease	-1	12535818
requ@@	O	-1	12535818
ir@@	O	-1	12535818
ing	O	-1	12535818
per@@	O	-1	12535818
man@@	O	-1	12535818
ent	O	-1	12535818
pac@@	O	-1	12535818
em@@	O	-1	12535818
ak@@	O	-1	12535818
er	O	-1	12535818
in	O	-1	12535818
el@@	O	-1	12535818
der@@	O	-1	12535818
ly	O	-1	12535818
patients	O	-1	12535818
with	O	-1	12535818
atrial	B-Disease	D001281	12535818
fibrill@@	I-Disease	-1	12535818
ation	I-Disease	-1	12535818
and	O	-1	12535818
prior	O	-1	12535818
myocardial	B-Disease	D009203	12535818
infarction	I-Disease	-1	12535818
.	O	-1	12535818
OBJECTIV@@	O	-1	12535818
E@@	O	-1	12535818
S:	O	-1	12535818
The	O	-1	12535818
a@@	O	-1	12535818
im	O	-1	12535818
of	O	-1	12535818
this	O	-1	12535818
study	O	-1	12535818
was	O	-1	12535818
to	O	-1	12535818
determine	O	-1	12535818
whether	O	-1	12535818
the	O	-1	12535818
use	O	-1	12535818
of	O	-1	12535818
am@@	B-Chemical	D000638	12535818
iodar@@	I-Chemical	-1	12535818
one	I-Chemical	-1	12535818
in	O	-1	12535818
patients	O	-1	12535818
with	O	-1	12535818
atrial	B-Disease	D001281	12535818
fibrill@@	I-Disease	-1	12535818
ation	I-Disease	-1	12535818
(	O	-1	12535818
A@@	B-Disease	D001281	12535818
F	I-Disease	-1	12535818
)	O	-1	12535818
increases	O	-1	12535818
the	O	-1	12535818
risk	O	-1	12535818
of	O	-1	12535818
brady@@	B-Disease	D001919	12535818
arrhyth@@	I-Disease	-1	12535818
mia	I-Disease	-1	12535818
requ@@	O	-1	12535818
ir@@	O	-1	12535818
ing	O	-1	12535818
a	O	-1	12535818
per@@	O	-1	12535818
man@@	O	-1	12535818
ent	O	-1	12535818
pac@@	O	-1	12535818
em@@	O	-1	12535818
ak@@	O	-1	12535818
er.	O	-1	12535818
BACKGROUND:	O	-1	12535818
Re@@	O	-1	12535818
por@@	O	-1	12535818
ts	O	-1	12535818
of	O	-1	12535818
severe	O	-1	12535818
brady@@	B-Disease	D001919	12535818
arrhyth@@	I-Disease	-1	12535818
mia	I-Disease	-1	12535818
during	O	-1	12535818
am@@	B-Chemical	D000638	12535818
iodar@@	I-Chemical	-1	12535818
one	I-Chemical	-1	12535818
therapy	O	-1	12535818
are	O	-1	12535818
inf@@	O	-1	12535818
requ@@	O	-1	12535818
ent	O	-1	12535818
and	O	-1	12535818
lim@@	O	-1	12535818
ited	O	-1	12535818
to	O	-1	12535818
studies	O	-1	12535818
assess@@	O	-1	12535818
ing	O	-1	12535818
the	O	-1	12535818
therap@@	O	-1	12535818
y@@	O	-1	12535818
's	O	-1	12535818
use	O	-1	12535818
in	O	-1	12535818
the	O	-1	12535818
man@@	O	-1	12535818
ag@@	O	-1	12535818
ement	O	-1	12535818
of	O	-1	12535818
patients	O	-1	12535818
with	O	-1	12535818
ventricular	B-Disease	D001145	12535818
arrhyth@@	I-Disease	-1	12535818
mi@@	I-Disease	-1	12535818
as	I-Disease	-1	12535818
.	O	-1	12535818
METHODS:	O	-1	12535818
A	O	-1	12535818
study	O	-1	12535818
co@@	O	-1	12535818
h@@	O	-1	12535818
ort	O	-1	12535818
of	O	-1	12535818
8@@	O	-1	12535818
,@@	O	-1	12535818
7@@	O	-1	12535818
7@@	O	-1	12535818
0	O	-1	12535818
patients	O	-1	12535818
age	O	-1	12535818
>	O	-1	12535818
or	O	-1	12535818
=@@	O	-1	12535818
6@@	O	-1	12535818
5	O	-1	12535818
years	O	-1	12535818
with	O	-1	12535818
a	O	-1	12535818
new	O	-1	12535818
diagnosis	O	-1	12535818
of	O	-1	12535818
A@@	B-Disease	D001281	12535818
F	I-Disease	-1	12535818
was	O	-1	12535818
identi@@	O	-1	12535818
fied	O	-1	12535818
from	O	-1	12535818
a	O	-1	12535818
prov@@	O	-1	12535818
in@@	O	-1	12535818
ce@@	O	-1	12535818
w@@	O	-1	12535818
ide	O	-1	12535818
dat@@	O	-1	12535818
ab@@	O	-1	12535818
ase	O	-1	12535818
of	O	-1	12535818
Q@@	O	-1	12535818
u@@	O	-1	12535818
e@@	O	-1	12535818
be@@	O	-1	12535818
c	O	-1	12535818
re@@	O	-1	12535818
si@@	O	-1	12535818
d@@	O	-1	12535818
ents	O	-1	12535818
with	O	-1	12535818
a	O	-1	12535818
myocardial	B-Disease	D009203	12535818
infarction	I-Disease	-1	12535818
(	O	-1	12535818
M@@	B-Disease	D009203	12535818
I	I-Disease	-1	12535818
)	O	-1	12535818
between	O	-1	12535818
19@@	O	-1	12535818
9@@	O	-1	12535818
1	O	-1	12535818
and	O	-1	12535818
19@@	O	-1	12535818
9@@	O	-1	12535818
9@@	O	-1	12535818
.	O	-1	12535818
U@@	O	-1	12535818
s@@	O	-1	12535818
ing	O	-1	12535818
a	O	-1	12535818
ne@@	O	-1	12535818
st@@	O	-1	12535818
ed	O	-1	12535818
cas@@	O	-1	12535818
e-@@	O	-1	12535818
control	O	-1	12535818
de@@	O	-1	12535818
sign@@	O	-1	12535818
,	O	-1	12535818
4@@	O	-1	12535818
7@@	O	-1	12535818
7	O	-1	12535818
cases	O	-1	12535818
of	O	-1	12535818
brady@@	B-Disease	D001919	12535818
arrhyth@@	I-Disease	-1	12535818
mia	I-Disease	-1	12535818
requ@@	O	-1	12535818
ir@@	O	-1	12535818
ing	O	-1	12535818
a	O	-1	12535818
per@@	O	-1	12535818
man@@	O	-1	12535818
ent	O	-1	12535818
pac@@	O	-1	12535818
em@@	O	-1	12535818
ak@@	O	-1	12535818
er	O	-1	12535818
were	O	-1	12535818
mat@@	O	-1	12535818
ch@@	O	-1	12535818
ed	O	-1	12535818
(1@@	O	-1	12535818
:@@	O	-1	12535818
4@@	O	-1	12535818
)	O	-1	12535818
to	O	-1	12535818
1@@	O	-1	12535818
,@@	O	-1	12535818
9@@	O	-1	12535818
0@@	O	-1	12535818
8	O	-1	12535818
controls.	O	-1	12535818
M@@	O	-1	12535818
ul@@	O	-1	12535818
tiv@@	O	-1	12535818
ari@@	O	-1	12535818
able	O	-1	12535818
log@@	O	-1	12535818
istic	O	-1	12535818
reg@@	O	-1	12535818
res@@	O	-1	12535818
sion	O	-1	12535818
was	O	-1	12535818
used	O	-1	12535818
to	O	-1	12535818
estim@@	O	-1	12535818
ate	O	-1	12535818
the	O	-1	12535818
o@@	O	-1	12535818
d@@	O	-1	12535818
ds	O	-1	12535818
rati@@	O	-1	12535818
o	O	-1	12535818
(@@	O	-1	12535818
O@@	O	-1	12535818
R@@	O	-1	12535818
)	O	-1	12535818
of	O	-1	12535818
pac@@	O	-1	12535818
em@@	O	-1	12535818
ak@@	O	-1	12535818
er	O	-1	12535818
in@@	O	-1	12535818
ser@@	O	-1	12535818
tion	O	-1	12535818
associated	O	-1	12535818
with	O	-1	12535818
am@@	B-Chemical	D000638	12535818
iodar@@	I-Chemical	-1	12535818
one	I-Chemical	-1	12535818
use@@	O	-1	12535818
,	O	-1	12535818
contro@@	O	-1	12535818
ll@@	O	-1	12535818
ing	O	-1	12535818
for	O	-1	12535818
baseline	O	-1	12535818
risk	O	-1	12535818
factors	O	-1	12535818
and	O	-1	12535818
exposure	O	-1	12535818
to	O	-1	12535818
s@@	B-Chemical	D013015	12535818
ot@@	I-Chemical	-1	12535818
al@@	I-Chemical	-1	12535818
ol	I-Chemical	-1	12535818
,	O	-1	12535818
C@@	O	-1	12535818
las@@	O	-1	12535818
s	O	-1	12535818
I	O	-1	12535818
anti@@	O	-1	12535818
arrhyth@@	O	-1	12535818
mic	O	-1	12535818
agent@@	O	-1	12535818
s,	O	-1	12535818
beta-@@	O	-1	12535818
block@@	O	-1	12535818
er@@	O	-1	12535818
s,	O	-1	12535818
calcium	B-Chemical	D002118	12535818
channel	O	-1	12535818
block@@	O	-1	12535818
er@@	O	-1	12535818
s,	O	-1	12535818
and	O	-1	12535818
di@@	B-Chemical	D004077	12535818
g@@	I-Chemical	-1	12535818
ox@@	I-Chemical	-1	12535818
in	I-Chemical	-1	12535818
.	O	-1	12535818
RESULTS:	O	-1	12535818
am@@	B-Chemical	D000638	12535818
iodar@@	I-Chemical	-1	12535818
one	I-Chemical	-1	12535818
use	O	-1	12535818
was	O	-1	12535818
associated	O	-1	12535818
with	O	-1	12535818
an	O	-1	12535818
increased	O	-1	12535818
risk	O	-1	12535818
of	O	-1	12535818
pac@@	O	-1	12535818
em@@	O	-1	12535818
ak@@	O	-1	12535818
er	O	-1	12535818
in@@	O	-1	12535818
ser@@	O	-1	12535818
tion	O	-1	12535818
(@@	O	-1	12535818
O@@	O	-1	12535818
R@@	O	-1	12535818
:	O	-1	12535818
2.@@	O	-1	12535818
14@@	O	-1	12535818
,	O	-1	12535818
95%	O	-1	12535818
conf@@	O	-1	12535818
idence	O	-1	12535818
interv@@	O	-1	12535818
al	O	-1	12535818
[@@	O	-1	12535818
CI@@	O	-1	12535818
]@@	O	-1	12535818
:	O	-1	12535818
1.@@	O	-1	12535818
30	O	-1	12535818
to	O	-1	12535818
3.@@	O	-1	12535818
5@@	O	-1	12535818
4@@	O	-1	12535818
).	O	-1	12535818
This	O	-1	12535818
effect	O	-1	12535818
was	O	-1	12535818
mo@@	O	-1	12535818
di@@	O	-1	12535818
fied	O	-1	12535818
by	O	-1	12535818
gen@@	O	-1	12535818
der@@	O	-1	12535818
,	O	-1	12535818
with	O	-1	12535818
a	O	-1	12535818
greater	O	-1	12535818
risk	O	-1	12535818
in	O	-1	12535818
women	O	-1	12535818
versus	O	-1	12535818
men	O	-1	12535818
(@@	O	-1	12535818
O@@	O	-1	12535818
R@@	O	-1	12535818
:	O	-1	12535818
3.@@	O	-1	12535818
8@@	O	-1	12535818
6,	O	-1	12535818
95%	O	-1	12535818
CI@@	O	-1	12535818
:	O	-1	12535818
1.@@	O	-1	12535818
7@@	O	-1	12535818
0	O	-1	12535818
to	O	-1	12535818
8.@@	O	-1	12535818
7@@	O	-1	12535818
5	O	-1	12535818
vs.	O	-1	12535818
O@@	O	-1	12535818
R@@	O	-1	12535818
:	O	-1	12535818
1.@@	O	-1	12535818
5@@	O	-1	12535818
2,	O	-1	12535818
95%	O	-1	12535818
CI@@	O	-1	12535818
:	O	-1	12535818
0.@@	O	-1	12535818
8@@	O	-1	12535818
0	O	-1	12535818
to	O	-1	12535818
2.@@	O	-1	12535818
8@@	O	-1	12535818
9@@	O	-1	12535818
).	O	-1	12535818
D@@	B-Chemical	D004077	12535818
ig@@	I-Chemical	-1	12535818
ox@@	I-Chemical	-1	12535818
in	I-Chemical	-1	12535818
was	O	-1	12535818
the	O	-1	12535818
only	O	-1	12535818
other	O	-1	12535818
medic@@	O	-1	12535818
ation	O	-1	12535818
associated	O	-1	12535818
with	O	-1	12535818
an	O	-1	12535818
increased	O	-1	12535818
risk	O	-1	12535818
of	O	-1	12535818
pac@@	O	-1	12535818
em@@	O	-1	12535818
ak@@	O	-1	12535818
er	O	-1	12535818
in@@	O	-1	12535818
ser@@	O	-1	12535818
tion	O	-1	12535818
(@@	O	-1	12535818
O@@	O	-1	12535818
R@@	O	-1	12535818
:	O	-1	12535818
1.@@	O	-1	12535818
7@@	O	-1	12535818
8@@	O	-1	12535818
,	O	-1	12535818
95%	O	-1	12535818
CI@@	O	-1	12535818
:	O	-1	12535818
1.@@	O	-1	12535818
3@@	O	-1	12535818
7	O	-1	12535818
to	O	-1	12535818
2.@@	O	-1	12535818
3@@	O	-1	12535818
1).	O	-1	12535818
CONCLUSIONS:	O	-1	12535818
This	O	-1	12535818
study	O	-1	12535818
suggests	O	-1	12535818
that	O	-1	12535818
the	O	-1	12535818
use	O	-1	12535818
of	O	-1	12535818
am@@	B-Chemical	D000638	12535818
iodar@@	I-Chemical	-1	12535818
one	I-Chemical	-1	12535818
in	O	-1	12535818
el@@	O	-1	12535818
der@@	O	-1	12535818
ly	O	-1	12535818
patients	O	-1	12535818
with	O	-1	12535818
A@@	B-Disease	D001281	12535818
F	I-Disease	-1	12535818
and	O	-1	12535818
a	O	-1	12535818
previ@@	O	-1	12535818
ous	O	-1	12535818
M@@	B-Disease	D009203	12535818
I	I-Disease	-1	12535818
increases	O	-1	12535818
the	O	-1	12535818
risk	O	-1	12535818
of	O	-1	12535818
brady@@	B-Disease	D001919	12535818
arrhyth@@	I-Disease	-1	12535818
mia	I-Disease	-1	12535818
requ@@	O	-1	12535818
ir@@	O	-1	12535818
ing	O	-1	12535818
a	O	-1	12535818
per@@	O	-1	12535818
man@@	O	-1	12535818
ent	O	-1	12535818
pac@@	O	-1	12535818
em@@	O	-1	12535818
ak@@	O	-1	12535818
er.	O	-1	12535818
The	O	-1	12535818
find@@	O	-1	12535818
ing	O	-1	12535818
of	O	-1	12535818
an	O	-1	12535818
au@@	O	-1	12535818
g@@	O	-1	12535818
ment@@	O	-1	12535818
ed	O	-1	12535818
risk	O	-1	12535818
of	O	-1	12535818
pac@@	O	-1	12535818
em@@	O	-1	12535818
ak@@	O	-1	12535818
er	O	-1	12535818
in@@	O	-1	12535818
ser@@	O	-1	12535818
tion	O	-1	12535818
in	O	-1	12535818
el@@	O	-1	12535818
der@@	O	-1	12535818
ly	O	-1	12535818
women	O	-1	12535818
receiving	O	-1	12535818
am@@	B-Chemical	D000638	12535818
iodar@@	I-Chemical	-1	12535818
one	I-Chemical	-1	12535818
requ@@	O	-1	12535818
i@@	O	-1	12535818
res	O	-1	12535818
further	O	-1	12535818
investig@@	O	-1	12535818
ation.	O	-1	12535818

In@@	B-Chemical	D007213	12559315
do@@	I-Chemical	-1	12559315
meth@@	I-Chemical	-1	12559315
ac@@	I-Chemical	-1	12559315
in	I-Chemical	-1	12559315
-induced	O	-1	12559315
morph@@	O	-1	12559315
ologic	O	-1	12559315
changes	O	-1	12559315
in	O	-1	12559315
the	O	-1	12559315
rat	O	-1	12559315
urinary	O	-1	12559315
bladder	O	-1	12559315
epi@@	O	-1	12559315
the@@	O	-1	12559315
li@@	O	-1	12559315
um@@	O	-1	12559315
.	O	-1	12559315
OBJECTIV@@	O	-1	12559315
E@@	O	-1	12559315
S:	O	-1	12559315
To	O	-1	12559315
evalu@@	O	-1	12559315
ate	O	-1	12559315
the	O	-1	12559315
morph@@	O	-1	12559315
ologic	O	-1	12559315
changes	O	-1	12559315
in	O	-1	12559315
rat	O	-1	12559315
uro@@	O	-1	12559315
the@@	O	-1	12559315
li@@	O	-1	12559315
um	O	-1	12559315
induced	O	-1	12559315
by	O	-1	12559315
in@@	B-Chemical	D007213	12559315
do@@	I-Chemical	-1	12559315
meth@@	I-Chemical	-1	12559315
ac@@	I-Chemical	-1	12559315
in	I-Chemical	-1	12559315
.	O	-1	12559315
N@@	O	-1	12559315
on@@	O	-1	12559315
steroid@@	O	-1	12559315
al	O	-1	12559315
anti@@	O	-1	12559315
-@@	O	-1	12559315
inflam@@	O	-1	12559315
mat@@	O	-1	12559315
ory	O	-1	12559315
drug@@	O	-1	12559315
-induced	O	-1	12559315
cys@@	B-Disease	D003556	12559315
ti@@	I-Disease	-1	12559315
tis	I-Disease	-1	12559315
is	O	-1	12559315
a	O	-1	12559315
po@@	O	-1	12559315
or@@	O	-1	12559315
ly	O	-1	12559315
reco@@	O	-1	12559315
gn@@	O	-1	12559315
ized	O	-1	12559315
and	O	-1	12559315
under@@	O	-1	12559315
-@@	O	-1	12559315
reported	O	-1	12559315
condi@@	O	-1	12559315
tion.	O	-1	12559315
In	O	-1	12559315
addition	O	-1	12559315
to	O	-1	12559315
ti@@	B-Chemical	C021270	12559315
a@@	I-Chemical	-1	12559315
prof@@	I-Chemical	-1	12559315
en@@	I-Chemical	-1	12559315
ic	I-Chemical	-1	12559315
acid	I-Chemical	-1	12559315
,	O	-1	12559315
in@@	B-Chemical	D007213	12559315
do@@	I-Chemical	-1	12559315
meth@@	I-Chemical	-1	12559315
ac@@	I-Chemical	-1	12559315
in	I-Chemical	-1	12559315
has	O	-1	12559315
been	O	-1	12559315
reported	O	-1	12559315
to	O	-1	12559315
be	O	-1	12559315
associated	O	-1	12559315
with	O	-1	12559315
this	O	-1	12559315
condi@@	O	-1	12559315
tion.	O	-1	12559315
METHODS:	O	-1	12559315
Th@@	O	-1	12559315
ree	O	-1	12559315
groups	O	-1	12559315
were	O	-1	12559315
est@@	O	-1	12559315
abl@@	O	-1	12559315
is@@	O	-1	12559315
he@@	O	-1	12559315
d@@	O	-1	12559315
:	O	-1	12559315
a	O	-1	12559315
control	O	-1	12559315
group	O	-1	12559315
(n	O	-1	12559315
=	O	-1	12559315
10@@	O	-1	12559315
),	O	-1	12559315
a	O	-1	12559315
high-dose	O	-1	12559315
group	O	-1	12559315
(n	O	-1	12559315
=	O	-1	12559315
10@@	O	-1	12559315
),	O	-1	12559315
treated	O	-1	12559315
with	O	-1	12559315
one	O	-1	12559315
intra@@	O	-1	12559315
per@@	O	-1	12559315
it@@	O	-1	12559315
one@@	O	-1	12559315
al	O	-1	12559315
injection	O	-1	12559315
of	O	-1	12559315
in@@	B-Chemical	D007213	12559315
do@@	I-Chemical	-1	12559315
meth@@	I-Chemical	-1	12559315
ac@@	I-Chemical	-1	12559315
in	I-Chemical	-1	12559315
20	O	-1	12559315
mg/kg@@	O	-1	12559315
,	O	-1	12559315
and	O	-1	12559315
a	O	-1	12559315
therapeutic	O	-1	12559315
dose	O	-1	12559315
group	O	-1	12559315
(n	O	-1	12559315
=	O	-1	12559315
10@@	O	-1	12559315
)	O	-1	12559315
in	O	-1	12559315
which	O	-1	12559315
oral	O	-1	12559315
in@@	B-Chemical	D007213	12559315
do@@	I-Chemical	-1	12559315
meth@@	I-Chemical	-1	12559315
ac@@	I-Chemical	-1	12559315
in	I-Chemical	-1	12559315
was	O	-1	12559315
administered	O	-1	12559315
3.@@	O	-1	12559315
25	O	-1	12559315
mg/kg	O	-1	12559315
body	O	-1	12559315
weight	O	-1	12559315
daily	O	-1	12559315
for	O	-1	12559315
3	O	-1	12559315
week@@	O	-1	12559315
s.	O	-1	12559315
The	O	-1	12559315
animals	O	-1	12559315
were	O	-1	12559315
then	O	-1	12559315
k@@	O	-1	12559315
ill@@	O	-1	12559315
ed	O	-1	12559315
and	O	-1	12559315
the	O	-1	12559315
blad@@	O	-1	12559315
der@@	O	-1	12559315
s	O	-1	12559315
re@@	O	-1	12559315
mo@@	O	-1	12559315
ved	O	-1	12559315
for	O	-1	12559315
li@@	O	-1	12559315
ght	O	-1	12559315
and	O	-1	12559315
electro@@	O	-1	12559315
n	O	-1	12559315
micro@@	O	-1	12559315
sco@@	O	-1	12559315
p@@	O	-1	12559315
ic	O	-1	12559315
studi@@	O	-1	12559315
es.	O	-1	12559315
RESULTS:	O	-1	12559315
The	O	-1	12559315
li@@	O	-1	12559315
ght	O	-1	12559315
micro@@	O	-1	12559315
sco@@	O	-1	12559315
p@@	O	-1	12559315
ic	O	-1	12559315
findings	O	-1	12559315
showed	O	-1	12559315
some	O	-1	12559315
foc@@	O	-1	12559315
al	O	-1	12559315
epi@@	O	-1	12559315
thelial	O	-1	12559315
de@@	O	-1	12559315
generation	O	-1	12559315
that	O	-1	12559315
was	O	-1	12559315
more	O	-1	12559315
pro@@	O	-1	12559315
min@@	O	-1	12559315
ent	O	-1	12559315
in	O	-1	12559315
the	O	-1	12559315
high-dose	O	-1	12559315
group.	O	-1	12559315
Whe@@	O	-1	12559315
n	O	-1	12559315
compared	O	-1	12559315
with	O	-1	12559315
the	O	-1	12559315
control	O	-1	12559315
group@@	O	-1	12559315
,	O	-1	12559315
both	O	-1	12559315
in@@	B-Chemical	D007213	12559315
do@@	I-Chemical	-1	12559315
meth@@	I-Chemical	-1	12559315
ac@@	I-Chemical	-1	12559315
in	I-Chemical	-1	12559315
groups	O	-1	12559315
revealed	O	-1	12559315
statis@@	O	-1	12559315
tically	O	-1	12559315
increased	O	-1	12559315
numb@@	O	-1	12559315
ers	O	-1	12559315
of	O	-1	12559315
m@@	O	-1	12559315
ast	O	-1	12559315
cells	O	-1	12559315
in	O	-1	12559315
the	O	-1	12559315
m@@	O	-1	12559315
u@@	O	-1	12559315
co@@	O	-1	12559315
s@@	O	-1	12559315
a	O	-1	12559315
(P	O	-1	12559315
<@@	O	-1	12559315
0.00@@	O	-1	12559315
0@@	O	-1	12559315
1)	O	-1	12559315
and	O	-1	12559315
pen@@	O	-1	12559315
et@@	O	-1	12559315
ration	O	-1	12559315
of	O	-1	12559315
l@@	B-Chemical	C016534	12559315
an@@	I-Chemical	-1	12559315
th@@	I-Chemical	-1	12559315
an@@	I-Chemical	-1	12559315
um	I-Chemical	-1	12559315
nit@@	I-Chemical	-1	12559315
rate	I-Chemical	-1	12559315
through	O	-1	12559315
inter@@	O	-1	12559315
cell@@	O	-1	12559315
ular	O	-1	12559315
a@@	O	-1	12559315
reas	O	-1	12559315
of	O	-1	12559315
the	O	-1	12559315
epi@@	O	-1	12559315
the@@	O	-1	12559315
li@@	O	-1	12559315
um@@	O	-1	12559315
.	O	-1	12559315
F@@	O	-1	12559315
ur@@	O	-1	12559315
ther@@	O	-1	12559315
mo@@	O	-1	12559315
re,	O	-1	12559315
the	O	-1	12559315
difference	O	-1	12559315
in	O	-1	12559315
m@@	O	-1	12559315
ast	O	-1	12559315
cell	O	-1	12559315
coun@@	O	-1	12559315
ts	O	-1	12559315
between	O	-1	12559315
the	O	-1	12559315
high	O	-1	12559315
and	O	-1	12559315
therapeutic	O	-1	12559315
dose	O	-1	12559315
groups	O	-1	12559315
was	O	-1	12559315
also	O	-1	12559315
statis@@	O	-1	12559315
tically	O	-1	12559315
significant	O	-1	12559315
(P	O	-1	12559315
<@@	O	-1	12559315
0.00@@	O	-1	12559315
0@@	O	-1	12559315
1).	O	-1	12559315
CONCLUSIONS:	O	-1	12559315
In@@	B-Chemical	D007213	12559315
do@@	I-Chemical	-1	12559315
meth@@	I-Chemical	-1	12559315
ac@@	I-Chemical	-1	12559315
in	I-Chemical	-1	12559315
resulted	O	-1	12559315
in	O	-1	12559315
histo@@	O	-1	12559315
path@@	O	-1	12559315
ologic	O	-1	12559315
findings	O	-1	12559315
typ@@	O	-1	12559315
ical	O	-1	12559315
of	O	-1	12559315
interstitial	B-Disease	D018856	12559315
cys@@	I-Disease	-1	12559315
ti@@	I-Disease	-1	12559315
tis	I-Disease	-1	12559315
,	O	-1	12559315
such	O	-1	12559315
as	O	-1	12559315
le@@	O	-1	12559315
ak@@	O	-1	12559315
y	O	-1	12559315
bladder	O	-1	12559315
epi@@	O	-1	12559315
the@@	O	-1	12559315
li@@	O	-1	12559315
um	O	-1	12559315
and	O	-1	12559315
m@@	O	-1	12559315
u@@	O	-1	12559315
co@@	O	-1	12559315
s@@	O	-1	12559315
al	O	-1	12559315
ma@@	B-Disease	D008415	12559315
st@@	I-Disease	-1	12559315
ocyto@@	I-Disease	-1	12559315
sis	I-Disease	-1	12559315
.	O	-1	12559315
The	O	-1	12559315
t@@	O	-1	12559315
ru@@	O	-1	12559315
e	O	-1	12559315
incidence	O	-1	12559315
of	O	-1	12559315
non@@	O	-1	12559315
steroid@@	O	-1	12559315
al	O	-1	12559315
anti@@	O	-1	12559315
-@@	O	-1	12559315
inflam@@	O	-1	12559315
mat@@	O	-1	12559315
ory	O	-1	12559315
drug@@	O	-1	12559315
-induced	O	-1	12559315
cys@@	B-Disease	D003556	12559315
ti@@	I-Disease	-1	12559315
tis	I-Disease	-1	12559315
in	O	-1	12559315
hum@@	O	-1	12559315
ans	O	-1	12559315
mus@@	O	-1	12559315
t	O	-1	12559315
be	O	-1	12559315
cl@@	O	-1	12559315
ar@@	O	-1	12559315
if@@	O	-1	12559315
ied	O	-1	12559315
by	O	-1	12559315
pro@@	O	-1	12559315
sp@@	O	-1	12559315
ective	O	-1	12559315
clinical	O	-1	12559315
tri@@	O	-1	12559315
al@@	O	-1	12559315
s.	O	-1	12559315

An	O	-1	12644816
o@@	O	-1	12644816
pen@@	O	-1	12644816
-@@	O	-1	12644816
l@@	O	-1	12644816
a@@	O	-1	12644816
be@@	O	-1	12644816
l	O	-1	12644816
phase	O	-1	12644816
II	O	-1	12644816
study	O	-1	12644816
of	O	-1	12644816
low@@	O	-1	12644816
-@@	O	-1	12644816
dose	O	-1	12644816
thal@@	B-Chemical	D013792	12644816
id@@	I-Chemical	-1	12644816
om@@	I-Chemical	-1	12644816
ide	I-Chemical	-1	12644816
in	O	-1	12644816
and@@	B-Chemical	D000728	12644816
ro@@	I-Chemical	-1	12644816
gen	I-Chemical	-1	12644816
-@@	O	-1	12644816
in@@	O	-1	12644816
dependent	O	-1	12644816
pro@@	B-Disease	D011471	12644816
state	I-Disease	-1	12644816
cancer	I-Disease	-1	12644816
.	O	-1	12644816
The	O	-1	12644816
anti@@	O	-1	12644816
angio@@	O	-1	12644816
genic	O	-1	12644816
effects	O	-1	12644816
of	O	-1	12644816
thal@@	B-Chemical	D013792	12644816
id@@	I-Chemical	-1	12644816
om@@	I-Chemical	-1	12644816
ide	I-Chemical	-1	12644816
have	O	-1	12644816
been	O	-1	12644816
assessed	O	-1	12644816
in	O	-1	12644816
clinical	O	-1	12644816
tri@@	O	-1	12644816
als	O	-1	12644816
in	O	-1	12644816
patients	O	-1	12644816
with	O	-1	12644816
various	O	-1	12644816
sol@@	O	-1	12644816
id	O	-1	12644816
and	O	-1	12644816
haem@@	B-Disease	D019337	12644816
at@@	I-Disease	-1	12644816
ological	I-Disease	-1	12644816
mal@@	I-Disease	-1	12644816
i@@	I-Disease	-1	12644816
gn@@	I-Disease	-1	12644816
an@@	I-Disease	-1	12644816
ci@@	I-Disease	-1	12644816
es	I-Disease	-1	12644816
.	O	-1	12644816
Th@@	B-Chemical	D013792	12644816
al@@	I-Chemical	-1	12644816
id@@	I-Chemical	-1	12644816
om@@	I-Chemical	-1	12644816
ide	I-Chemical	-1	12644816
block@@	O	-1	12644816
s	O	-1	12644816
the	O	-1	12644816
activity	O	-1	12644816
of	O	-1	12644816
angio@@	O	-1	12644816
genic	O	-1	12644816
agents	O	-1	12644816
including	O	-1	12644816
b@@	O	-1	12644816
F@@	O	-1	12644816
GF@@	O	-1	12644816
,	O	-1	12644816
V@@	O	-1	12644816
E@@	O	-1	12644816
G@@	O	-1	12644816
F	O	-1	12644816
and	O	-1	12644816
I@@	O	-1	12644816
L-@@	O	-1	12644816
6@@	O	-1	12644816
.	O	-1	12644816
We	O	-1	12644816
under@@	O	-1	12644816
to@@	O	-1	12644816
o@@	O	-1	12644816
k	O	-1	12644816
an	O	-1	12644816
o@@	O	-1	12644816
pen@@	O	-1	12644816
-@@	O	-1	12644816
l@@	O	-1	12644816
a@@	O	-1	12644816
be@@	O	-1	12644816
l	O	-1	12644816
study	O	-1	12644816
using	O	-1	12644816
thal@@	B-Chemical	D013792	12644816
id@@	I-Chemical	-1	12644816
om@@	I-Chemical	-1	12644816
ide	I-Chemical	-1	12644816
100	O	-1	12644816
mg	O	-1	12644816
on@@	O	-1	12644816
ce	O	-1	12644816
daily	O	-1	12644816
for	O	-1	12644816
up	O	-1	12644816
to	O	-1	12644816
6	O	-1	12644816
months	O	-1	12644816
in	O	-1	12644816
20	O	-1	12644816
men	O	-1	12644816
with	O	-1	12644816
and@@	B-Chemical	D000728	12644816
ro@@	I-Chemical	-1	12644816
gen	I-Chemical	-1	12644816
-@@	O	-1	12644816
in@@	O	-1	12644816
dependent	O	-1	12644816
pro@@	B-Disease	D011471	12644816
state	I-Disease	-1	12644816
cancer	I-Disease	-1	12644816
.	O	-1	12644816
The	O	-1	12644816
mean	O	-1	12644816
time	O	-1	12644816
of	O	-1	12644816
study	O	-1	12644816
was	O	-1	12644816
10@@	O	-1	12644816
9	O	-1	12644816
days	O	-1	12644816
(@@	O	-1	12644816
median	O	-1	12644816
10@@	O	-1	12644816
7@@	O	-1	12644816
,	O	-1	12644816
range	O	-1	12644816
4@@	O	-1	12644816
-1@@	O	-1	12644816
8@@	O	-1	12644816
4	O	-1	12644816
da@@	O	-1	12644816
ys@@	O	-1	12644816
).	O	-1	12644816
Patients	O	-1	12644816
under@@	O	-1	12644816
w@@	O	-1	12644816
ent	O	-1	12644816
reg@@	O	-1	12644816
ular	O	-1	12644816
meas@@	O	-1	12644816
ure@@	O	-1	12644816
ment	O	-1	12644816
of	O	-1	12644816
pro@@	O	-1	12644816
stat@@	O	-1	12644816
e-@@	O	-1	12644816
specific	O	-1	12644816
anti@@	O	-1	12644816
gen	O	-1	12644816
(P@@	O	-1	12644816
S@@	O	-1	12644816
A@@	O	-1	12644816
),	O	-1	12644816
ure@@	B-Chemical	D014508	12644816
a	I-Chemical	-1	12644816
and	O	-1	12644816
electro@@	O	-1	12644816
ly@@	O	-1	12644816
t@@	O	-1	12644816
es,	O	-1	12644816
serum	O	-1	12644816
b@@	O	-1	12644816
F@@	O	-1	12644816
G@@	O	-1	12644816
F	O	-1	12644816
and	O	-1	12644816
V@@	O	-1	12644816
E@@	O	-1	12644816
GF@@	O	-1	12644816
.	O	-1	12644816
Th@@	O	-1	12644816
ree	O	-1	12644816
men	O	-1	12644816
(1@@	O	-1	12644816
5@@	O	-1	12644816
%)	O	-1	12644816
showed	O	-1	12644816
a	O	-1	12644816
dec@@	O	-1	12644816
line	O	-1	12644816
in	O	-1	12644816
serum	O	-1	12644816
P@@	O	-1	12644816
S@@	O	-1	12644816
A	O	-1	12644816
of	O	-1	12644816
at	O	-1	12644816
le@@	O	-1	12644816
ast	O	-1	12644816
50@@	O	-1	12644816
%,	O	-1	12644816
su@@	O	-1	12644816
st@@	O	-1	12644816
ained	O	-1	12644816
throu@@	O	-1	12644816
gh@@	O	-1	12644816
out	O	-1	12644816
treatment.	O	-1	12644816
Of	O	-1	12644816
16	O	-1	12644816
men	O	-1	12644816
treated	O	-1	12644816
for	O	-1	12644816
at	O	-1	12644816
le@@	O	-1	12644816
ast	O	-1	12644816
2	O	-1	12644816
month@@	O	-1	12644816
s,	O	-1	12644816
six	O	-1	12644816
(3@@	O	-1	12644816
7.@@	O	-1	12644816
5@@	O	-1	12644816
%)	O	-1	12644816
showed	O	-1	12644816
a	O	-1	12644816
f@@	O	-1	12644816
all	O	-1	12644816
in	O	-1	12644816
abs@@	O	-1	12644816
ol@@	O	-1	12644816
ute	O	-1	12644816
P@@	O	-1	12644816
S@@	O	-1	12644816
A	O	-1	12644816
by	O	-1	12644816
a	O	-1	12644816
median	O	-1	12644816
of	O	-1	12644816
4@@	O	-1	12644816
8@@	O	-1	12644816
%.	O	-1	12644816
In@@	O	-1	12644816
c@@	O	-1	12644816
reas@@	O	-1	12644816
ing	O	-1	12644816
levels	O	-1	12644816
of	O	-1	12644816
serum	O	-1	12644816
b@@	O	-1	12644816
F@@	O	-1	12644816
G@@	O	-1	12644816
F	O	-1	12644816
and	O	-1	12644816
V@@	O	-1	12644816
E@@	O	-1	12644816
G@@	O	-1	12644816
F	O	-1	12644816
were	O	-1	12644816
associated	O	-1	12644816
with	O	-1	12644816
progressive	O	-1	12644816
diseas@@	O	-1	12644816
e@@	O	-1	12644816
;	O	-1	12644816
five	O	-1	12644816
of	O	-1	12644816
six	O	-1	12644816
men	O	-1	12644816
who	O	-1	12644816
demonstrated	O	-1	12644816
a	O	-1	12644816
f@@	O	-1	12644816
all	O	-1	12644816
in	O	-1	12644816
P@@	O	-1	12644816
S@@	O	-1	12644816
A	O	-1	12644816
also	O	-1	12644816
showed	O	-1	12644816
a	O	-1	12644816
dec@@	O	-1	12644816
line	O	-1	12644816
in	O	-1	12644816
b@@	O	-1	12644816
F@@	O	-1	12644816
G@@	O	-1	12644816
F	O	-1	12644816
and	O	-1	12644816
V@@	O	-1	12644816
E@@	O	-1	12644816
G@@	O	-1	12644816
F	O	-1	12644816
level@@	O	-1	12644816
s,	O	-1	12644816
and	O	-1	12644816
three	O	-1	12644816
of	O	-1	12644816
four	O	-1	12644816
men	O	-1	12644816
with	O	-1	12644816
a	O	-1	12644816
ris@@	O	-1	12644816
ing	O	-1	12644816
P@@	O	-1	12644816
S@@	O	-1	12644816
A	O	-1	12644816
showed	O	-1	12644816
an	O	-1	12644816
increase	O	-1	12644816
in	O	-1	12644816
both	O	-1	12644816
growth	O	-1	12644816
fact@@	O	-1	12644816
or@@	O	-1	12644816
s.	O	-1	12644816
Ad@@	O	-1	12644816
verse	O	-1	12644816
effects	O	-1	12644816
included	O	-1	12644816
con@@	B-Disease	D003248	12644816
sti@@	I-Disease	-1	12644816
p@@	I-Disease	-1	12644816
ation	I-Disease	-1	12644816
,	O	-1	12644816
mor@@	O	-1	12644816
ning	O	-1	12644816
dro@@	B-Disease	D006970	12644816
w@@	I-Disease	-1	12644816
s@@	I-Disease	-1	12644816
in@@	I-Disease	-1	12644816
ess	I-Disease	-1	12644816
,	O	-1	12644816
di@@	B-Disease	D004244	12644816
z@@	I-Disease	-1	12644816
z@@	I-Disease	-1	12644816
in@@	I-Disease	-1	12644816
ess	I-Disease	-1	12644816
and	O	-1	12644816
r@@	B-Disease	D005076	12644816
as@@	I-Disease	-1	12644816
h	I-Disease	-1	12644816
,	O	-1	12644816
and	O	-1	12644816
resulted	O	-1	12644816
in	O	-1	12644816
withdrawal	O	-1	12644816
from	O	-1	12644816
the	O	-1	12644816
study	O	-1	12644816
by	O	-1	12644816
three	O	-1	12644816
men@@	O	-1	12644816
.	O	-1	12644816
E@@	O	-1	12644816
v@@	O	-1	12644816
idence	O	-1	12644816
of	O	-1	12644816
peripheral	B-Disease	D010523	12644816
sens@@	I-Disease	-1	12644816
ory	I-Disease	-1	12644816
neuropathy	I-Disease	-1	12644816
was	O	-1	12644816
found	O	-1	12644816
in	O	-1	12644816
n@@	O	-1	12644816
ine	O	-1	12644816
of	O	-1	12644816
13	O	-1	12644816
men	O	-1	12644816
before	O	-1	12644816
treatment.	O	-1	12644816
In	O	-1	12644816
the	O	-1	12644816
seven	O	-1	12644816
men	O	-1	12644816
who	O	-1	12644816
comple@@	O	-1	12644816
ted	O	-1	12644816
six	O	-1	12644816
months	O	-1	12644816
on	O	-1	12644816
thal@@	B-Chemical	D013792	12644816
id@@	I-Chemical	-1	12644816
om@@	I-Chemical	-1	12644816
ide	I-Chemical	-1	12644816
,	O	-1	12644816
sub@@	O	-1	12644816
clinical	O	-1	12644816
evidence	O	-1	12644816
of	O	-1	12644816
peripheral	B-Disease	D010523	12644816
neuropathy	I-Disease	-1	12644816
was	O	-1	12644816
found	O	-1	12644816
in	O	-1	12644816
four	O	-1	12644816
before	O	-1	12644816
treatment,	O	-1	12644816
but	O	-1	12644816
in	O	-1	12644816
all	O	-1	12644816
seven	O	-1	12644816
at	O	-1	12644816
repe@@	O	-1	12644816
at	O	-1	12644816
test@@	O	-1	12644816
ing.	O	-1	12644816
The	O	-1	12644816
findings	O	-1	12644816
indicate	O	-1	12644816
that	O	-1	12644816
thal@@	B-Chemical	D013792	12644816
id@@	I-Chemical	-1	12644816
om@@	I-Chemical	-1	12644816
ide	I-Chemical	-1	12644816
may	O	-1	12644816
be	O	-1	12644816
an	O	-1	12644816
op@@	O	-1	12644816
tion	O	-1	12644816
for	O	-1	12644816
patients	O	-1	12644816
who	O	-1	12644816
have	O	-1	12644816
fail@@	O	-1	12644816
ed	O	-1	12644816
other	O	-1	12644816
form@@	O	-1	12644816
s	O	-1	12644816
of	O	-1	12644816
therapy,	O	-1	12644816
pro@@	O	-1	12644816
vid@@	O	-1	12644816
ed	O	-1	12644816
clo@@	O	-1	12644816
se	O	-1	12644816
follow-up	O	-1	12644816
is	O	-1	12644816
maint@@	O	-1	12644816
ained	O	-1	12644816
for	O	-1	12644816
development	O	-1	12644816
of	O	-1	12644816
peripheral	B-Disease	D010523	12644816
neuropathy	I-Disease	-1	12644816
.	O	-1	12644816

C@@	B-Disease	D020258	12677626
entr@@	I-Disease	-1	12677626
al	I-Disease	-1	12677626
ner@@	I-Disease	-1	12677626
v@@	I-Disease	-1	12677626
ous	I-Disease	-1	12677626
system	I-Disease	-1	12677626
toxicity	I-Disease	-1	12677626
following	O	-1	12677626
the	O	-1	12677626
administration	O	-1	12677626
of	O	-1	12677626
levo@@	B-Chemical	C476513	12677626
bupivac@@	I-Chemical	-1	12677626
aine	I-Chemical	-1	12677626
for	O	-1	12677626
l@@	O	-1	12677626
umb@@	O	-1	12677626
ar	O	-1	12677626
ple@@	O	-1	12677626
x@@	O	-1	12677626
us	O	-1	12677626
block@@	O	-1	12677626
:	O	-1	12677626
A	O	-1	12677626
report	O	-1	12677626
of	O	-1	12677626
two	O	-1	12677626
cas@@	O	-1	12677626
es.	O	-1	12677626
BACKGROUN@@	O	-1	12677626
D	O	-1	12677626
AN@@	O	-1	12677626
D	O	-1	12677626
OBJECTIV@@	O	-1	12677626
E@@	O	-1	12677626
S:	O	-1	12677626
C@@	B-Disease	D020258	12677626
entr@@	I-Disease	-1	12677626
al	I-Disease	-1	12677626
ner@@	I-Disease	-1	12677626
v@@	I-Disease	-1	12677626
ous	I-Disease	-1	12677626
system	I-Disease	-1	12677626
and	I-Disease	-1	12677626
cardiac	I-Disease	-1	12677626
toxicity	I-Disease	-1	12677626
C@@	B-Disease	D066126	12677626
entr@@	I-Disease	-1	12677626
al	I-Disease	-1	12677626
ner@@	I-Disease	-1	12677626
v@@	I-Disease	-1	12677626
ous	I-Disease	-1	12677626
system	I-Disease	-1	12677626
and	I-Disease	-1	12677626
cardiac	I-Disease	-1	12677626
toxicity	I-Disease	-1	12677626
following	O	-1	12677626
the	O	-1	12677626
administration	O	-1	12677626
of	O	-1	12677626
loc@@	O	-1	12677626
al	O	-1	12677626
anesthe@@	O	-1	12677626
tics	O	-1	12677626
is	O	-1	12677626
a	O	-1	12677626
reco@@	O	-1	12677626
gn@@	O	-1	12677626
ized	O	-1	12677626
complication	O	-1	12677626
of	O	-1	12677626
regi@@	O	-1	12677626
on@@	O	-1	12677626
al	O	-1	12677626
anesthe@@	O	-1	12677626
sia.	O	-1	12677626
L@@	B-Chemical	C476513	12677626
evo@@	I-Chemical	-1	12677626
bupivac@@	I-Chemical	-1	12677626
aine	I-Chemical	-1	12677626
,	O	-1	12677626
the	O	-1	12677626
p@@	O	-1	12677626
ure	O	-1	12677626
S@@	O	-1	12677626
(-@@	O	-1	12677626
)	O	-1	12677626
en@@	O	-1	12677626
anti@@	O	-1	12677626
om@@	O	-1	12677626
er	O	-1	12677626
of	O	-1	12677626
bupivac@@	B-Chemical	D002045	12677626
aine	I-Chemical	-1	12677626
,	O	-1	12677626
was	O	-1	12677626
developed	O	-1	12677626
to	O	-1	12677626
impro@@	O	-1	12677626
ve	O	-1	12677626
the	O	-1	12677626
cardiac	O	-1	12677626
safety	O	-1	12677626
prof@@	O	-1	12677626
ile	O	-1	12677626
of	O	-1	12677626
bupivac@@	B-Chemical	D002045	12677626
aine	I-Chemical	-1	12677626
.	O	-1	12677626
We	O	-1	12677626
describe	O	-1	12677626
2	O	-1	12677626
cases	O	-1	12677626
of	O	-1	12677626
g@@	B-Disease	D004830	12677626
r@@	I-Disease	-1	12677626
and	I-Disease	-1	12677626
m@@	I-Disease	-1	12677626
al	I-Disease	-1	12677626
seizures	I-Disease	-1	12677626
following	O	-1	12677626
ac@@	O	-1	12677626
c@@	O	-1	12677626
id@@	O	-1	12677626
ental	O	-1	12677626
intra@@	O	-1	12677626
vascular	O	-1	12677626
injection	O	-1	12677626
of	O	-1	12677626
levo@@	B-Chemical	C476513	12677626
bupivac@@	I-Chemical	-1	12677626
aine	I-Chemical	-1	12677626
.	O	-1	12677626
CA@@	O	-1	12677626
S@@	O	-1	12677626
E	O	-1	12677626
R@@	O	-1	12677626
EP@@	O	-1	12677626
O@@	O	-1	12677626
R@@	O	-1	12677626
T@@	O	-1	12677626
:	O	-1	12677626
Two	O	-1	12677626
patients	O	-1	12677626
present@@	O	-1	12677626
ing	O	-1	12677626
for	O	-1	12677626
el@@	O	-1	12677626
ective	O	-1	12677626
or@@	O	-1	12677626
th@@	O	-1	12677626
o@@	O	-1	12677626
pe@@	O	-1	12677626
di@@	O	-1	12677626
c	O	-1	12677626
surger@@	O	-1	12677626
y	O	-1	12677626
of	O	-1	12677626
the	O	-1	12677626
lower	O	-1	12677626
lim@@	O	-1	12677626
b	O	-1	12677626
under@@	O	-1	12677626
w@@	O	-1	12677626
ent	O	-1	12677626
block@@	O	-1	12677626
ade	O	-1	12677626
of	O	-1	12677626
the	O	-1	12677626
l@@	O	-1	12677626
umb@@	O	-1	12677626
ar	O	-1	12677626
ple@@	O	-1	12677626
x@@	O	-1	12677626
us	O	-1	12677626
vi@@	O	-1	12677626
a	O	-1	12677626
the	O	-1	12677626
po@@	O	-1	12677626
ster@@	O	-1	12677626
ior	O	-1	12677626
appro@@	O	-1	12677626
ac@@	O	-1	12677626
h@@	O	-1	12677626
.	O	-1	12677626
Im@@	O	-1	12677626
medi@@	O	-1	12677626
ately	O	-1	12677626
after	O	-1	12677626
the	O	-1	12677626
administration	O	-1	12677626
of	O	-1	12677626
levo@@	B-Chemical	C476513	12677626
bupivac@@	I-Chemical	-1	12677626
aine	I-Chemical	-1	12677626
0.@@	O	-1	12677626
5%	O	-1	12677626
with	O	-1	12677626
ep@@	B-Chemical	D004837	12677626
ine@@	I-Chemical	-1	12677626
phrine	I-Chemical	-1	12677626
2.@@	O	-1	12677626
5	O	-1	12677626
microgram@@	O	-1	12677626
/@@	O	-1	12677626
m@@	O	-1	12677626
L@@	O	-1	12677626
,	O	-1	12677626
the	O	-1	12677626
patients	O	-1	12677626
developed	O	-1	12677626
g@@	B-Disease	D004830	12677626
r@@	I-Disease	-1	12677626
and	I-Disease	-1	12677626
m@@	I-Disease	-1	12677626
al	I-Disease	-1	12677626
seizures	I-Disease	-1	12677626
,	O	-1	12677626
des@@	O	-1	12677626
pit@@	O	-1	12677626
e	O	-1	12677626
negative	O	-1	12677626
as@@	O	-1	12677626
pi@@	O	-1	12677626
ration	O	-1	12677626
for	O	-1	12677626
blood	O	-1	12677626
and	O	-1	12677626
no	O	-1	12677626
clinical	O	-1	12677626
signs	O	-1	12677626
of	O	-1	12677626
intravenous	O	-1	12677626
ep@@	B-Chemical	D004837	12677626
ine@@	I-Chemical	-1	12677626
phrine	I-Chemical	-1	12677626
administr@@	O	-1	12677626
ation.	O	-1	12677626
The	O	-1	12677626
seizures	B-Disease	D012640	12677626
were	O	-1	12677626
suc@@	O	-1	12677626
cess@@	O	-1	12677626
ful@@	O	-1	12677626
ly	O	-1	12677626
treated	O	-1	12677626
with	O	-1	12677626
sodium	B-Chemical	D013874	12677626
th@@	I-Chemical	-1	12677626
io@@	I-Chemical	-1	12677626
p@@	I-Chemical	-1	12677626
ental	I-Chemical	-1	12677626
in	O	-1	12677626
addition	O	-1	12677626
to	O	-1	12677626
suc@@	B-Chemical	D013390	12677626
cin@@	I-Chemical	-1	12677626
ylcholine	I-Chemical	-1	12677626
in	O	-1	12677626
1	O	-1	12677626
patient@@	O	-1	12677626
.	O	-1	12677626
N@@	O	-1	12677626
either	O	-1	12677626
patient	O	-1	12677626
developed	O	-1	12677626
signs	O	-1	12677626
of	O	-1	12677626
cardiovascular	B-Disease	D002318	12677626
toxicity	I-Disease	-1	12677626
.	O	-1	12677626
B@@	O	-1	12677626
oth	O	-1	12677626
patients	O	-1	12677626
were	O	-1	12677626
treated	O	-1	12677626
pre@@	O	-1	12677626
o@@	O	-1	12677626
per@@	O	-1	12677626
atively	O	-1	12677626
with	O	-1	12677626
beta-@@	O	-1	12677626
adrenergic	O	-1	12677626
antagonist	O	-1	12677626
medic@@	O	-1	12677626
ation@@	O	-1	12677626
s,	O	-1	12677626
which	O	-1	12677626
may	O	-1	12677626
have	O	-1	12677626
mas@@	O	-1	12677626
ked	O	-1	12677626
the	O	-1	12677626
cardiovascular	O	-1	12677626
signs	O	-1	12677626
of	O	-1	12677626
the	O	-1	12677626
un@@	O	-1	12677626
int@@	O	-1	12677626
en@@	O	-1	12677626
tional	O	-1	12677626
intra@@	O	-1	12677626
vascular	O	-1	12677626
administration	O	-1	12677626
of	O	-1	12677626
levo@@	B-Chemical	C476513	12677626
bupivac@@	I-Chemical	-1	12677626
aine	I-Chemical	-1	12677626
with	O	-1	12677626
ep@@	B-Chemical	D004837	12677626
ine@@	I-Chemical	-1	12677626
phrine	I-Chemical	-1	12677626
.	O	-1	12677626
CONCLUSIONS:	O	-1	12677626
Although	O	-1	12677626
levo@@	B-Chemical	C476513	12677626
bupivac@@	I-Chemical	-1	12677626
aine	I-Chemical	-1	12677626
may	O	-1	12677626
have	O	-1	12677626
a	O	-1	12677626
saf@@	O	-1	12677626
er	O	-1	12677626
cardiac	B-Disease	D066126	12677626
toxicity	I-Disease	-1	12677626
prof@@	O	-1	12677626
ile	O	-1	12677626
than	O	-1	12677626
rac@@	O	-1	12677626
em@@	O	-1	12677626
ic	O	-1	12677626
bupivac@@	B-Chemical	D002045	12677626
aine	I-Chemical	-1	12677626
,	O	-1	12677626
if	O	-1	12677626
ade@@	O	-1	12677626
qu@@	O	-1	12677626
ate	O	-1	12677626
amoun@@	O	-1	12677626
ts	O	-1	12677626
of	O	-1	12677626
levo@@	B-Chemical	C476513	12677626
bupivac@@	I-Chemical	-1	12677626
aine	I-Chemical	-1	12677626
reac@@	O	-1	12677626
h	O	-1	12677626
the	O	-1	12677626
cir@@	O	-1	12677626
cul@@	O	-1	12677626
ation,	O	-1	12677626
it	O	-1	12677626
wil@@	O	-1	12677626
l	O	-1	12677626
result	O	-1	12677626
in	O	-1	12677626
convul@@	B-Disease	D012640	12677626
sions	I-Disease	-1	12677626
.	O	-1	12677626
P@@	O	-1	12677626
las@@	O	-1	12677626
ma	O	-1	12677626
concentrations	O	-1	12677626
suffici@@	O	-1	12677626
ent	O	-1	12677626
to	O	-1	12677626
result	O	-1	12677626
in	O	-1	12677626
central	B-Disease	D020258	12677626
ner@@	I-Disease	-1	12677626
v@@	I-Disease	-1	12677626
ous	I-Disease	-1	12677626
system	I-Disease	-1	12677626
toxicity	I-Disease	-1	12677626
did	O	-1	12677626
not	O	-1	12677626
produce	O	-1	12677626
man@@	O	-1	12677626
if@@	O	-1	12677626
est@@	O	-1	12677626
ations	O	-1	12677626
of	O	-1	12677626
cardiac	B-Disease	D066126	12677626
toxicity	I-Disease	-1	12677626
in	O	-1	12677626
these	O	-1	12677626
2	O	-1	12677626
patients.	O	-1	12677626

An@@	O	-1	12699527
a@@	O	-1	12699527
esthe@@	O	-1	12699527
tic	O	-1	12699527
complications	O	-1	12699527
associated	O	-1	12699527
with	O	-1	12699527
my@@	B-Disease	D009224	12699527
oton@@	I-Disease	-1	12699527
ia	I-Disease	-1	12699527
con@@	I-Disease	-1	12699527
gen@@	I-Disease	-1	12699527
it@@	I-Disease	-1	12699527
a	I-Disease	-1	12699527
:	O	-1	12699527
case	O	-1	12699527
study	O	-1	12699527
and	O	-1	12699527
compar@@	O	-1	12699527
ison	O	-1	12699527
with	O	-1	12699527
other	O	-1	12699527
my@@	B-Disease	D020967	12699527
oton@@	I-Disease	-1	12699527
ic	I-Disease	-1	12699527
disorder@@	I-Disease	-1	12699527
s	I-Disease	-1	12699527
.	O	-1	12699527
M@@	B-Disease	D009224	12699527
y@@	I-Disease	-1	12699527
oton@@	I-Disease	-1	12699527
ia	I-Disease	-1	12699527
con@@	I-Disease	-1	12699527
gen@@	I-Disease	-1	12699527
it@@	I-Disease	-1	12699527
a	I-Disease	-1	12699527
(	O	-1	12699527
M@@	B-Disease	D009224	12699527
C	I-Disease	-1	12699527
)	O	-1	12699527
is	O	-1	12699527
caused	O	-1	12699527
by	O	-1	12699527
a	O	-1	12699527
def@@	O	-1	12699527
ect	O	-1	12699527
in	O	-1	12699527
the	O	-1	12699527
s@@	O	-1	12699527
ke@@	O	-1	12699527
le@@	O	-1	12699527
t@@	O	-1	12699527
al	O	-1	12699527
musc@@	O	-1	12699527
le	O	-1	12699527
chlor@@	B-Chemical	D002712	12699527
ide	I-Chemical	-1	12699527
channel	O	-1	12699527
func@@	O	-1	12699527
tion,	O	-1	12699527
which	O	-1	12699527
may	O	-1	12699527
cause	O	-1	12699527
su@@	B-Disease	-1	12699527
st@@	I-Disease	-1	12699527
ained	I-Disease	-1	12699527
membran@@	I-Disease	-1	12699527
e	I-Disease	-1	12699527
de@@	I-Disease	-1	12699527
pol@@	I-Disease	-1	12699527
ar@@	I-Disease	-1	12699527
is@@	I-Disease	-1	12699527
ation	I-Disease	-1	12699527
.	O	-1	12699527
We	O	-1	12699527
describe	O	-1	12699527
a	O	-1	12699527
previously	O	-1	12699527
healthy	O	-1	12699527
3@@	O	-1	12699527
2-@@	O	-1	12699527
year-old	O	-1	12699527
woman	O	-1	12699527
who	O	-1	12699527
developed	O	-1	12699527
a	O	-1	12699527
lif@@	O	-1	12699527
e-@@	O	-1	12699527
th@@	O	-1	12699527
reat@@	O	-1	12699527
en@@	O	-1	12699527
ing	O	-1	12699527
musc@@	B-Disease	D013035	12699527
le	I-Disease	-1	12699527
sp@@	I-Disease	-1	12699527
as@@	I-Disease	-1	12699527
m	I-Disease	-1	12699527
and	O	-1	12699527
secondary	O	-1	12699527
ven@@	O	-1	12699527
til@@	O	-1	12699527
ation	O	-1	12699527
diff@@	O	-1	12699527
ic@@	O	-1	12699527
ul@@	O	-1	12699527
ties	O	-1	12699527
following	O	-1	12699527
a	O	-1	12699527
pre@@	O	-1	12699527
o@@	O	-1	12699527
perative	O	-1	12699527
injection	O	-1	12699527
of	O	-1	12699527
su@@	B-Chemical	D013390	12699527
xameth@@	I-Chemical	-1	12699527
oni@@	I-Chemical	-1	12699527
um	I-Chemical	-1	12699527
.	O	-1	12699527
The	O	-1	12699527
musc@@	B-Disease	D013035	12699527
le	I-Disease	-1	12699527
sp@@	I-Disease	-1	12699527
as@@	I-Disease	-1	12699527
ms	I-Disease	-1	12699527
dis@@	O	-1	12699527
appe@@	O	-1	12699527
a@@	O	-1	12699527
red	O	-1	12699527
spont@@	O	-1	12699527
ane@@	O	-1	12699527
ously	O	-1	12699527
and	O	-1	12699527
the	O	-1	12699527
surger@@	O	-1	12699527
y	O	-1	12699527
proce@@	O	-1	12699527
ed@@	O	-1	12699527
ed	O	-1	12699527
without	O	-1	12699527
further	O	-1	12699527
pro@@	O	-1	12699527
ble@@	O	-1	12699527
m@@	O	-1	12699527
s.	O	-1	12699527
Whe@@	O	-1	12699527
n	O	-1	12699527
subsequ@@	O	-1	12699527
ently	O	-1	12699527
qu@@	O	-1	12699527
es@@	O	-1	12699527
tion@@	O	-1	12699527
ed,	O	-1	12699527
sh@@	O	-1	12699527
e	O	-1	12699527
reported	O	-1	12699527
min@@	O	-1	12699527
or	O	-1	12699527
symptoms	O	-1	12699527
suggesting	O	-1	12699527
a	O	-1	12699527
my@@	B-Disease	D020967	12699527
oton@@	I-Disease	-1	12699527
ic	I-Disease	-1	12699527
condi@@	I-Disease	-1	12699527
tion	I-Disease	-1	12699527
.	O	-1	12699527
M@@	B-Disease	D009222	12699527
y@@	I-Disease	-1	12699527
oton@@	I-Disease	-1	12699527
ia	I-Disease	-1	12699527
was	O	-1	12699527
found	O	-1	12699527
on	O	-1	12699527
clinical	O	-1	12699527
examin@@	O	-1	12699527
ation	O	-1	12699527
and	O	-1	12699527
E@@	O	-1	12699527
M@@	O	-1	12699527
G@@	O	-1	12699527
.	O	-1	12699527
The	O	-1	12699527
diagnosis	O	-1	12699527
M@@	B-Disease	D009224	12699527
C	I-Disease	-1	12699527
was	O	-1	12699527
con@@	O	-1	12699527
fir@@	O	-1	12699527
m@@	O	-1	12699527
ed	O	-1	12699527
gene@@	O	-1	12699527
tic@@	O	-1	12699527
all@@	O	-1	12699527
y.	O	-1	12699527
N@@	O	-1	12699527
either	O	-1	12699527
the	O	-1	12699527
patient	O	-1	12699527
n@@	O	-1	12699527
or	O	-1	12699527
the	O	-1	12699527
anaesthe@@	O	-1	12699527
ti@@	O	-1	12699527
st	O	-1	12699527
were	O	-1	12699527
aw@@	O	-1	12699527
are	O	-1	12699527
of	O	-1	12699527
the	O	-1	12699527
diagnosis	O	-1	12699527
before	O	-1	12699527
this	O	-1	12699527
potenti@@	O	-1	12699527
ally	O	-1	12699527
le@@	O	-1	12699527
th@@	O	-1	12699527
al	O	-1	12699527
complication	O	-1	12699527
occur@@	O	-1	12699527
red.	O	-1	12699527
We	O	-1	12699527
gi@@	O	-1	12699527
ve	O	-1	12699527
a	O	-1	12699527
b@@	O	-1	12699527
ri@@	O	-1	12699527
e@@	O	-1	12699527
f	O	-1	12699527
over@@	O	-1	12699527
vie@@	O	-1	12699527
w	O	-1	12699527
of	O	-1	12699527
i@@	B-Disease	-1	12699527
on	I-Disease	-1	12699527
channel	I-Disease	-1	12699527
disorder@@	I-Disease	-1	12699527
s	I-Disease	-1	12699527
including	O	-1	12699527
mal@@	B-Disease	D008305	12699527
i@@	I-Disease	-1	12699527
gn@@	I-Disease	-1	12699527
ant	I-Disease	-1	12699527
hyper@@	I-Disease	-1	12699527
ther@@	I-Disease	-1	12699527
mia	I-Disease	-1	12699527
and	O	-1	12699527
their	O	-1	12699527
anaesthe@@	O	-1	12699527
tic	O	-1	12699527
con@@	O	-1	12699527
si@@	O	-1	12699527
der@@	O	-1	12699527
ations.	O	-1	12699527

R@@	O	-1	12752472
es@@	O	-1	12752472
piratory	O	-1	12752472
pat@@	O	-1	12752472
ter@@	O	-1	12752472
n	O	-1	12752472
in	O	-1	12752472
a	O	-1	12752472
rat	O	-1	12752472
model	O	-1	12752472
of	O	-1	12752472
epilep@@	B-Disease	D004827	12752472
sy	I-Disease	-1	12752472
.	O	-1	12752472
P@@	O	-1	12752472
U@@	O	-1	12752472
R@@	O	-1	12752472
P@@	O	-1	12752472
O@@	O	-1	12752472
S@@	O	-1	12752472
E:	O	-1	12752472
A@@	B-Disease	D001049	12752472
p@@	I-Disease	-1	12752472
ne@@	I-Disease	-1	12752472
a	I-Disease	-1	12752472
is	O	-1	12752472
known	O	-1	12752472
to	O	-1	12752472
occ@@	O	-1	12752472
ur	O	-1	12752472
during	O	-1	12752472
seizures	B-Disease	D012640	12752472
,	O	-1	12752472
but	O	-1	12752472
system@@	O	-1	12752472
atic	O	-1	12752472
studies	O	-1	12752472
of	O	-1	12752472
ic@@	O	-1	12752472
t@@	O	-1	12752472
al	O	-1	12752472
respiratory	O	-1	12752472
changes	O	-1	12752472
in	O	-1	12752472
ad@@	O	-1	12752472
ult@@	O	-1	12752472
s	O	-1	12752472
are	O	-1	12752472
fe@@	O	-1	12752472
w@@	O	-1	12752472
.	O	-1	12752472
D@@	O	-1	12752472
at@@	O	-1	12752472
a	O	-1	12752472
reg@@	O	-1	12752472
ar@@	O	-1	12752472
ding	O	-1	12752472
respiratory	O	-1	12752472
pat@@	O	-1	12752472
ter@@	O	-1	12752472
n	O	-1	12752472
def@@	O	-1	12752472
ects	O	-1	12752472
during	O	-1	12752472
inter@@	O	-1	12752472
ic@@	O	-1	12752472
t@@	O	-1	12752472
al	O	-1	12752472
perio@@	O	-1	12752472
ds	O	-1	12752472
also	O	-1	12752472
are	O	-1	12752472
s@@	O	-1	12752472
car@@	O	-1	12752472
ce@@	O	-1	12752472
.	O	-1	12752472
H@@	O	-1	12752472
ere	O	-1	12752472
we	O	-1	12752472
s@@	O	-1	12752472
ou@@	O	-1	12752472
ght	O	-1	12752472
to	O	-1	12752472
gener@@	O	-1	12752472
ate	O	-1	12752472
inf@@	O	-1	12752472
orm@@	O	-1	12752472
ation	O	-1	12752472
with	O	-1	12752472
reg@@	O	-1	12752472
ard	O	-1	12752472
to	O	-1	12752472
the	O	-1	12752472
inter@@	O	-1	12752472
ic@@	O	-1	12752472
t@@	O	-1	12752472
al	O	-1	12752472
period	O	-1	12752472
in	O	-1	12752472
animals	O	-1	12752472
with	O	-1	12752472
pilocar@@	B-Chemical	D010862	12752472
pine	I-Chemical	-1	12752472
-induced	O	-1	12752472
epilep@@	B-Disease	D004827	12752472
sy	I-Disease	-1	12752472
.	O	-1	12752472
METHODS:	O	-1	12752472
T@@	O	-1	12752472
we@@	O	-1	12752472
l@@	O	-1	12752472
ve	O	-1	12752472
rats	O	-1	12752472
(@@	O	-1	12752472
six	O	-1	12752472
chron@@	O	-1	12752472
ically	O	-1	12752472
epileptic	B-Disease	D004827	12752472
animals	O	-1	12752472
and	O	-1	12752472
six	O	-1	12752472
control@@	O	-1	12752472
s)	O	-1	12752472
were	O	-1	12752472
anesthe@@	O	-1	12752472
tiz@@	O	-1	12752472
ed,	O	-1	12752472
given	O	-1	12752472
trac@@	O	-1	12752472
he@@	O	-1	12752472
ot@@	O	-1	12752472
om@@	O	-1	12752472
i@@	O	-1	12752472
es,	O	-1	12752472
and	O	-1	12752472
subj@@	O	-1	12752472
ected	O	-1	12752472
to	O	-1	12752472
hyper@@	B-Disease	D006985	12752472
ven@@	I-Disease	-1	12752472
til@@	I-Disease	-1	12752472
ation	I-Disease	-1	12752472
or	O	-1	12752472
hypo@@	O	-1	12752472
ven@@	O	-1	12752472
til@@	O	-1	12752472
ation	O	-1	12752472
condi@@	O	-1	12752472
tions.	O	-1	12752472
B@@	O	-1	12752472
re@@	O	-1	12752472
ath@@	O	-1	12752472
ing	O	-1	12752472
mo@@	O	-1	12752472
ve@@	O	-1	12752472
ments	O	-1	12752472
caused	O	-1	12752472
changes	O	-1	12752472
in	O	-1	12752472
th@@	O	-1	12752472
or@@	O	-1	12752472
ac@@	O	-1	12752472
ic	O	-1	12752472
volume	O	-1	12752472
and	O	-1	12752472
for@@	O	-1	12752472
c@@	O	-1	12752472
ed	O	-1	12752472
a@@	O	-1	12752472
ir	O	-1	12752472
to	O	-1	12752472
flow	O	-1	12752472
tid@@	O	-1	12752472
ally	O	-1	12752472
through	O	-1	12752472
a	O	-1	12752472
p@@	O	-1	12752472
ne@@	O	-1	12752472
um@@	O	-1	12752472
ot@@	O	-1	12752472
ac@@	O	-1	12752472
ho@@	O	-1	12752472
graph@@	O	-1	12752472
.	O	-1	12752472
This	O	-1	12752472
flow	O	-1	12752472
was	O	-1	12752472
measured	O	-1	12752472
by	O	-1	12752472
using	O	-1	12752472
a	O	-1	12752472
differen@@	O	-1	12752472
tial	O	-1	12752472
pressure	O	-1	12752472
trans@@	O	-1	12752472
duc@@	O	-1	12752472
er,	O	-1	12752472
p@@	O	-1	12752472
ass@@	O	-1	12752472
ed	O	-1	12752472
through	O	-1	12752472
a	O	-1	12752472
poly@@	O	-1	12752472
graph@@	O	-1	12752472
,	O	-1	12752472
and	O	-1	12752472
from	O	-1	12752472
this	O	-1	12752472
to	O	-1	12752472
a	O	-1	12752472
comp@@	O	-1	12752472
u@@	O	-1	12752472
ter	O	-1	12752472
with	O	-1	12752472
c@@	O	-1	12752472
u@@	O	-1	12752472
sto@@	O	-1	12752472
m	O	-1	12752472
s@@	O	-1	12752472
of@@	O	-1	12752472
tw@@	O	-1	12752472
are	O	-1	12752472
that	O	-1	12752472
der@@	O	-1	12752472
i@@	O	-1	12752472
ved	O	-1	12752472
ven@@	O	-1	12752472
til@@	O	-1	12752472
ation	O	-1	12752472
(V@@	O	-1	12752472
E@@	O	-1	12752472
),	O	-1	12752472
tid@@	O	-1	12752472
al	O	-1	12752472
volume	O	-1	12752472
(V@@	O	-1	12752472
T@@	O	-1	12752472
),	O	-1	12752472
in@@	O	-1	12752472
s@@	O	-1	12752472
piratory	O	-1	12752472
time	O	-1	12752472
(@@	O	-1	12752472
TI@@	O	-1	12752472
),	O	-1	12752472
ex@@	O	-1	12752472
piratory	O	-1	12752472
time	O	-1	12752472
(T@@	O	-1	12752472
E@@	O	-1	12752472
),	O	-1	12752472
b@@	O	-1	12752472
re@@	O	-1	12752472
ath@@	O	-1	12752472
ing	O	-1	12752472
frequency	O	-1	12752472
(@@	O	-1	12752472
f@@	O	-1	12752472
),	O	-1	12752472
and	O	-1	12752472
mean	O	-1	12752472
in@@	O	-1	12752472
s@@	O	-1	12752472
piratory	O	-1	12752472
flow	O	-1	12752472
(V@@	O	-1	12752472
T@@	O	-1	12752472
/@@	O	-1	12752472
TI@@	O	-1	12752472
)	O	-1	12752472
on	O	-1	12752472
a	O	-1	12752472
b@@	O	-1	12752472
re@@	O	-1	12752472
ath@@	O	-1	12752472
-@@	O	-1	12752472
b@@	O	-1	12752472
y-@@	O	-1	12752472
b@@	O	-1	12752472
reat@@	O	-1	12752472
h	O	-1	12752472
b@@	O	-1	12752472
a@@	O	-1	12752472
sis.	O	-1	12752472
RESULTS:	O	-1	12752472
The	O	-1	12752472
hyper@@	B-Disease	D006985	12752472
ven@@	I-Disease	-1	12752472
til@@	I-Disease	-1	12752472
ation	I-Disease	-1	12752472
man@@	O	-1	12752472
eu@@	O	-1	12752472
ver	O	-1	12752472
caused	O	-1	12752472
a	O	-1	12752472
decrease	O	-1	12752472
in	O	-1	12752472
spont@@	O	-1	12752472
aneous	O	-1	12752472
ven@@	O	-1	12752472
til@@	O	-1	12752472
ation	O	-1	12752472
in	O	-1	12752472
pilocar@@	B-Chemical	D010862	12752472
pine	I-Chemical	-1	12752472
-treated	O	-1	12752472
and	O	-1	12752472
control	O	-1	12752472
rats.	O	-1	12752472
Although	O	-1	12752472
V@@	O	-1	12752472
E	O	-1	12752472
had	O	-1	12752472
a	O	-1	12752472
similar	O	-1	12752472
decrease	O	-1	12752472
in	O	-1	12752472
both	O	-1	12752472
group@@	O	-1	12752472
s,	O	-1	12752472
in	O	-1	12752472
the	O	-1	12752472
epileptic	B-Disease	D004827	12752472
group@@	O	-1	12752472
,	O	-1	12752472
the	O	-1	12752472
decrease	O	-1	12752472
in	O	-1	12752472
V@@	O	-1	12752472
E	O	-1	12752472
was	O	-1	12752472
due	O	-1	12752472
to	O	-1	12752472
a	O	-1	12752472
significant	O	-1	12752472
(p	O	-1	12752472
<	O	-1	12752472
0.05@@	O	-1	12752472
)	O	-1	12752472
increase	O	-1	12752472
in	O	-1	12752472
T@@	O	-1	12752472
E	O	-1	12752472
pe@@	O	-1	12752472
a@@	O	-1	12752472
k	O	-1	12752472
in	O	-1	12752472
rel@@	O	-1	12752472
ation	O	-1	12752472
to	O	-1	12752472
that	O	-1	12752472
of	O	-1	12752472
the	O	-1	12752472
control	O	-1	12752472
anim@@	O	-1	12752472
al@@	O	-1	12752472
s.	O	-1	12752472
The	O	-1	12752472
hypo@@	O	-1	12752472
ven@@	O	-1	12752472
til@@	O	-1	12752472
ation	O	-1	12752472
man@@	O	-1	12752472
eu@@	O	-1	12752472
ver	O	-1	12752472
l@@	O	-1	12752472
ed	O	-1	12752472
to	O	-1	12752472
an	O	-1	12752472
increase	O	-1	12752472
in	O	-1	12752472
the	O	-1	12752472
arterial	O	-1	12752472
P@@	O	-1	12752472
ac@@	O	-1	12752472
o@@	O	-1	12752472
2,	O	-1	12752472
followed	O	-1	12752472
by	O	-1	12752472
an	O	-1	12752472
increase	O	-1	12752472
in	O	-1	12752472
V@@	O	-1	12752472
E@@	O	-1	12752472
.	O	-1	12752472
In	O	-1	12752472
the	O	-1	12752472
epileptic	B-Disease	D004827	12752472
group@@	O	-1	12752472
,	O	-1	12752472
the	O	-1	12752472
increase	O	-1	12752472
in	O	-1	12752472
V@@	O	-1	12752472
E	O	-1	12752472
was	O	-1	12752472
mediated	O	-1	12752472
by	O	-1	12752472
a	O	-1	12752472
significant	O	-1	12752472
(p	O	-1	12752472
<	O	-1	12752472
0.05@@	O	-1	12752472
)	O	-1	12752472
decrease	O	-1	12752472
in	O	-1	12752472
T@@	O	-1	12752472
E	O	-1	12752472
pe@@	O	-1	12752472
a@@	O	-1	12752472
k	O	-1	12752472
compared	O	-1	12752472
with	O	-1	12752472
the	O	-1	12752472
control	O	-1	12752472
group.	O	-1	12752472
S@@	O	-1	12752472
y@@	O	-1	12752472
st@@	O	-1	12752472
em@@	O	-1	12752472
ic	O	-1	12752472
ap@@	O	-1	12752472
plic@@	O	-1	12752472
ation	O	-1	12752472
of	O	-1	12752472
K@@	O	-1	12752472
C@@	O	-1	12752472
N@@	O	-1	12752472
,	O	-1	12752472
to	O	-1	12752472
evalu@@	O	-1	12752472
ate	O	-1	12752472
the	O	-1	12752472
effects	O	-1	12752472
of	O	-1	12752472
peripheral	O	-1	12752472
chemo@@	O	-1	12752472
rece@@	O	-1	12752472
ption	O	-1	12752472
activation	O	-1	12752472
on	O	-1	12752472
ven@@	O	-1	12752472
til@@	O	-1	12752472
ation,	O	-1	12752472
l@@	O	-1	12752472
ed	O	-1	12752472
to	O	-1	12752472
a	O	-1	12752472
similar	O	-1	12752472
increase	O	-1	12752472
in	O	-1	12752472
V@@	O	-1	12752472
E	O	-1	12752472
for	O	-1	12752472
both	O	-1	12752472
groups.	O	-1	12752472
CONCLUSIONS:	O	-1	12752472
The	O	-1	12752472
data	O	-1	12752472
indicate	O	-1	12752472
that	O	-1	12752472
pilocar@@	B-Chemical	D010862	12752472
pine	I-Chemical	-1	12752472
-treated	O	-1	12752472
animals	O	-1	12752472
have	O	-1	12752472
an	O	-1	12752472
al@@	O	-1	12752472
te@@	O	-1	12752472
red	O	-1	12752472
ability	O	-1	12752472
to	O	-1	12752472
reac@@	O	-1	12752472
t	O	-1	12752472
to	O	-1	12752472
(@@	O	-1	12752472
or	O	-1	12752472
com@@	O	-1	12752472
pen@@	O	-1	12752472
s@@	O	-1	12752472
ate	O	-1	12752472
for@@	O	-1	12752472
)	O	-1	12752472
blood	O	-1	12752472
g@@	O	-1	12752472
as	O	-1	12752472
changes	O	-1	12752472
with	O	-1	12752472
changes	O	-1	12752472
in	O	-1	12752472
ven@@	O	-1	12752472
til@@	O	-1	12752472
ation	O	-1	12752472
and	O	-1	12752472
suggest	O	-1	12752472
that	O	-1	12752472
it	O	-1	12752472
is	O	-1	12752472
centr@@	O	-1	12752472
ally	O	-1	12752472
deter@@	O	-1	12752472
m@@	O	-1	12752472
ine@@	O	-1	12752472
d.	O	-1	12752472
We	O	-1	12752472
spec@@	O	-1	12752472
ul@@	O	-1	12752472
ate	O	-1	12752472
on	O	-1	12752472
the	O	-1	12752472
possible	O	-1	12752472
rel@@	O	-1	12752472
ation	O	-1	12752472
of	O	-1	12752472
the	O	-1	12752472
current	O	-1	12752472
findings	O	-1	12752472
on	O	-1	12752472
treat@@	O	-1	12752472
ing	O	-1	12752472
different	O	-1	12752472
epilep@@	B-Disease	D004827	12752472
sy	I-Disease	-1	12752472
-@@	O	-1	12752472
associated	O	-1	12752472
condi@@	O	-1	12752472
tions.	O	-1	12752472

In@@	O	-1	12828076
c@@	O	-1	12828076
reas@@	O	-1	12828076
ed	O	-1	12828076
serum	O	-1	12828076
sol@@	O	-1	12828076
ub@@	O	-1	12828076
le	O	-1	12828076
F@@	O	-1	12828076
as	O	-1	12828076
in	O	-1	12828076
patients	O	-1	12828076
with	O	-1	12828076
acute	B-Disease	D017114	12828076
liver	I-Disease	-1	12828076
failure	I-Disease	-1	12828076
due	O	-1	12828076
to	O	-1	12828076
par@@	B-Chemical	D000082	12828076
acet@@	I-Chemical	-1	12828076
am@@	I-Chemical	-1	12828076
ol	I-Chemical	-1	12828076
over@@	B-Disease	D062787	12828076
dose	I-Disease	-1	12828076
.	O	-1	12828076
BACKGROUND@@	O	-1	12828076
/@@	O	-1	12828076
A@@	O	-1	12828076
I@@	O	-1	12828076
M@@	O	-1	12828076
S:	O	-1	12828076
E@@	O	-1	12828076
x@@	O	-1	12828076
per@@	O	-1	12828076
im@@	O	-1	12828076
ental	O	-1	12828076
studies	O	-1	12828076
have	O	-1	12828076
suggested	O	-1	12828076
that	O	-1	12828076
apo@@	O	-1	12828076
pto@@	O	-1	12828076
sis	O	-1	12828076
vi@@	O	-1	12828076
a	O	-1	12828076
the	O	-1	12828076
F@@	O	-1	12828076
as@@	O	-1	12828076
/@@	O	-1	12828076
F@@	O	-1	12828076
as	O	-1	12828076
L@@	O	-1	12828076
ig@@	O	-1	12828076
and	O	-1	12828076
sign@@	O	-1	12828076
al@@	O	-1	12828076
ing	O	-1	12828076
system	O	-1	12828076
may	O	-1	12828076
pl@@	O	-1	12828076
ay	O	-1	12828076
an	O	-1	12828076
important	O	-1	12828076
role	O	-1	12828076
in	O	-1	12828076
the	O	-1	12828076
development	O	-1	12828076
of	O	-1	12828076
acute	B-Disease	D017114	12828076
liver	I-Disease	-1	12828076
failure	I-Disease	-1	12828076
.	O	-1	12828076
The	O	-1	12828076
a@@	O	-1	12828076
im	O	-1	12828076
of	O	-1	12828076
the	O	-1	12828076
study	O	-1	12828076
was	O	-1	12828076
to	O	-1	12828076
investigate	O	-1	12828076
the	O	-1	12828076
sol@@	O	-1	12828076
ub@@	O	-1	12828076
le	O	-1	12828076
form	O	-1	12828076
of	O	-1	12828076
F@@	O	-1	12828076
as	O	-1	12828076
in	O	-1	12828076
patients	O	-1	12828076
with	O	-1	12828076
acute	B-Disease	D017114	12828076
liver	I-Disease	-1	12828076
failure	I-Disease	-1	12828076
.	O	-1	12828076
METHOD@@	O	-1	12828076
O@@	O	-1	12828076
L@@	O	-1	12828076
O@@	O	-1	12828076
G@@	O	-1	12828076
Y@@	O	-1	12828076
:	O	-1	12828076
S@@	O	-1	12828076
er@@	O	-1	12828076
um	O	-1	12828076
levels	O	-1	12828076
of	O	-1	12828076
s@@	O	-1	12828076
F@@	O	-1	12828076
as	O	-1	12828076
(@@	O	-1	12828076
sol@@	O	-1	12828076
ub@@	O	-1	12828076
le	O	-1	12828076
F@@	O	-1	12828076
as@@	O	-1	12828076
)	O	-1	12828076
were	O	-1	12828076
measured	O	-1	12828076
by	O	-1	12828076
E@@	O	-1	12828076
L@@	O	-1	12828076
I@@	O	-1	12828076
S@@	O	-1	12828076
A	O	-1	12828076
in	O	-1	12828076
24	O	-1	12828076
patients	O	-1	12828076
with	O	-1	12828076
acute	B-Disease	D017114	12828076
liver	I-Disease	-1	12828076
failure	I-Disease	-1	12828076
and	O	-1	12828076
10	O	-1	12828076
normal	O	-1	12828076
control	O	-1	12828076
subj@@	O	-1	12828076
ect@@	O	-1	12828076
s.	O	-1	12828076
S@@	O	-1	12828076
er@@	O	-1	12828076
um	O	-1	12828076
levels	O	-1	12828076
of	O	-1	12828076
tumor	B-Disease	D009369	12828076
necro@@	B-Disease	D009336	12828076
sis	I-Disease	-1	12828076
fact@@	O	-1	12828076
or@@	O	-1	12828076
-@@	O	-1	12828076
al@@	O	-1	12828076
ph@@	O	-1	12828076
a	O	-1	12828076
and	O	-1	12828076
inter@@	O	-1	12828076
fer@@	O	-1	12828076
on@@	O	-1	12828076
-@@	O	-1	12828076
gam@@	O	-1	12828076
ma	O	-1	12828076
were	O	-1	12828076
also	O	-1	12828076
determined	O	-1	12828076
by	O	-1	12828076
E@@	O	-1	12828076
L@@	O	-1	12828076
I@@	O	-1	12828076
S@@	O	-1	12828076
A@@	O	-1	12828076
.	O	-1	12828076
RESULTS:	O	-1	12828076
S@@	O	-1	12828076
er@@	O	-1	12828076
um	O	-1	12828076
s@@	O	-1	12828076
F@@	O	-1	12828076
as	O	-1	12828076
was	O	-1	12828076
significantly	O	-1	12828076
increased	O	-1	12828076
in	O	-1	12828076
patients	O	-1	12828076
with	O	-1	12828076
acute	B-Disease	D017114	12828076
liver	I-Disease	-1	12828076
failure	I-Disease	-1	12828076
(@@	O	-1	12828076
medi@@	O	-1	12828076
an@@	O	-1	12828076
,	O	-1	12828076
2@@	O	-1	12828076
6.@@	O	-1	12828076
8	O	-1	12828076
U@@	O	-1	12828076
/@@	O	-1	12828076
m@@	O	-1	12828076
L@@	O	-1	12828076
;	O	-1	12828076
rang@@	O	-1	12828076
e,	O	-1	12828076
6.@@	O	-1	12828076
9@@	O	-1	12828076
-@@	O	-1	12828076
5@@	O	-1	12828076
2.@@	O	-1	12828076
7	O	-1	12828076
U@@	O	-1	12828076
/@@	O	-1	12828076
m@@	O	-1	12828076
L@@	O	-1	12828076
)	O	-1	12828076
compared	O	-1	12828076
to	O	-1	12828076
the	O	-1	12828076
normal	O	-1	12828076
controls	O	-1	12828076
(@@	O	-1	12828076
medi@@	O	-1	12828076
an@@	O	-1	12828076
,	O	-1	12828076
8.@@	O	-1	12828076
6	O	-1	12828076
U@@	O	-1	12828076
/@@	O	-1	12828076
m@@	O	-1	12828076
L@@	O	-1	12828076
;	O	-1	12828076
rang@@	O	-1	12828076
e,	O	-1	12828076
6.@@	O	-1	12828076
5-@@	O	-1	12828076
1@@	O	-1	12828076
2.@@	O	-1	12828076
0	O	-1	12828076
U@@	O	-1	12828076
/@@	O	-1	12828076
m@@	O	-1	12828076
L@@	O	-1	12828076
,	O	-1	12828076
P	O	-1	12828076
<	O	-1	12828076
0.00@@	O	-1	12828076
0@@	O	-1	12828076
1).	O	-1	12828076
L@@	O	-1	12828076
e@@	O	-1	12828076
vel@@	O	-1	12828076
s	O	-1	12828076
were	O	-1	12828076
significantly	O	-1	12828076
greater	O	-1	12828076
in	O	-1	12828076
patients	O	-1	12828076
with	O	-1	12828076
acute	B-Disease	D017114	12828076
liver	I-Disease	-1	12828076
failure	I-Disease	-1	12828076
due	O	-1	12828076
to	O	-1	12828076
par@@	B-Chemical	D000082	12828076
acet@@	I-Chemical	-1	12828076
am@@	I-Chemical	-1	12828076
ol	I-Chemical	-1	12828076
over@@	B-Disease	D062787	12828076
dose	I-Disease	-1	12828076
(@@	O	-1	12828076
medi@@	O	-1	12828076
an@@	O	-1	12828076
,	O	-1	12828076
2@@	O	-1	12828076
8.@@	O	-1	12828076
7	O	-1	12828076
U@@	O	-1	12828076
/@@	O	-1	12828076
m@@	O	-1	12828076
L@@	O	-1	12828076
;	O	-1	12828076
rang@@	O	-1	12828076
e,	O	-1	12828076
1@@	O	-1	12828076
2.@@	O	-1	12828076
8@@	O	-1	12828076
-@@	O	-1	12828076
5@@	O	-1	12828076
2.@@	O	-1	12828076
7	O	-1	12828076
U@@	O	-1	12828076
/@@	O	-1	12828076
m@@	O	-1	12828076
L@@	O	-1	12828076
,	O	-1	12828076
n	O	-1	12828076
=	O	-1	12828076
17@@	O	-1	12828076
)	O	-1	12828076
than	O	-1	12828076
those	O	-1	12828076
due	O	-1	12828076
to	O	-1	12828076
non-@@	O	-1	12828076
A	O	-1	12828076
to	O	-1	12828076
E	O	-1	12828076
hepatitis	B-Disease	D056486	12828076
(@@	O	-1	12828076
medi@@	O	-1	12828076
an@@	O	-1	12828076
,	O	-1	12828076
1@@	O	-1	12828076
2.@@	O	-1	12828076
5	O	-1	12828076
U@@	O	-1	12828076
/@@	O	-1	12828076
m@@	O	-1	12828076
L@@	O	-1	12828076
;	O	-1	12828076
rang@@	O	-1	12828076
e,	O	-1	12828076
6.@@	O	-1	12828076
9@@	O	-1	12828076
-@@	O	-1	12828076
4@@	O	-1	12828076
6.@@	O	-1	12828076
0	O	-1	12828076
U@@	O	-1	12828076
/@@	O	-1	12828076
m@@	O	-1	12828076
L@@	O	-1	12828076
,	O	-1	12828076
n	O	-1	12828076
=	O	-1	12828076
7@@	O	-1	12828076
,	O	-1	12828076
P	O	-1	12828076
<	O	-1	12828076
0.0@@	O	-1	12828076
1).	O	-1	12828076
There	O	-1	12828076
was	O	-1	12828076
no	O	-1	12828076
rel@@	O	-1	12828076
ationship	O	-1	12828076
of	O	-1	12828076
s@@	O	-1	12828076
F@@	O	-1	12828076
as	O	-1	12828076
to	O	-1	12828076
event@@	O	-1	12828076
ual	O	-1	12828076
outcom@@	O	-1	12828076
e	O	-1	12828076
in	O	-1	12828076
the	O	-1	12828076
patients.	O	-1	12828076
A	O	-1	12828076
significant	O	-1	12828076
correl@@	O	-1	12828076
ation	O	-1	12828076
was	O	-1	12828076
observed	O	-1	12828076
between	O	-1	12828076
serum	O	-1	12828076
s@@	O	-1	12828076
F@@	O	-1	12828076
as	O	-1	12828076
levels	O	-1	12828076
and	O	-1	12828076
as@@	B-Chemical	D001224	12828076
part@@	I-Chemical	-1	12828076
ate	I-Chemical	-1	12828076
amin@@	O	-1	12828076
ot@@	O	-1	12828076
ran@@	O	-1	12828076
s@@	O	-1	12828076
fer@@	O	-1	12828076
ase	O	-1	12828076
(@@	O	-1	12828076
r	O	-1	12828076
=	O	-1	12828076
0.@@	O	-1	12828076
6@@	O	-1	12828076
13@@	O	-1	12828076
,	O	-1	12828076
P	O	-1	12828076
<	O	-1	12828076
0.0@@	O	-1	12828076
1).	O	-1	12828076
CONCLUSIONS:	O	-1	12828076
The	O	-1	12828076
increased	O	-1	12828076
concentration	O	-1	12828076
of	O	-1	12828076
s@@	O	-1	12828076
F@@	O	-1	12828076
as	O	-1	12828076
in	O	-1	12828076
serum	O	-1	12828076
of	O	-1	12828076
patients	O	-1	12828076
with	O	-1	12828076
acute	B-Disease	D017114	12828076
liver	I-Disease	-1	12828076
failure	I-Disease	-1	12828076
may	O	-1	12828076
ref@@	O	-1	12828076
l@@	O	-1	12828076
ect	O	-1	12828076
activation	O	-1	12828076
of	O	-1	12828076
F@@	O	-1	12828076
as@@	O	-1	12828076
-@@	O	-1	12828076
mediated	O	-1	12828076
apo@@	O	-1	12828076
pto@@	O	-1	12828076
sis	O	-1	12828076
in	O	-1	12828076
the	O	-1	12828076
liver	O	-1	12828076
and	O	-1	12828076
this	O	-1	12828076
to@@	O	-1	12828076
ge@@	O	-1	12828076
ther	O	-1	12828076
with	O	-1	12828076
increased	O	-1	12828076
tumor	B-Disease	D009369	12828076
necro@@	B-Disease	D009336	12828076
sis	I-Disease	-1	12828076
fact@@	O	-1	12828076
or@@	O	-1	12828076
-@@	O	-1	12828076
al@@	O	-1	12828076
ph@@	O	-1	12828076
a	O	-1	12828076
may	O	-1	12828076
be	O	-1	12828076
an	O	-1	12828076
important	O	-1	12828076
factor	O	-1	12828076
in	O	-1	12828076
liver	O	-1	12828076
cell	O	-1	12828076
los@@	O	-1	12828076
s.	O	-1	12828076

B@@	O	-1	12865514
il@@	O	-1	12865514
ateral	O	-1	12865514
sub@@	O	-1	12865514
thal@@	O	-1	12865514
am@@	O	-1	12865514
ic	O	-1	12865514
nucle@@	O	-1	12865514
us	O	-1	12865514
stimulation	O	-1	12865514
for	O	-1	12865514
Parkinson's	B-Disease	D010300	12865514
disease	I-Disease	-1	12865514
.	O	-1	12865514
H@@	O	-1	12865514
i@@	O	-1	12865514
gh	O	-1	12865514
frequency	O	-1	12865514
stimulation	O	-1	12865514
of	O	-1	12865514
the	O	-1	12865514
sub@@	O	-1	12865514
thal@@	O	-1	12865514
am@@	O	-1	12865514
ic	O	-1	12865514
nucle@@	O	-1	12865514
us	O	-1	12865514
(S@@	O	-1	12865514
T@@	O	-1	12865514
N@@	O	-1	12865514
)	O	-1	12865514
is	O	-1	12865514
known	O	-1	12865514
to	O	-1	12865514
ame@@	O	-1	12865514
li@@	O	-1	12865514
or@@	O	-1	12865514
ate	O	-1	12865514
the	O	-1	12865514
signs	O	-1	12865514
and	O	-1	12865514
symptoms	O	-1	12865514
of	O	-1	12865514
adv@@	O	-1	12865514
anced	O	-1	12865514
Parkinson's	B-Disease	D010300	12865514
disease	I-Disease	-1	12865514
.	O	-1	12865514
A@@	O	-1	12865514
I@@	O	-1	12865514
M@@	O	-1	12865514
:	O	-1	12865514
We	O	-1	12865514
studied	O	-1	12865514
the	O	-1	12865514
effect	O	-1	12865514
of	O	-1	12865514
high	O	-1	12865514
frequency	O	-1	12865514
S@@	O	-1	12865514
T@@	O	-1	12865514
N	O	-1	12865514
stimulation	O	-1	12865514
in	O	-1	12865514
2@@	O	-1	12865514
3	O	-1	12865514
patients.	O	-1	12865514
METHOD@@	O	-1	12865514
:	O	-1	12865514
Tw@@	O	-1	12865514
ent@@	O	-1	12865514
y-@@	O	-1	12865514
three	O	-1	12865514
patients	O	-1	12865514
suff@@	O	-1	12865514
ering	O	-1	12865514
from	O	-1	12865514
severe	O	-1	12865514
Parkinson's	B-Disease	D010300	12865514
disease	I-Disease	-1	12865514
(S@@	O	-1	12865514
t@@	O	-1	12865514
ages	O	-1	12865514
II@@	O	-1	12865514
I@@	O	-1	12865514
-@@	O	-1	12865514
V	O	-1	12865514
on	O	-1	12865514
Ho@@	O	-1	12865514
e@@	O	-1	12865514
h@@	O	-1	12865514
n	O	-1	12865514
and	O	-1	12865514
Y@@	O	-1	12865514
a@@	O	-1	12865514
h@@	O	-1	12865514
r	O	-1	12865514
s@@	O	-1	12865514
cal@@	O	-1	12865514
e@@	O	-1	12865514
)	O	-1	12865514
and@@	O	-1	12865514
,	O	-1	12865514
partic@@	O	-1	12865514
ul@@	O	-1	12865514
arly	O	-1	12865514
brady@@	B-Disease	D018476	12865514
kine@@	I-Disease	-1	12865514
sia	I-Disease	-1	12865514
,	O	-1	12865514
rig@@	B-Disease	D009127	12865514
idity	I-Disease	-1	12865514
,	O	-1	12865514
and	O	-1	12865514
levo@@	B-Chemical	D007980	12865514
dopa	I-Chemical	-1	12865514
-induced	O	-1	12865514
dyskine@@	B-Disease	D004409	12865514
si@@	I-Disease	-1	12865514
as	I-Disease	-1	12865514
under@@	O	-1	12865514
w@@	O	-1	12865514
ent	O	-1	12865514
bil@@	O	-1	12865514
ateral	O	-1	12865514
im@@	O	-1	12865514
pl@@	O	-1	12865514
ant@@	O	-1	12865514
ation	O	-1	12865514
of	O	-1	12865514
electro@@	O	-1	12865514
des	O	-1	12865514
in	O	-1	12865514
the	O	-1	12865514
S@@	O	-1	12865514
T@@	O	-1	12865514
N@@	O	-1	12865514
.	O	-1	12865514
Pre@@	O	-1	12865514
o@@	O	-1	12865514
perative	O	-1	12865514
and	O	-1	12865514
postoperative	O	-1	12865514
assess@@	O	-1	12865514
ments	O	-1	12865514
of	O	-1	12865514
these	O	-1	12865514
patients	O	-1	12865514
at	O	-1	12865514
1,	O	-1	12865514
3,	O	-1	12865514
6	O	-1	12865514
and	O	-1	12865514
12	O	-1	12865514
months	O	-1	12865514
follow-@@	O	-1	12865514
up@@	O	-1	12865514
,	O	-1	12865514
in	O	-1	12865514
"@@	O	-1	12865514
on@@	O	-1	12865514
"	O	-1	12865514
and	O	-1	12865514
"@@	O	-1	12865514
o@@	O	-1	12865514
ff@@	O	-1	12865514
"	O	-1	12865514
drug	O	-1	12865514
condi@@	O	-1	12865514
tion@@	O	-1	12865514
s,	O	-1	12865514
was	O	-1	12865514
car@@	O	-1	12865514
ri@@	O	-1	12865514
ed	O	-1	12865514
out	O	-1	12865514
using	O	-1	12865514
U@@	O	-1	12865514
n@@	O	-1	12865514
if@@	O	-1	12865514
ied	O	-1	12865514
Parkinson's	B-Disease	D010300	12865514
Di@@	I-Disease	-1	12865514
se@@	I-Disease	-1	12865514
ase	I-Disease	-1	12865514
R@@	O	-1	12865514
ating	O	-1	12865514
S@@	O	-1	12865514
cal@@	O	-1	12865514
e,	O	-1	12865514
Ho@@	O	-1	12865514
e@@	O	-1	12865514
h@@	O	-1	12865514
n	O	-1	12865514
and	O	-1	12865514
Y@@	O	-1	12865514
a@@	O	-1	12865514
h@@	O	-1	12865514
r	O	-1	12865514
st@@	O	-1	12865514
ag@@	O	-1	12865514
ing,	O	-1	12865514
E@@	O	-1	12865514
n@@	O	-1	12865514
gl@@	O	-1	12865514
and	O	-1	12865514
ac@@	O	-1	12865514
ti@@	O	-1	12865514
vi@@	O	-1	12865514
ties	O	-1	12865514
of	O	-1	12865514
daily	O	-1	12865514
li@@	O	-1	12865514
ving	O	-1	12865514
scor@@	O	-1	12865514
e	O	-1	12865514
and	O	-1	12865514
vi@@	O	-1	12865514
de@@	O	-1	12865514
o	O	-1	12865514
recor@@	O	-1	12865514
d@@	O	-1	12865514
ing@@	O	-1	12865514
s.	O	-1	12865514
RESULTS:	O	-1	12865514
After	O	-1	12865514
one	O	-1	12865514
year	O	-1	12865514
of	O	-1	12865514
elect@@	O	-1	12865514
r@@	O	-1	12865514
ical	O	-1	12865514
stimulation	O	-1	12865514
of	O	-1	12865514
the	O	-1	12865514
S@@	O	-1	12865514
T@@	O	-1	12865514
N@@	O	-1	12865514
,	O	-1	12865514
the	O	-1	12865514
patient@@	O	-1	12865514
s@@	O	-1	12865514
'	O	-1	12865514
sco@@	O	-1	12865514
res	O	-1	12865514
for	O	-1	12865514
ac@@	O	-1	12865514
ti@@	O	-1	12865514
vi@@	O	-1	12865514
ties	O	-1	12865514
of	O	-1	12865514
daily	O	-1	12865514
li@@	O	-1	12865514
ving	O	-1	12865514
and	O	-1	12865514
motor	O	-1	12865514
examin@@	O	-1	12865514
ation	O	-1	12865514
sco@@	O	-1	12865514
res	O	-1	12865514
(@@	O	-1	12865514
U@@	O	-1	12865514
n@@	O	-1	12865514
if@@	O	-1	12865514
ied	O	-1	12865514
Parkinson's	B-Disease	D010300	12865514
Di@@	I-Disease	-1	12865514
se@@	I-Disease	-1	12865514
ase	I-Disease	-1	12865514
R@@	O	-1	12865514
ating	O	-1	12865514
S@@	O	-1	12865514
cal@@	O	-1	12865514
e	O	-1	12865514
par@@	O	-1	12865514
ts	O	-1	12865514
II	O	-1	12865514
and	O	-1	12865514
II@@	O	-1	12865514
I@@	O	-1	12865514
)	O	-1	12865514
of@@	O	-1	12865514
f	O	-1	12865514
medic@@	O	-1	12865514
ation	O	-1	12865514
improved	O	-1	12865514
by	O	-1	12865514
6@@	O	-1	12865514
2@@	O	-1	12865514
%	O	-1	12865514
and	O	-1	12865514
6@@	O	-1	12865514
1@@	O	-1	12865514
%	O	-1	12865514
respecti@@	O	-1	12865514
vely	O	-1	12865514
(p@@	O	-1	12865514
<@@	O	-1	12865514
0.00@@	O	-1	12865514
0@@	O	-1	12865514
5@@	O	-1	12865514
).	O	-1	12865514
The	O	-1	12865514
sub@@	O	-1	12865514
sco@@	O	-1	12865514
res	O	-1	12865514
for	O	-1	12865514
the	O	-1	12865514
ak@@	B-Disease	D004409	12865514
ine@@	I-Disease	-1	12865514
sia	I-Disease	-1	12865514
,	O	-1	12865514
rig@@	B-Disease	D009127	12865514
idity	I-Disease	-1	12865514
,	O	-1	12865514
trem@@	B-Disease	D014202	12865514
or	I-Disease	-1	12865514
and	O	-1	12865514
g@@	O	-1	12865514
a@@	O	-1	12865514
it	O	-1	12865514
also	O	-1	12865514
impro@@	O	-1	12865514
ved.	O	-1	12865514
(p@@	O	-1	12865514
<@@	O	-1	12865514
0.00@@	O	-1	12865514
0@@	O	-1	12865514
5@@	O	-1	12865514
).	O	-1	12865514
The	O	-1	12865514
average	O	-1	12865514
levo@@	B-Chemical	D007980	12865514
dopa	I-Chemical	-1	12865514
dose	O	-1	12865514
decreased	O	-1	12865514
from	O	-1	12865514
8@@	O	-1	12865514
13	O	-1	12865514
mg	O	-1	12865514
to	O	-1	12865514
3@@	O	-1	12865514
5@@	O	-1	12865514
9	O	-1	12865514
mg@@	O	-1	12865514
.	O	-1	12865514
The	O	-1	12865514
cognitive	O	-1	12865514
func@@	O	-1	12865514
tions	O	-1	12865514
remained	O	-1	12865514
un@@	O	-1	12865514
chang@@	O	-1	12865514
ed.	O	-1	12865514
Two	O	-1	12865514
patients	O	-1	12865514
developed	O	-1	12865514
de@@	O	-1	12865514
v@@	O	-1	12865514
ic@@	O	-1	12865514
e-@@	O	-1	12865514
related	O	-1	12865514
complications	O	-1	12865514
and	O	-1	12865514
two	O	-1	12865514
patients	O	-1	12865514
experienced	O	-1	12865514
ab@@	O	-1	12865514
normal	O	-1	12865514
weight	O	-1	12865514
g@@	O	-1	12865514
ain@@	O	-1	12865514
.	O	-1	12865514
CONCLUSION:	O	-1	12865514
B@@	O	-1	12865514
il@@	O	-1	12865514
ateral	O	-1	12865514
sub@@	O	-1	12865514
thal@@	O	-1	12865514
am@@	O	-1	12865514
ic	O	-1	12865514
nucle@@	O	-1	12865514
us	O	-1	12865514
stimulation	O	-1	12865514
is	O	-1	12865514
an	O	-1	12865514
effective	O	-1	12865514
treatment	O	-1	12865514
for	O	-1	12865514
adv@@	O	-1	12865514
anced	O	-1	12865514
Parkinson's	B-Disease	D010300	12865514
disease	I-Disease	-1	12865514
.	O	-1	12865514
It	O	-1	12865514
reduc@@	O	-1	12865514
es	O	-1	12865514
the	O	-1	12865514
severity	O	-1	12865514
of	O	-1	12865514
"@@	O	-1	12865514
o@@	O	-1	12865514
ff@@	O	-1	12865514
"	O	-1	12865514
phase	O	-1	12865514
symptom@@	O	-1	12865514
s,	O	-1	12865514
impro@@	O	-1	12865514
v@@	O	-1	12865514
es	O	-1	12865514
the	O	-1	12865514
ax@@	O	-1	12865514
ial	O	-1	12865514
symptoms	O	-1	12865514
and	O	-1	12865514
reduc@@	O	-1	12865514
es	O	-1	12865514
levo@@	B-Chemical	D007980	12865514
dopa	I-Chemical	-1	12865514
requ@@	O	-1	12865514
i@@	O	-1	12865514
re@@	O	-1	12865514
ment@@	O	-1	12865514
s.	O	-1	12865514
The	O	-1	12865514
reduction	O	-1	12865514
in	O	-1	12865514
the	O	-1	12865514
levo@@	B-Chemical	D007980	12865514
dopa	I-Chemical	-1	12865514
dose	O	-1	12865514
is	O	-1	12865514
use@@	O	-1	12865514
ful	O	-1	12865514
in	O	-1	12865514
contro@@	O	-1	12865514
ll@@	O	-1	12865514
ing	O	-1	12865514
drug@@	B-Disease	D004409	12865514
-induced	I-Disease	-1	12865514
dyskine@@	I-Disease	-1	12865514
si@@	I-Disease	-1	12865514
as	I-Disease	-1	12865514
.	O	-1	12865514

O@@	O	-1	12912689
cular	O	-1	12912689
mo@@	O	-1	12912689
til@@	O	-1	12912689
ity	O	-1	12912689
changes	O	-1	12912689
after	O	-1	12912689
sub@@	O	-1	12912689
ten@@	O	-1	12912689
on	O	-1	12912689
car@@	B-Chemical	D016190	12912689
bo@@	I-Chemical	-1	12912689
pl@@	I-Chemical	-1	12912689
atin	I-Chemical	-1	12912689
chemotherapy	O	-1	12912689
for	O	-1	12912689
ret@@	B-Disease	D012175	12912689
in@@	I-Disease	-1	12912689
ob@@	I-Disease	-1	12912689
l@@	I-Disease	-1	12912689
ast@@	I-Disease	-1	12912689
oma	I-Disease	-1	12912689
.	O	-1	12912689
BACKGROUND:	O	-1	12912689
F@@	O	-1	12912689
oc@@	O	-1	12912689
al	O	-1	12912689
sub@@	O	-1	12912689
ten@@	O	-1	12912689
on	O	-1	12912689
car@@	B-Chemical	D016190	12912689
bo@@	I-Chemical	-1	12912689
pl@@	I-Chemical	-1	12912689
atin	I-Chemical	-1	12912689
injec@@	O	-1	12912689
tions	O	-1	12912689
have	O	-1	12912689
rec@@	O	-1	12912689
ently	O	-1	12912689
been	O	-1	12912689
used	O	-1	12912689
as	O	-1	12912689
a	O	-1	12912689
pres@@	O	-1	12912689
um@@	O	-1	12912689
ably	O	-1	12912689
toxicity	B-Disease	D064420	12912689
-@@	O	-1	12912689
free	O	-1	12912689
adj@@	O	-1	12912689
unc@@	O	-1	12912689
t	O	-1	12912689
to	O	-1	12912689
systemic	O	-1	12912689
chemotherapy	O	-1	12912689
for	O	-1	12912689
intra@@	O	-1	12912689
oc@@	O	-1	12912689
ular	O	-1	12912689
ret@@	B-Disease	D012175	12912689
in@@	I-Disease	-1	12912689
ob@@	I-Disease	-1	12912689
l@@	I-Disease	-1	12912689
ast@@	I-Disease	-1	12912689
oma	I-Disease	-1	12912689
.	O	-1	12912689
OBJECTIVE:	O	-1	12912689
To	O	-1	12912689
report	O	-1	12912689
our	O	-1	12912689
clinical	O	-1	12912689
experi@@	O	-1	12912689
ence	O	-1	12912689
with	O	-1	12912689
ab@@	B-Disease	D015835	12912689
normal	I-Disease	-1	12912689
oc@@	I-Disease	-1	12912689
ular	I-Disease	-1	12912689
mo@@	I-Disease	-1	12912689
til@@	I-Disease	-1	12912689
ity	I-Disease	-1	12912689
in	O	-1	12912689
patients	O	-1	12912689
treated	O	-1	12912689
with	O	-1	12912689
sub@@	O	-1	12912689
ten@@	O	-1	12912689
on	O	-1	12912689
car@@	B-Chemical	D016190	12912689
bo@@	I-Chemical	-1	12912689
pl@@	I-Chemical	-1	12912689
atin	I-Chemical	-1	12912689
chemo@@	O	-1	12912689
therapy.	O	-1	12912689
METHODS:	O	-1	12912689
We	O	-1	12912689
not@@	O	-1	12912689
ed	O	-1	12912689
ab@@	B-Disease	D015835	12912689
normal	I-Disease	-1	12912689
oc@@	I-Disease	-1	12912689
ular	I-Disease	-1	12912689
mo@@	I-Disease	-1	12912689
til@@	I-Disease	-1	12912689
ity	I-Disease	-1	12912689
in	O	-1	12912689
10	O	-1	12912689
con@@	O	-1	12912689
sec@@	O	-1	12912689
utive	O	-1	12912689
patients	O	-1	12912689
with	O	-1	12912689
ret@@	B-Disease	D012175	12912689
in@@	I-Disease	-1	12912689
ob@@	I-Disease	-1	12912689
l@@	I-Disease	-1	12912689
ast@@	I-Disease	-1	12912689
oma	I-Disease	-1	12912689
who	O	-1	12912689
had	O	-1	12912689
received	O	-1	12912689
sub@@	O	-1	12912689
ten@@	O	-1	12912689
on	O	-1	12912689
car@@	B-Chemical	D016190	12912689
bo@@	I-Chemical	-1	12912689
pl@@	I-Chemical	-1	12912689
atin	I-Chemical	-1	12912689
.	O	-1	12912689
D@@	O	-1	12912689
uring	O	-1	12912689
oc@@	O	-1	12912689
ular	O	-1	12912689
man@@	O	-1	12912689
ip@@	O	-1	12912689
ulation	O	-1	12912689
under	O	-1	12912689
gener@@	O	-1	12912689
al	O	-1	12912689
anesthe@@	O	-1	12912689
si@@	O	-1	12912689
a,	O	-1	12912689
we	O	-1	12912689
assessed	O	-1	12912689
their	O	-1	12912689
e@@	O	-1	12912689
y@@	O	-1	12912689
es	O	-1	12912689
by	O	-1	12912689
for@@	O	-1	12912689
c@@	O	-1	12912689
ed	O	-1	12912689
duction	O	-1	12912689
test@@	O	-1	12912689
ing,	O	-1	12912689
compar@@	O	-1	12912689
ing	O	-1	12912689
oc@@	O	-1	12912689
ular	O	-1	12912689
mo@@	O	-1	12912689
til@@	O	-1	12912689
ity	O	-1	12912689
after	O	-1	12912689
tumor	B-Disease	D009369	12912689
control	O	-1	12912689
with	O	-1	12912689
oc@@	O	-1	12912689
ular	O	-1	12912689
mo@@	O	-1	12912689
til@@	O	-1	12912689
ity	O	-1	12912689
at	O	-1	12912689
diagno@@	O	-1	12912689
sis.	O	-1	12912689
E@@	O	-1	12912689
y@@	O	-1	12912689
es	O	-1	12912689
subsequ@@	O	-1	12912689
ently	O	-1	12912689
en@@	O	-1	12912689
ucle@@	O	-1	12912689
ated	O	-1	12912689
because	O	-1	12912689
of	O	-1	12912689
treatment	O	-1	12912689
failure	O	-1	12912689
(n	O	-1	12912689
=	O	-1	12912689
4@@	O	-1	12912689
)	O	-1	12912689
were	O	-1	12912689
examined	O	-1	12912689
hist@@	O	-1	12912689
olog@@	O	-1	12912689
ic@@	O	-1	12912689
all@@	O	-1	12912689
y.	O	-1	12912689
RESULTS:	O	-1	12912689
L@@	O	-1	12912689
im@@	O	-1	12912689
it@@	O	-1	12912689
ation	O	-1	12912689
of	O	-1	12912689
oc@@	O	-1	12912689
ular	O	-1	12912689
mo@@	O	-1	12912689
til@@	O	-1	12912689
ity	O	-1	12912689
was	O	-1	12912689
det@@	O	-1	12912689
ected	O	-1	12912689
in	O	-1	12912689
all	O	-1	12912689
12	O	-1	12912689
e@@	O	-1	12912689
y@@	O	-1	12912689
es	O	-1	12912689
of	O	-1	12912689
10	O	-1	12912689
patients	O	-1	12912689
treated	O	-1	12912689
for	O	-1	12912689
intra@@	O	-1	12912689
oc@@	O	-1	12912689
ular	O	-1	12912689
ret@@	B-Disease	D012175	12912689
in@@	I-Disease	-1	12912689
ob@@	I-Disease	-1	12912689
l@@	I-Disease	-1	12912689
ast@@	I-Disease	-1	12912689
oma	I-Disease	-1	12912689
with	O	-1	12912689
1	O	-1	12912689
to	O	-1	12912689
6	O	-1	12912689
injec@@	O	-1	12912689
tions	O	-1	12912689
of	O	-1	12912689
sub@@	O	-1	12912689
ten@@	O	-1	12912689
on	O	-1	12912689
car@@	B-Chemical	D016190	12912689
bo@@	I-Chemical	-1	12912689
pl@@	I-Chemical	-1	12912689
atin	I-Chemical	-1	12912689
as	O	-1	12912689
par@@	O	-1	12912689
t	O	-1	12912689
of	O	-1	12912689
multi@@	O	-1	12912689
mod@@	O	-1	12912689
ality	O	-1	12912689
therapy.	O	-1	12912689
H@@	O	-1	12912689
ist@@	O	-1	12912689
o@@	O	-1	12912689
path@@	O	-1	12912689
ological	O	-1	12912689
examin@@	O	-1	12912689
ation	O	-1	12912689
revealed	O	-1	12912689
man@@	O	-1	12912689
y	O	-1	12912689
li@@	O	-1	12912689
po@@	O	-1	12912689
ph@@	O	-1	12912689
ages	O	-1	12912689
in	O	-1	12912689
the	O	-1	12912689
peri@@	O	-1	12912689
or@@	O	-1	12912689
b@@	O	-1	12912689
it@@	O	-1	12912689
al	O	-1	12912689
f@@	O	-1	12912689
at	O	-1	12912689
sur@@	O	-1	12912689
ro@@	O	-1	12912689
un@@	O	-1	12912689
ding	O	-1	12912689
the	O	-1	12912689
op@@	O	-1	12912689
tic	O	-1	12912689
nerve	O	-1	12912689
in	O	-1	12912689
1	O	-1	12912689
e@@	O	-1	12912689
y@@	O	-1	12912689
e,	O	-1	12912689
indic@@	O	-1	12912689
ative	O	-1	12912689
of	O	-1	12912689
ph@@	O	-1	12912689
ag@@	O	-1	12912689
ocyto@@	O	-1	12912689
sis	O	-1	12912689
of	O	-1	12912689
previously	O	-1	12912689
ex@@	O	-1	12912689
ist@@	O	-1	12912689
ing	O	-1	12912689
f@@	O	-1	12912689
at	O	-1	12912689
cells	O	-1	12912689
and	O	-1	12912689
suggesting	O	-1	12912689
prior	O	-1	12912689
f@@	O	-1	12912689
at	O	-1	12912689
necro@@	B-Disease	D009336	12912689
sis	I-Disease	-1	12912689
.	O	-1	12912689
The	O	-1	12912689
en@@	O	-1	12912689
ucle@@	O	-1	12912689
ations	O	-1	12912689
were	O	-1	12912689
t@@	O	-1	12912689
ech@@	O	-1	12912689
n@@	O	-1	12912689
ically	O	-1	12912689
diff@@	O	-1	12912689
ic@@	O	-1	12912689
ult	O	-1	12912689
and	O	-1	12912689
ha@@	O	-1	12912689
z@@	O	-1	12912689
ar@@	O	-1	12912689
d@@	O	-1	12912689
ous	O	-1	12912689
for	O	-1	12912689
glo@@	O	-1	12912689
be	O	-1	12912689
ru@@	B-Disease	D012421	12912689
pt@@	I-Disease	-1	12912689
ure	I-Disease	-1	12912689
because	O	-1	12912689
of	O	-1	12912689
exten@@	O	-1	12912689
sive	O	-1	12912689
or@@	O	-1	12912689
b@@	O	-1	12912689
it@@	O	-1	12912689
al	O	-1	12912689
so@@	O	-1	12912689
ft	O	-1	12912689
tissue	O	-1	12912689
ad@@	O	-1	12912689
he@@	O	-1	12912689
sion@@	O	-1	12912689
s.	O	-1	12912689
CONCLUSIONS:	O	-1	12912689
S@@	O	-1	12912689
ub@@	O	-1	12912689
ten@@	O	-1	12912689
on	O	-1	12912689
car@@	B-Chemical	D016190	12912689
bo@@	I-Chemical	-1	12912689
pl@@	I-Chemical	-1	12912689
atin	I-Chemical	-1	12912689
chemotherapy	O	-1	12912689
is	O	-1	12912689
associated	O	-1	12912689
with	O	-1	12912689
significant	O	-1	12912689
fib@@	B-Disease	D005355	12912689
ro@@	I-Disease	-1	12912689
sis	I-Disease	-1	12912689
of	O	-1	12912689
or@@	O	-1	12912689
b@@	O	-1	12912689
it@@	O	-1	12912689
al	O	-1	12912689
so@@	O	-1	12912689
ft	O	-1	12912689
tissu@@	O	-1	12912689
es,	O	-1	12912689
lead@@	O	-1	12912689
ing	O	-1	12912689
to	O	-1	12912689
mechan@@	O	-1	12912689
ical	O	-1	12912689
re@@	O	-1	12912689
stric@@	O	-1	12912689
tion	O	-1	12912689
of	O	-1	12912689
e@@	O	-1	12912689
y@@	O	-1	12912689
e	O	-1	12912689
mo@@	O	-1	12912689
ve@@	O	-1	12912689
ments	O	-1	12912689
and	O	-1	12912689
ma@@	O	-1	12912689
king	O	-1	12912689
subsequ@@	O	-1	12912689
ent	O	-1	12912689
en@@	O	-1	12912689
ucle@@	O	-1	12912689
ation	O	-1	12912689
diff@@	O	-1	12912689
ic@@	O	-1	12912689
ult@@	O	-1	12912689
.	O	-1	12912689
S@@	O	-1	12912689
ub@@	O	-1	12912689
ten@@	O	-1	12912689
on	O	-1	12912689
car@@	B-Chemical	D016190	12912689
bo@@	I-Chemical	-1	12912689
pl@@	I-Chemical	-1	12912689
atin	I-Chemical	-1	12912689
is	O	-1	12912689
not	O	-1	12912689
free	O	-1	12912689
of	O	-1	12912689
toxicity	B-Disease	D064420	12912689
,	O	-1	12912689
and	O	-1	12912689
its	O	-1	12912689
use	O	-1	12912689
is	O	-1	12912689
b@@	O	-1	12912689
est	O	-1	12912689
re@@	O	-1	12912689
stric@@	O	-1	12912689
ted	O	-1	12912689
to	O	-1	12912689
specific	O	-1	12912689
indic@@	O	-1	12912689
ations.	O	-1	12912689

E@@	B-Chemical	D004977	12948256
th@@	I-Chemical	-1	12948256
am@@	I-Chemical	-1	12948256
bu@@	I-Chemical	-1	12948256
to@@	I-Chemical	-1	12948256
l	I-Chemical	-1	12948256
and	O	-1	12948256
op@@	B-Disease	D009901	12948256
tic	I-Disease	-1	12948256
neuropathy	I-Disease	-1	12948256
.	O	-1	12948256
P@@	O	-1	12948256
U@@	O	-1	12948256
R@@	O	-1	12948256
P@@	O	-1	12948256
O@@	O	-1	12948256
S@@	O	-1	12948256
E:	O	-1	12948256
To	O	-1	12948256
demon@@	O	-1	12948256
st@@	O	-1	12948256
rate	O	-1	12948256
the	O	-1	12948256
association	O	-1	12948256
between	O	-1	12948256
eth@@	B-Chemical	D004977	12948256
am@@	I-Chemical	-1	12948256
bu@@	I-Chemical	-1	12948256
to@@	I-Chemical	-1	12948256
l	I-Chemical	-1	12948256
and	O	-1	12948256
op@@	B-Disease	D009901	12948256
tic	I-Disease	-1	12948256
neuropathy	I-Disease	-1	12948256
.	O	-1	12948256
METHOD@@	O	-1	12948256
:	O	-1	12948256
Th@@	O	-1	12948256
ir@@	O	-1	12948256
te@@	O	-1	12948256
en	O	-1	12948256
patients	O	-1	12948256
who	O	-1	12948256
developed	O	-1	12948256
op@@	B-Disease	D009901	12948256
tic	I-Disease	-1	12948256
neuropathy	I-Disease	-1	12948256
after	O	-1	12948256
being	O	-1	12948256
treated	O	-1	12948256
with	O	-1	12948256
eth@@	B-Chemical	D004977	12948256
am@@	I-Chemical	-1	12948256
bu@@	I-Chemical	-1	12948256
to@@	I-Chemical	-1	12948256
l	I-Chemical	-1	12948256
for	O	-1	12948256
tub@@	B-Disease	D014397	12948256
er@@	I-Disease	-1	12948256
c@@	I-Disease	-1	12948256
ulo@@	I-Disease	-1	12948256
sis	I-Disease	-1	12948256
of	I-Disease	-1	12948256
the	I-Disease	-1	12948256
l@@	I-Disease	-1	12948256
un@@	I-Disease	-1	12948256
g	I-Disease	-1	12948256
or	I-Disease	-1	12948256
lym@@	I-Disease	-1	12948256
p@@	I-Disease	-1	12948256
h	I-Disease	-1	12948256
no@@	I-Disease	-1	12948256
de	I-Disease	-1	12948256
tub@@	B-Disease	D014388	12948256
er@@	I-Disease	-1	12948256
c@@	I-Disease	-1	12948256
ulo@@	I-Disease	-1	12948256
sis	I-Disease	-1	12948256
of	I-Disease	-1	12948256
the	I-Disease	-1	12948256
l@@	I-Disease	-1	12948256
un@@	I-Disease	-1	12948256
g	I-Disease	-1	12948256
or	I-Disease	-1	12948256
lym@@	I-Disease	-1	12948256
p@@	I-Disease	-1	12948256
h	I-Disease	-1	12948256
no@@	I-Disease	-1	12948256
de	I-Disease	-1	12948256
at	O	-1	12948256
Si@@	O	-1	12948256
ri@@	O	-1	12948256
ra@@	O	-1	12948256
j	O	-1	12948256
H@@	O	-1	12948256
ospit@@	O	-1	12948256
al	O	-1	12948256
between	O	-1	12948256
19@@	O	-1	12948256
9@@	O	-1	12948256
7	O	-1	12948256
and	O	-1	12948256
20@@	O	-1	12948256
0@@	O	-1	12948256
1	O	-1	12948256
were	O	-1	12948256
ret@@	O	-1	12948256
ro@@	O	-1	12948256
sp@@	O	-1	12948256
ectively	O	-1	12948256
revie@@	O	-1	12948256
we@@	O	-1	12948256
d.	O	-1	12948256
The	O	-1	12948256
clinical	O	-1	12948256
character@@	O	-1	12948256
is@@	O	-1	12948256
tics	O	-1	12948256
and	O	-1	12948256
initial	O	-1	12948256
and	O	-1	12948256
f@@	O	-1	12948256
inal	O	-1	12948256
visual	O	-1	12948256
ac@@	O	-1	12948256
u@@	O	-1	12948256
ity	O	-1	12948256
were	O	-1	12948256
analy@@	O	-1	12948256
zed	O	-1	12948256
to	O	-1	12948256
determine	O	-1	12948256
visual	O	-1	12948256
out@@	O	-1	12948256
co@@	O	-1	12948256
me.	O	-1	12948256
RESULTS:	O	-1	12948256
All	O	-1	12948256
patients	O	-1	12948256
had	O	-1	12948256
op@@	B-Disease	D009901	12948256
tic	I-Disease	-1	12948256
neuropathy	I-Disease	-1	12948256
between	O	-1	12948256
1	O	-1	12948256
to	O	-1	12948256
6	O	-1	12948256
months	O	-1	12948256
(@@	O	-1	12948256
mean	O	-1	12948256
=	O	-1	12948256
2.@@	O	-1	12948256
9	O	-1	12948256
month@@	O	-1	12948256
s)	O	-1	12948256
after	O	-1	12948256
star@@	O	-1	12948256
ting	O	-1	12948256
eth@@	B-Chemical	D004977	12948256
am@@	I-Chemical	-1	12948256
bu@@	I-Chemical	-1	12948256
to@@	I-Chemical	-1	12948256
l	I-Chemical	-1	12948256
therapy	O	-1	12948256
at	O	-1	12948256
a	O	-1	12948256
dos@@	O	-1	12948256
age	O	-1	12948256
rang@@	O	-1	12948256
ing	O	-1	12948256
from	O	-1	12948256
13	O	-1	12948256
to	O	-1	12948256
20	O	-1	12948256
mg/k@@	O	-1	12948256
g/@@	O	-1	12948256
day	O	-1	12948256
(@@	O	-1	12948256
mean	O	-1	12948256
=	O	-1	12948256
17	O	-1	12948256
mg/k@@	O	-1	12948256
g/@@	O	-1	12948256
day@@	O	-1	12948256
).	O	-1	12948256
S@@	O	-1	12948256
even	O	-1	12948256
(5@@	O	-1	12948256
4@@	O	-1	12948256
%)	O	-1	12948256
of	O	-1	12948256
the	O	-1	12948256
13	O	-1	12948256
patients	O	-1	12948256
experienced	O	-1	12948256
visual	O	-1	12948256
recovery	O	-1	12948256
after	O	-1	12948256
sto@@	O	-1	12948256
pp@@	O	-1	12948256
ing	O	-1	12948256
the	O	-1	12948256
drug.	O	-1	12948256
Of	O	-1	12948256
6	O	-1	12948256
patients	O	-1	12948256
with	O	-1	12948256
ir@@	O	-1	12948256
reversible	O	-1	12948256
visual	B-Disease	D014786	12948256
impair@@	I-Disease	-1	12948256
ment	I-Disease	-1	12948256
,	O	-1	12948256
4	O	-1	12948256
patients	O	-1	12948256
had	O	-1	12948256
dia@@	B-Disease	D003920	12948256
bet@@	I-Disease	-1	12948256
es	I-Disease	-1	12948256
me@@	I-Disease	-1	12948256
ll@@	I-Disease	-1	12948256
it@@	I-Disease	-1	12948256
us	I-Disease	-1	12948256
,	O	-1	12948256
gl@@	B-Disease	D005901	12948256
au@@	I-Disease	-1	12948256
com@@	I-Disease	-1	12948256
a	I-Disease	-1	12948256
and	O	-1	12948256
a	O	-1	12948256
hist@@	O	-1	12948256
ory	O	-1	12948256
of	O	-1	12948256
he@@	O	-1	12948256
av@@	O	-1	12948256
y	O	-1	12948256
smo@@	O	-1	12948256
k@@	O	-1	12948256
ing.	O	-1	12948256
CONCLUSION:	O	-1	12948256
E@@	O	-1	12948256
arly	O	-1	12948256
reco@@	O	-1	12948256
gn@@	O	-1	12948256
ition	O	-1	12948256
of	O	-1	12948256
op@@	B-Disease	D009901	12948256
tic	I-Disease	-1	12948256
neuropathy	I-Disease	-1	12948256
should	O	-1	12948256
be	O	-1	12948256
considered	O	-1	12948256
in	O	-1	12948256
patients	O	-1	12948256
with	O	-1	12948256
eth@@	B-Chemical	D004977	12948256
am@@	I-Chemical	-1	12948256
bu@@	I-Chemical	-1	12948256
to@@	I-Chemical	-1	12948256
l	I-Chemical	-1	12948256
therapy.	O	-1	12948256
A	O	-1	12948256
low	O	-1	12948256
dose	O	-1	12948256
and	O	-1	12948256
pro@@	O	-1	12948256
m@@	O	-1	12948256
p@@	O	-1	12948256
t	O	-1	12948256
discontinu@@	O	-1	12948256
ation	O	-1	12948256
of	O	-1	12948256
the	O	-1	12948256
drug	O	-1	12948256
is	O	-1	12948256
recomm@@	O	-1	12948256
en@@	O	-1	12948256
ded	O	-1	12948256
partic@@	O	-1	12948256
ul@@	O	-1	12948256
arly	O	-1	12948256
in	O	-1	12948256
individ@@	O	-1	12948256
u@@	O	-1	12948256
als	O	-1	12948256
with	O	-1	12948256
dia@@	B-Disease	D003920	12948256
bet@@	I-Disease	-1	12948256
es	I-Disease	-1	12948256
me@@	I-Disease	-1	12948256
ll@@	I-Disease	-1	12948256
it@@	I-Disease	-1	12948256
us	I-Disease	-1	12948256
,	O	-1	12948256
gl@@	B-Disease	D005901	12948256
au@@	I-Disease	-1	12948256
com@@	I-Disease	-1	12948256
a	I-Disease	-1	12948256
or	O	-1	12948256
who	O	-1	12948256
are	O	-1	12948256
he@@	O	-1	12948256
av@@	O	-1	12948256
y	O	-1	12948256
smo@@	O	-1	12948256
k@@	O	-1	12948256
ers.	O	-1	12948256

Treat@@	O	-1	12950111
ment	O	-1	12950111
of	O	-1	12950111
com@@	O	-1	12950111
pen@@	O	-1	12950111
s@@	O	-1	12950111
atory	O	-1	12950111
gu@@	B-Disease	D013547	12950111
stat@@	I-Disease	-1	12950111
ory	I-Disease	-1	12950111
hyper@@	I-Disease	-1	12950111
h@@	I-Disease	-1	12950111
id@@	I-Disease	-1	12950111
ro@@	I-Disease	-1	12950111
sis	I-Disease	-1	12950111
with	O	-1	12950111
to@@	O	-1	12950111
p@@	O	-1	12950111
ical	O	-1	12950111
gly@@	B-Chemical	D006024	12950111
co@@	I-Chemical	-1	12950111
py@@	I-Chemical	-1	12950111
r@@	I-Chemical	-1	12950111
ro@@	I-Chemical	-1	12950111
l@@	I-Chemical	-1	12950111
ate	I-Chemical	-1	12950111
.	O	-1	12950111
G@@	B-Disease	D013547	12950111
u@@	I-Disease	-1	12950111
stat@@	I-Disease	-1	12950111
ory	I-Disease	-1	12950111
hyper@@	I-Disease	-1	12950111
h@@	I-Disease	-1	12950111
id@@	I-Disease	-1	12950111
ro@@	I-Disease	-1	12950111
sis	I-Disease	-1	12950111
is	O	-1	12950111
fac@@	O	-1	12950111
ial	O	-1	12950111
s@@	B-Disease	D013547	12950111
we@@	I-Disease	-1	12950111
ating	I-Disease	-1	12950111
us@@	O	-1	12950111
ually	O	-1	12950111
associated	O	-1	12950111
with	O	-1	12950111
the	O	-1	12950111
e@@	O	-1	12950111
ating	O	-1	12950111
of	O	-1	12950111
ho@@	O	-1	12950111
t	O	-1	12950111
sp@@	O	-1	12950111
ic@@	O	-1	12950111
y	O	-1	12950111
fo@@	O	-1	12950111
od	O	-1	12950111
or	O	-1	12950111
even	O	-1	12950111
s@@	O	-1	12950111
me@@	O	-1	12950111
ll@@	O	-1	12950111
ing	O	-1	12950111
this	O	-1	12950111
fo@@	O	-1	12950111
o@@	O	-1	12950111
d.	O	-1	12950111
C@@	O	-1	12950111
ur@@	O	-1	12950111
rent	O	-1	12950111
op@@	O	-1	12950111
tions	O	-1	12950111
of	O	-1	12950111
treatment	O	-1	12950111
includ@@	O	-1	12950111
e	O	-1	12950111
oral	O	-1	12950111
anti@@	O	-1	12950111
cholinergic	O	-1	12950111
drug@@	O	-1	12950111
s,	O	-1	12950111
the	O	-1	12950111
to@@	O	-1	12950111
p@@	O	-1	12950111
ical	O	-1	12950111
ap@@	O	-1	12950111
plic@@	O	-1	12950111
ation	O	-1	12950111
of	O	-1	12950111
anti@@	O	-1	12950111
chol@@	O	-1	12950111
in@@	O	-1	12950111
erg@@	O	-1	12950111
ic@@	O	-1	12950111
s	O	-1	12950111
or	O	-1	12950111
alu@@	B-Chemical	C010845	12950111
min@@	I-Chemical	-1	12950111
um	I-Chemical	-1	12950111
chlor@@	I-Chemical	-1	12950111
ide	I-Chemical	-1	12950111
,	O	-1	12950111
and	O	-1	12950111
the	O	-1	12950111
injection	O	-1	12950111
of	O	-1	12950111
b@@	O	-1	12950111
ot@@	O	-1	12950111
ul@@	O	-1	12950111
in@@	O	-1	12950111
um	O	-1	12950111
tox@@	O	-1	12950111
in.	O	-1	12950111
Th@@	O	-1	12950111
ir@@	O	-1	12950111
te@@	O	-1	12950111
en	O	-1	12950111
patients	O	-1	12950111
have	O	-1	12950111
been	O	-1	12950111
treated	O	-1	12950111
to	O	-1	12950111
d@@	O	-1	12950111
ate	O	-1	12950111
with	O	-1	12950111
1.@@	O	-1	12950111
5%	O	-1	12950111
or	O	-1	12950111
2@@	O	-1	12950111
%	O	-1	12950111
to@@	O	-1	12950111
p@@	O	-1	12950111
ical	O	-1	12950111
gly@@	B-Chemical	D006024	12950111
co@@	I-Chemical	-1	12950111
py@@	I-Chemical	-1	12950111
r@@	I-Chemical	-1	12950111
ro@@	I-Chemical	-1	12950111
l@@	I-Chemical	-1	12950111
ate	I-Chemical	-1	12950111
.	O	-1	12950111
All	O	-1	12950111
patients	O	-1	12950111
had	O	-1	12950111
gu@@	B-Disease	D013547	12950111
stat@@	I-Disease	-1	12950111
ory	I-Disease	-1	12950111
hyper@@	I-Disease	-1	12950111
h@@	I-Disease	-1	12950111
id@@	I-Disease	-1	12950111
ro@@	I-Disease	-1	12950111
sis	I-Disease	-1	12950111
,	O	-1	12950111
which	O	-1	12950111
inter@@	O	-1	12950111
fe@@	O	-1	12950111
red	O	-1	12950111
with	O	-1	12950111
their	O	-1	12950111
s@@	O	-1	12950111
oci@@	O	-1	12950111
al	O	-1	12950111
ac@@	O	-1	12950111
ti@@	O	-1	12950111
vi@@	O	-1	12950111
ti@@	O	-1	12950111
es,	O	-1	12950111
after	O	-1	12950111
trans@@	O	-1	12950111
th@@	O	-1	12950111
ro@@	O	-1	12950111
ac@@	O	-1	12950111
ic	O	-1	12950111
en@@	O	-1	12950111
dos@@	O	-1	12950111
co@@	O	-1	12950111
p@@	O	-1	12950111
ic	O	-1	12950111
sym@@	O	-1	12950111
path@@	O	-1	12950111
ect@@	O	-1	12950111
om@@	O	-1	12950111
y,	O	-1	12950111
and	O	-1	12950111
which	O	-1	12950111
was	O	-1	12950111
associated	O	-1	12950111
with	O	-1	12950111
com@@	O	-1	12950111
pen@@	O	-1	12950111
s@@	O	-1	12950111
atory	O	-1	12950111
foc@@	O	-1	12950111
al	O	-1	12950111
hyper@@	B-Disease	D006945	12950111
h@@	I-Disease	-1	12950111
id@@	I-Disease	-1	12950111
ro@@	I-Disease	-1	12950111
sis	I-Disease	-1	12950111
.	O	-1	12950111
After	O	-1	12950111
ap@@	O	-1	12950111
pl@@	O	-1	12950111
y@@	O	-1	12950111
ing	O	-1	12950111
to@@	O	-1	12950111
p@@	O	-1	12950111
ical	O	-1	12950111
gly@@	B-Chemical	D006024	12950111
co@@	I-Chemical	-1	12950111
py@@	I-Chemical	-1	12950111
r@@	I-Chemical	-1	12950111
ro@@	I-Chemical	-1	12950111
l@@	I-Chemical	-1	12950111
ate	I-Chemical	-1	12950111
,	O	-1	12950111
the	O	-1	12950111
subj@@	O	-1	12950111
ective	O	-1	12950111
effect	O	-1	12950111
was	O	-1	12950111
ex@@	O	-1	12950111
cell@@	O	-1	12950111
ent	O	-1	12950111
(@@	O	-1	12950111
no	O	-1	12950111
s@@	B-Disease	D013547	12950111
we@@	I-Disease	-1	12950111
ating	I-Disease	-1	12950111
after	O	-1	12950111
e@@	O	-1	12950111
ating	O	-1	12950111
ho@@	O	-1	12950111
t	O	-1	12950111
sp@@	O	-1	12950111
ic@@	O	-1	12950111
y	O	-1	12950111
fo@@	O	-1	12950111
o@@	O	-1	12950111
d@@	O	-1	12950111
)	O	-1	12950111
in	O	-1	12950111
10	O	-1	12950111
patients	O	-1	12950111
(@@	O	-1	12950111
7@@	O	-1	12950111
7@@	O	-1	12950111
%),	O	-1	12950111
and	O	-1	12950111
f@@	O	-1	12950111
a@@	O	-1	12950111
ir	O	-1	12950111
(@@	O	-1	12950111
clear@@	O	-1	12950111
ly	O	-1	12950111
reduced	O	-1	12950111
s@@	B-Disease	D013547	12950111
we@@	I-Disease	-1	12950111
ating	I-Disease	-1	12950111
)	O	-1	12950111
in	O	-1	12950111
3	O	-1	12950111
patients	O	-1	12950111
(2@@	O	-1	12950111
3@@	O	-1	12950111
%).	O	-1	12950111
All	O	-1	12950111
had	O	-1	12950111
reported	O	-1	12950111
inc@@	O	-1	12950111
id@@	O	-1	12950111
ents	O	-1	12950111
of	O	-1	12950111
being	O	-1	12950111
very	O	-1	12950111
emb@@	O	-1	12950111
ar@@	O	-1	12950111
r@@	O	-1	12950111
ass@@	O	-1	12950111
ed	O	-1	12950111
wh@@	O	-1	12950111
il@@	O	-1	12950111
st	O	-1	12950111
e@@	O	-1	12950111
ating	O	-1	12950111
ho@@	O	-1	12950111
t	O	-1	12950111
sp@@	O	-1	12950111
ic@@	O	-1	12950111
y	O	-1	12950111
fo@@	O	-1	12950111
o@@	O	-1	12950111
d@@	O	-1	12950111
s.	O	-1	12950111
Ad@@	O	-1	12950111
verse	O	-1	12950111
effects	O	-1	12950111
included	O	-1	12950111
a	O	-1	12950111
mil@@	O	-1	12950111
d@@	O	-1	12950111
ly	O	-1	12950111
d@@	B-Disease	D014987	12950111
r@@	I-Disease	-1	12950111
y	I-Disease	-1	12950111
mou@@	I-Disease	-1	12950111
th	I-Disease	-1	12950111
and	O	-1	12950111
a	O	-1	12950111
s@@	B-Disease	D010612	12950111
or@@	I-Disease	-1	12950111
e	I-Disease	-1	12950111
th@@	I-Disease	-1	12950111
ro@@	I-Disease	-1	12950111
at	I-Disease	-1	12950111
in	O	-1	12950111
2	O	-1	12950111
patients	O	-1	12950111
(2@@	O	-1	12950111
%	O	-1	12950111
gly@@	B-Chemical	D006024	12950111
co@@	I-Chemical	-1	12950111
py@@	I-Chemical	-1	12950111
r@@	I-Chemical	-1	12950111
ro@@	I-Chemical	-1	12950111
l@@	I-Chemical	-1	12950111
ate	I-Chemical	-1	12950111
),	O	-1	12950111
a	O	-1	12950111
li@@	O	-1	12950111
ght	O	-1	12950111
headac@@	B-Disease	D006261	12950111
he	I-Disease	-1	12950111
in	O	-1	12950111
1	O	-1	12950111
patient	O	-1	12950111
(1@@	O	-1	12950111
.@@	O	-1	12950111
5%	O	-1	12950111
gly@@	B-Chemical	D006024	12950111
co@@	I-Chemical	-1	12950111
py@@	I-Chemical	-1	12950111
r@@	I-Chemical	-1	12950111
ro@@	I-Chemical	-1	12950111
l@@	I-Chemical	-1	12950111
ate	I-Chemical	-1	12950111
).	O	-1	12950111
The	O	-1	12950111
to@@	O	-1	12950111
p@@	O	-1	12950111
ical	O	-1	12950111
ap@@	O	-1	12950111
plic@@	O	-1	12950111
ation	O	-1	12950111
of	O	-1	12950111
a	O	-1	12950111
gly@@	B-Chemical	D006024	12950111
co@@	I-Chemical	-1	12950111
py@@	I-Chemical	-1	12950111
r@@	I-Chemical	-1	12950111
ro@@	I-Chemical	-1	12950111
l@@	I-Chemical	-1	12950111
ate	I-Chemical	-1	12950111
pa@@	O	-1	12950111
d	O	-1	12950111
appe@@	O	-1	12950111
a@@	O	-1	12950111
red	O	-1	12950111
to	O	-1	12950111
be	O	-1	12950111
saf@@	O	-1	12950111
e,	O	-1	12950111
efficac@@	O	-1	12950111
i@@	O	-1	12950111
ou@@	O	-1	12950111
s,	O	-1	12950111
well	O	-1	12950111
toler@@	O	-1	12950111
at@@	O	-1	12950111
ed,	O	-1	12950111
and	O	-1	12950111
a	O	-1	12950111
con@@	O	-1	12950111
ven@@	O	-1	12950111
i@@	O	-1	12950111
ent	O	-1	12950111
meth@@	O	-1	12950111
od	O	-1	12950111
of	O	-1	12950111
treatment	O	-1	12950111
for	O	-1	12950111
moder@@	O	-1	12950111
ate	O	-1	12950111
to	O	-1	12950111
severe	O	-1	12950111
symptoms	O	-1	12950111
of	O	-1	12950111
gu@@	B-Disease	D013547	12950111
stat@@	I-Disease	-1	12950111
ory	I-Disease	-1	12950111
hyper@@	I-Disease	-1	12950111
h@@	I-Disease	-1	12950111
id@@	I-Disease	-1	12950111
ro@@	I-Disease	-1	12950111
sis	I-Disease	-1	12950111
in	O	-1	12950111
pos@@	O	-1	12950111
t	O	-1	12950111
trans@@	O	-1	12950111
th@@	O	-1	12950111
or@@	O	-1	12950111
ac@@	O	-1	12950111
ic	O	-1	12950111
en@@	O	-1	12950111
dos@@	O	-1	12950111
co@@	O	-1	12950111
p@@	O	-1	12950111
ic	O	-1	12950111
sym@@	O	-1	12950111
path@@	O	-1	12950111
ect@@	O	-1	12950111
om@@	O	-1	12950111
y	O	-1	12950111
or	O	-1	12950111
sym@@	O	-1	12950111
path@@	O	-1	12950111
icot@@	O	-1	12950111
om@@	O	-1	12950111
y	O	-1	12950111
patients,	O	-1	12950111
with	O	-1	12950111
fe@@	O	-1	12950111
w	O	-1	12950111
side	O	-1	12950111
effects.	O	-1	12950111

Ph@@	O	-1	14616590
armac@@	O	-1	14616590
ological	O	-1	14616590
character@@	O	-1	14616590
is@@	O	-1	14616590
tics	O	-1	14616590
and	O	-1	14616590
side	O	-1	14616590
effects	O	-1	14616590
of	O	-1	14616590
a	O	-1	14616590
new	O	-1	14616590
g@@	O	-1	14616590
al@@	O	-1	14616590
en@@	O	-1	14616590
ic	O	-1	14616590
form@@	O	-1	14616590
ulation	O	-1	14616590
of	O	-1	14616590
pro@@	B-Chemical	D015742	14616590
po@@	I-Chemical	-1	14616590
f@@	I-Chemical	-1	14616590
ol	I-Chemical	-1	14616590
without	O	-1	14616590
so@@	O	-1	14616590
y@@	O	-1	14616590
a@@	O	-1	14616590
be@@	O	-1	14616590
an	O	-1	14616590
o@@	O	-1	14616590
il@@	O	-1	14616590
.	O	-1	14616590
We	O	-1	14616590
compared	O	-1	14616590
the	O	-1	14616590
pharmac@@	O	-1	14616590
o@@	O	-1	14616590
kine@@	O	-1	14616590
tic@@	O	-1	14616590
s,	O	-1	14616590
pharmac@@	O	-1	14616590
o@@	O	-1	14616590
dynam@@	O	-1	14616590
ic@@	O	-1	14616590
s	O	-1	14616590
and	O	-1	14616590
safety	O	-1	14616590
prof@@	O	-1	14616590
ile	O	-1	14616590
of	O	-1	14616590
a	O	-1	14616590
new	O	-1	14616590
g@@	O	-1	14616590
al@@	O	-1	14616590
en@@	O	-1	14616590
ic	O	-1	14616590
form@@	O	-1	14616590
ulation	O	-1	14616590
of	O	-1	14616590
pro@@	B-Chemical	D015742	14616590
po@@	I-Chemical	-1	14616590
f@@	I-Chemical	-1	14616590
ol	I-Chemical	-1	14616590
(A@@	O	-1	14616590
M@@	O	-1	14616590
14@@	O	-1	14616590
9	O	-1	14616590
1@@	O	-1	14616590
%),	O	-1	14616590
which	O	-1	14616590
does	O	-1	14616590
not	O	-1	14616590
cont@@	O	-1	14616590
ain	O	-1	14616590
so@@	O	-1	14616590
y@@	O	-1	14616590
a@@	O	-1	14616590
be@@	O	-1	14616590
an	O	-1	14616590
o@@	O	-1	14616590
il@@	O	-1	14616590
,	O	-1	14616590
with	O	-1	14616590
a	O	-1	14616590
standard	O	-1	14616590
form@@	O	-1	14616590
ulation	O	-1	14616590
of	O	-1	14616590
pro@@	B-Chemical	D015742	14616590
po@@	I-Chemical	-1	14616590
f@@	I-Chemical	-1	14616590
ol	I-Chemical	-1	14616590
(	O	-1	14616590
D@@	B-Chemical	D015742	14616590
iso@@	I-Chemical	-1	14616590
pri@@	I-Chemical	-1	14616590
v@@	I-Chemical	-1	14616590
an	I-Chemical	-1	14616590
1@@	O	-1	14616590
%).	O	-1	14616590
In	O	-1	14616590
a	O	-1	14616590
ran@@	O	-1	14616590
do@@	O	-1	14616590
mi@@	O	-1	14616590
se@@	O	-1	14616590
d,	O	-1	14616590
double-bl@@	O	-1	14616590
ind@@	O	-1	14616590
,	O	-1	14616590
cros@@	O	-1	14616590
s-@@	O	-1	14616590
over	O	-1	14616590
study,	O	-1	14616590
30	O	-1	14616590
healthy	O	-1	14616590
vol@@	O	-1	14616590
un@@	O	-1	14616590
te@@	O	-1	14616590
ers	O	-1	14616590
received	O	-1	14616590
a	O	-1	14616590
single	O	-1	14616590
intravenous	O	-1	14616590
b@@	O	-1	14616590
ol@@	O	-1	14616590
us	O	-1	14616590
injection	O	-1	14616590
of	O	-1	14616590
2.@@	O	-1	14616590
5	O	-1	14616590
mg@@	O	-1	14616590
.@@	O	-1	14616590
kg@@	O	-1	14616590
-1	O	-1	14616590
pro@@	B-Chemical	D015742	14616590
po@@	I-Chemical	-1	14616590
f@@	I-Chemical	-1	14616590
ol	I-Chemical	-1	14616590
.	O	-1	14616590
P@@	O	-1	14616590
las@@	O	-1	14616590
ma	O	-1	14616590
pro@@	B-Chemical	D015742	14616590
po@@	I-Chemical	-1	14616590
f@@	I-Chemical	-1	14616590
ol	I-Chemical	-1	14616590
levels	O	-1	14616590
were	O	-1	14616590
measured	O	-1	14616590
for	O	-1	14616590
4@@	O	-1	14616590
8	O	-1	14616590
h	O	-1	14616590
following	O	-1	14616590
drug	O	-1	14616590
administration	O	-1	14616590
and	O	-1	14616590
evaluated	O	-1	14616590
ac@@	O	-1	14616590
cor@@	O	-1	14616590
ding	O	-1	14616590
to	O	-1	14616590
a	O	-1	14616590
th@@	O	-1	14616590
re@@	O	-1	14616590
e-@@	O	-1	14616590
compar@@	O	-1	14616590
t@@	O	-1	14616590
ment	O	-1	14616590
model@@	O	-1	14616590
.	O	-1	14616590
The	O	-1	14616590
pharmac@@	O	-1	14616590
o@@	O	-1	14616590
dynam@@	O	-1	14616590
ic	O	-1	14616590
par@@	O	-1	14616590
ame@@	O	-1	14616590
ters	O	-1	14616590
assessed	O	-1	14616590
included	O	-1	14616590
induction	O	-1	14616590
and	O	-1	14616590
em@@	O	-1	14616590
er@@	O	-1	14616590
gen@@	O	-1	14616590
ce	O	-1	14616590
tim@@	O	-1	14616590
es,	O	-1	14616590
respiratory	O	-1	14616590
and	O	-1	14616590
cardiovascular	O	-1	14616590
effect@@	O	-1	14616590
s,	O	-1	14616590
and	O	-1	14616590
pain	B-Disease	D010146	14616590
on	O	-1	14616590
injec@@	O	-1	14616590
tion.	O	-1	14616590
Patients	O	-1	14616590
were	O	-1	14616590
monit@@	O	-1	14616590
o@@	O	-1	14616590
red	O	-1	14616590
for	O	-1	14616590
side	O	-1	14616590
effects	O	-1	14616590
over	O	-1	14616590
4@@	O	-1	14616590
8	O	-1	14616590
h@@	O	-1	14616590
.	O	-1	14616590
O@@	O	-1	14616590
w@@	O	-1	14616590
ing	O	-1	14616590
to	O	-1	14616590
a	O	-1	14616590
high	O	-1	14616590
incidence	O	-1	14616590
of	O	-1	14616590
thrombo@@	B-Disease	D013924	14616590
ph@@	I-Disease	-1	14616590
le@@	I-Disease	-1	14616590
b@@	I-Disease	-1	14616590
iti@@	I-Disease	-1	14616590
s	I-Disease	-1	14616590
,	O	-1	14616590
the	O	-1	14616590
study	O	-1	14616590
was	O	-1	14616590
ter@@	O	-1	14616590
min@@	O	-1	14616590
ated	O	-1	14616590
pre@@	O	-1	14616590
mat@@	O	-1	14616590
ure@@	O	-1	14616590
ly	O	-1	14616590
and	O	-1	14616590
only	O	-1	14616590
the	O	-1	14616590
data	O	-1	14616590
of	O	-1	14616590
the	O	-1	14616590
two	O	-1	14616590
par@@	O	-1	14616590
al@@	O	-1	14616590
le@@	O	-1	14616590
l	O	-1	14616590
treatment	O	-1	14616590
groups	O	-1	14616590
(1@@	O	-1	14616590
5	O	-1	14616590
patients	O	-1	14616590
in	O	-1	14616590
each	O	-1	14616590
group@@	O	-1	14616590
)	O	-1	14616590
were	O	-1	14616590
analy@@	O	-1	14616590
sed.	O	-1	14616590
P@@	O	-1	14616590
las@@	O	-1	14616590
ma	O	-1	14616590
concentrations	O	-1	14616590
did	O	-1	14616590
not	O	-1	14616590
diff@@	O	-1	14616590
er	O	-1	14616590
significantly	O	-1	14616590
between	O	-1	14616590
the	O	-1	14616590
two	O	-1	14616590
form@@	O	-1	14616590
ul@@	O	-1	14616590
ations.	O	-1	14616590
An@@	O	-1	14616590
a@@	O	-1	14616590
esthe@@	O	-1	14616590
sia	O	-1	14616590
induction	O	-1	14616590
and	O	-1	14616590
em@@	O	-1	14616590
er@@	O	-1	14616590
gen@@	O	-1	14616590
ce	O	-1	14616590
tim@@	O	-1	14616590
es,	O	-1	14616590
respiratory	O	-1	14616590
and	O	-1	14616590
cardiovascular	O	-1	14616590
vari@@	O	-1	14616590
able@@	O	-1	14616590
s	O	-1	14616590
showed	O	-1	14616590
no	O	-1	14616590
significant	O	-1	14616590
differences	O	-1	14616590
between	O	-1	14616590
the	O	-1	14616590
two	O	-1	14616590
treatment	O	-1	14616590
groups.	O	-1	14616590
P@@	B-Disease	D010146	14616590
ain	I-Disease	-1	14616590
on	O	-1	14616590
injection	O	-1	14616590
(@@	O	-1	14616590
8@@	O	-1	14616590
0	O	-1	14616590
vs.	O	-1	14616590
20@@	O	-1	14616590
%,	O	-1	14616590
p	O	-1	14616590
<	O	-1	14616590
0.0@@	O	-1	14616590
1)	O	-1	14616590
and	O	-1	14616590
thrombo@@	B-Disease	D013924	14616590
ph@@	I-Disease	-1	14616590
le@@	I-Disease	-1	14616590
b@@	I-Disease	-1	14616590
iti@@	I-Disease	-1	14616590
s	I-Disease	-1	14616590
(@@	O	-1	14616590
9@@	O	-1	14616590
3.@@	O	-1	14616590
3	O	-1	14616590
vs.	O	-1	14616590
6.@@	O	-1	14616590
6@@	O	-1	14616590
%,	O	-1	14616590
p	O	-1	14616590
<	O	-1	14616590
0.00@@	O	-1	14616590
1)	O	-1	14616590
occurred	O	-1	14616590
more	O	-1	14616590
frequ@@	O	-1	14616590
ently	O	-1	14616590
with	O	-1	14616590
AM@@	O	-1	14616590
14@@	O	-1	14616590
9	O	-1	14616590
than	O	-1	14616590
with	O	-1	14616590
D@@	B-Chemical	D015742	14616590
iso@@	I-Chemical	-1	14616590
pri@@	I-Chemical	-1	14616590
v@@	I-Chemical	-1	14616590
an	I-Chemical	-1	14616590
.	O	-1	14616590
Although	O	-1	14616590
both	O	-1	14616590
form@@	O	-1	14616590
ul@@	O	-1	14616590
ations	O	-1	14616590
had	O	-1	14616590
similar	O	-1	14616590
pharmac@@	O	-1	14616590
o@@	O	-1	14616590
kine@@	O	-1	14616590
tic	O	-1	14616590
and	O	-1	14616590
pharmac@@	O	-1	14616590
o@@	O	-1	14616590
dynam@@	O	-1	14616590
ic	O	-1	14616590
pro@@	O	-1	14616590
fi@@	O	-1	14616590
le@@	O	-1	14616590
s	O	-1	14616590
the	O	-1	14616590
new	O	-1	14616590
form@@	O	-1	14616590
ulation	O	-1	14616590
is	O	-1	14616590
not	O	-1	14616590
su@@	O	-1	14616590
it@@	O	-1	14616590
able	O	-1	14616590
for	O	-1	14616590
clinical	O	-1	14616590
use	O	-1	14616590
due	O	-1	14616590
to	O	-1	14616590
the	O	-1	14616590
high	O	-1	14616590
incidence	O	-1	14616590
of	O	-1	14616590
thrombo@@	B-Disease	D013924	14616590
ph@@	I-Disease	-1	14616590
le@@	I-Disease	-1	14616590
b@@	I-Disease	-1	14616590
iti@@	I-Disease	-1	14616590
s	I-Disease	-1	14616590
produc@@	O	-1	14616590
ed.	O	-1	14616590

V@@	B-Chemical	C030852	14748761
ino@@	I-Chemical	-1	14748761
rel@@	I-Chemical	-1	14748761
b@@	I-Chemical	-1	14748761
ine	I-Chemical	-1	14748761
-@@	O	-1	14748761
related	O	-1	14748761
cardiac	O	-1	14748761
event@@	O	-1	14748761
s:	O	-1	14748761
a	O	-1	14748761
met@@	O	-1	14748761
a@@	O	-1	14748761
-@@	O	-1	14748761
analysis	O	-1	14748761
of	O	-1	14748761
randomized	O	-1	14748761
clinical	O	-1	14748761
tri@@	O	-1	14748761
al@@	O	-1	14748761
s.	O	-1	14748761
S@@	O	-1	14748761
e@@	O	-1	14748761
ver@@	O	-1	14748761
al	O	-1	14748761
cases	O	-1	14748761
of	O	-1	14748761
cardiac	O	-1	14748761
adverse	O	-1	14748761
reactions	O	-1	14748761
related	O	-1	14748761
to	O	-1	14748761
v@@	B-Chemical	C030852	14748761
ino@@	I-Chemical	-1	14748761
rel@@	I-Chemical	-1	14748761
b@@	I-Chemical	-1	14748761
ine	I-Chemical	-1	14748761
(	O	-1	14748761
V@@	B-Chemical	C030852	14748761
N@@	I-Chemical	-1	14748761
R	I-Chemical	-1	14748761
)	O	-1	14748761
have	O	-1	14748761
been	O	-1	14748761
reported	O	-1	14748761
in	O	-1	14748761
the	O	-1	14748761
literat@@	O	-1	14748761
ure.	O	-1	14748761
In	O	-1	14748761
or@@	O	-1	14748761
der	O	-1	14748761
to	O	-1	14748761
qu@@	O	-1	14748761
anti@@	O	-1	14748761
f@@	O	-1	14748761
y	O	-1	14748761
the	O	-1	14748761
incidence	O	-1	14748761
of	O	-1	14748761
these	O	-1	14748761
cardiac	O	-1	14748761
event@@	O	-1	14748761
s,	O	-1	14748761
we	O	-1	14748761
performed	O	-1	14748761
a	O	-1	14748761
met@@	O	-1	14748761
a@@	O	-1	14748761
-@@	O	-1	14748761
analysis	O	-1	14748761
of	O	-1	14748761
clinical	O	-1	14748761
tri@@	O	-1	14748761
als	O	-1	14748761
compar@@	O	-1	14748761
ing	O	-1	14748761
V@@	B-Chemical	C030852	14748761
N@@	I-Chemical	-1	14748761
R	I-Chemical	-1	14748761
with	O	-1	14748761
other	O	-1	14748761
chemo@@	O	-1	14748761
therapeutic	O	-1	14748761
agents	O	-1	14748761
in	O	-1	14748761
the	O	-1	14748761
treatment	O	-1	14748761
of	O	-1	14748761
various	O	-1	14748761
mal@@	B-Disease	D009369	14748761
i@@	I-Disease	-1	14748761
gn@@	I-Disease	-1	14748761
an@@	I-Disease	-1	14748761
ci@@	I-Disease	-1	14748761
es	I-Disease	-1	14748761
.	O	-1	14748761
R@@	O	-1	14748761
an@@	O	-1	14748761
dom@@	O	-1	14748761
ized	O	-1	14748761
clinical	O	-1	14748761
tri@@	O	-1	14748761
als	O	-1	14748761
compar@@	O	-1	14748761
ing	O	-1	14748761
V@@	B-Chemical	C030852	14748761
N@@	I-Chemical	-1	14748761
R	I-Chemical	-1	14748761
with	O	-1	14748761
other	O	-1	14748761
drugs	O	-1	14748761
in	O	-1	14748761
the	O	-1	14748761
treatment	O	-1	14748761
of	O	-1	14748761
cancer	B-Disease	D009369	14748761
were	O	-1	14748761
se@@	O	-1	14748761
ar@@	O	-1	14748761
ch@@	O	-1	14748761
ed	O	-1	14748761
in	O	-1	14748761
M@@	O	-1	14748761
ed@@	O	-1	14748761
l@@	O	-1	14748761
ine,	O	-1	14748761
E@@	O	-1	14748761
m@@	O	-1	14748761
bas@@	O	-1	14748761
e,	O	-1	14748761
E@@	O	-1	14748761
vid@@	O	-1	14748761
ence@@	O	-1	14748761
-@@	O	-1	14748761
bas@@	O	-1	14748761
ed	O	-1	14748761
M@@	O	-1	14748761
ed@@	O	-1	14748761
ic@@	O	-1	14748761
ine	O	-1	14748761
Re@@	O	-1	14748761
vie@@	O	-1	14748761
w@@	O	-1	14748761
s	O	-1	14748761
dat@@	O	-1	14748761
ab@@	O	-1	14748761
as@@	O	-1	14748761
es	O	-1	14748761
and	O	-1	14748761
the	O	-1	14748761
C@@	O	-1	14748761
och@@	O	-1	14748761
ran@@	O	-1	14748761
e	O	-1	14748761
li@@	O	-1	14748761
b@@	O	-1	14748761
r@@	O	-1	14748761
ary	O	-1	14748761
from	O	-1	14748761
19@@	O	-1	14748761
8@@	O	-1	14748761
7	O	-1	14748761
to	O	-1	14748761
20@@	O	-1	14748761
0@@	O	-1	14748761
2@@	O	-1	14748761
.	O	-1	14748761
O@@	O	-1	14748761
ut@@	O	-1	14748761
com@@	O	-1	14748761
es	O	-1	14748761
of	O	-1	14748761
in@@	O	-1	14748761
te@@	O	-1	14748761
res@@	O	-1	14748761
t	O	-1	14748761
were	O	-1	14748761
severe	O	-1	14748761
cardiac	O	-1	14748761
event@@	O	-1	14748761
s,	O	-1	14748761
toxic	O	-1	14748761
de@@	O	-1	14748761
ath@@	O	-1	14748761
s	O	-1	14748761
and	O	-1	14748761
cardiac	O	-1	14748761
event@@	O	-1	14748761
-@@	O	-1	14748761
related	O	-1	14748761
de@@	O	-1	14748761
ath@@	O	-1	14748761
s	O	-1	14748761
reported	O	-1	14748761
in	O	-1	14748761
each	O	-1	14748761
pu@@	O	-1	14748761
bl@@	O	-1	14748761
ic@@	O	-1	14748761
ation.	O	-1	14748761
We	O	-1	14748761
found	O	-1	14748761
1@@	O	-1	14748761
9	O	-1	14748761
tri@@	O	-1	14748761
al@@	O	-1	14748761
s,	O	-1	14748761
invol@@	O	-1	14748761
ving	O	-1	14748761
2@@	O	-1	14748761
4@@	O	-1	14748761
4@@	O	-1	14748761
1	O	-1	14748761
patients	O	-1	14748761
treated	O	-1	14748761
by	O	-1	14748761
V@@	B-Chemical	C030852	14748761
N@@	I-Chemical	-1	14748761
R	I-Chemical	-1	14748761
and	O	-1	14748761
20@@	O	-1	14748761
50	O	-1	14748761
control	O	-1	14748761
patients.	O	-1	14748761
The	O	-1	14748761
incidence	O	-1	14748761
of	O	-1	14748761
cardiac	O	-1	14748761
events	O	-1	14748761
with	O	-1	14748761
V@@	B-Chemical	C030852	14748761
N@@	I-Chemical	-1	14748761
R	I-Chemical	-1	14748761
was	O	-1	14748761
1.@@	O	-1	14748761
19@@	O	-1	14748761
%	O	-1	14748761
[@@	O	-1	14748761
95%	O	-1	14748761
conf@@	O	-1	14748761
idence	O	-1	14748761
interv@@	O	-1	14748761
al	O	-1	14748761
(C@@	O	-1	14748761
I@@	O	-1	14748761
)	O	-1	14748761
(0.@@	O	-1	14748761
7@@	O	-1	14748761
5@@	O	-1	14748761
;	O	-1	14748761
1.@@	O	-1	14748761
6@@	O	-1	14748761
7@@	O	-1	14748761
)@@	O	-1	14748761
]@@	O	-1	14748761
.	O	-1	14748761
There	O	-1	14748761
was	O	-1	14748761
no	O	-1	14748761
difference	O	-1	14748761
in	O	-1	14748761
the	O	-1	14748761
risk	O	-1	14748761
of	O	-1	14748761
cardiac	O	-1	14748761
events	O	-1	14748761
between	O	-1	14748761
V@@	B-Chemical	C030852	14748761
N@@	I-Chemical	-1	14748761
R	I-Chemical	-1	14748761
and	O	-1	14748761
other	O	-1	14748761
drugs	O	-1	14748761
[@@	O	-1	14748761
o@@	O	-1	14748761
d@@	O	-1	14748761
ds	O	-1	14748761
rati@@	O	-1	14748761
o@@	O	-1	14748761
:	O	-1	14748761
0.@@	O	-1	14748761
9@@	O	-1	14748761
2,	O	-1	14748761
95%	O	-1	14748761
C@@	O	-1	14748761
I	O	-1	14748761
(0.@@	O	-1	14748761
5@@	O	-1	14748761
4@@	O	-1	14748761
;	O	-1	14748761
1.@@	O	-1	14748761
55@@	O	-1	14748761
)@@	O	-1	14748761
]@@	O	-1	14748761
.	O	-1	14748761
The	O	-1	14748761
risk	O	-1	14748761
of	O	-1	14748761
V@@	B-Chemical	C030852	14748761
N@@	I-Chemical	-1	14748761
R	I-Chemical	-1	14748761
cardiac	O	-1	14748761
events	O	-1	14748761
was	O	-1	14748761
similar	O	-1	14748761
to	O	-1	14748761
v@@	B-Chemical	D014751	14748761
ind@@	I-Chemical	-1	14748761
es@@	I-Chemical	-1	14748761
ine	I-Chemical	-1	14748761
(	O	-1	14748761
V@@	B-Chemical	D014751	14748761
D@@	I-Chemical	-1	14748761
S	I-Chemical	-1	14748761
)	O	-1	14748761
and	O	-1	14748761
other	O	-1	14748761
cardi@@	B-Disease	D066126	14748761
ot@@	I-Disease	-1	14748761
ox@@	I-Disease	-1	14748761
ic	I-Disease	-1	14748761
drugs	O	-1	14748761
[	O	-1	14748761
fluoro@@	B-Chemical	D005472	14748761
urac@@	I-Chemical	-1	14748761
il	I-Chemical	-1	14748761
,	O	-1	14748761
an@@	B-Chemical	D018943	14748761
th@@	I-Chemical	-1	14748761
rac@@	I-Chemical	-1	14748761
y@@	I-Chemical	-1	14748761
clin@@	I-Chemical	-1	14748761
es	I-Chemical	-1	14748761
,	O	-1	14748761
g@@	B-Chemical	C056507	14748761
em@@	I-Chemical	-1	14748761
cit@@	I-Chemical	-1	14748761
ab@@	I-Chemical	-1	14748761
ine	I-Chemical	-1	14748761
(	O	-1	14748761
G@@	B-Chemical	C056507	14748761
E@@	I-Chemical	-1	14748761
M	I-Chemical	-1	14748761
)	O	-1	14748761
em	O	-1	14748761
lead@@	O	-1	14748761
er	O	-1	14748761
]@@	O	-1	14748761
.	O	-1	14748761
E@@	O	-1	14748761
ven	O	-1	14748761
if	O	-1	14748761
it	O	-1	14748761
did	O	-1	14748761
not	O	-1	14748761
reac@@	O	-1	14748761
h	O	-1	14748761
statis@@	O	-1	14748761
tical	O	-1	14748761
signific@@	O	-1	14748761
ance	O	-1	14748761
because	O	-1	14748761
of	O	-1	14748761
a	O	-1	14748761
fe@@	O	-1	14748761
w	O	-1	14748761
number	O	-1	14748761
of	O	-1	14748761
cas@@	O	-1	14748761
es,	O	-1	14748761
the	O	-1	14748761
risk	O	-1	14748761
was	O	-1	14748761
lower	O	-1	14748761
in	O	-1	14748761
tri@@	O	-1	14748761
als	O	-1	14748761
ex@@	O	-1	14748761
cl@@	O	-1	14748761
ud@@	O	-1	14748761
ing	O	-1	14748761
patients	O	-1	14748761
with	O	-1	14748761
cardiac	O	-1	14748761
hist@@	O	-1	14748761
or@@	O	-1	14748761
y,	O	-1	14748761
and	O	-1	14748761
se@@	O	-1	14748761
em@@	O	-1	14748761
ed	O	-1	14748761
to	O	-1	14748761
be	O	-1	14748761
higher	O	-1	14748761
in	O	-1	14748761
tri@@	O	-1	14748761
als	O	-1	14748761
including	O	-1	14748761
patients	O	-1	14748761
with	O	-1	14748761
pre-@@	O	-1	14748761
ex@@	O	-1	14748761
ist@@	O	-1	14748761
ing	O	-1	14748761
cardiac	B-Disease	D006331	14748761
diseas@@	I-Disease	-1	14748761
es	I-Disease	-1	14748761
.	O	-1	14748761
V@@	B-Chemical	C030852	14748761
ino@@	I-Chemical	-1	14748761
rel@@	I-Chemical	-1	14748761
b@@	I-Chemical	-1	14748761
ine	I-Chemical	-1	14748761
-@@	O	-1	14748761
related	O	-1	14748761
cardiac	O	-1	14748761
events	O	-1	14748761
con@@	O	-1	14748761
cer@@	O	-1	14748761
n	O	-1	14748761
about	O	-1	14748761
1@@	O	-1	14748761
%	O	-1	14748761
of	O	-1	14748761
treated	O	-1	14748761
patients	O	-1	14748761
in	O	-1	14748761
clinical	O	-1	14748761
tri@@	O	-1	14748761
al@@	O	-1	14748761
s.	O	-1	14748761
However,	O	-1	14748761
the	O	-1	14748761
risk	O	-1	14748761
associated	O	-1	14748761
with	O	-1	14748761
V@@	B-Chemical	C030852	14748761
N@@	I-Chemical	-1	14748761
R	I-Chemical	-1	14748761
se@@	O	-1	14748761
em@@	O	-1	14748761
s	O	-1	14748761
to	O	-1	14748761
be	O	-1	14748761
similar	O	-1	14748761
to	O	-1	14748761
that	O	-1	14748761
of	O	-1	14748761
other	O	-1	14748761
chemo@@	O	-1	14748761
therapeutic	O	-1	14748761
agents	O	-1	14748761
in	O	-1	14748761
the	O	-1	14748761
same	O	-1	14748761
indic@@	O	-1	14748761
ations.	O	-1	14748761

MR@@	O	-1	15018178
I	O	-1	15018178
findings	O	-1	15018178
of	O	-1	15018178
hypo@@	O	-1	15018178
x@@	O	-1	15018178
ic	O	-1	15018178
cor@@	O	-1	15018178
tical	O	-1	15018178
l@@	O	-1	15018178
amin@@	O	-1	15018178
ar	O	-1	15018178
necro@@	B-Disease	D009336	15018178
sis	I-Disease	-1	15018178
in	O	-1	15018178
a	O	-1	15018178
ch@@	O	-1	15018178
il@@	O	-1	15018178
d	O	-1	15018178
with	O	-1	15018178
hemolytic	B-Disease	D000743	15018178
anemia	I-Disease	-1	15018178
cri@@	O	-1	15018178
sis.	O	-1	15018178
We	O	-1	15018178
present	O	-1	15018178
mag@@	O	-1	15018178
ne@@	O	-1	15018178
tic	O	-1	15018178
res@@	O	-1	15018178
on@@	O	-1	15018178
ance	O	-1	15018178
imaging	O	-1	15018178
findings	O	-1	15018178
of	O	-1	15018178
a	O	-1	15018178
5-@@	O	-1	15018178
year-old	O	-1	15018178
gi@@	O	-1	15018178
r@@	O	-1	15018178
l	O	-1	15018178
who	O	-1	15018178
had	O	-1	15018178
a	O	-1	15018178
ra@@	O	-1	15018178
pid@@	O	-1	15018178
ly	O	-1	15018178
in@@	O	-1	15018178
st@@	O	-1	15018178
all@@	O	-1	15018178
ing	O	-1	15018178
hemolytic	B-Disease	D000743	15018178
anemia	I-Disease	-1	15018178
cri@@	O	-1	15018178
sis	O	-1	15018178
induced	O	-1	15018178
by	O	-1	15018178
tri@@	B-Chemical	D015662	15018178
meth@@	I-Chemical	-1	15018178
o@@	I-Chemical	-1	15018178
prim@@	I-Chemical	-1	15018178
-@@	I-Chemical	-1	15018178
sul@@	I-Chemical	-1	15018178
fo@@	I-Chemical	-1	15018178
meth@@	I-Chemical	-1	15018178
ox@@	I-Chemical	-1	15018178
azole	I-Chemical	-1	15018178
,	O	-1	15018178
result@@	O	-1	15018178
ing	O	-1	15018178
in	O	-1	15018178
cerebral	B-Disease	D002534	15018178
an@@	I-Disease	-1	15018178
ox@@	I-Disease	-1	15018178
ia	I-Disease	-1	15018178
lead@@	O	-1	15018178
ing	O	-1	15018178
to	O	-1	15018178
per@@	O	-1	15018178
man@@	O	-1	15018178
ent	O	-1	15018178
dam@@	O	-1	15018178
age.	O	-1	15018178
M@@	O	-1	15018178
ag@@	O	-1	15018178
ne@@	O	-1	15018178
tic	O	-1	15018178
R@@	O	-1	15018178
es@@	O	-1	15018178
on@@	O	-1	15018178
ance	O	-1	15018178
imaging	O	-1	15018178
revealed	O	-1	15018178
cor@@	O	-1	15018178
tical	O	-1	15018178
l@@	O	-1	15018178
amin@@	O	-1	15018178
ar	O	-1	15018178
necro@@	B-Disease	D009336	15018178
sis	I-Disease	-1	15018178
in	O	-1	15018178
arterial	O	-1	15018178
b@@	O	-1	15018178
or@@	O	-1	15018178
der	O	-1	15018178
z@@	O	-1	15018178
on@@	O	-1	15018178
es	O	-1	15018178
in	O	-1	15018178
both	O	-1	15018178
cerebral	O	-1	15018178
he@@	O	-1	15018178
mis@@	O	-1	15018178
ph@@	O	-1	15018178
e@@	O	-1	15018178
res@@	O	-1	15018178
,	O	-1	15018178
ischem@@	O	-1	15018178
ic	O	-1	15018178
changes	O	-1	15018178
in	O	-1	15018178
sub@@	O	-1	15018178
cor@@	O	-1	15018178
tical	O	-1	15018178
wh@@	O	-1	15018178
ite	O	-1	15018178
mat@@	O	-1	15018178
ter	O	-1	15018178
of	O	-1	15018178
left	O	-1	15018178
cerebral	O	-1	15018178
he@@	O	-1	15018178
mis@@	O	-1	15018178
ph@@	O	-1	15018178
e@@	O	-1	15018178
re,	O	-1	15018178
and	O	-1	15018178
in	O	-1	15018178
the	O	-1	15018178
left	O	-1	15018178
p@@	O	-1	15018178
ut@@	O	-1	15018178
am@@	O	-1	15018178
en@@	O	-1	15018178
.	O	-1	15018178
Although	O	-1	15018178
cor@@	O	-1	15018178
tical	O	-1	15018178
l@@	O	-1	15018178
amin@@	O	-1	15018178
ar	O	-1	15018178
necro@@	B-Disease	D009336	15018178
sis	I-Disease	-1	15018178
is	O	-1	15018178
a	O	-1	15018178
cl@@	O	-1	15018178
as@@	O	-1	15018178
sic	O	-1	15018178
enti@@	O	-1	15018178
t@@	O	-1	15018178
y	O	-1	15018178
in	O	-1	15018178
ad@@	O	-1	15018178
ul@@	O	-1	15018178
th@@	O	-1	15018178
o@@	O	-1	15018178
od	O	-1	15018178
related	O	-1	15018178
to	O	-1	15018178
condi@@	O	-1	15018178
tions	O	-1	15018178
of	O	-1	15018178
en@@	O	-1	15018178
erg@@	O	-1	15018178
y	O	-1	15018178
deple@@	O	-1	15018178
tion@@	O	-1	15018178
s,	O	-1	15018178
there	O	-1	15018178
are	O	-1	15018178
fe@@	O	-1	15018178
w	O	-1	15018178
reports	O	-1	15018178
av@@	O	-1	15018178
ail@@	O	-1	15018178
able	O	-1	15018178
in	O	-1	15018178
child@@	O	-1	15018178
ren@@	O	-1	15018178
.	O	-1	15018178
A	O	-1	15018178
w@@	O	-1	15018178
ide	O	-1	15018178
revie@@	O	-1	15018178
w	O	-1	15018178
of	O	-1	15018178
the	O	-1	15018178
literat@@	O	-1	15018178
ure	O	-1	15018178
is	O	-1	15018178
also	O	-1	15018178
present@@	O	-1	15018178
ed.	O	-1	15018178

The	O	-1	15094729
n@@	O	-1	15094729
at@@	O	-1	15094729
ural	O	-1	15094729
hist@@	O	-1	15094729
ory	O	-1	15094729
of	O	-1	15094729
V@@	B-Chemical	D020888	15094729
ig@@	I-Chemical	-1	15094729
ab@@	I-Chemical	-1	15094729
at@@	I-Chemical	-1	15094729
rin	I-Chemical	-1	15094729
associated	O	-1	15094729
visual	B-Disease	D014786	15094729
fi@@	I-Disease	-1	15094729
el@@	I-Disease	-1	15094729
d	I-Disease	-1	15094729
def@@	I-Disease	-1	15094729
ects	I-Disease	-1	15094729
in	O	-1	15094729
patients	O	-1	15094729
elect@@	O	-1	15094729
ing	O	-1	15094729
to	O	-1	15094729
continu@@	O	-1	15094729
e	O	-1	15094729
their	O	-1	15094729
medic@@	O	-1	15094729
ation.	O	-1	15094729
P@@	O	-1	15094729
U@@	O	-1	15094729
R@@	O	-1	15094729
P@@	O	-1	15094729
O@@	O	-1	15094729
S@@	O	-1	15094729
E:	O	-1	15094729
To	O	-1	15094729
determine	O	-1	15094729
the	O	-1	15094729
n@@	O	-1	15094729
at@@	O	-1	15094729
ural	O	-1	15094729
hist@@	O	-1	15094729
ory	O	-1	15094729
of	O	-1	15094729
visual	B-Disease	D014786	15094729
fi@@	I-Disease	-1	15094729
el@@	I-Disease	-1	15094729
d	I-Disease	-1	15094729
def@@	I-Disease	-1	15094729
ects	I-Disease	-1	15094729
in	O	-1	15094729
a	O	-1	15094729
group	O	-1	15094729
of	O	-1	15094729
patients	O	-1	15094729
known	O	-1	15094729
to	O	-1	15094729
have	O	-1	15094729
V@@	B-Chemical	D020888	15094729
ig@@	I-Chemical	-1	15094729
ab@@	I-Chemical	-1	15094729
at@@	I-Chemical	-1	15094729
rin	I-Chemical	-1	15094729
-@@	O	-1	15094729
associated	O	-1	15094729
changes	O	-1	15094729
who	O	-1	15094729
el@@	O	-1	15094729
ected	O	-1	15094729
to	O	-1	15094729
continu@@	O	-1	15094729
e	O	-1	15094729
the	O	-1	15094729
medic@@	O	-1	15094729
ation	O	-1	15094729
because	O	-1	15094729
of	O	-1	15094729
go@@	O	-1	15094729
od	O	-1	15094729
seizure	B-Disease	D012640	15094729
control@@	O	-1	15094729
.	O	-1	15094729
METHODS:	O	-1	15094729
All	O	-1	15094729
patients	O	-1	15094729
taking	O	-1	15094729
V@@	B-Chemical	D020888	15094729
ig@@	I-Chemical	-1	15094729
ab@@	I-Chemical	-1	15094729
at@@	I-Chemical	-1	15094729
rin	I-Chemical	-1	15094729
alone	O	-1	15094729
or	O	-1	15094729
in	O	-1	15094729
combination	O	-1	15094729
with	O	-1	15094729
other	O	-1	15094729
anti@@	O	-1	15094729
epileptic	O	-1	15094729
drugs	O	-1	15094729
for	O	-1	15094729
at	O	-1	15094729
le@@	O	-1	15094729
ast	O	-1	15094729
5	O	-1	15094729
years	O	-1	15094729
(@@	O	-1	15094729
range	O	-1	15094729
5-@@	O	-1	15094729
12	O	-1	15094729
year@@	O	-1	15094729
s)	O	-1	15094729
were	O	-1	15094729
ent@@	O	-1	15094729
ered	O	-1	15094729
into	O	-1	15094729
a	O	-1	15094729
visual	O	-1	15094729
sur@@	O	-1	15094729
ve@@	O	-1	15094729
ill@@	O	-1	15094729
ance	O	-1	15094729
pro@@	O	-1	15094729
gram@@	O	-1	15094729
me.	O	-1	15094729
Patients	O	-1	15094729
were	O	-1	15094729
followed	O	-1	15094729
up	O	-1	15094729
at	O	-1	15094729
6-@@	O	-1	15094729
month@@	O	-1	15094729
ly	O	-1	15094729
interv@@	O	-1	15094729
als	O	-1	15094729
for	O	-1	15094729
not	O	-1	15094729
less	O	-1	15094729
than	O	-1	15094729
1@@	O	-1	15094729
8	O	-1	15094729
months	O	-1	15094729
(@@	O	-1	15094729
range	O	-1	15094729
18@@	O	-1	15094729
-@@	O	-1	15094729
4@@	O	-1	15094729
3	O	-1	15094729
month@@	O	-1	15094729
s@@	O	-1	15094729
).	O	-1	15094729
In	O	-1	15094729
all@@	O	-1	15094729
,	O	-1	15094729
16	O	-1	15094729
patients	O	-1	15094729
with	O	-1	15094729
un@@	O	-1	15094729
equ@@	O	-1	15094729
i@@	O	-1	15094729
v@@	O	-1	15094729
oc@@	O	-1	15094729
al	O	-1	15094729
def@@	O	-1	15094729
ects	O	-1	15094729
continu@@	O	-1	15094729
ed	O	-1	15094729
the	O	-1	15094729
medic@@	O	-1	15094729
ation.	O	-1	15094729
F@@	O	-1	15094729
ol@@	O	-1	15094729
low@@	O	-1	15094729
ing	O	-1	15094729
al@@	O	-1	15094729
re@@	O	-1	15094729
ad@@	O	-1	15094729
y	O	-1	15094729
pu@@	O	-1	15094729
bl@@	O	-1	15094729
ished	O	-1	15094729
meth@@	O	-1	15094729
o@@	O	-1	15094729
do@@	O	-1	15094729
log@@	O	-1	15094729
y	O	-1	15094729
(@@	O	-1	15094729
E@@	O	-1	15094729
y@@	O	-1	15094729
e	O	-1	15094729
20@@	O	-1	15094729
0@@	O	-1	15094729
2@@	O	-1	15094729
;	O	-1	15094729
1@@	O	-1	15094729
6@@	O	-1	15094729
;@@	O	-1	15094729
5@@	O	-1	15094729
6@@	O	-1	15094729
7-@@	O	-1	15094729
5@@	O	-1	15094729
7@@	O	-1	15094729
1)	O	-1	15094729
mon@@	O	-1	15094729
oc@@	O	-1	15094729
ular	O	-1	15094729
mean	O	-1	15094729
radi@@	O	-1	15094729
al	O	-1	15094729
de@@	O	-1	15094729
gre@@	O	-1	15094729
es	O	-1	15094729
(@@	O	-1	15094729
MR@@	O	-1	15094729
D@@	O	-1	15094729
s)	O	-1	15094729
to	O	-1	15094729
the	O	-1	15094729
I@@	O	-1	15094729
/@@	O	-1	15094729
4@@	O	-1	15094729
e	O	-1	15094729
iso@@	O	-1	15094729
p@@	O	-1	15094729
ter	O	-1	15094729
on	O	-1	15094729
G@@	O	-1	15094729
ol@@	O	-1	15094729
d@@	O	-1	15094729
man@@	O	-1	15094729
n	O	-1	15094729
peri@@	O	-1	15094729
met@@	O	-1	15094729
r@@	O	-1	15094729
y	O	-1	15094729
was	O	-1	15094729
calc@@	O	-1	15094729
ul@@	O	-1	15094729
ated	O	-1	15094729
for	O	-1	15094729
the	O	-1	15094729
right	O	-1	15094729
e@@	O	-1	15094729
y@@	O	-1	15094729
e	O	-1	15094729
at	O	-1	15094729
the	O	-1	15094729
time	O	-1	15094729
of	O	-1	15094729
dis@@	O	-1	15094729
co@@	O	-1	15094729
very	O	-1	15094729
of	O	-1	15094729
a	O	-1	15094729
visual	B-Disease	D014786	15094729
fi@@	I-Disease	-1	15094729
el@@	I-Disease	-1	15094729
d	I-Disease	-1	15094729
def@@	I-Disease	-1	15094729
ect	I-Disease	-1	15094729
and	O	-1	15094729
ag@@	O	-1	15094729
ain	O	-1	15094729
after	O	-1	15094729
not	O	-1	15094729
less	O	-1	15094729
than	O	-1	15094729
1@@	O	-1	15094729
8	O	-1	15094729
months	O	-1	15094729
follow-@@	O	-1	15094729
up@@	O	-1	15094729
.	O	-1	15094729
RESULTS:	O	-1	15094729
M@@	O	-1	15094729
e@@	O	-1	15094729
an	O	-1	15094729
right	O	-1	15094729
e@@	O	-1	15094729
y@@	O	-1	15094729
e	O	-1	15094729
MR@@	O	-1	15094729
D	O	-1	15094729
at	O	-1	15094729
present@@	O	-1	15094729
ation	O	-1	15094729
was	O	-1	15094729
3@@	O	-1	15094729
6.@@	O	-1	15094729
9@@	O	-1	15094729
8	O	-1	15094729
de@@	O	-1	15094729
gre@@	O	-1	15094729
es	O	-1	15094729
(@@	O	-1	15094729
range	O	-1	15094729
2@@	O	-1	15094729
2.@@	O	-1	15094729
2@@	O	-1	15094729
5-@@	O	-1	15094729
5@@	O	-1	15094729
1.@@	O	-1	15094729
0@@	O	-1	15094729
),	O	-1	15094729
compared	O	-1	15094729
to	O	-1	15094729
3@@	O	-1	15094729
8.@@	O	-1	15094729
40	O	-1	15094729
de@@	O	-1	15094729
gre@@	O	-1	15094729
es	O	-1	15094729
(@@	O	-1	15094729
range	O	-1	15094729
2@@	O	-1	15094729
2.@@	O	-1	15094729
5-@@	O	-1	15094729
4@@	O	-1	15094729
9.@@	O	-1	15094729
7@@	O	-1	15094729
5@@	O	-1	15094729
)	O	-1	15094729
after	O	-1	15094729
follow-@@	O	-1	15094729
up@@	O	-1	15094729
;	O	-1	15094729
P@@	O	-1	15094729
=@@	O	-1	15094729
0.@@	O	-1	15094729
3@@	O	-1	15094729
3@@	O	-1	15094729
8	O	-1	15094729
un@@	O	-1	15094729
pa@@	O	-1	15094729
ired	O	-1	15094729
t-@@	O	-1	15094729
test@@	O	-1	15094729
.	O	-1	15094729
On@@	O	-1	15094729
ly	O	-1	15094729
one	O	-1	15094729
patient	O	-1	15094729
demonstrated	O	-1	15094729
a	O	-1	15094729
deter@@	B-Disease	D014786	15094729
i@@	I-Disease	-1	15094729
or@@	I-Disease	-1	15094729
ation	I-Disease	-1	15094729
in	I-Disease	-1	15094729
visual	I-Disease	-1	15094729
fi@@	I-Disease	-1	15094729
el@@	I-Disease	-1	15094729
d	I-Disease	-1	15094729
during	O	-1	15094729
the	O	-1	15094729
study	O	-1	15094729
period	O	-1	15094729
and	O	-1	15094729
discontinu@@	O	-1	15094729
ed	O	-1	15094729
treatment.	O	-1	15094729
CONCLUSION:	O	-1	15094729
E@@	O	-1	15094729
st@@	O	-1	15094729
abl@@	O	-1	15094729
ished	O	-1	15094729
visual	B-Disease	D014786	15094729
fi@@	I-Disease	-1	15094729
el@@	I-Disease	-1	15094729
d	I-Disease	-1	15094729
def@@	I-Disease	-1	15094729
ects	I-Disease	-1	15094729
pres@@	O	-1	15094729
um@@	O	-1	15094729
ed	O	-1	15094729
to	O	-1	15094729
be	O	-1	15094729
due	O	-1	15094729
to	O	-1	15094729
V@@	B-Chemical	D020888	15094729
ig@@	I-Chemical	-1	15094729
ab@@	I-Chemical	-1	15094729
at@@	I-Chemical	-1	15094729
rin	I-Chemical	-1	15094729
therapy	O	-1	15094729
did	O	-1	15094729
not	O	-1	15094729
us@@	O	-1	15094729
ually	O	-1	15094729
progres@@	O	-1	15094729
s	O	-1	15094729
in	O	-1	15094729
sp@@	O	-1	15094729
ite	O	-1	15094729
of	O	-1	15094729
continu@@	O	-1	15094729
ing	O	-1	15094729
use	O	-1	15094729
of	O	-1	15094729
the	O	-1	15094729
medic@@	O	-1	15094729
ation.	O	-1	15094729
These	O	-1	15094729
data	O	-1	15094729
gi@@	O	-1	15094729
ve	O	-1	15094729
suppor@@	O	-1	15094729
t	O	-1	15094729
to	O	-1	15094729
the	O	-1	15094729
hypo@@	O	-1	15094729
thesis	O	-1	15094729
that	O	-1	15094729
the	O	-1	15094729
path@@	O	-1	15094729
o@@	O	-1	15094729
genesis	O	-1	15094729
of	O	-1	15094729
V@@	B-Chemical	D020888	15094729
ig@@	I-Chemical	-1	15094729
ab@@	I-Chemical	-1	15094729
at@@	I-Chemical	-1	15094729
rin	I-Chemical	-1	15094729
-@@	O	-1	15094729
associated	O	-1	15094729
visual	B-Disease	D014786	15094729
fi@@	I-Disease	-1	15094729
el@@	I-Disease	-1	15094729
d	I-Disease	-1	15094729
def@@	I-Disease	-1	15094729
ects	I-Disease	-1	15094729
may	O	-1	15094729
be	O	-1	15094729
an	O	-1	15094729
i@@	O	-1	15094729
di@@	O	-1	15094729
os@@	O	-1	15094729
yn@@	O	-1	15094729
c@@	O	-1	15094729
r@@	O	-1	15094729
atic	O	-1	15094729
adverse	O	-1	15094729
drug	O	-1	15094729
reaction	O	-1	15094729
ra@@	O	-1	15094729
ther	O	-1	15094729
than	O	-1	15094729
dose-@@	O	-1	15094729
dependent	O	-1	15094729
toxicity	B-Disease	D064420	15094729
.	O	-1	15094729

In@@	O	-1	15096374
duction	O	-1	15096374
of	O	-1	15096374
ros@@	O	-1	15096374
ace@@	O	-1	15096374
if@@	O	-1	15096374
or@@	O	-1	15096374
m	O	-1	15096374
der@@	B-Disease	D003872	15096374
m@@	I-Disease	-1	15096374
ati@@	I-Disease	-1	15096374
tis	I-Disease	-1	15096374
during	O	-1	15096374
treatment	O	-1	15096374
of	O	-1	15096374
fac@@	B-Disease	D005148	15096374
ial	I-Disease	-1	15096374
inflam@@	I-Disease	-1	15096374
mat@@	I-Disease	-1	15096374
ory	I-Disease	-1	15096374
der@@	I-Disease	-1	15096374
mat@@	I-Disease	-1	15096374
o@@	I-Disease	-1	15096374
ses	I-Disease	-1	15096374
with	O	-1	15096374
tacrolimus	B-Chemical	D016559	15096374
o@@	O	-1	15096374
int@@	O	-1	15096374
ment.	O	-1	15096374
BACKGROUND:	O	-1	15096374
T@@	B-Chemical	D016559	15096374
ac@@	I-Chemical	-1	15096374
rolimus	I-Chemical	-1	15096374
o@@	O	-1	15096374
int@@	O	-1	15096374
ment	O	-1	15096374
is	O	-1	15096374
increas@@	O	-1	15096374
ing@@	O	-1	15096374
ly	O	-1	15096374
used	O	-1	15096374
for	O	-1	15096374
anti@@	O	-1	15096374
-@@	O	-1	15096374
inflam@@	O	-1	15096374
mat@@	O	-1	15096374
ory	O	-1	15096374
treatment	O	-1	15096374
of	O	-1	15096374
sensitive	O	-1	15096374
a@@	O	-1	15096374
reas	O	-1	15096374
such	O	-1	15096374
as	O	-1	15096374
the	O	-1	15096374
fac@@	O	-1	15096374
e,	O	-1	15096374
and	O	-1	15096374
rec@@	O	-1	15096374
ent	O	-1	15096374
observ@@	O	-1	15096374
ations	O	-1	15096374
indicate	O	-1	15096374
that	O	-1	15096374
the	O	-1	15096374
treatment	O	-1	15096374
is	O	-1	15096374
effective	O	-1	15096374
in	O	-1	15096374
ster@@	B-Chemical	D013256	15096374
oid	I-Chemical	-1	15096374
-@@	O	-1	15096374
ag@@	O	-1	15096374
gra@@	O	-1	15096374
v@@	O	-1	15096374
ated	O	-1	15096374
ros@@	B-Disease	D012393	15096374
ace@@	I-Disease	-1	15096374
a	I-Disease	-1	15096374
and	O	-1	15096374
peri@@	B-Disease	D019557	15096374
oral	I-Disease	-1	15096374
der@@	I-Disease	-1	15096374
m@@	I-Disease	-1	15096374
ati@@	I-Disease	-1	15096374
tis	I-Disease	-1	15096374
.	O	-1	15096374
We	O	-1	15096374
report	O	-1	15096374
on	O	-1	15096374
ros@@	O	-1	15096374
ace@@	O	-1	15096374
if@@	O	-1	15096374
or@@	O	-1	15096374
m	O	-1	15096374
der@@	B-Disease	D003872	15096374
m@@	I-Disease	-1	15096374
ati@@	I-Disease	-1	15096374
tis	I-Disease	-1	15096374
as	O	-1	15096374
a	O	-1	15096374
complication	O	-1	15096374
of	O	-1	15096374
treatment	O	-1	15096374
with	O	-1	15096374
tacrolimus	B-Chemical	D016559	15096374
o@@	O	-1	15096374
int@@	O	-1	15096374
ment.	O	-1	15096374
OB@@	O	-1	15096374
S@@	O	-1	15096374
E@@	O	-1	15096374
R@@	O	-1	15096374
V@@	O	-1	15096374
AT@@	O	-1	15096374
ION@@	O	-1	15096374
S:	O	-1	15096374
Si@@	O	-1	15096374
x	O	-1	15096374
ad@@	O	-1	15096374
ult	O	-1	15096374
patients	O	-1	15096374
with	O	-1	15096374
inflam@@	B-Disease	D005148	15096374
mat@@	I-Disease	-1	15096374
ory	I-Disease	-1	15096374
fac@@	I-Disease	-1	15096374
ial	I-Disease	-1	15096374
der@@	I-Disease	-1	15096374
mat@@	I-Disease	-1	15096374
o@@	I-Disease	-1	15096374
ses	I-Disease	-1	15096374
were	O	-1	15096374
treated	O	-1	15096374
with	O	-1	15096374
tacrolimus	B-Chemical	D016559	15096374
o@@	O	-1	15096374
int@@	O	-1	15096374
ment	O	-1	15096374
because	O	-1	15096374
of	O	-1	15096374
the	O	-1	15096374
ine@@	O	-1	15096374
ff@@	O	-1	15096374
ec@@	O	-1	15096374
tiv@@	O	-1	15096374
en@@	O	-1	15096374
ess	O	-1	15096374
of	O	-1	15096374
standard	O	-1	15096374
treatment@@	O	-1	15096374
s.	O	-1	15096374
W@@	O	-1	15096374
i@@	O	-1	15096374
th@@	O	-1	15096374
in	O	-1	15096374
2	O	-1	15096374
to	O	-1	15096374
3	O	-1	15096374
weeks	O	-1	15096374
of	O	-1	15096374
initi@@	O	-1	15096374
ally	O	-1	15096374
effective	O	-1	15096374
and	O	-1	15096374
we@@	O	-1	15096374
ll@@	O	-1	15096374
-@@	O	-1	15096374
toler@@	O	-1	15096374
ated	O	-1	15096374
treatment,	O	-1	15096374
3	O	-1	15096374
patients	O	-1	15096374
with	O	-1	15096374
a	O	-1	15096374
hist@@	O	-1	15096374
ory	O	-1	15096374
of	O	-1	15096374
ros@@	B-Disease	D012393	15096374
ace@@	I-Disease	-1	15096374
a	I-Disease	-1	15096374
and	O	-1	15096374
1	O	-1	15096374
with	O	-1	15096374
a	O	-1	15096374
hist@@	O	-1	15096374
ory	O	-1	15096374
of	O	-1	15096374
ac@@	B-Disease	D000152	15096374
n@@	I-Disease	-1	15096374
e	I-Disease	-1	15096374
experienced	O	-1	15096374
su@@	O	-1	15096374
d@@	O	-1	15096374
de@@	O	-1	15096374
n	O	-1	15096374
wor@@	O	-1	15096374
sen@@	O	-1	15096374
ing	O	-1	15096374
with	O	-1	15096374
p@@	O	-1	15096374
ust@@	O	-1	15096374
ular	O	-1	15096374
ros@@	O	-1	15096374
ace@@	O	-1	15096374
if@@	O	-1	15096374
or@@	O	-1	15096374
m	O	-1	15096374
le@@	O	-1	15096374
sion@@	O	-1	15096374
s.	O	-1	15096374
B@@	O	-1	15096374
io@@	O	-1	15096374
p@@	O	-1	15096374
sy	O	-1	15096374
revealed	O	-1	15096374
an	O	-1	15096374
ab@@	O	-1	15096374
und@@	O	-1	15096374
ance	O	-1	15096374
of	O	-1	15096374
D@@	O	-1	15096374
em@@	O	-1	15096374
o@@	O	-1	15096374
de@@	O	-1	15096374
x	O	-1	15096374
mit@@	O	-1	15096374
es	O	-1	15096374
in	O	-1	15096374
2	O	-1	15096374
of	O	-1	15096374
these	O	-1	15096374
patients.	O	-1	15096374
In	O	-1	15096374
1	O	-1	15096374
patient	O	-1	15096374
with	O	-1	15096374
e@@	O	-1	15096374
ye@@	O	-1	15096374
li@@	O	-1	15096374
d	O	-1	15096374
ec@@	B-Disease	D004485	15096374
z@@	I-Disease	-1	15096374
em@@	I-Disease	-1	15096374
a	I-Disease	-1	15096374
,	O	-1	15096374
ros@@	O	-1	15096374
ace@@	O	-1	15096374
if@@	O	-1	15096374
or@@	O	-1	15096374
m	O	-1	15096374
peri@@	B-Disease	D019557	15096374
oc@@	I-Disease	-1	15096374
ular	I-Disease	-1	15096374
der@@	I-Disease	-1	15096374
m@@	I-Disease	-1	15096374
ati@@	I-Disease	-1	15096374
tis	I-Disease	-1	15096374
gra@@	O	-1	15096374
du@@	O	-1	15096374
ally	O	-1	15096374
appe@@	O	-1	15096374
a@@	O	-1	15096374
red	O	-1	15096374
after	O	-1	15096374
3	O	-1	15096374
weeks	O	-1	15096374
of	O	-1	15096374
treatment.	O	-1	15096374
In	O	-1	15096374
1	O	-1	15096374
patient	O	-1	15096374
with	O	-1	15096374
at@@	B-Disease	D003876	15096374
op@@	I-Disease	-1	15096374
ic	I-Disease	-1	15096374
der@@	I-Disease	-1	15096374
m@@	I-Disease	-1	15096374
ati@@	I-Disease	-1	15096374
tis	I-Disease	-1	15096374
,	O	-1	15096374
te@@	O	-1	15096374
l@@	O	-1	15096374
angi@@	O	-1	15096374
ect@@	O	-1	15096374
atic	O	-1	15096374
and	O	-1	15096374
pap@@	B-Disease	D012393	15096374
ular	I-Disease	-1	15096374
ros@@	I-Disease	-1	15096374
ace@@	I-Disease	-1	15096374
a	I-Disease	-1	15096374
in@@	O	-1	15096374
si@@	O	-1	15096374
di@@	O	-1	15096374
ously	O	-1	15096374
appe@@	O	-1	15096374
a@@	O	-1	15096374
red	O	-1	15096374
after	O	-1	15096374
5	O	-1	15096374
months	O	-1	15096374
of	O	-1	15096374
treatment.	O	-1	15096374
CONCLUSIONS:	O	-1	15096374
Our	O	-1	15096374
observ@@	O	-1	15096374
ations	O	-1	15096374
suggest	O	-1	15096374
that	O	-1	15096374
the	O	-1	15096374
sp@@	O	-1	15096374
ect@@	O	-1	15096374
ru@@	O	-1	15096374
m	O	-1	15096374
of	O	-1	15096374
ros@@	O	-1	15096374
ace@@	O	-1	15096374
if@@	O	-1	15096374
or@@	O	-1	15096374
m	O	-1	15096374
der@@	B-Disease	D003872	15096374
m@@	I-Disease	-1	15096374
ati@@	I-Disease	-1	15096374
tis	I-Disease	-1	15096374
as	O	-1	15096374
a	O	-1	15096374
complication	O	-1	15096374
of	O	-1	15096374
treatment	O	-1	15096374
with	O	-1	15096374
tacrolimus	B-Chemical	D016559	15096374
o@@	O	-1	15096374
int@@	O	-1	15096374
ment	O	-1	15096374
is	O	-1	15096374
he@@	O	-1	15096374
ter@@	O	-1	15096374
o@@	O	-1	15096374
gene@@	O	-1	15096374
ou@@	O	-1	15096374
s.	O	-1	15096374
A	O	-1	15096374
vari@@	O	-1	15096374
ety	O	-1	15096374
of	O	-1	15096374
fact@@	O	-1	15096374
or@@	O	-1	15096374
s,	O	-1	15096374
such	O	-1	15096374
as	O	-1	15096374
vas@@	O	-1	15096374
o@@	O	-1	15096374
active	O	-1	15096374
pro@@	O	-1	15096374
per@@	O	-1	15096374
ties	O	-1	15096374
of	O	-1	15096374
tacrolimus	B-Chemical	D016559	15096374
,	O	-1	15096374
pro@@	O	-1	15096374
li@@	O	-1	15096374
fer@@	O	-1	15096374
ation	O	-1	15096374
of	O	-1	15096374
D@@	O	-1	15096374
em@@	O	-1	15096374
o@@	O	-1	15096374
de@@	O	-1	15096374
x	O	-1	15096374
due	O	-1	15096374
to	O	-1	15096374
loc@@	O	-1	15096374
al	O	-1	15096374
immunosup@@	O	-1	15096374
pres@@	O	-1	15096374
sion,	O	-1	15096374
and	O	-1	15096374
the	O	-1	15096374
oc@@	O	-1	15096374
cl@@	O	-1	15096374
u@@	O	-1	15096374
sive	O	-1	15096374
pro@@	O	-1	15096374
per@@	O	-1	15096374
ties	O	-1	15096374
of	O	-1	15096374
the	O	-1	15096374
o@@	O	-1	15096374
int@@	O	-1	15096374
ment@@	O	-1	15096374
,	O	-1	15096374
may	O	-1	15096374
be	O	-1	15096374
involved	O	-1	15096374
in	O	-1	15096374
the	O	-1	15096374
observed	O	-1	15096374
phen@@	O	-1	15096374
om@@	O	-1	15096374
en@@	O	-1	15096374
a.	O	-1	15096374
F@@	O	-1	15096374
ut@@	O	-1	15096374
ure	O	-1	15096374
studies	O	-1	15096374
are	O	-1	15096374
ne@@	O	-1	15096374
ed@@	O	-1	15096374
ed	O	-1	15096374
to	O	-1	15096374
identi@@	O	-1	15096374
f@@	O	-1	15096374
y	O	-1	15096374
individ@@	O	-1	15096374
ual	O	-1	15096374
risk	O	-1	15096374
fact@@	O	-1	15096374
or@@	O	-1	15096374
s.	O	-1	15096374

S@@	O	-1	15229250
tr@@	O	-1	15229250
uc@@	O	-1	15229250
t@@	O	-1	15229250
ural	O	-1	15229250
abnormal@@	O	-1	15229250
ities	O	-1	15229250
in	O	-1	15229250
the	O	-1	15229250
bra@@	O	-1	15229250
ins	O	-1	15229250
of	O	-1	15229250
human	O	-1	15229250
subjects	O	-1	15229250
who	O	-1	15229250
use	O	-1	15229250
meth@@	B-Chemical	D008694	15229250
amphetamine	I-Chemical	-1	15229250
.	O	-1	15229250
We	O	-1	15229250
vi@@	O	-1	15229250
su@@	O	-1	15229250
al@@	O	-1	15229250
iz@@	O	-1	15229250
e,	O	-1	15229250
for	O	-1	15229250
the	O	-1	15229250
first	O	-1	15229250
ti@@	O	-1	15229250
me,	O	-1	15229250
the	O	-1	15229250
prof@@	O	-1	15229250
ile	O	-1	15229250
of	O	-1	15229250
struct@@	B-Disease	D001930	15229250
ural	I-Disease	-1	15229250
defic@@	I-Disease	-1	15229250
its	I-Disease	-1	15229250
in	I-Disease	-1	15229250
the	I-Disease	-1	15229250
human	I-Disease	-1	15229250
brain	I-Disease	-1	15229250
associated	O	-1	15229250
with	O	-1	15229250
chronic	O	-1	15229250
meth@@	B-Chemical	D008694	15229250
amphetamine	I-Chemical	-1	15229250
(	O	-1	15229250
M@@	B-Chemical	D008694	15229250
A	I-Chemical	-1	15229250
)	O	-1	15229250
ab@@	O	-1	15229250
use.	O	-1	15229250
S@@	O	-1	15229250
t@@	O	-1	15229250
udi@@	O	-1	15229250
es	O	-1	15229250
of	O	-1	15229250
human	O	-1	15229250
subjects	O	-1	15229250
who	O	-1	15229250
have	O	-1	15229250
used	O	-1	15229250
M@@	B-Chemical	D008694	15229250
A	I-Chemical	-1	15229250
chron@@	O	-1	15229250
ically	O	-1	15229250
have	O	-1	15229250
revealed	O	-1	15229250
defic@@	O	-1	15229250
its	O	-1	15229250
in	O	-1	15229250
dop@@	O	-1	15229250
aminergic	O	-1	15229250
and	O	-1	15229250
seroton@@	O	-1	15229250
ergic	O	-1	15229250
system@@	O	-1	15229250
s	O	-1	15229250
and	O	-1	15229250
cerebral	O	-1	15229250
met@@	B-Disease	D008659	15229250
ab@@	I-Disease	-1	15229250
olic	I-Disease	-1	15229250
abnormal@@	I-Disease	-1	15229250
ities	I-Disease	-1	15229250
.	O	-1	15229250
U@@	O	-1	15229250
s@@	O	-1	15229250
ing	O	-1	15229250
mag@@	O	-1	15229250
ne@@	O	-1	15229250
tic	O	-1	15229250
res@@	O	-1	15229250
on@@	O	-1	15229250
ance	O	-1	15229250
imaging	O	-1	15229250
(@@	O	-1	15229250
MR@@	O	-1	15229250
I@@	O	-1	15229250
)	O	-1	15229250
and	O	-1	15229250
new	O	-1	15229250
comp@@	O	-1	15229250
ut@@	O	-1	15229250
ation@@	O	-1	15229250
al	O	-1	15229250
bra@@	O	-1	15229250
in-@@	O	-1	15229250
m@@	O	-1	15229250
app@@	O	-1	15229250
ing	O	-1	15229250
t@@	O	-1	15229250
ech@@	O	-1	15229250
n@@	O	-1	15229250
i@@	O	-1	15229250
qu@@	O	-1	15229250
es,	O	-1	15229250
we	O	-1	15229250
determined	O	-1	15229250
the	O	-1	15229250
pat@@	O	-1	15229250
ter@@	O	-1	15229250
n	O	-1	15229250
of	O	-1	15229250
struct@@	O	-1	15229250
ural	O	-1	15229250
brain	O	-1	15229250
al@@	O	-1	15229250
ter@@	O	-1	15229250
ations	O	-1	15229250
associated	O	-1	15229250
with	O	-1	15229250
chronic	O	-1	15229250
M@@	B-Chemical	D008694	15229250
A	I-Chemical	-1	15229250
ab@@	O	-1	15229250
use	O	-1	15229250
in	O	-1	15229250
human	O	-1	15229250
subjects	O	-1	15229250
and	O	-1	15229250
related	O	-1	15229250
these	O	-1	15229250
defic@@	O	-1	15229250
its	O	-1	15229250
to	O	-1	15229250
cognitive	B-Disease	D003072	15229250
impair@@	I-Disease	-1	15229250
ment	I-Disease	-1	15229250
.	O	-1	15229250
We	O	-1	15229250
used	O	-1	15229250
high-@@	O	-1	15229250
resol@@	O	-1	15229250
u@@	O	-1	15229250
tion	O	-1	15229250
MR@@	O	-1	15229250
I	O	-1	15229250
and	O	-1	15229250
sur@@	O	-1	15229250
fac@@	O	-1	15229250
e-@@	O	-1	15229250
bas@@	O	-1	15229250
ed	O	-1	15229250
comp@@	O	-1	15229250
ut@@	O	-1	15229250
ation@@	O	-1	15229250
al	O	-1	15229250
im@@	O	-1	15229250
age	O	-1	15229250
analy@@	O	-1	15229250
ses	O	-1	15229250
to	O	-1	15229250
ma@@	O	-1	15229250
p	O	-1	15229250
regi@@	O	-1	15229250
on@@	O	-1	15229250
al	O	-1	15229250
abnormal@@	B-Disease	D001930	15229250
ities	I-Disease	-1	15229250
in	I-Disease	-1	15229250
the	I-Disease	-1	15229250
cor@@	I-Disease	-1	15229250
t@@	I-Disease	-1	15229250
ex@@	I-Disease	-1	15229250
,	I-Disease	-1	15229250
hippocamp@@	I-Disease	-1	15229250
us,	I-Disease	-1	15229250
wh@@	I-Disease	-1	15229250
ite	I-Disease	-1	15229250
mat@@	I-Disease	-1	15229250
ter@@	I-Disease	-1	15229250
,	I-Disease	-1	15229250
and	I-Disease	-1	15229250
ventric@@	I-Disease	-1	15229250
le@@	I-Disease	-1	15229250
s	I-Disease	-1	15229250
in	O	-1	15229250
2@@	O	-1	15229250
2	O	-1	15229250
human	O	-1	15229250
subjects	O	-1	15229250
who	O	-1	15229250
used	O	-1	15229250
M@@	B-Chemical	D008694	15229250
A	I-Chemical	-1	15229250
and	O	-1	15229250
21	O	-1	15229250
ag@@	O	-1	15229250
e-@@	O	-1	15229250
mat@@	O	-1	15229250
ch@@	O	-1	15229250
ed,	O	-1	15229250
healthy	O	-1	15229250
controls.	O	-1	15229250
C@@	O	-1	15229250
or@@	O	-1	15229250
tical	O	-1	15229250
m@@	O	-1	15229250
ap@@	O	-1	15229250
s	O	-1	15229250
revealed	O	-1	15229250
severe	O	-1	15229250
gra@@	O	-1	15229250
y-@@	O	-1	15229250
mat@@	O	-1	15229250
ter	O	-1	15229250
defic@@	O	-1	15229250
its	O	-1	15229250
in	O	-1	15229250
the	O	-1	15229250
c@@	O	-1	15229250
ing@@	O	-1	15229250
ul@@	O	-1	15229250
ate,	O	-1	15229250
lim@@	O	-1	15229250
b@@	O	-1	15229250
ic@@	O	-1	15229250
,	O	-1	15229250
and	O	-1	15229250
par@@	O	-1	15229250
al@@	O	-1	15229250
im@@	O	-1	15229250
b@@	O	-1	15229250
ic	O	-1	15229250
cor@@	O	-1	15229250
tic@@	O	-1	15229250
es	O	-1	15229250
of	O	-1	15229250
M@@	B-Chemical	D008694	15229250
A	I-Chemical	-1	15229250
ab@@	O	-1	15229250
users	O	-1	15229250
(@@	O	-1	15229250
aver@@	O	-1	15229250
ag@@	O	-1	15229250
ing	O	-1	15229250
1@@	O	-1	15229250
1.@@	O	-1	15229250
3@@	O	-1	15229250
%	O	-1	15229250
be@@	O	-1	15229250
low	O	-1	15229250
control@@	O	-1	15229250
;	O	-1	15229250
p	O	-1	15229250
<	O	-1	15229250
0.05@@	O	-1	15229250
).	O	-1	15229250
O@@	O	-1	15229250
n	O	-1	15229250
aver@@	O	-1	15229250
age,	O	-1	15229250
M@@	B-Chemical	D008694	15229250
A	I-Chemical	-1	15229250
ab@@	O	-1	15229250
users	O	-1	15229250
had	O	-1	15229250
7.@@	O	-1	15229250
8@@	O	-1	15229250
%	O	-1	15229250
sm@@	O	-1	15229250
all@@	O	-1	15229250
er	O	-1	15229250
hippocamp@@	O	-1	15229250
al	O	-1	15229250
volum@@	O	-1	15229250
es	O	-1	15229250
than	O	-1	15229250
control	O	-1	15229250
subjects	O	-1	15229250
(p	O	-1	15229250
<	O	-1	15229250
0.0@@	O	-1	15229250
1@@	O	-1	15229250
;	O	-1	15229250
le@@	O	-1	15229250
f@@	O	-1	15229250
t,	O	-1	15229250
p	O	-1	15229250
=	O	-1	15229250
0.0@@	O	-1	15229250
1@@	O	-1	15229250
;	O	-1	15229250
ri@@	O	-1	15229250
gh@@	O	-1	15229250
t,	O	-1	15229250
p	O	-1	15229250
<	O	-1	15229250
0.05@@	O	-1	15229250
)	O	-1	15229250
and	O	-1	15229250
significant	O	-1	15229250
wh@@	O	-1	15229250
it@@	O	-1	15229250
e-@@	O	-1	15229250
mat@@	O	-1	15229250
ter	O	-1	15229250
hyper@@	B-Disease	D006984	15229250
tro@@	I-Disease	-1	15229250
ph@@	I-Disease	-1	15229250
y	I-Disease	-1	15229250
(@@	O	-1	15229250
7.@@	O	-1	15229250
0@@	O	-1	15229250
%@@	O	-1	15229250
;	O	-1	15229250
p	O	-1	15229250
<	O	-1	15229250
0.0@@	O	-1	15229250
1).	O	-1	15229250
H@@	O	-1	15229250
ip@@	O	-1	15229250
p@@	O	-1	15229250
ocamp@@	O	-1	15229250
al	O	-1	15229250
defic@@	O	-1	15229250
its	O	-1	15229250
were	O	-1	15229250
m@@	O	-1	15229250
app@@	O	-1	15229250
ed	O	-1	15229250
and	O	-1	15229250
cor@@	O	-1	15229250
related	O	-1	15229250
with	O	-1	15229250
memory	O	-1	15229250
perform@@	O	-1	15229250
ance	O	-1	15229250
on	O	-1	15229250
a	O	-1	15229250
wor@@	O	-1	15229250
d-@@	O	-1	15229250
rec@@	O	-1	15229250
all	O	-1	15229250
test	O	-1	15229250
(p	O	-1	15229250
<	O	-1	15229250
0.05@@	O	-1	15229250
).	O	-1	15229250
MR@@	O	-1	15229250
I@@	O	-1	15229250
-@@	O	-1	15229250
bas@@	O	-1	15229250
ed	O	-1	15229250
m@@	O	-1	15229250
ap@@	O	-1	15229250
s	O	-1	15229250
suggest	O	-1	15229250
that	O	-1	15229250
chronic	O	-1	15229250
meth@@	B-Chemical	D008694	15229250
amphetamine	I-Chemical	-1	15229250
ab@@	O	-1	15229250
use	O	-1	15229250
causes	O	-1	15229250
a	O	-1	15229250
selective	O	-1	15229250
pat@@	O	-1	15229250
ter@@	O	-1	15229250
n	O	-1	15229250
of	O	-1	15229250
cerebral	O	-1	15229250
deter@@	O	-1	15229250
i@@	O	-1	15229250
or@@	O	-1	15229250
ation	O	-1	15229250
that	O	-1	15229250
cont@@	O	-1	15229250
ri@@	O	-1	15229250
but@@	O	-1	15229250
es	O	-1	15229250
to	O	-1	15229250
impaired	B-Disease	D008569	15229250
memory	I-Disease	-1	15229250
perform@@	I-Disease	-1	15229250
ance	I-Disease	-1	15229250
.	O	-1	15229250
M@@	B-Chemical	D008694	15229250
A	I-Chemical	-1	15229250
may	O	-1	15229250
sel@@	O	-1	15229250
ectively	O	-1	15229250
damage	O	-1	15229250
the	O	-1	15229250
medi@@	O	-1	15229250
al	O	-1	15229250
tempor@@	O	-1	15229250
al	O	-1	15229250
lo@@	O	-1	15229250
be	O	-1	15229250
and@@	O	-1	15229250
,	O	-1	15229250
consist@@	O	-1	15229250
ent	O	-1	15229250
with	O	-1	15229250
met@@	O	-1	15229250
ab@@	O	-1	15229250
olic	O	-1	15229250
studi@@	O	-1	15229250
es,	O	-1	15229250
the	O	-1	15229250
c@@	O	-1	15229250
ing@@	O	-1	15229250
ul@@	O	-1	15229250
at@@	O	-1	15229250
e-@@	O	-1	15229250
lim@@	O	-1	15229250
b@@	O	-1	15229250
ic	O	-1	15229250
cor@@	O	-1	15229250
t@@	O	-1	15229250
ex@@	O	-1	15229250
,	O	-1	15229250
induc@@	O	-1	15229250
ing	O	-1	15229250
neuro@@	O	-1	15229250
ad@@	O	-1	15229250
ap@@	O	-1	15229250
t@@	O	-1	15229250
ation,	O	-1	15229250
neuro@@	O	-1	15229250
pi@@	O	-1	15229250
l	O	-1	15229250
reduc@@	O	-1	15229250
tion,	O	-1	15229250
or	O	-1	15229250
cell	O	-1	15229250
de@@	O	-1	15229250
ath@@	O	-1	15229250
.	O	-1	15229250
Pro@@	O	-1	15229250
min@@	O	-1	15229250
ent	O	-1	15229250
wh@@	O	-1	15229250
it@@	O	-1	15229250
e-@@	O	-1	15229250
mat@@	O	-1	15229250
ter	O	-1	15229250
hyper@@	B-Disease	D006984	15229250
tro@@	I-Disease	-1	15229250
ph@@	I-Disease	-1	15229250
y	I-Disease	-1	15229250
may	O	-1	15229250
result	O	-1	15229250
from	O	-1	15229250
al@@	O	-1	15229250
te@@	O	-1	15229250
red	O	-1	15229250
my@@	O	-1	15229250
el@@	O	-1	15229250
in@@	O	-1	15229250
ation	O	-1	15229250
and	O	-1	15229250
ad@@	O	-1	15229250
ap@@	O	-1	15229250
tive	O	-1	15229250
g@@	O	-1	15229250
lial	O	-1	15229250
chang@@	O	-1	15229250
es,	O	-1	15229250
including	O	-1	15229250
g@@	B-Disease	D005911	15229250
li@@	I-Disease	-1	15229250
o@@	I-Disease	-1	15229250
sis	I-Disease	-1	15229250
secondary	O	-1	15229250
to	O	-1	15229250
neuron@@	B-Disease	D009422	15229250
al	I-Disease	-1	15229250
damage	I-Disease	-1	15229250
.	O	-1	15229250
These	O	-1	15229250
brain	O	-1	15229250
sub@@	O	-1	15229250
strat@@	O	-1	15229250
es	O	-1	15229250
may	O	-1	15229250
he@@	O	-1	15229250
l@@	O	-1	15229250
p	O	-1	15229250
ac@@	O	-1	15229250
coun@@	O	-1	15229250
t	O	-1	15229250
for	O	-1	15229250
the	O	-1	15229250
symptoms	O	-1	15229250
of	O	-1	15229250
M@@	B-Chemical	D008694	15229250
A	I-Chemical	-1	15229250
ab@@	O	-1	15229250
use@@	O	-1	15229250
,	O	-1	15229250
pro@@	O	-1	15229250
vid@@	O	-1	15229250
ing	O	-1	15229250
therapeutic	O	-1	15229250
t@@	O	-1	15229250
arg@@	O	-1	15229250
et@@	O	-1	15229250
s	O	-1	15229250
for	O	-1	15229250
drug@@	O	-1	15229250
-induced	O	-1	15229250
brain	B-Disease	D001930	15229250
injury	I-Disease	-1	15229250
.	O	-1	15229250

D@@	O	-1	15265979
is@@	O	-1	15265979
ru@@	O	-1	15265979
ption	O	-1	15265979
of	O	-1	15265979
hepatic	O	-1	15265979
li@@	O	-1	15265979
pid	O	-1	15265979
ho@@	O	-1	15265979
me@@	O	-1	15265979
ost@@	O	-1	15265979
asis	O	-1	15265979
in	O	-1	15265979
mice	O	-1	15265979
after	O	-1	15265979
am@@	B-Chemical	D000638	15265979
iodar@@	I-Chemical	-1	15265979
one	I-Chemical	-1	15265979
treatment	O	-1	15265979
is	O	-1	15265979
associated	O	-1	15265979
with	O	-1	15265979
per@@	O	-1	15265979
ox@@	O	-1	15265979
is@@	O	-1	15265979
ome	O	-1	15265979
pro@@	O	-1	15265979
li@@	O	-1	15265979
fer@@	O	-1	15265979
at@@	O	-1	15265979
or@@	O	-1	15265979
-@@	O	-1	15265979
activ@@	O	-1	15265979
ated	O	-1	15265979
receptor@@	O	-1	15265979
-@@	O	-1	15265979
al@@	O	-1	15265979
ph@@	O	-1	15265979
a	O	-1	15265979
t@@	O	-1	15265979
arg@@	O	-1	15265979
et	O	-1	15265979
gen@@	O	-1	15265979
e	O	-1	15265979
activ@@	O	-1	15265979
ation.	O	-1	15265979
A@@	B-Chemical	D000638	15265979
m@@	I-Chemical	-1	15265979
iodar@@	I-Chemical	-1	15265979
one	I-Chemical	-1	15265979
,	O	-1	15265979
an	O	-1	15265979
efficac@@	O	-1	15265979
i@@	O	-1	15265979
ous	O	-1	15265979
and	O	-1	15265979
wi@@	O	-1	15265979
de@@	O	-1	15265979
ly	O	-1	15265979
used	O	-1	15265979
anti@@	O	-1	15265979
arrhyth@@	O	-1	15265979
mic	O	-1	15265979
agent@@	O	-1	15265979
,	O	-1	15265979
has	O	-1	15265979
been	O	-1	15265979
reported	O	-1	15265979
to	O	-1	15265979
cause	O	-1	15265979
hepat@@	B-Disease	D056486	15265979
otoxicity	I-Disease	-1	15265979
in	O	-1	15265979
some	O	-1	15265979
patients.	O	-1	15265979
To	O	-1	15265979
g@@	O	-1	15265979
ain	O	-1	15265979
in@@	O	-1	15265979
si@@	O	-1	15265979
ght	O	-1	15265979
into	O	-1	15265979
the	O	-1	15265979
mechanism	O	-1	15265979
of	O	-1	15265979
this	O	-1	15265979
un@@	O	-1	15265979
w@@	O	-1	15265979
ant@@	O	-1	15265979
ed	O	-1	15265979
effect@@	O	-1	15265979
,	O	-1	15265979
mice	O	-1	15265979
were	O	-1	15265979
administered	O	-1	15265979
various	O	-1	15265979
doses	O	-1	15265979
of	O	-1	15265979
am@@	B-Chemical	D000638	15265979
iodar@@	I-Chemical	-1	15265979
one	I-Chemical	-1	15265979
and	O	-1	15265979
examined	O	-1	15265979
for	O	-1	15265979
changes	O	-1	15265979
in	O	-1	15265979
hepatic	O	-1	15265979
hist@@	O	-1	15265979
ology	O	-1	15265979
and	O	-1	15265979
gen@@	O	-1	15265979
e	O	-1	15265979
reg@@	O	-1	15265979
ul@@	O	-1	15265979
ation.	O	-1	15265979
A@@	B-Chemical	D000638	15265979
m@@	I-Chemical	-1	15265979
iodar@@	I-Chemical	-1	15265979
one	I-Chemical	-1	15265979
induced	O	-1	15265979
hepat@@	B-Disease	D006529	15265979
o@@	I-Disease	-1	15265979
me@@	I-Disease	-1	15265979
g@@	I-Disease	-1	15265979
al@@	I-Disease	-1	15265979
y	I-Disease	-1	15265979
,	O	-1	15265979
hepat@@	O	-1	15265979
ocyte	O	-1	15265979
micro@@	O	-1	15265979
ve@@	O	-1	15265979
si@@	O	-1	15265979
cular	O	-1	15265979
li@@	O	-1	15265979
pid	O	-1	15265979
accum@@	O	-1	15265979
ul@@	O	-1	15265979
ation,	O	-1	15265979
and	O	-1	15265979
a	O	-1	15265979
significant	O	-1	15265979
decrease	O	-1	15265979
in	O	-1	15265979
serum	O	-1	15265979
tri@@	B-Chemical	D014280	15265979
glycer@@	I-Chemical	-1	15265979
i@@	I-Chemical	-1	15265979
des	I-Chemical	-1	15265979
and	O	-1	15265979
g@@	B-Chemical	D005947	15265979
lu@@	I-Chemical	-1	15265979
co@@	I-Chemical	-1	15265979
se	I-Chemical	-1	15265979
.	O	-1	15265979
N@@	O	-1	15265979
or@@	O	-1	15265979
ther@@	O	-1	15265979
n	O	-1	15265979
blo@@	O	-1	15265979
t	O	-1	15265979
analysis	O	-1	15265979
of	O	-1	15265979
hepatic	O	-1	15265979
R@@	O	-1	15265979
NA	O	-1	15265979
revealed	O	-1	15265979
a	O	-1	15265979
dose-@@	O	-1	15265979
dependent	O	-1	15265979
increase	O	-1	15265979
in	O	-1	15265979
the	O	-1	15265979
expression	O	-1	15265979
of	O	-1	15265979
a	O	-1	15265979
number	O	-1	15265979
of	O	-1	15265979
gen@@	O	-1	15265979
es	O	-1	15265979
cri@@	O	-1	15265979
tical	O	-1	15265979
for	O	-1	15265979
f@@	B-Chemical	D005227	15265979
at@@	I-Chemical	-1	15265979
t@@	I-Chemical	-1	15265979
y	I-Chemical	-1	15265979
acid	I-Chemical	-1	15265979
oxid@@	O	-1	15265979
ation,	O	-1	15265979
li@@	O	-1	15265979
po@@	O	-1	15265979
protein	O	-1	15265979
as@@	O	-1	15265979
se@@	O	-1	15265979
m@@	O	-1	15265979
bl@@	O	-1	15265979
y,	O	-1	15265979
and	O	-1	15265979
li@@	O	-1	15265979
pid	O	-1	15265979
trans@@	O	-1	15265979
port@@	O	-1	15265979
.	O	-1	15265979
M@@	O	-1	15265979
any	O	-1	15265979
of	O	-1	15265979
these	O	-1	15265979
gen@@	O	-1	15265979
es	O	-1	15265979
are	O	-1	15265979
reg@@	O	-1	15265979
ul@@	O	-1	15265979
ated	O	-1	15265979
by	O	-1	15265979
the	O	-1	15265979
per@@	O	-1	15265979
ox@@	O	-1	15265979
is@@	O	-1	15265979
ome	O	-1	15265979
pro@@	O	-1	15265979
li@@	O	-1	15265979
fer@@	O	-1	15265979
at@@	O	-1	15265979
or@@	O	-1	15265979
-@@	O	-1	15265979
activ@@	O	-1	15265979
ated	O	-1	15265979
receptor@@	O	-1	15265979
-@@	O	-1	15265979
al@@	O	-1	15265979
ph@@	O	-1	15265979
a	O	-1	15265979
(P@@	O	-1	15265979
PA@@	O	-1	15265979
R@@	O	-1	15265979
alpha@@	O	-1	15265979
),	O	-1	15265979
a	O	-1	15265979
li@@	O	-1	15265979
g@@	O	-1	15265979
and@@	O	-1	15265979
-@@	O	-1	15265979
activ@@	O	-1	15265979
ated	O	-1	15265979
nucle@@	O	-1	15265979
ar	O	-1	15265979
h@@	O	-1	15265979
orm@@	O	-1	15265979
one	O	-1	15265979
receptor	O	-1	15265979
trans@@	O	-1	15265979
cri@@	O	-1	15265979
ption	O	-1	15265979
fact@@	O	-1	15265979
or@@	O	-1	15265979
.	O	-1	15265979
The	O	-1	15265979
absence	O	-1	15265979
of	O	-1	15265979
induction	O	-1	15265979
of	O	-1	15265979
these	O	-1	15265979
gen@@	O	-1	15265979
es	O	-1	15265979
as	O	-1	15265979
well	O	-1	15265979
as	O	-1	15265979
hepat@@	B-Disease	D006529	15265979
o@@	I-Disease	-1	15265979
me@@	I-Disease	-1	15265979
g@@	I-Disease	-1	15265979
al@@	I-Disease	-1	15265979
y	I-Disease	-1	15265979
in	O	-1	15265979
P@@	O	-1	15265979
PA@@	O	-1	15265979
R@@	O	-1	15265979
al@@	O	-1	15265979
ph@@	O	-1	15265979
a	O	-1	15265979
k@@	O	-1	15265979
n@@	O	-1	15265979
oc@@	O	-1	15265979
k@@	O	-1	15265979
out	O	-1	15265979
[@@	O	-1	15265979
P@@	O	-1	15265979
PA@@	O	-1	15265979
R@@	O	-1	15265979
alpha-@@	O	-1	15265979
/@@	O	-1	15265979
-@@	O	-1	15265979
]	O	-1	15265979
mice	O	-1	15265979
indic@@	O	-1	15265979
ated	O	-1	15265979
that	O	-1	15265979
the	O	-1	15265979
effects	O	-1	15265979
of	O	-1	15265979
am@@	B-Chemical	D000638	15265979
iodar@@	I-Chemical	-1	15265979
one	I-Chemical	-1	15265979
were	O	-1	15265979
dependent	O	-1	15265979
up@@	O	-1	15265979
on	O	-1	15265979
the	O	-1	15265979
presence	O	-1	15265979
of	O	-1	15265979
a	O	-1	15265979
functional	O	-1	15265979
P@@	O	-1	15265979
PA@@	O	-1	15265979
R@@	O	-1	15265979
al@@	O	-1	15265979
ph@@	O	-1	15265979
a	O	-1	15265979
gen@@	O	-1	15265979
e.	O	-1	15265979
Com@@	O	-1	15265979
pared	O	-1	15265979
to	O	-1	15265979
wil@@	O	-1	15265979
d-@@	O	-1	15265979
type	O	-1	15265979
mic@@	O	-1	15265979
e,	O	-1	15265979
treatment	O	-1	15265979
of	O	-1	15265979
P@@	O	-1	15265979
PA@@	O	-1	15265979
R@@	O	-1	15265979
alpha-@@	O	-1	15265979
/@@	O	-1	15265979
-	O	-1	15265979
mice	O	-1	15265979
with	O	-1	15265979
am@@	B-Chemical	D000638	15265979
iodar@@	I-Chemical	-1	15265979
one	I-Chemical	-1	15265979
resulted	O	-1	15265979
in	O	-1	15265979
an	O	-1	15265979
increased	O	-1	15265979
rate	O	-1	15265979
and	O	-1	15265979
ext@@	O	-1	15265979
ent	O	-1	15265979
of	O	-1	15265979
total	O	-1	15265979
body	O	-1	15265979
weight	B-Disease	D015431	15265979
loss	I-Disease	-1	15265979
.	O	-1	15265979
The	O	-1	15265979
in@@	O	-1	15265979
ability	O	-1	15265979
of	O	-1	15265979
am@@	B-Chemical	D000638	15265979
iodar@@	I-Chemical	-1	15265979
one	I-Chemical	-1	15265979
to	O	-1	15265979
direc@@	O	-1	15265979
tly	O	-1	15265979
activ@@	O	-1	15265979
ate	O	-1	15265979
either	O	-1	15265979
human	O	-1	15265979
or	O	-1	15265979
mouse	O	-1	15265979
P@@	O	-1	15265979
PA@@	O	-1	15265979
R@@	O	-1	15265979
al@@	O	-1	15265979
ph@@	O	-1	15265979
a	O	-1	15265979
transi@@	O	-1	15265979
ently	O	-1	15265979
ex@@	O	-1	15265979
press@@	O	-1	15265979
ed	O	-1	15265979
in	O	-1	15265979
human	O	-1	15265979
H@@	O	-1	15265979
ep@@	O	-1	15265979
G@@	O	-1	15265979
2	O	-1	15265979
hepat@@	B-Disease	D006528	15265979
oma	I-Disease	-1	15265979
cells	O	-1	15265979
indic@@	O	-1	15265979
ates	O	-1	15265979
that	O	-1	15265979
the	O	-1	15265979
effects	O	-1	15265979
of	O	-1	15265979
am@@	B-Chemical	D000638	15265979
iodar@@	I-Chemical	-1	15265979
one	I-Chemical	-1	15265979
on	O	-1	15265979
the	O	-1	15265979
function	O	-1	15265979
of	O	-1	15265979
this	O	-1	15265979
receptor	O	-1	15265979
were	O	-1	15265979
in@@	O	-1	15265979
direc@@	O	-1	15265979
t.	O	-1	15265979
B@@	O	-1	15265979
as@@	O	-1	15265979
ed	O	-1	15265979
up@@	O	-1	15265979
on	O	-1	15265979
these	O	-1	15265979
result@@	O	-1	15265979
s,	O	-1	15265979
we	O	-1	15265979
concl@@	O	-1	15265979
ude	O	-1	15265979
that	O	-1	15265979
am@@	B-Chemical	D000638	15265979
iodar@@	I-Chemical	-1	15265979
one	I-Chemical	-1	15265979
dis@@	O	-1	15265979
ru@@	O	-1	15265979
pt@@	O	-1	15265979
s	O	-1	15265979
hepatic	O	-1	15265979
li@@	O	-1	15265979
pid	O	-1	15265979
ho@@	O	-1	15265979
me@@	O	-1	15265979
ost@@	O	-1	15265979
asis	O	-1	15265979
and	O	-1	15265979
that	O	-1	15265979
the	O	-1	15265979
increased	O	-1	15265979
expression	O	-1	15265979
of	O	-1	15265979
P@@	O	-1	15265979
PA@@	O	-1	15265979
R@@	O	-1	15265979
al@@	O	-1	15265979
ph@@	O	-1	15265979
a	O	-1	15265979
t@@	O	-1	15265979
arg@@	O	-1	15265979
et	O	-1	15265979
gen@@	O	-1	15265979
es	O	-1	15265979
is	O	-1	15265979
secondary	O	-1	15265979
to	O	-1	15265979
this	O	-1	15265979
toxic	O	-1	15265979
effect@@	O	-1	15265979
.	O	-1	15265979
These	O	-1	15265979
results	O	-1	15265979
prov@@	O	-1	15265979
ide	O	-1	15265979
important	O	-1	15265979
new	O	-1	15265979
mechanis@@	O	-1	15265979
tic	O	-1	15265979
inf@@	O	-1	15265979
orm@@	O	-1	15265979
ation	O	-1	15265979
reg@@	O	-1	15265979
ar@@	O	-1	15265979
ding	O	-1	15265979
the	O	-1	15265979
hepat@@	B-Disease	D056486	15265979
ot@@	I-Disease	-1	15265979
ox@@	I-Disease	-1	15265979
ic	I-Disease	-1	15265979
effects	O	-1	15265979
of	O	-1	15265979
am@@	B-Chemical	D000638	15265979
iodar@@	I-Chemical	-1	15265979
one	I-Chemical	-1	15265979
and	O	-1	15265979
indicate	O	-1	15265979
that	O	-1	15265979
P@@	O	-1	15265979
PA@@	O	-1	15265979
R@@	O	-1	15265979
al@@	O	-1	15265979
ph@@	O	-1	15265979
a	O	-1	15265979
prot@@	O	-1	15265979
ects	O	-1	15265979
against	O	-1	15265979
am@@	B-Chemical	D000638	15265979
iodar@@	I-Chemical	-1	15265979
one	I-Chemical	-1	15265979
-induced	O	-1	15265979
hepat@@	B-Disease	D056486	15265979
otoxicity	I-Disease	-1	15265979
.	O	-1	15265979

S@@	O	-1	15276093
af@@	O	-1	15276093
ety	O	-1	15276093
and	O	-1	15276093
com@@	O	-1	15276093
pl@@	O	-1	15276093
i@@	O	-1	15276093
ance	O	-1	15276093
with	O	-1	15276093
on@@	O	-1	15276093
ce@@	O	-1	15276093
-@@	O	-1	15276093
daily	O	-1	15276093
n@@	B-Chemical	C451780	15276093
i@@	I-Chemical	-1	15276093
ac@@	I-Chemical	-1	15276093
in	I-Chemical	-1	15276093
exten@@	I-Chemical	-1	15276093
de@@	I-Chemical	-1	15276093
d-@@	I-Chemical	-1	15276093
rele@@	I-Chemical	-1	15276093
as@@	I-Chemical	-1	15276093
e@@	I-Chemical	-1	15276093
/@@	I-Chemical	-1	15276093
lo@@	I-Chemical	-1	15276093
vastatin	I-Chemical	-1	15276093
as	O	-1	15276093
initial	O	-1	15276093
therapy	O	-1	15276093
in	O	-1	15276093
the	O	-1	15276093
Im@@	O	-1	15276093
pac@@	O	-1	15276093
t	O	-1	15276093
of	O	-1	15276093
M@@	O	-1	15276093
ed@@	O	-1	15276093
ical	O	-1	15276093
S@@	O	-1	15276093
ub@@	O	-1	15276093
spec@@	O	-1	15276093
i@@	O	-1	15276093
al@@	O	-1	15276093
t@@	O	-1	15276093
y	O	-1	15276093
on	O	-1	15276093
Pati@@	O	-1	15276093
ent	O	-1	15276093
Com@@	O	-1	15276093
pl@@	O	-1	15276093
i@@	O	-1	15276093
ance	O	-1	15276093
to	O	-1	15276093
Treat@@	O	-1	15276093
ment	O	-1	15276093
(@@	O	-1	15276093
I@@	O	-1	15276093
MP@@	O	-1	15276093
AC@@	O	-1	15276093
T)	O	-1	15276093
study.	O	-1	15276093
N@@	B-Chemical	C451780	15276093
i@@	I-Chemical	-1	15276093
ac@@	I-Chemical	-1	15276093
in	I-Chemical	-1	15276093
exten@@	I-Chemical	-1	15276093
de@@	I-Chemical	-1	15276093
d-@@	I-Chemical	-1	15276093
rele@@	I-Chemical	-1	15276093
as@@	I-Chemical	-1	15276093
e@@	I-Chemical	-1	15276093
/@@	I-Chemical	-1	15276093
lo@@	I-Chemical	-1	15276093
vastatin	I-Chemical	-1	15276093
is	O	-1	15276093
a	O	-1	15276093
new	O	-1	15276093
combination	O	-1	15276093
produc@@	O	-1	15276093
t	O	-1	15276093
appro@@	O	-1	15276093
ved	O	-1	15276093
for	O	-1	15276093
treatment	O	-1	15276093
of	O	-1	15276093
prim@@	O	-1	15276093
ary	O	-1	15276093
hyper@@	B-Disease	D006937	15276093
cholester@@	I-Disease	-1	15276093
ol@@	I-Disease	-1	15276093
emia	I-Disease	-1	15276093
and	O	-1	15276093
mi@@	O	-1	15276093
x@@	O	-1	15276093
ed	O	-1	15276093
dys@@	B-Disease	D050171	15276093
li@@	I-Disease	-1	15276093
pi@@	I-Disease	-1	15276093
de@@	I-Disease	-1	15276093
mia	I-Disease	-1	15276093
.	O	-1	15276093
This	O	-1	15276093
o@@	O	-1	15276093
pen@@	O	-1	15276093
-@@	O	-1	15276093
l@@	O	-1	15276093
a@@	O	-1	15276093
be@@	O	-1	15276093
le@@	O	-1	15276093
d,	O	-1	15276093
mul@@	O	-1	15276093
tic@@	O	-1	15276093
ent@@	O	-1	15276093
er	O	-1	15276093
study	O	-1	15276093
evaluated	O	-1	15276093
the	O	-1	15276093
safety	O	-1	15276093
of	O	-1	15276093
be@@	O	-1	15276093
d@@	O	-1	15276093
time	O	-1	15276093
n@@	B-Chemical	C451780	15276093
i@@	I-Chemical	-1	15276093
ac@@	I-Chemical	-1	15276093
in	I-Chemical	-1	15276093
exten@@	I-Chemical	-1	15276093
de@@	I-Chemical	-1	15276093
d-@@	I-Chemical	-1	15276093
rele@@	I-Chemical	-1	15276093
as@@	I-Chemical	-1	15276093
e@@	I-Chemical	-1	15276093
/@@	I-Chemical	-1	15276093
lo@@	I-Chemical	-1	15276093
vastatin	I-Chemical	-1	15276093
when	O	-1	15276093
dos@@	O	-1	15276093
ed	O	-1	15276093
as	O	-1	15276093
initial	O	-1	15276093
therapy	O	-1	15276093
and	O	-1	15276093
patient	O	-1	15276093
com@@	O	-1	15276093
pl@@	O	-1	15276093
i@@	O	-1	15276093
ance	O	-1	15276093
to	O	-1	15276093
treatment	O	-1	15276093
in	O	-1	15276093
various	O	-1	15276093
clinical	O	-1	15276093
p@@	O	-1	15276093
rac@@	O	-1	15276093
ti@@	O	-1	15276093
ce	O	-1	15276093
se@@	O	-1	15276093
t@@	O	-1	15276093
t@@	O	-1	15276093
ing@@	O	-1	15276093
s.	O	-1	15276093
A	O	-1	15276093
total	O	-1	15276093
of	O	-1	15276093
4@@	O	-1	15276093
,@@	O	-1	15276093
4@@	O	-1	15276093
9@@	O	-1	15276093
9	O	-1	15276093
patients	O	-1	15276093
with	O	-1	15276093
dys@@	B-Disease	D050171	15276093
li@@	I-Disease	-1	15276093
pi@@	I-Disease	-1	15276093
de@@	I-Disease	-1	15276093
mia	I-Disease	-1	15276093
requ@@	O	-1	15276093
ir@@	O	-1	15276093
ing	O	-1	15276093
drug	O	-1	15276093
inter@@	O	-1	15276093
ven@@	O	-1	15276093
tion	O	-1	15276093
was	O	-1	15276093
en@@	O	-1	15276093
ro@@	O	-1	15276093
lled	O	-1	15276093
at	O	-1	15276093
1@@	O	-1	15276093
,@@	O	-1	15276093
0@@	O	-1	15276093
8@@	O	-1	15276093
1	O	-1	15276093
sit@@	O	-1	15276093
es.	O	-1	15276093
Patients	O	-1	15276093
were	O	-1	15276093
treated	O	-1	15276093
with	O	-1	15276093
1	O	-1	15276093
t@@	O	-1	15276093
able@@	O	-1	15276093
t	O	-1	15276093
(5@@	O	-1	15276093
00	O	-1	15276093
mg	O	-1	15276093
of	O	-1	15276093
n@@	B-Chemical	D009525	15276093
i@@	I-Chemical	-1	15276093
ac@@	I-Chemical	-1	15276093
in	I-Chemical	-1	15276093
exten@@	O	-1	15276093
de@@	O	-1	15276093
d-@@	O	-1	15276093
rele@@	O	-1	15276093
as@@	O	-1	15276093
e@@	O	-1	15276093
/@@	O	-1	15276093
20	O	-1	15276093
mg	O	-1	15276093
of	O	-1	15276093
lo@@	B-Chemical	D008148	15276093
vastatin	I-Chemical	-1	15276093
)	O	-1	15276093
on@@	O	-1	15276093
ce	O	-1	15276093
n@@	O	-1	15276093
igh@@	O	-1	15276093
tly	O	-1	15276093
for	O	-1	15276093
4	O	-1	15276093
weeks	O	-1	15276093
and	O	-1	15276093
then	O	-1	15276093
2	O	-1	15276093
t@@	O	-1	15276093
able@@	O	-1	15276093
ts	O	-1	15276093
for	O	-1	15276093
8	O	-1	15276093
week@@	O	-1	15276093
s.	O	-1	15276093
Patients	O	-1	15276093
also	O	-1	15276093
received	O	-1	15276093
di@@	O	-1	15276093
et@@	O	-1	15276093
ary	O	-1	15276093
coun@@	O	-1	15276093
sel@@	O	-1	15276093
ing,	O	-1	15276093
e@@	O	-1	15276093
duc@@	O	-1	15276093
ation@@	O	-1	15276093
al	O	-1	15276093
mat@@	O	-1	15276093
er@@	O	-1	15276093
i@@	O	-1	15276093
al@@	O	-1	15276093
s,	O	-1	15276093
and	O	-1	15276093
re@@	O	-1	15276093
min@@	O	-1	15276093
der@@	O	-1	15276093
s	O	-1	15276093
to	O	-1	15276093
c@@	O	-1	15276093
all	O	-1	15276093
a	O	-1	15276093
t@@	O	-1	15276093
ol@@	O	-1	15276093
l@@	O	-1	15276093
-@@	O	-1	15276093
free	O	-1	15276093
number	O	-1	15276093
that	O	-1	15276093
pro@@	O	-1	15276093
vid@@	O	-1	15276093
ed	O	-1	15276093
further	O	-1	15276093
e@@	O	-1	15276093
duc@@	O	-1	15276093
ation	O	-1	15276093
about	O	-1	15276093
dys@@	B-Disease	D050171	15276093
li@@	I-Disease	-1	15276093
pi@@	I-Disease	-1	15276093
de@@	I-Disease	-1	15276093
mia	I-Disease	-1	15276093
and	O	-1	15276093
n@@	B-Chemical	C451780	15276093
i@@	I-Chemical	-1	15276093
ac@@	I-Chemical	-1	15276093
in	I-Chemical	-1	15276093
exten@@	I-Chemical	-1	15276093
de@@	I-Chemical	-1	15276093
d-@@	I-Chemical	-1	15276093
rele@@	I-Chemical	-1	15276093
as@@	I-Chemical	-1	15276093
e@@	I-Chemical	-1	15276093
/@@	I-Chemical	-1	15276093
lo@@	I-Chemical	-1	15276093
vastatin	I-Chemical	-1	15276093
.	O	-1	15276093
P@@	O	-1	15276093
ri@@	O	-1	15276093
m@@	O	-1	15276093
ary	O	-1	15276093
end	O	-1	15276093
po@@	O	-1	15276093
int@@	O	-1	15276093
s	O	-1	15276093
were	O	-1	15276093
study	O	-1	15276093
com@@	O	-1	15276093
pl@@	O	-1	15276093
i@@	O	-1	15276093
ance@@	O	-1	15276093
,	O	-1	15276093
increases	O	-1	15276093
in	O	-1	15276093
liver	O	-1	15276093
trans@@	O	-1	15276093
amin@@	O	-1	15276093
as@@	O	-1	15276093
es	O	-1	15276093
to	O	-1	15276093
>@@	O	-1	15276093
3	O	-1	15276093
times	O	-1	15276093
the	O	-1	15276093
up@@	O	-1	15276093
per	O	-1	15276093
lim@@	O	-1	15276093
it	O	-1	15276093
of	O	-1	15276093
normal@@	O	-1	15276093
,	O	-1	15276093
and	O	-1	15276093
clinical	O	-1	15276093
my@@	B-Disease	D009135	15276093
o@@	I-Disease	-1	15276093
pathy	I-Disease	-1	15276093
.	O	-1	15276093
F@@	O	-1	15276093
inal	O	-1	15276093
study	O	-1	15276093
status	O	-1	15276093
was	O	-1	15276093
av@@	O	-1	15276093
ail@@	O	-1	15276093
able	O	-1	15276093
for	O	-1	15276093
4@@	O	-1	15276093
,@@	O	-1	15276093
2@@	O	-1	15276093
17	O	-1	15276093
patients	O	-1	15276093
(@@	O	-1	15276093
9@@	O	-1	15276093
4@@	O	-1	15276093
%).	O	-1	15276093
Com@@	O	-1	15276093
pl@@	O	-1	15276093
i@@	O	-1	15276093
ance	O	-1	15276093
to	O	-1	15276093
n@@	B-Chemical	C451780	15276093
i@@	I-Chemical	-1	15276093
ac@@	I-Chemical	-1	15276093
in	I-Chemical	-1	15276093
exten@@	I-Chemical	-1	15276093
de@@	I-Chemical	-1	15276093
d-@@	I-Chemical	-1	15276093
rele@@	I-Chemical	-1	15276093
as@@	I-Chemical	-1	15276093
e@@	I-Chemical	-1	15276093
/@@	I-Chemical	-1	15276093
lo@@	I-Chemical	-1	15276093
vastatin	I-Chemical	-1	15276093
was	O	-1	15276093
7@@	O	-1	15276093
7@@	O	-1	15276093
%,	O	-1	15276093
with	O	-1	15276093
3@@	O	-1	15276093
,@@	O	-1	15276093
2@@	O	-1	15276093
4@@	O	-1	15276093
5	O	-1	15276093
patients	O	-1	15276093
comple@@	O	-1	15276093
ting	O	-1	15276093
the	O	-1	15276093
study.	O	-1	15276093
Patients	O	-1	15276093
in	O	-1	15276093
the	O	-1	15276093
s@@	O	-1	15276093
ou@@	O	-1	15276093
the@@	O	-1	15276093
ast	O	-1	15276093
and	O	-1	15276093
those	O	-1	15276093
en@@	O	-1	15276093
ro@@	O	-1	15276093
lled	O	-1	15276093
by	O	-1	15276093
en@@	O	-1	15276093
doc@@	O	-1	15276093
r@@	O	-1	15276093
in@@	O	-1	15276093
olog@@	O	-1	15276093
ist@@	O	-1	15276093
s	O	-1	15276093
had	O	-1	15276093
the	O	-1	15276093
low@@	O	-1	15276093
est	O	-1	15276093
com@@	O	-1	15276093
pl@@	O	-1	15276093
i@@	O	-1	15276093
ance	O	-1	15276093
and	O	-1	15276093
high@@	O	-1	15276093
est	O	-1	15276093
adverse	O	-1	15276093
ev@@	O	-1	15276093
ent	O	-1	15276093
rat@@	O	-1	15276093
es.	O	-1	15276093
F@@	B-Disease	D005483	15276093
l@@	I-Disease	-1	15276093
us@@	I-Disease	-1	15276093
h@@	I-Disease	-1	15276093
ing	I-Disease	-1	15276093
was	O	-1	15276093
the	O	-1	15276093
most	O	-1	15276093
common	O	-1	15276093
adverse	O	-1	15276093
event@@	O	-1	15276093
,	O	-1	15276093
reported	O	-1	15276093
by	O	-1	15276093
18@@	O	-1	15276093
%	O	-1	15276093
of	O	-1	15276093
patients	O	-1	15276093
and	O	-1	15276093
lead@@	O	-1	15276093
ing	O	-1	15276093
to	O	-1	15276093
discontinu@@	O	-1	15276093
ation	O	-1	15276093
by	O	-1	15276093
6@@	O	-1	15276093
%.	O	-1	15276093
In@@	O	-1	15276093
c@@	O	-1	15276093
idence	O	-1	15276093
of	O	-1	15276093
increased	O	-1	15276093
as@@	B-Chemical	D001224	15276093
part@@	I-Chemical	-1	15276093
ate	I-Chemical	-1	15276093
amin@@	O	-1	15276093
ot@@	O	-1	15276093
ran@@	O	-1	15276093
s@@	O	-1	15276093
fer@@	O	-1	15276093
ase	O	-1	15276093
and/or	O	-1	15276093
al@@	B-Chemical	D000409	15276093
an@@	I-Chemical	-1	15276093
ine	I-Chemical	-1	15276093
amin@@	O	-1	15276093
ot@@	O	-1	15276093
ran@@	O	-1	15276093
s@@	O	-1	15276093
fer@@	O	-1	15276093
ase	O	-1	15276093
>@@	O	-1	15276093
3	O	-1	15276093
times	O	-1	15276093
the	O	-1	15276093
up@@	O	-1	15276093
per	O	-1	15276093
lim@@	O	-1	15276093
it	O	-1	15276093
of	O	-1	15276093
normal	O	-1	15276093
was	O	-1	15276093
<@@	O	-1	15276093
0.@@	O	-1	15276093
3@@	O	-1	15276093
%.	O	-1	15276093
An	O	-1	15276093
increase	O	-1	15276093
of	O	-1	15276093
creat@@	B-Chemical	D003401	15276093
ine	I-Chemical	-1	15276093
phosph@@	O	-1	15276093
o@@	O	-1	15276093
kin@@	O	-1	15276093
ase	O	-1	15276093
to	O	-1	15276093
>@@	O	-1	15276093
5	O	-1	15276093
times	O	-1	15276093
the	O	-1	15276093
up@@	O	-1	15276093
per	O	-1	15276093
lim@@	O	-1	15276093
it	O	-1	15276093
of	O	-1	15276093
normal	O	-1	15276093
occurred	O	-1	15276093
in	O	-1	15276093
0.@@	O	-1	15276093
2@@	O	-1	15276093
4@@	O	-1	15276093
%	O	-1	15276093
of	O	-1	15276093
patients,	O	-1	15276093
and	O	-1	15276093
no	O	-1	15276093
cases	O	-1	15276093
of	O	-1	15276093
drug@@	O	-1	15276093
-induced	O	-1	15276093
my@@	B-Disease	D009135	15276093
o@@	I-Disease	-1	15276093
pathy	I-Disease	-1	15276093
were	O	-1	15276093
obser@@	O	-1	15276093
ved.	O	-1	15276093
N@@	B-Chemical	C451780	15276093
i@@	I-Chemical	-1	15276093
ac@@	I-Chemical	-1	15276093
in	I-Chemical	-1	15276093
exten@@	I-Chemical	-1	15276093
de@@	I-Chemical	-1	15276093
d-@@	I-Chemical	-1	15276093
rele@@	I-Chemical	-1	15276093
as@@	I-Chemical	-1	15276093
e@@	I-Chemical	-1	15276093
/@@	I-Chemical	-1	15276093
lo@@	I-Chemical	-1	15276093
vastatin	I-Chemical	-1	15276093
1@@	O	-1	15276093
,@@	O	-1	15276093
0@@	O	-1	15276093
0@@	O	-1	15276093
0@@	O	-1	15276093
/@@	O	-1	15276093
40	O	-1	15276093
mg@@	O	-1	15276093
,	O	-1	15276093
dos@@	O	-1	15276093
ed	O	-1	15276093
as	O	-1	15276093
initial	O	-1	15276093
therapy,	O	-1	15276093
was	O	-1	15276093
associated	O	-1	15276093
with	O	-1	15276093
go@@	O	-1	15276093
od	O	-1	15276093
com@@	O	-1	15276093
pl@@	O	-1	15276093
i@@	O	-1	15276093
ance	O	-1	15276093
and	O	-1	15276093
safety	O	-1	15276093
and	O	-1	15276093
had	O	-1	15276093
very	O	-1	15276093
low	O	-1	15276093
inc@@	O	-1	15276093
id@@	O	-1	15276093
enc@@	O	-1	15276093
es	O	-1	15276093
of	O	-1	15276093
increased	O	-1	15276093
liver	O	-1	15276093
and	O	-1	15276093
musc@@	O	-1	15276093
le	O	-1	15276093
enzym@@	O	-1	15276093
es.	O	-1	15276093

Pro@@	O	-1	15282950
t@@	O	-1	15282950
ective	O	-1	15282950
effect	O	-1	15282950
of	O	-1	15282950
T@@	B-Chemical	D010936	15282950
er@@	I-Chemical	-1	15282950
min@@	I-Chemical	-1	15282950
al@@	I-Chemical	-1	15282950
ia	I-Chemical	-1	15282950
ch@@	I-Chemical	-1	15282950
e@@	I-Chemical	-1	15282950
b@@	I-Chemical	-1	15282950
ul@@	I-Chemical	-1	15282950
a	I-Chemical	-1	15282950
against	O	-1	15282950
experimental	O	-1	15282950
myocardial	B-Disease	D009202	15282950
injury	I-Disease	-1	15282950
induced	O	-1	15282950
by	O	-1	15282950
isoproteren@@	B-Chemical	D007545	15282950
ol	I-Chemical	-1	15282950
.	O	-1	15282950
C@@	O	-1	15282950
ardi@@	O	-1	15282950
o@@	O	-1	15282950
protective	O	-1	15282950
effect	O	-1	15282950
of	O	-1	15282950
eth@@	B-Chemical	D010936	15282950
an@@	I-Chemical	-1	15282950
olic	I-Chemical	-1	15282950
extrac@@	I-Chemical	-1	15282950
t	I-Chemical	-1	15282950
of	I-Chemical	-1	15282950
T@@	I-Chemical	-1	15282950
er@@	I-Chemical	-1	15282950
min@@	I-Chemical	-1	15282950
al@@	I-Chemical	-1	15282950
ia	I-Chemical	-1	15282950
ch@@	I-Chemical	-1	15282950
e@@	I-Chemical	-1	15282950
b@@	I-Chemical	-1	15282950
ul@@	I-Chemical	-1	15282950
a	I-Chemical	-1	15282950
f@@	I-Chemical	-1	15282950
ru@@	I-Chemical	-1	15282950
its	I-Chemical	-1	15282950
(5@@	O	-1	15282950
00	O	-1	15282950
mg/kg	O	-1	15282950
body	O	-1	15282950
w@@	O	-1	15282950
t@@	O	-1	15282950
)	O	-1	15282950
was	O	-1	15282950
examined	O	-1	15282950
in	O	-1	15282950
isoproteren@@	B-Chemical	D007545	15282950
ol	I-Chemical	-1	15282950
(2@@	O	-1	15282950
00	O	-1	15282950
mg/kg	O	-1	15282950
body	O	-1	15282950
w@@	O	-1	15282950
t@@	O	-1	15282950
)	O	-1	15282950
induced	O	-1	15282950
myocardial	B-Disease	D009202	15282950
damage	I-Disease	-1	15282950
in	O	-1	15282950
rats.	O	-1	15282950
In	O	-1	15282950
isoproteren@@	B-Chemical	D007545	15282950
ol	I-Chemical	-1	15282950
administered	O	-1	15282950
rats,	O	-1	15282950
the	O	-1	15282950
level	O	-1	15282950
of	O	-1	15282950
li@@	O	-1	15282950
pid	O	-1	15282950
per@@	B-Chemical	D010545	15282950
ox@@	I-Chemical	-1	15282950
i@@	I-Chemical	-1	15282950
des	I-Chemical	-1	15282950
increased	O	-1	15282950
significantly	O	-1	15282950
in	O	-1	15282950
the	O	-1	15282950
serum	O	-1	15282950
and	O	-1	15282950
hear@@	O	-1	15282950
t.	O	-1	15282950
A	O	-1	15282950
significant	O	-1	15282950
decrease	O	-1	15282950
was	O	-1	15282950
observed	O	-1	15282950
in	O	-1	15282950
the	O	-1	15282950
activity	O	-1	15282950
of	O	-1	15282950
the	O	-1	15282950
myocardial	O	-1	15282950
mark@@	O	-1	15282950
er	O	-1	15282950
enzym@@	O	-1	15282950
es	O	-1	15282950
with	O	-1	15282950
a	O	-1	15282950
concomit@@	O	-1	15282950
ant	O	-1	15282950
increase	O	-1	15282950
in	O	-1	15282950
their	O	-1	15282950
activity	O	-1	15282950
in	O	-1	15282950
ser@@	O	-1	15282950
um@@	O	-1	15282950
.	O	-1	15282950
H@@	O	-1	15282950
ist@@	O	-1	15282950
o@@	O	-1	15282950
path@@	O	-1	15282950
ological	O	-1	15282950
examin@@	O	-1	15282950
ation	O	-1	15282950
was	O	-1	15282950
car@@	O	-1	15282950
ri@@	O	-1	15282950
ed	O	-1	15282950
out	O	-1	15282950
to	O	-1	15282950
con@@	O	-1	15282950
fir@@	O	-1	15282950
m	O	-1	15282950
the	O	-1	15282950
myocardial	O	-1	15282950
necro@@	B-Disease	D009336	15282950
sis	I-Disease	-1	15282950
.	O	-1	15282950
T@@	B-Chemical	D010936	15282950
.	I-Chemical	-1	15282950
ch@@	I-Chemical	-1	15282950
e@@	I-Chemical	-1	15282950
b@@	I-Chemical	-1	15282950
ul@@	I-Chemical	-1	15282950
a	I-Chemical	-1	15282950
extrac@@	I-Chemical	-1	15282950
t	I-Chemical	-1	15282950
pretreatment	O	-1	15282950
was	O	-1	15282950
found	O	-1	15282950
to	O	-1	15282950
ame@@	O	-1	15282950
li@@	O	-1	15282950
or@@	O	-1	15282950
ate	O	-1	15282950
the	O	-1	15282950
effect	O	-1	15282950
of	O	-1	15282950
isoproteren@@	B-Chemical	D007545	15282950
ol	I-Chemical	-1	15282950
on	O	-1	15282950
li@@	O	-1	15282950
pid	O	-1	15282950
per@@	B-Chemical	D010545	15282950
ox@@	I-Chemical	-1	15282950
ide	I-Chemical	-1	15282950
formation	O	-1	15282950
and	O	-1	15282950
ret@@	O	-1	15282950
ained	O	-1	15282950
the	O	-1	15282950
ac@@	O	-1	15282950
ti@@	O	-1	15282950
vi@@	O	-1	15282950
ties	O	-1	15282950
of	O	-1	15282950
the	O	-1	15282950
diagnos@@	O	-1	15282950
tic	O	-1	15282950
mark@@	O	-1	15282950
er	O	-1	15282950
enzym@@	O	-1	15282950
es.	O	-1	15282950

A	O	-1	15321332
case	O	-1	15321332
of	O	-1	15321332
postoperative	O	-1	15321332
an@@	B-Disease	D001008	15321332
xi@@	I-Disease	-1	15321332
ety	I-Disease	-1	15321332
due	O	-1	15321332
to	O	-1	15321332
low	O	-1	15321332
dose	O	-1	15321332
dro@@	B-Chemical	D004329	15321332
perid@@	I-Chemical	-1	15321332
ol	I-Chemical	-1	15321332
used	O	-1	15321332
with	O	-1	15321332
patient@@	O	-1	15321332
-@@	O	-1	15321332
controlled	O	-1	15321332
analge@@	O	-1	15321332
sia.	O	-1	15321332
A	O	-1	15321332
multi@@	O	-1	15321332
pa@@	O	-1	15321332
rou@@	O	-1	15321332
s	O	-1	15321332
woman	O	-1	15321332
in	O	-1	15321332
go@@	O	-1	15321332
od	O	-1	15321332
psych@@	O	-1	15321332
ological	O	-1	15321332
heal@@	O	-1	15321332
th	O	-1	15321332
under@@	O	-1	15321332
w@@	O	-1	15321332
ent	O	-1	15321332
ur@@	O	-1	15321332
g@@	O	-1	15321332
ent	O	-1	15321332
ca@@	O	-1	15321332
es@@	O	-1	15321332
a@@	O	-1	15321332
re@@	O	-1	15321332
an	O	-1	15321332
sec@@	O	-1	15321332
tion	O	-1	15321332
in	O	-1	15321332
l@@	O	-1	15321332
ab@@	O	-1	15321332
o@@	O	-1	15321332
ur@@	O	-1	15321332
.	O	-1	15321332
P@@	O	-1	15321332
o@@	O	-1	15321332
sto@@	O	-1	15321332
per@@	O	-1	15321332
ati@@	O	-1	15321332
vel@@	O	-1	15321332
y,	O	-1	15321332
sh@@	O	-1	15321332
e	O	-1	15321332
was	O	-1	15321332
given	O	-1	15321332
a	O	-1	15321332
patient@@	O	-1	15321332
-@@	O	-1	15321332
controlled	O	-1	15321332
analge@@	O	-1	15321332
sia	O	-1	15321332
de@@	O	-1	15321332
v@@	O	-1	15321332
ic@@	O	-1	15321332
e	O	-1	15321332
de@@	O	-1	15321332
li@@	O	-1	15321332
ver@@	O	-1	15321332
ing	O	-1	15321332
b@@	O	-1	15321332
ol@@	O	-1	15321332
u@@	O	-1	15321332
ses	O	-1	15321332
of	O	-1	15321332
di@@	B-Chemical	D003932	15321332
am@@	I-Chemical	-1	15321332
or@@	I-Chemical	-1	15321332
ph@@	I-Chemical	-1	15321332
ine	I-Chemical	-1	15321332
0.@@	O	-1	15321332
5	O	-1	15321332
mg	O	-1	15321332
and	O	-1	15321332
dro@@	B-Chemical	D004329	15321332
perid@@	I-Chemical	-1	15321332
ol	I-Chemical	-1	15321332
0.0@@	O	-1	15321332
25	O	-1	15321332
mg@@	O	-1	15321332
.	O	-1	15321332
W@@	O	-1	15321332
h@@	O	-1	15321332
il@@	O	-1	15321332
st	O	-1	15321332
using	O	-1	15321332
the	O	-1	15321332
de@@	O	-1	15321332
v@@	O	-1	15321332
ic@@	O	-1	15321332
e	O	-1	15321332
sh@@	O	-1	15321332
e	O	-1	15321332
gra@@	O	-1	15321332
du@@	O	-1	15321332
ally	O	-1	15321332
b@@	O	-1	15321332
ec@@	O	-1	15321332
am@@	O	-1	15321332
e	O	-1	15321332
an@@	O	-1	15321332
xi@@	O	-1	15321332
ou@@	O	-1	15321332
s,	O	-1	15321332
the	O	-1	15321332
fe@@	O	-1	15321332
el@@	O	-1	15321332
ing	O	-1	15321332
wor@@	O	-1	15321332
sen@@	O	-1	15321332
ing	O	-1	15321332
after	O	-1	15321332
each	O	-1	15321332
b@@	O	-1	15321332
ol@@	O	-1	15321332
us.	O	-1	15321332
The	O	-1	15321332
diagnosis	O	-1	15321332
of	O	-1	15321332
dro@@	B-Chemical	D004329	15321332
perid@@	I-Chemical	-1	15321332
ol	I-Chemical	-1	15321332
-induced	O	-1	15321332
psych@@	B-Disease	D001008	15321332
ological	I-Disease	-1	15321332
dist@@	I-Disease	-1	15321332
urb@@	I-Disease	-1	15321332
ance	I-Disease	-1	15321332
was	O	-1	15321332
not	O	-1	15321332
m@@	O	-1	15321332
ade	O	-1	15321332
stra@@	O	-1	15321332
ight	O	-1	15321332
aw@@	O	-1	15321332
ay	O	-1	15321332
although	O	-1	15321332
on	O	-1	15321332
subsequ@@	O	-1	15321332
ent	O	-1	15321332
clo@@	O	-1	15321332
se	O	-1	15321332
qu@@	O	-1	15321332
es@@	O	-1	15321332
tion@@	O	-1	15321332
ing	O	-1	15321332
the	O	-1	15321332
patient	O	-1	15321332
g@@	O	-1	15321332
a@@	O	-1	15321332
ve	O	-1	15321332
a	O	-1	15321332
very	O	-1	15321332
c@@	O	-1	15321332
le@@	O	-1	15321332
ar	O	-1	15321332
hist@@	O	-1	15321332
or@@	O	-1	15321332
y.	O	-1	15321332
After	O	-1	15321332
sh@@	O	-1	15321332
e	O	-1	15321332
had	O	-1	15321332
received	O	-1	15321332
a	O	-1	15321332
total	O	-1	15321332
of	O	-1	15321332
only	O	-1	15321332
0.@@	O	-1	15321332
9	O	-1	15321332
mg	O	-1	15321332
dro@@	B-Chemical	D004329	15321332
perid@@	I-Chemical	-1	15321332
ol	I-Chemical	-1	15321332
,	O	-1	15321332
a	O	-1	15321332
sy@@	O	-1	15321332
r@@	O	-1	15321332
ing@@	O	-1	15321332
e	O	-1	15321332
containing	O	-1	15321332
di@@	B-Chemical	D003932	15321332
am@@	I-Chemical	-1	15321332
or@@	I-Chemical	-1	15321332
ph@@	I-Chemical	-1	15321332
ine	I-Chemical	-1	15321332
only	O	-1	15321332
was	O	-1	15321332
sub@@	O	-1	15321332
sti@@	O	-1	15321332
t@@	O	-1	15321332
ut@@	O	-1	15321332
ed	O	-1	15321332
and	O	-1	15321332
h@@	O	-1	15321332
er	O	-1	15321332
un@@	O	-1	15321332
e@@	O	-1	15321332
ase	O	-1	15321332
resol@@	O	-1	15321332
ved	O	-1	15321332
complete@@	O	-1	15321332
ly.	O	-1	15321332
We	O	-1	15321332
fe@@	O	-1	15321332
el	O	-1	15321332
th@@	O	-1	15321332
at@@	O	-1	15321332
,	O	-1	15321332
although	O	-1	15321332
the	O	-1	15321332
d@@	O	-1	15321332
ram@@	O	-1	15321332
atic	O	-1	15321332
ext@@	O	-1	15321332
ra@@	O	-1	15321332
py@@	O	-1	15321332
ram@@	O	-1	15321332
idal	O	-1	15321332
side	O	-1	15321332
effects	O	-1	15321332
of	O	-1	15321332
dop@@	O	-1	15321332
aminergic	O	-1	15321332
anti@@	O	-1	15321332
e@@	O	-1	15321332
me@@	O	-1	15321332
tics	O	-1	15321332
are	O	-1	15321332
well	O	-1	15321332
know@@	O	-1	15321332
n@@	O	-1	15321332
,	O	-1	15321332
more	O	-1	15321332
sub@@	O	-1	15321332
t@@	O	-1	15321332
le	O	-1	15321332
man@@	O	-1	15321332
if@@	O	-1	15321332
est@@	O	-1	15321332
ations	O	-1	15321332
may	O	-1	15321332
e@@	O	-1	15321332
a@@	O	-1	15321332
si@@	O	-1	15321332
ly	O	-1	15321332
be	O	-1	15321332
over@@	O	-1	15321332
lo@@	O	-1	15321332
o@@	O	-1	15321332
k@@	O	-1	15321332
ed.	O	-1	15321332

Ac@@	O	-1	15366550
cur@@	O	-1	15366550
ate	O	-1	15366550
patient	O	-1	15366550
hist@@	O	-1	15366550
ory	O	-1	15366550
cont@@	O	-1	15366550
ri@@	O	-1	15366550
but@@	O	-1	15366550
es	O	-1	15366550
to	O	-1	15366550
differen@@	O	-1	15366550
ti@@	O	-1	15366550
ating	O	-1	15366550
dia@@	B-Disease	D003919	15366550
bet@@	I-Disease	-1	15366550
es	I-Disease	-1	15366550
in@@	I-Disease	-1	15366550
si@@	I-Disease	-1	15366550
pid@@	I-Disease	-1	15366550
us	I-Disease	-1	15366550
:	O	-1	15366550
a	O	-1	15366550
case	O	-1	15366550
study.	O	-1	15366550
This	O	-1	15366550
case	O	-1	15366550
study	O	-1	15366550
high@@	O	-1	15366550
li@@	O	-1	15366550
gh@@	O	-1	15366550
ts	O	-1	15366550
the	O	-1	15366550
important	O	-1	15366550
cont@@	O	-1	15366550
ri@@	O	-1	15366550
bu@@	O	-1	15366550
tion	O	-1	15366550
of	O	-1	15366550
n@@	O	-1	15366550
ur@@	O	-1	15366550
s@@	O	-1	15366550
ing	O	-1	15366550
in	O	-1	15366550
obt@@	O	-1	15366550
aining	O	-1	15366550
an	O	-1	15366550
ac@@	O	-1	15366550
cur@@	O	-1	15366550
ate	O	-1	15366550
heal@@	O	-1	15366550
th	O	-1	15366550
hist@@	O	-1	15366550
or@@	O	-1	15366550
y.	O	-1	15366550
The	O	-1	15366550
case	O	-1	15366550
discus@@	O	-1	15366550
sed	O	-1	15366550
he@@	O	-1	15366550
re@@	O	-1	15366550
in	O	-1	15366550
initi@@	O	-1	15366550
ally	O	-1	15366550
appe@@	O	-1	15366550
a@@	O	-1	15366550
red	O	-1	15366550
to	O	-1	15366550
be	O	-1	15366550
neuro@@	B-Disease	D018500	15366550
genic	I-Disease	-1	15366550
dia@@	I-Disease	-1	15366550
bet@@	I-Disease	-1	15366550
es	I-Disease	-1	15366550
in@@	I-Disease	-1	15366550
si@@	I-Disease	-1	15366550
pid@@	I-Disease	-1	15366550
us	I-Disease	-1	15366550
(	O	-1	15366550
D@@	B-Disease	D003919	15366550
I	I-Disease	-1	15366550
)	O	-1	15366550
secondary	O	-1	15366550
to	O	-1	15366550
a	O	-1	15366550
tra@@	B-Disease	D001930	15366550
um@@	I-Disease	-1	15366550
atic	I-Disease	-1	15366550
brain	I-Disease	-1	15366550
injury	I-Disease	-1	15366550
.	O	-1	15366550
The	O	-1	15366550
n@@	O	-1	15366550
ur@@	O	-1	15366550
s@@	O	-1	15366550
ing	O	-1	15366550
st@@	O	-1	15366550
aff@@	O	-1	15366550
,	O	-1	15366550
by	O	-1	15366550
revie@@	O	-1	15366550
w@@	O	-1	15366550
ing	O	-1	15366550
the	O	-1	15366550
patient@@	O	-1	15366550
's	O	-1	15366550
heal@@	O	-1	15366550
th	O	-1	15366550
hist@@	O	-1	15366550
ory	O	-1	15366550
with	O	-1	15366550
h@@	O	-1	15366550
is	O	-1	15366550
f@@	O	-1	15366550
am@@	O	-1	15366550
il@@	O	-1	15366550
y,	O	-1	15366550
dis@@	O	-1	15366550
co@@	O	-1	15366550
vered	O	-1	15366550
a	O	-1	15366550
hist@@	O	-1	15366550
ory	O	-1	15366550
of	O	-1	15366550
poly@@	B-Disease	D059606	15366550
di@@	I-Disease	-1	15366550
p@@	I-Disease	-1	15366550
sia	I-Disease	-1	15366550
and	O	-1	15366550
long@@	O	-1	15366550
-@@	O	-1	15366550
stand@@	O	-1	15366550
ing	O	-1	15366550
lithium	B-Chemical	D008094	15366550
use.	O	-1	15366550
L@@	B-Chemical	D008094	15366550
i@@	I-Chemical	-1	15366550
thi@@	I-Chemical	-1	15366550
um	I-Chemical	-1	15366550
is	O	-1	15366550
implic@@	O	-1	15366550
ated	O	-1	15366550
in	O	-1	15366550
drug@@	O	-1	15366550
-induced	O	-1	15366550
nephro@@	B-Disease	D018500	15366550
genic	I-Disease	-1	15366550
D@@	I-Disease	-1	15366550
I	I-Disease	-1	15366550
,	O	-1	15366550
and	O	-1	15366550
because	O	-1	15366550
the	O	-1	15366550
patient	O	-1	15366550
had	O	-1	15366550
not	O	-1	15366550
received	O	-1	15366550
lithium	B-Chemical	D008094	15366550
s@@	O	-1	15366550
inc@@	O	-1	15366550
e	O	-1	15366550
being	O	-1	15366550
ad@@	O	-1	15366550
mit@@	O	-1	15366550
ted	O	-1	15366550
to	O	-1	15366550
the	O	-1	15366550
hospit@@	O	-1	15366550
al,	O	-1	15366550
h@@	O	-1	15366550
is	O	-1	15366550
treatment	O	-1	15366550
chang@@	O	-1	15366550
ed	O	-1	15366550
to	O	-1	15366550
foc@@	O	-1	15366550
us	O	-1	15366550
on	O	-1	15366550
nephro@@	B-Disease	D018500	15366550
genic	I-Disease	-1	15366550
D@@	I-Disease	-1	15366550
I	I-Disease	-1	15366550
.	O	-1	15366550
B@@	O	-1	15366550
y	O	-1	15366550
combin@@	O	-1	15366550
ing	O	-1	15366550
inf@@	O	-1	15366550
orm@@	O	-1	15366550
ation	O	-1	15366550
from	O	-1	15366550
the	O	-1	15366550
patient	O	-1	15366550
hist@@	O	-1	15366550
or@@	O	-1	15366550
y,	O	-1	15366550
the	O	-1	15366550
physi@@	O	-1	15366550
c@@	O	-1	15366550
al	O	-1	15366550
examin@@	O	-1	15366550
ation,	O	-1	15366550
and	O	-1	15366550
radi@@	O	-1	15366550
ologic	O	-1	15366550
and	O	-1	15366550
labor@@	O	-1	15366550
atory	O	-1	15366550
studi@@	O	-1	15366550
es,	O	-1	15366550
the	O	-1	15366550
cri@@	O	-1	15366550
tical	O	-1	15366550
car@@	O	-1	15366550
e	O	-1	15366550
te@@	O	-1	15366550
am	O	-1	15366550
demonstrated	O	-1	15366550
that	O	-1	15366550
the	O	-1	15366550
patient	O	-1	15366550
had	O	-1	15366550
been	O	-1	15366550
sel@@	O	-1	15366550
f@@	O	-1	15366550
-@@	O	-1	15366550
treat@@	O	-1	15366550
ing	O	-1	15366550
h@@	O	-1	15366550
is	O	-1	15366550
lithium	B-Chemical	D008094	15366550
-induced	O	-1	15366550
nephro@@	B-Disease	D018500	15366550
genic	I-Disease	-1	15366550
D@@	I-Disease	-1	15366550
I	I-Disease	-1	15366550
and	O	-1	15366550
developed	O	-1	15366550
neuro@@	B-Disease	D018500	15366550
genic	I-Disease	-1	15366550
D@@	I-Disease	-1	15366550
I	I-Disease	-1	15366550
secondary	O	-1	15366550
to	O	-1	15366550
brain	B-Disease	D001930	15366550
tra@@	I-Disease	-1	15366550
um@@	I-Disease	-1	15366550
a	I-Disease	-1	15366550
.	O	-1	15366550
Th@@	O	-1	15366550
us	O	-1	15366550
suc@@	O	-1	15366550
cess@@	O	-1	15366550
ful	O	-1	15366550
treatment	O	-1	15366550
requ@@	O	-1	15366550
ired	O	-1	15366550
that	O	-1	15366550
nephro@@	O	-1	15366550
genic	O	-1	15366550
and	O	-1	15366550
neuro@@	B-Disease	D018500	15366550
genic	I-Disease	-1	15366550
D@@	I-Disease	-1	15366550
I	I-Disease	-1	15366550
be	O	-1	15366550
treated	O	-1	15366550
concomit@@	O	-1	15366550
ant@@	O	-1	15366550
ly.	O	-1	15366550

F@@	O	-1	15482540
act@@	O	-1	15482540
ors	O	-1	15482540
cont@@	O	-1	15482540
ri@@	O	-1	15482540
but@@	O	-1	15482540
ing	O	-1	15482540
to	O	-1	15482540
rib@@	B-Chemical	D012254	15482540
avi@@	I-Chemical	-1	15482540
rin	I-Chemical	-1	15482540
-induced	O	-1	15482540
anemia	B-Disease	D000740	15482540
.	O	-1	15482540
BACKGROUN@@	O	-1	15482540
D	O	-1	15482540
AN@@	O	-1	15482540
D	O	-1	15482540
A@@	O	-1	15482540
I@@	O	-1	15482540
M@@	O	-1	15482540
:	O	-1	15482540
In@@	B-Chemical	D016898	15482540
ter@@	I-Chemical	-1	15482540
fer@@	I-Chemical	-1	15482540
on	I-Chemical	-1	15482540
and	O	-1	15482540
rib@@	B-Chemical	D012254	15482540
avi@@	I-Chemical	-1	15482540
rin	I-Chemical	-1	15482540
combination	O	-1	15482540
therapy	O	-1	15482540
for	O	-1	15482540
chronic	B-Disease	D019698	15482540
hepatitis	I-Disease	-1	15482540
C	I-Disease	-1	15482540
produc@@	O	-1	15482540
es	O	-1	15482540
hemolytic	B-Disease	D000743	15482540
anemia	I-Disease	-1	15482540
.	O	-1	15482540
This	O	-1	15482540
study	O	-1	15482540
was	O	-1	15482540
con@@	O	-1	15482540
duc@@	O	-1	15482540
ted	O	-1	15482540
to	O	-1	15482540
identi@@	O	-1	15482540
f@@	O	-1	15482540
y	O	-1	15482540
the	O	-1	15482540
factors	O	-1	15482540
cont@@	O	-1	15482540
ri@@	O	-1	15482540
but@@	O	-1	15482540
ing	O	-1	15482540
to	O	-1	15482540
rib@@	B-Chemical	D012254	15482540
avi@@	I-Chemical	-1	15482540
rin	I-Chemical	-1	15482540
-induced	O	-1	15482540
anemia	B-Disease	D000740	15482540
.	O	-1	15482540
METHODS:	O	-1	15482540
E@@	O	-1	15482540
igh@@	O	-1	15482540
ty-@@	O	-1	15482540
e@@	O	-1	15482540
ight	O	-1	15482540
patients	O	-1	15482540
with	O	-1	15482540
chronic	B-Disease	D019698	15482540
hepatitis	I-Disease	-1	15482540
C	I-Disease	-1	15482540
who	O	-1	15482540
received	O	-1	15482540
inter@@	B-Chemical	D016898	15482540
fer@@	I-Chemical	-1	15482540
on@@	I-Chemical	-1	15482540
-@@	I-Chemical	-1	15482540
alpha-@@	I-Chemical	-1	15482540
2@@	I-Chemical	-1	15482540
b	I-Chemical	-1	15482540
at	O	-1	15482540
a	O	-1	15482540
dose	O	-1	15482540
of	O	-1	15482540
6	O	-1	15482540
M@@	O	-1	15482540
U	O	-1	15482540
administered	O	-1	15482540
int@@	O	-1	15482540
ram@@	O	-1	15482540
us@@	O	-1	15482540
cul@@	O	-1	15482540
arly	O	-1	15482540
for	O	-1	15482540
24	O	-1	15482540
weeks	O	-1	15482540
in	O	-1	15482540
combination	O	-1	15482540
with	O	-1	15482540
rib@@	B-Chemical	D012254	15482540
avi@@	I-Chemical	-1	15482540
rin	I-Chemical	-1	15482540
administered	O	-1	15482540
or@@	O	-1	15482540
ally	O	-1	15482540
at	O	-1	15482540
a	O	-1	15482540
dose	O	-1	15482540
of	O	-1	15482540
6@@	O	-1	15482540
00	O	-1	15482540
mg	O	-1	15482540
or	O	-1	15482540
8@@	O	-1	15482540
00	O	-1	15482540
mg	O	-1	15482540
partic@@	O	-1	15482540
ip@@	O	-1	15482540
ated	O	-1	15482540
in	O	-1	15482540
the	O	-1	15482540
study.	O	-1	15482540
A	O	-1	15482540
hemo@@	O	-1	15482540
globin	O	-1	15482540
concentration	O	-1	15482540
of	O	-1	15482540
<@@	O	-1	15482540
10	O	-1	15482540
g/@@	O	-1	15482540
d@@	O	-1	15482540
L	O	-1	15482540
was	O	-1	15482540
def@@	O	-1	15482540
in@@	O	-1	15482540
ed	O	-1	15482540
as	O	-1	15482540
rib@@	B-Chemical	D012254	15482540
avi@@	I-Chemical	-1	15482540
rin	I-Chemical	-1	15482540
-induced	O	-1	15482540
anemia	B-Disease	D000740	15482540
.	O	-1	15482540
RESULTS:	O	-1	15482540
R@@	B-Chemical	D012254	15482540
i@@	I-Chemical	-1	15482540
b@@	I-Chemical	-1	15482540
avi@@	I-Chemical	-1	15482540
rin	I-Chemical	-1	15482540
-induced	O	-1	15482540
anemia	B-Disease	D000740	15482540
occurred	O	-1	15482540
in	O	-1	15482540
1@@	O	-1	15482540
8	O	-1	15482540
(2@@	O	-1	15482540
0.@@	O	-1	15482540
5@@	O	-1	15482540
%)	O	-1	15482540
patients	O	-1	15482540
during	O	-1	15482540
treatment.	O	-1	15482540
A	O	-1	15482540
2	O	-1	15482540
g/@@	O	-1	15482540
d@@	O	-1	15482540
L	O	-1	15482540
decrease	O	-1	15482540
in	O	-1	15482540
hemo@@	O	-1	15482540
globin	O	-1	15482540
concentrations	O	-1	15482540
in	O	-1	15482540
patients	O	-1	15482540
with	O	-1	15482540
anemia	B-Disease	D000740	15482540
was	O	-1	15482540
observed	O	-1	15482540
at	O	-1	15482540
week	O	-1	15482540
2	O	-1	15482540
after	O	-1	15482540
the	O	-1	15482540
star@@	O	-1	15482540
t	O	-1	15482540
of	O	-1	15482540
treatment.	O	-1	15482540
The	O	-1	15482540
hemo@@	O	-1	15482540
globin	O	-1	15482540
concentration	O	-1	15482540
in	O	-1	15482540
patients	O	-1	15482540
with	O	-1	15482540
>	O	-1	15482540
or	O	-1	15482540
=@@	O	-1	15482540
2	O	-1	15482540
g/@@	O	-1	15482540
d@@	O	-1	15482540
L	O	-1	15482540
decrease	O	-1	15482540
at	O	-1	15482540
week	O	-1	15482540
2	O	-1	15482540
was	O	-1	15482540
observed	O	-1	15482540
to	O	-1	15482540
be	O	-1	15482540
significantly	O	-1	15482540
lower	O	-1	15482540
even	O	-1	15482540
after	O	-1	15482540
week	O	-1	15482540
2	O	-1	15482540
than	O	-1	15482540
in	O	-1	15482540
patients	O	-1	15482540
with	O	-1	15482540
<@@	O	-1	15482540
2	O	-1	15482540
g/@@	O	-1	15482540
d@@	O	-1	15482540
L	O	-1	15482540
decrease	O	-1	15482540
(P	O	-1	15482540
<	O	-1	15482540
0.0@@	O	-1	15482540
1).	O	-1	15482540
A	O	-1	15482540
significant	O	-1	15482540
rel@@	O	-1	15482540
ationship	O	-1	15482540
was	O	-1	15482540
observed	O	-1	15482540
between	O	-1	15482540
the	O	-1	15482540
rate	O	-1	15482540
of	O	-1	15482540
reduction	O	-1	15482540
of	O	-1	15482540
hemo@@	O	-1	15482540
globin	O	-1	15482540
concentrations	O	-1	15482540
at	O	-1	15482540
week	O	-1	15482540
2	O	-1	15482540
and	O	-1	15482540
the	O	-1	15482540
severity	O	-1	15482540
of	O	-1	15482540
anemia	B-Disease	D000740	15482540
(P	O	-1	15482540
<	O	-1	15482540
0.0@@	O	-1	15482540
1).	O	-1	15482540
S@@	O	-1	15482540
uc@@	O	-1	15482540
h	O	-1	15482540
factors	O	-1	15482540
as	O	-1	15482540
se@@	O	-1	15482540
x	O	-1	15482540
(@@	O	-1	15482540
femal@@	O	-1	15482540
e@@	O	-1	15482540
),	O	-1	15482540
age	O	-1	15482540
(@@	O	-1	15482540
>	O	-1	15482540
or	O	-1	15482540
=@@	O	-1	15482540
60	O	-1	15482540
years	O	-1	15482540
ol@@	O	-1	15482540
d@@	O	-1	15482540
),	O	-1	15482540
and	O	-1	15482540
the	O	-1	15482540
rib@@	B-Chemical	D012254	15482540
avi@@	I-Chemical	-1	15482540
rin	I-Chemical	-1	15482540
dose	O	-1	15482540
by	O	-1	15482540
body	O	-1	15482540
weight	O	-1	15482540
(1@@	O	-1	15482540
2	O	-1	15482540
mg/kg	O	-1	15482540
or	O	-1	15482540
mo@@	O	-1	15482540
re@@	O	-1	15482540
)	O	-1	15482540
were	O	-1	15482540
significant	O	-1	15482540
by	O	-1	15482540
un@@	O	-1	15482540
i@@	O	-1	15482540
vari@@	O	-1	15482540
ate	O	-1	15482540
analy@@	O	-1	15482540
sis.	O	-1	15482540
CONCLUSIONS:	O	-1	15482540
Ca@@	O	-1	15482540
ref@@	O	-1	15482540
u@@	O	-1	15482540
l	O	-1	15482540
administration	O	-1	15482540
is	O	-1	15482540
nec@@	O	-1	15482540
ess@@	O	-1	15482540
ary	O	-1	15482540
in	O	-1	15482540
patients	O	-1	15482540
>	O	-1	15482540
or	O	-1	15482540
=@@	O	-1	15482540
60	O	-1	15482540
years	O	-1	15482540
ol@@	O	-1	15482540
d,	O	-1	15482540
in	O	-1	15482540
female	O	-1	15482540
patients,	O	-1	15482540
and	O	-1	15482540
in	O	-1	15482540
patients	O	-1	15482540
receiving	O	-1	15482540
a	O	-1	15482540
rib@@	B-Chemical	D012254	15482540
avi@@	I-Chemical	-1	15482540
rin	I-Chemical	-1	15482540
dose	O	-1	15482540
of	O	-1	15482540
12	O	-1	15482540
mg/kg	O	-1	15482540
or	O	-1	15482540
mo@@	O	-1	15482540
re.	O	-1	15482540
Patients	O	-1	15482540
who	O	-1	15482540
experi@@	O	-1	15482540
ence	O	-1	15482540
a	O	-1	15482540
f@@	O	-1	15482540
all	O	-1	15482540
in	O	-1	15482540
hemo@@	O	-1	15482540
globin	O	-1	15482540
concentrations	O	-1	15482540
of	O	-1	15482540
2	O	-1	15482540
g/@@	O	-1	15482540
d@@	O	-1	15482540
L	O	-1	15482540
or	O	-1	15482540
more	O	-1	15482540
at	O	-1	15482540
week	O	-1	15482540
2	O	-1	15482540
after	O	-1	15482540
the	O	-1	15482540
star@@	O	-1	15482540
t	O	-1	15482540
of	O	-1	15482540
treatment	O	-1	15482540
should	O	-1	15482540
be	O	-1	15482540
monit@@	O	-1	15482540
o@@	O	-1	15482540
red	O	-1	15482540
with	O	-1	15482540
partic@@	O	-1	15482540
ular	O	-1	15482540
ca@@	O	-1	15482540
re.	O	-1	15482540

O@@	O	-1	15605432
x@@	O	-1	15605432
id@@	O	-1	15605432
ative	O	-1	15605432
damage	O	-1	15605432
pre@@	O	-1	15605432
ce@@	O	-1	15605432
des	O	-1	15605432
nit@@	O	-1	15605432
r@@	O	-1	15605432
ative	O	-1	15605432
damage	O	-1	15605432
in	O	-1	15605432
adriam@@	B-Chemical	D004317	15605432
ycin	I-Chemical	-1	15605432
-induced	O	-1	15605432
cardiac	O	-1	15605432
mitochondrial	B-Disease	D028361	15605432
injury	I-Disease	-1	15605432
.	O	-1	15605432
The	O	-1	15605432
pur@@	O	-1	15605432
p@@	O	-1	15605432
ose	O	-1	15605432
of	O	-1	15605432
the	O	-1	15605432
present	O	-1	15605432
study	O	-1	15605432
was	O	-1	15605432
to	O	-1	15605432
determine	O	-1	15605432
if	O	-1	15605432
elevated	O	-1	15605432
reac@@	O	-1	15605432
tive	O	-1	15605432
oxy@@	B-Chemical	D010100	15605432
gen	I-Chemical	-1	15605432
(@@	O	-1	15605432
RO@@	O	-1	15605432
S@@	O	-1	15605432
)@@	O	-1	15605432
/	O	-1	15605432
nitro@@	B-Chemical	D009584	15605432
gen	I-Chemical	-1	15605432
spec@@	O	-1	15605432
i@@	O	-1	15605432
es	O	-1	15605432
(@@	O	-1	15605432
R@@	O	-1	15605432
N@@	O	-1	15605432
S)	O	-1	15605432
reported	O	-1	15605432
to	O	-1	15605432
be	O	-1	15605432
present	O	-1	15605432
in	O	-1	15605432
adriam@@	B-Chemical	D004317	15605432
ycin	I-Chemical	-1	15605432
(	O	-1	15605432
AD@@	B-Chemical	D004317	15605432
R	I-Chemical	-1	15605432
)@@	O	-1	15605432
-induced	O	-1	15605432
cardi@@	B-Disease	D066126	15605432
otoxicity	I-Disease	-1	15605432
act@@	O	-1	15605432
ually	O	-1	15605432
resulted	O	-1	15605432
in	O	-1	15605432
cardi@@	O	-1	15605432
om@@	O	-1	15605432
y@@	O	-1	15605432
ocyte	O	-1	15605432
oxid@@	O	-1	15605432
ati@@	O	-1	15605432
ve@@	O	-1	15605432
/@@	O	-1	15605432
nit@@	O	-1	15605432
r@@	O	-1	15605432
ative	O	-1	15605432
dam@@	O	-1	15605432
age,	O	-1	15605432
and	O	-1	15605432
to	O	-1	15605432
qu@@	O	-1	15605432
anti@@	O	-1	15605432
t@@	O	-1	15605432
atively	O	-1	15605432
determine	O	-1	15605432
the	O	-1	15605432
time	O	-1	15605432
course	O	-1	15605432
and	O	-1	15605432
sub@@	O	-1	15605432
cell@@	O	-1	15605432
ular	O	-1	15605432
lo@@	O	-1	15605432
cal@@	O	-1	15605432
ization	O	-1	15605432
of	O	-1	15605432
these	O	-1	15605432
post@@	O	-1	15605432
ul@@	O	-1	15605432
ated	O	-1	15605432
damage	O	-1	15605432
produc@@	O	-1	15605432
ts	O	-1	15605432
using	O	-1	15605432
an	O	-1	15605432
in	O	-1	15605432
viv@@	O	-1	15605432
o	O	-1	15605432
appro@@	O	-1	15605432
ac@@	O	-1	15605432
h@@	O	-1	15605432
.	O	-1	15605432
B@@	O	-1	15605432
6@@	O	-1	15605432
C@@	O	-1	15605432
3	O	-1	15605432
mice	O	-1	15605432
were	O	-1	15605432
treated	O	-1	15605432
with	O	-1	15605432
a	O	-1	15605432
single	O	-1	15605432
dose	O	-1	15605432
of	O	-1	15605432
20	O	-1	15605432
mg/kg	O	-1	15605432
AD@@	B-Chemical	D004317	15605432
R	I-Chemical	-1	15605432
.	O	-1	15605432
U@@	O	-1	15605432
l@@	O	-1	15605432
tra@@	O	-1	15605432
struct@@	O	-1	15605432
ural	O	-1	15605432
damage	O	-1	15605432
and	O	-1	15605432
levels	O	-1	15605432
of	O	-1	15605432
4-@@	B-Chemical	C027576	15605432
hydrox@@	I-Chemical	-1	15605432
y-@@	I-Chemical	-1	15605432
2-@@	I-Chemical	-1	15605432
non@@	I-Chemical	-1	15605432
en@@	I-Chemical	-1	15605432
al	I-Chemical	-1	15605432
(	O	-1	15605432
4@@	B-Chemical	C027576	15605432
H@@	I-Chemical	-1	15605432
N@@	I-Chemical	-1	15605432
E	I-Chemical	-1	15605432
)-@@	O	-1	15605432
protein	O	-1	15605432
ad@@	O	-1	15605432
duc@@	O	-1	15605432
ts	O	-1	15605432
and	O	-1	15605432
3-@@	B-Chemical	C002744	15605432
nitro@@	I-Chemical	-1	15605432
ty@@	I-Chemical	-1	15605432
ros@@	I-Chemical	-1	15605432
ine	I-Chemical	-1	15605432
(	O	-1	15605432
3@@	B-Chemical	C002744	15605432
N@@	I-Chemical	-1	15605432
T	I-Chemical	-1	15605432
)	O	-1	15605432
were	O	-1	15605432
analy@@	O	-1	15605432
z@@	O	-1	15605432
ed.	O	-1	15605432
Q@@	O	-1	15605432
u@@	O	-1	15605432
anti@@	O	-1	15605432
t@@	O	-1	15605432
ative	O	-1	15605432
ult@@	O	-1	15605432
ra@@	O	-1	15605432
struct@@	O	-1	15605432
ural	O	-1	15605432
damage	O	-1	15605432
using	O	-1	15605432
comp@@	O	-1	15605432
u@@	O	-1	15605432
ter@@	O	-1	15605432
ized	O	-1	15605432
im@@	O	-1	15605432
age	O	-1	15605432
t@@	O	-1	15605432
ech@@	O	-1	15605432
n@@	O	-1	15605432
i@@	O	-1	15605432
qu@@	O	-1	15605432
es	O	-1	15605432
showed	O	-1	15605432
cardi@@	O	-1	15605432
om@@	O	-1	15605432
y@@	O	-1	15605432
ocyte	O	-1	15605432
injury	O	-1	15605432
as	O	-1	15605432
early	O	-1	15605432
as	O	-1	15605432
3	O	-1	15605432
hour@@	O	-1	15605432
s,	O	-1	15605432
with	O	-1	15605432
mitochond@@	O	-1	15605432
ri@@	O	-1	15605432
a	O	-1	15605432
being	O	-1	15605432
the	O	-1	15605432
most	O	-1	15605432
exten@@	O	-1	15605432
si@@	O	-1	15605432
vely	O	-1	15605432
and	O	-1	15605432
progres@@	O	-1	15605432
si@@	O	-1	15605432
vely	O	-1	15605432
inj@@	O	-1	15605432
ured	O	-1	15605432
sub@@	O	-1	15605432
cell@@	O	-1	15605432
ular	O	-1	15605432
org@@	O	-1	15605432
an@@	O	-1	15605432
el@@	O	-1	15605432
le@@	O	-1	15605432
.	O	-1	15605432
An@@	O	-1	15605432
aly@@	O	-1	15605432
sis	O	-1	15605432
of	O	-1	15605432
4@@	B-Chemical	C027576	15605432
H@@	I-Chemical	-1	15605432
N@@	I-Chemical	-1	15605432
E	I-Chemical	-1	15605432
protein	O	-1	15605432
ad@@	O	-1	15605432
duc@@	O	-1	15605432
ts	O	-1	15605432
by	O	-1	15605432
immuno@@	O	-1	15605432
g@@	O	-1	15605432
old	O	-1	15605432
electro@@	O	-1	15605432
n	O	-1	15605432
micro@@	O	-1	15605432
sco@@	O	-1	15605432
p@@	O	-1	15605432
y	O	-1	15605432
showed	O	-1	15605432
appear@@	O	-1	15605432
ance	O	-1	15605432
of	O	-1	15605432
4@@	B-Chemical	C027576	15605432
H@@	I-Chemical	-1	15605432
N@@	I-Chemical	-1	15605432
E	I-Chemical	-1	15605432
protein	O	-1	15605432
ad@@	O	-1	15605432
duc@@	O	-1	15605432
ts	O	-1	15605432
in	O	-1	15605432
mitochond@@	O	-1	15605432
ri@@	O	-1	15605432
a	O	-1	15605432
as	O	-1	15605432
early	O	-1	15605432
as	O	-1	15605432
3	O	-1	15605432
hour@@	O	-1	15605432
s,	O	-1	15605432
with	O	-1	15605432
a	O	-1	15605432
pe@@	O	-1	15605432
a@@	O	-1	15605432
k	O	-1	15605432
at	O	-1	15605432
6	O	-1	15605432
hours	O	-1	15605432
and	O	-1	15605432
subsequ@@	O	-1	15605432
ent	O	-1	15605432
dec@@	O	-1	15605432
line	O	-1	15605432
at	O	-1	15605432
24	O	-1	15605432
hour@@	O	-1	15605432
s.	O	-1	15605432
3@@	B-Chemical	C002744	15605432
N@@	I-Chemical	-1	15605432
T	I-Chemical	-1	15605432
levels	O	-1	15605432
were	O	-1	15605432
significantly	O	-1	15605432
increased	O	-1	15605432
in	O	-1	15605432
all	O	-1	15605432
sub@@	O	-1	15605432
cell@@	O	-1	15605432
ular	O	-1	15605432
compar@@	O	-1	15605432
t@@	O	-1	15605432
ments	O	-1	15605432
at	O	-1	15605432
6	O	-1	15605432
hours	O	-1	15605432
and	O	-1	15605432
subsequ@@	O	-1	15605432
ently	O	-1	15605432
dec@@	O	-1	15605432
lin@@	O	-1	15605432
ed	O	-1	15605432
at	O	-1	15605432
24	O	-1	15605432
hour@@	O	-1	15605432
s.	O	-1	15605432
Our	O	-1	15605432
data	O	-1	15605432
showed	O	-1	15605432
AD@@	B-Chemical	D004317	15605432
R	I-Chemical	-1	15605432
induced	O	-1	15605432
4@@	B-Chemical	C027576	15605432
H@@	I-Chemical	-1	15605432
N@@	I-Chemical	-1	15605432
E	I-Chemical	-1	15605432
-@@	O	-1	15605432
protein	O	-1	15605432
ad@@	O	-1	15605432
duc@@	O	-1	15605432
ts	O	-1	15605432
in	O	-1	15605432
mitochond@@	O	-1	15605432
ri@@	O	-1	15605432
a	O	-1	15605432
at	O	-1	15605432
the	O	-1	15605432
same	O	-1	15605432
time	O	-1	15605432
po@@	O	-1	15605432
in@@	O	-1	15605432
t	O	-1	15605432
as	O	-1	15605432
when	O	-1	15605432
mitochondrial	B-Disease	D028361	15605432
injury	I-Disease	-1	15605432
initi@@	O	-1	15605432
ally	O	-1	15605432
appe@@	O	-1	15605432
a@@	O	-1	15605432
red.	O	-1	15605432
These	O	-1	15605432
results	O	-1	15605432
doc@@	O	-1	15605432
u@@	O	-1	15605432
ment	O	-1	15605432
for	O	-1	15605432
the	O	-1	15605432
first	O	-1	15605432
time	O	-1	15605432
in	O	-1	15605432
viv@@	O	-1	15605432
o	O	-1	15605432
that	O	-1	15605432
mitochondrial	B-Disease	D028361	15605432
oxid@@	I-Disease	-1	15605432
ative	I-Disease	-1	15605432
damage	I-Disease	-1	15605432
pre@@	O	-1	15605432
ce@@	O	-1	15605432
des	O	-1	15605432
nit@@	O	-1	15605432
r@@	O	-1	15605432
ative	O	-1	15605432
dam@@	O	-1	15605432
age.	O	-1	15605432
The	O	-1	15605432
progressive	O	-1	15605432
n@@	O	-1	15605432
at@@	O	-1	15605432
ure	O	-1	15605432
of	O	-1	15605432
mitochondrial	B-Disease	D028361	15605432
injury	I-Disease	-1	15605432
suggests	O	-1	15605432
that	O	-1	15605432
mitochond@@	O	-1	15605432
ri@@	O	-1	15605432
a,	O	-1	15605432
not	O	-1	15605432
other	O	-1	15605432
sub@@	O	-1	15605432
cell@@	O	-1	15605432
ular	O	-1	15605432
org@@	O	-1	15605432
ane@@	O	-1	15605432
ll@@	O	-1	15605432
es,	O	-1	15605432
are	O	-1	15605432
the	O	-1	15605432
major	O	-1	15605432
sit@@	O	-1	15605432
e	O	-1	15605432
of	O	-1	15605432
intrac@@	O	-1	15605432
ell@@	O	-1	15605432
ular	O	-1	15605432
injur@@	O	-1	15605432
y.	O	-1	15605432

S@@	B-Chemical	D013015	15609701
ot@@	I-Chemical	-1	15609701
al@@	I-Chemical	-1	15609701
ol	I-Chemical	-1	15609701
-induced	O	-1	15609701
coronary	B-Disease	D003329	15609701
sp@@	I-Disease	-1	15609701
as@@	I-Disease	-1	15609701
m	I-Disease	-1	15609701
in	O	-1	15609701
a	O	-1	15609701
patient	O	-1	15609701
with	O	-1	15609701
di@@	B-Disease	D002311	15609701
l@@	I-Disease	-1	15609701
ated	I-Disease	-1	15609701
cardi@@	I-Disease	-1	15609701
om@@	I-Disease	-1	15609701
yo@@	I-Disease	-1	15609701
pathy	I-Disease	-1	15609701
associated	O	-1	15609701
with	O	-1	15609701
su@@	O	-1	15609701
st@@	O	-1	15609701
ained	O	-1	15609701
ventricular	B-Disease	D017180	15609701
tachycardia	I-Disease	-1	15609701
.	O	-1	15609701
A	O	-1	15609701
5@@	O	-1	15609701
4-@@	O	-1	15609701
year-old	O	-1	15609701
man	O	-1	15609701
with	O	-1	15609701
severe	O	-1	15609701
left	O	-1	15609701
ventricular	B-Disease	D018754	15609701
dysfunction	I-Disease	-1	15609701
due	O	-1	15609701
to	O	-1	15609701
di@@	B-Disease	D002311	15609701
l@@	I-Disease	-1	15609701
ated	I-Disease	-1	15609701
cardi@@	I-Disease	-1	15609701
om@@	I-Disease	-1	15609701
yo@@	I-Disease	-1	15609701
pathy	I-Disease	-1	15609701
was	O	-1	15609701
ref@@	O	-1	15609701
er@@	O	-1	15609701
red	O	-1	15609701
to	O	-1	15609701
our	O	-1	15609701
hospit@@	O	-1	15609701
al	O	-1	15609701
for	O	-1	15609701
symptom@@	O	-1	15609701
atic	O	-1	15609701
inc@@	O	-1	15609701
ess@@	O	-1	15609701
ant	O	-1	15609701
su@@	O	-1	15609701
st@@	O	-1	15609701
ained	O	-1	15609701
ventricular	B-Disease	D017180	15609701
tachycardia	I-Disease	-1	15609701
(	O	-1	15609701
V@@	B-Disease	D017180	15609701
T	I-Disease	-1	15609701
).	O	-1	15609701
After	O	-1	15609701
the	O	-1	15609701
administration	O	-1	15609701
of	O	-1	15609701
n@@	B-Chemical	C076259	15609701
if@@	I-Chemical	-1	15609701
e@@	I-Chemical	-1	15609701
k@@	I-Chemical	-1	15609701
al@@	I-Chemical	-1	15609701
ant	I-Chemical	-1	15609701
hydro@@	I-Chemical	-1	15609701
chlor@@	I-Chemical	-1	15609701
ide	I-Chemical	-1	15609701
,	O	-1	15609701
su@@	O	-1	15609701
st@@	O	-1	15609701
ained	O	-1	15609701
V@@	B-Disease	D017180	15609701
T	I-Disease	-1	15609701
was	O	-1	15609701
ter@@	O	-1	15609701
min@@	O	-1	15609701
ated.	O	-1	15609701
An	O	-1	15609701
al@@	O	-1	15609701
tern@@	O	-1	15609701
ate	O	-1	15609701
cl@@	O	-1	15609701
as@@	O	-1	15609701
s	O	-1	15609701
I@@	O	-1	15609701
II	O	-1	15609701
agent@@	O	-1	15609701
,	O	-1	15609701
s@@	B-Chemical	D013015	15609701
ot@@	I-Chemical	-1	15609701
al@@	I-Chemical	-1	15609701
ol	I-Chemical	-1	15609701
,	O	-1	15609701
was	O	-1	15609701
also	O	-1	15609701
effective	O	-1	15609701
for	O	-1	15609701
the	O	-1	15609701
pre@@	O	-1	15609701
ven@@	O	-1	15609701
tion	O	-1	15609701
of	O	-1	15609701
V@@	B-Disease	D017180	15609701
T	I-Disease	-1	15609701
.	O	-1	15609701
However,	O	-1	15609701
one	O	-1	15609701
mon@@	O	-1	15609701
th	O	-1	15609701
after	O	-1	15609701
switch@@	O	-1	15609701
ing	O	-1	15609701
over	O	-1	15609701
n@@	B-Chemical	C076259	15609701
if@@	I-Chemical	-1	15609701
e@@	I-Chemical	-1	15609701
k@@	I-Chemical	-1	15609701
al@@	I-Chemical	-1	15609701
ant	I-Chemical	-1	15609701
to	O	-1	15609701
s@@	B-Chemical	D013015	15609701
ot@@	I-Chemical	-1	15609701
al@@	I-Chemical	-1	15609701
ol	I-Chemical	-1	15609701
,	O	-1	15609701
a	O	-1	15609701
sh@@	O	-1	15609701
ort	O	-1	15609701
duration	O	-1	15609701
of	O	-1	15609701
S@@	O	-1	15609701
T	O	-1	15609701
elev@@	O	-1	15609701
ation	O	-1	15609701
was	O	-1	15609701
doc@@	O	-1	15609701
um@@	O	-1	15609701
ent@@	O	-1	15609701
ed	O	-1	15609701
in	O	-1	15609701
EC@@	O	-1	15609701
G	O	-1	15609701
monit@@	O	-1	15609701
or@@	O	-1	15609701
ing	O	-1	15609701
at	O	-1	15609701
al@@	O	-1	15609701
most	O	-1	15609701
the	O	-1	15609701
same	O	-1	15609701
time	O	-1	15609701
for	O	-1	15609701
three	O	-1	15609701
con@@	O	-1	15609701
sec@@	O	-1	15609701
utive	O	-1	15609701
days.	O	-1	15609701
S@@	O	-1	15609701
T	O	-1	15609701
elev@@	O	-1	15609701
ation	O	-1	15609701
with	O	-1	15609701
ch@@	O	-1	15609701
est	O	-1	15609701
dis@@	O	-1	15609701
com@@	O	-1	15609701
for@@	O	-1	15609701
t	O	-1	15609701
dis@@	O	-1	15609701
appe@@	O	-1	15609701
a@@	O	-1	15609701
red	O	-1	15609701
s@@	O	-1	15609701
inc@@	O	-1	15609701
e	O	-1	15609701
he	O	-1	15609701
be@@	O	-1	15609701
g@@	O	-1	15609701
an	O	-1	15609701
taking	O	-1	15609701
long@@	O	-1	15609701
-@@	O	-1	15609701
act@@	O	-1	15609701
ing	O	-1	15609701
di@@	B-Chemical	D004110	15609701
l@@	I-Chemical	-1	15609701
ti@@	I-Chemical	-1	15609701
az@@	I-Chemical	-1	15609701
em	I-Chemical	-1	15609701
.	O	-1	15609701
C@@	B-Disease	D003329	15609701
or@@	I-Disease	-1	15609701
onary	I-Disease	-1	15609701
vas@@	I-Disease	-1	15609701
os@@	I-Disease	-1	15609701
p@@	I-Disease	-1	15609701
as@@	I-Disease	-1	15609701
m	I-Disease	-1	15609701
may	O	-1	15609701
be	O	-1	15609701
induced	O	-1	15609701
by	O	-1	15609701
the	O	-1	15609701
non-@@	O	-1	15609701
selective	O	-1	15609701
beta-@@	O	-1	15609701
block@@	O	-1	15609701
ing	O	-1	15609701
pro@@	O	-1	15609701
per@@	O	-1	15609701
ties	O	-1	15609701
of	O	-1	15609701
s@@	B-Chemical	D013015	15609701
ot@@	I-Chemical	-1	15609701
al@@	I-Chemical	-1	15609701
ol	I-Chemical	-1	15609701
.	O	-1	15609701

Eff@@	O	-1	15614572
ects	O	-1	15614572
of	O	-1	15614572
the	O	-1	15614572
antidepress@@	O	-1	15614572
ant	O	-1	15614572
tra@@	B-Chemical	D014196	15614572
z@@	I-Chemical	-1	15614572
o@@	I-Chemical	-1	15614572
d@@	I-Chemical	-1	15614572
one	I-Chemical	-1	15614572
,	O	-1	15614572
a	O	-1	15614572
5-@@	B-Chemical	D012701	15614572
H@@	I-Chemical	-1	15614572
T	I-Chemical	-1	15614572
2@@	O	-1	15614572
A@@	O	-1	15614572
/@@	O	-1	15614572
2@@	O	-1	15614572
C	O	-1	15614572
receptor	O	-1	15614572
antagonist@@	O	-1	15614572
,	O	-1	15614572
on	O	-1	15614572
dopamine	B-Chemical	D004298	15614572
-@@	O	-1	15614572
dependent	O	-1	15614572
behavi@@	O	-1	15614572
ors	O	-1	15614572
in	O	-1	15614572
rats.	O	-1	15614572
R@@	O	-1	15614572
AT@@	O	-1	15614572
ION@@	O	-1	15614572
AL@@	O	-1	15614572
E:	O	-1	15614572
5-@@	B-Chemical	D012701	15614572
H@@	I-Chemical	-1	15614572
y@@	I-Chemical	-1	15614572
dro@@	I-Chemical	-1	15614572
x@@	I-Chemical	-1	15614572
y@@	I-Chemical	-1	15614572
tr@@	I-Chemical	-1	15614572
y@@	I-Chemical	-1	15614572
pt@@	I-Chemical	-1	15614572
amine	I-Chemical	-1	15614572
,	O	-1	15614572
vi@@	O	-1	15614572
a	O	-1	15614572
stimulation	O	-1	15614572
of	O	-1	15614572
5-@@	B-Chemical	D012701	15614572
H@@	I-Chemical	-1	15614572
T	I-Chemical	-1	15614572
2@@	O	-1	15614572
C	O	-1	15614572
receptor@@	O	-1	15614572
s,	O	-1	15614572
ex@@	O	-1	15614572
er@@	O	-1	15614572
ts	O	-1	15614572
a	O	-1	15614572
t@@	O	-1	15614572
onic	O	-1	15614572
inhibit@@	O	-1	15614572
ory	O	-1	15614572
influence	O	-1	15614572
on	O	-1	15614572
dop@@	O	-1	15614572
aminergic	O	-1	15614572
neuro@@	O	-1	15614572
trans@@	O	-1	15614572
mis@@	O	-1	15614572
sion,	O	-1	15614572
whereas	O	-1	15614572
activation	O	-1	15614572
of	O	-1	15614572
5-@@	B-Chemical	D012701	15614572
H@@	I-Chemical	-1	15614572
T	I-Chemical	-1	15614572
2@@	O	-1	15614572
A	O	-1	15614572
receptors	O	-1	15614572
enh@@	O	-1	15614572
anc@@	O	-1	15614572
es	O	-1	15614572
stimul@@	O	-1	15614572
ated	O	-1	15614572
D@@	O	-1	15614572
A@@	O	-1	15614572
ergic	O	-1	15614572
neuro@@	O	-1	15614572
trans@@	O	-1	15614572
mis@@	O	-1	15614572
sion.	O	-1	15614572
The	O	-1	15614572
antidepress@@	O	-1	15614572
ant	O	-1	15614572
tra@@	B-Chemical	D014196	15614572
z@@	I-Chemical	-1	15614572
o@@	I-Chemical	-1	15614572
d@@	I-Chemical	-1	15614572
one	I-Chemical	-1	15614572
is	O	-1	15614572
a	O	-1	15614572
5-@@	B-Chemical	D012701	15614572
H@@	I-Chemical	-1	15614572
T	I-Chemical	-1	15614572
2@@	O	-1	15614572
A@@	O	-1	15614572
/@@	O	-1	15614572
2@@	O	-1	15614572
C	O	-1	15614572
receptor	O	-1	15614572
antagonist@@	O	-1	15614572
.	O	-1	15614572
OBJECTIV@@	O	-1	15614572
E@@	O	-1	15614572
S:	O	-1	15614572
To	O	-1	15614572
evalu@@	O	-1	15614572
ate	O	-1	15614572
the	O	-1	15614572
effect	O	-1	15614572
of	O	-1	15614572
tra@@	B-Chemical	D014196	15614572
z@@	I-Chemical	-1	15614572
o@@	I-Chemical	-1	15614572
d@@	I-Chemical	-1	15614572
one	I-Chemical	-1	15614572
treatment	O	-1	15614572
on	O	-1	15614572
behavi@@	O	-1	15614572
ors	O	-1	15614572
dependent	O	-1	15614572
on	O	-1	15614572
the	O	-1	15614572
functional	O	-1	15614572
status	O	-1	15614572
of	O	-1	15614572
the	O	-1	15614572
n@@	O	-1	15614572
ig@@	O	-1	15614572
ro@@	O	-1	15614572
stri@@	O	-1	15614572
atal	O	-1	15614572
D@@	O	-1	15614572
A@@	O	-1	15614572
ergic	O	-1	15614572
system@@	O	-1	15614572
.	O	-1	15614572
METHODS:	O	-1	15614572
The	O	-1	15614572
effect	O	-1	15614572
of	O	-1	15614572
pretreatment	O	-1	15614572
with	O	-1	15614572
tra@@	B-Chemical	D014196	15614572
z@@	I-Chemical	-1	15614572
o@@	I-Chemical	-1	15614572
d@@	I-Chemical	-1	15614572
one	I-Chemical	-1	15614572
on	O	-1	15614572
de@@	B-Chemical	D003913	15614572
x@@	I-Chemical	-1	15614572
amphetamine	I-Chemical	-1	15614572
-	O	-1	15614572
and	O	-1	15614572
apo@@	B-Chemical	D001058	15614572
morphine	I-Chemical	-1	15614572
-induced	O	-1	15614572
oral	B-Disease	D009062	15614572
ste@@	I-Disease	-1	15614572
re@@	I-Disease	-1	15614572
ot@@	I-Disease	-1	15614572
y@@	I-Disease	-1	15614572
pi@@	I-Disease	-1	15614572
es	I-Disease	-1	15614572
,	O	-1	15614572
on	O	-1	15614572
cat@@	B-Disease	D002375	15614572
al@@	I-Disease	-1	15614572
ep@@	I-Disease	-1	15614572
sy	I-Disease	-1	15614572
induced	O	-1	15614572
by	O	-1	15614572
haloperidol	B-Chemical	D006220	15614572
and	O	-1	15614572
apo@@	B-Chemical	D001058	15614572
morphine	I-Chemical	-1	15614572
(@@	O	-1	15614572
0.0@@	O	-1	15614572
5	O	-1	15614572
mg/kg@@	O	-1	15614572
,	O	-1	15614572
i.p.@@	O	-1	15614572
),	O	-1	15614572
on	O	-1	15614572
erg@@	B-Chemical	D004874	15614572
o@@	I-Chemical	-1	15614572
met@@	I-Chemical	-1	15614572
rine	I-Chemical	-1	15614572
-induced	O	-1	15614572
we@@	O	-1	15614572
t	O	-1	15614572
do@@	O	-1	15614572
g	O	-1	15614572
s@@	O	-1	15614572
ha@@	O	-1	15614572
k@@	O	-1	15614572
e	O	-1	15614572
(@@	O	-1	15614572
W@@	O	-1	15614572
D@@	O	-1	15614572
S)	O	-1	15614572
behavi@@	O	-1	15614572
or	O	-1	15614572
and	O	-1	15614572
flu@@	B-Chemical	D005473	15614572
ox@@	I-Chemical	-1	15614572
et@@	I-Chemical	-1	15614572
ine	I-Chemical	-1	15614572
-induced	O	-1	15614572
pen@@	O	-1	15614572
ile	O	-1	15614572
e@@	O	-1	15614572
rec@@	O	-1	15614572
tions	O	-1	15614572
was	O	-1	15614572
studied	O	-1	15614572
in	O	-1	15614572
rats.	O	-1	15614572
We	O	-1	15614572
also	O	-1	15614572
investigated	O	-1	15614572
whether	O	-1	15614572
tra@@	B-Chemical	D014196	15614572
z@@	I-Chemical	-1	15614572
o@@	I-Chemical	-1	15614572
d@@	I-Chemical	-1	15614572
one	I-Chemical	-1	15614572
induc@@	O	-1	15614572
es	O	-1	15614572
cat@@	B-Disease	D002375	15614572
al@@	I-Disease	-1	15614572
ep@@	I-Disease	-1	15614572
sy	I-Disease	-1	15614572
in	O	-1	15614572
rats.	O	-1	15614572
RESULTS:	O	-1	15614572
T@@	B-Chemical	D014196	15614572
ra@@	I-Chemical	-1	15614572
z@@	I-Chemical	-1	15614572
o@@	I-Chemical	-1	15614572
d@@	I-Chemical	-1	15614572
one	I-Chemical	-1	15614572
at	O	-1	15614572
2.@@	O	-1	15614572
5-@@	O	-1	15614572
20	O	-1	15614572
mg/kg	O	-1	15614572
i.@@	O	-1	15614572
p@@	O	-1	15614572
.	O	-1	15614572
did	O	-1	15614572
not	O	-1	15614572
induce	O	-1	15614572
cat@@	B-Disease	D002375	15614572
al@@	I-Disease	-1	15614572
ep@@	I-Disease	-1	15614572
sy	I-Disease	-1	15614572
,	O	-1	15614572
and	O	-1	15614572
did	O	-1	15614572
not	O	-1	15614572
antagon@@	O	-1	15614572
iz@@	O	-1	15614572
e	O	-1	15614572
apo@@	B-Chemical	D001058	15614572
morphine	I-Chemical	-1	15614572
(1@@	O	-1	15614572
.@@	O	-1	15614572
5	O	-1	15614572
and	O	-1	15614572
3	O	-1	15614572
mg/kg)	O	-1	15614572
ste@@	O	-1	15614572
re@@	O	-1	15614572
ot@@	O	-1	15614572
yp@@	O	-1	15614572
y	O	-1	15614572
and	O	-1	15614572
apo@@	B-Chemical	D001058	15614572
morphine	I-Chemical	-1	15614572
(@@	O	-1	15614572
0.0@@	O	-1	15614572
5	O	-1	15614572
mg/kg@@	O	-1	15614572
)@@	O	-1	15614572
-induced	O	-1	15614572
cat@@	B-Disease	D002375	15614572
al@@	I-Disease	-1	15614572
ep@@	I-Disease	-1	15614572
sy	I-Disease	-1	15614572
.	O	-1	15614572
However,	O	-1	15614572
pretreatment	O	-1	15614572
with	O	-1	15614572
5,	O	-1	15614572
10	O	-1	15614572
and	O	-1	15614572
20	O	-1	15614572
mg/kg	O	-1	15614572
i.@@	O	-1	15614572
p@@	O	-1	15614572
.	O	-1	15614572
tra@@	B-Chemical	D014196	15614572
z@@	I-Chemical	-1	15614572
o@@	I-Chemical	-1	15614572
d@@	I-Chemical	-1	15614572
one	I-Chemical	-1	15614572
enhanced	O	-1	15614572
de@@	B-Chemical	D003913	15614572
x@@	I-Chemical	-1	15614572
amphetamine	I-Chemical	-1	15614572
ste@@	O	-1	15614572
re@@	O	-1	15614572
ot@@	O	-1	15614572
yp@@	O	-1	15614572
y,	O	-1	15614572
and	O	-1	15614572
antagon@@	O	-1	15614572
ized	O	-1	15614572
haloperidol	B-Chemical	D006220	15614572
cat@@	B-Disease	D002375	15614572
al@@	I-Disease	-1	15614572
ep@@	I-Disease	-1	15614572
sy	I-Disease	-1	15614572
,	O	-1	15614572
erg@@	B-Chemical	D004874	15614572
o@@	I-Chemical	-1	15614572
met@@	I-Chemical	-1	15614572
rine	I-Chemical	-1	15614572
-induced	O	-1	15614572
W@@	O	-1	15614572
D@@	O	-1	15614572
S	O	-1	15614572
behavi@@	O	-1	15614572
or	O	-1	15614572
and	O	-1	15614572
flu@@	B-Chemical	D005473	15614572
ox@@	I-Chemical	-1	15614572
et@@	I-Chemical	-1	15614572
ine	I-Chemical	-1	15614572
-induced	O	-1	15614572
pen@@	O	-1	15614572
ile	O	-1	15614572
e@@	O	-1	15614572
rec@@	O	-1	15614572
tions.	O	-1	15614572
T@@	B-Chemical	D014196	15614572
ra@@	I-Chemical	-1	15614572
z@@	I-Chemical	-1	15614572
o@@	I-Chemical	-1	15614572
d@@	I-Chemical	-1	15614572
one	I-Chemical	-1	15614572
at	O	-1	15614572
3@@	O	-1	15614572
0@@	O	-1	15614572
,	O	-1	15614572
40	O	-1	15614572
and	O	-1	15614572
50	O	-1	15614572
mg/kg	O	-1	15614572
i.@@	O	-1	15614572
p@@	O	-1	15614572
.	O	-1	15614572
induced	O	-1	15614572
cat@@	B-Disease	D002375	15614572
al@@	I-Disease	-1	15614572
ep@@	I-Disease	-1	15614572
sy	I-Disease	-1	15614572
and	O	-1	15614572
antagon@@	O	-1	15614572
ized	O	-1	15614572
apo@@	B-Chemical	D001058	15614572
morphine	I-Chemical	-1	15614572
and	O	-1	15614572
de@@	B-Chemical	D003913	15614572
x@@	I-Chemical	-1	15614572
amphetamine	I-Chemical	-1	15614572
ste@@	O	-1	15614572
re@@	O	-1	15614572
ot@@	O	-1	15614572
y@@	O	-1	15614572
pi@@	O	-1	15614572
es.	O	-1	15614572
CONCLUSIONS:	O	-1	15614572
Our	O	-1	15614572
results	O	-1	15614572
indicate	O	-1	15614572
that	O	-1	15614572
tra@@	B-Chemical	D014196	15614572
z@@	I-Chemical	-1	15614572
o@@	I-Chemical	-1	15614572
d@@	I-Chemical	-1	15614572
one	I-Chemical	-1	15614572
at	O	-1	15614572
2.@@	O	-1	15614572
5-@@	O	-1	15614572
20	O	-1	15614572
mg/kg	O	-1	15614572
does	O	-1	15614572
not	O	-1	15614572
bloc@@	O	-1	15614572
k	O	-1	15614572
pre@@	O	-1	15614572
-	O	-1	15614572
and	O	-1	15614572
post@@	O	-1	15614572
syn@@	O	-1	15614572
ap@@	O	-1	15614572
tic	O	-1	15614572
stri@@	O	-1	15614572
atal	O	-1	15614572
D2	O	-1	15614572
D@@	O	-1	15614572
A	O	-1	15614572
receptor@@	O	-1	15614572
s,	O	-1	15614572
while	O	-1	15614572
at	O	-1	15614572
3@@	O	-1	15614572
0@@	O	-1	15614572
,	O	-1	15614572
40	O	-1	15614572
and	O	-1	15614572
50	O	-1	15614572
mg/kg	O	-1	15614572
it	O	-1	15614572
block@@	O	-1	15614572
s	O	-1	15614572
post@@	O	-1	15614572
syn@@	O	-1	15614572
ap@@	O	-1	15614572
tic	O	-1	15614572
stri@@	O	-1	15614572
atal	O	-1	15614572
D2	O	-1	15614572
D@@	O	-1	15614572
A	O	-1	15614572
receptor@@	O	-1	15614572
s.	O	-1	15614572
F@@	O	-1	15614572
ur@@	O	-1	15614572
ther@@	O	-1	15614572
mo@@	O	-1	15614572
re,	O	-1	15614572
at	O	-1	15614572
5,	O	-1	15614572
10	O	-1	15614572
and	O	-1	15614572
20	O	-1	15614572
mg/kg@@	O	-1	15614572
,	O	-1	15614572
tra@@	B-Chemical	D014196	15614572
z@@	I-Chemical	-1	15614572
o@@	I-Chemical	-1	15614572
d@@	I-Chemical	-1	15614572
one	I-Chemical	-1	15614572
block@@	O	-1	15614572
s	O	-1	15614572
5-@@	B-Chemical	D012701	15614572
H@@	I-Chemical	-1	15614572
T	I-Chemical	-1	15614572
2@@	O	-1	15614572
A	O	-1	15614572
and	O	-1	15614572
5-@@	B-Chemical	D012701	15614572
H@@	I-Chemical	-1	15614572
T	I-Chemical	-1	15614572
2@@	O	-1	15614572
C	O	-1	15614572
receptor@@	O	-1	15614572
s.	O	-1	15614572
We	O	-1	15614572
suggest	O	-1	15614572
that	O	-1	15614572
tra@@	B-Chemical	D014196	15614572
z@@	I-Chemical	-1	15614572
o@@	I-Chemical	-1	15614572
d@@	I-Chemical	-1	15614572
one	I-Chemical	-1	15614572
(5@@	O	-1	15614572
,	O	-1	15614572
10	O	-1	15614572
and	O	-1	15614572
20	O	-1	15614572
mg/kg@@	O	-1	15614572
),	O	-1	15614572
by	O	-1	15614572
block@@	O	-1	15614572
ing	O	-1	15614572
the	O	-1	15614572
5-@@	B-Chemical	D012701	15614572
H@@	I-Chemical	-1	15614572
T	I-Chemical	-1	15614572
2@@	O	-1	15614572
C	O	-1	15614572
receptor@@	O	-1	15614572
s,	O	-1	15614572
rele@@	O	-1	15614572
as@@	O	-1	15614572
es	O	-1	15614572
the	O	-1	15614572
n@@	O	-1	15614572
ig@@	O	-1	15614572
ro@@	O	-1	15614572
stri@@	O	-1	15614572
atal	O	-1	15614572
D@@	O	-1	15614572
A@@	O	-1	15614572
ergic	O	-1	15614572
neuron@@	O	-1	15614572
s	O	-1	15614572
from	O	-1	15614572
t@@	O	-1	15614572
onic	O	-1	15614572
inhibition	O	-1	15614572
caused	O	-1	15614572
by	O	-1	15614572
5-@@	B-Chemical	D012701	15614572
H@@	I-Chemical	-1	15614572
T	I-Chemical	-1	15614572
,	O	-1	15614572
and	O	-1	15614572
the@@	O	-1	15614572
re@@	O	-1	15614572
by	O	-1	15614572
potenti@@	O	-1	15614572
ates	O	-1	15614572
de@@	B-Chemical	D003913	15614572
x@@	I-Chemical	-1	15614572
amphetamine	I-Chemical	-1	15614572
ste@@	O	-1	15614572
re@@	O	-1	15614572
ot@@	O	-1	15614572
yp@@	O	-1	15614572
y	O	-1	15614572
and	O	-1	15614572
antagon@@	O	-1	15614572
iz@@	O	-1	15614572
es	O	-1	15614572
haloperidol	B-Chemical	D006220	15614572
cat@@	B-Disease	D002375	15614572
al@@	I-Disease	-1	15614572
ep@@	I-Disease	-1	15614572
sy	I-Disease	-1	15614572
.	O	-1	15614572

S@@	B-Disease	D020447	15625689
w@@	I-Disease	-1	15625689
al@@	I-Disease	-1	15625689
low@@	I-Disease	-1	15625689
ing	I-Disease	-1	15625689
abnormal@@	I-Disease	-1	15625689
ities	I-Disease	-1	15625689
and	O	-1	15625689
dyskine@@	B-Disease	D004409	15625689
sia	I-Disease	-1	15625689
in	O	-1	15625689
Parkinson's	B-Disease	D010300	15625689
disease	I-Disease	-1	15625689
.	O	-1	15625689
G@@	B-Disease	D005767	15625689
ast@@	I-Disease	-1	15625689
ro@@	I-Disease	-1	15625689
in@@	I-Disease	-1	15625689
test@@	I-Disease	-1	15625689
inal	I-Disease	-1	15625689
abnormal@@	I-Disease	-1	15625689
ities	I-Disease	-1	15625689
in	O	-1	15625689
Parkinson's	B-Disease	D010300	15625689
disease	I-Disease	-1	15625689
(	O	-1	15625689
P@@	B-Disease	D010300	15625689
D	I-Disease	-1	15625689
)	O	-1	15625689
have	O	-1	15625689
been	O	-1	15625689
known	O	-1	15625689
for	O	-1	15625689
al@@	O	-1	15625689
most	O	-1	15625689
two	O	-1	15625689
c@@	O	-1	15625689
ent@@	O	-1	15625689
ur@@	O	-1	15625689
i@@	O	-1	15625689
es,	O	-1	15625689
but	O	-1	15625689
man@@	O	-1	15625689
y	O	-1	15625689
as@@	O	-1	15625689
p@@	O	-1	15625689
ects	O	-1	15625689
con@@	O	-1	15625689
cer@@	O	-1	15625689
ning	O	-1	15625689
their	O	-1	15625689
path@@	O	-1	15625689
oph@@	O	-1	15625689
ysi@@	O	-1	15625689
ology	O	-1	15625689
have	O	-1	15625689
not	O	-1	15625689
been	O	-1	15625689
complete@@	O	-1	15625689
ly	O	-1	15625689
cl@@	O	-1	15625689
ar@@	O	-1	15625689
if@@	O	-1	15625689
i@@	O	-1	15625689
ed.	O	-1	15625689
The	O	-1	15625689
a@@	O	-1	15625689
im	O	-1	15625689
of	O	-1	15625689
this	O	-1	15625689
study	O	-1	15625689
was	O	-1	15625689
to	O	-1	15625689
character@@	O	-1	15625689
iz@@	O	-1	15625689
e	O	-1	15625689
the	O	-1	15625689
o@@	O	-1	15625689
ro@@	O	-1	15625689
ph@@	O	-1	15625689
ar@@	O	-1	15625689
yn@@	O	-1	15625689
ge@@	O	-1	15625689
al	O	-1	15625689
dynam@@	O	-1	15625689
ic@@	O	-1	15625689
s	O	-1	15625689
in	O	-1	15625689
P@@	B-Disease	D010300	15625689
D	I-Disease	-1	15625689
patients	O	-1	15625689
with	O	-1	15625689
and	O	-1	15625689
without	O	-1	15625689
levo@@	B-Chemical	D007980	15625689
dopa	I-Chemical	-1	15625689
-induced	O	-1	15625689
dyskine@@	B-Disease	D004409	15625689
sia	I-Disease	-1	15625689
.	O	-1	15625689
F@@	O	-1	15625689
if@@	O	-1	15625689
te@@	O	-1	15625689
en	O	-1	15625689
dyskine@@	B-Disease	D004409	15625689
tic	I-Disease	-1	15625689
,	O	-1	15625689
12	O	-1	15625689
non@@	O	-1	15625689
dyskine@@	O	-1	15625689
tic	O	-1	15625689
patients,	O	-1	15625689
and	O	-1	15625689
a	O	-1	15625689
control	O	-1	15625689
group	O	-1	15625689
were	O	-1	15625689
inc@@	O	-1	15625689
lu@@	O	-1	15625689
de@@	O	-1	15625689
d.	O	-1	15625689
Patients	O	-1	15625689
were	O	-1	15625689
as@@	O	-1	15625689
ked	O	-1	15625689
about	O	-1	15625689
dys@@	B-Disease	D003680	15625689
ph@@	I-Disease	-1	15625689
ag@@	I-Disease	-1	15625689
ia	I-Disease	-1	15625689
and	O	-1	15625689
evaluated	O	-1	15625689
with	O	-1	15625689
the	O	-1	15625689
U@@	O	-1	15625689
n@@	O	-1	15625689
if@@	O	-1	15625689
ied	O	-1	15625689
Parkinson's	B-Disease	D010300	15625689
Di@@	I-Disease	-1	15625689
se@@	I-Disease	-1	15625689
ase	I-Disease	-1	15625689
R@@	O	-1	15625689
ating	O	-1	15625689
S@@	O	-1	15625689
cal@@	O	-1	15625689
e	O	-1	15625689
P@@	O	-1	15625689
ar@@	O	-1	15625689
ts	O	-1	15625689
II	O	-1	15625689
and	O	-1	15625689
I@@	O	-1	15625689
II	O	-1	15625689
and	O	-1	15625689
the	O	-1	15625689
Ho@@	O	-1	15625689
e@@	O	-1	15625689
h@@	O	-1	15625689
n	O	-1	15625689
and	O	-1	15625689
Y@@	O	-1	15625689
a@@	O	-1	15625689
h@@	O	-1	15625689
r	O	-1	15625689
s@@	O	-1	15625689
cal@@	O	-1	15625689
e.	O	-1	15625689
De@@	O	-1	15625689
g@@	O	-1	15625689
lu@@	O	-1	15625689
ti@@	O	-1	15625689
tion	O	-1	15625689
was	O	-1	15625689
assessed	O	-1	15625689
using	O	-1	15625689
mo@@	O	-1	15625689
di@@	O	-1	15625689
fied	O	-1	15625689
b@@	B-Chemical	D001464	15625689
ari@@	I-Chemical	-1	15625689
um	I-Chemical	-1	15625689
s@@	O	-1	15625689
w@@	O	-1	15625689
al@@	O	-1	15625689
low	O	-1	15625689
with	O	-1	15625689
vi@@	O	-1	15625689
de@@	O	-1	15625689
o@@	O	-1	15625689
fluoro@@	O	-1	15625689
sco@@	O	-1	15625689
p@@	O	-1	15625689
y.	O	-1	15625689
N@@	O	-1	15625689
on@@	O	-1	15625689
dyskine@@	O	-1	15625689
tic	O	-1	15625689
patients,	O	-1	15625689
but	O	-1	15625689
not	O	-1	15625689
the	O	-1	15625689
dyskine@@	B-Disease	D004409	15625689
tic	I-Disease	-1	15625689
on@@	O	-1	15625689
es,	O	-1	15625689
showed	O	-1	15625689
less	O	-1	15625689
o@@	O	-1	15625689
ro@@	O	-1	15625689
ph@@	O	-1	15625689
ar@@	O	-1	15625689
yn@@	O	-1	15625689
ge@@	O	-1	15625689
al	O	-1	15625689
s@@	O	-1	15625689
w@@	O	-1	15625689
al@@	O	-1	15625689
low@@	O	-1	15625689
ing	O	-1	15625689
eff@@	O	-1	15625689
ici@@	O	-1	15625689
ency	O	-1	15625689
(@@	O	-1	15625689
O@@	O	-1	15625689
P@@	O	-1	15625689
S@@	O	-1	15625689
E@@	O	-1	15625689
)	O	-1	15625689
for	O	-1	15625689
li@@	O	-1	15625689
qu@@	O	-1	15625689
id	O	-1	15625689
fo@@	O	-1	15625689
od	O	-1	15625689
than	O	-1	15625689
controls	O	-1	15625689
(D@@	O	-1	15625689
un@@	O	-1	15625689
ne@@	O	-1	15625689
t@@	O	-1	15625689
t,	O	-1	15625689
P	O	-1	15625689
=	O	-1	15625689
0.0@@	O	-1	15625689
2@@	O	-1	15625689
).	O	-1	15625689
D@@	B-Disease	D004409	15625689
ys@@	I-Disease	-1	15625689
kine@@	I-Disease	-1	15625689
tic	I-Disease	-1	15625689
patients	O	-1	15625689
ten@@	O	-1	15625689
ded	O	-1	15625689
to	O	-1	15625689
have	O	-1	15625689
a	O	-1	15625689
greater	O	-1	15625689
O@@	O	-1	15625689
P@@	O	-1	15625689
S@@	O	-1	15625689
E	O	-1	15625689
than	O	-1	15625689
non@@	O	-1	15625689
dyskine@@	O	-1	15625689
tic	O	-1	15625689
(D@@	O	-1	15625689
un@@	O	-1	15625689
ne@@	O	-1	15625689
t@@	O	-1	15625689
t,	O	-1	15625689
P	O	-1	15625689
=	O	-1	15625689
0.0@@	O	-1	15625689
6@@	O	-1	15625689
).	O	-1	15625689
Patients	O	-1	15625689
who	O	-1	15625689
were	O	-1	15625689
using	O	-1	15625689
a	O	-1	15625689
higher	O	-1	15625689
dose	O	-1	15625689
of	O	-1	15625689
levo@@	B-Chemical	D007980	15625689
dopa	I-Chemical	-1	15625689
had	O	-1	15625689
a	O	-1	15625689
greater	O	-1	15625689
O@@	O	-1	15625689
P@@	O	-1	15625689
S@@	O	-1	15625689
E	O	-1	15625689
and	O	-1	15625689
a	O	-1	15625689
tre@@	O	-1	15625689
n@@	O	-1	15625689
d	O	-1	15625689
to@@	O	-1	15625689
war@@	O	-1	15625689
d	O	-1	15625689
a	O	-1	15625689
sm@@	O	-1	15625689
all@@	O	-1	15625689
er	O	-1	15625689
oral	O	-1	15625689
transi@@	O	-1	15625689
t	O	-1	15625689
time	O	-1	15625689
(P@@	O	-1	15625689
ear@@	O	-1	15625689
son@@	O	-1	15625689
's	O	-1	15625689
correl@@	O	-1	15625689
ation,	O	-1	15625689
P	O	-1	15625689
=	O	-1	15625689
0.0@@	O	-1	15625689
1	O	-1	15625689
and	O	-1	15625689
0.0@@	O	-1	15625689
8@@	O	-1	15625689
,	O	-1	15625689
respectivel@@	O	-1	15625689
y@@	O	-1	15625689
).	O	-1	15625689
N@@	O	-1	15625689
either	O	-1	15625689
the	O	-1	15625689
report	O	-1	15625689
of	O	-1	15625689
dys@@	B-Disease	D003680	15625689
ph@@	I-Disease	-1	15625689
ag@@	I-Disease	-1	15625689
ia	I-Disease	-1	15625689
n@@	O	-1	15625689
or	O	-1	15625689
any	O	-1	15625689
of	O	-1	15625689
the	O	-1	15625689
P@@	B-Disease	D010300	15625689
D	I-Disease	-1	15625689
severity	O	-1	15625689
par@@	O	-1	15625689
ame@@	O	-1	15625689
ters	O	-1	15625689
cor@@	O	-1	15625689
related	O	-1	15625689
to	O	-1	15625689
the	O	-1	15625689
vi@@	O	-1	15625689
de@@	O	-1	15625689
o@@	O	-1	15625689
fluoro@@	O	-1	15625689
sco@@	O	-1	15625689
p@@	O	-1	15625689
ic	O	-1	15625689
vari@@	O	-1	15625689
abl@@	O	-1	15625689
es.	O	-1	15625689
In	O	-1	15625689
the	O	-1	15625689
current	O	-1	15625689
study,	O	-1	15625689
dyskine@@	B-Disease	D004409	15625689
tic	I-Disease	-1	15625689
patients	O	-1	15625689
performed	O	-1	15625689
bet@@	O	-1	15625689
ter	O	-1	15625689
in	O	-1	15625689
s@@	O	-1	15625689
w@@	O	-1	15625689
al@@	O	-1	15625689
low@@	O	-1	15625689
ing	O	-1	15625689
func@@	O	-1	15625689
tion,	O	-1	15625689
which	O	-1	15625689
could	O	-1	15625689
be	O	-1	15625689
expl@@	O	-1	15625689
ained	O	-1	15625689
on	O	-1	15625689
the	O	-1	15625689
b@@	O	-1	15625689
asis	O	-1	15625689
of	O	-1	15625689
a	O	-1	15625689
greater	O	-1	15625689
levo@@	B-Chemical	D007980	15625689
dopa	I-Chemical	-1	15625689
dose.	O	-1	15625689
Our	O	-1	15625689
results	O	-1	15625689
suggest	O	-1	15625689
a	O	-1	15625689
role	O	-1	15625689
for	O	-1	15625689
levo@@	B-Chemical	D007980	15625689
dopa	I-Chemical	-1	15625689
in	O	-1	15625689
the	O	-1	15625689
oral	O	-1	15625689
phase	O	-1	15625689
of	O	-1	15625689
de@@	O	-1	15625689
g@@	O	-1	15625689
lu@@	O	-1	15625689
ti@@	O	-1	15625689
tion	O	-1	15625689
and	O	-1	15625689
con@@	O	-1	15625689
fir@@	O	-1	15625689
m	O	-1	15625689
that	O	-1	15625689
dys@@	B-Disease	D003680	15625689
ph@@	I-Disease	-1	15625689
ag@@	I-Disease	-1	15625689
ia	I-Disease	-1	15625689
is	O	-1	15625689
not	O	-1	15625689
a	O	-1	15625689
go@@	O	-1	15625689
od	O	-1	15625689
predic@@	O	-1	15625689
t@@	O	-1	15625689
or	O	-1	15625689
of	O	-1	15625689
de@@	O	-1	15625689
g@@	O	-1	15625689
lu@@	O	-1	15625689
ti@@	O	-1	15625689
tion	O	-1	15625689
al@@	O	-1	15625689
ter@@	O	-1	15625689
ations	O	-1	15625689
in	O	-1	15625689
P@@	B-Disease	D010300	15625689
D	I-Disease	-1	15625689
.	O	-1	15625689

In@@	O	-1	15627798
hib@@	O	-1	15627798
ition	O	-1	15627798
of	O	-1	15627798
nucle@@	O	-1	15627798
ar	O	-1	15627798
fact@@	O	-1	15627798
or@@	O	-1	15627798
-@@	O	-1	15627798
k@@	O	-1	15627798
appa@@	O	-1	15627798
B	O	-1	15627798
activation	O	-1	15627798
attenu@@	O	-1	15627798
ates	O	-1	15627798
tu@@	B-Disease	D009395	15627798
bu@@	I-Disease	-1	15627798
lo@@	I-Disease	-1	15627798
interstitial	I-Disease	-1	15627798
neph@@	I-Disease	-1	15627798
ritis	I-Disease	-1	15627798
induced	O	-1	15627798
by	O	-1	15627798
g@@	B-Chemical	D005839	15627798
ent@@	I-Chemical	-1	15627798
am@@	I-Chemical	-1	15627798
icin	I-Chemical	-1	15627798
.	O	-1	15627798
BACKGROUND:	O	-1	15627798
An@@	O	-1	15627798
im@@	O	-1	15627798
als	O	-1	15627798
treated	O	-1	15627798
with	O	-1	15627798
g@@	B-Chemical	D005839	15627798
ent@@	I-Chemical	-1	15627798
am@@	I-Chemical	-1	15627798
icin	I-Chemical	-1	15627798
can	O	-1	15627798
show	O	-1	15627798
re@@	O	-1	15627798
si@@	O	-1	15627798
du@@	O	-1	15627798
al	O	-1	15627798
a@@	O	-1	15627798
reas	O	-1	15627798
of	O	-1	15627798
interstitial	O	-1	15627798
fib@@	B-Disease	D005355	15627798
ro@@	I-Disease	-1	15627798
sis	I-Disease	-1	15627798
in	O	-1	15627798
the	O	-1	15627798
renal	O	-1	15627798
cor@@	O	-1	15627798
t@@	O	-1	15627798
ex@@	O	-1	15627798
.	O	-1	15627798
This	O	-1	15627798
study	O	-1	15627798
investigated	O	-1	15627798
the	O	-1	15627798
expression	O	-1	15627798
of	O	-1	15627798
nucle@@	O	-1	15627798
ar	O	-1	15627798
fact@@	O	-1	15627798
or@@	O	-1	15627798
-@@	O	-1	15627798
k@@	O	-1	15627798
appa@@	O	-1	15627798
B	O	-1	15627798
(N@@	O	-1	15627798
F@@	O	-1	15627798
-@@	O	-1	15627798
k@@	O	-1	15627798
appa@@	O	-1	15627798
B@@	O	-1	15627798
),	O	-1	15627798
mit@@	O	-1	15627798
o@@	O	-1	15627798
gen@@	O	-1	15627798
-@@	O	-1	15627798
activ@@	O	-1	15627798
ated	O	-1	15627798
protein	O	-1	15627798
(@@	O	-1	15627798
MA@@	O	-1	15627798
P)	O	-1	15627798
kin@@	O	-1	15627798
as@@	O	-1	15627798
es	O	-1	15627798
and	O	-1	15627798
mac@@	O	-1	15627798
ro@@	O	-1	15627798
ph@@	O	-1	15627798
ages	O	-1	15627798
in	O	-1	15627798
the	O	-1	15627798
renal	O	-1	15627798
cor@@	O	-1	15627798
te@@	O	-1	15627798
x	O	-1	15627798
and	O	-1	15627798
struct@@	O	-1	15627798
ural	O	-1	15627798
and	O	-1	15627798
functional	O	-1	15627798
renal	O	-1	15627798
changes	O	-1	15627798
of	O	-1	15627798
rats	O	-1	15627798
treated	O	-1	15627798
with	O	-1	15627798
g@@	B-Chemical	D005839	15627798
ent@@	I-Chemical	-1	15627798
am@@	I-Chemical	-1	15627798
icin	I-Chemical	-1	15627798
or	O	-1	15627798
g@@	B-Chemical	D005839	15627798
ent@@	I-Chemical	-1	15627798
am@@	I-Chemical	-1	15627798
icin	I-Chemical	-1	15627798
+	O	-1	15627798
py@@	B-Chemical	C020972	15627798
r@@	I-Chemical	-1	15627798
ro@@	I-Chemical	-1	15627798
l@@	I-Chemical	-1	15627798
idine	I-Chemical	-1	15627798
di@@	I-Chemical	-1	15627798
thi@@	I-Chemical	-1	15627798
oc@@	I-Chemical	-1	15627798
arb@@	I-Chemical	-1	15627798
am@@	I-Chemical	-1	15627798
ate	I-Chemical	-1	15627798
(	O	-1	15627798
P@@	B-Chemical	C020972	15627798
D@@	I-Chemical	-1	15627798
T@@	I-Chemical	-1	15627798
C	I-Chemical	-1	15627798
),	O	-1	15627798
an	O	-1	15627798
N@@	O	-1	15627798
F@@	O	-1	15627798
-@@	O	-1	15627798
k@@	O	-1	15627798
appa@@	O	-1	15627798
B	O	-1	15627798
inhibitor@@	O	-1	15627798
.	O	-1	15627798
METHODS:	O	-1	15627798
3@@	O	-1	15627798
8	O	-1	15627798
female	O	-1	15627798
Wistar	O	-1	15627798
rats	O	-1	15627798
were	O	-1	15627798
injected	O	-1	15627798
with	O	-1	15627798
g@@	B-Chemical	D005839	15627798
ent@@	I-Chemical	-1	15627798
am@@	I-Chemical	-1	15627798
icin	I-Chemical	-1	15627798
,	O	-1	15627798
40	O	-1	15627798
mg/kg@@	O	-1	15627798
,	O	-1	15627798
tw@@	O	-1	15627798
ic@@	O	-1	15627798
e	O	-1	15627798
a	O	-1	15627798
day	O	-1	15627798
for	O	-1	15627798
9	O	-1	15627798
day@@	O	-1	15627798
s,	O	-1	15627798
3@@	O	-1	15627798
8	O	-1	15627798
with	O	-1	15627798
g@@	B-Chemical	D005839	15627798
ent@@	I-Chemical	-1	15627798
am@@	I-Chemical	-1	15627798
icin	I-Chemical	-1	15627798
+	O	-1	15627798
P@@	B-Chemical	C020972	15627798
D@@	I-Chemical	-1	15627798
T@@	I-Chemical	-1	15627798
C	I-Chemical	-1	15627798
,	O	-1	15627798
and	O	-1	15627798
2@@	O	-1	15627798
8	O	-1	15627798
with	O	-1	15627798
0.@@	O	-1	15627798
15	O	-1	15627798
M	O	-1	15627798
Na@@	B-Chemical	D012965	15627798
C@@	I-Chemical	-1	15627798
l	I-Chemical	-1	15627798
sol@@	O	-1	15627798
u@@	O	-1	15627798
tion.	O	-1	15627798
The	O	-1	15627798
animals	O	-1	15627798
were	O	-1	15627798
k@@	O	-1	15627798
ill@@	O	-1	15627798
ed	O	-1	15627798
5	O	-1	15627798
and	O	-1	15627798
30	O	-1	15627798
days	O	-1	15627798
after	O	-1	15627798
these	O	-1	15627798
injec@@	O	-1	15627798
tions	O	-1	15627798
and	O	-1	15627798
the	O	-1	15627798
kidne@@	O	-1	15627798
ys	O	-1	15627798
were	O	-1	15627798
re@@	O	-1	15627798
mo@@	O	-1	15627798
ved	O	-1	15627798
for	O	-1	15627798
hist@@	O	-1	15627798
ological	O	-1	15627798
and	O	-1	15627798
immuno@@	O	-1	15627798
histo@@	O	-1	15627798
chemical	O	-1	15627798
studi@@	O	-1	15627798
es.	O	-1	15627798
The	O	-1	15627798
results	O	-1	15627798
of	O	-1	15627798
the	O	-1	15627798
immuno@@	O	-1	15627798
histo@@	O	-1	15627798
chemical	O	-1	15627798
studies	O	-1	15627798
were	O	-1	15627798
sco@@	O	-1	15627798
red	O	-1	15627798
ac@@	O	-1	15627798
cor@@	O	-1	15627798
ding	O	-1	15627798
to	O	-1	15627798
the	O	-1	15627798
ext@@	O	-1	15627798
ent	O	-1	15627798
of	O	-1	15627798
st@@	O	-1	15627798
ain@@	O	-1	15627798
ing.	O	-1	15627798
The	O	-1	15627798
frac@@	O	-1	15627798
tional	O	-1	15627798
interstitial	O	-1	15627798
a@@	O	-1	15627798
re@@	O	-1	15627798
a	O	-1	15627798
was	O	-1	15627798
determined	O	-1	15627798
by	O	-1	15627798
morph@@	O	-1	15627798
o@@	O	-1	15627798
met@@	O	-1	15627798
r@@	O	-1	15627798
y.	O	-1	15627798
RESULTS:	O	-1	15627798
G@@	B-Chemical	D005839	15627798
ent@@	I-Chemical	-1	15627798
am@@	I-Chemical	-1	15627798
icin	I-Chemical	-1	15627798
-treated	O	-1	15627798
rats	O	-1	15627798
presented	O	-1	15627798
a	O	-1	15627798
trans@@	O	-1	15627798
it@@	O	-1	15627798
ory	O	-1	15627798
increase	O	-1	15627798
in	O	-1	15627798
plasma	O	-1	15627798
creatinine	B-Chemical	D003404	15627798
level@@	O	-1	15627798
s.	O	-1	15627798
In@@	O	-1	15627798
c@@	O	-1	15627798
reas@@	O	-1	15627798
ed	O	-1	15627798
E@@	O	-1	15627798
D@@	O	-1	15627798
-1@@	O	-1	15627798
,	O	-1	15627798
MA@@	O	-1	15627798
P	O	-1	15627798
kin@@	O	-1	15627798
as@@	O	-1	15627798
es	O	-1	15627798
and	O	-1	15627798
N@@	O	-1	15627798
F@@	O	-1	15627798
-@@	O	-1	15627798
k@@	O	-1	15627798
appa@@	O	-1	15627798
B	O	-1	15627798
st@@	O	-1	15627798
aining	O	-1	15627798
were	O	-1	15627798
also	O	-1	15627798
observed	O	-1	15627798
in	O	-1	15627798
the	O	-1	15627798
renal	O	-1	15627798
cor@@	O	-1	15627798
te@@	O	-1	15627798
x	O	-1	15627798
from	O	-1	15627798
all	O	-1	15627798
g@@	B-Chemical	D005839	15627798
ent@@	I-Chemical	-1	15627798
am@@	I-Chemical	-1	15627798
icin	I-Chemical	-1	15627798
-treated	O	-1	15627798
rats	O	-1	15627798
compared	O	-1	15627798
to	O	-1	15627798
control	O	-1	15627798
(p	O	-1	15627798
<	O	-1	15627798
0.05@@	O	-1	15627798
).	O	-1	15627798
The	O	-1	15627798
animals	O	-1	15627798
k@@	O	-1	15627798
ill@@	O	-1	15627798
ed	O	-1	15627798
on	O	-1	15627798
day	O	-1	15627798
30	O	-1	15627798
also	O	-1	15627798
presented	O	-1	15627798
fib@@	B-Disease	D005355	15627798
ro@@	I-Disease	-1	15627798
sis	I-Disease	-1	15627798
in	O	-1	15627798
the	O	-1	15627798
renal	O	-1	15627798
cor@@	O	-1	15627798
te@@	O	-1	15627798
x	O	-1	15627798
des@@	O	-1	15627798
pit@@	O	-1	15627798
e	O	-1	15627798
the	O	-1	15627798
recovery	O	-1	15627798
of	O	-1	15627798
renal	O	-1	15627798
func@@	O	-1	15627798
tion.	O	-1	15627798
Treat@@	O	-1	15627798
ment	O	-1	15627798
with	O	-1	15627798
P@@	B-Chemical	C020972	15627798
D@@	I-Chemical	-1	15627798
T@@	I-Chemical	-1	15627798
C	I-Chemical	-1	15627798
reduced	O	-1	15627798
the	O	-1	15627798
functional	O	-1	15627798
and	O	-1	15627798
struct@@	O	-1	15627798
ural	O	-1	15627798
changes	O	-1	15627798
induced	O	-1	15627798
by	O	-1	15627798
g@@	B-Chemical	D005839	15627798
ent@@	I-Chemical	-1	15627798
am@@	I-Chemical	-1	15627798
icin	I-Chemical	-1	15627798
.	O	-1	15627798
CONCLUSIONS:	O	-1	15627798
These	O	-1	15627798
data	O	-1	15627798
show	O	-1	15627798
that	O	-1	15627798
inhibition	O	-1	15627798
of	O	-1	15627798
N@@	O	-1	15627798
F@@	O	-1	15627798
-@@	O	-1	15627798
k@@	O	-1	15627798
appa@@	O	-1	15627798
B	O	-1	15627798
activation	O	-1	15627798
attenu@@	O	-1	15627798
ates	O	-1	15627798
tu@@	B-Disease	D009395	15627798
bu@@	I-Disease	-1	15627798
lo@@	I-Disease	-1	15627798
interstitial	I-Disease	-1	15627798
neph@@	I-Disease	-1	15627798
ritis	I-Disease	-1	15627798
induced	O	-1	15627798
by	O	-1	15627798
g@@	B-Chemical	D005839	15627798
ent@@	I-Chemical	-1	15627798
am@@	I-Chemical	-1	15627798
icin	I-Chemical	-1	15627798
.	O	-1	15627798

G@@	B-Chemical	D005947	15630069
lu@@	I-Chemical	-1	15630069
co@@	I-Chemical	-1	15630069
se	I-Chemical	-1	15630069
metabol@@	O	-1	15630069
ism	O	-1	15630069
in	O	-1	15630069
patients	O	-1	15630069
with	O	-1	15630069
sch@@	B-Disease	D012559	15630069
iz@@	I-Disease	-1	15630069
oph@@	I-Disease	-1	15630069
ren@@	I-Disease	-1	15630069
ia	I-Disease	-1	15630069
treated	O	-1	15630069
with	O	-1	15630069
at@@	O	-1	15630069
yp@@	O	-1	15630069
ical	O	-1	15630069
anti@@	O	-1	15630069
psycho@@	O	-1	15630069
tic	O	-1	15630069
agent@@	O	-1	15630069
s:	O	-1	15630069
a	O	-1	15630069
frequ@@	O	-1	15630069
ently	O	-1	15630069
sam@@	O	-1	15630069
pl@@	O	-1	15630069
ed	O	-1	15630069
intravenous	O	-1	15630069
g@@	B-Chemical	D005947	15630069
lu@@	I-Chemical	-1	15630069
co@@	I-Chemical	-1	15630069
se	I-Chemical	-1	15630069
toler@@	O	-1	15630069
ance	O	-1	15630069
test	O	-1	15630069
and	O	-1	15630069
minim@@	O	-1	15630069
al	O	-1	15630069
model	O	-1	15630069
analy@@	O	-1	15630069
sis.	O	-1	15630069
BACKGROUND:	O	-1	15630069
W@@	O	-1	15630069
h@@	O	-1	15630069
ile	O	-1	15630069
the	O	-1	15630069
incidence	O	-1	15630069
of	O	-1	15630069
ne@@	O	-1	15630069
w@@	O	-1	15630069
-@@	O	-1	15630069
onset	O	-1	15630069
dia@@	B-Disease	D003920	15630069
bet@@	I-Disease	-1	15630069
es	I-Disease	-1	15630069
me@@	I-Disease	-1	15630069
ll@@	I-Disease	-1	15630069
it@@	I-Disease	-1	15630069
us	I-Disease	-1	15630069
may	O	-1	15630069
be	O	-1	15630069
increas@@	O	-1	15630069
ing	O	-1	15630069
in	O	-1	15630069
patients	O	-1	15630069
with	O	-1	15630069
sch@@	B-Disease	D012559	15630069
iz@@	I-Disease	-1	15630069
oph@@	I-Disease	-1	15630069
ren@@	I-Disease	-1	15630069
ia	I-Disease	-1	15630069
treated	O	-1	15630069
with	O	-1	15630069
cer@@	O	-1	15630069
t@@	O	-1	15630069
ain	O	-1	15630069
at@@	O	-1	15630069
yp@@	O	-1	15630069
ical	O	-1	15630069
anti@@	O	-1	15630069
psycho@@	O	-1	15630069
tic	O	-1	15630069
agent@@	O	-1	15630069
s,	O	-1	15630069
it	O	-1	15630069
remain@@	O	-1	15630069
s	O	-1	15630069
unc@@	O	-1	15630069
le@@	O	-1	15630069
ar	O	-1	15630069
whether	O	-1	15630069
at@@	O	-1	15630069
yp@@	O	-1	15630069
ical	O	-1	15630069
agents	O	-1	15630069
are	O	-1	15630069
direc@@	O	-1	15630069
tly	O	-1	15630069
aff@@	O	-1	15630069
ect@@	O	-1	15630069
ing	O	-1	15630069
g@@	B-Chemical	D005947	15630069
lu@@	I-Chemical	-1	15630069
co@@	I-Chemical	-1	15630069
se	I-Chemical	-1	15630069
metabol@@	O	-1	15630069
ism	O	-1	15630069
or	O	-1	15630069
sim@@	O	-1	15630069
p@@	O	-1	15630069
ly	O	-1	15630069
increas@@	O	-1	15630069
ing	O	-1	15630069
known	O	-1	15630069
risk	O	-1	15630069
factors	O	-1	15630069
for	O	-1	15630069
dia@@	B-Disease	D003920	15630069
bet@@	I-Disease	-1	15630069
es	I-Disease	-1	15630069
.	O	-1	15630069
OBJECTIVE:	O	-1	15630069
To	O	-1	15630069
study	O	-1	15630069
the	O	-1	15630069
2	O	-1	15630069
drugs	O	-1	15630069
most	O	-1	15630069
clear@@	O	-1	15630069
ly	O	-1	15630069
implic@@	O	-1	15630069
ated	O	-1	15630069
(	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
and	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
)	O	-1	15630069
and	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
using	O	-1	15630069
a	O	-1	15630069
frequ@@	O	-1	15630069
ently	O	-1	15630069
sam@@	O	-1	15630069
pl@@	O	-1	15630069
ed	O	-1	15630069
intravenous	O	-1	15630069
g@@	B-Chemical	D005947	15630069
lu@@	I-Chemical	-1	15630069
co@@	I-Chemical	-1	15630069
se	I-Chemical	-1	15630069
toler@@	O	-1	15630069
ance	O	-1	15630069
test@@	O	-1	15630069
.	O	-1	15630069
D@@	O	-1	15630069
ES@@	O	-1	15630069
I@@	O	-1	15630069
G@@	O	-1	15630069
N@@	O	-1	15630069
:	O	-1	15630069
A	O	-1	15630069
cros@@	O	-1	15630069
s-@@	O	-1	15630069
sec@@	O	-1	15630069
tional	O	-1	15630069
desi@@	O	-1	15630069
g@@	O	-1	15630069
n	O	-1	15630069
in	O	-1	15630069
st@@	O	-1	15630069
able@@	O	-1	15630069
,	O	-1	15630069
treated	O	-1	15630069
patients	O	-1	15630069
with	O	-1	15630069
sch@@	B-Disease	D012559	15630069
iz@@	I-Disease	-1	15630069
oph@@	I-Disease	-1	15630069
ren@@	I-Disease	-1	15630069
ia	I-Disease	-1	15630069
evaluated	O	-1	15630069
using	O	-1	15630069
a	O	-1	15630069
frequ@@	O	-1	15630069
ently	O	-1	15630069
sam@@	O	-1	15630069
pl@@	O	-1	15630069
ed	O	-1	15630069
intravenous	O	-1	15630069
g@@	B-Chemical	D005947	15630069
lu@@	I-Chemical	-1	15630069
co@@	I-Chemical	-1	15630069
se	I-Chemical	-1	15630069
toler@@	O	-1	15630069
ance	O	-1	15630069
test	O	-1	15630069
and	O	-1	15630069
the	O	-1	15630069
B@@	O	-1	15630069
erg@@	O	-1	15630069
man	O	-1	15630069
minim@@	O	-1	15630069
al	O	-1	15630069
model	O	-1	15630069
analy@@	O	-1	15630069
sis.	O	-1	15630069
S@@	O	-1	15630069
ET@@	O	-1	15630069
TI@@	O	-1	15630069
N@@	O	-1	15630069
G@@	O	-1	15630069
:	O	-1	15630069
S@@	O	-1	15630069
ub@@	O	-1	15630069
j@@	O	-1	15630069
ects	O	-1	15630069
were	O	-1	15630069
rec@@	O	-1	15630069
ru@@	O	-1	15630069
ited	O	-1	15630069
from	O	-1	15630069
an	O	-1	15630069
urb@@	O	-1	15630069
an	O	-1	15630069
com@@	O	-1	15630069
mun@@	O	-1	15630069
ity	O	-1	15630069
mental	O	-1	15630069
heal@@	O	-1	15630069
th	O	-1	15630069
clin@@	O	-1	15630069
ic	O	-1	15630069
and	O	-1	15630069
were	O	-1	15630069
studied	O	-1	15630069
at	O	-1	15630069
a	O	-1	15630069
gener@@	O	-1	15630069
al	O	-1	15630069
clinical	O	-1	15630069
re@@	O	-1	15630069
se@@	O	-1	15630069
arc@@	O	-1	15630069
h	O	-1	15630069
c@@	O	-1	15630069
ent@@	O	-1	15630069
er.	O	-1	15630069
Patients	O	-1	15630069
F@@	O	-1	15630069
if@@	O	-1	15630069
t@@	O	-1	15630069
y	O	-1	15630069
subjects	O	-1	15630069
signed	O	-1	15630069
inf@@	O	-1	15630069
orm@@	O	-1	15630069
ed	O	-1	15630069
con@@	O	-1	15630069
s@@	O	-1	15630069
ent	O	-1	15630069
and	O	-1	15630069
4@@	O	-1	15630069
1	O	-1	15630069
under@@	O	-1	15630069
w@@	O	-1	15630069
ent	O	-1	15630069
the	O	-1	15630069
frequ@@	O	-1	15630069
ently	O	-1	15630069
sam@@	O	-1	15630069
pl@@	O	-1	15630069
ed	O	-1	15630069
intravenous	O	-1	15630069
g@@	B-Chemical	D005947	15630069
lu@@	I-Chemical	-1	15630069
co@@	I-Chemical	-1	15630069
se	I-Chemical	-1	15630069
toler@@	O	-1	15630069
ance	O	-1	15630069
test@@	O	-1	15630069
.	O	-1	15630069
Th@@	O	-1	15630069
ir@@	O	-1	15630069
ty-@@	O	-1	15630069
six	O	-1	15630069
non@@	O	-1	15630069
ob@@	O	-1	15630069
ese	O	-1	15630069
subjects	O	-1	15630069
with	O	-1	15630069
sch@@	B-Disease	D012559	15630069
iz@@	I-Disease	-1	15630069
oph@@	I-Disease	-1	15630069
ren@@	I-Disease	-1	15630069
ia	I-Disease	-1	15630069
or	O	-1	15630069
sch@@	B-Disease	D011618	15630069
iz@@	I-Disease	-1	15630069
o@@	I-Disease	-1	15630069
aff@@	I-Disease	-1	15630069
ective	I-Disease	-1	15630069
disor@@	I-Disease	-1	15630069
der	I-Disease	-1	15630069
,	O	-1	15630069
mat@@	O	-1	15630069
ch@@	O	-1	15630069
ed	O	-1	15630069
by	O	-1	15630069
body	O	-1	15630069
mas@@	O	-1	15630069
s	O	-1	15630069
in@@	O	-1	15630069
de@@	O	-1	15630069
x	O	-1	15630069
and	O	-1	15630069
treated	O	-1	15630069
with	O	-1	15630069
either	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
,	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
,	O	-1	15630069
or	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
,	O	-1	15630069
were	O	-1	15630069
included	O	-1	15630069
in	O	-1	15630069
the	O	-1	15630069
analy@@	O	-1	15630069
sis.	O	-1	15630069
MA@@	O	-1	15630069
I@@	O	-1	15630069
N	O	-1	15630069
O@@	O	-1	15630069
U@@	O	-1	15630069
T@@	O	-1	15630069
CO@@	O	-1	15630069
M@@	O	-1	15630069
E	O	-1	15630069
M@@	O	-1	15630069
E@@	O	-1	15630069
A@@	O	-1	15630069
S@@	O	-1	15630069
U@@	O	-1	15630069
R@@	O	-1	15630069
E@@	O	-1	15630069
S:	O	-1	15630069
F@@	O	-1	15630069
ast@@	O	-1	15630069
ing	O	-1	15630069
plasma	O	-1	15630069
g@@	B-Chemical	D005947	15630069
lu@@	I-Chemical	-1	15630069
co@@	I-Chemical	-1	15630069
se	I-Chemical	-1	15630069
and	O	-1	15630069
f@@	O	-1	15630069
ast@@	O	-1	15630069
ing	O	-1	15630069
serum	O	-1	15630069
in@@	O	-1	15630069
sul@@	O	-1	15630069
in	O	-1	15630069
level@@	O	-1	15630069
s,	O	-1	15630069
in@@	B-Disease	D007333	15630069
sul@@	I-Disease	-1	15630069
in	I-Disease	-1	15630069
sensitivity	I-Disease	-1	15630069
in@@	O	-1	15630069
de@@	O	-1	15630069
x@@	O	-1	15630069
,	O	-1	15630069
ho@@	O	-1	15630069
me@@	O	-1	15630069
ost@@	O	-1	15630069
asis	O	-1	15630069
model	O	-1	15630069
assess@@	O	-1	15630069
ment	O	-1	15630069
of	O	-1	15630069
in@@	B-Disease	D007333	15630069
sul@@	I-Disease	-1	15630069
in	I-Disease	-1	15630069
resist@@	I-Disease	-1	15630069
ance	I-Disease	-1	15630069
,	O	-1	15630069
and	O	-1	15630069
g@@	B-Chemical	D005947	15630069
lu@@	I-Chemical	-1	15630069
co@@	I-Chemical	-1	15630069
se	I-Chemical	-1	15630069
eff@@	O	-1	15630069
ec@@	O	-1	15630069
tiv@@	O	-1	15630069
en@@	O	-1	15630069
es@@	O	-1	15630069
s.	O	-1	15630069
RESULTS:	O	-1	15630069
The	O	-1	15630069
mean	O	-1	15630069
+/-	O	-1	15630069
S@@	O	-1	15630069
D	O	-1	15630069
duration	O	-1	15630069
of	O	-1	15630069
treatment	O	-1	15630069
with	O	-1	15630069
the	O	-1	15630069
identi@@	O	-1	15630069
fied	O	-1	15630069
at@@	O	-1	15630069
yp@@	O	-1	15630069
ical	O	-1	15630069
anti@@	O	-1	15630069
psycho@@	O	-1	15630069
tic	O	-1	15630069
agent	O	-1	15630069
was	O	-1	15630069
6@@	O	-1	15630069
8.@@	O	-1	15630069
3	O	-1	15630069
+/-	O	-1	15630069
2@@	O	-1	15630069
8.@@	O	-1	15630069
9	O	-1	15630069
months	O	-1	15630069
(	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
),	O	-1	15630069
2@@	O	-1	15630069
9.@@	O	-1	15630069
5	O	-1	15630069
+/-	O	-1	15630069
1@@	O	-1	15630069
7.@@	O	-1	15630069
5	O	-1	15630069
months	O	-1	15630069
(	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
),	O	-1	15630069
and	O	-1	15630069
4@@	O	-1	15630069
0.@@	O	-1	15630069
9	O	-1	15630069
+/-	O	-1	15630069
3@@	O	-1	15630069
3.@@	O	-1	15630069
7	O	-1	15630069
(	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
).	O	-1	15630069
F@@	O	-1	15630069
ast@@	O	-1	15630069
ing	O	-1	15630069
serum	O	-1	15630069
in@@	O	-1	15630069
sul@@	O	-1	15630069
in	O	-1	15630069
concentrations	O	-1	15630069
di@@	O	-1	15630069
ffe@@	O	-1	15630069
red	O	-1	15630069
among	O	-1	15630069
groups	O	-1	15630069
(@@	O	-1	15630069
F@@	O	-1	15630069
(3@@	O	-1	15630069
3@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
3.@@	O	-1	15630069
3@@	O	-1	15630069
5@@	O	-1	15630069
;	O	-1	15630069
P	O	-1	15630069
=	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
4@@	O	-1	15630069
7@@	O	-1	15630069
)	O	-1	15630069
(	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
>	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
>	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
)	O	-1	15630069
with	O	-1	15630069
significant	O	-1	15630069
differences	O	-1	15630069
between	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
and	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
(@@	O	-1	15630069
t@@	O	-1	15630069
(3@@	O	-1	15630069
3@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
2.@@	O	-1	15630069
3@@	O	-1	15630069
2@@	O	-1	15630069
;	O	-1	15630069
P	O	-1	15630069
=	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
3@@	O	-1	15630069
)	O	-1	15630069
and	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
and	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
(@@	O	-1	15630069
t@@	O	-1	15630069
(3@@	O	-1	15630069
3@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
2.@@	O	-1	15630069
1@@	O	-1	15630069
5@@	O	-1	15630069
;	O	-1	15630069
P	O	-1	15630069
=	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
4@@	O	-1	15630069
).	O	-1	15630069
There	O	-1	15630069
was	O	-1	15630069
a	O	-1	15630069
significant	O	-1	15630069
difference	O	-1	15630069
in	O	-1	15630069
in@@	B-Disease	D007333	15630069
sul@@	I-Disease	-1	15630069
in	I-Disease	-1	15630069
sensitivity	I-Disease	-1	15630069
in@@	O	-1	15630069
de@@	O	-1	15630069
x	O	-1	15630069
among	O	-1	15630069
groups	O	-1	15630069
(@@	O	-1	15630069
F@@	O	-1	15630069
(3@@	O	-1	15630069
3@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
1@@	O	-1	15630069
0.@@	O	-1	15630069
6@@	O	-1	15630069
6@@	O	-1	15630069
;	O	-1	15630069
P@@	O	-1	15630069
<@@	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
0@@	O	-1	15630069
1)	O	-1	15630069
(	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
<	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
<	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
),	O	-1	15630069
with	O	-1	15630069
subjects	O	-1	15630069
who	O	-1	15630069
received	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
and	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
ex@@	O	-1	15630069
hib@@	O	-1	15630069
it@@	O	-1	15630069
ing	O	-1	15630069
significant	O	-1	15630069
in@@	B-Disease	D007333	15630069
sul@@	I-Disease	-1	15630069
in	I-Disease	-1	15630069
resist@@	I-Disease	-1	15630069
ance	I-Disease	-1	15630069
compared	O	-1	15630069
with	O	-1	15630069
subjects	O	-1	15630069
who	O	-1	15630069
were	O	-1	15630069
treated	O	-1	15630069
with	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
(	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
v@@	O	-1	15630069
s	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
,	O	-1	15630069
t@@	O	-1	15630069
(3@@	O	-1	15630069
3@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
-@@	O	-1	15630069
4.@@	O	-1	15630069
2@@	O	-1	15630069
9@@	O	-1	15630069
;	O	-1	15630069
P@@	O	-1	15630069
<@@	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
0@@	O	-1	15630069
1@@	O	-1	15630069
;	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
v@@	O	-1	15630069
s	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
,	O	-1	15630069
t@@	O	-1	15630069
(3@@	O	-1	15630069
3@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
-@@	O	-1	15630069
3.@@	O	-1	15630069
6@@	O	-1	15630069
2@@	O	-1	15630069
;	O	-1	15630069
P	O	-1	15630069
=	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
0@@	O	-1	15630069
1	O	-1	15630069
[@@	O	-1	15630069
P@@	O	-1	15630069
<@@	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
0@@	O	-1	15630069
1@@	O	-1	15630069
]@@	O	-1	15630069
).	O	-1	15630069
The	O	-1	15630069
ho@@	O	-1	15630069
me@@	O	-1	15630069
ost@@	O	-1	15630069
asis	O	-1	15630069
model	O	-1	15630069
assess@@	O	-1	15630069
ment	O	-1	15630069
of	O	-1	15630069
in@@	B-Disease	D007333	15630069
sul@@	I-Disease	-1	15630069
in	I-Disease	-1	15630069
resist@@	I-Disease	-1	15630069
ance	I-Disease	-1	15630069
also	O	-1	15630069
di@@	O	-1	15630069
ffe@@	O	-1	15630069
red	O	-1	15630069
significantly	O	-1	15630069
among	O	-1	15630069
groups	O	-1	15630069
(@@	O	-1	15630069
F@@	O	-1	15630069
(3@@	O	-1	15630069
3@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
4.@@	O	-1	15630069
9@@	O	-1	15630069
2@@	O	-1	15630069
;	O	-1	15630069
P	O	-1	15630069
=	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
1)	O	-1	15630069
(	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
>	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
>	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
)	O	-1	15630069
(	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
v@@	O	-1	15630069
s	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
,	O	-1	15630069
t@@	O	-1	15630069
(3@@	O	-1	15630069
3@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
2.@@	O	-1	15630069
9@@	O	-1	15630069
4@@	O	-1	15630069
;	O	-1	15630069
P	O	-1	15630069
=	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
0@@	O	-1	15630069
6@@	O	-1	15630069
;	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
v@@	O	-1	15630069
s	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
,	O	-1	15630069
t@@	O	-1	15630069
(3@@	O	-1	15630069
3@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
2.@@	O	-1	15630069
4@@	O	-1	15630069
2@@	O	-1	15630069
;	O	-1	15630069
P	O	-1	15630069
=	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
2@@	O	-1	15630069
).	O	-1	15630069
There	O	-1	15630069
was	O	-1	15630069
a	O	-1	15630069
significant	O	-1	15630069
difference	O	-1	15630069
among	O	-1	15630069
groups	O	-1	15630069
in	O	-1	15630069
g@@	B-Chemical	D005947	15630069
lu@@	I-Chemical	-1	15630069
co@@	I-Chemical	-1	15630069
se	I-Chemical	-1	15630069
eff@@	O	-1	15630069
ec@@	O	-1	15630069
tiv@@	O	-1	15630069
en@@	O	-1	15630069
ess	O	-1	15630069
(@@	O	-1	15630069
F@@	O	-1	15630069
(3@@	O	-1	15630069
0@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
4.@@	O	-1	15630069
18@@	O	-1	15630069
;	O	-1	15630069
P	O	-1	15630069
=	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
2)	O	-1	15630069
(	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
<	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
<	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
)	O	-1	15630069
with	O	-1	15630069
significant	O	-1	15630069
differences	O	-1	15630069
between	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
and	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
(@@	O	-1	15630069
t@@	O	-1	15630069
(3@@	O	-1	15630069
0@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
-@@	O	-1	15630069
2.@@	O	-1	15630069
5@@	O	-1	15630069
9@@	O	-1	15630069
;	O	-1	15630069
P	O	-1	15630069
=	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
2)	O	-1	15630069
and	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
and	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
(@@	O	-1	15630069
t@@	O	-1	15630069
(3@@	O	-1	15630069
0@@	O	-1	15630069
)	O	-1	15630069
=	O	-1	15630069
-@@	O	-1	15630069
2.@@	O	-1	15630069
34@@	O	-1	15630069
,	O	-1	15630069
P	O	-1	15630069
=	O	-1	15630069
.@@	O	-1	15630069
0@@	O	-1	15630069
3@@	O	-1	15630069
).	O	-1	15630069
CONCLUSIONS:	O	-1	15630069
B@@	O	-1	15630069
oth	O	-1	15630069
non@@	O	-1	15630069
ob@@	O	-1	15630069
ese	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
-	O	-1	15630069
and	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
-treated	O	-1	15630069
groups	O	-1	15630069
dis@@	O	-1	15630069
pl@@	O	-1	15630069
ayed	O	-1	15630069
significant	O	-1	15630069
in@@	B-Disease	D007333	15630069
sul@@	I-Disease	-1	15630069
in	I-Disease	-1	15630069
resist@@	I-Disease	-1	15630069
ance	I-Disease	-1	15630069
and	O	-1	15630069
impair@@	O	-1	15630069
ment	O	-1	15630069
of	O	-1	15630069
g@@	B-Chemical	D005947	15630069
lu@@	I-Chemical	-1	15630069
co@@	I-Chemical	-1	15630069
se	I-Chemical	-1	15630069
eff@@	O	-1	15630069
ec@@	O	-1	15630069
tiv@@	O	-1	15630069
en@@	O	-1	15630069
ess	O	-1	15630069
compared	O	-1	15630069
with	O	-1	15630069
ris@@	B-Chemical	D018967	15630069
perid@@	I-Chemical	-1	15630069
one	I-Chemical	-1	15630069
-treated	O	-1	15630069
subj@@	O	-1	15630069
ect@@	O	-1	15630069
s.	O	-1	15630069
Patients	O	-1	15630069
taking	O	-1	15630069
cloz@@	B-Chemical	D003024	15630069
apine	I-Chemical	-1	15630069
and	O	-1	15630069
ol@@	B-Chemical	C076029	15630069
an@@	I-Chemical	-1	15630069
z@@	I-Chemical	-1	15630069
apine	I-Chemical	-1	15630069
mus@@	O	-1	15630069
t	O	-1	15630069
be	O	-1	15630069
examined	O	-1	15630069
for	O	-1	15630069
in@@	B-Disease	D007333	15630069
sul@@	I-Disease	-1	15630069
in	I-Disease	-1	15630069
resist@@	I-Disease	-1	15630069
ance	I-Disease	-1	15630069
and	O	-1	15630069
its	O	-1	15630069
con@@	O	-1	15630069
sequ@@	O	-1	15630069
enc@@	O	-1	15630069
es.	O	-1	15630069

F@@	O	-1	15815446
oc@@	O	-1	15815446
al	O	-1	15815446
cerebral	B-Disease	D002545	15815446
ischem@@	I-Disease	-1	15815446
ia	I-Disease	-1	15815446
in	O	-1	15815446
rat@@	O	-1	15815446
s:	O	-1	15815446
effect	O	-1	15815446
of	O	-1	15815446
pheny@@	B-Chemical	D010656	15815446
le@@	I-Chemical	-1	15815446
phrine	I-Chemical	-1	15815446
-induced	O	-1	15815446
hypertension	B-Disease	D006973	15815446
during	O	-1	15815446
re@@	O	-1	15815446
per@@	O	-1	15815446
fu@@	O	-1	15815446
sion.	O	-1	15815446
After	O	-1	15815446
18@@	O	-1	15815446
0	O	-1	15815446
min	O	-1	15815446
of	O	-1	15815446
tempor@@	O	-1	15815446
ary	O	-1	15815446
mid@@	B-Disease	D020244	15815446
d@@	I-Disease	-1	15815446
le	I-Disease	-1	15815446
cerebral	I-Disease	-1	15815446
artery	I-Disease	-1	15815446
oc@@	I-Disease	-1	15815446
cl@@	I-Disease	-1	15815446
usion	I-Disease	-1	15815446
in	O	-1	15815446
spont@@	O	-1	15815446
ane@@	O	-1	15815446
ously	O	-1	15815446
hypertensive	B-Disease	D006973	15815446
rats,	O	-1	15815446
the	O	-1	15815446
effect	O	-1	15815446
of	O	-1	15815446
pheny@@	B-Chemical	D010656	15815446
le@@	I-Chemical	-1	15815446
phrine	I-Chemical	-1	15815446
-induced	O	-1	15815446
hypertension	B-Disease	D006973	15815446
on	O	-1	15815446
ischem@@	B-Disease	D001930	15815446
ic	I-Disease	-1	15815446
brain	I-Disease	-1	15815446
injury	I-Disease	-1	15815446
and	O	-1	15815446
blo@@	O	-1	15815446
o@@	O	-1	15815446
d-@@	O	-1	15815446
brain	O	-1	15815446
bar@@	O	-1	15815446
ri@@	O	-1	15815446
er	O	-1	15815446
per@@	O	-1	15815446
me@@	O	-1	15815446
ability	O	-1	15815446
was	O	-1	15815446
deter@@	O	-1	15815446
m@@	O	-1	15815446
ine@@	O	-1	15815446
d.	O	-1	15815446
B@@	O	-1	15815446
lo@@	O	-1	15815446
od	O	-1	15815446
pressure	O	-1	15815446
was	O	-1	15815446
man@@	O	-1	15815446
ip@@	O	-1	15815446
ul@@	O	-1	15815446
ated	O	-1	15815446
by	O	-1	15815446
one	O	-1	15815446
of	O	-1	15815446
the	O	-1	15815446
following	O	-1	15815446
sch@@	O	-1	15815446
ed@@	O	-1	15815446
ul@@	O	-1	15815446
es	O	-1	15815446
during	O	-1	15815446
1@@	O	-1	15815446
20	O	-1	15815446
min	O	-1	15815446
of	O	-1	15815446
re@@	O	-1	15815446
per@@	O	-1	15815446
fu@@	O	-1	15815446
sion@@	O	-1	15815446
:	O	-1	15815446
C@@	O	-1	15815446
ont@@	O	-1	15815446
ro@@	O	-1	15815446
l@@	O	-1	15815446
,	O	-1	15815446
norm@@	O	-1	15815446
oten@@	O	-1	15815446
sive	O	-1	15815446
re@@	O	-1	15815446
per@@	O	-1	15815446
fu@@	O	-1	15815446
sion@@	O	-1	15815446
;	O	-1	15815446
9@@	O	-1	15815446
0@@	O	-1	15815446
/	O	-1	15815446
hypertension	B-Disease	D006973	15815446
(@@	O	-1	15815446
9@@	O	-1	15815446
0@@	O	-1	15815446
/	O	-1	15815446
H@@	B-Disease	D006973	15815446
T@@	I-Disease	-1	15815446
N	I-Disease	-1	15815446
),	O	-1	15815446
blood	O	-1	15815446
pressure	O	-1	15815446
was	O	-1	15815446
increased	O	-1	15815446
by	O	-1	15815446
3@@	O	-1	15815446
5	O	-1	15815446
mm	O	-1	15815446
H@@	O	-1	15815446
g	O	-1	15815446
during	O	-1	15815446
the	O	-1	15815446
initial	O	-1	15815446
9@@	O	-1	15815446
0	O	-1	15815446
min	O	-1	15815446
of	O	-1	15815446
re@@	O	-1	15815446
per@@	O	-1	15815446
f@@	O	-1	15815446
usion	O	-1	15815446
on@@	O	-1	15815446
ly@@	O	-1	15815446
;	O	-1	15815446
1@@	O	-1	15815446
5@@	O	-1	15815446
/	O	-1	15815446
hypertension	B-Disease	D006973	15815446
(1@@	O	-1	15815446
5@@	O	-1	15815446
/	O	-1	15815446
H@@	B-Disease	D006973	15815446
T@@	I-Disease	-1	15815446
N	I-Disease	-1	15815446
),	O	-1	15815446
norm@@	O	-1	15815446
oten@@	O	-1	15815446
sive	O	-1	15815446
re@@	O	-1	15815446
per@@	O	-1	15815446
f@@	O	-1	15815446
usion	O	-1	15815446
for	O	-1	15815446
30	O	-1	15815446
min	O	-1	15815446
followed	O	-1	15815446
by	O	-1	15815446
15	O	-1	15815446
min	O	-1	15815446
of	O	-1	15815446
hypertension	B-Disease	D006973	15815446
and	O	-1	15815446
7@@	O	-1	15815446
5	O	-1	15815446
min	O	-1	15815446
of	O	-1	15815446
norm@@	O	-1	15815446
oten@@	O	-1	15815446
sion.	O	-1	15815446
P@@	O	-1	15815446
ar@@	O	-1	15815446
t	O	-1	15815446
A@@	O	-1	15815446
,	O	-1	15815446
for	O	-1	15815446
e@@	O	-1	15815446
ight	O	-1	15815446
rats	O	-1	15815446
in	O	-1	15815446
each	O	-1	15815446
group	O	-1	15815446
brain	B-Disease	D001930	15815446
injury	I-Disease	-1	15815446
was	O	-1	15815446
evaluated	O	-1	15815446
by	O	-1	15815446
st@@	O	-1	15815446
aining	O	-1	15815446
tissue	O	-1	15815446
using	O	-1	15815446
2@@	B-Chemical	C009591	15815446
,@@	I-Chemical	-1	15815446
3@@	I-Chemical	-1	15815446
,@@	I-Chemical	-1	15815446
5-@@	I-Chemical	-1	15815446
tri@@	I-Chemical	-1	15815446
phenyl@@	I-Chemical	-1	15815446
te@@	I-Chemical	-1	15815446
tra@@	I-Chemical	-1	15815446
z@@	I-Chemical	-1	15815446
ol@@	I-Chemical	-1	15815446
i@@	I-Chemical	-1	15815446
um	I-Chemical	-1	15815446
chlor@@	I-Chemical	-1	15815446
ide	I-Chemical	-1	15815446
and	O	-1	15815446
e@@	B-Disease	D004487	15815446
de@@	I-Disease	-1	15815446
ma	I-Disease	-1	15815446
was	O	-1	15815446
evaluated	O	-1	15815446
by	O	-1	15815446
micro@@	O	-1	15815446
gra@@	O	-1	15815446
vi@@	O	-1	15815446
met@@	O	-1	15815446
r@@	O	-1	15815446
y.	O	-1	15815446
P@@	O	-1	15815446
ar@@	O	-1	15815446
t	O	-1	15815446
B@@	O	-1	15815446
,	O	-1	15815446
for	O	-1	15815446
e@@	O	-1	15815446
ight	O	-1	15815446
different	O	-1	15815446
rats	O	-1	15815446
in	O	-1	15815446
each	O	-1	15815446
group	O	-1	15815446
blo@@	O	-1	15815446
o@@	O	-1	15815446
d-@@	O	-1	15815446
brain	O	-1	15815446
bar@@	O	-1	15815446
ri@@	O	-1	15815446
er	O	-1	15815446
per@@	O	-1	15815446
me@@	O	-1	15815446
ability	O	-1	15815446
was	O	-1	15815446
evaluated	O	-1	15815446
by	O	-1	15815446
meas@@	O	-1	15815446
uring	O	-1	15815446
the	O	-1	15815446
amoun@@	O	-1	15815446
t	O	-1	15815446
and	O	-1	15815446
ext@@	O	-1	15815446
ent	O	-1	15815446
of	O	-1	15815446
ext@@	O	-1	15815446
ra@@	O	-1	15815446
vas@@	O	-1	15815446
ation	O	-1	15815446
of	O	-1	15815446
E@@	O	-1	15815446
v@@	O	-1	15815446
ans	O	-1	15815446
B@@	O	-1	15815446
lu@@	O	-1	15815446
e	O	-1	15815446
dy@@	O	-1	15815446
e.	O	-1	15815446
B@@	B-Disease	D001930	15815446
ra@@	I-Disease	-1	15815446
in	I-Disease	-1	15815446
injury	I-Disease	-1	15815446
(@@	O	-1	15815446
perc@@	O	-1	15815446
ent@@	O	-1	15815446
age	O	-1	15815446
of	O	-1	15815446
the	O	-1	15815446
ischem@@	B-Disease	D002545	15815446
ic	I-Disease	-1	15815446
he@@	I-Disease	-1	15815446
mis@@	I-Disease	-1	15815446
ph@@	I-Disease	-1	15815446
ere	I-Disease	-1	15815446
)	O	-1	15815446
was	O	-1	15815446
less	O	-1	15815446
in	O	-1	15815446
the	O	-1	15815446
1@@	O	-1	15815446
5@@	O	-1	15815446
/	O	-1	15815446
H@@	B-Disease	D006973	15815446
T@@	I-Disease	-1	15815446
N	I-Disease	-1	15815446
group	O	-1	15815446
(1@@	O	-1	15815446
6	O	-1	15815446
+/-	O	-1	15815446
6,	O	-1	15815446
mean	O	-1	15815446
+/-	O	-1	15815446
S@@	O	-1	15815446
D)	O	-1	15815446
versus	O	-1	15815446
the	O	-1	15815446
9@@	O	-1	15815446
0@@	O	-1	15815446
/	O	-1	15815446
H@@	B-Disease	D006973	15815446
T@@	I-Disease	-1	15815446
N	I-Disease	-1	15815446
group	O	-1	15815446
(@@	O	-1	15815446
30	O	-1	15815446
+/-	O	-1	15815446
6@@	O	-1	15815446
),	O	-1	15815446
which	O	-1	15815446
was	O	-1	15815446
in	O	-1	15815446
t@@	O	-1	15815446
ur@@	O	-1	15815446
n	O	-1	15815446
less	O	-1	15815446
than	O	-1	15815446
the	O	-1	15815446
control	O	-1	15815446
group	O	-1	15815446
(4@@	O	-1	15815446
2	O	-1	15815446
+/-	O	-1	15815446
5@@	O	-1	15815446
).	O	-1	15815446
S@@	O	-1	15815446
p@@	O	-1	15815446
ec@@	O	-1	15815446
if@@	O	-1	15815446
ic	O	-1	15815446
gra@@	O	-1	15815446
v@@	O	-1	15815446
ity	O	-1	15815446
was	O	-1	15815446
greater	O	-1	15815446
in	O	-1	15815446
the	O	-1	15815446
1@@	O	-1	15815446
5@@	O	-1	15815446
/	O	-1	15815446
H@@	B-Disease	D006973	15815446
T@@	I-Disease	-1	15815446
N	I-Disease	-1	15815446
group	O	-1	15815446
(1@@	O	-1	15815446
.@@	O	-1	15815446
0@@	O	-1	15815446
4@@	O	-1	15815446
3	O	-1	15815446
+/-	O	-1	15815446
0.00@@	O	-1	15815446
2)	O	-1	15815446
versus	O	-1	15815446
the	O	-1	15815446
9@@	O	-1	15815446
0@@	O	-1	15815446
/	O	-1	15815446
H@@	B-Disease	D006973	15815446
T@@	I-Disease	-1	15815446
N	I-Disease	-1	15815446
(1@@	O	-1	15815446
.@@	O	-1	15815446
0@@	O	-1	15815446
3@@	O	-1	15815446
6	O	-1	15815446
+/-	O	-1	15815446
0.00@@	O	-1	15815446
3@@	O	-1	15815446
)	O	-1	15815446
and	O	-1	15815446
control	O	-1	15815446
(1@@	O	-1	15815446
.@@	O	-1	15815446
0@@	O	-1	15815446
3@@	O	-1	15815446
7	O	-1	15815446
+/-	O	-1	15815446
0.00@@	O	-1	15815446
3@@	O	-1	15815446
)	O	-1	15815446
groups.	O	-1	15815446
E@@	B-Chemical	D005070	15815446
v@@	I-Chemical	-1	15815446
ans	I-Chemical	-1	15815446
B@@	I-Chemical	-1	15815446
lu@@	I-Chemical	-1	15815446
e	I-Chemical	-1	15815446
(@@	O	-1	15815446
m@@	O	-1	15815446
u@@	O	-1	15815446
g	O	-1	15815446
g@@	O	-1	15815446
-1	O	-1	15815446
of	O	-1	15815446
brain	O	-1	15815446
tissu@@	O	-1	15815446
e@@	O	-1	15815446
)	O	-1	15815446
was	O	-1	15815446
greater	O	-1	15815446
in	O	-1	15815446
the	O	-1	15815446
9@@	O	-1	15815446
0@@	O	-1	15815446
/	O	-1	15815446
H@@	B-Disease	D006973	15815446
T@@	I-Disease	-1	15815446
N	I-Disease	-1	15815446
group	O	-1	15815446
(2@@	O	-1	15815446
4.@@	O	-1	15815446
4	O	-1	15815446
+/-	O	-1	15815446
6.@@	O	-1	15815446
0@@	O	-1	15815446
)	O	-1	15815446
versus	O	-1	15815446
the	O	-1	15815446
control	O	-1	15815446
group	O	-1	15815446
(1@@	O	-1	15815446
2.@@	O	-1	15815446
3	O	-1	15815446
+/-	O	-1	15815446
4.@@	O	-1	15815446
1),	O	-1	15815446
which	O	-1	15815446
was	O	-1	15815446
in	O	-1	15815446
t@@	O	-1	15815446
ur@@	O	-1	15815446
n	O	-1	15815446
greater	O	-1	15815446
than	O	-1	15815446
the	O	-1	15815446
1@@	O	-1	15815446
5@@	O	-1	15815446
/	O	-1	15815446
H@@	B-Disease	D006973	15815446
T@@	I-Disease	-1	15815446
N	I-Disease	-1	15815446
group	O	-1	15815446
(@@	O	-1	15815446
7.@@	O	-1	15815446
3	O	-1	15815446
+/-	O	-1	15815446
3.@@	O	-1	15815446
2@@	O	-1	15815446
).	O	-1	15815446
This	O	-1	15815446
study	O	-1	15815446
suppor@@	O	-1	15815446
ts	O	-1	15815446
a	O	-1	15815446
hypo@@	O	-1	15815446
thesis	O	-1	15815446
that	O	-1	15815446
during	O	-1	15815446
re@@	O	-1	15815446
per@@	O	-1	15815446
fu@@	O	-1	15815446
sion,	O	-1	15815446
a	O	-1	15815446
sh@@	O	-1	15815446
ort	O	-1	15815446
interv@@	O	-1	15815446
al	O	-1	15815446
of	O	-1	15815446
hypertension	B-Disease	D006973	15815446
decreas@@	O	-1	15815446
es	O	-1	15815446
brain	B-Disease	D001930	15815446
injury	I-Disease	-1	15815446
and	O	-1	15815446
e@@	B-Disease	D004487	15815446
de@@	I-Disease	-1	15815446
ma	I-Disease	-1	15815446
;	O	-1	15815446
and	O	-1	15815446
that	O	-1	15815446
su@@	O	-1	15815446
st@@	O	-1	15815446
ained	O	-1	15815446
hypertension	B-Disease	D006973	15815446
increases	O	-1	15815446
the	O	-1	15815446
risk	O	-1	15815446
of	O	-1	15815446
vas@@	B-Disease	D001929	15815446
o@@	I-Disease	-1	15815446
genic	I-Disease	-1	15815446
e@@	I-Disease	-1	15815446
de@@	I-Disease	-1	15815446
ma	I-Disease	-1	15815446
.	O	-1	15815446

P@@	O	-1	15817013
e@@	O	-1	15817013
o@@	O	-1	15817013
ple	O	-1	15817013
aged	O	-1	15817013
over	O	-1	15817013
7@@	O	-1	15817013
5	O	-1	15817013
in	O	-1	15817013
atrial	B-Disease	D001281	15817013
fibrill@@	I-Disease	-1	15817013
ation	I-Disease	-1	15817013
on	O	-1	15817013
war@@	B-Chemical	D014859	15817013
farin	I-Chemical	-1	15817013
:	O	-1	15817013
the	O	-1	15817013
rate	O	-1	15817013
of	O	-1	15817013
major	O	-1	15817013
hemorrh@@	B-Disease	D006470	15817013
age	I-Disease	-1	15817013
and	O	-1	15817013
strok@@	B-Disease	D020521	15817013
e	I-Disease	-1	15817013
in	O	-1	15817013
more	O	-1	15817013
than	O	-1	15817013
5@@	O	-1	15817013
00	O	-1	15817013
patient@@	O	-1	15817013
-@@	O	-1	15817013
years	O	-1	15817013
of	O	-1	15817013
follow-@@	O	-1	15817013
up@@	O	-1	15817013
.	O	-1	15817013
OBJECTIV@@	O	-1	15817013
E@@	O	-1	15817013
S:	O	-1	15817013
To	O	-1	15817013
determine	O	-1	15817013
the	O	-1	15817013
incidence	O	-1	15817013
of	O	-1	15817013
major	O	-1	15817013
hemorrh@@	B-Disease	D006470	15817013
age	I-Disease	-1	15817013
and	O	-1	15817013
strok@@	B-Disease	D020521	15817013
e	I-Disease	-1	15817013
in	O	-1	15817013
pe@@	O	-1	15817013
o@@	O	-1	15817013
ple	O	-1	15817013
aged	O	-1	15817013
7@@	O	-1	15817013
6	O	-1	15817013
and	O	-1	15817013
ol@@	O	-1	15817013
der	O	-1	15817013
with	O	-1	15817013
atrial	B-Disease	D001281	15817013
fibrill@@	I-Disease	-1	15817013
ation	I-Disease	-1	15817013
on	O	-1	15817013
adjust@@	O	-1	15817013
ed@@	O	-1	15817013
-@@	O	-1	15817013
dose	O	-1	15817013
war@@	B-Chemical	D014859	15817013
farin	I-Chemical	-1	15817013
who	O	-1	15817013
had	O	-1	15817013
been	O	-1	15817013
rec@@	O	-1	15817013
ently	O	-1	15817013
been	O	-1	15817013
ad@@	O	-1	15817013
mit@@	O	-1	15817013
ted	O	-1	15817013
to	O	-1	15817013
hospit@@	O	-1	15817013
al.	O	-1	15817013
D@@	O	-1	15817013
ES@@	O	-1	15817013
I@@	O	-1	15817013
G@@	O	-1	15817013
N@@	O	-1	15817013
:	O	-1	15817013
A	O	-1	15817013
ret@@	O	-1	15817013
ro@@	O	-1	15817013
sp@@	O	-1	15817013
ective	O	-1	15817013
observ@@	O	-1	15817013
ation@@	O	-1	15817013
al	O	-1	15817013
co@@	O	-1	15817013
h@@	O	-1	15817013
ort	O	-1	15817013
study.	O	-1	15817013
S@@	O	-1	15817013
ET@@	O	-1	15817013
TI@@	O	-1	15817013
N@@	O	-1	15817013
G@@	O	-1	15817013
:	O	-1	15817013
A	O	-1	15817013
major	O	-1	15817013
health@@	O	-1	15817013
car@@	O	-1	15817013
e	O	-1	15817013
ne@@	O	-1	15817013
tw@@	O	-1	15817013
or@@	O	-1	15817013
k	O	-1	15817013
invol@@	O	-1	15817013
ving	O	-1	15817013
four	O	-1	15817013
ter@@	O	-1	15817013
ti@@	O	-1	15817013
ary	O	-1	15817013
hospit@@	O	-1	15817013
al@@	O	-1	15817013
s.	O	-1	15817013
PA@@	O	-1	15817013
R@@	O	-1	15817013
TI@@	O	-1	15817013
CI@@	O	-1	15817013
PA@@	O	-1	15817013
N@@	O	-1	15817013
T@@	O	-1	15817013
S:	O	-1	15817013
Two	O	-1	15817013
h@@	O	-1	15817013
und@@	O	-1	15817013
red	O	-1	15817013
thir@@	O	-1	15817013
ty-@@	O	-1	15817013
five	O	-1	15817013
patients	O	-1	15817013
aged	O	-1	15817013
7@@	O	-1	15817013
6	O	-1	15817013
and	O	-1	15817013
ol@@	O	-1	15817013
der	O	-1	15817013
ad@@	O	-1	15817013
mit@@	O	-1	15817013
ted	O	-1	15817013
to	O	-1	15817013
a	O	-1	15817013
major	O	-1	15817013
health@@	O	-1	15817013
car@@	O	-1	15817013
e	O	-1	15817013
ne@@	O	-1	15817013
tw@@	O	-1	15817013
or@@	O	-1	15817013
k	O	-1	15817013
between	O	-1	15817013
J@@	O	-1	15817013
ul@@	O	-1	15817013
y	O	-1	15817013
1,	O	-1	15817013
20@@	O	-1	15817013
0@@	O	-1	15817013
1,	O	-1	15817013
and	O	-1	15817013
J@@	O	-1	15817013
un@@	O	-1	15817013
e	O	-1	15817013
3@@	O	-1	15817013
0@@	O	-1	15817013
,	O	-1	15817013
20@@	O	-1	15817013
0@@	O	-1	15817013
2,	O	-1	15817013
with	O	-1	15817013
atrial	B-Disease	D001281	15817013
fibrill@@	I-Disease	-1	15817013
ation	I-Disease	-1	15817013
on	O	-1	15817013
war@@	B-Chemical	D014859	15817013
farin	I-Chemical	-1	15817013
were	O	-1	15817013
en@@	O	-1	15817013
ro@@	O	-1	15817013
l@@	O	-1	15817013
le@@	O	-1	15817013
d.	O	-1	15817013
M@@	O	-1	15817013
E@@	O	-1	15817013
A@@	O	-1	15817013
S@@	O	-1	15817013
U@@	O	-1	15817013
R@@	O	-1	15817013
E@@	O	-1	15817013
M@@	O	-1	15817013
E@@	O	-1	15817013
N@@	O	-1	15817013
T@@	O	-1	15817013
S:	O	-1	15817013
In@@	O	-1	15817013
formation	O	-1	15817013
reg@@	O	-1	15817013
ar@@	O	-1	15817013
ding	O	-1	15817013
major	O	-1	15817013
ble@@	B-Disease	D006470	15817013
ed@@	I-Disease	-1	15817013
ing	I-Disease	-1	15817013
episo@@	O	-1	15817013
d@@	O	-1	15817013
es,	O	-1	15817013
strok@@	B-Disease	D020521	15817013
es	I-Disease	-1	15817013
,	O	-1	15817013
and	O	-1	15817013
war@@	B-Chemical	D014859	15817013
farin	I-Chemical	-1	15817013
use	O	-1	15817013
was	O	-1	15817013
obtained	O	-1	15817013
from	O	-1	15817013
patients,	O	-1	15817013
rel@@	O	-1	15817013
ati@@	O	-1	15817013
v@@	O	-1	15817013
es,	O	-1	15817013
prim@@	O	-1	15817013
ary	O	-1	15817013
physi@@	O	-1	15817013
ci@@	O	-1	15817013
an@@	O	-1	15817013
s,	O	-1	15817013
and	O	-1	15817013
med@@	O	-1	15817013
ical	O	-1	15817013
recor@@	O	-1	15817013
d@@	O	-1	15817013
s.	O	-1	15817013
RESULTS:	O	-1	15817013
Two	O	-1	15817013
h@@	O	-1	15817013
und@@	O	-1	15817013
red	O	-1	15817013
tw@@	O	-1	15817013
ent@@	O	-1	15817013
y-@@	O	-1	15817013
e@@	O	-1	15817013
ight	O	-1	15817013
patients	O	-1	15817013
(4@@	O	-1	15817013
2@@	O	-1	15817013
%	O	-1	15817013
men@@	O	-1	15817013
)	O	-1	15817013
with	O	-1	15817013
a	O	-1	15817013
mean	O	-1	15817013
age	O	-1	15817013
of	O	-1	15817013
8@@	O	-1	15817013
1.@@	O	-1	15817013
1	O	-1	15817013
(@@	O	-1	15817013
range	O	-1	15817013
7@@	O	-1	15817013
6-@@	O	-1	15817013
9@@	O	-1	15817013
4@@	O	-1	15817013
)	O	-1	15817013
were	O	-1	15817013
included	O	-1	15817013
in	O	-1	15817013
the	O	-1	15817013
analy@@	O	-1	15817013
sis.	O	-1	15817013
T@@	O	-1	15817013
ot@@	O	-1	15817013
al	O	-1	15817013
follow-up	O	-1	15817013
on	O	-1	15817013
war@@	B-Chemical	D014859	15817013
farin	I-Chemical	-1	15817013
was	O	-1	15817013
5@@	O	-1	15817013
30	O	-1	15817013
years	O	-1	15817013
(@@	O	-1	15817013
mean	O	-1	15817013
2@@	O	-1	15817013
8	O	-1	15817013
month@@	O	-1	15817013
s@@	O	-1	15817013
).	O	-1	15817013
There	O	-1	15817013
were	O	-1	15817013
5@@	O	-1	15817013
3	O	-1	15817013
major	O	-1	15817013
hemorrh@@	B-Disease	D006470	15817013
ages	I-Disease	-1	15817013
,	O	-1	15817013
for	O	-1	15817013
an	O	-1	15817013
an@@	O	-1	15817013
n@@	O	-1	15817013
ual	O	-1	15817013
rate	O	-1	15817013
of	O	-1	15817013
1@@	O	-1	15817013
0.0@@	O	-1	15817013
%,	O	-1	15817013
including	O	-1	15817013
24	O	-1	15817013
(4@@	O	-1	15817013
5.@@	O	-1	15817013
3@@	O	-1	15817013
%)	O	-1	15817013
lif@@	O	-1	15817013
e-@@	O	-1	15817013
th@@	O	-1	15817013
reat@@	O	-1	15817013
en@@	O	-1	15817013
ing	O	-1	15817013
and	O	-1	15817013
five	O	-1	15817013
(@@	O	-1	15817013
9.@@	O	-1	15817013
4@@	O	-1	15817013
%)	O	-1	15817013
f@@	O	-1	15817013
atal	O	-1	15817013
ble@@	O	-1	15817013
ed@@	O	-1	15817013
s.	O	-1	15817013
The	O	-1	15817013
an@@	O	-1	15817013
n@@	O	-1	15817013
ual	O	-1	15817013
strok@@	B-Disease	D020521	15817013
e	I-Disease	-1	15817013
rate	O	-1	15817013
after	O	-1	15817013
initi@@	O	-1	15817013
ation	O	-1	15817013
of	O	-1	15817013
war@@	B-Chemical	D014859	15817013
farin	I-Chemical	-1	15817013
was	O	-1	15817013
2.@@	O	-1	15817013
6@@	O	-1	15817013
%.	O	-1	15817013
CONCLUSION:	O	-1	15817013
The	O	-1	15817013
rate	O	-1	15817013
of	O	-1	15817013
major	O	-1	15817013
hemorrh@@	B-Disease	D006470	15817013
age	I-Disease	-1	15817013
was	O	-1	15817013
high	O	-1	15817013
in	O	-1	15817013
this	O	-1	15817013
ol@@	O	-1	15817013
d,	O	-1	15817013
f@@	O	-1	15817013
ra@@	O	-1	15817013
il	O	-1	15817013
group@@	O	-1	15817013
,	O	-1	15817013
but	O	-1	15817013
ex@@	O	-1	15817013
cl@@	O	-1	15817013
ud@@	O	-1	15817013
ing	O	-1	15817013
f@@	O	-1	15817013
at@@	O	-1	15817013
al@@	O	-1	15817013
iti@@	O	-1	15817013
es,	O	-1	15817013
resulted	O	-1	15817013
in	O	-1	15817013
no	O	-1	15817013
long-term	O	-1	15817013
sequ@@	O	-1	15817013
el@@	O	-1	15817013
a@@	O	-1	15817013
e,	O	-1	15817013
and	O	-1	15817013
the	O	-1	15817013
strok@@	B-Disease	D020521	15817013
e	I-Disease	-1	15817013
rate	O	-1	15817013
on	O	-1	15817013
war@@	B-Chemical	D014859	15817013
farin	I-Chemical	-1	15817013
was	O	-1	15817013
low@@	O	-1	15817013
,	O	-1	15817013
demon@@	O	-1	15817013
strat@@	O	-1	15817013
ing	O	-1	15817013
ho@@	O	-1	15817013
w	O	-1	15817013
effective	O	-1	15817013
war@@	B-Chemical	D014859	15817013
farin	I-Chemical	-1	15817013
treatment	O	-1	15817013
i@@	O	-1	15817013
s.	O	-1	15817013

S@@	O	-1	15859361
af@@	O	-1	15859361
ety	O	-1	15859361
of	O	-1	15859361
ce@@	B-Chemical	C105934	15859361
l@@	I-Chemical	-1	15859361
ec@@	I-Chemical	-1	15859361
ox@@	I-Chemical	-1	15859361
i@@	I-Chemical	-1	15859361
b	I-Chemical	-1	15859361
in	O	-1	15859361
patients	O	-1	15859361
with	O	-1	15859361
adverse	O	-1	15859361
s@@	B-Disease	D003875	15859361
k@@	I-Disease	-1	15859361
in	I-Disease	-1	15859361
reactions	I-Disease	-1	15859361
to	O	-1	15859361
acet@@	B-Chemical	D000082	15859361
aminoph@@	I-Chemical	-1	15859361
en	I-Chemical	-1	15859361
(	O	-1	15859361
par@@	B-Chemical	D000082	15859361
acet@@	I-Chemical	-1	15859361
am@@	I-Chemical	-1	15859361
ol	I-Chemical	-1	15859361
)	O	-1	15859361
and	O	-1	15859361
n@@	B-Chemical	C012655	15859361
im@@	I-Chemical	-1	15859361
es@@	I-Chemical	-1	15859361
ul@@	I-Chemical	-1	15859361
ide	I-Chemical	-1	15859361
associated	O	-1	15859361
or	O	-1	15859361
not	O	-1	15859361
with	O	-1	15859361
common	O	-1	15859361
non-@@	O	-1	15859361
steroid@@	O	-1	15859361
al	O	-1	15859361
anti@@	O	-1	15859361
-@@	O	-1	15859361
inflam@@	O	-1	15859361
mat@@	O	-1	15859361
ory	O	-1	15859361
drug@@	O	-1	15859361
s.	O	-1	15859361
BACKGROUND:	O	-1	15859361
A@@	B-Chemical	D000082	15859361
ce@@	I-Chemical	-1	15859361
t@@	I-Chemical	-1	15859361
aminoph@@	I-Chemical	-1	15859361
en	I-Chemical	-1	15859361
(	O	-1	15859361
par@@	B-Chemical	D000082	15859361
acet@@	I-Chemical	-1	15859361
am@@	I-Chemical	-1	15859361
ol	I-Chemical	-1	15859361
-@@	O	-1	15859361
-	O	-1	15859361
P	B-Chemical	D000082	15859361
)	O	-1	15859361
and	O	-1	15859361
N@@	B-Chemical	C012655	15859361
im@@	I-Chemical	-1	15859361
es@@	I-Chemical	-1	15859361
ul@@	I-Chemical	-1	15859361
ide	I-Chemical	-1	15859361
(	O	-1	15859361
N	B-Chemical	C012655	15859361
)	O	-1	15859361
are	O	-1	15859361
wi@@	O	-1	15859361
de@@	O	-1	15859361
ly	O	-1	15859361
used	O	-1	15859361
analge@@	O	-1	15859361
si@@	O	-1	15859361
c@@	O	-1	15859361
-@@	O	-1	15859361
anti@@	O	-1	15859361
py@@	O	-1	15859361
re@@	O	-1	15859361
tic@@	O	-1	15859361
/@@	O	-1	15859361
anti@@	O	-1	15859361
-@@	O	-1	15859361
inflam@@	O	-1	15859361
mat@@	O	-1	15859361
ory	O	-1	15859361
drug@@	O	-1	15859361
s.	O	-1	15859361
The	O	-1	15859361
rate	O	-1	15859361
of	O	-1	15859361
adverse	O	-1	15859361
hyper@@	B-Disease	D004342	15859361
sensitivity	I-Disease	-1	15859361
reactions	O	-1	15859361
to	O	-1	15859361
these	O	-1	15859361
agents	O	-1	15859361
is	O	-1	15859361
gener@@	O	-1	15859361
ally	O	-1	15859361
low@@	O	-1	15859361
.	O	-1	15859361
O@@	O	-1	15859361
n	O	-1	15859361
the	O	-1	15859361
contr@@	O	-1	15859361
ary	O	-1	15859361
non-@@	O	-1	15859361
steroid@@	O	-1	15859361
al	O	-1	15859361
anti@@	O	-1	15859361
-@@	O	-1	15859361
inflam@@	O	-1	15859361
mat@@	O	-1	15859361
ory	O	-1	15859361
drugs	O	-1	15859361
(N@@	O	-1	15859361
S@@	O	-1	15859361
A@@	O	-1	15859361
I@@	O	-1	15859361
D@@	O	-1	15859361
s)	O	-1	15859361
are	O	-1	15859361
common@@	O	-1	15859361
ly	O	-1	15859361
involved	O	-1	15859361
in	O	-1	15859361
such	O	-1	15859361
reac@@	O	-1	15859361
tions.	O	-1	15859361
C@@	B-Chemical	C105934	15859361
el@@	I-Chemical	-1	15859361
ec@@	I-Chemical	-1	15859361
ox@@	I-Chemical	-1	15859361
i@@	I-Chemical	-1	15859361
b	I-Chemical	-1	15859361
(	O	-1	15859361
C@@	B-Chemical	C105934	15859361
E	I-Chemical	-1	15859361
)	O	-1	15859361
is	O	-1	15859361
a	O	-1	15859361
novel	O	-1	15859361
drug@@	O	-1	15859361
,	O	-1	15859361
with	O	-1	15859361
high	O	-1	15859361
sel@@	O	-1	15859361
ec@@	O	-1	15859361
tivity	O	-1	15859361
and	O	-1	15859361
aff@@	O	-1	15859361
in@@	O	-1	15859361
ity	O	-1	15859361
for	O	-1	15859361
CO@@	O	-1	15859361
X@@	O	-1	15859361
-@@	O	-1	15859361
2	O	-1	15859361
enz@@	O	-1	15859361
y@@	O	-1	15859361
me.	O	-1	15859361
OBJECTIVE:	O	-1	15859361
We	O	-1	15859361
evaluated	O	-1	15859361
the	O	-1	15859361
toler@@	O	-1	15859361
ability	O	-1	15859361
of	O	-1	15859361
C@@	B-Chemical	C105934	15859361
E	I-Chemical	-1	15859361
in	O	-1	15859361
a	O	-1	15859361
group	O	-1	15859361
of	O	-1	15859361
patients	O	-1	15859361
with	O	-1	15859361
doc@@	O	-1	15859361
um@@	O	-1	15859361
ent@@	O	-1	15859361
ed	O	-1	15859361
hist@@	O	-1	15859361
ory	O	-1	15859361
of	O	-1	15859361
adverse	O	-1	15859361
c@@	B-Disease	D003875	15859361
utaneous	I-Disease	-1	15859361
reactions	I-Disease	-1	15859361
to	O	-1	15859361
P	B-Chemical	D000082	15859361
and	O	-1	15859361
N	B-Chemical	C012655	15859361
associated	O	-1	15859361
or	O	-1	15859361
not	O	-1	15859361
to	O	-1	15859361
cl@@	O	-1	15859361
as@@	O	-1	15859361
sic	O	-1	15859361
N@@	O	-1	15859361
S@@	O	-1	15859361
A@@	O	-1	15859361
I@@	O	-1	15859361
D@@	O	-1	15859361
s.	O	-1	15859361
METHODS:	O	-1	15859361
We	O	-1	15859361
studied	O	-1	15859361
9	O	-1	15859361
patients	O	-1	15859361
with	O	-1	15859361
hyper@@	B-Disease	D004342	15859361
sensitivity	I-Disease	-1	15859361
to	O	-1	15859361
P	B-Chemical	D000082	15859361
and	O	-1	15859361
N	B-Chemical	C012655	15859361
with	O	-1	15859361
or	O	-1	15859361
without	O	-1	15859361
associated	O	-1	15859361
reactions	O	-1	15859361
to	O	-1	15859361
cl@@	O	-1	15859361
as@@	O	-1	15859361
sic	O	-1	15859361
N@@	O	-1	15859361
S@@	O	-1	15859361
A@@	O	-1	15859361
I@@	O	-1	15859361
D@@	O	-1	15859361
s.	O	-1	15859361
The	O	-1	15859361
diagnosis	O	-1	15859361
of	O	-1	15859361
P	B-Chemical	D000082	15859361
and	O	-1	15859361
N	B-Chemical	C012655	15859361
-induced	O	-1	15859361
s@@	B-Disease	D003875	15859361
k@@	I-Disease	-1	15859361
in	I-Disease	-1	15859361
reactions	I-Disease	-1	15859361
was	O	-1	15859361
bas@@	O	-1	15859361
ed	O	-1	15859361
in	O	-1	15859361
viv@@	O	-1	15859361
o	O	-1	15859361
ch@@	O	-1	15859361
all@@	O	-1	15859361
en@@	O	-1	15859361
g@@	O	-1	15859361
e.	O	-1	15859361
The	O	-1	15859361
placebo	O	-1	15859361
was	O	-1	15859361
bl@@	O	-1	15859361
ind@@	O	-1	15859361
ly	O	-1	15859361
administered	O	-1	15859361
at	O	-1	15859361
the	O	-1	15859361
be@@	O	-1	15859361
g@@	O	-1	15859361
in@@	O	-1	15859361
ning	O	-1	15859361
of	O	-1	15859361
each	O	-1	15859361
ch@@	O	-1	15859361
all@@	O	-1	15859361
en@@	O	-1	15859361
g@@	O	-1	15859361
e.	O	-1	15859361
After	O	-1	15859361
three	O	-1	15859361
day@@	O	-1	15859361
s,	O	-1	15859361
a	O	-1	15859361
cum@@	O	-1	15859361
ul@@	O	-1	15859361
ative	O	-1	15859361
dos@@	O	-1	15859361
age	O	-1	15859361
of	O	-1	15859361
2@@	O	-1	15859361
00	O	-1	15859361
mg	O	-1	15859361
of	O	-1	15859361
C@@	B-Chemical	C105934	15859361
E	I-Chemical	-1	15859361
in	O	-1	15859361
ref@@	O	-1	15859361
rac@@	O	-1	15859361
ted	O	-1	15859361
doses	O	-1	15859361
were	O	-1	15859361
gi@@	O	-1	15859361
ven@@	O	-1	15859361
.	O	-1	15859361
After	O	-1	15859361
2-@@	O	-1	15859361
3	O	-1	15859361
day@@	O	-1	15859361
s,	O	-1	15859361
a	O	-1	15859361
single	O	-1	15859361
dose	O	-1	15859361
of	O	-1	15859361
2@@	O	-1	15859361
00	O	-1	15859361
mg	O	-1	15859361
was	O	-1	15859361
administ@@	O	-1	15859361
e@@	O	-1	15859361
red.	O	-1	15859361
All	O	-1	15859361
patients	O	-1	15859361
were	O	-1	15859361
observed	O	-1	15859361
for	O	-1	15859361
6	O	-1	15859361
hours	O	-1	15859361
after	O	-1	15859361
each	O	-1	15859361
ch@@	O	-1	15859361
all@@	O	-1	15859361
en@@	O	-1	15859361
g@@	O	-1	15859361
e,	O	-1	15859361
and	O	-1	15859361
controlled	O	-1	15859361
ag@@	O	-1	15859361
ain	O	-1	15859361
after	O	-1	15859361
24	O	-1	15859361
hours	O	-1	15859361
to	O	-1	15859361
ex@@	O	-1	15859361
cl@@	O	-1	15859361
ude	O	-1	15859361
del@@	O	-1	15859361
ayed	O	-1	15859361
reac@@	O	-1	15859361
tions.	O	-1	15859361
The	O	-1	15859361
ch@@	O	-1	15859361
all@@	O	-1	15859361
enge	O	-1	15859361
was	O	-1	15859361
considered	O	-1	15859361
positive	O	-1	15859361
if	O	-1	15859361
one	O	-1	15859361
or	O	-1	15859361
more	O	-1	15859361
of	O	-1	15859361
the	O	-1	15859361
following	O	-1	15859361
appe@@	O	-1	15859361
a@@	O	-1	15859361
re@@	O	-1	15859361
d@@	O	-1	15859361
:	O	-1	15859361
eryth@@	B-Disease	D004890	15859361
em@@	I-Disease	-1	15859361
a	I-Disease	-1	15859361
,	O	-1	15859361
r@@	O	-1	15859361
us@@	O	-1	15859361
h	O	-1	15859361
or	O	-1	15859361
ur@@	B-Disease	D014581	15859361
ti@@	I-Disease	-1	15859361
car@@	I-Disease	-1	15859361
ia	I-Disease	-1	15859361
-	O	-1	15859361
angio@@	B-Disease	D000799	15859361
e@@	I-Disease	-1	15859361
de@@	I-Disease	-1	15859361
ma	I-Disease	-1	15859361
.	O	-1	15859361
RESULTS:	O	-1	15859361
No	O	-1	15859361
reaction	O	-1	15859361
was	O	-1	15859361
observed	O	-1	15859361
with	O	-1	15859361
placebo	O	-1	15859361
and	O	-1	15859361
e@@	O	-1	15859361
ight	O	-1	15859361
patients	O	-1	15859361
(@@	O	-1	15859361
8@@	O	-1	15859361
8.@@	O	-1	15859361
8@@	O	-1	15859361
%)	O	-1	15859361
toler@@	O	-1	15859361
ated	O	-1	15859361
C@@	B-Chemical	C105934	15859361
E	I-Chemical	-1	15859361
.	O	-1	15859361
On@@	O	-1	15859361
ly	O	-1	15859361
one	O	-1	15859361
patient	O	-1	15859361
developed	O	-1	15859361
a	O	-1	15859361
moder@@	O	-1	15859361
ate	O	-1	15859361
angio@@	B-Disease	D000799	15859361
e@@	I-Disease	-1	15859361
de@@	I-Disease	-1	15859361
ma	I-Disease	-1	15859361
of	O	-1	15859361
the	O	-1	15859361
li@@	O	-1	15859361
p@@	O	-1	15859361
s.	O	-1	15859361
CONCLUSION:	O	-1	15859361
On@@	O	-1	15859361
ly	O	-1	15859361
one	O	-1	15859361
hyper@@	B-Disease	D004342	15859361
sensitivity	I-Disease	-1	15859361
reaction	O	-1	15859361
to	O	-1	15859361
C@@	B-Chemical	C105934	15859361
E	I-Chemical	-1	15859361
was	O	-1	15859361
doc@@	O	-1	15859361
um@@	O	-1	15859361
ent@@	O	-1	15859361
ed	O	-1	15859361
among	O	-1	15859361
9	O	-1	15859361
P	B-Chemical	D000082	15859361
and	O	-1	15859361
N	B-Chemical	C012655	15859361
-@@	O	-1	15859361
high@@	O	-1	15859361
ly	O	-1	15859361
N@@	O	-1	15859361
S@@	O	-1	15859361
A@@	O	-1	15859361
I@@	O	-1	15859361
D@@	O	-1	15859361
s	O	-1	15859361
int@@	O	-1	15859361
oler@@	O	-1	15859361
ant	O	-1	15859361
patients.	O	-1	15859361
Th@@	O	-1	15859361
us,	O	-1	15859361
we	O	-1	15859361
concl@@	O	-1	15859361
ude	O	-1	15859361
that	O	-1	15859361
C@@	B-Chemical	C105934	15859361
E	I-Chemical	-1	15859361
is	O	-1	15859361
a	O	-1	15859361
reas@@	O	-1	15859361
on@@	O	-1	15859361
ably	O	-1	15859361
saf@@	O	-1	15859361
e	O	-1	15859361
al@@	O	-1	15859361
tern@@	O	-1	15859361
ative	O	-1	15859361
to	O	-1	15859361
be	O	-1	15859361
used	O	-1	15859361
in	O	-1	15859361
subjects	O	-1	15859361
who	O	-1	15859361
d@@	O	-1	15859361
o	O	-1	15859361
not	O	-1	15859361
toler@@	O	-1	15859361
ate	O	-1	15859361
P	B-Chemical	D000082	15859361
and	O	-1	15859361
N	B-Chemical	C012655	15859361
.	O	-1	15859361

C@@	O	-1	15882284
as@@	O	-1	15882284
e-@@	O	-1	15882284
control	O	-1	15882284
study	O	-1	15882284
of	O	-1	15882284
reg@@	O	-1	15882284
ular	O	-1	15882284
analge@@	O	-1	15882284
sic	O	-1	15882284
and	O	-1	15882284
non@@	O	-1	15882284
steroid@@	O	-1	15882284
al	O	-1	15882284
anti@@	O	-1	15882284
-@@	O	-1	15882284
inflam@@	O	-1	15882284
mat@@	O	-1	15882284
ory	O	-1	15882284
use	O	-1	15882284
and	O	-1	15882284
en@@	B-Disease	D007676	15882284
d-@@	I-Disease	-1	15882284
st@@	I-Disease	-1	15882284
age	I-Disease	-1	15882284
renal	I-Disease	-1	15882284
disease	I-Disease	-1	15882284
.	O	-1	15882284
BACKGROUND:	O	-1	15882284
S@@	O	-1	15882284
t@@	O	-1	15882284
udi@@	O	-1	15882284
es	O	-1	15882284
on	O	-1	15882284
the	O	-1	15882284
association	O	-1	15882284
between	O	-1	15882284
the	O	-1	15882284
long-term	O	-1	15882284
use	O	-1	15882284
of	O	-1	15882284
as@@	B-Chemical	D001241	15882284
pi@@	I-Chemical	-1	15882284
rin	I-Chemical	-1	15882284
and	O	-1	15882284
other	O	-1	15882284
analge@@	O	-1	15882284
sic	O	-1	15882284
and	O	-1	15882284
non@@	O	-1	15882284
steroid@@	O	-1	15882284
al	O	-1	15882284
anti@@	O	-1	15882284
-@@	O	-1	15882284
inflam@@	O	-1	15882284
mat@@	O	-1	15882284
ory	O	-1	15882284
drugs	O	-1	15882284
(N@@	O	-1	15882284
S@@	O	-1	15882284
A@@	O	-1	15882284
I@@	O	-1	15882284
D@@	O	-1	15882284
s)	O	-1	15882284
and	O	-1	15882284
en@@	B-Disease	D007676	15882284
d-@@	I-Disease	-1	15882284
st@@	I-Disease	-1	15882284
age	I-Disease	-1	15882284
renal	I-Disease	-1	15882284
disease	I-Disease	-1	15882284
(	O	-1	15882284
ES@@	B-Disease	D007676	15882284
R@@	I-Disease	-1	15882284
D	I-Disease	-1	15882284
)	O	-1	15882284
have	O	-1	15882284
given	O	-1	15882284
conf@@	O	-1	15882284
l@@	O	-1	15882284
ic@@	O	-1	15882284
ting	O	-1	15882284
result@@	O	-1	15882284
s.	O	-1	15882284
In	O	-1	15882284
or@@	O	-1	15882284
der	O	-1	15882284
to	O	-1	15882284
ex@@	O	-1	15882284
amine	O	-1	15882284
this	O	-1	15882284
associ@@	O	-1	15882284
ation,	O	-1	15882284
a	O	-1	15882284
cas@@	O	-1	15882284
e-@@	O	-1	15882284
control	O	-1	15882284
study	O	-1	15882284
with	O	-1	15882284
inc@@	O	-1	15882284
id@@	O	-1	15882284
ent	O	-1	15882284
cases	O	-1	15882284
of	O	-1	15882284
ES@@	B-Disease	D007676	15882284
R@@	I-Disease	-1	15882284
D	I-Disease	-1	15882284
was	O	-1	15882284
car@@	O	-1	15882284
ri@@	O	-1	15882284
ed	O	-1	15882284
out@@	O	-1	15882284
.	O	-1	15882284
METHODS:	O	-1	15882284
The	O	-1	15882284
cases	O	-1	15882284
were	O	-1	15882284
all	O	-1	15882284
patients	O	-1	15882284
ent@@	O	-1	15882284
ering	O	-1	15882284
the	O	-1	15882284
loc@@	O	-1	15882284
al	O	-1	15882284
dialy@@	O	-1	15882284
sis	O	-1	15882284
pro@@	O	-1	15882284
gra@@	O	-1	15882284
m	O	-1	15882284
because	O	-1	15882284
of	O	-1	15882284
ES@@	B-Disease	D007676	15882284
R@@	I-Disease	-1	15882284
D	I-Disease	-1	15882284
in	O	-1	15882284
the	O	-1	15882284
study	O	-1	15882284
a@@	O	-1	15882284
re@@	O	-1	15882284
a	O	-1	15882284
between	O	-1	15882284
J@@	O	-1	15882284
un@@	O	-1	15882284
e	O	-1	15882284
1,	O	-1	15882284
19@@	O	-1	15882284
9@@	O	-1	15882284
5	O	-1	15882284
and	O	-1	15882284
N@@	O	-1	15882284
o@@	O	-1	15882284
ve@@	O	-1	15882284
mb@@	O	-1	15882284
er	O	-1	15882284
3@@	O	-1	15882284
0@@	O	-1	15882284
,	O	-1	15882284
19@@	O	-1	15882284
9@@	O	-1	15882284
7@@	O	-1	15882284
.	O	-1	15882284
The@@	O	-1	15882284
y	O	-1	15882284
were	O	-1	15882284
cl@@	O	-1	15882284
assi@@	O	-1	15882284
fied	O	-1	15882284
ac@@	O	-1	15882284
cor@@	O	-1	15882284
ding	O	-1	15882284
to	O	-1	15882284
the	O	-1	15882284
underlying	O	-1	15882284
diseas@@	O	-1	15882284
e,	O	-1	15882284
which	O	-1	15882284
had	O	-1	15882284
pres@@	O	-1	15882284
um@@	O	-1	15882284
ably	O	-1	15882284
l@@	O	-1	15882284
ed	O	-1	15882284
the@@	O	-1	15882284
m	O	-1	15882284
to	O	-1	15882284
ES@@	B-Disease	D007676	15882284
R@@	I-Disease	-1	15882284
D	I-Disease	-1	15882284
.	O	-1	15882284
C@@	O	-1	15882284
ont@@	O	-1	15882284
ro@@	O	-1	15882284
l@@	O	-1	15882284
s	O	-1	15882284
were	O	-1	15882284
patients	O	-1	15882284
ad@@	O	-1	15882284
mit@@	O	-1	15882284
ted	O	-1	15882284
to	O	-1	15882284
the	O	-1	15882284
same	O	-1	15882284
hospit@@	O	-1	15882284
als	O	-1	15882284
from	O	-1	15882284
wh@@	O	-1	15882284
ere	O	-1	15882284
the	O	-1	15882284
cases	O	-1	15882284
a@@	O	-1	15882284
ro@@	O	-1	15882284
se@@	O	-1	15882284
,	O	-1	15882284
also	O	-1	15882284
mat@@	O	-1	15882284
ch@@	O	-1	15882284
ed	O	-1	15882284
by	O	-1	15882284
age	O	-1	15882284
and	O	-1	15882284
sex@@	O	-1	15882284
.	O	-1	15882284
O@@	O	-1	15882284
d@@	O	-1	15882284
ds	O	-1	15882284
rati@@	O	-1	15882284
o@@	O	-1	15882284
s	O	-1	15882284
were	O	-1	15882284
calc@@	O	-1	15882284
ul@@	O	-1	15882284
ated	O	-1	15882284
using	O	-1	15882284
a	O	-1	15882284
condi@@	O	-1	15882284
tional	O	-1	15882284
log@@	O	-1	15882284
istic	O	-1	15882284
model@@	O	-1	15882284
,	O	-1	15882284
including	O	-1	15882284
potential	O	-1	15882284
conf@@	O	-1	15882284
oun@@	O	-1	15882284
ding	O	-1	15882284
fact@@	O	-1	15882284
or@@	O	-1	15882284
s,	O	-1	15882284
both	O	-1	15882284
for	O	-1	15882284
the	O	-1	15882284
wh@@	O	-1	15882284
ole	O	-1	15882284
study	O	-1	15882284
po@@	O	-1	15882284
p@@	O	-1	15882284
ulation	O	-1	15882284
and	O	-1	15882284
for	O	-1	15882284
the	O	-1	15882284
various	O	-1	15882284
underlying	O	-1	15882284
diseas@@	O	-1	15882284
es.	O	-1	15882284
RESULTS:	O	-1	15882284
F@@	O	-1	15882284
i@@	O	-1	15882284
ve	O	-1	15882284
h@@	O	-1	15882284
und@@	O	-1	15882284
red	O	-1	15882284
and	O	-1	15882284
e@@	O	-1	15882284
igh@@	O	-1	15882284
ty-@@	O	-1	15882284
three	O	-1	15882284
cases	O	-1	15882284
and	O	-1	15882284
1@@	O	-1	15882284
19@@	O	-1	15882284
0	O	-1	15882284
controls	O	-1	15882284
were	O	-1	15882284
included	O	-1	15882284
in	O	-1	15882284
the	O	-1	15882284
analy@@	O	-1	15882284
sis.	O	-1	15882284
L@@	O	-1	15882284
on@@	O	-1	15882284
g@@	O	-1	15882284
-term	O	-1	15882284
use	O	-1	15882284
of	O	-1	15882284
any	O	-1	15882284
analge@@	O	-1	15882284
sic	O	-1	15882284
was	O	-1	15882284
associated	O	-1	15882284
with	O	-1	15882284
an	O	-1	15882284
over@@	O	-1	15882284
all	O	-1	15882284
o@@	O	-1	15882284
d@@	O	-1	15882284
ds	O	-1	15882284
rati@@	O	-1	15882284
o	O	-1	15882284
of	O	-1	15882284
1.@@	O	-1	15882284
2@@	O	-1	15882284
2	O	-1	15882284
(@@	O	-1	15882284
95%	O	-1	15882284
CI@@	O	-1	15882284
,	O	-1	15882284
0.@@	O	-1	15882284
8@@	O	-1	15882284
9@@	O	-1	15882284
-@@	O	-1	15882284
1.@@	O	-1	15882284
6@@	O	-1	15882284
6@@	O	-1	15882284
).	O	-1	15882284
F@@	O	-1	15882284
or	O	-1	15882284
specific	O	-1	15882284
groups	O	-1	15882284
of	O	-1	15882284
drug@@	O	-1	15882284
s,	O	-1	15882284
the	O	-1	15882284
ris@@	O	-1	15882284
k@@	O	-1	15882284
s	O	-1	15882284
were	O	-1	15882284
1.@@	O	-1	15882284
5@@	O	-1	15882284
6	O	-1	15882284
(1@@	O	-1	15882284
.@@	O	-1	15882284
0@@	O	-1	15882284
5-@@	O	-1	15882284
2.@@	O	-1	15882284
3@@	O	-1	15882284
0@@	O	-1	15882284
)	O	-1	15882284
for	O	-1	15882284
as@@	B-Chemical	D001241	15882284
pi@@	I-Chemical	-1	15882284
rin	I-Chemical	-1	15882284
,	O	-1	15882284
1.@@	O	-1	15882284
0@@	O	-1	15882284
3	O	-1	15882284
(0.@@	O	-1	15882284
6@@	O	-1	15882284
0-@@	O	-1	15882284
1.@@	O	-1	15882284
7@@	O	-1	15882284
6@@	O	-1	15882284
)	O	-1	15882284
for	O	-1	15882284
py@@	B-Chemical	D047069	15882284
ra@@	I-Chemical	-1	15882284
z@@	I-Chemical	-1	15882284
ol@@	I-Chemical	-1	15882284
on@@	I-Chemical	-1	15882284
es	I-Chemical	-1	15882284
,	O	-1	15882284
0.@@	O	-1	15882284
8@@	O	-1	15882284
0	O	-1	15882284
(0.@@	O	-1	15882284
3@@	O	-1	15882284
9@@	O	-1	15882284
-@@	O	-1	15882284
1.@@	O	-1	15882284
6@@	O	-1	15882284
3@@	O	-1	15882284
)	O	-1	15882284
for	O	-1	15882284
par@@	B-Chemical	D000082	15882284
acet@@	I-Chemical	-1	15882284
am@@	I-Chemical	-1	15882284
ol	I-Chemical	-1	15882284
,	O	-1	15882284
and	O	-1	15882284
0.@@	O	-1	15882284
9@@	O	-1	15882284
4	O	-1	15882284
(0.@@	O	-1	15882284
5@@	O	-1	15882284
7-@@	O	-1	15882284
1.@@	O	-1	15882284
5@@	O	-1	15882284
6@@	O	-1	15882284
)	O	-1	15882284
for	O	-1	15882284
non@@	O	-1	15882284
as@@	O	-1	15882284
pi@@	O	-1	15882284
rin	O	-1	15882284
N@@	O	-1	15882284
S@@	O	-1	15882284
A@@	O	-1	15882284
I@@	O	-1	15882284
D@@	O	-1	15882284
s.	O	-1	15882284
The	O	-1	15882284
risk	O	-1	15882284
of	O	-1	15882284
ES@@	B-Disease	D007676	15882284
R@@	I-Disease	-1	15882284
D	I-Disease	-1	15882284
associated	O	-1	15882284
with	O	-1	15882284
as@@	B-Chemical	D001241	15882284
pi@@	I-Chemical	-1	15882284
rin	I-Chemical	-1	15882284
was	O	-1	15882284
related	O	-1	15882284
to	O	-1	15882284
the	O	-1	15882284
cum@@	O	-1	15882284
ul@@	O	-1	15882284
ated	O	-1	15882284
dose	O	-1	15882284
and	O	-1	15882284
duration	O	-1	15882284
of	O	-1	15882284
use@@	O	-1	15882284
,	O	-1	15882284
and	O	-1	15882284
it	O	-1	15882284
was	O	-1	15882284
partic@@	O	-1	15882284
ul@@	O	-1	15882284
arly	O	-1	15882284
high	O	-1	15882284
among	O	-1	15882284
the	O	-1	15882284
sub@@	O	-1	15882284
set	O	-1	15882284
of	O	-1	15882284
patients	O	-1	15882284
with	O	-1	15882284
vascular	O	-1	15882284
nephro@@	B-Disease	D007674	15882284
pathy	I-Disease	-1	15882284
as	O	-1	15882284
underlying	O	-1	15882284
disease	O	-1	15882284
[@@	O	-1	15882284
2.@@	O	-1	15882284
3@@	O	-1	15882284
5	O	-1	15882284
(1@@	O	-1	15882284
.@@	O	-1	15882284
17@@	O	-1	15882284
-@@	O	-1	15882284
4.@@	O	-1	15882284
7@@	O	-1	15882284
2@@	O	-1	15882284
)@@	O	-1	15882284
]@@	O	-1	15882284
.	O	-1	15882284
CONCLUSION:	O	-1	15882284
Our	O	-1	15882284
data	O	-1	15882284
indicate	O	-1	15882284
that	O	-1	15882284
long-term	O	-1	15882284
use	O	-1	15882284
of	O	-1	15882284
non@@	O	-1	15882284
as@@	O	-1	15882284
pi@@	O	-1	15882284
rin	O	-1	15882284
analge@@	O	-1	15882284
sic	O	-1	15882284
drugs	O	-1	15882284
and	O	-1	15882284
N@@	O	-1	15882284
S@@	O	-1	15882284
A@@	O	-1	15882284
I@@	O	-1	15882284
D@@	O	-1	15882284
s	O	-1	15882284
is	O	-1	15882284
not	O	-1	15882284
associated	O	-1	15882284
with	O	-1	15882284
an	O	-1	15882284
increased	O	-1	15882284
risk	O	-1	15882284
of	O	-1	15882284
ES@@	B-Disease	D007676	15882284
R@@	I-Disease	-1	15882284
D	I-Disease	-1	15882284
.	O	-1	15882284
However,	O	-1	15882284
the	O	-1	15882284
chronic	O	-1	15882284
use	O	-1	15882284
of	O	-1	15882284
as@@	B-Chemical	D001241	15882284
pi@@	I-Chemical	-1	15882284
rin	I-Chemical	-1	15882284
may	O	-1	15882284
increase	O	-1	15882284
the	O	-1	15882284
risk	O	-1	15882284
of	O	-1	15882284
ES@@	B-Disease	D007676	15882284
R@@	I-Disease	-1	15882284
D	I-Disease	-1	15882284
.	O	-1	15882284

Two	O	-1	15953230
cases	O	-1	15953230
of	O	-1	15953230
am@@	B-Chemical	C012052	15953230
is@@	I-Chemical	-1	15953230
ul@@	I-Chemical	-1	15953230
pri@@	I-Chemical	-1	15953230
de	I-Chemical	-1	15953230
over@@	B-Disease	D062787	15953230
dose	I-Disease	-1	15953230
:	O	-1	15953230
a	O	-1	15953230
cause	O	-1	15953230
for	O	-1	15953230
prolonged	B-Disease	D008133	15953230
Q@@	I-Disease	-1	15953230
T	I-Disease	-1	15953230
syndrome	I-Disease	-1	15953230
.	O	-1	15953230
Two	O	-1	15953230
cases	O	-1	15953230
of	O	-1	15953230
de@@	O	-1	15953230
li@@	O	-1	15953230
b@@	O	-1	15953230
er@@	O	-1	15953230
ate	O	-1	15953230
sel@@	O	-1	15953230
f@@	O	-1	15953230
-	O	-1	15953230
po@@	B-Disease	D011041	15953230
is@@	I-Disease	-1	15953230
on@@	I-Disease	-1	15953230
ing	I-Disease	-1	15953230
with	O	-1	15953230
5	O	-1	15953230
g	O	-1	15953230
and	O	-1	15953230
3.@@	O	-1	15953230
6	O	-1	15953230
g	O	-1	15953230
of	O	-1	15953230
am@@	B-Chemical	C012052	15953230
is@@	I-Chemical	-1	15953230
ul@@	I-Chemical	-1	15953230
pri@@	I-Chemical	-1	15953230
de	I-Chemical	-1	15953230
,	O	-1	15953230
respectivel@@	O	-1	15953230
y,	O	-1	15953230
are	O	-1	15953230
repor@@	O	-1	15953230
ted.	O	-1	15953230
In	O	-1	15953230
both	O	-1	15953230
cas@@	O	-1	15953230
es,	O	-1	15953230
Q@@	B-Disease	D008133	15953230
T	I-Disease	-1	15953230
prolong@@	I-Disease	-1	15953230
ation	I-Disease	-1	15953230
and	O	-1	15953230
hy@@	B-Disease	D006996	15953230
p@@	I-Disease	-1	15953230
oc@@	I-Disease	-1	15953230
al@@	I-Disease	-1	15953230
ca@@	I-Disease	-1	15953230
emia	I-Disease	-1	15953230
were	O	-1	15953230
not@@	O	-1	15953230
ed.	O	-1	15953230
The	O	-1	15953230
Q@@	B-Disease	D008133	15953230
T	I-Disease	-1	15953230
prolong@@	I-Disease	-1	15953230
ation	I-Disease	-1	15953230
appe@@	O	-1	15953230
a@@	O	-1	15953230
red	O	-1	15953230
to	O	-1	15953230
respon@@	O	-1	15953230
d	O	-1	15953230
to	O	-1	15953230
administration	O	-1	15953230
of	O	-1	15953230
i.v@@	O	-1	15953230
.	O	-1	15953230
calcium	B-Chemical	D002125	15953230
gl@@	I-Chemical	-1	15953230
uc@@	I-Chemical	-1	15953230
on@@	I-Chemical	-1	15953230
ate	I-Chemical	-1	15953230
.	O	-1	15953230

G@@	O	-1	15987266
row@@	O	-1	15987266
th@@	O	-1	15987266
-@@	O	-1	15987266
associated	O	-1	15987266
protein	O	-1	15987266
4@@	O	-1	15987266
3	O	-1	15987266
expression	O	-1	15987266
in	O	-1	15987266
hippocamp@@	O	-1	15987266
al	O	-1	15987266
mol@@	O	-1	15987266
ec@@	O	-1	15987266
ular	O	-1	15987266
l@@	O	-1	15987266
ay@@	O	-1	15987266
er	O	-1	15987266
of	O	-1	15987266
chronic	O	-1	15987266
epileptic	B-Disease	D004827	15987266
rats	O	-1	15987266
treated	O	-1	15987266
with	O	-1	15987266
cyclo@@	B-Chemical	D003513	15987266
he@@	I-Chemical	-1	15987266
xim@@	I-Chemical	-1	15987266
ide	I-Chemical	-1	15987266
.	O	-1	15987266
P@@	O	-1	15987266
U@@	O	-1	15987266
R@@	O	-1	15987266
P@@	O	-1	15987266
O@@	O	-1	15987266
S@@	O	-1	15987266
E:	O	-1	15987266
G@@	O	-1	15987266
A@@	O	-1	15987266
P@@	O	-1	15987266
4@@	O	-1	15987266
3	O	-1	15987266
has	O	-1	15987266
been	O	-1	15987266
thou@@	O	-1	15987266
ght	O	-1	15987266
to	O	-1	15987266
be	O	-1	15987266
lin@@	O	-1	15987266
ked	O	-1	15987266
with	O	-1	15987266
m@@	O	-1	15987266
os@@	O	-1	15987266
sy	O	-1	15987266
fib@@	O	-1	15987266
er	O	-1	15987266
s@@	O	-1	15987266
pro@@	O	-1	15987266
ut@@	O	-1	15987266
ing	O	-1	15987266
(@@	O	-1	15987266
M@@	O	-1	15987266
F@@	O	-1	15987266
S)	O	-1	15987266
in	O	-1	15987266
various	O	-1	15987266
experimental	O	-1	15987266
models	O	-1	15987266
of	O	-1	15987266
epilep@@	B-Disease	D004827	15987266
sy	I-Disease	-1	15987266
.	O	-1	15987266
To	O	-1	15987266
investigate	O	-1	15987266
ho@@	O	-1	15987266
w	O	-1	15987266
G@@	O	-1	15987266
A@@	O	-1	15987266
P@@	O	-1	15987266
4@@	O	-1	15987266
3	O	-1	15987266
expression	O	-1	15987266
(@@	O	-1	15987266
G@@	O	-1	15987266
A@@	O	-1	15987266
P@@	O	-1	15987266
4@@	O	-1	15987266
3-@@	O	-1	15987266
ir@@	O	-1	15987266
)	O	-1	15987266
correl@@	O	-1	15987266
ates	O	-1	15987266
with	O	-1	15987266
M@@	O	-1	15987266
F@@	O	-1	15987266
S@@	O	-1	15987266
,	O	-1	15987266
we	O	-1	15987266
assessed	O	-1	15987266
the	O	-1	15987266
int@@	O	-1	15987266
ensity	O	-1	15987266
(@@	O	-1	15987266
d@@	O	-1	15987266
en@@	O	-1	15987266
sit@@	O	-1	15987266
o@@	O	-1	15987266
met@@	O	-1	15987266
r@@	O	-1	15987266
y@@	O	-1	15987266
)	O	-1	15987266
and	O	-1	15987266
exten@@	O	-1	15987266
sion	O	-1	15987266
(@@	O	-1	15987266
w@@	O	-1	15987266
id@@	O	-1	15987266
th@@	O	-1	15987266
)	O	-1	15987266
of	O	-1	15987266
G@@	O	-1	15987266
A@@	O	-1	15987266
P@@	O	-1	15987266
4@@	O	-1	15987266
3-@@	O	-1	15987266
ir	O	-1	15987266
in	O	-1	15987266
the	O	-1	15987266
in@@	O	-1	15987266
n@@	O	-1	15987266
er	O	-1	15987266
mol@@	O	-1	15987266
ec@@	O	-1	15987266
ular	O	-1	15987266
l@@	O	-1	15987266
ay@@	O	-1	15987266
er	O	-1	15987266
of	O	-1	15987266
the	O	-1	15987266
d@@	O	-1	15987266
ent@@	O	-1	15987266
ate	O	-1	15987266
g@@	O	-1	15987266
y@@	O	-1	15987266
ru@@	O	-1	15987266
s	O	-1	15987266
(@@	O	-1	15987266
I@@	O	-1	15987266
M@@	O	-1	15987266
L@@	O	-1	15987266
)	O	-1	15987266
of	O	-1	15987266
rats	O	-1	15987266
subj@@	O	-1	15987266
ect	O	-1	15987266
to	O	-1	15987266
status	B-Disease	D013226	15987266
epilep@@	I-Disease	-1	15987266
tic@@	I-Disease	-1	15987266
us	I-Disease	-1	15987266
induced	O	-1	15987266
by	O	-1	15987266
pilocar@@	B-Chemical	D010862	15987266
pine	I-Chemical	-1	15987266
(	O	-1	15987266
P@@	B-Chemical	D010862	15987266
il@@	I-Chemical	-1	15987266
o	I-Chemical	-1	15987266
),	O	-1	15987266
previously	O	-1	15987266
injected	O	-1	15987266
or	O	-1	15987266
not	O	-1	15987266
with	O	-1	15987266
cyclo@@	B-Chemical	D003513	15987266
he@@	I-Chemical	-1	15987266
xim@@	I-Chemical	-1	15987266
ide	I-Chemical	-1	15987266
(	O	-1	15987266
C@@	B-Chemical	D003513	15987266
H@@	I-Chemical	-1	15987266
X	I-Chemical	-1	15987266
),	O	-1	15987266
which	O	-1	15987266
has	O	-1	15987266
been	O	-1	15987266
shown	O	-1	15987266
to	O	-1	15987266
inhib@@	O	-1	15987266
it	O	-1	15987266
M@@	O	-1	15987266
F@@	O	-1	15987266
S@@	O	-1	15987266
.	O	-1	15987266
METHODS:	O	-1	15987266
C@@	B-Chemical	D003513	15987266
H@@	I-Chemical	-1	15987266
X	I-Chemical	-1	15987266
was	O	-1	15987266
injected	O	-1	15987266
before	O	-1	15987266
the	O	-1	15987266
P@@	B-Chemical	D010862	15987266
il@@	I-Chemical	-1	15987266
o	I-Chemical	-1	15987266
injection	O	-1	15987266
in	O	-1	15987266
ad@@	O	-1	15987266
ult	O	-1	15987266
Wistar	O	-1	15987266
rats.	O	-1	15987266
The	O	-1	15987266
P@@	B-Chemical	D010862	15987266
il@@	I-Chemical	-1	15987266
o	I-Chemical	-1	15987266
group	O	-1	15987266
was	O	-1	15987266
injected	O	-1	15987266
with	O	-1	15987266
the	O	-1	15987266
same	O	-1	15987266
drug@@	O	-1	15987266
s,	O	-1	15987266
ex@@	O	-1	15987266
cep@@	O	-1	15987266
t	O	-1	15987266
for	O	-1	15987266
C@@	B-Chemical	D003513	15987266
H@@	I-Chemical	-1	15987266
X	I-Chemical	-1	15987266
.	O	-1	15987266
An@@	O	-1	15987266
im@@	O	-1	15987266
als	O	-1	15987266
were	O	-1	15987266
k@@	O	-1	15987266
ill@@	O	-1	15987266
ed	O	-1	15987266
between	O	-1	15987266
30	O	-1	15987266
and	O	-1	15987266
60	O	-1	15987266
days	O	-1	15987266
lat@@	O	-1	15987266
er,	O	-1	15987266
and	O	-1	15987266
brain	O	-1	15987266
sec@@	O	-1	15987266
tions	O	-1	15987266
were	O	-1	15987266
pro@@	O	-1	15987266
cess@@	O	-1	15987266
ed	O	-1	15987266
for	O	-1	15987266
G@@	O	-1	15987266
A@@	O	-1	15987266
P@@	O	-1	15987266
4@@	O	-1	15987266
3	O	-1	15987266
immuno@@	O	-1	15987266
histo@@	O	-1	15987266
chem@@	O	-1	15987266
ist@@	O	-1	15987266
r@@	O	-1	15987266
y.	O	-1	15987266
RESULTS:	O	-1	15987266
D@@	O	-1	15987266
en@@	O	-1	15987266
sit@@	O	-1	15987266
o@@	O	-1	15987266
met@@	O	-1	15987266
r@@	O	-1	15987266
y	O	-1	15987266
showed	O	-1	15987266
no	O	-1	15987266
significant	O	-1	15987266
difference	O	-1	15987266
reg@@	O	-1	15987266
ar@@	O	-1	15987266
ding	O	-1	15987266
G@@	O	-1	15987266
A@@	O	-1	15987266
P@@	O	-1	15987266
4@@	O	-1	15987266
3-@@	O	-1	15987266
ir	O	-1	15987266
in	O	-1	15987266
the	O	-1	15987266
I@@	O	-1	15987266
M@@	O	-1	15987266
L	O	-1	15987266
between	O	-1	15987266
P@@	B-Chemical	D010862	15987266
il@@	I-Chemical	-1	15987266
o	I-Chemical	-1	15987266
,	O	-1	15987266
C@@	B-Chemical	D003513	15987266
H@@	I-Chemical	-1	15987266
X	I-Chemical	-1	15987266
+	O	-1	15987266
P@@	B-Chemical	D010862	15987266
il@@	I-Chemical	-1	15987266
o	I-Chemical	-1	15987266
,	O	-1	15987266
and	O	-1	15987266
control	O	-1	15987266
groups.	O	-1	15987266
However,	O	-1	15987266
the	O	-1	15987266
results	O	-1	15987266
of	O	-1	15987266
the	O	-1	15987266
w@@	O	-1	15987266
id@@	O	-1	15987266
th	O	-1	15987266
of	O	-1	15987266
the	O	-1	15987266
G@@	O	-1	15987266
A@@	O	-1	15987266
P@@	O	-1	15987266
4@@	O	-1	15987266
3-@@	O	-1	15987266
ir	O	-1	15987266
b@@	O	-1	15987266
and	O	-1	15987266
in	O	-1	15987266
the	O	-1	15987266
I@@	O	-1	15987266
M@@	O	-1	15987266
L	O	-1	15987266
showed	O	-1	15987266
that	O	-1	15987266
C@@	B-Chemical	D003513	15987266
H@@	I-Chemical	-1	15987266
X	I-Chemical	-1	15987266
+	O	-1	15987266
P@@	B-Chemical	D010862	15987266
il@@	I-Chemical	-1	15987266
o	I-Chemical	-1	15987266
and	O	-1	15987266
control	O	-1	15987266
animals	O	-1	15987266
had	O	-1	15987266
a	O	-1	15987266
significantly	O	-1	15987266
larg@@	O	-1	15987266
er	O	-1	15987266
b@@	O	-1	15987266
and	O	-1	15987266
(p	O	-1	15987266
=	O	-1	15987266
0.0@@	O	-1	15987266
3@@	O	-1	15987266
)	O	-1	15987266
as	O	-1	15987266
compared	O	-1	15987266
with	O	-1	15987266
that	O	-1	15987266
in	O	-1	15987266
the	O	-1	15987266
P@@	B-Chemical	D010862	15987266
il@@	I-Chemical	-1	15987266
o	I-Chemical	-1	15987266
group.	O	-1	15987266
CONCLUSIONS:	O	-1	15987266
Our	O	-1	15987266
current	O	-1	15987266
find@@	O	-1	15987266
ing	O	-1	15987266
that	O	-1	15987266
animals	O	-1	15987266
in	O	-1	15987266
the	O	-1	15987266
C@@	B-Chemical	D003513	15987266
H@@	I-Chemical	-1	15987266
X	I-Chemical	-1	15987266
+	O	-1	15987266
P@@	B-Chemical	D010862	15987266
il@@	I-Chemical	-1	15987266
o	I-Chemical	-1	15987266
group	O	-1	15987266
have	O	-1	15987266
a	O	-1	15987266
G@@	O	-1	15987266
A@@	O	-1	15987266
P@@	O	-1	15987266
4@@	O	-1	15987266
3-@@	O	-1	15987266
ir	O	-1	15987266
b@@	O	-1	15987266
and	O	-1	15987266
in	O	-1	15987266
the	O	-1	15987266
I@@	O	-1	15987266
M@@	O	-1	15987266
L@@	O	-1	15987266
,	O	-1	15987266
similar	O	-1	15987266
to	O	-1	15987266
that	O	-1	15987266
of	O	-1	15987266
control@@	O	-1	15987266
s,	O	-1	15987266
re@@	O	-1	15987266
inf@@	O	-1	15987266
or@@	O	-1	15987266
ces	O	-1	15987266
prior	O	-1	15987266
data	O	-1	15987266
on	O	-1	15987266
the	O	-1	15987266
block@@	O	-1	15987266
ade	O	-1	15987266
of	O	-1	15987266
M@@	O	-1	15987266
F@@	O	-1	15987266
S	O	-1	15987266
in	O	-1	15987266
these	O	-1	15987266
anim@@	O	-1	15987266
al@@	O	-1	15987266
s.	O	-1	15987266
The	O	-1	15987266
change	O	-1	15987266
in	O	-1	15987266
G@@	O	-1	15987266
A@@	O	-1	15987266
P@@	O	-1	15987266
4@@	O	-1	15987266
3-@@	O	-1	15987266
ir	O	-1	15987266
present	O	-1	15987266
in	O	-1	15987266
P@@	B-Chemical	D010862	15987266
il@@	I-Chemical	-1	15987266
o	I-Chemical	-1	15987266
-treated	O	-1	15987266
animals	O	-1	15987266
was	O	-1	15987266
a	O	-1	15987266
th@@	O	-1	15987266
in@@	O	-1	15987266
ning	O	-1	15987266
of	O	-1	15987266
the	O	-1	15987266
b@@	O	-1	15987266
and	O	-1	15987266
to	O	-1	15987266
a	O	-1	15987266
very	O	-1	15987266
n@@	O	-1	15987266
ar@@	O	-1	15987266
ro@@	O	-1	15987266
w	O	-1	15987266
l@@	O	-1	15987266
ay@@	O	-1	15987266
er	O	-1	15987266
j@@	O	-1	15987266
us@@	O	-1	15987266
t	O	-1	15987266
ab@@	O	-1	15987266
o@@	O	-1	15987266
ve	O	-1	15987266
the	O	-1	15987266
gran@@	O	-1	15987266
ul@@	O	-1	15987266
e	O	-1	15987266
cell	O	-1	15987266
l@@	O	-1	15987266
ay@@	O	-1	15987266
er	O	-1	15987266
that	O	-1	15987266
is	O	-1	15987266
likely	O	-1	15987266
to	O	-1	15987266
be	O	-1	15987266
associated	O	-1	15987266
with	O	-1	15987266
the	O	-1	15987266
loss	O	-1	15987266
of	O	-1	15987266
h@@	O	-1	15987266
il@@	O	-1	15987266
ar	O	-1	15987266
cell	O	-1	15987266
pro@@	O	-1	15987266
j@@	O	-1	15987266
ec@@	O	-1	15987266
tions	O	-1	15987266
that	O	-1	15987266
ex@@	O	-1	15987266
pres@@	O	-1	15987266
s	O	-1	15987266
G@@	O	-1	15987266
A@@	O	-1	15987266
P@@	O	-1	15987266
-@@	O	-1	15987266
4@@	O	-1	15987266
3@@	O	-1	15987266
.	O	-1	15987266

N@@	B-Chemical	D009538	15991002
icot@@	I-Chemical	-1	15991002
ine	I-Chemical	-1	15991002
antagon@@	O	-1	15991002
iz@@	O	-1	15991002
es	O	-1	15991002
caffe@@	B-Chemical	D002110	15991002
ine	I-Chemical	-1	15991002
-	O	-1	15991002
but	O	-1	15991002
not	O	-1	15991002
pent@@	B-Chemical	D010433	15991002
yl@@	I-Chemical	-1	15991002
en@@	I-Chemical	-1	15991002
e@@	I-Chemical	-1	15991002
te@@	I-Chemical	-1	15991002
tra@@	I-Chemical	-1	15991002
z@@	I-Chemical	-1	15991002
ole	I-Chemical	-1	15991002
-induced	O	-1	15991002
an@@	O	-1	15991002
x@@	O	-1	15991002
io@@	O	-1	15991002
genic	O	-1	15991002
effect	O	-1	15991002
in	O	-1	15991002
mice.	O	-1	15991002
R@@	O	-1	15991002
AT@@	O	-1	15991002
ION@@	O	-1	15991002
AL@@	O	-1	15991002
E:	O	-1	15991002
N@@	B-Chemical	D009538	15991002
icot@@	I-Chemical	-1	15991002
ine	I-Chemical	-1	15991002
and	O	-1	15991002
caffe@@	B-Chemical	D002110	15991002
ine	I-Chemical	-1	15991002
are	O	-1	15991002
wi@@	O	-1	15991002
de@@	O	-1	15991002
ly	O	-1	15991002
consum@@	O	-1	15991002
ed	O	-1	15991002
l@@	O	-1	15991002
ic@@	O	-1	15991002
it	O	-1	15991002
psycho@@	O	-1	15991002
active	O	-1	15991002
drugs	O	-1	15991002
wor@@	O	-1	15991002
l@@	O	-1	15991002
d@@	O	-1	15991002
wi@@	O	-1	15991002
de@@	O	-1	15991002
.	O	-1	15991002
E@@	O	-1	15991002
pi@@	O	-1	15991002
de@@	O	-1	15991002
m@@	O	-1	15991002
io@@	O	-1	15991002
log@@	O	-1	15991002
ical	O	-1	15991002
studies	O	-1	15991002
showed	O	-1	15991002
that	O	-1	15991002
they	O	-1	15991002
were	O	-1	15991002
gener@@	O	-1	15991002
ally	O	-1	15991002
used	O	-1	15991002
con@@	O	-1	15991002
cur@@	O	-1	15991002
ren@@	O	-1	15991002
t@@	O	-1	15991002
ly.	O	-1	15991002
Although	O	-1	15991002
some	O	-1	15991002
studies	O	-1	15991002
in	O	-1	15991002
experimental	O	-1	15991002
animals	O	-1	15991002
indicate	O	-1	15991002
c@@	O	-1	15991002
le@@	O	-1	15991002
ar	O	-1	15991002
pharmac@@	O	-1	15991002
ological	O	-1	15991002
inter@@	O	-1	15991002
ac@@	O	-1	15991002
tions	O	-1	15991002
between	O	-1	15991002
th@@	O	-1	15991002
em@@	O	-1	15991002
,	O	-1	15991002
no	O	-1	15991002
studies	O	-1	15991002
have	O	-1	15991002
shown	O	-1	15991002
a	O	-1	15991002
specific	O	-1	15991002
inter@@	O	-1	15991002
action	O	-1	15991002
on	O	-1	15991002
an@@	B-Disease	D001008	15991002
xi@@	I-Disease	-1	15991002
ety	I-Disease	-1	15991002
respon@@	O	-1	15991002
s@@	O	-1	15991002
es.	O	-1	15991002
OBJECTIV@@	O	-1	15991002
E@@	O	-1	15991002
S:	O	-1	15991002
The	O	-1	15991002
present	O	-1	15991002
study	O	-1	15991002
investig@@	O	-1	15991002
ates	O	-1	15991002
the	O	-1	15991002
effects	O	-1	15991002
of	O	-1	15991002
nicotine	B-Chemical	D009538	15991002
on	O	-1	15991002
an@@	B-Disease	D001008	15991002
xi@@	I-Disease	-1	15991002
ety	I-Disease	-1	15991002
induced	O	-1	15991002
by	O	-1	15991002
caffe@@	B-Chemical	D002110	15991002
ine	I-Chemical	-1	15991002
and	O	-1	15991002
an@@	O	-1	15991002
other	O	-1	15991002
an@@	O	-1	15991002
x@@	O	-1	15991002
io@@	O	-1	15991002
genic	O	-1	15991002
drug@@	O	-1	15991002
,	O	-1	15991002
pent@@	B-Chemical	D010433	15991002
yl@@	I-Chemical	-1	15991002
en@@	I-Chemical	-1	15991002
e@@	I-Chemical	-1	15991002
te@@	I-Chemical	-1	15991002
tra@@	I-Chemical	-1	15991002
z@@	I-Chemical	-1	15991002
ole	I-Chemical	-1	15991002
,	O	-1	15991002
in	O	-1	15991002
mice.	O	-1	15991002
The	O	-1	15991002
elevated	O	-1	15991002
pl@@	O	-1	15991002
us@@	O	-1	15991002
-@@	O	-1	15991002
ma@@	O	-1	15991002
ze	O	-1	15991002
(@@	O	-1	15991002
EP@@	O	-1	15991002
M@@	O	-1	15991002
)	O	-1	15991002
test	O	-1	15991002
was	O	-1	15991002
used	O	-1	15991002
to	O	-1	15991002
evalu@@	O	-1	15991002
ate	O	-1	15991002
the	O	-1	15991002
effects	O	-1	15991002
of	O	-1	15991002
drugs	O	-1	15991002
on	O	-1	15991002
an@@	B-Disease	D001008	15991002
xi@@	I-Disease	-1	15991002
ety	I-Disease	-1	15991002
.	O	-1	15991002
METHODS:	O	-1	15991002
Ad@@	O	-1	15991002
ult	O	-1	15991002
male	O	-1	15991002
S@@	O	-1	15991002
w@@	O	-1	15991002
is@@	O	-1	15991002
s	O	-1	15991002
W@@	O	-1	15991002
e@@	O	-1	15991002
b@@	O	-1	15991002
st@@	O	-1	15991002
er	O	-1	15991002
mice	O	-1	15991002
(2@@	O	-1	15991002
5-@@	O	-1	15991002
3@@	O	-1	15991002
2	O	-1	15991002
g@@	O	-1	15991002
)	O	-1	15991002
were	O	-1	15991002
given	O	-1	15991002
nicotine	B-Chemical	D009538	15991002
(@@	O	-1	15991002
0.0@@	O	-1	15991002
5-@@	O	-1	15991002
0.@@	O	-1	15991002
25	O	-1	15991002
mg/kg	O	-1	15991002
s@@	O	-1	15991002
.@@	O	-1	15991002
c@@	O	-1	15991002
.)	O	-1	15991002
or	O	-1	15991002
saline	O	-1	15991002
10	O	-1	15991002
min	O	-1	15991002
before	O	-1	15991002
caffe@@	B-Chemical	D002110	15991002
ine	I-Chemical	-1	15991002
(@@	O	-1	15991002
7@@	O	-1	15991002
0	O	-1	15991002
mg/kg	O	-1	15991002
i.p.@@	O	-1	15991002
)	O	-1	15991002
or	O	-1	15991002
pent@@	B-Chemical	D010433	15991002
yl@@	I-Chemical	-1	15991002
en@@	I-Chemical	-1	15991002
e@@	I-Chemical	-1	15991002
te@@	I-Chemical	-1	15991002
tra@@	I-Chemical	-1	15991002
z@@	I-Chemical	-1	15991002
ole	I-Chemical	-1	15991002
(1@@	O	-1	15991002
5	O	-1	15991002
and	O	-1	15991002
30	O	-1	15991002
mg/kg	O	-1	15991002
i.p.@@	O	-1	15991002
)	O	-1	15991002
injec@@	O	-1	15991002
tions.	O	-1	15991002
After	O	-1	15991002
15	O	-1	15991002
min@@	O	-1	15991002
,	O	-1	15991002
mice	O	-1	15991002
were	O	-1	15991002
evaluated	O	-1	15991002
for	O	-1	15991002
their	O	-1	15991002
o@@	O	-1	15991002
pen@@	O	-1	15991002
-	O	-1	15991002
and	O	-1	15991002
clo@@	O	-1	15991002
se@@	O	-1	15991002
d-@@	O	-1	15991002
ar@@	O	-1	15991002
m	O	-1	15991002
time	O	-1	15991002
and	O	-1	15991002
ent@@	O	-1	15991002
ri@@	O	-1	15991002
es	O	-1	15991002
on	O	-1	15991002
the	O	-1	15991002
EP@@	O	-1	15991002
M	O	-1	15991002
for	O	-1	15991002
a	O	-1	15991002
10-@@	O	-1	15991002
min	O	-1	15991002
s@@	O	-1	15991002
es@@	O	-1	15991002
sion.	O	-1	15991002
L@@	O	-1	15991002
o@@	O	-1	15991002
com@@	O	-1	15991002
otor	O	-1	15991002
activity	O	-1	15991002
was	O	-1	15991002
recor@@	O	-1	15991002
ded	O	-1	15991002
for	O	-1	15991002
individ@@	O	-1	15991002
ual	O	-1	15991002
groups	O	-1	15991002
by	O	-1	15991002
using	O	-1	15991002
the	O	-1	15991002
same	O	-1	15991002
treatment	O	-1	15991002
pro@@	O	-1	15991002
to@@	O	-1	15991002
co@@	O	-1	15991002
l	O	-1	15991002
with	O	-1	15991002
the	O	-1	15991002
EP@@	O	-1	15991002
M	O	-1	15991002
test@@	O	-1	15991002
.	O	-1	15991002
RESULTS:	O	-1	15991002
N@@	B-Chemical	D009538	15991002
icot@@	I-Chemical	-1	15991002
ine	I-Chemical	-1	15991002
(@@	O	-1	15991002
0.0@@	O	-1	15991002
5-@@	O	-1	15991002
0.@@	O	-1	15991002
25	O	-1	15991002
mg/kg)	O	-1	15991002
it@@	O	-1	15991002
sel@@	O	-1	15991002
f	O	-1	15991002
did	O	-1	15991002
not	O	-1	15991002
produce	O	-1	15991002
any	O	-1	15991002
significant	O	-1	15991002
effect	O	-1	15991002
in	O	-1	15991002
the	O	-1	15991002
EP@@	O	-1	15991002
M	O	-1	15991002
test@@	O	-1	15991002
,	O	-1	15991002
whereas	O	-1	15991002
caffe@@	B-Chemical	D002110	15991002
ine	I-Chemical	-1	15991002
(@@	O	-1	15991002
7@@	O	-1	15991002
0	O	-1	15991002
mg/kg)	O	-1	15991002
and	O	-1	15991002
pent@@	B-Chemical	D010433	15991002
yl@@	I-Chemical	-1	15991002
en@@	I-Chemical	-1	15991002
e@@	I-Chemical	-1	15991002
te@@	I-Chemical	-1	15991002
tra@@	I-Chemical	-1	15991002
z@@	I-Chemical	-1	15991002
ole	I-Chemical	-1	15991002
(@@	O	-1	15991002
30	O	-1	15991002
mg/kg)	O	-1	15991002
produced	O	-1	15991002
an	O	-1	15991002
an@@	O	-1	15991002
x@@	O	-1	15991002
io@@	O	-1	15991002
genic	O	-1	15991002
effect@@	O	-1	15991002
,	O	-1	15991002
appa@@	O	-1	15991002
rent	O	-1	15991002
with	O	-1	15991002
decreas@@	O	-1	15991002
es	O	-1	15991002
in	O	-1	15991002
o@@	O	-1	15991002
pen@@	O	-1	15991002
-@@	O	-1	15991002
ar@@	O	-1	15991002
m	O	-1	15991002
time	O	-1	15991002
and	O	-1	15991002
entr@@	O	-1	15991002
y.	O	-1	15991002
N@@	B-Chemical	D009538	15991002
icot@@	I-Chemical	-1	15991002
ine	I-Chemical	-1	15991002
(0.@@	O	-1	15991002
25	O	-1	15991002
mg/kg)	O	-1	15991002
pretreatment	O	-1	15991002
block@@	O	-1	15991002
ed	O	-1	15991002
the	O	-1	15991002
caffe@@	B-Chemical	D002110	15991002
ine	I-Chemical	-1	15991002
-	O	-1	15991002
but	O	-1	15991002
not	O	-1	15991002
pent@@	B-Chemical	D010433	15991002
yl@@	I-Chemical	-1	15991002
en@@	I-Chemical	-1	15991002
e@@	I-Chemical	-1	15991002
te@@	I-Chemical	-1	15991002
tra@@	I-Chemical	-1	15991002
z@@	I-Chemical	-1	15991002
ole	I-Chemical	-1	15991002
-induced	O	-1	15991002
an@@	B-Disease	D001008	15991002
xi@@	I-Disease	-1	15991002
ety	I-Disease	-1	15991002
.	O	-1	15991002
Ad@@	O	-1	15991002
minist@@	O	-1	15991002
ration	O	-1	15991002
of	O	-1	15991002
each	O	-1	15991002
drug	O	-1	15991002
and	O	-1	15991002
their	O	-1	15991002
combin@@	O	-1	15991002
ations	O	-1	15991002
did	O	-1	15991002
not	O	-1	15991002
produce	O	-1	15991002
any	O	-1	15991002
effect	O	-1	15991002
on	O	-1	15991002
locomotor	O	-1	15991002
activ@@	O	-1	15991002
ity.	O	-1	15991002
CONCLUSIONS:	O	-1	15991002
Our	O	-1	15991002
results	O	-1	15991002
suggest	O	-1	15991002
that	O	-1	15991002
the	O	-1	15991002
antagon@@	O	-1	15991002
istic	O	-1	15991002
effect	O	-1	15991002
of	O	-1	15991002
nicotine	B-Chemical	D009538	15991002
on	O	-1	15991002
caffe@@	B-Chemical	D002110	15991002
ine	I-Chemical	-1	15991002
-induced	O	-1	15991002
an@@	B-Disease	D001008	15991002
xi@@	I-Disease	-1	15991002
ety	I-Disease	-1	15991002
is	O	-1	15991002
specific	O	-1	15991002
to	O	-1	15991002
caffe@@	B-Chemical	D002110	15991002
ine	I-Chemical	-1	15991002
,	O	-1	15991002
in@@	O	-1	15991002
ste@@	O	-1	15991002
ad	O	-1	15991002
of	O	-1	15991002
a	O	-1	15991002
non-@@	O	-1	15991002
specific	O	-1	15991002
an@@	O	-1	15991002
xi@@	O	-1	15991002
oly@@	O	-1	15991002
tic	O	-1	15991002
effect@@	O	-1	15991002
.	O	-1	15991002
Th@@	O	-1	15991002
us,	O	-1	15991002
it	O	-1	15991002
may	O	-1	15991002
exten@@	O	-1	15991002
d	O	-1	15991002
the	O	-1	15991002
current	O	-1	15991002
findings	O	-1	15991002
on	O	-1	15991002
the	O	-1	15991002
inter@@	O	-1	15991002
action	O	-1	15991002
between	O	-1	15991002
nicotine	B-Chemical	D009538	15991002
and	O	-1	15991002
caffe@@	B-Chemical	D002110	15991002
ine	I-Chemical	-1	15991002
.	O	-1	15991002

L@@	O	-1	16034922
ong	O	-1	16034922
term	O	-1	16034922
h@@	O	-1	16034922
orm@@	O	-1	16034922
one	O	-1	16034922
therapy	O	-1	16034922
for	O	-1	16034922
per@@	O	-1	16034922
imen@@	O	-1	16034922
o@@	O	-1	16034922
pa@@	O	-1	16034922
us@@	O	-1	16034922
al	O	-1	16034922
and	O	-1	16034922
post@@	O	-1	16034922
men@@	O	-1	16034922
o@@	O	-1	16034922
pa@@	O	-1	16034922
us@@	O	-1	16034922
al	O	-1	16034922
wom@@	O	-1	16034922
en@@	O	-1	16034922
.	O	-1	16034922
BACKGROUND:	O	-1	16034922
H@@	O	-1	16034922
orm@@	O	-1	16034922
one	O	-1	16034922
therapy	O	-1	16034922
(@@	O	-1	16034922
H@@	O	-1	16034922
T)	O	-1	16034922
is	O	-1	16034922
wi@@	O	-1	16034922
de@@	O	-1	16034922
ly	O	-1	16034922
used	O	-1	16034922
for	O	-1	16034922
contro@@	O	-1	16034922
ll@@	O	-1	16034922
ing	O	-1	16034922
men@@	B-Disease	D008594	16034922
o@@	I-Disease	-1	16034922
pa@@	I-Disease	-1	16034922
us@@	I-Disease	-1	16034922
al	I-Disease	-1	16034922
symptoms	I-Disease	-1	16034922
.	O	-1	16034922
It	O	-1	16034922
has	O	-1	16034922
also	O	-1	16034922
been	O	-1	16034922
used	O	-1	16034922
for	O	-1	16034922
the	O	-1	16034922
man@@	O	-1	16034922
ag@@	O	-1	16034922
ement	O	-1	16034922
and	O	-1	16034922
pre@@	O	-1	16034922
ven@@	O	-1	16034922
tion	O	-1	16034922
of	O	-1	16034922
cardiovascular	B-Disease	D002318	16034922
disease	I-Disease	-1	16034922
,	O	-1	16034922
ost@@	B-Disease	D010024	16034922
e@@	I-Disease	-1	16034922
o@@	I-Disease	-1	16034922
po@@	I-Disease	-1	16034922
ro@@	I-Disease	-1	16034922
sis	I-Disease	-1	16034922
and	O	-1	16034922
de@@	B-Disease	D003704	16034922
m@@	I-Disease	-1	16034922
enti@@	I-Disease	-1	16034922
a	I-Disease	-1	16034922
in	O	-1	16034922
ol@@	O	-1	16034922
der	O	-1	16034922
women	O	-1	16034922
but	O	-1	16034922
the	O	-1	16034922
evidence	O	-1	16034922
sup@@	O	-1	16034922
port@@	O	-1	16034922
ing	O	-1	16034922
its	O	-1	16034922
use	O	-1	16034922
for	O	-1	16034922
these	O	-1	16034922
indic@@	O	-1	16034922
ations	O	-1	16034922
is	O	-1	16034922
larg@@	O	-1	16034922
ely	O	-1	16034922
observ@@	O	-1	16034922
ation@@	O	-1	16034922
al.	O	-1	16034922
OBJECTIV@@	O	-1	16034922
E@@	O	-1	16034922
S:	O	-1	16034922
To	O	-1	16034922
ass@@	O	-1	16034922
ess	O	-1	16034922
the	O	-1	16034922
effect	O	-1	16034922
of	O	-1	16034922
long-term	O	-1	16034922
H@@	O	-1	16034922
T	O	-1	16034922
on	O	-1	16034922
mor@@	O	-1	16034922
t@@	O	-1	16034922
al@@	O	-1	16034922
ity,	O	-1	16034922
heart	B-Disease	D006331	16034922
disease	I-Disease	-1	16034922
,	O	-1	16034922
venous	B-Disease	D054556	16034922
thrombo@@	I-Disease	-1	16034922
emb@@	I-Disease	-1	16034922
ol@@	I-Disease	-1	16034922
ism	I-Disease	-1	16034922
,	O	-1	16034922
strok@@	B-Disease	D020521	16034922
e	I-Disease	-1	16034922
,	O	-1	16034922
transi@@	B-Disease	D002546	16034922
ent	I-Disease	-1	16034922
is@@	I-Disease	-1	16034922
ch@@	I-Disease	-1	16034922
a@@	I-Disease	-1	16034922
em@@	I-Disease	-1	16034922
ic	I-Disease	-1	16034922
at@@	I-Disease	-1	16034922
tac@@	I-Disease	-1	16034922
k@@	I-Disease	-1	16034922
s	I-Disease	-1	16034922
,	O	-1	16034922
b@@	B-Disease	D001943	16034922
reas@@	I-Disease	-1	16034922
t	I-Disease	-1	16034922
cancer	I-Disease	-1	16034922
,	O	-1	16034922
co@@	B-Disease	D015179	16034922
lo@@	I-Disease	-1	16034922
rec@@	I-Disease	-1	16034922
t@@	I-Disease	-1	16034922
al	I-Disease	-1	16034922
cancer	I-Disease	-1	16034922
,	O	-1	16034922
o@@	B-Disease	D010051	16034922
vari@@	I-Disease	-1	16034922
an	I-Disease	-1	16034922
cancer	I-Disease	-1	16034922
,	O	-1	16034922
endo@@	B-Disease	D016889	16034922
me@@	I-Disease	-1	16034922
trial	I-Disease	-1	16034922
cancer	I-Disease	-1	16034922
,	O	-1	16034922
g@@	B-Disease	D005705	16034922
all@@	I-Disease	-1	16034922
bladder	I-Disease	-1	16034922
disease	I-Disease	-1	16034922
,	O	-1	16034922
cognitive	O	-1	16034922
func@@	O	-1	16034922
tion,	O	-1	16034922
de@@	B-Disease	D003704	16034922
m@@	I-Disease	-1	16034922
enti@@	I-Disease	-1	16034922
a	I-Disease	-1	16034922
,	O	-1	16034922
frac@@	B-Disease	D050723	16034922
t@@	I-Disease	-1	16034922
ures	I-Disease	-1	16034922
and	O	-1	16034922
qu@@	O	-1	16034922
ality	O	-1	16034922
of	O	-1	16034922
lif@@	O	-1	16034922
e.	O	-1	16034922
S@@	O	-1	16034922
E@@	O	-1	16034922
A@@	O	-1	16034922
R@@	O	-1	16034922
C@@	O	-1	16034922
H	O	-1	16034922
S@@	O	-1	16034922
TR@@	O	-1	16034922
AT@@	O	-1	16034922
E@@	O	-1	16034922
G@@	O	-1	16034922
Y@@	O	-1	16034922
:	O	-1	16034922
We	O	-1	16034922
se@@	O	-1	16034922
ar@@	O	-1	16034922
ch@@	O	-1	16034922
ed	O	-1	16034922
the	O	-1	16034922
following	O	-1	16034922
dat@@	O	-1	16034922
ab@@	O	-1	16034922
as@@	O	-1	16034922
es	O	-1	16034922
up	O	-1	16034922
to	O	-1	16034922
N@@	O	-1	16034922
o@@	O	-1	16034922
ve@@	O	-1	16034922
mb@@	O	-1	16034922
er	O	-1	16034922
20@@	O	-1	16034922
0@@	O	-1	16034922
4@@	O	-1	16034922
:	O	-1	16034922
the	O	-1	16034922
C@@	O	-1	16034922
och@@	O	-1	16034922
ran@@	O	-1	16034922
e	O	-1	16034922
M@@	O	-1	16034922
en@@	O	-1	16034922
st@@	O	-1	16034922
ru@@	O	-1	16034922
al	O	-1	16034922
D@@	O	-1	16034922
is@@	O	-1	16034922
or@@	O	-1	16034922
der@@	O	-1	16034922
s	O	-1	16034922
and	O	-1	16034922
S@@	O	-1	16034922
ub@@	O	-1	16034922
fer@@	O	-1	16034922
til@@	O	-1	16034922
ity	O	-1	16034922
Group	O	-1	16034922
T@@	O	-1	16034922
ri@@	O	-1	16034922
als	O	-1	16034922
Re@@	O	-1	16034922
g@@	O	-1	16034922
ist@@	O	-1	16034922
er,	O	-1	16034922
C@@	O	-1	16034922
och@@	O	-1	16034922
ran@@	O	-1	16034922
e	O	-1	16034922
C@@	O	-1	16034922
entr@@	O	-1	16034922
al	O	-1	16034922
Re@@	O	-1	16034922
g@@	O	-1	16034922
ist@@	O	-1	16034922
er	O	-1	16034922
of	O	-1	16034922
C@@	O	-1	16034922
ont@@	O	-1	16034922
ro@@	O	-1	16034922
lled	O	-1	16034922
T@@	O	-1	16034922
ri@@	O	-1	16034922
als	O	-1	16034922
(C@@	O	-1	16034922
E@@	O	-1	16034922
N@@	O	-1	16034922
TR@@	O	-1	16034922
AL@@	O	-1	16034922
),	O	-1	16034922
M@@	O	-1	16034922
E@@	O	-1	16034922
D@@	O	-1	16034922
L@@	O	-1	16034922
IN@@	O	-1	16034922
E@@	O	-1	16034922
,	O	-1	16034922
E@@	O	-1	16034922
M@@	O	-1	16034922
BA@@	O	-1	16034922
S@@	O	-1	16034922
E@@	O	-1	16034922
,	O	-1	16034922
B@@	O	-1	16034922
io@@	O	-1	16034922
log@@	O	-1	16034922
ical	O	-1	16034922
A@@	O	-1	16034922
b@@	O	-1	16034922
st@@	O	-1	16034922
rac@@	O	-1	16034922
t@@	O	-1	16034922
s.	O	-1	16034922
R@@	O	-1	16034922
elev@@	O	-1	16034922
ant	O	-1	16034922
non-@@	O	-1	16034922
in@@	O	-1	16034922
de@@	O	-1	16034922
x@@	O	-1	16034922
ed	O	-1	16034922
j@@	O	-1	16034922
o@@	O	-1	16034922
ur@@	O	-1	16034922
n@@	O	-1	16034922
als	O	-1	16034922
and	O	-1	16034922
con@@	O	-1	16034922
fe@@	O	-1	16034922
rence	O	-1	16034922
ab@@	O	-1	16034922
st@@	O	-1	16034922
rac@@	O	-1	16034922
ts	O	-1	16034922
were	O	-1	16034922
also	O	-1	16034922
se@@	O	-1	16034922
ar@@	O	-1	16034922
ch@@	O	-1	16034922
ed.	O	-1	16034922
S@@	O	-1	16034922
E@@	O	-1	16034922
L@@	O	-1	16034922
EC@@	O	-1	16034922
TI@@	O	-1	16034922
O@@	O	-1	16034922
N	O	-1	16034922
CR@@	O	-1	16034922
I@@	O	-1	16034922
TE@@	O	-1	16034922
R@@	O	-1	16034922
I@@	O	-1	16034922
A@@	O	-1	16034922
:	O	-1	16034922
R@@	O	-1	16034922
an@@	O	-1	16034922
dom@@	O	-1	16034922
is@@	O	-1	16034922
ed	O	-1	16034922
double-bl@@	O	-1	16034922
ind	O	-1	16034922
tri@@	O	-1	16034922
als	O	-1	16034922
of	O	-1	16034922
H@@	O	-1	16034922
T	O	-1	16034922
(	O	-1	16034922
o@@	B-Chemical	D004967	16034922
est@@	I-Chemical	-1	16034922
ro@@	I-Chemical	-1	16034922
gen@@	I-Chemical	-1	16034922
s	I-Chemical	-1	16034922
with	O	-1	16034922
or	O	-1	16034922
without	O	-1	16034922
pro@@	B-Chemical	D011374	16034922
g@@	I-Chemical	-1	16034922
est@@	I-Chemical	-1	16034922
o@@	I-Chemical	-1	16034922
gen@@	I-Chemical	-1	16034922
s	I-Chemical	-1	16034922
)	O	-1	16034922
versus	O	-1	16034922
placebo@@	O	-1	16034922
,	O	-1	16034922
tak@@	O	-1	16034922
en	O	-1	16034922
for	O	-1	16034922
at	O	-1	16034922
le@@	O	-1	16034922
ast	O	-1	16034922
one	O	-1	16034922
year	O	-1	16034922
by	O	-1	16034922
per@@	O	-1	16034922
imen@@	O	-1	16034922
o@@	O	-1	16034922
pa@@	O	-1	16034922
us@@	O	-1	16034922
al	O	-1	16034922
or	O	-1	16034922
post@@	O	-1	16034922
men@@	O	-1	16034922
o@@	O	-1	16034922
pa@@	O	-1	16034922
us@@	O	-1	16034922
al	O	-1	16034922
wom@@	O	-1	16034922
en@@	O	-1	16034922
.	O	-1	16034922
D@@	O	-1	16034922
AT@@	O	-1	16034922
A	O	-1	16034922
CO@@	O	-1	16034922
L@@	O	-1	16034922
L@@	O	-1	16034922
EC@@	O	-1	16034922
TI@@	O	-1	16034922
O@@	O	-1	16034922
N	O	-1	16034922
AN@@	O	-1	16034922
D	O	-1	16034922
AN@@	O	-1	16034922
AL@@	O	-1	16034922
Y@@	O	-1	16034922
S@@	O	-1	16034922
I@@	O	-1	16034922
S:	O	-1	16034922
F@@	O	-1	16034922
if@@	O	-1	16034922
te@@	O	-1	16034922
en	O	-1	16034922
R@@	O	-1	16034922
C@@	O	-1	16034922
T@@	O	-1	16034922
s	O	-1	16034922
were	O	-1	16034922
inc@@	O	-1	16034922
lu@@	O	-1	16034922
de@@	O	-1	16034922
d.	O	-1	16034922
T@@	O	-1	16034922
ri@@	O	-1	16034922
als	O	-1	16034922
were	O	-1	16034922
assessed	O	-1	16034922
for	O	-1	16034922
qu@@	O	-1	16034922
ality	O	-1	16034922
and	O	-1	16034922
two	O	-1	16034922
revie@@	O	-1	16034922
w	O	-1	16034922
au@@	O	-1	16034922
th@@	O	-1	16034922
ors	O	-1	16034922
extrac@@	O	-1	16034922
ted	O	-1	16034922
data	O	-1	16034922
in@@	O	-1	16034922
depend@@	O	-1	16034922
ent@@	O	-1	16034922
ly.	O	-1	16034922
The@@	O	-1	16034922
y	O	-1	16034922
calc@@	O	-1	16034922
ul@@	O	-1	16034922
ated	O	-1	16034922
risk	O	-1	16034922
rati@@	O	-1	16034922
o@@	O	-1	16034922
s	O	-1	16034922
for	O	-1	16034922
dic@@	O	-1	16034922
h@@	O	-1	16034922
ot@@	O	-1	16034922
om@@	O	-1	16034922
ous	O	-1	16034922
outcom@@	O	-1	16034922
es	O	-1	16034922
and	O	-1	16034922
weigh@@	O	-1	16034922
ted	O	-1	16034922
mean	O	-1	16034922
differences	O	-1	16034922
for	O	-1	16034922
continu@@	O	-1	16034922
ous	O	-1	16034922
outcom@@	O	-1	16034922
es.	O	-1	16034922
Clin@@	O	-1	16034922
ical	O	-1	16034922
he@@	O	-1	16034922
ter@@	O	-1	16034922
o@@	O	-1	16034922
gene@@	O	-1	16034922
ity	O	-1	16034922
pre@@	O	-1	16034922
cl@@	O	-1	16034922
uded	O	-1	16034922
met@@	O	-1	16034922
a@@	O	-1	16034922
-@@	O	-1	16034922
analysis	O	-1	16034922
for	O	-1	16034922
most	O	-1	16034922
outcom@@	O	-1	16034922
es.	O	-1	16034922
MA@@	O	-1	16034922
I@@	O	-1	16034922
N	O	-1	16034922
RESULTS:	O	-1	16034922
All	O	-1	16034922
the	O	-1	16034922
statis@@	O	-1	16034922
tically	O	-1	16034922
significant	O	-1	16034922
results	O	-1	16034922
were	O	-1	16034922
der@@	O	-1	16034922
i@@	O	-1	16034922
ved	O	-1	16034922
from	O	-1	16034922
the	O	-1	16034922
two	O	-1	16034922
b@@	O	-1	16034922
ig@@	O	-1	16034922
g@@	O	-1	16034922
est	O	-1	16034922
tri@@	O	-1	16034922
al@@	O	-1	16034922
s.	O	-1	16034922
In	O	-1	16034922
rel@@	O	-1	16034922
atively	O	-1	16034922
healthy	O	-1	16034922
wom@@	O	-1	16034922
en@@	O	-1	16034922
,	O	-1	16034922
combined	O	-1	16034922
continu@@	O	-1	16034922
ous	O	-1	16034922
H@@	O	-1	16034922
T	O	-1	16034922
significantly	O	-1	16034922
increased	O	-1	16034922
the	O	-1	16034922
risk	O	-1	16034922
of	O	-1	16034922
venous	B-Disease	D054556	16034922
thrombo@@	I-Disease	-1	16034922
emb@@	I-Disease	-1	16034922
ol@@	I-Disease	-1	16034922
ism	I-Disease	-1	16034922
or	O	-1	16034922
coronary	O	-1	16034922
ev@@	O	-1	16034922
ent	O	-1	16034922
(@@	O	-1	16034922
after	O	-1	16034922
one	O	-1	16034922
year@@	O	-1	16034922
's	O	-1	16034922
use@@	O	-1	16034922
),	O	-1	16034922
strok@@	B-Disease	D020521	16034922
e	I-Disease	-1	16034922
(@@	O	-1	16034922
after	O	-1	16034922
3	O	-1	16034922
year@@	O	-1	16034922
s),	O	-1	16034922
b@@	B-Disease	D001943	16034922
reas@@	I-Disease	-1	16034922
t	I-Disease	-1	16034922
cancer	I-Disease	-1	16034922
(@@	O	-1	16034922
after	O	-1	16034922
5	O	-1	16034922
year@@	O	-1	16034922
s)	O	-1	16034922
and	O	-1	16034922
g@@	B-Disease	D005705	16034922
all@@	I-Disease	-1	16034922
bladder	I-Disease	-1	16034922
disease	I-Disease	-1	16034922
.	O	-1	16034922
L@@	O	-1	16034922
on@@	O	-1	16034922
g@@	O	-1	16034922
-term	O	-1	16034922
o@@	B-Chemical	D004967	16034922
est@@	I-Chemical	-1	16034922
ro@@	I-Chemical	-1	16034922
gen	I-Chemical	-1	16034922
-@@	O	-1	16034922
only	O	-1	16034922
H@@	O	-1	16034922
T	O	-1	16034922
also	O	-1	16034922
significantly	O	-1	16034922
increased	O	-1	16034922
the	O	-1	16034922
risk	O	-1	16034922
of	O	-1	16034922
strok@@	B-Disease	D020521	16034922
e	I-Disease	-1	16034922
and	O	-1	16034922
g@@	B-Disease	D005705	16034922
all@@	I-Disease	-1	16034922
bladder	I-Disease	-1	16034922
disease	I-Disease	-1	16034922
.	O	-1	16034922
O@@	O	-1	16034922
ver@@	O	-1	16034922
all@@	O	-1	16034922
,	O	-1	16034922
the	O	-1	16034922
only	O	-1	16034922
statis@@	O	-1	16034922
tically	O	-1	16034922
significant	O	-1	16034922
ben@@	O	-1	16034922
e@@	O	-1	16034922
f@@	O	-1	16034922
its	O	-1	16034922
of	O	-1	16034922
H@@	O	-1	16034922
T	O	-1	16034922
were	O	-1	16034922
a	O	-1	16034922
decreased	O	-1	16034922
incidence	O	-1	16034922
of	O	-1	16034922
frac@@	B-Disease	D050723	16034922
t@@	I-Disease	-1	16034922
ures	I-Disease	-1	16034922
and	O	-1	16034922
co@@	B-Disease	D003110	16034922
l@@	I-Disease	-1	16034922
on	I-Disease	-1	16034922
cancer	I-Disease	-1	16034922
with	O	-1	16034922
long-term	O	-1	16034922
use.	O	-1	16034922
A@@	O	-1	16034922
mon@@	O	-1	16034922
g	O	-1	16034922
rel@@	O	-1	16034922
atively	O	-1	16034922
healthy	O	-1	16034922
women	O	-1	16034922
over	O	-1	16034922
6@@	O	-1	16034922
5	O	-1	16034922
years	O	-1	16034922
taking	O	-1	16034922
continu@@	O	-1	16034922
ous	O	-1	16034922
combined	O	-1	16034922
H@@	O	-1	16034922
T@@	O	-1	16034922
,	O	-1	16034922
there	O	-1	16034922
was	O	-1	16034922
a	O	-1	16034922
statis@@	O	-1	16034922
tically	O	-1	16034922
significant	O	-1	16034922
increase	O	-1	16034922
in	O	-1	16034922
the	O	-1	16034922
incidence	O	-1	16034922
of	O	-1	16034922
de@@	B-Disease	D003704	16034922
m@@	I-Disease	-1	16034922
enti@@	I-Disease	-1	16034922
a	I-Disease	-1	16034922
.	O	-1	16034922
A@@	O	-1	16034922
mon@@	O	-1	16034922
g	O	-1	16034922
women	O	-1	16034922
with	O	-1	16034922
cardiovascular	B-Disease	D002318	16034922
disease	I-Disease	-1	16034922
,	O	-1	16034922
long-term	O	-1	16034922
use	O	-1	16034922
of	O	-1	16034922
combined	O	-1	16034922
continu@@	O	-1	16034922
ous	O	-1	16034922
H@@	O	-1	16034922
T	O	-1	16034922
significantly	O	-1	16034922
increased	O	-1	16034922
the	O	-1	16034922
risk	O	-1	16034922
of	O	-1	16034922
venous	B-Disease	D054556	16034922
thrombo@@	I-Disease	-1	16034922
emb@@	I-Disease	-1	16034922
ol@@	I-Disease	-1	16034922
ism	I-Disease	-1	16034922
.	O	-1	16034922
No	O	-1	16034922
tri@@	O	-1	16034922
als	O	-1	16034922
foc@@	O	-1	16034922
us@@	O	-1	16034922
sed	O	-1	16034922
spec@@	O	-1	16034922
ific@@	O	-1	16034922
ally	O	-1	16034922
on	O	-1	16034922
youn@@	O	-1	16034922
g@@	O	-1	16034922
er	O	-1	16034922
wom@@	O	-1	16034922
en@@	O	-1	16034922
.	O	-1	16034922
However,	O	-1	16034922
one	O	-1	16034922
trial	O	-1	16034922
an@@	O	-1	16034922
al@@	O	-1	16034922
ys@@	O	-1	16034922
ed	O	-1	16034922
sub@@	O	-1	16034922
groups	O	-1	16034922
of	O	-1	16034922
2@@	O	-1	16034922
8@@	O	-1	16034922
3@@	O	-1	16034922
9	O	-1	16034922
rel@@	O	-1	16034922
atively	O	-1	16034922
healthy	O	-1	16034922
50	O	-1	16034922
to	O	-1	16034922
5@@	O	-1	16034922
9	O	-1	16034922
year-old	O	-1	16034922
women	O	-1	16034922
taking	O	-1	16034922
combined	O	-1	16034922
continu@@	O	-1	16034922
ous	O	-1	16034922
H@@	O	-1	16034922
T	O	-1	16034922
and	O	-1	16034922
1@@	O	-1	16034922
6@@	O	-1	16034922
3@@	O	-1	16034922
7	O	-1	16034922
taking	O	-1	16034922
o@@	B-Chemical	D004967	16034922
est@@	I-Chemical	-1	16034922
ro@@	I-Chemical	-1	16034922
gen	I-Chemical	-1	16034922
-@@	O	-1	16034922
only	O	-1	16034922
H@@	O	-1	16034922
T@@	O	-1	16034922
,	O	-1	16034922
versus	O	-1	16034922
simil@@	O	-1	16034922
ar@@	O	-1	16034922
-@@	O	-1	16034922
si@@	O	-1	16034922
zed	O	-1	16034922
placebo	O	-1	16034922
groups.	O	-1	16034922
The	O	-1	16034922
only	O	-1	16034922
significantly	O	-1	16034922
increased	O	-1	16034922
risk	O	-1	16034922
reported	O	-1	16034922
was	O	-1	16034922
for	O	-1	16034922
venous	B-Disease	D054556	16034922
thrombo@@	I-Disease	-1	16034922
emb@@	I-Disease	-1	16034922
ol@@	I-Disease	-1	16034922
ism	I-Disease	-1	16034922
in	O	-1	16034922
women	O	-1	16034922
taking	O	-1	16034922
combined	O	-1	16034922
continu@@	O	-1	16034922
ous	O	-1	16034922
H@@	O	-1	16034922
T@@	O	-1	16034922
;	O	-1	16034922
their	O	-1	16034922
abs@@	O	-1	16034922
ol@@	O	-1	16034922
ute	O	-1	16034922
risk	O	-1	16034922
remained	O	-1	16034922
very	O	-1	16034922
low@@	O	-1	16034922
.	O	-1	16034922
A@@	O	-1	16034922
U@@	O	-1	16034922
T@@	O	-1	16034922
HO@@	O	-1	16034922
R@@	O	-1	16034922
S@@	O	-1	16034922
'	O	-1	16034922
CONCLUSIONS:	O	-1	16034922
H@@	O	-1	16034922
T	O	-1	16034922
is	O	-1	16034922
not	O	-1	16034922
indic@@	O	-1	16034922
ated	O	-1	16034922
for	O	-1	16034922
the	O	-1	16034922
ro@@	O	-1	16034922
ut@@	O	-1	16034922
ine	O	-1	16034922
man@@	O	-1	16034922
ag@@	O	-1	16034922
ement	O	-1	16034922
of	O	-1	16034922
chronic	B-Disease	D002908	16034922
disease	I-Disease	-1	16034922
.	O	-1	16034922
We	O	-1	16034922
need	O	-1	16034922
more	O	-1	16034922
evidence	O	-1	16034922
on	O	-1	16034922
the	O	-1	16034922
safety	O	-1	16034922
of	O	-1	16034922
H@@	O	-1	16034922
T	O	-1	16034922
for	O	-1	16034922
men@@	O	-1	16034922
o@@	O	-1	16034922
pa@@	O	-1	16034922
us@@	O	-1	16034922
al	O	-1	16034922
sympto@@	O	-1	16034922
m	O	-1	16034922
control@@	O	-1	16034922
,	O	-1	16034922
though	O	-1	16034922
sh@@	O	-1	16034922
ort@@	O	-1	16034922
-term	O	-1	16034922
use	O	-1	16034922
appear@@	O	-1	16034922
s	O	-1	16034922
to	O	-1	16034922
be	O	-1	16034922
rel@@	O	-1	16034922
atively	O	-1	16034922
saf@@	O	-1	16034922
e	O	-1	16034922
for	O	-1	16034922
healthy	O	-1	16034922
youn@@	O	-1	16034922
g@@	O	-1	16034922
er	O	-1	16034922
wom@@	O	-1	16034922
en@@	O	-1	16034922
.	O	-1	16034922

D@@	B-Disease	D056486	16083708
ru@@	I-Disease	-1	16083708
g@@	I-Disease	-1	16083708
-induced	I-Disease	-1	16083708
liver	I-Disease	-1	16083708
injury	I-Disease	-1	16083708
:	O	-1	16083708
an	O	-1	16083708
analysis	O	-1	16083708
of	O	-1	16083708
4@@	O	-1	16083708
6@@	O	-1	16083708
1	O	-1	16083708
inc@@	O	-1	16083708
id@@	O	-1	16083708
enc@@	O	-1	16083708
es	O	-1	16083708
sub@@	O	-1	16083708
mit@@	O	-1	16083708
ted	O	-1	16083708
to	O	-1	16083708
the	O	-1	16083708
S@@	O	-1	16083708
p@@	O	-1	16083708
an@@	O	-1	16083708
is@@	O	-1	16083708
h	O	-1	16083708
reg@@	O	-1	16083708
ist@@	O	-1	16083708
r@@	O	-1	16083708
y	O	-1	16083708
over	O	-1	16083708
a	O	-1	16083708
10-@@	O	-1	16083708
year	O	-1	16083708
perio@@	O	-1	16083708
d.	O	-1	16083708
BACKGROUN@@	O	-1	16083708
D	O	-1	16083708
&	O	-1	16083708
A@@	O	-1	16083708
I@@	O	-1	16083708
M@@	O	-1	16083708
S:	O	-1	16083708
Pro@@	O	-1	16083708
gres@@	O	-1	16083708
s	O	-1	16083708
in	O	-1	16083708
the	O	-1	16083708
under@@	O	-1	16083708
stand@@	O	-1	16083708
ing	O	-1	16083708
of	O	-1	16083708
sus@@	O	-1	16083708
cep@@	O	-1	16083708
ti@@	O	-1	16083708
b@@	O	-1	16083708
ility	O	-1	16083708
factors	O	-1	16083708
to	O	-1	16083708
drug@@	B-Disease	D056486	16083708
-induced	I-Disease	-1	16083708
liver	I-Disease	-1	16083708
injury	I-Disease	-1	16083708
(	O	-1	16083708
D@@	B-Disease	D056486	16083708
I@@	I-Disease	-1	16083708
L@@	I-Disease	-1	16083708
I	I-Disease	-1	16083708
)	O	-1	16083708
and	O	-1	16083708
outcom@@	O	-1	16083708
e	O	-1	16083708
predic@@	O	-1	16083708
t@@	O	-1	16083708
ability	O	-1	16083708
are	O	-1	16083708
h@@	O	-1	16083708
am@@	O	-1	16083708
pe@@	O	-1	16083708
red	O	-1	16083708
by	O	-1	16083708
the	O	-1	16083708
l@@	O	-1	16083708
ac@@	O	-1	16083708
k	O	-1	16083708
of	O	-1	16083708
system@@	O	-1	16083708
atic	O	-1	16083708
pro@@	O	-1	16083708
gram@@	O	-1	16083708
s	O	-1	16083708
to	O	-1	16083708
det@@	O	-1	16083708
ect	O	-1	16083708
b@@	O	-1	16083708
on@@	O	-1	16083708
a	O	-1	16083708
f@@	O	-1	16083708
ide	O	-1	16083708
cas@@	O	-1	16083708
es.	O	-1	16083708
METHODS:	O	-1	16083708
A	O	-1	16083708
co@@	O	-1	16083708
o@@	O	-1	16083708
perative	O	-1	16083708
ne@@	O	-1	16083708
tw@@	O	-1	16083708
or@@	O	-1	16083708
k	O	-1	16083708
was	O	-1	16083708
cre@@	O	-1	16083708
ated	O	-1	16083708
in	O	-1	16083708
19@@	O	-1	16083708
9@@	O	-1	16083708
4	O	-1	16083708
in	O	-1	16083708
S@@	O	-1	16083708
pain	O	-1	16083708
to	O	-1	16083708
identi@@	O	-1	16083708
f@@	O	-1	16083708
y	O	-1	16083708
all	O	-1	16083708
sus@@	O	-1	16083708
p@@	O	-1	16083708
ici@@	O	-1	16083708
ons	O	-1	16083708
of	O	-1	16083708
D@@	B-Disease	D056486	16083708
I@@	I-Disease	-1	16083708
L@@	I-Disease	-1	16083708
I	I-Disease	-1	16083708
following	O	-1	16083708
a	O	-1	16083708
pro@@	O	-1	16083708
sp@@	O	-1	16083708
ective	O	-1	16083708
struct@@	O	-1	16083708
ured	O	-1	16083708
report	O	-1	16083708
form@@	O	-1	16083708
.	O	-1	16083708
The	O	-1	16083708
liver	B-Disease	D056486	16083708
damage	I-Disease	-1	16083708
was	O	-1	16083708
character@@	O	-1	16083708
ized	O	-1	16083708
ac@@	O	-1	16083708
cor@@	O	-1	16083708
ding	O	-1	16083708
to	O	-1	16083708
hepat@@	O	-1	16083708
oc@@	O	-1	16083708
ell@@	O	-1	16083708
ul@@	O	-1	16083708
ar@@	O	-1	16083708
,	O	-1	16083708
cholest@@	B-Disease	D002779	16083708
atic	I-Disease	-1	16083708
,	O	-1	16083708
and	O	-1	16083708
mi@@	O	-1	16083708
x@@	O	-1	16083708
ed	O	-1	16083708
labor@@	O	-1	16083708
atory	O	-1	16083708
c@@	O	-1	16083708
rit@@	O	-1	16083708
er@@	O	-1	16083708
ia	O	-1	16083708
and	O	-1	16083708
to	O	-1	16083708
hist@@	O	-1	16083708
ologic	O	-1	16083708
c@@	O	-1	16083708
rit@@	O	-1	16083708
er@@	O	-1	16083708
ia	O	-1	16083708
when	O	-1	16083708
av@@	O	-1	16083708
ail@@	O	-1	16083708
able@@	O	-1	16083708
.	O	-1	16083708
F@@	O	-1	16083708
urther	O	-1	16083708
evalu@@	O	-1	16083708
ation	O	-1	16083708
of	O	-1	16083708
ca@@	O	-1	16083708
us@@	O	-1	16083708
ality	O	-1	16083708
assess@@	O	-1	16083708
ment	O	-1	16083708
was	O	-1	16083708
centr@@	O	-1	16083708
ally	O	-1	16083708
per@@	O	-1	16083708
for@@	O	-1	16083708
me@@	O	-1	16083708
d.	O	-1	16083708
RESULTS:	O	-1	16083708
S@@	O	-1	16083708
inc@@	O	-1	16083708
e	O	-1	16083708
A@@	O	-1	16083708
pri@@	O	-1	16083708
l	O	-1	16083708
19@@	O	-1	16083708
9@@	O	-1	16083708
4	O	-1	16083708
to	O	-1	16083708
A@@	O	-1	16083708
u@@	O	-1	16083708
g@@	O	-1	16083708
us@@	O	-1	16083708
t	O	-1	16083708
20@@	O	-1	16083708
0@@	O	-1	16083708
4@@	O	-1	16083708
,	O	-1	16083708
4@@	O	-1	16083708
6@@	O	-1	16083708
1	O	-1	16083708
out	O	-1	16083708
of	O	-1	16083708
5@@	O	-1	16083708
7@@	O	-1	16083708
0	O	-1	16083708
sub@@	O	-1	16083708
mit@@	O	-1	16083708
ted	O	-1	16083708
cas@@	O	-1	16083708
es,	O	-1	16083708
invol@@	O	-1	16083708
ving	O	-1	16083708
50@@	O	-1	16083708
5	O	-1	16083708
drug@@	O	-1	16083708
s,	O	-1	16083708
were	O	-1	16083708
de@@	O	-1	16083708
em@@	O	-1	16083708
ed	O	-1	16083708
to	O	-1	16083708
be	O	-1	16083708
related	O	-1	16083708
to	O	-1	16083708
D@@	B-Disease	D056486	16083708
I@@	I-Disease	-1	16083708
L@@	I-Disease	-1	16083708
I	I-Disease	-1	16083708
.	O	-1	16083708
The	O	-1	16083708
anti@@	O	-1	16083708
inf@@	O	-1	16083708
ective	O	-1	16083708
group	O	-1	16083708
of	O	-1	16083708
drugs	O	-1	16083708
was	O	-1	16083708
the	O	-1	16083708
more	O	-1	16083708
frequ@@	O	-1	16083708
ently	O	-1	16083708
inc@@	O	-1	16083708
ri@@	O	-1	16083708
min@@	O	-1	16083708
at@@	O	-1	16083708
ed,	O	-1	16083708
am@@	B-Chemical	D019980	16083708
oxic@@	I-Chemical	-1	16083708
ill@@	I-Chemical	-1	16083708
in-@@	I-Chemical	-1	16083708
cl@@	I-Chemical	-1	16083708
av@@	I-Chemical	-1	16083708
ul@@	I-Chemical	-1	16083708
an@@	I-Chemical	-1	16083708
ate	I-Chemical	-1	16083708
ac@@	O	-1	16083708
coun@@	O	-1	16083708
ting	O	-1	16083708
for	O	-1	16083708
the	O	-1	16083708
1@@	O	-1	16083708
2.@@	O	-1	16083708
8@@	O	-1	16083708
%	O	-1	16083708
of	O	-1	16083708
the	O	-1	16083708
wh@@	O	-1	16083708
ole	O	-1	16083708
seri@@	O	-1	16083708
es.	O	-1	16083708
The	O	-1	16083708
hepat@@	O	-1	16083708
oc@@	O	-1	16083708
ell@@	O	-1	16083708
ular	O	-1	16083708
pat@@	O	-1	16083708
ter@@	O	-1	16083708
n	O	-1	16083708
of	O	-1	16083708
damage	O	-1	16083708
was	O	-1	16083708
the	O	-1	16083708
most	O	-1	16083708
common	O	-1	16083708
(5@@	O	-1	16083708
8@@	O	-1	16083708
%),	O	-1	16083708
was	O	-1	16083708
in@@	O	-1	16083708
ver@@	O	-1	16083708
se@@	O	-1	16083708
ly	O	-1	16083708
cor@@	O	-1	16083708
related	O	-1	16083708
with	O	-1	16083708
age	O	-1	16083708
(P	O	-1	16083708
<	O	-1	16083708
.@@	O	-1	16083708
0@@	O	-1	16083708
0@@	O	-1	16083708
0@@	O	-1	16083708
1),	O	-1	16083708
and	O	-1	16083708
had	O	-1	16083708
the	O	-1	16083708
wor@@	O	-1	16083708
st	O	-1	16083708
outcom@@	O	-1	16083708
e	O	-1	16083708
(C@@	O	-1	16083708
o@@	O	-1	16083708
x	O	-1	16083708
reg@@	O	-1	16083708
res@@	O	-1	16083708
sion,	O	-1	16083708
P	O	-1	16083708
<	O	-1	16083708
.@@	O	-1	16083708
0@@	O	-1	16083708
34@@	O	-1	16083708
).	O	-1	16083708
In@@	O	-1	16083708
de@@	O	-1	16083708
ed,	O	-1	16083708
the	O	-1	16083708
incidence	O	-1	16083708
of	O	-1	16083708
liver	O	-1	16083708
transplant@@	O	-1	16083708
ation	O	-1	16083708
and	O	-1	16083708
death	O	-1	16083708
in	O	-1	16083708
this	O	-1	16083708
group	O	-1	16083708
was	O	-1	16083708
1@@	O	-1	16083708
1.@@	O	-1	16083708
7@@	O	-1	16083708
%	O	-1	16083708
if	O	-1	16083708
patients	O	-1	16083708
had	O	-1	16083708
j@@	B-Disease	D007565	16083708
a@@	I-Disease	-1	16083708
un@@	I-Disease	-1	16083708
dic@@	I-Disease	-1	16083708
e	I-Disease	-1	16083708
at	O	-1	16083708
present@@	O	-1	16083708
ation,	O	-1	16083708
whereas	O	-1	16083708
the	O	-1	16083708
cor@@	O	-1	16083708
respon@@	O	-1	16083708
ding	O	-1	16083708
fi@@	O	-1	16083708
g@@	O	-1	16083708
ure	O	-1	16083708
was	O	-1	16083708
3.@@	O	-1	16083708
8@@	O	-1	16083708
%	O	-1	16083708
in	O	-1	16083708
non@@	O	-1	16083708
j@@	O	-1	16083708
a@@	O	-1	16083708
un@@	O	-1	16083708
dic@@	O	-1	16083708
ed	O	-1	16083708
patients	O	-1	16083708
(P	O	-1	16083708
<	O	-1	16083708
.@@	O	-1	16083708
0@@	O	-1	16083708
4@@	O	-1	16083708
).	O	-1	16083708
F@@	O	-1	16083708
act@@	O	-1	16083708
ors	O	-1	16083708
associated	O	-1	16083708
with	O	-1	16083708
the	O	-1	16083708
development	O	-1	16083708
of	O	-1	16083708
ful@@	B-Disease	D017114	16083708
min@@	I-Disease	-1	16083708
ant	I-Disease	-1	16083708
hepatic	I-Disease	-1	16083708
failure	I-Disease	-1	16083708
were	O	-1	16083708
female	O	-1	16083708
se@@	O	-1	16083708
x	O	-1	16083708
(@@	O	-1	16083708
O@@	O	-1	16083708
R	O	-1	16083708
=	O	-1	16083708
25@@	O	-1	16083708
;	O	-1	16083708
95%	O	-1	16083708
CI@@	O	-1	16083708
:	O	-1	16083708
4.@@	O	-1	16083708
1@@	O	-1	16083708
-1@@	O	-1	16083708
5@@	O	-1	16083708
1@@	O	-1	16083708
;	O	-1	16083708
P	O	-1	16083708
<	O	-1	16083708
.@@	O	-1	16083708
0@@	O	-1	16083708
0@@	O	-1	16083708
0@@	O	-1	16083708
1),	O	-1	16083708
hepat@@	O	-1	16083708
oc@@	O	-1	16083708
ell@@	O	-1	16083708
ular	O	-1	16083708
damage	O	-1	16083708
(@@	O	-1	16083708
O@@	O	-1	16083708
R	O	-1	16083708
=	O	-1	16083708
7.@@	O	-1	16083708
9@@	O	-1	16083708
;	O	-1	16083708
95%	O	-1	16083708
CI@@	O	-1	16083708
:	O	-1	16083708
1.@@	O	-1	16083708
6-@@	O	-1	16083708
3@@	O	-1	16083708
7@@	O	-1	16083708
;	O	-1	16083708
P	O	-1	16083708
<	O	-1	16083708
.@@	O	-1	16083708
0@@	O	-1	16083708
0@@	O	-1	16083708
9@@	O	-1	16083708
),	O	-1	16083708
and	O	-1	16083708
higher	O	-1	16083708
baseline	O	-1	16083708
plasma	O	-1	16083708
bil@@	B-Chemical	D001663	16083708
i@@	I-Chemical	-1	16083708
ru@@	I-Chemical	-1	16083708
bin	I-Chemical	-1	16083708
valu@@	O	-1	16083708
e	O	-1	16083708
(@@	O	-1	16083708
O@@	O	-1	16083708
R	O	-1	16083708
=	O	-1	16083708
1.@@	O	-1	16083708
1@@	O	-1	16083708
5@@	O	-1	16083708
;	O	-1	16083708
95%	O	-1	16083708
CI@@	O	-1	16083708
:	O	-1	16083708
1.@@	O	-1	16083708
0@@	O	-1	16083708
9@@	O	-1	16083708
-@@	O	-1	16083708
1.@@	O	-1	16083708
2@@	O	-1	16083708
2@@	O	-1	16083708
;	O	-1	16083708
P	O	-1	16083708
<	O	-1	16083708
.@@	O	-1	16083708
0@@	O	-1	16083708
0@@	O	-1	16083708
0@@	O	-1	16083708
1).	O	-1	16083708
CONCLUSIONS:	O	-1	16083708
Patients	O	-1	16083708
with	O	-1	16083708
drug@@	O	-1	16083708
-induced	O	-1	16083708
hepat@@	O	-1	16083708
oc@@	O	-1	16083708
ell@@	O	-1	16083708
ular	O	-1	16083708
j@@	B-Disease	D007565	16083708
a@@	I-Disease	-1	16083708
un@@	I-Disease	-1	16083708
dic@@	I-Disease	-1	16083708
e	I-Disease	-1	16083708
have	O	-1	16083708
1@@	O	-1	16083708
1.@@	O	-1	16083708
7@@	O	-1	16083708
%	O	-1	16083708
ch@@	O	-1	16083708
ance	O	-1	16083708
of	O	-1	16083708
progres@@	O	-1	16083708
s@@	O	-1	16083708
ing	O	-1	16083708
to	O	-1	16083708
death	O	-1	16083708
or	O	-1	16083708
transplant@@	O	-1	16083708
ation.	O	-1	16083708
A@@	B-Chemical	D019980	16083708
mo@@	I-Chemical	-1	16083708
x@@	I-Chemical	-1	16083708
icill@@	I-Chemical	-1	16083708
in-@@	I-Chemical	-1	16083708
cl@@	I-Chemical	-1	16083708
av@@	I-Chemical	-1	16083708
ul@@	I-Chemical	-1	16083708
an@@	I-Chemical	-1	16083708
ate	I-Chemical	-1	16083708
stand@@	O	-1	16083708
s	O	-1	16083708
out	O	-1	16083708
as	O	-1	16083708
the	O	-1	16083708
most	O	-1	16083708
common	O	-1	16083708
drug	O	-1	16083708
related	O	-1	16083708
to	O	-1	16083708
D@@	B-Disease	D056486	16083708
I@@	I-Disease	-1	16083708
L@@	I-Disease	-1	16083708
I	I-Disease	-1	16083708
.	O	-1	16083708

M@@	O	-1	16092435
or@@	O	-1	16092435
ph@@	O	-1	16092435
ological	O	-1	16092435
evalu@@	O	-1	16092435
ation	O	-1	16092435
of	O	-1	16092435
the	O	-1	16092435
effect	O	-1	16092435
of	O	-1	16092435
d-@@	B-Chemical	D012266	16092435
rib@@	I-Chemical	-1	16092435
ose	I-Chemical	-1	16092435
on	O	-1	16092435
adriam@@	B-Chemical	D004317	16092435
ycin	I-Chemical	-1	16092435
-@@	O	-1	16092435
evoked	O	-1	16092435
cardi@@	B-Disease	D066126	16092435
otoxicity	I-Disease	-1	16092435
in	O	-1	16092435
rats.	O	-1	16092435
The	O	-1	16092435
influence	O	-1	16092435
of	O	-1	16092435
d-@@	B-Chemical	D012266	16092435
rib@@	I-Chemical	-1	16092435
ose	I-Chemical	-1	16092435
on	O	-1	16092435
adriam@@	B-Chemical	D004317	16092435
ycin	I-Chemical	-1	16092435
-induced	O	-1	16092435
myocardi@@	B-Disease	D009202	16092435
o@@	I-Disease	-1	16092435
pathy	I-Disease	-1	16092435
in	O	-1	16092435
rats	O	-1	16092435
was	O	-1	16092435
studi@@	O	-1	16092435
ed.	O	-1	16092435
Ad@@	B-Chemical	D004317	16092435
riam@@	I-Chemical	-1	16092435
ycin	I-Chemical	-1	16092435
in	O	-1	16092435
the	O	-1	16092435
cum@@	O	-1	16092435
ul@@	O	-1	16092435
ative	O	-1	16092435
dose	O	-1	16092435
of	O	-1	16092435
25	O	-1	16092435
mg/kg	O	-1	16092435
evoked	O	-1	16092435
ful@@	O	-1	16092435
ly	O	-1	16092435
developed	O	-1	16092435
cardiac	B-Disease	D066126	16092435
toxicity	I-Disease	-1	16092435
.	O	-1	16092435
D-@@	B-Chemical	D012266	16092435
rib@@	I-Chemical	-1	16092435
ose	I-Chemical	-1	16092435
in	O	-1	16092435
the	O	-1	16092435
multiple	O	-1	16092435
doses	O	-1	16092435
of	O	-1	16092435
2@@	O	-1	16092435
00	O	-1	16092435
mg/kg	O	-1	16092435
did	O	-1	16092435
not	O	-1	16092435
influence	O	-1	16092435
AD@@	B-Chemical	D004317	16092435
R	I-Chemical	-1	16092435
cardi@@	B-Disease	D066126	16092435
otoxicity	I-Disease	-1	16092435
.	O	-1	16092435

In	O	-1	16112787
viv@@	O	-1	16112787
o	O	-1	16112787
ev@@	O	-1	16112787
id@@	O	-1	16112787
enc@@	O	-1	16112787
es	O	-1	16112787
suggesting	O	-1	16112787
the	O	-1	16112787
role	O	-1	16112787
of	O	-1	16112787
oxid@@	O	-1	16112787
ative	O	-1	16112787
stres@@	O	-1	16112787
s	O	-1	16112787
in	O	-1	16112787
path@@	O	-1	16112787
o@@	O	-1	16112787
genesis	O	-1	16112787
of	O	-1	16112787
v@@	B-Chemical	D014640	16112787
an@@	I-Chemical	-1	16112787
com@@	I-Chemical	-1	16112787
ycin	I-Chemical	-1	16112787
-induced	O	-1	16112787
nephro@@	B-Disease	D007674	16112787
toxicity	I-Disease	-1	16112787
:	O	-1	16112787
prot@@	O	-1	16112787
ection	O	-1	16112787
by	O	-1	16112787
er@@	B-Chemical	C048498	16112787
do@@	I-Chemical	-1	16112787
ste@@	I-Chemical	-1	16112787
ine	I-Chemical	-1	16112787
.	O	-1	16112787
The	O	-1	16112787
a@@	O	-1	16112787
im@@	O	-1	16112787
s	O	-1	16112787
of	O	-1	16112787
this	O	-1	16112787
study	O	-1	16112787
were	O	-1	16112787
to	O	-1	16112787
ex@@	O	-1	16112787
amine	O	-1	16112787
v@@	B-Chemical	D014640	16112787
an@@	I-Chemical	-1	16112787
com@@	I-Chemical	-1	16112787
ycin	I-Chemical	-1	16112787
(	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
)@@	O	-1	16112787
-induced	O	-1	16112787
oxid@@	O	-1	16112787
ative	O	-1	16112787
stres@@	O	-1	16112787
s	O	-1	16112787
that	O	-1	16112787
pro@@	O	-1	16112787
m@@	O	-1	16112787
ot@@	O	-1	16112787
es	O	-1	16112787
pro@@	O	-1	16112787
duction	O	-1	16112787
of	O	-1	16112787
reac@@	O	-1	16112787
tive	O	-1	16112787
oxy@@	B-Chemical	D010100	16112787
gen	I-Chemical	-1	16112787
spec@@	O	-1	16112787
i@@	O	-1	16112787
es	O	-1	16112787
(@@	O	-1	16112787
RO@@	O	-1	16112787
S)	O	-1	16112787
and	O	-1	16112787
to	O	-1	16112787
investigate	O	-1	16112787
the	O	-1	16112787
role	O	-1	16112787
of	O	-1	16112787
er@@	B-Chemical	C048498	16112787
do@@	I-Chemical	-1	16112787
ste@@	I-Chemical	-1	16112787
ine	I-Chemical	-1	16112787
,	O	-1	16112787
an	O	-1	16112787
ex@@	O	-1	16112787
p@@	O	-1	16112787
ect@@	O	-1	16112787
or@@	O	-1	16112787
ant	O	-1	16112787
agent@@	O	-1	16112787
,	O	-1	16112787
which	O	-1	16112787
has	O	-1	16112787
also	O	-1	16112787
anti@@	O	-1	16112787
oxid@@	O	-1	16112787
ant	O	-1	16112787
pro@@	O	-1	16112787
per@@	O	-1	16112787
ti@@	O	-1	16112787
es,	O	-1	16112787
on	O	-1	16112787
kidney	O	-1	16112787
tissue	O	-1	16112787
against	O	-1	16112787
the	O	-1	16112787
possible	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
-induced	O	-1	16112787
renal	B-Disease	D007674	16112787
impair@@	I-Disease	-1	16112787
ment	I-Disease	-1	16112787
in	O	-1	16112787
rats.	O	-1	16112787
R@@	O	-1	16112787
at@@	O	-1	16112787
s	O	-1	16112787
were	O	-1	16112787
divid@@	O	-1	16112787
ed	O	-1	16112787
into	O	-1	16112787
three	O	-1	16112787
group@@	O	-1	16112787
s:	O	-1	16112787
sh@@	O	-1	16112787
am@@	O	-1	16112787
,	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
and	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
plus	O	-1	16112787
er@@	B-Chemical	C048498	16112787
do@@	I-Chemical	-1	16112787
ste@@	I-Chemical	-1	16112787
ine	I-Chemical	-1	16112787
.	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
was	O	-1	16112787
administr@@	O	-1	16112787
ated	O	-1	16112787
intra@@	O	-1	16112787
per@@	O	-1	16112787
it@@	O	-1	16112787
one@@	O	-1	16112787
ally	O	-1	16112787
(@@	O	-1	16112787
i.p.@@	O	-1	16112787
)	O	-1	16112787
with	O	-1	16112787
20@@	O	-1	16112787
0@@	O	-1	16112787
mg@@	O	-1	16112787
kg@@	O	-1	16112787
(@@	O	-1	16112787
-1@@	O	-1	16112787
)	O	-1	16112787
tw@@	O	-1	16112787
ic@@	O	-1	16112787
e	O	-1	16112787
daily	O	-1	16112787
for	O	-1	16112787
7	O	-1	16112787
days.	O	-1	16112787
E@@	B-Chemical	C048498	16112787
r@@	I-Chemical	-1	16112787
do@@	I-Chemical	-1	16112787
ste@@	I-Chemical	-1	16112787
ine	I-Chemical	-1	16112787
was	O	-1	16112787
administered	O	-1	16112787
or@@	O	-1	16112787
all@@	O	-1	16112787
y.	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
administration	O	-1	16112787
to	O	-1	16112787
control	O	-1	16112787
rats	O	-1	16112787
significantly	O	-1	16112787
increased	O	-1	16112787
renal	O	-1	16112787
mal@@	B-Chemical	D008315	16112787
on@@	I-Chemical	-1	16112787
di@@	I-Chemical	-1	16112787
al@@	I-Chemical	-1	16112787
de@@	I-Chemical	-1	16112787
hy@@	I-Chemical	-1	16112787
de	I-Chemical	-1	16112787
(	O	-1	16112787
MD@@	B-Chemical	D008315	16112787
A	I-Chemical	-1	16112787
)	O	-1	16112787
and	O	-1	16112787
urinary	O	-1	16112787
N@@	O	-1	16112787
-@@	O	-1	16112787
acet@@	O	-1	16112787
yl@@	O	-1	16112787
-@@	O	-1	16112787
beta-@@	O	-1	16112787
d-@@	O	-1	16112787
g@@	O	-1	16112787
lu@@	O	-1	16112787
co@@	O	-1	16112787
s@@	O	-1	16112787
amin@@	O	-1	16112787
id@@	O	-1	16112787
ase	O	-1	16112787
(N@@	O	-1	16112787
A@@	O	-1	16112787
G@@	O	-1	16112787
,	O	-1	16112787
a	O	-1	16112787
mark@@	O	-1	16112787
er	O	-1	16112787
of	O	-1	16112787
renal	B-Disease	D007674	16112787
tub@@	I-Disease	-1	16112787
ular	I-Disease	-1	16112787
injury	I-Disease	-1	16112787
)	O	-1	16112787
ex@@	O	-1	16112787
cre@@	O	-1	16112787
tion	O	-1	16112787
but	O	-1	16112787
decreased	O	-1	16112787
su@@	B-Chemical	D013481	16112787
per@@	I-Chemical	-1	16112787
ox@@	I-Chemical	-1	16112787
ide	I-Chemical	-1	16112787
dis@@	O	-1	16112787
mut@@	O	-1	16112787
ase	O	-1	16112787
(S@@	O	-1	16112787
O@@	O	-1	16112787
D)	O	-1	16112787
and	O	-1	16112787
cat@@	O	-1	16112787
al@@	O	-1	16112787
ase	O	-1	16112787
(C@@	O	-1	16112787
AT@@	O	-1	16112787
)	O	-1	16112787
ac@@	O	-1	16112787
ti@@	O	-1	16112787
vi@@	O	-1	16112787
ti@@	O	-1	16112787
es.	O	-1	16112787
E@@	B-Chemical	C048498	16112787
r@@	I-Chemical	-1	16112787
do@@	I-Chemical	-1	16112787
ste@@	I-Chemical	-1	16112787
ine	I-Chemical	-1	16112787
administration	O	-1	16112787
with	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
injec@@	O	-1	16112787
tions	O	-1	16112787
caused	O	-1	16112787
significantly	O	-1	16112787
decreased	O	-1	16112787
renal	O	-1	16112787
MD@@	B-Chemical	D008315	16112787
A	I-Chemical	-1	16112787
and	O	-1	16112787
urinary	O	-1	16112787
N@@	O	-1	16112787
A@@	O	-1	16112787
G	O	-1	16112787
ex@@	O	-1	16112787
cre@@	O	-1	16112787
tion,	O	-1	16112787
and	O	-1	16112787
increased	O	-1	16112787
S@@	O	-1	16112787
O@@	O	-1	16112787
D	O	-1	16112787
activ@@	O	-1	16112787
ity,	O	-1	16112787
but	O	-1	16112787
not	O	-1	16112787
CA@@	O	-1	16112787
T	O	-1	16112787
activity	O	-1	16112787
in	O	-1	16112787
renal	O	-1	16112787
tissue	O	-1	16112787
when	O	-1	16112787
compared	O	-1	16112787
with	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
al@@	O	-1	16112787
one.	O	-1	16112787
E@@	B-Chemical	C048498	16112787
r@@	I-Chemical	-1	16112787
do@@	I-Chemical	-1	16112787
ste@@	I-Chemical	-1	16112787
ine	I-Chemical	-1	16112787
showed	O	-1	16112787
histo@@	O	-1	16112787
path@@	O	-1	16112787
ological	O	-1	16112787
prot@@	O	-1	16112787
ection	O	-1	16112787
against	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
-induced	O	-1	16112787
nephro@@	B-Disease	D007674	16112787
toxicity	I-Disease	-1	16112787
.	O	-1	16112787
There	O	-1	16112787
were	O	-1	16112787
a	O	-1	16112787
significant	O	-1	16112787
di@@	O	-1	16112787
lat@@	O	-1	16112787
ation	O	-1	16112787
of	O	-1	16112787
tub@@	O	-1	16112787
ular	O	-1	16112787
l@@	O	-1	16112787
um@@	O	-1	16112787
en@@	O	-1	16112787
s,	O	-1	16112787
exten@@	O	-1	16112787
sive	O	-1	16112787
epi@@	O	-1	16112787
thelial	O	-1	16112787
cell	O	-1	16112787
vac@@	O	-1	16112787
u@@	O	-1	16112787
ol@@	O	-1	16112787
iz@@	O	-1	16112787
ation,	O	-1	16112787
atro@@	B-Disease	D001284	16112787
ph@@	I-Disease	-1	16112787
y	I-Disease	-1	16112787
,	O	-1	16112787
des@@	B-Disease	-1	16112787
qu@@	I-Disease	-1	16112787
am@@	I-Disease	-1	16112787
ation	I-Disease	-1	16112787
,	O	-1	16112787
and	O	-1	16112787
necro@@	B-Disease	D009336	16112787
sis	I-Disease	-1	16112787
in	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
-treated	O	-1	16112787
rats	O	-1	16112787
more	O	-1	16112787
than	O	-1	16112787
those	O	-1	16112787
of	O	-1	16112787
the	O	-1	16112787
control	O	-1	16112787
and	O	-1	16112787
the	O	-1	16112787
er@@	B-Chemical	C048498	16112787
do@@	I-Chemical	-1	16112787
ste@@	I-Chemical	-1	16112787
ine	I-Chemical	-1	16112787
groups.	O	-1	16112787
E@@	B-Chemical	C048498	16112787
r@@	I-Chemical	-1	16112787
do@@	I-Chemical	-1	16112787
ste@@	I-Chemical	-1	16112787
ine	I-Chemical	-1	16112787
caused	O	-1	16112787
a	O	-1	16112787
mark@@	O	-1	16112787
ed	O	-1	16112787
reduction	O	-1	16112787
in	O	-1	16112787
the	O	-1	16112787
ext@@	O	-1	16112787
ent	O	-1	16112787
of	O	-1	16112787
tub@@	O	-1	16112787
ular	O	-1	16112787
dam@@	O	-1	16112787
age.	O	-1	16112787
It	O	-1	16112787
is	O	-1	16112787
concl@@	O	-1	16112787
uded	O	-1	16112787
that	O	-1	16112787
oxid@@	O	-1	16112787
ative	O	-1	16112787
tub@@	O	-1	16112787
ular	O	-1	16112787
damage	O	-1	16112787
pl@@	O	-1	16112787
ays	O	-1	16112787
an	O	-1	16112787
important	O	-1	16112787
role	O	-1	16112787
in	O	-1	16112787
the	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
-induced	O	-1	16112787
nephro@@	B-Disease	D007674	16112787
toxicity	I-Disease	-1	16112787
and	O	-1	16112787
the	O	-1	16112787
mod@@	O	-1	16112787
ulation	O	-1	16112787
of	O	-1	16112787
oxid@@	O	-1	16112787
ative	O	-1	16112787
stres@@	O	-1	16112787
s	O	-1	16112787
with	O	-1	16112787
er@@	B-Chemical	C048498	16112787
do@@	I-Chemical	-1	16112787
ste@@	I-Chemical	-1	16112787
ine	I-Chemical	-1	16112787
reduc@@	O	-1	16112787
es	O	-1	16112787
the	O	-1	16112787
V@@	B-Chemical	D014640	16112787
C@@	I-Chemical	-1	16112787
M	I-Chemical	-1	16112787
-induced	O	-1	16112787
kidney	B-Disease	D007674	16112787
damage	I-Disease	-1	16112787
both	O	-1	16112787
at	O	-1	16112787
the	O	-1	16112787
bio@@	O	-1	16112787
chemical	O	-1	16112787
and	O	-1	16112787
hist@@	O	-1	16112787
ological	O	-1	16112787
level@@	O	-1	16112787
s.	O	-1	16112787

D@@	O	-1	16309808
o@@	O	-1	16309808
es	O	-1	16309808
dom@@	B-Chemical	D004294	16309808
perid@@	I-Chemical	-1	16309808
one	I-Chemical	-1	16309808
potenti@@	O	-1	16309808
ate	O	-1	16309808
m@@	B-Chemical	C035133	16309808
ir@@	I-Chemical	-1	16309808
t@@	I-Chemical	-1	16309808
az@@	I-Chemical	-1	16309808
apine	I-Chemical	-1	16309808
-@@	O	-1	16309808
associated	O	-1	16309808
rest@@	B-Disease	D012148	16309808
less	I-Disease	-1	16309808
le@@	I-Disease	-1	16309808
g@@	I-Disease	-1	16309808
s	I-Disease	-1	16309808
syndrome	I-Disease	-1	16309808
?	O	-1	16309808
There	O	-1	16309808
is	O	-1	16309808
no@@	O	-1	16309808
w	O	-1	16309808
evidence	O	-1	16309808
to	O	-1	16309808
suggest	O	-1	16309808
a	O	-1	16309808
central	O	-1	16309808
role	O	-1	16309808
for	O	-1	16309808
the	O	-1	16309808
dop@@	O	-1	16309808
aminergic	O	-1	16309808
system	O	-1	16309808
in	O	-1	16309808
rest@@	B-Disease	D012148	16309808
less	I-Disease	-1	16309808
le@@	I-Disease	-1	16309808
g@@	I-Disease	-1	16309808
s	I-Disease	-1	16309808
syndrome	I-Disease	-1	16309808
(	O	-1	16309808
R@@	B-Disease	D012148	16309808
L@@	I-Disease	-1	16309808
S	I-Disease	-1	16309808
).	O	-1	16309808
F@@	O	-1	16309808
or	O	-1	16309808
ex@@	O	-1	16309808
am@@	O	-1	16309808
ple@@	O	-1	16309808
,	O	-1	16309808
the	O	-1	16309808
symptoms	O	-1	16309808
of	O	-1	16309808
R@@	B-Disease	D012148	16309808
L@@	I-Disease	-1	16309808
S	I-Disease	-1	16309808
can	O	-1	16309808
be	O	-1	16309808
d@@	O	-1	16309808
ram@@	O	-1	16309808
ati@@	O	-1	16309808
c@@	O	-1	16309808
ally	O	-1	16309808
improved	O	-1	16309808
by	O	-1	16309808
levo@@	B-Chemical	D007980	16309808
dopa	I-Chemical	-1	16309808
and	O	-1	16309808
dopamine	B-Chemical	D004298	16309808
agon@@	O	-1	16309808
ist@@	O	-1	16309808
s,	O	-1	16309808
whereas	O	-1	16309808
central	O	-1	16309808
dopamine	B-Chemical	D004298	16309808
D2	O	-1	16309808
receptor	O	-1	16309808
antagonist@@	O	-1	16309808
s	O	-1	16309808
can	O	-1	16309808
induce	O	-1	16309808
or	O	-1	16309808
ag@@	O	-1	16309808
gra@@	O	-1	16309808
v@@	O	-1	16309808
ate	O	-1	16309808
R@@	B-Disease	D012148	16309808
L@@	I-Disease	-1	16309808
S	I-Disease	-1	16309808
symptom@@	O	-1	16309808
s.	O	-1	16309808
To	O	-1	16309808
our	O	-1	16309808
know@@	O	-1	16309808
le@@	O	-1	16309808
d@@	O	-1	16309808
g@@	O	-1	16309808
e,	O	-1	16309808
there	O	-1	16309808
is	O	-1	16309808
no	O	-1	16309808
previ@@	O	-1	16309808
ous	O	-1	16309808
report	O	-1	16309808
reg@@	O	-1	16309808
ar@@	O	-1	16309808
ding	O	-1	16309808
whether	O	-1	16309808
dom@@	B-Chemical	D004294	16309808
perid@@	I-Chemical	-1	16309808
one	I-Chemical	-1	16309808
,	O	-1	16309808
a	O	-1	16309808
peripheral	O	-1	16309808
dopamine	B-Chemical	D004298	16309808
D2	O	-1	16309808
receptor	O	-1	16309808
antagonist@@	O	-1	16309808
,	O	-1	16309808
can	O	-1	16309808
also	O	-1	16309808
induce	O	-1	16309808
or	O	-1	16309808
ag@@	O	-1	16309808
gra@@	O	-1	16309808
v@@	O	-1	16309808
ate	O	-1	16309808
symptoms	O	-1	16309808
of	O	-1	16309808
R@@	B-Disease	D012148	16309808
L@@	I-Disease	-1	16309808
S	I-Disease	-1	16309808
.	O	-1	16309808
M@@	B-Chemical	C035133	16309808
ir@@	I-Chemical	-1	16309808
t@@	I-Chemical	-1	16309808
az@@	I-Chemical	-1	16309808
apine	I-Chemical	-1	16309808
,	O	-1	16309808
the	O	-1	16309808
first	O	-1	16309808
nor@@	O	-1	16309808
adrenergic	O	-1	16309808
and	O	-1	16309808
specific	O	-1	16309808
seroton@@	O	-1	16309808
ergic	O	-1	16309808
antidepress@@	O	-1	16309808
ant	O	-1	16309808
(@@	O	-1	16309808
Na@@	O	-1	16309808
S@@	O	-1	16309808
S@@	O	-1	16309808
A@@	O	-1	16309808
),	O	-1	16309808
has	O	-1	16309808
been	O	-1	16309808
associated	O	-1	16309808
with	O	-1	16309808
R@@	B-Disease	D012148	16309808
L@@	I-Disease	-1	16309808
S	I-Disease	-1	16309808
in	O	-1	16309808
several	O	-1	16309808
rec@@	O	-1	16309808
ent	O	-1	16309808
pu@@	O	-1	16309808
bl@@	O	-1	16309808
ic@@	O	-1	16309808
ations.	O	-1	16309808
The	O	-1	16309808
au@@	O	-1	16309808
th@@	O	-1	16309808
ors	O	-1	16309808
report	O	-1	16309808
h@@	O	-1	16309808
ere	O	-1	16309808
a	O	-1	16309808
depress@@	O	-1	16309808
ed	O	-1	16309808
patient	O	-1	16309808
com@@	O	-1	16309808
or@@	O	-1	16309808
b@@	O	-1	16309808
id	O	-1	16309808
with	O	-1	16309808
post@@	B-Disease	D004415	16309808
p@@	I-Disease	-1	16309808
ran@@	I-Disease	-1	16309808
di@@	I-Disease	-1	16309808
al	I-Disease	-1	16309808
dys@@	I-Disease	-1	16309808
p@@	I-Disease	-1	16309808
ep@@	I-Disease	-1	16309808
sia	I-Disease	-1	16309808
who	O	-1	16309808
developed	O	-1	16309808
R@@	B-Disease	D012148	16309808
L@@	I-Disease	-1	16309808
S	I-Disease	-1	16309808
after	O	-1	16309808
m@@	B-Chemical	C035133	16309808
ir@@	I-Chemical	-1	16309808
t@@	I-Chemical	-1	16309808
az@@	I-Chemical	-1	16309808
apine	I-Chemical	-1	16309808
had	O	-1	16309808
been	O	-1	16309808
ad@@	O	-1	16309808
ded	O	-1	16309808
to	O	-1	16309808
h@@	O	-1	16309808
is	O	-1	16309808
dom@@	B-Chemical	D004294	16309808
perid@@	I-Chemical	-1	16309808
one	I-Chemical	-1	16309808
therapy.	O	-1	16309808
Our	O	-1	16309808
patient	O	-1	16309808
star@@	O	-1	16309808
ted	O	-1	16309808
to	O	-1	16309808
have	O	-1	16309808
symptoms	O	-1	16309808
of	O	-1	16309808
R@@	B-Disease	D012148	16309808
L@@	I-Disease	-1	16309808
S	I-Disease	-1	16309808
only	O	-1	16309808
after	O	-1	16309808
he	O	-1	16309808
had	O	-1	16309808
been	O	-1	16309808
treated	O	-1	16309808
with	O	-1	16309808
m@@	B-Chemical	C035133	16309808
ir@@	I-Chemical	-1	16309808
t@@	I-Chemical	-1	16309808
az@@	I-Chemical	-1	16309808
apine	I-Chemical	-1	16309808
,	O	-1	16309808
and	O	-1	16309808
h@@	O	-1	16309808
is	O	-1	16309808
R@@	B-Disease	D012148	16309808
L@@	I-Disease	-1	16309808
S	I-Disease	-1	16309808
symptoms	O	-1	16309808
resol@@	O	-1	16309808
ved	O	-1	16309808
complete@@	O	-1	16309808
ly	O	-1	16309808
up@@	O	-1	16309808
on	O	-1	16309808
discontinu@@	O	-1	16309808
ation	O	-1	16309808
of	O	-1	16309808
h@@	O	-1	16309808
is	O	-1	16309808
m@@	B-Chemical	C035133	16309808
ir@@	I-Chemical	-1	16309808
t@@	I-Chemical	-1	16309808
az@@	I-Chemical	-1	16309808
apine	I-Chemical	-1	16309808
.	O	-1	16309808
S@@	O	-1	16309808
uc@@	O	-1	16309808
h	O	-1	16309808
a	O	-1	16309808
tempor@@	O	-1	16309808
al	O	-1	16309808
rel@@	O	-1	16309808
ationship	O	-1	16309808
between	O	-1	16309808
the	O	-1	16309808
use	O	-1	16309808
of	O	-1	16309808
m@@	B-Chemical	C035133	16309808
ir@@	I-Chemical	-1	16309808
t@@	I-Chemical	-1	16309808
az@@	I-Chemical	-1	16309808
apine	I-Chemical	-1	16309808
and	O	-1	16309808
the	O	-1	16309808
symptoms	O	-1	16309808
of	O	-1	16309808
R@@	B-Disease	D012148	16309808
L@@	I-Disease	-1	16309808
S	I-Disease	-1	16309808
in	O	-1	16309808
our	O	-1	16309808
patient	O	-1	16309808
did	O	-1	16309808
not	O	-1	16309808
suppor@@	O	-1	16309808
t	O	-1	16309808
a	O	-1	16309808
potenti@@	O	-1	16309808
ating	O	-1	16309808
effect	O	-1	16309808
of	O	-1	16309808
dom@@	B-Chemical	D004294	16309808
peri@@	I-Chemical	-1	16309808
one	I-Chemical	-1	16309808
on	O	-1	16309808
m@@	B-Chemical	C035133	16309808
ir@@	I-Chemical	-1	16309808
t@@	I-Chemical	-1	16309808
az@@	I-Chemical	-1	16309808
apine	I-Chemical	-1	16309808
-@@	O	-1	16309808
associated	O	-1	16309808
R@@	B-Disease	D012148	16309808
L@@	I-Disease	-1	16309808
S	I-Disease	-1	16309808
.	O	-1	16309808
However,	O	-1	16309808
physi@@	O	-1	16309808
ci@@	O	-1	16309808
ans	O	-1	16309808
should	O	-1	16309808
be	O	-1	16309808
aw@@	O	-1	16309808
are	O	-1	16309808
of	O	-1	16309808
the	O	-1	16309808
possib@@	O	-1	16309808
ility	O	-1	16309808
that	O	-1	16309808
m@@	B-Chemical	C035133	16309808
ir@@	I-Chemical	-1	16309808
t@@	I-Chemical	-1	16309808
az@@	I-Chemical	-1	16309808
apine	I-Chemical	-1	16309808
can	O	-1	16309808
be	O	-1	16309808
associated	O	-1	16309808
with	O	-1	16309808
R@@	B-Disease	D012148	16309808
L@@	I-Disease	-1	16309808
S	I-Disease	-1	16309808
in	O	-1	16309808
some	O	-1	16309808
individ@@	O	-1	16309808
u@@	O	-1	16309808
al@@	O	-1	16309808
s,	O	-1	16309808
es@@	O	-1	16309808
p@@	O	-1	16309808
ec@@	O	-1	16309808
i@@	O	-1	16309808
ally	O	-1	16309808
those	O	-1	16309808
receiving	O	-1	16309808
concomit@@	O	-1	16309808
ant	O	-1	16309808
dopamine	B-Chemical	D004298	16309808
D2	O	-1	16309808
receptor	O	-1	16309808
antagonist@@	O	-1	16309808
s.	O	-1	16309808

An@@	O	-1	16323982
ti@@	O	-1	16323982
and@@	O	-1	16323982
ro@@	O	-1	16323982
genic	O	-1	16323982
therapy	O	-1	16323982
can	O	-1	16323982
cause	O	-1	16323982
coronary	B-Disease	D003324	16323982
arterial	I-Disease	-1	16323982
disease	I-Disease	-1	16323982
.	O	-1	16323982
A@@	O	-1	16323982
I@@	O	-1	16323982
M@@	O	-1	16323982
:	O	-1	16323982
To	O	-1	16323982
study	O	-1	16323982
the	O	-1	16323982
change	O	-1	16323982
of	O	-1	16323982
li@@	O	-1	16323982
pid	O	-1	16323982
metabol@@	O	-1	16323982
ism	O	-1	16323982
by	O	-1	16323982
anti@@	O	-1	16323982
and@@	O	-1	16323982
ro@@	O	-1	16323982
gen	O	-1	16323982
therapy	O	-1	16323982
in	O	-1	16323982
patients	O	-1	16323982
with	O	-1	16323982
pro@@	B-Disease	D011471	16323982
state	I-Disease	-1	16323982
cancer	I-Disease	-1	16323982
.	O	-1	16323982
M@@	O	-1	16323982
AT@@	O	-1	16323982
E@@	O	-1	16323982
R@@	O	-1	16323982
I@@	O	-1	16323982
AL@@	O	-1	16323982
S	O	-1	16323982
AN@@	O	-1	16323982
D	O	-1	16323982
METHODS:	O	-1	16323982
We	O	-1	16323982
studied	O	-1	16323982
with	O	-1	16323982
a	O	-1	16323982
2.@@	O	-1	16323982
5	O	-1	16323982
years	O	-1	16323982
follow-up	O	-1	16323982
the	O	-1	16323982
changes	O	-1	16323982
in	O	-1	16323982
plasma	O	-1	16323982
cholester@@	B-Chemical	D002784	16323982
ol@@	I-Chemical	-1	16323982
s	I-Chemical	-1	16323982
(	O	-1	16323982
C	B-Chemical	D002784	16323982
),	O	-1	16323982
tri@@	B-Chemical	D014280	16323982
glycer@@	I-Chemical	-1	16323982
i@@	I-Chemical	-1	16323982
des	I-Chemical	-1	16323982
(	O	-1	16323982
T@@	B-Chemical	D014280	16323982
G	I-Chemical	-1	16323982
),	O	-1	16323982
li@@	O	-1	16323982
po@@	O	-1	16323982
protein@@	O	-1	16323982
s	O	-1	16323982
(@@	O	-1	16323982
L@@	O	-1	16323982
P@@	O	-1	16323982
),	O	-1	16323982
and	O	-1	16323982
ap@@	O	-1	16323982
ol@@	O	-1	16323982
i@@	O	-1	16323982
po@@	O	-1	16323982
protein@@	O	-1	16323982
s	O	-1	16323982
(A@@	O	-1	16323982
po@@	O	-1	16323982
)	O	-1	16323982
B@@	O	-1	16323982
-@@	O	-1	16323982
10@@	O	-1	16323982
0@@	O	-1	16323982
,	O	-1	16323982
A@@	O	-1	16323982
-@@	O	-1	16323982
I@@	O	-1	16323982
,	O	-1	16323982
and	O	-1	16323982
A@@	O	-1	16323982
-@@	O	-1	16323982
II	O	-1	16323982
pr@@	O	-1	16323982
o	O	-1	16323982
f@@	O	-1	16323982
i	O	-1	16323982
le@@	O	-1	16323982
s	O	-1	16323982
in	O	-1	16323982
24	O	-1	16323982
patients	O	-1	16323982
of	O	-1	16323982
mean	O	-1	16323982
age	O	-1	16323982
60	O	-1	16323982
years	O	-1	16323982
with	O	-1	16323982
low	O	-1	16323982
risk	O	-1	16323982
pro@@	B-Disease	D011471	16323982
state	I-Disease	-1	16323982
cancer	I-Disease	-1	16323982
(@@	O	-1	16323982
st@@	O	-1	16323982
ag@@	O	-1	16323982
e@@	O	-1	16323982
:	O	-1	16323982
T@@	O	-1	16323982
1@@	O	-1	16323982
c@@	O	-1	16323982
N@@	O	-1	16323982
0@@	O	-1	16323982
M@@	O	-1	16323982
0@@	O	-1	16323982
,	O	-1	16323982
G@@	O	-1	16323982
le@@	O	-1	16323982
as@@	O	-1	16323982
on	O	-1	16323982
sco@@	O	-1	16323982
re@@	O	-1	16323982
:	O	-1	16323982
2-@@	O	-1	16323982
5@@	O	-1	16323982
)	O	-1	16323982
during	O	-1	16323982
treatment	O	-1	16323982
with	O	-1	16323982
cy@@	B-Chemical	D017373	16323982
pro@@	I-Chemical	-1	16323982
ter@@	I-Chemical	-1	16323982
one	I-Chemical	-1	16323982
acet@@	I-Chemical	-1	16323982
ate	I-Chemical	-1	16323982
(	O	-1	16323982
C@@	B-Chemical	D017373	16323982
P@@	I-Chemical	-1	16323982
A	I-Chemical	-1	16323982
)	O	-1	16323982
without	O	-1	16323982
surg@@	O	-1	16323982
ical	O	-1	16323982
man@@	O	-1	16323982
ag@@	O	-1	16323982
ement	O	-1	16323982
or	O	-1	16323982
radi@@	O	-1	16323982
ation	O	-1	16323982
therapy.	O	-1	16323982
RESULTS:	O	-1	16323982
Si@@	O	-1	16323982
gn@@	O	-1	16323982
ific@@	O	-1	16323982
ant	O	-1	16323982
decreas@@	O	-1	16323982
es	O	-1	16323982
of	O	-1	16323982
H@@	O	-1	16323982
D@@	O	-1	16323982
L-@@	O	-1	16323982
C@@	O	-1	16323982
,	O	-1	16323982
A@@	O	-1	16323982
p@@	O	-1	16323982
o	O	-1	16323982
A@@	O	-1	16323982
-@@	O	-1	16323982
I	O	-1	16323982
and	O	-1	16323982
A@@	O	-1	16323982
p@@	O	-1	16323982
o	O	-1	16323982
A@@	O	-1	16323982
-@@	O	-1	16323982
II	O	-1	16323982
and	O	-1	16323982
an	O	-1	16323982
increase	O	-1	16323982
of	O	-1	16323982
tri@@	B-Chemical	D014280	16323982
glycer@@	I-Chemical	-1	16323982
ide	I-Chemical	-1	16323982
levels	O	-1	16323982
in	O	-1	16323982
V@@	O	-1	16323982
L@@	O	-1	16323982
D@@	O	-1	16323982
L	O	-1	16323982
were	O	-1	16323982
induced	O	-1	16323982
by	O	-1	16323982
C@@	B-Chemical	D017373	16323982
P@@	I-Chemical	-1	16323982
A	I-Chemical	-1	16323982
.	O	-1	16323982
After	O	-1	16323982
a	O	-1	16323982
period	O	-1	16323982
of	O	-1	16323982
2.@@	O	-1	16323982
5	O	-1	16323982
years	O	-1	16323982
on	O	-1	16323982
C@@	B-Chemical	D017373	16323982
P@@	I-Chemical	-1	16323982
A	I-Chemical	-1	16323982
treatment,	O	-1	16323982
four	O	-1	16323982
patients	O	-1	16323982
out	O	-1	16323982
of	O	-1	16323982
tw@@	O	-1	16323982
ent@@	O	-1	16323982
y-@@	O	-1	16323982
four	O	-1	16323982
were	O	-1	16323982
found	O	-1	16323982
to	O	-1	16323982
be	O	-1	16323982
affected	O	-1	16323982
by	O	-1	16323982
coronary	B-Disease	D003327	16323982
heart	I-Disease	-1	16323982
disease	I-Disease	-1	16323982
.	O	-1	16323982
CONCLUSIONS:	O	-1	16323982
I@@	O	-1	16323982
sch@@	O	-1	16323982
a@@	O	-1	16323982
em@@	O	-1	16323982
ic	O	-1	16323982
coronary	B-Disease	D003324	16323982
arter@@	I-Disease	-1	16323982
i@@	I-Disease	-1	16323982
os@@	I-Disease	-1	16323982
clero@@	I-Disease	-1	16323982
sis	I-Disease	-1	16323982
with	O	-1	16323982
an	O	-1	16323982
incidence	O	-1	16323982
rate	O	-1	16323982
of	O	-1	16323982
1@@	O	-1	16323982
6.@@	O	-1	16323982
6%	O	-1	16323982
as	O	-1	16323982
caused	O	-1	16323982
by	O	-1	16323982
prolonged	O	-1	16323982
C@@	B-Chemical	D017373	16323982
P@@	I-Chemical	-1	16323982
A	I-Chemical	-1	16323982
therapy	O	-1	16323982
is	O	-1	16323982
mediated	O	-1	16323982
through	O	-1	16323982
changes	O	-1	16323982
in	O	-1	16323982
H@@	O	-1	16323982
D@@	O	-1	16323982
L	O	-1	16323982
cholester@@	B-Chemical	D002784	16323982
ol	I-Chemical	-1	16323982
,	O	-1	16323982
A@@	O	-1	16323982
p@@	O	-1	16323982
o	O	-1	16323982
A@@	O	-1	16323982
-@@	O	-1	16323982
I	O	-1	16323982
and	O	-1	16323982
A@@	O	-1	16323982
p@@	O	-1	16323982
o	O	-1	16323982
A@@	O	-1	16323982
-@@	O	-1	16323982
II	O	-1	16323982
pr@@	O	-1	16323982
o	O	-1	16323982
f@@	O	-1	16323982
i	O	-1	16323982
l@@	O	-1	16323982
es,	O	-1	16323982
other	O	-1	16323982
than	O	-1	16323982
the	O	-1	16323982
we@@	O	-1	16323982
ll@@	O	-1	16323982
-@@	O	-1	16323982
known	O	-1	16323982
hyper@@	B-Disease	D050171	16323982
glycer@@	I-Disease	-1	16323982
ide@@	I-Disease	-1	16323982
mic	I-Disease	-1	16323982
effect	I-Disease	-1	16323982
caused	O	-1	16323982
by	O	-1	16323982
est@@	B-Chemical	D004967	16323982
ro@@	I-Chemical	-1	16323982
gen	I-Chemical	-1	16323982
.	O	-1	16323982

5-@@	B-Chemical	D005472	16369751
F@@	I-Chemical	-1	16369751
lu@@	I-Chemical	-1	16369751
o@@	I-Chemical	-1	16369751
ro@@	I-Chemical	-1	16369751
urac@@	I-Chemical	-1	16369751
il	I-Chemical	-1	16369751
cardi@@	B-Disease	D066126	16369751
otoxicity	I-Disease	-1	16369751
induced	O	-1	16369751
by	O	-1	16369751
alpha-@@	B-Chemical	C032348	16369751
fluoro@@	I-Chemical	-1	16369751
-@@	I-Chemical	-1	16369751
beta-@@	I-Chemical	-1	16369751
al@@	I-Chemical	-1	16369751
an@@	I-Chemical	-1	16369751
ine	I-Chemical	-1	16369751
.	O	-1	16369751
C@@	B-Disease	D066126	16369751
ardi@@	I-Disease	-1	16369751
otoxicity	I-Disease	-1	16369751
is	O	-1	16369751
a	O	-1	16369751
r@@	O	-1	16369751
are	O	-1	16369751
complication	O	-1	16369751
occur@@	O	-1	16369751
r@@	O	-1	16369751
ing	O	-1	16369751
during	O	-1	16369751
5-@@	B-Chemical	D005472	16369751
fluoro@@	I-Chemical	-1	16369751
urac@@	I-Chemical	-1	16369751
il	I-Chemical	-1	16369751
(	O	-1	16369751
5-@@	B-Chemical	D005472	16369751
F@@	I-Chemical	-1	16369751
U	I-Chemical	-1	16369751
)	O	-1	16369751
treatment	O	-1	16369751
for	O	-1	16369751
mal@@	B-Disease	D009369	16369751
i@@	I-Disease	-1	16369751
gn@@	I-Disease	-1	16369751
an@@	I-Disease	-1	16369751
ci@@	I-Disease	-1	16369751
es	I-Disease	-1	16369751
.	O	-1	16369751
We	O	-1	16369751
he@@	O	-1	16369751
re@@	O	-1	16369751
in	O	-1	16369751
report	O	-1	16369751
the	O	-1	16369751
case	O	-1	16369751
of	O	-1	16369751
a	O	-1	16369751
7@@	O	-1	16369751
0-@@	O	-1	16369751
year-old	O	-1	16369751
man	O	-1	16369751
with	O	-1	16369751
5-@@	B-Chemical	D005472	16369751
F@@	I-Chemical	-1	16369751
U	I-Chemical	-1	16369751
-induced	O	-1	16369751
cardi@@	B-Disease	D066126	16369751
otoxicity	I-Disease	-1	16369751
,	O	-1	16369751
in	O	-1	16369751
whom	O	-1	16369751
a	O	-1	16369751
high	O	-1	16369751
serum	O	-1	16369751
level	O	-1	16369751
of	O	-1	16369751
alpha-@@	B-Chemical	C032348	16369751
fluoro@@	I-Chemical	-1	16369751
-@@	I-Chemical	-1	16369751
beta-@@	I-Chemical	-1	16369751
al@@	I-Chemical	-1	16369751
an@@	I-Chemical	-1	16369751
ine	I-Chemical	-1	16369751
(	O	-1	16369751
F@@	B-Chemical	C032348	16369751
BA@@	I-Chemical	-1	16369751
L	I-Chemical	-1	16369751
)	O	-1	16369751
was	O	-1	16369751
obser@@	O	-1	16369751
ved.	O	-1	16369751
The	O	-1	16369751
patient@@	O	-1	16369751
,	O	-1	16369751
who	O	-1	16369751
had	O	-1	16369751
un@@	O	-1	16369751
res@@	O	-1	16369751
ect@@	O	-1	16369751
able	O	-1	16369751
co@@	B-Disease	D003110	16369751
l@@	I-Disease	-1	16369751
on	I-Disease	-1	16369751
cancer	I-Disease	-1	16369751
met@@	O	-1	16369751
ast@@	O	-1	16369751
as@@	O	-1	16369751
es	O	-1	16369751
to	O	-1	16369751
the	O	-1	16369751
liver	O	-1	16369751
and	O	-1	16369751
l@@	O	-1	16369751
un@@	O	-1	16369751
g@@	O	-1	16369751
,	O	-1	16369751
was	O	-1	16369751
ref@@	O	-1	16369751
er@@	O	-1	16369751
red	O	-1	16369751
to	O	-1	16369751
us	O	-1	16369751
for	O	-1	16369751
chemotherapy	O	-1	16369751
from	O	-1	16369751
an	O	-1	16369751
aff@@	O	-1	16369751
il@@	O	-1	16369751
i@@	O	-1	16369751
ated	O	-1	16369751
hospit@@	O	-1	16369751
al@@	O	-1	16369751
;	O	-1	16369751
he	O	-1	16369751
had	O	-1	16369751
no	O	-1	16369751
cardiac	O	-1	16369751
hist@@	O	-1	16369751
or@@	O	-1	16369751
y.	O	-1	16369751
After	O	-1	16369751
ad@@	O	-1	16369751
mis@@	O	-1	16369751
sion,	O	-1	16369751
the	O	-1	16369751
patient	O	-1	16369751
received	O	-1	16369751
a	O	-1	16369751
continu@@	O	-1	16369751
ous	O	-1	16369751
intravenous	O	-1	16369751
infusion	O	-1	16369751
of	O	-1	16369751
5-@@	B-Chemical	D005472	16369751
F@@	I-Chemical	-1	16369751
U	I-Chemical	-1	16369751
(@@	O	-1	16369751
10@@	O	-1	16369751
00	O	-1	16369751
mg/@@	O	-1	16369751
day@@	O	-1	16369751
),	O	-1	16369751
during	O	-1	16369751
which	O	-1	16369751
pre@@	B-Disease	D002637	16369751
cor@@	I-Disease	-1	16369751
di@@	I-Disease	-1	16369751
al	I-Disease	-1	16369751
pain	I-Disease	-1	16369751
with	O	-1	16369751
right	B-Disease	D002037	16369751
b@@	I-Disease	-1	16369751
und@@	I-Disease	-1	16369751
le	I-Disease	-1	16369751
b@@	I-Disease	-1	16369751
ran@@	I-Disease	-1	16369751
ch	I-Disease	-1	16369751
bloc@@	I-Disease	-1	16369751
k	I-Disease	-1	16369751
occurred	O	-1	16369751
concomit@@	O	-1	16369751
ant@@	O	-1	16369751
ly	O	-1	16369751
with	O	-1	16369751
a	O	-1	16369751
high	O	-1	16369751
serum	O	-1	16369751
F@@	B-Chemical	C032348	16369751
BA@@	I-Chemical	-1	16369751
L	I-Chemical	-1	16369751
concentration	O	-1	16369751
of	O	-1	16369751
19@@	O	-1	16369751
5@@	O	-1	16369751
5	O	-1	16369751
n@@	O	-1	16369751
g/@@	O	-1	16369751
ml@@	O	-1	16369751
.	O	-1	16369751
B@@	O	-1	16369751
oth	O	-1	16369751
the	O	-1	16369751
pre@@	B-Disease	D002637	16369751
cor@@	I-Disease	-1	16369751
di@@	I-Disease	-1	16369751
al	I-Disease	-1	16369751
pain	I-Disease	-1	16369751
and	O	-1	16369751
the	O	-1	16369751
electro@@	O	-1	16369751
cardio@@	O	-1	16369751
graph@@	O	-1	16369751
ic	O	-1	16369751
changes	O	-1	16369751
dis@@	O	-1	16369751
appe@@	O	-1	16369751
a@@	O	-1	16369751
red	O	-1	16369751
spont@@	O	-1	16369751
ane@@	O	-1	16369751
ously	O	-1	16369751
after	O	-1	16369751
the	O	-1	16369751
discontinu@@	O	-1	16369751
ation	O	-1	16369751
of	O	-1	16369751
5-@@	B-Chemical	D005472	16369751
F@@	I-Chemical	-1	16369751
U	I-Chemical	-1	16369751
.	O	-1	16369751
A@@	O	-1	16369751
s	O	-1	16369751
the	O	-1	16369751
pre@@	B-Disease	D002637	16369751
cor@@	I-Disease	-1	16369751
di@@	I-Disease	-1	16369751
al	I-Disease	-1	16369751
pain	I-Disease	-1	16369751
in	O	-1	16369751
this	O	-1	16369751
patient	O	-1	16369751
was	O	-1	16369751
considered	O	-1	16369751
to	O	-1	16369751
have	O	-1	16369751
been	O	-1	16369751
due	O	-1	16369751
to	O	-1	16369751
5-@@	B-Chemical	D005472	16369751
F@@	I-Chemical	-1	16369751
U	I-Chemical	-1	16369751
-induced	O	-1	16369751
cardi@@	B-Disease	D066126	16369751
otoxicity	I-Disease	-1	16369751
,	O	-1	16369751
the	O	-1	16369751
administration	O	-1	16369751
of	O	-1	16369751
5-@@	B-Chemical	D005472	16369751
F@@	I-Chemical	-1	16369751
U	I-Chemical	-1	16369751
was	O	-1	16369751
ab@@	O	-1	16369751
and@@	O	-1	16369751
on@@	O	-1	16369751
ed.	O	-1	16369751
In@@	O	-1	16369751
ste@@	O	-1	16369751
ad@@	O	-1	16369751
,	O	-1	16369751
oral	O	-1	16369751
administration	O	-1	16369751
of	O	-1	16369751
S@@	O	-1	16369751
-1	O	-1	16369751
(@@	O	-1	16369751
a	O	-1	16369751
der@@	O	-1	16369751
i@@	O	-1	16369751
v@@	O	-1	16369751
ative	O	-1	16369751
of	O	-1	16369751
5-@@	B-Chemical	D005472	16369751
F@@	I-Chemical	-1	16369751
U	I-Chemical	-1	16369751
),	O	-1	16369751
at	O	-1	16369751
2@@	O	-1	16369751
00	O	-1	16369751
mg/@@	O	-1	16369751
day	O	-1	16369751
tw@@	O	-1	16369751
ic@@	O	-1	16369751
e	O	-1	16369751
a	O	-1	16369751
week@@	O	-1	16369751
,	O	-1	16369751
was	O	-1	16369751
insti@@	O	-1	16369751
tu@@	O	-1	16369751
te@@	O	-1	16369751
d,	O	-1	16369751
because	O	-1	16369751
S@@	O	-1	16369751
-1	O	-1	16369751
has	O	-1	16369751
a	O	-1	16369751
st@@	O	-1	16369751
ron@@	O	-1	16369751
g	O	-1	16369751
inhibit@@	O	-1	16369751
ory	O	-1	16369751
effect	O	-1	16369751
on	O	-1	16369751
di@@	B-Chemical	C020047	16369751
hydro@@	I-Chemical	-1	16369751
pyri@@	I-Chemical	-1	16369751
m@@	I-Chemical	-1	16369751
idine	I-Chemical	-1	16369751
de@@	O	-1	16369751
hydro@@	O	-1	16369751
gen@@	O	-1	16369751
ase,	O	-1	16369751
which	O	-1	16369751
cat@@	O	-1	16369751
aly@@	O	-1	16369751
z@@	O	-1	16369751
es	O	-1	16369751
the	O	-1	16369751
de@@	O	-1	16369751
gra@@	O	-1	16369751
d@@	O	-1	16369751
ative	O	-1	16369751
of	O	-1	16369751
5-@@	B-Chemical	D005472	16369751
F@@	I-Chemical	-1	16369751
U	I-Chemical	-1	16369751
into	O	-1	16369751
F@@	B-Chemical	C032348	16369751
BA@@	I-Chemical	-1	16369751
L	I-Chemical	-1	16369751
.	O	-1	16369751
The	O	-1	16369751
serum	O	-1	16369751
F@@	B-Chemical	C032348	16369751
BA@@	I-Chemical	-1	16369751
L	I-Chemical	-1	16369751
concentration	O	-1	16369751
subsequ@@	O	-1	16369751
ently	O	-1	16369751
decreased	O	-1	16369751
to	O	-1	16369751
3@@	O	-1	16369751
5@@	O	-1	16369751
2	O	-1	16369751
n@@	O	-1	16369751
g/@@	O	-1	16369751
ml@@	O	-1	16369751
,	O	-1	16369751
the	O	-1	16369751
same	O	-1	16369751
as	O	-1	16369751
the	O	-1	16369751
valu@@	O	-1	16369751
e	O	-1	16369751
measured	O	-1	16369751
on	O	-1	16369751
the	O	-1	16369751
first	O	-1	16369751
day	O	-1	16369751
of	O	-1	16369751
S@@	O	-1	16369751
-1	O	-1	16369751
administr@@	O	-1	16369751
ation.	O	-1	16369751
The@@	O	-1	16369751
re@@	O	-1	16369751
af@@	O	-1	16369751
ter@@	O	-1	16369751
,	O	-1	16369751
no	O	-1	16369751
cardiac	B-Disease	D009461	16369751
symptoms	I-Disease	-1	16369751
were	O	-1	16369751
obser@@	O	-1	16369751
ved.	O	-1	16369751
The	O	-1	16369751
patient	O	-1	16369751
achi@@	O	-1	16369751
ev@@	O	-1	16369751
ed	O	-1	16369751
a	O	-1	16369751
partial	O	-1	16369751
response	O	-1	16369751
6	O	-1	16369751
months	O	-1	16369751
after	O	-1	16369751
the	O	-1	16369751
initi@@	O	-1	16369751
ation	O	-1	16369751
of	O	-1	16369751
the	O	-1	16369751
S@@	O	-1	16369751
-1	O	-1	16369751
treatment.	O	-1	16369751
The	O	-1	16369751
experi@@	O	-1	16369751
ence	O	-1	16369751
of	O	-1	16369751
this	O	-1	16369751
cas@@	O	-1	16369751
e,	O	-1	16369751
to@@	O	-1	16369751
ge@@	O	-1	16369751
ther	O	-1	16369751
with	O	-1	16369751
a	O	-1	16369751
revie@@	O	-1	16369751
w	O	-1	16369751
of	O	-1	16369751
the	O	-1	16369751
literat@@	O	-1	16369751
ure,	O	-1	16369751
suggests	O	-1	16369751
that	O	-1	16369751
F@@	B-Chemical	C032348	16369751
BA@@	I-Chemical	-1	16369751
L	I-Chemical	-1	16369751
is	O	-1	16369751
related	O	-1	16369751
to	O	-1	16369751
5-@@	B-Chemical	D005472	16369751
F@@	I-Chemical	-1	16369751
U	I-Chemical	-1	16369751
-induced	O	-1	16369751
cardi@@	B-Disease	D066126	16369751
otoxicity	I-Disease	-1	16369751
.	O	-1	16369751
S@@	O	-1	16369751
-1	O	-1	16369751
may	O	-1	16369751
be	O	-1	16369751
administered	O	-1	16369751
saf@@	O	-1	16369751
ely	O	-1	16369751
to	O	-1	16369751
patients	O	-1	16369751
with	O	-1	16369751
5-@@	B-Chemical	D005472	16369751
F@@	I-Chemical	-1	16369751
U	I-Chemical	-1	16369751
-induced	O	-1	16369751
cardi@@	B-Disease	D066126	16369751
otoxicity	I-Disease	-1	16369751
.	O	-1	16369751

The	O	-1	16565833
influence	O	-1	16565833
of	O	-1	16565833
the	O	-1	16565833
time	O	-1	16565833
interv@@	O	-1	16565833
al	O	-1	16565833
between	O	-1	16565833
mon@@	B-Chemical	C522803	16565833
o@@	I-Chemical	-1	16565833
H@@	I-Chemical	-1	16565833
E@@	I-Chemical	-1	16565833
R	I-Chemical	-1	16565833
and	O	-1	16565833
dox@@	B-Chemical	D004317	16565833
orub@@	I-Chemical	-1	16565833
icin	I-Chemical	-1	16565833
administration	O	-1	16565833
on	O	-1	16565833
the	O	-1	16565833
prot@@	O	-1	16565833
ection	O	-1	16565833
against	O	-1	16565833
dox@@	B-Chemical	D004317	16565833
orub@@	I-Chemical	-1	16565833
icin	I-Chemical	-1	16565833
-induced	O	-1	16565833
cardi@@	B-Disease	D066126	16565833
otoxicity	I-Disease	-1	16565833
in	O	-1	16565833
mice.	O	-1	16565833
P@@	O	-1	16565833
U@@	O	-1	16565833
R@@	O	-1	16565833
P@@	O	-1	16565833
O@@	O	-1	16565833
S@@	O	-1	16565833
E:	O	-1	16565833
D@@	O	-1	16565833
es@@	O	-1	16565833
pit@@	O	-1	16565833
e	O	-1	16565833
its	O	-1	16565833
we@@	O	-1	16565833
ll@@	O	-1	16565833
-@@	O	-1	16565833
known	O	-1	16565833
cardi@@	B-Disease	D066126	16565833
otoxicity	I-Disease	-1	16565833
,	O	-1	16565833
the	O	-1	16565833
an@@	O	-1	16565833
th@@	O	-1	16565833
rac@@	O	-1	16565833
y@@	O	-1	16565833
cl@@	O	-1	16565833
in	O	-1	16565833
dox@@	B-Chemical	D004317	16565833
orub@@	I-Chemical	-1	16565833
icin	I-Chemical	-1	16565833
(	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
)	O	-1	16565833
continu@@	O	-1	16565833
es	O	-1	16565833
to	O	-1	16565833
be	O	-1	16565833
an	O	-1	16565833
effective	O	-1	16565833
and	O	-1	16565833
wi@@	O	-1	16565833
de@@	O	-1	16565833
ly	O	-1	16565833
used	O	-1	16565833
chemo@@	O	-1	16565833
therapeutic	O	-1	16565833
agent@@	O	-1	16565833
.	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
-induced	O	-1	16565833
cardiac	B-Disease	D006331	16565833
damage	I-Disease	-1	16565833
pres@@	O	-1	16565833
um@@	O	-1	16565833
ably	O	-1	16565833
results	O	-1	16565833
from	O	-1	16565833
the	O	-1	16565833
formation	O	-1	16565833
of	O	-1	16565833
free	O	-1	16565833
ra@@	O	-1	16565833
dic@@	O	-1	16565833
als	O	-1	16565833
by	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
.	O	-1	16565833
Re@@	O	-1	16565833
active	O	-1	16565833
oxy@@	B-Chemical	D010100	16565833
gen	I-Chemical	-1	16565833
spec@@	O	-1	16565833
i@@	O	-1	16565833
es	O	-1	16565833
partic@@	O	-1	16565833
ul@@	O	-1	16565833
arly	O	-1	16565833
aff@@	O	-1	16565833
ect	O	-1	16565833
the	O	-1	16565833
cardiac	O	-1	16565833
my@@	O	-1	16565833
ocy@@	O	-1	16565833
tes	O	-1	16565833
because	O	-1	16565833
these	O	-1	16565833
cells	O	-1	16565833
se@@	O	-1	16565833
em	O	-1	16565833
to	O	-1	16565833
have	O	-1	16565833
a	O	-1	16565833
rel@@	O	-1	16565833
atively	O	-1	16565833
po@@	O	-1	16565833
or	O	-1	16565833
anti@@	O	-1	16565833
oxid@@	O	-1	16565833
ant	O	-1	16565833
def@@	O	-1	16565833
en@@	O	-1	16565833
se	O	-1	16565833
system@@	O	-1	16565833
.	O	-1	16565833
The	O	-1	16565833
se@@	O	-1	16565833
mis@@	O	-1	16565833
yn@@	O	-1	16565833
thetic	O	-1	16565833
f@@	B-Chemical	D005419	16565833
l@@	I-Chemical	-1	16565833
av@@	I-Chemical	-1	16565833
on@@	I-Chemical	-1	16565833
oid	I-Chemical	-1	16565833
mon@@	B-Chemical	C522803	16565833
o@@	I-Chemical	-1	16565833
hydrox@@	I-Chemical	-1	16565833
y@@	I-Chemical	-1	16565833
eth@@	I-Chemical	-1	16565833
yl@@	I-Chemical	-1	16565833
ru@@	I-Chemical	-1	16565833
to@@	I-Chemical	-1	16565833
side	I-Chemical	-1	16565833
(	O	-1	16565833
mon@@	B-Chemical	C522803	16565833
o@@	I-Chemical	-1	16565833
H@@	I-Chemical	-1	16565833
E@@	I-Chemical	-1	16565833
R	I-Chemical	-1	16565833
)	O	-1	16565833
showed	O	-1	16565833
cardio@@	O	-1	16565833
prot@@	O	-1	16565833
ection	O	-1	16565833
against	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
-induced	O	-1	16565833
cardi@@	B-Disease	D066126	16565833
otoxicity	I-Disease	-1	16565833
through	O	-1	16565833
its	O	-1	16565833
ra@@	O	-1	16565833
d@@	O	-1	16565833
ical	O	-1	16565833
s@@	O	-1	16565833
ca@@	O	-1	16565833
ven@@	O	-1	16565833
g@@	O	-1	16565833
ing	O	-1	16565833
and	O	-1	16565833
i@@	B-Chemical	D007501	16565833
ro@@	I-Chemical	-1	16565833
n	I-Chemical	-1	16565833
ch@@	O	-1	16565833
el@@	O	-1	16565833
ating	O	-1	16565833
pro@@	O	-1	16565833
per@@	O	-1	16565833
ti@@	O	-1	16565833
es.	O	-1	16565833
B@@	O	-1	16565833
ecause	O	-1	16565833
of	O	-1	16565833
the	O	-1	16565833
rel@@	O	-1	16565833
atively	O	-1	16565833
sh@@	O	-1	16565833
ort	O	-1	16565833
f@@	O	-1	16565833
inal	O	-1	16565833
h@@	O	-1	16565833
al@@	O	-1	16565833
f@@	O	-1	16565833
-@@	O	-1	16565833
lif@@	O	-1	16565833
e	O	-1	16565833
of	O	-1	16565833
mon@@	B-Chemical	C522803	16565833
o@@	I-Chemical	-1	16565833
H@@	I-Chemical	-1	16565833
E@@	I-Chemical	-1	16565833
R	I-Chemical	-1	16565833
(@@	O	-1	16565833
about	O	-1	16565833
30	O	-1	16565833
min@@	O	-1	16565833
),	O	-1	16565833
it	O	-1	16565833
is	O	-1	16565833
ex@@	O	-1	16565833
p@@	O	-1	16565833
ected	O	-1	16565833
that	O	-1	16565833
the	O	-1	16565833
time	O	-1	16565833
interv@@	O	-1	16565833
al	O	-1	16565833
between	O	-1	16565833
mon@@	B-Chemical	C522803	16565833
o@@	I-Chemical	-1	16565833
H@@	I-Chemical	-1	16565833
E@@	I-Chemical	-1	16565833
R	I-Chemical	-1	16565833
and	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
might	O	-1	16565833
be	O	-1	16565833
of	O	-1	16565833
influence	O	-1	16565833
on	O	-1	16565833
the	O	-1	16565833
cardio@@	O	-1	16565833
protective	O	-1	16565833
effect	O	-1	16565833
of	O	-1	16565833
mon@@	B-Chemical	C522803	16565833
o@@	I-Chemical	-1	16565833
H@@	I-Chemical	-1	16565833
E@@	I-Chemical	-1	16565833
R	I-Chemical	-1	16565833
.	O	-1	16565833
The@@	O	-1	16565833
refore,	O	-1	16565833
the	O	-1	16565833
a@@	O	-1	16565833
im	O	-1	16565833
of	O	-1	16565833
the	O	-1	16565833
present	O	-1	16565833
study	O	-1	16565833
was	O	-1	16565833
to	O	-1	16565833
investigate	O	-1	16565833
this	O	-1	16565833
possible	O	-1	16565833
effect@@	O	-1	16565833
.	O	-1	16565833
METHODS:	O	-1	16565833
Si@@	O	-1	16565833
x	O	-1	16565833
groups	O	-1	16565833
of	O	-1	16565833
6	O	-1	16565833
BA@@	O	-1	16565833
L@@	O	-1	16565833
B@@	O	-1	16565833
/@@	O	-1	16565833
c	O	-1	16565833
mice	O	-1	16565833
were	O	-1	16565833
treated	O	-1	16565833
with	O	-1	16565833
sal@@	O	-1	16565833
ine,	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
alone	O	-1	16565833
or	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
(@@	O	-1	16565833
4	O	-1	16565833
mg/kg	O	-1	16565833
i.v@@	O	-1	16565833
.)	O	-1	16565833
pre@@	O	-1	16565833
ce@@	O	-1	16565833
ded	O	-1	16565833
by	O	-1	16565833
mon@@	B-Chemical	C522803	16565833
o@@	I-Chemical	-1	16565833
H@@	I-Chemical	-1	16565833
E@@	I-Chemical	-1	16565833
R	I-Chemical	-1	16565833
(5@@	O	-1	16565833
00	O	-1	16565833
mg/kg	O	-1	16565833
i.p.@@	O	-1	16565833
)	O	-1	16565833
with	O	-1	16565833
an	O	-1	16565833
interv@@	O	-1	16565833
al	O	-1	16565833
of	O	-1	16565833
10@@	O	-1	16565833
,	O	-1	16565833
3@@	O	-1	16565833
0@@	O	-1	16565833
,	O	-1	16565833
60	O	-1	16565833
or	O	-1	16565833
1@@	O	-1	16565833
20	O	-1	16565833
min@@	O	-1	16565833
.	O	-1	16565833
After	O	-1	16565833
a	O	-1	16565833
6-@@	O	-1	16565833
week	O	-1	16565833
treatment	O	-1	16565833
period	O	-1	16565833
and	O	-1	16565833
addi@@	O	-1	16565833
tional	O	-1	16565833
observ@@	O	-1	16565833
ation	O	-1	16565833
for	O	-1	16565833
2	O	-1	16565833
week@@	O	-1	16565833
s,	O	-1	16565833
the	O	-1	16565833
mice	O	-1	16565833
were	O	-1	16565833
s@@	O	-1	16565833
ac@@	O	-1	16565833
ri@@	O	-1	16565833
fic@@	O	-1	16565833
ed.	O	-1	16565833
The@@	O	-1	16565833
ir	O	-1	16565833
cardiac	O	-1	16565833
tissu@@	O	-1	16565833
es	O	-1	16565833
were	O	-1	16565833
pro@@	O	-1	16565833
cess@@	O	-1	16565833
ed	O	-1	16565833
for	O	-1	16565833
li@@	O	-1	16565833
ght	O	-1	16565833
micro@@	O	-1	16565833
sco@@	O	-1	16565833
p@@	O	-1	16565833
y,	O	-1	16565833
after	O	-1	16565833
which	O	-1	16565833
cardi@@	B-Disease	D009202	16565833
om@@	I-Disease	-1	16565833
y@@	I-Disease	-1	16565833
ocyte	I-Disease	-1	16565833
damage	I-Disease	-1	16565833
was	O	-1	16565833
evaluated	O	-1	16565833
ac@@	O	-1	16565833
cor@@	O	-1	16565833
ding	O	-1	16565833
to	O	-1	16565833
B@@	O	-1	16565833
ill@@	O	-1	16565833
ing@@	O	-1	16565833
ha@@	O	-1	16565833
m	O	-1	16565833
(@@	O	-1	16565833
in	O	-1	16565833
C@@	B-Disease	D009369	16565833
anc@@	I-Disease	-1	16565833
er	I-Disease	-1	16565833
T@@	O	-1	16565833
re@@	O	-1	16565833
at	O	-1	16565833
R@@	O	-1	16565833
ep	O	-1	16565833
6@@	O	-1	16565833
2@@	O	-1	16565833
(6@@	O	-1	16565833
)@@	O	-1	16565833
:@@	O	-1	16565833
8@@	O	-1	16565833
6@@	O	-1	16565833
5-@@	O	-1	16565833
8@@	O	-1	16565833
7@@	O	-1	16565833
2,	O	-1	16565833
19@@	O	-1	16565833
7@@	O	-1	16565833
8@@	O	-1	16565833
).	O	-1	16565833
M@@	O	-1	16565833
ic@@	O	-1	16565833
ro@@	O	-1	16565833
sco@@	O	-1	16565833
p@@	O	-1	16565833
ic	O	-1	16565833
evalu@@	O	-1	16565833
ation	O	-1	16565833
revealed	O	-1	16565833
that	O	-1	16565833
treatment	O	-1	16565833
with	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
alone	O	-1	16565833
induced	O	-1	16565833
significant	O	-1	16565833
cardiac	B-Disease	D006331	16565833
damage	I-Disease	-1	16565833
in	O	-1	16565833
compar@@	O	-1	16565833
ison	O	-1	16565833
to	O	-1	16565833
the	O	-1	16565833
saline	O	-1	16565833
control	O	-1	16565833
group	O	-1	16565833
(P@@	O	-1	16565833
<@@	O	-1	16565833
0.00@@	O	-1	16565833
1).	O	-1	16565833
RESULTS:	O	-1	16565833
The	O	-1	16565833
number	O	-1	16565833
of	O	-1	16565833
dam@@	O	-1	16565833
aged	O	-1	16565833
cardi@@	O	-1	16565833
om@@	O	-1	16565833
y@@	O	-1	16565833
ocy@@	O	-1	16565833
tes	O	-1	16565833
was	O	-1	16565833
9.@@	O	-1	16565833
6-@@	O	-1	16565833
fol@@	O	-1	16565833
d	O	-1	16565833
(@@	O	-1	16565833
95%	O	-1	16565833
C@@	O	-1	16565833
I	O	-1	16565833
4.@@	O	-1	16565833
4-@@	O	-1	16565833
2@@	O	-1	16565833
1.@@	O	-1	16565833
0@@	O	-1	16565833
)	O	-1	16565833
higher	O	-1	16565833
in	O	-1	16565833
mice	O	-1	16565833
treated	O	-1	16565833
with	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
alone	O	-1	16565833
than	O	-1	16565833
that	O	-1	16565833
in	O	-1	16565833
animals	O	-1	16565833
of	O	-1	16565833
the	O	-1	16565833
control	O	-1	16565833
group.	O	-1	16565833
The	O	-1	16565833
rati@@	O	-1	16565833
o	O	-1	16565833
of	O	-1	16565833
ab@@	O	-1	16565833
er@@	O	-1	16565833
ran@@	O	-1	16565833
t	O	-1	16565833
cardi@@	O	-1	16565833
om@@	O	-1	16565833
y@@	O	-1	16565833
ocy@@	O	-1	16565833
tes	O	-1	16565833
in	O	-1	16565833
mice	O	-1	16565833
treated	O	-1	16565833
with	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
pre@@	O	-1	16565833
ce@@	O	-1	16565833
ded	O	-1	16565833
by	O	-1	16565833
mon@@	B-Chemical	C522803	16565833
o@@	I-Chemical	-1	16565833
H@@	I-Chemical	-1	16565833
E@@	I-Chemical	-1	16565833
R	I-Chemical	-1	16565833
and	O	-1	16565833
those	O	-1	16565833
in	O	-1	16565833
mice	O	-1	16565833
treated	O	-1	16565833
with	O	-1	16565833
saline	O	-1	16565833
rang@@	O	-1	16565833
ed	O	-1	16565833
from	O	-1	16565833
1.@@	O	-1	16565833
6	O	-1	16565833
to	O	-1	16565833
2.@@	O	-1	16565833
8	O	-1	16565833
(@@	O	-1	16565833
mean	O	-1	16565833
2.@@	O	-1	16565833
2,	O	-1	16565833
95%	O	-1	16565833
C@@	O	-1	16565833
I	O	-1	16565833
1.@@	O	-1	16565833
2-@@	O	-1	16565833
4.@@	O	-1	16565833
1,	O	-1	16565833
P@@	O	-1	16565833
=@@	O	-1	16565833
0.0@@	O	-1	16565833
19@@	O	-1	16565833
).	O	-1	16565833
The	O	-1	16565833
mean	O	-1	16565833
protective	O	-1	16565833
effect	O	-1	16565833
by	O	-1	16565833
ad@@	O	-1	16565833
ding	O	-1	16565833
mon@@	B-Chemical	C522803	16565833
o@@	I-Chemical	-1	16565833
H@@	I-Chemical	-1	16565833
E@@	I-Chemical	-1	16565833
R	I-Chemical	-1	16565833
before	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
l@@	O	-1	16565833
ed	O	-1	16565833
to	O	-1	16565833
a	O	-1	16565833
significant	O	-1	16565833
4.@@	O	-1	16565833
4-@@	O	-1	16565833
fol@@	O	-1	16565833
d	O	-1	16565833
reduction	O	-1	16565833
(P@@	O	-1	16565833
<@@	O	-1	16565833
0.00@@	O	-1	16565833
1,	O	-1	16565833
95%	O	-1	16565833
C@@	O	-1	16565833
I	O	-1	16565833
2.@@	O	-1	16565833
3-@@	O	-1	16565833
8.@@	O	-1	16565833
2)	O	-1	16565833
of	O	-1	16565833
ab@@	O	-1	16565833
normal	O	-1	16565833
cardi@@	O	-1	16565833
om@@	O	-1	16565833
y@@	O	-1	16565833
ocy@@	O	-1	16565833
t@@	O	-1	16565833
es.	O	-1	16565833
This	O	-1	16565833
protective	O	-1	16565833
effect	O	-1	16565833
did	O	-1	16565833
not	O	-1	16565833
depen@@	O	-1	16565833
d	O	-1	16565833
on	O	-1	16565833
the	O	-1	16565833
time	O	-1	16565833
interv@@	O	-1	16565833
al	O	-1	16565833
between	O	-1	16565833
mon@@	B-Chemical	C522803	16565833
o@@	I-Chemical	-1	16565833
H@@	I-Chemical	-1	16565833
E@@	I-Chemical	-1	16565833
R	I-Chemical	-1	16565833
and	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
administration	O	-1	16565833
(P@@	O	-1	16565833
=@@	O	-1	16565833
0.@@	O	-1	16565833
34@@	O	-1	16565833
5@@	O	-1	16565833
).	O	-1	16565833
CONCLUSION:	O	-1	16565833
The	O	-1	16565833
results	O	-1	16565833
indicate	O	-1	16565833
that	O	-1	16565833
in	O	-1	16565833
an	O	-1	16565833
out@@	O	-1	16565833
patient	O	-1	16565833
clinical	O	-1	16565833
se@@	O	-1	16565833
t@@	O	-1	16565833
ting	O	-1	16565833
mon@@	B-Chemical	C522803	16565833
o@@	I-Chemical	-1	16565833
H@@	I-Chemical	-1	16565833
E@@	I-Chemical	-1	16565833
R	I-Chemical	-1	16565833
may	O	-1	16565833
be	O	-1	16565833
administered	O	-1	16565833
sh@@	O	-1	16565833
ort@@	O	-1	16565833
ly	O	-1	16565833
before	O	-1	16565833
DO@@	B-Chemical	D004317	16565833
X	I-Chemical	-1	16565833
.	O	-1	16565833

Clin@@	O	-1	16723784
ical	O	-1	16723784
evalu@@	O	-1	16723784
ation	O	-1	16723784
of	O	-1	16723784
adverse	O	-1	16723784
effects	O	-1	16723784
during	O	-1	16723784
be@@	B-Chemical	D015764	16723784
pri@@	I-Chemical	-1	16723784
di@@	I-Chemical	-1	16723784
l	I-Chemical	-1	16723784
administration	O	-1	16723784
for	O	-1	16723784
atrial	B-Disease	D001281	16723784
fibrill@@	I-Disease	-1	16723784
ation	I-Disease	-1	16723784
and	I-Disease	-1	16723784
f@@	I-Disease	-1	16723784
l@@	I-Disease	-1	16723784
ut@@	I-Disease	-1	16723784
ter	I-Disease	-1	16723784
atrial	B-Disease	D001282	16723784
fibrill@@	I-Disease	-1	16723784
ation	I-Disease	-1	16723784
and	I-Disease	-1	16723784
f@@	I-Disease	-1	16723784
l@@	I-Disease	-1	16723784
ut@@	I-Disease	-1	16723784
ter	I-Disease	-1	16723784
.	O	-1	16723784
BACKGROUND:	O	-1	16723784
B@@	B-Chemical	D015764	16723784
ep@@	I-Chemical	-1	16723784
ri@@	I-Chemical	-1	16723784
di@@	I-Chemical	-1	16723784
l	I-Chemical	-1	16723784
hydro@@	I-Chemical	-1	16723784
chlor@@	I-Chemical	-1	16723784
ide	I-Chemical	-1	16723784
(	O	-1	16723784
B@@	B-Chemical	D015764	16723784
p@@	I-Chemical	-1	16723784
d	I-Chemical	-1	16723784
)	O	-1	16723784
has	O	-1	16723784
at@@	O	-1	16723784
trac@@	O	-1	16723784
ted	O	-1	16723784
atten@@	O	-1	16723784
tion	O	-1	16723784
as	O	-1	16723784
an	O	-1	16723784
effective	O	-1	16723784
drug	O	-1	16723784
for	O	-1	16723784
atrial	B-Disease	D001281	16723784
fibrill@@	I-Disease	-1	16723784
ation	I-Disease	-1	16723784
(	O	-1	16723784
A@@	B-Disease	D001281	16723784
F	I-Disease	-1	16723784
)	O	-1	16723784
and	O	-1	16723784
atrial	B-Disease	D001282	16723784
f@@	I-Disease	-1	16723784
l@@	I-Disease	-1	16723784
ut@@	I-Disease	-1	16723784
ter	I-Disease	-1	16723784
(	O	-1	16723784
A@@	B-Disease	D001282	16723784
F@@	I-Disease	-1	16723784
L	I-Disease	-1	16723784
).	O	-1	16723784
However,	O	-1	16723784
seri@@	O	-1	16723784
ous	O	-1	16723784
adverse	O	-1	16723784
effect@@	O	-1	16723784
s,	O	-1	16723784
including	O	-1	16723784
t@@	B-Disease	D016171	16723784
or@@	I-Disease	-1	16723784
s@@	I-Disease	-1	16723784
ade	I-Disease	-1	16723784
de	I-Disease	-1	16723784
po@@	I-Disease	-1	16723784
int@@	I-Disease	-1	16723784
es	I-Disease	-1	16723784
(	O	-1	16723784
T@@	B-Disease	D016171	16723784
d@@	I-Disease	-1	16723784
p	I-Disease	-1	16723784
),	O	-1	16723784
have	O	-1	16723784
been	O	-1	16723784
repor@@	O	-1	16723784
ted.	O	-1	16723784
METHOD@@	O	-1	16723784
S	O	-1	16723784
AN@@	O	-1	16723784
D	O	-1	16723784
RESULTS:	O	-1	16723784
Ad@@	O	-1	16723784
verse	O	-1	16723784
effects	O	-1	16723784
of	O	-1	16723784
B@@	B-Chemical	D015764	16723784
p@@	I-Chemical	-1	16723784
d	I-Chemical	-1	16723784
requ@@	O	-1	16723784
ir@@	O	-1	16723784
ing	O	-1	16723784
discontinu@@	O	-1	16723784
ation	O	-1	16723784
of	O	-1	16723784
treatment	O	-1	16723784
were	O	-1	16723784
evalu@@	O	-1	16723784
ated.	O	-1	16723784
B@@	B-Chemical	D015764	16723784
p@@	I-Chemical	-1	16723784
d	I-Chemical	-1	16723784
was	O	-1	16723784
administered	O	-1	16723784
to	O	-1	16723784
4@@	O	-1	16723784
5@@	O	-1	16723784
9	O	-1	16723784
patients	O	-1	16723784
(3@@	O	-1	16723784
6@@	O	-1	16723784
1	O	-1	16723784
mal@@	O	-1	16723784
es,	O	-1	16723784
6@@	O	-1	16723784
3@@	O	-1	16723784
+/@@	O	-1	16723784
-1@@	O	-1	16723784
2	O	-1	16723784
years	O	-1	16723784
ol@@	O	-1	16723784
d@@	O	-1	16723784
)	O	-1	16723784
comp@@	O	-1	16723784
ris@@	O	-1	16723784
ing	O	-1	16723784
3@@	O	-1	16723784
7@@	O	-1	16723784
8	O	-1	16723784
A@@	B-Disease	D001281	16723784
F	I-Disease	-1	16723784
and	O	-1	16723784
8@@	O	-1	16723784
1	O	-1	16723784
A@@	B-Disease	D001282	16723784
F@@	I-Disease	-1	16723784
L	I-Disease	-1	16723784
cas@@	O	-1	16723784
es.	O	-1	16723784
M@@	O	-1	16723784
e@@	O	-1	16723784
an	O	-1	16723784
left	O	-1	16723784
ventricular	O	-1	16723784
e@@	O	-1	16723784
j@@	O	-1	16723784
ection	O	-1	16723784
frac@@	O	-1	16723784
tion	O	-1	16723784
and	O	-1	16723784
atrial	O	-1	16723784
di@@	O	-1	16723784
men@@	O	-1	16723784
sion	O	-1	16723784
(@@	O	-1	16723784
L@@	O	-1	16723784
A@@	O	-1	16723784
D)	O	-1	16723784
were	O	-1	16723784
6@@	O	-1	16723784
6@@	O	-1	16723784
+/@@	O	-1	16723784
-1@@	O	-1	16723784
1@@	O	-1	16723784
%	O	-1	16723784
and	O	-1	16723784
4@@	O	-1	16723784
0@@	O	-1	16723784
+/-@@	O	-1	16723784
6	O	-1	16723784
mm@@	O	-1	16723784
,	O	-1	16723784
respectively.	O	-1	16723784
Ad@@	O	-1	16723784
verse	O	-1	16723784
effects	O	-1	16723784
were	O	-1	16723784
observed	O	-1	16723784
in	O	-1	16723784
1@@	O	-1	16723784
9	O	-1	16723784
patients	O	-1	16723784
(4@@	O	-1	16723784
%)	O	-1	16723784
during	O	-1	16723784
an	O	-1	16723784
average	O	-1	16723784
follow-up	O	-1	16723784
of	O	-1	16723784
20	O	-1	16723784
months.	O	-1	16723784
There	O	-1	16723784
was	O	-1	16723784
mark@@	O	-1	16723784
ed	O	-1	16723784
Q@@	B-Disease	D008133	16723784
T	I-Disease	-1	16723784
prolong@@	I-Disease	-1	16723784
ation	I-Disease	-1	16723784
greater	O	-1	16723784
than	O	-1	16723784
0.@@	O	-1	16723784
5@@	O	-1	16723784
5	O	-1	16723784
s	O	-1	16723784
in	O	-1	16723784
13	O	-1	16723784
patients,	O	-1	16723784
brady@@	B-Disease	D001919	16723784
cardia	I-Disease	-1	16723784
less	O	-1	16723784
than	O	-1	16723784
40	O	-1	16723784
be@@	O	-1	16723784
at@@	O	-1	16723784
s/@@	O	-1	16723784
min	O	-1	16723784
in	O	-1	16723784
6	O	-1	16723784
patients,	O	-1	16723784
di@@	B-Disease	D004244	16723784
z@@	I-Disease	-1	16723784
z@@	I-Disease	-1	16723784
in@@	I-Disease	-1	16723784
ess	I-Disease	-1	16723784
and	O	-1	16723784
gener@@	O	-1	16723784
al	O	-1	16723784
f@@	B-Disease	D005221	16723784
ati@@	I-Disease	-1	16723784
gu@@	I-Disease	-1	16723784
e	I-Disease	-1	16723784
in	O	-1	16723784
1	O	-1	16723784
patient	O	-1	16723784
e@@	O	-1	16723784
ac@@	O	-1	16723784
h@@	O	-1	16723784
.	O	-1	16723784
In	O	-1	16723784
4	O	-1	16723784
of	O	-1	16723784
13	O	-1	16723784
patients	O	-1	16723784
with	O	-1	16723784
Q@@	B-Disease	D008133	16723784
T	I-Disease	-1	16723784
prolong@@	I-Disease	-1	16723784
ation	I-Disease	-1	16723784
,	O	-1	16723784
T@@	B-Disease	D016171	16723784
d@@	I-Disease	-1	16723784
p	I-Disease	-1	16723784
occur@@	O	-1	16723784
red.	O	-1	16723784
The	O	-1	16723784
major	O	-1	16723784
tri@@	O	-1	16723784
g@@	O	-1	16723784
g@@	O	-1	16723784
ering	O	-1	16723784
factors	O	-1	16723784
of	O	-1	16723784
T@@	B-Disease	D016171	16723784
d@@	I-Disease	-1	16723784
p	I-Disease	-1	16723784
were	O	-1	16723784
hypo@@	B-Disease	D007008	16723784
k@@	I-Disease	-1	16723784
al@@	I-Disease	-1	16723784
emia	I-Disease	-1	16723784
and	O	-1	16723784
su@@	O	-1	16723784
d@@	O	-1	16723784
de@@	O	-1	16723784
n	O	-1	16723784
decrease	O	-1	16723784
in	O	-1	16723784
heart	O	-1	16723784
rat@@	O	-1	16723784
e.	O	-1	16723784
There	O	-1	16723784
were	O	-1	16723784
no	O	-1	16723784
differences	O	-1	16723784
in	O	-1	16723784
the	O	-1	16723784
clinical	O	-1	16723784
bac@@	O	-1	16723784
kg@@	O	-1	16723784
ro@@	O	-1	16723784
un@@	O	-1	16723784
ds	O	-1	16723784
of	O	-1	16723784
the	O	-1	16723784
patients	O	-1	16723784
with	O	-1	16723784
and	O	-1	16723784
without	O	-1	16723784
T@@	B-Disease	D016171	16723784
d@@	I-Disease	-1	16723784
p	I-Disease	-1	16723784
other	O	-1	16723784
than	O	-1	16723784
L@@	O	-1	16723784
A@@	O	-1	16723784
D	O	-1	16723784
and	O	-1	16723784
age,	O	-1	16723784
which	O	-1	16723784
were	O	-1	16723784
larg@@	O	-1	16723784
er	O	-1	16723784
and	O	-1	16723784
ol@@	O	-1	16723784
der	O	-1	16723784
in	O	-1	16723784
the	O	-1	16723784
patients	O	-1	16723784
with	O	-1	16723784
T@@	B-Disease	D016171	16723784
d@@	I-Disease	-1	16723784
p	I-Disease	-1	16723784
.	O	-1	16723784
CONCLUSION:	O	-1	16723784
Ca@@	O	-1	16723784
ref@@	O	-1	16723784
u@@	O	-1	16723784
l	O	-1	16723784
observ@@	O	-1	16723784
ation	O	-1	16723784
of	O	-1	16723784
serum	O	-1	16723784
pot@@	B-Chemical	D011188	16723784
assi@@	I-Chemical	-1	16723784
um	I-Chemical	-1	16723784
concentration	O	-1	16723784
and	O	-1	16723784
the	O	-1	16723784
EC@@	O	-1	16723784
G	O	-1	16723784
should	O	-1	16723784
al@@	O	-1	16723784
w@@	O	-1	16723784
ays	O	-1	16723784
be	O	-1	16723784
d@@	O	-1	16723784
one	O	-1	16723784
during	O	-1	16723784
B@@	B-Chemical	D015764	16723784
p@@	I-Chemical	-1	16723784
d	I-Chemical	-1	16723784
administr@@	O	-1	16723784
ation,	O	-1	16723784
partic@@	O	-1	16723784
ul@@	O	-1	16723784
arly	O	-1	16723784
in	O	-1	16723784
el@@	O	-1	16723784
der@@	O	-1	16723784
ly	O	-1	16723784
patients.	O	-1	16723784

E@@	O	-1	16731636
n@@	O	-1	16731636
h@@	O	-1	16731636
anced	O	-1	16731636
isoproteren@@	B-Chemical	D007545	16731636
ol	I-Chemical	-1	16731636
-induced	O	-1	16731636
cardiac	B-Disease	D006332	16731636
hyper@@	I-Disease	-1	16731636
tro@@	I-Disease	-1	16731636
ph@@	I-Disease	-1	16731636
y	I-Disease	-1	16731636
in	O	-1	16731636
trans@@	O	-1	16731636
genic	O	-1	16731636
rats	O	-1	16731636
with	O	-1	16731636
low	O	-1	16731636
brain	O	-1	16731636
angiotens@@	O	-1	16731636
ino@@	O	-1	16731636
gen@@	O	-1	16731636
.	O	-1	16731636
We	O	-1	16731636
have	O	-1	16731636
previously	O	-1	16731636
shown	O	-1	16731636
that	O	-1	16731636
a	O	-1	16731636
per@@	O	-1	16731636
man@@	O	-1	16731636
ent	O	-1	16731636
defici@@	O	-1	16731636
ency	O	-1	16731636
in	O	-1	16731636
the	O	-1	16731636
brain	O	-1	16731636
ren@@	O	-1	16731636
in@@	O	-1	16731636
-	O	-1	16731636
angiotens@@	B-Chemical	D000804	16731636
in	I-Chemical	-1	16731636
system	O	-1	16731636
(@@	O	-1	16731636
R@@	O	-1	16731636
A@@	O	-1	16731636
S)	O	-1	16731636
may	O	-1	16731636
increase	O	-1	16731636
the	O	-1	16731636
sensitivity	O	-1	16731636
of	O	-1	16731636
the	O	-1	16731636
b@@	O	-1	16731636
a@@	O	-1	16731636
ro@@	O	-1	16731636
ref@@	O	-1	16731636
le@@	O	-1	16731636
x	O	-1	16731636
control	O	-1	16731636
of	O	-1	16731636
heart	O	-1	16731636
rat@@	O	-1	16731636
e.	O	-1	16731636
In	O	-1	16731636
this	O	-1	16731636
study	O	-1	16731636
we	O	-1	16731636
a@@	O	-1	16731636
im@@	O	-1	16731636
ed	O	-1	16731636
at	O	-1	16731636
stud@@	O	-1	16731636
y@@	O	-1	16731636
ing	O	-1	16731636
the	O	-1	16731636
invol@@	O	-1	16731636
vement	O	-1	16731636
of	O	-1	16731636
the	O	-1	16731636
brain	O	-1	16731636
R@@	O	-1	16731636
A@@	O	-1	16731636
S	O	-1	16731636
in	O	-1	16731636
the	O	-1	16731636
cardiac	O	-1	16731636
re@@	O	-1	16731636
activity	O	-1	16731636
to	O	-1	16731636
the	O	-1	16731636
beta-@@	O	-1	16731636
adren@@	O	-1	16731636
oc@@	O	-1	16731636
e@@	O	-1	16731636
pt@@	O	-1	16731636
or	O	-1	16731636
(@@	O	-1	16731636
beta-@@	O	-1	16731636
A@@	O	-1	16731636
R@@	O	-1	16731636
)	O	-1	16731636
agon@@	O	-1	16731636
ist	O	-1	16731636
isoproteren@@	B-Chemical	D007545	16731636
ol	I-Chemical	-1	16731636
(	O	-1	16731636
I@@	B-Chemical	D007545	16731636
so	I-Chemical	-1	16731636
).	O	-1	16731636
T@@	O	-1	16731636
ran@@	O	-1	16731636
s@@	O	-1	16731636
genic	O	-1	16731636
rats	O	-1	16731636
with	O	-1	16731636
low	O	-1	16731636
brain	O	-1	16731636
angiotens@@	O	-1	16731636
ino@@	O	-1	16731636
gen	O	-1	16731636
(T@@	O	-1	16731636
G@@	O	-1	16731636
R@@	O	-1	16731636
)	O	-1	16731636
were	O	-1	16731636
use@@	O	-1	16731636
d.	O	-1	16731636
In	O	-1	16731636
isol@@	O	-1	16731636
ated	O	-1	16731636
hear@@	O	-1	16731636
t@@	O	-1	16731636
s,	O	-1	16731636
I@@	B-Chemical	D007545	16731636
so	I-Chemical	-1	16731636
induced	O	-1	16731636
a	O	-1	16731636
significantly	O	-1	16731636
greater	O	-1	16731636
increase	O	-1	16731636
in	O	-1	16731636
left	O	-1	16731636
ventricular	O	-1	16731636
(@@	O	-1	16731636
L@@	O	-1	16731636
V@@	O	-1	16731636
)	O	-1	16731636
pressure	O	-1	16731636
and	O	-1	16731636
maxim@@	O	-1	16731636
al	O	-1	16731636
contrac@@	O	-1	16731636
tion	O	-1	16731636
(@@	O	-1	16731636
+@@	O	-1	16731636
d@@	O	-1	16731636
P@@	O	-1	16731636
/@@	O	-1	16731636
d@@	O	-1	16731636
t@@	O	-1	16731636
(@@	O	-1	16731636
ma@@	O	-1	16731636
x@@	O	-1	16731636
)@@	O	-1	16731636
)	O	-1	16731636
in	O	-1	16731636
the	O	-1	16731636
T@@	O	-1	16731636
G@@	O	-1	16731636
R	O	-1	16731636
than	O	-1	16731636
in	O	-1	16731636
the	O	-1	16731636
S@@	O	-1	16731636
pra@@	O	-1	16731636
gu@@	O	-1	16731636
e-@@	O	-1	16731636
D@@	O	-1	16731636
aw@@	O	-1	16731636
le@@	O	-1	16731636
y	O	-1	16731636
(S@@	O	-1	16731636
D)	O	-1	16731636
rats.	O	-1	16731636
L@@	B-Disease	D006332	16731636
V	I-Disease	-1	16731636
hyper@@	I-Disease	-1	16731636
tro@@	I-Disease	-1	16731636
ph@@	I-Disease	-1	16731636
y	I-Disease	-1	16731636
induced	O	-1	16731636
by	O	-1	16731636
I@@	B-Chemical	D007545	16731636
so	I-Chemical	-1	16731636
treatment	O	-1	16731636
was	O	-1	16731636
significantly	O	-1	16731636
higher	O	-1	16731636
in	O	-1	16731636
T@@	O	-1	16731636
G@@	O	-1	16731636
R	O	-1	16731636
than	O	-1	16731636
in	O	-1	16731636
S@@	O	-1	16731636
D	O	-1	16731636
rats	O	-1	16731636
(@@	O	-1	16731636
in	O	-1	16731636
g	O	-1	16731636
L@@	O	-1	16731636
V	O	-1	16731636
w@@	O	-1	16731636
t@@	O	-1	16731636
/@@	O	-1	16731636
100	O	-1	16731636
g	O	-1	16731636
body	O	-1	16731636
w@@	O	-1	16731636
t,	O	-1	16731636
0.@@	O	-1	16731636
2@@	O	-1	16731636
8	O	-1	16731636
+/-	O	-1	16731636
0.00@@	O	-1	16731636
4	O	-1	16731636
vs.	O	-1	16731636
0.@@	O	-1	16731636
24	O	-1	16731636
+/-	O	-1	16731636
0.00@@	O	-1	16731636
4@@	O	-1	16731636
,	O	-1	16731636
respectivel@@	O	-1	16731636
y@@	O	-1	16731636
).	O	-1	16731636
The	O	-1	16731636
greater	O	-1	16731636
L@@	B-Disease	D006332	16731636
V	I-Disease	-1	16731636
hyper@@	I-Disease	-1	16731636
tro@@	I-Disease	-1	16731636
ph@@	I-Disease	-1	16731636
y	I-Disease	-1	16731636
in	O	-1	16731636
T@@	O	-1	16731636
G@@	O	-1	16731636
R	O	-1	16731636
rats	O	-1	16731636
was	O	-1	16731636
associated	O	-1	16731636
with	O	-1	16731636
more	O	-1	16731636
p@@	O	-1	16731636
ron@@	O	-1	16731636
oun@@	O	-1	16731636
c@@	O	-1	16731636
ed	O	-1	16731636
do@@	O	-1	16731636
w@@	O	-1	16731636
n@@	O	-1	16731636
reg@@	O	-1	16731636
ulation	O	-1	16731636
of	O	-1	16731636
beta-@@	O	-1	16731636
A@@	O	-1	16731636
R	O	-1	16731636
and	O	-1	16731636
u@@	O	-1	16731636
pre@@	O	-1	16731636
g@@	O	-1	16731636
ulation	O	-1	16731636
of	O	-1	16731636
L@@	O	-1	16731636
V	O	-1	16731636
beta-@@	O	-1	16731636
A@@	O	-1	16731636
R	O	-1	16731636
kin@@	O	-1	16731636
as@@	O	-1	16731636
e-@@	O	-1	16731636
1	O	-1	16731636
mRNA	O	-1	16731636
levels	O	-1	16731636
compared	O	-1	16731636
with	O	-1	16731636
those	O	-1	16731636
in	O	-1	16731636
S@@	O	-1	16731636
D	O	-1	16731636
rats.	O	-1	16731636
The	O	-1	16731636
decrease	O	-1	16731636
in	O	-1	16731636
the	O	-1	16731636
heart	O	-1	16731636
rate	O	-1	16731636
(@@	O	-1	16731636
H@@	O	-1	16731636
R@@	O	-1	16731636
)	O	-1	16731636
induced	O	-1	16731636
by	O	-1	16731636
the	O	-1	16731636
beta-@@	O	-1	16731636
A@@	O	-1	16731636
R	O	-1	16731636
antagonist	O	-1	16731636
me@@	B-Chemical	D008790	16731636
to@@	I-Chemical	-1	16731636
pro@@	I-Chemical	-1	16731636
lol	I-Chemical	-1	16731636
in	O	-1	16731636
con@@	O	-1	16731636
s@@	O	-1	16731636
ci@@	O	-1	16731636
ous	O	-1	16731636
rats	O	-1	16731636
was	O	-1	16731636
significantly	O	-1	16731636
attenu@@	O	-1	16731636
ated	O	-1	16731636
in	O	-1	16731636
T@@	O	-1	16731636
G@@	O	-1	16731636
R	O	-1	16731636
compared	O	-1	16731636
with	O	-1	16731636
S@@	O	-1	16731636
D	O	-1	16731636
rats	O	-1	16731636
(-@@	O	-1	16731636
9.@@	O	-1	16731636
9	O	-1	16731636
+/-	O	-1	16731636
1.@@	O	-1	16731636
7@@	O	-1	16731636
%	O	-1	16731636
vs.	O	-1	16731636
-1@@	O	-1	16731636
8.@@	O	-1	16731636
1	O	-1	16731636
+/-	O	-1	16731636
1.@@	O	-1	16731636
5@@	O	-1	16731636
%),	O	-1	16731636
whereas	O	-1	16731636
the	O	-1	16731636
effect	O	-1	16731636
of	O	-1	16731636
par@@	O	-1	16731636
as@@	O	-1	16731636
ym@@	O	-1	16731636
pa@@	O	-1	16731636
thetic	O	-1	16731636
block@@	O	-1	16731636
ade	O	-1	16731636
by	O	-1	16731636
atro@@	B-Chemical	D001285	16731636
pine	I-Chemical	-1	16731636
on	O	-1	16731636
H@@	O	-1	16731636
R	O	-1	16731636
was	O	-1	16731636
similar	O	-1	16731636
in	O	-1	16731636
both	O	-1	16731636
stra@@	O	-1	16731636
in@@	O	-1	16731636
s.	O	-1	16731636
These	O	-1	16731636
results	O	-1	16731636
indicate	O	-1	16731636
that	O	-1	16731636
T@@	O	-1	16731636
G@@	O	-1	16731636
R	O	-1	16731636
are	O	-1	16731636
more	O	-1	16731636
sensitive	O	-1	16731636
to	O	-1	16731636
beta-@@	O	-1	16731636
A@@	O	-1	16731636
R	O	-1	16731636
agon@@	O	-1	16731636
ist@@	O	-1	16731636
-induced	O	-1	16731636
cardiac	B-Disease	D006331	16731636
in@@	I-Disease	-1	16731636
ot@@	I-Disease	-1	16731636
ro@@	I-Disease	-1	16731636
p@@	I-Disease	-1	16731636
ic	I-Disease	-1	16731636
response	O	-1	16731636
and	O	-1	16731636
hyper@@	B-Disease	D006984	16731636
tro@@	I-Disease	-1	16731636
ph@@	I-Disease	-1	16731636
y	I-Disease	-1	16731636
,	O	-1	16731636
possib@@	O	-1	16731636
ly	O	-1	16731636
due	O	-1	16731636
to	O	-1	16731636
chron@@	O	-1	16731636
ically	O	-1	16731636
low	O	-1	16731636
sym@@	O	-1	16731636
pa@@	O	-1	16731636
thetic	O	-1	16731636
out@@	O	-1	16731636
flow	O	-1	16731636
direc@@	O	-1	16731636
ted	O	-1	16731636
to	O	-1	16731636
the	O	-1	16731636
hear@@	O	-1	16731636
t.	O	-1	16731636

D@@	O	-1	16801510
ru@@	O	-1	16801510
g@@	O	-1	16801510
-induced	O	-1	16801510
lon@@	B-Disease	D008133	16801510
g	I-Disease	-1	16801510
Q@@	I-Disease	-1	16801510
T	I-Disease	-1	16801510
syndrome	I-Disease	-1	16801510
in	O	-1	16801510
injection	O	-1	16801510
drug	O	-1	16801510
users	O	-1	16801510
receiving	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
:	O	-1	16801510
high	O	-1	16801510
frequency	O	-1	16801510
in	O	-1	16801510
hospit@@	O	-1	16801510
al@@	O	-1	16801510
ized	O	-1	16801510
patients	O	-1	16801510
and	O	-1	16801510
risk	O	-1	16801510
fact@@	O	-1	16801510
or@@	O	-1	16801510
s.	O	-1	16801510
BACKGROUND:	O	-1	16801510
D@@	O	-1	16801510
ru@@	O	-1	16801510
g@@	O	-1	16801510
-induced	O	-1	16801510
lon@@	B-Disease	D008133	16801510
g	I-Disease	-1	16801510
Q@@	I-Disease	-1	16801510
T	I-Disease	-1	16801510
syndrome	I-Disease	-1	16801510
is	O	-1	16801510
a	O	-1	16801510
seri@@	O	-1	16801510
ous	O	-1	16801510
adverse	O	-1	16801510
drug	O	-1	16801510
reac@@	O	-1	16801510
tion.	O	-1	16801510
M@@	B-Chemical	D008691	16801510
eth@@	I-Chemical	-1	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
prolong@@	O	-1	16801510
s	O	-1	16801510
the	O	-1	16801510
Q@@	O	-1	16801510
T	O	-1	16801510
interv@@	O	-1	16801510
al	O	-1	16801510
in	O	-1	16801510
vit@@	O	-1	16801510
r@@	O	-1	16801510
o	O	-1	16801510
in	O	-1	16801510
a	O	-1	16801510
dose-@@	O	-1	16801510
dependent	O	-1	16801510
man@@	O	-1	16801510
ner@@	O	-1	16801510
.	O	-1	16801510
In	O	-1	16801510
the	O	-1	16801510
in@@	O	-1	16801510
patient	O	-1	16801510
se@@	O	-1	16801510
t@@	O	-1	16801510
t@@	O	-1	16801510
ing,	O	-1	16801510
the	O	-1	16801510
frequency	O	-1	16801510
of	O	-1	16801510
Q@@	B-Disease	D008133	16801510
T	I-Disease	-1	16801510
interv@@	I-Disease	-1	16801510
al	I-Disease	-1	16801510
prolong@@	I-Disease	-1	16801510
ation	I-Disease	-1	16801510
with	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
treatment,	O	-1	16801510
its	O	-1	16801510
dose	O	-1	16801510
depend@@	O	-1	16801510
ence@@	O	-1	16801510
,	O	-1	16801510
and	O	-1	16801510
the	O	-1	16801510
import@@	O	-1	16801510
ance	O	-1	16801510
of	O	-1	16801510
co@@	O	-1	16801510
factors	O	-1	16801510
such	O	-1	16801510
as	O	-1	16801510
drug@@	O	-1	16801510
-@@	O	-1	16801510
drug	O	-1	16801510
inter@@	O	-1	16801510
ac@@	O	-1	16801510
tions	O	-1	16801510
re@@	O	-1	16801510
ma@@	O	-1	16801510
in	O	-1	16801510
un@@	O	-1	16801510
know@@	O	-1	16801510
n@@	O	-1	16801510
.	O	-1	16801510
METHODS:	O	-1	16801510
We	O	-1	16801510
performed	O	-1	16801510
a	O	-1	16801510
system@@	O	-1	16801510
ati@@	O	-1	16801510
c@@	O	-1	16801510
,	O	-1	16801510
ret@@	O	-1	16801510
ro@@	O	-1	16801510
sp@@	O	-1	16801510
ective	O	-1	16801510
study	O	-1	16801510
compar@@	O	-1	16801510
ing	O	-1	16801510
active	O	-1	16801510
or	O	-1	16801510
form@@	O	-1	16801510
er	O	-1	16801510
intravenous	O	-1	16801510
drug	O	-1	16801510
users	O	-1	16801510
receiving	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
and	O	-1	16801510
those	O	-1	16801510
not	O	-1	16801510
receiving	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
among	O	-1	16801510
all	O	-1	16801510
patients	O	-1	16801510
hospit@@	O	-1	16801510
al@@	O	-1	16801510
ized	O	-1	16801510
over	O	-1	16801510
a	O	-1	16801510
5-@@	O	-1	16801510
year	O	-1	16801510
period	O	-1	16801510
in	O	-1	16801510
a	O	-1	16801510
ter@@	O	-1	16801510
ti@@	O	-1	16801510
ary	O	-1	16801510
car@@	O	-1	16801510
e	O	-1	16801510
hospit@@	O	-1	16801510
al.	O	-1	16801510
A	O	-1	16801510
total	O	-1	16801510
of	O	-1	16801510
1@@	O	-1	16801510
6@@	O	-1	16801510
7	O	-1	16801510
patients	O	-1	16801510
receiving	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
ful@@	O	-1	16801510
f@@	O	-1	16801510
ill@@	O	-1	16801510
ed	O	-1	16801510
the	O	-1	16801510
inc@@	O	-1	16801510
lu@@	O	-1	16801510
sion	O	-1	16801510
c@@	O	-1	16801510
rit@@	O	-1	16801510
er@@	O	-1	16801510
ia	O	-1	16801510
and	O	-1	16801510
were	O	-1	16801510
compared	O	-1	16801510
with	O	-1	16801510
a	O	-1	16801510
control	O	-1	16801510
group	O	-1	16801510
of	O	-1	16801510
8@@	O	-1	16801510
0	O	-1	16801510
injection	O	-1	16801510
drug	O	-1	16801510
users	O	-1	16801510
not	O	-1	16801510
receiving	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
.	O	-1	16801510
In	O	-1	16801510
addition	O	-1	16801510
to	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
dose@@	O	-1	16801510
,	O	-1	16801510
15	O	-1	16801510
de@@	O	-1	16801510
mo@@	O	-1	16801510
graph@@	O	-1	16801510
ic@@	O	-1	16801510
,	O	-1	16801510
bio@@	O	-1	16801510
log@@	O	-1	16801510
ic@@	O	-1	16801510
al,	O	-1	16801510
and	O	-1	16801510
pharmac@@	O	-1	16801510
ological	O	-1	16801510
vari@@	O	-1	16801510
able@@	O	-1	16801510
s	O	-1	16801510
were	O	-1	16801510
considered	O	-1	16801510
as	O	-1	16801510
potential	O	-1	16801510
risk	O	-1	16801510
factors	O	-1	16801510
for	O	-1	16801510
Q@@	B-Disease	D008133	16801510
T	I-Disease	-1	16801510
prolong@@	I-Disease	-1	16801510
ation	I-Disease	-1	16801510
.	O	-1	16801510
RESULTS:	O	-1	16801510
A@@	O	-1	16801510
mon@@	O	-1	16801510
g	O	-1	16801510
1@@	O	-1	16801510
6@@	O	-1	16801510
7	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
maint@@	O	-1	16801510
en@@	O	-1	16801510
ance	O	-1	16801510
patients,	O	-1	16801510
the	O	-1	16801510
prev@@	O	-1	16801510
al@@	O	-1	16801510
ence	O	-1	16801510
of	O	-1	16801510
Q@@	O	-1	16801510
T@@	O	-1	16801510
c	O	-1	16801510
prolong@@	O	-1	16801510
ation	O	-1	16801510
to	O	-1	16801510
0.@@	O	-1	16801510
50	O	-1	16801510
second@@	O	-1	16801510
(@@	O	-1	16801510
(1@@	O	-1	16801510
/@@	O	-1	16801510
2@@	O	-1	16801510
)@@	O	-1	16801510
)	O	-1	16801510
or	O	-1	16801510
long@@	O	-1	16801510
er	O	-1	16801510
was	O	-1	16801510
1@@	O	-1	16801510
6.@@	O	-1	16801510
2@@	O	-1	16801510
%	O	-1	16801510
compared	O	-1	16801510
with	O	-1	16801510
0%	O	-1	16801510
in	O	-1	16801510
8@@	O	-1	16801510
0	O	-1	16801510
control	O	-1	16801510
subj@@	O	-1	16801510
ect@@	O	-1	16801510
s.	O	-1	16801510
Si@@	O	-1	16801510
x	O	-1	16801510
patients	O	-1	16801510
(@@	O	-1	16801510
3.@@	O	-1	16801510
6@@	O	-1	16801510
%)	O	-1	16801510
in	O	-1	16801510
the	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
group	O	-1	16801510
presented	O	-1	16801510
t@@	B-Disease	D016171	16801510
or@@	I-Disease	-1	16801510
sa@@	I-Disease	-1	16801510
des	I-Disease	-1	16801510
de	I-Disease	-1	16801510
po@@	I-Disease	-1	16801510
int@@	I-Disease	-1	16801510
es	I-Disease	-1	16801510
.	O	-1	16801510
Q@@	O	-1	16801510
T@@	O	-1	16801510
c	O	-1	16801510
l@@	O	-1	16801510
en@@	O	-1	16801510
g@@	O	-1	16801510
th	O	-1	16801510
was	O	-1	16801510
we@@	O	-1	16801510
ak@@	O	-1	16801510
ly	O	-1	16801510
but	O	-1	16801510
significantly	O	-1	16801510
associated	O	-1	16801510
with	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
daily	O	-1	16801510
dose	O	-1	16801510
(S@@	O	-1	16801510
p@@	O	-1	16801510
ear@@	O	-1	16801510
man	O	-1	16801510
ran@@	O	-1	16801510
k	O	-1	16801510
correl@@	O	-1	16801510
ation	O	-1	16801510
co@@	O	-1	16801510
eff@@	O	-1	16801510
ici@@	O	-1	16801510
ent@@	O	-1	16801510
,	O	-1	16801510
0.@@	O	-1	16801510
20@@	O	-1	16801510
;	O	-1	16801510
P@@	O	-1	16801510
<@@	O	-1	16801510
.@@	O	-1	16801510
0@@	O	-1	16801510
1).	O	-1	16801510
M@@	O	-1	16801510
ul@@	O	-1	16801510
tiv@@	O	-1	16801510
ari@@	O	-1	16801510
ate	O	-1	16801510
reg@@	O	-1	16801510
res@@	O	-1	16801510
sion	O	-1	16801510
analysis	O	-1	16801510
al@@	O	-1	16801510
low@@	O	-1	16801510
ed	O	-1	16801510
at@@	O	-1	16801510
tri@@	O	-1	16801510
bu@@	O	-1	16801510
tion	O	-1	16801510
of	O	-1	16801510
3@@	O	-1	16801510
1.@@	O	-1	16801510
8@@	O	-1	16801510
%	O	-1	16801510
of	O	-1	16801510
Q@@	O	-1	16801510
T@@	O	-1	16801510
c	O	-1	16801510
vari@@	O	-1	16801510
ability	O	-1	16801510
to	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
dose@@	O	-1	16801510
,	O	-1	16801510
cyto@@	O	-1	16801510
ch@@	O	-1	16801510
rom@@	O	-1	16801510
e	O	-1	16801510
P@@	O	-1	16801510
-@@	O	-1	16801510
4@@	O	-1	16801510
50	O	-1	16801510
3@@	O	-1	16801510
A@@	O	-1	16801510
4	O	-1	16801510
drug@@	O	-1	16801510
-@@	O	-1	16801510
drug	O	-1	16801510
inter@@	O	-1	16801510
ac@@	O	-1	16801510
tion@@	O	-1	16801510
s,	O	-1	16801510
hypo@@	B-Disease	D007008	16801510
k@@	I-Disease	-1	16801510
al@@	I-Disease	-1	16801510
emia	I-Disease	-1	16801510
,	O	-1	16801510
and	O	-1	16801510
al@@	O	-1	16801510
te@@	O	-1	16801510
red	O	-1	16801510
liver	O	-1	16801510
func@@	O	-1	16801510
tion.	O	-1	16801510
CONCLUSIONS:	O	-1	16801510
Q@@	B-Disease	D008133	16801510
T	I-Disease	-1	16801510
interv@@	I-Disease	-1	16801510
al	I-Disease	-1	16801510
prolong@@	I-Disease	-1	16801510
ation	I-Disease	-1	16801510
in	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
maint@@	O	-1	16801510
en@@	O	-1	16801510
ance	O	-1	16801510
patients	O	-1	16801510
hospit@@	O	-1	16801510
al@@	O	-1	16801510
ized	O	-1	16801510
in	O	-1	16801510
a	O	-1	16801510
ter@@	O	-1	16801510
ti@@	O	-1	16801510
ary	O	-1	16801510
car@@	O	-1	16801510
e	O	-1	16801510
c@@	O	-1	16801510
ent@@	O	-1	16801510
er	O	-1	16801510
is	O	-1	16801510
a	O	-1	16801510
frequent	O	-1	16801510
find@@	O	-1	16801510
ing.	O	-1	16801510
M@@	B-Chemical	D008691	16801510
eth@@	I-Chemical	-1	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
dose@@	O	-1	16801510
,	O	-1	16801510
presence	O	-1	16801510
of	O	-1	16801510
cyto@@	O	-1	16801510
ch@@	O	-1	16801510
rom@@	O	-1	16801510
e	O	-1	16801510
P@@	O	-1	16801510
-@@	O	-1	16801510
4@@	O	-1	16801510
50	O	-1	16801510
3@@	O	-1	16801510
A@@	O	-1	16801510
4	O	-1	16801510
inhibitor@@	O	-1	16801510
s,	O	-1	16801510
pot@@	B-Chemical	D011188	16801510
assi@@	I-Chemical	-1	16801510
um	I-Chemical	-1	16801510
level@@	O	-1	16801510
,	O	-1	16801510
and	O	-1	16801510
liver	O	-1	16801510
function	O	-1	16801510
cont@@	O	-1	16801510
rib@@	O	-1	16801510
ute	O	-1	16801510
to	O	-1	16801510
Q@@	B-Disease	D008133	16801510
T	I-Disease	-1	16801510
prolong@@	I-Disease	-1	16801510
ation	I-Disease	-1	16801510
.	O	-1	16801510
L@@	B-Disease	D008133	16801510
ong	I-Disease	-1	16801510
Q@@	I-Disease	-1	16801510
T	I-Disease	-1	16801510
syndrome	I-Disease	-1	16801510
can	O	-1	16801510
occ@@	O	-1	16801510
ur	O	-1	16801510
with	O	-1	16801510
low	O	-1	16801510
doses	O	-1	16801510
of	O	-1	16801510
meth@@	B-Chemical	D008691	16801510
ad@@	I-Chemical	-1	16801510
one	I-Chemical	-1	16801510
.	O	-1	16801510

M@@	O	-1	16810074
echan@@	O	-1	16810074
is@@	O	-1	16810074
ms	O	-1	16810074
of	O	-1	16810074
hypertension	B-Disease	D006973	16810074
induced	O	-1	16810074
by	O	-1	16810074
nit@@	B-Chemical	D009569	16810074
ric	I-Chemical	-1	16810074
ox@@	I-Chemical	-1	16810074
ide	I-Chemical	-1	16810074
(	O	-1	16810074
N@@	B-Chemical	D009569	16810074
O	I-Chemical	-1	16810074
)	O	-1	16810074
defici@@	O	-1	16810074
enc@@	O	-1	16810074
y@@	O	-1	16810074
:	O	-1	16810074
foc@@	O	-1	16810074
us	O	-1	16810074
on	O	-1	16810074
venous	O	-1	16810074
func@@	O	-1	16810074
tion.	O	-1	16810074
L@@	O	-1	16810074
os@@	O	-1	16810074
s	O	-1	16810074
of	O	-1	16810074
endothelial	O	-1	16810074
cell@@	O	-1	16810074
-@@	O	-1	16810074
der@@	O	-1	16810074
i@@	O	-1	16810074
ved	O	-1	16810074
nit@@	B-Chemical	D009569	16810074
ric	I-Chemical	-1	16810074
ox@@	I-Chemical	-1	16810074
ide	I-Chemical	-1	16810074
(	O	-1	16810074
N@@	B-Chemical	D009569	16810074
O	I-Chemical	-1	16810074
)	O	-1	16810074
in	O	-1	16810074
hypertension	B-Disease	D006973	16810074
is	O	-1	16810074
a	O	-1	16810074
h@@	O	-1	16810074
all@@	O	-1	16810074
m@@	O	-1	16810074
ar@@	O	-1	16810074
k	O	-1	16810074
of	O	-1	16810074
arterial	B-Disease	D018754	16810074
dysfunction	I-Disease	-1	16810074
.	O	-1	16810074
E@@	O	-1	16810074
x@@	O	-1	16810074
per@@	O	-1	16810074
im@@	O	-1	16810074
ental	O	-1	16810074
hypertension	B-Disease	D006973	16810074
cre@@	O	-1	16810074
ated	O	-1	16810074
by	O	-1	16810074
the	O	-1	16810074
re@@	O	-1	16810074
mo@@	O	-1	16810074
v@@	O	-1	16810074
al	O	-1	16810074
of	O	-1	16810074
N@@	B-Chemical	D009569	16810074
O	I-Chemical	-1	16810074
,	O	-1	16810074
however,	O	-1	16810074
invol@@	O	-1	16810074
v@@	O	-1	16810074
es	O	-1	16810074
mechanisms	O	-1	16810074
in	O	-1	16810074
addition	O	-1	16810074
to	O	-1	16810074
decreased	O	-1	16810074
arterial	O	-1	16810074
vas@@	O	-1	16810074
odi@@	O	-1	16810074
lat@@	O	-1	16810074
or	O	-1	16810074
activ@@	O	-1	16810074
ity.	O	-1	16810074
These	O	-1	16810074
includ@@	O	-1	16810074
e	O	-1	16810074
au@@	O	-1	16810074
g@@	O	-1	16810074
ment@@	O	-1	16810074
ed	O	-1	16810074
endo@@	O	-1	16810074
the@@	O	-1	16810074
l@@	O	-1	16810074
in-@@	O	-1	16810074
1	O	-1	16810074
(@@	O	-1	16810074
ET@@	O	-1	16810074
-1@@	O	-1	16810074
)	O	-1	16810074
rele@@	O	-1	16810074
ase,	O	-1	16810074
increased	O	-1	16810074
sym@@	O	-1	16810074
pa@@	O	-1	16810074
thetic	O	-1	16810074
ner@@	O	-1	16810074
v@@	O	-1	16810074
ous	O	-1	16810074
system	O	-1	16810074
activ@@	O	-1	16810074
ity,	O	-1	16810074
and	O	-1	16810074
elevated	O	-1	16810074
tissue	O	-1	16810074
oxid@@	O	-1	16810074
ative	O	-1	16810074
stres@@	O	-1	16810074
s.	O	-1	16810074
We	O	-1	16810074
hypo@@	O	-1	16810074
the@@	O	-1	16810074
si@@	O	-1	16810074
zed	O	-1	16810074
that	O	-1	16810074
increased	O	-1	16810074
venous	O	-1	16810074
smo@@	O	-1	16810074
oth	O	-1	16810074
musc@@	O	-1	16810074
le	O	-1	16810074
(@@	O	-1	16810074
ven@@	O	-1	16810074
om@@	O	-1	16810074
ot@@	O	-1	16810074
or@@	O	-1	16810074
)	O	-1	16810074
t@@	O	-1	16810074
one	O	-1	16810074
pl@@	O	-1	16810074
ays	O	-1	16810074
a	O	-1	16810074
role	O	-1	16810074
in	O	-1	16810074
N@@	B-Chemical	D019335	16810074
o@@	I-Chemical	-1	16810074
me@@	I-Chemical	-1	16810074
g@@	I-Chemical	-1	16810074
a@@	I-Chemical	-1	16810074
-@@	I-Chemical	-1	16810074
nitro@@	I-Chemical	-1	16810074
-@@	I-Chemical	-1	16810074
L-@@	I-Chemical	-1	16810074
arg@@	I-Chemical	-1	16810074
inine	I-Chemical	-1	16810074
(	O	-1	16810074
L@@	B-Chemical	D019335	16810074
N@@	I-Chemical	-1	16810074
NA	I-Chemical	-1	16810074
)	O	-1	16810074
hypertension	B-Disease	D006973	16810074
through	O	-1	16810074
these	O	-1	16810074
mechanis@@	O	-1	16810074
m@@	O	-1	16810074
s.	O	-1	16810074
R@@	O	-1	16810074
at@@	O	-1	16810074
s	O	-1	16810074
were	O	-1	16810074
treated	O	-1	16810074
with	O	-1	16810074
the	O	-1	16810074
N@@	B-Chemical	D009569	16810074
O	I-Chemical	-1	16810074
syn@@	O	-1	16810074
th@@	O	-1	16810074
ase	O	-1	16810074
inhibitor	O	-1	16810074
L@@	B-Chemical	D019335	16810074
N@@	I-Chemical	-1	16810074
NA	I-Chemical	-1	16810074
(0.@@	O	-1	16810074
5	O	-1	16810074
g/@@	O	-1	16810074
L	O	-1	16810074
in	O	-1	16810074
d@@	O	-1	16810074
r@@	O	-1	16810074
in@@	O	-1	16810074
king	O	-1	16810074
w@@	O	-1	16810074
at@@	O	-1	16810074
er@@	O	-1	16810074
)	O	-1	16810074
for	O	-1	16810074
2	O	-1	16810074
week@@	O	-1	16810074
s.	O	-1	16810074
M@@	O	-1	16810074
e@@	O	-1	16810074
an	O	-1	16810074
arterial	O	-1	16810074
pressure	O	-1	16810074
of	O	-1	16810074
con@@	O	-1	16810074
s@@	O	-1	16810074
ci@@	O	-1	16810074
ous	O	-1	16810074
rats	O	-1	16810074
was	O	-1	16810074
1@@	O	-1	16810074
1@@	O	-1	16810074
9	O	-1	16810074
+/-	O	-1	16810074
2	O	-1	16810074
mm	O	-1	16810074
H@@	O	-1	16810074
g	O	-1	16810074
in	O	-1	16810074
control	O	-1	16810074
and	O	-1	16810074
19@@	O	-1	16810074
4	O	-1	16810074
+/-	O	-1	16810074
5	O	-1	16810074
mm	O	-1	16810074
H@@	O	-1	16810074
g	O	-1	16810074
in	O	-1	16810074
L@@	B-Chemical	D019335	16810074
N@@	I-Chemical	-1	16810074
NA	I-Chemical	-1	16810074
rats	O	-1	16810074
(P@@	O	-1	16810074
<@@	O	-1	16810074
0.05@@	O	-1	16810074
).	O	-1	16810074
Ca@@	O	-1	16810074
ro@@	O	-1	16810074
ti@@	O	-1	16810074
d	O	-1	16810074
arter@@	O	-1	16810074
i@@	O	-1	16810074
es	O	-1	16810074
and	O	-1	16810074
ven@@	O	-1	16810074
a	O	-1	16810074
ca@@	O	-1	16810074
v@@	O	-1	16810074
a	O	-1	16810074
were	O	-1	16810074
re@@	O	-1	16810074
mo@@	O	-1	16810074
ved	O	-1	16810074
for	O	-1	16810074
meas@@	O	-1	16810074
ure@@	O	-1	16810074
ment	O	-1	16810074
of	O	-1	16810074
iso@@	O	-1	16810074
me@@	O	-1	16810074
tri@@	O	-1	16810074
c	O	-1	16810074
contrac@@	O	-1	16810074
tion.	O	-1	16810074
M@@	O	-1	16810074
ax@@	O	-1	16810074
im@@	O	-1	16810074
al	O	-1	16810074
contrac@@	O	-1	16810074
tion	O	-1	16810074
to	O	-1	16810074
no@@	B-Chemical	D009638	16810074
re@@	I-Chemical	-1	16810074
p@@	I-Chemical	-1	16810074
ine@@	I-Chemical	-1	16810074
phrine	I-Chemical	-1	16810074
was	O	-1	16810074
mode@@	O	-1	16810074
st@@	O	-1	16810074
ly	O	-1	16810074
reduced	O	-1	16810074
in	O	-1	16810074
arter@@	O	-1	16810074
i@@	O	-1	16810074
es	O	-1	16810074
from	O	-1	16810074
L@@	B-Chemical	D019335	16810074
N@@	I-Chemical	-1	16810074
NA	I-Chemical	-1	16810074
compared	O	-1	16810074
with	O	-1	16810074
control	O	-1	16810074
rats	O	-1	16810074
whereas	O	-1	16810074
the	O	-1	16810074
maxim@@	O	-1	16810074
um	O	-1	16810074
contrac@@	O	-1	16810074
tion	O	-1	16810074
to	O	-1	16810074
ET@@	O	-1	16810074
-1	O	-1	16810074
was	O	-1	16810074
significantly	O	-1	16810074
reduced	O	-1	16810074
(5@@	O	-1	16810074
4@@	O	-1	16810074
%	O	-1	16810074
control@@	O	-1	16810074
).	O	-1	16810074
M@@	O	-1	16810074
ax@@	O	-1	16810074
im@@	O	-1	16810074
um	O	-1	16810074
contrac@@	O	-1	16810074
tion	O	-1	16810074
of	O	-1	16810074
ven@@	O	-1	16810074
a	O	-1	16810074
ca@@	O	-1	16810074
v@@	O	-1	16810074
a	O	-1	16810074
to	O	-1	16810074
no@@	B-Chemical	D009638	16810074
re@@	I-Chemical	-1	16810074
p@@	I-Chemical	-1	16810074
ine@@	I-Chemical	-1	16810074
phrine	I-Chemical	-1	16810074
(3@@	O	-1	16810074
7@@	O	-1	16810074
%	O	-1	16810074
control@@	O	-1	16810074
)	O	-1	16810074
also	O	-1	16810074
was	O	-1	16810074
reduced	O	-1	16810074
but	O	-1	16810074
no	O	-1	16810074
change	O	-1	16810074
in	O	-1	16810074
response	O	-1	16810074
to	O	-1	16810074
ET@@	O	-1	16810074
-1	O	-1	16810074
was	O	-1	16810074
obser@@	O	-1	16810074
ved.	O	-1	16810074
M@@	O	-1	16810074
e@@	O	-1	16810074
an	O	-1	16810074
cir@@	O	-1	16810074
cul@@	O	-1	16810074
atory	O	-1	16810074
f@@	O	-1	16810074
ill@@	O	-1	16810074
ing	O	-1	16810074
pressu@@	O	-1	16810074
re,	O	-1	16810074
an	O	-1	16810074
in	O	-1	16810074
viv@@	O	-1	16810074
o	O	-1	16810074
meas@@	O	-1	16810074
ure	O	-1	16810074
of	O	-1	16810074
ven@@	O	-1	16810074
om@@	O	-1	16810074
otor	O	-1	16810074
t@@	O	-1	16810074
one,	O	-1	16810074
was	O	-1	16810074
not	O	-1	16810074
elevated	O	-1	16810074
in	O	-1	16810074
L@@	B-Chemical	D019335	16810074
N@@	I-Chemical	-1	16810074
NA	I-Chemical	-1	16810074
hypertension	B-Disease	D006973	16810074
at	O	-1	16810074
1	O	-1	16810074
or	O	-1	16810074
2	O	-1	16810074
weeks	O	-1	16810074
after	O	-1	16810074
L@@	B-Chemical	D019335	16810074
N@@	I-Chemical	-1	16810074
NA	I-Chemical	-1	16810074
.	O	-1	16810074
The	O	-1	16810074
su@@	B-Chemical	D013481	16810074
per@@	I-Chemical	-1	16810074
ox@@	I-Chemical	-1	16810074
ide	I-Chemical	-1	16810074
s@@	O	-1	16810074
ca@@	O	-1	16810074
ven@@	O	-1	16810074
g@@	O	-1	16810074
er	O	-1	16810074
tem@@	B-Chemical	C001803	16810074
po@@	I-Chemical	-1	16810074
l	I-Chemical	-1	16810074
(3@@	O	-1	16810074
0@@	O	-1	16810074
,	O	-1	16810074
10@@	O	-1	16810074
0@@	O	-1	16810074
,	O	-1	16810074
and	O	-1	16810074
3@@	O	-1	16810074
00	O	-1	16810074
micro@@	O	-1	16810074
mo@@	O	-1	16810074
l	O	-1	16810074
kg@@	O	-1	16810074
(@@	O	-1	16810074
-1@@	O	-1	16810074
),	O	-1	16810074
I@@	O	-1	16810074
V@@	O	-1	16810074
)	O	-1	16810074
did	O	-1	16810074
not	O	-1	16810074
change	O	-1	16810074
arterial	O	-1	16810074
pressure	O	-1	16810074
in	O	-1	16810074
control	O	-1	16810074
rats	O	-1	16810074
but	O	-1	16810074
caused	O	-1	16810074
a	O	-1	16810074
dose-@@	O	-1	16810074
dependent	O	-1	16810074
decrease	O	-1	16810074
in	O	-1	16810074
L@@	B-Chemical	D019335	16810074
N@@	I-Chemical	-1	16810074
NA	I-Chemical	-1	16810074
rats	O	-1	16810074
(@@	O	-1	16810074
-1@@	O	-1	16810074
8	O	-1	16810074
+/-	O	-1	16810074
8@@	O	-1	16810074
,	O	-1	16810074
-@@	O	-1	16810074
2@@	O	-1	16810074
6	O	-1	16810074
+/-	O	-1	16810074
1@@	O	-1	16810074
5,	O	-1	16810074
and	O	-1	16810074
-@@	O	-1	16810074
5@@	O	-1	16810074
4	O	-1	16810074
+/-	O	-1	16810074
11	O	-1	16810074
mm	O	-1	16810074
H@@	O	-1	16810074
g@@	O	-1	16810074
).	O	-1	16810074
S@@	O	-1	16810074
im@@	O	-1	16810074
il@@	O	-1	16810074
ar@@	O	-1	16810074
ly,	O	-1	16810074
g@@	O	-1	16810074
ang@@	O	-1	16810074
li@@	O	-1	16810074
onic	O	-1	16810074
block@@	O	-1	16810074
ade	O	-1	16810074
with	O	-1	16810074
he@@	B-Chemical	D018738	16810074
xameth@@	I-Chemical	-1	16810074
oni@@	I-Chemical	-1	16810074
um	I-Chemical	-1	16810074
caused	O	-1	16810074
a	O	-1	16810074
significantly	O	-1	16810074
greater	O	-1	16810074
f@@	O	-1	16810074
all	O	-1	16810074
in	O	-1	16810074
L@@	B-Chemical	D019335	16810074
N@@	I-Chemical	-1	16810074
NA	I-Chemical	-1	16810074
hypertensive	B-Disease	D006973	16810074
rats	O	-1	16810074
(@@	O	-1	16810074
7@@	O	-1	16810074
6	O	-1	16810074
+/-	O	-1	16810074
9	O	-1	16810074
mm	O	-1	16810074
H@@	O	-1	16810074
g@@	O	-1	16810074
)	O	-1	16810074
compared	O	-1	16810074
with	O	-1	16810074
control	O	-1	16810074
rats	O	-1	16810074
(3@@	O	-1	16810074
5	O	-1	16810074
+/-	O	-1	16810074
10	O	-1	16810074
mm	O	-1	16810074
H@@	O	-1	16810074
g@@	O	-1	16810074
).	O	-1	16810074
Ca@@	O	-1	16810074
ro@@	O	-1	16810074
ti@@	O	-1	16810074
d	O	-1	16810074
arter@@	O	-1	16810074
i@@	O	-1	16810074
es,	O	-1	16810074
ven@@	O	-1	16810074
a	O	-1	16810074
ca@@	O	-1	16810074
v@@	O	-1	16810074
a,	O	-1	16810074
and	O	-1	16810074
sym@@	O	-1	16810074
pa@@	O	-1	16810074
thetic	O	-1	16810074
g@@	O	-1	16810074
ang@@	O	-1	16810074
li@@	O	-1	16810074
a	O	-1	16810074
from	O	-1	16810074
L@@	B-Chemical	D019335	16810074
N@@	I-Chemical	-1	16810074
NA	I-Chemical	-1	16810074
rats	O	-1	16810074
had	O	-1	16810074
higher	O	-1	16810074
bas@@	O	-1	16810074
al	O	-1	16810074
levels	O	-1	16810074
of	O	-1	16810074
su@@	B-Chemical	D013481	16810074
per@@	I-Chemical	-1	16810074
ox@@	I-Chemical	-1	16810074
ide	I-Chemical	-1	16810074
compared	O	-1	16810074
with	O	-1	16810074
those	O	-1	16810074
from	O	-1	16810074
control	O	-1	16810074
rats.	O	-1	16810074
These	O	-1	16810074
data	O	-1	16810074
suggest	O	-1	16810074
that	O	-1	16810074
while	O	-1	16810074
N@@	B-Chemical	D009569	16810074
O	I-Chemical	-1	16810074
defici@@	O	-1	16810074
ency	O	-1	16810074
increases	O	-1	16810074
oxid@@	O	-1	16810074
ative	O	-1	16810074
stres@@	O	-1	16810074
s	O	-1	16810074
and	O	-1	16810074
sym@@	O	-1	16810074
pa@@	O	-1	16810074
thetic	O	-1	16810074
activity	O	-1	16810074
in	O	-1	16810074
both	O	-1	16810074
arterial	O	-1	16810074
and	O	-1	16810074
venous	O	-1	16810074
v@@	O	-1	16810074
es@@	O	-1	16810074
sel@@	O	-1	16810074
s,	O	-1	16810074
the	O	-1	16810074
im@@	O	-1	16810074
pac@@	O	-1	16810074
t	O	-1	16810074
on	O	-1	16810074
ve@@	O	-1	16810074
ins	O	-1	16810074
does	O	-1	16810074
not	O	-1	16810074
ma@@	O	-1	16810074
k@@	O	-1	16810074
e	O	-1	16810074
a	O	-1	16810074
major	O	-1	16810074
cont@@	O	-1	16810074
ri@@	O	-1	16810074
bu@@	O	-1	16810074
tion	O	-1	16810074
to	O	-1	16810074
this	O	-1	16810074
form	O	-1	16810074
of	O	-1	16810074
hypertension	B-Disease	D006973	16810074
.	O	-1	16810074

A@@	O	-1	16867246
s@@	O	-1	16867246
s@@	O	-1	16867246
oci@@	O	-1	16867246
ation	O	-1	16867246
of	O	-1	16867246
D@@	O	-1	16867246
RD@@	O	-1	16867246
2	O	-1	16867246
poly@@	O	-1	16867246
morph@@	O	-1	16867246
is@@	O	-1	16867246
ms	O	-1	16867246
and	O	-1	16867246
chlor@@	B-Chemical	D002746	16867246
pro@@	I-Chemical	-1	16867246
ma@@	I-Chemical	-1	16867246
z@@	I-Chemical	-1	16867246
ine	I-Chemical	-1	16867246
-induced	O	-1	16867246
ext@@	B-Disease	D001480	16867246
ra@@	I-Disease	-1	16867246
py@@	I-Disease	-1	16867246
ram@@	I-Disease	-1	16867246
idal	I-Disease	-1	16867246
syndrome	I-Disease	-1	16867246
in	O	-1	16867246
Ch@@	O	-1	16867246
in@@	O	-1	16867246
ese	O	-1	16867246
sch@@	B-Disease	D012559	16867246
iz@@	I-Disease	-1	16867246
oph@@	I-Disease	-1	16867246
ren@@	I-Disease	-1	16867246
ic	I-Disease	-1	16867246
patients.	O	-1	16867246
A@@	O	-1	16867246
I@@	O	-1	16867246
M@@	O	-1	16867246
:	O	-1	16867246
E@@	B-Disease	D001480	16867246
x@@	I-Disease	-1	16867246
tra@@	I-Disease	-1	16867246
py@@	I-Disease	-1	16867246
ram@@	I-Disease	-1	16867246
idal	I-Disease	-1	16867246
syndrome	I-Disease	-1	16867246
(	O	-1	16867246
EP@@	B-Disease	D001480	16867246
S	I-Disease	-1	16867246
)	O	-1	16867246
is	O	-1	16867246
most	O	-1	16867246
common@@	O	-1	16867246
ly	O	-1	16867246
affected	O	-1	16867246
by	O	-1	16867246
typ@@	O	-1	16867246
ical	O	-1	16867246
anti@@	O	-1	16867246
psycho@@	O	-1	16867246
tic	O	-1	16867246
drugs	O	-1	16867246
that	O	-1	16867246
have	O	-1	16867246
a	O	-1	16867246
high	O	-1	16867246
aff@@	O	-1	16867246
in@@	O	-1	16867246
ity	O	-1	16867246
with	O	-1	16867246
the	O	-1	16867246
D2	O	-1	16867246
receptor@@	O	-1	16867246
.	O	-1	16867246
Rec@@	O	-1	16867246
ent@@	O	-1	16867246
ly,	O	-1	16867246
man@@	O	-1	16867246
y	O	-1	16867246
re@@	O	-1	16867246
se@@	O	-1	16867246
arc@@	O	-1	16867246
h	O	-1	16867246
groups	O	-1	16867246
have	O	-1	16867246
reported	O	-1	16867246
on	O	-1	16867246
the	O	-1	16867246
positive	O	-1	16867246
rel@@	O	-1	16867246
ationship	O	-1	16867246
between	O	-1	16867246
the	O	-1	16867246
gene@@	O	-1	16867246
tic	O	-1	16867246
vari@@	O	-1	16867246
ations	O	-1	16867246
in	O	-1	16867246
the	O	-1	16867246
D@@	O	-1	16867246
RD@@	O	-1	16867246
2	O	-1	16867246
gen@@	O	-1	16867246
e	O	-1	16867246
and	O	-1	16867246
the	O	-1	16867246
therapeutic	O	-1	16867246
response	O	-1	16867246
in	O	-1	16867246
sch@@	B-Disease	D012559	16867246
iz@@	I-Disease	-1	16867246
oph@@	I-Disease	-1	16867246
ren@@	I-Disease	-1	16867246
ia	I-Disease	-1	16867246
patients	O	-1	16867246
as	O	-1	16867246
a	O	-1	16867246
result	O	-1	16867246
of	O	-1	16867246
the	O	-1	16867246
role	O	-1	16867246
of	O	-1	16867246
vari@@	O	-1	16867246
ations	O	-1	16867246
in	O	-1	16867246
the	O	-1	16867246
receptor	O	-1	16867246
in	O	-1	16867246
mod@@	O	-1	16867246
ul@@	O	-1	16867246
ating	O	-1	16867246
receptor	O	-1	16867246
ex@@	O	-1	16867246
pres@@	O	-1	16867246
sion.	O	-1	16867246
In	O	-1	16867246
this	O	-1	16867246
study,	O	-1	16867246
we	O	-1	16867246
evalu@@	O	-1	16867246
ate	O	-1	16867246
the	O	-1	16867246
role	O	-1	16867246
D@@	O	-1	16867246
RD@@	O	-1	16867246
2	O	-1	16867246
pl@@	O	-1	16867246
ays	O	-1	16867246
in	O	-1	16867246
chlor@@	B-Chemical	D002746	16867246
pro@@	I-Chemical	-1	16867246
ma@@	I-Chemical	-1	16867246
z@@	I-Chemical	-1	16867246
ine	I-Chemical	-1	16867246
-induced	O	-1	16867246
EP@@	B-Disease	D001480	16867246
S	I-Disease	-1	16867246
in	O	-1	16867246
sch@@	B-Disease	D012559	16867246
iz@@	I-Disease	-1	16867246
oph@@	I-Disease	-1	16867246
ren@@	I-Disease	-1	16867246
ic	I-Disease	-1	16867246
patients.	O	-1	16867246
METHODS:	O	-1	16867246
We	O	-1	16867246
identi@@	O	-1	16867246
fied	O	-1	16867246
seven	O	-1	16867246
S@@	O	-1	16867246
N@@	O	-1	16867246
P@@	O	-1	16867246
(@@	O	-1	16867246
single	O	-1	16867246
nucle@@	O	-1	16867246
o@@	O	-1	16867246
ti@@	O	-1	16867246
de	O	-1	16867246
poly@@	O	-1	16867246
morph@@	O	-1	16867246
is@@	O	-1	16867246
m@@	O	-1	16867246
)	O	-1	16867246
(@@	O	-1	16867246
-1@@	O	-1	16867246
4@@	O	-1	16867246
1@@	O	-1	16867246
C@@	O	-1	16867246
in@@	O	-1	16867246
s@@	O	-1	16867246
>@@	O	-1	16867246
del@@	O	-1	16867246
,	O	-1	16867246
T@@	O	-1	16867246
a@@	O	-1	16867246
q@@	O	-1	16867246
I@@	O	-1	16867246
B@@	O	-1	16867246
,	O	-1	16867246
T@@	O	-1	16867246
a@@	O	-1	16867246
q@@	O	-1	16867246
I@@	O	-1	16867246
D@@	O	-1	16867246
,	O	-1	16867246
S@@	O	-1	16867246
er@@	O	-1	16867246
3@@	O	-1	16867246
1@@	O	-1	16867246
1@@	O	-1	16867246
C@@	O	-1	16867246
y@@	O	-1	16867246
s,	O	-1	16867246
r@@	O	-1	16867246
s@@	O	-1	16867246
6@@	O	-1	16867246
27@@	O	-1	16867246
5,	O	-1	16867246
r@@	O	-1	16867246
s@@	O	-1	16867246
6@@	O	-1	16867246
27@@	O	-1	16867246
7	O	-1	16867246
and	O	-1	16867246
T@@	O	-1	16867246
a@@	O	-1	16867246
q@@	O	-1	16867246
I@@	O	-1	16867246
A@@	O	-1	16867246
)	O	-1	16867246
in	O	-1	16867246
the	O	-1	16867246
D@@	O	-1	16867246
RD@@	O	-1	16867246
2	O	-1	16867246
gen@@	O	-1	16867246
e	O	-1	16867246
in	O	-1	16867246
14@@	O	-1	16867246
6	O	-1	16867246
sch@@	B-Disease	D012559	16867246
iz@@	I-Disease	-1	16867246
oph@@	I-Disease	-1	16867246
ren@@	I-Disease	-1	16867246
ic	I-Disease	-1	16867246
in@@	O	-1	16867246
patients	O	-1	16867246
(5@@	O	-1	16867246
9	O	-1	16867246
with	O	-1	16867246
EP@@	B-Disease	D001480	16867246
S	I-Disease	-1	16867246
and	O	-1	16867246
8@@	O	-1	16867246
7	O	-1	16867246
without	O	-1	16867246
EP@@	B-Disease	D001480	16867246
S	I-Disease	-1	16867246
ac@@	O	-1	16867246
cor@@	O	-1	16867246
ding	O	-1	16867246
to	O	-1	16867246
the	O	-1	16867246
S@@	O	-1	16867246
im@@	O	-1	16867246
p@@	O	-1	16867246
son@@	O	-1	16867246
-@@	O	-1	16867246
An@@	O	-1	16867246
g@@	O	-1	16867246
us	O	-1	16867246
S@@	O	-1	16867246
cal@@	O	-1	16867246
e@@	O	-1	16867246
)	O	-1	16867246
treated	O	-1	16867246
with	O	-1	16867246
chlor@@	B-Chemical	D002746	16867246
pro@@	I-Chemical	-1	16867246
ma@@	I-Chemical	-1	16867246
z@@	I-Chemical	-1	16867246
ine	I-Chemical	-1	16867246
after	O	-1	16867246
8	O	-1	16867246
week@@	O	-1	16867246
s.	O	-1	16867246
The	O	-1	16867246
al@@	O	-1	16867246
le@@	O	-1	16867246
le@@	O	-1	16867246
s	O	-1	16867246
of	O	-1	16867246
all	O	-1	16867246
loc@@	O	-1	16867246
i	O	-1	16867246
were	O	-1	16867246
determined	O	-1	16867246
by	O	-1	16867246
P@@	O	-1	16867246
C@@	O	-1	16867246
R	O	-1	16867246
(@@	O	-1	16867246
poly@@	O	-1	16867246
mer@@	O	-1	16867246
ase	O	-1	16867246
ch@@	O	-1	16867246
ain	O	-1	16867246
reac@@	O	-1	16867246
tion@@	O	-1	16867246
).	O	-1	16867246
RESULTS:	O	-1	16867246
P@@	O	-1	16867246
oly@@	O	-1	16867246
morph@@	O	-1	16867246
is@@	O	-1	16867246
ms	O	-1	16867246
T@@	O	-1	16867246
a@@	O	-1	16867246
q@@	O	-1	16867246
I@@	O	-1	16867246
D@@	O	-1	16867246
,	O	-1	16867246
S@@	O	-1	16867246
er@@	O	-1	16867246
3@@	O	-1	16867246
1@@	O	-1	16867246
1@@	O	-1	16867246
C@@	O	-1	16867246
ys	O	-1	16867246
and	O	-1	16867246
r@@	O	-1	16867246
s@@	O	-1	16867246
6@@	O	-1	16867246
27@@	O	-1	16867246
7	O	-1	16867246
were	O	-1	16867246
not	O	-1	16867246
poly@@	O	-1	16867246
morph@@	O	-1	16867246
ic	O	-1	16867246
in	O	-1	16867246
the	O	-1	16867246
po@@	O	-1	16867246
p@@	O	-1	16867246
ulation	O	-1	16867246
rec@@	O	-1	16867246
ru@@	O	-1	16867246
ited	O	-1	16867246
in	O	-1	16867246
the	O	-1	16867246
present	O	-1	16867246
study.	O	-1	16867246
No	O	-1	16867246
statis@@	O	-1	16867246
tical	O	-1	16867246
signific@@	O	-1	16867246
ance	O	-1	16867246
was	O	-1	16867246
found	O	-1	16867246
in	O	-1	16867246
the	O	-1	16867246
al@@	O	-1	16867246
le@@	O	-1	16867246
le	O	-1	16867246
di@@	O	-1	16867246
stri@@	O	-1	16867246
bu@@	O	-1	16867246
tion	O	-1	16867246
of	O	-1	16867246
-1@@	O	-1	16867246
4@@	O	-1	16867246
1@@	O	-1	16867246
C@@	O	-1	16867246
in@@	O	-1	16867246
s@@	O	-1	16867246
>@@	O	-1	16867246
del@@	O	-1	16867246
,	O	-1	16867246
T@@	O	-1	16867246
a@@	O	-1	16867246
q@@	O	-1	16867246
I@@	O	-1	16867246
B@@	O	-1	16867246
,	O	-1	16867246
r@@	O	-1	16867246
s@@	O	-1	16867246
6@@	O	-1	16867246
27@@	O	-1	16867246
5	O	-1	16867246
and	O	-1	16867246
T@@	O	-1	16867246
a@@	O	-1	16867246
q@@	O	-1	16867246
I@@	O	-1	16867246
A	O	-1	16867246
or	O	-1	16867246
in	O	-1	16867246
the	O	-1	16867246
estim@@	O	-1	16867246
ated	O	-1	16867246
h@@	O	-1	16867246
ap@@	O	-1	16867246
lo@@	O	-1	16867246
typ@@	O	-1	16867246
es	O	-1	16867246
(@@	O	-1	16867246
con@@	O	-1	16867246
sti@@	O	-1	16867246
t@@	O	-1	16867246
ut@@	O	-1	16867246
ed	O	-1	16867246
by	O	-1	16867246
T@@	O	-1	16867246
a@@	O	-1	16867246
q@@	O	-1	16867246
I@@	O	-1	16867246
B@@	O	-1	16867246
,	O	-1	16867246
r@@	O	-1	16867246
s@@	O	-1	16867246
6@@	O	-1	16867246
27@@	O	-1	16867246
5	O	-1	16867246
and	O	-1	16867246
T@@	O	-1	16867246
a@@	O	-1	16867246
q@@	O	-1	16867246
I@@	O	-1	16867246
A@@	O	-1	16867246
)	O	-1	16867246
in	O	-1	16867246
lin@@	O	-1	16867246
k@@	O	-1	16867246
age	O	-1	16867246
dise@@	O	-1	16867246
qu@@	O	-1	16867246
il@@	O	-1	16867246
i@@	O	-1	16867246
b@@	O	-1	16867246
ri@@	O	-1	16867246
um	O	-1	16867246
between	O	-1	16867246
the	O	-1	16867246
two	O	-1	16867246
groups.	O	-1	16867246
CONCLUSION:	O	-1	16867246
Our	O	-1	16867246
results	O	-1	16867246
did	O	-1	16867246
not	O	-1	16867246
l@@	O	-1	16867246
end	O	-1	16867246
st@@	O	-1	16867246
ron@@	O	-1	16867246
g	O	-1	16867246
suppor@@	O	-1	16867246
t	O	-1	16867246
to	O	-1	16867246
the	O	-1	16867246
vie@@	O	-1	16867246
w	O	-1	16867246
that	O	-1	16867246
the	O	-1	16867246
gene@@	O	-1	16867246
tic	O	-1	16867246
vari@@	O	-1	16867246
ation	O	-1	16867246
of	O	-1	16867246
the	O	-1	16867246
D@@	O	-1	16867246
RD@@	O	-1	16867246
2	O	-1	16867246
gen@@	O	-1	16867246
e	O	-1	16867246
pl@@	O	-1	16867246
ays	O	-1	16867246
a	O	-1	16867246
major	O	-1	16867246
role	O	-1	16867246
in	O	-1	16867246
the	O	-1	16867246
individ@@	O	-1	16867246
ually	O	-1	16867246
vari@@	O	-1	16867246
able	O	-1	16867246
adverse	O	-1	16867246
effect	O	-1	16867246
induced	O	-1	16867246
by	O	-1	16867246
chlor@@	B-Chemical	D002746	16867246
pro@@	I-Chemical	-1	16867246
ma@@	I-Chemical	-1	16867246
z@@	I-Chemical	-1	16867246
ine	I-Chemical	-1	16867246
,	O	-1	16867246
at	O	-1	16867246
le@@	O	-1	16867246
ast	O	-1	16867246
in	O	-1	16867246
Ch@@	O	-1	16867246
in@@	O	-1	16867246
ese	O	-1	16867246
patients	O	-1	16867246
with	O	-1	16867246
sch@@	B-Disease	D012559	16867246
iz@@	I-Disease	-1	16867246
oph@@	I-Disease	-1	16867246
ren@@	I-Disease	-1	16867246
ia	I-Disease	-1	16867246
.	O	-1	16867246
Our	O	-1	16867246
results	O	-1	16867246
con@@	O	-1	16867246
fir@@	O	-1	16867246
m@@	O	-1	16867246
ed	O	-1	16867246
a	O	-1	16867246
previ@@	O	-1	16867246
ous	O	-1	16867246
study	O	-1	16867246
on	O	-1	16867246
the	O	-1	16867246
rel@@	O	-1	16867246
ationship	O	-1	16867246
between	O	-1	16867246
D@@	O	-1	16867246
RD@@	O	-1	16867246
2	O	-1	16867246
and	O	-1	16867246
EP@@	B-Disease	D001480	16867246
S	I-Disease	-1	16867246
in	O	-1	16867246
Ca@@	O	-1	16867246
uc@@	O	-1	16867246
a@@	O	-1	16867246
si@@	O	-1	16867246
an@@	O	-1	16867246
s.	O	-1	16867246

P@@	O	-1	16876986
hy@@	O	-1	16876986
si@@	O	-1	16876986
c@@	O	-1	16876986
al	O	-1	16876986
tra@@	O	-1	16876986
in@@	O	-1	16876986
ing	O	-1	16876986
decreas@@	O	-1	16876986
es	O	-1	16876986
sus@@	O	-1	16876986
cep@@	O	-1	16876986
ti@@	O	-1	16876986
b@@	O	-1	16876986
ility	O	-1	16876986
to	O	-1	16876986
subsequ@@	O	-1	16876986
ent	O	-1	16876986
pilocar@@	B-Chemical	D010862	16876986
pine	I-Chemical	-1	16876986
-induced	O	-1	16876986
seizures	B-Disease	D012640	16876986
in	O	-1	16876986
the	O	-1	16876986
rat@@	O	-1	16876986
.	O	-1	16876986
Re@@	O	-1	16876986
g@@	O	-1	16876986
ular	O	-1	16876986
motor	O	-1	16876986
activity	O	-1	16876986
has	O	-1	16876986
man@@	O	-1	16876986
y	O	-1	16876986
ben@@	O	-1	16876986
e@@	O	-1	16876986
f@@	O	-1	16876986
its	O	-1	16876986
for	O	-1	16876986
mental	O	-1	16876986
and	O	-1	16876986
physi@@	O	-1	16876986
c@@	O	-1	16876986
al	O	-1	16876986
condi@@	O	-1	16876986
tion	O	-1	16876986
but	O	-1	16876986
its	O	-1	16876986
implic@@	O	-1	16876986
ations	O	-1	16876986
for	O	-1	16876986
epilep@@	B-Disease	D004827	16876986
sy	I-Disease	-1	16876986
are	O	-1	16876986
sti@@	O	-1	16876986
ll	O	-1	16876986
contro@@	O	-1	16876986
ver@@	O	-1	16876986
si@@	O	-1	16876986
al.	O	-1	16876986
In	O	-1	16876986
or@@	O	-1	16876986
der	O	-1	16876986
to	O	-1	16876986
el@@	O	-1	16876986
uc@@	O	-1	16876986
id@@	O	-1	16876986
ate	O	-1	16876986
this	O	-1	16876986
pro@@	O	-1	16876986
ble@@	O	-1	16876986
m@@	O	-1	16876986
,	O	-1	16876986
we	O	-1	16876986
have	O	-1	16876986
studied	O	-1	16876986
the	O	-1	16876986
effect	O	-1	16876986
of	O	-1	16876986
long-term	O	-1	16876986
physi@@	O	-1	16876986
c@@	O	-1	16876986
al	O	-1	16876986
activity	O	-1	16876986
on	O	-1	16876986
sus@@	O	-1	16876986
cep@@	O	-1	16876986
ti@@	O	-1	16876986
b@@	O	-1	16876986
ility	O	-1	16876986
to	O	-1	16876986
subsequ@@	O	-1	16876986
ent	O	-1	16876986
seizures	B-Disease	D012640	16876986
.	O	-1	16876986
M@@	O	-1	16876986
al@@	O	-1	16876986
e	O	-1	16876986
Wistar	O	-1	16876986
rats	O	-1	16876986
were	O	-1	16876986
subj@@	O	-1	16876986
ected	O	-1	16876986
to	O	-1	16876986
repe@@	O	-1	16876986
ated	O	-1	16876986
tra@@	O	-1	16876986
in@@	O	-1	16876986
ing	O	-1	16876986
s@@	O	-1	16876986
es@@	O	-1	16876986
sions	O	-1	16876986
in	O	-1	16876986
a	O	-1	16876986
tre@@	O	-1	16876986
ad@@	O	-1	16876986
mil@@	O	-1	16876986
l	O	-1	16876986
and	O	-1	16876986
s@@	O	-1	16876986
w@@	O	-1	16876986
im@@	O	-1	16876986
m@@	O	-1	16876986
ing	O	-1	16876986
po@@	O	-1	16876986
ol@@	O	-1	16876986
.	O	-1	16876986
The@@	O	-1	16876986
re@@	O	-1	16876986
af@@	O	-1	16876986
ter@@	O	-1	16876986
,	O	-1	16876986
seizures	B-Disease	D012640	16876986
were	O	-1	16876986
induced	O	-1	16876986
by	O	-1	16876986
pilocar@@	B-Chemical	D010862	16876986
pine	I-Chemical	-1	16876986
injec@@	O	-1	16876986
tions	O	-1	16876986
in	O	-1	16876986
tra@@	O	-1	16876986
in@@	O	-1	16876986
ed	O	-1	16876986
and	O	-1	16876986
non-@@	O	-1	16876986
tra@@	O	-1	16876986
in@@	O	-1	16876986
ed	O	-1	16876986
control	O	-1	16876986
groups.	O	-1	16876986
D@@	O	-1	16876986
uring	O	-1	16876986
the	O	-1	16876986
acute	O	-1	16876986
period	O	-1	16876986
of	O	-1	16876986
status	B-Disease	D013226	16876986
epilep@@	I-Disease	-1	16876986
tic@@	I-Disease	-1	16876986
us	I-Disease	-1	16876986
,	O	-1	16876986
we	O	-1	16876986
meas@@	O	-1	16876986
ure@@	O	-1	16876986
d@@	O	-1	16876986
:	O	-1	16876986
(1@@	O	-1	16876986
)	O	-1	16876986
the	O	-1	16876986
lat@@	O	-1	16876986
ency	O	-1	16876986
of	O	-1	16876986
the	O	-1	16876986
first	O	-1	16876986
motor	O	-1	16876986
sign@@	O	-1	16876986
,	O	-1	16876986
(2@@	O	-1	16876986
)	O	-1	16876986
the	O	-1	16876986
int@@	O	-1	16876986
ensity	O	-1	16876986
of	O	-1	16876986
seizures	B-Disease	D012640	16876986
,	O	-1	16876986
(3@@	O	-1	16876986
)	O	-1	16876986
the	O	-1	16876986
time	O	-1	16876986
when	O	-1	16876986
it	O	-1	16876986
occurred	O	-1	16876986
within	O	-1	16876986
the	O	-1	16876986
6-@@	O	-1	16876986
h	O	-1	16876986
observ@@	O	-1	16876986
ation	O	-1	16876986
perio@@	O	-1	16876986
d,	O	-1	16876986
and	O	-1	16876986
(4@@	O	-1	16876986
)	O	-1	16876986
the	O	-1	16876986
time	O	-1	16876986
when	O	-1	16876986
the	O	-1	16876986
acute	O	-1	16876986
period	O	-1	16876986
en@@	O	-1	16876986
de@@	O	-1	16876986
d.	O	-1	16876986
All	O	-1	16876986
these	O	-1	16876986
behavioral	O	-1	16876986
par@@	O	-1	16876986
ame@@	O	-1	16876986
ters	O	-1	16876986
showed	O	-1	16876986
statis@@	O	-1	16876986
tically	O	-1	16876986
significant	O	-1	16876986
changes	O	-1	16876986
suggesting	O	-1	16876986
that	O	-1	16876986
reg@@	O	-1	16876986
ular	O	-1	16876986
physi@@	O	-1	16876986
c@@	O	-1	16876986
al	O	-1	16876986
ex@@	O	-1	16876986
er@@	O	-1	16876986
ci@@	O	-1	16876986
ses	O	-1	16876986
decrease	O	-1	16876986
sus@@	O	-1	16876986
cep@@	O	-1	16876986
ti@@	O	-1	16876986
b@@	O	-1	16876986
ility	O	-1	16876986
to	O	-1	16876986
subsequ@@	O	-1	16876986
ently	O	-1	16876986
induced	O	-1	16876986
seizures	B-Disease	D012640	16876986
and	O	-1	16876986
ame@@	O	-1	16876986
li@@	O	-1	16876986
or@@	O	-1	16876986
ate	O	-1	16876986
the	O	-1	16876986
course	O	-1	16876986
of	O	-1	16876986
experim@@	O	-1	16876986
ent@@	O	-1	16876986
ally	O	-1	16876986
induced	O	-1	16876986
status	B-Disease	D013226	16876986
epilep@@	I-Disease	-1	16876986
tic@@	I-Disease	-1	16876986
us	I-Disease	-1	16876986
.	O	-1	16876986

T@@	O	-1	16880771
onic	O	-1	16880771
dop@@	O	-1	16880771
aminergic	O	-1	16880771
stimulation	O	-1	16880771
impair@@	B-Disease	D007859	16880771
s	I-Disease	-1	16880771
associ@@	I-Disease	-1	16880771
ative	I-Disease	-1	16880771
lear@@	I-Disease	-1	16880771
ning	I-Disease	-1	16880771
in	O	-1	16880771
healthy	O	-1	16880771
subj@@	O	-1	16880771
ect@@	O	-1	16880771
s.	O	-1	16880771
E@@	O	-1	16880771
n@@	O	-1	16880771
do@@	O	-1	16880771
gen@@	O	-1	16880771
ous	O	-1	16880771
dopamine	B-Chemical	D004298	16880771
pl@@	O	-1	16880771
ays	O	-1	16880771
a	O	-1	16880771
central	O	-1	16880771
role	O	-1	16880771
in	O	-1	16880771
sal@@	O	-1	16880771
i@@	O	-1	16880771
ence	O	-1	16880771
co@@	O	-1	16880771
ding	O	-1	16880771
during	O	-1	16880771
associ@@	O	-1	16880771
ative	O	-1	16880771
lear@@	O	-1	16880771
n@@	O	-1	16880771
ing.	O	-1	16880771
Ad@@	O	-1	16880771
minist@@	O	-1	16880771
ration	O	-1	16880771
of	O	-1	16880771
the	O	-1	16880771
dopamine	B-Chemical	D004298	16880771
pre@@	O	-1	16880771
cur@@	O	-1	16880771
s@@	O	-1	16880771
or	O	-1	16880771
levo@@	B-Chemical	D007980	16880771
dopa	I-Chemical	-1	16880771
enh@@	O	-1	16880771
anc@@	O	-1	16880771
es	O	-1	16880771
lear@@	O	-1	16880771
ning	O	-1	16880771
in	O	-1	16880771
healthy	O	-1	16880771
subjects	O	-1	16880771
and	O	-1	16880771
strok@@	B-Disease	D020521	16880771
e	I-Disease	-1	16880771
patients.	O	-1	16880771
B@@	O	-1	16880771
ecause	O	-1	16880771
levo@@	B-Chemical	D007980	16880771
dopa	I-Chemical	-1	16880771
increases	O	-1	16880771
both	O	-1	16880771
pha@@	O	-1	16880771
sic	O	-1	16880771
and	O	-1	16880771
t@@	O	-1	16880771
onic	O	-1	16880771
dop@@	O	-1	16880771
aminergic	O	-1	16880771
neuro@@	O	-1	16880771
trans@@	O	-1	16880771
mis@@	O	-1	16880771
sion,	O	-1	16880771
the	O	-1	16880771
cri@@	O	-1	16880771
tical	O	-1	16880771
mechanism	O	-1	16880771
medi@@	O	-1	16880771
ating	O	-1	16880771
the	O	-1	16880771
enh@@	O	-1	16880771
ance@@	O	-1	16880771
ment	O	-1	16880771
of	O	-1	16880771
lear@@	O	-1	16880771
ning	O	-1	16880771
is	O	-1	16880771
un@@	O	-1	16880771
resol@@	O	-1	16880771
ved.	O	-1	16880771
We	O	-1	16880771
h@@	O	-1	16880771
ere	O	-1	16880771
prob@@	O	-1	16880771
ed	O	-1	16880771
ho@@	O	-1	16880771
w	O	-1	16880771
selective	O	-1	16880771
t@@	O	-1	16880771
onic	O	-1	16880771
dop@@	O	-1	16880771
aminergic	O	-1	16880771
stimulation	O	-1	16880771
aff@@	O	-1	16880771
ects	O	-1	16880771
associ@@	O	-1	16880771
ative	O	-1	16880771
lear@@	O	-1	16880771
n@@	O	-1	16880771
ing.	O	-1	16880771
F@@	O	-1	16880771
ort@@	O	-1	16880771
y	O	-1	16880771
healthy	O	-1	16880771
subjects	O	-1	16880771
were	O	-1	16880771
tra@@	O	-1	16880771
in@@	O	-1	16880771
ed	O	-1	16880771
in	O	-1	16880771
a	O	-1	16880771
novel	O	-1	16880771
v@@	O	-1	16880771
oc@@	O	-1	16880771
ab@@	O	-1	16880771
ul@@	O	-1	16880771
ary	O	-1	16880771
of	O	-1	16880771
4@@	O	-1	16880771
5	O	-1	16880771
con@@	O	-1	16880771
c@@	O	-1	16880771
ret@@	O	-1	16880771
e	O	-1	16880771
n@@	O	-1	16880771
oun@@	O	-1	16880771
s	O	-1	16880771
over	O	-1	16880771
the	O	-1	16880771
course	O	-1	16880771
of	O	-1	16880771
5	O	-1	16880771
con@@	O	-1	16880771
sec@@	O	-1	16880771
utive	O	-1	16880771
tra@@	O	-1	16880771
in@@	O	-1	16880771
ing	O	-1	16880771
days	O	-1	16880771
in	O	-1	16880771
a	O	-1	16880771
pro@@	O	-1	16880771
sp@@	O	-1	16880771
ecti@@	O	-1	16880771
ve,	O	-1	16880771
random@@	O	-1	16880771
iz@@	O	-1	16880771
ed,	O	-1	16880771
double-bl@@	O	-1	16880771
ind@@	O	-1	16880771
,	O	-1	16880771
placebo@@	O	-1	16880771
-@@	O	-1	16880771
controlled	O	-1	16880771
de@@	O	-1	16880771
sign@@	O	-1	16880771
.	O	-1	16880771
S@@	O	-1	16880771
ub@@	O	-1	16880771
j@@	O	-1	16880771
ects	O	-1	16880771
received	O	-1	16880771
the	O	-1	16880771
t@@	O	-1	16880771
on@@	O	-1	16880771
ically	O	-1	16880771
stimul@@	O	-1	16880771
ating	O	-1	16880771
dopamine	B-Chemical	D004298	16880771
-@@	O	-1	16880771
receptor	O	-1	16880771
agon@@	O	-1	16880771
ist	O	-1	16880771
per@@	B-Chemical	D010479	16880771
g@@	I-Chemical	-1	16880771
ol@@	I-Chemical	-1	16880771
ide	I-Chemical	-1	16880771
(0.@@	O	-1	16880771
1	O	-1	16880771
mg@@	O	-1	16880771
)	O	-1	16880771
v@@	O	-1	16880771
s	O	-1	16880771
placebo	O	-1	16880771
1@@	O	-1	16880771
20	O	-1	16880771
min	O	-1	16880771
before	O	-1	16880771
tra@@	O	-1	16880771
in@@	O	-1	16880771
ing	O	-1	16880771
on	O	-1	16880771
each	O	-1	16880771
tra@@	O	-1	16880771
in@@	O	-1	16880771
ing	O	-1	16880771
da@@	O	-1	16880771
y.	O	-1	16880771
The	O	-1	16880771
dopamine	B-Chemical	D004298	16880771
agon@@	O	-1	16880771
ist	O	-1	16880771
significantly	O	-1	16880771
impaired	B-Disease	D007859	16880771
novel	I-Disease	-1	16880771
wor@@	I-Disease	-1	16880771
d	I-Disease	-1	16880771
lear@@	I-Disease	-1	16880771
ning	I-Disease	-1	16880771
compared	O	-1	16880771
to	O	-1	16880771
placebo@@	O	-1	16880771
.	O	-1	16880771
This	O	-1	16880771
lear@@	O	-1	16880771
ning	O	-1	16880771
dec@@	O	-1	16880771
re@@	O	-1	16880771
ment	O	-1	16880771
per@@	O	-1	16880771
sist@@	O	-1	16880771
ed	O	-1	16880771
up	O	-1	16880771
to	O	-1	16880771
the	O	-1	16880771
las@@	O	-1	16880771
t	O	-1	16880771
follow-up	O	-1	16880771
4	O	-1	16880771
weeks	O	-1	16880771
post@@	O	-1	16880771
-@@	O	-1	16880771
tra@@	O	-1	16880771
in@@	O	-1	16880771
ing.	O	-1	16880771
S@@	O	-1	16880771
ub@@	O	-1	16880771
j@@	O	-1	16880771
ects	O	-1	16880771
treated	O	-1	16880771
with	O	-1	16880771
per@@	B-Chemical	D010479	16880771
g@@	I-Chemical	-1	16880771
ol@@	I-Chemical	-1	16880771
ide	I-Chemical	-1	16880771
also	O	-1	16880771
showed	O	-1	16880771
re@@	O	-1	16880771
stric@@	O	-1	16880771
ted	O	-1	16880771
em@@	O	-1	16880771
o@@	O	-1	16880771
tional	O	-1	16880771
responses	O	-1	16880771
compared	O	-1	16880771
to	O	-1	16880771
the	O	-1	16880771
P@@	O	-1	16880771
L@@	O	-1	16880771
AC@@	O	-1	16880771
E@@	O	-1	16880771
B@@	O	-1	16880771
O	O	-1	16880771
group.	O	-1	16880771
The	O	-1	16880771
ext@@	O	-1	16880771
ent	O	-1	16880771
of	O	-1	16880771
'@@	O	-1	16880771
f@@	O	-1	16880771
lat@@	O	-1	16880771
ten@@	O	-1	16880771
ed@@	O	-1	16880771
'	O	-1	16880771
aff@@	O	-1	16880771
ect	O	-1	16880771
with	O	-1	16880771
per@@	B-Chemical	D010479	16880771
g@@	I-Chemical	-1	16880771
ol@@	I-Chemical	-1	16880771
ide	I-Chemical	-1	16880771
was	O	-1	16880771
related	O	-1	16880771
to	O	-1	16880771
the	O	-1	16880771
de@@	O	-1	16880771
g@@	O	-1	16880771
ree	O	-1	16880771
of	O	-1	16880771
lear@@	O	-1	16880771
ning	O	-1	16880771
inhib@@	O	-1	16880771
i@@	O	-1	16880771
tion.	O	-1	16880771
These	O	-1	16880771
findings	O	-1	16880771
suggest	O	-1	16880771
that	O	-1	16880771
t@@	O	-1	16880771
onic	O	-1	16880771
occ@@	O	-1	16880771
up@@	O	-1	16880771
ation	O	-1	16880771
of	O	-1	16880771
dopamine	B-Chemical	D004298	16880771
receptors	O	-1	16880771
impair@@	O	-1	16880771
s	O	-1	16880771
lear@@	O	-1	16880771
ning	O	-1	16880771
by	O	-1	16880771
comp@@	O	-1	16880771
e@@	O	-1	16880771
ti@@	O	-1	16880771
tion	O	-1	16880771
with	O	-1	16880771
pha@@	O	-1	16880771
sic	O	-1	16880771
dopamine	B-Chemical	D004298	16880771
sign@@	O	-1	16880771
al@@	O	-1	16880771
s.	O	-1	16880771
Th@@	O	-1	16880771
us,	O	-1	16880771
pha@@	O	-1	16880771
sic	O	-1	16880771
sign@@	O	-1	16880771
al@@	O	-1	16880771
ing	O	-1	16880771
se@@	O	-1	16880771
em@@	O	-1	16880771
s	O	-1	16880771
to	O	-1	16880771
be	O	-1	16880771
the	O	-1	16880771
cri@@	O	-1	16880771
tical	O	-1	16880771
mechanism	O	-1	16880771
by	O	-1	16880771
which	O	-1	16880771
dopamine	B-Chemical	D004298	16880771
enh@@	O	-1	16880771
anc@@	O	-1	16880771
es	O	-1	16880771
associ@@	O	-1	16880771
ative	O	-1	16880771
lear@@	O	-1	16880771
ning	O	-1	16880771
in	O	-1	16880771
healthy	O	-1	16880771
subjects	O	-1	16880771
and	O	-1	16880771
strok@@	B-Disease	D020521	16880771
e	I-Disease	-1	16880771
patients.	O	-1	16880771

M@@	B-Chemical	D008911	16906379
in@@	I-Chemical	-1	16906379
ocy@@	I-Chemical	-1	16906379
cl@@	I-Chemical	-1	16906379
ine	I-Chemical	-1	16906379
-induced	O	-1	16906379
vas@@	B-Disease	D014657	16906379
cul@@	I-Disease	-1	16906379
iti@@	I-Disease	-1	16906379
s	I-Disease	-1	16906379
ful@@	O	-1	16906379
f@@	O	-1	16906379
ill@@	O	-1	16906379
ing	O	-1	16906379
the	O	-1	16906379
c@@	O	-1	16906379
rit@@	O	-1	16906379
er@@	O	-1	16906379
ia	O	-1	16906379
of	O	-1	16906379
poly@@	B-Disease	D010488	16906379
arter@@	I-Disease	-1	16906379
iti@@	I-Disease	-1	16906379
s	I-Disease	-1	16906379
no@@	I-Disease	-1	16906379
dos@@	I-Disease	-1	16906379
a	I-Disease	-1	16906379
.	O	-1	16906379
A	O	-1	16906379
4@@	O	-1	16906379
7-@@	O	-1	16906379
year-old	O	-1	16906379
man	O	-1	16906379
who	O	-1	16906379
had	O	-1	16906379
been	O	-1	16906379
taking	O	-1	16906379
min@@	B-Chemical	D008911	16906379
ocy@@	I-Chemical	-1	16906379
cl@@	I-Chemical	-1	16906379
ine	I-Chemical	-1	16906379
for	O	-1	16906379
p@@	B-Disease	D011565	16906379
al@@	I-Disease	-1	16906379
mo@@	I-Disease	-1	16906379
pl@@	I-Disease	-1	16906379
ant@@	I-Disease	-1	16906379
ar	I-Disease	-1	16906379
p@@	I-Disease	-1	16906379
ust@@	I-Disease	-1	16906379
ulo@@	I-Disease	-1	16906379
sis	I-Disease	-1	16906379
developed	O	-1	16906379
f@@	B-Disease	D005334	16906379
ev@@	I-Disease	-1	16906379
er	I-Disease	-1	16906379
,	O	-1	16906379
my@@	B-Disease	D063806	16906379
al@@	I-Disease	-1	16906379
gi@@	I-Disease	-1	16906379
as	I-Disease	-1	16906379
,	O	-1	16906379
poly@@	B-Disease	D011115	16906379
neuropathy	I-Disease	-1	16906379
,	O	-1	16906379
and	O	-1	16906379
t@@	B-Disease	D013733	16906379
es@@	I-Disease	-1	16906379
tic@@	I-Disease	-1	16906379
ular	I-Disease	-1	16906379
pain	I-Disease	-1	16906379
,	O	-1	16906379
with	O	-1	16906379
elevated	O	-1	16906379
C@@	O	-1	16906379
-@@	O	-1	16906379
reac@@	O	-1	16906379
tive	O	-1	16906379
protein	O	-1	16906379
(C@@	O	-1	16906379
R@@	O	-1	16906379
P@@	O	-1	16906379
).	O	-1	16906379
N@@	O	-1	16906379
either	O	-1	16906379
my@@	O	-1	16906379
e@@	O	-1	16906379
lo@@	O	-1	16906379
per@@	O	-1	16906379
oxid@@	O	-1	16906379
as@@	O	-1	16906379
e@@	O	-1	16906379
-	O	-1	16906379
n@@	O	-1	16906379
or	O	-1	16906379
protein@@	O	-1	16906379
as@@	O	-1	16906379
e-@@	O	-1	16906379
3-@@	O	-1	16906379
ant@@	O	-1	16906379
ine@@	O	-1	16906379
ut@@	O	-1	16906379
ro@@	O	-1	16906379
ph@@	O	-1	16906379
il	O	-1	16906379
cyto@@	O	-1	16906379
plas@@	O	-1	16906379
mic	O	-1	16906379
anti@@	O	-1	16906379
body	O	-1	16906379
was	O	-1	16906379
posi@@	O	-1	16906379
ti@@	O	-1	16906379
ve.	O	-1	16906379
These	O	-1	16906379
man@@	O	-1	16906379
if@@	O	-1	16906379
est@@	O	-1	16906379
ations	O	-1	16906379
me@@	O	-1	16906379
t	O	-1	16906379
the	O	-1	16906379
A@@	O	-1	16906379
mer@@	O	-1	16906379
ic@@	O	-1	16906379
an	O	-1	16906379
C@@	O	-1	16906379
ol@@	O	-1	16906379
le@@	O	-1	16906379
ge	O	-1	16906379
of	O	-1	16906379
R@@	O	-1	16906379
he@@	O	-1	16906379
um@@	O	-1	16906379
at@@	O	-1	16906379
ology	O	-1	16906379
19@@	O	-1	16906379
9@@	O	-1	16906379
0	O	-1	16906379
c@@	O	-1	16906379
rit@@	O	-1	16906379
er@@	O	-1	16906379
ia	O	-1	16906379
for	O	-1	16906379
the	O	-1	16906379
cl@@	O	-1	16906379
assi@@	O	-1	16906379
fic@@	O	-1	16906379
ation	O	-1	16906379
of	O	-1	16906379
poly@@	B-Disease	D010488	16906379
arter@@	I-Disease	-1	16906379
iti@@	I-Disease	-1	16906379
s	I-Disease	-1	16906379
no@@	I-Disease	-1	16906379
dos@@	I-Disease	-1	16906379
a	I-Disease	-1	16906379
.	O	-1	16906379
S@@	O	-1	16906379
to@@	O	-1	16906379
pp@@	O	-1	16906379
ing	O	-1	16906379
min@@	B-Chemical	D008911	16906379
ocy@@	I-Chemical	-1	16906379
cl@@	I-Chemical	-1	16906379
ine	I-Chemical	-1	16906379
l@@	O	-1	16906379
ed	O	-1	16906379
to	O	-1	16906379
ame@@	O	-1	16906379
li@@	O	-1	16906379
or@@	O	-1	16906379
ation	O	-1	16906379
of	O	-1	16906379
symptoms	O	-1	16906379
and	O	-1	16906379
normal@@	O	-1	16906379
ization	O	-1	16906379
of	O	-1	16906379
CR@@	O	-1	16906379
P	O	-1	16906379
level@@	O	-1	16906379
.	O	-1	16906379
To	O	-1	16906379
our	O	-1	16906379
know@@	O	-1	16906379
le@@	O	-1	16906379
d@@	O	-1	16906379
g@@	O	-1	16906379
e,	O	-1	16906379
this	O	-1	16906379
is	O	-1	16906379
the	O	-1	16906379
second	O	-1	16906379
case	O	-1	16906379
of	O	-1	16906379
min@@	B-Chemical	D008911	16906379
ocy@@	I-Chemical	-1	16906379
cl@@	I-Chemical	-1	16906379
ine	I-Chemical	-1	16906379
-induced	O	-1	16906379
vas@@	B-Disease	D014657	16906379
cul@@	I-Disease	-1	16906379
iti@@	I-Disease	-1	16906379
s	I-Disease	-1	16906379
s@@	O	-1	16906379
atis@@	O	-1	16906379
f@@	O	-1	16906379
y@@	O	-1	16906379
ing	O	-1	16906379
the	O	-1	16906379
c@@	O	-1	16906379
rit@@	O	-1	16906379
er@@	O	-1	16906379
ia.	O	-1	16906379
Di@@	O	-1	16906379
fferen@@	O	-1	16906379
tial	O	-1	16906379
diagnosis	O	-1	16906379
for	O	-1	16906379
drug@@	O	-1	16906379
-induced	O	-1	16906379
disease	O	-1	16906379
is	O	-1	16906379
inv@@	O	-1	16906379
alu@@	O	-1	16906379
able	O	-1	16906379
even	O	-1	16906379
for	O	-1	16906379
patients	O	-1	16906379
with	O	-1	16906379
cl@@	O	-1	16906379
assi@@	O	-1	16906379
c@@	O	-1	16906379
al	O	-1	16906379
poly@@	B-Disease	D010488	16906379
arter@@	I-Disease	-1	16906379
iti@@	I-Disease	-1	16906379
s	I-Disease	-1	16906379
no@@	I-Disease	-1	16906379
dos@@	I-Disease	-1	16906379
a	I-Disease	-1	16906379
.	O	-1	16906379

In@@	O	-1	16911931
t@@	O	-1	16911931
ram@@	O	-1	16911931
us@@	O	-1	16911931
cular	O	-1	16911931
hepatitis	B-Disease	D006509	16911931
B	I-Disease	-1	16911931
immun@@	O	-1	16911931
e	O	-1	16911931
glo@@	O	-1	16911931
b@@	O	-1	16911931
ul@@	O	-1	16911931
in	O	-1	16911931
combined	O	-1	16911931
with	O	-1	16911931
lamivud@@	B-Chemical	D019259	16911931
ine	I-Chemical	-1	16911931
in	O	-1	16911931
pre@@	O	-1	16911931
ven@@	O	-1	16911931
tion	O	-1	16911931
of	O	-1	16911931
hepatitis	B-Disease	D006509	16911931
B	I-Disease	-1	16911931
recur@@	O	-1	16911931
rence	O	-1	16911931
after	O	-1	16911931
liver	O	-1	16911931
transplant@@	O	-1	16911931
ation.	O	-1	16911931
BACKGROUND:	O	-1	16911931
Com@@	O	-1	16911931
bin@@	O	-1	16911931
ed	O	-1	16911931
hepatitis	B-Disease	D006509	16911931
B	I-Disease	-1	16911931
immun@@	O	-1	16911931
e	O	-1	16911931
glo@@	O	-1	16911931
b@@	O	-1	16911931
ul@@	O	-1	16911931
in	O	-1	16911931
(@@	O	-1	16911931
HB@@	O	-1	16911931
I@@	O	-1	16911931
g@@	O	-1	16911931
)	O	-1	16911931
and	O	-1	16911931
lamivud@@	B-Chemical	D019259	16911931
ine	I-Chemical	-1	16911931
in	O	-1	16911931
pro@@	O	-1	16911931
phyl@@	O	-1	16911931
ax@@	O	-1	16911931
is	O	-1	16911931
of	O	-1	16911931
the	O	-1	16911931
recur@@	O	-1	16911931
rence	O	-1	16911931
of	O	-1	16911931
hepatitis	B-Disease	D006509	16911931
B	I-Disease	-1	16911931
after	O	-1	16911931
liver	O	-1	16911931
transplant@@	O	-1	16911931
ation	O	-1	16911931
has	O	-1	16911931
significantly	O	-1	16911931
improved	O	-1	16911931
the	O	-1	16911931
sur@@	O	-1	16911931
viv@@	O	-1	16911931
al	O	-1	16911931
of	O	-1	16911931
HB@@	B-Chemical	D006514	16911931
s@@	I-Chemical	-1	16911931
A@@	I-Chemical	-1	16911931
g	I-Chemical	-1	16911931
positive	O	-1	16911931
patients.	O	-1	16911931
This	O	-1	16911931
study	O	-1	16911931
was	O	-1	16911931
under@@	O	-1	16911931
tak@@	O	-1	16911931
en	O	-1	16911931
to	O	-1	16911931
evalu@@	O	-1	16911931
ate	O	-1	16911931
the	O	-1	16911931
outcom@@	O	-1	16911931
es	O	-1	16911931
of	O	-1	16911931
liver	O	-1	16911931
transplant@@	O	-1	16911931
ation	O	-1	16911931
for	O	-1	16911931
patients	O	-1	16911931
with	O	-1	16911931
hepatitis	B-Disease	D006509	16911931
B	I-Disease	-1	16911931
vi@@	O	-1	16911931
ru@@	O	-1	16911931
s	O	-1	16911931
(@@	O	-1	16911931
HB@@	O	-1	16911931
V@@	O	-1	16911931
).	O	-1	16911931
METHODS:	O	-1	16911931
A	O	-1	16911931
ret@@	O	-1	16911931
ro@@	O	-1	16911931
sp@@	O	-1	16911931
ective	O	-1	16911931
ch@@	O	-1	16911931
ar@@	O	-1	16911931
t	O	-1	16911931
analysis	O	-1	16911931
and	O	-1	16911931
a	O	-1	16911931
revie@@	O	-1	16911931
w	O	-1	16911931
of	O	-1	16911931
the	O	-1	16911931
org@@	O	-1	16911931
an	O	-1	16911931
transplant	O	-1	16911931
dat@@	O	-1	16911931
ab@@	O	-1	16911931
ase	O	-1	16911931
identi@@	O	-1	16911931
fied	O	-1	16911931
5@@	O	-1	16911931
1	O	-1	16911931
patients	O	-1	16911931
(4@@	O	-1	16911931
3	O	-1	16911931
men	O	-1	16911931
and	O	-1	16911931
8	O	-1	16911931
wom@@	O	-1	16911931
en@@	O	-1	16911931
)	O	-1	16911931
transplant@@	O	-1	16911931
ed	O	-1	16911931
for	O	-1	16911931
ben@@	O	-1	16911931
ig@@	O	-1	16911931
n	O	-1	16911931
HB@@	O	-1	16911931
V@@	O	-1	16911931
-@@	O	-1	16911931
related	O	-1	16911931
cir@@	B-Disease	D008103	16911931
r@@	I-Disease	-1	16911931
ho@@	I-Disease	-1	16911931
tic	I-Disease	-1	16911931
diseas@@	I-Disease	-1	16911931
es	I-Disease	-1	16911931
between	O	-1	16911931
J@@	O	-1	16911931
un@@	O	-1	16911931
e	O	-1	16911931
20@@	O	-1	16911931
0@@	O	-1	16911931
2	O	-1	16911931
and	O	-1	16911931
D@@	O	-1	16911931
ec@@	O	-1	16911931
emb@@	O	-1	16911931
er	O	-1	16911931
20@@	O	-1	16911931
0@@	O	-1	16911931
4	O	-1	16911931
who	O	-1	16911931
had	O	-1	16911931
sur@@	O	-1	16911931
vi@@	O	-1	16911931
ved	O	-1	16911931
more	O	-1	16911931
than	O	-1	16911931
3	O	-1	16911931
months.	O	-1	16911931
HB@@	O	-1	16911931
I@@	O	-1	16911931
g	O	-1	16911931
was	O	-1	16911931
administered	O	-1	16911931
intra@@	O	-1	16911931
ven@@	O	-1	16911931
ously	O	-1	16911931
during	O	-1	16911931
the	O	-1	16911931
first	O	-1	16911931
week	O	-1	16911931
and	O	-1	16911931
int@@	O	-1	16911931
ram@@	O	-1	16911931
us@@	O	-1	16911931
cul@@	O	-1	16911931
arly	O	-1	16911931
the@@	O	-1	16911931
re@@	O	-1	16911931
af@@	O	-1	16911931
ter@@	O	-1	16911931
.	O	-1	16911931
RESULTS:	O	-1	16911931
A@@	O	-1	16911931
t	O	-1	16911931
a	O	-1	16911931
median	O	-1	16911931
follow-up	O	-1	16911931
of	O	-1	16911931
1@@	O	-1	16911931
4.@@	O	-1	16911931
1	O	-1	16911931
month@@	O	-1	16911931
s,	O	-1	16911931
the	O	-1	16911931
over@@	O	-1	16911931
all	O	-1	16911931
recur@@	O	-1	16911931
rence	O	-1	16911931
rate	O	-1	16911931
in	O	-1	16911931
the	O	-1	16911931
5@@	O	-1	16911931
1	O	-1	16911931
patients	O	-1	16911931
was	O	-1	16911931
3.@@	O	-1	16911931
9@@	O	-1	16911931
%	O	-1	16911931
(2@@	O	-1	16911931
/@@	O	-1	16911931
5@@	O	-1	16911931
1).	O	-1	16911931
The	O	-1	16911931
over@@	O	-1	16911931
all	O	-1	16911931
patient	O	-1	16911931
sur@@	O	-1	16911931
viv@@	O	-1	16911931
al	O	-1	16911931
was	O	-1	16911931
8@@	O	-1	16911931
8.@@	O	-1	16911931
3@@	O	-1	16911931
%,	O	-1	16911931
and	O	-1	16911931
8@@	O	-1	16911931
2.@@	O	-1	16911931
4@@	O	-1	16911931
%	O	-1	16911931
after	O	-1	16911931
1	O	-1	16911931
and	O	-1	16911931
2	O	-1	16911931
year@@	O	-1	16911931
s,	O	-1	16911931
respectively.	O	-1	16911931
A	O	-1	16911931
daily	O	-1	16911931
oral	O	-1	16911931
dose	O	-1	16911931
of	O	-1	16911931
100	O	-1	16911931
mg	O	-1	16911931
lamivud@@	B-Chemical	D019259	16911931
ine	I-Chemical	-1	16911931
for	O	-1	16911931
2	O	-1	16911931
weeks	O	-1	16911931
before	O	-1	16911931
transplant@@	O	-1	16911931
ation	O	-1	16911931
for	O	-1	16911931
10	O	-1	16911931
patients	O	-1	16911931
en@@	O	-1	16911931
abl@@	O	-1	16911931
ed	O	-1	16911931
5@@	O	-1	16911931
7.@@	O	-1	16911931
1@@	O	-1	16911931
%	O	-1	16911931
(4@@	O	-1	16911931
/@@	O	-1	16911931
7@@	O	-1	16911931
)	O	-1	16911931
and	O	-1	16911931
6@@	O	-1	16911931
2.@@	O	-1	16911931
5%	O	-1	16911931
(5@@	O	-1	16911931
/@@	O	-1	16911931
8@@	O	-1	16911931
)	O	-1	16911931
of	O	-1	16911931
HB@@	O	-1	16911931
V@@	O	-1	16911931
-@@	O	-1	16911931
D@@	O	-1	16911931
NA	O	-1	16911931
and	O	-1	16911931
HB@@	B-Chemical	D006513	16911931
e@@	I-Chemical	-1	16911931
A@@	I-Chemical	-1	16911931
g	I-Chemical	-1	16911931
positive	O	-1	16911931
patients	O	-1	16911931
respecti@@	O	-1	16911931
vely	O	-1	16911931
to	O	-1	16911931
conver@@	O	-1	16911931
t	O	-1	16911931
to	O	-1	16911931
be	O	-1	16911931
neg@@	O	-1	16911931
ati@@	O	-1	16911931
ve.	O	-1	16911931
In@@	O	-1	16911931
t@@	O	-1	16911931
ram@@	O	-1	16911931
us@@	O	-1	16911931
cular	O	-1	16911931
HB@@	O	-1	16911931
I@@	O	-1	16911931
g	O	-1	16911931
was	O	-1	16911931
well	O	-1	16911931
toler@@	O	-1	16911931
ated	O	-1	16911931
in	O	-1	16911931
all	O	-1	16911931
patients.	O	-1	16911931
CONCLUSION:	O	-1	16911931
L@@	B-Chemical	D019259	16911931
amivud@@	I-Chemical	-1	16911931
ine	I-Chemical	-1	16911931
combined	O	-1	16911931
with	O	-1	16911931
int@@	O	-1	16911931
ram@@	O	-1	16911931
us@@	O	-1	16911931
cular	O	-1	16911931
HB@@	O	-1	16911931
I@@	O	-1	16911931
g	O	-1	16911931
can	O	-1	16911931
eff@@	O	-1	16911931
ectively	O	-1	16911931
prev@@	O	-1	16911931
ent	O	-1	16911931
allogra@@	O	-1	16911931
ft	O	-1	16911931
from	O	-1	16911931
the	O	-1	16911931
recur@@	O	-1	16911931
rence	O	-1	16911931
of	O	-1	16911931
HBV	O	-1	16911931
after	O	-1	16911931
liver	O	-1	16911931
transplant@@	O	-1	16911931
ation.	O	-1	16911931

An@@	O	-1	16920333
ti@@	O	-1	16920333
convul@@	O	-1	16920333
s@@	O	-1	16920333
ant	O	-1	16920333
effect	O	-1	16920333
of	O	-1	16920333
es@@	B-Chemical	C416835	16920333
l@@	I-Chemical	-1	16920333
ic@@	I-Chemical	-1	16920333
arb@@	I-Chemical	-1	16920333
azepine	I-Chemical	-1	16920333
acet@@	I-Chemical	-1	16920333
ate	I-Chemical	-1	16920333
(	O	-1	16920333
B@@	B-Chemical	C416835	16920333
I@@	I-Chemical	-1	16920333
A	I-Chemical	-1	16920333
2-@@	I-Chemical	-1	16920333
0@@	I-Chemical	-1	16920333
9@@	I-Chemical	-1	16920333
3	I-Chemical	-1	16920333
)	O	-1	16920333
on	O	-1	16920333
seizures	B-Disease	D012640	16920333
induced	O	-1	16920333
by	O	-1	16920333
micro@@	O	-1	16920333
per@@	O	-1	16920333
f@@	O	-1	16920333
usion	O	-1	16920333
of	O	-1	16920333
p@@	B-Chemical	D010852	16920333
ic@@	I-Chemical	-1	16920333
ro@@	I-Chemical	-1	16920333
tox@@	I-Chemical	-1	16920333
in	I-Chemical	-1	16920333
in	O	-1	16920333
the	O	-1	16920333
hippocamp@@	O	-1	16920333
us	O	-1	16920333
of	O	-1	16920333
f@@	O	-1	16920333
re@@	O	-1	16920333
ely	O	-1	16920333
mo@@	O	-1	16920333
ving	O	-1	16920333
rats.	O	-1	16920333
E@@	B-Chemical	C416835	16920333
s@@	I-Chemical	-1	16920333
l@@	I-Chemical	-1	16920333
ic@@	I-Chemical	-1	16920333
arb@@	I-Chemical	-1	16920333
azepine	I-Chemical	-1	16920333
acet@@	I-Chemical	-1	16920333
ate	I-Chemical	-1	16920333
(	O	-1	16920333
B@@	B-Chemical	C416835	16920333
I@@	I-Chemical	-1	16920333
A	I-Chemical	-1	16920333
2-@@	I-Chemical	-1	16920333
0@@	I-Chemical	-1	16920333
9@@	I-Chemical	-1	16920333
3	I-Chemical	-1	16920333
,	O	-1	16920333
S@@	B-Chemical	C416835	16920333
-@@	I-Chemical	-1	16920333
(-@@	I-Chemical	-1	16920333
)-@@	I-Chemical	-1	16920333
10-@@	I-Chemical	-1	16920333
ace@@	I-Chemical	-1	16920333
tox@@	I-Chemical	-1	16920333
y-@@	I-Chemical	-1	16920333
10@@	I-Chemical	-1	16920333
,@@	I-Chemical	-1	16920333
1@@	I-Chemical	-1	16920333
1-@@	I-Chemical	-1	16920333
di@@	I-Chemical	-1	16920333
hydro@@	I-Chemical	-1	16920333
-@@	I-Chemical	-1	16920333
5@@	I-Chemical	-1	16920333
H@@	I-Chemical	-1	16920333
-@@	I-Chemical	-1	16920333
di@@	I-Chemical	-1	16920333
b@@	I-Chemical	-1	16920333
enz@@	I-Chemical	-1	16920333
o@@	I-Chemical	-1	16920333
/@@	I-Chemical	-1	16920333
b@@	I-Chemical	-1	16920333
,@@	I-Chemical	-1	16920333
f@@	I-Chemical	-1	16920333
/@@	I-Chemical	-1	16920333
azep@@	I-Chemical	-1	16920333
ine-@@	I-Chemical	-1	16920333
5-@@	I-Chemical	-1	16920333
carb@@	I-Chemical	-1	16920333
ox@@	I-Chemical	-1	16920333
amide	I-Chemical	-1	16920333
)	O	-1	16920333
is	O	-1	16920333
a	O	-1	16920333
novel	O	-1	16920333
anti@@	O	-1	16920333
epileptic	O	-1	16920333
drug@@	O	-1	16920333
,	O	-1	16920333
no@@	O	-1	16920333
w	O	-1	16920333
in	O	-1	16920333
Ph@@	O	-1	16920333
ase	O	-1	16920333
I@@	O	-1	16920333
II	O	-1	16920333
clinical	O	-1	16920333
tri@@	O	-1	16920333
al@@	O	-1	16920333
s,	O	-1	16920333
de@@	O	-1	16920333
signed	O	-1	16920333
with	O	-1	16920333
the	O	-1	16920333
a@@	O	-1	16920333
im	O	-1	16920333
of	O	-1	16920333
impro@@	O	-1	16920333
ving	O	-1	16920333
efficacy	O	-1	16920333
and	O	-1	16920333
safety	O	-1	16920333
in	O	-1	16920333
compar@@	O	-1	16920333
ison	O	-1	16920333
with	O	-1	16920333
the	O	-1	16920333
struct@@	O	-1	16920333
ur@@	O	-1	16920333
ally	O	-1	16920333
related	O	-1	16920333
drugs	O	-1	16920333
carbamazepine	B-Chemical	D002220	16920333
(	O	-1	16920333
C@@	B-Chemical	D002220	16920333
B@@	I-Chemical	-1	16920333
Z	I-Chemical	-1	16920333
)	O	-1	16920333
and	O	-1	16920333
ox@@	B-Chemical	C036006	16920333
carb@@	I-Chemical	-1	16920333
azepine	I-Chemical	-1	16920333
(	O	-1	16920333
O@@	B-Chemical	C036006	16920333
X@@	I-Chemical	-1	16920333
C	I-Chemical	-1	16920333
).	O	-1	16920333
We	O	-1	16920333
have	O	-1	16920333
studied	O	-1	16920333
the	O	-1	16920333
effects	O	-1	16920333
of	O	-1	16920333
oral	O	-1	16920333
treatment	O	-1	16920333
with	O	-1	16920333
es@@	B-Chemical	C416835	16920333
l@@	I-Chemical	-1	16920333
ic@@	I-Chemical	-1	16920333
arb@@	I-Chemical	-1	16920333
azepine	I-Chemical	-1	16920333
acet@@	I-Chemical	-1	16920333
ate	I-Chemical	-1	16920333
on	O	-1	16920333
a	O	-1	16920333
wh@@	O	-1	16920333
ol@@	O	-1	16920333
e-@@	O	-1	16920333
anim@@	O	-1	16920333
al	O	-1	16920333
model	O	-1	16920333
in	O	-1	16920333
which	O	-1	16920333
partial	O	-1	16920333
seizures	B-Disease	D012640	16920333
can	O	-1	16920333
be	O	-1	16920333
el@@	O	-1	16920333
ic@@	O	-1	16920333
ited	O	-1	16920333
repe@@	O	-1	16920333
ated@@	O	-1	16920333
ly	O	-1	16920333
on	O	-1	16920333
different	O	-1	16920333
days	O	-1	16920333
without	O	-1	16920333
changes	O	-1	16920333
in	O	-1	16920333
th@@	O	-1	16920333
res@@	O	-1	16920333
h@@	O	-1	16920333
old	O	-1	16920333
or	O	-1	16920333
seizure	B-Disease	D012640	16920333
pat@@	O	-1	16920333
tern@@	O	-1	16920333
s.	O	-1	16920333
In	O	-1	16920333
the	O	-1	16920333
animals	O	-1	16920333
treated	O	-1	16920333
with	O	-1	16920333
th@@	O	-1	16920333
res@@	O	-1	16920333
h@@	O	-1	16920333
old	O	-1	16920333
doses	O	-1	16920333
of	O	-1	16920333
p@@	B-Chemical	D010852	16920333
ic@@	I-Chemical	-1	16920333
ro@@	I-Chemical	-1	16920333
tox@@	I-Chemical	-1	16920333
in	I-Chemical	-1	16920333
,	O	-1	16920333
the	O	-1	16920333
average	O	-1	16920333
number	O	-1	16920333
of	O	-1	16920333
seizures	B-Disease	D012640	16920333
was	O	-1	16920333
2.@@	O	-1	16920333
3@@	O	-1	16920333
+/-@@	O	-1	16920333
1.@@	O	-1	16920333
2,	O	-1	16920333
and	O	-1	16920333
average	O	-1	16920333
seizure	B-Disease	D012640	16920333
duration	O	-1	16920333
was	O	-1	16920333
3@@	O	-1	16920333
9.@@	O	-1	16920333
5@@	O	-1	16920333
+/-@@	O	-1	16920333
8.@@	O	-1	16920333
4@@	O	-1	16920333
s.	O	-1	16920333
Pre@@	O	-1	16920333
-@@	O	-1	16920333
treatment	O	-1	16920333
with	O	-1	16920333
a	O	-1	16920333
dose	O	-1	16920333
of	O	-1	16920333
30	O	-1	16920333
mg/kg	O	-1	16920333
2@@	O	-1	16920333
h	O	-1	16920333
before	O	-1	16920333
p@@	B-Chemical	D010852	16920333
ic@@	I-Chemical	-1	16920333
ro@@	I-Chemical	-1	16920333
tox@@	I-Chemical	-1	16920333
in	I-Chemical	-1	16920333
micro@@	O	-1	16920333
per@@	O	-1	16920333
f@@	O	-1	16920333
usion	O	-1	16920333
prevent@@	O	-1	16920333
ed	O	-1	16920333
seizures	B-Disease	D012640	16920333
in	O	-1	16920333
the	O	-1	16920333
7@@	O	-1	16920333
5%	O	-1	16920333
of	O	-1	16920333
the	O	-1	16920333
rats.	O	-1	16920333
L@@	O	-1	16920333
o@@	O	-1	16920333
w@@	O	-1	16920333
er	O	-1	16920333
doses	O	-1	16920333
(@@	O	-1	16920333
3	O	-1	16920333
and	O	-1	16920333
10@@	O	-1	16920333
mg/kg)	O	-1	16920333
did	O	-1	16920333
not	O	-1	16920333
sup@@	O	-1	16920333
pres@@	O	-1	16920333
s	O	-1	16920333
seizures	B-Disease	D012640	16920333
,	O	-1	16920333
however,	O	-1	16920333
after	O	-1	16920333
administration	O	-1	16920333
of	O	-1	16920333
10@@	O	-1	16920333
mg/kg@@	O	-1	16920333
,	O	-1	16920333
significant	O	-1	16920333
reduc@@	O	-1	16920333
tions	O	-1	16920333
in	O	-1	16920333
seizures	B-Disease	D012640	16920333
duration	O	-1	16920333
(2@@	O	-1	16920333
4.@@	O	-1	16920333
3@@	O	-1	16920333
+/-@@	O	-1	16920333
6.@@	O	-1	16920333
8@@	O	-1	16920333
s)	O	-1	16920333
and	O	-1	16920333
seizure	B-Disease	D012640	16920333
number	O	-1	16920333
(1@@	O	-1	16920333
.@@	O	-1	16920333
6@@	O	-1	16920333
+/-@@	O	-1	16920333
0.@@	O	-1	16920333
34@@	O	-1	16920333
)	O	-1	16920333
were	O	-1	16920333
f@@	O	-1	16920333
oun@@	O	-1	16920333
d.	O	-1	16920333
No	O	-1	16920333
adverse	O	-1	16920333
effects	O	-1	16920333
of	O	-1	16920333
es@@	B-Chemical	C416835	16920333
l@@	I-Chemical	-1	16920333
ic@@	I-Chemical	-1	16920333
arb@@	I-Chemical	-1	16920333
azepine	I-Chemical	-1	16920333
acet@@	I-Chemical	-1	16920333
ate	I-Chemical	-1	16920333
were	O	-1	16920333
observed	O	-1	16920333
in	O	-1	16920333
the	O	-1	16920333
behavi@@	O	-1	16920333
or@@	O	-1	16920333
al@@	O	-1	16920333
/@@	O	-1	16920333
E@@	O	-1	16920333
E@@	O	-1	16920333
G	O	-1	16920333
pat@@	O	-1	16920333
tern@@	O	-1	16920333
s	O	-1	16920333
studi@@	O	-1	16920333
ed,	O	-1	16920333
including	O	-1	16920333
sle@@	O	-1	16920333
ep@@	O	-1	16920333
/@@	O	-1	16920333
w@@	O	-1	16920333
ak@@	O	-1	16920333
e@@	O	-1	16920333
ful@@	O	-1	16920333
ness	O	-1	16920333
cyc@@	O	-1	16920333
le@@	O	-1	16920333
,	O	-1	16920333
at	O	-1	16920333
the	O	-1	16920333
doses	O	-1	16920333
studi@@	O	-1	16920333
ed.	O	-1	16920333

Ac@@	B-Disease	D058186	17028363
ute	I-Disease	-1	17028363
renal	I-Disease	-1	17028363
failure	I-Disease	-1	17028363
associated	O	-1	17028363
with	O	-1	17028363
prolonged	O	-1	17028363
int@@	O	-1	17028363
ake	O	-1	17028363
of	O	-1	17028363
s@@	O	-1	17028363
lim@@	O	-1	17028363
m@@	O	-1	17028363
ing	O	-1	17028363
p@@	O	-1	17028363
ill@@	O	-1	17028363
s	O	-1	17028363
containing	O	-1	17028363
an@@	B-Chemical	D000880	17028363
th@@	I-Chemical	-1	17028363
ra@@	I-Chemical	-1	17028363
qu@@	I-Chemical	-1	17028363
in@@	I-Chemical	-1	17028363
on@@	I-Chemical	-1	17028363
es	I-Chemical	-1	17028363
.	O	-1	17028363
Ch@@	B-Chemical	D004365	17028363
in@@	I-Chemical	-1	17028363
ese	I-Chemical	-1	17028363
h@@	I-Chemical	-1	17028363
er@@	I-Chemical	-1	17028363
b@@	I-Chemical	-1	17028363
al	I-Chemical	-1	17028363
medic@@	O	-1	17028363
ine	O	-1	17028363
pre@@	O	-1	17028363
par@@	O	-1	17028363
ations	O	-1	17028363
are	O	-1	17028363
wi@@	O	-1	17028363
de@@	O	-1	17028363
ly	O	-1	17028363
av@@	O	-1	17028363
ail@@	O	-1	17028363
able	O	-1	17028363
and	O	-1	17028363
often	O	-1	17028363
reg@@	O	-1	17028363
ar@@	O	-1	17028363
ded	O	-1	17028363
by	O	-1	17028363
the	O	-1	17028363
pu@@	O	-1	17028363
bl@@	O	-1	17028363
ic	O	-1	17028363
as	O	-1	17028363
n@@	O	-1	17028363
at@@	O	-1	17028363
ural	O	-1	17028363
and	O	-1	17028363
saf@@	O	-1	17028363
e	O	-1	17028363
re@@	O	-1	17028363
medi@@	O	-1	17028363
es	O	-1	17028363
for	O	-1	17028363
a	O	-1	17028363
vari@@	O	-1	17028363
ety	O	-1	17028363
of	O	-1	17028363
med@@	O	-1	17028363
ical	O	-1	17028363
condi@@	O	-1	17028363
tions.	O	-1	17028363
Ne@@	B-Disease	D007674	17028363
ph@@	I-Disease	-1	17028363
ro@@	I-Disease	-1	17028363
pathy	I-Disease	-1	17028363
caused	O	-1	17028363
by	O	-1	17028363
Ch@@	B-Chemical	D004365	17028363
in@@	I-Chemical	-1	17028363
ese	I-Chemical	-1	17028363
h@@	I-Chemical	-1	17028363
er@@	I-Chemical	-1	17028363
b@@	I-Chemical	-1	17028363
s	I-Chemical	-1	17028363
has	O	-1	17028363
previously	O	-1	17028363
been	O	-1	17028363
repor@@	O	-1	17028363
te@@	O	-1	17028363
d,	O	-1	17028363
us@@	O	-1	17028363
ually	O	-1	17028363
invol@@	O	-1	17028363
ving	O	-1	17028363
the	O	-1	17028363
use	O	-1	17028363
of	O	-1	17028363
ar@@	B-Chemical	D034341	17028363
ist@@	I-Chemical	-1	17028363
o@@	I-Chemical	-1	17028363
lo@@	I-Chemical	-1	17028363
ch@@	I-Chemical	-1	17028363
ic	I-Chemical	-1	17028363
acid@@	I-Chemical	-1	17028363
s	I-Chemical	-1	17028363
.	O	-1	17028363
We	O	-1	17028363
report	O	-1	17028363
a	O	-1	17028363
2@@	O	-1	17028363
3-@@	O	-1	17028363
year-old	O	-1	17028363
woman	O	-1	17028363
who	O	-1	17028363
developed	O	-1	17028363
acute	B-Disease	D058186	17028363
renal	I-Disease	-1	17028363
failure	I-Disease	-1	17028363
following	O	-1	17028363
prolonged	O	-1	17028363
use	O	-1	17028363
of	O	-1	17028363
a	O	-1	17028363
pro@@	O	-1	17028363
pri@@	O	-1	17028363
et@@	O	-1	17028363
ary	O	-1	17028363
Ch@@	B-Chemical	D004365	17028363
in@@	I-Chemical	-1	17028363
ese	I-Chemical	-1	17028363
h@@	I-Chemical	-1	17028363
er@@	I-Chemical	-1	17028363
b@@	I-Chemical	-1	17028363
al	I-Chemical	-1	17028363
s@@	O	-1	17028363
lim@@	O	-1	17028363
m@@	O	-1	17028363
ing	O	-1	17028363
p@@	O	-1	17028363
il@@	O	-1	17028363
l	O	-1	17028363
that	O	-1	17028363
cont@@	O	-1	17028363
ained	O	-1	17028363
an@@	B-Chemical	D000880	17028363
th@@	I-Chemical	-1	17028363
ra@@	I-Chemical	-1	17028363
qu@@	I-Chemical	-1	17028363
in@@	I-Chemical	-1	17028363
one	I-Chemical	-1	17028363
der@@	O	-1	17028363
i@@	O	-1	17028363
v@@	O	-1	17028363
ati@@	O	-1	17028363
v@@	O	-1	17028363
es,	O	-1	17028363
extrac@@	O	-1	17028363
ted	O	-1	17028363
from	O	-1	17028363
R@@	O	-1	17028363
hi@@	O	-1	17028363
z@@	O	-1	17028363
oma	O	-1	17028363
R@@	O	-1	17028363
he@@	O	-1	17028363
i	O	-1	17028363
(@@	O	-1	17028363
rh@@	O	-1	17028363
ub@@	O	-1	17028363
arb@@	O	-1	17028363
).	O	-1	17028363
The	O	-1	17028363
renal	B-Disease	D058186	17028363
injury	I-Disease	-1	17028363
was	O	-1	17028363
prob@@	O	-1	17028363
ably	O	-1	17028363
ag@@	O	-1	17028363
gra@@	O	-1	17028363
v@@	O	-1	17028363
ated	O	-1	17028363
by	O	-1	17028363
the	O	-1	17028363
concomit@@	O	-1	17028363
ant	O	-1	17028363
int@@	O	-1	17028363
ake	O	-1	17028363
of	O	-1	17028363
a	O	-1	17028363
non-@@	O	-1	17028363
steroid@@	O	-1	17028363
al	O	-1	17028363
anti@@	O	-1	17028363
-@@	O	-1	17028363
inflam@@	O	-1	17028363
mat@@	O	-1	17028363
ory	O	-1	17028363
drug@@	O	-1	17028363
,	O	-1	17028363
dic@@	B-Chemical	D004008	17028363
lo@@	I-Chemical	-1	17028363
f@@	I-Chemical	-1	17028363
en@@	I-Chemical	-1	17028363
a@@	I-Chemical	-1	17028363
c	I-Chemical	-1	17028363
.	O	-1	17028363
R@@	O	-1	17028363
en@@	O	-1	17028363
al	O	-1	17028363
path@@	O	-1	17028363
ology	O	-1	17028363
was	O	-1	17028363
that	O	-1	17028363
of	O	-1	17028363
hy@@	O	-1	17028363
p@@	O	-1	17028363
oc@@	O	-1	17028363
ell@@	O	-1	17028363
ular	O	-1	17028363
interstitial	O	-1	17028363
fib@@	B-Disease	D005355	17028363
ro@@	I-Disease	-1	17028363
sis	I-Disease	-1	17028363
.	O	-1	17028363
S@@	O	-1	17028363
p@@	O	-1	17028363
ont@@	O	-1	17028363
aneous	O	-1	17028363
renal	O	-1	17028363
recovery	O	-1	17028363
occurred	O	-1	17028363
up@@	O	-1	17028363
on	O	-1	17028363
cess@@	O	-1	17028363
ation	O	-1	17028363
of	O	-1	17028363
the	O	-1	17028363
s@@	O	-1	17028363
lim@@	O	-1	17028363
m@@	O	-1	17028363
ing	O	-1	17028363
p@@	O	-1	17028363
ill@@	O	-1	17028363
s,	O	-1	17028363
but	O	-1	17028363
mil@@	O	-1	17028363
d	O	-1	17028363
interstitial	O	-1	17028363
fib@@	B-Disease	D005355	17028363
ro@@	I-Disease	-1	17028363
sis	I-Disease	-1	17028363
and	O	-1	17028363
tub@@	O	-1	17028363
ular	O	-1	17028363
atro@@	B-Disease	D001284	17028363
ph@@	I-Disease	-1	17028363
y	I-Disease	-1	17028363
was	O	-1	17028363
sti@@	O	-1	17028363
ll	O	-1	17028363
ev@@	O	-1	17028363
id@@	O	-1	17028363
ent	O	-1	17028363
hist@@	O	-1	17028363
olog@@	O	-1	17028363
ically	O	-1	17028363
4	O	-1	17028363
months	O	-1	17028363
lat@@	O	-1	17028363
er.	O	-1	17028363
Although	O	-1	17028363
a	O	-1	17028363
ca@@	O	-1	17028363
us@@	O	-1	17028363
al	O	-1	17028363
rel@@	O	-1	17028363
ationship	O	-1	17028363
between	O	-1	17028363
the	O	-1	17028363
use	O	-1	17028363
of	O	-1	17028363
an	O	-1	17028363
an@@	B-Chemical	D000880	17028363
th@@	I-Chemical	-1	17028363
ra@@	I-Chemical	-1	17028363
qu@@	I-Chemical	-1	17028363
in@@	I-Chemical	-1	17028363
one	I-Chemical	-1	17028363
-@@	O	-1	17028363
containing	O	-1	17028363
h@@	O	-1	17028363
er@@	O	-1	17028363
b@@	O	-1	17028363
al	O	-1	17028363
agent	O	-1	17028363
and	O	-1	17028363
renal	B-Disease	D058186	17028363
injury	I-Disease	-1	17028363
remain@@	O	-1	17028363
s	O	-1	17028363
to	O	-1	17028363
be	O	-1	17028363
pro@@	O	-1	17028363
ven@@	O	-1	17028363
,	O	-1	17028363
ph@@	O	-1	17028363
y@@	O	-1	17028363
to@@	O	-1	17028363
therap@@	O	-1	17028363
y-@@	O	-1	17028363
associated	O	-1	17028363
interstitial	O	-1	17028363
nephro@@	B-Disease	D007674	17028363
pathy	I-Disease	-1	17028363
should	O	-1	17028363
be	O	-1	17028363
considered	O	-1	17028363
in	O	-1	17028363
patients	O	-1	17028363
who	O	-1	17028363
present	O	-1	17028363
with	O	-1	17028363
un@@	O	-1	17028363
expl@@	O	-1	17028363
ained	O	-1	17028363
renal	B-Disease	D051437	17028363
failure	I-Disease	-1	17028363
.	O	-1	17028363

Ch@@	B-Chemical	C004656	17035713
loro@@	I-Chemical	-1	17035713
acet@@	I-Chemical	-1	17035713
al@@	I-Chemical	-1	17035713
de@@	I-Chemical	-1	17035713
hy@@	I-Chemical	-1	17035713
de	I-Chemical	-1	17035713
as	O	-1	17035713
a	O	-1	17035713
sulf@@	B-Chemical	-1	17035713
hy@@	I-Chemical	-1	17035713
d@@	I-Chemical	-1	17035713
r@@	I-Chemical	-1	17035713
yl	I-Chemical	-1	17035713
re@@	O	-1	17035713
agent@@	O	-1	17035713
:	O	-1	17035713
the	O	-1	17035713
role	O	-1	17035713
of	O	-1	17035713
cri@@	O	-1	17035713
tical	O	-1	17035713
th@@	B-Chemical	D013438	17035713
io@@	I-Chemical	-1	17035713
l	I-Chemical	-1	17035713
groups	O	-1	17035713
in	O	-1	17035713
if@@	B-Chemical	D007069	17035713
os@@	I-Chemical	-1	17035713
f@@	I-Chemical	-1	17035713
amide	I-Chemical	-1	17035713
nephro@@	B-Disease	D007674	17035713
pathy	I-Disease	-1	17035713
.	O	-1	17035713
Ch@@	B-Chemical	C004656	17035713
loro@@	I-Chemical	-1	17035713
acet@@	I-Chemical	-1	17035713
al@@	I-Chemical	-1	17035713
de@@	I-Chemical	-1	17035713
hy@@	I-Chemical	-1	17035713
de	I-Chemical	-1	17035713
(	O	-1	17035713
CA@@	B-Chemical	C004656	17035713
A	I-Chemical	-1	17035713
)	O	-1	17035713
is	O	-1	17035713
a	O	-1	17035713
metabol@@	O	-1	17035713
ite	O	-1	17035713
of	O	-1	17035713
the	O	-1	17035713
al@@	O	-1	17035713
k@@	O	-1	17035713
yl@@	O	-1	17035713
ating	O	-1	17035713
agent	O	-1	17035713
if@@	B-Chemical	D007069	17035713
os@@	I-Chemical	-1	17035713
f@@	I-Chemical	-1	17035713
amide	I-Chemical	-1	17035713
(	O	-1	17035713
I@@	B-Chemical	D007069	17035713
F@@	I-Chemical	-1	17035713
O	I-Chemical	-1	17035713
)	O	-1	17035713
and	O	-1	17035713
p@@	O	-1	17035713
ut@@	O	-1	17035713
atively	O	-1	17035713
respon@@	O	-1	17035713
sible	O	-1	17035713
for	O	-1	17035713
renal	B-Disease	D007674	17035713
damage	I-Disease	-1	17035713
following	O	-1	17035713
anti@@	O	-1	17035713
-	O	-1	17035713
tumor	B-Disease	D009369	17035713
therapy	O	-1	17035713
with	O	-1	17035713
I@@	B-Chemical	D007069	17035713
F@@	I-Chemical	-1	17035713
O	I-Chemical	-1	17035713
.	O	-1	17035713
D@@	O	-1	17035713
ep@@	O	-1	17035713
le@@	O	-1	17035713
tion	O	-1	17035713
of	O	-1	17035713
sulf@@	B-Chemical	-1	17035713
hy@@	I-Chemical	-1	17035713
d@@	I-Chemical	-1	17035713
r@@	I-Chemical	-1	17035713
yl	I-Chemical	-1	17035713
(	O	-1	17035713
S@@	B-Chemical	-1	17035713
H	I-Chemical	-1	17035713
)	O	-1	17035713
groups	O	-1	17035713
has	O	-1	17035713
been	O	-1	17035713
reported	O	-1	17035713
from	O	-1	17035713
cell	O	-1	17035713
c@@	O	-1	17035713
ult@@	O	-1	17035713
ure,	O	-1	17035713
anim@@	O	-1	17035713
al	O	-1	17035713
and	O	-1	17035713
clinical	O	-1	17035713
studi@@	O	-1	17035713
es.	O	-1	17035713
In	O	-1	17035713
this	O	-1	17035713
wor@@	O	-1	17035713
k	O	-1	17035713
the	O	-1	17035713
effect	O	-1	17035713
of	O	-1	17035713
CA@@	B-Chemical	C004656	17035713
A	I-Chemical	-1	17035713
on	O	-1	17035713
human	O	-1	17035713
pro@@	O	-1	17035713
xim@@	O	-1	17035713
al	O	-1	17035713
tub@@	O	-1	17035713
ul@@	O	-1	17035713
e	O	-1	17035713
cells	O	-1	17035713
in	O	-1	17035713
prim@@	O	-1	17035713
ary	O	-1	17035713
c@@	O	-1	17035713
ult@@	O	-1	17035713
ure	O	-1	17035713
(@@	O	-1	17035713
h@@	O	-1	17035713
R@@	O	-1	17035713
P@@	O	-1	17035713
T@@	O	-1	17035713
EC@@	O	-1	17035713
)	O	-1	17035713
was	O	-1	17035713
investig@@	O	-1	17035713
ated.	O	-1	17035713
T@@	B-Disease	D064420	17035713
oxic@@	I-Disease	-1	17035713
ity	I-Disease	-1	17035713
of	O	-1	17035713
CA@@	B-Chemical	C004656	17035713
A	I-Chemical	-1	17035713
was	O	-1	17035713
determined	O	-1	17035713
by	O	-1	17035713
protein	O	-1	17035713
cont@@	O	-1	17035713
ent@@	O	-1	17035713
,	O	-1	17035713
cell	O	-1	17035713
numb@@	O	-1	17035713
er,	O	-1	17035713
L@@	O	-1	17035713
D@@	O	-1	17035713
H	O	-1	17035713
rele@@	O	-1	17035713
ase,	O	-1	17035713
tr@@	B-Chemical	D014343	17035713
yp@@	I-Chemical	-1	17035713
an	I-Chemical	-1	17035713
b@@	I-Chemical	-1	17035713
lu@@	I-Chemical	-1	17035713
e	I-Chemical	-1	17035713
ex@@	O	-1	17035713
cl@@	O	-1	17035713
usion	O	-1	17035713
ass@@	O	-1	17035713
ay	O	-1	17035713
and	O	-1	17035713
cas@@	O	-1	17035713
p@@	O	-1	17035713
as@@	O	-1	17035713
e-@@	O	-1	17035713
3	O	-1	17035713
activ@@	O	-1	17035713
ity.	O	-1	17035713
F@@	O	-1	17035713
ree	O	-1	17035713
thi@@	B-Chemical	D013438	17035713
ol@@	I-Chemical	-1	17035713
s	I-Chemical	-1	17035713
were	O	-1	17035713
measured	O	-1	17035713
by	O	-1	17035713
the	O	-1	17035713
meth@@	O	-1	17035713
od	O	-1	17035713
of	O	-1	17035713
E@@	O	-1	17035713
ll@@	O	-1	17035713
man@@	O	-1	17035713
.	O	-1	17035713
CA@@	B-Chemical	C004656	17035713
A	I-Chemical	-1	17035713
reduced	O	-1	17035713
h@@	O	-1	17035713
R@@	O	-1	17035713
P@@	O	-1	17035713
TE@@	O	-1	17035713
C	O	-1	17035713
cell	O	-1	17035713
number	O	-1	17035713
and	O	-1	17035713
protein@@	O	-1	17035713
,	O	-1	17035713
induced	O	-1	17035713
a	O	-1	17035713
loss	O	-1	17035713
in	O	-1	17035713
free	O	-1	17035713
intrac@@	O	-1	17035713
ell@@	O	-1	17035713
ular	O	-1	17035713
thi@@	B-Chemical	D013438	17035713
ol@@	I-Chemical	-1	17035713
s	I-Chemical	-1	17035713
and	O	-1	17035713
an	O	-1	17035713
increase	O	-1	17035713
in	O	-1	17035713
necro@@	B-Disease	D009336	17035713
sis	I-Disease	-1	17035713
mark@@	O	-1	17035713
ers.	O	-1	17035713
CA@@	B-Chemical	C004656	17035713
A	I-Chemical	-1	17035713
but	O	-1	17035713
not	O	-1	17035713
ac@@	B-Chemical	D000171	17035713
ro@@	I-Chemical	-1	17035713
le@@	I-Chemical	-1	17035713
in	I-Chemical	-1	17035713
inhibited	O	-1	17035713
the	O	-1	17035713
cy@@	B-Chemical	D003545	17035713
ste@@	I-Chemical	-1	17035713
ine	I-Chemical	-1	17035713
prote@@	O	-1	17035713
as@@	O	-1	17035713
es	O	-1	17035713
cas@@	O	-1	17035713
p@@	O	-1	17035713
as@@	O	-1	17035713
e-@@	O	-1	17035713
3,	O	-1	17035713
cas@@	O	-1	17035713
p@@	O	-1	17035713
as@@	O	-1	17035713
e-@@	O	-1	17035713
8	O	-1	17035713
and	O	-1	17035713
ca@@	O	-1	17035713
the@@	O	-1	17035713
p@@	O	-1	17035713
s@@	O	-1	17035713
in	O	-1	17035713
B@@	O	-1	17035713
.	O	-1	17035713
C@@	O	-1	17035713
as@@	O	-1	17035713
p@@	O	-1	17035713
ase	O	-1	17035713
activation	O	-1	17035713
by	O	-1	17035713
cisplatin	B-Chemical	D002945	17035713
was	O	-1	17035713
inhibited	O	-1	17035713
by	O	-1	17035713
CA@@	B-Chemical	C004656	17035713
A	I-Chemical	-1	17035713
.	O	-1	17035713
In	O	-1	17035713
cells	O	-1	17035713
st@@	O	-1	17035713
ained	O	-1	17035713
with	O	-1	17035713
fluo@@	O	-1	17035713
res@@	O	-1	17035713
c@@	O	-1	17035713
ent	O	-1	17035713
dy@@	O	-1	17035713
es	O	-1	17035713
t@@	O	-1	17035713
arg@@	O	-1	17035713
et@@	O	-1	17035713
ing	O	-1	17035713
l@@	O	-1	17035713
ys@@	O	-1	17035713
os@@	O	-1	17035713
om@@	O	-1	17035713
es,	O	-1	17035713
CA@@	B-Chemical	C004656	17035713
A	I-Chemical	-1	17035713
induced	O	-1	17035713
an	O	-1	17035713
increase	O	-1	17035713
in	O	-1	17035713
l@@	O	-1	17035713
ys@@	O	-1	17035713
os@@	O	-1	17035713
om@@	O	-1	17035713
al	O	-1	17035713
size	O	-1	17035713
and	O	-1	17035713
l@@	O	-1	17035713
ys@@	O	-1	17035713
os@@	O	-1	17035713
om@@	O	-1	17035713
al	O	-1	17035713
le@@	O	-1	17035713
ak@@	O	-1	17035713
age.	O	-1	17035713
The	O	-1	17035713
effects	O	-1	17035713
of	O	-1	17035713
CA@@	B-Chemical	C004656	17035713
A	I-Chemical	-1	17035713
on	O	-1	17035713
cy@@	B-Chemical	D003545	17035713
ste@@	I-Chemical	-1	17035713
ine	I-Chemical	-1	17035713
prote@@	O	-1	17035713
ase	O	-1	17035713
ac@@	O	-1	17035713
ti@@	O	-1	17035713
vi@@	O	-1	17035713
ties	O	-1	17035713
and	O	-1	17035713
thi@@	B-Chemical	D013438	17035713
ol@@	I-Chemical	-1	17035713
s	I-Chemical	-1	17035713
could	O	-1	17035713
be	O	-1	17035713
re@@	O	-1	17035713
produced	O	-1	17035713
in	O	-1	17035713
cell	O	-1	17035713
l@@	O	-1	17035713
ys@@	O	-1	17035713
at@@	O	-1	17035713
e.	O	-1	17035713
A@@	O	-1	17035713
ci@@	O	-1	17035713
di@@	O	-1	17035713
fic@@	O	-1	17035713
ation,	O	-1	17035713
which	O	-1	17035713
s@@	O	-1	17035713
low@@	O	-1	17035713
ed	O	-1	17035713
the	O	-1	17035713
reaction	O	-1	17035713
of	O	-1	17035713
CA@@	B-Chemical	C004656	17035713
A	I-Chemical	-1	17035713
with	O	-1	17035713
th@@	B-Chemical	D013438	17035713
io@@	I-Chemical	-1	17035713
l	I-Chemical	-1	17035713
d@@	O	-1	17035713
on@@	O	-1	17035713
or@@	O	-1	17035713
s,	O	-1	17035713
could	O	-1	17035713
also	O	-1	17035713
attenu@@	O	-1	17035713
ate	O	-1	17035713
effects	O	-1	17035713
of	O	-1	17035713
CA@@	B-Chemical	C004656	17035713
A	I-Chemical	-1	17035713
on	O	-1	17035713
necro@@	B-Disease	D009336	17035713
sis	I-Disease	-1	17035713
mark@@	O	-1	17035713
er@@	O	-1	17035713
s,	O	-1	17035713
th@@	B-Chemical	D013438	17035713
io@@	I-Chemical	-1	17035713
l	I-Chemical	-1	17035713
deple@@	O	-1	17035713
tion	O	-1	17035713
and	O	-1	17035713
cy@@	B-Chemical	D003545	17035713
ste@@	I-Chemical	-1	17035713
ine	I-Chemical	-1	17035713
prote@@	O	-1	17035713
ase	O	-1	17035713
inhibition	O	-1	17035713
in	O	-1	17035713
li@@	O	-1	17035713
ving	O	-1	17035713
cell@@	O	-1	17035713
s.	O	-1	17035713
Th@@	O	-1	17035713
us,	O	-1	17035713
CA@@	B-Chemical	C004656	17035713
A	I-Chemical	-1	17035713
direc@@	O	-1	17035713
tly	O	-1	17035713
re@@	O	-1	17035713
act@@	O	-1	17035713
s	O	-1	17035713
with	O	-1	17035713
cell@@	O	-1	17035713
ular	O	-1	17035713
protein	O	-1	17035713
and	O	-1	17035713
non-@@	O	-1	17035713
protein	O	-1	17035713
thi@@	B-Chemical	D013438	17035713
ol@@	I-Chemical	-1	17035713
s	I-Chemical	-1	17035713
,	O	-1	17035713
medi@@	O	-1	17035713
ating	O	-1	17035713
its	O	-1	17035713
toxicity	B-Disease	D064420	17035713
on	O	-1	17035713
h@@	O	-1	17035713
R@@	O	-1	17035713
P@@	O	-1	17035713
T@@	O	-1	17035713
EC@@	O	-1	17035713
.	O	-1	17035713
This	O	-1	17035713
effect	O	-1	17035713
can	O	-1	17035713
be	O	-1	17035713
reduced	O	-1	17035713
by	O	-1	17035713
ac@@	O	-1	17035713
i@@	O	-1	17035713
di@@	O	-1	17035713
fic@@	O	-1	17035713
ation.	O	-1	17035713
The@@	O	-1	17035713
refore,	O	-1	17035713
urinary	O	-1	17035713
ac@@	O	-1	17035713
i@@	O	-1	17035713
di@@	O	-1	17035713
fic@@	O	-1	17035713
ation	O	-1	17035713
could	O	-1	17035713
be	O	-1	17035713
an	O	-1	17035713
op@@	O	-1	17035713
tion	O	-1	17035713
to	O	-1	17035713
prev@@	O	-1	17035713
ent	O	-1	17035713
I@@	B-Chemical	D007069	17035713
F@@	I-Chemical	-1	17035713
O	I-Chemical	-1	17035713
nephro@@	B-Disease	D007674	17035713
pathy	I-Disease	-1	17035713
in	O	-1	17035713
patients.	O	-1	17035713

S@@	O	-1	17042797
te@@	O	-1	17042797
re@@	O	-1	17042797
ological	O	-1	17042797
meth@@	O	-1	17042797
o@@	O	-1	17042797
ds	O	-1	17042797
reve@@	O	-1	17042797
al	O	-1	17042797
the	O	-1	17042797
ro@@	O	-1	17042797
b@@	O	-1	17042797
us@@	O	-1	17042797
t	O	-1	17042797
size	O	-1	17042797
and	O	-1	17042797
st@@	O	-1	17042797
ability	O	-1	17042797
of	O	-1	17042797
ect@@	O	-1	17042797
op@@	O	-1	17042797
ic	O	-1	17042797
h@@	O	-1	17042797
il@@	O	-1	17042797
ar	O	-1	17042797
gran@@	O	-1	17042797
ul@@	O	-1	17042797
e	O	-1	17042797
cells	O	-1	17042797
after	O	-1	17042797
pilocar@@	B-Chemical	D010862	17042797
pine	I-Chemical	-1	17042797
-induced	O	-1	17042797
status	B-Disease	D013226	17042797
epilep@@	I-Disease	-1	17042797
tic@@	I-Disease	-1	17042797
us	I-Disease	-1	17042797
in	O	-1	17042797
the	O	-1	17042797
ad@@	O	-1	17042797
ult	O	-1	17042797
rat@@	O	-1	17042797
.	O	-1	17042797
F@@	O	-1	17042797
ol@@	O	-1	17042797
low@@	O	-1	17042797
ing	O	-1	17042797
status	B-Disease	D013226	17042797
epilep@@	I-Disease	-1	17042797
tic@@	I-Disease	-1	17042797
us	I-Disease	-1	17042797
in	O	-1	17042797
the	O	-1	17042797
rat@@	O	-1	17042797
,	O	-1	17042797
d@@	O	-1	17042797
ent@@	O	-1	17042797
ate	O	-1	17042797
gran@@	O	-1	17042797
ul@@	O	-1	17042797
e	O	-1	17042797
cell	O	-1	17042797
neuro@@	O	-1	17042797
genesis	O	-1	17042797
increases	O	-1	17042797
great@@	O	-1	17042797
ly,	O	-1	17042797
and	O	-1	17042797
man@@	O	-1	17042797
y	O	-1	17042797
of	O	-1	17042797
the	O	-1	17042797
new	O	-1	17042797
neuron@@	O	-1	17042797
s	O	-1	17042797
appe@@	O	-1	17042797
ar	O	-1	17042797
to	O	-1	17042797
deve@@	O	-1	17042797
lo@@	O	-1	17042797
p	O	-1	17042797
ect@@	O	-1	17042797
op@@	O	-1	17042797
ic@@	O	-1	17042797
ally,	O	-1	17042797
in	O	-1	17042797
the	O	-1	17042797
h@@	O	-1	17042797
il@@	O	-1	17042797
ar	O	-1	17042797
regi@@	O	-1	17042797
on	O	-1	17042797
of	O	-1	17042797
the	O	-1	17042797
hippocamp@@	O	-1	17042797
al	O	-1	17042797
form@@	O	-1	17042797
ation.	O	-1	17042797
It	O	-1	17042797
has	O	-1	17042797
been	O	-1	17042797
suggested	O	-1	17042797
that	O	-1	17042797
the	O	-1	17042797
ect@@	O	-1	17042797
op@@	O	-1	17042797
ic	O	-1	17042797
h@@	O	-1	17042797
il@@	O	-1	17042797
ar	O	-1	17042797
gran@@	O	-1	17042797
ul@@	O	-1	17042797
e	O	-1	17042797
cells	O	-1	17042797
could	O	-1	17042797
cont@@	O	-1	17042797
rib@@	O	-1	17042797
ute	O	-1	17042797
to	O	-1	17042797
the	O	-1	17042797
spont@@	O	-1	17042797
aneous	O	-1	17042797
seizures	B-Disease	D012640	17042797
that	O	-1	17042797
ul@@	O	-1	17042797
tim@@	O	-1	17042797
ately	O	-1	17042797
deve@@	O	-1	17042797
lo@@	O	-1	17042797
p	O	-1	17042797
after	O	-1	17042797
status	B-Disease	D013226	17042797
epilep@@	I-Disease	-1	17042797
tic@@	I-Disease	-1	17042797
us	I-Disease	-1	17042797
.	O	-1	17042797
However,	O	-1	17042797
the	O	-1	17042797
po@@	O	-1	17042797
p@@	O	-1	17042797
ulation	O	-1	17042797
has	O	-1	17042797
ne@@	O	-1	17042797
ver	O	-1	17042797
been	O	-1	17042797
qu@@	O	-1	17042797
anti@@	O	-1	17042797
fi@@	O	-1	17042797
ed,	O	-1	17042797
so	O	-1	17042797
it	O	-1	17042797
is	O	-1	17042797
unc@@	O	-1	17042797
le@@	O	-1	17042797
ar	O	-1	17042797
whether	O	-1	17042797
it	O	-1	17042797
is	O	-1	17042797
subst@@	O	-1	17042797
anti@@	O	-1	17042797
al	O	-1	17042797
en@@	O	-1	17042797
ou@@	O	-1	17042797
gh	O	-1	17042797
to	O	-1	17042797
have	O	-1	17042797
a	O	-1	17042797
st@@	O	-1	17042797
ron@@	O	-1	17042797
g	O	-1	17042797
influence	O	-1	17042797
on	O	-1	17042797
epile@@	O	-1	17042797
pto@@	O	-1	17042797
gene@@	O	-1	17042797
sis.	O	-1	17042797
To	O	-1	17042797
qu@@	O	-1	17042797
anti@@	O	-1	17042797
f@@	O	-1	17042797
y	O	-1	17042797
this	O	-1	17042797
po@@	O	-1	17042797
pul@@	O	-1	17042797
ation,	O	-1	17042797
the	O	-1	17042797
total	O	-1	17042797
number	O	-1	17042797
of	O	-1	17042797
ect@@	O	-1	17042797
op@@	O	-1	17042797
ic	O	-1	17042797
h@@	O	-1	17042797
il@@	O	-1	17042797
ar	O	-1	17042797
gran@@	O	-1	17042797
ul@@	O	-1	17042797
e	O	-1	17042797
cells	O	-1	17042797
was	O	-1	17042797
estim@@	O	-1	17042797
ated	O	-1	17042797
using	O	-1	17042797
un@@	O	-1	17042797
b@@	O	-1	17042797
i@@	O	-1	17042797
as@@	O	-1	17042797
ed	O	-1	17042797
ste@@	O	-1	17042797
re@@	O	-1	17042797
ology	O	-1	17042797
at	O	-1	17042797
different	O	-1	17042797
times	O	-1	17042797
after	O	-1	17042797
pilocar@@	B-Chemical	D010862	17042797
pine	I-Chemical	-1	17042797
-induced	O	-1	17042797
status	B-Disease	D013226	17042797
epilep@@	I-Disease	-1	17042797
tic@@	I-Disease	-1	17042797
us	I-Disease	-1	17042797
.	O	-1	17042797
The	O	-1	17042797
number	O	-1	17042797
of	O	-1	17042797
h@@	O	-1	17042797
il@@	O	-1	17042797
ar	O	-1	17042797
neuron@@	O	-1	17042797
s	O	-1	17042797
immuno@@	O	-1	17042797
reac@@	O	-1	17042797
tive	O	-1	17042797
for	O	-1	17042797
Pro@@	O	-1	17042797
x@@	O	-1	17042797
-1@@	O	-1	17042797
,	O	-1	17042797
a	O	-1	17042797
gran@@	O	-1	17042797
ul@@	O	-1	17042797
e-@@	O	-1	17042797
cell@@	O	-1	17042797
-@@	O	-1	17042797
specific	O	-1	17042797
mark@@	O	-1	17042797
er,	O	-1	17042797
was	O	-1	17042797
estim@@	O	-1	17042797
ated	O	-1	17042797
using	O	-1	17042797
the	O	-1	17042797
op@@	O	-1	17042797
tical	O	-1	17042797
frac@@	O	-1	17042797
tion@@	O	-1	17042797
at@@	O	-1	17042797
or	O	-1	17042797
meth@@	O	-1	17042797
o@@	O	-1	17042797
d.	O	-1	17042797
The	O	-1	17042797
results	O	-1	17042797
indicate	O	-1	17042797
that	O	-1	17042797
the	O	-1	17042797
size	O	-1	17042797
of	O	-1	17042797
the	O	-1	17042797
h@@	O	-1	17042797
il@@	O	-1	17042797
ar	O	-1	17042797
ect@@	O	-1	17042797
op@@	O	-1	17042797
ic	O	-1	17042797
gran@@	O	-1	17042797
ul@@	O	-1	17042797
e	O	-1	17042797
cell	O	-1	17042797
po@@	O	-1	17042797
p@@	O	-1	17042797
ulation	O	-1	17042797
after	O	-1	17042797
status	B-Disease	D013226	17042797
epilep@@	I-Disease	-1	17042797
tic@@	I-Disease	-1	17042797
us	I-Disease	-1	17042797
is	O	-1	17042797
subst@@	O	-1	17042797
anti@@	O	-1	17042797
al,	O	-1	17042797
and	O	-1	17042797
st@@	O	-1	17042797
able	O	-1	17042797
over	O	-1	17042797
ti@@	O	-1	17042797
me.	O	-1	17042797
In@@	O	-1	17042797
te@@	O	-1	17042797
rest@@	O	-1	17042797
ing@@	O	-1	17042797
ly,	O	-1	17042797
the	O	-1	17042797
size	O	-1	17042797
of	O	-1	17042797
the	O	-1	17042797
po@@	O	-1	17042797
p@@	O	-1	17042797
ulation	O	-1	17042797
appear@@	O	-1	17042797
s	O	-1	17042797
to	O	-1	17042797
be	O	-1	17042797
cor@@	O	-1	17042797
related	O	-1	17042797
with	O	-1	17042797
the	O	-1	17042797
frequency	O	-1	17042797
of	O	-1	17042797
behavioral	O	-1	17042797
seizures	B-Disease	D012640	17042797
,	O	-1	17042797
because	O	-1	17042797
animals	O	-1	17042797
with	O	-1	17042797
more	O	-1	17042797
ect@@	O	-1	17042797
op@@	O	-1	17042797
ic	O	-1	17042797
gran@@	O	-1	17042797
ul@@	O	-1	17042797
e	O	-1	17042797
cells	O	-1	17042797
in	O	-1	17042797
the	O	-1	17042797
h@@	O	-1	17042797
il@@	O	-1	17042797
us	O	-1	17042797
have	O	-1	17042797
more	O	-1	17042797
frequent	O	-1	17042797
behavioral	O	-1	17042797
seizures	B-Disease	D012640	17042797
.	O	-1	17042797
The	O	-1	17042797
h@@	O	-1	17042797
il@@	O	-1	17042797
ar	O	-1	17042797
ect@@	O	-1	17042797
op@@	O	-1	17042797
ic	O	-1	17042797
gran@@	O	-1	17042797
ul@@	O	-1	17042797
e	O	-1	17042797
cell	O	-1	17042797
po@@	O	-1	17042797
p@@	O	-1	17042797
ulation	O	-1	17042797
does	O	-1	17042797
not	O	-1	17042797
appe@@	O	-1	17042797
ar	O	-1	17042797
to	O	-1	17042797
v@@	O	-1	17042797
ary	O	-1	17042797
system@@	O	-1	17042797
ati@@	O	-1	17042797
c@@	O	-1	17042797
ally	O	-1	17042797
ac@@	O	-1	17042797
ros@@	O	-1	17042797
s	O	-1	17042797
the	O	-1	17042797
se@@	O	-1	17042797
pt@@	O	-1	17042797
ot@@	O	-1	17042797
em@@	O	-1	17042797
por@@	O	-1	17042797
al	O	-1	17042797
ax@@	O	-1	17042797
is@@	O	-1	17042797
,	O	-1	17042797
although	O	-1	17042797
it	O	-1	17042797
is	O	-1	17042797
associated	O	-1	17042797
with	O	-1	17042797
an	O	-1	17042797
increase	O	-1	17042797
in	O	-1	17042797
volume	O	-1	17042797
of	O	-1	17042797
the	O	-1	17042797
h@@	O	-1	17042797
il@@	O	-1	17042797
us.	O	-1	17042797
The	O	-1	17042797
results	O	-1	17042797
prov@@	O	-1	17042797
ide	O	-1	17042797
new	O	-1	17042797
in@@	O	-1	17042797
si@@	O	-1	17042797
ght	O	-1	17042797
into	O	-1	17042797
the	O	-1	17042797
potential	O	-1	17042797
role	O	-1	17042797
of	O	-1	17042797
ect@@	O	-1	17042797
op@@	O	-1	17042797
ic	O	-1	17042797
h@@	O	-1	17042797
il@@	O	-1	17042797
ar	O	-1	17042797
gran@@	O	-1	17042797
ul@@	O	-1	17042797
e	O	-1	17042797
cells	O	-1	17042797
in	O	-1	17042797
the	O	-1	17042797
pilocar@@	B-Chemical	D010862	17042797
pine	I-Chemical	-1	17042797
model	O	-1	17042797
of	O	-1	17042797
tempor@@	B-Disease	D004833	17042797
al	I-Disease	-1	17042797
lo@@	I-Disease	-1	17042797
be	I-Disease	-1	17042797
epilep@@	I-Disease	-1	17042797
sy	I-Disease	-1	17042797
.	O	-1	17042797

A	O	-1	17069550
pro@@	O	-1	17069550
sp@@	O	-1	17069550
ecti@@	O	-1	17069550
ve,	O	-1	17069550
o@@	O	-1	17069550
pen@@	O	-1	17069550
-@@	O	-1	17069550
l@@	O	-1	17069550
a@@	O	-1	17069550
be@@	O	-1	17069550
l	O	-1	17069550
trial	O	-1	17069550
of	O	-1	17069550
g@@	B-Chemical	D005702	17069550
al@@	I-Chemical	-1	17069550
ant@@	I-Chemical	-1	17069550
amine	I-Chemical	-1	17069550
in	O	-1	17069550
au@@	B-Disease	D001321	17069550
tis@@	I-Disease	-1	17069550
tic	I-Disease	-1	17069550
disor@@	I-Disease	-1	17069550
der	I-Disease	-1	17069550
.	O	-1	17069550
OBJECTIVE:	O	-1	17069550
P@@	O	-1	17069550
ost@@	O	-1	17069550
-@@	O	-1	17069550
mor@@	O	-1	17069550
te@@	O	-1	17069550
m	O	-1	17069550
studies	O	-1	17069550
have	O	-1	17069550
reported	O	-1	17069550
abnormal@@	O	-1	17069550
ities	O	-1	17069550
of	O	-1	17069550
the	O	-1	17069550
cholinergic	O	-1	17069550
system	O	-1	17069550
in	O	-1	17069550
au@@	B-Disease	D001321	17069550
tis@@	I-Disease	-1	17069550
m	I-Disease	-1	17069550
.	O	-1	17069550
The	O	-1	17069550
pur@@	O	-1	17069550
p@@	O	-1	17069550
ose	O	-1	17069550
of	O	-1	17069550
this	O	-1	17069550
study	O	-1	17069550
was	O	-1	17069550
to	O	-1	17069550
ass@@	O	-1	17069550
ess	O	-1	17069550
the	O	-1	17069550
use	O	-1	17069550
of	O	-1	17069550
g@@	B-Chemical	D005702	17069550
al@@	I-Chemical	-1	17069550
ant@@	I-Chemical	-1	17069550
amine	I-Chemical	-1	17069550
,	O	-1	17069550
an	O	-1	17069550
acet@@	O	-1	17069550
ylchol@@	O	-1	17069550
ine@@	O	-1	17069550
ster@@	O	-1	17069550
ase	O	-1	17069550
inhibitor	O	-1	17069550
and	O	-1	17069550
nicot@@	O	-1	17069550
inic	O	-1	17069550
receptor	O	-1	17069550
mod@@	O	-1	17069550
ul@@	O	-1	17069550
at@@	O	-1	17069550
or@@	O	-1	17069550
,	O	-1	17069550
in	O	-1	17069550
the	O	-1	17069550
treatment	O	-1	17069550
of	O	-1	17069550
inter@@	O	-1	17069550
fer@@	O	-1	17069550
ing	O	-1	17069550
behavi@@	O	-1	17069550
ors	O	-1	17069550
in	O	-1	17069550
children	O	-1	17069550
with	O	-1	17069550
au@@	B-Disease	D001321	17069550
tis@@	I-Disease	-1	17069550
m	I-Disease	-1	17069550
.	O	-1	17069550
METHODS:	O	-1	17069550
Th@@	O	-1	17069550
ir@@	O	-1	17069550
te@@	O	-1	17069550
en	O	-1	17069550
medic@@	O	-1	17069550
ation@@	O	-1	17069550
-@@	O	-1	17069550
free	O	-1	17069550
children	O	-1	17069550
with	O	-1	17069550
au@@	B-Disease	D001321	17069550
tis@@	I-Disease	-1	17069550
m	I-Disease	-1	17069550
(@@	O	-1	17069550
mean	O	-1	17069550
age,	O	-1	17069550
8.@@	O	-1	17069550
8	O	-1	17069550
+/-	O	-1	17069550
3.@@	O	-1	17069550
5	O	-1	17069550
year@@	O	-1	17069550
s)	O	-1	17069550
partic@@	O	-1	17069550
ip@@	O	-1	17069550
ated	O	-1	17069550
in	O	-1	17069550
a	O	-1	17069550
1@@	O	-1	17069550
2-@@	O	-1	17069550
week@@	O	-1	17069550
,	O	-1	17069550
o@@	O	-1	17069550
pen@@	O	-1	17069550
-@@	O	-1	17069550
l@@	O	-1	17069550
a@@	O	-1	17069550
be@@	O	-1	17069550
l	O	-1	17069550
trial	O	-1	17069550
of	O	-1	17069550
g@@	B-Chemical	D005702	17069550
al@@	I-Chemical	-1	17069550
ant@@	I-Chemical	-1	17069550
amine	I-Chemical	-1	17069550
.	O	-1	17069550
Patients	O	-1	17069550
were	O	-1	17069550
r@@	O	-1	17069550
ated	O	-1	17069550
month@@	O	-1	17069550
ly	O	-1	17069550
by	O	-1	17069550
pa@@	O	-1	17069550
ren@@	O	-1	17069550
ts	O	-1	17069550
on	O	-1	17069550
the	O	-1	17069550
A@@	O	-1	17069550
b@@	O	-1	17069550
er@@	O	-1	17069550
ran@@	O	-1	17069550
t	O	-1	17069550
B@@	O	-1	17069550
e@@	O	-1	17069550
havi@@	O	-1	17069550
or	O	-1	17069550
Ch@@	O	-1	17069550
ec@@	O	-1	17069550
k@@	O	-1	17069550
l@@	O	-1	17069550
ist	O	-1	17069550
(A@@	O	-1	17069550
BC@@	O	-1	17069550
)	O	-1	17069550
and	O	-1	17069550
the	O	-1	17069550
Con@@	O	-1	17069550
ner@@	O	-1	17069550
s@@	O	-1	17069550
'	O	-1	17069550
P@@	O	-1	17069550
a@@	O	-1	17069550
rent	O	-1	17069550
R@@	O	-1	17069550
ating	O	-1	17069550
S@@	O	-1	17069550
cal@@	O	-1	17069550
e-@@	O	-1	17069550
Re@@	O	-1	17069550
vi@@	O	-1	17069550
se@@	O	-1	17069550
d,	O	-1	17069550
and	O	-1	17069550
by	O	-1	17069550
a	O	-1	17069550
physi@@	O	-1	17069550
ci@@	O	-1	17069550
an	O	-1	17069550
using	O	-1	17069550
the	O	-1	17069550
Ch@@	O	-1	17069550
ild@@	O	-1	17069550
ren@@	O	-1	17069550
's	O	-1	17069550
P@@	O	-1	17069550
sy@@	O	-1	17069550
ch@@	O	-1	17069550
i@@	O	-1	17069550
atric	O	-1	17069550
R@@	O	-1	17069550
ating	O	-1	17069550
S@@	O	-1	17069550
cal@@	O	-1	17069550
e	O	-1	17069550
and	O	-1	17069550
the	O	-1	17069550
Clin@@	O	-1	17069550
ical	O	-1	17069550
G@@	O	-1	17069550
lo@@	O	-1	17069550
b@@	O	-1	17069550
al	O	-1	17069550
Im@@	O	-1	17069550
pres@@	O	-1	17069550
sions	O	-1	17069550
s@@	O	-1	17069550
cal@@	O	-1	17069550
e.	O	-1	17069550
RESULTS:	O	-1	17069550
Patients	O	-1	17069550
showed	O	-1	17069550
a	O	-1	17069550
significant	O	-1	17069550
reduction	O	-1	17069550
in	O	-1	17069550
pa@@	O	-1	17069550
ren@@	O	-1	17069550
t-@@	O	-1	17069550
r@@	O	-1	17069550
ated	O	-1	17069550
ir@@	B-Disease	D001523	17069550
rit@@	I-Disease	-1	17069550
ability	I-Disease	-1	17069550
and	O	-1	17069550
s@@	O	-1	17069550
oci@@	O	-1	17069550
al	O	-1	17069550
withdrawal	O	-1	17069550
on	O	-1	17069550
the	O	-1	17069550
A@@	O	-1	17069550
B@@	O	-1	17069550
C	O	-1	17069550
as	O	-1	17069550
well	O	-1	17069550
as	O	-1	17069550
significant	O	-1	17069550
impro@@	O	-1	17069550
ve@@	O	-1	17069550
ments	O	-1	17069550
in	O	-1	17069550
em@@	O	-1	17069550
o@@	O	-1	17069550
tional	O	-1	17069550
l@@	O	-1	17069550
ability	O	-1	17069550
and	O	-1	17069550
in@@	O	-1	17069550
atten@@	O	-1	17069550
tion	O	-1	17069550
on	O	-1	17069550
the	O	-1	17069550
Con@@	O	-1	17069550
ner@@	O	-1	17069550
s@@	O	-1	17069550
'	O	-1	17069550
P@@	O	-1	17069550
a@@	O	-1	17069550
rent	O	-1	17069550
R@@	O	-1	17069550
ating	O	-1	17069550
S@@	O	-1	17069550
cal@@	O	-1	17069550
e-@@	O	-1	17069550
-@@	O	-1	17069550
Re@@	O	-1	17069550
vi@@	O	-1	17069550
sed.	O	-1	17069550
S@@	O	-1	17069550
im@@	O	-1	17069550
il@@	O	-1	17069550
ar@@	O	-1	17069550
ly,	O	-1	17069550
clin@@	O	-1	17069550
ici@@	O	-1	17069550
an	O	-1	17069550
rat@@	O	-1	17069550
ings	O	-1	17069550
showed	O	-1	17069550
reduc@@	O	-1	17069550
tions	O	-1	17069550
in	O	-1	17069550
the	O	-1	17069550
ang@@	O	-1	17069550
er	O	-1	17069550
sub@@	O	-1	17069550
s@@	O	-1	17069550
cal@@	O	-1	17069550
e	O	-1	17069550
of	O	-1	17069550
the	O	-1	17069550
Ch@@	O	-1	17069550
ild@@	O	-1	17069550
ren@@	O	-1	17069550
's	O	-1	17069550
P@@	O	-1	17069550
sy@@	O	-1	17069550
ch@@	O	-1	17069550
i@@	O	-1	17069550
atric	O	-1	17069550
R@@	O	-1	17069550
ating	O	-1	17069550
S@@	O	-1	17069550
cal@@	O	-1	17069550
e.	O	-1	17069550
E@@	O	-1	17069550
ight	O	-1	17069550
of	O	-1	17069550
13	O	-1	17069550
partic@@	O	-1	17069550
ip@@	O	-1	17069550
ants	O	-1	17069550
were	O	-1	17069550
r@@	O	-1	17069550
ated	O	-1	17069550
as	O	-1	17069550
respon@@	O	-1	17069550
der@@	O	-1	17069550
s	O	-1	17069550
on	O	-1	17069550
the	O	-1	17069550
b@@	O	-1	17069550
asis	O	-1	17069550
of	O	-1	17069550
their	O	-1	17069550
impro@@	O	-1	17069550
vement	O	-1	17069550
sco@@	O	-1	17069550
res	O	-1	17069550
on	O	-1	17069550
the	O	-1	17069550
Clin@@	O	-1	17069550
ical	O	-1	17069550
G@@	O	-1	17069550
lo@@	O	-1	17069550
b@@	O	-1	17069550
al	O	-1	17069550
Im@@	O	-1	17069550
pres@@	O	-1	17069550
sions	O	-1	17069550
s@@	O	-1	17069550
cal@@	O	-1	17069550
e.	O	-1	17069550
O@@	O	-1	17069550
ver@@	O	-1	17069550
all@@	O	-1	17069550
,	O	-1	17069550
g@@	B-Chemical	D005702	17069550
al@@	I-Chemical	-1	17069550
ant@@	I-Chemical	-1	17069550
amine	I-Chemical	-1	17069550
was	O	-1	17069550
we@@	O	-1	17069550
ll@@	O	-1	17069550
-@@	O	-1	17069550
toler@@	O	-1	17069550
at@@	O	-1	17069550
ed,	O	-1	17069550
with	O	-1	17069550
no	O	-1	17069550
significant	O	-1	17069550
adverse	O	-1	17069550
effects	O	-1	17069550
ap@@	O	-1	17069550
ar@@	O	-1	17069550
t	O	-1	17069550
from	O	-1	17069550
headac@@	B-Disease	D006261	17069550
h@@	I-Disease	-1	17069550
es	I-Disease	-1	17069550
in	O	-1	17069550
one	O	-1	17069550
patient@@	O	-1	17069550
.	O	-1	17069550
CONCLUSION:	O	-1	17069550
In	O	-1	17069550
this	O	-1	17069550
op@@	O	-1	17069550
en	O	-1	17069550
tri@@	O	-1	17069550
al,	O	-1	17069550
g@@	B-Chemical	D005702	17069550
al@@	I-Chemical	-1	17069550
ant@@	I-Chemical	-1	17069550
amine	I-Chemical	-1	17069550
was	O	-1	17069550
we@@	O	-1	17069550
ll@@	O	-1	17069550
-@@	O	-1	17069550
toler@@	O	-1	17069550
ated	O	-1	17069550
and	O	-1	17069550
appe@@	O	-1	17069550
a@@	O	-1	17069550
red	O	-1	17069550
to	O	-1	17069550
be	O	-1	17069550
ben@@	O	-1	17069550
e@@	O	-1	17069550
fic@@	O	-1	17069550
ial	O	-1	17069550
for	O	-1	17069550
the	O	-1	17069550
treatment	O	-1	17069550
of	O	-1	17069550
inter@@	O	-1	17069550
fer@@	O	-1	17069550
ing	O	-1	17069550
behavi@@	O	-1	17069550
ors	O	-1	17069550
in	O	-1	17069550
children	O	-1	17069550
with	O	-1	17069550
au@@	B-Disease	D001321	17069550
tis@@	I-Disease	-1	17069550
m	I-Disease	-1	17069550
,	O	-1	17069550
partic@@	O	-1	17069550
ul@@	O	-1	17069550
arly	O	-1	17069550
ag@@	B-Disease	D001523	17069550
gres@@	I-Disease	-1	17069550
sion	I-Disease	-1	17069550
,	O	-1	17069550
behavioral	B-Disease	D002653	17069550
dys@@	I-Disease	-1	17069550
control	I-Disease	-1	17069550
,	O	-1	17069550
and	O	-1	17069550
in@@	B-Disease	D019958	17069550
atten@@	I-Disease	-1	17069550
tion	I-Disease	-1	17069550
.	O	-1	17069550
F@@	O	-1	17069550
urther	O	-1	17069550
controlled	O	-1	17069550
tri@@	O	-1	17069550
als	O	-1	17069550
are	O	-1	17069550
war@@	O	-1	17069550
ran@@	O	-1	17069550
ted.	O	-1	17069550

R@@	O	-1	17151160
an@@	O	-1	17151160
dom@@	O	-1	17151160
ized	O	-1	17151160
compar@@	O	-1	17151160
ison	O	-1	17151160
of	O	-1	17151160
ol@@	B-Chemical	C076029	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
versus	O	-1	17151160
ris@@	B-Chemical	D018967	17151160
perid@@	I-Chemical	-1	17151160
one	I-Chemical	-1	17151160
for	O	-1	17151160
the	O	-1	17151160
treatment	O	-1	17151160
of	O	-1	17151160
fir@@	O	-1	17151160
st@@	O	-1	17151160
-@@	O	-1	17151160
episo@@	O	-1	17151160
de	O	-1	17151160
sch@@	B-Disease	D012559	17151160
iz@@	I-Disease	-1	17151160
oph@@	I-Disease	-1	17151160
ren@@	I-Disease	-1	17151160
ia	I-Disease	-1	17151160
:	O	-1	17151160
4-@@	O	-1	17151160
mon@@	O	-1	17151160
th	O	-1	17151160
outcom@@	O	-1	17151160
es.	O	-1	17151160
OBJECTIVE:	O	-1	17151160
The	O	-1	17151160
au@@	O	-1	17151160
th@@	O	-1	17151160
ors	O	-1	17151160
compared	O	-1	17151160
4-@@	O	-1	17151160
mon@@	O	-1	17151160
th	O	-1	17151160
treatment	O	-1	17151160
outcom@@	O	-1	17151160
es	O	-1	17151160
for	O	-1	17151160
ol@@	B-Chemical	C076029	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
versus	O	-1	17151160
ris@@	B-Chemical	D018967	17151160
perid@@	I-Chemical	-1	17151160
one	I-Chemical	-1	17151160
in	O	-1	17151160
patients	O	-1	17151160
with	O	-1	17151160
fir@@	O	-1	17151160
st@@	O	-1	17151160
-@@	O	-1	17151160
episo@@	O	-1	17151160
de	O	-1	17151160
sch@@	B-Disease	D012559	17151160
iz@@	I-Disease	-1	17151160
oph@@	I-Disease	-1	17151160
ren@@	I-Disease	-1	17151160
ia	I-Disease	-1	17151160
sp@@	O	-1	17151160
ect@@	O	-1	17151160
ru@@	O	-1	17151160
m	O	-1	17151160
disorder@@	O	-1	17151160
s.	O	-1	17151160
METHOD@@	O	-1	17151160
:	O	-1	17151160
One	O	-1	17151160
h@@	O	-1	17151160
und@@	O	-1	17151160
red	O	-1	17151160
t@@	O	-1	17151160
we@@	O	-1	17151160
l@@	O	-1	17151160
ve	O	-1	17151160
subjects	O	-1	17151160
(@@	O	-1	17151160
7@@	O	-1	17151160
0%	O	-1	17151160
mal@@	O	-1	17151160
e@@	O	-1	17151160
;	O	-1	17151160
mean	O	-1	17151160
ag@@	O	-1	17151160
e@@	O	-1	17151160
=@@	O	-1	17151160
2@@	O	-1	17151160
3.@@	O	-1	17151160
3	O	-1	17151160
years	O	-1	17151160
[@@	O	-1	17151160
S@@	O	-1	17151160
D	O	-1	17151160
=	O	-1	17151160
5.@@	O	-1	17151160
1@@	O	-1	17151160
]@@	O	-1	17151160
)	O	-1	17151160
with	O	-1	17151160
fir@@	O	-1	17151160
st@@	O	-1	17151160
-@@	O	-1	17151160
episo@@	O	-1	17151160
de	O	-1	17151160
sch@@	B-Disease	D012559	17151160
iz@@	I-Disease	-1	17151160
oph@@	I-Disease	-1	17151160
ren@@	I-Disease	-1	17151160
ia	I-Disease	-1	17151160
(@@	O	-1	17151160
7@@	O	-1	17151160
5@@	O	-1	17151160
%),	O	-1	17151160
sch@@	B-Disease	D011618	17151160
iz@@	I-Disease	-1	17151160
oph@@	I-Disease	-1	17151160
ren@@	I-Disease	-1	17151160
if@@	I-Disease	-1	17151160
or@@	I-Disease	-1	17151160
m	I-Disease	-1	17151160
disor@@	I-Disease	-1	17151160
der	I-Disease	-1	17151160
(1@@	O	-1	17151160
7@@	O	-1	17151160
%),	O	-1	17151160
or	O	-1	17151160
sch@@	B-Disease	D011618	17151160
iz@@	I-Disease	-1	17151160
o@@	I-Disease	-1	17151160
aff@@	I-Disease	-1	17151160
ective	I-Disease	-1	17151160
disor@@	I-Disease	-1	17151160
der	I-Disease	-1	17151160
(@@	O	-1	17151160
8@@	O	-1	17151160
%)	O	-1	17151160
were	O	-1	17151160
random@@	O	-1	17151160
ly	O	-1	17151160
as@@	O	-1	17151160
signed	O	-1	17151160
to	O	-1	17151160
treatment	O	-1	17151160
with	O	-1	17151160
ol@@	B-Chemical	C076029	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
(2@@	O	-1	17151160
.@@	O	-1	17151160
5-@@	O	-1	17151160
20	O	-1	17151160
mg/@@	O	-1	17151160
day@@	O	-1	17151160
)	O	-1	17151160
or	O	-1	17151160
ris@@	B-Chemical	D018967	17151160
perid@@	I-Chemical	-1	17151160
one	I-Chemical	-1	17151160
(1@@	O	-1	17151160
-@@	O	-1	17151160
6	O	-1	17151160
mg/@@	O	-1	17151160
day@@	O	-1	17151160
).	O	-1	17151160
RESULTS:	O	-1	17151160
R@@	O	-1	17151160
es@@	O	-1	17151160
p@@	O	-1	17151160
on@@	O	-1	17151160
se	O	-1	17151160
rat@@	O	-1	17151160
es	O	-1	17151160
did	O	-1	17151160
not	O	-1	17151160
significantly	O	-1	17151160
diff@@	O	-1	17151160
er	O	-1	17151160
between	O	-1	17151160
ol@@	B-Chemical	C076029	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
(4@@	O	-1	17151160
3.@@	O	-1	17151160
7@@	O	-1	17151160
%,	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
2@@	O	-1	17151160
8.@@	O	-1	17151160
8@@	O	-1	17151160
%@@	O	-1	17151160
-@@	O	-1	17151160
5@@	O	-1	17151160
8.@@	O	-1	17151160
6@@	O	-1	17151160
%)	O	-1	17151160
and	O	-1	17151160
ris@@	B-Chemical	D018967	17151160
perid@@	I-Chemical	-1	17151160
one	I-Chemical	-1	17151160
(5@@	O	-1	17151160
4.@@	O	-1	17151160
3@@	O	-1	17151160
%,	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
3@@	O	-1	17151160
9.@@	O	-1	17151160
9@@	O	-1	17151160
%@@	O	-1	17151160
-@@	O	-1	17151160
6@@	O	-1	17151160
8.@@	O	-1	17151160
7@@	O	-1	17151160
%).	O	-1	17151160
A@@	O	-1	17151160
mon@@	O	-1	17151160
g	O	-1	17151160
those	O	-1	17151160
respon@@	O	-1	17151160
ding	O	-1	17151160
to	O	-1	17151160
treatment,	O	-1	17151160
more	O	-1	17151160
subjects	O	-1	17151160
in	O	-1	17151160
the	O	-1	17151160
ol@@	B-Chemical	C076029	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
group	O	-1	17151160
(4@@	O	-1	17151160
0.@@	O	-1	17151160
9@@	O	-1	17151160
%,	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
1@@	O	-1	17151160
6.@@	O	-1	17151160
8@@	O	-1	17151160
%@@	O	-1	17151160
-@@	O	-1	17151160
6@@	O	-1	17151160
5.@@	O	-1	17151160
0@@	O	-1	17151160
%)	O	-1	17151160
than	O	-1	17151160
in	O	-1	17151160
the	O	-1	17151160
ris@@	B-Chemical	D018967	17151160
perid@@	I-Chemical	-1	17151160
one	I-Chemical	-1	17151160
group	O	-1	17151160
(1@@	O	-1	17151160
8.@@	O	-1	17151160
9@@	O	-1	17151160
%,	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
0@@	O	-1	17151160
%@@	O	-1	17151160
-@@	O	-1	17151160
3@@	O	-1	17151160
9.@@	O	-1	17151160
2@@	O	-1	17151160
%)	O	-1	17151160
had	O	-1	17151160
subsequ@@	O	-1	17151160
ent	O	-1	17151160
rat@@	O	-1	17151160
ings	O	-1	17151160
not	O	-1	17151160
me@@	O	-1	17151160
et@@	O	-1	17151160
ing	O	-1	17151160
response	O	-1	17151160
c@@	O	-1	17151160
rit@@	O	-1	17151160
er@@	O	-1	17151160
ia.	O	-1	17151160
Ne@@	O	-1	17151160
g@@	O	-1	17151160
ative	O	-1	17151160
sympto@@	O	-1	17151160
m	O	-1	17151160
outcom@@	O	-1	17151160
es	O	-1	17151160
and	O	-1	17151160
meas@@	O	-1	17151160
ures	O	-1	17151160
of	O	-1	17151160
par@@	B-Disease	D010302	17151160
k@@	I-Disease	-1	17151160
inson@@	I-Disease	-1	17151160
ism	I-Disease	-1	17151160
and	O	-1	17151160
ak@@	B-Disease	D017109	17151160
athi@@	I-Disease	-1	17151160
sia	I-Disease	-1	17151160
did	O	-1	17151160
not	O	-1	17151160
diff@@	O	-1	17151160
er	O	-1	17151160
between	O	-1	17151160
medic@@	O	-1	17151160
ations.	O	-1	17151160
E@@	B-Disease	D001480	17151160
x@@	I-Disease	-1	17151160
tra@@	I-Disease	-1	17151160
py@@	I-Disease	-1	17151160
ram@@	I-Disease	-1	17151160
idal	I-Disease	-1	17151160
sympto@@	I-Disease	-1	17151160
m	I-Disease	-1	17151160
severity	O	-1	17151160
sco@@	O	-1	17151160
res	O	-1	17151160
were	O	-1	17151160
1.@@	O	-1	17151160
4	O	-1	17151160
(@@	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
1.@@	O	-1	17151160
2-@@	O	-1	17151160
1.@@	O	-1	17151160
6@@	O	-1	17151160
)	O	-1	17151160
with	O	-1	17151160
ris@@	B-Chemical	D018967	17151160
perid@@	I-Chemical	-1	17151160
one	I-Chemical	-1	17151160
and	O	-1	17151160
1.@@	O	-1	17151160
2	O	-1	17151160
(@@	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
1.@@	O	-1	17151160
0-@@	O	-1	17151160
1.@@	O	-1	17151160
4@@	O	-1	17151160
)	O	-1	17151160
with	O	-1	17151160
ol@@	B-Chemical	C076029	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
.	O	-1	17151160
Si@@	O	-1	17151160
gn@@	O	-1	17151160
ific@@	O	-1	17151160
ant@@	O	-1	17151160
ly	O	-1	17151160
more	O	-1	17151160
weight	B-Disease	D015430	17151160
g@@	I-Disease	-1	17151160
ain	I-Disease	-1	17151160
occurred	O	-1	17151160
with	O	-1	17151160
ol@@	B-Chemical	C076029	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
than	O	-1	17151160
with	O	-1	17151160
ris@@	B-Chemical	D018967	17151160
perid@@	I-Chemical	-1	17151160
one	I-Chemical	-1	17151160
:	O	-1	17151160
the	O	-1	17151160
increase	O	-1	17151160
in	O	-1	17151160
weight	O	-1	17151160
at	O	-1	17151160
4	O	-1	17151160
months	O	-1	17151160
rel@@	O	-1	17151160
ative	O	-1	17151160
to	O	-1	17151160
baseline	O	-1	17151160
weight	O	-1	17151160
was	O	-1	17151160
1@@	O	-1	17151160
7.@@	O	-1	17151160
3@@	O	-1	17151160
%	O	-1	17151160
(@@	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
1@@	O	-1	17151160
4.@@	O	-1	17151160
2@@	O	-1	17151160
%@@	O	-1	17151160
-@@	O	-1	17151160
2@@	O	-1	17151160
0.@@	O	-1	17151160
5@@	O	-1	17151160
%)	O	-1	17151160
with	O	-1	17151160
ol@@	B-Chemical	C076029	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
and	O	-1	17151160
1@@	O	-1	17151160
1.@@	O	-1	17151160
3@@	O	-1	17151160
%	O	-1	17151160
(@@	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
8.@@	O	-1	17151160
4@@	O	-1	17151160
%@@	O	-1	17151160
-1@@	O	-1	17151160
4.@@	O	-1	17151160
3@@	O	-1	17151160
%)	O	-1	17151160
with	O	-1	17151160
ris@@	B-Chemical	D018967	17151160
perid@@	I-Chemical	-1	17151160
one	I-Chemical	-1	17151160
.	O	-1	17151160
B@@	O	-1	17151160
o@@	O	-1	17151160
dy	O	-1	17151160
mas@@	O	-1	17151160
s	O	-1	17151160
in@@	O	-1	17151160
de@@	O	-1	17151160
x	O	-1	17151160
at	O	-1	17151160
baseline	O	-1	17151160
and	O	-1	17151160
at	O	-1	17151160
4	O	-1	17151160
months	O	-1	17151160
was	O	-1	17151160
2@@	O	-1	17151160
4.@@	O	-1	17151160
3	O	-1	17151160
(@@	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
2@@	O	-1	17151160
2.@@	O	-1	17151160
8@@	O	-1	17151160
-@@	O	-1	17151160
2@@	O	-1	17151160
5.@@	O	-1	17151160
7@@	O	-1	17151160
)	O	-1	17151160
versus	O	-1	17151160
2@@	O	-1	17151160
8.@@	O	-1	17151160
2	O	-1	17151160
(@@	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
2@@	O	-1	17151160
6.@@	O	-1	17151160
7-@@	O	-1	17151160
2@@	O	-1	17151160
9.@@	O	-1	17151160
7@@	O	-1	17151160
)	O	-1	17151160
with	O	-1	17151160
ol@@	B-Chemical	C076029	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
and	O	-1	17151160
2@@	O	-1	17151160
3.@@	O	-1	17151160
9	O	-1	17151160
(@@	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
2@@	O	-1	17151160
2.@@	O	-1	17151160
5-@@	O	-1	17151160
2@@	O	-1	17151160
5.@@	O	-1	17151160
3@@	O	-1	17151160
)	O	-1	17151160
versus	O	-1	17151160
2@@	O	-1	17151160
6.@@	O	-1	17151160
7	O	-1	17151160
(@@	O	-1	17151160
95%	O	-1	17151160
CI@@	O	-1	17151160
=@@	O	-1	17151160
2@@	O	-1	17151160
5.@@	O	-1	17151160
2-@@	O	-1	17151160
2@@	O	-1	17151160
8.@@	O	-1	17151160
2)	O	-1	17151160
with	O	-1	17151160
ris@@	B-Chemical	D018967	17151160
perid@@	I-Chemical	-1	17151160
one	I-Chemical	-1	17151160
.	O	-1	17151160
CONCLUSIONS:	O	-1	17151160
Clin@@	O	-1	17151160
ical	O	-1	17151160
outcom@@	O	-1	17151160
es	O	-1	17151160
with	O	-1	17151160
ris@@	B-Chemical	D018967	17151160
perid@@	I-Chemical	-1	17151160
one	I-Chemical	-1	17151160
were	O	-1	17151160
equ@@	O	-1	17151160
al	O	-1	17151160
to	O	-1	17151160
those	O	-1	17151160
with	O	-1	17151160
ol@@	B-Chemical	C076029	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
,	O	-1	17151160
and	O	-1	17151160
response	O	-1	17151160
may	O	-1	17151160
be	O	-1	17151160
more	O	-1	17151160
st@@	O	-1	17151160
able@@	O	-1	17151160
.	O	-1	17151160
O@@	B-Chemical	C076029	17151160
l@@	I-Chemical	-1	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
may	O	-1	17151160
have	O	-1	17151160
an	O	-1	17151160
adv@@	O	-1	17151160
ant@@	O	-1	17151160
age	O	-1	17151160
for	O	-1	17151160
motor	O	-1	17151160
side	O	-1	17151160
effects.	O	-1	17151160
B@@	O	-1	17151160
oth	O	-1	17151160
medic@@	O	-1	17151160
ations	O	-1	17151160
caused	O	-1	17151160
subst@@	O	-1	17151160
anti@@	O	-1	17151160
al	O	-1	17151160
ra@@	O	-1	17151160
pid	O	-1	17151160
weight	B-Disease	D015430	17151160
g@@	I-Disease	-1	17151160
ain	I-Disease	-1	17151160
,	O	-1	17151160
but	O	-1	17151160
weight	B-Disease	D015430	17151160
g@@	I-Disease	-1	17151160
ain	I-Disease	-1	17151160
was	O	-1	17151160
greater	O	-1	17151160
with	O	-1	17151160
ol@@	B-Chemical	C076029	17151160
an@@	I-Chemical	-1	17151160
z@@	I-Chemical	-1	17151160
apine	I-Chemical	-1	17151160
.	O	-1	17151160

E@@	O	-1	17159032
arly	O	-1	17159032
par@@	O	-1	17159032
ac@@	O	-1	17159032
entr@@	O	-1	17159032
al	O	-1	17159032
visual	B-Disease	D014786	17159032
fi@@	I-Disease	-1	17159032
el@@	I-Disease	-1	17159032
d	I-Disease	-1	17159032
loss	I-Disease	-1	17159032
in	O	-1	17159032
patients	O	-1	17159032
taking	O	-1	17159032
hydrox@@	B-Chemical	D006886	17159032
y@@	I-Chemical	-1	17159032
ch@@	I-Chemical	-1	17159032
loro@@	I-Chemical	-1	17159032
qu@@	I-Chemical	-1	17159032
ine	I-Chemical	-1	17159032
.	O	-1	17159032
OBJECTIVE:	O	-1	17159032
To	O	-1	17159032
revie@@	O	-1	17159032
w	O	-1	17159032
the	O	-1	17159032
n@@	O	-1	17159032
at@@	O	-1	17159032
ural	O	-1	17159032
hist@@	O	-1	17159032
ory	O	-1	17159032
and	O	-1	17159032
oc@@	O	-1	17159032
ular	O	-1	17159032
and	O	-1	17159032
systemic	O	-1	17159032
adverse	O	-1	17159032
effects	O	-1	17159032
of	O	-1	17159032
patients	O	-1	17159032
taking	O	-1	17159032
hydrox@@	B-Chemical	D006886	17159032
y@@	I-Chemical	-1	17159032
ch@@	I-Chemical	-1	17159032
loro@@	I-Chemical	-1	17159032
qu@@	I-Chemical	-1	17159032
ine	I-Chemical	-1	17159032
sulf@@	I-Chemical	-1	17159032
ate	I-Chemical	-1	17159032
who	O	-1	17159032
atten@@	O	-1	17159032
ded	O	-1	17159032
an	O	-1	17159032
oph@@	O	-1	17159032
thal@@	O	-1	17159032
mic	O	-1	17159032
s@@	O	-1	17159032
cre@@	O	-1	17159032
en@@	O	-1	17159032
ing	O	-1	17159032
pro@@	O	-1	17159032
gram@@	O	-1	17159032
.	O	-1	17159032
D@@	O	-1	17159032
ES@@	O	-1	17159032
I@@	O	-1	17159032
G@@	O	-1	17159032
N@@	O	-1	17159032
:	O	-1	17159032
R@@	O	-1	17159032
et@@	O	-1	17159032
ro@@	O	-1	17159032
sp@@	O	-1	17159032
ective	O	-1	17159032
study.	O	-1	17159032
RESULTS:	O	-1	17159032
Rec@@	O	-1	17159032
or@@	O	-1	17159032
ds	O	-1	17159032
of	O	-1	17159032
2@@	O	-1	17159032
6@@	O	-1	17159032
2	O	-1	17159032
patients	O	-1	17159032
who	O	-1	17159032
were	O	-1	17159032
taking	O	-1	17159032
hydrox@@	B-Chemical	D006886	17159032
y@@	I-Chemical	-1	17159032
ch@@	I-Chemical	-1	17159032
loro@@	I-Chemical	-1	17159032
qu@@	I-Chemical	-1	17159032
ine	I-Chemical	-1	17159032
and	O	-1	17159032
s@@	O	-1	17159032
cre@@	O	-1	17159032
en@@	O	-1	17159032
ed	O	-1	17159032
in	O	-1	17159032
the	O	-1	17159032
De@@	O	-1	17159032
part@@	O	-1	17159032
ment	O	-1	17159032
of	O	-1	17159032
O@@	O	-1	17159032
ph@@	O	-1	17159032
thal@@	O	-1	17159032
mo@@	O	-1	17159032
log@@	O	-1	17159032
y	O	-1	17159032
were	O	-1	17159032
revie@@	O	-1	17159032
we@@	O	-1	17159032
d.	O	-1	17159032
Of	O	-1	17159032
the	O	-1	17159032
2@@	O	-1	17159032
6@@	O	-1	17159032
2	O	-1	17159032
patients,	O	-1	17159032
14	O	-1	17159032
(1@@	O	-1	17159032
8@@	O	-1	17159032
%)	O	-1	17159032
of	O	-1	17159032
7@@	O	-1	17159032
6	O	-1	17159032
who	O	-1	17159032
had	O	-1	17159032
sto@@	O	-1	17159032
pp@@	O	-1	17159032
ed	O	-1	17159032
treatment	O	-1	17159032
at	O	-1	17159032
the	O	-1	17159032
time	O	-1	17159032
of	O	-1	17159032
the	O	-1	17159032
study	O	-1	17159032
experienced	O	-1	17159032
doc@@	O	-1	17159032
um@@	O	-1	17159032
ent@@	O	-1	17159032
ed	O	-1	17159032
adverse	O	-1	17159032
effects.	O	-1	17159032
S@@	O	-1	17159032
y@@	O	-1	17159032
st@@	O	-1	17159032
em@@	O	-1	17159032
ic	O	-1	17159032
adverse	O	-1	17159032
effects	O	-1	17159032
occurred	O	-1	17159032
in	O	-1	17159032
8	O	-1	17159032
patients	O	-1	17159032
(1@@	O	-1	17159032
0.@@	O	-1	17159032
5@@	O	-1	17159032
%)	O	-1	17159032
and	O	-1	17159032
oc@@	O	-1	17159032
ular	O	-1	17159032
adverse	O	-1	17159032
effect@@	O	-1	17159032
s,	O	-1	17159032
in	O	-1	17159032
5	O	-1	17159032
(@@	O	-1	17159032
6.@@	O	-1	17159032
5@@	O	-1	17159032
%).	O	-1	17159032
Th@@	O	-1	17159032
ir@@	O	-1	17159032
ty-@@	O	-1	17159032
five	O	-1	17159032
patients	O	-1	17159032
(1@@	O	-1	17159032
3.@@	O	-1	17159032
4@@	O	-1	17159032
%)	O	-1	17159032
had	O	-1	17159032
visual	B-Disease	D014786	17159032
fi@@	I-Disease	-1	17159032
el@@	I-Disease	-1	17159032
d	I-Disease	-1	17159032
abnormal@@	I-Disease	-1	17159032
ities	I-Disease	-1	17159032
,	O	-1	17159032
which	O	-1	17159032
were	O	-1	17159032
at@@	O	-1	17159032
tri@@	O	-1	17159032
but@@	O	-1	17159032
ed	O	-1	17159032
to	O	-1	17159032
hydrox@@	B-Chemical	D006886	17159032
y@@	I-Chemical	-1	17159032
ch@@	I-Chemical	-1	17159032
loro@@	I-Chemical	-1	17159032
qu@@	I-Chemical	-1	17159032
ine	I-Chemical	-1	17159032
treatment	O	-1	17159032
in	O	-1	17159032
4	O	-1	17159032
patients	O	-1	17159032
(1@@	O	-1	17159032
.@@	O	-1	17159032
5@@	O	-1	17159032
%).	O	-1	17159032
Th@@	O	-1	17159032
ree	O	-1	17159032
of	O	-1	17159032
the	O	-1	17159032
4	O	-1	17159032
patients	O	-1	17159032
were	O	-1	17159032
taking	O	-1	17159032
less	O	-1	17159032
than	O	-1	17159032
6.@@	O	-1	17159032
5	O	-1	17159032
mg/kg	O	-1	17159032
per	O	-1	17159032
day	O	-1	17159032
and	O	-1	17159032
all	O	-1	17159032
patients	O	-1	17159032
had	O	-1	17159032
normal	O	-1	17159032
renal	O	-1	17159032
and	O	-1	17159032
liver	O	-1	17159032
function	O	-1	17159032
test	O	-1	17159032
result@@	O	-1	17159032
s.	O	-1	17159032
CONCLUSIONS:	O	-1	17159032
The	O	-1	17159032
current	O	-1	17159032
study	O	-1	17159032
used	O	-1	17159032
a	O	-1	17159032
pro@@	O	-1	17159032
to@@	O	-1	17159032
co@@	O	-1	17159032
l	O	-1	17159032
of	O	-1	17159032
visual	O	-1	17159032
ac@@	O	-1	17159032
u@@	O	-1	17159032
ity	O	-1	17159032
and	O	-1	17159032
co@@	O	-1	17159032
lo@@	O	-1	17159032
r	O	-1	17159032
vi@@	O	-1	17159032
sion	O	-1	17159032
assess@@	O	-1	17159032
ment@@	O	-1	17159032
,	O	-1	17159032
f@@	O	-1	17159032
und@@	O	-1	17159032
us@@	O	-1	17159032
co@@	O	-1	17159032
p@@	O	-1	17159032
y,	O	-1	17159032
and	O	-1	17159032
H@@	O	-1	17159032
um@@	O	-1	17159032
ph@@	O	-1	17159032
re@@	O	-1	17159032
y	O	-1	17159032
10-@@	O	-1	17159032
2	O	-1	17159032
visual	O	-1	17159032
fi@@	O	-1	17159032
el@@	O	-1	17159032
d	O	-1	17159032
test@@	O	-1	17159032
ing	O	-1	17159032
and	O	-1	17159032
show@@	O	-1	17159032
s	O	-1	17159032
that	O	-1	17159032
visual	B-Disease	D014786	17159032
fi@@	I-Disease	-1	17159032
el@@	I-Disease	-1	17159032
d	I-Disease	-1	17159032
def@@	I-Disease	-1	17159032
ects	I-Disease	-1	17159032
appe@@	O	-1	17159032
a@@	O	-1	17159032
red	O	-1	17159032
before	O	-1	17159032
any	O	-1	17159032
cor@@	O	-1	17159032
respon@@	O	-1	17159032
ding	O	-1	17159032
changes	O	-1	17159032
in	O	-1	17159032
any	O	-1	17159032
other	O	-1	17159032
tested	O	-1	17159032
clinical	O	-1	17159032
par@@	O	-1	17159032
ame@@	O	-1	17159032
ter@@	O	-1	17159032
s;	O	-1	17159032
the	O	-1	17159032
def@@	O	-1	17159032
ects	O	-1	17159032
were	O	-1	17159032
re@@	O	-1	17159032
produc@@	O	-1	17159032
i@@	O	-1	17159032
ble	O	-1	17159032
and	O	-1	17159032
the	O	-1	17159032
test	O	-1	17159032
par@@	O	-1	17159032
ame@@	O	-1	17159032
ters	O	-1	17159032
were	O	-1	17159032
re@@	O	-1	17159032
li@@	O	-1	17159032
able@@	O	-1	17159032
.	O	-1	17159032
Patients	O	-1	17159032
taking	O	-1	17159032
hydrox@@	B-Chemical	D006886	17159032
y@@	I-Chemical	-1	17159032
ch@@	I-Chemical	-1	17159032
loro@@	I-Chemical	-1	17159032
qu@@	I-Chemical	-1	17159032
ine	I-Chemical	-1	17159032
can	O	-1	17159032
demon@@	O	-1	17159032
st@@	O	-1	17159032
rate	O	-1	17159032
a	O	-1	17159032
toxic	O	-1	17159032
reaction	O	-1	17159032
in	O	-1	17159032
the	O	-1	17159032
ret@@	O	-1	17159032
in@@	O	-1	17159032
a	O	-1	17159032
des@@	O	-1	17159032
pit@@	O	-1	17159032
e	O	-1	17159032
the	O	-1	17159032
absence	O	-1	17159032
of	O	-1	17159032
known	O	-1	17159032
risk	O	-1	17159032
fact@@	O	-1	17159032
or@@	O	-1	17159032
s.	O	-1	17159032
S@@	O	-1	17159032
cre@@	O	-1	17159032
en@@	O	-1	17159032
ing,	O	-1	17159032
including	O	-1	17159032
H@@	O	-1	17159032
um@@	O	-1	17159032
ph@@	O	-1	17159032
re@@	O	-1	17159032
y	O	-1	17159032
10-@@	O	-1	17159032
2	O	-1	17159032
visual	O	-1	17159032
fi@@	O	-1	17159032
el@@	O	-1	17159032
d	O	-1	17159032
assess@@	O	-1	17159032
ment@@	O	-1	17159032
,	O	-1	17159032
is	O	-1	17159032
recomm@@	O	-1	17159032
en@@	O	-1	17159032
ded	O	-1	17159032
2	O	-1	17159032
years	O	-1	17159032
after	O	-1	17159032
the	O	-1	17159032
initial	O	-1	17159032
baseline	O	-1	17159032
and	O	-1	17159032
year@@	O	-1	17159032
ly	O	-1	17159032
the@@	O	-1	17159032
re@@	O	-1	17159032
af@@	O	-1	17159032
ter@@	O	-1	17159032
.	O	-1	17159032

P@@	O	-1	17223814
er@@	O	-1	17223814
i@@	O	-1	17223814
-@@	O	-1	17223814
o@@	O	-1	17223814
perative	O	-1	17223814
atri@@	B-Disease	D054537	17223814
o@@	I-Disease	-1	17223814
ventricular	I-Disease	-1	17223814
bloc@@	I-Disease	-1	17223814
k	I-Disease	-1	17223814
as	O	-1	17223814
a	O	-1	17223814
result	O	-1	17223814
of	O	-1	17223814
chemotherapy	O	-1	17223814
with	O	-1	17223814
epi@@	B-Chemical	D015251	17223814
ru@@	I-Chemical	-1	17223814
b@@	I-Chemical	-1	17223814
icin	I-Chemical	-1	17223814
and	O	-1	17223814
paclitax@@	B-Chemical	D017239	17223814
el	I-Chemical	-1	17223814
.	O	-1	17223814
A	O	-1	17223814
4@@	O	-1	17223814
7-@@	O	-1	17223814
year-old	O	-1	17223814
woman	O	-1	17223814
presented	O	-1	17223814
for	O	-1	17223814
ma@@	O	-1	17223814
st@@	O	-1	17223814
ect@@	O	-1	17223814
om@@	O	-1	17223814
y	O	-1	17223814
and	O	-1	17223814
immedi@@	O	-1	17223814
ate	O	-1	17223814
l@@	O	-1	17223814
atis@@	O	-1	17223814
sim@@	O	-1	17223814
us	O	-1	17223814
d@@	O	-1	17223814
or@@	O	-1	17223814
s@@	O	-1	17223814
i	O	-1	17223814
f@@	O	-1	17223814
l@@	O	-1	17223814
a@@	O	-1	17223814
p	O	-1	17223814
re@@	O	-1	17223814
con@@	O	-1	17223814
struc@@	O	-1	17223814
tion	O	-1	17223814
ha@@	O	-1	17223814
ving	O	-1	17223814
been	O	-1	17223814
diagnos@@	O	-1	17223814
ed	O	-1	17223814
with	O	-1	17223814
carcin@@	B-Disease	D001943	17223814
oma	I-Disease	-1	17223814
of	I-Disease	-1	17223814
the	I-Disease	-1	17223814
b@@	I-Disease	-1	17223814
reas@@	I-Disease	-1	17223814
t	I-Disease	-1	17223814
6	O	-1	17223814
months	O	-1	17223814
previ@@	O	-1	17223814
ous@@	O	-1	17223814
ly.	O	-1	17223814
In	O	-1	17223814
the	O	-1	17223814
pre@@	O	-1	17223814
ce@@	O	-1	17223814
ding	O	-1	17223814
months	O	-1	17223814
sh@@	O	-1	17223814
e	O	-1	17223814
had	O	-1	17223814
received	O	-1	17223814
ne@@	O	-1	17223814
o@@	O	-1	17223814
-@@	O	-1	17223814
adj@@	O	-1	17223814
u@@	O	-1	17223814
v@@	O	-1	17223814
ant	O	-1	17223814
chemotherapy	O	-1	17223814
with	O	-1	17223814
epi@@	B-Chemical	D015251	17223814
ru@@	I-Chemical	-1	17223814
b@@	I-Chemical	-1	17223814
icin	I-Chemical	-1	17223814
,	O	-1	17223814
paclitax@@	B-Chemical	D017239	17223814
el	I-Chemical	-1	17223814
(	O	-1	17223814
T@@	B-Chemical	D017239	17223814
ax@@	I-Chemical	-1	17223814
ol	I-Chemical	-1	17223814
)	O	-1	17223814
and	O	-1	17223814
cyclophosph@@	B-Chemical	D003520	17223814
amide	I-Chemical	-1	17223814
.	O	-1	17223814
This	O	-1	17223814
had	O	-1	17223814
been	O	-1	17223814
appa@@	O	-1	17223814
ren@@	O	-1	17223814
tly	O	-1	17223814
un@@	O	-1	17223814
complic@@	O	-1	17223814
ated	O	-1	17223814
and	O	-1	17223814
sh@@	O	-1	17223814
e	O	-1	17223814
had	O	-1	17223814
maint@@	O	-1	17223814
ained	O	-1	17223814
a	O	-1	17223814
re@@	O	-1	17223814
mark@@	O	-1	17223814
ably	O	-1	17223814
high	O	-1	17223814
level	O	-1	17223814
of	O	-1	17223814
physi@@	O	-1	17223814
c@@	O	-1	17223814
al	O	-1	17223814
activ@@	O	-1	17223814
ity.	O	-1	17223814
S@@	O	-1	17223814
he	O	-1	17223814
was	O	-1	17223814
found	O	-1	17223814
to	O	-1	17223814
be	O	-1	17223814
brady@@	B-Disease	D001919	17223814
cardi@@	I-Disease	-1	17223814
c	I-Disease	-1	17223814
at	O	-1	17223814
pre-@@	O	-1	17223814
o@@	O	-1	17223814
perative	O	-1	17223814
assess@@	O	-1	17223814
ment	O	-1	17223814
but	O	-1	17223814
had	O	-1	17223814
no	O	-1	17223814
cardiac	O	-1	17223814
symptom@@	O	-1	17223814
s.	O	-1	17223814
S@@	O	-1	17223814
ec@@	O	-1	17223814
on@@	O	-1	17223814
d	O	-1	17223814
de@@	O	-1	17223814
g@@	O	-1	17223814
ree	O	-1	17223814
M@@	O	-1	17223814
ob@@	O	-1	17223814
it@@	O	-1	17223814
z	O	-1	17223814
type	O	-1	17223814
II	O	-1	17223814
atri@@	B-Disease	D054537	17223814
o@@	I-Disease	-1	17223814
ventricular	I-Disease	-1	17223814
bloc@@	I-Disease	-1	17223814
k	I-Disease	-1	17223814
was	O	-1	17223814
diagnos@@	O	-1	17223814
ed	O	-1	17223814
on	O	-1	17223814
electro@@	O	-1	17223814
cardio@@	O	-1	17223814
gram@@	O	-1	17223814
,	O	-1	17223814
and	O	-1	17223814
tempor@@	O	-1	17223814
ary	O	-1	17223814
trans@@	O	-1	17223814
venous	O	-1	17223814
ventricular	O	-1	17223814
pac@@	O	-1	17223814
ing	O	-1	17223814
insti@@	O	-1	17223814
t@@	O	-1	17223814
ut@@	O	-1	17223814
ed	O	-1	17223814
in	O	-1	17223814
the	O	-1	17223814
peri@@	O	-1	17223814
-@@	O	-1	17223814
o@@	O	-1	17223814
perative	O	-1	17223814
perio@@	O	-1	17223814
d.	O	-1	17223814
We	O	-1	17223814
discus@@	O	-1	17223814
s	O	-1	17223814
ho@@	O	-1	17223814
w	O	-1	17223814
ev@@	O	-1	17223814
id@@	O	-1	17223814
ence@@	O	-1	17223814
-@@	O	-1	17223814
bas@@	O	-1	17223814
ed	O	-1	17223814
gu@@	O	-1	17223814
ide@@	O	-1	17223814
lin@@	O	-1	17223814
es	O	-1	17223814
wo@@	O	-1	17223814
uld	O	-1	17223814
not	O	-1	17223814
have	O	-1	17223814
been	O	-1	17223814
he@@	O	-1	17223814
l@@	O	-1	17223814
p@@	O	-1	17223814
ful	O	-1	17223814
in	O	-1	17223814
this	O	-1	17223814
cas@@	O	-1	17223814
e,	O	-1	17223814
and	O	-1	17223814
ho@@	O	-1	17223814
w	O	-1	17223814
chemotherapy	O	-1	17223814
can	O	-1	17223814
ex@@	O	-1	17223814
hib@@	O	-1	17223814
it	O	-1	17223814
subst@@	O	-1	17223814
anti@@	O	-1	17223814
al	O	-1	17223814
cardi@@	B-Disease	D066126	17223814
otoxicity	I-Disease	-1	17223814
that	O	-1	17223814
may	O	-1	17223814
deve@@	O	-1	17223814
lo@@	O	-1	17223814
p	O	-1	17223814
over	O	-1	17223814
man@@	O	-1	17223814
y	O	-1	17223814
year@@	O	-1	17223814
s.	O	-1	17223814
We	O	-1	17223814
suggest	O	-1	17223814
that	O	-1	17223814
patients	O	-1	17223814
who	O	-1	17223814
have	O	-1	17223814
received	O	-1	17223814
chemotherapy	O	-1	17223814
at	O	-1	17223814
any	O	-1	17223814
time	O	-1	17223814
should	O	-1	17223814
have	O	-1	17223814
a	O	-1	17223814
pre-@@	O	-1	17223814
o@@	O	-1	17223814
perative	O	-1	17223814
electro@@	O	-1	17223814
cardio@@	O	-1	17223814
gra@@	O	-1	17223814
m	O	-1	17223814
even	O	-1	17223814
if	O	-1	17223814
they	O	-1	17223814
are	O	-1	17223814
as@@	O	-1	17223814
ym@@	O	-1	17223814
pto@@	O	-1	17223814
m@@	O	-1	17223814
ati@@	O	-1	17223814
c@@	O	-1	17223814
.	O	-1	17223814

R@@	O	-1	17255138
is@@	O	-1	17255138
k@@	O	-1	17255138
s	O	-1	17255138
and	O	-1	17255138
ben@@	O	-1	17255138
e@@	O	-1	17255138
f@@	O	-1	17255138
its	O	-1	17255138
of	O	-1	17255138
CO@@	B-Chemical	D052246	17255138
X@@	I-Chemical	-1	17255138
-@@	I-Chemical	-1	17255138
2	I-Chemical	-1	17255138
inhibitors	I-Chemical	-1	17255138
v@@	O	-1	17255138
s	O	-1	17255138
non-@@	O	-1	17255138
selective	O	-1	17255138
N@@	O	-1	17255138
S@@	O	-1	17255138
A@@	O	-1	17255138
I@@	O	-1	17255138
D@@	O	-1	17255138
s:	O	-1	17255138
does	O	-1	17255138
their	O	-1	17255138
cardiovascular	O	-1	17255138
risk	O	-1	17255138
ex@@	O	-1	17255138
ce@@	O	-1	17255138
ed	O	-1	17255138
their	O	-1	17255138
gast@@	O	-1	17255138
ro@@	O	-1	17255138
in@@	O	-1	17255138
test@@	O	-1	17255138
inal	O	-1	17255138
ben@@	O	-1	17255138
e@@	O	-1	17255138
f@@	O	-1	17255138
it@@	O	-1	17255138
?	O	-1	17255138
A	O	-1	17255138
ret@@	O	-1	17255138
ro@@	O	-1	17255138
sp@@	O	-1	17255138
ective	O	-1	17255138
co@@	O	-1	17255138
h@@	O	-1	17255138
ort	O	-1	17255138
study.	O	-1	17255138
OBJECTIV@@	O	-1	17255138
E@@	O	-1	17255138
S:	O	-1	17255138
The	O	-1	17255138
risk	O	-1	17255138
of	O	-1	17255138
acute	B-Disease	D009203	17255138
myocardial	I-Disease	-1	17255138
infarction	I-Disease	-1	17255138
(	O	-1	17255138
AM@@	B-Disease	D009203	17255138
I	I-Disease	-1	17255138
)	O	-1	17255138
with	O	-1	17255138
CO@@	B-Chemical	D052246	17255138
X@@	I-Chemical	-1	17255138
-@@	I-Chemical	-1	17255138
2	I-Chemical	-1	17255138
inhibitors	I-Chemical	-1	17255138
may	O	-1	17255138
o@@	O	-1	17255138
ff@@	O	-1	17255138
set	O	-1	17255138
their	O	-1	17255138
gast@@	O	-1	17255138
ro@@	O	-1	17255138
in@@	O	-1	17255138
test@@	O	-1	17255138
inal	O	-1	17255138
(@@	O	-1	17255138
G@@	O	-1	17255138
I@@	O	-1	17255138
)	O	-1	17255138
ben@@	O	-1	17255138
e@@	O	-1	17255138
fi@@	O	-1	17255138
t	O	-1	17255138
compared	O	-1	17255138
with	O	-1	17255138
non-@@	O	-1	17255138
selective	O	-1	17255138
(N@@	O	-1	17255138
S)	O	-1	17255138
non-@@	B-Chemical	D000894	17255138
steroid@@	I-Chemical	-1	17255138
al	I-Chemical	-1	17255138
anti@@	I-Chemical	-1	17255138
-@@	I-Chemical	-1	17255138
inflam@@	I-Chemical	-1	17255138
mat@@	I-Chemical	-1	17255138
ory	I-Chemical	-1	17255138
drugs	I-Chemical	-1	17255138
(N@@	O	-1	17255138
S@@	O	-1	17255138
A@@	O	-1	17255138
I@@	O	-1	17255138
D@@	O	-1	17255138
s@@	O	-1	17255138
).	O	-1	17255138
We	O	-1	17255138
a@@	O	-1	17255138
im@@	O	-1	17255138
ed	O	-1	17255138
to	O	-1	17255138
compar@@	O	-1	17255138
e	O	-1	17255138
the	O	-1	17255138
ris@@	O	-1	17255138
k@@	O	-1	17255138
s	O	-1	17255138
of	O	-1	17255138
hospit@@	O	-1	17255138
al@@	O	-1	17255138
ization	O	-1	17255138
for	O	-1	17255138
AM@@	B-Disease	D009203	17255138
I	I-Disease	-1	17255138
and	O	-1	17255138
G@@	B-Disease	D006471	17255138
I	I-Disease	-1	17255138
ble@@	I-Disease	-1	17255138
ed@@	I-Disease	-1	17255138
ing	I-Disease	-1	17255138
among	O	-1	17255138
el@@	O	-1	17255138
der@@	O	-1	17255138
ly	O	-1	17255138
patients	O	-1	17255138
using	O	-1	17255138
CO@@	B-Chemical	D052246	17255138
X@@	I-Chemical	-1	17255138
-@@	I-Chemical	-1	17255138
2	I-Chemical	-1	17255138
inhibitors	I-Chemical	-1	17255138
,	O	-1	17255138
N@@	O	-1	17255138
S@@	O	-1	17255138
-@@	O	-1	17255138
N@@	O	-1	17255138
S@@	O	-1	17255138
A@@	O	-1	17255138
I@@	O	-1	17255138
D@@	O	-1	17255138
s	O	-1	17255138
and	O	-1	17255138
acet@@	B-Chemical	D000082	17255138
aminoph@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
.	O	-1	17255138
METHODS:	O	-1	17255138
We	O	-1	17255138
con@@	O	-1	17255138
duc@@	O	-1	17255138
ted	O	-1	17255138
a	O	-1	17255138
ret@@	O	-1	17255138
ro@@	O	-1	17255138
sp@@	O	-1	17255138
ective	O	-1	17255138
co@@	O	-1	17255138
h@@	O	-1	17255138
ort	O	-1	17255138
study	O	-1	17255138
using	O	-1	17255138
administr@@	O	-1	17255138
ative	O	-1	17255138
data	O	-1	17255138
of	O	-1	17255138
patients	O	-1	17255138
>	O	-1	17255138
or	O	-1	17255138
=@@	O	-1	17255138
6@@	O	-1	17255138
5	O	-1	17255138
years	O	-1	17255138
of	O	-1	17255138
age	O	-1	17255138
who	O	-1	17255138
f@@	O	-1	17255138
ill@@	O	-1	17255138
ed	O	-1	17255138
a	O	-1	17255138
prescri@@	O	-1	17255138
ption	O	-1	17255138
for	O	-1	17255138
N@@	O	-1	17255138
S@@	O	-1	17255138
A@@	O	-1	17255138
I@@	O	-1	17255138
D	O	-1	17255138
or	O	-1	17255138
acet@@	B-Chemical	D000082	17255138
aminoph@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
during	O	-1	17255138
19@@	O	-1	17255138
9@@	O	-1	17255138
9@@	O	-1	17255138
-@@	O	-1	17255138
20@@	O	-1	17255138
0@@	O	-1	17255138
2@@	O	-1	17255138
.	O	-1	17255138
O@@	O	-1	17255138
ut@@	O	-1	17255138
com@@	O	-1	17255138
es	O	-1	17255138
were	O	-1	17255138
compared	O	-1	17255138
using	O	-1	17255138
C@@	O	-1	17255138
o@@	O	-1	17255138
x	O	-1	17255138
reg@@	O	-1	17255138
res@@	O	-1	17255138
sion	O	-1	17255138
models	O	-1	17255138
with	O	-1	17255138
ti@@	O	-1	17255138
me@@	O	-1	17255138
-@@	O	-1	17255138
dependent	O	-1	17255138
expos@@	O	-1	17255138
ures@@	O	-1	17255138
.	O	-1	17255138
RESULTS:	O	-1	17255138
P@@	O	-1	17255138
er@@	O	-1	17255138
son@@	O	-1	17255138
-@@	O	-1	17255138
years	O	-1	17255138
of	O	-1	17255138
exposure	O	-1	17255138
among	O	-1	17255138
non-@@	O	-1	17255138
users	O	-1	17255138
of	O	-1	17255138
as@@	B-Chemical	D001241	17255138
pi@@	I-Chemical	-1	17255138
rin	I-Chemical	-1	17255138
we@@	O	-1	17255138
re@@	O	-1	17255138
:	O	-1	17255138
7@@	O	-1	17255138
5@@	O	-1	17255138
,@@	O	-1	17255138
7@@	O	-1	17255138
6@@	O	-1	17255138
1	O	-1	17255138
to	O	-1	17255138
acet@@	B-Chemical	D000082	17255138
aminoph@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
,	O	-1	17255138
4@@	O	-1	17255138
2@@	O	-1	17255138
,@@	O	-1	17255138
6@@	O	-1	17255138
7@@	O	-1	17255138
1	O	-1	17255138
to	O	-1	17255138
ro@@	B-Chemical	C116926	17255138
f@@	I-Chemical	-1	17255138
ec@@	I-Chemical	-1	17255138
ox@@	I-Chemical	-1	17255138
i@@	I-Chemical	-1	17255138
b	I-Chemical	-1	17255138
6@@	O	-1	17255138
5@@	O	-1	17255138
,@@	O	-1	17255138
8@@	O	-1	17255138
60	O	-1	17255138
to	O	-1	17255138
ce@@	B-Chemical	C105934	17255138
l@@	I-Chemical	-1	17255138
ec@@	I-Chemical	-1	17255138
ox@@	I-Chemical	-1	17255138
i@@	I-Chemical	-1	17255138
b	I-Chemical	-1	17255138
,	O	-1	17255138
and	O	-1	17255138
3@@	O	-1	17255138
7@@	O	-1	17255138
,@@	O	-1	17255138
4@@	O	-1	17255138
9@@	O	-1	17255138
5	O	-1	17255138
to	O	-1	17255138
N@@	O	-1	17255138
S@@	O	-1	17255138
-@@	O	-1	17255138
N@@	O	-1	17255138
S@@	O	-1	17255138
A@@	O	-1	17255138
I@@	O	-1	17255138
D@@	O	-1	17255138
s.	O	-1	17255138
A@@	O	-1	17255138
mon@@	O	-1	17255138
g	O	-1	17255138
users	O	-1	17255138
of	O	-1	17255138
as@@	B-Chemical	D001241	17255138
pi@@	I-Chemical	-1	17255138
rin	I-Chemical	-1	17255138
,	O	-1	17255138
they	O	-1	17255138
we@@	O	-1	17255138
re@@	O	-1	17255138
:	O	-1	17255138
14@@	O	-1	17255138
,@@	O	-1	17255138
6@@	O	-1	17255138
7@@	O	-1	17255138
1	O	-1	17255138
to	O	-1	17255138
ro@@	B-Chemical	C116926	17255138
f@@	I-Chemical	-1	17255138
ec@@	I-Chemical	-1	17255138
ox@@	I-Chemical	-1	17255138
i@@	I-Chemical	-1	17255138
b	I-Chemical	-1	17255138
,	O	-1	17255138
2@@	O	-1	17255138
2@@	O	-1	17255138
,@@	O	-1	17255138
8@@	O	-1	17255138
7@@	O	-1	17255138
5	O	-1	17255138
to	O	-1	17255138
ce@@	B-Chemical	C105934	17255138
l@@	I-Chemical	-1	17255138
ec@@	I-Chemical	-1	17255138
ox@@	I-Chemical	-1	17255138
i@@	I-Chemical	-1	17255138
b	I-Chemical	-1	17255138
,	O	-1	17255138
9@@	O	-1	17255138
,@@	O	-1	17255138
8@@	O	-1	17255138
3@@	O	-1	17255138
2	O	-1	17255138
to	O	-1	17255138
N@@	O	-1	17255138
S@@	O	-1	17255138
-@@	O	-1	17255138
N@@	O	-1	17255138
S@@	O	-1	17255138
A@@	O	-1	17255138
I@@	O	-1	17255138
D@@	O	-1	17255138
s	O	-1	17255138
and	O	-1	17255138
3@@	O	-1	17255138
8@@	O	-1	17255138
,@@	O	-1	17255138
0@@	O	-1	17255138
4@@	O	-1	17255138
8	O	-1	17255138
to	O	-1	17255138
acet@@	B-Chemical	D000082	17255138
aminoph@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
.	O	-1	17255138
A@@	O	-1	17255138
mon@@	O	-1	17255138
g	O	-1	17255138
non-@@	O	-1	17255138
users	O	-1	17255138
of	O	-1	17255138
as@@	B-Chemical	D001241	17255138
pi@@	I-Chemical	-1	17255138
rin	I-Chemical	-1	17255138
,	O	-1	17255138
the	O	-1	17255138
adjust@@	O	-1	17255138
ed	O	-1	17255138
ha@@	O	-1	17255138
z@@	O	-1	17255138
ard	O	-1	17255138
rati@@	O	-1	17255138
o@@	O	-1	17255138
s	O	-1	17255138
(@@	O	-1	17255138
95%	O	-1	17255138
conf@@	O	-1	17255138
idence	O	-1	17255138
inter@@	O	-1	17255138
val@@	O	-1	17255138
)	O	-1	17255138
of	O	-1	17255138
hospit@@	O	-1	17255138
al@@	O	-1	17255138
ization	O	-1	17255138
for	O	-1	17255138
AM@@	B-Disease	D009203	17255138
I	I-Disease	-1	17255138
/@@	O	-1	17255138
G@@	O	-1	17255138
I	O	-1	17255138
v@@	O	-1	17255138
s	O	-1	17255138
the	O	-1	17255138
acet@@	B-Chemical	D000082	17255138
aminoph@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
(@@	O	-1	17255138
with	O	-1	17255138
no	O	-1	17255138
as@@	B-Chemical	D001241	17255138
pi@@	I-Chemical	-1	17255138
rin	I-Chemical	-1	17255138
)	O	-1	17255138
group	O	-1	17255138
we@@	O	-1	17255138
re@@	O	-1	17255138
:	O	-1	17255138
ro@@	B-Chemical	C116926	17255138
f@@	I-Chemical	-1	17255138
ec@@	I-Chemical	-1	17255138
ox@@	I-Chemical	-1	17255138
i@@	I-Chemical	-1	17255138
b	I-Chemical	-1	17255138
1.@@	O	-1	17255138
2@@	O	-1	17255138
7	O	-1	17255138
(1@@	O	-1	17255138
.@@	O	-1	17255138
13@@	O	-1	17255138
,	O	-1	17255138
1.@@	O	-1	17255138
4@@	O	-1	17255138
2@@	O	-1	17255138
),	O	-1	17255138
ce@@	B-Chemical	C105934	17255138
l@@	I-Chemical	-1	17255138
ec@@	I-Chemical	-1	17255138
ox@@	I-Chemical	-1	17255138
i@@	I-Chemical	-1	17255138
b	I-Chemical	-1	17255138
0.@@	O	-1	17255138
9@@	O	-1	17255138
3	O	-1	17255138
(0.@@	O	-1	17255138
8@@	O	-1	17255138
3,	O	-1	17255138
1.@@	O	-1	17255138
0@@	O	-1	17255138
3@@	O	-1	17255138
),	O	-1	17255138
na@@	B-Chemical	D009288	17255138
pro@@	I-Chemical	-1	17255138
x@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
1.@@	O	-1	17255138
5@@	O	-1	17255138
9	O	-1	17255138
(1@@	O	-1	17255138
.@@	O	-1	17255138
3@@	O	-1	17255138
1,	O	-1	17255138
1.@@	O	-1	17255138
9@@	O	-1	17255138
3@@	O	-1	17255138
),	O	-1	17255138
dic@@	B-Chemical	D004008	17255138
lo@@	I-Chemical	-1	17255138
f@@	I-Chemical	-1	17255138
en@@	I-Chemical	-1	17255138
a@@	I-Chemical	-1	17255138
c	I-Chemical	-1	17255138
1.@@	O	-1	17255138
17	O	-1	17255138
(0.@@	O	-1	17255138
9@@	O	-1	17255138
9@@	O	-1	17255138
,	O	-1	17255138
1.@@	O	-1	17255138
3@@	O	-1	17255138
8@@	O	-1	17255138
)	O	-1	17255138
and	O	-1	17255138
i@@	B-Chemical	D007052	17255138
bu@@	I-Chemical	-1	17255138
prof@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
1.@@	O	-1	17255138
0@@	O	-1	17255138
5	O	-1	17255138
(0.@@	O	-1	17255138
7@@	O	-1	17255138
4@@	O	-1	17255138
,	O	-1	17255138
1.@@	O	-1	17255138
5@@	O	-1	17255138
1).	O	-1	17255138
A@@	O	-1	17255138
mon@@	O	-1	17255138
g	O	-1	17255138
users	O	-1	17255138
of	O	-1	17255138
as@@	B-Chemical	D001241	17255138
pi@@	I-Chemical	-1	17255138
rin	I-Chemical	-1	17255138
,	O	-1	17255138
they	O	-1	17255138
we@@	O	-1	17255138
re@@	O	-1	17255138
:	O	-1	17255138
ro@@	B-Chemical	C116926	17255138
f@@	I-Chemical	-1	17255138
ec@@	I-Chemical	-1	17255138
ox@@	I-Chemical	-1	17255138
i@@	I-Chemical	-1	17255138
b	I-Chemical	-1	17255138
1.@@	O	-1	17255138
7@@	O	-1	17255138
3	O	-1	17255138
(1@@	O	-1	17255138
.@@	O	-1	17255138
5@@	O	-1	17255138
2,	O	-1	17255138
1.@@	O	-1	17255138
9@@	O	-1	17255138
8@@	O	-1	17255138
),	O	-1	17255138
ce@@	B-Chemical	C105934	17255138
l@@	I-Chemical	-1	17255138
ec@@	I-Chemical	-1	17255138
ox@@	I-Chemical	-1	17255138
i@@	I-Chemical	-1	17255138
b	I-Chemical	-1	17255138
1.@@	O	-1	17255138
3@@	O	-1	17255138
4	O	-1	17255138
(1@@	O	-1	17255138
.@@	O	-1	17255138
19@@	O	-1	17255138
,	O	-1	17255138
1.@@	O	-1	17255138
5@@	O	-1	17255138
2@@	O	-1	17255138
),	O	-1	17255138
i@@	B-Chemical	D007052	17255138
bu@@	I-Chemical	-1	17255138
prof@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
1.@@	O	-1	17255138
5@@	O	-1	17255138
1	O	-1	17255138
(0.@@	O	-1	17255138
9@@	O	-1	17255138
5,	O	-1	17255138
2.@@	O	-1	17255138
4@@	O	-1	17255138
1),	O	-1	17255138
dic@@	B-Chemical	D004008	17255138
lo@@	I-Chemical	-1	17255138
f@@	I-Chemical	-1	17255138
en@@	I-Chemical	-1	17255138
a@@	I-Chemical	-1	17255138
c	I-Chemical	-1	17255138
1.@@	O	-1	17255138
6@@	O	-1	17255138
9	O	-1	17255138
(1@@	O	-1	17255138
.@@	O	-1	17255138
3@@	O	-1	17255138
5,	O	-1	17255138
2.@@	O	-1	17255138
10@@	O	-1	17255138
),	O	-1	17255138
na@@	B-Chemical	D009288	17255138
pro@@	I-Chemical	-1	17255138
x@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
1.@@	O	-1	17255138
3@@	O	-1	17255138
5	O	-1	17255138
(0.@@	O	-1	17255138
9@@	O	-1	17255138
7@@	O	-1	17255138
,	O	-1	17255138
1.@@	O	-1	17255138
8@@	O	-1	17255138
8@@	O	-1	17255138
)	O	-1	17255138
and	O	-1	17255138
acet@@	B-Chemical	D000082	17255138
aminoph@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
1.@@	O	-1	17255138
2@@	O	-1	17255138
9	O	-1	17255138
(1@@	O	-1	17255138
.@@	O	-1	17255138
17@@	O	-1	17255138
,	O	-1	17255138
1.@@	O	-1	17255138
4@@	O	-1	17255138
2@@	O	-1	17255138
).	O	-1	17255138
CONCLUSION:	O	-1	17255138
A@@	O	-1	17255138
mon@@	O	-1	17255138
g	O	-1	17255138
non-@@	O	-1	17255138
users	O	-1	17255138
of	O	-1	17255138
as@@	B-Chemical	D001241	17255138
pi@@	I-Chemical	-1	17255138
rin	I-Chemical	-1	17255138
,	O	-1	17255138
na@@	B-Chemical	D009288	17255138
pro@@	I-Chemical	-1	17255138
x@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
se@@	O	-1	17255138
em@@	O	-1	17255138
ed	O	-1	17255138
to	O	-1	17255138
car@@	O	-1	17255138
r@@	O	-1	17255138
y	O	-1	17255138
the	O	-1	17255138
high@@	O	-1	17255138
est	O	-1	17255138
risk	O	-1	17255138
for	O	-1	17255138
AM@@	B-Disease	D009203	17255138
I	I-Disease	-1	17255138
/	O	-1	17255138
G@@	B-Disease	D006471	17255138
I	I-Disease	-1	17255138
ble@@	I-Disease	-1	17255138
ed@@	I-Disease	-1	17255138
ing	I-Disease	-1	17255138
.	O	-1	17255138
The	O	-1	17255138
AM@@	B-Disease	D009203	17255138
I	I-Disease	-1	17255138
/@@	O	-1	17255138
G@@	O	-1	17255138
I	O	-1	17255138
toxicity	B-Disease	D064420	17255138
of	O	-1	17255138
ce@@	B-Chemical	C105934	17255138
l@@	I-Chemical	-1	17255138
ec@@	I-Chemical	-1	17255138
ox@@	I-Chemical	-1	17255138
i@@	I-Chemical	-1	17255138
b	I-Chemical	-1	17255138
was	O	-1	17255138
similar	O	-1	17255138
to	O	-1	17255138
that	O	-1	17255138
of	O	-1	17255138
acet@@	B-Chemical	D000082	17255138
aminoph@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
and	O	-1	17255138
se@@	O	-1	17255138
em@@	O	-1	17255138
ed	O	-1	17255138
to	O	-1	17255138
be	O	-1	17255138
bet@@	O	-1	17255138
ter	O	-1	17255138
than	O	-1	17255138
those	O	-1	17255138
of	O	-1	17255138
ro@@	B-Chemical	C116926	17255138
f@@	I-Chemical	-1	17255138
ec@@	I-Chemical	-1	17255138
ox@@	I-Chemical	-1	17255138
i@@	I-Chemical	-1	17255138
b	I-Chemical	-1	17255138
and	O	-1	17255138
N@@	O	-1	17255138
S@@	O	-1	17255138
-@@	O	-1	17255138
N@@	O	-1	17255138
S@@	O	-1	17255138
A@@	O	-1	17255138
I@@	O	-1	17255138
D@@	O	-1	17255138
s.	O	-1	17255138
A@@	O	-1	17255138
mon@@	O	-1	17255138
g	O	-1	17255138
users	O	-1	17255138
of	O	-1	17255138
as@@	B-Chemical	D001241	17255138
pi@@	I-Chemical	-1	17255138
rin	I-Chemical	-1	17255138
,	O	-1	17255138
both	O	-1	17255138
ce@@	B-Chemical	C105934	17255138
l@@	I-Chemical	-1	17255138
ec@@	I-Chemical	-1	17255138
ox@@	I-Chemical	-1	17255138
i@@	I-Chemical	-1	17255138
b	I-Chemical	-1	17255138
and	O	-1	17255138
na@@	B-Chemical	D009288	17255138
pro@@	I-Chemical	-1	17255138
x@@	I-Chemical	-1	17255138
en	I-Chemical	-1	17255138
se@@	O	-1	17255138
em@@	O	-1	17255138
ed	O	-1	17255138
to	O	-1	17255138
be	O	-1	17255138
the	O	-1	17255138
le@@	O	-1	17255138
ast	O	-1	17255138
toxic@@	O	-1	17255138
.	O	-1	17255138

Q@@	B-Chemical	D011803	17297207
u@@	I-Chemical	-1	17297207
inine	I-Chemical	-1	17297207
-induced	O	-1	17297207
arrhyth@@	B-Disease	D001145	17297207
mia	I-Disease	-1	17297207
in	O	-1	17297207
a	O	-1	17297207
patient	O	-1	17297207
with	O	-1	17297207
severe	B-Disease	D016778	17297207
mal@@	I-Disease	-1	17297207
ar@@	I-Disease	-1	17297207
ia	I-Disease	-1	17297207
.	O	-1	17297207
It	O	-1	17297207
was	O	-1	17297207
reported	O	-1	17297207
that	O	-1	17297207
there	O	-1	17297207
was	O	-1	17297207
a	O	-1	17297207
case	O	-1	17297207
of	O	-1	17297207
severe	B-Disease	D016778	17297207
mal@@	I-Disease	-1	17297207
ar@@	I-Disease	-1	17297207
ia	I-Disease	-1	17297207
patient	O	-1	17297207
with	O	-1	17297207
j@@	B-Disease	D007565	17297207
a@@	I-Disease	-1	17297207
un@@	I-Disease	-1	17297207
dic@@	I-Disease	-1	17297207
e	I-Disease	-1	17297207
who	O	-1	17297207
presented	O	-1	17297207
with	O	-1	17297207
arrhyth@@	B-Disease	D001145	17297207
mia	I-Disease	-1	17297207
(	O	-1	17297207
pre@@	B-Disease	D018879	17297207
mat@@	I-Disease	-1	17297207
ure	I-Disease	-1	17297207
ventricular	I-Disease	-1	17297207
contrac@@	I-Disease	-1	17297207
tion	I-Disease	-1	17297207
)	O	-1	17297207
while	O	-1	17297207
g@@	O	-1	17297207
et@@	O	-1	17297207
ting	O	-1	17297207
qu@@	B-Chemical	D011803	17297207
inine	I-Chemical	-1	17297207
infusion	O	-1	17297207
was	O	-1	17297207
repor@@	O	-1	17297207
ted.	O	-1	17297207
A	O	-1	17297207
man@@	O	-1	17297207
,	O	-1	17297207
25	O	-1	17297207
years	O	-1	17297207
ol@@	O	-1	17297207
d,	O	-1	17297207
was	O	-1	17297207
ad@@	O	-1	17297207
mit@@	O	-1	17297207
ted	O	-1	17297207
to	O	-1	17297207
hospit@@	O	-1	17297207
al	O	-1	17297207
with	O	-1	17297207
high	O	-1	17297207
f@@	B-Disease	D005334	17297207
ev@@	I-Disease	-1	17297207
er	I-Disease	-1	17297207
,	O	-1	17297207
ch@@	B-Disease	D023341	17297207
il@@	I-Disease	-1	17297207
l	I-Disease	-1	17297207
,	O	-1	17297207
v@@	B-Disease	D014839	17297207
om@@	I-Disease	-1	17297207
it@@	I-Disease	-1	17297207
ing	I-Disease	-1	17297207
,	O	-1	17297207
j@@	B-Disease	D007565	17297207
a@@	I-Disease	-1	17297207
un@@	I-Disease	-1	17297207
dic@@	I-Disease	-1	17297207
e	I-Disease	-1	17297207
.	O	-1	17297207
The	O	-1	17297207
patient	O	-1	17297207
was	O	-1	17297207
ful@@	O	-1	17297207
ly	O	-1	17297207
con@@	O	-1	17297207
s@@	O	-1	17297207
ci@@	O	-1	17297207
ou@@	O	-1	17297207
s,	O	-1	17297207
blood	O	-1	17297207
pressure	O	-1	17297207
1@@	O	-1	17297207
20@@	O	-1	17297207
/@@	O	-1	17297207
8@@	O	-1	17297207
0	O	-1	17297207
mm@@	O	-1	17297207
H@@	O	-1	17297207
g@@	O	-1	17297207
,	O	-1	17297207
pul@@	O	-1	17297207
se	O	-1	17297207
rate	O	-1	17297207
100	O	-1	17297207
x@@	O	-1	17297207
/@@	O	-1	17297207
min@@	O	-1	17297207
u@@	O	-1	17297207
te@@	O	-1	17297207
,	O	-1	17297207
reg@@	O	-1	17297207
ul@@	O	-1	17297207
ar@@	O	-1	17297207
.	O	-1	17297207
O@@	O	-1	17297207
n	O	-1	17297207
ad@@	O	-1	17297207
mis@@	O	-1	17297207
sion,	O	-1	17297207
labor@@	O	-1	17297207
atory	O	-1	17297207
examin@@	O	-1	17297207
ation	O	-1	17297207
showed	O	-1	17297207
P@@	O	-1	17297207
las@@	O	-1	17297207
mo@@	O	-1	17297207
di@@	O	-1	17297207
um	O	-1	17297207
f@@	O	-1	17297207
al@@	O	-1	17297207
ci@@	O	-1	17297207
par@@	O	-1	17297207
um	O	-1	17297207
(@@	O	-1	17297207
+@@	O	-1	17297207
+@@	O	-1	17297207
+@@	O	-1	17297207
+@@	O	-1	17297207
),	O	-1	17297207
total	O	-1	17297207
bil@@	B-Chemical	D001663	17297207
i@@	I-Chemical	-1	17297207
ru@@	I-Chemical	-1	17297207
bin	I-Chemical	-1	17297207
8.@@	O	-1	17297207
25	O	-1	17297207
mg/d@@	O	-1	17297207
L@@	O	-1	17297207
,	O	-1	17297207
con@@	O	-1	17297207
j@@	O	-1	17297207
u@@	O	-1	17297207
g@@	O	-1	17297207
ated	O	-1	17297207
bil@@	B-Chemical	D001663	17297207
i@@	I-Chemical	-1	17297207
ru@@	I-Chemical	-1	17297207
bin	I-Chemical	-1	17297207
4.@@	O	-1	17297207
3@@	O	-1	17297207
6	O	-1	17297207
mg/d@@	O	-1	17297207
L@@	O	-1	17297207
,	O	-1	17297207
un@@	O	-1	17297207
con@@	O	-1	17297207
j@@	O	-1	17297207
u@@	O	-1	17297207
g@@	O	-1	17297207
ated	O	-1	17297207
bil@@	B-Chemical	D001663	17297207
i@@	I-Chemical	-1	17297207
ru@@	I-Chemical	-1	17297207
bin	I-Chemical	-1	17297207
3.@@	O	-1	17297207
8@@	O	-1	17297207
9	O	-1	17297207
mg/d@@	O	-1	17297207
L@@	O	-1	17297207
,	O	-1	17297207
pot@@	B-Chemical	D011188	17297207
assi@@	I-Chemical	-1	17297207
um	I-Chemical	-1	17297207
3.@@	O	-1	17297207
5@@	O	-1	17297207
2	O	-1	17297207
me@@	O	-1	17297207
q@@	O	-1	17297207
/@@	O	-1	17297207
L	O	-1	17297207
Pati@@	O	-1	17297207
ent	O	-1	17297207
was	O	-1	17297207
diagnos@@	O	-1	17297207
ed	O	-1	17297207
as	O	-1	17297207
severe	B-Disease	D016778	17297207
mal@@	I-Disease	-1	17297207
ar@@	I-Disease	-1	17297207
ia	I-Disease	-1	17297207
with	O	-1	17297207
j@@	B-Disease	D007565	17297207
a@@	I-Disease	-1	17297207
un@@	I-Disease	-1	17297207
dic@@	I-Disease	-1	17297207
e	I-Disease	-1	17297207
and	O	-1	17297207
go@@	O	-1	17297207
t	O	-1	17297207
qu@@	B-Chemical	D011803	17297207
inine	I-Chemical	-1	17297207
infusion	O	-1	17297207
in	O	-1	17297207
de@@	B-Chemical	D005947	17297207
x@@	I-Chemical	-1	17297207
tro@@	I-Chemical	-1	17297207
se	I-Chemical	-1	17297207
5%	O	-1	17297207
5@@	O	-1	17297207
00	O	-1	17297207
mg/@@	O	-1	17297207
8	O	-1	17297207
hour@@	O	-1	17297207
.	O	-1	17297207
O@@	O	-1	17297207
n	O	-1	17297207
the	O	-1	17297207
second	O	-1	17297207
day	O	-1	17297207
the	O	-1	17297207
patient	O	-1	17297207
had	O	-1	17297207
v@@	B-Disease	D014839	17297207
om@@	I-Disease	-1	17297207
it@@	I-Disease	-1	17297207
us	I-Disease	-1	17297207
,	O	-1	17297207
di@@	B-Disease	D003967	17297207
ar@@	I-Disease	-1	17297207
r@@	I-Disease	-1	17297207
he@@	I-Disease	-1	17297207
a	I-Disease	-1	17297207
,	O	-1	17297207
t@@	B-Disease	D014012	17297207
in@@	I-Disease	-1	17297207
nit@@	I-Disease	-1	17297207
us	I-Disease	-1	17297207
,	O	-1	17297207
loss	B-Disease	D034381	17297207
of	I-Disease	-1	17297207
hearing	I-Disease	-1	17297207
.	O	-1	17297207
After	O	-1	17297207
30	O	-1	17297207
hours	O	-1	17297207
of	O	-1	17297207
qu@@	B-Chemical	D011803	17297207
inine	I-Chemical	-1	17297207
infusion	O	-1	17297207
the	O	-1	17297207
patient	O	-1	17297207
f@@	O	-1	17297207
el@@	O	-1	17297207
t	O	-1	17297207
p@@	B-Disease	-1	17297207
al@@	I-Disease	-1	17297207
pit@@	I-Disease	-1	17297207
ation	I-Disease	-1	17297207
and	O	-1	17297207
electro@@	O	-1	17297207
cardio@@	O	-1	17297207
graph@@	O	-1	17297207
y	O	-1	17297207
(@@	O	-1	17297207
EC@@	O	-1	17297207
G@@	O	-1	17297207
)	O	-1	17297207
recor@@	O	-1	17297207
ding	O	-1	17297207
showed	O	-1	17297207
pre@@	B-Disease	D018879	17297207
mat@@	I-Disease	-1	17297207
ure	I-Disease	-1	17297207
ventricular	I-Disease	-1	17297207
contrac@@	I-Disease	-1	17297207
tion	I-Disease	-1	17297207
(	O	-1	17297207
P@@	B-Disease	D018879	17297207
V@@	I-Disease	-1	17297207
C	I-Disease	-1	17297207
)	O	-1	17297207
>	O	-1	17297207
5	O	-1	17297207
x@@	O	-1	17297207
/@@	O	-1	17297207
min@@	O	-1	17297207
u@@	O	-1	17297207
te@@	O	-1	17297207
,	O	-1	17297207
tri@@	O	-1	17297207
g@@	O	-1	17297207
em@@	O	-1	17297207
in@@	O	-1	17297207
i@@	O	-1	17297207
,	O	-1	17297207
con@@	O	-1	17297207
st@@	O	-1	17297207
ant	O	-1	17297207
ty@@	O	-1	17297207
pe@@	O	-1	17297207
-@@	O	-1	17297207
-	O	-1	17297207
s@@	B-Disease	D012848	17297207
ino@@	I-Disease	-1	17297207
atrial	I-Disease	-1	17297207
bloc@@	I-Disease	-1	17297207
k	I-Disease	-1	17297207
,	O	-1	17297207
positive	O	-1	17297207
U	O	-1	17297207
w@@	O	-1	17297207
a@@	O	-1	17297207
ve.	O	-1	17297207
H@@	O	-1	17297207
e	O	-1	17297207
was	O	-1	17297207
treated	O	-1	17297207
with	O	-1	17297207
lidocaine	B-Chemical	D008012	17297207
50	O	-1	17297207
mg	O	-1	17297207
intra@@	O	-1	17297207
ven@@	O	-1	17297207
ously	O	-1	17297207
followed	O	-1	17297207
by	O	-1	17297207
infusion	O	-1	17297207
1@@	O	-1	17297207
5@@	O	-1	17297207
00	O	-1	17297207
mg	O	-1	17297207
in	O	-1	17297207
de@@	B-Chemical	D005947	17297207
x@@	I-Chemical	-1	17297207
tro@@	I-Chemical	-1	17297207
se	I-Chemical	-1	17297207
5@@	O	-1	17297207
%@@	O	-1	17297207
/@@	O	-1	17297207
24	O	-1	17297207
h@@	O	-1	17297207
our	O	-1	17297207
and	O	-1	17297207
pot@@	B-Chemical	D001224	17297207
assi@@	I-Chemical	-1	17297207
um	I-Chemical	-1	17297207
as@@	I-Chemical	-1	17297207
part@@	I-Chemical	-1	17297207
ate	I-Chemical	-1	17297207
t@@	O	-1	17297207
able@@	O	-1	17297207
t.	O	-1	17297207
Q@@	B-Chemical	D011803	17297207
u@@	I-Chemical	-1	17297207
inine	I-Chemical	-1	17297207
infusion	O	-1	17297207
was	O	-1	17297207
discontinu@@	O	-1	17297207
ed	O	-1	17297207
and	O	-1	17297207
chang@@	O	-1	17297207
ed	O	-1	17297207
with	O	-1	17297207
sulf@@	O	-1	17297207
ate	O	-1	17297207
qu@@	B-Chemical	D011803	17297207
inine	I-Chemical	-1	17297207
t@@	O	-1	17297207
able@@	O	-1	17297207
t@@	O	-1	17297207
s.	O	-1	17297207
Th@@	O	-1	17297207
ree	O	-1	17297207
hours	O	-1	17297207
lat@@	O	-1	17297207
er	O	-1	17297207
the	O	-1	17297207
patient	O	-1	17297207
f@@	O	-1	17297207
el@@	O	-1	17297207
t	O	-1	17297207
bet@@	O	-1	17297207
ter@@	O	-1	17297207
,	O	-1	17297207
the	O	-1	17297207
frequency	O	-1	17297207
of	O	-1	17297207
P@@	B-Disease	D018879	17297207
V@@	I-Disease	-1	17297207
C	I-Disease	-1	17297207
reduced	O	-1	17297207
to	O	-1	17297207
4	O	-1	17297207
-	O	-1	17297207
5	O	-1	17297207
x@@	O	-1	17297207
/@@	O	-1	17297207
min@@	O	-1	17297207
ute	O	-1	17297207
and	O	-1	17297207
on	O	-1	17297207
the	O	-1	17297207
thir@@	O	-1	17297207
d	O	-1	17297207
day	O	-1	17297207
EC@@	O	-1	17297207
G	O	-1	17297207
was	O	-1	17297207
normal@@	O	-1	17297207
,	O	-1	17297207
pot@@	B-Chemical	D011188	17297207
assi@@	I-Chemical	-1	17297207
um	I-Chemical	-1	17297207
level	O	-1	17297207
was	O	-1	17297207
3.@@	O	-1	17297207
3@@	O	-1	17297207
4	O	-1	17297207
me@@	O	-1	17297207
q@@	O	-1	17297207
/@@	O	-1	17297207
L@@	O	-1	17297207
.	O	-1	17297207
H@@	O	-1	17297207
e	O	-1	17297207
was	O	-1	17297207
dis@@	O	-1	17297207
ch@@	O	-1	17297207
arg@@	O	-1	17297207
ed	O	-1	17297207
on	O	-1	17297207
7@@	O	-1	17297207
th	O	-1	17297207
day	O	-1	17297207
in	O	-1	17297207
go@@	O	-1	17297207
od	O	-1	17297207
condi@@	O	-1	17297207
tion.	O	-1	17297207
Q@@	B-Chemical	D011803	17297207
u@@	I-Chemical	-1	17297207
inine	I-Chemical	-1	17297207
,	O	-1	17297207
like	O	-1	17297207
qu@@	B-Chemical	D011802	17297207
in@@	I-Chemical	-1	17297207
idine	I-Chemical	-1	17297207
,	O	-1	17297207
is	O	-1	17297207
a	O	-1	17297207
ch@@	O	-1	17297207
in@@	O	-1	17297207
con@@	O	-1	17297207
a	O	-1	17297207
al@@	O	-1	17297207
k@@	O	-1	17297207
alo@@	O	-1	17297207
id	O	-1	17297207
that	O	-1	17297207
has	O	-1	17297207
anti@@	O	-1	17297207
-	O	-1	17297207
arrhyth@@	B-Disease	D001145	17297207
mic	I-Disease	-1	17297207
pro@@	O	-1	17297207
per@@	O	-1	17297207
t@@	O	-1	17297207
y,	O	-1	17297207
although	O	-1	17297207
it	O	-1	17297207
also	O	-1	17297207
pro@@	O	-1	17297207
-	O	-1	17297207
arrhyth@@	B-Disease	D001145	17297207
mic	I-Disease	-1	17297207
that	O	-1	17297207
can	O	-1	17297207
cause	O	-1	17297207
various	O	-1	17297207
arrhyth@@	B-Disease	D001145	17297207
mi@@	I-Disease	-1	17297207
as	I-Disease	-1	17297207
,	O	-1	17297207
including	O	-1	17297207
severe	O	-1	17297207
arrhyth@@	B-Disease	D001145	17297207
mia	I-Disease	-1	17297207
such	O	-1	17297207
as	O	-1	17297207
multiple	O	-1	17297207
P@@	B-Disease	D018879	17297207
V@@	I-Disease	-1	17297207
C	I-Disease	-1	17297207
.	O	-1	17297207
Ad@@	O	-1	17297207
minist@@	O	-1	17297207
ration	O	-1	17297207
of	O	-1	17297207
pa@@	O	-1	17297207
ren@@	O	-1	17297207
ter@@	O	-1	17297207
al	O	-1	17297207
qu@@	B-Chemical	D011803	17297207
inine	I-Chemical	-1	17297207
mus@@	O	-1	17297207
t	O	-1	17297207
be	O	-1	17297207
d@@	O	-1	17297207
one	O	-1	17297207
ca@@	O	-1	17297207
ref@@	O	-1	17297207
ul@@	O	-1	17297207
ly	O	-1	17297207
and	O	-1	17297207
with	O	-1	17297207
go@@	O	-1	17297207
od	O	-1	17297207
observ@@	O	-1	17297207
ation	O	-1	17297207
because	O	-1	17297207
of	O	-1	17297207
its	O	-1	17297207
pro@@	O	-1	17297207
-	O	-1	17297207
arrhyth@@	B-Disease	D001145	17297207
mic	I-Disease	-1	17297207
effect@@	O	-1	17297207
,	O	-1	17297207
es@@	O	-1	17297207
p@@	O	-1	17297207
ec@@	O	-1	17297207
i@@	O	-1	17297207
ally	O	-1	17297207
in	O	-1	17297207
ol@@	O	-1	17297207
der	O	-1	17297207
patients	O	-1	17297207
who	O	-1	17297207
have	O	-1	17297207
heart	B-Disease	D006331	17297207
diseas@@	I-Disease	-1	17297207
es	I-Disease	-1	17297207
or	O	-1	17297207
patients	O	-1	17297207
with	O	-1	17297207
electro@@	B-Disease	D014883	17297207
ly@@	I-Disease	-1	17297207
te	I-Disease	-1	17297207
disor@@	I-Disease	-1	17297207
der	I-Disease	-1	17297207
(	O	-1	17297207
hypo@@	B-Disease	D007008	17297207
k@@	I-Disease	-1	17297207
al@@	I-Disease	-1	17297207
emia	I-Disease	-1	17297207
)	O	-1	17297207
which	O	-1	17297207
frequ@@	O	-1	17297207
ently	O	-1	17297207
occur@@	O	-1	17297207
s	O	-1	17297207
due	O	-1	17297207
to	O	-1	17297207
v@@	B-Disease	D014839	17297207
om@@	I-Disease	-1	17297207
it@@	I-Disease	-1	17297207
ing	I-Disease	-1	17297207
and	O	-1	17297207
or	O	-1	17297207
di@@	B-Disease	D003967	17297207
ar@@	I-Disease	-1	17297207
r@@	I-Disease	-1	17297207
he@@	I-Disease	-1	17297207
a	I-Disease	-1	17297207
in	O	-1	17297207
mal@@	B-Disease	D008288	17297207
ar@@	I-Disease	-1	17297207
ia	I-Disease	-1	17297207
cas@@	O	-1	17297207
es.	O	-1	17297207

P@@	B-Chemical	D010396	17346443
en@@	I-Chemical	-1	17346443
icill@@	I-Chemical	-1	17346443
amine	I-Chemical	-1	17346443
-@@	O	-1	17346443
related	O	-1	17346443
l@@	B-Disease	D017512	17346443
ic@@	I-Disease	-1	17346443
h@@	I-Disease	-1	17346443
en@@	I-Disease	-1	17346443
oid	I-Disease	-1	17346443
der@@	I-Disease	-1	17346443
m@@	I-Disease	-1	17346443
ati@@	I-Disease	-1	17346443
tis	I-Disease	-1	17346443
and	O	-1	17346443
u@@	O	-1	17346443
til@@	O	-1	17346443
ity	O	-1	17346443
of	O	-1	17346443
z@@	B-Chemical	D019345	17346443
in@@	I-Chemical	-1	17346443
c	I-Chemical	-1	17346443
acet@@	I-Chemical	-1	17346443
ate	I-Chemical	-1	17346443
in	O	-1	17346443
a	O	-1	17346443
W@@	B-Disease	D006527	17346443
il@@	I-Disease	-1	17346443
s@@	I-Disease	-1	17346443
on	I-Disease	-1	17346443
disease	I-Disease	-1	17346443
patient	O	-1	17346443
with	O	-1	17346443
hepatic	O	-1	17346443
present@@	O	-1	17346443
ation,	O	-1	17346443
an@@	B-Disease	D001008	17346443
xi@@	I-Disease	-1	17346443
ety	I-Disease	-1	17346443
and	O	-1	17346443
S@@	O	-1	17346443
P@@	O	-1	17346443
EC@@	O	-1	17346443
T	O	-1	17346443
abnormal@@	O	-1	17346443
iti@@	O	-1	17346443
es.	O	-1	17346443
W@@	B-Disease	D006527	17346443
il@@	I-Disease	-1	17346443
son@@	I-Disease	-1	17346443
's	I-Disease	-1	17346443
disease	I-Disease	-1	17346443
is	O	-1	17346443
an	O	-1	17346443
a@@	O	-1	17346443
ut@@	O	-1	17346443
os@@	O	-1	17346443
om@@	O	-1	17346443
al	O	-1	17346443
rec@@	O	-1	17346443
es@@	O	-1	17346443
sive	O	-1	17346443
disor@@	O	-1	17346443
der	O	-1	17346443
of	O	-1	17346443
hepatic	O	-1	17346443
co@@	B-Chemical	D003300	17346443
p@@	I-Chemical	-1	17346443
per	I-Chemical	-1	17346443
metabol@@	O	-1	17346443
ism	O	-1	17346443
with	O	-1	17346443
con@@	O	-1	17346443
sequ@@	O	-1	17346443
ent	O	-1	17346443
co@@	B-Chemical	D003300	17346443
p@@	I-Chemical	-1	17346443
per	I-Chemical	-1	17346443
accum@@	O	-1	17346443
ulation	O	-1	17346443
and	O	-1	17346443
toxicity	B-Disease	D064420	17346443
in	O	-1	17346443
man@@	O	-1	17346443
y	O	-1	17346443
tissu@@	O	-1	17346443
es	O	-1	17346443
and	O	-1	17346443
con@@	O	-1	17346443
sequ@@	O	-1	17346443
ent	O	-1	17346443
hepati@@	B-Disease	D056486	17346443
c@@	I-Disease	-1	17346443
,	I-Disease	-1	17346443
neurolog@@	I-Disease	-1	17346443
ic	I-Disease	-1	17346443
and	I-Disease	-1	17346443
psych@@	I-Disease	-1	17346443
i@@	I-Disease	-1	17346443
atric	I-Disease	-1	17346443
disorder@@	I-Disease	-1	17346443
s	I-Disease	-1	17346443
hepati@@	B-Disease	D009422	17346443
c@@	I-Disease	-1	17346443
,	I-Disease	-1	17346443
neurolog@@	I-Disease	-1	17346443
ic	I-Disease	-1	17346443
and	I-Disease	-1	17346443
psych@@	I-Disease	-1	17346443
i@@	I-Disease	-1	17346443
atric	I-Disease	-1	17346443
disorder@@	I-Disease	-1	17346443
s	I-Disease	-1	17346443
hepati@@	B-Disease	D001523	17346443
c@@	I-Disease	-1	17346443
,	I-Disease	-1	17346443
neurolog@@	I-Disease	-1	17346443
ic	I-Disease	-1	17346443
and	I-Disease	-1	17346443
psych@@	I-Disease	-1	17346443
i@@	I-Disease	-1	17346443
atric	I-Disease	-1	17346443
disorder@@	I-Disease	-1	17346443
s	I-Disease	-1	17346443
.	O	-1	17346443
We	O	-1	17346443
report	O	-1	17346443
a	O	-1	17346443
case	O	-1	17346443
of	O	-1	17346443
W@@	B-Disease	D006527	17346443
il@@	I-Disease	-1	17346443
son@@	I-Disease	-1	17346443
's	I-Disease	-1	17346443
disease	I-Disease	-1	17346443
with	O	-1	17346443
chronic	B-Disease	D008107	17346443
liver	I-Disease	-1	17346443
disease	I-Disease	-1	17346443
;	O	-1	17346443
mo@@	O	-1	17346443
re@@	O	-1	17346443
o@@	O	-1	17346443
ver,	O	-1	17346443
in	O	-1	17346443
our	O	-1	17346443
patient@@	O	-1	17346443
,	O	-1	17346443
present@@	O	-1	17346443
ing	O	-1	17346443
also	O	-1	17346443
with	O	-1	17346443
high	O	-1	17346443
levels	O	-1	17346443
of	O	-1	17346443
state	O	-1	17346443
an@@	B-Disease	D001008	17346443
xi@@	I-Disease	-1	17346443
ety	I-Disease	-1	17346443
without	O	-1	17346443
de@@	B-Disease	D003866	17346443
pression	I-Disease	-1	17346443
,	O	-1	17346443
9@@	O	-1	17346443
9@@	O	-1	17346443
m@@	O	-1	17346443
T@@	O	-1	17346443
c@@	O	-1	17346443
-@@	O	-1	17346443
EC@@	O	-1	17346443
D-@@	O	-1	17346443
S@@	O	-1	17346443
P@@	O	-1	17346443
EC@@	O	-1	17346443
T	O	-1	17346443
showed	O	-1	17346443
cor@@	O	-1	17346443
tical	O	-1	17346443
hypo@@	O	-1	17346443
per@@	O	-1	17346443
f@@	O	-1	17346443
usion	O	-1	17346443
in	O	-1	17346443
fron@@	O	-1	17346443
t@@	O	-1	17346443
al	O	-1	17346443
lo@@	O	-1	17346443
b@@	O	-1	17346443
es,	O	-1	17346443
more	O	-1	17346443
mark@@	O	-1	17346443
ed	O	-1	17346443
on	O	-1	17346443
the	O	-1	17346443
left	O	-1	17346443
fron@@	O	-1	17346443
t@@	O	-1	17346443
al	O	-1	17346443
lo@@	O	-1	17346443
be@@	O	-1	17346443
.	O	-1	17346443
D@@	O	-1	17346443
uring	O	-1	17346443
the	O	-1	17346443
follow-up	O	-1	17346443
of	O	-1	17346443
our	O	-1	17346443
patient@@	O	-1	17346443
,	O	-1	17346443
pen@@	B-Chemical	D010396	17346443
icill@@	I-Chemical	-1	17346443
amine	I-Chemical	-1	17346443
was	O	-1	17346443
inter@@	O	-1	17346443
ru@@	O	-1	17346443
pt@@	O	-1	17346443
ed	O	-1	17346443
after	O	-1	17346443
the	O	-1	17346443
appear@@	O	-1	17346443
ance	O	-1	17346443
of	O	-1	17346443
a	O	-1	17346443
l@@	B-Disease	D017512	17346443
ic@@	I-Disease	-1	17346443
h@@	I-Disease	-1	17346443
en@@	I-Disease	-1	17346443
oid	I-Disease	-1	17346443
der@@	I-Disease	-1	17346443
m@@	I-Disease	-1	17346443
ati@@	I-Disease	-1	17346443
tis	I-Disease	-1	17346443
,	O	-1	17346443
and	O	-1	17346443
z@@	B-Chemical	D019345	17346443
in@@	I-Chemical	-1	17346443
c	I-Chemical	-1	17346443
acet@@	I-Chemical	-1	17346443
ate	I-Chemical	-1	17346443
per@@	O	-1	17346443
mit@@	O	-1	17346443
ted	O	-1	17346443
to	O	-1	17346443
continu@@	O	-1	17346443
e	O	-1	17346443
the	O	-1	17346443
suc@@	O	-1	17346443
cess@@	O	-1	17346443
ful	O	-1	17346443
treatment	O	-1	17346443
of	O	-1	17346443
the	O	-1	17346443
patient	O	-1	17346443
without	O	-1	17346443
side@@	O	-1	17346443
-@@	O	-1	17346443
effects.	O	-1	17346443
In	O	-1	17346443
our	O	-1	17346443
case	O	-1	17346443
the	O	-1	17346443
therapy	O	-1	17346443
with	O	-1	17346443
z@@	B-Chemical	D019345	17346443
in@@	I-Chemical	-1	17346443
c	I-Chemical	-1	17346443
acet@@	I-Chemical	-1	17346443
ate	I-Chemical	-1	17346443
re@@	O	-1	17346443
presented	O	-1	17346443
an	O	-1	17346443
effective	O	-1	17346443
treatment	O	-1	17346443
for	O	-1	17346443
a	O	-1	17346443
W@@	B-Disease	D006527	17346443
il@@	I-Disease	-1	17346443
son@@	I-Disease	-1	17346443
's	I-Disease	-1	17346443
disease	I-Disease	-1	17346443
patient	O	-1	17346443
in	O	-1	17346443
which	O	-1	17346443
pen@@	B-Chemical	D010396	17346443
icill@@	I-Chemical	-1	17346443
amine	I-Chemical	-1	17346443
-@@	O	-1	17346443
related	O	-1	17346443
side	O	-1	17346443
effects	O	-1	17346443
appe@@	O	-1	17346443
a@@	O	-1	17346443
red.	O	-1	17346443
The	O	-1	17346443
safety	O	-1	17346443
of	O	-1	17346443
the	O	-1	17346443
z@@	B-Chemical	D019345	17346443
in@@	I-Chemical	-1	17346443
c	I-Chemical	-1	17346443
acet@@	I-Chemical	-1	17346443
ate	I-Chemical	-1	17346443
al@@	O	-1	17346443
low@@	O	-1	17346443
ed	O	-1	17346443
us	O	-1	17346443
to	O	-1	17346443
av@@	O	-1	17346443
oid	O	-1	17346443
other	O	-1	17346443
potenti@@	O	-1	17346443
ally	O	-1	17346443
toxic	O	-1	17346443
ch@@	O	-1	17346443
el@@	O	-1	17346443
ating	O	-1	17346443
drug@@	O	-1	17346443
s;	O	-1	17346443
this	O	-1	17346443
observ@@	O	-1	17346443
ation	O	-1	17346443
is	O	-1	17346443
in	O	-1	17346443
line	O	-1	17346443
with	O	-1	17346443
the	O	-1	17346443
grow@@	O	-1	17346443
ing	O	-1	17346443
evidence	O	-1	17346443
on	O	-1	17346443
the	O	-1	17346443
efficacy	O	-1	17346443
of	O	-1	17346443
the	O	-1	17346443
drug	O	-1	17346443
in	O	-1	17346443
the	O	-1	17346443
treatment	O	-1	17346443
of	O	-1	17346443
W@@	B-Disease	D006527	17346443
il@@	I-Disease	-1	17346443
son@@	I-Disease	-1	17346443
's	I-Disease	-1	17346443
disease	I-Disease	-1	17346443
.	O	-1	17346443
S@@	O	-1	17346443
inc@@	O	-1	17346443
e	O	-1	17346443
most	O	-1	17346443
of	O	-1	17346443
W@@	B-Disease	D006527	17346443
il@@	I-Disease	-1	17346443
son@@	I-Disease	-1	17346443
's	I-Disease	-1	17346443
disease	I-Disease	-1	17346443
pen@@	B-Chemical	D010396	17346443
icill@@	I-Chemical	-1	17346443
amine	I-Chemical	-1	17346443
-treated	O	-1	17346443
patients	O	-1	17346443
d@@	O	-1	17346443
o	O	-1	17346443
not	O	-1	17346443
se@@	O	-1	17346443
em	O	-1	17346443
to	O	-1	17346443
deve@@	O	-1	17346443
lo@@	O	-1	17346443
p	O	-1	17346443
this	O	-1	17346443
s@@	B-Disease	D012871	17346443
k@@	I-Disease	-1	17346443
in	I-Disease	-1	17346443
le@@	I-Disease	-1	17346443
sion	I-Disease	-1	17346443
,	O	-1	17346443
it	O	-1	17346443
could	O	-1	17346443
be	O	-1	17346443
con@@	O	-1	17346443
ce@@	O	-1	17346443
i@@	O	-1	17346443
v@@	O	-1	17346443
able	O	-1	17346443
that	O	-1	17346443
a	O	-1	17346443
specific	O	-1	17346443
gene@@	O	-1	17346443
tic	O	-1	17346443
factor	O	-1	17346443
is	O	-1	17346443
involved	O	-1	17346443
in	O	-1	17346443
drug	O	-1	17346443
respon@@	O	-1	17346443
se.	O	-1	17346443
F@@	O	-1	17346443
urther	O	-1	17346443
studies	O	-1	17346443
are	O	-1	17346443
ne@@	O	-1	17346443
ed@@	O	-1	17346443
ed	O	-1	17346443
for	O	-1	17346443
a	O	-1	17346443
bet@@	O	-1	17346443
ter	O	-1	17346443
cl@@	O	-1	17346443
ar@@	O	-1	17346443
ification	O	-1	17346443
of	O	-1	17346443
W@@	B-Disease	D006527	17346443
il@@	I-Disease	-1	17346443
son@@	I-Disease	-1	17346443
's	I-Disease	-1	17346443
disease	I-Disease	-1	17346443
therapy,	O	-1	17346443
and	O	-1	17346443
in	O	-1	17346443
partic@@	O	-1	17346443
ular	O	-1	17346443
to	O	-1	17346443
differen@@	O	-1	17346443
ti@@	O	-1	17346443
ate	O	-1	17346443
specific	O	-1	17346443
therap@@	O	-1	17346443
i@@	O	-1	17346443
es	O	-1	17346443
for	O	-1	17346443
different	O	-1	17346443
W@@	B-Disease	D006527	17346443
il@@	I-Disease	-1	17346443
son@@	I-Disease	-1	17346443
's	I-Disease	-1	17346443
disease	I-Disease	-1	17346443
phen@@	O	-1	17346443
ot@@	O	-1	17346443
yp@@	O	-1	17346443
es.	O	-1	17346443

A	O	-1	17351238
d@@	O	-1	17351238
ram@@	O	-1	17351238
atic	O	-1	17351238
dro@@	B-Disease	D007022	17351238
p	I-Disease	-1	17351238
in	I-Disease	-1	17351238
blood	I-Disease	-1	17351238
pressure	I-Disease	-1	17351238
following	O	-1	17351238
pre@@	O	-1	17351238
hospit@@	O	-1	17351238
al	O	-1	17351238
G@@	B-Chemical	D005996	17351238
T@@	I-Chemical	-1	17351238
N	I-Chemical	-1	17351238
administr@@	O	-1	17351238
ation.	O	-1	17351238
A	O	-1	17351238
male	O	-1	17351238
in	O	-1	17351238
h@@	O	-1	17351238
is	O	-1	17351238
si@@	O	-1	17351238
x@@	O	-1	17351238
ties	O	-1	17351238
with	O	-1	17351238
no	O	-1	17351238
hist@@	O	-1	17351238
ory	O	-1	17351238
of	O	-1	17351238
cardiac	O	-1	17351238
ch@@	B-Disease	D002637	17351238
est	I-Disease	-1	17351238
pain	I-Disease	-1	17351238
a@@	O	-1	17351238
wo@@	O	-1	17351238
k@@	O	-1	17351238
e	O	-1	17351238
with	O	-1	17351238
ch@@	B-Disease	D002637	17351238
est	I-Disease	-1	17351238
pain	I-Disease	-1	17351238
following	O	-1	17351238
an	O	-1	17351238
af@@	O	-1	17351238
ter@@	O	-1	17351238
no@@	O	-1	17351238
on	O	-1	17351238
sle@@	O	-1	17351238
ep@@	O	-1	17351238
.	O	-1	17351238
The	O	-1	17351238
patient	O	-1	17351238
did	O	-1	17351238
not	O	-1	17351238
sel@@	O	-1	17351238
f	O	-1	17351238
medic@@	O	-1	17351238
at@@	O	-1	17351238
e.	O	-1	17351238
The	O	-1	17351238
patient@@	O	-1	17351238
's	O	-1	17351238
observ@@	O	-1	17351238
ations	O	-1	17351238
were	O	-1	17351238
within	O	-1	17351238
normal	O	-1	17351238
lim@@	O	-1	17351238
it@@	O	-1	17351238
s,	O	-1	17351238
he	O	-1	17351238
was	O	-1	17351238
administered	O	-1	17351238
oxy@@	B-Chemical	D010100	17351238
gen	I-Chemical	-1	17351238
vi@@	O	-1	17351238
a	O	-1	17351238
a	O	-1	17351238
fac@@	O	-1	17351238
e	O	-1	17351238
mas@@	O	-1	17351238
k	O	-1	17351238
and	O	-1	17351238
glyc@@	B-Chemical	D005996	17351238
ery@@	I-Chemical	-1	17351238
l	I-Chemical	-1	17351238
tr@@	I-Chemical	-1	17351238
in@@	I-Chemical	-1	17351238
it@@	I-Chemical	-1	17351238
rate	I-Chemical	-1	17351238
(	O	-1	17351238
G@@	B-Chemical	D005996	17351238
T@@	I-Chemical	-1	17351238
N	I-Chemical	-1	17351238
).	O	-1	17351238
S@@	O	-1	17351238
e@@	O	-1	17351238
ver@@	O	-1	17351238
al	O	-1	17351238
minutes	O	-1	17351238
after	O	-1	17351238
the	O	-1	17351238
G@@	B-Chemical	D005996	17351238
T@@	I-Chemical	-1	17351238
N	I-Chemical	-1	17351238
the	O	-1	17351238
patient	O	-1	17351238
experienced	O	-1	17351238
a	O	-1	17351238
su@@	O	-1	17351238
d@@	O	-1	17351238
de@@	O	-1	17351238
n	O	-1	17351238
dro@@	B-Disease	D007022	17351238
p	I-Disease	-1	17351238
in	I-Disease	-1	17351238
blood	I-Disease	-1	17351238
pressure	I-Disease	-1	17351238
and	O	-1	17351238
heart	O	-1	17351238
rat@@	O	-1	17351238
e,	O	-1	17351238
this	O	-1	17351238
was	O	-1	17351238
rec@@	O	-1	17351238
ti@@	O	-1	17351238
fied	O	-1	17351238
by	O	-1	17351238
atro@@	B-Chemical	D001285	17351238
pine	I-Chemical	-1	17351238
sul@@	I-Chemical	-1	17351238
ph@@	I-Chemical	-1	17351238
ate	I-Chemical	-1	17351238
and	O	-1	17351238
a	O	-1	17351238
flu@@	O	-1	17351238
id	O	-1	17351238
ch@@	O	-1	17351238
all@@	O	-1	17351238
en@@	O	-1	17351238
g@@	O	-1	17351238
e.	O	-1	17351238
There	O	-1	17351238
was	O	-1	17351238
no	O	-1	17351238
further	O	-1	17351238
deter@@	O	-1	17351238
i@@	O	-1	17351238
or@@	O	-1	17351238
ation	O	-1	17351238
in	O	-1	17351238
the	O	-1	17351238
patient@@	O	-1	17351238
's	O	-1	17351238
condi@@	O	-1	17351238
tion	O	-1	17351238
during	O	-1	17351238
trans@@	O	-1	17351238
por@@	O	-1	17351238
t	O	-1	17351238
to	O	-1	17351238
hospit@@	O	-1	17351238
al.	O	-1	17351238
There	O	-1	17351238
are	O	-1	17351238
very	O	-1	17351238
fe@@	O	-1	17351238
w	O	-1	17351238
doc@@	O	-1	17351238
um@@	O	-1	17351238
ent@@	O	-1	17351238
ed	O	-1	17351238
case	O	-1	17351238
like	O	-1	17351238
this	O	-1	17351238
in	O	-1	17351238
the	O	-1	17351238
pre@@	O	-1	17351238
hospit@@	O	-1	17351238
al	O	-1	17351238
s@@	O	-1	17351238
ci@@	O	-1	17351238
enti@@	O	-1	17351238
f@@	O	-1	17351238
ic	O	-1	17351238
literat@@	O	-1	17351238
ure.	O	-1	17351238
The	O	-1	17351238
cause	O	-1	17351238
appear@@	O	-1	17351238
s	O	-1	17351238
to	O	-1	17351238
be	O	-1	17351238
the	O	-1	17351238
B@@	O	-1	17351238
e@@	O	-1	17351238
z@@	O	-1	17351238
ol@@	O	-1	17351238
d-@@	O	-1	17351238
J@@	O	-1	17351238
ar@@	O	-1	17351238
is@@	O	-1	17351238
h	O	-1	17351238
ref@@	O	-1	17351238
le@@	O	-1	17351238
x@@	O	-1	17351238
,	O	-1	17351238
stimulation	O	-1	17351238
of	O	-1	17351238
the	O	-1	17351238
ventricular	O	-1	17351238
w@@	O	-1	17351238
all@@	O	-1	17351238
s	O	-1	17351238
which	O	-1	17351238
in	O	-1	17351238
t@@	O	-1	17351238
ur@@	O	-1	17351238
n	O	-1	17351238
decreas@@	O	-1	17351238
es	O	-1	17351238
sym@@	O	-1	17351238
pa@@	O	-1	17351238
thetic	O	-1	17351238
out@@	O	-1	17351238
flow	O	-1	17351238
from	O	-1	17351238
the	O	-1	17351238
vas@@	O	-1	17351238
om@@	O	-1	17351238
otor	O	-1	17351238
c@@	O	-1	17351238
ent@@	O	-1	17351238
re.	O	-1	17351238
Pre@@	O	-1	17351238
hospit@@	O	-1	17351238
al	O	-1	17351238
car@@	O	-1	17351238
e	O	-1	17351238
pro@@	O	-1	17351238
vid@@	O	-1	17351238
ers	O	-1	17351238
who	O	-1	17351238
are	O	-1	17351238
man@@	O	-1	17351238
ag@@	O	-1	17351238
ing	O	-1	17351238
any	O	-1	17351238
patient	O	-1	17351238
with	O	-1	17351238
a	O	-1	17351238
syn@@	B-Disease	D013575	17351238
co@@	I-Disease	-1	17351238
p@@	I-Disease	-1	17351238
al	I-Disease	-1	17351238
episo@@	I-Disease	-1	17351238
de	I-Disease	-1	17351238
that	O	-1	17351238
fail@@	O	-1	17351238
s	O	-1	17351238
to	O	-1	17351238
reco@@	O	-1	17351238
ver	O	-1	17351238
within	O	-1	17351238
a	O	-1	17351238
reas@@	O	-1	17351238
on@@	O	-1	17351238
able	O	-1	17351238
time	O	-1	17351238
f@@	O	-1	17351238
ram@@	O	-1	17351238
e	O	-1	17351238
should	O	-1	17351238
con@@	O	-1	17351238
si@@	O	-1	17351238
der	O	-1	17351238
the	O	-1	17351238
B@@	O	-1	17351238
e@@	O	-1	17351238
z@@	O	-1	17351238
ol@@	O	-1	17351238
d-@@	O	-1	17351238
J@@	O	-1	17351238
ar@@	O	-1	17351238
is@@	O	-1	17351238
ch	O	-1	17351238
ref@@	O	-1	17351238
le@@	O	-1	17351238
x	O	-1	17351238
as	O	-1	17351238
the	O	-1	17351238
cause	O	-1	17351238
and	O	-1	17351238
man@@	O	-1	17351238
age	O	-1	17351238
the	O	-1	17351238
patient	O	-1	17351238
ac@@	O	-1	17351238
cor@@	O	-1	17351238
d@@	O	-1	17351238
ing@@	O	-1	17351238
ly.	O	-1	17351238

Ac@@	B-Disease	D020803	17356399
ute	I-Disease	-1	17356399
encephalo@@	I-Disease	-1	17356399
pathy	I-Disease	-1	17356399
and	O	-1	17356399
cerebral	B-Disease	D020301	17356399
vas@@	I-Disease	-1	17356399
os@@	I-Disease	-1	17356399
p@@	I-Disease	-1	17356399
as@@	I-Disease	-1	17356399
m	I-Disease	-1	17356399
after	O	-1	17356399
multi@@	O	-1	17356399
agent	O	-1	17356399
chemotherapy	O	-1	17356399
including	O	-1	17356399
P@@	B-Chemical	C042705	17356399
E@@	I-Chemical	-1	17356399
G@@	I-Chemical	-1	17356399
-@@	I-Chemical	-1	17356399
as@@	I-Chemical	-1	17356399
par@@	I-Chemical	-1	17356399
ag@@	I-Chemical	-1	17356399
in@@	I-Chemical	-1	17356399
ase	I-Chemical	-1	17356399
and	O	-1	17356399
intra@@	O	-1	17356399
th@@	O	-1	17356399
ec@@	O	-1	17356399
al	O	-1	17356399
cy@@	B-Chemical	D003561	17356399
t@@	I-Chemical	-1	17356399
ar@@	I-Chemical	-1	17356399
ab@@	I-Chemical	-1	17356399
ine	I-Chemical	-1	17356399
for	O	-1	17356399
the	O	-1	17356399
treatment	O	-1	17356399
of	O	-1	17356399
acute	B-Disease	D054198	17356399
lymph@@	I-Disease	-1	17356399
ob@@	I-Disease	-1	17356399
las@@	I-Disease	-1	17356399
tic	I-Disease	-1	17356399
leuk@@	I-Disease	-1	17356399
emia	I-Disease	-1	17356399
.	O	-1	17356399
A	O	-1	17356399
7-@@	O	-1	17356399
year-old	O	-1	17356399
gi@@	O	-1	17356399
r@@	O	-1	17356399
l	O	-1	17356399
with	O	-1	17356399
an	O	-1	17356399
un@@	O	-1	17356399
us@@	O	-1	17356399
ual	O	-1	17356399
reaction	O	-1	17356399
to	O	-1	17356399
induction	O	-1	17356399
chemotherapy	O	-1	17356399
for	O	-1	17356399
pre@@	O	-1	17356399
cur@@	O	-1	17356399
s@@	O	-1	17356399
or	O	-1	17356399
B@@	O	-1	17356399
-@@	O	-1	17356399
cell	O	-1	17356399
acute	B-Disease	D054198	17356399
lymph@@	I-Disease	-1	17356399
ob@@	I-Disease	-1	17356399
las@@	I-Disease	-1	17356399
tic	I-Disease	-1	17356399
leuk@@	I-Disease	-1	17356399
emia	I-Disease	-1	17356399
(	O	-1	17356399
AL@@	B-Disease	D054198	17356399
L	I-Disease	-1	17356399
)	O	-1	17356399
is	O	-1	17356399
descri@@	O	-1	17356399
be@@	O	-1	17356399
d.	O	-1	17356399
The	O	-1	17356399
patient	O	-1	17356399
developed	O	-1	17356399
acute	B-Disease	D020803	17356399
encephalo@@	I-Disease	-1	17356399
pathy	I-Disease	-1	17356399
ev@@	O	-1	17356399
id@@	O	-1	17356399
enc@@	O	-1	17356399
ed	O	-1	17356399
by	O	-1	17356399
behavioral	O	-1	17356399
chang@@	O	-1	17356399
es,	O	-1	17356399
a@@	B-Disease	D001037	17356399
pha@@	I-Disease	-1	17356399
sia	I-Disease	-1	17356399
,	O	-1	17356399
in@@	B-Disease	D014549	17356399
contin@@	I-Disease	-1	17356399
ence	I-Disease	-1	17356399
,	O	-1	17356399
visual	B-Disease	D006212	17356399
h@@	I-Disease	-1	17356399
all@@	I-Disease	-1	17356399
uc@@	I-Disease	-1	17356399
in@@	I-Disease	-1	17356399
ations	I-Disease	-1	17356399
,	O	-1	17356399
and	O	-1	17356399
ri@@	O	-1	17356399
gh@@	O	-1	17356399
t-@@	O	-1	17356399
si@@	O	-1	17356399
ded	O	-1	17356399
we@@	B-Disease	D018908	17356399
ak@@	I-Disease	-1	17356399
ness	I-Disease	-1	17356399
with	O	-1	17356399
diff@@	O	-1	17356399
use	O	-1	17356399
cerebral	B-Disease	D020301	17356399
vas@@	I-Disease	-1	17356399
os@@	I-Disease	-1	17356399
p@@	I-Disease	-1	17356399
as@@	I-Disease	-1	17356399
m	I-Disease	-1	17356399
on	O	-1	17356399
mag@@	O	-1	17356399
ne@@	O	-1	17356399
tic	O	-1	17356399
res@@	O	-1	17356399
on@@	O	-1	17356399
ance	O	-1	17356399
angio@@	O	-1	17356399
graph@@	O	-1	17356399
y	O	-1	17356399
after	O	-1	17356399
the	O	-1	17356399
administration	O	-1	17356399
of	O	-1	17356399
intra@@	O	-1	17356399
th@@	O	-1	17356399
ec@@	O	-1	17356399
al	O	-1	17356399
cy@@	B-Chemical	D003561	17356399
t@@	I-Chemical	-1	17356399
ar@@	I-Chemical	-1	17356399
ab@@	I-Chemical	-1	17356399
ine	I-Chemical	-1	17356399
.	O	-1	17356399
V@@	B-Chemical	D014750	17356399
inc@@	I-Chemical	-1	17356399
ri@@	I-Chemical	-1	17356399
st@@	I-Chemical	-1	17356399
ine	I-Chemical	-1	17356399
,	O	-1	17356399
de@@	B-Chemical	D003907	17356399
xameth@@	I-Chemical	-1	17356399
as@@	I-Chemical	-1	17356399
one	I-Chemical	-1	17356399
,	O	-1	17356399
and	O	-1	17356399
poly@@	B-Chemical	C042705	17356399
eth@@	I-Chemical	-1	17356399
yl@@	I-Chemical	-1	17356399
ene	I-Chemical	-1	17356399
gly@@	I-Chemical	-1	17356399
co@@	I-Chemical	-1	17356399
l@@	I-Chemical	-1	17356399
-@@	I-Chemical	-1	17356399
as@@	I-Chemical	-1	17356399
par@@	I-Chemical	-1	17356399
ag@@	I-Chemical	-1	17356399
in@@	I-Chemical	-1	17356399
ase	I-Chemical	-1	17356399
were	O	-1	17356399
also	O	-1	17356399
administered	O	-1	17356399
before	O	-1	17356399
the	O	-1	17356399
episo@@	O	-1	17356399
de	O	-1	17356399
as	O	-1	17356399
par@@	O	-1	17356399
t	O	-1	17356399
of	O	-1	17356399
induction	O	-1	17356399
therapy.	O	-1	17356399
Ne@@	O	-1	17356399
uro@@	O	-1	17356399
log@@	O	-1	17356399
ic	O	-1	17356399
status	O	-1	17356399
retur@@	O	-1	17356399
n@@	O	-1	17356399
ed	O	-1	17356399
to	O	-1	17356399
baseline	O	-1	17356399
within	O	-1	17356399
10	O	-1	17356399
days	O	-1	17356399
of	O	-1	17356399
the	O	-1	17356399
acute	O	-1	17356399
event@@	O	-1	17356399
,	O	-1	17356399
and	O	-1	17356399
mag@@	O	-1	17356399
ne@@	O	-1	17356399
tic	O	-1	17356399
res@@	O	-1	17356399
on@@	O	-1	17356399
ance	O	-1	17356399
angio@@	O	-1	17356399
graph@@	O	-1	17356399
y	O	-1	17356399
findings	O	-1	17356399
retur@@	O	-1	17356399
n@@	O	-1	17356399
ed	O	-1	17356399
to	O	-1	17356399
normal	O	-1	17356399
4	O	-1	17356399
months	O	-1	17356399
lat@@	O	-1	17356399
er.	O	-1	17356399

Com@@	O	-1	17379047
par@@	O	-1	17379047
ison	O	-1	17379047
of	O	-1	17379047
val@@	B-Chemical	C081489	17379047
s@@	I-Chemical	-1	17379047
ar@@	I-Chemical	-1	17379047
t@@	I-Chemical	-1	17379047
an	I-Chemical	-1	17379047
/	O	-1	17379047
hydro@@	B-Chemical	D006852	17379047
ch@@	I-Chemical	-1	17379047
loro@@	I-Chemical	-1	17379047
thi@@	I-Chemical	-1	17379047
az@@	I-Chemical	-1	17379047
ide	I-Chemical	-1	17379047
combination	O	-1	17379047
therapy	O	-1	17379047
at	O	-1	17379047
doses	O	-1	17379047
up	O	-1	17379047
to	O	-1	17379047
3@@	O	-1	17379047
20@@	O	-1	17379047
/@@	O	-1	17379047
25	O	-1	17379047
mg	O	-1	17379047
versus	O	-1	17379047
mon@@	O	-1	17379047
o@@	O	-1	17379047
therap@@	O	-1	17379047
y@@	O	-1	17379047
:	O	-1	17379047
a	O	-1	17379047
double-bl@@	O	-1	17379047
ind@@	O	-1	17379047
,	O	-1	17379047
placebo@@	O	-1	17379047
-@@	O	-1	17379047
controlled	O	-1	17379047
study	O	-1	17379047
followed	O	-1	17379047
by	O	-1	17379047
long-term	O	-1	17379047
combination	O	-1	17379047
therapy	O	-1	17379047
in	O	-1	17379047
hypertensive	B-Disease	D006973	17379047
ad@@	O	-1	17379047
ult@@	O	-1	17379047
s.	O	-1	17379047
BACKGROUND:	O	-1	17379047
One	O	-1	17379047
thir@@	O	-1	17379047
d	O	-1	17379047
of	O	-1	17379047
patients	O	-1	17379047
treated	O	-1	17379047
for	O	-1	17379047
hypertension	B-Disease	D006973	17379047
at@@	O	-1	17379047
t@@	O	-1	17379047
ain	O	-1	17379047
ade@@	O	-1	17379047
qu@@	O	-1	17379047
ate	O	-1	17379047
blood	O	-1	17379047
pressure	O	-1	17379047
(B@@	O	-1	17379047
P)	O	-1	17379047
control@@	O	-1	17379047
,	O	-1	17379047
and	O	-1	17379047
multi@@	O	-1	17379047
drug	O	-1	17379047
regimen@@	O	-1	17379047
s	O	-1	17379047
are	O	-1	17379047
often	O	-1	17379047
requ@@	O	-1	17379047
i@@	O	-1	17379047
red.	O	-1	17379047
G@@	O	-1	17379047
i@@	O	-1	17379047
ven	O	-1	17379047
the	O	-1	17379047
lif@@	O	-1	17379047
el@@	O	-1	17379047
ong	O	-1	17379047
n@@	O	-1	17379047
at@@	O	-1	17379047
ure	O	-1	17379047
of	O	-1	17379047
hypertension	B-Disease	D006973	17379047
,	O	-1	17379047
there	O	-1	17379047
is	O	-1	17379047
a	O	-1	17379047
need	O	-1	17379047
to	O	-1	17379047
evalu@@	O	-1	17379047
ate	O	-1	17379047
the	O	-1	17379047
long-term	O	-1	17379047
efficacy	O	-1	17379047
and	O	-1	17379047
toler@@	O	-1	17379047
ability	O	-1	17379047
of	O	-1	17379047
higher	O	-1	17379047
doses	O	-1	17379047
of	O	-1	17379047
combination	O	-1	17379047
anti@@	O	-1	17379047
-	O	-1	17379047
hypertensive	B-Disease	D006973	17379047
therap@@	O	-1	17379047
i@@	O	-1	17379047
es.	O	-1	17379047
OBJECTIVE:	O	-1	17379047
This	O	-1	17379047
study	O	-1	17379047
investigated	O	-1	17379047
the	O	-1	17379047
efficacy	O	-1	17379047
and	O	-1	17379047
toler@@	O	-1	17379047
ability	O	-1	17379047
of	O	-1	17379047
val@@	B-Chemical	C081489	17379047
s@@	I-Chemical	-1	17379047
ar@@	I-Chemical	-1	17379047
t@@	I-Chemical	-1	17379047
an	I-Chemical	-1	17379047
(	O	-1	17379047
V@@	B-Chemical	C081489	17379047
A@@	I-Chemical	-1	17379047
L	I-Chemical	-1	17379047
)	O	-1	17379047
or	O	-1	17379047
hydro@@	B-Chemical	D006852	17379047
ch@@	I-Chemical	-1	17379047
loro@@	I-Chemical	-1	17379047
thi@@	I-Chemical	-1	17379047
az@@	I-Chemical	-1	17379047
ide	I-Chemical	-1	17379047
(	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
)-@@	O	-1	17379047
mon@@	O	-1	17379047
o@@	O	-1	17379047
therapy	O	-1	17379047
and	O	-1	17379047
high@@	O	-1	17379047
er@@	O	-1	17379047
-@@	O	-1	17379047
dose	O	-1	17379047
combin@@	O	-1	17379047
ations	O	-1	17379047
in	O	-1	17379047
patients	O	-1	17379047
with	O	-1	17379047
es@@	B-Disease	C562386	17379047
sen@@	I-Disease	-1	17379047
tial	I-Disease	-1	17379047
hypertension	I-Disease	-1	17379047
.	O	-1	17379047
METHODS:	O	-1	17379047
The	O	-1	17379047
first	O	-1	17379047
par@@	O	-1	17379047
t	O	-1	17379047
of	O	-1	17379047
this	O	-1	17379047
study	O	-1	17379047
was	O	-1	17379047
an	O	-1	17379047
8@@	O	-1	17379047
-@@	O	-1	17379047
week@@	O	-1	17379047
,	O	-1	17379047
mul@@	O	-1	17379047
tic@@	O	-1	17379047
ent@@	O	-1	17379047
er,	O	-1	17379047
random@@	O	-1	17379047
iz@@	O	-1	17379047
ed,	O	-1	17379047
double-bl@@	O	-1	17379047
ind@@	O	-1	17379047
,	O	-1	17379047
placebo	O	-1	17379047
control@@	O	-1	17379047
le@@	O	-1	17379047
d,	O	-1	17379047
par@@	O	-1	17379047
al@@	O	-1	17379047
le@@	O	-1	17379047
l@@	O	-1	17379047
-@@	O	-1	17379047
group	O	-1	17379047
tri@@	O	-1	17379047
al.	O	-1	17379047
Patients	O	-1	17379047
with	O	-1	17379047
es@@	B-Disease	C562386	17379047
sen@@	I-Disease	-1	17379047
tial	I-Disease	-1	17379047
hypertension	I-Disease	-1	17379047
(@@	O	-1	17379047
mean	O	-1	17379047
sit@@	O	-1	17379047
ting	O	-1	17379047
di@@	O	-1	17379047
ast@@	O	-1	17379047
olic	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
[@@	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
D@@	O	-1	17379047
B@@	O	-1	17379047
P@@	O	-1	17379047
]@@	O	-1	17379047
,	O	-1	17379047
>	O	-1	17379047
or	O	-1	17379047
=@@	O	-1	17379047
9@@	O	-1	17379047
5	O	-1	17379047
mm	O	-1	17379047
H@@	O	-1	17379047
g	O	-1	17379047
and	O	-1	17379047
<@@	O	-1	17379047
1@@	O	-1	17379047
10	O	-1	17379047
mm	O	-1	17379047
H@@	O	-1	17379047
g@@	O	-1	17379047
)	O	-1	17379047
were	O	-1	17379047
randomized	O	-1	17379047
to	O	-1	17379047
1	O	-1	17379047
of	O	-1	17379047
8	O	-1	17379047
treatment	O	-1	17379047
group@@	O	-1	17379047
s:	O	-1	17379047
V@@	B-Chemical	C081489	17379047
A@@	I-Chemical	-1	17379047
L	I-Chemical	-1	17379047
1@@	O	-1	17379047
60	O	-1	17379047
or	O	-1	17379047
3@@	O	-1	17379047
20	O	-1	17379047
mg@@	O	-1	17379047
;	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
1@@	O	-1	17379047
2.@@	O	-1	17379047
5	O	-1	17379047
or	O	-1	17379047
25	O	-1	17379047
mg@@	O	-1	17379047
;	O	-1	17379047
V@@	B-Chemical	C081489	17379047
A@@	I-Chemical	-1	17379047
L	I-Chemical	-1	17379047
/	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
1@@	O	-1	17379047
6@@	O	-1	17379047
0@@	O	-1	17379047
/@@	O	-1	17379047
1@@	O	-1	17379047
2.@@	O	-1	17379047
5,	O	-1	17379047
3@@	O	-1	17379047
20@@	O	-1	17379047
/@@	O	-1	17379047
1@@	O	-1	17379047
2.@@	O	-1	17379047
5,	O	-1	17379047
or	O	-1	17379047
3@@	O	-1	17379047
20@@	O	-1	17379047
/@@	O	-1	17379047
25	O	-1	17379047
mg@@	O	-1	17379047
;	O	-1	17379047
or	O	-1	17379047
placebo@@	O	-1	17379047
.	O	-1	17379047
M@@	O	-1	17379047
e@@	O	-1	17379047
an	O	-1	17379047
changes	O	-1	17379047
in	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
D@@	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
and	O	-1	17379047
mean	O	-1	17379047
sit@@	O	-1	17379047
ting	O	-1	17379047
systolic	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
(@@	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
S@@	O	-1	17379047
B@@	O	-1	17379047
P)	O	-1	17379047
were	O	-1	17379047
analy@@	O	-1	17379047
zed	O	-1	17379047
at	O	-1	17379047
the	O	-1	17379047
8@@	O	-1	17379047
-@@	O	-1	17379047
week	O	-1	17379047
cor@@	O	-1	17379047
e	O	-1	17379047
study	O	-1	17379047
end	O	-1	17379047
po@@	O	-1	17379047
int@@	O	-1	17379047
.	O	-1	17379047
V@@	B-Chemical	C081489	17379047
A@@	I-Chemical	-1	17379047
L	I-Chemical	-1	17379047
/	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
3@@	O	-1	17379047
20@@	O	-1	17379047
/@@	O	-1	17379047
1@@	O	-1	17379047
2.@@	O	-1	17379047
5	O	-1	17379047
and	O	-1	17379047
3@@	O	-1	17379047
20@@	O	-1	17379047
/@@	O	-1	17379047
25	O	-1	17379047
mg	O	-1	17379047
were	O	-1	17379047
further	O	-1	17379047
investigated	O	-1	17379047
in	O	-1	17379047
a	O	-1	17379047
5@@	O	-1	17379047
4-@@	O	-1	17379047
week@@	O	-1	17379047
,	O	-1	17379047
o@@	O	-1	17379047
pen@@	O	-1	17379047
-@@	O	-1	17379047
l@@	O	-1	17379047
a@@	O	-1	17379047
be@@	O	-1	17379047
l	O	-1	17379047
exten@@	O	-1	17379047
sion.	O	-1	17379047
R@@	O	-1	17379047
es@@	O	-1	17379047
p@@	O	-1	17379047
on@@	O	-1	17379047
se	O	-1	17379047
was	O	-1	17379047
def@@	O	-1	17379047
in@@	O	-1	17379047
ed	O	-1	17379047
as	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
D@@	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
<@@	O	-1	17379047
9@@	O	-1	17379047
0	O	-1	17379047
mm	O	-1	17379047
H@@	O	-1	17379047
g	O	-1	17379047
or	O	-1	17379047
a	O	-1	17379047
>	O	-1	17379047
or	O	-1	17379047
=@@	O	-1	17379047
10	O	-1	17379047
mm	O	-1	17379047
H@@	O	-1	17379047
g	O	-1	17379047
decrease	O	-1	17379047
compared	O	-1	17379047
to	O	-1	17379047
basel@@	O	-1	17379047
ine.	O	-1	17379047
C@@	O	-1	17379047
ont@@	O	-1	17379047
ro@@	O	-1	17379047
l	O	-1	17379047
was	O	-1	17379047
def@@	O	-1	17379047
in@@	O	-1	17379047
ed	O	-1	17379047
as	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
D@@	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
<@@	O	-1	17379047
9@@	O	-1	17379047
0	O	-1	17379047
mm	O	-1	17379047
H@@	O	-1	17379047
g	O	-1	17379047
compared	O	-1	17379047
with	O	-1	17379047
basel@@	O	-1	17379047
ine.	O	-1	17379047
T@@	O	-1	17379047
oler@@	O	-1	17379047
ability	O	-1	17379047
was	O	-1	17379047
assessed	O	-1	17379047
by	O	-1	17379047
monit@@	O	-1	17379047
or@@	O	-1	17379047
ing	O	-1	17379047
adverse	O	-1	17379047
events	O	-1	17379047
at	O	-1	17379047
random@@	O	-1	17379047
ization	O	-1	17379047
and	O	-1	17379047
all	O	-1	17379047
subsequ@@	O	-1	17379047
ent	O	-1	17379047
study	O	-1	17379047
v@@	O	-1	17379047
is@@	O	-1	17379047
its	O	-1	17379047
and	O	-1	17379047
reg@@	O	-1	17379047
ular	O	-1	17379047
evalu@@	O	-1	17379047
ation	O	-1	17379047
of	O	-1	17379047
hemat@@	O	-1	17379047
ology	O	-1	17379047
and	O	-1	17379047
blood	O	-1	17379047
chem@@	O	-1	17379047
ist@@	O	-1	17379047
r@@	O	-1	17379047
y.	O	-1	17379047
RESULTS:	O	-1	17379047
A	O	-1	17379047
total	O	-1	17379047
of	O	-1	17379047
13@@	O	-1	17379047
4@@	O	-1	17379047
6	O	-1	17379047
patients	O	-1	17379047
were	O	-1	17379047
randomized	O	-1	17379047
into	O	-1	17379047
the	O	-1	17379047
8@@	O	-1	17379047
-@@	O	-1	17379047
week	O	-1	17379047
cor@@	O	-1	17379047
e	O	-1	17379047
study	O	-1	17379047
(@@	O	-1	17379047
7@@	O	-1	17379047
3@@	O	-1	17379047
4	O	-1	17379047
men@@	O	-1	17379047
,	O	-1	17379047
6@@	O	-1	17379047
12	O	-1	17379047
wom@@	O	-1	17379047
en@@	O	-1	17379047
;	O	-1	17379047
9@@	O	-1	17379047
24	O	-1	17379047
wh@@	O	-1	17379047
it@@	O	-1	17379047
e,	O	-1	17379047
2@@	O	-1	17379047
9@@	O	-1	17379047
1	O	-1	17379047
bl@@	O	-1	17379047
ac@@	O	-1	17379047
k@@	O	-1	17379047
,	O	-1	17379047
2@@	O	-1	17379047
3	O	-1	17379047
A@@	O	-1	17379047
si@@	O	-1	17379047
an@@	O	-1	17379047
,	O	-1	17379047
10@@	O	-1	17379047
8	O	-1	17379047
o@@	O	-1	17379047
ther@@	O	-1	17379047
;	O	-1	17379047
mean	O	-1	17379047
age,	O	-1	17379047
5@@	O	-1	17379047
2.@@	O	-1	17379047
7	O	-1	17379047
year@@	O	-1	17379047
s;	O	-1	17379047
mean	O	-1	17379047
weigh@@	O	-1	17379047
t,	O	-1	17379047
9@@	O	-1	17379047
2.@@	O	-1	17379047
6	O	-1	17379047
kg@@	O	-1	17379047
).	O	-1	17379047
All	O	-1	17379047
active	O	-1	17379047
treat@@	O	-1	17379047
ments	O	-1	17379047
were	O	-1	17379047
associated	O	-1	17379047
with	O	-1	17379047
significantly	O	-1	17379047
reduced	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
S@@	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
and	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
D@@	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
during	O	-1	17379047
the	O	-1	17379047
cor@@	O	-1	17379047
e	O	-1	17379047
8@@	O	-1	17379047
-@@	O	-1	17379047
week	O	-1	17379047
study,	O	-1	17379047
with	O	-1	17379047
each	O	-1	17379047
mon@@	O	-1	17379047
o@@	O	-1	17379047
therapy	O	-1	17379047
significantly	O	-1	17379047
cont@@	O	-1	17379047
ri@@	O	-1	17379047
but@@	O	-1	17379047
ing	O	-1	17379047
to	O	-1	17379047
the	O	-1	17379047
over@@	O	-1	17379047
all	O	-1	17379047
effect	O	-1	17379047
of	O	-1	17379047
combination	O	-1	17379047
therapy	O	-1	17379047
(	O	-1	17379047
V@@	B-Chemical	C081489	17379047
A@@	I-Chemical	-1	17379047
L	I-Chemical	-1	17379047
and	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
,	O	-1	17379047
P	O	-1	17379047
<	O	-1	17379047
0.00@@	O	-1	17379047
1).	O	-1	17379047
E@@	O	-1	17379047
ach	O	-1	17379047
combination	O	-1	17379047
was	O	-1	17379047
associated	O	-1	17379047
with	O	-1	17379047
significantly	O	-1	17379047
greater	O	-1	17379047
reduc@@	O	-1	17379047
tions	O	-1	17379047
in	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
S@@	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
and	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
D@@	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
compared	O	-1	17379047
with	O	-1	17379047
the	O	-1	17379047
mon@@	O	-1	17379047
o@@	O	-1	17379047
therap@@	O	-1	17379047
i@@	O	-1	17379047
es	O	-1	17379047
and	O	-1	17379047
placebo	O	-1	17379047
(@@	O	-1	17379047
all@@	O	-1	17379047
,	O	-1	17379047
P	O	-1	17379047
<	O	-1	17379047
0.00@@	O	-1	17379047
1).	O	-1	17379047
The	O	-1	17379047
mean	O	-1	17379047
reduction	O	-1	17379047
in	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
S@@	O	-1	17379047
B@@	O	-1	17379047
P@@	O	-1	17379047
/@@	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
D@@	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
with	O	-1	17379047
V@@	B-Chemical	C081489	17379047
A@@	I-Chemical	-1	17379047
L	I-Chemical	-1	17379047
/	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
3@@	O	-1	17379047
20@@	O	-1	17379047
/@@	O	-1	17379047
25	O	-1	17379047
mg	O	-1	17379047
was	O	-1	17379047
2@@	O	-1	17379047
4.@@	O	-1	17379047
7@@	O	-1	17379047
/@@	O	-1	17379047
1@@	O	-1	17379047
6.@@	O	-1	17379047
6	O	-1	17379047
mm	O	-1	17379047
H@@	O	-1	17379047
g@@	O	-1	17379047
,	O	-1	17379047
compared	O	-1	17379047
with	O	-1	17379047
5.@@	O	-1	17379047
9@@	O	-1	17379047
/@@	O	-1	17379047
7.@@	O	-1	17379047
0	O	-1	17379047
mm	O	-1	17379047
H@@	O	-1	17379047
g	O	-1	17379047
with	O	-1	17379047
placebo@@	O	-1	17379047
.	O	-1	17379047
The	O	-1	17379047
reduction	O	-1	17379047
in	O	-1	17379047
M@@	O	-1	17379047
S@@	O	-1	17379047
S@@	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
was	O	-1	17379047
significantly	O	-1	17379047
greater	O	-1	17379047
with	O	-1	17379047
V@@	B-Chemical	C081489	17379047
A@@	I-Chemical	-1	17379047
L	I-Chemical	-1	17379047
/	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
3@@	O	-1	17379047
20@@	O	-1	17379047
/@@	O	-1	17379047
25	O	-1	17379047
mg	O	-1	17379047
compared	O	-1	17379047
with	O	-1	17379047
V@@	B-Chemical	C081489	17379047
A@@	I-Chemical	-1	17379047
L	I-Chemical	-1	17379047
/	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
1@@	O	-1	17379047
6@@	O	-1	17379047
0@@	O	-1	17379047
/@@	O	-1	17379047
1@@	O	-1	17379047
2.@@	O	-1	17379047
5	O	-1	17379047
mg	O	-1	17379047
(P	O	-1	17379047
<	O	-1	17379047
0.00@@	O	-1	17379047
2@@	O	-1	17379047
).	O	-1	17379047
R@@	O	-1	17379047
ates	O	-1	17379047
of	O	-1	17379047
response	O	-1	17379047
and	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
control	O	-1	17379047
were	O	-1	17379047
significantly	O	-1	17379047
higher	O	-1	17379047
in	O	-1	17379047
the	O	-1	17379047
groups	O	-1	17379047
that	O	-1	17379047
received	O	-1	17379047
combination	O	-1	17379047
treatment	O	-1	17379047
compared	O	-1	17379047
with	O	-1	17379047
those	O	-1	17379047
that	O	-1	17379047
received	O	-1	17379047
mon@@	O	-1	17379047
o@@	O	-1	17379047
therapy.	O	-1	17379047
The	O	-1	17379047
incidence	O	-1	17379047
of	O	-1	17379047
hypo@@	B-Disease	D007008	17379047
k@@	I-Disease	-1	17379047
al@@	I-Disease	-1	17379047
emia	I-Disease	-1	17379047
was	O	-1	17379047
lower	O	-1	17379047
with	O	-1	17379047
V@@	B-Chemical	C081489	17379047
A@@	I-Chemical	-1	17379047
L	I-Chemical	-1	17379047
/	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
combin@@	O	-1	17379047
ations	O	-1	17379047
(1@@	O	-1	17379047
.@@	O	-1	17379047
8@@	O	-1	17379047
%@@	O	-1	17379047
-@@	O	-1	17379047
6.@@	O	-1	17379047
1@@	O	-1	17379047
%)	O	-1	17379047
than	O	-1	17379047
with	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
mon@@	O	-1	17379047
o@@	O	-1	17379047
therap@@	O	-1	17379047
i@@	O	-1	17379047
es	O	-1	17379047
(@@	O	-1	17379047
7.@@	O	-1	17379047
1@@	O	-1	17379047
%@@	O	-1	17379047
-1@@	O	-1	17379047
3.@@	O	-1	17379047
3@@	O	-1	17379047
%).	O	-1	17379047
The	O	-1	17379047
maj@@	O	-1	17379047
or@@	O	-1	17379047
ity	O	-1	17379047
of	O	-1	17379047
adverse	O	-1	17379047
events	O	-1	17379047
in	O	-1	17379047
the	O	-1	17379047
cor@@	O	-1	17379047
e	O	-1	17379047
study	O	-1	17379047
were	O	-1	17379047
of	O	-1	17379047
mil@@	O	-1	17379047
d	O	-1	17379047
to	O	-1	17379047
moder@@	O	-1	17379047
ate	O	-1	17379047
sever@@	O	-1	17379047
ity.	O	-1	17379047
The	O	-1	17379047
efficacy	O	-1	17379047
and	O	-1	17379047
toler@@	O	-1	17379047
ability	O	-1	17379047
of	O	-1	17379047
V@@	B-Chemical	C081489	17379047
A@@	I-Chemical	-1	17379047
L	I-Chemical	-1	17379047
/	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
combin@@	O	-1	17379047
ations	O	-1	17379047
were	O	-1	17379047
maint@@	O	-1	17379047
ained	O	-1	17379047
during	O	-1	17379047
the	O	-1	17379047
exten@@	O	-1	17379047
sion	O	-1	17379047
(@@	O	-1	17379047
7@@	O	-1	17379047
9@@	O	-1	17379047
7	O	-1	17379047
patient@@	O	-1	17379047
s@@	O	-1	17379047
).	O	-1	17379047
CONCLUSIONS:	O	-1	17379047
In	O	-1	17379047
this	O	-1	17379047
study	O	-1	17379047
po@@	O	-1	17379047
pul@@	O	-1	17379047
ation,	O	-1	17379047
combination	O	-1	17379047
therap@@	O	-1	17379047
i@@	O	-1	17379047
es	O	-1	17379047
with	O	-1	17379047
V@@	B-Chemical	C081489	17379047
A@@	I-Chemical	-1	17379047
L	I-Chemical	-1	17379047
/	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
were	O	-1	17379047
associated	O	-1	17379047
with	O	-1	17379047
significantly	O	-1	17379047
greater	O	-1	17379047
B@@	O	-1	17379047
P	O	-1	17379047
reduc@@	O	-1	17379047
tions	O	-1	17379047
compared	O	-1	17379047
with	O	-1	17379047
either	O	-1	17379047
mon@@	O	-1	17379047
o@@	O	-1	17379047
therapy,	O	-1	17379047
were	O	-1	17379047
well	O	-1	17379047
toler@@	O	-1	17379047
at@@	O	-1	17379047
ed,	O	-1	17379047
and	O	-1	17379047
were	O	-1	17379047
associated	O	-1	17379047
with	O	-1	17379047
less	O	-1	17379047
hypo@@	B-Disease	D007008	17379047
k@@	I-Disease	-1	17379047
al@@	I-Disease	-1	17379047
emia	I-Disease	-1	17379047
than	O	-1	17379047
HC@@	B-Chemical	D006852	17379047
T@@	I-Chemical	-1	17379047
Z	I-Chemical	-1	17379047
al@@	O	-1	17379047
one.	O	-1	17379047

S@@	B-Chemical	D004113	17384765
uc@@	I-Chemical	-1	17384765
c@@	I-Chemical	-1	17384765
im@@	I-Chemical	-1	17384765
er	I-Chemical	-1	17384765
ch@@	O	-1	17384765
el@@	O	-1	17384765
ation	O	-1	17384765
impro@@	O	-1	17384765
v@@	O	-1	17384765
es	O	-1	17384765
lear@@	O	-1	17384765
n@@	O	-1	17384765
ing,	O	-1	17384765
atten@@	O	-1	17384765
tion,	O	-1	17384765
and	O	-1	17384765
a@@	O	-1	17384765
ro@@	O	-1	17384765
us@@	O	-1	17384765
al	O	-1	17384765
reg@@	O	-1	17384765
ulation	O	-1	17384765
in	O	-1	17384765
le@@	B-Chemical	D007854	17384765
ad	I-Chemical	-1	17384765
-@@	O	-1	17384765
exposed	O	-1	17384765
rats	O	-1	17384765
but	O	-1	17384765
produc@@	O	-1	17384765
es	O	-1	17384765
l@@	O	-1	17384765
ast@@	O	-1	17384765
ing	O	-1	17384765
cognitive	B-Disease	D003072	17384765
impair@@	I-Disease	-1	17384765
ment	I-Disease	-1	17384765
in	O	-1	17384765
the	O	-1	17384765
absence	O	-1	17384765
of	O	-1	17384765
le@@	B-Chemical	D007854	17384765
ad	I-Chemical	-1	17384765
expos@@	O	-1	17384765
ure.	O	-1	17384765
BACKGROUND:	O	-1	17384765
There	O	-1	17384765
is	O	-1	17384765
grow@@	O	-1	17384765
ing	O	-1	17384765
pressure	O	-1	17384765
for	O	-1	17384765
clin@@	O	-1	17384765
ici@@	O	-1	17384765
ans	O	-1	17384765
to	O	-1	17384765
prescri@@	O	-1	17384765
be	O	-1	17384765
ch@@	O	-1	17384765
el@@	O	-1	17384765
ation	O	-1	17384765
therapy	O	-1	17384765
at	O	-1	17384765
only	O	-1	17384765
s@@	O	-1	17384765
li@@	O	-1	17384765
gh@@	O	-1	17384765
tly	O	-1	17384765
elevated	O	-1	17384765
blood	O	-1	17384765
le@@	B-Chemical	D007854	17384765
ad	I-Chemical	-1	17384765
level@@	O	-1	17384765
s.	O	-1	17384765
However,	O	-1	17384765
very	O	-1	17384765
fe@@	O	-1	17384765
w	O	-1	17384765
studies	O	-1	17384765
have	O	-1	17384765
evaluated	O	-1	17384765
whether	O	-1	17384765
ch@@	O	-1	17384765
el@@	O	-1	17384765
ation	O	-1	17384765
impro@@	O	-1	17384765
v@@	O	-1	17384765
es	O	-1	17384765
cognitive	O	-1	17384765
outcom@@	O	-1	17384765
es	O	-1	17384765
in	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
-@@	O	-1	17384765
exposed	O	-1	17384765
child@@	O	-1	17384765
ren@@	O	-1	17384765
,	O	-1	17384765
or	O	-1	17384765
whether	O	-1	17384765
these	O	-1	17384765
agents	O	-1	17384765
have	O	-1	17384765
adverse	O	-1	17384765
effects	O	-1	17384765
that	O	-1	17384765
may	O	-1	17384765
aff@@	O	-1	17384765
ect	O	-1	17384765
brain	O	-1	17384765
development	O	-1	17384765
in	O	-1	17384765
the	O	-1	17384765
absence	O	-1	17384765
of	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
expos@@	O	-1	17384765
ure.	O	-1	17384765
OBJECTIV@@	O	-1	17384765
E@@	O	-1	17384765
S:	O	-1	17384765
The	O	-1	17384765
present	O	-1	17384765
study	O	-1	17384765
was	O	-1	17384765
de@@	O	-1	17384765
signed	O	-1	17384765
to	O	-1	17384765
an@@	O	-1	17384765
s@@	O	-1	17384765
w@@	O	-1	17384765
er	O	-1	17384765
these	O	-1	17384765
qu@@	O	-1	17384765
es@@	O	-1	17384765
tion@@	O	-1	17384765
s,	O	-1	17384765
using	O	-1	17384765
a	O	-1	17384765
ro@@	O	-1	17384765
d@@	O	-1	17384765
ent	O	-1	17384765
model	O	-1	17384765
of	O	-1	17384765
early	O	-1	17384765
child@@	O	-1	17384765
ho@@	O	-1	17384765
od	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
exposure	O	-1	17384765
and	O	-1	17384765
treatment	O	-1	17384765
with	O	-1	17384765
suc@@	B-Chemical	D004113	17384765
c@@	I-Chemical	-1	17384765
im@@	I-Chemical	-1	17384765
er	I-Chemical	-1	17384765
,	O	-1	17384765
a	O	-1	17384765
wi@@	O	-1	17384765
de@@	O	-1	17384765
ly	O	-1	17384765
used	O	-1	17384765
ch@@	O	-1	17384765
el@@	O	-1	17384765
ating	O	-1	17384765
agent	O	-1	17384765
for	O	-1	17384765
the	O	-1	17384765
treatment	O	-1	17384765
of	O	-1	17384765
P@@	B-Disease	D007855	17384765
b	I-Disease	-1	17384765
po@@	I-Disease	-1	17384765
is@@	I-Disease	-1	17384765
on@@	I-Disease	-1	17384765
ing	I-Disease	-1	17384765
.	O	-1	17384765
RESULTS:	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
exposure	O	-1	17384765
produced	O	-1	17384765
l@@	O	-1	17384765
ast@@	O	-1	17384765
ing	O	-1	17384765
impair@@	B-Disease	D007859	17384765
ments	I-Disease	-1	17384765
in	I-Disease	-1	17384765
lear@@	I-Disease	-1	17384765
n@@	I-Disease	-1	17384765
ing,	I-Disease	-1	17384765
atten@@	I-Disease	-1	17384765
tion,	I-Disease	-1	17384765
inhibit@@	I-Disease	-1	17384765
ory	I-Disease	-1	17384765
control@@	I-Disease	-1	17384765
,	I-Disease	-1	17384765
and	I-Disease	-1	17384765
a@@	I-Disease	-1	17384765
ro@@	I-Disease	-1	17384765
us@@	I-Disease	-1	17384765
al	I-Disease	-1	17384765
reg@@	I-Disease	-1	17384765
ulation	I-Disease	-1	17384765
impair@@	B-Disease	D019958	17384765
ments	I-Disease	-1	17384765
in	I-Disease	-1	17384765
lear@@	I-Disease	-1	17384765
n@@	I-Disease	-1	17384765
ing,	I-Disease	-1	17384765
atten@@	I-Disease	-1	17384765
tion,	I-Disease	-1	17384765
inhibit@@	I-Disease	-1	17384765
ory	I-Disease	-1	17384765
control@@	I-Disease	-1	17384765
,	I-Disease	-1	17384765
and	I-Disease	-1	17384765
a@@	I-Disease	-1	17384765
ro@@	I-Disease	-1	17384765
us@@	I-Disease	-1	17384765
al	I-Disease	-1	17384765
reg@@	I-Disease	-1	17384765
ulation	I-Disease	-1	17384765
,	O	-1	17384765
par@@	O	-1	17384765
al@@	O	-1	17384765
le@@	O	-1	17384765
l@@	O	-1	17384765
ing	O	-1	17384765
the	O	-1	17384765
a@@	O	-1	17384765
reas	O	-1	17384765
of	O	-1	17384765
dysfunction	O	-1	17384765
seen	O	-1	17384765
in	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
-@@	O	-1	17384765
exposed	O	-1	17384765
child@@	O	-1	17384765
ren@@	O	-1	17384765
.	O	-1	17384765
S@@	B-Chemical	D004113	17384765
uc@@	I-Chemical	-1	17384765
c@@	I-Chemical	-1	17384765
im@@	I-Chemical	-1	17384765
er	I-Chemical	-1	17384765
treatment	O	-1	17384765
of	O	-1	17384765
the	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
-@@	O	-1	17384765
exposed	O	-1	17384765
rats	O	-1	17384765
significantly	O	-1	17384765
improved	O	-1	17384765
lear@@	O	-1	17384765
n@@	O	-1	17384765
ing,	O	-1	17384765
atten@@	O	-1	17384765
tion,	O	-1	17384765
and	O	-1	17384765
a@@	O	-1	17384765
ro@@	O	-1	17384765
us@@	O	-1	17384765
al	O	-1	17384765
reg@@	O	-1	17384765
ul@@	O	-1	17384765
ation,	O	-1	17384765
although	O	-1	17384765
the	O	-1	17384765
efficacy	O	-1	17384765
of	O	-1	17384765
the	O	-1	17384765
treatment	O	-1	17384765
vari@@	O	-1	17384765
ed	O	-1	17384765
as	O	-1	17384765
a	O	-1	17384765
function	O	-1	17384765
of	O	-1	17384765
the	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
exposure	O	-1	17384765
level	O	-1	17384765
and	O	-1	17384765
the	O	-1	17384765
specific	O	-1	17384765
functional	O	-1	17384765
defic@@	O	-1	17384765
it@@	O	-1	17384765
.	O	-1	17384765
In	O	-1	17384765
contrast@@	O	-1	17384765
,	O	-1	17384765
suc@@	B-Chemical	D004113	17384765
c@@	I-Chemical	-1	17384765
im@@	I-Chemical	-1	17384765
er	I-Chemical	-1	17384765
treatment	O	-1	17384765
of	O	-1	17384765
rats	O	-1	17384765
not	O	-1	17384765
previously	O	-1	17384765
exposed	O	-1	17384765
to	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
produced	O	-1	17384765
l@@	O	-1	17384765
ast@@	O	-1	17384765
ing	O	-1	17384765
and	O	-1	17384765
per@@	O	-1	17384765
v@@	O	-1	17384765
a@@	O	-1	17384765
sive	O	-1	17384765
cognitive	B-Disease	D003072	17384765
and	I-Disease	-1	17384765
aff@@	I-Disease	-1	17384765
ective	I-Disease	-1	17384765
dysfunction	I-Disease	-1	17384765
cognitive	B-Disease	D019964	17384765
and	I-Disease	-1	17384765
aff@@	I-Disease	-1	17384765
ective	I-Disease	-1	17384765
dysfunction	I-Disease	-1	17384765
compar@@	O	-1	17384765
able	O	-1	17384765
in	O	-1	17384765
mag@@	O	-1	17384765
nit@@	O	-1	17384765
ude	O	-1	17384765
to	O	-1	17384765
that	O	-1	17384765
produced	O	-1	17384765
by	O	-1	17384765
the	O	-1	17384765
higher	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
exposure	O	-1	17384765
regimen@@	O	-1	17384765
.	O	-1	17384765
CONCLUSIONS:	O	-1	17384765
These	O	-1	17384765
are	O	-1	17384765
the	O	-1	17384765
first	O	-1	17384765
dat@@	O	-1	17384765
a,	O	-1	17384765
to	O	-1	17384765
our	O	-1	17384765
know@@	O	-1	17384765
le@@	O	-1	17384765
d@@	O	-1	17384765
g@@	O	-1	17384765
e,	O	-1	17384765
to	O	-1	17384765
show	O	-1	17384765
that	O	-1	17384765
treatment	O	-1	17384765
with	O	-1	17384765
any	O	-1	17384765
ch@@	O	-1	17384765
el@@	O	-1	17384765
ating	O	-1	17384765
agent	O	-1	17384765
can	O	-1	17384765
al@@	O	-1	17384765
le@@	O	-1	17384765
vi@@	O	-1	17384765
ate	O	-1	17384765
cognitive	B-Disease	D003072	17384765
defic@@	I-Disease	-1	17384765
its	I-Disease	-1	17384765
due	O	-1	17384765
to	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
expos@@	O	-1	17384765
ure.	O	-1	17384765
These	O	-1	17384765
findings	O	-1	17384765
suggest	O	-1	17384765
that	O	-1	17384765
it	O	-1	17384765
may	O	-1	17384765
be	O	-1	17384765
possible	O	-1	17384765
to	O	-1	17384765
identi@@	O	-1	17384765
f@@	O	-1	17384765
y	O	-1	17384765
a	O	-1	17384765
suc@@	B-Chemical	D004113	17384765
c@@	I-Chemical	-1	17384765
im@@	I-Chemical	-1	17384765
er	I-Chemical	-1	17384765
treatment	O	-1	17384765
pro@@	O	-1	17384765
to@@	O	-1	17384765
co@@	O	-1	17384765
l	O	-1	17384765
that	O	-1	17384765
impro@@	O	-1	17384765
v@@	O	-1	17384765
es	O	-1	17384765
cognitive	O	-1	17384765
outcom@@	O	-1	17384765
es	O	-1	17384765
in	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
-@@	O	-1	17384765
exposed	O	-1	17384765
child@@	O	-1	17384765
ren@@	O	-1	17384765
.	O	-1	17384765
However,	O	-1	17384765
they	O	-1	17384765
also	O	-1	17384765
suggest	O	-1	17384765
that	O	-1	17384765
suc@@	B-Chemical	D004113	17384765
c@@	I-Chemical	-1	17384765
im@@	I-Chemical	-1	17384765
er	I-Chemical	-1	17384765
treatment	O	-1	17384765
should	O	-1	17384765
be	O	-1	17384765
st@@	O	-1	17384765
ron@@	O	-1	17384765
g@@	O	-1	17384765
ly	O	-1	17384765
dis@@	O	-1	17384765
cour@@	O	-1	17384765
aged	O	-1	17384765
for	O	-1	17384765
children	O	-1	17384765
who	O	-1	17384765
d@@	O	-1	17384765
o	O	-1	17384765
not	O	-1	17384765
have	O	-1	17384765
elevated	O	-1	17384765
tissue	O	-1	17384765
levels	O	-1	17384765
of	O	-1	17384765
P@@	B-Chemical	D007854	17384765
b	I-Chemical	-1	17384765
or	O	-1	17384765
other	O	-1	17384765
he@@	O	-1	17384765
av@@	O	-1	17384765
y	O	-1	17384765
met@@	O	-1	17384765
al@@	O	-1	17384765
s.	O	-1	17384765

Ca@@	B-Chemical	D002110	17445520
ffe@@	I-Chemical	-1	17445520
ine	I-Chemical	-1	17445520
ch@@	O	-1	17445520
all@@	O	-1	17445520
enge	O	-1	17445520
test	O	-1	17445520
in	O	-1	17445520
p@@	B-Disease	D016584	17445520
anic	I-Disease	-1	17445520
disor@@	I-Disease	-1	17445520
der	I-Disease	-1	17445520
and	O	-1	17445520
de@@	B-Disease	D003866	17445520
pression	I-Disease	-1	17445520
with	O	-1	17445520
p@@	B-Disease	D016584	17445520
anic	I-Disease	-1	17445520
at@@	I-Disease	-1	17445520
tac@@	I-Disease	-1	17445520
k@@	I-Disease	-1	17445520
s	I-Disease	-1	17445520
.	O	-1	17445520
Our	O	-1	17445520
a@@	O	-1	17445520
im	O	-1	17445520
was	O	-1	17445520
to	O	-1	17445520
obser@@	O	-1	17445520
ve	O	-1	17445520
if	O	-1	17445520
patients	O	-1	17445520
with	O	-1	17445520
p@@	B-Disease	D016584	17445520
anic	I-Disease	-1	17445520
disor@@	I-Disease	-1	17445520
der	I-Disease	-1	17445520
(	O	-1	17445520
P@@	B-Disease	D016584	17445520
D	I-Disease	-1	17445520
)	O	-1	17445520
and	O	-1	17445520
patients	O	-1	17445520
with	O	-1	17445520
major	B-Disease	D003865	17445520
de@@	I-Disease	-1	17445520
pression	I-Disease	-1	17445520
with	O	-1	17445520
p@@	B-Disease	D016584	17445520
anic	I-Disease	-1	17445520
at@@	I-Disease	-1	17445520
tac@@	I-Disease	-1	17445520
k@@	I-Disease	-1	17445520
s	I-Disease	-1	17445520
(	O	-1	17445520
MD@@	B-Disease	D003865	17445520
P	I-Disease	-1	17445520
MD@@	B-Disease	D016584	17445520
P	I-Disease	-1	17445520
)	O	-1	17445520
(D@@	O	-1	17445520
i@@	O	-1	17445520
ag@@	O	-1	17445520
nos@@	O	-1	17445520
tic	O	-1	17445520
and	O	-1	17445520
S@@	O	-1	17445520
t@@	O	-1	17445520
atis@@	O	-1	17445520
tical	O	-1	17445520
M@@	O	-1	17445520
an@@	O	-1	17445520
ual	O	-1	17445520
of	O	-1	17445520
M@@	B-Disease	D001523	17445520
ental	I-Disease	-1	17445520
D@@	I-Disease	-1	17445520
is@@	I-Disease	-1	17445520
or@@	I-Disease	-1	17445520
der@@	I-Disease	-1	17445520
s	I-Disease	-1	17445520
,	O	-1	17445520
F@@	O	-1	17445520
o@@	O	-1	17445520
ur@@	O	-1	17445520
th	O	-1	17445520
E@@	O	-1	17445520
di@@	O	-1	17445520
tion	O	-1	17445520
c@@	O	-1	17445520
rit@@	O	-1	17445520
er@@	O	-1	17445520
ia@@	O	-1	17445520
)	O	-1	17445520
respon@@	O	-1	17445520
d	O	-1	17445520
in	O	-1	17445520
a	O	-1	17445520
similar	O	-1	17445520
w@@	O	-1	17445520
ay	O	-1	17445520
to	O	-1	17445520
the	O	-1	17445520
induction	O	-1	17445520
of	O	-1	17445520
p@@	B-Disease	D016584	17445520
anic	I-Disease	-1	17445520
at@@	I-Disease	-1	17445520
tac@@	I-Disease	-1	17445520
k@@	I-Disease	-1	17445520
s	I-Disease	-1	17445520
by	O	-1	17445520
an	O	-1	17445520
oral	O	-1	17445520
caffe@@	B-Chemical	D002110	17445520
ine	I-Chemical	-1	17445520
ch@@	O	-1	17445520
all@@	O	-1	17445520
enge	O	-1	17445520
test@@	O	-1	17445520
.	O	-1	17445520
We	O	-1	17445520
random@@	O	-1	17445520
ly	O	-1	17445520
sel@@	O	-1	17445520
ected	O	-1	17445520
2@@	O	-1	17445520
9	O	-1	17445520
patients	O	-1	17445520
with	O	-1	17445520
P@@	B-Disease	D016584	17445520
D	I-Disease	-1	17445520
,	O	-1	17445520
2@@	O	-1	17445520
7	O	-1	17445520
with	O	-1	17445520
MD@@	B-Disease	D003865	17445520
P	I-Disease	-1	17445520
MD@@	B-Disease	D016584	17445520
P	I-Disease	-1	17445520
,	O	-1	17445520
25	O	-1	17445520
with	O	-1	17445520
major	B-Disease	D003865	17445520
de@@	I-Disease	-1	17445520
pression	I-Disease	-1	17445520
without	O	-1	17445520
p@@	B-Disease	D016584	17445520
anic	I-Disease	-1	17445520
at@@	I-Disease	-1	17445520
tac@@	I-Disease	-1	17445520
k@@	I-Disease	-1	17445520
s	I-Disease	-1	17445520
(	O	-1	17445520
M@@	B-Disease	D003865	17445520
D	I-Disease	-1	17445520
),	O	-1	17445520
and	O	-1	17445520
2@@	O	-1	17445520
8	O	-1	17445520
healthy	O	-1	17445520
vol@@	O	-1	17445520
un@@	O	-1	17445520
te@@	O	-1	17445520
ers.	O	-1	17445520
The	O	-1	17445520
patients	O	-1	17445520
had	O	-1	17445520
no	O	-1	17445520
psych@@	O	-1	17445520
ot@@	O	-1	17445520
ro@@	O	-1	17445520
p@@	O	-1	17445520
ic	O	-1	17445520
drug	O	-1	17445520
for	O	-1	17445520
at	O	-1	17445520
le@@	O	-1	17445520
ast	O	-1	17445520
a	O	-1	17445520
4-@@	O	-1	17445520
week	O	-1	17445520
perio@@	O	-1	17445520
d.	O	-1	17445520
In	O	-1	17445520
a	O	-1	17445520
randomized	O	-1	17445520
double-bl@@	O	-1	17445520
ind	O	-1	17445520
experim@@	O	-1	17445520
ent	O	-1	17445520
performed	O	-1	17445520
in	O	-1	17445520
2	O	-1	17445520
oc@@	O	-1	17445520
ca@@	O	-1	17445520
sions	O	-1	17445520
7	O	-1	17445520
days	O	-1	17445520
ap@@	O	-1	17445520
ar@@	O	-1	17445520
t,	O	-1	17445520
4@@	O	-1	17445520
8@@	O	-1	17445520
0	O	-1	17445520
mg	O	-1	17445520
caffe@@	B-Chemical	D002110	17445520
ine	I-Chemical	-1	17445520
and	O	-1	17445520
a	O	-1	17445520
caffe@@	B-Chemical	D002110	17445520
ine	I-Chemical	-1	17445520
-@@	O	-1	17445520
free	O	-1	17445520
(@@	O	-1	17445520
placebo@@	O	-1	17445520
)	O	-1	17445520
sol@@	O	-1	17445520
u@@	O	-1	17445520
tion	O	-1	17445520
were	O	-1	17445520
administered	O	-1	17445520
in	O	-1	17445520
a	O	-1	17445520
co@@	O	-1	17445520
ffe@@	O	-1	17445520
e	O	-1	17445520
form	O	-1	17445520
and	O	-1	17445520
an@@	B-Disease	D001008	17445520
xi@@	I-Disease	-1	17445520
ety	I-Disease	-1	17445520
s@@	O	-1	17445520
cal@@	O	-1	17445520
es	O	-1	17445520
were	O	-1	17445520
ap@@	O	-1	17445520
pl@@	O	-1	17445520
ied	O	-1	17445520
before	O	-1	17445520
and	O	-1	17445520
after	O	-1	17445520
each	O	-1	17445520
test@@	O	-1	17445520
.	O	-1	17445520
A	O	-1	17445520
total	O	-1	17445520
of	O	-1	17445520
5@@	O	-1	17445520
8.@@	O	-1	17445520
6%	O	-1	17445520
(n	O	-1	17445520
=	O	-1	17445520
17@@	O	-1	17445520
)	O	-1	17445520
of	O	-1	17445520
patients	O	-1	17445520
with	O	-1	17445520
P@@	B-Disease	D016584	17445520
D	I-Disease	-1	17445520
,	O	-1	17445520
4@@	O	-1	17445520
4.@@	O	-1	17445520
4@@	O	-1	17445520
%	O	-1	17445520
(n	O	-1	17445520
=	O	-1	17445520
12@@	O	-1	17445520
)	O	-1	17445520
of	O	-1	17445520
patients	O	-1	17445520
with	O	-1	17445520
MD@@	B-Disease	D003865	17445520
P	I-Disease	-1	17445520
MD@@	B-Disease	D016584	17445520
P	I-Disease	-1	17445520
,	O	-1	17445520
1@@	O	-1	17445520
2.@@	O	-1	17445520
0%	O	-1	17445520
(n	O	-1	17445520
=	O	-1	17445520
3@@	O	-1	17445520
)	O	-1	17445520
of	O	-1	17445520
patients	O	-1	17445520
with	O	-1	17445520
M@@	B-Disease	D003865	17445520
D	I-Disease	-1	17445520
,	O	-1	17445520
and	O	-1	17445520
7.@@	O	-1	17445520
1@@	O	-1	17445520
%	O	-1	17445520
(n@@	O	-1	17445520
=	O	-1	17445520
2)	O	-1	17445520
of	O	-1	17445520
control	O	-1	17445520
subjects	O	-1	17445520
had	O	-1	17445520
a	O	-1	17445520
p@@	B-Disease	D016584	17445520
anic	I-Disease	-1	17445520
at@@	I-Disease	-1	17445520
tac@@	I-Disease	-1	17445520
k	I-Disease	-1	17445520
after	O	-1	17445520
the	O	-1	17445520
4@@	O	-1	17445520
8@@	O	-1	17445520
0-@@	O	-1	17445520
mg	O	-1	17445520
caffe@@	B-Chemical	D002110	17445520
ine	I-Chemical	-1	17445520
ch@@	O	-1	17445520
all@@	O	-1	17445520
enge	O	-1	17445520
test	O	-1	17445520
(@@	O	-1	17445520
ch@@	O	-1	17445520
i@@	O	-1	17445520
(2@@	O	-1	17445520
)@@	O	-1	17445520
(3@@	O	-1	17445520
)	O	-1	17445520
=	O	-1	17445520
1@@	O	-1	17445520
6.@@	O	-1	17445520
2@@	O	-1	17445520
2,	O	-1	17445520
P	O	-1	17445520
=	O	-1	17445520
.@@	O	-1	17445520
0@@	O	-1	17445520
0@@	O	-1	17445520
1).	O	-1	17445520
The	O	-1	17445520
patients	O	-1	17445520
with	O	-1	17445520
P@@	B-Disease	D016584	17445520
D	I-Disease	-1	17445520
and	O	-1	17445520
MD@@	B-Disease	D003865	17445520
P	I-Disease	-1	17445520
MD@@	B-Disease	D016584	17445520
P	I-Disease	-1	17445520
were	O	-1	17445520
more	O	-1	17445520
sensitive	O	-1	17445520
to	O	-1	17445520
caffe@@	B-Chemical	D002110	17445520
ine	I-Chemical	-1	17445520
than	O	-1	17445520
were	O	-1	17445520
patients	O	-1	17445520
with	O	-1	17445520
M@@	B-Disease	D003865	17445520
D	I-Disease	-1	17445520
and	O	-1	17445520
healthy	O	-1	17445520
vol@@	O	-1	17445520
un@@	O	-1	17445520
te@@	O	-1	17445520
ers.	O	-1	17445520
No	O	-1	17445520
p@@	B-Disease	D016584	17445520
anic	I-Disease	-1	17445520
at@@	I-Disease	-1	17445520
tac@@	I-Disease	-1	17445520
k	I-Disease	-1	17445520
was	O	-1	17445520
observed	O	-1	17445520
after	O	-1	17445520
the	O	-1	17445520
caffe@@	B-Chemical	D002110	17445520
ine	I-Chemical	-1	17445520
-@@	O	-1	17445520
free	O	-1	17445520
sol@@	O	-1	17445520
u@@	O	-1	17445520
tion	O	-1	17445520
int@@	O	-1	17445520
ak@@	O	-1	17445520
e.	O	-1	17445520
The	O	-1	17445520
patients	O	-1	17445520
with	O	-1	17445520
M@@	B-Disease	D003865	17445520
D	I-Disease	-1	17445520
had	O	-1	17445520
a	O	-1	17445520
lower	O	-1	17445520
heart	O	-1	17445520
rate	O	-1	17445520
response	O	-1	17445520
to	O	-1	17445520
the	O	-1	17445520
test	O	-1	17445520
than	O	-1	17445520
all	O	-1	17445520
the	O	-1	17445520
other	O	-1	17445520
groups	O	-1	17445520
(2@@	O	-1	17445520
-@@	O	-1	17445520
w@@	O	-1	17445520
ay	O	-1	17445520
analysis	O	-1	17445520
of	O	-1	17445520
vari@@	O	-1	17445520
ance@@	O	-1	17445520
,	O	-1	17445520
group	O	-1	17445520
by	O	-1	17445520
time	O	-1	17445520
inter@@	O	-1	17445520
action	O	-1	17445520
with	O	-1	17445520
G@@	O	-1	17445520
re@@	O	-1	17445520
enh@@	O	-1	17445520
ou@@	O	-1	17445520
se@@	O	-1	17445520
-@@	O	-1	17445520
G@@	O	-1	17445520
e@@	O	-1	17445520
is@@	O	-1	17445520
s@@	O	-1	17445520
er	O	-1	17445520
cor@@	O	-1	17445520
rec@@	O	-1	17445520
tion@@	O	-1	17445520
:	O	-1	17445520
F@@	O	-1	17445520
(3@@	O	-1	17445520
,@@	O	-1	17445520
7@@	O	-1	17445520
6@@	O	-1	17445520
2)	O	-1	17445520
=	O	-1	17445520
2.@@	O	-1	17445520
8@@	O	-1	17445520
5,	O	-1	17445520
P	O	-1	17445520
=	O	-1	17445520
.@@	O	-1	17445520
0@@	O	-1	17445520
2@@	O	-1	17445520
6@@	O	-1	17445520
).	O	-1	17445520
Our	O	-1	17445520
data	O	-1	17445520
suggest	O	-1	17445520
that	O	-1	17445520
there	O	-1	17445520
is	O	-1	17445520
an	O	-1	17445520
association	O	-1	17445520
between	O	-1	17445520
p@@	B-Disease	D016584	17445520
anic	I-Disease	-1	17445520
at@@	I-Disease	-1	17445520
tac@@	I-Disease	-1	17445520
k@@	I-Disease	-1	17445520
s	I-Disease	-1	17445520
,	O	-1	17445520
no	O	-1	17445520
mat@@	O	-1	17445520
ter	O	-1	17445520
if	O	-1	17445520
associated	O	-1	17445520
with	O	-1	17445520
P@@	B-Disease	D016584	17445520
D	I-Disease	-1	17445520
or	O	-1	17445520
MD@@	B-Disease	D003865	17445520
P	I-Disease	-1	17445520
MD@@	B-Disease	D016584	17445520
P	I-Disease	-1	17445520
,	O	-1	17445520
and	O	-1	17445520
hyper@@	O	-1	17445520
re@@	O	-1	17445520
activity	O	-1	17445520
to	O	-1	17445520
an	O	-1	17445520
oral	O	-1	17445520
caffe@@	B-Chemical	D002110	17445520
ine	I-Chemical	-1	17445520
ch@@	O	-1	17445520
all@@	O	-1	17445520
enge	O	-1	17445520
test@@	O	-1	17445520
.	O	-1	17445520

M@@	O	-1	17484470
it@@	O	-1	17484470
ral	O	-1	17484470
an@@	O	-1	17484470
n@@	O	-1	17484470
ulo@@	O	-1	17484470
pl@@	O	-1	17484470
ast@@	O	-1	17484470
y	O	-1	17484470
as	O	-1	17484470
a	O	-1	17484470
ventricular	O	-1	17484470
rest@@	O	-1	17484470
or@@	O	-1	17484470
ation	O	-1	17484470
meth@@	O	-1	17484470
od	O	-1	17484470
for	O	-1	17484470
the	O	-1	17484470
fail@@	B-Disease	D006333	17484470
ing	I-Disease	-1	17484470
left	I-Disease	-1	17484470
ventric@@	I-Disease	-1	17484470
le	I-Disease	-1	17484470
:	O	-1	17484470
a	O	-1	17484470
pilo@@	O	-1	17484470
t	O	-1	17484470
study.	O	-1	17484470
BACKGROUN@@	O	-1	17484470
D	O	-1	17484470
AN@@	O	-1	17484470
D	O	-1	17484470
A@@	O	-1	17484470
I@@	O	-1	17484470
M	O	-1	17484470
O@@	O	-1	17484470
F	O	-1	17484470
T@@	O	-1	17484470
H@@	O	-1	17484470
E	O	-1	17484470
S@@	O	-1	17484470
T@@	O	-1	17484470
U@@	O	-1	17484470
D@@	O	-1	17484470
Y@@	O	-1	17484470
:	O	-1	17484470
U@@	O	-1	17484470
n@@	O	-1	17484470
der@@	O	-1	17484470
si@@	O	-1	17484470
zed	O	-1	17484470
mit@@	O	-1	17484470
ral	O	-1	17484470
an@@	O	-1	17484470
n@@	O	-1	17484470
ulo@@	O	-1	17484470
pl@@	O	-1	17484470
ast@@	O	-1	17484470
y	O	-1	17484470
(@@	O	-1	17484470
MA@@	O	-1	17484470
P)	O	-1	17484470
is	O	-1	17484470
effective	O	-1	17484470
in	O	-1	17484470
patients	O	-1	17484470
with	O	-1	17484470
di@@	B-Disease	D002311	17484470
l@@	I-Disease	-1	17484470
ated	I-Disease	-1	17484470
cardi@@	I-Disease	-1	17484470
om@@	I-Disease	-1	17484470
yo@@	I-Disease	-1	17484470
pathy	I-Disease	-1	17484470
and	O	-1	17484470
functional	O	-1	17484470
mit@@	B-Disease	D008944	17484470
ral	I-Disease	-1	17484470
reg@@	I-Disease	-1	17484470
ur@@	I-Disease	-1	17484470
g@@	I-Disease	-1	17484470
it@@	I-Disease	-1	17484470
ation	I-Disease	-1	17484470
(	O	-1	17484470
M@@	B-Disease	D008944	17484470
R	I-Disease	-1	17484470
)	O	-1	17484470
s@@	O	-1	17484470
in@@	O	-1	17484470
ce@@	O	-1	17484470
,	O	-1	17484470
as	O	-1	17484470
well	O	-1	17484470
as	O	-1	17484470
ad@@	O	-1	17484470
d@@	O	-1	17484470
res@@	O	-1	17484470
s@@	O	-1	17484470
ing	O	-1	17484470
the	O	-1	17484470
M@@	B-Disease	D008944	17484470
R	I-Disease	-1	17484470
,	O	-1	17484470
the	O	-1	17484470
MA@@	O	-1	17484470
P	O	-1	17484470
may	O	-1	17484470
also	O	-1	17484470
res@@	O	-1	17484470
h@@	O	-1	17484470
ap@@	O	-1	17484470
e	O	-1	17484470
the	O	-1	17484470
di@@	O	-1	17484470
l@@	O	-1	17484470
ated	O	-1	17484470
left	O	-1	17484470
ventricular	O	-1	17484470
(@@	O	-1	17484470
L@@	O	-1	17484470
V@@	O	-1	17484470
)	O	-1	17484470
bas@@	O	-1	17484470
e.	O	-1	17484470
However,	O	-1	17484470
the	O	-1	17484470
direct	O	-1	17484470
ben@@	O	-1	17484470
e@@	O	-1	17484470
f@@	O	-1	17484470
its	O	-1	17484470
of	O	-1	17484470
this	O	-1	17484470
possible	O	-1	17484470
res@@	O	-1	17484470
h@@	O	-1	17484470
ap@@	O	-1	17484470
ing	O	-1	17484470
on	O	-1	17484470
L@@	O	-1	17484470
V	O	-1	17484470
function	O	-1	17484470
in	O	-1	17484470
the	O	-1	17484470
absence	O	-1	17484470
of	O	-1	17484470
underlying	O	-1	17484470
M@@	B-Disease	D008944	17484470
R	I-Disease	-1	17484470
re@@	O	-1	17484470
ma@@	O	-1	17484470
in	O	-1	17484470
in@@	O	-1	17484470
complete@@	O	-1	17484470
ly	O	-1	17484470
under@@	O	-1	17484470
sto@@	O	-1	17484470
o@@	O	-1	17484470
d.	O	-1	17484470
The	O	-1	17484470
study	O	-1	17484470
a@@	O	-1	17484470
im	O	-1	17484470
was	O	-1	17484470
to	O	-1	17484470
identi@@	O	-1	17484470
f@@	O	-1	17484470
y	O	-1	17484470
these	O	-1	17484470
ben@@	O	-1	17484470
e@@	O	-1	17484470
f@@	O	-1	17484470
its	O	-1	17484470
in	O	-1	17484470
a	O	-1	17484470
can@@	O	-1	17484470
ine	O	-1	17484470
model	O	-1	17484470
of	O	-1	17484470
acute	O	-1	17484470
heart	B-Disease	D006333	17484470
failure	I-Disease	-1	17484470
.	O	-1	17484470
METHODS:	O	-1	17484470
Si@@	O	-1	17484470
x	O	-1	17484470
dog@@	O	-1	17484470
s	O	-1	17484470
under@@	O	-1	17484470
w@@	O	-1	17484470
ent	O	-1	17484470
MA@@	O	-1	17484470
P	O	-1	17484470
with	O	-1	17484470
a	O	-1	17484470
pro@@	O	-1	17484470
s@@	O	-1	17484470
thetic	O	-1	17484470
b@@	O	-1	17484470
and	O	-1	17484470
on	O	-1	17484470
the	O	-1	17484470
po@@	O	-1	17484470
ster@@	O	-1	17484470
ior	O	-1	17484470
mit@@	O	-1	17484470
ral	O	-1	17484470
an@@	O	-1	17484470
n@@	O	-1	17484470
ul@@	O	-1	17484470
us,	O	-1	17484470
using	O	-1	17484470
four	O	-1	17484470
mat@@	O	-1	17484470
t@@	O	-1	17484470
res@@	O	-1	17484470
s	O	-1	17484470
su@@	O	-1	17484470
tu@@	O	-1	17484470
res@@	O	-1	17484470
.	O	-1	17484470
The	O	-1	17484470
su@@	O	-1	17484470
t@@	O	-1	17484470
ures	O	-1	17484470
were	O	-1	17484470
p@@	O	-1	17484470
ass@@	O	-1	17484470
ed	O	-1	17484470
individ@@	O	-1	17484470
ually	O	-1	17484470
through	O	-1	17484470
four	O	-1	17484470
to@@	O	-1	17484470
ur@@	O	-1	17484470
n@@	O	-1	17484470
i@@	O	-1	17484470
qu@@	O	-1	17484470
et@@	O	-1	17484470
s	O	-1	17484470
and	O	-1	17484470
ex@@	O	-1	17484470
ter@@	O	-1	17484470
i@@	O	-1	17484470
or@@	O	-1	17484470
ized	O	-1	17484470
un@@	O	-1	17484470
ti@@	O	-1	17484470
ed	O	-1	17484470
vi@@	O	-1	17484470
a	O	-1	17484470
the	O	-1	17484470
left	O	-1	17484470
atri@@	O	-1	17484470
ot@@	O	-1	17484470
om@@	O	-1	17484470
y.	O	-1	17484470
S@@	O	-1	17484470
on@@	O	-1	17484470
om@@	O	-1	17484470
ic@@	O	-1	17484470
ro@@	O	-1	17484470
met@@	O	-1	17484470
r@@	O	-1	17484470
y	O	-1	17484470
c@@	O	-1	17484470
r@@	O	-1	17484470
y@@	O	-1	17484470
st@@	O	-1	17484470
als	O	-1	17484470
were	O	-1	17484470
im@@	O	-1	17484470
pl@@	O	-1	17484470
ant@@	O	-1	17484470
ed	O	-1	17484470
a@@	O	-1	17484470
ro@@	O	-1	17484470
un@@	O	-1	17484470
d	O	-1	17484470
the	O	-1	17484470
mit@@	O	-1	17484470
ral	O	-1	17484470
an@@	O	-1	17484470
n@@	O	-1	17484470
ul@@	O	-1	17484470
us	O	-1	17484470
and	O	-1	17484470
left	O	-1	17484470
ventric@@	O	-1	17484470
le	O	-1	17484470
to	O	-1	17484470
meas@@	O	-1	17484470
ure	O	-1	17484470
ge@@	O	-1	17484470
o@@	O	-1	17484470
met@@	O	-1	17484470
r@@	O	-1	17484470
y	O	-1	17484470
and	O	-1	17484470
regi@@	O	-1	17484470
on@@	O	-1	17484470
al	O	-1	17484470
func@@	O	-1	17484470
tion.	O	-1	17484470
Ac@@	O	-1	17484470
ute	O	-1	17484470
heart	B-Disease	D006333	17484470
failure	I-Disease	-1	17484470
was	O	-1	17484470
induced	O	-1	17484470
by	O	-1	17484470
prop@@	B-Chemical	D011433	17484470
ran@@	I-Chemical	-1	17484470
o@@	I-Chemical	-1	17484470
lol	I-Chemical	-1	17484470
and	O	-1	17484470
volume	O	-1	17484470
lo@@	O	-1	17484470
ad@@	O	-1	17484470
ing	O	-1	17484470
after	O	-1	17484470
we@@	O	-1	17484470
an@@	O	-1	17484470
ing	O	-1	17484470
from	O	-1	17484470
cardio@@	O	-1	17484470
pulmonary	O	-1	17484470
b@@	O	-1	17484470
yp@@	O	-1	17484470
ass@@	O	-1	17484470
;	O	-1	17484470
an	O	-1	17484470
absence	O	-1	17484470
of	O	-1	17484470
M@@	B-Disease	D008944	17484470
R	I-Disease	-1	17484470
was	O	-1	17484470
con@@	O	-1	17484470
fir@@	O	-1	17484470
m@@	O	-1	17484470
ed	O	-1	17484470
by	O	-1	17484470
echocardiograph@@	O	-1	17484470
y.	O	-1	17484470
MA@@	O	-1	17484470
P	O	-1	17484470
was	O	-1	17484470
ac@@	O	-1	17484470
com@@	O	-1	17484470
pl@@	O	-1	17484470
ished	O	-1	17484470
by	O	-1	17484470
cin@@	O	-1	17484470
ch@@	O	-1	17484470
ing	O	-1	17484470
the	O	-1	17484470
to@@	O	-1	17484470
ur@@	O	-1	17484470
n@@	O	-1	17484470
i@@	O	-1	17484470
qu@@	O	-1	17484470
et@@	O	-1	17484470
s.	O	-1	17484470
D@@	O	-1	17484470
at@@	O	-1	17484470
a	O	-1	17484470
were	O	-1	17484470
ac@@	O	-1	17484470
qu@@	O	-1	17484470
ired	O	-1	17484470
at	O	-1	17484470
basel@@	O	-1	17484470
ine,	O	-1	17484470
after	O	-1	17484470
induction	O	-1	17484470
of	O	-1	17484470
acute	O	-1	17484470
heart	B-Disease	D006333	17484470
failure	I-Disease	-1	17484470
,	O	-1	17484470
and	O	-1	17484470
after	O	-1	17484470
MA@@	O	-1	17484470
P@@	O	-1	17484470
.	O	-1	17484470
RESULTS:	O	-1	17484470
MA@@	O	-1	17484470
P	O	-1	17484470
decreased	O	-1	17484470
mit@@	O	-1	17484470
ral	O	-1	17484470
an@@	O	-1	17484470
n@@	O	-1	17484470
ular	O	-1	17484470
di@@	O	-1	17484470
men@@	O	-1	17484470
sions	O	-1	17484470
in	O	-1	17484470
both	O	-1	17484470
comm@@	O	-1	17484470
is@@	O	-1	17484470
su@@	O	-1	17484470
re@@	O	-1	17484470
-@@	O	-1	17484470
comm@@	O	-1	17484470
is@@	O	-1	17484470
s@@	O	-1	17484470
ure	O	-1	17484470
and	O	-1	17484470
se@@	O	-1	17484470
pt@@	O	-1	17484470
al@@	O	-1	17484470
-@@	O	-1	17484470
lat@@	O	-1	17484470
eral	O	-1	17484470
direc@@	O	-1	17484470
tions.	O	-1	17484470
Con@@	O	-1	17484470
comit@@	O	-1	17484470
ant@@	O	-1	17484470
ly,	O	-1	17484470
the	O	-1	17484470
di@@	O	-1	17484470
ast@@	O	-1	17484470
olic	O	-1	17484470
di@@	O	-1	17484470
ame@@	O	-1	17484470
ter	O	-1	17484470
of	O	-1	17484470
the	O	-1	17484470
L@@	O	-1	17484470
V	O	-1	17484470
b@@	O	-1	17484470
ase	O	-1	17484470
and	O	-1	17484470
L@@	O	-1	17484470
V	O	-1	17484470
s@@	O	-1	17484470
ph@@	O	-1	17484470
er@@	O	-1	17484470
ic@@	O	-1	17484470
ity	O	-1	17484470
decreased	O	-1	17484470
(@@	O	-1	17484470
i.@@	O	-1	17484470
e@@	O	-1	17484470
.,	O	-1	17484470
impro@@	O	-1	17484470
ve@@	O	-1	17484470
d@@	O	-1	17484470
)	O	-1	17484470
from	O	-1	17484470
3@@	O	-1	17484470
7.@@	O	-1	17484470
4	O	-1	17484470
+/-	O	-1	17484470
9.@@	O	-1	17484470
3	O	-1	17484470
to	O	-1	17484470
3@@	O	-1	17484470
5.@@	O	-1	17484470
9	O	-1	17484470
+/-	O	-1	17484470
10	O	-1	17484470
mm	O	-1	17484470
(p	O	-1	17484470
=	O	-1	17484470
0.0@@	O	-1	17484470
6@@	O	-1	17484470
3@@	O	-1	17484470
),	O	-1	17484470
and	O	-1	17484470
from	O	-1	17484470
6@@	O	-1	17484470
7.@@	O	-1	17484470
9	O	-1	17484470
+/-	O	-1	17484470
1@@	O	-1	17484470
8.@@	O	-1	17484470
6%	O	-1	17484470
to	O	-1	17484470
6@@	O	-1	17484470
5.@@	O	-1	17484470
3	O	-1	17484470
+/-	O	-1	17484470
1@@	O	-1	17484470
8.@@	O	-1	17484470
9@@	O	-1	17484470
%	O	-1	17484470
(p	O	-1	17484470
=	O	-1	17484470
0.0@@	O	-1	17484470
1@@	O	-1	17484470
6@@	O	-1	17484470
),	O	-1	17484470
respectively.	O	-1	17484470
D@@	O	-1	17484470
ec@@	O	-1	17484470
reas@@	O	-1	17484470
es	O	-1	17484470
were	O	-1	17484470
ev@@	O	-1	17484470
id@@	O	-1	17484470
ent	O	-1	17484470
in	O	-1	17484470
both	O	-1	17484470
L@@	O	-1	17484470
V	O	-1	17484470
en@@	O	-1	17484470
d-@@	O	-1	17484470
di@@	O	-1	17484470
ast@@	O	-1	17484470
olic	O	-1	17484470
pressure	O	-1	17484470
(@@	O	-1	17484470
from	O	-1	17484470
17	O	-1	17484470
+/-	O	-1	17484470
7	O	-1	17484470
to	O	-1	17484470
15	O	-1	17484470
+/-	O	-1	17484470
6	O	-1	17484470
mm@@	O	-1	17484470
H@@	O	-1	17484470
g@@	O	-1	17484470
,	O	-1	17484470
p	O	-1	17484470
=	O	-1	17484470
0.0@@	O	-1	17484470
4@@	O	-1	17484470
8@@	O	-1	17484470
0	O	-1	17484470
and	O	-1	17484470
T@@	O	-1	17484470
a@@	O	-1	17484470
u	O	-1	17484470
(@@	O	-1	17484470
from	O	-1	17484470
4@@	O	-1	17484470
8	O	-1	17484470
+/-	O	-1	17484470
8	O	-1	17484470
to	O	-1	17484470
4@@	O	-1	17484470
5	O	-1	17484470
+/-	O	-1	17484470
8	O	-1	17484470
m@@	O	-1	17484470
s,	O	-1	17484470
p	O	-1	17484470
<@@	O	-1	17484470
0.0@@	O	-1	17484470
1),	O	-1	17484470
while	O	-1	17484470
frac@@	O	-1	17484470
tional	O	-1	17484470
sh@@	O	-1	17484470
or@@	O	-1	17484470
ten@@	O	-1	17484470
ing	O	-1	17484470
at	O	-1	17484470
the	O	-1	17484470
L@@	O	-1	17484470
V	O	-1	17484470
b@@	O	-1	17484470
ase	O	-1	17484470
increased	O	-1	17484470
from	O	-1	17484470
7.@@	O	-1	17484470
7	O	-1	17484470
+/-	O	-1	17484470
4.@@	O	-1	17484470
5%	O	-1	17484470
to	O	-1	17484470
9.@@	O	-1	17484470
4	O	-1	17484470
+/-	O	-1	17484470
4.@@	O	-1	17484470
5%	O	-1	17484470
(p	O	-1	17484470
=	O	-1	17484470
0.0@@	O	-1	17484470
4@@	O	-1	17484470
5@@	O	-1	17484470
).	O	-1	17484470
After	O	-1	17484470
MA@@	O	-1	17484470
P@@	O	-1	17484470
,	O	-1	17484470
increases	O	-1	17484470
were	O	-1	17484470
identi@@	O	-1	17484470
fied	O	-1	17484470
in	O	-1	17484470
both	O	-1	17484470
cardiac	O	-1	17484470
out@@	O	-1	17484470
pu@@	O	-1	17484470
t	O	-1	17484470
(@@	O	-1	17484470
from	O	-1	17484470
1.@@	O	-1	17484470
5@@	O	-1	17484470
4	O	-1	17484470
+/-	O	-1	17484470
0.@@	O	-1	17484470
5@@	O	-1	17484470
7	O	-1	17484470
to	O	-1	17484470
1.@@	O	-1	17484470
6@@	O	-1	17484470
5	O	-1	17484470
+/-	O	-1	17484470
0.@@	O	-1	17484470
5@@	O	-1	17484470
7	O	-1	17484470
1@@	O	-1	17484470
/@@	O	-1	17484470
min@@	O	-1	17484470
)	O	-1	17484470
and	O	-1	17484470
E@@	O	-1	17484470
ma@@	O	-1	17484470
x	O	-1	17484470
(@@	O	-1	17484470
from	O	-1	17484470
1.@@	O	-1	17484470
8@@	O	-1	17484470
6	O	-1	17484470
+/-	O	-1	17484470
0.@@	O	-1	17484470
9	O	-1	17484470
to	O	-1	17484470
2.@@	O	-1	17484470
4@@	O	-1	17484470
1	O	-1	17484470
+/-	O	-1	17484470
1.@@	O	-1	17484470
3@@	O	-1	17484470
1	O	-1	17484470
mm@@	O	-1	17484470
H@@	O	-1	17484470
g/@@	O	-1	17484470
ml@@	O	-1	17484470
).	O	-1	17484470
CONCLUSION:	O	-1	17484470
The	O	-1	17484470
data	O	-1	17484470
ac@@	O	-1	17484470
qu@@	O	-1	17484470
ired	O	-1	17484470
suggest	O	-1	17484470
that	O	-1	17484470
isol@@	O	-1	17484470
ated	O	-1	17484470
MA@@	O	-1	17484470
P	O	-1	17484470
may	O	-1	17484470
have	O	-1	17484470
cer@@	O	-1	17484470
t@@	O	-1	17484470
ain	O	-1	17484470
ben@@	O	-1	17484470
e@@	O	-1	17484470
f@@	O	-1	17484470
its	O	-1	17484470
on	O	-1	17484470
L@@	O	-1	17484470
V	O	-1	17484470
di@@	O	-1	17484470
men@@	O	-1	17484470
sion@@	O	-1	17484470
/@@	O	-1	17484470
function	O	-1	17484470
in	O	-1	17484470
acute	O	-1	17484470
heart	B-Disease	D006333	17484470
failure	I-Disease	-1	17484470
,	O	-1	17484470
even	O	-1	17484470
in	O	-1	17484470
the	O	-1	17484470
absence	O	-1	17484470
of	O	-1	17484470
M@@	B-Disease	D008944	17484470
R	I-Disease	-1	17484470
.	O	-1	17484470
However,	O	-1	17484470
further	O	-1	17484470
investig@@	O	-1	17484470
ations	O	-1	17484470
are	O	-1	17484470
war@@	O	-1	17484470
ran@@	O	-1	17484470
ted	O	-1	17484470
in	O	-1	17484470
a	O	-1	17484470
model	O	-1	17484470
of	O	-1	17484470
chronic	O	-1	17484470
heart	B-Disease	D006333	17484470
failure	I-Disease	-1	17484470
.	O	-1	17484470

P@@	B-Chemical	C085143	17496739
i@@	I-Chemical	-1	17496739
per@@	I-Chemical	-1	17496739
ac@@	I-Chemical	-1	17496739
ill@@	I-Chemical	-1	17496739
in@@	I-Chemical	-1	17496739
/@@	I-Chemical	-1	17496739
t@@	I-Chemical	-1	17496739
az@@	I-Chemical	-1	17496739
ob@@	I-Chemical	-1	17496739
act@@	I-Chemical	-1	17496739
am	I-Chemical	-1	17496739
-induced	O	-1	17496739
seizure	B-Disease	D012640	17496739
ra@@	O	-1	17496739
pid@@	O	-1	17496739
ly	O	-1	17496739
reversed	O	-1	17496739
by	O	-1	17496739
high	O	-1	17496739
flu@@	O	-1	17496739
x	O	-1	17496739
hemo@@	O	-1	17496739
dialy@@	O	-1	17496739
sis	O	-1	17496739
in	O	-1	17496739
a	O	-1	17496739
patient	O	-1	17496739
on	O	-1	17496739
per@@	O	-1	17496739
it@@	O	-1	17496739
one@@	O	-1	17496739
al	O	-1	17496739
dialy@@	O	-1	17496739
sis.	O	-1	17496739
D@@	O	-1	17496739
es@@	O	-1	17496739
pit@@	O	-1	17496739
e	O	-1	17496739
po@@	O	-1	17496739
p@@	O	-1	17496739
ular	O	-1	17496739
use	O	-1	17496739
of	O	-1	17496739
pi@@	B-Chemical	D010878	17496739
per@@	I-Chemical	-1	17496739
ac@@	I-Chemical	-1	17496739
ill@@	I-Chemical	-1	17496739
in	I-Chemical	-1	17496739
,	O	-1	17496739
the	O	-1	17496739
di@@	O	-1	17496739
r@@	O	-1	17496739
e	O	-1	17496739
neuro@@	B-Disease	D020258	17496739
toxicity	I-Disease	-1	17496739
associated	O	-1	17496739
with	O	-1	17496739
pi@@	B-Chemical	D010878	17496739
per@@	I-Chemical	-1	17496739
ac@@	I-Chemical	-1	17496739
ill@@	I-Chemical	-1	17496739
in	I-Chemical	-1	17496739
sti@@	O	-1	17496739
ll	O	-1	17496739
go@@	O	-1	17496739
es	O	-1	17496739
un@@	O	-1	17496739
reco@@	O	-1	17496739
gn@@	O	-1	17496739
iz@@	O	-1	17496739
ed,	O	-1	17496739
lead@@	O	-1	17496739
ing	O	-1	17496739
to	O	-1	17496739
a	O	-1	17496739
del@@	O	-1	17496739
ay	O	-1	17496739
in	O	-1	17496739
appro@@	O	-1	17496739
pri@@	O	-1	17496739
ate	O	-1	17496739
man@@	O	-1	17496739
ag@@	O	-1	17496739
em@@	O	-1	17496739
ent@@	O	-1	17496739
.	O	-1	17496739
We	O	-1	17496739
report	O	-1	17496739
a	O	-1	17496739
5@@	O	-1	17496739
7-@@	O	-1	17496739
year-old	O	-1	17496739
woman	O	-1	17496739
with	O	-1	17496739
en@@	B-Disease	D007676	17496739
d-@@	I-Disease	-1	17496739
st@@	I-Disease	-1	17496739
age	I-Disease	-1	17496739
renal	I-Disease	-1	17496739
disease	I-Disease	-1	17496739
receiving	O	-1	17496739
continu@@	O	-1	17496739
ous	O	-1	17496739
am@@	O	-1	17496739
b@@	O	-1	17496739
ul@@	O	-1	17496739
atory	O	-1	17496739
per@@	O	-1	17496739
it@@	O	-1	17496739
one@@	O	-1	17496739
al	O	-1	17496739
dialy@@	O	-1	17496739
sis	O	-1	17496739
(C@@	O	-1	17496739
A@@	O	-1	17496739
P@@	O	-1	17496739
D@@	O	-1	17496739
),	O	-1	17496739
who	O	-1	17496739
developed	O	-1	17496739
s@@	O	-1	17496739
lur@@	O	-1	17496739
red	O	-1	17496739
sp@@	O	-1	17496739
e@@	O	-1	17496739
ech@@	O	-1	17496739
,	O	-1	17496739
trem@@	B-Disease	D014202	17496739
or	I-Disease	-1	17496739
,	O	-1	17496739
b@@	O	-1	17496739
iz@@	O	-1	17496739
ar@@	O	-1	17496739
r@@	O	-1	17496739
e	O	-1	17496739
behavi@@	O	-1	17496739
or@@	O	-1	17496739
,	O	-1	17496739
progressive	O	-1	17496739
mental	O	-1	17496739
conf@@	B-Disease	D003221	17496739
usion	I-Disease	-1	17496739
,	O	-1	17496739
and	O	-1	17496739
2	O	-1	17496739
episo@@	O	-1	17496739
des	O	-1	17496739
of	O	-1	17496739
gener@@	O	-1	17496739
al@@	O	-1	17496739
ized	O	-1	17496739
t@@	B-Disease	D004830	17496739
on@@	I-Disease	-1	17496739
ic@@	I-Disease	-1	17496739
-@@	I-Disease	-1	17496739
clon@@	I-Disease	-1	17496739
ic	I-Disease	-1	17496739
seizure	I-Disease	-1	17496739
(	O	-1	17496739
G@@	B-Disease	D004830	17496739
T@@	I-Disease	-1	17496739
C@@	I-Disease	-1	17496739
S	I-Disease	-1	17496739
)	O	-1	17496739
after	O	-1	17496739
5	O	-1	17496739
doses	O	-1	17496739
of	O	-1	17496739
pi@@	B-Chemical	C085143	17496739
per@@	I-Chemical	-1	17496739
ac@@	I-Chemical	-1	17496739
ill@@	I-Chemical	-1	17496739
in@@	I-Chemical	-1	17496739
/@@	I-Chemical	-1	17496739
t@@	I-Chemical	-1	17496739
az@@	I-Chemical	-1	17496739
ob@@	I-Chemical	-1	17496739
act@@	I-Chemical	-1	17496739
am	I-Chemical	-1	17496739
(@@	O	-1	17496739
2	O	-1	17496739
g/@@	O	-1	17496739
2@@	O	-1	17496739
50	O	-1	17496739
mg@@	O	-1	17496739
)	O	-1	17496739
were	O	-1	17496739
given	O	-1	17496739
for	O	-1	17496739
b@@	B-Disease	D001987	17496739
ron@@	I-Disease	-1	17496739
ch@@	I-Disease	-1	17496739
i@@	I-Disease	-1	17496739
ect@@	I-Disease	-1	17496739
asis	I-Disease	-1	17496739
with	O	-1	17496739
secondary	B-Disease	D060085	17496739
inf@@	I-Disease	-1	17496739
ection	I-Disease	-1	17496739
.	O	-1	17496739
The	O	-1	17496739
labor@@	O	-1	17496739
atory	O	-1	17496739
data	O	-1	17496739
revealed	O	-1	17496739
normal	O	-1	17496739
plasma	O	-1	17496739
electro@@	O	-1	17496739
ly@@	O	-1	17496739
te	O	-1	17496739
and	O	-1	17496739
am@@	B-Chemical	D000641	17496739
mon@@	I-Chemical	-1	17496739
ia	I-Chemical	-1	17496739
levels	O	-1	17496739
but	O	-1	17496739
leuk@@	B-Disease	D007964	17496739
ocyto@@	I-Disease	-1	17496739
sis	I-Disease	-1	17496739
.	O	-1	17496739
Ne@@	O	-1	17496739
uro@@	O	-1	17496739
log@@	O	-1	17496739
ic	O	-1	17496739
examin@@	O	-1	17496739
ations	O	-1	17496739
showed	O	-1	17496739
dys@@	B-Disease	D004401	17496739
arth@@	I-Disease	-1	17496739
ri@@	I-Disease	-1	17496739
a	I-Disease	-1	17496739
and	O	-1	17496739
bil@@	O	-1	17496739
ateral	O	-1	17496739
B@@	O	-1	17496739
ab@@	O	-1	17496739
in@@	O	-1	17496739
s@@	O	-1	17496739
k@@	O	-1	17496739
i	O	-1	17496739
sign@@	O	-1	17496739
.	O	-1	17496739
Com@@	O	-1	17496739
p@@	O	-1	17496739
ut@@	O	-1	17496739
ed	O	-1	17496739
to@@	O	-1	17496739
mo@@	O	-1	17496739
graph@@	O	-1	17496739
y	O	-1	17496739
of	O	-1	17496739
brain	O	-1	17496739
and	O	-1	17496739
electro@@	O	-1	17496739
encephalo@@	O	-1	17496739
gra@@	O	-1	17496739
m	O	-1	17496739
were	O	-1	17496739
un@@	O	-1	17496739
re@@	O	-1	17496739
mark@@	O	-1	17496739
able@@	O	-1	17496739
.	O	-1	17496739
D@@	O	-1	17496739
es@@	O	-1	17496739
pit@@	O	-1	17496739
e	O	-1	17496739
the	O	-1	17496739
use	O	-1	17496739
of	O	-1	17496739
anti@@	O	-1	17496739
epileptic	O	-1	17496739
agent@@	O	-1	17496739
s,	O	-1	17496739
an@@	O	-1	17496739
other	O	-1	17496739
G@@	B-Disease	D004830	17496739
T@@	I-Disease	-1	17496739
C@@	I-Disease	-1	17496739
S	I-Disease	-1	17496739
episo@@	O	-1	17496739
de	O	-1	17496739
recur@@	O	-1	17496739
red	O	-1	17496739
after	O	-1	17496739
the	O	-1	17496739
si@@	O	-1	17496739
x@@	O	-1	17496739
th	O	-1	17496739
dose	O	-1	17496739
of	O	-1	17496739
pi@@	B-Chemical	C085143	17496739
per@@	I-Chemical	-1	17496739
ac@@	I-Chemical	-1	17496739
ill@@	I-Chemical	-1	17496739
in@@	I-Chemical	-1	17496739
/@@	I-Chemical	-1	17496739
t@@	I-Chemical	-1	17496739
az@@	I-Chemical	-1	17496739
ob@@	I-Chemical	-1	17496739
act@@	I-Chemical	-1	17496739
am	I-Chemical	-1	17496739
.	O	-1	17496739
B@@	O	-1	17496739
ra@@	O	-1	17496739
in	O	-1	17496739
mag@@	O	-1	17496739
ne@@	O	-1	17496739
tic	O	-1	17496739
res@@	O	-1	17496739
on@@	O	-1	17496739
ance	O	-1	17496739
imaging	O	-1	17496739
did	O	-1	17496739
not	O	-1	17496739
demon@@	O	-1	17496739
st@@	O	-1	17496739
rate	O	-1	17496739
acute	O	-1	17496739
infarction	B-Disease	D007238	17496739
and	O	-1	17496739
org@@	B-Disease	-1	17496739
anic	I-Disease	-1	17496739
brain	I-Disease	-1	17496739
lesions	I-Disease	-1	17496739
.	O	-1	17496739
In@@	O	-1	17496739
iti@@	O	-1	17496739
ation	O	-1	17496739
of	O	-1	17496739
high-@@	O	-1	17496739
flu@@	O	-1	17496739
x	O	-1	17496739
hemo@@	O	-1	17496739
dialy@@	O	-1	17496739
sis	O	-1	17496739
ra@@	O	-1	17496739
pid@@	O	-1	17496739
ly	O	-1	17496739
reversed	O	-1	17496739
the	O	-1	17496739
neurolog@@	O	-1	17496739
ic	O	-1	17496739
symptoms	O	-1	17496739
within	O	-1	17496739
4	O	-1	17496739
hour@@	O	-1	17496739
s.	O	-1	17496739
P@@	B-Chemical	D010878	17496739
i@@	I-Chemical	-1	17496739
per@@	I-Chemical	-1	17496739
ac@@	I-Chemical	-1	17496739
ill@@	I-Chemical	-1	17496739
in	I-Chemical	-1	17496739
-induced	O	-1	17496739
encephalo@@	B-Disease	D001927	17496739
pathy	I-Disease	-1	17496739
should	O	-1	17496739
be	O	-1	17496739
considered	O	-1	17496739
in	O	-1	17496739
any	O	-1	17496739
ure@@	B-Disease	D006463	17496739
mic	I-Disease	-1	17496739
patients	O	-1	17496739
with	O	-1	17496739
un@@	O	-1	17496739
expl@@	O	-1	17496739
ained	O	-1	17496739
neurolog@@	O	-1	17496739
ical	O	-1	17496739
man@@	O	-1	17496739
if@@	O	-1	17496739
est@@	O	-1	17496739
ations.	O	-1	17496739
CA@@	O	-1	17496739
P@@	O	-1	17496739
D	O	-1	17496739
is	O	-1	17496739
ine@@	O	-1	17496739
ff@@	O	-1	17496739
ici@@	O	-1	17496739
ent	O	-1	17496739
in	O	-1	17496739
re@@	O	-1	17496739
mo@@	O	-1	17496739
ving	O	-1	17496739
pi@@	B-Chemical	D010878	17496739
per@@	I-Chemical	-1	17496739
ac@@	I-Chemical	-1	17496739
ill@@	I-Chemical	-1	17496739
in	I-Chemical	-1	17496739
,	O	-1	17496739
whereas	O	-1	17496739
hemo@@	O	-1	17496739
dialy@@	O	-1	17496739
sis	O	-1	17496739
can	O	-1	17496739
ra@@	O	-1	17496739
pid@@	O	-1	17496739
ly	O	-1	17496739
ter@@	O	-1	17496739
min@@	O	-1	17496739
ate	O	-1	17496739
the	O	-1	17496739
pi@@	B-Chemical	D010878	17496739
per@@	I-Chemical	-1	17496739
ac@@	I-Chemical	-1	17496739
ill@@	I-Chemical	-1	17496739
in	I-Chemical	-1	17496739
-induced	O	-1	17496739
encephalo@@	B-Disease	D001927	17496739
pathy	I-Disease	-1	17496739
.	O	-1	17496739

F@@	O	-1	17543491
requ@@	O	-1	17543491
ency	O	-1	17543491
of	O	-1	17543491
transi@@	O	-1	17543491
ent	O	-1	17543491
ip@@	O	-1	17543491
si@@	O	-1	17543491
lat@@	O	-1	17543491
eral	O	-1	17543491
v@@	B-Disease	D014826	17543491
oc@@	I-Disease	-1	17543491
al	I-Disease	-1	17543491
cor@@	I-Disease	-1	17543491
d	I-Disease	-1	17543491
par@@	I-Disease	-1	17543491
aly@@	I-Disease	-1	17543491
sis	I-Disease	-1	17543491
in	O	-1	17543491
patients	O	-1	17543491
under@@	O	-1	17543491
go@@	O	-1	17543491
ing	O	-1	17543491
ca@@	O	-1	17543491
ro@@	O	-1	17543491
ti@@	O	-1	17543491
d	O	-1	17543491
en@@	O	-1	17543491
d@@	O	-1	17543491
ar@@	O	-1	17543491
te@@	O	-1	17543491
rec@@	O	-1	17543491
to@@	O	-1	17543491
m@@	O	-1	17543491
y	O	-1	17543491
under	O	-1	17543491
loc@@	O	-1	17543491
al	O	-1	17543491
anesthe@@	O	-1	17543491
sia.	O	-1	17543491
BACKGROUND:	O	-1	17543491
E@@	O	-1	17543491
spec@@	O	-1	17543491
i@@	O	-1	17543491
ally	O	-1	17543491
because	O	-1	17543491
of	O	-1	17543491
impro@@	O	-1	17543491
ve@@	O	-1	17543491
ments	O	-1	17543491
in	O	-1	17543491
clinical	O	-1	17543491
neurolog@@	O	-1	17543491
ic	O	-1	17543491
monit@@	O	-1	17543491
or@@	O	-1	17543491
ing,	O	-1	17543491
ca@@	O	-1	17543491
ro@@	O	-1	17543491
ti@@	O	-1	17543491
d	O	-1	17543491
en@@	O	-1	17543491
d@@	O	-1	17543491
ar@@	O	-1	17543491
te@@	O	-1	17543491
rec@@	O	-1	17543491
to@@	O	-1	17543491
m@@	O	-1	17543491
y	O	-1	17543491
d@@	O	-1	17543491
one	O	-1	17543491
under	O	-1	17543491
loc@@	O	-1	17543491
al	O	-1	17543491
anesthe@@	O	-1	17543491
sia	O	-1	17543491
has	O	-1	17543491
b@@	O	-1	17543491
ec@@	O	-1	17543491
ome	O	-1	17543491
the	O	-1	17543491
t@@	O	-1	17543491
ech@@	O	-1	17543491
n@@	O	-1	17543491
i@@	O	-1	17543491
qu@@	O	-1	17543491
e	O	-1	17543491
of	O	-1	17543491
ch@@	O	-1	17543491
o@@	O	-1	17543491
ic@@	O	-1	17543491
e	O	-1	17543491
in	O	-1	17543491
several	O	-1	17543491
c@@	O	-1	17543491
ent@@	O	-1	17543491
ers.	O	-1	17543491
T@@	O	-1	17543491
em@@	O	-1	17543491
por@@	O	-1	17543491
ary	O	-1	17543491
ip@@	O	-1	17543491
si@@	O	-1	17543491
lat@@	O	-1	17543491
eral	O	-1	17543491
v@@	B-Disease	D014826	17543491
oc@@	I-Disease	-1	17543491
al	I-Disease	-1	17543491
nerve	I-Disease	-1	17543491
p@@	I-Disease	-1	17543491
al@@	I-Disease	-1	17543491
si@@	I-Disease	-1	17543491
es	I-Disease	-1	17543491
due	O	-1	17543491
to	O	-1	17543491
loc@@	O	-1	17543491
al	O	-1	17543491
anesthe@@	O	-1	17543491
tics	O	-1	17543491
have	O	-1	17543491
been	O	-1	17543491
descri@@	O	-1	17543491
be@@	O	-1	17543491
d,	O	-1	17543491
ho@@	O	-1	17543491
we@@	O	-1	17543491
ver@@	O	-1	17543491
.	O	-1	17543491
S@@	O	-1	17543491
uc@@	O	-1	17543491
h	O	-1	17543491
complications	O	-1	17543491
are	O	-1	17543491
most	O	-1	17543491
important	O	-1	17543491
in	O	-1	17543491
sit@@	O	-1	17543491
u@@	O	-1	17543491
ations	O	-1	17543491
wh@@	O	-1	17543491
ere	O	-1	17543491
there	O	-1	17543491
is	O	-1	17543491
a	O	-1	17543491
pre-@@	O	-1	17543491
ex@@	O	-1	17543491
ist@@	O	-1	17543491
ing	O	-1	17543491
contr@@	O	-1	17543491
al@@	O	-1	17543491
ateral	O	-1	17543491
par@@	B-Disease	D010243	17543491
aly@@	I-Disease	-1	17543491
sis	I-Disease	-1	17543491
.	O	-1	17543491
We	O	-1	17543491
the@@	O	-1	17543491
re@@	O	-1	17543491
fore	O	-1	17543491
examined	O	-1	17543491
the	O	-1	17543491
effect	O	-1	17543491
of	O	-1	17543491
loc@@	O	-1	17543491
al	O	-1	17543491
anesthe@@	O	-1	17543491
sia	O	-1	17543491
on	O	-1	17543491
v@@	O	-1	17543491
oc@@	O	-1	17543491
al	O	-1	17543491
cor@@	O	-1	17543491
d	O	-1	17543491
function	O	-1	17543491
to	O	-1	17543491
bet@@	O	-1	17543491
ter	O	-1	17543491
under@@	O	-1	17543491
st@@	O	-1	17543491
and	O	-1	17543491
its	O	-1	17543491
possible	O	-1	17543491
con@@	O	-1	17543491
sequ@@	O	-1	17543491
enc@@	O	-1	17543491
es.	O	-1	17543491
METHODS:	O	-1	17543491
This	O	-1	17543491
pro@@	O	-1	17543491
sp@@	O	-1	17543491
ective	O	-1	17543491
study	O	-1	17543491
included	O	-1	17543491
2@@	O	-1	17543491
8	O	-1	17543491
patients	O	-1	17543491
under@@	O	-1	17543491
go@@	O	-1	17543491
ing	O	-1	17543491
ca@@	O	-1	17543491
ro@@	O	-1	17543491
ti@@	O	-1	17543491
d	O	-1	17543491
en@@	O	-1	17543491
d@@	O	-1	17543491
ar@@	O	-1	17543491
te@@	O	-1	17543491
rec@@	O	-1	17543491
to@@	O	-1	17543491
m@@	O	-1	17543491
y	O	-1	17543491
under	O	-1	17543491
loc@@	O	-1	17543491
al	O	-1	17543491
anesthe@@	O	-1	17543491
sia.	O	-1	17543491
V@@	O	-1	17543491
oc@@	O	-1	17543491
al	O	-1	17543491
cor@@	O	-1	17543491
d	O	-1	17543491
function	O	-1	17543491
was	O	-1	17543491
evaluated	O	-1	17543491
be@@	O	-1	17543491
fo@@	O	-1	17543491
re,	O	-1	17543491
dur@@	O	-1	17543491
ing,	O	-1	17543491
and	O	-1	17543491
after	O	-1	17543491
surger@@	O	-1	17543491
y	O	-1	17543491
(@@	O	-1	17543491
postoperative	O	-1	17543491
day	O	-1	17543491
1)	O	-1	17543491
using	O	-1	17543491
f@@	O	-1	17543491
le@@	O	-1	17543491
xi@@	O	-1	17543491
ble	O	-1	17543491
l@@	O	-1	17543491
ar@@	O	-1	17543491
yn@@	O	-1	17543491
g@@	O	-1	17543491
os@@	O	-1	17543491
co@@	O	-1	17543491
p@@	O	-1	17543491
y.	O	-1	17543491
An@@	O	-1	17543491
esthe@@	O	-1	17543491
sia	O	-1	17543491
was	O	-1	17543491
performed	O	-1	17543491
by	O	-1	17543491
inj@@	O	-1	17543491
ect@@	O	-1	17543491
ing	O	-1	17543491
20	O	-1	17543491
to	O	-1	17543491
40	O	-1	17543491
m@@	O	-1	17543491
L	O	-1	17543491
of	O	-1	17543491
a	O	-1	17543491
mi@@	O	-1	17543491
x@@	O	-1	17543491
t@@	O	-1	17543491
ure	O	-1	17543491
of	O	-1	17543491
long@@	O	-1	17543491
-@@	O	-1	17543491
act@@	O	-1	17543491
ing	O	-1	17543491
(	O	-1	17543491
ro@@	B-Chemical	C037663	17543491
pivac@@	I-Chemical	-1	17543491
aine	I-Chemical	-1	17543491
)	O	-1	17543491
and	O	-1	17543491
sh@@	O	-1	17543491
ort@@	O	-1	17543491
-@@	O	-1	17543491
act@@	O	-1	17543491
ing	O	-1	17543491
(	O	-1	17543491
pri@@	B-Chemical	D011318	17543491
lo@@	I-Chemical	-1	17543491
ca@@	I-Chemical	-1	17543491
ine	I-Chemical	-1	17543491
)	O	-1	17543491
anesthe@@	O	-1	17543491
tic@@	O	-1	17543491
.	O	-1	17543491
RESULTS:	O	-1	17543491
All	O	-1	17543491
patients	O	-1	17543491
had	O	-1	17543491
normal	O	-1	17543491
v@@	O	-1	17543491
oc@@	O	-1	17543491
al	O	-1	17543491
cor@@	O	-1	17543491
d	O	-1	17543491
function	O	-1	17543491
pre@@	O	-1	17543491
o@@	O	-1	17543491
per@@	O	-1	17543491
ati@@	O	-1	17543491
vel@@	O	-1	17543491
y.	O	-1	17543491
T@@	O	-1	17543491
we@@	O	-1	17543491
l@@	O	-1	17543491
ve	O	-1	17543491
patients	O	-1	17543491
(4@@	O	-1	17543491
3@@	O	-1	17543491
%)	O	-1	17543491
were	O	-1	17543491
found	O	-1	17543491
to	O	-1	17543491
have	O	-1	17543491
intra@@	O	-1	17543491
o@@	O	-1	17543491
perative	O	-1	17543491
ip@@	O	-1	17543491
si@@	O	-1	17543491
lat@@	O	-1	17543491
eral	O	-1	17543491
v@@	B-Disease	D014826	17543491
oc@@	I-Disease	-1	17543491
al	I-Disease	-1	17543491
cor@@	I-Disease	-1	17543491
d	I-Disease	-1	17543491
par@@	I-Disease	-1	17543491
aly@@	I-Disease	-1	17543491
sis	I-Disease	-1	17543491
.	O	-1	17543491
It	O	-1	17543491
resol@@	O	-1	17543491
ved	O	-1	17543491
in	O	-1	17543491
all	O	-1	17543491
cases	O	-1	17543491
<	O	-1	17543491
or	O	-1	17543491
=@@	O	-1	17543491
24	O	-1	17543491
hour@@	O	-1	17543491
s.	O	-1	17543491
There	O	-1	17543491
were	O	-1	17543491
no	O	-1	17543491
significant	O	-1	17543491
differences	O	-1	17543491
in	O	-1	17543491
o@@	O	-1	17543491
per@@	O	-1	17543491
ating	O	-1	17543491
time	O	-1	17543491
or	O	-1	17543491
volume	O	-1	17543491
or	O	-1	17543491
frequency	O	-1	17543491
of	O	-1	17543491
anesthe@@	O	-1	17543491
tic	O	-1	17543491
administration	O	-1	17543491
in	O	-1	17543491
patients	O	-1	17543491
with	O	-1	17543491
tempor@@	O	-1	17543491
ary	O	-1	17543491
v@@	B-Disease	D014826	17543491
oc@@	I-Disease	-1	17543491
al	I-Disease	-1	17543491
cor@@	I-Disease	-1	17543491
d	I-Disease	-1	17543491
par@@	I-Disease	-1	17543491
aly@@	I-Disease	-1	17543491
sis	I-Disease	-1	17543491
compared	O	-1	17543491
with	O	-1	17543491
those	O	-1	17543491
with@@	O	-1	17543491
out@@	O	-1	17543491
.	O	-1	17543491
CONCLUSION:	O	-1	17543491
L@@	O	-1	17543491
oc@@	O	-1	17543491
al	O	-1	17543491
anesthe@@	O	-1	17543491
sia	O	-1	17543491
l@@	O	-1	17543491
ed	O	-1	17543491
to	O	-1	17543491
tempor@@	O	-1	17543491
ary	O	-1	17543491
ip@@	O	-1	17543491
si@@	O	-1	17543491
lat@@	O	-1	17543491
eral	O	-1	17543491
v@@	B-Disease	D014826	17543491
oc@@	I-Disease	-1	17543491
al	I-Disease	-1	17543491
cor@@	I-Disease	-1	17543491
d	I-Disease	-1	17543491
par@@	I-Disease	-1	17543491
aly@@	I-Disease	-1	17543491
sis	I-Disease	-1	17543491
in	O	-1	17543491
al@@	O	-1	17543491
most	O	-1	17543491
h@@	O	-1	17543491
al@@	O	-1	17543491
f	O	-1	17543491
of	O	-1	17543491
these	O	-1	17543491
patients.	O	-1	17543491
B@@	O	-1	17543491
ecause	O	-1	17543491
pre-@@	O	-1	17543491
ex@@	O	-1	17543491
ist@@	O	-1	17543491
ing	O	-1	17543491
par@@	B-Disease	D010243	17543491
aly@@	I-Disease	-1	17543491
sis	I-Disease	-1	17543491
is	O	-1	17543491
of	O	-1	17543491
a	O	-1	17543491
re@@	O	-1	17543491
lev@@	O	-1	17543491
ant	O	-1	17543491
frequency	O	-1	17543491
(@@	O	-1	17543491
up	O	-1	17543491
to	O	-1	17543491
3@@	O	-1	17543491
%),	O	-1	17543491
a	O	-1	17543491
pre@@	O	-1	17543491
o@@	O	-1	17543491
perative	O	-1	17543491
evalu@@	O	-1	17543491
ation	O	-1	17543491
of	O	-1	17543491
v@@	O	-1	17543491
oc@@	O	-1	17543491
al	O	-1	17543491
cor@@	O	-1	17543491
d	O	-1	17543491
function	O	-1	17543491
before	O	-1	17543491
ca@@	O	-1	17543491
ro@@	O	-1	17543491
ti@@	O	-1	17543491
d	O	-1	17543491
en@@	O	-1	17543491
d@@	O	-1	17543491
ar@@	O	-1	17543491
te@@	O	-1	17543491
rec@@	O	-1	17543491
to@@	O	-1	17543491
m@@	O	-1	17543491
y	O	-1	17543491
under	O	-1	17543491
loc@@	O	-1	17543491
al	O	-1	17543491
anesthe@@	O	-1	17543491
sia	O	-1	17543491
is	O	-1	17543491
recomm@@	O	-1	17543491
en@@	O	-1	17543491
ded	O	-1	17543491
to	O	-1	17543491
av@@	O	-1	17543491
oid	O	-1	17543491
intra@@	O	-1	17543491
o@@	O	-1	17543491
perative	O	-1	17543491
bil@@	O	-1	17543491
ateral	O	-1	17543491
par@@	B-Disease	D010243	17543491
aly@@	I-Disease	-1	17543491
sis	I-Disease	-1	17543491
.	O	-1	17543491
In	O	-1	17543491
patients	O	-1	17543491
with	O	-1	17543491
pre@@	O	-1	17543491
o@@	O	-1	17543491
perative	O	-1	17543491
contr@@	O	-1	17543491
al@@	O	-1	17543491
ateral	O	-1	17543491
v@@	B-Disease	D014826	17543491
oc@@	I-Disease	-1	17543491
al	I-Disease	-1	17543491
cor@@	I-Disease	-1	17543491
d	I-Disease	-1	17543491
par@@	I-Disease	-1	17543491
aly@@	I-Disease	-1	17543491
sis	I-Disease	-1	17543491
,	O	-1	17543491
surger@@	O	-1	17543491
y	O	-1	17543491
under	O	-1	17543491
gener@@	O	-1	17543491
al	O	-1	17543491
anesthe@@	O	-1	17543491
sia	O	-1	17543491
should	O	-1	17543491
be	O	-1	17543491
conside@@	O	-1	17543491
red.	O	-1	17543491

Ne@@	O	-1	17572393
uro@@	O	-1	17572393
protective	O	-1	17572393
effects	O	-1	17572393
of	O	-1	17572393
me@@	B-Chemical	D008550	17572393
lat@@	I-Chemical	-1	17572393
on@@	I-Chemical	-1	17572393
in	I-Chemical	-1	17572393
up@@	O	-1	17572393
on	O	-1	17572393
the	O	-1	17572393
o@@	O	-1	17572393
ff@@	O	-1	17572393
sp@@	O	-1	17572393
r@@	O	-1	17572393
ing	O	-1	17572393
ce@@	O	-1	17572393
re@@	O	-1	17572393
bell@@	O	-1	17572393
ar	O	-1	17572393
cor@@	O	-1	17572393
te@@	O	-1	17572393
x	O	-1	17572393
in	O	-1	17572393
the	O	-1	17572393
rat	O	-1	17572393
model	O	-1	17572393
of	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
-induced	O	-1	17572393
cor@@	B-Disease	D054220	17572393
tical	I-Disease	-1	17572393
dys@@	I-Disease	-1	17572393
pl@@	I-Disease	-1	17572393
a@@	I-Disease	-1	17572393
sia	I-Disease	-1	17572393
.	O	-1	17572393
C@@	B-Disease	D054220	17572393
or@@	I-Disease	-1	17572393
tical	I-Disease	-1	17572393
dys@@	I-Disease	-1	17572393
pl@@	I-Disease	-1	17572393
a@@	I-Disease	-1	17572393
sia	I-Disease	-1	17572393
is	O	-1	17572393
a	O	-1	17572393
mal@@	O	-1	17572393
formation	O	-1	17572393
character@@	O	-1	17572393
ized	O	-1	17572393
by	O	-1	17572393
def@@	O	-1	17572393
ects	O	-1	17572393
in	O	-1	17572393
pro@@	O	-1	17572393
li@@	O	-1	17572393
fer@@	O	-1	17572393
ation,	O	-1	17572393
mi@@	O	-1	17572393
g@@	O	-1	17572393
ration	O	-1	17572393
and	O	-1	17572393
mat@@	O	-1	17572393
ur@@	O	-1	17572393
ation.	O	-1	17572393
This	O	-1	17572393
study	O	-1	17572393
was	O	-1	17572393
de@@	O	-1	17572393
signed	O	-1	17572393
to	O	-1	17572393
evalu@@	O	-1	17572393
ate	O	-1	17572393
the	O	-1	17572393
al@@	O	-1	17572393
ter@@	O	-1	17572393
ations	O	-1	17572393
in	O	-1	17572393
o@@	O	-1	17572393
ff@@	O	-1	17572393
sp@@	O	-1	17572393
r@@	O	-1	17572393
ing	O	-1	17572393
rat	O	-1	17572393
ce@@	O	-1	17572393
re@@	O	-1	17572393
bell@@	O	-1	17572393
um	O	-1	17572393
induced	O	-1	17572393
by	O	-1	17572393
mat@@	O	-1	17572393
er@@	O	-1	17572393
n@@	O	-1	17572393
al	O	-1	17572393
exposure	O	-1	17572393
to	O	-1	17572393
car@@	B-Chemical	D002330	17572393
m@@	I-Chemical	-1	17572393
ust@@	I-Chemical	-1	17572393
ine	I-Chemical	-1	17572393
-@@	O	-1	17572393
[	O	-1	17572393
1@@	B-Chemical	D002330	17572393
,@@	I-Chemical	-1	17572393
3-@@	I-Chemical	-1	17572393
b@@	I-Chemical	-1	17572393
is	I-Chemical	-1	17572393
(2@@	I-Chemical	-1	17572393
-@@	I-Chemical	-1	17572393
ch@@	I-Chemical	-1	17572393
loro@@	I-Chemical	-1	17572393
eth@@	I-Chemical	-1	17572393
yl@@	I-Chemical	-1	17572393
)@@	I-Chemical	-1	17572393
-1@@	I-Chemical	-1	17572393
-@@	I-Chemical	-1	17572393
nit@@	I-Chemical	-1	17572393
ros@@	I-Chemical	-1	17572393
o@@	I-Chemical	-1	17572393
ure	I-Chemical	-1	17572393
]	O	-1	17572393
(	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
)	O	-1	17572393
and	O	-1	17572393
to	O	-1	17572393
investigate	O	-1	17572393
the	O	-1	17572393
effects	O	-1	17572393
of	O	-1	17572393
ex@@	O	-1	17572393
o@@	O	-1	17572393
gen@@	O	-1	17572393
ous	O	-1	17572393
me@@	B-Chemical	D008550	17572393
lat@@	I-Chemical	-1	17572393
on@@	I-Chemical	-1	17572393
in	I-Chemical	-1	17572393
up@@	O	-1	17572393
on	O	-1	17572393
ce@@	O	-1	17572393
re@@	O	-1	17572393
bell@@	O	-1	17572393
ar	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
-induced	O	-1	17572393
cor@@	B-Disease	D054220	17572393
tical	I-Disease	-1	17572393
dys@@	I-Disease	-1	17572393
pl@@	I-Disease	-1	17572393
a@@	I-Disease	-1	17572393
sia	I-Disease	-1	17572393
,	O	-1	17572393
using	O	-1	17572393
hist@@	O	-1	17572393
ological	O	-1	17572393
and	O	-1	17572393
bio@@	O	-1	17572393
chemical	O	-1	17572393
an@@	O	-1	17572393
al@@	O	-1	17572393
ys@@	O	-1	17572393
es.	O	-1	17572393
Pre@@	O	-1	17572393
gn@@	O	-1	17572393
ant	O	-1	17572393
Wistar	O	-1	17572393
rats	O	-1	17572393
were	O	-1	17572393
as@@	O	-1	17572393
signed	O	-1	17572393
to	O	-1	17572393
five	O	-1	17572393
group@@	O	-1	17572393
s:	O	-1	17572393
int@@	O	-1	17572393
act@@	O	-1	17572393
-@@	O	-1	17572393
control@@	O	-1	17572393
,	O	-1	17572393
sal@@	O	-1	17572393
ine-@@	O	-1	17572393
control@@	O	-1	17572393
,	O	-1	17572393
me@@	B-Chemical	D008550	17572393
lat@@	I-Chemical	-1	17572393
on@@	I-Chemical	-1	17572393
in	I-Chemical	-1	17572393
-@@	O	-1	17572393
treat@@	O	-1	17572393
ed,	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
-@@	O	-1	17572393
exposed	O	-1	17572393
and	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
-@@	O	-1	17572393
exposed	O	-1	17572393
plus	O	-1	17572393
me@@	B-Chemical	D008550	17572393
lat@@	I-Chemical	-1	17572393
on@@	I-Chemical	-1	17572393
in	I-Chemical	-1	17572393
.	O	-1	17572393
R@@	O	-1	17572393
at@@	O	-1	17572393
s	O	-1	17572393
were	O	-1	17572393
exposed	O	-1	17572393
to	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
on	O	-1	17572393
emb@@	O	-1	17572393
r@@	O	-1	17572393
y@@	O	-1	17572393
onic	O	-1	17572393
day	O	-1	17572393
15	O	-1	17572393
and	O	-1	17572393
me@@	B-Chemical	D008550	17572393
lat@@	I-Chemical	-1	17572393
on@@	I-Chemical	-1	17572393
in	I-Chemical	-1	17572393
was	O	-1	17572393
given	O	-1	17572393
un@@	O	-1	17572393
ti@@	O	-1	17572393
l	O	-1	17572393
de@@	O	-1	17572393
li@@	O	-1	17572393
ver@@	O	-1	17572393
y.	O	-1	17572393
Im@@	O	-1	17572393
mun@@	O	-1	17572393
o@@	O	-1	17572393
/@@	O	-1	17572393
histo@@	O	-1	17572393
chem@@	O	-1	17572393
ist@@	O	-1	17572393
r@@	O	-1	17572393
y	O	-1	17572393
and	O	-1	17572393
electro@@	O	-1	17572393
n	O	-1	17572393
micro@@	O	-1	17572393
sco@@	O	-1	17572393
p@@	O	-1	17572393
y	O	-1	17572393
were	O	-1	17572393
car@@	O	-1	17572393
ri@@	O	-1	17572393
ed	O	-1	17572393
out	O	-1	17572393
on	O	-1	17572393
the	O	-1	17572393
o@@	O	-1	17572393
ff@@	O	-1	17572393
sp@@	O	-1	17572393
r@@	O	-1	17572393
ing	O	-1	17572393
ce@@	O	-1	17572393
re@@	O	-1	17572393
bell@@	O	-1	17572393
um,	O	-1	17572393
and	O	-1	17572393
levels	O	-1	17572393
of	O	-1	17572393
mal@@	B-Chemical	D008315	17572393
on@@	I-Chemical	-1	17572393
di@@	I-Chemical	-1	17572393
al@@	I-Chemical	-1	17572393
de@@	I-Chemical	-1	17572393
hy@@	I-Chemical	-1	17572393
de	I-Chemical	-1	17572393
and	O	-1	17572393
su@@	B-Chemical	D013481	17572393
per@@	I-Chemical	-1	17572393
ox@@	I-Chemical	-1	17572393
ide	I-Chemical	-1	17572393
dis@@	O	-1	17572393
mut@@	O	-1	17572393
ase	O	-1	17572393
were	O	-1	17572393
deter@@	O	-1	17572393
m@@	O	-1	17572393
ine@@	O	-1	17572393
d.	O	-1	17572393
H@@	O	-1	17572393
ist@@	O	-1	17572393
o@@	O	-1	17572393
path@@	O	-1	17572393
olog@@	O	-1	17572393
ic@@	O	-1	17572393
ally,	O	-1	17572393
typ@@	O	-1	17572393
ical	O	-1	17572393
findings	O	-1	17572393
were	O	-1	17572393
observed	O	-1	17572393
in	O	-1	17572393
the	O	-1	17572393
ce@@	O	-1	17572393
re@@	O	-1	17572393
bell@@	O	-1	17572393
a	O	-1	17572393
from	O	-1	17572393
the	O	-1	17572393
control	O	-1	17572393
group@@	O	-1	17572393
s,	O	-1	17572393
but	O	-1	17572393
the	O	-1	17572393
findings	O	-1	17572393
consist@@	O	-1	17572393
ent	O	-1	17572393
with	O	-1	17572393
early	O	-1	17572393
emb@@	O	-1	17572393
r@@	O	-1	17572393
y@@	O	-1	17572393
onic	O	-1	17572393
development	O	-1	17572393
were	O	-1	17572393
not@@	O	-1	17572393
ed	O	-1	17572393
in	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
-@@	O	-1	17572393
exposed	O	-1	17572393
cor@@	B-Disease	D054220	17572393
tical	I-Disease	-1	17572393
dys@@	I-Disease	-1	17572393
pl@@	I-Disease	-1	17572393
a@@	I-Disease	-1	17572393
sia	I-Disease	-1	17572393
group.	O	-1	17572393
There	O	-1	17572393
was	O	-1	17572393
a	O	-1	17572393
mark@@	O	-1	17572393
ed	O	-1	17572393
increase	O	-1	17572393
in	O	-1	17572393
the	O	-1	17572393
number	O	-1	17572393
of	O	-1	17572393
T@@	O	-1	17572393
UN@@	O	-1	17572393
E@@	O	-1	17572393
L	O	-1	17572393
positive	O	-1	17572393
cells	O	-1	17572393
and	O	-1	17572393
n@@	O	-1	17572393
es@@	O	-1	17572393
tin	O	-1	17572393
positive	O	-1	17572393
cells	O	-1	17572393
in	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
-@@	O	-1	17572393
exposed	O	-1	17572393
group@@	O	-1	17572393
,	O	-1	17572393
but	O	-1	17572393
a	O	-1	17572393
decreased	O	-1	17572393
immuno@@	O	-1	17572393
re@@	O	-1	17572393
activity	O	-1	17572393
to	O	-1	17572393
g@@	O	-1	17572393
lial	O	-1	17572393
fibrill@@	O	-1	17572393
ary	O	-1	17572393
ac@@	O	-1	17572393
i@@	O	-1	17572393
di@@	O	-1	17572393
c	O	-1	17572393
protein@@	O	-1	17572393
,	O	-1	17572393
syn@@	O	-1	17572393
ap@@	O	-1	17572393
to@@	O	-1	17572393
ph@@	O	-1	17572393
ys@@	O	-1	17572393
in	O	-1	17572393
and	O	-1	17572393
trans@@	O	-1	17572393
form@@	O	-1	17572393
ing	O	-1	17572393
growth	O	-1	17572393
factor	O	-1	17572393
beta@@	O	-1	17572393
1	O	-1	17572393
was	O	-1	17572393
obser@@	O	-1	17572393
ve@@	O	-1	17572393
d,	O	-1	17572393
indicating	O	-1	17572393
a	O	-1	17572393
del@@	O	-1	17572393
ayed	O	-1	17572393
mat@@	O	-1	17572393
ur@@	O	-1	17572393
ation,	O	-1	17572393
and	O	-1	17572393
me@@	B-Chemical	D008550	17572393
lat@@	I-Chemical	-1	17572393
on@@	I-Chemical	-1	17572393
in	I-Chemical	-1	17572393
significantly	O	-1	17572393
reversed	O	-1	17572393
these	O	-1	17572393
chang@@	O	-1	17572393
es.	O	-1	17572393
M@@	B-Chemical	D008315	17572393
al@@	I-Chemical	-1	17572393
on@@	I-Chemical	-1	17572393
di@@	I-Chemical	-1	17572393
al@@	I-Chemical	-1	17572393
de@@	I-Chemical	-1	17572393
hy@@	I-Chemical	-1	17572393
de	I-Chemical	-1	17572393
level	O	-1	17572393
in	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
-@@	O	-1	17572393
exposed	O	-1	17572393
group	O	-1	17572393
was	O	-1	17572393
higher	O	-1	17572393
than	O	-1	17572393
those	O	-1	17572393
in	O	-1	17572393
control	O	-1	17572393
groups	O	-1	17572393
and	O	-1	17572393
me@@	B-Chemical	D008550	17572393
lat@@	I-Chemical	-1	17572393
on@@	I-Chemical	-1	17572393
in	I-Chemical	-1	17572393
decreased	O	-1	17572393
mal@@	B-Chemical	D008315	17572393
on@@	I-Chemical	-1	17572393
di@@	I-Chemical	-1	17572393
al@@	I-Chemical	-1	17572393
de@@	I-Chemical	-1	17572393
hy@@	I-Chemical	-1	17572393
de	I-Chemical	-1	17572393
levels	O	-1	17572393
in	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
group	O	-1	17572393
(P@@	O	-1	17572393
<@@	O	-1	17572393
0.0@@	O	-1	17572393
1),	O	-1	17572393
while	O	-1	17572393
there	O	-1	17572393
were	O	-1	17572393
no	O	-1	17572393
significant	O	-1	17572393
differences	O	-1	17572393
in	O	-1	17572393
the	O	-1	17572393
su@@	B-Chemical	D013481	17572393
per@@	I-Chemical	-1	17572393
ox@@	I-Chemical	-1	17572393
ide	I-Chemical	-1	17572393
dis@@	O	-1	17572393
mut@@	O	-1	17572393
ase	O	-1	17572393
levels	O	-1	17572393
between	O	-1	17572393
these	O	-1	17572393
groups.	O	-1	17572393
These	O	-1	17572393
data	O	-1	17572393
suggest	O	-1	17572393
that	O	-1	17572393
exposure	O	-1	17572393
of	O	-1	17572393
animals	O	-1	17572393
to	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
during	O	-1	17572393
pregn@@	O	-1	17572393
anc@@	O	-1	17572393
y	O	-1	17572393
lead@@	O	-1	17572393
s	O	-1	17572393
to	O	-1	17572393
del@@	O	-1	17572393
ayed	O	-1	17572393
mat@@	O	-1	17572393
ur@@	O	-1	17572393
ation	O	-1	17572393
of	O	-1	17572393
o@@	O	-1	17572393
ff@@	O	-1	17572393
sp@@	O	-1	17572393
r@@	O	-1	17572393
ing	O	-1	17572393
ce@@	O	-1	17572393
re@@	O	-1	17572393
bell@@	O	-1	17572393
um	O	-1	17572393
and	O	-1	17572393
me@@	B-Chemical	D008550	17572393
lat@@	I-Chemical	-1	17572393
on@@	I-Chemical	-1	17572393
in	I-Chemical	-1	17572393
prot@@	O	-1	17572393
ects	O	-1	17572393
the	O	-1	17572393
ce@@	O	-1	17572393
re@@	O	-1	17572393
bell@@	O	-1	17572393
um	O	-1	17572393
against	O	-1	17572393
the	O	-1	17572393
effects	O	-1	17572393
of	O	-1	17572393
BC@@	B-Chemical	D002330	17572393
N@@	I-Chemical	-1	17572393
U	I-Chemical	-1	17572393
.	O	-1	17572393

M@@	B-Chemical	C002647	17828434
yo@@	I-Chemical	-1	17828434
-@@	I-Chemical	-1	17828434
in@@	I-Chemical	-1	17828434
os@@	I-Chemical	-1	17828434
it@@	I-Chemical	-1	17828434
ol@@	I-Chemical	-1	17828434
-1@@	I-Chemical	-1	17828434
-@@	I-Chemical	-1	17828434
phosph@@	I-Chemical	-1	17828434
ate	I-Chemical	-1	17828434
(	O	-1	17828434
M@@	B-Chemical	C002647	17828434
I@@	I-Chemical	-1	17828434
P	I-Chemical	-1	17828434
)	O	-1	17828434
syn@@	O	-1	17828434
th@@	O	-1	17828434
ase	O	-1	17828434
inhib@@	O	-1	17828434
i@@	O	-1	17828434
tion@@	O	-1	17828434
:	O	-1	17828434
in-@@	O	-1	17828434
viv@@	O	-1	17828434
o	O	-1	17828434
study	O	-1	17828434
in	O	-1	17828434
rats.	O	-1	17828434
L@@	B-Chemical	D008094	17828434
i@@	I-Chemical	-1	17828434
thi@@	I-Chemical	-1	17828434
um	I-Chemical	-1	17828434
and	O	-1	17828434
valpro@@	B-Chemical	D014635	17828434
ate	I-Chemical	-1	17828434
are	O	-1	17828434
the	O	-1	17828434
prot@@	O	-1	17828434
ot@@	O	-1	17828434
yp@@	O	-1	17828434
ic	O	-1	17828434
mo@@	O	-1	17828434
od	O	-1	17828434
st@@	O	-1	17828434
abil@@	O	-1	17828434
iz@@	O	-1	17828434
ers	O	-1	17828434
and	O	-1	17828434
have	O	-1	17828434
di@@	O	-1	17828434
verse	O	-1	17828434
struct@@	O	-1	17828434
ures	O	-1	17828434
and	O	-1	17828434
t@@	O	-1	17828434
arg@@	O	-1	17828434
et@@	O	-1	17828434
s.	O	-1	17828434
B@@	O	-1	17828434
oth	O	-1	17828434
drugs	O	-1	17828434
influence	O	-1	17828434
in@@	B-Chemical	D007294	17828434
os@@	I-Chemical	-1	17828434
it@@	I-Chemical	-1	17828434
ol	I-Chemical	-1	17828434
metabol@@	O	-1	17828434
is@@	O	-1	17828434
m.	O	-1	17828434
L@@	B-Chemical	D008094	17828434
i@@	I-Chemical	-1	17828434
thi@@	I-Chemical	-1	17828434
um	I-Chemical	-1	17828434
inhibit@@	O	-1	17828434
s	O	-1	17828434
I@@	O	-1	17828434
MP@@	O	-1	17828434
ase	O	-1	17828434
and	O	-1	17828434
valpro@@	B-Chemical	D014635	17828434
ate	I-Chemical	-1	17828434
inhibit@@	O	-1	17828434
s	O	-1	17828434
M@@	B-Chemical	C002647	17828434
I@@	I-Chemical	-1	17828434
P	I-Chemical	-1	17828434
syn@@	O	-1	17828434
th@@	O	-1	17828434
as@@	O	-1	17828434
e.	O	-1	17828434
This	O	-1	17828434
study	O	-1	17828434
show@@	O	-1	17828434
s	O	-1	17828434
that	O	-1	17828434
M@@	B-Chemical	C002647	17828434
I@@	I-Chemical	-1	17828434
P	I-Chemical	-1	17828434
syn@@	O	-1	17828434
th@@	O	-1	17828434
ase	O	-1	17828434
inhibition	O	-1	17828434
does	O	-1	17828434
not	O	-1	17828434
re@@	O	-1	17828434
plic@@	O	-1	17828434
ate	O	-1	17828434
or	O	-1	17828434
au@@	O	-1	17828434
g@@	O	-1	17828434
ment	O	-1	17828434
the	O	-1	17828434
effects	O	-1	17828434
of	O	-1	17828434
lithium	B-Chemical	D008094	17828434
in	O	-1	17828434
the	O	-1	17828434
in@@	B-Chemical	D007294	17828434
os@@	I-Chemical	-1	17828434
it@@	I-Chemical	-1	17828434
ol	I-Chemical	-1	17828434
sensitive	O	-1	17828434
pilocar@@	B-Chemical	D010862	17828434
pine	I-Chemical	-1	17828434
-induced	O	-1	17828434
seizures	B-Disease	D012640	17828434
model@@	O	-1	17828434
.	O	-1	17828434
This	O	-1	17828434
l@@	O	-1	17828434
ac@@	O	-1	17828434
k	O	-1	17828434
of	O	-1	17828434
effects	O	-1	17828434
may	O	-1	17828434
st@@	O	-1	17828434
em	O	-1	17828434
from	O	-1	17828434
the	O	-1	17828434
low	O	-1	17828434
cont@@	O	-1	17828434
ri@@	O	-1	17828434
bu@@	O	-1	17828434
tion	O	-1	17828434
of	O	-1	17828434
de@@	O	-1	17828434
-@@	O	-1	17828434
no@@	O	-1	17828434
v@@	O	-1	17828434
o	O	-1	17828434
syn@@	O	-1	17828434
thesis	O	-1	17828434
to	O	-1	17828434
cell@@	O	-1	17828434
ular	O	-1	17828434
in@@	B-Chemical	D007294	17828434
os@@	I-Chemical	-1	17828434
it@@	I-Chemical	-1	17828434
ol	I-Chemical	-1	17828434
sup@@	O	-1	17828434
p@@	O	-1	17828434
ly	O	-1	17828434
or	O	-1	17828434
to	O	-1	17828434
the	O	-1	17828434
inhibition	O	-1	17828434
of	O	-1	17828434
the	O	-1	17828434
de@@	O	-1	17828434
-@@	O	-1	17828434
no@@	O	-1	17828434
v@@	O	-1	17828434
o	O	-1	17828434
syn@@	O	-1	17828434
thesis	O	-1	17828434
by	O	-1	17828434
lithium	B-Chemical	D008094	17828434
it@@	O	-1	17828434
sel@@	O	-1	17828434
f@@	O	-1	17828434
.	O	-1	17828434

N@@	O	-1	17879100
on@@	O	-1	17879100
-@@	O	-1	17879100
steroid@@	O	-1	17879100
al	O	-1	17879100
anti@@	O	-1	17879100
-@@	O	-1	17879100
inflam@@	O	-1	17879100
mat@@	O	-1	17879100
ory	O	-1	17879100
drug@@	O	-1	17879100
s-@@	O	-1	17879100
associated	O	-1	17879100
acute	O	-1	17879100
interstitial	B-Disease	D009395	17879100
neph@@	I-Disease	-1	17879100
ritis	I-Disease	-1	17879100
with	O	-1	17879100
gran@@	O	-1	17879100
ular	O	-1	17879100
tub@@	O	-1	17879100
ular	O	-1	17879100
bas@@	O	-1	17879100
ement	O	-1	17879100
membran@@	O	-1	17879100
e	O	-1	17879100
de@@	O	-1	17879100
pos@@	O	-1	17879100
it@@	O	-1	17879100
s.	O	-1	17879100
Ac@@	B-Disease	C564356	17879100
ute	I-Disease	-1	17879100
tu@@	I-Disease	-1	17879100
bu@@	I-Disease	-1	17879100
lo@@	I-Disease	-1	17879100
-@@	I-Disease	-1	17879100
interstitial	I-Disease	-1	17879100
neph@@	I-Disease	-1	17879100
ritis	I-Disease	-1	17879100
(	O	-1	17879100
A@@	B-Disease	C564356	17879100
TI@@	I-Disease	-1	17879100
N	I-Disease	-1	17879100
)	O	-1	17879100
is	O	-1	17879100
an	O	-1	17879100
important	O	-1	17879100
cause	O	-1	17879100
of	O	-1	17879100
acute	B-Disease	D058186	17879100
renal	I-Disease	-1	17879100
failure	I-Disease	-1	17879100
result@@	O	-1	17879100
ing	O	-1	17879100
from	O	-1	17879100
a	O	-1	17879100
vari@@	O	-1	17879100
ety	O	-1	17879100
of	O	-1	17879100
in@@	O	-1	17879100
s@@	O	-1	17879100
ult@@	O	-1	17879100
s,	O	-1	17879100
including	O	-1	17879100
immun@@	O	-1	17879100
e	O	-1	17879100
comple@@	O	-1	17879100
x@@	O	-1	17879100
-@@	O	-1	17879100
mediated	O	-1	17879100
tu@@	B-Disease	D009395	17879100
bu@@	I-Disease	-1	17879100
lo@@	I-Disease	-1	17879100
-@@	I-Disease	-1	17879100
interstitial	I-Disease	-1	17879100
injury	I-Disease	-1	17879100
,	O	-1	17879100
but	O	-1	17879100
drugs	O	-1	17879100
such	O	-1	17879100
as	O	-1	17879100
non-@@	O	-1	17879100
steroid@@	O	-1	17879100
al	O	-1	17879100
anti@@	O	-1	17879100
-@@	O	-1	17879100
inflam@@	O	-1	17879100
mat@@	O	-1	17879100
ory	O	-1	17879100
drugs	O	-1	17879100
(N@@	O	-1	17879100
S@@	O	-1	17879100
A@@	O	-1	17879100
I@@	O	-1	17879100
D@@	O	-1	17879100
s)	O	-1	17879100
are	O	-1	17879100
a	O	-1	17879100
f@@	O	-1	17879100
ar	O	-1	17879100
more	O	-1	17879100
frequent	O	-1	17879100
ca@@	O	-1	17879100
use.	O	-1	17879100
O@@	O	-1	17879100
ver@@	O	-1	17879100
all@@	O	-1	17879100
,	O	-1	17879100
as	O	-1	17879100
an	O	-1	17879100
enti@@	O	-1	17879100
t@@	O	-1	17879100
y,	O	-1	17879100
A@@	B-Disease	C564356	17879100
TI@@	I-Disease	-1	17879100
N	I-Disease	-1	17879100
remain@@	O	-1	17879100
s	O	-1	17879100
under@@	O	-1	17879100
-@@	O	-1	17879100
diagno@@	O	-1	17879100
se@@	O	-1	17879100
d,	O	-1	17879100
as	O	-1	17879100
symptoms	O	-1	17879100
resol@@	O	-1	17879100
ve	O	-1	17879100
spont@@	O	-1	17879100
ane@@	O	-1	17879100
ously	O	-1	17879100
if	O	-1	17879100
the	O	-1	17879100
medic@@	O	-1	17879100
ation	O	-1	17879100
is	O	-1	17879100
sto@@	O	-1	17879100
pp@@	O	-1	17879100
ed.	O	-1	17879100
We	O	-1	17879100
report	O	-1	17879100
on	O	-1	17879100
a	O	-1	17879100
1@@	O	-1	17879100
4-@@	O	-1	17879100
year-old	O	-1	17879100
bo@@	O	-1	17879100
y	O	-1	17879100
who	O	-1	17879100
developed	O	-1	17879100
acute	B-Disease	D058186	17879100
renal	I-Disease	-1	17879100
failure	I-Disease	-1	17879100
2	O	-1	17879100
weeks	O	-1	17879100
after	O	-1	17879100
a@@	O	-1	17879100
or@@	O	-1	17879100
tic	O	-1	17879100
val@@	O	-1	17879100
ve	O	-1	17879100
surger@@	O	-1	17879100
y.	O	-1	17879100
H@@	O	-1	17879100
e	O	-1	17879100
was	O	-1	17879100
pu@@	O	-1	17879100
t	O	-1	17879100
on	O	-1	17879100
as@@	B-Chemical	D001241	17879100
pi@@	I-Chemical	-1	17879100
rin	I-Chemical	-1	17879100
following	O	-1	17879100
surger@@	O	-1	17879100
y	O	-1	17879100
and	O	-1	17879100
to@@	O	-1	17879100
o@@	O	-1	17879100
k	O	-1	17879100
i@@	B-Chemical	D007052	17879100
bu@@	I-Chemical	-1	17879100
prof@@	I-Chemical	-1	17879100
en	I-Chemical	-1	17879100
for	O	-1	17879100
f@@	B-Disease	D005334	17879100
ev@@	I-Disease	-1	17879100
er	I-Disease	-1	17879100
for	O	-1	17879100
ne@@	O	-1	17879100
arly	O	-1	17879100
a	O	-1	17879100
week	O	-1	17879100
prior	O	-1	17879100
to	O	-1	17879100
present@@	O	-1	17879100
ation.	O	-1	17879100
H@@	O	-1	17879100
e	O	-1	17879100
then	O	-1	17879100
presented	O	-1	17879100
to	O	-1	17879100
the	O	-1	17879100
em@@	O	-1	17879100
er@@	O	-1	17879100
gen@@	O	-1	17879100
c@@	O	-1	17879100
y	O	-1	17879100
de@@	O	-1	17879100
part@@	O	-1	17879100
ment	O	-1	17879100
fe@@	O	-1	17879100
el@@	O	-1	17879100
ing	O	-1	17879100
qu@@	O	-1	17879100
ite	O	-1	17879100
il@@	O	-1	17879100
l	O	-1	17879100
and	O	-1	17879100
was	O	-1	17879100
found	O	-1	17879100
to	O	-1	17879100
have	O	-1	17879100
a	O	-1	17879100
blood	B-Chemical	D001806	17879100
ure@@	I-Chemical	-1	17879100
a	I-Chemical	-1	17879100
nitro@@	I-Chemical	-1	17879100
gen	I-Chemical	-1	17879100
(	O	-1	17879100
B@@	B-Chemical	D001806	17879100
U@@	I-Chemical	-1	17879100
N	I-Chemical	-1	17879100
)	O	-1	17879100
concentration	O	-1	17879100
of	O	-1	17879100
of	O	-1	17879100
14@@	O	-1	17879100
7	O	-1	17879100
mg/d@@	O	-1	17879100
l@@	O	-1	17879100
,	O	-1	17879100
creatinine	B-Chemical	D003404	17879100
of	O	-1	17879100
1@@	O	-1	17879100
5.@@	O	-1	17879100
3	O	-1	17879100
mg/d@@	O	-1	17879100
l	O	-1	17879100
and	O	-1	17879100
serum	O	-1	17879100
pot@@	B-Chemical	D011188	17879100
assi@@	I-Chemical	-1	17879100
um	I-Chemical	-1	17879100
of	O	-1	17879100
8.@@	O	-1	17879100
7	O	-1	17879100
m@@	O	-1	17879100
E@@	O	-1	17879100
q@@	O	-1	17879100
/@@	O	-1	17879100
l@@	O	-1	17879100
.	O	-1	17879100
Di@@	O	-1	17879100
aly@@	O	-1	17879100
sis	O	-1	17879100
was	O	-1	17879100
immedi@@	O	-1	17879100
ately	O	-1	17879100
initi@@	O	-1	17879100
ated.	O	-1	17879100
A	O	-1	17879100
kidney	O	-1	17879100
biop@@	O	-1	17879100
sy	O	-1	17879100
showed	O	-1	17879100
inflam@@	O	-1	17879100
mat@@	O	-1	17879100
ory	O	-1	17879100
inf@@	O	-1	17879100
ilt@@	O	-1	17879100
rate	O	-1	17879100
consist@@	O	-1	17879100
ent	O	-1	17879100
with	O	-1	17879100
A@@	B-Disease	C564356	17879100
TI@@	I-Disease	-1	17879100
N	I-Disease	-1	17879100
.	O	-1	17879100
However,	O	-1	17879100
in	O	-1	17879100
the	O	-1	17879100
tub@@	O	-1	17879100
ular	O	-1	17879100
bas@@	O	-1	17879100
ement	O	-1	17879100
membran@@	O	-1	17879100
e	O	-1	17879100
(T@@	O	-1	17879100
B@@	O	-1	17879100
M@@	O	-1	17879100
),	O	-1	17879100
very	O	-1	17879100
int@@	O	-1	17879100
en@@	O	-1	17879100
se	O	-1	17879100
gran@@	O	-1	17879100
ular	O	-1	17879100
de@@	O	-1	17879100
pos@@	O	-1	17879100
its	O	-1	17879100
of	O	-1	17879100
poly@@	O	-1	17879100
clon@@	O	-1	17879100
al	O	-1	17879100
I@@	O	-1	17879100
g@@	O	-1	17879100
G	O	-1	17879100
and	O	-1	17879100
C@@	O	-1	17879100
3	O	-1	17879100
were	O	-1	17879100
not@@	O	-1	17879100
ed.	O	-1	17879100
H@@	O	-1	17879100
e	O	-1	17879100
ne@@	O	-1	17879100
ed@@	O	-1	17879100
ed	O	-1	17879100
dialy@@	O	-1	17879100
sis	O	-1	17879100
for	O	-1	17879100
2	O	-1	17879100
weeks	O	-1	17879100
and	O	-1	17879100
was	O	-1	17879100
treated	O	-1	17879100
suc@@	O	-1	17879100
cess@@	O	-1	17879100
ful@@	O	-1	17879100
ly	O	-1	17879100
with	O	-1	17879100
steroid@@	B-Chemical	D013256	17879100
s	I-Chemical	-1	17879100
for	O	-1	17879100
6	O	-1	17879100
months.	O	-1	17879100
H@@	O	-1	17879100
is	O	-1	17879100
renal	O	-1	17879100
recovery	O	-1	17879100
and	O	-1	17879100
dis@@	O	-1	17879100
appear@@	O	-1	17879100
ance	O	-1	17879100
of	O	-1	17879100
proteinuria	B-Disease	D011507	17879100
to@@	O	-1	17879100
o@@	O	-1	17879100
k	O	-1	17879100
a	O	-1	17879100
year@@	O	-1	17879100
.	O	-1	17879100
In	O	-1	17879100
concl@@	O	-1	17879100
u@@	O	-1	17879100
sion,	O	-1	17879100
this	O	-1	17879100
is	O	-1	17879100
a	O	-1	17879100
first	O	-1	17879100
report	O	-1	17879100
of	O	-1	17879100
N@@	O	-1	17879100
S@@	O	-1	17879100
A@@	O	-1	17879100
I@@	O	-1	17879100
D@@	O	-1	17879100
s-@@	O	-1	17879100
associated	O	-1	17879100
A@@	B-Disease	C564356	17879100
TI@@	I-Disease	-1	17879100
N	I-Disease	-1	17879100
,	O	-1	17879100
show@@	O	-1	17879100
ing	O	-1	17879100
de@@	O	-1	17879100
pos@@	O	-1	17879100
its	O	-1	17879100
of	O	-1	17879100
gran@@	O	-1	17879100
ular	O	-1	17879100
immun@@	O	-1	17879100
e	O	-1	17879100
comple@@	O	-1	17879100
x	O	-1	17879100
present	O	-1	17879100
only	O	-1	17879100
in	O	-1	17879100
the	O	-1	17879100
T@@	O	-1	17879100
B@@	O	-1	17879100
M	O	-1	17879100
and	O	-1	17879100
not	O	-1	17879100
in	O	-1	17879100
the	O	-1	17879100
glomerul@@	O	-1	17879100
i@@	O	-1	17879100
.	O	-1	17879100

R@@	B-Chemical	D012293	17879217
if@@	I-Chemical	-1	17879217
amp@@	I-Chemical	-1	17879217
icin	I-Chemical	-1	17879217
-@@	O	-1	17879217
associated	O	-1	17879217
seg@@	O	-1	17879217
mental	O	-1	17879217
necro@@	O	-1	17879217
tiz@@	O	-1	17879217
ing	O	-1	17879217
glomerul@@	B-Disease	D005921	17879217
one@@	I-Disease	-1	17879217
ph@@	I-Disease	-1	17879217
ritis	I-Disease	-1	17879217
in	O	-1	17879217
st@@	B-Disease	D013203	17879217
a@@	I-Disease	-1	17879217
ph@@	I-Disease	-1	17879217
y@@	I-Disease	-1	17879217
lo@@	I-Disease	-1	17879217
co@@	I-Disease	-1	17879217
c@@	I-Disease	-1	17879217
c@@	I-Disease	-1	17879217
al	I-Disease	-1	17879217
en@@	I-Disease	-1	17879217
d@@	I-Disease	-1	17879217
ocardi@@	I-Disease	-1	17879217
tis	I-Disease	-1	17879217
st@@	B-Disease	D004696	17879217
a@@	I-Disease	-1	17879217
ph@@	I-Disease	-1	17879217
y@@	I-Disease	-1	17879217
lo@@	I-Disease	-1	17879217
co@@	I-Disease	-1	17879217
c@@	I-Disease	-1	17879217
c@@	I-Disease	-1	17879217
al	I-Disease	-1	17879217
en@@	I-Disease	-1	17879217
d@@	I-Disease	-1	17879217
ocardi@@	I-Disease	-1	17879217
tis	I-Disease	-1	17879217
.	O	-1	17879217
S@@	O	-1	17879217
e@@	O	-1	17879217
g@@	O	-1	17879217
mental	O	-1	17879217
necro@@	O	-1	17879217
tis@@	O	-1	17879217
ing	O	-1	17879217
glomerul@@	B-Disease	D005921	17879217
one@@	I-Disease	-1	17879217
ph@@	I-Disease	-1	17879217
ritis	I-Disease	-1	17879217
has	O	-1	17879217
been	O	-1	17879217
reported	O	-1	17879217
as	O	-1	17879217
complication	O	-1	17879217
of	O	-1	17879217
ri@@	B-Chemical	D012293	17879217
f@@	I-Chemical	-1	17879217
amp@@	I-Chemical	-1	17879217
icin	I-Chemical	-1	17879217
therapy	O	-1	17879217
in	O	-1	17879217
patients	O	-1	17879217
receiving	O	-1	17879217
treatment	O	-1	17879217
for	O	-1	17879217
tub@@	B-Disease	D014376	17879217
er@@	I-Disease	-1	17879217
c@@	I-Disease	-1	17879217
ulo@@	I-Disease	-1	17879217
sis	I-Disease	-1	17879217
.	O	-1	17879217
Ch@@	O	-1	17879217
ang@@	O	-1	17879217
ing	O	-1	17879217
epi@@	O	-1	17879217
de@@	O	-1	17879217
m@@	O	-1	17879217
io@@	O	-1	17879217
log@@	O	-1	17879217
y	O	-1	17879217
of	O	-1	17879217
inf@@	B-Disease	D007239	17879217
ec@@	I-Disease	-1	17879217
tions	I-Disease	-1	17879217
such	O	-1	17879217
as	O	-1	17879217
inf@@	B-Disease	D004696	17879217
ective	I-Disease	-1	17879217
en@@	I-Disease	-1	17879217
d@@	I-Disease	-1	17879217
ocardi@@	I-Disease	-1	17879217
tis	I-Disease	-1	17879217
(	O	-1	17879217
I@@	B-Disease	D004696	17879217
E	I-Disease	-1	17879217
)	O	-1	17879217
has	O	-1	17879217
l@@	O	-1	17879217
ed	O	-1	17879217
to	O	-1	17879217
an	O	-1	17879217
increase	O	-1	17879217
in	O	-1	17879217
the	O	-1	17879217
use	O	-1	17879217
of	O	-1	17879217
ri@@	B-Chemical	D012293	17879217
f@@	I-Chemical	-1	17879217
amp@@	I-Chemical	-1	17879217
icin	I-Chemical	-1	17879217
for	O	-1	17879217
S@@	B-Disease	D013203	17879217
t@@	I-Disease	-1	17879217
a@@	I-Disease	-1	17879217
ph@@	I-Disease	-1	17879217
y@@	I-Disease	-1	17879217
lo@@	I-Disease	-1	17879217
co@@	I-Disease	-1	17879217
c@@	I-Disease	-1	17879217
c@@	I-Disease	-1	17879217
al	I-Disease	-1	17879217
inf@@	I-Disease	-1	17879217
ec@@	I-Disease	-1	17879217
tions	I-Disease	-1	17879217
.	O	-1	17879217
We	O	-1	17879217
describe	O	-1	17879217
a	O	-1	17879217
case	O	-1	17879217
of	O	-1	17879217
a	O	-1	17879217
patient	O	-1	17879217
with	O	-1	17879217
S@@	B-Disease	D013203	17879217
t@@	I-Disease	-1	17879217
a@@	I-Disease	-1	17879217
ph@@	I-Disease	-1	17879217
y@@	I-Disease	-1	17879217
lo@@	I-Disease	-1	17879217
co@@	I-Disease	-1	17879217
c@@	I-Disease	-1	17879217
c@@	I-Disease	-1	17879217
al	I-Disease	-1	17879217
I@@	I-Disease	-1	17879217
E	I-Disease	-1	17879217
S@@	B-Disease	D004696	17879217
t@@	I-Disease	-1	17879217
a@@	I-Disease	-1	17879217
ph@@	I-Disease	-1	17879217
y@@	I-Disease	-1	17879217
lo@@	I-Disease	-1	17879217
co@@	I-Disease	-1	17879217
c@@	I-Disease	-1	17879217
c@@	I-Disease	-1	17879217
al	I-Disease	-1	17879217
I@@	I-Disease	-1	17879217
E	I-Disease	-1	17879217
who	O	-1	17879217
developed	O	-1	17879217
acute	B-Disease	D058186	17879217
renal	I-Disease	-1	17879217
failure	I-Disease	-1	17879217
secondary	O	-1	17879217
to	O	-1	17879217
a	O	-1	17879217
seg@@	O	-1	17879217
mental	O	-1	17879217
necro@@	O	-1	17879217
tis@@	O	-1	17879217
ing	O	-1	17879217
glomerul@@	B-Disease	D005921	17879217
one@@	I-Disease	-1	17879217
ph@@	I-Disease	-1	17879217
ritis	I-Disease	-1	17879217
while	O	-1	17879217
being	O	-1	17879217
treated	O	-1	17879217
with	O	-1	17879217
ri@@	B-Chemical	D012293	17879217
f@@	I-Chemical	-1	17879217
amp@@	I-Chemical	-1	17879217
icin	I-Chemical	-1	17879217
,	O	-1	17879217
and	O	-1	17879217
revie@@	O	-1	17879217
w	O	-1	17879217
the	O	-1	17879217
literat@@	O	-1	17879217
ure	O	-1	17879217
reg@@	O	-1	17879217
ar@@	O	-1	17879217
ding	O	-1	17879217
this	O	-1	17879217
complication	O	-1	17879217
of	O	-1	17879217
ri@@	B-Chemical	D012293	17879217
f@@	I-Chemical	-1	17879217
amp@@	I-Chemical	-1	17879217
icin	I-Chemical	-1	17879217
therapy.	O	-1	17879217

R@@	O	-1	17954033
ate	O	-1	17954033
of	O	-1	17954033
Y@@	O	-1	17954033
MD@@	O	-1	17954033
D	O	-1	17954033
mo@@	O	-1	17954033
ti@@	O	-1	17954033
f	O	-1	17954033
mut@@	O	-1	17954033
ants	O	-1	17954033
in	O	-1	17954033
lamivud@@	B-Chemical	D019259	17954033
ine	I-Chemical	-1	17954033
-@@	O	-1	17954033
un@@	O	-1	17954033
treated	O	-1	17954033
I@@	O	-1	17954033
ran@@	O	-1	17954033
i@@	O	-1	17954033
an	O	-1	17954033
patients	O	-1	17954033
with	O	-1	17954033
chronic	B-Disease	D019694	17954033
hepatitis	I-Disease	-1	17954033
B	I-Disease	-1	17954033
vi@@	I-Disease	-1	17954033
ru@@	I-Disease	-1	17954033
s	I-Disease	-1	17954033
inf@@	I-Disease	-1	17954033
ection	I-Disease	-1	17954033
.	O	-1	17954033
BACKGROUND:	O	-1	17954033
L@@	B-Chemical	D019259	17954033
amivud@@	I-Chemical	-1	17954033
ine	I-Chemical	-1	17954033
is	O	-1	17954033
used	O	-1	17954033
for	O	-1	17954033
the	O	-1	17954033
treatment	O	-1	17954033
of	O	-1	17954033
chronic	B-Disease	D019694	17954033
hepatitis	I-Disease	-1	17954033
B	I-Disease	-1	17954033
patients.	O	-1	17954033
Rec@@	O	-1	17954033
ent	O	-1	17954033
studies	O	-1	17954033
show	O	-1	17954033
that	O	-1	17954033
the	O	-1	17954033
Y@@	O	-1	17954033
MD@@	O	-1	17954033
D	O	-1	17954033
mo@@	O	-1	17954033
ti@@	O	-1	17954033
f	O	-1	17954033
mut@@	O	-1	17954033
ants	O	-1	17954033
(@@	O	-1	17954033
resist@@	O	-1	17954033
ant	O	-1	17954033
hepatitis	B-Disease	D006509	17954033
B	I-Disease	-1	17954033
vi@@	O	-1	17954033
r@@	O	-1	17954033
us@@	O	-1	17954033
)	O	-1	17954033
occ@@	O	-1	17954033
ur	O	-1	17954033
as	O	-1	17954033
n@@	O	-1	17954033
at@@	O	-1	17954033
ural	O	-1	17954033
gen@@	O	-1	17954033
ome	O	-1	17954033
vari@@	O	-1	17954033
ability	O	-1	17954033
in	O	-1	17954033
lamivud@@	B-Chemical	D019259	17954033
ine	I-Chemical	-1	17954033
-@@	O	-1	17954033
un@@	O	-1	17954033
treated	O	-1	17954033
chronic	B-Disease	D019694	17954033
hepatitis	I-Disease	-1	17954033
B	I-Disease	-1	17954033
patients.	O	-1	17954033
In	O	-1	17954033
this	O	-1	17954033
study	O	-1	17954033
we	O	-1	17954033
a@@	O	-1	17954033
im@@	O	-1	17954033
ed	O	-1	17954033
to	O	-1	17954033
determine	O	-1	17954033
the	O	-1	17954033
rate	O	-1	17954033
of	O	-1	17954033
Y@@	O	-1	17954033
MD@@	O	-1	17954033
D	O	-1	17954033
mo@@	O	-1	17954033
ti@@	O	-1	17954033
f	O	-1	17954033
mut@@	O	-1	17954033
ants	O	-1	17954033
in	O	-1	17954033
lamivud@@	B-Chemical	D019259	17954033
ine	I-Chemical	-1	17954033
-@@	O	-1	17954033
un@@	O	-1	17954033
treated	O	-1	17954033
chronic	B-Disease	D019694	17954033
hepatitis	I-Disease	-1	17954033
B	I-Disease	-1	17954033
patients	O	-1	17954033
in	O	-1	17954033
I@@	O	-1	17954033
ran@@	O	-1	17954033
.	O	-1	17954033
PA@@	O	-1	17954033
TI@@	O	-1	17954033
E@@	O	-1	17954033
N@@	O	-1	17954033
T@@	O	-1	17954033
S	O	-1	17954033
AN@@	O	-1	17954033
D	O	-1	17954033
METHODS:	O	-1	17954033
A	O	-1	17954033
total	O	-1	17954033
of	O	-1	17954033
7@@	O	-1	17954033
7	O	-1	17954033
chronic	B-Disease	D019694	17954033
hepatitis	I-Disease	-1	17954033
B	I-Disease	-1	17954033
patients	O	-1	17954033
who	O	-1	17954033
had	O	-1	17954033
not	O	-1	17954033
been	O	-1	17954033
treated	O	-1	17954033
with	O	-1	17954033
lamivud@@	B-Chemical	D019259	17954033
ine	I-Chemical	-1	17954033
were	O	-1	17954033
included	O	-1	17954033
in	O	-1	17954033
the	O	-1	17954033
study.	O	-1	17954033
S@@	O	-1	17954033
er@@	O	-1	17954033
um	O	-1	17954033
sam@@	O	-1	17954033
ple@@	O	-1	17954033
s	O	-1	17954033
from	O	-1	17954033
patients	O	-1	17954033
were	O	-1	17954033
tested	O	-1	17954033
by	O	-1	17954033
poly@@	O	-1	17954033
mer@@	O	-1	17954033
ase	O	-1	17954033
ch@@	O	-1	17954033
ain	O	-1	17954033
reac@@	O	-1	17954033
tion@@	O	-1	17954033
-@@	O	-1	17954033
re@@	O	-1	17954033
stric@@	O	-1	17954033
tion	O	-1	17954033
f@@	O	-1	17954033
ra@@	O	-1	17954033
g@@	O	-1	17954033
ment	O	-1	17954033
l@@	O	-1	17954033
en@@	O	-1	17954033
g@@	O	-1	17954033
th	O	-1	17954033
poly@@	O	-1	17954033
morph@@	O	-1	17954033
ism	O	-1	17954033
(P@@	O	-1	17954033
CR@@	O	-1	17954033
-@@	O	-1	17954033
R@@	O	-1	17954033
F@@	O	-1	17954033
L@@	O	-1	17954033
P)	O	-1	17954033
for	O	-1	17954033
det@@	O	-1	17954033
ection	O	-1	17954033
of	O	-1	17954033
Y@@	O	-1	17954033
MD@@	O	-1	17954033
D	O	-1	17954033
mo@@	O	-1	17954033
ti@@	O	-1	17954033
f	O	-1	17954033
mut@@	O	-1	17954033
ant@@	O	-1	17954033
s.	O	-1	17954033
All	O	-1	17954033
patients	O	-1	17954033
were	O	-1	17954033
also	O	-1	17954033
tested	O	-1	17954033
for	O	-1	17954033
liver	O	-1	17954033
enzym@@	O	-1	17954033
es,	O	-1	17954033
anti@@	O	-1	17954033
-H@@	O	-1	17954033
C@@	O	-1	17954033
V@@	O	-1	17954033
,	O	-1	17954033
HB@@	B-Chemical	D006513	17954033
e@@	I-Chemical	-1	17954033
A@@	I-Chemical	-1	17954033
g	I-Chemical	-1	17954033
,	O	-1	17954033
and	O	-1	17954033
anti@@	O	-1	17954033
-@@	O	-1	17954033
HB@@	O	-1	17954033
e.	O	-1	17954033
RESULTS:	O	-1	17954033
Of	O	-1	17954033
the	O	-1	17954033
7@@	O	-1	17954033
7	O	-1	17954033
patients	O	-1	17954033
en@@	O	-1	17954033
ro@@	O	-1	17954033
lled	O	-1	17954033
in	O	-1	17954033
the	O	-1	17954033
study,	O	-1	17954033
7@@	O	-1	17954033
3@@	O	-1	17954033
%	O	-1	17954033
were	O	-1	17954033
male	O	-1	17954033
and	O	-1	17954033
27@@	O	-1	17954033
%	O	-1	17954033
were	O	-1	17954033
femal@@	O	-1	17954033
e.	O	-1	17954033
M@@	O	-1	17954033
e@@	O	-1	17954033
an	O	-1	17954033
AL@@	O	-1	17954033
T	O	-1	17954033
and	O	-1	17954033
A@@	O	-1	17954033
S@@	O	-1	17954033
T	O	-1	17954033
levels	O	-1	17954033
were	O	-1	17954033
12@@	O	-1	17954033
4.@@	O	-1	17954033
4@@	O	-1	17954033
+/-@@	O	-1	17954033
7@@	O	-1	17954033
3.@@	O	-1	17954033
4	O	-1	17954033
and	O	-1	17954033
10@@	O	-1	17954033
3.@@	O	-1	17954033
1@@	O	-1	17954033
+/-@@	O	-1	17954033
8@@	O	-1	17954033
1	O	-1	17954033
I@@	O	-1	17954033
U@@	O	-1	17954033
/@@	O	-1	17954033
l@@	O	-1	17954033
,	O	-1	17954033
respectively.	O	-1	17954033
HB@@	B-Chemical	D006513	17954033
e@@	I-Chemical	-1	17954033
A@@	I-Chemical	-1	17954033
g	I-Chemical	-1	17954033
was	O	-1	17954033
positive	O	-1	17954033
in	O	-1	17954033
4@@	O	-1	17954033
0%	O	-1	17954033
and	O	-1	17954033
anti@@	O	-1	17954033
-@@	O	-1	17954033
HB@@	O	-1	17954033
e	O	-1	17954033
in	O	-1	17954033
6@@	O	-1	17954033
0%	O	-1	17954033
of	O	-1	17954033
the	O	-1	17954033
patients.	O	-1	17954033
An@@	O	-1	17954033
ti@@	O	-1	17954033
-H@@	O	-1	17954033
C@@	O	-1	17954033
V	O	-1	17954033
was	O	-1	17954033
negative	O	-1	17954033
in	O	-1	17954033
all	O	-1	17954033
of	O	-1	17954033
th@@	O	-1	17954033
em@@	O	-1	17954033
.	O	-1	17954033
Y@@	O	-1	17954033
MD@@	O	-1	17954033
D	O	-1	17954033
mo@@	O	-1	17954033
ti@@	O	-1	17954033
f	O	-1	17954033
mut@@	O	-1	17954033
ants	O	-1	17954033
were	O	-1	17954033
not	O	-1	17954033
det@@	O	-1	17954033
ected	O	-1	17954033
in	O	-1	17954033
any	O	-1	17954033
of	O	-1	17954033
the	O	-1	17954033
patients	O	-1	17954033
des@@	O	-1	17954033
pit@@	O	-1	17954033
e	O	-1	17954033
the	O	-1	17954033
liver	O	-1	17954033
enzyme	O	-1	17954033
levels	O	-1	17954033
and	O	-1	17954033
the	O	-1	17954033
presence	O	-1	17954033
of	O	-1	17954033
HB@@	B-Chemical	D006513	17954033
e@@	I-Chemical	-1	17954033
A@@	I-Chemical	-1	17954033
g	I-Chemical	-1	17954033
or	O	-1	17954033
anti@@	O	-1	17954033
-@@	O	-1	17954033
HB@@	O	-1	17954033
e.	O	-1	17954033
CONCLUSION:	O	-1	17954033
Although	O	-1	17954033
the	O	-1	17954033
n@@	O	-1	17954033
at@@	O	-1	17954033
ural	O	-1	17954033
occur@@	O	-1	17954033
rence	O	-1	17954033
of	O	-1	17954033
Y@@	O	-1	17954033
MD@@	O	-1	17954033
D	O	-1	17954033
mo@@	O	-1	17954033
ti@@	O	-1	17954033
f	O	-1	17954033
mut@@	O	-1	17954033
ants	O	-1	17954033
in	O	-1	17954033
lamivud@@	B-Chemical	D019259	17954033
ine	I-Chemical	-1	17954033
-@@	O	-1	17954033
un@@	O	-1	17954033
treated	O	-1	17954033
patients	O	-1	17954033
with	O	-1	17954033
chronic	B-Disease	D019694	17954033
hepatitis	I-Disease	-1	17954033
B	I-Disease	-1	17954033
has	O	-1	17954033
been	O	-1	17954033
repor@@	O	-1	17954033
te@@	O	-1	17954033
d,	O	-1	17954033
these	O	-1	17954033
mut@@	O	-1	17954033
ants	O	-1	17954033
were	O	-1	17954033
not	O	-1	17954033
det@@	O	-1	17954033
ected	O	-1	17954033
in	O	-1	17954033
I@@	O	-1	17954033
ran@@	O	-1	17954033
i@@	O	-1	17954033
an	O	-1	17954033
lamivud@@	B-Chemical	D019259	17954033
ine	I-Chemical	-1	17954033
-@@	O	-1	17954033
un@@	O	-1	17954033
treated	O	-1	17954033
chronic	B-Disease	D019694	17954033
hepatitis	I-Disease	-1	17954033
B	I-Disease	-1	17954033
patients.	O	-1	17954033

B@@	O	-1	18025637
ran@@	O	-1	18025637
ch	O	-1	18025637
ret@@	B-Disease	D012170	18025637
inal	I-Disease	-1	18025637
ve@@	I-Disease	-1	18025637
in	I-Disease	-1	18025637
oc@@	I-Disease	-1	18025637
cl@@	I-Disease	-1	18025637
usion	I-Disease	-1	18025637
and	O	-1	18025637
flu@@	B-Chemical	D005473	18025637
ox@@	I-Chemical	-1	18025637
et@@	I-Chemical	-1	18025637
ine	I-Chemical	-1	18025637
.	O	-1	18025637
A	O	-1	18025637
case	O	-1	18025637
of	O	-1	18025637
b@@	O	-1	18025637
ran@@	O	-1	18025637
ch	O	-1	18025637
ret@@	B-Disease	D012170	18025637
inal	I-Disease	-1	18025637
ve@@	I-Disease	-1	18025637
in	I-Disease	-1	18025637
oc@@	I-Disease	-1	18025637
cl@@	I-Disease	-1	18025637
usion	I-Disease	-1	18025637
associated	O	-1	18025637
with	O	-1	18025637
flu@@	B-Chemical	D005473	18025637
ox@@	I-Chemical	-1	18025637
et@@	I-Chemical	-1	18025637
ine	I-Chemical	-1	18025637
-induced	O	-1	18025637
secondary	O	-1	18025637
hypertension	B-Disease	D006973	18025637
is	O	-1	18025637
descri@@	O	-1	18025637
be@@	O	-1	18025637
d.	O	-1	18025637
Although	O	-1	18025637
an	O	-1	18025637
inf@@	O	-1	18025637
requ@@	O	-1	18025637
ent	O	-1	18025637
complication	O	-1	18025637
of	O	-1	18025637
selective	O	-1	18025637
seroton@@	B-Chemical	D012701	18025637
in	I-Chemical	-1	18025637
re@@	O	-1	18025637
u@@	O	-1	18025637
pt@@	O	-1	18025637
ake	O	-1	18025637
inhibitor	O	-1	18025637
therapy,	O	-1	18025637
it	O	-1	18025637
is	O	-1	18025637
important	O	-1	18025637
that	O	-1	18025637
oph@@	O	-1	18025637
thal@@	O	-1	18025637
mo@@	O	-1	18025637
log@@	O	-1	18025637
ist@@	O	-1	18025637
s	O	-1	18025637
are	O	-1	18025637
aw@@	O	-1	18025637
are	O	-1	18025637
that	O	-1	18025637
these	O	-1	18025637
agents	O	-1	18025637
can	O	-1	18025637
cause	O	-1	18025637
hypertension	B-Disease	D006973	18025637
because	O	-1	18025637
this	O	-1	18025637
cl@@	O	-1	18025637
as@@	O	-1	18025637
s	O	-1	18025637
of	O	-1	18025637
drugs	O	-1	18025637
is	O	-1	18025637
wi@@	O	-1	18025637
de@@	O	-1	18025637
ly	O	-1	18025637
prescri@@	O	-1	18025637
be@@	O	-1	18025637
d.	O	-1	18025637

The	O	-1	18165598
differen@@	O	-1	18165598
tial	O	-1	18165598
effects	O	-1	18165598
of	O	-1	18165598
bupivac@@	B-Chemical	D002045	18165598
aine	I-Chemical	-1	18165598
and	O	-1	18165598
lidocaine	B-Chemical	D008012	18165598
on	O	-1	18165598
pro@@	B-Chemical	D015232	18165598
st@@	I-Chemical	-1	18165598
ag@@	I-Chemical	-1	18165598
l@@	I-Chemical	-1	18165598
and@@	I-Chemical	-1	18165598
in	I-Chemical	-1	18165598
E@@	I-Chemical	-1	18165598
2	I-Chemical	-1	18165598
rele@@	O	-1	18165598
ase,	O	-1	18165598
cyclo@@	O	-1	18165598
oxy@@	O	-1	18165598
gen@@	O	-1	18165598
ase	O	-1	18165598
gen@@	O	-1	18165598
e	O	-1	18165598
expression	O	-1	18165598
and	O	-1	18165598
pain	B-Disease	D010146	18165598
in	O	-1	18165598
a	O	-1	18165598
clinical	O	-1	18165598
pain	B-Disease	D010146	18165598
model@@	O	-1	18165598
.	O	-1	18165598
BACKGROUND:	O	-1	18165598
In	O	-1	18165598
addition	O	-1	18165598
to	O	-1	18165598
block@@	O	-1	18165598
ing	O	-1	18165598
n@@	O	-1	18165598
ocicep@@	O	-1	18165598
tive	O	-1	18165598
in@@	O	-1	18165598
pu@@	O	-1	18165598
t	O	-1	18165598
from	O	-1	18165598
surg@@	O	-1	18165598
ical	O	-1	18165598
sit@@	O	-1	18165598
es,	O	-1	18165598
long@@	O	-1	18165598
-@@	O	-1	18165598
act@@	O	-1	18165598
ing	O	-1	18165598
loc@@	O	-1	18165598
al	O	-1	18165598
anesthe@@	O	-1	18165598
tics	O	-1	18165598
might	O	-1	18165598
direc@@	O	-1	18165598
tly	O	-1	18165598
mod@@	O	-1	18165598
ul@@	O	-1	18165598
ate	O	-1	18165598
inflam@@	B-Disease	D007249	18165598
m@@	I-Disease	-1	18165598
ation	I-Disease	-1	18165598
.	O	-1	18165598
In	O	-1	18165598
the	O	-1	18165598
present	O	-1	18165598
study,	O	-1	18165598
we	O	-1	18165598
describe	O	-1	18165598
the	O	-1	18165598
pro@@	O	-1	18165598
inflam@@	O	-1	18165598
mat@@	O	-1	18165598
ory	O	-1	18165598
effects	O	-1	18165598
of	O	-1	18165598
bupivac@@	B-Chemical	D002045	18165598
aine	I-Chemical	-1	18165598
on	O	-1	18165598
loc@@	O	-1	18165598
al	O	-1	18165598
pro@@	B-Chemical	D015232	18165598
st@@	I-Chemical	-1	18165598
ag@@	I-Chemical	-1	18165598
l@@	I-Chemical	-1	18165598
and@@	I-Chemical	-1	18165598
in	I-Chemical	-1	18165598
E@@	I-Chemical	-1	18165598
2	I-Chemical	-1	18165598
(	O	-1	18165598
PG@@	B-Chemical	D015232	18165598
E@@	I-Chemical	-1	18165598
2	I-Chemical	-1	18165598
)	O	-1	18165598
pro@@	O	-1	18165598
duction	O	-1	18165598
and	O	-1	18165598
cyclo@@	O	-1	18165598
oxy@@	O	-1	18165598
gen@@	O	-1	18165598
ase	O	-1	18165598
(C@@	O	-1	18165598
O@@	O	-1	18165598
X@@	O	-1	18165598
)	O	-1	18165598
gen@@	O	-1	18165598
e	O	-1	18165598
expression	O	-1	18165598
that	O	-1	18165598
increases	O	-1	18165598
postoperative	B-Disease	D010149	18165598
pain	I-Disease	-1	18165598
in	O	-1	18165598
human	O	-1	18165598
subj@@	O	-1	18165598
ect@@	O	-1	18165598
s.	O	-1	18165598
METHODS:	O	-1	18165598
S@@	O	-1	18165598
ub@@	O	-1	18165598
j@@	O	-1	18165598
ects	O	-1	18165598
(n	O	-1	18165598
=	O	-1	18165598
1@@	O	-1	18165598
14@@	O	-1	18165598
)	O	-1	18165598
under@@	O	-1	18165598
go@@	O	-1	18165598
ing	O	-1	18165598
extrac@@	O	-1	18165598
tion	O	-1	18165598
of	O	-1	18165598
im@@	O	-1	18165598
pac@@	O	-1	18165598
ted	O	-1	18165598
thir@@	O	-1	18165598
d	O	-1	18165598
mol@@	O	-1	18165598
ar@@	O	-1	18165598
s	O	-1	18165598
received	O	-1	18165598
either	O	-1	18165598
2@@	O	-1	18165598
%	O	-1	18165598
lidocaine	B-Chemical	D008012	18165598
or	O	-1	18165598
0.@@	O	-1	18165598
5%	O	-1	18165598
bupivac@@	B-Chemical	D002045	18165598
aine	I-Chemical	-1	18165598
before	O	-1	18165598
surger@@	O	-1	18165598
y	O	-1	18165598
and	O	-1	18165598
either	O	-1	18165598
ro@@	B-Chemical	C116926	18165598
f@@	I-Chemical	-1	18165598
ec@@	I-Chemical	-1	18165598
ox@@	I-Chemical	-1	18165598
i@@	I-Chemical	-1	18165598
b	I-Chemical	-1	18165598
50	O	-1	18165598
mg	O	-1	18165598
or	O	-1	18165598
placebo	O	-1	18165598
or@@	O	-1	18165598
ally	O	-1	18165598
9@@	O	-1	18165598
0	O	-1	18165598
min	O	-1	18165598
before	O	-1	18165598
surger@@	O	-1	18165598
y	O	-1	18165598
and	O	-1	18165598
for	O	-1	18165598
the	O	-1	18165598
following	O	-1	18165598
4@@	O	-1	18165598
8	O	-1	18165598
h@@	O	-1	18165598
.	O	-1	18165598
O@@	O	-1	18165598
ral	O	-1	18165598
m@@	O	-1	18165598
u@@	O	-1	18165598
co@@	O	-1	18165598
s@@	O	-1	18165598
al	O	-1	18165598
biop@@	O	-1	18165598
si@@	O	-1	18165598
es	O	-1	18165598
were	O	-1	18165598
tak@@	O	-1	18165598
en	O	-1	18165598
before	O	-1	18165598
surger@@	O	-1	18165598
y	O	-1	18165598
and	O	-1	18165598
4@@	O	-1	18165598
8	O	-1	18165598
h	O	-1	18165598
after	O	-1	18165598
surger@@	O	-1	18165598
y.	O	-1	18165598
After	O	-1	18165598
extrac@@	O	-1	18165598
tion,	O	-1	18165598
a	O	-1	18165598
micro@@	O	-1	18165598
dialy@@	O	-1	18165598
sis	O	-1	18165598
pro@@	O	-1	18165598
be	O	-1	18165598
was	O	-1	18165598
pl@@	O	-1	18165598
ac@@	O	-1	18165598
ed	O	-1	18165598
at	O	-1	18165598
the	O	-1	18165598
surg@@	O	-1	18165598
ical	O	-1	18165598
sit@@	O	-1	18165598
e	O	-1	18165598
for	O	-1	18165598
PG@@	B-Chemical	D015232	18165598
E@@	I-Chemical	-1	18165598
2	I-Chemical	-1	18165598
and	O	-1	18165598
throm@@	B-Chemical	D013929	18165598
b@@	I-Chemical	-1	18165598
ox@@	I-Chemical	-1	18165598
ane	I-Chemical	-1	18165598
B@@	I-Chemical	-1	18165598
2	I-Chemical	-1	18165598
(	O	-1	18165598
T@@	B-Chemical	D013929	18165598
X@@	I-Chemical	-1	18165598
B@@	I-Chemical	-1	18165598
2	I-Chemical	-1	18165598
)	O	-1	18165598
meas@@	O	-1	18165598
ure@@	O	-1	18165598
ment@@	O	-1	18165598
s.	O	-1	18165598
RESULTS:	O	-1	18165598
The	O	-1	18165598
bupivac@@	B-Chemical	D002045	18165598
aine	I-Chemical	-1	18165598
/	O	-1	18165598
ro@@	B-Chemical	C116926	18165598
f@@	I-Chemical	-1	18165598
ec@@	I-Chemical	-1	18165598
ox@@	I-Chemical	-1	18165598
i@@	I-Chemical	-1	18165598
b	I-Chemical	-1	18165598
group	O	-1	18165598
reported	O	-1	18165598
significantly	O	-1	18165598
less	O	-1	18165598
pain	B-Disease	D010146	18165598
,	O	-1	18165598
as	O	-1	18165598
assessed	O	-1	18165598
by	O	-1	18165598
a	O	-1	18165598
visual	O	-1	18165598
an@@	O	-1	18165598
alo@@	O	-1	18165598
g	O	-1	18165598
s@@	O	-1	18165598
cal@@	O	-1	18165598
e,	O	-1	18165598
compared	O	-1	18165598
with	O	-1	18165598
the	O	-1	18165598
other	O	-1	18165598
three	O	-1	18165598
treatment	O	-1	18165598
groups	O	-1	18165598
over	O	-1	18165598
the	O	-1	18165598
first	O	-1	18165598
4	O	-1	18165598
h@@	O	-1	18165598
.	O	-1	18165598
However,	O	-1	18165598
the	O	-1	18165598
bupivac@@	B-Chemical	D002045	18165598
aine	I-Chemical	-1	18165598
/@@	O	-1	18165598
placebo	O	-1	18165598
group	O	-1	18165598
reported	O	-1	18165598
significantly	O	-1	18165598
more	O	-1	18165598
pain	B-Disease	D010146	18165598
at	O	-1	18165598
24	O	-1	18165598
h	O	-1	18165598
and	O	-1	18165598
PG@@	B-Chemical	D015232	18165598
E@@	I-Chemical	-1	18165598
2	I-Chemical	-1	18165598
levels	O	-1	18165598
during	O	-1	18165598
the	O	-1	18165598
first	O	-1	18165598
4	O	-1	18165598
h	O	-1	18165598
were	O	-1	18165598
significantly	O	-1	18165598
higher	O	-1	18165598
than	O	-1	18165598
the	O	-1	18165598
other	O	-1	18165598
three	O	-1	18165598
treatment	O	-1	18165598
groups.	O	-1	18165598
M@@	O	-1	18165598
ore@@	O	-1	18165598
o@@	O	-1	18165598
ver,	O	-1	18165598
bupivac@@	B-Chemical	D002045	18165598
aine	I-Chemical	-1	18165598
significantly	O	-1	18165598
increased	O	-1	18165598
CO@@	O	-1	18165598
X@@	O	-1	18165598
-@@	O	-1	18165598
2	O	-1	18165598
gen@@	O	-1	18165598
e	O	-1	18165598
expression	O	-1	18165598
at	O	-1	18165598
4@@	O	-1	18165598
8	O	-1	18165598
h	O	-1	18165598
as	O	-1	18165598
compared	O	-1	18165598
with	O	-1	18165598
the	O	-1	18165598
lidocaine	B-Chemical	D008012	18165598
/@@	O	-1	18165598
placebo	O	-1	18165598
group.	O	-1	18165598
Th@@	B-Chemical	D013931	18165598
rom@@	I-Chemical	-1	18165598
b@@	I-Chemical	-1	18165598
ox@@	I-Chemical	-1	18165598
ane	I-Chemical	-1	18165598
levels	O	-1	18165598
were	O	-1	18165598
not	O	-1	18165598
significantly	O	-1	18165598
affected	O	-1	18165598
by	O	-1	18165598
any	O	-1	18165598
of	O	-1	18165598
the	O	-1	18165598
treatment@@	O	-1	18165598
s,	O	-1	18165598
indicating	O	-1	18165598
that	O	-1	18165598
the	O	-1	18165598
effects	O	-1	18165598
seen	O	-1	18165598
were	O	-1	18165598
at@@	O	-1	18165598
tri@@	O	-1	18165598
but@@	O	-1	18165598
able	O	-1	18165598
to	O	-1	18165598
inhibition	O	-1	18165598
of	O	-1	18165598
CO@@	O	-1	18165598
X@@	O	-1	18165598
-@@	O	-1	18165598
2,	O	-1	18165598
but	O	-1	18165598
not	O	-1	18165598
CO@@	O	-1	18165598
X@@	O	-1	18165598
-1@@	O	-1	18165598
.	O	-1	18165598
CONCLUSIONS:	O	-1	18165598
These	O	-1	18165598
results	O	-1	18165598
suggest	O	-1	18165598
that	O	-1	18165598
bupivac@@	B-Chemical	D002045	18165598
aine	I-Chemical	-1	18165598
stimul@@	O	-1	18165598
ates	O	-1	18165598
CO@@	O	-1	18165598
X@@	O	-1	18165598
-@@	O	-1	18165598
2	O	-1	18165598
gen@@	O	-1	18165598
e	O	-1	18165598
expression	O	-1	18165598
after	O	-1	18165598
tissue	B-Disease	D017695	18165598
injury	I-Disease	-1	18165598
,	O	-1	18165598
which	O	-1	18165598
is	O	-1	18165598
associated	O	-1	18165598
with	O	-1	18165598
higher	O	-1	18165598
PG@@	B-Chemical	D015232	18165598
E@@	I-Chemical	-1	18165598
2	I-Chemical	-1	18165598
pro@@	O	-1	18165598
duction	O	-1	18165598
and	O	-1	18165598
pain	B-Disease	D010146	18165598
after	O	-1	18165598
the	O	-1	18165598
loc@@	O	-1	18165598
al	O	-1	18165598
anesthe@@	O	-1	18165598
tic	O	-1	18165598
effect	O	-1	18165598
dis@@	O	-1	18165598
si@@	O	-1	18165598
pat@@	O	-1	18165598
es.	O	-1	18165598

p@@	O	-1	18189308
7@@	O	-1	18189308
5@@	O	-1	18189308
N@@	O	-1	18189308
T@@	O	-1	18189308
R	O	-1	18189308
expression	O	-1	18189308
in	O	-1	18189308
rat	O	-1	18189308
urinary	O	-1	18189308
bladder	O	-1	18189308
sens@@	O	-1	18189308
ory	O	-1	18189308
neuron@@	O	-1	18189308
s	O	-1	18189308
and	O	-1	18189308
spinal	O	-1	18189308
cor@@	O	-1	18189308
d	O	-1	18189308
with	O	-1	18189308
cyclophosph@@	B-Chemical	D003520	18189308
amide	I-Chemical	-1	18189308
-induced	O	-1	18189308
cys@@	B-Disease	D003556	18189308
ti@@	I-Disease	-1	18189308
tis	I-Disease	-1	18189308
.	O	-1	18189308
A	O	-1	18189308
role	O	-1	18189308
for	O	-1	18189308
nerve	O	-1	18189308
growth	O	-1	18189308
factor	O	-1	18189308
(N@@	O	-1	18189308
GF@@	O	-1	18189308
)	O	-1	18189308
in	O	-1	18189308
cont@@	O	-1	18189308
ri@@	O	-1	18189308
but@@	O	-1	18189308
ing	O	-1	18189308
to	O	-1	18189308
increased	O	-1	18189308
v@@	O	-1	18189308
oid@@	O	-1	18189308
ing	O	-1	18189308
frequency	O	-1	18189308
and	O	-1	18189308
al@@	O	-1	18189308
te@@	O	-1	18189308
red	O	-1	18189308
sens@@	O	-1	18189308
ation	O	-1	18189308
from	O	-1	18189308
the	O	-1	18189308
urinary	O	-1	18189308
bladder	O	-1	18189308
has	O	-1	18189308
been	O	-1	18189308
suggest@@	O	-1	18189308
ed.	O	-1	18189308
Pre@@	O	-1	18189308
vi@@	O	-1	18189308
ous	O	-1	18189308
studies	O	-1	18189308
have	O	-1	18189308
examined	O	-1	18189308
the	O	-1	18189308
expression	O	-1	18189308
and	O	-1	18189308
reg@@	O	-1	18189308
ulation	O	-1	18189308
of	O	-1	18189308
ty@@	B-Chemical	D014443	18189308
ros@@	I-Chemical	-1	18189308
ine	I-Chemical	-1	18189308
kin@@	O	-1	18189308
ase	O	-1	18189308
receptors	O	-1	18189308
(T@@	O	-1	18189308
r@@	O	-1	18189308
k@@	O	-1	18189308
s)	O	-1	18189308
in	O	-1	18189308
mic@@	O	-1	18189308
t@@	O	-1	18189308
ur@@	O	-1	18189308
ition	O	-1	18189308
ref@@	O	-1	18189308
le@@	O	-1	18189308
x@@	O	-1	18189308
es	O	-1	18189308
with	O	-1	18189308
urinary	B-Disease	D003556	18189308
bladder	I-Disease	-1	18189308
inflam@@	I-Disease	-1	18189308
m@@	I-Disease	-1	18189308
ation	I-Disease	-1	18189308
.	O	-1	18189308
The	O	-1	18189308
present	O	-1	18189308
studies	O	-1	18189308
ex@@	O	-1	18189308
amine	O	-1	18189308
the	O	-1	18189308
expression	O	-1	18189308
and	O	-1	18189308
reg@@	O	-1	18189308
ulation	O	-1	18189308
of	O	-1	18189308
an@@	O	-1	18189308
other	O	-1	18189308
receptor	O	-1	18189308
known	O	-1	18189308
to	O	-1	18189308
bin@@	O	-1	18189308
d	O	-1	18189308
N@@	O	-1	18189308
GF@@	O	-1	18189308
,	O	-1	18189308
p@@	O	-1	18189308
7@@	O	-1	18189308
5@@	O	-1	18189308
(N@@	O	-1	18189308
TR@@	O	-1	18189308
),	O	-1	18189308
after	O	-1	18189308
various	O	-1	18189308
dur@@	O	-1	18189308
ations	O	-1	18189308
of	O	-1	18189308
bladder	B-Disease	D003556	18189308
inflam@@	I-Disease	-1	18189308
m@@	I-Disease	-1	18189308
ation	I-Disease	-1	18189308
induced	O	-1	18189308
by	O	-1	18189308
cyclophosph@@	B-Chemical	D003520	18189308
amide	I-Chemical	-1	18189308
(	O	-1	18189308
C@@	B-Chemical	D003520	18189308
Y@@	I-Chemical	-1	18189308
P	I-Chemical	-1	18189308
).	O	-1	18189308
C@@	B-Chemical	D003520	18189308
Y@@	I-Chemical	-1	18189308
P	I-Chemical	-1	18189308
-induced	O	-1	18189308
cys@@	B-Disease	D003556	18189308
ti@@	I-Disease	-1	18189308
tis	I-Disease	-1	18189308
increased	O	-1	18189308
(P	O	-1	18189308
<	O	-1	18189308
or	O	-1	18189308
=	O	-1	18189308
0.00@@	O	-1	18189308
1)	O	-1	18189308
p@@	O	-1	18189308
7@@	O	-1	18189308
5@@	O	-1	18189308
(N@@	O	-1	18189308
TR@@	O	-1	18189308
)	O	-1	18189308
expression	O	-1	18189308
in	O	-1	18189308
the	O	-1	18189308
su@@	O	-1	18189308
per@@	O	-1	18189308
fic@@	O	-1	18189308
ial	O	-1	18189308
lat@@	O	-1	18189308
eral	O	-1	18189308
and	O	-1	18189308
medi@@	O	-1	18189308
al	O	-1	18189308
d@@	O	-1	18189308
or@@	O	-1	18189308
s@@	O	-1	18189308
al	O	-1	18189308
h@@	O	-1	18189308
or@@	O	-1	18189308
n	O	-1	18189308
in	O	-1	18189308
L@@	O	-1	18189308
1-@@	O	-1	18189308
L@@	O	-1	18189308
2	O	-1	18189308
and	O	-1	18189308
L@@	O	-1	18189308
6-@@	O	-1	18189308
S@@	O	-1	18189308
1	O	-1	18189308
spinal	O	-1	18189308
seg@@	O	-1	18189308
ment@@	O	-1	18189308
s.	O	-1	18189308
The	O	-1	18189308
number	O	-1	18189308
of	O	-1	18189308
p@@	O	-1	18189308
7@@	O	-1	18189308
5@@	O	-1	18189308
(N@@	O	-1	18189308
TR@@	O	-1	18189308
)-@@	O	-1	18189308
immuno@@	O	-1	18189308
reac@@	O	-1	18189308
tive	O	-1	18189308
(-@@	O	-1	18189308
I@@	O	-1	18189308
R@@	O	-1	18189308
)	O	-1	18189308
cells	O	-1	18189308
in	O	-1	18189308
the	O	-1	18189308
l@@	O	-1	18189308
umb@@	O	-1	18189308
os@@	O	-1	18189308
ac@@	O	-1	18189308
ral	O	-1	18189308
d@@	O	-1	18189308
or@@	O	-1	18189308
s@@	O	-1	18189308
al	O	-1	18189308
ro@@	O	-1	18189308
o@@	O	-1	18189308
t	O	-1	18189308
g@@	O	-1	18189308
ang@@	O	-1	18189308
li@@	O	-1	18189308
a	O	-1	18189308
(D@@	O	-1	18189308
R@@	O	-1	18189308
G@@	O	-1	18189308
)	O	-1	18189308
also	O	-1	18189308
increased	O	-1	18189308
(P	O	-1	18189308
<	O	-1	18189308
or	O	-1	18189308
=	O	-1	18189308
0.05@@	O	-1	18189308
)	O	-1	18189308
with	O	-1	18189308
C@@	B-Chemical	D003520	18189308
Y@@	I-Chemical	-1	18189308
P	I-Chemical	-1	18189308
-induced	O	-1	18189308
cys@@	B-Disease	D003556	18189308
ti@@	I-Disease	-1	18189308
tis	I-Disease	-1	18189308
(@@	O	-1	18189308
ac@@	O	-1	18189308
u@@	O	-1	18189308
te@@	O	-1	18189308
,	O	-1	18189308
inter@@	O	-1	18189308
medi@@	O	-1	18189308
ate,	O	-1	18189308
and	O	-1	18189308
chron@@	O	-1	18189308
ic@@	O	-1	18189308
).	O	-1	18189308
Q@@	O	-1	18189308
u@@	O	-1	18189308
anti@@	O	-1	18189308
t@@	O	-1	18189308
ati@@	O	-1	18189308
ve,	O	-1	18189308
re@@	O	-1	18189308
al@@	O	-1	18189308
-@@	O	-1	18189308
time	O	-1	18189308
poly@@	O	-1	18189308
mer@@	O	-1	18189308
ase	O	-1	18189308
ch@@	O	-1	18189308
ain	O	-1	18189308
reaction	O	-1	18189308
also	O	-1	18189308
demonstrated	O	-1	18189308
significant	O	-1	18189308
increases	O	-1	18189308
(P	O	-1	18189308
<	O	-1	18189308
or	O	-1	18189308
=	O	-1	18189308
0.0@@	O	-1	18189308
1)	O	-1	18189308
in	O	-1	18189308
p@@	O	-1	18189308
7@@	O	-1	18189308
5@@	O	-1	18189308
(N@@	O	-1	18189308
TR@@	O	-1	18189308
)	O	-1	18189308
mRNA	O	-1	18189308
in	O	-1	18189308
D@@	O	-1	18189308
R@@	O	-1	18189308
G	O	-1	18189308
with	O	-1	18189308
inter@@	O	-1	18189308
medi@@	O	-1	18189308
ate	O	-1	18189308
and	O	-1	18189308
chronic	O	-1	18189308
C@@	B-Chemical	D003520	18189308
Y@@	I-Chemical	-1	18189308
P	I-Chemical	-1	18189308
-induced	O	-1	18189308
cys@@	B-Disease	D003556	18189308
ti@@	I-Disease	-1	18189308
tis	I-Disease	-1	18189308
.	O	-1	18189308
R@@	O	-1	18189308
et@@	O	-1	18189308
ro@@	O	-1	18189308
gra@@	O	-1	18189308
de	O	-1	18189308
dy@@	O	-1	18189308
e-@@	O	-1	18189308
trac@@	O	-1	18189308
ing	O	-1	18189308
t@@	O	-1	18189308
ech@@	O	-1	18189308
n@@	O	-1	18189308
i@@	O	-1	18189308
qu@@	O	-1	18189308
es	O	-1	18189308
with	O	-1	18189308
F@@	O	-1	18189308
ast@@	O	-1	18189308
b@@	O	-1	18189308
lu@@	O	-1	18189308
e	O	-1	18189308
were	O	-1	18189308
used	O	-1	18189308
to	O	-1	18189308
identi@@	O	-1	18189308
f@@	O	-1	18189308
y	O	-1	18189308
pres@@	O	-1	18189308
um@@	O	-1	18189308
p@@	O	-1	18189308
tive	O	-1	18189308
bladder	O	-1	18189308
a@@	O	-1	18189308
fferen@@	O	-1	18189308
t	O	-1	18189308
cells	O	-1	18189308
in	O	-1	18189308
the	O	-1	18189308
l@@	O	-1	18189308
umb@@	O	-1	18189308
os@@	O	-1	18189308
ac@@	O	-1	18189308
ral	O	-1	18189308
D@@	O	-1	18189308
R@@	O	-1	18189308
G@@	O	-1	18189308
.	O	-1	18189308
In	O	-1	18189308
bladder	O	-1	18189308
a@@	O	-1	18189308
fferen@@	O	-1	18189308
t	O	-1	18189308
cells	O	-1	18189308
in	O	-1	18189308
D@@	O	-1	18189308
R@@	O	-1	18189308
G@@	O	-1	18189308
,	O	-1	18189308
p@@	O	-1	18189308
7@@	O	-1	18189308
5@@	O	-1	18189308
(N@@	O	-1	18189308
TR@@	O	-1	18189308
)-@@	O	-1	18189308
I@@	O	-1	18189308
R	O	-1	18189308
was	O	-1	18189308
also	O	-1	18189308
increased	O	-1	18189308
(P	O	-1	18189308
<	O	-1	18189308
or	O	-1	18189308
=	O	-1	18189308
0.0@@	O	-1	18189308
1)	O	-1	18189308
with	O	-1	18189308
cys@@	B-Disease	D003556	18189308
ti@@	I-Disease	-1	18189308
tis	I-Disease	-1	18189308
.	O	-1	18189308
In	O	-1	18189308
addition	O	-1	18189308
to	O	-1	18189308
increases	O	-1	18189308
in	O	-1	18189308
p@@	O	-1	18189308
7@@	O	-1	18189308
5@@	O	-1	18189308
(N@@	O	-1	18189308
TR@@	O	-1	18189308
)-@@	O	-1	18189308
I@@	O	-1	18189308
R	O	-1	18189308
in	O	-1	18189308
D@@	O	-1	18189308
R@@	O	-1	18189308
G	O	-1	18189308
cell	O	-1	18189308
bo@@	O	-1	18189308
di@@	O	-1	18189308
es,	O	-1	18189308
increases	O	-1	18189308
(P	O	-1	18189308
<	O	-1	18189308
or	O	-1	18189308
=	O	-1	18189308
0.00@@	O	-1	18189308
1)	O	-1	18189308
in	O	-1	18189308
per@@	O	-1	18189308
ic@@	O	-1	18189308
ell@@	O	-1	18189308
ular	O	-1	18189308
(@@	O	-1	18189308
en@@	O	-1	18189308
cir@@	O	-1	18189308
cl@@	O	-1	18189308
ing	O	-1	18189308
D@@	O	-1	18189308
R@@	O	-1	18189308
G	O	-1	18189308
cell@@	O	-1	18189308
s)	O	-1	18189308
p@@	O	-1	18189308
7@@	O	-1	18189308
5@@	O	-1	18189308
(N@@	O	-1	18189308
TR@@	O	-1	18189308
)-@@	O	-1	18189308
I@@	O	-1	18189308
R	O	-1	18189308
in	O	-1	18189308
D@@	O	-1	18189308
R@@	O	-1	18189308
G	O	-1	18189308
also	O	-1	18189308
increas@@	O	-1	18189308
ed.	O	-1	18189308
Con@@	O	-1	18189308
foc@@	O	-1	18189308
al	O	-1	18189308
analy@@	O	-1	18189308
ses	O	-1	18189308
demonstrated	O	-1	18189308
that	O	-1	18189308
per@@	O	-1	18189308
ic@@	O	-1	18189308
ell@@	O	-1	18189308
ular	O	-1	18189308
p@@	O	-1	18189308
7@@	O	-1	18189308
5@@	O	-1	18189308
(N@@	O	-1	18189308
TR@@	O	-1	18189308
)-@@	O	-1	18189308
I@@	O	-1	18189308
R	O	-1	18189308
was	O	-1	18189308
not	O	-1	18189308
co@@	O	-1	18189308
lo@@	O	-1	18189308
cal@@	O	-1	18189308
ized	O	-1	18189308
with	O	-1	18189308
the	O	-1	18189308
g@@	O	-1	18189308
lial	O	-1	18189308
mark@@	O	-1	18189308
er,	O	-1	18189308
g@@	O	-1	18189308
lial	O	-1	18189308
fibrill@@	O	-1	18189308
ary	O	-1	18189308
ac@@	O	-1	18189308
i@@	O	-1	18189308
di@@	O	-1	18189308
c	O	-1	18189308
protein	O	-1	18189308
(@@	O	-1	18189308
GF@@	O	-1	18189308
A@@	O	-1	18189308
P@@	O	-1	18189308
).	O	-1	18189308
These	O	-1	18189308
studies	O	-1	18189308
demon@@	O	-1	18189308
st@@	O	-1	18189308
rate	O	-1	18189308
that	O	-1	18189308
p@@	O	-1	18189308
7@@	O	-1	18189308
5@@	O	-1	18189308
(N@@	O	-1	18189308
TR@@	O	-1	18189308
)	O	-1	18189308
expression	O	-1	18189308
in	O	-1	18189308
mic@@	O	-1	18189308
t@@	O	-1	18189308
ur@@	O	-1	18189308
ition	O	-1	18189308
ref@@	O	-1	18189308
le@@	O	-1	18189308
x@@	O	-1	18189308
es	O	-1	18189308
is	O	-1	18189308
present	O	-1	18189308
con@@	O	-1	18189308
sti@@	O	-1	18189308
tu@@	O	-1	18189308
ti@@	O	-1	18189308
vely	O	-1	18189308
and	O	-1	18189308
mo@@	O	-1	18189308
di@@	O	-1	18189308
fied	O	-1	18189308
by	O	-1	18189308
bladder	B-Disease	D003556	18189308
inflam@@	I-Disease	-1	18189308
m@@	I-Disease	-1	18189308
ation	I-Disease	-1	18189308
.	O	-1	18189308
The	O	-1	18189308
functional	O	-1	18189308
signific@@	O	-1	18189308
ance	O	-1	18189308
of	O	-1	18189308
p@@	O	-1	18189308
7@@	O	-1	18189308
5@@	O	-1	18189308
(N@@	O	-1	18189308
TR@@	O	-1	18189308
)	O	-1	18189308
expression	O	-1	18189308
in	O	-1	18189308
mic@@	O	-1	18189308
t@@	O	-1	18189308
ur@@	O	-1	18189308
ition	O	-1	18189308
ref@@	O	-1	18189308
le@@	O	-1	18189308
x@@	O	-1	18189308
es	O	-1	18189308
remain@@	O	-1	18189308
s	O	-1	18189308
to	O	-1	18189308
be	O	-1	18189308
deter@@	O	-1	18189308
m@@	O	-1	18189308
ine@@	O	-1	18189308
d.	O	-1	18189308

A@@	B-Chemical	D001379	18340638
z@@	I-Chemical	-1	18340638
ath@@	I-Chemical	-1	18340638
io@@	I-Chemical	-1	18340638
p@@	I-Chemical	-1	18340638
rine	I-Chemical	-1	18340638
-induced	O	-1	18340638
su@@	O	-1	18340638
ic@@	O	-1	18340638
idal	O	-1	18340638
erythro@@	O	-1	18340638
cy@@	O	-1	18340638
te	O	-1	18340638
de@@	O	-1	18340638
ath@@	O	-1	18340638
.	O	-1	18340638
BACKGROUND:	O	-1	18340638
A@@	B-Chemical	D001379	18340638
z@@	I-Chemical	-1	18340638
ath@@	I-Chemical	-1	18340638
io@@	I-Chemical	-1	18340638
p@@	I-Chemical	-1	18340638
rine	I-Chemical	-1	18340638
is	O	-1	18340638
wi@@	O	-1	18340638
de@@	O	-1	18340638
ly	O	-1	18340638
used	O	-1	18340638
as	O	-1	18340638
an	O	-1	18340638
immunosup@@	O	-1	18340638
pressive	O	-1	18340638
drug.	O	-1	18340638
The	O	-1	18340638
side	O	-1	18340638
effects	O	-1	18340638
of	O	-1	18340638
az@@	B-Chemical	D001379	18340638
ath@@	I-Chemical	-1	18340638
io@@	I-Chemical	-1	18340638
p@@	I-Chemical	-1	18340638
rine	I-Chemical	-1	18340638
includ@@	O	-1	18340638
e	O	-1	18340638
anemia	B-Disease	D000740	18340638
,	O	-1	18340638
which	O	-1	18340638
has	O	-1	18340638
been	O	-1	18340638
at@@	O	-1	18340638
tri@@	O	-1	18340638
but@@	O	-1	18340638
ed	O	-1	18340638
to	O	-1	18340638
b@@	O	-1	18340638
one	O	-1	18340638
m@@	O	-1	18340638
ar@@	O	-1	18340638
ro@@	O	-1	18340638
w	O	-1	18340638
sup@@	O	-1	18340638
pres@@	O	-1	18340638
sion.	O	-1	18340638
Al@@	O	-1	18340638
tern@@	O	-1	18340638
ati@@	O	-1	18340638
vel@@	O	-1	18340638
y,	O	-1	18340638
anemia	B-Disease	D000740	18340638
could	O	-1	18340638
result	O	-1	18340638
from	O	-1	18340638
ac@@	O	-1	18340638
ce@@	O	-1	18340638
l@@	O	-1	18340638
er@@	O	-1	18340638
ated	O	-1	18340638
su@@	O	-1	18340638
ic@@	O	-1	18340638
idal	O	-1	18340638
erythro@@	O	-1	18340638
cy@@	O	-1	18340638
te	O	-1	18340638
death	O	-1	18340638
or	O	-1	18340638
ery@@	O	-1	18340638
pto@@	O	-1	18340638
sis,	O	-1	18340638
which	O	-1	18340638
is	O	-1	18340638
character@@	O	-1	18340638
ized	O	-1	18340638
by	O	-1	18340638
exposure	O	-1	18340638
of	O	-1	18340638
phosph@@	B-Chemical	D010718	18340638
ati@@	I-Chemical	-1	18340638
d@@	I-Chemical	-1	18340638
yl@@	I-Chemical	-1	18340638
ser@@	I-Chemical	-1	18340638
ine	I-Chemical	-1	18340638
(	O	-1	18340638
P@@	B-Chemical	D010718	18340638
S	I-Chemical	-1	18340638
)	O	-1	18340638
at	O	-1	18340638
the	O	-1	18340638
erythro@@	O	-1	18340638
cy@@	O	-1	18340638
te	O	-1	18340638
sur@@	O	-1	18340638
fac@@	O	-1	18340638
e	O	-1	18340638
and	O	-1	18340638
by	O	-1	18340638
cell	O	-1	18340638
sh@@	O	-1	18340638
r@@	O	-1	18340638
in@@	O	-1	18340638
k@@	O	-1	18340638
age.	O	-1	18340638
METHODS:	O	-1	18340638
The	O	-1	18340638
present	O	-1	18340638
experim@@	O	-1	18340638
ents	O	-1	18340638
ex@@	O	-1	18340638
p@@	O	-1	18340638
lo@@	O	-1	18340638
red	O	-1	18340638
whether	O	-1	18340638
az@@	B-Chemical	D001379	18340638
ath@@	I-Chemical	-1	18340638
io@@	I-Chemical	-1	18340638
p@@	I-Chemical	-1	18340638
rine	I-Chemical	-1	18340638
influ@@	O	-1	18340638
enc@@	O	-1	18340638
es	O	-1	18340638
ery@@	O	-1	18340638
pto@@	O	-1	18340638
sis.	O	-1	18340638
Ac@@	O	-1	18340638
cor@@	O	-1	18340638
ding	O	-1	18340638
to	O	-1	18340638
an@@	O	-1	18340638
ne@@	O	-1	18340638
x@@	O	-1	18340638
in	O	-1	18340638
V	O	-1	18340638
b@@	O	-1	18340638
ind@@	O	-1	18340638
ing,	O	-1	18340638
erythro@@	O	-1	18340638
cy@@	O	-1	18340638
tes	O	-1	18340638
from	O	-1	18340638
patients	O	-1	18340638
in@@	O	-1	18340638
de@@	O	-1	18340638
ed	O	-1	18340638
showed	O	-1	18340638
a	O	-1	18340638
significant	O	-1	18340638
increase	O	-1	18340638
of	O	-1	18340638
P@@	B-Chemical	D010718	18340638
S	I-Chemical	-1	18340638
exposure	O	-1	18340638
within	O	-1	18340638
1	O	-1	18340638
week	O	-1	18340638
of	O	-1	18340638
treatment	O	-1	18340638
with	O	-1	18340638
az@@	B-Chemical	D001379	18340638
ath@@	I-Chemical	-1	18340638
io@@	I-Chemical	-1	18340638
p@@	I-Chemical	-1	18340638
rine	I-Chemical	-1	18340638
.	O	-1	18340638
In	O	-1	18340638
a	O	-1	18340638
second	O	-1	18340638
seri@@	O	-1	18340638
es,	O	-1	18340638
cy@@	O	-1	18340638
t@@	O	-1	18340638
os@@	O	-1	18340638
olic	O	-1	18340638
C@@	B-Chemical	D002118	18340638
a	I-Chemical	-1	18340638
2@@	O	-1	18340638
+	O	-1	18340638
activity	O	-1	18340638
(	O	-1	18340638
F@@	B-Chemical	C059715	18340638
lu@@	I-Chemical	-1	18340638
o@@	I-Chemical	-1	18340638
3	I-Chemical	-1	18340638
fluo@@	O	-1	18340638
res@@	O	-1	18340638
c@@	O	-1	18340638
ence@@	O	-1	18340638
),	O	-1	18340638
cell	O	-1	18340638
volume	O	-1	18340638
(@@	O	-1	18340638
for@@	O	-1	18340638
war@@	O	-1	18340638
d	O	-1	18340638
s@@	O	-1	18340638
cat@@	O	-1	18340638
ter@@	O	-1	18340638
),	O	-1	18340638
and	O	-1	18340638
P@@	B-Chemical	D010718	18340638
S	I-Chemical	-1	18340638
-@@	O	-1	18340638
exposure	O	-1	18340638
(@@	O	-1	18340638
an@@	O	-1	18340638
ne@@	O	-1	18340638
x@@	O	-1	18340638
in	O	-1	18340638
V	O	-1	18340638
b@@	O	-1	18340638
ind@@	O	-1	18340638
ing@@	O	-1	18340638
)	O	-1	18340638
were	O	-1	18340638
determined	O	-1	18340638
by	O	-1	18340638
F@@	O	-1	18340638
AC@@	O	-1	18340638
S	O	-1	18340638
analysis	O	-1	18340638
in	O	-1	18340638
erythro@@	O	-1	18340638
cy@@	O	-1	18340638
tes	O	-1	18340638
from	O	-1	18340638
healthy	O	-1	18340638
vol@@	O	-1	18340638
un@@	O	-1	18340638
te@@	O	-1	18340638
ers.	O	-1	18340638
RESULTS:	O	-1	18340638
E@@	O	-1	18340638
x@@	O	-1	18340638
pos@@	O	-1	18340638
ure	O	-1	18340638
to	O	-1	18340638
az@@	B-Chemical	D001379	18340638
ath@@	I-Chemical	-1	18340638
io@@	I-Chemical	-1	18340638
p@@	I-Chemical	-1	18340638
rine	I-Chemical	-1	18340638
(@@	O	-1	18340638
>	O	-1	18340638
or	O	-1	18340638
=@@	O	-1	18340638
2	O	-1	18340638
micro@@	O	-1	18340638
g/@@	O	-1	18340638
m@@	O	-1	18340638
L@@	O	-1	18340638
)	O	-1	18340638
for	O	-1	18340638
4@@	O	-1	18340638
8	O	-1	18340638
hours	O	-1	18340638
increased	O	-1	18340638
cy@@	O	-1	18340638
t@@	O	-1	18340638
os@@	O	-1	18340638
olic	O	-1	18340638
C@@	B-Chemical	D002118	18340638
a	I-Chemical	-1	18340638
2@@	O	-1	18340638
+	O	-1	18340638
activity	O	-1	18340638
and	O	-1	18340638
an@@	O	-1	18340638
ne@@	O	-1	18340638
x@@	O	-1	18340638
in	O	-1	18340638
V	O	-1	18340638
b@@	O	-1	18340638
ind@@	O	-1	18340638
ing	O	-1	18340638
and	O	-1	18340638
decreased	O	-1	18340638
for@@	O	-1	18340638
war@@	O	-1	18340638
d	O	-1	18340638
s@@	O	-1	18340638
cat@@	O	-1	18340638
ter@@	O	-1	18340638
.	O	-1	18340638
The	O	-1	18340638
effect	O	-1	18340638
of	O	-1	18340638
az@@	B-Chemical	D001379	18340638
ath@@	I-Chemical	-1	18340638
io@@	I-Chemical	-1	18340638
p@@	I-Chemical	-1	18340638
rine	I-Chemical	-1	18340638
on	O	-1	18340638
both	O	-1	18340638
an@@	O	-1	18340638
ne@@	O	-1	18340638
x@@	O	-1	18340638
in	O	-1	18340638
V	O	-1	18340638
b@@	O	-1	18340638
ind@@	O	-1	18340638
ing	O	-1	18340638
and	O	-1	18340638
for@@	O	-1	18340638
war@@	O	-1	18340638
d	O	-1	18340638
s@@	O	-1	18340638
cat@@	O	-1	18340638
ter	O	-1	18340638
was	O	-1	18340638
significantly	O	-1	18340638
bl@@	O	-1	18340638
un@@	O	-1	18340638
ted	O	-1	18340638
in	O	-1	18340638
the	O	-1	18340638
no@@	O	-1	18340638
min@@	O	-1	18340638
al	O	-1	18340638
absence	O	-1	18340638
of	O	-1	18340638
extrac@@	O	-1	18340638
ell@@	O	-1	18340638
ular	O	-1	18340638
C@@	B-Chemical	D002118	18340638
a	I-Chemical	-1	18340638
2@@	O	-1	18340638
+@@	O	-1	18340638
.	O	-1	18340638
CONCLUSIONS:	O	-1	18340638
A@@	B-Chemical	D001379	18340638
z@@	I-Chemical	-1	18340638
ath@@	I-Chemical	-1	18340638
io@@	I-Chemical	-1	18340638
p@@	I-Chemical	-1	18340638
rine	I-Chemical	-1	18340638
tri@@	O	-1	18340638
g@@	O	-1	18340638
g@@	O	-1	18340638
ers	O	-1	18340638
su@@	O	-1	18340638
ic@@	O	-1	18340638
idal	O	-1	18340638
erythro@@	O	-1	18340638
cy@@	O	-1	18340638
te	O	-1	18340638
de@@	O	-1	18340638
ath@@	O	-1	18340638
,	O	-1	18340638
an	O	-1	18340638
effect	O	-1	18340638
pres@@	O	-1	18340638
um@@	O	-1	18340638
ably	O	-1	18340638
cont@@	O	-1	18340638
ri@@	O	-1	18340638
but@@	O	-1	18340638
ing	O	-1	18340638
to	O	-1	18340638
az@@	B-Chemical	D001379	18340638
ath@@	I-Chemical	-1	18340638
io@@	I-Chemical	-1	18340638
p@@	I-Chemical	-1	18340638
rine	I-Chemical	-1	18340638
-induced	O	-1	18340638
anemia	B-Disease	D000740	18340638
.	O	-1	18340638

Clin@@	O	-1	18399341
ical	O	-1	18399341
compar@@	O	-1	18399341
ison	O	-1	18399341
of	O	-1	18399341
cardio@@	O	-1	18399341
respiratory	O	-1	18399341
effects	O	-1	18399341
during	O	-1	18399341
un@@	O	-1	18399341
il@@	O	-1	18399341
ateral	O	-1	18399341
and	O	-1	18399341
con@@	O	-1	18399341
ven@@	O	-1	18399341
tional	O	-1	18399341
spinal	O	-1	18399341
anaesthe@@	O	-1	18399341
sia.	O	-1	18399341
BACKGROUND:	O	-1	18399341
S@@	O	-1	18399341
p@@	O	-1	18399341
inal	O	-1	18399341
anaesthe@@	O	-1	18399341
sia	O	-1	18399341
is	O	-1	18399341
wi@@	O	-1	18399341
de@@	O	-1	18399341
ly	O	-1	18399341
em@@	O	-1	18399341
p@@	O	-1	18399341
lo@@	O	-1	18399341
y@@	O	-1	18399341
ed	O	-1	18399341
in	O	-1	18399341
clinical	O	-1	18399341
p@@	O	-1	18399341
rac@@	O	-1	18399341
ti@@	O	-1	18399341
ce	O	-1	18399341
but	O	-1	18399341
has	O	-1	18399341
the	O	-1	18399341
ma@@	O	-1	18399341
in	O	-1	18399341
draw@@	O	-1	18399341
bac@@	O	-1	18399341
k	O	-1	18399341
of	O	-1	18399341
post@@	O	-1	18399341
-@@	O	-1	18399341
spinal	O	-1	18399341
bloc@@	O	-1	18399341
k	O	-1	18399341
hypotension	B-Disease	D007022	18399341
.	O	-1	18399341
Eff@@	O	-1	18399341
or@@	O	-1	18399341
ts	O	-1	18399341
mus@@	O	-1	18399341
t	O	-1	18399341
the@@	O	-1	18399341
re@@	O	-1	18399341
fore	O	-1	18399341
continu@@	O	-1	18399341
e	O	-1	18399341
to	O	-1	18399341
be	O	-1	18399341
m@@	O	-1	18399341
ade	O	-1	18399341
to	O	-1	18399341
ob@@	O	-1	18399341
vi@@	O	-1	18399341
ate	O	-1	18399341
this	O	-1	18399341
se@@	O	-1	18399341
t@@	O	-1	18399341
bac@@	O	-1	18399341
k	O	-1	18399341
OBJECTIVE:	O	-1	18399341
To	O	-1	18399341
evalu@@	O	-1	18399341
ate	O	-1	18399341
the	O	-1	18399341
cardiovascular	O	-1	18399341
and	O	-1	18399341
respiratory	O	-1	18399341
changes	O	-1	18399341
during	O	-1	18399341
un@@	O	-1	18399341
il@@	O	-1	18399341
ateral	O	-1	18399341
and	O	-1	18399341
con@@	O	-1	18399341
ven@@	O	-1	18399341
tional	O	-1	18399341
spinal	O	-1	18399341
anaesthe@@	O	-1	18399341
sia.	O	-1	18399341
METHODS:	O	-1	18399341
W@@	O	-1	18399341
it@@	O	-1	18399341
h	O	-1	18399341
eth@@	O	-1	18399341
ical	O	-1	18399341
appro@@	O	-1	18399341
val@@	O	-1	18399341
,	O	-1	18399341
we	O	-1	18399341
studied	O	-1	18399341
7@@	O	-1	18399341
4	O	-1	18399341
A@@	O	-1	18399341
mer@@	O	-1	18399341
ic@@	O	-1	18399341
an	O	-1	18399341
S@@	O	-1	18399341
oci@@	O	-1	18399341
ety	O	-1	18399341
of	O	-1	18399341
An@@	O	-1	18399341
esthe@@	O	-1	18399341
si@@	O	-1	18399341
olog@@	O	-1	18399341
ist@@	O	-1	18399341
s	O	-1	18399341
(A@@	O	-1	18399341
S@@	O	-1	18399341
A@@	O	-1	18399341
),	O	-1	18399341
physi@@	O	-1	18399341
c@@	O	-1	18399341
al	O	-1	18399341
status	O	-1	18399341
cl@@	O	-1	18399341
as@@	O	-1	18399341
s	O	-1	18399341
1	O	-1	18399341
and	O	-1	18399341
2	O	-1	18399341
patients	O	-1	18399341
sch@@	O	-1	18399341
ed@@	O	-1	18399341
ul@@	O	-1	18399341
ed	O	-1	18399341
for	O	-1	18399341
el@@	O	-1	18399341
ective	O	-1	18399341
un@@	O	-1	18399341
il@@	O	-1	18399341
ateral	O	-1	18399341
lower	O	-1	18399341
lim@@	O	-1	18399341
b	O	-1	18399341
surger@@	O	-1	18399341
y.	O	-1	18399341
Patients	O	-1	18399341
were	O	-1	18399341
random@@	O	-1	18399341
ly	O	-1	18399341
al@@	O	-1	18399341
loc@@	O	-1	18399341
ated	O	-1	18399341
into	O	-1	18399341
one	O	-1	18399341
of	O	-1	18399341
two	O	-1	18399341
group@@	O	-1	18399341
s:	O	-1	18399341
lat@@	O	-1	18399341
eral	O	-1	18399341
and	O	-1	18399341
con@@	O	-1	18399341
ven@@	O	-1	18399341
tional	O	-1	18399341
spinal	O	-1	18399341
anaesthe@@	O	-1	18399341
sia	O	-1	18399341
groups.	O	-1	18399341
In	O	-1	18399341
the	O	-1	18399341
lat@@	O	-1	18399341
eral	O	-1	18399341
posi@@	O	-1	18399341
tion	O	-1	18399341
with	O	-1	18399341
o@@	O	-1	18399341
perative	O	-1	18399341
side	O	-1	18399341
do@@	O	-1	18399341
w@@	O	-1	18399341
n@@	O	-1	18399341
,	O	-1	18399341
patients	O	-1	18399341
re@@	O	-1	18399341
ci@@	O	-1	18399341
ved	O	-1	18399341
10	O	-1	18399341
mg	O	-1	18399341
(2@@	O	-1	18399341
ml@@	O	-1	18399341
s)	O	-1	18399341
of	O	-1	18399341
0.@@	O	-1	18399341
5%	O	-1	18399341
hyper@@	O	-1	18399341
bar@@	O	-1	18399341
ic	O	-1	18399341
bupivac@@	B-Chemical	D002045	18399341
aine	I-Chemical	-1	18399341
through	O	-1	18399341
a	O	-1	18399341
2@@	O	-1	18399341
5-@@	O	-1	18399341
g@@	O	-1	18399341
au@@	O	-1	18399341
ge	O	-1	18399341
spinal	O	-1	18399341
ne@@	O	-1	18399341
ed@@	O	-1	18399341
le@@	O	-1	18399341
.	O	-1	18399341
Patients	O	-1	18399341
in	O	-1	18399341
the	O	-1	18399341
un@@	O	-1	18399341
il@@	O	-1	18399341
ateral	O	-1	18399341
group	O	-1	18399341
were	O	-1	18399341
maint@@	O	-1	18399341
ained	O	-1	18399341
in	O	-1	18399341
the	O	-1	18399341
lat@@	O	-1	18399341
eral	O	-1	18399341
posi@@	O	-1	18399341
tion	O	-1	18399341
for	O	-1	18399341
15	O	-1	18399341
minutes	O	-1	18399341
following	O	-1	18399341
spinal	O	-1	18399341
injection	O	-1	18399341
while	O	-1	18399341
those	O	-1	18399341
in	O	-1	18399341
the	O	-1	18399341
con@@	O	-1	18399341
ven@@	O	-1	18399341
tional	O	-1	18399341
group	O	-1	18399341
were	O	-1	18399341
t@@	O	-1	18399341
ur@@	O	-1	18399341
n@@	O	-1	18399341
ed	O	-1	18399341
sup@@	O	-1	18399341
ine	O	-1	18399341
immedi@@	O	-1	18399341
ately	O	-1	18399341
after	O	-1	18399341
injec@@	O	-1	18399341
tion.	O	-1	18399341
B@@	O	-1	18399341
lo@@	O	-1	18399341
od	O	-1	18399341
pressu@@	O	-1	18399341
re,	O	-1	18399341
heart	O	-1	18399341
rat@@	O	-1	18399341
e,	O	-1	18399341
respiratory	O	-1	18399341
rate	O	-1	18399341
and	O	-1	18399341
oxy@@	B-Chemical	D010100	18399341
gen	I-Chemical	-1	18399341
s@@	O	-1	18399341
at@@	O	-1	18399341
ur@@	O	-1	18399341
ation	O	-1	18399341
were	O	-1	18399341
monit@@	O	-1	18399341
o@@	O	-1	18399341
red	O	-1	18399341
over	O	-1	18399341
1	O	-1	18399341
hour@@	O	-1	18399341
.	O	-1	18399341
RESULTS:	O	-1	18399341
Th@@	O	-1	18399341
ree	O	-1	18399341
patients	O	-1	18399341
(@@	O	-1	18399341
8.@@	O	-1	18399341
1@@	O	-1	18399341
%)	O	-1	18399341
in	O	-1	18399341
the	O	-1	18399341
un@@	O	-1	18399341
il@@	O	-1	18399341
ateral	O	-1	18399341
group	O	-1	18399341
and	O	-1	18399341
5	O	-1	18399341
(1@@	O	-1	18399341
3.@@	O	-1	18399341
5@@	O	-1	18399341
%)	O	-1	18399341
in	O	-1	18399341
the	O	-1	18399341
con@@	O	-1	18399341
ven@@	O	-1	18399341
tional	O	-1	18399341
group	O	-1	18399341
developed	O	-1	18399341
hypotension	B-Disease	D007022	18399341
,	O	-1	18399341
P@@	O	-1	18399341
=	O	-1	18399341
0.@@	O	-1	18399341
7@@	O	-1	18399341
1@@	O	-1	18399341
.	O	-1	18399341
F@@	O	-1	18399341
our	O	-1	18399341
(1@@	O	-1	18399341
0.@@	O	-1	18399341
8@@	O	-1	18399341
%)	O	-1	18399341
patients	O	-1	18399341
in	O	-1	18399341
the	O	-1	18399341
con@@	O	-1	18399341
ven@@	O	-1	18399341
tional	O	-1	18399341
group	O	-1	18399341
and	O	-1	18399341
1	O	-1	18399341
(2@@	O	-1	18399341
.@@	O	-1	18399341
7@@	O	-1	18399341
%)	O	-1	18399341
in	O	-1	18399341
the	O	-1	18399341
un@@	O	-1	18399341
il@@	O	-1	18399341
ateral	O	-1	18399341
group@@	O	-1	18399341
,	O	-1	18399341
P@@	O	-1	18399341
=	O	-1	18399341
0.@@	O	-1	18399341
17	O	-1	18399341
requ@@	O	-1	18399341
ired	O	-1	18399341
ep@@	B-Chemical	D004837	18399341
ine@@	I-Chemical	-1	18399341
phrine	I-Chemical	-1	18399341
infusion	O	-1	18399341
to	O	-1	18399341
tre@@	O	-1	18399341
at	O	-1	18399341
hypotension	B-Disease	D007022	18399341
.	O	-1	18399341
Patients	O	-1	18399341
in	O	-1	18399341
the	O	-1	18399341
con@@	O	-1	18399341
ven@@	O	-1	18399341
tional	O	-1	18399341
group	O	-1	18399341
had	O	-1	18399341
statis@@	O	-1	18399341
tically	O	-1	18399341
significant	O	-1	18399341
greater	O	-1	18399341
f@@	O	-1	18399341
all	O	-1	18399341
in	O	-1	18399341
the	O	-1	18399341
systolic	O	-1	18399341
blood	O	-1	18399341
pressu@@	O	-1	18399341
res	O	-1	18399341
at	O	-1	18399341
1@@	O	-1	18399341
5,	O	-1	18399341
30	O	-1	18399341
and	O	-1	18399341
4@@	O	-1	18399341
5	O	-1	18399341
minutes	O	-1	18399341
when	O	-1	18399341
compared	O	-1	18399341
to	O	-1	18399341
the	O	-1	18399341
baseline	O	-1	18399341
(P@@	O	-1	18399341
=	O	-1	18399341
0.00@@	O	-1	18399341
3,	O	-1	18399341
0.00@@	O	-1	18399341
1	O	-1	18399341
and	O	-1	18399341
0.00@@	O	-1	18399341
4@@	O	-1	18399341
).	O	-1	18399341
The	O	-1	18399341
mean	O	-1	18399341
respiratory	O	-1	18399341
rate	O	-1	18399341
and	O	-1	18399341
oxy@@	B-Chemical	D010100	18399341
gen	I-Chemical	-1	18399341
s@@	O	-1	18399341
at@@	O	-1	18399341
ur@@	O	-1	18399341
ations	O	-1	18399341
in	O	-1	18399341
the	O	-1	18399341
two	O	-1	18399341
groups	O	-1	18399341
were	O	-1	18399341
simil@@	O	-1	18399341
ar@@	O	-1	18399341
.	O	-1	18399341
CONCLUSION:	O	-1	18399341
Com@@	O	-1	18399341
pared	O	-1	18399341
to	O	-1	18399341
con@@	O	-1	18399341
ven@@	O	-1	18399341
tional	O	-1	18399341
spinal	O	-1	18399341
anaesthe@@	O	-1	18399341
si@@	O	-1	18399341
a,	O	-1	18399341
un@@	O	-1	18399341
il@@	O	-1	18399341
ateral	O	-1	18399341
spinal	O	-1	18399341
anaesthe@@	O	-1	18399341
sia	O	-1	18399341
was	O	-1	18399341
associated	O	-1	18399341
with	O	-1	18399341
fe@@	O	-1	18399341
w@@	O	-1	18399341
er	O	-1	18399341
cardiovascular	O	-1	18399341
per@@	O	-1	18399341
t@@	O	-1	18399341
urb@@	O	-1	18399341
ations.	O	-1	18399341
Al@@	O	-1	18399341
so@@	O	-1	18399341
,	O	-1	18399341
the	O	-1	18399341
type	O	-1	18399341
of	O	-1	18399341
spinal	O	-1	18399341
bloc@@	O	-1	18399341
k	O	-1	18399341
insti@@	O	-1	18399341
t@@	O	-1	18399341
ut@@	O	-1	18399341
ed	O	-1	18399341
affected	O	-1	18399341
ne@@	O	-1	18399341
ither	O	-1	18399341
the	O	-1	18399341
respiratory	O	-1	18399341
rate	O	-1	18399341
n@@	O	-1	18399341
or	O	-1	18399341
the	O	-1	18399341
arterial	O	-1	18399341
oxy@@	B-Chemical	D010100	18399341
gen	I-Chemical	-1	18399341
s@@	O	-1	18399341
at@@	O	-1	18399341
ur@@	O	-1	18399341
ation.	O	-1	18399341

S@@	O	-1	18422462
p@@	O	-1	18422462
ect@@	O	-1	18422462
ru@@	O	-1	18422462
m	O	-1	18422462
of	O	-1	18422462
adverse	O	-1	18422462
events	O	-1	18422462
after	O	-1	18422462
gener@@	O	-1	18422462
ic	O	-1	18422462
H@@	O	-1	18422462
A@@	O	-1	18422462
A@@	O	-1	18422462
R@@	O	-1	18422462
T	O	-1	18422462
in	O	-1	18422462
s@@	O	-1	18422462
ou@@	O	-1	18422462
ther@@	O	-1	18422462
n	O	-1	18422462
In@@	O	-1	18422462
di@@	O	-1	18422462
an	O	-1	18422462
H@@	B-Disease	D015658	18422462
I@@	I-Disease	-1	18422462
V@@	I-Disease	-1	18422462
-@@	I-Disease	-1	18422462
inf@@	I-Disease	-1	18422462
ected	I-Disease	-1	18422462
patients.	O	-1	18422462
To	O	-1	18422462
determine	O	-1	18422462
the	O	-1	18422462
incidence	O	-1	18422462
of	O	-1	18422462
clin@@	O	-1	18422462
ically	O	-1	18422462
significant	O	-1	18422462
adverse	O	-1	18422462
events	O	-1	18422462
after	O	-1	18422462
long@@	O	-1	18422462
-@@	O	-1	18422462
ter@@	O	-1	18422462
m@@	O	-1	18422462
,	O	-1	18422462
fi@@	O	-1	18422462
x@@	O	-1	18422462
ed@@	O	-1	18422462
-@@	O	-1	18422462
dose@@	O	-1	18422462
,	O	-1	18422462
gener@@	O	-1	18422462
ic	O	-1	18422462
high@@	O	-1	18422462
ly	O	-1	18422462
active	O	-1	18422462
anti@@	O	-1	18422462
ret@@	O	-1	18422462
ro@@	O	-1	18422462
viral	O	-1	18422462
therapy	O	-1	18422462
(@@	O	-1	18422462
H@@	O	-1	18422462
A@@	O	-1	18422462
A@@	O	-1	18422462
R@@	O	-1	18422462
T)	O	-1	18422462
use	O	-1	18422462
among	O	-1	18422462
H@@	B-Disease	D015658	18422462
I@@	I-Disease	-1	18422462
V@@	I-Disease	-1	18422462
-@@	I-Disease	-1	18422462
inf@@	I-Disease	-1	18422462
ected	I-Disease	-1	18422462
individ@@	O	-1	18422462
u@@	O	-1	18422462
als	O	-1	18422462
in	O	-1	18422462
S@@	O	-1	18422462
ou@@	O	-1	18422462
th	O	-1	18422462
In@@	O	-1	18422462
di@@	O	-1	18422462
a,	O	-1	18422462
we	O	-1	18422462
examined	O	-1	18422462
the	O	-1	18422462
experienc@@	O	-1	18422462
es	O	-1	18422462
of	O	-1	18422462
3@@	O	-1	18422462
1@@	O	-1	18422462
5@@	O	-1	18422462
4	O	-1	18422462
H@@	B-Disease	D015658	18422462
I@@	I-Disease	-1	18422462
V@@	I-Disease	-1	18422462
-@@	I-Disease	-1	18422462
inf@@	I-Disease	-1	18422462
ected	I-Disease	-1	18422462
individ@@	O	-1	18422462
u@@	O	-1	18422462
als	O	-1	18422462
who	O	-1	18422462
received	O	-1	18422462
a	O	-1	18422462
minim@@	O	-1	18422462
um	O	-1	18422462
of	O	-1	18422462
3	O	-1	18422462
months	O	-1	18422462
of	O	-1	18422462
gener@@	O	-1	18422462
ic	O	-1	18422462
H@@	O	-1	18422462
A@@	O	-1	18422462
A@@	O	-1	18422462
R@@	O	-1	18422462
T	O	-1	18422462
between	O	-1	18422462
F@@	O	-1	18422462
e@@	O	-1	18422462
b@@	O	-1	18422462
ru@@	O	-1	18422462
ary	O	-1	18422462
19@@	O	-1	18422462
9@@	O	-1	18422462
6	O	-1	18422462
and	O	-1	18422462
D@@	O	-1	18422462
ec@@	O	-1	18422462
emb@@	O	-1	18422462
er	O	-1	18422462
20@@	O	-1	18422462
0@@	O	-1	18422462
6	O	-1	18422462
at	O	-1	18422462
a	O	-1	18422462
ter@@	O	-1	18422462
ti@@	O	-1	18422462
ary	O	-1	18422462
H@@	O	-1	18422462
IV	O	-1	18422462
car@@	O	-1	18422462
e	O	-1	18422462
ref@@	O	-1	18422462
er@@	O	-1	18422462
ral	O	-1	18422462
c@@	O	-1	18422462
ent@@	O	-1	18422462
er	O	-1	18422462
in	O	-1	18422462
S@@	O	-1	18422462
ou@@	O	-1	18422462
th	O	-1	18422462
In@@	O	-1	18422462
di@@	O	-1	18422462
a.	O	-1	18422462
The	O	-1	18422462
most	O	-1	18422462
common	O	-1	18422462
regimen@@	O	-1	18422462
s	O	-1	18422462
were	O	-1	18422462
3@@	B-Chemical	D019259	18422462
T@@	I-Chemical	-1	18422462
C	I-Chemical	-1	18422462
+	O	-1	18422462
d@@	B-Chemical	D018119	18422462
4@@	I-Chemical	-1	18422462
T	I-Chemical	-1	18422462
+	O	-1	18422462
ne@@	B-Chemical	D019829	18422462
vi@@	I-Chemical	-1	18422462
ra@@	I-Chemical	-1	18422462
pine	I-Chemical	-1	18422462
(	O	-1	18422462
N@@	B-Chemical	D019829	18422462
V@@	I-Chemical	-1	18422462
P	I-Chemical	-1	18422462
)	O	-1	18422462
(5@@	O	-1	18422462
4.@@	O	-1	18422462
8@@	O	-1	18422462
%),	O	-1	18422462
z@@	B-Chemical	D015215	18422462
id@@	I-Chemical	-1	18422462
o@@	I-Chemical	-1	18422462
vud@@	I-Chemical	-1	18422462
ine	I-Chemical	-1	18422462
(	O	-1	18422462
A@@	B-Chemical	D015215	18422462
Z@@	I-Chemical	-1	18422462
T	I-Chemical	-1	18422462
)	O	-1	18422462
+	O	-1	18422462
3@@	B-Chemical	D019259	18422462
T@@	I-Chemical	-1	18422462
C	I-Chemical	-1	18422462
+	O	-1	18422462
N@@	B-Chemical	D019829	18422462
V@@	I-Chemical	-1	18422462
P	I-Chemical	-1	18422462
(1@@	O	-1	18422462
4.@@	O	-1	18422462
5@@	O	-1	18422462
%),	O	-1	18422462
3@@	B-Chemical	D019259	18422462
T@@	I-Chemical	-1	18422462
C	I-Chemical	-1	18422462
+	O	-1	18422462
d@@	B-Chemical	D018119	18422462
4@@	I-Chemical	-1	18422462
T	I-Chemical	-1	18422462
+	O	-1	18422462
e@@	B-Chemical	C098320	18422462
f@@	I-Chemical	-1	18422462
avi@@	I-Chemical	-1	18422462
ren@@	I-Chemical	-1	18422462
z	I-Chemical	-1	18422462
(	O	-1	18422462
E@@	B-Chemical	C098320	18422462
F@@	I-Chemical	-1	18422462
V	I-Chemical	-1	18422462
)	O	-1	18422462
(2@@	O	-1	18422462
0.@@	O	-1	18422462
1@@	O	-1	18422462
%),	O	-1	18422462
and	O	-1	18422462
A@@	B-Chemical	D015215	18422462
Z@@	I-Chemical	-1	18422462
T	I-Chemical	-1	18422462
+	O	-1	18422462
3@@	B-Chemical	D019259	18422462
T@@	I-Chemical	-1	18422462
C	I-Chemical	-1	18422462
+	O	-1	18422462
E@@	B-Chemical	C098320	18422462
F@@	I-Chemical	-1	18422462
V	I-Chemical	-1	18422462
(@@	O	-1	18422462
5.@@	O	-1	18422462
4@@	O	-1	18422462
%).	O	-1	18422462
The	O	-1	18422462
most	O	-1	18422462
common	O	-1	18422462
adverse	O	-1	18422462
events	O	-1	18422462
and	O	-1	18422462
median	O	-1	18422462
C@@	O	-1	18422462
D@@	O	-1	18422462
4	O	-1	18422462
at	O	-1	18422462
time	O	-1	18422462
of	O	-1	18422462
ev@@	O	-1	18422462
ent	O	-1	18422462
were	O	-1	18422462
r@@	B-Disease	D005076	18422462
as@@	I-Disease	-1	18422462
h	I-Disease	-1	18422462
(1@@	O	-1	18422462
5.@@	O	-1	18422462
2@@	O	-1	18422462
%@@	O	-1	18422462
;	O	-1	18422462
C@@	O	-1	18422462
D@@	O	-1	18422462
4@@	O	-1	18422462
,	O	-1	18422462
2@@	O	-1	18422462
8@@	O	-1	18422462
5	O	-1	18422462
cell@@	O	-1	18422462
s/@@	O	-1	18422462
micro@@	O	-1	18422462
L@@	O	-1	18422462
)	O	-1	18422462
and	O	-1	18422462
peripheral	B-Disease	D010523	18422462
neuropathy	I-Disease	-1	18422462
(@@	O	-1	18422462
9.@@	O	-1	18422462
0%	O	-1	18422462
and	O	-1	18422462
34@@	O	-1	18422462
8	O	-1	18422462
cell@@	O	-1	18422462
s/@@	O	-1	18422462
micro@@	O	-1	18422462
L@@	O	-1	18422462
).	O	-1	18422462
Clin@@	O	-1	18422462
ically	O	-1	18422462
significant	O	-1	18422462
anemia	B-Disease	D000740	18422462
(@@	O	-1	18422462
hemo@@	O	-1	18422462
globin	O	-1	18422462
<@@	O	-1	18422462
7	O	-1	18422462
g/@@	O	-1	18422462
d@@	O	-1	18422462
L@@	O	-1	18422462
)	O	-1	18422462
was	O	-1	18422462
observed	O	-1	18422462
in	O	-1	18422462
5.@@	O	-1	18422462
4@@	O	-1	18422462
%	O	-1	18422462
of	O	-1	18422462
patients	O	-1	18422462
(C@@	O	-1	18422462
D@@	O	-1	18422462
4@@	O	-1	18422462
,	O	-1	18422462
1@@	O	-1	18422462
6@@	O	-1	18422462
5	O	-1	18422462
cell@@	O	-1	18422462
s/@@	O	-1	18422462
micro@@	O	-1	18422462
L@@	O	-1	18422462
)	O	-1	18422462
and	O	-1	18422462
hepatitis	B-Disease	D056486	18422462
(@@	O	-1	18422462
clinical	O	-1	18422462
j@@	B-Disease	D007565	18422462
a@@	I-Disease	-1	18422462
un@@	I-Disease	-1	18422462
dic@@	I-Disease	-1	18422462
e	I-Disease	-1	18422462
with	O	-1	18422462
al@@	B-Chemical	D000409	18422462
an@@	I-Chemical	-1	18422462
ine	I-Chemical	-1	18422462
amin@@	O	-1	18422462
ot@@	O	-1	18422462
ran@@	O	-1	18422462
s@@	O	-1	18422462
fer@@	O	-1	18422462
ase	O	-1	18422462
>	O	-1	18422462
5	O	-1	18422462
times	O	-1	18422462
up@@	O	-1	18422462
per	O	-1	18422462
lim@@	O	-1	18422462
its	O	-1	18422462
of	O	-1	18422462
normal@@	O	-1	18422462
)	O	-1	18422462
in	O	-1	18422462
3.@@	O	-1	18422462
5%	O	-1	18422462
of	O	-1	18422462
patients	O	-1	18422462
(C@@	O	-1	18422462
D@@	O	-1	18422462
4@@	O	-1	18422462
,	O	-1	18422462
2@@	O	-1	18422462
60	O	-1	18422462
cell@@	O	-1	18422462
s/@@	O	-1	18422462
micro@@	O	-1	18422462
L@@	O	-1	18422462
).	O	-1	18422462
W@@	O	-1	18422462
o@@	O	-1	18422462
men	O	-1	18422462
were	O	-1	18422462
significantly	O	-1	18422462
more	O	-1	18422462
likely	O	-1	18422462
to	O	-1	18422462
experi@@	O	-1	18422462
ence	O	-1	18422462
l@@	B-Disease	D000140	18422462
ac@@	I-Disease	-1	18422462
tic	I-Disease	-1	18422462
acid@@	I-Disease	-1	18422462
o@@	I-Disease	-1	18422462
sis	I-Disease	-1	18422462
,	O	-1	18422462
while	O	-1	18422462
men	O	-1	18422462
were	O	-1	18422462
significantly	O	-1	18422462
more	O	-1	18422462
likely	O	-1	18422462
to	O	-1	18422462
experi@@	O	-1	18422462
ence	O	-1	18422462
immun@@	B-Disease	D054019	18422462
e	I-Disease	-1	18422462
re@@	I-Disease	-1	18422462
con@@	I-Disease	-1	18422462
sti@@	I-Disease	-1	18422462
tu@@	I-Disease	-1	18422462
tion	I-Disease	-1	18422462
syndrome	I-Disease	-1	18422462
(p	O	-1	18422462
<	O	-1	18422462
0.05@@	O	-1	18422462
).	O	-1	18422462
A@@	O	-1	18422462
mon@@	O	-1	18422462
g	O	-1	18422462
the	O	-1	18422462
patients	O	-1	18422462
with	O	-1	18422462
1	O	-1	18422462
year	O	-1	18422462
of	O	-1	18422462
follow-@@	O	-1	18422462
up@@	O	-1	18422462
,	O	-1	18422462
N@@	B-Chemical	D019829	18422462
V@@	I-Chemical	-1	18422462
P	I-Chemical	-1	18422462
therapy	O	-1	18422462
was	O	-1	18422462
significantly	O	-1	18422462
associated	O	-1	18422462
with	O	-1	18422462
develop@@	O	-1	18422462
ing	O	-1	18422462
r@@	B-Disease	D005076	18422462
as@@	I-Disease	-1	18422462
h	I-Disease	-1	18422462
and	O	-1	18422462
d@@	B-Chemical	D018119	18422462
4@@	I-Chemical	-1	18422462
T	I-Chemical	-1	18422462
therapy	O	-1	18422462
with	O	-1	18422462
develop@@	O	-1	18422462
ing	O	-1	18422462
peripheral	B-Disease	D010523	18422462
neuropathy	I-Disease	-1	18422462
(p	O	-1	18422462
<	O	-1	18422462
0.05@@	O	-1	18422462
).	O	-1	18422462
A@@	B-Disease	D000740	18422462
ne@@	I-Disease	-1	18422462
mia	I-Disease	-1	18422462
and	O	-1	18422462
hepatitis	B-Disease	D056486	18422462
often	O	-1	18422462
occ@@	O	-1	18422462
ur	O	-1	18422462
within	O	-1	18422462
12	O	-1	18422462
weeks	O	-1	18422462
of	O	-1	18422462
initi@@	O	-1	18422462
ating	O	-1	18422462
gener@@	O	-1	18422462
ic	O	-1	18422462
H@@	O	-1	18422462
A@@	O	-1	18422462
A@@	O	-1	18422462
R@@	O	-1	18422462
T@@	O	-1	18422462
.	O	-1	18422462
F@@	O	-1	18422462
requ@@	O	-1	18422462
ent	O	-1	18422462
and	O	-1	18422462
early	O	-1	18422462
monit@@	O	-1	18422462
or@@	O	-1	18422462
ing	O	-1	18422462
for	O	-1	18422462
these	O	-1	18422462
toxic@@	B-Disease	D064420	18422462
ities	I-Disease	-1	18422462
is	O	-1	18422462
war@@	O	-1	18422462
ran@@	O	-1	18422462
ted	O	-1	18422462
in	O	-1	18422462
develop@@	O	-1	18422462
ing	O	-1	18422462
coun@@	O	-1	18422462
tri@@	O	-1	18422462
es	O	-1	18422462
wh@@	O	-1	18422462
ere	O	-1	18422462
gener@@	O	-1	18422462
ic	O	-1	18422462
H@@	O	-1	18422462
A@@	O	-1	18422462
A@@	O	-1	18422462
R@@	O	-1	18422462
T	O	-1	18422462
is	O	-1	18422462
increas@@	O	-1	18422462
ing@@	O	-1	18422462
ly	O	-1	18422462
av@@	O	-1	18422462
ail@@	O	-1	18422462
able@@	O	-1	18422462
.	O	-1	18422462

Th@@	B-Chemical	D013792	18450790
al@@	I-Chemical	-1	18450790
id@@	I-Chemical	-1	18450790
om@@	I-Chemical	-1	18450790
ide	I-Chemical	-1	18450790
and	O	-1	18450790
sens@@	B-Disease	D010523	18450790
ory	I-Disease	-1	18450790
neuro@@	I-Disease	-1	18450790
toxicity	I-Disease	-1	18450790
:	O	-1	18450790
a	O	-1	18450790
neuro@@	O	-1	18450790
physi@@	O	-1	18450790
ological	O	-1	18450790
study.	O	-1	18450790
BACKGROUND:	O	-1	18450790
Rec@@	O	-1	18450790
ent	O	-1	18450790
studies	O	-1	18450790
con@@	O	-1	18450790
fir@@	O	-1	18450790
m@@	O	-1	18450790
ed	O	-1	18450790
a	O	-1	18450790
high	O	-1	18450790
incidence	O	-1	18450790
of	O	-1	18450790
sens@@	B-Disease	D010523	18450790
ory	I-Disease	-1	18450790
ax@@	I-Disease	-1	18450790
on@@	I-Disease	-1	18450790
al	I-Disease	-1	18450790
neuropathy	I-Disease	-1	18450790
in	O	-1	18450790
patients	O	-1	18450790
treated	O	-1	18450790
with	O	-1	18450790
different	O	-1	18450790
doses	O	-1	18450790
of	O	-1	18450790
thal@@	B-Chemical	D013792	18450790
id@@	I-Chemical	-1	18450790
om@@	I-Chemical	-1	18450790
ide	I-Chemical	-1	18450790
.	O	-1	18450790
The	O	-1	18450790
stud@@	O	-1	18450790
y@@	O	-1	18450790
's	O	-1	18450790
a@@	O	-1	18450790
im@@	O	-1	18450790
s	O	-1	18450790
were	O	-1	18450790
to	O	-1	18450790
meas@@	O	-1	18450790
ure	O	-1	18450790
vari@@	O	-1	18450790
ations	O	-1	18450790
in	O	-1	18450790
sur@@	O	-1	18450790
al	O	-1	18450790
nerve	O	-1	18450790
sens@@	O	-1	18450790
ory	O	-1	18450790
action	O	-1	18450790
potential	O	-1	18450790
(S@@	O	-1	18450790
A@@	O	-1	18450790
P)	O	-1	18450790
am@@	O	-1	18450790
pl@@	O	-1	18450790
it@@	O	-1	18450790
ude	O	-1	18450790
in	O	-1	18450790
patients	O	-1	18450790
with	O	-1	18450790
ref@@	O	-1	18450790
rac@@	O	-1	18450790
t@@	O	-1	18450790
ory	O	-1	18450790
c@@	B-Disease	D008178	18450790
utaneous	I-Disease	-1	18450790
lu@@	I-Disease	-1	18450790
p@@	I-Disease	-1	18450790
us	I-Disease	-1	18450790
eryth@@	I-Disease	-1	18450790
em@@	I-Disease	-1	18450790
at@@	I-Disease	-1	18450790
os@@	I-Disease	-1	18450790
us	I-Disease	-1	18450790
(	O	-1	18450790
CL@@	B-Disease	D008178	18450790
E	I-Disease	-1	18450790
)	O	-1	18450790
treated	O	-1	18450790
with	O	-1	18450790
thal@@	B-Chemical	D013792	18450790
id@@	I-Chemical	-1	18450790
om@@	I-Chemical	-1	18450790
ide	I-Chemical	-1	18450790
and	O	-1	18450790
use	O	-1	18450790
these	O	-1	18450790
findings	O	-1	18450790
to	O	-1	18450790
identi@@	O	-1	18450790
f@@	O	-1	18450790
y	O	-1	18450790
the	O	-1	18450790
neuro@@	B-Disease	D020258	18450790
toxic	I-Disease	-1	18450790
potential	O	-1	18450790
of	O	-1	18450790
thal@@	B-Chemical	D013792	18450790
id@@	I-Chemical	-1	18450790
om@@	I-Chemical	-1	18450790
ide	I-Chemical	-1	18450790
and	O	-1	18450790
the	O	-1	18450790
recovery	O	-1	18450790
cap@@	O	-1	18450790
ac@@	O	-1	18450790
ity	O	-1	18450790
of	O	-1	18450790
sens@@	O	-1	18450790
ory	O	-1	18450790
fib@@	O	-1	18450790
res	O	-1	18450790
after	O	-1	18450790
discontinu@@	O	-1	18450790
ation	O	-1	18450790
of	O	-1	18450790
treatment.	O	-1	18450790
PA@@	O	-1	18450790
TI@@	O	-1	18450790
E@@	O	-1	18450790
N@@	O	-1	18450790
T@@	O	-1	18450790
S	O	-1	18450790
AN@@	O	-1	18450790
D	O	-1	18450790
METHODS:	O	-1	18450790
Clin@@	O	-1	18450790
ical	O	-1	18450790
and	O	-1	18450790
electro@@	O	-1	18450790
physi@@	O	-1	18450790
ological	O	-1	18450790
data	O	-1	18450790
in	O	-1	18450790
12	O	-1	18450790
female	O	-1	18450790
patients	O	-1	18450790
with	O	-1	18450790
CL@@	B-Disease	D008178	18450790
E	I-Disease	-1	18450790
during	O	-1	18450790
treatment	O	-1	18450790
with	O	-1	18450790
thal@@	B-Chemical	D013792	18450790
id@@	I-Chemical	-1	18450790
om@@	I-Chemical	-1	18450790
ide	I-Chemical	-1	18450790
and	O	-1	18450790
up	O	-1	18450790
to	O	-1	18450790
4@@	O	-1	18450790
7	O	-1	18450790
months	O	-1	18450790
after	O	-1	18450790
discontinu@@	O	-1	18450790
ation	O	-1	18450790
of	O	-1	18450790
treatment	O	-1	18450790
were	O	-1	18450790
analy@@	O	-1	18450790
sed.	O	-1	18450790
S@@	O	-1	18450790
ural	O	-1	18450790
nerve	O	-1	18450790
S@@	O	-1	18450790
A@@	O	-1	18450790
P	O	-1	18450790
am@@	O	-1	18450790
pl@@	O	-1	18450790
it@@	O	-1	18450790
ude	O	-1	18450790
reduction	O	-1	18450790
>	O	-1	18450790
or	O	-1	18450790
=@@	O	-1	18450790
4@@	O	-1	18450790
0%	O	-1	18450790
was	O	-1	18450790
the	O	-1	18450790
c@@	O	-1	18450790
rit@@	O	-1	18450790
er@@	O	-1	18450790
ia	O	-1	18450790
for	O	-1	18450790
discontinu@@	O	-1	18450790
ing	O	-1	18450790
therapy.	O	-1	18450790
RESULTS:	O	-1	18450790
D@@	O	-1	18450790
uring	O	-1	18450790
treatment,	O	-1	18450790
11	O	-1	18450790
patients	O	-1	18450790
showed	O	-1	18450790
a	O	-1	18450790
reduction	O	-1	18450790
in	O	-1	18450790
sur@@	O	-1	18450790
al	O	-1	18450790
nerve	O	-1	18450790
S@@	O	-1	18450790
A@@	O	-1	18450790
P	O	-1	18450790
am@@	O	-1	18450790
pl@@	O	-1	18450790
it@@	O	-1	18450790
ude	O	-1	18450790
compared	O	-1	18450790
to	O	-1	18450790
baseline	O	-1	18450790
values	O	-1	18450790
(@@	O	-1	18450790
9	O	-1	18450790
with	O	-1	18450790
a	O	-1	18450790
reduction	O	-1	18450790
>	O	-1	18450790
or	O	-1	18450790
=@@	O	-1	18450790
50@@	O	-1	18450790
%	O	-1	18450790
and	O	-1	18450790
2	O	-1	18450790
<@@	O	-1	18450790
50@@	O	-1	18450790
%).	O	-1	18450790
One	O	-1	18450790
patient	O	-1	18450790
showed	O	-1	18450790
no	O	-1	18450790
changes	O	-1	18450790
in	O	-1	18450790
S@@	O	-1	18450790
A@@	O	-1	18450790
P	O	-1	18450790
am@@	O	-1	18450790
pl@@	O	-1	18450790
it@@	O	-1	18450790
u@@	O	-1	18450790
de@@	O	-1	18450790
.	O	-1	18450790
F@@	O	-1	18450790
i@@	O	-1	18450790
ve	O	-1	18450790
patients	O	-1	18450790
com@@	O	-1	18450790
pl@@	O	-1	18450790
ained	O	-1	18450790
of	O	-1	18450790
pa@@	B-Disease	D010292	18450790
res@@	I-Disease	-1	18450790
the@@	I-Disease	-1	18450790
si@@	I-Disease	-1	18450790
as	I-Disease	-1	18450790
and	O	-1	18450790
le@@	O	-1	18450790
g	O	-1	18450790
c@@	B-Disease	D009120	18450790
ram@@	I-Disease	-1	18450790
p@@	I-Disease	-1	18450790
s	I-Disease	-1	18450790
.	O	-1	18450790
After	O	-1	18450790
thal@@	B-Chemical	D013792	18450790
id@@	I-Chemical	-1	18450790
om@@	I-Chemical	-1	18450790
ide	I-Chemical	-1	18450790
treatment,	O	-1	18450790
sur@@	O	-1	18450790
al	O	-1	18450790
S@@	O	-1	18450790
A@@	O	-1	18450790
P	O	-1	18450790
am@@	O	-1	18450790
pl@@	O	-1	18450790
it@@	O	-1	18450790
ude	O	-1	18450790
reco@@	O	-1	18450790
vered	O	-1	18450790
in	O	-1	18450790
3	O	-1	18450790
patients.	O	-1	18450790
A@@	O	-1	18450790
t	O	-1	18450790
det@@	O	-1	18450790
ection	O	-1	18450790
of	O	-1	18450790
reduction	O	-1	18450790
in	O	-1	18450790
sur@@	O	-1	18450790
al	O	-1	18450790
nerve	O	-1	18450790
S@@	O	-1	18450790
A@@	O	-1	18450790
P	O	-1	18450790
am@@	O	-1	18450790
pl@@	O	-1	18450790
it@@	O	-1	18450790
u@@	O	-1	18450790
de@@	O	-1	18450790
,	O	-1	18450790
the	O	-1	18450790
median	O	-1	18450790
thal@@	B-Chemical	D013792	18450790
id@@	I-Chemical	-1	18450790
om@@	I-Chemical	-1	18450790
ide	I-Chemical	-1	18450790
cum@@	O	-1	18450790
ul@@	O	-1	18450790
ative	O	-1	18450790
dose	O	-1	18450790
was	O	-1	18450790
2@@	O	-1	18450790
1.@@	O	-1	18450790
4	O	-1	18450790
g@@	O	-1	18450790
.	O	-1	18450790
The	O	-1	18450790
th@@	O	-1	18450790
res@@	O	-1	18450790
h@@	O	-1	18450790
old	O	-1	18450790
neuro@@	B-Disease	D020258	18450790
toxic	I-Disease	-1	18450790
dos@@	O	-1	18450790
age	O	-1	18450790
is	O	-1	18450790
lower	O	-1	18450790
than	O	-1	18450790
previously	O	-1	18450790
repor@@	O	-1	18450790
ted.	O	-1	18450790
CONCLUSIONS:	O	-1	18450790
S@@	O	-1	18450790
ural	O	-1	18450790
nerve	O	-1	18450790
S@@	O	-1	18450790
A@@	O	-1	18450790
P	O	-1	18450790
am@@	O	-1	18450790
pl@@	O	-1	18450790
it@@	O	-1	18450790
ude	O	-1	18450790
reduction	O	-1	18450790
is	O	-1	18450790
a	O	-1	18450790
re@@	O	-1	18450790
li@@	O	-1	18450790
able	O	-1	18450790
and	O	-1	18450790
sensitive	O	-1	18450790
mark@@	O	-1	18450790
er	O	-1	18450790
of	O	-1	18450790
de@@	O	-1	18450790
generation	O	-1	18450790
and	O	-1	18450790
recovery	O	-1	18450790
of	O	-1	18450790
sens@@	O	-1	18450790
ory	O	-1	18450790
fib@@	O	-1	18450790
res@@	O	-1	18450790
.	O	-1	18450790
This	O	-1	18450790
electro@@	O	-1	18450790
physi@@	O	-1	18450790
ological	O	-1	18450790
par@@	O	-1	18450790
ame@@	O	-1	18450790
ter	O	-1	18450790
pro@@	O	-1	18450790
vi@@	O	-1	18450790
des	O	-1	18450790
inf@@	O	-1	18450790
orm@@	O	-1	18450790
ation	O	-1	18450790
about	O	-1	18450790
sub@@	O	-1	18450790
clinical	O	-1	18450790
neuro@@	B-Disease	D020258	18450790
toxic	I-Disease	-1	18450790
potential	O	-1	18450790
of	O	-1	18450790
thal@@	B-Chemical	D013792	18450790
id@@	I-Chemical	-1	18450790
om@@	I-Chemical	-1	18450790
ide	I-Chemical	-1	18450790
but	O	-1	18450790
is	O	-1	18450790
not	O	-1	18450790
he@@	O	-1	18450790
l@@	O	-1	18450790
p@@	O	-1	18450790
ful	O	-1	18450790
in	O	-1	18450790
predic@@	O	-1	18450790
ting	O	-1	18450790
the	O	-1	18450790
appear@@	O	-1	18450790
ance	O	-1	18450790
of	O	-1	18450790
sens@@	O	-1	18450790
ory	O	-1	18450790
symptom@@	O	-1	18450790
s.	O	-1	18450790

A@@	B-Chemical	D000638	18801087
m@@	I-Chemical	-1	18801087
iodar@@	I-Chemical	-1	18801087
one	I-Chemical	-1	18801087
-@@	O	-1	18801087
related	O	-1	18801087
pulmonary	B-Disease	D055370	18801087
mas@@	I-Disease	-1	18801087
s	I-Disease	-1	18801087
and	O	-1	18801087
un@@	O	-1	18801087
i@@	O	-1	18801087
qu@@	O	-1	18801087
e	O	-1	18801087
membran@@	B-Disease	D015433	18801087
ous	I-Disease	-1	18801087
glomerul@@	I-Disease	-1	18801087
one@@	I-Disease	-1	18801087
ph@@	I-Disease	-1	18801087
ritis	I-Disease	-1	18801087
in	O	-1	18801087
a	O	-1	18801087
patient	O	-1	18801087
with	O	-1	18801087
val@@	B-Disease	D006349	18801087
v@@	I-Disease	-1	18801087
ular	I-Disease	-1	18801087
heart	I-Disease	-1	18801087
disease	I-Disease	-1	18801087
:	O	-1	18801087
Di@@	O	-1	18801087
ag@@	O	-1	18801087
nos@@	O	-1	18801087
tic	O	-1	18801087
pit@@	O	-1	18801087
f@@	O	-1	18801087
all	O	-1	18801087
and	O	-1	18801087
new	O	-1	18801087
find@@	O	-1	18801087
ing@@	O	-1	18801087
s.	O	-1	18801087
A@@	B-Chemical	D000638	18801087
m@@	I-Chemical	-1	18801087
iodar@@	I-Chemical	-1	18801087
one	I-Chemical	-1	18801087
is	O	-1	18801087
an	O	-1	18801087
anti@@	O	-1	18801087
-	O	-1	18801087
arrhyth@@	B-Disease	D001145	18801087
mic	I-Disease	-1	18801087
drug	O	-1	18801087
for	O	-1	18801087
lif@@	O	-1	18801087
e-@@	O	-1	18801087
th@@	O	-1	18801087
reat@@	O	-1	18801087
en@@	O	-1	18801087
ing	O	-1	18801087
tachycardia	B-Disease	D013610	18801087
,	O	-1	18801087
but	O	-1	18801087
various	O	-1	18801087
adverse	O	-1	18801087
effects	O	-1	18801087
have	O	-1	18801087
been	O	-1	18801087
repor@@	O	-1	18801087
ted.	O	-1	18801087
Re@@	O	-1	18801087
por@@	O	-1	18801087
ted	O	-1	18801087
he@@	O	-1	18801087
re@@	O	-1	18801087
in	O	-1	18801087
is	O	-1	18801087
an	O	-1	18801087
auto@@	O	-1	18801087
p@@	O	-1	18801087
sy	O	-1	18801087
case	O	-1	18801087
of	O	-1	18801087
val@@	B-Disease	D006349	18801087
v@@	I-Disease	-1	18801087
ular	I-Disease	-1	18801087
heart	I-Disease	-1	18801087
disease	I-Disease	-1	18801087
,	O	-1	18801087
in	O	-1	18801087
a	O	-1	18801087
patient	O	-1	18801087
who	O	-1	18801087
developed	O	-1	18801087
a	O	-1	18801087
l@@	B-Disease	D055370	18801087
un@@	I-Disease	-1	18801087
g	I-Disease	-1	18801087
mas@@	I-Disease	-1	18801087
s	I-Disease	-1	18801087
(1@@	O	-1	18801087
.@@	O	-1	18801087
5	O	-1	18801087
c@@	O	-1	18801087
m	O	-1	18801087
in	O	-1	18801087
di@@	O	-1	18801087
ame@@	O	-1	18801087
ter@@	O	-1	18801087
)	O	-1	18801087
and	O	-1	18801087
proteinuria	B-Disease	D011507	18801087
(2@@	O	-1	18801087
.@@	O	-1	18801087
7@@	O	-1	18801087
6	O	-1	18801087
g/@@	O	-1	18801087
day@@	O	-1	18801087
)	O	-1	18801087
after	O	-1	18801087
treatment	O	-1	18801087
with	O	-1	18801087
am@@	B-Chemical	D000638	18801087
iodar@@	I-Chemical	-1	18801087
one	I-Chemical	-1	18801087
for	O	-1	18801087
a	O	-1	18801087
lon@@	O	-1	18801087
g	O	-1	18801087
ti@@	O	-1	18801087
me.	O	-1	18801087
The	O	-1	18801087
l@@	B-Disease	D055370	18801087
un@@	I-Disease	-1	18801087
g	I-Disease	-1	18801087
mas@@	I-Disease	-1	18801087
s	I-Disease	-1	18801087
was	O	-1	18801087
high@@	O	-1	18801087
ly	O	-1	18801087
sus@@	O	-1	18801087
p@@	O	-1	18801087
ected	O	-1	18801087
to	O	-1	18801087
be	O	-1	18801087
l@@	B-Disease	D008175	18801087
un@@	I-Disease	-1	18801087
g	I-Disease	-1	18801087
cancer	I-Disease	-1	18801087
on	O	-1	18801087
C@@	O	-1	18801087
T	O	-1	18801087
and	O	-1	18801087
pos@@	O	-1	18801087
it@@	O	-1	18801087
ro@@	O	-1	18801087
n	O	-1	18801087
em@@	O	-1	18801087
is@@	O	-1	18801087
sion	O	-1	18801087
to@@	O	-1	18801087
mo@@	O	-1	18801087
graph@@	O	-1	18801087
y,	O	-1	18801087
but	O	-1	18801087
hist@@	O	-1	18801087
olog@@	O	-1	18801087
ically	O	-1	18801087
the	O	-1	18801087
le@@	O	-1	18801087
sion	O	-1	18801087
was	O	-1	18801087
com@@	O	-1	18801087
pos@@	O	-1	18801087
ed	O	-1	18801087
of	O	-1	18801087
lymph@@	O	-1	18801087
o@@	O	-1	18801087
plas@@	O	-1	18801087
mac@@	O	-1	18801087
y@@	O	-1	18801087
tic	O	-1	18801087
inf@@	O	-1	18801087
ilt@@	O	-1	18801087
rat@@	O	-1	18801087
es	O	-1	18801087
in	O	-1	18801087
al@@	O	-1	18801087
ve@@	O	-1	18801087
ol@@	O	-1	18801087
ar	O	-1	18801087
w@@	O	-1	18801087
all@@	O	-1	18801087
s	O	-1	18801087
and	O	-1	18801087
intra@@	O	-1	18801087
-@@	O	-1	18801087
al@@	O	-1	18801087
ve@@	O	-1	18801087
ol@@	O	-1	18801087
ar	O	-1	18801087
accum@@	O	-1	18801087
ulation	O	-1	18801087
of	O	-1	18801087
fo@@	O	-1	18801087
am@@	O	-1	18801087
y	O	-1	18801087
mac@@	O	-1	18801087
ro@@	O	-1	18801087
ph@@	O	-1	18801087
ages	O	-1	18801087
containing	O	-1	18801087
character@@	O	-1	18801087
istic	O	-1	18801087
my@@	O	-1	18801087
el@@	O	-1	18801087
in@@	O	-1	18801087
oid	O	-1	18801087
bo@@	O	-1	18801087
di@@	O	-1	18801087
es,	O	-1	18801087
indicating	O	-1	18801087
that	O	-1	18801087
it	O	-1	18801087
was	O	-1	18801087
an	O	-1	18801087
am@@	B-Chemical	D000638	18801087
iodar@@	I-Chemical	-1	18801087
one	I-Chemical	-1	18801087
-@@	O	-1	18801087
related	O	-1	18801087
le@@	O	-1	18801087
sion.	O	-1	18801087
In	O	-1	18801087
addi@@	O	-1	18801087
tion,	O	-1	18801087
the	O	-1	18801087
l@@	O	-1	18801087
un@@	O	-1	18801087
g	O	-1	18801087
tissue	O	-1	18801087
had	O	-1	18801087
un@@	O	-1	18801087
ev@@	O	-1	18801087
en@@	O	-1	18801087
ly	O	-1	18801087
di@@	O	-1	18801087
stri@@	O	-1	18801087
but@@	O	-1	18801087
ed	O	-1	18801087
hemo@@	B-Disease	D006486	18801087
si@@	I-Disease	-1	18801087
der@@	I-Disease	-1	18801087
in	I-Disease	-1	18801087
de@@	O	-1	18801087
posi@@	O	-1	18801087
tion,	O	-1	18801087
and	O	-1	18801087
ab@@	O	-1	18801087
norm@@	O	-1	18801087
ally	O	-1	18801087
t@@	O	-1	18801087
or@@	O	-1	18801087
tu@@	O	-1	18801087
ous	O	-1	18801087
cap@@	O	-1	18801087
ill@@	O	-1	18801087
ari@@	O	-1	18801087
es	O	-1	18801087
were	O	-1	18801087
seen	O	-1	18801087
in	O	-1	18801087
the	O	-1	18801087
mas@@	O	-1	18801087
s	O	-1	18801087
and	O	-1	18801087
in	O	-1	18801087
he@@	O	-1	18801087
avi@@	O	-1	18801087
ly	O	-1	18801087
hemo@@	B-Disease	D006486	18801087
si@@	I-Disease	-1	18801087
der@@	I-Disease	-1	18801087
o@@	I-Disease	-1	18801087
tic	I-Disease	-1	18801087
l@@	O	-1	18801087
un@@	O	-1	18801087
g	O	-1	18801087
por@@	O	-1	18801087
tions	O	-1	18801087
out@@	O	-1	18801087
side	O	-1	18801087
the	O	-1	18801087
mas@@	O	-1	18801087
s.	O	-1	18801087
In	O	-1	18801087
the	O	-1	18801087
kidne@@	O	-1	18801087
y@@	O	-1	18801087
s,	O	-1	18801087
glomerul@@	O	-1	18801087
i	O	-1	18801087
had	O	-1	18801087
membran@@	O	-1	18801087
e	O	-1	18801087
s@@	O	-1	18801087
pi@@	O	-1	18801087
k@@	O	-1	18801087
es,	O	-1	18801087
pro@@	O	-1	18801087
min@@	O	-1	18801087
ent	O	-1	18801087
s@@	O	-1	18801087
we@@	O	-1	18801087
ll@@	O	-1	18801087
ing	O	-1	18801087
of	O	-1	18801087
po@@	O	-1	18801087
d@@	O	-1	18801087
ocy@@	O	-1	18801087
tes	O	-1	18801087
and	O	-1	18801087
su@@	O	-1	18801087
be@@	O	-1	18801087
pi@@	O	-1	18801087
thelial	O	-1	18801087
de@@	O	-1	18801087
pos@@	O	-1	18801087
it@@	O	-1	18801087
s,	O	-1	18801087
which	O	-1	18801087
were	O	-1	18801087
so@@	O	-1	18801087
me@@	O	-1	18801087
times	O	-1	18801087
larg@@	O	-1	18801087
e	O	-1	18801087
and	O	-1	18801087
hum@@	O	-1	18801087
p@@	O	-1	18801087
-@@	O	-1	18801087
lik@@	O	-1	18801087
e.	O	-1	18801087
A@@	B-Disease	D001327	18801087
u@@	I-Disease	-1	18801087
to@@	I-Disease	-1	18801087
immun@@	I-Disease	-1	18801087
e	I-Disease	-1	18801087
diseas@@	I-Disease	-1	18801087
es	I-Disease	-1	18801087
,	O	-1	18801087
viral	B-Disease	D006525	18801087
hepatitis	I-Disease	-1	18801087
,	O	-1	18801087
mal@@	O	-1	18801087
i@@	O	-1	18801087
gn@@	O	-1	18801087
ant	O	-1	18801087
ne@@	B-Disease	D009369	18801087
o@@	I-Disease	-1	18801087
plas@@	I-Disease	-1	18801087
ms	I-Disease	-1	18801087
or	O	-1	18801087
other	O	-1	18801087
diseas@@	O	-1	18801087
es	O	-1	18801087
with	O	-1	18801087
a	O	-1	18801087
known	O	-1	18801087
rel@@	O	-1	18801087
ationship	O	-1	18801087
to	O	-1	18801087
membran@@	B-Disease	D015433	18801087
ous	I-Disease	-1	18801087
glomerul@@	I-Disease	-1	18801087
one@@	I-Disease	-1	18801087
ph@@	I-Disease	-1	18801087
ritis	I-Disease	-1	18801087
were	O	-1	18801087
not	O	-1	18801087
f@@	O	-1	18801087
oun@@	O	-1	18801087
d.	O	-1	18801087
The	O	-1	18801087
present	O	-1	18801087
case	O	-1	18801087
high@@	O	-1	18801087
li@@	O	-1	18801087
gh@@	O	-1	18801087
ts	O	-1	18801087
the	O	-1	18801087
possib@@	O	-1	18801087
ility	O	-1	18801087
that	O	-1	18801087
differen@@	O	-1	18801087
tial	O	-1	18801087
diagnosis	O	-1	18801087
between	O	-1	18801087
an	O	-1	18801087
am@@	B-Chemical	D000638	18801087
iodar@@	I-Chemical	-1	18801087
one	I-Chemical	-1	18801087
-@@	O	-1	18801087
related	O	-1	18801087
pulmonary	B-Disease	D055370	18801087
le@@	I-Disease	-1	18801087
sion	I-Disease	-1	18801087
and	O	-1	18801087
a	O	-1	18801087
ne@@	B-Disease	D009369	18801087
o@@	I-Disease	-1	18801087
plas@@	I-Disease	-1	18801087
m	I-Disease	-1	18801087
can	O	-1	18801087
be	O	-1	18801087
very	O	-1	18801087
diff@@	O	-1	18801087
ic@@	O	-1	18801087
ult	O	-1	18801087
radi@@	O	-1	18801087
olog@@	O	-1	18801087
ic@@	O	-1	18801087
ally,	O	-1	18801087
and	O	-1	18801087
suggests	O	-1	18801087
that	O	-1	18801087
membran@@	B-Disease	D015433	18801087
ous	I-Disease	-1	18801087
glomerul@@	I-Disease	-1	18801087
one@@	I-Disease	-1	18801087
ph@@	I-Disease	-1	18801087
ritis	I-Disease	-1	18801087
might	O	-1	18801087
be	O	-1	18801087
an@@	O	-1	18801087
other	O	-1	18801087
possible	O	-1	18801087
complication	O	-1	18801087
of	O	-1	18801087
am@@	B-Chemical	D000638	18801087
iodar@@	I-Chemical	-1	18801087
one	I-Chemical	-1	18801087
treatment.	O	-1	18801087

R@@	O	-1	18945509
is@@	O	-1	18945509
k	O	-1	18945509
of	O	-1	18945509
coronary	B-Disease	D003324	18945509
artery	I-Disease	-1	18945509
disease	I-Disease	-1	18945509
associated	O	-1	18945509
with	O	-1	18945509
initial	O	-1	18945509
sul@@	B-Chemical	-1	18945509
ph@@	I-Chemical	-1	18945509
on@@	I-Chemical	-1	18945509
yl@@	I-Chemical	-1	18945509
ure@@	I-Chemical	-1	18945509
a	I-Chemical	-1	18945509
treatment	O	-1	18945509
of	O	-1	18945509
patients	O	-1	18945509
with	O	-1	18945509
type	B-Disease	D003924	18945509
2	I-Disease	-1	18945509
dia@@	I-Disease	-1	18945509
bet@@	I-Disease	-1	18945509
es	I-Disease	-1	18945509
:	O	-1	18945509
a	O	-1	18945509
mat@@	O	-1	18945509
ch@@	O	-1	18945509
ed	O	-1	18945509
cas@@	O	-1	18945509
e-@@	O	-1	18945509
control	O	-1	18945509
study.	O	-1	18945509
A@@	O	-1	18945509
I@@	O	-1	18945509
M@@	O	-1	18945509
S:	O	-1	18945509
This	O	-1	18945509
study	O	-1	18945509
s@@	O	-1	18945509
ou@@	O	-1	18945509
ght	O	-1	18945509
to	O	-1	18945509
ass@@	O	-1	18945509
ess	O	-1	18945509
the	O	-1	18945509
risk	O	-1	18945509
of	O	-1	18945509
develop@@	O	-1	18945509
ing	O	-1	18945509
coronary	B-Disease	D003324	18945509
artery	I-Disease	-1	18945509
disease	I-Disease	-1	18945509
(	O	-1	18945509
CA@@	B-Disease	D003324	18945509
D	I-Disease	-1	18945509
)	O	-1	18945509
associated	O	-1	18945509
with	O	-1	18945509
initial	O	-1	18945509
treatment	O	-1	18945509
of	O	-1	18945509
type	B-Disease	D003924	18945509
2	I-Disease	-1	18945509
dia@@	I-Disease	-1	18945509
bet@@	I-Disease	-1	18945509
es	I-Disease	-1	18945509
with	O	-1	18945509
different	O	-1	18945509
sul@@	B-Chemical	-1	18945509
ph@@	I-Chemical	-1	18945509
on@@	I-Chemical	-1	18945509
yl@@	I-Chemical	-1	18945509
ure@@	I-Chemical	-1	18945509
as	I-Chemical	-1	18945509
.	O	-1	18945509
METHODS:	O	-1	18945509
In	O	-1	18945509
type	B-Disease	D003924	18945509
2	I-Disease	-1	18945509
dia@@	I-Disease	-1	18945509
be@@	I-Disease	-1	18945509
tic	I-Disease	-1	18945509
patients,	O	-1	18945509
cases	O	-1	18945509
who	O	-1	18945509
developed	O	-1	18945509
CA@@	B-Disease	D003324	18945509
D	I-Disease	-1	18945509
were	O	-1	18945509
compared	O	-1	18945509
ret@@	O	-1	18945509
ro@@	O	-1	18945509
sp@@	O	-1	18945509
ectively	O	-1	18945509
with	O	-1	18945509
controls	O	-1	18945509
that	O	-1	18945509
did	O	-1	18945509
not@@	O	-1	18945509
.	O	-1	18945509
The	O	-1	18945509
20@@	O	-1	18945509
-@@	O	-1	18945509
year	O	-1	18945509
risk	O	-1	18945509
of	O	-1	18945509
CA@@	B-Disease	D003324	18945509
D	I-Disease	-1	18945509
at	O	-1	18945509
diagnosis	O	-1	18945509
of	O	-1	18945509
dia@@	B-Disease	D003920	18945509
bet@@	I-Disease	-1	18945509
es	I-Disease	-1	18945509
,	O	-1	18945509
using	O	-1	18945509
the	O	-1	18945509
U@@	O	-1	18945509
K@@	O	-1	18945509
P@@	O	-1	18945509
D@@	O	-1	18945509
S	O	-1	18945509
risk	O	-1	18945509
en@@	O	-1	18945509
g@@	O	-1	18945509
ine,	O	-1	18945509
was	O	-1	18945509
used	O	-1	18945509
to	O	-1	18945509
mat@@	O	-1	18945509
ch	O	-1	18945509
cases	O	-1	18945509
with	O	-1	18945509
controls.	O	-1	18945509
RESULTS:	O	-1	18945509
The	O	-1	18945509
7@@	O	-1	18945509
6	O	-1	18945509
cases	O	-1	18945509
of	O	-1	18945509
CA@@	B-Disease	D003324	18945509
D	I-Disease	-1	18945509
were	O	-1	18945509
compared	O	-1	18945509
with	O	-1	18945509
1@@	O	-1	18945509
5@@	O	-1	18945509
2	O	-1	18945509
controls.	O	-1	18945509
The	O	-1	18945509
ha@@	O	-1	18945509
z@@	O	-1	18945509
ard	O	-1	18945509
of	O	-1	18945509
develop@@	O	-1	18945509
ing	O	-1	18945509
CA@@	B-Disease	D003324	18945509
D	I-Disease	-1	18945509
(@@	O	-1	18945509
95%	O	-1	18945509
CI@@	O	-1	18945509
)	O	-1	18945509
associated	O	-1	18945509
with	O	-1	18945509
initial	O	-1	18945509
treatment	O	-1	18945509
increased	O	-1	18945509
by	O	-1	18945509
2.@@	O	-1	18945509
4-@@	O	-1	18945509
fol@@	O	-1	18945509
d	O	-1	18945509
(1@@	O	-1	18945509
.@@	O	-1	18945509
3-@@	O	-1	18945509
4.@@	O	-1	18945509
3,	O	-1	18945509
P@@	O	-1	18945509
=@@	O	-1	18945509
0.00@@	O	-1	18945509
4@@	O	-1	18945509
)	O	-1	18945509
with	O	-1	18945509
g@@	B-Chemical	D005905	18945509
li@@	I-Chemical	-1	18945509
ben@@	I-Chemical	-1	18945509
cl@@	I-Chemical	-1	18945509
amide	I-Chemical	-1	18945509
;	O	-1	18945509
2-@@	O	-1	18945509
fol@@	O	-1	18945509
d	O	-1	18945509
(0.@@	O	-1	18945509
9@@	O	-1	18945509
-@@	O	-1	18945509
4.@@	O	-1	18945509
6,	O	-1	18945509
P@@	O	-1	18945509
=@@	O	-1	18945509
0.0@@	O	-1	18945509
9@@	O	-1	18945509
9@@	O	-1	18945509
)	O	-1	18945509
with	O	-1	18945509
g@@	B-Chemical	D005913	18945509
li@@	I-Chemical	-1	18945509
p@@	I-Chemical	-1	18945509
iz@@	I-Chemical	-1	18945509
ide	I-Chemical	-1	18945509
;	O	-1	18945509
2.@@	O	-1	18945509
9@@	O	-1	18945509
-@@	O	-1	18945509
fol@@	O	-1	18945509
d	O	-1	18945509
(1@@	O	-1	18945509
.@@	O	-1	18945509
6-@@	O	-1	18945509
5.@@	O	-1	18945509
1,	O	-1	18945509
P@@	O	-1	18945509
=@@	O	-1	18945509
0.00@@	O	-1	18945509
0@@	O	-1	18945509
)	O	-1	18945509
with	O	-1	18945509
e@@	O	-1	18945509
i@@	O	-1	18945509
ther@@	O	-1	18945509
,	O	-1	18945509
and	O	-1	18945509
was	O	-1	18945509
un@@	O	-1	18945509
chang@@	O	-1	18945509
ed	O	-1	18945509
with	O	-1	18945509
met@@	B-Chemical	D008687	18945509
form@@	I-Chemical	-1	18945509
in	I-Chemical	-1	18945509
.	O	-1	18945509
The	O	-1	18945509
ha@@	O	-1	18945509
z@@	O	-1	18945509
ard	O	-1	18945509
decreased	O	-1	18945509
0.@@	O	-1	18945509
3-@@	O	-1	18945509
fol@@	O	-1	18945509
d	O	-1	18945509
(0.@@	O	-1	18945509
7-@@	O	-1	18945509
1.@@	O	-1	18945509
7@@	O	-1	18945509
,	O	-1	18945509
P@@	O	-1	18945509
=@@	O	-1	18945509
0.@@	O	-1	18945509
3@@	O	-1	18945509
8@@	O	-1	18945509
5@@	O	-1	18945509
)	O	-1	18945509
with	O	-1	18945509
g@@	B-Chemical	C057619	18945509
li@@	I-Chemical	-1	18945509
me@@	I-Chemical	-1	18945509
pi@@	I-Chemical	-1	18945509
ri@@	I-Chemical	-1	18945509
de	I-Chemical	-1	18945509
,	O	-1	18945509
0.@@	O	-1	18945509
4-@@	O	-1	18945509
fol@@	O	-1	18945509
d	O	-1	18945509
(0.@@	O	-1	18945509
7-@@	O	-1	18945509
1.@@	O	-1	18945509
3,	O	-1	18945509
P@@	O	-1	18945509
=@@	O	-1	18945509
0.@@	O	-1	18945509
19@@	O	-1	18945509
2)	O	-1	18945509
with	O	-1	18945509
gl@@	B-Chemical	D005907	18945509
ic@@	I-Chemical	-1	18945509
l@@	I-Chemical	-1	18945509
az@@	I-Chemical	-1	18945509
ide	I-Chemical	-1	18945509
,	O	-1	18945509
and	O	-1	18945509
0.@@	O	-1	18945509
4-@@	O	-1	18945509
fol@@	O	-1	18945509
d	O	-1	18945509
(0.@@	O	-1	18945509
7-@@	O	-1	18945509
1.@@	O	-1	18945509
1,	O	-1	18945509
P@@	O	-1	18945509
=@@	O	-1	18945509
0.0@@	O	-1	18945509
9@@	O	-1	18945509
)	O	-1	18945509
with	O	-1	18945509
e@@	O	-1	18945509
i@@	O	-1	18945509
ther@@	O	-1	18945509
.	O	-1	18945509
CONCLUSIONS:	O	-1	18945509
In@@	O	-1	18945509
iti@@	O	-1	18945509
ating	O	-1	18945509
treatment	O	-1	18945509
of	O	-1	18945509
type	B-Disease	D003924	18945509
2	I-Disease	-1	18945509
dia@@	I-Disease	-1	18945509
bet@@	I-Disease	-1	18945509
es	I-Disease	-1	18945509
with	O	-1	18945509
g@@	B-Chemical	D005905	18945509
li@@	I-Chemical	-1	18945509
ben@@	I-Chemical	-1	18945509
cl@@	I-Chemical	-1	18945509
amide	I-Chemical	-1	18945509
or	O	-1	18945509
g@@	B-Chemical	D005913	18945509
li@@	I-Chemical	-1	18945509
p@@	I-Chemical	-1	18945509
iz@@	I-Chemical	-1	18945509
ide	I-Chemical	-1	18945509
is	O	-1	18945509
associated	O	-1	18945509
with	O	-1	18945509
increased	O	-1	18945509
risk	O	-1	18945509
of	O	-1	18945509
CA@@	B-Disease	D003324	18945509
D	I-Disease	-1	18945509
in	O	-1	18945509
compar@@	O	-1	18945509
ison	O	-1	18945509
to	O	-1	18945509
gl@@	B-Chemical	D005907	18945509
ic@@	I-Chemical	-1	18945509
l@@	I-Chemical	-1	18945509
az@@	I-Chemical	-1	18945509
ide	I-Chemical	-1	18945509
or	O	-1	18945509
g@@	B-Chemical	C057619	18945509
li@@	I-Chemical	-1	18945509
me@@	I-Chemical	-1	18945509
pi@@	I-Chemical	-1	18945509
ri@@	I-Chemical	-1	18945509
de	I-Chemical	-1	18945509
.	O	-1	18945509
I@@	O	-1	18945509
f	O	-1	18945509
con@@	O	-1	18945509
fir@@	O	-1	18945509
me@@	O	-1	18945509
d,	O	-1	18945509
this	O	-1	18945509
may	O	-1	18945509
be	O	-1	18945509
important	O	-1	18945509
because	O	-1	18945509
most	O	-1	18945509
In@@	O	-1	18945509
di@@	O	-1	18945509
an	O	-1	18945509
patients	O	-1	18945509
recei@@	O	-1	18945509
ve	O	-1	18945509
the	O	-1	18945509
ch@@	O	-1	18945509
e@@	O	-1	18945509
ap@@	O	-1	18945509
er	O	-1	18945509
ol@@	O	-1	18945509
der	O	-1	18945509
sul@@	B-Chemical	-1	18945509
ph@@	I-Chemical	-1	18945509
on@@	I-Chemical	-1	18945509
yl@@	I-Chemical	-1	18945509
ure@@	I-Chemical	-1	18945509
as	I-Chemical	-1	18945509
,	O	-1	18945509
and	O	-1	18945509
present	O	-1	18945509
gu@@	O	-1	18945509
ide@@	O	-1	18945509
lin@@	O	-1	18945509
es	O	-1	18945509
d@@	O	-1	18945509
o	O	-1	18945509
not	O	-1	18945509
dist@@	O	-1	18945509
ing@@	O	-1	18945509
u@@	O	-1	18945509
is@@	O	-1	18945509
h	O	-1	18945509
between	O	-1	18945509
individ@@	O	-1	18945509
ual	O	-1	18945509
agent@@	O	-1	18945509
s.	O	-1	18945509

Re@@	O	-1	18987260
duced	O	-1	18987260
progres@@	O	-1	18987260
sion	O	-1	18987260
of	O	-1	18987260
adriam@@	B-Chemical	D004317	18987260
ycin	I-Chemical	-1	18987260
nephro@@	B-Disease	D007674	18987260
pathy	I-Disease	-1	18987260
in	O	-1	18987260
spont@@	O	-1	18987260
ane@@	O	-1	18987260
ously	O	-1	18987260
hypertensive	B-Disease	D006973	18987260
rats	O	-1	18987260
treated	O	-1	18987260
by	O	-1	18987260
los@@	B-Chemical	D019808	18987260
ar@@	I-Chemical	-1	18987260
t@@	I-Chemical	-1	18987260
an	I-Chemical	-1	18987260
.	O	-1	18987260
BACKGROUND:	O	-1	18987260
The	O	-1	18987260
a@@	O	-1	18987260
im	O	-1	18987260
of	O	-1	18987260
the	O	-1	18987260
study	O	-1	18987260
was	O	-1	18987260
to	O	-1	18987260
investigate	O	-1	18987260
the	O	-1	18987260
anti@@	O	-1	18987260
hypertensive	O	-1	18987260
effects	O	-1	18987260
of	O	-1	18987260
angiotens@@	B-Chemical	D000804	18987260
in	I-Chemical	-1	18987260
II	I-Chemical	-1	18987260
ty@@	O	-1	18987260
pe@@	O	-1	18987260
-1	O	-1	18987260
receptor	O	-1	18987260
block@@	O	-1	18987260
er,	O	-1	18987260
los@@	B-Chemical	D019808	18987260
ar@@	I-Chemical	-1	18987260
t@@	I-Chemical	-1	18987260
an	I-Chemical	-1	18987260
,	O	-1	18987260
and	O	-1	18987260
its	O	-1	18987260
potential	O	-1	18987260
in	O	-1	18987260
s@@	O	-1	18987260
low@@	O	-1	18987260
ing	O	-1	18987260
do@@	O	-1	18987260
w@@	O	-1	18987260
n	O	-1	18987260
renal	B-Disease	D007674	18987260
disease	I-Disease	-1	18987260
progres@@	O	-1	18987260
sion	O	-1	18987260
in	O	-1	18987260
spont@@	O	-1	18987260
ane@@	O	-1	18987260
ously	O	-1	18987260
hypertensive	B-Disease	D006973	18987260
rats	O	-1	18987260
(S@@	O	-1	18987260
H@@	O	-1	18987260
R@@	O	-1	18987260
)	O	-1	18987260
with	O	-1	18987260
adriam@@	B-Chemical	D004317	18987260
ycin	I-Chemical	-1	18987260
(	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
)	O	-1	18987260
nephro@@	B-Disease	D007674	18987260
pathy	I-Disease	-1	18987260
.	O	-1	18987260
METHODS:	O	-1	18987260
Si@@	O	-1	18987260
x@@	O	-1	18987260
-@@	O	-1	18987260
month@@	O	-1	18987260
-old	O	-1	18987260
female	O	-1	18987260
S@@	O	-1	18987260
H@@	O	-1	18987260
R	O	-1	18987260
were	O	-1	18987260
random@@	O	-1	18987260
ly	O	-1	18987260
sel@@	O	-1	18987260
ected	O	-1	18987260
in	O	-1	18987260
six	O	-1	18987260
groups.	O	-1	18987260
Two	O	-1	18987260
control	O	-1	18987260
groups	O	-1	18987260
(S@@	O	-1	18987260
H@@	O	-1	18987260
(6@@	O	-1	18987260
),	O	-1	18987260
S@@	O	-1	18987260
H@@	O	-1	18987260
(1@@	O	-1	18987260
2@@	O	-1	18987260
)@@	O	-1	18987260
)	O	-1	18987260
received	O	-1	18987260
ve@@	O	-1	18987260
h@@	O	-1	18987260
ic@@	O	-1	18987260
le@@	O	-1	18987260
.	O	-1	18987260
Grou@@	O	-1	18987260
p@@	O	-1	18987260
s	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
(6@@	O	-1	18987260
),	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
+	O	-1	18987260
L@@	B-Chemical	D019808	18987260
O@@	I-Chemical	-1	18987260
S	I-Chemical	-1	18987260
(6@@	O	-1	18987260
)	O	-1	18987260
and	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
(1@@	O	-1	18987260
2@@	O	-1	18987260
),	O	-1	18987260
and	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
+	O	-1	18987260
L@@	B-Chemical	D019808	18987260
O@@	I-Chemical	-1	18987260
S	I-Chemical	-1	18987260
(1@@	O	-1	18987260
2)	O	-1	18987260
received	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
(@@	O	-1	18987260
2	O	-1	18987260
mg/k@@	O	-1	18987260
g/@@	O	-1	18987260
b@@	O	-1	18987260
.@@	O	-1	18987260
w@@	O	-1	18987260
.	O	-1	18987260
i.v@@	O	-1	18987260
.)	O	-1	18987260
tw@@	O	-1	18987260
ic@@	O	-1	18987260
e	O	-1	18987260
in	O	-1	18987260
a	O	-1	18987260
3-@@	O	-1	18987260
week	O	-1	18987260
inter@@	O	-1	18987260
val@@	O	-1	18987260
.	O	-1	18987260
Group	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
+	O	-1	18987260
L@@	B-Chemical	D019808	18987260
O@@	I-Chemical	-1	18987260
S	I-Chemical	-1	18987260
(6@@	O	-1	18987260
)	O	-1	18987260
received	O	-1	18987260
los@@	B-Chemical	D019808	18987260
ar@@	I-Chemical	-1	18987260
t@@	I-Chemical	-1	18987260
an	I-Chemical	-1	18987260
(10	O	-1	18987260
mg/k@@	O	-1	18987260
g/@@	O	-1	18987260
b@@	O	-1	18987260
.@@	O	-1	18987260
w@@	O	-1	18987260
.@@	O	-1	18987260
/@@	O	-1	18987260
day	O	-1	18987260
by	O	-1	18987260
g@@	O	-1	18987260
av@@	O	-1	18987260
ag@@	O	-1	18987260
es@@	O	-1	18987260
)	O	-1	18987260
for	O	-1	18987260
6	O	-1	18987260
weeks	O	-1	18987260
and	O	-1	18987260
group	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
+	O	-1	18987260
L@@	B-Chemical	D019808	18987260
O@@	I-Chemical	-1	18987260
S	I-Chemical	-1	18987260
(1@@	O	-1	18987260
2)	O	-1	18987260
for	O	-1	18987260
12	O	-1	18987260
weeks	O	-1	18987260
after	O	-1	18987260
second	O	-1	18987260
injection	O	-1	18987260
of	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
.	O	-1	18987260
An@@	O	-1	18987260
im@@	O	-1	18987260
als	O	-1	18987260
were	O	-1	18987260
k@@	O	-1	18987260
ill@@	O	-1	18987260
ed	O	-1	18987260
after	O	-1	18987260
6	O	-1	18987260
or	O	-1	18987260
12	O	-1	18987260
week@@	O	-1	18987260
s,	O	-1	18987260
respectively.	O	-1	18987260
H@@	O	-1	18987260
a@@	O	-1	18987260
em@@	O	-1	18987260
o@@	O	-1	18987260
dynam@@	O	-1	18987260
ic	O	-1	18987260
meas@@	O	-1	18987260
ure@@	O	-1	18987260
ments	O	-1	18987260
were	O	-1	18987260
performed	O	-1	18987260
on	O	-1	18987260
anaesthe@@	O	-1	18987260
tiz@@	O	-1	18987260
ed	O	-1	18987260
anim@@	O	-1	18987260
al@@	O	-1	18987260
s,	O	-1	18987260
blood	O	-1	18987260
and	O	-1	18987260
urine	O	-1	18987260
sam@@	O	-1	18987260
ple@@	O	-1	18987260
s	O	-1	18987260
were	O	-1	18987260
tak@@	O	-1	18987260
en	O	-1	18987260
for	O	-1	18987260
bio@@	O	-1	18987260
chemical	O	-1	18987260
analysis	O	-1	18987260
and	O	-1	18987260
the	O	-1	18987260
left	O	-1	18987260
kidney	O	-1	18987260
was	O	-1	18987260
pro@@	O	-1	18987260
cess@@	O	-1	18987260
ed	O	-1	18987260
for	O	-1	18987260
morph@@	O	-1	18987260
ological	O	-1	18987260
studi@@	O	-1	18987260
es.	O	-1	18987260
RESULTS:	O	-1	18987260
S@@	O	-1	18987260
h@@	O	-1	18987260
ort@@	O	-1	18987260
-term	O	-1	18987260
los@@	B-Chemical	D019808	18987260
ar@@	I-Chemical	-1	18987260
t@@	I-Chemical	-1	18987260
an	I-Chemical	-1	18987260
treatment,	O	-1	18987260
be@@	O	-1	18987260
side@@	O	-1	18987260
s	O	-1	18987260
anti@@	O	-1	18987260
hypertensive	O	-1	18987260
effect@@	O	-1	18987260
,	O	-1	18987260
improved	O	-1	18987260
glomerular	O	-1	18987260
f@@	O	-1	18987260
iltration	O	-1	18987260
rate	O	-1	18987260
and	O	-1	18987260
ame@@	O	-1	18987260
li@@	O	-1	18987260
or@@	O	-1	18987260
ated	O	-1	18987260
glomer@@	B-Disease	D005921	18987260
u@@	I-Disease	-1	18987260
los@@	I-Disease	-1	18987260
clero@@	I-Disease	-1	18987260
sis	I-Disease	-1	18987260
result@@	O	-1	18987260
ing	O	-1	18987260
in	O	-1	18987260
decreased	O	-1	18987260
proteinuria	B-Disease	D011507	18987260
.	O	-1	18987260
Pro@@	O	-1	18987260
long@@	O	-1	18987260
ed	O	-1	18987260
treatment	O	-1	18987260
with	O	-1	18987260
los@@	B-Chemical	D019808	18987260
ar@@	I-Chemical	-1	18987260
t@@	I-Chemical	-1	18987260
an	I-Chemical	-1	18987260
showed	O	-1	18987260
further	O	-1	18987260
reduction	O	-1	18987260
of	O	-1	18987260
glomer@@	B-Disease	D005921	18987260
u@@	I-Disease	-1	18987260
los@@	I-Disease	-1	18987260
clero@@	I-Disease	-1	18987260
sis	I-Disease	-1	18987260
associated	O	-1	18987260
with	O	-1	18987260
reduced	O	-1	18987260
progres@@	O	-1	18987260
sion	O	-1	18987260
of	O	-1	18987260
tub@@	O	-1	18987260
ular	O	-1	18987260
atro@@	B-Disease	D001284	18987260
ph@@	I-Disease	-1	18987260
y	I-Disease	-1	18987260
and	O	-1	18987260
interstitial	B-Disease	D005355	18987260
fib@@	I-Disease	-1	18987260
ro@@	I-Disease	-1	18987260
sis	I-Disease	-1	18987260
,	O	-1	18987260
th@@	O	-1	18987260
us	O	-1	18987260
prevent@@	O	-1	18987260
ing	O	-1	18987260
he@@	O	-1	18987260
av@@	O	-1	18987260
y	O	-1	18987260
proteinuria	B-Disease	D011507	18987260
and	O	-1	18987260
chronic	B-Disease	D007676	18987260
renal	I-Disease	-1	18987260
failure	I-Disease	-1	18987260
.	O	-1	18987260
L@@	B-Chemical	D019808	18987260
os@@	I-Chemical	-1	18987260
ar@@	I-Chemical	-1	18987260
t@@	I-Chemical	-1	18987260
an	I-Chemical	-1	18987260
reduced	O	-1	18987260
ur@@	B-Disease	D014511	18987260
a@@	I-Disease	-1	18987260
emia	I-Disease	-1	18987260
and	O	-1	18987260
increased	O	-1	18987260
ure@@	B-Chemical	D014508	18987260
a	I-Chemical	-1	18987260
clear@@	O	-1	18987260
ance	O	-1	18987260
in	O	-1	18987260
adv@@	O	-1	18987260
anced	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
nephro@@	B-Disease	D007674	18987260
pathy	I-Disease	-1	18987260
in	O	-1	18987260
S@@	O	-1	18987260
H@@	O	-1	18987260
R@@	O	-1	18987260
.	O	-1	18987260
H@@	O	-1	18987260
ist@@	O	-1	18987260
ological	O	-1	18987260
examin@@	O	-1	18987260
ation	O	-1	18987260
showed	O	-1	18987260
that	O	-1	18987260
los@@	B-Chemical	D019808	18987260
ar@@	I-Chemical	-1	18987260
t@@	I-Chemical	-1	18987260
an	I-Chemical	-1	18987260
could	O	-1	18987260
prev@@	O	-1	18987260
ent	O	-1	18987260
tub@@	O	-1	18987260
ular	O	-1	18987260
atro@@	B-Disease	D001284	18987260
ph@@	I-Disease	-1	18987260
y	I-Disease	-1	18987260
,	O	-1	18987260
interstitial	O	-1	18987260
inf@@	O	-1	18987260
iltration	O	-1	18987260
and	O	-1	18987260
fib@@	B-Disease	D005355	18987260
ro@@	I-Disease	-1	18987260
sis	I-Disease	-1	18987260
in	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
nephro@@	B-Disease	D007674	18987260
pathy	I-Disease	-1	18987260
.	O	-1	18987260
CONCLUSION:	O	-1	18987260
L@@	B-Chemical	D019808	18987260
os@@	I-Chemical	-1	18987260
ar@@	I-Chemical	-1	18987260
t@@	I-Chemical	-1	18987260
an	I-Chemical	-1	18987260
reduc@@	O	-1	18987260
es	O	-1	18987260
the	O	-1	18987260
rate	O	-1	18987260
of	O	-1	18987260
progres@@	O	-1	18987260
sion	O	-1	18987260
of	O	-1	18987260
AD@@	B-Chemical	D004317	18987260
R	I-Chemical	-1	18987260
-induced	O	-1	18987260
foc@@	B-Disease	D005923	18987260
al	I-Disease	-1	18987260
seg@@	I-Disease	-1	18987260
mental	I-Disease	-1	18987260
glomer@@	I-Disease	-1	18987260
u@@	I-Disease	-1	18987260
los@@	I-Disease	-1	18987260
clero@@	I-Disease	-1	18987260
sis	I-Disease	-1	18987260
to	O	-1	18987260
en@@	B-Disease	D007676	18987260
d-@@	I-Disease	-1	18987260
st@@	I-Disease	-1	18987260
age	I-Disease	-1	18987260
renal	I-Disease	-1	18987260
disease	I-Disease	-1	18987260
in	O	-1	18987260
S@@	O	-1	18987260
H@@	O	-1	18987260
R@@	O	-1	18987260
.	O	-1	18987260

The	O	-1	19020118
ris@@	O	-1	19020118
k@@	O	-1	19020118
s	O	-1	19020118
of	O	-1	19020118
a@@	O	-1	19020118
prot@@	O	-1	19020118
in@@	O	-1	19020118
in	O	-1	19020118
and	O	-1	19020118
tran@@	B-Chemical	D014148	19020118
ex@@	I-Chemical	-1	19020118
am@@	I-Chemical	-1	19020118
ic	I-Chemical	-1	19020118
acid	I-Chemical	-1	19020118
in	O	-1	19020118
cardiac	O	-1	19020118
surg@@	O	-1	19020118
ery@@	O	-1	19020118
:	O	-1	19020118
a	O	-1	19020118
on@@	O	-1	19020118
e-@@	O	-1	19020118
year	O	-1	19020118
follow-up	O	-1	19020118
of	O	-1	19020118
1@@	O	-1	19020118
18@@	O	-1	19020118
8	O	-1	19020118
con@@	O	-1	19020118
sec@@	O	-1	19020118
utive	O	-1	19020118
patients.	O	-1	19020118
BACKGROUND:	O	-1	19020118
Our	O	-1	19020118
a@@	O	-1	19020118
im	O	-1	19020118
was	O	-1	19020118
to	O	-1	19020118
investigate	O	-1	19020118
postoperative	O	-1	19020118
complications	O	-1	19020118
and	O	-1	19020118
mor@@	O	-1	19020118
t@@	O	-1	19020118
ality	O	-1	19020118
after	O	-1	19020118
administration	O	-1	19020118
of	O	-1	19020118
a@@	O	-1	19020118
prot@@	O	-1	19020118
in@@	O	-1	19020118
in	O	-1	19020118
compared	O	-1	19020118
to	O	-1	19020118
tran@@	B-Chemical	D014148	19020118
ex@@	I-Chemical	-1	19020118
am@@	I-Chemical	-1	19020118
ic	I-Chemical	-1	19020118
acid	I-Chemical	-1	19020118
in	O	-1	19020118
an	O	-1	19020118
un@@	O	-1	19020118
sel@@	O	-1	19020118
ect@@	O	-1	19020118
ed,	O	-1	19020118
con@@	O	-1	19020118
sec@@	O	-1	19020118
utive	O	-1	19020118
co@@	O	-1	19020118
h@@	O	-1	19020118
ort@@	O	-1	19020118
.	O	-1	19020118
METHODS:	O	-1	19020118
P@@	O	-1	19020118
er@@	O	-1	19020118
io@@	O	-1	19020118
perative	O	-1	19020118
data	O	-1	19020118
from	O	-1	19020118
con@@	O	-1	19020118
sec@@	O	-1	19020118
utive	O	-1	19020118
cardiac	O	-1	19020118
surger@@	O	-1	19020118
y	O	-1	19020118
patients	O	-1	19020118
were	O	-1	19020118
pro@@	O	-1	19020118
sp@@	O	-1	19020118
ectively	O	-1	19020118
coll@@	O	-1	19020118
ected	O	-1	19020118
between	O	-1	19020118
S@@	O	-1	19020118
e@@	O	-1	19020118
pt@@	O	-1	19020118
emb@@	O	-1	19020118
er	O	-1	19020118
20@@	O	-1	19020118
0@@	O	-1	19020118
5	O	-1	19020118
and	O	-1	19020118
J@@	O	-1	19020118
un@@	O	-1	19020118
e	O	-1	19020118
20@@	O	-1	19020118
0@@	O	-1	19020118
6	O	-1	19020118
in	O	-1	19020118
a	O	-1	19020118
un@@	O	-1	19020118
i@@	O	-1	19020118
ver@@	O	-1	19020118
sit@@	O	-1	19020118
y-@@	O	-1	19020118
aff@@	O	-1	19020118
il@@	O	-1	19020118
i@@	O	-1	19020118
ated	O	-1	19020118
clin@@	O	-1	19020118
ic	O	-1	19020118
(n	O	-1	19020118
=	O	-1	19020118
1@@	O	-1	19020118
18@@	O	-1	19020118
8@@	O	-1	19020118
).	O	-1	19020118
D@@	O	-1	19020118
uring	O	-1	19020118
the	O	-1	19020118
first	O	-1	19020118
5	O	-1	19020118
mo@@	O	-1	19020118
,	O	-1	19020118
5@@	O	-1	19020118
9@@	O	-1	19020118
6	O	-1	19020118
patients	O	-1	19020118
received	O	-1	19020118
a@@	O	-1	19020118
prot@@	O	-1	19020118
in@@	O	-1	19020118
in	O	-1	19020118
(@@	O	-1	19020118
Group	O	-1	19020118
A@@	O	-1	19020118
);	O	-1	19020118
in	O	-1	19020118
the	O	-1	19020118
ne@@	O	-1	19020118
x@@	O	-1	19020118
t	O	-1	19020118
5	O	-1	19020118
mo@@	O	-1	19020118
,	O	-1	19020118
5@@	O	-1	19020118
9@@	O	-1	19020118
2	O	-1	19020118
patients	O	-1	19020118
were	O	-1	19020118
treated	O	-1	19020118
with	O	-1	19020118
tran@@	B-Chemical	D014148	19020118
ex@@	I-Chemical	-1	19020118
am@@	I-Chemical	-1	19020118
ic	I-Chemical	-1	19020118
acid	I-Chemical	-1	19020118
(@@	O	-1	19020118
Group	O	-1	19020118
T@@	O	-1	19020118
).	O	-1	19020118
E@@	O	-1	19020118
x@@	O	-1	19020118
cep@@	O	-1	19020118
t	O	-1	19020118
for	O	-1	19020118
anti@@	O	-1	19020118
fib@@	O	-1	19020118
r@@	O	-1	19020118
in@@	O	-1	19020118
oly@@	O	-1	19020118
tic	O	-1	19020118
therapy,	O	-1	19020118
the	O	-1	19020118
anesthe@@	O	-1	19020118
tic	O	-1	19020118
and	O	-1	19020118
surg@@	O	-1	19020118
ical	O	-1	19020118
pro@@	O	-1	19020118
to@@	O	-1	19020118
co@@	O	-1	19020118
l@@	O	-1	19020118
s	O	-1	19020118
remained	O	-1	19020118
un@@	O	-1	19020118
chang@@	O	-1	19020118
ed.	O	-1	19020118
RESULTS:	O	-1	19020118
The	O	-1	19020118
pre@@	O	-1	19020118
-	O	-1	19020118
and	O	-1	19020118
intra@@	O	-1	19020118
o@@	O	-1	19020118
perative	O	-1	19020118
vari@@	O	-1	19020118
able@@	O	-1	19020118
s	O	-1	19020118
were	O	-1	19020118
compar@@	O	-1	19020118
able	O	-1	19020118
between	O	-1	19020118
the	O	-1	19020118
treatment	O	-1	19020118
groups.	O	-1	19020118
P@@	O	-1	19020118
o@@	O	-1	19020118
sto@@	O	-1	19020118
per@@	O	-1	19020118
ati@@	O	-1	19020118
vel@@	O	-1	19020118
y,	O	-1	19020118
a	O	-1	19020118
significantly	O	-1	19020118
higher	O	-1	19020118
incidence	O	-1	19020118
of	O	-1	19020118
seizures	B-Disease	D012640	19020118
was	O	-1	19020118
found	O	-1	19020118
in	O	-1	19020118
Group	O	-1	19020118
T	O	-1	19020118
(@@	O	-1	19020118
4.@@	O	-1	19020118
6%	O	-1	19020118
v@@	O	-1	19020118
s	O	-1	19020118
1.@@	O	-1	19020118
2@@	O	-1	19020118
%,	O	-1	19020118
P	O	-1	19020118
<	O	-1	19020118
0.00@@	O	-1	19020118
1).	O	-1	19020118
This	O	-1	19020118
difference	O	-1	19020118
was	O	-1	19020118
also	O	-1	19020118
significant	O	-1	19020118
in	O	-1	19020118
the	O	-1	19020118
prim@@	O	-1	19020118
ary	O	-1	19020118
val@@	O	-1	19020118
ve	O	-1	19020118
surger@@	O	-1	19020118
y	O	-1	19020118
and	O	-1	19020118
the	O	-1	19020118
high	O	-1	19020118
risk	O	-1	19020118
surger@@	O	-1	19020118
y	O	-1	19020118
sub@@	O	-1	19020118
groups	O	-1	19020118
(@@	O	-1	19020118
7.@@	O	-1	19020118
9@@	O	-1	19020118
%	O	-1	19020118
v@@	O	-1	19020118
s	O	-1	19020118
1.@@	O	-1	19020118
2@@	O	-1	19020118
%,	O	-1	19020118
P	O	-1	19020118
=	O	-1	19020118
0.00@@	O	-1	19020118
3@@	O	-1	19020118
;	O	-1	19020118
7.@@	O	-1	19020118
3@@	O	-1	19020118
%	O	-1	19020118
v@@	O	-1	19020118
s	O	-1	19020118
2.@@	O	-1	19020118
4@@	O	-1	19020118
%,	O	-1	19020118
P	O	-1	19020118
=	O	-1	19020118
0.0@@	O	-1	19020118
3@@	O	-1	19020118
5,	O	-1	19020118
respectivel@@	O	-1	19020118
y@@	O	-1	19020118
).	O	-1	19020118
P@@	O	-1	19020118
er@@	O	-1	19020118
sist@@	O	-1	19020118
ent	O	-1	19020118
atrial	O	-1	19020118
fibrill@@	O	-1	19020118
ation	O	-1	19020118
(@@	O	-1	19020118
7.@@	O	-1	19020118
9@@	O	-1	19020118
%	O	-1	19020118
v@@	O	-1	19020118
s	O	-1	19020118
2.@@	O	-1	19020118
3@@	O	-1	19020118
%,	O	-1	19020118
P	O	-1	19020118
=	O	-1	19020118
0.0@@	O	-1	19020118
20@@	O	-1	19020118
)	O	-1	19020118
and	O	-1	19020118
renal	B-Disease	D051437	19020118
failure	I-Disease	-1	19020118
(@@	O	-1	19020118
9.@@	O	-1	19020118
7@@	O	-1	19020118
%	O	-1	19020118
v@@	O	-1	19020118
s	O	-1	19020118
1.@@	O	-1	19020118
7@@	O	-1	19020118
%,	O	-1	19020118
P	O	-1	19020118
=	O	-1	19020118
0.00@@	O	-1	19020118
2)	O	-1	19020118
were	O	-1	19020118
also	O	-1	19020118
more	O	-1	19020118
common	O	-1	19020118
in	O	-1	19020118
Group	O	-1	19020118
T@@	O	-1	19020118
,	O	-1	19020118
in	O	-1	19020118
the	O	-1	19020118
prim@@	O	-1	19020118
ary	O	-1	19020118
val@@	O	-1	19020118
ve	O	-1	19020118
surger@@	O	-1	19020118
y	O	-1	19020118
sub@@	O	-1	19020118
group.	O	-1	19020118
O@@	O	-1	19020118
n	O	-1	19020118
the	O	-1	19020118
contr@@	O	-1	19020118
ar@@	O	-1	19020118
y,	O	-1	19020118
among	O	-1	19020118
prim@@	O	-1	19020118
ary	O	-1	19020118
coronary	O	-1	19020118
artery	O	-1	19020118
b@@	O	-1	19020118
yp@@	O	-1	19020118
as@@	O	-1	19020118
s	O	-1	19020118
surger@@	O	-1	19020118
y	O	-1	19020118
patients,	O	-1	19020118
there	O	-1	19020118
were	O	-1	19020118
more	O	-1	19020118
acute	O	-1	19020118
myocardial	B-Disease	D009203	19020118
infarc@@	I-Disease	-1	19020118
tions	I-Disease	-1	19020118
and	O	-1	19020118
renal	B-Disease	D007674	19020118
dysfunction	I-Disease	-1	19020118
in	O	-1	19020118
Group	O	-1	19020118
A	O	-1	19020118
(@@	O	-1	19020118
5.@@	O	-1	19020118
8@@	O	-1	19020118
%	O	-1	19020118
v@@	O	-1	19020118
s	O	-1	19020118
2.@@	O	-1	19020118
0@@	O	-1	19020118
%,	O	-1	19020118
P	O	-1	19020118
=	O	-1	19020118
0.0@@	O	-1	19020118
27@@	O	-1	19020118
;	O	-1	19020118
2@@	O	-1	19020118
2.@@	O	-1	19020118
5%	O	-1	19020118
v@@	O	-1	19020118
s	O	-1	19020118
1@@	O	-1	19020118
5.@@	O	-1	19020118
2@@	O	-1	19020118
%,	O	-1	19020118
P	O	-1	19020118
=	O	-1	19020118
0.0@@	O	-1	19020118
3@@	O	-1	19020118
6,	O	-1	19020118
respectivel@@	O	-1	19020118
y@@	O	-1	19020118
).	O	-1	19020118
The	O	-1	19020118
1-@@	O	-1	19020118
y@@	O	-1	19020118
r	O	-1	19020118
mor@@	O	-1	19020118
t@@	O	-1	19020118
ality	O	-1	19020118
was	O	-1	19020118
significantly	O	-1	19020118
higher	O	-1	19020118
after	O	-1	19020118
a@@	O	-1	19020118
prot@@	O	-1	19020118
in@@	O	-1	19020118
in	O	-1	19020118
treatment	O	-1	19020118
in	O	-1	19020118
the	O	-1	19020118
high	O	-1	19020118
risk	O	-1	19020118
surger@@	O	-1	19020118
y	O	-1	19020118
group	O	-1	19020118
(1@@	O	-1	19020118
7.@@	O	-1	19020118
7@@	O	-1	19020118
%	O	-1	19020118
v@@	O	-1	19020118
s	O	-1	19020118
9.@@	O	-1	19020118
8@@	O	-1	19020118
%,	O	-1	19020118
P	O	-1	19020118
=	O	-1	19020118
0.0@@	O	-1	19020118
34@@	O	-1	19020118
).	O	-1	19020118
CONCLUSION:	O	-1	19020118
B@@	O	-1	19020118
oth	O	-1	19020118
anti@@	O	-1	19020118
fib@@	O	-1	19020118
r@@	O	-1	19020118
in@@	O	-1	19020118
oly@@	O	-1	19020118
tic	O	-1	19020118
drugs	O	-1	19020118
be@@	O	-1	19020118
ar	O	-1	19020118
the	O	-1	19020118
risk	O	-1	19020118
of	O	-1	19020118
adverse	O	-1	19020118
outcom@@	O	-1	19020118
e	O	-1	19020118
depend@@	O	-1	19020118
ing	O	-1	19020118
on	O	-1	19020118
the	O	-1	19020118
type	O	-1	19020118
of	O	-1	19020118
cardiac	O	-1	19020118
surger@@	O	-1	19020118
y.	O	-1	19020118
Ad@@	O	-1	19020118
minist@@	O	-1	19020118
ration	O	-1	19020118
of	O	-1	19020118
a@@	O	-1	19020118
prot@@	O	-1	19020118
in@@	O	-1	19020118
in	O	-1	19020118
should	O	-1	19020118
be	O	-1	19020118
avoid@@	O	-1	19020118
ed	O	-1	19020118
in	O	-1	19020118
coronary	O	-1	19020118
artery	O	-1	19020118
b@@	O	-1	19020118
yp@@	O	-1	19020118
as@@	O	-1	19020118
s	O	-1	19020118
gra@@	O	-1	19020118
ft	O	-1	19020118
and	O	-1	19020118
high	O	-1	19020118
risk	O	-1	19020118
patients,	O	-1	19020118
whereas	O	-1	19020118
administration	O	-1	19020118
of	O	-1	19020118
tran@@	B-Chemical	D014148	19020118
ex@@	I-Chemical	-1	19020118
am@@	I-Chemical	-1	19020118
ic	I-Chemical	-1	19020118
acid	I-Chemical	-1	19020118
is	O	-1	19020118
not	O	-1	19020118
recomm@@	O	-1	19020118
en@@	O	-1	19020118
ded	O	-1	19020118
in	O	-1	19020118
val@@	O	-1	19020118
ve	O	-1	19020118
surger@@	O	-1	19020118
y.	O	-1	19020118

The	O	-1	19108278
bio@@	O	-1	19108278
log@@	O	-1	19108278
ical	O	-1	19108278
pro@@	O	-1	19108278
per@@	O	-1	19108278
ties	O	-1	19108278
of	O	-1	19108278
the	O	-1	19108278
op@@	O	-1	19108278
tical	O	-1	19108278
is@@	O	-1	19108278
om@@	O	-1	19108278
ers	O	-1	19108278
of	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
and	O	-1	19108278
their	O	-1	19108278
effects	O	-1	19108278
on	O	-1	19108278
cardiac	B-Disease	D001145	19108278
arrhyth@@	I-Disease	-1	19108278
mi@@	I-Disease	-1	19108278
as	I-Disease	-1	19108278
.	O	-1	19108278
1@@	O	-1	19108278
.	O	-1	19108278
The	O	-1	19108278
op@@	O	-1	19108278
tical	O	-1	19108278
is@@	O	-1	19108278
om@@	O	-1	19108278
ers	O	-1	19108278
of	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
have	O	-1	19108278
been	O	-1	19108278
compared	O	-1	19108278
for	O	-1	19108278
their	O	-1	19108278
beta-@@	O	-1	19108278
block@@	O	-1	19108278
ing	O	-1	19108278
and	O	-1	19108278
anti@@	O	-1	19108278
arrhyth@@	O	-1	19108278
mic	O	-1	19108278
ac@@	O	-1	19108278
ti@@	O	-1	19108278
vi@@	O	-1	19108278
ti@@	O	-1	19108278
es@@	O	-1	19108278
.@@	O	-1	19108278
2@@	O	-1	19108278
.	O	-1	19108278
In	O	-1	19108278
block@@	O	-1	19108278
ing	O	-1	19108278
the	O	-1	19108278
positive	O	-1	19108278
in@@	O	-1	19108278
ot@@	O	-1	19108278
ro@@	O	-1	19108278
p@@	O	-1	19108278
ic	O	-1	19108278
and	O	-1	19108278
chron@@	O	-1	19108278
ot@@	O	-1	19108278
ro@@	O	-1	19108278
p@@	O	-1	19108278
ic	O	-1	19108278
responses	O	-1	19108278
to	O	-1	19108278
iso@@	B-Chemical	D007545	19108278
p@@	I-Chemical	-1	19108278
ren@@	I-Chemical	-1	19108278
aline	I-Chemical	-1	19108278
,	O	-1	19108278
(@@	O	-1	19108278
+@@	O	-1	19108278
)@@	O	-1	19108278
-	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
had	O	-1	19108278
less	O	-1	19108278
than	O	-1	19108278
one	O	-1	19108278
h@@	O	-1	19108278
und@@	O	-1	19108278
re@@	O	-1	19108278
d@@	O	-1	19108278
th	O	-1	19108278
the	O	-1	19108278
poten@@	O	-1	19108278
c@@	O	-1	19108278
y	O	-1	19108278
of	O	-1	19108278
(-@@	O	-1	19108278
)@@	O	-1	19108278
-	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
.	O	-1	19108278
A@@	O	-1	19108278
t	O	-1	19108278
dose	O	-1	19108278
levels	O	-1	19108278
of	O	-1	19108278
(@@	O	-1	19108278
+@@	O	-1	19108278
)@@	O	-1	19108278
-	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
which	O	-1	19108278
attenu@@	O	-1	19108278
ated	O	-1	19108278
the	O	-1	19108278
responses	O	-1	19108278
to	O	-1	19108278
iso@@	B-Chemical	D007545	19108278
p@@	I-Chemical	-1	19108278
ren@@	I-Chemical	-1	19108278
aline	I-Chemical	-1	19108278
,	O	-1	19108278
there	O	-1	19108278
was	O	-1	19108278
a	O	-1	19108278
significant	O	-1	19108278
prolong@@	O	-1	19108278
ation	O	-1	19108278
of	O	-1	19108278
the	O	-1	19108278
P@@	O	-1	19108278
R	O	-1	19108278
interv@@	O	-1	19108278
al	O	-1	19108278
of	O	-1	19108278
the	O	-1	19108278
electro@@	O	-1	19108278
cardio@@	O	-1	19108278
gram@@	O	-1	19108278
.@@	O	-1	19108278
3@@	O	-1	19108278
.	O	-1	19108278
The	O	-1	19108278
met@@	O	-1	19108278
ab@@	O	-1	19108278
olic	O	-1	19108278
responses	O	-1	19108278
to	O	-1	19108278
iso@@	B-Chemical	D007545	19108278
p@@	I-Chemical	-1	19108278
ren@@	I-Chemical	-1	19108278
aline	I-Chemical	-1	19108278
in	O	-1	19108278
dog@@	O	-1	19108278
s	O	-1	19108278
(@@	O	-1	19108278
an	O	-1	19108278
increase	O	-1	19108278
in	O	-1	19108278
cir@@	O	-1	19108278
cul@@	O	-1	19108278
ating	O	-1	19108278
g@@	B-Chemical	D005947	19108278
lu@@	I-Chemical	-1	19108278
co@@	I-Chemical	-1	19108278
se	I-Chemical	-1	19108278
,	O	-1	19108278
l@@	B-Chemical	D019344	19108278
act@@	I-Chemical	-1	19108278
ate	I-Chemical	-1	19108278
and	O	-1	19108278
free	O	-1	19108278
f@@	B-Chemical	D005227	19108278
at@@	I-Chemical	-1	19108278
t@@	I-Chemical	-1	19108278
y	I-Chemical	-1	19108278
acid@@	I-Chemical	-1	19108278
s	I-Chemical	-1	19108278
)	O	-1	19108278
were	O	-1	19108278
all	O	-1	19108278
block@@	O	-1	19108278
ed	O	-1	19108278
by	O	-1	19108278
(-@@	O	-1	19108278
)@@	O	-1	19108278
-	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
.	O	-1	19108278
(@@	O	-1	19108278
+@@	O	-1	19108278
)@@	O	-1	19108278
-	O	-1	19108278
Pro@@	B-Chemical	D011433	19108278
p@@	I-Chemical	-1	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
had	O	-1	19108278
no	O	-1	19108278
effect	O	-1	19108278
on	O	-1	19108278
f@@	B-Chemical	D005227	19108278
at@@	I-Chemical	-1	19108278
t@@	I-Chemical	-1	19108278
y	I-Chemical	-1	19108278
acid	I-Chemical	-1	19108278
mo@@	O	-1	19108278
bil@@	O	-1	19108278
ization	O	-1	19108278
but	O	-1	19108278
significantly	O	-1	19108278
reduced	O	-1	19108278
the	O	-1	19108278
inc@@	O	-1	19108278
re@@	O	-1	19108278
ments	O	-1	19108278
in	O	-1	19108278
both	O	-1	19108278
l@@	B-Chemical	D019344	19108278
act@@	I-Chemical	-1	19108278
ate	I-Chemical	-1	19108278
and	O	-1	19108278
g@@	B-Chemical	D005947	19108278
lu@@	I-Chemical	-1	19108278
co@@	I-Chemical	-1	19108278
se	I-Chemical	-1	19108278
.@@	O	-1	19108278
4@@	O	-1	19108278
.	O	-1	19108278
B@@	O	-1	19108278
oth	O	-1	19108278
is@@	O	-1	19108278
om@@	O	-1	19108278
ers	O	-1	19108278
of	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
pos@@	O	-1	19108278
s@@	O	-1	19108278
ess@@	O	-1	19108278
ed	O	-1	19108278
similar	O	-1	19108278
depress@@	O	-1	19108278
ant	O	-1	19108278
poten@@	O	-1	19108278
c@@	O	-1	19108278
y	O	-1	19108278
on	O	-1	19108278
isol@@	O	-1	19108278
ated	O	-1	19108278
atrial	O	-1	19108278
musc@@	O	-1	19108278
le	O	-1	19108278
tak@@	O	-1	19108278
en	O	-1	19108278
from	O	-1	19108278
gu@@	O	-1	19108278
ine@@	O	-1	19108278
a@@	O	-1	19108278
-@@	O	-1	19108278
pi@@	O	-1	19108278
g@@	O	-1	19108278
s@@	O	-1	19108278
.@@	O	-1	19108278
5@@	O	-1	19108278
.	O	-1	19108278
The	O	-1	19108278
is@@	O	-1	19108278
om@@	O	-1	19108278
ers	O	-1	19108278
of	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
ex@@	O	-1	19108278
hib@@	O	-1	19108278
ited	O	-1	19108278
similar	O	-1	19108278
loc@@	O	-1	19108278
al	O	-1	19108278
anaesthe@@	O	-1	19108278
tic	O	-1	19108278
poten@@	O	-1	19108278
ci@@	O	-1	19108278
es	O	-1	19108278
on	O	-1	19108278
an	O	-1	19108278
isol@@	O	-1	19108278
ated	O	-1	19108278
f@@	O	-1	19108278
ro@@	O	-1	19108278
g	O	-1	19108278
nerve	O	-1	19108278
pre@@	O	-1	19108278
par@@	O	-1	19108278
ation	O	-1	19108278
at	O	-1	19108278
a	O	-1	19108278
level	O	-1	19108278
appro@@	O	-1	19108278
xim@@	O	-1	19108278
ately	O	-1	19108278
three	O	-1	19108278
times	O	-1	19108278
that	O	-1	19108278
of	O	-1	19108278
pro@@	B-Chemical	D011343	19108278
ca@@	I-Chemical	-1	19108278
ine	I-Chemical	-1	19108278
.	O	-1	19108278
The	O	-1	19108278
rac@@	O	-1	19108278
em@@	O	-1	19108278
ic	O	-1	19108278
comp@@	O	-1	19108278
ound	O	-1	19108278
was	O	-1	19108278
significantly	O	-1	19108278
less	O	-1	19108278
pot@@	O	-1	19108278
ent	O	-1	19108278
than	O	-1	19108278
either	O	-1	19108278
is@@	O	-1	19108278
om@@	O	-1	19108278
er@@	O	-1	19108278
.@@	O	-1	19108278
6@@	O	-1	19108278
.	O	-1	19108278
B@@	O	-1	19108278
oth	O	-1	19108278
is@@	O	-1	19108278
om@@	O	-1	19108278
ers	O	-1	19108278
of	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
were	O	-1	19108278
cap@@	O	-1	19108278
able	O	-1	19108278
of	O	-1	19108278
prevent@@	O	-1	19108278
ing	O	-1	19108278
adren@@	B-Chemical	D004837	19108278
aline	I-Chemical	-1	19108278
-induced	O	-1	19108278
cardiac	B-Disease	D001145	19108278
arrhyth@@	I-Disease	-1	19108278
mi@@	I-Disease	-1	19108278
as	I-Disease	-1	19108278
in	O	-1	19108278
cat@@	O	-1	19108278
s	O	-1	19108278
anaesthe@@	O	-1	19108278
tiz@@	O	-1	19108278
ed	O	-1	19108278
with	O	-1	19108278
halo@@	B-Chemical	D006221	19108278
th@@	I-Chemical	-1	19108278
ane	I-Chemical	-1	19108278
,	O	-1	19108278
but	O	-1	19108278
the	O	-1	19108278
mean	O	-1	19108278
dose	O	-1	19108278
of	O	-1	19108278
(-@@	O	-1	19108278
)@@	O	-1	19108278
-	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
was	O	-1	19108278
0.0@@	O	-1	19108278
9@@	O	-1	19108278
+/-@@	O	-1	19108278
0.0@@	O	-1	19108278
2	O	-1	19108278
mg/kg	O	-1	19108278
whereas	O	-1	19108278
that	O	-1	19108278
of	O	-1	19108278
(@@	O	-1	19108278
+@@	O	-1	19108278
)@@	O	-1	19108278
-	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
was	O	-1	19108278
4.@@	O	-1	19108278
2@@	O	-1	19108278
+/-@@	O	-1	19108278
1.@@	O	-1	19108278
2	O	-1	19108278
mg/kg@@	O	-1	19108278
.	O	-1	19108278
A@@	O	-1	19108278
t	O	-1	19108278
the	O	-1	19108278
effective	O	-1	19108278
dose	O	-1	19108278
level	O	-1	19108278
of	O	-1	19108278
(@@	O	-1	19108278
+@@	O	-1	19108278
)@@	O	-1	19108278
-	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
there	O	-1	19108278
was	O	-1	19108278
a	O	-1	19108278
significant	O	-1	19108278
prolong@@	O	-1	19108278
ation	O	-1	19108278
of	O	-1	19108278
the	O	-1	19108278
P@@	O	-1	19108278
R	O	-1	19108278
interv@@	O	-1	19108278
al	O	-1	19108278
of	O	-1	19108278
the	O	-1	19108278
electro@@	O	-1	19108278
cardio@@	O	-1	19108278
gram@@	O	-1	19108278
.	O	-1	19108278
B@@	O	-1	19108278
loc@@	O	-1	19108278
k@@	O	-1	19108278
ade	O	-1	19108278
of	O	-1	19108278
arrhyth@@	B-Disease	D001145	19108278
mi@@	I-Disease	-1	19108278
as	I-Disease	-1	19108278
with	O	-1	19108278
both	O	-1	19108278
is@@	O	-1	19108278
om@@	O	-1	19108278
ers	O	-1	19108278
was	O	-1	19108278
sur@@	O	-1	19108278
m@@	O	-1	19108278
oun@@	O	-1	19108278
t@@	O	-1	19108278
able	O	-1	19108278
by	O	-1	19108278
increas@@	O	-1	19108278
ing	O	-1	19108278
the	O	-1	19108278
dose	O	-1	19108278
of	O	-1	19108278
adren@@	B-Chemical	D004837	19108278
aline	I-Chemical	-1	19108278
.@@	O	-1	19108278
7@@	O	-1	19108278
.	O	-1	19108278
B@@	O	-1	19108278
oth	O	-1	19108278
is@@	O	-1	19108278
om@@	O	-1	19108278
ers	O	-1	19108278
of	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
were	O	-1	19108278
also	O	-1	19108278
cap@@	O	-1	19108278
able	O	-1	19108278
of	O	-1	19108278
rever@@	O	-1	19108278
s@@	O	-1	19108278
ing	O	-1	19108278
ventricular	B-Disease	D017180	19108278
tachycardia	I-Disease	-1	19108278
caused	O	-1	19108278
by	O	-1	19108278
ou@@	B-Chemical	D010042	19108278
ab@@	I-Chemical	-1	19108278
ain	I-Chemical	-1	19108278
in	O	-1	19108278
anaesthe@@	O	-1	19108278
tiz@@	O	-1	19108278
ed	O	-1	19108278
cat@@	O	-1	19108278
s	O	-1	19108278
and	O	-1	19108278
dog@@	O	-1	19108278
s.	O	-1	19108278
The	O	-1	19108278
dose	O	-1	19108278
of	O	-1	19108278
(-@@	O	-1	19108278
)@@	O	-1	19108278
-	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
was	O	-1	19108278
significantly	O	-1	19108278
sm@@	O	-1	19108278
all@@	O	-1	19108278
er	O	-1	19108278
than	O	-1	19108278
that	O	-1	19108278
of	O	-1	19108278
(@@	O	-1	19108278
+@@	O	-1	19108278
)@@	O	-1	19108278
-	O	-1	19108278
prop@@	B-Chemical	D011433	19108278
ran@@	I-Chemical	-1	19108278
o@@	I-Chemical	-1	19108278
lol	I-Chemical	-1	19108278
in	O	-1	19108278
both	O	-1	19108278
spec@@	O	-1	19108278
i@@	O	-1	19108278
es	O	-1	19108278
but	O	-1	19108278
m@@	O	-1	19108278
uc@@	O	-1	19108278
h	O	-1	19108278
higher	O	-1	19108278
than	O	-1	19108278
that	O	-1	19108278
requ@@	O	-1	19108278
ired	O	-1	19108278
to	O	-1	19108278
produce	O	-1	19108278
evidence	O	-1	19108278
of	O	-1	19108278
beta-@@	O	-1	19108278
block@@	O	-1	19108278
ade@@	O	-1	19108278
.@@	O	-1	19108278
8@@	O	-1	19108278
.	O	-1	19108278
The	O	-1	19108278
implic@@	O	-1	19108278
ations	O	-1	19108278
of	O	-1	19108278
these	O	-1	19108278
results	O	-1	19108278
are	O	-1	19108278
discus@@	O	-1	19108278
sed.	O	-1	19108278

T@@	B-Chemical	D019772	19139825
op@@	I-Chemical	-1	19139825
ot@@	I-Chemical	-1	19139825
ec@@	I-Chemical	-1	19139825
an	I-Chemical	-1	19139825
in	O	-1	19139825
combination	O	-1	19139825
with	O	-1	19139825
radi@@	O	-1	19139825
o@@	O	-1	19139825
therapy	O	-1	19139825
in	O	-1	19139825
un@@	O	-1	19139825
res@@	O	-1	19139825
ect@@	O	-1	19139825
able	O	-1	19139825
g@@	B-Disease	D005909	19139825
li@@	I-Disease	-1	19139825
ob@@	I-Disease	-1	19139825
l@@	I-Disease	-1	19139825
ast@@	I-Disease	-1	19139825
oma	I-Disease	-1	19139825
:	O	-1	19139825
a	O	-1	19139825
phase	O	-1	19139825
2	O	-1	19139825
study.	O	-1	19139825
Im@@	O	-1	19139825
pro@@	O	-1	19139825
ving	O	-1	19139825
g@@	B-Disease	D005909	19139825
li@@	I-Disease	-1	19139825
ob@@	I-Disease	-1	19139825
l@@	I-Disease	-1	19139825
ast@@	I-Disease	-1	19139825
oma	I-Disease	-1	19139825
multi@@	I-Disease	-1	19139825
form@@	I-Disease	-1	19139825
e	I-Disease	-1	19139825
(	O	-1	19139825
G@@	B-Disease	D005909	19139825
B@@	I-Disease	-1	19139825
M	I-Disease	-1	19139825
)	O	-1	19139825
treatment	O	-1	19139825
with	O	-1	19139825
radi@@	O	-1	19139825
o@@	O	-1	19139825
-@@	O	-1	19139825
chemotherapy	O	-1	19139825
remain@@	O	-1	19139825
s	O	-1	19139825
a	O	-1	19139825
ch@@	O	-1	19139825
all@@	O	-1	19139825
en@@	O	-1	19139825
g@@	O	-1	19139825
e.	O	-1	19139825
T@@	B-Chemical	D019772	19139825
op@@	I-Chemical	-1	19139825
ot@@	I-Chemical	-1	19139825
ec@@	I-Chemical	-1	19139825
an	I-Chemical	-1	19139825
is	O	-1	19139825
an	O	-1	19139825
at@@	O	-1	19139825
trac@@	O	-1	19139825
tive	O	-1	19139825
op@@	O	-1	19139825
tion	O	-1	19139825
as	O	-1	19139825
it	O	-1	19139825
ex@@	O	-1	19139825
hib@@	O	-1	19139825
its	O	-1	19139825
growth	O	-1	19139825
inhibition	O	-1	19139825
of	O	-1	19139825
human	O	-1	19139825
g@@	B-Disease	D005910	19139825
li@@	I-Disease	-1	19139825
oma	I-Disease	-1	19139825
as	O	-1	19139825
well	O	-1	19139825
as	O	-1	19139825
brain	O	-1	19139825
pen@@	O	-1	19139825
et@@	O	-1	19139825
r@@	O	-1	19139825
ation.	O	-1	19139825
The	O	-1	19139825
present	O	-1	19139825
study	O	-1	19139825
assessed	O	-1	19139825
the	O	-1	19139825
combination	O	-1	19139825
of	O	-1	19139825
radi@@	O	-1	19139825
o@@	O	-1	19139825
therapy	O	-1	19139825
(@@	O	-1	19139825
60	O	-1	19139825
G@@	O	-1	19139825
y@@	O	-1	19139825
/@@	O	-1	19139825
30	O	-1	19139825
frac@@	O	-1	19139825
tion@@	O	-1	19139825
s/@@	O	-1	19139825
40	O	-1	19139825
da@@	O	-1	19139825
ys@@	O	-1	19139825
)	O	-1	19139825
and	O	-1	19139825
to@@	B-Chemical	D019772	19139825
pot@@	I-Chemical	-1	19139825
ec@@	I-Chemical	-1	19139825
an	I-Chemical	-1	19139825
(0.@@	O	-1	19139825
9	O	-1	19139825
mg/m@@	O	-1	19139825
(2@@	O	-1	19139825
)@@	O	-1	19139825
/@@	O	-1	19139825
day	O	-1	19139825
on	O	-1	19139825
days	O	-1	19139825
1-@@	O	-1	19139825
5	O	-1	19139825
on	O	-1	19139825
weeks	O	-1	19139825
1,	O	-1	19139825
3	O	-1	19139825
and	O	-1	19139825
5@@	O	-1	19139825
)	O	-1	19139825
in	O	-1	19139825
50	O	-1	19139825
ad@@	O	-1	19139825
ult@@	O	-1	19139825
s	O	-1	19139825
with	O	-1	19139825
hist@@	O	-1	19139825
olog@@	O	-1	19139825
ically	O	-1	19139825
pro@@	O	-1	19139825
ven	O	-1	19139825
and	O	-1	19139825
un@@	O	-1	19139825
treated	O	-1	19139825
G@@	B-Disease	D005909	19139825
B@@	I-Disease	-1	19139825
M	I-Disease	-1	19139825
.	O	-1	19139825
The	O	-1	19139825
incidence	O	-1	19139825
of	O	-1	19139825
non-@@	O	-1	19139825
hemat@@	O	-1	19139825
ological	O	-1	19139825
toxic@@	B-Disease	D064420	19139825
ities	I-Disease	-1	19139825
was	O	-1	19139825
low	O	-1	19139825
and	O	-1	19139825
gra@@	O	-1	19139825
de	O	-1	19139825
3-@@	O	-1	19139825
4	O	-1	19139825
hemat@@	O	-1	19139825
ological	O	-1	19139825
toxic@@	B-Disease	D064420	19139825
ities	I-Disease	-1	19139825
were	O	-1	19139825
reported	O	-1	19139825
in	O	-1	19139825
20	O	-1	19139825
patients	O	-1	19139825
(@@	O	-1	19139825
main@@	O	-1	19139825
ly	O	-1	19139825
lymph@@	B-Disease	D008231	19139825
o@@	I-Disease	-1	19139825
pen@@	I-Disease	-1	19139825
ia	I-Disease	-1	19139825
and	O	-1	19139825
ne@@	B-Disease	D009503	19139825
ut@@	I-Disease	-1	19139825
ro@@	I-Disease	-1	19139825
pen@@	I-Disease	-1	19139825
ia	I-Disease	-1	19139825
).	O	-1	19139825
P@@	O	-1	19139825
ar@@	O	-1	19139825
tial	O	-1	19139825
response	O	-1	19139825
and	O	-1	19139825
st@@	O	-1	19139825
abil@@	O	-1	19139825
ization	O	-1	19139825
rat@@	O	-1	19139825
es	O	-1	19139825
were	O	-1	19139825
2@@	O	-1	19139825
%	O	-1	19139825
and	O	-1	19139825
3@@	O	-1	19139825
2@@	O	-1	19139825
%,	O	-1	19139825
respectivel@@	O	-1	19139825
y,	O	-1	19139825
with	O	-1	19139825
an	O	-1	19139825
over@@	O	-1	19139825
all	O	-1	19139825
time	O	-1	19139825
to	O	-1	19139825
progres@@	O	-1	19139825
sion	O	-1	19139825
of	O	-1	19139825
12	O	-1	19139825
week@@	O	-1	19139825
s.	O	-1	19139825
O@@	O	-1	19139825
ne@@	O	-1	19139825
-@@	O	-1	19139825
year	O	-1	19139825
over@@	O	-1	19139825
all	O	-1	19139825
sur@@	O	-1	19139825
viv@@	O	-1	19139825
al	O	-1	19139825
(@@	O	-1	19139825
O@@	O	-1	19139825
S)	O	-1	19139825
rate	O	-1	19139825
was	O	-1	19139825
4@@	O	-1	19139825
2@@	O	-1	19139825
%,	O	-1	19139825
with	O	-1	19139825
a	O	-1	19139825
median	O	-1	19139825
O@@	O	-1	19139825
S	O	-1	19139825
of	O	-1	19139825
40	O	-1	19139825
week@@	O	-1	19139825
s.	O	-1	19139825
T@@	B-Chemical	D019772	19139825
op@@	I-Chemical	-1	19139825
ot@@	I-Chemical	-1	19139825
ec@@	I-Chemical	-1	19139825
an	I-Chemical	-1	19139825
in	O	-1	19139825
combination	O	-1	19139825
with	O	-1	19139825
radi@@	O	-1	19139825
o@@	O	-1	19139825
therapy	O	-1	19139825
was	O	-1	19139825
well	O	-1	19139825
toler@@	O	-1	19139825
ated.	O	-1	19139825
However,	O	-1	19139825
while	O	-1	19139825
response	O	-1	19139825
and	O	-1	19139825
st@@	O	-1	19139825
abil@@	O	-1	19139825
ization	O	-1	19139825
con@@	O	-1	19139825
cer@@	O	-1	19139825
n@@	O	-1	19139825
ed	O	-1	19139825
on@@	O	-1	19139825
e-@@	O	-1	19139825
thir@@	O	-1	19139825
d	O	-1	19139825
of	O	-1	19139825
the	O	-1	19139825
patients,	O	-1	19139825
the	O	-1	19139825
study	O	-1	19139825
did	O	-1	19139825
not	O	-1	19139825
show	O	-1	19139825
increased	O	-1	19139825
ben@@	O	-1	19139825
e@@	O	-1	19139825
f@@	O	-1	19139825
its	O	-1	19139825
in	O	-1	19139825
ter@@	O	-1	19139825
ms	O	-1	19139825
of	O	-1	19139825
sur@@	O	-1	19139825
viv@@	O	-1	19139825
al	O	-1	19139825
in	O	-1	19139825
patients	O	-1	19139825
with	O	-1	19139825
un@@	O	-1	19139825
res@@	O	-1	19139825
ect@@	O	-1	19139825
able	O	-1	19139825
G@@	B-Disease	D005909	19139825
B@@	I-Disease	-1	19139825
M	I-Disease	-1	19139825
.	O	-1	19139825

L@@	O	-1	19154241
on@@	O	-1	19154241
g@@	O	-1	19154241
-term	O	-1	19154241
lithium	B-Chemical	D008094	19154241
therapy	O	-1	19154241
lead@@	O	-1	19154241
ing	O	-1	19154241
to	O	-1	19154241
hyper@@	B-Disease	D006961	19154241
par@@	I-Disease	-1	19154241
ath@@	I-Disease	-1	19154241
yro@@	I-Disease	-1	19154241
i@@	I-Disease	-1	19154241
dis@@	I-Disease	-1	19154241
m	I-Disease	-1	19154241
:	O	-1	19154241
a	O	-1	19154241
case	O	-1	19154241
repor@@	O	-1	19154241
t.	O	-1	19154241
P@@	O	-1	19154241
U@@	O	-1	19154241
R@@	O	-1	19154241
P@@	O	-1	19154241
O@@	O	-1	19154241
S@@	O	-1	19154241
E:	O	-1	19154241
This	O	-1	19154241
pap@@	O	-1	19154241
er	O	-1	19154241
revie@@	O	-1	19154241
w@@	O	-1	19154241
s	O	-1	19154241
the	O	-1	19154241
effect	O	-1	19154241
of	O	-1	19154241
chronic	O	-1	19154241
lithium	B-Chemical	D008094	19154241
therapy	O	-1	19154241
on	O	-1	19154241
serum	O	-1	19154241
calcium	B-Chemical	D002118	19154241
level	O	-1	19154241
and	O	-1	19154241
par@@	O	-1	19154241
ath@@	O	-1	19154241
yro@@	O	-1	19154241
id	O	-1	19154241
gl@@	O	-1	19154241
and@@	O	-1	19154241
s,	O	-1	19154241
its	O	-1	19154241
path@@	O	-1	19154241
o@@	O	-1	19154241
gene@@	O	-1	19154241
sis,	O	-1	19154241
and	O	-1	19154241
treatment	O	-1	19154241
op@@	O	-1	19154241
tions.	O	-1	19154241
We	O	-1	19154241
examined	O	-1	19154241
the	O	-1	19154241
case	O	-1	19154241
of	O	-1	19154241
a	O	-1	19154241
lithium	B-Chemical	D008094	19154241
-treated	O	-1	19154241
patient	O	-1	19154241
who	O	-1	19154241
had	O	-1	19154241
recur@@	O	-1	19154241
rent	O	-1	19154241
hyper@@	B-Disease	D006934	19154241
cal@@	I-Disease	-1	19154241
ce@@	I-Disease	-1	19154241
mia	I-Disease	-1	19154241
to	O	-1	19154241
bet@@	O	-1	19154241
ter	O	-1	19154241
under@@	O	-1	19154241
st@@	O	-1	19154241
and	O	-1	19154241
the	O	-1	19154241
disease	O	-1	19154241
pro@@	O	-1	19154241
ces@@	O	-1	19154241
s.	O	-1	19154241
CONCLUSION:	O	-1	19154241
P@@	B-Disease	D049950	19154241
ri@@	I-Disease	-1	19154241
m@@	I-Disease	-1	19154241
ary	I-Disease	-1	19154241
hyper@@	I-Disease	-1	19154241
par@@	I-Disease	-1	19154241
ath@@	I-Disease	-1	19154241
yro@@	I-Disease	-1	19154241
i@@	I-Disease	-1	19154241
dis@@	I-Disease	-1	19154241
m	I-Disease	-1	19154241
is	O	-1	19154241
a	O	-1	19154241
r@@	O	-1	19154241
are	O	-1	19154241
but	O	-1	19154241
potenti@@	O	-1	19154241
ally	O	-1	19154241
lif@@	O	-1	19154241
e-@@	O	-1	19154241
th@@	O	-1	19154241
reat@@	O	-1	19154241
en@@	O	-1	19154241
ing	O	-1	19154241
side	O	-1	19154241
effect	O	-1	19154241
of	O	-1	19154241
long-term	O	-1	19154241
lithium	B-Chemical	D008094	19154241
therapy.	O	-1	19154241
Ca@@	O	-1	19154241
ref@@	O	-1	19154241
u@@	O	-1	19154241
l	O	-1	19154241
patient	O	-1	19154241
sel@@	O	-1	19154241
ection	O	-1	19154241
and	O	-1	19154241
long-term	O	-1	19154241
follow-up	O	-1	19154241
can	O	-1	19154241
re@@	O	-1	19154241
duce	O	-1	19154241
mor@@	O	-1	19154241
b@@	O	-1	19154241
id@@	O	-1	19154241
ity.	O	-1	19154241
P@@	O	-1	19154241
R@@	O	-1	19154241
AC@@	O	-1	19154241
TI@@	O	-1	19154241
CA@@	O	-1	19154241
L	O	-1	19154241
I@@	O	-1	19154241
MP@@	O	-1	19154241
L@@	O	-1	19154241
IC@@	O	-1	19154241
AT@@	O	-1	19154241
ION@@	O	-1	19154241
S:	O	-1	19154241
A@@	O	-1	19154241
s	O	-1	19154241
m@@	O	-1	19154241
uc@@	O	-1	19154241
h	O	-1	19154241
as	O	-1	19154241
1@@	O	-1	19154241
5%	O	-1	19154241
of	O	-1	19154241
lithium	B-Chemical	D008094	19154241
-treated	O	-1	19154241
patients	O	-1	19154241
b@@	O	-1	19154241
ec@@	O	-1	19154241
ome	O	-1	19154241
hyper@@	B-Disease	D006934	19154241
cal@@	I-Disease	-1	19154241
ce@@	I-Disease	-1	19154241
mic	I-Disease	-1	19154241
.	O	-1	19154241
B@@	O	-1	19154241
y	O	-1	19154241
ro@@	O	-1	19154241
ut@@	O	-1	19154241
ine@@	O	-1	19154241
ly	O	-1	19154241
monit@@	O	-1	19154241
or@@	O	-1	19154241
ing	O	-1	19154241
serum	O	-1	19154241
calcium	B-Chemical	D002118	19154241
level@@	O	-1	19154241
s,	O	-1	19154241
health@@	O	-1	19154241
car@@	O	-1	19154241
e	O	-1	19154241
pro@@	O	-1	19154241
vid@@	O	-1	19154241
ers	O	-1	19154241
can	O	-1	19154241
impro@@	O	-1	19154241
ve	O	-1	19154241
the	O	-1	19154241
qu@@	O	-1	19154241
ality	O	-1	19154241
of	O	-1	19154241
lif@@	O	-1	19154241
e	O	-1	19154241
of	O	-1	19154241
this	O	-1	19154241
patient	O	-1	19154241
group.	O	-1	19154241

Com@@	O	-1	19178808
par@@	O	-1	19178808
ison	O	-1	19178808
of	O	-1	19178808
l@@	O	-1	19178808
ar@@	O	-1	19178808
yn@@	O	-1	19178808
ge@@	O	-1	19178808
al	O	-1	19178808
mas@@	O	-1	19178808
k	O	-1	19178808
with	O	-1	19178808
en@@	O	-1	19178808
d@@	O	-1	19178808
ot@@	O	-1	19178808
rac@@	O	-1	19178808
he@@	O	-1	19178808
al	O	-1	19178808
tu@@	O	-1	19178808
be	O	-1	19178808
for	O	-1	19178808
anesthe@@	O	-1	19178808
sia	O	-1	19178808
in	O	-1	19178808
en@@	O	-1	19178808
dos@@	O	-1	19178808
co@@	O	-1	19178808
p@@	O	-1	19178808
ic	O	-1	19178808
s@@	O	-1	19178808
in@@	O	-1	19178808
us	O	-1	19178808
surger@@	O	-1	19178808
y.	O	-1	19178808
BACKGROUND:	O	-1	19178808
The	O	-1	19178808
pur@@	O	-1	19178808
p@@	O	-1	19178808
ose	O	-1	19178808
of	O	-1	19178808
this	O	-1	19178808
study	O	-1	19178808
was	O	-1	19178808
to	O	-1	19178808
compar@@	O	-1	19178808
e	O	-1	19178808
surg@@	O	-1	19178808
ical	O	-1	19178808
condi@@	O	-1	19178808
tion@@	O	-1	19178808
s,	O	-1	19178808
including	O	-1	19178808
the	O	-1	19178808
amoun@@	O	-1	19178808
t	O	-1	19178808
of	O	-1	19178808
intra@@	O	-1	19178808
o@@	O	-1	19178808
perative	O	-1	19178808
ble@@	B-Disease	D006470	19178808
ed@@	I-Disease	-1	19178808
ing	I-Disease	-1	19178808
as	O	-1	19178808
well	O	-1	19178808
as	O	-1	19178808
intra@@	O	-1	19178808
o@@	O	-1	19178808
perative	O	-1	19178808
blood	O	-1	19178808
pressu@@	O	-1	19178808
re,	O	-1	19178808
during	O	-1	19178808
functional	O	-1	19178808
en@@	O	-1	19178808
dos@@	O	-1	19178808
co@@	O	-1	19178808
p@@	O	-1	19178808
ic	O	-1	19178808
s@@	O	-1	19178808
in@@	O	-1	19178808
us	O	-1	19178808
surger@@	O	-1	19178808
y	O	-1	19178808
(@@	O	-1	19178808
F@@	O	-1	19178808
ES@@	O	-1	19178808
S)	O	-1	19178808
using	O	-1	19178808
f@@	O	-1	19178808
le@@	O	-1	19178808
xi@@	O	-1	19178808
ble	O	-1	19178808
re@@	O	-1	19178808
inf@@	O	-1	19178808
or@@	O	-1	19178808
c@@	O	-1	19178808
ed	O	-1	19178808
l@@	O	-1	19178808
ar@@	O	-1	19178808
yn@@	O	-1	19178808
ge@@	O	-1	19178808
al	O	-1	19178808
mas@@	O	-1	19178808
k	O	-1	19178808
a@@	O	-1	19178808
ir@@	O	-1	19178808
w@@	O	-1	19178808
ay	O	-1	19178808
(@@	O	-1	19178808
F@@	O	-1	19178808
R@@	O	-1	19178808
L@@	O	-1	19178808
MA@@	O	-1	19178808
)	O	-1	19178808
versus	O	-1	19178808
en@@	O	-1	19178808
d@@	O	-1	19178808
ot@@	O	-1	19178808
rac@@	O	-1	19178808
he@@	O	-1	19178808
al	O	-1	19178808
tu@@	O	-1	19178808
be	O	-1	19178808
(@@	O	-1	19178808
ET@@	O	-1	19178808
T)	O	-1	19178808
in	O	-1	19178808
maint@@	O	-1	19178808
aining	O	-1	19178808
controlled	O	-1	19178808
hypotension	B-Disease	D007022	19178808
anesthe@@	O	-1	19178808
sia	O	-1	19178808
induced	O	-1	19178808
by	O	-1	19178808
pro@@	B-Chemical	D015742	19178808
po@@	I-Chemical	-1	19178808
f@@	I-Chemical	-1	19178808
ol	I-Chemical	-1	19178808
-	O	-1	19178808
re@@	B-Chemical	C071741	19178808
m@@	I-Chemical	-1	19178808
if@@	I-Chemical	-1	19178808
entan@@	I-Chemical	-1	19178808
il	I-Chemical	-1	19178808
total	O	-1	19178808
i.v@@	O	-1	19178808
.	O	-1	19178808
anesthe@@	O	-1	19178808
sia	O	-1	19178808
(@@	O	-1	19178808
TIV@@	O	-1	19178808
A@@	O	-1	19178808
).	O	-1	19178808
METHODS:	O	-1	19178808
Si@@	O	-1	19178808
x@@	O	-1	19178808
t@@	O	-1	19178808
y	O	-1	19178808
norm@@	O	-1	19178808
oten@@	O	-1	19178808
sive	O	-1	19178808
A@@	O	-1	19178808
mer@@	O	-1	19178808
ic@@	O	-1	19178808
an	O	-1	19178808
S@@	O	-1	19178808
oci@@	O	-1	19178808
ety	O	-1	19178808
of	O	-1	19178808
An@@	O	-1	19178808
esthe@@	O	-1	19178808
si@@	O	-1	19178808
olog@@	O	-1	19178808
ist@@	O	-1	19178808
s	O	-1	19178808
I@@	O	-1	19178808
-@@	O	-1	19178808
II	O	-1	19178808
ad@@	O	-1	19178808
ult	O	-1	19178808
patients	O	-1	19178808
under@@	O	-1	19178808
go@@	O	-1	19178808
ing	O	-1	19178808
F@@	O	-1	19178808
ES@@	O	-1	19178808
S	O	-1	19178808
under	O	-1	19178808
controlled	O	-1	19178808
hypotension	B-Disease	D007022	19178808
anesthe@@	O	-1	19178808
sia	O	-1	19178808
caused	O	-1	19178808
by	O	-1	19178808
pro@@	B-Chemical	D015742	19178808
po@@	I-Chemical	-1	19178808
f@@	I-Chemical	-1	19178808
ol	I-Chemical	-1	19178808
-	O	-1	19178808
re@@	B-Chemical	C071741	19178808
m@@	I-Chemical	-1	19178808
if@@	I-Chemical	-1	19178808
entan@@	I-Chemical	-1	19178808
il	I-Chemical	-1	19178808
-@@	O	-1	19178808
TIV@@	O	-1	19178808
A	O	-1	19178808
were	O	-1	19178808
random@@	O	-1	19178808
ly	O	-1	19178808
as@@	O	-1	19178808
signed	O	-1	19178808
into	O	-1	19178808
two	O	-1	19178808
group@@	O	-1	19178808
s:	O	-1	19178808
group	O	-1	19178808
I@@	O	-1	19178808
,	O	-1	19178808
F@@	O	-1	19178808
R@@	O	-1	19178808
L@@	O	-1	19178808
MA@@	O	-1	19178808
;	O	-1	19178808
group	O	-1	19178808
II@@	O	-1	19178808
,	O	-1	19178808
ET@@	O	-1	19178808
T@@	O	-1	19178808
.	O	-1	19178808
H@@	B-Disease	D006470	19178808
em@@	I-Disease	-1	19178808
or@@	I-Disease	-1	19178808
rh@@	I-Disease	-1	19178808
age	I-Disease	-1	19178808
was	O	-1	19178808
measured	O	-1	19178808
and	O	-1	19178808
the	O	-1	19178808
vi@@	O	-1	19178808
sib@@	O	-1	19178808
ility	O	-1	19178808
of	O	-1	19178808
the	O	-1	19178808
o@@	O	-1	19178808
perative	O	-1	19178808
fi@@	O	-1	19178808
el@@	O	-1	19178808
d	O	-1	19178808
was	O	-1	19178808
evaluated	O	-1	19178808
ac@@	O	-1	19178808
cor@@	O	-1	19178808
ding	O	-1	19178808
to	O	-1	19178808
a	O	-1	19178808
si@@	O	-1	19178808
x@@	O	-1	19178808
-@@	O	-1	19178808
po@@	O	-1	19178808
in@@	O	-1	19178808
t	O	-1	19178808
s@@	O	-1	19178808
cal@@	O	-1	19178808
e.	O	-1	19178808
RESULTS:	O	-1	19178808
C@@	O	-1	19178808
ont@@	O	-1	19178808
ro@@	O	-1	19178808
lled	O	-1	19178808
hypotension	B-Disease	D007022	19178808
was	O	-1	19178808
achi@@	O	-1	19178808
ev@@	O	-1	19178808
ed	O	-1	19178808
within	O	-1	19178808
a	O	-1	19178808
sh@@	O	-1	19178808
or@@	O	-1	19178808
ter	O	-1	19178808
period	O	-1	19178808
using	O	-1	19178808
l@@	O	-1	19178808
ar@@	O	-1	19178808
yn@@	O	-1	19178808
ge@@	O	-1	19178808
al	O	-1	19178808
mas@@	O	-1	19178808
k	O	-1	19178808
using	O	-1	19178808
lower	O	-1	19178808
rat@@	O	-1	19178808
es	O	-1	19178808
of	O	-1	19178808
re@@	B-Chemical	C071741	19178808
m@@	I-Chemical	-1	19178808
if@@	I-Chemical	-1	19178808
entan@@	I-Chemical	-1	19178808
il	I-Chemical	-1	19178808
infusion	O	-1	19178808
and	O	-1	19178808
lower	O	-1	19178808
total	O	-1	19178808
dose	O	-1	19178808
of	O	-1	19178808
re@@	B-Chemical	C071741	19178808
m@@	I-Chemical	-1	19178808
if@@	I-Chemical	-1	19178808
entan@@	I-Chemical	-1	19178808
il	I-Chemical	-1	19178808
.	O	-1	19178808
CONCLUSION:	O	-1	19178808
In	O	-1	19178808
su@@	O	-1	19178808
mm@@	O	-1	19178808
ar@@	O	-1	19178808
y,	O	-1	19178808
our	O	-1	19178808
results	O	-1	19178808
indicate	O	-1	19178808
that	O	-1	19178808
a@@	O	-1	19178808
ir@@	O	-1	19178808
w@@	O	-1	19178808
ay	O	-1	19178808
man@@	O	-1	19178808
ag@@	O	-1	19178808
ement	O	-1	19178808
using	O	-1	19178808
F@@	O	-1	19178808
R@@	O	-1	19178808
L@@	O	-1	19178808
M@@	O	-1	19178808
A	O	-1	19178808
during	O	-1	19178808
controlled	O	-1	19178808
hypotension	B-Disease	D007022	19178808
anesthe@@	O	-1	19178808
sia	O	-1	19178808
pro@@	O	-1	19178808
vid@@	O	-1	19178808
ed	O	-1	19178808
bet@@	O	-1	19178808
ter	O	-1	19178808
surg@@	O	-1	19178808
ical	O	-1	19178808
condi@@	O	-1	19178808
tions	O	-1	19178808
in	O	-1	19178808
ter@@	O	-1	19178808
ms	O	-1	19178808
of	O	-1	19178808
qu@@	O	-1	19178808
ality	O	-1	19178808
of	O	-1	19178808
o@@	O	-1	19178808
perative	O	-1	19178808
fi@@	O	-1	19178808
el@@	O	-1	19178808
d	O	-1	19178808
and	O	-1	19178808
blood	O	-1	19178808
loss	O	-1	19178808
and	O	-1	19178808
al@@	O	-1	19178808
low@@	O	-1	19178808
ed	O	-1	19178808
for	O	-1	19178808
con@@	O	-1	19178808
ven@@	O	-1	19178808
i@@	O	-1	19178808
ent	O	-1	19178808
induced	O	-1	19178808
hypotension	B-Disease	D007022	19178808
with	O	-1	19178808
low	O	-1	19178808
doses	O	-1	19178808
of	O	-1	19178808
re@@	B-Chemical	C071741	19178808
m@@	I-Chemical	-1	19178808
if@@	I-Chemical	-1	19178808
entan@@	I-Chemical	-1	19178808
il	I-Chemical	-1	19178808
during	O	-1	19178808
TIV@@	O	-1	19178808
A	O	-1	19178808
in	O	-1	19178808
patients	O	-1	19178808
under@@	O	-1	19178808
go@@	O	-1	19178808
ing	O	-1	19178808
F@@	O	-1	19178808
ES@@	O	-1	19178808
S@@	O	-1	19178808
.	O	-1	19178808

N@@	B-Disease	D065626	19184102
on@@	I-Disease	-1	19184102
alco@@	I-Disease	-1	19184102
h@@	I-Disease	-1	19184102
olic	I-Disease	-1	19184102
f@@	I-Disease	-1	19184102
at@@	I-Disease	-1	19184102
t@@	I-Disease	-1	19184102
y	I-Disease	-1	19184102
liver	I-Disease	-1	19184102
disease	I-Disease	-1	19184102
during	O	-1	19184102
valpro@@	B-Chemical	D014635	19184102
ate	I-Chemical	-1	19184102
therapy.	O	-1	19184102
V@@	B-Chemical	D014635	19184102
al@@	I-Chemical	-1	19184102
pro@@	I-Chemical	-1	19184102
ic	I-Chemical	-1	19184102
acid	I-Chemical	-1	19184102
(	O	-1	19184102
V@@	B-Chemical	D014635	19184102
P@@	I-Chemical	-1	19184102
A	I-Chemical	-1	19184102
)	O	-1	19184102
is	O	-1	19184102
effective	O	-1	19184102
for	O	-1	19184102
the	O	-1	19184102
treatment	O	-1	19184102
of	O	-1	19184102
man@@	O	-1	19184102
y	O	-1	19184102
typ@@	O	-1	19184102
es	O	-1	19184102
of	O	-1	19184102
epilep@@	B-Disease	D004827	19184102
sy	I-Disease	-1	19184102
,	O	-1	19184102
but	O	-1	19184102
its	O	-1	19184102
use	O	-1	19184102
can	O	-1	19184102
be	O	-1	19184102
associated	O	-1	19184102
with	O	-1	19184102
an	O	-1	19184102
increase	O	-1	19184102
in	O	-1	19184102
body	O	-1	19184102
weigh@@	O	-1	19184102
t.	O	-1	19184102
We	O	-1	19184102
report	O	-1	19184102
a	O	-1	19184102
case	O	-1	19184102
of	O	-1	19184102
non@@	B-Disease	D065626	19184102
alco@@	I-Disease	-1	19184102
h@@	I-Disease	-1	19184102
olic	I-Disease	-1	19184102
f@@	I-Disease	-1	19184102
at@@	I-Disease	-1	19184102
t@@	I-Disease	-1	19184102
y	I-Disease	-1	19184102
liver	I-Disease	-1	19184102
disease	I-Disease	-1	19184102
(	O	-1	19184102
N@@	B-Disease	D065626	19184102
A@@	I-Disease	-1	19184102
F@@	I-Disease	-1	19184102
L@@	I-Disease	-1	19184102
D	I-Disease	-1	19184102
)	O	-1	19184102
ar@@	O	-1	19184102
is@@	O	-1	19184102
ing	O	-1	19184102
in	O	-1	19184102
a	O	-1	19184102
ch@@	O	-1	19184102
il@@	O	-1	19184102
d	O	-1	19184102
who	O	-1	19184102
developed	O	-1	19184102
ob@@	B-Disease	D009765	19184102
es@@	I-Disease	-1	19184102
ity	I-Disease	-1	19184102
during	O	-1	19184102
V@@	B-Chemical	D014635	19184102
P@@	I-Chemical	-1	19184102
A	I-Chemical	-1	19184102
treatment.	O	-1	19184102
L@@	O	-1	19184102
abor@@	O	-1	19184102
atory	O	-1	19184102
data	O	-1	19184102
revealed	O	-1	19184102
hyper@@	B-Disease	D006946	19184102
in@@	I-Disease	-1	19184102
sul@@	I-Disease	-1	19184102
ine@@	I-Disease	-1	19184102
mia	I-Disease	-1	19184102
with	O	-1	19184102
in@@	B-Disease	D007333	19184102
sul@@	I-Disease	-1	19184102
in	I-Disease	-1	19184102
resist@@	I-Disease	-1	19184102
ance	I-Disease	-1	19184102
.	O	-1	19184102
After	O	-1	19184102
the	O	-1	19184102
withdrawal	O	-1	19184102
of	O	-1	19184102
V@@	B-Chemical	D014635	19184102
P@@	I-Chemical	-1	19184102
A	I-Chemical	-1	19184102
therapy,	O	-1	19184102
our	O	-1	19184102
patient	O	-1	19184102
showed	O	-1	19184102
a	O	-1	19184102
significant	O	-1	19184102
weight	B-Disease	D015431	19184102
loss	I-Disease	-1	19184102
,	O	-1	19184102
a	O	-1	19184102
decrease	O	-1	19184102
of	O	-1	19184102
body	O	-1	19184102
mas@@	O	-1	19184102
s	O	-1	19184102
in@@	O	-1	19184102
de@@	O	-1	19184102
x@@	O	-1	19184102
,	O	-1	19184102
and	O	-1	19184102
normal@@	O	-1	19184102
ization	O	-1	19184102
of	O	-1	19184102
met@@	O	-1	19184102
ab@@	O	-1	19184102
olic	O	-1	19184102
and	O	-1	19184102
en@@	O	-1	19184102
doc@@	O	-1	19184102
rine	O	-1	19184102
par@@	O	-1	19184102
ame@@	O	-1	19184102
ter@@	O	-1	19184102
s;	O	-1	19184102
mo@@	O	-1	19184102
re@@	O	-1	19184102
o@@	O	-1	19184102
ver,	O	-1	19184102
ult@@	O	-1	19184102
r@@	O	-1	19184102
as@@	O	-1	19184102
ound	O	-1	19184102
meas@@	O	-1	19184102
ure@@	O	-1	19184102
ments	O	-1	19184102
showed	O	-1	19184102
a	O	-1	19184102
complete	O	-1	19184102
normal@@	O	-1	19184102
iz@@	O	-1	19184102
ation.	O	-1	19184102
The	O	-1	19184102
present	O	-1	19184102
case	O	-1	19184102
suggests	O	-1	19184102
that	O	-1	19184102
ob@@	B-Disease	D009765	19184102
es@@	I-Disease	-1	19184102
ity	I-Disease	-1	19184102
,	O	-1	19184102
hyper@@	B-Disease	D006946	19184102
in@@	I-Disease	-1	19184102
sul@@	I-Disease	-1	19184102
ine@@	I-Disease	-1	19184102
mia	I-Disease	-1	19184102
,	O	-1	19184102
in@@	B-Disease	D007333	19184102
sul@@	I-Disease	-1	19184102
in	I-Disease	-1	19184102
resist@@	I-Disease	-1	19184102
ance	I-Disease	-1	19184102
,	O	-1	19184102
and	O	-1	19184102
long-term	O	-1	19184102
treatment	O	-1	19184102
with	O	-1	19184102
V@@	B-Chemical	D014635	19184102
P@@	I-Chemical	-1	19184102
A	I-Chemical	-1	19184102
may	O	-1	19184102
be	O	-1	19184102
all	O	-1	19184102
associated	O	-1	19184102
with	O	-1	19184102
the	O	-1	19184102
development	O	-1	19184102
of	O	-1	19184102
N@@	B-Disease	D065626	19184102
A@@	I-Disease	-1	19184102
F@@	I-Disease	-1	19184102
L@@	I-Disease	-1	19184102
D	I-Disease	-1	19184102
;	O	-1	19184102
this	O	-1	19184102
side	O	-1	19184102
effect	O	-1	19184102
is	O	-1	19184102
reversible	O	-1	19184102
after	O	-1	19184102
V@@	B-Chemical	D014635	19184102
P@@	I-Chemical	-1	19184102
A	I-Chemical	-1	19184102
withdraw@@	O	-1	19184102
al.	O	-1	19184102

C@@	B-Chemical	D002231	19263707
arb@@	I-Chemical	-1	19263707
im@@	I-Chemical	-1	19263707
azole	I-Chemical	-1	19263707
induced	O	-1	19263707
AN@@	B-Disease	D056648	19263707
C@@	I-Disease	-1	19263707
A	I-Disease	-1	19263707
positive	I-Disease	-1	19263707
vas@@	I-Disease	-1	19263707
cul@@	I-Disease	-1	19263707
iti@@	I-Disease	-1	19263707
s	I-Disease	-1	19263707
.	O	-1	19263707
An@@	B-Chemical	D013956	19263707
ti@@	I-Chemical	-1	19263707
-@@	I-Chemical	-1	19263707
th@@	I-Chemical	-1	19263707
yro@@	I-Chemical	-1	19263707
id	I-Chemical	-1	19263707
drugs	I-Chemical	-1	19263707
,	O	-1	19263707
like	O	-1	19263707
carb@@	B-Chemical	D002231	19263707
im@@	I-Chemical	-1	19263707
azole	I-Chemical	-1	19263707
and	O	-1	19263707
prop@@	B-Chemical	D011441	19263707
yl@@	I-Chemical	-1	19263707
th@@	I-Chemical	-1	19263707
io@@	I-Chemical	-1	19263707
urac@@	I-Chemical	-1	19263707
il	I-Chemical	-1	19263707
(	O	-1	19263707
P@@	B-Chemical	D011441	19263707
T@@	I-Chemical	-1	19263707
U	I-Chemical	-1	19263707
)	O	-1	19263707
are	O	-1	19263707
common@@	O	-1	19263707
ly	O	-1	19263707
prescri@@	O	-1	19263707
bed	O	-1	19263707
for	O	-1	19263707
the	O	-1	19263707
treatment	O	-1	19263707
of	O	-1	19263707
hyper@@	B-Disease	D006980	19263707
th@@	I-Disease	-1	19263707
yro@@	I-Disease	-1	19263707
i@@	I-Disease	-1	19263707
dis@@	I-Disease	-1	19263707
m	I-Disease	-1	19263707
.	O	-1	19263707
One	O	-1	19263707
should	O	-1	19263707
be	O	-1	19263707
aw@@	O	-1	19263707
are	O	-1	19263707
of	O	-1	19263707
the	O	-1	19263707
side	O	-1	19263707
effects	O	-1	19263707
of	O	-1	19263707
anti@@	B-Chemical	D013956	19263707
th@@	I-Chemical	-1	19263707
yro@@	I-Chemical	-1	19263707
id	I-Chemical	-1	19263707
medic@@	I-Chemical	-1	19263707
ations	I-Chemical	-1	19263707
.	O	-1	19263707
An@@	B-Disease	D056648	19263707
t@@	I-Disease	-1	19263707
ine@@	I-Disease	-1	19263707
ut@@	I-Disease	-1	19263707
ro@@	I-Disease	-1	19263707
ph@@	I-Disease	-1	19263707
il	I-Disease	-1	19263707
cyto@@	I-Disease	-1	19263707
plas@@	I-Disease	-1	19263707
mic	I-Disease	-1	19263707
anti@@	I-Disease	-1	19263707
body	I-Disease	-1	19263707
(A@@	I-Disease	-1	19263707
N@@	I-Disease	-1	19263707
CA@@	I-Disease	-1	19263707
)-@@	I-Disease	-1	19263707
-@@	I-Disease	-1	19263707
associated	I-Disease	-1	19263707
vas@@	I-Disease	-1	19263707
cul@@	I-Disease	-1	19263707
iti@@	I-Disease	-1	19263707
s	I-Disease	-1	19263707
is	O	-1	19263707
a	O	-1	19263707
potenti@@	O	-1	19263707
ally	O	-1	19263707
lif@@	O	-1	19263707
e-@@	O	-1	19263707
th@@	O	-1	19263707
reat@@	O	-1	19263707
en@@	O	-1	19263707
ing	O	-1	19263707
adverse	O	-1	19263707
effect	O	-1	19263707
of	O	-1	19263707
anti@@	B-Chemical	D013956	19263707
th@@	I-Chemical	-1	19263707
yro@@	I-Chemical	-1	19263707
id@@	I-Chemical	-1	19263707
medic@@	I-Chemical	-1	19263707
ations	I-Chemical	-1	19263707
.	O	-1	19263707
We	O	-1	19263707
report	O	-1	19263707
a	O	-1	19263707
patient	O	-1	19263707
with	O	-1	19263707
G@@	B-Disease	D006111	19263707
ra@@	I-Disease	-1	19263707
v@@	I-Disease	-1	19263707
es@@	I-Disease	-1	19263707
'	I-Disease	-1	19263707
disease	I-Disease	-1	19263707
who	O	-1	19263707
developed	O	-1	19263707
AN@@	O	-1	19263707
C@@	O	-1	19263707
A	O	-1	19263707
positive	O	-1	19263707
carb@@	B-Chemical	D002231	19263707
im@@	I-Chemical	-1	19263707
azole	I-Chemical	-1	19263707
induced	O	-1	19263707
vas@@	B-Disease	D014657	19263707
cul@@	I-Disease	-1	19263707
iti@@	I-Disease	-1	19263707
s	I-Disease	-1	19263707
.	O	-1	19263707
The	O	-1	19263707
episo@@	O	-1	19263707
de	O	-1	19263707
was	O	-1	19263707
character@@	O	-1	19263707
ized	O	-1	19263707
by	O	-1	19263707
a	O	-1	19263707
vas@@	B-Disease	D014657	19263707
cul@@	I-Disease	-1	19263707
i@@	I-Disease	-1	19263707
tic	I-Disease	-1	19263707
s@@	B-Disease	D005076	19263707
k@@	I-Disease	-1	19263707
in	I-Disease	-1	19263707
r@@	I-Disease	-1	19263707
as@@	I-Disease	-1	19263707
h	I-Disease	-1	19263707
associated	O	-1	19263707
with	O	-1	19263707
larg@@	O	-1	19263707
e	O	-1	19263707
j@@	O	-1	19263707
o@@	O	-1	19263707
in@@	O	-1	19263707
t	O	-1	19263707
arth@@	B-Disease	D001168	19263707
ritis	I-Disease	-1	19263707
,	O	-1	19263707
py@@	B-Disease	D005334	19263707
re@@	I-Disease	-1	19263707
x@@	I-Disease	-1	19263707
ia	I-Disease	-1	19263707
and	O	-1	19263707
pa@@	B-Disease	D010309	19263707
ro@@	I-Disease	-1	19263707
ti@@	I-Disease	-1	19263707
di@@	I-Disease	-1	19263707
tis	I-Disease	-1	19263707
but	O	-1	19263707
no	O	-1	19263707
renal	O	-1	19263707
or	O	-1	19263707
pulmonary	O	-1	19263707
invol@@	O	-1	19263707
ve@@	O	-1	19263707
ment.	O	-1	19263707
H@@	O	-1	19263707
e	O	-1	19263707
was	O	-1	19263707
ref@@	O	-1	19263707
er@@	O	-1	19263707
red	O	-1	19263707
to	O	-1	19263707
us	O	-1	19263707
for	O	-1	19263707
neurolog@@	O	-1	19263707
ical	O	-1	19263707
evalu@@	O	-1	19263707
ation	O	-1	19263707
because	O	-1	19263707
he	O	-1	19263707
had	O	-1	19263707
diff@@	O	-1	19263707
ic@@	O	-1	19263707
ult@@	O	-1	19263707
y	O	-1	19263707
in	O	-1	19263707
g@@	O	-1	19263707
et@@	O	-1	19263707
ting	O	-1	19263707
up	O	-1	19263707
from	O	-1	19263707
s@@	O	-1	19263707
qu@@	O	-1	19263707
at@@	O	-1	19263707
ting	O	-1	19263707
posi@@	O	-1	19263707
tion	O	-1	19263707
and	O	-1	19263707
was	O	-1	19263707
sus@@	O	-1	19263707
p@@	O	-1	19263707
ected	O	-1	19263707
to	O	-1	19263707
have	O	-1	19263707
my@@	B-Disease	D009220	19263707
o@@	I-Disease	-1	19263707
si@@	I-Disease	-1	19263707
tis	I-Disease	-1	19263707
.	O	-1	19263707
C@@	B-Chemical	D002231	19263707
arb@@	I-Chemical	-1	19263707
im@@	I-Chemical	-1	19263707
azole	I-Chemical	-1	19263707
and	O	-1	19263707
meth@@	B-Chemical	D008713	19263707
im@@	I-Chemical	-1	19263707
azole	I-Chemical	-1	19263707
have	O	-1	19263707
a	O	-1	19263707
lower	O	-1	19263707
incidence	O	-1	19263707
of	O	-1	19263707
reported	O	-1	19263707
AN@@	O	-1	19263707
C@@	O	-1	19263707
A	O	-1	19263707
positive	O	-1	19263707
side	O	-1	19263707
effects	O	-1	19263707
than	O	-1	19263707
P@@	O	-1	19263707
U@@	O	-1	19263707
T@@	O	-1	19263707
.	O	-1	19263707
To	O	-1	19263707
the	O	-1	19263707
b@@	O	-1	19263707
est	O	-1	19263707
of	O	-1	19263707
our	O	-1	19263707
know@@	O	-1	19263707
le@@	O	-1	19263707
d@@	O	-1	19263707
ge	O	-1	19263707
this	O	-1	19263707
is	O	-1	19263707
the	O	-1	19263707
first	O	-1	19263707
AN@@	O	-1	19263707
C@@	O	-1	19263707
A	O	-1	19263707
positive	O	-1	19263707
carb@@	B-Chemical	D002231	19263707
im@@	I-Chemical	-1	19263707
azole	I-Chemical	-1	19263707
induced	O	-1	19263707
vas@@	B-Disease	D014657	19263707
cul@@	I-Disease	-1	19263707
iti@@	I-Disease	-1	19263707
s	I-Disease	-1	19263707
case	O	-1	19263707
reported	O	-1	19263707
from	O	-1	19263707
In@@	O	-1	19263707
di@@	O	-1	19263707
a.	O	-1	19263707

A@@	B-Chemical	D001241	19293073
s@@	I-Chemical	-1	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
for	O	-1	19293073
the	O	-1	19293073
prim@@	O	-1	19293073
ary	O	-1	19293073
pre@@	O	-1	19293073
ven@@	O	-1	19293073
tion	O	-1	19293073
of	O	-1	19293073
cardiovascular	O	-1	19293073
event@@	O	-1	19293073
s:	O	-1	19293073
an	O	-1	19293073
up@@	O	-1	19293073
d@@	O	-1	19293073
ate	O	-1	19293073
of	O	-1	19293073
the	O	-1	19293073
evidence	O	-1	19293073
for	O	-1	19293073
the	O	-1	19293073
U@@	O	-1	19293073
.@@	O	-1	19293073
S@@	O	-1	19293073
.	O	-1	19293073
Pre@@	O	-1	19293073
ven@@	O	-1	19293073
tive	O	-1	19293073
S@@	O	-1	19293073
er@@	O	-1	19293073
v@@	O	-1	19293073
ic@@	O	-1	19293073
es	O	-1	19293073
T@@	O	-1	19293073
as@@	O	-1	19293073
k	O	-1	19293073
F@@	O	-1	19293073
or@@	O	-1	19293073
ce@@	O	-1	19293073
.	O	-1	19293073
BACKGROUND:	O	-1	19293073
C@@	B-Disease	D003327	19293073
or@@	I-Disease	-1	19293073
onary	I-Disease	-1	19293073
heart	I-Disease	-1	19293073
disease	I-Disease	-1	19293073
and	O	-1	19293073
ce@@	B-Disease	D002561	19293073
reb@@	I-Disease	-1	19293073
ro@@	I-Disease	-1	19293073
vascular	I-Disease	-1	19293073
disease	I-Disease	-1	19293073
are	O	-1	19293073
lead@@	O	-1	19293073
ing	O	-1	19293073
causes	O	-1	19293073
of	O	-1	19293073
death	O	-1	19293073
in	O	-1	19293073
the	O	-1	19293073
U@@	O	-1	19293073
nit@@	O	-1	19293073
ed	O	-1	19293073
S@@	O	-1	19293073
t@@	O	-1	19293073
at@@	O	-1	19293073
es.	O	-1	19293073
In	O	-1	19293073
20@@	O	-1	19293073
0@@	O	-1	19293073
2,	O	-1	19293073
the	O	-1	19293073
U@@	O	-1	19293073
.@@	O	-1	19293073
S@@	O	-1	19293073
.	O	-1	19293073
Pre@@	O	-1	19293073
ven@@	O	-1	19293073
tive	O	-1	19293073
S@@	O	-1	19293073
er@@	O	-1	19293073
v@@	O	-1	19293073
ic@@	O	-1	19293073
es	O	-1	19293073
T@@	O	-1	19293073
as@@	O	-1	19293073
k	O	-1	19293073
F@@	O	-1	19293073
or@@	O	-1	19293073
ce	O	-1	19293073
(@@	O	-1	19293073
US@@	O	-1	19293073
P@@	O	-1	19293073
S@@	O	-1	19293073
T@@	O	-1	19293073
F@@	O	-1	19293073
)	O	-1	19293073
st@@	O	-1	19293073
ron@@	O	-1	19293073
g@@	O	-1	19293073
ly	O	-1	19293073
recomm@@	O	-1	19293073
en@@	O	-1	19293073
ded	O	-1	19293073
that	O	-1	19293073
clin@@	O	-1	19293073
ici@@	O	-1	19293073
ans	O	-1	19293073
discus@@	O	-1	19293073
s	O	-1	19293073
as@@	B-Chemical	D001241	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
with	O	-1	19293073
ad@@	O	-1	19293073
ult@@	O	-1	19293073
s	O	-1	19293073
who	O	-1	19293073
are	O	-1	19293073
at	O	-1	19293073
increased	O	-1	19293073
risk	O	-1	19293073
for	O	-1	19293073
coronary	B-Disease	D003327	19293073
heart	I-Disease	-1	19293073
disease	I-Disease	-1	19293073
.	O	-1	19293073
P@@	O	-1	19293073
U@@	O	-1	19293073
R@@	O	-1	19293073
P@@	O	-1	19293073
O@@	O	-1	19293073
S@@	O	-1	19293073
E:	O	-1	19293073
To	O	-1	19293073
determine	O	-1	19293073
the	O	-1	19293073
ben@@	O	-1	19293073
e@@	O	-1	19293073
f@@	O	-1	19293073
its	O	-1	19293073
and	O	-1	19293073
h@@	O	-1	19293073
ar@@	O	-1	19293073
ms	O	-1	19293073
of	O	-1	19293073
taking	O	-1	19293073
as@@	B-Chemical	D001241	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
for	O	-1	19293073
the	O	-1	19293073
prim@@	O	-1	19293073
ary	O	-1	19293073
pre@@	O	-1	19293073
ven@@	O	-1	19293073
tion	O	-1	19293073
of	O	-1	19293073
myocardial	B-Disease	D009203	19293073
infarc@@	I-Disease	-1	19293073
tions	I-Disease	-1	19293073
,	O	-1	19293073
strok@@	B-Disease	D020521	19293073
es	I-Disease	-1	19293073
,	O	-1	19293073
and	O	-1	19293073
de@@	O	-1	19293073
ath@@	O	-1	19293073
.	O	-1	19293073
D@@	O	-1	19293073
AT@@	O	-1	19293073
A	O	-1	19293073
S@@	O	-1	19293073
O@@	O	-1	19293073
U@@	O	-1	19293073
R@@	O	-1	19293073
C@@	O	-1	19293073
E@@	O	-1	19293073
S:	O	-1	19293073
M@@	O	-1	19293073
E@@	O	-1	19293073
D@@	O	-1	19293073
L@@	O	-1	19293073
IN@@	O	-1	19293073
E	O	-1	19293073
and	O	-1	19293073
C@@	O	-1	19293073
och@@	O	-1	19293073
ran@@	O	-1	19293073
e	O	-1	19293073
L@@	O	-1	19293073
i@@	O	-1	19293073
b@@	O	-1	19293073
r@@	O	-1	19293073
ary	O	-1	19293073
(@@	O	-1	19293073
se@@	O	-1	19293073
arc@@	O	-1	19293073
h	O	-1	19293073
dat@@	O	-1	19293073
es,	O	-1	19293073
1	O	-1	19293073
J@@	O	-1	19293073
an@@	O	-1	19293073
u@@	O	-1	19293073
ary	O	-1	19293073
20@@	O	-1	19293073
0@@	O	-1	19293073
1	O	-1	19293073
to	O	-1	19293073
2@@	O	-1	19293073
8	O	-1	19293073
A@@	O	-1	19293073
u@@	O	-1	19293073
g@@	O	-1	19293073
us@@	O	-1	19293073
t	O	-1	19293073
20@@	O	-1	19293073
0@@	O	-1	19293073
8@@	O	-1	19293073
),	O	-1	19293073
rec@@	O	-1	19293073
ent	O	-1	19293073
system@@	O	-1	19293073
atic	O	-1	19293073
revie@@	O	-1	19293073
w@@	O	-1	19293073
s,	O	-1	19293073
ref@@	O	-1	19293073
e@@	O	-1	19293073
rence	O	-1	19293073
li@@	O	-1	19293073
st@@	O	-1	19293073
s	O	-1	19293073
of	O	-1	19293073
re@@	O	-1	19293073
tri@@	O	-1	19293073
ev@@	O	-1	19293073
ed	O	-1	19293073
ar@@	O	-1	19293073
ti@@	O	-1	19293073
cl@@	O	-1	19293073
es,	O	-1	19293073
and	O	-1	19293073
sugg@@	O	-1	19293073
es@@	O	-1	19293073
tions	O	-1	19293073
from	O	-1	19293073
exper@@	O	-1	19293073
t@@	O	-1	19293073
s.	O	-1	19293073
S@@	O	-1	19293073
T@@	O	-1	19293073
U@@	O	-1	19293073
D@@	O	-1	19293073
Y	O	-1	19293073
S@@	O	-1	19293073
E@@	O	-1	19293073
L@@	O	-1	19293073
EC@@	O	-1	19293073
T@@	O	-1	19293073
ION@@	O	-1	19293073
:	O	-1	19293073
E@@	O	-1	19293073
n@@	O	-1	19293073
gl@@	O	-1	19293073
ish@@	O	-1	19293073
-@@	O	-1	19293073
l@@	O	-1	19293073
ang@@	O	-1	19293073
u@@	O	-1	19293073
age	O	-1	19293073
random@@	O	-1	19293073
iz@@	O	-1	19293073
ed,	O	-1	19293073
controlled	O	-1	19293073
tri@@	O	-1	19293073
als	O	-1	19293073
(@@	O	-1	19293073
R@@	O	-1	19293073
C@@	O	-1	19293073
T@@	O	-1	19293073
s@@	O	-1	19293073
);	O	-1	19293073
cas@@	O	-1	19293073
e-@@	O	-1	19293073
control	O	-1	19293073
studi@@	O	-1	19293073
es@@	O	-1	19293073
;	O	-1	19293073
met@@	O	-1	19293073
a@@	O	-1	19293073
-@@	O	-1	19293073
an@@	O	-1	19293073
al@@	O	-1	19293073
ys@@	O	-1	19293073
es@@	O	-1	19293073
;	O	-1	19293073
and	O	-1	19293073
system@@	O	-1	19293073
atic	O	-1	19293073
revie@@	O	-1	19293073
w@@	O	-1	19293073
s	O	-1	19293073
of	O	-1	19293073
as@@	B-Chemical	D001241	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
versus	O	-1	19293073
control	O	-1	19293073
for	O	-1	19293073
the	O	-1	19293073
prim@@	O	-1	19293073
ary	O	-1	19293073
pre@@	O	-1	19293073
ven@@	O	-1	19293073
tion	O	-1	19293073
of	O	-1	19293073
cardiovascular	B-Disease	D002318	19293073
disease	I-Disease	-1	19293073
(	O	-1	19293073
C@@	B-Disease	D002318	19293073
V@@	I-Disease	-1	19293073
D	I-Disease	-1	19293073
)	O	-1	19293073
were	O	-1	19293073
sel@@	O	-1	19293073
ected	O	-1	19293073
to	O	-1	19293073
an@@	O	-1	19293073
s@@	O	-1	19293073
w@@	O	-1	19293073
er	O	-1	19293073
the	O	-1	19293073
following	O	-1	19293073
qu@@	O	-1	19293073
es@@	O	-1	19293073
tion@@	O	-1	19293073
s:	O	-1	19293073
D@@	O	-1	19293073
o@@	O	-1	19293073
es	O	-1	19293073
as@@	B-Chemical	D001241	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
decrease	O	-1	19293073
coronary	O	-1	19293073
heart	O	-1	19293073
event@@	O	-1	19293073
s,	O	-1	19293073
strok@@	B-Disease	D020521	19293073
es	I-Disease	-1	19293073
,	O	-1	19293073
death	O	-1	19293073
from	O	-1	19293073
coronary	O	-1	19293073
heart	O	-1	19293073
events	O	-1	19293073
or	O	-1	19293073
strok@@	B-Disease	D020521	19293073
e	I-Disease	-1	19293073
,	O	-1	19293073
or	O	-1	19293073
all@@	O	-1	19293073
-@@	O	-1	19293073
cause	O	-1	19293073
mor@@	O	-1	19293073
t@@	O	-1	19293073
ality	O	-1	19293073
in	O	-1	19293073
ad@@	O	-1	19293073
ult@@	O	-1	19293073
s	O	-1	19293073
without	O	-1	19293073
known	O	-1	19293073
C@@	B-Disease	D002318	19293073
V@@	I-Disease	-1	19293073
D	I-Disease	-1	19293073
?	O	-1	19293073
D@@	O	-1	19293073
o@@	O	-1	19293073
es	O	-1	19293073
as@@	B-Chemical	D001241	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
increase	O	-1	19293073
gast@@	B-Disease	D006471	19293073
ro@@	I-Disease	-1	19293073
in@@	I-Disease	-1	19293073
test@@	I-Disease	-1	19293073
inal	I-Disease	-1	19293073
ble@@	I-Disease	-1	19293073
ed@@	I-Disease	-1	19293073
ing	I-Disease	-1	19293073
or	O	-1	19293073
hemorrh@@	B-Disease	D020300	19293073
ag@@	I-Disease	-1	19293073
ic	I-Disease	-1	19293073
strok@@	I-Disease	-1	19293073
es	I-Disease	-1	19293073
hemorrh@@	B-Disease	D020521	19293073
ag@@	I-Disease	-1	19293073
ic	I-Disease	-1	19293073
strok@@	I-Disease	-1	19293073
es	I-Disease	-1	19293073
?	O	-1	19293073
D@@	O	-1	19293073
AT@@	O	-1	19293073
A	O	-1	19293073
E@@	O	-1	19293073
X@@	O	-1	19293073
TR@@	O	-1	19293073
AC@@	O	-1	19293073
T@@	O	-1	19293073
ION@@	O	-1	19293073
:	O	-1	19293073
All	O	-1	19293073
studies	O	-1	19293073
were	O	-1	19293073
revie@@	O	-1	19293073
we@@	O	-1	19293073
d,	O	-1	19293073
ab@@	O	-1	19293073
st@@	O	-1	19293073
rac@@	O	-1	19293073
te@@	O	-1	19293073
d,	O	-1	19293073
and	O	-1	19293073
r@@	O	-1	19293073
ated	O	-1	19293073
for	O	-1	19293073
qu@@	O	-1	19293073
ality	O	-1	19293073
by	O	-1	19293073
using	O	-1	19293073
pre@@	O	-1	19293073
def@@	O	-1	19293073
in@@	O	-1	19293073
ed	O	-1	19293073
US@@	O	-1	19293073
P@@	O	-1	19293073
S@@	O	-1	19293073
T@@	O	-1	19293073
F	O	-1	19293073
c@@	O	-1	19293073
rit@@	O	-1	19293073
er@@	O	-1	19293073
ia.	O	-1	19293073
D@@	O	-1	19293073
AT@@	O	-1	19293073
A	O	-1	19293073
S@@	O	-1	19293073
Y@@	O	-1	19293073
N@@	O	-1	19293073
T@@	O	-1	19293073
H@@	O	-1	19293073
ES@@	O	-1	19293073
I@@	O	-1	19293073
S:	O	-1	19293073
Ne@@	O	-1	19293073
w	O	-1	19293073
evidence	O	-1	19293073
from	O	-1	19293073
1	O	-1	19293073
go@@	O	-1	19293073
o@@	O	-1	19293073
d-@@	O	-1	19293073
qu@@	O	-1	19293073
ality	O	-1	19293073
R@@	O	-1	19293073
C@@	O	-1	19293073
T@@	O	-1	19293073
,	O	-1	19293073
1	O	-1	19293073
go@@	O	-1	19293073
o@@	O	-1	19293073
d-@@	O	-1	19293073
qu@@	O	-1	19293073
ality	O	-1	19293073
met@@	O	-1	19293073
a@@	O	-1	19293073
-@@	O	-1	19293073
analy@@	O	-1	19293073
sis,	O	-1	19293073
and	O	-1	19293073
2	O	-1	19293073
f@@	O	-1	19293073
a@@	O	-1	19293073
ir@@	O	-1	19293073
-@@	O	-1	19293073
qu@@	O	-1	19293073
ality	O	-1	19293073
sub@@	O	-1	19293073
analy@@	O	-1	19293073
ses	O	-1	19293073
of	O	-1	19293073
R@@	O	-1	19293073
C@@	O	-1	19293073
T@@	O	-1	19293073
s	O	-1	19293073
demon@@	O	-1	19293073
strat@@	O	-1	19293073
es	O	-1	19293073
that	O	-1	19293073
as@@	B-Chemical	D001241	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
use	O	-1	19293073
reduc@@	O	-1	19293073
es	O	-1	19293073
the	O	-1	19293073
number	O	-1	19293073
of	O	-1	19293073
C@@	B-Disease	D002318	19293073
V@@	I-Disease	-1	19293073
D	I-Disease	-1	19293073
events	O	-1	19293073
in	O	-1	19293073
patients	O	-1	19293073
without	O	-1	19293073
known	O	-1	19293073
C@@	B-Disease	D002318	19293073
V@@	I-Disease	-1	19293073
D	I-Disease	-1	19293073
.	O	-1	19293073
M@@	O	-1	19293073
en	O	-1	19293073
in	O	-1	19293073
these	O	-1	19293073
studies	O	-1	19293073
experienced	O	-1	19293073
fe@@	O	-1	19293073
w@@	O	-1	19293073
er	O	-1	19293073
myocardial	B-Disease	D009203	19293073
infarc@@	I-Disease	-1	19293073
tions	I-Disease	-1	19293073
and	O	-1	19293073
women	O	-1	19293073
experienced	O	-1	19293073
fe@@	O	-1	19293073
w@@	O	-1	19293073
er	O	-1	19293073
ischem@@	O	-1	19293073
ic	O	-1	19293073
strok@@	B-Disease	D020521	19293073
es	I-Disease	-1	19293073
.	O	-1	19293073
A@@	B-Chemical	D001241	19293073
s@@	I-Chemical	-1	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
does	O	-1	19293073
not	O	-1	19293073
se@@	O	-1	19293073
em	O	-1	19293073
to	O	-1	19293073
aff@@	O	-1	19293073
ect	O	-1	19293073
C@@	B-Disease	D002318	19293073
V@@	I-Disease	-1	19293073
D	I-Disease	-1	19293073
mor@@	O	-1	19293073
t@@	O	-1	19293073
ality	O	-1	19293073
or	O	-1	19293073
all@@	O	-1	19293073
-@@	O	-1	19293073
cause	O	-1	19293073
mor@@	O	-1	19293073
t@@	O	-1	19293073
ality	O	-1	19293073
in	O	-1	19293073
either	O	-1	19293073
men	O	-1	19293073
or	O	-1	19293073
wom@@	O	-1	19293073
en@@	O	-1	19293073
.	O	-1	19293073
The	O	-1	19293073
use	O	-1	19293073
of	O	-1	19293073
as@@	B-Chemical	D001241	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
for	O	-1	19293073
prim@@	O	-1	19293073
ary	O	-1	19293073
pre@@	O	-1	19293073
ven@@	O	-1	19293073
tion	O	-1	19293073
increases	O	-1	19293073
the	O	-1	19293073
risk	O	-1	19293073
for	O	-1	19293073
major	O	-1	19293073
ble@@	B-Disease	D006470	19293073
ed@@	I-Disease	-1	19293073
ing	I-Disease	-1	19293073
event@@	O	-1	19293073
s,	O	-1	19293073
prim@@	O	-1	19293073
ari@@	O	-1	19293073
ly	O	-1	19293073
gast@@	B-Disease	D006471	19293073
ro@@	I-Disease	-1	19293073
in@@	I-Disease	-1	19293073
test@@	I-Disease	-1	19293073
inal	I-Disease	-1	19293073
ble@@	I-Disease	-1	19293073
ed@@	I-Disease	-1	19293073
ing	I-Disease	-1	19293073
event@@	O	-1	19293073
s,	O	-1	19293073
in	O	-1	19293073
both	O	-1	19293073
men	O	-1	19293073
and	O	-1	19293073
wom@@	O	-1	19293073
en@@	O	-1	19293073
.	O	-1	19293073
M@@	O	-1	19293073
en	O	-1	19293073
have	O	-1	19293073
an	O	-1	19293073
increased	O	-1	19293073
risk	O	-1	19293073
for	O	-1	19293073
hemorrh@@	B-Disease	D020300	19293073
ag@@	I-Disease	-1	19293073
ic	I-Disease	-1	19293073
strok@@	I-Disease	-1	19293073
es	I-Disease	-1	19293073
hemorrh@@	B-Disease	D020521	19293073
ag@@	I-Disease	-1	19293073
ic	I-Disease	-1	19293073
strok@@	I-Disease	-1	19293073
es	I-Disease	-1	19293073
with	O	-1	19293073
as@@	B-Chemical	D001241	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
use.	O	-1	19293073
A	O	-1	19293073
new	O	-1	19293073
R@@	O	-1	19293073
C@@	O	-1	19293073
T	O	-1	19293073
and	O	-1	19293073
met@@	O	-1	19293073
a@@	O	-1	19293073
-@@	O	-1	19293073
analysis	O	-1	19293073
suggest	O	-1	19293073
that	O	-1	19293073
the	O	-1	19293073
risk	O	-1	19293073
for	O	-1	19293073
hemorrh@@	B-Disease	D020300	19293073
ag@@	I-Disease	-1	19293073
ic	I-Disease	-1	19293073
strok@@	I-Disease	-1	19293073
es	I-Disease	-1	19293073
hemorrh@@	B-Disease	D020521	19293073
ag@@	I-Disease	-1	19293073
ic	I-Disease	-1	19293073
strok@@	I-Disease	-1	19293073
es	I-Disease	-1	19293073
in	O	-1	19293073
women	O	-1	19293073
is	O	-1	19293073
not	O	-1	19293073
statis@@	O	-1	19293073
tically	O	-1	19293073
significantly	O	-1	19293073
increas@@	O	-1	19293073
ed.	O	-1	19293073
L@@	O	-1	19293073
I@@	O	-1	19293073
M@@	O	-1	19293073
I@@	O	-1	19293073
T@@	O	-1	19293073
AT@@	O	-1	19293073
ION@@	O	-1	19293073
S:	O	-1	19293073
Ne@@	O	-1	19293073
w	O	-1	19293073
evidence	O	-1	19293073
on	O	-1	19293073
as@@	B-Chemical	D001241	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
for	O	-1	19293073
the	O	-1	19293073
prim@@	O	-1	19293073
ary	O	-1	19293073
pre@@	O	-1	19293073
ven@@	O	-1	19293073
tion	O	-1	19293073
of	O	-1	19293073
C@@	B-Disease	D002318	19293073
V@@	I-Disease	-1	19293073
D	I-Disease	-1	19293073
is	O	-1	19293073
lim@@	O	-1	19293073
it@@	O	-1	19293073
ed.	O	-1	19293073
The	O	-1	19293073
dose	O	-1	19293073
of	O	-1	19293073
as@@	B-Chemical	D001241	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
used	O	-1	19293073
in	O	-1	19293073
the	O	-1	19293073
R@@	O	-1	19293073
C@@	O	-1	19293073
T@@	O	-1	19293073
s	O	-1	19293073
vari@@	O	-1	19293073
ed,	O	-1	19293073
which	O	-1	19293073
prevent@@	O	-1	19293073
ed	O	-1	19293073
the	O	-1	19293073
estim@@	O	-1	19293073
ation	O	-1	19293073
of	O	-1	19293073
the	O	-1	19293073
most	O	-1	19293073
appro@@	O	-1	19293073
pri@@	O	-1	19293073
ate	O	-1	19293073
dose	O	-1	19293073
for	O	-1	19293073
prim@@	O	-1	19293073
ary	O	-1	19293073
pre@@	O	-1	19293073
ven@@	O	-1	19293073
tion.	O	-1	19293073
S@@	O	-1	19293073
e@@	O	-1	19293073
ver@@	O	-1	19293073
al	O	-1	19293073
of	O	-1	19293073
the	O	-1	19293073
R@@	O	-1	19293073
C@@	O	-1	19293073
T@@	O	-1	19293073
s	O	-1	19293073
were	O	-1	19293073
con@@	O	-1	19293073
duc@@	O	-1	19293073
ted	O	-1	19293073
within	O	-1	19293073
po@@	O	-1	19293073
pul@@	O	-1	19293073
ations	O	-1	19293073
of	O	-1	19293073
heal@@	O	-1	19293073
th	O	-1	19293073
prof@@	O	-1	19293073
es@@	O	-1	19293073
sion@@	O	-1	19293073
al@@	O	-1	19293073
s,	O	-1	19293073
which	O	-1	19293073
potenti@@	O	-1	19293073
ally	O	-1	19293073
lim@@	O	-1	19293073
its	O	-1	19293073
gener@@	O	-1	19293073
al@@	O	-1	19293073
iz@@	O	-1	19293073
abil@@	O	-1	19293073
ity.	O	-1	19293073
CONCLUSION:	O	-1	19293073
A@@	B-Chemical	D001241	19293073
s@@	I-Chemical	-1	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
reduc@@	O	-1	19293073
es	O	-1	19293073
the	O	-1	19293073
risk	O	-1	19293073
for	O	-1	19293073
myocardial	B-Disease	D009203	19293073
infarction	I-Disease	-1	19293073
in	O	-1	19293073
men	O	-1	19293073
and	O	-1	19293073
strok@@	B-Disease	D020521	19293073
es	I-Disease	-1	19293073
in	O	-1	19293073
wom@@	O	-1	19293073
en@@	O	-1	19293073
.	O	-1	19293073
A@@	B-Chemical	D001241	19293073
s@@	I-Chemical	-1	19293073
pi@@	I-Chemical	-1	19293073
rin	I-Chemical	-1	19293073
use	O	-1	19293073
increases	O	-1	19293073
the	O	-1	19293073
risk	O	-1	19293073
for	O	-1	19293073
seri@@	O	-1	19293073
ous	O	-1	19293073
ble@@	B-Disease	D006470	19293073
ed@@	I-Disease	-1	19293073
ing	I-Disease	-1	19293073
event@@	O	-1	19293073
s.	O	-1	19293073

Re@@	O	-1	19338378
duc@@	O	-1	19338378
ing	O	-1	19338378
h@@	O	-1	19338378
ar@@	O	-1	19338378
m	O	-1	19338378
associated	O	-1	19338378
with	O	-1	19338378
anti@@	O	-1	19338378
co@@	O	-1	19338378
ag@@	O	-1	19338378
ul@@	O	-1	19338378
ation@@	O	-1	19338378
:	O	-1	19338378
p@@	O	-1	19338378
rac@@	O	-1	19338378
tical	O	-1	19338378
con@@	O	-1	19338378
si@@	O	-1	19338378
der@@	O	-1	19338378
ations	O	-1	19338378
of	O	-1	19338378
arg@@	B-Chemical	C031942	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
therapy	O	-1	19338378
in	O	-1	19338378
hepar@@	B-Chemical	D006493	19338378
in	I-Chemical	-1	19338378
-induced	O	-1	19338378
throm@@	B-Disease	D013921	19338378
b@@	I-Disease	-1	19338378
ocyto@@	I-Disease	-1	19338378
pen@@	I-Disease	-1	19338378
ia	I-Disease	-1	19338378
.	O	-1	19338378
A@@	B-Chemical	C031942	19338378
r@@	I-Chemical	-1	19338378
g@@	I-Chemical	-1	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
is	O	-1	19338378
a	O	-1	19338378
hepati@@	O	-1	19338378
c@@	O	-1	19338378
ally	O	-1	19338378
metabol@@	O	-1	19338378
iz@@	O	-1	19338378
ed,	O	-1	19338378
direct	O	-1	19338378
throm@@	O	-1	19338378
bin	O	-1	19338378
inhibitor	O	-1	19338378
used	O	-1	19338378
for	O	-1	19338378
pro@@	O	-1	19338378
phyl@@	O	-1	19338378
ax@@	O	-1	19338378
is	O	-1	19338378
or	O	-1	19338378
treatment	O	-1	19338378
of	O	-1	19338378
thrombo@@	B-Disease	D013927	19338378
sis	I-Disease	-1	19338378
in	O	-1	19338378
hepar@@	B-Chemical	D006493	19338378
in	I-Chemical	-1	19338378
-induced	O	-1	19338378
throm@@	B-Disease	D013921	19338378
b@@	I-Disease	-1	19338378
ocyto@@	I-Disease	-1	19338378
pen@@	I-Disease	-1	19338378
ia	I-Disease	-1	19338378
(	O	-1	19338378
H@@	B-Disease	D013921	19338378
I@@	I-Disease	-1	19338378
T	I-Disease	-1	19338378
)	O	-1	19338378
and	O	-1	19338378
for	O	-1	19338378
patients	O	-1	19338378
with	O	-1	19338378
or	O	-1	19338378
at	O	-1	19338378
risk	O	-1	19338378
of	O	-1	19338378
H@@	B-Disease	D013921	19338378
I@@	I-Disease	-1	19338378
T	I-Disease	-1	19338378
under@@	O	-1	19338378
go@@	O	-1	19338378
ing	O	-1	19338378
perc@@	O	-1	19338378
utaneous	O	-1	19338378
coronary	O	-1	19338378
inter@@	O	-1	19338378
ven@@	O	-1	19338378
tion	O	-1	19338378
(P@@	O	-1	19338378
CI@@	O	-1	19338378
).	O	-1	19338378
The	O	-1	19338378
ob@@	O	-1	19338378
j@@	O	-1	19338378
ective	O	-1	19338378
of	O	-1	19338378
this	O	-1	19338378
revie@@	O	-1	19338378
w	O	-1	19338378
is	O	-1	19338378
to	O	-1	19338378
su@@	O	-1	19338378
mm@@	O	-1	19338378
ar@@	O	-1	19338378
iz@@	O	-1	19338378
e	O	-1	19338378
p@@	O	-1	19338378
rac@@	O	-1	19338378
tical	O	-1	19338378
con@@	O	-1	19338378
si@@	O	-1	19338378
der@@	O	-1	19338378
ations	O	-1	19338378
of	O	-1	19338378
arg@@	B-Chemical	C031942	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
therapy	O	-1	19338378
in	O	-1	19338378
H@@	B-Disease	D013921	19338378
I@@	I-Disease	-1	19338378
T	I-Disease	-1	19338378
.	O	-1	19338378
The	O	-1	19338378
U@@	O	-1	19338378
S	O	-1	19338378
F@@	O	-1	19338378
D@@	O	-1	19338378
A@@	O	-1	19338378
-@@	O	-1	19338378
recomm@@	O	-1	19338378
en@@	O	-1	19338378
ded	O	-1	19338378
arg@@	B-Chemical	C031942	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
dose	O	-1	19338378
in	O	-1	19338378
H@@	B-Disease	D013921	19338378
I@@	I-Disease	-1	19338378
T	I-Disease	-1	19338378
is	O	-1	19338378
2	O	-1	19338378
micro@@	O	-1	19338378
g/@@	O	-1	19338378
k@@	O	-1	19338378
g/@@	O	-1	19338378
min	O	-1	19338378
(@@	O	-1	19338378
reduced	O	-1	19338378
in	O	-1	19338378
patients	O	-1	19338378
with	O	-1	19338378
hepatic	B-Disease	D008107	19338378
impair@@	I-Disease	-1	19338378
ment	I-Disease	-1	19338378
and	O	-1	19338378
in	O	-1	19338378
pa@@	O	-1	19338378
edi@@	O	-1	19338378
atric	O	-1	19338378
patient@@	O	-1	19338378
s),	O	-1	19338378
adjust@@	O	-1	19338378
ed	O	-1	19338378
to	O	-1	19338378
achi@@	O	-1	19338378
e@@	O	-1	19338378
ve	O	-1	19338378
activ@@	O	-1	19338378
ated	O	-1	19338378
partial	O	-1	19338378
thrombo@@	O	-1	19338378
plas@@	O	-1	19338378
tin	O	-1	19338378
times	O	-1	19338378
(@@	O	-1	19338378
a@@	O	-1	19338378
P@@	O	-1	19338378
T@@	O	-1	19338378
T@@	O	-1	19338378
s)	O	-1	19338378
1.@@	O	-1	19338378
5-@@	O	-1	19338378
3	O	-1	19338378
times	O	-1	19338378
baseline	O	-1	19338378
(@@	O	-1	19338378
not	O	-1	19338378
>@@	O	-1	19338378
100	O	-1	19338378
second@@	O	-1	19338378
s@@	O	-1	19338378
).	O	-1	19338378
C@@	O	-1	19338378
ont@@	O	-1	19338378
em@@	O	-1	19338378
por@@	O	-1	19338378
ary	O	-1	19338378
experienc@@	O	-1	19338378
es	O	-1	19338378
indicate	O	-1	19338378
that	O	-1	19338378
reduced	O	-1	19338378
doses	O	-1	19338378
are	O	-1	19338378
also	O	-1	19338378
ne@@	O	-1	19338378
ed@@	O	-1	19338378
ed	O	-1	19338378
in	O	-1	19338378
patients	O	-1	19338378
with	O	-1	19338378
condi@@	O	-1	19338378
tions	O	-1	19338378
associated	O	-1	19338378
with	O	-1	19338378
hepatic	O	-1	19338378
hypo@@	O	-1	19338378
per@@	O	-1	19338378
fu@@	O	-1	19338378
sion,	O	-1	19338378
e@@	O	-1	19338378
.@@	O	-1	19338378
g@@	O	-1	19338378
.	O	-1	19338378
heart	B-Disease	D006333	19338378
failure	I-Disease	-1	19338378
,	O	-1	19338378
y@@	O	-1	19338378
et	O	-1	19338378
are	O	-1	19338378
un@@	O	-1	19338378
nec@@	O	-1	19338378
ess@@	O	-1	19338378
ary	O	-1	19338378
for	O	-1	19338378
renal	B-Disease	D007674	19338378
dysfunction	I-Disease	-1	19338378
,	O	-1	19338378
ad@@	O	-1	19338378
ult	O	-1	19338378
age,	O	-1	19338378
sex@@	O	-1	19338378
,	O	-1	19338378
rac@@	O	-1	19338378
e@@	O	-1	19338378
/@@	O	-1	19338378
eth@@	O	-1	19338378
n@@	O	-1	19338378
ic@@	O	-1	19338378
ity	O	-1	19338378
or	O	-1	19338378
ob@@	B-Disease	D009765	19338378
es@@	I-Disease	-1	19338378
ity	I-Disease	-1	19338378
.	O	-1	19338378
A@@	B-Chemical	C031942	19338378
r@@	I-Chemical	-1	19338378
g@@	I-Chemical	-1	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
0.@@	O	-1	19338378
5-@@	O	-1	19338378
1.@@	O	-1	19338378
2	O	-1	19338378
micro@@	O	-1	19338378
g/@@	O	-1	19338378
k@@	O	-1	19338378
g/@@	O	-1	19338378
min	O	-1	19338378
typ@@	O	-1	19338378
ically	O	-1	19338378
suppor@@	O	-1	19338378
ts	O	-1	19338378
therapeutic	O	-1	19338378
a@@	O	-1	19338378
P@@	O	-1	19338378
T@@	O	-1	19338378
T@@	O	-1	19338378
s.	O	-1	19338378
The	O	-1	19338378
F@@	O	-1	19338378
D@@	O	-1	19338378
A@@	O	-1	19338378
-@@	O	-1	19338378
recomm@@	O	-1	19338378
en@@	O	-1	19338378
ded	O	-1	19338378
dose	O	-1	19338378
during	O	-1	19338378
P@@	O	-1	19338378
C@@	O	-1	19338378
I	O	-1	19338378
is	O	-1	19338378
25	O	-1	19338378
micro@@	O	-1	19338378
g/@@	O	-1	19338378
k@@	O	-1	19338378
g/@@	O	-1	19338378
min	O	-1	19338378
(3@@	O	-1	19338378
50	O	-1	19338378
micro@@	O	-1	19338378
g/@@	O	-1	19338378
k@@	O	-1	19338378
g	O	-1	19338378
initial	O	-1	19338378
b@@	O	-1	19338378
ol@@	O	-1	19338378
us@@	O	-1	19338378
),	O	-1	19338378
adjust@@	O	-1	19338378
ed	O	-1	19338378
to	O	-1	19338378
achi@@	O	-1	19338378
e@@	O	-1	19338378
ve	O	-1	19338378
activ@@	O	-1	19338378
ated	O	-1	19338378
clo@@	O	-1	19338378
t@@	O	-1	19338378
ting	O	-1	19338378
times	O	-1	19338378
(@@	O	-1	19338378
AC@@	O	-1	19338378
T@@	O	-1	19338378
s)	O	-1	19338378
of	O	-1	19338378
3@@	O	-1	19338378
0@@	O	-1	19338378
0-@@	O	-1	19338378
4@@	O	-1	19338378
50	O	-1	19338378
sec@@	O	-1	19338378
.	O	-1	19338378
F@@	O	-1	19338378
or	O	-1	19338378
P@@	O	-1	19338378
CI@@	O	-1	19338378
,	O	-1	19338378
arg@@	B-Chemical	C031942	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
has	O	-1	19338378
not	O	-1	19338378
been	O	-1	19338378
investigated	O	-1	19338378
in	O	-1	19338378
hepati@@	O	-1	19338378
c@@	O	-1	19338378
ally	O	-1	19338378
impaired	O	-1	19338378
patient@@	O	-1	19338378
s;	O	-1	19338378
dose	O	-1	19338378
adjust@@	O	-1	19338378
ment	O	-1	19338378
is	O	-1	19338378
un@@	O	-1	19338378
nec@@	O	-1	19338378
ess@@	O	-1	19338378
ary	O	-1	19338378
for	O	-1	19338378
ad@@	O	-1	19338378
ult	O	-1	19338378
age,	O	-1	19338378
sex@@	O	-1	19338378
,	O	-1	19338378
rac@@	O	-1	19338378
e@@	O	-1	19338378
/@@	O	-1	19338378
eth@@	O	-1	19338378
n@@	O	-1	19338378
ic@@	O	-1	19338378
ity	O	-1	19338378
or	O	-1	19338378
ob@@	B-Disease	D009765	19338378
es@@	I-Disease	-1	19338378
ity	I-Disease	-1	19338378
,	O	-1	19338378
and	O	-1	19338378
l@@	O	-1	19338378
ess@@	O	-1	19338378
er	O	-1	19338378
doses	O	-1	19338378
may	O	-1	19338378
be	O	-1	19338378
ade@@	O	-1	19338378
qu@@	O	-1	19338378
ate	O	-1	19338378
with	O	-1	19338378
con@@	O	-1	19338378
current	O	-1	19338378
gly@@	O	-1	19338378
co@@	O	-1	19338378
protein	O	-1	19338378
II@@	O	-1	19338378
b@@	O	-1	19338378
/@@	O	-1	19338378
II@@	O	-1	19338378
I@@	O	-1	19338378
a	O	-1	19338378
inhib@@	O	-1	19338378
i@@	O	-1	19338378
tion.	O	-1	19338378
A@@	B-Chemical	C031942	19338378
r@@	I-Chemical	-1	19338378
g@@	I-Chemical	-1	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
prolong@@	O	-1	19338378
s	O	-1	19338378
the	O	-1	19338378
In@@	O	-1	19338378
tern@@	O	-1	19338378
ation@@	O	-1	19338378
al	O	-1	19338378
N@@	O	-1	19338378
orm@@	O	-1	19338378
al@@	O	-1	19338378
ized	O	-1	19338378
R@@	O	-1	19338378
ati@@	O	-1	19338378
o@@	O	-1	19338378
,	O	-1	19338378
and	O	-1	19338378
pu@@	O	-1	19338378
bl@@	O	-1	19338378
ished	O	-1	19338378
appro@@	O	-1	19338378
ac@@	O	-1	19338378
h@@	O	-1	19338378
es	O	-1	19338378
for	O	-1	19338378
monit@@	O	-1	19338378
or@@	O	-1	19338378
ing	O	-1	19338378
the	O	-1	19338378
arg@@	B-Chemical	C031942	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
-@@	O	-1	19338378
to@@	O	-1	19338378
-	O	-1	19338378
war@@	B-Chemical	D014859	19338378
farin	I-Chemical	-1	19338378
transi@@	O	-1	19338378
tion	O	-1	19338378
should	O	-1	19338378
be	O	-1	19338378
fol@@	O	-1	19338378
lo@@	O	-1	19338378
we@@	O	-1	19338378
d.	O	-1	19338378
M@@	O	-1	19338378
a@@	O	-1	19338378
j@@	O	-1	19338378
or	O	-1	19338378
ble@@	B-Disease	D006470	19338378
ed@@	I-Disease	-1	19338378
ing	I-Disease	-1	19338378
with	O	-1	19338378
arg@@	B-Chemical	C031942	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
is	O	-1	19338378
0-@@	O	-1	19338378
10@@	O	-1	19338378
%	O	-1	19338378
in	O	-1	19338378
the	O	-1	19338378
non-@@	O	-1	19338378
inter@@	O	-1	19338378
ven@@	O	-1	19338378
tional	O	-1	19338378
se@@	O	-1	19338378
t@@	O	-1	19338378
ting	O	-1	19338378
and	O	-1	19338378
0-@@	O	-1	19338378
5.@@	O	-1	19338378
8@@	O	-1	19338378
%	O	-1	19338378
peri@@	O	-1	19338378
proce@@	O	-1	19338378
dur@@	O	-1	19338378
all@@	O	-1	19338378
y.	O	-1	19338378
A@@	B-Chemical	C031942	19338378
r@@	I-Chemical	-1	19338378
g@@	I-Chemical	-1	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
has	O	-1	19338378
no	O	-1	19338378
specific	O	-1	19338378
anti@@	O	-1	19338378
d@@	O	-1	19338378
ot@@	O	-1	19338378
e,	O	-1	19338378
and	O	-1	19338378
if	O	-1	19338378
ex@@	O	-1	19338378
ces@@	O	-1	19338378
sive	O	-1	19338378
anti@@	O	-1	19338378
co@@	O	-1	19338378
ag@@	O	-1	19338378
ulation	O	-1	19338378
occur@@	O	-1	19338378
s,	O	-1	19338378
arg@@	B-Chemical	C031942	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
infusion	O	-1	19338378
should	O	-1	19338378
be	O	-1	19338378
sto@@	O	-1	19338378
pp@@	O	-1	19338378
ed	O	-1	19338378
or	O	-1	19338378
reduc@@	O	-1	19338378
ed.	O	-1	19338378
Im@@	O	-1	19338378
pro@@	O	-1	19338378
ved	O	-1	19338378
f@@	O	-1	19338378
am@@	O	-1	19338378
il@@	O	-1	19338378
i@@	O	-1	19338378
ar@@	O	-1	19338378
ity	O	-1	19338378
of	O	-1	19338378
health@@	O	-1	19338378
car@@	O	-1	19338378
e	O	-1	19338378
prof@@	O	-1	19338378
es@@	O	-1	19338378
sion@@	O	-1	19338378
als	O	-1	19338378
with	O	-1	19338378
arg@@	B-Chemical	C031942	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
therapy	O	-1	19338378
in	O	-1	19338378
H@@	B-Disease	D013921	19338378
I@@	I-Disease	-1	19338378
T	I-Disease	-1	19338378
,	O	-1	19338378
including	O	-1	19338378
in	O	-1	19338378
spec@@	O	-1	19338378
ial	O	-1	19338378
po@@	O	-1	19338378
pul@@	O	-1	19338378
ations	O	-1	19338378
and	O	-1	19338378
during	O	-1	19338378
P@@	O	-1	19338378
CI@@	O	-1	19338378
,	O	-1	19338378
may	O	-1	19338378
fac@@	O	-1	19338378
il@@	O	-1	19338378
it@@	O	-1	19338378
ate	O	-1	19338378
reduction	O	-1	19338378
of	O	-1	19338378
h@@	O	-1	19338378
ar@@	O	-1	19338378
m	O	-1	19338378
associated	O	-1	19338378
with	O	-1	19338378
H@@	B-Disease	D013921	19338378
I@@	I-Disease	-1	19338378
T	I-Disease	-1	19338378
(@@	O	-1	19338378
e@@	O	-1	19338378
.@@	O	-1	19338378
g@@	O	-1	19338378
.	O	-1	19338378
fe@@	O	-1	19338378
w@@	O	-1	19338378
er	O	-1	19338378
throm@@	O	-1	19338378
b@@	O	-1	19338378
os@@	O	-1	19338378
es@@	O	-1	19338378
)	O	-1	19338378
or	O	-1	19338378
its	O	-1	19338378
treatment	O	-1	19338378
(@@	O	-1	19338378
e@@	O	-1	19338378
.@@	O	-1	19338378
g@@	O	-1	19338378
.	O	-1	19338378
fe@@	O	-1	19338378
w@@	O	-1	19338378
er	O	-1	19338378
arg@@	B-Chemical	C031942	19338378
atro@@	I-Chemical	-1	19338378
b@@	I-Chemical	-1	19338378
an	I-Chemical	-1	19338378
medic@@	O	-1	19338378
ation	O	-1	19338378
er@@	O	-1	19338378
ro@@	O	-1	19338378
r@@	O	-1	19338378
s@@	O	-1	19338378
).	O	-1	19338378

R@@	B-Disease	D012206	19392810
h@@	I-Disease	-1	19392810
ab@@	I-Disease	-1	19392810
do@@	I-Disease	-1	19392810
my@@	I-Disease	-1	19392810
oly@@	I-Disease	-1	19392810
sis	I-Disease	-1	19392810
and	O	-1	19392810
brain	O	-1	19392810
ischem@@	B-Disease	D002544	19392810
ic	I-Disease	-1	19392810
strok@@	I-Disease	-1	19392810
e	I-Disease	-1	19392810
in	O	-1	19392810
a	O	-1	19392810
h@@	B-Chemical	D003932	19392810
ero@@	I-Chemical	-1	19392810
in	I-Chemical	-1	19392810
-@@	O	-1	19392810
dependent	O	-1	19392810
male	O	-1	19392810
under	O	-1	19392810
meth@@	B-Chemical	D008691	19392810
ad@@	I-Chemical	-1	19392810
one	I-Chemical	-1	19392810
maint@@	O	-1	19392810
en@@	O	-1	19392810
ance	O	-1	19392810
therapy.	O	-1	19392810
OBJECTIVE:	O	-1	19392810
There	O	-1	19392810
are	O	-1	19392810
several	O	-1	19392810
complications	O	-1	19392810
associated	O	-1	19392810
with	O	-1	19392810
h@@	B-Disease	D006556	19392810
ero@@	I-Disease	-1	19392810
in	I-Disease	-1	19392810
ab@@	I-Disease	-1	19392810
use	I-Disease	-1	19392810
,	O	-1	19392810
some	O	-1	19392810
of	O	-1	19392810
which	O	-1	19392810
are	O	-1	19392810
lif@@	O	-1	19392810
e-@@	O	-1	19392810
th@@	O	-1	19392810
reat@@	O	-1	19392810
en@@	O	-1	19392810
ing.	O	-1	19392810
M@@	B-Chemical	D008691	19392810
eth@@	I-Chemical	-1	19392810
ad@@	I-Chemical	-1	19392810
one	I-Chemical	-1	19392810
may	O	-1	19392810
ag@@	O	-1	19392810
gra@@	O	-1	19392810
v@@	O	-1	19392810
ate	O	-1	19392810
this	O	-1	19392810
pro@@	O	-1	19392810
ble@@	O	-1	19392810
m.	O	-1	19392810
METHOD@@	O	-1	19392810
:	O	-1	19392810
A	O	-1	19392810
clinical	O	-1	19392810
case	O	-1	19392810
descri@@	O	-1	19392810
p@@	O	-1	19392810
tion.	O	-1	19392810
RESULTS:	O	-1	19392810
A	O	-1	19392810
3@@	O	-1	19392810
3-@@	O	-1	19392810
year-old	O	-1	19392810
man	O	-1	19392810
presented	O	-1	19392810
with	O	-1	19392810
rh@@	B-Disease	D012206	19392810
ab@@	I-Disease	-1	19392810
do@@	I-Disease	-1	19392810
my@@	I-Disease	-1	19392810
oly@@	I-Disease	-1	19392810
sis	I-Disease	-1	19392810
and	O	-1	19392810
cerebral	O	-1	19392810
ischem@@	B-Disease	D002544	19392810
ic	I-Disease	-1	19392810
strok@@	I-Disease	-1	19392810
e	I-Disease	-1	19392810
after	O	-1	19392810
intravenous	O	-1	19392810
h@@	B-Chemical	D003932	19392810
ero@@	I-Chemical	-1	19392810
in	I-Chemical	-1	19392810
.	O	-1	19392810
H@@	O	-1	19392810
e	O	-1	19392810
had	O	-1	19392810
used	O	-1	19392810
h@@	B-Chemical	D003932	19392810
ero@@	I-Chemical	-1	19392810
in	I-Chemical	-1	19392810
s@@	O	-1	19392810
inc@@	O	-1	19392810
e	O	-1	19392810
age	O	-1	19392810
20@@	O	-1	19392810
,	O	-1	19392810
and	O	-1	19392810
had	O	-1	19392810
used	O	-1	19392810
1@@	O	-1	19392810
50	O	-1	19392810
mg	O	-1	19392810
meth@@	B-Chemical	D008691	19392810
ad@@	I-Chemical	-1	19392810
one	I-Chemical	-1	19392810
daily	O	-1	19392810
for	O	-1	19392810
6	O	-1	19392810
months.	O	-1	19392810
H@@	O	-1	19392810
e	O	-1	19392810
was	O	-1	19392810
found	O	-1	19392810
un@@	B-Disease	D014474	19392810
con@@	I-Disease	-1	19392810
s@@	I-Disease	-1	19392810
ci@@	I-Disease	-1	19392810
ous@@	I-Disease	-1	19392810
ness	I-Disease	-1	19392810
at	O	-1	19392810
ho@@	O	-1	19392810
m@@	O	-1	19392810
e	O	-1	19392810
and	O	-1	19392810
was	O	-1	19392810
s@@	O	-1	19392810
ent	O	-1	19392810
to	O	-1	19392810
our	O	-1	19392810
hospit@@	O	-1	19392810
al.	O	-1	19392810
In	O	-1	19392810
the	O	-1	19392810
E@@	O	-1	19392810
R@@	O	-1	19392810
,	O	-1	19392810
h@@	O	-1	19392810
is	O	-1	19392810
o@@	O	-1	19392810
pi@@	O	-1	19392810
ate	O	-1	19392810
level	O	-1	19392810
was	O	-1	19392810
4@@	O	-1	19392810
4@@	O	-1	19392810
9@@	O	-1	19392810
7	O	-1	19392810
n@@	O	-1	19392810
g/@@	O	-1	19392810
ml@@	O	-1	19392810
.	O	-1	19392810
In	O	-1	19392810
the	O	-1	19392810
IC@@	O	-1	19392810
U@@	O	-1	19392810
,	O	-1	19392810
we	O	-1	19392810
found	O	-1	19392810
rh@@	B-Disease	D012206	19392810
ab@@	I-Disease	-1	19392810
do@@	I-Disease	-1	19392810
my@@	I-Disease	-1	19392810
oly@@	I-Disease	-1	19392810
sis	I-Disease	-1	19392810
,	O	-1	19392810
acute	B-Disease	D058186	19392810
renal	I-Disease	-1	19392810
failure	I-Disease	-1	19392810
and	O	-1	19392810
acute	O	-1	19392810
respiratory	B-Disease	D012131	19392810
failure	I-Disease	-1	19392810
.	O	-1	19392810
After	O	-1	19392810
trans@@	O	-1	19392810
f@@	O	-1	19392810
er	O	-1	19392810
to	O	-1	19392810
an	O	-1	19392810
inter@@	O	-1	19392810
n@@	O	-1	19392810
al	O	-1	19392810
war@@	O	-1	19392810
d,	O	-1	19392810
we	O	-1	19392810
not@@	O	-1	19392810
ed	O	-1	19392810
a@@	B-Disease	D001037	19392810
pha@@	I-Disease	-1	19392810
sia	I-Disease	-1	19392810
and	O	-1	19392810
we@@	B-Disease	D018908	19392810
ak@@	I-Disease	-1	19392810
ness	I-Disease	-1	19392810
of	O	-1	19392810
h@@	O	-1	19392810
is	O	-1	19392810
left	O	-1	19392810
lim@@	O	-1	19392810
b@@	O	-1	19392810
s.	O	-1	19392810
After	O	-1	19392810
MR@@	O	-1	19392810
I@@	O	-1	19392810
,	O	-1	19392810
we	O	-1	19392810
found	O	-1	19392810
cerebral	B-Disease	D002544	19392810
ischem@@	I-Disease	-1	19392810
ic	I-Disease	-1	19392810
infarction	I-Disease	-1	19392810
.	O	-1	19392810
CONCLUSION:	O	-1	19392810
Th@@	O	-1	19392810
ose	O	-1	19392810
using	O	-1	19392810
meth@@	B-Chemical	D008691	19392810
ad@@	I-Chemical	-1	19392810
one	I-Chemical	-1	19392810
and	O	-1	19392810
h@@	B-Chemical	D003932	19392810
ero@@	I-Chemical	-1	19392810
in	I-Chemical	-1	19392810
sim@@	O	-1	19392810
ult@@	O	-1	19392810
ane@@	O	-1	19392810
ously	O	-1	19392810
may	O	-1	19392810
increase	O	-1	19392810
risk	O	-1	19392810
of	O	-1	19392810
rh@@	B-Disease	D012206	19392810
ab@@	I-Disease	-1	19392810
do@@	I-Disease	-1	19392810
my@@	I-Disease	-1	19392810
oly@@	I-Disease	-1	19392810
sis	I-Disease	-1	19392810
and	O	-1	19392810
ischem@@	B-Disease	D002544	19392810
ic	I-Disease	-1	19392810
strok@@	I-Disease	-1	19392810
e	I-Disease	-1	19392810
.	O	-1	19392810
Patients	O	-1	19392810
under	O	-1	19392810
meth@@	B-Chemical	D008691	19392810
ad@@	I-Chemical	-1	19392810
one	I-Chemical	-1	19392810
maint@@	O	-1	19392810
en@@	O	-1	19392810
ance	O	-1	19392810
therapy	O	-1	19392810
should	O	-1	19392810
be	O	-1	19392810
war@@	O	-1	19392810
n@@	O	-1	19392810
ed	O	-1	19392810
reg@@	O	-1	19392810
ar@@	O	-1	19392810
ding	O	-1	19392810
these	O	-1	19392810
seri@@	O	-1	19392810
ous	O	-1	19392810
adverse	O	-1	19392810
event@@	O	-1	19392810
s.	O	-1	19392810
H@@	O	-1	19392810
y@@	O	-1	19392810
po@@	O	-1	19392810
th@@	O	-1	19392810
es@@	O	-1	19392810
es	O	-1	19392810
of	O	-1	19392810
h@@	B-Chemical	D003932	19392810
ero@@	I-Chemical	-1	19392810
in	I-Chemical	-1	19392810
-@@	O	-1	19392810
related	O	-1	19392810
rh@@	B-Disease	D012206	19392810
ab@@	I-Disease	-1	19392810
do@@	I-Disease	-1	19392810
my@@	I-Disease	-1	19392810
oly@@	I-Disease	-1	19392810
sis	I-Disease	-1	19392810
and	O	-1	19392810
strok@@	B-Disease	D020521	19392810
e	I-Disease	-1	19392810
in	O	-1	19392810
h@@	B-Chemical	D003932	19392810
ero@@	I-Chemical	-1	19392810
in	I-Chemical	-1	19392810
ab@@	O	-1	19392810
users	O	-1	19392810
are	O	-1	19392810
discus@@	O	-1	19392810
sed.	O	-1	19392810

In@@	O	-1	19419794
c@@	O	-1	19419794
reas@@	O	-1	19419794
ed	O	-1	19419794
vul@@	O	-1	19419794
ner@@	O	-1	19419794
ability	O	-1	19419794
to	O	-1	19419794
6-@@	B-Chemical	D016627	19419794
hydrox@@	I-Chemical	-1	19419794
y@@	I-Chemical	-1	19419794
dopamine	I-Chemical	-1	19419794
le@@	O	-1	19419794
sion	O	-1	19419794
and	O	-1	19419794
reduced	O	-1	19419794
development	O	-1	19419794
of	O	-1	19419794
dyskine@@	B-Disease	D004409	19419794
si@@	I-Disease	-1	19419794
as	I-Disease	-1	19419794
in	O	-1	19419794
mice	O	-1	19419794
l@@	O	-1	19419794
ac@@	O	-1	19419794
king	O	-1	19419794
C@@	O	-1	19419794
B@@	O	-1	19419794
1	O	-1	19419794
can@@	O	-1	19419794
n@@	O	-1	19419794
ab@@	O	-1	19419794
in@@	O	-1	19419794
oid	O	-1	19419794
receptor@@	O	-1	19419794
s.	O	-1	19419794
M@@	O	-1	19419794
otor	O	-1	19419794
impair@@	O	-1	19419794
ment@@	O	-1	19419794
,	O	-1	19419794
dopamine	B-Chemical	D004298	19419794
(	O	-1	19419794
D@@	B-Chemical	D004298	19419794
A	I-Chemical	-1	19419794
)	O	-1	19419794
neuron@@	O	-1	19419794
al	O	-1	19419794
activity	O	-1	19419794
and	O	-1	19419794
pro@@	B-Chemical	C029992	19419794
en@@	I-Chemical	-1	19419794
ke@@	I-Chemical	-1	19419794
ph@@	I-Chemical	-1	19419794
al@@	I-Chemical	-1	19419794
in	I-Chemical	-1	19419794
(	O	-1	19419794
P@@	B-Chemical	C029992	19419794
E@@	I-Chemical	-1	19419794
N@@	I-Chemical	-1	19419794
K	I-Chemical	-1	19419794
)	O	-1	19419794
gen@@	O	-1	19419794
e	O	-1	19419794
expression	O	-1	19419794
in	O	-1	19419794
the	O	-1	19419794
ca@@	O	-1	19419794
ud@@	O	-1	19419794
at@@	O	-1	19419794
e-@@	O	-1	19419794
p@@	O	-1	19419794
ut@@	O	-1	19419794
am@@	O	-1	19419794
en	O	-1	19419794
(C@@	O	-1	19419794
P@@	O	-1	19419794
u@@	O	-1	19419794
)	O	-1	19419794
were	O	-1	19419794
measured	O	-1	19419794
in	O	-1	19419794
6-@@	B-Chemical	D016627	19419794
O@@	I-Chemical	-1	19419794
H@@	I-Chemical	-1	19419794
D@@	I-Chemical	-1	19419794
A	I-Chemical	-1	19419794
-@@	O	-1	19419794
le@@	O	-1	19419794
sion@@	O	-1	19419794
ed	O	-1	19419794
and	O	-1	19419794
treated	O	-1	19419794
(	O	-1	19419794
L-@@	B-Chemical	C005177	19419794
DO@@	I-Chemical	-1	19419794
PA@@	I-Chemical	-1	19419794
+@@	I-Chemical	-1	19419794
ben@@	I-Chemical	-1	19419794
ser@@	I-Chemical	-1	19419794
az@@	I-Chemical	-1	19419794
ide	I-Chemical	-1	19419794
)	O	-1	19419794
C@@	O	-1	19419794
B@@	O	-1	19419794
1	O	-1	19419794
K@@	O	-1	19419794
O	O	-1	19419794
and	O	-1	19419794
W@@	O	-1	19419794
T	O	-1	19419794
mice.	O	-1	19419794
A	O	-1	19419794
le@@	O	-1	19419794
sion	O	-1	19419794
induced	O	-1	19419794
by	O	-1	19419794
6-@@	B-Chemical	D016627	19419794
O@@	I-Chemical	-1	19419794
H@@	I-Chemical	-1	19419794
D@@	I-Chemical	-1	19419794
A	I-Chemical	-1	19419794
produced	O	-1	19419794
more	O	-1	19419794
severe	O	-1	19419794
motor	O	-1	19419794
deter@@	O	-1	19419794
i@@	O	-1	19419794
or@@	O	-1	19419794
ation	O	-1	19419794
in	O	-1	19419794
C@@	O	-1	19419794
B@@	O	-1	19419794
1	O	-1	19419794
K@@	O	-1	19419794
O	O	-1	19419794
mice	O	-1	19419794
ac@@	O	-1	19419794
comp@@	O	-1	19419794
an@@	O	-1	19419794
ied	O	-1	19419794
by	O	-1	19419794
more	O	-1	19419794
loss	O	-1	19419794
of	O	-1	19419794
D@@	B-Chemical	D004298	19419794
A	I-Chemical	-1	19419794
neuron@@	O	-1	19419794
s	O	-1	19419794
and	O	-1	19419794
increased	O	-1	19419794
P@@	B-Chemical	C029992	19419794
E@@	I-Chemical	-1	19419794
N@@	I-Chemical	-1	19419794
K	I-Chemical	-1	19419794
gen@@	O	-1	19419794
e	O	-1	19419794
expression	O	-1	19419794
in	O	-1	19419794
the	O	-1	19419794
C@@	O	-1	19419794
P@@	O	-1	19419794
u@@	O	-1	19419794
.	O	-1	19419794
O@@	O	-1	19419794
x@@	O	-1	19419794
id@@	O	-1	19419794
ati@@	O	-1	19419794
ve@@	O	-1	19419794
/@@	O	-1	19419794
nit@@	O	-1	19419794
ros@@	O	-1	19419794
ative	O	-1	19419794
and	O	-1	19419794
neuro@@	O	-1	19419794
inflam@@	O	-1	19419794
mat@@	O	-1	19419794
ory	O	-1	19419794
par@@	O	-1	19419794
ame@@	O	-1	19419794
ters	O	-1	19419794
were	O	-1	19419794
estim@@	O	-1	19419794
ated	O	-1	19419794
in	O	-1	19419794
the	O	-1	19419794
C@@	O	-1	19419794
P@@	O	-1	19419794
u	O	-1	19419794
and	O	-1	19419794
c@@	O	-1	19419794
ing@@	O	-1	19419794
ul@@	O	-1	19419794
ate	O	-1	19419794
cor@@	O	-1	19419794
te@@	O	-1	19419794
x	O	-1	19419794
(C@@	O	-1	19419794
g@@	O	-1	19419794
).	O	-1	19419794
C@@	O	-1	19419794
B@@	O	-1	19419794
1	O	-1	19419794
K@@	O	-1	19419794
O	O	-1	19419794
mice	O	-1	19419794
ex@@	O	-1	19419794
hib@@	O	-1	19419794
ited	O	-1	19419794
higher	O	-1	19419794
MD@@	B-Chemical	D008315	19419794
A	I-Chemical	-1	19419794
levels	O	-1	19419794
and	O	-1	19419794
i@@	O	-1	19419794
NO@@	O	-1	19419794
S	O	-1	19419794
protein	O	-1	19419794
expression	O	-1	19419794
in	O	-1	19419794
the	O	-1	19419794
C@@	O	-1	19419794
P@@	O	-1	19419794
u	O	-1	19419794
and	O	-1	19419794
C@@	O	-1	19419794
g	O	-1	19419794
compared	O	-1	19419794
to	O	-1	19419794
W@@	O	-1	19419794
T	O	-1	19419794
mice.	O	-1	19419794
Treat@@	O	-1	19419794
ment	O	-1	19419794
with	O	-1	19419794
L-@@	B-Chemical	C005177	19419794
DO@@	I-Chemical	-1	19419794
PA@@	I-Chemical	-1	19419794
+@@	I-Chemical	-1	19419794
ben@@	I-Chemical	-1	19419794
ser@@	I-Chemical	-1	19419794
az@@	I-Chemical	-1	19419794
ide	I-Chemical	-1	19419794
(1@@	O	-1	19419794
2	O	-1	19419794
week@@	O	-1	19419794
s)	O	-1	19419794
resulted	O	-1	19419794
in	O	-1	19419794
less	O	-1	19419794
severe	O	-1	19419794
dyskine@@	B-Disease	D004409	19419794
si@@	I-Disease	-1	19419794
as	I-Disease	-1	19419794
in	O	-1	19419794
C@@	O	-1	19419794
B@@	O	-1	19419794
1	O	-1	19419794
K@@	O	-1	19419794
O	O	-1	19419794
than	O	-1	19419794
in	O	-1	19419794
W@@	O	-1	19419794
T	O	-1	19419794
mice.	O	-1	19419794
The	O	-1	19419794
results	O	-1	19419794
revealed	O	-1	19419794
that	O	-1	19419794
the	O	-1	19419794
l@@	O	-1	19419794
ac@@	O	-1	19419794
k	O	-1	19419794
of	O	-1	19419794
can@@	O	-1	19419794
n@@	O	-1	19419794
ab@@	O	-1	19419794
in@@	O	-1	19419794
oid	O	-1	19419794
C@@	O	-1	19419794
B@@	O	-1	19419794
1	O	-1	19419794
receptors	O	-1	19419794
increased	O	-1	19419794
the	O	-1	19419794
severity	O	-1	19419794
of	O	-1	19419794
motor	O	-1	19419794
impair@@	O	-1	19419794
ment	O	-1	19419794
and	O	-1	19419794
D@@	B-Chemical	D004298	19419794
A	I-Chemical	-1	19419794
le@@	O	-1	19419794
sion,	O	-1	19419794
and	O	-1	19419794
reduced	O	-1	19419794
L-@@	B-Chemical	D007980	19419794
DO@@	I-Chemical	-1	19419794
P@@	I-Chemical	-1	19419794
A	I-Chemical	-1	19419794
-induced	O	-1	19419794
dyskine@@	B-Disease	D004409	19419794
si@@	I-Disease	-1	19419794
as	I-Disease	-1	19419794
.	O	-1	19419794
These	O	-1	19419794
results	O	-1	19419794
suggest	O	-1	19419794
that	O	-1	19419794
activation	O	-1	19419794
of	O	-1	19419794
C@@	O	-1	19419794
B@@	O	-1	19419794
1	O	-1	19419794
receptors	O	-1	19419794
o@@	O	-1	19419794
ff@@	O	-1	19419794
ers	O	-1	19419794
neuro@@	O	-1	19419794
prot@@	O	-1	19419794
ection	O	-1	19419794
against	O	-1	19419794
dop@@	O	-1	19419794
aminergic	O	-1	19419794
le@@	O	-1	19419794
sion	O	-1	19419794
and	O	-1	19419794
the	O	-1	19419794
development	O	-1	19419794
of	O	-1	19419794
L-@@	B-Chemical	D007980	19419794
DO@@	I-Chemical	-1	19419794
P@@	I-Chemical	-1	19419794
A	I-Chemical	-1	19419794
-induced	O	-1	19419794
dyskine@@	B-Disease	D004409	19419794
si@@	I-Disease	-1	19419794
as	I-Disease	-1	19419794
.	O	-1	19419794

An@@	O	-1	19447152
im@@	O	-1	19447152
al	O	-1	19447152
model	O	-1	19447152
of	O	-1	19447152
man@@	B-Disease	D001714	19447152
ia	I-Disease	-1	19447152
induced	O	-1	19447152
by	O	-1	19447152
ou@@	B-Chemical	D010042	19447152
ab@@	I-Chemical	-1	19447152
ain	I-Chemical	-1	19447152
:	O	-1	19447152
E@@	O	-1	19447152
v@@	O	-1	19447152
idence	O	-1	19447152
of	O	-1	19447152
oxid@@	O	-1	19447152
ative	O	-1	19447152
stres@@	O	-1	19447152
s	O	-1	19447152
in	O	-1	19447152
sub@@	O	-1	19447152
mitochondrial	O	-1	19447152
partic@@	O	-1	19447152
le@@	O	-1	19447152
s	O	-1	19447152
of	O	-1	19447152
the	O	-1	19447152
rat	O	-1	19447152
bra@@	O	-1	19447152
in.	O	-1	19447152
The	O	-1	19447152
intrac@@	O	-1	19447152
e@@	O	-1	19447152
reb@@	O	-1	19447152
ro@@	O	-1	19447152
ventricular	O	-1	19447152
(@@	O	-1	19447152
IC@@	O	-1	19447152
V@@	O	-1	19447152
)	O	-1	19447152
administration	O	-1	19447152
of	O	-1	19447152
ou@@	B-Chemical	D010042	19447152
ab@@	I-Chemical	-1	19447152
ain	I-Chemical	-1	19447152
(@@	O	-1	19447152
a	O	-1	19447152
N@@	B-Chemical	D012964	19447152
a	I-Chemical	-1	19447152
(@@	O	-1	19447152
+@@	O	-1	19447152
)@@	O	-1	19447152
/	O	-1	19447152
K	B-Chemical	D011188	19447152
(@@	O	-1	19447152
+@@	O	-1	19447152
)-@@	O	-1	19447152
AT@@	O	-1	19447152
P@@	O	-1	19447152
ase	O	-1	19447152
inhibitor@@	O	-1	19447152
)	O	-1	19447152
in	O	-1	19447152
rats	O	-1	19447152
has	O	-1	19447152
been	O	-1	19447152
suggested	O	-1	19447152
to	O	-1	19447152
m@@	O	-1	19447152
im@@	O	-1	19447152
ic	O	-1	19447152
some	O	-1	19447152
symptoms	O	-1	19447152
of	O	-1	19447152
human	O	-1	19447152
b@@	B-Disease	D001714	19447152
ip@@	I-Disease	-1	19447152
ol@@	I-Disease	-1	19447152
ar	I-Disease	-1	19447152
man@@	I-Disease	-1	19447152
ia	I-Disease	-1	19447152
.	O	-1	19447152
Clin@@	O	-1	19447152
ical	O	-1	19447152
studies	O	-1	19447152
have	O	-1	19447152
shown	O	-1	19447152
that	O	-1	19447152
b@@	B-Disease	D001714	19447152
ip@@	I-Disease	-1	19447152
ol@@	I-Disease	-1	19447152
ar	I-Disease	-1	19447152
disor@@	I-Disease	-1	19447152
der	I-Disease	-1	19447152
may	O	-1	19447152
be	O	-1	19447152
related	O	-1	19447152
to	O	-1	19447152
mitochondrial	B-Disease	D028361	19447152
dysfunction	I-Disease	-1	19447152
.	O	-1	19447152
He@@	O	-1	19447152
re@@	O	-1	19447152
in,	O	-1	19447152
we	O	-1	19447152
investigated	O	-1	19447152
the	O	-1	19447152
behavioral	O	-1	19447152
and	O	-1	19447152
bio@@	O	-1	19447152
chemical	O	-1	19447152
effects	O	-1	19447152
induced	O	-1	19447152
by	O	-1	19447152
the	O	-1	19447152
IC@@	O	-1	19447152
V	O	-1	19447152
administration	O	-1	19447152
of	O	-1	19447152
ou@@	B-Chemical	D010042	19447152
ab@@	I-Chemical	-1	19447152
ain	I-Chemical	-1	19447152
in	O	-1	19447152
rats.	O	-1	19447152
To	O	-1	19447152
achi@@	O	-1	19447152
e@@	O	-1	19447152
ve	O	-1	19447152
this	O	-1	19447152
a@@	O	-1	19447152
im@@	O	-1	19447152
,	O	-1	19447152
the	O	-1	19447152
effects	O	-1	19447152
of	O	-1	19447152
ou@@	B-Chemical	D010042	19447152
ab@@	I-Chemical	-1	19447152
ain	I-Chemical	-1	19447152
injection	O	-1	19447152
immedi@@	O	-1	19447152
ately	O	-1	19447152
after	O	-1	19447152
and	O	-1	19447152
7	O	-1	19447152
days	O	-1	19447152
following	O	-1	19447152
a	O	-1	19447152
single	O	-1	19447152
IC@@	O	-1	19447152
V	O	-1	19447152
administration	O	-1	19447152
(@@	O	-1	19447152
at	O	-1	19447152
concentrations	O	-1	19447152
of	O	-1	19447152
10@@	O	-1	19447152
(-@@	O	-1	19447152
2)	O	-1	19447152
and	O	-1	19447152
10@@	O	-1	19447152
(-@@	O	-1	19447152
3@@	O	-1	19447152
)@@	O	-1	19447152
M@@	O	-1	19447152
)	O	-1	19447152
on	O	-1	19447152
locom@@	O	-1	19447152
o@@	O	-1	19447152
tion	O	-1	19447152
was	O	-1	19447152
measured	O	-1	19447152
using	O	-1	19447152
the	O	-1	19447152
o@@	O	-1	19447152
pen@@	O	-1	19447152
-@@	O	-1	19447152
fi@@	O	-1	19447152
el@@	O	-1	19447152
d	O	-1	19447152
test@@	O	-1	19447152
.	O	-1	19447152
Ad@@	O	-1	19447152
di@@	O	-1	19447152
tion@@	O	-1	19447152
ally,	O	-1	19447152
th@@	B-Chemical	C029684	19447152
io@@	I-Chemical	-1	19447152
b@@	I-Chemical	-1	19447152
arbit@@	I-Chemical	-1	19447152
ur@@	I-Chemical	-1	19447152
ic	I-Chemical	-1	19447152
acid	I-Chemical	-1	19447152
reac@@	O	-1	19447152
tive	O	-1	19447152
subst@@	O	-1	19447152
anc@@	O	-1	19447152
es	O	-1	19447152
(T@@	O	-1	19447152
BA@@	O	-1	19447152
R@@	O	-1	19447152
S@@	O	-1	19447152
s)	O	-1	19447152
and	O	-1	19447152
su@@	B-Chemical	D013481	19447152
per@@	I-Chemical	-1	19447152
ox@@	I-Chemical	-1	19447152
ide	I-Chemical	-1	19447152
pro@@	O	-1	19447152
duction	O	-1	19447152
were	O	-1	19447152
measured	O	-1	19447152
in	O	-1	19447152
sub@@	O	-1	19447152
mitochondrial	O	-1	19447152
partic@@	O	-1	19447152
le@@	O	-1	19447152
s	O	-1	19447152
of	O	-1	19447152
the	O	-1	19447152
pre@@	O	-1	19447152
fron@@	O	-1	19447152
t@@	O	-1	19447152
al	O	-1	19447152
cor@@	O	-1	19447152
t@@	O	-1	19447152
ex@@	O	-1	19447152
,	O	-1	19447152
hippocamp@@	O	-1	19447152
us,	O	-1	19447152
striat@@	O	-1	19447152
um	O	-1	19447152
and	O	-1	19447152
am@@	O	-1	19447152
y@@	O	-1	19447152
g@@	O	-1	19447152
d@@	O	-1	19447152
al@@	O	-1	19447152
a.	O	-1	19447152
Our	O	-1	19447152
findings	O	-1	19447152
demonstrated	O	-1	19447152
that	O	-1	19447152
ou@@	B-Chemical	D010042	19447152
ab@@	I-Chemical	-1	19447152
ain	I-Chemical	-1	19447152
at	O	-1	19447152
10@@	O	-1	19447152
(-@@	O	-1	19447152
2)	O	-1	19447152
and	O	-1	19447152
10@@	O	-1	19447152
(-@@	O	-1	19447152
3@@	O	-1	19447152
)@@	O	-1	19447152
M	O	-1	19447152
induced	O	-1	19447152
hyper@@	B-Disease	D009069	19447152
locom@@	I-Disease	-1	19447152
o@@	I-Disease	-1	19447152
tion	I-Disease	-1	19447152
in	O	-1	19447152
rats,	O	-1	19447152
and	O	-1	19447152
this	O	-1	19447152
response	O	-1	19447152
remained	O	-1	19447152
up	O	-1	19447152
to	O	-1	19447152
7	O	-1	19447152
days	O	-1	19447152
following	O	-1	19447152
a	O	-1	19447152
single	O	-1	19447152
IC@@	O	-1	19447152
V	O	-1	19447152
injec@@	O	-1	19447152
tion.	O	-1	19447152
In	O	-1	19447152
addi@@	O	-1	19447152
tion,	O	-1	19447152
we	O	-1	19447152
observed	O	-1	19447152
that	O	-1	19447152
the	O	-1	19447152
per@@	O	-1	19447152
sist@@	O	-1	19447152
ent	O	-1	19447152
increase	O	-1	19447152
in	O	-1	19447152
the	O	-1	19447152
rat	O	-1	19447152
spont@@	O	-1	19447152
aneous	O	-1	19447152
locom@@	O	-1	19447152
o@@	O	-1	19447152
tion	O	-1	19447152
is	O	-1	19447152
associated	O	-1	19447152
with	O	-1	19447152
increased	O	-1	19447152
T@@	O	-1	19447152
BA@@	O	-1	19447152
R@@	O	-1	19447152
S	O	-1	19447152
levels	O	-1	19447152
and	O	-1	19447152
su@@	B-Chemical	D013481	19447152
per@@	I-Chemical	-1	19447152
ox@@	I-Chemical	-1	19447152
ide	I-Chemical	-1	19447152
generation	O	-1	19447152
in	O	-1	19447152
sub@@	O	-1	19447152
mitochondrial	O	-1	19447152
partic@@	O	-1	19447152
le@@	O	-1	19447152
s	O	-1	19447152
in	O	-1	19447152
the	O	-1	19447152
pre@@	O	-1	19447152
fron@@	O	-1	19447152
t@@	O	-1	19447152
al	O	-1	19447152
cor@@	O	-1	19447152
t@@	O	-1	19447152
ex@@	O	-1	19447152
,	O	-1	19447152
striat@@	O	-1	19447152
um	O	-1	19447152
and	O	-1	19447152
am@@	O	-1	19447152
y@@	O	-1	19447152
g@@	O	-1	19447152
d@@	O	-1	19447152
al@@	O	-1	19447152
a.	O	-1	19447152
In	O	-1	19447152
concl@@	O	-1	19447152
u@@	O	-1	19447152
sion,	O	-1	19447152
ou@@	B-Chemical	D010042	19447152
ab@@	I-Chemical	-1	19447152
ain	I-Chemical	-1	19447152
-induced	O	-1	19447152
man@@	B-Disease	D001714	19447152
ia	I-Disease	-1	19447152
-@@	O	-1	19447152
like	O	-1	19447152
behavi@@	O	-1	19447152
or	O	-1	19447152
may	O	-1	19447152
prov@@	O	-1	19447152
ide	O	-1	19447152
a	O	-1	19447152
use@@	O	-1	19447152
ful	O	-1	19447152
anim@@	O	-1	19447152
al	O	-1	19447152
model	O	-1	19447152
to	O	-1	19447152
test	O	-1	19447152
the	O	-1	19447152
hypo@@	O	-1	19447152
thesis	O	-1	19447152
of	O	-1	19447152
the	O	-1	19447152
invol@@	O	-1	19447152
vement	O	-1	19447152
of	O	-1	19447152
oxid@@	O	-1	19447152
ative	O	-1	19447152
stres@@	O	-1	19447152
s	O	-1	19447152
in	O	-1	19447152
b@@	B-Disease	D001714	19447152
ip@@	I-Disease	-1	19447152
ol@@	I-Disease	-1	19447152
ar	I-Disease	-1	19447152
disor@@	I-Disease	-1	19447152
der	I-Disease	-1	19447152
.	O	-1	19447152

In@@	O	-1	19515070
tra@@	O	-1	19515070
o@@	O	-1	19515070
perative	O	-1	19515070
dialy@@	O	-1	19515070
sis	O	-1	19515070
during	O	-1	19515070
liver	O	-1	19515070
transplant@@	O	-1	19515070
ation	O	-1	19515070
with	O	-1	19515070
cit@@	B-Chemical	D019343	19515070
rate	I-Chemical	-1	19515070
di@@	O	-1	19515070
al@@	O	-1	19515070
ys@@	O	-1	19515070
at@@	O	-1	19515070
e.	O	-1	19515070
L@@	O	-1	19515070
i@@	O	-1	19515070
ver	O	-1	19515070
transplant@@	O	-1	19515070
ation	O	-1	19515070
for	O	-1	19515070
ac@@	O	-1	19515070
u@@	O	-1	19515070
te@@	O	-1	19515070
ly	O	-1	19515070
il@@	O	-1	19515070
l	O	-1	19515070
patients	O	-1	19515070
with	O	-1	19515070
ful@@	B-Disease	D017114	19515070
min@@	I-Disease	-1	19515070
ant	I-Disease	-1	19515070
liver	I-Disease	-1	19515070
failure	I-Disease	-1	19515070
car@@	O	-1	19515070
ri@@	O	-1	19515070
es	O	-1	19515070
high	O	-1	19515070
intra@@	O	-1	19515070
o@@	O	-1	19515070
perative	O	-1	19515070
and	O	-1	19515070
immedi@@	O	-1	19515070
ate	O	-1	19515070
postoperative	O	-1	19515070
ris@@	O	-1	19515070
k@@	O	-1	19515070
s.	O	-1	19515070
These	O	-1	19515070
are	O	-1	19515070
increased	O	-1	19515070
with	O	-1	19515070
the	O	-1	19515070
presence	O	-1	19515070
of	O	-1	19515070
concomit@@	O	-1	19515070
ant	O	-1	19515070
acute	B-Disease	D058186	19515070
kidney	I-Disease	-1	19515070
injury	I-Disease	-1	19515070
(	O	-1	19515070
A@@	B-Disease	D058186	19515070
K@@	I-Disease	-1	19515070
I	I-Disease	-1	19515070
)	O	-1	19515070
and	O	-1	19515070
intra@@	O	-1	19515070
o@@	O	-1	19515070
perative	O	-1	19515070
dialy@@	O	-1	19515070
sis	O	-1	19515070
is	O	-1	19515070
so@@	O	-1	19515070
me@@	O	-1	19515070
times	O	-1	19515070
requ@@	O	-1	19515070
ired	O	-1	19515070
to	O	-1	19515070
al@@	O	-1	19515070
low	O	-1	19515070
the	O	-1	19515070
transplant	O	-1	19515070
to	O	-1	19515070
proce@@	O	-1	19515070
ed.	O	-1	19515070
The	O	-1	19515070
der@@	O	-1	19515070
ang@@	O	-1	19515070
em@@	O	-1	19515070
ents	O	-1	19515070
in	O	-1	19515070
the	O	-1	19515070
pro@@	O	-1	19515070
co@@	O	-1	19515070
ag@@	O	-1	19515070
ul@@	O	-1	19515070
ant	O	-1	19515070
and	O	-1	19515070
anti@@	O	-1	19515070
co@@	O	-1	19515070
ag@@	O	-1	19515070
ul@@	O	-1	19515070
ant	O	-1	19515070
path@@	O	-1	19515070
w@@	O	-1	19515070
ays	O	-1	19515070
during	O	-1	19515070
ful@@	B-Disease	D017114	19515070
min@@	I-Disease	-1	19515070
ant	I-Disease	-1	19515070
liver	I-Disease	-1	19515070
failure	I-Disease	-1	19515070
can	O	-1	19515070
le@@	O	-1	19515070
ad	O	-1	19515070
to	O	-1	19515070
diff@@	O	-1	19515070
ic@@	O	-1	19515070
ul@@	O	-1	19515070
ties	O	-1	19515070
with	O	-1	19515070
anti@@	O	-1	19515070
co@@	O	-1	19515070
ag@@	O	-1	19515070
ulation	O	-1	19515070
during	O	-1	19515070
dialy@@	O	-1	19515070
sis,	O	-1	19515070
es@@	O	-1	19515070
p@@	O	-1	19515070
ec@@	O	-1	19515070
i@@	O	-1	19515070
ally	O	-1	19515070
when	O	-1	19515070
continu@@	O	-1	19515070
ed	O	-1	19515070
in	O	-1	19515070
the	O	-1	19515070
o@@	O	-1	19515070
per@@	O	-1	19515070
ating	O	-1	19515070
ro@@	O	-1	19515070
om@@	O	-1	19515070
.	O	-1	19515070
S@@	O	-1	19515070
y@@	O	-1	19515070
st@@	O	-1	19515070
em@@	O	-1	19515070
ic	O	-1	19515070
anti@@	O	-1	19515070
co@@	O	-1	19515070
ag@@	O	-1	19515070
ulation	O	-1	19515070
is	O	-1	19515070
un@@	O	-1	19515070
saf@@	O	-1	19515070
e	O	-1	19515070
and	O	-1	19515070
regi@@	O	-1	19515070
on@@	O	-1	19515070
al	O	-1	19515070
cit@@	B-Chemical	D019343	19515070
rate	I-Chemical	-1	19515070
anti@@	O	-1	19515070
co@@	O	-1	19515070
ag@@	O	-1	19515070
ulation	O	-1	19515070
in	O	-1	19515070
the	O	-1	19515070
absence	O	-1	19515070
of	O	-1	19515070
a	O	-1	19515070
functional	O	-1	19515070
liver	O	-1	19515070
car@@	O	-1	19515070
ri@@	O	-1	19515070
es	O	-1	19515070
the	O	-1	19515070
risk	O	-1	19515070
of	O	-1	19515070
cit@@	B-Chemical	D019343	19515070
rate	I-Chemical	-1	19515070
toxicity	B-Disease	D064420	19515070
.	O	-1	19515070
C@@	B-Chemical	D019343	19515070
it@@	I-Chemical	-1	19515070
rate	I-Chemical	-1	19515070
di@@	O	-1	19515070
al@@	O	-1	19515070
ys@@	O	-1	19515070
ate,	O	-1	19515070
a	O	-1	19515070
new	O	-1	19515070
di@@	O	-1	19515070
al@@	O	-1	19515070
ys@@	O	-1	19515070
ate	O	-1	19515070
with	O	-1	19515070
cit@@	B-Chemical	D019343	19515070
ric	I-Chemical	-1	19515070
acid	I-Chemical	-1	19515070
can	O	-1	19515070
be	O	-1	19515070
used	O	-1	19515070
for	O	-1	19515070
anti@@	O	-1	19515070
co@@	O	-1	19515070
ag@@	O	-1	19515070
ulation	O	-1	19515070
in	O	-1	19515070
patients	O	-1	19515070
who	O	-1	19515070
can@@	O	-1	19515070
not	O	-1	19515070
toler@@	O	-1	19515070
ate	O	-1	19515070
hepar@@	B-Chemical	D006493	19515070
in	I-Chemical	-1	19515070
or	O	-1	19515070
regi@@	O	-1	19515070
on@@	O	-1	19515070
al	O	-1	19515070
cit@@	B-Chemical	D019343	19515070
rate	I-Chemical	-1	19515070
.	O	-1	19515070
We	O	-1	19515070
report	O	-1	19515070
a	O	-1	19515070
case	O	-1	19515070
of	O	-1	19515070
a	O	-1	19515070
4@@	O	-1	19515070
0-@@	O	-1	19515070
year-old	O	-1	19515070
female	O	-1	19515070
with	O	-1	19515070
acet@@	B-Chemical	D000082	19515070
aminoph@@	I-Chemical	-1	19515070
en	I-Chemical	-1	19515070
-induced	O	-1	19515070
ful@@	B-Disease	D017114	19515070
min@@	I-Disease	-1	19515070
ant	I-Disease	-1	19515070
liver	I-Disease	-1	19515070
failure	I-Disease	-1	19515070
with	O	-1	19515070
associated	O	-1	19515070
A@@	B-Disease	D058186	19515070
K@@	I-Disease	-1	19515070
I	I-Disease	-1	19515070
who	O	-1	19515070
under@@	O	-1	19515070
w@@	O	-1	19515070
ent	O	-1	19515070
intra@@	O	-1	19515070
o@@	O	-1	19515070
perative	O	-1	19515070
dialy@@	O	-1	19515070
tic	O	-1	19515070
suppor@@	O	-1	19515070
t	O	-1	19515070
during	O	-1	19515070
liver	O	-1	19515070
transplant@@	O	-1	19515070
ation	O	-1	19515070
anti@@	O	-1	19515070
co@@	O	-1	19515070
ag@@	O	-1	19515070
ul@@	O	-1	19515070
ated	O	-1	19515070
with	O	-1	19515070
cit@@	B-Chemical	D019343	19515070
rate	I-Chemical	-1	19515070
di@@	O	-1	19515070
al@@	O	-1	19515070
ys@@	O	-1	19515070
ate	O	-1	19515070
during	O	-1	19515070
the	O	-1	19515070
enti@@	O	-1	19515070
r@@	O	-1	19515070
e	O	-1	19515070
proce@@	O	-1	19515070
d@@	O	-1	19515070
ure.	O	-1	19515070
The	O	-1	19515070
patient	O	-1	19515070
toler@@	O	-1	19515070
ated	O	-1	19515070
the	O	-1	19515070
proce@@	O	-1	19515070
d@@	O	-1	19515070
ure	O	-1	19515070
well	O	-1	19515070
without	O	-1	19515070
any	O	-1	19515070
signs	O	-1	19515070
of	O	-1	19515070
cit@@	B-Chemical	D019343	19515070
rate	I-Chemical	-1	19515070
toxicity	B-Disease	D064420	19515070
and	O	-1	19515070
maint@@	O	-1	19515070
ained	O	-1	19515070
ade@@	O	-1	19515070
qu@@	O	-1	19515070
ate	O	-1	19515070
anti@@	O	-1	19515070
co@@	O	-1	19515070
ag@@	O	-1	19515070
ulation	O	-1	19515070
for	O	-1	19515070
pat@@	O	-1	19515070
ency	O	-1	19515070
of	O	-1	19515070
the	O	-1	19515070
dialy@@	O	-1	19515070
sis	O	-1	19515070
cir@@	O	-1	19515070
c@@	O	-1	19515070
u@@	O	-1	19515070
it@@	O	-1	19515070
.	O	-1	19515070
C@@	B-Chemical	D019343	19515070
it@@	I-Chemical	-1	19515070
rate	I-Chemical	-1	19515070
di@@	O	-1	19515070
al@@	O	-1	19515070
ys@@	O	-1	19515070
ate	O	-1	19515070
is	O	-1	19515070
a	O	-1	19515070
saf@@	O	-1	19515070
e	O	-1	19515070
al@@	O	-1	19515070
tern@@	O	-1	19515070
ative	O	-1	19515070
for	O	-1	19515070
intra@@	O	-1	19515070
dialy@@	O	-1	19515070
tic	O	-1	19515070
suppor@@	O	-1	19515070
t	O	-1	19515070
of	O	-1	19515070
liver	O	-1	19515070
transplant@@	O	-1	19515070
ation	O	-1	19515070
in	O	-1	19515070
ful@@	B-Disease	D017114	19515070
min@@	I-Disease	-1	19515070
ant	I-Disease	-1	19515070
liver	I-Disease	-1	19515070
failure	I-Disease	-1	19515070
.	O	-1	19515070

De@@	B-Disease	D003693	19531695
li@@	I-Disease	-1	19531695
ri@@	I-Disease	-1	19531695
um	I-Disease	-1	19531695
in	O	-1	19531695
a	O	-1	19531695
patient	O	-1	19531695
with	O	-1	19531695
toxic	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
plasma	O	-1	19531695
concentr@@	O	-1	19531695
ation@@	O	-1	19531695
s:	O	-1	19531695
the	O	-1	19531695
role	O	-1	19531695
of	O	-1	19531695
a	O	-1	19531695
pharmac@@	O	-1	19531695
o@@	O	-1	19531695
kine@@	O	-1	19531695
tic	O	-1	19531695
drug	O	-1	19531695
inter@@	O	-1	19531695
action	O	-1	19531695
with	O	-1	19531695
pa@@	B-Chemical	D017374	19531695
ro@@	I-Chemical	-1	19531695
x@@	I-Chemical	-1	19531695
et@@	I-Chemical	-1	19531695
ine	I-Chemical	-1	19531695
.	O	-1	19531695
OBJECTIVE:	O	-1	19531695
To	O	-1	19531695
describe	O	-1	19531695
a	O	-1	19531695
case	O	-1	19531695
of	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
-induced	O	-1	19531695
de@@	B-Disease	D003693	19531695
li@@	I-Disease	-1	19531695
ri@@	I-Disease	-1	19531695
um	I-Disease	-1	19531695
associated	O	-1	19531695
with	O	-1	19531695
a	O	-1	19531695
pharmac@@	O	-1	19531695
o@@	O	-1	19531695
kine@@	O	-1	19531695
tic	O	-1	19531695
drug	O	-1	19531695
inter@@	O	-1	19531695
action	O	-1	19531695
with	O	-1	19531695
pa@@	B-Chemical	D017374	19531695
ro@@	I-Chemical	-1	19531695
x@@	I-Chemical	-1	19531695
et@@	I-Chemical	-1	19531695
ine	I-Chemical	-1	19531695
.	O	-1	19531695
CA@@	O	-1	19531695
S@@	O	-1	19531695
E	O	-1	19531695
S@@	O	-1	19531695
U@@	O	-1	19531695
M@@	O	-1	19531695
MA@@	O	-1	19531695
R@@	O	-1	19531695
Y@@	O	-1	19531695
:	O	-1	19531695
A	O	-1	19531695
6@@	O	-1	19531695
9@@	O	-1	19531695
-@@	O	-1	19531695
year-old	O	-1	19531695
wh@@	O	-1	19531695
ite	O	-1	19531695
female	O	-1	19531695
presented	O	-1	19531695
to	O	-1	19531695
the	O	-1	19531695
em@@	O	-1	19531695
er@@	O	-1	19531695
gen@@	O	-1	19531695
c@@	O	-1	19531695
y	O	-1	19531695
de@@	O	-1	19531695
part@@	O	-1	19531695
ment	O	-1	19531695
with	O	-1	19531695
a	O	-1	19531695
hist@@	O	-1	19531695
ory	O	-1	19531695
of	O	-1	19531695
conf@@	B-Disease	D003221	19531695
usion	I-Disease	-1	19531695
and	O	-1	19531695
par@@	B-Disease	D010259	19531695
an@@	I-Disease	-1	19531695
o@@	I-Disease	-1	19531695
ia	I-Disease	-1	19531695
over	O	-1	19531695
the	O	-1	19531695
p@@	O	-1	19531695
ast	O	-1	19531695
several	O	-1	19531695
days.	O	-1	19531695
O@@	O	-1	19531695
n	O	-1	19531695
ad@@	O	-1	19531695
mission	O	-1	19531695
the	O	-1	19531695
patient	O	-1	19531695
was	O	-1	19531695
taking	O	-1	19531695
car@@	B-Chemical	C043211	19531695
ve@@	I-Chemical	-1	19531695
di@@	I-Chemical	-1	19531695
lol	I-Chemical	-1	19531695
12	O	-1	19531695
mg	O	-1	19531695
tw@@	O	-1	19531695
ic@@	O	-1	19531695
e	O	-1	19531695
da@@	O	-1	19531695
il@@	O	-1	19531695
y,	O	-1	19531695
war@@	B-Chemical	D014859	19531695
farin	I-Chemical	-1	19531695
2	O	-1	19531695
mg/@@	O	-1	19531695
da@@	O	-1	19531695
y,	O	-1	19531695
fol@@	B-Chemical	D005492	19531695
ic	I-Chemical	-1	19531695
acid	I-Chemical	-1	19531695
1	O	-1	19531695
mg/@@	O	-1	19531695
da@@	O	-1	19531695
y,	O	-1	19531695
levo@@	B-Chemical	D013974	19531695
th@@	I-Chemical	-1	19531695
yro@@	I-Chemical	-1	19531695
x@@	I-Chemical	-1	19531695
ine	I-Chemical	-1	19531695
100	O	-1	19531695
micro@@	O	-1	19531695
g/@@	O	-1	19531695
da@@	O	-1	19531695
y,	O	-1	19531695
p@@	B-Chemical	C064276	19531695
an@@	I-Chemical	-1	19531695
to@@	I-Chemical	-1	19531695
praz@@	I-Chemical	-1	19531695
ole	I-Chemical	-1	19531695
40	O	-1	19531695
mg/@@	O	-1	19531695
da@@	O	-1	19531695
y,	O	-1	19531695
pa@@	B-Chemical	D017374	19531695
ro@@	I-Chemical	-1	19531695
x@@	I-Chemical	-1	19531695
et@@	I-Chemical	-1	19531695
ine	I-Chemical	-1	19531695
40	O	-1	19531695
mg/@@	O	-1	19531695
da@@	O	-1	19531695
y,	O	-1	19531695
and	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
100	O	-1	19531695
mg	O	-1	19531695
tw@@	O	-1	19531695
ic@@	O	-1	19531695
e	O	-1	19531695
da@@	O	-1	19531695
il@@	O	-1	19531695
y.	O	-1	19531695
F@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
had	O	-1	19531695
been	O	-1	19531695
star@@	O	-1	19531695
ted	O	-1	19531695
2	O	-1	19531695
weeks	O	-1	19531695
prior	O	-1	19531695
for	O	-1	19531695
atrial	B-Disease	D001281	19531695
fibrill@@	I-Disease	-1	19531695
ation	I-Disease	-1	19531695
.	O	-1	19531695
L@@	O	-1	19531695
abor@@	O	-1	19531695
atory	O	-1	19531695
test	O	-1	19531695
findings	O	-1	19531695
on	O	-1	19531695
ad@@	O	-1	19531695
mission	O	-1	19531695
were	O	-1	19531695
not@@	O	-1	19531695
able	O	-1	19531695
only	O	-1	19531695
for	O	-1	19531695
a	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
plasma	O	-1	19531695
concentration	O	-1	19531695
of	O	-1	19531695
13@@	O	-1	19531695
60	O	-1	19531695
micro@@	O	-1	19531695
g/@@	O	-1	19531695
L	O	-1	19531695
(@@	O	-1	19531695
ref@@	O	-1	19531695
e@@	O	-1	19531695
rence	O	-1	19531695
range	O	-1	19531695
20@@	O	-1	19531695
0-@@	O	-1	19531695
10@@	O	-1	19531695
0@@	O	-1	19531695
0@@	O	-1	19531695
).	O	-1	19531695
A	O	-1	19531695
met@@	O	-1	19531695
ab@@	O	-1	19531695
olic	O	-1	19531695
drug	O	-1	19531695
inter@@	O	-1	19531695
action	O	-1	19531695
between	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
and	O	-1	19531695
pa@@	B-Chemical	D017374	19531695
ro@@	I-Chemical	-1	19531695
x@@	I-Chemical	-1	19531695
et@@	I-Chemical	-1	19531695
ine	I-Chemical	-1	19531695
,	O	-1	19531695
which	O	-1	19531695
the	O	-1	19531695
patient	O	-1	19531695
had	O	-1	19531695
been	O	-1	19531695
taking	O	-1	19531695
for	O	-1	19531695
more	O	-1	19531695
than	O	-1	19531695
5	O	-1	19531695
year@@	O	-1	19531695
s,	O	-1	19531695
was	O	-1	19531695
conside@@	O	-1	19531695
red.	O	-1	19531695
P@@	B-Chemical	D017374	19531695
a@@	I-Chemical	-1	19531695
ro@@	I-Chemical	-1	19531695
x@@	I-Chemical	-1	19531695
et@@	I-Chemical	-1	19531695
ine	I-Chemical	-1	19531695
was	O	-1	19531695
discontinu@@	O	-1	19531695
ed	O	-1	19531695
and	O	-1	19531695
the	O	-1	19531695
dose	O	-1	19531695
of	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
was	O	-1	19531695
reduced	O	-1	19531695
to	O	-1	19531695
50	O	-1	19531695
mg	O	-1	19531695
tw@@	O	-1	19531695
ic@@	O	-1	19531695
e	O	-1	19531695
da@@	O	-1	19531695
il@@	O	-1	19531695
y.	O	-1	19531695
H@@	O	-1	19531695
er	O	-1	19531695
de@@	B-Disease	D003693	19531695
li@@	I-Disease	-1	19531695
ri@@	I-Disease	-1	19531695
um	I-Disease	-1	19531695
resol@@	O	-1	19531695
ved	O	-1	19531695
3	O	-1	19531695
days	O	-1	19531695
lat@@	O	-1	19531695
er.	O	-1	19531695
D@@	O	-1	19531695
I@@	O	-1	19531695
S@@	O	-1	19531695
C@@	O	-1	19531695
US@@	O	-1	19531695
S@@	O	-1	19531695
ION@@	O	-1	19531695
:	O	-1	19531695
F@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
and	O	-1	19531695
pharmac@@	O	-1	19531695
olog@@	O	-1	19531695
ically	O	-1	19531695
similar	O	-1	19531695
agents	O	-1	19531695
that	O	-1	19531695
inter@@	O	-1	19531695
ac@@	O	-1	19531695
t	O	-1	19531695
with	O	-1	19531695
sodium	B-Chemical	D012964	19531695
channe@@	O	-1	19531695
l@@	O	-1	19531695
s	O	-1	19531695
may	O	-1	19531695
cause	O	-1	19531695
de@@	B-Disease	D003693	19531695
li@@	I-Disease	-1	19531695
ri@@	I-Disease	-1	19531695
um	I-Disease	-1	19531695
in	O	-1	19531695
sus@@	O	-1	19531695
cep@@	O	-1	19531695
ti@@	O	-1	19531695
ble	O	-1	19531695
patients.	O	-1	19531695
A	O	-1	19531695
M@@	O	-1	19531695
E@@	O	-1	19531695
D@@	O	-1	19531695
L@@	O	-1	19531695
IN@@	O	-1	19531695
E	O	-1	19531695
se@@	O	-1	19531695
arc@@	O	-1	19531695
h	O	-1	19531695
(1@@	O	-1	19531695
9@@	O	-1	19531695
6@@	O	-1	19531695
6-@@	O	-1	19531695
J@@	O	-1	19531695
an@@	O	-1	19531695
u@@	O	-1	19531695
ary	O	-1	19531695
20@@	O	-1	19531695
0@@	O	-1	19531695
9@@	O	-1	19531695
)	O	-1	19531695
revealed	O	-1	19531695
one	O	-1	19531695
in	O	-1	19531695
viv@@	O	-1	19531695
o	O	-1	19531695
pharmac@@	O	-1	19531695
o@@	O	-1	19531695
kine@@	O	-1	19531695
tic	O	-1	19531695
study	O	-1	19531695
on	O	-1	19531695
the	O	-1	19531695
inter@@	O	-1	19531695
action	O	-1	19531695
between	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
,	O	-1	19531695
a	O	-1	19531695
C@@	O	-1	19531695
Y@@	O	-1	19531695
P@@	O	-1	19531695
2@@	O	-1	19531695
D@@	O	-1	19531695
6	O	-1	19531695
sub@@	O	-1	19531695
strat@@	O	-1	19531695
e,	O	-1	19531695
and	O	-1	19531695
pa@@	B-Chemical	D017374	19531695
ro@@	I-Chemical	-1	19531695
x@@	I-Chemical	-1	19531695
et@@	I-Chemical	-1	19531695
ine	I-Chemical	-1	19531695
,	O	-1	19531695
a	O	-1	19531695
C@@	O	-1	19531695
Y@@	O	-1	19531695
P@@	O	-1	19531695
2@@	O	-1	19531695
D@@	O	-1	19531695
6	O	-1	19531695
inhibitor@@	O	-1	19531695
,	O	-1	19531695
as	O	-1	19531695
well	O	-1	19531695
as	O	-1	19531695
3	O	-1	19531695
case	O	-1	19531695
reports	O	-1	19531695
of	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
-induced	O	-1	19531695
de@@	B-Disease	D003693	19531695
li@@	I-Disease	-1	19531695
ri@@	I-Disease	-1	19531695
um	I-Disease	-1	19531695
.	O	-1	19531695
Ac@@	O	-1	19531695
cor@@	O	-1	19531695
ding	O	-1	19531695
to	O	-1	19531695
the	O	-1	19531695
N@@	O	-1	19531695
ar@@	O	-1	19531695
an@@	O	-1	19531695
j@@	O	-1	19531695
o	O	-1	19531695
prob@@	O	-1	19531695
ability	O	-1	19531695
s@@	O	-1	19531695
cal@@	O	-1	19531695
e,	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
was	O	-1	19531695
the	O	-1	19531695
prob@@	O	-1	19531695
able	O	-1	19531695
cause	O	-1	19531695
of	O	-1	19531695
the	O	-1	19531695
patient@@	O	-1	19531695
's	O	-1	19531695
de@@	B-Disease	D003693	19531695
li@@	I-Disease	-1	19531695
ri@@	I-Disease	-1	19531695
um	I-Disease	-1	19531695
;	O	-1	19531695
the	O	-1	19531695
H@@	O	-1	19531695
or@@	O	-1	19531695
n	O	-1	19531695
D@@	O	-1	19531695
ru@@	O	-1	19531695
g	O	-1	19531695
In@@	O	-1	19531695
ter@@	O	-1	19531695
action	O	-1	19531695
Pro@@	O	-1	19531695
b@@	O	-1	19531695
ability	O	-1	19531695
S@@	O	-1	19531695
cal@@	O	-1	19531695
e	O	-1	19531695
indic@@	O	-1	19531695
ates	O	-1	19531695
a	O	-1	19531695
possible	O	-1	19531695
pharmac@@	O	-1	19531695
o@@	O	-1	19531695
kine@@	O	-1	19531695
tic	O	-1	19531695
drug	O	-1	19531695
inter@@	O	-1	19531695
action	O	-1	19531695
between	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
and	O	-1	19531695
pa@@	B-Chemical	D017374	19531695
ro@@	I-Chemical	-1	19531695
x@@	I-Chemical	-1	19531695
et@@	I-Chemical	-1	19531695
ine	I-Chemical	-1	19531695
.	O	-1	19531695
CONCLUSIONS:	O	-1	19531695
S@@	O	-1	19531695
up@@	O	-1	19531695
ra@@	O	-1	19531695
therapeutic	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
plasma	O	-1	19531695
concentrations	O	-1	19531695
may	O	-1	19531695
cause	O	-1	19531695
de@@	B-Disease	D003693	19531695
li@@	I-Disease	-1	19531695
ri@@	I-Disease	-1	19531695
um	I-Disease	-1	19531695
.	O	-1	19531695
B@@	O	-1	19531695
ecause	O	-1	19531695
toxicity	B-Disease	D064420	19531695
may	O	-1	19531695
occ@@	O	-1	19531695
ur	O	-1	19531695
when	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
is	O	-1	19531695
prescri@@	O	-1	19531695
bed	O	-1	19531695
with	O	-1	19531695
pa@@	B-Chemical	D017374	19531695
ro@@	I-Chemical	-1	19531695
x@@	I-Chemical	-1	19531695
et@@	I-Chemical	-1	19531695
ine	I-Chemical	-1	19531695
and	O	-1	19531695
other	O	-1	19531695
pot@@	O	-1	19531695
ent	O	-1	19531695
C@@	O	-1	19531695
Y@@	O	-1	19531695
P@@	O	-1	19531695
2@@	O	-1	19531695
D@@	O	-1	19531695
6	O	-1	19531695
inhibitor@@	O	-1	19531695
s,	O	-1	19531695
f@@	B-Chemical	D005424	19531695
l@@	I-Chemical	-1	19531695
ec@@	I-Chemical	-1	19531695
ain@@	I-Chemical	-1	19531695
ide	I-Chemical	-1	19531695
plasma	O	-1	19531695
concentrations	O	-1	19531695
should	O	-1	19531695
be	O	-1	19531695
monit@@	O	-1	19531695
o@@	O	-1	19531695
red	O	-1	19531695
clo@@	O	-1	19531695
se@@	O	-1	19531695
ly	O	-1	19531695
with	O	-1	19531695
comm@@	O	-1	19531695
ence@@	O	-1	19531695
ment	O	-1	19531695
of	O	-1	19531695
C@@	O	-1	19531695
Y@@	O	-1	19531695
P@@	O	-1	19531695
2@@	O	-1	19531695
D@@	O	-1	19531695
6	O	-1	19531695
inhibitor@@	O	-1	19531695
s.	O	-1	19531695

Eff@@	O	-1	19549709
icac@@	O	-1	19549709
y	O	-1	19549709
of	O	-1	19549709
e@@	B-Chemical	C107135	19549709
ver@@	I-Chemical	-1	19549709
ol@@	I-Chemical	-1	19549709
im@@	I-Chemical	-1	19549709
us	I-Chemical	-1	19549709
(	O	-1	19549709
R@@	B-Chemical	C107135	19549709
AD@@	I-Chemical	-1	19549709
0@@	I-Chemical	-1	19549709
0@@	I-Chemical	-1	19549709
1	I-Chemical	-1	19549709
)	O	-1	19549709
in	O	-1	19549709
patients	O	-1	19549709
with	O	-1	19549709
adv@@	O	-1	19549709
anced	O	-1	19549709
N@@	B-Disease	D002289	19549709
S@@	I-Disease	-1	19549709
CL@@	I-Disease	-1	19549709
C	I-Disease	-1	19549709
previously	O	-1	19549709
treated	O	-1	19549709
with	O	-1	19549709
chemotherapy	O	-1	19549709
alone	O	-1	19549709
or	O	-1	19549709
with	O	-1	19549709
chemotherapy	O	-1	19549709
and	O	-1	19549709
E@@	O	-1	19549709
GF@@	O	-1	19549709
R	O	-1	19549709
inhibitor@@	O	-1	19549709
s.	O	-1	19549709
BACKGROUND:	O	-1	19549709
Treat@@	O	-1	19549709
ment	O	-1	19549709
op@@	O	-1	19549709
tions	O	-1	19549709
are	O	-1	19549709
s@@	O	-1	19549709
car@@	O	-1	19549709
ce	O	-1	19549709
in	O	-1	19549709
pre@@	O	-1	19549709
treated	O	-1	19549709
adv@@	O	-1	19549709
anced	O	-1	19549709
non-@@	B-Disease	D002289	19549709
sm@@	I-Disease	-1	19549709
all@@	I-Disease	-1	19549709
-@@	I-Disease	-1	19549709
cell	I-Disease	-1	19549709
l@@	I-Disease	-1	19549709
un@@	I-Disease	-1	19549709
g	I-Disease	-1	19549709
cancer	I-Disease	-1	19549709
(	O	-1	19549709
N@@	B-Disease	D002289	19549709
S@@	I-Disease	-1	19549709
CL@@	I-Disease	-1	19549709
C	I-Disease	-1	19549709
)	O	-1	19549709
patients.	O	-1	19549709
R@@	B-Chemical	C107135	19549709
AD@@	I-Chemical	-1	19549709
0@@	I-Chemical	-1	19549709
0@@	I-Chemical	-1	19549709
1	I-Chemical	-1	19549709
,	O	-1	19549709
an	O	-1	19549709
oral	O	-1	19549709
inhibitor	O	-1	19549709
of	O	-1	19549709
the	O	-1	19549709
m@@	O	-1	19549709
am@@	O	-1	19549709
mal@@	O	-1	19549709
i@@	O	-1	19549709
an	O	-1	19549709
t@@	O	-1	19549709
arg@@	O	-1	19549709
et	O	-1	19549709
of	O	-1	19549709
ra@@	B-Chemical	D020123	19549709
p@@	I-Chemical	-1	19549709
am@@	I-Chemical	-1	19549709
ycin	I-Chemical	-1	19549709
(@@	O	-1	19549709
m@@	O	-1	19549709
T@@	O	-1	19549709
O@@	O	-1	19549709
R@@	O	-1	19549709
),	O	-1	19549709
has	O	-1	19549709
shown	O	-1	19549709
phase	O	-1	19549709
I	O	-1	19549709
efficacy	O	-1	19549709
in	O	-1	19549709
N@@	B-Disease	D002289	19549709
S@@	I-Disease	-1	19549709
CL@@	I-Disease	-1	19549709
C	I-Disease	-1	19549709
.	O	-1	19549709
METHODS:	O	-1	19549709
S@@	O	-1	19549709
t@@	O	-1	19549709
age	O	-1	19549709
II@@	O	-1	19549709
I@@	O	-1	19549709
b	O	-1	19549709
or	O	-1	19549709
IV	O	-1	19549709
N@@	B-Disease	D002289	19549709
S@@	I-Disease	-1	19549709
CL@@	I-Disease	-1	19549709
C	I-Disease	-1	19549709
patients,	O	-1	19549709
with	O	-1	19549709
two	O	-1	19549709
or	O	-1	19549709
fe@@	O	-1	19549709
w@@	O	-1	19549709
er	O	-1	19549709
prior	O	-1	19549709
chemotherapy	O	-1	19549709
regimen@@	O	-1	19549709
s,	O	-1	19549709
one	O	-1	19549709
pl@@	B-Chemical	D010984	19549709
at@@	I-Chemical	-1	19549709
in@@	I-Chemical	-1	19549709
um	I-Chemical	-1	19549709
bas@@	O	-1	19549709
ed	O	-1	19549709
(@@	O	-1	19549709
strat@@	O	-1	19549709
um	O	-1	19549709
1)	O	-1	19549709
or	O	-1	19549709
both	O	-1	19549709
chemotherapy	O	-1	19549709
and	O	-1	19549709
ep@@	O	-1	19549709
id@@	O	-1	19549709
er@@	O	-1	19549709
m@@	O	-1	19549709
al	O	-1	19549709
growth	O	-1	19549709
factor	O	-1	19549709
receptor	O	-1	19549709
ty@@	B-Chemical	D014443	19549709
ros@@	I-Chemical	-1	19549709
ine	I-Chemical	-1	19549709
kin@@	O	-1	19549709
ase	O	-1	19549709
inhibitors	O	-1	19549709
(@@	O	-1	19549709
strat@@	O	-1	19549709
um	O	-1	19549709
2@@	O	-1	19549709
),	O	-1	19549709
received	O	-1	19549709
R@@	B-Chemical	C107135	19549709
AD@@	I-Chemical	-1	19549709
0@@	I-Chemical	-1	19549709
0@@	I-Chemical	-1	19549709
1	I-Chemical	-1	19549709
10	O	-1	19549709
mg/@@	O	-1	19549709
day	O	-1	19549709
un@@	O	-1	19549709
ti@@	O	-1	19549709
l	O	-1	19549709
progres@@	O	-1	19549709
sion	O	-1	19549709
or	O	-1	19549709
un@@	O	-1	19549709
ac@@	O	-1	19549709
ce@@	O	-1	19549709
pt@@	O	-1	19549709
able	O	-1	19549709
toxicity	B-Disease	D064420	19549709
.	O	-1	19549709
P@@	O	-1	19549709
ri@@	O	-1	19549709
m@@	O	-1	19549709
ary	O	-1	19549709
ob@@	O	-1	19549709
j@@	O	-1	19549709
ective	O	-1	19549709
was	O	-1	19549709
over@@	O	-1	19549709
all	O	-1	19549709
response	O	-1	19549709
rate	O	-1	19549709
(@@	O	-1	19549709
O@@	O	-1	19549709
R@@	O	-1	19549709
R@@	O	-1	19549709
).	O	-1	19549709
An@@	O	-1	19549709
aly@@	O	-1	19549709
ses	O	-1	19549709
of	O	-1	19549709
mark@@	O	-1	19549709
ers	O	-1	19549709
associated	O	-1	19549709
with	O	-1	19549709
the	O	-1	19549709
m@@	O	-1	19549709
T@@	O	-1	19549709
O@@	O	-1	19549709
R	O	-1	19549709
path@@	O	-1	19549709
w@@	O	-1	19549709
ay	O	-1	19549709
were	O	-1	19549709
car@@	O	-1	19549709
ri@@	O	-1	19549709
ed	O	-1	19549709
out	O	-1	19549709
on	O	-1	19549709
ar@@	O	-1	19549709
ch@@	O	-1	19549709
i@@	O	-1	19549709
v@@	O	-1	19549709
al	O	-1	19549709
tumor	B-Disease	D009369	19549709
from	O	-1	19549709
a	O	-1	19549709
sub@@	O	-1	19549709
group	O	-1	19549709
using	O	-1	19549709
immuno@@	O	-1	19549709
histo@@	O	-1	19549709
chem@@	O	-1	19549709
ist@@	O	-1	19549709
r@@	O	-1	19549709
y	O	-1	19549709
(@@	O	-1	19549709
I@@	O	-1	19549709
HC@@	O	-1	19549709
)	O	-1	19549709
and	O	-1	19549709
direct	O	-1	19549709
mut@@	O	-1	19549709
ation	O	-1	19549709
sequ@@	O	-1	19549709
enc@@	O	-1	19549709
ing.	O	-1	19549709
RESULTS:	O	-1	19549709
E@@	O	-1	19549709
igh@@	O	-1	19549709
ty-@@	O	-1	19549709
five	O	-1	19549709
patients	O	-1	19549709
were	O	-1	19549709
en@@	O	-1	19549709
ro@@	O	-1	19549709
l@@	O	-1	19549709
le@@	O	-1	19549709
d,	O	-1	19549709
4@@	O	-1	19549709
2	O	-1	19549709
in	O	-1	19549709
strat@@	O	-1	19549709
um	O	-1	19549709
1	O	-1	19549709
and	O	-1	19549709
4@@	O	-1	19549709
3	O	-1	19549709
in	O	-1	19549709
strat@@	O	-1	19549709
um@@	O	-1	19549709
.	O	-1	19549709
O@@	O	-1	19549709
R@@	O	-1	19549709
R	O	-1	19549709
was	O	-1	19549709
4.@@	O	-1	19549709
7@@	O	-1	19549709
%	O	-1	19549709
(@@	O	-1	19549709
7.@@	O	-1	19549709
1@@	O	-1	19549709
%	O	-1	19549709
strat@@	O	-1	19549709
um	O	-1	19549709
1@@	O	-1	19549709
;	O	-1	19549709
2.@@	O	-1	19549709
3@@	O	-1	19549709
%	O	-1	19549709
strat@@	O	-1	19549709
um	O	-1	19549709
2@@	O	-1	19549709
).	O	-1	19549709
O@@	O	-1	19549709
ver@@	O	-1	19549709
all	O	-1	19549709
disease	O	-1	19549709
control	O	-1	19549709
rate	O	-1	19549709
was	O	-1	19549709
4@@	O	-1	19549709
7.@@	O	-1	19549709
1@@	O	-1	19549709
%.	O	-1	19549709
M@@	O	-1	19549709
edi@@	O	-1	19549709
an	O	-1	19549709
progres@@	O	-1	19549709
sion@@	O	-1	19549709
-@@	O	-1	19549709
free	O	-1	19549709
sur@@	O	-1	19549709
viv@@	O	-1	19549709
als	O	-1	19549709
(P@@	O	-1	19549709
F@@	O	-1	19549709
S@@	O	-1	19549709
s)	O	-1	19549709
were	O	-1	19549709
2.@@	O	-1	19549709
6	O	-1	19549709
(@@	O	-1	19549709
strat@@	O	-1	19549709
um	O	-1	19549709
1)	O	-1	19549709
and	O	-1	19549709
2.@@	O	-1	19549709
7	O	-1	19549709
months	O	-1	19549709
(@@	O	-1	19549709
strat@@	O	-1	19549709
um	O	-1	19549709
2@@	O	-1	19549709
).	O	-1	19549709
Com@@	O	-1	19549709
m@@	O	-1	19549709
on	O	-1	19549709
>	O	-1	19549709
or	O	-1	19549709
=@@	O	-1	19549709
gra@@	O	-1	19549709
de	O	-1	19549709
3	O	-1	19549709
events	O	-1	19549709
were	O	-1	19549709
f@@	B-Disease	D005221	19549709
ati@@	I-Disease	-1	19549709
gu@@	I-Disease	-1	19549709
e	I-Disease	-1	19549709
,	O	-1	19549709
dys@@	B-Disease	D004417	19549709
p@@	I-Disease	-1	19549709
ne@@	I-Disease	-1	19549709
a	I-Disease	-1	19549709
,	O	-1	19549709
st@@	B-Disease	D013280	19549709
om@@	I-Disease	-1	19549709
ati@@	I-Disease	-1	19549709
tis	I-Disease	-1	19549709
,	O	-1	19549709
anemia	B-Disease	D000740	19549709
,	O	-1	19549709
and	O	-1	19549709
throm@@	B-Disease	D013921	19549709
b@@	I-Disease	-1	19549709
ocyto@@	I-Disease	-1	19549709
pen@@	I-Disease	-1	19549709
ia	I-Disease	-1	19549709
.	O	-1	19549709
P@@	B-Disease	D011014	19549709
ne@@	I-Disease	-1	19549709
um@@	I-Disease	-1	19549709
on@@	I-Disease	-1	19549709
iti@@	I-Disease	-1	19549709
s	I-Disease	-1	19549709
,	O	-1	19549709
prob@@	O	-1	19549709
ably	O	-1	19549709
or	O	-1	19549709
possib@@	O	-1	19549709
ly	O	-1	19549709
rel@@	O	-1	19549709
at@@	O	-1	19549709
ed,	O	-1	19549709
main@@	O	-1	19549709
ly	O	-1	19549709
gra@@	O	-1	19549709
de	O	-1	19549709
1@@	O	-1	19549709
/@@	O	-1	19549709
2,	O	-1	19549709
occurred	O	-1	19549709
in	O	-1	19549709
25@@	O	-1	19549709
%.	O	-1	19549709
C@@	O	-1	19549709
o@@	O	-1	19549709
x	O	-1	19549709
reg@@	O	-1	19549709
res@@	O	-1	19549709
sion	O	-1	19549709
analysis	O	-1	19549709
of	O	-1	19549709
I@@	O	-1	19549709
H@@	O	-1	19549709
C	O	-1	19549709
sco@@	O	-1	19549709
res	O	-1	19549709
found	O	-1	19549709
that	O	-1	19549709
only	O	-1	19549709
phosph@@	O	-1	19549709
o	O	-1	19549709
A@@	O	-1	19549709
K@@	O	-1	19549709
T	O	-1	19549709
(p@@	O	-1	19549709
A@@	O	-1	19549709
K@@	O	-1	19549709
T)	O	-1	19549709
was	O	-1	19549709
a	O	-1	19549709
significant	O	-1	19549709
in@@	O	-1	19549709
dependent	O	-1	19549709
predic@@	O	-1	19549709
t@@	O	-1	19549709
or	O	-1	19549709
of	O	-1	19549709
wor@@	O	-1	19549709
se	O	-1	19549709
P@@	O	-1	19549709
F@@	O	-1	19549709
S@@	O	-1	19549709
.	O	-1	19549709
CONCLUSIONS:	O	-1	19549709
R@@	B-Chemical	C107135	19549709
AD@@	I-Chemical	-1	19549709
0@@	I-Chemical	-1	19549709
0@@	I-Chemical	-1	19549709
1	I-Chemical	-1	19549709
10	O	-1	19549709
mg/@@	O	-1	19549709
day	O	-1	19549709
was	O	-1	19549709
well	O	-1	19549709
toler@@	O	-1	19549709
at@@	O	-1	19549709
ed,	O	-1	19549709
show@@	O	-1	19549709
ing	O	-1	19549709
mod@@	O	-1	19549709
est	O	-1	19549709
clinical	O	-1	19549709
activity	O	-1	19549709
in	O	-1	19549709
pre@@	O	-1	19549709
treated	O	-1	19549709
N@@	B-Disease	D002289	19549709
S@@	I-Disease	-1	19549709
CL@@	I-Disease	-1	19549709
C	I-Disease	-1	19549709
.	O	-1	19549709
E@@	O	-1	19549709
valu@@	O	-1	19549709
ation	O	-1	19549709
of	O	-1	19549709
R@@	B-Chemical	C107135	19549709
AD@@	I-Chemical	-1	19549709
0@@	I-Chemical	-1	19549709
0@@	I-Chemical	-1	19549709
1	I-Chemical	-1	19549709
plus	O	-1	19549709
standard	O	-1	19549709
therapy	O	-1	19549709
for	O	-1	19549709
met@@	O	-1	19549709
ast@@	O	-1	19549709
atic	O	-1	19549709
N@@	B-Disease	D002289	19549709
S@@	I-Disease	-1	19549709
CL@@	I-Disease	-1	19549709
C	I-Disease	-1	19549709
continu@@	O	-1	19549709
es.	O	-1	19549709

P@@	O	-1	19553912
ost@@	O	-1	19553912
transplant	O	-1	19553912
anemia	B-Disease	D000740	19553912
:	O	-1	19553912
the	O	-1	19553912
role	O	-1	19553912
of	O	-1	19553912
sirolimus	B-Chemical	D020123	19553912
.	O	-1	19553912
P@@	O	-1	19553912
ost@@	O	-1	19553912
transplant	O	-1	19553912
anemia	B-Disease	D000740	19553912
is	O	-1	19553912
a	O	-1	19553912
common	O	-1	19553912
pro@@	O	-1	19553912
ble@@	O	-1	19553912
m	O	-1	19553912
that	O	-1	19553912
may	O	-1	19553912
h@@	O	-1	19553912
ind@@	O	-1	19553912
er	O	-1	19553912
patient@@	O	-1	19553912
s@@	O	-1	19553912
'	O	-1	19553912
qu@@	O	-1	19553912
ality	O	-1	19553912
of	O	-1	19553912
lif@@	O	-1	19553912
e.	O	-1	19553912
It	O	-1	19553912
occur@@	O	-1	19553912
s	O	-1	19553912
in	O	-1	19553912
12	O	-1	19553912
to	O	-1	19553912
7@@	O	-1	19553912
6%	O	-1	19553912
of	O	-1	19553912
patients,	O	-1	19553912
and	O	-1	19553912
is	O	-1	19553912
most	O	-1	19553912
common	O	-1	19553912
in	O	-1	19553912
the	O	-1	19553912
immedi@@	O	-1	19553912
ate	O	-1	19553912
post@@	O	-1	19553912
transplant	O	-1	19553912
perio@@	O	-1	19553912
d.	O	-1	19553912
A	O	-1	19553912
vari@@	O	-1	19553912
ety	O	-1	19553912
of	O	-1	19553912
factors	O	-1	19553912
have	O	-1	19553912
been	O	-1	19553912
identi@@	O	-1	19553912
fied	O	-1	19553912
that	O	-1	19553912
increase	O	-1	19553912
the	O	-1	19553912
risk	O	-1	19553912
of	O	-1	19553912
post@@	O	-1	19553912
transplant	O	-1	19553912
anemia	B-Disease	D000740	19553912
,	O	-1	19553912
of	O	-1	19553912
which	O	-1	19553912
the	O	-1	19553912
level	O	-1	19553912
of	O	-1	19553912
renal	O	-1	19553912
function	O	-1	19553912
is	O	-1	19553912
most	O	-1	19553912
import@@	O	-1	19553912
ant@@	O	-1	19553912
.	O	-1	19553912
Si@@	B-Chemical	D020123	19553912
rolimus	I-Chemical	-1	19553912
,	O	-1	19553912
a	O	-1	19553912
m@@	O	-1	19553912
am@@	O	-1	19553912
mal@@	O	-1	19553912
i@@	O	-1	19553912
an	O	-1	19553912
t@@	O	-1	19553912
arg@@	O	-1	19553912
et	O	-1	19553912
of	O	-1	19553912
ra@@	B-Chemical	D020123	19553912
p@@	I-Chemical	-1	19553912
am@@	I-Chemical	-1	19553912
ycin	I-Chemical	-1	19553912
inhibitor@@	O	-1	19553912
,	O	-1	19553912
has	O	-1	19553912
been	O	-1	19553912
implic@@	O	-1	19553912
ated	O	-1	19553912
as	O	-1	19553912
pl@@	O	-1	19553912
ay@@	O	-1	19553912
ing	O	-1	19553912
a	O	-1	19553912
spec@@	O	-1	19553912
ial	O	-1	19553912
role	O	-1	19553912
in	O	-1	19553912
post@@	O	-1	19553912
transplant	O	-1	19553912
anemia	B-Disease	D000740	19553912
.	O	-1	19553912
This	O	-1	19553912
revie@@	O	-1	19553912
w	O	-1	19553912
con@@	O	-1	19553912
si@@	O	-1	19553912
der@@	O	-1	19553912
s	O	-1	19553912
anemia	B-Disease	D000740	19553912
associated	O	-1	19553912
with	O	-1	19553912
sirolimus	B-Chemical	D020123	19553912
,	O	-1	19553912
including	O	-1	19553912
its	O	-1	19553912
present@@	O	-1	19553912
ation,	O	-1	19553912
mechanis@@	O	-1	19553912
m@@	O	-1	19553912
s,	O	-1	19553912
and	O	-1	19553912
man@@	O	-1	19553912
ag@@	O	-1	19553912
em@@	O	-1	19553912
ent@@	O	-1	19553912
.	O	-1	19553912

C@@	O	-1	19655282
or@@	O	-1	19655282
onary	O	-1	19655282
comp@@	O	-1	19655282
u@@	O	-1	19655282
ter@@	O	-1	19655282
ized	O	-1	19655282
to@@	O	-1	19655282
mo@@	O	-1	19655282
graph@@	O	-1	19655282
y	O	-1	19655282
angio@@	O	-1	19655282
graph@@	O	-1	19655282
y	O	-1	19655282
for	O	-1	19655282
ra@@	O	-1	19655282
pid	O	-1	19655282
dis@@	O	-1	19655282
ch@@	O	-1	19655282
arg@@	O	-1	19655282
e	O	-1	19655282
of	O	-1	19655282
low@@	O	-1	19655282
-@@	O	-1	19655282
risk	O	-1	19655282
patients	O	-1	19655282
with	O	-1	19655282
cocaine	B-Chemical	D003042	19655282
-@@	O	-1	19655282
associated	O	-1	19655282
ch@@	B-Disease	D002637	19655282
est	I-Disease	-1	19655282
pain	I-Disease	-1	19655282
.	O	-1	19655282
BACKGROUND:	O	-1	19655282
M@@	O	-1	19655282
ost	O	-1	19655282
patients	O	-1	19655282
present@@	O	-1	19655282
ing	O	-1	19655282
to	O	-1	19655282
em@@	O	-1	19655282
er@@	O	-1	19655282
gen@@	O	-1	19655282
c@@	O	-1	19655282
y	O	-1	19655282
de@@	O	-1	19655282
part@@	O	-1	19655282
ments	O	-1	19655282
(@@	O	-1	19655282
E@@	O	-1	19655282
D@@	O	-1	19655282
s)	O	-1	19655282
with	O	-1	19655282
cocaine	B-Chemical	D003042	19655282
-@@	O	-1	19655282
associated	O	-1	19655282
ch@@	B-Disease	D002637	19655282
est	I-Disease	-1	19655282
pain	I-Disease	-1	19655282
are	O	-1	19655282
ad@@	O	-1	19655282
mit@@	O	-1	19655282
ted	O	-1	19655282
for	O	-1	19655282
at	O	-1	19655282
le@@	O	-1	19655282
ast	O	-1	19655282
12	O	-1	19655282
hours	O	-1	19655282
and	O	-1	19655282
recei@@	O	-1	19655282
ve	O	-1	19655282
a	O	-1	19655282
"@@	O	-1	19655282
r@@	O	-1	19655282
ul@@	O	-1	19655282
e	O	-1	19655282
out	O	-1	19655282
acute	B-Disease	D054058	19655282
coronary	I-Disease	-1	19655282
syndrome	I-Disease	-1	19655282
"	O	-1	19655282
pro@@	O	-1	19655282
to@@	O	-1	19655282
co@@	O	-1	19655282
l@@	O	-1	19655282
,	O	-1	19655282
often	O	-1	19655282
with	O	-1	19655282
non@@	O	-1	19655282
inv@@	O	-1	19655282
a@@	O	-1	19655282
sive	O	-1	19655282
test@@	O	-1	19655282
ing	O	-1	19655282
prior	O	-1	19655282
to	O	-1	19655282
dis@@	O	-1	19655282
ch@@	O	-1	19655282
arg@@	O	-1	19655282
e.	O	-1	19655282
In	O	-1	19655282
patients	O	-1	19655282
without	O	-1	19655282
cocaine	B-Chemical	D003042	19655282
use@@	O	-1	19655282
,	O	-1	19655282
coronary	O	-1	19655282
comp@@	O	-1	19655282
u@@	O	-1	19655282
ter@@	O	-1	19655282
ized	O	-1	19655282
to@@	O	-1	19655282
mo@@	O	-1	19655282
graph@@	O	-1	19655282
y	O	-1	19655282
angio@@	O	-1	19655282
graph@@	O	-1	19655282
y	O	-1	19655282
(C@@	O	-1	19655282
TA@@	O	-1	19655282
)	O	-1	19655282
has	O	-1	19655282
been	O	-1	19655282
shown	O	-1	19655282
to	O	-1	19655282
be	O	-1	19655282
use@@	O	-1	19655282
ful	O	-1	19655282
for	O	-1	19655282
identi@@	O	-1	19655282
f@@	O	-1	19655282
y@@	O	-1	19655282
ing	O	-1	19655282
a	O	-1	19655282
group	O	-1	19655282
of	O	-1	19655282
patients	O	-1	19655282
at	O	-1	19655282
low	O	-1	19655282
risk	O	-1	19655282
for	O	-1	19655282
cardiac	O	-1	19655282
events	O	-1	19655282
who	O	-1	19655282
can	O	-1	19655282
be	O	-1	19655282
saf@@	O	-1	19655282
ely	O	-1	19655282
dis@@	O	-1	19655282
ch@@	O	-1	19655282
arg@@	O	-1	19655282
ed.	O	-1	19655282
It	O	-1	19655282
is	O	-1	19655282
unc@@	O	-1	19655282
le@@	O	-1	19655282
ar	O	-1	19655282
whether	O	-1	19655282
a	O	-1	19655282
coronary	O	-1	19655282
C@@	O	-1	19655282
T@@	O	-1	19655282
A	O	-1	19655282
strat@@	O	-1	19655282
e@@	O	-1	19655282
g@@	O	-1	19655282
y	O	-1	19655282
wo@@	O	-1	19655282
uld	O	-1	19655282
be	O	-1	19655282
efficac@@	O	-1	19655282
i@@	O	-1	19655282
ous	O	-1	19655282
in	O	-1	19655282
cocaine	B-Chemical	D003042	19655282
-@@	O	-1	19655282
associated	O	-1	19655282
ch@@	B-Disease	D002637	19655282
est	I-Disease	-1	19655282
pain	I-Disease	-1	19655282
,	O	-1	19655282
as	O	-1	19655282
coronary	B-Disease	D003329	19655282
vas@@	I-Disease	-1	19655282
os@@	I-Disease	-1	19655282
p@@	I-Disease	-1	19655282
as@@	I-Disease	-1	19655282
m	I-Disease	-1	19655282
may	O	-1	19655282
ac@@	O	-1	19655282
coun@@	O	-1	19655282
t	O	-1	19655282
for	O	-1	19655282
some	O	-1	19655282
of	O	-1	19655282
the	O	-1	19655282
ischem@@	B-Disease	D007511	19655282
ia	I-Disease	-1	19655282
.	O	-1	19655282
We	O	-1	19655282
studied	O	-1	19655282
whether	O	-1	19655282
a	O	-1	19655282
negative	O	-1	19655282
coronary	O	-1	19655282
C@@	O	-1	19655282
T@@	O	-1	19655282
A	O	-1	19655282
in	O	-1	19655282
patients	O	-1	19655282
with	O	-1	19655282
cocaine	B-Chemical	D003042	19655282
-@@	O	-1	19655282
associated	O	-1	19655282
ch@@	B-Disease	D002637	19655282
est	I-Disease	-1	19655282
pain	I-Disease	-1	19655282
could	O	-1	19655282
identi@@	O	-1	19655282
f@@	O	-1	19655282
y	O	-1	19655282
a	O	-1	19655282
sub@@	O	-1	19655282
set	O	-1	19655282
saf@@	O	-1	19655282
e	O	-1	19655282
for	O	-1	19655282
dis@@	O	-1	19655282
ch@@	O	-1	19655282
arg@@	O	-1	19655282
e.	O	-1	19655282
METHODS:	O	-1	19655282
We	O	-1	19655282
pro@@	O	-1	19655282
sp@@	O	-1	19655282
ectively	O	-1	19655282
evaluated	O	-1	19655282
the	O	-1	19655282
safety	O	-1	19655282
of	O	-1	19655282
coronary	O	-1	19655282
C@@	O	-1	19655282
T@@	O	-1	19655282
A	O	-1	19655282
for	O	-1	19655282
low@@	O	-1	19655282
-@@	O	-1	19655282
risk	O	-1	19655282
patients	O	-1	19655282
who	O	-1	19655282
presented	O	-1	19655282
to	O	-1	19655282
the	O	-1	19655282
E@@	O	-1	19655282
D	O	-1	19655282
with	O	-1	19655282
coca@@	O	-1	19655282
ine@@	O	-1	19655282
associated	O	-1	19655282
ch@@	B-Disease	D002637	19655282
est	I-Disease	-1	19655282
pain	I-Disease	-1	19655282
(@@	O	-1	19655282
sel@@	O	-1	19655282
f@@	O	-1	19655282
-@@	O	-1	19655282
reported	O	-1	19655282
or	O	-1	19655282
positive	O	-1	19655282
urine	O	-1	19655282
test@@	O	-1	19655282
).	O	-1	19655282
Con@@	O	-1	19655282
sec@@	O	-1	19655282
utive	O	-1	19655282
patients	O	-1	19655282
received	O	-1	19655282
either	O	-1	19655282
immedi@@	O	-1	19655282
ate	O	-1	19655282
coronary	O	-1	19655282
C@@	O	-1	19655282
T@@	O	-1	19655282
A	O	-1	19655282
in	O	-1	19655282
the	O	-1	19655282
E@@	O	-1	19655282
D	O	-1	19655282
(@@	O	-1	19655282
without	O	-1	19655282
ser@@	O	-1	19655282
ial	O	-1	19655282
mark@@	O	-1	19655282
er@@	O	-1	19655282
s)	O	-1	19655282
or	O	-1	19655282
under@@	O	-1	19655282
w@@	O	-1	19655282
ent	O	-1	19655282
coronary	O	-1	19655282
C@@	O	-1	19655282
T@@	O	-1	19655282
A	O	-1	19655282
after	O	-1	19655282
a	O	-1	19655282
b@@	O	-1	19655282
ri@@	O	-1	19655282
e@@	O	-1	19655282
f	O	-1	19655282
observ@@	O	-1	19655282
ation	O	-1	19655282
period	O	-1	19655282
with	O	-1	19655282
ser@@	O	-1	19655282
ial	O	-1	19655282
cardiac	O	-1	19655282
mark@@	O	-1	19655282
er	O	-1	19655282
meas@@	O	-1	19655282
ure@@	O	-1	19655282
ment@@	O	-1	19655282
s.	O	-1	19655282
Patients	O	-1	19655282
with	O	-1	19655282
negative	O	-1	19655282
coronary	O	-1	19655282
C@@	O	-1	19655282
T@@	O	-1	19655282
A	O	-1	19655282
(@@	O	-1	19655282
maxim@@	O	-1	19655282
al	O	-1	19655282
st@@	B-Disease	D003251	19655282
en@@	I-Disease	-1	19655282
o@@	I-Disease	-1	19655282
sis	I-Disease	-1	19655282
less	O	-1	19655282
than	O	-1	19655282
50@@	O	-1	19655282
%)	O	-1	19655282
were	O	-1	19655282
dis@@	O	-1	19655282
ch@@	O	-1	19655282
arg@@	O	-1	19655282
ed.	O	-1	19655282
The	O	-1	19655282
ma@@	O	-1	19655282
in	O	-1	19655282
outcom@@	O	-1	19655282
e	O	-1	19655282
was	O	-1	19655282
3@@	O	-1	19655282
0-@@	O	-1	19655282
day	O	-1	19655282
cardiovascular	O	-1	19655282
death	O	-1	19655282
or	O	-1	19655282
myocardial	B-Disease	D009203	19655282
infarction	I-Disease	-1	19655282
.	O	-1	19655282
RESULTS:	O	-1	19655282
A	O	-1	19655282
total	O	-1	19655282
of	O	-1	19655282
5@@	O	-1	19655282
9	O	-1	19655282
patients	O	-1	19655282
with	O	-1	19655282
cocaine	B-Chemical	D003042	19655282
-@@	O	-1	19655282
associated	O	-1	19655282
ch@@	B-Disease	D002637	19655282
est	I-Disease	-1	19655282
pain	I-Disease	-1	19655282
were	O	-1	19655282
evalu@@	O	-1	19655282
ated.	O	-1	19655282
Patients	O	-1	19655282
had	O	-1	19655282
a	O	-1	19655282
mean	O	-1	19655282
age	O	-1	19655282
of	O	-1	19655282
4@@	O	-1	19655282
5.@@	O	-1	19655282
6	O	-1	19655282
+/-	O	-1	19655282
6.@@	O	-1	19655282
6	O	-1	19655282
y@@	O	-1	19655282
r@@	O	-1	19655282
s	O	-1	19655282
and	O	-1	19655282
were	O	-1	19655282
8@@	O	-1	19655282
6%	O	-1	19655282
bl@@	O	-1	19655282
ac@@	O	-1	19655282
k@@	O	-1	19655282
,	O	-1	19655282
6@@	O	-1	19655282
6%	O	-1	19655282
mal@@	O	-1	19655282
e.	O	-1	19655282
S@@	O	-1	19655282
event@@	O	-1	19655282
y-@@	O	-1	19655282
n@@	O	-1	19655282
ine	O	-1	19655282
perc@@	O	-1	19655282
ent	O	-1	19655282
had	O	-1	19655282
a	O	-1	19655282
normal	O	-1	19655282
or	O	-1	19655282
non@@	O	-1	19655282
specific	O	-1	19655282
EC@@	O	-1	19655282
G	O	-1	19655282
and	O	-1	19655282
8@@	O	-1	19655282
5%	O	-1	19655282
had	O	-1	19655282
a	O	-1	19655282
TI@@	O	-1	19655282
M@@	O	-1	19655282
I	O	-1	19655282
scor@@	O	-1	19655282
e	O	-1	19655282
<@@	O	-1	19655282
2@@	O	-1	19655282
.	O	-1	19655282
Tw@@	O	-1	19655282
ent@@	O	-1	19655282
y	O	-1	19655282
patients	O	-1	19655282
received	O	-1	19655282
coronary	O	-1	19655282
C@@	O	-1	19655282
T@@	O	-1	19655282
A	O	-1	19655282
immedi@@	O	-1	19655282
ately	O	-1	19655282
in	O	-1	19655282
the	O	-1	19655282
E@@	O	-1	19655282
D@@	O	-1	19655282
,	O	-1	19655282
1@@	O	-1	19655282
8	O	-1	19655282
of	O	-1	19655282
whom	O	-1	19655282
were	O	-1	19655282
dis@@	O	-1	19655282
ch@@	O	-1	19655282
arg@@	O	-1	19655282
ed	O	-1	19655282
following	O	-1	19655282
C@@	O	-1	19655282
T@@	O	-1	19655282
A	O	-1	19655282
(@@	O	-1	19655282
9@@	O	-1	19655282
0@@	O	-1	19655282
%).	O	-1	19655282
Th@@	O	-1	19655282
ir@@	O	-1	19655282
ty-@@	O	-1	19655282
n@@	O	-1	19655282
ine	O	-1	19655282
received	O	-1	19655282
coronary	O	-1	19655282
C@@	O	-1	19655282
T@@	O	-1	19655282
A	O	-1	19655282
after	O	-1	19655282
a	O	-1	19655282
b@@	O	-1	19655282
ri@@	O	-1	19655282
e@@	O	-1	19655282
f	O	-1	19655282
observ@@	O	-1	19655282
ation	O	-1	19655282
perio@@	O	-1	19655282
d,	O	-1	19655282
with	O	-1	19655282
3@@	O	-1	19655282
7	O	-1	19655282
dis@@	O	-1	19655282
ch@@	O	-1	19655282
arg@@	O	-1	19655282
ed	O	-1	19655282
ho@@	O	-1	19655282
m@@	O	-1	19655282
e	O	-1	19655282
following	O	-1	19655282
C@@	O	-1	19655282
T@@	O	-1	19655282
A	O	-1	19655282
(@@	O	-1	19655282
9@@	O	-1	19655282
5@@	O	-1	19655282
%).	O	-1	19655282
Si@@	O	-1	19655282
x	O	-1	19655282
patients	O	-1	19655282
had	O	-1	19655282
coronary	B-Disease	D023921	19655282
st@@	I-Disease	-1	19655282
en@@	I-Disease	-1	19655282
o@@	I-Disease	-1	19655282
sis	I-Disease	-1	19655282
>@@	O	-1	19655282
or@@	O	-1	19655282
=@@	O	-1	19655282
50@@	O	-1	19655282
%.	O	-1	19655282
D@@	O	-1	19655282
uring	O	-1	19655282
the	O	-1	19655282
3@@	O	-1	19655282
0-@@	O	-1	19655282
day	O	-1	19655282
follow-up	O	-1	19655282
perio@@	O	-1	19655282
d,	O	-1	19655282
no	O	-1	19655282
patients	O	-1	19655282
di@@	O	-1	19655282
ed	O	-1	19655282
of	O	-1	19655282
a	O	-1	19655282
cardiovascular	O	-1	19655282
ev@@	O	-1	19655282
ent	O	-1	19655282
(@@	O	-1	19655282
0@@	O	-1	19655282
%@@	O	-1	19655282
;	O	-1	19655282
95%	O	-1	19655282
CI@@	O	-1	19655282
,	O	-1	19655282
0-@@	O	-1	19655282
6.@@	O	-1	19655282
1@@	O	-1	19655282
%)	O	-1	19655282
and	O	-1	19655282
no	O	-1	19655282
patient	O	-1	19655282
su@@	O	-1	19655282
st@@	O	-1	19655282
ained	O	-1	19655282
a	O	-1	19655282
non@@	O	-1	19655282
f@@	O	-1	19655282
atal	O	-1	19655282
myocardial	B-Disease	D009203	19655282
infarction	I-Disease	-1	19655282
(@@	O	-1	19655282
0@@	O	-1	19655282
%@@	O	-1	19655282
;	O	-1	19655282
95%	O	-1	19655282
CI@@	O	-1	19655282
,	O	-1	19655282
0-@@	O	-1	19655282
6.@@	O	-1	19655282
1@@	O	-1	19655282
%).	O	-1	19655282
CONCLUSIONS:	O	-1	19655282
Although	O	-1	19655282
cocaine	B-Chemical	D003042	19655282
-@@	O	-1	19655282
associated	O	-1	19655282
myocardial	B-Disease	D017202	19655282
ischem@@	I-Disease	-1	19655282
ia	I-Disease	-1	19655282
can	O	-1	19655282
result	O	-1	19655282
from	O	-1	19655282
coronary	O	-1	19655282
vas@@	O	-1	19655282
o@@	O	-1	19655282
con@@	O	-1	19655282
stric@@	O	-1	19655282
tion,	O	-1	19655282
patients	O	-1	19655282
with	O	-1	19655282
cocaine	B-Chemical	D003042	19655282
associated	O	-1	19655282
ch@@	B-Disease	D002637	19655282
est	I-Disease	-1	19655282
pain	I-Disease	-1	19655282
,	O	-1	19655282
a	O	-1	19655282
non@@	O	-1	19655282
-	O	-1	19655282
ischem@@	B-Disease	D007511	19655282
ic	I-Disease	-1	19655282
EC@@	O	-1	19655282
G@@	O	-1	19655282
,	O	-1	19655282
and	O	-1	19655282
a	O	-1	19655282
TI@@	O	-1	19655282
M@@	O	-1	19655282
I	O	-1	19655282
risk	O	-1	19655282
scor@@	O	-1	19655282
e	O	-1	19655282
<@@	O	-1	19655282
2	O	-1	19655282
may	O	-1	19655282
be	O	-1	19655282
saf@@	O	-1	19655282
ely	O	-1	19655282
dis@@	O	-1	19655282
ch@@	O	-1	19655282
arg@@	O	-1	19655282
ed	O	-1	19655282
from	O	-1	19655282
the	O	-1	19655282
E@@	O	-1	19655282
D	O	-1	19655282
after	O	-1	19655282
a	O	-1	19655282
negative	O	-1	19655282
coronary	O	-1	19655282
C@@	O	-1	19655282
T@@	O	-1	19655282
A	O	-1	19655282
with	O	-1	19655282
a	O	-1	19655282
low	O	-1	19655282
risk	O	-1	19655282
of	O	-1	19655282
3@@	O	-1	19655282
0-@@	O	-1	19655282
day	O	-1	19655282
adverse	O	-1	19655282
event@@	O	-1	19655282
s.	O	-1	19655282

L@@	O	-1	19715529
ate	O	-1	19715529
ful@@	O	-1	19715529
min@@	O	-1	19715529
ant	O	-1	19715529
po@@	B-Disease	D054038	19715529
ster@@	I-Disease	-1	19715529
ior	I-Disease	-1	19715529
reversible	I-Disease	-1	19715529
encephalo@@	I-Disease	-1	19715529
pathy	I-Disease	-1	19715529
syndrome	I-Disease	-1	19715529
after	O	-1	19715529
liver	O	-1	19715529
transplant@@	O	-1	19715529
.	O	-1	19715529
OBJECTIV@@	O	-1	19715529
E@@	O	-1	19715529
S:	O	-1	19715529
P@@	B-Disease	D054038	19715529
o@@	I-Disease	-1	19715529
ster@@	I-Disease	-1	19715529
ior	I-Disease	-1	19715529
leuk@@	I-Disease	-1	19715529
o@@	I-Disease	-1	19715529
encephalo@@	I-Disease	-1	19715529
pathy	I-Disease	-1	19715529
due	O	-1	19715529
to	O	-1	19715529
calc@@	O	-1	19715529
ine@@	O	-1	19715529
ur@@	O	-1	19715529
in-@@	O	-1	19715529
inhibitor@@	O	-1	19715529
-@@	O	-1	19715529
related	O	-1	19715529
neuro@@	B-Disease	D020258	19715529
toxicity	I-Disease	-1	19715529
is	O	-1	19715529
a	O	-1	19715529
r@@	O	-1	19715529
are	O	-1	19715529
but	O	-1	19715529
severe	O	-1	19715529
complication	O	-1	19715529
that	O	-1	19715529
results	O	-1	19715529
from	O	-1	19715529
treatment	O	-1	19715529
with	O	-1	19715529
immunosup@@	O	-1	19715529
pressive	O	-1	19715529
agents	O	-1	19715529
(@@	O	-1	19715529
prim@@	O	-1	19715529
ari@@	O	-1	19715529
ly	O	-1	19715529
those	O	-1	19715529
administered	O	-1	19715529
after	O	-1	19715529
a	O	-1	19715529
liver	O	-1	19715529
or	O	-1	19715529
kidney	O	-1	19715529
transplant@@	O	-1	19715529
).	O	-1	19715529
The	O	-1	19715529
path@@	O	-1	19715529
oph@@	O	-1	19715529
ysi@@	O	-1	19715529
ologic	O	-1	19715529
mechanisms	O	-1	19715529
of	O	-1	19715529
that	O	-1	19715529
disor@@	O	-1	19715529
der	O	-1	19715529
re@@	O	-1	19715529
ma@@	O	-1	19715529
in	O	-1	19715529
un@@	O	-1	19715529
know@@	O	-1	19715529
n@@	O	-1	19715529
.	O	-1	19715529
CA@@	O	-1	19715529
S@@	O	-1	19715529
E:	O	-1	19715529
We	O	-1	19715529
report	O	-1	19715529
the	O	-1	19715529
case	O	-1	19715529
of	O	-1	19715529
a	O	-1	19715529
4@@	O	-1	19715529
6-@@	O	-1	19715529
year-old	O	-1	19715529
woman	O	-1	19715529
who	O	-1	19715529
received	O	-1	19715529
a	O	-1	19715529
liver	O	-1	19715529
transplant	O	-1	19715529
in	O	-1	19715529
our	O	-1	19715529
c@@	O	-1	19715529
ent@@	O	-1	19715529
er	O	-1	19715529
as	O	-1	19715529
treatment	O	-1	19715529
for	O	-1	19715529
alco@@	B-Disease	D008104	19715529
h@@	I-Disease	-1	19715529
olic	I-Disease	-1	19715529
cir@@	I-Disease	-1	19715529
r@@	I-Disease	-1	19715529
ho@@	I-Disease	-1	19715529
sis	I-Disease	-1	19715529
and	O	-1	19715529
in	O	-1	19715529
whom	O	-1	19715529
either	O	-1	19715529
a	O	-1	19715529
ful@@	O	-1	19715529
min@@	O	-1	19715529
ant	O	-1	19715529
course	O	-1	19715529
of	O	-1	19715529
po@@	B-Disease	D054038	19715529
ster@@	I-Disease	-1	19715529
ior	I-Disease	-1	19715529
leuk@@	I-Disease	-1	19715529
o@@	I-Disease	-1	19715529
encephalo@@	I-Disease	-1	19715529
pathy	I-Disease	-1	19715529
or	O	-1	19715529
po@@	B-Disease	D054038	19715529
ster@@	I-Disease	-1	19715529
ior	I-Disease	-1	19715529
reversible	I-Disease	-1	19715529
encephalo@@	I-Disease	-1	19715529
pathy	I-Disease	-1	19715529
syndrome	I-Disease	-1	19715529
developed	O	-1	19715529
1@@	O	-1	19715529
10	O	-1	19715529
days	O	-1	19715529
after	O	-1	19715529
transplant@@	O	-1	19715529
.	O	-1	19715529
After	O	-1	19715529
an	O	-1	19715529
initi@@	O	-1	19715529
ally	O	-1	19715529
un@@	O	-1	19715529
event@@	O	-1	19715529
ful	O	-1	19715529
course	O	-1	19715529
after	O	-1	19715529
the	O	-1	19715529
transplant@@	O	-1	19715529
,	O	-1	19715529
the	O	-1	19715529
patient	O	-1	19715529
ra@@	O	-1	19715529
pid@@	O	-1	19715529
ly	O	-1	19715529
f@@	O	-1	19715529
el@@	O	-1	19715529
l	O	-1	19715529
into	O	-1	19715529
de@@	O	-1	19715529
ep	O	-1	19715529
com@@	O	-1	19715529
a.	O	-1	19715529
RESULTS:	O	-1	19715529
C@@	O	-1	19715529
e@@	O	-1	19715529
rebral	O	-1	19715529
MR@@	O	-1	19715529
I	O	-1	19715529
s@@	O	-1	19715529
can	O	-1	19715529
showed	O	-1	19715529
typ@@	O	-1	19715529
ical	O	-1	19715529
signs	O	-1	19715529
of	O	-1	19715529
enh@@	O	-1	19715529
ance@@	O	-1	19715529
ment	O	-1	19715529
in	O	-1	19715529
the	O	-1	19715529
p@@	O	-1	19715529
ont@@	O	-1	19715529
ine	O	-1	19715529
and	O	-1	19715529
po@@	O	-1	19715529
ster@@	O	-1	19715529
ior	O	-1	19715529
regi@@	O	-1	19715529
on@@	O	-1	19715529
s.	O	-1	19715529
S@@	O	-1	19715529
witch@@	O	-1	19715529
ing	O	-1	19715529
the	O	-1	19715529
immunosup@@	O	-1	19715529
pressive	O	-1	19715529
regi@@	O	-1	19715529
men	O	-1	19715529
from	O	-1	19715529
tacrolimus	B-Chemical	D016559	19715529
to	O	-1	19715529
cyclospor@@	B-Chemical	D016572	19715529
ine	I-Chemical	-1	19715529
did	O	-1	19715529
not	O	-1	19715529
impro@@	O	-1	19715529
ve	O	-1	19715529
the	O	-1	19715529
clinical	O	-1	19715529
sit@@	O	-1	19715529
u@@	O	-1	19715529
ation.	O	-1	19715529
The	O	-1	19715529
ter@@	O	-1	19715529
min@@	O	-1	19715529
ation	O	-1	19715529
of	O	-1	19715529
treatment	O	-1	19715529
with	O	-1	19715529
any	O	-1	19715529
calc@@	O	-1	19715529
ine@@	O	-1	19715529
ur@@	O	-1	19715529
in	O	-1	19715529
inhibitor	O	-1	19715529
resulted	O	-1	19715529
in	O	-1	19715529
a	O	-1	19715529
complete	O	-1	19715529
resol@@	O	-1	19715529
u@@	O	-1	19715529
tion	O	-1	19715529
of	O	-1	19715529
that	O	-1	19715529
complic@@	O	-1	19715529
ation.	O	-1	19715529
CONCLUSIONS:	O	-1	19715529
P@@	B-Disease	D054038	19715529
o@@	I-Disease	-1	19715529
ster@@	I-Disease	-1	19715529
ior	I-Disease	-1	19715529
reversible	I-Disease	-1	19715529
encephalo@@	I-Disease	-1	19715529
pathy	I-Disease	-1	19715529
syndrome	I-Disease	-1	19715529
after	O	-1	19715529
liver	O	-1	19715529
transplant	O	-1	19715529
is	O	-1	19715529
ra@@	O	-1	19715529
re.	O	-1	19715529
We	O	-1	19715529
recomm@@	O	-1	19715529
end	O	-1	19715529
a	O	-1	19715529
complete	O	-1	19715529
cess@@	O	-1	19715529
ation	O	-1	19715529
of	O	-1	19715529
any	O	-1	19715529
calc@@	O	-1	19715529
ine@@	O	-1	19715529
ur@@	O	-1	19715529
in	O	-1	19715529
inhibitor	O	-1	19715529
ra@@	O	-1	19715529
ther	O	-1	19715529
than	O	-1	19715529
a	O	-1	19715529
dose	O	-1	19715529
reduc@@	O	-1	19715529
tion.	O	-1	19715529

Pro@@	O	-1	19728177
long@@	O	-1	19728177
ed	O	-1	19728177
hypo@@	B-Disease	D007035	19728177
ther@@	I-Disease	-1	19728177
mia	I-Disease	-1	19728177
as	O	-1	19728177
a	O	-1	19728177
b@@	O	-1	19728177
ri@@	O	-1	19728177
d@@	O	-1	19728177
ge	O	-1	19728177
to	O	-1	19728177
recovery	O	-1	19728177
for	O	-1	19728177
cerebral	B-Disease	D001929	19728177
e@@	I-Disease	-1	19728177
de@@	I-Disease	-1	19728177
ma	I-Disease	-1	19728177
and	O	-1	19728177
intrac@@	B-Disease	D019586	19728177
ranial	I-Disease	-1	19728177
hypertension	I-Disease	-1	19728177
associated	O	-1	19728177
with	O	-1	19728177
ful@@	B-Disease	D017114	19728177
min@@	I-Disease	-1	19728177
ant	I-Disease	-1	19728177
hepatic	I-Disease	-1	19728177
failure	I-Disease	-1	19728177
.	O	-1	19728177
BACKGROUND:	O	-1	19728177
To	O	-1	19728177
revie@@	O	-1	19728177
w	O	-1	19728177
ev@@	O	-1	19728177
id@@	O	-1	19728177
ence@@	O	-1	19728177
-@@	O	-1	19728177
bas@@	O	-1	19728177
ed	O	-1	19728177
treatment	O	-1	19728177
op@@	O	-1	19728177
tions	O	-1	19728177
in	O	-1	19728177
patients	O	-1	19728177
with	O	-1	19728177
cerebral	B-Disease	D001929	19728177
e@@	I-Disease	-1	19728177
de@@	I-Disease	-1	19728177
ma	I-Disease	-1	19728177
complic@@	O	-1	19728177
ating	O	-1	19728177
ful@@	B-Disease	D017114	19728177
min@@	I-Disease	-1	19728177
ant	I-Disease	-1	19728177
hepatic	I-Disease	-1	19728177
failure	I-Disease	-1	19728177
(	O	-1	19728177
F@@	B-Disease	D017114	19728177
H@@	I-Disease	-1	19728177
F	I-Disease	-1	19728177
)	O	-1	19728177
and	O	-1	19728177
discus@@	O	-1	19728177
s	O	-1	19728177
the	O	-1	19728177
potential	O	-1	19728177
ap@@	O	-1	19728177
plic@@	O	-1	19728177
ations	O	-1	19728177
of	O	-1	19728177
hypo@@	B-Disease	D007035	19728177
ther@@	I-Disease	-1	19728177
mia	I-Disease	-1	19728177
.	O	-1	19728177
METHOD@@	O	-1	19728177
:	O	-1	19728177
C@@	O	-1	19728177
as@@	O	-1	19728177
e-@@	O	-1	19728177
bas@@	O	-1	19728177
ed	O	-1	19728177
observ@@	O	-1	19728177
ations	O	-1	19728177
from	O	-1	19728177
a	O	-1	19728177
med@@	O	-1	19728177
ical	O	-1	19728177
int@@	O	-1	19728177
en@@	O	-1	19728177
sive	O	-1	19728177
car@@	O	-1	19728177
e	O	-1	19728177
un@@	O	-1	19728177
it	O	-1	19728177
(@@	O	-1	19728177
M@@	O	-1	19728177
IC@@	O	-1	19728177
U@@	O	-1	19728177
)	O	-1	19728177
in	O	-1	19728177
a	O	-1	19728177
ter@@	O	-1	19728177
ti@@	O	-1	19728177
ary	O	-1	19728177
car@@	O	-1	19728177
e	O	-1	19728177
fac@@	O	-1	19728177
ility	O	-1	19728177
in	O	-1	19728177
a	O	-1	19728177
27@@	O	-1	19728177
-@@	O	-1	19728177
year-old	O	-1	19728177
female	O	-1	19728177
with	O	-1	19728177
F@@	B-Disease	D017114	19728177
H@@	I-Disease	-1	19728177
F	I-Disease	-1	19728177
from	O	-1	19728177
acet@@	B-Chemical	D000082	19728177
aminoph@@	I-Chemical	-1	19728177
en	I-Chemical	-1	19728177
and	O	-1	19728177
result@@	O	-1	19728177
ant	O	-1	19728177
cerebral	B-Disease	D001929	19728177
e@@	I-Disease	-1	19728177
de@@	I-Disease	-1	19728177
ma	I-Disease	-1	19728177
.	O	-1	19728177
RESULTS:	O	-1	19728177
Our	O	-1	19728177
patient	O	-1	19728177
was	O	-1	19728177
ad@@	O	-1	19728177
mit@@	O	-1	19728177
ted	O	-1	19728177
to	O	-1	19728177
the	O	-1	19728177
M@@	O	-1	19728177
IC@@	O	-1	19728177
U	O	-1	19728177
after	O	-1	19728177
being	O	-1	19728177
found	O	-1	19728177
un@@	O	-1	19728177
respon@@	O	-1	19728177
sive	O	-1	19728177
with	O	-1	19728177
pres@@	O	-1	19728177
um@@	O	-1	19728177
ed	O	-1	19728177
toxicity	B-Disease	D064420	19728177
from	O	-1	19728177
acet@@	B-Chemical	D000082	19728177
aminoph@@	I-Chemical	-1	19728177
en	I-Chemical	-1	19728177
which	O	-1	19728177
was	O	-1	19728177
ing@@	O	-1	19728177
est@@	O	-1	19728177
ed	O	-1	19728177
over	O	-1	19728177
a	O	-1	19728177
2-@@	O	-1	19728177
day	O	-1	19728177
perio@@	O	-1	19728177
d.	O	-1	19728177
The	O	-1	19728177
patient	O	-1	19728177
had	O	-1	19728177
depress@@	O	-1	19728177
ed	O	-1	19728177
of	O	-1	19728177
mental	O	-1	19728177
status	O	-1	19728177
l@@	O	-1	19728177
ast@@	O	-1	19728177
ing	O	-1	19728177
at	O	-1	19728177
le@@	O	-1	19728177
ast	O	-1	19728177
24	O	-1	19728177
h	O	-1	19728177
prior	O	-1	19728177
to	O	-1	19728177
ad@@	O	-1	19728177
mis@@	O	-1	19728177
sion.	O	-1	19728177
In@@	O	-1	19728177
iti@@	O	-1	19728177
al	O	-1	19728177
evalu@@	O	-1	19728177
ation	O	-1	19728177
con@@	O	-1	19728177
fir@@	O	-1	19728177
m@@	O	-1	19728177
ed	O	-1	19728177
F@@	B-Disease	D017114	19728177
H@@	I-Disease	-1	19728177
F	I-Disease	-1	19728177
from	O	-1	19728177
acet@@	B-Chemical	D000082	19728177
aminoph@@	I-Chemical	-1	19728177
en	I-Chemical	-1	19728177
and	O	-1	19728177
cerebral	B-Disease	D001929	19728177
e@@	I-Disease	-1	19728177
de@@	I-Disease	-1	19728177
ma	I-Disease	-1	19728177
.	O	-1	19728177
The	O	-1	19728177
patient	O	-1	19728177
was	O	-1	19728177
treated	O	-1	19728177
with	O	-1	19728177
hyper@@	O	-1	19728177
os@@	O	-1	19728177
mol@@	O	-1	19728177
ar	O	-1	19728177
therapy,	O	-1	19728177
hyper@@	B-Disease	D006985	19728177
ven@@	I-Disease	-1	19728177
til@@	I-Disease	-1	19728177
ation	I-Disease	-1	19728177
,	O	-1	19728177
sed@@	O	-1	19728177
ation,	O	-1	19728177
and	O	-1	19728177
chemical	O	-1	19728177
par@@	B-Disease	D010243	19728177
aly@@	I-Disease	-1	19728177
sis	I-Disease	-1	19728177
.	O	-1	19728177
H@@	O	-1	19728177
er	O	-1	19728177
intrac@@	O	-1	19728177
ranial	O	-1	19728177
pressure	O	-1	19728177
remained	O	-1	19728177
elevated	O	-1	19728177
des@@	O	-1	19728177
pit@@	O	-1	19728177
e	O	-1	19728177
maxim@@	O	-1	19728177
al	O	-1	19728177
med@@	O	-1	19728177
ical	O	-1	19728177
therapy.	O	-1	19728177
We	O	-1	19728177
then	O	-1	19728177
initi@@	O	-1	19728177
ated	O	-1	19728177
therapeutic	O	-1	19728177
hypo@@	B-Disease	D007035	19728177
ther@@	I-Disease	-1	19728177
mia	I-Disease	-1	19728177
which	O	-1	19728177
was	O	-1	19728177
continu@@	O	-1	19728177
ed	O	-1	19728177
for	O	-1	19728177
5	O	-1	19728177
days.	O	-1	19728177
A@@	O	-1	19728177
t	O	-1	19728177
re@@	O	-1	19728177
-@@	O	-1	19728177
war@@	O	-1	19728177
min@@	O	-1	19728177
g@@	O	-1	19728177
,	O	-1	19728177
patient	O	-1	19728177
had	O	-1	19728177
resol@@	O	-1	19728177
u@@	O	-1	19728177
tion	O	-1	19728177
of	O	-1	19728177
h@@	O	-1	19728177
er	O	-1	19728177
cerebral	B-Disease	D001929	19728177
e@@	I-Disease	-1	19728177
de@@	I-Disease	-1	19728177
ma	I-Disease	-1	19728177
and	O	-1	19728177
intrac@@	B-Disease	D019586	19728177
ranial	I-Disease	-1	19728177
hypertension	I-Disease	-1	19728177
.	O	-1	19728177
A@@	O	-1	19728177
t	O	-1	19728177
dis@@	O	-1	19728177
ch@@	O	-1	19728177
arg@@	O	-1	19728177
e,	O	-1	19728177
sh@@	O	-1	19728177
e	O	-1	19728177
had	O	-1	19728177
complete	O	-1	19728177
recovery	O	-1	19728177
of	O	-1	19728177
neurolog@@	O	-1	19728177
ical	O	-1	19728177
and	O	-1	19728177
hepatic	O	-1	19728177
func@@	O	-1	19728177
tions.	O	-1	19728177
CONCLUSION:	O	-1	19728177
In	O	-1	19728177
patients	O	-1	19728177
with	O	-1	19728177
F@@	B-Disease	D017114	19728177
H@@	I-Disease	-1	19728177
F	I-Disease	-1	19728177
and	O	-1	19728177
cerebral	B-Disease	D001929	19728177
e@@	I-Disease	-1	19728177
de@@	I-Disease	-1	19728177
ma	I-Disease	-1	19728177
from	O	-1	19728177
acet@@	B-Chemical	D000082	19728177
aminoph@@	I-Chemical	-1	19728177
en	I-Chemical	-1	19728177
over@@	B-Disease	D062787	19728177
dose	I-Disease	-1	19728177
,	O	-1	19728177
prolonged	O	-1	19728177
therapeutic	O	-1	19728177
hypo@@	B-Disease	D007035	19728177
ther@@	I-Disease	-1	19728177
mia	I-Disease	-1	19728177
could	O	-1	19728177
potenti@@	O	-1	19728177
ally	O	-1	19728177
be	O	-1	19728177
used	O	-1	19728177
as	O	-1	19728177
a	O	-1	19728177
lif@@	O	-1	19728177
e	O	-1	19728177
sa@@	O	-1	19728177
ving	O	-1	19728177
therapy	O	-1	19728177
and	O	-1	19728177
a	O	-1	19728177
b@@	O	-1	19728177
ri@@	O	-1	19728177
d@@	O	-1	19728177
ge	O	-1	19728177
to	O	-1	19728177
hepatic	O	-1	19728177
and	O	-1	19728177
neurolog@@	O	-1	19728177
ical	O	-1	19728177
reco@@	O	-1	19728177
ver@@	O	-1	19728177
y.	O	-1	19728177
A	O	-1	19728177
clinical	O	-1	19728177
trial	O	-1	19728177
of	O	-1	19728177
hypo@@	B-Disease	D007035	19728177
ther@@	I-Disease	-1	19728177
mia	I-Disease	-1	19728177
in	O	-1	19728177
patients	O	-1	19728177
with	O	-1	19728177
this	O	-1	19728177
condi@@	O	-1	19728177
tion	O	-1	19728177
is	O	-1	19728177
war@@	O	-1	19728177
ran@@	O	-1	19728177
ted.	O	-1	19728177

B@@	B-Disease	D014786	19815465
in@@	I-Disease	-1	19815465
as@@	I-Disease	-1	19815465
al	I-Disease	-1	19815465
visual	I-Disease	-1	19815465
fi@@	I-Disease	-1	19815465
el@@	I-Disease	-1	19815465
d	I-Disease	-1	19815465
def@@	I-Disease	-1	19815465
ects	I-Disease	-1	19815465
are	O	-1	19815465
not	O	-1	19815465
specific	O	-1	19815465
to	O	-1	19815465
vi@@	B-Chemical	D020888	19815465
g@@	I-Chemical	-1	19815465
ab@@	I-Chemical	-1	19815465
at@@	I-Chemical	-1	19815465
rin	I-Chemical	-1	19815465
.	O	-1	19815465
This	O	-1	19815465
study	O	-1	19815465
investigated	O	-1	19815465
the	O	-1	19815465
visual	B-Disease	D014786	19815465
def@@	I-Disease	-1	19815465
ects	I-Disease	-1	19815465
associated	O	-1	19815465
with	O	-1	19815465
the	O	-1	19815465
anti@@	O	-1	19815465
epileptic	O	-1	19815465
drug	O	-1	19815465
vi@@	B-Chemical	D020888	19815465
g@@	I-Chemical	-1	19815465
ab@@	I-Chemical	-1	19815465
at@@	I-Chemical	-1	19815465
rin	I-Chemical	-1	19815465
(	O	-1	19815465
V@@	B-Chemical	D020888	19815465
G@@	I-Chemical	-1	19815465
B	I-Chemical	-1	19815465
).	O	-1	19815465
Two	O	-1	19815465
h@@	O	-1	19815465
und@@	O	-1	19815465
red	O	-1	19815465
four	O	-1	19815465
pe@@	O	-1	19815465
o@@	O	-1	19815465
ple	O	-1	19815465
with	O	-1	19815465
epilep@@	B-Disease	D004827	19815465
sy	I-Disease	-1	19815465
were	O	-1	19815465
group@@	O	-1	19815465
ed	O	-1	19815465
on	O	-1	19815465
the	O	-1	19815465
b@@	O	-1	19815465
asis	O	-1	19815465
of	O	-1	19815465
anti@@	O	-1	19815465
epileptic	O	-1	19815465
drug	O	-1	19815465
therapy	O	-1	19815465
(@@	O	-1	19815465
cur@@	O	-1	19815465
ren@@	O	-1	19815465
t,	O	-1	19815465
previ@@	O	-1	19815465
ou@@	O	-1	19815465
s,	O	-1	19815465
or	O	-1	19815465
no	O	-1	19815465
exposure	O	-1	19815465
to	O	-1	19815465
V@@	B-Chemical	D020888	19815465
G@@	I-Chemical	-1	19815465
B	I-Chemical	-1	19815465
).	O	-1	19815465
Grou@@	O	-1	19815465
p@@	O	-1	19815465
s	O	-1	19815465
were	O	-1	19815465
mat@@	O	-1	19815465
ch@@	O	-1	19815465
ed	O	-1	19815465
with	O	-1	19815465
resp@@	O	-1	19815465
ect	O	-1	19815465
to	O	-1	19815465
age,	O	-1	19815465
gen@@	O	-1	19815465
der@@	O	-1	19815465
,	O	-1	19815465
and	O	-1	19815465
seizure	B-Disease	D012640	19815465
frequ@@	O	-1	19815465
enc@@	O	-1	19815465
y.	O	-1	19815465
All	O	-1	19815465
patients	O	-1	19815465
under@@	O	-1	19815465
w@@	O	-1	19815465
ent	O	-1	19815465
ob@@	O	-1	19815465
j@@	O	-1	19815465
ective	O	-1	19815465
assess@@	O	-1	19815465
ment	O	-1	19815465
of	O	-1	19815465
electro@@	O	-1	19815465
physi@@	O	-1	19815465
ological	O	-1	19815465
function	O	-1	19815465
(@@	O	-1	19815465
wi@@	O	-1	19815465
de@@	O	-1	19815465
-@@	O	-1	19815465
fi@@	O	-1	19815465
el@@	O	-1	19815465
d	O	-1	19815465
multi@@	O	-1	19815465
foc@@	O	-1	19815465
al	O	-1	19815465
electro@@	O	-1	19815465
ret@@	O	-1	19815465
in@@	O	-1	19815465
ograph@@	O	-1	19815465
y@@	O	-1	19815465
)	O	-1	19815465
and	O	-1	19815465
con@@	O	-1	19815465
ven@@	O	-1	19815465
tional	O	-1	19815465
visual	O	-1	19815465
fi@@	O	-1	19815465
el@@	O	-1	19815465
d	O	-1	19815465
test@@	O	-1	19815465
ing	O	-1	19815465
(@@	O	-1	19815465
st@@	O	-1	19815465
atic	O	-1	19815465
peri@@	O	-1	19815465
met@@	O	-1	19815465
r@@	O	-1	19815465
y@@	O	-1	19815465
).	O	-1	19815465
B@@	O	-1	19815465
il@@	O	-1	19815465
ateral	O	-1	19815465
visual	O	-1	19815465
fi@@	O	-1	19815465
el@@	O	-1	19815465
d	O	-1	19815465
con@@	O	-1	19815465
stric@@	O	-1	19815465
tion	O	-1	19815465
was	O	-1	19815465
observed	O	-1	19815465
in	O	-1	19815465
5@@	O	-1	19815465
9@@	O	-1	19815465
%	O	-1	19815465
of	O	-1	19815465
patients	O	-1	19815465
cur@@	O	-1	19815465
ren@@	O	-1	19815465
tly	O	-1	19815465
taking	O	-1	19815465
V@@	B-Chemical	D020888	19815465
G@@	I-Chemical	-1	19815465
B	I-Chemical	-1	19815465
,	O	-1	19815465
4@@	O	-1	19815465
3@@	O	-1	19815465
%	O	-1	19815465
of	O	-1	19815465
patients	O	-1	19815465
who	O	-1	19815465
previously	O	-1	19815465
to@@	O	-1	19815465
o@@	O	-1	19815465
k	O	-1	19815465
V@@	B-Chemical	D020888	19815465
G@@	I-Chemical	-1	19815465
B	I-Chemical	-1	19815465
,	O	-1	19815465
and	O	-1	19815465
2@@	O	-1	19815465
4@@	O	-1	19815465
%	O	-1	19815465
of	O	-1	19815465
patients	O	-1	19815465
with	O	-1	19815465
no	O	-1	19815465
exposure	O	-1	19815465
to	O	-1	19815465
V@@	B-Chemical	D020888	19815465
G@@	I-Chemical	-1	19815465
B	I-Chemical	-1	19815465
.	O	-1	19815465
A@@	O	-1	19815465
s@@	O	-1	19815465
s@@	O	-1	19815465
ess@@	O	-1	19815465
ment	O	-1	19815465
of	O	-1	19815465
ret@@	O	-1	19815465
inal	O	-1	19815465
function	O	-1	19815465
revealed	O	-1	19815465
ab@@	O	-1	19815465
normal	O	-1	19815465
responses	O	-1	19815465
in	O	-1	19815465
4@@	O	-1	19815465
8@@	O	-1	19815465
%	O	-1	19815465
of	O	-1	19815465
current	O	-1	19815465
V@@	B-Chemical	D020888	19815465
G@@	I-Chemical	-1	19815465
B	I-Chemical	-1	19815465
users	O	-1	19815465
and	O	-1	19815465
2@@	O	-1	19815465
2@@	O	-1	19815465
%	O	-1	19815465
of	O	-1	19815465
prior	O	-1	19815465
V@@	B-Chemical	D020888	19815465
G@@	I-Chemical	-1	19815465
B	I-Chemical	-1	19815465
us@@	O	-1	19815465
er@@	O	-1	19815465
s,	O	-1	19815465
but	O	-1	19815465
in	O	-1	19815465
n@@	O	-1	19815465
one	O	-1	19815465
of	O	-1	19815465
the	O	-1	19815465
patients	O	-1	19815465
without	O	-1	19815465
previ@@	O	-1	19815465
ous	O	-1	19815465
exposure	O	-1	19815465
to	O	-1	19815465
V@@	B-Chemical	D020888	19815465
G@@	I-Chemical	-1	19815465
B	I-Chemical	-1	19815465
.	O	-1	19815465
B@@	B-Disease	D014786	19815465
il@@	I-Disease	-1	19815465
ateral	I-Disease	-1	19815465
visual	I-Disease	-1	19815465
fi@@	I-Disease	-1	19815465
el@@	I-Disease	-1	19815465
d	I-Disease	-1	19815465
abnormal@@	I-Disease	-1	19815465
ities	I-Disease	-1	19815465
are	O	-1	19815465
common	O	-1	19815465
in	O	-1	19815465
the	O	-1	19815465
treated	O	-1	19815465
epilep@@	B-Disease	D004827	19815465
sy	I-Disease	-1	19815465
po@@	O	-1	19815465
pul@@	O	-1	19815465
ation,	O	-1	19815465
ir@@	O	-1	19815465
resp@@	O	-1	19815465
ective	O	-1	19815465
of	O	-1	19815465
drug	O	-1	19815465
hist@@	O	-1	19815465
or@@	O	-1	19815465
y.	O	-1	19815465
A@@	O	-1	19815465
s@@	O	-1	19815465
s@@	O	-1	19815465
ess@@	O	-1	19815465
ment	O	-1	19815465
by	O	-1	19815465
con@@	O	-1	19815465
ven@@	O	-1	19815465
tional	O	-1	19815465
st@@	O	-1	19815465
atic	O	-1	19815465
peri@@	O	-1	19815465
met@@	O	-1	19815465
r@@	O	-1	19815465
y	O	-1	19815465
may	O	-1	19815465
ne@@	O	-1	19815465
ither	O	-1	19815465
be	O	-1	19815465
suffici@@	O	-1	19815465
ently	O	-1	19815465
sensitive	O	-1	19815465
n@@	O	-1	19815465
or	O	-1	19815465
specific	O	-1	19815465
to	O	-1	19815465
re@@	O	-1	19815465
li@@	O	-1	19815465
ably	O	-1	19815465
identi@@	O	-1	19815465
f@@	O	-1	19815465
y	O	-1	19815465
ret@@	B-Disease	D012164	19815465
inal	I-Disease	-1	19815465
toxicity	I-Disease	-1	19815465
associated	O	-1	19815465
with	O	-1	19815465
V@@	B-Chemical	D020888	19815465
G@@	I-Chemical	-1	19815465
B	I-Chemical	-1	19815465
.	O	-1	19815465

S@@	O	-1	19841052
mo@@	O	-1	19841052
king	O	-1	19841052
of	O	-1	19841052
c@@	B-Chemical	D016578	19841052
rac@@	I-Chemical	-1	19841052
k	I-Chemical	-1	19841052
cocaine	I-Chemical	-1	19841052
as	O	-1	19841052
a	O	-1	19841052
risk	O	-1	19841052
factor	O	-1	19841052
for	O	-1	19841052
H@@	B-Disease	D015658	19841052
IV	I-Disease	-1	19841052
inf@@	I-Disease	-1	19841052
ection	I-Disease	-1	19841052
among	O	-1	19841052
pe@@	O	-1	19841052
o@@	O	-1	19841052
ple	O	-1	19841052
who	O	-1	19841052
use	O	-1	19841052
injection	O	-1	19841052
drug@@	O	-1	19841052
s.	O	-1	19841052
BACKGROUND:	O	-1	19841052
L@@	O	-1	19841052
it@@	O	-1	19841052
t@@	O	-1	19841052
le	O	-1	19841052
is	O	-1	19841052
known	O	-1	19841052
about	O	-1	19841052
the	O	-1	19841052
possible	O	-1	19841052
role	O	-1	19841052
that	O	-1	19841052
smo@@	O	-1	19841052
king	O	-1	19841052
c@@	B-Chemical	D016578	19841052
rac@@	I-Chemical	-1	19841052
k	I-Chemical	-1	19841052
cocaine	I-Chemical	-1	19841052
has	O	-1	19841052
on	O	-1	19841052
the	O	-1	19841052
incidence	O	-1	19841052
of	O	-1	19841052
H@@	B-Disease	D015658	19841052
IV	I-Disease	-1	19841052
inf@@	I-Disease	-1	19841052
ection	I-Disease	-1	19841052
.	O	-1	19841052
G@@	O	-1	19841052
i@@	O	-1	19841052
ven	O	-1	19841052
the	O	-1	19841052
increas@@	O	-1	19841052
ing	O	-1	19841052
use	O	-1	19841052
of	O	-1	19841052
c@@	B-Chemical	D016578	19841052
rac@@	I-Chemical	-1	19841052
k	I-Chemical	-1	19841052
cocaine	I-Chemical	-1	19841052
,	O	-1	19841052
we	O	-1	19841052
s@@	O	-1	19841052
ou@@	O	-1	19841052
ght	O	-1	19841052
to	O	-1	19841052
ex@@	O	-1	19841052
amine	O	-1	19841052
whether	O	-1	19841052
use	O	-1	19841052
of	O	-1	19841052
this	O	-1	19841052
ill@@	O	-1	19841052
ic@@	O	-1	19841052
it	O	-1	19841052
drug	O	-1	19841052
has	O	-1	19841052
b@@	O	-1	19841052
ec@@	O	-1	19841052
ome	O	-1	19841052
a	O	-1	19841052
risk	O	-1	19841052
factor	O	-1	19841052
for	O	-1	19841052
H@@	B-Disease	D015658	19841052
IV	I-Disease	-1	19841052
inf@@	I-Disease	-1	19841052
ection	I-Disease	-1	19841052
.	O	-1	19841052
METHODS:	O	-1	19841052
We	O	-1	19841052
included	O	-1	19841052
data	O	-1	19841052
from	O	-1	19841052
pe@@	O	-1	19841052
o@@	O	-1	19841052
ple	O	-1	19841052
partic@@	O	-1	19841052
ip@@	O	-1	19841052
ating	O	-1	19841052
in	O	-1	19841052
the	O	-1	19841052
V@@	O	-1	19841052
an@@	O	-1	19841052
co@@	O	-1	19841052
u@@	O	-1	19841052
ver	O	-1	19841052
In@@	O	-1	19841052
j@@	O	-1	19841052
ection	O	-1	19841052
D@@	O	-1	19841052
ru@@	O	-1	19841052
g	O	-1	19841052
U@@	O	-1	19841052
ser@@	O	-1	19841052
s	O	-1	19841052
S@@	O	-1	19841052
t@@	O	-1	19841052
ud@@	O	-1	19841052
y	O	-1	19841052
who	O	-1	19841052
reported	O	-1	19841052
inj@@	O	-1	19841052
ect@@	O	-1	19841052
ing	O	-1	19841052
ill@@	O	-1	19841052
ic@@	O	-1	19841052
it	O	-1	19841052
drugs	O	-1	19841052
at	O	-1	19841052
le@@	O	-1	19841052
ast	O	-1	19841052
on@@	O	-1	19841052
ce	O	-1	19841052
in	O	-1	19841052
the	O	-1	19841052
mon@@	O	-1	19841052
th	O	-1	19841052
before	O	-1	19841052
en@@	O	-1	19841052
ro@@	O	-1	19841052
l@@	O	-1	19841052
ment@@	O	-1	19841052
,	O	-1	19841052
li@@	O	-1	19841052
ved	O	-1	19841052
in	O	-1	19841052
the	O	-1	19841052
greater	O	-1	19841052
V@@	O	-1	19841052
an@@	O	-1	19841052
co@@	O	-1	19841052
u@@	O	-1	19841052
ver	O	-1	19841052
a@@	O	-1	19841052
re@@	O	-1	19841052
a,	O	-1	19841052
were	O	-1	19841052
H@@	O	-1	19841052
I@@	O	-1	19841052
V@@	O	-1	19841052
-@@	O	-1	19841052
negative	O	-1	19841052
at	O	-1	19841052
en@@	O	-1	19841052
ro@@	O	-1	19841052
l@@	O	-1	19841052
ment	O	-1	19841052
and	O	-1	19841052
comple@@	O	-1	19841052
ted	O	-1	19841052
at	O	-1	19841052
le@@	O	-1	19841052
ast	O	-1	19841052
1	O	-1	19841052
follow-up	O	-1	19841052
study	O	-1	19841052
v@@	O	-1	19841052
is@@	O	-1	19841052
it@@	O	-1	19841052
.	O	-1	19841052
To	O	-1	19841052
determine	O	-1	19841052
whether	O	-1	19841052
the	O	-1	19841052
risk	O	-1	19841052
of	O	-1	19841052
H@@	B-Disease	D006679	19841052
IV	I-Disease	-1	19841052
ser@@	I-Disease	-1	19841052
o@@	I-Disease	-1	19841052
conver@@	I-Disease	-1	19841052
sion	I-Disease	-1	19841052
among	O	-1	19841052
daily	O	-1	19841052
smo@@	O	-1	19841052
k@@	O	-1	19841052
ers	O	-1	19841052
of	O	-1	19841052
c@@	B-Chemical	D016578	19841052
rac@@	I-Chemical	-1	19841052
k	I-Chemical	-1	19841052
cocaine	I-Chemical	-1	19841052
chang@@	O	-1	19841052
ed	O	-1	19841052
over	O	-1	19841052
ti@@	O	-1	19841052
me,	O	-1	19841052
we	O	-1	19841052
used	O	-1	19841052
C@@	O	-1	19841052
o@@	O	-1	19841052
x	O	-1	19841052
pro@@	O	-1	19841052
por@@	O	-1	19841052
tional	O	-1	19841052
ha@@	O	-1	19841052
z@@	O	-1	19841052
ar@@	O	-1	19841052
ds	O	-1	19841052
reg@@	O	-1	19841052
res@@	O	-1	19841052
sion	O	-1	19841052
and	O	-1	19841052
divid@@	O	-1	19841052
ed	O	-1	19841052
the	O	-1	19841052
study	O	-1	19841052
into	O	-1	19841052
3	O	-1	19841052
perio@@	O	-1	19841052
d@@	O	-1	19841052
s:	O	-1	19841052
M@@	O	-1	19841052
ay	O	-1	19841052
1,	O	-1	19841052
19@@	O	-1	19841052
9@@	O	-1	19841052
6-@@	O	-1	19841052
N@@	O	-1	19841052
o@@	O	-1	19841052
v@@	O	-1	19841052
.	O	-1	19841052
3@@	O	-1	19841052
0@@	O	-1	19841052
,	O	-1	19841052
19@@	O	-1	19841052
9@@	O	-1	19841052
9	O	-1	19841052
(@@	O	-1	19841052
period	O	-1	19841052
1),	O	-1	19841052
D@@	O	-1	19841052
ec@@	O	-1	19841052
.	O	-1	19841052
1,	O	-1	19841052
19@@	O	-1	19841052
9@@	O	-1	19841052
9@@	O	-1	19841052
-@@	O	-1	19841052
N@@	O	-1	19841052
o@@	O	-1	19841052
v@@	O	-1	19841052
.	O	-1	19841052
3@@	O	-1	19841052
0@@	O	-1	19841052
,	O	-1	19841052
20@@	O	-1	19841052
0@@	O	-1	19841052
2	O	-1	19841052
(@@	O	-1	19841052
period	O	-1	19841052
2@@	O	-1	19841052
),	O	-1	19841052
and	O	-1	19841052
D@@	O	-1	19841052
ec@@	O	-1	19841052
.	O	-1	19841052
1,	O	-1	19841052
20@@	O	-1	19841052
0@@	O	-1	19841052
2-@@	O	-1	19841052
D@@	O	-1	19841052
ec@@	O	-1	19841052
.	O	-1	19841052
3@@	O	-1	19841052
0@@	O	-1	19841052
,	O	-1	19841052
20@@	O	-1	19841052
0@@	O	-1	19841052
5	O	-1	19841052
(@@	O	-1	19841052
period	O	-1	19841052
3@@	O	-1	19841052
).	O	-1	19841052
RESULTS:	O	-1	19841052
O@@	O	-1	19841052
ver@@	O	-1	19841052
all@@	O	-1	19841052
,	O	-1	19841052
10@@	O	-1	19841052
4@@	O	-1	19841052
8	O	-1	19841052
e@@	O	-1	19841052
li@@	O	-1	19841052
gi@@	O	-1	19841052
ble	O	-1	19841052
injection	O	-1	19841052
drug	O	-1	19841052
users	O	-1	19841052
were	O	-1	19841052
included	O	-1	19841052
in	O	-1	19841052
our	O	-1	19841052
study.	O	-1	19841052
Of	O	-1	19841052
th@@	O	-1	19841052
es@@	O	-1	19841052
e,	O	-1	19841052
13@@	O	-1	19841052
7	O	-1	19841052
ac@@	O	-1	19841052
qu@@	O	-1	19841052
ired	O	-1	19841052
H@@	B-Disease	D015658	19841052
IV	I-Disease	-1	19841052
inf@@	I-Disease	-1	19841052
ection	I-Disease	-1	19841052
during	O	-1	19841052
follow-@@	O	-1	19841052
up@@	O	-1	19841052
.	O	-1	19841052
The	O	-1	19841052
mean	O	-1	19841052
pro@@	O	-1	19841052
por@@	O	-1	19841052
tion	O	-1	19841052
of	O	-1	19841052
partic@@	O	-1	19841052
ip@@	O	-1	19841052
ants	O	-1	19841052
who	O	-1	19841052
reported	O	-1	19841052
daily	O	-1	19841052
smo@@	O	-1	19841052
king	O	-1	19841052
of	O	-1	19841052
c@@	B-Chemical	D016578	19841052
rac@@	I-Chemical	-1	19841052
k	I-Chemical	-1	19841052
cocaine	I-Chemical	-1	19841052
increased	O	-1	19841052
from	O	-1	19841052
1@@	O	-1	19841052
1.@@	O	-1	19841052
6%	O	-1	19841052
in	O	-1	19841052
period	O	-1	19841052
1	O	-1	19841052
to	O	-1	19841052
3@@	O	-1	19841052
9.@@	O	-1	19841052
7@@	O	-1	19841052
%	O	-1	19841052
in	O	-1	19841052
period	O	-1	19841052
3@@	O	-1	19841052
.	O	-1	19841052
After	O	-1	19841052
adjust@@	O	-1	19841052
ing	O	-1	19841052
for	O	-1	19841052
potential	O	-1	19841052
conf@@	O	-1	19841052
oun@@	O	-1	19841052
der@@	O	-1	19841052
s,	O	-1	19841052
we	O	-1	19841052
found	O	-1	19841052
that	O	-1	19841052
the	O	-1	19841052
risk	O	-1	19841052
of	O	-1	19841052
H@@	B-Disease	D006679	19841052
IV	I-Disease	-1	19841052
ser@@	I-Disease	-1	19841052
o@@	I-Disease	-1	19841052
conver@@	I-Disease	-1	19841052
sion	I-Disease	-1	19841052
among	O	-1	19841052
partic@@	O	-1	19841052
ip@@	O	-1	19841052
ants	O	-1	19841052
who	O	-1	19841052
were	O	-1	19841052
daily	O	-1	19841052
smo@@	O	-1	19841052
k@@	O	-1	19841052
ers	O	-1	19841052
of	O	-1	19841052
c@@	B-Chemical	D016578	19841052
rac@@	I-Chemical	-1	19841052
k	I-Chemical	-1	19841052
cocaine	I-Chemical	-1	19841052
increased	O	-1	19841052
over	O	-1	19841052
time	O	-1	19841052
(@@	O	-1	19841052
period	O	-1	19841052
1@@	O	-1	19841052
:	O	-1	19841052
ha@@	O	-1	19841052
z@@	O	-1	19841052
ard	O	-1	19841052
rati@@	O	-1	19841052
o	O	-1	19841052
[@@	O	-1	19841052
H@@	O	-1	19841052
R@@	O	-1	19841052
]	O	-1	19841052
1.@@	O	-1	19841052
0@@	O	-1	19841052
3,	O	-1	19841052
95%	O	-1	19841052
conf@@	O	-1	19841052
idence	O	-1	19841052
interv@@	O	-1	19841052
al	O	-1	19841052
[@@	O	-1	19841052
CI@@	O	-1	19841052
]	O	-1	19841052
0.@@	O	-1	19841052
5@@	O	-1	19841052
7-@@	O	-1	19841052
1.@@	O	-1	19841052
8@@	O	-1	19841052
5@@	O	-1	19841052
;	O	-1	19841052
period	O	-1	19841052
2@@	O	-1	19841052
:	O	-1	19841052
H@@	O	-1	19841052
R	O	-1	19841052
1.@@	O	-1	19841052
6@@	O	-1	19841052
8@@	O	-1	19841052
,	O	-1	19841052
95%	O	-1	19841052
C@@	O	-1	19841052
I	O	-1	19841052
1.@@	O	-1	19841052
0@@	O	-1	19841052
1-@@	O	-1	19841052
2.@@	O	-1	19841052
80@@	O	-1	19841052
;	O	-1	19841052
and	O	-1	19841052
period	O	-1	19841052
3@@	O	-1	19841052
:	O	-1	19841052
H@@	O	-1	19841052
R	O	-1	19841052
2.@@	O	-1	19841052
7@@	O	-1	19841052
4@@	O	-1	19841052
,	O	-1	19841052
95%	O	-1	19841052
C@@	O	-1	19841052
I	O	-1	19841052
1.@@	O	-1	19841052
0@@	O	-1	19841052
6-@@	O	-1	19841052
7.@@	O	-1	19841052
1@@	O	-1	19841052
1).	O	-1	19841052
IN@@	O	-1	19841052
TE@@	O	-1	19841052
R@@	O	-1	19841052
P@@	O	-1	19841052
R@@	O	-1	19841052
ET@@	O	-1	19841052
AT@@	O	-1	19841052
ION@@	O	-1	19841052
:	O	-1	19841052
S@@	O	-1	19841052
mo@@	O	-1	19841052
king	O	-1	19841052
of	O	-1	19841052
c@@	B-Chemical	D016578	19841052
rac@@	I-Chemical	-1	19841052
k	I-Chemical	-1	19841052
cocaine	I-Chemical	-1	19841052
was	O	-1	19841052
found	O	-1	19841052
to	O	-1	19841052
be	O	-1	19841052
an	O	-1	19841052
in@@	O	-1	19841052
dependent	O	-1	19841052
risk	O	-1	19841052
factor	O	-1	19841052
for	O	-1	19841052
H@@	B-Disease	D006679	19841052
IV	I-Disease	-1	19841052
ser@@	I-Disease	-1	19841052
o@@	I-Disease	-1	19841052
conver@@	I-Disease	-1	19841052
sion	I-Disease	-1	19841052
among	O	-1	19841052
pe@@	O	-1	19841052
o@@	O	-1	19841052
ple	O	-1	19841052
who	O	-1	19841052
were	O	-1	19841052
injection	O	-1	19841052
drug	O	-1	19841052
us@@	O	-1	19841052
ers.	O	-1	19841052
This	O	-1	19841052
find@@	O	-1	19841052
ing	O	-1	19841052
po@@	O	-1	19841052
int@@	O	-1	19841052
s	O	-1	19841052
to	O	-1	19841052
the	O	-1	19841052
ur@@	O	-1	19841052
g@@	O	-1	19841052
ent	O	-1	19841052
need	O	-1	19841052
for	O	-1	19841052
ev@@	O	-1	19841052
id@@	O	-1	19841052
ence@@	O	-1	19841052
-@@	O	-1	19841052
bas@@	O	-1	19841052
ed	O	-1	19841052
pu@@	O	-1	19841052
bl@@	O	-1	19841052
ic	O	-1	19841052
heal@@	O	-1	19841052
th	O	-1	19841052
initi@@	O	-1	19841052
ati@@	O	-1	19841052
v@@	O	-1	19841052
es	O	-1	19841052
t@@	O	-1	19841052
arg@@	O	-1	19841052
et@@	O	-1	19841052
ed	O	-1	19841052
at	O	-1	19841052
pe@@	O	-1	19841052
o@@	O	-1	19841052
ple	O	-1	19841052
who	O	-1	19841052
smo@@	O	-1	19841052
k@@	O	-1	19841052
e	O	-1	19841052
c@@	B-Chemical	D016578	19841052
rac@@	I-Chemical	-1	19841052
k	I-Chemical	-1	19841052
cocaine	I-Chemical	-1	19841052
.	O	-1	19841052

F@@	B-Chemical	D005473	19914299
lu@@	I-Chemical	-1	19914299
ox@@	I-Chemical	-1	19914299
et@@	I-Chemical	-1	19914299
ine	I-Chemical	-1	19914299
impro@@	O	-1	19914299
v@@	O	-1	19914299
es	O	-1	19914299
the	O	-1	19914299
memory	B-Disease	D008569	19914299
defic@@	I-Disease	-1	19914299
its	I-Disease	-1	19914299
caused	O	-1	19914299
by	O	-1	19914299
the	O	-1	19914299
chemotherapy	O	-1	19914299
agent	O	-1	19914299
5-@@	B-Chemical	D005472	19914299
fluoro@@	I-Chemical	-1	19914299
urac@@	I-Chemical	-1	19914299
il	I-Chemical	-1	19914299
.	O	-1	19914299
C@@	B-Disease	D009369	19914299
anc@@	I-Disease	-1	19914299
er	I-Disease	-1	19914299
patients	O	-1	19914299
who	O	-1	19914299
have	O	-1	19914299
been	O	-1	19914299
treated	O	-1	19914299
with	O	-1	19914299
systemic	O	-1	19914299
adj@@	O	-1	19914299
u@@	O	-1	19914299
v@@	O	-1	19914299
ant	O	-1	19914299
chemotherapy	O	-1	19914299
have	O	-1	19914299
descri@@	O	-1	19914299
bed	O	-1	19914299
experienc@@	O	-1	19914299
ing	O	-1	19914299
deter@@	O	-1	19914299
i@@	O	-1	19914299
or@@	O	-1	19914299
ations	O	-1	19914299
in	O	-1	19914299
cogn@@	O	-1	19914299
i@@	O	-1	19914299
tion.	O	-1	19914299
A	O	-1	19914299
wi@@	O	-1	19914299
de@@	O	-1	19914299
ly	O	-1	19914299
used	O	-1	19914299
chemo@@	O	-1	19914299
therapeutic	O	-1	19914299
agent@@	O	-1	19914299
,	O	-1	19914299
5-@@	B-Chemical	D005472	19914299
fluoro@@	I-Chemical	-1	19914299
urac@@	I-Chemical	-1	19914299
il	I-Chemical	-1	19914299
(	O	-1	19914299
5-@@	B-Chemical	D005472	19914299
F@@	I-Chemical	-1	19914299
U	I-Chemical	-1	19914299
),	O	-1	19914299
re@@	O	-1	19914299
a@@	O	-1	19914299
di@@	O	-1	19914299
ly	O	-1	19914299
cros@@	O	-1	19914299
ses	O	-1	19914299
the	O	-1	19914299
blo@@	O	-1	19914299
o@@	O	-1	19914299
d-@@	O	-1	19914299
brain	O	-1	19914299
bar@@	O	-1	19914299
ri@@	O	-1	19914299
er	O	-1	19914299
and	O	-1	19914299
so	O	-1	19914299
could	O	-1	19914299
have	O	-1	19914299
a	O	-1	19914299
direct	O	-1	19914299
effect	O	-1	19914299
on	O	-1	19914299
brain	O	-1	19914299
func@@	O	-1	19914299
tion.	O	-1	19914299
In	O	-1	19914299
partic@@	O	-1	19914299
ular	O	-1	19914299
this	O	-1	19914299
ant@@	O	-1	19914299
i	O	-1	19914299
mit@@	O	-1	19914299
o@@	O	-1	19914299
tic	O	-1	19914299
drug	O	-1	19914299
could	O	-1	19914299
re@@	O	-1	19914299
duce	O	-1	19914299
cell	O	-1	19914299
pro@@	O	-1	19914299
li@@	O	-1	19914299
fer@@	O	-1	19914299
ation	O	-1	19914299
in	O	-1	19914299
the	O	-1	19914299
neuro@@	O	-1	19914299
genic	O	-1	19914299
regi@@	O	-1	19914299
ons	O	-1	19914299
of	O	-1	19914299
the	O	-1	19914299
ad@@	O	-1	19914299
ult	O	-1	19914299
bra@@	O	-1	19914299
in.	O	-1	19914299
In	O	-1	19914299
contr@@	O	-1	19914299
ast	O	-1	19914299
reports	O	-1	19914299
indicate	O	-1	19914299
that	O	-1	19914299
hippocamp@@	O	-1	19914299
al	O	-1	19914299
dependent	O	-1	19914299
neuro@@	O	-1	19914299
genesis	O	-1	19914299
and	O	-1	19914299
cogn@@	O	-1	19914299
ition	O	-1	19914299
are	O	-1	19914299
enhanced	O	-1	19914299
by	O	-1	19914299
the	O	-1	19914299
S@@	B-Chemical	D017367	19914299
SR@@	I-Chemical	-1	19914299
I	I-Chemical	-1	19914299
antidepress@@	O	-1	19914299
ant	O	-1	19914299
F@@	B-Chemical	D005473	19914299
lu@@	I-Chemical	-1	19914299
ox@@	I-Chemical	-1	19914299
et@@	I-Chemical	-1	19914299
ine	I-Chemical	-1	19914299
.	O	-1	19914299
In	O	-1	19914299
this	O	-1	19914299
investig@@	O	-1	19914299
ation	O	-1	19914299
the	O	-1	19914299
behavi@@	O	-1	19914299
o@@	O	-1	19914299
ural	O	-1	19914299
effects	O	-1	19914299
of	O	-1	19914299
chronic	O	-1	19914299
(@@	O	-1	19914299
two	O	-1	19914299
week@@	O	-1	19914299
)	O	-1	19914299
treatment	O	-1	19914299
with	O	-1	19914299
5-@@	B-Chemical	D005472	19914299
F@@	I-Chemical	-1	19914299
U	I-Chemical	-1	19914299
and	O	-1	19914299
(@@	O	-1	19914299
three	O	-1	19914299
week@@	O	-1	19914299
s)	O	-1	19914299
with	O	-1	19914299
F@@	B-Chemical	D005473	19914299
lu@@	I-Chemical	-1	19914299
ox@@	I-Chemical	-1	19914299
et@@	I-Chemical	-1	19914299
ine	I-Chemical	-1	19914299
either	O	-1	19914299
se@@	O	-1	19914299
par@@	O	-1	19914299
ately	O	-1	19914299
or	O	-1	19914299
in	O	-1	19914299
combination	O	-1	19914299
with	O	-1	19914299
5-@@	B-Chemical	D005472	19914299
F@@	I-Chemical	-1	19914299
U	I-Chemical	-1	19914299
were	O	-1	19914299
tested	O	-1	19914299
on	O	-1	19914299
ad@@	O	-1	19914299
ult	O	-1	19914299
L@@	O	-1	19914299
ist@@	O	-1	19914299
er	O	-1	19914299
ho@@	O	-1	19914299
o@@	O	-1	19914299
ded	O	-1	19914299
rats.	O	-1	19914299
B@@	O	-1	19914299
e@@	O	-1	19914299
havi@@	O	-1	19914299
o@@	O	-1	19914299
ural	O	-1	19914299
effects	O	-1	19914299
were	O	-1	19914299
tested	O	-1	19914299
using	O	-1	19914299
a	O	-1	19914299
cont@@	O	-1	19914299
ex@@	O	-1	19914299
t	O	-1	19914299
dependent	O	-1	19914299
condi@@	O	-1	19914299
tion@@	O	-1	19914299
ed	O	-1	19914299
em@@	O	-1	19914299
o@@	O	-1	19914299
tional	O	-1	19914299
response	O	-1	19914299
test	O	-1	19914299
(C@@	O	-1	19914299
E@@	O	-1	19914299
R@@	O	-1	19914299
)	O	-1	19914299
which	O	-1	19914299
showed	O	-1	19914299
that	O	-1	19914299
animals	O	-1	19914299
treated	O	-1	19914299
with	O	-1	19914299
5-@@	B-Chemical	D005472	19914299
F@@	I-Chemical	-1	19914299
U	I-Chemical	-1	19914299
had	O	-1	19914299
a	O	-1	19914299
significant	O	-1	19914299
reduction	O	-1	19914299
in	O	-1	19914299
f@@	O	-1	19914299
re@@	O	-1	19914299
e@@	O	-1	19914299
z@@	O	-1	19914299
ing	O	-1	19914299
time	O	-1	19914299
compared	O	-1	19914299
to	O	-1	19914299
controls.	O	-1	19914299
A	O	-1	19914299
se@@	O	-1	19914299
par@@	O	-1	19914299
ate	O	-1	19914299
group	O	-1	19914299
of	O	-1	19914299
animals	O	-1	19914299
was	O	-1	19914299
tested	O	-1	19914299
using	O	-1	19914299
a	O	-1	19914299
hippocamp@@	O	-1	19914299
al	O	-1	19914299
dependent	O	-1	19914299
s@@	O	-1	19914299
pati@@	O	-1	19914299
al	O	-1	19914299
wor@@	O	-1	19914299
king	O	-1	19914299
memory	O	-1	19914299
test@@	O	-1	19914299
,	O	-1	19914299
the	O	-1	19914299
ob@@	O	-1	19914299
j@@	O	-1	19914299
ect	O	-1	19914299
loc@@	O	-1	19914299
ation	O	-1	19914299
reco@@	O	-1	19914299
gn@@	O	-1	19914299
ition	O	-1	19914299
test	O	-1	19914299
(@@	O	-1	19914299
O@@	O	-1	19914299
L@@	O	-1	19914299
R@@	O	-1	19914299
).	O	-1	19914299
An@@	O	-1	19914299
im@@	O	-1	19914299
als	O	-1	19914299
treated	O	-1	19914299
only	O	-1	19914299
with	O	-1	19914299
5-@@	B-Chemical	D005472	19914299
F@@	I-Chemical	-1	19914299
U	I-Chemical	-1	19914299
showed	O	-1	19914299
significant	O	-1	19914299
defic@@	O	-1	19914299
its	O	-1	19914299
in	O	-1	19914299
their	O	-1	19914299
ability	O	-1	19914299
to	O	-1	19914299
car@@	O	-1	19914299
r@@	O	-1	19914299
y	O	-1	19914299
out	O	-1	19914299
the	O	-1	19914299
O@@	O	-1	19914299
L@@	O	-1	19914299
R	O	-1	19914299
t@@	O	-1	19914299
as@@	O	-1	19914299
k	O	-1	19914299
but	O	-1	19914299
c@@	O	-1	19914299
o	O	-1	19914299
administration	O	-1	19914299
of	O	-1	19914299
F@@	B-Chemical	D005473	19914299
lu@@	I-Chemical	-1	19914299
ox@@	I-Chemical	-1	19914299
et@@	I-Chemical	-1	19914299
ine	I-Chemical	-1	19914299
improved	O	-1	19914299
their	O	-1	19914299
perform@@	O	-1	19914299
ance@@	O	-1	19914299
.	O	-1	19914299
5-@@	B-Chemical	D005472	19914299
F@@	I-Chemical	-1	19914299
U	I-Chemical	-1	19914299
chemotherapy	O	-1	19914299
caused	O	-1	19914299
a	O	-1	19914299
significant	O	-1	19914299
reduction	O	-1	19914299
in	O	-1	19914299
the	O	-1	19914299
number	O	-1	19914299
of	O	-1	19914299
pro@@	O	-1	19914299
li@@	O	-1	19914299
fer@@	O	-1	19914299
ating	O	-1	19914299
cells	O	-1	19914299
in	O	-1	19914299
the	O	-1	19914299
su@@	O	-1	19914299
b	O	-1	19914299
gran@@	O	-1	19914299
ular	O	-1	19914299
z@@	O	-1	19914299
one	O	-1	19914299
of	O	-1	19914299
the	O	-1	19914299
d@@	O	-1	19914299
ent@@	O	-1	19914299
ate	O	-1	19914299
g@@	O	-1	19914299
y@@	O	-1	19914299
ru@@	O	-1	19914299
s	O	-1	19914299
compared	O	-1	19914299
to	O	-1	19914299
controls.	O	-1	19914299
This	O	-1	19914299
reduction	O	-1	19914299
was	O	-1	19914299
el@@	O	-1	19914299
im@@	O	-1	19914299
in@@	O	-1	19914299
ated	O	-1	19914299
when	O	-1	19914299
F@@	B-Chemical	D005473	19914299
lu@@	I-Chemical	-1	19914299
ox@@	I-Chemical	-1	19914299
et@@	I-Chemical	-1	19914299
ine	I-Chemical	-1	19914299
was	O	-1	19914299
c@@	O	-1	19914299
o	O	-1	19914299
administered	O	-1	19914299
with	O	-1	19914299
5-@@	B-Chemical	D005472	19914299
F@@	I-Chemical	-1	19914299
U	I-Chemical	-1	19914299
.	O	-1	19914299
F@@	B-Chemical	D005473	19914299
lu@@	I-Chemical	-1	19914299
ox@@	I-Chemical	-1	19914299
et@@	I-Chemical	-1	19914299
ine	I-Chemical	-1	19914299
on	O	-1	19914299
its	O	-1	19914299
o@@	O	-1	19914299
w@@	O	-1	19914299
n	O	-1	19914299
had	O	-1	19914299
no	O	-1	19914299
effect	O	-1	19914299
on	O	-1	19914299
pro@@	O	-1	19914299
li@@	O	-1	19914299
fer@@	O	-1	19914299
ating	O	-1	19914299
cell	O	-1	19914299
number	O	-1	19914299
or	O	-1	19914299
behavi@@	O	-1	19914299
o@@	O	-1	19914299
ur@@	O	-1	19914299
.	O	-1	19914299
These	O	-1	19914299
findings	O	-1	19914299
suggest	O	-1	19914299
that	O	-1	19914299
5-@@	B-Chemical	D005472	19914299
F@@	I-Chemical	-1	19914299
U	I-Chemical	-1	19914299
can	O	-1	19914299
neg@@	O	-1	19914299
atively	O	-1	19914299
aff@@	O	-1	19914299
ect	O	-1	19914299
both	O	-1	19914299
cell	O	-1	19914299
pro@@	O	-1	19914299
li@@	O	-1	19914299
fer@@	O	-1	19914299
ation	O	-1	19914299
and	O	-1	19914299
hippocamp@@	O	-1	19914299
al	O	-1	19914299
dependent	O	-1	19914299
wor@@	O	-1	19914299
king	O	-1	19914299
memory	O	-1	19914299
and	O	-1	19914299
that	O	-1	19914299
these	O	-1	19914299
defic@@	O	-1	19914299
its	O	-1	19914299
can	O	-1	19914299
be	O	-1	19914299
reversed	O	-1	19914299
by	O	-1	19914299
the	O	-1	19914299
sim@@	O	-1	19914299
ult@@	O	-1	19914299
aneous	O	-1	19914299
administration	O	-1	19914299
of	O	-1	19914299
the	O	-1	19914299
antidepress@@	O	-1	19914299
ant	O	-1	19914299
F@@	B-Chemical	D005473	19914299
lu@@	I-Chemical	-1	19914299
ox@@	I-Chemical	-1	19914299
et@@	I-Chemical	-1	19914299
ine	I-Chemical	-1	19914299
.	O	-1	19914299

L@@	O	-1	19920070
i@@	O	-1	19920070
ver@@	O	-1	19920070
-@@	O	-1	19920070
specific	O	-1	19920070
abl@@	O	-1	19920070
ation	O	-1	19920070
of	O	-1	19920070
in@@	O	-1	19920070
te@@	O	-1	19920070
g@@	O	-1	19920070
r@@	O	-1	19920070
in-@@	O	-1	19920070
lin@@	O	-1	19920070
ked	O	-1	19920070
kin@@	O	-1	19920070
ase	O	-1	19920070
in	O	-1	19920070
mice	O	-1	19920070
results	O	-1	19920070
in	O	-1	19920070
enhanced	O	-1	19920070
and	O	-1	19920070
prolonged	O	-1	19920070
cell	O	-1	19920070
pro@@	O	-1	19920070
li@@	O	-1	19920070
fer@@	O	-1	19920070
ation	O	-1	19920070
and	O	-1	19920070
hepat@@	B-Disease	D006529	19920070
o@@	I-Disease	-1	19920070
me@@	I-Disease	-1	19920070
g@@	I-Disease	-1	19920070
al@@	I-Disease	-1	19920070
y	I-Disease	-1	19920070
after	O	-1	19920070
phenobarbit@@	B-Chemical	D010634	19920070
al	I-Chemical	-1	19920070
administr@@	O	-1	19920070
ation.	O	-1	19920070
We	O	-1	19920070
have	O	-1	19920070
rec@@	O	-1	19920070
ently	O	-1	19920070
demonstrated	O	-1	19920070
that	O	-1	19920070
dis@@	O	-1	19920070
ru@@	O	-1	19920070
ption	O	-1	19920070
of	O	-1	19920070
extrac@@	O	-1	19920070
ell@@	O	-1	19920070
ular	O	-1	19920070
mat@@	O	-1	19920070
ri@@	O	-1	19920070
x	O	-1	19920070
(@@	O	-1	19920070
EC@@	O	-1	19920070
M@@	O	-1	19920070
)@@	O	-1	19920070
/@@	O	-1	19920070
in@@	O	-1	19920070
te@@	O	-1	19920070
g@@	O	-1	19920070
rin	O	-1	19920070
sign@@	O	-1	19920070
al@@	O	-1	19920070
ing	O	-1	19920070
vi@@	O	-1	19920070
a	O	-1	19920070
el@@	O	-1	19920070
im@@	O	-1	19920070
in@@	O	-1	19920070
ation	O	-1	19920070
of	O	-1	19920070
in@@	O	-1	19920070
te@@	O	-1	19920070
g@@	O	-1	19920070
r@@	O	-1	19920070
in-@@	O	-1	19920070
lin@@	O	-1	19920070
ked	O	-1	19920070
kin@@	O	-1	19920070
ase	O	-1	19920070
(@@	O	-1	19920070
I@@	O	-1	19920070
L@@	O	-1	19920070
K@@	O	-1	19920070
)	O	-1	19920070
in	O	-1	19920070
hepat@@	O	-1	19920070
ocy@@	O	-1	19920070
tes	O	-1	19920070
inter@@	O	-1	19920070
fe@@	O	-1	19920070
res	O	-1	19920070
with	O	-1	19920070
sign@@	O	-1	19920070
als	O	-1	19920070
lead@@	O	-1	19920070
ing	O	-1	19920070
to	O	-1	19920070
ter@@	O	-1	19920070
min@@	O	-1	19920070
ation	O	-1	19920070
of	O	-1	19920070
liver	O	-1	19920070
re@@	O	-1	19920070
gener@@	O	-1	19920070
ation.	O	-1	19920070
This	O	-1	19920070
study	O	-1	19920070
investig@@	O	-1	19920070
ates	O	-1	19920070
the	O	-1	19920070
role	O	-1	19920070
of	O	-1	19920070
I@@	O	-1	19920070
L@@	O	-1	19920070
K	O	-1	19920070
in	O	-1	19920070
liver	O	-1	19920070
en@@	O	-1	19920070
larg@@	O	-1	19920070
ement	O	-1	19920070
induced	O	-1	19920070
by	O	-1	19920070
phenobarbit@@	B-Chemical	D010634	19920070
al	I-Chemical	-1	19920070
(	O	-1	19920070
P@@	B-Chemical	D010634	19920070
B	I-Chemical	-1	19920070
).	O	-1	19920070
W@@	O	-1	19920070
il@@	O	-1	19920070
d-@@	O	-1	19920070
type	O	-1	19920070
(@@	O	-1	19920070
W@@	O	-1	19920070
T)	O	-1	19920070
and	O	-1	19920070
I@@	O	-1	19920070
L@@	O	-1	19920070
K@@	O	-1	19920070
:@@	O	-1	19920070
li@@	O	-1	19920070
ver@@	O	-1	19920070
-@@	O	-1	19920070
/@@	O	-1	19920070
-	O	-1	19920070
mice	O	-1	19920070
were	O	-1	19920070
given	O	-1	19920070
P@@	B-Chemical	D010634	19920070
B	I-Chemical	-1	19920070
(0.@@	O	-1	19920070
1@@	O	-1	19920070
%	O	-1	19920070
in	O	-1	19920070
d@@	O	-1	19920070
r@@	O	-1	19920070
in@@	O	-1	19920070
king	O	-1	19920070
w@@	O	-1	19920070
at@@	O	-1	19920070
er@@	O	-1	19920070
)	O	-1	19920070
for	O	-1	19920070
10	O	-1	19920070
days.	O	-1	19920070
L@@	O	-1	19920070
i@@	O	-1	19920070
ver@@	O	-1	19920070
s	O	-1	19920070
were	O	-1	19920070
h@@	O	-1	19920070
ar@@	O	-1	19920070
ve@@	O	-1	19920070
st@@	O	-1	19920070
ed	O	-1	19920070
on	O	-1	19920070
2,	O	-1	19920070
5,	O	-1	19920070
and	O	-1	19920070
10	O	-1	19920070
days	O	-1	19920070
during	O	-1	19920070
P@@	B-Chemical	D010634	19920070
B	I-Chemical	-1	19920070
administr@@	O	-1	19920070
ation.	O	-1	19920070
In	O	-1	19920070
the	O	-1	19920070
hepat@@	O	-1	19920070
ocy@@	O	-1	19920070
te@@	O	-1	19920070
-@@	O	-1	19920070
specific	O	-1	19920070
I@@	O	-1	19920070
L@@	O	-1	19920070
K@@	O	-1	19920070
/@@	O	-1	19920070
li@@	O	-1	19920070
ver@@	O	-1	19920070
-@@	O	-1	19920070
/@@	O	-1	19920070
-	O	-1	19920070
mic@@	O	-1	19920070
e,	O	-1	19920070
the	O	-1	19920070
li@@	O	-1	19920070
ver@@	O	-1	19920070
:@@	O	-1	19920070
body	O	-1	19920070
weight	O	-1	19920070
rati@@	O	-1	19920070
o	O	-1	19920070
was	O	-1	19920070
more	O	-1	19920070
than	O	-1	19920070
dou@@	O	-1	19920070
ble	O	-1	19920070
as	O	-1	19920070
compared	O	-1	19920070
to	O	-1	19920070
0	O	-1	19920070
h	O	-1	19920070
at	O	-1	19920070
day	O	-1	19920070
2	O	-1	19920070
(2@@	O	-1	19920070
.@@	O	-1	19920070
5	O	-1	19920070
tim@@	O	-1	19920070
es@@	O	-1	19920070
),	O	-1	19920070
while	O	-1	19920070
at	O	-1	19920070
days	O	-1	19920070
5	O	-1	19920070
and	O	-1	19920070
10@@	O	-1	19920070
,	O	-1	19920070
it	O	-1	19920070
was	O	-1	19920070
en@@	O	-1	19920070
larg@@	O	-1	19920070
ed	O	-1	19920070
three	O	-1	19920070
tim@@	O	-1	19920070
es.	O	-1	19920070
In	O	-1	19920070
the	O	-1	19920070
W@@	O	-1	19920070
T	O	-1	19920070
mic@@	O	-1	19920070
e,	O	-1	19920070
the	O	-1	19920070
increase	O	-1	19920070
was	O	-1	19920070
as	O	-1	19920070
ex@@	O	-1	19920070
p@@	O	-1	19920070
ected	O	-1	19920070
from	O	-1	19920070
previ@@	O	-1	19920070
ous	O	-1	19920070
literat@@	O	-1	19920070
ure	O	-1	19920070
(1@@	O	-1	19920070
.@@	O	-1	19920070
8	O	-1	19920070
tim@@	O	-1	19920070
es@@	O	-1	19920070
)	O	-1	19920070
and	O	-1	19920070
se@@	O	-1	19920070
em@@	O	-1	19920070
s	O	-1	19920070
to	O	-1	19920070
have	O	-1	19920070
level@@	O	-1	19920070
ed	O	-1	19920070
of@@	O	-1	19920070
f	O	-1	19920070
after	O	-1	19920070
day	O	-1	19920070
2@@	O	-1	19920070
.	O	-1	19920070
There	O	-1	19920070
were	O	-1	19920070
s@@	O	-1	19920070
li@@	O	-1	19920070
gh@@	O	-1	19920070
tly	O	-1	19920070
increased	O	-1	19920070
pro@@	O	-1	19920070
li@@	O	-1	19920070
fer@@	O	-1	19920070
ating	O	-1	19920070
cell	O	-1	19920070
nucle@@	O	-1	19920070
ar	O	-1	19920070
anti@@	O	-1	19920070
gen@@	O	-1	19920070
-@@	O	-1	19920070
positive	O	-1	19920070
cells	O	-1	19920070
in	O	-1	19920070
the	O	-1	19920070
I@@	O	-1	19920070
L@@	O	-1	19920070
K@@	O	-1	19920070
/@@	O	-1	19920070
li@@	O	-1	19920070
ver@@	O	-1	19920070
-@@	O	-1	19920070
/@@	O	-1	19920070
-	O	-1	19920070
animals	O	-1	19920070
at	O	-1	19920070
day	O	-1	19920070
2	O	-1	19920070
as	O	-1	19920070
compared	O	-1	19920070
to	O	-1	19920070
W@@	O	-1	19920070
T	O	-1	19920070
after	O	-1	19920070
P@@	B-Chemical	D010634	19920070
B	I-Chemical	-1	19920070
administr@@	O	-1	19920070
ation.	O	-1	19920070
In	O	-1	19920070
the	O	-1	19920070
W@@	O	-1	19920070
T	O	-1	19920070
anim@@	O	-1	19920070
al@@	O	-1	19920070
s,	O	-1	19920070
the	O	-1	19920070
pro@@	O	-1	19920070
li@@	O	-1	19920070
fer@@	O	-1	19920070
ative	O	-1	19920070
response	O	-1	19920070
had	O	-1	19920070
com@@	O	-1	19920070
e	O	-1	19920070
bac@@	O	-1	19920070
k	O	-1	19920070
to	O	-1	19920070
normal	O	-1	19920070
by	O	-1	19920070
days	O	-1	19920070
5	O	-1	19920070
and	O	-1	19920070
10@@	O	-1	19920070
.	O	-1	19920070
H@@	O	-1	19920070
ep@@	O	-1	19920070
at@@	O	-1	19920070
ocy@@	O	-1	19920070
tes	O	-1	19920070
of	O	-1	19920070
the	O	-1	19920070
I@@	O	-1	19920070
L@@	O	-1	19920070
K@@	O	-1	19920070
/@@	O	-1	19920070
li@@	O	-1	19920070
ver@@	O	-1	19920070
-@@	O	-1	19920070
/@@	O	-1	19920070
-	O	-1	19920070
mice	O	-1	19920070
continu@@	O	-1	19920070
ed	O	-1	19920070
to	O	-1	19920070
pro@@	O	-1	19920070
li@@	O	-1	19920070
fer@@	O	-1	19920070
ate	O	-1	19920070
up	O	-1	19920070
un@@	O	-1	19920070
ti@@	O	-1	19920070
l	O	-1	19920070
day	O	-1	19920070
10@@	O	-1	19920070
.	O	-1	19920070
I@@	O	-1	19920070
L@@	O	-1	19920070
K@@	O	-1	19920070
/@@	O	-1	19920070
li@@	O	-1	19920070
ver@@	O	-1	19920070
-@@	O	-1	19920070
/@@	O	-1	19920070
-	O	-1	19920070
mice	O	-1	19920070
also	O	-1	19920070
showed	O	-1	19920070
increased	O	-1	19920070
expression	O	-1	19920070
of	O	-1	19920070
ke@@	O	-1	19920070
y	O	-1	19920070
gen@@	O	-1	19920070
es	O	-1	19920070
involved	O	-1	19920070
in	O	-1	19920070
hepat@@	O	-1	19920070
ocyte	O	-1	19920070
pro@@	O	-1	19920070
li@@	O	-1	19920070
fer@@	O	-1	19920070
ation	O	-1	19920070
at	O	-1	19920070
different	O	-1	19920070
time	O	-1	19920070
po@@	O	-1	19920070
int@@	O	-1	19920070
s	O	-1	19920070
during	O	-1	19920070
P@@	B-Chemical	D010634	19920070
B	I-Chemical	-1	19920070
administr@@	O	-1	19920070
ation.	O	-1	19920070
In	O	-1	19920070
su@@	O	-1	19920070
mm@@	O	-1	19920070
ar@@	O	-1	19920070
y,	O	-1	19920070
EC@@	O	-1	19920070
M	O	-1	19920070
protein@@	O	-1	19920070
s	O	-1	19920070
com@@	O	-1	19920070
mun@@	O	-1	19920070
ic@@	O	-1	19920070
ate	O	-1	19920070
with	O	-1	19920070
the	O	-1	19920070
sign@@	O	-1	19920070
al@@	O	-1	19920070
ing	O	-1	19920070
mac@@	O	-1	19920070
h@@	O	-1	19920070
in@@	O	-1	19920070
er@@	O	-1	19920070
y	O	-1	19920070
of	O	-1	19920070
divid@@	O	-1	19920070
ing	O	-1	19920070
cells	O	-1	19920070
vi@@	O	-1	19920070
a	O	-1	19920070
I@@	O	-1	19920070
L@@	O	-1	19920070
K	O	-1	19920070
to	O	-1	19920070
reg@@	O	-1	19920070
ul@@	O	-1	19920070
ate	O	-1	19920070
hepat@@	O	-1	19920070
ocyte	O	-1	19920070
pro@@	O	-1	19920070
li@@	O	-1	19920070
fer@@	O	-1	19920070
ation	O	-1	19920070
and	O	-1	19920070
ter@@	O	-1	19920070
min@@	O	-1	19920070
ation	O	-1	19920070
of	O	-1	19920070
the	O	-1	19920070
pro@@	O	-1	19920070
li@@	O	-1	19920070
fer@@	O	-1	19920070
ative	O	-1	19920070
respon@@	O	-1	19920070
se.	O	-1	19920070
L@@	O	-1	19920070
ac@@	O	-1	19920070
k	O	-1	19920070
of	O	-1	19920070
I@@	O	-1	19920070
L@@	O	-1	19920070
K	O	-1	19920070
in	O	-1	19920070
the	O	-1	19920070
hepat@@	O	-1	19920070
ocy@@	O	-1	19920070
tes	O	-1	19920070
im@@	O	-1	19920070
par@@	O	-1	19920070
ts	O	-1	19920070
prolonged	O	-1	19920070
pro@@	O	-1	19920070
li@@	O	-1	19920070
fer@@	O	-1	19920070
ative	O	-1	19920070
response	O	-1	19920070
not	O	-1	19920070
only	O	-1	19920070
to	O	-1	19920070
stimul@@	O	-1	19920070
i	O	-1	19920070
related	O	-1	19920070
to	O	-1	19920070
liver	O	-1	19920070
re@@	O	-1	19920070
generation	O	-1	19920070
but	O	-1	19920070
also	O	-1	19920070
to	O	-1	19920070
x@@	O	-1	19920070
en@@	O	-1	19920070
ob@@	O	-1	19920070
io@@	O	-1	19920070
tic	O	-1	19920070
chemical	O	-1	19920070
mit@@	O	-1	19920070
o@@	O	-1	19920070
gen@@	O	-1	19920070
s,	O	-1	19920070
such	O	-1	19920070
as	O	-1	19920070
P@@	B-Chemical	D010634	19920070
B	I-Chemical	-1	19920070
.	O	-1	19920070

D@@	O	-1	19967075
ec@@	O	-1	19967075
reas@@	O	-1	19967075
ed	O	-1	19967075
E@@	O	-1	19967075
x@@	O	-1	19967075
pression	O	-1	19967075
of	O	-1	19967075
N@@	B-Chemical	D012964	19967075
a	I-Chemical	-1	19967075
/	O	-1	19967075
K	B-Chemical	D011188	19967075
-@@	O	-1	19967075
AT@@	O	-1	19967075
P@@	O	-1	19967075
ase,	O	-1	19967075
N@@	O	-1	19967075
H@@	O	-1	19967075
E@@	O	-1	19967075
3,	O	-1	19967075
N@@	O	-1	19967075
BC@@	O	-1	19967075
1,	O	-1	19967075
A@@	O	-1	19967075
Q@@	O	-1	19967075
P@@	O	-1	19967075
1	O	-1	19967075
and	O	-1	19967075
O@@	O	-1	19967075
A@@	O	-1	19967075
T	O	-1	19967075
in	O	-1	19967075
G@@	B-Chemical	D005839	19967075
ent@@	I-Chemical	-1	19967075
am@@	I-Chemical	-1	19967075
icin	I-Chemical	-1	19967075
-induced	O	-1	19967075
Ne@@	B-Disease	D007674	19967075
ph@@	I-Disease	-1	19967075
ro@@	I-Disease	-1	19967075
pathy	I-Disease	-1	19967075
.	O	-1	19967075
The	O	-1	19967075
present	O	-1	19967075
study	O	-1	19967075
was	O	-1	19967075
a@@	O	-1	19967075
im@@	O	-1	19967075
ed	O	-1	19967075
to	O	-1	19967075
determine	O	-1	19967075
whether	O	-1	19967075
there	O	-1	19967075
is	O	-1	19967075
an	O	-1	19967075
al@@	O	-1	19967075
te@@	O	-1	19967075
red	O	-1	19967075
reg@@	O	-1	19967075
ulation	O	-1	19967075
of	O	-1	19967075
tub@@	O	-1	19967075
ular	O	-1	19967075
trans@@	O	-1	19967075
por@@	O	-1	19967075
ters	O	-1	19967075
in	O	-1	19967075
g@@	B-Chemical	D005839	19967075
ent@@	I-Chemical	-1	19967075
am@@	I-Chemical	-1	19967075
icin	I-Chemical	-1	19967075
-induced	O	-1	19967075
nephro@@	B-Disease	D007674	19967075
pathy	I-Disease	-1	19967075
.	O	-1	19967075
S@@	O	-1	19967075
pra@@	O	-1	19967075
gu@@	O	-1	19967075
e-@@	O	-1	19967075
D@@	O	-1	19967075
aw@@	O	-1	19967075
le@@	O	-1	19967075
y	O	-1	19967075
male	O	-1	19967075
rats	O	-1	19967075
(2@@	O	-1	19967075
0@@	O	-1	19967075
0@@	O	-1	19967075
~@@	O	-1	19967075
2@@	O	-1	19967075
50	O	-1	19967075
g@@	O	-1	19967075
)	O	-1	19967075
were	O	-1	19967075
sub@@	O	-1	19967075
c@@	O	-1	19967075
ut@@	O	-1	19967075
ane@@	O	-1	19967075
ously	O	-1	19967075
injected	O	-1	19967075
with	O	-1	19967075
g@@	B-Chemical	D005839	19967075
ent@@	I-Chemical	-1	19967075
am@@	I-Chemical	-1	19967075
icin	I-Chemical	-1	19967075
(@@	O	-1	19967075
100	O	-1	19967075
mg/kg	O	-1	19967075
per	O	-1	19967075
day@@	O	-1	19967075
)	O	-1	19967075
for	O	-1	19967075
7	O	-1	19967075
day@@	O	-1	19967075
s,	O	-1	19967075
and	O	-1	19967075
the	O	-1	19967075
expression	O	-1	19967075
of	O	-1	19967075
tub@@	O	-1	19967075
ular	O	-1	19967075
trans@@	O	-1	19967075
por@@	O	-1	19967075
ters	O	-1	19967075
was	O	-1	19967075
determined	O	-1	19967075
by	O	-1	19967075
immun@@	O	-1	19967075
ob@@	O	-1	19967075
lo@@	O	-1	19967075
t@@	O	-1	19967075
ting	O	-1	19967075
and	O	-1	19967075
immuno@@	O	-1	19967075
histo@@	O	-1	19967075
chem@@	O	-1	19967075
ist@@	O	-1	19967075
r@@	O	-1	19967075
y.	O	-1	19967075
The	O	-1	19967075
mRNA	O	-1	19967075
and	O	-1	19967075
protein	O	-1	19967075
expression	O	-1	19967075
of	O	-1	19967075
O@@	O	-1	19967075
A@@	O	-1	19967075
T	O	-1	19967075
was	O	-1	19967075
also	O	-1	19967075
deter@@	O	-1	19967075
m@@	O	-1	19967075
ine@@	O	-1	19967075
d.	O	-1	19967075
G@@	B-Chemical	D005839	19967075
ent@@	I-Chemical	-1	19967075
am@@	I-Chemical	-1	19967075
icin	I-Chemical	-1	19967075
-treated	O	-1	19967075
rats	O	-1	19967075
ex@@	O	-1	19967075
hib@@	O	-1	19967075
ited	O	-1	19967075
significantly	O	-1	19967075
decreased	O	-1	19967075
creatinine	B-Chemical	D003404	19967075
clear@@	O	-1	19967075
ance	O	-1	19967075
al@@	O	-1	19967075
ong	O	-1	19967075
with	O	-1	19967075
increased	O	-1	19967075
plasma	O	-1	19967075
creatinine	B-Chemical	D003404	19967075
level@@	O	-1	19967075
s.	O	-1	19967075
Ac@@	O	-1	19967075
cor@@	O	-1	19967075
d@@	O	-1	19967075
ing@@	O	-1	19967075
ly,	O	-1	19967075
the	O	-1	19967075
frac@@	O	-1	19967075
tional	O	-1	19967075
ex@@	O	-1	19967075
cre@@	O	-1	19967075
tion	O	-1	19967075
of	O	-1	19967075
sodium	B-Chemical	D012964	19967075
increas@@	O	-1	19967075
ed.	O	-1	19967075
U@@	O	-1	19967075
rine	O	-1	19967075
volume	O	-1	19967075
was	O	-1	19967075
increas@@	O	-1	19967075
ed,	O	-1	19967075
while	O	-1	19967075
urine	O	-1	19967075
os@@	O	-1	19967075
mol@@	O	-1	19967075
ality	O	-1	19967075
and	O	-1	19967075
free	O	-1	19967075
w@@	O	-1	19967075
at@@	O	-1	19967075
er	O	-1	19967075
re@@	O	-1	19967075
abs@@	O	-1	19967075
or@@	O	-1	19967075
ption	O	-1	19967075
were	O	-1	19967075
decreas@@	O	-1	19967075
ed.	O	-1	19967075
Im@@	O	-1	19967075
mun@@	O	-1	19967075
ob@@	O	-1	19967075
lo@@	O	-1	19967075
t@@	O	-1	19967075
ting	O	-1	19967075
and	O	-1	19967075
immuno@@	O	-1	19967075
histo@@	O	-1	19967075
chem@@	O	-1	19967075
ist@@	O	-1	19967075
r@@	O	-1	19967075
y	O	-1	19967075
revealed	O	-1	19967075
decreased	O	-1	19967075
expression	O	-1	19967075
of	O	-1	19967075
N@@	B-Chemical	D012964	19967075
a	I-Chemical	-1	19967075
(@@	O	-1	19967075
+@@	O	-1	19967075
)@@	O	-1	19967075
/	O	-1	19967075
K	B-Chemical	D011188	19967075
(@@	O	-1	19967075
+@@	O	-1	19967075
)-@@	O	-1	19967075
AT@@	O	-1	19967075
P@@	O	-1	19967075
ase,	O	-1	19967075
N@@	O	-1	19967075
H@@	O	-1	19967075
E@@	O	-1	19967075
3,	O	-1	19967075
N@@	O	-1	19967075
BC@@	O	-1	19967075
1,	O	-1	19967075
and	O	-1	19967075
A@@	O	-1	19967075
Q@@	O	-1	19967075
P@@	O	-1	19967075
1	O	-1	19967075
in	O	-1	19967075
the	O	-1	19967075
kidney	O	-1	19967075
of	O	-1	19967075
g@@	B-Chemical	D005839	19967075
ent@@	I-Chemical	-1	19967075
am@@	I-Chemical	-1	19967075
icin	I-Chemical	-1	19967075
-treated	O	-1	19967075
rats.	O	-1	19967075
The	O	-1	19967075
expression	O	-1	19967075
of	O	-1	19967075
O@@	O	-1	19967075
AT@@	O	-1	19967075
1	O	-1	19967075
and	O	-1	19967075
O@@	O	-1	19967075
AT@@	O	-1	19967075
3	O	-1	19967075
was	O	-1	19967075
also	O	-1	19967075
decreas@@	O	-1	19967075
ed.	O	-1	19967075
G@@	B-Chemical	D005839	19967075
ent@@	I-Chemical	-1	19967075
am@@	I-Chemical	-1	19967075
icin	I-Chemical	-1	19967075
-induced	O	-1	19967075
nephro@@	B-Disease	D007674	19967075
pathy	I-Disease	-1	19967075
may	O	-1	19967075
at	O	-1	19967075
le@@	O	-1	19967075
ast	O	-1	19967075
in	O	-1	19967075
par@@	O	-1	19967075
t	O	-1	19967075
be	O	-1	19967075
ca@@	O	-1	19967075
us@@	O	-1	19967075
ally	O	-1	19967075
related	O	-1	19967075
with	O	-1	19967075
a	O	-1	19967075
decreased	O	-1	19967075
expression	O	-1	19967075
of	O	-1	19967075
N@@	B-Chemical	D012964	19967075
a	I-Chemical	-1	19967075
(@@	O	-1	19967075
+@@	O	-1	19967075
)@@	O	-1	19967075
/	O	-1	19967075
K	B-Chemical	D011188	19967075
(@@	O	-1	19967075
+@@	O	-1	19967075
)-@@	O	-1	19967075
AT@@	O	-1	19967075
P@@	O	-1	19967075
ase,	O	-1	19967075
N@@	O	-1	19967075
H@@	O	-1	19967075
E@@	O	-1	19967075
3,	O	-1	19967075
N@@	O	-1	19967075
BC@@	O	-1	19967075
1,	O	-1	19967075
A@@	O	-1	19967075
Q@@	O	-1	19967075
P@@	O	-1	19967075
1	O	-1	19967075
and	O	-1	19967075
O@@	O	-1	19967075
AT@@	O	-1	19967075
.	O	-1	19967075

L@@	O	-1	20024739
on@@	O	-1	20024739
g@@	O	-1	20024739
it@@	O	-1	20024739
ud@@	O	-1	20024739
inal	O	-1	20024739
association	O	-1	20024739
of	O	-1	20024739
alco@@	B-Chemical	D000431	20024739
hol	I-Chemical	-1	20024739
use	O	-1	20024739
with	O	-1	20024739
H@@	B-Disease	D015658	20024739
IV	I-Disease	-1	20024739
disease	I-Disease	-1	20024739
progres@@	O	-1	20024739
sion	O	-1	20024739
and	O	-1	20024739
psych@@	O	-1	20024739
ological	O	-1	20024739
heal@@	O	-1	20024739
th	O	-1	20024739
of	O	-1	20024739
women	O	-1	20024739
with	O	-1	20024739
H@@	O	-1	20024739
I@@	O	-1	20024739
V@@	O	-1	20024739
.	O	-1	20024739
We	O	-1	20024739
evaluated	O	-1	20024739
the	O	-1	20024739
association	O	-1	20024739
of	O	-1	20024739
alco@@	B-Chemical	D000431	20024739
hol	I-Chemical	-1	20024739
consum@@	O	-1	20024739
ption	O	-1	20024739
and	O	-1	20024739
de@@	B-Disease	D003866	20024739
pression	I-Disease	-1	20024739
,	O	-1	20024739
and	O	-1	20024739
their	O	-1	20024739
effects	O	-1	20024739
on	O	-1	20024739
H@@	B-Disease	D015658	20024739
IV	I-Disease	-1	20024739
disease	I-Disease	-1	20024739
progres@@	O	-1	20024739
sion	O	-1	20024739
among	O	-1	20024739
women	O	-1	20024739
with	O	-1	20024739
H@@	O	-1	20024739
I@@	O	-1	20024739
V@@	O	-1	20024739
.	O	-1	20024739
The	O	-1	20024739
study	O	-1	20024739
included	O	-1	20024739
8@@	O	-1	20024739
7@@	O	-1	20024739
1	O	-1	20024739
women	O	-1	20024739
with	O	-1	20024739
H@@	O	-1	20024739
IV	O	-1	20024739
who	O	-1	20024739
were	O	-1	20024739
rec@@	O	-1	20024739
ru@@	O	-1	20024739
ited	O	-1	20024739
from	O	-1	20024739
19@@	O	-1	20024739
9@@	O	-1	20024739
3@@	O	-1	20024739
-1@@	O	-1	20024739
9@@	O	-1	20024739
9@@	O	-1	20024739
5	O	-1	20024739
in	O	-1	20024739
four	O	-1	20024739
U@@	O	-1	20024739
S	O	-1	20024739
ci@@	O	-1	20024739
ti@@	O	-1	20024739
es.	O	-1	20024739
The	O	-1	20024739
partic@@	O	-1	20024739
ip@@	O	-1	20024739
ants	O	-1	20024739
had	O	-1	20024739
physi@@	O	-1	20024739
c@@	O	-1	20024739
al	O	-1	20024739
examin@@	O	-1	20024739
ation,	O	-1	20024739
med@@	O	-1	20024739
ical	O	-1	20024739
recor@@	O	-1	20024739
d	O	-1	20024739
extrac@@	O	-1	20024739
tion,	O	-1	20024739
and	O	-1	20024739
ven@@	O	-1	20024739
ip@@	O	-1	20024739
unc@@	O	-1	20024739
t@@	O	-1	20024739
ure,	O	-1	20024739
C@@	O	-1	20024739
D@@	O	-1	20024739
4@@	O	-1	20024739
+@@	O	-1	20024739
T@@	O	-1	20024739
-@@	O	-1	20024739
cell	O	-1	20024739
coun@@	O	-1	20024739
ts	O	-1	20024739
determin@@	O	-1	20024739
ation,	O	-1	20024739
meas@@	O	-1	20024739
ure@@	O	-1	20024739
ment	O	-1	20024739
of	O	-1	20024739
de@@	B-Disease	D003866	20024739
pression	I-Disease	-1	20024739
symptoms	O	-1	20024739
(@@	O	-1	20024739
using	O	-1	20024739
the	O	-1	20024739
sel@@	O	-1	20024739
f@@	O	-1	20024739
-@@	O	-1	20024739
report	O	-1	20024739
C@@	O	-1	20024739
ent@@	O	-1	20024739
er	O	-1	20024739
for	O	-1	20024739
E@@	O	-1	20024739
pi@@	O	-1	20024739
de@@	O	-1	20024739
m@@	O	-1	20024739
io@@	O	-1	20024739
log@@	O	-1	20024739
ical	O	-1	20024739
S@@	O	-1	20024739
t@@	O	-1	20024739
udi@@	O	-1	20024739
es@@	O	-1	20024739
-	O	-1	20024739
De@@	B-Disease	D003866	20024739
pression	I-Disease	-1	20024739
S@@	O	-1	20024739
cal@@	O	-1	20024739
e@@	O	-1	20024739
),	O	-1	20024739
and	O	-1	20024739
alco@@	B-Chemical	D000431	20024739
hol	I-Chemical	-1	20024739
use	O	-1	20024739
assess@@	O	-1	20024739
ment	O	-1	20024739
at	O	-1	20024739
en@@	O	-1	20024739
ro@@	O	-1	20024739
ll@@	O	-1	20024739
ment@@	O	-1	20024739
,	O	-1	20024739
and	O	-1	20024739
se@@	O	-1	20024739
mi@@	O	-1	20024739
an@@	O	-1	20024739
n@@	O	-1	20024739
ually	O	-1	20024739
un@@	O	-1	20024739
ti@@	O	-1	20024739
l	O	-1	20024739
M@@	O	-1	20024739
arc@@	O	-1	20024739
h	O	-1	20024739
20@@	O	-1	20024739
0@@	O	-1	20024739
0@@	O	-1	20024739
.	O	-1	20024739
M@@	O	-1	20024739
ul@@	O	-1	20024739
ti@@	O	-1	20024739
level	O	-1	20024739
ran@@	O	-1	20024739
do@@	O	-1	20024739
m	O	-1	20024739
co@@	O	-1	20024739
eff@@	O	-1	20024739
ici@@	O	-1	20024739
ent	O	-1	20024739
or@@	O	-1	20024739
d@@	O	-1	20024739
inal	O	-1	20024739
models	O	-1	20024739
as	O	-1	20024739
well	O	-1	20024739
as	O	-1	20024739
multi@@	O	-1	20024739
level	O	-1	20024739
models	O	-1	20024739
with	O	-1	20024739
j@@	O	-1	20024739
o@@	O	-1	20024739
in@@	O	-1	20024739
t	O	-1	20024739
responses	O	-1	20024739
were	O	-1	20024739
used	O	-1	20024739
in	O	-1	20024739
the	O	-1	20024739
analy@@	O	-1	20024739
sis.	O	-1	20024739
There	O	-1	20024739
was	O	-1	20024739
no	O	-1	20024739
significant	O	-1	20024739
association	O	-1	20024739
between	O	-1	20024739
level	O	-1	20024739
of	O	-1	20024739
alco@@	B-Chemical	D000431	20024739
hol	I-Chemical	-1	20024739
use	O	-1	20024739
and	O	-1	20024739
C@@	O	-1	20024739
D@@	O	-1	20024739
4@@	O	-1	20024739
+	O	-1	20024739
T@@	O	-1	20024739
-@@	O	-1	20024739
cell	O	-1	20024739
coun@@	O	-1	20024739
t@@	O	-1	20024739
s.	O	-1	20024739
Whe@@	O	-1	20024739
n	O	-1	20024739
partic@@	O	-1	20024739
ip@@	O	-1	20024739
ants	O	-1	20024739
were	O	-1	20024739
str@@	O	-1	20024739
ati@@	O	-1	20024739
fied	O	-1	20024739
by	O	-1	20024739
anti@@	O	-1	20024739
ret@@	O	-1	20024739
ro@@	O	-1	20024739
viral	O	-1	20024739
therapy	O	-1	20024739
(A@@	O	-1	20024739
R@@	O	-1	20024739
T)	O	-1	20024739
use@@	O	-1	20024739
,	O	-1	20024739
the	O	-1	20024739
association	O	-1	20024739
between	O	-1	20024739
alco@@	B-Chemical	D000431	20024739
hol	I-Chemical	-1	20024739
and	O	-1	20024739
C@@	O	-1	20024739
D@@	O	-1	20024739
4@@	O	-1	20024739
+	O	-1	20024739
T@@	O	-1	20024739
-@@	O	-1	20024739
cell	O	-1	20024739
did	O	-1	20024739
not	O	-1	20024739
reac@@	O	-1	20024739
h	O	-1	20024739
statis@@	O	-1	20024739
tical	O	-1	20024739
signific@@	O	-1	20024739
ance@@	O	-1	20024739
.	O	-1	20024739
The	O	-1	20024739
association	O	-1	20024739
between	O	-1	20024739
alco@@	B-Chemical	D000431	20024739
hol	I-Chemical	-1	20024739
consum@@	O	-1	20024739
ption	O	-1	20024739
and	O	-1	20024739
de@@	B-Disease	D003866	20024739
pression	I-Disease	-1	20024739
was	O	-1	20024739
significant	O	-1	20024739
(p@@	O	-1	20024739
<@@	O	-1	20024739
0.00@@	O	-1	20024739
1).	O	-1	20024739
De@@	B-Disease	D003866	20024739
pression	I-Disease	-1	20024739
had	O	-1	20024739
a	O	-1	20024739
significant	O	-1	20024739
negative	O	-1	20024739
effect	O	-1	20024739
on	O	-1	20024739
C@@	O	-1	20024739
D@@	O	-1	20024739
4@@	O	-1	20024739
+	O	-1	20024739
T@@	O	-1	20024739
-@@	O	-1	20024739
cell	O	-1	20024739
coun@@	O	-1	20024739
ts	O	-1	20024739
over	O	-1	20024739
time	O	-1	20024739
reg@@	O	-1	20024739
ar@@	O	-1	20024739
d@@	O	-1	20024739
less	O	-1	20024739
of	O	-1	20024739
A@@	O	-1	20024739
R@@	O	-1	20024739
T	O	-1	20024739
use.	O	-1	20024739
Our	O	-1	20024739
findings	O	-1	20024739
suggest	O	-1	20024739
that	O	-1	20024739
alco@@	B-Chemical	D000431	20024739
hol	I-Chemical	-1	20024739
consum@@	O	-1	20024739
ption	O	-1	20024739
has	O	-1	20024739
a	O	-1	20024739
direct	O	-1	20024739
association	O	-1	20024739
with	O	-1	20024739
de@@	B-Disease	D003866	20024739
pression	I-Disease	-1	20024739
.	O	-1	20024739
M@@	O	-1	20024739
ore@@	O	-1	20024739
o@@	O	-1	20024739
ver,	O	-1	20024739
de@@	B-Disease	D003866	20024739
pression	I-Disease	-1	20024739
is	O	-1	20024739
associated	O	-1	20024739
with	O	-1	20024739
H@@	B-Disease	D015658	20024739
IV	I-Disease	-1	20024739
disease	I-Disease	-1	20024739
progres@@	O	-1	20024739
sion.	O	-1	20024739
Our	O	-1	20024739
findings	O	-1	20024739
have	O	-1	20024739
implic@@	O	-1	20024739
ations	O	-1	20024739
for	O	-1	20024739
the	O	-1	20024739
pro@@	O	-1	20024739
vi@@	O	-1	20024739
sion	O	-1	20024739
of	O	-1	20024739
alco@@	B-Chemical	D000431	20024739
hol	I-Chemical	-1	20024739
use	O	-1	20024739
inter@@	O	-1	20024739
ven@@	O	-1	20024739
tions	O	-1	20024739
and	O	-1	20024739
psych@@	O	-1	20024739
ological	O	-1	20024739
res@@	O	-1	20024739
o@@	O	-1	20024739
ur@@	O	-1	20024739
ces	O	-1	20024739
to	O	-1	20024739
impro@@	O	-1	20024739
ve	O	-1	20024739
the	O	-1	20024739
heal@@	O	-1	20024739
th	O	-1	20024739
of	O	-1	20024739
women	O	-1	20024739
with	O	-1	20024739
H@@	O	-1	20024739
I@@	O	-1	20024739
V@@	O	-1	20024739
.	O	-1	20024739

C@@	O	-1	20034406
hemo@@	O	-1	20034406
k@@	O	-1	20034406
ine	O	-1	20034406
C@@	O	-1	20034406
CL@@	O	-1	20034406
2	O	-1	20034406
and	O	-1	20034406
its	O	-1	20034406
receptor	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2	O	-1	20034406
are	O	-1	20034406
increased	O	-1	20034406
in	O	-1	20034406
the	O	-1	20034406
hippocamp@@	O	-1	20034406
us	O	-1	20034406
following	O	-1	20034406
pilocar@@	B-Chemical	D010862	20034406
pine	I-Chemical	-1	20034406
-induced	O	-1	20034406
status	B-Disease	D013226	20034406
epilep@@	I-Disease	-1	20034406
tic@@	I-Disease	-1	20034406
us	I-Disease	-1	20034406
.	O	-1	20034406
BACKGROUND:	O	-1	20034406
Ne@@	B-Disease	D007249	20034406
uro@@	I-Disease	-1	20034406
inflam@@	I-Disease	-1	20034406
m@@	I-Disease	-1	20034406
ation	I-Disease	-1	20034406
occur@@	O	-1	20034406
s	O	-1	20034406
after	O	-1	20034406
seizures	B-Disease	D012640	20034406
and	O	-1	20034406
is	O	-1	20034406
implic@@	O	-1	20034406
ated	O	-1	20034406
in	O	-1	20034406
epile@@	O	-1	20034406
pto@@	O	-1	20034406
gene@@	O	-1	20034406
sis.	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2	O	-1	20034406
is	O	-1	20034406
a	O	-1	20034406
chemo@@	O	-1	20034406
k@@	O	-1	20034406
ine	O	-1	20034406
receptor	O	-1	20034406
for	O	-1	20034406
C@@	O	-1	20034406
CL@@	O	-1	20034406
2	O	-1	20034406
and	O	-1	20034406
their	O	-1	20034406
inter@@	O	-1	20034406
action	O	-1	20034406
medi@@	O	-1	20034406
ates	O	-1	20034406
mon@@	O	-1	20034406
ocyte	O	-1	20034406
inf@@	O	-1	20034406
iltration	O	-1	20034406
in	O	-1	20034406
the	O	-1	20034406
neuro@@	B-Disease	D007249	20034406
inflam@@	I-Disease	-1	20034406
mat@@	I-Disease	-1	20034406
ory	I-Disease	-1	20034406
cas@@	O	-1	20034406
c@@	O	-1	20034406
ade	O	-1	20034406
tri@@	O	-1	20034406
g@@	O	-1	20034406
ge@@	O	-1	20034406
red	O	-1	20034406
in	O	-1	20034406
different	O	-1	20034406
brain	O	-1	20034406
path@@	O	-1	20034406
olog@@	O	-1	20034406
i@@	O	-1	20034406
es.	O	-1	20034406
In	O	-1	20034406
this	O	-1	20034406
wor@@	O	-1	20034406
k	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2	O	-1	20034406
and	O	-1	20034406
C@@	O	-1	20034406
CL@@	O	-1	20034406
2	O	-1	20034406
expression	O	-1	20034406
were	O	-1	20034406
examined	O	-1	20034406
following	O	-1	20034406
status	B-Disease	D013226	20034406
epilep@@	I-Disease	-1	20034406
tic@@	I-Disease	-1	20034406
us	I-Disease	-1	20034406
(	O	-1	20034406
S@@	B-Disease	D013226	20034406
E	I-Disease	-1	20034406
)	O	-1	20034406
induced	O	-1	20034406
by	O	-1	20034406
pilocar@@	B-Chemical	D010862	20034406
pine	I-Chemical	-1	20034406
injec@@	O	-1	20034406
tion.	O	-1	20034406
METHODS:	O	-1	20034406
S@@	B-Disease	D013226	20034406
E	I-Disease	-1	20034406
was	O	-1	20034406
induced	O	-1	20034406
by	O	-1	20034406
pilocar@@	B-Chemical	D010862	20034406
pine	I-Chemical	-1	20034406
injec@@	O	-1	20034406
tion.	O	-1	20034406
C@@	O	-1	20034406
ont@@	O	-1	20034406
ro@@	O	-1	20034406
l	O	-1	20034406
rats	O	-1	20034406
were	O	-1	20034406
injected	O	-1	20034406
with	O	-1	20034406
saline	O	-1	20034406
in@@	O	-1	20034406
ste@@	O	-1	20034406
ad	O	-1	20034406
of	O	-1	20034406
pilocar@@	B-Chemical	D010862	20034406
pine	I-Chemical	-1	20034406
.	O	-1	20034406
F@@	O	-1	20034406
i@@	O	-1	20034406
ve	O	-1	20034406
days	O	-1	20034406
after	O	-1	20034406
S@@	B-Disease	D013226	20034406
E	I-Disease	-1	20034406
,	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2	O	-1	20034406
st@@	O	-1	20034406
aining	O	-1	20034406
in	O	-1	20034406
neuron@@	O	-1	20034406
s	O	-1	20034406
and	O	-1	20034406
g@@	O	-1	20034406
lial	O	-1	20034406
cells	O	-1	20034406
was	O	-1	20034406
examined	O	-1	20034406
using	O	-1	20034406
im@@	O	-1	20034406
un@@	O	-1	20034406
o@@	O	-1	20034406
histo@@	O	-1	20034406
chemical	O	-1	20034406
an@@	O	-1	20034406
al@@	O	-1	20034406
ys@@	O	-1	20034406
es.	O	-1	20034406
The	O	-1	20034406
number	O	-1	20034406
of	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2	O	-1	20034406
positive	O	-1	20034406
cells	O	-1	20034406
was	O	-1	20034406
determined	O	-1	20034406
using	O	-1	20034406
ste@@	O	-1	20034406
re@@	O	-1	20034406
ology	O	-1	20034406
prob@@	O	-1	20034406
es	O	-1	20034406
in	O	-1	20034406
the	O	-1	20034406
hippocamp@@	O	-1	20034406
us.	O	-1	20034406
C@@	O	-1	20034406
CL@@	O	-1	20034406
2	O	-1	20034406
expression	O	-1	20034406
in	O	-1	20034406
the	O	-1	20034406
hippocamp@@	O	-1	20034406
us	O	-1	20034406
was	O	-1	20034406
examined	O	-1	20034406
by	O	-1	20034406
mol@@	O	-1	20034406
ec@@	O	-1	20034406
ular	O	-1	20034406
ass@@	O	-1	20034406
a@@	O	-1	20034406
y.	O	-1	20034406
RESULTS:	O	-1	20034406
In@@	O	-1	20034406
c@@	O	-1	20034406
reas@@	O	-1	20034406
ed	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2	O	-1	20034406
was	O	-1	20034406
observed	O	-1	20034406
in	O	-1	20034406
the	O	-1	20034406
hippocamp@@	O	-1	20034406
us	O	-1	20034406
after	O	-1	20034406
S@@	B-Disease	D013226	20034406
E	I-Disease	-1	20034406
.	O	-1	20034406
S@@	B-Disease	D012640	20034406
e@@	I-Disease	-1	20034406
iz@@	I-Disease	-1	20034406
ures	I-Disease	-1	20034406
also	O	-1	20034406
resulted	O	-1	20034406
in	O	-1	20034406
al@@	O	-1	20034406
ter@@	O	-1	20034406
ations	O	-1	20034406
to	O	-1	20034406
the	O	-1	20034406
cell	O	-1	20034406
typ@@	O	-1	20034406
es	O	-1	20034406
ex@@	O	-1	20034406
press@@	O	-1	20034406
ing	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2@@	O	-1	20034406
.	O	-1	20034406
In@@	O	-1	20034406
c@@	O	-1	20034406
reas@@	O	-1	20034406
ed	O	-1	20034406
numb@@	O	-1	20034406
ers	O	-1	20034406
of	O	-1	20034406
neuron@@	O	-1	20034406
s	O	-1	20034406
that	O	-1	20034406
ex@@	O	-1	20034406
press@@	O	-1	20034406
ed	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2	O	-1	20034406
was	O	-1	20034406
observed	O	-1	20034406
following	O	-1	20034406
S@@	B-Disease	D013226	20034406
E	I-Disease	-1	20034406
.	O	-1	20034406
M@@	O	-1	20034406
ic@@	O	-1	20034406
ro@@	O	-1	20034406
g@@	O	-1	20034406
lial	O	-1	20034406
cells	O	-1	20034406
were	O	-1	20034406
more	O	-1	20034406
clo@@	O	-1	20034406
se@@	O	-1	20034406
ly	O	-1	20034406
ap@@	O	-1	20034406
pos@@	O	-1	20034406
ed	O	-1	20034406
to	O	-1	20034406
the	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2-@@	O	-1	20034406
l@@	O	-1	20034406
a@@	O	-1	20034406
be@@	O	-1	20034406
l@@	O	-1	20034406
ed	O	-1	20034406
cells	O	-1	20034406
in	O	-1	20034406
S@@	B-Disease	D013226	20034406
E	I-Disease	-1	20034406
rats.	O	-1	20034406
In	O	-1	20034406
addi@@	O	-1	20034406
tion,	O	-1	20034406
rats	O	-1	20034406
that	O	-1	20034406
experienced	O	-1	20034406
S@@	B-Disease	D013226	20034406
E	I-Disease	-1	20034406
ex@@	O	-1	20034406
hib@@	O	-1	20034406
ited	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2-@@	O	-1	20034406
l@@	O	-1	20034406
a@@	O	-1	20034406
be@@	O	-1	20034406
l@@	O	-1	20034406
ing	O	-1	20034406
in	O	-1	20034406
po@@	O	-1	20034406
pul@@	O	-1	20034406
ations	O	-1	20034406
of	O	-1	20034406
hyper@@	B-Disease	D006984	20034406
tro@@	I-Disease	-1	20034406
ph@@	I-Disease	-1	20034406
ied	I-Disease	-1	20034406
ast@@	O	-1	20034406
ro@@	O	-1	20034406
cy@@	O	-1	20034406
t@@	O	-1	20034406
es,	O	-1	20034406
es@@	O	-1	20034406
p@@	O	-1	20034406
ec@@	O	-1	20034406
i@@	O	-1	20034406
ally	O	-1	20034406
in	O	-1	20034406
CA@@	O	-1	20034406
1	O	-1	20034406
and	O	-1	20034406
d@@	O	-1	20034406
ent@@	O	-1	20034406
ate	O	-1	20034406
g@@	O	-1	20034406
y@@	O	-1	20034406
ru@@	O	-1	20034406
s.	O	-1	20034406
These	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2@@	O	-1	20034406
+	O	-1	20034406
ast@@	O	-1	20034406
ro@@	O	-1	20034406
c@@	O	-1	20034406
ty@@	O	-1	20034406
tes	O	-1	20034406
were	O	-1	20034406
not	O	-1	20034406
observed	O	-1	20034406
in	O	-1	20034406
control	O	-1	20034406
rats.	O	-1	20034406
E@@	O	-1	20034406
x@@	O	-1	20034406
amin@@	O	-1	20034406
ation	O	-1	20034406
of	O	-1	20034406
C@@	O	-1	20034406
CL@@	O	-1	20034406
2	O	-1	20034406
expression	O	-1	20034406
showed	O	-1	20034406
that	O	-1	20034406
it	O	-1	20034406
was	O	-1	20034406
elevated	O	-1	20034406
in	O	-1	20034406
the	O	-1	20034406
hippocamp@@	O	-1	20034406
us	O	-1	20034406
following	O	-1	20034406
S@@	B-Disease	D013226	20034406
E	I-Disease	-1	20034406
.	O	-1	20034406
CONCLUSION:	O	-1	20034406
The	O	-1	20034406
data	O	-1	20034406
show	O	-1	20034406
that	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2	O	-1	20034406
and	O	-1	20034406
C@@	O	-1	20034406
CL@@	O	-1	20034406
2	O	-1	20034406
are	O	-1	20034406
up@@	O	-1	20034406
-@@	O	-1	20034406
reg@@	O	-1	20034406
ul@@	O	-1	20034406
ated	O	-1	20034406
in	O	-1	20034406
the	O	-1	20034406
hippocamp@@	O	-1	20034406
us	O	-1	20034406
after	O	-1	20034406
pilocar@@	B-Chemical	D010862	20034406
pine	I-Chemical	-1	20034406
-induced	O	-1	20034406
S@@	B-Disease	D013226	20034406
E	I-Disease	-1	20034406
.	O	-1	20034406
S@@	B-Disease	D012640	20034406
e@@	I-Disease	-1	20034406
iz@@	I-Disease	-1	20034406
ures	I-Disease	-1	20034406
also	O	-1	20034406
result	O	-1	20034406
in	O	-1	20034406
changes	O	-1	20034406
to	O	-1	20034406
C@@	O	-1	20034406
CR@@	O	-1	20034406
2	O	-1	20034406
receptor	O	-1	20034406
expression	O	-1	20034406
in	O	-1	20034406
neuron@@	O	-1	20034406
s	O	-1	20034406
and	O	-1	20034406
ast@@	O	-1	20034406
ro@@	O	-1	20034406
cy@@	O	-1	20034406
t@@	O	-1	20034406
es.	O	-1	20034406
These	O	-1	20034406
changes	O	-1	20034406
might	O	-1	20034406
be	O	-1	20034406
involved	O	-1	20034406
in	O	-1	20034406
de@@	O	-1	20034406
tri@@	O	-1	20034406
mental	O	-1	20034406
neuro@@	O	-1	20034406
plas@@	O	-1	20034406
tic@@	O	-1	20034406
ity	O	-1	20034406
and	O	-1	20034406
neuro@@	B-Disease	D007249	20034406
inflam@@	I-Disease	-1	20034406
mat@@	I-Disease	-1	20034406
ory	I-Disease	-1	20034406
changes	O	-1	20034406
that	O	-1	20034406
occ@@	O	-1	20034406
ur	O	-1	20034406
following	O	-1	20034406
seizures	B-Disease	D012640	20034406
.	O	-1	20034406

M@@	B-Chemical	D008668	20046642
et@@	I-Chemical	-1	20046642
al@@	I-Chemical	-1	20046642
lo@@	I-Chemical	-1	20046642
thi@@	I-Chemical	-1	20046642
one@@	I-Chemical	-1	20046642
in	I-Chemical	-1	20046642
induction	O	-1	20046642
reduc@@	O	-1	20046642
es	O	-1	20046642
cas@@	O	-1	20046642
p@@	O	-1	20046642
as@@	O	-1	20046642
e-@@	O	-1	20046642
3	O	-1	20046642
activity	O	-1	20046642
and	O	-1	20046642
T@@	O	-1	20046642
N@@	O	-1	20046642
F@@	O	-1	20046642
al@@	O	-1	20046642
ph@@	O	-1	20046642
a	O	-1	20046642
levels	O	-1	20046642
with	O	-1	20046642
pres@@	O	-1	20046642
er@@	O	-1	20046642
v@@	O	-1	20046642
ation	O	-1	20046642
of	O	-1	20046642
cognitive	O	-1	20046642
function	O	-1	20046642
and	O	-1	20046642
int@@	O	-1	20046642
ac@@	O	-1	20046642
t	O	-1	20046642
hippocamp@@	O	-1	20046642
al	O	-1	20046642
neuron@@	O	-1	20046642
s	O	-1	20046642
in	O	-1	20046642
car@@	B-Chemical	D002330	20046642
m@@	I-Chemical	-1	20046642
ust@@	I-Chemical	-1	20046642
ine	I-Chemical	-1	20046642
-treated	O	-1	20046642
rats.	O	-1	20046642
H@@	O	-1	20046642
ip@@	O	-1	20046642
p@@	O	-1	20046642
ocamp@@	O	-1	20046642
al	O	-1	20046642
in@@	O	-1	20046642
te@@	O	-1	20046642
g@@	O	-1	20046642
r@@	O	-1	20046642
ity	O	-1	20046642
is	O	-1	20046642
es@@	O	-1	20046642
sen@@	O	-1	20046642
tial	O	-1	20046642
for	O	-1	20046642
cognitive	O	-1	20046642
func@@	O	-1	20046642
tions.	O	-1	20046642
O@@	O	-1	20046642
n	O	-1	20046642
the	O	-1	20046642
other	O	-1	20046642
h@@	O	-1	20046642
and@@	O	-1	20046642
,	O	-1	20046642
induction	O	-1	20046642
of	O	-1	20046642
met@@	B-Chemical	D008668	20046642
al@@	I-Chemical	-1	20046642
lo@@	I-Chemical	-1	20046642
thi@@	I-Chemical	-1	20046642
one@@	I-Chemical	-1	20046642
in	I-Chemical	-1	20046642
(	O	-1	20046642
M@@	B-Chemical	D008668	20046642
T	I-Chemical	-1	20046642
)	O	-1	20046642
by	O	-1	20046642
Z@@	B-Chemical	D019287	20046642
n@@	I-Chemical	-1	20046642
S@@	I-Chemical	-1	20046642
O@@	I-Chemical	-1	20046642
(4@@	I-Chemical	-1	20046642
)	I-Chemical	-1	20046642
and	O	-1	20046642
its	O	-1	20046642
role	O	-1	20046642
in	O	-1	20046642
neuro@@	O	-1	20046642
prot@@	O	-1	20046642
ection	O	-1	20046642
has	O	-1	20046642
been	O	-1	20046642
doc@@	O	-1	20046642
um@@	O	-1	20046642
ent@@	O	-1	20046642
ed.	O	-1	20046642
The	O	-1	20046642
present	O	-1	20046642
study	O	-1	20046642
a@@	O	-1	20046642
im@@	O	-1	20046642
ed	O	-1	20046642
to	O	-1	20046642
expl@@	O	-1	20046642
or@@	O	-1	20046642
e	O	-1	20046642
the	O	-1	20046642
effect	O	-1	20046642
of	O	-1	20046642
M@@	B-Chemical	D008668	20046642
T	I-Chemical	-1	20046642
induction	O	-1	20046642
on	O	-1	20046642
car@@	B-Chemical	D002330	20046642
m@@	I-Chemical	-1	20046642
ust@@	I-Chemical	-1	20046642
ine	I-Chemical	-1	20046642
(	O	-1	20046642
BC@@	B-Chemical	D002330	20046642
N@@	I-Chemical	-1	20046642
U	I-Chemical	-1	20046642
)@@	O	-1	20046642
-induced	O	-1	20046642
hippocamp@@	O	-1	20046642
al	O	-1	20046642
cognitive	B-Disease	D003072	20046642
dysfunction	I-Disease	-1	20046642
in	O	-1	20046642
rats.	O	-1	20046642
A	O	-1	20046642
total	O	-1	20046642
of	O	-1	20046642
60	O	-1	20046642
male	O	-1	20046642
Wistar	O	-1	20046642
al@@	O	-1	20046642
bin@@	O	-1	20046642
o	O	-1	20046642
rats	O	-1	20046642
were	O	-1	20046642
random@@	O	-1	20046642
ly	O	-1	20046642
divid@@	O	-1	20046642
ed	O	-1	20046642
into	O	-1	20046642
four	O	-1	20046642
groups	O	-1	20046642
(1@@	O	-1	20046642
5@@	O	-1	20046642
/@@	O	-1	20046642
group@@	O	-1	20046642
)@@	O	-1	20046642
:	O	-1	20046642
The	O	-1	20046642
control	O	-1	20046642
group	O	-1	20046642
injected	O	-1	20046642
with	O	-1	20046642
single	O	-1	20046642
doses	O	-1	20046642
of	O	-1	20046642
normal	O	-1	20046642
saline	O	-1	20046642
(@@	O	-1	20046642
i.@@	O	-1	20046642
c@@	O	-1	20046642
.@@	O	-1	20046642
v@@	O	-1	20046642
)	O	-1	20046642
followed	O	-1	20046642
24	O	-1	20046642
h	O	-1	20046642
lat@@	O	-1	20046642
er	O	-1	20046642
by	O	-1	20046642
BC@@	B-Chemical	D002330	20046642
N@@	I-Chemical	-1	20046642
U	I-Chemical	-1	20046642
sol@@	O	-1	20046642
v@@	O	-1	20046642
ent	O	-1	20046642
(@@	O	-1	20046642
i.v@@	O	-1	20046642
).	O	-1	20046642
The	O	-1	20046642
second	O	-1	20046642
group	O	-1	20046642
administered	O	-1	20046642
Z@@	B-Chemical	D019287	20046642
n@@	I-Chemical	-1	20046642
S@@	I-Chemical	-1	20046642
O@@	I-Chemical	-1	20046642
(4@@	I-Chemical	-1	20046642
)	I-Chemical	-1	20046642
(0.@@	O	-1	20046642
1	O	-1	20046642
mic@@	O	-1	20046642
rom@@	O	-1	20046642
ol@@	O	-1	20046642
/@@	O	-1	20046642
10	O	-1	20046642
micro@@	O	-1	20046642
l	O	-1	20046642
normal	O	-1	20046642
sal@@	O	-1	20046642
ine,	O	-1	20046642
i.@@	O	-1	20046642
c@@	O	-1	20046642
.@@	O	-1	20046642
v@@	O	-1	20046642
,	O	-1	20046642
on@@	O	-1	20046642
ce@@	O	-1	20046642
)	O	-1	20046642
then	O	-1	20046642
BC@@	B-Chemical	D002330	20046642
N@@	I-Chemical	-1	20046642
U	I-Chemical	-1	20046642
sol@@	O	-1	20046642
v@@	O	-1	20046642
ent	O	-1	20046642
(@@	O	-1	20046642
i.v@@	O	-1	20046642
)	O	-1	20046642
after	O	-1	20046642
24	O	-1	20046642
h@@	O	-1	20046642
.	O	-1	20046642
Th@@	O	-1	20046642
ir@@	O	-1	20046642
d	O	-1	20046642
group	O	-1	20046642
received	O	-1	20046642
BC@@	B-Chemical	D002330	20046642
N@@	I-Chemical	-1	20046642
U	I-Chemical	-1	20046642
(2@@	O	-1	20046642
0	O	-1	20046642
mg/kg@@	O	-1	20046642
,	O	-1	20046642
i.v@@	O	-1	20046642
,	O	-1	20046642
on@@	O	-1	20046642
ce@@	O	-1	20046642
)	O	-1	20046642
24	O	-1	20046642
h	O	-1	20046642
after	O	-1	20046642
injection	O	-1	20046642
with	O	-1	20046642
normal	O	-1	20046642
saline	O	-1	20046642
(@@	O	-1	20046642
i.@@	O	-1	20046642
c@@	O	-1	20046642
.@@	O	-1	20046642
v@@	O	-1	20046642
).	O	-1	20046642
F@@	O	-1	20046642
o@@	O	-1	20046642
ur@@	O	-1	20046642
th	O	-1	20046642
group	O	-1	20046642
received	O	-1	20046642
a	O	-1	20046642
single	O	-1	20046642
dose	O	-1	20046642
of	O	-1	20046642
Z@@	B-Chemical	D019287	20046642
n@@	I-Chemical	-1	20046642
S@@	I-Chemical	-1	20046642
O@@	I-Chemical	-1	20046642
(4@@	I-Chemical	-1	20046642
)	I-Chemical	-1	20046642
(0.@@	O	-1	20046642
1	O	-1	20046642
mic@@	O	-1	20046642
rom@@	O	-1	20046642
ol@@	O	-1	20046642
/@@	O	-1	20046642
10	O	-1	20046642
micro@@	O	-1	20046642
l	O	-1	20046642
normal	O	-1	20046642
sal@@	O	-1	20046642
ine,	O	-1	20046642
i.@@	O	-1	20046642
c@@	O	-1	20046642
.@@	O	-1	20046642
v@@	O	-1	20046642
)	O	-1	20046642
then	O	-1	20046642
BC@@	B-Chemical	D002330	20046642
N@@	I-Chemical	-1	20046642
U	I-Chemical	-1	20046642
(2@@	O	-1	20046642
0	O	-1	20046642
mg/kg@@	O	-1	20046642
,	O	-1	20046642
i.v@@	O	-1	20046642
,	O	-1	20046642
on@@	O	-1	20046642
ce@@	O	-1	20046642
)	O	-1	20046642
after	O	-1	20046642
24	O	-1	20046642
h@@	O	-1	20046642
.	O	-1	20046642
The	O	-1	20046642
obtained	O	-1	20046642
data	O	-1	20046642
revealed	O	-1	20046642
that	O	-1	20046642
BC@@	B-Chemical	D002330	20046642
N@@	I-Chemical	-1	20046642
U	I-Chemical	-1	20046642
administration	O	-1	20046642
resulted	O	-1	20046642
in	O	-1	20046642
deter@@	B-Disease	D007859	20046642
i@@	I-Disease	-1	20046642
or@@	I-Disease	-1	20046642
ation	I-Disease	-1	20046642
of	I-Disease	-1	20046642
lear@@	I-Disease	-1	20046642
ning	I-Disease	-1	20046642
and	I-Disease	-1	20046642
sh@@	I-Disease	-1	20046642
ort@@	I-Disease	-1	20046642
-term	I-Disease	-1	20046642
memory	I-Disease	-1	20046642
deter@@	B-Disease	D008569	20046642
i@@	I-Disease	-1	20046642
or@@	I-Disease	-1	20046642
ation	I-Disease	-1	20046642
of	I-Disease	-1	20046642
lear@@	I-Disease	-1	20046642
ning	I-Disease	-1	20046642
and	I-Disease	-1	20046642
sh@@	I-Disease	-1	20046642
ort@@	I-Disease	-1	20046642
-term	I-Disease	-1	20046642
memory	I-Disease	-1	20046642
(S@@	O	-1	20046642
T@@	O	-1	20046642
M@@	O	-1	20046642
),	O	-1	20046642
as	O	-1	20046642
measured	O	-1	20046642
by	O	-1	20046642
using	O	-1	20046642
radi@@	O	-1	20046642
al	O	-1	20046642
ar@@	O	-1	20046642
m	O	-1	20046642
w@@	O	-1	20046642
at@@	O	-1	20046642
er	O	-1	20046642
ma@@	O	-1	20046642
z@@	O	-1	20046642
e,	O	-1	20046642
ac@@	O	-1	20046642
comp@@	O	-1	20046642
an@@	O	-1	20046642
ied	O	-1	20046642
with	O	-1	20046642
decreased	O	-1	20046642
hippocamp@@	O	-1	20046642
al	O	-1	20046642
glut@@	B-Chemical	D005978	20046642
athi@@	I-Chemical	-1	20046642
one	I-Chemical	-1	20046642
reduc@@	O	-1	20046642
t@@	O	-1	20046642
ase	O	-1	20046642
(@@	O	-1	20046642
G@@	O	-1	20046642
R@@	O	-1	20046642
)	O	-1	20046642
activity	O	-1	20046642
and	O	-1	20046642
reduced	O	-1	20046642
glut@@	B-Chemical	D005978	20046642
athi@@	I-Chemical	-1	20046642
one	I-Chemical	-1	20046642
(	O	-1	20046642
G@@	B-Chemical	D005978	20046642
S@@	I-Chemical	-1	20046642
H	I-Chemical	-1	20046642
)	O	-1	20046642
cont@@	O	-1	20046642
ent@@	O	-1	20046642
.	O	-1	20046642
Al@@	O	-1	20046642
so@@	O	-1	20046642
,	O	-1	20046642
BC@@	B-Chemical	D002330	20046642
N@@	I-Chemical	-1	20046642
U	I-Chemical	-1	20046642
administration	O	-1	20046642
increased	O	-1	20046642
serum	O	-1	20046642
tumor	B-Disease	D009369	20046642
necro@@	B-Disease	D009336	20046642
sis	I-Disease	-1	20046642
fact@@	O	-1	20046642
or@@	O	-1	20046642
-@@	O	-1	20046642
al@@	O	-1	20046642
ph@@	O	-1	20046642
a	O	-1	20046642
(T@@	O	-1	20046642
N@@	O	-1	20046642
F@@	O	-1	20046642
alpha@@	O	-1	20046642
),	O	-1	20046642
hippocamp@@	O	-1	20046642
al	O	-1	20046642
M@@	B-Chemical	D008668	20046642
T	I-Chemical	-1	20046642
and	O	-1	20046642
mal@@	B-Chemical	D008315	20046642
on@@	I-Chemical	-1	20046642
di@@	I-Chemical	-1	20046642
al@@	I-Chemical	-1	20046642
de@@	I-Chemical	-1	20046642
hy@@	I-Chemical	-1	20046642
de	I-Chemical	-1	20046642
(	O	-1	20046642
MD@@	B-Chemical	D008315	20046642
A	I-Chemical	-1	20046642
)	O	-1	20046642
cont@@	O	-1	20046642
ents	O	-1	20046642
as	O	-1	20046642
well	O	-1	20046642
as	O	-1	20046642
cas@@	O	-1	20046642
p@@	O	-1	20046642
as@@	O	-1	20046642
e-@@	O	-1	20046642
3	O	-1	20046642
activity	O	-1	20046642
in	O	-1	20046642
addition	O	-1	20046642
to	O	-1	20046642
hist@@	O	-1	20046642
ological	O	-1	20046642
al@@	O	-1	20046642
ter@@	O	-1	20046642
ations.	O	-1	20046642
Z@@	B-Chemical	D019287	20046642
n@@	I-Chemical	-1	20046642
S@@	I-Chemical	-1	20046642
O@@	I-Chemical	-1	20046642
(4@@	I-Chemical	-1	20046642
)	I-Chemical	-1	20046642
pretreatment	O	-1	20046642
coun@@	O	-1	20046642
ter@@	O	-1	20046642
ac@@	O	-1	20046642
ted	O	-1	20046642
BC@@	B-Chemical	D002330	20046642
N@@	I-Chemical	-1	20046642
U	I-Chemical	-1	20046642
-induced	O	-1	20046642
inhibition	O	-1	20046642
of	O	-1	20046642
G@@	O	-1	20046642
R	O	-1	20046642
and	O	-1	20046642
deple@@	O	-1	20046642
tion	O	-1	20046642
of	O	-1	20046642
G@@	B-Chemical	D005978	20046642
S@@	I-Chemical	-1	20046642
H	I-Chemical	-1	20046642
and	O	-1	20046642
resulted	O	-1	20046642
in	O	-1	20046642
significant	O	-1	20046642
reduction	O	-1	20046642
in	O	-1	20046642
the	O	-1	20046642
levels	O	-1	20046642
of	O	-1	20046642
MD@@	B-Chemical	D008315	20046642
A	I-Chemical	-1	20046642
and	O	-1	20046642
T@@	O	-1	20046642
N@@	O	-1	20046642
F@@	O	-1	20046642
al@@	O	-1	20046642
ph@@	O	-1	20046642
a	O	-1	20046642
as	O	-1	20046642
well	O	-1	20046642
as	O	-1	20046642
the	O	-1	20046642
activity	O	-1	20046642
of	O	-1	20046642
cas@@	O	-1	20046642
p@@	O	-1	20046642
as@@	O	-1	20046642
e-@@	O	-1	20046642
3@@	O	-1	20046642
.	O	-1	20046642
The	O	-1	20046642
hist@@	O	-1	20046642
ological	O	-1	20046642
feat@@	O	-1	20046642
ures	O	-1	20046642
were	O	-1	20046642
improved	O	-1	20046642
in	O	-1	20046642
hippocamp@@	O	-1	20046642
us	O	-1	20046642
of	O	-1	20046642
rats	O	-1	20046642
treated	O	-1	20046642
with	O	-1	20046642
Z@@	B-Chemical	D019287	20046642
n@@	I-Chemical	-1	20046642
S@@	I-Chemical	-1	20046642
O@@	I-Chemical	-1	20046642
(4@@	I-Chemical	-1	20046642
)	I-Chemical	-1	20046642
+	O	-1	20046642
BC@@	B-Chemical	D002330	20046642
N@@	I-Chemical	-1	20046642
U	I-Chemical	-1	20046642
compared	O	-1	20046642
to	O	-1	20046642
only	O	-1	20046642
BC@@	B-Chemical	D002330	20046642
N@@	I-Chemical	-1	20046642
U	I-Chemical	-1	20046642
-treated	O	-1	20046642
anim@@	O	-1	20046642
al@@	O	-1	20046642
s.	O	-1	20046642
In	O	-1	20046642
concl@@	O	-1	20046642
u@@	O	-1	20046642
sion,	O	-1	20046642
M@@	B-Chemical	D008668	20046642
T	I-Chemical	-1	20046642
induction	O	-1	20046642
h@@	O	-1	20046642
al@@	O	-1	20046642
ts	O	-1	20046642
BC@@	B-Chemical	D002330	20046642
N@@	I-Chemical	-1	20046642
U	I-Chemical	-1	20046642
-induced	O	-1	20046642
hippocamp@@	O	-1	20046642
al	O	-1	20046642
toxicity	B-Disease	D064420	20046642
as	O	-1	20046642
it	O	-1	20046642
prevent@@	O	-1	20046642
ed	O	-1	20046642
G@@	O	-1	20046642
R	O	-1	20046642
inhibition	O	-1	20046642
and	O	-1	20046642
G@@	B-Chemical	D005978	20046642
S@@	I-Chemical	-1	20046642
H	I-Chemical	-1	20046642
deple@@	O	-1	20046642
tion	O	-1	20046642
and	O	-1	20046642
coun@@	O	-1	20046642
ter@@	O	-1	20046642
ac@@	O	-1	20046642
ted	O	-1	20046642
the	O	-1	20046642
increased	O	-1	20046642
levels	O	-1	20046642
of	O	-1	20046642
T@@	O	-1	20046642
N@@	O	-1	20046642
F@@	O	-1	20046642
alpha@@	O	-1	20046642
,	O	-1	20046642
MD@@	B-Chemical	D008315	20046642
A	I-Chemical	-1	20046642
and	O	-1	20046642
cas@@	O	-1	20046642
p@@	O	-1	20046642
as@@	O	-1	20046642
e-@@	O	-1	20046642
3	O	-1	20046642
activity	O	-1	20046642
with	O	-1	20046642
subsequ@@	O	-1	20046642
ent	O	-1	20046642
pres@@	O	-1	20046642
er@@	O	-1	20046642
v@@	O	-1	20046642
ation	O	-1	20046642
of	O	-1	20046642
cogn@@	O	-1	20046642
i@@	O	-1	20046642
tion.	O	-1	20046642

F@@	O	-1	20129423
atal	O	-1	20129423
carbamazepine	B-Chemical	D002220	20129423
induced	O	-1	20129423
ful@@	B-Disease	D004802	20129423
min@@	I-Disease	-1	20129423
ant	I-Disease	-1	20129423
e@@	I-Disease	-1	20129423
os@@	I-Disease	-1	20129423
in@@	I-Disease	-1	20129423
oph@@	I-Disease	-1	20129423
il@@	I-Disease	-1	20129423
ic	I-Disease	-1	20129423
(	O	-1	20129423
hyper@@	B-Disease	D004342	20129423
sensitivity	I-Disease	-1	20129423
)	O	-1	20129423
myocardi@@	B-Disease	D009205	20129423
tis	I-Disease	-1	20129423
:	O	-1	20129423
em@@	O	-1	20129423
pha@@	O	-1	20129423
sis	O	-1	20129423
on	O	-1	20129423
an@@	O	-1	20129423
at@@	O	-1	20129423
om@@	O	-1	20129423
ical	O	-1	20129423
and	O	-1	20129423
hist@@	O	-1	20129423
ological	O	-1	20129423
character@@	O	-1	20129423
is@@	O	-1	20129423
tic@@	O	-1	20129423
s,	O	-1	20129423
mechanisms	O	-1	20129423
and	O	-1	20129423
gene@@	O	-1	20129423
tics	O	-1	20129423
of	O	-1	20129423
drug	B-Disease	D004342	20129423
hyper@@	I-Disease	-1	20129423
sensitivity	I-Disease	-1	20129423
and	O	-1	20129423
differen@@	O	-1	20129423
tial	O	-1	20129423
diagno@@	O	-1	20129423
sis.	O	-1	20129423
The	O	-1	20129423
most	O	-1	20129423
severe	O	-1	20129423
adverse	O	-1	20129423
reactions	O	-1	20129423
to	O	-1	20129423
carbamazepine	B-Chemical	D002220	20129423
have	O	-1	20129423
been	O	-1	20129423
observed	O	-1	20129423
in	O	-1	20129423
the	O	-1	20129423
haem@@	O	-1	20129423
o@@	O	-1	20129423
po@@	O	-1	20129423
i@@	O	-1	20129423
e@@	O	-1	20129423
tic	O	-1	20129423
system@@	O	-1	20129423
,	O	-1	20129423
the	O	-1	20129423
liver	O	-1	20129423
and	O	-1	20129423
the	O	-1	20129423
cardiovascular	O	-1	20129423
system@@	O	-1	20129423
.	O	-1	20129423
A	O	-1	20129423
frequ@@	O	-1	20129423
ently	O	-1	20129423
f@@	O	-1	20129423
at@@	O	-1	20129423
al,	O	-1	20129423
although	O	-1	20129423
ex@@	O	-1	20129423
cep@@	O	-1	20129423
tion@@	O	-1	20129423
ally	O	-1	20129423
r@@	O	-1	20129423
are	O	-1	20129423
side	O	-1	20129423
effect	O	-1	20129423
of	O	-1	20129423
carbamazepine	B-Chemical	D002220	20129423
is	O	-1	20129423
necro@@	O	-1	20129423
tiz@@	O	-1	20129423
ing	O	-1	20129423
e@@	O	-1	20129423
os@@	O	-1	20129423
in@@	O	-1	20129423
oph@@	O	-1	20129423
il@@	O	-1	20129423
ic	O	-1	20129423
(	O	-1	20129423
hyper@@	B-Disease	D004342	20129423
sensitivity	I-Disease	-1	20129423
)	O	-1	20129423
myocardi@@	B-Disease	D009205	20129423
tis	I-Disease	-1	20129423
.	O	-1	20129423
We	O	-1	20129423
report	O	-1	20129423
a	O	-1	20129423
case	O	-1	20129423
of	O	-1	20129423
hyper@@	B-Disease	D004342	20129423
sensitivity	I-Disease	-1	20129423
myocardi@@	B-Disease	D009205	20129423
tis	I-Disease	-1	20129423
secondary	O	-1	20129423
to	O	-1	20129423
administration	O	-1	20129423
of	O	-1	20129423
carbamazepine	B-Chemical	D002220	20129423
.	O	-1	20129423
Ac@@	O	-1	20129423
ute	O	-1	20129423
hyper@@	B-Disease	D004342	20129423
sensitivity	I-Disease	-1	20129423
myocardi@@	B-Disease	D009205	20129423
tis	I-Disease	-1	20129423
was	O	-1	20129423
not	O	-1	20129423
sus@@	O	-1	20129423
p@@	O	-1	20129423
ected	O	-1	20129423
clin@@	O	-1	20129423
ic@@	O	-1	20129423
ally,	O	-1	20129423
and	O	-1	20129423
the	O	-1	20129423
diagnosis	O	-1	20129423
was	O	-1	20129423
m@@	O	-1	20129423
ade	O	-1	20129423
post@@	O	-1	20129423
-@@	O	-1	20129423
mor@@	O	-1	20129423
tem@@	O	-1	20129423
.	O	-1	20129423
H@@	O	-1	20129423
ist@@	O	-1	20129423
ology	O	-1	20129423
revealed	O	-1	20129423
diff@@	O	-1	20129423
use	O	-1	20129423
inf@@	O	-1	20129423
iltration	O	-1	20129423
of	O	-1	20129423
the	O	-1	20129423
myocardi@@	O	-1	20129423
um	O	-1	20129423
by	O	-1	20129423
e@@	O	-1	20129423
os@@	O	-1	20129423
in@@	O	-1	20129423
oph@@	O	-1	20129423
il@@	O	-1	20129423
s	O	-1	20129423
and	O	-1	20129423
lymph@@	O	-1	20129423
ocy@@	O	-1	20129423
tes	O	-1	20129423
with	O	-1	20129423
my@@	O	-1	20129423
ocyte	O	-1	20129423
dam@@	O	-1	20129423
age.	O	-1	20129423
Clin@@	O	-1	20129423
ic@@	O	-1	20129423
ally,	O	-1	20129423
death	O	-1	20129423
was	O	-1	20129423
due	O	-1	20129423
to	O	-1	20129423
cardio@@	B-Disease	D012770	20129423
genic	I-Disease	-1	20129423
sh@@	I-Disease	-1	20129423
oc@@	I-Disease	-1	20129423
k	I-Disease	-1	20129423
.	O	-1	20129423
To	O	-1	20129423
b@@	O	-1	20129423
est	O	-1	20129423
of	O	-1	20129423
our	O	-1	20129423
know@@	O	-1	20129423
le@@	O	-1	20129423
d@@	O	-1	20129423
ge	O	-1	20129423
this	O	-1	20129423
is	O	-1	20129423
the	O	-1	20129423
second	O	-1	20129423
case	O	-1	20129423
of	O	-1	20129423
f@@	O	-1	20129423
atal	O	-1	20129423
carbamazepine	B-Chemical	D002220	20129423
induced	O	-1	20129423
myocardi@@	B-Disease	D009205	20129423
tis	I-Disease	-1	20129423
reported	O	-1	20129423
in	O	-1	20129423
E@@	O	-1	20129423
n@@	O	-1	20129423
gl@@	O	-1	20129423
is@@	O	-1	20129423
h	O	-1	20129423
literat@@	O	-1	20129423
ure.	O	-1	20129423

Ne@@	O	-1	20169779
uro@@	O	-1	20169779
psych@@	O	-1	20169779
i@@	O	-1	20169779
atric	O	-1	20169779
behavi@@	O	-1	20169779
ors	O	-1	20169779
in	O	-1	20169779
the	O	-1	20169779
MP@@	B-Chemical	D015632	20169779
T@@	I-Chemical	-1	20169779
P	I-Chemical	-1	20169779
m@@	O	-1	20169779
ar@@	O	-1	20169779
mo@@	O	-1	20169779
set	O	-1	20169779
model	O	-1	20169779
of	O	-1	20169779
Parkinson's	B-Disease	D010302	20169779
disease	I-Disease	-1	20169779
.	O	-1	20169779
OBJECTIV@@	O	-1	20169779
E@@	O	-1	20169779
S:	O	-1	20169779
Ne@@	O	-1	20169779
uro@@	O	-1	20169779
psych@@	O	-1	20169779
i@@	O	-1	20169779
atric	O	-1	20169779
symptoms	O	-1	20169779
are	O	-1	20169779
increas@@	O	-1	20169779
ing@@	O	-1	20169779
ly	O	-1	20169779
reco@@	O	-1	20169779
gn@@	O	-1	20169779
is@@	O	-1	20169779
ed	O	-1	20169779
as	O	-1	20169779
a	O	-1	20169779
significant	O	-1	20169779
pro@@	O	-1	20169779
ble@@	O	-1	20169779
m	O	-1	20169779
in	O	-1	20169779
patients	O	-1	20169779
with	O	-1	20169779
Parkinson's	B-Disease	D010302	20169779
disease	I-Disease	-1	20169779
(	O	-1	20169779
P@@	B-Disease	D010302	20169779
D	I-Disease	-1	20169779
).	O	-1	20169779
These	O	-1	20169779
symptoms	O	-1	20169779
may	O	-1	20169779
be	O	-1	20169779
due	O	-1	20169779
to	O	-1	20169779
'@@	O	-1	20169779
sensi@@	O	-1	20169779
tis@@	O	-1	20169779
ation@@	O	-1	20169779
'	O	-1	20169779
following	O	-1	20169779
repe@@	O	-1	20169779
ated	O	-1	20169779
levo@@	B-Chemical	D007980	20169779
dopa	I-Chemical	-1	20169779
treatment	O	-1	20169779
or	O	-1	20169779
a	O	-1	20169779
direct	O	-1	20169779
effect	O	-1	20169779
of	O	-1	20169779
dopamine	B-Chemical	D004298	20169779
on	O	-1	20169779
the	O	-1	20169779
disease	O	-1	20169779
stat@@	O	-1	20169779
e.	O	-1	20169779
The	O	-1	20169779
levo@@	B-Chemical	D007980	20169779
dopa	I-Chemical	-1	20169779
-treated	O	-1	20169779
MP@@	B-Chemical	D015632	20169779
T@@	I-Chemical	-1	20169779
P	I-Chemical	-1	20169779
-@@	O	-1	20169779
le@@	O	-1	20169779
sion@@	O	-1	20169779
ed	O	-1	20169779
m@@	O	-1	20169779
ar@@	O	-1	20169779
mo@@	O	-1	20169779
set	O	-1	20169779
was	O	-1	20169779
used	O	-1	20169779
as	O	-1	20169779
a	O	-1	20169779
model	O	-1	20169779
of	O	-1	20169779
neuro@@	B-Disease	D001523	20169779
psych@@	I-Disease	-1	20169779
i@@	I-Disease	-1	20169779
atric	I-Disease	-1	20169779
symptoms	I-Disease	-1	20169779
in	O	-1	20169779
P@@	B-Disease	D010302	20169779
D	I-Disease	-1	20169779
patients.	O	-1	20169779
H@@	O	-1	20169779
ere	O	-1	20169779
we	O	-1	20169779
compar@@	O	-1	20169779
e	O	-1	20169779
the	O	-1	20169779
time	O	-1	20169779
course	O	-1	20169779
of	O	-1	20169779
levo@@	B-Chemical	D007980	20169779
dopa	I-Chemical	-1	20169779
-induced	O	-1	20169779
motor	O	-1	20169779
f@@	O	-1	20169779
l@@	O	-1	20169779
uc@@	O	-1	20169779
tu@@	O	-1	20169779
ations	O	-1	20169779
and	O	-1	20169779
neuro@@	B-Disease	D001523	20169779
psych@@	I-Disease	-1	20169779
i@@	I-Disease	-1	20169779
at@@	I-Disease	-1	20169779
r@@	I-Disease	-1	20169779
ic@@	I-Disease	-1	20169779
-@@	I-Disease	-1	20169779
like	I-Disease	-1	20169779
behavi@@	I-Disease	-1	20169779
ors	I-Disease	-1	20169779
to	O	-1	20169779
determine	O	-1	20169779
the	O	-1	20169779
rel@@	O	-1	20169779
ationship	O	-1	20169779
between	O	-1	20169779
duration	O	-1	20169779
of	O	-1	20169779
treatment	O	-1	20169779
and	O	-1	20169779
onset	O	-1	20169779
of	O	-1	20169779
symptom@@	O	-1	20169779
s.	O	-1	20169779
METHODS:	O	-1	20169779
M@@	O	-1	20169779
ar@@	O	-1	20169779
mo@@	O	-1	20169779
se@@	O	-1	20169779
ts	O	-1	20169779
were	O	-1	20169779
administered	O	-1	20169779
1-@@	B-Chemical	D015632	20169779
methyl@@	I-Chemical	-1	20169779
-@@	I-Chemical	-1	20169779
4-@@	I-Chemical	-1	20169779
phenyl@@	I-Chemical	-1	20169779
-1@@	I-Chemical	-1	20169779
,@@	I-Chemical	-1	20169779
2@@	I-Chemical	-1	20169779
,@@	I-Chemical	-1	20169779
3@@	I-Chemical	-1	20169779
,@@	I-Chemical	-1	20169779
6-@@	I-Chemical	-1	20169779
te@@	I-Chemical	-1	20169779
tra@@	I-Chemical	-1	20169779
hydro@@	I-Chemical	-1	20169779
pyri@@	I-Chemical	-1	20169779
d@@	I-Chemical	-1	20169779
ine	I-Chemical	-1	20169779
(2@@	O	-1	20169779
.@@	O	-1	20169779
0	O	-1	20169779
mg/kg	O	-1	20169779
s@@	O	-1	20169779
.@@	O	-1	20169779
c@@	O	-1	20169779
.)	O	-1	20169779
for	O	-1	20169779
five	O	-1	20169779
day@@	O	-1	20169779
s,	O	-1	20169779
result@@	O	-1	20169779
ing	O	-1	20169779
in	O	-1	20169779
st@@	O	-1	20169779
able	O	-1	20169779
par@@	B-Disease	D010302	20169779
k@@	I-Disease	-1	20169779
inson@@	I-Disease	-1	20169779
ism	I-Disease	-1	20169779
.	O	-1	20169779
L@@	B-Chemical	D007980	20169779
evo@@	I-Chemical	-1	20169779
dopa	I-Chemical	-1	20169779
(1@@	O	-1	20169779
5	O	-1	20169779
mg/kg	O	-1	20169779
and	O	-1	20169779
ben@@	B-Chemical	D001545	20169779
ser@@	I-Chemical	-1	20169779
az@@	I-Chemical	-1	20169779
ide	I-Chemical	-1	20169779
,	O	-1	20169779
3.@@	O	-1	20169779
7@@	O	-1	20169779
5	O	-1	20169779
mg/kg)	O	-1	20169779
p.@@	O	-1	20169779
o@@	O	-1	20169779
.	O	-1	20169779
b@@	O	-1	20169779
.@@	O	-1	20169779
i.@@	O	-1	20169779
d,	O	-1	20169779
was	O	-1	20169779
administered	O	-1	20169779
for	O	-1	20169779
30	O	-1	20169779
days.	O	-1	20169779
An@@	O	-1	20169779
im@@	O	-1	20169779
als	O	-1	20169779
were	O	-1	20169779
evaluated	O	-1	20169779
for	O	-1	20169779
par@@	B-Disease	D020734	20169779
k@@	I-Disease	-1	20169779
inson@@	I-Disease	-1	20169779
i@@	I-Disease	-1	20169779
an	I-Disease	-1	20169779
dis@@	I-Disease	-1	20169779
ability	I-Disease	-1	20169779
,	O	-1	20169779
dyskine@@	B-Disease	D004409	20169779
sia	I-Disease	-1	20169779
and	O	-1	20169779
on@@	O	-1	20169779
-@@	O	-1	20169779
time	O	-1	20169779
(@@	O	-1	20169779
motor	O	-1	20169779
f@@	O	-1	20169779
l@@	O	-1	20169779
uc@@	O	-1	20169779
tu@@	O	-1	20169779
ation@@	O	-1	20169779
s)	O	-1	20169779
and	O	-1	20169779
neuro@@	B-Disease	D001523	20169779
psych@@	I-Disease	-1	20169779
i@@	I-Disease	-1	20169779
at@@	I-Disease	-1	20169779
r@@	I-Disease	-1	20169779
ic@@	I-Disease	-1	20169779
-@@	I-Disease	-1	20169779
like	I-Disease	-1	20169779
behavi@@	I-Disease	-1	20169779
ors	I-Disease	-1	20169779
on	O	-1	20169779
D@@	O	-1	20169779
ay	O	-1	20169779
0	O	-1	20169779
(@@	O	-1	20169779
prior	O	-1	20169779
to	O	-1	20169779
levo@@	B-Chemical	D007980	20169779
dopa	I-Chemical	-1	20169779
)	O	-1	20169779
and	O	-1	20169779
on	O	-1	20169779
D@@	O	-1	20169779
ays	O	-1	20169779
1,	O	-1	20169779
7@@	O	-1	20169779
,	O	-1	20169779
13@@	O	-1	20169779
,	O	-1	20169779
2@@	O	-1	20169779
7	O	-1	20169779
and	O	-1	20169779
30	O	-1	20169779
of	O	-1	20169779
treatment	O	-1	20169779
using	O	-1	20169779
pos@@	O	-1	20169779
t	O	-1	20169779
ho@@	O	-1	20169779
c	O	-1	20169779
D@@	O	-1	20169779
V@@	O	-1	20169779
D	O	-1	20169779
analysis	O	-1	20169779
by	O	-1	20169779
a	O	-1	20169779
tra@@	O	-1	20169779
in@@	O	-1	20169779
ed	O	-1	20169779
rat@@	O	-1	20169779
er,	O	-1	20169779
bl@@	O	-1	20169779
ind	O	-1	20169779
to	O	-1	20169779
the	O	-1	20169779
treatment	O	-1	20169779
da@@	O	-1	20169779
y.	O	-1	20169779
RESULTS:	O	-1	20169779
The	O	-1	20169779
neuro@@	B-Disease	D001523	20169779
psych@@	I-Disease	-1	20169779
i@@	I-Disease	-1	20169779
at@@	I-Disease	-1	20169779
r@@	I-Disease	-1	20169779
ic@@	I-Disease	-1	20169779
-@@	I-Disease	-1	20169779
like	I-Disease	-1	20169779
behavi@@	I-Disease	-1	20169779
or	I-Disease	-1	20169779
rat@@	O	-1	20169779
ing	O	-1	20169779
s@@	O	-1	20169779
cal@@	O	-1	20169779
e	O	-1	20169779
demonstrated	O	-1	20169779
high	O	-1	20169779
inter@@	O	-1	20169779
rat@@	O	-1	20169779
er	O	-1	20169779
re@@	O	-1	20169779
li@@	O	-1	20169779
ability	O	-1	20169779
between	O	-1	20169779
three	O	-1	20169779
tra@@	O	-1	20169779
in@@	O	-1	20169779
ed	O	-1	20169779
rat@@	O	-1	20169779
ers	O	-1	20169779
of	O	-1	20169779
diff@@	O	-1	20169779
ering	O	-1	20169779
prof@@	O	-1	20169779
es@@	O	-1	20169779
sion@@	O	-1	20169779
al	O	-1	20169779
bac@@	O	-1	20169779
kg@@	O	-1	20169779
ro@@	O	-1	20169779
und@@	O	-1	20169779
s.	O	-1	20169779
A@@	O	-1	20169779
s	O	-1	20169779
anti@@	O	-1	20169779
ci@@	O	-1	20169779
pat@@	O	-1	20169779
ed,	O	-1	20169779
animals	O	-1	20169779
ex@@	O	-1	20169779
hib@@	O	-1	20169779
ited	O	-1	20169779
a	O	-1	20169779
progressive	O	-1	20169779
increase	O	-1	20169779
in	O	-1	20169779
levo@@	B-Chemical	D007980	20169779
dopa	I-Chemical	-1	20169779
-induced	O	-1	20169779
motor	O	-1	20169779
f@@	O	-1	20169779
l@@	O	-1	20169779
uc@@	O	-1	20169779
tu@@	O	-1	20169779
ation@@	O	-1	20169779
s,	O	-1	20169779
dyskine@@	B-Disease	D004409	20169779
sia	I-Disease	-1	20169779
and	O	-1	20169779
we@@	O	-1	20169779
ar@@	O	-1	20169779
ing@@	O	-1	20169779
-@@	O	-1	20169779
o@@	O	-1	20169779
ff@@	O	-1	20169779
,	O	-1	20169779
that	O	-1	20169779
cor@@	O	-1	20169779
related	O	-1	20169779
with	O	-1	20169779
the	O	-1	20169779
duration	O	-1	20169779
of	O	-1	20169779
levo@@	B-Chemical	D007980	20169779
dopa	I-Chemical	-1	20169779
therapy.	O	-1	20169779
In	O	-1	20169779
contrast@@	O	-1	20169779
,	O	-1	20169779
levo@@	B-Chemical	D007980	20169779
dopa	I-Chemical	-1	20169779
-induced	O	-1	20169779
neuro@@	B-Disease	D001523	20169779
psych@@	I-Disease	-1	20169779
i@@	I-Disease	-1	20169779
at@@	I-Disease	-1	20169779
r@@	I-Disease	-1	20169779
ic@@	I-Disease	-1	20169779
-@@	I-Disease	-1	20169779
like	I-Disease	-1	20169779
behavi@@	I-Disease	-1	20169779
ors	I-Disease	-1	20169779
were	O	-1	20169779
present	O	-1	20169779
on	O	-1	20169779
D@@	O	-1	20169779
ay	O	-1	20169779
1	O	-1	20169779
of	O	-1	20169779
levo@@	B-Chemical	D007980	20169779
dopa	I-Chemical	-1	20169779
treatment	O	-1	20169779
and	O	-1	20169779
their	O	-1	20169779
severity	O	-1	20169779
did	O	-1	20169779
not	O	-1	20169779
correl@@	O	-1	20169779
ate	O	-1	20169779
with	O	-1	20169779
duration	O	-1	20169779
of	O	-1	20169779
treatment.	O	-1	20169779
CONCLUSIONS:	O	-1	20169779
The	O	-1	20169779
data	O	-1	20169779
suggest	O	-1	20169779
that	O	-1	20169779
neuro@@	B-Disease	D001523	20169779
psych@@	I-Disease	-1	20169779
i@@	I-Disease	-1	20169779
atric	I-Disease	-1	20169779
disorder@@	I-Disease	-1	20169779
s	I-Disease	-1	20169779
in	O	-1	20169779
P@@	B-Disease	D010302	20169779
D	I-Disease	-1	20169779
are	O	-1	20169779
more	O	-1	20169779
likely	O	-1	20169779
an	O	-1	20169779
inter@@	O	-1	20169779
action	O	-1	20169779
between	O	-1	20169779
levo@@	B-Chemical	D007980	20169779
dopa	I-Chemical	-1	20169779
and	O	-1	20169779
the	O	-1	20169779
disease	O	-1	20169779
state	O	-1	20169779
than	O	-1	20169779
a	O	-1	20169779
con@@	O	-1	20169779
sequ@@	O	-1	20169779
ence	O	-1	20169779
of	O	-1	20169779
sensi@@	O	-1	20169779
tis@@	O	-1	20169779
ation	O	-1	20169779
to	O	-1	20169779
repe@@	O	-1	20169779
ated	O	-1	20169779
dop@@	O	-1	20169779
aminergic	O	-1	20169779
therapy.	O	-1	20169779

C@@	B-Chemical	D003287	20192893
ont@@	I-Chemical	-1	20192893
r@@	I-Chemical	-1	20192893
ast	I-Chemical	-1	20192893
medi@@	I-Chemical	-1	20192893
um	I-Chemical	-1	20192893
nephro@@	B-Disease	D007674	20192893
toxicity	I-Disease	-1	20192893
after	O	-1	20192893
renal	O	-1	20192893
artery	O	-1	20192893
and	O	-1	20192893
coronary	O	-1	20192893
angio@@	O	-1	20192893
pl@@	O	-1	20192893
ast@@	O	-1	20192893
y.	O	-1	20192893
BACKGROUND:	O	-1	20192893
R@@	B-Disease	D007674	20192893
en@@	I-Disease	-1	20192893
al	I-Disease	-1	20192893
dysfunction	I-Disease	-1	20192893
induced	O	-1	20192893
by	O	-1	20192893
iod@@	O	-1	20192893
in@@	O	-1	20192893
ated	O	-1	20192893
contr@@	B-Chemical	D003287	20192893
ast	I-Chemical	-1	20192893
medi@@	I-Chemical	-1	20192893
um	I-Chemical	-1	20192893
(	O	-1	20192893
C@@	B-Chemical	D003287	20192893
M	I-Chemical	-1	20192893
)	O	-1	20192893
administration	O	-1	20192893
can	O	-1	20192893
minim@@	O	-1	20192893
iz@@	O	-1	20192893
e	O	-1	20192893
the	O	-1	20192893
ben@@	O	-1	20192893
e@@	O	-1	20192893
fi@@	O	-1	20192893
t	O	-1	20192893
of	O	-1	20192893
the	O	-1	20192893
inter@@	O	-1	20192893
ven@@	O	-1	20192893
tional	O	-1	20192893
proce@@	O	-1	20192893
d@@	O	-1	20192893
ure	O	-1	20192893
in	O	-1	20192893
patients	O	-1	20192893
under@@	O	-1	20192893
go@@	O	-1	20192893
ing	O	-1	20192893
renal	O	-1	20192893
angio@@	O	-1	20192893
pl@@	O	-1	20192893
ast@@	O	-1	20192893
y	O	-1	20192893
(P@@	O	-1	20192893
TR@@	O	-1	20192893
A@@	O	-1	20192893
).	O	-1	20192893
P@@	O	-1	20192893
U@@	O	-1	20192893
R@@	O	-1	20192893
P@@	O	-1	20192893
O@@	O	-1	20192893
S@@	O	-1	20192893
E:	O	-1	20192893
To	O	-1	20192893
compar@@	O	-1	20192893
e	O	-1	20192893
the	O	-1	20192893
sus@@	O	-1	20192893
cep@@	O	-1	20192893
ti@@	O	-1	20192893
b@@	O	-1	20192893
ility	O	-1	20192893
to	O	-1	20192893
nephro@@	B-Disease	D007674	20192893
toxic	I-Disease	-1	20192893
effect	O	-1	20192893
of	O	-1	20192893
C@@	B-Chemical	D003287	20192893
M	I-Chemical	-1	20192893
in	O	-1	20192893
patients	O	-1	20192893
under@@	O	-1	20192893
go@@	O	-1	20192893
ing	O	-1	20192893
P@@	O	-1	20192893
TR@@	O	-1	20192893
A	O	-1	20192893
with	O	-1	20192893
that	O	-1	20192893
of	O	-1	20192893
patients	O	-1	20192893
sub@@	O	-1	20192893
mit@@	O	-1	20192893
ted	O	-1	20192893
to	O	-1	20192893
perc@@	O	-1	20192893
utaneous	O	-1	20192893
coronary	O	-1	20192893
inter@@	O	-1	20192893
ven@@	O	-1	20192893
tion	O	-1	20192893
(P@@	O	-1	20192893
CI@@	O	-1	20192893
).	O	-1	20192893
M@@	O	-1	20192893
AT@@	O	-1	20192893
E@@	O	-1	20192893
R@@	O	-1	20192893
I@@	O	-1	20192893
A@@	O	-1	20192893
L	O	-1	20192893
AN@@	O	-1	20192893
D	O	-1	20192893
METHODS:	O	-1	20192893
A	O	-1	20192893
total	O	-1	20192893
of	O	-1	20192893
3@@	O	-1	20192893
3	O	-1	20192893
patients	O	-1	20192893
suc@@	O	-1	20192893
cess@@	O	-1	20192893
ful@@	O	-1	20192893
ly	O	-1	20192893
treated	O	-1	20192893
with	O	-1	20192893
P@@	O	-1	20192893
TR@@	O	-1	20192893
A	O	-1	20192893
(P@@	O	-1	20192893
TR@@	O	-1	20192893
A	O	-1	20192893
group@@	O	-1	20192893
,	O	-1	20192893
mean	O	-1	20192893
age	O	-1	20192893
7@@	O	-1	20192893
0@@	O	-1	20192893
+/@@	O	-1	20192893
-1@@	O	-1	20192893
2	O	-1	20192893
year@@	O	-1	20192893
s,	O	-1	20192893
2@@	O	-1	20192893
3	O	-1	20192893
femal@@	O	-1	20192893
e,	O	-1	20192893
bas@@	O	-1	20192893
al	O	-1	20192893
creatinine	B-Chemical	D003404	20192893
1.@@	O	-1	20192893
4@@	O	-1	20192893
6@@	O	-1	20192893
+/-@@	O	-1	20192893
0.@@	O	-1	20192893
7@@	O	-1	20192893
9@@	O	-1	20192893
,	O	-1	20192893
range	O	-1	20192893
0.@@	O	-1	20192893
7-@@	O	-1	20192893
4.@@	O	-1	20192893
9	O	-1	20192893
mg/d@@	O	-1	20192893
l@@	O	-1	20192893
)	O	-1	20192893
were	O	-1	20192893
compared	O	-1	20192893
with	O	-1	20192893
3@@	O	-1	20192893
3	O	-1	20192893
patients	O	-1	20192893
under@@	O	-1	20192893
go@@	O	-1	20192893
ing	O	-1	20192893
suc@@	O	-1	20192893
cess@@	O	-1	20192893
ful	O	-1	20192893
P@@	O	-1	20192893
C@@	O	-1	20192893
I	O	-1	20192893
(P@@	O	-1	20192893
C@@	O	-1	20192893
I	O	-1	20192893
group@@	O	-1	20192893
),	O	-1	20192893
mat@@	O	-1	20192893
ch@@	O	-1	20192893
ed	O	-1	20192893
for	O	-1	20192893
bas@@	O	-1	20192893
al	O	-1	20192893
creatinine	B-Chemical	D003404	20192893
(1@@	O	-1	20192893
.@@	O	-1	20192893
4@@	O	-1	20192893
4@@	O	-1	20192893
+/-@@	O	-1	20192893
0.@@	O	-1	20192893
6,	O	-1	20192893
range	O	-1	20192893
0.@@	O	-1	20192893
7-@@	O	-1	20192893
3.@@	O	-1	20192893
4	O	-1	20192893
mg/d@@	O	-1	20192893
l@@	O	-1	20192893
),	O	-1	20192893
gen@@	O	-1	20192893
der@@	O	-1	20192893
,	O	-1	20192893
and	O	-1	20192893
age.	O	-1	20192893
In	O	-1	20192893
both	O	-1	20192893
groups	O	-1	20192893
post@@	O	-1	20192893
proce@@	O	-1	20192893
dur@@	O	-1	20192893
al	O	-1	20192893
(4@@	O	-1	20192893
8	O	-1	20192893
h@@	O	-1	20192893
)	O	-1	20192893
serum	O	-1	20192893
creatinine	B-Chemical	D003404	20192893
was	O	-1	20192893
meas@@	O	-1	20192893
ure@@	O	-1	20192893
d.	O	-1	20192893
RESULTS:	O	-1	20192893
P@@	O	-1	20192893
ost@@	O	-1	20192893
proce@@	O	-1	20192893
dur@@	O	-1	20192893
al	O	-1	20192893
creatinine	B-Chemical	D003404	20192893
level	O	-1	20192893
decreased	O	-1	20192893
non@@	O	-1	20192893
significantly	O	-1	20192893
in	O	-1	20192893
the	O	-1	20192893
P@@	O	-1	20192893
TR@@	O	-1	20192893
A	O	-1	20192893
group	O	-1	20192893
(1@@	O	-1	20192893
.@@	O	-1	20192893
4@@	O	-1	20192893
6@@	O	-1	20192893
+/-@@	O	-1	20192893
0.@@	O	-1	20192893
8	O	-1	20192893
vs.	O	-1	20192893
1.@@	O	-1	20192893
34@@	O	-1	20192893
+/-@@	O	-1	20192893
0.@@	O	-1	20192893
5	O	-1	20192893
mg/d@@	O	-1	20192893
l@@	O	-1	20192893
,	O	-1	20192893
P@@	O	-1	20192893
=@@	O	-1	20192893
N@@	O	-1	20192893
S)	O	-1	20192893
and	O	-1	20192893
increased	O	-1	20192893
significantly	O	-1	20192893
in	O	-1	20192893
the	O	-1	20192893
P@@	O	-1	20192893
C@@	O	-1	20192893
I	O	-1	20192893
group	O	-1	20192893
(1@@	O	-1	20192893
.@@	O	-1	20192893
4@@	O	-1	20192893
4@@	O	-1	20192893
+/-@@	O	-1	20192893
0.@@	O	-1	20192893
6	O	-1	20192893
vs.	O	-1	20192893
1.@@	O	-1	20192893
5@@	O	-1	20192893
7@@	O	-1	20192893
+/-@@	O	-1	20192893
0.@@	O	-1	20192893
7	O	-1	20192893
mg/d@@	O	-1	20192893
l@@	O	-1	20192893
,	O	-1	20192893
P@@	O	-1	20192893
<@@	O	-1	20192893
0.0@@	O	-1	20192893
2@@	O	-1	20192893
).	O	-1	20192893
Ch@@	O	-1	20192893
ang@@	O	-1	20192893
es	O	-1	20192893
in	O	-1	20192893
serum	O	-1	20192893
creatinine	B-Chemical	D003404	20192893
after	O	-1	20192893
inter@@	O	-1	20192893
ven@@	O	-1	20192893
tion	O	-1	20192893
(@@	O	-1	20192893
af@@	O	-1	20192893
ter@@	O	-1	20192893
-@@	O	-1	20192893
be@@	O	-1	20192893
fo@@	O	-1	20192893
re@@	O	-1	20192893
)	O	-1	20192893
were	O	-1	20192893
significantly	O	-1	20192893
different	O	-1	20192893
between	O	-1	20192893
the	O	-1	20192893
P@@	O	-1	20192893
TR@@	O	-1	20192893
A	O	-1	20192893
and	O	-1	20192893
P@@	O	-1	20192893
C@@	O	-1	20192893
I	O	-1	20192893
groups	O	-1	20192893
(-@@	O	-1	20192893
0.@@	O	-1	20192893
12@@	O	-1	20192893
+/-@@	O	-1	20192893
0.@@	O	-1	20192893
5	O	-1	20192893
vs.	O	-1	20192893
0.@@	O	-1	20192893
13@@	O	-1	20192893
+/-@@	O	-1	20192893
0.@@	O	-1	20192893
3,	O	-1	20192893
P@@	O	-1	20192893
=@@	O	-1	20192893
0.0@@	O	-1	20192893
14@@	O	-1	20192893
).	O	-1	20192893
This	O	-1	20192893
difference	O	-1	20192893
was	O	-1	20192893
not	O	-1	20192893
related	O	-1	20192893
to	O	-1	20192893
either	O	-1	20192893
a	O	-1	20192893
different	O	-1	20192893
clinical	O	-1	20192893
risk	O	-1	20192893
prof@@	O	-1	20192893
ile	O	-1	20192893
or	O	-1	20192893
to	O	-1	20192893
the	O	-1	20192893
volume	O	-1	20192893
of	O	-1	20192893
C@@	B-Chemical	D003287	20192893
M	I-Chemical	-1	20192893
administ@@	O	-1	20192893
e@@	O	-1	20192893
red.	O	-1	20192893
CONCLUSION:	O	-1	20192893
In	O	-1	20192893
this	O	-1	20192893
pre@@	O	-1	20192893
lim@@	O	-1	20192893
inary	O	-1	20192893
study	O	-1	20192893
patients	O	-1	20192893
sub@@	O	-1	20192893
mit@@	O	-1	20192893
ted	O	-1	20192893
to	O	-1	20192893
P@@	O	-1	20192893
TR@@	O	-1	20192893
A	O	-1	20192893
showed	O	-1	20192893
a	O	-1	20192893
lower	O	-1	20192893
sus@@	O	-1	20192893
cep@@	O	-1	20192893
ti@@	O	-1	20192893
b@@	O	-1	20192893
ility	O	-1	20192893
to	O	-1	20192893
renal	B-Disease	D007674	20192893
damage	I-Disease	-1	20192893
induced	O	-1	20192893
by	O	-1	20192893
C@@	B-Chemical	D003287	20192893
M	I-Chemical	-1	20192893
administration	O	-1	20192893
than	O	-1	20192893
P@@	O	-1	20192893
C@@	O	-1	20192893
I	O	-1	20192893
patients.	O	-1	20192893
The	O	-1	20192893
eff@@	O	-1	20192893
ec@@	O	-1	20192893
tiv@@	O	-1	20192893
en@@	O	-1	20192893
ess	O	-1	20192893
of	O	-1	20192893
P@@	O	-1	20192893
TR@@	O	-1	20192893
A	O	-1	20192893
on	O	-1	20192893
renal	O	-1	20192893
function	O	-1	20192893
se@@	O	-1	20192893
em@@	O	-1	20192893
s	O	-1	20192893
to	O	-1	20192893
be	O	-1	20192893
b@@	O	-1	20192893
a@@	O	-1	20192893
re@@	O	-1	20192893
ly	O	-1	20192893
influ@@	O	-1	20192893
enc@@	O	-1	20192893
ed	O	-1	20192893
by	O	-1	20192893
C@@	B-Chemical	D003287	20192893
M	I-Chemical	-1	20192893
toxicity	B-Disease	D064420	20192893
.	O	-1	20192893

M@@	O	-1	20408947
ed@@	O	-1	20408947
ical	O	-1	20408947
and	O	-1	20408947
psych@@	O	-1	20408947
i@@	O	-1	20408947
atric	O	-1	20408947
outcom@@	O	-1	20408947
es	O	-1	20408947
for	O	-1	20408947
patients	O	-1	20408947
transplant@@	O	-1	20408947
ed	O	-1	20408947
for	O	-1	20408947
acet@@	B-Chemical	D000082	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
acute	B-Disease	D017114	20408947
liver	I-Disease	-1	20408947
failure	I-Disease	-1	20408947
:	O	-1	20408947
a	O	-1	20408947
cas@@	O	-1	20408947
e-@@	O	-1	20408947
control	O	-1	20408947
study.	O	-1	20408947
BACKGROUND:	O	-1	20408947
A@@	B-Chemical	D000082	20408947
ce@@	I-Chemical	-1	20408947
t@@	I-Chemical	-1	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
hepat@@	B-Disease	D056486	20408947
otoxicity	I-Disease	-1	20408947
is	O	-1	20408947
the	O	-1	20408947
most	O	-1	20408947
common	O	-1	20408947
cause	O	-1	20408947
of	O	-1	20408947
acute	B-Disease	D017114	20408947
liver	I-Disease	-1	20408947
failure	I-Disease	-1	20408947
(	O	-1	20408947
AL@@	B-Disease	D017114	20408947
F	I-Disease	-1	20408947
)	O	-1	20408947
in	O	-1	20408947
the	O	-1	20408947
U@@	O	-1	20408947
K@@	O	-1	20408947
.	O	-1	20408947
Patients	O	-1	20408947
often	O	-1	20408947
consum@@	O	-1	20408947
e	O	-1	20408947
the	O	-1	20408947
drug	O	-1	20408947
with	O	-1	20408947
su@@	O	-1	20408947
ic@@	O	-1	20408947
idal	O	-1	20408947
int@@	O	-1	20408947
ent	O	-1	20408947
or	O	-1	20408947
with	O	-1	20408947
a	O	-1	20408947
bac@@	O	-1	20408947
kg@@	O	-1	20408947
ro@@	O	-1	20408947
un@@	O	-1	20408947
d	O	-1	20408947
of	O	-1	20408947
subst@@	O	-1	20408947
ance	O	-1	20408947
depend@@	O	-1	20408947
ence@@	O	-1	20408947
.	O	-1	20408947
A@@	O	-1	20408947
I@@	O	-1	20408947
M@@	O	-1	20408947
S	O	-1	20408947
AN@@	O	-1	20408947
D	O	-1	20408947
METHODS:	O	-1	20408947
We	O	-1	20408947
compared	O	-1	20408947
the	O	-1	20408947
severity	O	-1	20408947
of	O	-1	20408947
pre@@	O	-1	20408947
transplant	O	-1	20408947
ill@@	O	-1	20408947
n@@	O	-1	20408947
es@@	O	-1	20408947
s,	O	-1	20408947
psych@@	O	-1	20408947
i@@	O	-1	20408947
atric	O	-1	20408947
co-@@	O	-1	20408947
mor@@	O	-1	20408947
b@@	O	-1	20408947
id@@	O	-1	20408947
ity,	O	-1	20408947
med@@	O	-1	20408947
ical	O	-1	20408947
and	O	-1	20408947
psych@@	O	-1	20408947
os@@	O	-1	20408947
oci@@	O	-1	20408947
al	O	-1	20408947
outcom@@	O	-1	20408947
es	O	-1	20408947
of	O	-1	20408947
all	O	-1	20408947
patients	O	-1	20408947
who	O	-1	20408947
had	O	-1	20408947
under@@	O	-1	20408947
g@@	O	-1	20408947
one	O	-1	20408947
liver	O	-1	20408947
transplant@@	O	-1	20408947
ation	O	-1	20408947
(@@	O	-1	20408947
LT@@	O	-1	20408947
)	O	-1	20408947
em@@	O	-1	20408947
erg@@	O	-1	20408947
ently	O	-1	20408947
between	O	-1	20408947
19@@	O	-1	20408947
9@@	O	-1	20408947
9@@	O	-1	20408947
-@@	O	-1	20408947
20@@	O	-1	20408947
0@@	O	-1	20408947
4	O	-1	20408947
for	O	-1	20408947
acet@@	B-Chemical	D000082	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
AL@@	B-Disease	D017114	20408947
F	I-Disease	-1	20408947
(n@@	O	-1	20408947
=@@	O	-1	20408947
3@@	O	-1	20408947
6@@	O	-1	20408947
)	O	-1	20408947
with	O	-1	20408947
ag@@	O	-1	20408947
e@@	O	-1	20408947
-	O	-1	20408947
and	O	-1	20408947
sex@@	O	-1	20408947
-@@	O	-1	20408947
mat@@	O	-1	20408947
ch@@	O	-1	20408947
ed	O	-1	20408947
patients	O	-1	20408947
under@@	O	-1	20408947
go@@	O	-1	20408947
ing	O	-1	20408947
em@@	O	-1	20408947
erg@@	O	-1	20408947
ent	O	-1	20408947
L@@	O	-1	20408947
T	O	-1	20408947
for	O	-1	20408947
non@@	O	-1	20408947
-	O	-1	20408947
acet@@	B-Chemical	D000082	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
AL@@	B-Disease	D017114	20408947
F	I-Disease	-1	20408947
(n@@	O	-1	20408947
=@@	O	-1	20408947
3@@	O	-1	20408947
5@@	O	-1	20408947
)	O	-1	20408947
and	O	-1	20408947
el@@	O	-1	20408947
ective	O	-1	20408947
L@@	O	-1	20408947
T	O	-1	20408947
for	O	-1	20408947
chronic	B-Disease	D008107	20408947
liver	I-Disease	-1	20408947
disease	I-Disease	-1	20408947
(	O	-1	20408947
CL@@	B-Disease	D008107	20408947
D	I-Disease	-1	20408947
,	O	-1	20408947
n@@	O	-1	20408947
=@@	O	-1	20408947
34@@	O	-1	20408947
).	O	-1	20408947
RESULTS:	O	-1	20408947
A@@	B-Chemical	D000082	20408947
ce@@	I-Chemical	-1	20408947
t@@	I-Chemical	-1	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
AL@@	B-Disease	D017114	20408947
F	I-Disease	-1	20408947
patients	O	-1	20408947
under@@	O	-1	20408947
go@@	O	-1	20408947
ing	O	-1	20408947
L@@	O	-1	20408947
T	O	-1	20408947
had	O	-1	20408947
a	O	-1	20408947
greater	O	-1	20408947
severity	O	-1	20408947
of	O	-1	20408947
pre-@@	O	-1	20408947
L@@	O	-1	20408947
T	O	-1	20408947
ill@@	O	-1	20408947
ness	O	-1	20408947
ref@@	O	-1	20408947
l@@	O	-1	20408947
ected	O	-1	20408947
by	O	-1	20408947
higher	O	-1	20408947
Ac@@	O	-1	20408947
ute	O	-1	20408947
P@@	O	-1	20408947
hy@@	O	-1	20408947
si@@	O	-1	20408947
ology	O	-1	20408947
and	O	-1	20408947
Ch@@	O	-1	20408947
ron@@	O	-1	20408947
ic	O	-1	20408947
He@@	O	-1	20408947
al@@	O	-1	20408947
th	O	-1	20408947
E@@	O	-1	20408947
valu@@	O	-1	20408947
ation	O	-1	20408947
II	O	-1	20408947
sco@@	O	-1	20408947
res	O	-1	20408947
and	O	-1	20408947
requ@@	O	-1	20408947
i@@	O	-1	20408947
re@@	O	-1	20408947
ment	O	-1	20408947
for	O	-1	20408947
org@@	O	-1	20408947
an	O	-1	20408947
suppor@@	O	-1	20408947
t	O	-1	20408947
compared	O	-1	20408947
with	O	-1	20408947
the	O	-1	20408947
other	O	-1	20408947
two	O	-1	20408947
groups.	O	-1	20408947
Tw@@	O	-1	20408947
ent@@	O	-1	20408947
y	O	-1	20408947
(5@@	O	-1	20408947
6@@	O	-1	20408947
%)	O	-1	20408947
acet@@	B-Chemical	D000082	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
AL@@	B-Disease	D017114	20408947
F	I-Disease	-1	20408947
patients	O	-1	20408947
had	O	-1	20408947
a	O	-1	20408947
form@@	O	-1	20408947
al	O	-1	20408947
psych@@	O	-1	20408947
i@@	O	-1	20408947
atric	O	-1	20408947
diagnosis	O	-1	20408947
before	O	-1	20408947
L@@	O	-1	20408947
T	O	-1	20408947
(@@	O	-1	20408947
non@@	O	-1	20408947
-	O	-1	20408947
acet@@	B-Chemical	D000082	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
AL@@	B-Disease	D017114	20408947
F	I-Disease	-1	20408947
=@@	O	-1	20408947
0@@	O	-1	20408947
/@@	O	-1	20408947
3@@	O	-1	20408947
5,	O	-1	20408947
CL@@	B-Disease	D008107	20408947
D	I-Disease	-1	20408947
=@@	O	-1	20408947
2@@	O	-1	20408947
/@@	O	-1	20408947
34@@	O	-1	20408947
;	O	-1	20408947
P@@	O	-1	20408947
<@@	O	-1	20408947
0.0@@	O	-1	20408947
1	O	-1	20408947
for	O	-1	20408947
all@@	O	-1	20408947
)	O	-1	20408947
and	O	-1	20408947
n@@	O	-1	20408947
ine	O	-1	20408947
(2@@	O	-1	20408947
5@@	O	-1	20408947
%)	O	-1	20408947
had	O	-1	20408947
a	O	-1	20408947
previ@@	O	-1	20408947
ous	O	-1	20408947
su@@	O	-1	20408947
ic@@	O	-1	20408947
ide	O	-1	20408947
at@@	O	-1	20408947
tem@@	O	-1	20408947
pt@@	O	-1	20408947
.	O	-1	20408947
D@@	O	-1	20408947
uring	O	-1	20408947
follow-up	O	-1	20408947
(@@	O	-1	20408947
median	O	-1	20408947
5	O	-1	20408947
year@@	O	-1	20408947
s),	O	-1	20408947
there	O	-1	20408947
were	O	-1	20408947
no	O	-1	20408947
significant	O	-1	20408947
differences	O	-1	20408947
in	O	-1	20408947
re@@	O	-1	20408947
j@@	O	-1	20408947
ection	O	-1	20408947
(@@	O	-1	20408947
acute	O	-1	20408947
and	O	-1	20408947
chron@@	O	-1	20408947
ic@@	O	-1	20408947
),	O	-1	20408947
gra@@	O	-1	20408947
ft	O	-1	20408947
failure	O	-1	20408947
or	O	-1	20408947
sur@@	O	-1	20408947
viv@@	O	-1	20408947
al	O	-1	20408947
between	O	-1	20408947
the	O	-1	20408947
groups	O	-1	20408947
(	O	-1	20408947
acet@@	B-Chemical	D000082	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
AL@@	B-Disease	D017114	20408947
F	I-Disease	-1	20408947
1	O	-1	20408947
year	O	-1	20408947
8@@	O	-1	20408947
7@@	O	-1	20408947
%,	O	-1	20408947
5	O	-1	20408947
years	O	-1	20408947
7@@	O	-1	20408947
5@@	O	-1	20408947
%@@	O	-1	20408947
;	O	-1	20408947
non@@	O	-1	20408947
-	O	-1	20408947
acet@@	B-Chemical	D000082	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
AL@@	B-Disease	D017114	20408947
F	I-Disease	-1	20408947
8@@	O	-1	20408947
8@@	O	-1	20408947
%,	O	-1	20408947
7@@	O	-1	20408947
8@@	O	-1	20408947
%@@	O	-1	20408947
;	O	-1	20408947
CL@@	B-Disease	D008107	20408947
D	I-Disease	-1	20408947
9@@	O	-1	20408947
3@@	O	-1	20408947
%,	O	-1	20408947
8@@	O	-1	20408947
2@@	O	-1	20408947
%@@	O	-1	20408947
:	O	-1	20408947
P@@	O	-1	20408947
>@@	O	-1	20408947
0.@@	O	-1	20408947
6	O	-1	20408947
lo@@	O	-1	20408947
g	O	-1	20408947
ran@@	O	-1	20408947
k@@	O	-1	20408947
).	O	-1	20408947
Two	O	-1	20408947
acet@@	B-Chemical	D000082	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
AL@@	B-Disease	D017114	20408947
F	I-Disease	-1	20408947
patients	O	-1	20408947
reat@@	O	-1	20408947
tem@@	O	-1	20408947
pt@@	O	-1	20408947
ed	O	-1	20408947
su@@	O	-1	20408947
ic@@	O	-1	20408947
ide	O	-1	20408947
post@@	O	-1	20408947
-@@	O	-1	20408947
L@@	O	-1	20408947
T	O	-1	20408947
(@@	O	-1	20408947
one	O	-1	20408947
di@@	O	-1	20408947
ed	O	-1	20408947
8	O	-1	20408947
years	O	-1	20408947
post@@	O	-1	20408947
-@@	O	-1	20408947
LT@@	O	-1	20408947
).	O	-1	20408947
CONCLUSIONS:	O	-1	20408947
D@@	O	-1	20408947
es@@	O	-1	20408947
pit@@	O	-1	20408947
e	O	-1	20408947
a	O	-1	20408947
high	O	-1	20408947
prev@@	O	-1	20408947
al@@	O	-1	20408947
ence	O	-1	20408947
of	O	-1	20408947
psych@@	O	-1	20408947
i@@	O	-1	20408947
atric	O	-1	20408947
dist@@	O	-1	20408947
urb@@	O	-1	20408947
ance@@	O	-1	20408947
,	O	-1	20408947
outcom@@	O	-1	20408947
es	O	-1	20408947
for	O	-1	20408947
patients	O	-1	20408947
transplant@@	O	-1	20408947
ed	O	-1	20408947
em@@	O	-1	20408947
erg@@	O	-1	20408947
ently	O	-1	20408947
for	O	-1	20408947
acet@@	B-Chemical	D000082	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
AL@@	B-Disease	D017114	20408947
F	I-Disease	-1	20408947
were	O	-1	20408947
compar@@	O	-1	20408947
able	O	-1	20408947
to	O	-1	20408947
those	O	-1	20408947
transplant@@	O	-1	20408947
ed	O	-1	20408947
for	O	-1	20408947
non@@	O	-1	20408947
-	O	-1	20408947
acet@@	B-Chemical	D000082	20408947
aminoph@@	I-Chemical	-1	20408947
en	I-Chemical	-1	20408947
-induced	O	-1	20408947
AL@@	B-Disease	D017114	20408947
F	I-Disease	-1	20408947
and	O	-1	20408947
el@@	O	-1	20408947
ectively	O	-1	20408947
for	O	-1	20408947
CL@@	B-Disease	D008107	20408947
D	I-Disease	-1	20408947
.	O	-1	20408947
M@@	O	-1	20408947
ul@@	O	-1	20408947
ti@@	O	-1	20408947
dis@@	O	-1	20408947
ci@@	O	-1	20408947
pl@@	O	-1	20408947
inary	O	-1	20408947
appro@@	O	-1	20408947
ac@@	O	-1	20408947
h@@	O	-1	20408947
es	O	-1	20408947
with	O	-1	20408947
long-term	O	-1	20408947
psych@@	O	-1	20408947
i@@	O	-1	20408947
atric	O	-1	20408947
follow-up	O	-1	20408947
may	O	-1	20408947
cont@@	O	-1	20408947
rib@@	O	-1	20408947
ute	O	-1	20408947
to	O	-1	20408947
low	O	-1	20408947
post@@	O	-1	20408947
-@@	O	-1	20408947
transplant	O	-1	20408947
su@@	O	-1	20408947
ic@@	O	-1	20408947
ide	O	-1	20408947
rat@@	O	-1	20408947
es	O	-1	20408947
seen	O	-1	20408947
and	O	-1	20408947
low	O	-1	20408947
rat@@	O	-1	20408947
es	O	-1	20408947
of	O	-1	20408947
gra@@	O	-1	20408947
ft	O	-1	20408947
loss	O	-1	20408947
because	O	-1	20408947
of	O	-1	20408947
non-@@	O	-1	20408947
com@@	O	-1	20408947
pl@@	O	-1	20408947
i@@	O	-1	20408947
ance@@	O	-1	20408947
.	O	-1	20408947

S@@	O	-1	20447294
t@@	O	-1	20447294
udi@@	O	-1	20447294
es	O	-1	20447294
of	O	-1	20447294
syn@@	O	-1	20447294
erg@@	O	-1	20447294
y	O	-1	20447294
between	O	-1	20447294
morphine	B-Chemical	D009020	20447294
and	O	-1	20447294
a	O	-1	20447294
novel	O	-1	20447294
sodium	B-Chemical	D012964	20447294
channel	O	-1	20447294
block@@	O	-1	20447294
er,	O	-1	20447294
C@@	B-Chemical	C401121	20447294
N@@	I-Chemical	-1	20447294
S@@	I-Chemical	-1	20447294
B@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
2	I-Chemical	-1	20447294
,	O	-1	20447294
in	O	-1	20447294
rat	O	-1	20447294
models	O	-1	20447294
of	O	-1	20447294
inflam@@	O	-1	20447294
mat@@	O	-1	20447294
ory	O	-1	20447294
and	O	-1	20447294
neuro@@	B-Disease	D009437	20447294
path@@	I-Disease	-1	20447294
ic	I-Disease	-1	20447294
pain	I-Disease	-1	20447294
.	O	-1	20447294
OBJECTIVE:	O	-1	20447294
This	O	-1	20447294
study	O	-1	20447294
determined	O	-1	20447294
the	O	-1	20447294
anti@@	O	-1	20447294
hyperalge@@	O	-1	20447294
sic	O	-1	20447294
effect	O	-1	20447294
of	O	-1	20447294
C@@	B-Chemical	C401121	20447294
N@@	I-Chemical	-1	20447294
S@@	I-Chemical	-1	20447294
B@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
2	I-Chemical	-1	20447294
,	O	-1	20447294
a	O	-1	20447294
sodium	B-Chemical	D012964	20447294
channel	O	-1	20447294
block@@	O	-1	20447294
er	O	-1	20447294
with	O	-1	20447294
anti@@	O	-1	20447294
oxid@@	O	-1	20447294
ant	O	-1	20447294
pro@@	O	-1	20447294
per@@	O	-1	20447294
ties	O	-1	20447294
given	O	-1	20447294
alone	O	-1	20447294
and	O	-1	20447294
in	O	-1	20447294
combin@@	O	-1	20447294
ations	O	-1	20447294
with	O	-1	20447294
morphine	B-Chemical	D009020	20447294
in	O	-1	20447294
rat	O	-1	20447294
models	O	-1	20447294
of	O	-1	20447294
inflam@@	O	-1	20447294
mat@@	O	-1	20447294
ory	O	-1	20447294
and	O	-1	20447294
neuro@@	B-Disease	D009437	20447294
path@@	I-Disease	-1	20447294
ic	I-Disease	-1	20447294
pain	I-Disease	-1	20447294
.	O	-1	20447294
D@@	O	-1	20447294
ES@@	O	-1	20447294
I@@	O	-1	20447294
G@@	O	-1	20447294
N@@	O	-1	20447294
:	O	-1	20447294
D@@	O	-1	20447294
ose	O	-1	20447294
response	O	-1	20447294
cur@@	O	-1	20447294
v@@	O	-1	20447294
es	O	-1	20447294
for	O	-1	20447294
non@@	O	-1	20447294
sed@@	O	-1	20447294
ating	O	-1	20447294
doses	O	-1	20447294
of	O	-1	20447294
morphine	B-Chemical	D009020	20447294
and	O	-1	20447294
C@@	B-Chemical	C401121	20447294
N@@	I-Chemical	-1	20447294
S@@	I-Chemical	-1	20447294
B@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
2	I-Chemical	-1	20447294
given	O	-1	20447294
intra@@	O	-1	20447294
per@@	O	-1	20447294
it@@	O	-1	20447294
one@@	O	-1	20447294
ally	O	-1	20447294
alone	O	-1	20447294
and	O	-1	20447294
to@@	O	-1	20447294
ge@@	O	-1	20447294
ther	O	-1	20447294
in	O	-1	20447294
combin@@	O	-1	20447294
ations	O	-1	20447294
were	O	-1	20447294
con@@	O	-1	20447294
struc@@	O	-1	20447294
ted	O	-1	20447294
for	O	-1	20447294
anti@@	O	-1	20447294
hyperalge@@	O	-1	20447294
sic	O	-1	20447294
effect	O	-1	20447294
using	O	-1	20447294
pa@@	O	-1	20447294
w	O	-1	20447294
withdrawal	O	-1	20447294
from	O	-1	20447294
no@@	O	-1	20447294
xi@@	O	-1	20447294
ous	O	-1	20447294
he@@	O	-1	20447294
at	O	-1	20447294
in	O	-1	20447294
two	O	-1	20447294
rat	O	-1	20447294
pain	B-Disease	D010146	20447294
model@@	O	-1	20447294
s:	O	-1	20447294
car@@	B-Chemical	D002351	20447294
ra@@	I-Chemical	-1	20447294
ge@@	I-Chemical	-1	20447294
en@@	I-Chemical	-1	20447294
an	I-Chemical	-1	20447294
-induced	O	-1	20447294
pa@@	O	-1	20447294
w	O	-1	20447294
inflam@@	B-Disease	D007249	20447294
m@@	I-Disease	-1	20447294
ation	I-Disease	-1	20447294
and	O	-1	20447294
st@@	B-Chemical	D013311	20447294
re@@	I-Chemical	-1	20447294
pto@@	I-Chemical	-1	20447294
z@@	I-Chemical	-1	20447294
ot@@	I-Chemical	-1	20447294
oc@@	I-Chemical	-1	20447294
in	I-Chemical	-1	20447294
(	O	-1	20447294
S@@	B-Chemical	D013311	20447294
T@@	I-Chemical	-1	20447294
Z	I-Chemical	-1	20447294
)@@	O	-1	20447294
-induced	O	-1	20447294
dia@@	B-Disease	D003929	20447294
be@@	I-Disease	-1	20447294
tic	I-Disease	-1	20447294
neuropathy	I-Disease	-1	20447294
.	O	-1	20447294
RESULTS:	O	-1	20447294
The	O	-1	20447294
maxim@@	O	-1	20447294
um	O	-1	20447294
non@@	O	-1	20447294
sed@@	O	-1	20447294
ating	O	-1	20447294
doses	O	-1	20447294
we@@	O	-1	20447294
re@@	O	-1	20447294
:	O	-1	20447294
morphine	B-Chemical	D009020	20447294
,	O	-1	20447294
3.@@	O	-1	20447294
2	O	-1	20447294
mg/kg@@	O	-1	20447294
;	O	-1	20447294
C@@	B-Chemical	C401121	20447294
N@@	I-Chemical	-1	20447294
S@@	I-Chemical	-1	20447294
B@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
2	I-Chemical	-1	20447294
1@@	O	-1	20447294
0.@@	O	-1	20447294
0	O	-1	20447294
mg/kg@@	O	-1	20447294
;	O	-1	20447294
5.@@	O	-1	20447294
0	O	-1	20447294
mg/kg	O	-1	20447294
C@@	B-Chemical	C401121	20447294
N@@	I-Chemical	-1	20447294
S@@	I-Chemical	-1	20447294
B@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
2	I-Chemical	-1	20447294
with	O	-1	20447294
morphine	B-Chemical	D009020	20447294
3.@@	O	-1	20447294
2	O	-1	20447294
mg/kg	O	-1	20447294
in	O	-1	20447294
combin@@	O	-1	20447294
ation.	O	-1	20447294
The	O	-1	20447294
doses	O	-1	20447294
calc@@	O	-1	20447294
ul@@	O	-1	20447294
ated	O	-1	20447294
to	O	-1	20447294
cause	O	-1	20447294
50@@	O	-1	20447294
%	O	-1	20447294
rever@@	O	-1	20447294
s@@	O	-1	20447294
al	O	-1	20447294
of	O	-1	20447294
hyperalge@@	B-Disease	D006930	20447294
sia	I-Disease	-1	20447294
(@@	O	-1	20447294
E@@	O	-1	20447294
D@@	O	-1	20447294
50@@	O	-1	20447294
)	O	-1	20447294
were	O	-1	20447294
7.@@	O	-1	20447294
5@@	O	-1	20447294
4	O	-1	20447294
(1@@	O	-1	20447294
.@@	O	-1	20447294
8@@	O	-1	20447294
1)	O	-1	20447294
and	O	-1	20447294
4.@@	O	-1	20447294
8@@	O	-1	20447294
3	O	-1	20447294
(1@@	O	-1	20447294
.@@	O	-1	20447294
5@@	O	-1	20447294
4@@	O	-1	20447294
)	O	-1	20447294
in	O	-1	20447294
the	O	-1	20447294
car@@	B-Chemical	D002351	20447294
ra@@	I-Chemical	-1	20447294
ge@@	I-Chemical	-1	20447294
en@@	I-Chemical	-1	20447294
an	I-Chemical	-1	20447294
model	O	-1	20447294
and	O	-1	20447294
4@@	O	-1	20447294
4.@@	O	-1	20447294
1@@	O	-1	20447294
8	O	-1	20447294
(1@@	O	-1	20447294
.@@	O	-1	20447294
3@@	O	-1	20447294
7@@	O	-1	20447294
)	O	-1	20447294
and	O	-1	20447294
9.@@	O	-1	20447294
14	O	-1	20447294
(1@@	O	-1	20447294
.@@	O	-1	20447294
2@@	O	-1	20447294
4@@	O	-1	20447294
)	O	-1	20447294
in	O	-1	20447294
the	O	-1	20447294
S@@	B-Chemical	D013311	20447294
T@@	I-Chemical	-1	20447294
Z	I-Chemical	-1	20447294
-induced	O	-1	20447294
neuropathy	B-Disease	D009422	20447294
model	O	-1	20447294
for	O	-1	20447294
C@@	B-Chemical	C401121	20447294
N@@	I-Chemical	-1	20447294
S@@	I-Chemical	-1	20447294
B@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
2	I-Chemical	-1	20447294
and	O	-1	20447294
morphine	B-Chemical	D009020	20447294
,	O	-1	20447294
respecti@@	O	-1	20447294
vely	O	-1	20447294
(@@	O	-1	20447294
mg/kg@@	O	-1	20447294
;	O	-1	20447294
me@@	O	-1	20447294
an@@	O	-1	20447294
,	O	-1	20447294
S@@	O	-1	20447294
E@@	O	-1	20447294
M@@	O	-1	20447294
).	O	-1	20447294
These	O	-1	20447294
values	O	-1	20447294
were	O	-1	20447294
greater	O	-1	20447294
than	O	-1	20447294
the	O	-1	20447294
maxim@@	O	-1	20447294
um	O	-1	20447294
non@@	O	-1	20447294
sed@@	O	-1	20447294
ating	O	-1	20447294
dos@@	O	-1	20447294
es.	O	-1	20447294
The	O	-1	20447294
E@@	O	-1	20447294
D@@	O	-1	20447294
50	O	-1	20447294
values	O	-1	20447294
for	O	-1	20447294
morphine	B-Chemical	D009020	20447294
when	O	-1	20447294
given	O	-1	20447294
in	O	-1	20447294
combination	O	-1	20447294
with	O	-1	20447294
C@@	B-Chemical	C401121	20447294
N@@	I-Chemical	-1	20447294
S@@	I-Chemical	-1	20447294
B@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
2	I-Chemical	-1	20447294
(@@	O	-1	20447294
5	O	-1	20447294
mg/kg)	O	-1	20447294
were	O	-1	20447294
less	O	-1	20447294
than	O	-1	20447294
the	O	-1	20447294
maxim@@	O	-1	20447294
um	O	-1	20447294
non@@	O	-1	20447294
sed@@	O	-1	20447294
ating	O	-1	20447294
dose@@	O	-1	20447294
:	O	-1	20447294
0.@@	O	-1	20447294
5@@	O	-1	20447294
6	O	-1	20447294
(1@@	O	-1	20447294
.@@	O	-1	20447294
55@@	O	-1	20447294
)	O	-1	20447294
in	O	-1	20447294
the	O	-1	20447294
car@@	B-Chemical	D002351	20447294
ra@@	I-Chemical	-1	20447294
ge@@	I-Chemical	-1	20447294
en@@	I-Chemical	-1	20447294
an	I-Chemical	-1	20447294
model	O	-1	20447294
and	O	-1	20447294
1.@@	O	-1	20447294
3@@	O	-1	20447294
7	O	-1	20447294
(1@@	O	-1	20447294
.@@	O	-1	20447294
2@@	O	-1	20447294
3@@	O	-1	20447294
)	O	-1	20447294
in	O	-1	20447294
the	O	-1	20447294
neuropathy	B-Disease	D009422	20447294
model	O	-1	20447294
(@@	O	-1	20447294
mg/kg@@	O	-1	20447294
;	O	-1	20447294
me@@	O	-1	20447294
an@@	O	-1	20447294
,	O	-1	20447294
S@@	O	-1	20447294
E@@	O	-1	20447294
M@@	O	-1	20447294
).	O	-1	20447294
The	O	-1	20447294
ant@@	O	-1	20447294
in@@	O	-1	20447294
ocicep@@	O	-1	20447294
tion	O	-1	20447294
after	O	-1	20447294
morphine	B-Chemical	D009020	20447294
(@@	O	-1	20447294
3.@@	O	-1	20447294
2	O	-1	20447294
mg/kg)	O	-1	20447294
was	O	-1	20447294
increased	O	-1	20447294
by	O	-1	20447294
co-@@	O	-1	20447294
administration	O	-1	20447294
with	O	-1	20447294
C@@	B-Chemical	C401121	20447294
N@@	I-Chemical	-1	20447294
S@@	I-Chemical	-1	20447294
B@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
2	I-Chemical	-1	20447294
from	O	-1	20447294
2@@	O	-1	20447294
8.@@	O	-1	20447294
0	O	-1	20447294
and	O	-1	20447294
3@@	O	-1	20447294
1.@@	O	-1	20447294
7@@	O	-1	20447294
%	O	-1	20447294
to	O	-1	20447294
1@@	O	-1	20447294
1@@	O	-1	20447294
4.@@	O	-1	20447294
6	O	-1	20447294
and	O	-1	20447294
5@@	O	-1	20447294
6.@@	O	-1	20447294
9@@	O	-1	20447294
%	O	-1	20447294
rever@@	O	-1	20447294
s@@	O	-1	20447294
al	O	-1	20447294
of	O	-1	20447294
hyperalge@@	B-Disease	D006930	20447294
sia	I-Disease	-1	20447294
in	O	-1	20447294
the	O	-1	20447294
inflam@@	O	-1	20447294
mat@@	O	-1	20447294
ory	O	-1	20447294
and	O	-1	20447294
neuro@@	B-Disease	D009422	20447294
path@@	I-Disease	-1	20447294
ic	I-Disease	-1	20447294
model@@	O	-1	20447294
s,	O	-1	20447294
respecti@@	O	-1	20447294
vely	O	-1	20447294
(P	O	-1	20447294
<	O	-1	20447294
0.0@@	O	-1	20447294
1@@	O	-1	20447294
;	O	-1	20447294
on@@	O	-1	20447294
e-@@	O	-1	20447294
w@@	O	-1	20447294
ay	O	-1	20447294
analysis	O	-1	20447294
of	O	-1	20447294
vari@@	O	-1	20447294
ance@@	O	-1	20447294
-@@	O	-1	20447294
significantly	O	-1	20447294
greater	O	-1	20447294
than	O	-1	20447294
either	O	-1	20447294
drug	O	-1	20447294
given	O	-1	20447294
al@@	O	-1	20447294
one@@	O	-1	20447294
).	O	-1	20447294
CONCLUSIONS:	O	-1	20447294
The	O	-1	20447294
maxim@@	O	-1	20447294
um	O	-1	20447294
anti@@	O	-1	20447294
hyperalge@@	O	-1	20447294
sic	O	-1	20447294
effect	O	-1	20447294
achi@@	O	-1	20447294
ev@@	O	-1	20447294
able	O	-1	20447294
with	O	-1	20447294
non@@	O	-1	20447294
sed@@	O	-1	20447294
ating	O	-1	20447294
doses	O	-1	20447294
of	O	-1	20447294
morphine	B-Chemical	D009020	20447294
may	O	-1	20447294
be	O	-1	20447294
increased	O	-1	20447294
significantly	O	-1	20447294
when	O	-1	20447294
the	O	-1	20447294
drug	O	-1	20447294
is	O	-1	20447294
used	O	-1	20447294
in	O	-1	20447294
combination	O	-1	20447294
with	O	-1	20447294
C@@	B-Chemical	C401121	20447294
N@@	I-Chemical	-1	20447294
S@@	I-Chemical	-1	20447294
B@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
0@@	I-Chemical	-1	20447294
2	I-Chemical	-1	20447294
.	O	-1	20447294

He@@	B-Chemical	D006493	20495512
par@@	I-Chemical	-1	20495512
in	I-Chemical	-1	20495512
-induced	O	-1	20495512
throm@@	B-Disease	D013921	20495512
b@@	I-Disease	-1	20495512
ocyto@@	I-Disease	-1	20495512
pen@@	I-Disease	-1	20495512
ia	I-Disease	-1	20495512
:	O	-1	20495512
a	O	-1	20495512
p@@	O	-1	20495512
rac@@	O	-1	20495512
tical	O	-1	20495512
revie@@	O	-1	20495512
w@@	O	-1	20495512
.	O	-1	20495512
He@@	B-Chemical	D006493	20495512
par@@	I-Chemical	-1	20495512
in	I-Chemical	-1	20495512
-induced	O	-1	20495512
throm@@	B-Disease	D013921	20495512
b@@	I-Disease	-1	20495512
ocyto@@	I-Disease	-1	20495512
pen@@	I-Disease	-1	20495512
ia	I-Disease	-1	20495512
(	O	-1	20495512
H@@	B-Disease	D013921	20495512
I@@	I-Disease	-1	20495512
T	I-Disease	-1	20495512
)	O	-1	20495512
remain@@	O	-1	20495512
s	O	-1	20495512
under@@	O	-1	20495512
-@@	O	-1	20495512
reco@@	O	-1	20495512
gn@@	O	-1	20495512
ized	O	-1	20495512
des@@	O	-1	20495512
pit@@	O	-1	20495512
e	O	-1	20495512
its	O	-1	20495512
potenti@@	O	-1	20495512
ally	O	-1	20495512
de@@	O	-1	20495512
vast@@	O	-1	20495512
ating	O	-1	20495512
outcom@@	O	-1	20495512
es.	O	-1	20495512
It	O	-1	20495512
be@@	O	-1	20495512
g@@	O	-1	20495512
ins	O	-1	20495512
when	O	-1	20495512
hepar@@	B-Chemical	D006493	20495512
in	I-Chemical	-1	20495512
exposure	O	-1	20495512
stimul@@	O	-1	20495512
ates	O	-1	20495512
the	O	-1	20495512
formation	O	-1	20495512
of	O	-1	20495512
hepar@@	B-Chemical	D006493	20495512
in	I-Chemical	-1	20495512
-@@	O	-1	20495512
platele@@	O	-1	20495512
t	O	-1	20495512
factor	O	-1	20495512
4	O	-1	20495512
anti@@	O	-1	20495512
bo@@	O	-1	20495512
di@@	O	-1	20495512
es,	O	-1	20495512
which	O	-1	20495512
in	O	-1	20495512
t@@	O	-1	20495512
ur@@	O	-1	20495512
n	O	-1	20495512
tri@@	O	-1	20495512
g@@	O	-1	20495512
g@@	O	-1	20495512
ers	O	-1	20495512
the	O	-1	20495512
release	O	-1	20495512
of	O	-1	20495512
pro@@	O	-1	20495512
co@@	O	-1	20495512
ag@@	O	-1	20495512
ul@@	O	-1	20495512
ant	O	-1	20495512
platele@@	O	-1	20495512
t	O	-1	20495512
par@@	O	-1	20495512
ti@@	O	-1	20495512
cl@@	O	-1	20495512
es.	O	-1	20495512
Th@@	B-Disease	D013927	20495512
rom@@	I-Disease	-1	20495512
bo@@	I-Disease	-1	20495512
sis	I-Disease	-1	20495512
and	O	-1	20495512
throm@@	B-Disease	D013921	20495512
b@@	I-Disease	-1	20495512
ocyto@@	I-Disease	-1	20495512
pen@@	I-Disease	-1	20495512
ia	I-Disease	-1	20495512
that	O	-1	20495512
fol@@	O	-1	20495512
low	O	-1	20495512
comp@@	O	-1	20495512
ri@@	O	-1	20495512
se	O	-1	20495512
the	O	-1	20495512
2	O	-1	20495512
h@@	O	-1	20495512
all@@	O	-1	20495512
m@@	O	-1	20495512
ar@@	O	-1	20495512
k	O	-1	20495512
tra@@	O	-1	20495512
its	O	-1	20495512
of	O	-1	20495512
H@@	B-Disease	D013921	20495512
I@@	I-Disease	-1	20495512
T	I-Disease	-1	20495512
,	O	-1	20495512
with	O	-1	20495512
the	O	-1	20495512
form@@	O	-1	20495512
er	O	-1	20495512
larg@@	O	-1	20495512
ely	O	-1	20495512
respon@@	O	-1	20495512
sible	O	-1	20495512
for	O	-1	20495512
significant	O	-1	20495512
vascular	O	-1	20495512
complic@@	O	-1	20495512
ations.	O	-1	20495512
The	O	-1	20495512
prev@@	O	-1	20495512
al@@	O	-1	20495512
ence	O	-1	20495512
of	O	-1	20495512
H@@	B-Disease	D013921	20495512
I@@	I-Disease	-1	20495512
T	I-Disease	-1	20495512
vari@@	O	-1	20495512
es	O	-1	20495512
among	O	-1	20495512
several	O	-1	20495512
sub@@	O	-1	20495512
group@@	O	-1	20495512
s,	O	-1	20495512
with	O	-1	20495512
greater	O	-1	20495512
incidence	O	-1	20495512
in	O	-1	20495512
surg@@	O	-1	20495512
ical	O	-1	20495512
as	O	-1	20495512
compared	O	-1	20495512
with	O	-1	20495512
med@@	O	-1	20495512
ical	O	-1	20495512
po@@	O	-1	20495512
pul@@	O	-1	20495512
ations.	O	-1	20495512
H@@	B-Disease	D013921	20495512
I@@	I-Disease	-1	20495512
T	I-Disease	-1	20495512
mus@@	O	-1	20495512
t	O	-1	20495512
be	O	-1	20495512
ac@@	O	-1	20495512
know@@	O	-1	20495512
le@@	O	-1	20495512
d@@	O	-1	20495512
g@@	O	-1	20495512
ed	O	-1	20495512
for	O	-1	20495512
its	O	-1	20495512
int@@	O	-1	20495512
en@@	O	-1	20495512
se	O	-1	20495512
pre@@	O	-1	20495512
di@@	O	-1	20495512
l@@	O	-1	20495512
ection	O	-1	20495512
for	O	-1	20495512
thrombo@@	B-Disease	D013927	20495512
sis	I-Disease	-1	20495512
and	O	-1	20495512
sus@@	O	-1	20495512
p@@	O	-1	20495512
ected	O	-1	20495512
wh@@	O	-1	20495512
en@@	O	-1	20495512
ev@@	O	-1	20495512
er	O	-1	20495512
thrombo@@	B-Disease	D013927	20495512
sis	I-Disease	-1	20495512
occur@@	O	-1	20495512
s	O	-1	20495512
after	O	-1	20495512
hepar@@	B-Chemical	D006493	20495512
in	I-Chemical	-1	20495512
expos@@	O	-1	20495512
ure.	O	-1	20495512
E@@	O	-1	20495512
arly	O	-1	20495512
reco@@	O	-1	20495512
gn@@	O	-1	20495512
ition	O	-1	20495512
that	O	-1	20495512
inc@@	O	-1	20495512
or@@	O	-1	20495512
por@@	O	-1	20495512
ates	O	-1	20495512
the	O	-1	20495512
clinical	O	-1	20495512
and	O	-1	20495512
ser@@	O	-1	20495512
ologic	O	-1	20495512
cl@@	O	-1	20495512
u@@	O	-1	20495512
es	O	-1	20495512
is	O	-1	20495512
par@@	O	-1	20495512
amoun@@	O	-1	20495512
t	O	-1	20495512
to	O	-1	20495512
ti@@	O	-1	20495512
me@@	O	-1	20495512
ly	O	-1	20495512
insti@@	O	-1	20495512
tu@@	O	-1	20495512
tion	O	-1	20495512
of	O	-1	20495512
treatment,	O	-1	20495512
as	O	-1	20495512
its	O	-1	20495512
del@@	O	-1	20495512
ay	O	-1	20495512
may	O	-1	20495512
result	O	-1	20495512
in	O	-1	20495512
cat@@	O	-1	20495512
ast@@	O	-1	20495512
ro@@	O	-1	20495512
ph@@	O	-1	20495512
ic	O	-1	20495512
outcom@@	O	-1	20495512
es.	O	-1	20495512
The	O	-1	20495512
treatment	O	-1	20495512
of	O	-1	20495512
H@@	B-Disease	D013921	20495512
I@@	I-Disease	-1	20495512
T	I-Disease	-1	20495512
m@@	O	-1	20495512
and@@	O	-1	20495512
ates	O	-1	20495512
an	O	-1	20495512
immedi@@	O	-1	20495512
ate	O	-1	20495512
cess@@	O	-1	20495512
ation	O	-1	20495512
of	O	-1	20495512
all	O	-1	20495512
hepar@@	B-Chemical	D006493	20495512
in	I-Chemical	-1	20495512
exposure	O	-1	20495512
and	O	-1	20495512
the	O	-1	20495512
insti@@	O	-1	20495512
tu@@	O	-1	20495512
tion	O	-1	20495512
of	O	-1	20495512
an	O	-1	20495512
anti@@	O	-1	20495512
thrombotic	O	-1	20495512
therapy,	O	-1	20495512
most	O	-1	20495512
common@@	O	-1	20495512
ly	O	-1	20495512
using	O	-1	20495512
a	O	-1	20495512
direct	B-Chemical	D000991	20495512
throm@@	I-Chemical	-1	20495512
bin	I-Chemical	-1	20495512
inhibitor	I-Chemical	-1	20495512
.	O	-1	20495512
C@@	O	-1	20495512
ur@@	O	-1	20495512
rent	O	-1	20495512
"@@	O	-1	20495512
diagnos@@	O	-1	20495512
tic@@	O	-1	20495512
"	O	-1	20495512
test@@	O	-1	20495512
s,	O	-1	20495512
which	O	-1	20495512
prim@@	O	-1	20495512
ari@@	O	-1	20495512
ly	O	-1	20495512
includ@@	O	-1	20495512
e	O	-1	20495512
functional	O	-1	20495512
and	O	-1	20495512
anti@@	O	-1	20495512
genic	O	-1	20495512
ass@@	O	-1	20495512
ay@@	O	-1	20495512
s,	O	-1	20495512
have	O	-1	20495512
more	O	-1	20495512
of	O	-1	20495512
a	O	-1	20495512
con@@	O	-1	20495512
fir@@	O	-1	20495512
mat@@	O	-1	20495512
ory	O	-1	20495512
than	O	-1	20495512
diagnos@@	O	-1	20495512
tic	O	-1	20495512
role	O	-1	20495512
in	O	-1	20495512
the	O	-1	20495512
man@@	O	-1	20495512
ag@@	O	-1	20495512
ement	O	-1	20495512
of	O	-1	20495512
H@@	B-Disease	D013921	20495512
I@@	I-Disease	-1	20495512
T	I-Disease	-1	20495512
.	O	-1	20495512
S@@	O	-1	20495512
p@@	O	-1	20495512
ec@@	O	-1	20495512
ial	O	-1	20495512
atten@@	O	-1	20495512
tion	O	-1	20495512
mus@@	O	-1	20495512
t	O	-1	20495512
be	O	-1	20495512
pa@@	O	-1	20495512
id	O	-1	20495512
to	O	-1	20495512
cardiac	O	-1	20495512
patients	O	-1	20495512
who	O	-1	20495512
are	O	-1	20495512
often	O	-1	20495512
exposed	O	-1	20495512
to	O	-1	20495512
hepar@@	B-Chemical	D006493	20495512
in	I-Chemical	-1	20495512
multiple	O	-1	20495512
times	O	-1	20495512
during	O	-1	20495512
their	O	-1	20495512
course	O	-1	20495512
of	O	-1	20495512
treatment.	O	-1	20495512
Di@@	B-Chemical	D000991	20495512
rec@@	I-Chemical	-1	20495512
t	I-Chemical	-1	20495512
throm@@	I-Chemical	-1	20495512
bin	I-Chemical	-1	20495512
inhibitors	I-Chemical	-1	20495512
are	O	-1	20495512
appro@@	O	-1	20495512
pri@@	O	-1	20495512
ate,	O	-1	20495512
ev@@	O	-1	20495512
id@@	O	-1	20495512
ence@@	O	-1	20495512
-@@	O	-1	20495512
bas@@	O	-1	20495512
ed	O	-1	20495512
al@@	O	-1	20495512
tern@@	O	-1	20495512
ati@@	O	-1	20495512
v@@	O	-1	20495512
es	O	-1	20495512
to	O	-1	20495512
hepar@@	B-Chemical	D006493	20495512
in	I-Chemical	-1	20495512
in	O	-1	20495512
patients	O	-1	20495512
with	O	-1	20495512
a	O	-1	20495512
hist@@	O	-1	20495512
ory	O	-1	20495512
of	O	-1	20495512
H@@	B-Disease	D013921	20495512
I@@	I-Disease	-1	20495512
T	I-Disease	-1	20495512
,	O	-1	20495512
who	O	-1	20495512
need	O	-1	20495512
to	O	-1	20495512
under@@	O	-1	20495512
g@@	O	-1	20495512
o	O	-1	20495512
perc@@	O	-1	20495512
utaneous	O	-1	20495512
coronary	O	-1	20495512
inter@@	O	-1	20495512
ven@@	O	-1	20495512
tion.	O	-1	20495512
A@@	O	-1	20495512
s	O	-1	20495512
hepar@@	B-Chemical	D006493	20495512
in	I-Chemical	-1	20495512
remain@@	O	-1	20495512
s	O	-1	20495512
one	O	-1	20495512
of	O	-1	20495512
the	O	-1	20495512
most	O	-1	20495512
frequ@@	O	-1	20495512
ently	O	-1	20495512
used	O	-1	20495512
medic@@	O	-1	20495512
ations	O	-1	20495512
to@@	O	-1	20495512
day	O	-1	20495512
with	O	-1	20495512
potential	O	-1	20495512
for	O	-1	20495512
H@@	B-Disease	D013921	20495512
I@@	I-Disease	-1	20495512
T	I-Disease	-1	20495512
with	O	-1	20495512
every	O	-1	20495512
hepar@@	B-Chemical	D006493	20495512
in	I-Chemical	-1	20495512
expos@@	O	-1	20495512
ure,	O	-1	20495512
a	O	-1	20495512
clo@@	O	-1	20495512
se	O	-1	20495512
vi@@	O	-1	20495512
g@@	O	-1	20495512
il@@	O	-1	20495512
ance	O	-1	20495512
of	O	-1	20495512
platele@@	O	-1	20495512
t	O	-1	20495512
coun@@	O	-1	20495512
ts	O	-1	20495512
mus@@	O	-1	20495512
t	O	-1	20495512
be	O	-1	20495512
p@@	O	-1	20495512
rac@@	O	-1	20495512
tic@@	O	-1	20495512
ed	O	-1	20495512
wh@@	O	-1	20495512
en@@	O	-1	20495512
ev@@	O	-1	20495512
er	O	-1	20495512
hepar@@	B-Chemical	D006493	20495512
in	I-Chemical	-1	20495512
is	O	-1	20495512
initi@@	O	-1	20495512
ated.	O	-1	20495512

A@@	O	-1	20513036
b@@	O	-1	20513036
duc@@	O	-1	20513036
t@@	O	-1	20513036
or	O	-1	20513036
par@@	B-Disease	D010243	20513036
aly@@	I-Disease	-1	20513036
sis	I-Disease	-1	20513036
after	O	-1	20513036
b@@	B-Chemical	C542870	20513036
ot@@	I-Chemical	-1	20513036
o@@	I-Chemical	-1	20513036
x	I-Chemical	-1	20513036
injection	O	-1	20513036
for	O	-1	20513036
ad@@	B-Disease	D014826	20513036
duc@@	I-Disease	-1	20513036
t@@	I-Disease	-1	20513036
or	I-Disease	-1	20513036
sp@@	I-Disease	-1	20513036
as@@	I-Disease	-1	20513036
mo@@	I-Disease	-1	20513036
di@@	I-Disease	-1	20513036
c	I-Disease	-1	20513036
dys@@	I-Disease	-1	20513036
ph@@	I-Disease	-1	20513036
on@@	I-Disease	-1	20513036
ia	I-Disease	-1	20513036
.	O	-1	20513036
OBJECTIV@@	O	-1	20513036
ES@@	O	-1	20513036
/@@	O	-1	20513036
H@@	O	-1	20513036
Y@@	O	-1	20513036
P@@	O	-1	20513036
O@@	O	-1	20513036
T@@	O	-1	20513036
H@@	O	-1	20513036
ES@@	O	-1	20513036
I@@	O	-1	20513036
S:	O	-1	20513036
B@@	O	-1	20513036
ot@@	O	-1	20513036
ul@@	O	-1	20513036
in@@	O	-1	20513036
um	O	-1	20513036
tox@@	O	-1	20513036
in	O	-1	20513036
(	O	-1	20513036
B@@	B-Chemical	C542870	20513036
ot@@	I-Chemical	-1	20513036
o@@	I-Chemical	-1	20513036
x	I-Chemical	-1	20513036
)	O	-1	20513036
injec@@	O	-1	20513036
tions	O	-1	20513036
into	O	-1	20513036
the	O	-1	20513036
th@@	O	-1	20513036
yro@@	O	-1	20513036
ar@@	O	-1	20513036
y@@	O	-1	20513036
ten@@	O	-1	20513036
oid	O	-1	20513036
musc@@	O	-1	20513036
le@@	O	-1	20513036
s	O	-1	20513036
are	O	-1	20513036
the	O	-1	20513036
current	O	-1	20513036
standard	O	-1	20513036
of	O	-1	20513036
car@@	O	-1	20513036
e	O	-1	20513036
for	O	-1	20513036
ad@@	B-Disease	D014826	20513036
duc@@	I-Disease	-1	20513036
t@@	I-Disease	-1	20513036
or	I-Disease	-1	20513036
sp@@	I-Disease	-1	20513036
as@@	I-Disease	-1	20513036
mo@@	I-Disease	-1	20513036
di@@	I-Disease	-1	20513036
c	I-Disease	-1	20513036
dys@@	I-Disease	-1	20513036
ph@@	I-Disease	-1	20513036
on@@	I-Disease	-1	20513036
ia	I-Disease	-1	20513036
(	O	-1	20513036
AD@@	B-Disease	D014826	20513036
S@@	I-Disease	-1	20513036
D	I-Disease	-1	20513036
).	O	-1	20513036
Re@@	O	-1	20513036
por@@	O	-1	20513036
ted	O	-1	20513036
adverse	O	-1	20513036
effects	O	-1	20513036
includ@@	O	-1	20513036
e	O	-1	20513036
a	O	-1	20513036
period	O	-1	20513036
of	O	-1	20513036
b@@	O	-1	20513036
re@@	O	-1	20513036
ath@@	O	-1	20513036
in@@	O	-1	20513036
es@@	O	-1	20513036
s,	O	-1	20513036
th@@	B-Disease	D010612	20513036
ro@@	I-Disease	-1	20513036
at	I-Disease	-1	20513036
pain	I-Disease	-1	20513036
,	O	-1	20513036
and	O	-1	20513036
diff@@	O	-1	20513036
ic@@	O	-1	20513036
ult@@	O	-1	20513036
y	O	-1	20513036
with	O	-1	20513036
s@@	O	-1	20513036
w@@	O	-1	20513036
al@@	O	-1	20513036
low@@	O	-1	20513036
ing	O	-1	20513036
li@@	O	-1	20513036
qu@@	O	-1	20513036
id@@	O	-1	20513036
s.	O	-1	20513036
H@@	O	-1	20513036
ere	O	-1	20513036
we	O	-1	20513036
report	O	-1	20513036
multiple	O	-1	20513036
cases	O	-1	20513036
of	O	-1	20513036
bil@@	O	-1	20513036
ateral	O	-1	20513036
ab@@	O	-1	20513036
duc@@	O	-1	20513036
t@@	O	-1	20513036
or	O	-1	20513036
par@@	B-Disease	D010243	20513036
aly@@	I-Disease	-1	20513036
sis	I-Disease	-1	20513036
following	O	-1	20513036
B@@	B-Chemical	C542870	20513036
ot@@	I-Chemical	-1	20513036
o@@	I-Chemical	-1	20513036
x	I-Chemical	-1	20513036
injec@@	O	-1	20513036
tions	O	-1	20513036
for	O	-1	20513036
AD@@	B-Disease	D014826	20513036
S@@	I-Disease	-1	20513036
D	I-Disease	-1	20513036
,	O	-1	20513036
a	O	-1	20513036
complication	O	-1	20513036
previously	O	-1	20513036
un@@	O	-1	20513036
repor@@	O	-1	20513036
ted.	O	-1	20513036
S@@	O	-1	20513036
T@@	O	-1	20513036
U@@	O	-1	20513036
D@@	O	-1	20513036
Y	O	-1	20513036
D@@	O	-1	20513036
ES@@	O	-1	20513036
I@@	O	-1	20513036
G@@	O	-1	20513036
N@@	O	-1	20513036
:	O	-1	20513036
R@@	O	-1	20513036
et@@	O	-1	20513036
ro@@	O	-1	20513036
sp@@	O	-1	20513036
ective	O	-1	20513036
case	O	-1	20513036
seri@@	O	-1	20513036
es.	O	-1	20513036
METHODS:	O	-1	20513036
Patients	O	-1	20513036
that	O	-1	20513036
received	O	-1	20513036
B@@	B-Chemical	C542870	20513036
ot@@	I-Chemical	-1	20513036
o@@	I-Chemical	-1	20513036
x	I-Chemical	-1	20513036
injec@@	O	-1	20513036
tions	O	-1	20513036
for	O	-1	20513036
sp@@	B-Disease	D055154	20513036
as@@	I-Disease	-1	20513036
mo@@	I-Disease	-1	20513036
di@@	I-Disease	-1	20513036
c	I-Disease	-1	20513036
dys@@	I-Disease	-1	20513036
ph@@	I-Disease	-1	20513036
on@@	I-Disease	-1	20513036
ia	I-Disease	-1	20513036
between	O	-1	20513036
J@@	O	-1	20513036
an@@	O	-1	20513036
u@@	O	-1	20513036
ary	O	-1	20513036
20@@	O	-1	20513036
00	O	-1	20513036
and	O	-1	20513036
O@@	O	-1	20513036
c@@	O	-1	20513036
to@@	O	-1	20513036
b@@	O	-1	20513036
er	O	-1	20513036
20@@	O	-1	20513036
0@@	O	-1	20513036
9	O	-1	20513036
were	O	-1	20513036
evalu@@	O	-1	20513036
ated.	O	-1	20513036
Patients	O	-1	20513036
with	O	-1	20513036
AD@@	B-Disease	D014826	20513036
S@@	I-Disease	-1	20513036
D	I-Disease	-1	20513036
were	O	-1	20513036
identi@@	O	-1	20513036
fi@@	O	-1	20513036
ed.	O	-1	20513036
The	O	-1	20513036
number	O	-1	20513036
of	O	-1	20513036
treat@@	O	-1	20513036
ments	O	-1	20513036
received	O	-1	20513036
and	O	-1	20513036
adverse	O	-1	20513036
effects	O	-1	20513036
were	O	-1	20513036
not@@	O	-1	20513036
ed.	O	-1	20513036
F@@	O	-1	20513036
or	O	-1	20513036
patients	O	-1	20513036
with	O	-1	20513036
bil@@	O	-1	20513036
ateral	O	-1	20513036
ab@@	O	-1	20513036
duc@@	O	-1	20513036
t@@	O	-1	20513036
or	O	-1	20513036
par@@	B-Disease	D010243	20513036
aly@@	I-Disease	-1	20513036
sis	I-Disease	-1	20513036
,	O	-1	20513036
age,	O	-1	20513036
sex@@	O	-1	20513036
,	O	-1	20513036
par@@	O	-1	20513036
aly@@	O	-1	20513036
tic	O	-1	20513036
B@@	B-Chemical	C542870	20513036
ot@@	I-Chemical	-1	20513036
o@@	I-Chemical	-1	20513036
x	I-Chemical	-1	20513036
dose@@	O	-1	20513036
,	O	-1	20513036
prior	O	-1	20513036
B@@	B-Chemical	C542870	20513036
ot@@	I-Chemical	-1	20513036
o@@	I-Chemical	-1	20513036
x	I-Chemical	-1	20513036
dose@@	O	-1	20513036
,	O	-1	20513036
and	O	-1	20513036
course	O	-1	20513036
following	O	-1	20513036
par@@	B-Disease	D010243	20513036
aly@@	I-Disease	-1	20513036
sis	I-Disease	-1	20513036
were	O	-1	20513036
not@@	O	-1	20513036
ed.	O	-1	20513036
RESULTS:	O	-1	20513036
F@@	O	-1	20513036
rom	O	-1	20513036
a	O	-1	20513036
dat@@	O	-1	20513036
ab@@	O	-1	20513036
ase	O	-1	20513036
of	O	-1	20513036
4@@	O	-1	20513036
5@@	O	-1	20513036
2	O	-1	20513036
patients	O	-1	20513036
receiving	O	-1	20513036
B@@	B-Chemical	C542870	20513036
ot@@	I-Chemical	-1	20513036
o@@	I-Chemical	-1	20513036
x	I-Chemical	-1	20513036
,	O	-1	20513036
3@@	O	-1	20513036
5@@	O	-1	20513036
2	O	-1	20513036
patients	O	-1	20513036
had	O	-1	20513036
been	O	-1	20513036
diagnos@@	O	-1	20513036
ed	O	-1	20513036
with	O	-1	20513036
AD@@	B-Disease	D014826	20513036
S@@	I-Disease	-1	20513036
D	I-Disease	-1	20513036
.	O	-1	20513036
Of	O	-1	20513036
these	O	-1	20513036
3@@	O	-1	20513036
5@@	O	-1	20513036
2	O	-1	20513036
patients,	O	-1	20513036
e@@	O	-1	20513036
ight	O	-1	20513036
patients	O	-1	20513036
su@@	O	-1	20513036
ffe@@	O	-1	20513036
red	O	-1	20513036
bil@@	O	-1	20513036
ateral	O	-1	20513036
ab@@	O	-1	20513036
duc@@	O	-1	20513036
t@@	O	-1	20513036
or	O	-1	20513036
par@@	B-Disease	D010243	20513036
aly@@	I-Disease	-1	20513036
sis	I-Disease	-1	20513036
,	O	-1	20513036
and	O	-1	20513036
two	O	-1	20513036
su@@	O	-1	20513036
ffe@@	O	-1	20513036
red	O	-1	20513036
this	O	-1	20513036
complication	O	-1	20513036
tw@@	O	-1	20513036
ic@@	O	-1	20513036
e.	O	-1	20513036
All	O	-1	20513036
affected	O	-1	20513036
patients	O	-1	20513036
were	O	-1	20513036
femal@@	O	-1	20513036
es	O	-1	20513036
over	O	-1	20513036
the	O	-1	20513036
age	O	-1	20513036
of	O	-1	20513036
50	O	-1	20513036
year@@	O	-1	20513036
s.	O	-1	20513036
M@@	O	-1	20513036
ost	O	-1	20513036
patients	O	-1	20513036
had	O	-1	20513036
received	O	-1	20513036
treat@@	O	-1	20513036
ments	O	-1	20513036
prior	O	-1	20513036
to	O	-1	20513036
ab@@	O	-1	20513036
duc@@	O	-1	20513036
t@@	O	-1	20513036
or	O	-1	20513036
par@@	B-Disease	D010243	20513036
aly@@	I-Disease	-1	20513036
sis	I-Disease	-1	20513036
and	O	-1	20513036
continu@@	O	-1	20513036
ed	O	-1	20513036
receiving	O	-1	20513036
after	O	-1	20513036
par@@	B-Disease	D010243	20513036
aly@@	I-Disease	-1	20513036
sis	I-Disease	-1	20513036
.	O	-1	20513036
S@@	O	-1	20513036
even	O	-1	20513036
patients	O	-1	20513036
reco@@	O	-1	20513036
vered	O	-1	20513036
after	O	-1	20513036
a	O	-1	20513036
b@@	O	-1	20513036
ri@@	O	-1	20513036
e@@	O	-1	20513036
f	O	-1	20513036
period	O	-1	20513036
of	O	-1	20513036
activity	O	-1	20513036
re@@	O	-1	20513036
stric@@	O	-1	20513036
tion@@	O	-1	20513036
s,	O	-1	20513036
and	O	-1	20513036
one	O	-1	20513036
under@@	O	-1	20513036
w@@	O	-1	20513036
ent	O	-1	20513036
a	O	-1	20513036
trac@@	O	-1	20513036
he@@	O	-1	20513036
ot@@	O	-1	20513036
om@@	O	-1	20513036
y.	O	-1	20513036
The	O	-1	20513036
incidence	O	-1	20513036
of	O	-1	20513036
ab@@	O	-1	20513036
duc@@	O	-1	20513036
t@@	O	-1	20513036
or	O	-1	20513036
par@@	B-Disease	D010243	20513036
aly@@	I-Disease	-1	20513036
sis	I-Disease	-1	20513036
after	O	-1	20513036
B@@	B-Chemical	C542870	20513036
ot@@	I-Chemical	-1	20513036
o@@	I-Chemical	-1	20513036
x	I-Chemical	-1	20513036
injection	O	-1	20513036
for	O	-1	20513036
AD@@	B-Disease	D014826	20513036
S@@	I-Disease	-1	20513036
D	I-Disease	-1	20513036
was	O	-1	20513036
0.@@	O	-1	20513036
34@@	O	-1	20513036
%.	O	-1	20513036
CONCLUSIONS:	O	-1	20513036
B@@	O	-1	20513036
il@@	O	-1	20513036
ateral	O	-1	20513036
ab@@	O	-1	20513036
duc@@	O	-1	20513036
t@@	O	-1	20513036
or	O	-1	20513036
par@@	B-Disease	D010243	20513036
aly@@	I-Disease	-1	20513036
sis	I-Disease	-1	20513036
is	O	-1	20513036
a	O	-1	20513036
r@@	O	-1	20513036
are	O	-1	20513036
complication	O	-1	20513036
of	O	-1	20513036
B@@	B-Chemical	C542870	20513036
ot@@	I-Chemical	-1	20513036
o@@	I-Chemical	-1	20513036
x	I-Chemical	-1	20513036
injec@@	O	-1	20513036
tions	O	-1	20513036
for	O	-1	20513036
AD@@	B-Disease	D014826	20513036
S@@	I-Disease	-1	20513036
D	I-Disease	-1	20513036
,	O	-1	20513036
ca@@	O	-1	20513036
using	O	-1	20513036
diff@@	O	-1	20513036
ic@@	O	-1	20513036
ult@@	O	-1	20513036
y	O	-1	20513036
with	O	-1	20513036
b@@	O	-1	20513036
re@@	O	-1	20513036
ath@@	O	-1	20513036
ing	O	-1	20513036
up@@	O	-1	20513036
on	O	-1	20513036
ex@@	O	-1	20513036
er@@	O	-1	20513036
tion.	O	-1	20513036
The	O	-1	20513036
likely	O	-1	20513036
mechanism	O	-1	20513036
of	O	-1	20513036
par@@	B-Disease	D010243	20513036
aly@@	I-Disease	-1	20513036
sis	I-Disease	-1	20513036
is	O	-1	20513036
diff@@	O	-1	20513036
usion	O	-1	20513036
of	O	-1	20513036
B@@	B-Chemical	C542870	20513036
ot@@	I-Chemical	-1	20513036
o@@	I-Chemical	-1	20513036
x	I-Chemical	-1	20513036
a@@	O	-1	20513036
ro@@	O	-1	20513036
un@@	O	-1	20513036
d	O	-1	20513036
the	O	-1	20513036
mus@@	O	-1	20513036
cular	O	-1	20513036
pro@@	O	-1	20513036
cess	O	-1	20513036
of	O	-1	20513036
the	O	-1	20513036
ar@@	O	-1	20513036
y@@	O	-1	20513036
ten@@	O	-1	20513036
oid	O	-1	20513036
to	O	-1	20513036
the	O	-1	20513036
po@@	O	-1	20513036
ster@@	O	-1	20513036
ior	O	-1	20513036
c@@	O	-1	20513036
r@@	O	-1	20513036
ic@@	O	-1	20513036
o@@	O	-1	20513036
ar@@	O	-1	20513036
y@@	O	-1	20513036
ten@@	O	-1	20513036
oid	O	-1	20513036
mus@@	O	-1	20513036
cl@@	O	-1	20513036
es.	O	-1	20513036
The	O	-1	20513036
par@@	B-Disease	D010243	20513036
aly@@	I-Disease	-1	20513036
sis	I-Disease	-1	20513036
is	O	-1	20513036
tempor@@	O	-1	20513036
ar@@	O	-1	20513036
y,	O	-1	20513036
and	O	-1	20513036
w@@	O	-1	20513036
at@@	O	-1	20513036
ch@@	O	-1	20513036
ful	O	-1	20513036
w@@	O	-1	20513036
a@@	O	-1	20513036
it@@	O	-1	20513036
ing	O	-1	20513036
with	O	-1	20513036
re@@	O	-1	20513036
stric@@	O	-1	20513036
tion	O	-1	20513036
of	O	-1	20513036
activity	O	-1	20513036
is	O	-1	20513036
the	O	-1	20513036
recomm@@	O	-1	20513036
en@@	O	-1	20513036
ded	O	-1	20513036
man@@	O	-1	20513036
ag@@	O	-1	20513036
em@@	O	-1	20513036
ent@@	O	-1	20513036
.	O	-1	20513036

M@@	B-Disease	D028361	20566328
it@@	I-Disease	-1	20566328
ochond@@	I-Disease	-1	20566328
rial	I-Disease	-1	20566328
impair@@	I-Disease	-1	20566328
ment	I-Disease	-1	20566328
cont@@	O	-1	20566328
ri@@	O	-1	20566328
but@@	O	-1	20566328
es	O	-1	20566328
to	O	-1	20566328
cocaine	B-Chemical	D003042	20566328
-induced	O	-1	20566328
cardiac	B-Disease	D006331	20566328
dysfunction	I-Disease	-1	20566328
:	O	-1	20566328
Pre@@	O	-1	20566328
ven@@	O	-1	20566328
tion	O	-1	20566328
by	O	-1	20566328
the	O	-1	20566328
t@@	O	-1	20566328
arg@@	O	-1	20566328
et@@	O	-1	20566328
ed	O	-1	20566328
anti@@	O	-1	20566328
oxid@@	O	-1	20566328
ant	O	-1	20566328
M@@	B-Chemical	C476756	20566328
it@@	I-Chemical	-1	20566328
o@@	I-Chemical	-1	20566328
Q	I-Chemical	-1	20566328
.	O	-1	20566328
The	O	-1	20566328
go@@	O	-1	20566328
al	O	-1	20566328
of	O	-1	20566328
this	O	-1	20566328
study	O	-1	20566328
was	O	-1	20566328
to	O	-1	20566328
ass@@	O	-1	20566328
ess	O	-1	20566328
mitochondrial	O	-1	20566328
function	O	-1	20566328
and	O	-1	20566328
RO@@	O	-1	20566328
S	O	-1	20566328
pro@@	O	-1	20566328
duction	O	-1	20566328
in	O	-1	20566328
an	O	-1	20566328
experimental	O	-1	20566328
model	O	-1	20566328
of	O	-1	20566328
cocaine	B-Chemical	D003042	20566328
-induced	O	-1	20566328
cardiac	B-Disease	D006331	20566328
dysfunction	I-Disease	-1	20566328
.	O	-1	20566328
We	O	-1	20566328
hypo@@	O	-1	20566328
the@@	O	-1	20566328
si@@	O	-1	20566328
zed	O	-1	20566328
that	O	-1	20566328
cocaine	B-Disease	D019970	20566328
ab@@	I-Disease	-1	20566328
use	I-Disease	-1	20566328
may	O	-1	20566328
le@@	O	-1	20566328
ad	O	-1	20566328
to	O	-1	20566328
al@@	O	-1	20566328
te@@	O	-1	20566328
red	O	-1	20566328
mitochondrial	O	-1	20566328
function	O	-1	20566328
that	O	-1	20566328
in	O	-1	20566328
t@@	O	-1	20566328
ur@@	O	-1	20566328
n	O	-1	20566328
may	O	-1	20566328
cause	O	-1	20566328
left	B-Disease	D018487	20566328
ventricular	I-Disease	-1	20566328
dysfunction	I-Disease	-1	20566328
.	O	-1	20566328
S@@	O	-1	20566328
even	O	-1	20566328
days	O	-1	20566328
of	O	-1	20566328
cocaine	B-Chemical	D003042	20566328
administration	O	-1	20566328
to	O	-1	20566328
rats	O	-1	20566328
l@@	O	-1	20566328
ed	O	-1	20566328
to	O	-1	20566328
an	O	-1	20566328
increased	O	-1	20566328
oxy@@	B-Chemical	D010100	20566328
gen	I-Chemical	-1	20566328
consum@@	O	-1	20566328
ption	O	-1	20566328
det@@	O	-1	20566328
ected	O	-1	20566328
in	O	-1	20566328
cardiac	O	-1	20566328
fib@@	O	-1	20566328
er@@	O	-1	20566328
s,	O	-1	20566328
spec@@	O	-1	20566328
ific@@	O	-1	20566328
ally	O	-1	20566328
through	O	-1	20566328
comple@@	O	-1	20566328
x	O	-1	20566328
I	O	-1	20566328
and	O	-1	20566328
comple@@	O	-1	20566328
x	O	-1	20566328
II@@	O	-1	20566328
I@@	O	-1	20566328
.	O	-1	20566328
RO@@	O	-1	20566328
S	O	-1	20566328
levels	O	-1	20566328
were	O	-1	20566328
increas@@	O	-1	20566328
ed,	O	-1	20566328
spec@@	O	-1	20566328
ific@@	O	-1	20566328
ally	O	-1	20566328
in	O	-1	20566328
inter@@	O	-1	20566328
fibrill@@	O	-1	20566328
ar	O	-1	20566328
mitochond@@	O	-1	20566328
ri@@	O	-1	20566328
a.	O	-1	20566328
In	O	-1	20566328
par@@	O	-1	20566328
al@@	O	-1	20566328
le@@	O	-1	20566328
l	O	-1	20566328
there	O	-1	20566328
was	O	-1	20566328
a	O	-1	20566328
decrease	O	-1	20566328
in	O	-1	20566328
AT@@	B-Chemical	D000255	20566328
P	I-Chemical	-1	20566328
syn@@	O	-1	20566328
the@@	O	-1	20566328
sis,	O	-1	20566328
whereas	O	-1	20566328
no	O	-1	20566328
difference	O	-1	20566328
was	O	-1	20566328
observed	O	-1	20566328
in	O	-1	20566328
sub@@	O	-1	20566328
s@@	O	-1	20566328
ar@@	O	-1	20566328
co@@	O	-1	20566328
le@@	O	-1	20566328
mm@@	O	-1	20566328
al	O	-1	20566328
mitochond@@	O	-1	20566328
ri@@	O	-1	20566328
a.	O	-1	20566328
This	O	-1	20566328
un@@	O	-1	20566328
co@@	O	-1	20566328
u@@	O	-1	20566328
pl@@	O	-1	20566328
ing	O	-1	20566328
effect	O	-1	20566328
on	O	-1	20566328
oxid@@	O	-1	20566328
ative	O	-1	20566328
phosph@@	O	-1	20566328
or@@	O	-1	20566328
yl@@	O	-1	20566328
ation	O	-1	20566328
was	O	-1	20566328
not	O	-1	20566328
det@@	O	-1	20566328
ect@@	O	-1	20566328
able	O	-1	20566328
after	O	-1	20566328
sh@@	O	-1	20566328
ort@@	O	-1	20566328
-term	O	-1	20566328
exposure	O	-1	20566328
to	O	-1	20566328
cocaine	B-Chemical	D003042	20566328
,	O	-1	20566328
suggesting	O	-1	20566328
that	O	-1	20566328
these	O	-1	20566328
mitochondrial	B-Disease	D028361	20566328
abnormal@@	I-Disease	-1	20566328
ities	I-Disease	-1	20566328
were	O	-1	20566328
a	O	-1	20566328
l@@	O	-1	20566328
ate	O	-1	20566328
ra@@	O	-1	20566328
ther	O	-1	20566328
than	O	-1	20566328
a	O	-1	20566328
prim@@	O	-1	20566328
ary	O	-1	20566328
ev@@	O	-1	20566328
ent	O	-1	20566328
in	O	-1	20566328
the	O	-1	20566328
path@@	O	-1	20566328
ological	O	-1	20566328
response	O	-1	20566328
to	O	-1	20566328
cocaine	B-Chemical	D003042	20566328
.	O	-1	20566328
M@@	B-Chemical	C476756	20566328
it@@	I-Chemical	-1	20566328
o@@	I-Chemical	-1	20566328
Q	I-Chemical	-1	20566328
,	O	-1	20566328
a	O	-1	20566328
mitochond@@	O	-1	20566328
ri@@	O	-1	20566328
al@@	O	-1	20566328
-@@	O	-1	20566328
t@@	O	-1	20566328
arg@@	O	-1	20566328
et@@	O	-1	20566328
ed	O	-1	20566328
anti@@	O	-1	20566328
oxid@@	O	-1	20566328
ant@@	O	-1	20566328
,	O	-1	20566328
was	O	-1	20566328
shown	O	-1	20566328
to	O	-1	20566328
complete@@	O	-1	20566328
ly	O	-1	20566328
prev@@	O	-1	20566328
ent	O	-1	20566328
these	O	-1	20566328
mitochondrial	B-Disease	D028361	20566328
abnormal@@	I-Disease	-1	20566328
ities	I-Disease	-1	20566328
as	O	-1	20566328
well	O	-1	20566328
as	O	-1	20566328
cardiac	B-Disease	D006331	20566328
dysfunction	I-Disease	-1	20566328
character@@	O	-1	20566328
ized	O	-1	20566328
h@@	O	-1	20566328
ere	O	-1	20566328
by	O	-1	20566328
a	O	-1	20566328
di@@	B-Disease	-1	20566328
ast@@	I-Disease	-1	20566328
olic	I-Disease	-1	20566328
dysfunction	I-Disease	-1	20566328
studied	O	-1	20566328
with	O	-1	20566328
a	O	-1	20566328
con@@	O	-1	20566328
duc@@	O	-1	20566328
t@@	O	-1	20566328
ance	O	-1	20566328
ca@@	O	-1	20566328
the@@	O	-1	20566328
ter	O	-1	20566328
to	O	-1	20566328
obt@@	O	-1	20566328
ain	O	-1	20566328
pressu@@	O	-1	20566328
re@@	O	-1	20566328
-@@	O	-1	20566328
volume	O	-1	20566328
dat@@	O	-1	20566328
a.	O	-1	20566328
T@@	O	-1	20566328
ak@@	O	-1	20566328
en	O	-1	20566328
to@@	O	-1	20566328
ge@@	O	-1	20566328
ther@@	O	-1	20566328
,	O	-1	20566328
these	O	-1	20566328
results	O	-1	20566328
exten@@	O	-1	20566328
d	O	-1	20566328
previ@@	O	-1	20566328
ous	O	-1	20566328
studies	O	-1	20566328
and	O	-1	20566328
demon@@	O	-1	20566328
st@@	O	-1	20566328
rate	O	-1	20566328
that	O	-1	20566328
cocaine	B-Chemical	D003042	20566328
-induced	O	-1	20566328
cardiac	B-Disease	D006331	20566328
dysfunction	I-Disease	-1	20566328
may	O	-1	20566328
be	O	-1	20566328
due	O	-1	20566328
to	O	-1	20566328
a	O	-1	20566328
mitochondrial	B-Disease	D028361	20566328
def@@	I-Disease	-1	20566328
ect	I-Disease	-1	20566328
.	O	-1	20566328

T@@	B-Chemical	D014295	20589632
ri@@	I-Chemical	-1	20589632
meth@@	I-Chemical	-1	20589632
o@@	I-Chemical	-1	20589632
pri@@	I-Chemical	-1	20589632
m	I-Chemical	-1	20589632
-induced	O	-1	20589632
immun@@	O	-1	20589632
e	O	-1	20589632
hemolytic	B-Disease	D000743	20589632
anemia	I-Disease	-1	20589632
in	O	-1	20589632
a	O	-1	20589632
pe@@	O	-1	20589632
di@@	O	-1	20589632
atric	O	-1	20589632
on@@	O	-1	20589632
co@@	O	-1	20589632
log@@	O	-1	20589632
y	O	-1	20589632
patient	O	-1	20589632
present@@	O	-1	20589632
ing	O	-1	20589632
as	O	-1	20589632
an	O	-1	20589632
acute	O	-1	20589632
hemolytic	O	-1	20589632
trans@@	O	-1	20589632
f@@	O	-1	20589632
usion	O	-1	20589632
reac@@	O	-1	20589632
tion.	O	-1	20589632
A	O	-1	20589632
10-@@	O	-1	20589632
year-old	O	-1	20589632
male	O	-1	20589632
with	O	-1	20589632
acute	B-Disease	D015470	20589632
leuk@@	I-Disease	-1	20589632
emia	I-Disease	-1	20589632
presented	O	-1	20589632
with	O	-1	20589632
post@@	O	-1	20589632
-@@	O	-1	20589632
chemotherapy	O	-1	20589632
anemia	B-Disease	D000740	20589632
.	O	-1	20589632
D@@	O	-1	20589632
uring	O	-1	20589632
red	O	-1	20589632
cell	O	-1	20589632
trans@@	O	-1	20589632
fu@@	O	-1	20589632
sion,	O	-1	20589632
he	O	-1	20589632
developed	O	-1	20589632
hemo@@	B-Disease	D006456	20589632
glo@@	I-Disease	-1	20589632
bin@@	I-Disease	-1	20589632
uria	I-Disease	-1	20589632
.	O	-1	20589632
T@@	O	-1	20589632
ran@@	O	-1	20589632
s@@	O	-1	20589632
f@@	O	-1	20589632
usion	O	-1	20589632
reaction	O	-1	20589632
wor@@	O	-1	20589632
k@@	O	-1	20589632
up	O	-1	20589632
was	O	-1	20589632
neg@@	O	-1	20589632
ati@@	O	-1	20589632
ve.	O	-1	20589632
D@@	O	-1	20589632
ru@@	O	-1	20589632
g@@	O	-1	20589632
-induced	O	-1	20589632
immun@@	O	-1	20589632
e	O	-1	20589632
hemolytic	B-Disease	D000743	20589632
anemia	I-Disease	-1	20589632
was	O	-1	20589632
sus@@	O	-1	20589632
p@@	O	-1	20589632
ected	O	-1	20589632
because	O	-1	20589632
of	O	-1	20589632
positive	O	-1	20589632
direct	O	-1	20589632
anti@@	O	-1	20589632
glo@@	O	-1	20589632
b@@	O	-1	20589632
ul@@	O	-1	20589632
in	O	-1	20589632
test@@	O	-1	20589632
,	O	-1	20589632
negative	O	-1	20589632
el@@	O	-1	20589632
u@@	O	-1	20589632
ate,	O	-1	20589632
and	O	-1	20589632
micro@@	O	-1	20589632
s@@	O	-1	20589632
ph@@	O	-1	20589632
er@@	O	-1	20589632
ocy@@	O	-1	20589632
tes	O	-1	20589632
on	O	-1	20589632
s@@	O	-1	20589632
me@@	O	-1	20589632
ar	O	-1	20589632
pre@@	O	-1	20589632
-	O	-1	20589632
and	O	-1	20589632
post@@	O	-1	20589632
-@@	O	-1	20589632
trans@@	O	-1	20589632
fu@@	O	-1	20589632
sion.	O	-1	20589632
D@@	O	-1	20589632
ru@@	O	-1	20589632
g	O	-1	20589632
studies	O	-1	20589632
using	O	-1	20589632
the	O	-1	20589632
in@@	O	-1	20589632
direct	O	-1	20589632
anti@@	O	-1	20589632
glo@@	O	-1	20589632
b@@	O	-1	20589632
ul@@	O	-1	20589632
in	O	-1	20589632
test	O	-1	20589632
were	O	-1	20589632
st@@	O	-1	20589632
ron@@	O	-1	20589632
g@@	O	-1	20589632
ly	O	-1	20589632
positive	O	-1	20589632
with	O	-1	20589632
tri@@	B-Chemical	D014295	20589632
meth@@	I-Chemical	-1	20589632
o@@	I-Chemical	-1	20589632
pri@@	I-Chemical	-1	20589632
m	I-Chemical	-1	20589632
and	O	-1	20589632
tri@@	B-Chemical	D015662	20589632
meth@@	I-Chemical	-1	20589632
o@@	I-Chemical	-1	20589632
prim@@	I-Chemical	-1	20589632
-@@	I-Chemical	-1	20589632
sulf@@	I-Chemical	-1	20589632
ameth@@	I-Chemical	-1	20589632
ox@@	I-Chemical	-1	20589632
azole	I-Chemical	-1	20589632
but	O	-1	20589632
negative	O	-1	20589632
with	O	-1	20589632
sulf@@	B-Chemical	D013420	20589632
ameth@@	I-Chemical	-1	20589632
ox@@	I-Chemical	-1	20589632
azole	I-Chemical	-1	20589632
.	O	-1	20589632
The	O	-1	20589632
patient	O	-1	20589632
reco@@	O	-1	20589632
vered	O	-1	20589632
after	O	-1	20589632
discontinu@@	O	-1	20589632
ing	O	-1	20589632
the	O	-1	20589632
drug@@	O	-1	20589632
,	O	-1	20589632
with	O	-1	20589632
no	O	-1	20589632
recur@@	O	-1	20589632
rence	O	-1	20589632
in	O	-1	20589632
2	O	-1	20589632
year@@	O	-1	20589632
s.	O	-1	20589632
O@@	O	-1	20589632
ther	O	-1	20589632
causes	O	-1	20589632
of	O	-1	20589632
anemia	B-Disease	D000740	20589632
should	O	-1	20589632
be	O	-1	20589632
considered	O	-1	20589632
in	O	-1	20589632
patients	O	-1	20589632
with	O	-1	20589632
wor@@	O	-1	20589632
se@@	O	-1	20589632
-@@	O	-1	20589632
th@@	O	-1	20589632
an@@	O	-1	20589632
-@@	O	-1	20589632
ex@@	O	-1	20589632
p@@	O	-1	20589632
ected	O	-1	20589632
anemia	B-Disease	D000740	20589632
after	O	-1	20589632
chemo@@	O	-1	20589632
therapy.	O	-1	20589632
F@@	O	-1	20589632
ur@@	O	-1	20589632
ther@@	O	-1	20589632
mo@@	O	-1	20589632
re,	O	-1	20589632
hemoly@@	B-Disease	D006461	20589632
sis	I-Disease	-1	20589632
during	O	-1	20589632
trans@@	O	-1	20589632
f@@	O	-1	20589632
usion	O	-1	20589632
is	O	-1	20589632
not	O	-1	20589632
al@@	O	-1	20589632
w@@	O	-1	20589632
ays	O	-1	20589632
a	O	-1	20589632
trans@@	O	-1	20589632
f@@	O	-1	20589632
usion	O	-1	20589632
reac@@	O	-1	20589632
tion.	O	-1	20589632

B@@	O	-1	20682692
loc@@	O	-1	20682692
k@@	O	-1	20682692
ade	O	-1	20682692
of	O	-1	20682692
endo@@	O	-1	20682692
the@@	O	-1	20682692
li@@	O	-1	20682692
al@@	O	-1	20682692
-@@	O	-1	20682692
m@@	O	-1	20682692
es@@	O	-1	20682692
en@@	O	-1	20682692
ch@@	O	-1	20682692
ym@@	O	-1	20682692
al	O	-1	20682692
transi@@	O	-1	20682692
tion	O	-1	20682692
by	O	-1	20682692
a	O	-1	20682692
S@@	O	-1	20682692
m@@	O	-1	20682692
ad@@	O	-1	20682692
3	O	-1	20682692
inhibitor	O	-1	20682692
del@@	O	-1	20682692
ays	O	-1	20682692
the	O	-1	20682692
early	O	-1	20682692
development	O	-1	20682692
of	O	-1	20682692
st@@	B-Chemical	D013311	20682692
re@@	I-Chemical	-1	20682692
pto@@	I-Chemical	-1	20682692
z@@	I-Chemical	-1	20682692
ot@@	I-Chemical	-1	20682692
oc@@	I-Chemical	-1	20682692
in	I-Chemical	-1	20682692
-induced	O	-1	20682692
dia@@	B-Disease	D003928	20682692
be@@	I-Disease	-1	20682692
tic	I-Disease	-1	20682692
nephro@@	I-Disease	-1	20682692
pathy	I-Disease	-1	20682692
.	O	-1	20682692
OBJECTIVE:	O	-1	20682692
A	O	-1	20682692
mul@@	O	-1	20682692
tic@@	O	-1	20682692
ent@@	O	-1	20682692
er,	O	-1	20682692
controlled	O	-1	20682692
trial	O	-1	20682692
showed	O	-1	20682692
that	O	-1	20682692
early	O	-1	20682692
block@@	O	-1	20682692
ade	O	-1	20682692
of	O	-1	20682692
the	O	-1	20682692
ren@@	O	-1	20682692
in@@	O	-1	20682692
-	O	-1	20682692
angiotens@@	B-Chemical	D000804	20682692
in	I-Chemical	-1	20682692
system	O	-1	20682692
in	O	-1	20682692
patients	O	-1	20682692
with	O	-1	20682692
type	B-Disease	D003922	20682692
1	I-Disease	-1	20682692
dia@@	I-Disease	-1	20682692
bet@@	I-Disease	-1	20682692
es	I-Disease	-1	20682692
and	O	-1	20682692
nor@@	O	-1	20682692
mo@@	O	-1	20682692
al@@	O	-1	20682692
bu@@	O	-1	20682692
min@@	O	-1	20682692
uria	O	-1	20682692
did	O	-1	20682692
not	O	-1	20682692
ret@@	O	-1	20682692
ard	O	-1	20682692
the	O	-1	20682692
progres@@	O	-1	20682692
sion	O	-1	20682692
of	O	-1	20682692
nephro@@	B-Disease	D007674	20682692
pathy	I-Disease	-1	20682692
,	O	-1	20682692
suggesting	O	-1	20682692
that	O	-1	20682692
other	O	-1	20682692
mechanis@@	O	-1	20682692
m@@	O	-1	20682692
(@@	O	-1	20682692
s)	O	-1	20682692
are	O	-1	20682692
involved	O	-1	20682692
in	O	-1	20682692
the	O	-1	20682692
path@@	O	-1	20682692
o@@	O	-1	20682692
genesis	O	-1	20682692
of	O	-1	20682692
early	O	-1	20682692
dia@@	B-Disease	D003928	20682692
be@@	I-Disease	-1	20682692
tic	I-Disease	-1	20682692
nephro@@	I-Disease	-1	20682692
pathy	I-Disease	-1	20682692
(	O	-1	20682692
dia@@	B-Disease	D003928	20682692
be@@	I-Disease	-1	20682692
tic	I-Disease	-1	20682692
nephro@@	I-Disease	-1	20682692
pathy	I-Disease	-1	20682692
).	O	-1	20682692
We	O	-1	20682692
have	O	-1	20682692
previously	O	-1	20682692
demonstrated	O	-1	20682692
that	O	-1	20682692
endo@@	O	-1	20682692
the@@	O	-1	20682692
li@@	O	-1	20682692
al@@	O	-1	20682692
-@@	O	-1	20682692
m@@	O	-1	20682692
es@@	O	-1	20682692
en@@	O	-1	20682692
ch@@	O	-1	20682692
y@@	O	-1	20682692
mal@@	O	-1	20682692
-@@	O	-1	20682692
transi@@	O	-1	20682692
tion	O	-1	20682692
(@@	O	-1	20682692
E@@	O	-1	20682692
n@@	O	-1	20682692
do@@	O	-1	20682692
M@@	O	-1	20682692
T)	O	-1	20682692
cont@@	O	-1	20682692
ri@@	O	-1	20682692
but@@	O	-1	20682692
es	O	-1	20682692
to	O	-1	20682692
the	O	-1	20682692
early	O	-1	20682692
development	O	-1	20682692
of	O	-1	20682692
renal	O	-1	20682692
interstitial	O	-1	20682692
fib@@	B-Disease	D005355	20682692
ro@@	I-Disease	-1	20682692
sis	I-Disease	-1	20682692
in@@	O	-1	20682692
depend@@	O	-1	20682692
ently	O	-1	20682692
of	O	-1	20682692
micro@@	O	-1	20682692
al@@	O	-1	20682692
bu@@	O	-1	20682692
min@@	O	-1	20682692
uria	O	-1	20682692
in	O	-1	20682692
mice	O	-1	20682692
with	O	-1	20682692
st@@	B-Chemical	D013311	20682692
re@@	I-Chemical	-1	20682692
pto@@	I-Chemical	-1	20682692
z@@	I-Chemical	-1	20682692
ot@@	I-Chemical	-1	20682692
oc@@	I-Chemical	-1	20682692
in	I-Chemical	-1	20682692
(	O	-1	20682692
S@@	B-Chemical	D013311	20682692
T@@	I-Chemical	-1	20682692
Z	I-Chemical	-1	20682692
)@@	O	-1	20682692
-induced	O	-1	20682692
dia@@	B-Disease	D003920	20682692
bet@@	I-Disease	-1	20682692
es	I-Disease	-1	20682692
.	O	-1	20682692
In	O	-1	20682692
the	O	-1	20682692
present	O	-1	20682692
study,	O	-1	20682692
we	O	-1	20682692
hypo@@	O	-1	20682692
the@@	O	-1	20682692
si@@	O	-1	20682692
zed	O	-1	20682692
that	O	-1	20682692
block@@	O	-1	20682692
ing	O	-1	20682692
E@@	O	-1	20682692
n@@	O	-1	20682692
do@@	O	-1	20682692
M@@	O	-1	20682692
T	O	-1	20682692
reduc@@	O	-1	20682692
es	O	-1	20682692
the	O	-1	20682692
early	O	-1	20682692
development	O	-1	20682692
of	O	-1	20682692
dia@@	B-Disease	D003928	20682692
be@@	I-Disease	-1	20682692
tic	I-Disease	-1	20682692
nephro@@	I-Disease	-1	20682692
pathy	I-Disease	-1	20682692
.	O	-1	20682692
RES@@	O	-1	20682692
E@@	O	-1	20682692
A@@	O	-1	20682692
R@@	O	-1	20682692
C@@	O	-1	20682692
H	O	-1	20682692
D@@	O	-1	20682692
ES@@	O	-1	20682692
I@@	O	-1	20682692
G@@	O	-1	20682692
N	O	-1	20682692
AN@@	O	-1	20682692
D	O	-1	20682692
METHODS:	O	-1	20682692
E@@	O	-1	20682692
n@@	O	-1	20682692
do@@	O	-1	20682692
M@@	O	-1	20682692
T	O	-1	20682692
was	O	-1	20682692
induced	O	-1	20682692
in	O	-1	20682692
a	O	-1	20682692
mouse	O	-1	20682692
p@@	O	-1	20682692
anc@@	O	-1	20682692
re@@	O	-1	20682692
atic	O	-1	20682692
micro@@	O	-1	20682692
vascular	O	-1	20682692
endothelial	O	-1	20682692
cell	O	-1	20682692
line	O	-1	20682692
(@@	O	-1	20682692
M@@	O	-1	20682692
M@@	O	-1	20682692
EC@@	O	-1	20682692
)	O	-1	20682692
in	O	-1	20682692
the	O	-1	20682692
presence	O	-1	20682692
of	O	-1	20682692
adv@@	O	-1	20682692
anced	O	-1	20682692
glyc@@	O	-1	20682692
ation	O	-1	20682692
end	O	-1	20682692
produc@@	O	-1	20682692
ts	O	-1	20682692
(A@@	O	-1	20682692
G@@	O	-1	20682692
E@@	O	-1	20682692
s)	O	-1	20682692
and	O	-1	20682692
in	O	-1	20682692
the	O	-1	20682692
endothelial	O	-1	20682692
l@@	O	-1	20682692
ine@@	O	-1	20682692
ag@@	O	-1	20682692
e-@@	O	-1	20682692
trac@@	O	-1	20682692
e@@	O	-1	20682692
ble	O	-1	20682692
mouse	O	-1	20682692
line	O	-1	20682692
T@@	O	-1	20682692
i@@	O	-1	20682692
e@@	O	-1	20682692
2-@@	O	-1	20682692
C@@	O	-1	20682692
re@@	O	-1	20682692
;@@	O	-1	20682692
L@@	O	-1	20682692
ox@@	O	-1	20682692
p@@	O	-1	20682692
-@@	O	-1	20682692
E@@	O	-1	20682692
GF@@	O	-1	20682692
P	O	-1	20682692
by	O	-1	20682692
administration	O	-1	20682692
of	O	-1	20682692
A@@	O	-1	20682692
G@@	O	-1	20682692
E@@	O	-1	20682692
s,	O	-1	20682692
with	O	-1	20682692
non@@	O	-1	20682692
glyc@@	O	-1	20682692
ated	O	-1	20682692
mouse	O	-1	20682692
al@@	O	-1	20682692
b@@	O	-1	20682692
um@@	O	-1	20682692
in	O	-1	20682692
ser@@	O	-1	20682692
ving	O	-1	20682692
as	O	-1	20682692
a	O	-1	20682692
control@@	O	-1	20682692
.	O	-1	20682692
Ph@@	O	-1	20682692
osph@@	O	-1	20682692
or@@	O	-1	20682692
yl@@	O	-1	20682692
ated	O	-1	20682692
S@@	O	-1	20682692
m@@	O	-1	20682692
ad@@	O	-1	20682692
3	O	-1	20682692
was	O	-1	20682692
det@@	O	-1	20682692
ected	O	-1	20682692
by	O	-1	20682692
immuno@@	O	-1	20682692
pre@@	O	-1	20682692
ci@@	O	-1	20682692
pit@@	O	-1	20682692
ation@@	O	-1	20682692
/@@	O	-1	20682692
W@@	O	-1	20682692
est@@	O	-1	20682692
er@@	O	-1	20682692
n	O	-1	20682692
blo@@	O	-1	20682692
t@@	O	-1	20682692
ting	O	-1	20682692
and	O	-1	20682692
conf@@	O	-1	20682692
oc@@	O	-1	20682692
al	O	-1	20682692
micro@@	O	-1	20682692
sco@@	O	-1	20682692
p@@	O	-1	20682692
y.	O	-1	20682692
B@@	O	-1	20682692
loc@@	O	-1	20682692
king	O	-1	20682692
studies	O	-1	20682692
using	O	-1	20682692
receptor	O	-1	20682692
for	O	-1	20682692
A@@	O	-1	20682692
G@@	O	-1	20682692
E	O	-1	20682692
si@@	O	-1	20682692
R@@	O	-1	20682692
NA	O	-1	20682692
and	O	-1	20682692
a	O	-1	20682692
specific	O	-1	20682692
inhibitor	O	-1	20682692
of	O	-1	20682692
S@@	O	-1	20682692
m@@	O	-1	20682692
ad@@	O	-1	20682692
3	O	-1	20682692
(S@@	O	-1	20682692
I@@	O	-1	20682692
S@@	O	-1	20682692
3@@	O	-1	20682692
)	O	-1	20682692
were	O	-1	20682692
performed	O	-1	20682692
in	O	-1	20682692
M@@	O	-1	20682692
M@@	O	-1	20682692
EC@@	O	-1	20682692
s	O	-1	20682692
and	O	-1	20682692
in	O	-1	20682692
S@@	B-Chemical	D013311	20682692
T@@	I-Chemical	-1	20682692
Z	I-Chemical	-1	20682692
-induced	O	-1	20682692
dia@@	B-Disease	D003928	20682692
be@@	I-Disease	-1	20682692
tic	I-Disease	-1	20682692
nephro@@	I-Disease	-1	20682692
pathy	I-Disease	-1	20682692
in	O	-1	20682692
T@@	O	-1	20682692
i@@	O	-1	20682692
e@@	O	-1	20682692
2-@@	O	-1	20682692
C@@	O	-1	20682692
re@@	O	-1	20682692
;@@	O	-1	20682692
L@@	O	-1	20682692
ox@@	O	-1	20682692
p@@	O	-1	20682692
-@@	O	-1	20682692
E@@	O	-1	20682692
GF@@	O	-1	20682692
P	O	-1	20682692
mice.	O	-1	20682692
RESULTS:	O	-1	20682692
Con@@	O	-1	20682692
foc@@	O	-1	20682692
al	O	-1	20682692
micro@@	O	-1	20682692
sco@@	O	-1	20682692
p@@	O	-1	20682692
y	O	-1	20682692
and	O	-1	20682692
re@@	O	-1	20682692
al@@	O	-1	20682692
-@@	O	-1	20682692
time	O	-1	20682692
P@@	O	-1	20682692
C@@	O	-1	20682692
R	O	-1	20682692
demonstrated	O	-1	20682692
that	O	-1	20682692
A@@	O	-1	20682692
G@@	O	-1	20682692
E@@	O	-1	20682692
s	O	-1	20682692
induced	O	-1	20682692
E@@	O	-1	20682692
n@@	O	-1	20682692
do@@	O	-1	20682692
M@@	O	-1	20682692
T	O	-1	20682692
in	O	-1	20682692
M@@	O	-1	20682692
M@@	O	-1	20682692
EC@@	O	-1	20682692
s	O	-1	20682692
and	O	-1	20682692
in	O	-1	20682692
T@@	O	-1	20682692
i@@	O	-1	20682692
e@@	O	-1	20682692
2-@@	O	-1	20682692
C@@	O	-1	20682692
re@@	O	-1	20682692
;@@	O	-1	20682692
L@@	O	-1	20682692
ox@@	O	-1	20682692
p@@	O	-1	20682692
-@@	O	-1	20682692
E@@	O	-1	20682692
GF@@	O	-1	20682692
P	O	-1	20682692
mice.	O	-1	20682692
Im@@	O	-1	20682692
mun@@	O	-1	20682692
o@@	O	-1	20682692
pre@@	O	-1	20682692
ci@@	O	-1	20682692
pit@@	O	-1	20682692
ation@@	O	-1	20682692
/@@	O	-1	20682692
W@@	O	-1	20682692
est@@	O	-1	20682692
er@@	O	-1	20682692
n	O	-1	20682692
blo@@	O	-1	20682692
t@@	O	-1	20682692
ting	O	-1	20682692
showed	O	-1	20682692
that	O	-1	20682692
S@@	O	-1	20682692
m@@	O	-1	20682692
ad@@	O	-1	20682692
3	O	-1	20682692
was	O	-1	20682692
activ@@	O	-1	20682692
ated	O	-1	20682692
by	O	-1	20682692
A@@	O	-1	20682692
G@@	O	-1	20682692
E@@	O	-1	20682692
s	O	-1	20682692
but	O	-1	20682692
was	O	-1	20682692
inhibited	O	-1	20682692
by	O	-1	20682692
S@@	O	-1	20682692
I@@	O	-1	20682692
S@@	O	-1	20682692
3	O	-1	20682692
in	O	-1	20682692
M@@	O	-1	20682692
M@@	O	-1	20682692
EC@@	O	-1	20682692
s	O	-1	20682692
and	O	-1	20682692
in	O	-1	20682692
S@@	B-Chemical	D013311	20682692
T@@	I-Chemical	-1	20682692
Z	I-Chemical	-1	20682692
-induced	O	-1	20682692
dia@@	B-Disease	D003928	20682692
be@@	I-Disease	-1	20682692
tic	I-Disease	-1	20682692
nephro@@	I-Disease	-1	20682692
pathy	I-Disease	-1	20682692
.	O	-1	20682692
Con@@	O	-1	20682692
foc@@	O	-1	20682692
al	O	-1	20682692
micro@@	O	-1	20682692
sco@@	O	-1	20682692
p@@	O	-1	20682692
y	O	-1	20682692
and	O	-1	20682692
re@@	O	-1	20682692
al@@	O	-1	20682692
-@@	O	-1	20682692
time	O	-1	20682692
P@@	O	-1	20682692
C@@	O	-1	20682692
R	O	-1	20682692
further	O	-1	20682692
demonstrated	O	-1	20682692
that	O	-1	20682692
S@@	O	-1	20682692
I@@	O	-1	20682692
S@@	O	-1	20682692
3	O	-1	20682692
ab@@	O	-1	20682692
ro@@	O	-1	20682692
g@@	O	-1	20682692
ated	O	-1	20682692
E@@	O	-1	20682692
n@@	O	-1	20682692
do@@	O	-1	20682692
M@@	O	-1	20682692
T@@	O	-1	20682692
,	O	-1	20682692
reduced	O	-1	20682692
renal	O	-1	20682692
fib@@	B-Disease	D005355	20682692
ro@@	I-Disease	-1	20682692
sis	I-Disease	-1	20682692
,	O	-1	20682692
and	O	-1	20682692
ret@@	O	-1	20682692
ar@@	O	-1	20682692
ded	O	-1	20682692
progres@@	O	-1	20682692
sion	O	-1	20682692
of	O	-1	20682692
nephro@@	B-Disease	D007674	20682692
pathy	I-Disease	-1	20682692
.	O	-1	20682692
CONCLUSIONS:	O	-1	20682692
E@@	O	-1	20682692
n@@	O	-1	20682692
do@@	O	-1	20682692
M@@	O	-1	20682692
T	O	-1	20682692
is	O	-1	20682692
a	O	-1	20682692
novel	O	-1	20682692
path@@	O	-1	20682692
w@@	O	-1	20682692
ay	O	-1	20682692
lead@@	O	-1	20682692
ing	O	-1	20682692
to	O	-1	20682692
early	O	-1	20682692
development	O	-1	20682692
of	O	-1	20682692
dia@@	B-Disease	D003928	20682692
be@@	I-Disease	-1	20682692
tic	I-Disease	-1	20682692
nephro@@	I-Disease	-1	20682692
pathy	I-Disease	-1	20682692
.	O	-1	20682692
B@@	O	-1	20682692
loc@@	O	-1	20682692
k@@	O	-1	20682692
ade	O	-1	20682692
of	O	-1	20682692
E@@	O	-1	20682692
n@@	O	-1	20682692
do@@	O	-1	20682692
M@@	O	-1	20682692
T	O	-1	20682692
by	O	-1	20682692
S@@	O	-1	20682692
I@@	O	-1	20682692
S@@	O	-1	20682692
3	O	-1	20682692
may	O	-1	20682692
prov@@	O	-1	20682692
ide	O	-1	20682692
a	O	-1	20682692
new	O	-1	20682692
strat@@	O	-1	20682692
e@@	O	-1	20682692
g@@	O	-1	20682692
y	O	-1	20682692
to	O	-1	20682692
ret@@	O	-1	20682692
ard	O	-1	20682692
the	O	-1	20682692
progres@@	O	-1	20682692
sion	O	-1	20682692
of	O	-1	20682692
dia@@	B-Disease	D003928	20682692
be@@	I-Disease	-1	20682692
tic	I-Disease	-1	20682692
nephro@@	I-Disease	-1	20682692
pathy	I-Disease	-1	20682692
and	O	-1	20682692
other	O	-1	20682692
dia@@	B-Disease	D048909	20682692
bet@@	I-Disease	-1	20682692
es	I-Disease	-1	20682692
complications	I-Disease	-1	20682692
.	O	-1	20682692

C@@	O	-1	20828385
y@@	O	-1	20828385
to@@	O	-1	20828385
st@@	O	-1	20828385
atic	O	-1	20828385
and	O	-1	20828385
anti@@	O	-1	20828385
-@@	O	-1	20828385
angio@@	O	-1	20828385
genic	O	-1	20828385
effects	O	-1	20828385
of	O	-1	20828385
tem@@	B-Chemical	C401859	20828385
sirolimus	I-Chemical	-1	20828385
in	O	-1	20828385
ref@@	O	-1	20828385
rac@@	O	-1	20828385
t@@	O	-1	20828385
ory	O	-1	20828385
m@@	B-Disease	D020522	20828385
ant@@	I-Disease	-1	20828385
le	I-Disease	-1	20828385
cell	I-Disease	-1	20828385
lymph@@	I-Disease	-1	20828385
oma	I-Disease	-1	20828385
.	O	-1	20828385
M@@	B-Disease	D020522	20828385
ant@@	I-Disease	-1	20828385
le	I-Disease	-1	20828385
cell	I-Disease	-1	20828385
lymph@@	I-Disease	-1	20828385
oma	I-Disease	-1	20828385
(	O	-1	20828385
M@@	B-Disease	D020522	20828385
C@@	I-Disease	-1	20828385
L	I-Disease	-1	20828385
)	O	-1	20828385
is	O	-1	20828385
a	O	-1	20828385
r@@	O	-1	20828385
are	O	-1	20828385
and	O	-1	20828385
ag@@	O	-1	20828385
gres@@	O	-1	20828385
sive	O	-1	20828385
type	O	-1	20828385
of	O	-1	20828385
B@@	B-Disease	D008228	20828385
-@@	I-Disease	-1	20828385
cell	I-Disease	-1	20828385
non-@@	I-Disease	-1	20828385
Ho@@	I-Disease	-1	20828385
d@@	I-Disease	-1	20828385
g@@	I-Disease	-1	20828385
kin@@	I-Disease	-1	20828385
's	I-Disease	-1	20828385
lymph@@	I-Disease	-1	20828385
oma	I-Disease	-1	20828385
.	O	-1	20828385
Patients	O	-1	20828385
b@@	O	-1	20828385
ec@@	O	-1	20828385
ome	O	-1	20828385
progres@@	O	-1	20828385
si@@	O	-1	20828385
vely	O	-1	20828385
ref@@	O	-1	20828385
rac@@	O	-1	20828385
t@@	O	-1	20828385
ory	O	-1	20828385
to	O	-1	20828385
con@@	O	-1	20828385
ven@@	O	-1	20828385
tional	O	-1	20828385
chemo@@	O	-1	20828385
therapy,	O	-1	20828385
and	O	-1	20828385
their	O	-1	20828385
pro@@	O	-1	20828385
g@@	O	-1	20828385
no@@	O	-1	20828385
sis	O	-1	20828385
is	O	-1	20828385
po@@	O	-1	20828385
or@@	O	-1	20828385
.	O	-1	20828385
However,	O	-1	20828385
a	O	-1	20828385
3@@	O	-1	20828385
8@@	O	-1	20828385
%	O	-1	20828385
re@@	O	-1	20828385
mission	O	-1	20828385
rate	O	-1	20828385
has	O	-1	20828385
been	O	-1	20828385
rec@@	O	-1	20828385
ently	O	-1	20828385
reported	O	-1	20828385
in	O	-1	20828385
ref@@	O	-1	20828385
rac@@	O	-1	20828385
t@@	O	-1	20828385
ory	O	-1	20828385
M@@	B-Disease	D020522	20828385
C@@	I-Disease	-1	20828385
L	I-Disease	-1	20828385
treated	O	-1	20828385
with	O	-1	20828385
tem@@	B-Chemical	C401859	20828385
sirolimus	I-Chemical	-1	20828385
,	O	-1	20828385
a	O	-1	20828385
m@@	O	-1	20828385
T@@	O	-1	20828385
O@@	O	-1	20828385
R	O	-1	20828385
inhibitor@@	O	-1	20828385
.@@	O	-1	20828385
H@@	O	-1	20828385
ere	O	-1	20828385
we	O	-1	20828385
had	O	-1	20828385
the	O	-1	20828385
op@@	O	-1	20828385
port@@	O	-1	20828385
un@@	O	-1	20828385
ity	O	-1	20828385
to	O	-1	20828385
study	O	-1	20828385
a	O	-1	20828385
case	O	-1	20828385
of	O	-1	20828385
ref@@	O	-1	20828385
rac@@	O	-1	20828385
t@@	O	-1	20828385
ory	O	-1	20828385
M@@	B-Disease	D020522	20828385
C@@	I-Disease	-1	20828385
L	I-Disease	-1	20828385
who	O	-1	20828385
had	O	-1	20828385
tumor	B-Disease	D009369	20828385
reg@@	O	-1	20828385
res@@	O	-1	20828385
sion	O	-1	20828385
two	O	-1	20828385
months	O	-1	20828385
after	O	-1	20828385
tem@@	B-Chemical	C401859	20828385
sirolimus	I-Chemical	-1	20828385
treatment,	O	-1	20828385
and	O	-1	20828385
a	O	-1	20828385
progres@@	O	-1	20828385
sion@@	O	-1	20828385
-@@	O	-1	20828385
free	O	-1	20828385
sur@@	O	-1	20828385
viv@@	O	-1	20828385
al	O	-1	20828385
of	O	-1	20828385
10	O	-1	20828385
months.	O	-1	20828385
In	O	-1	20828385
this	O	-1	20828385
cas@@	O	-1	20828385
e,	O	-1	20828385
lym@@	O	-1	20828385
p@@	O	-1	20828385
h	O	-1	20828385
no@@	O	-1	20828385
de	O	-1	20828385
biop@@	O	-1	20828385
si@@	O	-1	20828385
es	O	-1	20828385
were	O	-1	20828385
performed	O	-1	20828385
before	O	-1	20828385
and	O	-1	20828385
six	O	-1	20828385
months	O	-1	20828385
after	O	-1	20828385
tem@@	B-Chemical	C401859	20828385
sirolimus	I-Chemical	-1	20828385
therapy.	O	-1	20828385
Com@@	O	-1	20828385
par@@	O	-1	20828385
ison	O	-1	20828385
of	O	-1	20828385
the	O	-1	20828385
two	O	-1	20828385
biop@@	O	-1	20828385
si@@	O	-1	20828385
es	O	-1	20828385
showed	O	-1	20828385
that	O	-1	20828385
tem@@	B-Chemical	C401859	20828385
sirolimus	I-Chemical	-1	20828385
inhibited	O	-1	20828385
tumor	B-Disease	D009369	20828385
cell	O	-1	20828385
pro@@	O	-1	20828385
li@@	O	-1	20828385
fer@@	O	-1	20828385
ation	O	-1	20828385
through	O	-1	20828385
cell	O	-1	20828385
cyc@@	O	-1	20828385
le	O	-1	20828385
ar@@	O	-1	20828385
rest@@	O	-1	20828385
,	O	-1	20828385
but	O	-1	20828385
did	O	-1	20828385
not	O	-1	20828385
induce	O	-1	20828385
any	O	-1	20828385
change	O	-1	20828385
in	O	-1	20828385
the	O	-1	20828385
number	O	-1	20828385
of	O	-1	20828385
apo@@	O	-1	20828385
pto@@	O	-1	20828385
tic	O	-1	20828385
tumor	B-Disease	D009369	20828385
cell@@	O	-1	20828385
s.	O	-1	20828385
A@@	O	-1	20828385
par@@	O	-1	20828385
t	O	-1	20828385
from	O	-1	20828385
this	O	-1	20828385
cyto@@	O	-1	20828385
st@@	O	-1	20828385
atic	O	-1	20828385
effect@@	O	-1	20828385
,	O	-1	20828385
tem@@	B-Chemical	C401859	20828385
sirolimus	I-Chemical	-1	20828385
had	O	-1	20828385
an	O	-1	20828385
anti@@	O	-1	20828385
angio@@	O	-1	20828385
genic	O	-1	20828385
effect	O	-1	20828385
with	O	-1	20828385
decrease	O	-1	20828385
of	O	-1	20828385
tumor	B-Disease	D009369	20828385
micro@@	O	-1	20828385
v@@	O	-1	20828385
es@@	O	-1	20828385
se@@	O	-1	20828385
l	O	-1	20828385
d@@	O	-1	20828385
ensity	O	-1	20828385
and	O	-1	20828385
of	O	-1	20828385
V@@	O	-1	20828385
E@@	O	-1	20828385
G@@	O	-1	20828385
F	O	-1	20828385
ex@@	O	-1	20828385
pres@@	O	-1	20828385
sion.	O	-1	20828385
M@@	O	-1	20828385
ore@@	O	-1	20828385
o@@	O	-1	20828385
ver,	O	-1	20828385
n@@	O	-1	20828385
um@@	O	-1	20828385
er@@	O	-1	20828385
ous	O	-1	20828385
pat@@	O	-1	20828385
ch@@	O	-1	20828385
y,	O	-1	20828385
we@@	O	-1	20828385
ll@@	O	-1	20828385
-@@	O	-1	20828385
lim@@	O	-1	20828385
ited	O	-1	20828385
fib@@	O	-1	20828385
ro@@	O	-1	20828385
tic	O	-1	20828385
a@@	O	-1	20828385
reas@@	O	-1	20828385
,	O	-1	20828385
com@@	O	-1	20828385
pati@@	O	-1	20828385
ble	O	-1	20828385
with	O	-1	20828385
post@@	O	-1	20828385
-	O	-1	20828385
necro@@	B-Disease	D009336	20828385
tic	I-Disease	-1	20828385
tissue	O	-1	20828385
re@@	O	-1	20828385
pa@@	O	-1	20828385
ir@@	O	-1	20828385
,	O	-1	20828385
were	O	-1	20828385
found	O	-1	20828385
after	O	-1	20828385
6-@@	O	-1	20828385
mon@@	O	-1	20828385
th	O	-1	20828385
tem@@	B-Chemical	C401859	20828385
sirolimus	I-Chemical	-1	20828385
therapy.	O	-1	20828385
Th@@	O	-1	20828385
us,	O	-1	20828385
tem@@	B-Chemical	C401859	20828385
sirolimus	I-Chemical	-1	20828385
reduced	O	-1	20828385
tumor	B-Disease	D009369	20828385
b@@	O	-1	20828385
ur@@	O	-1	20828385
de@@	O	-1	20828385
n	O	-1	20828385
through	O	-1	20828385
associated	O	-1	20828385
cyto@@	O	-1	20828385
st@@	O	-1	20828385
atic	O	-1	20828385
and	O	-1	20828385
anti@@	O	-1	20828385
-@@	O	-1	20828385
angio@@	O	-1	20828385
genic	O	-1	20828385
effect@@	O	-1	20828385
s@@	O	-1	20828385
.@@	O	-1	20828385
This	O	-1	20828385
du@@	O	-1	20828385
al	O	-1	20828385
effect	O	-1	20828385
of	O	-1	20828385
tem@@	B-Chemical	C401859	20828385
sirolimus	I-Chemical	-1	20828385
on	O	-1	20828385
tumor	B-Disease	D009369	20828385
tissue	O	-1	20828385
could	O	-1	20828385
cont@@	O	-1	20828385
rib@@	O	-1	20828385
ute	O	-1	20828385
to	O	-1	20828385
its	O	-1	20828385
rec@@	O	-1	20828385
ently	O	-1	20828385
reported	O	-1	20828385
eff@@	O	-1	20828385
ici@@	O	-1	20828385
ency	O	-1	20828385
in	O	-1	20828385
ref@@	O	-1	20828385
rac@@	O	-1	20828385
t@@	O	-1	20828385
ory	O	-1	20828385
M@@	B-Disease	D020522	20828385
C@@	I-Disease	-1	20828385
L	I-Disease	-1	20828385
resist@@	O	-1	20828385
ant	O	-1	20828385
to	O	-1	20828385
con@@	O	-1	20828385
ven@@	O	-1	20828385
tional	O	-1	20828385
chemo@@	O	-1	20828385
therapy.	O	-1	20828385

S@@	B-Disease	D013575	20859899
yn@@	I-Disease	-1	20859899
co@@	I-Disease	-1	20859899
p@@	I-Disease	-1	20859899
e	I-Disease	-1	20859899
caused	O	-1	20859899
by	O	-1	20859899
hyper@@	B-Disease	D006947	20859899
k@@	I-Disease	-1	20859899
al@@	I-Disease	-1	20859899
emia	I-Disease	-1	20859899
during	O	-1	20859899
use	O	-1	20859899
of	O	-1	20859899
a	O	-1	20859899
combined	O	-1	20859899
therapy	O	-1	20859899
with	O	-1	20859899
the	O	-1	20859899
angiotens@@	B-Chemical	D000809	20859899
in	I-Chemical	-1	20859899
-@@	O	-1	20859899
conver@@	O	-1	20859899
ting	O	-1	20859899
enzyme	O	-1	20859899
inhibitor	O	-1	20859899
and	O	-1	20859899
s@@	B-Chemical	D013148	20859899
pi@@	I-Chemical	-1	20859899
ron@@	I-Chemical	-1	20859899
ol@@	I-Chemical	-1	20859899
act@@	I-Chemical	-1	20859899
one	I-Chemical	-1	20859899
.	O	-1	20859899
A	O	-1	20859899
7@@	O	-1	20859899
6	O	-1	20859899
year-old	O	-1	20859899
woman	O	-1	20859899
with	O	-1	20859899
a	O	-1	20859899
hist@@	O	-1	20859899
ory	O	-1	20859899
of	O	-1	20859899
coronary	O	-1	20859899
artery	O	-1	20859899
b@@	O	-1	20859899
yp@@	O	-1	20859899
as@@	O	-1	20859899
s	O	-1	20859899
gra@@	O	-1	20859899
f@@	O	-1	20859899
ting	O	-1	20859899
and	O	-1	20859899
prior	O	-1	20859899
myocardial	B-Disease	D009203	20859899
infarction	I-Disease	-1	20859899
was	O	-1	20859899
trans@@	O	-1	20859899
fer@@	O	-1	20859899
red	O	-1	20859899
to	O	-1	20859899
the	O	-1	20859899
em@@	O	-1	20859899
er@@	O	-1	20859899
gen@@	O	-1	20859899
c@@	O	-1	20859899
y	O	-1	20859899
ro@@	O	-1	20859899
o@@	O	-1	20859899
m	O	-1	20859899
with	O	-1	20859899
loss	B-Disease	D014474	20859899
of	I-Disease	-1	20859899
con@@	I-Disease	-1	20859899
s@@	I-Disease	-1	20859899
ci@@	I-Disease	-1	20859899
ous@@	I-Disease	-1	20859899
ness	I-Disease	-1	20859899
due	O	-1	20859899
to	O	-1	20859899
mark@@	O	-1	20859899
ed	O	-1	20859899
brady@@	B-Disease	D001919	20859899
cardia	I-Disease	-1	20859899
caused	O	-1	20859899
by	O	-1	20859899
hyper@@	B-Disease	D006947	20859899
k@@	I-Disease	-1	20859899
al@@	I-Disease	-1	20859899
emia	I-Disease	-1	20859899
.	O	-1	20859899
The	O	-1	20859899
concentration	O	-1	20859899
of	O	-1	20859899
serum	O	-1	20859899
pot@@	B-Chemical	D011188	20859899
assi@@	I-Chemical	-1	20859899
um	I-Chemical	-1	20859899
was	O	-1	20859899
high@@	O	-1	20859899
,	O	-1	20859899
and	O	-1	20859899
normal	O	-1	20859899
s@@	O	-1	20859899
in@@	O	-1	20859899
us	O	-1	20859899
rhyth@@	O	-1	20859899
m	O	-1	20859899
was	O	-1	20859899
re@@	O	-1	20859899
sto@@	O	-1	20859899
red	O	-1	20859899
after	O	-1	20859899
cor@@	O	-1	20859899
rec@@	O	-1	20859899
tion	O	-1	20859899
of	O	-1	20859899
the	O	-1	20859899
serum	O	-1	20859899
pot@@	B-Chemical	D011188	20859899
assi@@	I-Chemical	-1	20859899
um	I-Chemical	-1	20859899
level@@	O	-1	20859899
.	O	-1	20859899
The	O	-1	20859899
cause	O	-1	20859899
of	O	-1	20859899
hyper@@	B-Disease	D006947	20859899
k@@	I-Disease	-1	20859899
al@@	I-Disease	-1	20859899
emia	I-Disease	-1	20859899
was	O	-1	20859899
considered	O	-1	20859899
to	O	-1	20859899
be	O	-1	20859899
several	O	-1	20859899
doses	O	-1	20859899
of	O	-1	20859899
s@@	B-Chemical	D013148	20859899
pi@@	I-Chemical	-1	20859899
ran@@	I-Chemical	-1	20859899
ol@@	I-Chemical	-1	20859899
act@@	I-Chemical	-1	20859899
one	I-Chemical	-1	20859899
,	O	-1	20859899
an	O	-1	20859899
al@@	B-Chemical	D000450	20859899
do@@	I-Chemical	-1	20859899
sterone	I-Chemical	-1	20859899
antagonist@@	O	-1	20859899
,	O	-1	20859899
in	O	-1	20859899
addition	O	-1	20859899
to	O	-1	20859899
the	O	-1	20859899
long-term	O	-1	20859899
int@@	O	-1	20859899
ake	O	-1	20859899
of	O	-1	20859899
ram@@	B-Chemical	D017257	20859899
i@@	I-Chemical	-1	20859899
pri@@	I-Chemical	-1	20859899
l	I-Chemical	-1	20859899
,	O	-1	20859899
an	O	-1	20859899
AC@@	O	-1	20859899
E	O	-1	20859899
inhibitor@@	O	-1	20859899
.	O	-1	20859899
This	O	-1	20859899
case	O	-1	20859899
is	O	-1	20859899
a	O	-1	20859899
go@@	O	-1	20859899
od	O	-1	20859899
ex@@	O	-1	20859899
am@@	O	-1	20859899
ple	O	-1	20859899
of	O	-1	20859899
electro@@	O	-1	20859899
ly@@	O	-1	20859899
te	O	-1	20859899
im@@	O	-1	20859899
b@@	O	-1	20859899
al@@	O	-1	20859899
ance	O	-1	20859899
ca@@	O	-1	20859899
using	O	-1	20859899
acute	O	-1	20859899
lif@@	O	-1	20859899
e-@@	O	-1	20859899
th@@	O	-1	20859899
reat@@	O	-1	20859899
en@@	O	-1	20859899
ing	O	-1	20859899
cardiac	O	-1	20859899
event@@	O	-1	20859899
s.	O	-1	20859899
Clin@@	O	-1	20859899
ici@@	O	-1	20859899
ans	O	-1	20859899
should	O	-1	20859899
be	O	-1	20859899
al@@	O	-1	20859899
er@@	O	-1	20859899
t	O	-1	20859899
to	O	-1	20859899
the	O	-1	20859899
possib@@	O	-1	20859899
ility	O	-1	20859899
of	O	-1	20859899
hyper@@	B-Disease	D006947	20859899
k@@	I-Disease	-1	20859899
al@@	I-Disease	-1	20859899
emia	I-Disease	-1	20859899
,	O	-1	20859899
es@@	O	-1	20859899
p@@	O	-1	20859899
ec@@	O	-1	20859899
i@@	O	-1	20859899
ally	O	-1	20859899
in	O	-1	20859899
el@@	O	-1	20859899
der@@	O	-1	20859899
ly	O	-1	20859899
patients	O	-1	20859899
using	O	-1	20859899
AC@@	O	-1	20859899
E@@	O	-1	20859899
/@@	O	-1	20859899
A@@	O	-1	20859899
R@@	O	-1	20859899
B	O	-1	20859899
in	O	-1	20859899
combination	O	-1	20859899
with	O	-1	20859899
pot@@	B-Chemical	D011188	20859899
assi@@	I-Chemical	-1	20859899
um	I-Chemical	-1	20859899
s@@	O	-1	20859899
par@@	O	-1	20859899
ing	O	-1	20859899
agents	O	-1	20859899
and	O	-1	20859899
who	O	-1	20859899
have	O	-1	20859899
mil@@	O	-1	20859899
d	O	-1	20859899
renal	B-Disease	D007674	20859899
dist@@	I-Disease	-1	20859899
urb@@	I-Disease	-1	20859899
ance	I-Disease	-1	20859899
.	O	-1	20859899

Di@@	O	-1	20927253
ff@@	O	-1	20927253
use	O	-1	20927253
s@@	O	-1	20927253
ke@@	O	-1	20927253
le@@	O	-1	20927253
t@@	O	-1	20927253
al	O	-1	20927253
pain	B-Disease	D010146	20927253
after	O	-1	20927253
administration	O	-1	20927253
of	O	-1	20927253
al@@	B-Chemical	D019386	20927253
en@@	I-Chemical	-1	20927253
d@@	I-Chemical	-1	20927253
ron@@	I-Chemical	-1	20927253
ate	I-Chemical	-1	20927253
.	O	-1	20927253
BACKGROUND:	O	-1	20927253
O@@	B-Disease	D010024	20927253
ste@@	I-Disease	-1	20927253
o@@	I-Disease	-1	20927253
po@@	I-Disease	-1	20927253
ro@@	I-Disease	-1	20927253
sis	I-Disease	-1	20927253
is	O	-1	20927253
caused	O	-1	20927253
by	O	-1	20927253
b@@	O	-1	20927253
one	O	-1	20927253
res@@	O	-1	20927253
or@@	O	-1	20927253
ption	O	-1	20927253
in	O	-1	20927253
ex@@	O	-1	20927253
cess	O	-1	20927253
of	O	-1	20927253
b@@	O	-1	20927253
one	O	-1	20927253
form@@	O	-1	20927253
ation,	O	-1	20927253
and	O	-1	20927253
b@@	B-Chemical	D004164	20927253
is@@	I-Chemical	-1	20927253
phosph@@	I-Chemical	-1	20927253
on@@	I-Chemical	-1	20927253
ates	I-Chemical	-1	20927253
,	O	-1	20927253
are	O	-1	20927253
used	O	-1	20927253
to	O	-1	20927253
inhib@@	O	-1	20927253
it	O	-1	20927253
b@@	O	-1	20927253
one	O	-1	20927253
res@@	O	-1	20927253
or@@	O	-1	20927253
p@@	O	-1	20927253
tion.	O	-1	20927253
Al@@	B-Chemical	D019386	20927253
en@@	I-Chemical	-1	20927253
d@@	I-Chemical	-1	20927253
ron@@	I-Chemical	-1	20927253
ate	I-Chemical	-1	20927253
,	O	-1	20927253
a	O	-1	20927253
b@@	B-Chemical	-1	20927253
i@@	I-Chemical	-1	20927253
phosph@@	I-Chemical	-1	20927253
on@@	I-Chemical	-1	20927253
ate	I-Chemical	-1	20927253
,	O	-1	20927253
is	O	-1	20927253
effective	O	-1	20927253
for	O	-1	20927253
both	O	-1	20927253
the	O	-1	20927253
treatment	O	-1	20927253
and	O	-1	20927253
pre@@	O	-1	20927253
ven@@	O	-1	20927253
tion	O	-1	20927253
of	O	-1	20927253
ost@@	B-Disease	D010024	20927253
e@@	I-Disease	-1	20927253
o@@	I-Disease	-1	20927253
po@@	I-Disease	-1	20927253
ro@@	I-Disease	-1	20927253
sis	I-Disease	-1	20927253
in	O	-1	20927253
post@@	O	-1	20927253
men@@	O	-1	20927253
o@@	O	-1	20927253
pa@@	O	-1	20927253
us@@	O	-1	20927253
al	O	-1	20927253
wom@@	O	-1	20927253
en@@	O	-1	20927253
.	O	-1	20927253
S@@	O	-1	20927253
ide	O	-1	20927253
effects	O	-1	20927253
are	O	-1	20927253
rel@@	O	-1	20927253
atively	O	-1	20927253
fe@@	O	-1	20927253
w	O	-1	20927253
and	O	-1	20927253
pro@@	O	-1	20927253
min@@	O	-1	20927253
ently	O	-1	20927253
gast@@	O	-1	20927253
ro@@	O	-1	20927253
in@@	O	-1	20927253
test@@	O	-1	20927253
in@@	O	-1	20927253
al.	O	-1	20927253
M@@	B-Disease	D059352	20927253
us@@	I-Disease	-1	20927253
c@@	I-Disease	-1	20927253
u@@	I-Disease	-1	20927253
los@@	I-Disease	-1	20927253
ke@@	I-Disease	-1	20927253
le@@	I-Disease	-1	20927253
t@@	I-Disease	-1	20927253
al	I-Disease	-1	20927253
pain	I-Disease	-1	20927253
may	O	-1	20927253
be	O	-1	20927253
an	O	-1	20927253
important	O	-1	20927253
side	O	-1	20927253
effect	O	-1	20927253
in	O	-1	20927253
these	O	-1	20927253
patients.	O	-1	20927253
We	O	-1	20927253
presented	O	-1	20927253
a	O	-1	20927253
patient	O	-1	20927253
ad@@	O	-1	20927253
mit@@	O	-1	20927253
ted	O	-1	20927253
to	O	-1	20927253
our	O	-1	20927253
out@@	O	-1	20927253
-@@	O	-1	20927253
patient	O	-1	20927253
clin@@	O	-1	20927253
ic	O	-1	20927253
with	O	-1	20927253
diff@@	O	-1	20927253
use	O	-1	20927253
s@@	O	-1	20927253
ke@@	O	-1	20927253
le@@	O	-1	20927253
t@@	O	-1	20927253
al	O	-1	20927253
pain	B-Disease	D010146	20927253
after	O	-1	20927253
three	O	-1	20927253
con@@	O	-1	20927253
sec@@	O	-1	20927253
utive	O	-1	20927253
administration	O	-1	20927253
of	O	-1	20927253
al@@	B-Chemical	D019386	20927253
en@@	I-Chemical	-1	20927253
d@@	I-Chemical	-1	20927253
ron@@	I-Chemical	-1	20927253
ate	I-Chemical	-1	20927253
.	O	-1	20927253
CONCLUSION:	O	-1	20927253
We	O	-1	20927253
concl@@	O	-1	20927253
ude	O	-1	20927253
that	O	-1	20927253
patients	O	-1	20927253
with	O	-1	20927253
ost@@	B-Disease	D010024	20927253
e@@	I-Disease	-1	20927253
o@@	I-Disease	-1	20927253
po@@	I-Disease	-1	20927253
ro@@	I-Disease	-1	20927253
sis	I-Disease	-1	20927253
can	O	-1	20927253
report	O	-1	20927253
pain	B-Disease	D010146	20927253
,	O	-1	20927253
and	O	-1	20927253
b@@	B-Chemical	D004164	20927253
is@@	I-Chemical	-1	20927253
phosph@@	I-Chemical	-1	20927253
on@@	I-Chemical	-1	20927253
ate	I-Chemical	-1	20927253
-@@	O	-1	20927253
related	O	-1	20927253
pain	B-Disease	D010146	20927253
should	O	-1	20927253
also	O	-1	20927253
be	O	-1	20927253
considered	O	-1	20927253
before	O	-1	20927253
as@@	O	-1	20927253
cri@@	O	-1	20927253
b@@	O	-1	20927253
ing	O	-1	20927253
this	O	-1	20927253
com@@	O	-1	20927253
pl@@	O	-1	20927253
ain@@	O	-1	20927253
t	O	-1	20927253
to	O	-1	20927253
ost@@	B-Disease	D010024	20927253
e@@	I-Disease	-1	20927253
o@@	I-Disease	-1	20927253
po@@	I-Disease	-1	20927253
ro@@	I-Disease	-1	20927253
sis	I-Disease	-1	20927253
.	O	-1	20927253

C@@	O	-1	20959502
e@@	O	-1	20959502
reb@@	O	-1	20959502
ro@@	O	-1	20959502
spinal	O	-1	20959502
flu@@	O	-1	20959502
id	O	-1	20959502
pen@@	O	-1	20959502
et@@	O	-1	20959502
ration	O	-1	20959502
of	O	-1	20959502
high-dose	O	-1	20959502
d@@	B-Chemical	D017576	20959502
ap@@	I-Chemical	-1	20959502
to@@	I-Chemical	-1	20959502
m@@	I-Chemical	-1	20959502
ycin	I-Chemical	-1	20959502
in	O	-1	20959502
sus@@	O	-1	20959502
p@@	O	-1	20959502
ected	O	-1	20959502
S@@	O	-1	20959502
t@@	O	-1	20959502
a@@	O	-1	20959502
ph@@	O	-1	20959502
y@@	O	-1	20959502
lo@@	O	-1	20959502
co@@	O	-1	20959502
c@@	O	-1	20959502
c@@	O	-1	20959502
us	O	-1	20959502
a@@	O	-1	20959502
ure@@	O	-1	20959502
us	O	-1	20959502
men@@	B-Disease	D008581	20959502
ing@@	I-Disease	-1	20959502
iti@@	I-Disease	-1	20959502
s	I-Disease	-1	20959502
.	O	-1	20959502
OBJECTIVE:	O	-1	20959502
To	O	-1	20959502
report	O	-1	20959502
a	O	-1	20959502
case	O	-1	20959502
of	O	-1	20959502
meth@@	B-Chemical	D008712	20959502
icill@@	I-Chemical	-1	20959502
in	I-Chemical	-1	20959502
-@@	O	-1	20959502
sensitive	O	-1	20959502
S@@	O	-1	20959502
t@@	O	-1	20959502
a@@	O	-1	20959502
ph@@	O	-1	20959502
y@@	O	-1	20959502
lo@@	O	-1	20959502
co@@	O	-1	20959502
c@@	O	-1	20959502
c@@	O	-1	20959502
us	O	-1	20959502
a@@	O	-1	20959502
ure@@	O	-1	20959502
us	O	-1	20959502
(@@	O	-1	20959502
M@@	O	-1	20959502
S@@	O	-1	20959502
S@@	O	-1	20959502
A@@	O	-1	20959502
)	O	-1	20959502
bac@@	B-Disease	D016470	20959502
te@@	I-Disease	-1	20959502
re@@	I-Disease	-1	20959502
mia	I-Disease	-1	20959502
with	O	-1	20959502
sus@@	O	-1	20959502
p@@	O	-1	20959502
ected	O	-1	20959502
M@@	O	-1	20959502
S@@	O	-1	20959502
S@@	O	-1	20959502
A	O	-1	20959502
men@@	B-Disease	D008581	20959502
ing@@	I-Disease	-1	20959502
iti@@	I-Disease	-1	20959502
s	I-Disease	-1	20959502
treated	O	-1	20959502
with	O	-1	20959502
high-dose	O	-1	20959502
d@@	B-Chemical	D017576	20959502
ap@@	I-Chemical	-1	20959502
to@@	I-Chemical	-1	20959502
m@@	I-Chemical	-1	20959502
ycin	I-Chemical	-1	20959502
assessed	O	-1	20959502
with	O	-1	20959502
con@@	O	-1	20959502
current	O	-1	20959502
serum	O	-1	20959502
and	O	-1	20959502
ce@@	O	-1	20959502
reb@@	O	-1	20959502
ro@@	O	-1	20959502
spinal	O	-1	20959502
flu@@	O	-1	20959502
id	O	-1	20959502
(C@@	O	-1	20959502
S@@	O	-1	20959502
F@@	O	-1	20959502
)	O	-1	20959502
concentr@@	O	-1	20959502
ations.	O	-1	20959502
CA@@	O	-1	20959502
S@@	O	-1	20959502
E	O	-1	20959502
S@@	O	-1	20959502
U@@	O	-1	20959502
M@@	O	-1	20959502
MA@@	O	-1	20959502
R@@	O	-1	20959502
Y@@	O	-1	20959502
:	O	-1	20959502
A	O	-1	20959502
5@@	O	-1	20959502
4-@@	O	-1	20959502
year-old	O	-1	20959502
male	O	-1	20959502
presented	O	-1	20959502
to	O	-1	20959502
the	O	-1	20959502
em@@	O	-1	20959502
er@@	O	-1	20959502
gen@@	O	-1	20959502
c@@	O	-1	20959502
y	O	-1	20959502
de@@	O	-1	20959502
part@@	O	-1	20959502
ment	O	-1	20959502
with	O	-1	20959502
gener@@	O	-1	20959502
al@@	O	-1	20959502
ized	O	-1	20959502
we@@	B-Disease	D018908	20959502
ak@@	I-Disease	-1	20959502
ness	I-Disease	-1	20959502
and	O	-1	20959502
pres@@	O	-1	20959502
um@@	O	-1	20959502
ed	O	-1	20959502
health@@	O	-1	20959502
-@@	O	-1	20959502
ca@@	O	-1	20959502
re@@	O	-1	20959502
-@@	O	-1	20959502
associated	O	-1	20959502
p@@	B-Disease	D011014	20959502
ne@@	I-Disease	-1	20959502
um@@	I-Disease	-1	20959502
on@@	I-Disease	-1	20959502
ia	I-Disease	-1	20959502
shown	O	-1	20959502
on	O	-1	20959502
ch@@	O	-1	20959502
est	O	-1	20959502
radi@@	O	-1	20959502
ograph@@	O	-1	20959502
.	O	-1	20959502
Treat@@	O	-1	20959502
ment	O	-1	20959502
was	O	-1	20959502
em@@	O	-1	20959502
pi@@	O	-1	20959502
r@@	O	-1	20959502
ically	O	-1	20959502
initi@@	O	-1	20959502
ated	O	-1	20959502
with	O	-1	20959502
v@@	B-Chemical	D014640	20959502
an@@	I-Chemical	-1	20959502
com@@	I-Chemical	-1	20959502
ycin	I-Chemical	-1	20959502
,	O	-1	20959502
lev@@	B-Chemical	D064704	20959502
of@@	I-Chemical	-1	20959502
lo@@	I-Chemical	-1	20959502
x@@	I-Chemical	-1	20959502
ac@@	I-Chemical	-1	20959502
in	I-Chemical	-1	20959502
,	O	-1	20959502
and	O	-1	20959502
pi@@	B-Chemical	D010878	20959502
per@@	I-Chemical	-1	20959502
ac@@	I-Chemical	-1	20959502
ill@@	I-Chemical	-1	20959502
in	I-Chemical	-1	20959502
/	O	-1	20959502
t@@	B-Chemical	C043265	20959502
az@@	I-Chemical	-1	20959502
ob@@	I-Chemical	-1	20959502
act@@	I-Chemical	-1	20959502
am	I-Chemical	-1	20959502
.	O	-1	20959502
B@@	O	-1	20959502
lo@@	O	-1	20959502
od	O	-1	20959502
c@@	O	-1	20959502
ult@@	O	-1	20959502
ures	O	-1	20959502
revealed	O	-1	20959502
S@@	O	-1	20959502
.	O	-1	20959502
a@@	O	-1	20959502
ure@@	O	-1	20959502
us	O	-1	20959502
sus@@	O	-1	20959502
cep@@	O	-1	20959502
ti@@	O	-1	20959502
ble	O	-1	20959502
to	O	-1	20959502
ox@@	B-Chemical	D010068	20959502
ac@@	I-Chemical	-1	20959502
ill@@	I-Chemical	-1	20959502
in	I-Chemical	-1	20959502
.	O	-1	20959502
E@@	O	-1	20959502
m@@	O	-1	20959502
pi@@	O	-1	20959502
ric	O	-1	20959502
anti@@	O	-1	20959502
bio@@	O	-1	20959502
tic	O	-1	20959502
treatment	O	-1	20959502
was	O	-1	20959502
n@@	O	-1	20959502
ar@@	O	-1	20959502
row@@	O	-1	20959502
ed	O	-1	20959502
to	O	-1	20959502
n@@	B-Chemical	D009254	20959502
af@@	I-Chemical	-1	20959502
c@@	I-Chemical	-1	20959502
ill@@	I-Chemical	-1	20959502
in	I-Chemical	-1	20959502
on	O	-1	20959502
day	O	-1	20959502
4@@	O	-1	20959502
.	O	-1	20959502
O@@	O	-1	20959502
n	O	-1	20959502
day	O	-1	20959502
8@@	O	-1	20959502
,	O	-1	20959502
the	O	-1	20959502
patient	O	-1	20959502
developed	O	-1	20959502
acute	B-Disease	D058186	20959502
renal	I-Disease	-1	20959502
failure	I-Disease	-1	20959502
(@@	O	-1	20959502
serum	O	-1	20959502
creatinine	B-Chemical	D003404	20959502
1.@@	O	-1	20959502
9	O	-1	20959502
mg/d@@	O	-1	20959502
L@@	O	-1	20959502
,	O	-1	20959502
increased	O	-1	20959502
from	O	-1	20959502
1.@@	O	-1	20959502
2	O	-1	20959502
mg/d@@	O	-1	20959502
L	O	-1	20959502
the	O	-1	20959502
previ@@	O	-1	20959502
ous	O	-1	20959502
day	O	-1	20959502
and	O	-1	20959502
0.@@	O	-1	20959502
8	O	-1	20959502
mg/d@@	O	-1	20959502
L	O	-1	20959502
on	O	-1	20959502
ad@@	O	-1	20959502
mis@@	O	-1	20959502
sion@@	O	-1	20959502
).	O	-1	20959502
The	O	-1	20959502
patient@@	O	-1	20959502
's	O	-1	20959502
G@@	O	-1	20959502
las@@	O	-1	20959502
go@@	O	-1	20959502
w	O	-1	20959502
C@@	O	-1	20959502
oma	O	-1	20959502
S@@	O	-1	20959502
cor@@	O	-1	20959502
e	O	-1	20959502
was	O	-1	20959502
3,	O	-1	20959502
with	O	-1	20959502
normal	O	-1	20959502
findings	O	-1	20959502
shown	O	-1	20959502
on	O	-1	20959502
comp@@	O	-1	20959502
ut@@	O	-1	20959502
ed	O	-1	20959502
to@@	O	-1	20959502
mo@@	O	-1	20959502
graph@@	O	-1	20959502
y	O	-1	20959502
s@@	O	-1	20959502
can	O	-1	20959502
of	O	-1	20959502
the	O	-1	20959502
he@@	O	-1	20959502
ad	O	-1	20959502
7@@	O	-1	20959502
2	O	-1	20959502
hours	O	-1	20959502
following	O	-1	20959502
an	O	-1	20959502
episo@@	O	-1	20959502
de	O	-1	20959502
of	O	-1	20959502
cardiac	B-Disease	D006323	20959502
ar@@	I-Disease	-1	20959502
res@@	I-Disease	-1	20959502
t	I-Disease	-1	20959502
on	O	-1	20959502
day	O	-1	20959502
10@@	O	-1	20959502
.	O	-1	20959502
The	O	-1	20959502
patient	O	-1	20959502
experienced	O	-1	20959502
rel@@	O	-1	20959502
ap@@	O	-1	20959502
s@@	O	-1	20959502
ing	O	-1	20959502
M@@	O	-1	20959502
S@@	O	-1	20959502
S@@	O	-1	20959502
A	O	-1	20959502
bac@@	B-Disease	D016470	20959502
te@@	I-Disease	-1	20959502
re@@	I-Disease	-1	20959502
mia	I-Disease	-1	20959502
on	O	-1	20959502
day	O	-1	20959502
9@@	O	-1	20959502
,	O	-1	20959502
increas@@	O	-1	20959502
ing	O	-1	20959502
the	O	-1	20959502
sus@@	O	-1	20959502
p@@	O	-1	20959502
ici@@	O	-1	20959502
on	O	-1	20959502
for	O	-1	20959502
a	O	-1	20959502
central	O	-1	20959502
ner@@	O	-1	20959502
v@@	O	-1	20959502
ous	O	-1	20959502
system	O	-1	20959502
(C@@	O	-1	20959502
N@@	O	-1	20959502
S)	O	-1	20959502
inf@@	B-Disease	D007239	20959502
ection	I-Disease	-1	20959502
.	O	-1	20959502
N@@	B-Chemical	D009254	20959502
af@@	I-Chemical	-1	20959502
c@@	I-Chemical	-1	20959502
ill@@	I-Chemical	-1	20959502
in	I-Chemical	-1	20959502
was	O	-1	20959502
discontinu@@	O	-1	20959502
ed	O	-1	20959502
and	O	-1	20959502
d@@	B-Chemical	D017576	20959502
ap@@	I-Chemical	-1	20959502
to@@	I-Chemical	-1	20959502
m@@	I-Chemical	-1	20959502
ycin	I-Chemical	-1	20959502
9	O	-1	20959502
mg/kg	O	-1	20959502
daily	O	-1	20959502
was	O	-1	20959502
initi@@	O	-1	20959502
ated	O	-1	20959502
for	O	-1	20959502
sus@@	O	-1	20959502
p@@	O	-1	20959502
ected	O	-1	20959502
men@@	B-Disease	D008581	20959502
ing@@	I-Disease	-1	20959502
iti@@	I-Disease	-1	20959502
s	I-Disease	-1	20959502
and	O	-1	20959502
was	O	-1	20959502
continu@@	O	-1	20959502
ed	O	-1	20959502
un@@	O	-1	20959502
ti@@	O	-1	20959502
l	O	-1	20959502
the	O	-1	20959502
patient@@	O	-1	20959502
's	O	-1	20959502
death	O	-1	20959502
on	O	-1	20959502
day	O	-1	20959502
1@@	O	-1	20959502
6@@	O	-1	20959502
.	O	-1	20959502
D@@	B-Chemical	D017576	20959502
ap@@	I-Chemical	-1	20959502
to@@	I-Chemical	-1	20959502
m@@	I-Chemical	-1	20959502
ycin	I-Chemical	-1	20959502
serum	O	-1	20959502
and	O	-1	20959502
C@@	O	-1	20959502
S@@	O	-1	20959502
F	O	-1	20959502
t@@	O	-1	20959502
rou@@	O	-1	20959502
gh	O	-1	20959502
concentrations	O	-1	20959502
were	O	-1	20959502
1@@	O	-1	20959502
1.@@	O	-1	20959502
21	O	-1	20959502
u@@	O	-1	20959502
g/@@	O	-1	20959502
m@@	O	-1	20959502
L	O	-1	20959502
and	O	-1	20959502
0.@@	O	-1	20959502
5@@	O	-1	20959502
2	O	-1	20959502
u@@	O	-1	20959502
g/@@	O	-1	20959502
m@@	O	-1	20959502
L@@	O	-1	20959502
,	O	-1	20959502
respectivel@@	O	-1	20959502
y,	O	-1	20959502
prior	O	-1	20959502
to	O	-1	20959502
the	O	-1	20959502
thir@@	O	-1	20959502
d	O	-1	20959502
dose.	O	-1	20959502
L@@	O	-1	20959502
umb@@	O	-1	20959502
ar	O	-1	20959502
p@@	O	-1	20959502
unc@@	O	-1	20959502
t@@	O	-1	20959502
ure	O	-1	20959502
results	O	-1	20959502
were	O	-1	20959502
in@@	O	-1	20959502
concl@@	O	-1	20959502
u@@	O	-1	20959502
sive	O	-1	20959502
and	O	-1	20959502
no	O	-1	20959502
further	O	-1	20959502
blood	O	-1	20959502
c@@	O	-1	20959502
ult@@	O	-1	20959502
ures	O	-1	20959502
were	O	-1	20959502
positive	O	-1	20959502
for	O	-1	20959502
M@@	O	-1	20959502
S@@	O	-1	20959502
S@@	O	-1	20959502
A@@	O	-1	20959502
.	O	-1	20959502
C@@	B-Chemical	D003401	20959502
reat@@	I-Chemical	-1	20959502
ine	I-Chemical	-1	20959502
kin@@	O	-1	20959502
ase	O	-1	20959502
levels	O	-1	20959502
were	O	-1	20959502
normal	O	-1	20959502
prior	O	-1	20959502
to	O	-1	20959502
d@@	B-Chemical	D017576	20959502
ap@@	I-Chemical	-1	20959502
to@@	I-Chemical	-1	20959502
m@@	I-Chemical	-1	20959502
ycin	I-Chemical	-1	20959502
therapy	O	-1	20959502
and	O	-1	20959502
were	O	-1	20959502
not	O	-1	20959502
reas@@	O	-1	20959502
s@@	O	-1	20959502
es@@	O	-1	20959502
sed.	O	-1	20959502
D@@	O	-1	20959502
I@@	O	-1	20959502
S@@	O	-1	20959502
C@@	O	-1	20959502
US@@	O	-1	20959502
S@@	O	-1	20959502
ION@@	O	-1	20959502
:	O	-1	20959502
D@@	B-Chemical	D017576	20959502
ap@@	I-Chemical	-1	20959502
to@@	I-Chemical	-1	20959502
m@@	I-Chemical	-1	20959502
ycin	I-Chemical	-1	20959502
was	O	-1	20959502
initi@@	O	-1	20959502
ated	O	-1	20959502
in	O	-1	20959502
our	O	-1	20959502
patient	O	-1	20959502
secondary	O	-1	20959502
to	O	-1	20959502
possible	O	-1	20959502
n@@	B-Chemical	D009254	20959502
af@@	I-Chemical	-1	20959502
c@@	I-Chemical	-1	20959502
ill@@	I-Chemical	-1	20959502
in	I-Chemical	-1	20959502
-induced	O	-1	20959502
acute	O	-1	20959502
interstitial	B-Disease	D009395	20959502
neph@@	I-Disease	-1	20959502
ritis	I-Disease	-1	20959502
and	O	-1	20959502
rel@@	O	-1	20959502
ap@@	O	-1	20959502
s@@	O	-1	20959502
ing	O	-1	20959502
bac@@	B-Disease	D016470	20959502
te@@	I-Disease	-1	20959502
re@@	I-Disease	-1	20959502
mia	I-Disease	-1	20959502
.	O	-1	20959502
A@@	O	-1	20959502
t	O	-1	20959502
a	O	-1	20959502
dose	O	-1	20959502
of	O	-1	20959502
9	O	-1	20959502
mg/kg@@	O	-1	20959502
,	O	-1	20959502
result@@	O	-1	20959502
ant	O	-1	20959502
pen@@	O	-1	20959502
et@@	O	-1	20959502
ration	O	-1	20959502
of	O	-1	20959502
5%	O	-1	20959502
was	O	-1	20959502
higher	O	-1	20959502
than	O	-1	20959502
in	O	-1	20959502
previ@@	O	-1	20959502
ous	O	-1	20959502
repor@@	O	-1	20959502
t@@	O	-1	20959502
s,	O	-1	20959502
more	O	-1	20959502
consist@@	O	-1	20959502
ent	O	-1	20959502
with	O	-1	20959502
inflam@@	O	-1	20959502
ed	O	-1	20959502
men@@	O	-1	20959502
ing@@	O	-1	20959502
es.	O	-1	20959502
CONCLUSIONS:	O	-1	20959502
H@@	O	-1	20959502
igh@@	O	-1	20959502
-@@	O	-1	20959502
dose	O	-1	20959502
d@@	B-Chemical	D017576	20959502
ap@@	I-Chemical	-1	20959502
to@@	I-Chemical	-1	20959502
m@@	I-Chemical	-1	20959502
ycin	I-Chemical	-1	20959502
may	O	-1	20959502
be	O	-1	20959502
an	O	-1	20959502
al@@	O	-1	20959502
tern@@	O	-1	20959502
ative	O	-1	20959502
op@@	O	-1	20959502
tion	O	-1	20959502
for	O	-1	20959502
M@@	O	-1	20959502
S@@	O	-1	20959502
S@@	O	-1	20959502
A	O	-1	20959502
bac@@	B-Disease	D016470	20959502
te@@	I-Disease	-1	20959502
re@@	I-Disease	-1	20959502
mia	I-Disease	-1	20959502
with	O	-1	20959502
or	O	-1	20959502
without	O	-1	20959502
a	O	-1	20959502
C@@	O	-1	20959502
N@@	O	-1	20959502
S	O	-1	20959502
so@@	O	-1	20959502
ur@@	O	-1	20959502
ce	O	-1	20959502
in	O	-1	20959502
patients	O	-1	20959502
who	O	-1	20959502
have	O	-1	20959502
fail@@	O	-1	20959502
ed	O	-1	20959502
or	O	-1	20959502
can@@	O	-1	20959502
not	O	-1	20959502
toler@@	O	-1	20959502
ate	O	-1	20959502
standard	O	-1	20959502
therapy.	O	-1	20959502
F@@	O	-1	20959502
urther	O	-1	20959502
clinical	O	-1	20959502
evalu@@	O	-1	20959502
ation	O	-1	20959502
in	O	-1	20959502
patients	O	-1	20959502
with	O	-1	20959502
con@@	O	-1	20959502
fir@@	O	-1	20959502
m@@	O	-1	20959502
ed	O	-1	20959502
men@@	B-Disease	D008581	20959502
ing@@	I-Disease	-1	20959502
iti@@	I-Disease	-1	20959502
s	I-Disease	-1	20959502
is	O	-1	20959502
war@@	O	-1	20959502
ran@@	O	-1	20959502
ted.	O	-1	20959502

The	O	-1	21195121
role	O	-1	21195121
of	O	-1	21195121
nit@@	B-Chemical	D009569	21195121
ric	I-Chemical	-1	21195121
ox@@	I-Chemical	-1	21195121
ide	I-Chemical	-1	21195121
in	O	-1	21195121
convul@@	B-Disease	D012640	21195121
sions	I-Disease	-1	21195121
induced	O	-1	21195121
by	O	-1	21195121
l@@	B-Chemical	D001556	21195121
ind@@	I-Chemical	-1	21195121
ane	I-Chemical	-1	21195121
in	O	-1	21195121
rats.	O	-1	21195121
L@@	B-Chemical	D001556	21195121
ind@@	I-Chemical	-1	21195121
ane	I-Chemical	-1	21195121
is	O	-1	21195121
an	O	-1	21195121
org@@	O	-1	21195121
an@@	O	-1	21195121
och@@	O	-1	21195121
lor@@	O	-1	21195121
ide	O	-1	21195121
p@@	O	-1	21195121
es@@	O	-1	21195121
tic@@	O	-1	21195121
ide	O	-1	21195121
and	O	-1	21195121
s@@	O	-1	21195121
c@@	O	-1	21195121
ab@@	O	-1	21195121
ici@@	O	-1	21195121
de@@	O	-1	21195121
.	O	-1	21195121
It	O	-1	21195121
evo@@	O	-1	21195121
k@@	O	-1	21195121
es	O	-1	21195121
convul@@	B-Disease	D012640	21195121
sions	I-Disease	-1	21195121
main@@	O	-1	21195121
ly	O	-1	21195121
t@@	O	-1	21195121
rou@@	O	-1	21195121
gh	O	-1	21195121
the	O	-1	21195121
block@@	O	-1	21195121
age	O	-1	21195121
of	O	-1	21195121
G@@	B-Chemical	D005680	21195121
A@@	I-Chemical	-1	21195121
B@@	I-Chemical	-1	21195121
A	I-Chemical	-1	21195121
(A@@	O	-1	21195121
)	O	-1	21195121
receptor@@	O	-1	21195121
s.	O	-1	21195121
N@@	B-Chemical	D009569	21195121
it@@	I-Chemical	-1	21195121
ric	I-Chemical	-1	21195121
ox@@	I-Chemical	-1	21195121
ide	I-Chemical	-1	21195121
(	O	-1	21195121
N@@	B-Chemical	D009569	21195121
O	I-Chemical	-1	21195121
),	O	-1	21195121
g@@	O	-1	21195121
as@@	O	-1	21195121
e@@	O	-1	21195121
ous	O	-1	21195121
neuro@@	O	-1	21195121
trans@@	O	-1	21195121
mit@@	O	-1	21195121
ter@@	O	-1	21195121
,	O	-1	21195121
has	O	-1	21195121
contra@@	O	-1	21195121
dic@@	O	-1	21195121
t@@	O	-1	21195121
or	O	-1	21195121
role	O	-1	21195121
in	O	-1	21195121
epile@@	O	-1	21195121
pto@@	O	-1	21195121
genesis	O	-1	21195121
due	O	-1	21195121
to	O	-1	21195121
op@@	O	-1	21195121
pos@@	O	-1	21195121
ite	O	-1	21195121
effects	O	-1	21195121
of	O	-1	21195121
L-@@	B-Chemical	D001120	21195121
arg@@	I-Chemical	-1	21195121
inine	I-Chemical	-1	21195121
,	O	-1	21195121
pre@@	O	-1	21195121
cur@@	O	-1	21195121
s@@	O	-1	21195121
or	O	-1	21195121
of	O	-1	21195121
N@@	B-Chemical	D009569	21195121
O	I-Chemical	-1	21195121
syn@@	O	-1	21195121
th@@	O	-1	21195121
es@@	O	-1	21195121
es	O	-1	21195121
(N@@	O	-1	21195121
O@@	O	-1	21195121
S@@	O	-1	21195121
),	O	-1	21195121
and	O	-1	21195121
L-@@	B-Chemical	D019331	21195121
N@@	I-Chemical	-1	21195121
AM@@	I-Chemical	-1	21195121
E	I-Chemical	-1	21195121
(N@@	O	-1	21195121
O@@	O	-1	21195121
S	O	-1	21195121
inhibitor@@	O	-1	21195121
)	O	-1	21195121
observed	O	-1	21195121
in	O	-1	21195121
different	O	-1	21195121
epilep@@	B-Disease	D004827	21195121
sy	I-Disease	-1	21195121
model@@	O	-1	21195121
s.	O	-1	21195121
The	O	-1	21195121
a@@	O	-1	21195121
im	O	-1	21195121
of	O	-1	21195121
the	O	-1	21195121
current	O	-1	21195121
study	O	-1	21195121
was	O	-1	21195121
to	O	-1	21195121
determine	O	-1	21195121
the	O	-1	21195121
effects	O	-1	21195121
of	O	-1	21195121
N@@	B-Chemical	D009569	21195121
O	I-Chemical	-1	21195121
on	O	-1	21195121
the	O	-1	21195121
behavioral	O	-1	21195121
and	O	-1	21195121
E@@	O	-1	21195121
E@@	O	-1	21195121
G	O	-1	21195121
character@@	O	-1	21195121
is@@	O	-1	21195121
tics	O	-1	21195121
of	O	-1	21195121
l@@	B-Chemical	D001556	21195121
ind@@	I-Chemical	-1	21195121
ane	I-Chemical	-1	21195121
-induced	O	-1	21195121
epilep@@	B-Disease	D004827	21195121
sy	I-Disease	-1	21195121
in	O	-1	21195121
male	O	-1	21195121
Wistar	O	-1	21195121
al@@	O	-1	21195121
bin@@	O	-1	21195121
o	O	-1	21195121
rats.	O	-1	21195121
The	O	-1	21195121
administration	O	-1	21195121
of	O	-1	21195121
L-@@	B-Chemical	D001120	21195121
arg@@	I-Chemical	-1	21195121
inine	I-Chemical	-1	21195121
(6@@	O	-1	21195121
0@@	O	-1	21195121
0@@	O	-1	21195121
,	O	-1	21195121
8@@	O	-1	21195121
00	O	-1	21195121
and	O	-1	21195121
10@@	O	-1	21195121
00	O	-1	21195121
mg/kg@@	O	-1	21195121
,	O	-1	21195121
i.p.@@	O	-1	21195121
)	O	-1	21195121
in	O	-1	21195121
dose-@@	O	-1	21195121
dependent	O	-1	21195121
man@@	O	-1	21195121
n@@	O	-1	21195121
er	O	-1	21195121
significantly	O	-1	21195121
increased	O	-1	21195121
convul@@	B-Disease	D012640	21195121
sion	I-Disease	-1	21195121
incidence	O	-1	21195121
and	O	-1	21195121
severity	O	-1	21195121
and	O	-1	21195121
sh@@	O	-1	21195121
or@@	O	-1	21195121
ten@@	O	-1	21195121
ed	O	-1	21195121
lat@@	O	-1	21195121
ency	O	-1	21195121
time	O	-1	21195121
to	O	-1	21195121
first	O	-1	21195121
convul@@	B-Disease	D012640	21195121
sion	I-Disease	-1	21195121
el@@	O	-1	21195121
ic@@	O	-1	21195121
ited	O	-1	21195121
by	O	-1	21195121
lower	O	-1	21195121
l@@	B-Chemical	D001556	21195121
ind@@	I-Chemical	-1	21195121
ane	I-Chemical	-1	21195121
dose	O	-1	21195121
(@@	O	-1	21195121
4	O	-1	21195121
mg/kg@@	O	-1	21195121
,	O	-1	21195121
i.p.@@	O	-1	21195121
).	O	-1	21195121
O@@	O	-1	21195121
n	O	-1	21195121
the	O	-1	21195121
contr@@	O	-1	21195121
ar@@	O	-1	21195121
y,	O	-1	21195121
pretreatment	O	-1	21195121
with	O	-1	21195121
L-@@	B-Chemical	D019331	21195121
N@@	I-Chemical	-1	21195121
AM@@	I-Chemical	-1	21195121
E	I-Chemical	-1	21195121
(@@	O	-1	21195121
50@@	O	-1	21195121
0@@	O	-1	21195121
,	O	-1	21195121
7@@	O	-1	21195121
00	O	-1	21195121
and	O	-1	21195121
9@@	O	-1	21195121
00	O	-1	21195121
mg/kg@@	O	-1	21195121
,	O	-1	21195121
i.p.@@	O	-1	21195121
)	O	-1	21195121
decreased	O	-1	21195121
convul@@	B-Disease	D012640	21195121
sion	I-Disease	-1	21195121
incidence	O	-1	21195121
and	O	-1	21195121
severity	O	-1	21195121
and	O	-1	21195121
prolonged	O	-1	21195121
lat@@	O	-1	21195121
ency	O	-1	21195121
time	O	-1	21195121
to	O	-1	21195121
convul@@	B-Disease	D012640	21195121
sion	I-Disease	-1	21195121
following	O	-1	21195121
injection	O	-1	21195121
with	O	-1	21195121
a	O	-1	21195121
convul@@	B-Disease	D012640	21195121
sive	I-Disease	-1	21195121
dose	O	-1	21195121
of	O	-1	21195121
l@@	B-Chemical	D001556	21195121
ind@@	I-Chemical	-1	21195121
ane	I-Chemical	-1	21195121
(@@	O	-1	21195121
8	O	-1	21195121
mg/kg@@	O	-1	21195121
,	O	-1	21195121
i.p.@@	O	-1	21195121
).	O	-1	21195121
E@@	O	-1	21195121
E@@	O	-1	21195121
G	O	-1	21195121
analy@@	O	-1	21195121
ses	O	-1	21195121
showed	O	-1	21195121
increase	O	-1	21195121
of	O	-1	21195121
number	O	-1	21195121
and	O	-1	21195121
duration	O	-1	21195121
of	O	-1	21195121
ic@@	O	-1	21195121
t@@	O	-1	21195121
al	O	-1	21195121
perio@@	O	-1	21195121
ds	O	-1	21195121
in	O	-1	21195121
E@@	O	-1	21195121
E@@	O	-1	21195121
G	O	-1	21195121
of	O	-1	21195121
rats	O	-1	21195121
receiving	O	-1	21195121
l@@	B-Chemical	D001120	21195121
-@@	I-Chemical	-1	21195121
arg@@	I-Chemical	-1	21195121
inine	I-Chemical	-1	21195121
prior	O	-1	21195121
to	O	-1	21195121
l@@	B-Chemical	D001556	21195121
ind@@	I-Chemical	-1	21195121
ane	I-Chemical	-1	21195121
and	O	-1	21195121
decrease	O	-1	21195121
of	O	-1	21195121
this	O	-1	21195121
number	O	-1	21195121
in	O	-1	21195121
rats	O	-1	21195121
pre@@	O	-1	21195121
treated	O	-1	21195121
with	O	-1	21195121
L-@@	B-Chemical	D019331	21195121
N@@	I-Chemical	-1	21195121
AM@@	I-Chemical	-1	21195121
E	I-Chemical	-1	21195121
.	O	-1	21195121
These	O	-1	21195121
results	O	-1	21195121
suppor@@	O	-1	21195121
t	O	-1	21195121
the	O	-1	21195121
concl@@	O	-1	21195121
usion	O	-1	21195121
that	O	-1	21195121
N@@	B-Chemical	D009569	21195121
O	I-Chemical	-1	21195121
pl@@	O	-1	21195121
ays	O	-1	21195121
a	O	-1	21195121
role	O	-1	21195121
of	O	-1	21195121
endo@@	O	-1	21195121
gen@@	O	-1	21195121
ous	O	-1	21195121
convul@@	O	-1	21195121
s@@	O	-1	21195121
ant	O	-1	21195121
in	O	-1	21195121
rat	O	-1	21195121
model	O	-1	21195121
of	O	-1	21195121
l@@	B-Chemical	D001556	21195121
ind@@	I-Chemical	-1	21195121
ane	I-Chemical	-1	21195121
seizures	B-Disease	D012640	21195121
.	O	-1	21195121

L@@	O	-1	24055495
on@@	O	-1	24055495
g@@	O	-1	24055495
-term	O	-1	24055495
oral	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
treatment	O	-1	24055495
prev@@	O	-1	24055495
ents	O	-1	24055495
cognitive	B-Disease	D003072	24055495
defic@@	I-Disease	-1	24055495
its	I-Disease	-1	24055495
in	O	-1	24055495
male	O	-1	24055495
Wistar	O	-1	24055495
rats	O	-1	24055495
treated	O	-1	24055495
intrac@@	O	-1	24055495
e@@	O	-1	24055495
reb@@	O	-1	24055495
ro@@	O	-1	24055495
ventric@@	O	-1	24055495
ul@@	O	-1	24055495
arly	O	-1	24055495
with	O	-1	24055495
st@@	B-Chemical	D013311	24055495
re@@	I-Chemical	-1	24055495
pto@@	I-Chemical	-1	24055495
z@@	I-Chemical	-1	24055495
ot@@	I-Chemical	-1	24055495
oc@@	I-Chemical	-1	24055495
in	I-Chemical	-1	24055495
.	O	-1	24055495
B@@	O	-1	24055495
a@@	O	-1	24055495
sic	O	-1	24055495
and	O	-1	24055495
clinical	O	-1	24055495
re@@	O	-1	24055495
se@@	O	-1	24055495
arc@@	O	-1	24055495
h	O	-1	24055495
has	O	-1	24055495
demonstrated	O	-1	24055495
that	O	-1	24055495
de@@	B-Disease	D003704	24055495
m@@	I-Disease	-1	24055495
enti@@	I-Disease	-1	24055495
a	I-Disease	-1	24055495
of	O	-1	24055495
s@@	O	-1	24055495
por@@	O	-1	24055495
a@@	O	-1	24055495
di@@	O	-1	24055495
c	O	-1	24055495
Al@@	B-Disease	D000544	24055495
z@@	I-Disease	-1	24055495
he@@	I-Disease	-1	24055495
im@@	I-Disease	-1	24055495
er@@	I-Disease	-1	24055495
's	I-Disease	-1	24055495
disease	I-Disease	-1	24055495
(@@	O	-1	24055495
s@@	O	-1	24055495
A@@	O	-1	24055495
D)	O	-1	24055495
type	O	-1	24055495
is	O	-1	24055495
associated	O	-1	24055495
with	O	-1	24055495
dysfunction	O	-1	24055495
of	O	-1	24055495
the	O	-1	24055495
in@@	O	-1	24055495
sul@@	O	-1	24055495
in-@@	O	-1	24055495
receptor	O	-1	24055495
(@@	O	-1	24055495
I@@	O	-1	24055495
R@@	O	-1	24055495
)	O	-1	24055495
system	O	-1	24055495
followed	O	-1	24055495
by	O	-1	24055495
decreased	O	-1	24055495
g@@	B-Chemical	D005947	24055495
lu@@	I-Chemical	-1	24055495
co@@	I-Chemical	-1	24055495
se	I-Chemical	-1	24055495
trans@@	O	-1	24055495
por@@	O	-1	24055495
t	O	-1	24055495
vi@@	O	-1	24055495
a	O	-1	24055495
g@@	B-Chemical	D005947	24055495
lu@@	I-Chemical	-1	24055495
co@@	I-Chemical	-1	24055495
se	I-Chemical	-1	24055495
trans@@	O	-1	24055495
por@@	O	-1	24055495
ter	O	-1	24055495
G@@	O	-1	24055495
L@@	O	-1	24055495
U@@	O	-1	24055495
T@@	O	-1	24055495
4	O	-1	24055495
and	O	-1	24055495
decreased	O	-1	24055495
g@@	B-Chemical	D005947	24055495
lu@@	I-Chemical	-1	24055495
co@@	I-Chemical	-1	24055495
se	I-Chemical	-1	24055495
metabol@@	O	-1	24055495
ism	O	-1	24055495
in	O	-1	24055495
brain	O	-1	24055495
cell@@	O	-1	24055495
s.	O	-1	24055495
An	O	-1	24055495
al@@	O	-1	24055495
tern@@	O	-1	24055495
ative	O	-1	24055495
so@@	O	-1	24055495
ur@@	O	-1	24055495
ce	O	-1	24055495
of	O	-1	24055495
en@@	O	-1	24055495
erg@@	O	-1	24055495
y	O	-1	24055495
is	O	-1	24055495
d-@@	B-Chemical	D005690	24055495
g@@	I-Chemical	-1	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
(@@	O	-1	24055495
the	O	-1	24055495
C@@	O	-1	24055495
-@@	O	-1	24055495
4-@@	O	-1	24055495
ep@@	O	-1	24055495
im@@	O	-1	24055495
er	O	-1	24055495
of	O	-1	24055495
d-@@	B-Chemical	D005947	24055495
g@@	I-Chemical	-1	24055495
lu@@	I-Chemical	-1	24055495
co@@	I-Chemical	-1	24055495
se	I-Chemical	-1	24055495
)	O	-1	24055495
which	O	-1	24055495
is	O	-1	24055495
trans@@	O	-1	24055495
por@@	O	-1	24055495
ted	O	-1	24055495
into	O	-1	24055495
the	O	-1	24055495
brain	O	-1	24055495
by	O	-1	24055495
in@@	O	-1	24055495
sul@@	O	-1	24055495
in-@@	O	-1	24055495
in@@	O	-1	24055495
dependent	O	-1	24055495
G@@	O	-1	24055495
L@@	O	-1	24055495
U@@	O	-1	24055495
T@@	O	-1	24055495
3	O	-1	24055495
trans@@	O	-1	24055495
por@@	O	-1	24055495
ter	O	-1	24055495
wh@@	O	-1	24055495
ere	O	-1	24055495
it	O	-1	24055495
might	O	-1	24055495
be	O	-1	24055495
metabol@@	O	-1	24055495
ized	O	-1	24055495
to	O	-1	24055495
g@@	B-Chemical	D005947	24055495
lu@@	I-Chemical	-1	24055495
co@@	I-Chemical	-1	24055495
se	I-Chemical	-1	24055495
vi@@	O	-1	24055495
a	O	-1	24055495
the	O	-1	24055495
L@@	O	-1	24055495
e@@	O	-1	24055495
lo@@	O	-1	24055495
ir	O	-1	24055495
path@@	O	-1	24055495
w@@	O	-1	24055495
a@@	O	-1	24055495
y.	O	-1	24055495
E@@	O	-1	24055495
x@@	O	-1	24055495
cl@@	O	-1	24055495
u@@	O	-1	24055495
si@@	O	-1	24055495
vely	O	-1	24055495
pa@@	O	-1	24055495
ren@@	O	-1	24055495
ter@@	O	-1	24055495
al	O	-1	24055495
daily	O	-1	24055495
injec@@	O	-1	24055495
tions	O	-1	24055495
of	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
induce	O	-1	24055495
memory	B-Disease	D008569	24055495
deter@@	I-Disease	-1	24055495
i@@	I-Disease	-1	24055495
or@@	I-Disease	-1	24055495
ation	I-Disease	-1	24055495
in	O	-1	24055495
ro@@	O	-1	24055495
d@@	O	-1	24055495
ents	O	-1	24055495
and	O	-1	24055495
are	O	-1	24055495
used	O	-1	24055495
to	O	-1	24055495
gener@@	O	-1	24055495
ate	O	-1	24055495
anim@@	O	-1	24055495
al	O	-1	24055495
ag@@	O	-1	24055495
ing	O	-1	24055495
model@@	O	-1	24055495
,	O	-1	24055495
but	O	-1	24055495
the	O	-1	24055495
effects	O	-1	24055495
of	O	-1	24055495
oral	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
treatment	O	-1	24055495
on	O	-1	24055495
cognitive	O	-1	24055495
func@@	O	-1	24055495
tions	O	-1	24055495
have	O	-1	24055495
ne@@	O	-1	24055495
ver	O	-1	24055495
been	O	-1	24055495
test@@	O	-1	24055495
ed.	O	-1	24055495
We	O	-1	24055495
have	O	-1	24055495
investigated	O	-1	24055495
the	O	-1	24055495
effects	O	-1	24055495
of	O	-1	24055495
continu@@	O	-1	24055495
ous	O	-1	24055495
daily	O	-1	24055495
oral	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
(2@@	O	-1	24055495
00	O	-1	24055495
mg/k@@	O	-1	24055495
g/@@	O	-1	24055495
day@@	O	-1	24055495
)	O	-1	24055495
treatment	O	-1	24055495
on	O	-1	24055495
cognitive	B-Disease	D003072	24055495
defic@@	I-Disease	-1	24055495
its	I-Disease	-1	24055495
in	O	-1	24055495
st@@	B-Chemical	D013311	24055495
re@@	I-Chemical	-1	24055495
pto@@	I-Chemical	-1	24055495
z@@	I-Chemical	-1	24055495
ot@@	I-Chemical	-1	24055495
oc@@	I-Chemical	-1	24055495
in	I-Chemical	-1	24055495
-induced	O	-1	24055495
(	O	-1	24055495
S@@	B-Chemical	D013311	24055495
T@@	I-Chemical	-1	24055495
Z	I-Chemical	-1	24055495
-@@	O	-1	24055495
ic@@	O	-1	24055495
v@@	O	-1	24055495
)	O	-1	24055495
rat	O	-1	24055495
model	O	-1	24055495
of	O	-1	24055495
s@@	O	-1	24055495
AD@@	O	-1	24055495
,	O	-1	24055495
tested	O	-1	24055495
by	O	-1	24055495
M@@	O	-1	24055495
or@@	O	-1	24055495
ri@@	O	-1	24055495
s	O	-1	24055495
W@@	O	-1	24055495
at@@	O	-1	24055495
er	O	-1	24055495
M@@	O	-1	24055495
az@@	O	-1	24055495
e	O	-1	24055495
and	O	-1	24055495
P@@	O	-1	24055495
as@@	O	-1	24055495
sive	O	-1	24055495
A@@	O	-1	24055495
v@@	O	-1	24055495
oid@@	O	-1	24055495
ance	O	-1	24055495
test@@	O	-1	24055495
,	O	-1	24055495
respectively.	O	-1	24055495
One	O	-1	24055495
mon@@	O	-1	24055495
th	O	-1	24055495
of	O	-1	24055495
oral	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
treatment	O	-1	24055495
initi@@	O	-1	24055495
ated	O	-1	24055495
immedi@@	O	-1	24055495
ately	O	-1	24055495
after	O	-1	24055495
the	O	-1	24055495
S@@	B-Chemical	D013311	24055495
T@@	I-Chemical	-1	24055495
Z	I-Chemical	-1	24055495
-@@	O	-1	24055495
ic@@	O	-1	24055495
v	O	-1	24055495
administr@@	O	-1	24055495
ation,	O	-1	24055495
suc@@	O	-1	24055495
cess@@	O	-1	24055495
ful@@	O	-1	24055495
ly	O	-1	24055495
prevent@@	O	-1	24055495
ed	O	-1	24055495
development	O	-1	24055495
of	O	-1	24055495
the	O	-1	24055495
S@@	B-Chemical	D013311	24055495
T@@	I-Chemical	-1	24055495
Z	I-Chemical	-1	24055495
-@@	O	-1	24055495
ic@@	O	-1	24055495
v@@	O	-1	24055495
-induced	O	-1	24055495
cognitive	B-Disease	D003072	24055495
defic@@	I-Disease	-1	24055495
its	I-Disease	-1	24055495
.	O	-1	24055495
B@@	O	-1	24055495
en@@	O	-1	24055495
e@@	O	-1	24055495
fic@@	O	-1	24055495
ial	O	-1	24055495
effect	O	-1	24055495
of	O	-1	24055495
oral	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
was	O	-1	24055495
in@@	O	-1	24055495
dependent	O	-1	24055495
of	O	-1	24055495
the	O	-1	24055495
rat	O	-1	24055495
age	O	-1	24055495
and	O	-1	24055495
of	O	-1	24055495
the	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
dose	O	-1	24055495
rang@@	O	-1	24055495
ing	O	-1	24055495
from	O	-1	24055495
100	O	-1	24055495
to	O	-1	24055495
3@@	O	-1	24055495
00	O	-1	24055495
mg/k@@	O	-1	24055495
g/@@	O	-1	24055495
da@@	O	-1	24055495
y.	O	-1	24055495
Ad@@	O	-1	24055495
di@@	O	-1	24055495
tion@@	O	-1	24055495
ally,	O	-1	24055495
oral	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
administration	O	-1	24055495
l@@	O	-1	24055495
ed	O	-1	24055495
to	O	-1	24055495
the	O	-1	24055495
appear@@	O	-1	24055495
ance	O	-1	24055495
of	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
in	O	-1	24055495
the	O	-1	24055495
blo@@	O	-1	24055495
o@@	O	-1	24055495
d.	O	-1	24055495
The	O	-1	24055495
increase	O	-1	24055495
of	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
concentration	O	-1	24055495
in	O	-1	24055495
the	O	-1	24055495
ce@@	O	-1	24055495
reb@@	O	-1	24055495
ro@@	O	-1	24055495
spinal	O	-1	24055495
flu@@	O	-1	24055495
id	O	-1	24055495
was	O	-1	24055495
several	O	-1	24055495
times	O	-1	24055495
lower	O	-1	24055495
after	O	-1	24055495
oral	O	-1	24055495
than	O	-1	24055495
after	O	-1	24055495
pa@@	O	-1	24055495
ren@@	O	-1	24055495
ter@@	O	-1	24055495
al	O	-1	24055495
administration	O	-1	24055495
of	O	-1	24055495
the	O	-1	24055495
same	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
dose.	O	-1	24055495
O@@	O	-1	24055495
ral	O	-1	24055495
g@@	B-Chemical	D005690	24055495
al@@	I-Chemical	-1	24055495
act@@	I-Chemical	-1	24055495
ose	I-Chemical	-1	24055495
exposure	O	-1	24055495
might	O	-1	24055495
have	O	-1	24055495
ben@@	O	-1	24055495
e@@	O	-1	24055495
fic@@	O	-1	24055495
ial	O	-1	24055495
effects	O	-1	24055495
on	O	-1	24055495
lear@@	O	-1	24055495
ning	O	-1	24055495
and	O	-1	24055495
memory	O	-1	24055495
ability	O	-1	24055495
and	O	-1	24055495
could	O	-1	24055495
be	O	-1	24055495
wor@@	O	-1	24055495
th	O	-1	24055495
investig@@	O	-1	24055495
ating	O	-1	24055495
for	O	-1	24055495
impro@@	O	-1	24055495
vement	O	-1	24055495
of	O	-1	24055495
cognitive	B-Disease	D003072	24055495
defic@@	I-Disease	-1	24055495
its	I-Disease	-1	24055495
associated	O	-1	24055495
with	O	-1	24055495
g@@	B-Disease	D018149	24055495
lu@@	I-Disease	-1	24055495
co@@	I-Disease	-1	24055495
se	I-Disease	-1	24055495
hypo@@	I-Disease	-1	24055495
metabol@@	I-Disease	-1	24055495
ism	I-Disease	-1	24055495
in	O	-1	24055495
A@@	B-Disease	D000544	24055495
D	I-Disease	-1	24055495
.	O	-1	24055495

